<SEC-DOCUMENT>0001370368-23-000048.txt : 20230515
<SEC-HEADER>0001370368-23-000048.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515164047
ACCESSION NUMBER:		0001370368-23-000048
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		254
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		23923453

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>nvs-20221231.htm
<DESCRIPTION>20-F/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:nvs="http://novartis.com/20221231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ns0="http://www.novartis.com/custom-units">
  <head>
    <title>20-F</title>
    <meta http-equiv="Content-Type" content="text/html" />
  </head>
  <body>
    <div style="display:none">
      <ix:header>
        <ix:hidden>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0">0</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0">0</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">0.60</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9996</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.7068</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9999</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9999</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">0.20</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityCentralIndexKey">0001114448</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AmendmentFlag">false</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Malaysia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Africa</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityIncorporationStateCountryCode">V8</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressAddressLine1">Lichtstrasse 35</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Algeria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Argentina</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bangladesh</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Brazil</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Brazil</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Canada</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Canada</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Chile</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Colombia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Croatia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Czech Republic</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Czech Republic</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Denmark</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Denmark</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ecuador</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Egypt</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Egypt</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Finland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Greece</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Hungary</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Hungary</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Indonesia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Israel</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Latvia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Luxembourg</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Luxembourg</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Mexico</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Mexico</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Morocco</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">New Zealand</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Norway</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Pakistan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Panama</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Philippines</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Philippines</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Romania</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Romania</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Saudi Arabia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovakia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovenia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovenia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Africa</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Korea</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Sweden</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Taiwan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Thailand</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ukraine</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Arab Emirates</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Venezuela</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Vietnam</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef d5p1:type="simple" d5p1:href="nvs-20221231.xsd" xmlns:d5p1="http://www.w3.org/1999/xlink" />
        </ix:references>
        <ix:resources>
          <xbrli:context id="AR_I-CurrentYearEnd">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-12-22</xbrli:startDate>
              <xbrli:endDate>2021-12-22</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-02-17</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-02-17</xbrli:startDate>
              <xbrli:endDate>2022-02-17</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-02-10</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-10-08</xbrli:startDate>
              <xbrli:endDate>2021-10-08</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-10-08</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-11-23</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2019-11-23</xbrli:startDate>
              <xbrli:endDate>2019-11-23</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-01-06</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-06</xbrli:startDate>
              <xbrli:endDate>2020-01-06</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-31</xbrli:startDate>
              <xbrli:endDate>2020-01-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-01-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2018-09-06</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-03-01</xbrli:startDate>
              <xbrli:endDate>2020-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ValueAdjustmentsRelatedToDivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2018-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:AmericanDepositarySharesEachRepresenting1ShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:OrdinarySharesNominalValueCHF0.50PerShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="USDPerShares">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:USD</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="CHFPerShares">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:CHF</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="Pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="EUR">
            <xbrli:measure>iso4217:EUR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Year">
            <xbrli:measure>ns0:year</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CHF">
            <xbrli:measure>iso4217:CHF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="JPY">
            <xbrli:measure>iso4217:JPY</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="DZD">
            <xbrli:measure>iso4217:DZD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ARS">
            <xbrli:measure>iso4217:ARS</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="AUD">
            <xbrli:measure>iso4217:AUD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="BDT">
            <xbrli:measure>iso4217:BDT</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="BRL">
            <xbrli:measure>iso4217:BRL</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CAD">
            <xbrli:measure>iso4217:CAD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CLP">
            <xbrli:measure>iso4217:CLP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HKD">
            <xbrli:measure>iso4217:HKD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="COP">
            <xbrli:measure>iso4217:COP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HRK">
            <xbrli:measure>iso4217:HRK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CZK">
            <xbrli:measure>iso4217:CZK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="DKK">
            <xbrli:measure>iso4217:DKK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="EGP">
            <xbrli:measure>iso4217:EGP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HUF">
            <xbrli:measure>iso4217:HUF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="INR">
            <xbrli:measure>iso4217:INR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="IDR">
            <xbrli:measure>iso4217:IDR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ILS">
            <xbrli:measure>iso4217:ILS</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MYR">
            <xbrli:measure>iso4217:MYR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MXN">
            <xbrli:measure>iso4217:MXN</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MAD">
            <xbrli:measure>iso4217:MAD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="NZD">
            <xbrli:measure>iso4217:NZD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="NOK">
            <xbrli:measure>iso4217:NOK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PKR">
            <xbrli:measure>iso4217:PKR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PHP">
            <xbrli:measure>iso4217:PHP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PLN">
            <xbrli:measure>iso4217:PLN</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="RON">
            <xbrli:measure>iso4217:RON</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="RUB">
            <xbrli:measure>iso4217:RUB</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SAR">
            <xbrli:measure>iso4217:SAR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SGD">
            <xbrli:measure>iso4217:SGD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ZAR">
            <xbrli:measure>iso4217:ZAR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="KRW">
            <xbrli:measure>iso4217:KRW</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SEK">
            <xbrli:measure>iso4217:SEK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="TWD">
            <xbrli:measure>iso4217:TWD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="THB">
            <xbrli:measure>iso4217:THB</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="TRY">
            <xbrli:measure>iso4217:TRY</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="UAH">
            <xbrli:measure>iso4217:UAH</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="AED">
            <xbrli:measure>iso4217:AED</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="GBP">
            <xbrli:measure>iso4217:GBP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="VEF">
            <xbrli:measure>iso4217:VEF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="VND">
            <xbrli:measure>iso4217:VND</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <br />
      <img src="x_coverfront.jpg" alt="picture" />
      <br />
      <br />
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>As filed with the Securities and Exchange Commission on May 15, 2023</b>
              </span>
            </div>
          </div>
          <div style="width:100%;padding-bottom:20px;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
              <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">UNITED STATES <br />SECURITIES AND EXCHANGE COMMISSION</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>Washington D.C. 20549</b>
              </span>
            </div>
          </div>
          <div style="Margin: 0 auto; WIDTH: 150px;padding-top:10px;">
            <div style="border-top: solid #000000 3px;"></div>
            <div style="TEXT-ALIGN: center; font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">
              <span>Form <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentType">20-F/A</ix:nonNumeric></span>
            </div>
            <div style="border-top: solid #000000 3px;padding-bottom:10px;"></div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Amendment No. 1)</span>
            </div>
          </div>
          <div style="padding-bottom:20px;"></div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentRegistrationStatement" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric>    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentShellCompanyReport" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date of event requiring this shell company report&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">For the transition period from _____ to _____</span>
            </div>
          </div>
          <div style="padding-bottom:20px;"></div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>Commission file number </b>
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityFileNumber">1-15024</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityRegistrantName">Novartis AG</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Exact name of Registrant as specified in its charter)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">NOVARTIS Inc.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Translation of Registrant&#x2019;s name into English)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">Switzerland</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Jurisdiction of incorporation or organization)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressAddressLine1">Lichtstrasse 35</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressPostalZipCode">4056</ix:nonNumeric>
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressCityOrTown">Basel</ix:nonNumeric>, <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Switzerland</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Address of principal executive offices)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:ContactPersonnelName">Karen L. Hale</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Chief Legal Officer</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis AG</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CH <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressPostalZipCode">4056</ix:nonNumeric><span>&#xA0;</span><ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressCityOrTown">Basel</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Switzerland</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Tel.: +<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CountryRegion">41</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CityAreaCode">61</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:LocalPhoneNumber">324-1111</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Fax: +<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CountryRegion">41</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CityAreaCode">61</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:ContactPersonnelFaxNumber">324-7826</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered or to be registered pursuant to Section 12(b) of the Act:</span>
            </div>
          </div>
          <div>
            <div style="padding-top:10px;"></div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Title of each class</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Trading Symbol(s)</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Name of each exchange on which registered</span>
              </div>
            </div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:Security12bTitle">American Depositary Shares each representing 1 share</ix:nonNumeric>
                  <br />
                </span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:TradingSymbol">NVS</ix:nonNumeric>
                  <br /> &#xA0;</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric>
                  <br /> &#xA0;</span>
              </div>
            </div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:Security12bTitle">Ordinary shares, nominal value CHF 0.50 per share</ix:nonNumeric>*</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:TradingSymbol">NOVN</ix:nonNumeric>
                </span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric>*</span>
              </div>
            </div>
          </div>
          <div style="TEXT-ALIGN: center; WIDTH: 33%; clear: both">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</span>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>None</b>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>None</b>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate the number of outstanding shares of each of the issuer&#x2019;s classes of capital or common stock as of the close of the period covered by the annual report:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; font-weight: bold; color:#000000;">
                <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd" name="dei:EntityCommonStockSharesOutstanding" decimals="0" scale="0" format="ixt:numdotdecimal">2 119 609 057</ix:nonFraction> ordinary shares</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0; Yes</b>&#xA0;&#xA0;&#xA0; &#x2610; &#xA0;&#xA0;&#xA0;<b><ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></b>&#xA0;&#xA0;&#xA0; &#x2612;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Note&#x2014;Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> &#xA0;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See&#xA0;definition of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric>&#xA0;&#x2612; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Accelerated filer&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Non-accelerated filer&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Emerging growth company&#xA0;&#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#x2020; The term &#x201C;new or revised financial accounting standard&#x201D; refers to any update issued by the Financial&#xA0;Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#xA7;240.10D-1(b). &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">U.S. GAAP&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board&#xA0;&#x2612; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Other&#xA0;&#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If &#x201C;Other&#x201D; has been checked in response to the previous question, indicate by check mark which financial&#xA0;statement item the registrant has elected to follow.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;Item 17</b>&#xA0;&#xA0;&#xA0; &#x2610; &#xA0;&#xA0;&#xA0;<b>Item 18</b>&#xA0;&#xA0;&#xA0; &#x2610; </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;Yes</b>&#xA0;&#xA0;&#xA0;<ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2612; </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">*  Not for trading but only in connection with the registration of American Depositary Shares representing such ordinary shares.</span>
            </div>
          </div>
          <div style="width:100%;padding-top:30px;padding-bottom:20px;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
              <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
            </div>
          </div>
        </div>
      </div>
      <div id="anchorId001210979"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Explanatory note</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG (the &#x201C;Company&#x201D;) is filing this Amendment No. 1 (&#x201C;Amendment No. 1&#x201D;) to the Annual Report on Form 20-F for the year ended December 31, 2022 (the &#x201C;Original Form 20-F&#x201D;), as filed with the United States Securities and Exchange Commission (the &#x201C;SEC&#x201D;) on February 1, 2022 (the &#x201C;Original Filing Date&#x201D;), solely to correct certain inadvertent typographical errors in Exhibits 13.1 and 13.2. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, this Amendment No. 1 also includes, as Exhibits 12.1 and 12.2, the certifications of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Except as described above, no changes have been made to the Original Form 20-F, and this Amendment No. 1 does not modify, amend or update the financial or other information contained in the Original Form 20-F. This Amendment No. 1 does not reflect any events that have occurred on or after the Original Filing Date. Among other things, the Company has not revised forward-looking statements made in the Original Form 20-F to reflect events that occurred or facts that became known to the Company after the Original Filing Date. Therefore, this Amendment No. 1 should be read in conjunction with the Original Form 20-F and&#xA0;any&#xA0;other documents that the Company has filed with the SEC on or after the Original Filing Date.</div>
      <div style="padding-bottom:30px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00122210979"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Table of contents</p>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00210980">Introduction and use of certain terms</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00210999">Forward-looking statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00311003">Part I</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00311005">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00311012">Item 2.  Offer Statistics and Expected Timetable</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00311018">Item 3.  Key Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311020">3.A [Reserved]</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311022">3.B Capitalization and indebtedness</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311026">3.C Reasons for the offer and use of proceeds</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311030">3.D Risk factors </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00311562">Item&#xA0;4.  Information on the Company</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311565">4.A History and development of Novartis</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311596">4.B Business overview</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;">
        <a style="text-decoration: none;" href="#anchorId00311660">Innovative Medicines</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;">
        <a style="text-decoration: none;" href="#anchorId00315217">Sandoz</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00316123">4.C Organizational structure</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00316141">4.D Property, plants and equipment</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00316354">Item&#xA0;4A.  Unresolved Staff Comments</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId0010011046">Item 5. Operating and Financial Review and&#xA0;Prospects</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010011049">5.A Operating results</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010024813">5.B Liquidity and capital resources</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028621">5.C Research and development, patents and licenses</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028639">5.D Trend information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028646">5.E Critical accounting estimates </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00410980">Item 6.  Directors, Senior Management and Employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00410982">6.A Directors and senior management</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00911131">6.B Compensation</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001011000">6.C Board practices </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00510992">6.D Employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00511847">6.E Share ownership</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00511868">Item&#xA0;7.  Major Shareholders and Related Party Transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00511871">7.A Major shareholders</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512320">7.B Related party transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512326">7.C Interests of experts and counsel</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512332">Item&#xA0;8.  Financial Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512335">8.A Consolidated statements and other financial information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512376">8.B Significant changes</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512383">Item&#xA0;9.  The Offer and Listing</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512386">9.A Offer and listing details</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512394">9.B Plan of distribution</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512398">9.C Markets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512404">9.D Selling shareholders</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512408">9.E Dilution</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512412">9.F Expenses of the issue</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512418">Item&#xA0;10.  Additional Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512421">10.A Share capital</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512425">10.B Memorandum and articles of association</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512681">10.C Material contracts</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512696">10.D Exchange controls</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512703">10.E Taxation</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513015">10.F Dividends and paying agents</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513019">10.G Statement by experts</a>
      </div>
      <div style="padding-bottom:50px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">2</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513025">10.H Documents on display</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513039">10.I Subsidiary information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513045">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513064">Item&#xA0;12.  Description of Securities Other Than Equity Securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513067">12.A Debt securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513071">12.B Warrants and rights</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513075">12.C Other securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513079">12.D American Depositary Shares</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00513273">PART II</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513275">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513282">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00610980">Item&#xA0;15.  Controls and Procedures</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710986">Item&#xA0;16A.  Audit Committee Financial Expert</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710995">Item&#xA0;16B.  Code of Ethics</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711004">Item&#xA0;16C.  Principal Accountant Fees and Services</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711015">Item&#xA0;16D.  Exemptions from the Listing Standards for Audit Committees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711022">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711707">Item&#xA0;16F.  Change in Registrant&#x2019;s Certifying Accountant</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711715">Item&#xA0;16G.  Corporate Governance</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711748">Item&#xA0;16H.  Mine Safety Disclosure</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711756">Item&#xA0;16I.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00711764">PART III</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711766">Item&#xA0;17.  Financial Statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711774">Item&#xA0;18.  Financial Statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001810985">Item&#xA0;19.  Exhibits</a>
      </div>
      <div style="padding-bottom:30px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">3</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00210980"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Introduction and use of certain terms</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG and its consolidated affiliates publish consolidated financial statements expressed in US dollars. Our consolidated financial statements responsive to Item 18 of this Annual Report on Form&#xA0;20-F (Annual Report) are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). &#x201C;Item 5. Operating and Financial Review and Prospects,&#x201D; together with the sections on products in development and key development projects of our businesses (see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B. Business overview&#x201D;), constitute the Operating and Financial Review (&#x201C;Lagebericht&#x201D;), as defined by the Swiss Code of Obligations.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unless the context requires otherwise, the words &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;us,&#x201D; &#x201C;Novartis,&#x201D; &#x201C;Group,&#x201D; &#x201C;Company,&#x201D; and similar words or phrases in this Annual Report refer to Novartis AG and its consolidated affiliates. However, each Group company is legally separate from all other Group companies and manages its business independently through its respective board of directors or similar supervisory body or other top local management body, if applicable. Each executive identified in this Annual Report reports directly to other executives of the Group company that employs the executive, or to that Group company&#x2019;s board of directors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In this Annual Report, references to &#x201C;US dollars,&#x201D; &#x201C;USD&#x201D; or &#x201C;$&#x201D; are to the lawful currency of the United States of America, references to &#x201C;CHF&#x201D; are to Swiss francs, and references to &#x201C;euro&#x201D; or &#x201C;EUR&#x201D; are to the lawful currency of 27 member states participating in the European Union; references to the &#x201C;United States&#x201D; or to &#x201C;US&#x201D; are to the United States of America, references to the &#x201C;European Union&#x201D; or to &#x201C;EU&#x201D; are to the European Union and its 27 member states, references to &#x201C;Latin America&#x201D; are to Central and South America, including the Caribbean, and references to &#x201C;Australasia&#x201D; are to Australia, New Zealand, Melanesia, Micronesia and Polynesia, unless the context otherwise requires; references to the &#x201C;EC&#x201D; are to the European Commission; references to &#x201C;associates&#x201D; are to employees of our affiliates; references to the &#x201C;SEC&#x201D; are to the US Securities and Exchange Commission; references to the &#x201C;FDA&#x201D; are to the US Food and Drug Administration; references to the &#x201C;EMA&#x201D; are to the European Medicines Agency, an agency of the EU, and references to the &#x201C;CHMP&#x201D; are to the Committee for Medicinal Products for Human Use of the EMA; references to &#x201C;ADR&#x201D; or &#x201C;ADRs&#x201D; are to Novartis American Depositary Receipts, and references to &#x201C;ADS&#x201D; or &#x201C;ADSs&#x201D; are to Novartis American Depositary Shares; references to the &#x201C;NYSE&#x201D; are to the New York Stock Exchange, and references to &#x201C;SIX&#x201D; are to the SIX Swiss Exchange; references to &#x201C;ECN&#x201D; are to the Executive Committee of Novartis; references to &#x201C;GSK&#x201D; are to GlaxoSmithKline plc; references to &#x201C;Roche&#x201D; are to Roche Holding AG; references to &#x201C;Gyroscope Therapeutics&#x201D; are to Gyroscope Therapeutics Holdings plc; references to &#x201C;AAA&#x201D; are to Advanced Accelerator Applications S.A., references to &#x201C;Novartis Gene Therapies&#x201D; are to Novartis Gene Therapies, Inc., and references to &#x201C;Endocyte&#x201D; are to Endocyte, Inc.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All product names appearing in italics are trademarks owned by or licensed to Group companies. Product names identified by a &#x201C;&#xAE;&#x201D; or a &#x201C;&#x2122;&#x201D; are trademarks that are not owned by or licensed to Group companies and are the property of their respective owners.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">4</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00210999"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Forward-looking statements</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This Annual Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), and the United States Private Securities Litigation Reform Act of 1995, as amended. Other written materials filed with or furnished to the SEC by Novartis, as well as other written and oral statements made to the public, may also contain forward-looking statements. Forward-looking statements can be identified by words such as &#x201C;potential,&#x201D; &#x201C;expected,&#x201D; &#x201C;will,&#x201D; &#x201C;planned,&#x201D; &#x201C;pipeline,&#x201D; &#x201C;outlook,&#x201D; &#x201C;may,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;seek,&#x201D; or similar terms, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of any of the transactions described; or regarding the potential impact of share buybacks; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or regarding potential future credit ratings of the Group; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.</div>
      <div style="padding-top:15px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In particular, our expectations could be affected by, among other things:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding the success of key products and commercial priorities;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global trends toward healthcare cost-containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The potential that the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities, our intention to separate our Sandoz Division into a new publicly traded standalone company by way of a 100% spin-off, or the implementation of our new organizational structure and operating model, may not be realized or may take longer to realize than expected;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;  Our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our performance on environmental, social and governance matters;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties in the development or adoption of potentially transformational digital technologies and business models;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties surrounding the implementation of our new Enterprise Resource Planning system and other IT projects;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our reliance on outsourcing key business functions to third parties;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding actual or potential legal proceedings, including, among others, litigation and other legal disputes with respect to our recent transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Safety, quality, data integrity or manufacturing issues;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability to attract, integrate and retain key personnel and qualified individuals;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this Annual Report;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">5</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability to comply with data privacy laws and regulations, and uncertainties regarding potential significant breaches of data privacy;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability  to adapt to major geopolitical and macroeconomic developments, including the effects of and efforts to mitigate pandemic diseases such as COVID-19, and the impact of the war in Ukraine;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties involved in predicting shareholder returns;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding the effects of recent and anticipated future changes in tax laws and their application to us;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding future global exchange rates; and</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding future demand for our products.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Some of these factors are discussed in more detail in this Annual Report, including under &#x201C;Item 3. Key Information&#x2014;Item 3.D. Risk factors,&#x201D; &#x201C;Item 4. Information on the Company,&#x201D; and &#x201C;Item 5. Operating and Financial Review and Prospects.&#x201D; Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Annual Report as anticipated, believed, estimated or expected. We provide the information in this Annual Report as of the date of its filing. We do not intend, and do not assume any obligation, to update any information or forward-looking statements set out in this Annual Report as a result of new information, future events or otherwise.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">6</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00311003"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">Part I</p>
      <div id="anchorId00311005"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">7</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00311012"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 2.  Offer Statistics and Expected Timetable</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">8</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00311018"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 3.  Key Information</p>
      <div id="anchorId00311020"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.A [Reserved]</p>
      <div id="anchorId00311022"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.B Capitalization and indebtedness</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00311026"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.C Reasons for the offer and use of proceeds</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00311030"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.D Risk factors </p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our businesses face significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in any Novartis securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Strategic risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key products and commercial priorities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to deliver key commercial priorities and successfully launch new products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our ability to maintain and grow our business and to replace revenue and income lost to generic, biosimilar and other competition depends heavily on the commercial success of our new or existing key products. The commercial success of these products could be impacted at any time by a number of factors, including pressure from new or existing competitive products, changes in the prescribing habits of healthcare professionals, unexpected side effects or safety signals, supply chain issues or other product shortages, pricing pressure, regulatory proceedings, changes in labeling, loss of intellectual property protection, and global pandemics. In addition, our revenue and margins could be significantly impacted by the timing and rate of commercial acceptance of new products. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Healthcare professionals, patients and payers may choose competitor products instead of ours for various reasons, including if they perceive them to be better in terms of efficacy, safety, cost, convenience or other reasons. The commercial success of our key products and launches in the face of increasing competition requires significant attention and management focus. Such competition could significantly affect the revenue from our products and our results of operations. This impact could also be compounded to the extent that such competition results in us making significant additional investments in research and development, marketing or sales.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Research and development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to successfully prioritize, integrate and execute our research and development programs for new products or new indications for existing products, given our focus on innovative medicines</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We engage in extensive and costly research and development activities, both through our own internal resources and through collaborations with third parties, in an effort to identify and develop new products and new indications for existing products that address unmet and changing medical needs, and that are commercially successful. Our ability to grow our business and our product pipeline; to replace sales lost due to branded competition, entry of generics, or other reasons; and to bring to market products that take advantage of new and potentially disruptive technologies, including cell, gene and radioligand therapies, depends in significant part on the success of these efforts. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Failure to successfully develop our pipeline products is typically the result of the inherent uncertainty of science, suboptimal internal execution, or both. Key elements of internal execution include our ability to prioritize our investments on our highest potential value assets, optimize the transition of assets from research to </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">9</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">development, integrate externally acquired assets in an efficient way, and execute the steps in our drug development process that enable our assets to be approved and reimbursed in a timely manner to positively impact clinical practice. See also &#x201C;Item 4. Information on the Company&#x2014; Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Research and development&#x201D; with regards to the research and development efforts of our Innovative Medicines Division.   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our new products must undergo intensive preclinical and clinical testing and are approved by means of a highly complex, lengthy, and expensive approval process that varies substantially from country to country and may have very specific requirements for the recruitment of patients for clinical trials. We face increasing and evolving regulatory approval and reimbursement requirements. If we fail to successfully progress late-stage assets and the core elements of drug development for key programs, this could have a negative impact on the development of our product pipeline, and ultimately on the success of our business and our financial results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in the US it is becoming increasingly challenging to adequately recruit a sufficient number of US patients in clinical trials due to new and changing requirements for recruitment of patients into such trials. As a result, we may be unable to develop the necessary clinical evidence to support the desired indications and product profile for a particular disease that is needed to drive clinical adoption of our new products, and thereby achieve the full potential of our assets (also known as the &#x201C;target product profile&#x201D;). Similarly, the post&#x2011;approval regulatory burden has also increased. These requirements make the maintenance of regulatory approvals for our products increasingly expensive, and further heighten the risk of recalls, product withdrawals, change to product specifications, loss of market share, and loss of revenue and profitability.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The clinical testing, regulatory processes and post-approval activities described above become more difficult during pandemics, such as the COVID-19 pandemic, as well as during periods of geopolitical and economic uncertainty. This is due to challenges related to recruiting, enrolling and treating patients in clinical trials, as well as ensuring the supply of trial materials. For a further description of the research and development of, and approval processes for, the products of our Innovative Medicines Division, see the sections headed &#x201C;Research and development&#x201D; and &#x201C;Regulation&#x201D; included in the description of our Innovative Medicines Division under &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division has made, and expects to continue to make, significant investments in the development of biotechnology&#x2011;based, &#x201C;biologic&#x201D; medicines that are intended for sale as bioequivalent or &#x201C;biosimilar&#x201D; versions of currently marketed biotechnology products. While the development of such products is typically significantly less costly and complex than the development of the equivalent originator medicines, it is nonetheless significantly more costly and complex than that for typical small-molecule generic products. For&#xA0;more information about the research and development efforts of our Sandoz Division, see &#x201C;Item 4.  Information on the Company&#x2014;Item 4.B Business overview&#x2014; Sandoz&#x2014;Development and registration.&#x201D; In addition, many countries do not yet have fully developed legislative or regulatory pathways to facilitate the development of biosimilars, and to permit their sale in such a way that they are readily substitutable alternatives to the originator product. Further delays or difficulties in the development or marketing of biosimilars could put at risk the significant investments that Sandoz has made, and will continue to make, in its Biopharmaceuticals business. Failure to successfully develop and market biosimilars could have a material adverse effect on the success of the Sandoz Division and the Group as a whole. For more information about the approval processes that must be followed to market Sandoz Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Regulation.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, our research and development activities must be conducted in an ethical and compliant manner. Among other things, we are concerned with patient safety (both pre- and post-product approval), data privacy, current Good Clinical Practices (cGCP) requirements, data integrity, the fair treatment of patients, diversity and inclusion in the recruitment of patients to clinical trials, and animal welfare. Should we fail to properly manage such issues, we risk injury to third parties, damage to our reputation, negative financial consequences as a result of potential claims for damages, sanctions and fines, and the potential that investments in research and development activities may not bring the expected benefits to the Group.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pricing, reimbursement and access</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pricing and reimbursement pressure, including pricing transparency and access to healthcare</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our business has continuously experienced significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products by governments, insurers and other payers. These pressures have many sources, including growth of healthcare costs as a percentage of gross domestic product; funding restrictions and policy changes; and public controversies, political debate, investigations and legal proceedings regarding pharmaceutical pricing. Pressures on pricing may negatively impact both our product pricing and the availability of our products. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we face numerous cost&#x2011;containment measures imposed by governments and other payers. These include government&#x2011;imposed industrywide price reductions, mandatory pricing systems, reference pricing systems, payers limiting access to treatments based on cost&#x2011;benefit analyses, the importation of drugs from lower&#x2011;cost countries to higher&#x2011;cost countries, the shifting of the payment burden to patients through higher co&#x2011;payments and co-pay accumulator programs, the limiting of physicians&#x2019; ability to choose among competing medicines, the mandatory substitution of generic drugs for the patented equivalent, pressure on physicians to reduce the prescribing of patented prescription medicines, increasing pressure on intellectual property </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">10</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">protections, and growing requirements for increased transparency on pricing. For more information on price controls, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Recent trends in the external environment may have an impact on the likelihood of these pricing and reimbursement pressures occurring. A worldwide slowdown in economic growth following the COVID-19 pandemic and the war in Ukraine (contributing to challenges such as high energy costs and inflation) has led to increased strain on fiscal budgets in many major economies. In addition, legislative developments such as those in the US (e.g., the Inflation Reduction Act) and in Europe (e.g., the EU Joint Health Technology Assessment) pose potential further pressures on pricing and timelines for reimbursement in these countries.  These external factors may materially affect our ability to achieve value-based prices; to achieve and maintain an acceptable return on our investments in the research and development of our products; and may impact our ability to research and develop new products. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, our Sandoz Division has faced and may continue to face intense competition from other generic and biosimilar pharmaceutical companies that aggressively compete for market share, including through significant price competition. Such competitive actions may increase the costs and risks associated with our efforts to introduce and market generic and biosimilar products, may delay the introduction or marketing of such products, and may further limit the prices at which we are able to sell these products. In particular, in the US in past years, industrywide price competition among generic pharmaceutical companies and consolidation of buyers caused significant declines in sales and profits of Sandoz.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Alliances, acquisitions and divestments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to identify, execute, and/or realize the expected benefits from our external business opportunities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As part of our strategy, from time to time we acquire and divest products or entire businesses and enter into strategic alliances and collaborations. For example, in February 2022, we closed the acquisition of Gyroscope Therapeutics. This strategy is partly dependent on our ability to identify strategic external business opportunities and to close transactions with third parties on acceptable terms.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once the terms of a strategic transaction have been agreed with a third party, we may not be able to complete the transaction in a timely manner or at all, nor can we be sure that pre-transaction due diligence will identify all possible issues that might arise during and after the transaction. Our efforts on such transactions can also divert management&#x2019;s attention from our existing businesses.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">After a transaction is closed, efforts to develop and market acquired or licensed products, to integrate the acquired business or to achieve expected synergies may fail or may not fully meet expectations. This may occur due to difficulties in retaining key personnel, customers and suppliers; failure to obtain marketing approval or reimbursement within expected time frames or at all; differences in corporate culture, standards, controls, processes and policies; or other factors. Transactions can also result in liabilities being incurred that were not known at the time of acquisition, or the creation of tax or accounting issues. Acquired businesses are not always in full compliance with legal, regulatory or Novartis standards, including, for example, Current Good Manufacturing Practices (cGMP) or cGCP standards, which can be costly and time-consuming to remediate. Furthermore, our strategic alliances and collaborations with third parties may not achieve their intended goals and objectives within expected time frames, or at all.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Similarly, we cannot ensure that we will be able to successfully divest or spin off businesses or other assets that we have identified for this purpose, or that any completed divestment or spin-off will achieve the expected strategic benefits, operational efficiencies or opportunities, or that the divestment or spin-off will ultimately maximize shareholder value.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Expiry, assertion or loss of intellectual property protection </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many products of our Innovative Medicines Division are protected by intellectual property rights, which may provide us with exclusive rights to market those products for a limited time, and to enable our purpose of reimagining medicine by sustainably financing our research and development. However, the strength and duration of those rights can vary significantly from product to product and from country to country, and they may be successfully challenged by third parties or governmental authorities. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Loss of intellectual property protection and the introduction of generic or biosimilar competition for a patented branded medicine in a country typically result in a significant and rapid reduction in net sales and operating income for the branded product. Such competition can occur after successful challenges to intellectual property rights or the regular expiration of the patent term or other intellectual property rights. Such competition can also result from the entry of generic or biosimilar versions of another medicine in the same therapeutic class as one of our drugs or in a competing therapeutic class, from a Declaration of Public Interest or the compulsory licensing of our intellectual property by governmental authorities, or as a result of a general weakening of intellectual property and governing laws in certain countries around the world. In addition, generic or biosimilar manufacturers may sometimes conduct so-called &#x201C;launches at risk&#x201D; of products that are still under legal challenge for infringement, or whose patents are still under legal challenge for validity, before final resolution of legal proceedings.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also rely in all aspects of our businesses on unpatented proprietary technology, know-how, trade secrets, </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">11</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and other confidential information, which we seek to protect through various measures, including confidentiality agreements with licensees, employees, third-party collaborators and consultants who may have had access to such information. If these agreements are breached or our other protective measures should fail, then our contractual or other remedies may not be adequate to cover our losses.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We may also be subject to assertions of intellectual property rights against our innovative medicines by third parties. If successful, these actions may involve payment of future royalties or damages, for example for patent infringement, and may also involve injunctive relief requiring the removal of one or more dosage strengths of a product from the market (or removal of a therapeutic indication from the product&#x2019;s approved labeling) for some period of time or throughout the life of the asserted intellectual property right. Such damages or such an injunction may have a material impact on our operating income and net sales.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In any given year, we may experience a potentially significant impact on our net sales from products that have already lost intellectual property protections, as well as products that may lose protection during the year. Because we may have substantially reduced marketing and research and development expenses related to products that are in their final years of exclusivity, the initial loss of protection for a product during a given year could also have an impact on our operating income for that year in an amount corresponding to a significant portion of the product&#x2019;s lost sales. The magnitude of the impact of generic or biosimilar competition on our income could depend on a number of factors. These include, with respect to income in a given year, the time of year at which the generic or biosimilar competitor is launched; the ease or difficulty of manufacturing a competitor product and obtaining regulatory approval to market it; the number of generic or biosimilar competitor products approved, including whether, in the US, a single competitor is granted an exclusive marketing period; whether an authorized generic is launched; the geographies in which generic or biosimilar competitor products are approved, including the strength of the market for generic or biosimilar pharmaceutical products in such geographies, and the comparative profitability of branded pharmaceutical products in such geographies; and our ability to successfully develop and launch new products for patients that may also offset the income lost to generic or biosimilar competition. For more information on the patent and generic competition status of our Innovative Medicines Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Intellectual property.&#x201D; </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Strategic transformations</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to meet organizational transformation programs objectives and/or unintended adverse impacts on our business  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From time to time, we reassess our business organization to ensure we have the optimal structure with which to execute our strategy. In April 2022, we announced a new organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in October 2021 we announced the commencement of a strategic review of our Sandoz Division. After exploring all options, ranging from retaining the business to separation, on August 25, 2022, we announced our intention to separate our Sandoz Division into a new publicly traded standalone company, by way of a 100% spin-off in order to maximize shareholder value. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Sandoz.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our inability to successfully implement our new organizational structure and operating model or to successfully complete the spin-off of our Sandoz Division could have a material adverse effect on the success of the Group as a whole, and could have a material adverse effect on our results of operations and financial condition. The overall extent and pace of these organizational changes, and the additional workload and complexity for our employees in some areas, could trigger uncertainty, stress and fatigue among employees, potentially resulting in instability within the organization that could lead to failure of these organizational changes to succeed or to achieve the desired benefits. As a result, the expected benefits of these organizational changes may never be fully realized or may take longer to realize than expected.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental, social and governance matters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to meet environmental, social and governance expectations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Increasingly, in addition to financial results, companies are being judged by performance on a variety of environmental, social and governance (ESG) matters, which can contribute to the long-term sustainability of our company&#x2019;s performance. An inability to successfully perform on ESG matters and to meet societal expectations can result in negative impacts on our recruitment, retention, operations, financial results, reputation, and share price.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Topics related to large societal changes such as social inequity, access to medicines and climate change are increasingly important to a wide range of our stakeholders. For example, a variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investments in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures in making their investment decisions. Our actions related </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">12</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">to ESG topics may in the long-term therefore impact our operations and ability to achieve our strategic goals, and ultimately could have a potential negative impact on the value of Novartis. For this reason, the role of our Board of Directors and executive officers in supervising various sustainability issues is becoming increasingly important.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We actively manage a broad range of ESG matters, taking into consideration their expected impact on the sustainability of our business over time, and the potential impact of our business on society and the environment. We have created a Sustainability &amp; ESG Office, which, in coordination with the ESG Committee of the Executive Committee of Novartis, is tasked with developing our ESG strategy and tracking our performance against our ESG targets. However, considering investors&#x2019; increasing focus on ESG matters, the fast pace of change of external expectations, and a range of upcoming regulations, there can be no certainty that we will manage such issues successfully, that the ESG standards we currently use to measure our performance against will remain the same, or that we will successfully meet society or investors&#x2019; expectations.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operational risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Cybersecurity and IT systems</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cybersecurity breaches, data loss and catastrophic loss of IT systems</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We are heavily dependent on critical, complex and interdependent information technology (IT) systems, including internet&#x2011;based systems to support our business processes. We have also outsourced significant parts of our IT infrastructure to third-party providers, and we currently use these providers to perform business-critical IT services for us. We are therefore vulnerable to cybersecurity attacks and incidents on such networks and systems, whether our own or those of the third-party providers we contract, and we have experienced and may in the future experience such cybersecurity threats and attacks. Cybersecurity threats and attacks take many forms, and the size, age and complexity of our IT systems make them potentially vulnerable to external and internal security threats; outages; malicious intrusions and attacks; cybercrimes, including state-sponsored cybercrimes; malware; misplaced data, lost data or data errors; programming or human errors; or other similar events. In the context of the COVID-19 pandemic, the risk of such threats and attacks has increased, as virtual and remote working has become more widely used, and sensitive data is accessed by employees working in less secure, home-based environments. In addition, due to our reliance on third-party providers, we have experienced and may in the future experience interruptions, delays or outages in IT service availability due to a variety of factors outside of our control, including technical failures, natural disasters, fraud, or security attacks experienced by or caused by third-party providers. Interruptions in the service provided by these third parties could affect our ability to perform critical tasks.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant information security or other event, such as a disruption or loss of availability of one or more of our IT systems, whether managed by us or a third-party service provider, has previously and could in the future negatively impact important business processes, such as the conduct of scientific research and clinical trials, the submission of data and information to health authorities, our manufacturing and supply chain processes, our shipments to customers, our compliance with legal obligations, and communication between employees and with third parties. IT issues have previously led to, and could in the future lead to, the compromise of trade secrets or other intellectual property that could be sold and used by competitors to accelerate the development or manufacturing of competing products; to the compromise of personal financial and health information; and to the compromise of IT security data such as usernames, passwords and encryption keys, as well as security strategies and information about network infrastructure, which could allow unauthorized parties to gain access to additional systems or data. In addition, malfunctions in software or medical devices that make significant use of IT could lead to a risk of direct harm to patients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we have experienced some of the events described above, to date they have not had a material impact on our operations. Nonetheless, the occurrence of any of the events described above in the future could disrupt our business operations and result in enforcement actions or liability, including potential government fines and penalties, claims for damages, and shareholder litigation or allegations that the public health, or the health of individuals, has been harmed.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any significant events of this type could require us to expend significant resources beyond those we already invest to remediate any damage, to further modify or enhance our protective measures, and to enable the continuity of our business.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Fragmented IT landscape and strategic technology programs implementation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to address fragmented business processes, unclear data ownership, and IT applications and infrastructure nearing their end-of-life, may disrupt our core business processes</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on various IT systems to operate our complex global business. Historically, while highly overlapping data strategy and architectural needs exist across our businesses, in the past we built distinct solutions across both prior business units and our various geographies, which have led to a fragmented and complex landscape of IT systems.  Additionally, several of our current IT systems are reaching the end of their useful life, which, together with our fragmented IT landscape, may cause disruptions to our operational stability. As a result, we started to implement several companywide IT programs with a view toward replacing and consolidating outdated IT systems. For example, we have completed the conceptual design phase and started to build a new global Enterprise Resource Planning (ERP) system that seeks to simplify, standardize and digitize processes in our </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">13</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">commercial, finance and operations functions, thereby helping to ensure efficient and compliant business operations across our businesses and geographies, as well as the availability of high-quality data necessary to aid our decision-making. We expect the first implementation of our new ERP system to begin in the first quarter of 2024, with full implementation by 2028. In addition, we are also implementing other IT projects, seeking to simplify and standardize our processes, systems and tools, and create a unified data marketplace. Implementation and operation of the new ERP system and other IT projects involves certain risks, including a failure of the new ERP system and other IT projects to operate as expected, a failure to properly integrate with other systems we use, potential loss of data or information, compliance issues, or cost overruns and delays. Any disruptions or malfunctions of the new ERP system and other IT projects could cause critical information to be delayed, lost, defective, corrupted, or rendered inadequate or inaccessible, which could negatively impact our operations and the effectiveness of our internal controls.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Talent management</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description    </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to attract, retain and motivate qualified individuals in key roles and markets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on attracting and retaining a diverse, highly skilled workforce across our businesses and functions to achieve our business objectives. If we are unable to sustain our supply of key personnel &#x2013; including senior members of our scientific and management teams, high&#x2011;quality researchers and development specialists and skilled employees in key markets &#x2013; our ability to achieve our major business objectives may be adversely affected. In addition, our brand and reputation could be negatively impacted, and the diversity of our workforce may decline.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The market for skilled talent has become increasingly competitive, and we anticipate this trend will persist long-term. We face a challenge to attract and retain top talent in several areas, including biology, chemistry, clinical development, drug manufacturing, IT, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy and &#x201C;xRNA&#x201D;). In addition, many biotechnology companies have received significant inflows of capital and are not only competing with us to attract the same skilled talent but are also aggressively pursuing our experienced talent. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In recent years, we have adopted new ways of working that include location flexibility and increasingly recruiting from a global pool of talent. However, the success of our business continues to depend on having employees who possess local knowledge of, and experience in, our key markets. The external talent supply is especially limited in many of the geographies that are expected to be sources of growth for Novartis. In the United States, China and several other markets, the geographic mobility of talent is decreasing, as they find ample career opportunities available closer to home.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in April 2022 we announced a new, integrated organizational structure and operating model. The corporate reorganization undertaken to implement this new organizational structure has resulted in significant redundancies and senior leadership changes that may reduce morale, increase employee distraction and prompt higher voluntary turnover, any of which could negatively impact our competitiveness and ability to achieve strategic objectives. For more information on this new organizational structure see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The risks associated with the challenging external talent market and the implementation of our new organizational structure will be exacerbated if we are unable to retain and effectively develop employees and maintain an internal pipeline with critical skills, experiences, and leadership to deliver our business priorities. As a result, development, engagement, motivation, succession planning and performance rewards for our critical talent are essential to achieve our business priorities.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Third-party management </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to maintain adequate governance and oversight over third-party relationships, and failure of third parties to meet their contractual, regulatory or other obligations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We outsource the performance of certain key business functions and services to third parties. Such activities include research and development collaborations, manufacturing operations, warehousing and distribution, certain finance functions, sales and marketing activities, data management and others. Some third parties, particularly those in developing countries, do not have internal compliance systems or resources comparable to those of Novartis. As a result, our investment and efforts in relation to third party management include focusing on risk management and the oversight of such third parties.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our reliance on third parties poses certain risks, including the misappropriation of our intellectual property, the failure of the third party to comply with regulatory and quality assurance requirements, the failure of the third party to comply with environmental, anti-bribery and human rights standards and regulations, unexpected supply disruptions, breach of our agreement by the third party, and the unexpected termination or nonrenewal of our agreement by the third party.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, governments require, and the public expects, Novartis to take responsibility for and report on compliance with various human rights, responsible sourcing and environmental practices, as well as other actions of our third-party contractors around the world. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Ultimately, if third parties fail to meet their obligations to us, we may lose our investment in the relationship with the third parties or fail to receive the expected benefits of our agreements with such third parties. In addition, should any of these third parties fail to comply with the law or our standards, or should they otherwise act inappropriately while performing services for us, there is a risk that we could be held responsible for their acts, that our reputation may suffer, and that penalties may be imposed on us.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">14</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Legal, ethics and compliance</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Challenges posed by evolving legal and regulatory requirements and societal expectations regarding ethical behavior</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We must comply with the laws of all countries in which we operate, and we sell products with respect to a wide and growing range of activities. Such legal requirements are extensive and complex. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The laws and regulations relevant to the healthcare industry and applicable to us are broad in scope, are subject to change, and have evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. For example, we have been, are currently, and may in the future be, subject to various significant legal proceedings, such as private party litigation, government investigations and law enforcement actions worldwide. These types of matters may take various forms based on evolving government enforcement and private party litigation priorities, and could include, for example, matters pertaining to pricing; bribery and corruption; trade regulation and embargo legislation; product liability; commercial disputes; employment and wrongful discharge; antitrust and competition; securities; government benefit programs; reimbursement; rebates; healthcare fraud; sales and marketing practices; insider trading; occupational health and safety; environmental regulations; tax; cybersecurity; data privacy; regulatory interactions; and intellectual property. Such matters can involve civil and/or criminal proceedings and can retroactively challenge practices previously considered to be legal.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that governance for our medical and patient support activities, and our interactions with governments, public officials/institutions, healthcare professionals, healthcare organizations and patient organizations may be inadequate or fail, or that we may undertake activities based on improper or inadequate scientific justification.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division may from time to time seek approval to market a generic version of a product before the expiration of patents claimed by the marketer of the patented product. We do this in cases in which we believe the relevant patents are invalid or unenforceable, or would not be infringed by our generic product. As a result, affiliates of our Sandoz Division frequently face patent litigation, and in certain circumstances we may make the business decision to market a generic product even though patent infringement actions are still pending. Should we elect to do so and conduct a so-called &#x201C;launch at risk,&#x201D; we could face substantial damages if the final court decision is adverse to us.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legal proceedings and investigations are inherently unpredictable, and large judgments sometimes occur. Consequently, we may in the future incur judgments that could involve large payments, including the potential repayment of amounts allegedly obtained improperly, and other penalties, including treble damages. In addition, such legal proceedings and investigations, even if meritless, may affect our reputation, may create a risk of potential exclusion from government reimbursement programs in the US and other countries, and may lead to civil litigation and/or criminal exposure. As a result, having considered all relevant factors, we have in the past and may again in the future enter into major settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements, which are intended to regulate company behavior for extended periods. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information on significant legal matters pending against us, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non&#x2011;current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">New requirements may also be imposed on us due to changing government and societal expectations regarding the healthcare industry, and acceptable corporate behavior generally. For example, we are faced with laws and regulations requiring changes in how we do business, including with respect to disclosures concerning our interactions with healthcare professionals, healthcare organizations and patient organizations. These laws and regulations include requirements that we disclose payments or other transfers of value made to healthcare professionals and organizations, as well as information relating to the costs and prices for our products, which represent evolving standards of acceptable corporate behavior. These requirements may incur significant costs, including substantial time and additional resources, that are necessary to bring our interactions with healthcare professionals and organizations into compliance with these evolving standards.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to legal and regulatory requirements, we aim to meet the evolving societal expectations of the public and our investors regarding ethical behavior and the increasing importance placed on ESG matters.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To support our efforts to comply with the many requirements that impact us, we have a significant global ethics and compliance program in place, and we devote substantial time and resources to efforts to ensure that we conduct business in a lawful manner, and in line with society&#x2019;s expectations. Despite our efforts, an actual or alleged failure to comply with the law or with heightened public expectations could lead to substantial liabilities that may not be covered by insurance, or to other significant losses.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Manufacturing and product quality</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to ensure proper controls in product development and product manufacturing, and failure to comply with applicable regulations and standards</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The development and manufacture of our products is complex and heavily regulated by governmental health authorities around the world. Whether or not our products and the related raw materials are developed and manufactured at our own manufacturing sites or by third </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">15</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">parties, we must ensure that all development and manufacturing processes comply with regulatory requirements, as well as our own quality standards in order to deliver novel therapies to patients with unmet needs while ensuring patient safety. Failure to comply with regulatory requirements has resulted in, and may in the future result in, warning letters, suspension of manufacturing, seizure of products, injunctions, product recalls, failure to secure product approvals, or debarment. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In recent years, global health authorities have substantially intensified their scrutiny of manufacturers&#x2019; compliance with regulatory requirements. Any significant failure by us or our third-party suppliers to comply with regulatory requirements, or with health authorities&#x2019; expectations, may create the need to suspend clinical trials, shut down production facilities or production lines, and recall commercial products. A failure to fully comply with regulatory requirements could also lead to a delay in the approval of new products, an inability to ship or import our products, and significant penalties and reputational harm.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the technically complex manufacturing processes required to manufacture many of our products increase the risk of both production failures and product recalls and can increase the cost of producing our goods. Some of our products require a supply of highly specialized raw materials, such as cell lines, tissue samples, bacteria, viral strains and radioisotopes. In addition, we manufacture and sell a number of sterile products, biologic products and products that involve advanced therapy platforms, such as CAR-T therapies, gene therapies and radioligand therapy products, all of which are particularly complex and involve highly specialized manufacturing technologies. As a result, even slight deviations at any point in their production processes or in material used have led to, and may in the future lead to, production failures or recalls. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B. Business overview&#x2014;Sandoz&#x2014;Production.&#x201D; </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Supply chain</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to maintain continuity of product supply</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our products are produced using technically complex manufacturing processes and require a supply of highly specialized raw materials. For some of our products and raw materials, we may rely on a single source of supply. In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and &#x201C;xRNA&#x201D;, all of which are particularly complex and involve highly specialized manufacturing technologies. Due to this complexity, there is a risk of production and supply of critical raw materials failures, which may result in supply interruptions or product recalls due to manufactured products not meeting required specifications.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, due to the inherent complexities of our manufacturing processes and the supply chains for advanced therapy platforms, we are required to plan our production activities and purchase of materials well in advance. If we suffer from third-party raw material shortages, underestimate market demand for a product, or fail to accurately predict when a new product will be approved for sale, then we may not be able to produce sufficient product to meet demand. These issues could be made worse during a pandemic, such as the COVID-19 pandemic, or geopolitical events, such as  the war in Ukraine, and could lead to (i) a sudden increase in demand for selected medicinal products, resulting in the short-term unavailability of critical materials; (ii) logistical and supply challenges that may lead to our inability to ship products from one place to another due to restrictions imposed as a result of a pandemic or geopolitical events and any related sanctions, which can also impact transportation and warehousing costs; or (iii) our inability to properly operate a manufacturing site due to restrictions imposed as the result of a pandemic or any issues arising from geopolitical events.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our or our third-party suppliers&#x2019; inability to manage such issues could lead to shutdowns, product shortages, or to us being entirely unable to supply products to patients for an extended period of time. Furthermore, as our products are intended to promote the health of patients, such shortages or shutdowns could endanger our reputation and have led to, and could continue to lead to, significant losses of sales revenue, potential litigation or allegations that the public health, or the health of individuals, has been harmed.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Data privacy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Noncompliance with personal data protection laws and regulations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We operate in an environment that relies on the collection, processing, analysis and interpretation of large sets of patients and other individuals&#x2019; personal information, including via social media and mobile technologies. In addition, the operation of our business requires data to flow across the borders of numerous countries in which there are different, potentially conflicting, and frequently changing, data privacy laws in effect. Examples of such laws include: the EU General Data Protection Regulation (GDPR), which took effect in May 2018; the California Consumer Privacy Act, which took effect in January 2020; Brazil&#x2019;s General Personal Data Protection Law, which entered into force in September 2020; and the Personal Information Protection Law in China, which took effect in November 2021. Such laws impose stringent requirements on how we and third parties with whom we contract collect, share, export or otherwise process personal information, and provide for significant penalties for noncompliance. Breaches of our systems or those of our third-party contractors, or other failures to protect the data we collect from misuse or breach by third parties, could expose such personal information to unauthorized persons.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Events involving the substantial loss of personal information, use of personal information without a legal basis, or other privacy violations could give rise to significant liability, reputational harm, damaged relationships with business partners, and potentially substantial monetary </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">16</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">penalties and other sanctions under laws enacted or being enacted around the world. Such events could also lead to restrictions on our ability to use personal information and/or transfer personal information across country borders. In addition, there is a trend of increasing divergence of data privacy legal frameworks, not only across these frameworks but also within individual legal frameworks themselves. This divergence may constrain the implementation of global business processes and may lead to different approaches on the use of health data for scientific research, which may have a negative impact on our business and operations.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Falsified medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of falsified medicines on patient safety, and reputational and financial harm to Novartis and our products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We continue to be challenged by the vulnerability of distribution channels to falsified medicines, which include counterfeit, stolen, tampered and illegally diverted medicines as defined by the World Health Organization. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Falsified medicines pose patient safety risks and can be seriously harmful or life-threatening. Reports of adverse events related to falsified medicines and increased levels of falsified medicines in the healthcare system affect patient confidence in genuine medicines and in healthcare systems in general. These events could also cause us substantial reputational and financial harm, and potentially lead to litigation if the adverse event from the falsified medicine is mistakenly attributed to the genuine one. Stolen or illegally diverted medicines that are not properly stored and later sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. Furthermore, there is a direct financial loss when, for example, falsified medicines replace sales of genuine medicines, or genuine medicines are recalled following the discovery of falsified products.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Emerging risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Geopolitical developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of geo- and socio-political threats</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Challenging political conditions currently exist in various parts of the world, including an economic downturn; risk of direct conflicts between nations, such as the war in Ukraine; a global pandemic; resistance in certain areas against free trade; anti-corporate sentiment; and social unrest.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The imposition of tariffs, including those imposed by the US and China, and the possibility of additional tariffs or other trade restrictions relating to trade could have a material negative impact on our business. Given that the outcome of ongoing trade negotiations remains uncertain, we cannot yet determine the nature or extent of the potential impact on our business. For example, if tariffs on pharmaceutical products or active pharmaceutical ingredients (APIs) were increased, this could impact the profitability of our products and disrupt our supply chain. Increasing opposition to free trade may increase the risks we face in our efforts to improve and harmonize standards in regulation and intellectual property.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, significant conflicts continue in certain parts of the world. Collectively, such unstable conditions could, among other things, disturb the international flow of goods and increase the costs and difficulties of international transactions, which could in turn significantly impact time to market and our ability to supply our products to patients in an undisrupted fashion, and further erode reimbursement levels for innovative therapies.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Macroeconomic developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of macroeconomic developments</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our business may be impacted by deteriorating macroeconomic and financial conditions directly affecting consumers. Given that patients, in many countries, directly pay a sizable portion of their own healthcare costs, there is a risk that consumers may cut back on prescription drugs due to financial constraints. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Negative macroeconomic developments may also adversely affect the ability of payers, as well as our distributors, customers, suppliers, and service providers, to pay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us. Although we make efforts to monitor the financial condition and liquidity of these third parties, our ability to do so is limited, and some of them may become unable to pay their bills in a timely manner or may even become insolvent. These risks may be elevated with respect to our interactions with fiscally challenged government payers, or with third parties with substantial exposure to such payers.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the same time, significant changes, and potential future volatility in financial markets, the consumer and business environment, the competitive landscape, and the global political and security landscape make it increasingly difficult for us to predict our revenues and earnings. As a result, any revenue or earnings guidance or outlook that we have given or might give may be overtaken by events or may otherwise prove to be inaccurate. Although we endeavor to give reasonable estimates of future revenues and earnings at the time at which we give such guidance, based on then&#x2011;current knowledge and conditions, there is a risk that such guidance or outlook will prove to be incorrect. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Asset price corrections in financial markets may also result in lower returns on our financial investments. In addition, pricing pressures in developed markets resulting from efforts to reduce the cost of healthcare (e.g., the Inflation Reduction Act in the US, which targets drug prices) may have a negative impact on our revenue and our net sales. In addition, inflation has an impact on our operating costs due to the increased cost of supplies. Higher costs for energy, raw materials, wages, and capital will increase our operating costs, potentially reducing our net sales.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">17</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Uncertainties around future central bank and other economic policies in the US and EU, as well as high debt levels in some countries could also impact world trade. Sudden increases in economic, currency or financial market volatility in different countries, such as the recent appreciation of the US dollar, have also impacted, and may continue to have an unpredictable impact on our business, or results of operations, including the conversion of our operating results into our reporting currency, the US dollar, as well as the value of our investments in our pension plans. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a discussion on the effect of price controls on our business, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B&#x2014;Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; See also &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency fluctuations,&#x201D; &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Condensed consolidated balance sheets,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Climate change</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of climate change and increased risk of major natural disasters</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to a broad range of climate risks such as transition risks (e.g., regulatory frameworks, carbon pricing, and the cost of and access to capital) and physical risks (e.g., heat, water scarcity, sea level rise, and flooding from severe weather events), which could vary in magnitude and impact across different countries. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Climate change has triggered, and may continue to trigger, the adoption of new regulatory requirements across the globe. To comply with such legislation, we may be required to increase our investment in technology to reduce our energy use, water use and greenhouse gas emissions. In addition, legislative and regulatory action, both current and in the future, includes or could include carbon pricing, climate risk related disclosures, and changes in zoning or building codes to increase climate resilience. As a result, the combined impact of these transition risks could increase our direct operating costs and impact our supply chain. We have also committed to incorporating the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) framework into our business, which includes providing qualitative and quantitative disclosures on climate-related topics on a recurring basis. As a result of these transition risks, we are committed to becoming carbon neutral in our own operations by 2025, and carbon neutral across our value chain by 2030. In addition, we are committed to achieving net zero across our value chain by 2040. Any failure to achieve these commitments in the expected time frame, or at all, could result in negative impacts on our reputation, our operations, and the price of our shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Climate change has created, and will continue to create, physical risks to our business. Some of our production facilities that depend on the availability of significant water supplies are located in areas where water is increasingly scarce. Other facilities are located in areas that, due to increasingly violent weather events, rising sea levels, or both, are increasingly at risk of substantial flooding. In regions where such a risk is present, this has an impact not only on our own operations but also our distributed supply chain. Such events may result in the loss of life, increased costs, business interruptions, destruction of facilities, and disruption to healthcare systems that patients use to access our medicines.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, our corporate headquarters, the headquarters of our Innovative Medicines and Sandoz Divisions, and a number of major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world. A major earthquake could result in loss of life, business interruptions and the destruction of our facilities.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Tax laws and developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in tax laws or their application</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. Changes in tax laws or in their application could lead to an increased risk of international tax disputes and an increase in our effective tax rate, which could adversely affect our financial results. The integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing. Most of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untried and can be expected to be very lengthy. Accruals for tax contingencies are made based on experience, interpretations of tax law, and judgments about potential actions by tax authorities. However, due to the complexity of tax contingencies, the ultimate resolution of any tax matter may result in payments materially different from the amounts accrued. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the Organization for Economic Co-operation and Development (OECD) launched a new initiative on behalf of the G20 to minimize profit shifting by working toward a global tax framework that ensures that corporate income taxes are paid where consumption takes place, in addition to introducing a global standard on minimum taxation combined with new tax dispute resolution processes. This project achieved OECD political consensus in October 2021, and the detailed principles are still under discussion by the OECD and political leaders. The OECD expects that the implementation of these new principles will begin globally in 2024. Once changes to the tax laws in any jurisdiction in which the Group </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">18</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">operates are enacted or substantially enacted, the Group may be subject to the OECD top-up tax, the aim of which is to bring the total amount of taxes paid on our profit in a jurisdiction up to a minimum rate of 15%. In 2020, the EU announced that it would introduce new centralized taxation powers (which have not yet been introduced) to address the financial impact of the COVID-19 pandemic. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, together with the related investigation into member states&#x2019; practices regarding the issuance of rulings on tax matters relating to individual companies. Although we have taken steps to comply with evolving initiatives such as these of the OECD and the EU, and we will continue to do so, significant uncertainties remain as to the outcome of our efforts. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 6. Income taxes&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities.&#x201D; </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Indebtedness</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our indebtedness could adversely affect our operations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, we had USD 20.2 billion of non&#x2011;current financial debt, and USD 5.9 billion of current financial debt. Our current and long&#x2011;term debt requires us to dedicate a portion of our cash flow to service interest and principal payments and, if interest rates rise, this amount may increase. As a result, our existing debt may limit our ability to use our cash flow to fund capital expenditures, to engage in transactions, or to meet other capital needs, or otherwise may place us at a competitive disadvantage relative to competitors that have less debt. Our debt could also limit our flexibility to plan for and react to changes in our business or industry, and increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy. We may also have difficulty refinancing our existing debt or incurring new debt on terms that we would consider to be commercially reasonable, if at all.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Goodwill and intangible assets</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill and intangible assets resulting in significant impairment charges</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We carry a significant amount of goodwill and other intangible assets on our consolidated balance sheet, including, in particular, substantial goodwill and other intangible assets obtained through acquisitions, including most recently through our acquisitions of Gyroscope Therapeutics, The Medicines Company, <i>Xiidra</i>, Endocyte, Novartis Gene Therapies, and AAA. As a result, we may incur significant impairment charges in the future if the fair value of the intangible assets and the groupings of cash-generating units containing goodwill would be less than their carrying value on the Group&#x2019;s consolidated balance sheet at any point in time.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We regularly review our intangible and tangible assets for impairment, including identifiable intangible assets and goodwill. Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. In 2022, for example, we recorded intangible asset impairment charges of USD 1.3 billion. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a detailed discussion of how we determine whether an impairment has occurred, what factors could result in an impairment, and the impact of impairment charges on our results of operations, see Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Foreign currency exchange rates</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Negative effect on financial results due to foreign currency exchange rate fluctuations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in exchange rates between the US dollar, our reporting currency, and other currencies can result in significant increases or decreases in our reported sales, costs and earnings as expressed in US dollars, and in the reported value of our assets, liabilities and cash flows.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to ordinary market risk, there is a risk that countries could take affirmative steps that could significantly impact the value of their currencies. Such steps could include &#x201C;quantitative easing&#x201D; measures and potential withdrawals by countries from common currencies. In addition, countries facing local financial difficulties, including countries experiencing high inflation rates, and highly indebted countries facing large capital outflows, may impose controls on the exchange of foreign currency. Currency exchange controls and sanctions could limit our ability to distribute retained earnings from our local affiliates, or to pay intercompany payables due from those countries. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite measures undertaken to reduce or hedge against foreign currency exchange risks, as a significant portion of our earnings and expenditures are in currencies other than the US dollar, including expenditures in Swiss francs that are significantly higher than our revenue in Swiss francs, any such exchange rate volatility may negatively and materially impact our results of operations and financial condition, and may impact the reported value of our net sales, earnings, assets and liabilities. In addition, the timing and extent of such volatility can be difficult to predict. Furthermore, depending on the movements of particular foreign exchange rates, we may be materially adversely affected at a time when the same currency movements are benefiting some of our competitors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on the effects of currency fluctuations on our consolidated financial statements and on how we manage currency risk, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">19</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">fluctuations&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key customers</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ongoing consolidation among our distributors and retailers, and the concentration of credit risk</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A significant portion of our global sales is made to a relatively small number of drug wholesalers, retail chains and other purchasing organizations. For example, our three most important customers globally accounted for approximately 16%, 11% and 7%, respectively, of net sales in 2022. The largest trade receivables outstanding were for these three customers, amounting to 16%, 14% and 7%, respectively, of the Group&#x2019;s trade receivables at December 31, 2022. The trend has been toward further consolidation among some distributors and retailers. As a result, we may be affected by fluctuations in the buying patterns of such customers. Furthermore, these customers are gaining additional purchasing leverage, increasing the pricing pressures facing our businesses. These pressures can impact our Sandoz Division in particular, the generic products of which can often be obtained from numerous competitors. Moreover, we are exposed to a concentration of credit risk as a result of this concentration among our customers. If one or more of our major customers experienced financial difficulties, the effect on us would be substantial, and could include a substantial loss of sales and an inability to collect amounts owed to us.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental matters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of environmental liabilities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The environmental laws of various jurisdictions impose actual and potential obligations on us to investigate and remediate contaminated sites, including in connection with activities in the past by businesses that are no longer part of Novartis. In some cases, these remediation efforts may take many years. While we have set aside provisions for known worldwide environmental liabilities that are probable and estimable, there is no guarantee that additional costs will not be incurred beyond the amounts for which we have provided in the Group consolidated financial statements. If environmental contamination resulting from our facility operations, business activities or products adversely impacts third parties or if we fail to properly manage the safety of our facilities, including the safety of our employees and contractors, and the environmental risks, we may face substantial one-time and recurring costs and other penalties, and be required to increase our provisions for environmental liabilities. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">See also &#x201C;Item 4. Information on the Company&#x2014;Item 4.D Property, plants and equipment&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non&#x2011;current liabilities.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pension plans   </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inaccuracies in the assumptions and estimates used to calculate our pension plan and other post-employment obligations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former employees. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the discount rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates that we use may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. Depending on events, such differences could have a material effect on our total equity, and may require us to make additional contributions to our pension funds.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 18. Financial Statements&#x2014;Note 25. Post-employment benefits for employees.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">20</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00311562"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4.  Information on the Company</p>
      <div id="anchorId00311565"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.A History and development of Novartis</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis AG</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG was incorporated on February&#xA0;29, 1996, under the laws of Switzerland as a stock corporation (&#x201C;Aktiengesellschaft&#x201D;) with an indefinite duration. On December&#xA0;20, 1996, our predecessor companies, Ciba&#x2011;Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. We are domiciled in and governed by the laws of Switzerland. Our registered office is located at the following address:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lichtstrasse 35</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">CH&#x2011;4056 Basel, Switzerland</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Telephone: +41&#x2011;61&#x2011;324&#x2011;1111</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Web: www.novartis.com</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. Novartis AG, our Swiss holding company, owns, directly or indirectly, all of our significant operating companies. For a list of our significant operating subsidiaries, see &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For a description of important corporate developments since January 1, 2020, see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D; For information regarding the Company&#x2019;s material commitments for capital expenditures, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Liquidity and Capital Resources&#x2014;Material short- and long-term cash requirements.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The SEC maintains an internet site at http://www.sec.gov that contains reports, information statements, and other information regarding issuers that file electronically with the SEC.</div>
      <div id="anchorId00311596"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.B Business overview</p>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our Company. Our vision is to become the most valued and trusted medicines company in the world. Our strategy is to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in research and development (R&amp;D) and novel access approaches. To support this strategy, we have clear focus areas and priorities, ensuring we deliver on our purpose and continue to create value for both stakeholders and society. See, &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating Results&#x2014;Overview&#x2014;Our strategy.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, Novartis achieved net sales from continuing operations of USD 50.5&#xA0;billion, and total net income amounted to USD 7.0 billion. Headquartered in Basel, Switzerland, our Group companies employed approximately 102 000 full&#x2011;time equivalent employees as of December&#xA0;31, 2022. Our products are sold in approximately 140 countries around the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group comprises two global operating divisions:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> &#xA0;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Innovative Medicines: innovative patent&#x2011;protected prescription medicines</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">For a description of our Innovative Medicines Division, see &#x201C;&#x2014;Innovative Medicines&#x2014;Overview&#x201D; below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sandoz: generic pharmaceuticals and biosimilars</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">For a description of our Sandoz Division, see &#x201C;&#x2014;Sandoz&#x201D; below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In April 2022, we announced a new, integrated organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. As part of this new organizational structure, we have integrated our former Pharmaceuticals and Oncology business units and created two separate commercial organizations&#x2014;Innovative Medicines US and Innovative Medicines International. The Innovative Medicines Division focuses on five core therapeutic areas&#x2014;cardiovascular, immunology, neuroscience, solid tumor, and hematology&#x2014;as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. For more information, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Innovative Medicines.&#x201D; We have also created a new Strategy and Growth function that combines corporate strategy, R&amp;D portfolio strategy and business development. The purpose of our Strategy and Growth function is to help drive the company&#x2019;s growth strategy </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">21</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">end-to-end and look across internal and external opportunities to strengthen the Novartis pipeline with medicines that are both transformational and can make significant contributions to growth. Finally, we have combined our former Novartis Technical Operations and Customer &amp; Technology Solutions units to create a new operations unit called Operations. This new unit seeks to provide a stronger and simpler operational backbone that can accelerate multiple technology transformation initiatives more efficiently, create novel digital solutions at scale, and increase productivity, while maintaining industry-leading quality and service levels.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under this new organizational structure, our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research (NIBR), Global Drug Development (GDD), and Operations. The financial results of these organizational units are included in the results of the divisions for which their work is performed. For more information about NIBR, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Research program&#x201D; below. For more information about GDD, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Development program&#x201D; below. For more information about Operations, see &#x201C;&#x2014;Item 4.D Property, plants and equipment&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate activities</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
      <div id="anchorId00311660"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Innovative Medicines</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division is a world leader in offering patent-protected medicines to patients and physicians. The Innovative Medicines Division researches, develops, manufactures, distributes and sells patented pharmaceuticals. The Innovative Medicines Division is organized into two commercial organizational units&#x2014;Innovative Medicines US and Innovative Medicines International. These units were created in April 2022 as part of our new, integrated organizational structure. Prior to April 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines Division focuses on core therapeutic areas&#x2014;cardiovascular, immunology, neuroscience, solid tumor, and hematology&#x2014;as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines Division is the larger of our two divisions in terms of consolidated net sales. It reported consolidated net sales of USD 41.3 billion in 2022, which represented 81.7% of the Group&#x2019;s net sales. The product portfolio of the Innovative Medicines Division includes a significant number of key marketed products, many of which are among the leaders in their respective therapeutic areas.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division products</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following summaries describe certain key marketed products in our Innovative Medicines Division, listed according to year-end net sales within each therapeutic area or reporting category. Some of the products described below have lost patent protection or are otherwise subject to generic competition. Others are subject to patent challenges by potential generic competitors. Please see &#x201C;&#x2014;Intellectual property&#x201D; for general information on intellectual property and regulatory data protection, and for more information on the status of patents and exclusivity for Innovative Medicines Division products.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While we typically seek to sell our marketed products throughout the world, not all products and indications are available in every country. The indications described in these summaries may therefore vary by country. In addition, a product may be available under different brand names depending on country and indication.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key marketed products</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Cardiovascular </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Entresto </i>(sacubitril/valsartan) is an oral, first&#x2011;in&#x2011;class angiotensin receptor neprilysin inhibitor. <i>Entresto</i> enhances the protective effects of a hormone system called the natriuretic peptide system, and simultaneously suppresses the harmful effects of a hormone system called the renin&#x2011;angiotensin&#x2011;aldosterone system. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US, the EU and other countries to treat adults who have symptomatic heart failure with reduced ejection fraction (HFrEF). HFrEF is a disease in which the heart cannot pump enough blood. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat most heart failure patients with preserved ejection fraction (HFpEF). HFpEF is another disease in which the heart cannot pump enough blood.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat children aged 1 year and older who have symptomatic heart failure with systemic left ventricular systolic dysfunction</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">22</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In China and Japan to treat patients with essential hypertension (a type of high blood pressure)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Leqvio</i> (inclisiran) is the first and only small-interfering RNA therapy to reduce LDL cholesterol, a risk factor for atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries. <i>Leqvio</i> is administered by a healthcare professional twice a year as an injection, following an initial dose and a dose at three months. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU and other countries to treat adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia. In patients unable to reach LDL cholesterol goals, <i>Leqvio</i> is used in combination with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated. Primary hypercholesterolemia and mixed dyslipidemia are disorders characterized by high levels of fats in the blood.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults with clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy, who require additional lowering of LDL cholesterol. HeFH is an inherited disorder that causes dangerously high levels of LDL cholesterol. (The effect of <i>Leqvio</i> on cardiovascular morbidity and mortality has not yet been determined).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis obtained global rights to develop, manufacture and commercialize <i>Leqvio</i> under a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Immunology</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Cosentyx</i> (secukinumab) is an injectable, fully human monoclonal antibody that selectively inhibits interleukin-17A (IL&#x2011;17A), a cytokine involved in several immunological diseases. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 6 years and older with moderate&#x2011;to&#x2011;severe plaque psoriasis. Psoriasis is a debilitating systemic inflammatory disease that is characterized by the appearance of raised, red patches on the skin.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with active ankylosing spondylitis (AS). AS is a progressive inflammatory disease that is characterized by chronic back pain, is generally visible on X-rays, and can cause structural damage to the bones and joints.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with active non-radiographic axial spondyloarthritis (nr-axSpA). This is a long-term inflammatory disease that is characterized by chronic back pain and is not visible on X-rays.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children (aged 2 years and older in the US and 6 years and older in the EU) with active psoriatic arthritis (PsA). PsA is a type of progressive inflammatory arthritis that results in swollen and painful joints and tendons, which can cause structural damage to the bones and joints.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Children (aged 4 years and older in the US and 6 years and older in the EU) with enthesitis-related arthritis (ERA) and children (aged 2 years and older in the US and 6 years and older in the EU) with juvenile psoriatic arthritis (JPsA). ERA and JPsA are subtypes of juvenile idiopathic arthritis. If left untreated, they can lead to high levels of pain and disability.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Xolair </i>(omalizumab) is an injectable prescription medicine and the only approved antibody designed to target and block immunoglobulin E (IgE). It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 6 years and older with moderate&#x2011;to&#x2011;severe, or severe, persistent allergic asthma </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 12 years and older with chronic spontaneous urticaria/chronic idiopathic urticaria (hives)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with nasal polyps or severe chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a chronic inflammation of the nose and the sinuses with the presence of benign lesions (nasal polyps) on the lining of the nasal sinuses or nasal cavity.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Xolair</i> is provided as lyophilized powder for reconstitution, and as liquid formulation in a pre&#x2011;filled syringe. Novartis co-promotes <i>Xolair</i> with Genentech in the US and shares a portion of operating income, but Novartis does not record any US sales. Novartis records all sales of <i>Xolair</i> outside the US. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 27. Transactions with related parties&#x2014;Roche Holding AG.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Ilaris</i> (canakinumab) is an injectable, selective, high-affinity, fully human monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), a key cytokine in the inflammatory pathway. It is approved in the US, the EU and other countries to treat patients with certain debilitating autoinflammatory disorders, including:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children with periodic fever syndromes. Periodic fever syndromes are a set of rare disorders characterized by recurrent episodes of illness, with fever as the main symptom.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with Still&#x2019;s disease, including systemic juvenile idiopathic arthritis and adult-onset Still&#x2019;s disease. Still&#x2019;s disease is a disorder that causes fevers, rash and joint pain.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with acute gouty arthritis. Gouty arthritis is a type of arthritis characterized by pain, redness, tenderness and swelling in one or more joints.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Neuroscience</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Gilenya</i>  (fingolimod) is an oral sphingosine-1-phosphate (S1P) receptor modulator that inhibits the movement of lymphocytes (a type of white blood cell) out of the lymph nodes into the central nervous system, thereby preventing nerve inflammation and nervous tissue damage. It is approved:  </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults and children aged 10 years and older with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">23</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#xA0;&#xA0;sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU to treat adults and children aged 10 years and older who have highly active RRMS despite treatment with at least one disease-modifying agent, or who have rapidly evolving severe RRMS </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Gilenya</i> is licensed from Mitsubishi Tanabe Pharma Corporation.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Zolgensma</i> (onasemnogene abeparvovec) is a one-time intravenous gene therapy designed to address the genetic root cause of spinal muscular atrophy (SMA) by replacing the function of the missing or nonworking SMN1 gene. <i>Zolgensma</i> delivers a new working copy of the SMN1 gene into a patient&#x2019;s cells. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Babies and young children who have SMA with biallelic mutations in the SMN1 gene. SMA is a rare, genetic neuromuscular disease resulting in the progressive and irreversible loss of motor neurons, which causes muscle weakness and atrophy.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kesimpta</i> (ofatumumab) is an anti-CD20 monoclonal antibody that enables the targeted depletion of B-cells, specifically in lymph nodes. <i>Kesimpta</i> is self-administered as a once-monthly injection via the <i>Sensoready</i> autoinjector pen. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU to treat adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features (i.e., relapse, disability, or lesions detected by MRI scans)  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary across other countries. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline (GSK). Novartis obtained the rights to ofatumumab from GSK across all indications.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Solid Tumor</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tafinlar</i> + <i>Mekinist</i> (dabrafenib + trametinib) is an oral combination therapy. <i>Tafinlar</i> and <i>Mekinist</i> are kinase inhibitors of the BRAF and MEK1/2 proteins, respectively, approved in combination in the US, the EU and other countries to treat patients who have certain types of cancer with a change in the BRAF gene (called a BRAF V600 mutation), including: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Melanoma is a form of skin cancer; unresectable melanoma cannot be removed with surgery and metastatic melanoma has spread to other parts of the body. <i>Tafinlar</i> and <i>Mekinist</i> are also approved as single agents for this indication.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with stage III melanoma with a BRAF V600 mutation as an adjuvant treatment (following surgery)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. NSCLC is the most common type of lung cancer. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600 mutation whose cancer has progressed following treatment, and who have no satisfactory alternative treatment options (US). ATC is a rare and aggressive form of thyroid cancer. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. Novartis has worldwide exclusive rights to develop, manufacture and commercialize trametinib granted by Japan Tobacco Inc.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kisqali</i> (ribociclib) is a selective oral cyclin&#x2011;dependent inhibitor of kinases 4 and 6 (CDK4/6) with somewhat greater inhibitory activity against CDK4 vs CDK6 &#x2013; the two enzymes involved in the control of cell cycle progression. <i>Kisqali</i> is approved in the US, the EU and other countries to treat: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pre-, peri- and postmenopausal women, and men (US), with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine&#x2011;based therapy. HR+/HER2- breast cancer is the most common subtype of breast cancer.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pre-, peri- (EU) and postmenopausal women, and men (US), with HR+/HER2- locally advanced or metastatic breast cancer, in combination with fulvestrant, as first- or second-line therapy</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Kisqali</i> was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Piqray</i> (alpelisib) is an oral kinase inhibitor that specifically targets the PIK3CA gene. This is the most commonly mutated gene in HR+/HER2- breast cancer, the most common subtype of breast cancer. <i>Piqray</i> is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Postmenopausal women, and men, with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer with a PIK3CA mutation. It is used in combination with fulvestrant after disease progression while on or following an endocrine-based regimen (US), or after disease progression following endocrine therapy as monotherapy (EU).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Pluvicto</i> (lutetium (<sup>177</sup>Lu) vipivotide tetraxetan) is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177). <i>Pluvicto</i> delivers radiation selectively to PSMA-positive cells and the surrounding cells. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with a type of advanced cancer that has spread to other parts of the body (metastatic) called prostate-specific membrane antigen&#x2013;positive </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">24</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#xA0;&#xA0;metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) who have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Hematology</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Promacta</i>/<i>Revolade</i> (eltrombopag) is a once&#x2011;daily oral thrombopoietin receptor agonist that works by stimulating bone marrow cells to produce platelets. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Immune thrombocytopenia (ITP) in patients who have had an insufficient response to or have failed previous therapies. ITP is a bleeding disorder caused by an unusually low number of platelets. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Thrombocytopenia in patients with chronic hepatitis C to allow them to initiate and maintain interferon&#x2011;based therapy</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with severe aplastic anemia (SAA). SAA is a condition in which the body does not produce enough blood cells</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Promacta</i>/<i>Revolade</i> is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tasigna</i> (nilotinib) is a twice-daily oral tyrosine kinase inhibitor that acts by blocking the BCR-ABL protein. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic and/or accelerated phase who are resistant or intolerant to existing treatment. Ph+ CML is a cancer that starts in the blood-forming cells of bone marrow.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Newly diagnosed adults and children with Ph+ CML in the chronic phase </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Jakavi</i> (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. It is the first therapy approved in the EU and other countries to treat: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. MF is a rare blood cancer characterized by abnormal blood cell production and scarring in the bone marrow, which can lead to an enlarged spleen.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with polycythemia vera (PV) who are resistant or intolerant to a medication called hydroxyurea. PV is a rare blood cancer in which the bone marrow produces too many red blood cells, resulting in serious problems like clots.   </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients aged 12 years and older with acute or chronic graft-versus-host disease (GvHD) and who have had an inadequate response to corticosteroids or other systemic therapies. GvHD occurs in stem-cell transplant patients when donor cells see the recipient&#x2019;s healthy cells as foreign and attack them.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and graft-versus-host disease outside the US. Incyte Corporation markets ruxolitinib as Jakafi<sup>&#xAE;</sup> in the US. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Scemblix</i> (asciminib) is an oral kinase inhibitor that works by binding to the ABL myristoyl pocket. It is approved: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US, the EU and other countries to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have previously been treated with two or more tyrosine kinase inhibitors (TKIs). CML is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. There are three phases of CML: chronic phase, accelerated phase and blast phase. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat adults with Ph+ CML in chronic phase with the T315I mutation. Some patients with CML develop mutations that cause resistance to TKI therapy, including the T315I mutation, which confers resistance to most available TKIs. As a result, patients with this mutation have limited treatment options.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Other Promoted Brands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>Lucentis</i> (ranibizumab) is a humanized, high-affinity antibody fragment that binds to vascular endothelial growth factor A (VEGF&#x2011;A), a protein that can cause the growth of blood vessels in the eye, potentially leading to vision loss. <i>Lucentis</i> is an anti-VEGF therapy that is injected into the eye. It is approved in the EU and other countries to treat patients with certain eye conditions, including:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with neovascular (wet) age&#x2011;related macular degeneration (AMD). Wet AMD develops when abnormal blood vessels grow under the macula and leak blood and other fluids in the back of the eye, which damages the macula.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with proliferative diabetic retinopathy, moderately severe to severe non-proliferative diabetic retinopathy, and/or diabetic macular edema. These conditions are complications of diabetes.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Adults with visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). Retinal vein occlusion&#xA0;is a blockage of the branch or central retinal veins, which carry blood away from the retina.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Lucentis</i> is licensed from Genentech, and Novartis holds the rights to commercialize the product outside the US. Genentech holds the rights to commercialize <i>Lucentis</i> in the US. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 27. Transactions with related parties&#x2014;Roche Holding AG.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Xiidra</i> (lifitegrast 0.5%), an LFA-1 antagonist, is a prescription eye drop designed to block the interaction of two key proteins called ICAM-1 and LFA-1, thereby reducing inflammation. It is approved in the US and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The signs and symptoms of dry eye disease in adults</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">25</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Established Brands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Sandostatin</i> SC (octreotide acetate for injection) and <i>Sandostatin</i> LAR (octreotide acetate for injectable suspension) are somatostatin analogs approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with acromegaly that is inadequately controlled by surgery or radiotherapy. Acromegaly is a chronic disease caused by the oversecretion of growth hormone.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with certain symptoms associated with carcinoid tumors and other types of functional gastrointestinal and pancreatic neuroendocrine tumors</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> LAR is also approved in the EU and other countries to treat patients with advanced neuroendocrine tumors of the midgut or of unknown primary tumor origin. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the key Innovative Medicines Division projects currently in the Confirmatory Development stage and may also describe certain projects in the Exploratory Development stage. Projects typically enter Confirmatory Development and become the responsibility of our Global Drug Development organization during Phase II testing. (For more information about our drug development program, see &#x201C;&#x2014;Research and development&#x2014;Development program.&#x201D;) Projects are listed in alphabetical order by compound code, or by product name where applicable. Projects include those seeking to develop potential uses of new molecular entities as well as potential additional indications or new formulations for already marketed products. The table below, entitled &#x201C;Projects removed from the development table since 2021,&#x201D; highlights changes to the table entitled &#x201C;Selected development projects&#x201D; from the previous year.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The year that each project entered the current phase of development refers to the year of the first patient&#x2019;s first visit in the first clinical trial of that phase. For projects in Phase II, the year refers to the first patient&#x2019;s first visit in the first Phase II trial, which can occur before the Confirmatory Development stage. Prior to 2020, we reported the current phase based on the year in which the decision to enter the phase was made. To maintain continuity, we have included certain previously disclosed projects, noted below, that have not yet achieved &#x201C;first patient, first visit&#x201D; in any Phase I-III study for the reported indication and route of administration. We have disclosed these projects using our previous reporting criteria.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> A reference to a project being in registration means that an application has been submitted to a health authority for marketing approval. Compounds and new indications in development are subject to required regulatory approvals and, in certain instances, contractual limitations. These compounds and indications are in various stages of development throughout the world. It may not be possible to obtain regulatory approval for any or all of the new compounds and new indications referred to in this Form&#xA0;20&#x2011;F in any country or in every country. See &#x201C;&#x2014;Regulation&#x201D; for more information on the approval process.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">26</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Selected development projects </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Compound/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Common <br /> name</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Mechanism <br /> of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Formulation/<br /> route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br /> entered<br /> current<br /> development<br /> phase</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Planned filing<br /> dates/current<br /> phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">AVXS-101<br />(OAV101)</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> onasemno-<br /> gene abepar-<br /> vovec</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Survival motor neuron <br /> (SMN) gene therapy<br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br /> (IT formulation)<br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intrathecal injection<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Beovu</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> brolucizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEGF inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic retinopathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CFZ533</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iscalimab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CD40 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Coartem</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> artemether + <br /> lumefantrine<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PGH-1 (artemisinin <br /> combination therapy)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, <br /> uncomplicated <br /> (&lt;5 kg patients)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Cosentyx</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> secukinumab<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL&#x2011;17A inhibitor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hidradenitis suppurativa<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US/EU <br /> registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Giant cell arteritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lupus nephritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriatic arthritis (IV formulation)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis (IV formulation)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JDQ443</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRAS inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer, 2/3L<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAE609</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> cipargamin</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PfATP4 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, severe</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAF156</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ganaplacide<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-artemisinin<br /> plasmodium<br /> falciparum inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Kisqali</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ribociclib<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CDK4 inhibitor<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hormone receptor-positive <br /> (HR+)/human epidermal growth <br /> factor receptor 2-negative (HER2-)<br /> early breast cancer (adjuvant)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Leqvio</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> inclisiran<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> siRNA <br /> (regulation of LDL-C)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br /> events in patients with elevated levels <br /> of LDL-C</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNA043</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ANGPTL3 agonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Knee osteoarthritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intra-articular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNP023</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iptacopan</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CFB inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgA nephropathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> C3 glomerulopathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal nocturnal hemoglobinuria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atypical hemolytic uremic syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LOU064</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> remibrutinib</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BTK inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multiple sclerosis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Lutathera</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> lutetium <br /> Lu 177 <br /> dotatate/<br /> lutetium <br /> (<sup>177</sup>Lu)<br /> oxodotreotide</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br /> targeting SSTR<br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gastroenteropancreatic <br /> neuroendocrine tumors, <br /> 1st line in G2/3 tumors<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LXE408</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Proteasome inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Visceral leishmaniasis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">MBG453</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> sabatolimab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TIM-3 antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelodysplastic syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Unfit acute myeloid leukemia</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">MIJ821</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> onfasprodil<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NR2B negative <br /> allosteric modulator</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Major depressive disorder<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">NIS793</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TGF-beta 1 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Pancreatic cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Piqray</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> alpelisib</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PI3K&#x2011;alpha inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ovarian cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pluvicto</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> lutetium<br /> Lu 177 <br /> vipivotide <br /> tetraxetan/<br /> lutetium <br /> (<sup>177</sup>Lu) <br /> vipivotide <br /> tetraxetan</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br /> targeting PSMA<br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic castration-resistant <br /> prostate cancer, pre-taxane<br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic hormone-sensitive <br /> prostate cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Project added to selected development projects table in 2022 &#x2013; entered Confirmatory Development</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">27</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Compound/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Common <br /> name</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Mechanism <br /> of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Formulation/<br /> route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br /> entered<br /> current<br /> development<br /> phase</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Planned filing<br /> dates/current<br /> phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PPY988<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gene therapy -<br /> complement<br /> factor I modulation</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Geographic atrophy<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subretinal injection<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ligelizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Food allergy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SAF312</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> libvatrep</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRPV1 antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic ocular surface pain</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Scemblix</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> asciminib<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BCR&#x2011;ABL inhibitor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br /> leukemia, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SKO136<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ensovibep<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multispecific DARPin<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Coronavirus infection<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not applicable<br /> (N/A)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<sup>4</sup>/II<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">TQJ230</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> pelacarsen<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ASO targeting<br /> lipoprotein(a)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br /> events in patients with elevated levels <br /> of lipoprotein(a)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAY736</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ianalumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BAFF-R inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Autoimmune hepatitis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lupus nephritis<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren&#x2019;s syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Warm autoimmune hemolytic anemia<br /> (wAIHA)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VDT482</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> tislelizumab<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-PD-1 monoclonal <br /> antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esophageal cancer, 2nd line<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US/EU <br /> registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non&#x2011;small cell lung cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EU registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nasopharyngeal carcinoma, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gastric cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esophageal cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Localized esophageal cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hepatocellular carcinoma, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Small cell lung cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Urothelial cell carcinoma, 1st line<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VPM087</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> gevokizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL-1 beta antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Colorectal cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/I</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Xolair</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> omalizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Food allergy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">XXB750<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NPR1 agonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Entered confirmatory development following the acquisition of Gyroscope Thereapeutics.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> In-licensed from Molecular Partners in 2021 (option deal)</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No definite submission date can be provided at this time</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Project added to selected development projects table in 2022 &#x2013; entered Confirmatory Development</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Formerly &#x201C;bladder urothelial cell carcinoma&#x201D;. Indication language updated in 2022 to reflect latest development plan</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">28</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Projects removed from the development table since 2021</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Compound/product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Change</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Reason</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ACZ885 (canakinumab)</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non&#x2011;small cell lung cancer, adjuvant</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                <i>Beovu</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic macular edema</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CFZ533 (iscalimab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Liver transplantation</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis head&#x2011;to&#x2011;head study versus   Sandoz biosimilar Hyrimoz (adalimumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lichen Planus</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CSJ117</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Asthma</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acute graft&#x2011;versus&#x2011;host disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic graft&#x2011;versus&#x2011;host disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsed/refractory follicular lymphoma</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LJN452</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nonalcoholic steatohepatitis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LMI070</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Huntington's disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNP023</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Membranous nephropathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vijoice<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PIK3CA-related overgrowth spectrum</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Triple negative breast cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Human epidermal growth factor   receptor 2-positive (HER2+)   advanced breast cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic castration-resistant prostate cancer, post-taxane</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QBW251 (icenticaftor)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic obstructive pulmonary disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031 (ligelizumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031 (ligelizumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic inducible urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia, 3rd line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UNR844</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Presbyopia</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Formerly listed as BYL719</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">29</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division sells products in approximately 130 countries worldwide. Net sales are primarily concentrated in the US and Europe. The following table sets forth the aggregate 2022 net sales of the Innovative Medicines Division by region:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 net sales  to third parties</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;899</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;554</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;929</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;914</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;548</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;748</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our Innovative Medicines Division products are used for chronic conditions that require patients to consume the product over long periods of time, ranging from months to years. However, certain of our marketed products and development projects, such as cell and gene therapies, are administered only once. Net sales of the vast majority of our products are not subject to material changes in seasonal demand.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our primary goal is to ensure the uninterrupted and timely supply of medicines that meet all product specifications and quality standards, and that are produced in the most cost-effective and sustainable manner. The manufacturing of our products is highly regulated by governmental health authorities around the world, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). In addition to regulatory requirements, many of our products involve technically complex manufacturing processes or require highly specialized raw materials.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we began to integrate Advanced Accelerator Applications (AAA), a Novartis company that focuses on radioligand therapies, into our existing manufacturing and supply structure. We manufacture our products across the following technologies at facilities worldwide: large molecules, small molecules, cell and gene therapy, RNA therapy and radioligand therapy (see also &#x201C;&#x2014;Item 4.D Property, plants and equipment&#x201D;). In our manufacturing network, we maintain state&#x2011;of&#x2011;the&#x2011;art processes, with quality as a priority, and require our suppliers to adhere to the same high standards we expect from our own people and processes. These processes include: chemical and biological syntheses; radioisotope handling, which relates to our radioligand therapies; sterile processing, including CAR-T cell processing; and formulation and packaging. We are constantly working to improve our existing manufacturing processes, develop new and innovative technologies, and review and adapt our manufacturing network to meet our needs and those of our patients and customers.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We produce raw materials for manufacturing in&#x2011;house or purchase them from a number of third-party suppliers. Where possible, we maintain multiple supply sources so that the business is not dependent on a single or limited number of suppliers. However, our ability to do so may at times be limited by regulatory or other requirements. We monitor market developments that could have an adverse effect on the supply of essential materials. Our suppliers of raw materials are required to comply with applicable regulations and Novartis quality standards.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because the manufacturing of our products is complex and highly regulated by governmental health authorities, supply is never guaranteed. If we or our third-party suppliers fail to comply with applicable regulations, then there could be a product recall or other disruption to our production activities. We have experienced supply interruptions for our products in the past, and there can be no assurance that supply will not be interrupted again in the future. However, we have implemented a global manufacturing strategy to maximize business continuity in case of such events.  </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division serves customers with 21 564 field force representatives, as of December 31, 2022, including supervisors and administrative personnel. These trained representatives present the therapeutic benefits and risks of our products to physicians, pharmacists, hospitals, insurance groups, managed care organizations and other healthcare professionals. In the US, Novartis advertises certain products via digital and traditional media channels, including the internet, television, newspapers and magazines. Novartis also pursues co&#x2011;promotion or co&#x2011;marketing opportunities as well as licensing and distribution agreements with other companies in various markets. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">30</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The marketplace for healthcare is evolving. Customer groups beyond prescribers have increasing influence on treatment decisions and guidelines, while patients continue to become more informed stakeholders in their healthcare decisions and look for solutions to meet their changing needs. Novartis is responding by adapting our business practices to engage appropriately with patients, customer groups and other stakeholders, including by delivering innovative solutions to drive education, access and improved patient care. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The COVID-19 pandemic has accelerated additional changes related to marketing and sales techniques in the healthcare industry. For example, many healthcare professionals have increased their use of virtual platforms when interacting with pharmaceutical companies, and prefer to receive information in a more convenient and personalized way. In response, Novartis is working to implement a new customer engagement model that combines traditional face-to-face visits with digital and other methods of engaging healthcare professionals to improve the efficiency and effectiveness of every interaction. We are similarly changing our approach to engaging healthcare systems, payers and other healthcare providers.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although specific distribution patterns vary by country, Novartis generally sells its prescription drugs primarily to wholesale and retail drug distributors, hospitals, clinics, government agencies and managed healthcare providers. The growing number of so&#x2011;called &#x201C;specialty&#x201D; drugs in our portfolio has resulted in increased engagement with specialty pharmacies.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the US Centers for Medicare &amp; Medicaid Services (CMS) is the largest single payer for healthcare services as a result of continuing changes in healthcare economics and an aging population. In addition, both commercial and government-sponsored managed care organizations continue to be among the largest groups of payers for healthcare services in the US. In other countries, national health services are often the only significant payer for healthcare services. In an effort to control prescription drug costs, almost all managed care organizations and national health services use formularies that list specific drugs that may be reimbursed and/or the level of reimbursement for each drug. Managed care organizations and national health services also increasingly use cost&#x2011;benefit analyses to determine whether or not newly approved drugs will be added to a formulary and/or the level of reimbursement for that drug, and to determine whether or not to continue to reimburse existing drugs. We have dedicated teams that actively seek to optimize patient access, including formulary positions, for our products.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The trend toward consolidation among distributors and retailers of Innovative Medicines Division products continues in the US and internationally, both within and across countries. This has increased our customers&#x2019; purchasing leverage and resulted in increased pricing pressure on our products. Moreover, we are exposed to increased concentration of credit risk as a result of the consolidation among our customers. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Drug pricing is an increasingly prominent issue in many countries as healthcare spending continues to rise. This issue has received significant attention in the US, especially with the recent passage of the Inflation Reduction Act (please see &#x201C;&#x2014;Price controls&#x201D; for more information). At Novartis, we are increasing our efforts to enable patient access through innovative pricing and access initiatives in the US, Europe and other markets. These include contract structures such as pay-over-time and outcome-based agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, Novartis reached an agreement with the National Health Service (NHS) in England to implement a first-of-its-kind population health management approach designed to provide faster and broader access to <i>Leqvio</i> for certain high-risk patients with atherosclerotic cardiovascular disease.  Novartis is engaging in similar collaborations with other countries. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Additionally, following conditional approval of <i>Zolgensma</i> in Europe in 2020, Novartis Gene Therapies established &#x201C;Day One&#x201D; early access agreements in multiple European countries. These agreements support early patient access by allowing a variety of customizable options, including retroactive rebates, deferred payments, installment options, outcome-based rebates, and collaborations with healthcare systems to optimize disease management. These efforts have expanded globally, and we now have multiple early access agreements and pay-for-performance agreements (i.e., outcome-based arrangements) in place in various markets around the world. <i>Zolgensma</i> is approved in 45 countries.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The global pharmaceutical market is highly competitive. We compete against other major international corporations that have substantial financial and other resources, as well as against smaller companies that operate regionally or nationally. Competition within the industry is intense and extends across a wide range of activities, including pricing, product characteristics, customer service, sales and marketing, and research and development.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Like other companies selling patented pharmaceuticals, Novartis faces challenges from companies selling competing patented products. Generic forms of our products may follow the expiry of intellectual property protection or regulatory exclusivities, and generic companies may also gain entry to the market through successfully challenging our intellectual property rights and exclusivities. We use appropriate, legally permissible measures to defend those rights and exclusivities. (See also &#x201C;&#x2014;Intellectual property&#x201D; below). We also may face competition from over-the-counter (OTC) products that do not require a prescription from a physician.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> There is ongoing consolidation in the pharmaceutical industry. At the same time, new entrants are looking to use their expertise to establish or expand their presence in healthcare, including technology companies seeking to benefit from the increasing importance of data and data management in our industry.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discovery and development of a new drug usually requires approximately 10 to 15&#xA0;years from the initial research to bringing a drug to market. This includes </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">31</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">approximately six to eight years from Phase&#xA0;I clinical trials to market entry. At each of these steps, there is a substantial risk that a compound (i.e., drug or biologic) or other therapeutic candidate will not meet the requirements to progress further. In such an event, we may be required to abandon the development of a potential therapy in which we have made a substantial investment.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We manage our research and development expenditures across our entire portfolio in accordance with our strategic priorities. We make decisions about whether or not to proceed with development projects on a project&#x2011;by&#x2011;project basis. These decisions are based on the project&#x2019;s potential to meet a significant unmet medical need or to improve patient outcomes, the strength of the science underlying the project, and the potential of the project (subject to the risks inherent in pharmaceutical development) to generate significant positive financial results for the Company. Once a management decision has been made to proceed with the development of a particular molecule, the level of research and development investment required will be driven by many factors. These include the medical indications for which it is being developed, the number of indications being pursued, whether the molecule is of a chemical or biological nature, the stage of development, and the level of evidence necessary to demonstrate clinical efficacy and safety. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Research program</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research program is conducted by the Novartis Institutes for BioMedical Research (NIBR), which is the research and early development innovation engine of Novartis. NIBR is responsible for the discovery of new medicines for diseases with unmet medical need. We focus our work in areas where we believe we can have the most impact for patients. This requires the hiring and retention of highly talented employees, a focus on fundamental disease mechanisms that are relevant across different disease areas, continuous improvement in technologies for drug discovery and potential therapies, working with patients to understand their diseases and the potential benefits of therapies, close alliances with clinical and commercial colleagues, and the establishment of strategic external alliances.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  Approximately 5 500 full&#x2011;time-equivalent scientists, physicians and business professionals work at NIBR sites in Basel, Switzerland; Cambridge, Massachusetts; East Hanover, New Jersey; San Diego, California; and Emeryville, California. They contribute to research into disease areas such as cardiovascular, renal and metabolic diseases; neuroscience; oncology; hematology; muscle disorders; ophthalmology; autoimmune diseases; and respiratory and allergic diseases. Research at the Friedrich Miescher Institute focuses on basic genetic and genomic research, and the Novartis Institute for Tropical Diseases (NITD), in Emeryville, California, focuses on discovering new medicines to fight tropical diseases, including malaria and cryptosporidiosis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  All drug candidates go through proof&#x2011;of&#x2011;concept trials to enable an early assessment of the safety and efficacy of the drug while collecting basic information on pharmacokinetics and tolerability, and adhering to the guidance for early clinical testing set forth by health authorities. Following proof of concept, our Global Drug Development unit conducts confirmatory trials on the drug candidates.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  In 2022, we integrated the Genomics Institute of the Novartis Research Foundation (GNF), which is based in San Diego, US, into NIBR. This enables closer collaboration with colleagues across NIBR and gives greater access to biological, therapeutic, and translational platforms to researchers across Novartis. The NIBR San Diego site is focused on developing novel technology to drive drug discovery research, including regenerative medicine, small interfering RNA therapy and covalent drug discovery. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Development program</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Global Drug Development (GDD) organization oversees and executes drug development activities, working collaboratively with NIBR, our commercial organization and other parts of the Company on our overall pipeline strategy. The GDD organization includes centralized global functions such as Regulatory Affairs and Global Development Operations, and global Development Units, and has approximately 12 800 full&#x2011;time equivalent employees worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The traditional model of clinical development consists of three phases:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;I:</b>  The first clinical trials of a new compound &#x2013; generally performed in a small number of healthy human volunteers &#x2013; to assess the drug&#x2019;s safety profile, including the safe dosage range. These trials also determine how a drug is absorbed, distributed, metabolized and excreted, and the duration of its action.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;II:</b>  Clinical studies performed with patients who have the target disease, with the aim of continuing the Phase&#xA0;I safety assessment in a larger group, assessing the efficacy of the drug in the patient population, and determining the appropriate doses for further evaluation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;III:</b>  Large&#x2011;scale clinical studies with several hundred to several thousand patients, which are conducted to establish the safety and efficacy of the drug in specific indications for regulatory approval. Phase&#xA0;III trials may also be used to compare a new drug against a current standard of care to evaluate the overall benefit&#x2011;risk relationship of the new medicine.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In each of these phases, physicians monitor volunteer patients closely to assess the safety and efficacy of a potential new drug or indication.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we use this traditional model, we have tailored the development process to be simpler, more flexible and more efficient. We divide the development process into two stages: Exploratory Development to establish proof of concept, followed by Confirmatory Development to confirm the concept in large numbers of patients. Exploratory Development consists of clinical proof-of-concept (PoC) studies, which are small clinical trials (typically involving between five and 15 patients) that combine elements of traditional Phase&#xA0;I/II testing. NIBR conducts these customized trials, which are designed to give early insights into issues such as safety, efficacy and toxicity for a drug in a given indication. Once a positive proof of concept has been established, the </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">32</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">drug moves to the Confirmatory Development stage and becomes the responsibility of GDD. Confirmatory Development has elements of traditional Phase&#xA0;II/III testing and includes trials aimed at confirming the safety and efficacy of the drug in the given indication, leading up to submission of a dossier to health authorities for approval. This stage can also include trials that compare the drug to the current standard of care for the disease in order to evaluate the drug&#x2019;s overall benefit-risk profile. Further, with new treatment approaches such as gene therapy for rare diseases, elements of Exploratory and Confirmatory Development may be combined and suffice for registration under certain conditions such as high unmet medical need and clinical data showing highly favorable benefit-risk. In these cases, additional post-approval studies may be required by the regulatory authorities to continue to gather important data to further support approval.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast amount of data that must be collected and evaluated makes clinical testing the most time&#x2011;consuming and expensive part of new drug development. The next stage in the drug development process is to seek registration for the new drug. For more information, see &#x201C;&#x2014;Regulation.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Innovation Management Board (IMB) is responsible for all strategic aspects of our development portfolio and oversees our drug development budget as well as major project phase transitions and milestones following a positive proof-of-concept outcome, including transitions to Confirmatory Development and the decision to submit a regulatory application to the health authorities. The IMB is also responsible for the endorsement of overall development strategy, the endorsement of development project priorities, and decisions on project discontinuations. Our Chief Executive Officer chairs the IMB, and other representatives from Novartis senior management, with expertise spanning multiple fields, are among its core and extended membership. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Alliances and acquisitions</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division enters into business development agreements with other pharmaceutical and biotechnology companies and with academic and other institutions to develop new products and access new markets. We license products that complement our current product line and are appropriate to our business strategy. We focus on strategic alliances and acquisition activities for key disease areas and indications that we expect to be growth drivers in the future. We review products and compounds we are considering licensing, using the same criteria that we use for our own internally discovered drugs. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In February 2022, Novartis completed the acquisition of Gyroscope Therapeutics Holdings Plc. Through the acquisition, Novartis added PPY988 (GT005), an investigational one-time gene therapy for geographic atrophy, to its portfolio.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For more information about recent business acquisitions, see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The international pharmaceutical industry is highly regulated. Regulatory authorities around the world administer numerous laws and regulations regarding the testing, approval, manufacturing, importing, labeling and marketing of drugs, and review the safety and efficacy of pharmaceutical products. Extensive controls exist on the non&#x2011;clinical and clinical development of pharmaceutical products. These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Health authorities, including those in the US and the EU, have high standards of technical evaluation. The introduction of new pharmaceutical products generally entails a lengthy approval process. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained. In recent years, the registration process has required increased testing and documentation for the approval of new drugs, with a corresponding increase in the expense of product introduction.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To register a pharmaceutical product, a registration dossier containing evidence establishing the safety, efficacy and quality of the product must be submitted to regulatory authorities. Generally, a therapeutic product must be registered in each country in which it will be sold. In every country, the submission of an application to a regulatory authority does not guarantee that approval to market the product will be granted. Although the criteria for the registration of therapeutic drugs are similar in most countries, the formal structure of the necessary registration documents and the specific requirements, including risk tolerance, of the local health authorities can vary significantly from country to country. Even if a drug is registered and marketed in one country, the registration authority in another country may request additional information from the pharmaceutical company prior to registration or even reject the product. A drug may be approved for different indications in different countries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration process generally takes between six months and several years, depending on the country, the quality of the data submitted, the efficiency of the registration authority&#x2019;s procedures, and the nature of the product. Many countries provide for accelerated processing of registration applications for innovative products of particular therapeutic interest. In recent years, the US and the EU have made efforts to harmonize registration requirements in order to achieve shorter development and registration times for medical products. However, the requirement in many countries to negotiate selling prices or reimbursement levels with government regulators and other payers can substantially extend the time until a product may finally be available to patients.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following provides a summary of the regulatory processes in the principal markets served by Innovative Medicines Division affiliates:</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">33</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, applications for drug registration are submitted to and reviewed by the FDA. The FDA regulates the testing, manufacturing, labeling and approval for marketing of pharmaceutical products intended for commercialization in the US. The FDA continues to monitor the safety of pharmaceutical products after they have been approved for sale in the US market. The pharmaceutical development and registration process is typically intensive, lengthy and rigorous. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, the company may file&#xA0;a New Drug Application (NDA) or Biologics License Application (BLA), as applicable, for the compound. The NDA or BLA must contain all the scientific information that has been gathered about the compound. This typically includes information regarding the clinical experiences of patients tested in the drug&#x2019;s clinical trials. A Supplemental New Drug Application (sNDA) or Supplemental Biologics License Application (sBLA) must be filed for new indications and dosage forms for a previously approved drug.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once an application is submitted, the FDA assigns reviewers from its staff, including experts in biopharmaceutics, chemistry, clinical microbiology, pharmacology/toxicology, and statistics. After a complete review, these content experts provide written evaluations of the NDA or BLA. These recommendations are consolidated and are used by senior FDA staff in its final evaluation of the NDA or BLA. Based on that final evaluation, the FDA then provides to the NDA or BLA&#x2019;s sponsor an approval, or a &#x201C;complete response&#x201D; letter if the NDA or BLA application is not approved. If not approved, the letter will state the specific deficiencies in the NDA or BLA that need to be addressed. The sponsor must then submit an adequate response to the deficiencies in order to restart the review procedure.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once the FDA has approved an NDA, BLA, sNDA or sBLA, the company can make the new drug available for physicians and other healthcare providers to prescribe. The drug owner must submit periodic reports to the FDA, including any cases of adverse reactions. For some medications, the FDA requires additional post&#x2011;approval studies (Phase&#xA0;IV) to evaluate long&#x2011;term effects or to gather information on the use of the product under specified conditions.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Throughout the life cycle of a product, the FDA requires compliance with standards relating to good laboratory, clinical and manufacturing practices. The FDA also requires compliance with rules pertaining to the manner in which we may promote our products.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European Union</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the EU, there are three main procedures for application for authorization to market pharmaceutical products in more than one EU member state at the same time: the centralized procedure, the mutual recognition procedure and the decentralized procedure. It is also possible to obtain a national authorization for products intended for commercialization in a single EU member state only. The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). The centralized procedure is mandatory for all biotechnology products; new chemical entities in cancer, neurodegenerative disorders, diabetes, AIDS, autoimmune diseases and other immune dysfunctions; advanced therapy medicines, such as gene therapy, somatic cell therapy and tissue-engineered medicines; and orphan medicines (medicines for rare diseases). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, the company may submit an application to the EMA. The EMA then receives and validates the application, and the specialized committee for human medicines, the CHMP, appoints a rapporteur and co&#x2011;rapporteur to review it. They use experts from their countries to carry out the assessment but can also draw on expertise from other member states (&#x201C;multinational teams&#x201D;). The entire review cycle must be completed within 210&#xA0;days, although there are &#x201C;clock stops&#x201D; to allow the company to respond to questions set forth in the rapporteur and co&#x2011;rapporteur&#x2019;s assessment report and agreed with the CHMP. The first clock stop is at Day 120 and the clock restarts on Day 121, when the company&#x2019;s complete response is received by the EMA. If there are further aspects of the dossier requiring clarification, the CHMP will issue further questions at Day 180, and may also request an oral explanation, in which case the sponsor must not only respond to the further questions but also appear before the committee to justify its responses. On Day 210, the CHMP will take a vote to recommend the approval or non&#x2011;approval of the application, and their opinion is transferred to the EC. The final EC decision under this centralized procedure is a single decision that is applicable to all member states. This decision occurs 60&#xA0;days, on average, after a positive CHMP recommendation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under both the mutual recognition procedure (MRP) and the decentralized procedure (DCP), the assessment is led by one member state, called the reference member state (RMS) which then liaises with other member states, known as the concerned member states. In the MRP, the company first obtains a marketing authorization in the RMS, which is then recognized by the concerned member states in 90 days. In the DCP, the application is done simultaneously in the RMS and all concerned member states. During the DCP, the RMS drafts an assessment report within 120&#xA0;days. Within an additional 90&#xA0;days, the concerned member states review the application and can issue objections or requests for additional information. On Day 90, each concerned member state must be assured that the product is safe and effective, and that it will cause no undue risks to the public health. Once an agreement has been reached, each member state grants national marketing authorizations for the product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">After receiving the marketing authorizations, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). In addition, pharmacovigilance measures must be implemented </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">34</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and monitored, including the collection, evaluation and expedited reporting of adverse events, and updates to risk management plans. For some medications, post-approval studies (Phase&#xA0;IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">European marketing authorizations have an initial duration of five years. The holder of the marketing authorization must actively apply for its renewal after this first five-year period. As part of the renewal procedure, the competent authority performs a full benefit&#x2011;risk review of the product. Should the authority conclude that the benefit&#x2011;risk balance is no longer positive, the marketing authorization can be suspended or revoked. Once renewed, the marketing authorization is valid for an unlimited period, unless it is determined that the product must be further monitored for safety reasons. In this case, the authority may require another renewal at 10 years. If the holder does not apply for renewal, the marketing authorization automatically lapses. Any marketing authorization that is not followed within three years of its granting by the actual placing on the market of the corresponding medicinal product ceases to be valid. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Price controls</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In most of the markets where we operate, the prices of pharmaceutical products are subject to both direct and indirect price controls and to drug reimbursement programs with varying price control mechanisms. Due to increasing political pressure and governmental budget constraints, we expect these mechanisms to remain robust &#x2013; and potentially even strengthened &#x2013; and to have a continued negative influence on the prices we are able to charge for our products.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Direct governmental efforts to control prices</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United States:  The Inflation Reduction Act of 2022 (the &#x201C;Act&#x201D;) was signed into law, which mandates the negotiation of eligible Medicare Part B and Part D drugs; redesigns the Medicare Part D benefit, including a USD 2 000 out-of-pocket cap for Medicare beneficiaries; and imposes penalties for Medicare drugs that increase in price faster than the rate of inflation. Under the Act, the US government is required to negotiate the Medicare prices of single-sourced small molecule drugs that have been on the market for seven years following FDA approval as well as single-sourced biologics that have been on the market for 11 years after FDA approval. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Medicare drugs with the highest total cost to the US government will be selected for negotiation once they become eligible. Exemptions include orphan drugs with an indication for one rare disease or condition, drugs with a total cost to the US government of less than USD&#xA0;200 million, and plasma-derived drugs.   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The negotiated price will be publicly available and will become effective for selected drugs nine years after FDA approval for eligible small molecules and 13 years after approval for eligible biologics. The negotiated price will be implemented as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  10 eligible Medicare Part D drugs in 2026;  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  an additional 15 eligible Medicare Part D drugs in 2027;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   an additional 15 eligible combined Medicare Part&#xA0;B and Part D drugs in 2028;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   an additional 20 eligible combined Medicare Part&#xA0;B and Part D drugs in 2029; and </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  an additional 20 eligible combined Medicare Part&#xA0;B and Part D drugs each year after 2029 </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis will participate in the Medicare negotiation process if Novartis drugs are selected. Pharmaceutical manufacturers that choose not to participate in the negotiation process will be subject to an excise tax of up to 95% of sales.  Novartis may also be affected by other provisions of the Act, such as price increase penalties for Medicare Part D drugs starting in 2022 and for Medicare Part B drugs in 2023, and rebates on eligible Medicare Part D sales starting in 2025.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, by December 31, 2022, 20 US states had passed legislation intended to impact pricing or requiring manufacturer price transparency reporting, with eight of these states also allowing for drug affordability (i.e., price control) review boards. The disclosure requirements vary by state. Many states require multiple types of reporting, including for new drug applications, new drug launches, prior notice of price increases, and quarterly or annual reporting. It is expected that state legislatures will continue to focus on drug pricing in 2023 and that similar bills will be passed in more states.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Europe: In Europe, our operations are subject to significant price and marketing regulations. Many governments are introducing healthcare reforms in a further attempt to curb increasing healthcare costs. In some member states, these include reforms to permit the reimbursed use of off-label medicines, despite the presence of licensed alternatives on the market. In the EU, governments influence the price of pharmaceutical products through their control of national healthcare systems that fund a large part of the cost of such products to patients. The downward pressure on healthcare costs in general in the EU, particularly with regard to prescription drugs, is intense. Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost&#x2011;benefit assessments. In addition, prices for marketed products are referenced within member states and across international borders, further impacting individual EU member state pricing. Member states also collaborate to enhance pricing transparency and have started conducting joint health technology assessments, joint pricing negotiations and/or joint purchasing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw&#x2011;backs on the pharmaceutical industry. The calculation of these rebates and claw&#x2011;backs may lack transparency in some cases and can be difficult to predict.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Regulations favoring generics and biosimilars</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In response to rising healthcare costs, most governments and private medical care providers have established reimbursement schemes that favor the substitution of generic pharmaceuticals for more expensive </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">35</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">brand&#x2011;name pharmaceuticals. All US states have generic substitution statutes. These statutes permit or require the dispensing pharmacist to substitute a less expensive generic drug instead of an original drug. Other countries, including many European countries, have similar laws. We expect that the pressure for generic substitution will continue to increase. In addition, the US, the EU and other jurisdictions are increasingly introducing laws and regulations encouraging the development of biosimilar versions of biologic drugs, which can also be expected to have an impact on pricing.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross&#x2011;border sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Price controls in one country can have an impact in other countries as a result of cross&#x2011;border sales. In the EU, products that we have sold to customers in countries with stringent price controls can be legally resold to customers in other EU countries at a lower price than the price at which the product is otherwise available in the importing country (known as parallel trade). In North America, products that we have sold to customers in Canada &#x2013; which has relatively stringent price controls &#x2013; are sometimes resold into the US, again at a lower price than the price at which the product is otherwise sold in the US. Such imports from Canada and other countries into the US are currently illegal in most states. However, six US states (Colorado, Florida, Minnesota, New Hampshire, New Mexico, and Vermont) have enacted laws allowing the import of pharmaceutical drugs from select foreign countries. The Secretary of the US Department of Health and Human Services (HHS) must certify that each state&#x2019;s importation plan is safe and cost-effective before it can be implemented. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We expect that pressures on pricing will continue worldwide and will likely increase. Because of these pressures, there can be no certainty that in every instance we will be able to charge prices for a product that, in a particular country or in the aggregate, would enable us to earn an adequate return on our investment in that product. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We attach great importance to intellectual property (IP) rights &#x2013; including patents, trademarks, copyrights, know&#x2011;how, trade secrets and regulatory data protection &#x2013; as essential to our purpose of reimagining medicine to improve and extend people&#x2019;s lives, and to protect our investment in research and development, manufacturing and marketing. The IP system provides a means to attract the investments needed to conduct and sustainably finance innovative R&amp;D, and to manage the risks inherent in our work. For example, we seek IP protection under applicable laws for significant product developments in major markets. Among other things, patents may cover the products themselves, including the product&#x2019;s active ingredient or ingredients and its formulation. Patents may cover processes for manufacturing a product, including processes for manufacturing intermediate substances used in the manufacture of the product. Patents may also cover particular uses of a product, such as its use to treat a particular disease, or its dosage regimen. In addition, patents may cover tests for certain diseases or biomarkers &#x2013; which can improve patient outcomes when administered with certain drugs &#x2013; as well as assays, research tools and other techniques used to identify new drugs. The protection afforded, which may vary from country to country, depends upon the type of patent, its duration and its scope of coverage.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US and other countries, the law recognizes that product development and review by the FDA and other health authorities can take an extended period, and provides an extension of patent term for a period related to the time taken for the conduct of clinical trials and for the health authority&#x2019;s review. However, the length of this extension and the patents to which it applies cannot be known in advance and can only be determined after the product is approved. In practice, it is not uncommon for patent term extensions (PTEs) or supplementary protection certificates (SPCs) to not fully account for the time it took to develop the product and receive marketing authorization. As a result, it is rarely the case, for example, that a `product&#x2019;s active ingredient(s) will have a full patent term at the time the product is approved by the FDA and other health authorities.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to patent protection, various countries provide regulatory-based protection, including regulatory data protection (RDP) and/or other market exclusivities, for a prescribed period of time. RDP is a distinct type of IP right providing exclusivity that precludes a potential competitor from filing a regulatory application that relies on the sponsor&#x2019;s clinical trial data, or that precludes the regulatory authority from approving the application for a set period of time. The RDP period can vary depending on the type of data included in the sponsor&#x2019;s application. When it is available, market exclusivity, unlike RDP, may preclude a competitor from obtaining marketing approval for a product even if a competitor&#x2019;s application relies on its own data. RDP and market exclusivity periods generally run from the date a product is approved, and so their expiration dates cannot be known with certainty until the product approval date is known and exclusivity has been granted by the relevant authorities.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, a patent issued from an application filed today will receive a term of 20&#xA0;years from the earliest application filing date, subject to potential patent term adjustments for delays in patent issuance based upon certain delays in prosecution by the United States Patent and Trademark Office (USPTO). A US pharmaceutical patent that claims a product, method of treatment using a product, or method of manufacturing a product may also be eligible for a PTE. This type of extension may only extend the patent term for a maximum of five&#xA0;years, and may not extend the patent term beyond 14&#xA0;years from regulatory approval. Only one patent may be extended for a product based on FDA review.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the FDA may provide regulatory-based protection, which runs in parallel to any patent protection. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   A new small&#x2011;molecule active pharmaceutical ingredient receives five years of RDP, during which time a competitor generally may not obtain final approval of an </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">36</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">application to the FDA based on a sponsor&#x2019;s clinical data.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   A new biologic active pharmaceutical ingredient receives 12 years of regulatory-based market exclusivity, during which time a competitor generally may not market the same or similar drug. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   The FDA may also request that a sponsor conduct pediatric studies and, in exchange, it will grant an additional six&#x2011;month period of pediatric market exclusivity if the sponsor makes a timely submission of the reports of the pediatric studies in response to the FDA&#x2019;s Written Request. The sponsor must also have a patent&#x2011;based and/or regulatory&#x2011;based exclusivity period for the product to which the pediatric market exclusivity is appended.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Orphan drug exclusivity provides seven years of market exclusivity for drugs designated by the FDA as orphan drugs, meaning drugs that treat rare diseases. During this period, a potential competitor generally may not market the same or similar drug for the same indication even if the competitor&#x2019;s application does not rely on data from the sponsor. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European Union</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country or countries. The EPO system permits a single application to be granted for the EU plus other non&#x2011;EU countries such as Switzerland, Turkey and the UK. When the EPO grants a patent, it is then validated in the countries that the patent owner designates. The term of a patent granted by the EPO or a European country office is 20&#xA0;years from the earliest application filing date. Pharmaceutical patents can be granted a further period of exclusivity under the SPC system. SPCs are designed, in part, to account for the time taken to receive marketing authorization of a product by the European health authorities. An SPC may be granted to provide, in combination with the patent, up to 15&#xA0;years of exclusivity from the date of the first European marketing authorization. However, an SPC cannot last longer than five&#xA0;years. The SPC duration may be extended by a further six&#xA0;months if the product is the subject of an agreed and successfully completed pediatric investigation plan. The post&#x2011;grant phase of patents, including the SPC system, is currently administered on a country&#x2011;by&#x2011;country basis under national laws that, while differing, are intended to (but do not always) have the same effect.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the EU provides a system of regulatory data protection for authorized human medicines that runs in parallel to any patent protection. The system for new drugs being approved today is usually referred to as &#x201C;8+2+1&#x201D; because it provides an initial period of eight&#xA0;years of data protection, during which a competitor cannot rely on the relevant data; a further period of two&#xA0;years of market exclusivity, during which the data can be used to support applications for marketing authorization but a competitive product cannot be launched; and a possible one&#x2011;year extension of the market exclusivity period if, during the initial eight&#x2011;year data exclusivity period, the sponsor registered a new therapeutic indication with &#x201C;significant clinical benefit.&#x201D; This system generally applies both to national and centralized authorizations in the EU plus other non-EU countries such as the UK. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The EU also has an orphan drug exclusivity system for medicines. If a medicine is designated as an orphan drug, then it benefits from 10&#xA0;years of market exclusivity after it is authorized, during which time an application for the same or similar medicine for the same indication will not generally be accepted or granted. Under certain circumstances, this exclusivity can be extended with a two&#x2011;year pediatric extension.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Third-party patents and challenges to intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Third parties can challenge our IP, including patents, patent term extensions, RDP and marketing exclusivities (such as pediatric extensions and orphan drug exclusivity), through various proceedings. For example, patents in the US can be challenged in the United States Patent and Trademark Office (USPTO) through various proceedings, including Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings. They may also be challenged through patent infringement litigation under the Abbreviated New Drug Application (ANDA) provisions of the Hatch&#x2011;Waxman Act or under the Biologics Price Competition and Innovation Act (BPCIA). In the EU, patents may be challenged through oppositions in the EPO, or national patents may be challenged in national courts or national patent offices. The outcomes of such challenges can be difficult to predict.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to directly challenging our IP rights, in some circumstances a competitor may be able to market a generic version of one of our products by, for example, designing around our patents or marketing the generic product for non&#x2011;patent-protected indications, or filing a separate New Drug Application (NDA) under the Hatch-Waxman Act (typically referred to as a 505(b)(2) application). Despite RDP, a competitor could opt to incur the costs of conducting its own clinical trials and preparing its own regulatory application, and avoid our RDP altogether. There is a risk that some countries may seek to impose limitations on or seek not to recognize the availability of IP rights for pharmaceutical products, or limit the extent to which such rights may be enforced. Also, even though we may own, co&#x2011;own or in&#x2011;license patents protecting our products, and conduct freedom&#x2011;to&#x2011;operate analyses, a third party may nevertheless assert that one of our products infringes a third-party patent for which we do not have a license, seeking remedies such as monetary damages or an injunction against our continued marketing of the product.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a result, there can be no assurance that our IP rights will protect our products or that we will be able to avoid adverse effects from the loss of IP protection or from third-party patents in the future.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intellectual property protection for certain key marketed products and compounds in development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We present additional details below regarding certain IP protection for the listed Innovative Medicines Division products. For each, we identify issued, unexpired </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">37</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">patents by their general subject matter and, in parentheses, years of expiry, if relevant, in the US and the EU. The identified patents are owned, co&#x2011;owned or exclusively in&#x2011;licensed by Novartis and relate to at least one dosage strength of the product or to the method of treatment or its use as it is currently approved and marketed or, in the case of a compound in development, as it is currently submitted to the FDA and/or the EMA for approval. Identification of an EU patent refers to national patents in EU countries and/or to the national patents that have been derived from a patent granted by the EPO. Novartis may own, co-own, control or have rights to additional patents, for example, relating to compound forms, methods of treatment or use, formulations, devices, processes, product-by-process, synthesis, purification and detection.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We identify unexpired RDP periods and, in parentheses, years of expiry if the relevant marketing authorizations have been authorized or granted. We identify certain unexpired patent term extensions and marketing exclusivities and, in parentheses, years of expiry if they are granted; their subject matter scope may be limited and is not specified. Marketing exclusivities and patent term extensions include orphan drug exclusivity (ODE), pediatric exclusivity (PE), patent term extension (PTE) and supplementary protection certificate (SPC). We designate these as &#x201C;pending&#x201D; if they have been applied for but not granted and include years of expiry if estimable. Such pending applications ultimately may or may not be granted. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the case of the EU, identification of a patent, supplementary protection certificate, marketing exclusivity or regulatory data protection means grant, authorization and maintenance in at least one EU country or the UK. However, it could be pending, not granted, expired or found invalid in others. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For each product below, we indicate whether there is current generic or biosimilar competition for one or more product versions in one or more approved indications in either the US or one or more EU countries, if IP is otherwise disclosed. We identify certain enforcement actions, or ongoing challenges to the disclosed IP, including IPRs or PGRs if instituted by the USPTO, that have not been finally resolved (including appeals) unless noted. Challenges identified as being in administrative entities, such as national patent offices, include judicial appeals from decisions of those entities. Resolution of challenges to the disclosed IP, which in the EU may involve IP in one or more EU countries, may include settlement agreements under which Novartis permits or does not permit future launch of generic versions of our products before expiration of that IP. We identify certain material terms of such settlement agreements where they could have a material adverse effect on our business. In other cases, such settlement agreements may contain confidentiality obligations restricting what may be disclosed.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the event that a product listed below does not have identified patents as described above, we provide information only on generic competition.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For additional information regarding commercial arrangements with respect to these products, see &#x201C;&#x2014;Key marketed products.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Cardiovascular</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Entresto</i>.  US: Four patents on combination (2023 (4)), PTE (2025), four PEs (2023, 2023, 2024, 2025); two patents on complex (2026, 2027), two PEs (2027, 2027); three patents on methods of treatment (2033 (3)); patent on dosage regimen (2036); RDP for new pediatric patient population (2022), PE (2023); RDP for labeling changes related to new clinical investigation (2024). EU: Patent on combination (2023), SPC (2028); two patents on complex (2026, 2026), two SPCs (2030, 2030); patent on formulation (2028); patent on method of use (2034); RDP (2025). There is no generic competition in the US or the EU. In the US, two combination patents, the two complex patents, and the dosage regimen patent are being challenged in ANDA proceedings against generic manufacturers. In the EU, one complex patent and the use patent are being opposed in the EPO. In some EU countries, the combination patent or its associated SPC is being challenged by generic manufacturers.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Leqvio</i>. US: Two patents on composition of matter (2027, 2034), PTE pending (2035); two patents on method of treatment and dosing regimen (2027, 2036); RDP (2026). EU: One patent on composition of matter (2033), SPC (2035); RDP (2030). There is no generic competition in the US or the EU. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Immunology</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Cosentyx</i>. US: Five patents on composition of matter (2025 (4), 2026), PTE (2029); patent on psoriatic arthritis use (2031); patent on psoriasis use (2032); two patents on ankylosing spondylitis use (2032, 2033); RDP (2027). EU: Four patents on composition of matter (2025 (4)), SPC (2030), PE (2030); patent on psoriasis use (2031); patent on ankylosing spondylitis use (2031); RDP (2026). There is no generic competition in the US or the EU. In the EU, the patent on ankylosing spondylitis use is being opposed in the EPO.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Xolair</i>. US: Two patents on syringe formulation (2024, 2025). EU: Three patents on syringe formulation (2024, 2024, 2025). There is no generic competition in the US or the EU. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Ilaris</i>. US: Patent on composition of matter (2024); patent on cryopyrin&#x2011;associated periodic syndromes use (2026); patent on familial Mediterranean fever (FMF) use (2026); patent on systemic onset juvenile idiopathic arthritis (SJIA) use (2028); patent on hyperimmunoglobulin D syndrome and tumor necrosis factor receptor-associated periodic syndrome use (2029); patent on formulation (2029). EU: Patent on composition of matter (2021), SPC (2024), PE (2025); patent on SJIA use (2026); patent on FMF use (2026); two patents on formulation (2029, 2029). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Neuroscience</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Gilenya.</i> US: Patent on dosage regimen (2027), PE (2027); patent on 0.25&#xA0;mg formulation (2032), PE (2032); patent on method of treatment (2027). EU: Patent on formulation (2024), SPC (2026); patent on </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">38</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">0.25&#xA0;mg formulation (2032); patent on dosing regimen (2027). There is generic competition in the US and in most EU countries. In the US, the dosage regimen patent was challenged in ANDA proceedings against a generic manufacturer and was found invalid by the US Court of Appeals for the Federal Circuit in June 2022.  Novartis has filed a petition seeking further review with the US Supreme Court. Novartis is also enforcing the method of treatment patent against a generic manufacturer. In the EU, Novartis is enforcing the dosing regimen patent against generic manufacturers. The dosing regimen patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Zolgensma</i>. US: Four patents on composition of matter (2024, 2024, 2026, 2033), PTE pending (2029); three patents on methods of treatment (2028, 2028, 2029); ODE for spinal muscular atrophy (SMA) in patients less than 2 years old with biallelic mutations in the SMN1 gene (2026); RDP (2031). EU: Three patents on composition of matter (2024, 2024, 2028), SPC (2029); two patents on methods of use (2028, 2028), SPC (2033), SPC pending (2033); ODE for SMA in patients with a biallelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with a biallelic mutation in the SMN1 gene and up to three copies of the SMN2 gene (2030); RDP (2030). There is no generic competition in the US or the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kesimpta</i>. US: Patent on compound (2031); patent on dosing regimen (2037). EU: Patent on compound (2023); patent on use (2023), SPC (2028); patent on formulation (2028), patent on formulation and use (2028), SPC (2033); patent on dosing regimen (2037). There is no generic competition in the US or the EU.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Solid Tumor</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tafinlar</i> and <i>Mekinist</i>.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Tafinlar.</i> US: Two patents on compound (2030, 2030); patent on method of treatment (2029). EU: Patent on compound (2029); RDP (2024). There is no generic competition in the US or the EU. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Mekinist</i>. US: Patent on compound (2025), PTE (2027); patent on method of treatment (2025); four patents on formulation (2032 (4)). EU: Patent on compound (2025), SPC (2029); patent on formulation (2031); RDP (2025). There is no generic competition in the US or the EU. In the EU, the formulation patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Use of <i>Mekinist</i> with <i>Tafinlar</i> or <i>Tafinlar</i> with <i>Mekinist</i>. US: Patent on combination (2030); four patents on method of use of combination (2025, 2030, 2030, 2033); ODE on non&#x2011;small cell lung cancer (2024); ODE on adjuvant treatment of melanoma (2025); ODE on anaplastic thyroid cancer (2025); ODE on metastatic solid tumors (2025). EU: Patent on combination (2030); patent on adjuvant for melanoma use (2033). There is no generic competition in the US or the EU. In the EU, the adjuvant use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Kisqali.</i> US: Three patents on compound (2028, 2030, 2031), PTE (2031); three patents on methods of treatment (2029, 2029, 2031); patent on salt form (2031); patent for tablet formulation (2036). EU: Patent on compound (2027); patent on compound (2029), SPC (2032); patent on salt form (2031); patent on methods of use with letrozole (2034); patent on formulation (2036); RDP (2027). There is no generic competition in the US or the EU. In the US, the three compound patents, the three method of treatment patents, the salt patent and the formulation patent are being challenged in ANDA proceedings against generic manufacturers. In the EU, the method of use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Piqray</i>. US: Patent on compound (2029); patent on compound and use (2029), PTE pending (2033); RDP (2024). EU: Patent on compound and use (2029), SPC (2034); RDP (2030). There is no generic competition in the US or the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Pluvicto</i>. US: Three patents on composition of matter (2028, 2028, 2034); RDP (2027). PTE pending. EU: RDP (2032). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Hematology</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Promacta</i>/<i>Revolade</i>. US: Patent on compound (2021), PTE (2022), PE (2023); patent on method of enhancing platelet production using salt (2023), PE (2023); patent on salt form and thrombocytopenia use (2025), PE (2026); five patents on tablet formulations of different dose strengths (2027 (5)), five PEs (2028 (5)); ODE on severe aplastic anemia patients in combination with standard immunosuppressive therapy (2025). EU: Patent on compound (2021), SPC (2025), PE (2025); patent on salt form (2023); patent on severe aplastic anemia use (2028). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. In the EU, the severe aplastic anemia use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; <i>Tasigna.</i> US: Patent on compound (2023), PE (2024); two patents on salt forms (2026, 2028), two PEs (2027, 2029); patent on polymorph compound form (2026), PE (2027); two patents on capsule form (2026, 2027), two PEs (2027, 2028); patent on method of treatment (2032), PE (2032). EU: Patent on compound (2023); patent on salt form (2026); patent on polymorph compound form (2026); patent on capsule form (2027); patent on method of treatment (2030). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Jakavi</i>. EU: Patent on compound (2026), SPC (2027); two patents on salt form (2028, 2028); patent on compound for polycythemia vera (PV) use (2026); patent on salt form for graft-versus-host disease (GvHD) use (2028). There is no generic competition in the EU<i>.</i></div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">39</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Scemblix</i>. US: Patent on compound (2033), PTE pending (2035); Patent on polymorph compound form (2040); RDP (2026); ODE (2028). EU: Patent on compound (2033), SPC pending (2037); RDP (2032); ODE&#xA0;(2032). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Other Promoted Brands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Lucentis.</i> EU:  There is generic competition in some EU markets.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Xiidra</i>. US: Four patents on compound (2024, 2024, 2025, 2026); two patents on formulation (2024, 2033); five patents on method of treatment (2024, 2024, 2026, 2029, 2029); one patent on polymorph compound form (2029). PTE pending. There is no generic competition in the US. <i>Xiidra</i> is not marketed in the EU. In the US, the compound, compound and use, formulation, method of treatment, and polymorph compound form patents are being challenged in ANDA proceedings against generic manufacturers. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Established Brands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Sandostatin</i> SC and <i>Sandostatin</i> LAR: </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> SC: There is generic competition in the US and the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> LAR: There is generic competition in most EU countries but no generic competition in the US.    </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We provide certain patent information for non&#x2011;marketed compounds in development that have been submitted to the FDA and/or the EMA for registration but have not yet been approved by either agency. For these products, Novartis will seek all appropriate RDP, will continue to seek additional intellectual property protection for significant product developments, and will apply for PTEs and SPCs in keeping with the great importance we attach to intellectual property.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  VDT482 (tislelizumab). US: Patent on composition of matter (2033). EU: Patent on composition of matter (2033).</div>
      <div id="anchorId00315217"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Sandoz</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Sandoz Division is a global leader in generic pharmaceuticals and biosimilars, and sells products in well over 100 countries. In 2022, the Sandoz Division achieved consolidated net sales of USD 9.2&#xA0;billion, representing 18.3% of the Group&#x2019;s total net sales. Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is organized globally into three franchises: Retail Generics, Anti&#x2011;Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small-molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form anti-infectives sold to third parties. In Anti&#x2011;Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates &#x2013; mainly antibiotics &#x2013; for internal use by Retail Generics and for sale to third&#x2011;party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein&#x2011; and other biotechnology&#x2011;based products, including biosimilars.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Sandoz strategic ambition is to be the world&#x2019;s leading and most valued generics and biosimilars company . Our divisional strategy focuses on three areas: developing a broad and consistent pipeline of generic and biosimilar launches across key geographies and across a broad range of therapeutic areas; positioning Sandoz to be &#x201C;first in&#x201D; by having a strong pipeline with a focus on being first to market and &#x201C;last out&#x201D; by way of competitive costs and stable supply; and instilling a true &#x201C;generic mindset,&#x201D; with a focus on priorities, simple and rapid decision-making, and focused resource allocation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is a global market leader in biosimilars, with a total of eight approved and marketed products, and a pipeline of over 15 molecules. In addition to internally developed projects, our biosimilar portfolio comprises publicly announced commercialization agreements with BioCon, Gan &amp; Lee, EirGenix, Polpharma Biologics and Bio-Thera Solutions Ltd. Availability of our biosimilars varies by country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is also the global market leader in generic antibiotics. Its Kundl, Austria, manufacturing site is the hub of the last fully vertically integrated penicillin production chain in Europe, which offers certain competitive advantages including added supply chain resilience. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In January 2020, we closed the previously announced acquisition of the Japanese business of Aspen Global Incorporated, consisting of off-patent branded medicines with a focus on anesthetics and specialty brands.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In July 2020, Sandoz and the Austrian government announced a planned combined investment of more than EUR 150 million to enhance the long-term competitiveness and supply resilience of European production for key antibiotics. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In May 2021, Sandoz confirmed details of a previously announced investment of EUR 100 million in antibiotic manufacturing technology for its Kundl, Austria, manufacturing site, and announced an additional EUR 50 million investment in a new sterile production line in Palafolls, Spain. In November 2022, Sandoz announced an additional EUR 50 million investment to support increased manufacturing capacity for finished dosage form penicillin at its Kundl, Austria, manufacturing site.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In October 2021, Sandoz announced that its planned acquisition of GSK&#x2019;s global cephalosporin antibiotics business, first announced in February 2021, had been successfully closed.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On October 1, 2021, Sandoz Inc., the US subsidiary of Sandoz, entered into a settlement agreement with the Civil Division of the US Department of Justice (DOJ) concerning the department&#x2019;s years-long pricing investigation into the US generic drug industry. This settlement </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">40</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">was an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying conduct. As part of the settlement, Sandoz agreed to certain corporate integrity obligations as part of a corporate integrity agreement with the Office of Inspector General of the US Department of Health and Human Services, which have now been implemented. The settlement contains no new factual allegations against Sandoz and, in 2020, the Group fully provisioned for this settlement and disclosed the agreement in principle as part of the March 2020 resolution. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2022, Novartis announced its intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off, concluding the Strategic Review announced in October 2021. The Strategic Review determined that a 100% spin-off would be in the best interests of shareholders as it would create two standalone companies focused on their respective growth strategies. The new company is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US. Completion of the transaction is subject to certain conditions, including consultation with works councils and employee representatives (as required), general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder approval in line with Swiss corporate law. The transaction is expected to be generally tax neutral to Novartis, with completion expected in the second half of 2023.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Key marketed products</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Sandoz global portfolio covers a wide range of therapeutic areas. The following are some of the Sandoz key marketed products in each of its franchises (availability varies by market):</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amoxicillin/clavulanic acid</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Augmentin<sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Antibiotic</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zoledronic acid</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Aclasta</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis treatment</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acetylcysteine</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Mucolytic agent</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tacrolimus</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunosuppressive agent</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti&#x2011;Infectives</span>
      </div>
      <div style="padding-top:10px; padding-bottom:10px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Active ingredients</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile penicillins</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left" style=";width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile cephalosporins</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Clavulanic acid and mixtures with clavulanic acid</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Beta&#x2011;lactam inhibitors</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Classical and semisynthetic macrolides</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Intermediates</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various cephalosporin intermediates</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left" style=";width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macrolide base intermediates</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various crude compounds produced by fermentation</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cyclosporine, ascomycin, rapamycin, mycophenolic acid, etc.</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">41</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Omnitrope</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Genotropin  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant human growth hormone to treat growth   disorders and growth hormone deficiency</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Binocrit</i> and Epoetin alfa <i>Hexal</i></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Eprex<sup>&#xAE;</sup>/Erypo  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (erythropoiesis-stimulating) agent  to treat anemia</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Zarzio</i>, <i>Zarxio</i> and Filgrastim <i>Hexal</i></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neupogen  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (granulocyte colony-stimulating   factor, short-acting) used in oncology</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Glatopa</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Copaxone<sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Treatment for relapsing forms of multiple sclerosis</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Erelzi<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Enbrel  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Fusion protein (TNF-alpha receptor) to treat multiple   immune-mediated inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rixathon</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MabThera    <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chimeric monoclonal antibody (directed against   CD20 protein on B-cells) to treat blood cancers   and immunological diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Hyrimoz</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Humira  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-alpha antibody) to treat multiple   immune-mediated inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zessly</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Remicade  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-alpha antibody) to treat multiple   immune-mediated  inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ziextenzo</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neulasta        <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEGylated form of a recombinant human granulocyte   colony-stimulating factor (long-acting) to   reduce duration of chemotherapy-induced neutropenia   and incidence of chemotherapy-induced febrile   neutropenia</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Approved in the US in 2016. In patent litigation with Amgen, which markets Enbrel&#xAE;, the US District Court of New Jersey ruled against Sandoz in August 2019, which was upheld on appeal. The decision is final and Sandoz cannot launch its <i>Erelzi</i> product in the US until 2029.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Selected development projects &#x2013; biosimilars in Phase&#xA0;III development and registration</span>
      </div>
      <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table describes Sandoz biosimilar projects that are in registration trial or in registration with a regulatory agency (including filing preparation):</div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Project/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Common <br /> name (INN)</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Mechanism of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Potential indication/indications</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Therapeutic areas</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Current phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GP2411</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> denosumab  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-RANKL   monoclonal antibody</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis (same as originator)  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Endocrinology,   Neurology</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SOK583</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> aflibercept  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant fusion protein   that blocks VEGF-A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology indication (same as originator)  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EGI014A1<sup>1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> trastuzumab    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-HER2 recombinant   IgG1, humanized   monoclonal antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HER2+ cancer tumors    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">DST356A1<sup>2</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> natalizumab  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-alpha4 integrin   monoclonal antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multiple sclerosis and Crohn&#x2019;s disease  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neurology,   Immunology (US only)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HFT896,  SMQ969,  PYB106<sup>3</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> insulin glargine,   lispro, aspart  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Long-acting (HFT896)/   rapid-acting insulin  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Endocrinology,   Diabetology  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III/  Phase I  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VVF379<sup>4</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bevacizumab    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant humanized   monoclonal antibody that   blocks VEGF</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid tumors    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Development in collaboration with EirGenix, Inc.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Development in collaboration with Polpharma Biologics</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Development in collaboration with Gan &amp; Lee</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Development in collaboration with Bio-Thera Solutions</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">42</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The two largest generics markets in the world &#x2013; the US and Europe &#x2013; are the principal markets for Sandoz. The following table sets forth the aggregate 2022 net sales of Sandoz by region:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 net sales  to third parties</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;913</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;754</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;613</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many Sandoz products are used for chronic conditions that require patients to consume the product over long periods of time, from months to years. Sales of our anti&#x2011;infective products and over-the-counter cough and cold products are subject to material changes in seasonal demand, while sales of the vast majority of our other products are not. The COVID-19 pandemic has substantially impacted seasonal variation in recent years. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For information on the production of our products, see &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Production.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2020, as part of a broader reorganization of Novartis Technical Operations (NTO), we established the Sandoz Technical Operations (STO) platform within NTO. STO focuses on producing generic medicines for Sandoz, as well as related external supply operations and supply chain. In October 2021, Sandoz created a new position, Global Head, Sandoz Operations. This new, broader role, includes full operational and financial accountability for manufacturing and supply as of January 1, 2023, and was established in anticipation of the intended Sandoz 100% spin-off. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to impurities found in the active ingredient batches sourced from third-party manufacturers, we recalled Sandoz valsartan, losartan and irbesartan products in the second half of 2018 and the first quarter of 2019, and ranitidine film-coated tablets in the second half of 2019, from several markets, in line with our quality standards for all of our marketed products. The discovery of nitrosamines in some types of drug products led several health regulators (e.g., EMA, FDA and others) to conduct a detailed analysis of these impurities in affected medicinal products. Novartis works with health authorities around the world to continuously review all chemical and biological human medicines for the possible presence of nitrosamines. The EMA, FDA and other health authorities have provided guidance to the pharmaceutical industry to prevent unacceptable levels of nitrosamines in medicines. The EMA review concluded in March 2021 for chemical human medicines and in July 2021 for biological human medicines. Based on guidance from health authorities, any chemical and/or biological human medicines products identified with a potential risk for nitrosamines will undergo further testing. For these products, we have provided initial testing and potential control strategy updates to the EMA and other health authorities. Due to constant and rapidly evolving health authority requirements, the risk assessment and related testing that we may be required to perform may increase.  We will submit and communicate the final outcome of any risk assessment and related testing to the relevant health authorities within their expected time frame, and make changes to the control strategy update, if necessary.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Beginning in September 2021, we initiated a voluntary recall of all finished product batches of losartan and losartan HCT products exceeding or potentially exceeding acceptable regulatory limits of the losartan azide impurity in the losartan drug substance. This impurity, which is viewed as an industrywide issue, was initially considered a mutagen that may increase the risk of cancer over time if allowed to rise above certain levels. This recall was unrelated to the nitrosamine-related recalls described above, and supply was re-established in March 2022. Since the voluntary recall, further information has been provided to the EMA by Novartis and other companies in the industry, and the EMA has concluded that the losartan azide impurity is to be classified as a non-mutagenic impurity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz sells a broad portfolio of products, including the products of our Retail Generics franchise and biosimilars, to wholesalers, pharmacies, hospitals and other healthcare outlets. Sandoz adapts its marketing and sales approach to local decision-making processes, depending on the structure of the market in each country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In response to rising healthcare costs, many governments and private medical care providers, such as health </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">43</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">maintenance organizations, have instituted reimbursement schemes that favor the substitution of bioequivalent generic versions of originator pharmaceutical products, such as those sold by our Retail Generics franchise. In the US, statutes have been enacted by all states that permit or require pharmacists to substitute a less expensive generic product for the brand&#x2011;name version of a drug that has been prescribed to a patient. Generic use is growing in Europe, but penetration rates in many EU countries (as a percentage of volume) remain well below those in the US.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Recent trends have been toward continued consolidation among distributors and retailers of Sandoz products, both in the US and internationally, which has increased our customers&#x2019; purchasing leverage.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legislative or regulatory changes can have a significant impact on our business in a country. For more information on such changes, see &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Anti&#x2011;Infectives franchise supplies active pharmaceutical ingredients and intermediates &#x2013; mainly antibiotics &#x2013; for internal use by Retail Generics and for sale to the pharmaceutical industry worldwide.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Biopharmaceuticals franchise operates in an already mature market framework in Europe and some other markets, while the business environment is rapidly evolving in the US and many international markets. Regulatory pathways for approving biosimilar products are at various stages of maturity by market, but in some cases are still relatively new or still in development. Policies have not yet been fully defined or implemented regarding the substitution and reimbursement of biosimilars in many markets, including the US. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The market for generic products is characterized by increasing demand for high&#x2011;quality pharmaceuticals that can be marketed at lower costs due to comparatively minimal initial research and development investments. Increasing pressure on healthcare expenditure and numerous patent and data exclusivity period expirations have encouraged more generic product launches, resulting in increased competition among the companies selling generic pharmaceutical products, leading to ongoing price pressure. In particular, Sandoz faces increased industrywide pressure on prices for generic products, particularly in the US, driven by factors including customer consolidation and growing competition from other manufacturers of generic medicines. These factors contributed to a decline in industrywide US sales that began in 2017 and continued through 2022. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Development and registration</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Development of Sandoz Biopharmaceuticals is jointly overseen by Sandoz and GDD, and is governed by the IMB. Development and registration activities for Retail Generics products, and registration activities for Biopharmaceuticals products, are also overseen by Sandoz.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Before a generic pharmaceutical may be marketed, intensive technical and clinical development work must be performed to demonstrate, in bioavailability studies, the bioequivalence of the generic product to the reference product. Nevertheless, research and development costs associated with generic pharmaceuticals are generally much lower than those of the originator pharmaceuticals, as no original drug discovery, preclinical studies or clinical trials on dose finding, safety and efficacy are typically performed by the generics company. As a result, the different focus and lower costs of the generic pharmaceutical model ultimately allow generic pharmaceutical products to be offered at lower prices, which support and contribute to the cost containment goals of healthcare systems.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While generic pharmaceuticals are follow&#x2011;on versions of chemically synthesized molecules, biosimilar products contain a version of the active substance of an already approved biological reference medicine. Due to the inherent variability and complexity of biologic products, including batch&#x2011;to&#x2011;batch differences and variations following manufacturing changes, the development and the regulatory pathway of biosimilars differ significantly from that of generics.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The development of a biosimilar product is much more technically challenging than the development of a typical generic small-molecule pharmaceutical. While generic pharmaceuticals normally do not require clinical studies in patients, regulators worldwide do still require such targeted studies for biosimilar products. International regulators are nonetheless increasingly discussing the potential for &#x201C;tailored development&#x201D; (which refers to proposals that seek to implement a more efficient and expedited biosimilar development process that eliminates the current need for comparative clinical efficacy and safety studies of biosimilars, without any resulting compromise on quality, safety or efficacy) for certain molecules. Biosimilars are engineered to match the reference medicine in quality, safety and efficacy. This is achieved by systematically defining the target range of the reference medicine and then comparing the biosimilar to the reference medicine at various development stages to confirm biosimilarity and to establish that there are no clinically meaningful differences between the proposed biosimilar and the reference biologic. Because the purpose of a biosimilar clinical development program is to confirm biosimilarity and not to establish efficacy and safety de novo, the clinical studies required are less than those required for a reference biologic. Therefore, the cost of development for a biosimilar is usually less than that of a reference biologic.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The development and registration staff employed by affiliates of the Sandoz Division are based worldwide, including at facilities in Holzkirchen, Germany; Hyderabad, India; Kundl, Austria; Ljubljana, Slovenia; and Rudolstadt, Germany. In November 2020, Sandoz completed (i) the previously announced closure of the Holzkirchen, Germany, development and registration site, with the exception of patch development and the project management group, and (ii) the closure of the product development and registration site as well as the maintenance and development regulatory centers in Unterach, Austria. We conduct an ongoing review of our global development and regulatory network to consolidate and streamline operations and optimize our network structure to enable Sandoz to compete sustainably in an increasingly challenging generics environment. In 2021, Sandoz completed the previously announced closures of its maintenance regulatory center in Barleben, Germany, its Fougera development center located in </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">44</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Melville, New York, as well as its product development center in Boucherville, Canada.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Generics</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Hatch&#x2011;Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown to be therapeutically equivalent to the reference product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the decision on whether a generic pharmaceutical is therapeutically equivalent to the original product is made by the FDA based on an Abbreviated New Drug Application (ANDA) filed by the generic product&#x2019;s manufacturer. An ANDA is generally permitted to be filed four years after the initial approval of the reference product and generally cannot be fully approved by the FDA until any regulatory exclusivity of the reference product has expired. The process typically takes nearly two years from the filing of the ANDA until FDA approval. However, delays can occur if issues arise, for example, regarding the interpretation of bioequivalence study data, labeling requirements for the generic product, or qualifying the supply of active ingredients. In addition, the Hatch&#x2011;Waxman Act requires a generic manufacturer to certify in certain situations that the generic product does not infringe on any current applicable patents on the product held by the holder of the marketing authorization for the reference product, or to certify that such patents are invalid. This certification often results in a patent infringement lawsuit being brought against the generics company. In the event of such a lawsuit, the Hatch&#x2011;Waxman Act imposes an automatic 30-month stay in the approval of the ANDA to allow the parties to resolve the intellectual property issues. For generic applicants who are the first to file their ANDA containing a certification claiming non&#x2011;infringement or patent invalidity, the Hatch&#x2011;Waxman Act generally provides those applicants with 180&#xA0;days of marketing exclusivity, enabling such generic applicants to exclusively market their product alongside the reference product at a certain point in time, which is generally after any intellectual property issues have been resolved. However, after such point in time, the generic applicants must launch their products within certain time frames or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. See &#x201C;&#x2014;Innovative Medicines&#x2014;Regulation&#x2014;European Union.&#x201D; Companies may submit abridged applications for approval of a generic medicinal product based upon its &#x201C;essential similarity&#x201D; to a medicinal product authorized and marketed in the EU following the expiration of the product&#x2019;s data exclusivity period. In such cases, the generics company is able to submit its abridged application based on the data submitted by the innovator company for the reference product, without the need to conduct extensive Phase&#xA0;III clinical trials of its own. For all products that received a marketing authorization in the EU after late 2005, the abridged application can be submitted throughout the EU. However, the data submitted by the innovator company in support of its application for a marketing authorization for the reference product is generally protected for 10 years after the first grant of marketing authorization in all member states, and can be extended for an additional year if, during the initial eight&#x2011;year data exclusivity period, the innovator company registers a new therapeutic indication with &#x201C;significant clinical benefit.&#x201D; In the case of orphan drugs, it may be extended with a two&#x2011;year pediatric extension. See &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Intellectual property.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biosimilars</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The regulatory pathways for approval of biosimilar medicines are still being developed and established in many countries of the world. A regulatory framework for the approval of biosimilars has been established in the EU, Japan, Canada and the US, while the World Health Organization (WHO) has issued guidance. Sandoz has successfully registered and launched the first biosimilar (or biosimilar-type) medicine in Europe, the US, Canada, Japan, Taiwan, Australia, and many countries in Latin America and Asia. Sandoz was the first company to secure approval for and launch a biosimilar under the US biosimilar pathway that was established as part of the Biologics Price Competition and Innovation Act (BPCIA). The approval of biosimilars in Europe follows a process similar to that followed for small molecules. However, biosimilars usually have to be approved through the centralized procedure because they are manufactured using recombinant DNA technology. As part of the approval process in the EU, biosimilars have to demonstrate comparability to the reference medicine in terms of safety, efficacy and quality through an extensive comparability exercise, based on strict guidelines set by the authorities. Regulators will only approve a biosimilar based on data that allows the regulators to conclude that there are no clinically meaningful differences between the reference medicine and the biosimilar.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, under the BPCIA, a biosimilar must be highly similar with no clinically meaningful differences compared to the reference medicine. Approval of a biosimilar in the US requires the submission of a BLA to the FDA, including an assessment of immunogenicity and pharmacokinetics; an efficacy study; and possibly a pharmacodynamics study. The BLA for a biosimilar can be submitted as soon as four years after the initial approval of the reference biologic, but can only be approved 12&#xA0;years after the initial approval of the reference biologic. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We take all reasonable steps to ensure that our products do not infringe valid intellectual property rights held by others, including taking steps to proactively challenge intellectual property rights that we believe should not have been granted. Nevertheless, competing companies </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">45</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">commonly assert patent and other intellectual property rights. As a result, we can become involved in significant litigation regarding our products. If we are unsuccessful in defending these suits, we could be subject to injunctions preventing us from selling our products and to potentially substantial damages.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Wherever possible, our products are protected by our own patents. Among other things, patents may cover the products themselves, including the product&#x2019;s formulation, or the processes for manufacturing a product. However, there can be no assurance that our intellectual property will protect our products or that we will be able to avoid adverse effects from the loss of intellectual property protection in the future.</div>
      <div id="anchorId00316123"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.C Organizational structure</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Organizational structure</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.A History and development of Novartis&#x201D; and &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.B Business overview&#x2014;Overview.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant subsidiaries</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div id="anchorId00316141"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.D Property, plants and equipment</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our principal executive offices are located in Basel, Switzerland. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We generally own our facilities or have entered into long-term lease arrangements for them. Some of our principal facilities are subject to mortgages and other security interests granted to secure certain debts. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis Operations manages the production, supply chains and quality of our Innovative Medicines and Sandoz Division products through a network of 55 manufacturing sites, as well as through external suppliers, and warehouse and distribution centers. In addition, Novartis Operations also manages non-production real estate owned or leased by Novartis around the world.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth our major headquarters and most significant production, research and development, and administrative facilities. See also &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Production&#x201D; and &#x201C;&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Production&#x201D; for a discussion of our manufacturing processes.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Major facilities</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Location</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Size of site <br /> (in square meters)</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Major activity</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel, Switzerland &#x2013; St.&#xA0;Johann</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589&#xA0;000    </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Group headquarters; global Innovative Medicines Division headquarters;   global Sandoz Division headquarters; research and development;   production of drug substances and drug intermediates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl and Schaftenau, Austria</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480&#xA0;000  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of biotechnological products, drug products and finished products,   anti&#x2011;infectives, active drug substances and nucleic acids; product development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, New Jersey</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 391&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Innovative Medicines Division US headquarters; research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben, Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 340&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of broad range of generics finished dosage forms</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Massachusetts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&#xA0;800</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Menges, Slovenia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of drug substances and drug intermediates</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai, China</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;700  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of sterile vials, pre&#x2011;filled syringes and ampoules; inhalation capsules,   tablets and transdermals; active pharmaceutical ingredients; and cell and gene therapies</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen, Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;200  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sandoz Division production of transdermal delivery systems and certain international   and global service functions.</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Huningue, France</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of drug substances for clinical and commercial supply</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Durham, North Carolina</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;794  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Manufacture, package and release commercial Zolgensma product   and certain clinical development activities</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, New Jersey</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;300</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sandoz Division US headquarters</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Schweizerhalle, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;880</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Manufacture of small-interfering RNA (siRNA) drug substance for Leqvio</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">46</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As our product portfolio evolves, Novartis Operations is adapting our manufacturing capacity and capabilities to meet our changing needs, shifting from high-volume products toward lower-volume, customized and personalized medicines. As of December 31, 2022, we have closed, exited or sold 19 manufacturing sites since 2019 and have announced the closure, exit or sale of seven additional manufacturing sites. We have continued to invest in new technologies implemented at our sites, such as the new targeted radioligand therapy production facility in Indianapolis, Indiana, which is currently under construction (with an expected size of approximately 67 thousand square meters), the FDA-approved <i>Zolgensma</i> production site in Durham, North Carolina, and the small-interfering RNA (siRNA) oligonucleotide manufacturing facility in Schweizerhalle, Switzerland. We are leveraging innovation to increase the reliability and productivity of our manufacturing network, including using data and digital technologies. We continue to seek opportunities to manage our production facilities as efficiently as possible, optimize external spend, and simplify and standardize across our manufacturing network to help us increase our cost competitiveness and optimize the value of our products. At the same time, we are working to improve our environmental sustainability, for example by reducing energy, waste disposal and water consumption at our sites by making our manufacturing processes more efficient, introducing new technologies, and switching to clean and renewable energy solutions. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of the impact of environmental matters, see &#x201C;Item&#xA0;3. Key Information&#x2014;Item&#xA0;3.D Risk factors&#x2014;Environmental, social and governance matters&#x2014;Failure to meet increasingly challenging environmental, social and governance expectations,&#x201D; &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Environmental matters&#x2014;Impact of environmental liabilities,&#x201D; and &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Climate change&#x2014;Climate change and increased risk of major natural disasters.&#x201D; See also &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;20. Provisions and other non&#x2011;current liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">47</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00316354"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4A.  Unresolved Staff Comments</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">48</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId0010011046"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 5. Operating and Financial Review and&#xA0;Prospects</p>
      <div id="anchorId0010011049"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.A Operating results</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This operating and financial review should be read with the Group&#x2019;s consolidated financial statements in this Annual Report, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as published by the International Accounting Standards Board (see &#x201C;Item 18. Financial Statements&#x201D;). &#x201C;Item 5. Operating and Financial Review and Prospects&#x201D; with the sections on compounds in development and selected development projects of our divisions (see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x201D;) constitute the Operating and Financial Review (Lagebericht), as defined by the Swiss Code of Obligations. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The discussion and analysis of the financial condition and results of operations of certain items from fiscal year ended December 31, 2020, and year-to-year comparison between fiscal year ended December 31, 2021, and December 31, 2020, that are not included in this Form 20-F can be found in &#x201C;Item 5. Operating and Financial Review and Prospects&#x201D; of our Form 20-F for the fiscal year ended December 31, 2021, which is incorporated by reference herein.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our Company. Our vision is to become the most valued and trusted medicines company in the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Innovative Medicines: innovative patent-protected prescription medicines</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sandoz: generic pharmaceuticals and biosimilars</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, we separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. Corporate also includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In April 2022, we announced a new, integrated organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. For information about this new organizational structure, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; Under this new organizational structure, our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research, Global Drug Development, and Novartis Operations. The financial results of these organizational units are included in the results of the divisions for which their work is performed. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant transactions are discussed in &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions,&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D; </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our business environment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Medical technology continues to accelerate, with new advanced treatments emerging to meet the growing need for high-quality healthcare. At the same time, aging populations are putting pressure on healthcare resources, while access to healthcare remains a challenge around the world. As a result, we see challenges and opportunities in our business environment: the need for continuous innovation in healthcare, increasing access to medicines, the adoption of new working practices and the growing use of data science and technology. The following are some major trends currently shaping our business environment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Spending on healthcare continues to grow.</i> The need for high-quality healthcare is more critical than ever. Over the next five years, global spending on medicines is forecast to rise faster than GDP in many developed countries. The price of medicines remains a key issue as increased healthcare spending and a more uncertain economic outlook weigh on government budgets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Aging populations are fueling a rise in chronic illness</i>. Aging and lifestyle changes are triggering an increase in noncommunicable diseases, such as cancer, heart disease and diabetes, causing millions of preventable deaths and putting further pressure on healthcare resources. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Medical science continues to accelerate. </i>Scientific innovation is advancing at an unprecedented pace. In recent years, new types of treatments have been approved, including RNA therapies, gene and cell therapies, and radioligand therapies, which offer targeted approaches to treating serious diseases. Because these medicines are complex, they require focused investment and expertise to bring them to reality for patients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Access to healthcare remains a formidable challenge. </i>Worldwide, millions of patients struggle to access the medicines they need. This may be because of cost, inequity, or structural issues in healthcare systems. While access to medicines remains an acute issue in lower-income countries, it is a problem in developed </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">49</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">countries too, where the COVID-19 pandemic highlighted that deep health inequities remain entrenched.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Patients are moving to the center of healthcare. </i>Patients are demanding more say over their treatment through patient representative groups and other means. In response, healthcare systems and pharmaceutical companies are adapting, moving toward a more integrated, end-to-end approach, with an increased focus on patient engagement in drug development and other areas. At the same time, patients are becoming more important as data owners &#x2013; as personal data allows more targeted treatments and supports development of new medicines.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Economic uncertainty is growing, post-COVID-19 pandemic</i>. The global economy is facing considerable uncertainty, driven by concerns over rising energy prices and geopolitical instability. Forecasts suggest the current economic slowdown is likely to continue in 2023. In our own industry, the COVID-19 pandemic put strain on supply chains and highlighted the importance of resilient supplies of active pharmaceutical ingredients &#x2013; the raw materials used to make finished medicines. See &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Pricing, reimbursement and access&#x2014;Pricing and reimbursement pressure, including pricing transparency and access to healthcare,&#x201D; and &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Macroeconomic developments&#x2014;Impact of macroeconomic developments.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Biopharma searches for more efficiency. </i>At a time of growing economic uncertainty, investors are looking for sustainable growth in margins and earnings. To remain competitive, pharmaceutical companies are moving to more agile, cost-efficient business models, particularly as they invest to build specialized capabilities in research and development (R&amp;D) and manufacturing. Meanwhile, rates of return on R&amp;D are increasing for the first time in several years, largely because of emergency approvals during the COVID-19 pandemic and faster innovation cycles.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>New technologies are reshaping our industry</i>. The use of data science and technology is increasing across the industry in everything from R&amp;D to manufacturing and marketing. This has brought greater efficiency, but it also requires new investment and skills. Importantly, new technologies are helping close gaps between companies, healthcare systems and patients &#x2013; for example, by providing insights into the social determinants of heart health enabling the development of new prevention measures.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Working practices are changing</i>. Working practices are changing in many countries. Demand for new skills is increasing, especially in areas such as data science. Workforces are becoming more flexible and more diverse, allowing companies to tap into new talent pools &#x2013; important at a time of skills shortages in many parts of the economy.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Climate change is increasingly affecting human health.</i> Climate change could undermine decades of progress in improving human health at a time when antimicrobial resistance is also rising. At the same time, more governments are looking to decarbonize their economies over the long-term, while companies also face increased scrutiny over the sustainability of their operations and supply chains. See &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Climate change&#x2014;Impact of climate change and increased risk of major natural disasters.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our strategy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our strategy as a focused medicines company is to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in R&amp;D and novel access approaches.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We have made significant progress in transforming Novartis from a diversified healthcare conglomerate into a focused medicines company. In doing so, we have divested or spun off non-core businesses and made targeted acquisitions to focus on our core business: discovering and developing new medicines and finding new ways to deliver them to as many people as possible.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we continued to execute on our strategy by putting in place a new organizational structure to support innovation, growth and productivity. We also updated our strategic priorities and announced our intention to spin-off our Sandoz business, which paves the way for Novartis to advance as a company focused fully on innovative medicines. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview&#x201D; and &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Sandoz.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our strategy has clear focus areas and priorities to meet the challenges and opportunities we see in our business environment, and ensure we continue to create value for our stakeholders and society. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our focus areas determine where we invest most of our time, energy and resources and include: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Core therapeutic areas </b>with high unmet patient needs: cardiovascular; immunology; neuroscience; solid tumors; and hematology.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Technology platforms </b>where we have the depth and scale to discover, develop and commercialize new therapies: Chemistry; biotherapeutics; xRNA; radioligand therapy; and gene and cell therapy.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Priority geographies </b>which, taken together, account for the majority of the forecast growth in global healthcare spending: US, China, Germany and Japan. While these are our priority countries, we will continue to invest in other markets worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our focus areas are supported by three strategic priorities, which determine how we implement our strategy. These three strategic priorities are:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Deliver high-value medicines to accelerate growth</i></b>. Delivering new medicines for major diseases is at the core of our purpose and value creation as a company. We focus on high-value innovative medicines with the potential to transform the treatment of diseases across our five core therapeutic areas.  To do this, we seek to maximize the potential of our key in-market and launch medicines, while finding new ways to deliver them to as many people as possible and investing in R&amp;D to deliver the next generation of high-value therapies for patients over the longer term. As part of our efforts, we continue our longstanding commitment to reduce the burden of infectious and tropical diseases that predominantly affect underserved populations in low- and middle-income countries.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">50</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Embed operational excellence to deliver returns</i></b>. We aim to drive efficiency and free up resources to invest in innovation for patients. This also underpins our financial performance and makes us more agile; better able to take quick decisions and scale the use of new technologies, with effective cooperation across our business. In everything we do, we maintain high standards of product quality and patient safety, while also working to reduce our environmental footprint.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Strengthen our foundations by</i></b>:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Unleashing the power of our people.</i>
        </span>  We continue to focus on culture as a key enabler of our strategy to drive innovation and long-term performance. For us, this is about building an agile, diverse workforce and making sure we attract and retain the right talent for the future.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Scaling data science and technology.</i>
        </span>  We are investing in data science and technology to increase efficiency, support innovation, better respond to the needs of patients and healthcare professionals, and ultimately improve the way we develop and deliver our medicines.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Building trust with society.</i>
        </span>  We aim to increase access to our medicines for underserved populations around the world and follow high standards of ethical behavior wherever we operate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">51</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Results of operations </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key figures<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;545</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;626</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;283</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15&#xA0;486</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15&#xA0;867</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&#xA0;010</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;886</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;996</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;540</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 805</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -57</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -54</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&#xA0;701</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;747</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -35</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -43</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">% of net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -64</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">52</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties for Novartis were USD 50.5 billion, down 2% in USD reported terms and up 4% measured in constant currencies (cc) to remove the impact of exchange rate movements. Sales growth was driven by volume growth of 11 percentage points, mainly driven by continued strong growth from <i>Entresto</i>, <i>Kesimpta</i>, <i>Kisqali, Pluvicto</i> and <i>Cosentyx</i>. Generic competition had a negative impact of 3 percentage points, mainly due to <i>Gilenya, Afinitor/Votubia</i>, <i>and Gleevec/Glivec</i>. Pricing had a negative impact of 4 percentage points. Sales in the US were USD 17.7 billion (+5%) and in the rest of the world USD 32.8 billion (-6%, +4% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">By division, Innovative Medicines delivered net sales of USD&#xA0;41.3 billion (-2%, +4% cc) and Sandoz net sales were USD&#xA0;9.2 billion (-4%, +4% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Emerging Growth Markets, which comprise all markets excluding the US, Canada, Western Europe, Japan, Australia and New Zealand, sales to third parties were USD&#xA0;13.5 billion (+2%, +9% cc) driven by China (USD&#xA0;3.1 billion) growing 2% (+6% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Operating income was USD 9.2 billion (-21%, -13% cc), mainly due to higher restructuring costs (USD 1.2 billion) primarily related to the implementation of the previously announced streamlined organizational model, higher impairments (USD 1.0 billion), and lower divestment gains (USD 0.6 billion). Operating income margin was 18.2% of net sales, decreasing by 4.4 percentage points (-3.8 percentage points cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net income was USD 7.0 billion compared with USD 24.0 billion in the prior year, impacted by Roche income in the prior year. Excluding the impact of Roche income, net income declined -9% (cc). Earnings per share were USD 3.19 compared with USD 10.71 in the prior year. Excluding the impact of Roche income, EPS declined -7% (cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows from operating activities amounted to USD 14.2 billion, compared with USD 15.1 billion in 2021. This decrease was mainly due to unfavorable changes in working capital and lower dividends from associated companies (2021 included the USD 0.5 billion dividends received from our investment in Roche, which was divested in the fourth quarter of 2021), partly offset by lower income taxes paid and favorable hedging results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow amounted to USD 11.9 billion (&#x2013;10% USD), compared with USD 13.3 billion in 2021, mainly due to a decrease in net cash flows from operating activities and lower divestment proceeds, partly offset by lower purchases of property, plant and equipment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also present our core results<sup>1</sup>, which exclude the impact of amortization, impairments, disposals, acquisitions, restructurings and other significant items, to help investors understand our underlying performance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 16.7 billion (0%, +8% cc), benefiting from higher sales, partly offset by higher research and development (R&amp;D) investments. Core operating income margin was 33.0% of net sales, increasing by 0.9 percentage points (+1.3 percentage points cc).  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core net income was USD 13.4 billion (-5%, +3% cc) as growth in core operating income was partly offset by the loss of Roche core income. Excluding the impact of Roche core income, core net income grew +11% (cc). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup> For an explanation of non-IFRS measures and reconciliation tables, see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">53</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by segment</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of net sales to third parties by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41&#xA0;995</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;545</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division delivered net sales of USD 41.3 billion (-2%, +4% cc) with volume contributing 12 percentage points to growth. Generic competition had a negative impact of 4 percentage points. Pricing had a negative impact of 4 percentage points. Sales in the US were USD 15.9 billion (+6%) and in the rest of the world USD 25.4 billion (-6%, +3% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sales growth was mainly driven by continued strong growth from <i>Entresto</i> (USD 4.6 billion, +31%, +37% cc), <i>Kesimpta</i> (USD 1.1 billion, +194%, +200% cc), <i>Kisqali</i> (USD 1.2 billion, +31%, +38% cc), <i>Pluvicto</i> (USD 271 million) and <i>Cosentyx</i> (USD 4.8 billion, +1%, +5% cc), partly offset by generic competition mainly for <i>Gilenya</i>, <i>Afinitor</i>/<i>Votubia</i> and <i>Gleevec</i>/<i>Glivec</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US (USD 15.9 billion +6%), sales growth was mainly driven by <i>Entresto</i>, <i>Kesimpta</i> and <i>Pluvicto</i>, partly offset by the impact of generic competition on <i>Afinitor</i>/<i>Votubia</i> and <i>Gilenya</i>. In Europe (USD 13.6 billion, -9%, +1% cc) sales growth was driven by <i>Entresto</i>, <i>Kisqali</i> and <i>Kesimpta</i>, partly offset by increased generic competition for <i>Gilenya</i>. Emerging Growth Markets grew +2% (+9% cc), with China sales USD 2.9 billion (+3%, +7% cc) driven by <i>Cosentyx</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by core therapeutic area; other promoted brands; and established brands in the Innovative Medicines Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cardiovascular</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;756</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Immunology</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;287</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;205</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Neuroscience</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;051</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;007</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Solid Tumors</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;723</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;101</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Hematology</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;452</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;430</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other Promoted Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;127</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&#xA0;396</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&#xA0;754</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Established Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;900</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> - 13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">54</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides the top 20 Innovative Medicines Division product net sales to third parties in 2022 as well as the change compared with 2021:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Brands</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Key indications</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD/cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td style=";width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td style=";width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;770          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;018          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;788          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;354  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;290  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;644  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;083    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;005    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;088    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;153  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 860  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -37  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -29  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;013  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -28  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -24  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 877  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;046  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;923  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;874      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;874      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Tafinlar</i> + <i>Mekinist</i></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 678          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;092          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;770          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11          </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;561      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;561      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 434  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 936  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;370  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;365    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;365    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 438  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;238  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 472  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 759  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;231  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 570    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 563    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;133    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 921  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;092  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Galvus</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -22      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 540      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -29      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 745      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -22      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Exforge</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 743</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Diovan</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 597</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 652</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 340        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 536        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2        </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 512    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -45    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -41    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;753</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&#xA0;384</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;146</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;013</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;159</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   15&#xA0;899</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   25&#xA0;397</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">55</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For the table providing the top 20 Innovative Medicines Division product net sales to third parties in 2021, see &#x201C;Item 18. Financial statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the approved indications for certain products described, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014; Innovative Medicines Division products.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Cardiovascular</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Cardiovascular therapeutic area were USD 4.8 billion (+34%, +40% cc), sales growth mainly driven by <i>Entresto.</i></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Entresto</i> (USD 4.6 billion, +31%, +37% cc) sustained robust demand-led growth, with increased patient share across all geographies. Guidelines position <i>Entresto</i> as the first choice RASi versus ACEi/ARB in patients with HFrEF. <i>Entresto</i> benefits from the adoption of guideline directed medical therapy for these patients in all geographies. In the US, <i>Entresto</i> benefits from being added to guidelines for patients with HFpEF (with LVEF below normal). In China, <i>Entresto</i> has been listed in the National Reimbursement Drug List (NRDL) for both HFrEF and hypertension, effective January 2022. In China and Japan, <i>Entresto</i> volume growth is fueled by increased penetration in hypertension in addition to growth in heart failure. It is estimated that around 10 million patients are on treatment with <i>Entresto</i>. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Leqvio</i> (USD 0.1 billion) launch in the US and other markets is ongoing, with focus on patient on-boarding, removing access hurdles and enhancing medical education. <i>Leqvio</i> is the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol approved in the US and was launched in January 2022. In the US, <i>Leqvio</i> is covered at or near label for 76% of patients eleven months after launch. <i>Leqvio</i> in the US has been assigned a unique Healthcare Common Procedure Coding System code (J-code) and average sales price. <i>Leqvio</i> is now approved in 70 countries. Novartis obtained global rights to develop, manufacture and commercialize <i>Leqvio</i> under a license and collaboration agreement with Alnylam Pharmaceuticals.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Immunology</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Immunology therapeutic area reached USD 7.3 billion (+1%, +7% cc), sales growth was mainly driven by <i>Cosentyx</i> and <i>Ilaris</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Cosentyx</i> (USD 4.8 billion, +1%, +5% cc) sales grew in Emerging Growth Markets, Europe and Japan, partly offset by decline in the US due to higher revenue deductions. In China, <i>Cosentyx</i> growth was fueled by increased biologic uptake and inclusion in approximately 1,900 hospital listings. Since initial approval in 2015, <i>Cosentyx</i> has proven its sustained efficacy and consistent safety profile across five systemic inflammatory conditions and has treated more than 960,000 patients worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Xolair</i> (USD 1.4 billion, -4%, +6% cc) sales grew (cc) in Emerging Growth Markets, Europe and Japan. Novartis co-promotes <i>Xolair</i> with Genentech in the US and shares a portion of revenue as operating income but does not record any US sales.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Ilaris</i> (USD 1.1 billion, +7%, +15% cc) showed continued growth across all geographies. Contributors to growth include the adult-onset Still&#x2019;s disease indication, together with the other adult rheumatology indications in the US and Europe, as well as strong performance for the Periodic Fevers Syndrome indications in Japan.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Neuroscience</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Neuroscience therapeutic area were USD 5.1 billion (+1%, +5% cc), sales growth (cc) mainly driven by <i>Kesimpta</i>, which was partly offset by sales decline of <i>Gilenya</i>. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Gilenya</i> (USD 2.0 billion, -28%, -24% cc) sales declined mainly in Europe and in the US due to generic pressure. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Zolgensma</i> (USD 1.4 billion, +1%, +5% cc) has been approved in 47 countries to date. As this represents most major markets, sales growth is now mainly driven by the Incident patient population where we&#x2019;ve seen double digit growth in 2022. Access pathways are now in place in 35 countries with negotiations ongoing in additional markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kesimpta</i> (USD 1.1 billion, +194%, +200% cc) showed strong sales growth driven by launch momentum across all geographies. <i>Kesimpta</i> is a targeted B-cell therapy that can deliver powerful and sustained high efficacy, with a favorable safety and tolerability profile and the flexibility of an at home self-administration for a broad population of RMS patients. <i>Kesimpta</i> is now approved in 80 countries with more than 36,000 patients treated.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Mayzent</i> (USD 0.4 billion, +27%, +32% cc) sales grew across all geographies in MS patients showing signs of progression despite being on other treatments. <i>Mayzent</i> is the first and only oral disease-modifying therapy studied and proven to delay disease progression in a broad SPMS patient population.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Aimovig</i> (USD 0.2 billion, +1%, +11% cc) sales grew in Europe and Emerging Growth Markets. <i>Aimovig</i> is reimbursed in 32 markets and has been prescribed to over 759,000 patients worldwide. Earlier this year, <i>Aimovig</i> was submitted for approval in China. In October 2022, Novartis reached an agreement in Germany by which <i>Aimovig</i> is reimbursed as a 1st line prophylactic migraine treatment based on the HER-MES trial.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Solid Tumors</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Solid Tumors therapeutic area were USD 4.7 billion (+15%, +21% cc), sales growth mainly driven by <i>Kisqali</i>, <i>Pluvicto</i> and <i>Tafinlar</i> + <i>Mekinist</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tafinlar</i> + <i>Mekinist</i> (USD 1.8 billion, +5%, +11% cc) sales grew across all geographies, driven by demand in BRAF+ adjuvant melanoma and NSCLC indications, while maintaining demand in the highly competitive BRAF+ metastatic melanoma market. <i>Tafinlar</i> + <i>Mekinist</i> remains the worldwide targeted therapy leader in BRAF+ melanoma. Following FDA approval in late June, <i>Tafinlar</i> + <i>Mekinist</i> is the first and only therapy with a tumor-agnostic indication for adult and pediatric patients with solid tumors that have a BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kisqali</i> (USD 1.2 billion, +31%, +38% cc) sales grew strongly across all geographies, based on increasing recognition of its overall survival and quality of life benefits in HR+/HER2- advanced breast cancer. It is a CDK4/6 </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">56</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">inhibitor with proven overall survival benefit across all three Phase III trials of the MONALEESA program regardless of menopausal status, line of therapy, site and number of metastases, endocrine resistance, or endocrine partner. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Votrient</i> (USD 0.5 billion, -18%, -13% cc) declined due to increased competition, especially from immuno-oncology agents in metastatic renal cell carcinoma.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Lutathera</i> (USD 0.5 billion, -1%, +3% cc) sales grew (cc) in Europe and Japan, partly offset by decline in the US. There are approximately 500 centers actively treating patients globally. In the second quarter of 2022, there was a temporary suspension in manufacturing during the quarter; production and deliveries of patient doses resumed in early June.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Piqray</i> (USD 0.4 billion, +13%, +14% cc) sales grew mainly in the US, benefiting from indication expansion into PIK3CA-related overgrowth spectrum (PROS). <i>Piqray</i> is the first and only therapy specifically developed for the approximately 40% of HR+/HER2- advanced breast cancer patients who have a PIK3CA mutation, which is associated with a worse prognosis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Pluvicto</i> (USD 0.3 billion) launch is progressing well, with more than 160 active centers ordering. <i>Pluvicto</i> is the first and only radioligand therapy approved by the FDA for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer, who have already been treated with other anticancer treatments (ARPI and taxane-based chemotherapy).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tabrecta</i> (USD 0.1 billion, +48%, +48% cc) sales grew across all geographies, as the first therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Hematology</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Hematology therapeutic area were USD 6.5 billion (0%, +7% cc), sales growth (cc) mainly driven by <i>Promacta</i>/<i>Revolade</i>, <i>Jakavi</i> and <i>Scemblix</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Promacta</i>/<i>Revolade</i> (USD 2.1 billion, +4%, +9% cc) growth was driven by the US, Europe and Emerging Growth Markets, partly offset by decline in Japan. Sales growth was driven by increased use in second-line persistent and chronic immune thrombocytopenia and as first-line and/or second-line treatment for severe aplastic anemia.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tasigna</i> (USD 1.9 billion, -7%, -1% cc) sales declined in Europe, Japan and the US, partly offset by growth in Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Jakavi</i> (USD 1.6 billion, -2%, +9% cc) sales grew (cc) in Europe, Emerging Growth Markets, Japan, driven by strong demand in both the myelofibrosis and polycythemia vera indications. In May, EC approved <i>Jakavi</i> for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kymriah</i> (USD 0.5 billion, -9%, -2% cc) sales declined in the US and Europe due to lower DLBCL demand in both geographies and was partly offset by growth in Emerging Growth Markets and Japan. In May, EC and FDA approved <i>Kymriah</i> for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Adakveo</i> (USD 0.2 billion, +18%, +19% cc) continued to grow worldwide, reaching more than 11,800 patients with vaso-occlusive crises caused by sickle cell disease to date.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Scemblix</i> (USD 0.1 billion) continued its strong launch uptake in the US, with launches underway in EU and Japan, demonstrating the high unmet need in CML, particularly patients previously treated with 2 or more tyrosine kinase inhibitors, or with the T315I mutation. In October 2022, US FDA converted the accelerated approval of <i>Scemblix</i> to a full approval, confirming the clinical benefit after longer exposure.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Other Promoted Brands</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales for Other Promoted Brands were USD 3.1 billion (-9%, -1% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Lucentis</i> (USD 1.9 billion, -13%, -4% cc) sales declined in Japan and Europe mainly due to competition, which was partly offset by growth in Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Xiidra</i> (USD 0.5 billion, +4%, +4% cc) sales grew mainly in the US. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Ultibro</i> Group (USD 0.5 billion, -18%, -9% cc) sales declined in Europe and Emerging Growth Markets due to competition and was partly offset by growth in Japan. <i>Ultibro</i> Group consists of <i>Ultibro Breezhaler</i>, <i>Seebri Breezhaler</i> and <i>Onbrez Breezhaler</i>.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Beovu</i> (USD 0.2 billion, +9%, +18% cc) sales grew in Europe, Emerging Growth Markets and Japan, partly offset by decline in the US. <i>Beovu</i> received approval for diabetic macular edema (DME) in the EU in the first quarter of 2022, and in the US in the second quarter of 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Established Brands</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Established Brands had sales of USD 9.9 billion (-19%, -13% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Sandostatin</i> (USD 1.2 billion, -12%, -10% cc) declined across all geographies due to ongoing competitive pressure, including generic competition ex-US.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Galvus</i> Group (USD 0.9 billion, -21%, -12% cc) declined in Japan, Europe and Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Gleevec</i>/<i>Glivec</i> (USD 0.7 billion, -27%, -22% cc) declined due to increased generic competition.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Exforge</i> Group (USD 0.7 billion, -18%, -12% cc) declined across all geographies.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Diovan</i> Group (USD 0.7 billion, -16%, -9% cc) declined in Emerging Growth Markets, Japan and Europe.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Afinitor</i>/<i>Votubia</i> (USD 0.5 billion, -45%, -41% cc) declined in the US and Europe driven by generic competition.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Voltaren</i>/<i>Cataflam</i> (USD 0.3 billion, -10%, 0% cc) sales were stable (cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Zortress</i>/<i>Certican</i> (USD 0.3 billion, -24%, -14% cc) declined in the US and Japan.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Exjade</i>/<i>Jadenu</i> (USD 0.3 billion, -43%, -38% cc) declined due to pressure from generic competition.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Neoral</i>/<i>Sandimmun(e)</i> (USD 0.3 billion, -16%, -8% cc) declined across all geographies.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">57</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz net sales were USD 9.2 billion (&#x2013;4%, +4% cc) with volume contributing 10 percentage points to growth. Pricing had a negative impact of 6 percentage points.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sales in Europe were USD 4.9 billion (&#x2013;7%, +4% cc), in the US USD 1.8 billion (&#x2013;4%) in Asia/Africa/Australasia USD 1.6 billion (&#x2013;3%, +6% cc) and in Canada and Latin America USD 969 million (+11%, +15% cc) driven by volume increases and tender wins.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by business franchise in the Sandoz Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup>1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;776</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;092</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;093</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives  (partner label/API)<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   380</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   423</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Retail sales were USD 6.8 billion (&#x2013;4%, +4% cc), growing across all regions ex-US.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- and other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. The Biopharmaceuticals business also includes <i>Glatopa</i>, a generic version of Copaxone&#xAE;, which treats relapsing forms of multiple sclerosis and is marketed in the US. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and <i>Glatopa</i>) grew to USD 2.1 billion (&#x2013;1%, +9% cc), growing across all regions.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti-Infectives</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total Anti-Infectives sales were USD 1.2 billion (+2%, +10% cc) of which USD 777 million were sold through the Retail Generics business franchise and USD 380 million were sold to other third-party companies through the Anti-Infectives business franchise. The sales of the Anti-Infectives business franchise declined mainly due to product discontinuations and supply challenges.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">58</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operating income</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of operating income by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15.7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -84</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Operating income was USD 9.2 billion (&#x2013;21%, &#x2013;13% cc), mainly due to higher restructuring (USD 1.2 billion) primarily related to the implementation of the previously announced streamlined organizational model, higher impairments (USD 1.0 billion) and lower divestment gains (USD 0.6 billion). Operating income margin was 18.2% of net sales, decreasing by 4.4 percentage points (-3.8 percentage points cc).</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core operating income key figures</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 40&#xA0;392</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;097</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;190</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;815</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;088</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;074</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">As % of net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The adjustments made to operating income to arrive at core operating income amounted to USD&#xA0;7.5 billion (compared with USD&#xA0;4.9 billion in the prior year). For details, please see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis&#x2014;2022 and 2021 reconciliation from IFRS results to core results.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 16.7 billion (0%, +8% cc) benefiting from higher sales, partly offset by higher R&amp;D investments. Core operating income margin was 33.0% of net sales, increasing by 0.9 percentage points (+1.3 percentage points cc).</div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core operating income by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 8.8 billion (&#x2013;18%, &#x2013;9% cc), driven by higher impairments, restructuring, lower divestment gains and higher R&amp;D expenses, partly offset by higher gross margin. Operating income margin was 21.3% of net sales, decreasing 4.2 percentage points (-3.4 percentage points in cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 6.5 billion, mainly due to amortization, impairments and restructuring, compared to USD 4.5 billion in prior year. Core adjustments increased compared to prior year, mainly due to higher impairments and restructuring.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 15.2 billion (0%, +8% cc), mainly driven by higher gross margin, partly offset </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">59</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">by higher R&amp;D investments. Core operating income margin was 36.9% of net sales, increasing 0.7 percentage points (+1.3 percentage points cc). Revenues as a percentage of sales increased by 0.1 percentage points (cc). Core cost of goods sold as a percentage of sales was in line with the prior year. Core R&amp;D expenses as a percentage of net sales increased by 0.2 percentage points (cc). Core selling, general and administration (SG&amp;A) expenses as a percentage of net sales decreased by 1.4 percentage points (cc). Core other income and expense as a percentage of net sales was in line with the prior year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 1.4 billion (&#x2013;10%, &#x2013;2% cc), with the decline mainly due to higher SG&amp;A investments to drive higher sales and inflationary pressures on input costs, which were partly offset by higher sales. Operating income margin was 15.7% of net sales, decreasing by 0.9 percentage points (-1.0 percentage points in cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 455 million, including USD 221 million of amortization. Prior year core adjustments were USD 464 million, including USD 236 million of amortization.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 1.9 billion (&#x2013;8%, &#x2013;1% cc), with the decline mainly due to higher SG&amp;A, partly offset by higher sales. Core operating margin was 20.6% of net sales, decreasing by 0.8 percentage points (-1.1 percentage points cc). Core gross margin as a percentage of sales decreased by 0.3 percentage points (cc), due to higher inflation and input costs. Core R&amp;D expenses as a percentage of net sales decreased by 0.5 percentage points (cc). Core SG&amp;A expenses increased by 0.9 percentage points (cc). Core other income and expense decreased the margin by 0.4 percentage points (cc).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate income and expense, net</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Corporate income and expense, which includes the cost of Group headquarter and coordination functions, amounted to an expense of USD 1.0 billion, compared to an expense of USD 599 million in 2021, mainly driven by higher restructuring costs, lower contributions from the Novartis Venture Fund and prior year income from a fair value adjustment on contingent receivables related to intellectual property rights, partly offset by prior year adjustments to provisions on M&amp;A transactions.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division research and development</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the reported and core research and development expense of the Innovative Medicines Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and exploratory development</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;938</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&#xA0;209</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Confirmatory development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&#xA0;234</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;432</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines Division research and development expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9&#xA0;172</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8&#xA0;641</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;As % of Innovative Medicines net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core research and exploratory development<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;784</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core confirmatory development<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total core Innovative Medicines Division research and development expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -8&#xA0;267</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8&#xA0;150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;As % of Innovative Medicines net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Core results exclude impairments, amortization and certain other items. For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Innovative Medicine Division research and exploratory development expense decreased by 8% (+6% cc) to USD 2.9 billion. Confirmatory development expense amounted to USD 6.2 billion, increasing by 15% (-20% cc) versus prior year mainly due to higher impairment charges and higher investments in development to support recently acquired assets.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total core research and development expense in the Innovative Medicine Division as a percentage of sales increased by 0.6 percentage points (+0.2 percentage points cc) to 20.0% of net sales, mainly driven by higher investments in recently acquired assets.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">60</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-operating income and expense </span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The term &#x201C;non-operating income and expense&#x201D; includes all income and expense items outside operating income. The following table provides an overview of non-operating income and expense:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -64</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful     </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income from associated companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income from associated companies was a loss of USD 9 million compared to an income of USD 15.3 billion in prior year. This decrease was due to the divestment of our investment in Roche that closed in the fourth quarter of 2021 where a gain of USD 14.6 billion was recognized.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense and other financial income and expense</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest expense amounted to USD 837 million, broadly in line with prior year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other financial income and expense amounted to an income of USD 20 million compared to an expense of USD 80 million in the prior year, as higher interest income was partly offset by financial expenses and currency losses.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income taxes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The tax rate was 16.9% compared to 8.1% in the prior year period. In the prior year, the tax rate was impacted by the Roche income from associated companies (including the divestment gain recognized on the sale of our investment in Roche in December 2021), the impact of increases in uncertain tax positions and prior-year items.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For comparability, excluding these impacts, the prior year tax rate would have been 16.8%, broadly in line with 16.9% in the current year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net income </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net income was USD 7.0 billion (&#x2013;71%, &#x2013;67% cc), impacted by Roche income in the prior year. Excluding the impact of Roche income, net income declined &#x2013;9% (cc). </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Earnings per share</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share were USD 3.19 compared with USD 10.71 in the prior year, mainly due to prior year Roche income. Excluding the impact of Roche income, EPS declined &#x2013;7% (cc).</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">61</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core non-operating income and expense</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core non-operating income and expense:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core (loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -41</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;960</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income from associated companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core income from associated companies was a loss of USD 9 million compared with an income of USD 993 million in prior year. This decrease was due to the divestment of our investment in Roche that closed in the fourth quarter of 2021. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core interest expense and other financial income and expense</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core interest expense amounted to USD 837 million, broadly in line with prior year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core other financial income and expense amounted to an income of USD 141 million compared to an expense of USD 41 million in the prior year as higher interest income was only partly offset by currency losses.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income taxes</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The core tax rate (core taxes as a percentage of core income before tax) was 16.3% compared to 15.8% in the prior year. For comparability, excluding Roche Income from associated companies (divested in December 2021), the prior year core tax rate would have been 16.7% compared to 16.3% in the current year, decreasing mainly as a result of a change in core profit mix.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core net income </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core net income was USD 13.4 billion (&#x2013;5%, +3% cc) as growth in core operating income was partly offset by the loss of Roche core income. Excluding the impact of Roche core income, core net income grew +11% (cc). </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core earnings per share</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core EPS was USD 6.12 (&#x2013;3%, +6% cc), benefiting from lower weighted average number of shares outstanding. Excluding the impact of Roche core income, core EPS grew +14% (cc). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup> For an explanation of non-IFRS measures and reconciliation tables, see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">62</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Results of operations excluding Roche investment impacts</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To enhance investors&#x2019; understanding of the Group&#x2019;s performance in comparison with the prior year, the following table provides a comparison of our 2022 published IFRS results and non-IFRS measures core results and free cash flow with the 2021 results, excluding the impacts related to our Roche investment, due to its divestment.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Excluding Roche investment impacts<sup>2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br /> cc<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -96</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;661</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;549</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;099</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.84</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> For a reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">63</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Factors affecting comparability of year-on-year results of operations</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions </span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">in 2022 and 2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The comparability of the year-on-year results of our operations for the total Group can be significantly affected by acquisitions and divestments. As part of our long-term strategy to focus Novartis as a leading medicines company, we announced and/or completed several acquisitions and divestments during 2022 and 2021.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A detailed description of significant transactions in 2022 and 2021, can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Internal control over financial reporting</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s management has assessed the effectiveness of internal control over financial reporting. The Group&#x2019;s independent statutory auditor also issued an opinion on the effectiveness of internal control over financial reporting. Both the Group&#x2019;s management and its external auditors concluded that the Group maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022. For more details, see &#x201C;Item 15. Controls and Procedures.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Approach to risk management</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Information and control systems&#x2014;Risk management&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Non-IFRS measures as defined by Novartis</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis uses certain non-IFRS metrics when measuring performance, especially when measuring current-year results against prior periods, including core results, constant currencies and free cash flow.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite the use of these measures by management in setting goals and measuring the Group&#x2019;s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS. As a result, such measures have limits in their usefulness to investors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how the Group&#x2019;s management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures, and should be viewed in conjunction with IFRS financials.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As an internal measure of Group performance, these non-IFRS measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">64</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core results</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s core results &#x2013; including core operating income, core net income and core earnings per share &#x2013; exclude fully the amortization and impairment charges of intangible assets, excluding software, net gains and losses on fund investments and equity securities valued at fair value through profit and loss, and certain acquisition- and divestment-related items. The following items that exceed a threshold of USD&#xA0;25 million are also excluded: integration- and divestment-related income and expenses; divestment gains and losses; restructuring charges/releases and related items; legal-related items; impairments of property, plant and equipment, software, and financial assets, and income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a USD&#xA0;25 million threshold. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that investor understanding of the Group&#x2019;s performance is enhanced by disclosing core measures of performance, since core measures exclude items that can vary significantly from year to year, they enable better comparison of business performance across years. For this same reason, Novartis uses these core measures in addition to IFRS and other measures as important factors in assessing the Group&#x2019;s performance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are examples of how these core measures are utilized:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Annual budgets are prepared for both IFRS and core measures. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As an internal measure of Group performance, the core results measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics. A limitation of the core results measures is that they provide a view of the Group&#x2019;s operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets, impairments to property, plant and equipment and restructurings and related items.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Constant currencies</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the relative values of non-US currencies to the US dollar can affect the Group&#x2019;s financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the consolidated income statement excluding the impact of fluctuations in exchanges rates:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The impact of translating the income statements of consolidated entities from their non-USD functional currencies to USD</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We calculate constant currency measures by translating the current year&#x2019;s foreign currency values for sales and other income statement items into USD (excluding the IAS 29 &#x201C;Financial Reporting in Hyperinflationary Economies&#x201D; adjustments to the local currency income statements of subsidiaries operating in hyperinflationary economies), using the average exchange rates from the prior year and comparing them to the prior year values in USD.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We use these constant currency measures in evaluating the Group&#x2019;s performance, since they may assist us in evaluating our ongoing performance from year to year. However, in performing our evaluation, we also consider equivalent measures of performance that are not affected by changes in the relative value of currencies.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Growth rate calculation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For ease of understanding, Novartis uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared with the prior year is shown as a positive growth.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Free cash flow</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines free cash flow as net cash flows from operating activities and cash flows from investing activities associated with purchases and sales of property, plant and equipment, of intangible assets, of financial assets and of other non-current assets. Excluded from free cash flow are cash flows from investing activities associated with acquisitions and divestments of businesses and of interests in associated companies, purchases and sales of marketable securities, commodities, time deposits and net cash flows from financing activities.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow is a non-IFRS measure and is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS. Free cash flow is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is a measure of the net cash generated that is available for investment in strategic opportunities, returning to shareholders and for debt repayment. Free cash flow is a non-IFRS measure, which means it should not be interpreted as a measure determined under IFRS. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">65</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional information</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">NET DEBT</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis calculates net debt as current financial debts and derivative financial instruments plus non-current financial debt less cash and cash equivalents and marketable securities, commodities, time deposits and derivative financial instruments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net debt is presented as additional information because it sets forth how management monitors net debt or liquidity and management believes it is a useful supplemental indicator of the Group&#x2019;s ability to pay dividends, to meet financial commitments, and to invest in new strategic opportunities, including strengthening its balance sheet. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the table that shows the Group&#x2019;s net debt, see &#x201C;&#x2014; Item 5.B Liquidity and capital resources &#x2014; Group liquidity, financial debts and net debt.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">EBITDA</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines earnings before interest, tax, depreciation and amortization (EBITDA) as operating income, excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortization of intangible assets, and impairments of property, plant and equipment, right-of-use assets and of intangible assets.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property,  plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of    right-of-use assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   300</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   318</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible  assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&#xA0;982</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   3&#xA0;903</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments of property,  plant and equipment, right-of-use assets and  intangible assets<sup style="white-space: nowrap"> &#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&#xA0;736</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     684</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">EBITDA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;378</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&#xA0;802</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> There were no impairments of right-of-use assets in 2021.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Enterprise value </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Enterprise value represents the total amount that shareholders and debt holders have invested in Novartis, less the Group&#x2019;s liquidity.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market capitalization</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191&#xA0;530</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;107</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;244</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;902</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and  derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities,  commodities, time deposits  and derivative financial  instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       -11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       -15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Enterprise value</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 198&#xA0;856</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 197&#xA0;142</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">66</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Reconciliation from IFRS results to core results </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide an overview of the reconciliation from IFRS results to core results:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">IFRS operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -599</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amortization of intangible assets</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;585</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;528</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;764</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;291</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;318</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 387</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Property, plant and equipment related to the Group-wide rationalization of manufacturing sites</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   219</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   284</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   226</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total impairment charges</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;662</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 619</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition or divestment of businesses and related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 106</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total acquisition or divestment of  businesses and related items, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   42</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   41</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Divestment gains</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -161</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -649</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -166</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -728</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial assets - fair value adjustments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -43</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 260</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -38</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Restructuring and related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -36</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -74</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 193</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;188</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;058</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Legal-related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 364</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 170</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 223</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additional income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -139</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -138</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -704</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -278</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additional expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 289</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 441</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total adjustments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;527</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 455</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 562</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -92</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;468</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;899</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 36.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 36.2%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 20.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 33.0%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 32.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;332</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to income from associated companies, net of tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;346</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;346</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes, adjusted for above items (core income taxes)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;097</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS  (USD)<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">67</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Group</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022 (USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible <br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;342</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;648</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 338</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 64</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 40&#xA0;392</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;092</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;283</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;197</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15&#xA0;486</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;648</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;350</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;190</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;996</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 954</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -204</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;088</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 805</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -414</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&#xA0;701</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 398</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -833</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold, research and development and other expense include impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and charges related to divestments; other income also includes adjustments to provisions; other expense includes stamp duties related to an acquisition</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: other revenues includes a net income from an outlicensing agreement; cost of goods sold, selling, general and administration, research and development, other income and other expense include restructuring income and charges related to the restructuring initiative to implement a new streamlined organizational model, the Sandoz strategic review, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; cost of goods sold, selling, general and administration, research and development and other expense include adjustments to provisions and related items; cost of goods sold and research and development also include contingent consideration adjustments; other income and other expense include fair value adjustments and divestment gains and losses on financial assets and legal-related items; other income also includes gains from the divestment of products and property, curtailment gains and an adjustment to an environmental provision; other expense includes a reversal of an accrual and other costs and items; other financial income and expense includes the monetary loss on the restatement of non-monetary items for subsidiaries in hyperinflationary economies and a revaluation impact of a financial liability incurred through the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 7.6 billion to arrive at the core results before tax amounts to USD 1.2 billion. The average tax rate on the adjustments is 15.7% since the full year core tax charge of 16.3% has been applied to the pre-tax income of the period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">68</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021 (USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&#xA0;010</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;655</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 414</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;097</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;764</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;974</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;531</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 496</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15&#xA0;867</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;655</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 414</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11&#xA0;780</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;886</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;815</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;540</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 369</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;041</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;265</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;747</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 366</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;074</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;556</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -41</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 210 million for the Novartis share of the estimated Roche core items</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to portfolio transformation and Alcon spin-off accruals; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution; other expense also includes adjustments to provisions; income from associated companies includes the gain related to the divestment of our investment in Roche; other financial income and expense includes other financial gains related to the divestment of our investment in Roche</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: cost of goods sold, research and development, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; cost of goods sold, research and development, other income and other expense also include adjustments to contingent consideration; selling, general and administration, research and development, other income and other expense include adjustments to provisions; other income and other expense also include gains and losses from the divestment of products and financial assets and fair value adjustments on financial assets, adjustments to environmental provisions and legal-related items; other financial income and expense includes a charge related to the monetary loss due to hyperinflation in Argentina and Venezuela and a revaluation impact of a financial liability incurred through the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 9.4 billion to arrive at the core results before tax amounts to USD 516 million. Excluding the gain on the divestment of our investment in Roche, the tax on the total adjustments of USD 5.2 billion to arrive at the core results before tax amounts to USD 516 million and the average tax rate on the adjustments was 10.0%.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">69</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Innovative Medicines</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&#xA0;801</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;427</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 314</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -29</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35&#xA0;513</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;585</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;662</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;163</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;569</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;427</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 314</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;771</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;679</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;629</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;172</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -206</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8&#xA0;267</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 531</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -311</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;695</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 396</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -599</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold, research and development and other expense include impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other expense includes stamp duties related to an acquisition and transitional service fee charges related to divestments</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: other revenues includes a net income from an outlicensing agreement; cost of goods sold, selling, general and administration, research and development, other income and other expense include restructuring income and charges related to the initiative to implement a new streamlined organizational model, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; cost of goods sold and research and development also include contingent consideration adjustments and adjustments to provisions and related items; other income and other expense include fair value adjustments and divestment gains and losses on financial assets and legal-related items; other income also includes gains from the divestment of products and property, curtailment gains and an adjustment to an environmental provision; other expense includes a reversal of an accrual and other costs and items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021 <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&#xA0;218</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;419</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 344</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&#xA0;981</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;528</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 619</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11&#xA0;751</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;419</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 344</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7&#xA0;988</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;306</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;235</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8&#xA0;641</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8&#xA0;150</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;732</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 781</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -646</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: research and development includes impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: cost of goods sold, research and development, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; cost of goods sold, research and development and other expense include adjustments to contingent consideration; selling, general and administration, research and development and other expense include adjustments to provisions; other income and other expense include gains and losses from the divestment of products and financial assets and fair value adjustments on financial assets; other expense also includes legal-related items and adjustments to environmental provisions</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">70</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS to core results &#x2013; Sandoz</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;504</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;842</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;978</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;640</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;062</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;053</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -824</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -821</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -273</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -152</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income includes a reversal of an impairment charge related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: cost of goods sold, selling, general and administration, research and development, other income and other expense include charges related to the Sandoz strategic review, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; other expense also includes legal-related items; cost of goods sold and selling, general and administration include adjustments to provisions and related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization <br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;725</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 70</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;049</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;147</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&#xA0;823</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -899</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -891</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -397</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -159</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: cost of goods sold, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites and other restructuring income and charges and related items; research and development includes adjustments to provisions; other income includes net gains from the divestment of a product; other income and other expense include legal-related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">71</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Corporate</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible<br /> assets</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -512</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -508</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -89</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -733</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 649</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Impairments: other expense includes impairment charges related to intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to provisions and transitional service fee income related to divestments</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: selling, general and administration, other income and other expense include restructuring income and charges related to the initiative to implement a new streamlined organizational model, the Sandoz strategic review and other net restructuring charges and related items; other income and other expense also include fair value adjustments and divestment gains and losses on financial assets; other income also includes a curtailment gain</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization <br /> of intangible<br /> assets</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 470</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -377</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -618</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 106</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -269</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to portfolio transformation and Alcon spin-off accruals; other income and other expense include transitional service fee income and expenses related to the Alcon distribution; other expense also includes adjustments to provisions</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Other items: other income includes an adjustment to a contingent consideration receivable; other income and other expense include fair value adjustments and divestment gains and losses on financial assets, adjustments to environmental provisions and restructuring income and charges and related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">72</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">To enhance investor understanding of the Group&#x2019;s performance in comparison with the prior year, we presented the 2021 IFRS results and non-IFRS measures core results and free cash flow excluding the impacts related to our Roche investment, due to its divestment in the fourth quarter of 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following tables provide a reconciliation of our 2021 published IFRS results and non-IFRS measures core results and free cash flow to the 2021 results, excluding the impacts related to our Roche investment, due to its divestment.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br />
                <br />
                <br /> Results as <br /> published</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Our Roche <br /> investment <br /> impacts<br /> excluding<br /> the divestment<br /> gain</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Gain on<br /> divestment<br /> of our<br /> investment<br /> in Roche</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Results <br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;556</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense and other financial  income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -891</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -907</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;780</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;661</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -0.35</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -6.50</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.86</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Effective tax rate<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 8.1%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 19.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core interest expense and core other  financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -852</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income before tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;734</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;099</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -0.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.84</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Core effective tax rate<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 15.8%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 16.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Effective tax rate is calculated as Income taxes divided by Income before tax.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Core effective tax rate is calculated as Core income taxes divided by Core income before tax.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The free cash flow impact represents the dividend received  in Q1 2021 from Roche in relation to the distribution of its 2020 net income.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">73</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div>
            </td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td colspan="5" style=";height:3;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td colspan="5" style=";height:3;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br />
                <br />
                <br /> Free cash flow <br /> as published</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dividends <br /> received from <br /> Roche in <br /> relation to <br /> the distribution<br /> of its 2020 <br /> net income<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Free cash <br /> flow excluding<br /> dividends <br /> received <br /> from Roche</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -953</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other operating cash flow items, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -878</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -878</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;549</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net purchases of property, plant and equipment, intangible assets, financial assets and  other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;789</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> In 2021, the dividend received from Roche in relation to the distribution of its 2020 net income was received in Q1 2021.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the percentage point impact from excluding the effect of the divestment of our investment in Roche (in the fourth quarter of 2021) on the USD and constant currencies % change on key Group figures.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> In USD</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> In constant currencies</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> % change<br /> as published<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change<br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Percentage<br /> point <br /> impact<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> % change<br /> as published<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change<br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Percentage<br /> point <br /> impact<br /> 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -58</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -59</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
        </table>
      </div>
      <div id="anchorId0010024813"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.B Liquidity and capital resources</p>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables summarize the Group&#x2019;s cash flows and net debt:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from investing activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;468</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in financing activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20&#xA0;562</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16&#xA0;264</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -266</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4&#xA0;890</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;749</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;509</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&#xA0;017</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current and non-current financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;022</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;847</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Change in net debt</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6&#xA0;377</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&#xA0;613</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt at January 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -868</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -24&#xA0;481</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -868</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">74</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Cash flow</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021 </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net cash flows from operating activities amounted to USD 14.2 billion, compared with USD 15.1 billion in 2021. This decrease was mainly due to unfavorable changes in working capital and lower dividends from associated companies (2021 included the USD 0.5 billion dividends received from our investment in Roche, which was divested in the fourth quarter of 2021), partly offset by lower income taxes paid and favorable hedging results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash inflows from investing activities amounted to USD 1.5 billion, compared with USD 4.2 billion in 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash inflows were driven by net proceeds of USD 4.7 billion from the sale of marketable securities, commodities and time deposits; USD 0.5 billion from the sale of intangible assets, financial assets and property, plant and equipment. These cash inflows were partly offset by cash outflows of USD 1.5 billion for purchases of intangible assets; USD 1.2 billion for purchases of property, plant and equipment; USD 0.1 billion for purchases of financial assets; and USD 0.9 billion for acquisitions and divestments of businesses, net (primarily the acquisition of Gyroscope Therapeutics Holdings plc for USD 0.8 billion). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, net cash inflows from investing activities of USD 4.2 billion were driven by proceeds of USD 20.7 billion from the divestment of our investment in Roche; USD 2.3 billion from the sale of marketable securities, commodities and time deposits; and USD 1.4 billion from the sale of intangible assets, financial assets and property, plant and equipment. These cash inflows were partly offset by USD 16.4 billion cash outflows for purchases of marketable securities and time deposits, mainly due to the investment of a portion of the proceeds from the divestment of our investment in Roche; USD 1.6 billion for purchases of intangible assets (including the upfront payment to in-license tislelizumab from an affiliate of BeiGene, Ltd); USD 1.4 billion for purchases of property, plant and equipment; USD 0.6 billion for acquisitions and divestments of businesses, net (including the acquisition of GSK&#x2019;s cephalosporin antibiotics business for USD 351 million); and USD 0.2 billion for purchases of financial assets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash outflows used in financing activities amounted to USD 20.6 billion, compared with USD 16.3 billion in 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash outflows were mainly driven by USD 10.6 billion for net treasury share transactions; USD 7.5 billion for the dividend payment; USD 2.5 billion in aggregate for the repayment of two US dollar bonds; and USD 0.3 billion payments of lease liabilities. These cash outflows were partly offset by cash inflows of USD 0.3 billion from the net increase in current financial debts. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, net cash outflows used in financing activities of USD 16.3 billion were driven by USD 7.4 billion for the dividend payment; USD 3.0 billion for net treasury share transactions; USD 3.5 billion net decrease in current financial debts; and USD 2.2 billion for the repayment of two bonds denominated in euro (notional amount of EUR 1.25 billion and of EUR 0.6 billion) at maturity. Payments of lease liabilities and other financing cash flows resulted in a net cash outflow of USD 0.2 billion.</div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Free cash flow</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Free cash flow is a non-IFRS measure, see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Free cash flow&#x201D; for further information. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table is a reconciliation of the three major categories of the IFRS consolidated statements of cash flows to free cash flow:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> IFRS <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Adjustments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Free <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> IFRS <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br /> Adjustments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> Free <br /> cash flow</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;468</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3&#xA0;759</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2&#xA0;291</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;208</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -5&#xA0;997</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&#xA0;789</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -20&#xA0;562</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&#xA0;562</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -16&#xA0;264</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;264</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excluded from the free cash flow are cash flows from investing activities associated with acquisitions and divestments of businesses and of interest in associated companies, purchases and sales of marketable securities, commodities and time deposits.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Net cash flows used in financing activities are excluded from the free cash flow.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">75</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table is a summary of the free cash flow:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation, amortization and impairments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;075</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Change in provisions and other non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;403</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 896</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&#xA0;501</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial receipts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -728</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -966</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;975</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -885</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;119</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in inventories and trade receivables less trade payables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;467</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 570</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;198</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;378</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;473</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;593</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 748</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -191</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -61</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Free cash flow amounted to USD 11.9 billion (&#x2013;10% USD), compared with USD 13.3 billion in 2021, mainly due to a decrease in net cash flows from operating activities and lower divestment proceeds, partly offset by lower purchases of property, plant and equipment.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">76</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Condensed consolidated balance sheets </span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;764</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&#xA0;545</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;431</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;561</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&#xA0;301</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&#xA0;595</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&#xA0;644</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34&#xA0;182</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 143</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 205</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;743</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets and other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;521</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;246</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80&#xA0;543</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;077</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;175</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;666</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;066</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&#xA0;005</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets and income tax receivables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;718</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;910</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 45&#xA0;718</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 117&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 131&#xA0;795</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59&#xA0;423</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67&#xA0;822</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;244</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;902</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;538</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;621</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;686</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;070</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;906</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;172</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;374</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&#xA0;765</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;146</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;553</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 275</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities and current income tax liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;328</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;085</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&#xA0;656</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 58&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63&#xA0;973</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 117&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 131&#xA0;795</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Assets</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current assets of USD 80.5 billion at December 31, 2022, decreased by USD 5.5 billion compared to December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets other than goodwill decreased by USD 2.5 billion as additions (including the acquisition of Gyroscope Therapeutics Holdings plc) were more than offset by amortization, impairments and unfavorable currency translation adjustments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill decreased by USD 0.3 billion, mainly due to unfavorable currency translation adjustments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment decreased by USD 0.8 billion, as net additions were more than offset by depreciation, unfavorable currency translation adjustments and impairments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Financial and other non-current assets decreased by USD 1.7 billion, driven by the decrease of the prepaid post-employment benefit plans of USD 0.9 billion, resulting mainly from the pension accounting effects from increases in actuarial discount rates and of USD 0.6 billion from fair value losses on listed equity and fund investments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets, investments in associated companies and deferred tax assets were broadly in line with December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current assets of USD 36.9 billion at December 31, 2022, decreased by USD 8.8 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Cash and cash equivalents decreased by USD 4.9 billion, mainly due to the dividend payment, the purchase of treasury shares and net repayments of financial debt, partly offset by the cash generated from operating activities and from investing activities, which includes the net proceeds from the sales of marketable securities, commodities and time deposits. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities, commodities, time deposits and derivative financial instruments decreased by USD 4.5 billion mainly driven by the net sales of marketable securities, commodities and time deposits.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventories increased by USD 0.5 billion and trade receivables and other current assets and income tax receivables were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We consider our provisions for doubtful trade receivables to be adequate. We particularly monitor the level of trade receivables in countries deemed to have an </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">77</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year were not significant in elevated credit risk countries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a table showing an overview of the aging analysis of total trade receivables and the total amount of the provision for doubtful trade receivables as of December 31, 2022, and 2021, see &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could devalue their currency. Currency exposures are described in more detail in &#x201C;&#x2014;Effects of currency fluctuations.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liabilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current liabilities of USD 29.4 billion decreased by USD 4.4 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-current financial debts decreased by USD 2.7 billion, mainly due to the reclassification of USD 2.3 billion from non-current to current financial debts of two EUR denominated bonds with notional amounts of EUR 750 million and EUR 1.25 billion maturing in 2023 and favorable currency translation adjustments of USD 0.4 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other non-current liabilities decreased by USD 1.3 billion, mainly driven by decreases in accrued liabilities for employee benefits of USD 1.2 billion (primarily due to a decrease in accrued liabilities for defined benefit pension plans of USD 0.9 billion, resulting from the pension accounting effects from increases in actuarial discount rates), and in contingent consideration of USD 0.3 billion, a reclassification of non-current legal matters provisions to current portion of USD 0.2 billion, partly offset by the increase in other non-current liabilities of USD 0.4 billion.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred tax liabilities decreased by USD 0.4 billion and non-current lease liabilities were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current liabilities of USD 28.7 billion decreased by USD 1.6 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other current liabilities and current income tax liabilities decreased by USD 0.8 billion, mainly driven by the decrease in the commitment for repurchase of own shares liability of USD 2.8 billion, partly offset by increases in restructuring provisions of USD 0.8 billion (primarily due to the initiative announced in April 2022, to implement a new streamlined organizational model), in provisions for legal matters of USD 0.5 billion, including a USD 0.2 billion reclassification from non-current provisions for legal matters, and in provisions for revenue deductions of USD 0.3 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments decreased by USD 0.4 billion, mainly due to the repayment of two US dollar bonds of USD 1.0 billion and USD 1.5 billion, the closure during the third quarter of 2022 of the interest-bearing accounts of employees payable on demand, which amounted to USD 1.8 billion at December 31, 2021, and favorable currency translation adjustments, partly offset by the reclassification from non-current to current financial debts of USD 2.3 billion and an increase of USD 1.9 billion in commercial paper.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Trade payables decreased by USD 0.4 billion and current lease liabilities were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In our key countries, Switzerland and the United States, assessments have been agreed by the tax authorities up to 2017 in Switzerland and up to 2014 in the United States, with the exception of one open United States position related to the 2007 tax filing. Uncertainties also exist on the application of a taxing right based on a German non-resident tax regulation for specific revenues derived from German registered intellectual property rights.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group`s equity decreased by USD 8.4 billion to USD 59.4 billion at December 31, 2022, compared to December 31, 2021. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This decrease was mainly due to the cash-dividend payment of USD 7.5 billion, purchase of treasury shares of USD 10.9 billion, unfavorable currency translation differences of USD 0.5 billion and fair value adjustments on equity securities of USD 0.4 billion. This was partially offset by the net income of USD 7.0 billion, decrease of the treasury share repurchase obligation of USD 2.8 billion, and equity-based compensation of USD 0.9 billion.  </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">78</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of equity movements attributable to Novartis AG shareholders</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of outstanding shares  (in millions)</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity attributable to   Novartis AG shareholders</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> USD millions</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;234.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;256.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&#xA0;655</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;598</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -126.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -30.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10&#xA0;787</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;775</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1.5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -123</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -145</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 854</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 745</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease/(increase) of treasury share repurchase  obligation under a share buyback trading plan</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&#xA0;809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;040</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;506</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7&#xA0;368</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the year attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -839</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;493</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 217</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;119.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;234.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67&#xA0;655</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Impact of hyperinflationary economies (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, Novartis repurchased a total of 126.2 million shares for USD 10.8 billion on the SIX Swiss Exchange second trading line, including 115.3 million shares (USD 9.9 billion) under the up-to USD 15 billion share buyback announced in December 2021 and 10.9 million shares (USD 0.9 billion) to mitigate dilution related to participation plans of associates. In addition, 1.4 million shares (USD 0.1 billion) were repurchased from associates. In the same period, 12.3 million shares (for an equity value of USD 0.9 billion) were delivered as a result of option exercises and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 115.3 million versus December 31, 2021. These treasury share transactions resulted in a decrease in equity of USD 10.0 billion and a net cash outflow of USD 10.6 billion.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, Novartis repurchased a total of 30.7 million shares for USD 2.8 billion on the SIX Swiss Exchange second trading line, including 19.6 million shares (USD 1.8 billion) under the up-to USD 2.5 billion share buyback announced in November 2020, 8.6 million shares (USD 0.8 billion) to mitigate dilution related to participation plans of associates and 2.5 million shares (USD 0.2 billion) under the up-to USD 15 billion share buyback announced in December 2021. In addition, 1.5 million shares (USD 0.1 billion) were repurchased from associates. In the same period, 10.3 million shares (for an equity value of USD 0.8 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 21.9 million versus December 31, 2020. These treasury share transactions resulted in a decrease in equity of USD 2.1 billion and a net cash outflow of USD 3.0 billion. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Treasury shares</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, our holding of treasury shares amounted to 284.1 million shares, or approximately 12% of the total number of issued shares. Approximately 99.0 million treasury shares were held in entities that restrict their availability for use.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At December 31, 2021, our holding of treasury shares amounted to 199.5 million shares, or approximately 8% of the total number of issued shares. Approximately 102.5 million treasury shares were held in entities that restrict their availability for use.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">79</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Effects of currency fluctuations</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We transact our business in many currencies other than the US dollar, our reporting currency.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table provides an overview of net sales and operating expenses based on IFRS values for 2022 and 2021, for currencies most important to the Group:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Net sales<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Operating<br /> expenses<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Net sales<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Operating<br /> expenses<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Operating expenses include cost of goods sold; selling, general and administration; research and development; other income and other expense.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare our consolidated financial statements in US dollars. As a result, fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations as well as the reported value of our assets, liabilities and cash flows. This in turn may significantly affect reported earnings (both positively and negatively) and the comparability of period-to-period results of operations.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of our consolidated balance sheets, we translate assets and liabilities denominated in other currencies into US dollars at the prevailing market exchange rates as of the relevant balance sheet date. For purposes of the Group&#x2019;s consolidated income and cash flow statements, revenue, expense and cash flow items in local currencies are translated into US dollars at average exchange rates prevailing during the relevant period. As a result, even if the amounts or values of these items remain unchanged in the respective local currency, changes in exchange rates have an impact on the amounts or values of these items in our consolidated financial statements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditure in Swiss francs is significantly higher than our revenue in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate, after taking into account the natural hedging afforded by our global business activity. In 2022 and 2021, we entered into various contracts that change in value with movements in foreign exchange rates, to preserve the value of assets, commitments and expected transactions. We use forward contracts and foreign currency options to hedge. For more information on how these transactions affect our consolidated financial statements and on how foreign exchange rate exposure is managed, see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 5. Interest expense and other financial income and expense,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">80</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth the foreign exchange rates of the US dollar against key currencies used for foreign currency translation when preparing the Group&#x2019;s consolidated financial statements:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average for year</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Year-end</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">USD per unit</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.695</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.752</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.678</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.726</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.186</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.189</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.180</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.769</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.798</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.738</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.048</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.081</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.093</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.155</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.144</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.157</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.054</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.183</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.065</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.376</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.207</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.351</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY (100))</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.766</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.912</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.757</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.868</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB (100))</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.481</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.357</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.380</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.336</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the currency impact on key Group figures due to their conversion into US dollars, the Group&#x2019;s reporting currency. For additional information on the constant currency calculation (&#x201C;cc&#x201D;), see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Constant currencies&#x201D;.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Currency impact on key figures</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change in<br /> USD %<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br />  constant<br />  currencies %<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Percentage<br /> point currency<br />  impact<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Change in<br /> USD %<br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in<br />  constant<br />  currencies %<br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Percentage<br /> point currency<br />  impact<br /> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Group</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 198</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 195</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -84</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional information on the effects of currency fluctuations, see &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">81</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group liquidity, financial debts and net debt</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows Group liquidity, financial debts and net debt:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20&#xA0;244</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -22&#xA0;902</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -26&#xA0;175</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -29&#xA0;197</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less liquidity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liquidity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&#xA0;930</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&#xA0;329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -868</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For further information about the net debt measure, which is a non-IFRS measure, see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Net debt.&#x201D;</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group net debt at December 31, 2022, increased to USD&#xA0;7.2 billion, compared with USD&#xA0;0.9 billion at December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total financial debts amounted to USD 26.2 billion at December 31, 2022, compared with USD 29.2 billion at December 31, 2021. Non-current financial debts decreased by USD 2.7 billion, mainly due to the reclassification of USD 2.3 billion from non-current to current financial debts of two EUR denominated bonds with notional amounts of EUR 750 million and EUR 1.25 billion maturing in 2023 and favorable foreign currency translation adjustments of USD 0.4 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments decreased by USD 0.4 billion, mainly due to the repayment of two US dollar bonds of USD 1.0 billion and USD 1.5 billion, the closure during the third quarter of 2022 of the interest-bearing accounts of employees payable on demand, which amounted to USD 1.8 billion at December 31, 2021, and favorable currency translation adjustments, partly offset by the reclassification from non-current to current financial debts of USD 2.3 billion and an increase of USD 1.9 billion in commercial paper.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD 9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY 150 billion (approximately USD 1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD 2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD 0.9 billion).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also has a committed credit facility of USD&#xA0;6.0 billion, which was extended in 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The extended facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total liquidity decreased to USD 18.9 billion compared with USD 28.3 billion at December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of year-end 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the tables showing the maturity schedule of our current financial assets, current and non-current financial debts and net debt at December 31, 2022 and December 31, 2021, see &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments&#x2014;Liquidity risk.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of risks and restrictions on the ability of subsidiaries to transfer funds to the Company via cash dividends, loan or advances, please see &#x201C;&#x2014;Liquidity/short-term funding&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments.&#x201D; </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information regarding the Company&#x2019;s material commitments for capital expenditures as of the end of 2022 and 2021 and an indication of the general purpose of such commitments and the anticipated sources of funds needed to fulfill such commitments are provided in &#x201C;&#x2014;Material short- and long-term cash requirements.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">82</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity and financial debt by currency </span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of liquidity and financial debt by currency as of December 31:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Liquidity<br /> in % 2022<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Liquidity<br /> in % 2021<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br /> debt in %<br /> 2022<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br /> debt in %<br /> 2021<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 92</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPY</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Liquidity includes cash and cash equivalents and marketable securities, including debt securities, commodities and time deposits.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Financial debt includes non-current and current financial debt.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bonds </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In April 2022, a 5-year USD denominated bond of USD 1.0 billion with a coupon of 2.40% was repaid, in advance of its maturity date at no additional cost. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2022, a 10-year USD denominated bond of USD 1.5 billion with a coupon of 2.40% was repaid at maturity.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2021, a 4-year EUR denominated bond of EUR 1.25 billion with a coupon of 0.00% was repaid at maturity.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2021, a 7-year EUR denominated bond of EUR 0.6 billion with a coupon of 0.75% was repaid at maturity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity/short-term funding</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s liquidity amounted to USD 18.9 billion at December 31, 2022, compared with USD 28.3 billion at December 31, 2021. Total non-current and current &#xFB01;nancial debts, including derivatives, amounted to USD 26.2 billion at December 31, 2022, compared with USD 29.2 billion at December 31, 2021.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The debt/equity ratio increased to 0.44:1 at December 31, 2022, compared with 0.43:1 at December 31, 2021. The net debt increased to USD 7.2 billion at December 31, 2022, compared with USD 0.9 billion at December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We continuously track our liquidity position and asset/liability profile. This involves modeling cash flow maturity profiles based on both historical experiences and contractual expectations to project our liquidity requirements. We seek to preserve prudent liquidity and funding capabilities. We are confident that we have sufficient liquidity to support our normal business activities for the foreseeable future.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are not aware of any significant demands to change the level of liquidity needed to support our normal business activities. We make use of various borrowing facilities provided by several financial institutions. We also successfully issued various bonds in previous years and raised funds through our commercial paper programs.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The maturity schedule of our net debt can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments&#x2014;Liquidity risk.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">83</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Material short- and long-term cash requirements</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the Group&#x2019;s material short- and long-term cash requirements:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="9" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Payments due by period</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Total</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Less than<br /> 1 year</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> 2&#x2013;3 years</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> 4&#x2013;5 years</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> After<br /> 5 years</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debt, including current portion</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&#xA0;485</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;241</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;428</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;547</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;269</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on non-current financial debt, including current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;532</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 476</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 821</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 611</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;624</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities, non-current and current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 357</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on lease liabilities, non-current and current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;227</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitments for leases not yet commenced</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 83</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unfunded pensions and other post-employment benefit plans</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;281</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 115</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 204</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 747</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development potential milestone commitments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;814</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;256</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;169</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 835</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 267</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment purchase commitments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 549</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total contractual cash obligations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&#xA0;784</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21&#xA0;269</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group intends to fund the research and development; property, plant and equipment; intangible asset purchase commitments with internally generated resources, and the acquisition of business commitment through available cash and short- and long-term borrowings. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other contingent liabilities, see &#x201C;Item 8. Financial Information&#x2014;Item 8.A Consolidated statements and other financial information,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 10. Right-of-use assets and lease liabilities,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities,&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">84</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId0010028621"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.C Research and development, patents and licenses</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research and development spending totaled USD&#xA0;10.0 billion and USD&#xA0;9.5 billion (Core research and development USD&#xA0;9.1 billion and USD&#xA0;9.0 billion) for the years 2022 and 2021, respectively. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each of our divisions has its own research and development and patents. Our divisions have numerous products in various stages of development. For further information on these policies and these products in development, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As described in the risk factors section and elsewhere in this Annual Report, our drug development efforts are subject to the risks and uncertainties inherent in any new drug development program. Due to the risks and uncertainties involved in progressing through preclinical development and clinical trials, and the time and cost involved in obtaining regulatory approvals, among other factors, we cannot reasonably estimate the timing, completion dates and costs, or range of costs, of our drug development programs, or of the development of any particular development compound (see &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x201D;). In addition, for a description of the research and development process for the development of new drugs and our other products, and the regulatory process for their approval, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview.&#x201D;</div>
      <div id="anchorId0010028639"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.D Trend information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Please see &#x201C;&#x2014;Item 5.A Operating results&#x201D;, &#x201C;&#x2014;Item 5.B Liquidity and capital resources&#x201D; and &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x201D; for trend information.</div>
      <div id="anchorId0010028646"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.E Critical accounting estimates </p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Our significant accounting policies that are set out in &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D; include a description of the estimates, assumptions and judgments applied in the preparation of the consolidated financial statements of the Group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Given the uncertainties inherent in our business activities, we must make certain estimates and assumptions that require difficult, subjective and complex judgments. Because of uncertainties inherent in such judgments, actual outcomes and results may differ from our assumptions and estimates, which could materially affect the Group&#x2019;s consolidated financial statements. Application of the following accounting policies requires certain assumptions and estimates that have the potential for the most significant impact on our consolidated financial statements.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management believes that the estimation uncertainties described below did not have or are not reasonably likely to have a material impact on the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Deductions from revenues</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As is typical in the pharmaceutical industry, the consideration we receive in exchange for goods and services maybe fixed or variable. The most common elements of variable consideration are primarily composed of rebates and discounts granted to wholesalers, retailers, government agencies, government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations and other customers. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. These elements of variable consideration represent estimates of the related obligations, requiring the use of judgment when estimating the effect of these considerations for a reporting period.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following summarizes the nature of some of these deductions and how the deduction is estimated. After recording these, net sales represent our best estimate of the cash that we expect to ultimately collect. The US market has the most complex arrangements related to revenue deductions.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States-specific healthcare plans and program rebates</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The United States Medicaid Drug Rebate Program is administered by state governments, using state and federal funds to provide assistance to certain vulnerable and needy individuals and families. Calculating the rebates to be paid related to this program involves use of estimates and interpreting relevant regulations, which are subject to challenge or change in interpretative </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">85</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">guidance by government authorities. Provisions for estimated Medicaid rebates are calculated using a combination of historical experience, product and population growth, product pricing, and the mix of contracts and specific terms in the individual state agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States Federal Medicare Program, which funds healthcare benefits to individuals aged 65 and older, and to people with certain disabilities, provides prescription drug benefits under the Part D section of the program. This benefit is provided and administered through private prescription drug plans. Calculating the rebates to be paid related to this program involves use of estimates and interpreting relevant regulations, which are subject to challenge or change in interpretative guidance by government authorities. Provisions for estimated Medicare Part D rebates are calculated based on the terms of individual plan agreements, product sales and population growth, product pricing, including inflation impacts, and the mix of contracts.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer rebates to key managed healthcare and private plans in an effort to ensure patient access to our products and to sustain and increase the market share of our products. These programs provide a rebate after the plans have demonstrated they have met all terms and conditions set forth in their contract with us. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These rebates and discounts, applied using provision rates, are estimated based on the specific terms in the individual states and plans agreements, historical experience, product pricing and projected product growth rates, as appropriate to the individual rebate and discount arrangements, and are recorded as a deduction from revenue at the time the related revenues are recorded. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These provisions are adjusted based on established processes and experiences from filing data with individual states and plans. There is often a time lag between recording of revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-United States-specific healthcare plans and program rebates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In certain countries other than the US, we provide rebates to governments and other entities. These rebates are often mandated by laws or government regulations. These rebates, applied using provision rates, are estimated based on government regulations, laws and terms of individual rebate arrangements, historical experience and other relevant factors, and are recorded as a deduction from revenue at the time the related revenue is recorded. These estimates are adjusted periodically to reflect actual experience. There is often a time lag between the recording of revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative pay-for-performance arrangements</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We enter into innovative pay-for-performance arrangements (i.e. outcome based arrangements) with certain healthcare providers and governments. Under these agreements, we may be required to make refunds, defer a portion of the sales price until anticipated treatment outcomes meet predefined targets, or to provide additional medicines free of charge if anticipated treatment outcomes do not meet predefined targets. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of potential refunds or a deferral of a portion of the sales price are estimated and recorded as a deduction from revenue at the time the related sales are recorded. The impact of the future delivery of additional medicines at no cost is estimated and recorded as a contract liability at the time the related revenues are recorded. Estimates are based on historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period of the refund right has expired.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These provisions for revenue deductions are adjusted periodically based on established processes and actual experience, including the products&#x2019; actual outcomes achieved compared with the anticipated predefined targets. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is often a time lag between recording of the revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-healthcare plans and program rebates, returns and other deductions</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We offer rebates to purchasing organizations and other direct and indirect customers to sustain and increase market share and to ensure patient access to our products. Since rebates are contractually agreed upon, the related provisions are estimated based on the terms of the individual agreements, historical experience and projected product sales growth rates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Chargebacks occur where our subsidiaries have arrangements with indirect customers to sell products at prices that are lower than the price charged to wholesalers. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer&#x2019;s contract price. We account for chargebacks by reducing revenue by the estimate of chargebacks attributable to a sales transaction. Provisions for estimated chargebacks are calculated using a combination of factors, such as historical experience, product growth rates, product pricing, level of inventory in the distribution channel, and the terms of individual agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When we sell a product providing a customer the right to return it, we record a provision for estimated sales returns based on our sales return policy and historical return rates. Other factors considered include actual product recalls, expected marketplace changes, the remaining shelf life of the product, and the expected entry of generic products. In 2021, sales returns amounted to approximately 1% of gross product sales. If sufficient experience is not available, sales are only recorded based on evidence of product consumption or when the right of return has expired.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We enter into distribution service agreements with major wholesalers, which provide a financial disincentive for the wholesalers to purchase product quantities in excess of current customer demand. Where possible, we adjust shipping patterns for our products to maintain wholesalers&#x2019; inventory levels consistent with underlying patient demand.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer cash discounts to customers to encourage prompt payment. Cash discounts are estimated and </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">86</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">provisioned at the time of revenue recognition and are deducted from revenue.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a decrease in the price of a product, we generally grant customers a &#x201C;shelf stock adjustment&#x201D; for their existing inventory for the relevant product. Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other sales discounts, such as consumer coupons, vouchers and copay discount cards, are offered in some markets. The estimated amounts of these discounts are recorded at the time of sale or when the coupons are issued, and are estimated utilizing historical experience and the specific terms for each program. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we offer global patient assistance programs.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We adjust provisions for revenue deductions periodically to reflect actual experience. To evaluate the adequacy of provision balances, we use internal and external estimates of the inventory in transit, the level of inventory in the distribution and retail channels, actual claims data received, and the time lag for processing rebate claims. External data sources include reports from wholesalers and third-party market data purchased by Novartis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For the table showing the worldwide extent of our revenue deductions provisions and related payment experiences for the Group see &#x201C;Item 18. Financial Statements&#x2014;Note 22. Provisions and other current liabilities.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill, intangible assets and property, plant and equipment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We review intangible assets and property, plant and equipment for impairment whenever events or changes in circumstance indicate that the asset&#x2019;s balance sheet carrying amount may not be recoverable. Goodwill and other intangible assets that are not yet amortized, are reviewed for impairment at least annually.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or cash generating units (CGUs), and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities as indicated in &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies.&#x201D; Due to these factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recoverable amount of the grouping of cash-generating units to which goodwill is allocated is based on fair value less costs of disposal. The valuations are derived from applying discounted future cash flows based on key assumptions, including the terminal growth rate and discount rate. For additional information on impairment charges recognized and reversed by divisions, see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill and other intangible assets represent a significant part of our consolidated balance sheet, primarily due to acquisitions. Although no significant additional impairments are currently anticipated based on our impairment assessment and review of reasonable possible changes in key assumptions to the respective impairment assessment, future impairment evaluation could lead to material impairment charges in the future. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For net impairment charges for property, plant and equipment see &#x201C;Item 18. Financial Statements&#x2014;Note 9. Property, plant and equipment.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Retirement and other post-employment benefit plans</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former employees. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the interest rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates used by the Group may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Depending on events, such differences could have a material effect on our total equity. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 18. Financial </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">87</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Statements&#x2014;Note 25. Post-employment benefits for employees.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare and file our tax returns based on an interpretation of tax laws and regulations, and we record estimates based on these judgments and interpretations. Our tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made, requiring payments of additional tax, interest or penalties. Since Novartis uses its intellectual property globally to deliver goods and services, the transfer prices within the Group as well as arrangements between subsidiaries to finance research and development and other activities may be challenged by the national tax authorities in any of the jurisdictions in which Novartis operates. Therefore, inherent uncertainties exist in our estimates of our tax positions, but we believe that our estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are appropriate based on currently known facts and circumstances. Uncertain (income) tax positions are periodically (re)assessed by the Company based on management&#x2019;s best judgment given any changes in the facts, circumstances and information available and applicable tax laws. When it is probable that the tax authorities will not accept the position taken, the Group recognizes income tax liabilities based on the most likely amount of the liability (recovery) or weighted average of various possible outcomes to reflect the effect of the uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses, unused tax credits or tax rates, to the extent that a reliable estimate can be made.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 6. Income taxes&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions and contingent liabilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of Group companies are involved in various government investigations and legal proceedings (intellectual property, sales and marketing practices, product liability, commercial, employment and wrongful discharge, environmental claims, etc.) arising out of the normal conduct of their businesses. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We record provisions for legal proceedings when it is probable that a liability has been incurred and the amount can be reliably estimated. These provisions are adjusted periodically as assessments change or additional information becomes available. For signi&#xFB01;cant product liability cases, the provision is actuarially determined based on factors such as past experience, amount and number of claims reported, and estimates of claims incurred but not yet reported.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions are recorded for environmental remediation costs when expenditure on remedial work is probable and the cost can be reliably estimated. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">88</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00410980"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 6.  Directors, Senior Management and Employees</p>
      <div id="anchorId00410982"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.A Directors and senior management</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Board of Directors&#x201D; and &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Executive Committee&#x201D; is incorporated by reference. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">89</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911131"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.B Compensation</p>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Dear shareholder, </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">I am pleased to share with you the Novartis Compensation Report for 2022. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We believe that our compensation system supports our strategy and motivates our executives to deliver sustainable growth, successful outcomes on our financial and strategic targets, and value creation for our shareholders. Over the course of 2022, we engaged with shareholders and proxy advisors to share how our compensation system is aligned with short and long-term performance, and to secure their continued support for our compensation system design.  Based on the feedback from these interactions and the positive response to our 2021 Compensation Report, which received a 90.7% vote in favor, we will retain the current design of our executive compensation system, with small enhancements as explained later in this letter.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 performance highlights</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2022 was a year of solid financial performance, with growth in constant currencies (cc) across sales, core profits and core margins. Sales growth drivers were <i>Entresto</i> (USD 4.6 billion), <i>Kesimpta</i> (USD 1.1 billion), <i>Kisqali</i> (USD 1.2 billion), <i>Cosentyx</i> (USD 4.8 billion), along with the <i>Pluvicto</i> launch. Our six in-market growth drivers with multi-billion sales potential (<i>Cosentyx</i>, <i>Entresto</i>, <i>Zolgensma</i>, <i>Kisqali</i>, <i>Kesimpta</i> and <i>Leqvio</i>) grew 26% (cc) in 2022, and now represent 32% of total Innovative Medicines sales, up from 26% in 2021. Overall sales were broadly in line with target.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In April 2022, we announced the introduction of a new organizational model designed to support the company&#x2019;s innovation, growth, and productivity ambitions as a focused medicines company. The restructuring will simplify the organization and our processes, and is expected to deliver USD 1.5 billion in savings by 2024 with a proportion of these savings already delivered in 2022, enabling us to raise our long-term core operating income margin guidance. These savings are expected to help us progress towards our aspiration of achieving ~40%+ core margin beyond 2027 and further invest in our pipeline, as a pure-play medicines company (after the planned Sandoz spin-off which is subject to approval of the Novartis AG Board of Directors and shareholders). Nonetheless, there was an immediate impact on Operating Income as we incorporated related costs in the latter part of the year, that, along with higher legal settlements and unfavorable fair market value adjustments on financial assets, impacted operating income growth. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we continued to deliver high value medicines to patients. We received 23 approvals in our key focus markets US, EU, China and Japan, including US and EU approvals for <i>Pluvicto</i>, a novel radioligand therapy for advanced prostate cancer. We advanced our focused pipeline of investigational medicines, with several important clinical data readouts paving the way for further launches in 2023 and beyond, a significant one being iptacopan, our investigational monotherapy in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). However, we also had disappointments as some clinical trials of experimental compounds did not meet their primary endpoints, including ACZ885 (canakinumab) in lung cancer, and UNR844 in presbyopia.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are proud that Novartis also continued to deliver on its commitments to broaden access to medicines and tackle major global health challenges. We pledged further investment in research into malaria and neglected tropical diseases, increased access to our innovative medicines for low- and middle-income countries and formed new collaborations with governments and other partners to strengthen healthcare systems. More details on our ESG efforts can be found in our Novartis in Society Integrated Report 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 CEO compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As a result of the above performance, the CEO was awarded a 2022 Annual Incentive of 100%, having overall met the financial targets and strategic objectives set at the beginning of the cycle. When determining performance against the operating income metric, the Board of Directors approved adjustments to exclude restructuring costs arising from the implementation of the new organizational model and costs related to the planned Sandoz spin-off, which are investments in the future of the company in terms of both sales and margin growth. These adjustments ensured that the performance assessment was consistent with the basis on which the original targets were set.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020-2022 Long-Term Performance Plan (LTPP) vested at 57% of target. The LTPP outcome was heavily affected by the relative Total Shareholder Return (rTSR) performance over the period, as well as reduced sales growth during 2020 and 2021, which was substantially impacted by the COVID-19 pandemic. No adjustments were made for the COVID-19 impact, or for any other factors. (For more information, please see &#x201C;&#x2014;LTPP performance outcomes&#x201D;).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite a solid 2022 performance, as outlined above, the CEO&#x2019;s 2022 total realized compensation was CHF 8&#xA0;452&#xA0;176, a decrease of 24.7% compared with prior year, driven mainly by the 2020-2022 LTPP outcome.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Changes to Executive Committee compensation system and disclosures</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the year, we reviewed our Executive Committee compensation system, with the aim of simplification and increased transparency of our performance assessment measures and strengthening our focus on key strategic priorities, while also considering developments in compensation best practices. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Effective the 2022-2024 cycle of the LTPP, we strengthened the assessment of research and early development performance under the Innovation metrics, </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">90</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">to ensure that targets are focused more directly on activities that create long-term value, and are measurable over a three-year performance period. For the innovation performance measure, the Science &amp; Technology Committee sets targets that take into account the expected Net Present Value (eNPV) of programs transitioning to late-stage clinical development rather than the previous approach to set targets related to early-stage milestones. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Effective from performance year 2023, we will remove &#x201C;Share of Peers&#x201D; as a financial performance measure for the Annual Incentive plan, to simplify the metrics and focus on targets that provide greater transparency. The weighting of the three remaining financial measures, Group Net Sales, Group Operating Income and Group Free Cash Flow, will be 40%, 30% and 30%, respectively. In addition, we will fold division specific financial targets, where applicable, into individual strategic objectives (40% weighting) of the related Executive Committee member. All Executive Committee members will be evaluated, with a 60% weighting, against the performance of Group financial measures mentioned above.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, we announced our intention to separate our Sandoz generics and biosimilars Division into a new publicly traded standalone company, by way of a 100% spin-off, subject to approval of the Novartis AG Board of Directors and shareholders.  Based on the planned completion of the spin-off in 2023, the Compensation Committee made some initial decisions on the 2023 compensation elements related to the spin-off. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Finally, the 2023 Compensation Report will also include additional disclosures following the reform of Swiss corporate law that came into effect on January 1, 2023. For more information, please see &#x201C;&#x2014;2023 Executive Compensation Changes&#x201D;.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Inflation and cost-of-living impact on broader employee group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board and the Executive Committee are mindful of the cost-of-living challenges that are impacting many of our associates in different markets.  The Executive Committee has considered these as part of its pay decisions and outcomes, and where appropriate, it has initiated local level initiatives to support associates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In most countries, our 2023 salary budgets are higher than in previous years, reflecting the overall higher market forecasts driven by inflation. In some of our larger markets we are making a one-time payment to certain employee populations.  Where legally possible, we have tried to target these one-time payments to our lower paid employees, who are most impacted. We will continue to monitor our compensation against the Living Wage, and regularly monitor and adjust wages in hyperinflation markets to support our local associates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These actions reflect our commitment to pay market-competitive and sustainable salaries, rather than to fully match the current volatile inflation environment. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">2023 base salary increases for ECN members, including the CEO, are made in line with policy, and no ECN member will receive any inflation related one-time payments. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2023 Annual General Meeting (AGM)</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the 2023 AGM, shareholders will be asked to vote on both the maximum aggregate amount of compensation for the Board of Directors from the 2023 AGM to the 2024 AGM, and the maximum aggregate amount of compensation for the Executive Committee for the financial year 2024. Furthermore, we will request an advisory vote on this Compensation Report.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We welcome your feedback, which is invaluable in driving improvements in our compensation system and practices. On behalf of the Compensation Committee, I would like to thank you for your continued support and trust. </div>
      <div style="padding-top:15px">
        <img src="comp_0028.gif" alt="WSGE_DP_Sign_CompChair"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Simon Moroney, D.Phil.</b>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chair of the Compensation Committee</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">91</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911228"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation&#xA0;at&#xA0;a&#xA0;glance</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2022 outcomes</span>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO pay for performance</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0029.gif" alt="WSGE_DP_Graph_ataglance_ceopfp"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 Annual Incentive% of target200%150%100%50%0%MaximumPayout: 100% of targetLong-Term Performance Plan (2020&#x2013;2022 performance)% of target200%150%100%50%0%MaximumTargetPayout: 57% of targetNet sales CAGR (43% of target)Core operating income CAGR (93% of target)Innovation (92% of target)Relative TSR (0% of target)</div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO total realized compensation</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2022 total realized compensation for the CEO was CHF 8 452 176. It includes payouts of the Annual Incentive and LTPP based on actual performance assessed for the cycles concluding in 2022. More information on the assessment of the CEO by the Board of Directors can be found in &#x201C;&#x2014;2022 CEO balanced scorecard&#x201D; and &#x201C;  &#x2014;LTPP performance outcomes&#x201D;.</div>
      <div style="padding-top:15px">
        <img src="comp_0030.gif" alt="WSGE_DP_Graph_ataglance_ceototal"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board compensation </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total actual compensation earned by Board members in the 2022 financial year is shown in the table below.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022<br /> total compensation<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 804</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other members of the Board</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4 703</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8 506</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes an amount of CHF 29&#xA0;250 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 453&#xA0;083 and provides a right to the maximum future insured government pension benefit for the Board members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">92</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 compensation systems</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An overview of the 2023 compensation systems for the Executive Committee and the Board of Directors is provided below. </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee compensation system</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Effective 2023, financial measures of the Annual Incentive plan comprise Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow (30%) for all Executive Committee members. Additionally, &#x201C;Share of Peers&#x201D; will be removed from the financial measures. </div>
      <div style="padding-top:15px">
        <img src="comp_0003.gif" alt="WSGE_DP_Graph_ataglance_ecsystem"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2023 fixed pay and benefitsAnnual base salaryPension and other benefitsPerformance-related variable pay2023 Annual IncentiveLong-Term Incentive awards cycle 2023-2025LTPP1PurposeReflects responsibilities, experience and skill setsProvide retirement and risk insurances (tailored to local market practices/regulations)Rewards performance against short-term financial and strategic objectives, and Values and BehaviorsRewards long-term shareholder value creation and innovation in line with our strategyForm of paymentCashCountry/individual-specific and aligned with other employees50% cash50% equity2 deferredfor three years3Equity, vesting following a three-year performance periodPerformance measuresBalanced scorecard comprising:&#x2022;Financial measures4 (60%)&#x2022;Strategic objectives5 (40%)&#x2022;Net sales  CAGR (25%)&#x2022;Core operating income CAGR (25%)&#x2022;Innovation (25%)&#x2022;Relative TSR (25%)1LTPP = Long-Term Performance Plan 2Executive Committee members may elect to receive more of their Annual Incentive in equity instead of cash3The Annual Incentive deferred in equity is granted under the Deferred Share Bonus Plan (DSBP)4Financial Measures are Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow (30%)5  Strategic objectives are aligned with our transformation to become a pure-play Innovative Medicines company: Strategy, Growth / Launches, Innovation, Operational excellence, Build trust with society</div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board compensation system </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no changes to the Board compensation system for 2023.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; font-style:italic; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> AGM 2023-2024<br /> annual fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;800</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br />&#x2022; Governance, Sustainability and Nomination Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br />&#x2022; Compensation Committee<br />&#x2022; Governance, Sustainability and Nomination Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br /> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">93</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911462"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee compensation&#xA0;philosophy and principles</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis compensation philosophy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our compensation philosophy aims to ensure that we attract and retain outstanding Executive Committee members and reward them according to their success in implementing the Company strategy, and their contribution to Company performance and long-term value creation.  The main elements of our compensation philosophy are set out in the table below.</div>
      <div style="padding-top:15px">
        <img src="comp_0006.gif" alt="WSGE_DP_Graph_ecncompensation_philosophy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Pay for performance&#x2022;Variable compensation is tied directly to the achievement of strategic Company targetsShareholderalignment&#x2022;Our incentives are significantly weighted toward long-term equity-based plans&#x2022;Measures under the Long-Term Incentive plans are calibrated to promote the creation of shareholder value&#x2022;Executive Committee members are expected to build and maintain substantial shareholdingsBalanced rewards&#x2022;Balanced set of measures to create sustainable value&#x2022;Mix of targets based on financial metrics, strategic objectives, and performance versus our competitorsBusiness ethics&#x2022;The Novartis Values and Behaviors are an integral part of our compensation system&#x2022;They underpin the assessment of overall performance for the Annual IncentiveCompetitive compensation&#x2022;Total compensation must be sufficient to attract and retain key global talent&#x2022;Overarching emphasis on pay for performance</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Alignment with Company strategy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive compensation is strongly connected to business strategy. In 2022, we refocused our strategy to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in research and development, and novel access approaches. Our strategy focuses on five core therapeutic areas with high unmet patient needs, two core and three emerging technology platforms, and four priority geographies, which together account for the majority of expected growth in global healthcare spending. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In line with this refocused strategy, we updated our strategic priorities to target innovation power, sales growth, delivering both margin and total shareholder returns, and sector leadership in material ESG factors. The Long-Term Incentive Plan was adapted, with greater emphasis now on the delivery of high value programs in our research and early development targets. The Annual Incentive plan has been simplified effective 2023, with three key financial metrics: Net Sales, weighted 40%; Operating Income, weighted 30%; and Free Cash Flow, weighted 30%.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Approach to market benchmarking</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There continues to be significant competition for top executive talent with deep expertise, the requisite competencies and proven performance within the pharmaceutical and biotechnology industries. As such, external peer compensation data is one of a number of key reference points considered by the Board of Directors and the Compensation Committee when making decisions on executive pay, so as to help ensure that the compensation system and compensation levels at Novartis remain competitive. Novartis is committed to confirming benchmarking practices, including the peer group, to shareholders on an annual basis. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee believes in a rigorous approach to peer group construction and maintenance. Furthermore, it believes that using a consistent set of peers that is similar in size and scope enables shareholders to evaluate the compensation year on year and make pay-for-performance comparisons. In 2022, the Compensation Committee decided to maintain the same primary peer group of <b>14 global healthcare companies</b>, as presented in the table below.</div>
      <div style="padding-top:15px">
        <img src="comp_0005.gif" alt="WSGE_DP_Graph_ecncompensation_peergroup"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Global healthcare peer groupAbbVieBiogen GlaxoSmithKlineNovo NordiskRocheAmgenBristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co.Johnson &amp; JohnsonPfizer</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The companies in this peer group reflect our industry and are similar to Novartis in terms of both size and scope of operations. Although Novartis is headquartered in Switzerland, more than a third of its sales come from the US market, and the US remains a significant talent pool for the recruitment of executives by the Company. It is therefore critical that Novartis is able to attract and retain key talent globally, especially from the US. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To ensure European and local practices were fully taken into account, in 2022 the Compensation Committee also reviewed a cross-industry peer group of Europe-headquartered multinational companies, selected based on comparability to Novartis in terms of industry, size, global scope of operations, and economic influence. Based on this review, the Committee retained the same group of <b>European peers</b> as in 2021: Anheuser-Busch InBev, AstraZeneca, Bayer, BMW, GlaxoSmithKline, L&#x2019;Or&#xE9;al, Merck KGaA, Nestl&#xE9;, Novo Nordisk, Reckitt Benckiser, Roche, Siemens, Sanofi, and Unilever.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">94</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee appointments compensation policy</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0007.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_ecnappointmentspolicy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyLevelThe overall package should be market-competitive to enable the recruitment of global executive talent with deep expertise and competencies.Annual base salaryThe Compensation Committee may appoint individuals who are new to a role on an annual base salary that is below the market level, with a view to increase this toward market level over a period of three to four years as an individual develops in the role.If the scope of an existing Executive Committee member&#x2019;s role changes significantly during the year, the Compensation Committee may make adjustments to the individual&#x2019;s base salary (and/or incentives) in consideration of the benchmark of the new role and the Executive Committee appointments compensation policy.This prudent approach ensures pay levels are merit-based, with increases dependent on strong performance and proven ability in the role over a sustained period.IncentivesThe compensation package will normally include the key compensation elements and incentive opportunities in line with those offered to current Executive Committee members.In exceptional circumstances, higher incentive opportunities than those offered to current Executive Committee members may be provided at the Compensation Committee&#x2019;s discretion.Performance measures may include business-specific measures tailored to the specific role.Pension and other benefitsNewly appointed Executive Committee members are eligible for the local country pension plan and other benefits in line with the wider employee group.BuyoutsThe Compensation Committee seeks to balance the need to offer competitive compensation opportunities to acquire the talent required by the business with the principle of maintaining a strong focus on pay for performance.As such, when an individual forfeits variable compensation as a result of an appointment at Novartis, the Compensation Committee may offer replacement awards to compensate the commercial equivalent value or fair value of payments and awards forfeited by the individual, in such form as the Compensation Committee considers appropriate, taking into account relevant factors.Relevant factors include the expected value of the forfeited award, the replacement vehicle (i.e., cash, restricted share units, restricted shares or performance share units), whether the award is contingent on meeting performance conditions or not, the timing of forfeiture (i.e., Novartis mirrors the blocking or vesting period of the forfeited award) and the leaver conditions, in case the recruited individual leaves Novartis prior to the end of the blocking or vesting period.International mobility If individuals are required to relocate or be assigned away from their home location to take up their position, relocation support may be provided in line with our global mobility policies (e.g., relocation support, tax equalization). This includes ongoing US state income tax liabilities on behalf of US citizens locally employed outside the US who have US workdays and therefore, US state taxable compensation that generates a US state tax liability.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">95</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treatment of variable compensation for Executive Committee leavers</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0008.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_ecnleaverspolicy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyAnnual Incentive &#x2013; cash elementRetirement, termination by the Company (for reasons other than performance or conduct), change of control, disability, death, i.e., &#x201C;good leavers&#x201D;Pro-rata Annual Incentive is paid to reflect the portion of the year the individual was employed.Voluntary resignation or termination by the Company for misconduct or poor performanceAnnual Incentive is fully forfeited.Annual Incentive &#x2013; mandatory deferral into restricted shares/ restricted share units (RSUs)Retirement, termination by the Company for reasons other than performance or conduct, and change of controlAwards are released on the original blocking end date. There is no accelerated vesting. All awards are subject to forfeiture in the event that a leaver joins a competitor company as defined in the applicable plan rules, before the end of the three-year blocking date, starting from the date of grant.Death or long-term disabilityAccelerated vesting is applied.Voluntary resignation or termination by the Company for misconduct or poor performanceUnvested restricted shares and restricted share units (RSUs) are forfeited.Annual Incentive &#x2013; voluntary restricted shares/RSUs/AmericanDepository Receipts (ADRs) (ADRs applicable for US employees only)Awards are not subject to forfeiture during the deferral period.  Long-Term Incentive &#x2013; mandatory performance share units (PSUs)Retirement, termination by the Company for reasons other than performance or conduct, and change of control Awards vest on the regular vesting date, subject to performance, on a pro-rata basis for time spent with the Company during the performance cycle. There is no accelerated vesting. All awards are subject to forfeiture in the event that a leaver joins a competitor company as defined in the applicable plan rules, until the vesting date.Death or long-term disabilityAccelerated vesting at target is applied.Voluntary resignation or termination by the Company for misconduct or poor performanceAll of the award is forfeited.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Malus and clawback</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any incentive compensation paid to Executive Committee members is subject to malus and clawback rules. This means that the Board of Directors for the CEO, and the Compensation Committee for the other Executive Committee members, may decide &#x2013; subject to applicable law &#x2013; to retain any unpaid or unvested incentive compensation (malus), or to recover incentive compensation that has been paid or vested in the past (clawback). This applies in cases where the payout has resulted from a violation of laws or conflicts with internal management standards, including Company and accounting policies. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This principle applies to both the short-term Annual Incentive and Long-Term Incentive (LTI) plans.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee is assessing the impact of the final clawback rule in the Federal Register published by the US Securities and Exchange Commission in 2022, and any required changes to the policy will be disclosed in the 2023 Compensation Report.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">96</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee performance&#xA0;management process</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To foster a high-performance culture, the Company applies a performance management process based on quantitative and qualitative criteria. The CEO and the other Executive Committee members are subject to a formal three-step process: objective setting, performance evaluation and compensation determination. This process is explained in the chart below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Performance targets are generally set before the start of the relevant performance cycle. A rigorous framework is in place for establishing targets to ensure they are suitably robust and challenging, and align with the strategic priorities of the Group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The key factors taken into account when setting targets include:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Internal and external market expectations </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Novartis strategic priorities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regulatory factors (e.g., new launches, patent expiries)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investment in capital expenditure</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Values and Behaviors</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The targets are challenged at multiple stages before they are ultimately approved by the Board of Directors. In line with good governance practices, the Compensation Committee works to set targets that are ambitious and challenging but do not encourage undue risk-taking. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the end of the performance cycle, the Board of Directors and the Compensation Committee consider performance against the targets originally set. The CEO and Executive Committee members are not present while the Board of Directors and the Compensation Committee discuss their individual performance evaluations and determine their individual compensation. Prior to determining the final outcome, related factors such as performance relative to peers, wider market conditions, general industry trends and good practice are used to inform the overall performance assessment. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:15px">
        <img src="comp_0009.gif" alt="WSGE_DP_Graph_ecnperformancemgtprocess_process"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Objective setting&#x2022;The CEO proposes their targets to the Board Chair; they are then reviewed and approved by the Board of Directors, based on input from the Compensation Committee.&#x2022;For other Executive Committee members, targets for their division or unit are initially discussed with the CEO and subsequently approved by the Board of Directors and the Compensation Committee.Performance evaluation&#x2022;The CEO&#x2019;s performance against the individual balanced scorecard is assessed by the Board of Directors.&#x2022;For Executive Committee members, the CEO discusses each member&#x2019;s performance (assessed against his or her individual balanced scorecard) with the Board Chair before making recommendations to the Board of Directors for final determination.&#x2022;Periodic assessments, including at the mid-year stage, ensure progress is suitably tracked.Compensation determination &#x2022;A recommendation for the CEO&#x2019;s variable pay is made by the Compensation Committee to the Board of Directors for final determination.&#x2022;For the Long-Term Incentive financial measures&#x2019; payout schedules, a formulaic approach applies, and the Compensation Committee can also exercise judgment to ensure there is appropriate alignment between payout levels and overall performance achieved. The same principle of discretion applies to the relative TSR and innovation performance measures.&#x2022;The CEO&#x2019;s recommendations for other Executive Committee members are considered and approved by the Compensation Committee, after which the Board of Directors is notified of the outcomes.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">97</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911572"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2022 Executive Committee compensation </p>
      <div style=" padding-bottom: 10px;"></div>
      <div style="padding-top:15px">
        <img src="comp_0010.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_fixedcompensation"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Annual base salaryOverview&#x2022;The annual base salary is reviewed each year, taking into account: the individual&#x2019;s role, performance and experience; business performance and the external environment; increases across the Group; and market movements.2022 annual base salariesThe 2022 annual base salaries were as follows:&#x2022;CEO (effective March 1, 2022): CHF 1 789 500.     &#x2022;OTHER EXECUTIVE COMMITTEE MEMBERS (effective March 1, 2022): All other members of the Executive Committee were awarded increases in line with the average of all Novartis employees, with the exception of five individuals as disclosed in Item 6.B of the 2021 Annual Report.Pension and other benefitsOverview&#x2022;Pension and other benefits do not constitute a significant proportion of total compensation and are provided to the Executive Committee on the same terms as all other employees based on local country practices and regulations. &#x2022;The CEO and all other Swiss-based members of the Executive Committee are members of the Novartis Swiss pension funds, which provide Company contributions on the base salary and Annual Incentive up to the legal cap on the insured salary of CHF 860 400. No supplementary pension plans or savings plans are provided. The CEO&#x2019;s employer pension contributions represent 9.77% of his base salary.&#x2022;Globally the Company operates both defined benefit and defined contribution pension plans (see also Note 25 to the Group&#x2019;s consolidated financial statements). &#x2022;Novartis may provide other benefits according to local market practice. These include Company car provision, tax and financial planning, and insurance benefits.&#x2022;Executive Committee members who are required to relocate internationally may also receive additional benefits (including tax equalization), in line with the Company&#x2019;s global mobility policies. </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">98</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2022 Annual Incentive</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0012.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_variablecompensation"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">PLAN OVERVIEWTarget Annual Incentive On-target opportunities&#x2022;CEO: 150% of annual base salary&#x2022;Other Executive Committee members: 80% to 120% of annual base salaryPerformance measures&#x2022;An Annual Incentive balanced scorecard containing:&#x2022;Financial performance measures (60% weighting) related to Group, division or business unit, where relevant &#x2022;Strategic objectives (40% weighting) are aligned with our transformation to become a pure-play Innovative Medicines company: Strategy, Growth / Launches, Innovation, Operational excellence, Build trust with society &#x2022;The balanced scorecard targets and achievements of the CEO are detailed on the next page.&#x2022;The balanced scorecards for other Executive Committee members include Group financial targets as well as financial or other quantitative targets that relate to their division or business unit, if applicable.&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture. As such, members of the Executive Committee are expected to demonstrate these to the highest standards.Target setting&#x2022;Financial targets are set at the beginning of each financial year and align with the strategic plan proposed by management to the Board of Directors for approval.&#x2022;The strategic objectives are aligned with the most important priorities in any performance year.Payout ranges&#x2022;The payout schedule for the Annual Incentive incorporates performance against financial and strategic objectives. The payout range is 0% to 200% of on-target opportunity based on performance, as shown below:PERFORMANCEPAYOUT (% of on-target)Outstanding170%  200%Exceeds expectations130%  160%Meets expectations80%  120%Partially meets expectations40%  70%Below expectations0%Payout formulaPayout vehicle&#x2022;At the end of the performance period, 50% is paid in cash, and the remaining 50% is delivered in Novartis restricted shares or RSUs, deferred for three years (see &#x201C;Executive Committee compensation system&#x201D;).&#x2022;Executives may choose to receive all or part of the cash portion of their Annual Incentive in Novartis shares or American Depositary Receipts (ADRs; US only) that will not be subject to forfeiture conditions. In the US, awards may also be delivered in cash under the US-deferred compensation plan.Dividend rights, voting rights and settlement&#x2022;Novartis restricted shares and ADRs carry voting rights and dividends during the vesting period. RSUs are of equivalent value but do not carry voting rights and dividends during the vesting period.&#x2022;Following the vesting period, settlement of RSUs is made in unrestricted Novartis shares or ADRs. Annual base salaryxTarget incentive (% of base salary)=Target Annual IncentiveAnnual base salaryxTarget incentive (% of base salary)xPayout factor (% of target: 0%200%)=Realized Annual Incentive</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">99</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0014.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_ceoscorecard"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 CEO BALANCED SCORECARD This section presents the balanced scorecard for the CEO. Balanced scorecard performance is measured in constant currencies (cc) to reflect operational performance that can be influenced. The Board of Directors uses a stringent process to set ambitious financial targets to incentivize superior performance. In addition to the financial targets, the CEO also has ambitious strategic objectives across key priority areas, including targets related to ESG matters. Achievement versusCEO achievements  2022TargettargetFinancial measures  60% of total Annual Incentive, comprising: Group net sales (cc) (30%) 54360 millionMetGroup operating income (cc) (30%)| 11630 million|Met*Group free cash flow as a % of sales (cc) (20%)| 24.8%|BelowShare of peers for Novartis Group  (20%) 7.3%MetOverall assessment of Group financial targets in constant currencies Met*The Board concluded that the achievement for Group operating income versus target was &#x201C;Met&#x201D; after approving adjustments mainly to exclude restructuring costs arising from the implementation of the new organizational model announced to investors on April 4, 2022 (and were not available at the time of target setting in January 2022), and costs related to the planned Sandoz spin-off, to transform Novartis into a focused medicines company. Strategic objectives  40% of total Annual Incentive, comprising:Strategy (15%)|MetIn 2022, the CEO launched a new strategy and laid the foundation to improve our growth profile via a strong focus on our five core therapeutic areas (cardiovascular, immunology, neuroscience, solid tumors, and hematology), two established (chemistry and biotherapeutics) and three emerging (gene &amp; cell therapy, radioligand therapy, and xRNA) technology platforms, and four key geographies (China, Germany and Japan, and a particular priority in the US market). This strategy will transform Novartis into a pure-play Innovative Medicines business, with multiple in-market brands of multi-billion dollar peak sales potential, and prioritize our pipeline to focus on high-value assets that address high disease burden and have substantial growth potential. Sandoz separation analysis was completed with spin-off being the preferred separation path given potential future value upside for shareholders. Substantial progress was also made on the preparation for the planned spin-off, which is expected to take place in the second half of 2023.Growth/Launches (15%)| MetRecent launch products Pluvicto (USD 271 million), Kesimpta (USD 1.1 billion), and Scemblix (USD 149 million) achieved higher than target sales. However, lower uptake for Leqvio resulted in sales behind target.In-market growth drivers (including Cosentyx, Entresto, Zolgesma, Kisqali, Kesimpta, and Leqvio) delivered combined sales of USD 13.2 billion, which was slightly behind target. This was largely due to the below target performance of Cosentyx (total sales of USD 4.8 billion, impacted by US payer pressures, China business and Inflation Reduction Act headwinds). This was partly offset by strong performance of Entresto (USD 4.6 billion) and Kisqali (USD 1.2 billion). Innovation (15%)|MetIn 2022, we received 23 approvals in our top four markets (US, EU, China and Japan). Major approvals included Pluvicto (US, EU), Scemblix (EU), and further indication expansions for Kymriah and Cosentyx. 24 submissions were made across the top four markets. We advanced our focused pipeline of investigational medicines, with several important clinical data readouts including Iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and deadly blood disorder, and Pluvicto in earlier lines of prostate cancer. Cosentyx was submitted to the US FDA for an additional indication, ahead of planned timelines.Among our early-stage development activities, we secured ten proofs of concept (POCs) / proofs of mechanisms (POMs). Additionally, we achieved First Patient First Visit in six pivotal trial-enabling studies against our Research and Development target of five.The year also experienced some disappointments, with important trials not meeting primary goals (such as canakinumab for lung cancer and UNR844 in presbyopia).</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">100</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0026.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_ceoscorecard_2"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 CEO BALANCED SCORECARD &#x2212; CONTINUEDOperational excellence (15%)|MetIn April 2022, we introduced a new operating model to make our organization more agile and efficient in support of our strategy. This simplified and leaner organization is expected to deliver identified cost savings of approximately USD 1.5 billion by 2024, and help drive mid-term Innovative Medicines margin to the low 40s. Financial performance for 2022 improved from prior year in constant currencies on core operating income and core margin to USD 16.7 billion and 33.0% respectively.The Operations unit, comprising our legacy Technical Operations unit and the legacy Customer and Technology Solutions unit, achieved savings of USD 998 million against a combined target of USD 785 million. However, these savings were partially offset by external headwinds, driven mainly by inflation, of approximately USD 350 million. Build trust with society (40%) | AboveINNOVATION AND ACCESS In 2022, we achieved a 26% increase in patient reach with our strategic innovative therapies, reaching 1.2 million patients, compared with the previous year (0.95 million).  All our product launches in 2022 included a tiered pricing strategy based on national income level and value-based pricing, in line with target.With our commitment to diversity in clinical trials, 100% of our US Phase 3 studies evaluated Diversity &amp; Inclusion principles in feasibility planning, in line with our target.  Through our Novartis Global Health flagship programs, we reached 31 million patients in 2022, beating our Sustainability-linked Bond target of 22.6 million patients by 2025. In 2022, we renewed our commitment to the research and development of new medicines for malaria and neglected tropical diseases, pledging to invest USD 250mn over five years (2021-2025), and we advanced the clinical development of next-generation malaria medicines. PEOPLE AND CULTUREWe progressed towards a &#x201C;Performance Culture&#x201D; mindset with the implementation of a new &#x201C;high support / high challenge&#x201D; approach.We remain committed in our efforts to increase workforce diversity. The percentage of women in management increased to 47%, slightly behind our target of 48%. ENVIRONMENTAL SUSTAINABILITYIn 2022, we reduced our Scope 1 and 2 carbon emissions by 49%, our water consumption by 42%, and our waste sent for disposal by 59%, compared with our 2016 baseline. This was broadly in line or ahead of our 50%, 41% and 50% targets, respectively.  To advance on our Scope 3 emissions target, environmental sustainability criteria have been integrated into supply contracts covering more than a third of our Scope 3 supplier emissions.ETHICAL BUSINESS PRACTICESWe assessed 100% of our applicable policies &amp; controls in the areas of Access to Medicine &amp; Artificial Intelligence and categorized them as either &#x201C;aligned with Human Right standards&#x201D; or &#x201C;needs update with defined scope to meet Human Rights standards&#x201D;, in line with our target. Overall assessment of strategic objectives Met Overall assessment of CEO balanced scorecardMetANNUAL INCENTIVE PAYOUTPayoutThe 2022 CEO performance showed solid financial results, including sales and operating income performance at target and most strategic objectives were achieved or exceeded. The launch of a new focused strategy transforming Novartis into a pure-play medicines company, performance of launch products and preparation for planned Sandoz spin-off were key highlights. However, Free Cash Flow performance was impacted by decrease in net cash flows from operating activities and lower divestment proceeds. On balance, based on the overall assessment, the Board of Directors decided on an Annual Incentive payout for the CEO amounting to CHF 2 684 321, which is 100% of target, within the range of 0200%.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">101</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan, 2020-2022 cycle</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0016.gif" alt="WSGE_DP_Graph_planstructure_LTPP"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">OVERVIEW OF LONG-TERM PERFORMANCE PLANAward vehiclePerformance share units (PSUs) are granted at the beginning of the three-year performance cycle and vest at the end of the cycle to the extent that performance conditions have been met. At the time of vesting, they are converted into Novartis shares.PSUs carry dividend equivalents that are paid in shares at the end of the cycle.Grant formula At the start of the performance cycle, PSUs are granted under the Long-Term Incentive plan, as follows:Target opportunity &#x2022;CEO: 325% of annual base salary&#x2022;Other Executive Committee members: between 180% and 260% of annual base salaryPerformance measures&#x2022;Net sales CAGR (25%)&#x2022;Core operating income CAGR (25%)&#x2022;Innovation (25%)&#x2022;Relative TSR (25%)Target settingFinancial targets: Targets for net sales CAGR and core operating income CAGR are set based on the strategic plan of the Company. Innovation: Global Drug Development (GDD) targets are based on targeted filings communicated at the start of each performance cycle, weighted 70%. The Science &amp; Technology Committee determines the most important Novartis Institutes for BioMedical Research (NIBR) milestones, weighted 30%. Effective the 2022-2024 LTPP cycle, NIBR targets set by the Science &amp; Technology Committee take into account the expected Net Present Value (eNPV) of programs transitioning to late-stage clinical development. Payout rangeFinancial targets: When assessing performance, achievements for threshold, target and maximum payout are defined for each metric, and a payout curve is applied to determine the corresponding payout between 0-200% against target.Innovation: At the end of the cycle, the Compensation Committee determines the payout factor in the range of 0150% based on the performance assessment made by the Science &amp; Technology Committee. A payout between 150-200% of target is only delivered for truly exceptional performance.Relative TSR: Performance on TSR is assessed relative to a global healthcare peer group, as outlined below. A three-month averaging method is used for both the start and the end of the performance cycle. Companies are then ranked in order of highest to lowest TSR in USD. The Compensation Committee may use its discretion on each metric, including deciding on the payout within the ranges where appropriate. In doing so, it takes into consideration factors such as the underlying assumptions of the targets set at the beginning of the cycle, overall economic conditions, currency fluctuations and other unforeseeable situations.Payout formulaStep 1Annual base salaryxTarget incentive %=Grant valueStep 2Grant value/Share price=Target number of PSUsGlobal healthcare peer groupAbbvieBiogenGlaxoSmithKlineNovo NordiskRocheAmgen Bristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co Johnson &amp; JohnsonPfizerNovartis position Payout rangein the peer group(% of target)Position 1  2Position 3  5Position 6  8Position 9  15170%  200% 130%  160%80%  120%0%Target number of PSUsxPerformance factor+Dividend equivalents=Realized PSUs</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">102</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">LTPP performance outcomes </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The charts below illustrate the performance of the 2020-2022 LTPP against target. </div>
      <div style="padding-top:15px">
        <img src="comp_0031.gif" alt="WSGE_DP_Graph_LTPP_outcome"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Net sales CAGR (25% weighting)Vesting range 0200% of target8%6%4%2%0%Maximum (200%): 8.7% (CAGR)Actual: 3.8% (CAGR)Target: 5.7% (CAGR)Net sales growth payout43% of targetNotes: A minimum achievement of 3.7% CAGR was required to receive a payout under this performance measureNovartis achieved a net sales CAGR of 3.8% (in constant currencies  cc) against the 5.7% target set at the beginning of the performance cycle. The lower than target performance was mainly due to the negative and unexpected impact of COVID-19 in 2020 and 2021, the Beovu safety update, and the slower uptake of Zolgensma. Following the application of the payout curve, the net sales CAGR (cc) achievement generates a payout factor of 43% (maximum 200%) for this metric.Core operating income (COI) CAGR(25% weighting)Vesting range 0200% of target16%12%8%4%0%Maximum (200%): 16.6% (CAGR)Actual: 9.9% (CAGR)Target: 10.6% (CAGR)COI growth payout93% of targetNotes: A minimum achievement of 6.6% CAGR was required to receive a payout under this performance measureActual performance was adjusted for mergers and acquisitions as well as business development and licensing projects not included in the targetNovartis achieved a COI CAGR of 9.9% (cc) against the 10.6% target set at the beginning of the performance cycle. This was mainly due to lower than target Innovative Medicines sales over the three-year cycle, which was partly offset by lower spend in selling, general and administrative expenses (SG&amp;A). In 2022, the Company took organizational transformative measures, delivering savings reflected in COI improvement for the year.Following the application of the payout curve, the COI CAGR (cc) achievement generates a payout factor of 93% (maximum 200%) for this metric.Relative Total Shareholder Return (TSR) (25% weighting)Novartis position Payout rangein the peer group(% of target)Position 1  2Position 3  5Position 6  8Position 9  15170%  200% 130%  160%80%  120%0%Actual ranking 12th = 0% of targetTSR for the 2020-2022 cycle was 5.5%. As a result, Novartis ranked No. 12 out of 15 healthcare companies (including Novartis). Considering that the relative TSR rank is below median, there was a zero payout for this metric.Innovation (25% weighting)The following developments were considered in our 2020-2022 LTPP innovation performance:&#x2022;US and EU approvals for Pluvicto&#x2022;EU approval for Scemblix for adult patients with chronic myeloid leukemia&#x2022;US approval for Kymriah in the treatment of adult patients with relapsed or refractory follicular lymphoma&#x2022;Filing of Cosentyx for Hidradenitis suppurativa with both the US FDA and the European Medicines Agency(EMA)&#x2022;Submission of Cosentyx for an additional indication ahead of planned timelines&#x2022;Tislelizumab&#x2019;s acceptance by the EMA for regulatory review in esophageal and lung cancers&#x2022;CANOPY trials, Ligelizumab PEARL studies in chronic spontaneous urticaria (CSU), and Sabatolimab STIMULUS MDS-1 where important trial milestones were delayed/not submitted&#x2022;In NIBR, advancement of multiple development candidates including two novel radioligand therapiesBased on input from the Science &amp; Technology Committee, the Board of Directors approved an innovation performance factor of 92% of target.2020-2022 LTPP PayoutOverall, the Board of Directors approved a 2020-2022 LTPP payout at 57% of target, within the range of 0200%. No adjustments, pandemic-related or otherwise, were made in the evaluation of performance, despite the substantial shortfall in sales growth caused by Covid-19. This resulted in an LTPP payout of CHF 3 307 422 for the CEO, including dividend equivalents of CHF 317 316.Net sales CAGR43% x 25%+COI CAGR93% x 25%+Innovation92% x 25%+Relative TSR0% x 25%Final vesting57% of target</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">103</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation for joining and departing Executive Committee members in&#xA0;2022</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 Executive Committee member appointments </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, four new appointments were made to the Executive Committee, which comprise an internal promotion and three external appointments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Victor Bulto was promoted internally as President, Innovative Medicines US, and joined the Executive Committee on May 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In line with our compensation policy, externally appointed Executive Committee members were granted buyout awards to compensate for entitlements forfeited by them as a result of joining Novartis, as described in the table below (see &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;). Further details on the vesting of the awards below will be provided in relevant future compensation reports.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> &#xA0;</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Name</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Date of appointment</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Cash payments</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity awards</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value at grant</div>
            </td>
            <td></td>
            <td></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye, President, Global Drug  Development and  Chief Medical Officer</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> May 16, 2022      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No cash buyout      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;708 RSUs,   vesting over the period 2023-2026    </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 491 915      </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal, Chief Strategy &amp; Growth Officer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> July 18, 2022  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 818&#xA0;202  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&#xA0;253 RSUs,   vesting over the period 2022-2023</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4 353 702  </div>
            </td>
            <td align="right"></td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall, President, Novartis Institutes  for BioMedical Research</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> November 1, 2022    </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD    </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 522 000 to be paid   out in March 2023  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&#xA0;861 RSUs and 9&#xA0;649 PSUs,   vesting over the period 2023-2026  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 886 801    </div>
            </td>
            <td align="right"></td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 Executive Committee member departures</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In determining the compensation arrangements for departing Executive Committee members, the Compensation Committee ensures that contractual entitlements are respected, and all payments are in line with our plan rules and the Swiss Ordinance against Excessive Compensation in Listed Companies. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All Executive Committee members have a 12-month notice period during which they are entitled to their contractual base salary, pension, Annual Incentive and other benefits. No new LTPP grants are made during the notice period. In line with the new regulations arising from the reform of Swiss corporate law, any compensation payments toward non-competition agreements from 2023 onwards, will not exceed the average annual compensation of the previous three financial years.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Equity plan rules state that malus and clawback as well as non-compete restrictions will continue to apply. No severance payments are made to departing Executive Committee members. Further details on the policy treatment of variable compensation for departing Executive Committee members can be found in &#x201C;&#x2014;Treatment of variable compensation for Executive Committee leavers.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former President of Novartis Oncology, Susanne Schaffert, stepped down from her role following the Company&#x2019;s decision to integrate the Pharmaceuticals and Oncology business units and create separate US and International commercial organizations under the Innovative Medicines (IM) Division, and started her notice period on May 1, 2022. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former Head of Customer &amp; Technology Solutions (CTS), Robert Weltevreden, stepped down from his role following the Company&#x2019;s decision to combine Novartis Technical Operations (NTO) and CTS into a new Operations unit, and started his notice period on May 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former Head of Global Drug Development and Chief Medical Officer, John Tsai, stepped down from his role effective May 15, 2022, and started his notice period on the same day.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former President of the Novartis Institutes for BioMedical Research (NIBR), James Bradner, stepped down from his role effective October 31, 2022, and started his notice period on November 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All four executives departed under good leaver conditions. Outstanding LTI grants will vest at the end of the relevant performance cycles on a pro-rata basis, as per their contractual agreements and in line with the said plan rules.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">To avoid a conflict of interest, Richard Saynor, Chief Executive Officer of Sandoz, stepped down from the Executive Committee with effect from October 25, 2022, following his appointment as CEO designate of the Sandoz standalone company that is planned to be created in the second half of 2023. He will continue to report directly to the CEO and to lead the Sandoz division.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">104</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Realized compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To aid shareholders&#x2019; understanding of the link between pay and performance, the Compensation Committee discloses the realized compensation for the CEO individually, and for the other members of the Executive Committee on an aggregated basis. Disclosing realized compensation means that the Annual Incentive and the LTI are disclosed at the end of their respective performance cycles, reflecting actual payouts based on performance.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total actual payout may vary year on year depending on multiple factors, including the composition of the Executive Committee and the tenure of its members (as new members may not have a vested LTI), compensation increases, payout of variable compensation based on actual performance, share price fluctuations of the LTI, and dividend equivalents.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below shows fixed and other compensation for the year, including the Annual Incentive for the 2022 performance year, the realized LTI for the 2020-2022 performance cycle, and any buyouts vesting in 2022. The portion of the Annual Incentive paid in shares for the year 2022 is disclosed using the underlying value of Novartis shares at the date of grant, while the realized values of any other equity awards (including dividend equivalents) are calculated using the share price on the date of vesting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the appropriateness of the 2022 CEO and executive compensation payouts under the Annual Incentive and LTI plans, the Board of Directors and the Compensation Committee reviewed management&#x2019;s performance and contribution, taking the following into consideration:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Operational and financial performance against targets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress toward strengthening our global product portfolio</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Accomplishments across all strategic pillars, with careful attention given to ESG performance</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The incentive performance outcomes, combined with base salary and other benefits, pension, and dividend equivalents, resulted in 2022 total realized compensation for the CEO of <b>CHF&#xA0;8 452 176</b>.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 annual base  salary    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022  pension  benefits<sup>1</sup></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive      </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term  Incentives  LTPP 2020 - 2022  cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2022   compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Equity<sup>2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Equity (value <br /> at vesting date)<sup>3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount<sup>4,5</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br /> compensation <br /> (incl. share<br /> price movement)<sup>6</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;786&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;488</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;125</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;196</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;307&#xA0;422</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&#xA0;445</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;452&#xA0;176</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized compensation of the  other 15 Executive Committee members,  including the members who stepped down  during the financial year 2022<sup style="white-space: nowrap"> &#xA0;7,8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       9&#xA0;122&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       1&#xA0;978&#xA0;304</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       4&#xA0;211&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       5&#xA0;918&#xA0;318</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       10&#xA0;025&#xA0;047</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       9&#xA0;716&#xA0;294</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       40&#xA0;972&#xA0;595</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;909&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;152&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;553&#xA0;966</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;260&#xA0;514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;332&#xA0;469</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;215&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&#xA0;424&#xA0;771</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See 2021 realized compensation for the CEO and other Executive Committee members for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 4&#xA0;560 for the CEO and CHF 67&#xA0;148 for the other current Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3&#xA0;937&#xA0;537 paid in 2022 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the 97&#xA0;361 LTPP PSUs vesting on January 25, 2023, to the CEO and other Executive Committee members for the 2020-2022 performance cycle and dividend equivalents for the three-year cycle (for details, see ''&#x2014;LTPP performance outcomes''). The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP performance factor (i.e., January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR. Robert Kowalski was promoted to the Executive Committee during the course of the 2021 performance period and Victor Bulto during the course of the 2022 performance period, and as such, the information disclosed reflects their pro-rata LTPP 2020-2022 payout attributable to the period in which they were members of the Executive Committee. Shreeram Aradhye rejoined Novartis and Karen Hale, Aharon Gal and Fiona Marshall joined Novartis after the 2020 LTI awards were made and hence did not receive an LTPP award for the 2020-2022 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The 2022 tax payments were CHF &#xA0;221&#xA0;633 for Richard Saynor, as well as CHF &#xA0;533&#xA0;927 for Victor Bulto, CHF &#xA0;127&#xA0;980 for Robert Kowalski, CHF &#xA0;109&#xA0;966 for Aharon Gal, and CHF &#xA0;417&#xA0;826 for Vas Narasimhan.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes 696 vested RSUs and 2&#xA0;765 PSUs (for a total value of CHF 268&#xA0;158), which vested on March 13, 2022, to John Tsai in lieu of the LTI that he forfeited when leaving his previous employer. Also includes 2&#xA0;348 vested RSUs and 1&#xA0;586 vested PSUs (for a total value of CHF 313&#xA0;815), which vested on February 13, 2022, to Richard Saynor in lieu of the LTI that he forfeited when leaving his previous employer, and 3&#xA0;675 vested PSUs (CHF 287&#xA0;238) on January 18, 2022, to Klaus Moosmayer in lieu of the LTI he forfeited when leaving his previous employer as well as 15 448 RSUs (CHF 1&#xA0;292&#xA0;225), which vested on December 1, 2022, to Aharon Gal in lieu of the LTI that he forfeited when leaving his previous employer.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due from the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Includes compensation of the following members who stepped down from the ECN: Richard Saynor, Sandoz CEO designate, James Bradner, former President NIBR, Susanne Schaffert, former CEO Oncology, John Tsai, former Global Head of Drug Development and Chiel Medical Officer and Robert Weltevreden, former Head of Customer and Technology Solutions, including the vesting of their Long-Term Incentives for 2020-2022 performance cycle, as per the plan rules. The compensation and benefits elements related to the period after the step-down dates are reported under the 'other 2022 compensation' column. See &#x201C;&#x2014;2022 Executive Committee member departures" for details.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.9548, which is the same average exchange rate used in the Group's 2022 consolidated financial statements (a similar rule applies to payments made in other currencies during the year).</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">105</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide additional details on awards granted as part of the 2020-2022 LTPP performance cycle, including the number of shares awarded and delivered, following the application of the payout factor and the addition of dividend equivalent shares.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020-2022 LTPP performance cycle </span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs at grant</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="9" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares delivered at vesting</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> PSUs<br /> (target number)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> PSUs<br /> (target value<br /> at grant date)<br /> (CHF)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Payout factor <br /> for ECN LTPP <br /> (% of target)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Performance shares <br /> delivered at vesting<br /> (number)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Performance shares <br /> delivered at vesting<br /> (value at vesting date)<br /> (CHF)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Dividend <br /> equivalent shares <br /> delivered at vesting<br /> (number)<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Dividend <br /> equivalent shares <br /> delivered at vesting<br /> (value at vesting date)<br /> (CHF)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total shares<br /> delivered at vesting<br /> (value at <br /> vesting date)<br /> (CHF)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&#xA0;498</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;712&#xA0;549</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;054</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;990&#xA0;106</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;720</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 317&#xA0;316</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;307&#xA0;422</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other 15 Executive Committee members,  including the members who stepped  down during the financial year 2022<sup style="white-space: nowrap"> &#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     183&#xA0;733</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     17&#xA0;005&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     57%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     105&#xA0;530</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     9&#xA0;058&#xA0;150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     11&#xA0;156</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     966&#xA0;897</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     10&#xA0;025&#xA0;047</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245&#xA0;231</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&#xA0;718&#xA0;356</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 140&#xA0;584</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;048&#xA0;256</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;876</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;284&#xA0;213</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;332&#xA0;469</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Robert Kowalski and Victor Bulto joined the Executive Committee during the course of the 2020-2022 performance period. As such, the information disclosed reflects their pro-rata LTPP 2020-2022 attributable to the period in which they were members of the Executive Committee.  Karen Hale, Aharon Gal, Fiona Marshall and Shreeram Aradhye joined Novartis after the 2020-2022 LTPP awards were made and hence did not receive an LTPP award for this performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The shown amounts represent the underlying share value of the target number of PSUs granted to each Executive Committee member for the  2020-2022 performance period, based on the closing share price on the grant date (January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The shown amounts represent the underlying share value of the number of PSUs vested for the 2020-2022 performance period, based on the closing share price on the day the Novartis Board of Directors approved the final LTPP performance payout factor (i.e., January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Dividend equivalent shares are calculated on the dividend each member of the Executive Committee would have received, based on the actual number of shares delivered at the end of the 2020-2022 performance period. At vesting, the dividend equivalents are credited in shares or ADRs.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes the LTPP vesting for Richard Saynor, Sandoz CEO Designate, James Bradner, former President NIBR, Susanne Schaffert, former CEO Oncology, John Tsai, former Global Head of Drug Development and Chiel Medical Officer and Robert Weltevreden, former Head of Customer and Technology Solutions for the 2020-2022 performance cycle, as per the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">106</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide details on the 2021 realized compensation for the CEO and other Executive Committee members, for comparative purposes. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 annual base  salary</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021  pension  benefits<sup>1</sup></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive  </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentives  </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2021   compensation</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2019-2021   cycle</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Equity<sup>2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Equity (value <br /> at vesting date)<sup>3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount<sup>2,4,5</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br /> compensation <br /> (incl. share<br /> price movement)<sup>6</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;769&#xA0;200</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176&#xA0;731</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;642</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;356&#xA0;128</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265&#xA0;401</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&#xA0;224&#xA0;727</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized compensation of the  other 14 Executive Committee members,  including the members who stepped down  during the financial year 2021<sup style="white-space: nowrap"> &#xA0;7,8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       8&#xA0;983&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       2&#xA0;065&#xA0;561</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       4&#xA0;174&#xA0;006</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       5&#xA0;400&#xA0;015</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       18&#xA0;770&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       6&#xA0;021&#xA0;712</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       45&#xA0;415&#xA0;164</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;753&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;502&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;126&#xA0;157</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;287&#xA0;113</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;639&#xA0;891</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 5&#xA0;498 for the CEO and CHF 53&#xA0;693 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 4&#xA0;966&#xA0;397 paid in 2021 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the 296 741 LTPP PSUs vested on January 22, 2022, to the CEO and other Executive Committee members for the 2019-2021 performance cycle, inclusive of earned Alcon Keep Whole awards and dividend equivalents for the three-year cycle (for details, see ''&#x2014;LTPP performance outcomes''). The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP performance factor (i.e., January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR. Marie-France Tschudin and Robert Kowalski were promoted to the Executive Committee during the course of the 2019-2021 performance period, and as such, the information disclosed reflects their pro-rata LTPP 2019-2021 payout attributable to the period in which they were members of the Executive Committee. Richard Saynor and Karen Hale joined Novartis after the 2019 LTI awards were made and hence did not receive an LTPP award for the 2019-2021 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The 2021 tax payments were CHF  127&#xA0;009 for Mr. Saynor, as well as CHF  822&#xA0;808 for Susanne Schaffert, and CHF  156&#xA0;788 for Vas Narasimhan.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes 6&#xA0;128 vested RSUs and 3&#xA0;546 PSUs (for a total value of CHF 782&#xA0;649), which vested partially on March 13, 2021, and partially on July 28, 2021, to John Tsai in lieu of the LTI that he forfeited when leaving his previous employer. Also includes 2&#xA0;584 vested RSUs and 2&#xA0;043 vested PSUs (for a total value of CHF 379&#xA0;414), which vested on February 14, 2021, to Mr. Saynor in lieu of the LTI that he forfeited when leaving his previous employer, and 4&#xA0;313 vested PSUs (CHF 370&#xA0;961) on January 18, 2021, to Klaus Moosmayer in lieu of the LTI he forfeited when leaving his previous employer.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due from the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Includes the first six weeks of Karen Hale's compensation, before her appointment to the Executive Committee, under other compensation. Comprises the compensation of Bertrand Bodson, former Chief Data Officer and Steven Baert, former Chief People &amp; Organization Officer, including the vesting of their Long-Term Incentives for 2019-2021 performance cycle, as per the plan rules. The compensation and benefits elements related to the period after the step-down dates are reported under the other compensation column. Unvested shares for Shannon Klinger were forfeited upon her departure from the Company. See &#x201C;&#x2014;2021 Executive Committee member departures" for details.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.9139, which is the same average exchange rate used in the Group's 2021 consolidated financial statements (a similar rule applies to payments made in other currencies during the year).</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Realized compensation for the CEO and other Executive Committee members for 2022 compared with&#xA0;2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2022 total realized compensation for the CEO was CHF 8&#xA0;452&#xA0;176. This is a reduction of 24.7% compared with the prior year, mainly due to the lower performance payout of the 2020-2022 LTPP (57% compared with the 107% payout for the 2019-2021 LTPP). At the end of the 2020-2022 LTPP performance cycle, the rTSR ranking for Novartis, which is weighted 25% of the overall LTPP opportunity, was below median, which resulted in zero payout for this measure. Payout for Net Sales CAGR performance, also weighted 25%, was significantly lower (43% compared with 119% in 2019-2021), mainly driven by the impact of Covid-19 on Sales growth during 2020 and 2021.  Furthermore, the Alcon &#x201C;keep-whole&#x201D; awards, granted at the time of Alcon spin-off in 2019, ended with the 2019-2021 LTPP payout. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The 2022 total realized compensation for the Executive Committee members, including the CEO, was CHF&#xA0;49&#xA0;424&#xA0;771. This decrease of 12.7% compared with the prior year can be attributed to the same reasons mentioned above. For more detail, please refer to &#x201C;&#x2014;LTPP performance outcomes&#x201D;.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">107</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation at grant value</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In accordance with the Swiss Ordinance against Excessive Compensation in Listed Companies, Novartis continues to disclose total compensation at grant value for the CEO and other Executive Committee members. The tables below disclose the following information for the CEO and other Executive Committee members:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fixed 2022 compensation (base salary and benefits)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Actual cash portion and the deferred portion granted in equity of the 2022 Annual Incentive</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   2022-2024 LTPP performance cycle awards, which are reported at target grant date value, based on the assumption that the awards will vest at 100% achievement, excluding any share price movement and dividend equivalents that may be accrued over the performance cycle. The future payout will be determined only after the performance cycle concludes in three years (i.e., at the end of 2024), with a payout range of 0% to 200% of the target value</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Other compensation for 2022, which includes other benefits, either paid in cash or granted in equity during the year</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The compensation paid, promised or granted to the members of the Executive Committee during financial year 2022 was within the amount approved by shareholders at the 2021 AGM.</div>
      <div style="border:solid #eeeeee 3px; background-color:#eeeeee;padding-bottom:0px;">
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To assess CEO actual pay for performance in 2022, including the Annual Incentive payout for the 2022 performance year and the LTI payouts for the 2020-2022 performance cycle, shareholders should refer to the 2022 realized  compensation table in &#x201C;&#x2014;2022 realized compensation for the CEO and other Executive Committee members.&#x201D;</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 compensation at grant value for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2022    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive   2022-2024 cycle  grants at target</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 annual base  salary    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 pension  benefits    </div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive   (performance achieved)    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2022-2024 cycle      </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2022  compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br /> (value at<br /> grant date)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br /> (target value<br /> at grant date)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">5</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;786&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;488</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;125</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;196</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;815&#xA0;886</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&#xA0;445</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;960&#xA0;639</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 538&#xA0;656</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&#xA0;959</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&#xA0;998</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;629&#xA0;233</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 581&#xA0;328</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;401&#xA0;215</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)<sup style="white-space: nowrap">&#xA0;7, 8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 622&#xA0;596</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;434</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310&#xA0;445</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310&#xA0;449</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 782&#xA0;443</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;948&#xA0;867</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)<sup style="white-space: nowrap">&#xA0;9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 363&#xA0;441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78&#xA0;083</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;043</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;576&#xA0;719</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;318&#xA0;285</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 845&#xA0;834</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 215&#xA0;842</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 935&#xA0;059</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;700&#xA0;058</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 146&#xA0;154</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;842&#xA0;946</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;082&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 177&#xA0;526</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 655&#xA0;820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 655&#xA0;872</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;818&#xA0;450</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;456</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;426&#xA0;373</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 705&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207&#xA0;628</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 349&#xA0;965</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 349&#xA0;986</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;272&#xA0;601</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 307&#xA0;969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;193&#xA0;982</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 840&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;675</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165&#xA0;136</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 935&#xA0;826</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;722&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;431</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;858&#xA0;923</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)<sup style="white-space: nowrap">&#xA0;8, 9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&#xA0;154</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;222</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;085</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;961&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;365&#xA0;688</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181&#xA0;112</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313&#xA0;740</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313&#xA0;819</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;045&#xA0;859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;026</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;466&#xA0;555</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 951&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164&#xA0;480</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527&#xA0;209</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527&#xA0;239</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;220&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;804</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;399&#xA0;040</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;466&#xA0;817</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;552&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;167&#xA0;896</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;874&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&#xA0;058&#xA0;209</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;732&#xA0;583</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&#xA0;852&#xA0;130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)<sup style="white-space: nowrap">&#xA0;8, 10</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;006&#xA0;294</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 605&#xA0;668</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 605&#xA0;771</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;030&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 651&#xA0;499</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;180&#xA0;024</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)<sup style="white-space: nowrap">&#xA0;11</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 641&#xA0;721</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;920</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 383&#xA0;977</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;493&#xA0;403</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706&#xA0;394</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;760&#xA0;436</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;12</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 292&#xA0;466</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59&#xA0;180</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;112</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;217</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;138&#xA0;458</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;306&#xA0;257</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;118&#xA0;690</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)<sup style="white-space: nowrap">&#xA0;13</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 321&#xA0;967</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67&#xA0;322</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;031</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;132</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;192&#xA0;544</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;396&#xA0;407</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;300&#xA0;403</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;14</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;479</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54&#xA0;721</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;638</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;678</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;374&#xA0;053</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;029&#xA0;246</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;886&#xA0;815</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;442&#xA0;475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 600&#xA0;225</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;386&#xA0;070</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;386&#xA0;456</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;091&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;060&#xA0;376</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&#xA0;967&#xA0;229</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;909&#xA0;292</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;152&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;553&#xA0;966</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;260&#xA0;514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;149&#xA0;836</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;792&#xA0;959</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;819&#xA0;358</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="left" colspan="3">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;background-color:#eeeeee;">&#xA0;Based on assumption of &#xA0;100% payout at target. &#xA0;Actual payout (0-200% of &#xA0;target) will be known at  &#xA0;the end of the three-year &#xA0;cycle in January 2025</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 4&#xA0;560 for the CEO and CHF 67&#xA0;148 for the other current Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3&#xA0;937&#xA0;537 paid in 2022 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the 2022-2024 performance cycle, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR for all members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The compensation and benefits elements related to the period after the step-down dates are also reported under &#x2018;other 2022 compensation&#x2019;.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Shreeram Aradhye received a pro-rata LTPP award of 18 905 PSUs on June 1, 2022 (at CHF 86.18 closing share price on grant date) upon joining the organization, as per contractual entitlement.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Victor Bulto received his 2022 LTPP grant before his appointment to Executive Committee, therefore the reported LTPP amount is pro-rated to reflect his time as Executive Committee member over the full performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts in USD for Victor Bulto, Fiona Marshall and James Bradner were converted at a rate of CHF 1.00 = USD 1.0473, which is the average rate used in the Group&#x2019;s 2022 consolidated financial statements.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;9&#xA0;</sup> Aharon Gal and Fiona Marshall did not receive a pro-rata LTPP award upon joining the organization, as they received buyout grants for their forfeited awards upon joining.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>10&#xA0;</sup> James Bradner stepped down from the Executive Committee on October 31, 2022 and will end his notice period on October 31, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>11&#xA0;</sup> Richard Saynor left the Executive Committee on October 25, 2022. The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle, subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>12&#xA0;</sup> Susanne Schaffert stepped down from the Executive Committee on April 4, 2022 and will end her notice period on April 30, 2023, in line with her contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>13&#xA0;</sup> John Tsai stepped down from the Executive Committee on May 15, 2022 and will end his notice period on May 15, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>14&#xA0;</sup> Robert Weltevreden stepped down from the Executive Committee on April 4, 2022 and will end his notice period on April 30, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">108</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021 compensation at grant value for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For comparative purposes, the table below provides the compensation at grant value for 2021. </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="margin-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight:bold; color:#000000;">Executive Committee member compensation at grant for financial year 2021</div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2021    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive  2021-2023 cycle  grants at target</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 annual base  salary    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 pension  benefits    </div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive   (performance achieved)    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP   2021-2023 cycle    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2021  compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br /> (value at<br /> grant date)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br /> (target value<br /> at grant date)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">5</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;769&#xA0;200</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176&#xA0;731</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;642</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;757&#xA0;423</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265&#xA0;401</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;626&#xA0;023</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;184&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 367&#xA0;246</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 712&#xA0;802</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 712&#xA0;839</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;970&#xA0;016</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 92&#xA0;286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;039&#xA0;652</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale (from May 15, 2021)<sup style="white-space: nowrap">&#xA0;7</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 519&#xA0;750</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85&#xA0;987</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261&#xA0;062</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261&#xA0;133</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;442&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;112&#xA0;992</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;072&#xA0;084</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177&#xA0;174</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354&#xA0;255</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;062&#xA0;820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;791&#xA0;111</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43&#xA0;617</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;501&#xA0;060</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski (from September 1, 2021)<sup style="white-space: nowrap">&#xA0;8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49&#xA0;692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 105&#xA0;288</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 105&#xA0;360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 448&#xA0;824</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;428</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;122&#xA0;925</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 780&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508&#xA0;680</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 763&#xA0;076</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;570&#xA0;027</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&#xA0;430</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;817&#xA0;459</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 566&#xA0;667</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 198&#xA0;992</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253&#xA0;004</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;035&#xA0;044</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49&#xA0;850</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;356&#xA0;557</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 785&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 190&#xA0;263</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;493&#xA0;478</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 416&#xA0;693</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;278&#xA0;506</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 794&#xA0;262</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;118&#xA0;082</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 856&#xA0;650</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;919&#xA0;415</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 875&#xA0;834</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186&#xA0;807</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306&#xA0;950</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 307&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;192&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201&#xA0;307</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;070&#xA0;477</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164&#xA0;980</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 706&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 706&#xA0;019</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;029&#xA0;750</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;488&#xA0;083</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 673&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 171&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 299&#xA0;200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 299&#xA0;275</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;292&#xA0;042</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;735&#xA0;202</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;121&#xA0;211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;098&#xA0;866</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;059&#xA0;259</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;885&#xA0;096</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;655&#xA0;408</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;548&#xA0;498</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert (until June 30, 2021)<sup style="white-space: nowrap">&#xA0;9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 400&#xA0;277</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87&#xA0;753</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399&#xA0;887</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 422&#xA0;223</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;831&#xA0;302</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;141&#xA0;442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson (until January 31, 2021)<sup style="white-space: nowrap">&#xA0;10</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;240</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43&#xA0;485</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;339&#xA0;471</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;452&#xA0;647</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger (until March 15, 2021)<sup style="white-space: nowrap">&#xA0;11</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177&#xA0;102</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40&#xA0;434</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 279&#xA0;791</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;018&#xA0;161</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;515&#xA0;487</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 631&#xA0;830</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 143&#xA0;427</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443&#xA0;372</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 702&#xA0;014</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;188&#xA0;934</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&#xA0;109&#xA0;576</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;753&#xA0;041</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;502&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;587&#xA0;110</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&#xA0;844&#xA0;343</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&#xA0;658&#xA0;074</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="left" colspan="3">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;background-color:#eeeeee;">&#xA0;Based on assumption of &#xA0;100% payout at target. &#xA0;Actual payout (0-200% of &#xA0;target) will be known at  &#xA0;the end of the three-year &#xA0;cycle in January 2024</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 5&#xA0;498 for the CEO and CHF 53&#xA0;693 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 4&#xA0;966 397 paid in 2021 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the 2021-2023 performance cycle, based on the closing share price on the grant date (January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR for all members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The compensation and benefits elements related to the period after the step-down dates are also reported under &#x2018;other 2021 compensation&#x2019;.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Amounts in USD for James Bradner were converted at a rate of CHF 1.00 = USD 1.0942, which is the average rate used in the Group&#x2019;s 2021 consolidated financial statements.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Karen Hale received a pro-rata LTPP award of 18&#xA0;639 PSUs on Apr-2, 2021 (at CHF 81.15 share price at grant) upon joining the organization, as per contractual entitlement. The other compensation amount includes the first six weeks of compensation before her appointment to the Executive Committee.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Robert Kowalski received his 2021 LTPP grant before his appointment to Executive Committee, therefore the reported LTPP amount is pro-rated to reflect his time as Executive Committee member over the full performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;9&#xA0;</sup> Steven Baert left the Executive Committee on June 30, 2021 and ended his notice period on September 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). He received his 2021 Annual Incentive 100% in cash on a pro-rata basis, and the LTPP grant for the 2021-2023 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>10&#xA0;</sup> Bertrand Bodson left the Executive Committee on January 31, 2021 and ended his notice period on November 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). He received his 2021 Annual Incentive 100% in cash on a pro-rata basis, and no LTPP was granted for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>11&#xA0;</sup> Shannon Klinger resigned as Chief Legal Officer as of March 15, 2021, and left the Company on May 31, 2021, in line with her reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The 2021 Annual Incentive and LTPP 2021-2023 cycle grant (23 586 PSUs), displayed at pro-rata value for the time she was in her role in 2021, were forfeited in full upon her departure.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation at grant value for the CEO and other Executive Committee members for 2022 compared with 2021</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Compensation at grant delivered in 2022 to the CEO and the other Executive Committee members, including those who stepped down, was CHF 70&#xA0;819&#xA0;358, which was an increase of 20.7% compared with the prior year. This increase was driven mainly by the change in composition of the Executive Committee during 2022. Compensation at grant for the active Executive Committee members on December 31, 2022 (11 active members versus 12 in prior year) was CHF 49&#xA0;852&#xA0;130, which is a reduction of 3.3% from December 31, 2021.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">109</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This section provides additional disclosures, including information about the shareholdings of the CEO and the other Executive Committee members.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Malus and clawback</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Consistent with our &#x201C;&#x2014;Executive Committee compensation philosophy and principles,&#x201D; in 2022 there was no legal or factual basis on which to exercise malus or clawback for current or former Executive Committee members. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for the financial year 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive  (performance achieved)</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2022-2024 cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> (number)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br /> (target number)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br /> (number)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;735</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74&#xA0;410</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;177</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;905</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;708</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;345</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;671</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;759</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&#xA0;253</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;962</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;751</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;060</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;103</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&#xA0;032</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;090</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&#xA0;510</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;679</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;181</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;404</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 68&#xA0;691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 241&#xA0;896</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&#xA0;471</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;527</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;502</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&#xA0;107</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;890</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)<sup style="white-space: nowrap">&#xA0;7</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;889</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;052</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;192</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;580</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 128&#xA0;068</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 84&#xA0;691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 369&#xA0;964</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&#xA0;471</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The values of the awards are reported in the table "2022 compensation at grant value for the CEO and other Executive Committee members."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for the 2022 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Target number of PSUs granted under the LTPP as applicable for the 2022-2024 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> James Bradner stepped down from the Executive Committee on October 31, 2022 and will end his notice period on October 31, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Richard Saynor left the Executive Committee on October 25, 2022. The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle, subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Susanne Schaffert stepped down from the Executive Committee on April 4, 2022 and will end her notice period on April 30, 2023, in line with her contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> John Tsai stepped down from the Executive Committee on May 15, 2022 and will end his notice period on May 15, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Robert Weltevreden stepped down from the Executive Committee on April 4, 2022 and will end his notice period on April 30, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">110</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for the financial year 2021 (comparative information)</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive  (performance achieved)</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2021-2023 cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> (number)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br /> (target number)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br /> (number)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;999</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66&#xA0;939</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30&#xA0;644</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale (from May 15, 2021)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;823</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&#xA0;598</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski (from September 1, 2021)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;348</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;067</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;254</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;034</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;515</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;364</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;162</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;928</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25&#xA0;492</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;033</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&#xA0;599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;829</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;022</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 289&#xA0;315</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert (until June 30, 2021)<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;909</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson (until January 31, 2021)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger (until March 15, 2021)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;162</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 297&#xA0;477</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The values of the awards are reported in the table "2021 compensation at grant value for the CEO and other Executive Committee members."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for the 2021 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Target number of PSUs granted under the LTPP as applicable for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Steven Baert left the Executive Committee on June 30, 2021 and ended his notice period on September 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The LTPP grant for the 2021-2023 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Bertrand Bodson left the Executive Committee on January 31, 2021 and ended his notice period on November 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). No LTPP was granted for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Shannon Klinger resigned as Chief Legal Officer as of March 15, 2021, and left the Company on May 31, 2021, in line with her reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The LTPP 2021-2023 cycle grant (23 586 PSUs), displayed at pro-rata value for the time she was in her role in 2021, was forfeited in full upon her departure.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">111</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for the CEO and other Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive Committee members are required to own at least a minimum multiple of their annual base salary in Novartis shares or RSUs within five years of hire or promotion, as set out in the table here. In addition, the CEO and CFO are required to hold the equity vesting under the LTPP plan (granted since 2022) for a minimum of two years after the vesting date. In the event of a substantial rise or drop in the share price, the Board of Directors may, at its discretion, amend that time period accordingly.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> &#xA0;</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Function</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Ownership level</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CEO</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 x base compensation</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other Executive Committee members</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 x base compensation</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The determination of equity amounts against the share ownership requirements is defined to include vested and unvested Novartis shares or American Depositary Receipts (ADRs), together with RSUs acquired under the Company&#x2019;s compensation plans. Unvested PSUs are, however, excluded. The determination also includes other shares and vested options of Novartis shares or ADRs that are owned directly or indirectly by &#x201C;persons closely linked&#x201D; to an Executive Committee member. The Compensation Committee reviews compliance with the share ownership guideline on an annual basis.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and other equity rights owned by Executive Committee members as at December 31, 2022<sup>1</sup></span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows, in alphabetical order after the CEO, the total number of shares, ADRs and other equity rights owned by the CEO and the other Executive Committee members and &#x201C;persons closely linked&#x201D; to them as at December 31, 2022. As at December 31, 2022, no members of the Executive Committee, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares or ADRs of Novartis. As at December 31, 2022, all members who have served at least five years on the Executive Committee have met or exceeded their personal Novartis share ownership requirements.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Vested shares <br /> and ADRs<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Unvested shares <br /> and other equity rights<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity ownership level <br /> as a multiple of <br /> annual base salary<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Unvested target PSUs <br /> (e.g., LTPP)<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total as at<br /> December 31, <br /> 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 228&#xA0;614</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69&#xA0;687</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13x</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 108&#xA0;201</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 406&#xA0;502</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;885</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;268</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;394</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;386</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;948</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;458</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&#xA0;110</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;568</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312&#xA0;682</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;816</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52&#xA0;450</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399&#xA0;948</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;398</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;097</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;495</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;383</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;797</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;237</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;951</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;980</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;713</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;524</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;184</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47&#xA0;421</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52&#xA0;818</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;447</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46&#xA0;699</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127&#xA0;964</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 748&#xA0;073</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 307&#xA0;853</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 309&#xA0;929</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;365&#xA0;855</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;231</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70&#xA0;171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&#xA0;402</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;843</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48&#xA0;117</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 142&#xA0;844</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44&#xA0;981</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 214&#xA0;070</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;550</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;812</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;826</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85&#xA0;188</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;755</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;436</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;317</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70&#xA0;508</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185&#xA0;149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 113&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 240&#xA0;412</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 539&#xA0;128</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 933&#xA0;222</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 421&#xA0;420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 550&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;904&#xA0;983</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes holdings of "persons closely linked" to Executive Committee members (see the &#x2018;persons closely linked&#x2019; definition).</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes unvested shares and ADRs as well as other equity rights applicable for the determination of equity amounts for the share ownership requirements, as per the definition above.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The multiple is calculated based on the full-year annual base salary and the closing share price as at the end of the 2022 financial year. The share price on the final trading day of 2022 was CHF 83.59 / USD 90.72 as at December 31, 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> The target number of PSUs is disclosed pro-rata to December 31, 2022, unless the award qualified for full vesting under the relevant plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">112</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Fixed and variable compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the annual base salary and variable compensation mix at grant value for the financial year 2022 for the CEO and other Executive Committee members.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Annual <br /> base salary<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable<br /> compensation<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16.6%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.4%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.6%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.3%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.4%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76.4%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.3%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.6%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 82.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excludes pension and other benefits and is pro-rated for ECN time.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> See the table &#x201C;2022 compensation at grant value for the CEO and other Executive Committee members&#x201D; with regard to the disclosure principles of variable compensation.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Excludes members, who stepped down during the year.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Executive Committee members </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no other payments or waivers of claims other than those set out in the tables (including the footnotes) contained in this Compensation Report were made to Executive Committee members or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the former Executive Committee members&#x2019;  contracts and in line with the Company&#x2019;s LTI plan rules, payments were made to 8 former members. Of this, CHF&#xA0;993 574 relates to the vesting of LTI awards. In addition, contractual amounts totaling CHF&#xA0;167 106 were made (comprising the base salary, the Annual Incentive and other benefits), and tax equalization on variable compensation granted during international assignments amounted to a total of CHF&#xA0;296 627.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No other payments (or waivers of claims) were made to former Executive Committee members or to &#x201C;persons closely linked&#x201D; to them during 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Persons closely linked</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Persons closely linked&#x201D; are (i) their spouse, (ii) their children (under 18 years of age), (iii) any legal entities that they own or otherwise control, and (iv) any legal or natural person who is acting as their fiduciary.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Note 27 to the Group&#x2019;s audited consolidated financial statements</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total expense for the year for compensation awarded to Executive Committee and Board members, using International Financial Reporting Standards (IFRS) measurement rules, is presented in Note 27 to the Group&#x2019;s audited consolidated financial statements.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Award and delivery of equity to Novartis employees </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 12.7 million unvested restricted shares (or ADRs), RSUs and target PSUs were granted, and 10.4 million Novartis vested shares (or ADRs) were delivered to Novartis employees under various equity-based participation plans. Current unvested equity instruments (restricted shares, RSUs and target PSUs) and outstanding equity options held by employees represent 1.05% of issued shares. Novartis delivers treasury shares to employees to fulfill these obligations and aims to offset the dilutive impact from its equity-based participation plans.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">113</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Interim update regarding ongoing LTI performance cycles </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Below we report how performance is tracking against our stretch targets for our ongoing LTI performance cycles. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021-2023 LTPP </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">After the first two years of the three-year LTPP performance cycle, both net sales CAGR and core operating income CAGR are tracking behind target, driven mainly by the impact of the safety update on Beovu. Innovation is on track. At the end of 2022, the relative TSR for Novartis was below median among our global healthcare peer group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales CAGR (25%)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022-2024 LTPP </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">After the first year of the three-year LTPP performance cycle, net sales CAGR is on target and core operating income CAGR is ahead of target, while innovation performance is on target. At the end of 2022, the relative TSR for Novartis was below the median among our global healthcare peer group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales CAGR (25%)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <span style="vertical-align: middle;">
          <img src="sign-full.jpg" alt="sign"></img>
        </span> On or ahead of target    <span style="vertical-align: middle;"><img src="sign-half.jpg" alt="sign"></img></span> Slightly behind or behind target    </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">114</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00919655"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2023 Executive Committee compensation</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Executive Committee compensation changes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee believes that the compensation system supports the company&#x2019;s strategy and ensures a strong link between pay and performance. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a positive vote of 90.6% in favor of our 2021 Compensation Report at the 2022 AGM, the Board and Compensation Committee decided to make evolutionary changes to the compensation system. The aim of these changes is to simplify and increase the transparency of our performance assessment measures, in addition to strengthening our focus on key strategic priorities, while also considering developments in compensation best practices.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There are also changes as a result of the Swiss Corporate Law reform, which came into effect on January 1, 2023. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assuming that the Sandoz spin-off will occur in 2023, some impact is expected on 2023 Executive Compensation. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Annual Incentive </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following a review, the Compensation Committee decided to adapt the financial performance in the Annual Incentive Plan effective as of performance year 2023 as below: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Remove &#x201C;Share of Peers&#x201D; from the financial performance measures in the Annual Incentive plan. As a result, the Annual Incentive financial performance measures are Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow<sup>1</sup> (30%), thereby retaining a strong link to our key priorities</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group financial measures will be weighted at 60% for all Executive Committee members. Financial targets that relate to a division or business unit, where applicable, will be part of the individual strategic objectives (40% weight)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Swiss Corporate Law reform  </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the reform of Swiss corporate law, which came into effect on January 1, 2023, the following changes will be made to compensation design and disclosure in the 2023 Compensation Report:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Contracts of Executive Committee members will be adapted so that any non-compete compensation will not exceed the average annual compensation of the previous three financial years</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In previous years, the Swiss regulations permitted companies to award compensation of up to 40% above the shareholder approved budget for newly appointed members of the Executive Committee, whether that be through internal promotions or external hires. From 2023, this additional budget of 40% will only be made available for external appointments of Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">These changes will require adjustments to the Articles of Incorporation of Novartis, which will be submitted to Novartis shareholders for their approval at the 2023 AGM. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz spin-off</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In August 2022, we announced our intention to separate Sandoz, our generics and biosimilars division, into a new publicly traded standalone company, by way of a 100% spin-off, subject to approval of the Novartis AG Board of Directors and shareholders. In view of the planned spin-off, the Compensation Committee made the following decisions.</div>
      <div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Sandoz CEO 2023 Annual Incentive</div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Based on the assumption that the spin-off will be implemented in the second half of 2023, the 2023 Balanced Scorecard for Richard Saynor, CEO designate of Sandoz, will be adapted so that his 2023 Annual Incentive will be based exclusively on the financial and strategic performance of Sandoz. </div>
      <div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Equity Restoration principles</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">If and when the planned spin-off occurs, holders of vested and unvested awards in the form of Novartis shares or ADRs will receive a dividend in kind resulting from the spin-off in the same way as other Novartis shareholders. Holders of unvested RSUs and PSUs will not receive the dividend in kind resulting from the spin-off. To compensate for the expected reduction in shareholder value after the issue of dividend in kind, Novartis will grant equity awards (called &#x201C;Keep Whole awards&#x201D;) to its employees, including the Executive Committee members, following the spin-off. This will be undertaken in accordance with the Sandoz equity restoration plan, as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Keep Whole awards will have a value similar to the value of the dividend in kind resulting from the spin-off that each RSU or PSU would have received had it been a Novartis share or ADR</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The aim of the Keep Whole awards is to ensure that Novartis employees who have been granted RSUs or PSUs, including Executive Committee members, are not disadvantaged by the spin-off relative to Novartis shareholders</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">More details will be shared at the time of the spin-off.</div>
      <div style="padding-top:15px; padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  For the purposes of the 2023 annual incentives, free cash flow is defined as net cash flows from operating activities less purchases of property, plant and equipment.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">115</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Executive Committee member compensation increases</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Each year, we collaborate with our external advisors to benchmark the compensation levels of the members of the Executive Committee and assess the competitiveness of their total target compensation. 2023 salary increases have been made in line with their demonstrated performance and ability in their respective roles, and commensurate to changes in responsibilities, if any, as outlined in our &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In general, Executive Committee members (including the CEO) will receive compensation changes applicable to associates in Switzerland or where applicable, the US. The members who will receive an additional increase based on the principles outlined above are mentioned below. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Karen Hale, Chief Legal Officer </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ms. Hale, who has joined the Executive Committee in May 2021, delivered many highlights in 2022, including effectively managing ongoing cases with the SEC/DOJ, creating a new, focused and efficient global legal function, preparing for the Sandoz spin-off effectively, and continuing to improve the governance of the company. Effective March 1, 2023, Ms. Hale will receive a 6% increase in annual base salary increase and a 10% increase LTI target, as a percentage of annual base salary. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Chief Ethics, Risk &amp; Compliance Officer </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the implementation of the new organization structure in 2022, Mr. Moosmayer took over additional management responsibilities in the areas of HSE governance, Data Privacy, and Digital &amp; Artificial Intelligence Compliance. He demonstrated strong leadership across all responsibilities of compliance, risk, ethics, and managing emerging issues including the company&#x2019;s continuing response to the global pandemic, the lockdown in China and crisis management related to the war in Ukraine. Effective March 1, 2023, Mr. Moosmayer will receive a 12% increase in annual base salary increase and a 10% increase LTI target, as a percentage of annual base salary, to recognize these additional responsibilities. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marie-France Tschudin, President, Innovative Medicines International &amp; Chief Commercial Officer </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following her appointment in April 2022 as the President, Innovative Medicines International &amp; Chief Commercial Officer, Ms. Tschudin effectively executed the creation of our new Innovative Medicines International organization and Chief Commercial Office. During the year, she designed the new organization structure, implementing a large restructuring program and creating new therapeutic areas with clear portfolio focus, while delivering strong commercial performance in Region International and ensuring growth above target for many key brands. Effective March 1, 2022, Ms. Tschudin will receive a 5% increase in annual base salary, and a 10% increase in both her Annual Incentive target and LTI target, as a percentage of annual base salary, to recognize her increased responsibilities as the Chief Commercial Officer. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Following an assessment of their compensation competitiveness and performance, recently appointed Executive Committee members Victor Bulto, Aharon (Ronny) Gal, and Robert Kowalski will receive a 10-20% increase in their Annual Incentive target and/or LTI target, in line with the &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;. Steffen Lang will also receive a 10% increase in LTI target as a result of his enhanced responsibilities in Operations.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">116</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00919754"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2022 Board compensation</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Philosophy and benchmarking</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Aligned with market practice in Switzerland, the Board of Directors sets compensation for its members at a level that allows for the attraction of high-caliber individuals, including both Swiss and international members, who have global experience.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Given their focus on corporate strategy, supervision and governance, Board members do not receive variable compensation. Each year at the AGM, shareholders are requested to approve, in a binding vote, the total compensation of the Board of Directors until the following AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board of Directors sets the level of compensation for its Chair and the other members to be in line with relevant benchmark companies, including other large Switzerland-based multinational companies such as ABB, Credit Suisse, Holcim, Nestl&#xE9;, Roche and UBS. This peer group was chosen for Board compensation due to the comparability of Swiss legal requirements, including broad personal and individual liabilities under Swiss law (and criminal liability under Swiss rules regarding board and executive committee compensation related to the Ordinance against Excessive Compensation in Listed Companies), and under US law (due to the Company&#x2019;s secondary listing on the New York Stock Exchange). The Board of Directors reviews the compensation of its members, including the Board Chair, each year based on a proposal by the Compensation Committee and advice from its independent advisor, including relevant benchmarking information. To ensure independence of decision-making, the peer group used for the Board of Directors is different to that used for the Executive Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board Chair&#x2019;s contract and the Board of Directors compensation policy do not provide for any termination-related payments.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As Board Chair, Joerg Reinhardt receives total annual compensation valued at CHF 3.8 million. The total compensation is comprised equally of cash and shares, as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Cash compensation: CHF 1.9 million per year</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Share compensation: annual value equal to CHF 1.9 million of unrestricted Novartis shares</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For 2022, the Board Chair voluntarily waived the increase in compensation to which he is contractually entitled. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other Board&#xA0;members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The annual fee rates for Board membership and additional functions are included in the table below. These were approved by the Board of Directors with effect from the 2022 AGM. Aggregate Board compensation is aligned with other large Swiss companies.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022-2023 AGM <br /> annual fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;800</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br />&#x2022; Governance, Nomination and <br /> Corporate Responsibilities Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit <br />and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br />&#x2022; Compensation Committee<br />&#x2022; Governance, Nomination and <br /> Corporate Responsibilities Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the following policies apply regarding Board compensation:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  50% of compensation is delivered in cash, paid on a quarterly basis in arrears. Board members may choose to receive more of their compensation in shares instead of cash</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  At least 50% of compensation is delivered in shares in two installments: one six months after the AGM; and one 12 months after the AGM</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members bear the full cost of their employee social security contributions, if any, and do not receive share options or pension benefits. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Board compensation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the Compensation Committee reviewed, together with its independent advisor, the Board of Directors&#x2019; compensation system against the Swiss Market Index. They found that the Board Chair fees and retainer fees of the other Board members are well positioned and competitive among the benchmarked companies in relation to the Company&#x2019;s size, operational complexity and corporate headquarter&#x2019;s location. Additional information on our Board benchmarking practices is provided in &#x201C;&#x2014;2022 Board compensation.&#x201D; The compensation system and fee levels for the Board of Directors will therefore remain unchanged in 2023.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">117</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Board   membership</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Audit and  Compliance  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Compensation   Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance,  Sustainability  and Nomination  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Science &amp;   Technology  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Risk  Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Shares   (number)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Cash   (CHF)  (A)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Shares   (CHF)  (B)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Other  (CHF)  (C)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&#xA0;574</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;803&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Vice-Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;695</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;834</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;834</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 456&#xA0;228</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Patrice Bula</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lead Independent   Director<sup style="white-space: nowrap"> &#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chair<sup style="white-space: nowrap"> &#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&#xA0;259</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   398&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;233</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;605</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;791</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;541</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 423&#xA0;334</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Daniel Hochstrasser</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 856</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 116&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 116&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 237&#xA0;894</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;838</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ana de Pro Gonzalo</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;192</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 329&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;327</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 368&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;233</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;466</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54&#xA0;610</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;791&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;541&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;250</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;362&#xA0;586</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2022 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;132</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;509</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;641</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 143&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&#xA0;251</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;861&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;611&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&#xA0;919</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;506&#xA0;255</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #ffffff 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2022 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2022 for the services from the 2021 AGM to the 2022 AGM, and (ii) the first of two equity installments delivered in August 2022 for the services from the 2022 AGM to the 2023 AGM. The second and final equity installment for the services from the 2022 AGM to the 2023 AGM will take place in February 2023.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes an amount of CHF 29&#xA0;250 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 453&#xA0;083 and provides a right to the maximum future insured government pension benefit for the Board members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No additional committee fees for chairing the Science &amp; Technology Committee were delivered to Joerg Reinhardt.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Until March 4, 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> From March 4, 2022.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">118</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2021</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Board   membership</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Audit and  Compliance  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Compensation   Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Governance,  Sustainability  and Nomination  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Science &amp;   Technology  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Risk  Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Shares   (number)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Cash   (CHF)  (A)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Shares   (CHF)  (B)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Other  (CHF)  (C)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chairman</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;830</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;804&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Enrico Vanni</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Vice Chairman /   Lead Independent   Director<sup>7</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     3&#xA0;035</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     244&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     244&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     492&#xA0;004</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 419&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;922</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 324&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;391</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 206&#xA0;250</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243&#xA0;750</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;128</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 189&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 189&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;334</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;257</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;333</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;333</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;187</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;556</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&#xA0;833</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&#xA0;833</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 405&#xA0;336</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;325</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;742</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;812&#xA0;917</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;653&#xA0;750</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;580</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;492&#xA0;247</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2021 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Srikant Datar<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;970</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&#xA0;712</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;835&#xA0;917</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;707&#xA0;417</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;580</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;568&#xA0;914</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #ffffff 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2021 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2021 for the services from the 2020 AGM to the 2021 AGM, and (ii) the first of two equity installments delivered in August 2021 for the services from the 2021 AGM to the 2022 AGM. The second and final equity installment for the services from the 2021 AGM to the 2022 AGM will take place in February 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes an amount of CHF 25&#xA0;580 for mandatory employer contributions for all Board members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 435&#xA0;204 and provides a right to the maximum future insured government pension benefit for the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No additional committee fees for chairing the Science &amp; Technology Committee were delivered to Joerg Reinhardt.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Until March 2, 2021.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> From March 2, 2021.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> No additonal compensation was paid for the Lead Independent Director role.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">119</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for Board members  </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair is required to own a minimum of 30000 Novartis shares, and other members of the Board of Directors are required to own at least 5000 Novartis shares within five years after joining the Board of Directors, to ensure their interests are aligned with those of shareholders. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Board members are prohibited from hedging or pledging their ownership positions in Novartis shares that are part of their guideline share ownership requirement and are required to hold these shares for 12 months after retiring from the Board of Directors. As at December 31, 2022, all current and former members of the Board of Directors who were required to meet the minimum share ownership requirements did so. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and share options owned by Board members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total number of vested Novartis shares and ADRs owned by members of the Board of Directors and &#x201C;persons closely linked&#x201D; to them as at December 31, 2022, is shown in the table below. As at December 31, 2022, no members of the Board, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares (or ADRs) of Novartis. As of the same date, no members of the Board of Directors held any share options to purchase Novartis shares.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of shares <br /> at December 31, 2022<sup style="white-space: nowrap">1,2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 632&#xA0;730</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;102</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;802</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;931</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;461</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;836</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;296</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Daniel Hochstrasser</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 804</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ana de Pro Gonzalo</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168&#xA0;717</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;888</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;659</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sub-Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 920&#xA0;491</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2022 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;078</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;751</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sub-Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44&#xA0;829</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 965&#xA0;320</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes holdings of "persons closely linked" to Board members (see definition &#x201C;Persons closely linked").</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Each share provides entitlement to one vote.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Board members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no payments (or waivers of claims) other than those set out in the Board member compensation table titled &#x201C;&#x2014;Board member total compensation earned for the financial year 2022&#x201D; (including in the table footnotes) were made to current members of the Board or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Board members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Board member compensation approved by shareholders</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total compensation earned by Board members from the 2021 AGM to the 2022 AGM was within the amount approved by shareholders at the 2021 AGM. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">120</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00922802"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation governance </p>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Legal framework</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Swiss Code of Obligations and the corporate governance guidelines of the SIX Swiss Exchange require listed companies to disclose certain information about the compensation of board and executive committee members, their equity participation, and loans made to them. This Annual Report fulfills that requirement in addition to being in line with the principles of the Swiss Code of Best Practice for Corporate Governance of the Swiss Business Federation (economiesuisse). For more details, please refer to &#x201C;&#x2014;Corporate Governance&#x201D; in Section 6C of this Report.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Risk management principles</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee, with support from its independent advisor, reviews market trends in compensation, and changes in corporate governance rules and best practices. Together with the Risk Committee, it also reviews the Novartis compensation systems to ensure that they do not encourage inappropriate or excessive risk-taking, and instead encourage behaviors that support sustainable value creation. A summary of the risk management principles is outlined below.</div>
      <div style="padding-top:15px">
        <img src="comp_0023.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_riskmanagementprinciples"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">RISK MANAGEMENT PRINCIPLES&#x2022;Rigorous performance management process, with approval of targets and evaluation of performance for the CEO by the Board of Directors&#x2022;Balanced mix of short-term and long-term variable compensation elements&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture&#x2022;Clawback and malus principles apply to all elements of the variable compensation&#x2022;Performance-vesting Long-Term Incentives only, with three-year cycles &#x2022;All variable compensation is capped at 200% of target&#x2022;Contractual notice period of 12months&#x2022;Post-contractual non-compete period is limited to a maximum of 12 months from the end of employment. Resulting compensation, if applicable, will not exceed the average annual compensation (annual base salary plus Annual Incentive) of the previous three financial years&#x2022;Good and bad leaver provisions apply to variable compensation of leavers&#x2022;No severance payments or change-of-control clauses&#x2022;Share ownership requirements; no hedging or pledging of Novartis share ownership&#x2022;No loans granted to current or former members of the Executive Committee and the Board of Directors or to &#x201C;persons closely linked&#x201D; to them</div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation decision-making authorities</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Authority for decisions related to compensation is governed by the Articles of Incorporation, Board Regulations and the Compensation Committee Charter, which are all published on the Company website: www.novartis.com/investors/company-overview/corporate-governance. The Compensation Committee serves as the supervisory and governing body for compensation policies and plans within Novartis, and has overall responsibility for determining, reviewing and proposing compensation policies and plans for approval by the Board of Directors in line with the Compensation Committee Charter. The discussions and conclusions of each committee meeting are delivered to the full Board of Directors. A summary of the compensation decision-making authorities is set out below.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation authorization levels within the parameters set by the shareholders&#x2019; meeting</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Decision on</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Decision-making authority</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of Board Chair and  other Board members</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors  </div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of CEO</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of other Executive  Committee members</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Compensation Committee  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Committee member independence</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee is composed exclusively of members of the Board of Directors who meet the independence criteria set forth in the Board Regulations. From the 2022 AGM, the Compensation Committee consisted of the following four members: Simon Moroney (as Chair), Patrice Bula, Bridgette Heller, and William Winters.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Role of the Compensation Committee&#x2019;s independent advisor</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The independent external compensation advisor supports the committee in determining the design and implementation of compensation and benefits. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee retained Mercer Limited, which was appointed in July 2017, as its independent external advisor until June 2022. As part of its normal governance practices, and with a view to ensuring the independence of the advisor, the Compensation Committee considered a change in the Committee advisor. To inform this decision, it conducted a market review of compensation advisors, with a focus on companies with extensive experience in European and US markets. Following a tendering process and an analysis to ensure that there were no conflicts of interest, the Compensation Committee appointed Mitul Shah of Deloitte AG as its independent compensation advisor with effect from July 2022. The independent advisors from Mercer Limited and Deloitte AG and their respective teams that advised and supported the committee are not responsible or rewarded for work beyond support provided to the Compensation Committee and the People &amp; Organization function on senior compensation.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Meetings held in 2022 and self-evaluation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the Compensation Committee held seven formal meetings. In line with prior years, it collaborated with the Science &amp; Technology Committee to review and endorse, for approval by the Board of Directors, the innovation targets and achievements of the Annual Incentive and LTPP. The Compensation Committee conducted a self-evaluation in 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(This page has been left blank intentionally.)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">122</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId001011000"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.C Board practices </p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:28pt; color:#000000; font-weight:bold;">Corporate governance </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Framework </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to effective corporate governance, and our corporate governance framework is intended to support sustainable financial performance and long-term value creation for our shareholders, patients, employees and other stakeholders based on our Values and Behaviors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Novartis corporate governance principles are further described in key governance documents, in  particular in our Articles of Incorporation and the Regulations of the&#xA0;Board, the Board Committees and the Executive Committee (&#x201C;Board Regulations&#x201D;) (www.novartis.com/investors/company-overview/corporate-governance). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Governance, Sustainability and Nomination Committee regularly reviews both the corporate governance principles and the key governance documents against evolving best practice standards and new developments in line with our commitment to maintaining the highest standards. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To better reflect its evolving role and responsibilities in sustainability and environmental, social and governance (ESG) matters, the Board of Directors (&#x201C;Board&#x201D;) amended, effective as of March 1, 2022, the Board Regulations and renamed the Governance, Nomination and Corporate Responsibilities Committee to the Governance, Sustainability and Nomination Committee (GSNC).</div>
      <div style="padding-top:15px">
        <img src="cogo_0002.gif" alt="WSGE_DP_Graph_GovernanceBodies_2"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Our leadership structureGovernance bodies General Meeting of ShareholdersApproves operating and financial review, Novartis Group consolidated financial statements, and financial statements of Novartis AG; decides appropriation of available earnings and dividend; approves compensation of Board and Executive Committee; elects Board members, Board Chair, Compensation Committee members, Independent Proxy and external auditor; adopts and modifies Articles of IncorporationExternal auditorProvides opinion on compliance of Novartis Group consolidated financial statements and the financial statements of NovartisAG with applicable standards and Swiss law, on compliance of the Compensation Report with applicable law, on effectiveness of internal controls over financial reporting, and limited assurance on selected performance indicators in the Novartis in Society Integrated ReportBoard of DirectorsAudit and Compliance CommitteeCompensation CommitteeGovernance, Sustainability and Nomination CommitteeRISK CommitteeSCIENCE &amp;TECHNOLOGYCommitteeSets strategic direction of Novartis, appoints and oversees key executives, approves major transactions andinvestments, adopts and modifies Board RegulationsExecutive CommitteeResponsible for operational management of Novartis</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">123</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group structure and shareholders</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group structure</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Novartis AG and Group companies</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG, the Group&#x2019;s holding company, is a corporation organized under Swiss law with issued registered shares and registered office at Lichtstrasse 35, CH-4056 Basel, Switzerland. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The principal subsidiaries and associated companies of the Novartis Group are shown in &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Divisions and business units</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two operating divisions: Innovative Medicines (IM), which specializes in patent-protected medicines, and Sandoz<sup>1</sup>, which sells generics and biosimilars. In 2022, Novartis integrated the Pharmaceuticals and Oncology business units under the IM Division and created two separate commercial organizations with a stronger geographic focus &#x2013; Innovative Medicines International and Innovative Medicines US. IM is supported by the Novartis Institutes for BioMedical Research (NIBR) and Global Drug Development (GDD). Both operating divisions are supported by Novartis Operations (which combines the former Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS) units), and corporate functions. The latter includes the newly created Strategy &amp; Growth function, which combines corporate strategy, R&amp;D portfolio strategy and business development. A&#xA0;detailed review of 2022 business results can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style="padding-top:15px">
        <img src="cogo_0026.gif" alt="WSGE_DP_Graph_CompanyStructure"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholdings</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Majority holdings in publicly traded Group companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group owns 70.68% of Novartis India Ltd., with registered office in Mumbai, India, and a listing on the BSE (formerly known as the Bombay Stock Exchange) (ISIN INE234A01025, symbol: HCBA). The total market value of the 29.32% free float of Novartis India Ltd. was USD&#xA0;59.0 million on December 31, 2022, using the quoted market share price at year-end. Applying this share price to all the shares of the company, the market capitalization of the whole company was USD&#xA0;201.2 million, and that of the shares owned by Novartis was USD&#xA0;142.2 million.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholders</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant shareholders</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Share Register, as of December&#xA0;31, 2022, the following registered shareholders, including nominees and the American Depositary Share (ADS) depositary, held more than 2% of the total share capital, with the right to vote all their shares based on exemptions granted by the Board (see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Shareholder participation&#x2014;Voting rights, restrictions and representation&#x2014;Registration restrictions&#x201D;):<sup>2</sup></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br /> share capital<br /> Dec 31, 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br /> share capital<br /> Dec 31, 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, Everett</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, SA/NV, Brussels</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">1  On August 25, 2022, Novartis announced its intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off, with completion expected in the second half of 2023.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>2</sup>  Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">124</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&#xA0;AG, Norges Bank (Central Bank of Norway), Oslo, held 2.3% of the share capital but was not registered in the Share Register as of December&#xA0;31, 2022. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&#xA0;AG and the SIX Swiss Exchange Regulation AG, BlackRock,&#xA0;Inc., New&#xA0;York, held between 5% and 10% but was registered with less than 2% of the share capital as of December&#xA0;31,&#xA0;2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Disclosure notifications pertaining to shareholdings filed with Novartis AG and the SIX Swiss Exchange are published on the latter&#x2019;s electronic publication platform: </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Duty to make an offer</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Swiss Federal Act on Financial Infrastructures, anyone who &#x2013; directly, indirectly or acting in concert with third parties &#x2013; acquires equity securities exceeding 33 1/3% of the voting rights of a company (whether or not such rights are exercisable) is required to make an offer to acquire all listed equity securities of that company. A company may raise this threshold up to 49% of the voting rights (&#x201C;opting up&#x201D;) or may, under certain circumstances, waive the threshold (&#x201C;opting out&#x201D;). Novartis AG has not adopted any such measures.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross shareholdings</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has no cross shareholdings in excess of 5% of capital, or voting rights with any other company.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview on shareholder structure</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables relate only to registered shareholders and cannot be assumed to represent the entire investor base because nominees and JPMorgan Chase Bank, N.A., as ADS depositary, are registered as shareholders for a large number of beneficial owners.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, Novartis AG had approximately 186 000 registered shareholders. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of registered shareholders/shares</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />As of December 31, 2022<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of<br /> registered <br /> shareholders</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % of <br /> share capital</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#x2013;100</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;085</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.08</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101&#x2013;1&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110&#xA0;467</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.86</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;001&#x2013;10&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37&#xA0;732</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.32</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10&#xA0;001&#x2013;100&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;212</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">100&#xA0;001&#x2013;1&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.85</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;000&#xA0;001&#x2013;5&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5&#xA0;000&#xA0;001 or more<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.14</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total registered shareholders/shares</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&#xA0;068</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67.03</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unregistered shares</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.97</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> At the record date of the 2022 Annual General Meeting of Shareholders (AGM), unregistered shares amounted to 17.0%.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Including significant registered shareholders as listed above</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by type</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Individual shareholders</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96.71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15.61</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal entities<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37.69</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nominees, fiduciaries  and ADS depositary</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0.04</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   46.70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by country<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Belgium</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.11</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.77</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.97</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.36</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.45</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.06</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.79</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United Kingdom</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.68</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other countries</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.95</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.45</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Registered shares held by nominees are shown in the country where the company/affiliate entered in the Share Register as shareholder has its registered seat.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">125</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Capital structure</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share capital</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the share capital amounted to CHF&#xA0;1201860626 fully paid-in and divided into 2403721252 registered shares with a nominal value of CHF&#xA0;0.50 each. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shares are listed on the SIX Swiss Exchange (ISIN CH0012005267, symbol: NOVN) and on the New York Stock Exchange (NYSE) in the form of American Depositary Receipts (ADRs) representing American Depositary Shares (ADSs) (ISIN US66987V1098, symbol: NVS).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No authorized and conditional capital exists as of December 31, 2022.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shares, participation certificates, non-voting equity securities, profit-sharing certificates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Convertible securities and options</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has not issued convertible or exchangeable bonds, warrants, options or other securities granting rights to shares, other than options (or similar instruments such as stock appreciation rights) granted under or in connection with equity-based participation plans of employees. Novartis AG does not grant any new stock options under these plans. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Limitation on transferability </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">No transferability restrictions are imposed on shares (for registration restrictions, see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Shareholder participation&#x2014;Voting rights, restrictions and representation&#x2014;Registration restrictions&#x201D;). The registration of shareholders in the Share Register or in the ADR register kept by JPMorgan Chase Bank, N.A., does not affect the tradability of shares or ADRs. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Changes to share capital</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />AGM</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shareholder decision</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shares canceled</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br /> share price (CHF)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 30.16 million (from CHF&#xA0;1&#x2005;263&#x2005;687&#x2005;410 to CHF&#xA0;1&#x2005;233&#x2005;530&#x2005;460)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&#xA0;313&#xA0;900</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 16.32 million (from CHF 1&#x2005;233&#x2005;530 460 to CHF 1&#x2005;217&#x2005;210&#x2005;460)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2021 AGM and the 2024 AGM</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;640&#xA0;000    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.57    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 15.35 million (from CHF 1&#x2005;217&#x2005;210&#x2005;460 to CHF 1 201 860 626)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2022 AGM and the 2025 AGM<sup>2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;699&#xA0;668    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81.82    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />AGM</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Proposal to the shareholders</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shares to be canceled</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br /> share price (CHF)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 63.12 million (from CHF&#xA0;1 201 860 626 to CHF 1 138 738 876)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2023 AGM and the 2026 AGM<sup>3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126&#xA0;243&#xA0;500    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81.56    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> All shares were repurchased on the SIX Swiss Exchange second trading line.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> In addition to the remaining authorization from the 2021 AGM</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> In addition to the remaining authorization from the 2022 AGM</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key Novartis share data</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Issued shares</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;403&#xA0;721&#xA0;252</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;434&#xA0;420&#xA0;920</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;467&#xA0;060&#xA0;920</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284&#xA0;112&#xA0;195</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199&#xA0;480&#xA0;972</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210&#xA0;238&#xA0;872</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding shares at December 31</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;119&#xA0;609&#xA0;057</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;234&#xA0;939&#xA0;948</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;256&#xA0;822&#xA0;048</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares outstanding</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;181&#xA0;180&#xA0;341</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;601&#xA0;173</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;277&#xA0;041&#xA0;940</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Approximately 99 million treasury shares (2021: 102 million, 2020: 103 million) are held in Novartis entities that restrict their availability for use.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">126</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Per-share information<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from continuing operations (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.19</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10.71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.55</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share from continuing operations (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10.63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.52</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from continuing operations (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6.72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.99</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end equity for Novartis AG shareholders (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30.31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25.07</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend (CHF)<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend (USD)<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.46</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Calculated on the weighted average number of shares outstanding, except year-end equity</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> 2022: proposal to shareholders for approval at the AGM on March 7, 2023.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Translated into US dollars at the December 31, 2022, rate of USD 1.081 to the Swiss franc. This translation is an example only, and should not be construed as a representation that the Swiss franc amount represents, or has been or could be converted into US dollars at that or any other rate. 2021 and 2020, dividends are translated into US dollars at the Bloomberg Market System Rate on the payment date.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key ratios &#x2013; December 31</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Price/earnings ratio<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend yield (%)<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on the Novartis share price at December 31 of each year</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key data on ADRs issued in the US</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end ADR price (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90.72</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87.47</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94.43</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98.47</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 99.01</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.61</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79.70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 70.67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of  ADRs outstanding<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   225&#xA0;435&#xA0;680</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   269&#xA0;891&#xA0;321</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   288&#xA0;755&#xA0;853</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on daily closing prices</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The depositary, JPMorgan Chase Bank, N.A., holds one Novartis AG share for every ADR issued.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share price (CHF)</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end share price</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.59</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80.28</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83.65</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.82</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86.75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95.82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.98</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.44</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69.96</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (USD billions)<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   191.5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   196.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   214.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (CHF billions)<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   177.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   179.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   188.8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on daily closing prices</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the year-end CHF/USD exchange rate.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">127</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001012614"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Shareholder participation </p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholder engagement</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholder engagement is fundamental to our commitment to governance and transparency, and the feedback we receive during these engagements helps us create long-term and sustainable value.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We concentrate our outreach efforts on our largest 100 shareholders &#x2013; portfolio managers, buy-side professionals, stewardship teams and ESG analysts &#x2013; who represent 60% of our ownership. While the Board Chair, CEO and CFO, together with Investor Relations, are accountable for ensuring effective shareholder engagement, other senior managers from within and outside the Executive Committee also participate in the meetings. We conduct regular outreach to investors throughout the year. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Types of engagements (select examples):<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  AGM and quarterly results teleconferences (TCs)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bank conferences and management roadshows</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  &#x201C;Meet Novartis Management&#x201D; capital markets event </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governance roadshow and TCs</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Chair&#x2019;s TCs for US and UK investors</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  ESG roadshows</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investor Update on Access &amp; Sustainability  (formerly known as ESG Investor Day)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Update on the new organizational model</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Update on the Sandoz business</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Topics discussed with shareholders during 2022:<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Growth:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Replacement power</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Growth drivers (<i>Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta,</i><i> Leqvio</i>)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Policy and pricing environment</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Life cycle management</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">INNOVATION:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress and milestones</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Data of pipeline projects </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Return on R&amp;D investments</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">PRODUCTIVITY:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress on financial, strategic and operational performance</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Long-term sustainability of financial performance</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Capital allocation strategy</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  New organization model</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Intention to separate Sandoz business</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">BUILDING TRUST WITH SOCIETY AND CULTURE:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board accountability on ESG, and integration of ESG and compensation</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Strong governance, enhanced process and focus on material ESG factors, leading to improved rating agency scores</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patient access to innovative medicines</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Learning from <i>Novartis Access</i> programs implemented over the decades, including integrated sustainable business models and access principles to help address access and inequities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  ESG targets: full carbon neutrality, patient access targets for strategic innovative therapies, and global health flagship programs</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress on culture and other human capital metrics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation AND Governance: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Diversity of the Board, the Executive Committee and the Company</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board renewal, succession planning and evaluation</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Link of compensation system to key strategic priorities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Risk oversight</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Stakeholder expectations from the Board on ESG matters</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We appreciate the value that shareholders attach to ESG matters. We will continue to integrate ESG into our strategy and to promote transparency through our comprehensive ESG engagement program. We have more than doubled the number of investor engagements on ESG matters in recent years, and in 2022, our CEO led our Investor Update on Access &amp; Sustainability (formerly known as ESG Investor Day) for the fourth time (marking our ninth dedicated ESG event for investors since 2014). We also held virtual roadshows in 2022 as part of our engagement with North American, European and Asian investors.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Voting rights, restrictions and representation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders have the right to vote and to execute all other rights as granted under Swiss law and the Articles of Incorporation (see, in particular, articles 17 and 18 of the Articles of Incorporation).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each share registered with the right to vote by the third business day before the General Meeting entitles the holder to one vote at General Meetings. Article 5, paragraph 2 of the Articles of Incorporation provides that to be registered with voting rights, a shareholder must declare that he or she acquired the shares in his or her own name and for his or her own account. According to article 5, paragraph 3 of the Articles of Incorporation, the Board may register nominees with the right to vote. The Share Register is an internal, non-public register subject to statutory confidentiality and data privacy. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation are available at www.novartis.com/investors/company-overview/corporate-governance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Article 5, paragraph 2 of the Articles of Incorporation provides that no shareholder shall be registered with the right to vote for more than 2% of the share capital. Given that shareholder representation at General Meetings has traditionally been comparatively low in Switzerland, Novartis AG considers registration restrictions necessary to prevent a minority shareholder from dominating a General Meeting. The Board may, upon request, grant an exemption. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered shareholders listed in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Group structure and shareholders&#x2014;Shareholders&#x2014;Significant shareholders.&#x201D; Exemptions also apply to the Novartis Foundation for Employee Participation, Basel, which as of December 31, 2022, was registered in the Share Register with less than 2% of the share capital, and to Norges Bank (Central Bank of Norway), Oslo, which as of December 31, 2022, was not registered but held 2.3% according to a disclosure notification filed with Novartis AG. No further exemptions were requested in 2022. The same restrictions indirectly apply to ADR holders. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Article 5, paragraph 3 of the Articles of Incorporation provides that no nominee shall be registered with the right to vote for more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">128</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. Exemptions are in force for the nominees listed in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Group structure and shareholders&#x2014;Shareholders&#x2014;Significant shareholders,&#x201D; and for the nominee Citibank, London, which in 2015 requested an exemption, but as of December 31, 2022, was not registered in the Share Register. The same restrictions indirectly apply to ADR holders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to article 5, paragraph 4 of the Articles of Incorporation, shareholders, ADR holders, or nominees who are linked to each other or who act in concert to circumvent registration restrictions are treated as one person or nominee for the purposes of the restrictions on registration.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration restrictions may be changed by resolution of the General Meeting, with approval of at least two-thirds of the votes represented at the meeting.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation are available at www.novartis.com/investors/company-overview/corporate-governance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Attendance, Representation and online Platform</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Registered shareholders will receive personal invitations to the General Meetings along with a registration/proxy form as well as a personal one-time password and a QR code to log in to our online platform. By returning the registration/proxy form or using the online platform, shareholders are able to order an admission card for the General Meeting or appoint another shareholder or the Independent Proxy to vote their shares on their behalf.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the Independent Proxy is appointed, shareholders can also give voting instructions on alternative or additional motions related to the agenda items either (i) following the recommendations of the Board for such alternative or additional motions, or (ii) opposing such alternative or additional motions. They can also abstain from voting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shareholders choosing not to receive the comprehensive invitation materials will be informed of upcoming General Meetings through a letter containing the login credentials to access the online platform as well as a reference to www.novartis.com/investors/shareholder-information/general-meetings, where all relevant information is available.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In accordance with Swiss legislation passed in response to the COVID-19 pandemic, and as in the previous year, physical attendance at the 2022 Annual General Meeting (AGM) was not possible, and shareholders could exercise their voting rights exclusively through the Independent Proxy. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">ADR holders</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ADR holders have the rights enumerated in the deposit agreement (such as the right to give voting instructions and to receive dividends). The ADS depositary of Novartis&#xA0;AG &#x2013; JPMorgan Chase Bank, N.A., New York &#x2013; holds the shares underlying the ADRs and is registered as a shareholder in the Share Register. An ADR is not a share, and an ADR holder is not a Novartis AG shareholder. Each ADR represents one share. ADR holders exercise their voting rights by instructing the depositary to exercise their voting rights. The ADS depositary exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General Meeting</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Convening </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The AGM must be held within six months after the end of our financial year (December 31), and normally takes place in late February/early March. Extraordinary General Meetings may be requested by the Board, the external auditor, or shareholders representing at least 10% of the share capital.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Agenda</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders representing shares with an aggregate nominal value of at least CHF&#xA0;1 million may request that an item be included in a General Meeting agenda. Such requests must be made in writing at least 45 days before the meeting, specifying the requested item and proposal.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 17 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following powers are vested exclusively in the General Meeting:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Adoption and amendment of the Articles of Incorporation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Election and removal of the Board Chair, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approval of the management report and the consolidated financial statements</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approval of the financial statements of Novartis AG, and the decision on the appropriation of available earnings shown on the balance sheet, including dividends</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM). If the maximum aggregate amount of compensation already approved by the AGM is not sufficient to cover the compensation of newly appointed or promoted Executive Committee members, Novartis may use up to 40% of the amount last approved for the newly appointed or promoted Executive Committee members.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Discharge of Board and Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Decision on other matters that are reserved by law or by the Articles of Incorporation (e.g., advisory vote on the Compensation Report) to the General Meeting </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Statutory Quorums</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The General Meeting passes resolutions and elections with the absolute majority of the votes represented at the meeting. However, under article 18 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the approval of two-thirds of the votes represented at the meeting is required for: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Alteration of the purpose of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Creation of shares with increased voting powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Authorized or conditional increase of the share capital</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Restriction or cancellation of subscription rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Change of the registered office of Novartis&#xA0;AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dissolution of Novartis AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">129</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Board of Directors</span>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0005.gif" alt="WSGE_DP_Graph_BoardOfDirectors"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2022)1BOARD Chair: J. ReinhardtVice-Chair:S. Moroneylead independent Director: P. BulaN. AndrewsT. BuechnerE. DohertyB. HellerD. Hochstrasser1F. van HoutenA. von Planta2A. de Pro GonzaloC. SawyersW. WintersAudit and Compliance CommitteeE. Doherty (Chair)T. BuechnerB. HellerF. van HoutenA. de Pro GonzaloCompensation CommitteeS. Moroney (Chair)P. BulaB. HellerW. WintersGovernance, Sustainability and Nomination CommitteeP. Bula (Chair)B. HellerA. von PlantaC. SawyersW. WintersRisk CommitteeT. Buechner (Chair)N. AndrewsE. DohertyA. von PlantaA. de Pro GonzaloScience &amp; Technology CommitteeJ. Reinhardt (Chair)N. AndrewsF. van HoutenS. MoroneyC. Sawyers1 Effective January 1, 2023, Mr. Hochstrasser became a member of the Audit and Compliance Committee and of the Governance, Sustainability and Nomination Committee.2 Mr. von Planta will not stand for re-election at the 2023 AGM.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Changes to the Board of Directors</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ana de Pro Gonzalo and Daniel Hochstrasser were elected as new Board members at the 2022 AGM. Ann Fudge, Board member since 2008, and Enrico Vanni, Board member and Vice-Chair since 2011 and Lead Independent Director since 2021, did not stand for re-election at the 2022 AGM. The biographies of Ms. Fudge and Mr. Vanni can be found in the 2021 Annual Report (pages 130 and 133), available at www.novartis.com/news/media-library/novartis-annual-report-2021.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Election and term of office</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members (including the Board Chair) and Compensation Committee members are elected individually by shareholders at the General Meeting for a one-year term of office. The term of office expires at the end of the next AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to article 20, paragraph 3 of the Articles of Incorporation, a member shall not serve on the Board for more than 12 years. Under special circumstances and if deemed to be in the best interest of the Company, the Board may recommend exceptions to the shareholders (www.novartis.com/investors/company-overview/corporate-governance).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The term limit supports our commitment to renew the Board on an ongoing basis and also follows international best practice. We believe age is still a  relevant factor in Board composition, and the GSNC will consider this and other factors &#x2013; including gender, nationality and ethnicity &#x2013; when evaluating candidates and exploring ways to increase Board diversity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Succession planning</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair, supported by the GSNC, ensures effective succession plans for the Board, the CEO and the Executive Committee. These plans are discussed by the Board in private meetings. A search for a new Board member is launched &#x2013; normally with the support of a professional executive search company &#x2013; with individual selection criteria defined based on the evolving needs of the Company and a continuing focus on diversity. The set of competencies (further explained in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Board of Directors&#x2014;Board skills&#x201D;) and a balance between continuity of experience and fresh perspectives are also important criteria for the GSNC when evaluating new candidates. Candidates are interviewed by the Board Chair, members of the GSNC, other Board members, and members of the Executive Committee. The GSNC then makes a recommendation to the full Board, and the Board ultimately decides who should be proposed for election at the upcoming AGM. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board will propose to the shareholders a new candidate for election at the 2023 AGM. Andreas von Planta already announced in 2021 that he will not stand for re-election at the 2023 AGM. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">130</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Independence</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All Board members &#x2013; including the Board Chair &#x2013; are non-executive and independent, pursuant to applicable corporate governance rules and Novartis independence criteria, which are outlined in Appendix II to the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In particular, no Board member is or was a member of the management of Novartis AG or of any other Novartis Group company in the last three financial years up to December 31, 2022, or has or had, except for Daniel Hochstrasser, a significant business relationship with Novartis AG or with any other Novartis Group company. Mr. Hochstrasser fulfilled the independence criteria following his resignation from B&#xE4;r &amp; Karrer, a Swiss law firm that has a business relationship with Novartis, as of December 31, 2022. During 2022, Mr. Hochstrasser did not belong to any Board committee. No separate meetings of independent Board members were held in 2022. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The independence of Board members is assessed annually. Each Board member completes an independence questionnaire that is subject to review by the GSNC. The GSNC then submits a proposal to the full Board, and the Board determines the independence status of each Board member.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Diversity of gender, age, nationality, ethnicity, viewpoints, professional backgrounds and expertise is a key factor to success and Board effectiveness in a constantly evolving environment. A diverse Board ensures that the appropriate balance of skills, expertise, experience and cultural background is represented to discharge its responsibilities and to support long-term value creation for shareholders, patients, employees and other stakeholders. Diversity remains a critical area of focus for the Board, and the GSNC is continuously looking for opportunities to further increase the Board&#x2019;s diversity when identifying new Board member candidates.</div>
      <div style="padding-top:15px">
        <img src="cogo_0027.gif" alt="WSGE_DP_Graph_Diversity"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pSwiss31%pAmerican23%pDutch11%pGerman11%pBritish8%pSpanish8%pIrish4%pNew Zealander4%GenderpMale69%pFemale31%Agep556015%p616562%p&gt;6523%Tenurep&lt;3y31%p36y31%p79y31%p&gt;9y7%1Please note that five Board members have dual nationalities. Each of these nationalities is counted as a half in the above chart.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Upon proposal by the GSNC, the Board has determined a diverse set of competencies for its members that aligns with our status as a listed company, as well as our business portfolio, geographic reach and culture. Based on this set of competencies, our Board members were asked to identify their most relevant skills highlighted by their educational background, professional experience and personal achievements. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The GSNC assesses the set of competencies as well as the individual skills annually to ensure that an appropriate balance of skills, expertise, experience and diversity is represented on the Board.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To learn more about our Board members and their individual skills, see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Board of Directors&#x2014;Members of the Board of Directors.&#x201D;</div>
      <div style="padding-top:15px">
        <img src="cogo_0059.gif" alt="WSGE_DP_Graph_DiversityBackground"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Board skill distributionMedicine/healthcare/R&amp;D46%6/13Leadership/management 92%12/13Finance/accounting46%6/13Law/regulatory/risk management69%9/13Data/digital23%3/13Environmental, social 38%5/13and governance (ESG)</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">131</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001013020"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Board of Directors</p>
      <div style="padding-top:15px">
        <img src="cogo_0030.jpg" alt="WSGE_DP_Pic_Reinhardt"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Joerg Reinhardt, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chair since 2013 | Nationality: German | Year of birth: 1956</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Joerg Reinhardt is a healthcare industry veteran whose career spans nearly 40 years. After receiving his doctorate in pharmaceutical sciences, Mr. Reinhardt joined Sandoz Pharma Ltd., a predecessor to Novartis, in 1982. He held a number of senior leadership positions at Novartis, including Chief Operating Officer and Head of the Vaccines and Diagnostics Division. Additionally, he led Bayer HealthCare AG as chair of the board of management and the executive committee from 2010 to 2013.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of management and the executive committee, Bayer HealthCare AG, Germany (2010&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chief Operating Officer, Novartis AG, Switzerland (2008&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of the Vaccines and Diagnostics Division, Novartis AG, Switzerland (2006&#x2013;2008)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various managerial positions at Sandoz Pharma Ltd. and Novartis AG, Switzerland (1982&#x2013;2006) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senate member, Helmholtz Association of German Research Centres, Germany</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, Novartis Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Swiss Re AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the European Advisory Panel, Temasek Holdings Private Ltd., Singapore</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Lonza Group AG, Switzerland (2012&#x2013;2013)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair, Genomics Institute of the Novartis Research Foundation, US (2000&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in pharmaceutical sciences, Saarland University, Germany</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;</div>
      <div style="padding-top:15px">
        <img src="cogo_0061.gif" alt="WSGE_DP_Pic_Moroney"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Simon Moroney, D.Phil.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2020 | Vice-Chair since March 4, 2022 | Nationality: German/New Zealander |  <br />Year of birth: 1959</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">As co-founder and CEO of MorphoSys AG, Simon Moroney played a central role in establishing the company as a force in the field of therapeutic antibodies, with one of the broadest pipelines of drug candidates in the industry. Mr. Moroney holds both a doctorate and a Master of Science in chemistry.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-founder and CEO, MorphoSys AG, Germany (1992&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Research associate, Department of Pharmacology, University of Cambridge, UK (1991&#x2013;1992)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Assistant professor, Department of Chemistry, University of British Columbia, Canada (1989&#x2013;1990)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the Remuneration and Nomination Committee, Biotalys NV, Belgium</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in chemistry, University of Oxford, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in chemistry, University of Waikato, New Zealand</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">132</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0028.jpg" alt="WSGE_DP_Pic_Andrews"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nancy C. Andrews, M.D., Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2015 | Nationality: American/Swiss | Year of birth: 1958</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Nancy C. Andrews has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke University School of Medicine. Dr. Andrews currently chairs the board of the American Academy of Arts and Sciences, and is credited with conducting research that led to advances in understanding iron biology and iron diseases.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and chief scientific officer, Boston Children&#x2019;s Hospital, US (2021&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Dean emerita, Duke University School of Medicine, and vice chancellor emerita for academic affairs, Duke University, US (2017&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dean, Duke University School of Medicine, and vice chancellor for academic affairs,   Duke University, US (2007&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Professor of pediatrics, pharmacology and cancer biology, Duke University, US (2007&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Dean for basic sciences and graduate studies, Harvard Medical School, US (2003&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Director, Harvard/MIT M.D.-Ph.D. Program, US (1999&#x2013;2003)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Biomedical research investigator, Howard Hughes Medical Institute, US (1993&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Maze Therapeutics Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the Science and Technology Committee, Charles River Laboratories International Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Council member, National Academy of Sciences, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Former council member (2013&#x2013;2019) and member, National Academy of Medicine, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board, American Academy of Arts and Sciences, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Scientific Advisory Board, Dyne Therapeutics Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the executive committee of the Corporation, Massachusetts Institute of Technology, US (2019-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the Scientific Management Review Board, National Institutes of Health, US (2014&#x2013;2019)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Burroughs Wellcome Fund, US (2011&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Harvard Medical School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in biology, Massachusetts Institute of Technology, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Master of Science and Bachelor of Science in molecular biophysics and biochemistry, Yale University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management  </div>
      <div style="padding-top:15px">
        <img src="cogo_0032.jpg" alt="WSGE_DP_Pic_Buechner"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ton Buechner</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: Dutch/Swiss | Year of birth: 1965</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Ton Buechner is an engineer by training who started his career in the oil and gas construction industry. Before becoming the CEO of Sulzer AG, he held several divisional leadership roles at the company and worked in markets including Asia. Mr. Buechner most recently served as CEO and chair of the executive board of AkzoNobel NV, where he introduced industry-leading ESG policies.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the executive board, AkzoNobel NV, Netherlands (2012&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Sulzer AG, Switzerland (2007&#x2013;2011)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Sulzer Pumps, Switzerland (2003&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Sulzer Turbomachinery Services, Switzerland (2000&#x2013;2002)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Sulzer AG, China and Switzerland (1994&#x2013;2000)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the sustainability board, Swiss Prime Site AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the Strategy and Sustainability Committee, Burckhardt Compression AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advisor, Ammega, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the presidential and shareholder committees, Voith GmbH &amp; Co. KGaA, Germany  (2014&#x2013;2020)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the supervisory board, Voith GmbH &amp; Co. KGaA, Germany (2014&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in civil engineering, Delft University of Technology, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-m.jpg" alt="sign"></img>
        </span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;  <span style="vertical-align: middle;"><img src="skill-z.jpg" alt="sign"></img></span>&#xA0;Environmental, social and governance (ESG)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">133</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0025.jpg" alt="WSGE_DP_Pic_Bula"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Patrice Bula</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2019 | Lead Independent Director since March 4, 2022 | Nationality: Swiss | Year of birth: 1956</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Patrice Bula has 40 years of global management experience and is a leader in the consumer goods industry across established and emerging markets. He has served in various senior roles at Nestl&#xE9; SA, including as general manager of its businesses in China, Germany and South Africa. Most recently, he successfully led the Nestl&#xE9; Group&#x2019;s brand strategies, digital marketing transformation and Nespresso business.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and head of strategic business units, marketing, sales and Nespresso, Nestl&#xE9; SA, Switzerland (2011&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Market head of the Greater China region, Nestl&#xE9; SA, Switzerland (2007&#x2013;2011)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Market head of Germany, Nestl&#xE9; SA, Switzerland (2003&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head of the confectionery and biscuits strategic business unit, Nestl&#xE9; SA, Switzerland (2000&#x2013;2003)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Nestl&#xE9; SA, Switzerland (1980&#x2013;2000) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, Froneri Lux Topco Sarl, Luxembourg </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Schindler AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the ESG Committee, New Tiger LLC, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-chair (2020&#x2013;2021) and board member (2015&#x2013;2021), Cereal Partners Worldwide SA, Switzerland (Nestl&#xE9; representative)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Froneri Lux Topco Sarl, Luxembourg (Nestl&#xE9; representative) (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Bobst Group SA, Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair, Blue Bottle Coffee Inc., US (Nestl&#xE9; representative) (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair, Nestl&#xE9; Nespresso SA, Switzerland (Nestl&#xE9; representative) (2011&#x2013;2019)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Hsu Fu Chi Food Companies, China (Nestl&#xE9; representative) (2011&#x2013;2019) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Program for Executive Development, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in economic sciences, HEC Lausanne, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-m.jpg" alt="sign"></img>
        </span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-y.jpg" alt="sign"></img></span>&#xA0;Data/digital</div>
      <div style="padding-top:15px">
        <img src="cogo_0035.jpg" alt="WSGE_DP_Pic_Doherty"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Elizabeth (Liz) Doherty</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: British/Irish | Year of birth: 1957 | Audit Committee Financial Expert</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Elizabeth (Liz) Doherty is an expert in finance and accounting who has broad operational experience in international consumer and retail businesses. She began her career in internal audit at Unilever&#xA0;PLC and has held senior finance and accounting roles there and at other companies including Tesco PLC and Reckitt Benckiser Group PLC.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO (interim), Cognita Schools Ltd., UK (2014&#x2013;2015) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO and board member, Reckitt Benckiser Group PLC, UK (2011&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CFO (interim), City Inn, UK (2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO, Brambles Ltd., Australia (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Group international finance director, Tesco PLC, UK (2001&#x2013;2007)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Unilever PLC, UK (1981&#x2013;2001)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the Audit Committee, Corbion NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the supervisory board and chair of the Audit Committee, Royal Philips NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advisor, Affinity Petcare SA and GB Foods SA, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Dunelm Group PLC, UK (2013&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, HM Courts &amp; Tribunals Service, UK (2015&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Ministry of Justice, UK (2015&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Delhaize Group, Belgium (2013&#x2013;2016)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Nokia Corp., Finland (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Chartered Institute of Management Accountants, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in liberal studies in science (physics), University of Manchester, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">134</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0060.gif" alt="WSGE_DP_Pic_Heller"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bridgette Heller</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2020 | Nationality: American | Year of birth: 1961</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Bridgette Heller has proven experience in the standalone divisions of companies such as Johnson &amp; Johnson, Merck &amp; Co. Inc. and Danone SA, and has served on the audit committees of ADT Corp. and Tech Data Corp. During her career, she has overseen the performance of CFOs and made decisions on strategic R&amp;D priorities. Ms.&#xA0;Heller is an advocate for diversity, equity and inclusion, and traveled globally to reinforce Danone&#x2019;s commitment to infant and maternal health, inclusive diversity, an equitable workforce for women, and sustainable communities. She is co-founder and CEO of the Shirley Proctor Puller Foundation, an education and youth empowerment nonprofit, and devotes much of her time to strengthening education and sustainability in an underserved community in the US.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-founder and CEO, Shirley Proctor Puller Foundation, US (2019&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP and president of specialized nutrition, Danone SA, Netherlands (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP of early life nutrition, Danone SA, Netherlands (2016&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP and president of consumer care, Merck &amp; Co. Inc., US (2010&#x2013;2015)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global president of the baby global business unit, Johnson &amp; Johnson, US (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President of the US baby, kids and wound care business and of global innovation development,  Johnson &amp; Johnson, US (2005&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Managing partner, Heller Associates: Ideas for Growth Inc., US (2004&#x2013;2005)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Chung&#x2019;s Gourmet Foods, US (2003&#x2013;2004)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Kraft Foods Inc., US (1985&#x2013;2003)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Integral Ad Science Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Aramark, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Dexcom Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Newman&#x2019;s Own Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of trustees, Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory board, Kellogg School of Management at Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Shirley Proctor Puller Foundation, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Newman&#x2019;s Own Foundation, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Tech Data Corp., US (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, ADT Corp., US (2012&#x2013;2016)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Girls Inc., US (2002&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in marketing and management policy, Kellogg School of Management at Northwestern University, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in economics and computer studies, Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;  <span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting</div>
      <div style="padding-top:15px">
        <img src="cogo_0066.gif" alt="WSGE_DP_Pic_Hochstrasser"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Daniel Hochstrasser</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since March 4, 2022 | Nationality: Swiss | Year of birth: 1960</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Daniel Hochstrasser is an independent dispute resolution specialist practicing in Zurich, Switzerland. Until the end of 2022, he has been leading B&#xE4;r &amp; Karrer&#x2019;s arbitration practice for 15 years. He frequently represented parties in complex disputes arising from matters such as M&amp;A transactions, industrial and infrastructure projects, and license, distribution and development agreements, particularly in the pharmaceutical industry. In addition, he led the firm as senior partner from 2011 until 2021. He has published extensively on arbitration and litigation, and lectures at the University of Zurich and the University of St. Gallen in Switzerland.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Attorney-at-law, Daniel Hochstrasser AG, Switzerland (since January 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Attorney-at-law and partner, B&#xE4;r &amp; Karrer AG, Switzerland (1993&#x2013;December 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior partner and chair of the board of directors, B&#xE4;r &amp; Karrer AG, Switzerland (2011-2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Lawyer, District Court of Affoltern, Court of Appeals/Court of Cassation of Zurich, Switzerland  (1987&#x2013;1992)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   In-house lawyer, Staubli SA, France (1986&#x2013;1987)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member (2015&#x2013;2021) and Vice President (since 2021), ICC Court of Arbitration, France</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Ethics Court, Zurich Bar Association, Switzerland (since 2004)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Finland Arbitration Institute, Finland (since 2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors, B&#xE4;r &amp; Karrer AG, Switzerland (2011-2021)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the Court, Swiss Arbitration Chambers, Switzerland (2004&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Laws (LL.M.), Cornell Law School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar examination, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Licentiatus iuris, University of Zurich, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">135</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0033.jpg" alt="WSGE_DP_Pic_vanHouten"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Frans van Houten</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2017 | Nationality: Dutch | Year of birth: 1960</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Frans van Houten is passionate about purpose-driven innovation, entrepreneurship and business transformation to drive customer value and competitiveness. Under his leadership as CEO of Royal Philips, the company transformed into a leading health technology solutions company, leveraging data and informatics to improve healthcare provider results, and became a forerunner across ESG dimensions, having become carbon neutral in its operations since 2020 and recycling over 90% of its waste. Mr. van Houten was an initiator of the World Economic Forum Compact for Responsive and Responsible Leadership as well as founder and co-chair of the Platform to Accelerate the Circular Economy.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Advisor, Royal Philips NV, Netherlands (October 2022&#x2013;April 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the executive committee and the board of management, Royal Philips NV, Netherlands (2011&#x2013;October 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Interim management, ING Group NV, Netherlands (2009&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the management board, NXP Semiconductors NV (formerly Philips Semiconductors NV), Netherlands (2004&#x2013;2009)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Royal Philips Electronics NV, Netherlands (1986&#x2013;2004) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the supervisory board, Erasmus Trust Foundation, Netherlands (2014&#x2013;February 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Founder and co-chair of the WEF Platform to Accelerate the Circular Economy (PACE),  Netherlands (2016-December 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the steering committee, European Round Table for Industry (ERT), Belgium  (2014-November 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, Graduate Entrepreneur Foundation, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, NL2025 Foundation, Netherlands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice chair and member of the supervisory board, Philips Lighting, Netherlands (2016&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in economics and business management, Erasmus University Rotterdam, Netherlands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in economics, Erasmus University Rotterdam, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;  <span style="vertical-align: middle;"><img src="skill-y.jpg" alt="sign"></img></span>&#xA0;Data/digital &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-top:15px">
        <img src="cogo_0038.jpg" alt="WSGE_DP_Pic_vonPlanta"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Andreas von Planta, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2006 | Nationality: Swiss | Year of birth: 1955</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Andreas von Planta is a leading expert in corporate governance, corporate law and stock exchange regulation. He advises boards of public companies on corporate governance matters and is a sought-after speaker and writer on these topics. He has co-authored the Switzerland chapter of the International Comparative Legal Guide to Corporate Governance for many years.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior counsel, Lenz &amp; Staehelin, Switzerland (2017&#x2013;present)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Partner, Lenz &amp; Staehelin, Switzerland (1988&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Holding AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of trustees, Novartis Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Schweizerische Lebensversicherungsgesellschaft AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Schweizerische Versicherungsgesellschaft AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, HSBC Private Bank (Suisse) SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, HSBC Private Banking Holdings (Suisse) SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Socotab Frana SA, Switzerland </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the regulatory board, SIX Swiss Exchange AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the Audit Committee, International Road Transport Union, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Soci&#xE9;t&#xE9; Immobili&#xE8;re Quai Gustave Ador 50 SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Burberry (Suisse) SA, Switzerland (2001-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice chair of the board of directors, A.P. Moller Finance SA, Switzerland (1997-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Raymond Weil SA, Switzerland (2007&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Clinique G&#xE9;n&#xE9;rale-Beaulieu SA, Switzerland (2008&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Schweizerische National Versicherungs AG, Switzerland (1997&#x2013;2015)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Holcim AG, Switzerland (2003&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Laws, Columbia Law School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar examination, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in law, University of Basel, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Licentiatus iuris, University of Basel, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">136</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0067.gif" alt="WSGE_DP_Pic_Gonzalo"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ana de Pro Gonzalo</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since March 4, 2022 | Nationality: Spanish | Year of birth: 1967 | Audit Committee Financial Expert</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Since starting her career at Arthur Andersen, Ana de Pro Gonzalo has worked across a variety of industries, ranging from construction and real estate to engineering and telecommunications. With deep expertise in finance, capital markets and technology, she has held executive positions at several multinational companies. Most recently, she spent 10 years as chief financial officer of Amadeus IT Group, a leading software provider for the global travel and tourism industry. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief financial officer, Amadeus IT Group SA, Spain (2010&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Corporate general manager, Sacyr Vallehermoso SA, Spain (2002&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Deputy general manager and finance director, Metrovacesa SA, Spain (1994&#x2013;2002)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior auditor, Arthur Andersen SA, Spain (1990&#x2013;1994)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the supervisory board and chair of the Audit Committee, STMicroelectronics NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, National Express Group PLC, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Indra Sistemas SA, Spain (2020-2022)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Merlin Properties Socimi SA, Spain (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Management Program (PDG), IESE Business School, Spain</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in business studies, Complutense University of Madrid, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-top:15px">
        <img src="cogo_0037.jpg" alt="WSGE_DP_Pic_Sawyers"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Charles L. Sawyers, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: American | Year of birth: 1959</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and  prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr.&#xA0;Sawyers co-developed the Novartis cancer drug <i>Gleevec</i>/<i>Glivec</i> and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, US (2006&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Professor of medicine (2008&#x2013;present), and professor of cell and developmental biology (2011&#x2013;present), Weill Cornell Graduate School of Medical Sciences, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Investigator, Howard Hughes Medical Institute, US (2002&#x2013;2006 and 2008&#x2013;present)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Associate chief, Division of Hematology-Oncology, University of California, Los Angeles, US (1996&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Medicine, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Sciences, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investigator, Howard Hughes Medical Institute, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Science advisor for the following US companies: Arsenal Capital Partners; BeiGene Ltd.; Blueprint Medicines Corp.; Foghorn Therapeutics Inc.; Housey Pharmaceutical Research Laboratories; KSQ Therapeutics Inc.; Nextech Invest Ltd.; ORIC Pharmaceuticals Inc.; PMV Pharmaceuticals Inc.; The Column Group </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Cancer Advisory Board, US (2012&#x2013;2020)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President, American Association for Cancer Research, US (2013&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Johns Hopkins University School of Medicine, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Arts, Princeton University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-z.jpg" alt="sign"></img></span>&#xA0;Environmental, social and governance (ESG)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">137</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0036.jpg" alt="WSGE_DP_Pic_Winters"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">William T. Winters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: British/American | Year of birth: 1961</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">William T. Winters has extensive leadership experience in the financial sector. He began his career at JPMorgan Chase &amp; Co. in 1983 and has held management roles across several market areas and in corporate finance. Mr. Winters founded Renshaw Bay LLP, an alternative asset management firm, and now serves as CEO of Standard Chartered PLC, where he is leading a digital transformation of the global bank.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Standard Chartered PLC, UK (2015&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair and CEO, Renshaw Bay LLP, UK (2011&#x2013;2015)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-CEO of the Investment Bank, JPMorgan Chase &amp; Co., UK (2004&#x2013;2010)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at JPMorgan Chase &amp; Co., UK and US (1983&#x2013;2004)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Standard Chartered Bank PLC, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of overseers, International Rescue Committee, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of trustees, The Coronet Theatre, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Commissioner, Independent Commission on Banking, UK (2010&#x2013;2011) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, Wharton School of the University of Pennsylvania, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in international relations, Colgate University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-y.jpg" alt="sign"></img>
        </span>&#xA0;Data/digital &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting</div>
      <div style="padding-top: 30px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate Secretary</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;font-weight:bold;padding-top:5px;padding-bottom:5px;">Charlotte Pamer-Wieser, Ph.D.</div>
      <div style="padding-top: 30px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Self-assessment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board and its committees conduct a self-assessment once a year, covering topics including Board composition, purpose, scope and responsibilities; succession planning; Board processes and governance; interaction between the Board and the Executive Committee; Board meetings and pre-reading material; team effectiveness; and Board Chair and peer evaluation.  Every third year, this process is conducted by an independent external consultant. This last occurred in 2020 with the consulting firm Egon Zehnder. </div>
      <div style="padding-top:15px">
        <img src="cogo_0063.gif" alt="WSGE_DP_Graph_BoardSelfAssessment"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Anonymous survey&#x2022;Each Board member fills out an anonymous survey.&#x2022;A report identifying key strengths and challenges is produced for the Board and its committees. Qualitative review&#x2022;Based on the results, the Board Chair and the committee chairs each lead a qualitative review with their colleagues and then with the entire Board. &#x2022;In addition, the Vice-Chair leads a qualitative review of the Board Chair&#x2019;s performance, without the Chair being present, and then provides the Board Chair with the Board&#x2019;s feedback. Outcome&#x2022;The last self-assessment of October 2022 determined that the Board and its committees are functioning effectively and efficiently. &#x2022;The feedback confirmed that the Board has an open culture, fostering a broad range of viewpoints.&#x2022;The results also identified key areas on which to focus, such as further development of Novartis strategy, oversight of a range of challenging technology and reorganizational projects, and the impact of the current geopolitical situation in Europe, the US and China, including pricing.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">138</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trainings</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Board receives regular briefings and trainings on ethics, risks and compliance, ESG and other relevant topics. In 2022, each Board member completed the following trainings: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Health, Safety and Environment Policy</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  &#x2018;Fit to Commit&#x2019;, which focused on anti-bribery, insider trading and procurement</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  An ESG educational session conducted by an external expert on holistic value creation</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Third Party Risk Management</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Chief Legal Officer also provides regular updates to our Board members on developments related to insider trading laws and regulations and briefs the members of the Board and the Executive Committee on an annual basis on their respective duties. In addition, the Company offers a broad range of external trainings to its Board members. </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Board and its committees</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board is responsible for the overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of decisions reserved for shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board has delegated certain of its duties and responsibilities to its five committees led by a Board-elected committee chair, as set out in the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In some cases, these responsibilities are of an advisory or preparatory nature. In other cases, the committee has decision-making power that is subject to final Board approval, or the responsibilities have been fully delegated to the committee. All committees have the authority to retain external consultants.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any Board member may request a Board or committee meeting and the inclusion of an agenda item. Before meetings, Board members receive materials to help them prepare for the discussions and to inform decision-making. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Attendance at Board and Board Committee Meetings in 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />Name</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Position</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Board</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Audit and <br /> Compliance <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Compensation <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance, <br /> Sustainability <br /> and Nomination <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Risk <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Science &amp; <br /> Technology <br /> Committee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">J. Reinhardt</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S. Moroney</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">P. Bula</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N. Andrews</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">T. Buechner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">E. Doherty</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">B. Heller</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">F. van Houten</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">D. Hochstrasser<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8/8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">A. von Planta</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">A. de Pro Gonzalo<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8/8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">C. Sawyers</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">W. Winters</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Ms. de Pro Gonzalo and Mr. Hochstrasser were elected at the 2022 AGM.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Further details can be found on pages 140 &#x2013; 145.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">139</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board of Directors</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Strategy: decides on the ultimate direction of the Group&#x2019;s business (including portfolio, markets, acquisitions and divestments), considering also key ESG aspects</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Structure and organization: determines major changes in the Group&#x2019;s structure and organization  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Culture: oversees the strategy and implementation of the corporate culture </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ethics and compliance: oversees the Group&#x2019;s ethics and compliance framework, including the approval of fundamental corporate policies such as the Novartis Code of Ethics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Risk management: oversees the Group&#x2019;s risk management system, the most significant risks, and how these risks are managed</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Finance: determines the Group&#x2019;s accounting system, financial controls and financial planning;    reviews&#xA0;and approves the Annual Report (including the Compensation Report)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Non-financial reporting: reviews and approves the Group&#x2019;s annual reporting on non-financial matters</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  People and organization: nominates or appoints, removes, and determines responsibilities of key executives,   and succession planning</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversaw the Company&#x2019;s strategy to become a fully focused medicines company with leading technology in key therapeutic and geographic areas </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the set-up and functioning of the Executive Committee in the context of the Company&#x2019;s new organizational structure</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the geopolitical situation in Europe, with a special focus on the impact on the Russian and Ukrainian markets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and closely monitored the Transformation for Growth project to ensure a smooth transition and the successful implementation of its objectives</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on the US market and our priorities to accelerate growth in Innovative Medicines and become a top player in the market</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on the German market and the Company&#x2019;s strategic ambition to become the market leader in Germany</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates from Global Drug Development and Operations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed strategic considerations around mergers and acquisitions, and the Company&#x2019;s larger strategic moves to drive sustainable growth</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Conducted detailed discussions about the strategic review of Sandoz, deciding that a separation through a 100% spin-off would offer the best value proposition to investors (subject to shareholders approval)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the Company&#x2019;s ESG strategy, plans and developments, and attended an ESG education session on holistic value creation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the upcoming non-financial disclosure regulations and Novartis non-financial reporting governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed longer-term Board succession planning and required profiles, proposing a new Board member candidate to be elected at the 2023 AGM</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the amendment of the Articles of Incorporation of Novartis AG as part of the reform of Swiss corporate law</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and reviewed the annual Board self-evaluation</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">13</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">6:30</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">98.5%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board met ten times in 2022. This includes regular meetings in January, April, June, August, October and December, and additional special meetings to deal with ad hoc matters. Board committees typically meet the day before the meetings of the full Board. The Board held virtual, hybrid and physical meetings, with participants joining in person when possible. </div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">J. Reinhardt (Board Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney (Vice-Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula (Lead Independent Director) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">9</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">D. Hochstrasser<sup>1 </sup></div>
        <div style="text-align: right; float:right; width: 100px;">8</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo<sup>1 </sup></div>
        <div style="text-align: right; float:right; width: 100px;">8</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">9</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Articles of Incorporation of Novartis AG </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Regulations </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  Ms. de Pro Gonzalo and Mr. Hochstrasser were elected at the 2022 AGM and have attended all Board meetings since their election.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">140</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Audit and Compliance Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supervises the external auditor, and selects and nominates the external auditor for election by the shareholders (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees Internal Audit (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees accounting policies, financial controls, and compliance with accounting and internal control standards (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approves financial statements for the first three quarters of each calendar year and the corresponding financial results releases (FD)**, and reviews the annual financial statements and the corresponding financial results releases (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the non-financial data contained in the Group&#x2019;s annual reporting (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees compliance with laws, regulations and internal policies related to its subject matter expertise (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates with regards to Quality Assurance and patient safety twice a year and Health Safety &amp; Environment once a year (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates from the SpeakUp Office twice a year (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the Group&#x2019;s tax policy every two years (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates in closed sessions with the Chief Financial Officer, Chief Audit Officer, and external auditor</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"></div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the performance of the external auditor KPMG during 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the accounting and financial reporting, focusing on those areas involving significant risk or judgment</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monitored the geopolitical situation and reviewed the treasury aspects and cash collection in Russia</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed the Company&#x2019;s approach to non-financial reporting and assurance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the timelines and milestones of the intended Sandoz spin-off</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on data privacy and its mechanisms of classifications and control</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on foreign exchange risk management at Novartis</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Liaised with the Risk Committee to ensure adequate oversight of the Company&#x2019;s key transformation projects (Enterprise Data Governance and Management and Lean Digital Core (LDC) program)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Received reports and updates from Internal Audit; Quality; Ethics, Risk &amp; Compliance; the SpeakUp Office; Health, Safety &amp; Environment; and Legal, and discussed&#xA0;progress on identifying and remedying the root causes of issues</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">2:35</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty (Chair, Audit Committee Financial Expert) </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo<sup>1 </sup> (Audit Committee Financial Expert)</div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  Ms. de Pro Gonzalo became a member of the Audit and Compliance Committee after the 2022 AGM and has attended all Audit and Compliance Committee meetings since that time.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">141</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Designs, reviews and recommends to the Board the compensation policies and programs (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advises the Board on the compensation of Board members and the CEO (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Decides on the compensation of Executive Committee members (FD)**</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Prepares the Compensation Report and the Say-on-Pay brochure, and submits them to the Board for approval (FBA)***</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Made decisions relating to Executive Committee and wider employee compensation during the year</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Established compensation to be paid for the future Sandoz board and executive committee members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Determined the critical performance measures (including financial, strategic, operational, innovation and ESG) to be considered in the 2022 and 2023 incentive plan targets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the achievement of incentive plan targets for the Executive Committee members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed shareholder and proxy advisor feedback related to Novartis compensation practices and disclosures and to those of peer companies</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed disclosures in the Novartis Compensation Report</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Proposed appropriate peer companies for comparisons of board and executive committee compensation, and assessed the Company&#x2019;s level of compensation against the peer group</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed incentive plan rules to secure pay-for-performance alignment while preserving market competitiveness</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appointed a new independent advisor to the Compensation Committee</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reflected on effectiveness of the Company&#x2019;s compensation programs in view of its strategy to become a fully focused medicines company, following announcements of the introduction of a new organizational structure and the intention to separate the Sandoz business by way of a 100% spin-off</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Compensation Committee charter</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">1:40</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">96.5%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">6</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">142</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Governance, Sustainability and Nomination Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the Company&#x2019;s strategy, governance and progress on sustainability, including access to medicine and healthcare, global health, environmental sustainability, human capital management and other material ESG aspects (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Recommends corporate governance best practices to the Board (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the Articles of Incorporation and Board Regulations on a periodic basis (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the composition and size of the Board and its committees as well as the skills matrix on a regular basis (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Identifies new Board member candidates and recommends to the Board whether existing Board members   should stand for re-election (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Prepares and reviews succession plans for the Board Chair, the Vice-Chair, the Lead Independent Director, Board&#xA0;members, committee members and chairs, and the CEO (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the independence of each Board member on an annual basis (FBA)***</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Reviews directorships and agreements of Board members for conflicts of interest, and deals with conflicts of interest (FBA)***</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated progress on sustainability at Novartis, focusing on material ESG factors, together with targets and metrics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates on ESG and Global Health covering the Company&#x2019;s ESG priorities and 5-year roadmap</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on environmental sustainability covering governance, strategy and progress against near- and longer-term targets for carbon emissions, waste reduction and water consumption</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on human capital management covering the Company&#x2019;s People &amp; Organization strategy, key people metrics and progress in its culture journey</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the results of the 2022 AGM as well as investor and analyst feedback from ESG / Governance roadshows held in 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and recommended to the Board amendments to the Articles of Incorporation of Novartis AG in connection with the reform of Swiss corporate law</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed candidates for the Sandoz board chair elect and the nomination process for the entire Sandoz board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the composition of, and the succession for, the (Novartis) Board and its committees on a regular basis</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings </span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">2:00</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">143</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Risk Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the risk management system and processes (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews, together with management, the prioritization and handling of risks, the risk portfolio,   and actions implemented by management (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Performs deep dives into key risk areas and fosters a culture of smart risk-taking (FBA)***</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates on cyber security on an annual basis (FD)**</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates on Enterprise Risk Management mitigation measures and results</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the emerging risks associated with the current geopolitical crisis in Russia and Ukraine, and mitigation actions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on launch excellence in Japan, evaluating opportunities and risks for Innovative Medicines</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed the current opportunities and risks at Global Drug Development</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the performance, risk management and transformation of Novartis Technical Operations associated supply chain</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates and closely monitored the Enterprise Data Governance and Management and the risk assessment and mitigation of the Lean Digital Core (LDC) program</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on falsified medicines covering the various types of falsification and indirect import</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the enterprise risks for Innovative Medicines in the US for 2022 related to the Transforming for Growth program, pipeline portfolio growth and diversity in clinical trials</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Third-Party Risk Management (TPRM) program</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the key risks associated with Intellectual Property (IP protection, IP enforcement, third-party assertion and trade secrets)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Analyzed the opportunities and risks around talent management in key areas and geographies</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a deep-dive update on cyber security, including on data loss protection, from the Chief Security Officer</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">1:50</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">144</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Science &amp; Technology Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monitors emerging scientific, data-related, technological and research trends and issues,   and brings recommendations to the Board (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Informs the Board on a periodic basis about critical developments for the success of the portfolio and for scientific, technological&#xA0;and research activities as well as benchmarking (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assists the Board with setting the Company&#x2019;s strategy for science, data, technology and research (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assists the Board with oversight and evaluation of the performance of the Company&#x2019;s scientific, technological  and&#xA0;R&amp;D activities (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews performance and proposed targets in the area of science, technology and research (FD)**</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews other matters in relation to science, data, technology and research that the committee may,   in its own discretion, deem desirable in connection with its responsibilities (A/P)*</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and provided guidance on the technology strategy for the Novartis Institutes of BioMedical Research (NIBR)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Company&#x2019;s early clinical pipeline</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the performance of Global Drug Development and its future strategy</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provided guidance on the build-up of the Strategy &amp; Growth function, and discussed the Company&#x2019;s innovation strategy with the Strategy &amp; Growth leadership</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">6:00</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">95%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">J. Reinhardt (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">145</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair leads the Board to represent the interests of all stakeholders and ensures an appropriate balance of power between the Board and the Executive Committee. In this role, the Board Chair:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provides leadership to the Board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supports and mentors the CEO</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures that the Board and its committees work effectively</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sets the agenda, style and tone of Board discussions, promoting constructive dialogue and effective decision-making</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures onboarding programs for new Board members, and continuing education for and specialization of all Board members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures the Board&#x2019;s annual performance evaluation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promotes effective relationships and communication between Board and Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures effective communication with the Company&#x2019;s shareholders, other stakeholders and the public</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vice-Chair and Lead&#xA0;Independent&#xA0;Director</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Vice-Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Vice-Chair has the following responsibilities:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the Board in case and as long as the Board Chair is incapacitated</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the yearly session of the Board members to evaluate the performance of the Board Chair, during which the Board Chair is not present</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Vice-Chair also provides advice and support to the Board Chair.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Lead Independent Director</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To support adequate control mechanisms, the Board Regulations outline the role of the Lead Independent Director. The Lead Independent Director has the following responsibilities: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chairs the sessions of the independent Board members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the independent Board members in the event of a crisis or matter requiring their separate consideration or decision</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The roles of the Vice-Chair and the Lead Independent Director can be held by two Board members or by one Board member (combined role). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board appointed Simon Moroney as Vice-Chair and Patrice Bula as Lead Independent Director, both roles effective as of March 4, 2022. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Honorary Chairmen</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Alex Krauer and Daniel Vasella were appointed Honorary Chairmen in recognition of their significant achievements on behalf of Novartis.  In December 2021, Mr. Krauer passed away at the age of 90. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Mr. Vasella is not provided with Board documents and does not attend Board meetings.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 1 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following limitations on mandates apply: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Holding a chair position of the board of directors in other listed companies counts as two mandates.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following mandates are not subject to the above-mentioned limitations: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed to be one mandate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">146</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001016049"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee</p>
      <div style="padding-top:15px">
        <img src="cogo_0021.gif" alt="WSGE_DP_Graph_Management"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2022)Vasant (Vas) NarasimhanChief Executive OfficerShreeram AradhyePresident, Global Drug Development&amp; Chief Medical OfficerVictor BultoPresident, InnovativeMedicines USAharon (Ronny) GalChief Strategy &amp; Growth OfficerKaren L. HaleChief Legal OfficerHarry KirschChief Financial OfficerRobert (Rob) KowalskiChief People &amp; Organization OfficerSteffen LangPresident, OperationsFiona H. MarshallPresident, Novartis Institutesfor BioMedical Research (NIBR)Klaus MoosmayerChief Ethics, Risk &amp; Compliance OfficerMarie-France TschudinPresident, Innovative Medicines International &amp; Chief Commercial Officer</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Changes to the Executive Committee</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Susanne Schaffert, President of Novartis Oncology since 2019, stepped down from her role following the Company&#x2019;s decision to integrate the Pharmaceuticals and Oncology business units and create separate US and International commercial organizations under the Innovative Medicines (IM) Division, effective April 4, 2022. Marie-France Tschudin, President of Novartis Pharmaceuticals since 2019, was appointed President, Innovative Medicines International &amp; Chief Commercial Officer, effective April 4, 2022. Victor Bulto, President, Novartis Pharmaceuticals Corporation, US, since 2019, was appointed President, Innovative Medicines US, effective April 4, 2022. He has been a member of the Executive Committee since May 1, 2022. Robert Weltevreden, Head of Customer &amp; Technology Solutions (CTS) since February 1, 2021, stepped down from his role following the Company&#x2019;s decision to combine Novartis Technical Operations (NTO) and CTS into a new Operations unit, effective April 4, 2022. Steffen Lang, Global Head of Novartis Technical Operations since 2017, was appointed President, Operations, effective April 4, 2022. John Tsai, Head of Global Drug Development and Chief Medical Officer, stepped down from his role effective May 15, 2022. Shreeram Aradhye was appointed President, Global Drug Development &amp; Chief Medical Officer, effective May 16, 2022. Aharon (Ronny) Gal was appointed Chief Strategy &amp; Growth Officer, effective July 18, 2022. From April 4, 2022, until July 17, 2022, Lutz Hegemann, President Global Health &amp; Sustainability, served as ad interim Chief Strategy &amp; Growth Officer but was not a member of the Executive Committee. Richard Saynor, Chief Executive Officer, Sandoz, stepped down from the Executive Committee effective October 25, 2022, following his appointment as CEO designate of the Sandoz standalone company expected to be created in the second half of 2023. James (Jay) Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), stepped down from his role effective October 31, 2022. Fiona H. Marshall was appointed President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1, 2022.&#xA0;The biographies of the former members of the Executive Committee can be found in the 2021 Annual Report (pages 147 - 149), available at www.novartis.com/news/media-library/novartis-annual-report-2021. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Executive Committee</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board has appointed the Executive Committee members and delegated the overall responsibility for and oversight of the operational management of Novartis to them, including:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Recruiting, appointing and promoting senior management</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring the efficient operation of the Group and the achievement of optimal results</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promoting an active internal and external communications policy </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Developing policies and strategic plans for Board approval, and implementing those approved</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Submitting the following to the Board for approval: investments, divestments, transactions, contracts and litigations with a value exceeding USD 500 million, and capital market and other important financing transactions, as well as all other matters of fundamental significance to the Novartis Group</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Preparing and submitting quarterly and annual reports to the Board and its committees</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Informing the Board of all matters of fundamental significance to the businesses</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dealing with any other matters delegated by the Board</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no contracts between Novartis and third parties whereby Novartis would delegate any business management tasks to such third parties.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">147</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">With the support of the Executive Committee, the CEO is responsible for the operational management of Novartis. This includes effectively implementing the Company strategy, delivering financial results, and shaping a corporate culture of empowerment and responsibility to help drive innovation, performance and reputation. &#xA0;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to other Board-assigned duties, the CEO leads the Executive Committee, and is responsible for building and maintaining an effective executive team. With the support of the Executive Committee, the CEO is responsible for:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring Novartis has the capabilities to achieve its long-term strategic objectives</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Developing robust management succession and development plans for presentation to the Board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promoting effective communication with shareholders and other stakeholders</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring Novartis conducts its business in a legal and ethical manner</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Developing an effective risk control framework for all business activities </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Ensuring the flow of information to the Board is accurate, timely and clear</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The composition as of December 31, 2022, in terms of nationality, gender, age and length of tenure, is shown in the following charts: </div>
      <div style="padding-top:15px">
        <img src="cogo_0039.gif" alt="WSGE_DP_Graph_Diversity_ECN"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pAmerican41%pGerman18%pSwiss18%pBritish9%pSpanish9%pIsraeli5%GenderpMale73%pFemale27%Agep&lt;459%p45509%p&gt;5082%Tenurep&lt;2y55%p24y27%p&gt;4y18%1Please note that three Executive Committee members have dual nationalities. Each of these nationalities is counted as a half in the above chart.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 2 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following limitations on mandates apply:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Holding a chair position of the board of directors in other listed companies is not allowed.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following mandates are not subject to the above-mentioned limitations: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed to be one mandate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">148</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001016252"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Executive Committee </p>
      <div style="padding-top:15px">
        <img src="cogo_0043.jpg" alt="WSGE_DP_Pic_Narasimhan"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vasant (Vas) Narasimhan, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Executive Officer of Novartis since 2018 | Nationality: American | Year of birth: 1976</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Drug Development and Chief Medical Officer, Novartis AG, Switzerland (2016&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Development, Novartis Pharmaceuticals, Switzerland (2014&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Biopharmaceuticals and Oncology Injectables, Sandoz International, Germany (2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Development, Novartis Vaccines, US (2012&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   North America Region Head, Novartis Vaccines, and US Country President, Novartis Vaccines and Diagnostics, US (2008&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 2005 </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Medicine, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair (since December 2022) and board member (2020&#x2013;2022), African Parks Network, South Africa</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Committee member, Biopharmaceutical CEOs Roundtable (BCR), International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA), Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of fellows, Harvard Medical School, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and treasurer, Pharmaceutical Research and Manufacturers of America (PhRMA), US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Harvard Medical School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in public policy, John F. Kennedy School of Government, Harvard University, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in biological sciences, University of Chicago, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0069.gif" alt="WSGE_DP_Pic_Aradhye"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shreeram Aradhye, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Global Drug Development &amp; Chief Medical Officer since May 16, 2022 | Nationality: American |  <br />Year of birth: 1962</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President &amp; Chief Medical Officer, Dicerna Pharmaceuticals, US (2020&#x2013;March 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President &amp; Chief Development Officer, Axcella Health, US (2019&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head, Medical Affairs and Chief Medical Officer, Pharmaceuticals, Novartis, US &amp; Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head, Development Franchise, Neuroscience, and US Head, Development, Novartis, US&#xA0;&amp;&#xA0;Switzerland (2013&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Global Program Head, Multiple Sclerosis, Novartis, Switzerland (2012&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head, Global Development India, Novartis, India (2011&#x2013;2012)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head, Global Clinical Development &amp; Medical Affairs, Biosimilars, Sandoz, Germany (2009&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 1999 holding positions of increasing responsibility</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Resident and Teaching Fellow in Internal Medicine, Newton Wellesley Hospital, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resident in Internal Medicine, Newton Wellesley Hospital, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow in Nephrology, St Luke&#x2019;s Roosevelt Medical Center, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resident in Internal Medicine (M.D.), All India Institute of Medical Sciences, India</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Medicine and Bachelor of Surgery, All India Institute of Medical Sciences, India</div>
      <div style="padding-top:15px">
        <img src="cogo_0068.gif" alt="WSGE_DP_Pic_Bulto"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Victor Bulto</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Innovative Medicines US since April 4, 2022 | Member of the Executive Committee as of May 1, 2022 | Nationality: Spanish | Year of birth: 1978</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Novartis Pharmaceuticals Corporation, US (2019&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice President &amp; Head US Immunology &amp; Dermatology Franchise, US (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice President &amp; Head US Alcon Pharmaceuticals, US (2016&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head Neuroscience Franchise, Region Europe, Novartis, Switzerland (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Business Franchise Head Neuroscience, Novartis, Spain (2012&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Business Franchise Head Neuroscience/MS, Respiratory, Osteoarticular, Spain, Novartis (2010&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Marketing Head Respiratory, Osteoarticular, Novartis, Spain (2009&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Biotechnology Innovation Organization (BIO), US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of business administration, ESADE Business School, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in health economics and pharmacoeconomics, Pompeu Fabra University Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in chemical engineering, Ramon Llull University, Spain</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s of science degree in chemistry, Ramon Llull University, Spain</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">149</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0070.gif" alt="WSGE_DP_Pic_Gal"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Aharon (Ronny) Gal, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Strategy &amp; Growth Officer since July 18, 2022 | Nationality: Israeli/American | Year of birth: 1966</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US biopharmaceutical, Sanford Bernstein, US (2020&#x2013;June 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US specialty pharmaceuticals and Biotech, Sanford Bernstein, US (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior analyst, US specialty pharmaceuticals and EU mid-cap pharmaceuticals, Sanford Bernstein,  US, UK (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US specialty pharmaceuticals, Sanford Bernstein, US (2004&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, Canon US Life Sciences, US (2003&#x2013;2004)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Consultant, team leader, manager, The Boston Consulting Group, Inc., US, Singapore, China  (1996&#x2013;2002)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Scientific advisor, Pure Honey Technologies, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ph.D. in Biochemistry, Massachusetts Institute of Technology, US </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  B.Sc. in Chemistry, Emory University, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0064.gif" alt="WSGE_DP_Pic_Hale"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Karen L. Hale</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Legal Officer of Novartis since May 15, 2021 | Nationality: American | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, deputy general counsel, AbbVie Inc., US (2019&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, chief ethics and compliance officer, AbbVie Inc., US (2013&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice president, litigation and legal specialty operations, AbbVie Inc., US (2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Divisional vice president, commercial litigation, Abbott Laboratories, US (2006&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Began practicing law in 1994 and joined Abbott in 1997</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar memberships: Illinois and Virginia, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Juris doctor, William &amp; Mary Law School, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in economics, Duke University, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0047.jpg" alt="WSGE_DP_Pic_Kirsch"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Harry Kirsch</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Financial Officer of Novartis since 2013 | Nationality: German/Swiss | Year of birth: 1965</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief Financial Officer of the Pharmaceuticals Division (now known as the Innovative Medicines Division), Novartis Pharmaceuticals, Switzerland (2010&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief Financial Officer of Pharma Europe, Novartis Pharmaceuticals, Switzerland (2008&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head of Business Planning &amp; Analysis for the Pharmaceuticals Division, Novartis Pharmaceuticals, Switzerland (2005&#x2013;2008) </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 2003 as Head Finance Global Primary Care, and over the years held positions of increasing responsibility within Finance </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Diploma degree in industrial engineering and economics, University of Karlsruhe, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0065.gif" alt="WSGE_DP_Pic_Kowalski"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Robert (Rob) Kowalski</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief People &amp; Organization Officer of Novartis since September 1, 2021 | Nationality: American | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President and Global Head of Regulatory Affairs (2018&#x2013;2021), and US Head of Global Drug Development (2009&#x2013;2015 and 2017&#x2013;2021), Novartis Pharmaceuticals Corporation, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ad interim President, Novartis Corporation, US (2021) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ad interim Head of Global Drug Development and Chief Medical Officer, Novartis AG,   Switzerland (2018) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior Vice President and Head of Regulatory Affairs, Novartis Pharmaceuticals Corporation, US   (2009&#x2013;2015 and 2017&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior Vice President and Head of Regulatory Affairs, Novartis Pharma AG, Switzerland (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Country Medical Development, Novartis Pharmaceuticals Corporation, US (2010&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Previously held regulatory leadership roles at Schering-Plough Corporation (now Merck) and Pharmacia Corporation (now Pfizer) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory board, Industry Pharmacists Organization, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of pharmacy, University of Wisconsin-Madison, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in pharmaceutical sciences, University of Wisconsin-Madison, US</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">150</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0045.jpg" alt="WSGE_DP_Pic_Lang"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Steffen Lang, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Operations since April 4, 2022 | Nationality: German/Swiss | Year of birth: 1967</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Novartis Technical Operations (NTO), Switzerland (2017&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Biologics Technical Development and Manufacturing, Novartis Technical Operations, Switzerland (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Technical Research and Development, Novartis Pharmaceuticals, Switzerland (2009&#x2013;2015)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 1994 as Head of Laboratory in Research, and over the years held positions of increasing responsibility within Pharmaceuticals Development</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Bachem Holding AG, Switzerland </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in pharmaceutical technology, Swiss Federal Institute of Technology, Switzerland </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in pharmaceutical sciences, University of Heidelberg, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0071.gif" alt="WSGE_DP_Pic_Marshall"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fiona H. Marshall, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Novartis Institutes for BioMedical Research (NIBR) since November 1, 2022 | Nationality: British |  <br />Year of birth: 1964</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior vice president, head of discovery, preclinical and translational medicine, Merck &amp; Co., US, (2021&#x2013;September 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, global head of neuroscience, Merck &amp; Co., US (2019&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, head of UK discovery research, Merck &amp; Co., UK (2018&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and chief scientific officer, Sosei Heptares, UK (2015&#x2013;2018)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief scientific officer and founder, Heptares Therapeutics, UK (2006&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Scientific Advisory Board, SciLifeLab, Sweden</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Royal Society, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Honorary Fellow, Royal Society of Chemistry, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Honorary Fellow, British Pharmacological Society, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, UK Academy of Medical Sciences, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Royal Society of Biology, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  PhD in Neuroscience, University of Cambridge, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  BSc in Biochemistry, University of Bath, UK</div>
      <div style="padding-top:15px">
        <img src="cogo_0044.jpg" alt="WSGE_DP_Pic_Moosmayer"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Ethics, Risk &amp; Compliance Officer of Novartis since 2018 | Nationality: German | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief compliance officer, Siemens AG, Germany (2014&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief counsel compliance, Siemens AG, Germany (2009&#x2013;2013)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Compliance operating officer, Siemens AG, Germany (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, SwissHoldings, the Swiss federation representing Swiss-based multinational companies, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the executive board, Business at OECD (BIAC), Paris </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-chair, B20 Integrity &amp; Compliance Task Force under the G20 presidencies of Indonesia (2022), Italy (2021), Saudi Arabia (2020), Argentina (2018), and Chair of the Task Force under the G20 presidency of Germany (2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory panel, Pharmaceutical Supply Chain Initiative, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-founder and board member, European Chief Compliance and Integrity Officers&#x2019; Forum</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the Anti-Corruption Committee of the Business and Industry Advisory Committee (BIAC), Organization for Economic Co-operation and Development (OECD), Paris (2013&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  First and second state examination in law, Germany</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of jurisprudence, University of Freiburg, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0049.jpg" alt="WSGE_DP_Pic_France"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marie-France Tschudin</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Innovative Medicines International &amp; Chief Commercial Officer since April 4, 2022 | Nationality: Swiss |  <br />Year of birth: 1971</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Novartis Pharmaceuticals, Switzerland (2019&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President, Advanced Accelerator Applications, France (2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Europe Region Head, Novartis Pharmaceuticals, Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Corporate vice president of hematology and oncology for Europe, the Middle East and Africa, Celgene International, Switzerland (2014&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Regional vice president of northern Europe, Celgene International, Switzerland (2012&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   General manager of Austria, Switzerland, the Czech Republic, Poland, Slovenia and Slovakia, Celgene International, Switzerland (2009&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Country manager of Switzerland, Celgene International, Switzerland (2008&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, IMD Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, AXA, France</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science, Georgetown University, US </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">151</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001016996"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information and control systems </p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board&#x2019;s information and control systems vis-&#xE0;-vis management include a steady flow of information from senior management; monthly financial reports; a comprehensive and integrated risk management framework; and the independent evaluation of our risk management and internal control framework by the Internal Audit function (see &#x201C;Item 15. Controls and Procedures&#x201D;).</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information from senior management</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board ensures that it receives sufficient information from the Executive Committee through:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monthly CEO reporting (including detailed written updates from each division and business unit head), frequent communications from the CEO on current developments, and a yearly presentation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Executive Committee meeting minutes</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regular meetings and teleconferences by the Board and/or Board committees with the CEO and/or other members of the Executive Committee (e.g., the CFO, the Chief Legal Officer, the Chief Ethics, Risk &amp; Compliance Officer), and regular meetings and teleconferences with senior management (e.g., the Chief Audit Officer)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Information from Executive Committee members or other Novartis employees, and visits to Novartis sites</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To get an outside view, the Board and/or Board committees occasionally invite external advisors (e.g., the independent advisor of the Compensation Committee, the external auditor) to attend a meeting and/or share their observations about a specific topic.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Monthly financial reports</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis produces comprehensive, consolidated (unaudited) financial statements on a monthly basis for the Group and its operating divisions. These are typically available within 10 days after the end of the month, and include the following:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Consolidated income statement of the month and year to date, in accordance with International Financial Reporting Standards (IFRS), as well as adjustments to arrive at core results, as defined by Novartis (see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x201D;). The IFRS and core figures are compared with the prior-year period and targets in both USD and on a constant currency basis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supplementary data on a monthly and year-to-date basis, such as free cash flow and earnings per share on a USD basis </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Management information related to the consolidated income statements and free cash flow is made available to Board members through the monthly CEO Report, which includes an analysis of key deviations from the prior year or target.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Prior to the release of each quarter&#x2019;s results, the Board receives the actual consolidated financial statement information and an outlook of the full-year results in accordance with IFRS and core results (as defined by Novartis), together with related commentary.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Annually, in the middle of the year, the Board approves the Company&#x2019;s strategic plan for the next three years. In the fourth quarter of the year, the Board approves the operating targets for the following year as well as the financial targets for the following three-year period, including a projected consolidated income statement in USD prepared in accordance with IFRS and non-IFRS measures as defined by Novartis (core results).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board does not have direct access to the Novartis financial and management reporting systems but can, at any time, request more detailed information.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">152</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Risk management</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our continued success depends on our ability to manage risk. Our Board has ultimate oversight of the Enterprise Risk Management (ERM) system and regularly reviews the most significant risks and how these risks are managed. As explained further below, the Board is supported by its committees. Furthermore, our Internal Audit function provides an independent evaluation of risk management (see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Information and control systems&#x2014;Internal Audit&#x201D;). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Board committees<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Risk committee</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the risk management system and processes</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews, together with management, the prioritization and handling of risks, the risk portfolio, and actions implemented by management</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Performs deep dives into key risk areas and fosters a culture of smart risk-taking</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives updates on cyber security on an annual basis</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives regular updates from designated risk owners as well as the Chief Ethics, Risk &amp; Compliance Officer and/or the Head of Risk &amp; Resilience</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Audit and compliance committee</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures that Internal Audit plans are aligned with key risks, and that the function provides independent assurance and insights around these risks</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Works closely with the Risk Committee to minimize gaps in risk&#xA0;coverage</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives a semiannual presentation from the Chief Ethics, Risk &amp; Compliance Officer</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives a quarterly presentation from the Chief Audit Officer on progress achieved in implementing the risk-based audit plan, and key insights about audit and advisory activities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pays particular attention to financial risk</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Has closed sessions with the Chief Audit Officer and, upon request, with the Chief Ethics, Risk &amp; Compliance Officer</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation committee</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Works closely with the Risk Committee to ensure that the compensation system does not lead to excessive risk-taking (see&#xA0;&#x201C;&#x2014;Item 6.B Compensation&#x2014;Compensation governance&#x2014;Risk&#xA0;management principles&#x201D;)  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Executive committee of NOVARTIS<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Regularly assesses risks and fosters a culture of risk awareness, in line with the Novartis Values and Behaviors and the Novartis Code&#xA0;of Ethics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Ethics, risk &amp; compliance<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governs the Novartis Code of Ethics</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provides an integrated ERM framework (further described in the following section)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governs the global compliance program within Novartis</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Administers the Enterprise Policy Management and global Internal Controls framework</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">SENIOR LEADERS OF DIVISIONS, ORGANIZATIONAL UNITS AND&#xA0;GROUP FUNCTIONS, AT ALL LEVELS<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provide appropriate risk management within their area of responsibility</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Establish adequate risk prevention and mitigation strategies when risk exposure is identified, including tracking progress and providing resources for possible actions</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assess emerging risks, trends and overall exposure as part of the ERM process</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Enterprise Risk Management framework</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Ethics, Risk &amp; Compliance (ERC) function provides an integrated ERM framework to obtain a holistic view of Company risks and drive a culture of smart risk-taking. Under the leadership of the Chief Ethics, Risk &amp; Compliance Officer, the Risk &amp; Resilience team is responsible for the overall ERM process. This process covers, but is not limited to, risks associated with: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The research, development, manufacturing, marketing and sales of products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Finance, taxes, intellectual property, compliance with law and regulations, security, product safety, human resources, and health, safety and environmental protection</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Business objectives and strategies, including mergers and acquisitions</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  External factors such as the social, political and economic environment</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ERM process continued to evolve in 2022. The Risk &amp; Resilience team conducted risk workshops and collaborated with all risk assurance and monitoring functions to identify key risks across the Company. Each Novartis unit organized a focused risk workshop at the leadership team level. In parallel, risk workshops were held in the top 11 countries (by revenue) and in certain focus markets. Once key risks were identified, mitigation action plans were created to address them in an effective way. The findings from these workshops were consolidated into the Novartis Risk Compass, which enables senior management, the Executive Committee and the Board to focus discussions on key risks and more closely align our corporate strategy with our risk exposure and ways of working.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we further matured our ERM framework within the Novartis Risk &amp; Resilience organization, developed additional risk management trainings, and integrated other critical risk management functions (like Third-Party Risk Management and Health, Safety and Environment) into the Risk &amp; Resilience department. Furthermore, the Enterprise Policy &amp; Internal Control team is progressing as planned to create a holistic framework, and the Central Monitoring Coordination team is expanding its scope to ensure a harmonized and coordinated monitoring process across the Company.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">SpeakUp Office</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our SpeakUp Office provides a safe place for employees to report potential misconduct, including the option to do so anonymously. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Global Security</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Global Security proactively collects and shares threat intelligence to protect Novartis from situations that may compromise the safety of people, products and assets, and/or the reputation of our organization. Global Security protects patients from counterfeit products and, as part of the SpeakUp process, performs fair and timely investigations into high-risk cases of alleged internal misconduct. It also provides personal security advice and support for Novartis executives and other employees with the utmost discretion. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">153</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Internal Audit</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The purpose of Internal Audit is to assist the Board and the Executive Committee in discharging their governance responsibilities by providing independent assurance and advice on the effectiveness, efficiency and adequacy of processes and controls that support Novartis in achieving its objectives, managing its major risks, and ensuring compliance with applicable policies, laws and regulations. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Chief Audit Officer reports administratively to the CEO, and functionally to the chair of the Audit and Compliance Committee (ACC). The Chief Audit Officer meets with the ACC at least once a quarter and confirms the organizational independence of the Internal Audit function to the ACC on an annual basis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, our Internal Audit function executed a risk-based audit plan and reported the results to the audited units, the Executive Committee and the ACC. Audit findings and action plans are stored and monitored in a single location to enable efficient and effective follow-up. The following outlines the number of audits, internal reviews and advisories performed in 2022, and key methodology steps when managing the Internal Audit cycle.</div>
      <div style="padding-top:15px">
        <img src="cogo_0062.gif" alt="WSGE_DP_Graph_InternalAuditActivities"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 Internal Audit Activitiesaudits 41internal reviews 14advisories8Internal Audit cycle methodology includes:Planning: Monitoring and information gathering via continuous risk assessment based on data analytics, business interviews and quarterly calibration of the audit planExecution and Reporting: 63 engagements delivered in 2022, all linked to group risks, emerging topics and company-wide initiativesFollow Up: Management is responsible for resolving issues, supported by Internal Audit to ensure timely closure of observations </div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal Audit performed 85% of planned activities (equating to 63 of 74 engagements) in 2022, conducted under a hybrid model of engagement delivery, choosing between remote and in-person auditing based on the engagement scope and COVID-19 situation within the audited entity.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">154</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017226"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Auditors</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Duration of the mandate and&#xA0;terms&#xA0;of&#xA0;office</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On behalf of the Board, the ACC selects and nominates an independent auditor for election at the AGM. KPMG commenced its auditing mandate for Novartis in 2022. Richard Broadbelt, Auditor in charge, and Sara Burke, Global Audit Partner, began serving in their roles in 2022. The ACC together with KPMG will ensure that these partners are rotated at least every five years. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Auditing fees and additional fees</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC monitors and preapproves the fees paid to the external auditor for all audit and non-audit services. It has developed and approved a policy with clear guidelines on the engagement of the independent auditor firm. This policy is designed to help ensure that the independence of the external auditor is maintained. It limits the scope of services that the external auditor may provide to the Group, stipulating certain permissible types of audit-related and non-audit services, including tax services and other services that have been preapproved by the ACC. The ACC preapproves all other services on a case-by-case basis. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The external auditor is required to report periodically to the ACC about the scope of the services it has provided to the Group and the fees for the services it has performed to date. KPMG fees for professional services related to the 12-month period ended December 31, 2022, and PwC fees for professional services related to the 12-month period ended December 31, 2021, are as follows: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> USD million</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> USD million</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit services</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit-related services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Audit services include work performed to issue opinions on consolidated financial statements and parent company financial statements of Novartis AG, to issue opinions related to the effectiveness of the Group&#x2019;s internal control over financial reporting, and to issue reports on local statutory financial statements. Also included are audit services that generally can only be provided by the statutory auditor, such as the audit of the Compensation Report, audits of the adoption of new accounting policies, audits of information systems and the related control environment, as well as reviews of quarterly financial results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Audit-related services include other assurance services provided by the independent auditor but not restricted to those that can only be provided by the statutory auditor. They include services such as: audits of pension and other employee benefit plans; audits in connection with non-recurring transactions; contract audits of third-party arrangements; corporate responsibility assurance; and other audit-related services.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax services include tax compliance, assistance with historical tax matters, and other tax-related services.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other services in 2021 included procedures related to corporate integrity agreements, benchmarking studies, and license fees for use of accounting and other reporting guidance databases.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information to the Board and the ACC</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC, acting on behalf of the Board, is responsible for overseeing the activities of the external auditor. In 2022, this committee held seven meetings. KPMG was invited to all of these meetings to attend the discussions on auditing matters and any other matters relevant to its audit.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC recommended to the Board to approve the audited consolidated financial statements and the separate parent company financial statements of Novartis&#xA0;AG for the year ended December 31, 2022. The Board proposed the acceptance of these financial statements for approval by the shareholders at the next AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC regularly evaluates the performance of the external auditor and, based on this, once a year determines whether the external auditor should be proposed to the shareholders for re-election. To assess the performance of the external auditor, the ACC  requests input from management and holds private meetings with the CFO and the Chief Audit Officer and, if necessary, obtains an independent external assessment. Criteria applied for the performance assessment of the external auditor include an evaluation of: its technical and operational competence; its independence and objectivity; the sufficiency of the resources it has employed; its focus on areas of significant risk to Novartis; its willingness to probe and challenge; its ability to provide effective, practical recommendations; and the openness and effectiveness of its communications and coordination with the ACC, the Internal Audit function and management. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once a year, the Auditor in charge and the Global Audit Partner report to the Board on the external auditor&#x2019;s activities during the current year, and on the audit plan for the coming year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On an annual basis, the external auditor provides the ACC with written disclosures required by the US Public Company Accounting Oversight Board, and the committee and the external auditor discuss the external auditor&#x2019;s independence from Novartis. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">155</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017365"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information policy</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to open and transparent communication with shareholders, investors, financial analysts, customers, suppliers and other stakeholders. Novartis disseminates information about material developments in its businesses in a broad and timely manner that complies with the rules of the SIX Swiss Exchange and&#xA0;the NYSE.  </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Communications</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis publishes this Annual Report to provide information on the Group&#x2019;s results and operations. Novartis discloses financial results in accordance with IFRS on a quarterly basis, and issues press releases from time to time regarding business developments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis publishes press releases related to financial results and material events to the US Securities and Exchange Commission (SEC) via Form 6-K. An archive containing annual reports, US SEC Form 20-F, quarterly results releases and all related materials &#x2013; including presentations and conference call webcasts &#x2013; is available at www.novartis.com/investors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also publishes a Novartis in Society Integrated Report, available at www.reporting.novartis.com, which highlights progress on the Company&#x2019;s strategic priorities and describes how Novartis creates value for diverse stakeholders. The Novartis in Society Integrated Report has been prepared in alignment with the Integrated Reporting Framework (part of the IFRS Foundation), the Task Force on Climate-related Financial Disclosures (TCFD), the Sustainability Accounting Standards Board (SASB) and the latest non-financial standards issued by the Global Reporting Initiative (GRI). It also contains our main disclosures against the Company&#x2019;s reporting requirement as a signatory of the United Nations Global Compact.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information on Board and Executive Committee compensation is outlined in the Compensation Report (see &#x201C;&#x2014;Item 6.B Compensation&#x201D; in general, and for certain compensation information with respect to our Board that is responsive to Item 6.C.2 of Form 20-F, see &#x201C;&#x2014;Item 6.B Compensation&#x2014;2022 Board compensation&#x2014;Philosophy and benchmarking&#x201D;). Please also refer to articles 29-35 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance). There are no change-of-control or &#x2018;golden parachute&#x2019; clauses benefiting Board members, Executive Committee members, or other members of senior management. Employment contracts with Executive Committee members are either for a fixed term not exceeding one year or for an  indefinite period with a notice period not exceeding 12&#xA0;months, and do not contain commissions for the acquisition or transfer of enterprises or severance payments. No loans or credits are granted to Board and Executive Committee members.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investor Relations </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Investor Relations manages the Group&#x2019;s interactions with the international financial community. Several events are held each year to provide institutional investors and analysts with various opportunities to learn more about Novartis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investor Relations is based at the Group&#x2019;s headquarters in Basel. Part of the team is located in the US to coordinate interaction with US investors. More information is available at www.novartis.com/investors.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Website information</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Topic</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Information</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share capital</div>
            </td>
            <td style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br /> www.novartis.com/investors/company-overview/corporate-governance<br /> Novartis key share data<br /> www.novartis.com/investors/share-data-analysis</div>
            </td>
            <td style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder rights</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual General Meeting of Shareholders</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Annual General Meeting of Shareholders<br /> www.novartis.com/investors/shareholder-information/annual-general-meeting</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board Regulations</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Regulations<br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis code for senior financial officers</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Code of Ethical Conduct for CEO and Senior Financial Officers<br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis in Society Integrated Report</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis in Society Integrated Report<br /> www.reporting.novartis.com</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis financial data</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis financial data<br /> www.novartis.com/investors/financial-data</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Press releases</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Press releases<br /> www.novartis.com/news/news-archive?type=media_release<br /> Email service<br /> www.novartis.com/news/stay-up-to-date</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Additional information <br />(including Novartis investor event calendar, registered office, <br />contact and email addresses, phone numbers, etc.)</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Investor Relations <br /> www.novartis.com/investors<br /></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">156</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017507"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Quiet periods</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Global Insider Policy, employees who have access to material non-public information on a regular basis are designated as Continuing Insiders and are banned from trading in Novartis securities during quiet periods. Limited exemptions for the expiry of options or warrants within a quiet period apply. Until June 14, 2022, our quarterly quiet periods commenced at the beginning of the last trading day of each calendar quarter and ended at the beginning of the first trading day after the subsequent release of the quarterly and/or annual results. Effective June 15, 2022, our quarterly quiet periods commence on the first trading day of each calendar quarter and end at the beginning of the first trading day after the subsequent release of the quarterly and/or annual results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the following quiet periods applied:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  December 30, 2021, until (and including) February 2, 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  March 31, 2022, until (and including) April 26, 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  July 1, 2022, until (and including) July 19, 2022</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  October 1, 2022, until (and including) October 25, 2022</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">157</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00510992"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.D Employees</p>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below sets forth the breakdown of the total year-end number of our full-time equivalent employees by main category of activity and geographic area for the past three years.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2022<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;003</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;740</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;358</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 825</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 599</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;525</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;678</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;078</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;781</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;028</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;853</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;856</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;513</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 932</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&#xA0;983</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&#xA0;615</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&#xA0;171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;437</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;284</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 101&#xA0;703</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2021<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;074</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;938</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;324</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 879</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 654</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;869</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;426</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 510</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 370</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;538</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;630</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;307</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;108</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;613</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 50&#xA0;821</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;927</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;570</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;812</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;696</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;090</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&#xA0;095</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;280</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&#xA0;953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;799</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;727</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 104&#xA0;323</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2020<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;978</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;954</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;554</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 636</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;942</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;405</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 504</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 928</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;524</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;066</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;628</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;043</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;506</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 52&#xA0;095</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;240</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;346</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;537</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;991</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&#xA0;233</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;214</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&#xA0;638</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;061</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;192</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 105&#xA0;794</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> relates to full time equivalent employees (FTEs) from our Operations unit, excluding the Operations units&#x2019; production and supply FTEs</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the total number of our full-time equivalent employees decreased by 2 620 compared with December 31, 2021, mainly driven by the initiative announced in April 2022 to implement a new, streamlined organizational model. For more information about this new organizational structure, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant number of our employees are represented by unions or works councils. We have not experienced any material work stoppages in recent years, and we consider our employee relations to be good.</div>
      <div id="anchorId00511847"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.E Share ownership</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2021 Executive Committee compensation&#x2014;Additional disclosures for the CEO and other Executive Committee members&#x2014;Shares, ADRs and other equity rights owned by Executive Committee members at December&#xA0;31, 2021&#x201D; and under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2021 Board compensation&#x2014;Additional disclosures&#x2014;Shares, ADRs and share options owned by Board members&#x201D; is incorporated by reference. For more information on our equity-based participation plans, see the information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;26. Equity&#x2011;based participation plans for employees,&#x201D; which is incorporated by reference.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">158</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00511868"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;7.  Major Shareholders and Related Party Transactions</p>
      <div id="anchorId00511871"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.A Major shareholders</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis shares are widely held. As of December&#xA0;31, 2022, Novartis had approximately 186 000 shareholders listed in the Share Register of Novartis, representing approximately 67.0% of issued shares. Based on the Novartis Share Register and excluding treasury shares, approximately 48.4% of the shares registered by name were held in Switzerland, and approximately 21.3% were held in the US. Approximately 15.6% of the shares registered in the Share Register were held by individual investors, while approximately 37.7% were held by legal entities (excluding 7.7% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries), and 46.7% were held by nominees, fiduciaries and the ADS depositary. Due to a change in Swiss corporate law, as of January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis (Foundation Shares) no longer carry the right to vote. As a result, in the future these Foundation Shares will be excluded from the calculation of the shares registered in the Share Register in the same way, as described above, that our treasury shares are excluded. This will impact some of the percentage holdings reported in this Item 7.A in future Form 20-F filings by Novartis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Share Register, we believe that we are not directly or indirectly owned or controlled by another corporation or government, or by any other natural or legal persons. There are no arrangements that may result in a change of control.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The tables below set forth information with respect to our major shareholders according to the Share Register as of December 31, 2022, excluding 7.7% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. The following registered shareholders (including nominees and the ADS depositary) held more than 2% of the total share capital of Novartis with the right to vote all their Novartis shares based on an exemption granted by the Board of Directors:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital beneficially owned   as of:</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br /> beneficially owned as of <br /> Dec 31, 2022</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Dec 31, 2022</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2021</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel, Switzerland</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89&#xA0;135&#xA0;960</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55&#xA0;906&#xA0;821</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;335&#xA0;879</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital held as of:</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br /> held as of <br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London, England</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&#xA0;853&#xA0;725</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London, England</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90&#xA0;962&#xA0;072</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68&#xA0;638&#xA0;910</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, Everett, MA</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 37&#xA0;227&#xA0;478</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22&#xA0;583&#xA0;699</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.1</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, SA/NV, Brussels, Belgium</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&#xA0;827&#xA0;733</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;529&#xA0;101</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.1</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to a disclosure notification filed with Novartis AG, Norges Bank (Central Bank of Norway), Oslo, Norway, held 2.3% of the share capital of Novartis AG, or  54 667 792 shares, as of December&#xA0;31, 2022, but was not registered in the Share Register as of December&#xA0;31, 2022. Provided that these shares are registered in the Share Register on the record date of the Annual General Meeting, Norges Bank will have full voting rights for all of these shares. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, BlackRock,&#xA0;Inc., New&#xA0;York, NY, held between 5% and 10%, but was registered with less than 2% of the share capital of </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">159</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG in the Share Register as of December&#xA0;31, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December&#xA0;31, 2022, no other shareholder was registered as owner of more than 2% of the registered share capital.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board of Directors may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports the Novartis goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered major shareholders as described above. Novartis has not entered into any agreement with any shareholder regarding the voting or holding of Novartis shares.</div>
      <div id="anchorId00512320"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.B Related party transactions</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;27. Transactions with related parties&#x201D; is incorporated by reference. </div>
      <div id="anchorId00512326"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.C Interests of experts and counsel</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">160</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512332"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;8.  Financial Information</p>
      <div id="anchorId00512335"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.A Consolidated statements and other financial information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&#xA0;18. Financial Statements.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Dividend policy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Subject to the dividend policy described below, our Board of Directors expects to recommend the payment of a dividend in respect of each financial year. If approved by our shareholders at the relevant annual shareholders&#x2019; meeting, the dividends will be payable shortly following such approval. Any shareholder who purchases our shares before the ex&#x2011;dividend date and holds the shares until that date shall be deemed to be entitled to receive the dividends approved at that meeting. Dividends are reflected in our financial statements in the year in which they are approved by our shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our dividend policy is to pay a growing annual dividend in Swiss francs per share. This policy is subject to our financial conditions and outlook at the time, the results of our operations, and other factors.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board will propose a dividend of CHF 3.20 per share to the shareholders for approval at the Annual General Meeting to be held on March 7, 2023. Because we pay dividends in Swiss francs, exchange rate fluctuations will affect the US dollar amounts received by holders of ADRs. For the amount of dividends we paid in the past three years, see &#x201C;Item 18. Financial Statements&#x2014;Note 18&#x2014;Equity.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Disclosure pursuant to Section&#xA0;219 of the Iran Threat Reduction&#xA0;and Syria Human Rights Act (ITRA)</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our purpose is to reimagine medicine to improve and extend people&#x2019;s lives, regardless of where they live. This includes the compliant sale of medicines and other healthcare products worldwide. To help us fulfill this mission, we have for many years maintained two representative offices located in Iran.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of October&#xA0;18, 2010, a non&#x2011;US affiliate within our Innovative Medicines Division entered into a non&#x2011;binding Memorandum of Understanding (MoU) with the Ministry of Health and Medical Education of the Islamic Republic of Iran. Pursuant to the MoU, the Iranian Ministry of Health acknowledges certain benefits that may apply to sales of certain Innovative Medicines Division medicines by third&#x2011;party distributors in Iran. These include fast&#x2011;track registration, market exclusivity, end&#x2011;user subsidies, and exemptions from customs tariffs. Novartis receives no payments from the Iranian Ministry of Health under the MoU, and the MoU creates no obligations on the part of either Novartis or the Iranian Ministry of Health.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2022, non&#x2011;US affiliates in our Innovative Medicines and Sandoz Divisions made payments to government entities in Iran related to patents, trademarks, exit fees and other transactions ordinarily incident to travel by doctors and other medical professionals resident in Iran to attend conferences or other events outside Iran. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2022, non&#x2011;US affiliates in our Innovative Medicines and Sandoz Divisions enter into agreements with hospitals, research institutes, medical associations and universities in Iran to provide grants and sponsor congresses, seminars and symposia, and with doctors and other healthcare professionals for consulting services, including participation in advisory boards and investigator services for observational (non&#x2011;interventional) studies. Some hospitals and research institutes are owned or controlled by the government of Iran, and some doctors and healthcare professionals are employed by hospitals that may be public or government&#x2011;owned.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our Innovative Medicines and Sandoz Divisions have operations in Iran, including employees, they obtain services and have other dealings incidental to their activities in that country, including paying taxes and salaries either directly or indirectly through a service provider, and obtaining office rentals, insurance, electricity, water and telecommunications services, office and similar supplies, and customs&#x2011;related services from Iranian companies that may be owned or controlled by the government of Iran. In addition, from time to time, representatives of our non-US affiliates participate in meetings with Iranian officials to discuss issues relevant to our business and the pharmaceutical industry.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-US affiliates in our Innovative Medicines and Sandoz Divisions maintain local accounts at banks that are, as of November 5, 2018, on the Specially Designated Nationals and Blocked Persons List (SDN List). These non-US affiliates make local transactions for employee payroll and local vendor payment purposes. These transactions are conducted for the purpose of facilitating the provision of medicine to Iran, in line with the humanitarian exceptions contained in Section 11 of Executive Order 13902 and other applicable sanctions legal authorities. No transactions are made with an Iranian financial institution designated on the SDN List in connection with Iran&#x2019;s support for international terrorism or proliferation of weapons of mass destruction. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">161</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId00512376"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.B Significant changes</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">162</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00512383"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;9.  The Offer and Listing</p>
      <div id="anchorId00512386"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.A Offer and listing details</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our shares are listed in Switzerland on the SIX Swiss Exchange (SIX).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">ADSs, each representing one share, have been available in the US through an ADR program since December 1996. This program was established pursuant to a deposit agreement that we entered into with JPMorgan Chase Bank, N.A., as depositary (&#x201C;Deposit Agreement&#x201D;). Our ADRs have been listed on the NYSE since May 2000 and are traded under the symbol NVS.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The depositary has informed us that as of January 25, 2023, there were 220 million ADRs outstanding, each representing one Novartis share (approximately 9% of total Novartis shares issued). On January 25, 2023, the closing price was CHF 85.30 per share on the SIX, and USD 92.81 per ADR on the NYSE.</div>
      <div id="anchorId00512394"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.B Plan of distribution</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512398"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.C Markets</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;&#x2014;Item&#xA0;9.A Offer and listing details.&#x201D;</div>
      <div id="anchorId00512404"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.D Selling shareholders</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512408"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.E Dilution</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512412"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.F Expenses of the issue</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">163</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512418"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;10.  Additional Information</p>
      <div id="anchorId00512421"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.A Share capital</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512425"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.B Memorandum and articles of association</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a non-exhaustive summary of certain provisions of our Articles of Incorporation (&#x201C;Articles&#x201D;); our Regulations of the Board, the Board Committees and the Executive Committee (&#x201C;Board Regulations&#x201D;); and Swiss law, particularly the Swiss Code of Obligations (&#x201C;Swiss CO&#x201D;), and is qualified in its entirety by reference to the Articles and the Board Regulations, which are an exhibit to this Form&#xA0;20&#x2011;F, and to Swiss law.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.1 Company purpose</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is registered in the commercial register of the canton of Basel&#x2011;Stadt, Switzerland, under number CHE&#x2011;103.867.266. Our business purpose, as stated in Article&#xA0;2 of the Articles, is to hold interests in enterprises in the area of healthcare or nutrition. We may also hold interests in enterprises in the areas of biology, chemistry, physics, information technology or related areas. We may acquire, mortgage, liquidate or sell real estate and intellectual property rights in Switzerland or abroad. In pursuing our business purpose, we strive to create sustainable value.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.2 Directors</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Articles, the Board of Directors (&#x201C;Board&#x201D;) consists of a minimum of eight and a maximum of 16 members. The members of the Board (including the Board Chair) are elected individually by the General Meeting of Shareholders (&#x201C;General Meeting&#x201D;) for a one-year term of office lasting until completion of the next Annual General Meeting of Shareholders (&#x201C;AGM&#x201D;).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)   A Board resolution requires the affirmative majority of the votes cast. According to our Board Regulations, a member of our Board (&#x201C;Director&#x201D;) may not participate in decisions and resolutions on matters that affect, or reasonably might affect, the Director&#x2019;s interests or the interests of a person close to the Director. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Compensation of the Directors is subject to the approval of the aggregate amounts of such compensation by a shareholders&#x2019; resolution under the Ordinance against Excessive Compensation in Public Companies of the Swiss Federal Council.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  The Articles prohibit the granting of loans or credits to Directors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  The Articles provide that a Director shall not serve on the Board for more than 12 years. The Board may, under certain circumstances and if deemed in the best interests of the Company, recommend exceptions to this rule to the General Meeting.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e)  Our Directors are not required to be shareholders at the time of the election by the General Meeting. However, according to our share ownership guidelines, the Board Chair is required to own a minimum of 30 000 Novartis AG shares, and other Directors are required to own at least 5 000 Novartis AG shares within five years after joining the Board, to ensure their interests are aligned with those of our shareholders.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.3 Shareholder rights</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Because Novartis AG has only one class of registered shares, the following information applies to all shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)  Under the Swiss CO, we may only pay dividends out of balance sheet profits or out of distributable reserves. In any event, under the Swiss CO, while the Board may propose that a dividend be paid, we may only pay dividends upon shareholders&#x2019; approval at a General Meeting. Furthermore, the Swiss CO requires us to accrue general legal reserves under certain circumstances so long as these reserves amount to less than 20% of our registered share capital, and Swiss law and the Articles permit us to accrue additional reserves beyond the statutory reserves. Our auditors must confirm that the dividend proposal of our Board conforms with the Swiss CO and the Articles. Our Board expects to recommend the payment of a dividend in respect of each financial year. See &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board Practices&#x2014;Capital Structure&#x2014;Limitation on transferability&#x2014;Per-share information&#x201D; and &#x201C;Item&#xA0;8.&#xA0;Financial Information&#x2014;Item&#xA0;8.A. Consolidated statements and other financial information&#x2014;Dividend policy.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Dividends are usually due and payable shortly after the shareholders have passed a resolution approving the payment. Dividends that have not been claimed within five years after the due date revert to us and are allocated to our general reserves. For information about deduction of the withholding tax or other duties from dividend payments, see &#x201C;&#x2014;Item&#xA0;10.E Taxation.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">164</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Each share is entitled to one vote at a General Meeting. Voting rights may only be exercised for shares registered with the right to vote on the record date for the applicable General Meeting. In order to do so, the shareholder must file&#xA0;a share registration form with us, setting forth the shareholder&#x2019;s name, address and citizenship (or, in the case of a legal entity, its registered office). If the shareholder has not timely registered its shares, then the shareholder may not vote at, or participate in, a General Meeting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">To vote its shares, the shareholder must also explicitly declare that it has acquired the shares in its own name and for its own account. If the shareholder refuses to make such a declaration, the shares may not be voted unless the Board recognizes such shareholder as a nominee.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Articles provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long&#x2011;term investment horizon. Furthermore, the Articles provide that no nominee shall be registered with the right to vote shares comprising more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses, and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. The same restrictions indirectly apply to ADR holders. We have in the past granted exemptions from the 2% rule for shareholders and the 0.5% rule for nominees. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">For purposes of the 2% rule for shareholders and the 0.5% rule for nominees, groups of companies and groups of shareholders acting in concert are considered to be one shareholder. These rules also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">After hearing the registered shareholder or nominee, the Board may cancel, with retroactive effect as of the date of registration, the registration of the shareholders if the registration was effected based on false information.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Registration restrictions in the Articles may only be removed upon a resolution carrying a two&#x2011;thirds majority of the votes represented at a General Meeting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Except as noted below, shareholders&#x2019; resolutions require the approval of an absolute majority of the votes present at a General Meeting. As a result, abstentions have the effect of votes against such resolutions. Some examples of shareholders&#x2019; resolutions requiring a vote by such &#x201C;absolute majority of the votes&#x201D; are: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Adoption and amendment of the Articles </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Election and removal of the Board Chair, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the management report and of the consolidated financial statements</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the financial statements of Novartis AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends, if any</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Discharge of Board and Executive Committee members from liability for matters disclosed to the General Meeting</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Decision on other matters that are reserved by law or by the Articles (e.g., advisory vote on the Compensation Report) to the General Meeting</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">According to the Articles and Swiss law, the following matters require the approval of a &#x201C;supermajority&#x201D; of at least two&#x2011;thirds of the votes present at a General Meeting: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Alteration of the purpose of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Creation of shares with increased voting powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Authorized or conditional increase of the share capital</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Restriction or cancellation of subscription rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;   Change of the registered office of Novartis&#xA0;AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Dissolution of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Our shareholders are required to annually elect all Directors (including the Board Chair), the Compensation Committee members, the external auditor and the Independent Proxy. The Articles do not provide for cumulative voting of shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">At a General Meeting, shareholders can be represented by a proxy, which must either be the shareholder&#x2019;s legal representative, another shareholder with the right to vote, or the Independent Proxy. Votes are taken either by a show of hands or by electronic voting, unless the General Meeting resolves to have a ballot or where a ballot is ordered by the chair of the meeting. ADSs, each representing one Novartis AG share and evidenced by ADRs, are issued by our depositary JPMorgan Chase Bank, N.A., New York, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share of Novartis AG in exchange for a certain number of </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">165</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;">ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the ADS depositary, holding our shares underlying the ADRs, is registered as shareholder in our share register. An ADR is not a Novartis AG share and an ADR holder is not a Novartis AG shareholder.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Deposit Agreement between our depositary, the ADR holder and us has granted certain indirect rights to vote to the ADR holders. ADR holders may not attend a General Meeting in person. ADR holders exercise their voting rights by instructing JPMorgan Chase Bank, N.A., our depositary, to exercise the voting rights attached to the registered shares underlying the ADRs. Each ADR represents one Novartis AG share. JPMorgan Chase Bank, N.A., exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder of Novartis AG. The same voting restrictions apply to ADR holders as to those holding Novartis AG shares (i.e., the right to vote up to 2% of the Novartis AG registered share capital &#x2013; unless otherwise granted an exemption by the Board &#x2013; and the disclosure requirement for nominees).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  Shareholders have the right to allocate the profit shown on our balance sheet and to distribute dividends by vote taken at the General Meeting, subject to the legal requirements described in &#x201C;Item&#xA0;10.B.3(a) Shareholder rights.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  Under the Swiss CO, any surplus arising out of a liquidation of Novartis AG (i.e., after the settlement of all claims of all creditors) would be distributed to the shareholders in proportion to the paid&#x2011;in nominal value of their shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e)  The Swiss CO limits a corporation&#x2019;s ability to hold or repurchase its own shares. We and our subsidiaries may only repurchase shares if we have sufficient freely disposable equity in the amount of the purchase price of the acquired shares. The aggregate nominal value of all Novartis AG shares held by us and our subsidiaries may not exceed 10% of our registered share capital. However, it is accepted that a Swiss corporation may repurchase its own shares beyond the statutory limit of 10% if the repurchased shares are clearly earmarked for cancellation. In addition, we are required to recognize a negative position, or if our subsidiaries acquire our shares, to create a special reserve on our balance sheet in the amount of the purchase price of the acquired shares. Repurchased shares held by us or our subsidiaries do not carry any rights to vote at a General Meeting, but are entitled to the economic benefits generally connected with the shares. The definition of subsidiaries, and therefore, treasury shares, for purposes of the above-described reserves requirement and voting restrictions, differs from the definition of subsidiaries for purposes of consolidation in our consolidated financial statements. The definition in the consolidated financial statements requires consolidation for financial reporting purposes of special purpose entities in instances where we have the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. Therefore, our consolidated financial statements include special purpose entities, mainly foundations, which do not qualify as subsidiaries subject to the reserve requirements and voting restrictions of the Swiss CO because we do not hold a majority participation in these special purpose entities. Accordingly, no reserve requirements apply to shares held by such special purpose entities, and such entities are not restricted from independently voting their shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Under the Swiss CO, we may not cancel treasury shares without the approval of a capital reduction by our shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(f)  Not applicable.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(g)  Since all of our issued and outstanding shares have been fully paid in, our shareholders are not obliged to make further contributions with respect to their shares. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(h)   See &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; and &#x201C;&#x2014;Item&#xA0;10.B.7 Change in control.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.4 Changes to shareholder rights</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO, we may not issue new shares without the prior approval of a capital increase by our shareholders. If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting by a supermajority of two&#x2011;thirds of the votes. In addition, we may not create shares with increased voting powers or place restrictions on the transfer of registered shares without the approval of a resolution adopted at a General Meeting by a supermajority of votes. In addition, see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; with regard to the Board&#x2019;s ability to cancel the registration of shares under limited circumstances.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.5 Shareholder meetings</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO and the Articles, we must hold an AGM within six months after the end of our financial year. A General Meeting may be convened by the Board or, if necessary, by the external auditor. The Board is further required to convene an extraordinary General Meeting if so resolved by a General Meeting, or if so requested by shareholders representing at least 10% of the share capital, specifying the items for the agenda and their proposals. Shareholders representing shares with an aggregate nominal value of at least CHF&#xA0;1&#xA0;000&#xA0;000 may request that an item be included in a General Meeting agenda. A General Meeting is convened by publishing a notice in the Swiss Official Gazette of Commerce  (Schweizerisches Handelsamtsblatt) at least 20&#xA0;days prior to such meeting. Shareholders may also be informed by mail. Neither the Swiss CO nor the Articles require a quorum for a General Meeting. In addition, see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising a shareholder&#x2019;s right to vote at a General Meeting.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">166</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.6 Limitations</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no limitations under the Swiss CO or our Articles on the right of non&#x2011;Swiss residents or nationals to own or vote shares other than the restrictions applicable to all shareholders. But see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising an ADR holder&#x2019;s right to vote at a shareholder meeting.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.7 Change in control</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Articles and the Board Regulations contain no provision that would have an effect of delaying, deferring or preventing a change in control of Novartis AG and that would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to the Swiss Merger Act, shareholders may pass a resolution to merge with another corporation at any time. Such a resolution would require the consent of at least two&#x2011;thirds of all votes present at the necessary General Meeting.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the Swiss Financial Market Infrastructure Act, shareholders and groups of shareholders acting in concert who acquire more than 33 1/3% of our shares would be under an obligation to make an offer to acquire all remaining Novartis AG shares. Novartis AG has neither opted out from the mandatory takeover offer obligation nor opted to increase the threshold for mandatory takeover offers in its Articles.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.8 Disclosure of shareholdings</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of our shares or purchase or sale rights relating to our shares are required to notify us and the SIX of the level of their holdings whenever such holdings reach, exceed or fall below certain thresholds &#x2013; 3%, 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3% &#x2013; of the voting rights represented by our share capital (whether exercisable or not). This also applies to anyone who has discretionary power to exercise voting rights associated with our shares. Following receipt of such notification, we are required to inform the public by publishing the information via the electronic publication platform operated by the SIX.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An additional disclosure obligation exists under the Swiss CO that requires us to disclose, once a year in the notes to the financial statements published in our Annual Report, the identity of all of our shareholders (or related groups of shareholders) who have been granted exemption entitling them to vote more than 2% of our registered share capital, as described in &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.9 Differences in the law</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See the references to Swiss law throughout this &#x201C;&#x2014;Item&#xA0;10.B Memorandum and articles of association.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.10 Changes in capital</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The requirements of the Articles regarding changes in capital are not more stringent than the requirements of Swiss law.</div>
      <div id="anchorId00512681"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.C Material contracts</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of The Medicines Company</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, we entered into an Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;) with US-based pharmaceutical company The Medicines Company. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. This merger broadens our cardiovascular portfolio by adding inclisiran, an investigational cholesterol-lowering therapy.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Divestment of Roche shares </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, we entered into a Share Repurchase Agreement with Roche under which we agreed to sell 53.3 million (approximately 33%) of Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. The transaction was approved by the shareholders of Roche on November&#xA0;26,&#xA0;2021, and closed on December 6, 2021.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">167</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512696"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.D Exchange controls</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no Swiss governmental laws, decrees or regulations that affect &#x2013; in a manner material to Novartis AG &#x2013; the export or import of capital, including the availability of cash and cash equivalents for use by Novartis or any foreign exchange controls that affect the remittance of dividends, interest or other payments to non&#x2011;residents or non&#x2011;citizens of Switzerland who hold Novartis AG securities. </div>
      <div id="anchorId00512703"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.E Taxation</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The taxation discussion set forth below is intended only as a descriptive summary and does not purport to be a complete analysis or listing of all potential tax effects relevant to the ownership or disposition of our shares or ADRs. The statements of US and Swiss tax laws set forth below are based on the laws and regulations in force as of the date of this 20&#x2011;F &#x2013; including the current Convention Between the US and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, entered into force on December&#xA0;19, 1997 (&#x201C;the Treaty&#x201D;); the US Internal Revenue Code of 1986, as amended (&#x201C;the Code&#x201D;); Treasury regulations; rulings; judicial decisions; and administrative pronouncements &#x2013; and may be subject to any changes in US and Swiss law, and in any double taxation convention or treaty between the US and Switzerland occurring after that date, which changes may have retroactive effect.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Swiss taxation</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Swiss residents</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <i>Withholding Tax on dividends and distributions.</i>  Dividends that we pay and similar cash or in&#x2011;kind distributions that we may make to a holder of shares or ADRs (including distributions of liquidation proceeds in excess of the nominal value, stock dividends and, under certain circumstances, proceeds from repurchases of shares by us in excess of the nominal value) are generally subject to a Swiss federal withholding tax (&#x201C;the Withholding Tax&#x201D;) at a current rate of 35%. Under certain circumstances, distributions out of capital contribution reserves made by shareholders after December&#xA0;31, 1996, are exempt from the Withholding Tax. We are required to withhold Withholding Tax due from the gross distribution and to pay the Withholding Tax to the Swiss Federal Tax Administration. The Withholding Tax is refundable in full to Swiss tax residents who are the beneficial owners of the taxable distribution at the time it is resolved and duly report the gross distribution received on their personal tax return or in their financial statements for tax purposes, as the case may be.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Income tax on dividends.</i>  A Swiss tax resident who receives dividends and similar distributions (including stock dividends and liquidation surplus) on shares or ADRs is required to include such amounts in the shareholder&#x2019;s personal income tax return. However, distributions out of qualified capital contribution reserves are not subject to income tax. A corporate shareholder may claim substantial relief from taxation of dividends and similar distributions received if the shares held represent a fair market value of at least CHF&#xA0;1&#xA0;million.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Capital gains tax upon disposal of shares.</i>  Under current Swiss tax law, the gain realized on shares held by a Swiss resident who holds shares or ADRs as part of his private property is generally not subject to any federal, cantonal or municipal income taxation on gains realized on the sale or other disposal of shares or ADRs. However, gains realized upon a repurchase of shares by us may be characterized as taxable dividend income if certain conditions are met. Book gains realized on shares or ADRs held by a Swiss corporate entity or by a Swiss resident individual as part of the shareholder&#x2019;s business property are, in general, included in the taxable income of such person. However, the Federal Law on the Direct Federal Tax of December&#xA0;14, 1990, and several cantonal laws on direct cantonal taxes provide for exceptions for Swiss corporate entities holding more than 10% of our voting stock for more than one year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Residents of other countries</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Recipients of dividends and similar distributions on our shares who are neither residents of Switzerland for tax purposes nor holding shares as part of a business conducted through a permanent establishment situated in Switzerland (&#x201C;Non&#x2011;Resident Holders&#x201D;) are not subject to Swiss income taxes in respect of such distributions. Moreover, gains realized by such recipients upon the disposal of shares are not subject to Swiss income taxes.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non&#x2011;Resident Holders of shares are, however, subject to the Withholding Tax on dividends and similar distributions mentioned above and, under certain circumstances, to the Stamp Duty described below. Such Non&#x2011;Resident Holders may be entitled to a partial refund of the Withholding Tax if the country in which they reside has entered into a bilateral treaty for the avoidance of double taxation with Switzerland. Non&#x2011;Resident Holders should be aware that the procedures for claiming treaty refunds (and the time frame required for obtaining a refund) may differ from country to country. Non&#x2011;Resident Holders should consult their own tax advisors regarding receipt, ownership, purchase, sale or other dispositions of shares or ADRs, and the procedures for claiming a refund of the Withholding Tax.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">168</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of January&#xA0;1, 2023, Switzerland has entered into bilateral treaties for the avoidance of double taxation with respect to income taxes with the following countries, whereby a part of the above&#x2011;mentioned Withholding Tax may be refunded (subject to the limitations set forth in such treaties):</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="column-count: 4;column-gap: 10px;padding-top:10px;">
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Albania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Algeria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Argentina</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Armenia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Australia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Austria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Azerbaijan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bahrain</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bangladesh</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belarus</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belgium</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Brazil</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bulgaria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Canada</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chile</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">China</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Colombia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Croatia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cyprus</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Czech Republic</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Denmark</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ecuador</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Egypt</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Estonia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Finland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">France</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Georgia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Germany</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ghana</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Greece</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hong Kong</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hungary</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iceland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">India</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Indonesia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iran</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Ireland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Israel</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Italy</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ivory Coast</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Jamaica</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Japan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kazakhstan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Korea</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(South Korea)</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kosovo</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kuwait</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kyrgyzstan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Latvia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liechtenstein</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lithuania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Luxembourg</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malaysia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malta</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mexico</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Moldova</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mongolia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Montenegro</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Morocco</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Netherlands</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">New Zealand</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">North Macedonia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Norway</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Oman</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pakistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Peru</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Philippines</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Poland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Portugal</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Qatar</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Romania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Russia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Saudi Arabia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Serbia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Singapore</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovak Republic</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovenia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">South Africa</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Spain</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sri Lanka</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sweden</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taiwan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tajikistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Thailand</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trinidad and Tobago</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tunisia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkey</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkmenistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ukraine</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Arab Emirates</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Kingdom</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United States of America</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uruguay</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uzbekistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Venezuela</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vietnam </div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Zambia</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Tax treaty negotiations are underway, or have been conducted, with Angola, Bosnia and Herzegovina, Cameroon, Costa Rica, Ethiopia, Jordan, Kenya, Libya, Nigeria, Rwanda, Senegal, Syria and Zimbabwe. Tax treaty negotiations between Switzerland and some of the countries listed in the immediately preceding sentence have been ongoing for an extended period of time, and we are not certain when or if such negotiations will be completed, and when or if the corresponding treaties will come into effect.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">A Non&#x2011;Resident Holder of shares or ADRs will not be liable for any Swiss taxes other than the Withholding Tax described above and, if the transfer occurs through or with a Swiss bank or other Swiss securities dealer, the Stamp Duty described below. If, however, the shares or ADRs of Non&#x2011;Resident Holders can be attributed to a permanent establishment or a fixed place of business maintained by such person within Switzerland during the relevant tax year, the shares or ADRs may be subject to Swiss income taxes in respect of income and gains realized on the shares or ADRs, and such person may qualify for a full refund of the Withholding Tax based on Swiss tax law.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Residents of the US.</i>  A Non&#x2011;Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 15% of the dividend, provided that such holder (i)&#xA0;qualifies for benefits under the Treaty, (ii)&#xA0;is not a company (or, if it is a company, such company directly holds less than 10% of our voting stock), and (iii)&#xA0;does not conduct business through a permanent establishment or fixed base in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a refund of the amount of the Withholding Tax in excess of the 15% Treaty rate. A Non&#x2011;Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 5% of the dividend, provided that such holder (i)&#xA0;is a company, (ii)&#xA0;qualifies for benefits under the Treaty, (iii)&#xA0;holds directly at least 10% of our voting stock, and (iv)&#xA0;does not conduct business through a permanent establishment or fixed place of business in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a refund of the amount of the Withholding Tax in excess of the 5% Treaty rate. Claims for refunds must be filed on Swiss Tax Form&#xA0;82 (82C for corporations; 82I for individuals; 82E for other entities), which may be obtained from any Swiss Consulate General in the US or from the Federal Tax Administration of Switzerland at the address below, together with an instruction form. Four copies of the form must be duly completed, signed before a notary public of the US, and sent to the Federal Tax Administration of Switzerland, Eigerstrasse 65, CH&#x2011;3003 Bern, Switzerland. The form must be accompanied by suitable evidence of deduction of Swiss tax withheld at source, such as certificates of deduction, signed bank vouchers or credit slips. The form may be filed on or after July&#xA0;1 or January&#xA0;1 following the date the dividend was payable, but no later than December&#xA0;31 of the third year following the calendar year in which the dividend became payable. For US resident holders of ADRs, JPMorgan Chase Bank, N.A., as depositary, will comply with these Swiss </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">169</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">procedures on behalf of the holders, and will remit the net amount to the holders.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Stamp Duty upon transfer of securities.</i>  The sale of shares, whether by Swiss residents or Non&#x2011;Resident Holders, may be subject to federal securities transfer Stamp Duty of 0.15%, calculated on the sale proceeds, if the sale occurs through or with a Swiss bank or other Swiss securities dealer, as defined in the Swiss Federal Stamp Duty Act. The Stamp Duty has to be paid by the securities dealer and may be charged to the parties in a taxable transaction who are not securities dealers. Stamp Duty may also be due if a sale of shares occurs with or through a non&#x2011;Swiss bank or securities dealer, provided that (i)&#xA0;such bank or dealer is a member of the SIX, and (ii)&#xA0;the sale takes place on the SIX. In addition to this Stamp Duty, the sale of shares by or through a member of the SIX may be subject to a minor stock exchange levy.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">US federal income taxation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a general discussion of the material US federal income tax consequences of the ownership and disposition of our shares or ADRs that may be relevant to you if you are a US Holder (as defined below). Because this discussion does not consider any specific circumstances of any particular holder of our shares or ADRs, persons who are subject to US taxation are strongly urged to consult their own tax advisors as to the overall US federal, state and local tax consequences, as well as to the overall Swiss and other foreign tax consequences, of the ownership and disposition of our shares or ADRs. In particular, additional or different rules may apply to US expatriates; banks and other financial institutions; regulated investment companies; traders in securities who elect to apply a mark&#x2011;to&#x2011;market method of accounting; dealers in securities or currencies; tax&#x2011;exempt entities; insurance companies; broker&#x2011;dealers; investors liable for alternative minimum tax; investors that hold shares or ADRs as part of a straddle, hedging or conversion transaction; holders whose functional currency is not the US dollar; partnerships or other pass-through entities; persons who acquired our shares pursuant to the exercise of employee stock options or otherwise as compensation; and persons who hold, directly, indirectly or by attribution, 10% or more of our outstanding shares. This discussion generally applies only to US Holders who hold the shares or ADRs as a capital asset (generally, for investment purposes), and whose functional currency is the US dollar. Investors are urged to consult their own tax advisors concerning whether they are eligible for benefits under the Treaty.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of this discussion, a US Holder is a beneficial owner of our shares or ADRs who is (i)&#xA0;an individual who is a citizen or resident of the US for US federal income tax purposes; (ii)&#xA0;a corporation (or other entity taxable as a corporation for US federal income tax purposes) created or organized in or under the laws of the US or a state thereof or the District of Columbia; (iii)&#xA0;an estate the income of which is subject to US federal income taxation regardless of its source; or (iv)&#xA0;a trust (i)&#xA0;subject to the primary supervision of a US court and the control of one or more US persons, or (ii)&#xA0;that has a valid election in place to be treated as a US person. If a partnership (or other entity treated as a partnership for US federal income tax purposes) holds shares or ADRs, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. Partners in a partnership that holds shares or ADRs are urged to consult their own tax advisor regarding the specific tax consequences of the owning and disposing of such shares or ADRs by the partnership.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For US federal income tax purposes, a US Holder of ADRs generally will be treated as the beneficial owner of our shares represented by the ADRs. However, see the discussion below under &#x201C;&#x2014;Dividends&#x201D; regarding certain statements made by the US Treasury concerning depositary arrangements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This discussion assumes that each obligation in the Deposit Agreement and any related agreement will be performed in accordance with its terms.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Dividends.</i>  US Holders will be required to include in gross income, as an item of ordinary income, the full amount (without reduction for any Withholding Tax) of the dividend paid with respect to our shares or ADRs at the time that such dividend is received by the US Holder, in the case of shares, or by the depositary, in the case of ADRs. For this purpose, a &#x201C;dividend&#x201D; will include any distribution paid by us with respect to our shares or ADRs (other than certain pro rata distributions of our capital stock) paid out of our current or accumulated earnings and profits, as determined under US federal income tax principles. To the extent the amount of a distribution by us exceeds our current and accumulated earnings and profits, such excess will first be treated as a tax&#x2011;free return of capital to the extent of a US Holder&#x2019;s tax basis in the shares or ADRs (with a corresponding reduction in such tax basis), and thereafter will be treated as capital gain, which will be long&#x2011;term capital gain if the US Holder held our shares or ADRs for more than one year. Under the Code, dividend payments by us on the shares or ADRs are not eligible for the dividends received deduction generally allowed to corporate shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Dividend income in respect of our shares or ADRs will constitute income from sources outside the US for US foreign tax credit purposes. Subject to the limitations and conditions provided in the Code, US Holders generally may claim as a credit against their US federal income tax liability, any Withholding Tax withheld from a dividend. The rules governing the foreign tax credit are complex. Each US Holder is urged to consult its own tax advisor concerning whether, and to what extent, a foreign tax credit will be available with respect to dividends received from us. Alternatively, a US Holder may claim the Withholding Tax as a deduction for the taxable year within which the Withholding Tax is paid or accrued, provided a deduction is claimed for all of the foreign income taxes the US Holder pays or accrues in the particular year. A deduction does not reduce US tax on a dollar&#x2011;for&#x2011;dollar basis like a tax credit. The deduction, however, is not subject to the limitations applicable to foreign tax credits, but may be subject to other limitations, and each US Holder is urged to consult its own tax advisor.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The US Treasury has expressed concern that parties to whom ADRs are released may be taking actions </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">170</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">inconsistent with the claiming of foreign tax credits for US Holders of ADRs. Accordingly, the summary above of the creditability of the Withholding Tax could be affected by future actions that may be taken by the US Treasury.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In general, a US Holder will be required to determine the amount of any dividend paid in Swiss francs, including the amount of any Withholding Tax imposed thereon, by translating the Swiss francs into US dollars at the spot rate on the date the dividend is actually or constructively received by a US Holder, in the case of shares, or by the depositary, in the case of ADRs, regardless of whether the Swiss francs are in fact converted into US dollars. If a US Holder converts the Swiss francs so received into US dollars on the date of receipt, the US Holder generally should not recognize foreign currency gain or loss on such conversion. If a US Holder does not convert the Swiss francs so received into US dollars on the date of receipt, the US Holder will have a tax basis in the Swiss francs equal to the US dollar value on such date. Any foreign currency gain or loss that a US Holder recognizes on a subsequent conversion or other disposition of the Swiss francs generally will be treated as US source ordinary income or loss.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a non&#x2011;corporate US Holder, the US dollar amount of any dividends paid that constitute qualified dividend income generally will be taxable at a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds), provided that the US Holder meets certain holding period and other requirements. In addition, the dividends could be subject to a 3.8% net investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. We currently believe that dividends paid with respect to our shares and ADRs will constitute qualified dividend income for US federal income tax purposes, provided that the US Holder meets certain holding period and other requirements. US Holders of shares or ADRs are urged to consult their own tax advisors regarding the availability to them of the reduced dividend rate in light of their own particular situation and the computations of their foreign tax credit limitation with respect to any qualified dividends paid to them, as applicable.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Sale or other taxable disposition.</i>  Upon a sale or other taxable disposition of shares or ADRs, US Holders generally will recognize capital gain or loss in an amount equal to the difference between the US dollar value of the amount realized on the disposition and the US Holder&#x2019;s tax basis (determined in US dollars) in the shares or ADRs. This capital gain or loss generally will be US source gain or loss and will be treated as long&#x2011;term capital gain or loss if the holding period in the shares or ADRs exceeds one year. In the case of a non&#x2011;corporate US Holder, any long-term capital gain generally will be subject to US federal income tax at preferential rates, with a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds). In addition, the gains could be subject to a 3.8% investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. The deductibility of capital losses is subject to significant limitations under the Code. Deposits or withdrawals of our shares by US Holders in exchanges for ADRs will not result in the realization of gain or loss for US federal income tax purposes.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>US information reporting and backup withholding.</i>  Dividend payments with respect to shares or ADRs and proceeds from the sale, exchange or other disposition of shares or ADRs received in the United States or through US&#x2011;related financial intermediaries may be subject to information reporting to the US Internal Revenue Service (IRS) and possible US backup withholding. Certain exempt recipients (such as corporations) are not subject to these information reporting and backup withholding requirements. Backup withholding will not apply to a US Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. Any US Holders required to establish their exempt status generally must provide a properly executed IRS Form&#xA0;W&#x2011;9 (Request for Taxpayer Identification Number and Certification). Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a US Holder&#x2019;s US federal income tax liability, and a US Holder may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information.</div>
      <div id="anchorId00513015"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.F Dividends and paying agents</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513019"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.G Statement by experts</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">171</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513025"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.H Documents on display</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any statement in this Form&#xA0;20&#x2011;F about any of our contracts or other documents is not necessarily complete. If the contract or document is filed as an exhibit to the Form&#xA0;20&#x2011;F, the contract or document is deemed to modify the description contained in this Form&#xA0;20&#x2011;F. You must review the exhibits themselves for a complete description of the contract or document.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are required to file or furnish reports and other information with the SEC under the Exchange Act and regulations under that act. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the form and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#xA0;16 of the Exchange Act.</div>
      <div id="anchorId00513039"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.I Subsidiary information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">172</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513045"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The major financial risks facing the Group are managed centrally by Group Treasury, which has established processes and procedures to identify, aggregate and manage our financial risk exposure. The Group Treasury function is included in management&#x2019;s internal control assessment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the effects of currency fluctuations and how we manage currency risk, see &#x201C;Item&#xA0;5. Operating and Financial Review and Prospects&#x2014;Item&#xA0;5.B Liquidity and capital resources.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;29. Financial instruments&#x2014;additional disclosures&#x201D; is incorporated by reference.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">173</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513064"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;12.  Description of Securities Other Than Equity Securities</p>
      <div id="anchorId00513067"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.A Debt securities</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513071"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.B Warrants and rights</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513075"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.C Other securities</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513079"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.D American Depositary Shares</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by ADR holders</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Deposit Agreement with the ADS depositary, JPMorgan Chase Bank, N.A. (JPMorgan), holders of our ADRs may have to pay to JPMorgan, either directly or indirectly, fees or charges up to the amounts set forth below:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Depositary actions</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Associated fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depositing or substituting <br />underlying shares</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of shares surrendered, and issuance of ADRs in exchange, <br /> including surrenders and issuances in respect of:<br /> &#x2014; Share distributions<br /> &#x2014; Stock split<br /> &#x2014; Rights<br /> &#x2014; Merger<br /> &#x2014; Exchange of shares or any other transaction or event or other distribution <br /> affecting the ADSs or the deposited shares</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof) <br /> evidenced by the new <br /> ADRs delivered<br /><br /><br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withdrawing <br />underlying shares</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of ADRs surrendered for withdrawal of deposited shares<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof) <br /> evidenced by the ADRs <br /> surrendered</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling or <br />exercising rights</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Distribution or sale of shares, the fee being in an amount equal to the fee <br /> for the execution and delivery of ADRs that would have been charged <br /> as a result of the deposit of such shares</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof)<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transferring, <br />splitting or <br />grouping receipts</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transfers, combining or grouping of depositary receipts<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 1.50 per ADR<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expenses of the <br />depositary</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses incurred on behalf of holders in connection with:<br /> &#x2014; Compliance with foreign exchange control regulations or any law or <br /> regulation relating to foreign investment<br /> &#x2014; The depositary&#x2019;s or its custodian&#x2019;s compliance with applicable law, <br /> rule or regulation<br /> &#x2014; Stock transfer or other taxes and other governmental charges<br /> &#x2014; Cable, telex and facsimile transmission and delivery<br /> &#x2014; Expenses of the depositary in connection with the conversion of foreign <br /> currency into US dollars (which are paid out of such foreign currency)<br /> &#x2014; Any other charge payable by any of the depositary or its agents</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses payable at the sole <br /> discretion of the depositary <br /> by billing holders or by <br /> deducting charges from one <br /> or more cash dividends or <br /> other cash distributions<br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advance tax relief</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Tax relief/reclamation process for qualified holders<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> A depositary service charge <br /> of USD 0.008 per ADS</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">174</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by the depositary to the issuer</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pursuant to an agreement effective as of May&#xA0;11, 2017 (&#x201C;the Agreement&#x201D;), JPMorgan, as our ADS depositary, has agreed to make an annual contribution payment to Novartis at the end of each 12-month period beginning on the effective date of the Agreement and on each subsequent anniversary of the effective date of the Agreement (each such 12-month period is a &#x201C;Contract Year&#x201D;). This annual contribution payment will equal: (a)(1) USD 1.7&#xA0;million less (a)(2) the custody costs, fees and expenses (including, without limitation, any central securities depository fees, charges and expenses) incurred during the applicable Contract Year (the items in (a)(2) collectively are the &#x201C;Custody Costs&#x201D;) plus (b)&#xA0;70% of the gross issuance and cancellation fees collected by JPMorgan under the Deposit Agreement during such Contract Year minus (c)&#xA0;that portion (if any) of JPMorgan&#x2019;s legal fees, charges and out-of-pocket expenses in excess of USD 50000 for such Contract Year. To the extent that the Custody Costs for a Contract Year exceed USD 1.7&#xA0;million, these costs would be capped at USD 1.7&#xA0;million.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">JPMorgan has further agreed to waive the USD 0.05 per ADS issuance fees that would normally be owed by Novartis in connection with our deposits of shares as part of our employee stock ownership and employee participation plans. Novartis is responsible for reimbursing JPMorgan for all taxes and governmental charges required to have been withheld and/or paid, and not so withheld and/or paid, arising from such waived fees.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">175</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513273"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART II</p>
      <div id="anchorId00513275"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">176</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513282"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">177</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00610980"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;15.  Controls and Procedures</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)   Novartis AG&#x2019;s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule&#xA0;13a-15(e)) as of the end of the period covered by this Annual Report, have concluded that, as of such date, our disclosure controls and procedures were effective.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Report of Novartis Management on Internal Control Over Financial Reporting: The Board of Directors and management of the Group are responsible for establishing and maintaining adequate internal control over financial reporting. The Group&#x2019;s internal control over financial reporting was designed to provide reasonable assurance to the Group&#x2019;s management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published consolidated financial statements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, even those internal controls over financial reporting determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Group management assessed the effectiveness of the Group&#x2019;s internal control over financial reporting as of December&#xA0;31, 2022. In making this assessment, it used the criteria established in <i>Internal Control&#x2014;Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment, management concluded that, as of December&#xA0;31, 2022, the Group&#x2019;s internal control over financial reporting is effective based on those criteria.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">KPMG AG, Switzerland, an independent registered public accounting firm, has issued an unqualified opinion on the effectiveness of the Group&#x2019;s internal control over financial reporting, which is included in this Annual Report under &#x201C;Item&#xA0;18. Financial Statements&#x2014;Report of independent registered public accounting firm.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  See the report of KPMG AG, an independent registered public accounting firm, included under &#x201C;Item&#xA0;18. Financial Statements&#x2014;Report of independent registered public accounting firm.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  There were no changes to our internal control over financial reporting that occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">178</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710986"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16A.  Audit Committee Financial Expert</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Audit and Compliance Committee has determined that Elizabeth Doherty and Ana de Pro Gonzalo possess specific accounting and financial management expertise, and that they are Audit Committee Financial Experts as defined by the SEC. The Board of Directors has also determined that Elizabeth Doherty and Ana de Pro Gonzalo are &#x201C;independent&#x201D; in accordance with the applicable requirements of Rule&#xA0;10A&#x2011;3 of the Exchange Act, and that other members of the Audit and Compliance Committee have sufficient experience and ability in finance and compliance matters to enable them to adequately discharge their responsibilities.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">179</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710995"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16B.  Code of Ethics</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to our Code of Ethics and Professional Practices Policy, which are applicable to all of our employees, we have adopted Ethical Conduct Requirements that impose additional obligations on our principal executive officer, principal financial officer, principal accounting officer, and persons performing similar functions. This document is accessible on our internet website at:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">https://www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">180</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711004"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16C.  Principal Accountant Fees and Services</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Auditors&#x201D; is incorporated by reference. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">181</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711015"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16D.  Exemptions from the Listing Standards for Audit Committees</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">182</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711022"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />2022</div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br /> Total number of <br /> shares purchased<br /> (a)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br /> Average price <br /> paid per share <br /> in USD<br /> (b)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total number <br /> of shares<br /> purchased <br /> as part of <br /> publicly <br /> announced <br /> plans or <br /> programs<br /> (c)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br /> approximate <br /> value of <br /> shares that <br /> may yet be <br /> purchased <br /> under the <br /> plans or <br /> programs <br /> (CHF millions)<br /> (d)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br /> approximate <br /> value of <br /> shares that <br /> may yet be <br /> purchased <br /> under the <br /> plans or <br /> programs <br /> (USD millions)<br /> (e)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jan. 1-31</div>
            </td>
            <td align="right" style=";width:8%;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;746&#xA0;816</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.76</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;773&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;831</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;405</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Feb. 1-28</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;160&#xA0;538</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;594</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mar. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;494&#xA0;338</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.43</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;470&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;451</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Apr. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;534&#xA0;769</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90.61</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;305</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;756</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">May 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;521&#xA0;350</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.04</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;399</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;996</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jun. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;524&#xA0;101</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.79</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;535</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;164</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jul. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;525&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;670</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aug. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;045&#xA0;776</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.91</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;775</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;098</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sep. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;035&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.65</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;922</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;172</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oct. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;524&#xA0;526</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;113</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;118</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nov. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;021&#xA0;724</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;216</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;675</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dec. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;520&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;324</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;999</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 127&#xA0;654&#xA0;460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 85.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 126&#xA0;243&#xA0;500</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Column (a) shows shares repurchased on the SIX Swiss Exchange second trading line plus shares we purchased from employees who had obtained the shares through a Novartis Employee Ownership Plan. See "Item 18. Financial Statements - Note 26 Equity-based participation plans for employees."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Column (c) shows shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2021 AGM and under the additional CHF 10 billion share buyback authority approved at the 2022 AGM for transactions in 2022. See "Item 6. Directors, Senior Management and Employees - Item 6C. Board Practices - Our capital structure - Changes in capital."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Column (e) shows the Swiss franc amount from column (d) converted into US dollars as of the month-end, using the Swiss franc/US dollar  exchange rate at the applicable month-end</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">183</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711707"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16F.  Change in Registrant&#x2019;s Certifying Accountant</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">184</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId00711715"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16G.  Corporate Governance</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is subject to and compliant with the laws and regulations of Switzerland (in particular, Swiss company and securities laws, SIX Swiss Exchange rules and the Swiss Code of Best Practice for Corporate Governance) and the securities laws of the United States, including New York Stock Exchange (NYSE) rules, as applicable to foreign private issuers of securities. The following summarizes some significant ways in which our corporate governance practices differ from those followed by domestic listed US companies under the listing standards of the NYSE:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Novartis AG shareholders do not receive written reports directly from Board committees.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  External auditors are appointed by shareholders at the Annual General Meeting of Shareholders (AGM), as opposed to being appointed by the Audit and Compliance Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  While shareholders cannot vote on all equity compensation plans, they are entitled to hold separate, yearly binding votes on Board and Executive Committee compensation.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Board has set up a separate Risk Committee that oversees the risk management system and processes, as opposed to delegating this responsibility to the Audit and Compliance Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The full Board is responsible for overseeing the performance evaluation of the Board and Executive Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The full Board is responsible for setting objectives relevant to the CEO&#x2019;s compensation and for evaluating his performance.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">185</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711748"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16H.  Mine Safety Disclosure</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">186</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00711756"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16I.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">187</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00711764"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART III</p>
      <div id="anchorId00711766"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;17.  Financial Statements</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See response to &#x201C;Item&#xA0;18. Financial Statements.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">188</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711774"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;18.  Financial Statements</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following financial statements are filed as part of this Annual Report.</div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001511154">Consolidated income statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001511723">Consolidated statements of comprehensive income</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001512179">Consolidated balance sheets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001513028">Consolidated statements of changes in equity</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001515657">Consolidated statements of cash flows</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001516788">Notes to the Novartis Group&#xA0;consolidated&#xA0;financial statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001516794">1. Significant accounting policies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001517458">2. Significant transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001517705">3. Segmentation of key figures 2022, 2021 and 2020</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530159">4. Associated companies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530632">5. Interest expense and&#xA0;other&#xA0;financial&#xA0;income&#xA0;and&#xA0;expense</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530884">6. Income taxes</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001531581">7. Earnings per share</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001531800">8. Changes in consolidated statements of&#xA0;comprehensive income</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001533452">9. Property, plant and equipment</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001534980">10. Right-of-use assets and lease liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001535930">11. Goodwill and intangible assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001538419">12. Deferred tax assets and liabilities </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001540678">13. Financial and other non-current assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001540931">14. Inventories</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541112">15. Trade receivables</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541662">16. Marketable securities, commodities, time&#xA0;deposits, derivative financial instruments, and&#xA0;cash and cash equivalents</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541818">17. Other current assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541932">18. Equity</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001543827">19. Non-current financial debt</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001545529">20. Provisions and other non-current liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001546397">21. Current financial debt and&#xA0;derivative&#xA0;financial&#xA0;instruments</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001546573">22. Provisions and other current liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001547223">23. Details to the consolidated statements of cash flows</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001549327">24. Acquisitions of businesses</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001549711">25. Post-employment benefits for employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001552874">26. Equity-based participation plans for employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001553971">27. Transactions with related parties</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001554416">28. Commitments and contingent liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001554566">29. Financial instruments&#xA0;&#x2013;&#xA0;additional disclosures</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001561740">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001561775">31. Principal Group subsidiaries and&#xA0;associated&#xA0;companies </a>
      </div>
      <div>
        <div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
            <a style="text-decoration: none;" href="#anchorAudit">Report of Independent Registered Public Accounting Firm &#x2013; KPMG AG </a>(PCAOB ID <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorFirmId">3240</ix:nonNumeric>)   </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
            <a style="text-decoration: none;" href="#anchorAudit2">Report of Independent Registered Public Accounting Firm &#x2013; PricewaterhouseCoopers AG </a>  (PCAOB ID <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorFirmId">1358</ix:nonNumeric>)   </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">191</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001810985"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;19.  Exhibits</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.1   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/0001114448/000110465921094707/tm2122611d1_ex4-1.htm">Articles of Incorporation of Novartis AG, as amended March 2, 2021 (English translation) (incorporated by reference to Exhibit&#xA0;4.1 to Novartis AG&#x2019;s registration statement on Form&#xA0;S-8 (File No.&#xA0;333-258081) as filed with the SEC on July 22, 2021).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.2   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036821000006/a21012620f-ex1_2.htm">Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG, effective January 1, 2021 (incorporated by reference to Exhibit 1.2 to Novartis AG&#x2019;s Annual Report on Form 20-F (File No. 001-15024) as filed with the SEC on January 26, 2021).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.1   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">Form of Second Amended and Restated Deposit Agreement among Novartis AG, JPMorgan Chase Bank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Receipts issued thereunder (incor</a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">porated by reference to Exhibit&#xA0;99.A to the Registration Statement on Form&#xA0;F-6 (File No.&#xA0;333-198623) as filed with the SEC on December 16, 2022). </a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.2   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">Form of American Depositary Receipt (incorporated by reference to Exhibit&#xA0;99.A to the Registration State</a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">ment on Form&#xA0;F-6 (File No.&#xA0;333-198623) as filed with the SEC on December 16, 2022).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.3   The total amount of long-term debt securities authorized under any instrument does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. We hereby agree to furnish to the SEC, upon its request, a copy of any instrument defining the rights of holders of long-term debt of the Company or of its subsidiaries for which consolidated or unconsolidated financial statements are required to be filed.</span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.4   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036823000006/a23020120f-ex2_4.htm">Description of Securities registered under Section 12 of the Exchange Act.*</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 8.1   <a style="-sec-extract:exhibit" href="#anchorNote31">For a list of all of our principal Group subsidiaries and associated companies, see &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;31. Principal Group subsidiaries and associated companies.&#x201D;</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.1   <a style="-sec-extract:exhibit" href="a23020120f-ex12_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.2   <a style="-sec-extract:exhibit" href="a23020120f-ex12_2.htm">Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.1   <a style="-sec-extract:exhibit" href="a23020120f-ex13_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, </a><a style="-sec-extract:exhibit" href="a23020120f-ex13_1.htm">as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.2   <a style="-sec-extract:exhibit" href="a23020120f-ex13_2.htm">Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 15.1   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036823000006/a23020120f-ex15_1.htm">Consent of KPMG AG.*</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 15.2   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036823000006/a23020120f-ex15_2.htm">Consent of PricewaterhouseCoopers AG.*</a></span>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">190</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.INS   XBRL Instance Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.SCH   XBRL Taxonomy Extension Schema Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.DEF   XBRL Taxonomy Extension Definition Linkbase Document</span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.LAB   XBRL Taxonomy Extension Label Linkbase Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document</span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit&#xA0;101).</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">* Previously filed with the Annual Report on Form 20-F for the year ended December 31, 2022 as filed with the SEC on February 1, 2023.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">191</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00810980"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">SIGNATURES</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The registrant hereby certifies that it meets all of the requirements for filing on Form&#xA0;20-F/A and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="margin-left:380px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis AG</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
      <div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:  /s/ Harry Kirsch</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Harry Kirsch</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Financial Officer of Novartis</i></div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
      <div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:  /s/ Karen Hale</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Karen Hale</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Legal Officer of Novartis</i></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Date: May&#xA0;15, 2023</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">192</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div>
        <div>
          <div id="anchorId001511150"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Novartis Group consolidated&#xA0;financial&#xA0;statements</p>
          <div id="anchorId001511154"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated income statements</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 486</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 121</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">36 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">34 777</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 253</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 197</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 996</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 980</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 701</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 190</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 197</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 152</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.19</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.71</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.55</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.63</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-1</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div id="anchorId001511723"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of comprehensive income</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Items that are or may be recycled into the consolidated income statement</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Novartis share of other comprehensive income recognized by associated companies, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Net investment hedge, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Currency translation effects, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">450</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 762</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 194</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items that are or may be recycled</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">359</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 500</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 937</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Items that will never be recycled into the consolidated income statement</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Actuarial (losses)/gains from defined benefit plans, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">103</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Fair value adjustments on equity securities, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items that will never be recycled</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">485</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 111</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 521</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 401</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 116</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">21 528</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">11 403</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-2</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001512179"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated balance sheets</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(At December 31, 2022 and 2021) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current assets</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Goodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Goodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 739</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction id="fact_188392" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 743</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 411</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 036</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 110</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 210</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">80 543</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">86 077</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">7 175</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">6 666</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax receivables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTaxAssetsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">268</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTaxAssetsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">278</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 413</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15 922</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 471</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 440</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">36 910</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">45 718</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reserves</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherReserves" decimals="-6" scale="6" format="ixt:numdotdecimal">58 544</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherReserves" decimals="-6" scale="6" format="ixt:numdotdecimal">66 802</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity attributable to Novartis AG shareholders</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:EquityAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">59 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:EquityAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">67 655</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 686</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction id="fact_188393" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 070</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 906</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 172</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">29 374</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">33 765</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTaxLiabilitiesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">2 533</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTaxLiabilitiesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">2 415</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 670</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">28 656</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">30 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">58 030</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">63 973</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:EquityAndLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:EquityAndLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="8" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="8" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-3</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001513028"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:10px;">
                  <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="center" colspan="3" style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Reserves</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td colspan="3" style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
              </tr>
              <tr>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
              </tr>
              <tr>
                <td style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td colspan="3" style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br />
                    <br /> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Share<br /> capital</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Treasury<br /> shares</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Retained<br /> earnings</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Total value<br /> adjustments</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> attributable <br /> to Novartis <br /> shareholders</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br /> Non-<br /> controlling<br /> interests</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Total<br /> equity</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at January 1, 2020</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 275</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 657</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">55 474</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">55 551</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 331</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 330</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">8 016</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 403</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 401</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 038</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">31</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repurchase of options</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">724</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 134</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">149</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 279</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 286</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2020</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">57 157</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 419</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">56 598</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">56 666</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 493</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 497</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">24 067</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 528</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 521</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 902</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">740</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 235</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">229</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 471</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 365</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2021</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">48</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">70 989</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 187</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 655</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">844</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 116</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 111</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 844</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">848</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 404</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 429</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 510</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2022</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">92</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">63 540</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 996</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="18" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="18" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-4</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001515657"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of cash flows</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adjustments to reconcile net income to net cash flows from operating activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of non-cash items and other adjustments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">11 546</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 299</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9 881</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">525</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest received</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest paid</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">696</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">664</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">703</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial receipts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial payments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">302</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 975</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 342</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 833</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities before working capital and  provision changes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">16 124</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">15 949</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">16 378</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 119</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 437</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in net current assets and other operating cash flow items</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 003</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">291</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 236</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">13 650</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 198</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 378</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 275</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 473</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 593</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 310</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">723</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of interests in associated companies, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">20 669</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of businesses, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">879</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">567</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 957</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of marketable securities, commodities and time deposits</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">34 695</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">16 403</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 900</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of marketable securities, commodities and time deposits</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39 357</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 298</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities from continuing operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 468</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">4 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13 055</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">127</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 468</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13 182</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends paid to shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 652</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 057</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 842</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from exercised options and other treasury share transactions, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 126</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 575</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 162</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 524</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 261</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financing cash flows, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">147</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20 562</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16 264</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 158</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in financing activities from discontinued operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">50</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20 562</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16 264</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 208</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents before effect of exchange  rate changes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 858</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">3 015</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 740</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">266</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 890</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">2 749</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 454</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents at January 1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 658</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">11 112</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents at December 31</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 658</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-5</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001516788"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Notes to the Novartis Group&#xA0;consolidated&#xA0;financial statements</p>
        </div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_0" escape="true" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_1">
          <div>
            <div id="anchorId001516794"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory" id="SectionBlock_39a10fbd-4182-48f5-ba9b-99c9a34135c7_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201C;subsidiaries.&#x201D; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="SectionBlock_07231127-9425-430c-b394-4d59666b16c9_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" id="SectionBlock_5d38989b-8be2-47c1-8eb6-af32cc0f7563_0" escape="true" continuedAt="SectionBlock_5d38989b-8be2-47c1-8eb6-af32cc0f7563_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-6</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_1" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_5d38989b-8be2-47c1-8eb6-af32cc0f7563_1">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" id="SectionBlock_b1b2b7e3-323a-4b9b-9a8f-6d81b4fbfb2b_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201C;&#x2014;Impairment of goodwill and intangible assets&#x201D; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="SectionBlock_0a3dd331-c789-4faa-87e7-d4da39c2eb98_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>
                    <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="SectionBlock_34de13cc-3418-4128-83a8-7eaa7bb3ace3_0" escape="true">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Machinery and equipment</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Furniture and vehicles</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Computer hardware</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                          </table>
                        </div>
                      </div>
                    </ix:nonNumeric>
                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="SectionBlock_5e3e419f-26c7-4cf8-b2b1-88964217cf82_0" escape="true" continuedAt="SectionBlock_5e3e419f-26c7-4cf8-b2b1-88964217cf82_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-7</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_2" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_5e3e419f-26c7-4cf8-b2b1-88964217cf82_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201C;Other income.&#x201D; </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory" id="SectionBlock_82603315-d767-4329-9e0d-f8bf4201d420_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201C;Other expense&#x201D; in the consolidated income statement.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" id="SectionBlock_2088dfc1-3b0e-4fd0-a301-a7591e64d360_0" escape="true">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201C;Other&#x201D; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>
                    <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" id="SectionBlock_16334c25-2e8d-4b69-a548-55d5fdaeea26_0" escape="true">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br />
                                  <br /> Useful life</div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br /> for amortization and<br /> impairment charges</div>
                              </td>
                              <td></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                          </table>
                        </div>
                      </div>
                    </ix:nonNumeric>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" id="SectionBlock_c3e1cc23-36ef-472c-942e-43427d19a088_0" escape="true">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201C;Research and development.&#x201D; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201C;Currently marketed products&#x201D; category.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" id="SectionBlock_66e712bd-20b8-47d4-b827-4eb36d688f88_0" escape="true" continuedAt="SectionBlock_66e712bd-20b8-47d4-b827-4eb36d688f88_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201C;Level 3&#x201D; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-8</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_3" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_4">
          <div>
            <div>
              <ix:continuation id="SectionBlock_66e712bd-20b8-47d4-b827-4eb36d688f88_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" id="SectionBlock_983fe451-b074-40a2-9972-59ca87ab180e_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" id="SectionBlock_0ce1f161-c385-4f83-afb2-5723971b4e95_0" escape="true" continuedAt="SectionBlock_0ce1f161-c385-4f83-afb2-5723971b4e95_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other income&#x201D; and &#x201C;Other expense&#x201D; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201C;Level 3&#x201D; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201C;solely payment of principal and interest&#x201D; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201C;Other financial income and expense.&#x201D; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201C;Other income&#x201D; for gains and &#x201C;Other expense&#x201D; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-9</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_4" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_0ce1f161-c385-4f83-afb2-5723971b4e95_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201C;Other expense&#x201D; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201C;Other income&#x201D; or &#x201C;Other financial income&#x201D; in the consolidated income statement, depending on the nature of the item.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="SectionBlock_9ae30d2d-61c0-48ba-9bde-7f5e2b679ebe_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="SectionBlock_9ef856b4-8a9c-4a9e-a0fc-ea2b3191b0e6_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201C;Cost of goods sold&#x201D; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201C;Cost of goods sold.&#x201D;</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" id="SectionBlock_6534693b-a560-44aa-8ab2-cd1be0ebbf45_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201C;Selling, general and administration&#x201D; expenses.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="SectionBlock_4147075a-0a09-430d-93de-b132724415d5_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" id="SectionBlock_ffba300c-0e5b-45bc-bed2-56dad24b7728_0" escape="true" continuedAt="SectionBlock_ffba300c-0e5b-45bc-bed2-56dad24b7728_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201C;Cost of goods sold&#x201D; for currently marketed products and in &#x201C;Research and development&#x201D; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; depending on their nature. </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-10</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_5" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_6">
          <div>
            <div>
              <ix:continuation id="SectionBlock_ffba300c-0e5b-45bc-bed2-56dad24b7728_1">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201C;Interest expense&#x201D; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201C;Other financial income and expense.&#x201D;</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="SectionBlock_505a237d-f10f-4367-99e0-757f698ed14d_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#xA0;other&#xA0;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201C;Other expense&#x201D; or &#x201C;Other income.&#x201D;</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory" id="SectionBlock_df6d0571-69ff-4f80-ba7c-d9881e9662a4_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#xA0;<ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ParValuePerShare" decimals="2" scale="0">0.50</ix:nonFraction> per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201C;Retained earnings&#x201D; in the consolidated statement of changes in equity.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="SectionBlock_da7928e2-e1f3-4eb8-9144-365c8d8b90f8_0" escape="true" continuedAt="SectionBlock_da7928e2-e1f3-4eb8-9144-365c8d8b90f8_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#x201C;Net sales to third parties&#x201D; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-11</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_6" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_7">
          <div>
            <div>
              <ix:continuation id="SectionBlock_da7928e2-e1f3-4eb8-9144-365c8d8b90f8_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#x201C;Other revenue&#x201D; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201C;Other revenue&#x201D; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="SectionBlock_caa17904-3a5a-4130-8b66-b502a69dc92b_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#x201C;Research and development&#x201D; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201C;Other expense&#x201D; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201C;Other income&#x201D; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="SectionBlock_f548d520-32d8-4845-aa13-e25e9f690f2d_0" escape="true" continuedAt="SectionBlock_f548d520-32d8-4845-aa13-e25e9f690f2d_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-12</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_7" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_8">
          <div>
            <div>
              <ix:continuation id="SectionBlock_f548d520-32d8-4845-aa13-e25e9f690f2d_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="SectionBlock_17a28d6a-d7e1-44b1-aed9-4fa56a15ab10_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" id="SectionBlock_c887e09e-556d-4316-a60c-ebba4ca9dd31_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201C;Other expense&#x201D; in the consolidated income statements. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" id="SectionBlock_ba217540-8056-4f88-b3e4-fb13e4416e8e_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201C;Revenue recognition&#x201D; in this Note 1, are recognized in &#x201C;Other expense&#x201D; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="SectionBlock_0d8c1266-6a61-46bf-bba0-f99bdf8c46c1_0" escape="true" continuedAt="SectionBlock_0d8c1266-6a61-46bf-bba0-f99bdf8c46c1_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-13</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_8" continuedAt="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_9">
          <div>
            <div>
              <ix:continuation id="SectionBlock_0d8c1266-6a61-46bf-bba0-f99bdf8c46c1_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="SectionBlock_5299fc15-c452-4359-bc5d-a91387e538b4_0" escape="true" continuedAt="SectionBlock_5299fc15-c452-4359-bc5d-a91387e538b4_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-14</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_9">
          <div>
            <div>
              <ix:continuation id="SectionBlock_5299fc15-c452-4359-bc5d-a91387e538b4_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfSignificantTransactionsTextBlock" id="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_0" escape="true" continuedAt="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_1">
          <div>
            <div id="anchorId001517458"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2022</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#x2013; acquisition of Gyroscope Therapeutics Holdings plc</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-8" scale="9">0.8</ix:nonFraction> billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-8" scale="9">0.7</ix:nonFraction> billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">1.0</ix:nonFraction> billion. The amount consisted of an upfront cash payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-8" scale="9">0.8</ix:nonFraction> billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-8" scale="9">0.2</ix:nonFraction> billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-8" scale="9">0.9</ix:nonFraction> billion, consisting primarily of intangible assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-8" scale="9">1.1</ix:nonFraction> billion and net deferred tax liabilities of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-8" scale="9">0.2</ix:nonFraction> billion. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-8" scale="9">0.1</ix:nonFraction> billion.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The results of operations since the date of acquisition are not material.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2021</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; acquisition of GSK&#x2019;s cephalosporin antibiotics business</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#x2019;s cephalosporin antibiotics business. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the agreement, Sandoz acquired the global rights to <ix:nonFraction unitRef="Pure" contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfBrandsInPortfolioToAcquire" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> established brands (Zinnat&#xAE;, Zinacef&#xAE; and Fortum&#xAE;) in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfMarketsForTheAcquiredBrands" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction> markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction> million upfront payment paid at closing and potential milestone payments up to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction> million. The amount consisted of a payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction> million, including purchase price adjustments, and the fair value of contingent consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction> million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction> million, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction> million intangible assets and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million deferred tax assets. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2021 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &#x2013; divestment of the investment in Roche Holding AG </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:NumberOfBearerShares" decimals="-5" scale="6">53.3</ix:nonFraction> million (approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span>) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The transaction closed on December 6, 2021. Novartis realized a gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9">14.6</ix:nonFraction> billion, recorded in income from associated companies.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#x2013; acquisition of The&#xA0;Medicines Company</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (&#x201C;the Merger Agreement&#x201D;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:CashOfferPerOrdinaryShare" decimals="1" scale="0" format="ixt:numdotdecimal">85</ix:nonFraction> per share, or a total consideration of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" decimals="-8" scale="9">9.6</ix:nonFraction> billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">9.6</ix:nonFraction> billion. The purchase price allocation resulted in net identifiable assets of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-8" scale="9">7.1</ix:nonFraction> billion, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-8" scale="9">8.5</ix:nonFraction> billion intangible assets, USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-8" scale="9">1.4</ix:nonFraction></div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-15</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_1" continuedAt="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_2">
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> billion net deferred tax liabilities and goodwill of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-8" scale="9">2.5</ix:nonFraction> billion. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; acquisition of the Japanese business of Aspen Global Incorporated </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction> million) upfront payment, less customary purchase price adjustment of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:CustomaryPurchasePriceAdjustment" decimals="-5" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:CustomaryPurchasePriceAdjustment" decimals="-5" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million), plus potential milestone payments of up to EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-5" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-5" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction> million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">294</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction> million). The amount consisted of a cash payment of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction> million) and the fair value of contingent consideration of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-5" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-5" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-5" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction> million, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction> million intangible assets, USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherNetAssets" decimals="-5" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million other net assets and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-5" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million net deferred tax assets. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction> million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:DivestmentDateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">0.8</ix:nonFraction> billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-5" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction> million) and amortization on intangible assets (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction> million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction> million was recognized in the first quarter of 2020 consolidated income statement.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.</div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-16</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_2">
          <div></div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_0" escape="true" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_1">
          <div>
            <div id="anchorId001517705"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2022, 2021 and 2020</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:NumberOfReportableSegments" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NumberOfCommercialOrganizationalUnits" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NumberOfBusinessUnits" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> global business units: Novartis Oncology and Novartis Pharmaceuticals.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfFranchises" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.</div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-17</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_1" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_2">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="SectionBlock_94a60ae5-89e2-4fcb-a93a-0b67f7bf2eff_0" escape="true" continuedAt="SectionBlock_94a60ae5-89e2-4fcb-a93a-0b67f7bf2eff_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">825</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 454</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 811</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 569</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 751</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">4 978</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 147</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 061</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 486</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">31 801</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">32 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 504</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">36 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">11 679</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12 306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 172</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 641</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">824</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 996</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 695</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 732</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">733</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 701</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 786</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 448</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 037</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">599</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">252</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">265</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Amortization of intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 728</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 638</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">134</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">126</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">260</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 069</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 368</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">721</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">1 048</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-18</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_2" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_94a60ae5-89e2-4fcb-a93a-0b67f7bf2eff_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">981</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">39 805</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 811</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">981</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 751</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">10 927</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 147</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 252</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 058</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">32 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">29 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 636</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">34 777</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12 306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">11 657</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 076</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 197</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 641</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 118</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 980</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 732</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 871</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">831</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 190</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">599</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 152</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">912</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">282</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">265</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Amortization of intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 638</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 080</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">370</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 462</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">440</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">335</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">721</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-19</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_3" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_4">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" id="SectionBlock_3eee49b6-a748-4b7a-a5ee-101cd0fd8a09_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">75 510</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">79 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">16 078</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">16 192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">25 865</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">36 383</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16 966</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 929</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 710</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 632</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">37 354</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">44 412</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">58 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">63 973</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">58 544</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">63 291</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7 161</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">66 668</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">68 690</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">8 488</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">9 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 861</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">842</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">991</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to right-of-use assets<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">51 357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">53 919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">9 230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">9 603</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">60 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">63 777</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 791</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total investment in associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">29 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">29 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" id="SectionBlock_fefb2f0c-8f54-4ad5-8d91-d6f5294ce23a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">970</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">23 708</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">25 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">17 653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 818</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 353</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 054</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 615</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 278</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 870</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 518</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 229</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 378</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 052</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 573</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">599</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">703</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 683</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 804</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 054</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73 483</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">77 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 467</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 525</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">21 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 463</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 806</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 966</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 781</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 041</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73 483</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">77 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-20</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_4" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_5">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_5" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_6">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CustomersWithNetSalesOverFivePercent" id="SectionBlock_60d6f47f-8b49-42f7-b024-3f309603bd5c_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">7</ix:nonFraction>%</span> of net sales to third parties, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively; 2020: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively). All segments had sales to these customers in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">14</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively, of the trade receivables at December 31, 2022 (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">12</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively).</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" id="SectionBlock_96ee93e0-29ef-4668-aa89-2397f674961b_0" escape="true" continuedAt="SectionBlock_96ee93e0-29ef-4668-aa89-2397f674961b_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021<br /> to 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020<br /> to 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 554</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15 899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">8 929</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 304</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">8 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 914</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 469</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">30 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">31 459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 643</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 748</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 278</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 754</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 613</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 662</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">969</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">872</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 855</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 776</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 557</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 467</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">17 653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 818</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 966</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 883</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 645</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">37 008</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">38 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">36 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 537</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 927</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-21</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_6" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_7">
          <div>
            <div>
              <ix:continuation id="SectionBlock_96ee93e0-29ef-4668-aa89-2397f674961b_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_7" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_8">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock" id="SectionBlock_2a2f22b0-c817-4b31-b2ef-031b77d30428_0" escape="true">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 756</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 788</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 287</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 787</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">920</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">372</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 051</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 007</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 272</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">937</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">475</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">445</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 723</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 101</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 666</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 016</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 060</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">623</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">104</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 451</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 148</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">31 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 754</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25 319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">21</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 024</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">45</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">334</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">323</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">563</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">310</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 944</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 694</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-22</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_8" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_9">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" id="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_0" escape="true" continuedAt="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_1">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 788</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 354</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 290</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 153</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 046</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">678</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">434</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">472</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">759</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">563</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">540</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">729</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">597</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12 753</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 384</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">32 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 159</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15 899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25 397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-23</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_9" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_10">
          <div>
            <div>
              <ix:continuation id="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_1" continuedAt="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_2">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 883</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 712</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 836</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 427</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 360</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 787</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">882</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 178</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 060</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">947</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 069</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 016</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">606</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 087</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">843</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">882</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">558</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">761</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 024</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">417</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">598</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">937</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">887</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">722</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 976</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">32 664</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 311</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 020</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 331</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">26 996</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-24</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_10" continuedAt="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_11">
          <div>
            <div>
              <ix:continuation id="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_2">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 516</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 479</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 562</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 441</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 099</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">833</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">569</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">973</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">964</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">920</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">369</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">515</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 126</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 916</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 881</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 097</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">24 671</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock" id="SectionBlock_eba89ff5-1c70-419a-bd8b-99a4ddcb0a3b_0" escape="true">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 776</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 116</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 928</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion), of which USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">777</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">707</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonFraction> million) is sold through the Retail Generics business franchise and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction> million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-25</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_11">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" id="SectionBlock_4926d87c-b09b-41cd-afc1-d0c23b6bdb27_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="SectionBlock_3e5bbd9c-1f4f-4f29-95c6-acb6d4566009_0" escape="true">
          <div>
            <div id="anchorId001530159"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="SectionBlock_bc7a172d-8194-47e3-bb62-2186a26ff0a5_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 387</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 385</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" decimals="-6" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> of Roche Holding AG (Roche) voting shares, representing approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" decimals="3" scale="-2">6.2</ix:nonFraction>%</span> of Roche&#x2019;s total outstanding voting and non-voting equity instruments, to Roche for USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9">14.6</ix:nonFraction> billion, recorded in income from associated companies. See Note 2.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s holding in Roche voting shares was <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> at December 31, 2020. This investment represented approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" decimals="3" scale="-2">6.2</ix:nonFraction>%</span> of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results were adjusted in the Group&#x2019;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#x2019;s consolidated financial statements.</div>
              </div>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:DividendsReceived" decimals="-6" scale="6" format="ixt:numdotdecimal">522</ix:nonFraction> million.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock" id="SectionBlock_274be8b0-50d8-43ee-9d81-db18741255e0_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:ShareOfCurrentYearNetIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">815</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:ShareOfCurrentYearNetIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:PriorYearAdjustment" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:PriorYearAdjustment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">70</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">172</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">14 556</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonFraction> billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-26</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInterestExpenseExplanatory" id="SectionBlock_db6fcc50-f24c-4205-a55a-8199c9aa22ca_0" escape="true">
          <div>
            <div id="anchorId001530632"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&#xA0;other&#xA0;financial&#xA0;income&#xA0;and&#xA0;expense</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:InterestExpenseTableTextBlock" id="SectionBlock_aa003d3c-ae7c-49e6-9007-46bb1904b4d5_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">669</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">651</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OtherFinancialIncomeAndExpenseTableTextBlock" id="SectionBlock_0c95a118-0c2c-4f79-a62a-d62c6a956d4f_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">184</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">69</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">135</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="SectionBlock_811479e0-5aba-4152-bd76-324857fd74c9_0" escape="true" continuedAt="SectionBlock_811479e0-5aba-4152-bd76-324857fd74c9_1">
          <div>
            <div id="anchorId001530884"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Income taxes</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:IncomeBeforeTaxesTableTextBlock" id="SectionBlock_2245204e-26cf-41ad-98e1-f9088d9951ec_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">5 986</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">22 028</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 786</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 385</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">4 109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9" format="ixt:numdotdecimal">14.6 </ix:nonFraction> billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock" id="SectionBlock_1ae83aa4-abd9-456d-8af3-386ea0d57a5e_0" escape="true">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">932</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 454</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 470</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 071</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 428</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 100</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">655</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">309</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">293</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The applicable tax rate changes from year to year due to changes in the mix of the Group&#x2019;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate and the effective tax rate are shown in the following table:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AnalysisOfTaxRateTableTextBlock" id="SectionBlock_bc4e921e-c03e-4b78-8995-930f42d29b77_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">16.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">14.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">13.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">2.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">7.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">3.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">2.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="-2" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">1.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">16.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">8.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">18.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b></b>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-<ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">7.3</ix:nonFraction></span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-27</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_811479e0-5aba-4152-bd76-324857fd74c9_1">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">that impact the comparability of the effective tax rate between years.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The utilization of tax-loss carry-forwards lowered the tax charge by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">1</ix:nonFraction> million in 2022, by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">5</ix:nonFraction> million in 2021, and by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">29</ix:nonFraction> million in 2020.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:EarningsPerShareExplanatory" id="SectionBlock_8e702e78-1736-41aa-a15c-346092ef57ba_0" escape="true" continuedAt="SectionBlock_8e702e78-1736-41aa-a15c-346092ef57ba_1">
          <div>
            <div id="anchorId001531581"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="SectionBlock_49227af3-d816-49a0-8a9d-fc6a80a1ff85_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 181</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 243</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
                  <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-28</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8e702e78-1736-41aa-a15c-346092ef57ba_1">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" id="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_0" escape="true" continuedAt="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_1">
          <div>
            <div id="anchorId001531800"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&#xA0;comprehensive income</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfComprehensiveIncomeTableTextBlock" id="SectionBlock_5ec7eff2-43d4-416d-8d39-9cd38dc55ac5_0" escape="true" continuedAt="SectionBlock_5ec7eff2-43d4-416d-8d39-9cd38dc55ac5_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Fair value<br /> adjustments <br /> on financial<br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Actuarial<br /> gains/(losses)<br /> from defined<br /> benefit plans</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Cumulative<br /> currency <br /> translation<br /> effects</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br /> adjustments<br /> attributable to <br /> Novartis AG <br /> shareholders</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Non-<br /> controlling<br /> interest</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total value<br /> adjustments</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 919</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 657</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 686</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">36</ix:nonFraction></span> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 193</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 193</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 992</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 386</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 773</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">4 134</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 419</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 448</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">323</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 757</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 757</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 762</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 541</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 968</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 187</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 220</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">103</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">444</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">444</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">353</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">844</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">198</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 038</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">760</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 996</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 034</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-29</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_1" continuedAt="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_5ec7eff2-43d4-416d-8d39-9cd38dc55ac5_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">8.1) In 2022, net cumulative currency translation gains of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction> million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-8" scale="9">3.2</ix:nonFraction> billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> currency translation losses or gains recycled through the income statement.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="SectionBlock_c6f2d8a9-afa9-42bd-802f-7fab885dd191_0" escape="true" continuedAt="SectionBlock_c6f2d8a9-afa9-42bd-802f-7fab885dd191_1">
          <div>
            <div id="anchorId001533452"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PropertyPlantAndEquipmentTableTextBlock" id="SectionBlock_45d52e46-4eaa-4876-9e9d-22161598a5a2_0" escape="true" continuedAt="SectionBlock_45d52e46-4eaa-4876-9e9d-22161598a5a2_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Land</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Buildings</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Construction <br /> in progress</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br /> and other <br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13 328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">27 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 744</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 602</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">964</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">667</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">780</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">437</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">726</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">166</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">57</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">288</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 672</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">451</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 184</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 842</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">24 873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">8 170</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 109</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 672</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">549</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:BorrowingCostsCapitalised" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-30</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_c6f2d8a9-afa9-42bd-802f-7fab885dd191_1">
          <div>
            <div>
              <ix:continuation id="SectionBlock_45d52e46-4eaa-4876-9e9d-22161598a5a2_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Land</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Buildings</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Construction <br /> in progress</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br /> and other <br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 377</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">14 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">28 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">66</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 063</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 955</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 975</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 975</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">610</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 027</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">293</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">755</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">203</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">84</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">199</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">509</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13 328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">27 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 744</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 602</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BorrowingCostsCapitalised" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" id="SectionBlock_32ec21d1-5255-4485-b396-a8f0b52bd724_0" escape="true">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">411</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">447</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfLeasesExplanatory" id="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_0" escape="true" continuedAt="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_1">
          <div></div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-31</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_1" continuedAt="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_2">
          <div>
            <div id="anchorId001534980"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock" id="SectionBlock_df810e39-bcfd-4ce2-b27e-6b749289218e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 676</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:LeaseContractTerminationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:LeaseContractTerminationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" id="SectionBlock_d11e550a-90e7-4d7a-a75e-9b065c045380_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br /> 2022<br /> carrying value</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br /> charge<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br /> 2021<br /> carrying value</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br /> charge<br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">505</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" id="SectionBlock_e70d24c1-a6ae-4d5f-9ed0-f6d505dfb2ec_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Lease liabilities<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br /> undiscounted<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Lease liabilities<br /> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br /> undiscounted<br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">201</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">982</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 243</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 908</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 025</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CommitmentsForLeasesNotYetCommenced" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentsForLeasesNotYetCommenced" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:MostMaterialLeaseWithLeaseTermExtension" decimals="-8" scale="9">0.7</ix:nonFraction> billion (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:MostMaterialLeaseWithLeaseTermExtension" decimals="-8" scale="9">0.6</ix:nonFraction> billion), has a determined lease term end date of <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:LeaseTermEndDate">2071</ix:nonNumeric> (2021: <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="nvs:LeaseTermEndDate">2071</ix:nonNumeric>). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="nvs:CashInflowForSaleAndLeaseback" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">49</ix:nonFraction> million and the recognition of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction> million of lease liabilities, and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction> million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million. There were no significant sale and leaseback transactions in 2021 or 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" id="SectionBlock_e10165ed-12a3-4346-9e01-9fcd5f380640_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">355</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Thereof:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Payments of interest<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Payments of lease liabilities<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The weighted average interest rate is <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction>%, 2020: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.4</ix:nonFraction>%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-32</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_2">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_0" escape="true" continuedAt="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_1">
          <div>
            <div id="anchorId001535930"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" id="SectionBlock_2d69d497-2de4-4dd1-93ac-5bfe724d3389_0" escape="true" continuedAt="SectionBlock_2d69d497-2de4-4dd1-93ac-5bfe724d3389_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">56 213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">68 211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">305</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 514</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29 107</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 505</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 429</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 403</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 603</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">342</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">917</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">427</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">176</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">243</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">432</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 596</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">58 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 305</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">69 684</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 671</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">917</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32 736</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 716</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38 040</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-33</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_1" continuedAt="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_2d69d497-2de4-4dd1-93ac-5bfe724d3389_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">6 893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 115</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">57 333</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 384</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">67 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">885</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">26 566</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 272</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30 916</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 700</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 700</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">270</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 607</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">642</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">584</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">672</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">56 213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">68 211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">305</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 514</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29 107</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 505</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" id="SectionBlock_46b5d5d4-cc61-426a-8711-581e92f84af1_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">21 531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">24 487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 826</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">21 562</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 313</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 091</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">32 357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 577</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As at December 31, 2022, the most significant intangible assets within currently marketed products category are <i>Leqvio</i> (Innovative Medicines: acquisition of The Medicines Company) and <i>Zolgensma</i> (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for <i>Leqvio</i> is USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">7.4</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">13</ix:nonNumeric> years, respectively (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">7.9</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">14</ix:nonNumeric> years, respectively), and for <i>Zolgensma</i> USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">5.9</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">8</ix:nonNumeric> years, respectively (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">6.6</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">9</ix:nonNumeric> years, respectively). </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-34</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_2" continuedAt="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_3">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock" id="SectionBlock_7283400a-d2cb-4f1c-a33b-f41a5dcac4f0_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(As a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br /> Medicines</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Sandoz</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#x201C;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201D; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges and reversals by reporting segment: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:IntangibleAssetImpairmentChargesTextBlock" id="SectionBlock_3c77806b-7b9b-412b-b856-1b0e9633954b_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> 2022 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> 2021 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> 2020 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-8" scale="9" format="ixt:numdotdecimal">0.9</ix:nonFraction> billion in 2022 and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-35</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_3">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" id="SectionBlock_2703deaf-07cf-4cac-9481-e5995b6d3cd1_0" escape="true" continuedAt="SectionBlock_2703deaf-07cf-4cac-9481-e5995b6d3cd1_1">
          <div>
            <div id="anchorId001538419"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="SectionBlock_e81a5d25-3e37-4ffc-9bd4-bdb078067dc0_0" escape="true" continuedAt="SectionBlock_e81a5d25-3e37-4ffc-9bd4-bdb078067dc0_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Property, <br /> plant and<br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br /> other benefit <br /> obligations <br /> of employees</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Inventories</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Tax loss<br /> carry-<br /> forwards</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Other assets,<br /> provisions<br /> and accruals</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 273</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 727</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">628</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">655</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 059</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 477</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 726</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">739</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 051</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 785</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 312</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 998</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 059</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 477</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" decimals="-6" scale="6" format="ixt:numdotdecimal">4 312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 739</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 686</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 502</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">507</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 658</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 344</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">430</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 344</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 552</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 918</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 343</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 918</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 343</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">22</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">309</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">323</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">317</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 273</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 727</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" decimals="-6" scale="6" format="ixt:numdotdecimal">4 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction id="fact_188392_1" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction id="fact_188393_1" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 070</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-36</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_2703deaf-07cf-4cac-9481-e5995b6d3cd1_1">
          <div>
            <div>
              <ix:continuation id="SectionBlock_e81a5d25-3e37-4ffc-9bd4-bdb078067dc0_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" decimals="-9" scale="9" format="ixt:numdotdecimal">32</ix:nonFraction> billion in 2022, (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" decimals="-9" scale="9" format="ixt:numdotdecimal">29</ix:nonFraction> billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="SectionBlock_09329877-cda6-42a0-b711-973ac96c5ccb_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 880</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 380</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">433</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 610</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 530</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 140</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 872</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 408</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 799</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" id="SectionBlock_665104ec-f67b-4b46-8de6-6a241467938d_0" escape="true">
          <div>
            <div id="anchorId001540678"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAssetsTableTextBlock" id="SectionBlock_b95f0e57-b8bc-4d04-a31d-39eebc99913d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsEquityInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsEquityInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 663</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAsstetsDebtSecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAsstetsDebtSecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsFundInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsFundInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsTotalFinancialInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 463</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsTotalFinancialInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2 063</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LongTermReceivablesFromFinanceSubleases" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongTermReceivablesFromFinanceSubleases" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">184</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLoansAndReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLoansAndReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 411</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 036</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock" id="SectionBlock_c83d7f4e-cf56-4191-9193-ee181dbd4c79_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:DeferredCompensationPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:DeferredCompensationPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 210</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-37</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="SectionBlock_a3683b67-1363-497e-8f7d-71d582c64df8_0" escape="true">
          <div>
            <div id="anchorId001540931"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfInventoryCurrentTableTextBlock" id="SectionBlock_601102b7-b545-437e-9f5e-0e7ae56bd172_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">934</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">870</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">3 673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">3 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">2 568</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">2 636</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">7 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">6 666</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#x201C;Cost of goods sold&#x201D; in the consolidated income statements: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" id="SectionBlock_0d8eb127-9524-498c-830a-b4d0b07d9802_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" id="SectionBlock_e612d4bc-e1db-4660-ba72-20aaa26c3ff4_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">633</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">573</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">702</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock" id="SectionBlock_8f0a4893-1d2b-4c5b-abcc-02519e4e75bd_0" escape="true" continuedAt="SectionBlock_8f0a4893-1d2b-4c5b-abcc-02519e4e75bd_1">
          <div>
            <div id="anchorId001541112"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ProvisionsForTradeReceivablesTableTextBlock" id="SectionBlock_70cfb4f9-fe1b-4628-81f3-dadcf50985b9_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TradeReceivablesProvisionMovementsTableTextBlock" id="SectionBlock_1d53d226-b03e-4b31-893a-86656fc1f579_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">93</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">95</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">93</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock" id="SectionBlock_0253630b-3afc-4492-ac28-0d3fc1719906_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">7 664</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">7 639</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-38</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8f0a4893-1d2b-4c5b-abcc-02519e4e75bd_1">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" id="SectionBlock_f44e0344-acab-4fa1-a0a3-6e3662a3b947_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">3 709</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">3 344</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 426</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 408</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">383</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" id="SectionBlock_7d5c18e3-dbbb-4ac9-aafb-ea0352908c2b_0" escape="true">
          <div>
            <div id="anchorId001541662"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&#xA0;deposits, derivative financial instruments, and&#xA0;cash and cash equivalents</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&#xA0;deposits and derivative financial instruments</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" id="SectionBlock_043cffcb-c500-4bd0-9b14-17b2a337a058_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:Commodities" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:Commodities" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DebtInstrumentsHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DebtInstrumentsHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">11 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 965</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DerivativeFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DerivativeFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15 922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashAndCashEquivalentsTableTextBlock" id="SectionBlock_6b22e8c8-9393-46e3-8ef3-47b152e8f071_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Cash" decimals="-6" scale="6" format="ixt:numdotdecimal">2 877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Cash" decimals="-6" scale="6" format="ixt:numdotdecimal">3 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">4 640</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 011</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-39</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="SectionBlock_ef9a4b09-078e-410c-9ee5-3513a3bc5acf_0" escape="true">
          <div>
            <div id="anchorId001541818"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OtherCurrentAssetsTableTextBlock" id="SectionBlock_f7bc064c-68bc-450d-bffe-4ea81869acf0_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentValueAddedTaxReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">509</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentValueAddedTaxReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:WithholdingTaxRecoverable" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WithholdingTaxRecoverable" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentPrepaidExpensesThirdParty" decimals="-6" scale="6" format="ixt:numdotdecimal">911</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentPrepaidExpensesThirdParty" decimals="-6" scale="6" format="ixt:numdotdecimal">1 102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationReceivableCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherReceivablesAndCurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherReceivablesAndCurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 471</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 440</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfEquityTextBlock" id="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_0" escape="true" continuedAt="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_1">
          <div>
            <div id="anchorId001541932"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MovementInTheShareCapitalTableTextBlock" id="SectionBlock_c1cc41fb-b80c-4512-bae5-76f11cb0b2a1_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Jan 1, 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Dec 31, 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Dec 31, 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br /> Dec 31, 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">856</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">853</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ParValuePerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction> each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MovementInTheShareslTableTextBlock" id="SectionBlock_3dd23758-dfdb-4a9c-aec4-c13a7dd29c48_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />Number of outstanding shares <br />(in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 434.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">199.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 234.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 467.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">210.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 256.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 527.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">262.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 265.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">30.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">60.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">60.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#xA0;5</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#xA0;5</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">84.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">115.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal">10.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">21.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">60.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal">52.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">8.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 403.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">284.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 119.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 434.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">199.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 234.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 467.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">210.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 256.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Approximately <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">99.0</ix:nonFraction> million treasury shares (2021: <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">102.5</ix:nonFraction> million; 2020: <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">103.0</ix:nonFraction> million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-2" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-1" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2021 AGM and the additional CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;5&#xA0;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DividendTableTextBlock" id="SectionBlock_33a1d528-3f63-4144-b763-23e72c53273d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd-1" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd-2" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.95</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-40</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_1" continuedAt="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_2">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:SummaryOfTreasurySharesMovementsTableTextBlock" id="SectionBlock_a129fd4e-3fd5-48e7-abfe-b106e2a737e7_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10 787</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 775</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 897</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">127.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">34.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">115.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">9 963</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">21.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">8.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">1 490</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-2" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-1" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2021 AGM and the additional CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:MaximalAmountOfShareBuybackProgramm" decimals="-8" scale="9">15.0</ix:nonFraction> billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-8" scale="9">2.8</ix:nonFraction> billion as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is <span>no</span> liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:MaximalAmountOfShareBuybackProgramm" decimals="-8" scale="9">2.5</ix:nonFraction> billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-8" scale="9">1.8</ix:nonFraction> billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:NumberOfOptionsRepurchased" decimals="-5" scale="6" sign="-">3.7</ix:nonFraction> million options were repurchased under this agreement. This agreement was terminated in November 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-41</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2022, the market maker held <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million; 2020: <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">66.07</ix:nonFraction> (2021: USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">61.45</ix:nonFraction>; 2020: USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">60.09</ix:nonFraction>), and they have contractual lives of <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsContractualLive" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> years, with remaining lives less than <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> year (2021: <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> years; 2020: <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> years). </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="SectionBlock_7d4803ee-8033-486a-a7d2-e2a51af6e473_0" escape="true" continuedAt="SectionBlock_7d4803ee-8033-486a-a7d2-e2a51af6e473_1">
          <div>
            <div id="anchorId001543827"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" id="SectionBlock_98b4e328-6abd-47cd-b636-d62bc882699c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LiabilitiesToBanksAndOtherInstitutions" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LiabilitiesToBanksAndOtherInstitutions" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:AverageInterestRateOnLoansReceived" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:AverageInterestRateOnLoansReceived" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt" decimals="2" scale="-2">86</ix:nonFraction>%</span> at December 31, 2022, and <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt" decimals="2" scale="-2">87</ix:nonFraction>%</span> at December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2022 was <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:AverageInterestRateOnBorrowings" decimals="3" scale="-2">2.4</ix:nonFraction>%</span> (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:AverageInterestRateOnBorrowings" decimals="3" scale="-2">1.9</ix:nonFraction>%</span>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-42</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7d4803ee-8033-486a-a7d2-e2a51af6e473_1">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" id="SectionBlock_4dbd830d-946d-452a-a54e-2e4af1ba97d4_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />Coupon</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Currency</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br /> amount<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Issuance <br /> year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Maturity <br /> year</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Issuer</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Issue price</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> (USD<br /> millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> (USD<br /> millions)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsIssuanceDate">2012</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsMaturity">2022</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.225</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 498</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.700</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsIssuanceDate">2012</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsMaturity">2042</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.325</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">2 150</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsMaturity">2024</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.287</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">4.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsMaturity">2044</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.196</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 827</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 826</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsMaturity">2026</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.697</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">676</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.250</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.640</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">541</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">547</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsMaturity">2029</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.502</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.050</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsMaturity">2035</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.479</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">352</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">356</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.010</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 740</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">4.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsMaturity">2045</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.029</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 221</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsIssuanceDate">2016</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsMaturity">2023</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.127</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 409</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsIssuanceDate">2016</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsMaturity">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.480</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">528</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">559</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsMaturity">2022</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.449</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.109</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">994</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.125</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.874</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.500</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsMaturity">2023</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.655</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.375</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsMaturity">2030</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.957</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.700</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsMaturity">2038</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.217</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.750</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.852</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.909</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.200</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsMaturity">2030</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.869</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 494</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.750</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsMaturity">2050</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">97.712</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 215</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="0" format="ixt:numdotdecimal">0.000</ix:nonFraction>%</span>
                            <sup style="white-space: nowrap">&#xA0;1</sup>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsMaturity">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.354</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction> million bond issued in 2020 features a coupon step-up of <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsInterestRateStepUp" decimals="4" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Breakdown by maturity:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" id="SectionBlock_d36f6143-68b2-43b6-8580-ad7407394d5a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">3 281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">3 284</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 909</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 916</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">11 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" id="SectionBlock_31badf28-4ca2-4b24-a4ab-a18965eb3493_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">13 376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">15 862</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 478</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">1 488</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">1 505</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" id="SectionBlock_c2ff21ff-7e97-40c8-a558-656deaaf8ee7_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> Balance<br /> sheet</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> Fair<br /> values</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> Balance<br /> sheet</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> Fair<br /> values</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">20 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">27 079</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">20 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">27 306</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-43</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_0" escape="true" continuedAt="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_1">
          <div>
            <div id="anchorId001545529"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" id="SectionBlock_edc1f0e8-df59-41d2-b0ac-f92719dd2750_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Defined benefit pension plans<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 723</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 640</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation" decimals="-6" scale="6" format="ixt:numdotdecimal">554</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other post-employment benefits<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherPostemploymentBenefits" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherPostemploymentBenefits" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationNonCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationNonCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">956</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 906</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock" id="SectionBlock_eb2ff43f-83a0-47a6-8e2e-d2a4d5047209_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">169</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>- <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal"> 105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">642</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" id="SectionBlock_d942b459-9e57-4477-87fa-7008d0abbe53_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br /> cash outflows</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#x2019; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-44</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_1" continuedAt="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingent liabilities.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#x2019;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#x2019; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction> million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction> million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" decimals="0" scale="0" format="ixt:numdotdecimal">50</ix:nonFraction> US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin&#xAE; matters</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin<sup>&#xAE;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-8" scale="9">1.3</ix:nonFraction> billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction> million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-45</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_2" continuedAt="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction> million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-5" scale="6">1.2</ix:nonFraction> million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million for moral damages allegedly arising from the conduct that was the subject of the Company&#x2019;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">340B Drug Pricing Program investigations</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#x2019;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#x2019;s determination and to enjoin HRSA from taking action with respect to NPC&#x2019;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#x2019;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#x2019;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#x2019;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#x2019;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Swiss and EU investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect <i>Cosentyx</i> from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonFraction> million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere&#xAE; (docetaxel)</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">3 100</ix:nonFraction> US product liability actions involving Taxotere&#xAE; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#xAE; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-46</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_3" continuedAt="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_4">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">400</ix:nonFraction> US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder derivative lawsuit</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation &#x2013; Concluded matter </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Entresto matter&#x2013; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation &#x2013; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" id="SectionBlock_1d1f3f5a-6847-4829-8086-faabb6032fc4_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 369</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">292</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 863</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">466</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">702</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">548</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-47</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_4">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" id="SectionBlock_8d7eada3-af1d-43b7-9382-beabf1c29fae_0" escape="true">
          <div>
            <div id="anchorId001546397"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&#xA0;derivative&#xA0;financial&#xA0;instruments</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" id="SectionBlock_8f57c294-b1a6-49ed-a39b-e93fd16423ca_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:InterestBearningAccountsOfAssociatesPayableOnDemand" decimals="-6" scale="6" format="ixt:numdotdecimal">1 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CommercialPapersIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CommercialPapersIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DerivativeFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DerivativeFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Weighted average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateAssociates" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>% through September 30, 2022 (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateAssociates" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> Weighted average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt" decimals="3" scale="-2" format="ixt:numdotdecimal">9.7</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt" decimals="3" scale="-2" format="ixt:numdotdecimal">6.1</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PaymentOfInterestBearingAccountsToBeneficiaries" decimals="-8" scale="9">0.9</ix:nonFraction> billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short-term borrowings are provided under &#x201C;Liquidity risk&#x201D; in Note&#xA0;29. </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" id="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_0" escape="true" continuedAt="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_1">
          <div>
            <div id="anchorId001546573"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" id="SectionBlock_85f45d9a-f982-42e7-a2b9-465e25ce5436_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">836</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">619</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermRestructuringProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">1 131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermRestructuringProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:AccrualsClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:AccrualsClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">1 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AccruedRoyaltiesPayableClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AccruedRoyaltiesPayableClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">752</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentInterestPayable" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentInterestPayable" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" decimals="-6" scale="6" format="ixt:numdotdecimal">2 321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" decimals="-6" scale="6" format="ixt:numdotdecimal">2 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationCurrentPortion" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationCurrentPortion" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentPayables" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentPayables" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-48</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_1" continuedAt="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_2">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ProvisionsForReductionOfRevenueTableTextBlock" id="SectionBlock_33e204c4-9044-41ef-ba80-2972435303ae_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 256</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">5 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">218</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">234</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">22 261</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">19 838</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">19 294</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">245</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">151</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">23 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">20 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">19 773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">113</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 256</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RestructuringProvisionsMovementsTableTextBlock" id="SectionBlock_5725d866-58ab-4cfd-808f-079ee014425c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">344</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">268</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, additions to provisions of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-8" scale="9">1.4</ix:nonFraction> billion were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp; Technology Solutions) 2021 restructuring initiatives.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, additions to provisions of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction> million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction> million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-49</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_2">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_0" escape="true" continuedAt="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_1">
          <div>
            <div id="anchorId001547223"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">
              <b>23. Details to the consolidated statements of cash flows</b>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Non-cash items and other adjustments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">cash flows.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" id="SectionBlock_7e5013d4-0013-4da1-b19e-3f6fdc37e67d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 489</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 758</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5 308</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">4 306</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">4 376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial assets<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 403</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 411</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">333</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">677</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">478</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">823</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">817</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">891</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">947</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherAdjustmentsForNoncashItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">11 546</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9 881</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> 2021 included the gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9" format="ixt:numdotdecimal">14.6</ix:nonFraction> billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction> million additions to intangible assets with deferred payments. In 2022, there were USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction> million, 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction> million) additions to right-of-use assets recognized.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of income taxes paid </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the total amount of income taxes paid was USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">2.0</ix:nonFraction> billion (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">2.3</ix:nonFraction> billion), which was included within &#x201C;Net cash flows from operating activities.&#x201D;</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, the total amount of income taxes paid was USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">1.9</ix:nonFraction> billion, of which USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-8" scale="9">1.8</ix:nonFraction> billion was included within &#x201C;Net cash flows from operating activities,&#x201D; and USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction> million was included within &#x201C;Net cash flows used in investing activities from discontinued operations.&#x201D;</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" id="SectionBlock_4702071f-730d-44e2-93b3-a9ee612f741e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">830</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">589</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">389</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">48</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">21</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">194</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">202</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">229</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">658</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 003</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">291</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, acquisitions and divestments of interests in associated companies, net included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion proceeds from the divestment of the Group&#x2019;s investment in Roche (see Notes 2 and 4).</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-50</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_1" continuedAt="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_2">
          <div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" id="SectionBlock_213b3d94-fc64-4a39-87d0-f4ab309d7da3_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 077</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">735</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10 173</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">864</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">633</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 006</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">879</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">567</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 957</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> In 2022, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction> million net cash outflows from divestments of businesses included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction> million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetIdentifiableAssetsOfDivestedBusiness" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction> million, comprised of non-current assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NoncurrentAssetsDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">132</ix:nonFraction> million, current assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:CurrentAssetsDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction> million, including USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million cash and cash equivalents and of non-current and current liabilities of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NoncurrentAndCurrentLiabilitiesDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction> million. Deferred sales price receivables and other adjustments amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:DeferredSalePriceAndOtherAdjustments" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction> million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2021, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction> million included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction> million net cash inflows from divestments in previous years, and a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction> million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2020, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction> million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" id="SectionBlock_f3ae1956-2298-4cc3-bd00-674cab660988_0" escape="true" continuedAt="SectionBlock_f3ae1956-2298-4cc3-bd00-674cab660988_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 575</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">366</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">401</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 325</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 325</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">224</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-51</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_f3ae1956-2298-4cc3-bd00-674cab660988_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9 785</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 162</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 524</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">774</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">309</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 624</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 624</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">247</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">20 353</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 703</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 126</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 067</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 067</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">250</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9 785</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, net cash flows used in investing activities from discontinued operations of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">127</ix:nonFraction> million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, net cash flows used in financing activities from discontinued operations of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">50</ix:nonFraction> million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-52</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="SectionBlock_0b997621-1ac7-41d6-bc5b-5e52935c7c47_0" escape="true">
          <div>
            <div id="anchorId001549327"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions of businesses:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" id="SectionBlock_cb7fa6de-176a-49f2-b17b-f8479c6f7440_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:RightOfUseAssetsAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:RightOfUseAssetsAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">8 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:FinancialAndOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1 977</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">1 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">612</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">7 669</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">2 580</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">1 077</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">735</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">10 173</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> goodwill (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> million) is tax deductible. </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_0" escape="true" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_1">
          <div>
            <div id="anchorId001549711"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for employees</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ConcentrationOfMajorPlansGeographic" id="SectionBlock_0f607534-21f9-45b8-bd8e-dc6e61a5db38_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:MajorPlansPercentageInGroupDBOPensions" decimals="2" scale="-2">95</ix:nonFraction>%</span> of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" decimals="2" scale="-2">83</ix:nonFraction>%</span> of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#x2013; for the principal plans &#x2013; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-53</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_1" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction> million (CHF <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-2" name="nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million) recognized in 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.</div>
                <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDefinedBenefitPlansTableTextBlock" id="SectionBlock_62a89c36-0428-4294-84e6-05e678bd11c1_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">25 602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">632</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">5 046</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">713</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">377</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">650</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">865</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">17 533</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 317</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 500</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">539</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">726</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanSettlementsPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanSettlementsPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 504</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestIncomeOnLimitationOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestIncomeOnLimitationOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 644</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">2 587</ix:nonFraction> million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-54</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_2" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" id="SectionBlock_258459ca-cea0-4f0b-8bc3-b62cbce0845c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">3 336</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 071</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 504</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 723</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 640</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" id="SectionBlock_eb302481-bb4e-437d-a53d-9f2e33149f5e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Switzerland</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Switzerland</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">11 824</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 746</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 963</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">17 533</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">15 268</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">3 645</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">4 670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">556</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">363</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Active</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">4 799</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">6 161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">6 478</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">620</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8 510</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Deferred pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">830</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">861</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 691</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 730</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">7 025</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9 681</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 817</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 528</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">12 135</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">14 701</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 978</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 266</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">16 436</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 551</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">3 433</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">697</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 094</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 237</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" id="SectionBlock_b240e56d-e896-4921-85d9-9dd40ab35870_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Active</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Deferred pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">286</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">400</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">87</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-55</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_3" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_4">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAssumptionsUsedTableTextBlock" id="SectionBlock_152fce46-9c49-4905-bd9d-7b2341a406c8_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">6.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.7</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.7</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#x2019;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#x2019;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" id="SectionBlock_da31e53a-02a9-4e2f-9a94-9d2a0c740463_0" escape="true" continuedAt="SectionBlock_da31e53a-02a9-4e2f-9a94-9d2a0c740463_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br /> year-end defined <br /> benefit pension <br /> obligation</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br /> year-end defined <br /> benefit pension <br /> obligation</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">466</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">790</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">839</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">136</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">58</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-56</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_4" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_da31e53a-02a9-4e2f-9a94-9d2a0c740463_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_5" continuedAt="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_6">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="SectionBlock_82907174-5821-4004-a4cf-e7aa402f7099_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2031</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#xA0;2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="SectionBlock_9daf4502-4011-439c-8fc0-d79eb1e47c08_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(as a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br /> target <br /> minimum</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br /> target <br /> maximum</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" id="SectionBlock_1b9aa832-6fbc-4638-a2f3-32fc72949372_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Number of shares (in millions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:EmployerSharesHeldByDefinedBenefitPlan" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:EmployerSharesHeldByDefinedBenefitPlan" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan" decimals="-8" scale="9" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan" decimals="-8" scale="9" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit pension obligation is <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:WeightedAverageDurationOfDefinedBenefitObligationYears" format="ixt-sec:duryear">11.8</ix:nonNumeric> years (2021: <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:WeightedAverageDurationOfDefinedBenefitObligationYears" format="ixt-sec:duryear">14.9</ix:nonNumeric> years).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="SectionBlock_b8cdde5f-7b1d-4b6d-b1ca-3ed4a25a400c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Pension plans</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br /> employment<br /> benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 268</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 441</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 114</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 099</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#x2013;2032</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 310</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfDefinedContributionPlansTableTextBlock" id="SectionBlock_1a0aace6-22b9-4d63-a82a-64101e94a30b_0" escape="true" continuedAt="SectionBlock_1a0aace6-22b9-4d63-a82a-64101e94a30b_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s total personnel costs amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:EmployeeBenefitsExpense" decimals="-8" scale="9">14.9</ix:nonFraction> billion in 2022.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-57</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_6">
          <div>
            <div>
              <ix:continuation id="SectionBlock_1a0aace6-22b9-4d63-a82a-64101e94a30b_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_0" escape="true" continuedAt="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_1">
          <div>
            <div id="anchorId001552874"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for employees</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" id="SectionBlock_58d0bbc7-1ca2-45a7-bfb7-0454d782f610_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">1 048</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_fac23996-f2b4-4994-a0b7-766de49f79a6_0" escape="false">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_fbf10437-518a-4d8d-8d8f-26f94cd51aae_0" escape="false">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Employee share savings plan</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201C;Select&#x201D; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_2def460a-2dba-4607-82b6-0f397de211ce_0" escape="false">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Employee share purchase plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#x201C;Select&#x201D;</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_1110b63f-1350-4cf3-879b-9a9dcd6c52df_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#x201C;Select&#x201D; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201C;Select.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#x201C;Select&#x201D; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10<sup>th</sup> anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10<sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; outside North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="SectionBlock_943531d9-b95f-4ab4-812a-0d30a0151300_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">58.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#xA0;<ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" decimals="1" scale="0">86.1</ix:nonFraction>. </div>
              </div>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; for North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period:</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-58</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_1" continuedAt="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_2">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="SectionBlock_ef8ef9d5-e3df-4ccc-a2a1-5058bed22c9a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> ADR<br /> options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> ADR<br /> options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">60.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#xA0;<ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" decimals="1" scale="0">89.1</ix:nonFraction>. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_92a38d22-1d8a-4995-8ced-6fc414f27854_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_e5b59076-384e-41f9-a61b-6c8616c22c7b_0" escape="false" continuedAt="SectionBlock_e5b59076-384e-41f9-a61b-6c8616c22c7b_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201C;buyouts&#x201D; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-59</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_2" continuedAt="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_e5b59076-384e-41f9-a61b-6c8616c22c7b_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_3">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of share grants</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="SectionBlock_33584103-7f55-41fa-a432-12fb2653f1d1_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Number<br /> of shares<br /> in millions</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br /> average fair<br /> value at grant<br /> date in USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Number<br /> of shares<br /> in millions</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br /> average fair<br /> value at grant<br /> date in USD</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">74.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">87.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">82.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">74.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">75.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">82.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">89.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">76.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">78.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">91.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_0" escape="true" continuedAt="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_1">
          <div></div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-60</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_1" continuedAt="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_2">
          <div>
            <div id="anchorId001553971"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NumberOfContractsWithRelatedParties" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> agreements with Genentech, Inc., United States (Genentech), and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member" name="nvs:NumberOfContractsWithRelatedParties" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Lucentis</i>
              </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of <i>Lucentis</i> products outside the United States. From January 1, 2021 until December 6, 2021, <i>Lucentis</i> sales of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">2.0</ix:nonFraction> billion (2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.9</ix:nonFraction> billion) were recognized by Novartis.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Xolair</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of <i>Xolair</i> of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.3</ix:nonFraction> billion (2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.3</ix:nonFraction> billion), including sales to Genentech/Roche for the United States market.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Luxturna</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction> million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction> million).</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember" name="nvs:BorrowingsCreditFacilityUncommitted" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">11</ix:nonFraction> Executive Committee members (&#x201C;Executive Officers&#x201D;). During 2022, <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" decimals="0" scale="0" format="ixt:numdotdecimal">5</ix:nonFraction> Executive Officers stepped down. At December 31, 2021, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">12</ix:nonFraction> Executive Officers. During 2021, <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" decimals="0" scale="0" format="ixt:numdotdecimal">3</ix:nonFraction> Executive Officers stepped down. At December 31, 2020, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">13</ix:nonFraction> Executive Officers. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total compensation for Executive Committee members and the <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">15</ix:nonFraction> Non-Executive Directors (<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction> in 2021 and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction> in 2020) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OfficerAndDirectorCompensationTableTextBlock" id="SectionBlock_f8ce85dd-5c43-4b83-871d-5af5fbcaae66_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">20.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">29.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">30.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">37.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">41.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">47.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">46.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">70.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">60.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">69.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">79.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">79.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-61</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely&#x201D; linked to them:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" id="SectionBlock_e5dd701d-4d9d-4379-ad23-80acfcde8ac2_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="0" scale="0" format="ixt:numdotdecimal">60 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="0" scale="0" format="ixt:numdotdecimal">60 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCommitmentsAndContingenciesTextBlock" id="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_0" escape="true" continuedAt="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_1">
          <div>
            <div id="anchorId001554416"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingent liabilities</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, the amount and estimated timing of the Group&#x2019;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfLeasingCommitmentsTableTextBlock" id="SectionBlock_6b5c1239-9656-406c-88fe-ce7b4fc5a4ca_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">448</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">282</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">3 169</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">5 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:UncalledCapitalCommitmentsForInvestmentsInFunds" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction> million. Note 29 contains further information on the Group&#x2019;s investments in funds.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent liabilities</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-62</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_1" continuedAt="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">claims that could have a material adverse effect on its results of operations or cash flow.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-63</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_2">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_0" escape="true" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_1">
          <div>
            <div id="anchorId001554566"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments&#xA0;&#x2013;&#xA0;additional disclosures</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" id="SectionBlock_83455b65-ee84-4322-bc8c-0ee8ab565917_0" escape="true" continuedAt="SectionBlock_83455b65-ee84-4322-bc8c-0ee8ab565917_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Financial<br /> instruments at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br /> Financial<br /> instruments at<br /> fair value<br /> through other<br /> comprehensive<br /> income</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br /> instruments at<br /> fair value<br /> through the<br /> consolidated<br /> income<br /> statement</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> Other<br /> financial<br /> liabilities at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">828</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">27 971</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 581</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 067</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">31 266</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-64</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_1" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_83455b65-ee84-4322-bc8c-0ee8ab565917_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Financial<br /> instruments at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Financial<br /> instruments at<br /> fair value<br /> through other<br /> comprehensive<br /> income</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br /> instruments at<br /> fair value<br /> through the<br /> consolidated<br /> income<br /> statement</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Other<br /> financial<br /> liabilities at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10 397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 965</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 195</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">32 492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 094</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">37 491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#xA0;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#xA0;2022 and 2021. </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="SectionBlock_bbe7a3f1-bd36-4956-9339-9215d10601c4_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">7 907</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">13 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13 347</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-65</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_2" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#xA0;31,&#xA0;2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" id="SectionBlock_d1ab7852-8b86-4823-b778-bfeb636da15c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">5 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">7 907</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">5 158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">6 605</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">13 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 605</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13 347</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory" id="SectionBlock_62f6dc80-01e8-4ae5-89bf-0e67786794f1_0" escape="true" continuedAt="SectionBlock_62f6dc80-01e8-4ae5-89bf-0e67786794f1_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">699</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 070</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-66</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_3" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_4">
          <div>
            <div>
              <ix:continuation id="SectionBlock_62f6dc80-01e8-4ae5-89bf-0e67786794f1_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 697</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 596</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 704</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 094</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 162</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" id="SectionBlock_9da19097-084d-48ba-affd-00fc749eb4f2_0" escape="true" continuedAt="SectionBlock_9da19097-084d-48ba-affd-00fc749eb4f2_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br /> companies at <br /> fair value  through<br /> profit and loss</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Fund<br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Long-term <br /> financial <br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Contingent <br /> consideration <br /> receivables</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Contingent <br /> consideration <br /> liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Other<br /> financial<br /> liabiltiies</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">530</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">231</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">699</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">835</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">74</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-67</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_4" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_9da19097-084d-48ba-affd-00fc749eb4f2_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br /> companies at <br /> fair value  through<br /> profit and loss</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Fund<br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Long-term <br /> financial <br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Contingent <br /> consideration <br /> receivables</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Contingent <br /> consideration <br /> payables</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 046</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">22</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">88</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">42</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div></div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" id="SectionBlock_ac7a5ed5-584b-4bc8-9e40-4ec9fdf6e40c_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6">44</ix:nonFraction> million (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6">73</ix:nonFraction> million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million).</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction> million and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction> million, respectively.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&#xA0;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" decimals="-6" scale="6">154</ix:nonFraction> million and USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" decimals="-6" scale="6" sign="-">140</ix:nonFraction> million, respectively.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">65</ix:nonFraction> non-listed equity securities (December 31, 2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">60</ix:nonFraction>) and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">46</ix:nonFraction> listed equity securities (December 31, 2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">40</ix:nonFraction>) in this category with the following fair values:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="SectionBlock_a230cb1a-e9ec-4f38-854e-af27c697c178_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">888</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">390</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">828</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 195</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction> million were sold (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction> million), and the USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction> million gain on disposal (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction> million), were sold, and the USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million loss on disposal (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million gain) was transferred from other comprehensive income to retained earnings (see Note 8).</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-68</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_5" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_6">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</span>
                </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#x201C;Financial reporting in Hyperinflationary Economies.&#x201D; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#xA0;<ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion (USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">2.0</ix:nonFraction> billion; December 31, 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">2.1</ix:nonFraction> billion), has been designated as a hedge instrument. During 2022, USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction> million of net of taxes unrealized income (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction> million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:MaximumMarginPercentageImpactOfCommodityPriceChange" decimals="2" scale="-2">10</ix:nonFraction>%</span> of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:MaximumHoldingInUnrelatedCompany" decimals="2" scale="-2">5</ix:nonFraction>%</span> of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-69</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_6" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_7">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">receivables over the entire holding period of the trade receivables.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s largest customer accounted for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">16</ix:nonFraction>%</span> of net sales to third parties, and the second largest and third largest customers accounted for <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">7</ix:nonFraction>%</span> of net sales to third parties, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively; 2020: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">14</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively, of the Group&#x2019;s trade receivables at December 31, 2022 (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">12</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively). There is no other significant concentration of customer credit risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">13.2</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.2</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">6.8</ix:nonFraction>%</span>, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.7</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.7</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">7.6</ix:nonFraction>%</span>, respectively). As of December 31, 2021, the Group&#x2019;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:PercentageOfGovernmentBackedDebtSecurities" decimals="2" scale="-2">16</ix:nonFraction>%</span> (2022: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:PercentageOfGovernmentBackedDebtSecurities" decimals="2" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> US commercial paper programs under which it can issue up to USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-9" scale="9">9.0</ix:nonFraction> billion in the aggregate of unsecured commercial paper notes. Novartis also has <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Japanese commercial paper program under which it can issue up to JPY&#xA0;<ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-9" scale="9">150</ix:nonFraction> billion (approximately USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">1.1</ix:nonFraction> billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">2.8</ix:nonFraction> billion under these <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> programs were outstanding as per December 31, 2022 (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">0.9</ix:nonFraction> billion). Novartis further has a committed credit facility of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCreditFacilityCommitted" decimals="-9" scale="9">6.0</ix:nonFraction> billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-70</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_7" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_8">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" id="SectionBlock_6ede1c8c-2045-424c-9224-55af834fb9ee_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 911</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">11 098</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4 011</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">3 506</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">10 564</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 002</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 394</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 396</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 515</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 876</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 517</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 878</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 519</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 405</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">2 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">11 134</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">14 585</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">15 706</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 406</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 001</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">19 650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 095</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 438</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 490</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 587</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">23 077</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 438</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 780</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 926</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 227</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 780</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 928</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 229</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 830</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">537</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 928</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 608</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19 113</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">1 833</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">8 460</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">14 296</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-71</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_8" continuedAt="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_9">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" id="SectionBlock_3defb8d3-21f0-4891-9ee7-418d75bf2263_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 598</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 943</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 029</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 712</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 062</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">843</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 482</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">847</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 516</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">457</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 820</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" id="SectionBlock_49e23e5c-d9f3-448d-8a54-4b28af29f6eb_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">412</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 432</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 624</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 532</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 020</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">437</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">82</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">445</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 628</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 908</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6 063</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">639</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 373</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">517</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sensitivity analysis</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The sensitivity analysis disclosures are in line with the Group&#x2019;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-72</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_9">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures below illustrate the potential impact on the Group&#x2019;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#x2019;s view of changes that are reasonably possible over a one-year period. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate sensitivity</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" decimals="2" scale="-2">5</ix:nonFraction>%</span> increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#x2019;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" id="SectionBlock_f8825478-f50f-4846-9d23-624d8b1cc861_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the Group designated EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion (December 31, 2021: EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" decimals="2" scale="-2">5</ix:nonFraction>%</span> increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#x2019;s consolidated equity as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" id="SectionBlock_2c20f494-743e-49d9-987b-c70507db517c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity price sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of these fund investments and equity securities was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:FairValueOfFundInvestmentsAndEquitySecurities" decimals="-8" scale="9">1.6</ix:nonFraction> billion as of December 31, 2022 (December 31, 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:FairValueOfFundInvestmentsAndEquitySecurities" decimals="-8" scale="9">2.2</ix:nonFraction> billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" decimals="2" scale="-2">15</ix:nonFraction>%</span> in the risk factors would have impacted the Group&#x2019;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" id="SectionBlock_5e0927b6-e24d-41ad-a5d6-8856dcca5c15_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">109</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">154</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A hypothetical increase or decrease of <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" decimals="2" scale="-2">15</ix:nonFraction>%</span> in the risk factors would have impacted the Group&#x2019;s consolidated equity as presented below:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" id="SectionBlock_d48c7316-5ef1-4f11-a893-c5a3990a0d76_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">179</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-73</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="SectionBlock_4b6a3970-287a-432a-a01a-a90cf72e8b6a_0" escape="true">
          <div>
            <div id="anchorId001561740"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">South Korea investigation &#x2013; Concluded matter</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2022 and approval of&#xA0;the Group&#x2019;s 2022 consolidated financial statements  </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" decimals="2" scale="0">3.20</ix:nonFraction> per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" decimals="-8" scale="9">7.3</ix:nonFraction> billion (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" decimals="-8" scale="9">7.5</ix:nonFraction>  billion), using the CHF/USD December 31, 2022, exchange rate.</div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-74</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" id="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_0" escape="true" continuedAt="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_1">
          <div>
            <div id="anchorId001561775"></div>
            <div id="anchorNote31"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Principal Group subsidiaries and&#xA0;associated&#xA0;companies </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#xAD;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>&#xA0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" id="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_0" escape="true" continuedAt="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Soci&#xE9;t&#xE9; par actions SANDOZ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Algiers</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DZD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">650.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Argentina S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Buenos Aires</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ARS" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">906.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Australia Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals
Australia Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Austria GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vienna</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vienna</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Kundl</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">32.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">EBEWE Pharma Ges.m.b.H Nfg. KG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Unterach am Attersee</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Bangladesh) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Gazipur</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BDT" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">162.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vilvoorde</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">72.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vilvoorde</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Alcon - Couvreur NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Puurs</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">110.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Investment Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">12 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Securities Investment Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">30 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance Services Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">20 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Triangle International Reinsurance Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Trinity River Insurance Co Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">370 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Bioci&#xEA;ncias S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">S&#xE3;o Paulo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BRL" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">507.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz do Brasil Ind&#xFA;stria Farmac&#xEA;utica Ltda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Camb&#xE9;, PR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BRL" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">190.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals Canada Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dorval, Quebec</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Canada Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Boucherville, Quebec</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">80.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Chile S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Santiago de Chile</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CLP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Beijing Novartis Pharma Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Beijing</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals (HK) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hong Kong</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HKD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">China Novartis Institutes for
BioMedical Research Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Shanghai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">320.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Suzhou Novartis Technical
Development Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Changshu</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Shanghai Novartis Trading Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Shanghai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz (China) Pharmaceutical
Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Zhongshan</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">57.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis de Colombia S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Santaf&#xE9; de Bogot&#xE1;</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="COP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">7.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz d.o.o. farmaceutska industrija</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Zagreb</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HRK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Prague</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CZK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Prague</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CZK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">44.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare A/S</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Copenhagen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DKK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz A/S</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Copenhagen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DKK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Ecuador S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Quito</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma S.A.E.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cairo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EGP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.96</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Egypt Pharma S.A.E.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">New Cairo City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EGP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">250 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finland Oy</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Espoo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">459 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Groupe France S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">903.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma S.A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">43.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies France SAS</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">10 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications
Molecular Imaging France</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Saint-Genis-Pouilly</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">CELLforCURE</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Les Ulis</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Levallois-Perret</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Deutschland GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Nuremberg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">155.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Business Services GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Wehr</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Nuremberg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Produktions GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Wehr</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz International GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">1 A Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">26 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">HEXAL AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">93.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Salutas Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Barleben</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">42.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Aeropharm GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rudolstadt</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">26 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Hellas) S.A.C.I.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Metamorphosis / Athens</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">233.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Hungary Healthcare Limited Liability
Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Budapest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HUF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">545.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Hungary Limited Liability Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Budapest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HUF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">883.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis India Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">123.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">70.68</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare Private Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Private Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">32.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">PT. Novartis Indonesia</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Jakarta</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="IDR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">7.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Ireland Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dublin</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Integrated Services Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cork City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies EU Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dublin</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Israel Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tel Aviv</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ILS" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farma S.p.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Milan</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">18.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications (Italy) S.r.l.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Pozzilli</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">119 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.p.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Origgio</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma K.K.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Ciba-Geigy Japan Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz K.K.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Baltics SIA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Riga</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Investments S.&#xE0; r.l.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Luxembourg City</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Luxembourg City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Corporation (Malaysia) Sdn. Bhd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Petaling Jaya</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MYR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farmac&#xE9;utica, S.A. de C.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mexico City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MXN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">205.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz, S.A. de C.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mexico City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MXN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">468.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Maroc SA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Casablanca</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Netherlands B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Amsterdam</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Amsterdam</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">IDB Holland BV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Baarle-Nassau</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">18 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Almere</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">907 560</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis New Zealand Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Auckland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="NZD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">820 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-75</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_1" continuedAt="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_1" continuedAt="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_2">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Norge AS</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Oslo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="NOK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma (Pakistan) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Karachi</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PKR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.99</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma (Logistics), Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Panama City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">10 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare Philippines, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Makati City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PHP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">298.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Philippines Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Makati City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PHP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Poland Sp. z o.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Warsaw</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">44.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Polska Sp. z o.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Warsaw</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Lek S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Strykow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">11.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Portugal, S.G.P.S., Lda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">500 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farma - Produtos Farmac&#xEA;uticos, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Farmac&#xEA;utica, Lda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">499 900</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Services Romania S.R.L.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bucharest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RON" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.R.L.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Targu-Mures</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RON" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">119.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Moscow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Neva LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">St. Petersburg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">JSC Sandoz</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Moscow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">57.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Saudi Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Riyadh</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Singapore) Pte Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Asia Pacific Pharmaceuticals
Pte Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">39.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Slovakia s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bratislava</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Lek Pharmaceuticals d.d.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ljubljana</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pharmaceuticals d.d.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ljubljana</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis South Africa (Pty) Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Midrand</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ZAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">86.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz South Africa (Pty) Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Midrand</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ZAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Korea Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Seoul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="KRW" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">24.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farmac&#xE9;utica, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Barcelona</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications
Iberica, S.L.U.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Esplugues de Llobregat</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Farmac&#xE9;utica S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Madrid</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">270 450</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Industrial Products
S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Les Franqueses del Vall&#xE9;s / Barcelona</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Abadia Retuerta S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Sard&#xF3;n de Duero / Valladolid</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Sverige AB</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Stockholm</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SEK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis International AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Holding AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis International Pharmaceutical Investment AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Bioventures AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Forschungsstiftung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Stiftung f&#xFC;r Kaderausbildung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis-Mitarbeiterbeteiligungsstiftung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Stiftung f&#xFC;r Mensch und Umwelt</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Stiftung der Novartis AG f&#xFC;r Erziehung,
Ausbildung und Bildung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Overseas Investments AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Japat AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">50 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Services AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Schweizerhalle AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Muttenz</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">18.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Stein AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Stein</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">251 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Schweiz AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Cellerys AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Schlieren</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">129 630</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Arctos Medical AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bern</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">360 020</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Innovative Therapies AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications International SA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Geneva</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pharmaceuticals AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Taiwan) Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Taipei</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TWD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">170.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Thailand) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bangkok</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="THB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">302.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Saglik, Gida ve Tarim &#xDC;r&#xFC;nleri Sanayi
ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">448.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Farmanova Saglik Hizmetleri Ltd. Sti.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Ila&#xE7; Sanayi ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">880.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.99</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Grup Saglik &#xDC;r&#xFC;nleri
Ila&#xE7;lari Sanayi ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Gebze - Kocaeli</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">96.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Ukraine LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Kyiv</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="UAH" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Middle East FZE</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dubai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AED" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis UK Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals UK Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Grimsby Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications (UK &amp; Ireland)</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Neutec Pharma Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="1" scale="0" format="ixt:numdotdecimal">7.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Gyroscope Therapeutics Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 492</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Frimley / Camberley</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">72.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Capital Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Services, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis US Foundation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications USA, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Millburn, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bannockburn, IL</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Technology LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Institutes for BioMedical
Research, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cambridge, MA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Cadent Therapeutics</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cambridge, MA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="1" scale="0" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Endocyte, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Navigate BioPharma Services, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Carlsbad, CA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">The Medicines Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Princeton, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Oriel Therapeutics, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Durham, NC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Fougera Pharmaceuticals Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Melville, NY</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Eon Labs, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Princeton, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis de Venezuela, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Caracas</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="VEF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Vietnam Company Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ho Chi Minh City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="VND" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-9" scale="9" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-76</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_2">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <div>
          <div id="anchorAudit"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Report of Independent Registered Public Accounting Firm</p>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">To the shareholders and the Board of Directors of Novartis AG</span>
          </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We have audited the accompanying consolidated balance sheet of Novartis AG, and its consolidated subsidiaries (the Group) as of December&#xA0;31, 2022, the related consolidated statements of income, comprehensive income, changes in equity, and cash flows for the year ended December&#xA0;31, 2022, and the related notes (collectively, the consolidated financial statements). We also have audited the Group&#x2019;s internal control over financial reporting as of December&#xA0;31, 2022, based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group as of December&#xA0;31, 2022, and the results of its operations and its cash flows for the year ended December&#xA0;31, 2022, in conformity with International Financial Reporting Standards (&#x201C;IFRS&#x201D;) as issued by the International Accounting Standards Board. Also in our opinion, the Group maintained, in all material respects, effective internal control over financial reporting as of December&#xA0;31, 2022 based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the COSO.  </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Basis for Opinions</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Novartis Management on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Group&#x2019;s consolidated financial statements and an opinion on the Group&#x2019;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our audit of the consolidated  financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span>
          </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1)&#xA0;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#xA0;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#xA0;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-77</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Critical Audit Matters</span>
          </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</div>
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Assessment of the recoverable amount for the Leqvio and Xiidra intangible assets</div>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As discussed in Note 1 to the consolidated financial statements, the Group determined the recoverable amount of the intangible assets other than goodwill based on the fair value less costs of disposal method for which no directly observable market inputs were available. As discussed in Note 11, the Group has intangible assets in its Innovative Medicines Division other than goodwill totaling USD 29 826 million as at December 31, 2022, a portion of which related to the currently marketed products <i>Leqvio</i> and <i>Xiidra</i>. </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We identified the assessment of the recoverable amount, specifically the sales forecasts of the <i>Leqvio</i> and <i>Xiidra</i> intangible assets, as a critical audit matter. Significant auditor judgment and subjectivity was required to assess the sales forecasts assumptions which were a significant input in the determination of the recoverable amount of these intangible assets.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are the primary procedures we performed to address this critical audit matter:</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the design and tested the operating effectiveness of a certain internal control related to the Group&#x2019;s intangible asset impairment process for Leqvio and Xiidra, including the development of the sales forecasts;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the reasonableness of management&#x2019;s sales forecasts for Leqvio and Xiidra by (1) comparing certain underlying assumptions to company-specific operational information and management&#x2019;s communications to the board of directors, (2) comparing the most recent sales performance to previous drug launches, and (3) comparing certain underlying assumptions to available external market and industry data; and </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We assessed management&#x2019;s ability to accurately forecast sales by comparing historical sales forecasts for Leqvio and Xiidra to actual results.</div>
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Provisions for deductions from revenue related to Innovative Medicines US Managed Care, Medicare Part D and Medicaid rebate programs</div>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As discussed in Note 1 to the consolidated financial statements, the Group records provisions for estimated rebates as a deduction from revenue when the related revenue is recognized. Rebates involve the use of assumptions and judgements in the determination of the provision rates at the time revenues are recorded. Provision rates are influenced by the terms and conditions in the individual agreements, historical experience, product sales and growth rate, population growth, product pricing, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, and channels and payers. As discussed in Note 22, provisions for deductions from revenue totaled USD 6 732 million as at December 31, 2022, a portion of which related to Innovative Medicines US Managed Care, Medicare Part D and Medicaid rebate programs (hereafter &#x201C;IM US rebates&#x201D;). </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We identified the estimation of the IM US rebates provisions, specifically the provision rebate rates, as a critical audit matter. The evaluation of the provision rebate rates required a high degree of subjective auditor judgment as it involved estimating the portion of the Group&#x2019;s revenue which will ultimately be subject to a related rebate.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-78</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are the primary audit procedures we performed to address this critical audit matter:</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the design and tested the operating effectiveness of certain internal controls over the Group&#x2019;s IM US rebates process related to the development of the provision rebate rates;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We developed our own independent expectation of the IM US rebates provisions, by using internal information, including historical experience and trend analysis of actual rebate claims paid, and comparing it to management&#x2019;s actual recorded balances;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  For a sample of actual rebate claims processed by the Group, we evaluated the claims against the contractual and mandated terms of the rebate arrangements; and</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We assessed management&#x2019;s ability to accurately estimate the IM US rebates provisions by comparing historically recorded provisions to the actual amount that was ultimately paid by the Group.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">/s/ <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorName">KPMG AG</ix:nonNumeric></div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We have served as the Company&#x2019;s auditor since 2022.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
            <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorLocation">Basel, Switzerland</ix:nonNumeric>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">January 31, 2023</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-79</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorAudit2"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Report of Independent Registered Public Accounting Firm</p>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">To the shareholders and Board of Directors of Novartis AG</span>
          </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Opinion on the Financial Statements</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We have audited the consolidated balance sheet of Novartis AG and its subsidiaries (the &#x201C;Group&#x201D;) as of December 31, 2021, and the related consolidated income statements, consolidated statements of comprehensive income, consolidated statements of changes in equity, and consolidated statements of cash flows, for each of the two years in the period ended December 31, 2021, including the related notes appearing in item 18 (collectively referred to as the &#x201C;consolidated financial statements&#x201D;).</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Group as of December 31, 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021 in conformity with International Financial Reporting Standards (&#x201C;IFRS&#x201D;) as issued by the International Accounting Standards Board.  </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Basis for Opinion</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">These consolidated financial statements are the responsibility of the Group&#x2019;s management. Our responsibility is to express an opinion on the Group&#x2019;s consolidated financial statements based on our audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.  </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">/s/ <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorName">PricewaterhouseCoopers AG</ix:nonNumeric></div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
            <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorLocation">Basel, Switzerland</ix:nonNumeric>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">February 1, 2022</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We served as the Company&#x2019;s auditor from at least 1940 to 2022. We have not been able to determine the specific year we began serving as auditor of the Group&#x2019;s predecessors.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-80</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <br />
      <img src="x_coverback.jpg" alt="picture" />
      <br />
      <br />
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>2
<FILENAME>a23020120f-ex12_1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>

<html>
<head>
<title>EXHIBIT 12.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;12.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Vasant Narasimhan, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.   I have reviewed this annual report on Form&nbsp;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material
   fact or omit to state a material fact necessary to make the statements made, in light
   of the circumstances under which such statements were made, not misleading with respect
   to the period covered by this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included
   in this report, fairly present in all material respects the financial condition, results
   of operations and cash flows of the company as of, and for, the periods presented
   in this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.   The company&#x2019;s other certifying officer and I are responsible for establishing and
   maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have:
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls
   and procedures to be designed under our supervision, to ensure that material information
   relating to the company, including its consolidated subsidiaries, is made known to
   us by others within those entities, particularly during the period in which this report
   is being prepared;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control
   over financial reporting to be designed under our supervision, to provide reasonable
   assurance regarding the reliability of financial reporting and the preparation of
   financial statements for external purposes in accordance with generally accepted accounting
   principles;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and
   presented in this report our conclusions about the effectiveness of the disclosure
   controls and procedures, as of the end of the period covered by this report based
   on such evaluation; and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial
   reporting that occurred during the period covered by the annual report that has materially
   affected, or is reasonably likely to materially affect, the company&#x2019;s internal control
   over financial reporting; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent
   evaluation of internal control over financial reporting, to the company&#x2019;s auditors
   and the audit committee of the company&#x2019;s board of directors (or persons performing
   the equivalent functions):
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of
   internal control over financial reporting which are reasonably likely to adversely
   affect the company&#x2019;s ability to record, process, summarize and report financial information;
   and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who
   have a significant role in the company&#x2019;s internal control over financial reporting.

</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: May 15, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Executive Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>3
<FILENAME>a23020120f-ex12_2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>

<html>
<head>
<title>EXHIBIT 12.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;12.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Harry Kirsch, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.   I have reviewed this annual report on Form&nbsp;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material
   fact or omit to state a material fact necessary to make the statements made, in light
   of the circumstances under which such statements were made, not misleading with respect
   to the period covered by this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included
   in this report, fairly present in all material respects the financial condition, results
   of operations and cash flows of the company as of, and for, the periods presented
   in this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.   The company&#x2019;s other certifying officer and I are responsible for establishing and
   maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have:
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls
   and procedures to be designed under our supervision, to ensure that material information
   relating to the company, including its consolidated subsidiaries, is made known to
   us by others within those entities, particularly during the period in which this report
   is being prepared;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control
   over financial reporting to be designed under our supervision, to provide reasonable
   assurance regarding the reliability of financial reporting and the preparation of
   financial statements for external purposes in accordance with generally accepted accounting
   principles;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and
   presented in this report our conclusions about the effectiveness of the disclosure
   controls and procedures, as of the end of the period covered by this report based
   on such evaluation; and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial
   reporting that occurred during the period covered by the annual report that has materially
   affected, or is reasonably likely to materially affect, the company&#x2019;s internal control
   over financial reporting; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent
   evaluation of internal control over financial reporting, to the company&#x2019;s auditors
   and the audit committee of the company&#x2019;s board of directors (or persons performing
   the equivalent functions):
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of
   internal control over financial reporting which are reasonably likely to adversely
   affect the company&#x2019;s ability to record, process, summarize and report financial information;
   and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who
   have a significant role in the company&#x2019;s internal control over financial reporting.

</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: May 15, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Financial Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>4
<FILENAME>a23020120f-ex13_1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>

<html>
<head>
<title>EXHIBIT 13.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;13.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF VASANT NARASIMHAN, CHIEF EXECUTIVE OFFICER OF   NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,   AS ADOPTED PURSUANT TO SECTION 906   OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
   of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer
   of Novartis AG, a Swiss corporation (the &#x201c;Company&#x201d;), hereby certifies, to the best
   of such officer&#x2019;s knowledge, that:
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2022 (the &#x201c;Form 20-F&#x201d;)
   of the Company fully complies with the requirements of Section 13(a) or 15(d) of the
   Securities Exchange Act of 1934; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects,
   the financial condition and results of operations of the Company.
</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: May 15, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Executive Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>5
<FILENAME>a23020120f-ex13_2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>

<html>
<head>
<title>EXHIBIT 13.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;13.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF HARRY KIRSCH, CHIEF FINANCIAL OFFICER OF   NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,    AS ADOPTED PURSUANT TO SECTION 906   OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
   of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer
   of Novartis AG, a Swiss corporation (the &#x201c;Company&#x201d;), hereby certifies, to the best
   of such officer&#x2019;s knowledge, that:
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2022 (the &#x201c;Form 20-F&#x201d;)
   of the Company fully complies with the requirements of Section 13(a) or 15(d) of the
   Securities Exchange Act of 1934; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects,
   the financial condition and results of operations of the Company.
</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: May 15, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Financial Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nvs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical" xlink:href="nvs-20221231.xsd#statementsOfCashFlowParenthetical" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncomeCalc2" xlink:href="nvs-20221231.xsd#statementOfIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets1" xlink:type="locator"/>
      <link:calculationArc order="10.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets1" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:calculationArc order="17.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:calculationArc order="5.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="2.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="16.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="17.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="15.7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="15.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="2.8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_Commodities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="4.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nvs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:href="nvs-20221231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:href="nvs-20221231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:href="nvs-20221231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
   <link:definitionLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="7.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:definitionArc order="8.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:definitionArc order="2.1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="6.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="6.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="3.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_EntityAddressesAddressTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_BusinessContactMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorLocation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorFirmId" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFileNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityIncorporationStateCountryCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressAddressLine1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCityOrTown" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressPostalZipCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCountry" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentRegistrationStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAccountingStandard" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CountryRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CityAreaCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_LocalPhoneNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelFaxNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_Security12bTitle" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems1" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems1" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_SecurityExchangeName" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="77.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="78.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:definitionArc order="79.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="80.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:definitionArc order="81.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBearerShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="82.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherNetCashInflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsMaterialToEntity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_EmployeeBenefitsExpense" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_NetInvestmentHedgeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseTermEndDate" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PluvictoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ScemblixMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherHematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherRespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContractManufacturingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MatureOphthaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherSolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="77.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="78.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:definitionArc order="79.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="80.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="81.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:definitionArc order="82.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:definitionArc order="83.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:definitionArc order="84.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:definitionArc order="85.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:definitionArc order="86.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="87.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="88.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="89.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="90.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="91.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:definitionArc order="92.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="93.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="94.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="95.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="96.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:definitionArc order="97.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="98.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:definitionArc order="99.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="100.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_JSCSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="101.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="102.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="103.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="104.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:definitionArc order="105.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="106.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="107.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:definitionArc order="108.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:definitionArc order="109.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="110.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="111.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="112.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:definitionArc order="113.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="114.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:definitionArc order="115.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:definitionArc order="116.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="117.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="118.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="119.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="120.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="121.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="122.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:definitionArc order="123.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="124.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="125.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="126.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="127.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="128.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:definitionArc order="129.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:definitionArc order="130.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="131.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:definitionArc order="132.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CellerysAGSchlierenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:definitionArc order="133.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ArctosMedicalAGBernMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="134.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="135.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="136.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="137.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:definitionArc order="138.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="139.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="140.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="141.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="142.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:definitionArc order="143.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:definitionArc order="144.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:definitionArc order="145.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="146.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="147.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="148.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:definitionArc order="149.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="150.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="151.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="152.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="153.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="154.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="155.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="156.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="157.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="158.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:definitionArc order="159.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:definitionArc order="160.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="161.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="162.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="163.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="164.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:definitionArc order="165.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="166.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="167.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:definitionArc order="168.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:definitionArc order="169.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="170.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="171.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:definitionArc order="172.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:definitionArc order="173.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:definitionArc order="174.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:definitionArc order="175.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="176.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="177.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="178.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:definitionArc order="179.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="180.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:definitionArc order="181.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="182.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:definitionArc order="183.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="184.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="185.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="186.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="187.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="188.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="189.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="190.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="191.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="192.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:definitionArc order="193.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="194.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="195.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:definitionArc order="196.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="197.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="198.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="199.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:definitionArc order="200.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="201.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="202.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="203.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="204.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:definitionArc order="205.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:definitionArc order="206.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:definitionArc order="207.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:definitionArc order="208.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="209.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:definitionArc order="210.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:definitionArc order="211.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:definitionArc order="212.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:definitionArc order="213.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:definitionArc order="214.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="215.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="216.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="217.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:definitionArc order="218.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="219.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="220.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="221.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="222.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="223.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="224.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="225.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="226.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="227.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="228.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="229.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="230.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="231.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="232.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:definitionArc order="233.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:definitionArc order="234.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:definitionArc order="235.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:definitionArc order="236.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:definitionArc order="237.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:definitionArc order="238.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:definitionArc order="239.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="240.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:definitionArc order="241.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:definitionArc order="242.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:definitionArc order="243.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:definitionArc order="244.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="245.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="246.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="247.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:definitionArc order="248.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:definitionArc order="249.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="250.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="251.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="252.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="253.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="254.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:definitionArc order="255.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="256.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="257.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="258.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="259.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="260.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="261.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="262.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="263.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="264.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:definitionArc order="265.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="266.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="267.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:definitionArc order="268.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="269.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="270.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="271.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="272.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="273.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:definitionArc order="274.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:definitionArc order="275.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:definitionArc order="276.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:definitionArc order="277.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="278.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="279.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="280.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="281.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="282.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="283.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="284.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:definitionArc order="285.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="286.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="287.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="288.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:definitionArc order="289.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="290.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="291.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="292.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="293.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="294.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
   </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nvs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
   <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:label id="id_33621d8b" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHF" xlink:to="lbl_CHF_labels" xlink:type="arc"/>
      <link:label id="id_2109f0bd" xlink:label="lbl_label554299581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="lbl_CH" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CH" xlink:to="lbl_label554299581" xlink:type="arc"/>
      <link:label id="id_30237143" xlink:label="lbl_label807629123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentType" xlink:to="lbl_label807629123" xlink:type="arc"/>
      <link:label id="id_bb438c4" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7fdd0dd5" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
      <link:label id="id_18b26df5" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_2d4bde06" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
      <link:label id="id_e8d83cc" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Assets" xlink:to="lbl_Assets_labels" xlink:type="arc"/>
      <link:label id="id_1c011115" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
      <link:label id="id_17d32c44" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasuryShares" xlink:to="lbl_TreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_210754dc" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_EquityAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_5c95b1b" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_6ada4c7f" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Equity" xlink:to="lbl_Equity_labels" xlink:type="arc"/>
      <link:label id="id_217508c4" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
      <link:label id="id_202888aa" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="lbl_NoncurrentProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentProvisions" xlink:to="lbl_NoncurrentProvisions_labels" xlink:type="arc"/>
      <link:label id="id_30c761c7" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current provisions</link:label>
      <link:label id="id_70a3cca2" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_46c178af" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
      <link:label id="id_37698457" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_422c0184" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
      <link:label id="id_6a28968d" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Liabilities" xlink:to="lbl_Liabilities_labels" xlink:type="arc"/>
      <link:label id="id_35c7371a" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_6baaabed" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_EquityAndLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3794ff9e" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
      <link:label id="id_5ecd50fe" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipment" xlink:to="lbl_PropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_5f7f6e84" xlink:label="lbl_label1602186884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Goodwill" xlink:to="lbl_label1602186884" xlink:type="arc"/>
      <link:label id="id_78569540" xlink:label="lbl_label2018940224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label2018940224" xlink:type="arc"/>
      <link:label id="id_600994ad" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssets" xlink:to="lbl_DeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_76aa2451" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_2dffac3d" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Inventories" xlink:to="lbl_Inventories_labels" xlink:type="arc"/>
      <link:label id="id_3b71d990" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_OtherCurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47798f64" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_c46389d" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapital" xlink:to="lbl_IssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_7fe108cb" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReserves" xlink:to="lbl_OtherReserves_labels" xlink:type="arc"/>
      <link:label id="id_62ed78ce" xlink:label="lbl_label1659730126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterests" xlink:to="lbl_label1659730126" xlink:type="arc"/>
      <link:label id="id_40cd0a97" xlink:label="lbl_label1087179415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other non-current payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPayables" xlink:label="lbl_NoncurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentPayables" xlink:to="lbl_label1087179415" xlink:type="arc"/>
      <link:label id="id_314a7125" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilities" xlink:to="lbl_DeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_15149ace" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_48a2d168" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_65fe4156" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_OtherCurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4f6a78d8" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxLiabilitiesCurrent" xlink:to="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_63598632" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_654cedce" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_288deb92" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_b623bea" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
      <link:label id="id_3c0375d2" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_5eaf97e4" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_48a98684" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts</link:label>
      <link:label id="id_126c9e67" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative financial instruments</link:label>
      <link:label id="id_4f2ac258" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
      <link:label id="id_1abd43d3" xlink:label="lbl_label448611283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_label448611283" xlink:type="arc"/>
      <link:label id="id_3da2017e" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentAccountedForUsingEquityMethod" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_6c3d0a" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in associated companies</link:label>
      <link:label id="id_551c0fc4" xlink:label="lbl_label1427902404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_label1427902404" xlink:type="arc"/>
      <link:label id="id_42437f89" xlink:label="lbl_label1111719817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_label1111719817" xlink:type="arc"/>
      <link:label id="id_6e6b7ee6" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_47a37331" xlink:label="lbl_label1201894193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_label1201894193" xlink:type="arc"/>
      <link:label id="id_131d39b3" xlink:label="lbl_label320682419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAbstract" xlink:to="lbl_label320682419" xlink:type="arc"/>
      <link:label id="id_7f542d" xlink:label="lbl_label8344621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_label8344621" xlink:type="arc"/>
      <link:label id="id_622df1d" xlink:label="lbl_label102948637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_label102948637" xlink:type="arc"/>
      <link:label id="id_7ba5a5ef" xlink:label="lbl_label2074453487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_label2074453487" xlink:type="arc"/>
      <link:label id="id_88ddaa5" xlink:label="lbl_label143514277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_label143514277" xlink:type="arc"/>
      <link:label id="id_47732be6" xlink:label="lbl_label1198730214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_label1198730214" xlink:type="arc"/>
      <link:label id="id_47bd73ec" xlink:label="lbl_label1203598316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_label1203598316" xlink:type="arc"/>
      <link:label id="id_bca487e" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_PropertyPlantAndEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_567bb83c" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LandMember" xlink:to="lbl_LandMember_labels" xlink:type="arc"/>
      <link:label id="id_16f548da" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
      <link:label id="id_a7eb90b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BuildingsMember" xlink:to="lbl_BuildingsMember_labels" xlink:type="arc"/>
      <link:label id="id_4d69998b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
      <link:label id="id_62ebaccc" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConstructionInProgressMember" xlink:to="lbl_ConstructionInProgressMember_labels" xlink:type="arc"/>
      <link:label id="id_74f44044" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
      <link:label id="id_451f7511" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MachineryMember" xlink:to="lbl_MachineryMember_labels" xlink:type="arc"/>
      <link:label id="id_50dda083" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and other equipment</link:label>
      <link:label id="id_6f28e51b" xlink:label="lbl_label1864951067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_label1864951067" xlink:type="arc"/>
      <link:label id="id_7c438c3d" xlink:label="lbl_label2084801597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_label2084801597" xlink:type="arc"/>
      <link:label id="id_5e0af6ee" xlink:label="lbl_label1577776878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_label1577776878" xlink:type="arc"/>
      <link:label id="id_345f7738" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossCarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember_labels" xlink:type="arc"/>
      <link:label id="id_77df9cb5" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
      <link:label id="id_4145517b" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
      <link:label id="id_1f5560c5" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_7baa32ee" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_3eb55d39" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_31501db" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_53833bce" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_648c3365" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_5803c369" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_54f4afbb" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
      <link:label id="id_f07d187" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationPropertyPlantAndEquipment" xlink:to="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_57f67848" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_6a50bcb" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_4bc845d6" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_6bc0d1d9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3cc1cda9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_2b7f313a" xlink:label="lbl_label729755962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net book value of Property, plant and equipment under finance lease contracts</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:to="lbl_label729755962" xlink:type="arc"/>
      <link:label id="id_260ca259" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_34818382" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments for purchases of property, plant and equipment</link:label>
      <link:label id="id_54bcbe9d" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing costs capitalised</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingCostsCapitalised" xlink:to="lbl_BorrowingCostsCapitalised_labels" xlink:type="arc"/>
      <link:label id="id_555c8c31" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:type="arc"/>
      <link:label id="id_4c298205" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRate" xlink:to="lbl_BorrowingsInterestRate_labels" xlink:type="arc"/>
      <link:label id="id_4611e1b4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on borrowings for new additions</link:label>
      <link:label id="id_3caaa61e" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized borrowing costs</link:label>
      <link:label id="id_5cb7a23f" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization rate used to determine the amount of borrowing costs eligible for capitalization</link:label>
      <link:label id="id_556c754b" xlink:label="lbl_label1433171275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementTable" xlink:to="lbl_label1433171275" xlink:type="arc"/>
      <link:label id="id_17e10fbe" xlink:label="lbl_label241915143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementLineItems" xlink:to="lbl_label241915143" xlink:type="arc"/>
      <link:label id="id_556e2a5d" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_62e43be9" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_7abef04f" xlink:label="lbl_label782106324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_label782106324" xlink:type="arc"/>
      <link:label id="id_611528f2" xlink:label="lbl_label1628776690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories Disclosure [abstract]</link:label>
      <link:label id="id_7f461082" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInventoriesExplanatory" xlink:to="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6d592b5d" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_label1628776690" xlink:type="arc"/>
      <link:label id="id_47e475f1" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1795799b" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories by class</link:label>
      <link:label id="id_543a8d3d" xlink:label="lbl_label1413123389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_label1413123389" xlink:type="arc"/>
      <link:label id="id_781cb00d" xlink:label="lbl_label2015145997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryAxis" xlink:to="lbl_label2015145997" xlink:type="arc"/>
      <link:label id="id_b0e25e5" xlink:label="lbl_label185476581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryMember" xlink:to="lbl_label185476581" xlink:type="arc"/>
      <link:label id="id_1b583e85" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRawMaterialsGrossMember" xlink:to="lbl_InventoryRawMaterialsGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_2bb8c828" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material, consumables</link:label>
      <link:label id="id_9dcab16" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in progress, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWorkInProgressGrossMember" xlink:to="lbl_InventoryWorkInProgressGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_696df603" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
      <link:label id="id_5b4c39ad" xlink:label="lbl_label1531722157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished products</link:label>
      <link:label id="id_2f569fbd" xlink:label="lbl_label794206141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished goods, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label794206141" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label1531722157" xlink:type="arc"/>
      <link:label id="id_4819bb17" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryLineItems_labels" xlink:type="arc"/>
      <link:label id="id_29f36af5" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_4b29af41" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:type="arc"/>
      <link:label id="id_2b41374" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as expense</link:label>
      <link:label id="id_11cae639" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWritedown2011" xlink:to="lbl_InventoryWritedown2011_labels" xlink:type="arc"/>
      <link:label id="id_1fa3a1d8" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_6f7b4a87" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversals of inventory provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfInventoryWritedown" xlink:to="lbl_ReversalOfInventoryWritedown_labels" xlink:type="arc"/>
      <link:label id="id_56e8eb36" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
      <link:label id="id_39ec1db2" xlink:label="lbl_label971775410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_label971775410" xlink:type="arc"/>
      <link:label id="id_58dc47d3" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareExplanatory" xlink:to="lbl_EarningsPerShareExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_20fad442" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_5ead42de" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5719e1f6" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_531039b4" xlink:label="lbl_label1393572276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_label1393572276" xlink:type="arc"/>
      <link:label id="id_6cb953c7" xlink:label="lbl_label1824084935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_label1824084935" xlink:type="arc"/>
      <link:label id="id_1efe1d89" xlink:label="lbl_label519970185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing and discontinued operations [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_label519970185" xlink:type="arc"/>
      <link:label id="id_26f22885" xlink:label="lbl_label653404293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate continuing and discontinued operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_label653404293" xlink:type="arc"/>
      <link:label id="id_a503764" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingOperationsMember" xlink:to="lbl_ContinuingOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_64674183" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_7aa601bd" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/loss attributable to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToOwnersOfParent" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_68d30e6d" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
      <link:label id="id_5a4aec87" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageShares" xlink:to="lbl_WeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_1d84ebe1" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding used in the basic earnings per share</link:label>
      <link:label id="id_4e4dd4b7" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:type="arc"/>
      <link:label id="id_4486a95d" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</link:label>
      <link:label id="id_627adbc2" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustedWeightedAverageShares" xlink:to="lbl_AdjustedWeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_3ec2f3b5" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares in diluted earnings per share</link:label>
      <link:label id="id_75396e0c" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_35298166" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Continuing operations</link:label>
      <link:label id="id_4d75874f" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_57208e0e" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Discontinued operations</link:label>
      <link:label id="id_3bf5aca3" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_51010c7c" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total basic earnings per share</link:label>
      <link:label id="id_48b2fef8" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_2cf2996b" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_4e26e1ff" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_28929982" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total diluted earnings per share</link:label>
      <link:label id="id_3969c29" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Continuing operations</link:label>
      <link:label id="id_aa58d2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Discontinued operations</link:label>
      <link:label id="id_10d604a9" xlink:label="lbl_label282461353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_label282461353" xlink:type="arc"/>
      <link:label id="id_6b10381b" xlink:label="lbl_label1796225051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_label1796225051" xlink:type="arc"/>
      <link:label id="id_40fad394" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_43e147c6" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:label id="id_56bb2315" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_51b234f9" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
      <link:label id="id_4c34e5bc" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Movements of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_49099ca4" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of goodwill and intangible assets</link:label>
      <link:label id="id_73128ea8" xlink:label="lbl_label1930596008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment</link:label>
      <link:label id="id_4a2c58f" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77ac0526" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation</link:label>
      <link:label id="id_63728238" xlink:label="lbl_label1668448824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1668448824" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1930596008" xlink:type="arc"/>
      <link:label id="id_db941d3" xlink:label="lbl_label230244819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Income Tax [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_label230244819" xlink:type="arc"/>
      <link:label id="id_21d3fbe0" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxExplanatory" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3e9356c7" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_78295b76" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Taxes [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeBeforeTaxesTableTextBlock" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c349cd3" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_12bf41b8" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and deferred Income Tax Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47b0c493" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and deferred income tax expense</link:label>
      <link:label id="id_553ce855" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of Tax Rate [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfTaxRateTableTextBlock" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3410484d" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of tax rate</link:label>
      <link:label id="id_58de322f" xlink:label="lbl_label1490956847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1490956847" xlink:type="arc"/>
      <link:label id="id_643ddbd0" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of interest expense [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseExplanatory" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_54a1e622" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other financial income and expense</link:label>
      <link:label id="id_1f6de87d" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseTableTextBlock" xlink:to="lbl_InterestExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6f7654df" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_3d171b85" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Income and Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_94ad887" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_4a94ff2f" xlink:label="lbl_label1934317586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Deferred Tax Assets and Liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1934317586" xlink:type="arc"/>
      <link:label id="id_7354dcb2" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7f591b1f" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liablities</link:label>
      <link:label id="id_1f4ff3aa" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21fac415" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:label id="id_36d33958" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</link:label>
      <link:label id="id_59f2fa2f" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_73861c88" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided</link:label>
      <link:label id="id_34022912" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1ccd7026" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value of tax-loss carry-forwards</link:label>
      <link:label id="id_3232a79c" xlink:label="lbl_label842180508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_label842180508" xlink:type="arc"/>
      <link:label id="id_4b3b4099" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3f1625ed" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
      <link:label id="id_3d96e2f9" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_56feb2c8" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment</link:label>
      <link:label id="id_8ac126c" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4312f4e1" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets</link:label>
      <link:label id="id_16da82f9" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for subsidiaries [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_61c4e7e5" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scope of consolidation</link:label>
      <link:label id="id_2b17ff8e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_57c3715e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currencies</link:label>
      <link:label id="id_18360a81" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b7df679" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of assets</link:label>
      <link:label id="id_9c406cf" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_634a44d" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment</link:label>
      <link:label id="id_785c05c7" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_64f7217c" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_5fb6702a" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27c2e0c0" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets available-for-use</link:label>
      <link:label id="id_980511b" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets not yet available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_31c63f04" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets not yet available-for-use</link:label>
      <link:label id="id_1a22e85b" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ecba446" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill and intangible assets</link:label>
      <link:label id="id_35764af6" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of associated companies accounted for at equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_547afa65" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of associated companies accounted for at equity</link:label>
      <link:label id="id_2741bbc2" xlink:label="lbl_label710888359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lbl_label710888359" xlink:type="arc"/>
      <link:label id="id_4c9d021c" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:type="arc"/>
      <link:label id="id_2dc53cba" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4f18679b" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7ee3df7f" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_5def73f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_63d0690f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and environmental liabilities</link:label>
      <link:label id="id_7371c5cb" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_55214b7d" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_7e49b25a" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23e7bf92" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans and other post retirement benefits</link:label>
      <link:label id="id_f50de43" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_21b13d04" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
      <link:label id="id_7b5ef0a7" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:type="arc"/>
      <link:label id="id_4f9fa5aa" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
      <link:label id="id_7912cc37" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_28239f2f" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_20541755" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b599b81" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
      <link:label id="id_1cb64794" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:type="arc"/>
      <link:label id="id_35eedb65" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
      <link:label id="id_11f1b42e" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_40e153e3" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
      <link:label id="id_2726a264" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_13936f53" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_4a557154" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7d2f6bd5" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale or held for distribution to owners</link:label>
      <link:label id="id_27c082e4" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:type="arc"/>
      <link:label id="id_455ebc" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of adopting significant new IFRS standards</link:label>
      <link:label id="id_11c5047" xlink:label="lbl_label18632775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="lbl_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentAbstract" xlink:to="lbl_label18632775" xlink:type="arc"/>
      <link:label id="id_7e2f70e6" xlink:label="lbl_label2117038310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangeAxis" xlink:to="lbl_label2117038310" xlink:type="arc"/>
      <link:label id="id_6a60d490" xlink:label="lbl_label1784730768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesMember" xlink:to="lbl_label1784730768" xlink:type="arc"/>
      <link:label id="id_64d1e224" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BottomOfRangeMember" xlink:to="lbl_BottomOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_5e09e4ca" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopOfRangeMember" xlink:to="lbl_TopOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_28553079" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="lbl_ComputerEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComputerEquipmentMember" xlink:to="lbl_ComputerEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_2be121a7" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and vehicles [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FurnitureAndVehiclesMember" xlink:label="lbl_FurnitureAndVehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FurnitureAndVehiclesMember" xlink:to="lbl_FurnitureAndVehiclesMember_labels" xlink:type="arc"/>
      <link:label id="id_613b73ea" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and vehicles</link:label>
      <link:label id="id_593b0650" xlink:label="lbl_label1497040464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_label1497040464" xlink:type="arc"/>
      <link:label id="id_42d9f411" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_3c815062" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brand names [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BrandNamesMember" xlink:label="lbl_BrandNamesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandNamesMember" xlink:to="lbl_BrandNamesMember_labels" xlink:type="arc"/>
      <link:label id="id_37b4dbd2" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsMember" xlink:to="lbl_OtherIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_7fe96854" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologybasedIntangibleAssetsMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_2340963a" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing related intangible assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketingRelatedIntangibleAssetsMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_44d0b847" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsMember" xlink:to="lbl_CurrentlyMarketedProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_796a6b5e" xlink:label="lbl_label2037017438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_label2037017438" xlink:type="arc"/>
      <link:label id="id_bc5c8b8" xlink:label="lbl_label197511352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_label197511352" xlink:type="arc"/>
      <link:label id="id_2449d337" xlink:label="lbl_label608817975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales or Research and Development [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CostOfSalesOrResearchAndDevelopmentMember" xlink:label="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:to="lbl_label608817975" xlink:type="arc"/>
      <link:label id="id_5073642b" xlink:label="lbl_label1349739563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_label1349739563" xlink:type="arc"/>
      <link:label id="id_7fef39d4" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense due to unwinding of discount on provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1de5231e" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpense_labels" xlink:type="arc"/>
      <link:label id="id_f4773bc" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expense arising from discounting long-term liabilities and capitalized borrowing costs</link:label>
      <link:label id="id_5a15aac0" xlink:label="lbl_label1549022431" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_7a288c00" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Interest Expense</link:label>
      <link:label id="id_55d5704a" xlink:label="lbl_label1440051274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1440051274" xlink:type="arc"/>
      <link:label id="id_1c654137" xlink:label="lbl_label476397879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income on forward contracts and options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeOnForwardContractsAndOptions" xlink:to="lbl_label476397879" xlink:type="arc"/>
      <link:label id="id_545ae83" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on net monetary position</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnNetMonetaryPosition" xlink:to="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:type="arc"/>
      <link:label id="id_550f9fc0" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary loss from hyperinflation</link:label>
      <link:label id="id_76a4da02" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_26393d9c" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency result, net</link:label>
      <link:label id="id_32d2b6d5" xlink:label="lbl_label852670165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_label852670165" xlink:type="arc"/>
      <link:label id="id_66ab5be5" xlink:label="lbl_label1722506213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_label1722506213" xlink:type="arc"/>
      <link:label id="id_4667b9e2" xlink:label="lbl_label1181202914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_label1181202914" xlink:type="arc"/>
      <link:label id="id_3f3ab48" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of domicile [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfDomicileMember" xlink:to="lbl_CountryOfDomicileMember_labels" xlink:type="arc"/>
      <link:label id="id_14841da" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign countries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ForeignCountriesMember" xlink:to="lbl_ForeignCountriesMember_labels" xlink:type="arc"/>
      <link:label id="id_56fc0dcb" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:label id="id_7d96a380" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
      <link:label id="id_58ec016" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossBeforeTax_labels" xlink:type="arc"/>
      <link:label id="id_55d23fd3" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccountingProfit" xlink:to="lbl_AccountingProfit_labels" xlink:type="arc"/>
      <link:label id="id_1207c251" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_d3303df" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income before taxes</link:label>
      <link:label id="id_5fb2cb43" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_477ea68" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:label id="id_4390e563" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpense" xlink:to="lbl_IncomeTaxExpense_labels" xlink:type="arc"/>
      <link:label id="id_c99559f" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_750153b3" xlink:label="lbl_label1963021235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of average effective tax rate and applicable tax rate [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_label1963021235" xlink:type="arc"/>
      <link:label id="id_5d2df8ac" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRate" xlink:to="lbl_ApplicableTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_74bd6dfe" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:label id="id_2c804df7" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of credits and allowances</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:type="arc"/>
      <link:label id="id_1d59fda1" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax credits and allowances</link:label>
      <link:label id="id_682f727c" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:to="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_514b6bd9" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write off of deferred tax assets</link:label>
      <link:label id="id_6710a9a" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from write down and reversal of write down of invest subsidiaries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_175786ff" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write down and reversal of write down of investments in subsidiaries</link:label>
      <link:label id="id_574b8256" xlink:label="lbl_label1464566358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax benefits expiring in 2017</link:label>
      <link:label id="id_5de8eaa3" xlink:label="lbl_label1575545507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from benefits expiring</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1575545507" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1464566358" xlink:type="arc"/>
      <link:label id="id_536d84ea" xlink:label="lbl_label1131311877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of non-deductible losses in Venezuela</link:label>
      <link:label id="id_4741211a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of adjustments for current tax of prior periods</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:type="arc"/>
      <link:label id="id_3fc4f53a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of prior year items</link:label>
      <link:label id="id_665323a" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of other items</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_dea5852" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_ee48bb4" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate continuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_37da283b" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for continuing operations</link:label>
      <link:label id="id_47841719" xlink:label="lbl_label1199839001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for discontinued operations</link:label>
      <link:label id="id_f9778dc" xlink:label="lbl_label261585116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label261585116" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label1199839001" xlink:type="arc"/>
      <link:label id="id_51bf64bc" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRate" xlink:to="lbl_AverageEffectiveTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_4e4514d0" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
      <link:label id="id_65d06a2f" xlink:label="lbl_label1708157487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1708157487" xlink:type="arc"/>
      <link:label id="id_482aa0f2" xlink:label="lbl_label1210753266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_label1210753266" xlink:type="arc"/>
      <link:label id="id_75d207b8" xlink:label="lbl_label1976698808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_label1976698808" xlink:type="arc"/>
      <link:label id="id_1bb2f625" xlink:label="lbl_label464713253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions and other benefit obligations of associates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:to="lbl_label464713253" xlink:type="arc"/>
      <link:label id="id_6d0f55ad" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesMember" xlink:to="lbl_InventoriesMember_labels" xlink:type="arc"/>
      <link:label id="id_7e43c96a" xlink:label="lbl_label2118371690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryforwardsMember" xlink:to="lbl_label2118371690" xlink:type="arc"/>
      <link:label id="id_112eae32" xlink:label="lbl_label288271922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets, provisions and accruals [member]</link:label>
      <link:label id="id_4d44190d" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_69dcdf60" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_65498be7" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilityAsset" xlink:to="lbl_DeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_46ad922f" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_637b5bc7" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_50e2e919" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
      <link:label id="id_54101181" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:type="arc"/>
      <link:label id="id_8409b0d" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to equity</link:label>
      <link:label id="id_5e5bb1e8" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_495f93f4" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to other comprehensive income</link:label>
      <link:label id="id_22e658d6" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_36e0af13" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_35a4b23c" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other movements deferred tax liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6e9211d6" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1e95490a" xlink:label="lbl_label513100042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:to="lbl_label513100042" xlink:type="arc"/>
      <link:label id="id_7845a7b2" xlink:label="lbl_label2017830834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:to="lbl_label2017830834" xlink:type="arc"/>
      <link:label id="id_76d7af65" xlink:label="lbl_label1993846629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesMember" xlink:to="lbl_label1993846629" xlink:type="arc"/>
      <link:label id="id_155fe654" xlink:label="lbl_label358606420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill from acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillFromAcquisitionsMember" xlink:to="lbl_label358606420" xlink:type="arc"/>
      <link:label id="id_2439e7db" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:type="arc"/>
      <link:label id="id_720fdd61" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax has been provided as they are permanent in nature</link:label>
      <link:label id="id_193f7081" xlink:label="lbl_label423587969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_label423587969" xlink:type="arc"/>
      <link:label id="id_6b884d65" xlink:label="lbl_label1804094821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_label1804094821" xlink:type="arc"/>
      <link:label id="id_37fff575" xlink:label="lbl_label939521397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_label939521397" xlink:type="arc"/>
      <link:label id="id_53909ff0" xlink:label="lbl_label1401987056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_label1401987056" xlink:type="arc"/>
      <link:label id="id_439c0ffd" xlink:label="lbl_label1134301181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalizedMember" xlink:to="lbl_label1134301181" xlink:type="arc"/>
      <link:label id="id_4f2ca3b1" xlink:label="lbl_label1328325553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotCapitalizedMember" xlink:to="lbl_label1328325553" xlink:type="arc"/>
      <link:label id="id_2654c6dd" xlink:label="lbl_label643090141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_label643090141" xlink:type="arc"/>
      <link:label id="id_4110ec53" xlink:label="lbl_label1091628115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_label1091628115" xlink:type="arc"/>
      <link:label id="id_5e6070e2" xlink:label="lbl_label1583378658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One year [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OneYearMember" xlink:to="lbl_label1583378658" xlink:type="arc"/>
      <link:label id="id_4ad3dc4f" xlink:label="lbl_label1255398479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TwoYearsMember" xlink:to="lbl_label1255398479" xlink:type="arc"/>
      <link:label id="id_5915ca9f" xlink:label="lbl_label1494600351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThreeYearsMember" xlink:to="lbl_label1494600351" xlink:type="arc"/>
      <link:label id="id_7bb728cd" xlink:label="lbl_label2075601101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FourYearsMember" xlink:to="lbl_label2075601101" xlink:type="arc"/>
      <link:label id="id_742ed8cf" xlink:label="lbl_label1949227215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FiveYearsMember" xlink:to="lbl_label1949227215" xlink:type="arc"/>
      <link:label id="id_347afbb1" xlink:label="lbl_label880475057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More than five years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MoreThanFiveYearsMember" xlink:to="lbl_label880475057" xlink:type="arc"/>
      <link:label id="id_74c41296" xlink:label="lbl_label94266701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</link:label>
      <link:label id="id_14f7a19b" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of tax loss carryforwards expired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:type="arc"/>
      <link:label id="id_6a5eff98" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards expired</link:label>
      <link:label id="id_70fd1364" xlink:label="lbl_label1895633764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1895633764" xlink:type="arc"/>
      <link:label id="id_522d9018" xlink:label="lbl_label1378717720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1378717720" xlink:type="arc"/>
      <link:label id="id_2f7867e" xlink:label="lbl_label49776254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:to="lbl_label49776254" xlink:type="arc"/>
      <link:label id="id_5d6e151" xlink:label="lbl_label97968465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:to="lbl_label97968465" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:type="locator"/>
      <link:label id="id_7db0af99" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses on available-for-sale securities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_27062936" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
      <link:label id="id_71a78a3a" xlink:label="lbl_label1906805306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_label1906805306" xlink:type="arc"/>
      <link:label id="id_52927dd" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f2bb8aa" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:label id="id_67e73888" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_634e228d" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_57b4381e" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6832ec2" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_1f868b2b" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of minimum finance lease payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2e528ce3" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum finance lease payments</link:label>
      <link:label id="id_6a1e58d8" xlink:label="lbl_label1780373720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_label1780373720" xlink:type="arc"/>
      <link:label id="id_574b2687" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2fe53b2a" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_2f9ef8c8" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsTableTextBlock" xlink:to="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c3d724c" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_229f76b0" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueAddedTaxReceivables" xlink:to="lbl_CurrentValueAddedTaxReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5dea7085" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT Receivable</link:label>
      <link:label id="id_68e173a" xlink:label="lbl_label1024297901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withholding tax recoverable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WithholdingTaxRecoverable" xlink:to="lbl_label1024297901" xlink:type="arc"/>
      <link:label id="id_7437ef3d" xlink:label="lbl_label905656156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - third party</link:label>
      <link:label id="id_6210dea9" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2201baf2" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - associated companies</link:label>
      <link:label id="id_61baeb33" xlink:label="lbl_label1639639859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAssociatedCompanies" xlink:to="lbl_label1639639859" xlink:type="arc"/>
      <link:label id="id_3ac7e1da" xlink:label="lbl_label986178010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables and current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReceivablesAndCurrentAssets" xlink:to="lbl_label986178010" xlink:type="arc"/>
      <link:label id="id_4072377e" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherCurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_e3db8e7" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial assets</link:label>
      <link:label id="id_d18502c" xlink:label="lbl_label219697196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_label219697196" xlink:type="arc"/>
      <link:label id="id_69021d0e" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4984da50" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash</link:label>
      <link:label id="id_24a0b3b8" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_443173b3" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments</link:label>
      <link:label id="id_34fe6088" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsTableTextBlock" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b8f74ee" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_808126e" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments held</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtInstrumentsHeld" xlink:to="lbl_DebtInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_6e00ca4f" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_22a6b8a5" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity instruments held</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInstrumentsHeld" xlink:to="lbl_EquityInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_724851f6" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_419c6f6a" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund instruments held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInstrumentsHeld" xlink:to="lbl_FundInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_53712316" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fund investments</link:label>
      <link:label id="id_17079bd" xlink:label="lbl_label1789088932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities</link:label>
      <link:label id="id_6c508a7b" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_24ec6e77" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short-term investments with original maturity more than 90 days</link:label>
      <link:label id="id_ef5ab87" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_4954716a" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
      <link:label id="id_57e2aa2d" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivable" xlink:to="lbl_InterestReceivable_labels" xlink:type="arc"/>
      <link:label id="id_6996ac87" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits</link:label>
      <link:label id="id_70ff77e4" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current accounts</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Cash" xlink:to="lbl_Cash_labels" xlink:type="arc"/>
      <link:label id="id_502a929f" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
      <link:label id="id_436c5591" xlink:label="lbl_label1131173265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsAbstract1" xlink:to="lbl_label1131173265" xlink:type="arc"/>
      <link:label id="id_20053f5" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:label id="id_47b73cba" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short term investments with original maturity less than 90 days</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashEquivalents" xlink:to="lbl_CashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_178a6550" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
      <link:label id="id_25a7d307" xlink:label="lbl_label631755527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities denominations [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesDenominationsAbstract" xlink:label="lbl_DebtSecuritiesDenominationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesDenominationsAbstract" xlink:to="lbl_label631755527" xlink:type="arc"/>
      <link:label id="id_6e4a0bf9" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt securities held</link:label>
      <link:label id="id_3758e5ae" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
      <link:label id="id_487fbdc1" xlink:label="lbl_label1216331201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in deferred tax balance [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_label1216331201" xlink:type="arc"/>
      <link:label id="id_41df7536" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period</link:label>
      <link:label id="id_2e28206a" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at end of period</link:label>
      <link:label id="id_4c171394" xlink:label="lbl_label1276580756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_label1276580756" xlink:type="arc"/>
      <link:label id="id_767010e4" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivable" xlink:to="lbl_ContingentConsiderationReceivable_labels" xlink:type="arc"/>
      <link:label id="id_1c964d9b" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables</link:label>
      <link:label id="id_1cc013c7" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47c06050" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
      <link:label id="id_2038ebb3" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
      <link:label id="id_7a406b1b" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current loans and receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLoansAndReceivables" xlink:to="lbl_NoncurrentLoansAndReceivables_labels" xlink:type="arc"/>
      <link:label id="id_69fe82c8" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current trade receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentTradeReceivables" xlink:to="lbl_NoncurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_56c9fa84" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets available-for-sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:to="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:type="arc"/>
      <link:label id="id_7f86a75a" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments</link:label>
      <link:label id="id_416abfec" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term receivables from customers</link:label>
      <link:label id="id_614e0e43" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans, advances and security deposits</link:label>
      <link:label id="id_2adc1935" xlink:label="lbl_label719067445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_label719067445" xlink:type="arc"/>
      <link:label id="id_372134b4" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_36e85d79" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
      <link:label id="id_3d890a89" xlink:label="lbl_label503420728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation plans assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredCompensationPlansAssets" xlink:to="lbl_label503420728" xlink:type="arc"/>
      <link:label id="id_5743c2dd" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid post-employment benefit plans assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:type="arc"/>
      <link:label id="id_509c8962" xlink:label="lbl_label1352436066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityAxis" xlink:to="lbl_label1352436066" xlink:type="arc"/>
      <link:label id="id_36becdba" xlink:label="lbl_label918474170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_label918474170" xlink:type="arc"/>
      <link:label id="id_19bac06a" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneYearMember" xlink:to="lbl_NotLaterThanOneYearMember_labels" xlink:type="arc"/>
      <link:label id="id_40351209" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_26dc6723" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsMember" xlink:to="lbl_LaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_678942b3" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not later than one year</link:label>
      <link:label id="id_65bceee2" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between one and five years</link:label>
      <link:label id="id_2043ab6e" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than five years</link:label>
      <link:label id="id_1c8984aa" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease provision</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseProvision" xlink:to="lbl_FinanceLeaseProvision_labels" xlink:type="arc"/>
      <link:label id="id_4a3761d0" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinanceLeaseReceivables" xlink:to="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5712ddf0" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
      <link:label id="id_3c5105da" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_IncomeStatementAbstract_labels" xlink:type="arc"/>
      <link:label id="id_3f03b5f7" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statements [abstract]</link:label>
      <link:label id="id_6acd9405" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoods_labels" xlink:type="arc"/>
      <link:label id="id_3a842f2" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_150c2b7f" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenue" xlink:to="lbl_OtherRevenue_labels" xlink:type="arc"/>
      <link:label id="id_127d952" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
      <link:label id="id_2760bdf6" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSales" xlink:to="lbl_CostOfSales_labels" xlink:type="arc"/>
      <link:label id="id_2b80a016" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
      <link:label id="id_57c5a20d" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossProfit" xlink:to="lbl_GrossProfit_labels" xlink:type="arc"/>
      <link:label id="id_526b4f9e" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:label id="id_39d76e39" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="lbl_SalesAndMarketingExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalesAndMarketingExpense" xlink:to="lbl_SalesAndMarketingExpense_labels" xlink:type="arc"/>
      <link:label id="id_28a0f9b9" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketing and Sales</link:label>
      <link:label id="id_10d069b8" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentExpense" xlink:to="lbl_ResearchAndDevelopmentExpense_labels" xlink:type="arc"/>
      <link:label id="id_6d2fdc24" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_57c6dbd9" xlink:label="lbl_label1472650201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIncome" xlink:to="lbl_label1472650201" xlink:type="arc"/>
      <link:label id="id_5f87ab8e" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_17803288" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
      <link:label id="id_1fe0c0c6" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_487c7d01" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss)/income from associated companies</link:label>
      <link:label id="id_36251eec" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_6dd27571" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_706453ab" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_1efbdca8" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_1ee0d5e9" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_390e92f5" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_62e876b4" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_6b81cf74" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_1f2a4c4f" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_41604097" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_68a67dec" xlink:label="lbl_label1755741676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_label1755741676" xlink:type="arc"/>
      <link:label id="id_4e036998" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_fc632c9" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6d6e73d7" xlink:label="lbl_label1835955159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_label1835955159" xlink:type="arc"/>
      <link:label id="id_78a7e003" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_2685ed2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_506c062c" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_4ec1d679" xlink:label="lbl_label1321326201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_label1321326201" xlink:type="arc"/>
      <link:label id="id_28aa5281" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the share capital [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareCapitalTableTextBlock" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_61f390ae" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the share capital</link:label>
      <link:label id="id_696322e3" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the shares [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareslTableTextBlock" xlink:to="lbl_MovementInTheShareslTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b7d854" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the shares</link:label>
      <link:label id="id_21fc0b5b" xlink:label="lbl_label570166107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_label570166107" xlink:type="arc"/>
      <link:label id="id_69f171dc" xlink:label="lbl_label1777431004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_label1777431004" xlink:type="arc"/>
      <link:label id="id_66229f4a" xlink:label="lbl_label1713545034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_label1713545034" xlink:type="arc"/>
      <link:label id="id_6258cf3f" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_ClassesOfShareCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_45684f10" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInEquity" xlink:to="lbl_ChangesInEquity_labels" xlink:type="arc"/>
      <link:label id="id_29e71b73" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in the year</link:label>
      <link:label id="id_4ed5effa" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMember" xlink:to="lbl_TreasurySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_17794e38" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesMember" xlink:to="lbl_OrdinarySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_b03287e" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:to="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:type="arc"/>
      <link:label id="id_1d73737e" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesOutstanding" xlink:to="lbl_NumberOfSharesOutstanding_labels" xlink:type="arc"/>
      <link:label id="id_4825d127" xlink:label="lbl_label1210437927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lbl_label1210437927" xlink:type="arc"/>
      <link:label id="id_4881ff43" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at beginning of period</link:label>
      <link:label id="id_40051e5a" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period</link:label>
      <link:label id="id_3bcbca2a" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at beginning of period</link:label>
      <link:label id="id_733911db" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at end of period</link:label>
      <link:label id="id_623febca" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital at beginning of period</link:label>
      <link:label id="id_35d913cc" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital at end of period</link:label>
      <link:label id="id_288f270c" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at end of period</link:label>
      <link:label id="id_140833fe" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at beginning of period</link:label>
      <link:label id="id_c7e7a97" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
      <link:label id="id_81b3b28" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
      <link:label id="id_102df8b6" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfTreasuryShares" xlink:to="lbl_PurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_151d9a8b" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale or issue of treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasuryShares" xlink:to="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_20b3b802" xlink:label="lbl_label548648962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_label548648962" xlink:type="arc"/>
      <link:label id="id_435514ee" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_176c4f1e" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events subsequent to the December 31 consolidated balance sheet date</link:label>
      <link:label id="id_34460981" xlink:label="lbl_label877005185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Typ [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_label877005185" xlink:type="arc"/>
      <link:label id="id_72e1dec5" xlink:label="lbl_label1927405253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_label1927405253" xlink:type="arc"/>
      <link:label id="id_1da2a9c4" xlink:label="lbl_label497199556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventMember" xlink:to="lbl_label497199556" xlink:type="arc"/>
      <link:label id="id_7f877b78" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_7b380046" xlink:label="lbl_label2067267654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_label2067267654" xlink:type="arc"/>
      <link:label id="id_16b78de2" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingencies [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4488d3fd" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:label id="id_2de2541f" xlink:label="lbl_label769807391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant transactions [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_label769807391" xlink:type="arc"/>
      <link:label id="id_157aa47d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Significant transactions [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_17fcde6d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant transactions</link:label>
      <link:label id="id_60f273a7" xlink:label="lbl_label1626502055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_label1626502055" xlink:type="arc"/>
      <link:label id="id_7edd823a" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7e94d6aa" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt</link:label>
      <link:label id="id_594cd676" xlink:label="lbl_label1498207862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_label1498207862" xlink:type="arc"/>
      <link:label id="id_716dfcd6" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ab48078" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments</link:label>
      <link:label id="id_3d80ff4e" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bcb7f48" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type</link:label>
      <link:label id="id_84597e5" xlink:label="lbl_label138778597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings</link:label>
      <link:label id="id_77855829" xlink:label="lbl_label2005227561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label2005227561" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label138778597" xlink:type="arc"/>
      <link:label id="id_689e379d" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4824ba8c" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by maturity</link:label>
      <link:label id="id_780939b8" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43204093" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by currency</link:label>
      <link:label id="id_75f0b654" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_18f19ce6" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison of balance sheet and fair value of total non-current financial debt including current portion</link:label>
      <link:label id="id_6962ebc4" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of collaerallized non-current financial debt and pledged assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1220efab" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaerallized non-current financial debt and pledged assets</link:label>
      <link:label id="id_4abca4e3" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1f8d2d9c" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative instruments</link:label>
      <link:label id="id_8188b7e" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Leasing commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77b05f18" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasing commitments</link:label>
      <link:label id="id_6662e9d6" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3f2ee562" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible purchase commitments</link:label>
      <link:label id="id_2a65b84f" xlink:label="lbl_label711309391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_label711309391" xlink:type="arc"/>
      <link:label id="id_1173f4bb" xlink:label="lbl_label292811963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_label292811963" xlink:type="arc"/>
      <link:label id="id_59b1ae19" xlink:label="lbl_label1504816665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_label1504816665" xlink:type="arc"/>
      <link:label id="id_a4d7aae" xlink:label="lbl_label172849838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lbl_label172849838" xlink:type="arc"/>
      <link:label id="id_717d4be6" xlink:label="lbl_label1904036838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lbl_label1904036838" xlink:type="arc"/>
      <link:label id="id_4d7a925b" xlink:label="lbl_label1299878491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lbl_label1299878491" xlink:type="arc"/>
      <link:label id="id_3b47450e" xlink:label="lbl_label994526478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lbl_label994526478" xlink:type="arc"/>
      <link:label id="id_4b9f759a" xlink:label="lbl_label1268741530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development and other intangible asset purchase commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_label1268741530" xlink:type="arc"/>
      <link:label id="id_714a8ba3" xlink:label="lbl_label1900710819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_label1900710819" xlink:type="arc"/>
      <link:label id="id_36fa2fba" xlink:label="lbl_label922365882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_label922365882" xlink:type="arc"/>
      <link:label id="id_5ab4de42" xlink:label="lbl_label632134259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments under long-term research and development agreements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:to="lbl_label632134259" xlink:type="arc"/>
      <link:label id="id_2ceef672" xlink:label="lbl_label753858162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:to="lbl_label753858162" xlink:type="arc"/>
      <link:label id="id_68d6c1f6" xlink:label="lbl_label1758904822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1758904822" xlink:type="arc"/>
      <link:label id="id_797bb3cc" xlink:label="lbl_label2038150092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:to="lbl_label2038150092" xlink:type="arc"/>
      <link:label id="id_7b1552fe" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermBorrowings" xlink:to="lbl_ShorttermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_5020629f" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank and other financial debt</link:label>
      <link:label id="id_13e39c07" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPapersIssued" xlink:to="lbl_CommercialPapersIssued_labels" xlink:type="arc"/>
      <link:label id="id_4fdebda8" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Papers</link:label>
      <link:label id="id_46dd5b19" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfLongtermBorrowings" xlink:to="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_7558c2a6" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:label id="id_36b8e550" xlink:label="lbl_label918086992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit derivative, fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditDerivativeFairValue" xlink:label="lbl_CreditDerivativeFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CreditDerivativeFairValue" xlink:to="lbl_label918086992" xlink:type="arc"/>
      <link:label id="id_3a9947a0" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_6dcd1b42" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative financial instruments</link:label>
      <link:label id="id_1dcb5ef8" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate, associates</link:label>
      <link:label id="id_2863fd2b" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current financial debt and derivative financial instruments</link:label>
      <link:label id="id_5aca2f89" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_74374cb6" xlink:label="lbl_label1949781174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_label1949781174" xlink:type="arc"/>
      <link:label id="id_7edb9957" xlink:label="lbl_label2128320855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:to="lbl_label2128320855" xlink:type="arc"/>
      <link:label id="id_10bc1963" xlink:label="lbl_label280762723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_label280762723" xlink:type="arc"/>
      <link:label id="id_300b69ab" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight bonds</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BondsIssued" xlink:to="lbl_BondsIssued_labels" xlink:type="arc"/>
      <link:label id="id_1e4e0830" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
      <link:label id="id_203f2415" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total including current portion of non-current financial debt</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Borrowings" xlink:to="lbl_Borrowings_labels" xlink:type="arc"/>
      <link:label id="id_1bc6ed35" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
      <link:label id="id_2e986311" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_355479bd" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current financial debts</link:label>
      <link:label id="id_162b1eed" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The amount of outstanding funds that the entity is obligated to repay</link:label>
      <link:label id="id_9d2aa80" xlink:label="lbl_label164801152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="lbl_label164801152" xlink:type="arc"/>
      <link:label id="id_adae114" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixYearsMember" xlink:to="lbl_LaterThanSixYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_2050f0fd" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than six years</link:label>
      <link:label id="id_7e44b35f" xlink:label="lbl_label72836716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_6a9e2b6" xlink:label="lbl_label111796918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_label111796918" xlink:type="arc"/>
      <link:label id="id_57bebc13" xlink:label="lbl_label1472117779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:to="lbl_label1472117779" xlink:type="arc"/>
      <link:label id="id_6cdc708" xlink:label="lbl_label114149128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_label114149128" xlink:type="arc"/>
      <link:label id="id_1ad42498" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:type="arc"/>
      <link:label id="id_4cf075ff" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts covered by collateral</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:type="arc"/>
      <link:label id="id_cf0451a" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amount of collateralized non-current financial debts</link:label>
      <link:label id="id_6e3a2d82" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net book value of property, plant and equipment pledged as collateral for non-current financial debts</link:label>
      <link:label id="id_139c747e" xlink:label="lbl_label329020542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_label329020542" xlink:type="arc"/>
      <link:label id="id_75a8b438" xlink:label="lbl_label1973990456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_label1973990456" xlink:type="arc"/>
      <link:label id="id_3e0c6c47" xlink:label="lbl_label1041001543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_label1041001543" xlink:type="arc"/>
      <link:label id="id_776f09d7" xlink:label="lbl_label2003765719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_label2003765719" xlink:type="arc"/>
      <link:label id="id_227fd573" xlink:label="lbl_label578803059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_label578803059" xlink:type="arc"/>
      <link:label id="id_40a70df4" xlink:label="lbl_label1084689908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:to="lbl_label1084689908" xlink:type="arc"/>
      <link:label id="id_59ab4811" xlink:label="lbl_label1504397329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:to="lbl_label1504397329" xlink:type="arc"/>
      <link:label id="id_57804983" xlink:label="lbl_label1468025219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:to="lbl_label1468025219" xlink:type="arc"/>
      <link:label id="id_7920acbc" xlink:label="lbl_label2032184508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:to="lbl_label2032184508" xlink:type="arc"/>
      <link:label id="id_3ab016cd" xlink:label="lbl_label984618701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:to="lbl_label984618701" xlink:type="arc"/>
      <link:label id="id_40a1b86b" xlink:label="lbl_label1084340331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:to="lbl_label1084340331" xlink:type="arc"/>
      <link:label id="id_78372e25" xlink:label="lbl_label2016882213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:to="lbl_label2016882213" xlink:type="arc"/>
      <link:label id="id_6e2b28f3" xlink:label="lbl_label1848322291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:to="lbl_label1848322291" xlink:type="arc"/>
      <link:label id="id_7c889c9" xlink:label="lbl_label130582985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:to="lbl_label130582985" xlink:type="arc"/>
      <link:label id="id_1321f0b" xlink:label="lbl_label20061963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:to="lbl_label20061963" xlink:type="arc"/>
      <link:label id="id_66ae9900" xlink:label="lbl_label1722718464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:to="lbl_label1722718464" xlink:type="arc"/>
      <link:label id="id_45d38312" xlink:label="lbl_label1171489554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:to="lbl_label1171489554" xlink:type="arc"/>
      <link:label id="id_63c4e1e7" xlink:label="lbl_label1673847271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:to="lbl_label1673847271" xlink:type="arc"/>
      <link:label id="id_497f0505" xlink:label="lbl_label1233061125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:to="lbl_label1233061125" xlink:type="arc"/>
      <link:label id="id_5233650c" xlink:label="lbl_label1379099916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:to="lbl_label1379099916" xlink:type="arc"/>
      <link:label id="id_5f125bc1" xlink:label="lbl_label1595038657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotionalAmount" xlink:to="lbl_label1595038657" xlink:type="arc"/>
      <link:label id="id_4a9f133" xlink:label="lbl_label78246195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, original currency</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsOriginalCurrency" xlink:to="lbl_label78246195" xlink:type="arc"/>
      <link:label id="id_3d3b01c0" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, maturity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsMaturity" xlink:to="lbl_BorrowingsMaturity_labels" xlink:type="arc"/>
      <link:label id="id_6970167" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, lender</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsLender" xlink:to="lbl_BorrowingsLender_labels" xlink:type="arc"/>
      <link:label id="id_2d26d7a1" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, premium discount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsPremiumDiscount" xlink:to="lbl_BorrowingsPremiumDiscount_labels" xlink:type="arc"/>
      <link:label id="id_43d0ad58" xlink:label="lbl_label1137749336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_label1137749336" xlink:type="arc"/>
      <link:label id="id_5168eb51" xlink:label="lbl_label1365830481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_label1365830481" xlink:type="arc"/>
      <link:label id="id_6ac35618" xlink:label="lbl_label1791186456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_label1791186456" xlink:type="arc"/>
      <link:label id="id_34e65236" xlink:label="lbl_label887509558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_label887509558" xlink:type="arc"/>
      <link:label id="id_71bada1c" xlink:label="lbl_label1908070940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_label1908070940" xlink:type="arc"/>
      <link:label id="id_7515173f" xlink:label="lbl_label1964316479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level1OfFairValueHierarchyMember" xlink:to="lbl_label1964316479" xlink:type="arc"/>
      <link:label id="id_17ccd63f" xlink:label="lbl_label399300159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level2OfFairValueHierarchyMember" xlink:to="lbl_label399300159" xlink:type="arc"/>
      <link:label id="id_93d606b" xlink:label="lbl_label155017323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level3OfFairValueHierarchyMember" xlink:to="lbl_label155017323" xlink:type="arc"/>
      <link:label id="id_7c0df05a" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialDebt" xlink:to="lbl_OtherNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_3aec21a3" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_661a115" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_45aae97f" xlink:label="lbl_label1168828799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_label1168828799" xlink:type="arc"/>
      <link:label id="id_374d1399" xlink:label="lbl_label927798169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_label927798169" xlink:type="arc"/>
      <link:label id="id_5786569c" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying reported amount fair value disclosure [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:type="arc"/>
      <link:label id="id_53a58f58" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value disclosure item amounts [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueDisclosureItemAmountsMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:type="arc"/>
      <link:label id="id_5d4ffc36" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values</link:label>
      <link:label id="id_749b453a" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet</link:label>
      <link:label id="id_670f6333" xlink:label="lbl_label1729061683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_label1729061683" xlink:type="arc"/>
      <link:label id="id_2d51324" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_669b15d1" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:type="arc"/>
      <link:label id="id_624c557e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income never to be recycled into the consolidated income statement</link:label>
      <link:label id="id_543798f6" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, available-for-sale financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_6e3138d0" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities, net of taxes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:type="arc"/>
      <link:label id="id_f9a3fe1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges, net of taxes</link:label>
      <link:label id="id_63d7965" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_57f5d574" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments on financial instruments, net of taxes</link:label>
      <link:label id="id_4fc35e7b" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:type="arc"/>
      <link:label id="id_5227f572" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6b11bff3" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_1e6e2048" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of items to eventually recycle</link:label>
      <link:label id="id_485691e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:type="arc"/>
      <link:label id="id_6465e8d4" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income to be eventually recycled into the consolidated income statement</link:label>
      <link:label id="id_2f7e508d" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_7c43d9ec" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_20ffa710" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_27277ccb" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
      <link:label id="id_5e2ce732" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_5ce83165" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_37725a9f" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_31bd4ac6" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_77aebdaf" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_30557ca" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_3783d7c" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_411d9c7f" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_4c054c08" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_f2e2db3" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other financial income and expense</link:label>
      <link:label id="id_53dc86a1" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_12f9d391" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_76e0ee52" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_533d4513" xlink:label="lbl_label1396524307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_label1396524307" xlink:type="arc"/>
      <link:label id="id_1706da9a" xlink:label="lbl_label386325146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_label386325146" xlink:type="arc"/>
      <link:label id="id_23f6c7e5" xlink:label="lbl_label603375589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_label603375589" xlink:type="arc"/>
      <link:label id="id_37845a12" xlink:label="lbl_label931420690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_label931420690" xlink:type="arc"/>
      <link:label id="id_ba7f520" xlink:label="lbl_label160680069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityMember" xlink:to="lbl_label160680069" xlink:type="arc"/>
      <link:label id="id_3004ac5a" xlink:label="lbl_label805612634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_label805612634" xlink:type="arc"/>
      <link:label id="id_4221701b" xlink:label="lbl_label1109487643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestsMember" xlink:to="lbl_label1109487643" xlink:type="arc"/>
      <link:label id="id_6ac2ea98" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMember" xlink:to="lbl_IssuedCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_37852f90" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetainedEarningsMember" xlink:to="lbl_RetainedEarningsMember_labels" xlink:type="arc"/>
      <link:label id="id_3014527f" xlink:label="lbl_label806638207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_label806638207" xlink:type="arc"/>
      <link:label id="id_7cb9019e" xlink:label="lbl_label2092499358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncome" xlink:to="lbl_label2092499358" xlink:type="arc"/>
      <link:label id="id_14c74049" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaid" xlink:to="lbl_DividendsPaid_labels" xlink:type="arc"/>
      <link:label id="id_55c8d5fc" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
      <link:label id="id_290fddfc" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:type="arc"/>
      <link:label id="id_35016d1a" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_4817c0e9" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_4d8eb67a" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of other equity movements</link:label>
      <link:label id="id_67a41ed4" xlink:label="lbl_label1738809044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:to="lbl_label1738809044" xlink:type="arc"/>
      <link:label id="id_63274027" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_403fccbc" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_74d7e6ee" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
      <link:label id="id_b4d100c" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_780100c2" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_62d0936a" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
      <link:label id="id_7b5cb6f6" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_39ba29d5" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
      <link:label id="id_1c3cdb2b" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_66b0d29c" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:label id="id_72973404" xlink:label="lbl_label1922511876" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities before working capital and provision changes</link:label>
      <link:label id="id_2f19480a" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2fccc455" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in net current assets and other operating cash flow items</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:type="arc"/>
      <link:label id="id_7e94f37" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_364038a2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations</link:label>
      <link:label id="id_2c0f5fb2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_658b02cd" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from discontinued operations</link:label>
      <link:label id="id_77c3c41b" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4017c1c6" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities</link:label>
      <link:label id="id_668e4218" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6c172e00" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:label id="id_79511d66" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5310686b" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4e39a447" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:label id="id_209f49b7" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fc66d2d" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
      <link:label id="id_4799c790" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5d62cc13" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of other non-current assets</link:label>
      <link:label id="id_4b05fa70" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2f0edb6a" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other non-current assets</link:label>
      <link:label id="id_220d8b31" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_1940f2ef" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities from continuing operations</link:label>
      <link:label id="id_bda8617" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_741f077b" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_34225142" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_140f33b4" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash flows used in investing activities</link:label>
      <link:label id="id_643efdb2" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:type="arc"/>
      <link:label id="id_6226a1d0" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares</link:label>
      <link:label id="id_4f16d177" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options and other treasury share transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1e868ebc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2bab504d" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
      <link:label id="id_5774a6d0" xlink:label="lbl_label1467262672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lbl_label1467262672" xlink:type="arc"/>
      <link:label id="id_649add65" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_605d8076" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:label id="id_153736f0" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:label id="id_354ffdea" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:label id="id_433b1725" xlink:label="lbl_label1127946021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows before working capital and provision changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1127946021" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1922511876" xlink:type="arc"/>
      <link:label id="id_7f2f5c65" xlink:label="lbl_label2133810277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:to="lbl_label2133810277" xlink:type="arc"/>
      <link:label id="id_429c1826" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, issuance date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsIssuanceDate" xlink:to="lbl_BorrowingsIssuanceDate_labels" xlink:type="arc"/>
      <link:label id="id_2669d99c" xlink:label="lbl_label644471196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency, others [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label644471196" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label72836716" xlink:type="arc"/>
      <link:label id="id_27412435" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_45c60d00" xlink:label="lbl_label1170607360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_label1170607360" xlink:type="arc"/>
      <link:label id="id_388165d3" xlink:label="lbl_label948004307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_label948004307" xlink:type="arc"/>
      <link:label id="id_7de10318" xlink:label="lbl_label2111898392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_label2111898392" xlink:type="arc"/>
      <link:label id="id_1b1dbf0c" xlink:label="lbl_label454934284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_label454934284" xlink:type="arc"/>
      <link:label id="id_1eb1092a" xlink:label="lbl_label514918698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_label514918698" xlink:type="arc"/>
      <link:label id="id_3d371bfe" xlink:label="lbl_label1027021822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsidiariesMember" xlink:to="lbl_label1027021822" xlink:type="arc"/>
      <link:label id="id_644266d7" xlink:label="lbl_label1682073303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeMember" xlink:to="lbl_label1682073303" xlink:type="arc"/>
      <link:label id="id_41ead269" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalIncMember" xlink:to="lbl_TranscendMedicalIncMember_labels" xlink:type="arc"/>
      <link:label id="id_7cc6732" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc.</link:label>
      <link:label id="id_5c37cd24" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelexysPharmaceuticalsCorporationMember" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_26bb8728" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation</link:label>
      <link:label id="id_f0f7125" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedMember" xlink:to="lbl_ZiarcoGroupLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_74cc0f0d" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited</link:label>
      <link:label id="id_2cf9a6d0" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionIncMember" xlink:to="lbl_EncoreVisionIncMember_labels" xlink:type="arc"/>
      <link:label id="id_14700202" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc.</link:label>
      <link:label id="id_4323a92b" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EliLillyAndCompanyMember" xlink:to="lbl_EliLillyAndCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_7d1163f7" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company</link:label>
      <link:label id="id_406cf0bb" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Oncology Products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKOncologyProductsMember" xlink:to="lbl_GSKOncologyProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_4dee8051" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Oncology Products</link:label>
      <link:label id="id_543b3534" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKVaccinesMember" xlink:to="lbl_GSKVaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_50145ee" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Vaccines</link:label>
      <link:label id="id_258b2077" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKConsumerHealthcareMember" xlink:to="lbl_GSKConsumerHealthcareMember_labels" xlink:type="arc"/>
      <link:label id="id_5cb81481" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare</link:label>
      <link:label id="id_2c752dc" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Total Transaction [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKTotalTransactionMember" xlink:to="lbl_GSKTotalTransactionMember_labels" xlink:type="arc"/>
      <link:label id="id_366ab1d6" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Total Transaction</link:label>
      <link:label id="id_2144f8b2" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CSLMember" xlink:to="lbl_CSLMember_labels" xlink:type="arc"/>
      <link:label id="id_5f983746" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CSL</link:label>
      <link:label id="id_1961772e" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexMember" xlink:to="lbl_SpinifexMember_labels" xlink:type="arc"/>
      <link:label id="id_7bf72331" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spinifex</link:label>
      <link:label id="id_72aed040" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Admune Theraputics [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdmuneTheraputicsMember" xlink:to="lbl_AdmuneTheraputicsMember_labels" xlink:type="arc"/>
      <link:label id="id_1b618d38" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Admune Theraputics</link:label>
      <link:label id="id_2608381e" xlink:label="lbl_label638072862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label638072862" xlink:type="arc"/>
      <link:label id="id_6adf03f3" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_29fb9219" xlink:label="lbl_label704352793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_label704352793" xlink:type="arc"/>
      <link:label id="id_7589cc7b" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:type="arc"/>
      <link:label id="id_770a51dc" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional recognition, goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalRecognitionGoodwill" xlink:to="lbl_AdditionalRecognitionGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_159fb0c8" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:type="arc"/>
      <link:label id="id_bb4840e" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1f8e7785" xlink:label="lbl_label529430405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:to="lbl_label529430405" xlink:type="arc"/>
      <link:label id="id_7a59b5df" xlink:label="lbl_label2052699615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:to="lbl_label2052699615" xlink:type="arc"/>
      <link:label id="id_3ce5a3b3" xlink:label="lbl_label1021682611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:to="lbl_label1021682611" xlink:type="arc"/>
      <link:label id="id_4e581a" xlink:label="lbl_label5134362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of arrangement for contingent consideration arrangements and indemnification assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:to="lbl_label5134362" xlink:type="arc"/>
      <link:label id="id_3ebaa53a" xlink:label="lbl_label1052419386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_label1052419386" xlink:type="arc"/>
      <link:label id="id_280373ad" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_58be9555" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_6f3dfdd7" xlink:label="lbl_label1866333655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of acquisition of businesses [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_label1866333655" xlink:type="arc"/>
      <link:label id="id_74ec4e33" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1fdc2fef" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of businesses</link:label>
      <link:label id="id_32cb811d" xlink:label="lbl_label852197661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_label852197661" xlink:type="arc"/>
      <link:label id="id_503f4b80" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_4572e29d" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of provisions and other current liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7df1458c" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_330b4ffd" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2487cf91" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue</link:label>
      <link:label id="id_cda5e36" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_50653a58" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements</link:label>
      <link:label id="id_51adf498" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_55fc13ca" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions</link:label>
      <link:label id="id_43a17f70" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ac74a65" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</link:label>
      <link:label id="id_7580bb7" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5d57abea" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the net liability table</link:label>
      <link:label id="id_8f2e3e1" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26221373" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</link:label>
      <link:label id="id_7b5fd886" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_83b4487" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal weighted average actuarial assumptions</link:label>
      <link:label id="id_5a767463" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of sensitivity analysis for actuarial assumptions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c6a492e" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</link:label>
      <link:label id="id_40d21ce7" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_28fc355" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The healthcare cost trend rate assumptions used for other post-employment benefits</link:label>
      <link:label id="id_37e4cfa4" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_a47f671" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The weighted average plan asset allocation of funded defined benefit pension plans</link:label>
      <link:label id="id_14ebebe1" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7cfc7cde" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The expected future cash flows in respect of pension and other post- employment benefit plans</link:label>
      <link:label id="id_5cc7b4f2" xlink:label="lbl_label1556591858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_label1556591858" xlink:type="arc"/>
      <link:label id="id_751ab231" xlink:label="lbl_label1964683825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_label1964683825" xlink:type="arc"/>
      <link:label id="id_4f2027d2" xlink:label="lbl_label1327507410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_label1327507410" xlink:type="arc"/>
      <link:label id="id_44180645" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_7b396a57" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_2a66227f" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_520a49db" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_79560b48" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2e2e2336" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2367c616" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5161ba57" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_62ae6b6f" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_4affdfb9" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_5c47e1cf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_59b962bd" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and financial and other current assets</link:label>
      <link:label id="id_13b05f40" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_33b144aa" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_262ed31" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquisitions of business</link:label>
      <link:label id="id_7c2d8d71" xlink:label="lbl_label2083360113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:to="lbl_label2083360113" xlink:type="arc"/>
      <link:label id="id_1e18b9d2" xlink:label="lbl_label504936914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:to="lbl_label504936914" xlink:type="arc"/>
      <link:label id="id_77fdfffd" xlink:label="lbl_label2013134845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially refundable consideration from acquisition</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:to="lbl_label2013134845" xlink:type="arc"/>
      <link:label id="id_240ec6" xlink:label="lbl_label2363078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of potentially refundable contingent consideration</link:label>
      <link:label id="id_5bb1899c" xlink:label="lbl_label1538361756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract right of first negotiation term</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractRightOfFirstNegotiationTerm" xlink:to="lbl_label1538361756" xlink:type="arc"/>
      <link:label id="id_3eeb75f2" xlink:label="lbl_label1055618546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquiree" xlink:to="lbl_label1055618546" xlink:type="arc"/>
      <link:label id="id_742dd0f8" xlink:label="lbl_label1949159672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree full year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquireeFullYear" xlink:to="lbl_label1949159672" xlink:type="arc"/>
      <link:label id="id_37ba66ca" xlink:label="lbl_label934962890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:to="lbl_label934962890" xlink:type="arc"/>
      <link:label id="id_53d61f56" xlink:label="lbl_label1406541654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized other than at fair value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:to="lbl_label1406541654" xlink:type="arc"/>
      <link:label id="id_6acd7a2d" xlink:label="lbl_label1791851053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent consideration arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label1791851053" xlink:type="arc"/>
      <link:label id="id_c33fcc1" xlink:label="lbl_label204733633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label204733633" xlink:type="arc"/>
      <link:label id="id_22e7f31e" xlink:label="lbl_label585626398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, fee paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:to="lbl_label585626398" xlink:type="arc"/>
      <link:label id="id_4739cf42" xlink:label="lbl_label1194970946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lbl_label1194970946" xlink:type="arc"/>
      <link:label id="id_7e1ee3b5" xlink:label="lbl_label2115953589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests contributed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsContributed" xlink:to="lbl_label2115953589" xlink:type="arc"/>
      <link:label id="id_376f146e" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCosts" xlink:to="lbl_TransactionRelatedCosts_labels" xlink:type="arc"/>
      <link:label id="id_2d34f9e9" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCostsPaid" xlink:to="lbl_TransactionRelatedCostsPaid_labels" xlink:type="arc"/>
      <link:label id="id_7a2e51fc" xlink:label="lbl_label690911032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLoss" xlink:to="lbl_label690911032" xlink:type="arc"/>
      <link:label id="id_67f3701a" xlink:label="lbl_label1744007194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLoss" xlink:to="lbl_label1744007194" xlink:type="arc"/>
      <link:label id="id_7cff95a1" xlink:label="lbl_label2097124769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_label2097124769" xlink:type="arc"/>
      <link:label id="id_772301d6" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for taxes other than income taxes, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2dc3de10" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current restructuring provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermRestructuringProvision" xlink:to="lbl_ShorttermRestructuringProvision_labels" xlink:type="arc"/>
      <link:label id="id_5b202ec3" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
      <link:label id="id_6d2493bb" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued royalties payable classified as current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_198471b1" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for royalties</link:label>
      <link:label id="id_3eae10b2" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes other than income taxes</link:label>
      <link:label id="id_4d2d81e4" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits accruals</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermEmployeeBenefitsAccruals" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:type="arc"/>
      <link:label id="id_28ce7ee" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for compensation and benefits including social security</link:label>
      <link:label id="id_dfd6824" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current legal proceedings provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="lbl_ShorttermLegalProceedingsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermLegalProceedingsProvision" xlink:to="lbl_ShorttermLegalProceedingsProvision_labels" xlink:type="arc"/>
      <link:label id="id_3dc37367" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_7364ea66" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentPayables" xlink:to="lbl_OtherCurrentPayables_labels" xlink:type="arc"/>
      <link:label id="id_53bd8e15" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
      <link:label id="id_16646c9e" xlink:label="lbl_label375680158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_label375680158" xlink:type="arc"/>
      <link:label id="id_236d2862" xlink:label="lbl_label594356322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_label594356322" xlink:type="arc"/>
      <link:label id="id_4ebad11d" xlink:label="lbl_label1320866077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_label1320866077" xlink:type="arc"/>
      <link:label id="id_40fd93ca" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvisionMember" xlink:label="lbl_RefundsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RefundsProvisionMember" xlink:to="lbl_RefundsProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_134ebfe2" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deductions from revenue</link:label>
      <link:label id="id_5e5b3081" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisions" xlink:to="lbl_OtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_21da05f2" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision at end of period</link:label>
      <link:label id="id_3b690ec5" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision at beginning of period</link:label>
      <link:label id="id_7d787c31" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through loss of control of subsidiary, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_ff50d0a" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_5bf5caac" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2a95f348" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_27eafa" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalProvisionsOtherProvisions" xlink:to="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2c66d271" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_fe1b238" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionUsedOtherProvisions" xlink:to="lbl_ProvisionUsedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_36a5293f" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/utilizations</link:label>
      <link:label id="id_359f477c" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_18735dbe" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_16f119f6" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_482a71cf" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnusedProvisionReversedOtherProvisions" xlink:to="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_28d3a14e" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_45b7ba0b" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_26660dfe" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionMember" xlink:to="lbl_RestructuringProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_23d5363a" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provision</link:label>
      <link:label id="id_79614e6" xlink:label="lbl_label127276262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_label127276262" xlink:type="arc"/>
      <link:label id="id_51cb80cd" xlink:label="lbl_label1372291277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_label1372291277" xlink:type="arc"/>
      <link:label id="id_2ea0d5c3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6dd7d3e3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_2c1cad42" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b131312" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables</link:label>
      <link:label id="id_2ef5991b" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77f758ca" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements</link:label>
      <link:label id="id_5d967f7b" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provisions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0e9f8f" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provision</link:label>
      <link:label id="id_22339022" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1c976f04" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies</link:label>
      <link:label id="id_3cb8d68f" xlink:label="lbl_label1018746511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_label1018746511" xlink:type="arc"/>
      <link:label id="id_43d6f278" xlink:label="lbl_label1138160248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_label1138160248" xlink:type="arc"/>
      <link:label id="id_4c9afaa7" xlink:label="lbl_label1285225127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_label1285225127" xlink:type="arc"/>
      <link:label id="id_3182649e" xlink:label="lbl_label830629022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_label830629022" xlink:type="arc"/>
      <link:label id="id_5ff48884" xlink:label="lbl_label1609861252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_label1609861252" xlink:type="arc"/>
      <link:label id="id_75e5081d" xlink:label="lbl_label123214748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesMember" xlink:to="lbl_label123214748" xlink:type="arc"/>
      <link:label id="id_2e086500" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivables" xlink:to="lbl_CurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_79f9d46a" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total trade receivables, net</link:label>
      <link:label id="id_3425f2e0" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables related to discontinued operations</link:label>
      <link:label id="id_4ce7ed6d" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_53792c91" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Utilization of provisions for doubtful trade receivables</link:label>
      <link:label id="id_74c340b1" xlink:label="lbl_label1958953137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_label1958953137" xlink:type="arc"/>
      <link:label id="id_6ce050f6" xlink:label="lbl_label1826640118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_label1826640118" xlink:type="arc"/>
      <link:label id="id_3284c13a" xlink:label="lbl_label847561018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_label847561018" xlink:type="arc"/>
      <link:label id="id_21859e37" xlink:label="lbl_label562404919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentMember" xlink:to="lbl_label562404919" xlink:type="arc"/>
      <link:label id="id_36a38547" xlink:label="lbl_label916686151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_label916686151" xlink:type="arc"/>
      <link:label id="id_5fbcb687" xlink:label="lbl_label1606203015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of receivables denominated in various currencies [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_label1606203015" xlink:type="arc"/>
      <link:label id="id_2efadcc4" xlink:label="lbl_label788192452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:to="lbl_label788192452" xlink:type="arc"/>
      <link:label id="id_d85c974" xlink:label="lbl_label226871668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:to="lbl_label226871668" xlink:type="arc"/>
      <link:label id="id_5358f3b4" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_7e49d670" xlink:label="lbl_label2118768240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_label2118768240" xlink:type="arc"/>
      <link:label id="id_5081e337" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_172e52ca" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_2f049798" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_678c8520" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_171309e1" xlink:label="lbl_label387123681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_label387123681" xlink:type="arc"/>
      <link:label id="id_7e6d2d55" xlink:label="lbl_label2121084245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_label2121084245" xlink:type="arc"/>
      <link:label id="id_5b223713" xlink:label="lbl_label1528968979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NameOfSubsidiary" xlink:to="lbl_label1528968979" xlink:type="arc"/>
      <link:label id="id_2bc20f05" xlink:label="lbl_label734138117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal place of business of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="lbl_label734138117" xlink:type="arc"/>
      <link:label id="id_5cbe6246" xlink:label="lbl_label1555980870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of incorporation of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lbl_label1555980870" xlink:type="arc"/>
      <link:label id="id_77c5a25c" xlink:label="lbl_label2009440860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lbl_label2009440860" xlink:type="arc"/>
      <link:label id="id_64c53647" xlink:label="lbl_label1690646087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lbl_label1690646087" xlink:type="arc"/>
      <link:label id="id_5c37870a" xlink:label="lbl_label1547142922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share/paid-in capital</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharePaidinCapital" xlink:to="lbl_label1547142922" xlink:type="arc"/>
      <link:label id="id_3c7cb5b5" xlink:label="lbl_label1014805941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Societe par actions SANDOZ, Algiers [member]</link:label>
      <link:label id="id_1fee848b" xlink:label="lbl_label535725195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Argentina S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:to="lbl_label535725195" xlink:type="arc"/>
      <link:label id="id_37e7fad0" xlink:label="lbl_label937949904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:to="lbl_label937949904" xlink:type="arc"/>
      <link:label id="id_3ea304fe" xlink:label="lbl_label1050871038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGBaselMember" xlink:to="lbl_label1050871038" xlink:type="arc"/>
      <link:label id="id_6ed1f5c4" xlink:label="lbl_label1859253700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_label1859253700" xlink:type="arc"/>
      <link:label id="id_258b1d67" xlink:label="lbl_label629874023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_label629874023" xlink:type="arc"/>
      <link:label id="id_d3021ba" xlink:label="lbl_label221258170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_label221258170" xlink:type="arc"/>
      <link:label id="id_7226aa6a" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
      <link:label id="id_494ba6f4" xlink:label="lbl_label1229694708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansMember" xlink:to="lbl_label1229694708" xlink:type="arc"/>
      <link:label id="id_1d4af2d7" xlink:label="lbl_label491451095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic defined benefit plans [member]</link:label>
      <link:label id="id_48d21535" xlink:label="lbl_label1221727541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign defined benefit plans [member]</link:label>
      <link:label id="id_53109a65" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of major plans, geographic</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConcentrationOfMajorPlansGeographic" xlink:to="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:type="arc"/>
      <link:label id="id_6dd86874" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the major plans and the concentration of the Group's DBO by geography.</link:label>
      <link:label id="id_55c3f642" xlink:label="lbl_label1438905922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of plan amendments, curtailments and settlements</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:to="lbl_label1438905922" xlink:type="arc"/>
      <link:label id="id_5774006e" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, recognized net gain (loss) due to curtailments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:type="arc"/>
      <link:label id="id_1a9c795a" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Pre-tax curtailment gain (loss)</link:label>
      <link:label id="id_3ccdda27" xlink:label="lbl_label1020123687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_label1020123687" xlink:type="arc"/>
      <link:label id="id_66c824b2" xlink:label="lbl_label1724392626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_label1724392626" xlink:type="arc"/>
      <link:label id="id_1c17a6ba" xlink:label="lbl_label471312058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_label471312058" xlink:type="arc"/>
      <link:label id="id_2219e14f" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionPlanMember" xlink:to="lbl_PensionPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_35fad562" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefitPlansMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_2e4ea0d1" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans</link:label>
      <link:label id="id_67c584f7" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans</link:label>
      <link:label id="id_3d342709" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationAtPresentValue" xlink:to="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_22ca7a55" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at beginning of period</link:label>
      <link:label id="id_7de6506d" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at end of period</link:label>
      <link:label id="id_30925057" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current service cost, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_38d91a7e" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_4281521a" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpense" xlink:to="lbl_AdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_603d3cd8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_48f72a8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement losses/(gains) arising from changes in financial assumptions</link:label>
      <link:label id="id_3f236d51" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_78d171f" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement (gains) arising from changes in demographic assumptions</link:label>
      <link:label id="id_783c6ad8" xlink:label="lbl_label220841955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_45220e6b" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from plan, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1ebcfd45" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_6368b27" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_481bb1bf" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_8f2ae87" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, benefit obligation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:type="arc"/>
      <link:label id="id_474719e9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_26d72366" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlanAssetsAtFairValue" xlink:to="lbl_PlanAssetsAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_753e351c" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of period</link:label>
      <link:label id="id_432fa1b8" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of period</link:label>
      <link:label id="id_66d6f9ff" xlink:label="lbl_label1273555602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_37b55377" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by employer, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_12bfbc9" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_2adf4a42" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Settlements, Plan Assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_6615f676" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4cd3f00b" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_410b8f27" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_c41cf6c" xlink:label="lbl_label205639532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in benefit obligation [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_label205639532" xlink:type="arc"/>
      <link:label id="id_3bf9f9ba" xlink:label="lbl_label1006238138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in fair value of plan assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_label1006238138" xlink:type="arc"/>
      <link:label id="id_290f00a6" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surplus (deficit) in plan</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurplusDeficitInPlan" xlink:to="lbl_SurplusDeficitInPlan_labels" xlink:type="arc"/>
      <link:label id="id_9610a9f" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_5aa411ee" xlink:label="lbl_label1520701934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_label1520701934" xlink:type="arc"/>
      <link:label id="id_161add1b" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_37321747" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net liability in the balance sheet at end of period</link:label>
      <link:label id="id_5bdc9111" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LimitationOnRecognitionOfFundSurplus" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_76d185b5" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at beginning of period</link:label>
      <link:label id="id_1ada4e58" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at end of period</link:label>
      <link:label id="id_155f6c71" xlink:label="lbl_label358575217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_label358575217" xlink:type="arc"/>
      <link:label id="id_25ebb8ae" xlink:label="lbl_label636205230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in net liability [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_label636205230" xlink:type="arc"/>
      <link:label id="id_54f9f34f" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net liability at end of period</link:label>
      <link:label id="id_56e703b2" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net liability at beginning of period</link:label>
      <link:label id="id_4c3018ba" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_493d88c7" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_58444b6a" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_b032860" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurements</link:label>
      <link:label id="id_16e626ad" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6f51c69e" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3d05f86e" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_594017b5" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f5fa1d1" xlink:label="lbl_label257925585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognized in the consolidated balance sheet [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_label257925585" xlink:type="arc"/>
      <link:label id="id_5b08b7db" xlink:label="lbl_label1527298011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_1ec53fdb" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit pension plan, accrued benefit liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_label1527298011" xlink:type="arc"/>
      <link:label id="id_1b1c172d" xlink:label="lbl_label454825773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_label454825773" xlink:type="arc"/>
      <link:label id="id_574cbf67" xlink:label="lbl_label1464647527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_label1464647527" xlink:type="arc"/>
      <link:label id="id_59c768c3" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ObligationByTypeMember_labels" xlink:type="arc"/>
      <link:label id="id_e411de0" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnfundedMember" xlink:to="lbl_UnfundedMember_labels" xlink:type="arc"/>
      <link:label id="id_206ca87f" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation by type</link:label>
      <link:label id="id_4964c411" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded</link:label>
      <link:label id="id_15c93075" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Active [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActiveMember" xlink:to="lbl_ActiveMember_labels" xlink:type="arc"/>
      <link:label id="id_4cc31394" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Active</link:label>
      <link:label id="id_4cfa00d5" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPensionersMember" xlink:to="lbl_DeferredPensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_452ea3f3" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred pensioners</link:label>
      <link:label id="id_9ccd7d0" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionersMember" xlink:to="lbl_PensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_77f4d5bf" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensioners</link:label>
      <link:label id="id_41aa0977" xlink:label="lbl_label1101662583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plans disclosures [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_label1101662583" xlink:type="arc"/>
      <link:label id="id_70b19e47" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRates" xlink:to="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:type="arc"/>
      <link:label id="id_30e2ed44" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_228400f7" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:type="arc"/>
      <link:label id="id_5ba9eb34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of pension increase</link:label>
      <link:label id="id_4f7f1dac" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:type="arc"/>
      <link:label id="id_2cc2bb1f" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of salary increase</link:label>
      <link:label id="id_1baffc03" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:type="arc"/>
      <link:label id="id_56eba13" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_646262cf" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, male</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:type="arc"/>
      <link:label id="id_32829bee" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old male</link:label>
      <link:label id="id_d9d966" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, female</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:type="arc"/>
      <link:label id="id_5516dd19" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old female</link:label>
      <link:label id="id_5918de81" xlink:label="lbl_label1494802049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_label1494802049" xlink:type="arc"/>
      <link:label id="id_689d3554" xlink:label="lbl_label1755133268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_label1755133268" xlink:type="arc"/>
      <link:label id="id_3e1a9660" xlink:label="lbl_label1041929824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_label1041929824" xlink:type="arc"/>
      <link:label id="id_2737de6b" xlink:label="lbl_label657972843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_label657972843" xlink:type="arc"/>
      <link:label id="id_70f6e61c" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:type="arc"/>
      <link:label id="id_1b153ebb" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_761309a6" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life expectancy [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LifeExpectancyMember" xlink:to="lbl_LifeExpectancyMember_labels" xlink:type="arc"/>
      <link:label id="id_527cf7bb" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life expectancy</link:label>
      <link:label id="id_70b51d3d" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b5a9ebb" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of pension increase</link:label>
      <link:label id="id_47824990" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:type="arc"/>
      <link:label id="id_32d0ccd0" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_742d5c34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_795db79c" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary increase</link:label>
      <link:label id="id_72dd0a47" xlink:label="lbl_label1927088711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_label1927088711" xlink:type="arc"/>
      <link:label id="id_6778fca" xlink:label="lbl_label108498890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_label108498890" xlink:type="arc"/>
      <link:label id="id_47ad1e48" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Decrease25BasisPointMember" xlink:to="lbl_Decrease25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_56d62cdb" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point decrease</link:label>
      <link:label id="id_3867e568" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase25BasisPointMember" xlink:to="lbl_Increase25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_5197441d" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point increase</link:label>
      <link:label id="id_1471972b" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 1 year [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase1YearMember" xlink:to="lbl_Increase1YearMember_labels" xlink:type="arc"/>
      <link:label id="id_4ce59d83" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 year increase</link:label>
      <link:label id="id_290932d1" xlink:label="lbl_label688468689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lbl_label688468689" xlink:type="arc"/>
      <link:label id="id_7dde43af" xlink:label="lbl_label2111718319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lbl_label2111718319" xlink:type="arc"/>
      <link:label id="id_a6a337a" xlink:label="lbl_label174732154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_label174732154" xlink:type="arc"/>
      <link:label id="id_3aac73e2" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:type="arc"/>
      <link:label id="id_6a35725f" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
      <link:label id="id_41b83777" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:type="arc"/>
      <link:label id="id_4f8e05fa" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
      <link:label id="id_6b154ebb" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:type="arc"/>
      <link:label id="id_1990f79d" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year that the rate reaches the ultimate trend rate</link:label>
      <link:label id="id_6d01266f" xlink:label="lbl_label1828791919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_label1828791919" xlink:type="arc"/>
      <link:label id="id_546e2ee7" xlink:label="lbl_label1416507111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_label1416507111" xlink:type="arc"/>
      <link:label id="id_351e0eb0" xlink:label="lbl_label891162288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_label891162288" xlink:type="arc"/>
      <link:label id="id_124636b7" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity investments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInvestmentsMember" xlink:to="lbl_EquityInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_77cea25b" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_1387f503" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesMember" xlink:to="lbl_DebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f4271a5" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_3fb49996" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real estate [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateMember" xlink:to="lbl_RealEstateMember_labels" xlink:type="arc"/>
      <link:label id="id_3b683c06" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate</link:label>
      <link:label id="id_40e14f9f" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlternativeInvestmentsMember" xlink:to="lbl_AlternativeInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_63169a31" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative investments</link:label>
      <link:label id="id_2f33748b" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and other investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndOtherInvestmentsMember" xlink:to="lbl_CashAndOtherInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_6087023c" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and other investments</link:label>
      <link:label id="id_36f85bd1" xlink:label="lbl_label922246097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range minimum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:to="lbl_label922246097" xlink:type="arc"/>
      <link:label id="id_568969aa" xlink:label="lbl_label1451846058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range maximum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:to="lbl_label1451846058" xlink:type="arc"/>
      <link:label id="id_73a6e694" xlink:label="lbl_label1940317844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, plan asset allocations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:to="lbl_label1940317844" xlink:type="arc"/>
      <link:label id="id_7df88f41" xlink:label="lbl_label2113441601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares held by defined benefit plan</link:label>
      <link:label id="id_638e4e2e" xlink:label="lbl_label1670270510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of shares held by defined benefit plan</link:label>
      <link:label id="id_1fe80675" xlink:label="lbl_label535299701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average duration of defined benefit obligation years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:to="lbl_label535299701" xlink:type="arc"/>
      <link:label id="id_3b7d1376" xlink:label="lbl_label998052726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_label998052726" xlink:type="arc"/>
      <link:label id="id_3dd16606" xlink:label="lbl_label1037133318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_label1037133318" xlink:type="arc"/>
      <link:label id="id_123e0aae" xlink:label="lbl_label306055854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_label306055854" xlink:type="arc"/>
      <link:label id="id_f1ad7e6" xlink:label="lbl_label253417446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lbl_label253417446" xlink:type="arc"/>
      <link:label id="id_103a32b5" xlink:label="lbl_label272249525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_label272249525" xlink:type="arc"/>
      <link:label id="id_3fa24799" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:type="arc"/>
      <link:label id="id_7a2e1ca0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_6e3282e0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_723df25e" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payments</link:label>
      <link:label id="id_b004db7" xlink:label="lbl_label910647463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions, next fiscal year (estimated)</link:label>
      <link:label id="id_489bf9be" xlink:label="lbl_label839490648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payment</link:label>
      <link:label id="id_20bc42c3" xlink:label="lbl_label549208771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_12ce3901" xlink:label="lbl_label315504897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label315504897" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label549208771" xlink:type="arc"/>
      <link:label id="id_47519d57" xlink:label="lbl_label1196531031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions, next fiscal year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label1196531031" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label910647463" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:to="lbl_label1014805941" xlink:type="arc"/>
      <link:label id="id_1b677399" xlink:label="lbl_label459764633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lbl_label459764633" xlink:type="arc"/>
      <link:label id="id_33287a64" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2e310112" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6868ef6e" xlink:label="lbl_label1751707502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of details to the consolidated statements of cash flows [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_label1751707502" xlink:type="arc"/>
      <link:label id="id_6b1bab45" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details to the consolidated statements of cash flows</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_d3696d1" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
      <link:label id="id_5827fd3a" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b12a0b7" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations</link:label>
      <link:label id="id_31e67efa" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3971a54e" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</link:label>
      <link:label id="id_1118f1b5" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c64ba26" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses</link:label>
      <link:label id="id_4c022ee6" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bd72b36" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations</link:label>
      <link:label id="id_2f1afbf8" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5cbbe15" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation</link:label>
      <link:label id="id_5a01c254" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses included in net income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExpensesIncludedInNetIncomeTableTextBlock" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:to="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2004e8bf" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses included in net income</link:label>
      <link:label id="id_10dd18ca" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to continuing segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:type="arc"/>
      <link:label id="id_2d4849c4" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing segments</link:label>
      <link:label id="id_398e8ede" xlink:label="lbl_label965643998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_label965643998" xlink:type="arc"/>
      <link:label id="id_136ba9dd" xlink:label="lbl_label325822941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsMember" xlink:to="lbl_label325822941" xlink:type="arc"/>
      <link:label id="id_211fcf4d" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VaccinesMember" xlink:label="lbl_VaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VaccinesMember" xlink:to="lbl_VaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b74f3f8" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumerHealthMember" xlink:to="lbl_ConsumerHealthMember_labels" xlink:type="arc"/>
      <link:label id="id_56f765a5" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CorporateMember" xlink:to="lbl_CorporateMember_labels" xlink:type="arc"/>
      <link:label id="id_18ef0ff6" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines</link:label>
      <link:label id="id_461a031f" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
      <link:label id="id_53139d8a" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
      <link:label id="id_448d3c2a" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeLossOfDiscontinuedOperations" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:to="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_720983c3" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:label id="id_72fd7ee5" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpenseOfDiscontinuedOperations" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:to="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_28dd046" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:label id="id_1f5a1a52" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_6a72e089" xlink:label="lbl_label1785913481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationExpense" xlink:label="lbl_DepreciationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationExpense" xlink:to="lbl_label1785913481" xlink:type="arc"/>
      <link:label id="id_25726f06" xlink:label="lbl_label628256518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationExpense" xlink:label="lbl_AmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationExpense" xlink:to="lbl_label628256518" xlink:type="arc"/>
      <link:label id="id_411f99ec" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_3b138d2b" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:type="arc"/>
      <link:label id="id_16efc802" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_1bd6fe9" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_1b76fc8a" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
      <link:label id="id_7b8e06f2" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_199a6c29" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets impaired [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsImpairedMember" xlink:to="lbl_FinancialAssetsImpairedMember_labels" xlink:type="arc"/>
      <link:label id="id_430aa9fa" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_580bc98f" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:type="arc"/>
      <link:label id="id_12db58d" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments on:</link:label>
      <link:label id="id_7cae4caa" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ed21581" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</link:label>
      <link:label id="id_353f4e60" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for share based payments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForSharebasedPayments" xlink:to="lbl_AdjustmentsForSharebasedPayments_labels" xlink:type="arc"/>
      <link:label id="id_728a3fc5" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled compensation expense</link:label>
      <link:label id="id_71026a6c" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for change in provisions and other non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7a811d6" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in provisions and other non-current liabilities</link:label>
      <link:label id="id_5215d26" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income (cost)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForFinanceIncomeCost" xlink:to="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_1e915c0" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_162e6aad" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:type="arc"/>
      <link:label id="id_7b5bcf12" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
      <link:label id="id_672b8eea" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:type="arc"/>
      <link:label id="id_47cff5e1" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in trade receivables</link:label>
      <link:label id="id_543bdc2c" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts payable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:type="arc"/>
      <link:label id="id_4059a0ed" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in trade payables</link:label>
      <link:label id="id_b388f81" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_64e8a2fc" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other net current assets and other operating cash flow items</link:label>
      <link:label id="id_63e2f9e4" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_118bdd59" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_671e3a1e" xlink:label="lbl_label1730034206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_label1730034206" xlink:type="arc"/>
      <link:label id="id_141b97fd" xlink:label="lbl_label337352701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_label337352701" xlink:type="arc"/>
      <link:label id="id_12050514" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsMember" xlink:to="lbl_AcquisitionsMember_labels" xlink:type="arc"/>
      <link:label id="id_7f5f8169" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
      <link:label id="id_415fd821" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsMember" xlink:to="lbl_DivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_7b19873c" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestments</link:label>
      <link:label id="id_177d8886" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsMember" xlink:to="lbl_OtherAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_fdd065b" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets [member]</link:label>
      <link:label id="id_7f9f59b1" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_1a3864c5" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_5b13ac00" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brand names</link:label>
      <link:label id="id_7d41899d" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_50dd9de4" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets (acquired) or divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowFromNetIdentifiableAssets" xlink:to="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:type="arc"/>
      <link:label id="id_4169909f" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested</link:label>
      <link:label id="id_6da3acb5" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), currency translation effects</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowCurrencyTranslationEffects" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:to="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:type="arc"/>
      <link:label id="id_28a59cd9" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6046e1a8" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4ec913e7" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), acquired/(divested) liquity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowAcquiredDivestedLiquity" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:to="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:type="arc"/>
      <link:label id="id_470c377e" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired/(divested) liquity</link:label>
      <link:label id="id_50fcd8ec" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
      <link:label id="id_51ec5468" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests.</link:label>
      <link:label id="id_33a842e" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:to="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:type="arc"/>
      <link:label id="id_cbc3f6c" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refinancing of intercompany financial debt, net</link:label>
      <link:label id="id_2f2298e2" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net.</link:label>
      <link:label id="id_7e82bd81" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowGoodwill" xlink:label="lbl_CashInflowOutflowGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowGoodwill" xlink:to="lbl_CashInflowOutflowGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3c41ff79" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_4f404f29" xlink:label="lbl_label1329614633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestment gain</link:label>
      <link:label id="id_250b8244" xlink:label="lbl_label621511236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Divestment gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowDivestmentGainLoss" xlink:label="lbl_CashInflowOutflowDivestmentGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label621511236" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label1329614633" xlink:type="arc"/>
      <link:label id="id_48ec9225" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:to="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:type="arc"/>
      <link:label id="id_69b7f35f" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables and payables contingent consideration, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_66ca8618" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other payments and deferred consideration, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_7403ad6c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPrepaidPortionOfSalesPrice" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:to="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:type="arc"/>
      <link:label id="id_7290427c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses.</link:label>
      <link:label id="id_55c25b5" xlink:label="lbl_label1423033786" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows</link:label>
      <link:label id="id_35ffff76" xlink:label="lbl_label905969526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPaid" xlink:to="lbl_label905969526" xlink:type="arc"/>
      <link:label id="id_344a7417" xlink:label="lbl_label877294615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_label877294615" xlink:type="arc"/>
      <link:label id="id_2a937996" xlink:label="lbl_label714307990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_label714307990" xlink:type="arc"/>
      <link:label id="id_e12f433" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Change25BasisPointMember" xlink:to="lbl_Change25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_a3f5c53" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point change</link:label>
      <link:label id="id_375463d0" xlink:label="lbl_label928277456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, amount per share</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayableAmountPerShare" xlink:to="lbl_label928277456" xlink:type="arc"/>
      <link:label id="id_43bd571e" xlink:label="lbl_label1136482078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeld" xlink:to="lbl_label1136482078" xlink:type="arc"/>
      <link:label id="id_57fc5a54" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be cancelled</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeCancelled" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:type="arc"/>
      <link:label id="id_324c0bd9" xlink:label="lbl_label843844569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchases" xlink:to="lbl_label843844569" xlink:type="arc"/>
      <link:label id="id_4ae190e3" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-purchase of treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharepurchaseOfTreasuryShares" xlink:to="lbl_SharepurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_191f6daa" xlink:label="lbl_label421490090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:to="lbl_label421490090" xlink:type="arc"/>
      <link:label id="id_3ea88f28" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired for cancellation, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredForCancellationValue" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:type="arc"/>
      <link:label id="id_6fbbc8cc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5d0bb4f" xlink:label="lbl_label97565519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_label97565519" xlink:type="arc"/>
      <link:label id="id_663e6f69" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1fe06852" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income</link:label>
      <link:label id="id_72bd6f82" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ec5912e" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:label id="id_55c48a63" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_b6f9702" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation</link:label>
      <link:label id="id_56e22f6a" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8052d36" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income</link:label>
      <link:label id="id_639839a6" xlink:label="lbl_label1670920614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_label1670920614" xlink:type="arc"/>
      <link:label id="id_46f3d26a" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3abc74f9" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based participation plans for employees</link:label>
      <link:label id="id_36b95a30" xlink:label="lbl_label918116912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_label918116912" xlink:type="arc"/>
      <link:label id="id_4f551c1c" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRelatedPartyExplanatory" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2142f37a" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with related parties</link:label>
      <link:label id="id_21a37a9f" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits for employees</link:label>
      <link:label id="id_250e99ed" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer and director compensation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_30161311" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers and Non-Executive Directors Compensation</link:label>
      <link:label id="id_332db2e6" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5ba16f3" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23eec797" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f141a24" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2cdc96dc" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity</link:label>
      <link:label id="id_5c5154d5" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward</link:label>
      <link:label id="id_44099e5b" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options</link:label>
      <link:label id="id_2a634859" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options</link:label>
      <link:label id="id_2b301a02" xlink:label="lbl_label724572674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_label724572674" xlink:type="arc"/>
      <link:label id="id_499d66e9" xlink:label="lbl_label1235052265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_label1235052265" xlink:type="arc"/>
      <link:label id="id_4bff5af2" xlink:label="lbl_label1275026162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_label1275026162" xlink:type="arc"/>
      <link:label id="id_4175504c" xlink:label="lbl_label1098207308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_label1098207308" xlink:type="arc"/>
      <link:label id="id_52e5607c" xlink:label="lbl_label1390764156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_label1390764156" xlink:type="arc"/>
      <link:label id="id_51571277" xlink:label="lbl_label1364660855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Executive Director [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonExecutiveDirectorMember" xlink:to="lbl_label1364660855" xlink:type="arc"/>
      <link:label id="id_77564460" xlink:label="lbl_label2002142304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_label2002142304" xlink:type="arc"/>
      <link:label id="id_7f01623c" xlink:label="lbl_label2130797116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_label2130797116" xlink:type="arc"/>
      <link:label id="id_2d55a2fa" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGMember" xlink:to="lbl_RocheHoldingAGMember_labels" xlink:type="arc"/>
      <link:label id="id_102c1151" xlink:label="lbl_label271323473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_label271323473" xlink:type="arc"/>
      <link:label id="id_7a1d10b6" xlink:label="lbl_label2048725174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_label2048725174" xlink:type="arc"/>
      <link:label id="id_4b6874" xlink:label="lbl_label4941940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lucentis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LucentisMember" xlink:to="lbl_label4941940" xlink:type="arc"/>
      <link:label id="id_4da120c0" xlink:label="lbl_label1302405312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xolair [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XolairMember" xlink:to="lbl_label1302405312" xlink:type="arc"/>
      <link:label id="id_40080a70" xlink:label="lbl_label1074268784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:to="lbl_label1074268784" xlink:type="arc"/>
      <link:label id="id_4fef4e77" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:type="arc"/>
      <link:label id="id_5866119e" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:type="arc"/>
      <link:label id="id_32134034" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:type="arc"/>
      <link:label id="id_40914b3d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensation_labels" xlink:type="arc"/>
      <link:label id="id_34c1eea8" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits</link:label>
      <link:label id="id_24fee3be" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:label id="id_5994538d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_a202e7c" xlink:label="lbl_label169881212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech, Inc., USA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechInc.USAMember" xlink:to="lbl_label169881212" xlink:type="arc"/>
      <link:label id="id_3ecec9c1" xlink:label="lbl_label1053739457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Brody [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrBrodyMember" xlink:to="lbl_label1053739457" xlink:type="arc"/>
      <link:label id="id_60abf97a" xlink:label="lbl_label1621883258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Zinkernagel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrZinkernagelMember" xlink:to="lbl_label1621883258" xlink:type="arc"/>
      <link:label id="id_707fbae9" xlink:label="lbl_label1887419113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Alex Krauer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrAlexKrauerMember" xlink:to="lbl_label1887419113" xlink:type="arc"/>
      <link:label id="id_5f1c0cdd" xlink:label="lbl_label1595673821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Daniel Vasella [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrDanielVasellaMember" xlink:to="lbl_label1595673821" xlink:type="arc"/>
      <link:label id="id_49199deb" xlink:label="lbl_label1226415595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. James Bradner [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrJamesBradnerMember" xlink:to="lbl_label1226415595" xlink:type="arc"/>
      <link:label id="id_12139c9c" xlink:label="lbl_label303275164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, daily rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:to="lbl_label303275164" xlink:type="arc"/>
      <link:label id="id_34648bf4" xlink:label="lbl_label879004660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, annual guaranteed minimum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:to="lbl_label879004660" xlink:type="arc"/>
      <link:label id="id_475cd1c7" xlink:label="lbl_label1197265351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:to="lbl_label1197265351" xlink:type="arc"/>
      <link:label id="id_7d46110e" xlink:label="lbl_label2101743886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, ownership interest acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:to="lbl_label2101743886" xlink:type="arc"/>
      <link:label id="id_41061f2c" xlink:label="lbl_label1090920236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_label1090920236" xlink:type="arc"/>
      <link:label id="id_2d82d11f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_2c74381f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities</link:label>
      <link:label id="id_1315ebbc" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:type="arc"/>
      <link:label id="id_2feb765f" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_41098a9f" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_66cb76c9" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans</link:label>
      <link:label id="id_2dc02a48" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:type="arc"/>
      <link:label id="id_167b29ff" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects</link:label>
      <link:label id="id_23f99baf" xlink:label="lbl_label603560879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_label603560879" xlink:type="arc"/>
      <link:label id="id_525fbfa4" xlink:label="lbl_label98094011" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at end of period</link:label>
      <link:label id="id_5f2ad26f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_56084e2" xlink:label="lbl_label492438188" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4f1abe21" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments</link:label>
      <link:label id="id_44ea9064" xlink:label="lbl_label521267934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments</link:label>
      <link:label id="id_172d7365" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_1d877185" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of marketable investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfMarketableInvestments" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfMarketableInvestments" xlink:to="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:type="arc"/>
      <link:label id="id_67ba82da" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities sold</link:label>
      <link:label id="id_2adbb944" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of other financial assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_24c923e8" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets sold</link:label>
      <link:label id="id_334897f4" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments during the year</link:label>
      <link:label id="id_36328be7" xlink:label="lbl_label909282279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:label="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:to="lbl_label909282279" xlink:type="arc"/>
      <link:label id="id_598b1d0a" xlink:label="lbl_label1502289162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_label1502289162" xlink:type="arc"/>
      <link:label id="id_42afb056" xlink:label="lbl_label1118810198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_label1118810198" xlink:type="arc"/>
      <link:label id="id_4854e53b" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillMember" xlink:to="lbl_GoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_5a809ba7" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets other than Goodwill</link:label>
      <link:label id="id_6fcb9ca9" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_789924e3" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_6768eaf7" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing know-how</link:label>
      <link:label id="id_1878d8ce" xlink:label="lbl_label410573006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_label410573006" xlink:type="arc"/>
      <link:label id="id_5927b5e9" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwill" xlink:to="lbl_IntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7c0ed12" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at beginning of period</link:label>
      <link:label id="id_747bc8d6" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at end of period</link:label>
      <link:label id="id_4eee4a8f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4295643b" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_fd8bae8" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_2975d791" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_37bb77c5" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31d55821" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_4b244fff" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_c2fe7ed" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_13c2a444" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7e269b8c" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3f53b387" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6e93cf7f" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_4895c20f" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31bd23bf" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_4c0505b8" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3a8c745b" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_46823638" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:label id="id_71feba23" xlink:label="lbl_label1912519203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_label1912519203" xlink:type="arc"/>
      <link:label id="id_76bd9383" xlink:label="lbl_label1992135555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_label1992135555" xlink:type="arc"/>
      <link:label id="id_e23d9e6" xlink:label="lbl_label237230566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingSegmentsMember" xlink:to="lbl_label237230566" xlink:type="arc"/>
      <link:label id="id_4e99f014" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InnovativeMedicinesMember" xlink:to="lbl_InnovativeMedicinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5cce9bca" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Medicines</link:label>
      <link:label id="id_62947297" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozMember" xlink:to="lbl_SandozMember_labels" xlink:type="arc"/>
      <link:label id="id_2d171b79" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sandoz</link:label>
      <link:label id="id_19f7b763" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconMember" xlink:to="lbl_AlconMember_labels" xlink:type="arc"/>
      <link:label id="id_82cbe5b" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon</link:label>
      <link:label id="id_40af0c2d" xlink:label="lbl_label1085213741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated amounts [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnallocatedAmountsMember" xlink:to="lbl_label1085213741" xlink:type="arc"/>
      <link:label id="id_2f427f57" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:type="arc"/>
      <link:label id="id_1f6b21d" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminal Growth Rate</link:label>
      <link:label id="id_6e31860b" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate used in current measurement of fair value less costs of disposal</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:type="arc"/>
      <link:label id="id_59daa167" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate (post-tax)</link:label>
      <link:label id="id_32f31c92" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6067b5a3" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_6697be1e" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of justification for using growth rate that exceeds long-term average growth rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:type="arc"/>
      <link:label id="id_576cfb66" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of growth rate</link:label>
      <link:label id="id_645c105b" xlink:label="lbl_label1683755099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_label1683755099" xlink:type="arc"/>
      <link:label id="id_86ca8ac" xlink:label="lbl_label141338796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_label141338796" xlink:type="arc"/>
      <link:label id="id_3cced209" xlink:label="lbl_label1020187145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_label1020187145" xlink:type="arc"/>
      <link:label id="id_b0eee5a" xlink:label="lbl_label185527898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_label185527898" xlink:type="arc"/>
      <link:label id="id_7bf97c21" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_2ae4d862" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_6fae6c02" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Leveraged Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_4b1054ab" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee Share Ownership Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_28d147a5" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation UK Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_43a6ccb8" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select" [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:type="arc"/>
      <link:label id="id_3073fb0" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_547a9da" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long Term Relative Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1f01ff40" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Special Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_89e9c6a" xlink:label="lbl_label144612458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:to="lbl_label144612458" xlink:type="arc"/>
      <link:label id="id_25616927" xlink:label="lbl_label627140903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of method of settlement for share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:to="lbl_label627140903" xlink:type="arc"/>
      <link:label id="id_7e605438" xlink:label="lbl_label2120242232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="lbl_label2120242232" xlink:type="arc"/>
      <link:label id="id_73de771d" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:type="arc"/>
      <link:label id="id_41659fd5" xlink:label="lbl_label1097179093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_label1097179093" xlink:type="arc"/>
      <link:label id="id_70e32ac1" xlink:label="lbl_label1893935809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_label1893935809" xlink:type="arc"/>
      <link:label id="id_1e53f765" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOutstandingShareOptions" xlink:to="lbl_NumberOfOutstandingShareOptions_labels" xlink:type="arc"/>
      <link:label id="id_71aeacaf" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at beginning of period</link:label>
      <link:label id="id_5962c0d" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at end of period</link:label>
      <link:label id="id_7fce5b76" xlink:label="lbl_label2144230262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_label2144230262" xlink:type="arc"/>
      <link:label id="id_3d4fe5a6" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_18341635" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_1df4b58c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_4c6be67e" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_476e4360" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited or expired</link:label>
      <link:label id="id_3c8a636c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable</link:label>
      <link:label id="id_18fcb954" xlink:label="lbl_label419215700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_label419215700" xlink:type="arc"/>
      <link:label id="id_3e8e4697" xlink:label="lbl_label1049511575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_label1049511575" xlink:type="arc"/>
      <link:label id="id_2cfcdafb" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fb4ce8d" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_6a904dd3" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans, total after tax</link:label>
      <link:label id="id_77782278" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_5e993e53" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans before tax</link:label>
      <link:label id="id_70219b11" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_24653928" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans before tax</link:label>
      <link:label id="id_2e31d75a" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:type="arc"/>
      <link:label id="id_258900b0" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation on above items</link:label>
      <link:label id="id_7496cde" xlink:label="lbl_label122252510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired, price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:to="lbl_label122252510" xlink:type="arc"/>
      <link:label id="id_77be955a" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_19d019b2" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label98094011" xlink:type="arc"/>
      <link:label id="id_53394b08" xlink:label="lbl_label1396263688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label1396263688" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label492438188" xlink:type="arc"/>
      <link:label id="id_5127c80" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total value adjustments attributable to Novartis shareholders [Member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:type="arc"/>
      <link:label id="id_11f1c5d1" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4fa34414" xlink:label="lbl_label1336099860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Novartis share options [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:to="lbl_label1336099860" xlink:type="arc"/>
      <link:label id="id_47c79757" xlink:label="lbl_label1204262743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:to="lbl_label1204262743" xlink:type="arc"/>
      <link:label id="id_5c4a8ca3" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_5368a3e4" xlink:label="lbl_label1399366628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_label1399366628" xlink:type="arc"/>
      <link:label id="id_2ded6718" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual incentive</link:label>
      <link:label id="id_5e84f23d" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share savings plans</link:label>
      <link:label id="id_47fd4dbd" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select</link:label>
      <link:label id="id_779d196a" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Performance Plan</link:label>
      <link:label id="id_39c41311" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Relative Performance Plan</link:label>
      <link:label id="id_1cf8204b" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special share awards</link:label>
      <link:label id="id_4b5d1837" xlink:label="lbl_label679367036" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at end of period</link:label>
      <link:label id="id_569121e3" xlink:label="lbl_label1373999706" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, fair value at grante date</link:label>
      <link:label id="id_6bf6969c" xlink:label="lbl_label766376780" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, fair value at grante date</link:label>
      <link:label id="id_6a253a0a" xlink:label="lbl_label1695476906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, fair value at grante date</link:label>
      <link:label id="id_5dafe477" xlink:label="lbl_label1571808375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_label1571808375" xlink:type="arc"/>
      <link:label id="id_64b72c46" xlink:label="lbl_label1689726022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_label1689726022" xlink:type="arc"/>
      <link:label id="id_195ec04a" xlink:label="lbl_label425640010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_label425640010" xlink:type="arc"/>
      <link:label id="id_776b087e" xlink:label="lbl_label2003503230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaterialReconcilingItemsMember" xlink:to="lbl_label2003503230" xlink:type="arc"/>
      <link:label id="id_13fb62a8" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to other segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:type="arc"/>
      <link:label id="id_71f1654a" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to discontinued segment</link:label>
      <link:label id="id_425f6b3f" xlink:label="lbl_label1113549631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromInterest" xlink:to="lbl_label1113549631" xlink:type="arc"/>
      <link:label id="id_6ed59bdd" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAndAmortisationExpense" xlink:to="lbl_DepreciationAndAmortisationExpense_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:type="arc"/>
      <link:label id="id_60788cbc" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_2bf65413" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetOperatingAssets" xlink:to="lbl_NetOperatingAssets_labels" xlink:type="arc"/>
      <link:label id="id_3832e6c2" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:label id="id_216a6d7c" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of interests in associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="lbl_PurchaseOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInterestsInAssociates" xlink:to="lbl_PurchaseOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_41f96a5e" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_5e202521" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_3b72597a" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtsAndDerivativeInstruments" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:type="arc"/>
      <link:label id="id_6e43b10" xlink:label="lbl_label1241182885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current income tax liabilities and deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:to="lbl_label1241182885" xlink:type="arc"/>
      <link:label id="id_2c7e10a7" xlink:label="lbl_label102429242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales (in % of total net sales)</link:label>
      <link:label id="id_7f20a04d" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total of selected non-current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_615b5ab6" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</link:label>
      <link:label id="id_46b9a3b0" xlink:label="lbl_label1358337308" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</link:label>
      <link:label id="id_439913bb" xlink:label="lbl_label1134105531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_557072dd" xlink:label="lbl_label1433432797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other countries [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1433432797" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1134105531" xlink:type="arc"/>
      <link:label id="id_56b7dac7" xlink:label="lbl_label1638353244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia/Africa/Australasia [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AsiaAfricaAustralasiaMember" xlink:to="lbl_label1638353244" xlink:type="arc"/>
      <link:label id="id_7ec1f871" xlink:label="lbl_label2126641265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysRevenue" xlink:to="lbl_label2126641265" xlink:type="arc"/>
      <link:label id="id_4a42fa89" xlink:label="lbl_label1245903497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_label1245903497" xlink:type="arc"/>
      <link:label id="id_77148ff4" xlink:label="lbl_label1997836276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_label1997836276" xlink:type="arc"/>
      <link:label id="id_3a785089" xlink:label="lbl_label980963465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_label980963465" xlink:type="arc"/>
      <link:label id="id_7a5a32d3" xlink:label="lbl_label2052731603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_label2052731603" xlink:type="arc"/>
      <link:label id="id_54ab46d" xlink:label="lbl_label88781933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_label88781933" xlink:type="arc"/>
      <link:label id="id_329eef9f" xlink:label="lbl_label849276831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestCustomerMember" xlink:to="lbl_label849276831" xlink:type="arc"/>
      <link:label id="id_3eacc0a0" xlink:label="lbl_label1051508896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestCustomerMember" xlink:to="lbl_label1051508896" xlink:type="arc"/>
      <link:label id="id_54e36398" xlink:label="lbl_label1424188312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestCustomerMember" xlink:to="lbl_label1424188312" xlink:type="arc"/>
      <link:label id="id_51bc0ac2" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_76ba88df" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation of key figures</link:label>
      <link:label id="id_596e3d72" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d44b3a2" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated income statements</link:label>
      <link:label id="id_910173d" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_f1f9461" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets</link:label>
      <link:label id="id_68241853" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8ba3eb7" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and total of selected non-current assets, by countries and regions</link:label>
      <link:label id="id_11d66710" xlink:label="lbl_label1965771458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_1b7ab5f2" xlink:label="lbl_label461026802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_label461026802" xlink:type="arc"/>
      <link:label id="id_15494420" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2bcfd6a6" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies</link:label>
      <link:label id="id_113707b2" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_38388c12" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates</link:label>
      <link:label id="id_27f02648" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ebb669f" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, balance sheet value</link:label>
      <link:label id="id_52795c5f" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a736cd0" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_467a3bcc" xlink:label="lbl_label1182415820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_label1182415820" xlink:type="arc"/>
      <link:label id="id_3a1d7e" xlink:label="lbl_label3808638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_label3808638" xlink:type="arc"/>
      <link:label id="id_6360193f" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Switzerland</link:label>
      <link:label id="id_5e0c8ce9" xlink:label="lbl_label1577880809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</link:label>
      <link:label id="id_197b34b2" xlink:label="lbl_label427504818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label427504818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label1577880809" xlink:type="arc"/>
      <link:label id="id_49715fd2" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others associates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OthersAssociatesMember" xlink:to="lbl_OthersAssociatesMember_labels" xlink:type="arc"/>
      <link:label id="id_4dbe4327" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_54a1c758" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of total comprehensive income of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_33c07958" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income effect</link:label>
      <link:label id="id_4b6b0442" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet value</link:label>
      <link:label id="id_2f5ba89e" xlink:label="lbl_label794536094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInAssociate" xlink:to="lbl_label794536094" xlink:type="arc"/>
      <link:label id="id_5dfb85ae" xlink:label="lbl_label1576764846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceived" xlink:to="lbl_label1576764846" xlink:type="arc"/>
      <link:label id="id_6e7640ef" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation increase (decrease), intangible assets other than goodwil</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_20824625" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of re-appraised intangible assets</link:label>
      <link:label id="id_3ec70a2" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implicit Novartis goodwill</link:label>
      <link:label id="id_2f773be1" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of estimated net assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfEstimatedNetAssets" xlink:to="lbl_ShareOfEstimatedNetAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ae8d097" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of estimated net assets</link:label>
      <link:label id="id_df32051" xlink:label="lbl_label234037329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value of share in net identifiable assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:to="lbl_label234037329" xlink:type="arc"/>
      <link:label id="id_2274c64a" xlink:label="lbl_label578078282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated equity accounting adjustments and translation effects less dividends received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:to="lbl_label578078282" xlink:type="arc"/>
      <link:label id="id_4dcb8141" xlink:label="lbl_label1305182529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement effects [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_label1305182529" xlink:type="arc"/>
      <link:label id="id_139af9b9" xlink:label="lbl_label328923577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis share of current year consolidated net income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfCurrentYearNetIncome" xlink:to="lbl_label328923577" xlink:type="arc"/>
      <link:label id="id_9a810fe" xlink:label="lbl_label162009342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior year adjustment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PriorYearAdjustment" xlink:to="lbl_label162009342" xlink:type="arc"/>
      <link:label id="id_78fa72de" xlink:label="lbl_label2029679326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label2029679326" xlink:type="arc"/>
      <link:label id="id_691026f" xlink:label="lbl_label110166639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label110166639" xlink:type="arc"/>
      <link:label id="id_7f5dcb1f" xlink:label="lbl_label2136853279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about provisions and non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_label2136853279" xlink:type="arc"/>
      <link:label id="id_ff7eee9" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d543140" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_55d4757f" xlink:label="lbl_label1439987071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:to="lbl_label1439987071" xlink:type="arc"/>
      <link:label id="id_5b6a3526" xlink:label="lbl_label1533687078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:to="lbl_label1533687078" xlink:type="arc"/>
      <link:label id="id_60a92ef1" xlink:label="lbl_label1621700337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:to="lbl_label1621700337" xlink:type="arc"/>
      <link:label id="id_345b34eb" xlink:label="lbl_label878392555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:to="lbl_label878392555" xlink:type="arc"/>
      <link:label id="id_48374a1f" xlink:label="lbl_label1211583007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_label1211583007" xlink:type="arc"/>
      <link:label id="id_31459c86" xlink:label="lbl_label826645638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_label826645638" xlink:type="arc"/>
      <link:label id="id_2ad08cd6" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current net defined benefit liability</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:type="arc"/>
      <link:label id="id_7487a2cd" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans</link:label>
      <link:label id="id_74710a33" xlink:label="lbl_label1953565235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term employee benefits and deferred compensation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:to="lbl_label1953565235" xlink:type="arc"/>
      <link:label id="id_26d5ce13" xlink:label="lbl_label651546131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefits</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefits" xlink:to="lbl_label651546131" xlink:type="arc"/>
      <link:label id="id_70976fa3" xlink:label="lbl_label304425068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions, non-current</link:label>
      <link:label id="id_5e14a65" xlink:label="lbl_label98650725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_5ed0917e" xlink:label="lbl_label1590727038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision [roll forward]</link:label>
      <link:label id="id_6aa8f98d" xlink:label="lbl_label448335871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_70108f36" xlink:label="lbl_label2143979670" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_52a74241" xlink:label="lbl_label1560928630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_57e9d2a0" xlink:label="lbl_label42481781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_5d09f298" xlink:label="lbl_label1902698328" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_6048622c" xlink:label="lbl_label1615356460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, fiscal year maturity [abstract]</link:label>
      <link:label id="id_f98ea01" xlink:label="lbl_label1750372676" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total environmental remediation liability provisions</link:label>
      <link:label id="id_2ccb9fb2" xlink:label="lbl_label1351152500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within two years</link:label>
      <link:label id="id_78ad40b" xlink:label="lbl_label771700847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than two years, but within five years</link:label>
      <link:label id="id_7cc5fad5" xlink:label="lbl_label1968177093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than five years, but within ten years</link:label>
      <link:label id="id_6e61547b" xlink:label="lbl_label757561900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
      <link:label id="id_4bc380f7" xlink:label="lbl_label1271103735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions [roll forward]</link:label>
      <link:label id="id_68422c0a" xlink:label="lbl_label1583004694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_efc629e" xlink:label="lbl_label1339267684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_6285ec7c" xlink:label="lbl_label1568927014" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_3f37b15b" xlink:label="lbl_label1379712140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_50e2f2bd" xlink:label="lbl_label1424862979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_73b301e7" xlink:label="lbl_label252843510" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at end of period</link:label>
      <link:label id="id_29a7abc" xlink:label="lbl_label438797926" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_2ace6c03" xlink:label="lbl_label1363494370" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</link:label>
      <link:label id="id_39eddf10" xlink:label="lbl_label971890448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsProvisionMember" xlink:to="lbl_label971890448" xlink:type="arc"/>
      <link:label id="id_1f2f7122" xlink:label="lbl_label523202850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solodyn [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolodynMember" xlink:to="lbl_label523202850" xlink:type="arc"/>
      <link:label id="id_10d3ac94" xlink:label="lbl_label282307732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Lenses [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensesMember" xlink:to="lbl_label282307732" xlink:type="arc"/>
      <link:label id="id_3e0809a2" xlink:label="lbl_label1040714146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecMember" xlink:to="lbl_label1040714146" xlink:type="arc"/>
      <link:label id="id_7edbae34" xlink:label="lbl_label2128326196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclast/Aclasta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclastAclastaMember" xlink:to="lbl_label2128326196" xlink:type="arc"/>
      <link:label id="id_2b94eceb" xlink:label="lbl_label731180267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tekturna/Rasilez/Valturna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TekturnaRasilezValturnaMember" xlink:to="lbl_label731180267" xlink:type="arc"/>
      <link:label id="id_6962e490" xlink:label="lbl_label1392715101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG and Novartis Pharma SpA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGAndNovartisPharmaSpAMember" xlink:to="lbl_label1392715101" xlink:type="arc"/>
      <link:label id="id_13f125ec" xlink:label="lbl_label400121727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">F Hoffman La Roche AG and Roche SpA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:to="lbl_label400121727" xlink:type="arc"/>
      <link:label id="id_5ce126b6" xlink:label="lbl_label1365859055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaKKMember" xlink:to="lbl_label1365859055" xlink:type="arc"/>
      <link:label id="id_4f6a2c55" xlink:label="lbl_label1494155554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGMember" xlink:to="lbl_label1494155554" xlink:type="arc"/>
      <link:label id="id_514c724a" xlink:label="lbl_label201735145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NPC and others [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NPCAndOthersMember" xlink:to="lbl_label201735145" xlink:type="arc"/>
      <link:label id="id_41e7b3b9" xlink:label="lbl_label770853776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNCMember" xlink:to="lbl_label770853776" xlink:type="arc"/>
      <link:label id="id_51394769" xlink:label="lbl_label1362708329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, number of cases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:to="lbl_label1362708329" xlink:type="arc"/>
      <link:label id="id_241b918a" xlink:label="lbl_label605786506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, best estimate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="lbl_label605786506" xlink:type="arc"/>
      <link:label id="id_2225e7d2" xlink:label="lbl_label572909522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lbl_label572909522" xlink:type="arc"/>
      <link:label id="id_7a029719" xlink:label="lbl_label2046990105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of legal questions referred to court</link:label>
      <link:label id="id_5477d4dd" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, maximum fine</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:type="arc"/>
      <link:label id="id_4b15d12d" xlink:label="lbl_label1259721005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of putative cases referred to court</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:to="lbl_label1259721005" xlink:type="arc"/>
      <link:label id="id_2dbbe7e6" xlink:label="lbl_label767289318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of other cases referred to court</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:to="lbl_label767289318" xlink:type="arc"/>
      <link:label id="id_2ca8b224" xlink:label="lbl_label749253156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of states with alleged violations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:to="lbl_label749253156" xlink:type="arc"/>
      <link:label id="id_5f79ad81" xlink:label="lbl_label1601809793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of cases still pending</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:to="lbl_label1601809793" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:to="lbl_label2046990105" xlink:type="arc"/>
      <link:label id="id_206c121e" xlink:label="lbl_label543953438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Revenue" xlink:to="lbl_label543953438" xlink:type="arc"/>
      <link:label id="id_16a8694f" xlink:label="lbl_label380135759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:to="lbl_label380135759" xlink:type="arc"/>
      <link:label id="id_37595e6f" xlink:label="lbl_label928603759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:to="lbl_label928603759" xlink:type="arc"/>
      <link:label id="id_3742c395" xlink:label="lbl_label927122325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:to="lbl_label927122325" xlink:type="arc"/>
      <link:label id="id_5358e820" xlink:label="lbl_label1398335520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:to="lbl_label1398335520" xlink:type="arc"/>
      <link:label id="id_7779807a" xlink:label="lbl_label2004451450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:to="lbl_label2004451450" xlink:type="arc"/>
      <link:label id="id_2af5dc98" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ade93c7" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors</link:label>
      <link:label id="id_3e931ad0" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total fair value adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalFairValueAdjustmentsMember" xlink:to="lbl_TotalFairValueAdjustmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fef6f2d" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments</link:label>
      <link:label id="id_2b0a5355" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions at beginning of period</link:label>
      <link:label id="id_7633694e" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions at end of period</link:label>
      <link:label id="id_55d5426d" xlink:label="lbl_label1440039533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses, third party</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label1440039533" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label905656156" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:label id="id_4ecd5cc2" xlink:label="lbl_label1322081474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_label1322081474" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:label id="id_3ada3bfa" xlink:label="lbl_label987380730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_label987380730" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:label id="id_7e01564" xlink:label="lbl_label132126052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_label132126052" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:label id="id_545eb47a" xlink:label="lbl_label1415492730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:to="lbl_label1415492730" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_7cfc55ea" xlink:label="lbl_label2096911850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearMember1" xlink:to="lbl_label2096911850" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_22980743" xlink:label="lbl_label580388675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:to="lbl_label580388675" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:label id="id_1f823f0f" xlink:label="lbl_label528629519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:to="lbl_label528629519" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:label id="id_1d54f07" xlink:label="lbl_label30756615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneMonthMember" xlink:to="lbl_label30756615" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:label id="id_69518" xlink:label="lbl_label431384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentLiabilities1" xlink:to="lbl_label431384" xlink:type="arc"/>
      <link:label id="id_7b946bcb" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_11be10a7" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_529b4b2a" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from change in tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:type="arc"/>
      <link:label id="id_9416195" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax rate change on current and deferred tax assets and liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:label id="id_753a14cc" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of expense not deductible in determining taxable profit tax loss</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:type="arc"/>
      <link:label id="id_4ff9c19a" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of disallowed expenditures</link:label>
      <link:label id="id_72f99baf" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of tax losses</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfTaxLosses1" xlink:to="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:type="arc"/>
      <link:label id="id_3858f2af" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of utilization of tax losses brought forward from prior periods</link:label>
      <link:label id="id_6100ccc9" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherExpenseByFunction" xlink:to="lbl_OtherExpenseByFunction_labels" xlink:type="arc"/>
      <link:label id="id_7b7f0633" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense, by function</link:label>
      <link:label id="id_295deb1d" xlink:label="lbl_label694020893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ParValuePerShare" xlink:to="lbl_label694020893" xlink:type="arc"/>
      <link:label id="id_223c2b0a" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_7418af90" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_7592952b" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_6a995f9c" xlink:label="lbl_label1788436380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxotereMember" xlink:to="lbl_label1788436380" xlink:type="arc"/>
      <link:label id="id_578eb571" xlink:label="lbl_label1468970353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amiodarone [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmiodaroneMember" xlink:to="lbl_label1468970353" xlink:type="arc"/>
      <link:label id="id_3bc6fd49" xlink:label="lbl_label1002896713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_label1002896713" xlink:type="arc"/>
      <link:label id="id_5120693" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityTextBlock" xlink:to="lbl_DisclosureOfEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6726d861" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:label id="id_3dc60187" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendTableTextBlock" xlink:to="lbl_DividendTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_258e3af2" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to Dividend</link:label>
      <link:label id="id_cb435c9" xlink:label="lbl_label213136841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmendmentFlag" xlink:to="lbl_label213136841" xlink:type="arc"/>
      <link:label id="id_5d388f3d" xlink:label="lbl_label1563987773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentPeriodEndDate" xlink:to="lbl_label1563987773" xlink:type="arc"/>
      <link:label id="id_1e619d64" xlink:label="lbl_label509713764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalYearFocus" xlink:to="lbl_label509713764" xlink:type="arc"/>
      <link:label id="id_7fb4d619" xlink:label="lbl_label2142557721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalPeriodFocus" xlink:to="lbl_label2142557721" xlink:type="arc"/>
      <link:label id="id_29f6dab9" xlink:label="lbl_label704043705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradingSymbol" xlink:to="lbl_label704043705" xlink:type="arc"/>
      <link:label id="id_30c984d" xlink:label="lbl_label51157069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityRegistrantName" xlink:to="lbl_label51157069" xlink:type="arc"/>
      <link:label id="id_387f1769" xlink:label="lbl_label947853161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCentralIndexKey" xlink:to="lbl_label947853161" xlink:type="arc"/>
      <link:label id="id_6f6c1fbf" xlink:label="lbl_label1869356991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFiscalYearEndDate" xlink:to="lbl_label1869356991" xlink:type="arc"/>
      <link:label id="id_6f81ea6f" xlink:label="lbl_label1870785135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityWellKnownSeasonedIssuer" xlink:to="lbl_label1870785135" xlink:type="arc"/>
      <link:label id="id_593907e" xlink:label="lbl_label93556862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCurrentReportingStatus" xlink:to="lbl_label93556862" xlink:type="arc"/>
      <link:label id="id_a350bde" xlink:label="lbl_label171248606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityVoluntaryFilers" xlink:to="lbl_label171248606" xlink:type="arc"/>
      <link:label id="id_1ebbff8e" xlink:label="lbl_label515637134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFilerCategory" xlink:to="lbl_label515637134" xlink:type="arc"/>
      <link:label id="id_2df8f48d" xlink:label="lbl_label771290253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCommonStockSharesOutstanding" xlink:to="lbl_label771290253" xlink:type="arc"/>
      <link:label id="id_6a10c99a" xlink:label="lbl_label1779485082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityPublicFloat" xlink:to="lbl_label1779485082" xlink:type="arc"/>
      <link:label id="id_60ad1327" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_US" xlink:to="lbl_US_labels" xlink:type="arc"/>
      <link:label id="id_45b4f0b8" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GB" xlink:to="lbl_GB_labels" xlink:type="arc"/>
      <link:label id="id_fa4133c" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DE" xlink:to="lbl_DE_labels" xlink:type="arc"/>
      <link:label id="id_4fab4920" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FR" xlink:to="lbl_FR_labels" xlink:type="arc"/>
      <link:label id="id_2409370a" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JP" xlink:to="lbl_JP_labels" xlink:type="arc"/>
      <link:label id="id_7e84627" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
      <link:label id="id_35cc0588" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK</link:label>
      <link:label id="id_11499416" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
      <link:label id="id_50732a2" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
      <link:label id="id_16ecebec" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
      <link:label id="id_47d2ec01" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IT" xlink:to="lbl_IT_labels" xlink:type="arc"/>
      <link:label id="id_3b372d9d" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
      <link:label id="id_53d1a5ee" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CA" xlink:to="lbl_CA_labels" xlink:type="arc"/>
      <link:label id="id_68cbde64" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
      <link:label id="id_87623f2" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USD" xlink:to="lbl_USD_labels" xlink:type="arc"/>
      <link:label id="id_73a7c19e" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD</link:label>
      <link:label id="id_78126268" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EUR" xlink:to="lbl_EUR_labels" xlink:type="arc"/>
      <link:label id="id_70708ef7" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR</link:label>
      <link:label id="id_12746a38" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPY" xlink:to="lbl_JPY_labels" xlink:type="arc"/>
      <link:label id="id_7b8f8056" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPY</link:label>
      <link:label id="id_7a7394c2" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China, Yuan Renminbi</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CNY" xlink:to="lbl_CNY_labels" xlink:type="arc"/>
      <link:label id="id_4d265dd0" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CNY</link:label>
      <link:label id="id_1c17f7c4" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GBP" xlink:to="lbl_GBP_labels" xlink:type="arc"/>
      <link:label id="id_1728da67" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GBP</link:label>
      <link:label id="id_436074ee" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHF</link:label>
      <link:label id="id_1da98c1e" xlink:label="lbl_label497650718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_label497650718" xlink:type="arc"/>
      <link:label id="id_12b84aa7" xlink:label="lbl_label314067623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_label314067623" xlink:type="arc"/>
      <link:label id="id_165ab5d4" xlink:label="lbl_label375043540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_label375043540" xlink:type="arc"/>
      <link:label id="id_238135db" xlink:label="lbl_label595670491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityDomain" xlink:to="lbl_label595670491" xlink:type="arc"/>
      <link:label id="id_1d17e2f2" xlink:label="lbl_label488104690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_label488104690" xlink:type="arc"/>
      <link:label id="id_1d7da856" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Need new ITEM here</link:label>
      <link:label id="id_751ef3e9" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and Administration</link:label>
      <link:label id="id_20c355f9" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in non-controling interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:type="arc"/>
      <link:label id="id_71d21c6b" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:label id="id_7d6a6449" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from associated companies and others</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4bdcb2fd" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received, classified as operating activities</link:label>
      <link:label id="id_d7b5832" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7e7ea58d" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial receipts</link:label>
      <link:label id="id_44baadd4" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs paid, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_68d65042" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial payments</link:label>
      <link:label id="id_36d7aeb1" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of interests in associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_df43529" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_789b89ac" xlink:label="lbl_label1718040268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_197c150c" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3ec8bcea" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:label id="id_7cc199f7" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromNoncurrentBorrowings" xlink:to="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_2e7bd9f2" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentsOfNoncurrentBorrowings" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_106de250" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of non-current financial debts</link:label>
      <link:label id="id_40f4d6a8" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
      <link:label id="id_1bde8770" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) increase (decrease) in current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_104baa70" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_367ad3ce" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing cash flows, net</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2a649f3d" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
      <link:label id="id_3f82a721" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefund" xlink:to="lbl_IncomeTaxesPaidRefund_labels" xlink:type="arc"/>
      <link:label id="id_53191c38" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_16a1607" xlink:label="lbl_label23729671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfReportableSegments" xlink:to="lbl_label23729671" xlink:type="arc"/>
      <link:label id="id_ff1b344" xlink:label="lbl_label267498308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Business Units</link:label>
      <link:label id="id_19aaa924" xlink:label="lbl_label430614820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Franchises</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfFranchises" xlink:to="lbl_label430614820" xlink:type="arc"/>
      <link:label id="id_3b0ef23" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant and equipment</link:label>
      <link:label id="id_528839cf" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets and goodwill</link:label>
      <link:label id="id_40106876" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_7458433e" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties</link:label>
      <link:label id="id_541cacbc" xlink:label="lbl_label1411165372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments, as percent of total net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label1411165372" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label102429242" xlink:type="arc"/>
      <link:label id="id_5aa03955" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected non-current assets, as percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_6c200908" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected non-current assets (in % of total selected non-current assets)</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_label1358337308" xlink:type="arc"/>
      <link:label id="id_6d471c75" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of investments in associates for which there are quoted market prices</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:type="arc"/>
      <link:label id="id_6319607c" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:label id="id_51c4430d" xlink:label="lbl_label1371816717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense, gross</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1371816717" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1549022431" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:label id="id_752e4898" xlink:label="lbl_label1965967512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromDividends" xlink:to="lbl_label1965967512" xlink:type="arc"/>
      <link:label id="id_6b7200d3" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss on commodities and available-for-sale securities, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:type="arc"/>
      <link:label id="id_4fa6704a" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of commodities and available-for-sale securities, net</link:label>
      <link:label id="id_6fd24c63" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance cost</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceCost" xlink:to="lbl_OtherFinanceCost_labels" xlink:type="arc"/>
      <link:label id="id_2d3e7598" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expense</link:label>
      <link:label id="id_2b07fd1f" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), discontinuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_671db01c" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_772c2e3e" xlink:label="lbl_label1999384126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from non-deductible losses</link:label>
      <link:label id="id_199436bd" xlink:label="lbl_label429143741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in uncertain tax positions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lbl_label429143741" xlink:type="arc"/>
      <link:label id="id_2016529c" xlink:label="lbl_label538333852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in enacted tax rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lbl_label538333852" xlink:type="arc"/>
      <link:label id="id_2aa51152" xlink:label="lbl_label1640547073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:to="lbl_label1640547073" xlink:type="arc"/>
      <link:label id="id_596243a4" xlink:label="lbl_label1689586548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax exchange differences on translation related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:to="lbl_label1689586548" xlink:type="arc"/>
      <link:label id="id_1a035b8a" xlink:label="lbl_label436427658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brands [axis]</link:label>
      <link:label id="id_7dfe6553" xlink:label="lbl_label2113824083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brands [member]</link:label>
      <link:label id="id_1c8ae042" xlink:label="lbl_label478863426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Brands [member]</link:label>
      <link:label id="id_6b138679" xlink:label="lbl_label1796441721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promoted Brands [member]</link:label>
      <link:label id="id_73d27a10" xlink:label="lbl_label1943173648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core therapeutic area; other promoted brands; and established brands [axis]</link:label>
      <link:label id="id_578f16d9" xlink:label="lbl_label1468995289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core therapeutic area; other promoted brands; and established brands [member]</link:label>
      <link:label id="id_7a3bb683" xlink:label="lbl_label2050733699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmology [member]</link:label>
      <link:label id="id_29ccb106" xlink:label="lbl_label701280518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeuroscienceMember" xlink:to="lbl_label701280518" xlink:type="arc"/>
      <link:label id="id_1b0191fc" xlink:label="lbl_label453087740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respiratory and Allergy [member]</link:label>
      <link:label id="id_43a1daf0" xlink:label="lbl_label1134680816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular [member]</link:label>
      <link:label id="id_393ea837" xlink:label="lbl_label960407607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMedicinesMember" xlink:to="lbl_label960407607" xlink:type="arc"/>
      <link:label id="id_5bf06316" xlink:label="lbl_label1542480662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_label1542480662" xlink:type="arc"/>
      <link:label id="id_38b2f5ea" xlink:label="lbl_label951252458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_label951252458" xlink:type="arc"/>
      <link:label id="id_77b41933" xlink:label="lbl_label2008291635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COPD [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_COPDMember" xlink:to="lbl_label2008291635" xlink:type="arc"/>
      <link:label id="id_7bd53aee" xlink:label="lbl_label2077571822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec/Glivec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecGlivecMember" xlink:to="lbl_label2077571822" xlink:type="arc"/>
      <link:label id="id_b0600c4" xlink:label="lbl_label184942788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tasigna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TasignaMember" xlink:to="lbl_label184942788" xlink:type="arc"/>
      <link:label id="id_3f81d4ef" xlink:label="lbl_label1065473263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandostatin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandostatinMember" xlink:to="lbl_label1065473263" xlink:type="arc"/>
      <link:label id="id_b64c3a5" xlink:label="lbl_label191153061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Afinitor/Votubia [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AfinitorVotubiaMember" xlink:to="lbl_label191153061" xlink:type="arc"/>
      <link:label id="id_7ee4b441" xlink:label="lbl_label2128917569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exjade/Jadenu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExjadeJadenuMember" xlink:to="lbl_label2128917569" xlink:type="arc"/>
      <link:label id="id_28e14893" xlink:label="lbl_label685852819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tafinlar + Mekinist [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TafinlarMekinistMember" xlink:to="lbl_label685852819" xlink:type="arc"/>
      <link:label id="id_67d8ca2f" xlink:label="lbl_label1742260783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promacta/Revolade [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromactaRevoladeMember" xlink:to="lbl_label1742260783" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmologyMember" xlink:to="lbl_label2050733699" xlink:type="arc"/>
      <link:label id="id_647651d6" xlink:label="lbl_label1685475798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Votrient [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VotrientMember" xlink:to="lbl_label1685475798" xlink:type="arc"/>
      <link:label id="id_2746717b" xlink:label="lbl_label658927995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jakavi [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JakaviMember" xlink:to="lbl_label658927995" xlink:type="arc"/>
      <link:label id="id_72117eb7" xlink:label="lbl_label1913749175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kisqali [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KisqaliMember" xlink:to="lbl_label1913749175" xlink:type="arc"/>
      <link:label id="id_4dee8d50" xlink:label="lbl_label1307479376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProductsMember" xlink:to="lbl_label1307479376" xlink:type="arc"/>
      <link:label id="id_6a7a37e6" xlink:label="lbl_label1786394598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travoprost Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TravoprostGroupMember" xlink:to="lbl_label1786394598" xlink:type="arc"/>
      <link:label id="id_3e01b08f" xlink:label="lbl_label1040298127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Systane Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SystaneGroupMember" xlink:to="lbl_label1040298127" xlink:type="arc"/>
      <link:label id="id_3ffa23d" xlink:label="lbl_label67084861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical Olopatadine Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopicalOlopatadineGroupMember" xlink:to="lbl_label67084861" xlink:type="arc"/>
      <link:label id="id_931b1f9" xlink:label="lbl_label154251769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cosentyx [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CosentyxMember" xlink:to="lbl_label154251769" xlink:type="arc"/>
      <link:label id="id_31cd0397" xlink:label="lbl_label835519383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neoral/Sandimmun(e) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeoralSandimmunEMember" xlink:to="lbl_label835519383" xlink:type="arc"/>
      <link:label id="id_48585481" xlink:label="lbl_label1213748353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zortress/Certican [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZortressCerticanMember" xlink:to="lbl_label1213748353" xlink:type="arc"/>
      <link:label id="id_d8aed9" xlink:label="lbl_label14200537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ilaris [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IlarisMember" xlink:to="lbl_label14200537" xlink:type="arc"/>
      <link:label id="id_612117f4" xlink:label="lbl_label1629558772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myfortic [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MyforticMember" xlink:to="lbl_label1629558772" xlink:type="arc"/>
      <link:label id="id_63153a75" xlink:label="lbl_label1662335605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilenya [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GilenyaMember" xlink:to="lbl_label1662335605" xlink:type="arc"/>
      <link:label id="id_79c9c9f8" xlink:label="lbl_label2043267576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroBreezhalerMember" xlink:to="lbl_label2043267576" xlink:type="arc"/>
      <link:label id="id_39edf745" xlink:label="lbl_label971896645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seebri Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SeebriBreezhalerMember" xlink:to="lbl_label971896645" xlink:type="arc"/>
      <link:label id="id_3093cd1d" xlink:label="lbl_label814992669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Onbrez Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OnbrezBreezhalerMember" xlink:to="lbl_label814992669" xlink:type="arc"/>
      <link:label id="id_61b9d990" xlink:label="lbl_label1639569808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entresto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntrestoMember" xlink:to="lbl_label1639569808" xlink:type="arc"/>
      <link:label id="id_ba5bf3e" xlink:label="lbl_label195411774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galvus Group [member]</link:label>
      <link:label id="id_4a18d85e" xlink:label="lbl_label1243142238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exforge Group [member]</link:label>
      <link:label id="id_75a7ce71" xlink:label="lbl_label1973931633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diovan Group [member]</link:label>
      <link:label id="id_2e0075fc" xlink:label="lbl_label771782140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voltaren/Cataflam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VoltarenCataflamMember" xlink:to="lbl_label771782140" xlink:type="arc"/>
      <link:label id="id_5304aa12" xlink:label="lbl_label1392814610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exelon/Exelon Patch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExelonExelonPatchMember" xlink:to="lbl_label1392814610" xlink:type="arc"/>
      <link:label id="id_10a15386" xlink:label="lbl_label279008134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ritalin/Focalin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RitalinFocalinMember" xlink:to="lbl_label279008134" xlink:type="arc"/>
      <link:label id="id_26f1359c" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals, property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_1c74ede2" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals and derecognitions</link:label>
      <link:label id="id_22aa91df" xlink:label="lbl_label1255943452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated impairments on disposals and derecognition</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:to="lbl_label1255943452" xlink:type="arc"/>
      <link:label id="id_626451ea" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:type="arc"/>
      <link:label id="id_d6a6395" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_52b9d0b7" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon brand name [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconBrandNameMember" xlink:to="lbl_AlconBrandNameMember_labels" xlink:type="arc"/>
      <link:label id="id_4db335d9" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alcon brand name</link:label>
      <link:label id="id_52290b49" xlink:label="lbl_label1378421577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross value of tax loss carry forwards expiring in future years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label1378421577" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label94266701" xlink:type="arc"/>
      <link:label id="id_70e22198" xlink:label="lbl_label198642827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %</link:label>
      <link:label id="id_330af3ff" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_2b7d0eda" xlink:label="lbl_label729616090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation gains/losses recycled through income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:to="lbl_label729616090" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:type="locator"/>
      <link:label id="id_19f22bed" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired loss on financial assets transferred to the income statement</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2ac3f739" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax</link:label>
      <link:label id="id_1bf8cda2" xlink:label="lbl_label469290402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, available-for-sale financial investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:label="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label469290402" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label521267934" xlink:type="arc"/>
      <link:label id="id_523cf50c" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, maketable securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:type="arc"/>
      <link:label id="id_64b0e4db" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_37e931e5" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseReceivables" xlink:to="lbl_FinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_f9fb296" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
      <link:label id="id_18330ebd" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements</link:label>
      <link:label id="id_5342799f" xlink:label="lbl_label1396865439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivableMember" xlink:to="lbl_label1396865439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Commodities" xlink:to="lbl_label1789088932" xlink:type="arc"/>
      <link:label id="id_2985d64f" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_OutstandingShareCapital_labels" xlink:type="arc"/>
      <link:label id="id_550535ae" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at beginning of period</link:label>
      <link:label id="id_75bd4d3d" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at end of period</link:label>
      <link:label id="id_551db3e0" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_736416f8" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMovement" xlink:to="lbl_IssuedCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_58515153" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital movement of period</link:label>
      <link:label id="id_416f3b0f" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_OutstandingShareCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_578dd06d" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares outstanding movement of period</link:label>
      <link:label id="id_6cc370cc" xlink:label="lbl_label1824747724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares cancelled for capital reduction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesCancelledForCapitalReduction" xlink:to="lbl_label1824747724" xlink:type="arc"/>
      <link:label id="id_138eeec4" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovement" xlink:to="lbl_TreasurySharesMovement_labels" xlink:type="arc"/>
      <link:label id="id_296c7c9b" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total number of outstanding treasury shares</link:label>
      <link:label id="id_3fd2a1c9" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_4f72913c" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_10472e97" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity impact of treasury share movements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityImpactOfTreasuryShareMovements" xlink:to="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_1cdf067d" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_495f6f85" xlink:label="lbl_label903405960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on loans received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnLoansReceived" xlink:to="lbl_label903405960" xlink:type="arc"/>
      <link:label id="id_57858aea" xlink:label="lbl_label1766025212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio fixed rate financial debt to total financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:to="lbl_label1766025212" xlink:type="arc"/>
      <link:label id="id_10cf25f4" xlink:label="lbl_label1048419104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnBorrowings" xlink:to="lbl_label1048419104" xlink:type="arc"/>
      <link:label id="id_2aee42a4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, coupon</link:label>
      <link:label id="id_176fa55a" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuance year</link:label>
      <link:label id="id_6ff69971" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity year</link:label>
      <link:label id="id_7a5c6046" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuer</link:label>
      <link:label id="id_30da0d60" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issue price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationNonCurrent" xlink:to="lbl_label98650725" xlink:type="arc"/>
      <link:label id="id_38f01585" xlink:label="lbl_label955258245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_label1590727038" xlink:type="arc"/>
      <link:label id="id_26f523d7" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_EnvironmentalProvision_labels" xlink:type="arc"/>
      <link:label id="id_2f8c0636" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at beginning of period</link:label>
      <link:label id="id_3ca05f15" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at end of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_label1750372676" xlink:type="arc"/>
      <link:label id="id_5bf2bac7" xlink:label="lbl_label1542634183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label1542634183" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label448335871" xlink:type="arc"/>
      <link:label id="id_1bbf0a1c" xlink:label="lbl_label465504796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, releases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label465504796" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label2143979670" xlink:type="arc"/>
      <link:label id="id_30109c5e" xlink:label="lbl_label806394974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, additions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label806394974" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label1560928630" xlink:type="arc"/>
      <link:label id="id_6528e847" xlink:label="lbl_label1697179719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1697179719" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label42481781" xlink:type="arc"/>
      <link:label id="id_69c992c5" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, Current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_EnvironmentalProvisionCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_label1902698328" xlink:type="arc"/>
      <link:label id="id_76c21b8c" xlink:label="lbl_label1992432524" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current environmental remediation provisions at end of period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label1992432524" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label955258245" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label304425068" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_label1615356460" xlink:type="arc"/>
      <link:label id="id_6deab0eb" xlink:label="lbl_label1844097259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, next two years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1844097259" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1351152500" xlink:type="arc"/>
      <link:label id="id_54b46e40" xlink:label="lbl_label1421110848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than two years, but within five years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label1421110848" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label771700847" xlink:type="arc"/>
      <link:label id="id_366842e4" xlink:label="lbl_label912802532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than five years, but within ten years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label912802532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label1968177093" xlink:type="arc"/>
      <link:label id="id_53179e3c" xlink:label="lbl_label1394056764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, after ten years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label1394056764" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label757561900" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_label1271103735" xlink:type="arc"/>
      <link:label id="id_5e9e598e" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1dcf084" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_label252843510" xlink:type="arc"/>
      <link:label id="id_71839c4e" xlink:label="lbl_label1904450638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1904450638" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1583004694" xlink:type="arc"/>
      <link:label id="id_53472504" xlink:label="lbl_label1397171460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1397171460" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1339267684" xlink:type="arc"/>
      <link:label id="id_3e905f98" xlink:label="lbl_label1049649048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, releases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1049649048" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1568927014" xlink:type="arc"/>
      <link:label id="id_61e84c26" xlink:label="lbl_label1642613798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, additions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1642613798" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1379712140" xlink:type="arc"/>
      <link:label id="id_6c695b53" xlink:label="lbl_label1818843987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1818843987" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1424862979" xlink:type="arc"/>
      <link:label id="id_54a4e6a7" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_label438797926" xlink:type="arc"/>
      <link:label id="id_acc6217" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, non-current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_label1363494370" xlink:type="arc"/>
      <link:label id="id_d93a8b" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateAssociates" xlink:to="lbl_WeightedAverageInterestRateAssociates_labels" xlink:type="arc"/>
      <link:label id="id_6be37912" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on interest bearning accounts of associates payable on demand.</link:label>
      <link:label id="id_1a1c62e1" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_1401b9c9" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:label id="id_7df4e11d" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation liabilities</link:label>
      <link:label id="id_19219108" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses for goods and services received but not invoiced</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualsClassifiedAsCurrent" xlink:to="lbl_AccrualsClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2731b8ee" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
      <link:label id="id_1dcdc504" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration, current portion</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationCurrentPortion" xlink:to="lbl_ContingentConsiderationCurrentPortion_labels" xlink:type="arc"/>
      <link:label id="id_cecd050" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_66cb3d62" xlink:label="lbl_label1724595554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for deduction from revenue [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_label1724595554" xlink:type="arc"/>
      <link:label id="id_62196d01" xlink:label="lbl_label1645833473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_label1645833473" xlink:type="arc"/>
      <link:label id="id_5c0c0960" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision transfers</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionTransfers" xlink:label="lbl_RestructuringProvisionTransfers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionTransfers" xlink:to="lbl_RestructuringProvisionTransfers_labels" xlink:type="arc"/>
      <link:label id="id_2238ed4d" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:type="locator"/>
      <link:label id="id_78c7fbb0" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on cash flow hedges, net of tax</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_b7c54f9" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized net losses on cash flow hedges transferred to the consolidated income statement</link:label>
      <link:label id="id_58b3a333" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables and deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5a90c79" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_2856a2a3" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_IdentifiableAssetsAcquired_labels" xlink:type="arc"/>
      <link:label id="id_205b065c" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net identifiable assets acquired</link:label>
      <link:label id="id_62f623d2" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_59f5d7c5" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_28728c08" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_4dd002d2" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_3be633c" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired divested research and development intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3369d331" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Acquired)/divested research and development</link:label>
      <link:label id="id_44229a8b" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technologies recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3e9ce44a" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_33f9a377" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_52667216" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2879f83e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_64556efa" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_63e0564e" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_7a3f0241" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4427bc74" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_5681fbbf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:label id="id_6359834c" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_47a6ced3" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_4d854151" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3ea67aa0" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_1be55693" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_65a5731d" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_5d12057a" xlink:label="lbl_label1419113480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Animal health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnimalHealthMember" xlink:label="lbl_AnimalHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnimalHealthMember" xlink:to="lbl_label1419113480" xlink:type="arc"/>
      <link:label id="id_6ab963bf" xlink:label="lbl_label1790534591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromSaleOfBusiness" xlink:label="lbl_ProceedsFromSaleOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSaleOfBusiness" xlink:to="lbl_label1790534591" xlink:type="arc"/>
      <link:label id="id_2cda3a42" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_7f35ae76" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at beginning of period</link:label>
      <link:label id="id_5e88cc26" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at end of period</link:label>
      <link:label id="id_32b354fd" xlink:label="lbl_label1199806184" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair values, lease interest and other changes, net</link:label>
      <link:label id="id_3eaf2bac" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfBondsDiscount" xlink:to="lbl_AmortizationOfBondsDiscount_labels" xlink:type="arc"/>
      <link:label id="id_4b9e2882" xlink:label="lbl_label1268656258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts [member]</link:label>
      <link:label id="id_24db2ae3" xlink:label="lbl_label618343139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debts and derivative financial instruments [member]</link:label>
      <link:label id="id_20254569" xlink:label="lbl_label539313513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:to="lbl_label539313513" xlink:type="arc"/>
      <link:label id="id_4171dffa" xlink:label="lbl_label1097981946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech / Roche [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechRocheMember" xlink:to="lbl_label1097981946" xlink:type="arc"/>
      <link:label id="id_21b59c45" xlink:label="lbl_label565550149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of contracts with related parties</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfContractsWithRelatedParties" xlink:to="lbl_label565550149" xlink:type="arc"/>
      <link:label id="id_12cdd92b" xlink:label="lbl_label1424538747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Committee members</link:label>
      <link:label id="id_4d39a061" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of non-executive directors</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:type="arc"/>
      <link:label id="id_2b93879e" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-executive directors</link:label>
      <link:label id="id_4c2ae7af" xlink:label="lbl_label1277880239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label1277880239" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label839490648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label2113441601" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label1670270510" xlink:type="arc"/>
      <link:label id="id_45a2931c" xlink:label="lbl_label1168282396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, foreign currency exchange rate gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label1168282396" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label220841955" xlink:type="arc"/>
      <link:label id="id_329368f1" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_label1273555602" xlink:type="arc"/>
      <link:label id="id_5b9bb55e" xlink:label="lbl_label1536931166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than ten years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lbl_label1536931166" xlink:type="arc"/>
      <link:label id="id_7cbb695f" xlink:label="lbl_label2092656991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_label2092656991" xlink:type="arc"/>
      <link:label id="id_675e88e3" xlink:label="lbl_label1734248675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_label1734248675" xlink:type="arc"/>
      <link:label id="id_6f8cf207" xlink:label="lbl_label1871507975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssets" xlink:to="lbl_label1871507975" xlink:type="arc"/>
      <link:label id="id_31c4b50a" xlink:label="lbl_label834974986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_label834974986" xlink:type="arc"/>
      <link:label id="id_3b500f38" xlink:label="lbl_label995102520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_label995102520" xlink:type="arc"/>
      <link:label id="id_5853963a" xlink:label="lbl_label1481872954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostMember" xlink:to="lbl_label1481872954" xlink:type="arc"/>
      <link:label id="id_15228c3a" xlink:label="lbl_label354585658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMember" xlink:to="lbl_label354585658" xlink:type="arc"/>
      <link:label id="id_2ea70" xlink:label="lbl_label191088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_label191088" xlink:type="arc"/>
      <link:label id="id_5fa2081d" xlink:label="lbl_label1604454429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_label1604454429" xlink:type="arc"/>
      <link:label id="id_7ddd290" xlink:label="lbl_label131977872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities [member]</link:label>
      <link:label id="id_36737cf8" xlink:label="lbl_label913538296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments [member]</link:label>
      <link:label id="id_5632a636" xlink:label="lbl_label1446159926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_label1446159926" xlink:type="arc"/>
      <link:label id="id_77e6aae0" xlink:label="lbl_label2011605728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_label2011605728" xlink:type="arc"/>
      <link:label id="id_39f42abc" xlink:label="lbl_label972303036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquitySecuritiesMember" xlink:to="lbl_label972303036" xlink:type="arc"/>
      <link:label id="id_34461243" xlink:label="lbl_label877007427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInvestmentsMember" xlink:to="lbl_label877007427" xlink:type="arc"/>
      <link:label id="id_3c80f6bd" xlink:label="lbl_label1015084733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets excluding pre-payments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:to="lbl_label1015084733" xlink:type="arc"/>
      <link:label id="id_71d621f1" xlink:label="lbl_label1909858801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesMember" xlink:to="lbl_label1909858801" xlink:type="arc"/>
      <link:label id="id_266ee04f" xlink:label="lbl_label644800591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:to="lbl_label644800591" xlink:type="arc"/>
      <link:label id="id_462cba41" xlink:label="lbl_label1177336385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:to="lbl_label1177336385" xlink:type="arc"/>
      <link:label id="id_1ada2efd" xlink:label="lbl_label450506493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:to="lbl_label450506493" xlink:type="arc"/>
      <link:label id="id_7c347590" xlink:label="lbl_label2083812752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated companies at fair value through profit and loss [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:to="lbl_label2083812752" xlink:type="arc"/>
      <link:label id="id_533b50d9" xlink:label="lbl_label1396396249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsMember" xlink:to="lbl_label1396396249" xlink:type="arc"/>
      <link:label id="id_551fe4b1" xlink:label="lbl_label1428153521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_label1428153521" xlink:type="arc"/>
      <link:label id="id_114f7584" xlink:label="lbl_label290420100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_label290420100" xlink:type="arc"/>
      <link:label id="id_3b35b195" xlink:label="lbl_label993374613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_label993374613" xlink:type="arc"/>
      <link:label id="id_68a64911" xlink:label="lbl_label1755728145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lbl_label1755728145" xlink:type="arc"/>
      <link:label id="id_6d1d78f2" xlink:label="lbl_label1830648050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1830648050" xlink:type="arc"/>
      <link:label id="id_27bb9ea8" xlink:label="lbl_label666607272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [axis]</link:label>
      <link:label id="id_7cf4bc91" xlink:label="lbl_label2096413841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [member]</link:label>
      <link:label id="id_68ba85b6" xlink:label="lbl_label1757054390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueMember" xlink:to="lbl_label1757054390" xlink:type="arc"/>
      <link:label id="id_3cee5982" xlink:label="lbl_label1022253442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label1022253442" xlink:type="arc"/>
      <link:label id="id_2d611cc9" xlink:label="lbl_label761339081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lbl_label761339081" xlink:type="arc"/>
      <link:label id="id_2c7b189f" xlink:label="lbl_label746264735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_label746264735" xlink:type="arc"/>
      <link:label id="id_153859c4" xlink:label="lbl_label356014532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_label356014532" xlink:type="arc"/>
      <link:label id="id_14968138" xlink:label="lbl_label345407800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label345407800" xlink:type="arc"/>
      <link:label id="id_2576e32b" xlink:label="lbl_label628548395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lbl_label628548395" xlink:type="arc"/>
      <link:label id="id_5a840ece" xlink:label="lbl_label1518603982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lbl_label1518603982" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_label666607272" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_label2096413841" xlink:type="arc"/>
      <link:label id="id_4718921c" xlink:label="lbl_label1192792604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt [member]</link:label>
      <link:label id="id_1748f73f" xlink:label="lbl_label390657855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debt [member]</link:label>
      <link:label id="id_7d47f3b5" xlink:label="lbl_label2101867445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesMember" xlink:to="lbl_label2101867445" xlink:type="arc"/>
      <link:label id="id_1ed425bd" xlink:label="lbl_label517219773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:to="lbl_label517219773" xlink:type="arc"/>
      <link:label id="id_7fb53de5" xlink:label="lbl_label2142584293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank and other financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BankAndOtherFinancialDebtMember" xlink:to="lbl_label2142584293" xlink:type="arc"/>
      <link:label id="id_36f483b7" xlink:label="lbl_label921994167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial paper [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPaperMember" xlink:to="lbl_label921994167" xlink:type="arc"/>
      <link:label id="id_2993bf16" xlink:label="lbl_label697548566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:to="lbl_label697548566" xlink:type="arc"/>
      <link:label id="id_7aa4522e" xlink:label="lbl_label2057589294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight bonds [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StraightBondsMember" xlink:to="lbl_label2057589294" xlink:type="arc"/>
      <link:label id="id_2e89197f" xlink:label="lbl_label780736895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:to="lbl_label780736895" xlink:type="arc"/>
      <link:label id="id_3cfbed2" xlink:label="lbl_label63946450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligations [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseObligationsMember" xlink:to="lbl_label63946450" xlink:type="arc"/>
      <link:label id="id_47b3aade" xlink:label="lbl_label1202957022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration and other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:to="lbl_label1202957022" xlink:type="arc"/>
      <link:label id="id_74b2144b" xlink:label="lbl_label1957827659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by type of contract [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_label1957827659" xlink:type="arc"/>
      <link:label id="id_11a7e82b" xlink:label="lbl_label296216619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_label296216619" xlink:type="arc"/>
      <link:label id="id_5a462aee" xlink:label="lbl_label1514547950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_label1514547950" xlink:type="arc"/>
      <link:label id="id_75469247" xlink:label="lbl_label1967559239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, at fair value currency related [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:to="lbl_label1967559239" xlink:type="arc"/>
      <link:label id="id_3583f9fa" xlink:label="lbl_label897841658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_label897841658" xlink:type="arc"/>
      <link:label id="id_102b0f85" xlink:label="lbl_label271257477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_label271257477" xlink:type="arc"/>
      <link:label id="id_3f464064" xlink:label="lbl_label1061568612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amout [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:to="lbl_label1061568612" xlink:type="arc"/>
      <link:label id="id_24f6d45c" xlink:label="lbl_label620155996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive fair values [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PositiveFairValuesMember" xlink:to="lbl_label620155996" xlink:type="arc"/>
      <link:label id="id_42b35305" xlink:label="lbl_label1119048453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Negative fair values [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NegativeFairValuesMember" xlink:to="lbl_label1119048453" xlink:type="arc"/>
      <link:label id="id_4c8abefe" xlink:label="lbl_label1284161278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1284161278" xlink:type="arc"/>
      <link:label id="id_5286c358" xlink:label="lbl_label1384563544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_label1384563544" xlink:type="arc"/>
      <link:label id="id_487fc207" xlink:label="lbl_label1216332295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilities" xlink:to="lbl_label1216332295" xlink:type="arc"/>
      <link:label id="id_453bddb" xlink:label="lbl_label72596955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstruments" xlink:to="lbl_label72596955" xlink:type="arc"/>
      <link:label id="id_397d852b" xlink:label="lbl_label964527403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, forward foreign exchange rate contracts</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:to="lbl_label964527403" xlink:type="arc"/>
      <link:label id="id_b3aed83" xlink:label="lbl_label188411267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, over-the-counter currency options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:to="lbl_label188411267" xlink:type="arc"/>
      <link:label id="id_24aeca58" xlink:label="lbl_label615434840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by currency contract [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_label615434840" xlink:type="arc"/>
      <link:label id="id_3d32bab6" xlink:label="lbl_label1026734774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_label1026734774" xlink:type="arc"/>
      <link:label id="id_3f252a8f" xlink:label="lbl_label1059400335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_label1059400335" xlink:type="arc"/>
      <link:label id="id_59852144" xlink:label="lbl_label1501897028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_label1501897028" xlink:type="arc"/>
      <link:label id="id_640cd1b3" xlink:label="lbl_label1678561715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecurringFairValueMeasurementMember" xlink:to="lbl_label1678561715" xlink:type="arc"/>
      <link:label id="id_6df52bda" xlink:label="lbl_label1844784090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, time deposits and derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:to="lbl_label1844784090" xlink:type="arc"/>
      <link:label id="id_469d8a26" xlink:label="lbl_label1184729638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial investments and long-term loans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:to="lbl_label1184729638" xlink:type="arc"/>
      <link:label id="id_3e1a7df6" xlink:label="lbl_label1041923574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total available-for-sale marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:to="lbl_label1041923574" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:to="lbl_label131977872" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:to="lbl_label913538296" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtMember" xlink:to="lbl_label1192792604" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtMember" xlink:to="lbl_label390657855" xlink:type="arc"/>
      <link:label id="id_55c289f5" xlink:label="lbl_label1438812661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:to="lbl_label1438812661" xlink:type="arc"/>
      <link:label id="id_4af993b7" xlink:label="lbl_label1257870263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_label1257870263" xlink:type="arc"/>
      <link:label id="id_5b807bec" xlink:label="lbl_label1535146988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valued at amortized cost [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValuedAtAmortizedCostMember" xlink:to="lbl_label1535146988" xlink:type="arc"/>
      <link:label id="id_6163f2e6" xlink:label="lbl_label1633940198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_label1633940198" xlink:type="arc"/>
      <link:label id="id_39b2a3b6" xlink:label="lbl_label968008630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_label968008630" xlink:type="arc"/>
      <link:label id="id_2dde0229" xlink:label="lbl_label769524265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayablesMember" xlink:to="lbl_label769524265" xlink:type="arc"/>
      <link:label id="id_648479c6" xlink:label="lbl_label1686403526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesMember" xlink:to="lbl_label1686403526" xlink:type="arc"/>
      <link:label id="id_7d19861f" xlink:label="lbl_label2098824735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:to="lbl_label2098824735" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:type="locator"/>
      <link:label id="id_6e8d8711" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed, cash per share</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:type="arc"/>
      <link:label id="id_5643fad7" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share</link:label>
      <link:label id="id_65bb0a73" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed</link:label>
      <link:label id="id_738a993" xlink:label="lbl_label121153939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease in fair value measurement liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label121153939" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label1199806184" xlink:type="arc"/>
      <link:label id="id_7ebb8632" xlink:label="lbl_label2126218802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValue" xlink:to="lbl_label2126218802" xlink:type="arc"/>
      <link:label id="id_5083795f" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValue" xlink:to="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_2d43301f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, hedges of net investments in foreign operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:type="arc"/>
      <link:label id="id_43e5ded1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_72a89a91" xlink:label="lbl_label1923652241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_731902b7" xlink:label="lbl_label1931018935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_1867bb0f" xlink:label="lbl_label409451279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_3d795141" xlink:label="lbl_label1031360833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_5d546db3" xlink:label="lbl_label1565814195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Austria GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustriaGmbHViennaMember" xlink:to="lbl_label1565814195" xlink:type="arc"/>
      <link:label id="id_2234921c" xlink:label="lbl_label573870620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHViennaMember" xlink:to="lbl_label573870620" xlink:type="arc"/>
      <link:label id="id_7dcc65cd" xlink:label="lbl_label2110547405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Ophthalmika GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconOphthalmikaGmbHViennaMember" xlink:to="lbl_label2110547405" xlink:type="arc"/>
      <link:label id="id_6649a095" xlink:label="lbl_label1716101269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz GmbH, Kundl [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGmbHViennaMember" xlink:to="lbl_label1716101269" xlink:type="arc"/>
      <link:label id="id_2af5dc99" xlink:label="lbl_label720755864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:to="lbl_label720755864" xlink:type="arc"/>
      <link:label id="id_710ef91f" xlink:label="lbl_label1896806687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Bangladesh) Limited, Gazipur [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBangladeshLimitedGazipurMember" xlink:to="lbl_label1896806687" xlink:type="arc"/>
      <link:label id="id_33533709" xlink:label="lbl_label861091593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma NV, Vilvoorde [member]</link:label>
      <link:label id="id_6bd26090" xlink:label="lbl_label1808949392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon - Couvreur NV, Puurs [member]</link:label>
      <link:label id="id_471d9dcf" xlink:label="lbl_label1193123279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon NV, Vilvoorde [member]</link:label>
      <link:label id="id_61e985d" xlink:label="lbl_label102668381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz NV, Vilvoorde [member]</link:label>
      <link:label id="id_3d34517c" xlink:label="lbl_label1026838908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Securities Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:to="lbl_label1026838908" xlink:type="arc"/>
      <link:label id="id_2e061bfd" xlink:label="lbl_label772152317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biociencias S.A., Sao Paulo [member]</link:label>
      <link:label id="id_608a61f5" xlink:label="lbl_label1619681781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</link:label>
      <link:label id="id_20501724" xlink:label="lbl_label542119716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:to="lbl_label542119716" xlink:type="arc"/>
      <link:label id="id_b170914" xlink:label="lbl_label186059028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label186059028" xlink:type="arc"/>
      <link:label id="id_3382e919" xlink:label="lbl_label864217369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label864217369" xlink:type="arc"/>
      <link:label id="id_4aad4cdd" xlink:label="lbl_label1252871389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Canada Inc., Boucherville, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:to="lbl_label1252871389" xlink:type="arc"/>
      <link:label id="id_467b0e02" xlink:label="lbl_label1182469634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Chile S.A., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:to="lbl_label1182469634" xlink:type="arc"/>
      <link:label id="id_4a31b636" xlink:label="lbl_label1244771894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios Chile Ltd., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:to="lbl_label1244771894" xlink:type="arc"/>
      <link:label id="id_61f8aada" xlink:label="lbl_label1643686618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing Novartis Pharma Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:to="lbl_label1643686618" xlink:type="arc"/>
      <link:label id="id_344a1881" xlink:label="lbl_label877271169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:to="lbl_label877271169" xlink:type="arc"/>
      <link:label id="id_2c879a70" xlink:label="lbl_label747084400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:to="lbl_label747084400" xlink:type="arc"/>
      <link:label id="id_44f2dcf0" xlink:label="lbl_label1156766960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Novartis Trading Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:to="lbl_label1156766960" xlink:type="arc"/>
      <link:label id="id_2b1815d1" xlink:label="lbl_label722998737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Hong Kong Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHongKongLimitedHongKongMember" xlink:to="lbl_label722998737" xlink:type="arc"/>
      <link:label id="id_57ba8d14" xlink:label="lbl_label1471843604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:to="lbl_label1471843604" xlink:type="arc"/>
      <link:label id="id_252cd53d" xlink:label="lbl_label623695165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:to="lbl_label623695165" xlink:type="arc"/>
      <link:label id="id_65e89b36" xlink:label="lbl_label1709742902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_1522bd0" xlink:label="lbl_label22162384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_2d82460" xlink:label="lbl_label47719520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:to="lbl_label47719520" xlink:type="arc"/>
      <link:label id="id_c60eb2a" xlink:label="lbl_label207678250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisS.r.o.PragueMember" xlink:to="lbl_label207678250" xlink:type="arc"/>
      <link:label id="id_402474ef" xlink:label="lbl_label1076131055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:to="lbl_label1076131055" xlink:type="arc"/>
      <link:label id="id_f1c4dd" xlink:label="lbl_label15844573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.r.o.PragueMember" xlink:to="lbl_label15844573" xlink:type="arc"/>
      <link:label id="id_6ea1eef6" xlink:label="lbl_label1856106230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcareASCopenhagenMember" xlink:to="lbl_label1856106230" xlink:type="arc"/>
      <link:label id="id_2dbeb314" xlink:label="lbl_label767472404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nordic A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNordicASCopenhagenMember" xlink:to="lbl_label767472404" xlink:type="arc"/>
      <link:label id="id_1e75de5c" xlink:label="lbl_label511041116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozASCopenhagenMember" xlink:to="lbl_label511041116" xlink:type="arc"/>
      <link:label id="id_574d51cf" xlink:label="lbl_label1464685007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ecuador S.A., Quito [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisEcuadorS.A.QuitoMember" xlink:to="lbl_label1464685007" xlink:type="arc"/>
      <link:label id="id_679520f0" xlink:label="lbl_label1737826544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.E., Cairo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.E.CairoMember" xlink:to="lbl_label1737826544" xlink:type="arc"/>
      <link:label id="id_575ca2d" xlink:label="lbl_label91605549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Egypt Pharma S.A.E., New Cairo City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:to="lbl_label91605549" xlink:type="arc"/>
      <link:label id="id_37f4e561" xlink:label="lbl_label938796385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finland Oy, Espoo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinlandOyEspooMember" xlink:to="lbl_label938796385" xlink:type="arc"/>
      <link:label id="id_42a0d3e7" xlink:label="lbl_label1117836263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Groupe France S.A., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:to="lbl_label1117836263" xlink:type="arc"/>
      <link:label id="id_7ba00702" xlink:label="lbl_label2074085122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:to="lbl_label2074085122" xlink:type="arc"/>
      <link:label id="id_d3dae7a" xlink:label="lbl_label222146170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratoires Alcon S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:to="lbl_label222146170" xlink:type="arc"/>
      <link:label id="id_3116dc5e" xlink:label="lbl_label823581790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.A.S., Levallois-Perret [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.S.LevalloisPerretMember" xlink:to="lbl_label823581790" xlink:type="arc"/>
      <link:label id="id_6e409e90" xlink:label="lbl_label1849728656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHWehrMember" xlink:to="lbl_label1849728656" xlink:type="arc"/>
      <link:label id="id_17634123" xlink:label="lbl_label392380707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHNurembergMember" xlink:to="lbl_label392380707" xlink:type="arc"/>
      <link:label id="id_1cd787d" xlink:label="lbl_label30242941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Produktions GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:to="lbl_label30242941" xlink:type="arc"/>
      <link:label id="id_401bb4ef" xlink:label="lbl_label1075557615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Business Services GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:to="lbl_label1075557615" xlink:type="arc"/>
      <link:label id="id_3672a73d" xlink:label="lbl_label913483581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharma GmbH, Freiburg im Breisgau [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:to="lbl_label913483581" xlink:type="arc"/>
      <link:label id="id_1fd8572e" xlink:label="lbl_label534271790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight GmbH, Erlangen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightGmbHErlangenMember" xlink:to="lbl_label534271790" xlink:type="arc"/>
      <link:label id="id_4649f215" xlink:label="lbl_label1179251221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision GmbH, Grosswallstadt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:to="lbl_label1179251221" xlink:type="arc"/>
      <link:label id="id_72338a4a" xlink:label="lbl_label1915980362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz International GmbH, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:to="lbl_label1915980362" xlink:type="arc"/>
      <link:label id="id_2c6debd5" xlink:label="lbl_label745401301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HEXAL AG, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HEXALAGHolzkirchenMember" xlink:to="lbl_label745401301" xlink:type="arc"/>
      <link:label id="id_3b790099" xlink:label="lbl_label997785753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salutas Pharma GmbH, Barleben [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalutasPharmaGmbHBarlebenMember" xlink:to="lbl_label997785753" xlink:type="arc"/>
      <link:label id="id_5a59fba6" xlink:label="lbl_label1515846566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1 A Pharma GmbH, Holzkirchen [member]</link:label>
      <link:label id="id_63faa754" xlink:label="lbl_label1677371220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aeropharm GmbH, Rudolstadt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AeropharmGmbHRudolstadtMember" xlink:to="lbl_label1677371220" xlink:type="arc"/>
      <link:label id="id_53a147c7" xlink:label="lbl_label1403078599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novista Insurance Limited, Gibraltar City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:to="lbl_label1403078599" xlink:type="arc"/>
      <link:label id="id_2881adea" xlink:label="lbl_label679587306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:to="lbl_label679587306" xlink:type="arc"/>
      <link:label id="id_24c810e" xlink:label="lbl_label38568206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:to="lbl_label38568206" xlink:type="arc"/>
      <link:label id="id_20010fd1" xlink:label="lbl_label536940497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label536940497" xlink:type="arc"/>
      <link:label id="id_3e0a5b35" xlink:label="lbl_label1040866101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Hungary Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label1040866101" xlink:type="arc"/>
      <link:label id="id_866e747" xlink:label="lbl_label140961607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis India Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIndiaLimitedMumbaiMember" xlink:to="lbl_label140961607" xlink:type="arc"/>
      <link:label id="id_5d283d4e" xlink:label="lbl_label1562918222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:to="lbl_label1562918222" xlink:type="arc"/>
      <link:label id="id_209ec8c8" xlink:label="lbl_label547277000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (India) Private Limited, Bangalore [member]</link:label>
      <link:label id="id_2bccb2e" xlink:label="lbl_label45927214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPrivateLimitedMumbaiMember" xlink:to="lbl_label45927214" xlink:type="arc"/>
      <link:label id="id_30564a91" xlink:label="lbl_label810961553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. Novartis Indonesia, Jakarta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.NovartisIndonesiaJakartaMember" xlink:to="lbl_label810961553" xlink:type="arc"/>
      <link:label id="id_bca100f" xlink:label="lbl_label197791759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. CIBA Vision Batam, Batam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.CIBAVisionBatamBatamMember" xlink:to="lbl_label197791759" xlink:type="arc"/>
      <link:label id="id_4fcc5f83" xlink:label="lbl_label1338793859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ireland Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIrelandLimitedDublinMember" xlink:to="lbl_label1338793859" xlink:type="arc"/>
      <link:label id="id_74708b2c" xlink:label="lbl_label1953532716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1953532716" xlink:type="arc"/>
      <link:label id="id_169e129" xlink:label="lbl_label23716137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Ireland Limited, Cork City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:to="lbl_label23716137" xlink:type="arc"/>
      <link:label id="id_1a15ed68" xlink:label="lbl_label437644648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Israel Ltd., Tel Aviv [member]</link:label>
      <link:label id="id_79225a64" xlink:label="lbl_label2032294500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optonol Ltd., Neve-Ilan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptonolLtd.NeveIlanMember" xlink:to="lbl_label2032294500" xlink:type="arc"/>
      <link:label id="id_572859e2" xlink:label="lbl_label1462262242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma S.p.A., Milan [member]</link:label>
      <link:label id="id_51e555ae" xlink:label="lbl_label1373984174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Italia S.p.A., Milan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconItaliaS.p.A.MilanMember" xlink:to="lbl_label1373984174" xlink:type="arc"/>
      <link:label id="id_39182a7" xlink:label="lbl_label59867815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.p.A.OriggioMember" xlink:to="lbl_label59867815" xlink:type="arc"/>
      <link:label id="id_23768229" xlink:label="lbl_label594969129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.p.A., Rovereto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:to="lbl_label594969129" xlink:type="arc"/>
      <link:label id="id_46070173" xlink:label="lbl_label1174864243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:to="lbl_label1174864243" xlink:type="arc"/>
      <link:label id="id_30b5637" xlink:label="lbl_label51074615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaK.K.TokyoMember" xlink:to="lbl_label51074615" xlink:type="arc"/>
      <link:label id="id_2358b28" xlink:label="lbl_label37063464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Japan Ltd., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconJapanLtd.TokyoMember" xlink:to="lbl_label37063464" xlink:type="arc"/>
      <link:label id="id_90ace63" xlink:label="lbl_label151703139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozK.K.TokyoMember" xlink:to="lbl_label151703139" xlink:type="arc"/>
      <link:label id="id_2d24611e" xlink:label="lbl_label757358878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investments S.a r.l., Luxembourg City [member]</link:label>
      <link:label id="id_6373cce9" xlink:label="lbl_label1668533481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance S.A., Luxembourg City [member]</link:label>
      <link:label id="id_495a738b" xlink:label="lbl_label1230664587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:label id="id_30ea85e" xlink:label="lbl_label51292254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label51292254" xlink:type="arc"/>
      <link:label id="id_2040f9e0" xlink:label="lbl_label541129184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label541129184" xlink:type="arc"/>
      <link:label id="id_23d9a520" xlink:label="lbl_label601466144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</link:label>
      <link:label id="id_7bc6228f" xlink:label="lbl_label2076582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2076582543" xlink:type="arc"/>
      <link:label id="id_77370b0a" xlink:label="lbl_label2000096010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2000096010" xlink:type="arc"/>
      <link:label id="id_7143fa4f" xlink:label="lbl_label1900280399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Maroc SA, Casablanca [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaMarocSACasablancaMember" xlink:to="lbl_label1900280399" xlink:type="arc"/>
      <link:label id="id_30236580" xlink:label="lbl_label807626112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:to="lbl_label807626112" xlink:type="arc"/>
      <link:label id="id_1fa13a8d" xlink:label="lbl_label530659981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.ArnhemMember" xlink:to="lbl_label530659981" xlink:type="arc"/>
      <link:label id="id_6a5dd736" xlink:label="lbl_label1784534838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nederland B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNederlandB.V.ArnhemMember" xlink:to="lbl_label1784534838" xlink:type="arc"/>
      <link:label id="id_89b7931" xlink:label="lbl_label144406833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz B.V., Almere [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozB.V.AlmereMember" xlink:to="lbl_label144406833" xlink:type="arc"/>
      <link:label id="id_7ae0d9be" xlink:label="lbl_label2061556158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis New Zealand Ltd, Auckland [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNewZealandLtdAucklandMember" xlink:to="lbl_label2061556158" xlink:type="arc"/>
      <link:label id="id_659fd8fc" xlink:label="lbl_label1704974588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Norge AS, Oslo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNorgeASOsloMember" xlink:to="lbl_label1704974588" xlink:type="arc"/>
      <link:label id="id_53e6555" xlink:label="lbl_label87975253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Pakistan) Limited, Karachi [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:to="lbl_label87975253" xlink:type="arc"/>
      <link:label id="id_2f1259ff" xlink:label="lbl_label789731839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Logistics), Inc., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:to="lbl_label789731839" xlink:type="arc"/>
      <link:label id="id_51335372" xlink:label="lbl_label1362318194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Centroamerica S.A., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:to="lbl_label1362318194" xlink:type="arc"/>
      <link:label id="id_240f2db1" xlink:label="lbl_label604974513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Philippines, Inc., Makati City [member]</link:label>
      <link:label id="id_2050b70f" xlink:label="lbl_label542160655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Philippines Corporation, Makati City [member]</link:label>
      <link:label id="id_5fffa6cd" xlink:label="lbl_label1610589901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Poland Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_74c896dd" xlink:label="lbl_label1959302877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_712c39fe" xlink:label="lbl_label1898723838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_4ba5de33" xlink:label="lbl_label1269161523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek S.A., Strykow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekS.A.StrykowMember" xlink:to="lbl_label1269161523" xlink:type="arc"/>
      <link:label id="id_520521db" xlink:label="lbl_label1376068059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Portugal SGPS Lda., Porto Salvo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:to="lbl_label1376068059" xlink:type="arc"/>
      <link:label id="id_c95dd37" xlink:label="lbl_label211148087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</link:label>
      <link:label id="id_881ce5c" xlink:label="lbl_label142724700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]</link:label>
      <link:label id="id_1c2378c4" xlink:label="lbl_label472086724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica Lda., Porto Salvo [member]</link:label>
      <link:label id="id_4a9bb1ea" xlink:label="lbl_label1251717610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:to="lbl_label1251717610" xlink:type="arc"/>
      <link:label id="id_30d12469" xlink:label="lbl_label819012713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:to="lbl_label819012713" xlink:type="arc"/>
      <link:label id="id_1a1b1a89" xlink:label="lbl_label437983881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.R.L., Targu-Mures [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.R.L.TarguMuresMember" xlink:to="lbl_label437983881" xlink:type="arc"/>
      <link:label id="id_620cd72f" xlink:label="lbl_label1645008687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLLCMoscowMember" xlink:to="lbl_label1645008687" xlink:type="arc"/>
      <link:label id="id_a4d4ccd" xlink:label="lbl_label172838093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Farmacevtika LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:to="lbl_label172838093" xlink:type="arc"/>
      <link:label id="id_4f8c203f" xlink:label="lbl_label1334583359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JSC Sandoz, Moscow [member]</link:label>
      <link:label id="id_3b17514" xlink:label="lbl_label61961492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Neva LLC, St. Petersburg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:to="lbl_label61961492" xlink:type="arc"/>
      <link:label id="id_2d25f558" xlink:label="lbl_label757462360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:to="lbl_label757462360" xlink:type="arc"/>
      <link:label id="id_ef37254" xlink:label="lbl_label250835540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Singapore) Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_27535d56" xlink:label="lbl_label659774806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_73caa11d" xlink:label="lbl_label1942659357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_5ac408db" xlink:label="lbl_label1522796763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_405feadd" xlink:label="lbl_label1080027869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]</link:label>
      <link:label id="id_5ad357d3" xlink:label="lbl_label1523800019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_5654aaaa" xlink:label="lbl_label1448389290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_1f0269e9" xlink:label="lbl_label520251881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Slovakia s.r.o., Bratislava [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:to="lbl_label520251881" xlink:type="arc"/>
      <link:label id="id_3337da30" xlink:label="lbl_label859298352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label859298352" xlink:type="arc"/>
      <link:label id="id_24583ab1" xlink:label="lbl_label609761969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label609761969" xlink:type="arc"/>
      <link:label id="id_25162424" xlink:label="lbl_label622208036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label622208036" xlink:type="arc"/>
      <link:label id="id_c4640a" xlink:label="lbl_label12870666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:to="lbl_label12870666" xlink:type="arc"/>
      <link:label id="id_44cecbf4" xlink:label="lbl_label1154403316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:label id="id_51e9e54d" xlink:label="lbl_label1374283085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisKoreaLtd.SeoulMember" xlink:to="lbl_label1374283085" xlink:type="arc"/>
      <link:label id="id_2fbc9bcb" xlink:label="lbl_label800889803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconKoreaLtd.SeoulMember" xlink:to="lbl_label800889803" xlink:type="arc"/>
      <link:label id="id_3acd65c6" xlink:label="lbl_label986539462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozKoreaLtd.SeoulMember" xlink:to="lbl_label986539462" xlink:type="arc"/>
      <link:label id="id_2cb12411" xlink:label="lbl_label749806609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A., Barcelona [member]</link:label>
      <link:label id="id_1788ee4f" xlink:label="lbl_label394849871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Cusi S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCusiS.A.BarcelonaMember" xlink:to="lbl_label394849871" xlink:type="arc"/>
      <link:label id="id_25c7e6c1" xlink:label="lbl_label633857729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica S.A., Madrid [member]</link:label>
      <link:label id="id_578d972e" xlink:label="lbl_label1468897070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]</link:label>
      <link:label id="id_6a673c57" xlink:label="lbl_label1785150551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:to="lbl_label1785150551" xlink:type="arc"/>
      <link:label id="id_6cfceac6" xlink:label="lbl_label1828514502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Sverige AB, Stockholm [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSverigeABStockholmMember" xlink:to="lbl_label1828514502" xlink:type="arc"/>
      <link:label id="id_1784eaf5" xlink:label="lbl_label394586869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalAGBaselMember" xlink:to="lbl_label394586869" xlink:type="arc"/>
      <link:label id="id_1cfce538" xlink:label="lbl_label486335800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingAGBaselMember" xlink:to="lbl_label486335800" xlink:type="arc"/>
      <link:label id="id_523c2f36" xlink:label="lbl_label1379675958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:to="lbl_label1379675958" xlink:type="arc"/>
      <link:label id="id_31c15b81" xlink:label="lbl_label834755457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaAGBaselMember" xlink:to="lbl_label834755457" xlink:type="arc"/>
      <link:label id="id_6bb5d046" xlink:label="lbl_label1807077446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesAGBaselMember" xlink:to="lbl_label1807077446" xlink:type="arc"/>
      <link:label id="id_151ca66f" xlink:label="lbl_label354199151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweizerhalle AG, Muttenz [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:to="lbl_label354199151" xlink:type="arc"/>
      <link:label id="id_7888d993" xlink:label="lbl_label2022234515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Stein AG, Stein [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSteinAGSteinMember" xlink:to="lbl_label2022234515" xlink:type="arc"/>
      <link:label id="id_46b0e62c" xlink:label="lbl_label1185998380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweiz AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizAGRischMember" xlink:to="lbl_label1185998380" xlink:type="arc"/>
      <link:label id="id_175b3164" xlink:label="lbl_label391852388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Switzerland SA, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSwitzerlandSARischMember" xlink:to="lbl_label391852388" xlink:type="arc"/>
      <link:label id="id_6dde1079" xlink:label="lbl_label1843269753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals Ltd., Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:to="lbl_label1843269753" xlink:type="arc"/>
      <link:label id="id_2056dcf1" xlink:label="lbl_label542563569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozAGBaselMember" xlink:to="lbl_label542563569" xlink:type="arc"/>
      <link:label id="id_c4607df" xlink:label="lbl_label205916127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsAGRischMember" xlink:to="lbl_label205916127" xlink:type="arc"/>
      <link:label id="id_2bda8165" xlink:label="lbl_label735740261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Taiwan) Co., Ltd., Taipei [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:to="lbl_label735740261" xlink:type="arc"/>
      <link:label id="id_1cc3a1bc" xlink:label="lbl_label482582972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisThailandLimitedBangkokMember" xlink:to="lbl_label482582972" xlink:type="arc"/>
      <link:label id="id_1e10820d" xlink:label="lbl_label504398349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:to="lbl_label504398349" xlink:type="arc"/>
      <link:label id="id_76d30813" xlink:label="lbl_label1993541651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_7653b21e" xlink:label="lbl_label1985196574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:to="lbl_label1985196574" xlink:type="arc"/>
      <link:label id="id_6083f415" xlink:label="lbl_label1619260437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_2c3cd0a2" xlink:label="lbl_label742183074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</link:label>
      <link:label id="id_775d02f4" xlink:label="lbl_label2002584308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Middle East FZE, Dubai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMiddleEastFZEDubaiMember" xlink:to="lbl_label2002584308" xlink:type="arc"/>
      <link:label id="id_629f2d5a" xlink:label="lbl_label1654599002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1654599002" xlink:type="arc"/>
      <link:label id="id_24628050" xlink:label="lbl_label610435152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label610435152" xlink:type="arc"/>
      <link:label id="id_72101279" xlink:label="lbl_label1913655929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:to="lbl_label1913655929" xlink:type="arc"/>
      <link:label id="id_41ed60da" xlink:label="lbl_label1106075866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Eye Care UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1106075866" xlink:type="arc"/>
      <link:label id="id_61fe5165" xlink:label="lbl_label1644056933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozLimitedFrimleyCamberleyMember" xlink:to="lbl_label1644056933" xlink:type="arc"/>
      <link:label id="id_5fa82378" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:type="arc"/>
      <link:label id="id_4687124a" xlink:label="lbl_label1183257162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationEastHanoverNYMember" xlink:to="lbl_label1183257162" xlink:type="arc"/>
      <link:label id="id_739f0d6b" xlink:label="lbl_label1939803499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:to="lbl_label1939803499" xlink:type="arc"/>
      <link:label id="id_6a2defad" xlink:label="lbl_label1781395373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:to="lbl_label1781395373" xlink:type="arc"/>
      <link:label id="id_2951cebe" xlink:label="lbl_label693227198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:to="lbl_label693227198" xlink:type="arc"/>
      <link:label id="id_10d13d66" xlink:label="lbl_label282148198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:to="lbl_label282148198" xlink:type="arc"/>
      <link:label id="id_2e63ddd" xlink:label="lbl_label48643549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:to="lbl_label48643549" xlink:type="arc"/>
      <link:label id="id_13ee6af1" xlink:label="lbl_label334392049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:to="lbl_label334392049" xlink:type="arc"/>
      <link:label id="id_5eea5c27" xlink:label="lbl_label1592417319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Services, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:to="lbl_label1592417319" xlink:type="arc"/>
      <link:label id="id_51dba865" xlink:label="lbl_label1373349989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Holding Corporation, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:to="lbl_label1373349989" xlink:type="arc"/>
      <link:label id="id_31a31f0b" xlink:label="lbl_label832773899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:to="lbl_label832773899" xlink:type="arc"/>
      <link:label id="id_c4acd60" xlink:label="lbl_label206228832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Refractivehorizons, LLC, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:to="lbl_label206228832" xlink:type="arc"/>
      <link:label id="id_48c065e" xlink:label="lbl_label76285534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Research, Ltd., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconResearchLtd.FortWorthTXMember" xlink:to="lbl_label76285534" xlink:type="arc"/>
      <link:label id="id_17312f5" xlink:label="lbl_label24318709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Lensx, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:to="lbl_label24318709" xlink:type="arc"/>
      <link:label id="id_305f2824" xlink:label="lbl_label811542564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInc.PrincetonNJMember" xlink:to="lbl_label811542564" xlink:type="arc"/>
      <link:label id="id_1810f51f" xlink:label="lbl_label403764511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eon Labs, Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EonLabsInc.PrincetonNJMember" xlink:to="lbl_label403764511" xlink:type="arc"/>
      <link:label id="id_1c839601" xlink:label="lbl_label478385665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fougera Pharmaceuticals Inc., Melville, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:to="lbl_label478385665" xlink:type="arc"/>
      <link:label id="id_7af3c86c" xlink:label="lbl_label2062796908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Venezuela, S.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:to="lbl_label2062796908" xlink:type="arc"/>
      <link:label id="id_51d78d0e" xlink:label="lbl_label1373080846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceutical, C.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:to="lbl_label1373080846" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:to="lbl_label772152317" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:to="lbl_label1619681781" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label1709742902" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label22162384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label601466144" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:to="lbl_label211148087" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:to="lbl_label142724700" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:to="lbl_label472086724" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:to="lbl_label749806609" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:to="lbl_label633857729" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1993541651" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1619260437" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:to="lbl_label742183074" xlink:type="arc"/>
      <link:label id="id_5219f8cb" xlink:label="lbl_label1377433803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments - additional disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_label1377433803" xlink:type="arc"/>
      <link:label id="id_7be99054" xlink:label="lbl_label2078904404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement [table]</link:label>
      <link:label id="id_373151e5" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:type="arc"/>
      <link:label id="id_3bebbf6d" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at beginning of period</link:label>
      <link:label id="id_fde9a71" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at end of period</link:label>
      <link:label id="id_38539773" xlink:label="lbl_label945002355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_label945002355" xlink:type="arc"/>
      <link:label id="id_3f162228" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_34d2b17f" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments recognized in the consolidated statement of comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_1f17c4f4" xlink:label="lbl_label521651444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases fair value measurement assets</link:label>
      <link:label id="id_712f0e18" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsFairValueMeasurementAssets" xlink:to="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_6183f24" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFairValueMeasurementAssets" xlink:to="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_21602cfa" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:type="arc"/>
      <link:label id="id_d0e5228" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</link:label>
      <link:label id="id_28030b1e" xlink:label="lbl_label671288094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_label671288094" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_label2078904404" xlink:type="arc"/>
      <link:label id="id_2f39f660" xlink:label="lbl_label792327776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity of net debt [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_label792327776" xlink:type="arc"/>
      <link:label id="id_58c89014" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debts</link:label>
      <link:label id="id_7d6c1038" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt</link:label>
      <link:label id="id_2fc36503" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial assets</link:label>
      <link:label id="id_54e7be06" xlink:label="lbl_label1424473606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:to="lbl_label1424473606" xlink:type="arc"/>
      <link:label id="id_2cb9fd3b" xlink:label="lbl_label750386491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommoditiesMember" xlink:to="lbl_label750386491" xlink:type="arc"/>
      <link:label id="id_31b4a926" xlink:label="lbl_label833923366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deriviative financial instruments and accrued interest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:to="lbl_label833923366" xlink:type="arc"/>
      <link:label id="id_75dba3db" xlink:label="lbl_label1977328603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtMember" xlink:to="lbl_label1977328603" xlink:type="arc"/>
      <link:label id="id_24faa4a5" xlink:label="lbl_label620405925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt - undiscounted [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtUndiscountedMember" xlink:to="lbl_label620405925" xlink:type="arc"/>
      <link:label id="id_2e5c234f" xlink:label="lbl_label777790287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three month and not later than twelve months [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:to="lbl_label777790287" xlink:type="arc"/>
      <link:label id="id_106ff37d" xlink:label="lbl_label275772285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label275772285" xlink:type="arc"/>
      <link:label id="id_7c18c756" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4ab97cb3" xlink:label="lbl_label1253670067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential inflows in various currencies - from financial derivative assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:to="lbl_label1253670067" xlink:type="arc"/>
      <link:label id="id_68a3968f" xlink:label="lbl_label1755551375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_label1755551375" xlink:type="arc"/>
      <link:label id="id_6f45bf77" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_60f25e47" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:label id="id_26c3488c" xlink:label="lbl_label650332300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_label650332300" xlink:type="arc"/>
      <link:label id="id_3ecf37ac" xlink:label="lbl_label1053767596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_label1053767596" xlink:type="arc"/>
      <link:label id="id_1d7eaa93" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:type="arc"/>
      <link:label id="id_4d7520d9" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to foreign currency exchange rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:type="arc"/>
      <link:label id="id_bc6d63c" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to equity market movements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:type="arc"/>
      <link:label id="id_7e591031" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to interest rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:type="arc"/>
      <link:label id="id_1a9805f" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All financial instruments</link:label>
      <link:label id="id_2ef01715" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to foreign currency exchange rates</link:label>
      <link:label id="id_74cd5fab" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to equity market movements</link:label>
      <link:label id="id_3073f174" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to interest rates</link:label>
      <link:label id="id_69bd9251" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageMember" xlink:to="lbl_WeightedAverageMember_labels" xlink:type="arc"/>
      <link:label id="id_301d16c7" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average</link:label>
      <link:label id="id_2a5fb07c" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">High</link:label>
      <link:label id="id_6654bf44" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Low</link:label>
      <link:label id="id_405da1b9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Worst case loss scenario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WorstCaseLossScenarioMember" xlink:to="lbl_WorstCaseLossScenarioMember_labels" xlink:type="arc"/>
      <link:label id="id_2e992db9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Worst case loss scenario</link:label>
      <link:label id="id_4ee2f2eb" xlink:label="lbl_label1323496171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash receipts and payments fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:to="lbl_label1323496171" xlink:type="arc"/>
      <link:label id="id_2d2549bd" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:label id="id_6773649" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_7a7f8744" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_5793c543" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_786524e" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_6744ae33" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Publicly quoted market value of the Novartis interest</link:label>
      <link:label id="id_24696e1c" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_471bbf88" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_2f35efb7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", outside North America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_58a34798" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select outside North America</link:label>
      <link:label id="id_5e36913a" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", North America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_49d8c8f7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select North America</link:label>
      <link:label id="id_7c2b7da9" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plans, granted to associates prior merger [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:type="arc"/>
      <link:label id="id_3be795e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_3e622c14" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of shares</link:label>
      <link:label id="id_179f71dc" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_13e82d94" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, number of shares</link:label>
      <link:label id="id_676b945a" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:type="arc"/>
      <link:label id="id_7c12048" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, number of shares</link:label>
      <link:label id="id_36172efd" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares at end of period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_60b0a4e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares at beginning of period</link:label>
      <link:label id="id_3531edda" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:label id="id_7874e637" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss/(income) from associated companies</link:label>
      <link:label id="id_32b80bd7" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Other Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_18282520" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share awards</link:label>
      <link:label id="id_46ef7a38" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon equity plans granted to associates prior merger</link:label>
      <link:label id="id_5f28436" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
      <link:label id="id_68171cd3" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leveraged Share Savings Plan (LSSP)</link:label>
      <link:label id="id_33a3b55c" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan (ESOP)</link:label>
      <link:label id="id_48de40b0" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK Share Savings Plan</link:label>
      <link:label id="id_71e8eb1f" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_68f6d949" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share movements in period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareMovements" xlink:to="lbl_ShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_10047f77" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total movements</link:label>
      <link:label id="id_5da2c69" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:label id="id_1b2e9a2e" xlink:label="lbl_NetInvestmentHedgeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeMember" xlink:to="lbl_NetInvestmentHedgeMember_labels" xlink:type="arc"/>
      <link:label id="id_6aadffe9" xlink:label="lbl_label1789788137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options held by market maker</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:to="lbl_label1789788137" xlink:type="arc"/>
      <link:label id="id_29617d6b" xlink:label="lbl_label694254955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLive" xlink:to="lbl_label694254955" xlink:type="arc"/>
      <link:label id="id_b107ceb" xlink:label="lbl_label185629931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live, remaining</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:to="lbl_label185629931" xlink:type="arc"/>
      <link:label id="id_292f5855" xlink:label="lbl_label690968661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, weighted average exercise price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:to="lbl_label690968661" xlink:type="arc"/>
      <link:label id="id_1e74829a" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
      <link:label id="id_764458f" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_657faa04" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests and other financing cash flows</link:label>
      <link:label id="id_4f246ab" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_3f1c8d8f" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseFairValueMeasurementAssets" xlink:to="lbl_label521651444" xlink:type="arc"/>
      <link:label id="id_cca13ad" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:label id="id_7ef7b9ed" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments, deferred consideration and other adjustments, net</link:label>
      <link:label id="id_47b366a2" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred portion of sales price</link:label>
      <link:label id="id_547e2ca5" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:type="arc"/>
      <link:label id="id_73838734" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</link:label>
      <link:label id="id_56c435e" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_12b02f16" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_26be22ce" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of non-cash items and other adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForReconcileProfitLoss" xlink:to="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_2cafaaf8" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reversal of non-cash items</link:label>
      <link:label id="id_4b753731" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss)</link:label>
      <link:label id="id_38c3816c" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund</link:label>
      <link:label id="id_156023e7" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund, classified as investing activities</link:label>
      <link:label id="id_4b858d4a" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income taxes refund/(paid), classified as operating activities</link:label>
      <link:label id="id_486e2543" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:label id="id_bf2d3c0" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:label id="id_555a0937" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_775477cb" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_408b9f0d" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income statement effect</link:label>
      <link:label id="id_2a46b40e" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of income taxed at reduced rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:type="arc"/>
      <link:label id="id_55aa23f7" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of income taxed at reduced rates</link:label>
      <link:label id="id_17e76531" xlink:label="lbl_label401040689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_label401040689" xlink:type="arc"/>
      <link:label id="id_3d749f5d" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsProvisionsAccrualsMember" xlink:to="lbl_label288271922" xlink:type="arc"/>
      <link:label id="id_5ac948f0" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets [member]</link:label>
      <link:label id="id_6dbb9ba2" xlink:label="lbl_label1841011618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_label1841011618" xlink:type="arc"/>
      <link:label id="id_44d33d7" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:type="arc"/>
      <link:label id="id_46c4badd" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_label679367036" xlink:type="arc"/>
      <link:label id="id_1c16a93d" xlink:label="lbl_label471247165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label471247165" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label1695476906" xlink:type="arc"/>
      <link:label id="id_657887a0" xlink:label="lbl_label1702397856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1702397856" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1373999706" xlink:type="arc"/>
      <link:label id="id_6cec499" xlink:label="lbl_label114214041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label114214041" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label766376780" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:to="lbl_label250835540" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:to="lbl_label659774806" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:to="lbl_label1942659357" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:to="lbl_label1522796763" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:to="lbl_label1080027869" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:to="lbl_label1523800019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPteLtdSingaporeMember" xlink:to="lbl_label1448389290" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:to="lbl_label547277000" xlink:type="arc"/>
      <link:label id="id_3f303d9f" xlink:label="lbl_label1060126111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:to="lbl_label1060126111" xlink:type="arc"/>
      <link:label id="id_7ab53501" xlink:label="lbl_label2058695937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.NewYorkNYMember" xlink:to="lbl_label2058695937" xlink:type="arc"/>
      <link:label id="id_71637428" xlink:label="lbl_label1902343208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:to="lbl_label1902343208" xlink:type="arc"/>
      <link:label id="id_631dbefb" xlink:label="lbl_label1662893819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Services Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:to="lbl_label1662893819" xlink:type="arc"/>
      <link:label id="id_682001cf" xlink:label="lbl_label1746928079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B2 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB2Ltd.HamiltonMember" xlink:to="lbl_label1746928079" xlink:type="arc"/>
      <link:label id="id_60c6aa6" xlink:label="lbl_label101477030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B3 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB3Ltd.HamiltonMember" xlink:to="lbl_label101477030" xlink:type="arc"/>
      <link:label id="id_4bc526b5" xlink:label="lbl_label1271211701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ciba-Geigy Japan Limited, Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:to="lbl_label1271211701" xlink:type="arc"/>
      <link:label id="id_518a9aeb" xlink:label="lbl_label1368038123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical Investment AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:to="lbl_label1368038123" xlink:type="arc"/>
      <link:label id="id_614bc25c" xlink:label="lbl_label1632354908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Bioventures AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBioventuresAGBaselMember" xlink:to="lbl_label1632354908" xlink:type="arc"/>
      <link:label id="id_8fecb9d" xlink:label="lbl_label150915997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Forschungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisForschungsstiftungBaselMember" xlink:to="lbl_label150915997" xlink:type="arc"/>
      <link:label id="id_600bda82" xlink:label="lbl_label1611389570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Kaderausbildung, Basel [member]</link:label>
      <link:label id="id_6fd3a22a" xlink:label="lbl_label1876140586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:to="lbl_label1876140586" xlink:type="arc"/>
      <link:label id="id_2d8acaf0" xlink:label="lbl_label764070640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</link:label>
      <link:label id="id_7d992496" xlink:label="lbl_label2107188374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</link:label>
      <link:label id="id_2bb02e62" xlink:label="lbl_label732966498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:to="lbl_label732966498" xlink:type="arc"/>
      <link:label id="id_6c99f32" xlink:label="lbl_label113876786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label113876786" xlink:type="arc"/>
      <link:label id="id_7dfa0e77" xlink:label="lbl_label2113539703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vivacta Limited, Frimley/Camberley, Surrey [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label2113539703" xlink:type="arc"/>
      <link:label id="id_5489f125" xlink:label="lbl_label1418326309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationNewYorkNYMember" xlink:to="lbl_label1418326309" xlink:type="arc"/>
      <link:label id="id_1c9b37d8" xlink:label="lbl_label479934424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corthera, Inc., San Mateo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CortheraInc.SanMateoCAMember" xlink:to="lbl_label479934424" xlink:type="arc"/>
      <link:label id="id_32e0fe6b" xlink:label="lbl_label853605995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CoStim Pharmaceuticals Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:to="lbl_label853605995" xlink:type="arc"/>
      <link:label id="id_39cff8c0" xlink:label="lbl_label969930944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Navigate BioPharma Services, Inc., Carlsbad, CA [member]</link:label>
      <link:label id="id_196cf67c" xlink:label="lbl_label426571388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:label id="id_72f336af" xlink:label="lbl_label1928541871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ClarVista Medical, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:to="lbl_label1928541871" xlink:type="arc"/>
      <link:label id="id_55c01a35" xlink:label="lbl_label1438652981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical, Inc., Lake Forest, IL [member]</link:label>
      <link:label id="id_4148f290" xlink:label="lbl_label1095299728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triangle International Reinsurance Limited, Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:to="lbl_label1095299728" xlink:type="arc"/>
      <link:label id="id_75fcbca" xlink:label="lbl_label123718602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trinity River Insurance Co Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:to="lbl_label123718602" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:to="lbl_label1611389570" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:to="lbl_label764070640" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:to="lbl_label2107188374" xlink:type="arc"/>
      <link:label id="id_7fb34e52" xlink:label="lbl_label2142457426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:to="lbl_label2142457426" xlink:type="arc"/>
      <link:label id="id_48e7e2a8" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Russia, Rubles</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RUB" xlink:to="lbl_RUB_labels" xlink:type="arc"/>
      <link:label id="id_2b6714e7" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RUB</link:label>
      <link:label id="id_6b134c2" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRL</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BRL" xlink:to="lbl_BRL_labels" xlink:type="arc"/>
      <link:label id="id_19bb001f" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brazil, Brazil Real</link:label>
      <link:label id="id_26408b72" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AUD" xlink:to="lbl_AUD_labels" xlink:type="arc"/>
      <link:label id="id_1c95476e" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AUD</link:label>
      <link:label id="id_547736b0" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAD</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CAD" xlink:to="lbl_CAD_labels" xlink:type="arc"/>
      <link:label id="id_5eb5601a" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
      <link:label id="id_58b8f0b8" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_435d0149" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates, net income effect [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_71b428a4" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, net income effect</link:label>
      <link:label id="id_d71a4cc" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates summarized financial information</link:label>
      <link:label id="id_303f5b81" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates</link:label>
      <link:label id="id_3ea56c51" xlink:label="lbl_label1051028561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets/liabilities, expected to have impact on current taxes payable</link:label>
      <link:label id="id_549c77e3" xlink:label="lbl_label1419540451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1419540451" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1051028561" xlink:type="arc"/>
      <link:label id="id_686d8bfd" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4726a0d4" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:label id="id_2be0cf3f" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26e57cfe" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as an expense in cost of goods sold</link:label>
      <link:label id="id_30833089" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3124df13" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized amount of inventory provisions and reversals of inventory provision</link:label>
      <link:label id="id_4d23afdc" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f55c02d" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries</link:label>
      <link:label id="id_540d35ce" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_295129f0" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency</link:label>
      <link:label id="id_22b42dd0" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of treasury shares movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7493f0ce" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related treasury shares movements</link:label>
      <link:label id="id_28836a6a" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77bb4dc1" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_63da54e2" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ea1dc4a" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities</link:label>
      <link:label id="id_ecb4868" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of asset allocation, investments in shares of Novartis AG [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6d5c5887" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset allocation, investments in shares of Novartis AG</link:label>
      <link:label id="id_583fe5ec" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined contribution plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4176cd8b" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plans</link:label>
      <link:label id="id_5864530c" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19e39c55" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</link:label>
      <link:label id="id_12c92048" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a3159a6" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities</link:label>
      <link:label id="id_5070bcfa" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5e4ef11c" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:label id="id_4b298c60" xlink:label="lbl_label1261014112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amount the derivative financial instruments, by currency</link:label>
      <link:label id="id_6bba442" xlink:label="lbl_label112960578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label112960578" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label1261014112" xlink:type="arc"/>
      <link:label id="id_7def025f" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_77677ae5" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value by hierarchy</link:label>
      <link:label id="id_3e022541" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in fair value measurement [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b36ee5a" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement</link:label>
      <link:label id="id_fde92c1" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2293ad67" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities</link:label>
      <link:label id="id_1cfe8d17" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ab7d205" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments</link:label>
      <link:label id="id_36cdbc5" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other contractual liabilities of the net debt or liquidity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36a9094b" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other contractual liabilities of the net debt or liquidity</link:label>
      <link:label id="id_6873d3e4" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_52a21cc6" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model</link:label>
      <link:label id="id_5cc8b03e" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_13881ac7" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, average, high, and low VAR amounts</link:label>
      <link:label id="id_41e588b8" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c01a973" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, worst case loss scenario</link:label>
      <link:label id="id_5ec493de" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KR" xlink:to="lbl_KR_labels" xlink:type="arc"/>
      <link:label id="id_685d93ad" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Korea</link:label>
      <link:label id="id_25a8beb4" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_43c445c8" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_53037399" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_449dfef2" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:label id="id_5f336b49" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:label id="id_1ebe8e22" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_7c3b4ddb" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation</link:label>
      <link:label id="id_37f79dee" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of release of contingent consideration liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:type="arc"/>
      <link:label id="id_7767d800" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of release of contingent consideration liability</link:label>
      <link:label id="id_3fbded99" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1999384126" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1131311877" xlink:type="arc"/>
      <link:label id="id_7da827c0" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_3b199e63" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_9457980" xlink:label="lbl_label155548032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset and liability valuation [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_label155548032" xlink:type="arc"/>
      <link:label id="id_1c2a973a" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax expense income recognised in profit or loss</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_44e2d573" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_31998635" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in deferred tax liability asset</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3ecc5b67" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in current income tax liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:type="arc"/>
      <link:label id="id_16a647a9" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_549d9bf8" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in consolidated income statement</link:label>
      <link:label id="id_5370a381" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in other comprehensive income</link:label>
      <link:label id="id_584b4926" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities</link:label>
      <link:label id="id_1d65bc0" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of current income tax liabilities</link:label>
      <link:label id="id_67c3f632" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_25c7d443" xlink:label="lbl_label633852995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_label633852995" xlink:type="arc"/>
      <link:label id="id_49f0b616" xlink:label="lbl_label1240512022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_label1240512022" xlink:type="arc"/>
      <link:label id="id_2bcc20cf" xlink:label="lbl_label734798031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementMember" xlink:to="lbl_label734798031" xlink:type="arc"/>
      <link:label id="id_5659c922" xlink:label="lbl_label1448724770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:to="lbl_label1448724770" xlink:type="arc"/>
      <link:label id="id_2a7f4c39" xlink:label="lbl_label712985657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted operating lease commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedOperatingLeaseCommitments" xlink:to="lbl_label712985657" xlink:type="arc"/>
      <link:label id="id_78817d05" xlink:label="lbl_label2021752069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution of business to joint venture</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionOfBusinessToJointVenture" xlink:to="lbl_label2021752069" xlink:type="arc"/>
      <link:label id="id_77130f8a" xlink:label="lbl_label1997737866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on the divestment gain on GSK investment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_label1997737866" xlink:type="arc"/>
      <link:label id="id_5b6d1716" xlink:label="lbl_label1533875990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="lbl_label1533875990" xlink:type="arc"/>
      <link:label id="id_11cc9e15" xlink:label="lbl_label298622485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:to="lbl_label298622485" xlink:type="arc"/>
      <link:label id="id_7418c9fe" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_12e2c645" xlink:label="lbl_label316851781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law effective tax rate after implemetation of new law changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:to="lbl_label316851781" xlink:type="arc"/>
      <link:label id="id_2bfd3952" xlink:label="lbl_label738015570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law tax on unremitted earnings period allowed for payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:to="lbl_label738015570" xlink:type="arc"/>
      <link:label id="id_34cb50dd" xlink:label="lbl_label885739741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:to="lbl_label885739741" xlink:type="arc"/>
      <link:label id="id_73b04098" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:type="arc"/>
      <link:label id="id_75b59f04" xlink:label="lbl_label1713201135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through finance lease contracts property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:to="lbl_label1713201135" xlink:type="arc"/>
      <link:label id="id_3eec7519" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal group companies materiality of assets or sales to third parties</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_c93c456" xlink:label="lbl_label211010646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangiblePurchaseCommitments" xlink:to="lbl_label211010646" xlink:type="arc"/>
      <link:label id="id_6759fd06" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:type="arc"/>
      <link:label id="id_624861c8" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_2f002958" xlink:label="lbl_label788539736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments - narrative [table]</link:label>
      <link:label id="id_684e1ed4" xlink:label="lbl_label1749950164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open hedges for anticipated transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OpenHedgesForAnticipatedTransactions" xlink:to="lbl_label1749950164" xlink:type="arc"/>
      <link:label id="id_38f600d1" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:type="arc"/>
      <link:label id="id_24d61d6" xlink:label="lbl_label38625750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when pricing parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label38625750" xlink:type="arc"/>
      <link:label id="id_8d1d7d" xlink:label="lbl_label9248125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most significant foreign exchange losses</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignificantForeignExchangeLosses" xlink:to="lbl_label9248125" xlink:type="arc"/>
      <link:label id="id_75c586da" xlink:label="lbl_label1975879386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial debt with a carrying amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:to="lbl_label1975879386" xlink:type="arc"/>
      <link:label id="id_189f8e8f" xlink:label="lbl_label413109903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label413109903" xlink:type="arc"/>
      <link:label id="id_19e141a6" xlink:label="lbl_label434192806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:to="lbl_label434192806" xlink:type="arc"/>
      <link:label id="id_7d454e3e" xlink:label="lbl_label2101694014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper limit on holdings on unrelated company</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:to="lbl_label2101694014" xlink:type="arc"/>
      <link:label id="id_1ccfbaa5" xlink:label="lbl_label483375781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum borrowing amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:to="lbl_label483375781" xlink:type="arc"/>
      <link:label id="id_665a2289" xlink:label="lbl_label1717183113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt/equity ratio</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtEquityRatio" xlink:to="lbl_label1717183113" xlink:type="arc"/>
      <link:label id="id_5597d347" xlink:label="lbl_label1436013383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VAR estimate confidence interval</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VAREstimateConfidenceInterval" xlink:to="lbl_label1436013383" xlink:type="arc"/>
      <link:label id="id_42729374" xlink:label="lbl_label1114805108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum amount outstanding</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:to="lbl_label1114805108" xlink:type="arc"/>
      <link:label id="id_6e4f3f5e" xlink:label="lbl_label1850687326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility committed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityCommitted" xlink:to="lbl_label1850687326" xlink:type="arc"/>
      <link:label id="id_40060c01" xlink:label="lbl_label1074138113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty risk [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_label1074138113" xlink:type="arc"/>
      <link:label id="id_16edbe31" xlink:label="lbl_label384679473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's cash and cash equivalents held with financial institution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:to="lbl_label384679473" xlink:type="arc"/>
      <link:label id="id_367e78c8" xlink:label="lbl_label914258120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorAxis" xlink:to="lbl_label914258120" xlink:type="arc"/>
      <link:label id="id_45057e7f" xlink:label="lbl_label1157987967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorMember" xlink:to="lbl_label1157987967" xlink:type="arc"/>
      <link:label id="id_bcf5c90" xlink:label="lbl_label198139024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestFinancialInstitutionMember" xlink:to="lbl_label198139024" xlink:type="arc"/>
      <link:label id="id_561f18c8" xlink:label="lbl_label1444878536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestFinancialInstitutionMember" xlink:to="lbl_label1444878536" xlink:type="arc"/>
      <link:label id="id_cbf0fed" xlink:label="lbl_label213848045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestFinancialInstitutionMember" xlink:to="lbl_label213848045" xlink:type="arc"/>
      <link:label id="id_3a76e486" xlink:label="lbl_label980870278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre tax profit (loss) from divestment of business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:to="lbl_label980870278" xlink:type="arc"/>
      <link:label id="id_5810372f" xlink:label="lbl_label1477457711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, divestment-date fair value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label1477457711" xlink:type="arc"/>
      <link:label id="id_4121b29e" xlink:label="lbl_label1092727454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential receivable from divestment</link:label>
      <link:label id="id_3cc9e79a" xlink:label="lbl_label1019864986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration received</link:label>
      <link:label id="id_5b569e4" xlink:label="lbl_label95775204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment already received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestonePaymentAlreadyReceived" xlink:to="lbl_label95775204" xlink:type="arc"/>
      <link:label id="id_63dee19f" xlink:label="lbl_label1675551135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future put option to sell business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FuturePutOptionToSellBusiness" xlink:to="lbl_label1675551135" xlink:type="arc"/>
      <link:label id="id_7e35f229" xlink:label="lbl_label2117464617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment put option</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentPutOption" xlink:to="lbl_label2117464617" xlink:type="arc"/>
      <link:label id="id_4b717d8e" xlink:label="lbl_label1265728910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest exchanged</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExchanged" xlink:to="lbl_label1265728910" xlink:type="arc"/>
      <link:label id="id_8fd1ef1" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:label id="id_2ef82d23" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_7c796053" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_64515558" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_79b0131b" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:label id="id_18855477" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding shares</link:label>
      <link:label id="id_34b6a8cb" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Novartis shares</link:label>
      <link:label id="id_20b38808" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total treasury shares</link:label>
      <link:label id="id_5dca543c" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other institutions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:type="arc"/>
      <link:label id="id_3901e819" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions</link:label>
      <link:label id="id_551ca7d0" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivableCurrent" xlink:to="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:type="arc"/>
      <link:label id="id_15fc798c" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
      <link:label id="id_249fb0f8" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of divestments, other provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfDivestmentsOtherProvisions" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_77b9898f" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_label788539736" xlink:type="arc"/>
      <link:label id="id_4241ab2c" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
      <link:label id="id_1264a0dc" xlink:label="lbl_label308584668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers with net sales over five percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomersWithNetSalesOverFivePercent" xlink:to="lbl_label308584668" xlink:type="arc"/>
      <link:label id="id_2af199bf" xlink:label="lbl_label720476607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label720476607" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1718040268" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1423033786" xlink:type="arc"/>
      <link:label id="id_2cbb9926" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment (loss) reversal of impairment loss recognised in profit or loss</link:label>
      <link:label id="id_eadbcd2" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_36976720" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid benefit cost</link:label>
      <link:label id="id_1c757af9" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued share-based payments</link:label>
      <link:label id="id_79c38d68" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_1dbfe68b" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_7bc2e092" xlink:label="lbl_label2076369042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables short-term [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:to="lbl_label2076369042" xlink:type="arc"/>
      <link:label id="id_1fd99bd1" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_2da8b675" xlink:label="lbl_label329619167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options excluded from the calculation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptionsExcludedFromTheCalculation" xlink:to="lbl_label329619167" xlink:type="arc"/>
      <link:label id="id_171116a0" xlink:label="lbl_label386995872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCommercialPaperProgramsMember" xlink:to="lbl_label386995872" xlink:type="arc"/>
      <link:label id="id_1fb8b12f" xlink:label="lbl_label532197679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JP commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPCommercialPaperProgramsMember" xlink:to="lbl_label532197679" xlink:type="arc"/>
      <link:label id="id_68bfdd9c" xlink:label="lbl_label1757404572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper, number of programs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:to="lbl_label1757404572" xlink:type="arc"/>
      <link:label id="id_4e21d3c" xlink:label="lbl_label81927484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when most significant parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label81927484" xlink:type="arc"/>
      <link:label id="id_5ccfc0db" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:type="arc"/>
      <link:label id="id_17ec29fe" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:type="arc"/>
      <link:label id="id_4991ae50" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA)</link:label>
      <link:label id="id_69548c9f" xlink:label="lbl_label1767148703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Share capital in tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalInTenderOffer" xlink:to="lbl_label1767148703" xlink:type="arc"/>
      <link:label id="id_5c76d079" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ordinary share</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerOrdinaryShare" xlink:to="lbl_CashOfferPerOrdinaryShare_labels" xlink:type="arc"/>
      <link:label id="id_741421fb" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ADS</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerADS" xlink:to="lbl_CashOfferPerADS_labels" xlink:type="arc"/>
      <link:label id="id_4236be0f" xlink:label="lbl_label1110883855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of ordinary share per ADS</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOrdinarySharePerADS" xlink:to="lbl_label1110883855" xlink:type="arc"/>
      <link:label id="id_471c5e7e" xlink:label="lbl_label1193041534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEquity" xlink:to="lbl_label1193041534" xlink:type="arc"/>
      <link:label id="id_72ec4d21" xlink:label="lbl_label454367578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximal amount of share buyback programm</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximalAmountOfShareBuybackProgramm" xlink:to="lbl_label454367578" xlink:type="arc"/>
      <link:label id="id_6eb334f8" xlink:label="lbl_label1857238264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Annual Incentive</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAnnualIncentive" xlink:to="lbl_label1857238264" xlink:type="arc"/>
      <link:label id="id_5c74f412" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:type="arc"/>
      <link:label id="id_5ba6657f" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:label id="id_7ae769dd" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_49cb7900" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBusinessUnits" xlink:to="lbl_label267498308" xlink:type="arc"/>
      <link:label id="id_8b05ce2" xlink:label="lbl_label145775842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label145775842" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label198642827" xlink:type="arc"/>
      <link:label id="id_5eb218a8" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:label id="id_4b99efa9" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax on above items</link:label>
      <link:label id="id_5952def9" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits other than equity-based compensation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:type="arc"/>
      <link:label id="id_389a5b52" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonCurrentFinancialDebtsMember" xlink:to="lbl_label1268656258" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:to="lbl_label618343139" xlink:type="arc"/>
      <link:label id="id_6987695e" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_76ff2ee3" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges and reversals</link:label>
      <link:label id="id_2dd3bece" xlink:label="lbl_label768851662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the expiration of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:to="lbl_label768851662" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:to="lbl_label2363078" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:to="lbl_label1019864986" xlink:type="arc"/>
      <link:label id="id_4875601b" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:label id="id_5201dd1d" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:label id="id_b9d0509" xlink:label="lbl_label770091111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets tax</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:to="lbl_label770091111" xlink:type="arc"/>
      <link:label id="id_55cbca11" xlink:label="lbl_label1439418897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum margin percentage impact of commodity price change</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:to="lbl_label1439418897" xlink:type="arc"/>
      <link:label id="id_a88bf0e" xlink:label="lbl_label176733966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum holding in unrelated company</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumHoldingInUnrelatedCompany" xlink:to="lbl_label176733966" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialReceivableFromDivestment" xlink:to="lbl_label1092727454" xlink:type="arc"/>
      <link:label id="id_2fe8aa88" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ADS.</link:label>
      <link:label id="id_74cb8111" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</link:label>
      <link:label id="id_4036843c" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a maximal amount.</link:label>
      <link:label id="id_64640b79" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a limit.</link:label>
      <link:label id="id_177cac6" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a reclassification that can be debit or credit.</link:label>
      <link:label id="id_5fdbc2b7" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_314a813f" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_4962d3fd" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SellingGeneralAndAdministrativeExpense" xlink:to="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_1f242104" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:type="arc"/>
      <link:label id="id_5aa89188" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_94ddbe4" xlink:label="lbl_label156097508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_label156097508" xlink:type="arc"/>
      <link:label id="id_4cdc11a9" xlink:label="lbl_label1289490857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported value [member]</link:label>
      <link:label id="id_501954f0" xlink:label="lbl_label1343837424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [member]</link:label>
      <link:label id="id_22153d9b" xlink:label="lbl_label571817371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change to prior year-end [member]</link:label>
      <link:label id="id_dc043" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDebt1" xlink:to="lbl_NetDebt_labels2" xlink:type="arc"/>
      <link:label id="id_8969c68" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_641074d9" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_476a5a91" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1548f70e" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
      <link:label id="id_2c18deb" xlink:label="lbl_label46239211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of preparation [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasisOfPreparationAbstract" xlink:label="lbl_BasisOfPreparationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasisOfPreparationAbstract" xlink:to="lbl_label46239211" xlink:type="arc"/>
      <link:label id="id_2df428b0" xlink:label="lbl_label770975920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedCriticalAccountingPoliciesAbstract" xlink:label="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:to="lbl_label770975920" xlink:type="arc"/>
      <link:label id="id_2a3a2ba4" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_6b45f171" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_2c2ab3f2" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
      <link:label id="id_4dd6c758" xlink:label="lbl_label1305921368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LegalProceedingsUpdateAbstract" xlink:label="lbl_LegalProceedingsUpdateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateAbstract" xlink:to="lbl_label1305921368" xlink:type="arc"/>
      <link:label id="id_62d75963" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LegalProceedingsUpdateTextBlock" xlink:label="lbl_LegalProceedingsUpdateTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateTextBlock" xlink:to="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47116fe6" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal proceedings update</link:label>
      <link:label id="id_6f65ab76" xlink:label="lbl_label1868934006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:to="lbl_label1868934006" xlink:type="arc"/>
      <link:label id="id_73aff3ab" xlink:label="lbl_label200796173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:to="lbl_label200796173" xlink:type="arc"/>
      <link:label id="id_9aad709" xlink:label="lbl_label162191113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for available-for-sale financial assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:to="lbl_label162191113" xlink:type="arc"/>
      <link:label id="id_59f07686" xlink:label="lbl_label1508931206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lbl_label1508931206" xlink:type="arc"/>
      <link:label id="id_4a00f82a" xlink:label="lbl_label1241577514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Revenue from Contracts with Customers [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:to="lbl_label1241577514" xlink:type="arc"/>
      <link:label id="id_68958299" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for other revenue [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_68991831" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_5460feda" xlink:label="lbl_label1415642842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated balance sheet by the adoption of IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:to="lbl_label1415642842" xlink:type="arc"/>
      <link:label id="id_5b4e8ef2" xlink:label="lbl_label1531875058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated statement of changes in equity by the adoption of IFRS 9 and IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:to="lbl_label1531875058" xlink:type="arc"/>
      <link:label id="id_e7f3472" xlink:label="lbl_label243217522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments additional disclosures table by the adoption of IFRS 9 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:to="lbl_label243217522" xlink:type="arc"/>
      <link:label id="id_71771d90" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4f219465" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales of Top 20 products [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b8de385" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales of Top 20 products</link:label>
      <link:label id="id_45ec2147" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, other revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7f01fd05" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_1894478a" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisIncMember" xlink:to="lbl_AveXisIncMember_labels" xlink:type="arc"/>
      <link:label id="id_43b60602" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AveXis, Inc.</link:label>
      <link:label id="id_6a7073ad" xlink:label="lbl_label1785754541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_label1785754541" xlink:type="arc"/>
      <link:label id="id_33459cb3" xlink:label="lbl_label860200115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedMember" xlink:to="lbl_label860200115" xlink:type="arc"/>
      <link:label id="id_41804a67" xlink:label="lbl_label1098926695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyStatedMember" xlink:to="lbl_label1098926695" xlink:type="arc"/>
      <link:label id="id_d0e08b6" xlink:label="lbl_label217930333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_label217930333" xlink:type="arc"/>
      <link:label id="id_4a438f95" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:type="arc"/>
      <link:label id="id_68a9252d" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 9</link:label>
      <link:label id="id_3803c2cc" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 15 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:type="arc"/>
      <link:label id="id_7f440478" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 15</link:label>
      <link:label id="id_6cbd5ed8" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI reserves [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OCIReservesMember" xlink:label="lbl_OCIReservesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OCIReservesMember" xlink:to="lbl_OCIReservesMember_labels" xlink:type="arc"/>
      <link:label id="id_37bd32c4" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCI reserves</link:label>
      <link:label id="id_3071cdbf" xlink:label="lbl_label812764607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retail Generics [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetailGenericsMember" xlink:to="lbl_label812764607" xlink:type="arc"/>
      <link:label id="id_22d00e67" xlink:label="lbl_label584060519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceuticals [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BiopharmaceuticalsMember" xlink:to="lbl_label584060519" xlink:type="arc"/>
      <link:label id="id_74e760f" xlink:label="lbl_label122582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesMember" xlink:to="lbl_label122582543" xlink:type="arc"/>
      <link:label id="id_2e5631da" xlink:label="lbl_label777400794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SurgicalMember" xlink:label="lbl_SurgicalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurgicalMember" xlink:to="lbl_label777400794" xlink:type="arc"/>
      <link:label id="id_5a63105" xlink:label="lbl_label94777605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vision Care [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VisionCareMember" xlink:label="lbl_VisionCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VisionCareMember" xlink:to="lbl_label94777605" xlink:type="arc"/>
      <link:label id="id_33d2b620" xlink:label="lbl_label869447200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumablesMember" xlink:label="lbl_ConsumablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumablesMember" xlink:to="lbl_label869447200" xlink:type="arc"/>
      <link:label id="id_3fe1336c" xlink:label="lbl_label1071723372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implantables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImplantablesMember" xlink:label="lbl_ImplantablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImplantablesMember" xlink:to="lbl_label1071723372" xlink:type="arc"/>
      <link:label id="id_6d32d4c6" xlink:label="lbl_label1832047814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment/Other [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquipmentOtherMember" xlink:label="lbl_EquipmentOtherMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquipmentOtherMember" xlink:to="lbl_label1832047814" xlink:type="arc"/>
      <link:label id="id_9208315" xlink:label="lbl_label153125653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmic OTC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OphthalmicOTCMember" xlink:label="lbl_OphthalmicOTCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmicOTCMember" xlink:to="lbl_label153125653" xlink:type="arc"/>
      <link:label id="id_3d77d223" xlink:label="lbl_label1031262755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact lens care [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensCareMember" xlink:label="lbl_ContactLensCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensCareMember" xlink:to="lbl_label1031262755" xlink:type="arc"/>
      <link:label id="id_5ff6168e" xlink:label="lbl_label1609963150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top 20 products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Top20ProductsMember" xlink:to="lbl_label1609963150" xlink:type="arc"/>
      <link:label id="id_1bc8878f" xlink:label="lbl_label466126735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfPortfolioMember" xlink:to="lbl_label466126735" xlink:type="arc"/>
      <link:label id="id_60f02df8" xlink:label="lbl_label1626353144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromRoyalties" xlink:to="lbl_label1626353144" xlink:type="arc"/>
      <link:label id="id_132c5856" xlink:label="lbl_label321673302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit sharing income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitSharingIncome" xlink:to="lbl_label321673302" xlink:type="arc"/>
      <link:label id="id_dd742a8" xlink:label="lbl_label232211112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestoneIncome" xlink:to="lbl_label232211112" xlink:type="arc"/>
      <link:label id="id_31af75cd" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue, other</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenueOther" xlink:to="lbl_OtherRevenueOther_labels" xlink:type="arc"/>
      <link:label id="id_41473bf" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_22e4d15f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities, as a percentage from net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:type="arc"/>
      <link:label id="id_3e5bb44f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income as % of net sales</link:label>
      <link:label id="id_3761b8d8" xlink:label="lbl_label929151192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada and Latin America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CanadaAndLatinAmericaMember" xlink:to="lbl_label929151192" xlink:type="arc"/>
      <link:label id="id_35dc7c05" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent, cc</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:type="arc"/>
      <link:label id="id_2402bc9" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %, cc</link:label>
      <link:label id="id_11578a03" xlink:label="lbl_label290949635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Markets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMarketsMember" xlink:to="lbl_label290949635" xlink:type="arc"/>
      <link:label id="id_1e6859ac" xlink:label="lbl_label510155180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Growth Markets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmergingGrowthMarketsMember" xlink:to="lbl_label510155180" xlink:type="arc"/>
      <link:label id="id_395d61a2" xlink:label="lbl_label962421154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of the world [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfTheWorldMember" xlink:to="lbl_label962421154" xlink:type="arc"/>
      <link:label id="id_2aeb33db" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired to be cancelled</link:label>
      <link:label id="id_16be2f1a" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_14bac1b3" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_10768f17" xlink:label="lbl_label276205335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.5% EUR 750 million 2018/2023 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.5EUR750Million20182023OfNovartisMember" xlink:label="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:to="lbl_label276205335" xlink:type="arc"/>
      <link:label id="id_6c222bbb" xlink:label="lbl_label1814178747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisMember" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:to="lbl_label1814178747" xlink:type="arc"/>
      <link:label id="id_42e49e27" xlink:label="lbl_label1122278951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.7% EUR 750 million 2018/2038 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.7EUR750Million20182038OfNovartisMember" xlink:label="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:to="lbl_label1122278951" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GalvusGroupMember" xlink:to="lbl_label195411774" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiovanGroupMember" xlink:to="lbl_label1973931633" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExforgeGroupMember" xlink:to="lbl_label1243142238" xlink:type="arc"/>
      <link:label id="id_15727011" xlink:label="lbl_label359821329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immunology [member]</link:label>
      <link:label id="id_86e5c43" xlink:label="lbl_label141450307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives sold under Sandoz name [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:to="lbl_label141450307" xlink:type="arc"/>
      <link:label id="id_194d5f34" xlink:label="lbl_label424501044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lbl_label424501044" xlink:type="arc"/>
      <link:label id="id_4f78aa77" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:type="arc"/>
      <link:label id="id_73e25c53" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_7e4ea322" xlink:label="lbl_label2119082786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_label2119082786" xlink:type="arc"/>
      <link:label id="id_306dde36" xlink:label="lbl_label812506678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_label812506678" xlink:type="arc"/>
      <link:label id="id_474e15ff" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchasesValue" xlink:to="lbl_OtherSharePurchasesValue_labels" xlink:type="arc"/>
      <link:label id="id_6ae68310" xlink:label="lbl_label1793491728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lutathera [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LutatheraMember" xlink:to="lbl_label1793491728" xlink:type="arc"/>
      <link:label id="id_5ba5546c" xlink:label="lbl_label1537561708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kymriah [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KymriahMember" xlink:to="lbl_label1537561708" xlink:type="arc"/>
      <link:label id="id_6c54b8f7" xlink:label="lbl_label1817491703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1817491703" xlink:type="arc"/>
      <link:label id="id_a269182" xlink:label="lbl_label170299778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid for share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label170299778" xlink:type="arc"/>
      <link:label id="id_7317bbcb" xlink:label="lbl_label1930935243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total percentage of share capital tendered after the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1930935243" xlink:type="arc"/>
      <link:label id="id_57adc4f7" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_281ffdcd" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity</link:label>
      <link:label id="id_2cc49159" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity paid</link:label>
      <link:label id="id_7df5c0c1" xlink:label="lbl_label2113257665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithRelatedPartiesAbstract" xlink:label="lbl_TransactionsWithRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesAbstract" xlink:to="lbl_label2113257665" xlink:type="arc"/>
      <link:label id="id_5c1d5da7" xlink:label="lbl_label1309162706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithRelatedPartiesTextBlock" xlink:label="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:to="lbl_label1309162706" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityPaid" xlink:to="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:type="arc"/>
      <link:label id="id_5de3849f" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquity" xlink:to="lbl_TransactionCostsRecordedInEquity_labels" xlink:type="arc"/>
      <link:label id="id_154fa58" xlink:label="lbl_label22346328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income recycled into the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:to="lbl_label22346328" xlink:type="arc"/>
      <link:label id="id_7c9a09e2" xlink:label="lbl_label2090469858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 fund investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:to="lbl_label2090469858" xlink:type="arc"/>
      <link:label id="id_36de49a0" xlink:label="lbl_label920537504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:to="lbl_label920537504" xlink:type="arc"/>
      <link:label id="id_1e72baf" xlink:label="lbl_label31927215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pension Fund [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPensionFundMember" xlink:to="lbl_label31927215" xlink:type="arc"/>
      <link:label id="id_6d9924d1" xlink:label="lbl_label1838752977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility uncommitted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityUncommitted" xlink:to="lbl_label1838752977" xlink:type="arc"/>
      <link:label id="id_60aed585" xlink:label="lbl_label1622070661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetAssets" xlink:to="lbl_label1622070661" xlink:type="arc"/>
      <link:label id="id_25566515" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_73ce5e23" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_68208ecc" xlink:label="lbl_label1746964172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocular health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OcularHealthMember" xlink:label="lbl_OcularHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OcularHealthMember" xlink:to="lbl_label1746964172" xlink:type="arc"/>
      <link:label id="id_7d654567" xlink:label="lbl_label2103788903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:to="lbl_label2103788903" xlink:type="arc"/>
      <link:label id="id_a1b491f" xlink:label="lbl_label169560351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:to="lbl_label169560351" xlink:type="arc"/>
      <link:label id="id_1f1416" xlink:label="lbl_label2036758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:to="lbl_label2036758" xlink:type="arc"/>
      <link:label id="id_63baf8ea" xlink:label="lbl_label1673197802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications International SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:to="lbl_label1673197802" xlink:type="arc"/>
      <link:label id="id_4bc832fa" xlink:label="lbl_label1271411450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Switzerland SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:to="lbl_label1271411450" xlink:type="arc"/>
      <link:label id="id_2658ed55" xlink:label="lbl_label643362133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies, Inc., Bannockburn, IL [member]</link:label>
      <link:label id="id_358de13" xlink:label="lbl_label56155667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications S.A., Rueil-Malmaison [member]</link:label>
      <link:label id="id_480bc7a" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share</link:label>
      <link:label id="id_4f788787" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share</link:label>
      <link:label id="id_579c77e7" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_6e4a53e8" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets without disposal group</link:label>
      <link:label id="id_4c7ed954" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_6f67d848" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_41ef90c7" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group held for sale</link:label>
      <link:label id="id_15dcecbd" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities without disposal group</link:label>
      <link:label id="id_6be52fb3" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2cc5f4f3" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_4201ce33" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total of items never to be recycled</link:label>
      <link:label id="id_3dedbea0" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administration</link:label>
      <link:label id="id_24ee551" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_50cb4109" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_24ba2cbb" xlink:label="lbl_label616180923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_label616180923" xlink:type="arc"/>
      <link:label id="id_2e51c9a9" xlink:label="lbl_label777111977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_label777111977" xlink:type="arc"/>
      <link:label id="id_54b5ab16" xlink:label="lbl_label1421191958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_label1421191958" xlink:type="arc"/>
      <link:label id="id_620a76ae" xlink:label="lbl_label1644852910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsHeldForSaleMember" xlink:label="lbl_NoncurrentAssetsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsHeldForSaleMember" xlink:to="lbl_label1644852910" xlink:type="arc"/>
      <link:label id="id_35b1993" xlink:label="lbl_label56301971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal groups classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:to="lbl_label56301971" xlink:type="arc"/>
      <link:label id="id_775bbb23" xlink:label="lbl_label2002500387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_label2002500387" xlink:type="arc"/>
      <link:label id="id_76d4000c" xlink:label="lbl_label1993605132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_label1993605132" xlink:type="arc"/>
      <link:label id="id_511c252" xlink:label="lbl_label85049938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_3a8a761b" xlink:label="lbl_label982152731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_2004a2a3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5c1266c3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
      <link:label id="id_1b44e5e7" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_753e354c" xlink:label="lbl_label1967011148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in cash settled share based payments liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:to="lbl_label1967011148" xlink:type="arc"/>
      <link:label id="id_3fb8017" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
      <link:label id="id_45184c03" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Non-controlling interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowNoncontrollingInterests" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowNoncontrollingInterests" xlink:to="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_3e6c4694" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_773be135" xlink:label="lbl_label1852230229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount recorded in equity related to hyperinflation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:to="lbl_label1852230229" xlink:type="arc"/>
      <link:label id="id_73d5e167" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:label id="id_1341dbff" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_346b395c" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4b1ad4e8" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fcaf057" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_17118b46" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1d85e3c0" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_4b8f7d44" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2918e43e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_5abfc6c6" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_40924196" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_4016f674" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interest in acquiree recognised at acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2ea65efd" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_2375ce31" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:type="arc"/>
      <link:label id="id_56d0df79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities, net of taxes</link:label>
      <link:label id="id_4663183e" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:label id="id_40c6b8fb" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:type="arc"/>
      <link:label id="id_3261fe4" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation, equity impact</link:label>
      <link:label id="id_cb4c548" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
      <link:label id="id_2a76513b" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCosts" xlink:to="lbl_TransactionCosts_labels" xlink:type="arc"/>
      <link:label id="id_19c4929e" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on divestment of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2500459a" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on divestment</link:label>
      <link:label id="id_198075f2" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f9715cf" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities</link:label>
      <link:label id="id_76d81b48" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_57bce160" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities</link:label>
      <link:label id="id_1fb67de2" xlink:label="lbl_label532053474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification to presentation required under IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:to="lbl_label532053474" xlink:type="arc"/>
      <link:label id="id_714a2d9" xlink:label="lbl_label118792921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated Value Adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedValueAdjustmentsMember" xlink:to="lbl_label118792921" xlink:type="arc"/>
      <link:label id="id_4587be64" xlink:label="lbl_label1595406142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:to="lbl_label1595406142" xlink:type="arc"/>
      <link:label id="id_2b6a8c9e" xlink:label="lbl_label858249235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, fund investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:to="lbl_label858249235" xlink:type="arc"/>
      <link:label id="id_6be6dda0" xlink:label="lbl_label1810292128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_label1810292128" xlink:type="arc"/>
      <link:label id="id_ea4af2a" xlink:label="lbl_label245673770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_label245673770" xlink:type="arc"/>
      <link:label id="id_341eabcf" xlink:label="lbl_label874425295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_label874425295" xlink:type="arc"/>
      <link:label id="id_2ef67b59" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_2bbf6984" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_5be6a6ba" xlink:label="lbl_label1541842618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_label1541842618" xlink:type="arc"/>
      <link:label id="id_5b1cb05e" xlink:label="lbl_label1528606814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1528606814" xlink:type="arc"/>
      <link:label id="id_131c72f5" xlink:label="lbl_label320631541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ListedEquitySecuritiesMember" xlink:to="lbl_label320631541" xlink:type="arc"/>
      <link:label id="id_58943bff" xlink:label="lbl_label1486109695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonlistedEquitySecuritiesMember" xlink:to="lbl_label1486109695" xlink:type="arc"/>
      <link:label id="id_466ea37d" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_328aa9b8" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale</link:label>
      <link:label id="id_663782d5" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f98604f" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_1786ac50" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_33784e41" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities measured at fair value through other comprehensive income</link:label>
      <link:label id="id_2785f328" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteMember" xlink:to="lbl_EndocyteMember_labels" xlink:type="arc"/>
      <link:label id="id_1ab891f2" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Endocyte</link:label>
      <link:label id="id_559cd899" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, cash and cash equivalents [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_63b9b41c" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_172750e3" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7ca31c97" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities and non-current financial assets</link:label>
      <link:label id="id_447d705c" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales and selected non-current assets, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36daedff" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and selected non-current assets, by countries and regions</link:label>
      <link:label id="id_24f609b0" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales, by segements and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27432d26" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4192e6ea" xlink:label="lbl_label235032989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of change in accounting policy</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:to="lbl_label235032989" xlink:type="arc"/>
      <link:label id="id_457ba061" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments aquisitions of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_49d2e101" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_625c07b4" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6066a3c9" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_580b40b6" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_3af4fc23" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6cd0a23e" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to disposal group held for sale</link:label>
      <link:label id="id_7f1eeac9" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSales" xlink:to="lbl_OtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_7be3c1db" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_6d6afa95" xlink:label="lbl_label1359067097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSalesEquityImpact" xlink:to="lbl_label1359067097" xlink:type="arc"/>
      <link:label id="id_3b6caa8a" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSales" xlink:to="lbl_NumberOfOtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_6db1b7c2" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_2d79675e" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSalesEquityImpact" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSalesEquityImpact" xlink:to="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:type="arc"/>
      <link:label id="id_4f13fea7" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:label id="id_35d72bee" xlink:label="lbl_label903293934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:to="lbl_label903293934" xlink:type="arc"/>
      <link:label id="id_269c946a" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1931018935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1923652241" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1031360833" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label409451279" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaNVVilvoordeMember" xlink:to="lbl_label861091593" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozNVVilvoordeMember" xlink:to="lbl_label102668381" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCouvreurNVPuursMember" xlink:to="lbl_label1808949392" xlink:type="arc"/>
      <link:label id="id_20428b8c" xlink:label="lbl_label541232012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Belgium BVBA, Puurs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:to="lbl_label541232012" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNVVilvoordeMember" xlink:to="lbl_label1193123279" xlink:type="arc"/>
      <link:label id="id_7f713e00" xlink:label="lbl_label2138127872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconAGFribourgMember" xlink:to="lbl_label2138127872" xlink:type="arc"/>
      <link:label id="id_3e12064" xlink:label="lbl_label65085540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:to="lbl_label65085540" xlink:type="arc"/>
      <link:label id="id_749e4361" xlink:label="lbl_label1956528993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Corporation LLC, Duluth, GA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:to="lbl_label1956528993" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:to="lbl_label426571388" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:to="lbl_label1610589901" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1898723838" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1959302877" xlink:type="arc"/>
      <link:label id="id_6d8d3375" xlink:label="lbl_label1837970293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Healthcare, S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:to="lbl_label1837970293" xlink:type="arc"/>
      <link:label id="id_3892d07e" xlink:label="lbl_label949145726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Innovative Therapies AG, Risch [member]</link:label>
      <link:label id="id_5097f514" xlink:label="lbl_label1352135956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ukraine LLC, Kyiv [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozUkraineLLCKievMember" xlink:to="lbl_label1352135956" xlink:type="arc"/>
      <link:label id="id_68b9cbd5" xlink:label="lbl_label1757006805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestment cost to sell</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentCostToSell" xlink:to="lbl_label1757006805" xlink:type="arc"/>
      <link:label id="id_3bde338f" xlink:label="lbl_label1004417935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfSettlementInPrinciple" xlink:to="lbl_label1004417935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:to="lbl_label969930944" xlink:type="arc"/>
      <link:label id="id_54d2c7cf" xlink:label="lbl_label1423099855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of products in portfolio to be sold</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfProductsInPortfolioToBeSold" xlink:to="lbl_label1423099855" xlink:type="arc"/>
      <link:label id="id_4f5a93ca" xlink:label="lbl_label1331336138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value of the divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingValueOfTheDivestedBusiness" xlink:to="lbl_label1331336138" xlink:type="arc"/>
      <link:label id="id_2bfacba6" xlink:label="lbl_label737856422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short term leases and low value leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShortTermLeasesAndLowValueLeases" xlink:to="lbl_label737856422" xlink:type="arc"/>
      <link:label id="id_1638753" xlink:label="lbl_label23299923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining lease commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingLeaseCommitments" xlink:to="lbl_label23299923" xlink:type="arc"/>
      <link:label id="id_3c454913" xlink:label="lbl_label1011173651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities to be recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesToBeRecognized" xlink:to="lbl_label1011173651" xlink:type="arc"/>
      <link:label id="id_46c00732" xlink:label="lbl_label1186989874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets to be recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsToBeRecognized" xlink:to="lbl_label1186989874" xlink:type="arc"/>
      <link:label id="id_5c114913" xlink:label="lbl_label1544636691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:to="lbl_label1544636691" xlink:type="arc"/>
      <link:label id="id_c04ac79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:type="arc"/>
      <link:label id="id_5fb3768f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</link:label>
      <link:label id="id_4dc28e6d" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncome" xlink:to="lbl_DeferredTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_77e968c5" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax income</link:label>
      <link:label id="id_2d4a780d" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxExpenseIncome" xlink:to="lbl_CurrentTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_bbe9642" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_5ac027e9" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income effect</link:label>
      <link:label id="id_2c40f598" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies' movements in comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:to="lbl_label757358878" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:to="lbl_label1668533481" xlink:type="arc"/>
      <link:label id="id_3d20cd78" xlink:label="lbl_label1025559928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., Lafayette, IN [member]</link:label>
      <link:label id="id_151d2726" xlink:label="lbl_label354232102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tear Film Innovations, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:to="lbl_label354232102" xlink:type="arc"/>
      <link:label id="id_1a32a075" xlink:label="lbl_label439525493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TrueVision Systems, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:to="lbl_label439525493" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalInc.LakeForestILMember" xlink:to="lbl_label1438652981" xlink:type="arc"/>
      <link:label id="id_279b1df4" xlink:label="lbl_label664477172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Baltics SIA, Riga [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBalticsSIARigaMember" xlink:to="lbl_label664477172" xlink:type="arc"/>
      <link:label id="id_5e85347d" xlink:label="lbl_label1585788029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biosciences Peru S.A., Lima [member]</link:label>
      <link:label id="id_62d68d5f" xlink:label="lbl_label1658228063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Overseas Investments AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:to="lbl_label1658228063" xlink:type="arc"/>
      <link:label id="id_254382a8" xlink:label="lbl_label625181352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japat AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JapatAGBaselMember" xlink:to="lbl_label625181352" xlink:type="arc"/>
      <link:label id="id_4cd3abe4" xlink:label="lbl_label1288940516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Management SA, Geneva [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconManagementSAGenevaMember" xlink:to="lbl_label1288940516" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.LafayetteINMember" xlink:to="lbl_label1025559928" xlink:type="arc"/>
      <link:label id="id_68b5f06f" xlink:label="lbl_label1756754031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oriel Therapeutics, Inc., Durham, NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:to="lbl_label1756754031" xlink:type="arc"/>
      <link:label id="id_60eaa13f" xlink:label="lbl_label1625989439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight, Inc., Sterling, VA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightInc.SterlingVAMember" xlink:to="lbl_label1625989439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:to="lbl_label1585788029" xlink:type="arc"/>
      <link:label id="id_5bdf673e" xlink:label="lbl_label1541367614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares with restricted use</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesWithRestrictedUse" xlink:to="lbl_label1541367614" xlink:type="arc"/>
      <link:label id="id_7fb088b9" xlink:label="lbl_label2142275769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of revenues exempt from taxation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:to="lbl_label2142275769" xlink:type="arc"/>
      <link:label id="id_6108aeff" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current interest payable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentInterestPayable" xlink:to="lbl_CurrentInterestPayable_labels" xlink:type="arc"/>
      <link:label id="id_1fc5ed9f" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interests on financial debt</link:label>
      <link:label id="id_6b7c4e62" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOwnShares" xlink:to="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:type="arc"/>
      <link:label id="id_5e285341" xlink:label="lbl_label130728687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial asstets debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:to="lbl_label130728687" xlink:type="arc"/>
      <link:label id="id_1f883fd2" xlink:label="lbl_label826017497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label826017497" xlink:type="arc"/>
      <link:label id="id_256b0374" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_4b6e3676" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial investments</link:label>
      <link:label id="id_2b3e006" xlink:label="lbl_label1209757713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proforma net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProformaNetSales" xlink:to="lbl_label1209757713" xlink:type="arc"/>
      <link:label id="id_2888ddc2" xlink:label="lbl_label680058306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serelaxin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SerelaxinMember" xlink:to="lbl_label680058306" xlink:type="arc"/>
      <link:label id="id_4e4f9507" xlink:label="lbl_label1313838343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyPass [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CyPassMember" xlink:to="lbl_label1313838343" xlink:type="arc"/>
      <link:label id="id_52281715" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of prior year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:type="arc"/>
      <link:label id="id_68901646" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions prior year</link:label>
      <link:label id="id_12f0be52" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of current year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:type="arc"/>
      <link:label id="id_10001b20" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions current year</link:label>
      <link:label id="id_53e07f22" xlink:label="lbl_label1407221538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_label1407221538" xlink:type="arc"/>
      <link:label id="id_64c2e5e1" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_359d5a9f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of currency translation and business combinations</link:label>
      <link:label id="id_73fc698b" xlink:label="lbl_label1945921931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:to="lbl_label1945921931" xlink:type="arc"/>
      <link:label id="id_6ee3c039" xlink:label="lbl_label1860419641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:to="lbl_label1860419641" xlink:type="arc"/>
      <link:label id="id_4ed2e3f9" xlink:label="lbl_label1322443769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:to="lbl_label1322443769" xlink:type="arc"/>
      <link:label id="id_7be11426" xlink:label="lbl_label1459075477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in from divestments of businesses classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1459075477" xlink:type="arc"/>
      <link:label id="id_63a31bcb" xlink:label="lbl_label625103893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsDivested" xlink:to="lbl_label625103893" xlink:type="arc"/>
      <link:label id="id_7f3ccd67" xlink:label="lbl_label654491613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsDivested" xlink:to="lbl_label654491613" xlink:type="arc"/>
      <link:label id="id_28fd0d0c" xlink:label="lbl_label2062437885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesDivested" xlink:to="lbl_label2062437885" xlink:type="arc"/>
      <link:label id="id_217212a3" xlink:label="lbl_label1484079992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial and other assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssets" xlink:to="lbl_label1484079992" xlink:type="arc"/>
      <link:label id="id_3b6cb989" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_411a4e68" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_481dd512" xlink:label="lbl_label1209914642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets divested acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:to="lbl_label1209914642" xlink:type="arc"/>
      <link:label id="id_2dad0e04" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesAndOtherLiabilities" xlink:to="lbl_TradePayablesAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1551e337" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:label id="id_29a54c7d" xlink:label="lbl_label698698877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets currency translation effects liquidity and fair value of equity interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:to="lbl_label698698877" xlink:type="arc"/>
      <link:label id="id_72d7c22d" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_469e951e" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested business</link:label>
      <link:label id="id_79d4ff23" xlink:label="lbl_label2044002083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of other financial assets sold</link:label>
      <link:label id="id_f9b4624" xlink:label="lbl_label261834276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, fair value through other comprehensive income [member]</link:label>
      <link:label id="id_3f7b625a" xlink:label="lbl_label1065050714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial investments, fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1065050714" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label261834276" xlink:type="arc"/>
      <link:label id="id_3373fda5" xlink:label="lbl_label863239589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_label863239589" xlink:type="arc"/>
      <link:label id="id_52f984e4" xlink:label="lbl_label1392084196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label1392084196" xlink:type="arc"/>
      <link:label id="id_3a1be35a" xlink:label="lbl_label974906202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label974906202" xlink:type="arc"/>
      <link:label id="id_52817cee" xlink:label="lbl_label1384217838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-healthcare plans and program-related rebates, returns and other deductions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:to="lbl_label1384217838" xlink:type="arc"/>
      <link:label id="id_518b30b7" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:label id="id_611b2741" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_35974485" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices for outstanding share options [member]</link:label>
      <link:label id="id_3da6037c" xlink:label="lbl_label1034290044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.7</link:label>
      <link:label id="id_5698bfcb" xlink:label="lbl_label1452851147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.7 [member]</link:label>
      <link:label id="id_df65a83" xlink:label="lbl_label1098297979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">54.5</link:label>
      <link:label id="id_26baf973" xlink:label="lbl_label1238972312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.0</link:label>
      <link:label id="id_5d51017e" xlink:label="lbl_label1565589886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.6</link:label>
      <link:label id="id_7925df2" xlink:label="lbl_label127032818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.6 [member]</link:label>
      <link:label id="id_50442a73" xlink:label="lbl_label61576322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.0</link:label>
      <link:label id="id_77b11616" xlink:label="lbl_label2008094230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label2008094230" xlink:type="arc"/>
      <link:label id="id_13923e74" xlink:label="lbl_label328351348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.4</link:label>
      <link:label id="id_26b025e5" xlink:label="lbl_label649078245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">53.7</link:label>
      <link:label id="id_15297d64" xlink:label="lbl_label355040612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.1</link:label>
      <link:label id="id_37ef180d" xlink:label="lbl_label938416141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">58.3</link:label>
      <link:label id="id_7963b4c" xlink:label="lbl_label127286092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.1</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1452851147" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1034290044" xlink:type="arc"/>
      <link:label id="id_7638cc32" xlink:label="lbl_label1983433778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 54.5 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1983433778" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1098297979" xlink:type="arc"/>
      <link:label id="id_625d280f" xlink:label="lbl_label1650272271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.0 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1650272271" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1238972312" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label127032818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label1565589886" xlink:type="arc"/>
      <link:label id="id_7f8b8ef4" xlink:label="lbl_label2139852532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.0 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label2139852532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label61576322" xlink:type="arc"/>
      <link:label id="id_1c214787" xlink:label="lbl_label471943047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.4 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label471943047" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label328351348" xlink:type="arc"/>
      <link:label id="id_60064b00" xlink:label="lbl_label1611025152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 53.7 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label1611025152" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label649078245" xlink:type="arc"/>
      <link:label id="id_3d7bc5f9" xlink:label="lbl_label1031521785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.1 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label1031521785" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label355040612" xlink:type="arc"/>
      <link:label id="id_5312799d" xlink:label="lbl_label1393719709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 58.3 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label1393719709" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label938416141" xlink:type="arc"/>
      <link:label id="id_11afcf8b" xlink:label="lbl_label296734603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.1 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label296734603" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label127286092" xlink:type="arc"/>
      <link:label id="id_602d9a64" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_1640eef1" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_4305d26a" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities from discontinued operations</link:label>
      <link:label id="id_1cb46ce6" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:label id="id_45074031" xlink:label="lbl_label1158103089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1158103089" xlink:type="arc"/>
      <link:label id="id_1787fdbc" xlink:label="lbl_label1284506961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling of the Novartis share of other comprehensive income from associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:to="lbl_label1284506961" xlink:type="arc"/>
      <link:label id="id_7702ef73" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_135f3eb7" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_1765273e" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquistions of businesses</link:label>
      <link:label id="id_4a08e514" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_71e76093" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:label id="id_608223c4" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_352bb146" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_6348f872" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label85049938" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label982152731" xlink:type="arc"/>
      <link:label id="id_31ca37cf" xlink:label="lbl_label835336143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label835336143" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_43b1908f" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets or deferred tax liabilities related to disposal group held for sale</link:label>
      <link:label id="id_3b7e23ba" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_774651e9" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_5fb55436" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_71230227" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_757b03e4" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_9217c59" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_eb62348" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_2ec0dcb9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_48bf4d53" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1a35a04f" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_39d0eccc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5209e6b5" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_2a14e1da" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_74f13ac0" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:label id="id_180b00c2" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from/(used in) investing activities from continuing operations</link:label>
      <link:label id="id_aca6a21" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in non-current financial debts</link:label>
      <link:label id="id_5e5a2737" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from/(used in) investing activities</link:label>
      <link:label id="id_12daaf08" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested interest in associate</link:label>
      <link:label id="id_595a0496" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in discontinued operations</link:label>
      <link:label id="id_6f1acb28" xlink:label="lbl_label1864026920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermFinancialInvestmentsMember" xlink:to="lbl_label1864026920" xlink:type="arc"/>
      <link:label id="id_24014c8f" xlink:label="lbl_label1836731146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_label1836731146" xlink:type="arc"/>
      <link:label id="id_7323afac" xlink:label="lbl_label1544871888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major plans percentage in group DBO pensions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:to="lbl_label1544871888" xlink:type="arc"/>
      <link:label id="id_192e72f5" xlink:label="lbl_label456555172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most signigicant countries percentage on group DBO post employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:to="lbl_label456555172" xlink:type="arc"/>
      <link:label id="id_7686c3c0" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4d6d4f53" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_764909d2" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, total financial investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:type="arc"/>
      <link:label id="id_2ba0d9fa" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold, reclassified to retained earnings</link:label>
      <link:label id="id_751d39ac" xlink:label="lbl_label1964849580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations before gain on distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:to="lbl_label1964849580" xlink:type="arc"/>
      <link:label id="id_3a463b8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:type="arc"/>
      <link:label id="id_2c57b1ca" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution</link:label>
      <link:label id="id_291f69d6" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:to="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:type="arc"/>
      <link:label id="id_2f7fc540" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssets" xlink:to="lbl_RightofuseAssets_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:label id="id_6acaf180" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind distribution liability</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayable" xlink:to="lbl_DividendsPayable_labels" xlink:type="arc"/>
      <link:label id="id_34ce2448" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, non-cash assets distributions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="locator"/>
      <link:label id="id_484edcc4" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_7adfa754" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of paren</link:label>
      <link:label id="id_590635ac" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_2476e743" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:label id="id_1ffd83cc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from discontinued operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:label id="id_6a49a8cd" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from continuing operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_59187aa8" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
      <link:label id="id_1d15aff4" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
      <link:label id="id_100aa035" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:type="arc"/>
      <link:label id="id_50620c89" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:label id="id_96ecbb0" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents of discontinued operations</link:label>
      <link:label id="id_2334b78" xlink:label="lbl_label36916088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_label36916088" xlink:type="arc"/>
      <link:label id="id_76c64958" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales to other segments</link:label>
      <link:label id="id_36af0a7f" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_58501f6b" xlink:label="lbl_label1481645931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period, YoY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YoYChangeMember" xlink:to="lbl_label1481645931" xlink:type="arc"/>
      <link:label id="id_3ed48330" xlink:label="lbl_label1054114608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_label1054114608" xlink:type="arc"/>
      <link:label id="id_43a1a553" xlink:label="lbl_label1134667091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_label1134667091" xlink:type="arc"/>
      <link:label id="id_3045b2a1" xlink:label="lbl_label809874081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VehiclesMember" xlink:to="lbl_label809874081" xlink:type="arc"/>
      <link:label id="id_64acc522" xlink:label="lbl_label1689044258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_label1689044258" xlink:type="arc"/>
      <link:label id="id_5367393f" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationRightofuseAssets" xlink:to="lbl_DepreciationRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4a6ffe17" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1b8dfafc" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery &amp; equipment and other assets</link:label>
      <link:label id="id_2da47e8f" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5905e579" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_328c2a61" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilities" xlink:to="lbl_CurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_543a77a3" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_234e965a" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_e7d4ee5" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:label id="id_7097e6f" xlink:label="lbl_label118062703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="lbl_PresentationOfLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeAbstract" xlink:to="lbl_label118062703" xlink:type="arc"/>
      <link:label id="id_171d0edf" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilities" xlink:to="lbl_LeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1c665876" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilities" xlink:to="lbl_GrossLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2c03c1ee" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments</link:label>
      <link:label id="id_1b0667c7" xlink:label="lbl_label453404615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lesses [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PresentationOfLeasesForLessesTable" xlink:label="lbl_PresentationOfLeasesForLessesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLessesTable" xlink:to="lbl_label453404615" xlink:type="arc"/>
      <link:label id="id_72b5e1b" xlink:label="lbl_label120282651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PresentationOfLeasesForLesseeLineItems" xlink:label="lbl_PresentationOfLeasesForLesseeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeLineItems" xlink:to="lbl_label120282651" xlink:type="arc"/>
      <link:label id="id_3a8f2f5a" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3f6e27d0" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a5f05cd" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3ae50249" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_375e4cce" xlink:label="lbl_label928926926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New lease arrangements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NewLeaseArrangements" xlink:to="lbl_label928926926" xlink:type="arc"/>
      <link:label id="id_c8ad2dc" xlink:label="lbl_label210424540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted future lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFutureLeasePayments" xlink:to="lbl_label210424540" xlink:type="arc"/>
      <link:label id="id_75283e38" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfDiscounting" xlink:to="lbl_EffectOfDiscounting_labels" xlink:type="arc"/>
      <link:label id="id_6ac0bebc" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_6447e039" xlink:label="lbl_label1682432057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about leases for lessee [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_label1682432057" xlink:type="arc"/>
      <link:label id="id_3e0ced0d" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseOnLeaseLiabilities" xlink:to="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7693425d" xlink:label="lbl_label1989362269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowForLeases" xlink:to="lbl_label1989362269" xlink:type="arc"/>
      <link:label id="id_26c71205" xlink:label="lbl_label650580485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="lbl_label650580485" xlink:type="arc"/>
      <link:label id="id_63dc6855" xlink:label="lbl_label1675389013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_label1675389013" xlink:type="arc"/>
      <link:label id="id_10622a16" xlink:label="lbl_label274868758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_label274868758" xlink:type="arc"/>
      <link:label id="id_24f1a439" xlink:label="lbl_label619815993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_label619815993" xlink:type="arc"/>
      <link:label id="id_67bf33b0" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties of discontinued operations</link:label>
      <link:label id="id_327f346c" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income of discontinued operations</link:label>
      <link:label id="id_64213541" xlink:label="lbl_label1679897921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentStatedMember" xlink:to="lbl_label1679897921" xlink:type="arc"/>
      <link:label id="id_5ebed7b4" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of treasury shares, number of shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:to="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:type="arc"/>
      <link:label id="id_22f85f35" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_25cdb408" xlink:label="lbl_label634237960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed information about significant transaction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DetailedInformationAboutSignificantTransaction" xlink:to="lbl_label634237960" xlink:type="arc"/>
      <link:label id="id_7eb3758e" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_6db37ab5" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
      <link:label id="id_ff14c14" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IFMTreInc.Member" xlink:to="lbl_IFMTreInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_5b8c5fe7" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc.</link:label>
      <link:label id="id_33428670" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PowerVision, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PowerVisionInc.Member" xlink:to="lbl_PowerVisionInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_7001a921" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PowerVision, Inc.</link:label>
      <link:label id="id_6bb5fe48" xlink:label="lbl_label1807089224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1807089224" xlink:type="arc"/>
      <link:label id="id_10d3bb4e" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:type="arc"/>
      <link:label id="id_e7bd10a" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:label id="id_390e560d" xlink:label="lbl_label957240845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRightofuseAssets" xlink:to="lbl_label957240845" xlink:type="arc"/>
      <link:label id="id_f3aa39f" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) arising from sale and leaseback transactions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1dfe7c52" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains or losses from sales leaseback</link:label>
      <link:label id="id_50d6583f" xlink:label="lbl_label1356224575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherBorrowings" xlink:to="lbl_label1356224575" xlink:type="arc"/>
      <link:label id="id_589c1537" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_1a2e3f6" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsLiabilities" xlink:to="lbl_NetAssetsLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4d789f55" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net assets</link:label>
      <link:label id="id_7d2cba5f" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease of distribution liability</link:label>
      <link:label id="id_24596c04" xlink:label="lbl_label609840132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential milestone maximum payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialMilestoneMaximumPayments" xlink:to="lbl_label609840132" xlink:type="arc"/>
      <link:label id="id_3dc6ce5a" xlink:label="lbl_label1036439130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees associated with the product transfer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:to="lbl_label1036439130" xlink:type="arc"/>
      <link:label id="id_3954535f" xlink:label="lbl_label961827679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalBorrowings" xlink:to="lbl_label961827679" xlink:type="arc"/>
      <link:label id="id_43740ee2" xlink:label="lbl_label1131679458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of equity interest shares received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEquityInterestSharesReceived" xlink:to="lbl_label1131679458" xlink:type="arc"/>
      <link:label id="id_79732968" xlink:label="lbl_label2037590376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between fair value of distribution liability and net assets at the date of distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:to="lbl_label2037590376" xlink:type="arc"/>
      <link:label id="id_431c3dd4" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares to consolidated foundations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:type="arc"/>
      <link:label id="id_ff7c4c3" xlink:label="lbl_label267896003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aimovig [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AimovigMember" xlink:to="lbl_label267896003" xlink:type="arc"/>
      <link:label id="id_4945ceaa" xlink:label="lbl_label1229311658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities and Right of use assets Disclosure Abstract</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_label1229311658" xlink:type="arc"/>
      <link:label id="id_79212b70" xlink:label="lbl_label2032216944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasesExplanatory" xlink:to="lbl_label2032216944" xlink:type="arc"/>
      <link:label id="id_4b496242" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReductionOfIssuedCapital" xlink:to="lbl_ReductionOfIssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_211a2da" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction of share capital</link:label>
      <link:label id="id_610df533" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_169b45c8" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_76378de3" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through exercise of options shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:type="arc"/>
      <link:label id="id_4cd892b4" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:label id="id_1efc7c8b" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through share based payment transactions shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:to="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:type="arc"/>
      <link:label id="id_1d05cf3d" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:label id="id_1a5eff2" xlink:label="lbl_label27652082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfLeaseLiability" xlink:to="lbl_label27652082" xlink:type="arc"/>
      <link:label id="id_7a957c7" xlink:label="lbl_label128538567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:to="lbl_label128538567" xlink:type="arc"/>
      <link:label id="id_50834b9f" xlink:label="lbl_label1350781855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of the right-of-use assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_label1350781855" xlink:type="arc"/>
      <link:label id="id_4004db36" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at beginning of period</link:label>
      <link:label id="id_63713767" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at end of period</link:label>
      <link:label id="id_491fa8b0" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseContractTerminationsRightofuseAssets" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_43e3ea12" xlink:label="lbl_label79581278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:to="lbl_label79581278" xlink:type="arc"/>
      <link:label id="id_750ea0e7" xlink:label="lbl_label1963892967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:to="lbl_label1963892967" xlink:type="arc"/>
      <link:label id="id_23a4b8a2" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnTreasuryShares" xlink:to="lbl_TaxesOnTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_2a977fac" xlink:label="lbl_label714571692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseIncentives" xlink:to="lbl_label714571692" xlink:type="arc"/>
      <link:label id="id_752a730a" xlink:label="lbl_label1965716234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForLeases" xlink:to="lbl_label1965716234" xlink:type="arc"/>
      <link:label id="id_56ca2a36" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsDerecognized" xlink:to="lbl_NetAssetsDerecognized_labels" xlink:type="arc"/>
      <link:label id="id_1b28c052" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of distribution liability</link:label>
      <link:label id="id_32e2fa92" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between net assets and distribution liability</link:label>
      <link:label id="id_5a5595b5" xlink:label="lbl_label1515558325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendToDividendBearingShares" xlink:to="lbl_label1515558325" xlink:type="arc"/>
      <link:label id="id_76193299" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_1fe7672a" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:type="arc"/>
      <link:label id="id_4fbc2a8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution of Alcon Inc. to Novartis AG shareholders</link:label>
      <link:label id="id_1b6a6442" xlink:label="lbl_label459957314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net provisions for transaction costs recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:label="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:to="lbl_label459957314" xlink:type="arc"/>
      <link:label id="id_68457d8c" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows attributable to divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusiness" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:type="arc"/>
      <link:label id="id_4f1d6584" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flows used in investing activities, net</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1bf16062" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as investing activities</link:label>
      <link:label id="id_1d66e74c" xlink:label="lbl_label493283148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherNoncurrentAssets" xlink:to="lbl_label493283148" xlink:type="arc"/>
      <link:label id="id_2b5de5f3" xlink:label="lbl_label727574003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:to="lbl_label727574003" xlink:type="arc"/>
      <link:label id="id_54b5d55e" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_5b8463eb" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_cbbfa93" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebt" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_2ce3e4d1" xlink:label="lbl_label753132753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets Disclosure and Lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_label753132753" xlink:type="arc"/>
      <link:label id="id_7eea5c8b" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_179a66c8" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability</link:label>
      <link:label id="id_61aad0c8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_41e189f8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets</link:label>
      <link:label id="id_74f2bff0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b1c78b0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward</link:label>
      <link:label id="id_21983c62" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3cad94ea" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge</link:label>
      <link:label id="id_59a39235" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_16173223" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability</link:label>
      <link:label id="id_349af9f2" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0fa89e" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="locator"/>
      <link:label id="id_41a9be15" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5f4cbeb8" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_20d2348f" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_24522acb" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_2dbe7019" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_665e2bc2" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_2124eb92" xlink:label="lbl_label556067730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesMember" xlink:to="lbl_label556067730" xlink:type="arc"/>
      <link:label id="id_25d32b75" xlink:label="lbl_label634596213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesMember" xlink:to="lbl_label634596213" xlink:type="arc"/>
      <link:label id="id_7905e1d7" xlink:label="lbl_label203360922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate, excluding exceptional items</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:to="lbl_label203360922" xlink:type="arc"/>
      <link:label id="id_65b2ed83" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:label id="id_2db983d5" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:label id="id_71df6444" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows Attributable to divested business before divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_43e3fc7" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions for transaction costs attributable to the divested business</link:label>
      <link:label id="id_4fb71438" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestedCashAndCashEquivalents" xlink:to="lbl_DivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_74caa513" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:label id="id_3a16e3f2" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:label id="id_5bc61768" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares obtained through consolidated foundation</link:label>
      <link:label id="id_32f424a5" xlink:label="lbl_label854860965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customary purchase price adjustment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomaryPurchasePriceAdjustment" xlink:to="lbl_label854860965" xlink:type="arc"/>
      <link:label id="id_4b0dbe44" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfIntercompanyBalances" xlink:to="lbl_RepaymentOfIntercompanyBalances_labels" xlink:type="arc"/>
      <link:label id="id_3ce6e6d2" xlink:label="lbl_label1021765330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax reform impact on deferred tax on treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:to="lbl_label1021765330" xlink:type="arc"/>
      <link:label id="id_1d9b087f" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend paid, non-cash assets distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendPaidNoncashAssetsDistribution" xlink:to="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:type="arc"/>
      <link:label id="id_49b7a9d9" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:label id="id_4f1253e8" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net gain at completion of spin-off [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_cd2ba12" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain at completion of spin-off</link:label>
      <link:label id="id_4a895e0" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_399cb44f" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_333e63f1" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b60d5f0" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations</link:label>
      <link:label id="id_6f1a698a" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6b21ae09" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations</link:label>
      <link:label id="id_4a52c922" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_54e8c608" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized</link:label>
      <link:label id="id_68686f96" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_74c77dde" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments</link:label>
      <link:label id="id_3a5e6480" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_2aebe53" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_14e1d56d" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_16d7d1ab" xlink:label="lbl_label383242667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lbl_label383242667" xlink:type="arc"/>
      <link:label id="id_364362e8" xlink:label="lbl_label910385896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label910385896" xlink:type="arc"/>
      <link:label id="id_3ff27324" xlink:label="lbl_label1072853796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lbl_label1072853796" xlink:type="arc"/>
      <link:label id="id_218c01ed" xlink:label="lbl_label562823661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lbl_label562823661" xlink:type="arc"/>
      <link:label id="id_7e9fd619" xlink:label="lbl_label2124404249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lbl_label2124404249" xlink:type="arc"/>
      <link:label id="id_726c27cc" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_5f37a474" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_88d7a8d" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_4f1e5db1" xlink:label="lbl_label1327390129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1327390129" xlink:type="arc"/>
      <link:label id="id_738f9077" xlink:label="lbl_label1938788471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1938788471" xlink:type="arc"/>
      <link:label id="id_236bf45e" xlink:label="lbl_label594277470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label594277470" xlink:type="arc"/>
      <link:label id="id_1e452462" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_19961677" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and right-of-use assets</link:label>
      <link:label id="id_7213f224" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for distribution by way of divindend in kind to shareholders</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:type="arc"/>
      <link:label id="id_73c6a1d7" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution by way of dividend in kind to shareholders</link:label>
      <link:label id="id_3b0bcb35" xlink:label="lbl_label373468922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated</link:label>
      <link:label id="id_505899ea" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Medicines Company, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TheMedicinesCompanyMember" xlink:to="lbl_TheMedicinesCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_3d4865bf" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Medicines Company</link:label>
      <link:label id="id_26a553b7" xlink:label="lbl_label648369079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piqray [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PiqrayMember" xlink:to="lbl_label648369079" xlink:type="arc"/>
      <link:label id="id_3dbe8202" xlink:label="lbl_label1035895298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xiidra [member]</link:label>
      <link:label id="id_725b9be" xlink:label="lbl_label119912894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zolgensma [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZolgensmaMember" xlink:to="lbl_label119912894" xlink:type="arc"/>
      <link:label id="id_7679d6e" xlink:label="lbl_label124231022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mayzent [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MayzentMember" xlink:to="lbl_label124231022" xlink:type="arc"/>
      <link:label id="id_18490fef" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations</link:label>
      <link:label id="id_c87ee03" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_479a229e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_18f65009" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4ee2113e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to discontinued operations</link:label>
      <link:label id="id_6422c211" xlink:label="lbl_label1679999505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:to="lbl_label1679999505" xlink:type="arc"/>
      <link:label id="id_36a944c" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period continuing operations</link:label>
      <link:label id="id_f49321b" xlink:label="lbl_label256455195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:to="lbl_label256455195" xlink:type="arc"/>
      <link:label id="id_59b158e6" xlink:label="lbl_label1504794854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label1504794854" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label373468922" xlink:type="arc"/>
      <link:label id="id_3dc8af6f" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted finance lease payments to be received</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:type="arc"/>
      <link:label id="id_334ff648" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total future payments</link:label>
      <link:label id="id_4ca139f0" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:type="arc"/>
      <link:label id="id_32f71aba" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unearned interest income</link:label>
      <link:label id="id_32d528ec" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum finace lease payments receivable at present value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_200aacc" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements, at present value</link:label>
      <link:label id="id_5e2f001b" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_270f5b37" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_60c53887" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3255d072" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
      <link:label id="id_78469395" xlink:label="lbl_label2017891221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from non-current to current, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:to="lbl_label2017891221" xlink:type="arc"/>
      <link:label id="id_37080272" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:label id="id_22d1162d" xlink:label="lbl_label584128045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesMember" xlink:to="lbl_label584128045" xlink:type="arc"/>
      <link:label id="id_5bd2b859" xlink:label="lbl_label1540536409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayable" xlink:label="lbl_ContingentConsiderationPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayable" xlink:to="lbl_label1540536409" xlink:type="arc"/>
      <link:label id="id_11db2be0" xlink:label="lbl_label299576288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label299576288" xlink:type="arc"/>
      <link:label id="id_358bdb60" xlink:label="lbl_label2144120781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 16 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:to="lbl_label2144120781" xlink:type="arc"/>
      <link:label id="id_5776de2" xlink:label="lbl_label91712994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, USD [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsUSDMember" xlink:to="lbl_label91712994" xlink:type="arc"/>
      <link:label id="id_37cf6b5c" xlink:label="lbl_label936340316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, EUR [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsEURMember" xlink:to="lbl_label936340316" xlink:type="arc"/>
      <link:label id="id_4e1f7ea0" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseLiabilities" xlink:to="lbl_FinanceLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_495a6466" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
      <link:label id="id_633ca478" xlink:label="lbl_label1664918648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedCompensationShares" xlink:to="lbl_label1664918648" xlink:type="arc"/>
      <link:label id="id_79aa7a52" xlink:label="lbl_label2041215570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:to="lbl_label2041215570" xlink:type="arc"/>
      <link:label id="id_6d34d6c2" xlink:label="lbl_label1832179394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_6fef109e" xlink:label="lbl_label1877938334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1877938334" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1832179394" xlink:type="arc"/>
      <link:label id="id_347a007d" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentReceivables" xlink:to="lbl_OtherNoncurrentReceivables_labels" xlink:type="arc"/>
      <link:label id="id_4871e871" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term receivables</link:label>
      <link:label id="id_4529bc84" xlink:label="lbl_label1160363140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:to="lbl_label1160363140" xlink:type="arc"/>
      <link:label id="id_5b371f8c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, impact of business combinations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:type="arc"/>
      <link:label id="id_3787190c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_4001cae9" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Impact of adoption of IFRS 16 Leases</link:label>
      <link:label id="id_2f708bd6" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial debts cash flows from continuing operations</link:label>
      <link:label id="id_7a3ed482" xlink:label="lbl_label2050937986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously reported finance lease obligation of divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:to="lbl_label2050937986" xlink:type="arc"/>
      <link:label id="id_34924f0b" xlink:label="lbl_label882003723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:to="lbl_label882003723" xlink:type="arc"/>
      <link:label id="id_15f358a7" xlink:label="lbl_label368269479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, options on equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:to="lbl_label368269479" xlink:type="arc"/>
      <link:label id="id_61acf165" xlink:label="lbl_label1591563240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, damages claimed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:to="lbl_label1591563240" xlink:type="arc"/>
      <link:label id="id_49032bd4" xlink:label="lbl_label1224944596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:to="lbl_label1224944596" xlink:type="arc"/>
      <link:label id="id_4b8a0c94" xlink:label="lbl_label1267338388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of resolved action</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfResolvedAction" xlink:to="lbl_label1267338388" xlink:type="arc"/>
      <link:label id="id_54d844bf" xlink:label="lbl_label1423459519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enoxaparin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnoxaparinMember" xlink:to="lbl_label1423459519" xlink:type="arc"/>
      <link:label id="id_29f14990" xlink:label="lbl_label703678864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Manufacturing Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozManufacturingInc.Member" xlink:to="lbl_label703678864" xlink:type="arc"/>
      <link:label id="id_1755f369" xlink:label="lbl_label391508841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institute for BioMedical Research Co.,Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:to="lbl_label391508841" xlink:type="arc"/>
      <link:label id="id_6dee5dc4" xlink:label="lbl_label1844338116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:to="lbl_label1844338116" xlink:type="arc"/>
      <link:label id="id_5443c473" xlink:label="lbl_label1413727347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCUREMember" xlink:to="lbl_label1413727347" xlink:type="arc"/>
      <link:label id="id_4cf512" xlink:label="lbl_label5043474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMember" xlink:to="lbl_label5043474" xlink:type="arc"/>
      <link:label id="id_4471df2c" xlink:label="lbl_label1148313388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:to="lbl_label1148313388" xlink:type="arc"/>
      <link:label id="id_424beb28" xlink:label="lbl_label1112271656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications (Italy) S.r.l. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:to="lbl_label1112271656" xlink:type="arc"/>
      <link:label id="id_5fad9749" xlink:label="lbl_label1605211977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVMember" xlink:to="lbl_label1605211977" xlink:type="arc"/>
      <link:label id="id_50283594" xlink:label="lbl_label1344812436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications Iberica, S.L.U. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:to="lbl_label1344812436" xlink:type="arc"/>
      <link:label id="id_6345aa6d" xlink:label="lbl_label1665509997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdMember" xlink:to="lbl_label1665509997" xlink:type="arc"/>
      <link:label id="id_2031baeb" xlink:label="lbl_label540130027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.Member" xlink:to="lbl_label540130027" xlink:type="arc"/>
      <link:label id="id_1af84be1" xlink:label="lbl_label452479969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCMember" xlink:to="lbl_label452479969" xlink:type="arc"/>
      <link:label id="id_388a06e4" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:type="arc"/>
      <link:label id="id_3b18f468" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid consisting of cash and cash equivalents upfront payment</link:label>
      <link:label id="id_47a0c115" xlink:label="lbl_label1201717525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partial release of deferred tax liability recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:to="lbl_label1201717525" xlink:type="arc"/>
      <link:label id="id_300e3078" xlink:label="lbl_label464719186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesUndiscounted" xlink:to="lbl_label464719186" xlink:type="arc"/>
      <link:label id="id_34d806ab" xlink:label="lbl_label1619923269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most material lease with lease term extension</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:to="lbl_label1619923269" xlink:type="arc"/>
      <link:label id="id_53edcb" xlink:label="lbl_label5500363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for short term and low value leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:to="lbl_label5500363" xlink:type="arc"/>
      <link:label id="id_30ae4b2" xlink:label="lbl_label51045554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for payments of leases interest</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:to="lbl_label51045554" xlink:type="arc"/>
      <link:label id="id_5a4733e9" xlink:label="lbl_label1514615785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform applicable tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1514615785" xlink:type="arc"/>
      <link:label id="id_63ed288d" xlink:label="lbl_label1676486797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform applicable blended tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1676486797" xlink:type="arc"/>
      <link:label id="id_3af42b4" xlink:label="lbl_label2021190939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term receivables from finance subleases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermReceivablesFromFinanceSubleases" xlink:to="lbl_label2021190939" xlink:type="arc"/>
      <link:label id="id_115b6ebf" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through liabilities related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_64b9f08d" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and lease liabilities related to discontinued operations</link:label>
      <link:label id="id_a7c0098" xlink:label="lbl_label175898776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility short term</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityShortTerm" xlink:to="lbl_label175898776" xlink:type="arc"/>
      <link:label id="id_3f8e8cf1" xlink:label="lbl_label1066306801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_label1066306801" xlink:type="arc"/>
      <link:label id="id_44dffa85" xlink:label="lbl_label1155529349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_label1155529349" xlink:type="arc"/>
      <link:label id="id_7feaeddc" xlink:label="lbl_label167109794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_label167109794" xlink:type="arc"/>
      <link:label id="id_2246514e" xlink:label="lbl_label2121837386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [member]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EuropeMember" xlink:to="lbl_label2121837386" xlink:type="arc"/>
      <link:label id="id_4c9a1836" xlink:label="lbl_label849028726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [member]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericasMember" xlink:to="lbl_label849028726" xlink:type="arc"/>
      <link:label id="id_295e5e69" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssetsMember" xlink:to="lbl_RightofuseAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_164ca513" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_4947c6a9" xlink:label="lbl_label1229440681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beovu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeovuMember" xlink:to="lbl_label1229440681" xlink:type="arc"/>
      <link:label id="id_22f028b0" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid (received)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidReceived" xlink:to="lbl_ConsiderationPaidReceived_labels" xlink:type="arc"/>
      <link:label id="id_3dc9426c" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash inflows from divestment</link:label>
      <link:label id="id_56521fba" xlink:label="lbl_label1448222650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash outflows from divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashOutflowsFromDivestments" xlink:to="lbl_label1448222650" xlink:type="arc"/>
      <link:label id="id_1d2114e2" xlink:label="lbl_label488707298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label488707298" xlink:type="arc"/>
      <link:label id="id_45aec51d" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_6eb0eb0c" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:label id="id_6bada554" xlink:label="lbl_label1806542164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesMember" xlink:to="lbl_label1806542164" xlink:type="arc"/>
      <link:label id="id_61717448" xlink:label="lbl_label1634825288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesMember" xlink:to="lbl_label1634825288" xlink:type="arc"/>
      <link:label id="id_2e9b8dad" xlink:label="lbl_label781946285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label781946285" xlink:type="arc"/>
      <link:label id="id_508846a9" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:type="arc"/>
      <link:label id="id_420e4c77" xlink:label="lbl_label1108233335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_label1108233335" xlink:type="arc"/>
      <link:label id="id_5c23b63c" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities</link:label>
      <link:label id="id_77f7d595" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_16b54793" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:to="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:type="arc"/>
      <link:label id="id_45e19527" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_63e83d46" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_226b60a4" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:label id="id_557effd1" xlink:label="lbl_label1434386385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax on transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:to="lbl_label1434386385" xlink:type="arc"/>
      <link:label id="id_5c1a2168" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write-off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_59102729" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of derecognition and reversals of derecognition of deferred tax assets</link:label>
      <link:label id="id_3df76505" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from current and non-current borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_64441db" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payment</link:label>
      <link:label id="id_11959a05" xlink:label="lbl_label295016965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncalled capital commitments for investments in funds</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:to="lbl_label295016965" xlink:type="arc"/>
      <link:label id="id_12c8e5a0" xlink:label="lbl_label315155872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_label315155872" xlink:type="arc"/>
      <link:label id="id_73c71c69" xlink:label="lbl_label1942428777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tennessee class action [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TennesseeClassActionMember" xlink:to="lbl_label1942428777" xlink:type="arc"/>
      <link:label id="id_17248af4" xlink:label="lbl_label388270836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Massachusetts case [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MassachusettsCaseMember" xlink:to="lbl_label388270836" xlink:type="arc"/>
      <link:label id="id_23bc1d31" xlink:label="lbl_label599530801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAnnualReport" xlink:to="lbl_label599530801" xlink:type="arc"/>
      <link:label id="id_34b5e034" xlink:label="lbl_label884334644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityShellCompany" xlink:to="lbl_label884334644" xlink:type="arc"/>
      <link:label id="id_481345ce" xlink:label="lbl_label1209222606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityEmergingGrowthCompany" xlink:to="lbl_label1209222606" xlink:type="arc"/>
      <link:label id="id_448d1a1f" xlink:label="lbl_label1150097951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityInteractiveDataCurrent" xlink:to="lbl_label1150097951" xlink:type="arc"/>
      <link:label id="id_8e53da4" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow from borrowings</link:label>
      <link:label id="id_39e22a7b" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction cost payments</link:label>
      <link:label id="id_4f32f729" xlink:label="lbl_label1328740137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxAssets" xlink:to="lbl_label1328740137" xlink:type="arc"/>
      <link:label id="id_182b8b94" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxLiabilities" xlink:to="lbl_GrossDeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3fcaf800" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:label id="id_12baf088" xlink:label="lbl_label314241160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount borrowed under the credit facility</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountBorrowedUnderTheCreditFacility" xlink:to="lbl_label314241160" xlink:type="arc"/>
      <link:label id="id_24f2fc6a" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationLiabilities" xlink:to="lbl_ContingentConsiderationLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_596ae769" xlink:label="lbl_label1500178281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation case [axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_label1500178281" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XiidraMember" xlink:to="lbl_label1035895298" xlink:type="arc"/>
      <link:label id="id_6dadd046" xlink:label="lbl_label1840107590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentTransitionReport" xlink:to="lbl_label1840107590" xlink:type="arc"/>
      <link:label id="id_287ed480" xlink:label="lbl_label679400576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentShellCompanyReport" xlink:to="lbl_label679400576" xlink:type="arc"/>
      <link:label id="id_6eada512" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:type="arc"/>
      <link:label id="id_b2dfb88" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment</link:label>
      <link:label id="id_4be49960" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_7d4d613b" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:label id="id_4eb0928b" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:label id="id_22a0ea85" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_15b36c9d" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:label id="id_55dcd44c" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a35ce5" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_40e677f7" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:label id="id_2d2e026c" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1ac53b1b" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:label id="id_e5f5961" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_7d7ce79e" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_42fb2d2e" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_4eb32c65" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_27322091" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:label id="id_7e6f87d8" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_25b1f7fc" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_148d311b" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_67019b8d" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_6e294aeb" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4bbdbc8c" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:label id="id_45ca4585" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:label id="id_42ccca61" xlink:label="lbl_label1120717409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entitys trade receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysTradeReceivable" xlink:to="lbl_label1120717409" xlink:type="arc"/>
      <link:label id="id_43ec36aa" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:label id="id_677ffa06" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForSaleAndLeaseback" xlink:to="lbl_CashInflowForSaleAndLeaseback_labels" xlink:type="arc"/>
      <link:label id="id_5bdc50eb" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and lease back [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleAndLeaseBackMember" xlink:to="lbl_SaleAndLeaseBackMember_labels" xlink:type="arc"/>
      <link:label id="id_73fe88ea" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and leaseback</link:label>
      <link:label id="id_1b2ddb15" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvision" xlink:to="lbl_CurrentRefundsProvision_labels" xlink:type="arc"/>
      <link:label id="id_6f9ec2d7" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue</link:label>
      <link:label id="id_782da91f" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at beginning of period</link:label>
      <link:label id="id_67f2691b" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at end of period</link:label>
      <link:label id="id_376d9857" xlink:label="lbl_label929929303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, commodity purchase contract</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:to="lbl_label929929303" xlink:type="arc"/>
      <link:label id="id_4c17362a" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_328352cc" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:label id="id_5a93baa1" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_1917780" xlink:label="lbl_label26310528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on divestment gain</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:to="lbl_label26310528" xlink:type="arc"/>
      <link:label id="id_6025ab0" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:label id="id_642f7fec" xlink:label="lbl_label1680834540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:to="lbl_label1680834540" xlink:type="arc"/>
      <link:label id="id_14fc3a32" xlink:label="lbl_label352074290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE, Les Ulis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCURELesUlisMember" xlink:to="lbl_label352074290" xlink:type="arc"/>
      <link:label id="id_372a8238" xlink:label="lbl_label925532728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:to="lbl_label925532728" xlink:type="arc"/>
      <link:label id="id_12a3185f" xlink:label="lbl_label312678495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:to="lbl_label312678495" xlink:type="arc"/>
      <link:label id="id_495d47ae" xlink:label="lbl_label1230849966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:to="lbl_label1230849966" xlink:type="arc"/>
      <link:label id="id_3b55a7b7" xlink:label="lbl_label995469239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV, Baarle-Nassau [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVBaarleNassauMember" xlink:to="lbl_label995469239" xlink:type="arc"/>
      <link:label id="id_33884b38" xlink:label="lbl_label864570168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saudi Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaudiLtd.RiyadhMember" xlink:to="lbl_label864570168" xlink:type="arc"/>
      <link:label id="id_222bb2dd" xlink:label="lbl_label573289181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]</link:label>
      <link:label id="id_10409dbe" xlink:label="lbl_label272670142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedLondonMember" xlink:to="lbl_label272670142" xlink:type="arc"/>
      <link:label id="id_63d11071" xlink:label="lbl_label1674645617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:to="lbl_label1674645617" xlink:type="arc"/>
      <link:label id="id_19392a8e" xlink:label="lbl_label423176846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedLondonMember" xlink:to="lbl_label423176846" xlink:type="arc"/>
      <link:label id="id_7c7620c7" xlink:label="lbl_label2088116423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdLondonMember" xlink:to="lbl_label2088116423" xlink:type="arc"/>
      <link:label id="id_51082ea6" xlink:label="lbl_label1359490726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedLondonMember" xlink:to="lbl_label1359490726" xlink:type="arc"/>
      <link:label id="id_70da7012" xlink:label="lbl_label1893363730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:to="lbl_label1893363730" xlink:type="arc"/>
      <link:label id="id_1a5c8917" xlink:label="lbl_label442272023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:to="lbl_label442272023" xlink:type="arc"/>
      <link:label id="id_2db5a3fb" xlink:label="lbl_label766878715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:to="lbl_label766878715" xlink:type="arc"/>
      <link:label id="id_5bd187f1" xlink:label="lbl_label1540458481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:to="lbl_label1540458481" xlink:type="arc"/>
      <link:label id="id_25dd15b1" xlink:label="lbl_label635246001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:to="lbl_label635246001" xlink:type="arc"/>
      <link:label id="id_561808b5" xlink:label="lbl_label1444415669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:to="lbl_label1444415669" xlink:type="arc"/>
      <link:label id="id_7ffed34c" xlink:label="lbl_label2147406668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:to="lbl_label2147406668" xlink:type="arc"/>
      <link:label id="id_4458c6ff" xlink:label="lbl_label1146668799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.EastHanoverNJMember" xlink:to="lbl_label1146668799" xlink:type="arc"/>
      <link:label id="id_68546348" xlink:label="lbl_label1750360904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:to="lbl_label1750360904" xlink:type="arc"/>
      <link:label id="id_2d054e5d" xlink:label="lbl_label755322461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:to="lbl_label755322461" xlink:type="arc"/>
      <link:label id="id_75833aa3" xlink:label="lbl_label1971534499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH, Marburg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMarburgMember" xlink:to="lbl_label1971534499" xlink:type="arc"/>
      <link:label id="id_3ce1ce66" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, net</link:label>
      <link:label id="id_7d5a543d" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_264ae6cd" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_541ef56a" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:label id="id_4edf1e96" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:label id="id_2efc8f07" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of the current portion of non-current financial debts</link:label>
      <link:label id="id_2d28f541" xlink:label="lbl_label757658945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of US tax reform legislation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfUSTaxReformLegislation" xlink:to="lbl_label757658945" xlink:type="arc"/>
      <link:label id="id_3c578d43" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredCashAndCashEquivalents" xlink:to="lbl_AcquiredCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_25ec28ce" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_4dc21030" xlink:label="lbl_label1304563760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16</link:label>
      <link:label id="id_284baaac" xlink:label="lbl_label676047532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label676047532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label1304563760" xlink:type="arc"/>
      <link:label id="id_7cee5446" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43467410" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information</link:label>
      <link:label id="id_47cec299" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_557771c9" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information</link:label>
      <link:label id="id_6c2f9126" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c013712" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities</link:label>
      <link:label id="id_cd95e1f" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5424fa1a" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_71dfb6f6" xlink:label="lbl_label1910486774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroGroupMember" xlink:to="lbl_label1910486774" xlink:type="arc"/>
      <link:label id="id_86983fb" xlink:label="lbl_label141132795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adakveo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdakveoMember" xlink:to="lbl_label141132795" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_label1289490857" xlink:type="arc"/>
      <link:label id="id_4b6d4dbb" xlink:label="lbl_label1265454523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:to="lbl_label1265454523" xlink:type="arc"/>
      <link:label id="id_506f7c31" xlink:label="lbl_label1349483569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:to="lbl_label1349483569" xlink:type="arc"/>
      <link:label id="id_2f497fb1" xlink:label="lbl_label793345969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:to="lbl_label793345969" xlink:type="arc"/>
      <link:label id="id_27dd04e2" xlink:label="lbl_label668796130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:to="lbl_label668796130" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPChangeMember" xlink:to="lbl_label1343837424" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPYEChangeMember" xlink:to="lbl_label571817371" xlink:type="arc"/>
      <link:label id="id_baa97ec" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxAssetsCurrent" xlink:to="lbl_CurrentTaxAssetsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_6f03bc65" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
      <link:label id="id_1b60e90f" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_4606d526" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other non-current liabilities</link:label>
      <link:label id="id_f38218c" xlink:label="lbl_label255336844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZPL389 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZPL389Member" xlink:to="lbl_label255336844" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfOtherFinancialAssetsSold" xlink:to="lbl_label2044002083" xlink:type="arc"/>
      <link:label id="id_4fe64fe" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:label id="id_17ced1e3" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_78162c1a" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_23e031e7" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non current lease liabilities as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5e1a35c1" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_2d827166" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_5854f481" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_280cd5b1" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
      <link:label id="id_4ae04f6d" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercised options and other treasury share transactions, net</link:label>
      <link:label id="id_1829dad9" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:label id="id_452d236c" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_1af64409" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_7a659997" xlink:label="lbl_label2053478807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid sales price for a business divestment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:to="lbl_label2053478807" xlink:type="arc"/>
      <link:label id="id_137fddb" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_5ae43d2a" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations</link:label>
      <link:label id="id_2214c4b6" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at beginning of period</link:label>
      <link:label id="id_64fab371" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at end of period</link:label>
      <link:label id="id_305e08c1" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivable" xlink:to="lbl_ProvisionForDoubtfulReceivable_labels" xlink:type="arc"/>
      <link:label id="id_17c9358" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at beginning of period</link:label>
      <link:label id="id_7c5a57a4" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at end of period</link:label>
      <link:label id="id_569afc65" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, Discontinued operations, at present value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_6cf5f158" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at beginning of period</link:label>
      <link:label id="id_4998d875" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at end of period</link:label>
      <link:label id="id_11da36c7" xlink:label="lbl_label299513543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities, impact of adoption of IFRS 16</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:label="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:to="lbl_label299513543" xlink:type="arc"/>
      <link:label id="id_664f7869" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:type="arc"/>
      <link:label id="id_5209ef33" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_34fc26b" xlink:label="lbl_label55558763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments, discontinued operations</link:label>
      <link:label id="id_61a2309d" xlink:label="lbl_label1638019229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label1638019229" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label55558763" xlink:type="arc"/>
      <link:label id="id_4087a31" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28188a68" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_1caaba88" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovementOfPeriod" xlink:to="lbl_TreasurySharesMovementOfPeriod_labels" xlink:type="arc"/>
      <link:label id="id_21690868" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_5def5bff" xlink:label="lbl_label1575967743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in finance leases receivable due to unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_label1575967743" xlink:type="arc"/>
      <link:label id="id_34d7edcd" xlink:label="lbl_label886566349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities, category [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:to="lbl_label886566349" xlink:type="arc"/>
      <link:label id="id_eec52d1" xlink:label="lbl_label250368721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsMember" xlink:to="lbl_label250368721" xlink:type="arc"/>
      <link:label id="id_354fdd57" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:type="arc"/>
      <link:label id="id_273f4f15" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Fair value adjustments on marketable securities</link:label>
      <link:label id="id_38a75dc3" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_e0e9730" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_92da590" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepurchaseOfOptions" xlink:to="lbl_RepurchaseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_4e1c053" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:label id="id_3b79b108" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4848a24f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_780c70ab" xlink:label="lbl_label2014081195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabrecta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TabrectaMember" xlink:to="lbl_label2014081195" xlink:type="arc"/>
      <link:label id="id_127152f2" xlink:label="lbl_label309416690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kesimpta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KesimptaMember" xlink:to="lbl_label309416690" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:type="arc"/>
      <link:label id="id_5de4f6ff" xlink:label="lbl_label1575286527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:to="lbl_label1575286527" xlink:type="arc"/>
      <link:label id="id_5914d9cb" xlink:label="lbl_label1494538699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:to="lbl_label1494538699" xlink:type="arc"/>
      <link:label id="id_5f78509e" xlink:label="lbl_label1601720478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:to="lbl_label1601720478" xlink:type="arc"/>
      <link:label id="id_1a77a5e5" xlink:label="lbl_label444048869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:to="lbl_label444048869" xlink:type="arc"/>
      <link:label id="id_57a4b51a" xlink:label="lbl_label1470412058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:to="lbl_label1470412058" xlink:type="arc"/>
      <link:label id="id_467a5e1d" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28811564" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7e37dc46" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through classified as held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_75e51f1c" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7eed015a" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3eecdcaa" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_653fa5ee" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:label id="id_6448b9fc" xlink:label="lbl_label1682487804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options repurchased</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOptionsRepurchased" xlink:to="lbl_label1682487804" xlink:type="arc"/>
      <link:label id="id_55dc85a" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_40c54b4d" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_7d17c10a" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_3c338d36" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssued" xlink:to="lbl_NumberOfSharesIssued_labels" xlink:type="arc"/>
      <link:label id="id_74f409ec" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at beginning of period</link:label>
      <link:label id="id_5895e9b5" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at end of period</link:label>
      <link:label id="id_4ad28146" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfTreasuryShares" xlink:to="lbl_NumberOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_3deddf6f" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at beginning of period</link:label>
      <link:label id="id_74b615a9" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at end of period</link:label>
      <link:label id="id_7f6e02de" xlink:label="lbl_label2137916126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not subject to expiry [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotSubjectToExpiryMember" xlink:to="lbl_label2137916126" xlink:type="arc"/>
      <link:label id="id_3faff48a" xlink:label="lbl_label1068496010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase of own shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:to="lbl_label1068496010" xlink:type="arc"/>
      <link:label id="id_3f65b5b6" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for healthcare contributions [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_340a972f" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare contributions</link:label>
      <link:label id="id_53107fec" xlink:label="lbl_label1393590252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development commitments for transactions entered into current year, closed after current year end</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:to="lbl_label1393590252" xlink:type="arc"/>
      <link:label id="id_3851ffb1" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payables, net</link:label>
      <link:label id="id_27060644" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CN" xlink:to="lbl_CN_labels" xlink:type="arc"/>
      <link:label id="id_cac1bd6" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
      <link:label id="id_38628cbd" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carry forwards</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryForwards" xlink:to="lbl_TaxLossCarryForwards_labels" xlink:type="arc"/>
      <link:label id="id_3d3df970" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Tax loss carryforwards expired</link:label>
      <link:label id="id_7429e4f6" xlink:label="lbl_label1948902646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="lbl_label1948902646" xlink:type="arc"/>
      <link:label id="id_5c2d9c4d" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_35a27c09" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_5725466" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:type="arc"/>
      <link:label id="id_536cdf9" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings interest rate step up</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRateStepUp" xlink:to="lbl_BorrowingsInterestRateStepUp_labels" xlink:type="arc"/>
      <link:label id="id_3f1e4d31" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Straight bonds</link:label>
      <link:label id="id_653e892c" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:type="arc"/>
      <link:label id="id_2997004f" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:label id="id_3110a540" xlink:label="lbl_label823174464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsMember" xlink:to="lbl_label823174464" xlink:type="arc"/>
      <link:label id="id_6718df7c" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated acquisition fair value of total consideration</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:type="arc"/>
      <link:label id="id_28d66ca1" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value purchase price</link:label>
      <link:label id="id_7dd0ab04" xlink:label="lbl_label2110827268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IcfrAuditorAttestationFlag" xlink:to="lbl_label2110827268" xlink:type="arc"/>
      <link:label id="id_76f3c7f1" xlink:label="lbl_label937578086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_7ce6c764" xlink:label="lbl_label2095499108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spark Therapeutics, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SparkTherapeuticsInc.Member" xlink:to="lbl_label2095499108" xlink:type="arc"/>
      <link:label id="id_704e7977" xlink:label="lbl_label1884191095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1884191095" xlink:type="arc"/>
      <link:label id="id_8bbdcdf" xlink:label="lbl_label146529503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies EU Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:to="lbl_label146529503" xlink:type="arc"/>
      <link:label id="id_6c2d9048" xlink:label="lbl_label1814925384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenJapanK.K.TokyoMember" xlink:to="lbl_label1814925384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:to="lbl_label542160655" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIsraelLtd.TelAvivMember" xlink:to="lbl_label437644648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:to="lbl_label604974513" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:to="lbl_label573289181" xlink:type="arc"/>
      <link:label id="id_2e2703c1" xlink:label="lbl_label774308801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:to="lbl_label774308801" xlink:type="arc"/>
      <link:label id="id_49af070a" xlink:label="lbl_label1236207370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (UK &amp; Ireland), London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:to="lbl_label1236207370" xlink:type="arc"/>
      <link:label id="id_2d344762" xlink:label="lbl_label758400866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neutec Pharma Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeutecPharmaLimitedLondonMember" xlink:to="lbl_label758400866" xlink:type="arc"/>
      <link:label id="id_5f46d997" xlink:label="lbl_label1598478743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalesce Product Development Limited, Cambridge, Cambs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:to="lbl_label1598478743" xlink:type="arc"/>
      <link:label id="id_2252cc66" xlink:label="lbl_label575851622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Optogenetics Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:to="lbl_label575851622" xlink:type="arc"/>
      <link:label id="id_454fa68d" xlink:label="lbl_label1162847885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amblyotech Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmblyotechInc.EastHanoverNJMember" xlink:to="lbl_label1162847885" xlink:type="arc"/>
      <link:label id="id_2caf6f16" xlink:label="lbl_label749694742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vietnam Company Limited, Ho Chi Minh City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:to="lbl_label749694742" xlink:type="arc"/>
      <link:label id="id_c2bfc15" xlink:label="lbl_label204209173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:to="lbl_label204209173" xlink:type="arc"/>
      <link:label id="id_3fb4623e" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:label id="id_28b07024" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of other accounting policies relevant to understanding of financial statements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:to="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:type="arc"/>
      <link:label id="id_11b1fb8b" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_3843cb01" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet and income statement [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_98f2233" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets and income statement</link:label>
      <link:label id="id_2c3b8a35" xlink:label="lbl_label742099509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of brands in portfolio to acquire</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:to="lbl_label742099509" xlink:type="arc"/>
      <link:label id="id_3cf6b00d" xlink:label="lbl_label1022799885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of markets for the acquired brands</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:to="lbl_label1022799885" xlink:type="arc"/>
      <link:label id="id_47dc0ad" xlink:label="lbl_label75350189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total anti-infectives net sales [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAntiinfectivesNetSalesMember" xlink:to="lbl_label75350189" xlink:type="arc"/>
      <link:label id="id_ee96e7" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline plc (GSK) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlinePlcGSKMember" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:type="arc"/>
      <link:label id="id_54094d6d" xlink:label="lbl_label1409895789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solid Tumors [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolidTumorMember" xlink:to="lbl_label1409895789" xlink:type="arc"/>
      <link:label id="id_1962519a" xlink:label="lbl_label425873818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hematology [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HematologyMember" xlink:to="lbl_label425873818" xlink:type="arc"/>
      <link:label id="id_77ba142f" xlink:label="lbl_label2008683567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income other than current contract liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:to="lbl_label2008683567" xlink:type="arc"/>
      <link:label id="id_20b013e7" xlink:label="lbl_label548410343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leqvio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeqvioMember" xlink:to="lbl_label548410343" xlink:type="arc"/>
      <link:label id="id_66cbd7ad" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_bc0b0d9" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Annual incentive</link:label>
      <link:label id="id_14778812" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Annual Incentive Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_76867cfb" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_2_Annual incentive</link:label>
      <link:label id="id_416bc8c8" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Annual Incentive Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_69e1d51b" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_3_Annual incentive</link:label>
      <link:label id="id_584cbdc1" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Share savings plans RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_42d79120" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_4_Annual incentive</link:label>
      <link:label id="id_75440e22" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Share savings plans Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_184477d8" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_5_Annual incentive</link:label>
      <link:label id="id_552e7090" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Novartis Equity Plan Select North America RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_21165e34" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_6_Annual incentive</link:label>
      <link:label id="id_265acda6" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Based Participation Novartis Equity Plan Select outside North America RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_26e7b908" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_7_Annual incentive</link:label>
      <link:label id="id_1b9c56ed" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_12d62a5f" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_8_Annual incentive</link:label>
      <link:label id="id_5176ec6e" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Long Term Performance PSU Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1da39f37" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_9_Annual incentive</link:label>
      <link:label id="id_72a01f6d" xlink:label="lbl_label879628916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Long Term Relative Performance Plan PSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:to="lbl_label879628916" xlink:type="arc"/>
      <link:label id="id_faf6a0a" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_222e1d60" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_11_Annual incentive</link:label>
      <link:label id="id_300c474e" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_4ab462d9" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_12_Annual incentive</link:label>
      <link:label id="id_5d4c3be2" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_2af8ae97" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_13_Annual incentive</link:label>
      <link:label id="id_10c1e834" xlink:label="lbl_label281143348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashTransferred" xlink:to="lbl_label281143348" xlink:type="arc"/>
      <link:label id="id_54fd1d1d" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_4a9a940e" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of financial assets</link:label>
      <link:label id="id_d3a0157" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of investments other than investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_64262234" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of financial assets</link:label>
      <link:label id="id_7cc530c9" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities, commodities and time deposits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6063858" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
      <link:label id="id_57cdae3e" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities, commodities and time deposits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_32d638e5" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
      <link:label id="id_25e69fb8" xlink:label="lbl_label635871160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment impairment charges and reversals [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:to="lbl_label635871160" xlink:type="arc"/>
      <link:label id="id_5371a3bc" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6da7434" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates</link:label>
      <link:label id="id_638aba8b" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21ea725d" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in equity prices</link:label>
      <link:label id="id_4ed81682" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2c8bb21f" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices</link:label>
      <link:label id="id_70fedb84" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Holdings plc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:type="arc"/>
      <link:label id="id_c88323e" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex</link:label>
      <link:label id="id_670c36c1" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline plc (GSK)</link:label>
      <link:label id="id_66b2b8c9" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Holdings plc.</link:label>
      <link:label id="id_3b328671" xlink:label="lbl_label993166961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorFirmId" xlink:to="lbl_label993166961" xlink:type="arc"/>
      <link:label id="id_52eb17e9" xlink:label="lbl_label1391138793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorName" xlink:to="lbl_label1391138793" xlink:type="arc"/>
      <link:label id="id_69b54c63" xlink:label="lbl_label1773489251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorLocation" xlink:to="lbl_label1773489251" xlink:type="arc"/>
      <link:label id="id_4daa9a92" xlink:label="lbl_label1303026322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessContactMember" xlink:to="lbl_label1303026322" xlink:type="arc"/>
      <link:label id="id_c0b25fa" xlink:label="lbl_label202057210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_label202057210" xlink:type="arc"/>
      <link:label id="id_7d6bc756" xlink:label="lbl_label2104215382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_label2104215382" xlink:type="arc"/>
      <link:label id="id_4b15f6ce" xlink:label="lbl_label1259730638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFileNumber" xlink:to="lbl_label1259730638" xlink:type="arc"/>
      <link:label id="id_cb4c549" xlink:label="lbl_label213173576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityIncorporationStateCountryCode" xlink:to="lbl_label213173576" xlink:type="arc"/>
      <link:label id="id_7002066c" xlink:label="lbl_label1879180908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressAddressLine1" xlink:to="lbl_label1879180908" xlink:type="arc"/>
      <link:label id="id_231d9907" xlink:label="lbl_label589142279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressCityOrTown" xlink:to="lbl_label589142279" xlink:type="arc"/>
      <link:label id="id_759bc02e" xlink:label="lbl_label1973141550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressPostalZipCode" xlink:to="lbl_label1973141550" xlink:type="arc"/>
      <link:label id="id_36117107" xlink:label="lbl_label907112711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressCountry" xlink:to="lbl_label907112711" xlink:type="arc"/>
      <link:label id="id_1349334c" xlink:label="lbl_label323564364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentRegistrationStatement" xlink:to="lbl_label323564364" xlink:type="arc"/>
      <link:label id="id_8bcd64b" xlink:label="lbl_label146593355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAccountingStandard" xlink:to="lbl_label146593355" xlink:type="arc"/>
      <link:label id="id_1ece2873" xlink:label="lbl_label516827251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactPersonnelName" xlink:to="lbl_label516827251" xlink:type="arc"/>
      <link:label id="id_5d3ab2af" xlink:label="lbl_label1564127919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LocalPhoneNumber" xlink:to="lbl_label1564127919" xlink:type="arc"/>
      <link:label id="id_259830c2" xlink:label="lbl_label630730946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Fax Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactPersonnelFaxNumber" xlink:to="lbl_label630730946" xlink:type="arc"/>
      <link:label id="id_6de35884" xlink:label="lbl_NetInvestmentHedgeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_6ca6935d" xlink:label="lbl_label1822856029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments for leases not yet commenced</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsForLeasesNotYetCommenced" xlink:to="lbl_label1822856029" xlink:type="arc"/>
      <link:label id="id_13bf3f02" xlink:label="lbl_GR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GREECE</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GR" xlink:to="lbl_GR_labels" xlink:type="arc"/>
      <link:label id="id_39e4c772" xlink:label="lbl_GR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greece</link:label>
      <link:label id="id_61475ff3" xlink:label="lbl_label1632067571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers into Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="lbl_label1632067571" xlink:type="arc"/>
      <link:label id="id_b7f875c" xlink:label="lbl_label192907100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract manufacturing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractManufacturingMember" xlink:to="lbl_label192907100" xlink:type="arc"/>
      <link:label id="id_55e87fb3" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4a80d6e0" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates</link:label>
      <link:label id="id_dc4b8a1" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27fefcf1" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in equity prices</link:label>
      <link:label id="id_20bc3fae" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) through new, modified, terminated leases, arising from financing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1d1ed0d6" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New, modified and terminated leases, net</link:label>
      <link:label id="id_530db955" xlink:label="lbl_ExercisePrice65.9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 65.9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice65.9Member" xlink:to="lbl_ExercisePrice65.9Member_labels" xlink:type="arc"/>
      <link:label id="id_74475349" xlink:label="lbl_ExercisePrice65.9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">65.9</link:label>
      <link:label id="id_1acbddfa" xlink:label="lbl_label449568250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_label449568250" xlink:type="arc"/>
      <link:label id="id_3e4ee4c3" xlink:label="lbl_label1045357763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_label1045357763" xlink:type="arc"/>
      <link:label id="id_7a98072b" xlink:label="lbl_label2056783659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 5% increase [member]</link:label>
      <link:label id="id_47d3e5de" xlink:label="lbl_label1205069278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 5% decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical5DecreaseMember" xlink:to="lbl_label1205069278" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical5IncreaseMember" xlink:to="lbl_label2056783659" xlink:type="arc"/>
      <link:label id="id_31d2c983" xlink:label="lbl_label835897731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 15% decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical15DecreaseMember" xlink:to="lbl_label835897731" xlink:type="arc"/>
      <link:label id="id_abead02" xlink:label="lbl_label180268290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 15% increase [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical15IncreaseMember" xlink:to="lbl_label180268290" xlink:type="arc"/>
      <link:label id="id_1ee533e3" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency exchange rate sensitivity impact against USD in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_2b84a753" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency exchange rate sensitivity impact against USD in the equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:type="arc"/>
      <link:label id="id_525e31ad" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_41ba09ce" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity price sensitivity impact of the risk factors in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_7f9c7937" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_7bfe27c4" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity price sensitivity impact of the risk factors in the equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:type="arc"/>
      <link:label id="id_5220467c" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_66ef14bd" xlink:label="lbl_label420328400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease percentage in currency rate sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:to="lbl_label420328400" xlink:type="arc"/>
      <link:label id="id_49e83ca3" xlink:label="lbl_label1418742448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease percentage in equity price sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:to="lbl_label1418742448" xlink:type="arc"/>
      <link:label id="id_c163c14" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespiratoryAndAllergyMember" xlink:label="lbl_RespiratoryAndAllergyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespiratoryAndAllergyMember" xlink:to="lbl_label453087740" xlink:type="arc"/>
      <link:label id="id_402111c4" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current and non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:type="arc"/>
      <link:label id="id_6350e48" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
      <link:label id="id_75acf913" xlink:label="lbl_label1974270227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursements from plan to employer net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label1974270227" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label937578086" xlink:type="arc"/>
      <link:label id="id_464a259d" xlink:label="lbl_label1179264413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lbl_label1179264413" xlink:type="arc"/>
      <link:label id="id_547cb455" xlink:label="lbl_label1417458773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of fund investments and equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:to="lbl_label1417458773" xlink:type="arc"/>
      <link:label id="id_72e0d44b" xlink:label="lbl_label1927337035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of government backed debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:to="lbl_label1927337035" xlink:type="arc"/>
      <link:label id="id_1d2f42f6" xlink:label="lbl_label489636598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_label489636598" xlink:type="arc"/>
      <link:label id="id_2702fb61" xlink:label="lbl_label654506849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:to="lbl_label654506849" xlink:type="arc"/>
      <link:label id="id_161f1ca2" xlink:label="lbl_label371137698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cellerys AG, Schlieren [member]</link:label>
      <link:label id="id_6e71caee" xlink:label="lbl_label1852951278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arctos Medical AG, Bern [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ArctosMedicalAGBernMember" xlink:to="lbl_label1852951278" xlink:type="arc"/>
      <link:label id="id_4ab85f4d" xlink:label="lbl_label1253597005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kedalion Therapeutics, Inc., Menlo Park, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:to="lbl_label1253597005" xlink:type="arc"/>
      <link:label id="id_742fae52" xlink:label="lbl_label1949281874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cadent Therapeutics, Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CadentTherapeuticsCambridgeMAMember" xlink:to="lbl_label1949281874" xlink:type="arc"/>
      <link:label id="id_570d756" xlink:label="lbl_label91281238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of bearer shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBearerShares" xlink:to="lbl_label91281238" xlink:type="arc"/>
      <link:label id="id_566fb369" xlink:label="lbl_label1450161001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Committee members who stepped down</link:label>
      <link:label id="id_182b9df6" xlink:label="lbl_label405511670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive committee members who stepped down</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:to="lbl_label405511670" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:to="lbl_label1450161001" xlink:type="arc"/>
      <link:label id="id_10b270a" xlink:label="lbl_label17508106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive committee members</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:to="lbl_label17508106" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:to="lbl_label1424538747" xlink:type="arc"/>
      <link:label id="id_2e777aef" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:type="arc"/>
      <link:label id="id_5d11279b" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold</link:label>
      <link:label id="id_57b96d8e" xlink:label="lbl_label1471769998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease due to revision of prior year amounts [member]</link:label>
      <link:label id="id_16a7a6d4" xlink:label="lbl_label380085972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryRegion" xlink:to="lbl_label380085972" xlink:type="arc"/>
      <link:label id="id_2a46da4c" xlink:label="lbl_label709286476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CityAreaCode" xlink:to="lbl_label709286476" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:to="lbl_label1471769998" xlink:type="arc"/>
      <link:label id="id_618f056b" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:label id="id_9fa0ce0" xlink:label="lbl_label167382240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:to="lbl_label167382240" xlink:type="arc"/>
      <link:label id="id_6b57cec" xlink:label="lbl_label112557292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Promoted Brands [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPromotedBrandsMember" xlink:to="lbl_label112557292" xlink:type="arc"/>
      <link:label id="id_7dc6145f" xlink:label="lbl_label2110133343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pluvicto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PluvictoMember" xlink:to="lbl_label2110133343" xlink:type="arc"/>
      <link:label id="id_2f37d592" xlink:label="lbl_label792188306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scemblix [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScemblixMember" xlink:to="lbl_label792188306" xlink:type="arc"/>
      <link:label id="id_123a75a0" xlink:label="lbl_label305821088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mature Ophtha [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MatureOphthaMember" xlink:to="lbl_label305821088" xlink:type="arc"/>
      <link:label id="id_f65a030" xlink:label="lbl_label258318384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Respiratory [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRespiratoryMember" xlink:to="lbl_label258318384" xlink:type="arc"/>
      <link:label id="id_55b7f134" xlink:label="lbl_label1438118196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contingent consideration liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:to="lbl_label1438118196" xlink:type="arc"/>
      <link:label id="id_1e2fd44" xlink:label="lbl_label31653188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial liabilities at fair value [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label31653188" xlink:type="arc"/>
      <link:label id="id_4cc26a40" xlink:label="lbl_label1287809600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities at fair value [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1287809600" xlink:type="arc"/>
      <link:label id="id_1d3f9d8" xlink:label="lbl_label30669272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:label="lbl_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:to="lbl_label30669272" xlink:type="arc"/>
      <link:label id="id_1f15808c" xlink:label="lbl_label521502860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Hematology [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherHematologyMember" xlink:to="lbl_label521502860" xlink:type="arc"/>
      <link:label id="id_64919d1" xlink:label="lbl_label105454033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Solid Tumor [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSolidTumorMember" xlink:to="lbl_label105454033" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandsAxis" xlink:to="lbl_label436427658" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromotedBrandsMember" xlink:to="lbl_label1796441721" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedBrandsMember" xlink:to="lbl_label478863426" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImmunologyMember" xlink:to="lbl_label359821329" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CardiovascularMember" xlink:to="lbl_label1134680816" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandsMember" xlink:to="lbl_label2113824083" xlink:type="arc"/>
      <link:label id="id_5fe8e377" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred sale price and other adjustments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredSalePriceAndOtherAdjustments" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:type="arc"/>
      <link:label id="id_53b25b83" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Divested business</link:label>
      <link:label id="id_7788c9c4" xlink:label="lbl_label2005453252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, compensation for moral damages</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:to="lbl_label2005453252" xlink:type="arc"/>
      <link:label id="id_5bea283f" xlink:label="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net cash inflows from divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetCashInflowsFromDivestments" xlink:to="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:type="arc"/>
      <link:label id="id_9e5f36a" xlink:label="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_2_Divested business</link:label>
      <link:label id="id_624a7149" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows due to derecognized cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_7dadb6b8" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_3_Divested business</link:label>
      <link:label id="id_365227bd" xlink:label="lbl_label911353789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of assets (other than through business combinations) by assuming directly related liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:to="lbl_label911353789" xlink:type="arc"/>
      <link:label id="id_7e67b1d4" xlink:label="lbl_label2120724948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of assets (right of use assets) through leasing</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:to="lbl_label2120724948" xlink:type="arc"/>
      <link:label id="id_5c839b8c" xlink:label="lbl_label1552128908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of commercial organizational units</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfCommercialOrganizationalUnits" xlink:to="lbl_label1552128908" xlink:type="arc"/>
      <link:label id="id_12b75cc4" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19625a5a" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects</link:label>
      <link:label id="id_3214fdb5" xlink:label="lbl_label840236469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_label840236469" xlink:type="arc"/>
      <link:label id="id_6920b611" xlink:label="lbl_label1763751441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseMember" xlink:to="lbl_label1763751441" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_label1943173648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_label1468995289" xlink:type="arc"/>
      <link:label id="id_4b05579c" xlink:label="lbl_label1258641308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current and current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:to="lbl_label1258641308" xlink:type="arc"/>
      <link:label id="id_423971d8" xlink:label="lbl_label1111060952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets of divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:to="lbl_label1111060952" xlink:type="arc"/>
      <link:label id="id_2ab1410a" xlink:label="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsForNoncashItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:type="arc"/>
      <link:label id="id_4860e3bc" xlink:label="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_7c4df0f8" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:label id="id_4eb8c0a5" xlink:label="lbl_label1320730789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:to="lbl_label1320730789" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:to="lbl_label1965771458" xlink:type="arc"/>
      <link:label id="id_3e695006" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value and remaining amortization period of the most significant assets within currently marketed products [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:to="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4e16bbbd" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value and remaining amortization period of the most significant assets within currently marketed products</link:label>
      <link:label id="id_301c3c1f" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in interest rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_38a5c91d" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in interest rates</link:label>
      <link:label id="id_38fcc081" xlink:label="lbl_label956088449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency translation reserve for net investment hedge, net of taxes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:to="lbl_label956088449" xlink:type="arc"/>
      <link:label id="id_5d2c3af7" xlink:label="lbl_label1563179767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease term end date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseTermEndDate" xlink:to="lbl_label1563179767" xlink:type="arc"/>
      <link:label id="id_218619d0" xlink:label="lbl_label562436560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 100-basis point increase [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical100basisPointIncreaseMember" xlink:to="lbl_label562436560" xlink:type="arc"/>
      <link:label id="id_6fe554fc" xlink:label="lbl_label1877300476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 100-basis point decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical100basisPointDecreaseMember" xlink:to="lbl_label1877300476" xlink:type="arc"/>
      <link:label id="id_d62236b" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate sensitivity impact in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_48b220e" xlink:label="lbl_label76227086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease basis point in interest rate sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:to="lbl_label76227086" xlink:type="arc"/>
      <link:label id="id_188250f1" xlink:label="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets material to entity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsMaterialToEntity" xlink:to="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:type="arc"/>
      <link:label id="id_7df5095a" xlink:label="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value</link:label>
      <link:label id="id_6daa6720" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:type="arc"/>
      <link:label id="id_6b853f8c" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amortisation period</link:label>
      <link:label id="id_2ceac042" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_52fdf5e3" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation other adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_420accaa" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_7c633bc" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_4b13c9e9" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Experience-related remeasurement losses/(gains)</link:label>
      <link:label id="id_821dab6" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_45985738" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income</link:label>
      <link:label id="id_4d969c16" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on changes in effect of limiting net defined benefit asset to asset ceiling excluding interest income or expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:type="arc"/>
      <link:label id="id_7762e663" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus</link:label>
      <link:label id="id_281010e4" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_1e65e677" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_57c0f5b" xlink:label="lbl_EmployeeBenefitsExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployeeBenefitsExpense" xlink:to="lbl_EmployeeBenefitsExpense_labels" xlink:type="arc"/>
      <link:label id="id_7284cb4" xlink:label="lbl_EmployeeBenefitsExpense_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs</link:label>
      <link:label id="id_6c89a7d6" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee share purchase plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_55a47bda" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share purchase plans</link:label>
      <link:label id="id_374e200" xlink:label="lbl_label57991680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:to="lbl_label57991680" xlink:type="arc"/>
      <link:label id="id_4d21bf40" xlink:label="lbl_label1294057280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:to="lbl_label1294057280" xlink:type="arc"/>
      <link:label id="id_7529fd98" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_1cdaf114" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_39b2fbdf" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_1ca9d034" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/Decrease through changes in foreign exchange rates fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_38e9ba3f" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_22acd556" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4738c409" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustments related to divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_357ac9f9" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaS.p.A.MilanMember" xlink:to="lbl_label1462262242" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label1230664587" xlink:type="arc"/>
      <link:label id="id_47bdaceb" xlink:label="lbl_label1203612907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:to="lbl_label1203612907" xlink:type="arc"/>
      <link:label id="id_8a9c069" xlink:label="lbl_label145342569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of interest bearing accounts to beneficiaries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:to="lbl_label145342569" xlink:type="arc"/>
      <link:label id="id_2c032f3e" xlink:label="lbl_label738406206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows from interest bearing accounts of employees payable on demand</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:to="lbl_label738406206" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JSCSandozMoscowMember" xlink:to="lbl_label1334583359" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label1154403316" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:to="lbl_label1468897070" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CellerysAGSchlierenMember" xlink:to="lbl_label371137698" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:to="lbl_label643362133" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:to="lbl_label949145726" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:to="lbl_label56155667" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1APharmaGmbHHolzkirchenMember" xlink:to="lbl_label1515846566" xlink:type="arc"/>
      <link:label id="id_4655e166" xlink:label="lbl_label1410133910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
      <link:label id="id_7cb5c64" xlink:label="lbl_label345068222" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_6bca1932" xlink:label="lbl_label1064847955" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_447ba916" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, interest cost</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_DefinedBenefitPlanInterestCost_labels" xlink:type="arc"/>
      <link:label id="id_5799a148" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_label1410133910" xlink:type="arc"/>
      <link:label id="id_469b45e" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administration costs not reflected in return on plan assets, defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_181c98c6" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label345068222" xlink:type="arc"/>
      <link:label id="id_1115ed8d" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income, defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1749266f" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_label1064847955" xlink:type="arc"/>
      <link:label id="id_60426bce" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares each representing 1 share [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:type="arc"/>
      <link:label id="id_12cd80ee" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares each representing 1 share</link:label>
      <link:label id="id_7ca4bc9d" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value CHF 0.50 per share [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:type="arc"/>
      <link:label id="id_6d66b543" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value CHF 0.50 per share*</link:label>
      <link:label id="id_49b6063d" xlink:label="lbl_label1236665917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Security12bTitle" xlink:to="lbl_label1236665917" xlink:type="arc"/>
      <link:label id="id_385a1eff" xlink:label="lbl_label945430271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecurityExchangeName" xlink:to="lbl_label945430271" xlink:type="arc"/>
      <link:label id="id_4d772ce7" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_3875ffaa" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, total financial investments</link:label>
      <link:label id="id_78a9e94a" xlink:label="lbl_label2024401226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of reasons for transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_label2024401226" xlink:type="arc"/>
   </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nvs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityTables" xlink:href="nvs-20221231.xsd#disclosureEquityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesTables" xlink:href="nvs-20221231.xsd#disclosureInventoriesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:href="nvs-20221231.xsd#disclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesTables" xlink:href="nvs-20221231.xsd#disclosureTaxesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEvents" xlink:href="nvs-20221231.xsd#disclosureSubsequentEvents" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingencies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedParties" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinesses" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatements" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebt" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquity" xlink:href="nvs-20221231.xsd#disclosureEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecurities" xlink:href="nvs-20221231.xsd#disclosureMarketableSecurities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivables" xlink:href="nvs-20221231.xsd#disclosureTradeReceivables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventories" xlink:href="nvs-20221231.xsd#disclosureInventories" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:href="nvs-20221231.xsd#disclosureRightOfUseAssetsAndLeaseLiability" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipment" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShare" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShare" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxes" xlink:href="nvs-20221231.xsd#disclosureTaxes" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompanies" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactions" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactions" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFigures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:href="nvs-20221231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:href="nvs-20221231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:href="nvs-20221231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorLocation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorFirmId" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFileNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityIncorporationStateCountryCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressAddressLine1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCityOrTown" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressPostalZipCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCountry" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentRegistrationStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAccountingStandard" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_EntityAddressesAddressTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_BusinessContactMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_LocalPhoneNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelFaxNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:presentationArc order="26.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CountryRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:presentationArc order="26.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CityAreaCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_DocumentInformationLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_Security12bTitle" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems1" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems1" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_SecurityExchangeName" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="5.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="5.92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="13.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_EarningsPerShareLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.65" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:presentationArc order="5.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:presentationArc order="19.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:presentationArc order="19.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:presentationArc order="17.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="17.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="2.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.75" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_Commodities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:presentationArc order="32.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="39.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="40.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:presentationArc order="41.5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="31.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="35.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="36.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="37.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="24.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="34.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="38.45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="38.35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:presentationArc order="39.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="37.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:presentationArc order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="20.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:presentationArc order="19.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="27.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="26.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_StatementOfChangesInEquityLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems1" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:presentationArc order="10.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems2" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems2" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:presentationArc order="10.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="9.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="6.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="6.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="8.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="9.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="10.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="7.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward1" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:presentationArc order="3.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:presentationArc order="3.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:presentationArc order="2.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:presentationArc order="3.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="59.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="61.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="63.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="65.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:presentationArc order="67.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:presentationArc order="76.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="77.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="78.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:presentationArc order="79.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="80.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="81.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:presentationArc order="82.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:presentationArc order="83.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:presentationArc order="84.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:presentationArc order="85.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:presentationArc order="86.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="87.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:presentationArc order="88.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:presentationArc order="89.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="90.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="91.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:presentationArc order="92.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="93.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="94.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="95.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="96.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:presentationArc order="97.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="98.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:presentationArc order="99.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="100.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_JSCSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="101.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="102.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="103.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="104.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:presentationArc order="105.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="106.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="107.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:presentationArc order="108.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:presentationArc order="109.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="110.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="111.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="112.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:presentationArc order="113.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="114.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:presentationArc order="115.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:presentationArc order="116.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="117.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="118.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="119.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="120.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="121.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="122.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:presentationArc order="123.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="124.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="125.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="126.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="127.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="128.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:presentationArc order="129.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:presentationArc order="130.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="131.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:presentationArc order="132.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CellerysAGSchlierenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:presentationArc order="133.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ArctosMedicalAGBernMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="134.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="135.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="136.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="137.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:presentationArc order="138.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="139.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="140.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="141.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="142.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:presentationArc order="143.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:presentationArc order="144.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:presentationArc order="145.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="146.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="147.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="148.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:presentationArc order="149.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="150.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="151.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="152.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="153.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="154.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="155.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="156.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="157.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="158.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:presentationArc order="159.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:presentationArc order="160.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="161.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="162.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="163.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="164.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:presentationArc order="165.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="166.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="167.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:presentationArc order="168.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:presentationArc order="169.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="170.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="171.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:presentationArc order="172.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:presentationArc order="173.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:presentationArc order="174.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:presentationArc order="175.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="176.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="177.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="178.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:presentationArc order="179.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="180.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:presentationArc order="181.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="182.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:presentationArc order="183.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="184.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="185.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="186.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="187.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="188.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="189.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="190.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="191.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="192.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:presentationArc order="193.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="194.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="195.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:presentationArc order="196.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="197.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="198.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="199.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:presentationArc order="200.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="201.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="202.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="203.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="204.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:presentationArc order="205.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:presentationArc order="206.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:presentationArc order="207.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:presentationArc order="208.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="209.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:presentationArc order="210.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:presentationArc order="211.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:presentationArc order="212.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:presentationArc order="213.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:presentationArc order="214.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="215.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="216.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="217.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:presentationArc order="218.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="219.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="220.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="221.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="222.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="223.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="224.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="225.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="226.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="227.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="228.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="229.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="230.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="231.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="232.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:presentationArc order="233.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:presentationArc order="234.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:presentationArc order="235.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:presentationArc order="236.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:presentationArc order="237.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:presentationArc order="238.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:presentationArc order="239.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="240.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:presentationArc order="241.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:presentationArc order="242.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:presentationArc order="243.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:presentationArc order="244.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="245.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="246.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="247.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:presentationArc order="248.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:presentationArc order="249.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="250.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="251.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="252.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="253.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="254.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:presentationArc order="255.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="256.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="257.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="258.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="259.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="260.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="261.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="262.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="263.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="264.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:presentationArc order="265.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="266.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="267.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:presentationArc order="268.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="269.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="270.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="271.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="272.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="273.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:presentationArc order="274.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:presentationArc order="275.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:presentationArc order="276.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:presentationArc order="277.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="278.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="279.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="280.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="281.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="282.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="283.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="284.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:presentationArc order="285.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="286.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="287.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="288.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:presentationArc order="289.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="290.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="291.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="292.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="293.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="294.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="3.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="-0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:presentationArc order="11.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="25.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:presentationArc order="4.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:presentationArc order="5.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:presentationArc order="5.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_EmployeeBenefitsExpense" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="2.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:presentationArc order="2.68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.69" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="2.695" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="2.77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="2.66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_NetInvestmentHedgeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="4.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:presentationArc order="14.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:presentationArc order="4.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="1.2" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:presentationArc order="5.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember1" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward1" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_EnvironmentalProvisionRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:presentationArc order="0.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis1" xlink:type="locator"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseAxis1" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:presentationArc order="3.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="8.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="8.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:presentationArc order="7.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:presentationArc order="8.67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="8.51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="8.46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="8.63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="8.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="8.77" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:presentationArc order="8.87" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchasesValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharepurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherShareSalesEquityImpact" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="11.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="11.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="13.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="3.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:presentationArc order="1.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MatureOphthaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="0.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="13.99955" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherSolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="0.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="0.97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="0.98" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:presentationArc order="0.99" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:presentationArc order="0.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="0.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="0.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="0.999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:presentationArc order="0.9995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:presentationArc order="0.9997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:presentationArc order="0.9998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PluvictoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:presentationArc order="0.9999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="0.99995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="1.35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:presentationArc order="1.37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ScemblixMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherHematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="1.39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:presentationArc order="1.395" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.397" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:presentationArc order="1.398" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.399" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherRespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="1.3995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.3997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="1.3998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.3999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.39995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="1.39997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="1.39998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="1.39999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="1.399995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="1.399997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:presentationArc order="1.399998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContractManufacturingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.399999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOptionsRepurchased" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="7.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityOfNetDebtLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:presentationArc order="5.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="6.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:presentationArc order="7.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:presentationArc order="8.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="10.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:presentationArc order="11.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="9.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:presentationArc order="4.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:presentationArc order="9.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="11.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="2.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="0.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="7.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="8.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="0.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="11.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:presentationArc order="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="0.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="0.57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="0.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="0.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="0.87" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="0.88" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="0.92" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="0.93" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="0.94" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.945" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="0.947" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.948" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.949" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="0.9495" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:presentationArc order="-2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:presentationArc order="-1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="-1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="-1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseTermEndDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:presentationArc order="2.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="5.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactions" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxes" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShare" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_DisclosureOfLeasesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventories" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfInventoriesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecurities" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquity" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DisclosureOfEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEvents" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_InterestExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareslTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DividendTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:presentationArc order="59.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="63.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="65.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="67.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="76.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="77.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="78.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:presentationArc order="79.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="80.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:presentationArc order="81.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBearerShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="82.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:presentationArc order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:presentationArc order="22.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="26.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherNetCashInflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsMaterialToEntity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
   </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>nvs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nvs="http://novartis.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" blockDefault="" elementFormDefault="qualified" finalDefault="" targetNamespace="http://novartis.com/20221231">
   <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
   <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
   <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
   <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
   <xsd:annotation>
      <xsd:appinfo>

      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
	  <link:roleType id="documentAndEntityInformation" roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation">
            <link:definition>0001000 - Document - Document and Entity Information</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncome" roleURI="http://novartis.com/20221231/role/StatementOfIncome">
            <link:definition>1001000 - Statement - Consolidated income statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncome" roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome">
            <link:definition>1002000 - Statement - Consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfChangesInEquity" roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity">
            <link:definition>1004000 - Statement - Consolidated statements of changes in equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="balanceSheet" roleURI="http://novartis.com/20221231/role/BalanceSheet">
            <link:definition>1003000 - Statement - Consolidated balance sheets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlow" roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow">
            <link:definition>1005000 - Statement - Consolidated cash flow statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails">
            <link:definition>2400900 - Disclosure - Property, plant and equipment (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails2" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2">
            <link:definition>2400901 - Disclosure - Property, plant and equipment (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipment" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment">
            <link:definition>2100900 - Disclosure - Property, plant and equipment</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentTables" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables">
            <link:definition>2300900 - Disclosure - Property, plant and equipment (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventories" roleURI="http://novartis.com/20221231/role/DisclosureInventories">
            <link:definition>2101400 - Disclosure - Inventories</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesTables" roleURI="http://novartis.com/20221231/role/DisclosureInventoriesTables">
            <link:definition>2301400 - Disclosure - Inventories (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesDetails" roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails">
            <link:definition>2401400 - Disclosure - Inventories (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShare" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShare">
            <link:definition>2100700 - Disclosure - Earnings per share</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareTables" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables">
            <link:definition>2300700 - Disclosure - Earnings per share (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareDetails" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails">
            <link:definition>2400700 - Disclosure - Earnings per share (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPolicies" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies">
            <link:definition>2100100 - Disclosure - Significant accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpense" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense">
            <link:definition>2100500 - Disclosure - Interest expense and other financial income and expense</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxes" roleURI="http://novartis.com/20221231/role/DisclosureTaxes">
            <link:definition>2100600 - Disclosure - Income taxes</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssets" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets">
            <link:definition>2101100 - Disclosure - Goodwill and intangible assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities">
            <link:definition>2101200 - Disclosure - Deferred tax assets and liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
            <link:definition>2200100 - Disclosure - Significant accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
            <link:definition>2300100 - Disclosure - Significant accounting policies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables">
            <link:definition>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables">
            <link:definition>2301100 - Disclosure - Goodwill and intangible assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables">
            <link:definition>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails">
            <link:definition>2400100 - Disclosure - Significant accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails">
            <link:definition>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2">
            <link:definition>2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesTables" roleURI="http://novartis.com/20221231/role/DisclosureTaxesTables">
            <link:definition>2300600 - Disclosure - Income taxes (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails">
            <link:definition>2400600 - Disclosure - Income taxes (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2">
            <link:definition>2400601 - Disclosure - Income taxes (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3">
            <link:definition>2400602 - Disclosure - Income taxes (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails">
            <link:definition>2401100 - Disclosure - Goodwill and intangible assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2">
            <link:definition>2401101 - Disclosure - Goodwill and intangible assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails">
            <link:definition>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4">
            <link:definition>2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails2">
            <link:definition>2400101 - Disclosure - Significant accounting policies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssets" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets">
            <link:definition>2101300 - Disclosure - Financial and other non-current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables">
            <link:definition>2301300 - Disclosure - Financial and other non-current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails">
            <link:definition>2401300 - Disclosure - Financial and other non-current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2">
            <link:definition>2401301 - Disclosure - Financial and other non-current assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3">
            <link:definition>2401302 - Disclosure - Financial and other non-current assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssets" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets">
            <link:definition>2101700 - Disclosure - Other current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables">
            <link:definition>2301700 - Disclosure - Other current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails">
            <link:definition>2401700 - Disclosure - Other current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecurities" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecurities">
            <link:definition>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesTables" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables">
            <link:definition>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails">
            <link:definition>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebt" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt">
            <link:definition>2101900 - Disclosure - Non-current financial debt</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactions" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactions">
            <link:definition>2100200 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments">
            <link:definition>2102100 - Disclosure - Current financial debt and derivative financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingencies" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies">
            <link:definition>2102800 - Disclosure - Commitments and contingencies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails">
            <link:definition>2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtTables" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables">
            <link:definition>2301900 - Disclosure - Non-current financial debt (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables">
            <link:definition>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesTables" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables">
            <link:definition>2302800 - Disclosure - Commitments and contingencies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails">
            <link:definition>2400200 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails">
            <link:definition>2401900 - Disclosure - Non-current financial debt (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails2" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2">
            <link:definition>2401901 - Disclosure - Non-current financial debt (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails3" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3">
            <link:definition>2401902 - Disclosure - Non-current financial debt (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails4" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4">
            <link:definition>2401903 - Disclosure - Non-current financial debt (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails5" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5">
            <link:definition>2401904 - Disclosure - Non-current financial debt (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails6" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6">
            <link:definition>2401905 - Disclosure - Non-current financial debt (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails">
            <link:definition>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails">
            <link:definition>2402800 - Disclosure - Commitments and contingencies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2">
            <link:definition>2402801 - Disclosure - Commitments and contingencies (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEvents" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEvents">
            <link:definition>2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureProvisionsAndOtherCurrentLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities">
            <link:definition>2102200 - Disclosure - Provisions and other current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinesses" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses">
            <link:definition>2102400 - Disclosure - Acquisitions of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociates" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates">
            <link:definition>2102500 - Disclosure - Post-employment benefits for employees</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables">
            <link:definition>2302200 - Disclosure - Provisions and other current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesTables" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables">
            <link:definition>2302400 - Disclosure - Acquisitions of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesTables" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables">
            <link:definition>2302500 - Disclosure - Post-employment benefits for employees (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails">
            <link:definition>2402200 - Disclosure - Provisions and other current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2">
            <link:definition>2402201 - Disclosure - Provisions and other current liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3">
            <link:definition>2402202 - Disclosure - Provisions and other current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesDetails" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails">
            <link:definition>2402400 - Disclosure - Acquisitions of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails">
            <link:definition>2402500 - Disclosure - Post-employment benefits for employees (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails2" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2">
            <link:definition>2402501 - Disclosure - Post-employment benefits for employees (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails3" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3">
            <link:definition>2402502 - Disclosure - Post-employment benefits for employees (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails4" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4">
            <link:definition>2402503 - Disclosure - Post-employment benefits for employees (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails5" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5">
            <link:definition>2402504 - Disclosure - Post-employment benefits for employees (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails6" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6">
            <link:definition>2402505 - Disclosure - Post-employment benefits for employees (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails7" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7">
            <link:definition>2402506 - Disclosure - Post-employment benefits for employees (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails8" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8">
            <link:definition>2402507 - Disclosure - Post-employment benefits for employees (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails9" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9">
            <link:definition>2402508 - Disclosure - Post-employment benefits for employees (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails10" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10">
            <link:definition>2402509 - Disclosure - Post-employment benefits for employees (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3">
            <link:definition>2401502 - Disclosure - Trade receivables (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2">
            <link:definition>2401501 - Disclosure - Trade receivables (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails">
            <link:definition>2401500 - Disclosure - Trade receivables (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesTables" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables">
            <link:definition>2301500 - Disclosure - Trade receivables (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivables" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivables">
            <link:definition>2101500 - Disclosure - Trade receivables</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4">
            <link:definition>2401503 - Disclosure - Trade receivables (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5">
            <link:definition>2401504 - Disclosure - Trade receivables (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies">
            <link:definition>2103100 - Disclosure - Principal Group subsidiaries and associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables">
            <link:definition>2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails">
            <link:definition>2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails2">
            <link:definition>2403001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails">
            <link:definition>2403000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTables" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsTables">
            <link:definition>2303000 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperations" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperations">
            <link:definition>2103000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4">
            <link:definition>2402304 - Disclosure - Details to the consolidated cash flow statements (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3">
            <link:definition>2402303 - Disclosure - Details to the consolidated cash flow statements (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2">
            <link:definition>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails">
            <link:definition>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsTables" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables">
            <link:definition>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatements" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements">
            <link:definition>2102300 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFigures" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures">
            <link:definition>2100300 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompanies" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompanies">
            <link:definition>2100400 - Disclosure - Associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome">
            <link:definition>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities">
            <link:definition>2102000 - Disclosure - Provisions and other non-current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociates" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates">
            <link:definition>2102600 - Disclosure - Equity-based participation plans for employees</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedParties" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties">
            <link:definition>2102700 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosures" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures">
            <link:definition>2102900 - Disclosure - Financial instruments - additional disclosures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTables" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables">
            <link:definition>2300300 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesTables" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables">
            <link:definition>2300400 - Disclosure - Associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables">
            <link:definition>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables">
            <link:definition>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesTables" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables">
            <link:definition>2302600 - Disclosure - Equity-based participation plans for employees (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesTables" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables">
            <link:definition>2302700 - Disclosure - Transactions with related parties (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresTables" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables">
            <link:definition>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails">
            <link:definition>2400300 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails">
            <link:definition>2400400 - Disclosure - Associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails">
            <link:definition>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4">
            <link:definition>2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails">
            <link:definition>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails">
            <link:definition>2402600 - Disclosure - Equity-based participation plans for employees (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2">
            <link:definition>2402601 - Disclosure - Equity-based participation plans for employees (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3">
            <link:definition>2402602 - Disclosure - Equity-based participation plans for employees (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4">
            <link:definition>2402603 - Disclosure - Equity-based participation plans for employees (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5">
            <link:definition>2402604 - Disclosure - Equity-based participation plans for employees (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6">
            <link:definition>2402605 - Disclosure - Equity-based participation plans for employees (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails7" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails7">
            <link:definition>2402606 - Disclosure - Equity-based participation plans for employees (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails8" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails8">
            <link:definition>2402607 - Disclosure - Equity-based participation plans for employees (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails9" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails9">
            <link:definition>2402608 - Disclosure - Equity-based participation plans for employees (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails">
            <link:definition>2041200 - Disclosure - Transactions with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2">
            <link:definition>2402701 - Disclosure - Transactions with related parties (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3">
            <link:definition>2402702 - Disclosure - Transactions with related parties (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails">
            <link:definition>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3">
            <link:definition>2401102 - Disclosure - Goodwill and intangible assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4">
            <link:definition>2401104 - Disclosure - Goodwill and intangible assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSegmentationOfKeyFiguresDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2">
            <link:definition>2400302 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3">
            <link:definition>2400303 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4">
            <link:definition>2400304 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5">
            <link:definition>2400305 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6">
            <link:definition>2400306 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7">
            <link:definition>2400308 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails2">
            <link:definition>2400401 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3">
            <link:definition>2400401 - Disclosure - Associated companies (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails4">
            <link:definition>2400403 - Disclosure - Associated companies (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails5">
            <link:definition>2400404 - Disclosure - Associated companies (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6">
            <link:definition>2400402 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2">
            <link:definition>2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3">
            <link:definition>2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4">
            <link:definition>2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5">
            <link:definition>2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6">
            <link:definition>2402005 - Disclosure - Provisions and other non-current liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquity" roleURI="http://novartis.com/20221231/role/DisclosureEquity">
            <link:definition>2101800 - Disclosure - Equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityTables" roleURI="http://novartis.com/20221231/role/DisclosureEquityTables">
            <link:definition>2301800 - Disclosure - Equity (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails">
            <link:definition>2401800 - Disclosure - Equity (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails2" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2">
            <link:definition>2401801 - Disclosure - Equity (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails3" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3">
            <link:definition>2401802 - Disclosure - Equity (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails4" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails4">
            <link:definition>2401803 - Disclosure - Equity (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlowParenthetical" roleURI="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical">
            <link:definition>1005010 - Statement - Consolidated cash flow statements (Parenthetical)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails1" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1">
            <link:definition>2400301 - Disclosure - Segmentation of key figures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails5" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5">
            <link:definition>2401804 - Disclosure - Equity (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5">
            <link:definition>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2">
            <link:definition>2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3">
            <link:definition>2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4">
            <link:definition>2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:labelLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5">
            <link:definition>2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6">
            <link:definition>2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7">
            <link:definition>2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8">
            <link:definition>2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9">
            <link:definition>2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10">
            <link:definition>2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11">
            <link:definition>2402916 - Disclosure - Financial instruments - additional disclosures (Details 16)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12">
            <link:definition>2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13">
            <link:definition>2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5">
            <link:definition>2401203 - Disclosure - Deferred tax assets and liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails3">
            <link:definition>2400102 - Disclosure - Significant accounting policies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureBasisOfPreparationQ" roleURI="http://novartis.com/20221231/role/DisclosureBasisOfPreparationQ">
            <link:definition>2010100 - Disclosure - Basis of preparation</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesQ">
            <link:definition>2010200 - Disclosure - Selected critical accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsQ">
            <link:definition>2010300 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersQ">
            <link:definition>2010400 - Disclosure - Summary of equity attributable to Novartis AG shareholders</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsQ">
            <link:definition>2010500 - Disclosure - Financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLegalProceedingsUpdateQ" roleURI="http://novartis.com/20221231/role/DisclosureLegalProceedingsUpdateQ">
            <link:definition>2010800 - Disclosure - Legal proceedings update</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsQ">
            <link:definition>2102900 - Disclosure - Impacts of adoption of new IFRS standards</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsQ" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsQ">
            <link:definition>2011100 - Disclosure - Subsequent events</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresQ">
            <link:definition>2010900 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesPoliciesQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ">
            <link:definition>2020200 - Disclosure - Selected critical accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersTablesQ">
            <link:definition>2030400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsTablesQ">
            <link:definition>2030500 - Disclosure - Financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ">
            <link:definition>2302900 - Disclosure - Impacts of adoption of new IFRS standards (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTablesQ">
            <link:definition>2031000 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesDetailsQ">
            <link:definition>2040200 - Disclosure - Selected critical accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetailsQ">
            <link:definition>2040300 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersDetailsQ">
            <link:definition>2040400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetailsQ">
            <link:definition>2040500 - Disclosure - Financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails2Q">
            <link:definition>2040501 - Disclosure - Financial instruments (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ">
            <link:definition>2402900 - Disclosure - Impacts of adoption of new IFRS standards (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q">
            <link:definition>2402901 - Disclosure - Impacts of adoption of new IFRS standards (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetailsQ">
            <link:definition>2040900 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2Q">
            <link:definition>2040901 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3Q">
            <link:definition>2040902 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4Q">
            <link:definition>2040903 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5Q">
            <link:definition>2040904 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6Q">
            <link:definition>2040905 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7Q">
            <link:definition>2040906 - Disclosure - Segmentation of key figures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8Q">
            <link:definition>2040907 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails9Q">
            <link:definition>2040908 - Disclosure - Segmentation of key figures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q">
            <link:definition>2402902 - Disclosure - Impacts of adoption of new IFRS standards (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q">
            <link:definition>2402903 - Disclosure - Impacts of adoption of new IFRS standards (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails3Q">
            <link:definition>2040502 - Disclosure - Financial instruments (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails4Q">
            <link:definition>2040503 - Disclosure - Financial instruments (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1">
            <link:definition>2402700 - Disclosure - Transaction with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q">
            <link:definition>2402904 - Disclosure - Impacts of adoption of new IFRS standards (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetailsQ">
            <link:definition>2011100 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8">
            <link:definition>2400310 - Disclosure - Segmentation of key figures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails9">
            <link:definition>2400312 - Disclosure - Segmentation of key figures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10">
            <link:definition>2400311 - Disclosure - Segmentation of key figures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDisposalGroupHeldForSaleDetails" roleURI="http://novartis.com/20221231/role/DisclosureDisposalGroupHeldForSaleDetails">
            <link:definition>2400202 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14">
            <link:definition>2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTables" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables">
            <link:definition>2300200 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails11" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11">
            <link:definition>2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails12" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12">
            <link:definition>2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6">
            <link:definition>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsQ">
            <link:definition>2011000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsQ">
            <link:definition>2010600 - Disclosure - Lease liabilities and right-of-use assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ">
            <link:definition>2010600 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTablesQ">
            <link:definition>2030300 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsTablesQ">
            <link:definition>2030600 - Disclosure - Lease liability and Right-of-use assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ">
            <link:definition>2030600 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsTablesQ">
            <link:definition>2031100 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ">
            <link:definition>2040600 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q">
            <link:definition>2040601 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q">
            <link:definition>2040602 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q">
            <link:definition>2040603 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails1Q">
            <link:definition>2040301 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetailsQ">
            <link:definition>2041000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ">
            <link:definition>2040600 - Disclosure - Details to the consolidated statements of cash flows (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q">
            <link:definition>2040601 - Disclosure - Details to the consolidated statements of cash flows (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesQ">
            <link:definition>2010700 - Disclosure - Acquisition of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesTablesQ">
            <link:definition>2030800 - Disclosure - Acquisition of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesDetailsQ">
            <link:definition>2040701 - Disclosure - Acquisition of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails1Q">
            <link:definition>2041001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails2Q">
            <link:definition>2041002 - Disclosure - Discontinued operations (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q">
            <link:definition>2040604 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q">
            <link:definition>2040605 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSignificantTransactionsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2Q">
            <link:definition>2040302 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails3Q">
            <link:definition>2041003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiability" roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability">
            <link:definition>2101000 - Disclosure - Right-of-use assets and lease liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiabilityTables" roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables">
            <link:definition>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2">
            <link:definition>2400201 - Disclosure - Significant transactions (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails3">
            <link:definition>2403005 - Disclosure - Discontinued operations (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails4">
            <link:definition>2403003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2">
            <link:definition>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4">
            <link:definition>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5">
            <link:definition>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6">
            <link:definition>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403004 - Disclosure - Discontinued operations (Details 5)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails6">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403002 - Disclosure - Discontinued operations (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401006 - Disclosure - Lease liability and Right-of-use assets (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403006 - Disclosure - Discontinued operations (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails8" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403007 - Disclosure - Discontinued operations (Details 8)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040602 - Disclosure - Details to the consolidated statements of cash flows (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040702 - Disclosure - Acquisition of businesses (Details 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040800 - Disclosure - Provisions and other non-current liabilities (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails9" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails9">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403008 - Disclosure - Discontinued operations (Details 9)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403001 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details 1)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncomeCalc2" roleURI="http://novartis.com/20221231/role/StatementOfIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1001000 - Statement - Consolidated income statements (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncomeCalc2" roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1002000 - Statement - Consolidated statements of comprehensive income (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesQ" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesQ">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2011000 - Disclosure - Commitments and contingencies</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetailsQ">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2041000 - Disclosure - Commitments and contingencies (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails8" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040909 - Disclosure - Segmentation of key figures (Details 10)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402914 - Disclosure - Financial instruments - additional disclosures (Details 14)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401103 - Disclosure - Goodwill and intangible assets (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType></xsd:appinfo>
   </xsd:annotation>
   <xsd:element abstract="true" id="nvs_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" name="NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_StatementTable" name="StatementTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StatementLineItems" name="StatementLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentTableTextBlock" name="PropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesDisclosureAbstract" name="InventoriesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfInventoryCurrentTableTextBlock" name="ScheduleOfInventoryCurrentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryCurrentTable" name="InventoryCurrentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryAxis" name="InventoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryMember" name="InventoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryRawMaterialsGrossMember" name="InventoryRawMaterialsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryWorkInProgressGrossMember" name="InventoryWorkInProgressGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryFinishedGoodsGrossMember" name="InventoryFinishedGoodsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryLineItems" name="InventoryLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" name="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" name="DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" name="AssumptionsUsedInTheCalculationOfValuationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" name="AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfIncomeTaxAbstract" name="DisclosureOfIncomeTaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeBeforeTaxesTableTextBlock" name="IncomeBeforeTaxesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" name="CurrentAndDeferredIncomeTaxExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AnalysisOfTaxRateTableTextBlock" name="AnalysisOfTaxRateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" name="DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseTableTextBlock" name="InterestExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherFinancialIncomeAndExpenseTableTextBlock" name="OtherFinancialIncomeAndExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" name="RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FurnitureAndVehiclesMember" name="FurnitureAndVehiclesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketingRelatedIntangibleAssetsMember" name="MarketingRelatedIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentlyMarketedProductsMember" name="CurrentlyMarketedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationAxis" name="IncomeStatementLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationMember" name="IncomeStatementLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesOrResearchAndDevelopmentMember" name="CostOfSalesOrResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestExpenseAbstract" name="InterestExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialIncomeAndExpenseAbstract" name="OtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeOnForwardContractsAndOptions" name="IncomeOnForwardContractsAndOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfCreditsAndAllowances" name="TaxRateEffectOfCreditsAndAllowances" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" name="TaxRateEffectOfWriteOffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" name="TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromBenefitsExpiring" name="TaxRateEffectFromBenefitsExpiring" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateContinuingOperations" name="AverageEffectiveTaxRateContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateDiscontinuedOperations" name="AverageEffectiveTaxRateDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" name="PensionsAndOtherBenefitObligationsOfAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesMember" name="InventoriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TaxLossCarryforwardsMember" name="TaxLossCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" name="IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" name="OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InvestmentsInSubsidiariesMember" name="InvestmentsInSubsidiariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GoodwillFromAcquisitionsMember" name="GoodwillFromAcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentAxis" name="BalanceSheetTreatmentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentMember" name="BalanceSheetTreatmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CapitalizedMember" name="CapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NotCapitalizedMember" name="NotCapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryAxis" name="YearOfExpiryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryMember" name="YearOfExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OneYearMember" name="OneYearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TwoYearsMember" name="TwoYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThreeYearsMember" name="ThreeYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FourYearsMember" name="FourYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FiveYearsMember" name="FiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MoreThanFiveYearsMember" name="MoreThanFiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueOfTaxLossCarryforwardsExpired" name="ValueOfTaxLossCarryforwardsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" name="UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" name="ProvisionForIncomeTaxesOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" name="DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" name="DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsTableTextBlock" name="DisclosureOfFinancialAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" name="DisclosureOfOtherNoncurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" name="DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherCurrentAssetsTableTextBlock" name="OtherCurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WithholdingTaxRecoverable" name="WithholdingTaxRecoverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesAssociatedCompanies" name="CurrentPrepaidExpensesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAssociatedCompanies" name="ReceivablesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherReceivablesAndCurrentAssets" name="OtherReceivablesAndCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" name="MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsTableTextBlock" name="CashAndCashEquivalentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FundInstrumentsHeld" name="FundInstrumentsHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DebtSecuritiesDenominationsAbstract" name="DebtSecuritiesDenominationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementInDeferredTaxBalanceRollForward" name="MovementInDeferredTaxBalanceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivable" name="ContingentConsiderationReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfOtherNoncurrentAssetsAbstract" name="DisclosureOfOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredCompensationPlansAssets" name="DeferredCompensationPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidPostemploymentBenefitPlansAssets" name="PrepaidPostemploymentBenefitPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseProvision" name="FinanceLeaseProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareCapitalTableTextBlock" name="MovementInTheShareCapitalTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareslTableTextBlock" name="MovementInTheShareslTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypAxis" name="SubsequentEventTypAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypeMember" name="SubsequentEventTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventMember" name="SubsequentEventMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" name="DisclosureOfCommitmentsAndContingenciesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfSignificantTransactionsAbstract" name="DisclosureOfSignificantTransactionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfSignificantTransactionsTextBlock" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" name="DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" name="DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" name="DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" name="DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLeasingCommitmentsTableTextBlock" name="DisclosureOfLeasingCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" name="DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeasingCommitmentsAbstract" name="LeasingCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ResearchAndDevelopmentCommitmentsAbstract" name="ResearchAndDevelopmentCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" name="ScheduleForCommitmentsUnderResearchAndDevelopmentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" name="ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsUnderLongtermResearchAgreements" name="CommitmentsUnderLongtermResearchAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" name="InterestBearningAccountsOfAssociatesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="LaterThanFiveYearsAndNotLaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanSixYearsMember" name="LaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialDebtsCoveredByCollateral" name="NoncurrentFinancialDebtsCoveredByCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" name="A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" name="A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" name="A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsLender" name="BorrowingsLender" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsPremiumDiscount" name="BorrowingsPremiumDiscount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherNoncurrentFinancialDebt" name="OtherNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisAxis" name="FairValueByMeasurementBasisAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisMember" name="FairValueByMeasurementBasisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CarryingReportedAmountFairValueDisclosureMember" name="CarryingReportedAmountFairValueDisclosureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueDisclosureItemAmountsMember" name="FairValueDisclosureItemAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" name="OtherComprehensiveIncomeNetOfTaxFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" name="IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRelatedToDivestments" name="FairValueAdjustmentsRelatedToDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" name="PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" name="ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" name="ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" name="CashFlowsBeforeWorkingCapitalAndProvisionChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" name="A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsIssuanceDate" name="BorrowingsIssuanceDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrencyOthersMember" name="CurrencyOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OperatingIncomeMember" name="OperatingIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalIncMember" name="TranscendMedicalIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelexysPharmaceuticalsCorporationMember" name="SelexysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedMember" name="ZiarcoGroupLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionIncMember" name="EncoreVisionIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EliLillyAndCompanyMember" name="EliLillyAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKOncologyProductsMember" name="GSKOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKVaccinesMember" name="GSKVaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKTotalTransactionMember" name="GSKTotalTransactionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexMember" name="SpinifexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdmuneTheraputicsMember" name="AdmuneTheraputicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfAcquisitionOfBusinessesAbstract" name="DisclosureOfAcquisitionOfBusinessesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForReductionOfRevenueTableTextBlock" name="ProvisionsForReductionOfRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionsMovementsTableTextBlock" name="RestructuringProvisionsMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" name="DisclosureOfDefinedBenefitPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" name="DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" name="BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssumptionsUsedTableTextBlock" name="ScheduleOfAssumptionsUsedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" name="ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" name="ScheduleOfHealthCareCostTrendRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" name="ScheduleOfAllocationOfPlanAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" name="ScheduleOfExpectedBenefitPaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" name="AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PotentiallyRefundableConsiderationFromAcquisition" name="PotentiallyRefundableConsiderationFromAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueOfAcquireeFullYear" name="RevenueOfAcquireeFullYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" name="SaleOfBusinessContingentOptionArrangementsFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfVotingEquityInterestsContributed" name="PercentageOfVotingEquityInterestsContributed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCosts" name="TransactionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCostsPaid" name="TransactionRelatedCostsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" name="ProvisionsAndOtherCurrentLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" name="AccrualForTaxesOtherThanIncomeTaxesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" name="AccruedRoyaltiesPayableClassifiedAsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionsForDeductionsFromRevenueRollForward" name="ProvisionsForDeductionsFromRevenueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInOffsetAgainstGrossTradeReceivables" name="ChangesInOffsetAgainstGrossTradeReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsRollForward" name="RestructuringProvisionsMovementsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTradeReceivablesAbstract" name="DisclosureOfTradeReceivablesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" name="DisclosureOfTradeReceivablesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForTradeReceivablesTableTextBlock" name="ProvisionsForTradeReceivablesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesProvisionMovementsTableTextBlock" name="TradeReceivablesProvisionMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" name="OverdueAmountsAndRelatedProvisionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" name="TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsTable" name="AnalysisOfOverdueAmountsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsLineItems" name="AnalysisOfOverdueAmountsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" name="DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" name="CurrentTradeReceivablesFromCloselyMonitoredCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" name="PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharePaidinCapital" name="SharePaidinCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisArgentinaS.A.BuenosAiresMember" name="NovartisArgentinaS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.BuenosAiresMember" name="AlconLaboratoriosS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGBaselMember" name="RocheHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConcentrationOfMajorPlansGeographic" name="ConcentrationOfMajorPlansGeographic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" name="DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeAxis" name="RetirementPlanTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeMember" name="RetirementPlanTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionPlanMember" name="PensionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPostemploymentBenefitPlansMember" name="OtherPostemploymentBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanSettlementsPlanAssets" name="DefinedBenefitPlanSettlementsPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" name="DefinedBenefitPlanChangeInBenefitObligationRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" name="DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" name="DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LimitationOnRecognitionOfFundSurplus" name="LimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" name="DefinedBenefitPlanChangeInNetLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" name="AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" name="DefinedBenefitPensionPlanAccruedBenefitLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" name="BreakdownOfDefinedBenefitObligationForPensionPlansTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeAxis" name="ObligationByTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeMember" name="ObligationByTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UnfundedMember" name="UnfundedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActiveMember" name="ActiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredPensionersMember" name="DeferredPensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionersMember" name="PensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" name="ScheduleOfDefinedBenefitPlansDisclosuresTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyMale" name="DefinedBenefitAssumptionLifeExpectancyMale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyFemale" name="DefinedBenefitAssumptionLifeExpectancyFemale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LifeExpectancyMember" name="LifeExpectancyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionAxis" name="ChangeInActuarialAssumptionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionMember" name="ChangeInActuarialAssumptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Decrease25BasisPointMember" name="Decrease25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase25BasisPointMember" name="Increase25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase1YearMember" name="Increase1YearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfHealthCareCostTrendRatesTable" name="ScheduleOfHealthCareCostTrendRatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" name="DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfAllocationOfPlanAssetsTable" name="ScheduleOfAllocationOfPlanAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RealEstateMember" name="RealEstateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlternativeInvestmentsMember" name="AlternativeInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndOtherInvestmentsMember" name="CashAndOtherInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanPlanAssetAllocations" name="DefinedBenefitPlanPlanAssetAllocations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" name="WeightedAverageDurationOfDefinedBenefitObligationYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfExpectedBenefitPaymentsTable" name="ScheduleOfExpectedBenefitPaymentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" name="DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" name="DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" name="PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" name="DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SocieteParActionsSANDOZAlgiersMember" name="SocieteParActionsSANDOZAlgiersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" name="DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" name="AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" name="CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" name="CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" name="CashFlowsFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" name="ConsolidatedIncomeStatementSegmentationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExpensesIncludedInNetIncomeTableTextBlock" name="ExpensesIncludedInNetIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" name="RevenueFromSaleOfGoodsSalesToContinuingSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumerHealthMember" name="ConsumerHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CorporateMember" name="CorporateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OperatingIncomeLossOfDiscontinuedOperations" name="OperatingIncomeLossOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpenseOfDiscontinuedOperations" name="IncomeTaxExpenseOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" name="AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsAxis" name="AcquisitionsAndDivestmentsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsMember" name="AcquisitionsAndDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsMember" name="AcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DivestmentsMember" name="DivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowCurrencyTranslationEffects" name="CashInflowOutflowCurrencyTranslationEffects" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowAcquiredDivestedLiquity" name="CashInflowOutflowAcquiredDivestedLiquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" name="CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowGoodwill" name="CashInflowOutflowGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowDivestmentGainLoss" name="CashInflowOutflowDivestmentGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" name="TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAndPayablesContingentConsiderationNet" name="ReceivablesAndPayablesContingentConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherPaymentsAndDeferredConsiderationNet" name="OtherPaymentsAndDeferredConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredPrepaidPortionOfSalesPrice" name="DeferredPrepaidPortionOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPaid" name="ContingentConsiderationPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Change25BasisPointMember" name="Change25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendsPayableAmountPerShare" name="DividendsPayableAmountPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeld" name="TreasurySharesAcquiredToBeHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeCancelled" name="TreasurySharesAcquiredToBeCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchases" name="OtherSharePurchases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharepurchaseOfTreasuryShares" name="SharepurchaseOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeldValue" name="TreasurySharesAcquiredToBeHeldValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredForCancellationValue" name="TreasurySharesAcquiredForCancellationValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfComprehensiveIncomeTableTextBlock" name="ScheduleOfComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" name="FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" name="ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OfficerAndDirectorCompensationTableTextBlock" name="OfficerAndDirectorCompensationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" name="ScheduleOfSharebasedCompensationActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonExecutiveDirectorMember" name="NonExecutiveDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGMember" name="RocheHoldingAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LucentisMember" name="LucentisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_XolairMember" name="XolairMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" name="NetExpenseRoyaltiesCostSharingAndProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechInc.USAMember" name="GenentechInc.USAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrBrodyMember" name="ProfDrBrodyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrZinkernagelMember" name="ProfDrZinkernagelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrAlexKrauerMember" name="DrAlexKrauerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrDanielVasellaMember" name="DrDanielVasellaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrJamesBradnerMember" name="DrJamesBradnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationDailyRate" name="KeyManagementPersonnelCompensationDailyRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" name="KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquired" name="KeyManagementPersonnelCompensationSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" name="KeyManagementPersonnelCompensationOwnershipInterestAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" name="FairValueAdjustmentsOnMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" name="FairValueAdjustmentsOnDeferredCashFlowHedgesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialLossesFromDefinedBenefitPlansMember" name="ActuarialLossesFromDefinedBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CumulativeCurrencyTranslationEffectsMember" name="CumulativeCurrencyTranslationEffectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfMarketableInvestments" name="GainLossOnSaleOfMarketableInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfOtherFinancialAssets" name="GainLossOnSaleOfOtherFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RemeasurementsFromDefinedBenefitPlansLineItems" name="RemeasurementsFromDefinedBenefitPlansLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InnovativeMedicinesMember" name="InnovativeMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozMember" name="SandozMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconMember" name="AlconMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentivePlanMember" name="EquityBasedParticipationAnnualIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlanMember" name="EquityBasedParticipationShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" name="EquityBasedParticipationLeveragedShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="EquityBasedParticipationEmployeeShareOwnershipPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationUKShareSavingsPlanMember" name="EquityBasedParticipationUKShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" name="EquityBasedParticipationNovartisEquityPlanSelectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePlanMember" name="EquityBasedParticipationLongTermPerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" name="EquityBasedParticipationLongTermRelativePerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationSpecialShareAwardsMember" name="EquityBasedParticipationSpecialShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationRestrictedSharesMember" name="EquityBasedParticipationRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" name="OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" name="KeyManagementPersonnelCompensationSharesAcquiredPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentOnComprehensiveIncome" name="ValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" name="GainsLossesOnValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="TotalValueAdjustmentsAttributableToNovartisShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" name="AlconInc.EquityPlanConvertedNovartisShareOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" name="AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" name="RevenueFromSaleOfGoodsSalesToOtherSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" name="ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetOperatingAssets" name="NetOperatingAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" name="CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialDebtsAndDerivativeInstruments" name="FinancialDebtsAndDerivativeInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" name="CurrentIncomeTaxAndDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssets" name="SelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherCountriesMember" name="OtherCountriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AsiaAfricaAustralasiaMember" name="AsiaAfricaAustralasiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestCustomerMember" name="SecondLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" name="DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" name="DisclosureOfAssociatesBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssociatesSummarizedFinancialInformationTableTextBlock" name="AssociatesSummarizedFinancialInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchasePriceAllocationAssociatesTableTextBlock" name="PurchasePriceAllocationAssociatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" name="GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OthersAssociatesMember" name="OthersAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfEstimatedNetAssets" name="ShareOfEstimatedNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" name="CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" name="AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsolidatedIncomeStatementEffectsTable" name="ConsolidatedIncomeStatementEffectsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfCurrentYearNetIncome" name="ShareOfCurrentYearNetIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PriorYearAdjustment" name="PriorYearAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" name="DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" name="AccrualForEnvironmentalLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" name="AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" name="AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" name="OtherLongtermEmployeeBenefitsAndDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherPostemploymentBenefits" name="OtherPostemploymentBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SolodynMember" name="SolodynMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensesMember" name="ContactLensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecMember" name="GleevecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclastAclastaMember" name="ReclastAclastaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TekturnaRasilezValturnaMember" name="TekturnaRasilezValturnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGAndNovartisPharmaSpAMember" name="NAGAndNovartisPharmaSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FHoffmanLaRocheAGAndRocheSpAMember" name="FHoffmanLaRocheAGAndRocheSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaKKMember" name="NovartisPharmaKKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGMember" name="NAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NPCAndOthersMember" name="NPCAndOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNCMember" name="NovartisNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" name="ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" name="ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" name="EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" name="A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" name="A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" name="TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalFairValueAdjustmentsMember" name="TotalFairValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesThirdParty" name="CurrentPrepaidExpensesThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TaxotereMember" name="TaxotereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmiodaroneMember" name="AmiodaroneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfEquityAbstract" name="DisclosureOfEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfEquityTextBlock" name="DisclosureOfEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendTableTextBlock" name="DividendTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInNoncontrolingInterests" name="IncreaseDecreaseInNoncontrolingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfReportableSegments" name="NumberOfReportableSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfFranchises" name="NumberOfFranchises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdParties" name="RevenueFromSaleOfGoodsThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" name="RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" name="SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" name="InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" name="ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxExpenseIncomeDiscontinuingOperations" name="TaxExpenseIncomeDiscontinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeuroscienceMember" name="NeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMedicinesMember" name="EstablishedMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioMember" name="ProductPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_COPDMember" name="COPDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecGlivecMember" name="GleevecGlivecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TasignaMember" name="TasignaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandostatinMember" name="SandostatinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AfinitorVotubiaMember" name="AfinitorVotubiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExjadeJadenuMember" name="ExjadeJadenuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TafinlarMekinistMember" name="TafinlarMekinistMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromactaRevoladeMember" name="PromactaRevoladeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmologyMember" name="OphthalmologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VotrientMember" name="VotrientMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JakaviMember" name="JakaviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KisqaliMember" name="KisqaliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TravoprostGroupMember" name="TravoprostGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SystaneGroupMember" name="SystaneGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TopicalOlopatadineGroupMember" name="TopicalOlopatadineGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CosentyxMember" name="CosentyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeoralSandimmunEMember" name="NeoralSandimmunEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZortressCerticanMember" name="ZortressCerticanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IlarisMember" name="IlarisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MyforticMember" name="MyforticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GilenyaMember" name="GilenyaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroBreezhalerMember" name="UltibroBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SeebriBreezhalerMember" name="SeebriBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OnbrezBreezhalerMember" name="OnbrezBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EntrestoMember" name="EntrestoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VoltarenCataflamMember" name="VoltarenCataflamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExelonExelonPatchMember" name="ExelonExelonPatchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RitalinFocalinMember" name="RitalinFocalinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" name="AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" name="AccumulatedImpairmentsOnDisposalsAndDerecognitions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquiredResearchAndDevelopmentMember" name="AcquiredResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconBrandNameMember" name="AlconBrandNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" name="GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" name="CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" name="OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeMaketableSecurities" name="OtherComprehensiveIncomeMaketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDoubtfulReceivableMember" name="ProvisionForDoubtfulReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_Commodities" name="Commodities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapital" name="OutstandingShareCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IssuedCapitalMovement" name="IssuedCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapitalMovement" name="OutstandingShareCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesCancelledForCapitalReduction" name="SharesCancelledForCapitalReduction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovement" name="TreasurySharesMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityImpactOfTreasuryShareMovements" name="EquityImpactOfTreasuryShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnLoansReceived" name="AverageInterestRateOnLoansReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" name="RatioFixedRateFinancialDebtToTotalFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnBorrowings" name="AverageInterestRateOnBorrowings" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationNonCurrent" name="ContingentConsiderationNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionRollForward" name="EnvironmentalProvisionRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvision" name="EnvironmentalProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionPayments" name="EnvironmentalProvisionPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionReleases" name="EnvironmentalProvisionReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionAdditions" name="EnvironmentalProvisionAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" name="EnvironmentalProvisionForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionCurrent" name="EnvironmentalProvisionCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalRemediationProvisionNoncurrent" name="EnvironmentalRemediationProvisionNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" name="EnvironmentalProvisionFiscalYearMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" name="EnvironmentalProvisionExpectedCashOutflowNextTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" name="EnvironmentalProvisionExpectedCashOutflowAfterTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateAssociates" name="WeightedAverageInterestRateAssociates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" name="WeightedAverageInterestRateOnBankAndOtherFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationCurrentPortion" name="ContingentConsiderationCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDeductionFromRevenueTable" name="ProvisionForDeductionFromRevenueTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesTable" name="ProvisionsAndOtherCurrentLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsTable" name="RestructuringProvisionsMovementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionTransfers" name="RestructuringProvisionTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" name="TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IdentifiableAssetsAcquired" name="IdentifiableAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashFlowFromNetIdentifiableAssets" name="CashFlowFromNetIdentifiableAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" name="PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" name="TechnologiesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" name="InventoryRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" name="CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" name="TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnimalHealthMember" name="AnimalHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSaleOfBusiness" name="ProceedsFromSaleOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfBondsDiscount" name="AmortizationOfBondsDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPortionOfNoncurrentFinancialDebt" name="CurrentPortionOfNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechRocheMember" name="GenentechRocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfContractsWithRelatedParties" name="NumberOfContractsWithRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfNonexecutiveDirectors" name="RelatedPartiesNumberOfNonexecutiveDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" name="DefinedBenefitPlanExpectedFutureBenefitPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EmployerSharesHeldByDefinedBenefitPlan" name="EmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" name="ValueOfEmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndCashEquivalentsMember" name="CashAndCashEquivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemAxis" name="BalanceSheetItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemMember" name="BalanceSheetItemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquitySecuritiesMember" name="EquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FundInvestmentsMember" name="FundInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" name="TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesMember" name="ContingentConsiderationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" name="AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="TimeDepositsWithOriginalMaturityMoreThan90DaysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="AssociatedCompaniesAtFairValueThroughProfitAndLossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsMember" name="DerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesAxis" name="GroupsOfFinancialAssetsLiabilitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesMember" name="GroupsOfFinancialAssetsLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradePayablesMember" name="TradePayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" name="InterestBearningAccountsOfAssociatesPayableOnDemandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BankAndOtherFinancialDebtMember" name="BankAndOtherFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommercialPaperMember" name="CommercialPaperMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentPortionOfNoncurrentDebtMember" name="CurrentPortionOfNoncurrentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StraightBondsMember" name="StraightBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" name="LiabilitiesToBanksAndOtherFinancialInstitutionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinanceLeaseObligationsMember" name="FinanceLeaseObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ContingentConsiderationAndOtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" name="DerivativeFinancialInstrumentNatureOfInstrumentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" name="DerivativeFinancialInstrumentNatureOfInstrumentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" name="DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsAxis" name="FinancialInstrumentsPrincipalAmountsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsMember" name="FinancialInstrumentsPrincipalAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContractOrUnderlyingPrincipalAmoutMember" name="ContractOrUnderlyingPrincipalAmoutMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PositiveFairValuesMember" name="PositiveFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NegativeFairValuesMember" name="NegativeFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" name="DisclosureOfDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstruments" name="DerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" name="DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" name="DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInvestmentsAndLongtermLoansGroupMember" name="FinancialInvestmentsAndLongtermLoansGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalAvailableforsaleMarketableSecuritiesMember" name="TotalAvailableforsaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableForSaleMarketableSecuritiesMember" name="AvailableForSaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleLongtermFinancialInvestmentsMember" name="AvailableforsaleLongtermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtMember" name="CurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialDebtMember" name="NoncurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleFinancialInvestmentsMember" name="AvailableforsaleFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValuedAtAmortizedCostMember" name="ValuedAtAmortizedCostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationPayablesMember" name="ContingentConsiderationPayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesMember" name="OtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" name="ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" name="IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustriaGmbHViennaMember" name="NovartisAustriaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHViennaMember" name="NovartisPharmaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconOphthalmikaGmbHViennaMember" name="AlconOphthalmikaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGmbHViennaMember" name="SandozGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" name="EBEWEPharmaGes.m.b.HNfg.KGViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBangladeshLimitedGazipurMember" name="NovartisBangladeshLimitedGazipurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" name="NovartisSecuritiesInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" name="NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCanadaInc.MississaugaOntarioMember" name="AlconCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" name="CIBAVisionCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozCanadaInc.BouchervilleQuebecMember" name="SandozCanadaInc.BouchervilleQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisChileS.A.SantiagoDeChileMember" name="NovartisChileS.A.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" name="AlconLaboratoriosChileLtd.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" name="BeijingNovartisPharmaCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" name="NovartisPharmaceuticalsHKLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" name="SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" name="ShanghaiNovartisTradingLtd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHongKongLimitedHongKongMember" name="AlconHongKongLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" name="AlconChinaOphthalmicProductCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" name="SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" name="SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisS.r.o.PragueMember" name="NovartisS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" name="AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.r.o.PragueMember" name="SandozS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcareASCopenhagenMember" name="NovartisHealthcareASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNordicASCopenhagenMember" name="AlconNordicASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozASCopenhagenMember" name="SandozASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisEcuadorS.A.QuitoMember" name="NovartisEcuadorS.A.QuitoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.E.CairoMember" name="NovartisPharmaS.A.E.CairoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" name="SandozEgyptPharmaS.A.E.NewCairoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinlandOyEspooMember" name="NovartisFinlandOyEspooMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" name="NovartisGroupeFranceS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" name="NovartisPharmaS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" name="LaboratoiresAlconS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.S.LevalloisPerretMember" name="SandozS.A.S.LevalloisPerretMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHWehrMember" name="NovartisDeutschlandGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHNurembergMember" name="NovartisPharmaGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaProduktionsGmbHWehrMember" name="NovartisPharmaProduktionsGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBusinessServicesGmbHWehrMember" name="NovartisBusinessServicesGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaGmbHFreiburgImBreisgauMember" name="AlconPharmaGmbHFreiburgImBreisgauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightGmbHErlangenMember" name="WaveLightGmbHErlangenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionGmbHGrosswallstadtMember" name="CIBAVisionGmbHGrosswallstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInternationalGmbHHolzkirchenMember" name="SandozInternationalGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HEXALAGHolzkirchenMember" name="HEXALAGHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SalutasPharmaGmbHBarlebenMember" name="SalutasPharmaGmbHBarlebenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AeropharmGmbHRudolstadtMember" name="AeropharmGmbHRudolstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovistaInsuranceLimitedGibraltarCityMember" name="NovistaInsuranceLimitedGibraltarCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="NovartisHellasS.A.C.I.MetamorphosisAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" name="AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" name="SandozHungaryLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIndiaLimitedMumbaiMember" name="NovartisIndiaLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePrivateLimitedMumbaiMember" name="NovartisHealthcarePrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPrivateLimitedMumbaiMember" name="SandozPrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.NovartisIndonesiaJakartaMember" name="PT.NovartisIndonesiaJakartaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.CIBAVisionBatamBatamMember" name="PT.CIBAVisionBatamBatamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIrelandLimitedDublinMember" name="NovartisIrelandLimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" name="NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" name="AlconLaboratoriesIrelandLimitedCorkCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OptonolLtd.NeveIlanMember" name="OptonolLtd.NeveIlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconItaliaS.p.A.MilanMember" name="AlconItaliaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.p.A.OriggioMember" name="SandozS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.p.A.RoveretoMember" name="SandozIndustrialProductsS.p.A.RoveretoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingJapanK.K.TokyoMember" name="NovartisHoldingJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaK.K.TokyoMember" name="NovartisPharmaK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconJapanLtd.TokyoMember" name="AlconJapanLtd.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozK.K.TokyoMember" name="SandozK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" name="AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" name="CIBAVisionJohorSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" name="AlconLaboratoriosS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.DeC.V.MexicoCityMember" name="SandozS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaMarocSACasablancaMember" name="NovartisPharmaMarocSACasablancaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.ArnhemMember" name="NovartisNetherlandsB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.ArnhemMember" name="NovartisPharmaB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNederlandB.V.ArnhemMember" name="AlconNederlandB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozB.V.AlmereMember" name="SandozB.V.AlmereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNewZealandLtdAucklandMember" name="NovartisNewZealandLtdAucklandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNorgeASOsloMember" name="NovartisNorgeASOsloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaPakistanLimitedKarachiMember" name="NovartisPharmaPakistanLimitedKarachiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLogisticsInc.PanamaCityMember" name="NovartisPharmaLogisticsInc.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCentroamericaS.A.PanamaCityMember" name="AlconCentroamericaS.A.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekS.A.StrykowMember" name="LekS.A.StrykowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPortugalSGPSLda.PortoSalvoMember" name="NovartisPortugalSGPSLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" name="NovartisPharmaServicesRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRomaniaS.R.L.BucharestMember" name="AlconRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.R.L.TarguMuresMember" name="SandozS.R.L.TarguMuresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLLCMoscowMember" name="NovartisPharmaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconFarmacevtikaLLCMoscowMember" name="AlconFarmacevtikaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNevaLLCSt.PetersburgMember" name="NovartisNevaLLCSt.PetersburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" name="SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSlovakiaS.r.o.BratislavaMember" name="NovartisSlovakiaS.r.o.BratislavaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekPharmaceuticalsD.d.LjubjanaMember" name="LekPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsD.d.LjubjanaMember" name="SandozPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSouthAfricaPtyLtdMidrandMember" name="NovartisSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" name="AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisKoreaLtd.SeoulMember" name="NovartisKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconKoreaLtd.SeoulMember" name="AlconKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozKoreaLtd.SeoulMember" name="SandozKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCusiS.A.BarcelonaMember" name="AlconCusiS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" name="AbadiaRetuertaS.A.SardonDeDueroValladolidMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSverigeABStockholmMember" name="NovartisSverigeABStockholmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalAGBaselMember" name="NovartisInternationalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingAGBaselMember" name="NovartisHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalAGBaselMember" name="NovartisInternationalPharmaceuticalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaAGBaselMember" name="NovartisPharmaAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesAGBaselMember" name="NovartisPharmaServicesAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" name="NovartisPharmaSchweizerhalleAGMuttenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSteinAGSteinMember" name="NovartisPharmaSteinAGSteinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizAGRischMember" name="NovartisPharmaSchweizAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSwitzerlandSARischMember" name="AlconSwitzerlandSARischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsLtd.FribourgMember" name="AlconPharmaceuticalsLtd.FribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozAGBaselMember" name="SandozAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsAGRischMember" name="SandozPharmaceuticalsAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTaiwanCo.Ltd.TaipeiMember" name="NovartisTaiwanCo.Ltd.TaipeiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisThailandLimitedBangkokMember" name="NovartisThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesThailandLimitedBangkokMember" name="AlconLaboratoriesThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" name="AlconLaboratuvarlariTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMiddleEastFZEDubaiMember" name="NovartisMiddleEastFZEDubaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedFrimleyCamberleyMember" name="NovartisUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" name="NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" name="NovartisGrimsbyLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" name="AlconEyeCareUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozLimitedFrimleyCamberleyMember" name="SandozLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" name="GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationEastHanoverNYMember" name="NovartisCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationNewYorkNYMember" name="NovartisFinanceCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkNYMember" name="NovartisCapitalCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" name="NovartisPharmaceuticalsCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" name="NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" name="NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" name="NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisServicesInc.EastHanoverNYMember" name="NovartisServicesInc.EastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" name="AlconLaboratoriesHoldingCorporationFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesInc.FortWorthTXMember" name="AlconLaboratoriesInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRefractivehorizonsLLCFortWorthTXMember" name="AlconRefractivehorizonsLLCFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconResearchLtd.FortWorthTXMember" name="AlconResearchLtd.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLensxInc.AlisoViejoCAMember" name="AlconLensxInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInc.PrincetonNJMember" name="SandozInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EonLabsInc.PrincetonNJMember" name="EonLabsInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" name="FougeraPharmaceuticalsInc.MelvilleNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeVenezuelaS.A.CaracasMember" name="NovartisDeVenezuelaS.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalC.A.CaracasMember" name="AlconPharmaceuticalC.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiocienciasS.A.SaoPauloMember" name="NovartisBiocienciasS.A.SaoPauloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" name="SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" name="NovartisDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" name="LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" name="NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" name="NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" name="AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaLda.PortoSalvoMember" name="SandozFarmaceuticaLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.BarcelonaMember" name="NovartisFarmaceuticaS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaS.A.MadridMember" name="SandozFarmaceuticaS.A.MadridMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" name="NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" name="SandozIlacSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" name="SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsAdditionalDisclosureAbstract" name="FinancialInstrumentsAdditionalDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsCarryingValueLevel3" name="FinancialInstrumentsCarryingValueLevel3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" name="GainsRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" name="LossesRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" name="FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisposalsFairValueMeasurementAssets" name="DisposalsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFairValueMeasurementAssets" name="ReclassificationFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" name="FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" name="MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" name="ReconciliationOfChangesInFairValueMeasurementAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MaturityOfNetDebtLineItems" name="MaturityOfNetDebtLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesAndTimeDepositsMember" name="MarketableSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommoditiesMember" name="CommoditiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="DeriviativeFinancialInstrumentsAndAccruedInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtMember" name="FinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtUndiscountedMember" name="FinancialDebtUndiscountedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" name="PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" name="PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractualInterestOnNoncurrentLiabilities" name="ContractualInterestOnNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelTable" name="TenDayLossFairValueVARModelTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelLineItems" name="TenDayLossFairValueVARModelLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputation" name="FinancialInstrumentsValueAtRiskComputation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" name="FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_WorstCaseLossScenarioMember" name="WorstCaseLossScenarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" name="CashReceiptsAndPaymentsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" name="AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsMember" name="EquityBasedParticipationOtherShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareMovements" name="ShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NetInvestmentHedgeMember" name="NetInvestmentHedgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsHeldByMarketMaker" name="WrittenCallOptionsHeldByMarketMaker" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLive" name="WrittenCallOptionsContractualLive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLiveRemaining" name="WrittenCallOptionsContractualLiveRemaining" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsWeightedAverageExercisePrice" name="WrittenCallOptionsWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PurchaseFairValueMeasurementAssets" name="PurchaseFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_StockRepurchaseProgramAuthorizedAmount1" name="StockRepurchaseProgramAuthorizedAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" name="TaxRateEffectOfIncomeTaxedAtReducedRates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfPropertyPlantAndEquipmentRollForward" name="MovementsOfPropertyPlantAndEquipmentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherAssetsProvisionsAccrualsMember" name="OtherAssetsProvisionsAccrualsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePteLtd.SingaporeMember" name="NovartisSingaporePteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" name="NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" name="NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" name="NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" name="AlconSingaporeManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" name="CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPteLtdSingaporeMember" name="AlconPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" name="AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" name="SpinifexPharmaceuticalsInc.WilmingtonNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.NewYorkNYMember" name="EncoreVisionInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentLtd.HamiltonMember" name="NovartisInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceServicesLtd.HamiltonMember" name="NovartisFinanceServicesLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB2Ltd.HamiltonMember" name="NovartisB2Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB3Ltd.HamiltonMember" name="NovartisB3Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CibaGeigyJapanLimitedTokyoMember" name="CibaGeigyJapanLimitedTokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" name="NovartisInternationalPharmaceuticalInvestmentAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBioventuresAGBaselMember" name="NovartisBioventuresAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisForschungsstiftungBaselMember" name="NovartisForschungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" name="NovartisMitarbeiterbeteiligungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" name="FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" name="ZiarcoGroupLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VivactaLimitedFrimleyCamberleySurreyMember" name="VivactaLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationNewYorkNYMember" name="NovartisUSFoundationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CortheraInc.SanMateoCAMember" name="CortheraInc.SanMateoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" name="CoStimPharmaceuticalsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ClarVistaMedicalInc.AlisoViejoCAMember" name="ClarVistaMedicalInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" name="TriangleInternationalReinsuranceLimitedHamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" name="TrinityRiverInsuranceCoLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerKaderausbildungBaselMember" name="NovartisStiftungFuerKaderausbildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" name="NovartisStiftungFuerMenschUndUmweltBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" name="StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" name="SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" name="DisclosureOfAssociatesNetIncomeEffectTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" name="DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" name="DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" name="DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" name="GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" name="DebtSecuritiesBreakdownByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SummaryOfTreasurySharesMovementsTableTextBlock" name="SummaryOfTreasurySharesMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" name="USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" name="ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" name="ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedContributionPlansTableTextBlock" name="ScheduleOfDefinedContributionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" name="ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" name="DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" name="DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" name="DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationMember" name="ReprixysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" name="TaxRateEffectOfReleaseOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromNondeductibleLossesInRegion" name="TaxRateEffectFromNondeductibleLossesInRegion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredTaxAssetAndLiabilityValuationAbstract" name="DeferredTaxAssetAndLiabilityValuationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" name="ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" name="ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" name="ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" name="ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationAxis" name="ImpactLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationMember" name="ImpactLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementMember" name="IncomeStatementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedOperatingLeaseCommitments" name="UndiscountedOperatingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionOfBusinessToJointVenture" name="ContributionOfBusinessToJointVenture" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" name="ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" name="ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" name="AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" name="PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangiblePurchaseCommitments" name="OtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" name="ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OpenHedgesForAnticipatedTransactions" name="OpenHedgesForAnticipatedTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MostSignificantForeignExchangeLosses" name="MostSignificantForeignExchangeLosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LongtermFinancialDebtWithACarryingAmount" name="LongtermFinancialDebtWithACarryingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" name="NetInvestmentHedgeRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UpperLimitOnHoldingsOnUnrelatedCompany" name="UpperLimitOnHoldingsOnUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" name="BorrowingsCommercialPaperMaximumBorrowingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DebtEquityRatio" name="DebtEquityRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_VAREstimateConfidenceInterval" name="VAREstimateConfidenceInterval" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" name="BorrowingsCommercialPaperMaximumAmountOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityCommitted" name="BorrowingsCreditFacilityCommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CounterpartyRiskAbstract" name="CounterpartyRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" name="CashAndCashEquivalentsHeldWithFinancialInstitution" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorAxis" name="VendorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorMember" name="VendorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestFinancialInstitutionMember" name="LargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestFinancialInstitutionMember" name="SecondLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestFinancialInstitutionMember" name="ThirdLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreTaxProfitLossFromDivestmentOfBusiness" name="PreTaxProfitLossFromDivestmentOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" name="DivestmentDateFairValueOfTotalConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FuturePutOptionToSellBusiness" name="FuturePutOptionToSellBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentPutOption" name="PaymentPutOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExchanged" name="InterestExchanged" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LiabilitiesToBanksAndOtherInstitutions" name="LiabilitiesToBanksAndOtherInstitutions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivableCurrent" name="ContingentConsiderationReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfDivestmentsOtherProvisions" name="ImpactOfDivestmentsOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialInstrumentsNarrativeTable" name="DisclosureOfFinancialInstrumentsNarrativeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomersWithNetSalesOverFivePercent" name="CustomersWithNetSalesOverFivePercent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesShorttermMember" name="ContingentConsiderationReceivablesShorttermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OptionsExcludedFromTheCalculation" name="OptionsExcludedFromTheCalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestonePaymentAlreadyReceived" name="MilestonePaymentAlreadyReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USCommercialPaperProgramsMember" name="USCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JPCommercialPaperProgramsMember" name="JPCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperNumberOfPrograms" name="BorrowingsCommercialPaperNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsAAAMember" name="AdvancedAcceleratorApplicationsAAAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalInTenderOffer" name="PercentageOfShareCapitalInTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerOrdinaryShare" name="CashOfferPerOrdinaryShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerADS" name="CashOfferPerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfOrdinarySharePerADS" name="NumberOfOrdinarySharePerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEquity" name="ValueOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MaximalAmountOfShareBuybackProgramm" name="MaximalAmountOfShareBuybackProgramm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAnnualIncentive" name="DescriptionOfAnnualIncentive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBusinessUnits" name="NumberOfBusinessUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonCurrentFinancialDebtsMember" name="NonCurrentFinancialDebtsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractRightOfFirstNegotiationTerm" name="ContractRightOfFirstNegotiationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IntangibleAssetImpairmentChargesTextBlock" name="IntangibleAssetImpairmentChargesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" name="AcquisitionFairValuePotentiallyRefundableContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentFairValueOfContingentConsiderationReceived" name="DivestmentFairValueOfContingentConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" name="MaximumMarginPercentageImpactOfCommodityPriceChange" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumHoldingInUnrelatedCompany" name="MaximumHoldingInUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialReceivableFromDivestment" name="PotentialReceivableFromDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ChangeOverPeriodAxis" name="ChangeOverPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasisOfPreparationAbstract" name="BasisOfPreparationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelectedCriticalAccountingPoliciesAbstract" name="SelectedCriticalAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LegalProceedingsUpdateAbstract" name="LegalProceedingsUpdateAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LegalProceedingsUpdateTextBlock" name="LegalProceedingsUpdateTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" name="ImpactsOfAdoptionOfNewIFRSStandardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" name="ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" name="DescriptionOfAccountingPolicyForOtherRevenueTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" name="ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" name="ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" name="FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" name="DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisIncMember" name="AveXisIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OCIReservesMember" name="OCIReservesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetailGenericsMember" name="RetailGenericsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BiopharmaceuticalsMember" name="BiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesMember" name="AntiInfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VisionCareMember" name="VisionCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumablesMember" name="ConsumablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImplantablesMember" name="ImplantablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquipmentOtherMember" name="EquipmentOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmicOTCMember" name="OphthalmicOTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensCareMember" name="ContactLensCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Top20ProductsMember" name="Top20ProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfPortfolioMember" name="RestOfPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitSharingIncome" name="ProfitSharingIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestoneIncome" name="MilestoneIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherRevenueOther" name="OtherRevenueOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" name="ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CanadaAndLatinAmericaMember" name="CanadaAndLatinAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMarketsMember" name="EstablishedMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EmergingGrowthMarketsMember" name="EmergingGrowthMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.5EUR750Million20182023OfNovartisMember" name="A0.5EUR750Million20182023OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisMember" name="A1.375EUR750Million20182030OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.7EUR750Million20182038OfNovartisMember" name="A1.7EUR750Million20182038OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GalvusGroupMember" name="GalvusGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DiovanGroupMember" name="DiovanGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExforgeGroupMember" name="ExforgeGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesSoldUnderSandozNameMember" name="AntiInfectivesSoldUnderSandozNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsOnFinancialAssetsSold" name="FairValueAdjustmentsOnFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioAxis" name="ProductPortfolioAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchasesValue" name="OtherSharePurchasesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LutatheraMember" name="LutatheraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KymriahMember" name="KymriahMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" name="TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityTextBlock" name="TransactionCostsRecordedInEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TransactionsWithRelatedPartiesAbstract" name="TransactionsWithRelatedPartiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithRelatedPartiesTextBlock" name="TransactionsWithRelatedPartiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityPaid" name="TransactionCostsRecordedInEquityPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquity" name="TransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" name="OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPensionFundMember" name="NovartisPensionFundMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityUncommitted" name="BorrowingsCreditFacilityUncommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetAssets" name="OtherNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OcularHealthMember" name="OcularHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" name="AdvancedAcceleratorApplicationsInternationalSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" name="AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleAbstract" name="DisposalGroupHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleLineItems" name="DisposalGroupHeldForSaleLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" name="ChangeInCashSettledShareBasedPaymentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowNoncontrollingInterests" name="CashInflowOutflowNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountRecordedInEquityRelatedToHyperinflation" name="AmountRecordedInEquityRelatedToHyperinflation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToInvestmentInAssociatedCompanies" name="AdditionsToInvestmentInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" name="OtherComprehensiveIncomeNetOfTaxDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" name="GainOnDivestmentOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDebtSecuritiesMember" name="FairValueAdjustmentsOnDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesMember" name="FairValueAdjustmentsOnEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" name="ReclassificationToPresentationRequiredUnderIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestatedValueAdjustmentsMember" name="RestatedValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsEquityInvestments" name="NoncurrentFinancialAssetsEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsFundInvestments" name="NoncurrentFinancialAssetsFundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ListedEquitySecuritiesMember" name="ListedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonlistedEquitySecuritiesMember" name="NonlistedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteMember" name="EndocyteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" name="DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" name="DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" name="DivestmentsAquisitionsOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSales" name="OtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSalesEquityImpact" name="OtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSales" name="NumberOfOtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSalesEquityImpact" name="NumberOfOtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeDebtSecurities" name="OtherComprehensiveIncomeDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPtyLtdMacquarieParkNSWMember" name="SandozPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" name="AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaNVVilvoordeMember" name="NovartisPharmaNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozNVVilvoordeMember" name="SandozNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCouvreurNVPuursMember" name="AlconCouvreurNVPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesBelgiumBVBAPuursMember" name="AlconLaboratoriesBelgiumBVBAPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNVVilvoordeMember" name="AlconNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconAGFribourgMember" name="AlconAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" name="AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCorporationLLCDuluthGAMember" name="CIBAVisionCorporationLLCDuluthGAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" name="ReprixysPharmaceuticalsCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPolandSp.ZO.o.WarsawMember" name="NovartisPolandSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPolskaSp.ZO.o.WarsawMember" name="SandozPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPolskaSp.ZO.o.WarsawMember" name="AlconPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHealthcareS.A.BarcelonaMember" name="AlconHealthcareS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozUkraineLLCKievMember" name="SandozUkraineLLCKievMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentCostToSell" name="DivestmentCostToSell" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfSettlementInPrinciple" name="AmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" name="NavigateBioPharmaServicesInc.CarlsbadCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfProductsInPortfolioToBeSold" name="NumberOfProductsInPortfolioToBeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CarryingValueOfTheDivestedBusiness" name="CarryingValueOfTheDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ShortTermLeasesAndLowValueLeases" name="ShortTermLeasesAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RemainingLeaseCommitments" name="RemainingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesToBeRecognized" name="LeaseLiabilitiesToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsToBeRecognized" name="RightOfUseAssetsToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" name="NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" name="NovartisInvestmentsS.aR.l.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceS.A.LuxembourgCityMember" name="NovartisFinanceS.A.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TearFilmInnovationsInc.FortWorthTXMember" name="TearFilmInnovationsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrueVisionSystemsInc.FortWorthTXMember" name="TrueVisionSystemsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalInc.LakeForestILMember" name="TranscendMedicalInc.LakeForestILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBalticsSIARigaMember" name="NovartisBalticsSIARigaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOverseasInvestmentsAGBaselMember" name="NovartisOverseasInvestmentsAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JapatAGBaselMember" name="JapatAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconManagementSAGenevaMember" name="AlconManagementSAGenevaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.LafayetteINMember" name="EndocyteInc.LafayetteINMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrielTherapeuticsInc.DurhamNCMember" name="OrielTherapeuticsInc.DurhamNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightInc.SterlingVAMember" name="WaveLightInc.SterlingVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiosciencesPeruS.A.LimaMember" name="NovartisBiosciencesPeruS.A.LimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesWithRestrictedUse" name="TreasurySharesWithRestrictedUse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentForRepurchaseOwnShares" name="CommitmentForRepurchaseOwnShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAsstetsDebtSecurities" name="NoncurrentFinancialAsstetsDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" name="AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" name="DepreciationChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProformaNetSales" name="ProformaNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SerelaxinMember" name="SerelaxinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CyPassMember" name="CyPassMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfPriorYear" name="IncomeStatementAdjustmentsOfPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfCurrentYear" name="IncomeStatementAdjustmentsOfCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesAxis" name="PlansAndProgramRebatesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" name="AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" name="ImpairmentChargesRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" name="ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" name="AdditionsIncludedInDisposalGroupToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAssetsDivested" name="NoncurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAssetsDivested" name="CurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLiabilitiesDivested" name="CurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssets" name="FinancialAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" name="CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradePayablesAndOtherLiabilities" name="TradePayablesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" name="CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" name="LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" name="MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesMember" name="PlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USspecificHealthcarePlansAndProgramRebatesMember" name="USspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" name="NonUSspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" name="NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.7Member" name="ExercisePrice46.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice54.5Member" name="ExercisePrice54.5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.0Member" name="ExercisePrice57.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.6Member" name="ExercisePrice57.6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.0Member" name="ExercisePrice66.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.4Member" name="ExercisePrice46.4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice53.7Member" name="ExercisePrice53.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.1Member" name="ExercisePrice57.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice58.3Member" name="ExercisePrice58.3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.1Member" name="ExercisePrice66.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrepaymentsAndAccruedLeasePayments" name="PrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" name="RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationPriorToClassificationToAssetsHeldForSale" name="AmortizationPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" name="NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongTermFinancialInvestmentsMember" name="LongTermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecurities" name="MarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MajorPlansPercentageInGroupDBOPensions" name="MajorPlansPercentageInGroupDBOPensions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" name="MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" name="NoncurrentFinancialAssetsTotalFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" name="NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" name="DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDiscontinuedOperationsAbstract" name="DisclosureOfDiscontinuedOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YoYChangeMember" name="YoYChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLessesTable" name="PresentationOfLeasesForLessesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLesseeLineItems" name="PresentationOfLeasesForLesseeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NewLeaseArrangements" name="NewLeaseArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedFutureLeasePayments" name="UndiscountedFutureLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfDiscounting" name="EffectOfDiscounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentStatedMember" name="CurrentStatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOrIssueOfTreasurySharesNumberOfShares" name="SaleOrIssueOfTreasurySharesNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DetailedInformationAboutSignificantTransaction" name="DetailedInformationAboutSignificantTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IFMTreInc.Member" name="IFMTreInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PowerVisionInc.Member" name="PowerVisionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" name="AdjustmentsForPrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialMilestoneMaximumPayments" name="PotentialMilestoneMaximumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" name="NumberOfEmployeesAssociatedWithTheProductTransfer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalBorrowings" name="AdditionalBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEquityInterestSharesReceived" name="PercentageOfEquityInterestSharesReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" name="DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" name="DistributionOfDividendBearingSharesToConsolidatedFoundations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AimovigMember" name="AimovigMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" name="LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" name="IncreaseDecreaseThroughExerciseOfOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" name="IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfLeaseLiability" name="RepaymentOfLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateLeaseLiabilities" name="WeightedAverageInterestRateLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfTheRightofuseAssetsRollForward" name="MovementsOfTheRightofuseAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseContractTerminationsRightofuseAssets" name="LeaseContractTerminationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" name="IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" name="SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnTreasuryShares" name="TaxesOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseIncentives" name="LeaseIncentives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForLeases" name="CashInflowForLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetAssetsDerecognized" name="NetAssetsDerecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendToDividendBearingShares" name="DistributionOfDividendToDividendBearingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" name="DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" name="NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusiness" name="CashFlowsAttributableToDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherNoncurrentAssets" name="FinancialAndOtherNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssets" name="TradeReceivablesAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradePayablesProvisionsAndOtherLiabilities" name="TradePayablesProvisionsAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebt" name="CurrentAndNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" name="RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" name="ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" name="DisclosureOfRightofuseAssetsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" name="DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" name="DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" name="AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLeaseLiabilitiesMember" name="NoncurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLeaseLiabilitiesMember" name="CurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ApplicableTaxRateExcludingExceptionalItems" name="ApplicableTaxRateExcludingExceptionalItems" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" name="CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestedCashAndCashEquivalents" name="DivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomaryPurchasePriceAdjustment" name="CustomaryPurchasePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfIntercompanyBalances" name="RepaymentOfIntercompanyBalances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" name="TaxReformImpactOnDeferredTaxOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendPaidNoncashAssetsDistribution" name="DividendPaidNoncashAssetsDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" name="DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" name="ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" name="DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" name="DisclosureOfNetAssetsDerecognizedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionByWayOfDivindendInKindToShareholders" name="DistributionByWayOfDivindendInKindToShareholders" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TheMedicinesCompanyMember" name="TheMedicinesCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PiqrayMember" name="PiqrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZolgensmaMember" name="ZolgensmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MayzentMember" name="MayzentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" name="DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" name="AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" name="NetDeferredTaxBalanceRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenGlobalIncorporatedMember" name="AspenGlobalIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" name="MinimumFinaceLeasePaymentsReceivableAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" name="InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFromNoncurrentToCurrentNet" name="ReclassificationFromNoncurrentToCurrentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPayable" name="ContingentConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsUSDMember" name="BorrowingsUSDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsEURMember" name="BorrowingsEURMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseLiabilities" name="FinanceLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EquityBasedCompensationShares" name="EquityBasedCompensationShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" name="ExerciseOfOptionsAndEmployeeTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" name="ExerciseOfOptionsAndEmployeeTransactionsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployees" name="SharesDeliveredToDivestedBusinessEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" name="PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" name="DerivativeFinancialInstrumentsOptionsOnEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" name="EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalAmountOfSettlementInPrinciple" name="AdditionalAmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfResolvedAction" name="AmountOfResolvedAction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnoxaparinMember" name="EnoxaparinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozManufacturingInc.Member" name="SandozManufacturingInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" name="ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCUREMember" name="CELLforCUREMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMember" name="NovartisManufacturingGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" name="AdvacedAcceleratorApplicationsItalyS.r.l.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVMember" name="IDBHollandBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" name="AdvacedAcceleratorApplicationsIbericaS.L.U.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdMember" name="ImagingEquipmentLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.Member" name="NovartisInflammasomeResearchInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCMember" name="NovartisTechnologyLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" name="PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" name="PartialReleaseOfDeferredTaxLiabilityRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesUndiscounted" name="LeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostMaterialLeaseWithLeaseTermExtension" name="MostMaterialLeaseWithLeaseTermExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForShortTermAndLowValueLeases" name="CashOutflowsForShortTermAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForPaymentsOfLeasesInterest" name="CashOutflowsForPaymentsOfLeasesInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LongTermReceivablesFromFinanceSubleases" name="LongTermReceivablesFromFinanceSubleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" name="DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityShortTerm" name="BorrowingsCreditFacilityShortTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BeovuMember" name="BeovuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashOutflowsFromDivestments" name="NetCashOutflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLiabilitiesMember" name="NoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLeaseLiabilitiesUndiscounted" name="CurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentLeaseLiabilitiesUndiscounted" name="NoncurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" name="ImpairmentChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxOnTransactionCostsRecordedInEquity" name="TaxOnTransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfWriteoffOfDeferredTaxAssets" name="EffectOfWriteoffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromCurrentAndNoncurrentBorrowings" name="ProceedsFromCurrentAndNoncurrentBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" name="UncalledCapitalCommitmentsForInvestmentsInFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_LitigationCaseMember" name="LitigationCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TennesseeClassActionMember" name="TennesseeClassActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MassachusettsCaseMember" name="MassachusettsCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxAssets" name="GrossDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxLiabilities" name="GrossDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountBorrowedUnderTheCreditFacility" name="AmountBorrowedUnderTheCreditFacility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationLiabilities" name="ContingentConsiderationLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_XiidraMember" name="XiidraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEntitysTradeReceivable" name="PercentageOfEntitysTradeReceivable" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForSaleAndLeaseback" name="CashInflowForSaleAndLeaseback" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaleAndLeaseBackMember" name="SaleAndLeaseBackMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" name="DerivativeFinancialInstrumentsCommodityPurchaseContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisposalsAndRetirementsRightofuseAssets" name="DisposalsAndRetirementsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" name="EffectOfIncomeNotSubjectToTaxOnDivestmentGain" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCURELesUlisMember" name="CELLforCURELesUlisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" name="AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.AmsterdamMember" name="NovartisNetherlandsB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.AmsterdamMember" name="NovartisPharmaB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVBaarleNassauMember" name="IDBHollandBVBaarleNassauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaudiLtd.RiyadhMember" name="NovartisSaudiLtd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedLondonMember" name="NovartisUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedLondonMember" name="NovartisPharmaceuticalsUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedLondonMember" name="NovartisGrimsbyLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdLondonMember" name="ImagingEquipmentLtdLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedLondonMember" name="ZiarcoGroupLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationEastHanoverNJMember" name="NovartisFinanceCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationEastHanoverNJMember" name="NovartisCapitalCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationEastHanoverNJMember" name="NovartisUSFoundationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" name="AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" name="NovartisInflammasomeResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" name="NovartisTechnologyLLCInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.EastHanoverNJMember" name="EncoreVisionInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.EastHanoverNJMember" name="EndocyteInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" name="NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" name="SpinifexPharmaceuticalsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMarburgMember" name="NovartisManufacturingGmbHMarburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfUSTaxReformLegislation" name="EffectOfUSTaxReformLegislation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredCashAndCashEquivalents" name="AcquiredCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" name="DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" name="ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BalanceSheetAdditionalInformationTableTextBlock" name="BalanceSheetAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" name="CashFlowsUsedInInvestingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" name="CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroGroupMember" name="UltibroGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdakveoMember" name="AdakveoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReportedValueMember" name="ReportedValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" name="NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPChangeMember" name="PoPChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPYEChangeMember" name="PoPYEChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZPL389Member" name="ZPL389Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfOtherFinancialAssetsSold" name="FairValueOfOtherFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsAsOfAcquisitionDate" name="RightOfUseAssetsAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" name="CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidSalesPriceForABusinessDivestment" name="PrepaidSalesPriceForABusinessDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentRefundsProvisionDiscontinuedOperations" name="CurrentRefundsProvisionDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProvisionForDoubtfulReceivable" name="ProvisionForDoubtfulReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" name="DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" name="LeaseLiabilitiesImpactOfAdoptionOfIFRS16" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" name="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossLeaseLiabilitiesDiscontinuedOperations" name="GrossLeaseLiabilitiesDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" name="IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovementOfPeriod" name="TreasurySharesMovementOfPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" name="DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesCategoryMember" name="OtherFinancialLiabilitiesCategoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsMember" name="OtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" name="FairValueAdjustmentsOnFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" name="ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepurchaseOfOptions" name="RepurchaseOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" name="AcquisitionsThroughBusinessCombinationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TabrectaMember" name="TabrectaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KesimptaMember" name="KesimptaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" name="OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" name="IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOptionsRepurchased" name="NumberOfOptionsRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfTreasuryShares" name="NumberOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NotSubjectToExpiryMember" name="NotSubjectToExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentForRepurchaseOfOwnSharesMember" name="CommitmentForRepurchaseOfOwnSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" name="DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" name="ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxLossCarryForwards" name="TaxLossCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" name="ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsInterestRateStepUp" name="BorrowingsInterestRateStepUp" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NoncurrentAssetsMember" name="NoncurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EstimatedAcquisitionFairValueOfTotalConsideration" name="EstimatedAcquisitionFairValueOfTotalConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SparkTherapeuticsInc.Member" name="SparkTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" name="NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesEULimitedDublinMember" name="NovartisGeneTherapiesEULimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenJapanK.K.TokyoMember" name="AspenJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPhilippinesCorporationMakatiCityMember" name="SandozPhilippinesCorporationMakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIsraelLtd.TelAvivMember" name="NovartisIsraelLtd.TelAvivMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" name="NovartisHealthcarePhilippinesInc.MakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" name="AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" name="CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" name="AdvancedAcceleratorApplicationsUKIrelandLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeutecPharmaLimitedLondonMember" name="NeutecPharmaLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" name="CoalesceProductDevelopmentLimitedCambridgeCambsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" name="NovartisOptogeneticsResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmblyotechInc.EastHanoverNJMember" name="AmblyotechInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" name="NovartisVietnamCompanyLimitedHoChiMinhCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHNurembergMember" name="NovartisDeutschlandGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBrandsInPortfolioToAcquire" name="NumberOfBrandsInPortfolioToAcquire" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfMarketsForTheAcquiredBrands" name="NumberOfMarketsForTheAcquiredBrands" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TotalAntiinfectivesNetSalesMember" name="TotalAntiinfectivesNetSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlinePlcGSKMember" name="GlaxoSmithKlinePlcGSKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SolidTumorMember" name="SolidTumorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HematologyMember" name="HematologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeqvioMember" name="LeqvioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveRSUMember" name="EquityBasedParticipationAnnualIncentiveRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveSharesMember" name="EquityBasedParticipationAnnualIncentiveSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlansRSUMember" name="EquityBasedParticipationShareSavingsPlansRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlansSharesMember" name="EquityBasedParticipationShareSavingsPlansSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" name="EquityBasedParticipationLongTermPerformancePSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" name="EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsRSUMember" name="EquityBasedParticipationOtherShareAwardsRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsSharesMember" name="EquityBasedParticipationOtherShareAwardsSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" name="PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GyroscopeTherapeuticsHoldingsPlcMember" name="GyroscopeTherapeuticsHoldingsPlcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsForLeasesNotYetCommenced" name="CommitmentsForLeasesNotYetCommenced" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" name="IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice65.9Member" name="ExercisePrice65.9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" name="CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" name="CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" name="EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" name="EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" name="HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" name="HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RespiratoryAndAllergyMember" name="RespiratoryAndAllergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" name="ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfFundInvestmentsAndEquitySecurities" name="FairValueOfFundInvestmentsAndEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfGovernmentBackedDebtSecurities" name="PercentageOfGovernmentBackedDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" name="NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ArctosMedicalAGBernMember" name="ArctosMedicalAGBernMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KedalionTherapeuticsInc.MenloParkCAMember" name="KedalionTherapeuticsInc.MenloParkCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CadentTherapeuticsCambridgeMAMember" name="CadentTherapeuticsCambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBearerShares" name="NumberOfBearerShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" name="RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" name="RelatedPartiesNumberOfExecutiveCommitteeMembers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="FairValueAdjustmentsOnEquitySecuritiesSoldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" name="IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" name="ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPromotedBrandsMember" name="OtherPromotedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PluvictoMember" name="PluvictoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScemblixMember" name="ScemblixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MatureOphthaMember" name="MatureOphthaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherRespiratoryMember" name="OtherRespiratoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentContingentConsiderationLiabilitiesMember" name="NoncurrentContingentConsiderationLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialLiabilitiesAtFairValueMember" name="CurrentFinancialLiabilitiesAtFairValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" name="NoncurrentFinancialLiabilitiesAtFairValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherHematologyMember" name="OtherHematologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherSolidTumorMember" name="OtherSolidTumorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BrandsAxis" name="BrandsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromotedBrandsMember" name="PromotedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedBrandsMember" name="EstablishedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImmunologyMember" name="ImmunologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CardiovascularMember" name="CardiovascularMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BrandsMember" name="BrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredSalePriceAndOtherAdjustments" name="DeferredSalePriceAndOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" name="EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetCashInflowsFromDivestments" name="OtherNetCashInflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" name="CashOutflowsDueToDerecognizedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" name="AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" name="AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfCommercialOrganizationalUnits" name="NumberOfCommercialOrganizationalUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" name="ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseAxis" name="FranchiseAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseMember" name="FranchiseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" name="CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" name="CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAndCurrentLiabilitiesDivested" name="NoncurrentAndCurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetIdentifiableAssetsOfDivestedBusiness" name="NetIdentifiableAssetsOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" name="Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" name="CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestRateSensitivityImpactInTheIncomeStatement" name="InterestRateSensitivityImpactInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseTermEndDate" name="LeaseTermEndDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" name="HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" name="EquityBasedParticipationEmployeeSharePurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" name="NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" name="AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestIncomeOnLimitationOfFundSurplus" name="InterestIncomeOnLimitationOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValueAdjustmentsRelatedToDivestmentsMember" name="ValueAdjustmentsRelatedToDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaS.p.A.MilanMember" name="NovartisFarmaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" name="NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GyroscopeTherapeuticsLimitedLondonMember" name="GyroscopeTherapeuticsLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentOfInterestBearingAccountsToBeneficiaries" name="PaymentOfInterestBearingAccountsToBeneficiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" name="CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JSCSandozMoscowMember" name="JSCSandozMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSouthAfricaPtyLtdMidrandMember" name="SandozSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" name="SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CellerysAGSchlierenMember" name="CellerysAGSchlierenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesInc.BannockburnILMember" name="NovartisGeneTherapiesInc.BannockburnILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInnovativeTherapiesAGRischMember" name="NovartisInnovativeTherapiesAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" name="AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1APharmaGmbHHolzkirchenMember" name="A1APharmaGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanInterestCost" name="DefinedBenefitPlanInterestCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" name="AdministrativeExpenseNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" name="InterestExpenseIncomeDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmericanDepositarySharesEachRepresenting1ShareMember" name="AmericanDepositarySharesEachRepresenting1ShareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" name="OrdinarySharesNominalValueCHF0.50PerShareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical100basisPointIncreaseMember" name="Hypothetical100basisPointIncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical100basisPointDecreaseMember" name="Hypothetical100basisPointDecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical15DecreaseMember" name="Hypothetical15DecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical15IncreaseMember" name="Hypothetical15IncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical5IncreaseMember" name="Hypothetical5IncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical5DecreaseMember" name="Hypothetical5DecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>x_coverfront.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverfront.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
M'0    <! 0$              0(#! 4&!P ("?_$ &80  $# P,!!@0$ P0%
M!0H 'P$" P0 !1$&$B$Q!Q,B05%A"!0R<4*!D:$5(U(S8K'!%B13<M$)%T."
MDB4THK*SM-+A\/$U1&-D<Y.5H],8&3=%5%5E=(,H5E=UE,(F)S9'A(7#_\0
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M39'!'6E?D/:-ULX.,4VA6)N-$)XQ0D*78;N)(J1!! C/6D.P>[&<4!8LVP"
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MX'_9J+F/8.F;;LX*/VJ/B$U!BP@H .0*6ZR6VA!^*RI)! JV+*I(B)-N;).
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M K814DJ&WBDQ]PH<(\Z7 Z"K>Z9- 4$+N?.D.@I<.>M 4!O]_P!Z!G;CZT
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MA;N2>:M[%;Y$U*!.:'8J%&0":$#2)F#(V8 Q466IDB[)2MM0]0:K\R?D,5R
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MBI<C!^4>NZIQ0I,:N2E*X"JM2*9,3WD]#2H5BB'<)QDT423#?,@<9HH+$%.
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M0<T!8(:4>:!V.&VE$C-5$R0:BDC)'-2\A6',921G%+L%AVXY5G/I0V-,8SV
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M*A;@0^:5"W ]^?>B@W!PL$9J#)6<'>>* W,62]Y&BB=CAMS)ZBD^PXOD=LN
M]2!Q21)CEM6 <4I#B*MND*J/)+@=!P8W9YH[ *LRL'FFF)H?,R/4T-C%3*R*
MA?(FO05C+W.!2N*A,G"_,G'8\^=9ID.R75NWW%Z.I$24II#H9>(\"E(5PI.[
M&0>HST.#5.3=M>WAFK#L4KERC(OA\[=O^>ZUW.TW^W1K;JO3CG=7*/')[AY.
MXH#[0420G>DI*23M..2%"L>AUKU*<9<27<V]1T"TK4H<Q?8\J7[2:E_&TYIH
M-G:_K-F1M _ K9(/[9KD2A_]X[?_ #?W.W"?_P!U[O\ RU_0]Q.:=<4HJ+2L
MDY^FO61DO4\<X/T"_P "*1@I4,>U/<O4CM8=ZU=V@<>7I3<B.TA94':<XZ>U
M,@1[C"=WE4K"AH\P,\"E8;1HZWM' IH4E0U>05$<&IE;"H;('(\Z9%!P,#&*
M!@%6/(T #OXZ4 )J6 ": &[CV>*B,*A63TQ2&/6<9!R.*F1)%F0E) R/UJ,F
M2B/$RT[1R/UJMW9:F@?G$^:D_K2Y"T(&7N)Y%7)<%8C\S[_O4:06)KD9Z&BA
MV$[\T)!9P>S4A6"%A7G49(G%BB",=120,Y9]Z8T)'K41A#4BKS 4?"2*"0EO
M(I6,#O<=<46*CN^3ZBG84>L$@*Z]*XYWAA.CI4!CUIP5,AD5HB2"ESIQ5SY1
MFCPQVAU"!N*<^]4UR7R=A7+F1P@X]JM465O(D&5<08ZLK&>[/^!JOP^2Q952
M/BF]_:K_ -]7^)KR![='U([&)+G_ #*Z%0D9QIV"/_G2:]EH_P!Q#Y(\+KO]
MQD^;,X^,%;BNPR]93Q\Y;_\ SA-4=5_VLON_,OZ/_O(_)_D>*^QW_P"NQHW'
M_P!W(?\ Y45YW1?[G'\T>IU_^UR?]+_(UCXU[=.:[0+'=G6U?*2K1W#*OP]X
MV\LK3]\.(/YUTNN1:S1EY-?U.5[/S3P2CYI_FO[%0^'WMHMW9!=;H;S9'IT&
M\-LH==C%(?9+9400%8"TG<<IR.0"*R].UT=%)[E:?XFOJG3Y:Z,=DJ:]>W)Z
M2<[;.PCM/L4W2UQU:S%CW:.J,\Q<6U1%X4.H4L% 4#@@Y." :] M?H]7C>*4
MJOUX_L>:?3M=H\BS1A;7/'/]R#B_"3V/OMM385UO[S:L+:>:N3:TJQR"%!O!
M_*JH]$TK5Q;_ !_L7/KVL7NR2_!_J;=D#@J)]SU-=DX=&#_&+;ILKLXMDZ.A
M2F(%W0N1CHE*VEH2H^VX@?=0KB]=BWIXR79/^AWO9Z<8ZF47W:X^YV>9NRO7
MG_-IKNVZR-L3<$PBXE;!7L44.(*%%"L':L Y!_XUYW1ZGZIF6:KH]-KM+]<P
M2PW5GL#3?Q5=CU[[L2;V_97E=6[E%4A(/IWB-R"/S%>HAUC2Y5RZ?Q1Y+)T3
M68GQ'<O@_P"G#(*+\,/89JY;]^L=[N,J-*>6]FW71E;#96HJVIVH.T#. ">!
M69=*TF;WX-M/T:HTOK&MP5"<4FO5._S->TMIZR]GND(FGH4QU-KLL=82],>"
ME(:!4LE:\ 8&3SC@"NEBQQTV)03X7J<K-EGJLKR->]+T/,W:9\8=\D7!ZW=F
M,>-#M[2BD7.6P'7G\?C0VKPMI]-P*B.3CI7!U76IM[=/PO5GH])T*"BI:GE^
MB[+]2@Q/B:[<($E$J1JKYI"_$&IEO9+;@]L(2<?8UECU;60=N5_-(V2Z-HIJ
ME&ODV>DNQ'M\M?:PV[:+A$;MFH8K?>N1D+*FI#8X+C1//!(W(.2,@Y(Y'H.G
M]2CK?<DJDOY_(\WU+I4M#[\7<'Y^GP?ZEH[5.U?3W9+I]-XO*5R94E2FH,%I
M0#DEP#)Y/TH3D;E'ID  D@5/5ZN&CANER_)>I5HM%DUT]D.$N[]#RK?_ (MN
MV2[2E.6N[0K&P5?RV(4-M9 ]"MT*4H_I]J\]DZQJIOW72^"_4]/BZ)I(*I)R
M?Q?Z$AH_XQ.U&RS&_P#2A4+4< JPZAQA$=_'GL=; &?]Y)'VJ>'K.H@_VE27
MX,AGZ%ILB_9W%_BOP9Z=OW:I&G=B-W[5M!2FW>XMCDJ*9#6[NGD* 4VZC/U)
M)((S[@X(-=S-JE/2/48?3_+/.X=&X:R.FS^M/^Q@'9Y\5_:WJ37VG=.7)VQF
M'=+K&AO]W;0E?=K<"5;5;N#@]:XVGZKJ,F6,)53:78[NIZ/IL6">2-VDWW/:
M%UN*[98;G.84@/Q8<B0WN&1O0TI2<CS&0*]#EXBW\&>8PJY*+\VCPM'^-CMQ
MD%@./:<_F; K%H'GC/X_>O++JVI?I^![!]%TJ]?Q-N^*7MNUUV17#3;&CUVU
M*+M&E.R/FXG?'<VML)V^(8X4:ZW4M;ET;@L=<WW1QNE:##K5-Y;X:[.O4S/3
M_P 9^J8^DKU+U/%M=POQD,,6>.Q&,=E*"A9=>>PHE24D(  ())QD#)K'CZQD
M6.3FDY>7E\[-V3H6-Y8K&VH\WS?R2%>R[XBNU74T/7MSO-R@/&Q:8D7:"TFW
MMH;;D(<0$D[>5)PH\$U+2]3U&59)3:]V+:X\R.LZ5IL3Q1@G[TDGSY$%HOXK
M.U>[:ULUKDIT\EJZ7.+$DK:M*4.+;<>2E7B"LYP3@G/-58>K:B>2,77+7E\2
M[/T;2X\4I*^$VN?@5_XDNU/6FK]5W715^1$%JTY?9B+>6H9:60E2FQN7GQ^$
M?KS5'4=5ES9'BGVBW7!HZ7I,6#''+#O**OG[RE]F/:9J_LNN\N[Z-1%5)FQA
M%>^8B&0GN]X7P 1@Y2.:S:759=))RQ=WQVLU:S28M9!0R]ESWH]&]H_;]VB:
M;[)>SS5T+^%"Y:H9DFY)?M^YLE&,!+95X1SR.:[>IZAGQ:;%E57*[X.!I.F:
M?+JLV)W4:KD<_#5VV:W[3M17>QZE3:DQ+?;DRF$0H(C[5EY*3T)&,$\8J?2]
M=EU4Y0R527DJ\R'5NGX='CC/'=MUR[\B0[<OB1A]FDU>E-,PF+GJ!"0J0IXG
MY>%N&4A8205N$$'8"  1D\XJ>OZFM*_#QJY?R7]ROIW27JUXN1U'^;_L>?'O
MB9[<9+RYK6L%,MH.5(8M[ 91[$%!Q^9KBOJFK;O=_)?H=Y=(T26W9_-W^9K7
M8[\7\N9=HVG>U-B(VW*6&FKQ&;[I+:SPGOVQX=I/&].,>8QDCI:+K+<E#4>?
MG^IR]?T-1B\FF\O+]/T-\[4>U"S=E.DG]57EI<@A:8\6*TH!<E]0)2@$\ 8!
M)5S@ GG@'L:K5QTF-Y)?AZLXFCTD];E6*''J_1'DBY?%1V^:SNBHVEGDP=^5
M-PK/; ^X$^ZE)6M6/7@>PKS<NK:S-*L?'P2O]3U$>C:'!&\O/Q;K]$)6[XI.
MW/2ET^6U0^W<"T07H5VMP8<P?[R$H6G/D<$>QHAU?6895D=_!JOT"?1=#GA>
M+CXIW^J/7?91V@V7M6TFQJNS(6R"LL2HSA!7&?3C<V2.#P00KS!!XY ]'IM7
M'5XUDC_\,\OJ]'/197BG]S]47<M$?2G-:=WH9=IYE^-S1-SN>G;%K>#'6ZQ8
MUO1)P2,]TT\4%#A]$[T[2?+>FN!UO%*<8Y5Y=_O/1>S^>,)RPR_BY7W&1_#G
M\047L5%]A7BR/W*!<T)DLHCJ2E:9;:2E(45<;%I.">2G (!Y%<_IW4%HMRDK
M3_,ZG5.FO7[7!TU^3_J46QZ=U7VW=HS\*UPN^N>H)SLN6IM)[J,AUPJ<=6?P
MMI"CR>N .2:R0QY-9FJ*YD[^1LR9<>@P7)\15+XUV7S/IA$A-V^)&@L;BU%:
M;803U*4)"03^0KVL8[4DCY]*6Z3;\P[BAZU,8F2#18'((!YIH!0)*B,"G=$6
MK';#2E* (JMR+$A\S& 7R*A*0U'DFX31;P0#TJES-$8#M452TD;>HI099-$+
M<+>$I4<=*OCW,LRNRXX235J*FR+=9&3FI,C8T4UR0*B2&SJ"GC%3CV(/N-G.
M.:!+L-G..35J[%3[C5;O4#FE8Z$BL@9Q3(#=;QW9\J$^08F723P*E8J"K<7Q
MQ2;&$WD]:$P![TCCFBPH[OC[T6%"@D# Y%( 0_SU% "HD>8(I6 HU(.[(]*'
MR2CPQVW)R?M4:)V.VI((QNIM4"8Y:?/K0DQMBQ?/K4)+DE%\"[+B< J-"B#8
MY[_;])S2&+MK4M8&.,T--H$U8_;4 !SS521.R+UQK^%V<:*O6LYZT[+5#6\V
MC/+CW1IL>ZEE(_.JM3D6#%+(_(OTN*6HS1Q1\_\ &>4?@)8N#G:5J;54A2BP
MS:>XD+_"M]^0E8'_ ,[6JN!T:$IY93^'YL]-US)&&&$/5_DB]2+(S)_Y0^VS
MM@[I=O1=SZ91;UMY_P"TD5;EQUU)?*_Y%.++?2G\Z_F>P%3[,N8;8F=%5-2@
M.&,'DEX(/16S.[!P><8KJ7S7F<CFK\AK*?@HR"D<>=6Q[%$N60LMQI?T*!JU
M(J=$+<$;DJ*!NX.!GK5E%+,(NOQ"6+3^O(^@]:Z3NVG9;ZD#YF4_'=CH2YGN
MW"IM1\"B,;O+SQ@USI=2ABS+#FBXOU=5_(Z<>DSRX'GPS4DO)7?\_,TJ:'V6
M7G6(RGW4(4I#06E)<4!PD*/ STR>*Z7*5I'+5-TV42P:\NNHM03[ _H*Z6M5
MI6AN<_)F15MLJ6WWC8 ;62O<D@^'(&><5GP:F67(\;QM5WY7S-6HTL,...19
M$[[4G\GW1+:EU)8M)6=^_P"H[BW"@Q@-[B\DDGHE*1RI1\DCDUHS9H8(/)D=
M)&;#@GJ9K'B5MD#'U1K>[0DW2R]G8;BN)WLHNMV1$DNH/(/=);6&\CH%J!]0
M*H6?/..^&/CXNG^%.OO9?+3Z?'+9DR\_"-K\;5_<AMI/M8LFI+\_H^Y6^;I_
M4D7/>6NX;=R\#.6G$G:X,<\8)'(!'-1P:Z&;(\,DXS7D_P"GJ2U/3LF#&L\&
MI0?FOZKR'/:'KMW0%K-\D:7N%SMS209,B(\R/ER5!(W)6H*()(Y (&>:LU>J
M>DAXC@W'S:K@IT6C6MGX:FHR\D[Y_ [0&MUZ_M";]&TY,MUO>23'>D2&5EXA
M12H!+:B4X(/U8IZ35/5P\11:7E=?T%K=(M%/PG-.2[TGQ^/]!#7.LY6CD1WS
MI2?=(\IYJ,AR)(82>_<7M0WL6H*))QR!CUQ@TM5J7IJ>QM.EPUW?ER&DTD=7
M:WJ+5OE/LN[M$Y;ER9<-F1.MSD!]:<N1G'$.*:/H5()23]CYUH@W))R5/T_^
M#-.,8R:B[7K_ /)2VNURQ.]J*^S!J&[\P@+;,PN)[LR$H"^Y">N<9&<]1C%8
M5U#&]5]4KGU^/>CH/I>1:+ZXWQZ?"ZLT%)]*Z#.85+M$[2E=F\!-VG:7GS[<
M5(;7*C2&4AMQ1(""A1W<XZ@8K%K-9]3COE!M>JHW:'0?7Y>'&:4O1I_TX& [
M7[HU8V-32.R[4AM#\=,H2HST:04LJ&X+4VE>\#')XXJKZ_/8LKQ2VM7:I\?*
MR[_3(/(\*S1W)U3M<_-JBT:4UUIW7%G1>]-7 2HQ44*!24K:6!DH6D\I/(/N
M#D9%:L&IQZJ&_$[1CU.DRZ3)X>94R.N?:!,C:FDZ6L^D+C>)$.&S,D.LR&&6
MVTNE00G+JAE7@)P/*H3U<HY7BA!R:2;Y2[_,MQZ-2PK-DR**;:7#;X^2*\UV
MV.OZP=T$WV?7@WMELNKC_.Q,!(0%D[]^WZ5 ]:SKJ5YGIUC>[TM?J:GTE+3K
M4O*MC\ZE\NU%CL6N)-RU,YI6ZZ5N%FF)@?Q%LR'V74.M=X&SM4TH\@GD?\:T
MXM2YY?"G!Q=7S7R\C)FTBQX?'A-25UQ:IU?F-.T/M-7V=1572Y:1N4RUI4VV
M9L:2QM#B^B2A2@L<C&<8J&LUOU1;Y0;CZIK_ .2S0Z#Z]+9#(E+T:?Y]B7T;
MJB;JVUMWA[3,RTQ9+3;\54J0RXI]"QD*"6U$I&,'Q8ZU;I\SSQWN+BGVNN?P
M*-5IXZ:?AJ:DUPZ3X_$;:M[08.EKE;=.Q;;)N]^O*B(5NC*2A2DCZG'%J\+:
M!@^(YZ' X-0U&JC@E'&E<I=DOS^"+=)HY:B$LK>V$>[?Y)>;&EY[0-4Z2:B3
MM4Z&91;I,MB&Y)M]W3(,93JPA"G$*;02G<0"4D_N*KR:K+@2EEAPVE:=U?KP
MB[%H\.I;CAR>\DW3C5USP[9>U':HI/4'%;SGI6)E8S2'04O( Y4* &ZY'. <
MU%C0FN2<8'7[TB>X0<E\ 9IH4G83YJI$3UWW^T\GC%<=1;['<;2[C9Z:SR%*
M_:K(XY)E;RQ(IYYL*R%5;MX,[Y? B_.:0R<*YI+&V-Y$N&0;]R(42%<5;&#,
MTY>@BY>#W2QN/T'R]J>QDE/A'R&=_M5_[RO\37A#Z(CZ?]BKR4]C>B 3TT_"
MS_\ *A7M=$O^[P?P1X3737UG(OBRA_& M*^PF]%)_P#ARW_^<)JCJS7U27S7
MYFCHS_[Y'Y/\CQ5V.?\ UVM&Y_\ N[#_ /*BO-:+_<X_FCU6O_VN3_I?Y'O_
M +1.SO2W:78%Z=U3#+S&[O676U;'HSN,!QM7D<'!!R"."#7L]3IL>JAX>1?V
M/"Z759='D\3$^?S/*NK_ (,M<VQYQW1U[MU\C9)0W(5\I( ]#G+:C]E#[5YW
M-T3-!_LFI+\'^AZ;!U_#-5FBXO\ %?J9!JOLS[0-#@JU7I&Y6YG.._<9W,$_
M_)$91^]<W-I<^#G)%I?R_$ZN'6:?4\8IIO\ G^'<==FW:IJSLONS<^PSG%0M
MX,JVK63'DH\P4]$JQT6,$'U'%2TNLRZ.6Z#X\UY,AK-#BUL-N1<^3\U_GH>_
M[-=H=^M$&^6Y95%N,9N4R3UV+2%#/O@\^]>YQS62"G'L^3P.3'+%-XY=TZ#W
M:U6N^VV39KS#9F09K99D,.C*7$'J#_QZ@@$<T3A')%PFK3(8YSQ24X.FCS/K
MCX-Y0D.S.SK4C"V%$J3 NA*5H_NI>2"%#_>2#ZD]:\[J.A.[P2X]'^IZ?3>T
M4:K41Y]5^GZ&/:F[$>U;2+;DB\:+GF,WRJ3$ DM >I4T3@?<"N5FZ?J<',X.
MOAS^1V,/4])J.(35^CX?\RM:9U1J'1UT;O>E[Q)MLQL@AUA>-P]%I^E:?5*@
M16?%EGAEOQNF:LV''GCLR*T>E.T_MID:S^&B-=V4)BW"^7%%FN3;60E*FP7'
M@GS"5A*#CT617=U6M>?0*:X<G3^[O^)YW1Z!:?J3@^5%;E]_"_ P7LKONC--
M:VA7_7=HDW2VP4K=3$8:0YWC^/Y96E9"2D'*B#U('%<?29,6+*IYE:7E\3N:
MW'FS87CP.F_/X>9NO:%\2G9!V@Z3N&F;EI*_+$AA0BN+CQ\QGPG^6XD]YE.%
M8Z>61YXKLZGJNEU.)XI1?P[</\3A:7H^LTN99837QY?*\_(\]]G^II>C=:63
M4\992N!-:<<QT4V2$N)^Q0I0_.N'ILSP9HY%Y/\ ^3OZK#'489XGYK_X+W\4
M6I9%_P"V"ZPE.J5%LB&K=&23PD! 6L_=2UDG[#TK9U;(YZJ47VCP8NBXECT<
M9+O+DW'X0]#V*WZ!&M'[>P]=;O*?0F0XV%*:CMJV)0@GZ<J"E''7(]*Z_1M+
M&.#QVN7?X(XO7-7*6H\!/A)?B^28[7/A?L?:?J%G4MKO3.GI"F2W,#, .)E*
M!\+A 4D!0&4D\YXSTJ>LZ7#5S\2+VOSX[E>BZQ/1X_#DMR\N>Q'3.R&3V-?#
MUVE6->K%7F-<(*I323$[CN%@)2O'C5G< CT^FJI:-Z+198;K35]J+8ZY:_7X
M9[::==[/+G9"=O:QHY7I?H1_^?)K@:3_ '$/FOS/2ZW_ &N3_I?Y'T9U3*)T
MS>1G_P"QLO\ \BNO9Y?L2^3_ "/!87^TC\U^9\N8/U1?NU_E7A(^1]&EYGJ7
MX[7>\NFB.<D09V?_ )8U7=ZXFI8_D_Z'G?9YIPR5ZK^IF?PV=D%N[7-:R(NH
M'7DV6SQA+F(97L6^I2MK;05U2"0HDCG"2!@G(Q=.TBU>5J?V5W.AU37/18DX
M_:?"_4]2]H799V<:![)-=3M&Z0@6F4]IN7&<?8"RMQO 5M45*.>0#^5=W4:7
M#@T^1XHI/:SS>EU>HU.JQ++-M;DSQ'V;\=HVEO\ ]>0/_.$5YC3?OH?-?F>N
MU7^WG_TO\F>J?CO6%:.TN!_]VI'_ )N:[_75^SA\W^1YSV=_>S^2_,H/P.*"
M>T'4>?.QC_SENLW0?W\_E_4U^T3K!#_J_H6GXZ2%6K1N/_MN=_Y-JM'7_LX_
MF_Z&;V<=RR?)?FRD?!U/3:=2ZRNRTA28.G%2E ^8;="\?^#63HLMF3)+TB;.
MO1WX\<?65?BC")]SEWVYR+S=I#CDFX/JDR7>JBMQ6Y1Y\^3C\JY$IO))SEW9
MVXP6.*A#LN/P/5FG_BG[%]+6"/IBR:)OK%NC,AD,_*QB'!C!4L=YXU*Y*B<Y
M)->BQ]6TN*"QP@Z7R_4\QEZ-K,V1Y)S5OXO]#S/KN;I>ZZNNMQT;;9$&R2WR
M[%B/I2E3*5 %2,)) 2%;L#/3%<'42QSR2EB51?D>CTT<L,48YG<EW9M7:._?
M^T+X7=$:L_FRCIN8]#N:AE1"4 LH>5[ );!/EOR:ZFI<]3T_'D[[73_*SCZ1
M0TO4LN+MN2:_.C/.QCMIO/8Q=)\ZVV6%<V;HTVU):?4IM>U"B4E#B>4_4<@@
M@\<<"L.CULM%)N*NS?K]!#7Q2DZ:-6OG;U\/O:]/M\CM=[-]01)$)M3#4N#/
M[U*$*4"0H(*%J2#R.#C)QUKH3U^DUC3U,&J\T_\ X.;CZ;K=%%K2Y$T_)K_Y
M/2_8GHCLHL6F%W7L>DB39;VZ'UNB:Y(!=0G:00YXFU '"DD ],CI75TD--CA
M>G[,XVMGJLLZU/VE\*_(O5[>@:=LTZ_WAY,>#;HSDN2Z>=C3:2I1QYG /'F<
M5IGDC"+E)\(R0PSR24(]V?-_MC[>M9=KUU>$F4_;[ EP_)6AE9#:49\*G<?V
MKA'4G(!X2 .OD=7KLFKERZCY+]?4]MHNG8M%'A7+S?Z>B(/7?9+K_LU@V:XZ
MSL+EO9OK!?BE2@HI(ZM.8^AT)*5%!YPH>X%6;39<"3R*K+\&KPZER6)W7^?@
M;)\.OQ!Z:[.^SK4VF[G;8$&[PH<BX6N8B.$JN3N#L8>(Y6M*R"G)Y1N'!3ST
M=!KX:?#.$E37*?K\&<GJ?39ZG/#)%MIM)KT^*_K\25[%_B5[9^T;M,L.D+C(
MLJX,MY2YQ9M:4*$=M"EN$*W>'H #[BKM%U'4ZC/'$ZI]^/(IU_2M)I=/++&[
M7;GS9ZV<5C&:]$TV>9N@@6DG%"BQ.:? .1FI4%CR'M4H9]:C/N":+'!MZ74A
M20,^]42FD:(1<NP^%N*5G<!53DGV+EC:)-AEE*4A7D*K:;+HTNX5UY" <$_I
M1%-!/DA;@\%!6,_I5\'R99KAE<F E9(JY69F13Z2,DU8N2 R5]1I43$G4Y&<
M5--)$&FV1[Z2 :!=B,?>P35GD5-JQF71SQ41VA,NDC%3H@%^KC!_2DE0 %.W
MFI-@$5D]!2[@$((\J .P?2@ "E1/ -*T.@%)4GJ*8@W/H:;8"C8*A@ U':QM
MB[3:\XQ3K;W#N^!;"D?50FF#4@[2R#Q1+@46/&E*R"*BI(E5CC>JDY*RR,70
MJEY02!NHWH-HN'3QS4"=H=LRPDC)J7D*T+";G@&D%GF7XVM6RV[1IK1K+I2S
M.>>N,D _6&L(;!]@I:C]P*\_UW*U&&)>?/X'H_9[$I3GF?E2_'N7[X7=,IT;
MV26N4&PF5J F[25>9"^&D_DV$_FHULZ5A6'31?G+G]/Y&'K&>6;5R2[1X7]?
MYC_Y-8^*2WZG2DY1HIY&['XA*#?^"Z<L2EKU/_R?U"&9QZ<X?^?^EDS\0VD8
M/:'V>3I@;[C4%ACNW&SW%G+<AAUM)6I"7$X4$+2D@C.,X/459K])'-@;7VER
MF0Z;K)X,Z3^S)TU\_P!"A_"MV]:B[0[/.TKJ^>Y.NMF:;?8FN?VDF*H[?YA_
M$M"L#=U(4,\@DX>DZJ6IB\<^6O/X&SK6B6EDLN+M+R]'_<W0SWB?JXKMI4<!
M[F<Y-"@>344Z+'R>?>TGLQM?:UK[6MEDEMB?'L-F>MLM0_L'MTH85ZMK'A4/
M3!Z@5RM3I8ZW-D@^^V-/X\G9TNLGH,&+(NVZ5KU7'\UY#7X>.U&Y*>D=CO:(
M'(VI+%N8B%\^.0TV.6B?Q+0,$'\3>#SCE]+U<K>DS\3CV^/P^[^:#J^BC2UF
MGYA+O\&_/Y/^3+CIE(.ONT3;YS[9_P"8(K=I_P!_F^<?_P!4YVJ_V^#Y2_\
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M(5WMJ<E*N4><3DHN*?#_ *&9?$VL*[*)(!_^R$/_ ,95<OK7^T?S1V/9]?\
M?E\F77LW='_-]IE)\K1$'_SI-;-'_M\?_2OR.?KE>JR?]3_,S'MI9U3HKM#L
MO;+9;<;C!@11#FM<D-)\8.[&2E*DN'"\8"ASUYY?4EETVHCK(*TE3_SXWW.U
MTEX=3I9Z#(Z;=K^7Y5V]"[Z6[4.SOM<MCME:D O26_Y]KF?RWL A64X.%@$
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M'N*S=0U4-/IY-]WPOFS9T[2RU.HBEV3M_)?J8Q\&VAKK$%VU[)96S#E1TVV
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MBP>RR2/_ +X1/_&57)ZU_M'\T=OV?=ZY?)ES[.G -!:; ZBTQ/\ R2:VZ/\
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M>4SZC+J,KS3?O?Y5?(\P:Z^$C5<&ZO/Z!E0[C:W5E3,>3)#,AA)Z()5X5@=
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M]4ZEAZABC'&FJ=\UZ?,DNVGX?;+VH23?K=,3:+^E 0N06RMF4E(PD.I'.0.
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M^U<A]2FG]D["Z3!K[3(U?_*-:E<&%=D5A_\ FK(_]"K/]7G_ ,%^)#_1<?\
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M:;NLJWSFVW&D2(JREP(<04+2"/ZDJ(_3S KFPG+&]T'3.MDQPRQVS5HW:?\
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MH-V1_ +=_P":MUZO$OV<?DOR/%YG^UE\W^9\NOBA?9_^F*[1 I]L'^/OY!6
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M!I]+%\7ZMT>S?A2[%-=:!TO+O_:7<KF[?[]W9$"9-<?-OC(R4H5N40'5$[E
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MYL=125^:HM';)\:^O>UC1DO0[>E[5IZW7)*47!R.^Z^\^V%!7=A2P A!(&<
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M\4#"*R?2@5,+N- ^0IRH8!Y-1H=G J1]1S0T2C-)VP2K/E4*+5D3"+R1Q37
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MHJR/1VF=G1./^<#2_/\ ]^HO_IU7XL/5?B:%@R?\7^#!<[2.SE2<#M#TO_\
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MK'Z5+Q>:%X)'3+,US@#/VJU9"IXD1$NP)QN!')Z;:FLE%4\2?"&Z=/[NF/\
MLT_%*_ !_@ 0>?\ Q:/$LE'#0L+.UW?/7[4>(A^$,W[.VI1 'GZ4U,B\?D-7
M=*%P$AKK[4>-0>!95[Q9U1"<JZ?W<58GR52B5R2"G(Q5Z7!G?<;\^5 P%(61
MP#3 1<;<2,X- [&;ZE^A%(A+N-E.<<J-!$:NNKR< XJ5\$7W$U.!0QTHL3&Z
MDK QN/Z5.T4[9":TN%/4TK'MD)*0YCS_ $I6&V00MN>8-"8]K\PBT+ ^DT-A
MM$-KAZ"EW)I4CMB_Z:8P=OO0 0C /-( B2<]*8@5$^GG0P!;;.2<]:@T3B"I
M!]*(JR3E0BMM0YH<1;T%"%'RHVCW'!M1.*-HMR#=VND3L,&5T!N![E7I10;C
M@TK/04!N#]VKTIAN/5AN"R,;!6?8:?%87YQ1ZI%'AH3R-@IG;>"!S0H(-[%D
M3T <XI[$-3="PN#9')HVH>\06^E3J5)/58_QIN-T0\1IGR NK3)NLX]RW_WV
M_P#@'^T57@9);F?2H-[43=O[+.T&[06+E:^SJ_3(DI <8?8M+KC;J#T4E03@
MCW%6QTV6:W1@VOD4RU6"#<932:^*'/\ S-=J/_Z*]3?_ #$>_P#0I_5,_P#P
M?X,C]=T__P"8OQ1[$^ JPZGT-8=:1]1:;N-E7,GPG&DS(:XY="6G 2D* W $
M@?G7:Z3IYQC/>FN5Y' ZUJ<<Y0\.2?#[.SU1_'%?B6#]S76\%'%\<#^- =<<
M^M'@H/'"NW@J1X0FI+"DB+SN^!NJY*4.=H_.I*"1%Y6_(X2\C/%2VH-P/S2?
M(IHVAN8*9.3Y4J!R#]_GC%)QL%*CDO9Y!I>&A^(Q=J5C(P.*'!$HS8LB5DXP
M.:A18G8N%DC-1:)&'?%1\1)[#--0X5@9CR=4WT+^10^G<U%91@+D.)_%@D)2
MGH59SPD@X-=JOJL4H_:?^6=#I^B^MS;E]E=_T/GY>-=]K?:I>B+GJ74^H[@^
M2I,9EUYWCSV,->%*1_=2 *\_++FSRY;;/31PX-/'A)+_ #S"V?7/:QV6WK%J
MU+J;3EQCD%<=QYYHCT"V7?"H'T4D@T1RY<$N&TPEBPZB/*31]!OA3^(M?;II
MN;;M1,1XVJ;"&S-#"=C4MA9(1(0G\'B!2M(X"L$<* '?T.K^LQ:E]I?Y9YSJ
M&B^J33C]E_R^!7?BQ^*M[LB<3H'00CO:LDL)>E2GD!QNUM+'@\!X6\H>(!7A
M2G"B#D"J]=KO _9X_M?D6=/Z?]9_:9/L_G_8\0_.]L_;)>'W6I&L-87%([QX
M,JD2BV#T)2CPMCT& /2N)>;4/SDSOU@TT?**^Y#S2_:MVT]B]_5'M6I+_99D
M18$FUW N*:/GM=C/<8(]@?0CK3AFS:>7#:^#_0CDT^#51MI->J_5'T7^'#M]
MM';UHYRYHC-V^_6M26+O;TK*DMK4"4.MD\EI>#C/*2%).<9/?TFI6IA?FNYY
MK6Z26DG7=/LS7 @$9S6HQAT^'H* /-/_ "A*4J[ 60M*5#_22!P1G\#]<[JG
M[C[T=7I'&H^Y_P!#YRVJQS[]<8]GLEF>N$^6ONV(L6,77758)PE"02HX!.!Z
M5P%%R=17)Z24E!;I.D6H=AG:^>G8_JW\K!(_]"K?J^7_ (/\"GZUA_YK\0'>
MPKMB4RX!V.ZN.4*&/X!(]/\ <I?5\O\ P?X#^LX?^:_$^NO9[&D0NS_2T*7'
M6P_'L=O:=:<24J;6F,V%)4#R""""/(BO38U4(I^B/(Y7>237J_S+(T@$;LTV
MZ8X=A7*D\ #%1MEB= ^](#CR,4"$%-@ G)JQ2*7$*V/'UH<K1&*IV*[12)OD
M2=0..301VG(;!&=QZT!M.6DHZ<T#2H!!W<$4[&(N'&0!4^$1H9N1E/D Y!Z4
M6/:<FU)Q_,X%24VB#Q)BS-NCH5D9/W%$\CDJ'CPI2L?IC,J0!L Q53=EZBD&
M$9H?AI;G$*08-(!R$TG)L=4*;04XZ5$!9/"0/:@ ^T5#<2HY(&:-UA0H#B@9
MVXT"9VXT"L,E1Q29.,F#N-%$MS%D_2*1) T =D>M.D0W,!0"AC-' -MA"TD_
MBID0BT!&-ISF@ 4-A8RHXI/D P:3ZFBZ)*-G%E)\S2'M.[I/J>*DE9&B%O<Y
M45HJ2E)R#FK88TVFRC)-QNBAW2?(?)[M!(-;4HKL8)9)-=B"=B2GU9V*R:M4
MTC.TY"0M$W/TJYI^(A;&.$V*:1E*5_I2ED1*.)L6CVB6TX-S:_TJ*R*R?A2]
M"Q6V)*4$H[K JK)-.5HT8H2I$\U;'% 9"A6:4C7'$VB0BVTM]4J/Y5'?8]C0
MNXRI*2-M15;KLDU*F1ST515D#BK=U%7AV)_P[OO"H$8YXHEDM4$</)PM:6\D
M9/WI*0Y8V-I$8 8*>:FI%;BT,_DUK. DXI6.@R+4H\D$?E4MSJ@4%W'RF6XS
M8R<\>?VJMV6*,:,_U-$$M9V)P#Z5O[/@YS2HI\JPK))PJM$9NJ9CE!78T-E<
M2?H53W(>T.W:'"<;#1XB0O#L5<T\ZL#"3^E#R6&P;+T@\YT!Q]J6\/#ON$5H
MAS8"4D_E1O#PQH[HQP>1J>_@K>+D35I';^$T;T'A!%:4S^''Y4[);4%.DC[_
M *"E8G$*K22B.AH;%0U=TLL$#9^U$94*4;$'=,.XP&_VI[A>&,G=-/H40&S^
ME24E1&46F-S8'\_V:OTI;D+;(#^ .?[-6?M2W? GL$G["MI)!0<X]*9!]A@Y
M;74?A-#I$+8DJWN$8"31PPMBS-JE*_Z-6*31.+8[1I^4X,A"Q^5)<$VMP)TY
M( \25YI[F+8)&POI.-J_TIIJA.+0(L;@_"Y^E.T+:Q3^ 2,_V:OTJ-HE3#?P
M%\<EM7Z46A4P#9G1^!7Z4K'0 M#F>4*_2BPKU#_P=?\ 2JG8<&\=[[U':6[@
MI>).,TMH]P53G0Y-&P-P!>4?.C8+?0'>J_J-&P/%%F9"@MOG\0_QIJ(.5H^3
M5S_^"LT__'3W_E%5\\E]I_,^H0^RODOR/=G8MVZ=DNGNR72-CO7:/9H,^!:6
M6),9U]06TL9RE0">M>LT6MTV/30C.:32/%=0Z?J\NJR3AC;3?#+M_P#3(=B6
MT@]J]A  R?\ 6%_^C6I]0TG_ .8C$^EZY_\ A,LFH]=Z;TMH^1KV[W4"S,14
MRQ(1XN]0L MAL?B4O<D)'F5#I5V3-CQ8WFD_=[_Y\S+BT^;-F6""]ZZ_6_D>
M).T#XN^UK65R7'TG<'=,6U:]D>+;P%2E@G"=[V"HJ/'",#/ SUKRNHZMJ,TO
MV?NKX=_Q_0]II>B:;3QO+[[]7V_#]2 >[5OB5T%(CSKQJO6MM,@[FA=D.EI[
MS(VOI*5?:J7JM;@=RE)?/^YH6CZ?J4U&,7\O['I_X</B@;[5)/\ H9K*/'@Z
MF2VIR,['!2Q<$I&5!*23L= Y*<D* )&,$5W.G=26J?A9%4OY/^YY[J?27HEX
MN+F'\U_8HOQ6=N':KV>=J+6G]&:PD6RWJM$626$,,K!=6IT*5E:">=H\_*LO
M5=9GT^?9CE2I>GQ-G1]#I]5IM^6-NWZ_ I*/C([38G9RW96;TJ7JF5.D.2+O
M(C-9BQ-J TVT@)""LGO"5$':,=2>,G^K9EAVW[UOGT1M_P!%P//NJH)+CU?G
M9):&[>.UU[L/[1-6/]H5REW:U7.S-0I3Y;=5'0\XL.I2"DI 4 ,\>7&*LPZW
M4/2Y,CF[3C7WE>HT&F6KQ8U!)-2O[NQ!Z#^,/M9LNH4W/6>IY=^MK,63BW*8
M8:2_(+1#(4M" I*0X4DD'H#5.'JN>$]V1VN>./N+]1T;3SAMQ1VOCGGMYE.U
M'\2?;?J>YJN<GM)N\/<HK;C6R08D=H9X"$-XX'JHJ/J36?)K]3EEN<VOEP:<
M73=+BCM6-/Y\LU;LQ^.#5NF],7>V:^CKU+<F8^ZR2U@(6X]D#NY*DXW( .[>
M!N\)2<Y!&[3]7GC@XY?>?E_<P:GHF/)DC+#[J\U^AE&H/B1[<=27)5SE=IUZ
MBJ6HK;8MTDQ&&QGHAMO P/?)]2:PSU^HR/<YO[N#H8^G:7$MJ@OOY/0_PE?%
M%J_5&KF.S'M)NBKJNXMK_A5S=2D2 \A)4675  .!24JVJ(W C!)!XZ73M?/)
M/P<KN^S.5U/IV/%C\?"JKNO+YGL]M9P!GBNR^YPURCQI\6WP_P#;;VK]K9U#
MI#2?\1LT>TQ(<9XW".UXD[U. )<6%#QK/..:XFOTF?/FW05JO5'?Z=K=/IL&
MV<J=OR9JWP<=BEZ[']$7-_6-A;MVI[O<%]^H/-NK$-M*0R@+;) 227%%(/4\
M]!6GI^FEIX/>JDW_ ",?4]5'59%X;N*7\S*O^4;FZ76=%P$K97J5M4IUS!!=
M1;U)2$!9Z[2Z"4@^BR/.LO6''W%_%_0V=$4_??\ #Q^)1_\ D^TR6>V*]7,A
M0M\+3,IR<H?2$]ZR4 _FE1'V-9^E_OF_*C5UBG@2\V^/YGGW76KI^N=87S6U
MU=4Y(O,Y^>X2>B5*)2D>R4;4CV2*P9,CR3<WYG1Q8UB@L<?+@^I'PT=GMN[-
MNQ;3-HAQD-R[A!9NES= PI^4^@.**CY[4J2@9Z!(Q7I-)B6+#%+YL\GKLSSY
MY2?9<+Y(QS_E#.S^VW/L^M/:4S%0FZ66X-6Y]\#Q.Q'PH)0H^80XE)3GIO5Z
MUDZIB3QK)YHV]'S..5XO)J_O1YW^";6,K2OQ!6.WH>4F+J9MZS249X45H+C1
M/N'&TX^Y]:P=/R.&=+UX.GU3$LFF;].3Z@H VC[5Z,\J#@4 >:O^4*2!V L$
M?_G) _\ $?KG=3_<?>CK=)_W'W/^AXD^&S45CTEV[:*U)J6ZL6RUV^Y=]*EO
MJ*6V4=TX-RB,X&2!^=<C2RC#-&4G21VM="633SC!6VCZ1-_%/\.J #_ST::S
MC'_?2_\ T:[[UFG_ .:/-+0ZG_\ +9-Z2[>^QW7-\9TUH[M,LMXNLE#CC4.*
M^I3BTH25+(!2. D$FB&HQ9);82389--FQQW3BTB_DI.,=?.KS.+L_15<NY;#
ML'J)(Z@#J "$9&#4D5L(E("ABF07<%Q12!B@D)E8/UT <%XX1TH XN*(P<4
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M^@?I2N0Z1EU=L\X%63@<T $R?6@ * .Q0!R/[5'^\/\ &@'V/E9<O_@I,_\
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MD_R/(?PH\_$+HS_\*?\ _-7J\_TW_=P_SR9Z;JW.CG_GFCV?\6H__)XU:?\
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M3,79X2(BI"6R@.E.?$$DDCKTR:[^FQ?5\,<5W2H\WJ\OUK//-5;G=%C;:45
M8-7[C,ER.%069D=V)+C-OL/MJ;=:<0%(<0H84E0/!!!((/7-0E35,OA<7:[G
MF;M#^!.VW2<]<^S34S5G0ZHJ_AEQ;6XPV3Y-.IRM*?1*@K'K7G-3T6+>[#*O
M@_U/4:7K\XQVZB-_%?U13K5\ _:._*2B\ZRTW"C9\3D</R%D>R2A S]U"LD>
MBY6_>DDOO-D_:#"E[L&W]R_4]0=C?8/HOL7M;K&GVWIERF)"9MTE =^^!R$
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MK*W-#=R45'/E4U$A*0@MQ74FIQC3*7(2+V> >E641L34Z#U-1:"PBGDI\Z5
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M?()T%/>MIR0,4J);@H<<5TQ10;@%E9QN('VHH%((2,]::1%R#)Y3UHH6Y"B
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M18T=;)&!0"&;D,K)R#^E2783?(#4!+?)Y^]-<$6Q8,H2.!4J"S@ !BE8@%'
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MQ3\ALJWI6,X'Z4;GZE;@EY"8B!'(\J%)LKX'+22!4NP*5\"F#Z46ATP"C=3
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M5(U8_LBZ7 /(U M2#[A4B)VX4 =N% ';A0!VX4 &"CC@T!0.]7K0*@XY H$
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MJ2PTVL/<EL)VXSY*1Y'WK57%F7?Y47[LG[89VDKBB/"[MJ(3L4PI>X/$'Q*
M]A6K3:EXY=CGZO1K,NY[B[--46;76GT7&SR%+"G<+"_J1GV\OM7;66.2.Y'
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MJ+"CMI'2BPH!0/'-#84<$\4)A08# Z4F- X'I0,[ ]* .P/2@#L#TH [ ]*
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M),7Q(J"^PRB1+4XXM2VMH0HY3^E-CX*=-6\LRU+>"5% (2/+[5<BA^96+OW
MCNK4K)Z%7_KJZ'<SY.Q1YKS9);5Z'!'[5M@<W(RJ/24I>2AI64D_S,GH:U)&
M)L9KDH)<3_C4D5LB5J"GE)VC!'BX\JNB5R)?14M<;4C++?#<C+?[&K49V:HE
M'_\ "4:0M>&G'RR5DY(6!D?EQ6M?9,DNY$:7O2[5K&!.GK2Z8UQ:=2K'5 5E
M(_(&A.BN2MGV-L:6G[- ?9)*%QFE@GKRD&KY/@RQ7(^VC^C]JKW%U X_N?M1
MN#:!M'^S_:C<PVG;1_L_VHW!M!#85QL'Z4K$U1Q83Y@5.#(M":V$YX-2L5!"
MS@\4T)KD#N3Z4Q =P:E:$ 62!FDVJ&A%? -$0D)Y]ZM?8@=GWI =N&.:!V-W
MG=KA'M4D0DQ!2B23ZTRIL*>E A!?B!'M028V<8\)J<7R5-,04T0,\U9N"@ D
MCJ*6ZQ-";F014BEIC=S@\9H''L)*)W'FI%;"'K5J[%3$5BF(,T-O-)NR450H
MMWP]:5%C=(3[X>M%? CN.*]Q'-#0;K%$DTB:';7055+N6Q["]0)!Z86 >0:$
M#Y$BDX_]=2LBHA%# ZTX\L)>ZK$%'K5B14Y#1Y8*AS5D(E4I#5T^/BI41L25
MUHH AZT@$R1CK4RH15T- (35G'.:"7 0I*N*!-6!W1]Z8MIL.1ZUQ#T!U !T
M=#30!Z8'4 =@^E '8/I0 "@=IXH 2R/6HT &Y/\ 4/UHH5H'(/0T##HZ&F@#
M\8ZBF,16#N. :=D'&Q(]:*8K0DM))Z&@=IA<&I$*8!!QTIH*8D00>15B*Y(
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M'(]113'N0WID#J!=@<9H[!8(;/7!I62B@=A]#19*C4B0.M<@[@*"#TI,!5!
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M669[/>*3@YX&:-GP*UEHJF+5<8X8$A!>"RXWM/A/%%-#\15R6?33EJ5!_ER
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M?''NX,F3(HJT)_Q$+X"^GO4_!*?K (FDG^TJ,L5$HY['3,K^7C?YU!XRV.4
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MVJR,?4KR9*=HBYVC8\:,[/DWT(0"!L<2#G/L>*U8X)LRSU#,6[0>VRPZ&>7
MC3&4+)V=[N.3Z@)&171PZ2,^YSL^NE'B)BFJ/B<D=\F+II$AY)SO2ILI*UGS
M&1P*U/1XZ,RUV2Q"U]I.I]3)CF=$E)2A1W;VR-WL#Z5EG@CC[&_'FEE7)LV@
M]7WZZ3+=IB# 9BP6UA;ZDI\2^>:P98*-R9OPR<FHI<'L'2T8W)F(X4G8D_\
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MV;MZOMT533;K_P#,0LY((.,_GBN1K\GBZ=2^9W^FX'IL[QLR_34)^<XZA*$
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M'FI41<B-=G+S]:NOK5B15*8*)*\\*.?+FH)43WB[4J0I82M2L'WHIAN'*75
MY)I;1V&[Y1Z&G06=WZQYFEM$*-/D]:-H]U#QI\Y'-52@6QF2\)6>?:J9K@U8
MW9.QWR,<G]:R3[G0QL>-R3O3CC\ZKHO3':GB6^M*J).7 V[]Q"B=ZN?>FBN3
M%"[O&5<GWHG#<K(QGM9G';?V=P>U#LWOVAI#*5N7&/WL;P@E,AL[FOMD\?:L
M74,'C:??Z'2Z/G6DU//\1XQT2;[IK0,32]\=4OY0*2D$G!2%'9D>HZ?E7B93
MYVH^C[=\5-DAHG?<-0H4XKO#NX /*?:H:CC&6Z97(]$6*WQ8_P#,2=@5@* \
M_O6&78UI6Z!FQ'EK,<*_U=144I.2E1]QYU/'+@L<."%N^D;8VTE4]J.V5XVM
M1U]TI6?0#FI<^19%J*Y&LKLF$N,B9 7.MZ6"-JGK@I63_=&:NQR=\F?+DM5'
MN0JNRK3%I>-SU)<I4IY 4O:2?"H_3E/4Y]JT*:[(I6*<W;+MV?69VW)8N5P^
M84F028\8N?RT@="$'D<5#)J5B5(;TDV_>+?++G=294B.EI;R2IL!.-B?+&>E
M<;4Y?%9LPXO"15XJ7W-.2KBWP@.JR/45''CI%ZEOD>1NVN^.R9RH;ZU;"M1"
M=QP.:Z&AQ4[,_49U%(I=IB"78'+>Y)::5OX0L<J)Y SY?>NA)T[.7C5QHTOL
MEN1T_J:++$MH*F,%AYM@GZDGG..NX?KBJ7-KDMV+\3T)"F6AR2I=P:<BME8[
ME+JR4J3YK2!^(?TJXJ/CET<"HG_] =+ZI476;O&="<J[Q\8R<="4X!5[)XQ4
MGD>14B&Q0=LJ&I.P5#DII$+6ETMJW4[V_EGE+2H#KA!*NGY55+4/%W1-8U/L
MVC)=>=B6CFK5/NEYUE>)TFVKW2TN+=4"UY$I PGG-3Q:QS?"*LVEOFRFKTQV
M?0A&?TX^S\P['#KX1'4^RP@'@J61D.%/.VKY:B7F5K1+O$N&F-+1M8WQ:D6Z
MVLV".C".]@_S7$X\7EQSYUGGF:7Q+UIUZ<"^N;3I.PLN0[+INW<IV*4S"W>'
MT)4:A&4I.VQRQP2I(\Q=HOR[#C*V801EQ6W:D #T\Z[&F=H\_K5M?!74/N.,
M#)/WS6OL85RAU D$#;DD#GK0(ZX+[]) 44@@].*97)6(,ZKA-QTVYI)(:25O
MJ2<8P0.?WJ:96X65?5NJ6Y49H-,[2'%R ?-20DI23^HJ2Y%5<%<TYJF]6FY0
MI]ON#K$QIQ#C*^\4,*1SD$=#3?!-)'W,^&?M&E]JW87H[64Y67Y5NVO.@Y+C
MC6Y"E$^9)%=/%*X)LX6:*CD:-4'2K2I=P>GBXXJ-EVU'!Q!.%D8I6)JAS'5%
MW'D_G2X)*Q[WD1">"!FD3&SCT=2O[0TAA"XWY#(]:9'=1W>(_I'Z4J'N"A2/
MZ /RJ3*T.6>E(L%*0'8S3 0>!3YTR#&ZB2>34T1$E_528@*D5ON-3U/WH'Y
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M^?<_I-&T/%!;GKW@E)Z&J\JX+,4[FI/XC&]W#Y:V2KBI81\FVIT%1P,@$_\
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M7W/XG&'*)+;R4;<?GFB6)-TC5BUDTO>Y,LUIVLZUGK3\FP\XI0ZK4D_N:G#
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M?!>82ZE;P0K*$JYQY&N9JM:L"<7WHW:;#XC4F>19JNU>^R9UW@W5UJ(I96V
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MJP12I$[85QY"<;!@U."3LA.;0=B:6E@YZ53DQ[BR&:B2-[WH"=XQ5<<5%CU
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M9NRQRK@5'87+/0Z1=R#G-)XRQ:D61=N\R%* Q5<L9?#4)B;DH+.0:@H YV%
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M-H;V)E90?6I"M!5O';T_>BK$Y)"?>GTIT0<K\@I)-#!? #[TAG8I$D&2@JH
M-LYQFG0ER#L]Z1)1!*,^=%$P.[SY_M0N .[K_P!L4["O@?/[L-[%;JJP3%&*
M"'%;MJN#GUKPT=^:]J/1Y98X\6;#K6Y"!V9R(1 ;=;C%*TGR(XK3GU;6C6%^
MISH:6+S[T89V8B.]<E*+)6A*MJTI] .M<&VH6CI9>%1.ZVMUF=D,2(J1WB3N
M4$G.TYZ5'ZPW&I$\,'=D:;XXZ4QDM>$\%1SBJ);5&R]1;D,G41H5P2MQE2E*
M.4K2*SWOCP:FE5%T@2$OQTO;1_+'0^=<_)!Q94X,R_M0TU%GM&YM11N2K>H@
M<D5U=%J>-C(N*(;1VJXK,9=J2<*!VX/E5F;%)3WH')-;1]+0MF4/]4"DGQ@I
MH@G(78NFF'%!E*'4X2H>'-+58&\?!4I*RYV=V2A3<1"U=VZ>1Y=:XLMT*1>T
MFCT!:NQVT2[$W/D00MQ;6XJ*1Z5Z[0Z#Q]*IM\G-S9-LZ1457"%HV7W2HP4B
M-D-C%<O4ZB6GEL+\./?R4>[]JS+]Y4A$,-M)Y24Y\)_.N4]5ME3\RYXV#>M1
MVB[Q=K;@W*Y*<#"C[UIGG48?,KC!V5M7S,**XB.YM#@R /\ *GI-3M=6&7%N
MY'6@>V6]=G0DL7MER1 >5N:"<[Q_EBN_@R>]OLRY86J1GO:'VT.:GU8;I;6R
MRRE&SQ$Y//G6U\*T0VNJ96WM5*6M<SO0IQ7K55,7AME?E7N9<'BM:_8 59&!
M8H477LDU?)TYJR"Z[)4W%W[G$YRDG[5;BEX>2_(63$Y1/2UY[6FG[A <AM;X
MS*\N.8Y^]=KZY&:5'/\ !:LU;1/;7;K_ '$6.*5%QO!7ST%:H:J.9[8D)P<%
M;-+5JNW1W&D/2V4.N*X258XJZ32C3[E,)-R)RWWVWS49COH('4[JIVWV-D<E
M#Q[<X@+"AMSP11&.UVRR<]R20I$E+84"%FJ<N.,B>/+*!,LZB?;  (_6L4]&
MI=C9#6N/<<KOSLJ/W2@D^_G57U7PR]ZKQ50PW$DDDU?&'!3NY&<QP)\ZTXXF
M7-(:(F@*">.31ML@LL8DBW\JI/>/*P!YU#(]J+HU/D87"[6^*E2OF&6P.BE'
MBI8FN[*LTMAC':3\0^G=%S$0%36UO+) V>N*LEK,>'@R/=E7!CMRF+[<)X:N
M\UUNUM'<ID.$!S)SS545#52N;X(3G+ N.XV[0F>SWL\LZF8B6"XR-J @Y6!C
MBHZO)I]*O#Q\BT[RY7;/."[]?>T763%DL[SD=IU0(6XKC'G@5YY06?)PSI2]
MR-L]8]GFCM.=E%N1>KM);2XK&^0^1N6?,CVKT&/3X=)!3F^3G^+/,Z1I=J^(
MG3SH#,196PD\.\X-9\W48R=0-N/#)*V3-I[>+7>;^W:X2PZ%$#=DX"O?VJMZ
MQ&J,#2[AK>T6.&S,E2V4A8!5N5TS5<];&B^$*Y)'37:3I?4#J6(-P96H]0%<
MU5]863L777):EO,J3N2L'TQ5V*+[LC.>[L1\B8I*@1C %:H0LSRR;1/Y]M0R
MM7/I4_#Y$LJ:Y&$U]"@2@]:OC SRRI$6\OO!C_"K,2,F62GV(O55K-]TC=K*
MZCO428:V@@\@D X-8>JXE+2Y'_Y6;.C99XM?AOMN1\_9KM[L-Q++CX+T1:VM
MQ'5.[@?8C-?.:43[7%O+CM$KH>]6L:A<,C:79/\ ,4I9R0L8QCT'7BK''BS)
M&/O4STUH^YM3[4(DE:5.+5M]R*S2!Q:9TJSM/)4MQY2$I*@< <8-4R3;X+8C
M)NT0.[<E_+!Y2,)[S>K!3_21TH2D7)AU.P&6$)3!9*DY.U/4>U71[$9)M\$-
M,>WR$LV^VM-E0RH]T"<U.R#3&+S:I!!>85M))<PD=!_QJNBU(@9MG:ER-K<4
MM,YY5YI%23H)QM<$S$BLQ6FXW\L*60E))X_.HME:BV93VU]H;L.V)MMH<;0L
MLJP<9*@#M4#^?2M>EQ*<N3-J)."I'D>\:@=!>#7\QQ6=ZE*R.?PXKMPA2.73
MEP%MFK)EGT\[;X;BBN0WW2G,?22?3J?+]*'%-ET(/'!EST?!F2H#<)A*VV5)
M[R7(QE*2.B4CJ>.ON:RYJ3LUZ:#E[J&VH'5.NKCM%:XS:.Y9'N/3V%1Q^IJG
M%=O(H=U<2V0A)!(X-;H(YF>D)1"D-E3P"=PJ;[F)<1W$47%S9W>X*@"4I2/P
M_:K.R.=-J<['7?+$EJW-.9?>.$@?AXZG[4-TK+M-IGJ,BBBY6FUMQX[;: ?Y
M8P?=7F:Y\\G)]4T6B^J:94N2UZ"U/<=#:ULVK;:]L<M4UN3STV@C=TY^G(IX
MLFU[EW(]1T,=1HY8IKEK^Q]98.LM.3D,S85QC+;FMHD,A*QREQ(4,^_./RKU
MV+50RI<^2/SWGP2TF6>*7DW^9++N:%M@ )W8YQ5V3&VK10LB""4GS4/UIK'P
M0>56&^;;_J'ZU+8+Q4=WS)3D&DD$IH;K>;)XQ4J*[4N [<X).T&C98UFV\"B
MW%.4JHDY;@6$#!))SFDQH4=?2TC /2FHV@<J&:[HI QQ4E JEFID7-GN.=%8
MJ^.)&6>=M$4Y*6#R>/6M48*J,,\CNPOS0/&ZGLH7BV$#NU6_/6EML>_;R'5/
M4D  XI[!>,-WWR^<G'3%3@J13DEN=B21M&,U,K#-K() JI]RV+I#MMP'%1HN
MBQQW_L*JY+[ #P!S_G2IA8HB3SP11MLDI4'5))'7.*2A1)SW#93^<@GI4E&R
MN3 WI/)4:=4*,N#MR?4D4$MPFLA7&34RERY$2HCG/2@-P1R5N;4 GJ.*",F,
M%=\I>2,#VIK@A]KA $*\P34TT0E!@%)/DJI6BK9(#NUGZ0:+0;&%[M>>0:3Y
M)Q5=Q9IM=1+4.ANP.*0 T $6C(S0 GL)ZTT#.+>/.G9&@-N*.XTJ"J(!H[!P
M%*P/2F*P4O;>F* W'!PYZ"HMDHBB5 ]:18@5* &10,!#P!YJ,B<'3Y#=^FH\
MD]R/+>B>T^TZ0B.V^?&+:2#M7C)^U>*T'6884TH]S;J-!ER.[,Z[5.U2V:B8
ME6VWQ=A=;+2%*. 1_P :JUFJQZGB*HOT>FGB;<V4+L[>DVV4ZZD!Q*QX^[.?
M_=7,EDI;4=">-2[EP<2W>75NH2$*/EC'-9<R5HGC;@AC$AJM<P)F,;FU'PJZ
M@?E561[HTBW'/FRWR['$?MB94=M"U*2%#CI67%+;+:RZ?:T0"!+::"20V,XV
MXYK3-194I3"S;8JZL_*H 4#Y8JG'!8Y[B)D-^TPC35\+K8[LN*YW'/6NY&?B
MPID=J3M%R1;P]9^]#_CV\$=2?2L>]XYT2:M$#:]3W.TW%$29$4IM)("O6NC*
M2GC*-JLW?1TBV3X*'G'4A_ 6V KI[5R9X<3>Z:[$O??V37CV_0[%IU5N>8[Q
M]IKN]@&-W%=/1]2\+'M\S+DT\G*V8M-U'?-37%V4IH!IQ14A'](]*Y?4,L<C
MW>9NP0:X*W=;7(CR%..M* 5UKDN$)^\^Z+7:9'O1EL/!P.G8DYP#0LRR^XR#
MX)"3<8UQB(:8D%#S8P/%6G#IE'D@Y7W*[<V)TH_*K=*RH83BNYA6R.YF65-F
M>W31]\C7,1$H5AXX3D9Q75PY%E5%?!;U=A&O(UC_ (Y\DM^,$;B ,&M"QRES
MZ IQ3HHT*&M,U,62"A2E[3Q])H::+D:C*[)7XEB:OL:X94,.;2,9'M1*"V)E
M7B-RVCB-JJY0H!93!W I !4DX ^]4[I8^8E4X%A[%M22+!K"3/FN*2E]!W9Y
M\O*IZ'5^#E]XISXU*-(O^HM1R=1ZE$OYY]B,PW_+*5;<GWQ76^NX\V3N9E!X
MXTBRZ)UK/LDKN6KFN2VI:4E).X\FM,<\%YC4)2[GJ/34E^=;6WG%X"@" :OW
M+(J1*$6F2:]R"/%G-1>.^Q)MH.DG'6DM\%0E3[CF.\4<"H23EW+X/;V'7S7&
M<\U#;Y%KGYC:3XP2?.K8VBC(]Q&)0YN"B>AJZDC"E*7<6DEU<5QH.!&Y. <9
MP:AX<)NI&F.2<(\'C_XA!VCZ9E.W&)J)QN(HXVA'K7/U./)C^QV)QS>+PSQW
MJV^7V[7=Y=UN3[[K:LI*CC ]JY,I-OWC3CA$D-+]HFL+?NC1I[R$ ;1@XXI/
M-)*DQ2Q18%XU+>[H\I4QU<M:E945J)P*S24Y\MDH1C$6T_.?M=PCWF#_ "GF
M%]X%#G)_SJF,I87<>Y.24E3+?JWM(U!JQAIJX/N);0!U/'Z5++JYYOM,IQXX
MP?!H_8K<]//0EIN4UIA>TY#JO#T]*ICE\/N:BX:28M-MOTZXV>ZI4<E0W'*5
M?[M6O-&78G<44WM6[:+U/?599+BD-((2%(&WH:<8;GSV+-[:J(V[-.T*Y:4F
M,W*)*=D)*AWB2LGPYS6J,5'L0<GYGNC0_:M;[U9F)BG&FRM*?Y:G/%G%=W3X
MXY(6S'ESN#I%P-^;E-A82E 4. %9S[UH6":[%+SQ?<B[G>T0&C(<7A ZU:L+
MKGN43S^41O:M3PKL@=PXA1/(&[D59&#2Y*5EM^\2;(.>Z5RM7(/D!4%[WOKL
M60CL?A/F3\_+U'7S$2#!ESK@[W$>*A9??60$-I"3E7/6N;U/40Q:>>_A-,Z_
M2]+FU.KQX<"W2M'@+M!MS((U&PAQ3*GU,NE1^M(SL6/3BOF\IJ<N#[/APO38
ME&?VNS,NU(BYV6=#U'9/YK84%%OKD>=:,4MRVLJR8]OO'H3LHUY!OD*+<F)7
MCVC;GC*O,D>7IBJ<L-I7:F[1K2+W'$8I+S:W7<N;%'J?6J8(G))!';YW3 :D
M,,H;=3N):'''E]S4QQH26Y$<:2&5I0HC.Y:2!^HHX\R5T1CBV(JW93[BD=V.
M%!6X'WP*E[K(6R!B:@+C;JDLDYSU5QA(_P"--QX)MU*B(DW>3/="0ZPVV>7=
MKGD.>*48^H3;[(IFINT)F+#D9W;U)4VC"QEM/G^?H:<<3<J*W*DV><.TG7*[
MC) AJ[P-([E*<<A./7S.?.NQIL,8JSFYLDI221EDET,-!^2V#XMR1^+-;TD2
MGBCACN+!HJRO7F>)+B=W.4[O(>E9\TMG8JQ3EG=&O,M-VJU&.Q-3&4 0LA/B
M(] :YTI.;Y.O@PJ**#J%UM*5EMQ:01D'/)]Q]ZTX>73'E@DN2CNM&4HJ.1MY
M^];KV]CBYX[G[HRNTKY6)X5>)T@,I]/7/K4H*V8=5-8\2C'N,67!;X2GEA17
MU !Y)/D*L[ODY^UTJ[LM&C+&\\&[E)9P\[D@*ZI3Z5CSYMO"/>>SG2XTLV5%
M\:BMM-D8P<USI3;=GN-C:I_9\AG(+2$!!/57'^=70ON9]:U]KS++ISMFU+IN
MX,.KN3[L6(TV&6PK\(KHX,TXL^%^TNFCCZA-+LTG^)[Q['^W&RZOML>,X^DR
MNZ2?KY''.:]7HLWUF&V/<\1J)>!.Y]C54W:.]RU*2,UN^KS]3++41?,0GSSA
M(VK'6AK''W9=RKQLE\=A;^)AOAQP#WJ&W&NZ+O%DPS<H.'>V^DU%J'H3QY6I
M"J'<*W*51C:FZ2)2:;MCP7 (2,$4MC;=DUE2[A1=<=5"D\5DEG2$7[D%@^(5
M..(A+.F1DB:?(U:L9CR9K&QE+Q]0JU1HJ>1L;N.;TD'SJ<;LKG6UB24BK6C/
M%AR24@&HHLD[0&P*ZYX]Z+%&*8(; ^FBR3@@"E0/6BQ;4"VT=V?.JVW9-15#
MA* GI0-!]H]ZKHT';1[T4!P %/D :.6"5 ;![TN0:LXI '&:?(EP<GZ12Y&#
M@4[9%Q3"AI!/-'(;4*&+'(P5"BV#C%G)C16SNSG\Z+81A"+L,40SU;_>BY$W
ML"*;B#HG'YT;I"VP?826W&)X'[T.38;(A"Q')S@_K1OD0>.-@I:93T!_6C=(
M-D4 0WZ?O5B(.A%:D@X% 4%R:1$"@#L"@ CG XJ2 065'D4F(;*4K<<FI*-H
M@^X&Y7K3VH0;OEXZT;424F<A]S<!D4MJ1-38J7%$8-*D2W,+N-&U!N8.X^U&
MU"W,\.ZTFNPTB1L;4R"/$!ZU\>TTI2=4>[EM*L[-TO*V.[T*=4GE(&<'UK5)
M3CR4M)EFT1"M<;QM1$A+F>HZUCS2D6J%H?M6\*NRD0F@DJ).$U'Q/=ME<\?)
M!W]V[V>ZI:FL$MK4 -U3AMFN"B:VELL%Q^8*6!PG RGRK%G6QV78LFY) :EL
MLA;GS,1&?M2PY=W<O=$/#C7. ?F/%@<U9++%LKHJ>O;0B_1/F0TD/)YW>>:Z
M>ERUP1:H+I..MBU(;FN%:D>:JKU#N7 >16=8Q[@ZZ9-MC;U-'.!YCSJ_#*N&
M425L=]F-\O,:^[I\93492AM1GA-5:I<4C1C:1HVN^]4ZQ+C.$[L$8J&GA%0]
M[N&1J4K)#3D6<F$U+WI2#Y$UR^HS4>$782RS(\*\0BVE:>]2,$^]<O3YG+@L
MG S.=;K@Q.,1\J[L=":M4>=R,[7D*-:594A3[3^QP\\'J:W8M1DX1"6.D<JV
M3HCK$I"7'NXX7MY)]S7H<:E/"89*I!]07>(Y<H,D,);4AQ&[CFM>C3AP5-'H
MIWM9T5#T&VQ-?;0IAA2.[/1S(Z'\Z[N'/&$&F998Y.2:/'D15K<UB+E<=C4=
MY:G,'IDGBL^[>S<FTN#UQV>]G%OU;%B2U3%N1BV"$'Z5#[5H\+<J,[R[62_:
MMH?3&GM//(9MZ3W;0P&VQX>*JU.#9$CXFYGCB_ZD>MD[=;EJ1S^&N/CQ.<S1
MMX'MCOTN>')1F.-N$9P5=:EX<X-T5M)$WH_74FR7YMQYW<T',KYZU.&>>-^\
M-I4>EG_B=AV&V,AM:E@I!!'EQ76_U)/&E'N4QAR-K%\7<:?<&F)27$-K4!N/
M2I8.H2<N19(<'H?3.L(.I83<B,ZDAS!!37<A-95:,>YHGTJ5GA9/O3<"<9@&
M4L**2H\4O#'XG([#Z5)&1GBAJB:=B*G4@=*7<BY)"8?"R$^M*4>""G;HH_:=
MV?QM=1C"G(!;5@CCS'E5LMN6.UE&[PY6CR]VK_"HTRC^(6MI*2WG>0,=!7(U
M/3I?:B;L.I3X9D<WL.O'R27;<<%1QE/7\JX\L;@Z9LC-,L%L[-H^@K$;C>T!
MYLJR[WC>Y9SY"FVHJA26Y\&2WBZQU7I2+8@);*B4I"<<9]*Q9598H#^+;WI[
M9W^#/)K&\L<7<J?#%6;3+C.G:ZM/V--9H9>Q/>3MDU'.L;G=]XLH_%SY55).
M#L'R,M2R6]0/?,)&"!S6[!G3X8X2V.Q;2MQMUN28\M20 #U/G75CD@E8YR<^
MQ*CM.U%;KFP+2Y(,=(3PVK@UKAJ$VE$KEBX;9ZI[*.U^\WUN+;I%KE-> $K6
M.M>CT\]T:HX&?W9\,O7:!K6';[,^;BYW*0PK;@]58X-2RRCCAO9#&I3R4CSM
MV,]K%W_TSE0KM=RN$ZO_ %=3JASD]*PZ;/XT]K-VJQ;(6NY['9U-;85E<N\^
M<TS$BI"GGE'@I]-O]7I574-1#I\'ER]C=T?1:CJF2.CTO,F><NU/M4N.OK@J
M+$6[$L$3B-%"\=\#P''0/J4?3R%?*.K];R=1S7Y'ZM]B?832>R^GA/-SEEW^
M'Y>A785N%]L)@RCN9DL_+*W= I/17Y&L>/+P<;KNF4-?)KLS$KQ"N5AEKL,S
M<YW+A2$J\A^$_F*Z<))QW(X.1.,J8MI2ZNZ<>*&I*HS4APJ64<=R1^(??I4Y
M>^C,H[6;+8>TF*J.ROO?YZ$[2K@E0-4N%$FU*B?3VAV1:=TMI#800K_K>M1:
M?D6*,?,9K[084V2B1$DJ5'4HYP<@CW]/RI.#)**D[1"ZE[48C3*HD=[:%]5
MYQ[41QON3<(K@J#W:.U%MA>CN*(>1W8Q_4>IK3&+?#(SBKLJ5[UT_#AK^3#K
MH4,EXH .[^G.:NACLIRQVU1F-\UE(4'&)3BWU/ EY1ZGT%:H8D^2M1<N&9W=
M+HV'2EYQ2G<[D)1R,>6?>MD$42V8>9=R'*9<R8VLD*"OP9Z?>KFTD<K.\DY6
M^QKVDF$6N*VZWN+BD[B$BN=GDVSJ:7%&DXDO*N*I49U<EKND-<HSYFL\5R=2
M"XY*%<GI%WD#O5$-CA/VK;!;%:,N:3R^XAC-BHBI6M0QM X]!ZU:GN,4H>%S
M(I$J8FYW4%A6]N,2E"?(I/55:XQVKD\YJLL=1E;B2UBMSE_NX6HCY!HCN_1:
MA_P-5Y9[8NCL=%Z3DZAE4DN$:[:[<F,G.T 8ZUQ<V2SZQI])&&%8H^0E<7 P
M%E*CSZ4H>\/495'&H>A5)\QUQ9;0LE0.4^U;<<3B9\KGP1=R9FQ;>F\)0LIB
M@M/!'*FT*Z+*?-(_;K6[%*#6Q]SYU[5=+RRE];KBDOP+MV/]HLO1=Z,TS%J;
M4@ E*\I2?O5BR9-++=!G@)8(9HU,]#V3XE-0.3VS%DAYD  I)%7XNM9HR]YF
M"?3H)<'I70G:5;=36CYIV64O>8KU.BU$-9'>^Z.1G@\+I%=[0>UR%:T.P8,H
M_-%!"//*J6JU6./"(X82?+*WHCM]=M]K2YJ625.I*@5J1R?2J,6NQ05S+I8F
MY>Z6_3?;Y:]4W@6RWO;E'!(VX\\5HT^KQ9I5$ADA."MFFHN#KK2<J*2.OO6M
MP<7R9?$<CC)4>2X?UI4@W,*I]P\!9(JR,51"4W8BXM9_$:=40Y83YA><;*=$
M[#!2B<%&*:C0F^!1-#((Y9(2,5%%C['-94>M(DAVVWQS4).BQ*P2A(/(J-CV
M@  '@5)$6$*E9ZTK'1W>GUI#L%*U%0R: #+40.**$F$[Q0ZF@9W>*/0T =WA
MZ$T!9P<P,"@+.WJ]: %-QQ3H5B*CX>"<T4+Q GC_ *S2JAN6[@[^9_73M"VL
M!2EIZJH[C3V@;SZFEM'O 4M6,@T;0WA4NG R>:-H;A/YA6>M3(6&R">:="W!
MJB,Z@#J ".>E20"2^#@4F18U='B-378B^X2F(X]*8 (^H4F30J"2:B2!) Z^
M= '4"/"\JQO7#3RHMR<4' D9Y]*^,XLZCGM=CW#,YLVF(#=W^26^YNW\'<?6
MNMFRJ4;0H]S8[; 8@,MLI)(0.M<>]S9I3X))IZ+$D(FY (\/%4R3K:5MV[#Z
MK7 NJ&93H24H3GIFJ\2E#@4VI%,LDU:KTLP9 [E'4'RK7DQ[X*S.O=+*]=IB
MHKN)21MJB&GKR+%,:Q)SBF^]>>2\@^G2J\D4GP6.0RN\>/*944E+8(SP*U89
M-(JE*T9C/N5QMUP(B.AU"%<H\L5U-BE'D2%X=RE1IY7+3_+>3DY\JBL6Y<";
MVELT_;C<W4Y;2EO.Y*@G%<G5YO [E^-;BWO65N>@1'U8<;'&/3RJK3:O='<$
M\34A]"L#[,/Y5M:B , D\US\FH7CW+L70AQP1WR5SLCY?5)&W/0FK<^HQ<**
M*XVF['%Z>@S(J);H"3[4\<')6B,Y"5F;T_*D=RM]06H<#-7X=/EG+<BN>6D7
MBVV:V]T4L8.Y)!XZUZ;';Q>&<J<WOLSG7^A-D>3-C\.)&Y ]Z%D\.5%RE:,)
MBJO]TO3=LN+KI;0H^$K)'7TKH9,Z4.!4+ZNC,-368R%GA)\^A%+3MODG$]']
MAO;;"LFFHEE;F[Y3#904$\@Y.*Z?UE8L9AS::67):-&U#KN3?["_,FQ5>!.!
M@_4/4USEUJ$9[9<FC)TF4X6F>,[U+9FRW]J DA]7EBJX\NT6+A4(V]2VTA 6
MH9]ZL:_B$^2Z6'1-QEL&=(3AHC(./TJ#Q^)RBINBOZC1<(L@QN]64(Z J-$4
MNQ9&F#IBX+1*"GT@I;YP:N2HC.-GH/LP[;T6&9&@)6HMK6,C<>/*NEI-7X*V
M,PY-,WR>R=*:BCWJ$B2T04NH!'.>:[<);EN*8K8Z9,I"2D' YJ'++> U+D+"
M;#YU,JL I'D.:E'N1:L7BM%U>%'('(S49NNQ;CQWW#7VRPYMH?9DH3A2>I2*
MS3E)Q:LUK$E5(P&_VBS1X\F-#*0XT21M&,5P<K4+;-"@S*M?ZLMO\$;MMR"=
MXRD#C\C7"U6K>1;8ET8;3SS=+1:_XB9D4CE6>E4X\LFJ9&3(K4.HW[6V&H;8
MW?:KL6!9>XHJSM/ZAN=S5L6WTZDU++IXX5:"2)^4['#"E.X"L9K/%N8)$!"G
MJD..(0/ #5^S8K'*%H2NDU$-!>V)..O IXW*3[DXPI$KH/6EG=E%4A@K[@I/
M"> *ZF!RQ<E62#:JSUUV8=JFAKA%;1;Y*.^",+! RD^@KTNEZA';MD<#4:";
ME9"]O]\M5VTW*[J4H!+.4%"SN)\^*AK-3&4-L2_0:.2RMR9YDT=<7/XQ"BQG
MMSR7T*3CE6/<5R/K:P>])T>CQ:#)K)>%AC;/3VI-<7'44%BSX(@1 E12#XG7
M/]HKU(Z8/&*\)UCK.3JDFMW"/TK[$>Q6#V7Q+).*<Y)/E)M6K_J569(2VE1]
M,D_?UK@0CMX/H,,;3<\GGV)W0,U,^WS8P6?Y,GC'/6NACCM5GSGVOC^V3CQ_
MB(_M*TE'OD5V_6]:4/VX 2$I&>\0/?J36C3S:C3/+9$F[]#'KHB.F,ER/)2^
M%#/3S_I-;879GR4UP/X3<MVVA^#GYE(Z=!BIMI/DJBO=X(QC54UN2&9L[:62
M2MA20>\_,U<HQKL5;W?+)9S5<<,,KCK2M9Y*$ ) Y]!5;B]SX+H7W*K?KW*?
M=*BGO<DG8G@I]JLC%KR-$5%]V0AO7?14-/A+:0K.XKPG]*L4)7PBS)BCC7[1
ME9U'KBR1/]35>V-B226V,N;3_P!7I^=70PS;Y1FEKM%B_BME$N>MERG%)M</
M:E1P7G5;B?MZ5LAAV]SE:CJDINL:X$8,"2I)=4@]>]4LGKCRJW<EP5I2FMTB
M<LL)I=P0^GJOQ$?>JLDN"I7*7)=X\A*7VFOY@0D^,I41@?E6.7)TL34$D3$X
MJN;2$_*N=VGWPDBJ8JF;E)R1!3T1(FY;JT!+8PEM/D*O5R)+ XRI?Q&;ZVU.
MIE'R[8_GRAM4D'Z4UT=/CLXG7-7#2+P8\OS*Y8X$ZXR1;H&$]X@%Q8X*4GR!
M\JORR6./)P.GZ:>NSJ$%P;WI+2C-N@M9:2 A/3:.OK7GM3JK>U,^U]'Z=_IT
M%B2[]RP2=C#1"0*RKDZ^9J"X*E<W]Q4,^M:\<3AZB5LCK1!3,F$JYP:OE+:C
M-@Q>),M'\/B-I*7&L[TE!QY@^1JF&5[C;J]#CRXMF9>Z^#-M3:<DZ1>1/MP(
MM3BL(5G^R=)^C'3ITSP<UV\.6.=;)=SXM[2^S>?H>;Q8*\;\R9T1=Y2+JRW'
MP<GD>7Z5GU.G;1YE.,>?4WVT:FOUGCA=ND<%!X!(K+ASSP\*3_$RY,,<G,D1
ML74\N=J1%RNRE;MP2$DDC/2K8ZB4Y]V5/#&$>QKRM/P;M"+JFP4(9Z >9KMP
MQ>+&SF2S)2VT+=B]JLJ-1SI+2<+96$'/E@^5=/I,,<<G+,VLR24#6KWVN6G3
M]S3;Y"? ZH()/E74U&MQX,JCW3,>##+)!LN5GO$>YL)=CD*0>AZULJ.:&^!1
M;A*I$FO 5L&*A%\662>YTA)0(/-/<F+:T'0VHG'K2<R$<<K%Q$7C'^50W<FJ
M,+5'?)J]:EO%X09$4I/BY^]1<AJ&WN'#&.F*C;)\!DI*>":!?('%( IZU,B^
MXD5C)XI6%!*L(!VSXA0^PUW%LCTJHL"G;Z"FA-T=X<'I3HCN$%^U-(385/TB
MI"%$+ .#2'8(<YQ0.T+;4_TC]*K)4@%I2!T% -"2^@H$@FW=0,*I(!Q0 &*D
MA,24!D\4""=W0 HCI3 &D!U '4  I.:3)1$U!(.#1OEY(C*B,FW.!#<4'5C<
M.O-3MU;X(5N[$6O5EI2]W)DH!/EQ1XF)=V/PY"DG5EGB?5+;_/%*;>'S&O>\
MAU OMLG)"VU)R>E."<EO$W3HDFTM/#<DBB6[NB2:%A&&>@-5^*UPT6QBI"GR
MP]!3\5#\,\33G%NH)2@+XZ5\,=Q=H]D59$$QKA\VM@)R?*NC'))PY$N&6U-]
M@AI#3Y22H8Z]*SXU*^Q*4N!G<Q'>;(B8PX.3Z5-7NY(I\#*T.2I:7(BW!])3
MUJ>9**M$4^0;#I]N%+D$J!)SFG#(Y)$W%,K=]U-&M(D#YA7F.*VP@Y]D0<:)
MS0MTMEZLH>"UE23G'_&L6IPRC+L#:]1W=[1<9)*H;H2V148M05/N1X,]GZ9=
MAW%3DB4A.<[BHX%=..3=#@DFF6?3.CDZAC]\^ZDI"L).>,53EU#Q*EYEL<7B
M%W,%%D899;(4$81D5R<N/ZPVV71CL[$N]:'(ZFKC&4%=XD$XYJJ&)8UL0YW5
MA%WMR!<$_,L+4DGDXXJG/I5*%Q[D<62GR.+Y!9O+0D)4G!&1SZUR\:;G4B[)
M!-6AM%T@AR#\LL[=P*1FNADU7@KW.2A8K[D*= *AW!!8<&[/7TK3INLJ$?>5
M%63!?8O6FXDF"K^>A1Y ''6M*ZQ&4KLSY-(]O".U6&Y#G=I0E6[Z@:HR=0;E
M=BA@I4S&KSH:Z1;R_=V6BEH))2$CK76P:R&9*.[DC/&X^1B=^=G3;R^WW:RM
M)VX"3FO2XJQX[95\@^F&+S;[\P\\V6F.\!2<$*]\U5/-CRPJ,DV2BFGRCUGI
MS5\.#:FXTM29*'D X2<GI_C7EM1IV\C?8ZL<ZV4CSUK"WK_TTEI90I"'#E)(
MP#SY5Z/%+;BMG-V$Y9>SQ^[2&"F2&@<%:L^59<6J<Y["+BDK/2UBLVFK=HHI
MD.M(?+>%.*4 00./UKM8:4:9@ROWN#R-JNYI;NDIH/%P=\L ^6,U4H^\V:,:
M9$Q>]5EUI6"0:E:+J]31>S7LPONIM\X2^Y0G\7F2.<5;#'OY17DE&)OW8MVF
M7?3&IF](7II1V>!OCZD^HKI:/.U/9(PZB"E'=$]<0I8>80ZDC!3G[5U9I1DT
M9(-N*8N5@<E0%1=1[CMA0[DXR*E3%P"O)20D9/H*:7(G:Y%(TAEM?\Y:1M/(
M)Z4I1W=BR&6NY$:Z[0K1IZSR'I;C6Q+9R2L#;Q6+*_#C+=P;834JIGERV]HU
MDOEV?3!6#W[AW.+4!QZ#UKRV:<IMI]C8W15=:=BEVU!<S*AW!)0XK<G)^GVK
M L2\2@\1T9IJG14W0K_R5Q7WBUH*POR/O54HK=42IMRY,TOT]E:3W@Y\_O6[
M38W%V703H+9-20(3.$IYJS487D'*+;'$C4,>5OZ9(XYJJ.GVDE$AFKVF'WG=
M$;B?6KGC<E5$J&LEQ=T2IUQ0"3PH>H/%*$%!DKX/4'8AV6Z6AZ.4]<T!;ZV]
MQYZ@@XKL:?PWCDY,Y>IS261)&0HA-1M;7-FU/NQ41WE!"VU8)_*LE.4N#:E[
MO(XEZDN%RB2X<^67EM'NTN*5G)/05HM0B[&L3G*,8^99NRS03FG8KMWN"=]Q
MEHPWD8++7I_O'_"O#=9ZAXLMF-\(_2'T>>R4>EX5U/60MOLC27'@A 2/05YU
M0V\H^D1Q2C+Q&[^!7KW<D16E$J'(/G6C%'<^2_/E\>.]\5SR,>PG5R+OJJ]V
M=S&UJ.B4>>A2L 5U]1B\/&F?,/:'.M1E?^>AN\UA+KOS##9 DC<IW'" .OZ]
M/SK'C=*I'F<C]Y.)B_:EV=)M\Q=VL+);M\S^:6B.&7/, ^AZUOPS<E3*<D$N
M41VG+5/E6Q0D-$*SQ@>6*,DML@BMR*[K#2C3T=>=J5XP%'DGV \JMQ9:(9,&
MY&27/2-P;W_+JDH.?J2ZI*O\:W0RQ\S*\<UPD04W0UWD-B:]?)80@8*.]43_
M (U<M1!<%,M%ER<V1;_9S<)8+H>><0H8 6YT]ZM6J@59>GZB2]Z02W=F*F71
MW^Y1)ZXJ;U:K@IATIN5MD["TO#@O+)8WX]N*J>=S.ABP0P\-6*O6AR0HMI&U
MH] @9W>U-3'DAQP/X$$1H7\0*4@J4&F4CJ5>N*C*5F:&-]RU62V'N2XM)#@Y
M=7C@J^_Z5EG+FCH8\6YVA&[7U$$]W'(("2"0> :<(.1OQ8GY(SC4%_8@1W94
MQ60M)*&Q^-7J:Z&*%NC-K]='08G._>,T09E[G*EN',E]8;0$^1\A6]UCC1X!
M;^H9_$?+;HWOLS[.!;HOS4IM/>N>)9Z$JK@:S6J79GV/V8]G8Z+'^TCRS1G&
MD1VTMI& D5R/M>\>T6)8,;3Y96;O+1N4D$?K6O$GW.1J<I4IKA>)2!G!\JW0
M5'&F]Q(V.,M"TJ2#[\57EDJ->C@]Q9Y%OD2F VR%!0YSC@UCC-+EG9RZ=[-S
MY3\EY"L&RN.1UPIL5N1'>04.-O)RE1/IZ'T-7+5*+M,RY.E?6<#TVH6Z#_D4
M1W2\GL]OC%P;:+UJE/=U&DJR5L*)_LW!YD^2NA'!KL0UL=1'8WR?#O:CV2S]
M$S.<8MP;X:_)_$O;FK!':\*T^$!1YZ ]#6*>-IOXGD9)9$O5"EDF_P 8N"VW
M%% 2 M*AYGVIJ'AJP<=R/1'959K_ *@L\EKODJ82DI2O/IY5U<&>3Q.*[F#)
MHXJ>YHILL7;L[U7<8[+FU;J@O[\UFQ:G)CEZ!/2PFBN:KU'<;M)<E37,Y&4\
M]#ZU'/JIR>ZQ8]+&":1N/P]:W[ZT*CS"E?<J4D@')40!TKU/0==+)'PY'*UN
ME6ZT;;I/6%BU'<EPF6DI=;.%<\BNPYO[*11CPI2MLO:[)%4 H)SGG(JI9=OV
MN#;/3IKW>11-OAL8S@9]Z@LDGV18]/"*Y8E(::0A2DJ&0/6I1<G)6BG)''&#
M::(]:SMXK2T8=XD5$\&DD#E8!.*=T($<^5#8 $'/0T@H;N@Y/%2\A5R)T),&
MT!D>HJPJM %8 X4,T-<!= =X3U(%0KX$MZ.+F/I(-.B+E9P<4>HIT*P0KCGB
MFD"8.1ZB@=H+D9ZU*B#?)S2U!0X.,TNR&NX\"DGHH52:#CSP.:.W<7?A!5 @
M<@BFW8FF@M(01?)R*"2$SUJ54187(]10 (YZ<T6@"J<0D$E:1CWII-]A6A!4
MQ@ Y6E7L#R:>U^@[0FW<(BE;4J2DGCDTJ?H%KU';:2HY2,D^E)M(.XC.E(BM
M*4X.$C)I[4UN?D'/8R76';-;;+)2VPV'% X5M.<"L63JD<'"5EL=.Y<F.=H7
M;"+G.8_ASBFPD>/%<C4]8EEDZ7!KQ8%%<F:776-V<NB+G&FR I'3"ZY<]3DR
M.S3&,4J(^YZWO]W5L>N;N!ZU.6HS3[L:PPCV)[3W:WJK3["8R) 6V.F3R*GB
MUF?$^_!">GA+DW_LT[98DR"DW1UL.GJI2P*[>EZM&JR.C%DT[O@U9CM#LRVD
M.I?9VJXW;QBMZUF'-PFOQ*?#E >_Z<VC_;M?]L59[@MTCR3,:^84XU"<2E6>
MM?')P5GKHY+*=<K!J7OE*6LE'48(K5!1BO>++L&+:EK:*79.7A^&K+@ ,=-W
M8WM.,+*/(U#)L?8!BU<9]KNB2ZTI#3B@-QJ3Q*<!,T:TQY[\1R= 93(WI.,#
MS\^M8<<)R>T/$4.YEW:!I4ZD!BQX#T22<Y2#CFNC@E+#W8W+Q.PST5'GZ%:%
MON"5'/A.[G-69:S/<BO;9=$ZM:=">[5X<X(((K-ETZ?)%QI"\VS6Z_H'?8&[
MG(]:@LKQ*BJ+:D6*U6"/9+1W<%1W8Z9K++-XL^3JX9U%D&XY<Y$I+"T**=^3
MS6ETHD%.V7X=XW!9:QDA-<UM;VS1*5Q&5S8:5&#KJ<$#SJ3D8Y<,;P'+@^^W
M&84@MJ QTKCY(QMMFS&^"RM1I,;^6\E1XRDU3Q5HE)D9>%EA25I=PH\UDFG-
M]A*2)&SWT=V \,D#@U!Q:X)\=QS=C#<8,MW"%$9&1UJR4Y))(HDN;(J:4+M:
MPM2-BTX/K5V/53T^2,HQL-BR1:9G,7LFL\RX+N;*2EPG=DD8-=/5^T&?)CV+
M@KAIE8EJO3EIA0E)EL(C/?2EW'&?*G[/Y=1+)4G8]1B45:)C0W9ZXY9XTC^)
M![O5#:0<X]J]IGTEK?(Y:S[)4:?JKX<[!/M2;HAI")3.WG<?SI]4QST>GWIE
M&BU+U,J9B6MA)T0I2(3X#C.<#VKC]!R2U/OY$=#-!15(SU&H=7ZE4\&+RZE*
M?J0DG%>INC$\:[E>EV.Y=^I4L**O4^9J4IJ"LL7 [MS"(SK:7E8'O5$\BJTB
M,FS9=%:^;T\TVS%6WM4G"DD>=2TFKVNY&3+!R+19=9V*!K.%>[F6=NPY>5P
M2>!6['JH/*IE4HR<:1Z:T[VL669:P]#F,/-[<;D'(XKU&">/4K<<K)+)C>TE
M]-]HELO[RV(TEIU2#@@'I5KQXLW"\B$LV2'<M;;NXX3R1[5"D7+(P[CV&U;@
M2 ,\=:A)<%GB-(P'MO[5=2:*6A^W,E4<G#G/(/-9>I9WH\>Z!+!!97R91H77
M'_.I>ELZQGK2R?$(A5@.)]Z\KDU\LTEN.K##M7!!]L&G;-8KY#C:6=+&3O\
MY:N&4YX''7-4:B7ARI&C&N.2QQM3ZUTW:&+V_P!Y+:[O*M^,X'GCTK.U%.T2
MX[&1Z[UW/UG<5S9C>Q(0$H Z"JHXJE:)I49U>XC:P5)Z$UKQ.F6)%.E;8)(#
MH!Y.*W)6.B/5>7@DD'H*>Q!M%K3WT]1*E'!YJ.3W(V%%R@6IIF,'7E\#D@^=
M<N>5[AJ-EDL_:7>;8P+89KICX(*D$]/(5IA-I%<L$9M-E0O.KGOXHN3 =[I1
M)"E*."?^-:X9%7)+P&G[O)<>Q_3-QO\ <'-071+AMK;O>!*AX9#PX3CV3U-<
M3J_48X8^#!\L^I_1[[(2ZSJ_K6LC6*//WHW]O@ K^I76O#N3W6?H+F4=F'[$
M1O-?2A.0JIQ[EF.-\F2=I&J##C.--+!40< 5V='IM[39YWK6O6'W+(?X5+\F
MX]J5ZMZ'4N*_@ZU.+'_2.EP'] .*Z_4<*C@BSY#DZH]7KIX%V2/5-JU0PZ]_
M"9$A*5L@H<0>J:XN?#VD:(9%V1(R92)$:5"DA2HX;W$ 9&T>9^U68GM15.FZ
M9&M6RWM1]D8)PRWNR$;=P/(I96[+,<5Y&:ZUEPW$I;5"+142$J]:,2=EKKT,
MFO*OX>XN2\<ISE*"<YKHXHN3HS9\BQ1LI,[54R.IQ,:,DI<4585Y<UO6EC)<
MG&GU.<'P-[;K>"ET)NMN>CM9^M)"TC_.E+2[5P6PZE&3]XNEL:MNI)"EP9C3
MC;>$NJ0H#:.H&#YUCR*6-'8QY,6>/NLEKI8$2"VU#B%(2G!P/J]\U5'*UW+U
MB4NQ$.:?;B,./(?2DIX42/IJY9KX*<F"NP@8S:W6)<MGNF6SEA \U>N/>GO$
MM/=-]@;WJ00(*8C82'GAN6E/5)/D?RIPQ[Y6;\&DDO??8R_4>J(]J04K)?D.
M9_EI.4K]SZ8_>NICQ-G,ZKU?#I8[<7<SXKF:@GCOE/8P5DGE 'Y?X5J2CC5L
M\)J-3FUN3GS-H[*.S%![J_7""I.%?ZNTL=$>_OYUQM;U!)N*9]5]C_9*,L:U
M>=5Z&UB,Q%0D(;VA(XKSTI.3/I[QQQKA$!>)P1N&<'%:<4.#F:K-46BCW*2I
MQSP\^1KI8U2//YY[A.%;UOK3E!.>M$IT58,+DRXV2RI!*BC Z5BS9#OZ32+S
M+9#MR$I *>,5AE,[N'!M1(M6YG:,IJO>S2L""2K9'<B+BN1VW([R2VZRL9"D
MGKSY??K5^'.T[\S#U#I.#J$'@S=F9QK'0TF'&_BE@2XN"%;G8X3E<?'K_4,>
M?45V]-JUD>W)W/A'M?[!9^D2>?3*X=_D0%JNZXTH K+.$I5N(( !\\UKRNNR
ML^;3PN7+=&[]F';0_I&W&$WM>2ZI1R#GKT-4+5>"]QG\/)=-\$1J_4EPU1='
M+R\DH6KA(S^&LD]9XCI$]E%9D+<DME#KO-$<DD^1;2:[/-3W+25R<("G(SR<
M8!^D^9KJ:;7/3/=$R9\*R+DTS3G:BW8;J]=6&5MA1!()Z\5K_P"T$W.T4?4D
MXFW]FGQ V[5+YC2W.[4C@))(KN:+70U?&4SY5/!]DT6_ZLCIM:GXTE*E)23Q
M]J["Q/'!M,S9<SDS%M*]MMYO.J)%HE-J2T@G8H_BK-I]5>3;(CDQ+9:-/MVL
M(\AX1G)"0X?+G-=&4X]C*HM<EE;4I: K'49'VJ";;'8;"O2G06@BUJ1C/&?>
MFHMD7DV\"2;A%"@VI\;R<8S1M%XK!=>0<^(<5-*A^)8ED*Y3S3(2Y \*@0#1
M8;4$1LW[0K)HL=!U)!XHL5(*$[3C--,C(-4B 11&<4T18)!"=Q'%,0 .<$4F
M-"B:K9=$500!DU6BYAW%]RV75' %2C%3=,COV<D'/U;;H.5/3&A@X(4:FXPA
MW%OE,;P=;6BX.AMB:RLGH$FH[X/A E*/<L(4'&DK0/"H9ZTE"G8;MPGM/D*;
M=NQ@=UGFE0#2=<8UO(2X^E!/J:DL:\Q-MF;]KO:!(L=B4]8U)^:7D((&0%>5
M5:G/X4&H]R>#'OE[QAC?:GVB.PD.W22&UK60<<<5R5J\S[LW/!C;X1*:0U[?
M6]1QG;C<BMAT[ DJR-Q/%78M3*,KDRJ>".WA'I^T7J&J.VZN2G.,JZUN4HS=
MF.G$JO:>NZ2;.^_97%;^Z4< XR/7FL^NE*.)["W$TY<GB>[O:D$R2[*+J@EP
M[B1G%>2<IS9T_=I4,6%&1O+R?$*JE&N (Z87$.$H3P#4L8R-=46G<^=6J+D7
M)!?F=Y'BYS5FQ1Y'5%RL DLL EU6PC. :P9GR0;'TN_71A*6V;DZ$H5N"0>M
M3Q9)1IHBTF/O^<.[?[5W_M5T/KN7U*O!B7V^08B2F7;&_'C*@#7C<\=C]T[6
M)7W&H<1-BB/("$+Z@$\FLD<DVZEV-*2\BNRK 8\L+9>4@J.3Z5IC.+0Z)V-"
M2TVDNJ:='4G/-5R>YU$3BRM=H$:/\DAV.A.X'/AZBMF#(OLLJ?!9^RO4!1:4
M(6@*"$D*W>]3PR4,CW&74QE*/NCB_P ^))FJD,Q4).TC(3YU7J9\\%NDN*J1
ME<[3]YOUV?6U)3L1R!G%6K-'%"GW-<<;EV(/4,*X- 1/G RM&!G..:EBG:MD
M&DG3)_26Z-&"+E=@IW\(W<9K/J(N?V$5;4WP:%&N;$>#NF/80E.0H<@BN1;C
M.C3);8B$%$2[+$FU3DJ.>F?/W]ZT2RNJ93"]W)84RIS80R^TI2AQG%8)2J1L
M7) :QCZ@F(4W!64I'D/*IXYI=RK+!OL0^F';G%DMLS72AQ!ZJ.!4LN)-6A0D
M^QI<6Z29!!7("MJ3GBL#C"/!*>YK@CKNY'E*"E+PI'45?CP1DN#/XDH/D69^
M3+"51E'(P#D53DTDK-$<R8?4]P8-G2&2K<G 5Q6?ZNU+DL>6+5%+N;\]B"AU
MMW+*AE7/2NMH98W&4*Y,TW).T1TCM%AV1+1;4%D@ E7 SZ5;/HCU'O-<#CJ&
MB*U'J]>M1_!Y<(-M.(REU%='0:2'3XH)Y'D1':'U#?\ 0]U19#,>E6[\!4,[
M/:MW4M1DR8*P]S+L2=R/0%K[6+Y?V$VMT(2UC"CGD^E>?P=3SZB>S4=A/2K#
MSC,@[<+&^ZGYOO.0,G!KT^FCBQT\782W->\9/IIN]VYYU<2.5)6<!5=&6?'&
M/++%'@N?RS,H!,YQ*7",D5PM9J\D%NQJT04>2/O>EHK$)4MDK)'/ JG1=6EF
MGX<E1*6,K%JG 20V7U<'H>M=Z<=U,IE%$C>Y,Q]QAE*5!*R$A:AD59BA%=V1
MVI'H'LCT1<(&CG)S=R4OO]RE-Y('3]J[.B\2";\CE:B<'DIH::$[26=+Z@#*
MT<J?+:P5>>ZK<&KE@R7(E/3++$]I::OT6\6-J:I22ISS%=G'<XV8I;(2H&XW
M^W0HKCG>@* .-W2GM:Y9-RA)4>7^UF_6G54MRWO3HRD@DD!?((]*\WU'5K*_
M#D=#38=O*//LA2M+W1+L1S>0[A*]V%%/IBN#X34CIIJN#09ED?O5D1?9"E,O
M!.4Y.0H=16B>">S=,Q_6(J6U%7NG:[>!:7+(J&V0AM3)>]1Y"L7#]U]S3"#?
M)0H]PBR5J*E! '4'UK0H^Z7I4-Y45N<E7RY*QDXQ4$U!\EBC10;_ &.8F7W?
M=J)/I6['EC5C:V]PB-*RD1E..QU#CSJ/UF#[!%.1&Q9@MKY:SM6%8P:G6]!3
MNJ+7&OS4V"64+*E] E(.2?MUK#D@HNVS3BP3R.HH?:?[.-;:D?"HT 1HZN5/
M3"6P!_N?4?VK)J.IZ?2Q5NW\#VO2?8'K'5/?\+9'UE<;^7')I^G.Q#3UKE)N
M5Z<-T=2D!+"DA+((YSZJ^QKAZKK,\JVPX/IO1/HUT>@E'-J9;Y>GE^IH\:.A
MEI"$9"6AAM P$CVP*XLI2G)R9])EC>R.+'%1BO)#@N+*<K/BIU%EL8+#)1Q_
M8\_4@K]/[F.I>_  .:MAC;DJ*<V>&G34CR_VK:Q4VZ^48"D90D'S41Y?XU[#
MI^G:BF?'_:[JT<6.4_-\+YEI^!^!G5M^O+_B2U#;82<]5J7G_*CK#_9QC$\%
MT*+WSRSY=4>F]8:??CR7M6V]*@IL R=ASE/]6/TKEJ2G2\CJXKQQ;GW)JPZB
M3=;0EQIW(!#;BL?4#U%9Y1<)&I2WQM$5J&5=H\)]3,M1<0X$AMKE6S'"A]JM
M263L..7;P9IJ2^QULEU^:IU+&=^1A6[SXJ[%IY7P.>LQXU<F8[>[S(NDW8T%
M!H$E'IBNICQK''DX>?.]1-N'8;(MZWU@K1G/-6/(_(HCBW/DAK_#1& 2$G/H
M!FB,W(EDPPCV'V@)/\)NZ):2WL<3W;J /K]SZ4LT-T&B6GR>%-,W>'(_B$($
MW0L-8SW:&>?UKC9(['V/4:3,\BI,J=^N$-"DI90XJ.TLE:EIVEQ6.F/3SJ>-
M6:WAEW\BF7G42AO>4[W6SHXOPI2C\_\ WUNQX&PS9,>FCNR-&;:E[0/FG51;
M*P75J;V*E=/#D\@?\:WX<%+D\MU+K[R2\'3?9\RGP8DV[R^[CNDNJ4$J=R2%
M9Z_H*V.H(\QSGF[9NO9=V8MR$M2'FEB*R=V".7E#S_W1_P"NN'K]<HW&)]&]
MD?9IZO+'+G7N>7Q-P8BMQV@AL#"/I&,5YJ<]SMGV^&EAA@H+LB/NLGNVU'(&
M!5F.+DS#J\FV)0KU,+CA2E76NIBA2/*ZK-NX1&QH/S"^><U<YJ*,V/$YEGM-
MJ0G:=G3K6+-E.SI-(RUPX:$)PE/6L<LEG>P8-I+,,J2!Q5$G;.A&%#YIH[0:
MJ;+5%"O=;CP/O4MZ78:P1:;GW\@'V&(T9R:ZX6DI07'2#X2 ,G(]*LQY9;DC
M-E7B8IX]2O=:=_@9$]H>USHZ9S(=@J?)?2E2BID$DG@>6<_:NY'7RQO;W/C'
M5OHXP:]>+I'3?-/L,._E:8<1#F1VF7E^)00<Y3^%0QU!]JO6.&KCN1\FZETS
M4=)RO39HU1(Q-2N7%*MA\"#C/EN]*I^J^'+@Y;OS"MW%2Y0:&X^O%7N#KDB^
M"RMJ1'92HC"CS6*5MT133X'<1U,E)2I7*OTJC;ME8WZ#BT0Y]JN0G1I:D#.<
M)56CZ]+$J@0>.,NYJ>D^TR6P]\A=)15'/&5'-=;I_7<\568YN?1;^8C6[W:V
M6C43-PMCZ#WQ(<*?('TK?'J$)9%-<$/JTE!IE^LE^MD25'N[UP2DD=%'UKMX
M.HXI/F1BE@R55&K6W7UFN"6VF9K;F$_@-=R.HPSBMLE^)AE&47RB3.HK>E7=
MEXDG&,58G%]I+\2MSKR94->]I,+33"%+5N!_7/\ PJC4:S'I%[[_  '#%+4.
MXF7Q^TV3+OR9?S:6V3R$E6*P0ZK@R2X9IEIIQB7BS=K<"7<ODRXA93U*CP:W
M8=;CS2VQ92\#C'<S185X@RFDNH= [SH/2ME%2FNQ7];ZV&EK8Y.1C:VA2CGS
MP*AGS0PPWWP+#"665&<:9^(J+/DK0^WW0S@J6G %<[#U;#D=(UY-%.,=QIMM
MUY:[FPEX2T*W?T$&NG'+"4=UHPRC.+JB?B2X\H9:>2HXZ9J6Y!%M\,7*@#C!
MIUYCL:7"Y,065+=6$@#)4>@I.51W>0O.B(@:MM=P)2S+2[M.#L(-+')9%PT.
M2<>Z)V.\V^,MJ! &34KO@4>1<$#K46BY>[W%6PKTQ]ZJ2LMDZ*3VBZZBV**L
M%U((3@!7 S4<LGC6X<8J:H\7Z\UUJ._WN0J/='4,J) 0E1 '-<7-J)2?<Z>*
M$(1[ :'UM>=&7V'+NDMYR+N 5DD]>G%/!F>.5R%GA'+&HGN'0^HFM06IN2PK
M(6 H8Z8P*]!&2R0M'*<?#E3+-UY!JM.E1+OV!VGU%&_X,*,A[>X=X;T\J3:'
M%A]!W*P<<=:JS2:CP6:?[7)YP?U7KJ]VYBX2HFR''Y05'A0!\ZY67).?)L6.
M*=%7U%?9MU90TN0$)W>(-^7-<[-J-O!HA!1#6^<^@L,MOG*5!6[/(Q5$<\Y$
MVD^QO6BM9S'#':G3$)"$A(ROJ!73TVK3X9S\V%^18=4=MUK92;&AE#RR@I+F
MWPI]LU+5Z]*H%.'3M<LILB?HJ59WUK[E;[@45X -<]ZC$H_$NJ=F"W-;34U[
MY=7@WG'VK!.2DS6NQ&27-_TX_.K,<25$)-4YWF0DG/%7QJC2B9LNGS,")"^H
M.0*S9LE$)2\BSK08K ;0.1QQ61>\RANB&=3)==( _6MT5%1X)Q"=Q*_I'ZU&
MR?!?[UJ1BTMEM<S:<;1STKS2B\O<ZD?=*VW?CWHN0EK4OH/0U-84N"Q,O5ON
M3=T@([UA:G7!P0*P9EL?!;'D>,6MZ.T2LD \@&JH3;9.42@:[?DP5I0VO<%'
MQ#UK9@=R,\D!IB7<(L<]V"A*T[DCV-;DE=E,U:HE[-.G3)"VWV%G@^=4:BNY
M;A@/8J?DE/%+93O3C/I624G)\EW,48_K:/,?OF6Y*N59P3Q79T^W9R9I-MDK
M9K0U-0A#LK#B1N3SYUGG*I<$::Y+0^;FU!%M?1EOIO/D*Y^?'%O=$LAEOABE
MFM3]K67[<ZM*5*WD#/6L/BV]LBS;?*+I8M1R'YB(LQ))'FK%.6%-;D6XW7#+
M9-+R$+6T$;3R"1FJ/#7F7NF4O4+9>:WA@I7_ %)JZ":X,V55S$)I?4++@,5Q
M9+V,$9K)J<+7*)87:Y$[Z)S4K+60%#(-7Z5^[R5Y8*P=+R9P=6W*7E(./SJW
M-1.$.!SJ\W%+ 2P,(41FL]196^)4.S9WY&G I2<CN^?O7/61X<V]=D:'CN)@
M6K=%WNZLNQX+Q20_N02#P<U[/1];PSAM9CECIEUL>G[JQIQL.,$RD(QNQZ5S
M<^H>;4^YV+8I*-CBR3I#I5;I]J_F@X"U#%=B4UBQ)S*9)2?!<+-&?A24*4=F
M[D5Y35/ZU*\!?B5?:'VOV&KS:.Z:(6L(.[BNCH^J_4JQ9O,A/%NE<2EZ2=CH
MCNQUPMJDD@;L<XK-U+49]1-/$^!J"2Y(5]N*K4RW9[@1'0G.,]#FNNHY9:1*
M*Y*56XN*9.FY\?Y=A8>01MX%>4G/+ILUSX-:@I(RS5&FX]GNR93*"E"E?I7N
M.D:Q:K%1ERPVNB5_B]ED04-.8[YL^'IP14IZ7/'4;D^"K:C0M$]M#=AL:[+)
M4DJ25!)R,'->BQ:MXHJ)S,VE4LCD9Q<9[[]Y=N;03E3O>(QY<U):B,N2^,:5
M&X:+^(J3;].HM<]AWYAM)"2VH */E6_'U%8XTSGSTKE*T5"]]KFL+T\^RY/<
M0RX3M2%<I%<G5=2FVVF7X\"5%%F?,E2Y?S2RZ3N*B3FN*M2\D^3I0CP5V7+G
MS9(6\\#M5D>U:I9*HE5%I=UI?%6D6N/*(1@#QG.*G+57':4+ MUE<?EMAM;3
MXW*4,D@^9K$TY2W&J,:(>/9UONK(<PC/2K]Y:HMEAL;MMMC:LO))2<*"E=#6
M7/XDNR)0QQ?-BRYEME/ET,!UWJEMM.]2O<8'/Y53-Y,:Y9MT^&6=[80MCERQ
MZDO#7=L6-45E2>'):@R%?8'Q?M54=9BQNKL]1H/8?J_45NQ8G7QX*3=="IL\
MH3M56RZHAI7N=5:XV6U>F5*S_A70AJEEC^S?)L7LMEZ7E3ZECDH>=?RYY-HT
M/8M,L6^-.LE@5!0Z@*'S3)$C']XJR1FO,]1RY7)IR/N7LWT3I,-''-IM.D_6
M23?\RW)92UDI"<GS(QG[XZURI;OXCT4,CG[MW7X(#J>.GI4"RJ0JGPC&*DAI
MB$AW:DG/2II$9,SCM'O:85L?"7#WGX!_576T&'Q)(\]US51Q8O$L\B:ON2KO
M=]G>E2&1W8/]2C]1KU^&"QQX/S[[0:MZ_7247[JNCU3\&NF'(NC[E>7BE"9\
M[8VKU#8P?WKB]5R>\HFWI.'9A<FNYZ?BH4&EID)0N.H +W#J*YL'P:YIU:*#
M?V8N@=2.(2XM=MN2N]:?4,!*B/I4>@]JNV^+'XD836*5/LR*O]\[Z-B-*[EQ
M(PXLCG'7],5+%#;W)Y6N\3$M97.(],4Q"<*\G+FT=3YFNGA5(Y6HE?".T3I:
M1>HSCC;25I"RG)/*![TL^90+-'@<T7-_1;42W%+3 4[@'<DYK,M1;-T-/3,H
MU-;I/\0#393WN>3Y"M>.7!CSP:8ZMFF9!9*ENI<"_J(Z8J;R<T4+&Z+>VB[M
M6[9!6,-IVAI1(&!T.?:J9*$GR:(9,F->Z4S4S.O"A/RT*"&R"H.K=)*%>H'G
M5N/%CL>7J&KA'W#)[ZBXR.\7J*ZN*(..[/"#CS %;X*,5P<C43RYN<K(Z#:Y
M%UV,P&EH9*MN[\;BO/GTQ5FZNYE6-2YB:_V>]F2I#@MZ&$[7"''U '(3['U)
M&*Y.NURQ1X/5^S?L]/J>=)+CS/0,&W-08[;+" WL 'A&  /(5Y>>9Y&VS]!:
M#I^'188PBJI!9+J6\Y')S4$K)ZG(_(IE^F*W;0>/.NCAC1YW6YMQ5@P9+Y.>
M":V;J1Q/#WR+):;4@ ':#CVK+DR'6TVE1:85O2E(\/OTK#.=G>T^!11,,1P
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M>M6*%G-U&38F4FXNE]60,^U=&/!YW(]['EIM04L%2??I5>3+2-.ETJE(N$"
ME"!X.OM6*<VSOX=,HDQ&CA(Y%9VZ-T84/4-IQD"HV6T&+>>E1L4GR'2WX1S1
M9&Q9  &*2Y?(U&TVRG7%0N>J'"V=R+8V$8\@ZOE6/<) _6MBK'C^9R([-3JF
MD_L?F_[!Y#>P]ZE?T^1XS48N3XHUY6X>ZXV_@2,66YE/=N.)('DGC]:KE%ON
M='%AVXU-I<_'G\!TAQB1E,V)N5Y/,C8H??VJ<7L[&6>%TXOLR*NNC]/7)9DI
MA-K<^E2HY*'!GS('"JW8==.*IGS_ *M[!],UK<H)PD_17?XF>:FT5,M/>OL
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MZ5?NI49EB<W;)B#:DY!JJ60UX\*)V/%2C\(_2L[9HC#:.@WMYQ4;+*#4@.H
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MS1#PFKZN)\O(RM;B>2GRJ]^$^6R*3=(B18)5M+K\M>U95D;O2H.4<G$13A&
M^N$J*;#\TAU"GT)*20>HJ[%BC%*RARL9:(<0D*GLO)4,^( ]35T\BCQ15)%]
M$ENX-*'>);R,<URM4K=HUZ?)2IF;71R7:[RMMQ"BDGP*\C6O#AA+"Y(3DU*F
M1<B6AET/23M2KS5YUS<SR)U%%RI]SI%QL;L4Y6E*TC.X&M>G6?+QV$XQ?<S:
MZ7V8W-=#$A3K1/A)Z"NQ%YY1V3X,THQB^!6R/OSIJ5/Y..AKFZO!+%%ION3@
M[?)H:'8*8R'9*6R8HWI!/*U$X&?6L.@T+SY=D>6S>G%1MC-<]QOFV0FY-P=2
MI"W4M@I92?) ]?4^=?2>F>QV*#6?JV58L:YVON_Y-'LNA]2R='QPS=%TWUC5
M3[.DXP^ZT[3I\>H=&F-27=H?Q:6K'D5J)('V\JZC]I/9CHL]G3\/B27G46OZ
M'<R>Q_MI[5+?US4>!%^47*+KT5[AY'T!$CHP^M+H'X6TX'[UBUGTHZZ:VZ?'
MM_SX,Z73?H(]F\34LZ;_ .K:_P#Z1ZUI*U-I&R&YGT[P8_PKBOVYZUDEOED2
M7WW^9ZB'T4^S6!>%CPJO6H__ +([;TS;L95"(_ZP/^5+_MSU9?Q_G^H/Z*?9
MQ_\ AK\%_P#LBZ+# 0#W<=:#Z\5&7MOU27,I)U\_U(KZ+>@8W<([?E7Z#N-:
M6F'D/-*4I0'TBK__ +1.J/$\+BOGS^ISW]$7L_DU"U2GD37DW&O_ -4DTJ&.
M1M/F*\?J]7FU^1YLW<^AZ#I^#IN!:?3*HH'<GUK(TS6T!4 "E2<=: $'% )/
M/-219%4-PV5KW8J1.^!XT !P?*@J85S:<<]>E313:3IC2;(CP8ZI,AQ* .FX
M]34X1<W2)R:@K9+=EO8?JWMTU.R$PU-6F(XER1*<1_*B('7C\;JO))Z#GK7H
M>E:*>27"X]3YO[8>T6#IUXY9/VO_ !]/1OXOR]#5GM):6TOVEZBM.F[*Q#@V
MQF)$0A"MZU*#>]2BKS))R?O6_6XH8I;$SY3AU675S>?(B9D,(90%$X'O7*9N
M3&+D=MQ!RC 5P#4*98F%;M[*!RL T42L=HB!"0IE?/3\J$@NP@!5(4@)(..3
M0R)5]31$AMP[<\U5+N6XW2*H("582ZA*!U!_%4>31::)&VQ7 X(T12P3PI2N
MOYTU&^65RG2HO=OB(M;"7)*^]D;1M<_I&*>VRN,J(2[ON2'-A!P>OVJ25]B4
M9-?:((6]A,@Y4,$\>]2=I";W.B0<F,V:(J:C;WS8/< ]%+'K[5@S9'$]%T?I
MLNHY5!QX107I;MQGR;A(=WJ>/)/D1Y?;TK'*WW/KVEQ1T&FCAPKY_@-'U=<&
MA)EZ47[S(MW*G-@&1BK4J17)[F+,0P,'%1;9)8Z)1AC:D''E5;8ZICGRJ(["
M9%.B8!(Q0D1; ZU(5AD C- !Z # @)ZTO,3[E9U0M,J[6JVA8X<5*4GS(0/^
M)'Z5HP<1E(QYZR9<<%ZW^!()/A&3SBJ7W.M'L@R>2,5$;%QSR*B1.) ZT "/
M6D(-D'H:17(40#CI2L@&H !?2A -G$CUJR+9<,I+ 5D[<X\JM4G7#Y(.'B<-
MT0LMHA95E0/H*TXG%?;5LP9H2C[N-+[^W_S_ %(E^/$6XV^N,EN4P<QWF^",
M'.U1\P3Y'RXK=AU.7$VU*UZ?U.#JN@Z/J;_;*Y_\Y<OY7_Q\Z+QHAGLRN%V2
MG5S#EO8=3O7(!(1'6.NY _ >,'RK5@U#R2VS9\R]JO8%XHO4:%;O5+R_L>A8
M7PYZ+DPX]PM[+,B));#K#R'^\#B#^(*'!%=['T^.2.Z,K/CFH67!D\+-%QEZ
M,D6?AWTJT 5VQ@\]5Y)JZ/3K_B*9SV?:X)"+V#Z2;('\*9QZ@<5KQZ.$.&9W
MG;?NEA@=DFFX8&VW,XP/^B%7/'%=B.^;\BS0M+6RV@B+$4FKE%1[$6FQ\U'0
MT1M;.1YT]U\(2C7(M@^E/GU)?<"!ZBA?,/N#(RGH*BT_)CX 7E1SM-$4ZY9"
M7?@+M/\ 2?TJ6U^I$[83Y&BVA@$?>C>QT@FU!X.,4VO0C2$7662/%@CVJ%-,
M:I"7R\3_ &=/[B>Y>@9$:*3D-YQ2<=W<-R]!PA+#0VI2!2V5V8;EZ!N\:''%
M"BP\2*\@I?:!QW><>?K4U!>;*W._(;.=VYG(J?A$'->@T<C1%J"5-\'@T_#]
M&5MWQ0U>L]N4KAL8J/A3_P"0;$(*L-M4>4@4XXY)^\[$X>@V7I:U*).T5/:B
M.UC*7HJT24[5H!J+PJ?84EZD)([+-/NY*V6E ^O6A:5>I6[\B(F=C^E'LI-L
M:/Y5+ZI%^9'Q)K@AI/8=I)PD?PUK]*B](O4DLLQH.PC1^<FTM?I5CT>$@L^4
M73V&Z,QC^#M$^A34/JF-]B:SY$ KL-T:!S8X^/\ =J2T</4'J,C&:^P'0ZU%
M3ECCX\LIIO2Q79D5J,C[@?\ ,!H/_P"XD;_LTOJJ]27CS,77I2VV^+W0<;6K
M&,[A7SW=;._;1 WR1!MS"%H(!0<=.*L6-R[$D[(5-X;NQ5AE"D$8W"E+#*+L
MD5/4<-2,F*GQYX KH8K?+$RIKUI<;.X$K9*N<#-:UA61$&1%_P!<3)<:1WQ[
MK>#M .>:MQZ2,>01-=D+NK8;:KTF0KN5<]TKD8HSY<:]UE&7'N-P9O"-1P$.
M17 Q)0CD#@YK%EP)F=-XGR1MFG_)37OF5$R%G!S6/)CI4:X9-Q>8,5\P5375
M!/&1XJX^=>]1NQRX&,37BHLLP'VRM*C@83FAZ>U98I<DK-G)<CEZ#!W.*Y^F
MB&)?Q,M?*(+;<YBTB2PII0/05?[L72*7P30LAGQN[>=.X# W4G/:R$DY$/*G
M+TLX&T("@>#CFJZ\0E'@?WR))=M\6\LN%:../3\JA%I-Q).-\C!_Y[NFY*BI
M6.0CUI6GP5[2?LT:<XA$ER)RGG)/E6:;2=&K''@L=ON\.XMO0'FO'TSMZ5JQ
M:>.W<8LF649T(=VW#0LIP0C)!-<W-%VS=CDDT435/S-\(;9?*$@\D&C _#[D
M,R4F-%VM@P40'EJP1M*L]:V1R-JS-*-,F;+IEBV0T-0'BH9RH'C%4Y,SD^1Q
M2D2\M#)0 Q)"5#RSCFISA<+(*2C,@-0J0TZPN2C)( )JC13][9Y&C(D^2AZ[
MG IC,1D\*Y)%:YP@K9!2(-]:(\(*>60I0\N:JPY_?J)8F107&E,J2AL%8Z<=
M:WY,DER0K<PEJN7\.E%I]DH2H>$X\_(?<^55SCXJW2^19QC1==&VBXW"4[=K
MBT!%2HLQ4*'+JB/$2#T \O>J<66/3I;EW/JGL%[%RZW+ZWJ56*/\R]Q8:8Z!
MW+3+.!@%">?UJC4ZS+K).>7(Z?D?<M)H>G:&*AH\/*[/D=!M/51)..:RQ\2'
M[FF;I99359. H"E#@U(>X79CDGQ"HMB<N VT;MN*1#<'0@ TGR)NQM<''8S?
MS$=O>M Z9QQ4HQOAE>2TMT5;$K;>(-R20VYM=2<*;5PH'[>GO4IPE JQ:B&3
MA=_0?[QG'/ITJEV6[Z.*P#BH$NXG0"$'%"IHM#- \&FNY&3I#EJ.IQ0*N$CD
MU-%+DAC<[I#MN]0=WGH$@9)/VJ:QRG0GD@ELEW?8GNR/LDOO;5KF+:][L.*P
MDNRI&S<B&U_6KR#AY"4G\ZZW3=%+-/8CR7M=[1X^@Z1PF[GY+X^OW'T)TGI"
MQ=GFCHVD]*15QX4-M1W;@5RUD^);BNI4>I)KW&GT\=,WCCY'YNUFOR]6R?6<
M_P!J3_(\?0IZ9_:5VCN'@Q;JTA()Z)[H8KSVNYRGH].MN!DT%+D+*%#PCGFN
M?1M3X$T%*G A1 23P:*"Q41D%TH"LE/7THVH6]AI;K49@ $[LCH,TMI*,[9Q
M8<#27Q@K6,\'RJ#1.R"O48I;,AT95TV^OO5<ER3CV(06YNX -@;,<D],5':3
MW$Y9[)'8PX@E03^(C!-32X(-\DK,:<4@8QC''-/:%E>F0@%$!9[P<D>7ZU*:
MV=B4'O[B,*"N4LEII3BT9) &> ,G]LU54OM/L702E)0CW90K[=''OG'$K/=)
M"NZ \AY?^_SKF97NF?:>C=,AHM"LO\5$<V@M,M)(Y+8*_P#>-5^9U\4MV--]
MQ):%'RJ2'W$T13G)%-L:5#MIG !Q4&R=\#@#  JMD3LB@!.IDC@,G H(L,$D
M4"2# 8H&#0!W]WS.30N2$W10;?/_ (SV@W>2E95'MK#<)L^6\C<K_A6V>/PL
M*7J<W2S\;6SDNT4E]_=EH3R!ZUC?<[Z=BC?&0?.HL!9) &#42)V4^= F!N5G
M H"Q=#>.3YU%LKF&6K!PGTI$  L8YH Y:P10@$%G/2K46B+OTDCTJ2[AYD3)
M0%*4:OB9\JLB)"$@C<//(JZ,J,#PRR6HC9;CS3B78SJFG4GPN 9P>F%#\23R
M"*LQRYY,V-;5*&3S-7[%OB%N79!BSW."J;H]Y_\ GQFU?S;2XO +[*C_ -$3
MU0>!S7?T.OEBE5_W_N?+?:[V-AK(2SZ9<KT\O['MF)<;7.@1Y]NN#%PA2F4O
M1Y+*]Z'6ST4"/<XQZ\5ZB$UJ8[X'PW48Y].F]-J5R+MM# V]*LNT8MNQ[1PD
M8%1+4$*R>*G8@*$!U2 Z@3!! H(G;P*:8F!WB?6G8CN\1ZT6 DIQ(SDU'S 2
M*DXZ_M5E$ A6WT*OVHH %%L]#^U*@!0I*<\]:-M@&[QL]54MH["E;6?JJ2B1
M;.W-?U4;16)*>93U4?TJVRL04XT2#G]J/,8)7'(Q_E4Z%N$G%-;>#^U+:)L(
MDHP>:-HMS04EM(P3UJ4>"$G8@O8>,U*R(B4-YY-,BQNXACGG]J3&(%MOKD4Z
M( #NLC/2@897RY'!_:GP FI,=7!/[4)"87NXWK^U.B)X<+[LF-O#C@6/(U\O
ME"49'JK3*O?FI5R97#<"PGS56O#*B+5!-*VWN%"&TO?M'K4LV2Q6,+I%OD>^
M=R8N6"-Q)_.K\,TX?$4D477#EO0]M6XA+H5SCH*Z.GW$"J.Z<DW0HDQ@'62,
MJ(S6EY5#B1!.GR:KHV],,1!8V6L ) W8XSBN3J<<7+<679):61.;OLO&Y.T\
M G@_:CZS"$;DRG+B\3L7:X:5=O,9-PB.!+K6,[:J\?'/L$,3@K8K!1>A%$%Q
M]2@D^]8\T(M[C7C)!ZTQ;/'1/GC:3ZCFLCR[GM2+JKFR1L=Y9GOI9BJ(!&<<
M<BL^6,DK+8S542SZ([LM*@ZI)3@*JG'D:XD3=-62??6K!;<=4"/.K&I2[!&*
M7+*WJRP/JA_.Q@EQLG(5[5;C=<,K:MVA>U/*-A1&EX5CI[51D?O<%D>%R)B-
M,E*28X24(]*-NU<D5&Q_994Y"UL2G0$ '@U7**?8L4JX#Q[A M;KKG=.*<63
MDC&*AC\52J^#+E<?0C#+NMP<=0RRL(5D<ULG&"7)7"3<D0DF'-MCJ4OK2 LY
M\^M9G",N47R;OD9W&0Z$*SX3D$9-68XJB&1-CB'<;LNVN*M[B2I/4D]#5>2$
M;IE>.XC&2JZJMWSSCW\Y!R<$UJA*+6PIEBGNL+ OB=00@W..5("@CUR*RK&L
M.54C4V]C*Y<H_P TQ(1YQ^1GS'M6QPB^Y&"W=BN.Q)US@=Y'0<)!'-9E''AR
M7ZECA*BE&YW"WW+Y9E.7D'SZ5V)XHRA9"+<7R:+I2VG5DAEMUI)6A)6X?)M/
MFH>_3'O7(U6;ZM'X?U/4^S?1I=;UD</EYFL0H3,5AI$1!0&T!" H\!/K]S7-
MW/+!K*?J71Z6/2=-#1X%4*%7&\*)W*-*,8RBE-'1QY)8(*&-+@4PI( &.::A
M&'V&T0DUEYR_R%4QRD=13LI3#@%(I=P?(9 &=QHHCR<5)/ I]ATPJMJDX(S1
M8T574FE6IO\ KL-U4:4V,H=;40I)]L5JQ9TEMD<_6:%9EO@ZDO-$-%U3JZQ-
M'_2"W?Q*(C.)$; ="?[R#U^]7/3XLOV'1SHZO5:5?MX[EZKO^!*V/M,T;?5B
M-#NJ6I X^7DCNG/MXNM49>GYL?O=_D:=-UK1ZA[%*GZ/@LP>"TA2!N"AP00<
MUBV23IHZRG!K<G8F1O5MP<^8(/%3<&B<<BGV'\:*5#)4D >M07VB&6:2H,](
M0T@H1UZ'[58WL?(2PR4=Q")AQ%2U.!16OA21C.Q8/"OTSQ6N,K<;[&;+B:PS
MR1^TNQ]$^P33&DM/=F]G1H<-/,3A\V[(</CDO_B"U>RL^$\<5[SIZQPT^_$N
M6?ESVIS:K5=2E'7/L_,O,Q*6V%8W'A9.1@Y(Y_>M&F<I)N7<X\TE-)+@^?5E
MN&WMF[3HF[ _BS)(]BV!7!U<?VB/4X^<,DB]N2%*?*6L)'3FL-EZ?""+:;0I
M)6K;D^=%DDQFJXK8WMA62#R?44$Z1T:8M^6"Y]&.<T6$HTB41(QN0@Y(\_+%
M1:LC9'2PMUS#V"G'05!Q)QE2&S<1*<;L;=Q(Q3VB;)=LAE"LX.[H$TJ!/R$W
M5N+2 G(Q344/WO005;I=UD,6VW0EORY"TMA'EE73)\A5N/3RU$JCR5RU"PQN
M::7JS0[[HZW]F79)J:8F8S)U#+A?+NR-P_D)44@MM@]2 2,UTM5IH:;19-[J
M5?U1H]FE_J'6M-7O8]W-=NS/+%SC9M@:8.U2F<9/XL#SKQ3E<[/T)%347!/@
M0MTA,Z$Q)P4A;8X/7CBE-;70\-M7Y"ZV_2DF:$EYLY*!CE)IM_$KR.,75H42
M,# 2:7'J0\2*\P:B^Y8G:L+3H+"4R8*1XA01%* .I,. 0DGI47*O(3:1&:EO
M,?3EHE7B6O:U%86ZI0]O_85HTF/Q\NU&36:B.EQ2SS^REW*-V81%1].)N$PY
ME7%:YCV>NYPYQ^0Q6W62W9/"CY&3HF-K3^+/O+E_>75M*PD$H)XKFR<4]K9W
MX.UQR<MTH&>[4?TIU?9EK@J]YU\QLY>+>P/]8F,M*]%NI!_QJ_%HLN?G$K^1
MR]1U'2:5UERQ7WB;.H+8Z\&D3(Y)\^^3C_&K<G2]7BCOEC=?(JCUKI>3W<>I
M@Y>B?/Y$ZTE/=AP@!)Z*W#!_.L$X['4W1LQY5EYQ\KX'=\C.,@_8YJ,8[U<>
M2<TXU:H["G#E"3@<9/%&UD&XKNQ-Q:&B M0SZ#RH<:YEPA1<LG[M.7R$W7BD
M$A)P//I4E%5<G2]2U)/A-7Z>83D\@Y^U2CS]KCYC;I6)K=2!L5X2>!FI.-/W
M>?D68H>-%SCV0P?6VA:BKIC%6KDSS:ODAY+[25E6,@#%71C9S,F66-WC9"3;
MGW1WMC!SCFM4,1S=7J;Y\Q!F:[,2[W9 ?9&63M"MPQXD*!X(4.*NBMDDO4SX
M<T\LG&'DOQ^'WFB_#I\3#?8Q?'-/:PEOOZ)N;@=2ZEL+<M;N<!Q",_1U"DCH
M.>M>AT6>6+^I\J]J?9_#U#?FQU:]3Z#VZ="ND-F?;93$J.^RW):<85N0XTL9
M2M)_$,?IYUWM\9P4X^9\:RX,F#)+'D[KS]19)*B=B@0>A\B*25D(23= 5(9U
M" ZI6 !.*+$P"L#RHLC84J!H(L \FF %.@"+&[I0D F1@9J=D!%22>AHL#D)
M4#R<TP.<W#&*:=":L!.2,FI$3B,TZ(MV%[I!Y.<TZ%R-G$K)P.@J(PI.#C!H
M0CE9QQ4]Q':PF%'J<TXR5A)<!5 BIV0IB:PKBEW$U0FI*\T4(;K#F\\T70A)
M;;BJ0Z$_E3_54R-!1%=)QN% 4'^0=/"E#% W%@BVJ)X4*$1<;%?X9_>%.Q;6
M?-,ZKU8PTMY4#)2K!"3GC]*\-+#C9Z),>6N^7>_MA)BE))P01BLV:,<2M$US
MP:?8M#QXEO1<)*@AY0W8/%<J6H;E1?X?%E2U=$>>=4(DI(6D8QGJ*Z."=1*Y
M(QS4ENL#3ZV9TS?()Y21Y_>NIAGG?V45-$G;@BPV%#C;(6TXD8&<<5#)&>27
M/<A*)$KU,_&>[R'&0V2><&KOJ_N^\$2U&ZW%FY03&5S*9'/]XUE^K8W EV)>
MWZBUA9;HB*ZASY9TY4HCC%4O#CC&T-/<Z+-?]2S8[295F7O="<E(3YU+$HRX
MD*2:[#&R]K$:[XM.KVE-+3QRGUJ>72PI.!4]Z=EML,6VHFF3:) 2A2?"<Y_]
MU<S48VER;\>5-#EU^;&?6IYM7B/!SUK"XJ^"4I.B*NMQO##*W,;$#H:T85&3
M#<]H[L6L9,^U*M[CP6,\Y-79<:CR5*;'RE2TM82E6SSXZ"LM1?)/>R>TLMU:
MPALY&><BJ,LE1?CE9(W6%L=!;(R>JAY5ECDMEG9C!VW-'8M2LX.:DF[*YP3Y
M#M7)#*^Y0$MX')ZYI9MS2(XE%2*]>VW[K*&7<]WR,"ECM(69<\%4OEDN<Y1&
M5M@'Z@>OY5KQ24452M(5TU!O5J/RZBI3+JN21569J7)7$M,^ROQ[>ZLJWA?&
MS&,9K)I9RE+DV94DN"BVS3<]I;JF7P"DJVI ZYKIY)Q339FVMJBMW-V\0)SP
M?;(0L%)'K3>2,UP."<2P6!UI,1J,AI #@.03TK#/'*4K9JA\3.+S#B-ZDEKW
MI!3R?8>U=7'O<%9!0W9$D;+H'3J+19OF5M;9,U(<P1A3:<<)/O@Y(]ZY&>:S
MSY[(_2'T?^SL>GZ'ZUF52F[7RK@M3;8;CA(_#P/M6;(_)'T/[<[\@K:2I7(H
MCQ%#R26YT+;-V,#I3*[#JXXH$$/2A @JE@)Q4AH24O!X\Z"0=!R#28!'B% M
MXYJMW=DXM4-7(+3C.U:0HD8.>:MCEE$JGAC/N9MK/LNM%U*G6XA;65$[FO":
MZNCZBU[LSSO5O9O%DCOQ=V1FE.R*ZL6^1)7J6[QGEKQ&;9E*2A*?7K5NIU^+
M<HQ2.7H/9W/''*<LDHOR2;HOVA]$W73H5.U'JRZ75Y1PVV\_EM _W?,UASYH
M3XA%(['3='FT_O9LCD_)7P6F3=82"F&W*2'G%!*1_P :S1QMNZ.G*:3Y(UNW
MW2>EN4Z7&8;^Y33F.'0E6T@>GWJ[41C"-^97HM6M>]J?!+083,-*@VCZACGD
MY]:R2RMI&J>-.>Q=D;!V#]LTSLUO*+3=WU2=/7!Q*)$<](ZS_P!*G^E(/)KM
M=(ZE/3Y.>QX+VW]D</M!IY9L"J4%^/\ EGM>1*C3;2FZM2 ^P\WO;>:(6AP$
M?4"/+'->YQ3C-N4'PS\^2QY,<E#*JDG5?(^:<6YH;^)?M)A[B M]ES'N&Q7!
MU?VDST^)>ZU\#5'E*[QA0..\'Z5@HO78.[_K2 G>=_EQYT4 $FW-NM=T'-BP
M!SC.:>TDI@,QTQFU!0W8'7I49*B:=\!FWDI: 1P2>3GK4!T"5I2G*U[B>G%
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M(WD!1ZUX58VX'J+Y)\=I3>B62W(6EU2D\)%9OJ+U#KM1;O20QB=I6F+U*_B
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MO.E/A).X].?M4)X(N5C(73>HHUU8E(GV+N$[B!M3R#3GC<7[I,L%B?LDA?\
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M[BL8R+5#F%1EV^,^"2?YK*5Y_45;'5Y8*D9-7HM!G5Y()OSX05K3UG9&&K-
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M*IQ**=27(DG%E3[+K_)AQG9CTE17N)W*\Z-3CC=(E+D5U_K*7,DE+,S>',)
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ME]J[7,G"8C2LA'NM0Z?;K74TG3LF?WGPCR77/;31='3P8OVD_@>=]5=H6O\
MM4F)M[C[B8KZQLA,)PVGTSYG\Z]!AT^'2JSY%U#JW5?:*>S<]K\O(UGLE[!X
ML((ONKH@>D A332APDUQ^H=6E'W,9]$]D_8?'CBM7JH^]\3>68[;#24-CA(P
M,CRKSC;G+=,^I8LTE#PUV0;))YZ42[>[P1<8)VER 49.1Q25U[SMDU+@#;[U
M*Q;@^WWI$:"GI0E81;3M! E)XY_,U.FNP2GD?FOP.[M"><?IQ1<G]ICW9'V?
MX\@+'I^_-!)<_:_03+>[E6">G2AT^1R<EQ!TCBR5 84$^X'-24Y1["C%)V[_
M ! ^40<;U*5]^:/$EW'OR;N'2^7/X@.LI>;+3R6W$8^A;84/WJ:R-.TW^+,^
M;2X-3^^CN^?/YE<F: T7<' [/TG:7EC\7RR0?VK1]>U'E-G)S^SO2<[MZ>'_
M +4/K?H[3$-(;@Z=ML5'_P 2C)!_7&:@]9J'_&_Q+L'1-!IE^RP8U_Z$_P"@
M^=TW8WVRU*L\%Y!&"E;"3_E3CK=1'G>_Q-&?I/3-5#;FT\+^$8K^A3;]V&Z
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MOP-M.D 5YX-%*MIYYZT<"H.BYI"<!/- P?FPOQ''-% (ORRGH15BBJ*GD=T
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MJ+43ZYTGV>P=/J616R^0H#<5(2$@8Z5SG*2X9Z9QQ\;!Z$#Z0.M0)=@VU*>
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MXJ<X-[WF#C^<@H_45OQ]CC9XM0:HJR ';<<J(7@YP,\]!6A+FSD*.^#1Z4^
M#4S,+5NI-".C:Y=XJ)S*MW)6P?$D#U*5?L:WZ*2C.GYGB/:;32R8]\*XY[GN
MQE@(VJW%0.1GRXKKU7!\_B]WO#YU3>P!!.<<U)$6-5R&(Z?YR,Y/D,TZ*SDO
M0U'?M4,^B:*"PSTIE:0E#? &.10 F)R%@@('I18PS+*%J!-,BPCC37>\]* '
M*/EVTY/VYH$<J;&90HC;S3 B)=P0^Z C@8QTI#7 5I[8K)H&+NA#Z?"1D^M
M"3HV  *3^M.A4-RM>.O[T@H696E"=ZL\4$6.4G<G>.E-*Q4)AV.LE"U8Q[44
M'(D]'1M*D$$5)<!W&2(Z7E''4>M' <C=]G.X-8RGKFI+L'89-R'$J(4>GI18
MZ'K<EM'!SD^U-,5!'Y"5<)/-#"A%M3JP5(YQ0/@06M]3FW&,>M(35BN7O:G9
M':SS9KFU]D2NRC#BW7IL1LAAQ2\E) _PKYCHLFI^L-2['I)**['E>%JQNX-)
MM\1W<4)(('7 /!KU2PIJV1H?0M034-JBRCM8)P KK4)X(]T(CY>F92G_ .(V
MR0MT'E3>?#C_ (T\>3;[LB++/H/64S1ET^:AJ6RP\H(EL$]3TS]JKU>GCJ8T
MA-6;X41[Q;6;HTE*X\M&[P]!7G98GADXOR*7=DSV2:JLVC;M(LFI2@6F7_9J
M= (23Y&NGT[4*3_:&?/"4E<>YJ.M^S33]RLRI=C82[%?1WI2V.!GI[8K;J<$
M7[^,P8<^2,JF>8[_ *=N6BKPZ([1,=PD\]/M7+R8?$5^9VL6535$'JB/;_E$
M7MB '5='F\ E(QFK=%FG%[)LLHC;+J#3LID+0WW0'U)QR/O6^=]PID_#L-GU
M".\AMX_O'@5EEJGC=,'!I$E!TC9K8HNN2VDN]$C<, U5DU4Y\11&%BA[-&M3
M22Y.N:5H4<I2VO Q54=0\?=$Y3:1,6[LAT3 <!D3 %CC;NYS5>3J&1\)"MLM
MC$.PV2.6(3S#:0#C)&:SK)ER>16X6RHZELUEOSG^NR&G<=$[N#45//CEPBZ,
M4BO([/M/H!3'M#*P3G*<4I:O4[J)-JB1C65%K:Q'B(C =,)JJ4L^7NQ;T'V,
M;5!YU(0H=,55X.1,/$0K&-F&$(?;R!CBE/'DH-UC:ZW2TVT!(<!7YD4H:;+-
M"(N!K*)\^&$32@>?I6E:.<40E"PMZU[I^4ERSRN[+BP0E0QC-..*2_:HLQIQ
M@HF:Z(T7/C]I+4U^&M# P^%D^$XZ&NGKM7&6B<?5'LO8;1O6=;Q.K497^!NU
MQ4XI5O8;:4YWDQ*58\DCS/M7E\79OX'Z;G';LC5W(GF6MRP\H<)!(_,U1+T.
MG'U"NK <+RCE1^D#RJ4>U"O^+S!0LN$8ZDY-2? 78_)\.T<50RX*A!!W'G-
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MZ5&6H;E4D0\%ZB&^+37JO,);8RU2"0C*33S.XVB.GQ8G.I/DT>QVAV66+>C
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MLJ+>G5)1Y;G4@XJ&/H&J3N4'9HS^VO1IKW<O\_[#.V]AO:9/22+-#0#R-\Q
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M%1BT^]HN>E_!@]" *PZCD]+TQ;2ZM2" C'X?2N;L/31R50TU#>BQ%P23N
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M_,2@K"?*.LDE+RN>.M&Y,GLKLP4M/[@>\5CS&:=H4DT/&QQFH,D*CI4&!U(
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M3=O>R<G^4$9/_5Q6S'U/4XU[LF<+/[,="U#W9M+"3^7]RLW+L.[/Y@_D6MV
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M:9'GM-:+3:2L* !XQ6/*>JTDI46.,AQ1 SQ621V<2;HG8;!*=JJRS[G7P0M
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M),LVI'?Y;ASCVK%IER=KJ.5N+;,GOKV7E$')W&N]B5(\%K<GO,<:82IV4WM
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M0C*T*VN8S[5V(T^3PS4H/WAS'=)6$^53[\$;HE6X^YKO#@5'<UP.D,G%]V>
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MH)T14TNPO:>SA;;XDS+JRV,_@&3FJ,NN4>RL6Y#M?9':WKNBXIO2D*]6V_\
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MRI6TDGRYK5&*.?DRNR.6ZM:B5$[O3-6J)DE-@I"P-Q/[TVA)L.R\=Q'-*@W
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M=9BEXN@SN,5SM=MOX+E$GH%F4AZ:9"%I!"0 59!Y\NM</VIU.@UL8O2QI_\
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M@")@)4K@<#IQ4W)T-:9OF@5V]2U94!QZ"HJ= ].WW&KUL]LXJ:R%&3!2(:=
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M(UP=F,?XO4?L]#5,C7 =M))Y%5-FCS'2 4IP:BR2#I&30+S%*@2#AQ)..:=
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M#BD #C2B J@!)?=KX*\8]*!@/I:#90!R1P: &K)()!Z"D#%%*3BF PE.;!N
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M]$PK:W'[Q^RG ^]4MV;8H>-#C[5!EJ%<XI#;!%  T#.H %'U"DP%4]:B :@
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MXG5\&_"Y$9))[D7'M+F/LV.2EDE))V@_>N7TO'MR[609BD*S+&7%.Y(RLGW
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M>\(XZ4K'0DN2XLX5TH ,'$;"D_4>E QNI*MV"H4@$7%K962#N'M0/N+-7)U
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MR9**+[:(I;0,E*MW)&:S39M@BY1 AA:5H;(2L)!3GJ!T&:I-"5 *\1?[M("
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MVH$9"M/SK;BW%87CP@?YU.1CQ0W=R^=D&@+G>$WK4C*4);M03$PH_4LC*O\
MU55GE[IDRK9)ECCLMKF(B.@^)>W(K)3[D]+D2EM$[_I=M.Y26^H]*<,K.GEP
M)*RFS=->'O"T?/BM"R&-XJ(IVP)"1EHA9&<8XJ:R%4L;0B;*AM&5MG=4MY6X
M,.BS)VY[H\T;[([&+-6L)6E*6SD'GBEO%L99K1;\^)6X>E52D70A2+C;(S+2
M1O;2>*SR9J@B?;;>?2EM"0 D)VK\E9J);5G(9<=>*'DI3M;7N+:OK23]0_*C
ML%6-7&8H<>905MEI!_F!.21]2D_;'%.R#2&$RV.][$?<=4\E*4O =#N(.U/Z
M?XFI)D=M,3N#):B-A:'4D)(" G.W)R03[4HOD<H\% DI[J>V'1N_FY45J&0D
M>_3\JUP9S\T:1:)=KNEK6W+""EM0"TG!&01FM#?!QYKWBSZ:U#.6XUE:?"<<
M9J,)*RJ<#;+(](N2$$G:%#\-=;#*T<_+[I98UJ4VD*2LY\B:TI&3<345I;3'
M\UW 'I3?82[B$B2X,%I94 :KLL09;\F5'V*2,>9'6I+E"? M;G_E@I!Y^]-,
M3$7'TRE. GIZ4=PJB.9CO_,+.?#GBD2'[@4T!@9H&)AI4M)<22D#G%'<?8!M
M!0H \CWI"$7([:G=V*!V<^O#82$@4,!)&T(.:2 %H)5GG HH81005D!7Z4 )
MAILN$J'0XIT%BA99(QDTN L3+*6P<>='8.XD2$YY-%C 9W+.32!CC::D(^?J
M(R&$I4I62CIS7,:.L+/.K4VF:DCO&CGIU%(39+PY<C4T1,)-N6P2,*>4G@4Z
MH78L.B-%FQ7IN:VZE]M'+H(SD_Y55ER41F[1Z*TU*+J#/EH$>*VGZ4C&ZN7D
MR-/@PS5NA:Z:L@LQW)<Z5\M!CHW;<X+@]*LQ)R8ECO@P?5W;:WK.Y'3MN97&
MAH!YW8"O^-=".*E;-6/"H<F;7"/*M$IR?;%<J5O*#_TA]":G!VS4Q8Q8^MX7
MSL=M427&X4G'"CYU*3VL@_=*H[ NL)Y3CD<H2E6S!'7WIVF/@EH<U+S?=IW)
M=1C'-1:$D6K2=S4U++,A>2H8]*S9H6K&7GNR&4D>9/Z5@@[?)&;X('4-YDZ?
MEL3(BL+'H,UKQX]PES'D=LW!VY*9NZU94KE1QCFJJ2E3(N-(2=[4]7ID/6]I
MW^2V<%) .16Q1:C3(K%%\E=F33=+LM]380LIRHD>?MZ4+W5P6Q22+#I:[/6>
MWO*$-+I4KS'6LLH[I<%<E;H>3];6MA:&Y]M0A2QD9\S4_ DI6NPMA&3KE8)[
M"G$QRVI)W)VJ(Y]:3<FW'R#;7<HDQ^3=9P8AN^)+FY7&>*OV;(<ED>#3=-%,
M9+3CJ25I:*<_WLUR]3-37P9-]N"M,=FMVU?JR1/N#:H\*.HK<>/ <23T'I4=
M1U+'T_3UYC@FU3+_ *<[1H;5P3I/3]C^788P%.-\ C.#SYUP]9TS)DA]:R2=
M\%\);9*B^(*"HJ; 3D)_3FLEJ4%+U/U'[-5#H^FQQ[;4_OH5!/4G-0H[Z#!9
M%)HG%AN\(QS2)[A5M9(S2HDI,5"QCFE1+>PP6G%*A[PQ63UH#>PG>>].A;@P
M<)'6D24K.*B:"1P/D:8!TJ '% 6#NS2 #(]* !"\=*CM0/E4SBO/D/TJ2*_#
M2YY_%@*Z4QJ30GYYH<> E-R5/\CLU%12$G0!('4"I5Z$7R%44E/04;0L+U%2
M2H-P0A.>G[T6&X[?CT_2E15M1P61P%J'V)IVPVQ] %--.?6@*_WAG_&IQR3C
MV;&\>)]X1?\ Z5^A'3-,:<FG=,L<%XGS<82?\JOAK,\>TC'GZ=HLZK)AA_[5
M^A"S.S+L^E9[S2D $]2A&PG]*T1ZCJ8]I'#U/LET?4?;PK[FU^1 S.PWL]D9
MV6=R.D]>ZD+3_P"JM$.LYX<2?\CFR^C[H<_X&G_U,B9'P]Z,)RW/NK7H.]2L
M#]15\>M9'W.=E^C/1S_<R:^_^Y$SOAYMCV?E+[,0CR[QM"A^W-:%UI15-?Y^
M!@R_1?"*M:BGZ5?]2//PYS%C;%U.PD>\,@_KFC_6L?\ Q.?/Z.,\>,6H_D_U
M$?\ Z7.[[OY6JXJ<?_&[@_SJS_5</_$@_HWZC'MG7X_W%?\ F!UA'2?E]41G
M![+>'["I+JVG?#17_P#9[UB+_9Y4WZ77\[%6>R;M8C>&+?4A Z$3G$?LH5+_
M %'2/NB:]A?:>'V)?_[%_P#M$A&T?VWQCLCW62K9SE-P&#^HYI/5:&?="E[-
M>UVEY3;_ /6G_4=H8[?X2^3<EC^ZXPL']>:C_P#=L^Z_,LCI_;33_9O\8L?L
MZC[<H8R];9:\>L1"C^U1^J]-R<_U9*76_;31/;--_P#I3_H+CM2[6H2?]9L#
MY(Z[K<4T?Z;TY]G_ #8_^V?M5B_>1_\ T%^@F]V^Z[A)_P!9L",CJ/E%YI?Z
M/H9=G_,C_P#:#[00^U#_ /1_L15P^)O5,<;7=/ME9Z -K%'^B:5<I_S(OZ1^
ML_Q07_M_L5^9\3&L7N/]'64@]>7*%T?31[&>7TC=4EWQK_/N*[<^V[55RR'+
M8E /NJKX=/Q0=HP:GVXU^IBX2CW_ ,]""?UEJ2Y*R(F2?(;A_C6F.&$#BY.K
MZO4OL()7K"404@( Z @5-[#/OULK._T>U1+7N>DI25>JR/\ "C=%=B#TNIR.
MVP_^@EU6K^;<F0?7<31XJ7D3CTS-+EL7;T ,8?N63YE*>*/'18NCY'W8[1H>
MTM %YU3OVX_PJ'BR9-=-A'[2)"%I.W-J*68@6/4DFD\K-&+IJDUM1:K?IQB,
MD$1TA.,X">:HEF?J=S3](5VXENTSI;YIP.[<#.<;<5AU&I<8]SUW2.D7-.BZ
MS;:V&TQTM@  $^^*YT<O-GJ\^FM*-=BK:Q6-.:1N&X$I0UO0KTR>GY9K9IFL
MN1-GG_:&<M)TN<?/BOO[GGLCO'2XYE7)ZGWKT:22I'Q64MSW/N/HCR42$N!1
M&??BH5Y&A9*JB\6'4-XMT*7;[,[L_B>T.)2>"1T./(^]52INF1UN%2Q[H]RP
MV-IV,PVY<U_ZPE>[!X.:IDJ['+PRVY$7AZV"YM(>8Y0I.2/2L4I*,J/4P3RX
M[(:XZ;2@AI#65$' SYU-3*I8RO72P(;>;2?,<$>7K5D9F>6,CF;$V\XI#KBL
MYX4$\5/>5^&@)5I+1"$L%6../\::F0E 48LJ(ZBXZ25$9P!3W$-E$K;;6XZ@
MEM! 5](Q5;ER6QA:)JVVM.2#D8X*R?!FH-ED8DSW(0R^TWWA"F@E)4  #Y_I
M2LL:H3B(:$TH;0E*F&4IWGID8_RH(+N<ZRXIP-(>:0%K/B!QE!Z@GWIV.B,D
ML S%,.EU*EK+H94?& #@$'TIV0:Y'<B<A$7Y(A(4K/B<Y7G^\GUJI7?!8WQ1
ME.JVXDAY2Q'>2O!(3@8X/.!_PYK;B.=J*+M==<-7JTQ( C%)98;;R1SPD#FK
M'*5T<626X;:83)+R<=-W'%2CW*IL]':-4RFWI2E/\P8\ZZ>GEP<[+%-EQCLK
M>;P,H/EDUN@W+N9)12%G+3*[K/?9!\A4I)D8OD:,,+C++:SS[U L;LDVB C;
MP<U(BSA$4"<CJ*.0X$&;>$NK<W8SY9H2$Q&4H1L]WXJ?8%R%8F%_AUO&*7<?
M87)*U C@9\N*8)C:0XI"O",^U1)H05+0$^)!!HL*"Y#W'04=Q@.I;;;P?\:"
M+8V4<)RV<"@+"MY0=Y/%(GW#E22<T<B#H2G.3GCWH?  O.M$;1YT,$-UALCG
M_&D2H3:<<2K8DC;]J+&TAQWRJ9 ^<L>1->/>!Y:QCD$USF=9\%UTI93/6AZ?
MX8O5>>@J+*VRQSKLS,EITOI5A*?ZWVA@BE-TB/Q9H^EM.+AM(;(W$ %U9ZD^
M]<O+-MD9R)Z]ZB9MD%2W'VVH[(RG)QG%1Q8MQ5&-LP;5O:9+U3>7;;&><$5&
M3X5>$^]=#'B6-6:5CI%.O%OCLMHE,D(D[P=B>//K6F,E)$T6NQ6N5K.6Q:8[
M60G =<\_O562<81M";HL.I)NE= 1T6J#W2Y)'\Q(^H&J,:GD>YD%<C+;KJB?
M='N\45I8W83Z9K6HT3VT)M]XVZTZ%$%9ZBAL:)93TB(XQ-:S_: *(ZTG&XC-
MCMKB;C8VY02 H<9\^*Y,X[<A7D[%5UO&<64.1D!2^H%:\,Z'#[)8-+6:9/M+
M%OC664IY?B*@R>IK+DYGN(3FD1.I^RW66GW'[N+2M(<4"3C&!ZUICJ8Y:BF$
M<B?8J]O6])<DR)36U0'=X]QYU9-T6(O.GX#1@,)EK\#BAU\SY"LT[[Q*FZ90
M.T:S7R3K.' @-NAAY00WW?K6S'F2QVR_'*-.R8;[,.T"9<W[-;K;*6J,P%K<
M4V5H"2,DGWK/+5X(>]-A2ER2O9'V$ZYU%?G[@_;WXEJMA4)TM\8+P'0(3_G6
M75Z[%.&V,N26TTF_=GSUL:CBUPW]ZW@EM"D[2XG/4BN=AFH8???8J3O*X#GM
M/<F::TK"TS;(VVXS0GO@D84D8Y-<?08GK-9+49^8+L:IQV(HMAM</34<)CXD
M3E'QK/*N:Z&IUD]1E>./V."*\F7^&ZI<=M2AM.$9Q]JPYXJ,Z7:C]2>SO'2]
M-_\ VXCO>/(UG.Y8<*XY-)DXL'?ZFE1+<&#I' .*5$MP?O#_ %4$K![T_P!5
M 6*!T8\Z5!N!WBB@L,%8'%!),,E6>M1+4P2L"FE8[!"P>E%!8(515 <5<T4,
M#=]Z*%9V[[T4#?!W>Y\Z=%5@;Q106%6OBA*A-A"JF*P"KB@5B+CJ@<!1%2HB
MV)]ZH@G<:*(V!WJ_ZJ!;@Z7!CZS11)-!DO<[0KFB@W(.%*.<GRH078D3QDU,
M@OB(KDNCPH&14E",N9$6L4_MN@BG%D84DT]L$5."7V)!04=0"">N*')KA(2B
MUW:." H_BH\27H34HKO0Z27$D>/]ZAM3'6!^0IWJO-0'V-1<$2K!'WD@R98;
MZ+YH20_$PO\ A1QN>T^)9QY8IN#DO=#Q,:[)(37=T 9*E4XXIE<\T%Z$;,OC
M8.[O#P/,U='3N7VF4_ZF\$=L*H@[CJSN$$)=7QZ*-;,>D3\SCZKK$>TJ*E<M
M827BI*3GGKGFMN/2QCYG!U76K6U65B9=9;ZSR><UMA"$?,\UJ-?*;?<AG0^Z
MH!14?N:MM'(FY3\A/^'OJ4%#-#DC/X,F^PZ;M#BP"YG%+<70TCEYT/6[8PC!
M[L TG*S0M(L7-V=M:22D)!%%D72$PZ-I; &,GC%%E36[S!' QC]J8J^(O#@O
MR74-LI!W'FE*>U%F/33U#J)<;/I0,MA3C:1^58<FHK@]=T_HT\<=TT6:#IOO
M7@>[' XXZ5DR:BD>ATO3U*78N-LM+<%G:I(Z9Z5SLF9Y.#U&'30P0X0A+"$K
MRI70TXIE.62NV4SM(3&N.D;C;$J&]QI11[$$$_X5T="G'(F>3]J5'-TS(EY4
M>>EQ7BM12@;5'(KT>\^+2PU$*EI]*\;.G2I6$842UJEOP7D.))2H'<"/6JI*
MS5%J7NLL\_41?6F0MU14!]1/-0JSB:C'X4S6.RJ]LW^T*<1@K0-KP_H6/P_I
MS7.U4-LK/1]/R[L>TM,VV'!E(1XDCC Y^P]ZSJ9JEC*XNQH?5A#8*LG<4\[#
M_2#Y^Y]:L\0I6),7&F0TWW;;.TN>:AQ^='BAX-#=S2Z4_2 2!RK&<>O7C%36
M2RN6$:&QM1EH5L*VUYSCDI]C4]Y2\20K&B]RL*2V4*/TMGK2<K&H4.FH+KCQ
M8$4!+O.=_0^=+</;Y4*2+>RM_#BG%$X'A/&!TS[4*02B&C6[!0X$ A2"I:O7
MGJ?RI[B*B<ZVV[$6V6 O:HI"TC&W'0>X]Z5CK@B'(DZ0E26W0E>X;5.'"7"3
MTW>6!D_E4TT5R39 W:7+8:>$YB,TMTG$A+F?".,!-2@K95.5(R^_O'OC(+SR
MCQW(=&U:L]016W&J1S\TK=&A:.TNNY0(\A0[S>G.3]Z7\1RL_N\E\A:?C6EL
M+6$I('IT-6M496[1=]$78?-[%*)2/*K\4Z9FR(T9^Y;6TN-DIQUQ76@S$T'C
MZC"0$[R3]ZG*1!1Y&%QNJU.I<W$<\^]0;+$A_ N27,*\J=B:)!5V&_8.>*=D
M:$T2E+W[DY)Z5)=A-"+#9"M[WB!YP:$.QP[W*QA#:1]A0(%'=-M95@F@%W(]
M,ELNJ*T@X]:C9904MM.N94!MH %YMI+>6_\ W4 -5@+1XS0)G%ML(X- @S+*
M'$A.<B@D(RF2WPCC'I2)(4'3 \Z0AJZTI)R2>*"2&B9&YSNRHTK)BH>0ES;F
MG9%H<^'TH$> K#8[S=)J2E+:(R3X@ .17.O@Z;HL&K[D;-:A;K:?$>#@\]*C
M%6^1(N793I=R-#:NLA([]]  X]>M8]7F_A15-FOL0T?+I8;7MX.Y6<<_>L,6
MVZ,[MNS"NUZ[7&YJ<MD8I##:]F0>OK75T^/:C5C21ED2&J#/!)/I6B?*+6[)
MIUM;JDI0,N*X02,\^503HB7*'J>!H&S"TV_$F[RD%4AP$ HSU.?*JY8O$(U9
MFU]DR[D1<9B?YKBR<]3C[U=%;51./>ADA!6EM'.,YQ3L;)E3);8;)'YTKHBA
MS;7D*>3"E<LRCL2?15#&;%H:(^B Y 7RE'"2?,5S=12F5R+G:=/6QM],B3&3
M)>'1! (K.Y/R*Y2-5TC<)+*DH9AH3@ !*4#('IQ47-&2>.S2$:):O,-3M_8$
M>*0<I<.1CWS57C*/V2JG'L9/KCL![,YS#SUNN?\ #%DE14" VH^6:OCEE)%\
M,T^S,RU%9]*PM/\ R-LN\>5<+=]7=JZD>=;80N%LOBW)\E=[+$/=H':G8K0S
M%#S3*BXZ#U[Q(/["LG4)+%II.S3IL=L]Y6#L_@Z:8DNNO)=E3RGOU  >#:!C
M\J^?ZG4/,H[7PK.FL>U.T ;1!B0Y:(B$)90DA"0D#<?<>=40G/>K9.DH68+J
MVYQ;7<D7V\/S'WVU[6X_=D-M>G/GZUZ')'?IE!,YJ59&S*M;:A7?;T[.*1WJ
M\H0>H ^]9=*E@AM3X+<LK*#=+NS:67%[LR% @D'VKL8,#R2W>1"'.7[T:);9
M ?B,/>K3?^%9=1[CVGZEZ+*NFZ=?^2(_"^,8K-1U-P=*^*BR<&'R.*C1;8;?
M@XH'N!"AGI0/< M>.*!.0"'?>@2D&2LCJ:1)2%$.^]%$E(72YE-1HM4K!W4#
ML$J]J!V<%4!;.*N: M@;O:@+8&^@CN9V\8.30%G;ACCK0%@%7K0*Q)Q6?.I)
M$=P@IPCS-242+E0F5D^=2HJ<N0I<PD\TZ$Y\!.]]Z>TAO.[\8'-&T/$X#)<2
M?I/-)Q)*2#]ZI/4TJ'NH'O,@\T4/?8F5@&I40<D 5Y\Z*%:"ES!P*=,6X'O<
M*'-%,-ROL+?,MIXSDT;2.^*$7IB0#@TU A++0U5/ YJ:QE4LZ0T=N@3NS5L<
M5F:6JHB)=Y5SL/[UHAAHQ9-80DNXO+S@UHCC1S,^HE+L0KZI+CO><X P16F,
M4CDY6Y,:&,Z$D'KZU;:,4M.WR)_PPKYR11N12](V*)MB$\>?VI>(*.B:%FH
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M.]L@[#UQ7.UL>S1IZ')^^C5X:TW&9WS9+C;9.,<J)]_M^]<Z5I';B[9;X<'
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M45#U9:GCG_$U^)P=!_I&/Z2#_A3<4O.QM1CQ&5AN]\/7BE06$[S)IT1L#?\
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M3[XK!J>BZ'6<XYTOA1NT?MKUSI*V9X_"G:(65\),)Q*Q9^T M[>0S)AC"<]
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M/SQ_,2CH==7E(*CG\/)S5B22IE&/?DEO\C>/A:LG\8[1W;I(B!QNTQW'$/\
M]+J@$I'Z9-<O7S484=7I6%SS[CU;(AW2"ZI-N=*TKY3W@'!K@3]X]7%;#K?9
M-5R) E2"VRGHHJ>Y7[[1TJ+<4J"*DY63S6FD+"529"U*!SCRJ#E1>H)AG+'$
M9>!WJ+CRMK8/TC[^E"DP<$AA+M[24K1N0VM*RD*.<+(Z@8J2;(.*&4F*CY22
MYXT.@AM:0/%D>0\B/>FG3HA)<,CG;:HR@E);BJ<0D%QP[_?:!ZXJZ,N#+*/)
M'SF$I;Q%*TN+0K(/U)"1UQ_G6B+LS9%M*_-F(DNH2;HR4M%'F<+4>>..0?\
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M?6(I<J@CEW9;_M5A./ZB!2V-B>LQQ\QM_I):693??RTX6DG"1NJ2P3DN"/\
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M4V8AHFY1=6/N69T)^84L]V/5/K75S0486D7;:[FI2.Q:+.L04W'4J5%_F%(
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M,W<'C$; *R/+WJN3H#6-)Z>7;(C66@%%L DBL&6>_L4SEM-"T=I,WR>I#_\
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MV!X-!(,-N.@I,:!'6HLG'N''6HE@<':HX\Q0^X^S#)2=W)\J!H H.3B@5!%
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M -,MB%V@<Y%!*J.X7U% =P=B!QB@=('8/0T!2#II#0!0G/ -,*.*,C%(*$G
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MA81E.+#CF>*:L&/.^[Y80#D#K3 72$.>!*_$.<4Q ?+N>] CQ)>;&_&49UN
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MDPY)$>Y8IIX+9-6>-%&*>ARR\Q%.G)KG1H\>HIO-%$)=,FO.SEZ9?'B6D?8
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M*HC@$93^=*6C0WA2'37:7<+HI3T@!A YW-DU%Z9(-B NNIKRPT'&)KBE.#*
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MWK!*?FSD9)O(3!B+;C175HV.%U [M2L9QD=:INY VE"AZY&7#EN(#24N+ 4
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M$;O/(Q5T5YBW,9WJUVUS(2\U^HJSL&YD+;XT:/+2@*!&>HJQ<CMEU<G6]F&
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M:R;[ EK'-,385DY'6H*5R#N:MHFXPGVRM_"CCS\JZ>&EW*I(L<-MA^?O;"0
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M(Y4#E/ZT=^X*X]@WRI_I%%(>Y^@=,? P101:;Y!^7'I0&T)W(]* H,&,'.*
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MY'2)\,I*<C%=&/8SMV$<2L)&.@]Z/,@Q+*O0T6Q'GW1EY8?NK41$<*:0X-Y
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M!RT)1C I@$*059(H ;NMK4O '% "2$J;6=R2I/F1Y4 -94N-DA+Z#CHD=30
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MF:>5QX*@_JB^/M#NX+A*0IT!"=P)_"D?T^N:OC!(RRR29"3[A,MY5(FF0M6
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MDXY)QZ]:@N2YLO<2SHM[#:8Z4E0.#Q4DB-CI]IMMG /)H!#!#$AS<A"05>5
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M7-_@62/W,!&'#X4I\_0&I1MCQVS,6RY(DF7.<2MYT@#!Z5:7,TRW-A,)K/!
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MT3NR9;;='A!) Z5,1&7&0"I+3"2IM"@5A/7'G41@Q$J2'5--.@.?0DN9Q^5
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MEH*_FIP"?/%.A#NP&.@17G8 <6SA8!/7VP*$!=$NMK4A"XK9^8/>(2WSM/\
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M0=93E9R0I*?_  171TRK$D1Q\Q*ZRC"SW:E<>]7E@]"N,'GCSJ("12L#ZQ0
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M,>Q)DM9>T5+[JHMS;Y!\*B,9%9\NGM7$7AI<EC>?1/=2B(=Z3C.#TJF$'#N
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M.*Q3;ND;X145;[%<[:.U%R>SIWLETE='46+L\AN169#"/#<)8!$B6K'X25*
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MA(.K)P2GP\<4 #WV,X_:@!%QXE"L@_G0)C5W<O:0#TQTH$)IR%T +%TCC!-
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M6R@=#0(.CNU9R:!I6 K:#X3D4!0% F"?*@ , \8ZT (Q\_)J:\@[0-OS 6V
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MDY'7FLT_>Y(OWG8HN/W8VG@CK6>46*@$N,LGDC-1V@/$34#J!4=K )+OXCI
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ML<T .D%#F%+/2@ -K17X1S0 #B7$C^7U/6@!N(JE[BLY_P J &SK);/ X]:
M&[P.<8H 2"$XY/-  ^U  ;@UP@Y'M0 "GCMH 0?4I:-H!ZT#0@E)2L*4,8H&
MQ^2F2UWI(_E#%!$30C>,D=>GN* #%M2>-IH 3+CX. Z !Y4 &'/3F@#J .H
MZ@#J %8R@'1R* )  [LGICK0 Z9YY% #H)..E !N\5T3U- "R%N@>)6:8!5
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M."@\<4 (O*6DC*3^E  ![)P?\* "-J#:5%9QDT (/DG!1_PH :O*< QCK[T
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M52 64^%J#;N$J\P?6K%( Z8$5T^+FFE9-RHD8\!A@>!/VJQ1KDJ<K)2.VI1
M \JLB09(MH 0 L5:5BG<H]J /)D'4EPAO!QXKWI5N2I*^E<B6)-4=1I(VS1.
MO4:A9;M]P2I+@3X7#R,_:N1J--+$]Z95*.[L1NM>SZV:A2X^4(;DH!*5XZ_\
M*UZ?4UQ(J4W%T4CN5Z%D1''E]\ETI04IXQDUL:CG5(OJT:4^VI4!N[VU96VM
M(+C*N!^6:X4X[<CB5+W7R5>8R\^YWJW2D'D-#Z<^];\25$9N^Q)PV$6YOY@
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M;;D+<PX!'WJ X.>E6Q6T&Z(AJ<7!(4ZD%2U9!'E4I-$),F=/-PIL%Y+Z/%C
MR,TX,A5@P8#"70@@*PKKBI*%LBX472#$B=VD);\0J^,**VDBRVZ4F/ 4QW R
M!C.>E3O@@T5.XQ7I$PN,J"<DY%(E5$E#BN-C*SG%32:(-V3D H<*0I/G5T>2
<%$HE 2? ,5:N"+%TC<,*YQ4RMN@=@]:!;C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>comp_0028.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0028.gif
M1TE&.#EASP!0 /8   0! @D%!@L'" X)"A$-#A,/$!81$AD5%AL7&!X:&R$=
M'B,?("8B(RDE)BLG*"TI*C$M+C,O,#4R,SDU-CLW.#TY.D$]/D,_0$5"0TE&
M1DI'2$U*2U%.3U)/4%524UE65EI76%U:6F%>7F)?8&5B8VAF9FIG:&QJ:G!N
M;G)O<'5R<WEV=WIW>'QZ>X%^?X)_@(2"@XB&AXF'B(R*BY".CY&/D)63DYB6
MEYF7F)R;FZ"?GZ&?H*2CHZBFIZFGJ*VKJ["OK[&OL+2SL[BVM[FWN+R[N\"_
MO\&_P,3#Q,C'Q\C'R,S+R]#/S]33T]C7U]C7V-S;W.#?W^3DY.CGY^CGZ.SK
M[/#O[_/S\____P
M
M                                                 "'Y!
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M&PA@P'?,(E!  ^A"J@ &"C0@ &^#Z$# 92 .<L42!Q!W!1$)9.#5S"!D8(
M)0N'VP]+:'MN(2(X^-D&"1SPZ3T"..SR3D\X8$ &%!C@()!$> #990F0Z<,!
ME^U\09"9M$! %!.3Z_0A5Y!P&;D-A& #OHYP8((3'3:0'2$<)&" Q(<T08 #
M,00A<  8_,!"<@%\C,$"D$47I@@&1(2! *-:8,[36 Q1L@(>]-!##O]=Y@"9
MA2"1  (**)"!#SV$($'2!R3<  ,@X!![ I<=H( *9&?"@0%['Y+D 0VP9P@N
M5?"5P QT/Y+D%3<PBT$A4CQP@ :X.4'$!OX% $!  K E$$  $%3 @Q-00*$
M F49@@0$& J20P /&#%($$T; D/KW4+ 6 (@@-H98'4;4($"%7B"#8#@,@K8
M&0  H"($'& #-G"5 0@8 ,LLZP;*Z\04)$" (2C*7 GXU"&HX+P3\,H0'-#!
M%<"&  L4H@C,F@LAW%. LM"  PNPX ) )X3!8.$)#"  X'8RA08,0 7*N ((
M>$8")OP@ 0586Q5V@ $"'- $I6N !T;P 1X4:%G>&(LW:M<Z"9R@!3*000QB
M0 2M8 $)<%0!!C+ %P:@SA-"6%GQ"/&$!B!@ 2I$A TL4X (_%$12[#A!Q!
M+L#A @4'M&,AB/Z *&4PH0A#(*$OGD:$'!HB!@'H@#Y*X+?6,6 !%2@!"38@
ME  TH 1V?,(3G"6/)[2O?5)HGR^A\(3@(8)#2AL%# 2@@4-(H0+DTY\C6&"
M!P1@B8LX 058L+(%)&!ON @"L^)7B"I$(((C:!$#FFF(&A"@4(9H00#268@?
M7 8!&]N9 !+0CQ/,8)"9H,T\*B.94,P@"1\0P/6P!R,#.*<*P6*;GC8000^\
M$$@.:&5&X2D((;1. 0\H212Q4 ++, "@>+N+(' ! P*$5'Z^4T$+./"!#US
MBPFP  QF8 (;(($*5+AH)ZZ@NJN!(CT^@!$/GC8%"]0./_.3W#$A4/X["_!2
M$3WXE0%X,(1&*N,'"BB M0Q 'T*8[0$V,L0& A >0RC!;S[X4082(  "9LH
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M084'8& P+1" Q$I0 :%"@@26^9 @8,#/ T1'"!T, 2X^\P/+;/5'%VD5[QA
MA6<: %>+D$(/YA$"+VJ. %?A+R*B@ ,>Z$"&N\@ .;' C^LIPPC&M$1F#["Y
M$XQO <R]P@K4/ @H9/0 2XU$0KF6  Q4( "2,7)]K/*J%40/(3(X0&.4P0,
MJ( 4?C4 #*#0@0(<P +9740W$E #&CO'92'X6 !PD ,O$D TE9#""W000DA(
M&A55B%@A/"" 1/YZ @/(\P!S$@ N2-B 8"&,0A'FDMH 6'003-AG B0&W WT
MVCC9G IBI0;03QPXO02H0'P?46L&5$ )2K !DP%0(2K@4\9U\@ $4@UN2" A
M /29!Q$$\($\:P(*7%/ "WZ]TA!H.P$3A  ,O(*#%;"7<_V>1 A>4H@; "#1
MH8#"\ Q @4?ZV@81X*<*>/#MC'-""@/0J\LH$ $C>@('-J9 #@S^B"HH(<$8
M=WDF3N" ORA! "8(A1(T$( $V,#F0@?&$X3<(N6N>Q-00%@ 3 #TJ <#!@P(
MTA4J(.Y.+%@ 'C"VUX&!%4,L8>N;R0  ,*#VM?]B" BX.!9L (#H,/[\$%-H
MJ08(;?=@>( "RX.&5"^1 PVTH%Z%9T84G&Z(ZT0@L)B PM\C'PO2=AT( 5@;
MYUV.BQ# 2U@  //HA4X% WQ:'W/%_.HS+@3B&8*S"NCZ[%GC@1(1 EH8X/GN
M48*!%!SB0H<=/KCQMI&9:$D FMF\\L]A'[V7D@'\GCY*6'H;0\Q@ (C7/FNN
M (&%%@($!%B3^"<S!0.((#<.&$#=US\1*1@@0S/I00 ^('WZ-Z,( , DA1 "
M ?!J_G<3'H=-5R !9'6 7Y$C4N46!U =#I@4)@!WA, " 7 C_5>!O[ " 6!4
M1^0S'G@31@ VFN1QBU>"'-%$F#,(?G55+"LH$=2P.7S75C-X$F_E>N[E%SEX
:$S& 9FA&>#^8$$3P 1(P8T68%,)7"8$  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>comp_0029.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0029.gif
M1TE&.#EA%P,G ?<   ,! 0D%!@L'" X)"Q$-#A,/$!81$QD5%AL7&!T9&B$=
M'B,?("8B(RDE)BLG*"XJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D,_0$5"0TE%
M1DI'2$U*2U%.3E)/4%524UE65EI76%U:6V%>7V)?8&5B8VEF9VIG:&UJ:W!N
M;G)O<'5R<WAV=WIW>'UZ>X!^?P!?K0!EK0!FL0!KLAUTM1UXN8)_@%.'K5B-
MLH6#@XB&AX.%B(F'B(:)C(R*BY".CXR.D9&/D(Z0DY23DYB6EY26F9F7F)>9
MFYV;G*">GYR>H:&?H)^AI*2CHZBFIZ6GJ:FGJ*>IJZVKJ["OKZRML+&OL*ZP
MLK2SL[BWM[6WN;FWN+R[N\"_OYVLPYZUQ8JGU8ZLVY"KUI&NW):RW9BSWJ"V
MQJNVP*:YQZ*QR+R^P;:^S)6SX,"_P+_ PK?$SKO R;G&T,3#Q,C'Q\+&S,C'
MR,S+S-#/S\+*T,G-T]#/T,_0TM/3U-C7U]76V-C7V-?8V=S;V^#?W\;5[>#?
MX.3DY.CGY^CGZ.SL[/#O[^_O\/#O\._P\/3T]/CW]O_Z]_;W^?CW^/___P
M
M
M
M
M
M
M
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M, T+ D" !#P@C?.)S]3(Y*D5 $ !!CA =K[VH XLH@ ; X  1& !G=Y0($P
M  @(%%$T,&(# *#G U)COPX H <G*  ##"#.%I1(9.DLQ $>T-,X@ !J! "
M!40@ %6-"Y8&B,  +K"(0R2  1+XZ , \;$#$  ! ""!.I,Z@ 9PZ"U?2R<D
M]I C/9C0$(\(Z /H^:H= . "" B  %P@&$@<H9IP($%#(5$" #"!#N$<R(.L
MT(<0;/8$G@4MD00"@@ T04(II?Z#9@6"VB/H00"KA<3)V&A:@:   $7X@P@V
MBZ^,0J(( *!  @80@!"\10CLC!DD;EL!2VFA2O1<@B$J(( &$( !XQ)! !YT
M@D$@\Z0"*,$$ !  (AEBO1!(P#-)T%X"G!,)1;.  $3F@-3 X5<""\%G6@
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M  H  ?XF-&VP0H$(0V EID\?$P!SEP'.MGOIE&45T -9=BH,<#@#H3CBU ,
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M)%.3$]!TZ40'"6 !CX !!K 'C?Y0"$-P*B)  %L0=\$T(K\Y&R0 B72  !F
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MHWDJ^$(REP6<T^*N!2NOIE&U0V91$]!>S4$! E ![PH?@X%:*5 UV@%3JQ8
M#< !$P OD""*\#$(X&J!1G-+2   !A!6R1I"6[!<OV( V7%9=L5>%0H'*E*X
MDV,0096XR0H]C#M/ U  KQ6Y@%MT8B*YF7=T*))\&# ;^/( 2T,!C.!%T;E
M \  T*('## DRY4=-$,>>_!%FK0  JAQRM>W_U(K0]=9H 8 MZ0'#6!N?WLJ
M36" S"20&B(:2<,4X=,#U LWK_Y2-4@P B7@C88@/CWP ]8[(CL@/D @/HCS
M!XJ44G"0 TT#!+-7>3AP!R.2 Z(!='SR"$)  D( =*<"""P  I^% ]/TOF\!
M=*"V0IK4 T/P%MW[ 2<0GN71 B#  A(7!3G ,GW OH;6 H5GP<RC!1H\$$U
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M"$) !]<-WZFW" [0 AM@/CY LPK1=EC3)1!P2QCQ%BYEX"T!!P=P! SP*AQ
M,A9B"-8&; *!>:E1X!4& #B(XAA^(7I@ "WC +D#O17F AIP J0D!2JI)@(A
M!,]7 ^"# QD  D#4 G10 JDA!-X!-ST[Y!RB!<%" OW<XB/Q%CT@9""  G2
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M#$ MH8<W*%!WT9WV%6'E!#, ?:#AZR&*<;*R@] '*R(A\_8$CO!D])$ Q.(
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MJ4AQ K*/C^QF-R=))0H8P@4]D$+]'D (1K3  RS 5V@,H#](6($D&E ($T(
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MK)TMDS^X6]R@C1[@@%"#6_N*C<](DK9EVH+0 JA\#B]+@*>( @@H@A:(@-L
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M"'Z(J/FB<'F-#R"C-$*;-*J#/WF7C_2 4K)'#FE")P@"(PB")!!A"D ) 6.
M1]@K8-N;QJ&(!Q@$%0 !YNRI+3A*-"D$$<" H]6"(W$$+1 " 6@2"3 =8QF
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MD)3@@[@EY) 1)$><X,*Q,&[@POY"@X10KR$66&$!OQO,61 C*BRR" 0\0=(
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M*N$W*/Y=20(#WFL4"4B7L1A8 P4R(@A#,&*%F@&!0C P"..&Y A0\4"MBM"
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M144/-,#6P$%TL$ 0P E(" $&C( +1$5%.!(_M< %D !Y(& &; !$0$(.%&7
MM8 /+(<6D$ <%<03<$ 'B*)S,/Z 'SR2(-2,<F@!'1T6JA0,1.3 \!2$IDF*
M0$H3018DCG6@7%Q?=;"!#F!!%CX2V W5BTA $^@!"S! 2]"! LS)(X ='>2
MUD42,#* Z F!!-!!(I3 .'I@Y4&C6VS! Z" \4G!P(5$"U!1'Q#8Q7B %N!2
MN&C!]W5);Q;"_BC$A@U"'## 'AC"!'C5#M3*"#P %10"')C-V= !SD0!(P!!
MUCA "@Q"$Z"*%D3 YVR V:PDFS$! L3!(%@ $$ "![2 (62!F^W !AB"($Q
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ME=8V#F(=SN:*+@0(;$"])(TC<?Z LW8 U5  @!B"!-Q)#B1"ES1K07A 5#Q
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M$?"1$GXL"&B ]W8+"'PL'1A""&  2.3 9NL'7]"!-=Z'$#3WCPV(2:R?"EP
M9VS5?E !$EC,(T@!$HB5B!;"2>_J\9P &>V'MGCJKLX':PR"C< !(QL5$(A
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MT"!64! 6>& #0W ("WH @@)UT7A1E"*WJ,A(2<K/?C7,HKIP.$D>_4\U6FC
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MD&\-^TL*HPH."6P1%H C&/ QRD7K$''@SK 0O07J*O'"%/[QFBZ0O1Y" T)
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M\;IC*G8 .D#@/."@!"A$"&[Q7!AN!JK$584#5H-C!NXST%[C2W<*$OH 1GP
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M$!H@3% @D%(730(*![2 !;+"?S&"!#8&$NJ (I[ +FXC4T:"$3*7#CI@CR0
M!16P($1B$2A.#_Y@ >; $:P8!&0$E\WYG)W1/M "!T1 .TJ@!FQ"!/H@ PQ!
M"J"#/** <K(1WP0J2^(,$DYICD&@KASF]5A "/[  6I [W"@#[*1(R&A RS$
MB=&YHBV:L0AB\R A#AI (![! =!B*ASU83IB_]X#,*,"$MZI3$)@)&2E(%3
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JN[S-^R.\T3N]U7N]V;N]W?N]X3N^Y7N^Z;N^[?N^\3N_]7N_!SD@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>comp_0030.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0030.gif
M1TE&.#EA%P/@ /<   ,  0D%!@L'" X)"A$-#A,/$!41$AD5%AL7&!X9&B$=
M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%
M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V!>7F)?8&5B8VAF9FIG:&UJ:W!N
M;G)O<'5R<WAV=WIW>'QZ>X!^?P!5IP!:J0!AK0!GL !KL@QNLPAPM!-SMAMT
MMQQWN!UXN2![NH)_@#."OS>%P$6)PDF2QE.6R5^>S&2DSV:ET&NFT7"KTWNN
MU7VPUH6"@XB&AXF'B(R*BY".CY&/D)23DYB6EYF7F)R;FZ">GZ&?H*2CHZBF
MIZFGJ*RKJ["OK[&OL+2SL[BWM[FWN+R[N\"_OXZLVY"NW(BUV8V[W):RW9FT
MWI6_WIRWX9^XX*&ZX<"_P+#%YK31Y[S7ZL3#Q,C'Q\;'R<C'R,S+S-#/S\[/
MT<'+V=#/T,_1TL;0W,C1W=+3U-C7U]C8U]77V-C7V-?8V=O<W.#?W\[;[][?
MX.#?X.3DY>CGY^;GZ.CGZ.?HZ>OK[/#O[^_O\/#O\._P\._S^O3T]/CW]_/V
M^OCW^/?Z_/___P
M
M
M
M
M
M
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MJ2*@F(@43J0YU"06-' 8!PLHEH<35!R62.Q=L%=%081, 46:LJJ@QQ. ():
MB(A%845R _D#' Y!!2W K!!2>(+ Y- &D/FA@:J+H 0UTH( 9( !G'F" "YP
M@ ", #$1($ $*'  W4'K !20  $@D+^)44 !&)A$'@A0 08$  *)F(2M*$
M+.2A ?[>B@()%%"(XRA@!XEXP 4Z$ #S0(TG!7%! -KP" -,B0D P$ #($"=
M '   &W800 248< C+"$B5" !"C K*T9@%Q<2( $&$ !QA1$!02P0 )$YZ05
M6J  >4@" ,)& 0@H0CRGFZ B%XD^!YWH"@%P@20T< !**"$ </L  4PXPQIU
M(9*42 !,^ 0%0AA  X]  @#<L"D]?:"25P  W#RP@*49 %2Q?$(BM. ]H;0A
M $GH @!N$P4H>*I571@ !L+6@@$D @X[<!(P'_&?2<AA "AX1 %&]P  [4$
MH(($):38)!($P ]QD*0<@'D( 20A$0)HPB,(4()%VO.>"?YI@P@L0,(_6 $
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M3@F$58<0@0&:( ((*8( !P 7IQ@1 %HE(0 H,($!G.@@ DR ! 2@;$J=0 (
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M1OB=$"UH3B" V .R]SV0=4&B,(]@A+M( @DF:%?=(+<)!_X>(! H-(  !,#
M=)1  ):BX !Z8 0$&I  !1A@ CO+@P@BX(&P@4P/(I" !SY.B2UL( (H4-JN
MU>JTHS#" @Q(  (<T"1ARWIW%B! IWR#LUX7S>M=?_5"RFTWA8BS"P3X,]'^
M< *6WFRK"1D$ 4 E!PV@? '/HL0%*%"01$!@4E9(0 ,.H( !@ HX5\" !%I
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M E20 3K'8!!P!53@ !Z (H1  @\@ 4T"!QX0!1D@ 9U""5-02'1&"8,@ @V
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M<,-:'X0$ J!0#  3A] %6B J;?!+QK0"&^(!FI<'?H @/N@"Q_@(*. F0Y(
M?D );1 B4 ( 4" 'MDD)<= %3L  <_)YFL,!"A %6! !"# (#5"*3#40>T
M&B,JT ,U$]6:)^"254  QC(!M/Y2$')  *+V24X02_]V86V@?T!I*X20 09@
M E!PD!^@ -?7E/*)$1J@>1#   <9!17@!TVP5I1@ @.0!QJ8);@!8K%)"(#"
M5@9 /P@ $P]  >*T)$F DR4@+2)B(=_UC#1AEA+@!FV0!P41/BAP CN0!(^P
M=W$S/=-1 3A'"4P0 'N0!!"XBMSBBK$IA?_) "C03!X: +?13'M0+0(Q,EI
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M K&8#04"A-< 3M,YN4(("#"O5D().+HC$? !!J %?-(IS20P9'L #5 Q6*
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M!LAV" :<"-)+5P% NP2A!VX@O8=@OXCQB[[;$.\[MX\0!W5P&NNCOR79!7D
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M<167.I. ".@]&.B]WNS=WNUM".Z-"/#MWO,=W_3]WH90W^V=".B=W_:MWW_
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M8@F(7!"4B@I"< $%2JB@*8H1HAAD/H@8&:$%#BR0(B<1.E@!"@T240*##C@
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MI!U0@0<X)"@=D-9+@K\\ 2EP I"""$60@!5P@24HSC\H-4JX NA\@FJM@$2
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M!"J@Z@\0 1[\#Q  @0Y@.J0@A%;;*4HXA)1-VK)6@;-.!+5VBCAH@19 3RY
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M27B$XNR/0: ();@ 2L@ -PF*"1C0)F2"<L\ _DAWE? ;/_XHNFJ/ P\+BBB
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MZL7BFSKKG#&2@@*]G93&!Y2<.10@#!"]8@=Y4$U)&Q(4!D?=),'A@;B)>/#
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MCX\HSP=45),--)("@%L1S9XISG&2\S(,Z4(!>_*$VM5$!8"IB0=4)(<)A%-
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M!E"%"33 !Q@;(&3  ]3-%A"@<AS@12D0"7  3QR"!&3>YFW@LHQ /[F3]""
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M"!B*1J@ !0Q"(G! !_QG:'*!)7Z "B#!!A0"!^3:L#S""&Q-!42*!EP AT:
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M)P4 !E   $R2'   8%!"%@! ;C   3#  B@ S?'% %A  G2FQ&$  !3/!P2
M 1!  %2)" A  @3 !H03$@! &B0!  S  !Q Z3("!1! !0" W8TM[YI&821!
M '!)U1QC6G!G+]4$%[1 $PC+% 0O26Q!',!!1VK!"EC!7-0!$NQ =TP"!3@>
M%NB'%UC!%6"!8<&!"S@!T3 "%#P!%Q  )(W((# !$C0=%[C %(C+(UC!'FB!
M$AS"("3!77 !'+C!#GQ3'+A $Z#/%>S!%B!!QE "("@!!NW1%:R % P%%20
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M)0!98$$ < $A!$!ZN$$ ( $C)/Z /L8M' C I1S" M0P2<@! C" V4INX44
M @C   2SO;3  #0  62 DM2$%BC '@R" .2&%\1.N@5 $S5! (C/>-BS?%0!
M +R-"05U$O2R%1NT:5=&0M>G90L, @"=25O'!E2 !1@ 15NT1J"-1D ! 1PN
M!C /T95- 8STU4" [+0  ,1('62R;(N?63M&'@C 1U$"<=,K%9PUIB@ 5A!
M>K0  63' N!3VVJ$""Q &M2M;$= "B!SW5A!  ASZCY WD !!EC !#3 AAT
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M ( OH@  #,(D$$#;6< !?');4P(3", ';  !>,$A,.X^!?,> , M'< )Z($
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M& &(%N 2"1N@E")5,",7Z#*")]B!!YI B2:LX'E4, $)9/4$%(@ )&THP0E
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M A,DT80+/ ()4BC$'DH5APX49 4/<!<2=%JL1W"@ GI0@@A4(-,4M15/ MD
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MIJG'KL(Z#I!C/"! 9$J7D, %E(\2M" %D* #"&%F]$"%K/X ^ #G"93 !;P
MA.)@"G"*#%=H3;2  ]"H(+B  SY #^(@  FA$36/X$1 #E! "I#@"N/ #P*0
MPT@&$CX SY J$I-@%@4"!;3 !4 B"C9 "9  !0JA#3A@9?Z@ J3Q!"@.))+
MHG*O(.+O<? ,!/:@!48@"7:@!4CFPBCA#U0(!)C$'%< B0Y!!/3  I1@!U"@
M#9 @8MHL1:* "0AH9N21$HJHB +HTBAA"C: ! AA$&9FQQZA#5 @"32 $$2
MGE9 !)+ !5:@0EA "UK 6T*1!)) $<A,A0I!!!PL"2@O8BAA!1S- P:A7P1"
M#P#H"JQHJ[P  [9QQ(*/_P3B _[^P!DIH0U20 DR0!&2H .UP'?6#B&QA 3D
MX 3V0!( : ]42 36I MNI0/V<06 JSWF<(7V( F4BF-00 -R1 3V! 6P !):
M  D\  ODH.$2 0.0 *.H0%<T *<$(@U60 N2 -GV$07D8 0Y(&):P(\L8 =
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M#Z#@@P9!7-@S9L!0R#S #YK@@_BGZIA$"Q1A!2)&#V(G$TG@$?X @&S2-97
MBE+ =WQ$5J9@.@&($?1P IA$W3:R@WRG$#;-#3[@>7:@X3QHQV:)X#) $C9
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M8 \HM" TP-%$@*1H<(6T8%-#Y'!$=$':A1(!:"'2[4"N8.!J4PH^B,,F(0X
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M'V<$(4J@BM)G!18D"K:&$E*@#MQ@ UQ !6=RNTB*.%>T"G9L!4S@=1%-!48
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M$>:+O_'EK6A"<M[17.ZCU1W"98[<(AC!UM>&$$8,00LA$1@E><6&$6Y](?1
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%)04$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>comp_0003.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0003.gif
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M^>O[__/T]/;W^/?X^O____CW]_#O[^#?X
M
M
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M-0^ ( TKR^L1 *N?Z_YFG:Z,CCKWS->&=>'LMS_0*Q>H@1H#%TCS@0*$'Z/
M"+)<X&TT])/&'L"G @0(3P\%<$ !V+ *!.A!%@<0P3- \ !DR"(#!C# !^JT
MB@<(( ,@,("X9*$ $EA   TPA#0,P0 $', "R$C" %@A#2080&G3X,$ %'"
M,4@#$/X&L$$#!" "3PV!6BXPP!"6DX0"N$ ! _#!:=9@  08P%M W &PBBB-
M3SC   78@32 D$ #&.(%&6#% AA@ !](8P<+@,  RN ^S<"B -K;7@"09X0$
M($ !AS'# 8X@ $"TH  ,:  Q]G"  QB !].@1@-6\($/L,( +X"  (#0LP)X
MBQ4/<.$$I*(""*P 69(B!@H*4  (T) 5$ #C"HZVG#,<( D"Z,,S1%   TR
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M! $@;S9M ( ACA& *[!BNM5=[1HBBP1BO$  U&##!Y#QBMY)(Y9O8$4B.0H
M0AA# #YX1GH%H9H7!( 'K1!! %S!"@L,8AH36.T%;EN& -!.L" NDRLR   ?
M3 .9]3N-!1SPN!&7N#>LN (%*$"QTY ! *T08 #:(! 2!$",U5  !7A@.P6X
MHIH"L4$"<!I$@1R2:'LX@@C.)HT)?" 6 ;"60&S%@P<<X!C<DA1< 7&& .08
M%EM=#OX2UJ9',YQ! "W@@6G/0"[YP=6@1.2!5IVK @4\[@,+0%H O$4,.5H
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M4J[@G4_E T/%4 C:I$M)# H@1@IQ20QPB4YZI1&1?QVAI0TUFGAW$""0 #M
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M +2P;6X0"B,P )6@UQX.XN2^_NH?[HB=[@,MV'N\_GE,[Z>AP*SL"55  #7
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M[:O!(OY20  <4,%85:@! 9RPB4=T(H*],H #WD> )C B 1I81 X&( 8N!&"
M)S  ))Y   V(@0,C9,1M#M$()WGB! 5X!!=XU043VA !BSA4NH2XKK"4Q5WT
M0F(2E;C$NY#.+\=PQ0%(L(PU!& ,TF@# -8@C3E<K0]:_%< ^+"P'T0C<F00
MSQI^0($!$ )F:HC&:6C&"LP$  G1,,087M  !?Q""0%@  K8$(TA%, %.R !
M + 0C6H40P0"D, + +&,8O0!"5,#P3- T !B),.2*D# !Z)AA #\01K0L$,
M^F #!A!C=%Q[3WS<8IZP#>( GY'-$98! @7L@ <6 ( HQOX0 %&,4@"Q($0"
M$) !+% ' 2[XA6J6$0TE & 56 C (*1AA &((FO)@,4:?$"!!/!!$#&3QAX
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M#PB@%7P @!K^M39UGB&T>LB% 2:@!Q%H$1  *,,S0.;&;/['$1H^D!LA4 "
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M. 9\(OZ[]*"/^9JE$*D/43B %5@&8 B1L/N! JC!S4 " R@P)#@ 5H %"T"
M!6  </,_:' %$C  <=,0)3  09"&)#B 55@&8_@%/(0 #.2#01A :?@# Y2&
M-4   A !(OR<*[1$&C&[MT"[6N %2E@ "2@6 Y" 6NB%-%"  3  (=@%6J"
M4+DE [B$4.B  1@ !1""R;NR7+0>*+LH*9,>."&IRNO%*8N\-=F3/OF30%D
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MGNU982Y:<>P #4#994:4L-#.8!Y?\DW9#>" F1#?FGT(N#H!.B@43>""$M"
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M9-T$(5!/5$"U)I"$XX"$4[B?+SB$ ( !;"R!YM8!5<B$XY!9GVB"^$&%)Q
M'="$!7B 9-\5+W@"$T*% ,*!5*!F A4*D<SN[8;WN3"&L?[][GHG.X#E2QW,
M!0LP@.I"@%CX#@90 5A(@@* @+IY@(<S@ XX@@&P@6CX@0"(O4%X.CXH  =0
M@0D0  >T@008 @\P@%: !0"AJ  @@T<4@!=X@0!X T.0  6P #ZH&$+@D ?P
M 6*0CC;X  <8+GOOFA0WZC0994 &90ZPA6$0]@>H&P:H!;EC@ M8  &@!#\
M@"A@!BP @#FHA0"1 H[XY 'HZE'N 0'  UKX#0N @ "( F%@*!.@  "0 U_
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MB2JZZ$C($#,-3!D! \T0 QBRS"L,C #-" V\$HT1>-DU0"LCE/5 !Q2L,D8
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MH$$3A0P/-F87E0A !W91BUZ$  "4F ( Y, ,(0"@$GX 0!"4$44IS (!!9B
M ](:'A/TH $!P$0EX"K$8-   +D9@ 5Z$9P.#",(IG/J'':Q@0*8T6!O#8(P
MZ@" *"BC!P%H0"5&,("4X8$  9A#;3I V0H4@!)B?0_/AG;'V ;-/>C9XT+Z
M&(E-S$  ,#C!E!Y!20"<30(!H$(JB/3;*7&B P1 1"8XH;D*1*  "\A$#0(
M@QH0 '"0.%(")- ![6J"$R480 DTH8D<C*D"Q]6$ACS!A014( 4)*$$F3#2#
M "B@O_X$T$$JJ#" !E2  &KB0@"FI  "<" 3$1B !B)  !A821.GV*\"%F
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M/"9$-%@B7;:?^@DE;<*F7_8F@N8FN<56)1;G7QY-TOP1%01 Y7P7!Q"  21
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M"W!@"1PA$Q9R$9J@$31A"P"2$_X(+!+,3@!^ $+6  #6P <" ,(L0 &DH0T
M@ 0 8 ]^0  LX  "0 2F81I68  L8 !(8!J(H0$L0 4 X BDH0\2  (:8 %<
MH?'L4GPLS)1X8 =Z3!J.X .B@0\F8 V0X )^80\FX /X8! H0,PN  G68 (
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ML/(H #L]=PB000$, 74_X1@<P X@9 6.X!<: !8@! 7,\P$"K\M@80A40,0
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M0 F:(1G:  (LP 9>@7V6@1 N((7&K*Y?  1^(!H>FP)>X!60@0(H^!G*P 4
M(0,,&QJ,\QDD8!5(; )6@1A00 (R@ VB81 NUT*7@7DE !I6H R@ 0(J8@*N
M4 )<87K;P! 8P 9<H#G7(!J,  (H  GNZH'B9P#5JLX:H S^0 ]@>_S<]AA
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M&)2!!2R !N)\ RZ!M[25X:Q(F'V'F!F@"K[ "SS@!$[A"1@ !J!V L3@"SR
M#F"@":R@"6# $PX!!D[@!+Z9$1[ $32!#AX C#R!'U/A"S2@ CK@$.)Y$>CY
M!'1@$QAA$S2 "\1  YR%"RK@%"J "S)!$KK  ZRN B:@"HAN"=YU F"@!$I@
M AJA!F;@6+9  S1A$SS@"4:!#B) X\PQ$3@@ C3@:&=@734!!THZ$7P=V!FA
M"_!=$ZB  5(@UK=@$2J@ CP O) 2$ 8@<B7$!@Q 2RX  AXX*R&$!P2@+OL
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M!DR]R%' '+5(\0 O?CS@QRU1I#",!'(,-4P/-#"#1P-^U"+$!<*D<<%0NTQ
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M'<$("!$-/AQA&<N0*31@X0(7(".=R<"9"_3P@S(08@C+>(9,-[6##+@ "TC
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M"6+@JA (J[.JO="9EIFX R/P 6,P#7/0 G>B J)@##<P!B-  4UE*R(@ A_
M!P3U V-@KD=@!]+ !Q\@ B30"M' !CX !!?P <"W ZYD!/"Y!_PK NWD2-:D
M N%+#;^P UA  A(P!JQF!!:@ D:0 9N7#(#P 1'<!_'*)2+P"JS@ NHJKRJ0
M,47C R(  D#P"\W0!PS,"L2  @W0P+!  B3P 6< CSM(L!2:B?NZ V8P ;_@
M1\L0PR/P \Q" 8,0#3LP!I56#"W "IZB!!\P 7I032H0O_X#N@9)\ S-8 9Q
MM -=1+-'T+^-A P[H 0J( %8D%*$\ $&%3'&X .NY+YK  (DT,#D]@P@P"MB
M= %L , C(,8#E01M$ U+&@V!L$@?4,)V8 1 , )2*<8?\ :LI@<7 %(6P*3K
MI[0%Z9"T( 0LP *5T'%X( (L  =80 N\< <L8 )2D(!I #=8(%LF4 F^$ H]
MH (]< FZT ,.0 -L>@N@T ,F( ,:,193T &ZO!=28 (LX!6U@ 640 -U  <.
M, )RL!(IAP<68 %8X N5@,M3H%IP< =1$ 5_$U=",,P?( >&"X"(N[B)V\^*
MJZ>OR5R'T1A9H $Y4 $3$ 9'A_X#]Y4"CQ ;,7 *B< !&O 9-7 *C' "': !
M3_ ^,5 #&E"Z7*!"BF$"FO <'E "CK )&+ %C^ !2T<')Y 85( !'A "BD"2
MG/ ()[ !&* #GM %\U4!DA &'. !&] %W)72,>T%#_  -< ( >8)57!?'! &
MIR &*8 #"0T&)"D))E8"&.#17<#5&# !8L!C,7! ,; !<L=WV;N]<SV-T9"3
MZ53%0R -R2"_SS !=H $+3 -O\  .T ,L? HT' !'\(*%I +JS  2- *A;P&
MKB !L2 -;^ !T4 &,I,,)/ #TF #.I4+$\ &L  !F*T'("!IQI0$1B -Q/
M>L8 0_[P2 I #%T$K"0P 3FX#!3P!IG] OCY [$0I-$@" [ PO-ZC<^@!Q*P
MURHP"*X  :Q@)A_P2!+POS_P M+ "B1@F9]7Q&BY#*M0 $>P"NVB!H+@)<^P
M D=+ :QP!"X@::GV )\0"PFP+F4 W3[ )K$P C2S M, #60B#0XP4<0 "*PM
M#2*P!M) 1LE@" K@"K#0 'N0#&SP ,]@!#<@#>V2+PN V4<01[\P90] LZ^0
MR,GP"AG0"M(P!DJ$ DD@#1,P"+G@ 'L0+@SP"W8P &H0"\<P FH@#:\0WZ[
M (5P#&90 "+:I(Y'D,)CFL'  C2 "VF@ ;U0"0T !VFU /Z\<#9X, L;X ;#
MX !X4 H#( 25T ,4, PL$ 2X( 0AX MP\ !I$ H,2.5Q7@0=( P]D!!XL !N
MH PR, *5$ >$,PP38 %14 F54 %!< F\L!;"; (B\.B<$PHL( 1CHP!"X >A
M4 !!X <;P#EHL  _(7,+68"C*= .*)OC<0 M% ,<D H(#0F<8 (G@ J,>@H:
M4 /5JP UD HEH .I  D2< A>D !-< BEP0F+X  6YAN.4 &-@ HGD .I4 %<
ML @,T B*X0"*$0&/D I/T&"EZP$PD F.X !>  8#H .)P @3X 6I$ 83$ F'
MT!_9@0.QX0&[P0". $$+_00/H/X)75  7? =T/&',* #JK (N=$%!O %WZ$!
MJ8 #&) 9&'"]+"C7="WRB-@OZ_0 9< &>]"_TN *#Q#@1S(!K+ ,TH $.[ *
M#* ';; '#; &0=-FT2 ">J &%] '-U( KE &PZVN+7 ,>=9FL$ ,8Y !1<\&
M!? )U*!.QQ +>C &#F!Z83)G%! +) #)SS (O9UES^ #%& &@V ,T5 &,_+@
MQW#VR^W"<98,JR !/W#:,'X!?] &=F  H@ +$@"O;^  2+ '+?IY$TK>J_
MB10-*Z &L/  .\ &(YM'#<!LS4(!J\ *$Y ,T, *$I ,9W($>Y D2O ".@,$
M0! -$OY "+'-XG_ !A,PH!.@*=1  :VP!@ J:*R0"Q!P!7; !RZ0,R,@ F=
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M RM C(4)A.L! SR#!.Z8J >(@A4.^$4S#-& 9;18"3".!2L:\(,C.& (T7@
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MP@,8R($'H!,)#WA !Q&8P7<TP84'Y" %$8@$S"?CO0CHP ,<T,1OEH ##T0
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M/@R"%;E8!BSLL (J0B,#?Q@4G/Z,01&"02<8<?B PEB@E@G<H1>WJ  EXN
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M"3$<L(H6*F0'6U55I!H8@5]( U'2@,4#7K&"(4AC&10@0ZJN, UHE&&K9Y#
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M#.AO%6#"D#20@P8)-*#62UT%6 ?1"D2/RGDK$9:9%]!(,( .JHC$"1:14TW
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M_HFIF";41$(%"UCLRQ6 @ 4T]'>,7^A+I@S"((P+JP #(?ZP0C.(2S&(0BQ
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MY\FU3OXE=/2"#(Q )<"! U!",%Q Q]4! ]1!,#1 '?C"!B3!+!"!" 1#)3A
M&F#"![C +(B "1!3 U@B</3"!<!!'1R2)=5!+T@ ',Q"" C!*Y\-6^/!+'1
M&I@O ]R!'S" &P@#"XA )6 ! CAM+4"M%&S 7%J &P2#!$A!+?0 #3 ##="O
M ^ ! ;_%+@0=*$1!" A#&GQ2'#S )>P"+?0"&DC )52"!%3",$Q "%""&RA
M*&#" K@!)8R  :=M-W/3$U3 (^#8(F@?##C"%AC "?0.#)1 )&3!!$A"%CQ
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M)$(D/ )Y_T<$.,(I8, 2"&,.5,#W>.. Y, I1( 8L(Z$T"9O\BM!^W>_BFB
MK[ D$*>B+;2!:_M0_7BW^XFE/6X#68 *_D$#_, +V, -#,(:J$ TO$(R=$ L
M$,(%_!H?9$"JC($TJ $([, 07  QE M5E<$+#(*G>. :0(1E?0H%$((T_,$(
M0  (L +)@D!U>CM4PK&0UP(OX,%_S<(M9<4%5((M\,)O"#<B/< -T( ,T, E
MI  6:+G(] +5>'8=*$,(R$$:R  O2  +L/S&]4(HN-P# *T<@P(,A( 1A(#4
MH+: <?X7)D@ %@9#$*"OT09#!Z"!,[N,*?, #90 +],O=8FAHZ?! Y2V#,B
M'\SV!D" "<Q";M_A"!QR!<C!,%P T$8,'M" %( -T3VWWZ'B=EB!!D0 \&Q"
M1Z5"%7" )C2")E2!!IQ #42 (C3"1''"!'@ #)Q "NC (O#ZC.  #JC"#,Q
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M%HGN%4TO(8GN"VE1=6B  2R  AZ [9 G!#[ !#;@$GAA _#@#3F@ 2&D!X3
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M]L HJ9QRRB:UT3&#%8F D<D7CAC7!2.1X$?% SHDPG0FF232A7>^<<&())F
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MV$1(4V$?26" "I)8@ ><X($-:*<")WB"!Q; B$R\1PP,>,(3)I (X]#&/9(
M! (.(( !   6R&.#--X  #W(X@"9(H8>C(<,$01@#Z\P@/X(I.&A 8H5>6V0
M1OIJZ H#4$ 6L%# !5225T  @ W$"  9IF$ '^@5 ;$@A  N0(PCN&\/ (C1
M^9@4@!T0PPB9U>L$%O+ TIHV&EF1 !^4$A.1$,,.%^G#!*2Q Q=@A$QF  %8
MD&#;0TWRM\ -KE:(05H;)D12;*! ,BI($FG\P 9@:85-KF"#I QA"-&0P!X8
M H%!2",#6EJ% D2QD!T808 B2.(*R$ 4%YP!%@QXQ?<>,(TE@J4-#(#&&D@@
M#1*0P;D<FL J9 L-:<0" 8&DP+G^D %H]($5T4#&! P1"PE4\!6Y (9P%?45
M,UUR9K2PP WN( 4%5*(6#JC$+OYHT8L.H&$7)F !"RC!@E"PP 67,(PN2I%B
M80Q#"'X(11T"QH(H]&(!0YZ%'X3Q+V$P@P9$&,9HJNFR:TY3,ZT!C9535LV8
MF<4T6]8,9[()&Y[5)@P*J(":(U"%5'! !ZA(Q0S468%V/F("=(#$ QRAB0@P
M(A5= - C(H"VZFPB"Q@XA1<JD H/+ $5J%B"2!F0A51$P@LQA>DF,+ %2=P'
M%8]@0"3P">DFB!02XPE#!4[!B0>((16HF,$)FO.(+C":U*GX0@0V40$O.&*C
MF5 J*CQ@T4^'^A%62#1/'S";VH@-%;S.PBABAYU1 &( *MB#'O3P#!X4X!?2
M>$4!?/[P"@'P "P#W.X.#+ C!>@6+#LH@'S%[4$*/&!''H)% )0 %A4<X!FO
M ,('?C<&:4P !'T @)8@0 %IY&( 2% ) %9AA )DP (6$( >#*LIY,4H Q.H
MH6E'GB;42J0B%%@#-'[QBV2L@A#HLH$-4)"!8[R"!!/(@%B5\ )H+&,,:ZS&
MAH=.=!<2UTPW;,8>=NB0"O*!&"-8X2\DS HSM  :S0 "$*(Q 5%HA *#>(8%
M^! -45# 4LL@Q 2@H8(U"$\"L"A&-%Q0!E>\2U432 8(VM 45E!@&6N8:QM$
M\(P+&.(9$V#%%7J>BV1D0!2M4/ R^) !@!NA@UQTQ0.,$?Z("US !A$INE;H
MY6'5V,(7OF"&#&30BP=08L6]T( ;@D&+.X@,#RF 0QI,T M3],(/$_@,+8;1
M"UWLW@82B (SXB"!"9C@$DR. B]Z(0,BT)[+H:FR,DN3FL^4)<MAIJ8NGBG-
M[0>&S+&933<?\ ANQHX3$Q##=+C@ 4],H)V-B  ='K%G1BB4$YDP 6&P!2+5
M?K[!"8S ;#603R%U B>P49L0:"%%.5]0 ?2! ;WA')FP".Q';)G "5UP:N\1
M:'S3.(VP-!C@4A789_(7"8S@ (]0 SF0!3HP V%P E20"A60!12U",GQ )&
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M#7UP <N%HTB@![#P BT7"ZS[<QG@7SNP#'IP!!9!""/@"L=@##L@"M.@!QX
M DK  Z*@7VI$!D#0(R.  F=@!CS@"C8PBWQ;G[!A+YRADB:P 19 D2R6!A=@
M 31@"I_1"W@@!;VP"WX0 B;P>ILQ"S3P 1N !L%P"2P0 D4@!PPC!QL  AV
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M?":3W+667+W2.R[0$!/0$'JLY7,3 0VY\ N;+!(28<I\F\K!=5P7&A:5<A7
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MA86PH(X2,^)())'.!,D66M*<:_Y-EW1@8((JOJ@ !PVN.F6))4J X10J-/#
M T<RR00'##R8P:BNDCKA"TTV>6*&5*SXW@-%,GD$ANQGT&21%)Z(((RL,IE!
M!ZM2J-4CLH>!)VS"?O@+PPP6@($NC,)['CC!(T;1A"6 +PPGP$$$8I %#T2
M"HJ2'_A<,@,<=# &DLI"!;)W"++@8 ,;.&&PVO*51G1"63?$80YUZ!=C4,N'
M/P1B$!V##&-8"UOQ>08?)!"-9:A@$+$8@!F, 0@%Q (6$&!%-/C0 ?5 P!7)
M^($*I$$"+%##!3XXAB$<L P]/, T/Y@8,$:S C9(@Q 3D,8:$""*9;B@!;)9
M03)8(?X!%T#C%W.LXR F$ TU<(P$8R#& @!Q##8D(!:Q2$"YU  !+5Z@&-%
M@@VDL0,5E 8"*VC&:%K1@%_ X@&B5$,(HO$ 0!3C FL S@':D(PU2, \B1E0
M70J$D0ETP 028 &.'D )7M#"%Q:(0R4F0(D+4((%EZ $'G;!$5^,  O**,4$
M*E$*!LCA%E@8 "C2\(%@!$,(+&!&"H(@#!G(X!:A<$#6TM"!7F3H$J70!2V"
MT8,0Z"(4%0B!,(J0@F$,(P58&(8,:%"+4$R3&7Z@@"_B,  IA.(2"+!!)70A
M BD(8Q86&&<#Y+"+-"3 #R7ZG9G$1*;@:81X<E&)4#2PA/Y-<.$ 8M!$##B
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MR)XGT $=R )(R(((@ D/.*H(6/X$FX $3?" +N">+L" 1'" "=0!*P@#1XB
M1'"*1\@?LP(J2* V2*B!&* J49,4#W""4_"JQ\) +O  *D@%#* "/&&@&,"!
M46 $23"*"H"!)< !)TBVHU"*J4BXAM/"+=PA9M&MB0/#,)0MT;B6BQL.U6B#
M-3")(;"!5S@ 5I &]P($0*  3#N#9SB"%3")/2 !:; NFS.$"<!#,9*&/U"!
M[4@&43B 9) &48@ :5 #%7B&9[ .:;" -C")%XBZT5B% YB:57B /.*8LXND
M/: D W"% @N/WEJ&(_@C:7B%-IB&6S()4IJ[91"%=_D%O=N!9#B&"P"$:+B
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M!E@$/_G #L*!&?"L4<B"!\ !&'B 1*"V1$"41VB ,#"@"E!"!QA,&("!LKK
M3-@$'OX\A41@ $G@U":8 17:A DP3$VH "J(*@]8@@C(@5'HJQ3  0<XPJ$P
MN*'(3,X$UW 5IN$0S7(UU\4X0XL[37(=#5<H@RL8A&@0A0%K.6,X!N+8 R38
M@V= !O-H@RLP!'Y=A5@XAE5@A6-XA4$@!FHHAC;  D-8!LL@N35H@V(0A4&
M!5&@CUA8A6-8AE50@K73V,#P##5H V2X6%@PA(*-A5<(!"9*!C<B!D+(N%\8
MA(QKV#$PA.?XV#'0 U<PA"(:CF,0!=,@AD%XA1["6(2U U:86?(<!,23FA:3
M"%_P@RA @UH8B($HLR5M"$R($*U- X[$"%^H!-336JUU@_XHN(0/\(-A&+\[
M4! CBQ!;D ,\T(4*&5/UJP5?P(0H@ -0H(2M 04LF()+D#%,$*F^K8,HF ->
M\ 5L<A$_,,A>.-LTJ!&MA0.VK81+X(6%J#2^G=,RP=/B:82O>(0J. 1& (-(
MR(1% (-,.(1#R E$H0(=  -%T01&D,!$V!26> I-. 5F'96GR((<R-VF8#4Z
M>(0L> 2N=(JGR 0/6#4=X),/# ,=> )8>=ZP@ 0P6 GXZ5U5.80P, I'" .G
M" -9?5[7W8(F.(3FC80PH!-)H-^:.%XOB)5,:(3>W12B.+A&6"UQ)> "9A;2
M+*(>.M<%9N!B@ ;3/(G*Z*$B.OZ&:(B&TS"$!JA@Z8J/!WZ.^-C@B(T.U#@-
M[1",!X[8^3B/:*@OGO'8^"CAZ&#ASFB68X"&^NJ,%SZ-7,B %RB##^C%8M@.
MSCAA)JK99("&UF#8P2AA(4X\TC@/:( /\7AAQ<C0N2@0F;0RX$,(70B&8:"2
MA["16FBG.16]80 ^B6BG8)" EU)1*S&(7; 1OBF%(&" #A'=76BG@FB(=K(1
M.?X1-&Z(,88IK=UCB>@%M4D1.NV(T.T=C+#)E-#3F]@$.\D5[G'=ROR34:A,
M3K"J3/ *I-"$IZP JF@)J%(4EH J1!D43?Z3")BW3<B)X+4JFZ"5.RF+3/ $
M3\B33/[(E5-I"4S6E3_Q!*/8%$9Q"9O8!$_XW].%*C\Y.&\MX&DN8,\\0P5N
MX&P.30B.X&PQT/-XA3](C:@1C6^V#&(XI/.(#]\X9\$PT'6.CW&&YW,^YW3V
MYH=[.':N#P?[@Y]#C.<<#'0VC$.JCV8AAB^,&GA6Z,,X#P(QDX RR(A("#)Q
M29<<$XL^B)"X U"("+ZEA32H@S&>"$G#Z()<OXP67=']$)>T4_6329HBB?<[
MW6@^.$G=B?&9H3L)@R9@E:_ ::[XB;48"JCP@@ZD"K"P:9J.A)E6ZJ9V:II6
MBF^EYJG>PH-.8&S6YJR>.&C EB+*.-(\PV-H!H@[:&>YT/[&N.$AAHS$(XQE
M-.AIN6*Y&*:4!A&ZMNOB<XC0]8A@\ 71[>B.ONNZ#FR^33^]'MV.B&1I4(EN
M?6H 5@N@8 E/9NR#LT*B4!53=NS&MDS-5NJC0)3,MD*J%NTM9);A &NM1NV(
M(P:N-D/2C&>PQHU\SN<@.NO"J&VSGNW4+H9FQ.*7]&V,!FQ)"RC?'FR[+FFZ
M-FSB9K^4IDE&]HCF!I[2Q:E0YNRTB&:@=HM@F6RU".HKA&KO;NSMWFSPCN:N
M&.#11F_7RKC/U.WV!B*P5E>4D."O1F F=@T:CF?"\.HA.F@B\DSV'HS-B(QE
M=._%*"[&F],0D5.)<(B._EPM$?YIO@WNP(Z("5>_Q^-CY#[LF103Z%9NY6[I
MQ(8_SI:$9O.*Z&T*X&V5RW0+\M:)ZV[L*W3QKZCNS$8M 4[O'&^MV+KM O=Q
MR+#F^.[F'CI#= 8,TAP$UN"#,4B&0Q*->':/=4YHH"N&=/:-V$Z-0R+R;P8.
M'T"\+&]G=@Z,7YCR*@=HWSASU(YKE)CK@@P"$P HE#;IB6:(')D%7Y "N7%)
M7! 3.I<(BTYN/T^(XSX(@V2ITPL%"V?P,>GH1R[NY3;CD1#Q238+ML#L25V$
M"$)JH.@*3@"#&NC6&<]IU!KU0QGO&G?J&7=Q0I%J'7?U8XD&U_[Q68>6,^1F
MD\"XC/X;#@].#1 3L2O@3A;&C7ZU8-=P8B:RC%](AF(GV0JNKV= =H]=]@ 3
M!5;:[0>NC"K^#=5@X0"/!@$78A;&ZFQN: 1GB& @O=?IVR\>;E\(D3^>A0:8
M!69@@2!@AF#@!8;X7!F;"#0>8UYHJ#'I!8[8FI (!D!#9$'^$%_0XWX?!EZP
MA5*0@F"8 A,5;M%U] UW:<+^\)"(Z3RU">X1WO\]Y5/(%571!$]8!!UH*T_F
MY+ XG[BDM4LG=53/[E07%JC6^9IG"QQ_]9]/%G*E]:$'<MQJ[0FFI",HEV/8
M@PD  E@H@QLP!!_0 ]>@AE9  BSX(F( A%PH@U5 #=5@!?XDN(*M!X18P (U
M6(8],()!6 98B- D,(-?>(95L(#P^ 4S. ) @ 97Z(-B (9D&(15@ :\4X/H
M\#DV. (]@(]DZ(,D*(-<&/<&YFVYKM-2Z('<,3\_$((IL+Q:P(-92 -F^I T
M@( HJ 49F(([Z %M OU2&/U@N 0B8%N#Z 4\,!N"&&DY* 5; $EMH@4I$(*7
MTI(Z$(+KPQ$_$)M2J 7AOX-M$@8W6)P(W_C!ELG@.>F9^@B;DFF6R(1$H ,Z
MF $K\/Y(2!_]M=]%Z (JR(0P^,"5QS5122 JX"!7CG%3M_E(T7E5A_&F-A2B
M (A.T@82+&CP(,*$"A<R;.CP(?[$B :C(3-6["+&C!HW<NSH\2/(D")'DBS9
MT9@Q8M$0/B-VD=@Q%RK6C+#Q;(T#%:O8,#ABAH&::'THJ+ERP=4Q"B-0$*(&
M;!FA"44OQ$HF0829"R.&'%'@BM4!%V-4=%BV:D*Q5Q=\G)EPYA>#5<M^.6"U
MY@(;'B*,47NQ@LV((]'>7-"SP\(OBR87FT2F,%JMR+M"F8! 1%<:"6EZ6 C%
MR\*'$7AZU:)%I($,4$(D1"&BP$\PT"'\5)* 1<J$2\/26'#3(X0M6[5Z=9 2
M+)B)*+LZ]$!3P8TR(1?F]# 1[%(#$2I"I>@QYP&667"<Q8D2K)9P])'7KT^O
M_KW[]_[LY[>73[\]K68)3362%&E3%@JDL$0%)V@"B08Q4%'!$ZC$$($'3SBB
MP"-T1(##$@]D<4H7#>2  X2<^.=?)"5&XA\G)II(8HDIJLBB)"ZN>***-=)H
M8XDLOJBBC#OB^*./D4 BD$1%&GDDDDDJ*0TQR##V))112CDE2<2D- U+5A+S
MC!X43!/-,Q#T(<T%@TA31@8KE:%"-!?8,9 /.T3S0!G1)'/1,VX.!,0.TDB@
MAS1Z//",-".P\8H"K$@3S01\N#+H$"T,% L#R?@PA#1LD$!, [$,E $?@D@
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M+]3!S$N!E*:!',A ",3!GLU"=<A *.C"JYD "\B!V G!!Z1!+UV=J\$!"[!
M&@Q]#XA :DAI)=" "1#!U-]!:P1#*51'#Y0"U[M <L#2+!"!"L  )?0");@!
M'-  +UP"#8@ ''1 ?G,U#PKB[NP=L8&DY1FZ%W! "IS RIR !W'"$GC "83!
M)EB! WA %A >)S2!!WA %PSJ(L3 MRU"*C34*&2"YD>^)JS0YEL!9L>Z+X9D
MZ"DB7$?">0*" .Q W1X! +Q!*PB "@!! "!!'PF  RP *_   CP $+P"!"@
M$"A  V12 $"  (R!'@  !&3  /X\P 5,  !@B@T  !*\  "820,,  5X/Q"
M.P"0P < 0,&3@ $<P04HP"L0!/EW_P!,@ 4\  "L-D"H,'#D@H)7TAX4('/!
M #4] ,8H$:"'&  ?T@0!6$,LP ,!0(XY@)!$P0=I#\=<&=!&6C1I+V&^)&8,
M63&:QW >*[:39T^?/X$&%3J4:%&C1Y$FY>DRYLMG,XO-Q(E,IU*K5[%FU7K5
M6#%D36-&JS6V%J\0)M)@Z6&B5+ T$T)5@A JU -:E1KX*=4!S; '(2BE41!J
MUP4AE81(Z.7&0J5*%NH(8R&BDA0#4H+1VD4I@F,(=7I="'))2 1=EQRXJ<3"
MA# 9"_Z$X+GU80HH(B9ZH4Y3:00+9318X()#(5B<!#;@S*)PN(<!/+W(VB([
MG;HNZM)K8:<^MAG8EZ8:28HD29&)&9'0:P)3X1&#+*A.Q$@UHX0C+A$6'8H
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M%.+@$FBA%,YS*[,4([,3/3^S,Z6R^K+32\5REMKC3S4!%=(F$R+A$3! !SQ
M$/LT!5)A$U(A#!8@#+ -!U!!$U(A;>0P#!R@70]@"U*!$_XBX FP;0OZ]1%&
M 09T !4\0 RNYBPA 9$>M2P1$!'A,T1K$D:0$U1%=F15<2:")8 Z4%4_$&5G
M%%535F4_\.P"R!BL<Q0[DQ=ZR 4^@ 5F%0LL8 <J(%T8HP<^( 2$( 4>0&@O
M@ 94P $0S0W.P@0N00+NX@*(U@2"P0T^0!EZ  1N( 0BX!*&00XF0 5H@ *P
M8!C"S$>MCRI/ZUNY$C.WE3W)@EQI\FNH( *X[1S#H-NRH (BH4(V(1$4(!'8
M=11.01 IB5_3-6VZ"Q)&(0<\8!02X3P>85\I*0N6P HN]@2:0&O"  ?>@]M&
M80D\@-OXAE-M\FXSE41RDF1A-_YVI0&E3C: 8'86B5($1_5VY6YF3S:H*(BT
M)" .A&$7/L /+H$!0D$82J$!+D$._&48(" (G.$.'F 8X  !EI<2%* 6YL
M*$&R', 7A, $G&$8HH 6X& #F$$&0@!@T$48( #-\"P-0,$"7B\SLQ+8V%8C
MP95+_]=MJ^,KS] E2M,<B8:[0&0U-Z&25"$%<" 5OL !("$3*K<&<$!?$S5.
M9T #MJW9((F!YY *"I=P/0 ',("[O@ #)#<,3@ 2<( *&C0+(H W3S0F;8EC
M3713.U5V??A3FX5^=I=W>Y?M=)>(2_!WHP)';;87>8$2)&#WXFH8IB %AJ$4
MAH$&I/Y #D8@&(Q7#CQH H(!#4S@BGMAJ^(@!(;A-![ 7"J@ VZ@$H0!#3Z
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M'LOK,(P/R, /,M"R"H2PBP8$JP<(0/GF/@>!. @##A+8Q3!"4 1F!$&M:6A
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M=*WZGR=+H$;:E<N)+;1*LDY:$J: JWO'%&'(!0Q I>C#"%3@45V0>"VB,PH
M+SIQK8XP"AY0 S2%"M]W)"A2A9MP" D4":A@ C5P"AP0!G1 ,:=P E2@"AX
M!E2  ZCP%:.0 S]%<!^*G>P:KSBQEV\1J&OKO>[IBW*[8UC#B[@9ON([8\+H
MGI.9&I,C \)0!ZC4 1;0 [XP"P_P-NVA 7%0"1-0""?' I= "2@X@@R0A$F:
MLLC9JO:XP,\TJZOJG$G*6_6XI 3QN5*Z%-++ >;CD" T \NK Z?@!0[@,(S
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M!*C  3$P"C&) ^73:[^VI0G@ 1S  :JG"1Y0 350 270M56 :YP0 MQD>!7
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MP;"X%IEP""GP"#^O%LO?_!L/](WM:R>0YD5![E1Q_9\X TN@)(RH XJ 7HE
M!>-_Y)+P!#F0AV1ZQ"E !41B]+>,EZP)"1Y_^+$9]9#_&:31^/H>\OCO)B@/
M$-($1K-5R^!!A+U8F*B$208$6L(NR!FF:Y>O8 :'#0M&:UB="L(,]N)HD):N
M8,-\7?Y$4\=7K909$=;BM='6KDL+9I7TY2?-+EJ[-NHZ&!,F'@L5I50*MLO@
MKEY!4P*MM2M8TUYRA%"B5;#@S*\&PQX,Z[56,X%ITYIJ%,EM)$AN)472!.:
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ML$3.L/["3*"# \@\#6" &4",SG +9<.C.)D+27B$$V -_YI,2Y2$;RR!"J@
M!?@]==.!"(B!$W" RH&$"(B S'L #7B$KH($3LB$W3N%+:@ #DBXO\ !%ZT
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MZ,$83, 1G $R?  2C,$'M((>?/[ &?C "[CC1K#""KS&-*R!$D@ &;P!4V1
M$I !" #"4% #""0DD>A!!I0!$+S ,:Q 23;D4!)E*[Z"'@"%#_P?1_QD1K7
M1O0!$NP!&VP$"+R"-"P5$DD#*^Q 1^B!#RC!-,!"&8P!$!S#-"C!$8Q!3D[#
M4VZE$20!,KS"&8R!*ZS!&!P!(.P 4M*&6P*"#QS#$0Q!*TC#&YB!'K !!0S"
M,20!$-0D&Y2!'JQ"&?B 'IP!#R #->#E'DA#&ZP!#W!F*P"!$:CC'@!!&4S#
M;[ !1$H#";2"#T1#(!R!$LAE&9"!#]134>KF;G;B*W#F1O' 1";4"KA"1HV
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M<OAM/I:NZ0+%Z'8$X0ZDZRKDD%3NY[0ND<PN?]PNZ*INYA;E(+0!DW)$&9#
M#J@ JOXRQ3/4I!Y,Y$":00NT0%CF+D>TK#3 K#0 0O0J!7G6RQYH*5&TPN1*
MPRIX[&R< ?C*!I;5#%<BQ_=*@ZD*Q<L*A1YTY6L [48(PK:ZQO<2PZT2A2OP
M;VM$ ].R0M]6U!H0<#-VKU&D*.@JP4LJ!;?Q[C:R BO\KPU49S1,PS1<Y3-X
M+"M4YT;$P@=[[#,<@R!\ #+ PBLH[3JN9Q\@U6^LP0X<UUYB)2!\(S4@PRHX
MQ40^0PX[174B@RL@0P:L@D;R<!^,;[5ZKEP:@C080J\JL30@@RPT,:\2:BL
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M\8I -?0!#Y0!2?) L^X!$K !$OR+'ICV#SPHG0*E$1!#2'KS-&@M:;8!T'Y
M)V]$*_Z,P2JD[!J0P!J  #+\ !",P5/R )/: #$ P1[P "SLP1JPJ!%4@P6P
M 0I<[PZ4@0WL 3%HK6S[P%J_P#.TP!$( AGH :?^@%V>@71N!'$3 P5T=_<:
MM50CPQZTP!I0@"P,@3I&-P\<@V"O0E<*PA!LA _(@A'X !D$Y15HJV1:P"
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M@ P^ !" [ Q 0#J(80]4H"=\("V:P@SHA2>S@B'T  F.8,I2XQAVH V4@ <
M8>?@;P1L;0>PP@N-  E0P'^:\@=(+Y_T@ UD@03&8$^(8@RZA"''J"F&(.1N
M(PE6@?X8K-*LI,&=7F!9#(0'R  (6A$IS!)X8D$NM\)' ),2D6 '\LE%?" V
MRB\4)<T'Q^ -2& 5 $P:UL (E.#2<$,$6D $@! )KLX5\FD/UN 5X X$/@\E
M-*4/=JHIHL$'B$'CQL!&4J,/-&4:$E$-,N %2*!69$$%AN 'JJ,,,J %2&"G
M;*",FB+/5M$@Z],^[Y-=_ @F<N:36,%_HF$_Z:A$.&8_8>(9XA-,^N48!,-
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M^J"TD&$/S$!BD& (=.53QF!*D&$,CF!]T,I=DP#+) @L>:J0]H,8^@ (E.!
M;Z,K?7 (SHPAQE(2;8(;S6 :WB#*&*(,JF,:/L%UX!(98D$Y*5-[DC(N@K>X
MO@,%^H4$!$)_&8H,#(%<& ((6"9X PH96N$5U$ )9 &$A_X )!;"$?EJ#'[
MD_1 ;4F@%\O@-YMB#2[EM\H@K92X#Z@!!&R &&XK1J%#(GX 4!BB.:=!#=9
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MH@P/0L(5HL&&,0#!$ QQ!1#&D!?/M $91E!FBOI@A"OL@2C$$$P;=I"08]B
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M#&0)%ZZ@!-/P 57)!B3($%>D!XOC)K# >6VB H*P!R8Q!$8!7F3EE>\E#6J
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)6)_UE@(2$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>comp_0006.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0006.gif
M1TE&.#EA=@'  ?<   H&!Q$-#A,/$!82$QD5%AL7&!X:&R$='B,?("8B(RDE
M)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%1DI'2$U*2U%-
M3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9VIG:&UJ:W!N;W)O<'5R<WAV
M=WIW>'UZ>X!^?P!,H@!4I@!=J@!7J !CK@MDK@!GL !KL@INM MGL!-MLQMJ
ML@UPM1-RMAISMAIWN!IYN1=WN!)EKR1]NRI^O"9VN#-]NP!&GX%_@"V"OB>
MO3&#OSJ#OC2&P#F(P3B'P4*-Q$>+PT60Q4J3QTV5R%*6R529REN<S%&1QE2/
MQ6*=S%^@SF.BSFNBSF>DT&JFT6ZHTG.KTWJNU7*FT7RQUG^TV'&ASH6#@XB&
MAXF'B(Z,C)".CI&/D)22DYB6EYF7F)V;FZ">GZ&?H*2CHZBFIZFGJ*RKJ["O
MK[&OL+2SL[BWM[FWN+R[N\"_OX&QUX2UV8RZVXFWV9.]W9B_W8&LU,&_P);
MWIG!WYS$X*+&XJ7)XZO,Y;#.YK/1Y[;3Z+W6ZK_8ZZ_0YL3#P\C'Q\C'R,S+
MR]#/S]#/T-33T]C7U]C7V-S;W.#?W\3;[,C>[N#?X,S@[\_B\-3E\MSJ]-GG
M\]#A[^3DY.CGY^CGZ.SL[/#O[^3N]O#O\.?P]^SS^>CQ^/3T]/CW]_+W^_CW
M^/7Y_/___P
M
M
M
M
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MO$YDJ R<$ 3*$C*\F6FH,B"I2@ZWMNMNJ3"<ZI C!V@KD 5DQ/)*0ANHH>]
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M4N +YJ;B-;X0)$!U!(F$ K2%@33$8@6(? 4#C!6 %$@B%AF8X09<^(C3N8$
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M,$ZZ"80!HV #W1A@!CG0P0.UV]<9C(M"5C2@6Y2(Z ?. #>1\>]M#PA@+-;
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M.(,=+E#'!,=" APK!1DV<%Z"8."$>26%!$Y@:37@(1(/^'0L4J "QAF,<19
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M'/,-!AC!"AY0[C($6/(G.($"+!;D"I!A A,#;OGG $PD1BA$=K$P;<]6 2I
M @U +!#%.@\P+ EP:TKW!@E !"D0:>]401@P :40"0=  D7&,2=  6-@ 3[&
M!OS%@@0!4I>@ "0P!A"04 IS07= "@>00PU  BJ@ #5C!@VP B1P &,D$!]@
M 2KP 0004@;@3C^S+RD0 364 9^V 6+D #-$"0@0 NO'2"J  &=S,P: 0"M
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M?R]C$(^04 HQ!@D0!Y$ ?S;8$I!P.AIQ;>W)$(SR!$M@!%T !9F"65L !DD
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M!W'("A/C 9NS 6S ,K%P G!71I#6BY+@".E;@8PF$ ^04-T4"R8D$"FP5@U
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MK\ V:W ^%4"S-5:":F/6$8!GQQP+%)"F^^(!@!0+#' )#(8X;0TW;W  </4
MII!H"!0+1(!$390O)B!C+/@*=E,X97 ^CK!N  9IF78)R%0)!' LFHL Z_?9
MZU8"Y48*D69T!R.>!W8!K[  .;5^)T;0M<,*%1 '%OPO>(!1L1.K/R/1"0/%
M'"W."< LK.")L7#%Q,(*CM  BO[7$,5Z"B87?:<  V<F"%;@">9Z2MO*?$Q-
M ]:]!4C"!3 @?)1L<BW@QE,0K:CD";# !'L0"Z'@ L+7)K"P"BY@-'[@!ZT$
M Y_@"E;0!ZJ@6%5=R=2"V*:0MP/%  FI!C.E 3B< 6N U;%@![(33YMF =<%
M-Q#."D#\"FE@8!!0,XZP ,]D 9[8T0L <7J7,F10.@Q0C2? ;**P (3= &<
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M@P5BP0$&,.\ S0M!!R#!!@/PZP%XN,0&X,9&-][A$AC@P",B<8!86$!MHD@
M*=XP 4I  @)G=, <1'$!3Q6%%0]@ RE(0()8A.  *L #*RJ ADN,@0,6\0 *
M1*$"#*QQ8R'8P"/>$(#)!0 %CC@!!"HU 5:H  )UB 7I8OXQ 11$8@4->,4E
M%. (45B #;'PGB/>8(!+.-($E)"#!5[! 'V50@$*\Q,##!4"!;R"%0D0A2DO
M40<(B((4!F"%,MO@B! ,(!9C4$ ='*& -XSO 75@Q0;&<(DSM/(2":#;!A3
MJY'I9P9@P"%%L@"#DN6 !DF$01&>0 ,FP"(3,/C.%%S A&#=0 HEW$$L.#'2
M$EZ+#RW @2L\ 5(><@(6/6C!(6*QA"[$P@HWZ$,LG!"%6&3"!E"$S]DN0HD
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M+-)P*?X.[&^-;XB$+HM$D0Q@0 0A&$%OVTH1#\!M!!NCA /,Z8!2>$!?#?A
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M(SD^Q(-D-+6*\("P8@4[(!4*?01.7!CT84'@H0 %7:>#^:M74)A7<02"$06
MP@A(D%&*8(4ZT*)702T_0Q(D$04)2 -34*V*2+<1.(,85<=LQ(,1P8,E%<7#
MM A*N/Z#5[" :/RK#JT$TV(W4JB##WT%T\$#.72;.F!(J/ 5*;@,3; !9@,I
M3\A!'&HO6. !+( %G8H%8=.".J6(/F 26!"I(HBH3-"!;_$$N8,%*/@!EA"$
MM?3+,Q2)JV( $8B%.X  $+" /A&!X;N$ R"5-(R%$<" [C,4$0 !"5@?#+
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M60I(2#T6!;N-"$@A"CMX*P*_\@]0\, >42A@47Z7"N5;E@$VY,$!@5= R\P
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M-9*$D*E!"(6 &8C"&'@;8]@%W)"$"K 7BHP "EP"&QQ:;-*)O*@ 7MU!"(#
M $$";E*"DE&"&RS27["!(YB !_R*&FQ"X*' ")3,6E ""?Q%)9!$C<4!!XS!
M'1@?6ZC!"J1$&WS "*P3DEQ<"'C8!?6F?JCG\J7!3MR![JEF1?A="G@A)9Q
MGN!!"'R A@'%&M0-&P 2&]1%UH$,)3W"@"X%*]@G0JA,"/R3'80 $5P"&M@&
M&YS *_ZX :*9P8]4QH1J%(5Z9FBNJ&E '7TE0"4\EXS.U"4<P(S>*%Q1VG$1
M%VA^!D"J$$/]56I)A4$I56.Y%EL<Z9-PUI 6*6ZQ5F)-UI">5DV5@J*P54H\
M5I1:!I-*EFMAJ9>V5I=.Q6.I:+[T*(MFB8OB*)NVJ9N"54NE:6&1YIO6J9W>
MJ305%9HN797\*)[^*: &JIE:E9P2EWRM:4P]@J1EQJC9U"7DXV5<HV5(JE.Q
MIZ!>JN04JJ96#J)*$QLDP!RQ5@-0%&+%R!,JU3RNR*=(PO(L5RQ40JN&*:9>
M:J'ZXYY.R=/)E"AD::<,*=&Q!02DCVVR'62QPL#$@@=$1?X^BM^W]=-#X-.Q
M(JD^$13[0,DHE.FLOBF+WNH,<&L_=BJ4B)L%5$!4[,<#; A*G, /F0!'3( *
MR)*GK$ &*!I'C  ;%(7X5,!'=$4"C@ $?(!"Y8%9<%+-5.L8Q%(*;$0L9"0&
M?$#IF<$&U U*>, QB8#)9  K@1)QR('$L@%%B ('8$ %R&>V_NFF:BJ=TM0$
M)!BLXJ4'G$ I[)4=E%<'G!2:M9/P/0)W90!C*$ &W),<3,!.J("3A$ %[$T#
MR$'RL<T=+  I) D!A5\I?, "%(?"CH&0A !)5D9*? "06,*UA$ ;:")Q7,)Q
MH '2]&+,@(=K6&K)VNG)=H:W]OZ+G]I+#!9FNH6 )45* Z0AUUC(,4' 3Y3"
M';3! T1%=7%?",R!')R! 2"K!'T &[2?=X#B<;@*\^3=!]!!')Q!ZX0 ZB"$
M(\R)&0C)*TQ<"G@>U%IB>W1A L1!V$  @;PMGL8M7?$HN'(I4RS(3JC!K!!1
M:I'"&&1  N1!+#C 3UB()3P"!(R ROS) R"(!H ,&:3!4NA=C+Q!&IC03D11
M,7I%&Z3$)>Q)!W2 &53O4DS25 3K!MC&"%0 &<2!%)KMPG9 2I#!"5R" IA!
M&91!&U@7[=:IW/+IG/++YN3N95 >(&$ FNAM9+W!V.;*WR6O?7# 2<3,V$:O
M+0D)G?XPA@<$4T(L*#VF"22<BX?$SE&JA E5Q$((C6I1G?X10$K8S.HJBP>4
MP"LH@&82D-L&<)O&J>T65=W:BQJ<:P=<P$YXP.RB2 *<P,85S8&@A )<PALT
M !FH@ 580#%*6BF,T J$G5<$R 90Q A80!'9(24DP <U  E@,9&89@>L0 ,8
MQ!@/*27 1D54@ B0 0DLP!N(@AK_I&XP@).T 0-0G7WX\)T>51!C#@)CAL/U
MICB561J8 8) PJ(\0E<X0G(04#O%TQM8LC;=!R7L\!WHY30]0L:E 2BZ$TJ$
M,H),LF4X0LN40AN\P36>DRHC21HXWS%1@AFT 5XI\@\W<OYH#C$Q)[,RW]2E
M&;/Y(3-]1;.FK59KR:KN-BE*2=5M+;.V$M;<EM_E0#,WCS,Y0XDQAV;*EK,Z
MD_,RG?.5B/,ZQS,WPY [:]4!RS,^QS.A%K!HZNDCYS- 9VL]-UTZ[Q:;8FM
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M$CV 1\PDG5B !R!=5*0!=T7 4CP"IPP8ZHT_IRBQ^.BD71R D^P'(E<&"4C
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M,"@YMM;H&*='5C!#H$LRNR2N"NQX X4F65%C!;18&>.!-R Z-@W &+MD##,
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MU( HZA  .P@P%J.*" 9(08D'U/,2.V0%&0A "CX:A T\/<$%2%&)!US4( Y
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M$CIQ$HD1.L)P\G9.]_*$%"#  \B@ E* B1P) V10 6;- \HF#4!')$IM!2@
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MDSW1,_XDSG-- J,\RU,^S\0\Y3,^T_,]Z?-/WA,_^W,]_?-, K0^W1,^[;-
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M.5@1XC86P  +8H$37N /8H$+CB!O8\ 35,$&I((0/A@6F& *A+,')H\,%P<
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M)4)@B%DA X@/+2 !$D]@!1A >WP003- =VV)$NZ@:A0K+HS'(#J #01(!5"
M"!Q 4"1A!5#@?HYH 3)@# 1BD&,A [:*$6.A%2! !%) !3;  EZ! Q[@ V+%
M(%0@X@ZOXQA*) :9+-*8MT(@I?XYP)*N1:)@2!8%*@14( 4\X(M:^2C,E098
MH 68>0E<>!"> !8RX8-/ 08*(1:HVJJ#N99IU1/P=A7:]0>48"L]P0N\( NF
MX)EEU%RGN>D*\G\V%;/JJ,%XY0,P@',LH#)H10T<@ !)0&(<0&1"20];(LP<
MX W$-DT>@58"K/!$XA$JIPTN00$< 0_R8"'#B\@,0HI%0A83&B<@P%WR;8T@
M&K/%5A)$P7X>*P4PA13B  30YP.\20/>H*5,P2"FK+&;Y!',@ &F=4G$^?DL
M EQ&0%"R:;A'(KP&"0+2( _N(!(N@16LYP[(A11BZ"Z@FVFI6X+)U6P' 1"V
M&A9T0/X55$$&F$"73R$5:%45:L )=!F]=<X5/L$%^" 6O  )8 $6:("&@> '
M"L$+9. PI: +A%,'PHY8O*/02,%I)$!Y#  Q+*$ V@**,&".7B&P8X$!#+LR
MUD886>$#5%DL. DM.D>,GR\ 'ZD#%(_(0D:@LL4@V@#(+L*NY$"A4<^TJX:-
M;*DY2. 20J#8)&!3*B SQH8$6$* , E]#&($BNTHZR"K8/$F%N@5+F$!4D,4
M%* Q1$)I,CD"-(?(",(@UF!@!@ P[F#-<BLU@*C!"H_JAF(1&-<@.&%PO:"_
M%0$4& $&0@$48. +])S/9> 3/.$G/@&8<X"9[79P@>"5[?Z6"5P@"AC7$S)!
M%>*:Z>9//S9  2#@ 1H@!#JRX#X DC(M(V[H TX !28@=D5& A!C#22  P#)
M, R(T3#ADAQ  V8))6T= SA  N*"<S>  HI/!1*@.0SB!"H@V!MC#DBLA[BB
M#BX*7NHB C8@UEX!$IJQ!%0@>]_@ 7Z:)4(7 TA FDH! DZO%#:@(BH $_+9
M C8  KBB)NX@ 90'B3@@ KS))E1@UNG=N4MNI8O=+9C] V(B&O-G$EB!X,,W
MZHB"!G(@2A,5!GZ@"&1 XF< !QH6!GC@"&! XW/ !G["!O:UK-'U7XO@"&0@
M466@!Y) YQJVZJY#&55.*[1[./Y2X[1.KS4@0A1>X3,^@Q0< ?8B 6BW@B8X
M+A(D*S":!2\X[A+N*3\XCB9"@BY$]14>@8=\WC!V5X^/Q#6"ON-NXNAO0A*:
M'B=( 4JVHO1B+^VMWB8FH:P*)B3X N@-8A(J=ZE)9$R/ BE$Y%^7(D^'8E=)
M!%@=UN8%CSRX-5 ;/^^>2U*/\5@%M?*1KBE#!&N>TO(YGT,P/Z@JZ&$[?_09
M1)4DWU B]U85'^K4<S[+ R=)GU7-]/2QU.]MWRAH( :40!5@M4J;DL%]LEL-
M8@Y,ZTW.( #K,T](0,5%8OFI52@OX2&>?_IC'^R&XD5_(D?;-59[=?ME-46S
MW_M15/X)8J$/7$ &?C3UA6KU&9^$-#PG1M(Y."#.D4=EOZ,2C*KZ^7X&^D +
MGD 0  (&C3V:"AV!X:7/C!Y\G,"(XJ='#CZ9#"F!\:,A%R\NF!PJA"56'Q=0
M$&GJDV.&RI4L6[I\"3.FS)4R5,(X$BNGSIT\=3KRX,',JUAK(.5,(RG6&PX=
MY,2R Z'"FEB41'1(P2H6)*=I[(3 <"<GI1$=4)2*]:$,&0MG<@:-]8K,AA"4
M=,85E5,-)58J/-"E^N"5HS<Y[3B-569NW9Z,&SM^##FRY,F4*UN6S)*&3D\T
M,L'Z\\F5C4*Q>$")M<@%J%@X3HG\!"L'3E6Q" 7)N<BUE_X?L1)Y@74(!LR:
M,XL;/W[3<JD&>"Y5:"MA:JP'=B@UN!2) 21*%SP\6OY&5(@3L<A@B)6 @Z,U
M"4JQ:O"&E CR(1;(<?1@3"P.9F*%$'&)'!.<-11;L8B2 "DAC$ *&Q50U4 L
M9IP7RPD>Q#)"" %*0,IE'GX(8H@BCK@3331\$DL4+CP1BQ\W3!'+'D7$@@4?
MJH R8R$P0''$#8?$LL0/L*0"A M^I,C"%[%TH40LAS2A1 _'33D<E2_)@%-E
MRYEQ"2MG:4!8+!7D04D"<HC"2E8DE!$+*Z*\<LD)',22QH4.1)(3!)&\@@F<
M)VRPGPHY/>) +!ZH44H"E(A"BOX$;64EAP6QL''A):^(\D:$ES 0BQH7QJ+"
M":@@L&@I%+ Y%(FJKLIJJYBQI,HI,R $RR>J?.+)'S/ DD@G?H!R9!0P\(&K
M)T#R9@@,," 2RP\PS#@2'[#DY$<,5EZ+K4O)67;)!A \@$<L&+"1DP5.V8'!
M Q5<$HL(*KS"2@H66'CA&7,^@.<K^,:2P@4F?/#!?F^\\HIUAK)1)@D+BE"'
M3J4\4(H'A+5A00@I2 !GA&ET -<8)UR2@,(BB#"'JR:?C#*)F=U* PPL@N&"
M#4\4X0(BKJ@"!".JJ"*#%+& P8(7L1S!0RPZPG#D%"W\Y@404^AP0R:E9<L2
M<507A_XEM^%.&J$%84* QW8YA1!P"&RJ4:A2%]8Y7;X/;")'A+'$<:$'@L:2
M1Z$?(*I JI?@!9=_<KE) +NE2!#+)86>\>D))["2@-^ ITQYY98S9F(LKJ@D
M R.Q(&(L%"[ F(H+?,2BR(JQ9/(';4SPE@@,6<?BB2LQ(D&[%ZY\0L/55UN-
M=9:446* &8Z0,&<*$=1!!@"/U%' ?1604>$#>=BA0"!T6/  *6><AX!1Z%&"
MAP)YS,&]*!\<\,8=#?2'@7XD5'"'&@HLEA,> *1PX )MW$$" T#B$@:(A2/8
M]X8$A" 6):! _12 I\M)<((H:XD7OK 2&G2A(A>900[T,/Z%F^AA"<*90B+X
MP 0]_."#4J@)#)QP"(OHX0DN4((A-,&''?ANA\@1WO!(8+>SL*(,'ZC#&^I2
MAQ!X( TY$04*XJ"4$)A!%&.@!"4(HP:\O"*+<Y,B%2EQASN4H0-MR,E]\N(!
M$N O)W%AEU9&@((KOH$5:1B*' Y5AX9-R@,B6",%_PC($+4$!BY@B0M<H*R5
M''(&,G !<93E@A@(9P:(7 DD9:"LEA'2D3SL9$QH,+M BG*4I"QEJUK2N\RX
M))4S8.5+7-G*5L(2EIZL)>=\6)E4L3%P=N%)JG3Y2\<0C)=LU*4O&6/,P 5S
ME\<TI3.?J1-;2G.:5(L!+J&)S?YL:O./U.RF-X.WS7"*<YPF^Z8Y@??-4))S
MG>QL9V3,"<]X;LN=]*RG.^.)3V^JTY[\["<V\TE-=%ZI2L=IV37]B="$<A.@
M#/7D/$.43,M$5*$4A<Q$)]A0*PDTHS,X:$4_"E)5<=0E&QVIMCSZF%#M1!0;
MH$,L4%"RB_8R)ZR04U::&,&9]F28S<P))$:A4YW<03\13:91=UHA/Q(SJ#15
MP09(08)\+76J<#EJ3LI +F7F9 UA8N8R=?J*1]PT<.(Y"S.9*B*3-K2DQ7DH
M4GMB@0#495IF $!_V/ (R@S%?6XTXX-4%8%P%;53?UT5 [:62ZTHP%)IZ.N(
MY!"6GOZ,AZJ26<#D<E(*,XR5<E.J"5O5:DZW2N8#$[@;*S P@?XL*A9UR(HI
M[,"32XR!#.P2!0D<F"JH3D .0ZF#"M20E5(\@A1I.(L=3G '2K@Q#[_-"AX@
M<(*ZX&$%B-H)&SY B1,<ABHK(,,F,)N&%>3!)\UE(QM4X!Q'\)(5:E#!UC!!
M"4AH=R>EN)@="I:F1\A6LV(9PQC<^ A1M->-[$W!UBZ!B9R\005Q&(H)[C8H
M4:2A+8\X@7K-^,2<Q.%]I%"N(YRR)[BL006192^)5P7:%(.S,8XHPV9SDH$Q
M3  5K.5 " 1E@?YX(& ;((].\-  M6CG$AEPP!ANVBTC5_ZH G(00<#*M $.
ML,(,#S!#"@8PE3-,@ TDT, KV*" #>"A#A*( PD@D)6AO$$!)2@#!$H0"SDL
MP UGD,!9,I""-RR B6F0 !M*D(&A;& #9?   O**60J0( T1H-X;"J ",BB@
M/T,1A0<8L(+WX $5!#";!3+P% 6P00T2P L$<DP"!KBG B)(PP,$]0$X8^ #
M<M" H$C OU1)H (3JD )QG" O)9  V[@ )S'H  -J8 !&SA#*0Y "E94+ T0
MX%\'2/"&_(B4<SO\[+6\S5#1YH2  "#!4BN APT0A@-O&(&@.,!$:9^ 8[LL
M<TX<Q%I0[[(.^CY,)#1E #R10OX!"1;3'!4 N H0I@+J30$&AB+6P&4J)P,7
MA2,JD9,'0.(5"0A7*2)1"@:XD<F0D!LI#)#75L1B#/0>10)0,0<(*/@"NW3$
M7R7@",CA110+8,4C%A/86$0@3 ^0A!KT?0DXEV %2E'P@TB @IUL.1:/B)RA
MSK IG3 @*0\ :@K^*HH&;)%"HCC!*QK@%%:(;T0JEB:XJ630QHB" 0 @0D\F
M\(BEO(<5'K#[!IB(-P 8)56L8,";"A:A-SQ\EV^XP% H$0(E(HX2#\A))"
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M;"F(Y/(!#7 "1*  #>,!;,(&F/8!=[C+-#D!YO8P%A Q2_@!!B!$%M !8\
MU#,"MA@"%O *:8"MTA8"9'"NSBNTL= &S9<'"J "*""W.Q&JH8*!2J$ *Q "
M=HP@(OZ= .QB"0_P8 R@7@X0RXN<$Q501F4"*A- !BA0K9);,I+;,((Z!@[
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M Z+.#_D*:Q!F/I:A$) &(H!FC5("U-86<4X&)_  'T &$G")'M  *C &KVA
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M4 L&4 ,\J( BBP4B ("_$ 4%> ,Y*@!*6 .-D@L[.  V>/X%!: $(7L#1[@
MCU@942B ALL2S1HPD5B#Y2&#!Y@#,PB )PHV/#@!55.!!KB#.RBQKQF#"7"$
M_^( 5L :&L.#5WB %+B#$@  &P.B +"X%*  "E R!B@#/,@ K_$ O?L -EL
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M "%:&U;@H11 'S;X@ _XQL- @\@2A10@A3;0LC48H3'J@#IP RT#1S)0@11
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M![BB!"A(#E  #* $49B 6@)#LOYH  X( 51\'!)P #R@! A(+ ]X!; Z+!*
MI0UH@+6!A AX1Z^AA D8@0<0!3-(  E(Q<,0@0L0USRX! E8  \PHTN%@ _
M@'6-A=<S,P@HA6/S ):"(P@  0BX(1) . BHHQ.X !* @!$@(P6(G!/  $*:
MO5&X  ^PV--PV!"8@.O!5Q+   V("!7@0 F8@XQ V%*P@+]@@PB86:P0!9+U
M  9(P<JC !.  #*(A"T]U(DM Y%E@"GEN X@!4J0 #P:B%&0 !'8  A8@0^H
M  QHSYB8&6O"T5@0!!_H)BF( 69B+O99@ER] N7R!"'8@UAX@FU: AWH RG
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M2*CAK[B>!U@;4M@KQ$L),_BNT"@-'(JW$V@QI&V,+;+<FA0%D>#6%-@DC9*
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M#DEW#FY,#C.0@ ^8 +VCB0]X(X<A@?))#F\7C6O-5 A)&&;-CG2?34I_C5*
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M&:"$DD$L,QT>ON$0BP%.%2,@/WKPL,Z$6&P?5ECS*H%J4@8>-R!>+!) 0HH
M;CP40@5#D9'1 Y*(0@!.CS PU/Y#H\@42PCJQ8+!&;$\  E^=T 6"5X:%F2
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MJ@*.X($'):1("FRMMS; 2@00.C!1U%7Q!%((0<7R0:Q+XY$')2 -]48#IJ)
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M( (DPD//JO*215H( ^H9"A& ^0 AH>!$",O*&)JR@=M 0&5&Q-,2N^G-D,'
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MV+N!E2^;0U:R;>(& V,HP?QB488*L&$$ZHD$ C;@@5*P80$<P(,C&E &,C"
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MZ9_>*9\J0I_RJ9X>JIT*ZJ+>J:+2:9T&JJ!**IPZ:I_&:2:XZ:9R*E2Y  R
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M>-\DL?Z3]WU$"+[!*T1"-DH5<\SJ)D^KGY1O+'1!"\R *GP"#9R"*LBJ*;.
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M#KB 'V@RW?X *-S]8#/PWP6F1FAVNLS0!+P)!X1(&PQ8/O9VI^C/Y8L&TJ'
M">QL!@3%)5C\D*@'#(?&RXW?"GQ -JE^!+F+ A !"CS )HA$&:@ !K3B&AC
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M'_! !G[#@ <0(19O,*$%A,<&?Y7@ B3 @ ,R8Q@&$.0!:TF#!$00@3B4H@&
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M]"R;2,"GY3F8!$2B!")@9\$@L)<II: A;ZAX"J@J@HPZ,B$G<,10F<V ##.
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M#"A@OHSO%11 $EXA2;-+ H2T%%"H#1;L (I+,8IDIA(" U#H 22- 2J#(NJ
M #*#$@Z@+=P,IT3![F*A R!55!_I#2* (B!! 5Y!!1A@9(:S.(?U*T+R$@@
M / 22Q, '77*SY:M#OR% 9Q+!2S 7QR U"!!!4Z  :QN$1O SQS#S"C! 8*K
MY3K@IK2K#>( N2"00"FB S! !5* !'PN!/9%%$8H%M(@H3P@73'!H"3@$"4
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>GN[KWN[O'N_S7N_WGN_[WN__'O #7_ '/R," @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>comp_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0005.gif
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MY>CGY^CGZ.WL[/#O[^/M]O#O\.;P]^SS^>CP]_7U]?+W^_7Y_/____CW]P
M
M
M
M
M
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MN[62B@W*W@F@2&_J<,I&-1"AG@YNN;G##K<UV0/%N.V PVVY]9A<( ^JJ(=
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M< (D4&ASP)"M$ %UT I^T "F(! 1L B1P  GV0H20 >M</X!9- *&) &>_@
MHZ &&# 0E9  -<AZ95B-#G!]D8"3K6 "'6D*#S"$'5F*"&@")6" S3@"+" 0
M(3 &C(80(_""=1 !V2<!UP<*KC *$8"(<O  $Z@*C8 09["3P7<'!\"&IL
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M "V0"1O(BF1JI@_P?2 0 ',@$*H @J%9!J"P HK)>B4PB,$'"@/P"+$X@2*
M K:X /Z/B $;D (:P(.-X(V5\ '+UP$IV H>4 0J.&CB%QIW4 "NT (2, G6
M^ :ML !BT IO ))VL  FV $-P I%$ !G8 9E4 ;;F (8, EVT "+$*=.N@"C
M  H,H :XB9]PT !^( D/< :1D "0$ D?\)E=&H:L@!!IT :90 ;U"0*1T J0
M0 9MH $@\(@(D8HMR0HM4(.2( (;< *BT'IAL AD%@9V8 HL$'QMD*"NP (_
M:0<8*@$"L0@>L $M,(%J\*:M,+",I@HJ<'W!YPHI$(=CL $;8 8"X08=  J1
MH)L%ZP$H$ DJ8 =S0 +A&9XD,(%DL $>\*:CP +PE[+PU_X((7"H&#@''; !
M@[D&&@L)*Y")Y8=\L%<'%S )H_ !'4FA/&M[8;&SI*=XY8<02)MZ +AG:_ !
M'L "$^AILO:T?->T^J=_3'NT_;@7.TM\13NV9%NV9CMJQ7FV:KNV;%NAH@=Z
MH$9ZD+>U\8=^#1&VFX=Y=ENI=X&T>]=I:4NWC"=JYU=^2TNXAF>WD > >H&W
M=PMZG/=HARMYDVM^CANYI:>U?INU;=NYGBL29Q"ZHCNZI%NZIGNZJ)NZI&L&
MJMNZKONZI4L&=W 7E$ &L'N[K<NZJ:N[N-N[OCNZ='H79/B[Q%N\QGN\I9L&
MH;"\H0 *S+N\SLN\T0N]S]N\TOYKO<_KO--+O=H;O=N+O=>;O<W;O:#PO=I;
MO>:+ON)KO>5;M666ONL;OM=;ON-+O_0+OM0;O_G+O?J+O]L+O^RKONG;O<TK
M9[TJ"@-\OO<[O^HKO]X;O]/[P/Q[O_\;O@G,O@2,O_Y;ODOZN1[\P2",%UJ+
M*R,<PAI2PB:<PBK,1"@,=T3;:(S6PGXAPV![>C2\PB;<M"]<:+T*"I4 B'#J
MOK'6PY7@B7<KQ'TA"C:C"J @Q$R,*Y-0!X_X%R>I"D9LBU=</+V:"9G@PQ-8
M@ZX@Q*. Q( XEHG8DGBA"HOPDR+A"HU0!VS\:AG@ !10 0^0HA? ?HZVN5\;
MN-W5 ?X,4 $5X #IR&=BD'^'NP@.:'X44( -L0@!8),EX0$, ,1_(6<D( $A
M, $?@,1-ZW\0$ ERH*>A0;%.1 *!/ %V[ =*J8X^&GP>,),EH7ZL, <[F0)5
M.<*N,+,3P @B$0D5, $8L  I:K6$%@&42 J0$([HB<2O!H%[. D+D* -T:MV
ML0:3>1<18(7E9P<)@)_$V  1D,6$NQ=N@( "40&^>(375Y];Z\X[O"$<0*FC
M0 KPEYZFX IQW &C6A*NP*,\: (O:&=QP) M( )]-PH,$*F9@ #;&,]<)@$)
MBA#KUPIDX*[2IP$BH*4DJ0&"V0+KFM$F ']Q8 9AT)[.W/Y4%<"$""$!%\D"
M=' !CN (VS@'$(L"KB )%_  ** *JH "&L !;^H*$F"%@6?3%\"<1= !%Z *
M9D#-C; "0KH!&E $P7<&<% "XT>+&Z";"+$&:PJ)[JJ.%6"&E%H&!#L&?M *
MG4BQ:& !'W!]:] !:5 !<6T\'"#+"9$): D)6!D:'8"5WT<*51D'BFD"82 )
M \VP(:B@%) )&4")#3$&/)@0=6"EW8H!D7IH%> !8L"7_(B1;N *#. &JA &
M# D*TYRR \"D$2".8>!\9'  =A *#.K'QX0!'# &8N !R\<*#9#'K% &@TB7
MDCJ3+' !V=H!)3 *=F#<$>#("?XQRF%@HZYP 6JP@&M0V50I"1" B"(@U2.0
M &>0"8O@ %8LG[^XRPL0 F10"?V: (M "1JP *V0UP)A 4Q(EW8P &DP"BNP
MBG!0 /^M I5-/""  600!BS@@.G9"G"PBM_'SPV1"0K0"G(0T"S "@GPB.6H
M$2$@ (/)9QU0E6/F!J$,"AHPT(96 1O0@B&@ 85*!V<P?2V]"&K0EV3I"F6
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M'3 "$5"#%3 "=, !M<@"SM<*+/Y@X]]% 1* E!T@WZ'*AF3@ :Z0 "M@!R&
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M9,E@6J3"EMB00)30'X46 Y'+N"(3M,E$!$PQBL$E$8F!@1(3FZB^J9@@!:W
M )=B @<)--%\*6#!0: T"AP>A(PG1)-@+*0!A^ (%'C!@'KF@ $05$ JD<!
MW$B@GD9H0 ,4X)(K'#"&EF2",2!H001$$ <-/( TCAC!*#3   V((@0D&$$$
M1K 8"<QA/Q(RR 9BMX%1O($$**" !3!'BA%DX )AV-,#WOX@)$K$+05QR.)B
MR& !E8@E%!_P  :* )4)9& %$NB-0>#@$2^"R007N( )%@,"V)2A AKX %["
MD((12* #VJE$!S(PD-5=8 ,>6,TB,. !"FQ&?.&A8BOTN8$*Q&$]$VA!!A[
M)3( 1P(:$$L;+M"!"T@'%-&T #!;40(6@. !*&"?!N(@ 23FR UM;,4*+H"!
M$(AE!1XP@00P(!83=#0"3S$%"#AP 16PI!$9T$ %U+,($*S  A'(SX18\8#C
MN,(.<*"#= ;8"@WXH15Q &(K3&"". #%%1%0SR0:D)\Y/  "&R@#*5K!" )(
MI0(8:,4=%"!0_O@A ICK0 =8H?X*!VS& B0HP$IP),N.@ (-"<"<!T[0"A'$
MD:K#_">%0+$ S*EB#G"P ^8VD 90I @.%UA,&$C0"C'TU!4/H$0E$M";,Q!
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M"O  ,6  TB"!"S"#%)" I^B #0B##T  P%$%[3F0!> (SU,\XFF%L5(+(WR
M&/& :8HYAV"#!Q #$  M5\" #AB#!Z"DF*(^#> YN&"(%'" %6 )%J@ ,KB
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M 1!@A5%08,QS -< 7JM2 T)>C%&;BA$  -?(0<8XOP4HD1?KE0W@CPMP@TA
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/V&&+/3;999M]-L ! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>comp_0007.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0007.gif
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M^OCW^/7Y_/___P
M
M
M
M
M
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M#<F08>"0UY@& % "AD&.;O$ #8"+BV$()K "$O  +$ "B: %'  9ZGAO@L
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M"M#M "1@R0!0"5HP (=  1V@" ?@LR1P  WP"14P 3!KB2?@SE=9X%+^VBC
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M6!=(9)-/6$ $'\  8RJ!@1"<X H2:$/8,-#%T51 AVR00"9*,$8L8* GA?A
M"<1PH;!9P .H 4LH3F !*\;,4\OJS1<H4$F-F& "(A"!2$@@/PEP@ 08 )--
MWE*"1^X*#%R<@ '!,DJR6. K6R 1"<9X!0QTH1)42\@%QOXFB!T-@@(>L( )
MAN("!NC&)C31%S*E)IYC4@!,8+C5!BH#1B.1@ ,0 )L**O!(92&"BZ+ P-B
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M*)K=D  V8 ,%F(-,:( N$(02. !$\ U!>  S( 0,$) NH !!" 0(R @% (%
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M.5[.69]3)?[TA#8HK#(C9('68X5&6T6.YX'&V1;XN&P5!$$K WSA6F0EPDI
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MX(+PP TU<($ND*)%T((KB!L+H ";6 0NN(+4@) C:X/E^ I,* ,>Y;@54)U
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MC$$0@+\F  +8]P#0^0)0,P"0FC0 @-[(@ #8@ 38;S,  (JF@ 9X^@# ERL
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M0(J?"HPA)B"2$P!!%.VBHQ8\8 ()#$4+F9H XQ2%0!)D $<A<)(H'O& 48P
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M,J-%EP8&P+_!PH\648DQ<> 0 *@4(=1;B:<#!P N,(\"2 "!*@4" "PX P4
M0(@Q/1 " N" "@;0:@-4+00 V/Z"F5@@B HHP!,H$  7NK" BB#2 @I@PQ<
MT 4.)& -5P# >B2P-0L4_O ;4 35 Q,*#Q   T4W.N8SWRB4!JYP>-R*"CA0
MB45<P$I%%\,!OF (-.Q=3 F^A @*=X6MD!DD:Z!6".Q8"0R$J"^5> 0&%L(
M%3.@$F" P"(\ 0(L=-<3BLA !IRO@#2(@@,'RX *+C&'&9NJD9I;C2<LL(%
M%"(\JIFB]AN E088!0SXR4"8U#^*,. ' V.H! /N#.&- \$2:Q I)N3:*+@
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MB "V\5ZTA()64J4):(@R:HA6FOY )H2""G1 "K#!!W18"V1 )F"!<5P",VF
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M)MS1$"E;$6&"V_+L(>PAHQ1"I;[((I@!X!I"Y(9JCP!NUV[NS8K$&:S Y#S
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M3<Y.BK,*B( )4$ 'K(118X)*>_YU.5U! U2 DY"$4RN"9J5(%]B:"&R7!H3
M!10$&J" "I3$(7CE"6P 8J!." !!!7" &7P ! @1$&R !WQ BI1 %TQ &JQ!
M21!"!M 125AV75B  X" @XU58H0U!HP4!Z3(>FH7:TM.&:R'M+( !C33)Z3!
MQ A"IKB?9:N&%EP!2,6U97N FHDC;$K 5=HG!DC$&IS .J^.Y/RD!MA+::@!
M9[  OI43_07HV6)  _QF:3Q"!C0 9GL "N2>;\ >%T" (63"!SRHG2E.D&(
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MA,(!B*?!A(0%!$)7805"YV0F6%\F:($%-/P)9(HRO6+!:&%:D)PH L<TM<$
M=,$B0"V%C_V_FM.J0@!=HJXEG/X!<11$I?EQ;<"%0Y6X9?P+F54"")! &8S!
M%2B &8W!K9=&^WR"\K2 "ZQ 5[UL!1S4OW1!ICR >QXJ9HB$(75*14@PXUP"
M&D 6 @IY:7P!W5G8!Y  &?!] @@&[_SN(\R%&82!&1C (?#R +8 _EV(&3Q
M%U0<M)8,&N3:)X# 0HS,*-"5(Y7&(C&K(IB!%G!A5LQ!&5V!;X2 %T".[3L$
M(:1/,X)]+4>Z1-B\H[\/!7#:N2P"[BEERD^O!#0L&9! ^HA"(8S!"E +&SC
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M L# Q-K% A4@61P@52Q -%Q@U;Y(6#9 #4[@0[A@U1BB#!R "S*R>:X@ \A
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M+!YN 5ZK$M#H$S_T)2[F>4Q51.R'(;( -=LH!+0 98HC6N9C=TCB"GHR!5K
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M3"#:3D 7LT #,D!QLH ,=,($-& #()@0/B O+S>#-7B#^<;67J4 ,=CT_A0
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M$S(%A7M8\FCO#'("]@(C#<H.G)=.F8VYG(=P"%U8FXNY(?24DV_Y"^['$[)
M"\HPFZ,9A$5)#71'.\0L.S#!/=-YH#TA.3S!"\ 4FGDO/"YA)1)!/EWYDQ^@
MC1C@#/YO# CG$Q; X")/.BIZD\],B*L#@;KG*)(OUPR@!5B@!53 @_H&$RA@
M(<8 D+P#H[8@##:  E"Y;Q!!!/ZJ-*8=HI]WN,D8J3NZ8%R^8Y4(9O?"P#3T
M3A1(H.9"CP12Y+<^*02>V3O:YBSLJ#L@P NOHQ)"X%X'VGG!R#D?:H>'\@Q(
M(I2OHP+@C@4Z )G7Z"8G<TK6H.QV9PPN]. ,I2$^X0RTL"$*@0R<Q1,:^@SB
M;*\9#K %.T&!@ ,:FM50Y)J5: P:.X;(0/ J090L(3E$Z1',0"VP:,U$P5-.
ME!!VK0_- +%?1PV<NNV&HU.E TI& PU8XSR$35K7@,CB#[%%R5+(9PR4C8 5
MX)DQ0&XQP0P\[435("<4(6))Y1(\@6S [ SL,3G8X $6T46[@'O:H S8+!0$
M>_@LX?X3S.!^! $-P*0-;%LPC$TST-M9@D01QF &1:&\&0* _*H-+*<2S& .
MG4<4*H&O$&$,#&X,,"@+!SOKR"#!/P 3!*@A'F$,U"(3[-6P 7NT18%[1 &W
M7Z<-R&#M/B$-SF!.,N$^\OH3(M->)SR*3ON1,"$4V"P01KSMQB"%,!P3-/P3
MP$""A,8%,J'<MO7,6GL#-*-L/@% SML2*"<Y=OS%!8.X"_KE3N #%"'H*B$-
M^ED0)D8J:'LM0+L,!)P-QD#8L'EE]:(0KH*3." 3'$3?F#N4*< ,0N,!3F!.
M!J$"(  C*B $ENQ\1@'#4*#.R4I^L^MT#J$"3M,"?*0%+/[@!"C@=,KE-"G@
M73!LLTXM,!#! O3'T0FA A[ !,9'"RH PP8B<U @!"Q5*LZ  E)  U9GNPNZ
M(BQH#CCK'47!!1C  M@ #-2(!-3' R( 0#!K!$*@5<=1 C*AV3-A)N9 ;#$A
M @@A%#Y@0"N <A+! D1 !"C R:DC#3) 01F  QX!#+!7-*/G"IZL0:6B U F
M_S !0*8L94.@:0!=1D@@RC#AETR P)C' KSB*4N7 3K@$+:@U\= %#RWT'M*
M$8C7=-DL$2"@! AL!48  [Q"%$3  ^:)33  !2I !%J2 33C!#*@!)(])Q8!
M QZ).52CQLX TBQ@!9!H)LZE _XPP#-,_:<\8PSZZ!%<7MA%*3"V@ )*@+-*
MHL]%@ %VX\=;@ /69U]*?C<4@0(&U (^Q(9?_C6@; 5NXR4&Z:*:98PB(L,\
M(#JL @6:?C<H8 YP$P+<D%V$W00@8#?& %7,,=?PO.DG)@,:P+M2X J\Q%>*
MG4!<0 *ZO;&TYSFBXZ0R@ 6D*!22;-49\FX@0 3L?COO1@+D?C@?20)ZT@2<
ME@+\Q,C.]44>Y 0\0$0^@0/^J'T@?WTL)@48( />LN\98#X$X=(_( 1 NHXK
MP#?" "8#(T/:"2+&"1/<9K^9O2$D ")P137&E5NZ:B$PH0$@S@!ZRA,4 !$U
M9SB?>?X#&H@%/ +Y\:=N2.(+)H!F-C$XRF:!5. $BI=<2(+M7<A3+" GML K
M#B12 &+,(0:?1AU2H&B40C8)+%2P(&&.0A8G3F 9=26$0C,:1G&XHE#%%T01
M%*:Q, J3!$^CNH 0]2#1* UI$$%0B F")86C*(3AR=,3!#8*-V@9]:#+J#()
M"EH@@RF!H5$E,(SZQ*#2HILJ68[*H&;4%@\FK7[@$I+%*%&C%"D@-.J$55$+
M+GTA.TH-2A(?4AH@ZJ)O585=4(8X.DJ%BE$23K!5Z(*#0B^7UHY",0'3J$(-
M-'MZ8.A,AE$@LDQ<',I@@YV8,'A*TX!EEXY79&)Z,.I,[/Z6HT,LOBPY!,A1
M+E*,>FMP#,]!#$P&ZDG(3 6%9YK#9OEE=(4THX"@&+7(P:@QTT>U(:OET*A,
MXM,P8 GFPJA *"^KI<"]2]_4 S4?,B"()0^P-(@$H[3PP$Z50! *&PQH%H95
M$IBA$ ;#I:9%":-<HD ;X#57QFBC#%+!8Z-40*$79%% E$=D5 *$0BN<<&""
M0/$T04)K/#C>=!6LH9 '/Z5V8Y%&'HEDDDHNR6233CX)99123GED!6",XD4'
M/*5VERB>2)#0)SIE(0$+**C  %QLD?& !BUX\EDEH3Q&T56C>""&(A18%@(8
M7I1Y9IH*9?+ (VL9<M,8&]SHB?X6*GBP9Q<BC!)*%QJE%@@#9K+P &(26#4*
M(08>0H$%)4PUB@5A<4&6!U\H!,(88_15$ ;JI;9&!(GL>@A+;$U0GP<;*$:"
M3A+(1*0@%+"5AE6*2% )EI)]\(50HW !00LGL," 1&Q=H!21F%@2B(%L@2$9
M!8.,8L:BH7P 1DZII>#"*)Y,D,@C-RVXTR@7G#'*!QF864*"%9!PY@:+LH6(
M!)^(HD(+E()I0@8JH%!" U1I(4HE%%@2BHJCB*!46Q)@<G **G P&@6" *5(
M!0>O2^DH)%PD%JU4;:'&:!(@O/)HJ7&Q'T]C2#8*&1U]TH4*(=QD!M(<]12(
M***DT?[7SRIS8)46#1A5D$*A%/N!<CT5PH+$H:#,KKMFC&8!=RUHN AN(IAF
M8L@H/#U*&AVQ:]4:%K!UYBA:](4!=VQ](5E!&:QQFV8%CK*"6J,L&$H:HUV]
M02808,(6$/42>04)EY\LBB40?**"!6:>P$!"J75!%EB8,'"Q"A5\1P@+*4@@
ML0HK6 ;4EW UJ] :&UC2P,4L5$"CB51.3WWUUE^/??9)6CG*%UH2.0H89'TB
M@7I"8:(%!X4$8D@B7K&%R1DB? S!(@I94DGI=FY0AIZ6>3"&+F3@$.QSGT(^
MDY 1)4HRXBJ3( Z!$DL1YE+S>4 A!$&(1$AN QAX#B$F\/X8-@!! >NJ %&(
M%C"T!&P,;:C/*" @$V;MJ4B$X*"'.- "0@3B$(H0"B)PH@@2+00EE3@9EL@R
M!A*0P71:R( A=FA A;1 1 HY@0FVPA.12> Y4[O3&'*2"?O8"TSZ"H4EC#B*
MQ 5,!3KDX9?&,(@'1DLAB9! &!5SE?HA;'V'D D)0+(("1B*=B/;@D(4$0%,
M4 ".<CR1AWC"ED!@00%$84L)8B0M.XG "VI8E 3@& A$S#&3"CE$*,KPMZ.)
M GJ!J,1TWJ801:71;-YC#!ATB(A'L,421]L D?@#AFR=;0N3&D4B< -+=L%-
M;B8 STW^6#-#> (#)FAEB9 'N/Y1L$$^8JR$!0*1 ?"%86%I9 ,F(E"00QA(
M>/=C4!JX*1JDR,1F]7K,%32TH&@)2!0I$ $?%0$^3'P3 QUS0!L$(0A1FN$!
M85"$%KZ#1^G9BP(_/(E)-(")!K !H8GHE_8^"M*0BG2D4Z+ J[J@)84L+@.>
M^,0#U.-211S" =$Z1 C"IDBX>"(!F" !C5+5A4HP0#V"8, E$D& L"0"(8AH
M0+00$0*OC.RG'Z 1&!;%$T(D@# :.YQ"O,J6+P%,%"'H%00&,0<'> )1HSB,
M0BKPDPF)8@N2\8 */= %491I#2I(@.SZ%A->)40H@@A$;,90'S,8AP2FFXD6
M+)& G?Z<8#J*:(!,NB 93&S@ D0YQ ,2HHBHUNP2#&@!)D*!!@,\QZ3K^>0+
MGT,&4'D # )BR0D6(Z9\X89YB&!+!<00"O*P!0TT*D$S,>*%FATSC(43DR+0
M0('4I*&9(HA1)1Y@/\Q2Q8@L6)0)-(1<QGB(2"; 9 ;0DAH2U L\#5C7019A
M!JN<H+%90 M;%M& EQ5" 9XH ZB.EHD#:,8,6R6#B,9@%3,TX QHD  (+E/,
M+%#&B -YS!C^MH6.1,02#.C"&D(@GO@J)+8GX@X+Z.8 4:SA 9KY@@4P<8#*
MI&&K9D@L2M1@Q[C\A@42,.1C%#'4^1! $)Y0@'JN()["C?["$BFV*+NF\[PU
MC$$!B%$($#[@B>ONA,F>: ,$PAB(QO*D!1) C 8,295!!*9"WT'!=T(1"*EZ
MP@$224-Y[.S8*G*'I'SNLY__;+T-*"<,8BXE!$3P"5M=Y0+J 0,%.$ !,@#%
MT1ZH $@P(:P,('H48:@ I $VB F0 -)H=C2DE?,83&]  Z(E P77<H(,D*")
M8EBB0KX 7H40PM,66 P+?H."*SP");MFF6A=D-\R3(H$K[)9<CWAM).H)Y(-
MD("U'["H%A@G,8O1'0<J\#),?&#5(& )"B00@A+0"@0G4_9$!A?+1U/@2D Y
M! 8D0 $(F,T0&." !23VE76=H?XO-ONB!5C2@AA]X@*+\.8G0A&""?P0"PV@
MT//\_1QQ9V #'!BE(EQSH'HE6CTML,"W/80"0UH" SOYPJ18$ (1;, "ZLF$
MP!06K0R\K&:'N  '-. !S;!%!4=)S1D\#=>E],43(<" !CA@*)Z<0=X_,8-&
MV-47%F @!%GP@!;6@!<S$#P0'V@!(9F^\0T8"@@4Z,"\>9*)IG>@ NO: %$J
MP5@S["D->.'[*#8 )"PLQIMAQ +2UU7R$&#! UD(1-_)8@D+C,8%PQF$ 4:I
M$#!(8 -5 1(0(%#5;&/R$A8(!=A-@I<QX!4%HXND U20"0OLA/0[T8*\]YQ5
M M@///[]Q@ )1)$("U15"Q-XA!;4$@K6/N8$+Q4$5MFPJ$5L' ,BD"J@KX_]
M[&/_86L!'T\^H9FPV0DGA+#^H B!^4/\$.[E5\@@]F0(CZ:D_47J(R2]?TA#
MB2*,81,%_D,U1YK!$^''$X6@'@/(%@7!?5?1,0!W")T!27 B@04A@#BA$)4
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M/1GP$YZ0A$]R 9_X&)6 >>+IH]\H"A P))"A'HE  IP7+8F@!6)P 5=P""2
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M8FYHUXN!IQE0G/I,X7WF"0RP+MSGI"V  EX2, TE 6PQ A>!N9[ !1V>&A-
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M;!0U$*@DC0; "*,!,D*ZY($NS"@A 3;"\V(,#!88!0RW/*")! ,P8>. +]+
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M"/@$+K" &FP86 J!;/D$.AL+-J  ,.$ 8<D #S"!"4@9REL$>2&!$)@ J,F
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M<,F[80!ZL8!L,83,*(&&NX*/J(#[\M#(O!T;N9L!,24+$?X$MR@!+$R/4;"
MR @$ ^"*#T@))KF(KZ" *^J FE  ;ZD$!;B2AFL81=@O%F 2+?@(>?&$SAD%
M11"/0%B \2 #"^%(,1V,$,RE Q03[TRA@=""KV"!)62:R#R#+*"2C4 5+9"
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M0/B$(_0$$RB(0;" #1C @<" 3PL%( 8)3/" #<@ $: 7_,@+1)@ V(,3C<
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MT0 S6.( 6CB$"K#S$"ULP!*)^-TH%B "0Y0A 9_(0@<\H099":(!"CG#>4+
M "T4XC^$P$0(E)>!+'SB"K7CCH'7P#@5C,(#HC0#@#X@(U%0H)R$NE\(5(")
M-5 @$QW(PB@>T0!,>"&^BK" (GETB =@HA(4 -XH,,N_#(@!6@I8W2 "B EB
MJ>L!'RB$"A)@!D(H@ VAL&PF"B0L K# , Z8PR$H<(5.ZD0#@P@P&E9KAE"P
M8#M9R, GYD"J0TA@$)@H@8RR0 %#M $"M0-<0BU(" *T$ 5&3( GNOSE-!S
M#(?@0 EF](!!I&$ BG[J*+X0P/Y#0* +GB@ ",;@B3!@X!&5P$!,)S"&4 #A
MFUW(@"?,@PE$2" 0F#@!ACW\"2L_! 0B0 09$-"@$IA0$!.@;0%,0 @S*  1
MHL# %S(!AA>=80"P]8"J)6"(0$ @51=81"4R4"L)Y'$-"3@$XXC$G4.<5Q$J
MB)\*-H3I%EX$$0ZH!"8(V50.%,(2"/" &#RA @X@ MN&H8 &"L&&<?<2L6 (
M *,46Y>+@- I6?AF0D$PBET>@@%?.,35"&$DA1!R$0TPR2X58H%!@&'"GF#
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MF$*$P!9@6R(40B(H "&L0=*E0?Q0@+(@G4ZL%R)< 8#T2NN4&0?\D4+\RD-
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M0I"!>T7=& !(I6V'!'@@&#R"!%1$E[4$/$Z13WAB*-P9&42-!)A!U8DD=H@
M%RS$!/G'K:EF EPAH83>&KP< @B$CA$("7P (IS.%GJ"8XY"(;"1";3 ![!/
M!:3?)20$'\[!.-)2[61$"#3:*)3 H[B20J1 Z(U"P]E>?_Z<@>2-PNJ-XD-(
MV<T]1 7T25E218@I1 N@P!H$"3GZDQBTWQAD00XJ!(=40$RABN1\P0?D8 N
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M90 &?/X$"'Q RG,($9) 8%G<0^ K> Z;&#U\I(R$!)  !<R:C%#3NJV 0JR
MM(=  ZBSHR],T4GA* !W>6H4TBN" :3?(GAA)BA)ZPP6 V 2%]RFZX["&7BA
M@BL$!#R"!6Y3D*RG0I2!$;&)1XYCX*R3!SP*'+5.&*R<>+K6LU=: [#/("B
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MU4(P+9,-+ !W# IN,L.T$!(*#221,E'2/4,DN"0^!P;O>@P&R 0*/O(Q@5#
M"Z((@0FV)@&MA< @$$@9B-; KE&<P2XDL(LG+J 1^E&@!*$0!0828H'0A2($
MA+B$ X1FG2MD@@$H,L0"$E&)!?[T)@T$&(0GT$ _J_T0B$$4XA").#5/6( $
M';# "4)#" MLH (&(<32!I*(#+0+ QRP@(0^D0'DC$LDH]C 3@*AD2]4X -7
M,,$)$J&!T!3":*-HP04VD(&Y.%%]+O"A(-"X BQ8P!,GN,PH2B"I-% @ R7@
M0&+<XH4+D& #%,C2%Q@8&D-@0'T0^QCQ,/&!#.@F)O7:B 9ZHS$+?$ %6KA
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M#$Y@20:B$EK@&WWC.Y!I(-: %?TD$52@!<9P(!8!'INF,)H&#9##$\C@$]C
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MV&41&@ +P@ #\$,1*(!H+" QPOXO+3Y! 63G+T4!1I>E67C" 2)%+(2& TC
M#$1 (PX! 3S@!"ZAG\  GX"@"Q0 .$I@ [[4C#0B!+R@)FZB#2  LF[(# P@
M"\#@ 1(B#2"@T12 #>[C3ZAH!>)B#"QC"QX@+M0@G\2  @YG%C$  \Q@$13@
M!,*  Y:F$BI "]#@ LI190@!N$8!"R3Q"C @%#;@(CC@\B80 EJ- <#Q T(
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M$V)8(;0B"Z-%13*@#2RU3LP6.^/62OGB 3S@$/2P)T0  2H  BC@ ,S # !
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M5* +7&  U@ 3!!D3QB  5@(, @"9&1<GG-D,$B $$D#R $ +?H8FT%20+<
MGO#PO#DT "5-[.(!BLD3M((T;K 3^V0@?!4S&.(0ZIF_;T?'^=L$'N$!Z,<2
M,L$P.,(PIG(@#"&&5,"OW9<AR!HTLJ(E[@I>-1I>>B("W(8$,"$!_@,3V"($
M+D]B& * U^#(8R0+.,("+*%S!OZ"#!2D!5VQ44O@$KA !5AX I3%++[ J&,D
M9C"Z#,Z[6)T:7V1D%,J BCP@##PA 3RFS"'X("0$$S*@"P*E)R@@$<I 7,!@
M.22@EP:!>])B"S@='D>B6[I@U)OF$P;<A#_"3H2F+ B)>$9!UG]#$!@ >5&Y
MM4[K"EA !++D@YIF#"69)S@ #"C;LJ=O?OG* 0;K6@HE]D+!T0<B2A*RM;H
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M:A8%>;&!!@Y64BF)&;30Q76BN)"!"5\@2M^%PEZ4B ==8(+"8I:HL-@:'FR
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M)$6$@, EKJ0A3")"EJ<C"$$R@0CJ'$44B[%()GKXLF;:KWJA6,P7,/")4%!
M$94 )TLH8"HNS.40E,01.->YQ418LSF? .CI*&#+6[J,()[0%W.HQ4S-+<(2
ME=C)11#A@(."98JY.\3XEN>)\5$4:>53J"\#NH$1Y4Z<HU!C0C6'"7:^=!0G
M.(%%TKD<-1J3.9YP0+'.=9%'R'*<<DO$\Y!:D$3(=" 6$ -+5$"":28TH#5E
M7VG(9M-#@%01*<J$W,J@'$1L,:OEH]8A9DC,MKI5@83(P/X&+  K0GB@!0!R
MD%U9@($(4(@,%N  ]T8QGA90 !$?:$ &+/&%&[D 41Y@ 0<@X#-"?  3'6B
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M9 $(V17C%4A  @A@X0IA'H7 MO!>,[#! 1#PBAH ;(%.52BP&P G"5+@ 0F
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MT():8 !*XA6$!0$AT 7;Y'O$6(Q_DP9VLAA:4 *(X!,6(1^)X!,$ 0)AH 7
MD2+AYWT:0@$HX0)5IP(^ P& X@D0L @:YR@2@!(=0 :2- 9@  9IT"B>\ 4D
ML !()/Z$[D<A'Q >\T<?V88L!;&.7F !8^ %8K &7^0)DJ@"AW "5^ S.9>
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M!HL@&2_# (:@"&$84PQ0"((  031&-RG(3='?0OQ%*XACC$E >9X&7%H$1T
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M!@Z04P)["">QJJJ[NLRA"&+04&VDE0TE",,Z!O<A'@58$$.W')8P!\Q2!HB
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MW,[N_/[.\!S/\CS/]/R;N$-&,%7/^KS/_-S/"<3$N2,Z@Q"]"5(;T3$'JF1
M>"P;TS,'6W01#/W(A*!/C)/(_[Q,@0#(T!$(&+P@G] &&GTV:C")AO %#XT@
M@0!2 V0(9S G]\M6;,.^G^S/@ ,!+E7)CVP19E!U[Q=3"2)(%EVR%6!3=\-)
MF7S'=;MO^KH<72"#"$("D'3)!1(""-$%3\D<(<TV64"5T_$)%G!(KF$(J70@
M<_"4$/# ":)+CL( "8W5\[/)9+  $5)KP=/)SX$ZH;$<6WA'AD.C$O@5(=
M(> !'Z !MXLVC340&:##-"TY5NG3^.0<CV!#\701E'0(&/Y<"3VT&,QT$5JZ
M&'[#3/G[4\9"V9K!3:710ZHRG:J"V>X#4P.L4JE]$3KZ"9;"8,P1O+S;59B4
M"*[#'%8-%D_%&(!B$5X@,[(]"M]DV2\S4L=3&N#$3 5U5-!=$!1G*HTW30%=
MR!"D"*ZS4ST$43;EW;N#$CD5"MK]%;?]/+:-4R6P&)1D">Q4R"-57T)IEY40
MOHR!PM?3V9^# B10PQ10PS!]"5TU1?+]'&MU.G)9$/]EV8:0OV?K5<NQ3I'8
M*1N$ 5^@*HOPV\7$5IAC*;K!&-;-W\7T/&E LDH6+KK[%>T-%C M"H9 +;)C
M=R$ WZCMTSCBX8V]-OHW"ARP OX=\  0MBA-=DF?L &FT@7 $9@;4 'KF0$<
M<$FLA0(A8 '#2EL0@# GP"4](5C>0@A0D@%A^C*E]0$3"K<,NV,9T"@98%21
M!0'KM%ZN(0C*82@+H0(E( (0L 4L4 &R*'P9\ $5D B&@%S>M0@;$ )Y A9C
M7N;4MV,]-@J& %H6X"">4%H;\ %M[3"1EEWLL0$[5!4:< )!85TJ< $2($:>
M$ )4-Q :!@%(9"9.\0$I$'6%$F(<P$\OX^H70Q"V'G6KY5X4@ 9I< *6D $I
M4@D:\ EH(&*U5.'GL@%:1HDB8 $6T"@M@ +7;@%,DNER5>TMX&$NL ;S=06)
ML $AJ?X<-X-B-LL!AT"Z1,;L*7(%H)5GAH(!(4 !<W0(%O  6K8!)0 "$@ <
M5H<!UVY++K!?%8 !0NQ?$$!9BD !W/( %**3'' !8H1HG98D)((!Y@5.BL !
M&5\H8_L 2V(!#@!';% !H<6X(E"K.*(!'F!H74(!S,6WU]8 $[#A)J !'- !
M&/P(%W(!A7(P/_%H5\ M*Q ((6"Q_P+M&P@M*%87EJ#R'O AP/XTR^&039)&
M1-\CF](&.]9YER(L)T &@O  *=N6;4 "W4,"IE("'N-=/=XVCZT B)((J?<5
M&2M\",,&$&"B8%5J<_L(CE@06( P'E !*"$"%.@%') B&_[0P@P *()P$H=@
M  @A!I>Q!G:T ?W!G021$2GB C)3-V%K"9Y @Z4! 8A@E/YE)Q^P 9\P" -@
M*B%0*0FP35X0'@^3(CM3$$6G" 9@(F9PI?DW,E<0 J+PDO:D"&U@QTW_&181
M!@Q@32>0^FNU ("B!@2 "6;  $PB>+=T(\%H$&O!4Q]0- W@,Y6@ (M0"0S
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M&.B2!-;@E$!4@@&/&(6I+N&6#/Y)Q07&7$@7/! ")Y%@E(( @S4%/& "%]C
M3P*- Q(' 5 I1@,<,,$#S%")!M1K#0[ 1*Y.D &->&(#$'Z <2M@@A(\H%Z!
M4(!'/""5%5C@!!2PC2"(-XJ:["0"*EC!I9QE3L5PP ,G&,HHVJ2>JIA! BC0
M0 B2MP$,G& #T/& I_)H41*((@,;0$$%/"6(%/_$ M:R  HXB2T]KH@#0([5
M[$RP 0U\(H\A.($$V/")!V"2(:>[\RA,?#$F:X$"1!):%S@X@29&@%408&J
MVB84IE[RH15XL6T208$0@(15CGX2:DK @$#P=0P",*<+)/!B%'#M,A48 0DH
MT)P7E_[@! ]8;ZLCO%Y%5$ $JFY."&QS$YX(<TPGX,!@P/"7,"!$SCM!@!;R
M Y-+ 1EW+H  "CCP >Q*I $A$ 42,WV)"0#V! X8! H ])%QWX0,"<#"SM+(
M,Q%P#@*@28,#.E(!GX2@R1 @*LA&[8$-G(4%JP-D++4P:@MXI)2D8@,$3. !
M"T1$!2,6 0/ PS45+, ,E[# K6TXFS;L.P.?P 0%/)""C*/$:%<)T!8@<(*,
MB^(,9^OC1*USEF$B@ (2H$ #6(/*BS'@$()X0 G&!-\N3  %+I[2M5& ;U(F
MP#T66(@E##!N3%C@ Q'VU8&UOG6N=_U BG!2(KB6"(U5)?X-Q1D%)@0E$2=5
M8@R1K<H:QF Q&0TB#$X2%JL6@7="C %4GQ 4X/$XX5%(3A'5WHC<+2;V4*S=
MA6+(NBC2( A/6*823A+\*"ZA6)R$@<>),&<@TO )FGS",O$]/4YV6I5*0+XJ
MGSC#&##TD?5NQ#BV5VPB0"X_43C $I@X/2;@JYBL83<1%9G-Y2=J?.0?0@P\
M_D36D*_[C2B"K*.I_$8ROY%"/'] T3<#\DG0A4*$P6+C)P08+!9?Z>L,[QLA
MA*#2,(?L Q_W$T6^(7Q"=I#)OBK.3P-3J[[2L+[J.PM$*HU#^#V+^3T!,01M
M$I104 2NF8/5TQDR((/W:X,Q2/Z])C&DJM@\*TD]YV,J^_- FJF*0! #XSB+
MV1@$Q1(%- B_ <&$,4!!XC.$[+,$B\F^_QL#ILJ$T^O!2D@T%SH$0V 80L"$
M4 B6ZHN(&J0D81&#1*N$";.$36J. L2_JCF[]_.Z+P3#,!1#">&0?!O#,R20
M4, M!?$P#U !"J"6:!)  [N($(A#1;M#-&R0.=3#/O3#/P3$0!1$.4R0.32U
M0W 2/AP017001A001U001X3$JGG$2H200"@#:#&02>1$2_0;2:R*1(#!JE"$
MB#!$ >-#19S$3?F;5/3$18Q$!#G%0MS$"%G%";E% H'$7!S$7O3%7P3&8!3&
M823&8OXTQF-$QF0L'.2)IK)3QC_DQ6J*QD'IPVE,0\*Q1@EQ1L')QF?TQF\$
MQW 4QW$DQW(TQW-$QW2DP1;PL1:B1$^<Q9KI M2XO?@:/E9\17C,Q[+C&L/"
MQW],0T;DQWPD$"V +UYTQ9H9D)OX@JSC-;@#R)2;/6K<B$M (1#,"TO8@LPA
M2,6X @[H@,-*C6N,R(1,C6TT2>6S#XIDR=F8@X@1 6A2Q7_D&E/CFBSPB1VL
MR(M4R$W1&$^X KQCQ.DP YK! I<RR474G,-XA.D8 S08R8Y4QZFDRJVK! @(
M 3,( PCPB&V4$!>(%:#:B$6HDFZ4D$%0BC!L *0RRZ@4D/XK6 A3XX!=.Y &
M,).%](]Q(Q45<(]"6(!<##D.,(,QH  \TSJOG*2ER,,%"8,$N((S8 $$J#W
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MFIO889:35I#@"'\J =OH@GUN@0/$@D,.6+18B# X'0;SG?[\D%\*GE]20:N
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M! 1>9(@&C"(,#E#!"19 ED)0H*Q=A>I7'A50MD#@!"1X@%?&0 $7?.!0A8J
M"4X  >%@ 01\*<$H0$ "(#3@-YO#A )*@!P,?8(#(F@!!=HPBBQD( L4P)!.
MKO !#$Q)%"38; -&4X(*G* $#?X0R"$JH (48  R9I" "CYP@5" @0.5R, #
M?GI:-W+F QDP$$5.4-4,>* $)6! ]<S TP_$910BX, 6+-"0+60 "Q7X:1<X
M,) KQ,4C%$A#)=*J @O 1S97:( 87@>3Z'J">UH(P63"8(%1E& M9T"N"#*
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MT(4NE*&)#_#N"2XPF:Z^3@1*V:>"(& )+XP -3--T!<LF^H #^+%[TTU4SU
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M6$)<#80$"$+^^5@F8, <B"+SH0"FS<[E0<L^<40FN 4B( *.A(+Z!:!P9$"
MH88#8,*ZR84$*$88 -PH:$ :^$X95,(8M)X'-%P'C $B6)LQ88('7($B',(C
M5()_].%&B(%\C<(&G$$BG-0A*,("T<0:> (*R%@:!0(+-$!I_<8HL-HBA" -
M08 :),(AX(A+/$(97%VR=>(HF$!A> ($8 )8K$$FJ(#-/$0:Q.- '(*U^<A
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M%UZ$ 451P!UYP@)4@@DLF@48!$>D99KNF4W!1R42Q*.HP%Y8@.R Z"#0X5-
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M&E3 :C!&<&7 "GB (%3"!OB')X@ !D!LA3BM!FQ 'QT"2^7%IFX 6F* !ZP
M%V  ?*1! DR)440&?([!3UG(TTZ&482")X0 ;^'E021$"8! )"$"1%@ L[K1
MB6) !4C-CKZ7W+J7R]X1"HB!8\B$4<B$56A !FQ$T+JL[!C%!L2&2PR(5;@L
M42Q$A&G _J@M!MS%2SA'!2B%&4S&9O*%5R@"Z6*=ZD:'UIKM2_P>2=&0DI$
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MSTXEG %%F(#4U)8OFLX9#$ #^"T!*$"7A(=5-#)]! ( *,6,R(0* ,#^? $
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MB%1*C0%*&"@+ +XXY  *. B@+P82D" ! *X0I8('6E" @E!$ &"10Q)H8(,
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M=RP(@64L1 ;<:>%^7G@ 9"C0.RTL(#,N20,!5# &#V0@,A:(3 /8 "U%>,(
M,R2![D;AFS1 D0T2F*(,RW#%T$#@"F3@@,\P$H@'@&&!7\B$"B!0F@Y@8 Q;
M4(!$1$""-JB 52WHH%N4U9$#."!0 U! )3Z0@$I\8@,)P 2J%&&)!&S $@+P
M@"$* 9D2&* 2(>#D[@#0'@&L(!0M $!2@"(&08Q"!0! !!H"H()2 D 0:\H+
M%@# K@TMP(DP2\ H7#" S( A "D0!1  H#8$*.(3'## )_Y4$(#6?,(E* @
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MP@'O\8 HX#20#Q"% H0@'HLR, 9,/& 4+8@M;<LRD$!<8!1J2.PH+D"&3R3
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M F [POX@4P;B$A#@JJ"& #RA!09 (L8@ 'CF#=G  _0G"-L@%%! SY0"!09
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M KSB$I99 SX"#!J C&!&$5J  :S%>CZ AJW#-[S@(]KGBC: *ZGJ*RPFW"O
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M2. C&N C0F'P5.H1&$ @#L%G3@\H(*!8P>P+D*8B&-0F7*)3!6(.". 2SJ
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M9:,&:WD #/  EW ""8 ! ^ !-_ZX@JWQ":)P B(0"G+2!1#  BBP &@P"H)
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M%4_Q$QB@J&B$L(=R1",J'EWK+8VH"&9R*P[PC9&"H6[!!2;0FBK!+9\8&9D
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M)UWP"9>/%X:A K.ZR;''$(GP '.!"-G_?Z1!%"S +2B %A(0>X9P  .3$BH
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M0B6PT/[8-F 5%'"*#! ),*"1*Z 1$&,<48  KRB3P&" B'")35$("BB6-E
M]DF$"M""2S"#!%B#U9,3+1B70PJ.CU"$ 6"!CM% 2R  $A"_M,*$V'N$+; ,
M06B 0+ $$J 1!PB$3!@ %6A!FGB 4!B$"4B$4$ N?OJ $K"$0B 4'A0!^PJ,
M M""<H$ 0@B$!,"$1)  P/" T'" -L@$ LB"2N@""! %08  0;,KZ'B<XQ $
M-B" -*@$$4@,$7 *"?@ 11"$!"@;!0B$1TB!!(@5AH!#3Y  M_D(0VB M."
M,W@$"[B"2K"$ Q !XB !$:B$S0H."3":04B 1$B$0:P$%?Y @-T9! @P@TP
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MCHH-J\S1$= *"Q"$%M * 5&$_AR%U[P($  #1( /.WT8@OZ2$X:0@$- RX\
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M_8 DV?XJPB$#F717X7@8D\" D@"##KB(,>"I"PB.!3HT#EH V[  L(T 5*D
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M@&FYB#289$O0-E%6 #8XA&$^4B^  *U@@!@)A0:8MP:XCX_(@KLZ$0GP A2
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M!)P]]$]W'5JMD#NU!'O9DTJPG$5(DT%P&S6(GCNLA$IX44LPWSSBY$(X2\V
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M4!<J0"+0$$(!)F !!%2@MC,\8 LJR( H#"%8%4C L K;0%(@X($6;  #;_G
M!EC@ ?ZC2.80#EB>(,+B 2R,2 (K2$T9)-.0,S@F#8EE00:T)($RCF(+#=A
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MH9\)%/Y(,5V+E$>1 BZ[H"$H( L$0#2*$K @%#(":4/(\)1!$+SI@4B ECZ
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M913<CD# )7S"!T" !@ )_%#@1T"&"7C !7E! QS"97A"&W@ !(U")LA&&WP
M"(1"_DBE**A??;2%"S:$!] '1!R"_Z5!&G@6>&A!X&F!"23"<T1')7C"V;&4
ME3F$>H!'!BA"&<)'5; ,%-+<%%9"9C@$O)7ACF# &F39!X3!XSG$!X@!:XQ"
MP(W"F8&'!AR/S0G*!;0%!\R.]ER"&,0)9)A!UFV!!ER"(ES"(HC"%\2)(DC
M;.A$(?Y<@6HX!"9\ID>V 0.<P26@08E\'8:,2 7,P2>P %-(0"YY09Q(0"*X
MV#15RF- P,PM B&$@>V\!5Y.CY:8G&4D1QGXH8D< O9!QR4H!PDT'RN&@B>$
M0B"(@$9"@ E=@@5H20:XCB%""%!@E -:@/65!U1JP03,@2>X &HEIQ8P0#ME
M @1@0>980!*-PAAD61C F2)8@B5X@DXL ADH0!N0@95\1C7FHV$YA!AD'62$
M@)1EP Z-T_%X0%O@(R0A7Q><B"=@P9-4*$>^V).:P09<@@/HQB:.8"C 7$.8
MP8NQ0?BYSI<V!"OBQ"$\@G0\"EQ6 @1@ G)PREN(@ <<S_X'N X'=)V@%.%L
M?-E K,53KE #?$(AW-_.@0$$L$$F*!9[W-!;8 $"Y4\QFL$#&-]6KD3=790&
ML("'*,<8. 9D!((#^,T85$8#E &3(H H'-K[D$"<4%9-Z(A'/80'1$":6@F)
M+$<7)L6$)()DP >R.00#D*0!'()SF)$#?@QM*D49.4 6+@ =>8$ K(:O[J'Q
M=<"?A%0H" (!C($E)$ 1?<"HAJD!C,8#0.A.N$ZD*H(HN,#E=8%[GNB+*4(#
MF$<@:!:6C<(B,, @S&+778+*.00*A-U!#$55,I;Y74<#C(((F, H/((#2%D#
MB$ F*)U4D&M=@8@@:.3'L  'Q/ZD!61!)C2 ZZP! T!'WXW"":C/)[A5&AC
MR(0!PJ9!?HQ"%VC&CWI=%O0K>*S!!#Q"ZLVL BQ/!6C!3+T89F6")WB ^E2?
MB:#(6Q3>"DD8A Q.RN72(R" WW@!T'Z,&&R@)3S 4[:4)R!&0V# & 1"3E3"
M!(!&!+C."GB )0@*6O1;(/ .>ZR9U'+7 6B<!/@I!3SE6YR 9EA"9(5"!7A
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M<:*TV)B4!"T^>6"SK[=@ X)U!4& $#5:WZGU#3X@0[29]"7C@37$+1R$:,E
MX/2")[7 :PO"?L!X!>JCB0+KY3YCTJ^U$ 6"G;-8;:) !OZ6GWX*# &"@VC-
M,$ 4+-#(*%"P-X!=K#Z96,0:4-"Z004H:V9@@R PX((L* =GF_M<%Y"E HE
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M* HS[,F..]G3*#B6"0G(1Q0K<($9('#$%FSA$6=8WAB6=X4.,& E9ZA "<*
M@?IH8 PLW0 ]K7FZ0NV.)A8(S$0$0=,K++,+U6+-(/B(DRY CHH>#(6G7) _
M07CB ?Z5$$59<4*!0ECTB$#P0BA40!66OF]KH[A &D0A @T X0I.>R!-#M$
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M Q:KSUAJ=T]@ 10A#2)@^4+! U!@"QA T@HE%#B _BR@(KZ  5A !1;@P[)
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M>4DPVB@4C";*11@DV$;GHFQAKQEY5=8 9BU,.\JRPJ*@E?XE$K" "0.Q!>*
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M LDS"F#0%2+ 4B*@!9] 0 OA 25Q$7SH$BQ% DRA OY!!K$S$)4T"D!1&1S
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M8,;<P3(+<0$D0 BQ.RYPN[F6?,D9A@DLL $=\$F580(=L )HI CB-@8RX0E
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M!H6 "2"@^1IR^ ^+ B"@!A@@;8. =QYA!B'Q"5TP%(IP'80 _!<Z"%V0%(/
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MP80^ >,!+2HYXP$7(0!C%!(80&&-0S;@\1,A"U$!A%$^8"&3%&84I;U"PK
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M@BA# W0(@2L(8@4!@$F-6H"!0S0I!$TNP*O"$(#%S+\09X" #Q"%$+"U!5$
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M$(DV$#WBRX*8Y *AT *5P(05\  3T*2$*(.2Z(E#D,4KJ!$46(%\02*4O)=
M&($3H#N1. 02\(!J\@D/" 'OP82//+NC((X*P@06Z,H*8HZ(Y *"V8)KN8DV
M$+/6HDL7J!$NL\22N +.*8&ZK)&KO,L0H*N5F .Q24D6"(^YM*..&,BC.<R0
M&44/@$R%( $3" 0R (PUD#N!2"9'D4=1(*A#Y,W>],W?!,[@W H&$<[B-,ZJ
M"(3!\:01>)7CY*\3F$"KR *$(YDP<L[KQ,Y"S*_S(CY#@OZ*[<2)W)F*_#(F
M[C1/[Q3/DXR*D"$N[\2)G@B9]'1/\$PJJ:#/-W0!F<BF]_1.\NS.].R)^YS/
M\%3/\WP*^N1/]V0, :U/^3Q0!2W0"'70 I60W-G.]DS0D"FD^DS0!7W0^I00
M,2!)I[E0@3M/]C30#RU0"U71DYQ0"EVLFWC1(>M0]<PU[&%1&)7/GMC0[/31
M'P72(!72(272(C72(T72)%72WD30)4V9%RW2)G72*>5-*'U2*L72+-72+>72
M+D49*?72,!73,15.;7H*-=#)ISC"[\0R[Y&*2=H*,)6*-1@:T-HD.S6D,W#'
MI[A1\)0)-J#._,*$9*Q1W\2$+/Z@*SG]"D6-"C3 +U!J _,!T.S!K*OP!&RB
M"CQ-@Z_,BI"ZU$^PTI3IB45HRK/C5*P TT_ HU)E5*JXT?$DTUC%.&V$'_0Z
M"OG4@/  TRNP,P<-A08(*J@(U:OH"1+@DY#<"BBM-$Q,"$_0 #?L3DMPCJK@
M@*]R4$-@@%<MSNRX&F)=5*UX #_SI/%HFBNX(YSX!'+"BCRBT0<-A$*# #2P
M3S;5@E=1!$#4N(E9"0]8C&&UBF(]"F0EF9XHA.V1U8/5+X10A"$+A&#%LN:+
M"2W0 "!Q%,JY"4^8 YV\A E@G&3KUIAH@TOP)IPPH4^A*2BZB41@@R'K"$CR
MV*>@4?Z$""E!T,EL4B<,<$=#" 0'92U%J!%/:(,T5;D6$RH12 $UJ5@\Q960
M5;,'8*2$$ 2'Q00V"(6,PHF&3;8*&#VA-2$)<91*&+*HO8EQ6],^FH.A(9B.
M")J5Z(A+F /Q%-N84-M0R(0*D-=MV1NA&H5,H+Z.$ 2%)=J(; ,)Z8A#"-P)
MN:Z;&(3#70E!Z%8+((1#R-L%>=MF%2HG.X3!Q0G[2 A' =5/8 -W!*U0$(XA
M&[?GP )ZV4[.U=NQ*15/& 2$0X0=)!A^R10+$ 1$^-BI%5V92--/0 $1P(1'
MH !!0KA$"(2RY2%U9%OQ8-B]Z=GG"(1%8(-V4U4UF]R54/Z$.<BU0+"0SA6V
MO<&$#,B"COA9Q/4@T&66YYA:3;+90- D-)" 2DA/K+7<1,A>A-5?JV@S%GB
M0, $Q^" NSD!#A !\&F+!S !3.  %7  0C !B@"V#] ]OF$ "] 8$M@ $,B
M"CH$"C!@#; V"5&! ?:9-4&I"*@A%9"Z[I"2$ZB P=J $.A@MK4 J:F$UTF$
M"BC@!GB($!B#4GD $O@$%H@E"<C?0^ EV1J$"@B!O)H0O/P #,B$NH,71."E
M"7@$#6BQ+Z  $)  ,0@%#VB #3 $3-B #\#+CFB5 18<QLB$#Q"!#[@ 3$ $
M"4"!#FB IHEC$""!#,B4NW(2 _Y1X_OKDUB*@*OI"4&H@ _( &M3XC&IH)Y0
M@832  FPD$M(8P^(JT2PP$S*@@7 D4S@@ [H  W(%!4H@0MP@:1 @0RP "WX
M  H8#D\0.1+ @ K: )2B $_9#B>>@(=@8#7^  _*A! ( 1"P@$S! %GZXCX"
M 4?,98/# -%@X1"X (2S@$+8VZ)3@PNPJSF!E2Z8 P>0 -'8)1( ONR!@/1L
M =$@FRL+R8-BI@;P&A;(@!"X846P  <  0;6$ HHYM:I !$P$93D@!%8"\:"
M  @01PFHY\9D 0S09X?]#A/(@-KA (9H P=@%A:X DRX %8:(TL(#:<-X'SV
M@$)+B/X,D)X1^( 0 )J;: $+^("XP#+'F.$:D6,2 .%0\!%) 2%\ 3EQ4@FU
M&6 ,$ DA-.@H60-KX0 &0(-+R( &^("OQ*4/V&FN"0$2J( -*-O]%>L#;8"C
M/1KE_( P:)>.( .&  /W^(0&0 &$ *8DNK*ZY68*4#XMF#%Z01&AHH"!*1A"
M0LFC: "*N(0%>(1,N)LMH)=93B Q2@@5.\G8PN%'2H0#:+'@^1*1&(,RLP1\
M;<88100" (/& 0\1RES$2<11,(%R.00#^ )/P"I$0(3I6Y#7J2J$" %B++$<
ME)[JH B94(.[( Y"L 0$@),UZ U!2)TJ&X4A1HCTFB:12/Z 3$F#*.F)3TB-
MF*@ ,< $ O""7//ICG"!$-)$O-B"3"" +J#M"))7$4"VQ]$=") :14  [_'I
MK[$$0ZBE#-D:]NNC*HHDJ3F$\3F!BCJ!8LJ> ML"F+"-/K*[1(C"5'F H1F#
M="NSD(& %LN$![B$-%B64< "[2"!5UF!6O*$!1B:-7B(1&" 4P4T=OXJ$=B"
M4$" *^.Z43N[=<NT"BB77T5NV9J0^EB# EB#^!P%(+"V2E" DB $V.#Q75N)
M%M#+WN!KXG@ Z<'D-"#&[OB$ ZA,W;D;#[@>$F*#1S"[#[FRGI!?1[&I_[$)
M#@","BC !U@,#H@2,Q ;%J@ GOY^E<OIHPG0 D]X@/7-P$!(@ KR@EL)!$4+
M,!+!/@M@-@J,T;'&]".) ,!\ !8 @ET"C@/NF(0  SNC&9WD #)8#?6$'N6;
MX2L MT-_@'%TH9@@ 0F0CYB0 *D1A0G@YDOH A?0K*,QG@[X "RX A1H &E"
M'QP>GR1K+;<(@<,4@S+;M @@@5)=";B(M ;( A?( B7Y! R@=*)-\ 5YL5"8
MWW5:K$60 "." !7X]#0^\)/LG9,<7VN!DWI_C_01-BUH@0<8')\1JG.&=0[P
MD!.  !+H1JA]L5$  Q"P+QG-$)LPJCE[MGSA@%PAG)+(JIGH#<)ZL@@QE]H)
M!0IHL?Y(I(^'0'G5?FOUG*F,]X#$:]8-X.&K45?K^G<7@("M(0&OT> L  (6
M&'$1:C%,R$!"LT0/*8':88'_5H&%']$"I] )J(0K6#5/H( I0R%<<1_R'?H$
M^(0Y^/&KL8!!:!(M< $M2(! J-Z$L[9%Z/J)/P&P;X'K=AHTN((2>(!/2(3E
M.0&UKP0E4P@L8 $&: -#?XZV8RPN<BPU&&,*.('.E!(Q4TT(D"8TN!4+\#,O
M.IXH.8-;48&*JJ?HQH1#T@*' GBVEPLN>NJA@'2/P#4L$AL,F$ -:/A,U_V"
MU\H'0,8T" 2=#(22JJ671Q^AX #5>'A*,C0188$T. - )?X;\Z+LW!G^"*@E
M3.XC",B[!W"!-O "!9G%!KXQ-C $KY6 "CJH3#AP<)+VIAF>QL6""$"VFRB$
M":@11UH#-$B#0="D-  (%@S C"KA8E0A":)&C9+P:(N(4:%&60KU2$(F40_
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M%H2-HLAQQ:%%1LPHIB$2MVM4-T<E#21]@B=F@'K20BT<9=QNPQ:M(] <4X1
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M$ (R (T#%-#")\;@"4N( 0T?P(^C0G""-*"3(65X5 =&7[00D& GBAB#($B
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M BC"(0P $/PB<43/&*@!!BC'27A  XP!7?2A%SB<&DQ (AP" 8! %IP6!+#
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MG8&.?/Y B:0*BY3( RP")OS*N7@+!.P=!#Q"&1".%WB"3H*5RXW$IYS$8Y#
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M)PA<5S% 2:566# ,%;E$!OQQ* 0".)_KJ;!!D&2=6BG$!20"&LSR"F?B/%D
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MX1ET("B 84C/*#B _K7GB_C/R#2*B8J"&<A&"AS2F1)"(GR R!>SGG!)3QS
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M!C-0+A)A J;F$20 (T* +D3 "Q1A"9L0 I[K+:)C%" @!8#@"CA@>T2A#%Q
M!-*M>#AO$*^@$+- =[QB$*YM4#Q@*=["R<H VL;@?F1-)^ZGN^I+ZW9P*33"
MR5  =\JMOAY !$+0*VA.)Z"M#.Y'(\ "5"RJ 2& [U8  DA@,7[M"EQ "R3
M11(B _[*8!2XC2I KM),X JNX -,#YRZ;]JR\0H\('5J#BC*8.%&@0*<(A,D
MH!+2H$'P#]M:K0DEX I**5,(SU',H$%.@'R8#PA@!S54P 5NT!,>H>:TX )-
M " =0"!S0O"NX]VH\04EX+D:[RTLH2%5  .PP 5:( '>0Q!P@@$"@1.[X (K
M@ 2T$<%$X0,HP 0*+!0H8"QH*J:HZA#_;P[68'L^ "$\X0N X!'K*P4R1:\T
M8HY0D )*H, ,L"GUQ!/:D3+$X@'8( W40";8Q#"0#UXND"HVX P4,%/BK21
MT#!$8;I SCK>(@QX"P63) /-P O&Z0S&1GZ839X>8$,(X?X5':4$?C #V( N
M"8%I%LD$-X,JTR -! $3@&"JWF(F,P4,(* +"N$$O@0$O* $+H$$S*-G'J %
M @$,BN<#W.0,!\J/Q-%03B #QN#.#H'FJ((0(F#+$"(4^F@/0RX$<"<$OD"Q
MJC(-!N$]-$+[%!$,PB,0G"D#1  -",$"1 ''"L'T".$!UB Q!<$2N(]]/-%1
M,,$3>-!1G,P,Q,X('V!"R& 5(T(%GN\0^'(4$P$%<DLE>6D+#NQ%N$\G,N@(
MX^XKNJ*!1,$,'F +"&$%<HL0M( "_J(!$A,X=VD4-" M:(XUF*W2N" QD;,D
MN(TU0D$"NN X%8$]HP@3,L$,T/Z1 F:P#]^Q]+!-02W4$KY@/S/@JV*/'R?J
M!*Y =Z*(!5P@%!Z -0 S!+C#1G%4(UC@(4%C A2A#1Y "P8!"#2C^30B^D(!
M!41@#>BR$&Z" KX $3P@+<8)2--1"]+@#/0H(=QPPS(%AAX'$39L>T@ )RW
MS^(- S"A,52@.K<GZQPE$+HQ XRC#:[@ 9ZK@YRR4'=$%!J@[/ZO"T+! 9 '
M!2JA$*X-^1Z!UU@#$1C $@+A 8@C#8PM4Y)MW>CP$"+ .C0"#/+3 ]Z2 S:G
MX5CB!*A";03* RRO!.HG%#-%/C?U;?(N&-.$)2) <E0@$0:A 8B##>XM4S;
M'R<@2?[*0 )RP@4@8#&TH!M9"@7=Y K$#@@>X"T^@'Q(0@'RPH$681':#SX0
M,C^OH '^1!%P4#<3 EXAH%%88"R&,^J>JSS,(/),Q 'T3@.N!RH;904.81%<
MM22LS#@@0!#,H#, +./ X 3! ,DXP/(ZH"LD($+B)$28C@*4SE_E<Q1$0 LL
MH:(.@0%$ 1'DQUUU0NSH+U,2H0%60K$\@026CYB&22T80-+(HP5 @^24$0*
M@V5/P$7&P"@TPEPW0>^,U@M$(?.FC0W6H**L+BT"X0 PX0P:) TZ0Q0JP#A\
M=A Q@A ,0.7\C483HO$@ $4>@"\< "2^8,ZHHO$>@&UO+_YK! %KJ=1V'L\$
MGJ^!&NX,'/80-&-MKX,!N"-N0T"SLDLGPH -%HE#NM$P)))##.!^SJ!4!Z+7
M1B$%-( HW\HDV% %AD<C D$"WL("V& .3)$-#?5US83&$B,#/*!3)8#.\"K"
M;$("=$,+*B $)$ N4.!W*;%H0H$$YLQ$0T3;GJ8!BH<W$P(S1P$+)@!XW<2B
M*  X'@$#/$RMHJT';=0D;M<%-:YX",$!BH<-(" $QI J5,"EBC=3U$ "2" %
MAK<[%2!KSD !E(NK3J %(( 02L!-L"R]KLMBG PH#I0$6. #2@".JLEC"U@$
M0, "IN83-& ",,$$<(<$)L.&V/YW<1WE04(" TS, E8"O4J@!2AK%,@@68N(
M?4'@$R#8*P+AP##@ MGLLBB .XR0%Y?7,C2@?E).(1( "])RAT-@ B*"!%ZN
M%DO@=RE@*:3.4;C-WTZ0/50%# Z, CX805% !2C $E) IKQX(&[WK 3(!1@@
M#3!!"ZEQ A0J S;  V*H)/A0C3:@CN^834)@SEPL,A_  TP 13.(VSC@$R3U
MCT=-:R3@ TB B3.%1)G/\E3@\=(  CX@S*H,CBTA 7#GGW8C BRCA<'@ 3Z@
MD!/!V@Y(!?KPGJ)4H-X7>.T##.A7!:I*%#!! 7 G$SA@ USR$#QA S0 TC+%
M:^UU[/[RDX67V#@"@0"F YC_5P+4X TACP(RX!,V( VT><XF@#D(%7;%64:L
M3!$&X:'6:4)"09)(0A'4H(5Z)B(PH5#XJ5*(B"4H36BZ$YS4X)80JG&B:9_?
MY7P6H9\30J'>94,\X9%*PA" :)Z!XA)*DAK+*"-P2#9"(A/D"2CF("] @@LX
ML"00P4X409<WQ6I&80X>AXAH^#JL Q,^:0T,P2LR*B$.JB0(82P\03@%Z!/6
M@ IKFJ;'AI/8R2:R"6=$80VX:(U(HA+ L J+FB6L0Z/5(@TV! RN1U18HZ:#
M.B$L00U&AR4F.A&J20VHRZ?#""@488F"@R0$(4(HQ"L$ ?X]+H4-D*>K%2$O
MYGF=$V(3%.%B[!HH$$$-<.V"68.JKT.-W#BC)$EH-IHE%AMGS%D4,H$J,B$0
M,**D/4%^\$DMUF!G\OHM#@VBQ:A1>.F=*618=B:-@(*T!T(W+ &F!2@3\OFT
MX7F<<7M)K$R&#":<4X8,_-E,?#M&,.9SN.5>HII+ACNWF;NYG9M''F&Y;T2Z
M]X2Z3\:ZGSN[-P:[M;N[O?N[P3N\Q7N\R?N#BKN\T3N]U7N]V3O5SKM'-.:>
MC7M:>*:]#<>^\3N_]5MBO"6(/H!72J4D+ $,A*9=@"(-5(X#\,UH^.11"D4C
M#N$$C:82Z/A\#*$,WD+!N<==4/Y \T2%S6I3& V%),9@^32B.3\\7.8[Q3>\
M4*)H8=X%#(!C!):BP-?%Q8W;4E:N>-)44OQBOX$\R(5<28+31C2B$AJ@6D(@
M8!V NIYDZ\:D3Z@B2"[E; WC 5#-1CI 44O" ZZ71KB@+=_%I/"%^$X\K,ED
M$=(Z1I!PR-W\S8,\%)J"+=!#S@V!!#K)7K? @77C$[[@SD<($T9,!01B(42@
M_$9!#;"9#&"H#$S  R1G$!#%:4SB U! (!1A "&Y)MC (LB@ OKD#!B".2+<
MBZTC$3I@ @C$ LB M.S$$E3@B6P\!+9 "S@ 1/XP(RJC!&:Z)S[@?_A3B9(F
M$S1O$/[,( PVP 5HR1&;II&V\-=9HQ+$8!!$P$+88!H'9RD* 5%4L"5"8#6\
M#P). )T>!PS8@+0:I1)8J@S H(4&X0Q\405PAC=$H%' X!!,0! >P3C20 1"
MP#A4\0JTH#_AO. -/KT_@0$X  W"0 $*@=4PP 4N(0.^A-#"9+I"H0$P  @V
MA&D>X LPP9:KLFXSA1 P  0B1 *JU E#05+3@! R "%(@@1*X!"^P((+80!<
M@ U" ,GF@ &6PP(<EBDDH#K7UA),X&M10]TKX R@,@340 L:0*,O0 L.8;,,
M);#&8 T@X$M(DZH\(#0?(!&\%C2C.'OJ!P-:0!0(8?S P/X P& -*E)D/8 -
MP&  -.]N+( %!($%+" 4#L$ V@)G,,Y]W2-_"&$#RL[;E*\KON !NB"LR*<!
M.$ -NL#I9+(%V( %!L #CY  L$ - DTG*F"NU5$1*X %'@$,3&\,($ -Y-XH
MN@ "UH ,&H!_#C[W==^[>72$4B#O'*!1.@"XDSPA3" G@I\QK@T"1HC*'<4$
MOL03(*#71:\$5$"AS,!?U:(!'J$[B>X@U:+F7,Y$RM$P%M9$.L,,Q%PCSJ M
M WCB%L$,F(N-% #5-.(#\M6&H@T,, %EM<L% "+-A5$$O8SZ\F%#"X*&)!SD
M0!#,ATP,/!'T &94J%%C!A*T@/[&TH)+!$M6"#2*0B45)CQA2L-@U <1B$99
M&I5)PJ=1(K:,DB"(H 1$;"J4G'!HE"B.%DHV0(1A#"9/+"!*,!/10THU! ,Y
MG+"&X!6()<N:/8LVK=JU;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZ_0L8KB>5HD0A
M' 5!T5(.9N8T]12J"PC$B926/"3!Y0-+HD(5<EB2!!!1GB0D+:WH@P82K%58
M'+6F@8D1)$*LP4Q0T(11&,QT3E1AZ2A,$!Z%$G4( L<-9L5LZ#R!T*A/$AYM
M@5!"!.ND&T&,.9Y<9AA"%*:'^D)"2XE0&PF&24!"ZZA"RKU\(-B%1"4)G4>5
M^*+1*/XNK.>)*"1L88D$QQ&T$0M7 #>*!QFP1@(*GWQ20@4/=#&*(M6-$H(6
M/PVBE 2)C*'53AA(MQ%ZHJA(Q@4?L"9"%BD-LA086CV02&$>)H@(>V9H)5Q@
M1AZ)9))*+LEDDTX^"664;(7B0%*CJ'#"3S6-T@$9E3104@DL_&3E9>4A%M0H
M9C05( D<>H+4**590@(6EUWV0$F)9&((!1L1LAL((H["!F@EHC0*&N6-099E
M8MP7"@6%E%@)&1E<5F0(5Q#4AD,A@($) ^VAT$(:;(ZR0B@2\;8I(0Y]$4)!
ML3;0AD80C!%@1R59D$:".Y4UB <N;#K"0@0=(DH:QR90R?XE"O+DTP1I4G!(
M(@Q@,@HB"=24(P8E.0 5&P1Y4ED%:>J8DK*$4B#*!+6.HD4'4LY+;[WVWHMO
MOOKN^U8H$'# 1AD*2*> (01AP 5/'P32A0.5B%)P21LIHH 6GH AP1II/(!5
M>R=8$$@H#$CWB0*)',) &(%DD()EHY#002!?-%!)(0PL)<@"A#*0QAH8.-#>
M*!AK_  9HW@Q4-!F+%#&)PV0*#(AGU# 0B J6&#11A\LT!@$(F9@)PD<"#*S
M8A6P((@)1FEQJ2('$(*( J-L<2F\EYX!00@DW&J9)Q:H($@*%H1B" ._EK7!
M HJ,<H@#7P2R@0FC3$ "(6- @/Y)J%=XXL&F"\Q!4 .@7T&!""(\P-TH9!R@
M12 A:,#1 SU#D!$#B'K1U.5IJ$'[W!"T808#$*D@!K_&'X]\\LHOS_R2?H]!
M @CBBJ+%34(']4D6'YC ;?5GB6$"MF6 $(*Z)2ER J[>B[)%):,,,L('')8E
M"A8S)J7(H)4,FH8'):C1A2*I*03E(\@@ %063US!!?!R7P-MH@(/J" 391F#
M&H#@ 02.H5;LNQ]!+A%!%F K$+A2DU1L)(@P=*5XGLC$&CXA H,(!Q,J^( (
M1[$_ 1(D#8,:!2%(\(%!88(%'PA!FLQ  D^805Q;6 1!FGBA2K!!%!0P6(Y
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MT,%I< "(HA&7L 8S4PB6P)IF0!*BD(1@ $84D AIL$AG:P9D,7@_D04+7 +
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M'% "+0"I9T*X9J J - &F/$ )="9R0( 1B.?:[!P7G2"^IHEAU" GK !#$!
M B"ZS[F;NV'2"Z$% ' &%\ ?8Q1GL*LLF)  'K ( Z "Z?[Y$Q0Z %NR-U=
M %O22,2+IA*#O)]!:Q5@Q ]S$+&BL_OF FN@%8&P&Q= T<A1'B.Z%"HP)B3P
ML&#0%#A7R^-G@_AQ-FMR,L^ROUIP!5?P!9-ROQ2P$W-=UUV0"%C@<1MA 95
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M6; (!V! #I%^5\(@"@!&$$,BHXH).?J(M*PF3I372U$)#O :9E )>T<0BI
M&C:D)"D3!I'8\Z8NA# 'H;)%$H! &U$G8Q0!)?$ ]!T""3-&9R(T9S1O8M0%
M&Y )#2!C'S (8W FSEWAE_  6Y0&?RH@.8<RHRX?YV,R0O[!!H-@*&-P. Q@
M8LBK!F($!*-H+(, )A4P"*$R16=@ )90Q4(#$1E00H>P<0W0Q$DG-*#Q!2GR
M 3&C@!L E0>P$QY"$"U 0$[V(=5,$%D@+QUB.&80;1J %5 =(/XMRP11 EJ
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MR>!AU!8-HP0]:-$"@B""$C9;^!0["Q80#PP)2O#3RP,L2)"@DJTPN8"$+"3
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M"@@%3)"1+J" ']&*2V  3'%"*FF 2O@-09  "P"#AYDQ"_B(0H( %_@8L.$
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M;QD;>+#!(HE4 ($(GESRP0884*TPB%FT8 (%SX\BR-X8G#Y*&!ADX$&]JI,
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M!G*-XA!I',@A-L"RTP7"!%>0@ K,L $)D$%Q+D!!!3; E/X5/"D3)7#B;KH
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MYFH$I@$@K0$$QUE-!B[A"1!<R01\P@0%GI.4-!C@#)GX @1"$0C:9J&9*J"
M(HC['!*H337IBF0$ B$F#W!Q$7'UQ E$4 G$6'$@? 0:!#S0$TNI#S ,^,0)
M4(B"$%AB$>29B2)(D %1;"$_HPA!=5J(B40D0!$<P@0'F)(4-"1I"Q:PA"=$
MT!KV6?XB$QP $08H-P9U+7(4%F"#.CLJL*1D@@*D(@0%/L$& K !$Q+8@"7*
MT(!1N  ! T3!@U3P),-ZHA+Y2D0#.GH"!)G%"_G)@@7*@@&&^3+*4D[1XQJ0
M!C.LH0%E $/_'@4!3V#A2CK$HR@JD08N-* 2ADC6%A(["@E43Q2'.,-T1R'>
M\'1@#'4:R,Q& 8''),X#( K;V 8B@<?P24CH<8 +V&";$)SGT +ADQ>PV951
M),K/6+%$!$+!A2[[N;\D2,,9MI" 4;"  EMPU''&*1!"J ;2 @E!&-  +8%0
MP!)@$/ H." &2ZA&!/\A01=^BA@2N"=(#KA=J!X5""U4X/X!M0SI UJ@!F9A
M@%1G(H09/I"?,ZA+G6; L@0DU) P<&# U3'B%SQ)R0'?3%25.(&.9*R3+V!3
M EE 0QI*D"3KL*!%G^!V""S-U0H(B@*#N,27,[6&+SA@X0] C BV0,T(CJ($
M>/3H451S@@^HX0Q@,$ HLB !+:"((!,(7R(<, K="$0%9,;XI ^Q @^$?.0O
ME]"T0!2*1*3A"@\(J;HR 5CK+.(!5?GP*( @9H%8P@$Q&L6]!B((+6"  5AI
MR(@H&0J)K<8$54Q0WLA> 1>D 0TJ2-:(!<(T0C2 !6E(DRQ'00&755'I%L#[
MS\]D")&J2P70M("4," E"A1"8?X06 .6$[ &05Q (!_ FB6&W@)HUJ0!HF@!
M"T*A4X' BGIV?\05-L#X,1@ $V(<A9:F[/K7"R0-#]C"%;#@!45<X02A:$@%
M,A'FAJ0 1-!FP1DJH(A#).NK NG E3[Q"?]>(0Q)2H0$=,(!,@QB2Z$(11?Z
M!X'$$R?Q&0#20>I)-@DD_A.)E@!J2+E2ZT 4 L;Y! 0JT>>$Q3\1H@!V*/J<
ME H<0@B$0!9<P1:805*4 0G8"&)X @3$R)Z% /E]P!C8VD#D6A8(C$^( !=4
M'H1(H!=@0G/YCW%%D@.\4/%80H4(2[R- B'<$@4$CAA9 O)PP15@DQE@@!HU
M@!;4WOX7&$=#@ &TB  DA0 8<-F9#,1LR L%' (*[(8B1(!9;('WL< 57$$7
M:)M H%*F< !U8(&E?4(&5%]!*-Q/B<(83$ *F $-6<($B$)N8-#0H98120BU
M( B$=  6 ($!^L09E$![,4LH%,?N=> )X-$HF("$),488%-X5( @G  '8,$5
M:,$8B (*'*()X)$*7( +D$$%A,)V70*?R N#O&%()4GV:,>+F$5X;( 69 +Y
M"<0&V$=X*!D2\HI]<$XH/ ($W(0B*$!AA$+L3"(7M,KJ64"KV!P&0(">-$3=
M28 @O&$(7@(%!((H,*#;: $7[)+@B1C5= $)$ +#-,080/X #V(!&#S"&D2>
M8H6*(@Q=%:(8@;@ "V2" [Q)*+"!F8 !"1Q"DIS !A"@%I !)E2 HSD7E,'>
M0O)2)3@ LXR!)12.0"!" O1?8G' ;B! XHG*3B5?_V@!KQ'"9G6/F2"?0'B
M&'@" US1*[X93:@?34@  .W*O/2+*%" 40BB(B#"!*Q&OU# 47U I,$DGP2"
M:D0+!HB"")P'C+0@ X1"&IC)@20 )KB V$5+&7P"%27 UHT"W @$%Z26"H;
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MW!DD"X8*!!BT0!OX4TCUF'T8'A?2FKQ8"%*.@DJN <-XP#NJ!A"H2_?<& M
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M#)3B-, 5M, $T$0(1, <J-,DAH"C$D("/ D8/,#,'%U#>/Y!Y.VJD$J("6!
M%F! !F; $$K <W@ 'BE"FN$,M!"" \A< ^!=0W1! F3FMUY!MAH"S,@(S[FE
M(&B6#HT?"TA "E2" KCJTJS%9HW!EH0 B/1K%U3" LQ)!@QIN64<!6B!"61
MI2"?"K@ CD)(BX@ B(2'&2  "<C0DWB"QVX2'HF QXP B=+F"3# &$AEYN5%
M&5R0]IC%"@B,:90!Q*9/ ;$> \@L!^0:0;" !62!!F 3"5P)&"3 %IB6IPD
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MR<F9XTI5! +E;(PE/ (86)H7C<(<$((BM-CT,E2FF(9@L(&-1U*<;XPBY+I
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M"'2 "%P 6XA"H,L+"0@,"^#H4_[\=0DH$*.&(Y2(@ A,0#.) @EL0 A8(T%
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M8D,(J1Y"(-T@=50H$PPR&&(# 86'!F3T\MVP8I26!A2^1!Z%*<,&$HE/>_B
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M.%+,$B0H2%9:1P%T%$,:*.B2!@S!Q( O0OF$@DLM6(.]$E0H*0T'%*(  @J
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M101:X ]""-$ %X0/ GY1U5)( !JIC$@]BC #!!ZTE*PTH -8( H:OC4*-K@
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M@@T2 ,$&.""*+BQ-=1X0@0:X70D,=& #&D@M;A3@UF?N4X,7^  %)&B:2FA
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M/99DO.IC10XA$RI2/5:D)#'A2VSH0P1E#-3)3A\54B-54B?U11DF!$) 0])
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M1'1J%Y=Q&]=Q _(04JT+JD0!0>1G_'!*G@T"[ T3OLJD-*00$N!RGRD-CM9
M(^-6)I':#+$"OA("+B6Q'J%*BC5.!I=T1@%O/^!('Y=W>]=W?S=P,J8+ J$$
M'L0$*B 0(M8,V( $%( 0U 8+/(&MTL ,'(!6/X("YD!YF;=@R80M,&#'0F$!
M%($0&"#[6J -KN  /&(!,B -QD !$L$02@8+Q(3CR$ !QF IV*!8SD1W@1>
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>comp_0008.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0008.gif
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M^OCW^/7Y_/___P
M
M
M
M
M
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MA,"*H5 )[_B<#%D)F3 *GU )K_Y8"8*0E:-P!@.0F/3G 0B0"-F)D%W9$)5
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M!O "H\ & Q &HX %!L  !V "W\F3$[D!!:"@!T ""1"9)PF5". % CH!!V
M&X )HC !&+ ! 7  @1 &!-  6AL$#$ (5ON?#? !H1 "!G  #]"5#>EBF^
M$["E"!"WBE !!U  &( )9&  #F  ;* %"+ (:W  *V  F3D"!H  #2"1*:
M)$  "> %&#"<Z<@&/FL 0%L)"N !$R  'WL&!>  !]"2AGB9/JL"H\ %!Y
M"/ %HX &!E"X7Z %CDL 33NY#8 (F-  )3 *&# !'I"U!%D)%F  "J  @7 &
M!M  !J &@H  .OL%"!"GJ%L)"_[@ 14PG&P["BQP ""@  1P J%@ 60Z"AL
M 06: @?   N0"!S@ !T@E6* D!A@  9@ >T8M"?0$%MK":&@ JN; #JK!@9
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MH  (D &;< C>N[(5<)0\>P 9H "HF\GVZP&]2(A9,+V*/ H?< !VG)YJ$0@
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M!@8@ 6>PE6:@EH@=UT5:  J  C_*D&@0OCU> $"> B2-E$![W&U@" ,  6>
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M9- %7/F?*8L)!V#.C%_,&&RE[@FCGC  +K"3V_O*#+!.8/T1%B"S#/#));
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M##$,8:-&A%80@)!0*@A2 !4\,8!)"Q[P)!0+SH+R!#8DH/Y@E"P$N/ U,K@
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M0$8 \)>9: $1'D!,2"3&@@#$ZHL<&$ + E&! ''@78A( (D.P\$6I/!M"3A
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M#CB %J" 5)D)O["N0S"!!(" ;TO2&(RI$(  CEHW)VF 5$D)!Z@ !!@*A&R
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MZ)) "*)*B)DSB X,^+,!6*I#8,NA)=[BC<.2F3N;((,*F  -( "#:0$% (#
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MVTL %%"! P@%+#  ,F'>,!@$5T$(1?   @B !X"*=;S?/P9D#RFDF2$#QS2
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M]2FD##!# 03,HQ -#*@,^XL4S$80!(6P8$4J4<0#.L: B@QO%"!@F0>0.(%
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MNXY^:FA# P:VKS.@5275RL G B$!UYWAZRT0F@H "2F1I&"=88!ILK6!O9%
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M@ 8H,.428,%'+MW'@2*E2I#!YM"7?R2H+V&"L407?4"H@/Z'A?('2AHH$+D
M [C=A?Z&J(B.*(F6*'_TAHG^!W.D*"+L98KZ)R:HI7Q4 FF^J(W>*([FJ([N
M*(_VJ(_^*) &J9 .*9$6J9$>*9(FJ9(N*9,VJ9,^*91&J91.*956J95>*99F
MJ99N*9=VJ9=^*9B&J9B.*9F6J9F>*9JFJ9JN*9NVJ9N^*9S&J9S.*=]DZ'S8
MJ7WA*9T"T9[VJ9_^*: &JJ .:;ZX#2J6P"/1UX)Z@%$DZ' N!")L)T1XYGM
M**4^ID*H0 B(IH/RZ:1ZAG>&XV59JH&6B*.6&J;&5*>:JC*!0"P>:"[Y2V<>
M0K*IJJH>*"% F*+&1R*<94!68:J>1"*@  9@@ M@X*6RZOZG?JJCVNJ!&@*-
MU$2S+FN$H,0'L "U=FI,*2NE!L(&Q$2&#N<A( *I9JNV>BJUVNFE5D==(0(*
M< "/G1J[IFNP[JJYZNF@6BDA (!$M@$ K!,0K0  ..=\8  #U)<IRBA^! (
M0*&UN0Z^YD<H((":^<<'1("+PL>^;F(!@.B==@P 7-9\>$ "B 0+ $#MR8<J
M*<  8, $ $ &X"9^60 !G$#&YH<G2$#%]HT9 (#RU(<#C): ;L  "$6^'JU^
M8 #FC0(+!$ '>0(9; %U8,$ T-5:6,6(;<4A>,%$_,L#G$'6A8'4KD90E<16
M*(22:6-0I0U#; $9#$<89$'MK?[!IY!6YR0"&GP$V++!69C(&6S!IWP"%AA
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M$D #'  "'$(((, W5X1*K !$2_[ <QR !-3Q0FR 3B<  &0)T[ZU2;CU!"
M7']" DB  G!,%P, !2B  ,".L@U !92T4P2 !@3 "9C  30 WZF!5I?U0FW
M 53  !"" _1P*(< 1D\ GB4  F#  *P(!Q3 8_]K56R 5LOV(3   T@  93/
M%F?I(12M(E"V)06 -0+ (6P!&F." :Q/( 0O)@PV202 (6/ I%F'"_Q$ L!,
M!A# "A"$"1  )GQ! ,3O*&RW"EANT48Q "1QR&*"&R0$!DR?"33O)WQ  8!N
M 'Q );@  (!M"T27!QS [ 2 G"C" 9# )1! S53" =R&!AQ 2>1V5AC @A]
M,S9  OZ$0;!AP@)<T",0@.L00@!@@2>DLA?$, & 0"6,P'J77MEEP,%BP8A;
M@@<,@"((0@L@19@<1 "8BAKXK"<0 $DEP+Z\=AI86P3<!!NT<OP-@ E@0@&X
M3@.D&Y<%SX($0 M4P@<(0"7(N%*0  $,\0"\]$(\<[CX:PM\PC\K0A@$@ =@
M0@APN1< @ IXPIQ[@2>T@%^)P !LPA?<<B6$0  L@A8$0$X  $;AA@.<$YKW
MRBV'P@,<@!>H!G*[P&@,@& ,P(<L  >$@@)4 +JH@>#V]Y<D1H ;Q0<, ":
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M84\$!Z0?#8G )RC ;8Q3**>Y!RR]:RB -HD!RNI\!R$W6B- )OHKSR3 K1-
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M<08,O$B*5C(#!1J0@=FEA! A>, #2H ?0GB@ 15 TV-6$#9#CL(+N=P7"R8
M@0UAH@0. ($6-!#.<1YJBA(Z /X%9(.43X! 3O-D  7NZ8%\SH0,"YW;CC:
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M6X/56 &U6)6U5IWU6J457']57#W55Z]U5[L56[VU6=,U4\,U5CWU6Q$A#,1
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M9B,+HH)%C8*\F*TXI53X8O@H".,0BH6\+&'$=BP06/.]VJ I?D((=8TG_F+
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M@B: 3H/@ TB8NGIG0KSP^B8@  (04;*?=+KLFK%'=+(;[+,C>[&].B<X2Q$
M( 6T=*Q!FS8J0\JL&@+D [A6."6<>KN. @(\H")>AQ".0P($0 *DKSZ 6[@3
MP0 (H@T&(#2^60$.P%JF8L[BK  LX0P0H 1RJ$(H0GH.0*TFX !TT#4FX +>
M.@'H(/X,", !#B 0[/D--2?6""L$P#GIF"LK$P $QD4$@B"3"2(<#R"W7H<"
M+*"\+\4-1B9&9*8-%" !$L "^LT U%L-*F%J$& "('(",, #D@X!K*4%\S)9
M8FU+1F$!VB,45 !WRN,,<LL! H$,-. 2JK"C0N,+'H !0  EJ-(+(* " N$$
M;-RA]0,"M*H2,&"7&> #/$$-%J"#%B0K)0!WK+,--H+'-\>>;"D,K.D!>-S'
M/P Q/:!I1H $$OD"E,X%'J !#&L-$J !'( -$(&G9B,#&H "+@7W7, $?H.-
M6\  L$ "'@!-/&":5& #UB@(<HL"%&$#'L">+6 Z[9D!LOXI)?@"70)N!*S$
MB0#E11#IFLA #!B RDO@Z#Z]/_ZMQC? 7W#I*/^\$B[@+CR! [1.0B1@ 1[
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M"P%4@@D!*;,P "$97-81&0^%T$!7P@Y-=-'&*H!; !AX@DD"&)Q!1J&C:!$
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M=[G;J*42^!.! ,Z B "H0'5<6,O*R,,G-3"G!6<(@D42,8"<D.QR)9SA*#J
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M A7XA 0<$(*>I*!=BSI# $A !C(4!P6LNZJ$H!4 9DDHI@/0'=C.H!@RP @
MA8CU6FYDB8NA2YNI,0&D)"B<1#R"!%QM92@@<+F=QO0$.1U%3 Z (18$0 T&
M5<$CB0;$B@DT202SI88)T)GF=079GSR &KY@  ?-"G, Z(NR,>$! KB!$ F8
MP"?*MJ6.G" !"DB=2O\]M$T\0/X"77G$ 5@)QG%Z10!H"$5=%+$& )35! ,@
M3QNX"E*=J)4OF$CUBK] B*E6E5GK.D,H#C&"NG$,;9[ 9B*ZD!BG=.0K8[/
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M!?"'5]44RK,"$@0GLQ->$)  GS8U C !&I  A^,0A)0P@A ?(]01J2% /O$
M!N"0-9-D'G$!!3!"8C  #9   ] &GO  3G,!$K=8RE4 UR$&!-  EI$Z)5D\
M%H  GT G&  !#3"(74$(3ND8@5$)"%,"J0$@BJ$%H["57<E$GV"$PM)+ ! "
M>KDO;N4!FR !5&F5R/<ZK)<D8Y( ?MD5W3.41A9% =(B'5$&\;$ "? Y&C
MZX0)"*!72'<GAT & 9"/77E$%5=Z!? )B.  !J  !% FD<@ ##   ]45GG C
MCD%5J?Z!4J'T  >P #(R6Z8X&I^3 $["=$#!C[XA 813"0H@ )PU (@0>TTI
M %<5A@#0 ;<A6V%TDQA  1)D2:/@)H& "0X@  DPGLK3%8D  0=@FV4B&UJ2
M /O";!60 =,U"O7)'X5F*2M@ =F3"$,ICF^V*)@06<*C)9B@@ N*"5WAH!^1
M;XG@F?EF"#;V":$0H1[!-%S1H0HH-)A0+(N""%FEH!\162MF":'PH2JZ*(]
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M84!+'@&M5=$&FY!(DU<5B$.M$+&R7N"G\LJLH9 &3Q$AJ &UA! *6/ %"I@
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M?+'/"L  A(Q3%) >E0< '   9J!&]($(68$!"7 YV,056 1"G$4 $H<>#;
M;E )4RD! U!EBK4A R "1[8 WX(N P(T3MC4"B "Y(,! U "S%$F,2*.)4 (
MM9D T/( 94T /Q4(P"0!%4  H+S5G64=2-5C!!  T5$=%1"?B* (2D, 'U )
M$*  WU(F6E  (1"<@^A "/FV7$  $>#3^$LO"?!\6S  $-D ZT0BRK@TB4
MES8 !/X02?2B &W0%$8-<O(9)%E"<]@[T\--W,5MW!E,=4OH-UX# &L@> "
M"+#$*I,9<7HA !7 !I[ ;"% ")> !<Z]DHI@:UPA 11P?PD0"(B  $"Q'8,H
M @-P5-TEKX?@TV)0"22P,1O@.!/0 (K RZ6C6 K0-97@,SHD<UQ0 97@4^=E
M +L47I] @T2\ 0( RDUQ8&V0.F)($O>938'Q.G!A&1ID @9 'L]S?PQ@H7F:
M+?ZLMHI K! U);V5.EWAXB"@812 !DT1&,P!%\EYC,PR>&-S!K--;1606GW[
M"5IP5L?-Y$WNY$_NOWA$'GBC @8PH!0P '!* *P"!@50 ?YZ2  JP!Q9PDY@
MTA$C8@$1 "Z1[$GE;6EZ-0H1D$YK](-=T11<A;PV,VFY(S+N= 8,N0 GX E0
M43&'H.?ID@9?$<><0S8/)#+P(U);XCD@R@&U70&*<B^31D3S48$QM6XZP>=J
M3JDQF0 G *\D &)IVQ50'5Y[->.S]3>+PFQ<US0A$&EV A5 +@!FRN/;$CH=
M81Z',(TN#>7%;NS'CNQ%0P+@ NMAH#<#78:5 !7<^$/;6TG&$6-ZHCHD4 E_
M4="Q3MZ5MD?"$P'L70#KY&V9AX9CE'47X "$D'UN@ F*, ALL))9@ FQ= BQ
ME"[HG#"%T *+4-TZT0"$@ B3@_X)&,  [2,S$HD)AT (9' JE9!6CS.0"P !
M$$\M-6,"76%9!H_P8>(26A$*P"7<8OLZ=4DV9J-;:Y'R*]8";4 COKHLZM,L
M$\$O'.%I'=@T< 0HE:#:]YKL0T_T1=_D:!  %H!7"*$( M !M'$[CP  3F<L
M#G &+<  @E">HW 0F]1N:C">A,#H40T!+&4VHX ];K<!^%LG8:  (N0NS)AY
M*^ E'O )%<  @> S7O!;"L %QY<R? (; T !7R".ED ' " !:G Q8FX!4T)U
M(* ",>G/BQ=2AF*/7=$ %.!6&. &=!)3M9(N8GX!'. )%]!O/O,%BD'LGXM
M80 H"?ZQDE5Z]Q>=%6=@"08@ 6( -MT= &H1V79"=1F "#K>$7Z#!5XP /9E
MRD;O_,\/_:SL!7GE!67,,0IO 8I2"1J@8HD  EA4EVJ  :"L!1BP3I[0&!S
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MH-A$C_[(R%<R0@)P0:PS*ACE!!3L=8PW%$Y0F=@'K6)S5@#TJLH-+9 4#04
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MJ$08 . %-B! J!L(P!94@ "-:00+ &!#&RAP!D4@8 $GV("O0N& #! B! '
M!(494(% ))B% >!"U48Q @&X2,.CB# &5G  !F 0 (<(PP$Z0@?<'*(#+O-*
MS4;!R!.0 888P)P$ $  ":B ,'TTX*T"H )"9-F3-).5G12S@8!2P"-;4-<9
M#J"7#82!$,3+0!E&X8$'K $3!\&<!R) 0)\DP@,2&:<!K>8B!G@@$*%00<I&
MH0&]E&L +C@2!@Q="0E4XA#'.@,&"K*"%& VNAIKP[%& 0(;06#-9D4$ P+A
M"2T8@# %0<$'/(&)BA[Z I7 !/X$#%T03XA !5I"P!D\X06IG,$"H.0R0709
MBD1 P",/V,"F/9"1"N2,$ <(: ,2<08#2"\$4M."IR&@"$4P2RQD,$ ;/M&%
M8\EN%!9PFF/1, H,."T1#% $&42@B'EJQ &(\#,A/$&"UZF  YZHA 6$"IU
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MUX&X4&@!,0R%5*,1-@@#"#@+N=.(#$C"9?&]!VB!-3 -15"#VR*,!PB+3WB
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M"^(""F@!$UV(2L "[20$TN*"+  H3"@G(\,HVKDW@OC'$'#%#^@"Z=C-DIH
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MB2[  H BBRTH"$PX+9L,T0KH.JY(4C(@#$0HJSR,OK,X@P$Z@38S 2UPO*G
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M]&U )2Q"!4",0(0!Z&W;?;C2(3B 1$C HZP !Z#E!@!'/YDB""@"(GR:(FP
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M!9*5CL(@'!4'J$?J" 0:C <F@$"ZMLK!AMZ9E #*?, HH<$&<!4(B(!$?")
MH0"N31%P8(*S8D S?<(*;, ):*)!W.I!$,(&8, &J >SBH:B10<9_.H(T ]P
MD,#NE,!,$5,&A "KX.@HM5=U&DP):$"9)5\&Y&OS3)]OJ<=NC (*D( )8,!\
M) 0Q8?Y VT7&]G1L=)P!!2R&(F% TF8!R!P$]A43?6C!N#;G,45-5/U&-+;
M!U@ HK7 !I2 )K+!I&@?)@V" KQD1=3MW88 &M0>/:E ;ZA V&+!A*1M!ARN
M>T","2 "(1A(Q&!2XZI ='@G!J  #!F%A)I-Y18(7Y! !X2""M1(>A10!SQK
MQF3.!G@ %Y !4R;J!EA ,[D0%M@N?$@HU$05%_RJ"E3M!I" &H" &J0.BO8L
M+96-)YP /5EFD20@!F  LIR'(<"N%JR<?!QK)HS WZ1J^+H$^#:$FU0"!YC
M07R"N%2-2+B;1S1,1_!'2<1O2]0O7W3$)KP$^Q))1]0O__XRQ/VJKQ>$ID (
M<$.$@@ #\-8PQ (O1 C8!?CR7T@<\$+4[P1WQ!.UK_IRQ"?L1OHV< ,#\/UB
ML%.P+_FRQ '#QF>&1AQYPOMJ1 D3Q0'#\'N!B0J+;PY[A6EP(LRD!)=$14X
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M[8S+W6BF5(OTW;2 /.,T K?*"1>&)QRG0_MU#M=>&("(NPA$"= ,?37/RG(
M9+!!ZE5O R>J!U" ,7: RAK$"C  :XU)!H  =;3+">P=&[#J8G^N!S2 !KA*
M"93 LD6'(E0V!@3K073!RD+'%+7 :M=V(6" !:Q G 7'\:FLV9FV!NR.)WS
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MU-DH9/Y"#>J8S)^  HR"&/31*#R1\\Z'*JF'(%0 .Q-3M# =>)=K@.!F@1,
M(7B" 9A :IR EBD"*F&" ;#(A#'>23DPH>M]E_CRF2BF0/2+25F"%VA)&9R!
M 2@"EV^!LSB$L_GH"8R/&I2!&CR 7-3;*/!81: A'T(*IYD!T(LF-!)<"H61
M]Y"!F.M(QY5 &IR!%E!]&0I$"%A3$(I2.0F:42CF)T2 N,!LDLB9"("!<YW!
MY$, Y8FC5\*8ZZ60LH+ ""#O%B@ U&W!&9R!L[H'%KB AI*(&Z@7OB$O%R3
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M/Y'@6^C( +"!0$:A;HU!"1*C$HCX2F X2D-YH*E1/K"J@2792M2Y450@@:!
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M@DZ0R8&/)&:N+RPTE)AP" *60-X5X P$I7O%ZFM@@LB@8)0@]F*I@3,^4<.
M0WP?ZP"Q*D'[?&TS^:3 3=.=G_[Z[;\?__PUZ[F]+QH8.0$880!S0@"H"I@@
M%""P0!9 H*%>]>43#]B ?X#2!0BXX ,6$ L$,'()"[0) N]27GY( *@/NDZ"
MGO! AS8P$"]<, 38R@\F*A "%_X\@#PM7,I 6C"!()@@ 6 PD DR@ 4,P"D1
MA:%,8S;@B0_<K0-T,XL+8CB<C'S 6%_0 $&XL$4.:"DA%K#A P9R-A6LH '/
MF=5O_O6?A%P@!%B P$!*H $LJ$ "*TABV"2 @1:@X &P>X"\3@ H#.SE3[3Y
MCP>"EP@$)((,(O% 43X0O$!8X (K.%U&S'2"%F0 +VW)@@LV@*TP)& @**B
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M!16MF.@.)@RQDT*,XA O@6!6VS,6+WC!3I61@!H!E-6:_"P,E<#$&CS!-<I
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MP* OS -!H*0$L+<0',>)(@!WE_Z(!4* -Q(A$0;%[%;%C_5C"];'5XH& D!
M!$8@ U8@$/ #(5(P65U8DJ/--D< F,Z@ 92K>B2&$\<&$R9L,3SA$RK!$])X
M_+;@$S!AE.MC;$[@ M=3B,) 0[3  VAEE$-A3)X&/S@I.C2$$"!#E E3KPBA
M'=-R@1U'0#0&@KVC B9X4F!GL1A@+OK" E;@)3) $11ADST@L;:YFWWE.@;)
M$S8!$S[+<32F7R=9G:=-ZZ+K'!/8!3#!#1"@$M;@ <SG T8@@:WB/@8.+]#
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M ",J0-<;E?G& I>>!0- @.?<@ $0P  \,Q1&@ $@@ !R:/X"4IGPU.^1VN
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M!@1@,/Y&)0EPX,D9 )QQ" !;?.(%%Z-4L, H+?1(R 0#),*& !6<,4*9E50
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ML8$&'$(!T2M.KNQRP 22(  ;8%+T;(6G%@Q $>^"C@;V-*1!\*EY&L$""!)
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M 6H9IF"C, 0!*B!ZD9"19P; 0"4^(10&*, Z(DD+(500!GQYRP ;'( :$O$
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M!;DG:VB]NP-XQ<$ :(#/.:$"6Z(&T+$4)J 7*O X:>_B:OX?(FQ +6J02AA
M!IX0 ?V#"7F>)_2]&B!2[9K"*BH0K59$^2SFBN3^^K!O>F&0 "X !B'@ (N@
M*;F;(+8!UA&@!F?0 &I0"0<PPT7/'I\Q"B7PJ5S0O466!6P@4%V,!>[E"16@
M FU0 KUH KJC!G5< 2%0"8ZA,,6S[U\PN6Y!B[)Q AG !LT_UA" !6Q0 @)
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MAG>ZYQ V#&E%X8,)E<HSG8M@0 !D):"+G $ LCK(!@BPI_Z2$G)>'[ 5" #
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M0P7\X@ M\.G'&'C3"1C0  Y]X 2?P4 ESI  !SR $&'@P"$\L+%/>( U7G
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MP (R@P 480 /"(102 $40 @-</XW&R& ,_@$DQN%,I  18B[#<"6#6BNY5@
M%$FU4: UA*  -J@$ JBA0%" 2C@$!N"T$Q")%;$ +5"H!B $3)B ,A"O@O.$
M,X  $\2"#+@6\SN$3P"V4"BTZFB #0@$3\ $)3P#"[@(%S"!4>" ++"Y%) N
M![",!-L$,AB ,/@<";",-<  PDJ(#_ $]_J.#>@2"Q@4 EB!!?F D+ S3!@+
M3&B#!U@$3U"!!HC""""$4# !"Z@$3)  J,B N< $"B J)JQ$$G#$-:B L, "
M$@B%,+B YMJ_HYB 1+ $ E"!2)2 # B$8V&-49" !9$ONBB# 5 #3P@#1TRR
M31@%+?X0@5$P 050@TI0!!Y\0NER-&KC@#R< ,>HJKVS'"T  ,L@.+$@ !(0
MBP#(@DH8 ' T!+^K! %0##8(@+E0!!79@ $@!#;0O-(Z,IN:BR\ @$#(@FV<
MC#88BPPP S)( *0Z*H1X -)H@0% $1,@ "0#@#;8@@%0! U@ #&P,  ($4+
M BW(@BS @OJB  O A -  4\P )";/@*HR >@M@.8-@[@0160QU$@@0'PA$
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M"H4+.  ,P  &, !$4 0!2 $;&?X KQ  %0B%0Q  K_"[*0$ ,=B$#% S$0B
M>82_TBJ 2[ I60F#?50!EEP5!+" #_" %("1"?@JJS2*&6V.$J#(3T" BL.
M4)@ !P@!#T !%0B1YTL !#@  FB3B\ "!/"" 7 #<O1!5DO1#7#)$S@ Y>"
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M11#8-L4(QA5  01H@T1(@!>)-N&=D@=0YNC5BX;[@ P(BP]0K_2 YS8 +A'
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MP-T0$@9/' (""4A+&"3^YS1L9YNY/CG*4WX3D7+@#&&P /ZM1Z$ QZSY*1-
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MCBS)Y@0FA*>-J!\8G,' R@2EY@?'B80G9('%EJS-<JP:=/YI2C' ]80 ?GJ
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M*6$@9/1'*((7;(%!>S07X%LA2!,A8 )$>P3^>H0(G*,_U_ZT[JI E)X$'7@
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M @#*O" ^TBJL%RC WW[$(/37T2H]2&2=4Y7]%RA ,Y%<,/-]4MD-=IT$"4Q
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M! (1@X '# @DB 4(F:!/3QKPX),0"CC@ 98T<\JJ!$"@   1L!B @!8XI<
M!1@(9)0**N @@ 0H=:.! 2S X  .4TW  DQ,.( !!BJIQ )C)2C,VP\:("0!
M$SA%@*"F/'E @H40F(#3"IC% !,R"G#  #:T2* 2-5PU8(M01C! 4CI&46$!
M$@A(P L+!'A@.S88$.\$J!3P@/Z"HA4YH^4#RH@M*P4:.""%4;J(] !D?UVA
M@"^V2 !HH3$(P %$,&&@A%$PF,"# ! @PR$+[E4@$#0*:,  -0(YX(M1ODA
M/((J:;H" 2" J"H6#O@@ 0)0",4""!32 (*[4#B@@>DX:("# 1 (PR$,##C
M@H:J0@, C@L*) Q+0NG<<-/5 )8! 58P(8 #3,]  @\&.&"+T^]E@%(7%"#!
M@ %6J"2!3=L.H2!%'DZ @U'&2/6 I3%9( 0++#!H PI(*&"JK T0@:DP#E#@
M '$QP:"!K-4819 (5,W@D5$X$($/%&]P7U! ! P@+KEP(%(/"$3;&'  %!!B
M !YX@/X ,-"003P  08(P2?:]H&X=:4!#+C4)Q10@;3E:Q1DB!\"-O")P(G
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MJ0K L@P6A=8!WID !F"B!1X(!1L \(5*4,!HHPBC(!"A@ E\X@($T !C-I"
M48@! &YP"B8>P  2D("IZ<P Q!)A@!/\A !G^ P 'J$?!JP@$5P 0!L\88$'
MC&(%!U4# ^QI5RQ\X@ <\(1IOOZ3 #)J 0 K\,0)VLJ5IXQA "T :18^X=&9
MM7(%B.B-"?Y* #!X 0 N\ 0!0 "W 6#A5Q08Q1DJ< A/($ #G]F()]0 @# @
MXEV/8&Q1#$>&+0!@:U5I00!$0 @3N).K#X2>U2IQ5JIL8+5G2(#)/""S1R3
M>E49[N 4]04 ;*$2'P! (@(A@ JH(0, *($:$N!:6JT@$!480"784(&E**!\
M00C !]10STH #;<AC4UI"&""1Q!" "!XQ'##\(D(@B!__R0 !L* B09@P!-(
M'9P'2BG>09#!-Y[ 0E$<T #T:@J E4U# B+@B05PN V6-8A+UZ ("#  M_NQ
M1!L,(/Z!,YP  &(8!0,6UB$OA,)E'Z!4;,Y .:\\( %A  , O!@"CH7AKH88
M  3.D +=6NT# 4!!(+"8"$5HR!/#7="]3M 1!TP $9Z8  ,0$0@";& 4 ZR
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M%!=P&PF&C@@L!" GRAS%(@+@ C<(@ ,E$ $ /(!3ZVV=8XLOS):J$HBD\I4
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M>9<+&"#.7W__^;___?__ 6*4P($$"QH\B#"APH4,&PK\=&!"FU .*UID* 8
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M,00%<%122"> #U5QG>QLISO?V3HOL&T##1B [#PP !)8P$/8V8CO8$*2#PA
M!!- DI+J,PHP $"!'P" )3XQ  Q@,S80J%8+%<BR-6#B 0GXP  >X(FD=*"A
M$GLA %Q ,C44,:$MTY$)3I"  GR"!"4CR9GT.8"V1&M'52(D QA $4B-HDP!
M&\  O, R$G0H<T%IY$TF$HJ2R/XK(@D( '!*9X!+&: H'J#)"<2%B8$9Q2$D
M"$ (CA2=6?V')"4(@ <J&HA/2&";#.!6)0#@@7]6C64'<,-0NB 00AS@ 2*
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M3[Q'!!40 0HX=H*BC((RBG!/*%S  1U  D%A F$P ?J'""! $94  D!G?!@
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MYQ*9T_2E'7L"/)%D]C@03ZD&&@FO.I8(9^ "$8",O1(W@M$ H9 "3].B %-
M@B!:6' J)]!L(M0&@!0W;7!N1XL%$+!"9Q!"-*L?3?,%#^ &F2 !(A &[F4!
M;> )$P"W$,<!&V%! ^%S;< 3//[&A8(!;&L0F1Z0>A'P"2IX!F>@ A3'=A00
M G&KK?H7E60B!IN* 2"AL2(4 ;.A/F,% F4P;L'( @RG J=8'Y9 ML'1N7KJ
M6!3!!0Q @QJPN1N !B60""Y*2&LP 2=P!O,IK +Q+"1Q"'^K%I)X;X%PF03$
M!@_@!5FP!6-@"((1!!S  +(32!%[!DMF;V$00#X3/"5!!I7"257AEI6P!17
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M,;=J( $J< 8;,&%9\ $/9#5%@0FFS  W6!+4,0H@H*&>' AMH![%@@7U40G
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M)?"]9T!QIAHP9KU6@K<!\QP&4OZC5 +1?Y"Q OOC'97P4GC9("%[LVQM'1B
M"?PJ$"8C0@2Q!1JIF)XPR@*QQPMX $&1L4R& E*J!I'RR +1!1JY" P <90L
M$"10 @)!AZ>D>P>P"8(AKD;AGN_8 '39.]<<"+GZ!5)C 3_LVT/' ?DX?6R'
M-7D,9"X $KO<GB'4 ?D(S#(QSXE@@FR0JS)K-7G8 C%1LJ=4")Y@;Y*"2^<[
M2WMH"6YP&ED)$H%K"85*WG)WSNM$!PH0HC8R30*P$9$U&UTP 5K0 N87"AO
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M$2>0!6Z0!4Z$"),&3EE_$.D_$'T4&$ 3,,GG"60P!I*F[)5@_-(_$&H !HH
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M+8HXP_Y;!T*6,T!@ V?P1 9(X 4+9+2(X_4/6<B@ET\X "(-0!JZ"-( V$2
M?1%1!'L30MQ1. "OT$W(!=10B03 ! )K\(1DLJ"7,2:$ V3 !$%'48&_CJ(,
M%8C) 3#!A5*J":@?2"070# *S"J8#(*( $8<8,-17. BA&! 30XQ.@M(1@4F
M* TB%" \"'1D B=LL5L5)U=,P#<A(O#+ RC*27"-8@+N(C'.; 0!1%2" 3]!
MA -&T0)YC:(0+6@P3 !8FA5D&'RC@)A9L1 *!@CO@L\;Q9>OG.'>T(&>$=E7
M0B"0B-"J9W0F&!\;=IR3!VSRNXE8P-P28</Z,J02Q\*"7OZ.YP!>N8%IHY
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M>X#=0/X# L"=%BM&!L"9!^B?,1' %=B$0Y"]TA@H AV?/)H9#DB!C$B 1"A
M%\B 2L $+32UT&D#!3B,;$F( 1V$ 8T^0/H @&RP,O $M1(5H^L"-3BQ4%"V
MTEC/FM!-I1A-3%B!9Z&SD5$# X@8"!"#MOI0+ZB 2I _+0BCW5"#"?B$<T'.
M^,,$)N+&7/O1 Q"6%=" 1( G0O"$ [NR#,"$Y1HJS_  ]2(("!B#3UB#XT(!
M#LB$3\  D,$ ]R2#CE&,A/A(B,* XE* 0\"$+#@,#P"JA& #! @%$P"J", 7
MLG IY!(!Y/N$&1D%&R-*2,4$$8@ @9A#\C0#3! # ""$IOY2!"7L'+)@@Q;3
MU'PZ ;<++*K!-[+P%S4(!39@- NH!#<X +<A  EEL2^E)S&(.DQ01,\*@:5A
M -C1 !;I# [XI4-H *5))=Y83&NMC$KH !,(!1*PD6Y5B@S(  [X%8+0P0GH
M@+6HA! (U^LB@:-0@XS*'T2@ "S   S %T\X)Q10@PX@A"R0C/5)"!-PM(TX
M@PO @"PP 5-%@0LX(X(+V/3Q"XAU@3,@BS((GJ 9#SQ=#Q(@BT3HV"O#@ QP
M =L@A K @@S8Q5$8A W @ VX"/6)B$H@@9_0U' 5%HB:M)@UJ] \A%)J PU@
MOBYZ!!+8NZ(-JG =@9^H!!$(U_[;,I>D)0HV6("F*-8,^#(TR*@@$-D6((R7
M78X0Z(P26(L2*(2@$MD08(@X*8U":%D'C(@L2)AZS0 0@ VFY0D2J(DYR@ 1
M0)5 "%HOB$5#X "7U0B4S8"N+<8-R  -P*LU2)3#+;Z*T@BLK,181(0Z3!][
M!8%%( P4P !7$J^$$(,/ (Q#(%Q>(P@3N%H5P(DTH  V( 1RF8F$H-U14(.?
MP8"%&-- ^8#!(XM/X(!$" .0*8'YS(D6:#TU($%3\XM0 (&_"@+E#0$UR)6(
M" 1[Q0(30(B2P@ /6*6<D%X26-XU( .*>M1P_8" 4H-PQ0#NT50+" (54(-/
M2, -*/XGFX@ AM@"D9W![CF!J]VT-="J\6 #"I 3]L6 &KE6!MX/&G2*:N4Y
MJ@B$T:E6Z_ $ZXRP,*&.JLA6AHBK!YX*9MF(0JA@IPAAJ$#AJHC@IWA@%>Z>
M0%&$#UB,SE!A*O&*%X;AX,CA#::3MOR+:K5A%GZ3'OYAJW#A(7Z*1A&*@0+'
MZ#@/J0AA%'X/%7Y@U=@,,F" 38B-:DWB%&Y@,+Z/[P"3!D&$L.7@WNBG/9F0
MJJ@E#B17*(Z)$!CB'ND/LK!-#_"?] "+&T%C")D.52D/-J8-(G:*,]B #4C=
M,:23,4X7-P'#M@R!IP7D,*YD2]X/+[YD3=XX'MYD3_YD4/Z6C],(95+VEE)^
MC%-.955>959N95=^95A^BD1@ P1!&CVV5$A."43(Y(B(,OXXA$Z^"KUQ#$Q
ML8UH(0[Y!(WC.#*-"D+PB&6V"MGQ#.VP"D2X9;98FN-QXJ>H!/ E'VQFE X*
MBVNN#$\XBG*.98:!)[6<"A?: !N9#8YBFK(=9(+0PW)9A+Q5Q2/#D%&@W<X
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MF"D_M?Z)OFT!!G@^1,BR-J"QNMD (BDI#2B!J@F%$:@$17 E#)!IC/" !M
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M+H3< HK"A'6U@(7; IL"@:Y6@8^L@ U@B#(C]Y8EN(AP@Q.00PK0&(1,! ^
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MJ3!8<@]RO-"GPDU@$(29P"&VL"8,F*0H'SC7UG8WJS!:P!-:8!+D0G'-*DT
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M WP$3Z9E&&0 B(0!!I"!F!AE X2 U]F%!TC %K2  @P&_FQ!"!Q X[4)!5E
MK36 %Y!!C_ D!BA-"(C 1,*(5V)F9FKF9G(F:235C'R" VR* V "&LP%)C2
M]'F3481!&XP3)G2%:;E74:SD*!1F5.B9\)3!Y7A+ S1<";!5&.3((<PD!R2)
M"0S$&?Z\IF]V9G,ZYW-"ITF&00>\600,AK]40A9(@(J(0 64#>HHC$=H9PF$
MP A4 "($1@18 '!5P/5H@<*X$D%XP!F$ ?"XQ_YA -:%0B*@Y49]V3=-BPML
MIPB(R8A%YX$B:((JZ#B&@<(,46_X"R8L"15]0C[6E64\!!9X (56PD^$B!HP
M@%[4IA:(A ?<5E28 6]620.PWFIV(&6D@ 8XR0F8!#AM 75B@O>@XX+R:(_Z
MZ(]2$I(5B%A%A$56@@.$(*$4"4DP0!D8Q ,D*0:$@@>80$HD&XHT1A8\A'B]
MDTG@#XDV@,DE%00H0B5X@&J!P F$ B$0F5& P/4]0!H@X/X%> 7, >F=XFF>
MZNG)5$('G, GD, P >H3NE@2:@8;9)9[:0 &= !P5$((+"J$A,%*(E92D$P+
MD P99 %_7B066 !]9= '.)NJ4*$%Y(T 98"A;L&Y[&FKNNJKPBIH6*%GB%Y$
M@*,B> "X/&;P)"2O;D:MQFJP"NNP1N>.7N)S[&@8:, &<  AO2(ETJ*Q$NNT
M4FNU!JNO6FNV:NNV<JLI=NNW@FNXBNNXDFNYFNNYHFNZJNNZLFN[NNN[PFN\
MRNN\TFN]VNN]XFN^ZNN^\FN_^NN_ FS "NS $FS!&NS!(FS"*NS",FS#.NS#
M0FS$2NS$4FS%6NS%8FS&:NS&QOYJ+V:FM"8CQXKLR))LR9KL/(8""HC "(C
M"EB=/OYBTH&+ %U/*69CB!3.S1)C'-H<#L%L,1YB*3+/)YR!!32<\#T'(6P
M#'H+!_Q'H,G:RAWD RWCR5JMNJ83 3Q  PP  =@I* 8" /P9 " '/VI&)1#
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MAL(F> )W8($   <D#P8(&, G9/(?>\(&+$0@&(#R9('Y$L8G1( ZR<I=80$
M*$(7  #2J<$AA,*7V&8!AZT'[*( .-4!*,P&Q%HF[\D&%+(*#, SZ; 7.[.V
MAJ\#-- 3JT$0&, %3( (<\$G;$$&5$ "]$D;P'&J , ]H8$J&\0!O-HHQ'(4
M-W-A6 ("E(!*K'/;1G$ ],8*$( B<("=A($LAX$ &$"N8$$  (<%,( %4( $
M#( AQ/*F6$![88(!R L9  #,5?[" 9 N)$MN !2"=@2  6P < 0""6" !!
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M-7PB:*E10D$ <_5DN,5UR7%WA8@-2+ F F$# .PV$PX0 &8 :-1,SA  !K0
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M(($@>,(3D3Y!C61]!C3,Q8_$+OY!)=3@ 3^'8H7A6T&$&H4(%"083H$0@0?
M() VW%D%(6C4HE40A@#TK057P02$4R*&#^!Z%%D8<PM:Z DMD*5&GYBUG542
M!BTL^@0^],06$)Z2B5?\$RY8C&Y3X@86X#D$P@D9%C80\4FV.9%?4  $7,#A
M,GP@!$0.0Q8(@60LD.$,M#IV" Y(B"KB."%94+?))ZD";XLL$"'H /@ ##V!
MA &Y#9 -(0P@@1,0  /B$D B*@& .P6"NY@00 (L\   D"$,"FC !S"A!@!\
M( @!6,$H((  !5" J0@!^UP$@FH%1" 4)2B "C!P@) 4@"\*  '=U>5V"7@
M 0 XA/[;&U !! S@$)@@ ,T6T*(--#L,EP! :DP0 "L!0%,2(, $)@  1:7D
M!*;7  #0H/D&%. IL$\ !&!5 @*L  ,&0(3M"7 "MS^@ @:H?.M/,X$"C&(%
M (A !0;@  ^.'@L"4($G- #Z[<XE]E4,0$&HSWH +%X@:S"  SS0^C:0X;[7
M&D#&P-  !GB@$EH@P/0)T(!/(.( ,& %".!.!.(0G"M $LH3@N\$)$#X,,$
M!$T!$( "*,  &"#C * !,B !C,<3$( !L* !*H*W(* "". !'B,M$ $  @;Z
M$L !0J 2-*#X'/ 0/.$ &.  +D(@7   )N $(8 "(@  N/X@% :  B!$ <+
MJS!!$1"@ 40   "DO#*@! +@3K   )"/ !A@$PAA !Y@< ;@*@9@=Q(! $I@
M%%0  #R@ F@/"Q( ,D2&^P;@!";  #8( 1;@ *0$0@(@ C)@ "1@$T*!!DT
M#Y=# ^QP @A@@Q) !\=((+)  S.  1QQ(Q*@!1#K"[=P %Q "V"0[2@Q!#R@
M""&D"QG@$!K  "Y !RF@ @X@ 3#A$   :PS .#@@ "2  @(@ZQ2! 19 !'8Q
M%-1@ #X !1YMLIIN>2K! $+@N)+% PS@4[P  -J "P(@$2!06 )! +X $Q @
MZ\!06#2@-A)!#;Z0R0J# -@'"_X"X$8(X'PTP  PB! " ,G,:@5J403<(! ^
M9:@&(@$^104&8&/P,2'.SA/4("0RP  \H1:O8A$.H 04(0!@910>X%T^#X(@
M(&P,X2*IPW,:H $*08X68/$,00!.H!+H( !.P!,8@ %J1 U"D@WCYP&D0@/H
MYAT+HL"X3@UHD0%DXQ "0$C<CC->,B4@  )"@0,.0%\DX $,A V4LA(.P -"
M00'>) %()25"0 $$0@L[HO2"C #^L00D+R4"80!R;R7@[RH280"(:RA+!0 (
M(_;V![G<S@4^00T0H1(\@  PP0L"X"J2T3HDS]Y0PD >X )P*RX)\!,>0 &J
M1R7&IOX@'#+)"# 4& "F&H!G"$%?DA$E[ P3*L#ZUA  % 'JEB;Z$&$%!*!&
MM+!O%N #1J&V<(P 3F,39BTCS4@@T "YG#$$0D$"$L -5"0$SI(N ( -P&YI
M*J$ 2F"[A,090< X$\ R!:(P=X4.<@OLB*@,S@H1#  D4D("9.,2#. V-T(!
MYFL N.#/I)*#L/ X L#8U* 2$D$"&F 42( Y,P !1L$'EV/8,"$#&H#K"@^D
MF-%Y-  "&*Q&)(!+KB\,N   N(X ".,>OR 3"'"2# !6ADI5#.$#'L 2LZ[L
M#.00!* +,B#K5,("4K,,;&OZ*D!89BH #& %0L$"_&\#4O[S"S+4K);&[<[
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M0/989$@@ $0@ P* #5B0 K1@9ST!U1RJ! S@ 3B@ !!AN\#,OL[ OD) !11
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M@LS;&C1\OD $2("$0N;@4H!@/"$+^D:W<ZT%,F$+"" ,\NR]_>WA1GFR]87
MG]F,5&,+^N+B5"#6PLT^Z  +]&4,=B7:".3$'=PT#D@15O[  ^I[+4N +P3"
MS?0E$%S@4]8@!-H,"VHDQUU["XB,0["[8%K S^35"SP !5#B$VI\)3Z@ <J
MDR6NRF'-XL(<R[5<);R #%$ X$*&XJ;-1G0H,+Q@:=8D!$2 R,X "Y@ERZ_B
M1H3CW0!("_A"#;(@%/!\,LQ P6RD!0X\)03!! 1%I P[E 2/ &SH)^#/ CY
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MONC;7I\2 8-)Y=0JH1!D@R78X( LNP-:R+(SH!(\ 20"0>0*1@TLH246LE$
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M>,(@%A&$1UQ@^J9(Q2I:\8HF\<(7MJA%+F[Q"UT$XQ?#2,8OBI&+811C%[W
M1C-JD8QI?",:XWA&,-)QC6/,H_X7]UC',NK1CFX\(QOO.$9"VM&08BQ<2,Z
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:4(VJ5*=*U:I:]:I8S:I6M\K5KGK5I $! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>comp_0009.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0009.gif
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MZ.SK[/#O[^/N]O#O\.;P]^SS^>CQ^/3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L      $#;@$ "/X I\BH0;"@P8,($R*DH;!A0H8.(THT"'&B
MQ8L.*V+<R+&C12&J6HD<*9(+#!T>4ZI<R;*ERY<P60XY19(D'Q@V5&KTN%,A
MPYX8?\8<2K0H3!H\.-5<RI15%!DYC4J=NK$G4*H+=6*M(0-**U9,I\#8FO+J
M1;,3T9)=R[:@#"5@F5X9V+:NW;)WSVHM2"-)2*: 1;):(@-EWI9J]=Y-;)1Q
MP\1F;\#8$MA)X<8/5SKV>5AQ7K.;)\*8\I6I%*B=4ZOF"#2T1-<'&</P&CBP
M*2%T#\/FO)KM[M0V9.PI75-5$M2>>RNO\?ME\YA7*]J H0<P*R:Y]RXG^IQ@
M=^? 8?YP(5Z[)J<>R+>K7\_>87!#2\&6"I*]O>ZL0?&GS9Q\M0X9@P!F"A+I
MV5=4:_GI9^!=.LSP1WF :9)#5;$M:.&%,-FP"6"<\/ =AE-]2):(+-%P"6"E
M#%$?B&N1R*)W_)6%"(1,)7+#@BY2J%EGWZ'5' U#F!)A5'7ER-IRW?78%E)*
M,=5)#D;R]>*!>&%VF(;DT=@*(2MRM]B44H(947!+Q$426(?<>.1]8K99H44[
MR8"$*F:2= F1;.[WIIYN)JB>#$((J25)?W3Y&4]Z18G79HKJJ%-PI,77RB"&
MP@@GE7WV::0,4335BB*5/M1HIH=>JIH,3 PZ$EAZX-21B_ZNC2KF<[(J1%U@
M?83:HG95;E5K1M"I-)T6@0528*:_\N8HLA,%=T666F:AZ[*D5KLGHA1M%%R
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M#+OACZE*,@B$V&H#%D&8+6HT" (7 J&'LA%D"UN@B!/T0"39V2 'K1,"'X+
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MF((3,."#C1C:!R LT6?#28+A]8 #^!@A5:50!0&R!>'V&C"A.+ F*03($C+
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M:7_&8?XR.((2 2 #(WJ%!S<L8!6.: #9+I J!GB@$7!(P)8F0(9(L(#":\@
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M55BOD+.#((PT2H@ -)'#74N%^V$ SZ.MQ3N!8YL$$)B !WB?R8LA4<"]P(D
M3,B@$J#"A]J :4DN:EF]1(F$#?" F;)$O$$%", ;+#J!50A$*JPE$" #):&$
M$)@ !V A)1F!8$N!1O& NRL[/%B%,K@<,A@!4UP\$T"!6I*,2#C$JOJ\WHF
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MYY.BRV%.9#$#!W@25.">5C!,>ID=AH@#!#B:(5T(L2G">].? KC"?)$W5)"
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M.J!S;Y03<VJ9..BR5>" .1#O.:&$->N2#L^<8"'T.C_E+HD#!VX>#1BQ1<
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MV= "&@#!!VJD\!8TH!%PD-0:+K3?#$RHF9'(#1NTQ 8_3>("J/I 38S H%1
MP-R?4O@?"(! 331"!&1 "F# ';"%!Y0 -SE"')#=*G2 "7C !81 84B%&63
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M!G  Y_#84O%% O $)0SB"(25(P ;Z"J+WRB)'*#*&E! -;8!!VA BD6"!D!
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M0/66@0%A@K\8%B,HJ=7QX*FA0B,,0 DTV06H0"2< 0%X&3&QP22, 06D0B-
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M!X@1"IPM\&"D#2U "Y0!U3T(*F# "DS"&^C([+QM!XC&"AS &/"4 LR!(X"
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MQ1!]WNF]WNV]+28A AP@&^^ >CH@ Q0DE$*$I\^S .9 HX1G3>5(O+KW#,:
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M(95XQ"X2I15$0,?Q)3@BH 76X/:#(@*""@_>2"S;_OK#;Q+LYP(8@()%JMW
MK%4(8_X,3E4-K'K'L?_40L$$NM;/F-Q=EB)[UN #ZD1X!)W;*D!_UI(-$-]-
M#'3& &(5J@B36H&*X*E5!3NMTG1HY>@"I0FKRE1HHX:-'5"M5K6"\Z!5QU:+
M-*!Z4'#5I) ARK2BA+!5F1"M(BSZF$$DAS>@'GB\4$?DB16M.(Q@D^:-GU 1
MR*Q1$Z>1R%:1(*!J-;05*@B>UDQHDX9-G5!O-HBT0*=5(PBM1J3I"!/4A#%/
MXS!J->&F1T]E.C"(-#6PX,&$"QL^C#BQXL6,&SM^##FRY,F4*UL.?%+%U4D)
MS(RLK%)D TDB.[SU>#FUZM6L6[L668>B2(\L'K;"XZ AB/[/!AU,8L4[0QPW
M%6Y'F$JF%1G;<CJL^DMR <<)?EJA^2#R0P@6QJ>6N2H2E0.B6B>,:*4A>:LQ
M&EJ!\!RWE1F:$N[&R=FJ \\'5R?@$5D"46-X()(G;VGP5BMW!"72)!%<E=5
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M\N_")T8)@\,?CWSRO:M 8)1J<>=?E">!HA])$UR% K07P-$*(]=C190#"46
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M6FN0VIA59""8E_,7*A:0!I[ZS*0K0.<D&) *DV: 3ZI9!![6@( Z])0RC4A
MXB[#@(3<044F12I'!ID:/- U,'.8 $O_"MC&Q.$!)M#=".QPE*DP8B@N$TDH
M$D NL_[EQ Y^%4P&H#65,<B&H"88PQW\6M,8L> $QFM$"E+PB!BA*$9!0<49
M3I &\,2ALS+R! OV&)XTP%:4IET!I5!!!A.P 36.R-Y6%S*&$FR2=G4802-
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M -0$&VU8G0L@'QW@"0=0!Z!P!L5A!J:"5',S4XZ0 7[U .WS1*%0 AK@"90
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M">]S =QAW!]@ 9N#FY.M%R< VR; <XFY 5Z"66]P?B:@ 9*@=N'- 1RQ 9$
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ML$*I8&(<$$K_2 H(L2FD<!L7\,B_@\<' !ALD!L^*Q)F<!Z>LC.K0,J LP"
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M&"#$,.U]*DBM",7L//!$$WCM8?ZK@, ;4'$^.&PR%&:0&V$8L A4U*H5H#A
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M!SB!25"#!4B#-U@ B7B#RF&#"?"$54  4$@#!%#)EP@!#8"#%#@ .W@$]8&
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M2HB,TUF$V- -28J#Z5"<DJ,W9PG%.Z@/9\F0<&$?1T@ <$M2#!*<+O$(F/$
M2ZEACBL<3FI=5LC75JB #0B!$/@ $B J$CF-H+F1"'BV5; D/%B $0 !$<@
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MX,2@AS%=2>@ VVX31SB-ETB#4+ #"@%MFE@ D& $EY #0715/!AV16F!':*
MOP0?)84[Q9D (RJ,#("0@< <3/ZBFDMY=6@&M7/%H*M2@17H9KP)A;AMTQ1
MDPPA"S[>=!N=A T D0G8U+B0'RPJ !!PX 0@BPM(@:\H$ +BI 4X T^0@S+O
M;G[Y  ^0A$2.A$@8@>1A 8(&@6D7%N]P #:@A"((DBLAD0[X $J(#95 'US*
M^$B(IH.I %A\"9)JQ51A@8X(=1GCK5;8C#+HB !G@4E8 P" D2MNA38@ + !
M6$JP4D\H@N2X )QP@#68A+I:!4;0W3F6VX1K@#N8A Z G<(N#"V&H 68^JH/
M 331 .9>"3-PB0Q@;@U  _A] TE8 0&@!$G I3@H@#':@'@QJ$EX@P"@B@E8
M 4A( ?[]. $/\(0[6(#/,9TS#( 5B(0V."/!]Q[#7X4%D 3%H@1'Z"L%IY T
M2(YOGH0Z0(!(2(4(,(-IW))5QF,.0"3]P<D\T)!TFC&+CRC2-X/2F(3X;86%
M7A?-!HS!*(,ZIX#N:8,"F*D&H%UQB82X\*\<%SF!0(%V8H YF(01> B^18@'
ML O$@0C@7@ V<(0.6-@08(%52 ")9($#^(J+ -GE?8#WR0D6R !/B OM6X'A
ME00-0!/ZK_K[Q_VKBH0&(#* **&AU046E. <4--J0HM):1:@BC.A52LX$U>U
MPL-@4B0/#T#A(9!F4I$(K>X42!-IS(-6)4RT>E!GH<$V#OY0L9@0R=.$-Z!6
M8*28806F. ?6D%+@J96G!*0B);@32<0!4*TPHFI !M6)$A1->#VA(1(C"'<H
MHDVK=BW;MF[?PFT;ATTK5"LHM6(TAF*<#1K&8!RSJ-4D%AC;Q&G5 DZ'#',H
M@C*AH0.C5I%8H(WT87+E#GN#.NKPIA6;#B88J9AS1^'5C'% 15C:40.)I:O(
M> C%=4.&-FDK :5X1H,&.!3+^%DK9^R=-!3EL#:C88-O5"E0V7&NMA*(#&;(
M,/*T K*(2!3-X&E5IX.&$$O+G(T$0D,)V9@)WX^K?S]__G;8LX"*>MJA1<EX
MK1A(D1U^!=C*&7:@A=$=9K2"!OZ$%<ZTB%]KM."))RI@%8(C%*4QDR<C8$!&
M&1!&TH%H+(02B@D?G,$(")Z,,4F!9+ QV6">S&@&(^[EV$H9'JC02 F--%(&
M17A0B--DZ2$8@@8@X-7*&QEX\$8+ E+DB94:7+C&AA11,D(&(N@H'IA2<G#A
MB5?JJ-D'<,@!$POF!8:!"6Q06 (9K?57J*%PT-7*(AYHD$(HB@Y*T9ZM.-("
MB3/9D<$(;^S%1F+KC3!A&H[LI:5?!+82B@H>D-$("*"P8,(*&:@@2BLHR)K!
M=:0EAE$CC#IJ60@?N&''"$P)](%Y>E'42*DD=G "(R;@@4<&9V0 @H[+I9'!
M!SJR,?Y:"XT@J\$'C[22RAA^#0K* R-B1(D('[!Q1PD_/8J*"H_6D4$';K3P
M*%IO:.")'+YI.=IM&G"0F*$/0QRQQ!,;26ZAD5P022@M7+!*4!2#'++((Y-<
MLLDGHYRRROIYHH' *\,<LPCY433"@3&K)5'.$TG\$Y@X QUTQ!^S172$:5FE
MEM%!$1V'!QW4IW31<1DM<=5O7;T6TUH+W3767!/:5M9'?YT6T4M+G3;984<X
M-MMPN:VVH6/3W8HH+WM-=:%;4W2VWEQCM(9O'ZOAQMMK2\UW?Q@QDA_CAL$M
M=ET_]ZVVXE5C7GG>FW/>N>>?@QZZZ*.37KKIIZ.>NNISK_[>>NMQ4ZSXR;"7
M3+OKG=M^N^:UZ]Z[[[\#'[SPPQ,O<N[%(Y]\T*CD0?G>2N/A/$7AF;V(]'DM
M%;U^H:07";J[KPQ*'OI1'R$>I, U";S$JZ]6(WB-S3U_C,@A1QQW'-\6'GBG
MJ@8+;8"I$3H:&R4LMI8"ZJ<1;+A>R?:7%@3F#W5R*((9LC0Z/"2M4)0P POD
M0#)4^"%N$9P8*O P0N4]#!036 H'=#0Q%5JP<AM(3!M0T H8A@TC%?#- EP(
M%SPXH!5C.,'A_E8VMN"A)7'I@&]4L(:Z,, \!^2 @,;0 >29@01,T8" -$ A
MMK# .8U@ -K8<H$'@  $$ZB 5?Y.N H'D"LH>6! !U9P@=BT8@.1FEH:0L"U
M;H$-+8Y80(,0%\A#LL4!@PD*&T @.=V!X@(36 $($#"3(CYLA(SS $4NL,C^
ML"$!(5#!!+B(2?#)C1(4",4J"D81$LSD>"=D"R@6L!04PJ424B14!L.6BM:
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MQ%$]RLY&@$D.$WBJ4W':&HQ,XJ<4B<0!F-J*"%AJKC\=ZRVU:IEA2J*93''
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M2-(",/[2%9F4&D:"%V+$!2B6Z0!1-ZF=Q=U5)-3!0+2"!GC010I7I/ A*%!
M"FQB:RU$9;1"!2Q")#@ "* !-,F!&6P 2Q6C&CJ"'*2=2XP!*CQ 40$D6FC
MH##-*E"" P1%'*17!:0''B18"93!*IAA*Y !J5$ (SBF%6:)!OB&0*S!&9 !
M GC"!9C )HZ 26#$EC33+TW"&HP! S3/8Z8*!,A5;_YF](C=17: &2P%'&
M-:$ >Q7/!-Q6,*+"& A46B@F1;P!2\&B4'A00WU96K!!! C&!XS&=[:"!:S
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MD]!@7>R<4*B!NX#)<E($'?0*8=AB"D J<8Z24#C'%:X" \P$&\CD4JDA:C+
M&GA"&ECNZJ3 YDD* Y!&L?H3&;WN?[IJ2Z0 ^KV!28# E(W&!% )N)+!D&E
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MEL1!HBW5#$N1'5S^2:G!"#1FF)A@(\C!*@S]X^HEZZ> CGRV 99 8+'! Y3
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MN*..">QX [TC-XA#A0-JL@R_1AVU[Z$T$ CA#%0T6 &/$/:+Y $SY(B@!9Z
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M"%X,10.'[00E($'56)#-'F>Y!/X.J 1[R8R7/!R@FB28%ALD"9,1?:@B@F$
M'/R$BD64TS?EQ "=V0835-A8#@I Q57]Y!?]#:1SD="))RY@!MC"A!*H*$-%
M",( F"7)82QK@'M"43X:/W5_GYER#M/0 <L\ @$9H40Y8P03)C$/)A:P@UE;
MX8A^#L0$^REC"$@RM'UYHA&W;L4%W!"U,NLU4I1.P_IF=J1=>N(,%RX)FQ:K
MSX'$JD2,Y5$K-C @2;;FN -10VN760:VGF$@%_@,!=JHW-JTFE*T;8]P0.'D
MJ)F 7FR&R05&:!0+M+&S:^@:#T$#)E(X8#X,J^N^Y[ (Y-6A:R'8I<0'$@D
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M8LNL0/XT%EG'YF6X-"P0<0*N4B_>@ !4IP,28%%(IC3O="!:X %JEA(.8 -
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ME_VYE7-9#BH ,5+@;*ZR!=X !*X'F#1LUNCE8X!YAM)F ZCH;*8')AK! SK
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MT5ZACL'^\KEAD$1R<+72!7BH<,%;<:'"" 42.:+!'2W(008+=-V77PMQ1,)
M?B7A$<H#GK3B"00\?:;BBBPR)-$8$:32RAR]M9)"!GJAU@HC$AB4 5JM8%!'
M* R4V H+1K;B1FRHQ($ *BQ\8% ;64VPAD$/V-&* ]41!<=_)]SDB0.16#3!
MEQZ<D?X4)@Q4APH;!Y29P9<<&72!=EK90>0C%D7@R$8%K1!5*W!(MD$;!IFA
M45HDJ'3D7ZV4D)(&B+:RP1NH*#!)*Z D\.5-@;6R2%8[2L9"" 8Y0E>+K+;*
M4!VDSGA B=1Y)!$E#:"&AR>P&H1*!ZA0(AE1<AC$1G ?V-1*&D9.P$92%_QT
M0DJM4+( *B.HF9 )+;3RB&1K2+GL"* <L)*PK:P1%6H3T&%0"E).H&6UBT0Z
M1BLGA)E:*W/5-<%*)*D4@2=QA$>802*D$4H!*S%F8@0KA8#&*@MT64(*1&&6
ML:L<=YP0)1. LFHK"_PID0- 3A )*@DX!E0;+'=Y <RZA?Y"YKLI12!@*V-$
MY9-R'* R:RNB0" P7AG@Z4F]!#*0VE_+I35&IO4R4D DI#S TXFKU!'?I:U$
MU@H'SW):[P7SHMU*!OZA9H<# Q8YU4'^X6'!@"!X,.0'&I2IP96<XH$*EZE.
M0LK G"+N\>*,DW'?" X4N]L ?R+$6 :H:/!ITEI!0((%(ZPD41P'3&"Z U^&
MTM8($F#&1@0FP+L3=0;=X< ((TR ,6J%EG"!"1(EBQ E"D0P@?$_R:>= YNV
M8E?>$U37^^\&@># (JBL'D&]&CR[2B00@%#"! 75%4$)*)A I@=E;W"E&1'@
MCGI2:2# AB/#CJK2!AJ,\(!_C/X+X&8D4H< @. #&5A L5"Q@$E$8@$'*8*5
M4$"B5G3@ VS0@%A P8 1A (/#CB#&1R0!_F4P2!C<  ;SN GA/S/1!-8P>OH
MH@&-H&8P&&N$ EIQAOB880.HB$ 1V%""!.!A#<$Y"!P8H 8R,( K=V" &<RP
M@#GP; %O8,P)UA !O6S@7LZ[5BM&$*9,>:(-%1@;&#LPAE5$@ 5$5( <4,$
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M3OF4I^8)"-![Y>0)94,"2.D ):(!=3 )#'!1$; KHB$J6>%&F'89DU 1!M$
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M$3P824"9!L*""; A6Z%P1$;6\C.DB,0J:&#$9LJ7@*-P)04_0<B1</0JT:T
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MF&"# Q'! M8@!P>4H14@6$ )TAE#/*# A)-@0!KJH($%F*D ^$3%!E;0<A&
MY *TKJ0D'M!G!OB(*VF@P#U-\ @2X*>D6DX/V&]<,+'G\/[!0/9-A6V<;;:W
M?35IB%Q,CL((V:2!!*!(85'68*)(1 (5=\AZ)$2". OZ45&HB,R"'$@:2KZA
M-DU)@<U!,Y(Z,/,$/S%?3.20BE6H $@Z^^L3[7"1$)BEV*U@ !M"D8J-3(!
MH(@ *N @FQQ- #BA@,A'=HH4I9" !&]:_+O)L,$SMF+VP+]] CQ160(UY76+
M0$4HJ!WF5G!HNF['?O:UOWT=#N0,?EQ%E^PC$C.4@!$B04632C2""DR@;Y@@
M@P?[*!=:+41/)1!)&ORHG$9D( +%L0H6&(BA"P'\<YHT>")*N !1@ !Z&X'Z
M<XX.R( 1Z)RG" $T& @0L+G^F_X ][NAUWL 5& #(#&#!R !$!@!#T"4#&2#
M!%2*$<# 5H@VX%@%$DB#$VBU52B:!0D0/'N $4!!%6R%:7& %. *A_.;YFJ%
M-B"*4."5!\"27AH(YF($L\@RU7 .3^@F3U !\!"R(3,R)7,$_U@#2>,PU)@$
MDK&?21@(.$@)Z_A"(W,=LG&.-$2*JD"RTU@#$*":02L!%NF #4 !FUB%X2L!
M%9,Q[E/$;-,_<OH,/Q"),R@!3Q@H;]H[ 6L!SR.0S: 82DB U\L_@)J.%4P#
M9BH!FYL$!$ 44" _C@JL&Y*QZ3F-$6 G @F!&KLY-0B%2DL#-'J ;J*DDXL[
M-\  TOZ8!-L(@5J1J7N2O#> *)BX@#IP WN" Z6@/C.QITU9A>SQA =X@TFH
MA)$ PH^@OE=RA 2P)5]B "NSPO48(#?QA!!2LOAH0Y&8N;5+#0T HSP\/YA0
M,?<8"#E8/-/0@%!9A'8<CSLX@S1  !-PJ54H@BYAA!((P55H@!)8 S58@0(@
MF$7TR!T;"#+PB*JBIXNXMURQLS0(@+USCDIH@!" B5X$$0>(@U!(@#MP!!-
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M28R ?AJ(-7  #(B#I*.*":BQ@?"$#G" %1F#"&"!%$@ 'V&!"S"#3]49=-&
MWA@#7?[5  ^2 XCJ1;L+$%.]@#EP-U0 JE>I)#(0UH)BC=NY#;I:@^2I*N6\
M (0,T&_EOD@H@]AS&#NP@$B@! Z0H0(;MLU$F Z0O/+8$D>@! _8H&M+"IB@
M! .0!,5I!0PPBY3H +-@ YN;@.ZH/F.ZM2%\"7VZB<"HA 40!;:""0^I#HS3
MU%:8@X90"9; @P3H)YL$!7\M 3*@(M+0S#2P)SL@F0U(B;' I 7 $$=XQA0
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MG=D ,!H!0)L A1A>>[)3Y"V#/)@ $(88?RHHAP.%2O $B%FX58B %J $5*B
MIN  I9(#$Y*L#HZW'-YAZ8" HW@5":"V%(#)Z459**;?+!9;P768P/TQMJ,$
MFUH%.!  29 #1"J@D9!9,\" VG"0&XJC,=" ] .?5E"!#KC-%!*HB#@#D8 #
M1#(^1 K(@5J%$;"].B" .U@%$EZ%.R@ 19;4118)/7/6\9J;%/"C7+$3F,
M9%H$R%J%-(C+C\"#B^*DGQBCX$B)2+@ )30!%* -"%AE"PB%.J@ 5&@;,SF
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MW):419*1:5QB)J:699IY9G<@:$#&&%*10&$K))A!"01@K4#A1IZ(9$)SK91
MX02.&14)&U(A=H(*1DTR0ARM%%'!"FQ0$$HH))G7P20/;+3*'-11@%0K%#BV
M41R&MH*!'2EDT (+8ZRQ"@K-?=7""*V@8:J*J#S 8"L5S/Z%1P6LM#("&:N
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MW.  ,ZR  2!R0!GDMP!&I  ":6#!!$+QOA24X0'TB@"_2+8",S"@*!3H@!I
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M" E QQD_+" $9?#  N!2!NF-@ 0?*(I;+# &%CB@5E,)&)K(:AD2 (A,J+A
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M:F=@P?Z/9=* @ Q<X (5 ,4B&B"F1C! /1CP+"C@A+8&9*1 ?IF.A,*'@C&
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M@GK081'= 5=1AB3< <UYAR?\H2<LDFCQ5F5X0HF$E[U%PE-,!B-@A62 @AW
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ME08+E!DJ$*)GM $"((0G>, $=*-D/$)&C(%A,4*=F$FXG/[D1OZD3:$""WC
M\J6, Y2 )\A!!\0!!ZR >JP!")1 28!"&SC""+C(1FS &E0&&I2B&7P%5)8
MF*!""Q E@\@!);W!EU2 !; !*@22&DP1''S-'81 "-RB;&V%.(U >4S""716
M[L2!L\@!)9! ")2$'=B!&6Q )"Q"!ZC 5[!B)/@9&WC""$! "WAD5(YE$7P
M"^0B5R@F8S*"!T#FM&RFR+4!'G@ I8F;8[@%'I0 "-P,):Q,X=A!'JP!;^2!
M"(0 % $E<%X4*F3 "2Q""TQ 0BP0*-0! J1!5WC/"GB (RB$!AU  2Z2!X
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M!A(5/D:9.0>+( ;/L<!QDH (]!4JK$"B;$2-1( %P!>QYOXL0D&I9&2 \$0
MRSFK7\ !R[A;6X!"#@KK!D!J,UU \G@"<#3@'^JG9+" *"R=HVZES+:%#OI&
M1?2*1%3(9%2 7$&" "".8;4" Q@B?41)*TA"=J@ 6ZQ-2;B!76"J%4(-^C$
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MODP ;YQ <>!!!'# "'"U0%! "'RN@PFU U!")%  NK0.&D1 !XR  4L&EW5
M"3"U"H]U!U2@7-,USZ!"". U4WO N%Z !3"(8?=78C/$"1@A*D!)#!H2?=R!
M7AS/"%! :JU"7G] ".A@C64 "4"@(SC"3(H<!5R,B#S "N1@"7P :V]=]4Q
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M2E! M6W$&*3%4'R[$47()/B<N1?]XX!"!D"AAR[""A3'1IP %DJA9)@V"%R
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M3R1 9P(4O,T!JZC GH)WN AR;A%]:P4J)L &1BP )WA 3ATP0!#$,2(\!-%
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M@ )0(""5(P0Z8!5$(? N8#0B+P,F;R%5\!N)@Q)$X,0$)P-ZY.R,)H),@+4
MMW1-UREXC"S,S,P0C<<<[71A-R9V#]-.+Y4BI%9V<3=W=7=W>;=W??=W@3=X
/A7=XB;=XC?=XB2(@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>comp_0010.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0010.gif
M1TE&.#EA_P+A ?8   ,! 0D%!@L'" X)"Q$-#A,/$!41$AD5%AL7&!X:&R$=
M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%
M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9FIG:&UJ:W!N
M;W)O<'5R<WAV=WIW>'UZ>X!^?P!:J0MBK0EOM QQM1QXN"!YN(%_@$22QDB4
MQU.9RH6#@XF&AXF'B(Z+C)".CY&/D)23DYB6EYF7F)R;FZ">GZ&?H*2CHZBF
MIZ>GJ*FGJ*RKJ["OKZ^OL+&OL+2SL[BWM[>WN+FWN+R[N\"_OYZ_UYZ_V+^_
MP,&_P)7 WIO$X,3#P\C'Q\?'R,C'R,?(R<S+R]#/S\_/T-#/T,_0T=33T]C7
MU];7V-C7V-?8V=S;W.#?W\G<[=[?X.#?X-_@X>3DY>CGY^;GZ.CGZ.?HZ>OK
MZ_/O[?/P[^[O\/#O\._P\?/S\_CW]_;W^/CW^/?X^?___P   "'Y!
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M")# C@?D=$ 4@D!T  (%&%F  _$-\H&9.^;Y0$QQ6.!E 3 J,, %_?"40&!
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M05RU31"/*%)+WOY0@C?Y,(6@#*4H,V0&E]SJ 0Y(Y0+80X%^ .^&\HD5^_R
M$ 2P#(@$4 +3B!BAW75L:A=KE 5<D )M;>]V4*I< A"PQ4'4X'->.$$ SN0
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MG$8'*L >(&A2 WX@A19HBSUKU6];T8/5]!* -MZ-LI2GO(H4>"H T8A'E :
M   TH07MB*)\)A. AD@@3A<8A!/,A&4_ ,&/+'* !@A '.L&*0$%&(  +&
M!!  #4T@5P#&)@@*$*#!\]"6H#9@" YX*E, <, ##!  S.Z R^6 $0($(#0_
M1.%+":"S&Q&P4+<*8%$PLIA"_< ! 4S&B0Z @ $$D)DN1<3308+DO+)U@ &0
M(0K3#  2#F&(%OY@5P%UHK*RE\UL391  QW@P(@&(00,>  #/@B"M3V G3EX
MH ,8"%<)-A?:J5D; W5K\7H"Y 4C8( #(3"$$N+J@ H4@0P:N+85M'#N= O"
M!!O @ [&L(&6.& %?9M#"J8#@1"\00<7V$ VG?"!Z3#@ 1I0L!EL V (D,!W
MA."#$#3P@*4\X /&G0-]JA,"-NQ  QP@P1Y4T%>9?PP##F@ !89@A@UXX )1
M\,*YV82((GS1N<U.NM*7CHL]N.$\B'@#U#7A!C/XA8MNR(LB\& &,O0-+6Y(
MP]4/P8<YD,'J8/^Z).* F$K, 0I1V  "'$  0C/][GC/^RJT+,I,>/XAUPN)
MP-CU3OC"&[[97A@ C+S$XL,[_O&0QZL;5-""%O1@VI'/O.8WS_G.>_[SH.<&
MWT-/^M*;_O2H3[WJ5\_ZUKO^];"/O>QG3_O:VSY4'!E$[@6Q^W0<HO? _[WP
M0SX(ON?^^+I//N^5[WOF+Y\0P8?^\)W??.HO/Q/Q0/[S$]'[[5=?$=V?/O@;
M$7[IB]_ZWW=^^=%O_D6LW_OP1T3XY\_]]H^?$>]/O_S)O__^G]_[^1> _(=_
M_G=__Z=_WR> !+B [C> ]H=^],=^$AA_!_B "&B!"!B!M[>!'-B!BZ &(!B"
M(CB")%B")GB"*)B"*KB"+-B"+OB",!B#,OXX@S18@S9X@SB8@SJX@SS8@S[X
M@T 8A$(XA$2(@R]PA$B8A$JHA#"PA$O8A$D(A5!XA%,XA53XA%>8A2]0A4C(
MA5IHA5WHA&*8A6 8AF.XA5KXA6>XAFS8AF[XAG 8AW(XAW18AW9XAWB8AWJX
MAWS8AW[XAX 8B((XB'8( U1 !5-P!8=X!5/0B(W(B(X(B8GXB(XXB97(B)((
MB9IHB9Q(B9N8B9OXB*&8B*-X!8J(B)FXB)78B9E(B9/8BJP8B:XHBJLXBY:(
MB51@BKJXB[FXBZ;8BUC0BZ88C+M(C+IHC,,HC(J(!;YX!<CHC,KXC,_8C(J8
MC-3(B]!XC<I8C/[1V(W<^(W'Z(WA"([4N(V_6([9V(S2*(Y4P(S+J(WN2([I
M:(WC>(WG.(_:B([WJ([B2(_^B(_K*(_3B(W-:([5>(^+")#]J)"\&(_U^(\!
M:8\'Z8L&69&Z:) ,^9 9"9$+.9 7J8\4^9'M2 <D20=Y4))UD)(D60<DF0=U
MD =X0 <LN9(T*9,E:9,X>9,DN0=3%9,T.9,J.9,WJ9(Z291#*90HR9)*>90I
MV90U"90ZF90YN90XB91569-'V9)6J74Q,WH>^)5'(75O('5/YP9Q  =N()9P
M$ =M  =M( =D299KB99N  =D^71T699I^71L\)9MT 9UJ9=[^712Q_X&>@F8
M@ND&;9F8BRF8C:F78ZF79[F7<#"7>)F8F'F7E3F9F*F7>0F9:;F6@/D&<4"8
M<Z .J/E\J=E\'+&:K=F:K,E[L(E\KBF;RP>;Z3";M[E]N-D'M:F:YJ>;K"F<
MK[F;PVF<Q>E[O?F;S!F;P%F;RXF<MJF<R<><Q#F=T,F;N]F<N.F<UBF=N0F>
MOBF>UQF>O>F=SIF>Y3F>U'F<[4F=T=F>R9F=L7F>]JF=]:F:Z[F?Y-F?]YF?
MU8>;8UF9!%J@!OJ6<B '""H'9VF@=EF7#DJ@8ND&"5JA%=J@!IJ6 RJA8XFA
M=AF9!2IU<>"A(2H'%!JA:(FB!,IV&ZJB*O[Z!BYJEQ$ZEE*7H&!YHSBJ""D:
MHY5IH1:*HB/JHAW*EC[ZED"JEAPZEQP:I$M*HA)*H7+ HRC:H1 JI0;*I%,Z
MHV^0H&Z@=CGZI6!II3VJH#XJIA$ZHCY:H2Z*I3'JI$JJHB=JIE?JIG(JIU&*
MEG( IGH:IF*:ID9:IP4:!Q6ZH'=ZIFP*J#Q:J(!ZJ(AJIB8*EWFZIY*Z@82:
MH(A9I3U:J8I:H&U@!YWZJ6T)!PE:H(-JJ::ZJ8V:JJJZJG4:J9Z0?Z3GE;0@
MJY-:5T4Z!WN !WE0=E5JH0N*H@KJJ9ZJJW8@JHJ:IFG*JLJZK,SJH%T*#'Q'
MJYLGK;5*4=3:"/Z^F@=GX (:H $K, 9X4)D+BJ!_&:IN>:?C:@=EL $_$*[E
M*JY_Z:GDJJ;-6J_VBJA1ZJJ5D 4>( (E4 (BL %>$ 77$%6Q@ 8MH&4]0'2(
M<*V6H&6IX0DG@'F>H --X+"28 A $!S$U["*$ 6OLPIYX 4&*P@MD&P[T%8E
MBP@[,&R)X$*3@+$>:PEF0+%V<Q59<$F2X 8F0#W$-C7%\@,*)@ANX!J"D EQ
ML *#YP=\$$%94"PY4 5,RPCQP'=>\#B=4%V', <E$%HR&POOYP4LI0F6VJEE
M( $!, $5(  .T 5X\+8*"I,)N@=]$*YP\+9S@ =S %7!V@=@0!EYT/ZI?; '
MPDJX;<"3<XL'YGJOC-NXB;H):  $2: !%9 $/T '.X!TL^!W#4 (&Q"RKN
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M!2)A%6,I"%IPQ11!QY C/&: ,FBP T/\0R=+ CUP"$H@PX,0!_H2!H,@MD'
M%D$ 'RW NW\\"%+ %F)K!)' R#K@.UMA!;R[)! @!&P1!T"P#()0 :>507[
M!G5A%4.P W!A!#FP%VFL++'L!D&P T2,&J2Q!T20 XWGPX(,%T[0 FWE!CW
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M^HH(2."RA_ ()R "@P,$#M ".:  PQ8%$O #+8 !Y6L!);!C3O$!$Z #*,
M4N$ 'I"Y:-,".)(V.V0$#E $+9 !9(.^AB "%; "+L  Z( $J=T"&H$&$P $
MLTT:). !18 !.JLJ%F $(8 VLJL#02 !* ,!7^!!)) $&' -QZT!2. $'C,U
M$*!E#9!!%8 $(H V@Z#8'B T)0#< B</ S('(14"/@($%2 $(H!9$^ 40'
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M?M!"4:($;^"RE%Y/^PX=$G 59) [D$Y+1F !1$<"Q1(!I08!81 &:.X'<>
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MCUW["#*D'#EM[(A9($'.G#9X,!P0DP4 $!(*\(Q @,'"! !#CLCT0W(!B2
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MEM<<5X@5A&"  K@8C+'''G1D(<$/02CC!AUO0%+(/6^TXH4.%D1D BVM2L&
M%&@Z\L$\A9"!P1"H7D.!%Y"XH<0"!Q$#A$#)9$2'&Y!L8 0'\(00!!L.O/'&
M')7[G$,+<9!P0J,/1+''&]XV=,T'FT#R R)NS"%B#1:@UKD;HA02Q1Q%H,KD
M1ZX6 =\8D\<1![@Y5(":"K&(($U(;D@@//&I22-!%$E8PB*,+U(P!NF6G78-
M+'Y08$4A%<RFP70BN'"-GM9P0(*(&LB(22%.S-%C(6.$843\/O]@)211:&F"
M&A1B6,48AULV /ZD-(U(&1)(0N@L=PTT3"()N\"3'Z)7B(4<K1PM6,$\T/"
M5_C"#V:81/42800T*(!63E &I;"5D2 HP S70$%E7F' "X+!7!0P0D8@"!(5
M&%!V<\! $?2P.A'-BAPZ.(<)4. <+Y@K'M.1PC_RPX,W*& Z@DJ- 9?EA\T4
M(@MN:,$YW% '-Q"C$!+(P1SF4($XU $";/ #J^:0@=ST0W_H$LE(Y("'*B#
M ",P00(,L 0\[($%!$!D'YXP ! \@0036 ,0 ! $C^%A"088 *>J$("L>,
M0AB"!-!7A4YZP2<-*(,=1E*R6,IREK)\5A_I4B$F.B(5U<@E'SQP)OY(]. ?
M>=# *C30J$S0@@&HR<-F3+D',S  ?0R@%5S&X+N/?" "(N( %*OI!R40@ Q
MN"()5.!,N34! V1;%!0O*)PPH8$!TF@ &XA ".@HHP/[62,*&J#'0O#! 6;@
M'(]\*,P&R>X@S[!%$!H0ID5)PP*Q<(,%N/"-!- *! Z API0%8)&26 34B!
MH_[F@+D$RP]^\4,:&J /#*#/# DP@P;]  0U\:<8#?"A'S0@P#=8  TG.,=+
M??$!?=CT(VY@ !3\, *C-L 7$" ?%)/JAP>\" )R.U412J  H>%#@)]CXT$J
M$(LH**D<O8I/8J1@@"CHP0$^5((K=("!7/[IHP% <@(#*I> V9  %208(0DJ
MHP(.D D(URH$!O11!(]$MAP:$ 8)DN<'-#3@%A<8T3%4H(PX5  3Y_0#&22
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MU] $" 820,9[8;E]77D-TW<-H&DD$3B8!OZY>]FGFMFW5C8$EJ7)D_'0,B%
M7HTIE7U4!UH9@)30691)#A\!@0 9E)8QFMQ#%_.(CPMVC$M)$D[IG$^I@6X
M L=R$#FP"600 GQ !BKP Q90 =N5!<<" C14!#N@ HYP O 0!!JP >A4#G@A
M 2FP#"&P:WJTGAK@GB#!!1;0 QGP*W[@!1&5!5"$=![  7N2!-)P C]P+\D4
MGAN@978T I=V)K&5<"/$"CG@ A6P <U1:!H@:]_ )#N@5A,0"UG GAN $=L9
M!$NS LF  5EP A+P3F3P :8V%TVP BW H=(86TVF*%IP+!Y 0^B' AZ0 9M
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ML ,BJ0%&\ 8-,'T[\D*S\ MN$ 4N0 BY@U.K$+L9$0=!, '''%A"UOX.1-
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MP5D?@IF\EB8P1<@K$H#VW (;^,"-C*[W(EA=Z_Y0?GKP@":0@ (4,:P)%MB
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M&*  8S!M(U  53"38( ! <"S=N ';5 " # ";YD*0%#+)A  6U $ 5!A*P
M2R &"( !<1D +5 &!7 ,29"K<_ #M7P" 5 %9V  );"A09#,?O $ G ":^ #
M8S 'Q&L'*0  0B &3] &40"?>[ $ - "BHL'$Z  3] %5<"[/Q#+%I  =K "
M ^ %9:#.<O#*<H " V "!5@!$6 ''X  D/[; 0;0!AB0 /\<!5.&"]AU/AFR
M"1Q0$QQ@!)T<(F+2"UO*I"=P(H8@!!? "3G  %I@TQ2Q"9?I!TJ )3^@#3R
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M#^ '',"D_" !8= $(1 %+K #R$(.?_SI* 8XL1V6L=@'14  &2 &2;D'.0
MYS &"T !?4 $!( !8##@7<  #= $BUFMM6M//&#,R*P//R  33 &!5 "?9 %
M!% #9?"\F!$ 1/ $ ' ,VQX%9W  X0RCN'H750"Z-0  1T#""K &5= $:J $
M"8 !3? :>' &5= %__8$WERZM0X 1! ;@?[* @0P!B[ [Q3_T !\=Q1M!QG
M +&\!=[\!%&@!NQI I@YI%A$P+PPKYO0 3W6 4BP%J?C!DC$SN>P"4H0 9L0
M BV1!1% /+=A5:,"RQ&2Y$O>Y$R*#T: 5SV2"):N5U%;LOSP \LE%W/PP%2/
M7(:P V;^%L&"1%EP":(=!4T@]G="PD) !Q@]*GONV!&0,!.,!GS !<(1!P[
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MI$"C( "  V-P0PH < );Q,$CM,B#%\Y2(PG " 0ZJ,4;:AG)+Q3E RQ(%*%
M1\<OD.$6;KB 4VCQ!@QHEA9ST (F]< +S,;!"VO\ 0G\P-M>DH  K/[ZW 2N
M58&6NL"D3S)I' Y (S0H0 M[.( FI4N5"N1S=36  #D,,(:DK)86+EB*$WS"
MF"9P0 !#B=P>WN"&/1BAH#VPB1$D$"H''&D.#J!1+30P#CI@M@.1]0,'4'!+
M!Q@A37<1JX,?'$0' N^)=KVK^.#Z3 M?6(!6U' #=58TQL!W,6@P@ 7H&(45
M"#8 O[5%!0Y QCI(( &8] ,2\.L'+5@@!!;0A0H8,($H)($!$&BI$"P@ @O
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M@1,X0,R68<B#@0:D@9-!"!P0!4.@  /@!EY 4#R@ SJ0 WG !  @ 4H@!1Z
M")!F:_Q%1CJP6A5@@WY(??*4 Z,&>WX0 BV5!Q(@;4A@'8/B"[1@!#Z5<! 0
M!W&@ 19 $&QH!@E0+$W@A,57:\5B!MX%!%](=HXSAG40<[2P 4KG!R@P:D*
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M(@( H L.8 !HH <-8 #,6[O<P (   $F0 $ 8&TU  #*\@, 0 1!$/X!%F
M"H !UU<" -!8 : /U<)79"  REL!^4N3:.   ^ !(5  !T 0+@  #D DB\4+
M(""5VB)=!""/ S   =$+4REH / !='"T#E  $3 !=^L-"G"]*5L$W!NU$P /
MB@4!)>P!E.,%!E  S-4" R  1WB]%7 !#M $:#"5, S!--P!=0D  2$" ?"[
MM2M/$&  &B$! /![U*83Q&B:^B@KC&$!CH(">S$9JD8+2I"ICD$'#S!KM1 "
M 3 4FVL+1T9!;U D[SF00*  0V$&#9 ## =1)8 !3J "#5 -)( !49#'9S%]
MC!$"<GR(Y=D P7H+L4D+[,HTO' ""&8N[_YH"U['<@:)/J=;NH.*R43)JH^1
M>@+,%,=+"[*+2>7K*$I0C!]0 -_G /#G4@WP '3D!0,0E[8@!PSP'KG[9P_@
MRK40!@10 7A2!QB@ 'G  P"P4T  O;0@77NY#P- $!Q@  2Q @"@!68P "/'
M&":@RWDT #7@!@0P 6O$S;J 4@[@B$60 !1@<0F0OP>J !:0 ()& +_'"^)K
MR1MP +2"NT_W*@#@S[7P!0E S$>RO F@"Q+P '[DR^RK *MUT E-=:%" !AQ
M HQ7AX=\2Q#  +Q9"/KT RW T <:QIE( BUP%DD  270H1?  >,@=B3P ]3B
M!BP0 HJA$ACI!/YD@4=>,!194 )8(BP<@ &=HA(8H"UZ( 0ET +5\ 50D 7R
MM!TBL /F4P0?$ 4AT&VUH 4;H #\2 N/QIL,\0$F9P8L^ 8'@$F^4 =J#0Q0
M10)@30L2A;A%H61T,-$"C0(E0"-O< (2T -YD(<[0 (P\J4DD IT!M4K0"UY
MD 1:0 (]L!TC,&>^%=A^0+;P*5@D *\JX )-  )3#%PG8 (PD@1HH -#T0,%
M%ZR[4@)#,0<H8(<B*MO=M@%%P ,B4*:^M0,&^C2;O$V^"MP8V,FY%F]:Z[^U
MX 8+D'@;F0"8Y0,#  (YD /C)D^JK (]H ,[P ?^-G![$ 4$D)A<D/Z+.U #
M99H$BS!J>1 !#+#=DQ=\ -!9()$'U1 )>ZO,7>(&"' !M3 "&%V^OR !MC8&
M+QP.YUT+=?  #."?U:#,_58MTNT'(  !'/  ^R !&G#A%R<"!I &1I  '9X&
M.IR8!)S/TTL+0B  (/ #.E #1Q($ _ !/L"+JQ4Y86  (H  0^ &!S "!B K
M$K  .; #.?"U.8X 09#6(W  "<T .S $)\  $D< **#=\"H!MYD%!X 121
M"M D/7I?Y+4!FG(!?!";&&(&.SL.'X "7V"W?I &7A4%$X#2;"X08Z #@J$!
M0N %B'BN<_9/.F 3+: "3'<"&V &A)Y'6?Z7KB%@!<Y):@F@ W1\"SJP?UKK
M0W$. 67*:4N5$XHA!=22%7[@ R;U!FB: V0GKX5F!7C@ "#J $60! ^@&"@
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M(5"3@%X:DH5LZ44% $B#&0"@G%"L %:6J !1I@$ 8G!O<@$Q80*ZM15(*0
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M::,!#< !:G0($E"4/C%6HR=E:/B<=[:&JJ !$Z"4KG5<?8@)$Z!Q<S !X\<
MB] $G:,!D5,!]C@06>!,(3 04D !4T<*W0ES)74*0( )/5 )'Q H7#  '?$!
MJZ&4'C$ F@$"N-$ 3U8!74("VV U=D$) /XA'3R3-@VP!R9X/SL0$BGC!W5
M 6:@/#LP$@@J#A3@.(+5ED- !PWP,:#A&<TQCCR %")@16, GE%! &ZPEE#%
M#7(31KCG!P[P!6Y0 "Z"(,@A >"R U # 1\@#2>0=R$@,230$5[@3$6V-R5
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MM450>Q$[L5AL:S[78Y80HZ3@!!" !$$P!$V0!RUP/U?X.X9S 1U! D2S(^(
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M00+#FS"*L#5FL+B,0*T'32)G5\!$( 1! ,N,X(4MD 4HL U"( )2X" AT(=
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M!/*:P"QV0((^.( :7OBD![A\:T.$6G\2( ,;(I D,O30#SW(GQ!<)OZ!.?
M ID6P08 58CHBI4H,\U!4O7 !PJXX=A^(,)?)F +\?) 9N.A@!G0^Z2@H:$$
M'U EH-CLAQ](0 (E. [?-H " 6MB Q*H *TV'"@2F!+>/IAWD7,@,_R ( AC
M^.1'@@#$*%0@ AJP'*E#0()O]L!BX[% 5S@!<3^(('DC-\0=4!QA/RR;W2+0
M0$C^X@=4VT,"M,G#-$/QR4#E .9^$$(#7L$%A_MA"'95P< ,871-2* .FHB
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M,D.1OG8!$0,!M-("%6 +*Q N<O@C=6B8S?[B';(1!R>P 1Q@!5:I%"O0#DG
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M@[&A!Q-@  - -&G0  U@ "*J&KNZ"V[0  Q0VS5X'J<M @3@  JP !P0!Q)
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M[8"&N^[>>:Z/T]GS#?#5F;W; R!V5CD #9  0D_9 L "PU3U5Z_9 ^!U%T
MB2WP#;  "3#DJJ $!H  43_7PNV( I#8&/Y/ !OP!A</ 0?PZ;,M  .#! 6@
M &7MWIL]]IZXWQ8  68=90]Q\91>ZXM- #!7B@:P #:_  1@'&A4  S@ ! @
MUS[OWD3! 0/0^7D>]6\P!  0[HHMW'>@ 0A Z!]_W>%N !B0!U^-\1DPW*CN
M+2H?T B>  (2!F2P PFP  Y.!BZ@]PG@ V: !$)O /G#\_*M 2L@ 0G0  >0
M/Q/@WFG: P%P  /@!DVP]@70#AH0\PKP VAP_=?= ,JS]CBO 2PP 91-Z*H
M"%X!!P$J<6X@" L,?DH%# L%&BT3" T'&WX^ PX(%4E*%@@,"A!T?JAO#0H+
M$$IH/ D-!1]Y7OX3"@<A9FYNJPP'$"L;!Z0,>7$+"P@85F,H!PT$47X:Q0H(
M"@XKJ'YIQLQ&11.R!$75!@P-269 L@,N?BT%JP<@*@WE+7XNG @Z9II 6&"
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MH((ZHM4ES1!^0,9!-A7XP0%;!R  P08YH':6:01D<=LE6808&20&G,#8+$(
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MH( +F*A)#"C!_A8A@"R4Z7_S*D*_%-  #_2/ 0'@1A)@.J^_>" !"[# Q$C
M$06 J@(<(<5B# #4;GS .27R%%&WQ #<=,1/)E%! /(A 0_\@@!&0(4&N,H
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M)V. =BO@7 FD) TG X (+"" TQ7@ .= A1 4<&*4&>  ^Q P $X6M/X[$@
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M04D0-4^KKZB0B,_6IA4@7RBALRO1M"!1<7L N8?; ..3!T-BN( C<FG;#4X
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M/_ &<8#E?F %#,"E T Z'^0'4@ ;>U4923  0# ^8U#E?D "^[ .T\P ;$,
M$&0$,HX*1<Q!() P15 !ACOIB.@ <94%#1 ;&'#!]%,C08 5)1!CD!-73L
M>Z %#:#2'J8"#C ':Y$[)8"J*K! ?F "F7"J-',F$X _:)  :1#E?A ''# ^
M&& 609 )1B#6I34O#G .6@#@>6  N*KE0S($@50!6: '!G F2< (4@#@ J8
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M GTA-9:2>$,@ 4"  H9A! Y@@7'0 #R" 7TQ&=ZV/GZA 188"6-  =+Z%!4
MJ1BP 2C@ @J@&1:  2Z@ D7S%X.  4'@ =:Q <H3 CGP!@RZ Q/P%$5  4*
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MT,_00 5W 5E@C1'3 U; VXM ;R00 N!M/ZJ@%RIP?WG0!->0*3X'QGGQ)E)
M0)B=!??9"3+( 7M$<^H'M>^W?3W!A:IM[.(2C.HBT7O !@T0944S#1ZP!W-@
M ; 1!QC T?\B#7@S!WG@ =* !(MBYP4!2PU ,$O8X[]#)SE;AAVZ,0Z0-&M3
MLM/1QK.F /VA!$U ;Z#C'(@]!_5D'(K0!+=, GV<33EP '2:,Y6D%T'  $QG
MOU-A 9HQ=Y*:!?XH=@!<L0(;T.>BT"??(2JG\<!PT11%L" ;D$T.H"03P .>
M_0%1CMA^@-E.X "\<]S:H &0T$9T\@"G @&? R#?D>/4L0D:4 @QV@61@#=
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MY@*#AA,[213+4J)0C2)^-*CX4,&CGQ+%O S#@*U0SDPN<)XX&H>$K1[?_')
MD^D-B1W;SK[Y0#4)!C=-*FRPX.3;!0R;_:#A8.&$"JZ%QG#X5-OANTGO"IG
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M[  (70<G&2:08S?TP >1F(,*+""%X&:A",7-1!-R4)DTF,$,["@$%QK0H?0
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M?Q,0>0LP!QXH!"KP/*\2B@:Z'V*6! -  ()8'R= "#S" XWG JG <X50 BR
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M\^<&)0 $.A %&U2= #$!$P "G/<&'  !&K!N/$ !_7E(;.&K[?"S'T ! N0
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M B9@ :-F/MFDP>%C/I7Q!@ZP!SD0%=@:K2)P A.0#BH0%3N!MCST +DB A"
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M!#SC %Q@VSWD /4B4\NC 3M!Q6FD%$!@ !520$*0KUX5'US\#UF  2"R!Q3
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MB<5/I=JU;'VUQ&7$ 8D0#I1,BC)A6Q]9>"",B;9'0P4ST;SDK2:AJ9]$620
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M#A]( (0?:#3J1Q$8:$!"(Q9X*\$/A#21@_X+%6SPEQ*;>N :!QMPT!0)GYY
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M@QL8X 0],( P)7 7 \@PAP;D;@@.\,,8"# $B5& $%&00&LP$ 1!3" *;@A
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M $HMEPB)H%T*ED5[ &)H<!@W9P(74@1KX@.U(H!9A!99L $AL ="X $$Q <
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M D,@ 7VV<B@0! ^@'!J0/YPY4B90.'UF2[KD 42B(<\D"*B970Q@"3^07BI
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MAXY;7@:4%&A@;BKP;WDP!"XP!FP017G@I))UL3Q;9IMC4HKQ!3E0!'60!&-
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M0: Q?H $4V0&%<!:<JD"$+!:"@#.MI8;$OX 1Y*WRP[0 \]""Y+^+*64!1,
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M E'8Q,&!!!O<](4$V$A!3 E*-IG1"9&Z,>D.;D@GP@D3[# ':"SXPH>?)U@
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M!@A"$B68U]Y<,*_T\&$.6;" "I)2A#Q$02!Y> 0&PG$!)Q#(9 7S P@2L18
M-<(,/U! ""V@A$$XQA%.>(,"NIB%G'2,&KYHA!=00)9!4& %;IA#!;PXDE]-
M8 YH:-K32+.S2EKRDIC,Y&H2";2? <$">?[8@P, DH>"I*$!:HD"@'JDHPF
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MA?0S.^ ]3P8!&-  $F !%# '(J C4D@:[+5<#2 "V) #"@!I%P !X9$')>
M'( !#X P&+!B! B -)*&HQ>,0&.!O>$%9OXG@\X@!-;8"2"@)!, 7;T1!RK
M"3\0&688C%K $SEU AB  ?L6-F&":R00!R;@ 1\0 B% %!\4 H*70?<%!0PP
M+_<3"]@P!&^V&ZMV@\[P!D=TBENXBAKYA5<7@,$8C)G0"=C !;!H32*9;+9X
MD@WF!\CF 4.">[P! 7NQ!Q( $I35+$]3 A40<4A@  _3 C?!!YH8@:.W**'
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M,2"0#X@B892QJDZ1*U$  >209CIQ GMP"1+C "(P!U:0 ''P!</$!QIP&49
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M $P0$^CQ ?GP "&E PQ@-!)  FFV$'$3 GN WSPP 46P F+U[H-@)6.0 #H
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M  1>A8&(:8"!P9A#'C=0@D%D80*(M$ /6M0*IM3O:4FH@ @LD @C<  %&X
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MJB^N=F: 1#3! 0'N&@FPYX -F2$!9VH(&@[@2C<P( QN@  EPM!:(R2 $BM
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M I2P$)C@S_%  <>-?&2U#A!( ALQ!BI0W^?214 @3#M  D#PHE&0!"&0!6Z
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MYRJE:!]DL' EZ&]%H"S:X$6?, )VN703 "Y!T&]FT "[00(Y, ;])8!#Q9J
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M\AS#^9@3![/XHA3D?&@''ZJ'/FS"!.4J1!Z\0(>,#*$#\6DI&6:F&7$5XI9
M-$4<))H&E +#%/X0JFS>0 ;N(8$"&WE#%_,@&S,@<0]C8(YV!NH'[NUAJ<#@
MZD<^H(YLG$ =/P3&&)C*TJNF52,>%.M5SUDY^ "4-'W)S0W9"@PA+*!+:3!
MSFBVT6Y41 \@!08:F&K.HFXB#_?T2!PP"O[1+NYQ7=A,[1TIJ)$XG'8]18
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M\Z$<LB$6)< !%&F1K^4I1N8'U?94.J"!/_ #13 !#V$!&Z #EQ);1= #0Y
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M8(<"Q0PD*0(+231>0'3!T80_8'(ND!<, Q[P 9CKH05!8"41"Z)*(_Z)7G
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MC)4'4C '<]!$4T4:2( $S('/&8$&<Z %E/*41H $GI7.Z1P%0Y C)?W/@\&
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MHRG<3:"6%7'%)_!#4; '/^  -2 (22#&#I[I3&\@FR[CG7Z8#< S.<  @N
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MH7,DX,4<*"20A^"=\("-#A6@848#1B@675Q95+ZK)T488$0>*C3$>S9V"6&
M$V8XP(D8#("8U \BO>.VF0[84\%%&M T+="WTJ$" G.$U D0[;" P1M:--"D
M X\PP$D8#1#G@CUX@0%U@ (#QG \NHRO$Q-HRO*DL<!=F8$!49B#/U)# 3.X
M 0/F\4,:"*"".21! 6D@3@_V( 1P)*L3(8!<G^:@!71Q0U$,V,,<&#"/$V!
M:5C2PJ2Z!L0@"G&(JAB;$8^(Q-Z8315W(PD&BB 9%* &8QK0P-6L ?ZZ>SQC
M#B?80.*4L*,=;& ?G= !(0I!"&KX029^4(++\C "#^P@"B%XPPDBLH*3!.@-
M)/  #Z+P@3W\0!VI8484O B$%H"G$RS8AAGBQ(-J\$ =1.  ":+0@B)883Y.
M$)WW%N<'-CPC#GV<8QU;P!B9  $A& A!3SJY$P]\H A%4($;+L.&.$5!=$Z
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MV,,)& B0"I"0! P\KRR2*4$52;#:+&! !!U'Y@FZ>(^G6X ?G4#""4P@$H8
MW4PJD, &5A"7(L3)#SY@F0?&\(8/Z, !;G"#X/E1A F8]V*=N/D$H+@##'!
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M)'"S*#153B%+$T$P%EK@ $( !/G975B[.Q7 FR&[!R' 'V9@%;W))>CP"!'
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M#G!&[X &C1D'=4("+PD^*! GBXPQ\D:[ G*FA' !TB!'5'$2PP:G1N !<W
MR.8%3;FPINL.*@@$#6$"LSN_?,,]'&L@;O!0ZIH&P>N,IU8<*O"6(.!_), !
M*BB!Q"P_P)8#<T " 1(&"2H"EQ$$#>$)^.H'%]$)6<!0$, $]/F:2>$&FI&^
M#R@"3=%/\#&T;X  C+&CUI !G2 RUN 5 =V__UF3SR !Y]2,!VRM)S,6S9BF
M$"S!$ZU6KH !#% !$U !#: %>Y,5*J 3@+P>"UAJN\=S2\( IL8 ZK #"5 $
M:I'. 7"I0P !/ZD!(M:-%B "#[ !G) ''_[8 A @&AS '61 JFM($-S!E%D1
M&)P( IKL!SV0 '9Q A7@ A,0)W2@ 1W0 K?Y"0[P)4/@%60T! XPQNW E,QX
MH@P0!T;  ,D" 4WQT]4<M^X0HWO2 FJT)DXP &$ ; U#+Q."#6,P 7^GJ&OT
MO#E0O=,BHGZ !&;M 1B0%2-R#<PG <IBCW%@ 4BG 42"!HW0>)OX" W@&OH)
M?>D5.1C0 B"P /H%CPW #!O0 2X  1Z'#F?$!_G4U09!9'8XQAO $350 3E0
M <]0D#D ?>!@! @ #RX NA4P%9X08-EP1GL*EPL0!9)) BM"+-:])%[1E1S@
M 8HM 9IQ @J0!?Y*T! 24P+MD0\5YHE[<)+#JU+%JD8G@\6>P 8,@!;TZ@</
MX 59\ #('0)Q:)P$X->ZAM7T/08FM[<88 AQX@;07:>N10&$Q*#A#-51( &0
MAP&<  (80-OP\'?<=  Y P)I" $_)'SDG1 %]Y-GX1D>L (=\#^0J3CI-KP=
M$0&0EUYS4&))$PE[XP)KR*B["AL4K>2[<6.N8 9:T-%<@!5H !Y[8"9D  1-
M0%-9\ /,X@5#X :/E@5FL <)K@=>T%58KN6A0'Q X-IU" 139 8 X6,UT1-S
M+B=*,F9IX=-1@!K)%1%9$(->&:ED-@8!,FUX?@]!8&_.YA!3Y-=Q$/[F/\"!
MG; (0- 9:*!H<V $%!IK7[!'X#%M;P W<T!+FE4'Q<0C7S 'W74/62YB<7!;
M6O #^E4'0V!,/N(&X+OG8= _ 3&P-.4$0/ &9:!D7^;G$(KIH/!LGM $RYX8
M4^0&P>X)_*=?8R $VQ %G) % V'MH&!G/.(:8P!DF>IFG#X$.=/L<] 9["X9
M2I $>M 2>> $Q08W>6 $0H TG><0:/$&1D 1=H8:@=8))<!1GI#@;@ >0D8&
MV:X5]4?.WQ:;?J %FCY%43"_F<:>I\DCCH/O0>!2;A $2-!5PQX1_)XT*Q4%
M0-!;>] $29 ':R,G2# $K2X3O$@$(),7</X3!TX0\^#Q!D*0! &B!V. +0EN
M!N"K%9&F7JRPY$\O#&4S65-?6#!-]79%!AX  0_:"GF  @P@FE?_4U!/]K[0
M5Q2<*1[&"FI/1&PO"F[_5GGP)6)/5YQ>;1>,"DGPYBA%]V95]G^O"V'8]X/?
M-7!/^(>/^);^4H#/^&23^(_O59 O^9,_5HUO^9B%]CT%:M!)^;/16Y.5!\S6
M^:,/69=O^9D?"GI0 ES_]J3 5&.@V@=1F]LF"G'PX4.@@J?0 F&/BJ%  F\@
M=:T0OI]@^+!@!E,Q!!QE9$R5!U'@=I=*"FOB ;S?";54"DT .2I@VZV/"BI@
M&&E@)B:P#:+?$?ZOE/O$/PI1P'43X )1]55L]/Z@$%5]8 I H!D.-B(\ /TB
M=@*?GVL= 0@J?H-^?(2%B(2&@W$D<X=H'GY9@BU ?F%>AYN<G80G8W$>CWY[
MAR)9@Z:+BIZNK["QLK.TM:YPN+FZN[R]OK_ P<+#Q,7&Q\AP;J2U>PUCMIXD
M)GYY08\/4; KU%E-@ZR<>GX;/[!\SW-!S7XB+='PG6,-?EY*YWYH#7%^29JR
M3BQT\I+$TS@@&OK]BW<H22HC%08]2-5I0D$@&!+!0G* "!LO$D0P'-E/DBQ3
M(EAXDJ#M59&,M@RYV7<HSB4D$9MH4T&"I"D)3OP$"4>H"!J22),J7?Y**)G3
MIU"C2IV:C!FM/!6T[%!AAE"2$S_RU-/BI(010I1:'/5B082627N:0%!!Q@^2
M$SSX'8*@S0PT)V1:J#A:#<B)(:8^K$LB-H\24W-TJ/!28<R>5%G&!#E!T4\1
M$DZR=!T4)H,';7-VH"@RR$M0/TX6#FJ"M\Z@R).C\!E#T0N7045.['@T9H(?
M-YJ*  DRA*(1%#OH^.$!84<<,H2=H,CA9A#@'%Q+04@5#ODD+T-,M!PD1)*7
MH]]1C+:V^M";>_4H.G&#/<^)"47D@8$3/(1'B!,2F.!&$2%D08(0A(RA0@NC
M#:)' ZP-@H8&;_@1AVKXF9%%%"9X,8<++OX\DID1)7PS2%K0T!&%A"W@$4=!
M@T2!1A92^-'$=FELXH8++7CQS0DYY CD(!A$$42)7J&@0X=&;' (%&/DD(,>
M9;WF1Q3;L>$'&Y6UX$*'>_281$)CL.'&!ALX<>,BF1$2!1D\H+"0%"JX0-B
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M!&%9L,$0*#C 3!$0?$!&$@KD8(0#'$<A01%"3 #-BPR0PLH;$["@A 7O%&&
M#CHX$$(0TOIA0@,Y!-' )4DTX$01$LSAQ@$D5(FL%=4T0)$2%63A0M&$O '!
M"D5L,.X)[_ P@1$Y0' 4!A?\L ,#FJR @18M6&E$0H10@$$1'%2PPOX///OA
MP^FINQ%' Q\,<4+4;B303T;NO&$!NQ=JLP=?A%A000\[!/^#!*A#T%4%4>21
M0!Y>.-!#$ P4!,$W&+3@! ;FM."!%R!8&>G^_,.#Z?\ #*  <Z&76NC! 2X*
M00[F0!,_2, *0M"?#D0B 1>=X 3MT$$U) "-S/DA!2;Y@EC&$07.]6 $?H!
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M2N/^@?3&.,YQ+C1E"V)BU \K& PL!]&A'GAQ!STYZ"#JT!U.;K N'AR#(;3
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M!1#H!Y-1#TOCCWF@ GUX%F^@ @B! 07AC).@$C\ (6;@ 6.5!TFW"1N0 R&
M <>7!RO0AQDR&?Y[4 +287X8H(LJD I1T(<BT!UH$ (;D(?]L(]KV)=(\8:
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6;-S&;OS&<!S'<CS'=%S'=HS%@0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>comp_0012.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0012.gif
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M_/3S]/____;X^@
M
M
M
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M#RW FO[\D%B)QVHM/:HL"A0(TN,LE1@-X9&JDH\J"*GPH!6L\^<?4S#"7B#
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M@V0G<&XG<"B(6ZQ0@[A5 18@=XZ0 !% A#+X@AV8@ES(@E)H"D88A6\G"W0
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M8 ARL H,*ZH%0*H"0 :S< A8.0MR8  =,)^D@*BN< J%4/X(2(:KKND00.I
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MN@L,FH +#H$'7?!&]S5%P! *H?X #*+@ C%$%1^",<P*%9M8,[8!!A]  B^
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M0PX,*R#PHL[SO  ,'U ''6 +HO[ ^KK "Y8/OC21R$JZ&\">X;S0 &;P"[=
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M*."  !Z%$VS=CR<I9N3#)KUYYY=#_6WHI9^>]%96S_T7OI;GHN_.?G'@ B8
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MDRFR!>V2#"#" S 0A4NHHY;$@V#@@U @N)[X ]A828:X! 3R@_JX$5L( R^
MFJS$2@#"A3IP(6?!!7<DB3[8 3NP/9]X06NLE!RD%VUT-\RCR](YA7"22TU
M@0<(LYG!O3*S.,O  RB12Y_0A1V00X]$DU;2G[=4G/W"O\2<F6:RS&O,R]*)
MK+BAK,:B06G*E[;A09+(MR1+"OY7HB):&84O0"DJI+A_VKV,L:]7Z@DKNLW<
MK"'=O!9:"88S0,C@2+4YT<2!49S:/*1P24[DD,R>B,O,))'-Y#QP#$UZD\[2
M9 @?A$[4#"'=PYWMI!G,L+J=# WP/)KG-$_CP,O4V0Z[9$_0(:/.#",QTCSI
M7)MQ9+?FM)3NI)3"3,]6.@[]V4DY^<^90<\")0T9'$WI9%!N#,?U!!7LX,O4
M="4VL=!IP= *S5")N5"7Z5 .!5$/S5!6&5'=W(P.';/<(TXSBP0(+-'<)-$-
MY5#?5,T//5$83<X8#=$;?5$4W=#%X0%MT<\ (@@?_5$-/5(9_= E3=(8U5$C
MW=$=%?Z7&F6(!T+0Z)PWS/L<H'$C!B4R;YS/+-T4[ 2&T[S2=^%/2)&:,Q68
MX3PJ F73=SG0.'V*,*W.GUE0\W#/NO12[K@>H* "(<@"+"#40C740T741%54
M0N6"14741G542(U41>6"07542K742V74+7 "(5!12%F**\A437W44:U41<T"
M2;W45"55+&!54GU50U752YW50JU5+M@"*PC2JR."(=""4UU48&744=746F74
M5HW553761$U61VW68!W4+2 ")Z!3]6S0/K4@SME33@F**_B!;P77<!77<277
M<C77<T77=%77=677<PT"(NC'?_H!(&C7>K77>\77?*U7>O[524OIA2((@B#0
MUX$EV((U6'.5@FHM#GG#4^H,,FW%1H?=&8A](V+IA5WHA8S5V(W56(S-6(_M
M!5W@V(\=V9(E69,=69#=6)'MV(M%V9=5V9/-6)9UV91%V7@]HIB5V8W569TM
M69^E69XMV:!MV9$EVIW5V*,56H[UV9?]V"'MC)J]V:FU6:9U6I@=VI_-VJKE
M6*4%6JHE684-CFVZ( ?%5L8Z%;%5V[5EV[9U6\LX6_J,V[EECK>UV[O%V[Q-
MS^<Q6[JEV_O4V\ 5W,$EW,KQV\-%W/,HW,5EW,9U7$NA#FCJE.H('56PE\F=
M7.98&S5:F\WEW,T%W>?(7%.@6/[2O5SX)-WE.-W47=W-[93.E=S55=W9C=S4
M-=W:K=W7-97'Y=W>]=W?#0I3* 7A)=Y2,-[B1=[A55[E+5[F7=[E<-[D%=[H
M9=[F)=[I15[LI5[JE=[C[=[JW5[G?5[C)5_RG=[C15_NW5Y3@),B=1/EDI4I
M=5'X==\B31?ZG97WO=\9U5]Q@=_W5:X ]E_[M5 !=E$(#. ;%6#<G-\!3N '
M)N (!F $5F#[I> ";N #EN -CM\,QM\'MB('_N ,KM_^_: )7N#YI6 2SM\+
M/N$21F #QF #AN$![F 9GE$/SF$<GF$7QDT4CF$5UE\6=N#5#.+_?>$63F$(
MGE(:5OYB'EU@-T&"*:;B*K;B*\;B+-;B+>9B+4Z"+@;C, [C+YYB,C;C)$#C
M-$:"-%;C,D;C+"9C*A8#8OG-+P@#, B#/%Y$/+[C1=3C/;;C/OYC/N;C029D
M/Q;D/.[C0SYD/7;D/[YC1<;C25;D2!;D249D2B[D/:[D2MYC0G[D2Z9D3XYD
M1(;D2PYE3);D4T9E5!YE3BYE3V9D1R[D1(;E43[E6[;D5(9D3 ;E6MYD5O;C
M6H[E5;;E5][E76[D7NYD7+;D85YD6B;E1[[E3$[F3+9F8)[E8L[E;)[F5EYE
M8.[F9[YF8_YD<);F879F;G[F1O[E;V9D52;F/#:#Q+7GN?Y-6^5,3?KE42%>
MS@0V8@S%7R5U4B7%T8'.X1 -8:.27X!.XA_E9PU>J(:6:']^X8>^T(S6X(%V
M:(<6T8Z6:-_4:!M=4HX6T=L<:8,6Z(T.Z8,&T936:(Q>:9F^Z Y^:"JM4)/6
M49M68<](:9S>X97>:0L^X(*XYZ/>',X#WJ5FZJ867*2&ZLTD4Z>FZJJVZKV-
MZJQ6ZKWI#*B]ZJ\&Z["&6^@H!55P!5?8UL--Z^'%E%48'5;8S.:8:K&FZ[JV
M:[*)#E>8A#F8@T9P!?!8!;3>F560A;[E#E60A570TT)H!%4@;.@M!+:>(%(!
MI^!XA3K( S0,A4_8!$W0!)3B!?X^J .)0LZC&"8VJ2^D>$><M!1<V"R2>(74
MKA11\.J[MFW?A0Y6@ (%$  !2  E<,]5( ,5< 1[Z3SA5@%$X!S)=@[FUA2V
M7H5",($Y4.Q4D(Y*@-Y5, 0  (%9&(/DG@4R   HD 7G%MZTKL]\'HT<8( 0
MX ".L+4%H( ,R( +" &9P ,'*) '\)*@T"KYN80-"(&502 PX)H7D(E@D $.
M:#U-D(JGD($&$!."48T1^*#RJTSF] F28^C;]O"K?@Y7&(, J( W< ,,"  H
M0&NS=FO%5MU2F(44" !$^.L5%^Q56 56J(X<-P57P/'EL'$89X$9=P7)]O'
M7@X<E_X%5C@%N#8%5G %N/YKYI %4WAL*\]QQ'8# !B#6<!RTG5K56 %6?AK
M'2^%&FB#68@! $@$63"$&# $'-=Q5G#QOS9K]!Y3X"B#!2B@.R" 7Y$R"]:$
M A"38"@0U?2#$$@ ^;F!K<*$ZWJ+!QB%7PB!!4&#O]" TR@!"OP)7)J ENJ)
M7\ E9/*)L3&*08H-"W<*$EB(8'H3:2&)49>548=U#B>(>_SP7+=JZ*B  CB$
M69 %1$B !U %)0 !*(  "I"#55!>5R #!6  ")@#5Y@!!W  %6AL$YB!)/
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MN!% $KX@4H )<P 0HBD.5' *!0<<(HLL<@2@AB]J",#&+/XZ"(#(AT@$ T4
M;D"D@B\U#)"(+V,$B80 4!02 P!NB ' "6+H01)(IYBTI4E:FH+*8RNQA08
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M*0J8P"$;K)R"00.35!#!*:7(TH8 8LQ"1I"^7)0(AV3,HB0<C0P0X,G]C0%
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M+PA@K (),$4,FC8+)43I0P&"@P!B@(@ J$ 6AHC(*B(0@5*80A9L"  2GA8
M)9C" P*KVM4$D#4 S8(% Y"#$X/4$#>(2 R-($,-5-8 "*@L;F[<$DJ(DRZ5
MX&!VP+C$ $:!BP;XYE:(*<"T(/,[OK$D K^8S6,TH*L/$/X.&'QP %O8(@,[
M!.-4GQ@D,/"@&,<\0%,7T)2S.H"#E!CF)X$*A@1*)0&VU X870@,N+KPB@(H
MY1(2 -Y*2O""E*R! Z(P0"T5 P;1E.X.E]AD,.Y /U[L0"FX4, G'D"67T0
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MX$<4.& '81C43VY06P7XX0P,.(,7JCE9#J1A Y)-R0@R$(<7= X%(:B##1Q
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M.$W 9Z'!L=A!<.252L LM69IKMI=E\2NELEN$I[F[(KF[>8NL9H$+_H1'PP
M L1B2MC" OB?FB4 3)#NX++*%[1 ,#A ^+V !A"&9,2$#+ &+N@"<*8$'@!
MXMS" Y1 WFJ #1Q3X:0$$\@KO>I6)5F3**A/86Q6"PP6_>#" IQ22FC"+Z1O
MZ)  &KS"[%C6+T  64I6!GR6^:[/&L2A*$# FS( #*  #*@%&C@ 3[C  \0G
M8Z2$!O[L3>KP @2(KPMLP'960+-8K.C4 5*,"QK$@06C  9_@AW8*UND@0.D
M9RTQCIU^)01\UMBRQ;6V!EF\P!^@0!J$ 2Q]*0VX4F <2PN05YAX[5E:GSN>
MEDI<0%#@0A\$ PSXP0JDP0:S12:H"EO40>?8P!*O!!ZL  Q @*ZT@!>D1 N
M@6L<R^36:TIT 6O8P@TH[*DH;C1"AJ[P"2_@0A^70%+\Q0V3U[5<\ /L#:J$
MJP@0$_A-<+E0P-YHP@O P 9TH0L8Q1QV(4-ZX>L^F^ZZ41/Z*A/N[N0YGRK/
M;M4)!Q\H*P<;A4J0:$I0@)Q\084V+S TP"7@@BW<@D(JU_Y*7*-P4*BE.$ P
M#_,O8()-IL0?_,+M%">]TK"V%"<8N$!)=L QBH(PKX0&-))C), ?X#%<V %2
ML,4+B,ODX$(:2!9DWI%B4"PPQ('CBD(%!,,F@.PPP\25!L,K"'/]G8$\<VWJ
M!(-G\<(P*\6=VD$<BD =@.]C7!?J"C0N^$8:=*'D_ (_KT#GQ 0)@#*>0L4$
M("32.LL?N$ P:(XM4$"8T #A7*FSC XA2?$E.$!KHFN@F1;^*H+S3@ NW ),
MGZ4#T$\8#./<.LOTB,8-D-<3RS$8F)8=VR0:</0.$(8#T+$MN.DK0 "CXJDM
M1U-:?($P'Y9'XP(F7, .\ %,Z_Z1+=!/,*BB*)B!;*)!-N> 44P )H1" N1!
M,/2!;L' .%E.NL9A*</N*>OBL-XBW 0K*R^V=N!<[R+')11 &+Q"JA6 13[
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M,P4-W<,*SXFM;]Y#2# Z ($S% \A:X# !I+'D6 XX!.'L?Z% :JXD4\P !?
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MNQP&!Y#Q"Z=UP$!DP#P-=$$4+8!!8UKP@#3TP0%+) $*;N&%#R@6 DY=P!]
M,8&W,N #?_ " Y*G 1EH8@47 (8=*'")/DP C"CXP"5V4 #-_L6,FO@# \HJ
M:UK;V@X/8.P#JEH"!KQ $;:(@!TVL8$E-IL/>5@ 04M0@EN$80/ 2$,!6I"&
M8%# !I=HP0&2# Q1/, ,F+@ #8!!@PU@X@QP!H8#.O"'+RP %Y=X@ RJ6 $O
MX*(%CA6!D0'NAR\D !AUH  P6L  /. A 3N%P08N888!H $8;P7NR0''QP-
M( (&"( 2"A& &LC"#0%(@B,.X/Z 0DQ"Q0-(Q"P\P%]?K/@0;1B !QK!BA0,
M0 ZF8, "3#$'F:N"#)1D00 ,T8;ISD(' =##B=W@BS:8H!$@2( A5.$! DQB
M8(<X@ 9D$5X= /T DP"! 0RQBCZ&<PRJ.(0!0#")HQ^"\*Q@@P#:,(LE", 0
M;AA !A"QBKNC'00(F 0&$B '0Q2"%&$CVRE.0;XT "  FC4(+AZ OI8"XQ<0
M &/KZ7B8+I3 BPY8J!G_@HD( (,$N/,RR1\@/%M4 !>X\-TO-*!9?__%%@MX
MQ2<>D#Q-E+H%@/:B'43! %O\90)WL,6322WO"731L,"(P%8G$ H\V#H8MDB
M^WA_@_Z!Y.'BFD@>'G;_B=WC0GB_Z, 2VT@P@F_]!N(7S. 7*("@M@<%<(&+
M!N("Y">J&,"-9,<.;&VE$' /YF\"@&$%F <87.#2@*$/&@ 8X(BN=DH3_H(/
MSJ@.=J_B+A 7%B#>7D &!D(4UL 6&L"D;(!Y(H"PW P8,F"G?N&?NJ #,.X+
M3)"P*N 3\  )JV\@6D )06H@1& -1L$!46X+U^8D](X 3D %4H ,9@$*"J "
M&J "%F"9!B %9L$47"$&!J 03L$!)L 46.$- H -V@  U$ ]5(  $($5'  #
M9D$/M@X*$J<"YK - D -9H$, F .8H  $L$49,$73@$"&/X  BP #=UI%;3+
M#=4@ -Q@%D#@  P! Q:@ AS %0_!$53  C#  #Q %J!@ 0*@ %1@%4HQ\92
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M[S NH+* X0.6Z'XN(2'_(@V0, A-T(TN0 '-@ -@@ 2LK 24, +N: *<D .
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M !J #4!@ #9/ !; ,@.@Z   "EQA%>#@\6J@6C-@ *"@!@( 7?/&)R8B% I
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M@0-:L@5"0/T"%A@:X(X<P"Q1X!?Z@ % 01,Z8/=(P,@F<" :X!-PC?>,C/<
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M8 7Y"@V[?@*,T_'")U$)51Z0]A *N!(H)?#"0S8"C&4AZQ.;H !=E%.'!JP
M#8:B@";N\"V'. L0 ,,:3=*@'/YI@D$1@ .*+2+ R-. 88\/T1HP;/  &.0!
M7)?X0S4_$+0O>.$,C%G1!6R@HV!\X (WT!%0[(#+,+3@2'!29#!<!0Q%&+-#
M9T !+EQ@@SW@@4XVD \-N@"(!@#Q# ;X@Q<"&<P-G,$+73" GH"Q'CV-@@%>
MF"<%8% F7'! 7@(-BT]$T3+1E&$'#.B#XUASBP?PPGP/29Y1CXH\"AD/J::X
MW5*;FM2C/HAYSFL>&EK0)0Y= &U;"4$=NN<03(1%!AJ(PVA$D:2PIN\!)S7*
MS&20 ;-J *V9;,@$3FH&%&BB 7RP QX $8PP:-!?W\J!2&RXAE$\K"$1@$H:
MKM6!._[<P@$VN$0&?907']DAKS3YQ7K.D <[_$&*AP27Z[AY)-#:P0^C"$4$
M*HN&R7PB.:QRX$,^9PL(&.4+&OA#'?)P"3C=(@THB")0TD"J3? 02R- %F :
M\@!8QG($N)@ +D;13=S4@0:?< $3F/4 ,^2A#J-EERAN()^9Q?$A*/"E#';V
MB3NZP)=^.@,@%II J'R@BT29P"BE%(8]U,$/H@ F$RB !E#(15-):8$?ZL '
MI]45!IR\;;]&,!.'#!(H%Z#O0V!0&0H0,@+^W @N*' L7CP %Q.ER07623TC
M/D21P2P+#,+PA;+8[9<A9-AW  H,H[@ #'_0P$/L #!@H/Y!+0YYP1<48>2M
MC")R'_8".9'3L3UY80(9\<D?,O 0/,!S 7ZU R"Z% P^Y( !&5;S N!2MX"N
MH$RLV>%!675?#X6B VG Z U@P! :6+0+?H# @_^*$OG @ 2^Y8,FC()2]FBD
M 67^@RW6DPL-[( / X9*#KI@&\M$P R@$,$Z;02,H/*B?46%T%.)Y]0(/?75
M&/H=K8GG:ED?CT)5[;6'=K4N8'S@JTI"83 2,$I1), 6\P-&)L+" 7R5H Q@
M5< H1['L9C^D 9F--C : )X<X.(,^<&26A31 $:^8@&C ,4=&R(!&.&2 WQ8
MPT)ED!\19'8$:6 ;G.(;#!',Q/Y>_7)(:8%Q@1.&Y0,#3\,?D/L0&V3D ]/)
M'"Y0T,6@6?H!1L&$4%&Z,QAP]0*.<L@F&  G.[&W+#; 91J4),W01. 6H.@F
ML28PHL'\) 2 ^A6[-O&)! #"%BBXXWH7!8P7V+$U]$7!3+B-BS 4H"41V&6^
M8$D"0-E!LAR9"$HA>0&*E &7F_!","X99 <,'%S].@/@,FH4A^S!2@\!Q  @
MLV$_#:LF2'M :"Y1 %SP(0$"^<0"+ITJY$0Y#3"#05G^P $1R-M'4 F&Q#8P
M]#P%F0&;X$.4K>D0MNF)%^#V0Y2EEC?H_J%O#R&!"W#Q 4;*#N&8*'*8E3.!
M=5IF$_Y^$ F:0O 'WYN!50ZQ _A*T +'"<2@-@/&'\ 7"NJ=Y@* _<!<SRD?
M&^2 ]*]HR V"D8.]\^HAH3!-I(E#@7XAYTJAH\'>^Y 73<CJ6!$H^0-\BNKU
M\"(3/0(&4W6]/+BC/!)B5+=6:P3X?__W5*T@?;Y&/QY" 4U$$]O3/0\A5BAQ
M3S>0'D0%#!<H"MTQ HFQ"3V" _>$ QS 74H29!3P :C! 7"2!^FD ?E!0@%T
M+5U  3(0 9\"<XUE+Y!U![H0 2Z@+<G2 H4!$871!8P1 7 A"E[1$]-A<,V%
M<*=%*J,P ?AQ5[I"A.BD"6'P #;P$6O! "7P @[@!P;U$/Y=$ $Z6!9\\ "P
MH@$IDTNAT3ZN$0)&\0O[1 +111.7X'M=0 (B@$-U1P )80/@\PH70 (E, $)
M 3;.MP$C$ ;&M )-UQMU<# [Q'3-TANB !MFH &?X%K2YU\S=@$B@ (1( J<
MZ$,5]1KGE "AX1TP0#!U$(>KF&$1IP#KU (;  -LPB%HL  G\@%?,"QY=PL;
M0 *#T1)AH$PM8"-PB (O\  S00+R$60?T $N, )WY'BY% )'9F1@2 ,<D!^M
M,Q",00%E@62WMQ5HT(;M>$P<\DTEX (J@5(7P $PH &5T0(48 ,4T$7Z\F5A
M9F27$ $K\ $;P N\D %6476_</X!$KD'Q7$!P*@!,(5J=H90H_  'W!B0_$0
MC*<])511$3<L:)!.$W1.ZN(0,I"#$) IJ29ISA8!DZ0!GL4>O\ !(0$EM[5X
MKV4#)- 4$-!]ZW$+Z]$!N) \IQ \"7B 4MD@OF.  XB55-D@I8 *#NB53 -I
MWO0+P=!]#4$<UT,KG] 1*E.6O] '?A!W97D]O_ +H$"6]&,_E^ 'U&,+>' L
M*(5$048<P! M)[66,^80OT <MV HN. '"1$*N""9#\&8#Q$MZQ-D?>!36\$+
MQ&$+&]26?+"9*-4'"0$* A$*>"!=H\ IN#"6@QE+=] 2E)D'?!"6#\% X9$'
M@+45BOZP!W2(4G2H"-+%E@_!"X$9#'Y@FP_1?9J@>ZRWE.&1,J&@4JF6,K;@
M62/R=;@@ _CB3=23G'T0=\2Q"7W "\&@(K23,E<SF*)P!Z,PF?2S">N)!X&Y
M%8('E\%04."IG-3S"7_0F9$A K]@![>R!LQ"/=BCF,%)F2FSH, P"G? F]CY
M2WAP*P_ZH$ Q"A;Z$!FJ,I_)!Z/4H7X "@^Z"7:@(DQ#)L3QH()W)2IS"7>B
M,HH@HUNA"Z.UH(/)&@]:/BC!51U:EO$II"GS"GB0HO'Y$%=3ED"QI"C%![Q9
M,"JS>H82'H-9,Z)REV89'@EQE5+9I;@F@,(SE4]I:U7I(/X7TI5?J:9KRJ95
MY3@IRJ8-V*;.TX!R.J=WRJ9H )QXZJ;-,PH4@ (RX'=W6@(=< ,3T!MF$$Y\
MRJA]>J=U<WH/D2N-2JF5:JE\F@=V>JF;^I5@"E5:":H!&*IAJI5?2JK*DZ:<
MJJHJ4U5VZ2&:2JFPNJJ.VJ:R.JN^%@R7P ?VV:::P >8B:NU*JR<^@MZ(JNV
M^JK)ZI6VBJRLZH!UVB'->JO'^JB,ZA"B.JH:<J;9BH"[5H!F:E2H(*VW2J[E
M:J[GBJ[IRB'CJJ[MZJ[O"J_QRJC;ZJF?:J]9Z:D9<I51V:U(9:K:2J^G:CRI
M>JGL:JX&2Z?E"JWPBK"<ND'IVOZP#"NO$TNQ%6NIW'JO& NJIKI4_WHA4V6Q
M(7NK=!BQ(DN9)6NR*:NR*\NR+;L5&@NSWHJM'ENO&1NJ^MI4EOH+.Q "'] X
MS,FK#P@4H1"6<@J>-T <U+J&LJ$R2"NT@8,Y>O(+3ML\"\LA:Z"->S*8O[ &
M87!2P+ )7[ ^P2!%S[H5?("$P583Q@H4H@ G?)!9:KLN+@-GT3JL>Y(79N!*
M=FJTZXJW#I@#>A*9?ZNI"&L+L FU?INXEDD")^&L59NP,U9GF_.TE=NAP.HA
M7RBW<@NM5FNWD*NLH+NXH*L+74"R+NM__)IK2D65L^:M_SHAL'NJK3NGT%H"
M(H )E_Z@ =?22PX8B<]J XC;:Y8''AUJ TT*N6N -+]PO'A:/Y6W)P'@2K8
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M8@^@BD3Q$O4G"@X &[>P5V&P$V2I "NP Q/ 2HKP0X,!#&G  )OR3>(=,L
M Q=@U;BP "V0B"T@ R-@3+KP&&<0 9L *C\D"BCG(R+P!1.0%WBP #20 PM0
M<DPC @X  Y(C$S.U%7O@ "ZP Q&P,\'0B#Y$$:'P4C@@OL0B$]K!- P@X1/@
M HM& 4;1!1I@!AM@&@ZA"6K'!!>0>'Q@Y#E0 <.R!E$&!OYTLKOVN^,JQR$<
M@((NP !$NV+!< & IB_Z8Q2VT #"&Z\*&-/Y:L$S'6O?>N>L2]/T2E5?J30
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M9X!+M,XA&A#7-H "9X<+/1]QZJ(!E&).*SW3+4W!A3_!G[KG,$NP7OD*"1
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M4+&#2];J5C!>3!+%#@6*VJ"H"-(SUR_ @+$%@FYS("Z"4.)X0!'"Z,M!ALF
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MTP%V[JH%=O!"SS[P)SY<X ,9>"!$?M$"#60 8\% 00X^0(&S!2,"5<F#0"\
M2F" X0(<"(%[7O&_8(B@21U@@D$1JH&K9=2BZ>'2 _X4$10<$B([B  %1M M
MIO3A,8C$)TN[\JGW7( 7$ EH!X!:!XPA<@5_0$%!/M"D$,S$#*?C0\]LD(8=
M8348G?Z[Q 4^421=0004&Q"!#<X@RA+H)1@PN( &$A617Z"@ RXPXB7\ ,8;
MH*$K9GA!5[G6 ::(X@-,,0,%.L !%>&"!!D@ 0T,<Q,8G T7Z('("*HBNC_\
M89-YV"1$;"$"HUI&/3#,@0AP<=?\8.(!7<!%!\C"!PILL LEL$65%#;8VG9
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M$5&X 3.8 !G0!!*8@,P1A1S0H0R0J3\0 1%  ?<H S. @0DP#".#"$Q8/XA
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M>=B+0[YUXI87?C;>@U\N^.26@VYPTD /IJ_11/^<[^E,R_YUM-.MMX6**:U
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MZO#0'?/[;VMHP)@98)951N "%YB !A14] E\X $EB/O1!P:#"VIO(E\(9.)
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M@ W,7B6A$@VX5@Z(P >(H2CL@!UDP"W@ @ID0 YTP6_@ @Q@H7-X 0-H@%G
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M1[%BS81! ?S!6'[5!O0C'R3 *_!"!&A&&;P4'C3 )X@"!]C>06@ F(&!U^W
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MR;[")6S !;G :I6 *'QMV-Z*U/;4%_R" NR**&A 7[*'W-+M?+Y %_R"$-E
MWFI"'AS +Y#D0:"!.T*4 Y2(&=@0!;1&Y4Y$!SQ43AG(4%P &'S")^S ]:FF
M XW3#8R WO+! 71$"SB G@RFQWG3K2!L^GU"&@A1%\22<0$#',KN :3<$IUJ
M*#'O%8V7T^1/:.7:J58@6HB"WFF<X%P@4\B>1;I ,#B #&!3#AQN:=!7581
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M9>-" Q0(!X1=8J[&8FS 5[2 A;V X@*N276!A?$":6@ 2R3R@B[(.C8V3ER
MC6A 90/#;#]'8^&!27! [HE"(-E">"XSA&X8&#%&&?+?*HW1'O_K)117 JC&
M*]3Q'Z1K&B1 LO[K+RAW$YG>Z-5:5$V@]#Z;/9-/PZP \/Y5A7*NV4O9@0.@
M@1DL@&:4'0&L !Z@ 'WMP"^# 01X'0<,!P/<@8(N&!C0EA?8T W,I0R(<0>0
MP!Z$A<,<U#>/TT3D(!]PN+$X0!H0N+-\  GP08RK:V'DP 3@P0UH+EB4 !^
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M\.)N[/X!#'A!=# (#"0)+U+*)KS$1$C(X96()MR\:XS8<HB(GE#&X5W2:\
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MW)+++KW\$LPPQ0RS2BD/M))*%3=#<"PLK8RQK4U<H"&''&AHX9-+XDAOJ%'
MR!&8-(+B4ZC;"F7IST/;6P^Y18_3LSFA^"#A$_1RU(4D8, 0CKO1O+"!!AID
ML"&GM?[4>X478/XXPZTZ1.C !N$B9531M%J2B*:";KE%4?T 92]'._JP+LDX
M"$(-.CP0JLZB4K_[!8P0/F BU;AR^Z5.8+ZHE$=:H=L6O#WV$.H66<M#C[11
M;NR4+=(^,0,8/E8J"LUZ4[07WWP]2VHV4'8P@X((S,CAEFC5NJ0!I"3B -[
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M#V@(+QY0J0UH]@-X 48)2-#283GD 1QYC0TVH($<[/<#.X@ /=/ @8* @03
MT$!*2_  . (B A%@&7=_P0"A30";FW@ $VZ@@5_<H@$?QB8P4,"!'2P&&!/@
M" PV@ 8-A $8H\KF)2:@X>-"X PE."L?(D""F;;T!BU(0'SJ"@8-E-$&#/C
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M'8_K,!A K=91'8-A!<J(-"Z@NG* QB:&9TJ#;!X"#%X !?2M,0H"#^9((C9
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M$W2! ?Y>"13<K? RP"<T8>IDH &\4Q][+@?^9%,+X@5HH" XP&.3:!CM)P(
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M)K;)8K(9.J%-!#14F[=[V[=_&[@% ZA+VR:&VTMD&[/%C_ZAE?NRFQN:G#M
M5&&T@YNZJ]NZKQN[LWL_/(.RU\1>UC2WH5M!*%J[R]N\SQN]TUN]#;K\3H1
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MV@-^!#/ #O0]4%$$>]( @V)<IK$!,"5DVL%#XY&PPT,=G.$HI& X@.2(9DR
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M%[0J+!)8B0:&!L<(B&(%AQK/>'+0GE#-YP'0"8/$P/ "33#@!C*@ 7Q"$8&
M*0)"5D'!M!Y0&YB)8@,D0)%61- UQ4B-:H(2A6YDV($1>*=K+^"2)B3%"Z2)
M(#,/X/Z0#&Z@PO'  #2_:$$'N@"#Q)AA;IKASW@F8(LS1" ':6&"+6X!@=T$
M(PP?:(#E'G(X#Z* (B5PR!<R8(,O4  \\RO@"DA&@@_@X)<.X=P7+D"#>?[B
M%O,+1@1T>8,UK(0C6YF;55HPJB9I0#9K6%L:^%.!%G#D!GBH&##LH$PX?6%
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M 45"H!T<,. /G]#++1C@@F"8TP^4&= .3I[R\?PA (7BPU#3L*"5S/P/EV#
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MB7#WL@,IH:INV0"?B*T%.AZ[)!.0$:8/,6,@4B[OIRMMN4$J\0L'0##<NA*
MXT%\$/YZ;^EZ),B7X^$"YD4N^@HG^:H6IQD!!F)SH+&8X^%F6S96P88' R Q
M8!FC1'IL$0N?,6JKS-9#&D RLS<>FV"F#Y$)$((+O64+O14*:4"8MV '?WA!
M>% 'O?4*N' ):^"FF^"%)2"I#MD :(5A9'@):2"28> "MU"JO>:QP2"2P# *
MN$!!#R$*:_ E1Q8,E^!!/DN&*W$+<?"'OW ??V 5N% '>4!:?Y &5OL0$[ G
M>-&T:0"UG] DN("H#^$':["HK[ &C-BTOX '7_().Z-2HL +=M HIOIMH"(*
M7PNU#]$',]NTO, 'MD(>YC%"*C&VK+4<KZ(2?L <8&(&)O[KIJ*PMBZQ2RA1
MN%_[A+: &VDP0J'0)/=!$GNP!B,T,.M*4W[!"W4@N!*V6K&2!D\8#(9K!V47
M5A+"4;KP"_@7"E;1A03Y$%][!U+FN[H O)J9!WP0"A,@98]1!W;PO/?A!UAS
M!_S8$LK+O+;@M+M!O=[J!;: !OB7MR>I$CB)"X5U9&AP"STYKFL0O!>S!KH0
M<:CY4KSP!W5PKQ>3!N&B-,RKB?>A"4A+$BU;.*+ &AI!:7$2 9\X3=P4$JL+
M" QDM\@I E^@ 1H&A2<+;&=9GQ$JL2D\L;Y:L;:ZGR^!E2X!!G5C V3#!$W#
M :-R"8)"2 _Q2X X 5W0 6H!E/Z$A#CT-P$VL .(QRD:<#_I5 8/0 ,KX #3
M,AZWL&@4A <7(&4DU044L#Z@(P,P@"U[,0$H,BH0\"76\PKKY13/!'PD<0$H
M0"EGL %A  &CT22 \ #SR!^"X7UOJ\0MP '8^T$?4 8^MA(/L FZ$ '3<@="
MK$,]9F/AM*XB( +L)A!N=@.9_#SE-0$PX (E\ "Z$ H/L (P0,</L0,7X,IQ
M,5X.]0"@$0P8D0.N @P3H,D; !4E4B:H20(B@ ,1(!LNP  B0(;!]'\C10$V
M4 *T 0Q[ "W%48;AY042$PH-P"$/8%XPX,PHP  :(3P#\0#W<0%4""ZZ[*XJ
M93-;9_X#$&!>P5 "'W ##S T?# !.T =-C7+W,( '_ *=Y B#6!!J!P,8' !
M'/>DL\0$,K IMM  E0,!E_(+':!#(E!B#S%+._#0?1H!*(!XN' !," #&N"F
M:T$!7I !#H$'#D #)$!/,! !YM4_+P #_H$]&5#2%V!!+@T#+2!W3N$ ,M "
M^@8,?C !.4 "?V8#2EP"#9 H!UL^&_ !-O !%$ A8-(!N,PP:R [U-(7'$ "
M$W"L=8(",D#.$2#5?O0'&N C#K "P3!@#Q%*^H0">Y,;.? BESD*"^ BA6('
M7',!NO5#"]J>4,3"+OS"%AN9++RD+>$'!(  4KU=#*;+B?[B!1;$PTPI*,GX
MPQ_B *P%+GT0,GAP;9<@1A]P*"*PKY"F %R9 -,RK@PP 11P 07@3P]R9)(B
M)ZV<&)KM>9+"'E,!5B/ ,#;3&EW# "E# ?[T"K/]$,!+$G[T"@30/1TP6W0]
M'FTR'L?DK_[# ;ZQ.V1( 9@0$0Y937"R;0^1!RW7 #7%:EVR/G6@ %:10KA
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M9G#N*L4I9; [X_$)DA)U*=8"=D4! 2;E4U:PK--<$8 )1H721^--),-6HY
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M'"B;VHP+@=BL)PD#K@@#G7  %%;AW:L(WTL,&B" D.B"", !&.B,X&P:IX
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M^,A=+6D-ZLN 3$#L @^& \>(Y=P)%F/Q8'#Q")")"1CE#5#N*=& 2TAQGE(
M[T8,8, !_;VX+B"=37@1/GA)$3 27+OI)X=R5H.UPV,RDMD!0""!6M$ *26!
M P@&O_D"N0D-#2BF#4@(#J O#H@+3;B=XB.).G" .DB#!> 1E &&,X"=5+*%
M 6@!/N!)A3@A?]H0[56(5UB '%"$$IA?C.B %O@#$BA8!Z#-5:;;Y*2;O[@#
M!JB#.( 7U#& #U@!%"#1Z+-S$:@5#D !/T"!^- .+[#NXE!'/$"!JCF>;T*#
MCO&" /Z8J@?D@XKS/3PP != [ 60"3YP@#B(@P88'Q$HCK.L"K\D3[Z8(H7@
M@'%)DP*JI1UP@"#I0E6/#^?+@3Z@ -(CKP< @SYX 0/(A#9]")G\ Q3( !'B
M P9(@SI8 #R8$;[XT159@# P]O6A]SK0]-*9ZXH+KEX*!458@#2P@X$/R3[H
M@@$8WA1LBQ$@@3\@(1'2&C#0$%]EC!O@ [TZ&CIIEY H@_B89#X@TXO8=H5(
M'#2X]VV"*JORKP5HQK/Q QE(@+9P@!7 A:LX SR@]\\( WAI%[0X2UP@71OH
M RZ:"0WP S-HC*LP SQP (83B07(&!0( 3]X@7B'$C@*!?[\5(@["!JJM_J$
MP,>581<#"(8]< B6:/0+:(T(N#C4BP 94$J2*(&%- ,(J(H'0('@(HSO_?O
M9\914@0O8 #"VLW+P(/[\0(\^  "" 8[>  _F(_J(;K4Z8(\J/Q@6(,$L .X
M_X,^"')B/2Q5N&DDZ\HH5[4(7C('%.6Z4ZA-P(-JNH$6&)^XJ3GW+B 6]'TJ
MJ8.)N(2I @0N=CI0?8PIT5Q<P(-+<($GE8O.-@/'N%P8PP$7 (/Q^H4PZ**
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M@(3)_A6E[%)%"E00L_@BP16' , )9)%0^UJ61.LU5YR,=($(B. #'$ !,$(
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M6X2 !!L(LB:@0!<\ "YLP@5L@ N(@$)LP@:$P 4PA@TL  4X10M\0 >T0)W
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M 7# '(2(+,Q  !P6!JB!*2@ !B#"# A (11" U@ &Y0"8&9 (1Q" )B:!2!
M"CPF",@"!A" &"S! $  K;7)Q82(5GU(*$0 !"P=,&P !91 @]'$!M3!*PS
M:)Q!!%A&"2P$!Q!% L38)R2 URV :>$!! ##!W@%";#$'TQ /@8G1)C!0@)#
M%Z09+SS +83" 'S!+01#!, '*/X00$Q,@$+<P@24AWI&Q&]^!9,!PQ]89P=<
M& DXP&/$ ;0!@Q>XP,0M %N 04!&'%>$(3!\)43,XD*$ ->=P0;4";TMQ ,$
M62@@)QYLP$)\039"1 M,@&JU (1=0$SP0AC>0@*4Q!X, +@Q ##$@0&PA0M
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MRAL-0",4/L0&U%L'F&$P9$ 8  ,#C(8=/,ES,MT?!,,"O!D?# !+ !Z)C.4
MS $W(8(<B $&#, AL$$ S, LJ$(%5( J^,(,#$ CU&P-D/Z!"0  &YC" ,3
M+'24+"1! &# #,"!++0!I9%!#02 "<Q"!4# -S4" ;# +!P" :2 *UB !213
M V" (Q1 "LR"*V0 :K[)FBQ?O[R(VHY):[K*&0   '!=G6B #/"!'=0!:'U
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M7$ H?$)\?BI0A$ >; (#K($9G,%Z&"]7F$$)+(!"/,1!Y_XR"GB%" 2D<[9
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ME"Y$;EJ\:MU\9I_?)01Z'@19_N9J1N!W=D% O6\;,'  ?)B!^"9N_OH<+G#
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MAP@-O("A</ G:!VB-D(@U90 !DI@90Z8 >8@$T8'FH!Q>/H@#4:-+2; L-$
M:!V97G$!T[0APU51HA@ .],!HQG*#BYE?+!IU )@:"A+Y@ ,%XH)-T*@P8@Q
MQX6K-OXP4N"S.N.'#U =VK@@\L(*8#FP4J !C,3"FUE1RH ![%/D-*-ACNY
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M"WPC&"X 9OS 3UX!!DC@!1[@:R  =2) (+I !,(##T)A H+!)DA@#S1A 5R
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M + #EH(A.J0%#-(!10 70K#,S" 0O]#VY L,(H@#9. 7,"$LF^X P ![=J
M.N8Z@L$,:- %[.T2%J!&/J K*X0.;4$$/",HO. ";.$5** K 6Y5+J $^N .
M7B !(/X' Y.B 0&! 3#A%V3 WJ+4?1Q@'X^K9AC@$GZ!MH#!,C B% P *-)
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MX@ &4_YXOB0*):Z8-CC21I:K;V,GV!)XLOIGB]V" CQ-B"G@ O$B#9A.D"A
MS,ZXM&[7+6C@39MKL[:8B0=X=5/X@:'*JAYW5H%*5L^W@^W(IZR7>A79D"%Y
MDGMWO&PA&'*Q.T)6B_46 =6I.1IX5:*'D#:#-C@&=DO@"77!O)QJ$]J094#I
M$SSRC^"G!89C3L:&-D(54<X@@@AY87;9;63(E+(#I/[H P=)</SH;#[P%A0H
MF4-9J0SE:W[9@C&"D8TR@[$9@QU)!E!8E<Q  V# 8WK9\U9E-4?@)?8@ BZ
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M\%]&<>SY$ 67\*%2HYJT ,9/$VA"[$\)+?1?2@25T)T,.MH"PP4,F'70LGR
M:@<'-M6A@0M=3"#4 [@ DV1]N)1P4H$7/%KF!I\T<*&@1ZT+S(CF1>"I4@T
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M8%B9I1@[B&TB#P##)61@ #_<0@'K$L4"Y+>) G S(QJ8 ![LL("WG8L/9UC
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M6^Q !I?01!@$?!:^V"(85A)!&='PO30DA1=>*$$7JHJ)%MC@$G50I"9V;(>
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M,H ""O V%V$#&Q \&8$6P2! "?Y43Q^@+DGR B[@ $SP(!4-##G0$2[0 5U
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M*CQ^!XH1:P01;ANP.CRQ8Q-P";=0MZ,00Z\ TA_"()B 0NO23U\Q)Y?PKG_
M<\"P RY 5!)16%GM%:,6$0330;*&"PI@'K>@ ;]P Z7C:'0#.*7CQ" M ]#4
MVP=A38JE/6435K&<">"A"&*#6J+S((_B)*_:( A!,1]P![R@ ()F )L "&(S
M 3N& E21IKSA 0:0  60 !Z0"*:;!"H0 010"(C Z$@@ ),@Z6HP"Z90 14
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ME,\^R.&3/S81Q69@7E"- \:H<L"6-$9H[Z@,_ #&# MO:R&4!C*ID6BD_'"
M"1N""_Z+A#".(B&-Z(S:Y#,P=@;F!AR.#6.4.BP,3RSR0!D%@M,^ 3L"36#E
MQ0P-0/E#$_9:P!*_X4C]!.U7+F!V<@U".1Z4L,-DT+3^(N %>.'-D,TH$M#@
M0U1@/+3923LL)=]\]#]A  Q1\) MC[C.N  40#())3!<\,$%U$+*!#"A%" U
MH$:7F)L=1&64) 'C# ]DSAGZ9!0*2&Y.S$F#'QH0!USD0#5?TAX,F "55\A/
M$7*;E0PTP =<?. 228-*!.3D@#J$T%%[\H.5NG:45]RA R?Z@Y60P@1%P654
M_+E4%WC! "^$XGQ+S-07-@@,4 ##!COX!0.Z$(H^<(@&;/XR"AX<L 9<=(%-
MM9%2)FS@*&#< @+5,HHM?A272^A*CCKJ  HN,8H+W"(8$7C%+1CPATLHXA.\
MR,1GPA0W#>""@,"PQ:RR=4E,XF05&AC (5QQBE*X@@P ( ,K/)"N68CA  40
M@RP088 *($(, :A!(P80@3=H0 !1\%< =."(5#C$ 1:0R!@   56M*1A\O(%
M%   ATD8@  8:  !QE * GB %'+P0"'<D  WR ($"&C$RHC2DYV8\V5 L<DZ
M36:*5F#26D:!P<ZJXKHNK  8#TA0,%; 'O*A#P:7,\!I8%25"?#G%P_  S!X
M\0 ^A$(!86M!!OK3@*(9Y1(9,/Y*'C+#T%TQX!,H<$X(SK!/V_C3%F6PD@T8
MX!Z+_@(^HW" !*.4!R8>I06J,<,%C'(&M(EO-A-HZ))T8R$(I-0%P2,?&8'Q
M!;N0X#XD.$.#>E=3_5%E EZH@P2.X@)+D6!YNXH337OWF18H"C1>.);:1)&;
M_!RE!%T A@NTL[HF96 XGW" VD:!@FH! WB>N6KA] F:+N B3EA4C@.!6( \
MQ%$!E[C% B8D43MR"!AIR,RH3H0'N_!5;;9 P2TVD*!?+"!X89+!43@PPK*X
MX!,_/$H$1<& X 5I%+35$Y4,51G2'(4")XQ @@3+)^ZA05<4L)L,^KE/I[PB
M 6 RV_XGF$  6\C =1=P5 0RT0<K.7!IR]&$ @Z#ED/M8"IW<(L,V%0X+P#B
MI<#(@:[VDZD<!&,!!PQ% H(1.D7,M[ZC<BH,KJ,!_DR 512X!!\<-+D#5&L4
M$WB%6<Q["0?=8G&[.@![_)  7?P";L#0P$FUV <2R_8+ _C$)>RB@>4Q5YXS
MUM9-5@$"!1QB%0XYQ20P0( *J$ !<IA%)QB@@)JX0@X.*$ !5$"*5<R@  =(
MP0+Z)0<($* -KG (!3!@L$9XH  14$$"]. &!*AA%F,H@!MF@8@:(($, Y@7
M'!Q   )T8!*F,$$!%K" *+33G>IT9TX$_9-#IU,HI\@6X?ZL=8,7B,4,:C7#
M5  Q 1)<X+U'0<$'2M"!#%1X!1QH 1@T$)90$,!.P&!6IE53UPB@8 6Y^<4'
M)C K&'PG @W-(PDHX"@4& 8_C''Q""Y  ZJ0@$4M$!4N-'"!%WR@#-&+"@5&
M0($#(D5O1['!!8P=/#0<-BDSPL0=7)>&G;FX+:T]RO>8FCX&X (&SCG.+2@P
M'5WQ8@,7 *L7@K&!$80(>#8H ^XB$ IJ]\>GN@A!!SH@ ET 8PT3*,$$PN("
MY[B@='E0P!=L08'3X($^2HE Q4U\% U\XN.G$<6]?S$"AXL@,'; ] 0,4[L.
M1: %(U#64>Q @8HS!N>[^H (0OXT@3_@(@*6ND/))U"Z.I2< IM>30F4_8&P
M;8("(LC 5/#@.*/X 7UX /H$3FH'QQUE V#Z _I:@#J*RX )MPZ!<3E@IQU<
MP-=V^L0%1*"!%A"N#A-H078L]8L;?* OFA!%W+MPZP]HX@\A.$H>9+.#LI\T
M>ATX3560C0=+;?$H-Z#K!SYP=$!X 8XW4 UH*QZ6&YS0]*5&^A<<-9WO $=6
M(V!5!VP#@ZVW0 -%.\KC46!Q2E[@ Z$(Y%%R<($6=$$$R&Y! QAT@1!LH 2=
MST$([E G3' H%!OXNUII?/ZDY(04>S[9*DYQB$FL8L^%6 ("0,!E4PCL$(CX
MI,$2T?X(5M@S4V %<,&)]7.(55 %^%N%3G"(1H 94V@$5W #!Q"#1C ! 2B$
M5=BQ_9,%53@%5T"$0F@$62@TE,D)0DLT$_P)<RJ%>$(_L3$3JK"98+"97\"$
M47B*#XB#JB$<\[B0P+@#74&*7\B$"D.*4%@.,PD&XD.*4;B$P"K"(_P%&K1!
M3% ;I-"$+%K"3]"%&KR0M,D$1[L0PA$%3:!!&4P*04H+J+!!QDN*8,@>I."%
M&K1!HY!!+B263F&07:G#I,@>/$2*3V"/\8#"HZ#"-CP*7(BX0"S$)CQ$2(S$
M_M@$PL$%3* C,PD%WA&<I+!$.B*<8%"Y73F-7Z@67*"L0OX,A:>8@$NPA=6"
M"DU01:J0P2]41$.<12+LE"6\0TV(N#6T0R#"!%J,Q=FXA;D)!EQ(H]-HJPO1
MA, 0I,Y#PZ.PA584FT=D0VRL0JH015R@0FT$!EVHQAG<QN7HQEH\Q$UX1C\D
MPZ, A0E)0TH2QPLIFC0<A2Q"QFGL%&)TJ!V(.%QH /:00>2!08($!D-3P5-(
M0(>0A1E   RH"8<H!55PA4-3!15$!9>Q,9MH)Y\XA5-HIQ1( )&!@ATS!550
M2!M#R15<299DR8XLR((D'V'#%A=8 %:!29S,29W<29Z$R3'L2: \BL:3PZ#$
M%@U0A*),2AKSCA9 /J5\2J@L2OXFN( 5F("QBLIK64&24<&61!E7( 5$""6<
M&)BN+$NS7$E4^,FH[,9+&@5+PDJXC$NYG,NUI,L^M,NH=,7 PDN^M$M<T(2W
MM,L5+!E"4S2S/(56*,RS9$$4;,S%/">>0(6^G$S*K$S+O$S,S$S-W$S.Q,O#
M-$'%?$R<4*?0#$T3Y$J7A)G.7$W6I#&UY,E.@4-L><W'@<IS;$W<S$W=S$V@
M2!G3[$K4++25^4T>0R?17,'@/)F7W,DQI,U&T\DX_(5?X 5>T$/GW$WLG*>B
MM(7KS$Z@[,Y$[,G;C,I?"$SO/$3PK,SC7$_(7+3C)$Z'"$[19#2<- I-B!*Q
MZ )%H?Y-F\$$R^"%"0"HIVA.; &$![B "9B "U"@.MC/&7-.4+R6",6%09G-
MV5!+1U-+ZZC-IY@@Q>N0$B@!++R#">G$,"!*:]&$$N  %]"17\ !#AB!5_2#
M$.  ,+ 9,^@ YV <"SV*%P":"Y7-:SD#0A0;(372(T6#$GU.#LU0[>0%, @,
M_A0NI#R#);46/+"0]!Q0V<R#RC%2)^W10Y%-^WP \QO3QXG0($732YK2\S,*
M$4"QGP3/+<U)]F1/TEPGY01-]I1/E<&)%\Q)#'L*6Y#%YSR#N B&,\S)8'B%
M7V@!$?@%M0F#+\7+4%B O7S*0LV6+@">/UB AMJ /:@#2_X)A0^ QR#)U*=X
M!08P U%H 4,) 1(8A3-8@"SZ P78@T_( .WH ZJ)'"TZ.6QYA08P3QHC*@XE
MR%W#RLHRUMGXA,"@ #M(5J.P R/:26N-RQRPI_.<C0N(+-PLSCN%P'$MU\?T
MTYM(-,4L"AC\!2;X !3HD4O0@#SP-/8 A(;:+%DUKE< *QF0U V CU\X UPX
M@U6S@\A*@P\@ <G9+!$@@6F]EF 1BS H 330 !L@Q>Z[G*3X@SI 5!@@/DHE
M =O8 1W!@VF- Q$0@6D-ABXH&EQ@*QEP !? PF  @TLH@0096=MX!3, /1+(
MHLGA !NH@VG]A2[X@!8@1/N<UOZ<'8$NJ$0&*-$U<(L+X 5;< L8B"Q0E($&
M: &U2=H26#6C" /TP04%H$8'6!_MT(""VPX%4 LVH0'HD(W9T(1.B]I@F%G>
M$!LP\#0[L84PP(,0& &F/0HT<( /L T^* $1N(\RN 04L TTV  9J .G" 8O
M$ $4F! 86=SVL)\0L!LS\ ,7V("R*-W3C=A;H($.<($<M 4S^ /#S8&O_017
MI0HO^(5/0(,TV( 7"(RJLH,;^0.$[9#A\#D1Z)H6/8HT(('EY1H1& %A:]T0
MD 'BJ]P;^-M.M &E51L*_3H1>$4)X@,88 U8H8$/D 'R2@,[: %%H  **#A<
M\%X7R/ZB <&#%I!=/.B &[@%&]" ? 4$%!"!J"W?%]B B-V$%?";SEN2$B!?
M%($!$GB!<F0+V4J*D1(!' @,#C #&D#=H_B$%OB &Y#.'0@,/WA;,\"$.L"#
M\RT+J'3/EX%/<QTTPWRGT;QAXU1-&"2!%GB%.F  8RR &P@%+Z@I+["4OW7%
M/0$&" "#5X !CI(!Z4DM6]B!RH& 2U@##G!B4-"$85D="18+&N!6-$@ // =
MU2B!C&6OSI.@ 3B#4/BTI]* 7Q#C8 @!NA(LC]T338  IU@ 5;2%!; %,\*#
MP'* # "#X>$H,<8%41" +A"%%W +,!"3/V" J4 !&/@%%_X)+# 0%0?P@U_@
M "S1*+3ID'@[+3X@ 4S8F2-$BCIX@#@(AA8@@?H!4D74D3](@.H8'V"H@[AX
M@'?[$D"("PWX QOX WP4Q ;  U$@@9TAWAQ""A<0 5'( Y&R!0'8 5&P@2%$
M"LS( 5R0GS/4@&F%  J(TC@P9@QSG!=H 5W@@PDXYPC(@1PDN4S0! H("PB0
MGD^-K @0Z 38 U7)$3"0#ELH .H-H#/B%3M!6UO@ P&(@_'3#@?X@_.P 5Z(
M@[W( 2T%!CXH@"\0A5P#!I#&!4U\!5%P@% 8A0BP#0VXE5'>+&/N@P>@/)M!
ML)7BG5L@ !L(A1SH+.&2&D  U?[5N%&S)>D!@($](*T/F!",E=VU]8,!> $^
M:&@;^(0.@"B1PX5C0<H/.*D)T(!-$#E1T+ T>(42L)0;* %<0 PL3 H**)T=
MR T7B#13LVO+<./5X !-R ,#$ 5)0IUHVZ>&>H$%J$$&"(4.$! ^&+D9SF%R
M[>'+SNP=%E?.[DH;;L_.UFS0YN&=D$STTV,?!6<&,!,*  1T P8'V(-;>-3+
M19]?&68FB8!1$(7/\.=@@( \F&T7D"U0-<<@M8'<*%O*JX[])>17^![&,(H<
M540&$ 5=T(53["L78S6WB "D)&F?.CA* HSHV$N(FL92Q##SX![,4!44>RH8
M4*Q/&/Z%7T"^G\J- AD<&>0#HSZ6O_R $=B$%K@$&[#<I'B%"/B%46B :LD!
M<4.*6G4*'$AN8,B#"] %D4**"W *2@$#/K"!2]B #GBN%F B7N@KI9-28%CP
M!@]> @H%!WD%/_@#57RA79GM44!EP8K8"\C72DLM!OD%#: K>K5KA&:US*
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M WDC2"I8>R6BI'@%%VA!,I8<-7KB)U9:(4*AK/W)" W6+OQ 4O) $,0")?2
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MS'U"!#P 2&C"!-A YSS(!,! JQ?(+WR N8R 7IB!261 "[1 !( -,.P JZ/
M!-Q/,FY"C P>4TP <\1!_WA%&/ (!=C"+5P +X@ <PR@VNP',/!" KS"'NB%
M5] $8%"&5Y  &-B"7N !"MB"\#T\HD7\M/DYF4X\%A)6*!R-5.6.%X $,,
M6:!!L+R"P>/!A$B309B!8P2(H16 3^1!S^7 F-C 7'S* KR;+63&)D3&)1B
ML/%D!SB&5VP 'C$!=GA%'H2%#;@ #'A!&H"!*&3+8+F 7G0!L0##'H1%!U1,
M\I@$!_YT@:7;P!_\@4F]/=P+-T.7:43/M4L3)U)+&A^:U2@L0-&O>0*4TXW
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M0 9DT (7K& 41)L)!VZ3G3$"@P9@F,E$1)$!72R(!K6\#BX0 HP_1* %(=C
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M0;'$E,@&6K"""$1&%Q]8 0DR4-.Z7F(/$: 7'^K3 BJU8%F[$H$91M&:.ZS
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M;+"#+VB@!1;JR C2XH('M" /:M'(!,!P@RX8 !/ "(4 C*R)XDQ$!&M(0P3
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MD&L%&$LB(@L%(@ 0@*&\0N #-H!>TN !4& %# 482(#K*O[ 1X"!S#9K)#9
M27@! @ !%!P !6J0X&(+G"+@-EQ  [*M7]8@ :2)!#K@!9C@ N1* R;@%]*
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M0PR5(LAP SX@2T9!!"X L/2C SH@'L$ J78"#XSL"^AD!$X&$#(@ S;@H]*
M T@@F8(A!^R45.=H2D/O2!?U;XQH<!XU/7-B!!0@UR:B!1*@J_XT)G2A5R
M'5'F*=O%*2-G%V6B4"5#.";B%_ZN:2+2(/L,;R8H22T$E21Q8P(RH@NR+T"
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M!\R ,BC@!N%6U33@%4,"!;X@!\#@#G;E!79,(40 6GZ,L'"@"S)Y!7$N)BX
MD[ZN!>I@!$8B#I3X 6ZA"TQB5VB-L'9%UH !KAI@+\YR>17" 38A#C1C5])
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ME56%%C9UU8478CAAATN9@@I/%_YT(<HG:!2 2Q<P//9 > M\< DN"8'E10C
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M )3!"Q'0'A, )6<(#!>P0F9 (%0YE6NP2&_T2&CY5'4P1[_@ *L$#'W@'R$
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M"@80 8> ! "0!(X0 #,P"VX0 %!@"B!0 &/0"%(Q^C'@"',@ ":0""80 'K
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M 0'>D/Z%E-P4<D65&1!(@( 43 M@#!=30."051R@H$:=%$1 @ P6  &[59!
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M4F,W.\BNL(B 3["%!% T3&@ /?[<-1CP.7.[ #^XA00 +$UH/UN(  8K 3
M!@<HK@UP,Q+H-G9+B]:#+ ;RBC!@ !N0@1)8 - " ]=*@^R:@*_*@9AC ,QJ
M/%N 0F!0!-*[A4P,BV!D,#[PK0G(A%!@@-G"!1' !5X01@?@MK?KN E00B1B
MNZ]P@0<$!!>XA#5 @>;["@+\BML#!C_(@+#PJ&C"K</P"A2P1AD8 0U@L B8
MQ@_0*S"8+3Q@-QKHN LX,Q'@Q!+H@J\ @ZAS@ ,#A@FX,,C0L9 #**Z0R!B$
M*F[:)VT2,I,SCTV2*1Z<BP_(OAL@@*^Z!((#AB $AA'0*PS3JP< N@BX!6#
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M; P4Z !ZVX$(&(518 "VE $0! 90H*L-T#5_! : /$-= _X&NK.L#_B 4'@
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M8/RR$A"!XN* 31C+K[@$5/M+4?YP@&@#!C3(+@I02"3B@_;3H0_@!13@, V
MLPOLM/;[@W0$"P!$*'D"J?8 ."0*@1L(A@78!'5[A5^XO#3@!4"0+^V\ /=:
M@^3["A53S5?XJP; -ANXQL1X2,3XL?I\*992C["!I/FTJAH\A8RI+KSPBAW(
M+J^XA +X!4WHPY-LOPY8.F\%!@; M# X  R[.5M8@.[B@*4#ADT8 ,C3A 3
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M'+!06["!'."#"_"*+[B #M@ 9;,%Y&V+\;2%#O"*4/@ K[BW#N@ P H%_;T
M%12%^^TP^N6\O\R!I>N"H04&,*  ]C6WNQ!,R&HF,]C2+5+.%JB##<"T/B@
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M+0JL8+#@U;!X1HX:"U7S(5$P9$D#S+'0! UXHU_XLK&X!0I;*./4+E'U-_@
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MF2/BO$ZKL/""WUQL,A8!4/@*(%V!%/4"YAZ+5R@!#<"]6M, #8CC6WB!"]
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M^A1!$S 8, PN^(2'0 Y<'1"BL $,4 1@=B8 D\% DZ@&:8 ]^/-KP Y<8!H
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M(%6IH?EHH(Y0L)1)!K2 ^:2!7S;X0A11F,CH@I'.S<0B/&"ZP(M01/'"(@U
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M]$:\D(J.,!>!<,+ DC+QB"UF4H)YJ0MR+;*1)D((C!T!PP4]2PL@:/, C,%
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MO10 ( *F6$4A#K  #@C@!*I0  -NHP +S,($ #"$*2I0@ P,  .N2$%S8%X
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M0 ('T&)@@*$,!N42*(#M9X(#*&H'N*DVSL!B/D%-;&!0<*$ (NH+8 (&&-\
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MWD\3KW B0Q#X%MDM%;"51F8O@&C9LYE=@.<.,#"T@XQK4+ R4EKJ+0I:HC@
M&S"A\')'D\:!P21#'20'BH+I4G3!)3>T<$LFHB %YI>1?85'!&%> ,.U%^#"
M=X8TY/!+ ]';$:D&>.2Y!Z?T)@T*L ,P-E"VILCM$CM80$@JL! *G&$4)CO@
M_Q11,1ADJB01F%2P@H6K$)IB5ZD*(0E1=4(1BBJ%O%+A"DOHPA;&D%6H^* -
M)2(P8)0@3&+*PR8B("<[^ 0-&4!(#CM F0<DQQ8): K-@'&&(JZ(!@T)4T)J
M,A&LR/ZI?<!XP$N"$:0S5(P$+_L 3J 8J16%"0)+<U!(C%,38(@@3 WX#$6
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M2*M9%!&!B82T)"VU13#X0!!VSG"QC!4A"QL+V<A*]E0U9*?C-O!'7(A@ QM
M 4%N0 $13, /TCM,,##+D!8D1Q,:$ $%A-8%!I 6M!_0P$)$H0%UH6!]I[S
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M>))[RP%%''!^$^!!K<@' $,1>% Q$* M]6A[:?!=P4<!9J$):_5[&U!=M\
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M6)&PQ0A<FR#L-1T!& R_[^.G;: IH:8 :.L\^&1K V)@2%  KS\6>.66$AP
MQH87+/MB E%N42"8+B:XY1<-/+HH!PM_R:".2XH#A@_W-L!AQ +0^"4\8&0(
MX99/(+@D$P,P >8&$=(RY113>O3QQQ]Y!%)(((OTD<@CC4QR2":-1')'):-\
M$LHH@ZR22BNSO+)(5$Q!)2@PPPR*B1!$,%.#3_@P3+4&<7&!@P_P F83$CA
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M4A/S>_##%W]\\LO_OBZBS%=_??;;=_]],4G SGOXZ[=?_ C8"XK^^_OW_W\
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MRX?.7H8!-:, Q_!P@7@?R@L7V!F>/M&!>+/N$SVY0PON%0%,!$,$#.# ?3]
M@@NL*R&R5HLH'F"+"<B)YB+) '9<MJ$-V*P$%% HF$)AXXO@>$'2/B]% ^;3
M[81B!#GHP ,H5X(S7.+%>?H 6!;P9-,XX %>X @.JJX\&[S\ \'H@]CCM@,L
MXX("]LF#IJQ<AZ!;-M0B,+L#]FH&I996+@S0 (B9[0(-; !/P? *2KQ',I!/
M>.W $->"2N""#'  3SLPEBB6F@%X_4&I!O?, C1P%%'\E%NV$,$'-&#/MC]
M.7_0P+[GQ@<7V$ #OVC! BXPT?X/N-XCMEA[&!80 3S\X6' 6(-R6@"&"+!.
M41UP@?=8WX$++"P-2BV\>'2L 0@H@EH;T("_85."2Z3A^&GX10<FH_MOA:H,
M+7C!!#80JCID .:9*!56>"&"'/@ !X"7A' !!J" 3_B"CZ$ IAFPUM, ;1$)
M/V"UM&  \6. GDF(6Z"U7,*U7?+ ZFHE7:.NZ2)!1V*C'HJ N+@%![@$41
M,-C H,B!AY$!0A$!*P,$ 9B-$% .84../+ % ?@"F^@ AH  RA$%!Q"%2R 5
M8.B N4D [%@K8MH#$4D,OYB V;B%"7B%4!  UM&$!!"%5U@ ^[B$!?@E""C
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M5Z \.[L L\R3VGP UDD*A;B$HPRF6V@ :RD!J@0#JSR#-2B 3U@XB_B%3&"
M.$ #/'B ,KB%XD #ND**B7J R? #!X"!.EBF1[FQ&P"%,, *\5!%*".5#XB
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MH(@# XA@1"D CND-;)%$Q)(+K($)Q\U([OJ '8" N/@%MP8[X8:!&Q"KWXF
M%I"!%F3<!Q V'N,N#;B!#^ *&X@  6< A7(!V,@#!["!H;.)"NF""]#D"Z
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M;$ !.]C  "'R@@;\D(,KA2(!(G!!UVR!@@B8X1<7^$ <9.   Y6@!8 809)
MTP(;@ 9EC6, &3\Q%CXP  U?<("6_A !.Z1!@Z"X@ ;P@(L+=($/%P#A"QY
M CO8P@ ?:,$OSI !/^Q@ QWI0 GJ@(($!-$CMZ" #? P ?X<  ,, ^Q"!"18
MAP]0X 9F2$ F@#&!"Y3!"PH(8A@NP(<NR"X/!-A!'1ZP V#<@ 2:($$'NL4
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M@@%I1L$"%0V:J8%&!)ZBCV$A\(N.Z->L7N*#4%%0HPF("@\<^(2V<5T'/G
MJLU\Q0<B$-91V6 $,.@2,E\PH!65H$8=\54?YIINCWCUW&FUP2\>H"8S\(X"
MJGE!#CP"@X[CD\$+KK!  5H4SE4(3A9N"LH'HB>69-%+FUC9)WCWAZ6)X#7&
MOLH%;+&)"70DT![A0!R"L2A>T" #7IF )TC88S[T@0&+0H.80N%?%(1&%/:$
M[LK,@'7L_*(."K!%!$3%!_QZ) *U!,8.7F +[0K,:;DYUR6XYR/Z+$K4P(B
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M\!0@'  :C$)[C(!(Y$ &X *I-1,87, KW$(?3I7!70(#4/[+#5QC"7A@*#
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M2#"A8 #!XY:'&(0/%^GP"# ^/&Q!@P2&1,F@BQ$4V@!"ATAH"9<&-E&( B^
MD8^/]ACZ[Q.%=,ECPHN""1&78$0!A9?II*1.R5^FPP3%A!1Y0)%@^),2$#[.
M"^8/^K0$YA8OF_20%SPT\1*8%LJP)<Q@6F@!H0/[4'(A3>P );Y?/H%.H5$:
MA*$+AC3!XY<+%#D2F%?.NT67,PNRXQ<9(CT2#TQ*M.5 BA*J4Q0\.DCH$SN:
M9.@7/%I]]18/;XFINDQXZ>^B R]5") ^LBST 3Z @<$+7.Q(<3P\5%5(TX1R
MA5-:]/C@(Z9E2:A2%V#2N^6.6?[="T47#ZG;$! %19$UH?2",56\A"8=9:%+
M_K E@A0U! :%'"HR(P)@7G"A(AC" .:&%BK2I(&80K'SH0/W"%=*31#:<(]N
M(RK.%1!JDV46)0*(PI$":CAD@!EFD4, ,F8P(#,3!DA 9!UF4<,  PI@@95#
M"O# @0$L.$06-Q08@(()SLI-:!444,&- =A@!82;*2B #40*R  " 1J81 P$
M%"A #C@4J.  "A ACCA52&D @U4F6< #5Y8H(($"9I#%A ,66&"2&0AP) 8%
M0D"@95=*L3F!# X00SA3(,#  P8.42"%EQ5   (+(' E!0.R'F")1 Q8P.]5
M0%  @OX!H'"\.%-04? A3>!C* ,^)A#ICX*#(>$#&"+0))0(VKMD F#,*%(#
M(\/8X(,6-J'  1ITB4"47S:0 04*-J9P@A4F^*6/"&[80.!;OD=A@F#P:" "
M-#Z9 /Y?2C #&"8ND"$"_"/! D0P"EM0X 4E$$%[TO" %J#@ 2*)S_=6H+Q/
M/  &+F" D7"A 1?8X *O (8'R82+"[B@!"%H3PM(<(,&_&$A:)B %S:P V"D
M80(P0,$"^D"A")2@!1=PF$,< H:#,& Z&EB80S"1@%_\@@%#2D@$1+(!&+0@
M F\"PP1H,$,?WF %.AIA"QZ "1R,@ )F\,,%$I(\#[U 8/YY,A(*. # 'NZP
M [9X@9$R0 (84. #"1'!!EX0@@L0<24D*)(M'A",5TR !"X0XK(T  ,1-. 6
M?W  !+SPBP^XP 41$*%";+ !+U"@#BNII @>$* [.! %$0!#18"Q@PBX  4-
MT,0M&KD!/"3D IJP@0WQ\( 58/$+P/@#%XM7D >XX 4/L,&"(-D"#;2D#A=@
MP@1NL)!00'(%&VC)"I()#!'4X1<3"*4H-@ (73C0!=),2 D\*(+SE<@%"^"
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M S  #C4(0 U<H8("P.$4$6! *0XQ T.(Q3"F< 4+!N (.0"@#84(0 Q.40,
ML,$4$;" ;%(P $3,X*QZ@, !2L$&LC;B!#&312E,@0$$>" K U"!*R"@@$*X
MX0"CB_Y!<MG6"#((8 EB#4 25@&%)!"G=JJPR"4.4(!'/.0"E[A$ H*A" C4
MLB7 P$/!+O!+&TPS!XBZ1,'.D !\ 6,-+?G% UZ1OH2DP5R?0$ >CG35A$S@
M$WXHV VSTX)(;8( ' 9&".KP"0;$Y!,M%44$PM4!".5IE@O(CBT2L(:*[&'$
M: B%* S0I(Z.I)PB@% #I@F,#]S8!<E,@$K^P.'S[&!(FGC #1M9RQII8);
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MZI PM$03\:. 'Q*R 3Z(8@$.N0,,=X"P5S1@0PM R*/_[.<+J/M(0$T(!.Z
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M 6 D#<0(5@I@!]*@ R!MA,J@(D0A 5"E 5R@"[J@DL1%!/Q/613""^QO(?+
M!F"  ;(C F8-!9+)(7+@!8 AWC1$__Z@I9ZL(H[GG30B#8%A F9M D(!4A)"
M%%#0(4RLC92' H:E#FHD#_/$AFA@FAP$ DH IA;"%KS@!C2@1EI W58@#$9!
MTA+B#PU.PH AOTPN&$BM?V@ &%8 #%ZARY8%## "!V3 EOZZ8,)B8L9P80\3
M @]:B@\>8 -PX$T 3<#0+<G0R0$\)-Y2+E-BC0;BR!8FP&-P(0("! 9L:"68
M !<6X 9H<0(>$1A$8<N\P :VL1MW@(L Y@%(X)> H0L0YJ+XH*4$K -,3CT8
MYMD<@E\\9)C\@ %V@!83P \4@>9(\1)HP(8<(K\,,#[ZY2&"Z O><0)40B'X
MQ "ZR08431,B[A(<8 -LX,$4X@]L0 86P#P<8)3Z" =NX >OSB9D(6LR3Q5"
MP*_N3A8*@0!F( &28!;XHA%4SQ?D .[<0 !B@ S(H WT0._\KA#V+O)48!8
M+P$&+V@(@ 56817ZR@V0( #@P/X7N)(-' $!_.X0$,!E: ,17($4X& ),F"]
MA ,I3($X&L $)N#P5H#Y? $1", $9*$"(& 59B$%$&#V"D$P;X\KW6 7DB
MR,!Q5.$O2V$5AL\4$@ #'(>B9@,!#-/V)@$.!& ,9L$4$($,2H=PXO(F4,$B
M@L$,R(UW& X7(( #7<K'Q"6B1$$#Y/!(U&<3*@08P*#H3*HE#&U6-,$,%N#=
M'$(3(L AQD03+@$3/L%?C),!((00,P$%5PP/S  ,FV3&^L,![.02/@$7 &'$
MQL\UE?,XUV 4F!-$&"P"2@X&^ <&Q>4![$01/F&41"&;BBY>OE$3K@<8@C A
MN!,8 OXJ(0BT(IB@2#90QT8HS2 LUH)D5G#! .!#$\Z  4 *#&K$(9K$!3K
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MQ2%PX.ET80249?V *0P^ 1 ^(20?XB;^P@/X,@4F( #JAF7\SA0F( $6 !$
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M.6P!XY**%]D(A#2A#A)@8>+C $2"%QH@283D2$K@0#I-#_\@$Q*5#Y -#R#
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M@0)-K_ZBG[/W*30@W@1UVAL3'Y2@YQX0:("Q2'^0( *5P'BAP0YWV$&DGL"
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M( I11"!Y(-'$ O*@B0\8U<' R(&1)C !,.#B#H1]P0+^(.,[ ",".Q#%%P1
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M$ .LPH(EU1=9L3?KMA@#TA@N 2'_ A)?8"1V=R0=\ $PT (NX 6V$ %#% :
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M>"H\!9,!#'0+E558+= "TW4#DL@4P6 '.($+08H)A?>5OP !.$&/>R)5M[,
MF$$#DJ@)<LH!L^,B>J(!GD0# K@^78 F+Q42W[*6=-$WC;  ## #%(!-C@
M)C +V0:%Y"10!2 JL"8' 4 !2+  $[ *G]8RV#0+2A  "2 'IK   G "J]
M"N *>O!0*C  (" +"W4(JZ  #A"$LS8+(#  )E !T88( ' "%3AKOG"M"0 '
M4R@1LSD8L8E2?2,3+] !F. %LR@"UC(9F\  9P (%%!F7Q !BI &"G R-D !
M?M % H )1366 >";%W #FK #!?Y0!T6E/PQ@!HI  2?C.B'! 2(D Q9;/@9@
M119ILDR 7I^P 'N4 'BP!@9P,FO@ 'N0!PR0.R8R "UP"3<@5;C  %W !Q0
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M!?%WFX =V\IC ]HH%84<"FC@ &)W$KHP 6@@"MTCVYKQ"Q10!J)P Q]:&9H
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M8MT" @1)E!<>$ 8OY. "FPF&%R+P@ NLP2,KL)3V,I6#'_T"# 3Y()@4,!-
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M6H$N- R,#M3,(YJ80**.FH8-?,(/F)C)&>X,C >(@@2-_$6C26#0I)JFIQ2
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M#4F$*R:(1=@;[2O-!<'UW"//H7D3RXT0],@.,F(6$O6PR5O&XQH,<-Y@W"E
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;9&'&Y4]89&,V9OB%YFB6YFFFYFJVYHH-"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>comp_0014.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0014.gif
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M\/#O\.;P]^_P\>OS^?3T]/CW]_7W^?CW^/7X^_____CX]P
M
M
M
M
M
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MN__]\(^__.?/Z%4@Q/[T/S_^[X___=\?+_TW+/Z7?P18@/0W@ :8@&\U"&C
M!FW@!FO !FR@"H. "!=1"H" @(HA")WP19GP!GM1"FY0"G>Q"B.((9P @EK3
M"6\P@(D0!IKP%YS@!GZQ"%_0 F70@0(1"!(H@6K0!OOG!BZ0!6U0%X+ !FK0
M@(M0%XT "!E2@5N#"(-0&)D@!HFP+(M@@=S#@@VQ"H% @HFF @T@ 0MP !$
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M8F !&4("*+ U*.".@W$("="0Q&(*;+DU3;F4I6"2AV%_;E")(8@ (XDU6?
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M""'0 !K@!H/P .E9 5^ $&S  1O F1<A 2L B"(JAQ,@CA?1!@8@B>NH"IV
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M)H !1*L)(-  &X &>\H!&8"M92"OG>"H.)H";(@A*"F5<T@""M %'BF5@T
MI8 ("M &@] !&6"'@Z  ;+"L&)"M#9 %@\ %#M (JL &"1 &@$ "#] );3 !
M(4"#"J"UG\F##-"?B#  'L &:&  U&I_)&  *^ &66  %B@""A "XL@%$/ &
M@% !;#@&#C (@0 !;-B/+3 (7<  2P@!#U &;^"XJU &#: "@[ (D3L((D !
M^Z<)6M  7Z );&  )^ &7Y"HJOX@N&T0""1JAXO  /?Y!A(@ MF* %R0"&"@
ME$4YA1:PG6_0 $Z( @2@!6]P @K0@2%@ 6_ !@Q0IU_0 &T@"*[:AAJ  6\
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MSPA1 IG0 N+-L7U;!@@PE,Z-$ \0"('PEP+1!F(*"%KHDSU9Y@*! AR $!C
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M%'"(<LNH'O !!B (9:#?A1 !2YD%"@ !'>"$('"J?_K'"B"'[,B&"G#?FNT
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M8*<&/!3#5PQ88FN13+2H !'Q%E0E RW&/$$FTIPKPP(,S*,(D4XX<&%,-AJ
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MX@$9:,&MIM-#!CQ@$&A0;$BZ4!$&@  %#% 3:9B6 1&@  %(<H,"4( "$TB
M!)Q 0"$2]H$5!!,"I>"?8!*P1#$H(($*4-T@&N#9!@C'IRD0P04$11T)7"!C
M$I@("B"P @]$(#M96E0#RL4BS!0D!0Y0P0<8:A:JJ8 !+ &$ DR@ A-,  2P
M[:XJM*  %>SSEQ01@V+_XM;BDBT!N%MC*23  #:,,# ;8-1?.*""!Y1@C85#
M %X>\(#@8<  $)CP QBH"DYH( $;X( ",)"=3 S@8J3)  (D( $()& $;#G!
M UA0 O[NL($,=2E#5XX7'%4DP$-@"-L'/J-4 "W *.$C6P4PD (0D)4G:$@
M"5KP  (EA -:U9:];C/.PH6-N1I8@01 P!8ND'4LF&&! V;,'3/$SBFE0&-X
M'="ZF3# A*C!C"8FD($53( #I;C@F22&@)UPH@)@EH#0&D &IS3@:A)X) ;4
MQ($*U#8$J<&L4R9XS0:$0 4*V&Q^'J "#FRXD44#07!(,#B>Y%85+*@;%]K7
M":6NH (9*$4G2E9;#D" $V! P D.>JTR&* Q%I"71=^, 5EYRU-92 !4+N"
ML56R, 5511;DM1BMJL #AD4* TQ@ K%VXG:9V5<8$B!L[?ZJ0A )H, B$*&
M$JC@!'AQ&>%DS1$)-(!CTFOK"M2<&PZ89DX(@(-3'KQ3ADN/< 4Z$T< 82-
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M0#CDA"JTPS?X-WL$A#$L1P5I."_4Q$40 TW0!+YCQ%+(/29" S9H S=@ S9
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M0<@"NFH!#>" YQN$#6B #AB$-O <CG !#:@GP/. #""![,@""*@ 1G**0/
M#2"!B!.#,NB6#7BX,GA3ZPF$+"@$#=@(-/" N9H(+8  "O *PS,),^#3%6 +
M3F@!0!B!"V"!1)F+70U557"#T7B\%AB$6S)6HM "3N485W6##)"IN02K7\D
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M3DB?'*^+_*IVV;"GLZ3HF\(?9\D0 \V"3$(F)/E,@\"G:_YW"JI2!0\ 3@R
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M*)5! C0&!P0%0()D:Z[COIQ,<\ )6XC-%H#>9LYF.S;'^I4D:VA"%G!@,I(
M=+RF;IXD-38%)V2!OYB! '%FW2"+1CKE0@8D/,9C]O@-4XAD-UZG0JZ""2"
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M?Z# :@R""HA!4\3M"H!!2<"KOS+A9JC O0Y&LKHE1? IK&A"&:3 F)E<%ZQ
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MP0E(@)$V@ 6H#02L%0DXFBJ,0 3P6FQ-" *\ 2)L0 .( $Z1Q2(X@ BTC@>
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M&$0"E @:+  +0-=%%$+(25<!P/[I!Q4J)CG R)X5W8+'"92""CA "4C;$+E
MS.CR"W_0@P5*6Q R"KA  L14)\#9&(  AM4-)+=  E#%53U8"&1U)@Q B$E
M&,@5<ES ]=P/=VS :I" 9X/V>$G !KCR(2UU!J!1JBS "FB!]5P&D;'L!"@/
M!?1J32Q""#  "!!F:K9 "!Q39=R6'U-*;QC D)9')IRQ"G6"D=9-$%B'O!R
MW"$H%_S.:K0/Q#5 "W#!;<5.!7  DHR;J)!W7&$ !+@$"UQS!I/'"51 %RA'
M"::H"=ST3ZC* U6 !@C<!'!(*4@ !I" "XP&"G5"!F< I>P$8O!6%OR6Z!1
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M)P3" I1$!8@7<74AF]).&;@ "2! ]S2 %*4";E#$0GG =4O$GJ1RJKC/=6!
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M7'#C"QL!X0!/'*0,*6  Y"0P!H>LH@SJHM'*5O( N6#  EP ! DNA8@M>(
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M[*)E $$$="<- U$$G$@,$FIQLD!P2H'N1  ./ *OX !7 OY!"PEP%;H@!%A
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M+( #(&0HG/,V.P$U_Y,_W_-!AR) V7- ^],\^9(V7S,])S0XY],ZNU,]Y;-
M6S-%530ROV5%7?1%831&971&:;1&!=,42--&=71'>;1'?;0QV?-'A71(B;1(
MC?1(D31)E71)%S-(F?1)A]1)H71**S,ZXY-*L31+M71+N;1+O?1+NS1'TQ!,
MR;1,C?0UW6"-]A(1/!!%'<?!]E,R!X(#^*\ESH \]/,\!T'7/."[J*\[]1)0
MY=0_]Y($N)%#.S0O0< 0"Y0EW( #WF9/<1,_$94Y@Q00-/X [@0UC9+N/5<!
M!#KB8-Q4+]F44A>3$VII5*\T7Y+GNA !(%&4)=J@5:7B#0Y46S(  R[  C!
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M CJ@ 11($$8F;9A#JE1!B9].!"(@1RSE=3@@!#0  2Z%"Q;@AS, @HA&ECU
M0C[  K LC#I! EB@DE7!"Q1@ S9  R"H#!P CCN@%-P@ AR@ @2A%%X-!!J@
M)E7!%/BYA<FJDB_  Q[";!PB0;'LJ+K ACD@%(R9 SI  B"D"P(Z RSY$"6@
M 2H $$JA V;. ;X(%1&@\%K"IOX'H20?("SJ<RXD@ 0P0 &H$@,HK8Y-0 ,R
M50QL6 ,R(<2.>"!NQX@;)Q$@H 42H#,\((X;0")!>*R1] P$"0XH!60ZHA0B
MH (DV':*!$<&&(+(92 JA[DP<14\H&[JXN2H!V2.!:EDZPS<8A$(H+6"X"72
M1174(+.0*CQ4H )8PD$Z@@.\=?54JB,&80&@$J HI_T0X -#H$,J@#0HH#I&
MZFT6B9X"0!^S8 )>1N 0(*% 8#A6JM\:U*LRN2-R"1-5005& "YR0P(XLE>C
M!1$( %$PH'NM8PS ZY DZ5$X00$\X"GU96)**00R0SQH%0T :A!>8KHWX&-,
M2' R(/Z,4J"@ E%@MML% J8W(4ICI^H!R(O*W, M_"-?O(0XPD,#UNH+!("3
M&(,#*N MSJ#-*-LA,&!B72NRW. TGF0K'N "$F$5$GP5<C6-\$5@HHF264(-
M%N @T+I#(, ")%@1NF>*4L.C >%LH$H5@J P*D +/=I!$$7T3.UYB4L%(!P!
MR(8E!.$ ,&"@/TV%." !'H -60*Q)DII!9=MS8  I$8, D!JQ@ D3)8TD@I(
M0(,E/$"V,$#H4J41S(Z%!"&TTXB8R7K-C10RVK)(U+HQ"+81OBX!YJ,%5L9Y
M'H\-X&#4U( W6()NJK@N8 <F-"%_!F$F6H+C-,&BE"<!,OZA@:8(!&[V46TD
M8!M$;.3O<S3"<RR&/K( ?M^  ;H 9#@@#!3ANC3!DU2./G(CC3H!#<9ID.QC
M(6R$F2UH1HPXURO% P9@JLX@:B2W"U++!98"L^!NQF%B2& (!BG ;6?=(3@B
MLX/P4?B(<"Y+,/1F30;A#$: -_X(C53  N! <$M 74HA+BV@(61M!=! 62$J
M@)2))!- U]*H<;MYOR6 #0*N01T@1S)@^L*\/T:FBX1)6UGB#>$6#4[@ :X"
MT__9*UCB#.HBB>I <E< )#Q<PT- ##P8*SBEV.! #;!G9#RZ/]! !7YJ@)>B
MA]A <L^  *9"XLGJJ@[B1, K1_X>H@362J?!X S*P SBZLC*P 0(H -6(;@F
M*@Q0; #ZCB5.?C=NWN&QE]6K@PNZ7& :!1%&K0W@MZV"JT@TH0%./;?9_.Q_
ME PO8%(6)V1*@9!Z(P0J@ 3DC3MR G@: ".=J@0&P:,?0M"'N(*RDUN)BR5,
M2MHJL.T1P0RB@@,HP*DN4 Q 1BZ.:-/MI#KH H;FXX8AWP2X(Q-20*G5O#=,
M8 )&(#&JXZWFLPR4R'ERY&3LYB#ZB0%46O8WH $B@&TQX(H@X"&^8 %(( 1"
M@ 18H!1VIA12(*;2KM8E!Y*+I<&N"J5FEUZ"T+&'9='9@(3X(Q!NAP6L2O$/
MH@16)/X$+C",R@ "/$ +/@LZ!AD!0ND004*<U.*X0B$!$+-+\@6GO.J/4MV*
MYH,Q ")#%E6J!C%0Q26#JE*JRF @"'$%"(*(+&18\45"J54. !'<HI#AF0JJ
M5#P8$4($B8%N'#!4M>B$!00F("Y\\(8@"P<B4I)PH6H,!56(,&10D5&3*A<;
M5+%),*(GB1.<7'!0M6I5&Y($5ZD"U*!4*0:#LJ[*TA1K002=;*K2E!/B( (Y
M&W!1=0KB!A5J58D9JNK,!()O'F0E(8'$%PME$#XDZ&&%JC<)0EB>NBB3@D5J
M-:G @  $0Z]N2YL^C3JUZM6L6[M^#3NV[-FT:P_B#-/ (/Y5#!#=;$-0# /2
M%-RH:N&!X ,V$!N50H0@$T$3$E1](4DB!,0N8M1F2H!;U8(WF@S@7H2@5)GJ
M)$A +*540AB(*#QRN*M* IJW^BLPE- 809FL@HAO;R' G%=H)/ 2!OM)\ 5$
M*@S"1@0048"?*B&84$I<JF"@0H<087""31,T5D$)JK1Q$$2XW8?!;C91H 5$
M%=Q507=>58 &(@F0Q@D"BXQE(!L0>$4"7PQQ,<() Y'V(0H$+6)A)[T1E(5"
M7652"@+[J0+&1, 1]$4#;GGUAIEP& ;90 J,J0H)F2!R$(L0+:=* G 05(H"
M.6508P;X#=+ *H,DP E!(3RFEOX*(A"T@7:J</( 5@UXM)92JHA@@76#N:B*
M&Q 0=-N4!@@"T2HX!??IE'Z1!$)R-[7E0G**, AJ&!:2"1A$@%2J"@1CZ"49
M:8(DT)9-B  @(T$)[,>" B^ID@D!+72E"AE<H?$I' ZHLF"#^W&1EBH=#/2=
MIC#!Q(!T1!G(20+,U49OO?;>BV^^^NZK6A<( ,*)&^"MDD 6BZSR)D%E;)9)
M%P-$F(4#;ZPB1@+D?;&9*BLPH ()%#R4$5$(B,%)&P0 1UH)%222B0B#(3(
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M@DX4(#FED( "!E&& -S% 0@ 7@#<DX +J,($!=@: Y*C@(>88 "E4 $!MM:
MIH @ /XL& ,"$%"&%02=$P(H02FXP"Q$$, !95 ! ,#] %R2!A&\ST]U*@ !
M3@P"AX<W@$3-$/129 $,JVC 0S)Q@&9&(/"!4(&)*P__^%<:Q0$HPRHV8(#X
M!<"J8@D% QZ","!@"@RP ?X# 2=@/@'0"2M@'GZG"@\  4OU  ' "?/#$ R@
M$($  &%P!@,  B<@ @#@?@$@&8,@>H<75*312-3W!=5"(B=0  _0>6P"/0B
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M$00$4"*3X@$%8)"-$0(*((P/D/X<;W W#9$ "*"/G8 (!L "!6$ =Y$%"+
M0]:0Y$<4$N"0#U 6$O 8FI !!L  "G 78(   ^ !#> >OJ< J6=B@_ &S:)!
M!9((B" )+O(&@2!YJ:$(::9]>+81]F5?TI5A\VAKJY (15D@"]=NH= )U5@*
M+H<53P@1-(==;6&6%"%SJ9)=$!%S+Q&69XD5G<!=I2 (N/%-#($*8OD62!:7
MRM(L:4D1,N0BOM$)QI5S+I(! Q   J !TM$" W"3!   )%$*)6   1  #6"/
MJ]% $J 1V$(" . ;_.9?%Z9-VI0&(7"4?4%MH92+*I L>Y0 'F @H;0 #9 "
M1,0"#_Z@ !Z0"%9):W5(  >@  8  -5A+UDP3L*I+V)  D/FF3;Q8EYQ!B<@
MC'Q2 0/@4\)'$EDP "8 !E_0!3<% "/P!F?P '6'B>UY)H;E%F^0!=,2C_32
M J0I&ZN  0,@$:J(?""@!7 G'?O9GU)RGR*@ @-@ 5WFG*;6"<"S 06  E^@
M8D1F$QB@  VJ+Z.I+NP67:I1 @ P.F(0  MY'"2P"L@GA(MP;Z31!@$ 7'XA
M 0Z  >2H5S,:G?GQ/0Y 4M;Q 9P!!PAW4:6P%U@1 BHB!M*8HUO@ 6 0 1DP
M"">@D[SY  _P)%.A/!G0"&RP  P  1.C6 \@ J.#%=7H(OX*B14I)&_*"7Y?
MH'DE,HR#,0'*"0($\'X:RFKWB2F:0 (-\  LH'(9\ 4H4!-A)P$MH %(DPF#
M!R#'H0 -8 %WBJ?EI5>Y"4:F8!(ZJ10M  )E, &:D D=L'CML1 HX*=W(0:6
MBBDG$ #[<5T)&0&@V0"+X :JR!"<P "A61 *&0@-8"%C0&]?   8L H5L'>C
M.1$A  "#0P AX 8(MPH>0'O+P@5L (U/D1PAF@$F8) CX $ X 6K1P!G$ 8!
MT 7Y@9,A&@*(H $(H *9 '1G\ :M-5Y#$A@!@ *+$ "5I'S:X3;@(@#-) E*
MD0@,((.3ZFJ5A0( ,"^8V0;">OX&G$  ">  7&""%\ %EA@A$^  ;: " 0 (
MHM( ;HJPM2$(%J  +< )7E!_UBH9TDJ FK ! [ %/C@8(V  :M %05<1"= "
MN,&J^Z%-X+D!/?%);"@9J,!P$? 2! )ZIQACA:(*A? &I4 !P/( )'$"!* )
M62  U>I\;/ & /!M A!@"U &;* ! * )+!  OB$!E:*O+= E&, &:)";I8!P
M! $!U6$]G(%\'] %'K(B7("%<7A=@!0 $J ))B@EN:$^+;"XX5$&!W  $%2R
MK>9\8T(U@+ " I %G9  _F%9 ; ;;Q  9F"")L &0#<1&X VF4L;*E  ;8%S
M@< %!_Z0'"0P /NQ" 6PD!.P.P;  6Q@!@A0*2M  +P%!B181R#0"3N+N41!
M (PB"((H%W%; A;  )HP <EEBA.0%1+0*2<@ )F@ D97M"3@!JO@KAX CA70
M ""P 25  HVP @, MR1A@BV .17  1Q@ BM01!# $!0P&)%I(&$P$P%P+5[!
MJK]7  P@7C!I+:8B*R98(IJ@ 0/PD5VA @+P 60JNZCF%9N+%2VP !J0H%D0
M"@2@8UE@NI,! &?@!@,P5!]@ G>1 0=;PNNV>@8@'6$ J3B6'"$@Q# !O 0Q
M 5"* !80P"?PD2E0 .&A"8\G!HE HF:B!0+  FB !C;,=?X \+,G"P"NJ@H^
M>)08N@HF( !EL0%#5 '**0&J=P(#H G@QQR,$ ;2(0*^>1=(+!UPT!T)ZALQ
M51 >K H.P!5GP!QS[!4(?!P"P!QA<"TS^!Z=X)6:G"H>(  3$I2J,+-OT FC
M:1P=,  I )3DN 4!P & ( A5^\.JEH[ (0D#H!T:R 6=8  ZUHXW0@$#, ;'
M*"6E( :[@0&S.LNOX14E4 "!4'[5P<L3(0)"LA 8$ !90 (%D %6H@$* QPF
M4'=0(@@0  "4R9(:<\Z:"0 '03,!0  #4  -I3 ", $;4'B']  (T  G2'A>
M$7>J, *D&:T#$ $#0 %*H08 8/[-B_!X$4!O<8*?CE<0 % 3;2"3#P  ??,
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M<,"@6/ZM:8F-6YT@!F( %U#H!C(R""U CF(0U 7!'2GG!FQ0V[;]%6C0%F<
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MYQ:G ^_U<CK3D@D>]T:Q@V6T:/X:C9ON\L<&!G"3C#F.$5WN:K$LVJ%ND5
M]68O$Q^/@B!C#W 77O$%$5";!O(%#V !NV$*(M#3I.$)J*PE"U$"D.46:H!8
MIL$!"M!<)!  ZG,O(@\ ]U,^0?_>^NT:7T ";5'4)/QA7O&,<%I?'+"L#K[P
M.M<&!; !7= %6=@)63"]]0T;XD>XS4$319]N]<)OC8"\:"!\W?&?69  %+P(
M @ ()3 8Y&+V<@$ V$D:I4"\KHDMR-=74.(!#'!=BN>;P;GQ$/$% 5 ':H$"
M 3#VTPGV! $" ] 6:\ %%3;QE;\:H^ "I0TE;3"?55]Y+WHM$&%4W1$"*N "
M#><;F?X0 @Y@I5[1^D$ ^PO1 E6*+A\0(2U#^P5U>2J"-1D@!AH  6T !@UP
M40NQ$Q5+WGWZ '3K*3JX&Z1:"I&!$!YP!KBD"L\O/JL% 5 JX.IF/8/0"#-S
MF+D:CAMX0^ 2%A'P?JN@!1'P -64"9X' 9+Q50K@ !,!$(@X/*B 1A4;!@T@
M&-P"P8&'1:HX+.BD2M4J56(,9"' Q6*8#6$J2!BC"J08"A+*J!IDP6 ;"X!4
MK:G@P (;55X"P+FHZD2 .JHV!%G! $0F59Q./)#PQ2*B#0TLO&&9X0N(!RI4
M?5'@H (B+B2@:E'5:0.+@Q0:@(AHT6U9% Z:/@7A8,+*4OX>6K!@L$*0A0A.
M$67@\L'!B5*F/K3($F*1!S&JT%0@B),+B%)L,HC! ,'I5@@5@F2@&HC36]2I
M5:]FW=KU:]BQ9<^F7=OV;=RY=>_FW=OW;]5L"E0@(>(H(@ E5#T@ (($@!"J
M/B!PPP6 P0<#G , H>IYEA4 M&2"K@H$=>ML.ADPT5,,  DG&!C84**\"0)G
MO@3P&.) FRX 8",1 %H81(/V'HA E5(0T$"5$@1@  --5AC@C# "^&(1 %@8
M9 ,28 N! 0\($("#4A 10+E5%B% !$X0X *#$\ KI8U2WFH!@"#"&."#4E(P
M@(,SW I# 0K*6"0!",KP(( W%O[9 ($3&&$# "[>*. #53J@Z*T-&,C$*XQ8
M &""$Q8PH!07X)//@$[@ ,"I, !PHQ,$/ #$ @16J9,JC%   )!2$C# . "T
MVF" L  HHU ,VO#  $T""8 !$RP0,) )%,B"DT4UJ4 !5=IPM)  3FCC 0HP
M0NT# ;@P 8 P2FF @3%$ $ -5>8C80,"'C@! @(T&42 !%!X#BT&$.AK$ !6
M**6Y04;80#H 0JD3@J4&R.0- #;@X@$!D0O15>#257===MMU]UUXXY47.#8.
M4.@!!A999 "M)'C H@8P4$430 !1(595_ 58 TT.B$Z5-P9Q\015,@G$X%A+
M*: ]C/[*T!#" 1KI-0-.$LB@#304:&#@BU?@#SD+M%@C1PHH*(M$550((+*2
M,6 C90@ $: "+=#(T:).NNB"BR^XD,FB$ 80H1 P.EPD !0L6F1(5>#8 (5#
M*GA# @HF0$H53Q1X,&< &B&PBYXN4J [Z]RHV  NOP  $08'&40,!BI0Q0,&
M<L3(1:U2$" 05;((P&Z7%]&[#54BAQ8,5<8(@')$ D$# TK%"$"F0$='90&!
M\23A:JU*141T%]C( H ND-/*#2Q5&0&!'#U(P)3W$%EAS1,,"(,-7>T^6A5$
M!J!8%3<0.<-1!A78H!2[5"DDVL8!."01YRV"0().),B7I?X LECO 1?.T$25
M$-9\;R7K!FF!@(BF9Z.4$0R:]W\ !E"  R1@ 0W8&C8(( 47P4CSM$(0!D%
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M''#!+0(;7(4$,K *!T"@%)I@@ B>N8). "!$&2V% 2C6,>J5X #O:T &4/$
M"UCD#&[01 !$H I T&X0)T *"02P" SDBPW-R=D #G&1T.C4#8$@*H0"T):R
M=$*KG?Y8WI6^8$P"K!%8;[@G "B'"N;]"P1KE$ 0+U(!!IPF VLB9QU=U0D%
M9* 35ZJCJ=#B.#2L @,)L(A7I%,XMV!@ 20( 0D8L* L>)*3 A E4#@9@$P(
M @ HR 0) A (O<F$! .(Y>AZHKA/*@"7>"5!2S%@"D08P$!SJE@8)$%,B G
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M!\B1BE@$YH*#Q&.N59BD'(&#Y,P13K@3V72#ML@$"-B?M^"$-U"$MR@YYN*
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M@0A8 60E6 I8A"C;BC4* :=X@PH(@0R@&$2@@!/P  ?848DUJ \)@3YJ 1+
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M*6X# VX!#C:#A.',08C0MV  1*"HB)!?^H4>#"B?']5?_I6(_\VQ]N DOX"
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M!*I\$<*,!;[!EXB%Z"BGJ'"6X@$$/*G(07>MP<%7)QIHT4DG+2!@@B8(L?$
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M(Q!!=$ !>4'#F1"R" <\!R&T418!ZN >$RQJ#)D(G=I4P8$O=.XHJZB =QJ
MH$XP0"M!FR 12[)#-U1 *2 0P]]4$27>F4$5'9C=<R1D/X$$@@0G,$# 'M"6
M3#R -6^P0"<@T!9$7.H-]UL4T/Y448&CJ.@!G?  JE2CB0>TP 59N, (5/$
M-ZFB$%EH00-\MZ<W*"D+,%S/"11Q*82$((H(<=YZ2B 0+H2K 6T9" M@Z!0.
MG.U/)-B3@30! A!D(0@G.-2:U*<*%H2++! 0XIJ^0*B! (*5/UI$&T@ PP"N
MB8 _^H(8,A&"0F# EHU010A24,1G0O,XB["@0&1"$()A$0)JT80;LJ N-OPI
M-B@<2!,300&G:"%<'1C#(F@(&@^0 8VUM)D$^#*!4$4SGR%9A006<8(LK&)X
M&2A#*1B0QRQ4(%S @6"A%' C!APBH,N4A!P%HL9.2$![:=P2S::X)@MXL!1R
M]( '!?Y1@3N:@0UL"(2#9MD;"2R0!"'['1R4E$Z!9.$$=QR(!OB#HTMMP3BJ
MT$().I>)50"I$R[PY*+.)@&$D&!W99RC"MJ@!D @0B,A4($J6A!++I7Q,*4@
MD LZ,Y!$,( 3I=A=@1)0BC*LD0NNJR8@N- H$FPF<_K<*U]9T@AJ2B^#"ME
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M6N!DA4D5B!AH@5)H EPL E\,@N8APA9,CD L I<VR4"4018<)T*\07N4@7&
MP)/(A79VP1DEV]95:JE.7!9H:?X-[0B7YAP8<$&H&%!K(.IT;H$8T$Q Z8@F
M- "!@(!0H8&NE$#' ,("K,(78(D*+ ["K4G6X.:1$DT&R \8E%"#:MNN2,"J
M 9.29 *A9 &"^*6T)D<(L)5[6-*$T.DF98"8- ^K8A&%E%PFP(6?,%0;-( '
M@, JN($$9($*2$ F -$9-4#S*  )L(#@$(06,, '( (72, &L "JA8 M;8:9
MK,"KZ<BK:0$(:, J9 V7ZIOTA-UN))@%Y%0#8(B@\= @7$IS_-.O=4E;A$\G
M_,^:E,$#A$$+K-@B'$X0J&QB8  )C$&5[<N9=$$+ (*+@B<$N$ +0$ AM($$
M6$!UQ?Z&=F7!<F'K>H;+%X"&('B9"W"+#:E X9 !04R =W3"T&K! R".OZ:9
M66S GBB$H F$&F257NA*!!P)0B09&M@,":"!&&Q&8I +N490U#C%&)P)IH@
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M[6A""^R)3'6V9R<')$D'%C$ E94!3^>T;\$!(,#T"32*N:) *9# "@@63BT
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MT #!>:&6&UC!%Q@P1Y\U8!  $X$%,@"&3ER@!%F00.JRP$=5I, $<=P "TH
M/QY-8&.+B)HJ)' &33R@D%=K@"I(D+KPC<!]6?# OBA95'*=!A$/8)XFG$C
M.FI!C1R 0Q:09U2K=FL0&SC!_51A A54(&PNR, 7/)""1=ZR?]<[004:@('
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MM3TX$@@A$C:!$!CATQ'ZO!=9N[?<S=N8PVO[I3$\%9!\H%/8$ 9HA8NQ#MB
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M4( 1O&$!\"F#I892E$R4@H8C<(,#(G"*#20 #D%XP""X ( RG.$!7RC%!!R
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M#6)P0!K>=(H+#& 3IHP "<YH" E]0 !!& $ OM )!RP #.H\ R<64( .=
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M58@!  @8 "'6(( 0C(4#"%A$+_X!, 8&?T$5<:P#)UF@"@%G )N;>$TJ&)$
M#Z B PJ(A"HBM0E)U $0%JQ *(PHY J<!,!C80,;7E8*1,"A#B4YP2=>,YA-
MJ ($"P 0(ZX<A$R9L !J4 4<!D#C333  X080 C<, 8"\!($"? R"0)0@B\
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M<_D& S""#T !> $@J*>49V  :?!A7@ 2", ('S92I2 ""/Z@,1&V :I0"F3
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MA& &FX (:8 (FY &=3 AH$"X:S (:?!!A!L$A' 3A! $*_[P1[GA!BW@!8M
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M$'@[LM& 04A#35 !9UJ!+UB$!] $0&C"#0B$3H@O#U@%XU.%$:B#,BB]+\"
M4N  1"B%#5@$0NR$+U L9B*U/VR!3@ !-:@[54"!>LL >0K '2N!2@P!-KBT
M54 #V.*Q1= $#%"% *LH4LR 1Y0\#\@$#M J1F3%,G"!7#/%$M $!\B$,*B
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M,="]+)C).K!%1#C$#?B"!7U-XXHD,M"]%LL[+5@$O,3(99*$#,@JXVK)0="
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M>EU5B%U5< $16T!89=A,R%,+8_[)!2X#+1B#K&6]W2*A1L" 2 H%O&S;1?@
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MS\L 8'*N2"J#TKRE*5>#+Q"Q01B!+." 0<@$[!9156!N#ZI#TX, R'8Q+L"
M0D@X]9PP.B99$&NG+"@!%]A:-*B ]4);>=N ,@B$1!XSH&0!%'B[-?YC%_N"
M#-"P4/[< -.3 -R#+1-@JDSX@.VSJE*0 *LR]$9PQZ%+620K3-Y-\/]60Q8
M;18(!-(,@@WH M)43Q"4@&KU++'$K( ZO! H@PKOZR"O*%CC7%5( 75ZR5+X
M@!YTO0QH Q$079<251GNH&]W)R[8,A9( 13XUS3,6-.%K2S0@M\<LS)@ ]2]
M<+L:0"Y8QM],,T[[6XCBPS0C* R(Z6L3@16H< O+ *,\@U50.5@S3OP2 16
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MB(D>4^/(@;11!4"=B G'E8(,(D00$A!!)V9W HF5@0LJ6 4;"AFB3Y8 DBN
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M0* JL $X @]"E !2#((^8H#CF8P9X*,JJ$!!KD 6).0BF/Y30G !!X0(&V#
MX[R3"L !07C;"KH!$Z$ '.C@36*%_[T!'!Y4*9C*K$V$'K5>%HR._P#"<;C!
M<; !"ZQ ((* J93"!W0D1N20"0P$Z47;2 0" )9("WB 20">='#"%NRC&X"E
M"[V!3:: #+: /')-WO@/)X  "+@'"ZB&_M7C:F2!>VB!!U@D'091%J!.'A:@
M;.ED%GB6.JFAVS@BQ<7,MP5B;YF:_JT"ZJC""I2!&'S!&\RA;20-(AC/!0*"
M;2)-+GF:8*I""0R-"[B'* ;"6\:3"J"!8T&:368"$L*FJ$ E0:J"?E%<(H1
M1>!58IA3)A 3R36%QG$ %PC8T/X<A MLC80M)K"(@?L5F1NT7B 8#S%A)QX:
M75=(@$=L#A>HW5)AEDI,& L5X(TIB >R03U!(!H<1RVVH$K8&*J1P!G<4594
M! >XS+W%D!O*#QP\H=N4 @=D0L:]SA>X 3Z.@0J40M* J-$Q!!D8D8(@ B(8
MHFZP#4) 8/2$Q,(]XK]Y#F:M @GDWR)$YQMH E+FE0U22. -11:4D$I0""+
MW8.:"A@T:=@40M(<!"$J1NZ 4U;PXT/DXKKI3.E,@"F%RM)%"**M'1>L @=(
M#+NEJ0:V 2=(0"=P@@9X#U*<P!MZSAN(XD$<V1NP@0781NMQ#=-MS;5916"0
MP&N@@/X:=&BJ98(6*,A#H  +6-.&O% @U"GCJ)IJ#H(+'(<+E %'/6BY=0((
M("5W0AH2\B:!KL;E,*DJJ($*?."3!@:Z#447:(+;E('\M  :A,'0:()-/,]#
MN  8:&%&0$TIZ.<JY"D33@0&<$(F)%@83@0BZ.))Y@9Y25Q(M &0(H4@&$_\
M=>8;E( F/-FM,459B:4JP,%!7:M@V(4$C,3 98&"< %MXN,=12E^)4T$(407
M@,"&K,4&T(T)N$<CM%Y=],HC)84HNHK!)ND!#L((@*N\)<NKJ0071!]"I 8@
ME(+MB2H-Q03@+8W(J0+86$4!!D(&U(%U<@(;'(<)C(M24/ZHDX%$5GJ>8&P
MCX28]YB$J35"A6$ 24G-%U#1E*% \>&FVYQ!II( "Z! "ZR"J5'<(F2"!+2!
M&82 *V&.!G!!(6 .%XP "X  F3KG:K21]*R$31Y$"WR JC)$! G"!RC@7L3A
MEPX%"61![<G;N,S0:O@J!"F(!XS%%PQG_GG %P2!!N@?L$00"_@>!G24)@S7
M%V  ( #"O;) K($ 3;G'6C;BC*+ &'@ &"QH9KB-K5J3IH# "DF*%H" %E3
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M"FP 2I 4+$E&"#R>\71!FPZG+_UA0>F@?/#RSK= S]>2"E0 S@RE1F]&!YG
M&Q@=Y&P-7:I ]JJ"-?.N*G 0*JMA*=%8)G3 "F7J?G,!":2 [TI&B)O8(-R0
M4'E.8 !"!+@?%[R0H+.L Y1G"(0 &G0=*96"%:G PO&?)G;""DC Q\2]R90
M <F<6>*?^R&$%P2!IS6"V^C?"J#E"E1$"[S!SK7 T/ /*%9 ",1')ZC!2YT
MG'QL&(2 "N0.&CQ IK:1;*U&N9+26!3"!(0 )PCQ[G=D"M 8'+A 4URM;'D
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M'D %5H$!&" !)* 4)F  3N !),<#%, !4& 52(  1. !'$ 35@$#!  #(
M@ 0%K28 +& " $"97@0!'N #!( JRJ#=,H !"& O ( JQ&  /" #"( ^Q, (
M*0  ?/X$!26 $%* X%H  )8M AB $RQ  4@  ?2##02 _@+@=BPB"PY@$!I
M/\@@Y!I"#,3P# P@$R(@FCYEKU@@ #R@!=_@#1J  2+ :\RB DCP.S2  $"
M 10@$[H@SPBH"ZX0! *@-SJ@]C[M 3:@#0!@JRJ  ":@ 0! 3E3@X1Y  .(M
M#74B! "@$P8! "C@!%S0-IR/5$X@ .(# !Q  @R  "AD P: Y!* $S2! 2!
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M2@$,   0IC(+[/(H1L  :&(H62 J#W(MM"  VB 3$&";4'+)- $K-($--
MV( 3L-(S(D RZT,,*F "*(  "*$3X%$5P,  *@ ")* !6( 532\!5 4"$M,
M=.XA)& "4L(- & ,6-%>0H$!-B 3!B %2E("(" ")" #5 X['J(%<A-+!F N
M)"#5"/Z.!0R  B"@ A@@##Z#  +@ 1R&WP:@30& 2%*" AX@JA;@ ;) ,"E1
M$.$$*T"@##A *K:T(=9 ,U/" Q"@,8IQ2P#A.E5  &"S$QC 13B  5XG$#Q
M BS  +!C4E_'/@: !<#@%75B"O]B QK@*:,/51>!"P+ _D[  #AA5C!5_)HO
MYDX@*G\QI7K2# 0S$!)K Q1 3,D4$#(R/%A5)QS 19+412XS##; .CP@ 2K@
M 2J@ : K)0*AZ![B(-\ TB2@ CJA =#B,E<C"/#S#PE!71* *AJ@+)HOD4K
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M"N!U*/X  5;87E: X*82 C   0@ '-=R!0K2-FC.@2CS%Z&#2+] ?@S !!K
M-A^/ EI@&4L!*NG#7)=M @) 7Q# 9Y\2 !#@* H! 2:@!1X  DKABV.N%D?@
M(O_C%57  @3@/0R@1 (! !ZC%@M!# C  4C@%M<" 4K$X=J 2).)5CT (Y/0
MX>RE! ; 8^D7$6:Q>Y=LD&:X!2:G#4C@4UR 6+ G [($!>SO.() 7;(  SR
M2#HA$/ C9?5DF+U- S1 "1OB@C# !=(E$%( F+/9+ Q 68HI [[ %*)X S)
MF3H!9!!A_K8N@RX&,DX  \0EBC6@ E[OVE*K$]S&(<:  _XVP $;8KH:0A-$
M  -DUS.ZP)GO9D#,R2'*@ 2\)A-6P )&H#,&200X81! H/1<P&N>0D?@Q2ZF
M18.,)IH Y 3F@@U,8#2Z0 ,Z106\XIZ_( R@P^X4@:+Y+A-,@#X8P03"0Q-6
M  -$P/Y>A 0P8"P Y*O:P*D#8:,ZH06V2G8";A"8VJD7H0$28DN^( ,XX&ZJ
M&@/LB%_@\P2(!*8S(0NY( 0V@#[0&FT+4!78H ,JX 003@QL.A!,0"?>@.\6
M 1#<QPQ@;CH;6I<#EA,:0 %0H 7]9R2JPR?33=W0("E, B*YQ T"X ).  $@
MH+H4&\DJ+=C\6=B<S2$HSP-<YOZU4N':T VU24432,";N2VV8;O3NLVT.Z+0
M+B*R?!NV&^*UMTVVLXW6SJW:N*W2BCO8E)NW;[O37ONVE_LNMJ[9@-NT4\+N
MT/.X<;NTWVJJ/: %KGNTS?N\T3N]Y>O<2D+<1AO4?OM+V%N]AVRZ'<*^7]N^
M'P*_(8*_5<&__?N^!?R_]WO "7S  ;S ]?O "7S!A]O 'SS"$SS"#3R_^[O"
M,9S"^7O!-UPB ES#*3S#,5R_/]S"(^+#&7RZ)QS$!9S#1=S$53S#7;S!/1S"
M4SS$67S$+SS' [S'&1S$'?S&"US"3]S&.WS(A3S)?7S&:;S(<7S%11S(=US)
M7SS*J_Z<QW_\QH,<Q:$\QZ4<R7T<RW&<OLF\S+]+"J1@"M1\"M!\S=F\S=O\
MS=4\SN<\S=<<S>W\SNV<SN5<S]V<S^O\S@/=S?L<S_.\S^L\S>-\T0^=S_&<
MT!G]SQN=S@&]T/?\T ?=T"5=TA7]T@?]T]^\TS-]TCD=T4W]T2/]U"<=TU,=
MU!\=U$>=T"']TBN]U%/=T5?=TET]UV%=UTU]U''=UCU=U84]UOU<S_.\TF\=
MTRT]V)'=UYT]T:&=U)^]UY==UE/]"2[!(4C!V)6=UJE=VJ_]V,5]V*,]U,D]
MW:T=SFF@W=W]W>$]WN5]WNF]WNW]WFE@!O!]W_F]W_W]W_X!/N %?N )ON -
M_N 1/N$5?N$9ON$=_N$AOMYGX!$<XA,B_N(Q?MY)8>,YON,]_N-!/N1%?N1)
MON1-_N11/N55?N59ON5=_N5A/N9E?N9ION9M_N9Q/N=U?N=YWN0AHN>!'N9%
MX>7-O.B-?L."_.B5?NG'_&S@&\F9/NJM+.G32R+8[.E)@NJE?NN]S+(R 68W
MD$PL<P4X0>LM B&X/NU)>Q$6 :_87K33JP4,8 !PT5XX29M]>U:TF;HK^R%(
M2(5))#QN!@0X0 .FJ@(HP/I<H)ZR(  F6NTA'\@RP0$,H&H"(0$,X"0AH@Q.
M *W8() 'X0Q^F*[HK>\3.@ J!?[K&\(M<^2R1]*> , ".L "5E8!6"@!7N0!
MV*H3$$!9(O_W>TS2&& 'JPX!,G_19@ZMDA<%_J(1A%8&2_ E1@8N/(E'Z6-2
M'R!#:!L",J">?D@"0$8,/-3S-$!V0>!0U2  %,  >D,+%( 3,B'2T%)$.\$#
MM%EUPQ[X]3_&,F%F$: W ,*"!04N5)5R$6%"&%5E&C2H$$C5*D0- "3(P*63
MJA8)+) I]<"  A"C'$AHLX' HBP(+(@I1>%!F1 #$)5BD, %!@ G$/%4=0(
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M8!DRD($3["@$*CC!!%:PS4%@)P3<^T(#LX!*<Z+  QF($=-:X((*>(!M6=A
M!BB8A:A9\$PRTTP)L'.B+#3  FYX Q>RT %WAL #&AB7A3QPB#QE8 ,9)*L%
M5K "0'SA@X.035C>X $.?.!,7^ ""B:@V,* H (M $$_F0C/5;#  QOP E'P
MJ I 9  #0_UF*4K0@.RL@ 0JF$ )Y%2*$VQ  P)5A1<>$B,VF%8$J^+"S_+T
MG!9\(?X$$R@I0RRP 2Y08%5EX$ 'XH1(";!@(X)0A1M,2]FMK&"H1951)C;P
M@!"(3P7[74A8!D&T,FA!!1(H0QDPH(&AN$ ,(J@ "]YU!@Y0\ T<R  (,M$)
M$FAD%2=HA"9 H $/H#4L8M! !C@8!A=W(6I8@@@^3U !=L8H"V?P0!=4464-
M"!,1PE0%%]!X@I70*!!?^( +)M#5L"""!5\ D141T0(Q6.! +;!R2<OP@ F<
M^5:'4*LJQK"!#?SX1PYFI"D-LMG.BJX->VVI&3=P84\@P@(0.$$G6H &"_@H
M"U9N9!>XX%@.JA<#65#!_V1[@9^=P<HD<)H6$+O$.!OD!/ZA>:T&/NC3^%"D
M%( 8 !HTH=_?)6D#P9' &E7A@9(24YPGZDHG&H!LR"WU-;QM'@/&@X$8 :("
M2W8,5L>R @FL0 4IV' 9'"VC>X?%%*+J1 U5D0+95 !@JIB CQ*  DFP(0&E
M<,,#"L$)$.SK@HE8! ,N%8%QB4$K9GB \SB04J)H85^<$)6-#@ (37 @."UH
M5B<P (@Q=.L-!CB1"(BV(Q<X#!$8X 0HO\"),@R "QT&04G?H-8Z0. -I= "
M"$K1B0U,Y<J: (0!SN"&E$X5GQ483Q;:)0((($(2#P 8U=E@ #2Z\P$L\H!!
M)/"I!\ AGV70!!<*$!&)! (";?XH!8T1D0D(]"8$1%O$!&SH&PMD@94-  0G
M,*L*PA.EO*J0P <D,8@$+*(0#!!$)DB@@%4T<54AR(@)0'"FDUC\4EHX2AL&
MP 9-E,#MSBS#OTF@XD&>B#!L>"@*$1$(!+#@\PZS0 6<-X%^8@ "9L@$1=K0
M"0FKP@( 0^0J,$ &5<"!W?FNH07W=8+@1%Y0"?  ],-B@@]H@O.DT8!,,G$&
ML4/0A P8"HC(19PFEJ$37V! (#*! 413+5V2"66P $$U "I@12NP 9JP"!.D
M<K96"@O0/(3$!A6@":M0 CM#&(% *2'0!8N@ 'FR(B77".8C 4/$ N_V;4-!
M H"4!?X88!,/D %J4 I9D &9 ("" @(34'$.@ 8W\6Q?, #_\X!?H ENX !\
MPF)Y@@&+D D30$$,,$2:P "EP 7 @@@7P#_)QA[+!@<60!3K1A:#@ $<L",G
M(2--%1;QMT5$$7\;1A8A9$M1TQ3*TP"!X :#X  Q0AB,518J4 %9$ 1!T$]C
M,"%AL53FQ$P&@0AM  (KXD%$@0'#$@&\(P&9$ (99 H1X0$N!@)F4 85, AO
M0'.:F$$.]3N<, AEX "(]P4.@V9N)WB $ @D@(80L JU]D:'EV\/T 7&H@H8
M8$5A(#!( 0A:0$C^MB,1\ 6   @FL &=X !Y0P(4! %#)/X!9Y(DI; (;D "
M;O>"1&$"&>$ 2>)=,K(($2 GG3 (9^  XW)X:'",$C N=R4!JU("O80"63"!
M;? &@W!<0,,!/T,"<J@*$) (*M!((- ;]S1]@C!O0?, G2-J;) !&Y8%'S5]
M@Q $SE5YJR&&JO &(UDM1_%M77$&<R0U8CB1<S(4"S2,!\8&%" <GL4"'4(4
M$S (9@ L*, %%!$( 0EN,I(!=OAMJ] "I.$8)=4 S>1,"BERP:$!&71LSM0
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M6B!W'=1('" H2Y58_Q86$L 4FOY0 2@ !@U&DFG,!8WG&&X[ @C ?PSP!5W
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M.Y[&\7 !/')J4[K?[NI?\+A_+!55\-AO4<*#(#;)\]E4ID 3UG-Q46K!_A(
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MC0HT664$YA3JQ 4-$"GE 14:84,!3S*1 #[7(B2 BT$TF2 Y%?KDX(%!),%
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M#7#,L8 $S*"),D@ $9H P5-"@+4VJ"B"$\1 =1+ "=<=2PL@2)("FE8![I3
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M0";,4/X[J'J4]5D$#CB!MP !8&*ZU%B(!%@$#U@G,= "S5&(,T"9,OB 4D
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M50@""?@"%!B)\"*($# /_;DAD-*""MB 4G@#! B/AD*/@QB$A.$$"E !,)
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MGL" $$BS4L"B#8"@$-B>,CC-1<AEC/!N4PNU#3@!$(" +]2""=B $IA$B;@
M$;> @T $4;8X#QBD4O  NZD/#Z@,#/"*O2APND"$B*$RGXN1LO. ]NY,;,0
M$,@ GB"![0(!-VB#!HB +&@$#F<!:*F Q\T"#= 5^-C#">6-P_" 5K-R%9@:
MU#B!"MB>"7 6@F"#!X" UI& %( 9YD #@L(P_2MPTW(!)6^DCV"<#[B H7"!
M"F)PMF EC5#R%N&/#6@!IT2$"3@7!6>G5L( %.  !^".&OZ'\ IBDZU4B!8
MH&WT"BWX\^00@1(0@0EHO1*I@ B_7Y50< PH8X? +O'&OECQ@ [PBKM9+X<
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M/BV7NMPE+YOVK'BU8!4BR!ZX .$P54P 1@]P@RH2 *,*C$$5#O!$(%02 K^
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M?NB\@A@B5 "B<,"WA$")7@R"@(&^61?"F T)> 7[=!Q[#-<# $4=U)@%P(C
M>< $8(4'A  )4$!TEH(&H$#6E/[H%Q@=!0C$<6D"!W2 !H0 ?2S"!63 "'!
MK54 3GH.>YR "7#G!5"1!]C(LVA9&2Q/ VS 6S' !*#!*J1 IUW B<1<!=0:
M!JB !7S4!T# ]V" "%3 >=JCDH7 !A#$!E C!##&B6Z "5B90:!);NJ*!TS/
MBC"&%MR5![3  ]1GE$0."YQL)X" !VP 1+!!*VK"!<R?QDR !G!:-)5!C0U0
M0;B UUD AJ! !23:4ZB!C<V%7)1 !81)O(79!*0."G" "5!:3VS :+0 !GP
M!IR(&TSM!'"HCSZ 7]!L1FA$F3*7"$Q 1[1!!S3%JV$ !6 $(!@<!E0(;*B
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M%9W& >BD<A# MV2" B!")@P 5H,%G$3 >I0"!;C>54='"%2(]VC$HBC,5X5
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M!$D#A8#Q"%0!$:J6I(<&N\ )$_Y-3<5*YIQ \416"6 :0:V";T92A \""H3
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M _+"4^4!@4J)X"(6*BA!@I:R$$$51"H( 80,.!F("PM4..&$@1 A0$C[JL2
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M>202E$6B;*C+/S%I42:U@0(>,"B39MJD-R2H2#6=5;Y<:JE6]?1)Q],I]U;
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M$30@!#*@!)Y(%7A0%8( !$P  RJ $T " DZ"#2K !%LB>DR  T8  3$B!%(
M!"R  T9H U+B +UJ UH =C @45!*"M_@)3(  A1B#=A"$S@@!#X !.!"/+P@
M4G@"$1H ES( !3S@ <J""SP "R= (*#& S* 4+2 7KI !4I!$$&@9^!  A[@
M!#H! SI!!!Q*!-HN SS )%2" TR@!P%A SZ@)90L$U.@0"0 "O'B9 3"*SK@
M @0"!-C@_U1@ QK )C:N]#A 7<J@QR1 .%9";#*@5+K.DSC@#4J!$*MF,BY
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M#5#  %Q$Y"3 5+Z 4(9C-DH!#5)T*;(@)4=% G#T#1K@"[3@"Q@ :8Y%%;;
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M\V-G!0),H07HQ04^L0%PRPT^HP*,C0(4,5L;8#8 4V>'*47*0 16@0&R8 M
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M&$ A6,8] E)VSZ #[(("!@D-2 )X!\(3'D)?"M)J(* 0//[( 6A"!/10=4Z
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M[((% %J@3QPCMB !R/=MAW96<A!H*@I!1L8!3,90," $+/Z @F=IHJM7%2[
MA7 \,5J4"RH5 L8'<$PA*W B!"9B;%("0ZA[QB: /%2- UB:/!P@$]3@5C+@
M?=22=YZ2!!P@$+Z;1&XQ5,)@5#! @R9@7+)V)XBSZ=K## Y Y50!4_P" 3;"
M6(8N)+Y@NV^& ?XC=DU'<.1%$RB@+C9%$R2 =YX-L7="!#0 4)@CXAQ"AI\#
M>*-WHG>B8/7"#G&O,E+ TS:#!%2@8 )A:PF;>6)D%>H  DA U'?C'1T&I4Y
M-,X@ 41CDDN@ IA4%>   @3'!)2-(#9 _T*  I C#!Y ;AY $4)!PU4A$""
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MN>Z5Z0U> )<:(' &B2#B"V<XF?X> X2&":C"!1!@P0D6,"6#P($!*"C!!$J
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M*0,\@ A!KF($(3C! #P4 A!,,H\K$D$'7% !+:C"#!8H2!A$MM0+>$@5G8
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M<7@&"&_@<:I !BP592'1"1+0$2Z@4C$7"("FA&V08IJ@15AQ;EF7:5C1B9K
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ML20!+I )B) )FX85:I"L9@FK>!5!)@>/1@@H4J<CF0!2#- )AT  F/$&"\!
M#O 3;<!2+7 KY?IO6-$)#< )9&!;JJ %#E<0$$!"8C !-;$"C J1$8M/:*!D
M'U83)?[P=RKP;@10"&  GOL2'B40 HAJ(4/;:1OZ /+3ALKH *IP!@X@-"^X
M;EOB 1\3$E_0MP-K$ESPJ[@ZC25@"H%@ )CA70!9-0D@$5WPJR(P=!6@!OEV
MKR3 M$(AKBK! " Q G-G :6B+E,JI6^@&%R )ZT;'L?G*R?@(9K 5()@ 1[@
M B&C"1Z@$5] *YX#-HV5 1Z@'(A0 1H5!B10 AF  6'Q!6O&"1[@ 2<@!A:
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M*)!Q$O[P 5 I" V  @M;%(,@<(T$$Q. 7QN@4X"=5:CT$QBU ANPH\'%3R"
M3TN!5RJ  @K@(6YP4_E5"A5 )Z8  8. 52N@ I3TS2W& @X&24OA!H6&^'D/
M>XPH5S3U42" ")N6!?LD$5^U>!-P;U7%!FBP&5]@82%0%)G@A!ZACRMP]MOB
M6-?W 2#04'J'3W0%;H!0!J/_>%G/ %""%E<HOPX@/VW 3"1 28!  1*0!:@'
M D$P 7GD5\VD ((@",Q/*X$O?B; !11 $!@0T (__N1?D-/G!M\&LJHP!M)3
M:9Y37&BQ[G=L5! P-QB0<1%0;]"U;ETF3@4Q!@#!0=4#-/ZJ2A6$<,9@054-
M.;1H>*',P$XM1#0,,T$5%PL-+:I:I:H1 TT&%:Q!!$&5"1(-S:QJ4Z$AIP>E
MS QJ"&%1IP2+5"%Z0Y-3PPIM0*H*\R D(@:KN+14I6+%P"P-+9!IZ"&$*@P3
M5:682K#A@T)'!WD-T66@0E4.%@5ZT! 1 IPARTAH^$4@&D$Y%X$!H>I-1PYB
M/)XX"J=!0SB(%DDH)5BFB0T-RVC$P*6APE605;&!TW!"Z F&54$(K8&-JC*5
MPY345%,3!$]'04!4Y:*RB@F1OV1HF(E!J1*:163(M*BWJ@X*URA59:9C0U47
MID;="L&HJA,MGR*M_%-E"X'<4?YL+-$00QM.7QJN0(R!(77Z]>W?QY]?_W[^
M_?W_!S!  0<DL$ ##T0P0047S \$]]C H"$W.BI%BQ)&>, G#]P+J2% 2CAA
M A=*>:"3AK9 @<1.0N(BO0P*6B6##E@"H2,V(+"@A$P^@Z""$DHZB@.OA!Q(
MDP_*6&451#K*(KV-1CB*#0I5 <&,QU19Q(()/ BM!0FZ.^$!G%HDP0%$-FH
M@Q96 80!%$@X00+W(FOQ* @R^>*BJ*:"X,Q.,@Q)C.Q$@#.#K21 ),D)<**.
M#1),>  ,522H:X)%NK@H) L".2J,P%89PP.0P"BAA 8*F4T5%#2#((02*/N
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M#]@ %V"1+S@!"C!"56@##_" $2@)#Q@#33B!#H&9-M  #C@!$_$"HT"##>B
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M!0 $31" %E@$-%" Y% )]4,Q_RL%CCB$50B!(%B% -.$3G" ,LB$+,@C_7F
M:/F ",BGX0@!%B"T$%B$1D@ +F@$+M@]@P@B[F!'"+@;+C*,!N < @C%+X"
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MG9$;3CB+!]@1,\$=N24#<L(<X HE8VD#C2"2SC*,6UTJ.,"+4I#;,F@ GZ
MG.@[N?B=P4F=9?I5_ &.:Q2.0,!)"!B#3-B]6Z$/"> LX(I*Z@#89J&2$QB$
M0! #!3"7-!L!Y$*!_PJP) G9F' /ZMP_SZA3>ID(%8 (;%7.CAB#"'FE"4 $
M0! $X]S8DE%?Z@ $:Q*$"@#>#!@E"+BS/R%*]3$%R'B^O+$G\N&""$ %)QL$
M$J" .V&#!V@!J<@"1 @$X "7K/Y=DA#X@J(Y#6,9!,3"1<,(@:I86@NP6)"
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MU3B#RHBD  *$3'A@W&& P"L%$ "!R00!#O )G5(5B% $SWB, %J$- L$?J4
MKW MMPZ$Y3$1W\$T$,P7O' #*S;>A1O/AIB6E*".-@@AX%@/!P*FT#"FTQ$,
MZ+T.%9AH_":8(YI*&:R,"@H]59X>+H"20=!R)B]R5=  AOB Q^X$SB&+A@ !
M-MN( &* 0&@-ZABE@[+=-E( SO[RYXPS"<X"5=$9&E6( &7J@LJ(X XH:P[X
M+]:(D 1@E @H"2P&'@IPWK@;5Y]0 P1 58.);!8(C-L-/DY !%%?7OH(T88P
M@19H/NI(=+?&B1+0NM4P9$%2"Q*0Q[ & >E-&?U+5L_&3M%0B!*HBD#8O3(P
M[=1IUR7_/M=.D+G)#"YX  5*@6G) E3JA 7PB0F7&PA0@3#P@&E:!0U()*]J
MBPHX\!4((#-0@"X +850 3DR :BY4A+P%'PYUC+0 @@@@94MK!:0B"SXIE50
M@0C:3WEN@3"  /=H <=S 5&)C""P@#&P7P^(D33# #$8A : R VXDPT@GD @
M@#2D(?X5*(,9D98O6%D4B,JBC@X P(D0@ ZM( ,68( LZ(0:*H,/ #M- ,M3
MTHPL* W>* G^9 U1SX PX(F!=LE52(0%R"<)0(&,F I&9<<YQBIRP@ 1@$8"
ML-RH0(#(@("/"H&IX((%".H%,)%%</N9B  2:,6MP(!1Y((1;PM F/"W9P 6
M.@JXX((O<(!18H.T_@S$#PX$J-,4B&<2:%\1V,S1I!T ![G0,H&B6PH%0$28
M;8A24;..E_P1VP!I_(+_EH T5 4VRH(O> "(3YT3N !D@8PV4(F00%BYX&,P
M>/B-@  QR(($*#ON %;[S:7:VD?B5("&EP!VQ  3$ ,58/Z +U@%!= X#2B!
MZ&> -]6 17@N_'G]+0@D"P!EU#R*$(" P;=7-2<!,E@!!I!'VD*$C_>0Y;8,
M"=B .!'@!E!. $@S%P"("6%00. TJ,$J50<3JEHU <.7+ P6J?( 0DR'$*I4
M;< 0*!,$%6$DM."X92.'+*I:,$"#:($J+A/*R/00Z@&@C:H6,="DZHN#+BP*
MF%$EL4PI"22^7)#P$T/#52 XB/F@H93.K%JW<NWJ]2O8L&+'DBUK-NR9%2O:
M;%PU)H@@3F%*L<%*UY,J32Y8(&K3256I+RK.-$13!LR7,@P5LE#Q1B<:%5RP
MOLDP2#)6565< .KTA6YFS9P[@?Y9%3A0J34;-659D5,5HM>QLV[N_&75&XJJ
MWB#:[0*IF$6!>N]T\%<5)RTJQ"3DC5Q+BC"+575"DW#0Z\!9$"T2@YQ+].F<
MN*A@N]&-9$X;V:A?9#[W(@N#5FCYVXE-PDY;5+#1R2;,>2IDH1Y@Y WRAD\Z
M+=+?;L0%,@A@8;11BAH)4;A8*>1]I@H&;)!'''NKJ&%7A5LMLA>$>3&H"8,;
ME=(&(BQDD:!F*MRVDQNJL)')1FUD4DHB>:E"P6OG?:%0BH.D:(:-H7%TAF I
M^JA@"RL$LM%L&YVA0A=896*>*F[HME,6*A3)Q@EG#'(E9"JT0%Q@*I2QD0O\
MG8#&1OZ=<*'%(HC,B49FXV71YYR+<*%)EH.PX()N8IY'44(7B8$"FWH.BHAW
MABY"UT:<M-@)C^H5=%];9:B7$!N2_>5IIRVN<L$;K>FVBAARZI0)%[VQ5MY&
M<! '2&^EA/$&A5JV0"P8G;1!(&!K9(8&"X$ 0I&P_672PA=][?283K4">!:X
MX8H[+KGEFGLNN&\\@"Z[8HDQ04GMRLO5(3#->^]&#W"+;[FE8* "&B1H,!VX
M$N#)+[H)K: 1PEY=\.VXFDB0!1H;D&#N*@P0US#''7O\,<A=)40P0R3K1'!;
M)T>UE<D,:4+8*M.5W%!6(]?,,LTIZYRRS#C?#$87,L?LL_Y7/>MLLU9(JYRT
MRIV<H?3-3._<%M13$[TTUJJ<P>-B**-L]5=5#YUURH%AZV3.(J>]$1J0DFUR
MUEU?777<607R&-Q?*ZUW6&ST)K317^?%!0N*[>PU5].9NC;C<H>-...'2WYT
MXV.'?#GFF6N^.>>=>_XYZ*&'++CHI9M^.NH=ET(CPIW(K0G:72'"NEF>, ON
M*K1S5<KM@.D>;BAOO'$<5YS$?FXI>+'\>^KD=D+\U>/F!WV[L#</V/%1;S4[
MN*N/Z_V\O)_E>KB9P#D(Z=>KS_',;EP05OI%:Y7!G(MQ4/]7*CC0'^1=F1+3
MQ>"'LT%08&9,^X)&;(; M,6O*_YM@(!%'H"GGHF "Y'3"2=80#W(!0%"7?
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MA.DL8JTT?8P4$P*&?)9D%6O]P/Y,=K*"+V3 (UI:ISU780J?GD %"=2)&C;
M@1/\I05E $$%)LJ"3&AB!6#(@ 5RHK0NS%<+.H+ !+BP" Q (+'8/#.Z2& "
M582B ==:,R(Z^08*J*($)WBD"U1Q A.88A$58%-"T$#,,$ E Q(8Q"(FI@H)
M%"4+%ZN =R3 A4R(@0#1E>@JX% !Z"%" F+H! LV8+X)Y)4##PB.-"_VAC9^
M00& R,0%"ML"H8*D$X@8P G:L(H.<&$5P[0U L+0XG&VX0&#R 0)LBA+5:!
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M&$ (!+2>0@S?"L1+&Z3<_1VEN%P (J# MH$;&&P:'$Q1"JQ 0A1@*33 -*U
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M9:D^;U@L @$PGH^>0*TL0!FHBXXP !=D 0)X61DX0$1@7,X8W IT@03LGP=
M !=\ <.J0@5\0!F<0,7YZVUNP*00P)QLE1B<@ 3<3I;F!!I P!=PP0.TW@7D
MU72L0%09L"9H03--K<6(P0HP !@<!,VT@%M=8?\9Z\6I0B&NE01<%%&1TP.$
M@18P@$:P00-P 1>\+_DUQ#J5@4^5PA9DWT:\,+;@6"?@G E\005,40@P0!:$
M00/,R0;03PUWP@.00">(P$6T0/X#E$0#O$8#/ 8'5 "FM!$(@, 82/&@E*XT
M.4 12V)%Q LG<-6[ *+Z*> X 2G-A #^A@" A8 %E$$0C! 8- !B2$"1+"L
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M^& !D$2))PAV. $"P@F7JEHPD-#F3 44&" $4C6RPP83&B66(N&A*"=59BJ
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MZA,Y+2(O-)HXI0A*D#1^J: ")8@ %WZ)G#8X@&,2( $)'E"&H10&I<-QU0A
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M8%@IRKN*12""RX@(\H4E N4N(P(I?K66>:V;9C6OF<UM]F<+6G::OB414JN
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M8!'>@$O8@  08EPV)2D>P)S,<2JILBI=(A,48 ,20*4D( ,4 $HR80-L$F-
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M$0IT# +@L'*QA?8C 4Y@-'&S0 /!,S<"0#8B XIQCH:Q4/.1 ++ #0:@J5:
M"U1J$%;  @A 4!L# G1%(D:@$3G!;D#  %JH ]3@JS(F"+J3 5!B2%5U53?0
M2%7 #1;@JA A/"-2!41S2E+  /AF*"A  'KE"Q2  -1 $@8 6UXQ"SI!"P!
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M.G4[$H$Q2L$-=O<J$>QO3@ %^JD-%((VXI GJW=]V?<!W?9]&$T %:TU6%
M4X$UZM<T\I=?#DTUZDP$)ZU_XW<<;X. IZO2J,R Z?=O!$V!0X72^#?1!@V
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M-:@XB1F,>J.) T  !!Z@3"*X-CQ@3@)C'0FX;VQ1AFLC" [BTA(D+"5-J$@
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MKK-705"Q$!"$@Q@\OO#4KL-,=VZ".O*)K))G.3Q7@A<[8IU)E;0J.2S@ S#
MBDY@G35 ?,+2 S( D.)0!3S@ 83D!!A@*O1Z3S) !-+</E;&Q+DL QJBS--R
MG6>R%"C@!.J<E[;# UB  ^+JT;/@ 5(')C-@! )D$3"@SSF@/D! #<""*G*4
M RJ "U:! QK@*!6!MBS T6NE-\L 0Q$D#+ %)MJ 1MY9$U"[$T*@*]C'G2:
M9$6  _Y@697:( (T(@0VD4[B@PT4@(3#C"ZN5B-P1CM60'('P6Q<XEWRH@Q"
M@#/M< -4X (RX&4D@'PY'2% 9 ($H1.&RB,L "LZ0@UF!RCFP@VVIC0\X O:
M("BB<"F./3DRH*U:P@7\)01*8"S$ *8G*1%/@ ,>H#)0@ % 0!-L902(AT0>
M8(W0H#=M41">(PNX5R(FB\''@)  + ,^FHYFO>7;X"TR( )4Z@V<AG_:IQ0
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MT+ZAN" E!9%>6520G4DEHGE;Z0K%]N*G@C2,#>XJ9"$:X"RA\&0B)  ?"<]
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MCW:FS $TF,("(2 !"#"0GA!,0!-F8%D+(!"Z@KB@1D)B0 8RT( =%]<#)'A
M.B50\PE H,A# 8%$0I""B5BL)?C2T@1B E:*F.1LZ<U KB6@O15<,YNH6G%+
MPB !W('@,[^:"#FOHX$2@(!6!1&$!+8=K4)[P&7 ^4*_,="4+@1EW("A+47:
M+@(HKL)5QS((5ZYS,?!J# T,P, &^C21,'4 Y?MYD@0H, $<IPEW0\F4;5B0
M\@E\9R(>R-HB'L#2H'3@1Y7Y0OY;'!\O$VP !,3;]>80D3!.,0$FH (G\ "
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M8N L:0<']9H1"MD)YSD^+#L(N@.**Y !@Z!;:<J#P7H4._X[2+4*!FLT"!)
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MY (<8"UXXS=0Z\=_S&H/V$6K8 %KQ!>S5!:<D !1 ;:.H1W-T0(I &>LT@#
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MV!!@1<1B&5R@ )E0O7!0"B+@2]P9 AL/\Y;1!0LP.WL45YSP[B]_1<"R 6K
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M@8L,-.'@+Y$R.:$%-"Q0I9,0XB.!/@<6$XG'##184)45,! A# _&0..$'4/
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M!*M#%<!03-G BK#AA!#@@"PH@=(TJF/]EA:-2%5 @V^DG4R0@ A=@19X@S;
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M!"B%COX0"388+5VB@&UM6(]1@33\ H94@(S;X$Y8 - X@9@[ 0L8@Q.0 (G
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M12 '=WC @8 NB-P_8QI-^(+G)I0PUHXSR*3I00,!_HXOD O^2>N.VXXR"/F
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MC*$49\! *00!@3*0[BVL4HH&.("(0"0 $:5(@#PML(JI,/$C:!C)(@S L"S
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M;1VRB@ET[B,MT((6V* "-VA@A/XDT$ +5)!4PT5  Z1#! DJ (&>R)+#IJA
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M%H" 1;D!&:D"(*30%[!$ P#?WY0"!D".>/1?0FA!\D5-&?E)*2#$!O"&)G"
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MB!P,((C'&XC!D?JL3FB"&PP""F3!B' "$;U!:#!<*:!7%J! BR "CW2M*KA
MZKE'H+5!>[B!V0I4GI;@"00:&LR9VW)&WYP!<P ""XB!-?:$X:E *]H8SN8I
M&G""/!V4A/)06U590L!!3Y2"\_YA+4O4(U"4+1>@0$\DI,AM!-921"E$1B#T
M!!HL2-!2"6X%@AOX"!O41 EF028 PAEH@J .R("<@.C]&,6J0B%H 2<L@KPJ
M2H1([+LLAAE0!!RH  J@64+0%)4 ;T(, LAVPAD@1!FDP J\UBKDR"J(00L
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M%9)2Y,9O(GQ CB3 B?M11JL0@4,I;.*W!/1,(FJ@ +FN8H$<E:0"M>*)5A4
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M#7)$$PI01C( 0SCA"Z[BJ\"M)!9!(-J&!=Z@$[J@$]B J2("#$X@" "#$[C
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M!0Q)"QA@ MB R3KA CX(!%0Q"S!@ QYX%4*@ 8CWSB2@##1!2B_ Y[+@ CI
M T*V AP !"++&C% !3   MJ \&0F!-8W$U88 TY@%;:  33N#?#D1=Z@ CC@
M4GIV \KL ;)D/2X@!$; P"#"#4! !2P  NB+"X07UGQ%!3@ !0#A 2 @)^#
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M+01J1Y/XXP*NH@(P)#+2HA&^+_X\YJA=&B WA,T=:\17$B(+P,I(!N$O,*,
M0N%3'D@!=$8#RF 1'N\+&&!#2*"HG0-"N",!EN(+$@-C7*(_.($!8G=G;".$
M?-959'80?$ZR#H,-%" Q/$!#V0:R%6-#Q.#YOL4 R.0,.NP+:B4"%$$3"( E
M:P=,5D$,!J4G;":ANBAR)VL5(&=LWJP,5L$%*-<3V(!)Q, ZT. "&(H-#& R
MV$#RMIDFEF)&!H4R^"@#E)$-!J ,.D$3&@!1_,(T#*",O*TW!F45>"10VH
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MT(*AN+$!(D"CKT2 @>C1Y@1W49"]A(."1@:*9*K@ERK@( &2E* %I:  "5:
M@@>T 0YK:T-U O$@$&0@,U^ @/5"\#956 \%$I".!%2#DC<8H (4J( $H 0!
M$6F"/JNH0,-@A!(1W#"7JBB!!2JIL625YB$JR(#&EL(JD71B Q#HP 0PX))2
M>( ")<B>:]#P2V%BX&=+Z81%5/ZA@LMEHC$E^(C##K*\!_0I@:I0#R(0YH6&
M(4*475Q/![Q0DI,4<RG*0X$*[(<($2CN SJ,Y9@<<)(4->!]JKA?&R*C110X
MLQ.=F  )1KBT+EC !2U@P!C@P*X3E :%OLNI3G?*4]V58A$H7$2I E&&5)6B
M#&_X:4S.D E.?&L1.S%(*5;2B>"=@0UHD5U!&B$KB=4*?G""*ARD"HBNJ@*H
M!4G$1=I0AE(=B@VCPHX;W+2(B]15(;52*B>*M->8E&$0I9 $T\@@$A6)Y#@U
M6L5=>6;752A5%84@@[1J=-?'GA4-\PH$Q]XP!NR@! PBR(2%#!((-2A'$)8=
M22 X\?Y3D@RTE@:!0QF*I-BL7H0393!#5]]0AJ\NPK.!T@1NZ7160)JJ#&>0
MU2H(P=JO[JFS#D-K;=\ IR\T;#.J.(,'. '=V/8V)CKK*\_$@)W:,A:OX%4(
M&GBRB$8\]K&=, -6&S0&GM2(J+ZM92<040A$#&(0DE L_&K%":4LMFMEF%=!
M!E$&D.H';MU=#1>N-0@U"&(U#&:#K$K!WT$XMT:ME5CPT' &V-XM$T5-H4OJ
M*F#QE@(-:$!+)F0ENS%<#J><0(-("K'74C45;F20!"?<*B 4:D(255TJ7.'W
MUQ,8:!!H*(4F9.<2)/?TREC.LI:WG&6<<KFGB.#:[KR<4_Z2@(%UNLL" Q3W
M91RI68>Y(W.-VA!#" +W#$MJLY[W_"/!P9;/-I)SD,#P84!7B5F&3K2B%PT4
MM+P'A8].K*"!LAI!>WG2/2*SIGNW:4:CI-(UX@2@,*VC0(P51Z3>)ZAYA)9!
MK"G0.>V$&C2\FOW>*-643BRK<R3G7J]:UW'^-;!W+6Q5!_O60,(U[I1=;-="
MVM/0CK:GF2WM:EO[VMC.MK:WS>UN>_O;C";)%\KZ:L.4Z@U9X (O2^$&&+-!
M9ZOY,X?-J@I%\-(@B!"1(%Q"ET[8E]>J,$,;P4WP'5&[X,A&N,(7SO"&.YS/
M%V)WL4:2 .*U( )96 $#3H((!/YLP)4;GW-"=B@!<!JH("T0%DI.E,FI+$ 3
M@&C.CI #[X?;_.8XS[G.=\YSG4-2%6XPU$@> (A5+&"H#U L RX2" 0@6A,K
M2,"->88 I0@B 2(B21 (@@A'D^1,^+F3013Q59+8NB CV%O/U\[VMKO][7"/
MNX\D0+R@ ^4!KGF "TKE":5G KLE2 A)-"$&_^WS#?)ADT9(HH4.6&\"(NF"
MQC0PE< 4(BN<^, &,D""A9S@!".8P <6(@8\ROWTJ$^]ZE?/^D1KH@&JL;O#
M3&F8"D   RW(#"*"MK&#F#Z[?5N-&)3E' 6LQPO5:4%",G";KPR"/R @2*9*
MHP$0F/YB%1#02 ,/WOKN>__[X __VA<!P*"C961&@5O%W-8SDG1!YB010P8-
MHHD00'XI2H.?VR9,KLISXFJ>@$F T!T<<!N8 QZ!P #T)GX,V( .^( 0J&V=
M\  7Y@81L!0-  B#H':J4#>=H !" P)+\QX;T3<D\08.P($DX0+;Y!5/HQ<:
MT'S_1T-?01*"0("8P@'@P0;\$8$^^(- &(1"J%,6,!6+@ "3U08%M @#8%]'
M @B:@"0*04#P- ;7Y1*9T #EAA);T$F&X0 =TW\A]7_5\3H% 7JU,08%H8.J
MH 59@5)#&(=R.(=T&(%<,'+#MP$;P "84@8-\ $E$ %+<_Z$$U !$Q RW+01
MY[(("M )8F  &5"($Q @]+(\#C 5RO<K4]$ G'"#PR(!@7<!@E$N9A(C&Z"&
M)S!R=;B*K-B*KMASG- J,=$&;.!6@:(&9;!N'09/!M$)M2(BG.!?_P58].>+
M9$!@*Y890/5>9K &645CG7 U"X%8KUB-UGB-V*AM;. :W-=3W5@C:'!JV3B.
MY%B.YKAGV%5I./6-DY9JSW:.\!B/\CB/O/.-]'B/^)B/^NAP[:@[W-=I.F>/
M9<9S ND[!9EM!UF/X;:0BY:08\:0BN:0^SB1%%F1%ND[,Y*1&KF1BY )&^F1
M'!F2&0F2(RF2)DF2,X*2)JF1C?[PD2L9DBJIDB]YDBXYDQH9DS9YDS69DQVY
MDSF)DSQ)DSH9E$#)DT7YDSYIDT<9E$DIDR^YE#,)E4^9E%%)E5,YE$9IE2LI
ME5NIE4)9DD29D9"6E5B)E&6IE%XIDESYE2FY""'PEB#PEB$  G$YEW 9EW5)
MEW8)EW))EWAYEWNIEW6YEW,IF("9EW_)EW>9F'UYF(VYF(&9F(:IF(0YF'X9
MF9AIF7TYF9S)F);9F9GYF(4IF:19F9M9FHAIFI3YF:CIF*L)FJFIF9 9FZY9
MF;!9FZP9FH6IFKQYF;2YF[(YFKHYF;;9FL IFK[IFL29F[^YG*<YG)[YG,T9
MG;.IG/[4*9S3V9NW>9RO29IQ^0&IP@G(N9W.69W<69[8:9W::9SHF9SG29<7
M&9_R.9_T69_V>9_XF9_ZN9_\V9_^^9\ &J ""G<2F6D&"7 #FJ *NI^7UG.=
M8(^K8(L+.J$4RI^(P +$XVBPEFO&]FM2MA"E< +CTJ$:NAI9( %@P0EM **(
ML B)@ B"<50.-C6A( &24Z$XFJ/C^#0M0#R!H@4MD'[&U@F<@$)L  !?@F4D
MX08#H!&($ !Z06V+( "^0@(!L!Y?$  $0   H#$5< $AAP@E4A!9$ "*HJ-H
MFJ:KV @($ "($7 !  "Q0691YU9M, !<EPGL!B>9("*!\/YOJB (OZ$0,,HS
M<"((:^ Y69H%17H&<*();0!2B:"G;@!/62  BV!&"-  ZT$"#0 '@, &<3,
M]((PD+,0B3  -Z6FK-JJ/Y@)## !"J :GJH >Q,*;E!T@1("!K"BV1$ !.$
M$V ! 6  4Q$""; ! R  !,$)&V  #&  8M LD[%&HV<!!/  !O %'=< !I S
M!B ?98  "V  &" 8$2 !Q%H  X<!H"(&'S !"3 O%; !9Y %%W:GK3,(:S-[
M,N>J !NPX)<)"M !"G 2#L !"E :@,  "O!+G? %!=  "& 4J] &P,H:!^ ;
MD!A- = "W9, I; " - &G> ! _Y@(@$ J26["![ $Q:@ +43 %>"" .0 IQ
M !LP"F\0 /)! <;Z!@<@<\(C<R)@ )K0"0:  !.P  # .17@KK9S!F<  I/E
MKG\FL%J[M7"7"0A  HV!" 3@ @C0) Z &(M0 ">P"B1@ (/ ,3W!K"&U) _P
M$R1  /,R @B0"12P-F@  (X* &6@ @B0&7"@ AS  -OA!H*[)ZIZI&AB 6XS
M 1?(&GAT).>R&;RJ":O@!A<6BTM7"N3%!G"A %I@ $J1 1'#M:S;NFRG"0:P
M BX@/74T %S01,K4 9M*3P7P51BK,1" -;?G) 8@(B20 )I0 0A#%0#0?"!
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MTS;KH0(1\* LD  (0 'V-0@/\$I[4@$)T $D( $H!0((H/X%G.  &A,(%8
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M DEJ$%E@ 5RP 1HC'"7@J2>A\R3P #VO3/?! AB@ A40!*QA%,6!" <4!"?
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MR$05^;R3@*L' %/E Q=4D4 0#C5Q X%$O,J$@<M6L "D!A!9I N03&BA,A-
M*B,$CVP#PR95!$$MD!A782 0519!L"L)E,H$/ U5V2 +[[*8X($)\/N*# 0N
MH* ""1;Y#I']K/R*@R"F[ H#-/XE (1(55SXZ+$3:#(SP@QG"B//!S11A0'
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M =NH0OX+'6O *0L10F-F 52-D-)7+  (323E/>;Z3A80@0CSU%!Q,A'$;CP
MAC0!KA09$*),OO >M-*$:X7SCK2LPYPSD& ,Y,(2&SB1@J-(H!!<6<0;Z>8O
M<=$')%!4S4Q8 AI5D!(D&FC#WF8B C&8 0.+D*4+:S6[Y_71N<^%;A\1H0!
M'JH-RIL2!T# B44@ E K6.LJ0E"T0""@#II8K'4, (BL,2X3</"*(B!0M#,P
MH#ZM&UTG/,!556B@E#29*4W:%X+]46 ,BY#2(,25A:*I8@03&(T!$50*#G27
M 1D2 P%D(A\1:$ 3W<W$*B;0 @U& #'1 4D7&*"*,23 3/YEX%:+7\RM<($$
MP9<!A)0BN:-  680!J 1MT0PHM>,9B8@J \$3*027\GG!"%8A7AW=!\6(X"[
M#WB>?%#0,00K:1 +T 0;#' 9-#R(=']ZS7TG4$H(C.8,!BC%&>K4%8?R907$
MY(D*7(//'$F I&4PSQLJY 8)\(4-KG$#7??6"%4<XCF8^51709 )BB+@,A7H
MV"H0/!HVA (S7\CG( J12BIY@-)J&#.B1*D*4U @!(TH18HJ5H'8'-0-L/(4
MC^^L"A5Q$@$!+(6+?5U Z@EH+SD&U!<, .P%E&$5*ZC+I:17*4I9R7QM0$0"
M0)(%1V6AFD$H6AO2F8DV>*4"Y?XF@0)41:M%:%N;CI+53<AE"@ZT;P.4[=X"
ME%1>,S6@?08<C;_?)X'1/.!;)4";!V['B0P,MK<,,M]1P".&H.HY@C1Q5WVN
MY;NC:&(![/I("'94" 2LP3Y*000"Q,")!A1B2;HBPQ174)WHUMSF-U?+(@X3
M"'&I A ]SQ<&Q)2E')6"!!2P  CX H8'#'UR;[2 !"8PN3>8N2L<J,_>OM68
M#51 XS,A0:T]98$-G!-K(-! !DR0N@IT'4%?N)TJ/%K709"] FCB @4T@((-
M$%5#79< !1[@F45L( ,9R%VI4H !$0!U#&6P0 DR0 ' ? $#))@\8'XX);IT
M?7ZJF?Y?&1*2A2TOXB.,Y4 &1$ 8)P]' _K9@'[R-8+#KWXN$=B "CRL"0TT
MMZ4/R!$;V@X;59 A\AF80+F[PO ,%7X#%B R&R*0@15D@!-M:##I-, 7+>1H
M%1N@$08\<((O5& 1(4@/)QO,0&T.GU2%S< JRL^!Z'7E=/+)! <D(*9:<P($
M%<@ "?"^"C R^4"#!Z  "3 .4,D$#]B_Z'$(REJ^#X" "8  :PF!^2&G01"*
M[@,)#^2"A. "$B F#;( ^B !SP ?[UC!(*" #4B!#9 $S% #"+  R&FIA&"!
M+-B 3(@\$+J=53B!#.B<##"#,2 >N'N,'*$+K_  P%"#3OXA <H:PL;; #&8
M'0%!N\OCG"YJCM'SGU6(O(BX$U.(O!FZDU7 + TIA1 X/!(@#!;0 /D8A L
M 17@ @S0A Y !!?* ,/SN_, E1.PEA.@+%OJ.BLI U!!A HP'@X8'4"@@ PH
MB-% @Q>L *400@O@ +#Q/9P#Q5#$N0WIGJ\HA2@KE?!)D"A#Q0ABQ25A(;1
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M!901B_OC! 10@3UU@?[P@KIH' +@I^-4"V3!C"Q(/+)8@1P1E@M%"S8@LK$
M@1PI 8DJS T8'39 5=[4A!*@Q1C%C$5@ $A%BPJ@FQ#8@)1$BRR8E(L* :,B
M&!;(/G^Q+S?( D5M3E,\#"W%UFS%5BX(JODXU--;E$$H!5@KI (BC$48 _AJ
MH@O( K[(A#(@J<#X"U4(@K5I(OX&6 7NF DWJ"9S4]4&68R9D  $28$T]">!
MF(DLJ)5,$(-XC3,S( Q-Z(0Z,#E-.#"LP8!!* /]P*<"4HX-D<LJ*D\L\PHP
M<-,628D,\$NOH--O*:!!$ -V1(0PR 03J _YT 00.($X]<B4**"5ZH3U3(D*
MF) R0(PVB%F0D 1-D[WRD9Y2@-D FME%N-3R!%DQD+U.* .C79*[XYGX0 .N
M?=JH_0J8U8]!V!!]DM@RF"0VP$(;,P4W$-LX*P/*.,HZ>-ORW,@P^ TW&(-B
MS)<P,#^N0 0QT!A-:ZFC+)-2J( [D4_=6@5*.P.7 P0S2)QC))6ZXH0R. ,(
MR8 VX/[1LC7<0NJ$:_J-[$&$%>J*04" 8%J!7S);@.3<71F$/O'.PF6T4A@#
MW"B%WUB$3@@ED&A*;27>XD5+$?@Z"D"#_CFH<C,?3H B#2F<$:0)"E"!"O",
M+%@ $GC7"5B!#8@F^5 80(&6*4&$!? $3F" $\@JL:" ,NA03F#1AU*)V"B#
M0V$1!E"!7+Q?%;@\ZZB U\T M\D %N"8%1"!" B%MJB@8;$.U-B@WCH*$&"0
M#9& 28F208A?OO@"BTJ-H?*4HEF?$,C33+R)"M")!UB1,(  A'L ?+L]"> "
M6)$/-Y J$]B "^@"79* _K  FSF\* ,!$%@!BU %',8 ]?YICH\X@0 .@1DY
MCP= . BHCWDEU>OUC$" @!98O%+H@@80'31@JD6X !($+16P7A%P$3;)0Q:X
M@/IHBF>Q"32  !)PBASQA,O+ @HPD3]4@:XKA5+8 !18@1GI!$82C-R3 ,HR
M8!48@35& 0]P@0<8#OSS  <0 4\( ^NEQ/*< !$@6O.U# K0N ANC@V@#8V0
M@/>T %#1)1 P@0'A!%G1'Q!XGP@@ 16 @#79$#?>@@RPDBR0 !5(-\!H%!+8
MB""4CP]HGX!Y']M@@0(FY261BA.8'%4 "A>8 #*@B0=P 1)H@$Q !+_YT$*3
MG@;@A&W2)@XP4.-UYW?N(PQ %OX7V("9 H%2.J ']I0<J;$-0 -?S1#]BMRZ
M0#"9F->/4:!GX1KQ%1KK  $(>  0N,H,:+H*@( [ 80'&,=?09 <^T1$V( &
M"(&44)B4<*&6 !$N(A&E>*.R680SH "N0-@R$ KD];D.8-,-^8[W<X#]LP J
MI@F+:IP%6)$O("1A0I,PZ)<0,"9S"127^XZCV)!3;9!T(H^Z, $+B$-4)3@9
M600PR"8WP.IKG9(Q$ H2:# /J(\&0)P'J.)48@"^$.128 /EH[S^JAC5>55_
M8:H3R*80X.4F8@[UF"4*L+P,88,$ )1,4(#PT;@38!"O4X] 6 0% (DW$-<&
MP [E\?[54FB!H"*!]F$ 4LF$6J-#@F:DVS"Y!)# F4"#!,@ !?@6(_&.F% 8
MVQAD52B$W8@DVZBAH="8"3 =-!.^P- "^0"$W<@"\^",'9& 6K, S^B+#_D*
MT;,Q@#E 'LD$,PBJ04"-$(@[#% *%+C94!8!*V$XRVMG>&;O]AX80^T"+JBU
M"E@L"Y /,1"7_K%)(>J@()P)FJX=S^ *E9:@A*Y7\V4 Q56P#D$AFA4?0-%B
MQ'ANGWNT<#P_!2((-A&$!5 !$T !"(!4VH$,Z9F 55 !F<$7JK8 $,$ _,T7
M!P",* &$\"%)H)J23/@XFF"JKUB$.[, UPBC^2"C*2D!C?YSLMO!M:M6!7@J
MSA2(NWFJ#$0H 0PHV/]1A2(OE3&P*)N^<OMD#BU;$]P0 ]#IBC(X 1,8E:9B
M::&  ,/1!$<9<6SVON: HY=I  09! "8GS.P":XP0I]# 120 "M!J*X:G1-X
M@'L;V2NW$JX8K"S(SQ7PC#!X@.9YGM/ #HOB"BZV#U%:TPLK/PZ- +L"E9/Q
M#OIN#JYY&Y  @Z+AA#! X+H(@P;3 AXKI"#X(// =0WYFE5P@+I2W<1)%S;Y
M70+W"S)YZ!,8\ PX'A#XB%!F7#.Y .7S #:8'51T 0*HJVIU[V[W=MU@D=T(
M2SE'E!(  W+)PCKRCA?)$=L"B?X(,!SKV(MGZ=;I6@4M0"206 "7\PH*B%>0
M"(ZN^*B2^@HU #I*000\S!=$. /P2R5$,(4VJ)-X(0_S2!60,"XJD9=K/J)B
M]8J!+<]?]XHP@!A-T Y;L=>9R#$L1(/W</>!$BZ0((&;!0E";A"I\KFZF/GB
M5 %4->(HSV54LLJ;Z(^N,.N;0!,2Z((WGXD2L!+<X.XI$5<2X( W* 4/4!6*
M!W!) HE&X!:3 (D3F'/10RX:V73M,M%NK0! 4(./BJ'(5KX+< /8,H,)8($(
M6<(IL0SJ)(T5D ^8"@'[GA+[F8N&>0P&N2&OT("CH(WYT0 VT,.;R#IS5H$1
M^1WY*/YRR3DE-A 7$T"3$(!AASJE03"/#'\6%/#UNM*"K^1H:M0.#-"8.A-?
M$K@ P#R#Q4*$3- $UVFB$B\%"J@K%N "$\"/04@]=?7VY%=^M-""V$'%XEZ!
M\2@$!2BW<<Z E#B#TA>75>" ',& X0"#^*N=@Z>-R_@Q-*A&#_@(.#" -HBR
M?^F$0>#("1A]5/*$$F(!^>4"9+*5HA&$J0&(3 G$J%*%)D&I+QE4K?K@(I,#
M3JH @5#EPH2J3A 2J>)"0E6"%*HX/2BCZH$F01-4L8%02D4)AC)#M%"5B0$;
M1(-TKD*$H$PG320LK%+E@8LJ-YID?J%0,,0&HTA5@4!:4OZ5SR\%"YY0@57!
MHE4E)*@*D47F"1*E5$D 5! "HC82UIZ):59F43$+[ZH2<18"P44)D$( U(F!
M6T$+.$DX@S7!&U45OJPJ<T'5"@]K2X101:*FJA(L9&IR(,@FAU)FG(9 P=+
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M  )Z48\#7%I+%M[ @?A\0<=BXID'0K KGG% RN++  10T(D,?"$$%@ JSS9
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M!O/#"0:4 1$H0, B.C$!-92""X0NCP?6N]F)/. -B_# 1QJ  3%PH@LB3>3
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MFZC!!-@D(B0 2VU%&]!'&=!'O<B=8Q7$!R %\$3 *G!" VB7*G1!121>1D@
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M<,)*9(\*/-L'N40E7DB<L87U#?X5)Z!!5!Q0&5A*!CC&(9CE,N;>!R BG:E
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M 7U*BEN\P65<)E26PGR@3]>M@5=Z&OQ<Y5HLPDJL[ U9B%M*QGB9P:R*22=
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MC-E69$+; <E5"AP'>$6\BD$'*/[ 1 P JH3 0K@!@#Z?323 JW7&!(0 &JQ
M!G1"!4 S"]"'(D-'LZK !*33 JR.]AV$&)Q!W 6)8)J' J#.&;@'&# OU!7$
M&32 &'P!3CC0)1;$ U#*BRZI"9Q!"RA %PR5"I1!"!# AK"9&1C; !F6FRJ
M&QRNA$$ 4BP 2[UH&(2! U!*0J$!OG2"BG%T!?2-NPR&3$8*8O C")B!"&#
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M8W45A,]&_5'H!D ,4C5PX"I57T*H,DBP($&#(((H9'@PP_Y$@B3>6-2XD>-
M$2PD-M08RH,FCHLF=.HH,5,#3BM-H%!EH<W*B8,2F+18"L0BD38Y+@0ZL(V"
M+$)##F5HL(P*59PH^$1JT> 9IU,[&LQ20M49F:48%/JI="-6LC8-=MEP=NG
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M#1X% 9!2.&!A@P?RE#I7$F2:BP%3  %!!0L@0$,5$AC P/X-55JX=P.?2M8
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M#85"(0>R59>%H>$,:R%1L3P0@4&4P@UB7-BH.B ;@VQ@#)D@0$9,6)D$5&8
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MQ@=(!Q$*2 X#5(!.")2A%-]3A1;$^ 4#R)(N8@E$ S)1H3=L0'0M\<D66I>
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M!1+ O/[8,ZD)%Z38 IE(0!!ND_C(%1*(]B)T$7(=[]&1?G0VB/O%W.W$K\0
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M#41@[,0.!#("LTZ%X"SC1^)#.3+!(,( ! C$!,Z WJ)H(%@@,>PB850!#AJ
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M [I./A?' E!  A[E"QY 4C#@Y.Q)/ B@7;X  53B#1 JN31@%;9 BK*@R$R
M GK&1 ;!>DB ,SM ;8Z$@<93=%R3HSR,7^30 _)DDT;0($:@/CK! 52C 4
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MD&L64!OJ(@%G  <JL0HGH $;  *"00(K@'@G<%6<H#,;X+RP<0*(AQ?FH6Q
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MPB--TGR:L6+A BX0"@:%D40<0QB@ 5F CL8<T\08 ?HX:JV:K5\P>!6 2&Z
M&4*E+4)CP3#:-2?L4DUUJ1PA EK! FD!@."6" 8E5"QZ @U1+C :0%W@M@.S
M5I@R!AG  (R"(0^ !H)H%WQL$%STQS"Q &4 !^U7(R>P$5IP>[,Q!L-C)8 0
M!B=@'&(@+&!:(WSMU\5SD_KB68=='\QC&;DR 8G V L1 E]0,QS1" 8UBUG0
M "Y1%R]1!NAE/B7P!9!$%^DJ+R.07[PS/F&@ FCS4H_QV?Y>\2SQ8@IS8AL*
M!)$JTP 0XC*V$0@HZS=<< !P,HM;D'!>=46X70((:#(=T2EW$G=H4@HN8"C,
M.3;K 4"?P1NWD1QM$ @-4"X*T 8ND%"*(XP3<"$D15N!<A%5430,T 5A$-8J
MH1B"@$<;D#@<L :# -ZJ<UD^QSG&6=(#3N"VB=\ET @D( 8;)0&QX@%=*P8F
M -_95@(,\",87$QOL!YOH0%MH"<18C"@UAM@,]2(8"L@Z#;IA CU'$ _N!)E
M5QDH4$UOX0%,)3M;JE'KAP(QET0[U$Y<\+69D "<P$^#,7\OL09I"WB5B +D
MM3(ZXWYSLQ0;,6P!--D!YSA=S/X!7]!CJJ"D' $&-M?%&[!'B=4!7;$*F6 <
MKK(0ERW+.($&N3)(VO(6), %],00]=$%JP0(&0 A$X"Z?HPQSL03JN,N"S$G
ME1T"R#%0A*P!7^ &%W J,*4P_WP@P\'=A'$R@]%JK*1A O8Y*N !OS,&;D!)
M$A $K02'./$6&K80MQI &/!?UB(C*O!,#%1/*H!_/]@P7Q4I78X!B8,!;N!;
MJ>,OFD#7*\$B+V$*Z"U :9$!JA$($U!D+&#%]0,&^!-8@Q :'01/J/E12L0&
M\T0Y#/"=!8[NZ8Z5YU%]G2L!E]H2@R!B>-5;5\-9:581JYQ+"-""I;  5-2D
MSLX&O/XA5$4T/@%B ?!W!OJ$7!'" )KE@\C!!OM23I*5.SU"(]XS*(V5D^:\
M(PG65YDP ">S"A_51*%A4N44-*O !@A@%WX'%Q: ''"1['S!2 [!9B^!"*-E
M*?+RY5Y^Z*J0" BPGO*2!<(B!BEV]!R1]-NL0>O!%HA@I(HS")IS="RUVQP!
MQITMZ)$T6R30!162+PC@RSZ?*V_  9J  %PT?(@>*+T. G'W!=\A8*C47P\
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M@,8>0()N6J4!:*( ;;)0@3*PP &9*,,#0D J#)1B >N$P'[JP 9;7S(!$Y'
MQB;@&_X,:*&F74Q>"VJ"B %<)PNN"0$)V" "XZ)D!2%P0UXF$H$QE&$"C^G"
M!,:0!09P BT&F?9@&@"",'3" EE  P9TTX8&?.$+$7#-0TT @<B&P0)HX,('
M-8$ $H0!!&FQB0H4D 4#^58%[^:)!500D_K(^^(;J,\7''""19#1#8@4FDFX
M,(9B=X+4"SV+!&+,@%V1V,3N>8,!6!"&"M0'Y2]_# H\P(83>*;F)@"#!S2P
MBL6>X#%$;8";2H"S54P@LG>V"2(4L(I4FNTG;LB <3411J.U-24-T, 77-"
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M,D"$Z"@@@\" F0F#FD"#\*L WQA"%YP9R.2$"1A,$>" ^H"#"I  #6@J";F
MHKJVOK3*4PN!$<" 9!03#Y  "E J%2),%2B$"  /E!"##C (+G"H$O"MMZC)
M$.  3:  H0HN4!0?4V0E$9#-#< J[;.E") =F\F"C2B%7FN!(E*+/"P(#* K
M[RR(#+B."/"-3@ !"9@ 9AQ"\*@M3AB$"1":18  3Y#,$4A/52BA?T*F# #(
M3I#,,VA+$)A--PB$E&RT+W"*>]J(-NBUP?" 0&BM#50;HDJ 5=BV'8(JJ\@
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M)3-VX'^4"9B "O![G?=RW%]U!5J$"G@BE6<9+7 H,$AB3I@A=2P$!* J1'"
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MU 0 (2D/KH( <.,"!" "$3%<H!16Z00;@K((!2 B"QZ0"R<,0()!H &'G5
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MDVH "A]5J,%V$9' 6Q/"B0<0Y?ZI+E"%C(RZP+WD-D*VXX()8E+9W:AB!2C
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ML%T+5K#I4D @G@UF@X0/@NZV_\?""+G9 T2P%,VJXB4OYT(=5JI-_SQ 2A.
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MN<%!00$"M#45[&W?$UI 4Q%*:3E$(ICA^5%D10X-"JS7%V"30I1  [@ %VP
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M& ">5,#IJ$"9M-@@'"":'<2YA  (*)DJF$"+B0$^8>=Y=&(8? $"7 F.\.0
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M  9T[,IL@ FD!G2\;.- J L<5LLD@AG@4BFTV"E%!2:UP?<XB.I(F!B8QP4
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MPKV75@40#"!-!BK) +.F\@M=J0 90U#/P*XF@H-0@%'8H,0+O$\5'(@91CC
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M 3<$HH2"0,0B*$5B$$#% ET8A" 6<9B! 8(3%^"$@A'R]DY80!.=L@T<7*"
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M#K)@ ?ZVZTL8X%+8@&56(2D(HKX2(>2^I+BDBY-R;0)88! 2 0.B!*&FK2P
M0]YHXJ=(@ /:0&"$0P*2(^/(  +,0!-6X((  1 L#>M6D14S @*&[@*D2GQ@
M1ZTN4#7>10+0116X8)Z^( M6(0&P PX0(,&4*&""$=^(41"4B ,@2ZG*H'K<
M:*$PH@L62@Q<8@.^8*XZXED (Z) 8";,:E1NAB"T0 22RE"0;!%VBU,N*0RB
M\;*>:E1, 036$;6DB0 $J0MV205,0!-.2A4$P0\["L14HA0\#AHQX@QBAB!
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M@E=B@>&'3WO3^>+O+BX8(ER-O32A J0V@R/8)-S  A0O*)>BK>B"!!@3(=X
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M(,0 DB$@$YCI,.#@(5I@E[( G!KR<13RDMA ?)DTLLK"!>)E#?\ZTA3  Q!
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MH VM:$=+VM*:]K2H3:UJ5\O:UKKVM;"-K6QG2]O:VO:VN,VM;G?+V][Z]K?
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/4IOZU*A.M:I7?=^    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>comp_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0026.gif
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M^OCW^/;Y_/____CX]_#P[P
M
M
M
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M.(JD6(JF>(JHF(JJN(JLV(JN^(JP&(NR.(NT6(NV>(NXF(NZN(N\V(N^^(O
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M ",:#/XX  !GX)Z "0 XH GG^0 %4 !R$ QR<  4X  -8*,.( $1T "], (
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M D *=@  IZF<EJ ' E "L."S>( ' %"Q9V !F@"L@TD""7"8O1 !%H 0<0
MD9H "C "&0  ?TD&$0 !84 #-9 '&2 #:0D& 2"R#SNZI#LTY=D"'# "CE
M8G  R,D '3"C"&"S+F  32J<RQD,O! ,<UL#L"  ." 0(?  ><  %& !Y4H!
MPU !MBD0A+ "&T !!2"R%E !J_Z9MKU M#8QMW# O<$ !P# H' P A?P  X@
M#$H0K +ALL=K 9GZN9\J$!4@M"P:KQ?@OA'0"QZ@JC4@ /=Z !R O * !GF0
MNW4  'BPK0PK$!G0 !E0 1-0 ((@$#&; 0C!!G0;#)9PH!R@ 'SY"(\ "Q>
M!UM* 7\)!N%;NBJ\PG(""P<P V(0 3@  7U0 &2P"92*O Q@FS)0 +>;!P7
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M& MF<@Z<82%,"P9P@C4 JVHT+ LPQ$0X(YC!4K( .QKD<X&!I'R"(P(VOLC
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M/OG"^[#C4L/88@)@$8-%@I$!1MR!.-!U023R!@N'0I0#3BN(&$C@@B^1H07
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MW"\-)9B[5K@?$:E@_W-2>3]5L-/QJ;1_8QNY?E;JKYE#74G_].^*^DD&#*B
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M:#0%7@ 6')" "<0/+YR!':S "'REU=W+:&I"(YK!P64 I#%DBIA&&#E"\UE
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MK !9&8PFI)5?\(L,I--=;$0)?$$OC,@W?5$E.,=9[)\89("628 M5(( 6!*
MA%U-XL$&%$YEG98=, "M09?FF$93GHP#P$$>2(#>V)0)F-(!L$8$9, 7W%D'
M] +T!(53<  9: (-B$QDF, #W(%0S4"6C(44\9$EM0 "K"(;1$!2S( )8$(<
M6  M<,(![%LOM( #V(&SRD ?HN-*RH8$?$ >L $SP4(!<"P,.(4<&%58!IL#
MX +1%$<%/)Z*#$,-4  =/&:-1LX'H(&?Q($EF(!)'014UFHPW,$(S #/T($%
M-,(C9(!#M$ '/)H"C$4$V(%2P/[7" #%"NA) 0R8.05.!<"!)J1 JBA&2[E>
MOBB '; ! RA8@*3(!_A19^1! :3 VWQ "P25 *#( = "(PP &4 KXZS0!,0!
M+ZB7(YQ!\AV$(V1 NIDF"^0!&"!)6 I")7" H3T->IB)&#@"#"A$!1@:#22
M2>17"CD'AX;J0DP"DGR!TIP!9WZJ\S[O[!FO"G89ZN:G JP$)J159)@!X0Z.
M](7M"#1"+("!@2V$\A[$]/3""*S,:3K%%^C) Q!9'/P&>N1$:!"E")0/DF0+
MT:P$%[J !%Q.7VS$I)&<!,C*!_S.=%'%)O1"15R$)000"IE 9N!!0YX,OY'
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M1&*?X48&2(?%+81%__+\\()*?/Z0>DF*&(RK5." 6A"KZ1A(BJ1*#I\'+\!
MH$P*/PM&!)B,3>#$_&S>_*)T"D0M+0B"T>33E8R RXS&EET;X8:E>K23? +G
M07 +2VS0;G!"+TE*$TL%.=O"YI1%"+!!+&3 ([B ''S!&>@)K[" "<5!!5 :
MO2Q$)$3 1A1-!%RB,Q>W<7?,U? ++0 7(R! 1%1 '*B/5-"" JP,]E6"!3#K
M09Q!*$* ; 0W>WR$,*SO558$GKSO;,B00M1O!UU*9( !+M,"2QF',W4?W^"@
MJ'&9;(P QAQ$&MS$-GY U"V$&*D-+#3T1J!FWAP$WWB?"8P9"=RG#V_><O[S
MRT1+&?[9S-M@SH,PQP?4]&:GD%RD@)5L0@70=+. !AVX7@0(W$+$"TN Q$ED
MD/2U $Z>^)[,5P3(A@4(YNGYB51WQDO@14UHP@A\0?#( 4CHH5!P1/R\00NX
MP,J\]9M%!-,9APSP3 RL1$?06R6H#[Z90/#T<1F(C/GL2*HDWULALV=#!)D4
M\;7DBZ'80J_%P7(<9G_@A=%\Q$Z$ZU5NLM.@#_/AB44L1'8>2@D8FI]PD R;
M0"BZF=2$YD)( (KL'1H,PPJ0@$'^-PS   68$%G),QG8S0]%P( ?-ZJG^E:0
M0 5P-P6P1PE8 !S@ 0N,AB88@![! )=0124T@##,0@@\MOX"B($=?$!YS7,!
MB-1*6,!=*$#-(4E^BT$%W$$</ "*,,!.V((R78D8%$ 9R%%GV4$!A%).9$ 8
M(,U=Q,@,4&AQR $ ?$&3T$"844#\]('_J@T.]!<"Q 'JO$P:]4$#Q$$/RW@)
M9<8'6$D%R( @ /83_<8*1*0%1^4(:+H8" !R6%09Z,@7+!8O(%8?/)1:TX@F
M++%Y19'.XD >N(  ?"5+.,"<S< UTE)1@&0)! \:78H84 99( "*4*\%,<(W
M277,_!%301H)(,!.]($#Y $>C,!%U%4:"(,$N(Q26$!9;$($A($@D "-?4!;
MI $ T)HK!04$0"H%Z,9]Y<$9%/Y \$Q]A^QD"  %"^@)UCS/+'3(%PB""81)
M"'R S07PCO+,Z$#$&SB%!) !(]#  3AI";^!!* ;5C)3'OB,;Z:0*N$&"?0!
M&)QN9;V4PUZ*ML/"-KU!'ER 8;N62N. (*Q >:6EP7P [EA%;,RS!,C!&>#Y
M"D#C'U5"(]"8JO\^\)-9"CAZ1/Q8-R$:&"0*RE?%+!2(+=1 HZI=#V*)')B!
M6&Q$&D"$&/""X.6!\\0!NM$:LO&+S%%_%'LK^Y#.^I$!TJC$X>E;#S("!#$;
M#&CS=N_$3"^$)L" "]Q=&,0"0) )%@R6F8%W2+C @Z;7P&!P& U\$S'6#!(U
M: 5C]/XF6(HO7T:D<3B05XV0$(.)@370$<=@FG#P&DC+X@Q;(^/T"49+C$Q&
M<(*9T?2R!0DY:8:.#$;'Q<HS)5@X"C9+3,-@<O $PR5FF$:7 \,,%3KP#*=>
M9&320ALL3XH4<ASV$>-0#HLOFL+D"49F1C TF"3&<8C)!8FY(U'&$N,K6!VX
M;%.8$#P0S @S<NP$.U,IV"88),#(M',GI4Q>9&YZ)O'%]!<3*70ZM).YEYF5
MDT16<N'"D1TSFPR2M*6W0V8QPC0%UW1&*1L7,L&0@+%RI"87<,5D/)N1T0H3
M(D>2R0A+QNJ,+\$TI//5H;"!9BPY?$,B1<2!8DR8J!,LTOX7I?\!#%#  0DL
MT, #$4Q0P049;-#!!R&,4,()&>3%C@]:H!! 2P[3T, /.O10Q!%)+-%$$GOA
M0(Q*Q)#@O!-AC%'&&6FLT<8;$6S(O0*MXM'!'7T\L 87;@JPH1X'1'(DF90"
M\C\E_W-R)"F#28,T$:G4,$L3MU0*R@&[%##++Q/\DDP"H=1DAA1@2,I ((^$
M$!@:P\31SCOQS%///?GLT\\_ 0U4T$$)+=300Q%-5-%%&6WTQ#H=C53222FM
MU-)+,<U4TTTY[=333T$-5=1122W5U#Z!A/341N=<U=5788U5UEEIK=766W'-
ME5%:V"##5S"R8H/)"'MAHZO_[/Z(#\(WP/ 3%AH$&4C58"JQ@[J9DE6*$3R&
MU>B.;B6:Q<X[I!JIES.8@_&-:VG,PSX8>9DVF%[.E%&3R5;M1:9>WGCQ0'[]
MG7%:6H#2]<]*$%AAMQ3@H.4#=A^D)02(!\H / ?M<("->FW\H(1)$G3!@A(>
M8&.@."0@H0(99N+ @Q DD,KA#D:(V=P/.,-Q!!P<:H@,"1X[<81R:ZPA1!,E
M0] ,%_#,HX17Y2 A&%X^4!9!7D+(.5!+&LC%8#\KD>"_?>/-PTU>[FAD('U[
MP</-8!S)8\=A'['CO \*EE:F/*P.!I,[SHNWETJ$P8$$)FVY0^N,+*%%IDHB
MZB6/:_Y[27MMF?#H^Q$\>J0E6Z5@H2"K@39G,B-:WH:# <P=X 66!B(:)@+!
M5@AA("4R"(:%#P;"(?<E@Q'FILF#L<0^TZPEJ:&<8;$C*7%G8K*/=X.)Q0Y>
M8&C6*EY68+F7C"K9%X]''.(NDIVX58H77MI.2E]JIW:H$L#77GXD6CH?J'EV
M\=!KII<HMA-JQ>8_C?"?0]Q5/HV0CR3DFDD'PG">NIUG//0;AD4H9@F[D<1T
M:2G>^J:6L_D5*2T;G(GB>B8;HFGD@$JA!1X6IY$5CB2!Y4/AO&Y2B89X[FTC
M>40>F,0^"['+$:,3(.H&PH@['$D,'%B)Z=BBM6#<82@!D_Z),/8FQ=(YA!=X
M.-__&L$96'#.(9I(7I1J^+X\2)$1C]A$!<#U-3Q5(@*QF-=,*, +1E# !2/0
M6##P4 $7?(!IC!#D"!X@$EZ4X ,FL( .*3"4%(0 !A:(B ?8PX@+N" $$?!/
M,+[ @154("MB& &&'D&!"*P@&':H0 HRP+)A<  &$7@$#$;  @G,8)"VU(@%
M7" "5CZB BU )'-XD0(/F* "$;F#!5; @4\ZI 8/N( <?*',%%A2=RNPP#2#
M$0<T.(0!MF #[QH2AA$$ P?V840$0!DMC<!S)!:P!"?XZ($,?*$$%3!!,-C
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MGN)%(",D.$,L4#PU"M B#NFR@%Y&%C 7],4"D(V 7JSB M72H"\5 ,\(_*,
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MV/3Q(+I*!-*E SX)*?V"I]BN///.*E-B"/$@ FYL;28 $S"!&_E#;-#@=\R
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M$C+ !!#P)DR@!?"V%\;1!#S@6FA!H$:@ EQC ^HJ&&JGDB)"#$@@!/Y)!BR
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M9,(P4E1ZX:DG)PE?]!:!1)$X$*9"C!Q@42\P,&C' 8\H9 <#M,#BP"._BJ$
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MH 4LD%#!83\%4\*]A%EB 8HM<#!"!1:= 13L%Z%R@0DNX. L')0&@\9-<4A
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M.P :X$$&1>':FUEPGB\@  9RB$4$XK")0\-B!1S8S 6,30$P.*(QP!X &/)
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M#. _WF8'L#"$V%S32+$"V!&QPN  2N (8A GBLD +!(!)&% "K&.P5##* &
M"T$19L (-8  >8#-O&(6<F"X@W+2O/@(12C6O<&$?7 !=7E4E&*;IY<!8_$&
M$J!D$3 V#' '^<8 E> (XIA]_Y, XRQN"O %<+ "?ST9T H& N (<<  QL$!
MO=P47%,#V#,N7Q ]JXM=9O$(#^!_'' >E9W%P; )'MT'+:  E5 )S!<,RZ<Q
MO@L'#/Z0(0!V*&E0SHDC)A^@TPHP"V;P0&7@$#VG$"&00"WP 7UP!MK( ,)
M6;BG-E939AFPK<!3R'8B!HZ&!AV4!KO""U]  C5WECZF?G*2!^3)I/OR8210
M \?6-T(1!K#@=KV  ZN"!@4*"S)  C@P8MJI"=JI9:WJ6BS0 G=@('W@CGG0
M2=[8)B[ G3)Y2T[:8@IA=5@,;'-CJ6V"%%^S+>^=X1AQ*,U1 E/S(<'P9RO"
M""J40WAI,O,D:@1^(N(=!V_&"^8E*Q5"!VI&45-D7"J -WVP C 0"6]P$H_
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MV 0&G(O*DKSW@ !]L11L&;M@2 &!: '*D(M84  :DK0(:/Z,1VB NPB,^8B
MLN@%"OB),QB!@?" ;HF 6;"W>5/"(SF/$4B#3:  N7@$3DL(.1H(04B*#G W
MN2@V1B !-C"#-#"#%<";")B!O3,#1Q,!.P"#IP@!W, !,9 #7K" @@(YK3,!
M:KF44NK ,[B?67 9!W"$'PH#N3.JFUM$1NR-&H@- G.I%D@=/$B*OWL<Y'@
M6)FW9&N*7\F#I%"O(Q0PMI"#^<*ND>@#,:JO8/@"A\NO[PJ:_HHC:KD;7OBB
M!=&$,\ \_,JP<U,*N0 ?@>"$BAL(.8 %.C@W35" /;&P@9@J$S"8$&B-2A"!
MQ N&1ZBL90,6(VP!$NB%6;  &?[0!(-A!#$:B%F8D8$@ <-0,^I@ .^)!01P
M!%H0@(\+A@OXC ?HFDI(@&Y1DQ3H&AEH&CMPG8]P@%EP(H*PP"_S+NBS%#08
MAMB(@Y=A 8_(ES-@-U5P %Z0@YJB2)B!!03 $%B(#55<%QPP)0D (!K[LSR
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M#DB@I#$H1K #3K.^[RDT&,@ 6A"&"O" 4Y$+&>  ,7"U%5"37O@ /D29>9*
M+X !((**<I&0,4.C"L"!E*P$7G I.]@W.JBLL8"!+W@ 1#F#"  #&6B +KF+
M.%" +^"$":@!,5B!*_(VU["$#,@ &.@>Y?#/$L@ &[D)9C*7$9,!]2.:A, #
M!@B!%J" $, 0#4L!"A6D8&@!!?X0& K@@#8B 5PAC@KX AJ(@(.X@P=P 1D8
MMAUQ@(<(EH'(@-9@ %@@ ]'RC&!P@-28.#' +," @(IH!%.J@;>$BBZB P9
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M!(7V9X5@CZG(#D+FBY]PYG4^9HM>Q$"""UU>1$5V@=2X@RL<B(*=KS!(V(S
MB$> @/'AA0S@@'@F"#41@Z<#BD7AC=JHYZY @S^&BL]M"VV-B!#<9X7 A!+L
M"A8P#$A6@<&YH4GTD&"@@S>-9%FC"A+DBO[*E@H( 3,*W_5XBYN9M=U@6P<H
M5^>JF;9098@0@8,09Y*MB)3 1@KP* GX%1Q  ,48@38B@PRP4KSR/2MMS1;(
M  NP#_Z+X(5HV@0(&!O1>LJ+;FS?,(]8B(@BX104J8KX@)*(2&?O<&B%D "\
M"I&[<(3*NJ^'UA$V8#>N&^CYT)$44""@J*QN7H@IBPA0LA$0B6U&41&"2 /C
M((A\21M#V9%,<4Z+F Y.Z85(D0#;QNF1@ '7'HAAP.?*9N<^89(=:2[;KH.]
M3 @9, S,MH@B$1+1'@@5\A." #&(!I&=36^(@.B*<,N% &=J/H](SFV%F.P.
M6FW7P WW&($T9HB#<@T6H(P1,!A:< "\D0$/HX7 00A:P80*H<+2,(,=-I 5
M& %:(,$RH&X3\Q-^0LQ.,8_Y=FP2)XAAV*SB&8@SR%G&8/Z$,K$$%J"%\8F$
M^@A66*$%$[  %I"!;/( @=&21^@F.OP(%8 %3@@!#[@M )$!,K  7CCR%'K=
M-\"!<.D::PF!&!"&7LB@"A"$+W" !M,$YHB%"^^ SSB>/VF:$F!>"7*-7IB!
M]#&,IXJ K2 !$/I:'_< 6.D%&9B7HH #D,D--PE8"^@6$Y"FU)L==/FH9FE%
M WV $&"@>8E+&& #_D&#LTD:&ZD$L.& L$@#T5(3#L !$IB N'0$=(ET5/F
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M%R2X  M&D"\.>$##\+5("1*M@/[ E8D"8#"!!7CQHJQHFM,^(Y,9' "#+TB
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M"-\S ,"""S#R'43  Y 6!V"T"@! L9!!5_L'5<0  'R!&0C WP# LQ&UFRB
M/ W &Z0! )@!)G1  LB )L ! !B&!7!<#A7 X8!! < ""3" S_2S[53 U;3>
M#%! '>!%'MAC#0A %I_T;--V;5.4 'P!'H,3+50  J3+ !C'8[M &B0 672
M 01#(T"V)@R "M@!(6.0'1A !KA "UA !#@"<^?+'>0Q+ P CJ P)T% U07
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M!#1$'H#P0;-PJ52" @@VVN=0 PA  U"  %0"'E? OE,(&PR  +2A610 _@*
MK.#PG,   #P%!3  F1QT14@[!81  5#(BCL !%3<'2   SA  =A+!"2 AQV
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M0"5;/A2B5\$FE!*8D0) JPSVW(F^DM*+$%#@#'!8@0(NTA S["LA'G G"@>
MD& X (UG4MB>%/"%..   30S :<:T@$ 8,(AP0C!W#(R$U@H@&)Y ,#N5O"
M+RAA! J@8AI'4+V$;*( >_D" FS: @5$(B<CD, 9WK FH^R*!C.@@0OX1P$2
MV*%JD7L$ V: !^%Q*J)YU:M4>J&G-%@P#]"S1!## *6$Q&$%)OB"!7.RV(2<
M818U.0--TF"F.U Q(8^ P4[!FA \K(86I\*(&0S[6)&<H?XF;[ +([XPJ#0X
M] RE!9A+&0&#%-1 MG%@00IHYJP:**$&7Y@!CLR0QU'% @<K:$$0]]I<Y\Y
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M5UHG&$A@!%@@ SB@-2Q )%;@ TB@ V@A$BQ@)R8A:,0@ U+  JAH&'BI!$C
MGFJ"@/;)V=@@X7KAA<Z !7I!#FB"Y=ZE#@##*<Y@=SJ !4R  K[G#"K !"H
MM5R@!3)@6%K@ TP@ X J$BZ@!4;@>V;@ U3E(ACA DR  [@)(S*@$F"A K[E
M <*@)N @$3\@ I:"%TB !)X1%N@@ OXI&.0O&&"@ TQ@ _))!D*@!<R*3"3
M2S!B!E:  Q0C!OXQ \!*$S8 ,DQ@\'JE MA1!MJF RK@U0IQ3PHH&#H@$G!
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MC4DC>RXA8*!XRBHAZ*"<TD!/*O[ $53/G'QF!MCT \B12Z!'!2R %K0S&%R
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MDX(A!1Z@321@@$YX*)8(B5O%$BR !$*  V1K!C)@!6J ().'B#"EK:]U*2A
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MT@):9& %):" P5I%@P=8  ]OL$#V'L 76'R@!")(06,>L8'\2>!EC^@ #"1
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MU@MWD#FEX1M^HSQB8P?]8PE"UQMW@"VIP4I&$0G241&.4!E>L15)05Y!<A;
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M%=59)B1PE&NB"0^@F85)/& P P:)!Y!6 \&(&#)  E]0$I60=8]0.W!0"3,
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M"9@@ #5P!R2 4Q:!&[S  ,?&.KV@GK1@"83Q!=94"5P!!BOX<,Z4!@>@:!2
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MB5>O* TNO A5.!6I0Y<7<# 0" *L"4$#-$ +Z]E&9V +AV<+F_P&>/!WO>
M+$TA=@"Z>K%7_'-@=H')J9D0= "ZMH#)]-D\<.5L324&-^%B"=$".>L A"$'
M]N%'+C!E+O RAY<0*P#!"$0"9Y40%' 5,4!RM# 6L& S;O4VR&P+$--TCD$3
M"7T18Y(!*(D&%E,)0\,(<$4'$< (2B(,^Q8WMX1P!9(&NO[EG0E! F?0TL34
M%2:-:&O!'[3#I"\A9,-P!KPVSI.5$(AB('7C"(/DL%TQU^ET(S0C :B1!Y*3
M,&P]=JRS B_3"\.6!AP0-YHPQLU3$"DP QLE!PBBL<%  G)0!QG "Q2M +2
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M)KYA<@89@'^]  ,68*LIP *5CH2FL;ML8#%"H5_(%@Q#?1943EC^;'W:)Z
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M(1GT^8EOR:&>V4=% F8P"0"1(5@P/!P&!J-% 15"";Q&R!A(0DXP,2R"#9O
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MA/E9 19P)1CX+- 81M*H!,KKA4D(13((@</P#%[4K,PPC3!XQXC$1$P:"#0
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M.[ #;^&%!WB,L20!^%*+,@@68_ED5*F*5>H*"+"E-$@X"[ #6W@ T(E=36@
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M;IP_Y.$ "@@!-CERR)&!2$F!,\"#CO:*$> +YL8!"J"G%8@M6." "OB L^(
M.\=A@W =-1V(/& C"R )%@85Y*$ 7V$##8H &6GM8*@!2$\!2;>$O,LFUR <
M,=04$OZ8#N%*N3?@B@\@FA4H@:*K@,&XN^!@$:[39MVQA9= @]I0BO5C%?K
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M@)<F"!8'5@C#*PUM@1(JR4@1##"-8!(>T9% *QB-IFF^"X3[17 P"S5X.7*
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M+[N)LWPAM)6@A1V^T$Q-"(,7=J.MTUB+I8.01A.:J,07Q,0<Q1C+;ME-KL?
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M+[" =<!"!*2)"?0(+4S #"Q41^0!6@Y=4^#!8]I!;*6C95XF9CY3H<A !UB
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MX8MHP$(+T&!"=.S!=-6HO*LY;N%#L!T9M0]5J46/+(0<*/[?#'1*!M !+T1
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M&U# 3:V 8+C W*3 GF0$'K .FR!(@>S7!-Q4"Y@ ,'P*&9" WQF+#'2*&!B
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M0H.!0S$94N(EA*):4 )28(M=R_Z":%N#% U&<A8#T>L.LB0$$VBQ8X2^>(D
M*49:.D@B$^&$)0];$$!KF C<0U3(I;([:(,^-('[H#AX(:-E1AR@92^]1TK)
MO:E4G  M,42*J!&@@JD!!O[\BX"7-USKQ0%8&.$IF#P\9\B!ZV[]P.*ZPQ I
MOF$$4G.B$DG$D(2L&$$X&#G,#!989U?:M:869%SRIH$CZ 6O-!'B)0,X,:VD
M <$)8N2."Q"28]Y&#G(VA;4: 1BU@[ZG("M,&'#.[!&3FLP#Y"7(HTQ+39#[
M<P>"$:,]$VJ !3:&&C#404M )J0OH>1B*:K.J!"80 4ND($-5* #T$>9G%G
M.0I "O[NQ%"#RP1#"1(0U@'TP@8*>  & *N!P&;0%Y/ 909DD(#-\.  )>"
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M@4)= 'D'8\HZ-_$ &)RA S@QR0F#P8"6V,(!-\*$ $8055:11J@UV&0PV""
M%$@5%G$  !A'D)$^=. ZCD" 6DC@( B%P P<*,H(2'"&&42 !A)U@!PJ0;\P
MW'&O0LH !UK  9N9I \1 ,,7(OZ@%S,(1P8'R(,F&H U%<$K#%9%F",<4 -
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M_1R!O1#Z@S!U]-@"7>C7:?JHKG,=1H A#$4^.J:&00>3")T.:)GYDB3;"#"
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M[D"9L.D@]@JA--#Y6+ %7? %87"!:*QNL$9P>F0^ZN41<F=3.,0@O(S&8$<
M+X580L!F)JFI7*V@$*+3+ 7^3*(2H.G;] @A2&_V!&])0,0*%VT'#R*G-,%#
M1$(,)/X $\!P282)%C#A 19,"V/#/5*B >LE>8805+J+%AY <&@!:^!O[>RP
MN_:P!6!C^ [B=SP@O21@+60@ X"C @;"$A1 #LB,^I(##AXA#Z8K!C$Q$S5Q
M$ROO#3Y@:P0GDH")!HY*+[BO$O(G!"# !"J!3%#0.:Z#0V(!$V(@&-Y "68@
MF+C-9LX@^WI!!CS  ZZL$D(@ [Z@ S#D\U3A#M4DHA@A!#I@!%IB$F1 ##;
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M'@ 6*OY!;X1! N@R*?8# M( 2$V 6E;@41#B X#F/X2O3BZE$AH2+3Z/3CO
MH/#@ ,* %^!BL Z" F9"#M2*!);,3-#@#9M%$UJG/%>F9=[ < (UFSY+)=3F
M"P!F)00'8VC! >P 2$O2%G*G3(QG F9!62S UBR%';\-;EI@0&9G[3XGF-PS
M%B-@3'MAKB8"#[Y <-P 0#PT6(5U6+U2$SY@!,B@B_@#.?) ,3I 599K11W!
M OBK L:#%UE !;Y+ IA,,4YSB$3B TA@-FUJ!FB@!L" $23C04P@38ZPNRJ
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M1D0!C!)N(*MX/8T!5G )&8#)]"B%UJ,O+" K[*"@\B@,<. !]&(%.( ,7.
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M Q:8H#MQ*!49,*66"E9)2<6ZDPM:T(%1E5$B<4C>DR1" P0NYPQRXQ4CY/
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M8["^$@*^LG*.,(N\, P-00<FH ";@ D"2P<<,"Y@ !N[#/ZPOU8!,V ',#
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M+#9"L>)E)RAQ!C!PVE]@!RU@OVM_*33\02Z <A70-:^2!@7Q!GC82W[Q 2X
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MC CNJ#.L/"*PPY$,Z@L#@3<>&4$C&;@*@85'S&" %Q52J"0.!F@()@,T0WN
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M<(A1CTB!"O"02UX>Y*P'@<,'6" 'K6W$#EH#0Y%\.8*C76\&)FA:"S0#41K
M(2R/D,%/S. <2\# $FQ [#TO\H40I#88C+C8J<) RC<TC"&\H$%]%!H7B\ B
MFA-1"OZLL$F:Y_0!. 8]"'>_X!6!YE&S+# !'>PP@UA\H7V*9&][W?M>]\Z
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M".YF@/X2AE@!$1BM ="1G'L<CY"$ :"!SYL)-LB /I"#" D&"." NS _\J&
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M@ 5R&T=@C190%B29I.ZJC154E!'Y"!,)"5I0@MK(.V*2-#N B>5A" O(#(M
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M&=B/?MFB#&@$ZOD/Q,&#*@&.,QFN!_#+U1FI2( P(E&4>"F1TP$3,1!1/(@
MM2 #%H$.!P!/O9F0,) $&MB/KG*!6,D@4GL#"4"I9&R-HT$_S&B35VL3,Z
M1F $"<B*,Y*T"@B#2B"# \@*%\@ 1^@8P$.;?PD&,CF('OYLB8YI"14($5ZH
MHCL83D;H@ J@!1&XNQZA+000.G%K $O @0^H!#IX@!8 D^,+0W7)&@BI@4@
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M4>7@#>B NZHT%Z" "M"<@W !Y9(#,+J#"L,A"YB<!YX+$0# &GB.K^, #LB
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MDQ88 3K@0AA^@^L<E9H9YI2(@#,X'T9Y$S;P/#CPISGR" YH&#:(R@3(-@Y
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M4%-'\O  ,TBU 7( PZB"(8&L>D29>; /0<@J# GT8@9A@,%&-,,&,-PT&"&
M4X(,HLP^1( $9)@:0>QHP_S$(K!/^\*<'& &,)CAJ[!X7D$RT)$(N*42N3(!
M<J)R/OX8E"N7(-'$&;X0@7B)CR 5(*TY1Y++&>3T:C:A06L)DA+.WDL.M)#
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M I8F6]_)SL(FC##J!NJ 7T8$!M6JQ@JN>I$'HXX@7IK(U1T6))(FAT$&O7C
M&W"-!TWLUB$5(L@%&)$'_L$A#HR8A2#8&NQ'!!-H:8C$!B"CXI/:Q\4XI@4)
M5IESN@C^TG*[C=+]A0>=$L0DC& KZ_(I SG P0XM^0(.8% )&7S0@G6A@%<N
M'8LSN"=#P&H@[4@0+YM$(@P<$& (_-F!_@&<(&DXLUM /0EEKL\$DUV+!>X
M%)-PVOXEPRMSGLW BP<$QP1^'KDE)B!H0V,_^]KOSR4M4)-*/,!>TQU5'FAG
M$ID3A ZYPL&H#+02"=2!%@R(@R9HH  7'2D"=@I&#6CQV O*0"68DQU4 *ZX
M10W 0F 45B?!WO,,PP/0604<11I8P%G,0#\)4P2I@%Z]W@Q<W!<\3PO &JH
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M%80%Q!E!9-E7+%\PH$&>C4@(K( FV $"Z)9\K=/U;=]",J3V>< PFE7R9(U
M_H]-@ $%J$ *1,#$U$!9C1.7X/Y3)7S !YB!!<@*6Y&*!%R(>RR;A53 (_3"
M!W1 "U# 4<"!2F; VJ0 !ZA #''-+%A !@R#'%@+![2?00Z0*=U'!;1 #,!
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M.!U25$ EY &GE@\)"0._/H)BP/[ <WI'1<RJP0;#>MC4Q/Q%O"9IRJJL]M&
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MH4$=?@4C,,"=*9,8R!<>A!(9P-5)A5(8?-/;<4?VA$$$_4H'2!<))"UE/3/
M6G-#._1#0W2AS<!-40#93)&-]?X"'W]E!-C!AB (V:2!2J()>[*5.9-(!A3S
MFK0DC*!LUI3 5_(/&JCD"D2 XHB!M= TV7A30=2 FU# E."=T+E !#R")E1
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M#?2/([3 "L29K\! X<Y&"\" .0^2KI$L&]37OC.6NIQZP<Z E!06+6C"!V0
M'.!U0;@!:+_!G,/"!>"!H+O%(PBZNQ.$'%0"F3-JHL- 5EGKP==1"K@ 9\0"
MJ$=\'KR!Z[U$"%P [?B*"QB)(WPQ(]P8U+, F!,$'JQ "Y"%)J!]&JQ%Q=X9
M9-!"D/""8X>!2'""'.1!XO3Z"JQ$)60[K)WZL'GZIJ'E'<#!"'QH0= !\:X
M+ C"O!7Q"ES%>]Q!')1 GTP]J7-&)2BZ(-R8)L1 "MS8&AL'+#"""8B!4K#!
M%P]$+/ZHV@JXP$"8%LC/-NK80@58 JSL;%/+ <U8; ,X#BRD@66]2D8H0 K
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M/A(B@&.&!V (SHQ@3"@ADB\^>.T ,^20 +(SLK*# EXT><!0Z(+1A (V\N@
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M7IP")?+ "!^&F#X #-# 1^!P5OJ !$+@Q(*!$0!H$Y,P!$I@@KY $8,!#T8
M6HPF!&H C98C!4""$4H@!+Y I#213D31;P@"%EI $%T##11/870Q!6HKB>+
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M#4U $6D +$K&$D8P##S 17Z!P2(@<("U TC@+]5"7$;@&3FB!9 B#@CC#5R
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MLBCA-$$ SF 3E !'9J #4A2?4 (P=/=F."<8.F88XF  P-#8VL<IWJN4"J,
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M"R;AI#+8 _ L 1T #&+A 69 E7&@#^2 H;CN7-3"!$)E=<GIK$".!#K #,"
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MTJ %FL]SRXP".L %WICKDBR7>X$_@K$CA#8,Q" "#B0.5O[4/APA8NK+!=#
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M^>BG'U1\LB.TPK:F16#!979\8$+AS7E5@1P(=8!D"YX)#@5R8XD*#",8PN@
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MT +#9,,#9!"""L3"9Q&(0:]?311SY80#O-G)"CZ0!SP8ARAI>").'L V@DA
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MD0$+$.<- 12.2H&# [.,@-RD9+OLZNY'L6S"%GV>Q>FPZT>F]('UD3D#!?+
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M!6A@-NW#,3'2KL]R'VBJ"8R2$C(@!GCP!2Y0"2V@2IH IL5S927T "U@J!D
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M.B@,(T &-! +4<4L(5 "8/,!C=!]<N"/'<*L'0 +EC!=%C;").PJ6TP1TK:
MBH$)C_YP$/'(/WW  '7' &+ "9)@,+C@ &3 "8\P";2@5 /1,W)@UM AJ&:0
M 4P1!K39/RBJ&O0**B$ *E(A(1\P \*0!P;@"%FA.'"P(2HP3"L0%@_ /U98
M);U@ 4C2''=2V<R* ' J'>W3DS(0*8R@ (T0CV C!X[C B4@%A\ *B8 S2D
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MNE1%5F3%02J(,, $@KN#P$FC@)HD,.@ S\"N&GD (-FG7A"$2\N(".B7/A@
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MHP"\HX ,N(I*<-4*R%M>F,Z=(8&_'4[7H5L/B"N66($/6/X!-. 71JB #["
MOVH!#MB\CA@!1[A<&)LJ.YBJ9"I?FSI'-,R 7_.CG0&5H R&O<0O9EK)\#I#
M.>T >BQ"+L*O5E%!&2 !#C !DC !"I((HS4L'X67&@@#4#F_WPN![ZE/>'PQ
MA6#:%-"9%*@##V8F$#;#A'#>A'@#"^#=^)V$:;J 6$IAATB#"R !,8 !&*B$
MDWJ$D:N!"_B Y^V\%(C(6%H!"QB!;VD(6TB!OW4!B8B#W"6(.CC:"U ZO#(!
M]6P!@(H(%K" H[6(&=J 5ZN/6WR$1C'6#QT20<A2I34K&$@(6E@!$KA%'N.
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M!-/!@3.<) 9!:#QE@G(?].7 ([158L9VP=Q17#"V1"":3&!)4%8P(P9S7P@
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M,<Y0,KC!#G[P%XYE!NSTZ31Y@&M0SG"2W,:&1-")0)XR )[<(.5K!'&$ \X
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M#,"+)JR')? J(P0;:T2IYKZ4&QC*Z 5N&#6"(_PJ5G[!"OZ$4932K#09Q&Y
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MZ""5%IZTIQ*$'<!&&)RI4"PH"8^/@E3" Z@.R?7539]C&&1%"%A,>*T >)@
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M,&$&W/X.D,.%E? M+9L%&53 81I*<2!U#<R H%  +/AV4%  )D!6,,SP%U!
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MS38K'R#C$1,8",8.-C?JA8,1^JBD!H9@B2 -35I(BX8.*F$D@J1"J !("<C
MBX-.)[!2F&":>Z,2.!1HI"(Q(HADDP[.@$4!.QBY+#P$2C,AA&#( -8288/Q
M*Q@&-*$E@C,T^>*"(CW:J%)HOSCIBVHWLR."(E/0Y( Z8,$AA%X>^((3;SDK
M=805+)'C@4JHLVXA3#_0Q!()YH-AJW\!#EC@@0DNV."!'OX1 PT/+!RH$A(Z
MBV6@.$(( 8R!P" )(XV#B>.O+S0.@Z1'1G CF$E,\* %-%>5(X]>7SPO*"5(
MP.&1%2H9!L5@:('A Q(TSJ/B-+Y <R [8A/CN?">(_DO.T:8\:Z/4O@ 4C$[
M^.*,I#(PHX0.[.HZY;EJ,+J%%3?"8X0/D!L(C:$'FB$U&BZZ8P1&:(%K(#E&
M8($1,(;,8^T:[J*%IV#Z6-N$U!2JX8,0EF8$XAEX&6@2%;0+RO$0K,QCR(&@
MY&6&NV 9/:@W&*$XF%6+I/<1&B7+\@NK[TB3\HK8J+A4:TT@@Q<9*C?<(A-N
MLF.W+ZP+Y@N@!A*=!# >";<B6/Y2 *.7&6SA689@(E$B&#;F4M1J-FK(?.\0
M/MC=DK8W"B.$$>@8B)$/4H #AV J\5XI7ASW((653E:"SF1.#(]+2C!&\(5,
M?0XCCXN#4B3W.!=M1 SHP\%=WM !&:1A2&!8P1<ZX *)?>&#(423R/""IDJ4
MP ,L0),<9+:18WU@!6BB0VP>LQ))*2HV4/N "CAAD:J-X#EA<%'>?J8QN<4-
M%M=#GVMN=C I3I&*5;3B%;'X%#B$0#1OR2+![J64!S#.6L&1U1?1:!4/TD(3
M%<!A&N$8QW]9X(!5K(%&*G)'.>Z1CWWTXQ\!:;!>B"$P%Y3*U +IF8T( P9D
M# JK./[@FD!6A'5H; D)0K"[-")RD@*K),!JT(<KPN&->'IC'(&QE%1VDI6M
M=.4K81E+6<Z2EK6TY2UQF4M=[I*7O?3E+X$93&$.DYC%-.8QD9E,92Z3F<UT
MYC.A&4UI3I.:U;3F-;&936UNDYO=].8WP1E.<8Z3G.4TYSG1F4YUKI.=[73G
M.^$93WG.DY[UM.<]\9E/?>Z3G_WTYS\!&E"!#I2@!37H01&:4(4NE*$-=>A#
M(1I1B4Z4HA6UZ$4QFE&-;I2C'?7H1T$:4I&.E*0E->E)49I2E:Z4I2UUZ4MA
M&E.9SI2F-;7I37&:4U?2HG)9I$68_M4+\_%FJ 8KJE1XT?[3J!Q5ITU]J29"
MT)@.9" A*]B !S[@@0SLQ@0<LP-X8"&"60PD#QRH  528#Y:*&L@L" !4\OJ
M@0YPP 7:28/>+!("[>2& QP@ 9I@P<5@I.!^\A,(+4+0 <7ZM1>\<,$&^DH2
M8#@V WT5Y49BP($/<, #HF0$9^<JF(W  (^@FX %*O 7Q'(VJQ:X6 A2XX@.
MG'4$:*+%"!0;6NV<(0,>L, IG1K<E5:" ;QB1!ZLXXC4*8 .C(A$,+KS2#1,
MP"CV*0D"T@ +2XS@)#V*P+ &H@D%2&PI;"#.<3E0@B)]8'7X0P":+/ %6L#"
M!6S21 (NPH$!: P/WT*% N3 B/[CDD0&(=@$+=Z @)7(X .<0/ ! #@0"\A
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M(, Z2" R!L( "*6HO"B\& #NGOXO!2'J$0[@"\A #,3 #'CA+BJ0<1K$^LQ
M)RJA "XB$A2@!?#@UP3B78RM #B!% S@"V 0>1XI#:;D#,R  V2-25K #B2P
M)YQDRR+A"Q1 - I@)8 MO Q +,2E!EY0#,*@%[[  >+@$>)  1X"!]C0#>%P
M]R*@5.X"3Q+E+ARA 'BA/S;B 89D!A3@#/( !PY E"IGY*8&%@X@)IC$!.Z
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M%S* 39M"!D; !3[@3*]B!8KT*::L05T =IJ"%V"K3;#NC^S  <) *6CA 2I
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M-_!  B+@4#T@#KRF(GCK>I\CL#;+'H-!$!1X4X.A=4ML2+28!#R B2O"!1S
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MQ4#W).!#) !-KIE:4-5H[N(. ."8$4D.(D(RV.MU"<("7(,",+HZM(\OY&
MXH 6. $"2.(H+($#PR.46V 9[Z(%X((">J+>2()T?@(O+(!'LL:CYR(#7 2#
M]&9O#V &. $80B#4.*!V1N B[$#60N!^M!21/N!^A$&,<4";-\)$>"8"M,,V
M+B+,RA<YY%0.>F$"K(,6LF,%X"(6;I@-NLL%(HP71"4\#%=Y"K B-H .+(!>
M7" C%I4$/N<#DN(!SK@ \F 2OF7S*F<&=@,"W., 2&*<):-:Z'$CAB$# H!>
MBHH#DH(#'HA,*<!E9>."O"0H</X7(SPB]@;" \Q")_I@17H[&+C[D6C (\[
MUAI9(-*@ WC3 B:H BP!NL%Y!,H@Q^@E#PH %CAAL2<A1MA@S6" (LH:_\@@
M%OX:?]B:HD@:#6YX!.2@!4HE UP "F' _+8.#L1C>V9 LO,3-%B #>ZBC:%0
M!G2B!B9 !L8< EH@#2J' UA RR.BR3D"/!"I!9"#!0SZ+F*<+I+B+L#[9&#
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M2WGIPE7!2-!'F0@]DE$%1 GE@HY.I<8 )@-%($>'' 83B0.;:%2&?1S(5(%
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M"6O5FT$)-D +VZA$!B*@:+#,TX@&R/",+OA !WBQ430<A00ZM 1ZPN";8.!
MB7E"P^W2<!0J6K$"O,$!&9F(O*0J=:E,32HL'*68'-GA#<&#171N)A5'L*%B
M#WD#'9!E!SB$1JM]5(Q7P0J'?B$$%FQX!"_6B$"H6N(-X:P;&^#Z*%R":S*P
MH*M*-J'6R>"!J@R3@R9H@9>M=<8./T%=)2Q BSCT\1$7H 4<^D@+WL B,7TM
MZR7D@)KQP.(F;W"4)M 5B;;J* 5GJ$0:H-H+.L@!7:=-C4KZ\(8U:H(QLRIA
M+. 0A^!%-C<E-.@;#H606:A()?Z[?0AC&D&+MT[&$JI%R,HB&UR^XH4QAYW,
M,!C1"\2NU5'#W=$CY""51O2BM@BAQ1NF1PL[R,02O-'$>Q7[*#C %ZJIR1$L
MULB(NZK$%G&HPV3LBTW[T@%=PY!#'/B[%.A:B[ '9@HO3)L87L1AKS=C0RQF
M08OUJN0.I7V(,$2\%+B2.!8[PNVA+.&H_TZ&%V[9[&2T* S=,D6\ Y'#;%-L
M73D(!+S-'>^CR&O:,'6V,[S);# V&UF51 "YCWA#F&B!7![WPL?(JD1UFPKF
M,(MYS,-S#IG/C.8C/8);HS)9FB<S@@N^><YTKK.=[XSG/"_5%AJ<@06TI.=
M"WK0._[";Z%_9&8?&3K1"&%TD0P]&4<#"=([<K2D@<2+X@;#%IV;=(\HC5]'
M:P+"P"0>I55R:E07+]&65LFED9?J3_?HU9%6JJ1C+21</[IXE*:UCG0]:R#Y
M.M=!RD,<-'TI0BM[V<QNMK.?#>UH2WO:U*ZVM:^-;:8R@M1I%D8?D)5L'S$"
MKRK!!++?3 NNJL01Y,YU?5V];K?D =Q"NO0C(.DC+>H(1SQB-\-<UE1:W,''
M<< 5+P31HTF("LU]X/:GY[VC2EA"XD;"A# P06_AT:*LQXN%NI-*"X1/]]R3
MV;BXV< +1BRPXFZB]K"S#?,\?Z1(;VC>JA]E@78GKTH/&?X!03*%9T8P!Q8?
M8,H'(C<DYY#A#FAXEXY$(*Z<'B_.04J!N.YP-0EPG' :R0,#,GX\@C#" ",H
M^P-J9@G(\H@%-D?*[AJMHPPZ'$@5J(ZN81&?6I]A!#ZM]8\L@8-(<*;2A->1
MF7NFU#P,RM$R.,B1\D!($J0$Z#]B!)MU) @&G,4"^!Y2&&Z'9COD+<RP"$'P
M8HYZX65'U;# -R\D%8)[);H2>,VGF<$@@EZ8.1(K7^O"N50)1_?+S+PH_G11
M$U"'D&!H4_)8._/T",5&(GA^>G*[,YVC2+!X1Y,(#4$B$0'>+'\8OR>,<%5B
M II%CA8E3$$9;/8H2**K$HI%W?YD>B&I%ECJQ)?>VALNP!064 FMIR,?4!-B
M%P$(Q2.TL#*5@"PW 6&1 &[4A$ )(!/(,FI+T11@\'HCE0**!5.VL%:1HA+T
MI2,$R#!NT0&YL7KW)X**L5NMD1H )@9]H$-\U7F\D!AY8"^/@4&3H".3T'N/
M4GZ6, N.P!S-40FGUR/E=UB1X(/!@ FBT@MQAB[L]VL\HH"\,#AAD">1(&FC
MEG;,!4EF<#N*90DYHB$Z0G]I\$N3,0F!]63E5PG;IQ&<0&Y+J"-ID %; V.&
M]RAK9 G@-GTS)H$/$7ZIIXC"4P,>(#]NT0+Q0P$F0!!T4 $=X (6L%>EAQY2
M@P..R/X!FY!*JG0?&3 "'' GA_0!+1 " L&'(6 !7\$()3 #C6)Z<&"*'P!9
MM)!''4 # 7('EYB)S$<+(?  'P +9] !,) !%> 0CO \&9!,'^!G(Y &(2 !
M<F8'&Y "&: YE7!"&?!VA!*-&1$)(\"+#^ !G- ")< "%F!Z-U..-T,"-2"#
M&J()0!@&?Y$!,E$"9& Y*8$&%> !$T0+=# ",I !%) 2MF "(>!%SL$(%M ^
M' "03]8!O70U'P!XKU4!;40+!4D"_#,9'\!SP> ()@,'9A(,9" E-; "!@0&
M.+"05\$(?\$!-6$'(= ]]S0E;H80#J!R+Y4F&6 ",E,U(O[@ A< 69M2/=8A
M"!Q0 A50);'! 8+ BR00 BU $"L  R9  2O@'#^$B9-4-1]@ A[ &RLP1E62
M1 V$&%G9/HKQ5L@B###0 ?XD$"RP4^72"XQ@"S]A!B8 0SD7#'U@BO:2+J;(
M 0[1"R:0 22P CSQ"!U0 A: =+.0D8HQ(F@0D\TX'KR0 A8@F2,R#"E  B-
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M-: 4PC "1Q$#&2""'6 I,\"5*G%TBI$GL4 !0,@&ZA&++Y,G:/$(:#$>=E
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M!F3 !FIC!J-7KS70/W;+-AB4/9ZC%) "!F: !AVP HNC$B%P$ 0A'4P!!BR
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MAF#P(&P@ 2[@ 3'K"!/0SO8!,&O$"]6;0BLD!P\  RFP 5!URRWU 3?!(;1
MD</PC]DD+G  /Q]0=/I4NSLB'8'> GIJOF.2&N@QMVQU.V=P%!=E B!_%<WD
M @ Z&2:,$ .$$!9T,PX@&14@<D_Z"\&0DQK1!PW YB3@[&:2 EI1$8=BAL$@
M B.00A2 !BM\M2K!" [P@FGC"  C%6:0 2MP)<% J/ M)7&@ (,7!A(  WG$
M%!V0/7 A,1]04HT.%-7A9Q<OE-0D,2JP$!P +COL12,0%8P  5Y: 4"X([3
M 2;0 A0P'HH9:L$PZ.)O)F:@^_[;#R49P$'V(=Y1PP$C<@;A(S^A84VUQ"%D
M( %0-,:*40$FVP', 1!I*,B8,8*#L# *S@1S<<'%A!K!) :#=4!.L#0(: 5C
M1$%BB0B5S)20",9$L%X4+9APT<%",%X?0KB($ ?C!Y01-%62D-*1!)@R:<()
MEB=""Q855@03%@Q.!!<I,L02)D*$"PEV@L6AX"($"8D6/K@P80'65J@A/FR4
MZ,A!BF!UNH88D5*B"3#!-$DX&V9$,#EI.VS$4<&%!1<P,V30--'Q8\B1)4^F
M7-GR9<R9-6^N#"M.I6".>,%BJXDM(S:P8,UR3"L.G8F>03O:6.F11$UI^N#6
M&BP6A/[3:2Q)Y-58HJ5>G"HY>L3(5C!:<N38#?8H#6FV$F$Q@GX6NG%-;_(0
MQZ3=.R;JO>B,US1<$QLYV7&GP4-\>+!9NTF;E[CI37V4RILL%CD<"2826O9#
M;Q:;)(( %ELVD8@6XWB!(P[JK#/-.XEL,6X3ME;#C3M->,'-1-RRX^4^URI)
MD"+O-&F*0HGLT J62HJ;T#B8[DLQF.'P$% ,L%33+A:)*@%MHDK2L,,N6A@Q
MT9'X.-*K-!0922/!C3:18[;BAG',CCB*FS&.-SB,S XXL)S,2!AQ8V.WB1AY
MPT=:_NL%O#?D0'&B/)X<#@<9<A,P&%O>N$/'8"J1XRSN@OYIY#Y'WEC2,4U2
M8I317ABAY<7N'!OFC2=YM"/-"24$$B7C]IS(CM1B2^,16CC!](TR7T55(D[$
MF\B"1\AT#);_(-/$0(H4?4S$8 2<Q3AB>Y/HD3>0A8X1ZCC3=EMNN_7V6W##
M?2R6#$R8@0(RQ%5W778WXX6N&2S H5UZZQU3 AE:H& 2>_OUE]T:X/IWX(&!
M<2R"VPA6>&&&&YY,F&R_C?BQB//XC%V#_VW*86W[@"-ACD.>C!8ZZI!/9)0K
MV]A;6'A,^67+LG419IIKMOEFG'/6>6>>>_;Y9Z"#%IKC8>B<]E)V>\&##NDB
M[26/B)O"A%^'H]1,$Y =ZX,60?[^Q"UK8PUT1,UN'7&9%Z.'5GMMMMMV^VVX
M(YN$@8U2(J&%>C5!X ,21HC@+U@L<'FB&DYR[ T8-I,C,<X8B4"S+_YRK*D,
MV CA(L?$6"ICR,3 B00TPC4AW1K$J.Z!B;O-8ZEP4P P;MACEWUVVD7F*3L5
M8D!),M-Z'/;2&0]-29,'V.*%@8NHT^0L$[]('&0Q0H RDLC:F\CS7C:N9'!+
MY+,D%DLJ8%+5W6U!,1)>TC#<EDKL^H*1+\#>G=?!SR#)KI1:;@UIIBA+:049
M5$=\FD"2L08GD95!ASIPN,"?MO<86MBE>X^9&4HL\(;YU4Z#&^1@!STXF4I$
M@#HK2/Y<",83C!#<1@0SZ$ &U$<!UM6@ R;H0'E:$!4*D.!/Q,N.!&S"@;.L
M( ,D4 %<P- !&&2  JAH! 4BL!0X#+$"T@H&#CPP@@S PA%.7(HE/D##B#SB
M RRL"4I:8 $2L" #>IEA!R+2"Q* (0);XP '4C""I<BA7!6XR'!\-)$T)&X$
M,O#;#! 8##. I05L",8@1X OB>A1!!F(%!LW4@.\ >,#FI@!J1X@@2]H@@)D
M3(-C>)&"#GQ13(N42 KN$(L1X$ "QJF$!2)@ EO (@0F&(M>1E #G? "BR8P
M00 MT8$0<,!T7W! !4KY06A&4YK3'%HE'$ 7$93  1&9(OY**-"(8"@D&#-P
M0 0=X(A8B$ B,TB,'6$2 6EIP@%HD$,<9J!#7CS %F?(0%-<(#XQ\"48)DB<
M&.H2# IH)0\TF,@F&) 2,C"2#-*K8ADD$@%:5.( W!%(,,2P@92D "A?2%<P
M9AF,!Z2@,20(("PD@+<)7(01 9P,&/[B@"_HI0$\,L-?0F!1G.J% 2V3P$8>
M80'J=#,$:PQA,$B04Q;,H!>64, = /.X_K7 <"E@03 ^8 :)<" ^!?@"+#;6
M"SAPP$1GF%<P)M"] N#@+# X22_X%HP,8(Z2O=@ '!)(3< &5K"#)5@E(&"'
M/N2!$1\(8 :TTHL*<&<"9S&#P/XZ !O7B"$# >P YD* 0=PX8 0F( $#P$J+
MHHZ D=59(PX8)P:X)%(B-1@(%7NQU!H@"PU@F18::O  6$1"? (,1@<:](CA
M1L*W$"B/!(9#BPBHB@Q@^0*^J!B9,IR$ L:IP&U2(ML1@/6M$MEN&BK !C*D
M(0'<24D-:@ +%[C@$6=82@G"P!"&/L(C>J$ _B2P)$L\C@0+\:K)@/(8.71@
M(I9  S,C 8L'3"2RD5P!+!IP!C,(Q) <@ UA/?QA$(>8,SQ9&0GQ"J +&.BD
M8C!<!O)@"0G P ZN+2YH.T 4W.AS6@F(8 1L40(",^(E7V =D1')VZ+4H *2
MFT@<8/[P "4$XPR2D\$&R- (QDQBN(P0GUB9,HF7S" #5^8 :"8 &EA$P#MH
M,!PC:B"6U$F$#">9 ++.O+N>-A*L$KB-,"2P"3-DX UH$$]V&#%@-,0A#"O0
M2@E,YP*&\L1$E9B ?^\3X&  62(?H$,L). UP"@X&%^H0!@8T8%&>!I%%P!0
M&E9 O#>DP4GEZ:R(;7UK7(-X$D7M7PH25P&;:((!C^C%B@UW@4?85"( # 8'
M; Q:O3R@50\ #4;I (%*; *+P5!"5T>]%")1A+>]4(!W^H"W8-SA<7GN10(:
M0PL'\$*X$NE(,&+ .C!X1 &@@?=9_BN1RDDD!'@; 8H8X/XR-9E!NPFC@'<1
M^1<2@+7AY,7:@4<MGQ%TH!*<\( (<#%0TZT@C!28='\G$H*<CAHG(\BI+1[P
MRD\CF ,2<0"=I(U:%(E!<):PP%(0)A$SW,:Q*"%;KHU^=*3#KA+%FX@)\':&
M!ZR@!0^XC0,:$P;>6B /(83!#%BPW<^&%=I4Y9$#+B+M8+PA R50@H)QP#H<
MG 0/"DC,&670 6]#AP,AD$$%P)H'!B3&!1R0@0PN4(-'')@10(%%!5CBDF#
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M77;.X>]V\[CN;US( SJX[_Q>Z^6M T%0<K+%A4"@ SWOY1#.7@^.<SMW@TK
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MH->$"5@ ,Y@$-U" !IB$N&WRS#565$ %8'AB7]!<8$ %3&!Y7WB# ' #4C@
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MH!+$@ H*6* A>ZB;$GQBR:ZAX@ JX$4L>,$]"R@A<#41PP<8,  TF*@$#PC
M#. P !&TP 5*0,,O\D!9 5A@%K/X* ,"  <Y!, ,P&C! 2:!"PC$B@$68('F
MQE"]"=3$ AC(2#6OF8M)K(@7P< ;(_ 0 "5TA"IE"$$#@AF,#7C/FP,0!"^>
MY8 8Q/X@:'"$)JLLX +-A:$2#P#!+WX!@@>@P@.A/'&GH%*37R1! 'GXQ?E$
M4%$3_*(7R)L$AB[4@!:L@ 8UB!M-T)()7HPA +\T26M5$"71WJ$ 'V!!"Y1
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M+,C!/_8"+<Q #* "*D# !>"")#345V@C05(%+S0"&Z@343"")LSD(_S7!31
M1&2C&SB"VQG%5=[D) 2")L "(\ D+H034?&")KB!'!C$6=P!&MP!)9X9$AV1
MNWQ,NCS140G5QCC,89X0I9'0FO[=(E35(L@LYA=ERQ9A)J%IB[LHWL(8)MX9
M3&)ZYF& 9F:F$!:-2V0RHN@5)FD.FNJ!IN5I9B06E6-NIL&H9J*QY@5]YFOJ
M4+PP0B5D$R/00EQ: DF00AR48U%( A[H45HP!B_XPD$4!DC$XB\,A8LL52X
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ME-\N"Z;+<_DR3A_C)2^%.4Q^54(3@E#  B0PQ284@ !Q!*$(,T$)6ZR  )#
MY!P.D(%+;/ # IB#'9H "5+DX0MYJ 4=7#"#/@#-#&[(0RTAH007B&&*:B"
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M&P%DL L7$,#3<]## 2AP@06HX19O2, #)@" )M2B! "PK@(>,8< >#H&"$9
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M$WB !2A! 0EHI1)*T$ %(." 2^@9#9)80 H<%__YU[\2WN ! L"F2LH""*
M+B /S/Y@ 2R@C1B@!#3AOP@@ L:@%M@  @A0!"J!O7QA!21,%2 @ Y"*=]1O
M C#O]%3! B9 %=Z  )J -,[I $S@*FA  .Q@#P*@!@!J-)[,ISYF#]X@$TB@
M .: $@B!$#C!#A9 ^GR($""@F2X!%O1L>"@A FAN##K  B)  2 A!]/J#4+
MC0K #?:@[WS!#?0.!P3@OB:I%C*  1SPS-[@ QQ $E0A#:N0%,: QQ1@!2ZA
M S2O$FH!&""!VD:CDN1 ]N8 %PCA 2*  B: Z/;@ ?2M$G9A&#1A#D2  BK
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M!,$7T$ %^L#,5&$78@  0 K*5&$2(, 8+9(.**&-0J@&9, ./H\4TC -](
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M>!@7]@<'C1 ,87"$A!$+B)@8C\ &$0(+O! ,C5"&>-&)P1" %<5WI8 ! H
M!B  !K &IR!ZIU *[U8*L/@)LMAR"=ANI?"*^1:"IY $#! (K;B"M.>"CD>,
MPOA^<2&#..  '? %,L +)( #=[$"&= "#P &!O$&$< "&6 "!D$+&3 "*_
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M, F@R8GIJ8GY)Y^]4 EK2@MO8*4&T8/328AUB85V< ?Y1_X'M)DP("=Z((
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MD> (CZ )?%@#%/X0=_T0FTR@(_Y@ FG8"Q]0 H48#!W S 9A 2[[ ")J$&"
MUP8!"PC0F6^@U!/^".)<"8TPN[=:O?*'!XV9!M@>#"L !NXMAK8]B 8:#&FP
MW1<  XP "QG0"W80[G+@W_0ZB)H@!Q5@"8Y0"9I@"Q A#'DP WR9!^%.!QY
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MI'HCJ !)7)"!%)#A V0 74%H,+D,M.8-NJL 3F B@PVD0 PA$$,6=6,46'3
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M !EXA%^)A:9X UHXHV! @P*@ 3R@!26P@#Q+ 1/0A#MX@-:(@ LP@_ZKCS=
M !QXA$Y:#9"C _G0A 'X@DFH@0H@$ J@" DPE!7(.$6YJV"8A BH!%[P #:
MA9J;B6  !DXP@;);@0NQ U&,@SND XX @THH P%X!&'0@#.@!30XDAR! ^0
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M@)F\E^7L#Q:P5#E@@%ZH $KZ0_[8E$U\P22=X 4&(-%-R( 3?0/XH05>X(1
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MC#;T"M J+6"["DNHUDVI Q*!"2!%@]8"P?G8CX00VG>DI!4H#15&#C-8@6%
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M?BDQ &!-*!=8^ ++H04<6(&K00Z+R .E+5D\Z$?$*FP9V)<Y$80W6 &C(B)
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M1@84:/Z:P9*:L.$(0<XFVVL<<@2I'B.T6")!'*+6UP<<SA(D:C#*UJ'B)!+
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M(.D4<*%-.."7%" ('H!$2#.4(!@4\&4%\$ +!WBN3XR( Y(P<5P\?-"*9%%
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MW, !9<J!7,FV)R-(PR0)DH>.0^"#/-($?V6VQ!2,AQ84@,4U.YZ""F@94&=
M90CBX/Z(,QJ$##.N(@G8X"1[SF"-6<S "B9AD Y\$"AY..-.SD!,R,)!! 1Y
MNG-5%7!<U2 &&4"E"6Z]@@.[T>L8*T@EV X_,?R.!CME0"7B(-2,38 6$L:*
MN2DP$'P:/A@>($LE)F#:+3[@$2_?R28,;@+^ $71'9\!!7;8$Q*,9R<6*),R
M"_+H7IUAHVLR]U#W;:\--"(.W2Z(OQE)R*G6Y%%7/<Q6M2I^5*L$.0IQP0[!
M .+#OZ$%"X95,!"/Z^Y6(@T02$-!*\&(2FB"%[8FR"846T'P0EAHEM<Q&YW
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M)A@<0519!8A-,+B!4!G:(\A>_-@!+81 P_0<KA@<,F*>)41 (U2@)KA'3Z1
M LK7A4A =>U$"Y".!;C S,A6E04#*-H@05R (T @YO4"#L+.J+E&5I&?C&1'
M^-T.[XP)3UG" V +A\V"'!16(2F0"8A))2! 'X@>0=1 "L3" P3()D@4&U1
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M0( 42@68@1C@=7LU<)&3SYJD@0.XNP/XD@18@B8PF0SB@.I76@. P1D\P!F
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M4M9FJ?4E24&))0Y@K2K" B,:"4;&T/. 1GD-%G(8@$TK@ --)&$!M'C$ _(
M"Q/L2PYZ!08%OD"+CUR1 8X@$@)@\089I8$X->  +!PA 3R:R@.6J(3;%!15
M,U3 $K#X0*LL\ %+"/$-O6! K;YP@+Z>DC.TT$0)SB6S-/ZT[T0J, $L&O$
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MZ,!>S& Q,[PE#GH=W7+3L!<R1/Z5+ K(:#!F !$Q6.!)&0!#,(9!@;<\(JY
M:D$L&O$IARA NV2P@"8VT8%+1>"I=C",?SAP:)*41R0(L<0F7CN[%,#B6V*$
M% />\(@T(  P%@@#+>AP #G@@0&3& 8,YB2![U! .08)0XTV>*$T3"#-'B!<
M+S*P%TTD( 9@M?:NT!K#;&^;V]V>"2A2,HD,D$%13]5$"_QC"Q=TX /?42P'
M:O"%L#W" R% @PPF:H</?, %&J%%"^:DMU794B112X$=:G &1C@Q#Z@!,@=6
M0(8OD,0#7S !!UH5C/^-9,X=<'@'!L4!_43-!';  1D>,4PPS"\/+$AA&3H
M"S88AOX7@OG FFCA@JW]VZX%<<%5LN0!AZ-!=I.$40="L$>Y5(($M)-#"F:!
M5$2C.Q)W<X1<A('D](ED$B$(-0UP/))'7+P#1;0F26?0!Q)HX@L4K(%Y(N%U
M,- @/;!8 =)QC ,3-#T$QPD&(T;@@0\\U>(TX,!Q66.>G_N<G2.):%P,L@D8
M^ <&8!)))4R@D3-,7%"*NE0P7("GSGL@RYHXT6;8$XD1=( $QZ&% OPNJ.^
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M,QH/-^ES)'8R!\DJ(\]0+3O1*-1*0X%B%#JR)"S!!'"  RB@F@@F!#J@4>(
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M*$!]2  ']B\ *6 /.>L#HF?\LHM.:2$/R*/::/ BAP4IUI(9/=18.F$$WZH
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MP $?40)K4@$D8 (I\ $SX A:@A RUR,4$ *$0J$T\0B+MUER  '!P )4T:#
M,Z&2@Q'+L7E4L0)Q40D?<3)# 7UQ@!NUDAN/$@$K8 (JP $CTQ@9X#5^:0<D
ML (BL(LA0 'A9A$6P*2N" L6P/X(Y9$'@A8M5V4C=,$!Z,0!0QDV%# 3=H!@
M)/,!MRFD'C 2H3(2'.$!<I =\T$\#B"D'? %1E8+9-,"M"<! [$0!M@8FI"H
MM!)W;P<OO$$!%$ "M.!X3)H"'$ EE$J/'4$!%1!::D$H9_!O3RH&$L"D*K !
ML$ &XP4&EGD&0J%#Y9$"2F >CM(("Q$"'<"A(P!!4$@3'R #C$ 7'$&+YA&B
M.I(0EOE9=!$2](80CLH1)D &.W$_-: 2]!(!%705:/!OG<BI4D8"+J-#'RDX
M.?H&N%$!,P$,G- !%9 !6D8[VU(>=1@,$P"B(BH#C] E]&)>P2 !_T,'YX6I
M*9 "[/X"L+E1:+DA!@_!$3!0 [P@ ;;@$Q2@-Y;P$2NP$7D!$YPP 7K3"Q20
M 29  @5 '"Y0$N\Y=%HFI78P&&:P(+0@?"X0 4 4 ?V983_U1^%HH!L643QU
MH)4A7(>DD,$P M*Q$1EQ%??( O%($W1@"1>1&WLA 3?A"[P0"^%)$R60%6$"
M"SAPFE.E;XW1 7XA$@R!%)FD":#"%&EP!A80=RA(HR/! /[1"PO1@KSAKEIF
M">\EK7@A3AGP.1:*=K;2".?%+;R !PH "S3@:G%GN(XYIW@! 07S!F6QI@SA
MJ<A3 :<VIW;@ ?Q7*K3 )C10>Q1P.':!&[8  :<+"[R0)/X'$0&3E@&^1!=@
MF1MJ808<<36E4@D68&Y[L0F)&@E).[O"2YVP4![#.Q+6AZH,T0&"@ ;=ZA-)
M):N6B085YA@KD)A=TJM**Q$($7<T,6TT<08=\+8T40,N8 L*<"&Q0!=F\&^.
M, $T,0(M@1#+2KUQ8+$%@Q T *V"DP"\\*=I\&]H4!;F&PPID"C#X#)]:PDS
MRA!@(!\50!R]0"BT( <2292Y<KW!P+H'P0MM$P$"9 =(A[!>,[ 4L#C"<,+M
MJXHC41YP<+G[&\"P2 $]$380\ 8(40&]  LCBQ=&S!!W( %W0 =W, )^X0*'
MX;(9@$X7T @'RQ#V&PPAT (P0?X"-[&HNU6T+06T1?MA&)6.!V!I=+".]$<O
M3PP+@O  2R$"+; )>9  <O, C$ +," ?89 !FK ).!D,&S #L& ' [!O\FM$
M"W$&M'4'"/ %CL ()1#&SL$4^*$)!7#(=K".PC<,CQ !OX(#PJ  C:!B"  +
M>/=N='$&)S&$(T$!9>#!&LM#C4&OE1"><= (#4 +FU "%# ,&3 #M$!_5?0
MLO,%Y\58FU )]-H8+; FHGP7%+!@%;!4O?  9\ C7=)=%D$"L/#,%P*1#U '
M8YL!"$$&#N.>:V()H!<,('Q?LF,&!6 )?7 5,U# VNR.9V#/EJ@)P_ !95 )
M\F4+7_[ G#4P"S=""PD("[00 F8@?0$= GC++60 ?>$VGG% "V8 C:ATCRJ!
M!D@J!M"S B00?HG$"#-:,HX "[/2&%X:!W!@!F ($3( "WG@ )4 "PHP(3+
M +10!K:(*+ @!P(0AK$@ 6P .XN*'%*U,W(0!S60 "WQH@DQ&#MA/YK8"RO=
M![!@ BHA!WM,+"N067,<#!! ',)  6 P#(BDAO9Q<A& &V)P 8+\ >1BI9F%
M ); RNUQ<A)0%F1@ 9@ "Q\@$1W@ HA< #;J<Q1@!B#$+[?9+Y@9-@S "$&&
M )H0"YA)?WHSHC31!P=@$6K% HI! 4-Y,X_  (\ L ^!*/Z:>@!L8 N^+,:E
M4<:S5,;?>([D"%3X! HO]1B5,&X=T&8^$9,KX0)"0F2TX (>T*<,00>3V<4,
M$0:3.1+QJJ$U@ -W(0?0'0(SH7&.T0@CL(PN, L,008>9 8>A!?D1Q\U @LL
M, (X\&BT@ :KM;DF8 <X0 93QQ!]4!)F@-VSF3,?0!P)V1@X< 8*DRA@\ $P
MMP*>!AP<@&1-U1SC<2 F8 9-21XT,)E(AFOU\FUGP &64 F21&@',0.3*9*#
M]JLID$$K.E4@'I*T4]UT2@)Q( 8U8 E1\08JB3C^Q^,5T>(=( ,8N[D=0 *$
M @LIT $>L#B]\%<<  /5R@'Q=_X4:%0'B5(#(L0(OSH"A,+CO"$18!T5F"Q
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M,B(XK\\,(C"!EA!@*(%>A1C)( 0.PN5)!CYSLR3+$<28"?Z/!V8R@86/XNB
MA(:#R<,$&BI@X8T/)!@TF!DXZ&#@8+XP:X:+2, A93/B<B"#1])PR8493*"
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M 7@4H -=0F +"63%$1;@"4]:\("LL" $P3##V90(!MP%@P*/R$,$LG*&YY
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M><_+"/YAW+@P=NB##%*0*Y54 "X=^)R!Y0"\%B1EN\%PX4<\D"^4*<0.P*L
M#234@IBJ)P+MJ<0;:!!:TP;/+B]6R!W6: &:O<$%->6)+"/B@NY,(#VY/4MH
M0$/<40$7,@@?#<,5GIE1(-<HM%B5'*45C/R2P"E X84$OF &,[R!*A5((,EY
M)Y,TK+$2&=B$@LA@ 320X0QTZ U/5J 2=?,"CS7 @WB]0P<<N"0$.>/)4%R
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MB .XFE'+&+_(GKD;@4'1A)IJ@;,IMKAH$PM0"<!SP-ZP(Z@Y(0Z@$&H;+#-
MH@,0PF (@4%I@2>B@^U+ P!HF#[0D7Q)$)*P(M 3/=*+B$I0  8P@SZ( U;A
M"1H8 /X[L(4O.)#?&X%$"0$!> 1+0(,T> ,+>( SZ H=L8-8$ , ^()9V @S
MR(,X2 UDE E'1 ,.Z)66&91&$#+M8Z,4Z 7:4H@.8 1-B*F#C @*>*^<F:RH
M6R6600Y-H"*]R1DXN GU6,A^0XX/V+H]4XT[#,:DX+N9 +A@J(0$P(B;> .R
MBP5JHH4W. !8>(19FQ5>F 4)\"1>6)*&&H%>&+=/? MGZHMP(Q1L T&%N(#T
M D.9:$J/\0[,<@2F@JJ$$"GWRIAQ6PB[$ ,#3)8U(H'8>P2FFJVNH!\YXC,D
MU)0GC,*Y5,*Z#!4<^J&)>RPANC@)0 P/(($9D("+J 0)(/Y&"*"*"$@@":"*
M%$A,#]Q &E&(&?#!#(BUAY& _7N .E"@#:@!&;C,G:  S!R!$: !"5 ).G
M%X !!TB7-%" 4'J83U0""^ <CM&$P)F)V=*)8E&(WZR!<ON8*+L#!^  $WB
MR@J1_+& "$C% SHQ![ PA8 %"N"[,Q($/(BI#G *W:PD"V"!7H.+M!-/!U )
M!Y"36; S,)S(&B@."["H%4J6#*@!>HL(&G" -Y@%"] ="4@]A0 #@A  *5$/
M%N&)9#N T . 6)N)&@  !B@ @Q@/GFB[ 5   3"!AQD !$"  6">IHI):J0
M#AV 2*)'!2B  0"^8'@1(.G.C_[8A & S0+H#4:8-4?8I35*@PD8.^<#24<
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LVJFGGX(:JJBCDEJJJ:>BFJJJJ[+:JJNOPAJKK+/26JNMM^*:JZZ[#AD0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>comp_0016.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0016.gif
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MN0IGL !PO UQM1)SMAUYN1EVN!-NLR-\NRE\NS-\NR)CD1U^P8%_@"R"OB>
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M]O#O\.WT^>CP]_3S\_CW]_'V^O7Y_/____CW^._P[P
M
M
M
M
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M!$AX6RB"+9YPA>3E*6F0*,49@,"%6PU1"<B+A2V81PA%>&$(> P"$ZYXA5.
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M6(F>6(J$V(F7Z(EK&(JDF(J*R(JJ.(J9&(N6*(J?*(N.V"A/2(4UMHN\^(O
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M<V"I9X,+#V )C%('@G +*S"R@PHGDT !M\ *". &B2L"(G +E,  ?< )?Y
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M YD$<)F!M5 %YK"$$4 !+*2]%4B)0\2?$3B!D&(%;PD!$6L)/Q !4(0-2D@
MV)@%&*B_Z)@$SV"VWX.!I[F%&Q ;/U"!/\"#])@#FU&%$[@ J^A"D!@LD, ?
M$2B!!L&?\GN+67"!<KLYG.,40GD2V7(2V>JN(?!&(OA&0O'&<<RYK?M&3CD"
M;-2M[B*"'^C&(>"[;]3&W2("<P3'(-C&(X 2?/R[?O3'4?Y!HVID$NL0R%\1
M2%7!1<Q*2()<$F,"'H2\.5I(2$5ZR(/\"#ABDA7HB8IDBUF@!2;A2((T 4
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M!%5-1952VV14MJ"!AC%)2@@ ]HD)GV(+2P"7"J@WV!Q(%X )%SBY2%T2%*"
M-UU2S+*!M\B#6L*LKI3&N3BK+S5,),757 6O\[RY:VH),E--8)4*S)O)&VV-
ML.Q(;9F *O55D,B$[6"+S$B)$\@+##W6@;S1L=#)I?$)5K!*MI@ D@0)7UT2
M3CB*5#/$);G6F%R>AP2)!W&K=4V(IZ& 3PV,/F *DX#+?OYJB7I%R(<D5["$
M@04RIE7UR(\X2H6A*K: A8>4UX)%R(2-C8J4R:7@D>IX$3Z"GJW(293<5U@R
MC&)%S(]U 8_ T$I35ZU,2XJQM:4 B0LPP(:L"A48 7P!A,)HB3\HC L@28GE
MV)B,,H:T#HB-#;&$)%> @*A\3(=]&A& EX -65M32 <XB,&RUNS,+%W5VJTM
ME0IE$L<X 1-@!4R@@*/!ETHH6\]0 1AP 0F @91DQA,835R( 1(0@5>2QL2(
M *;1@PH0@2F,S#EHPN"KOHR8F,%S@!)0A<AP 0IX 2T]@?*K)X2@@]^K,3V(
M"A*<A!!P/8(0& =1-1%XBPZR ?X'J  CJ5S@:X780(&,2,'.D  7T%(4* '1
M71(Z$ $24-,5>(L]B(%92 '#M5,1$ &JP 48T%NJN '3#0[E8 #%R8,1,#@L
M-0P7D)<480/F]0D_,* *"($N:SW)<P. 80.BE "/H 37.TVX@($YF !.H $W
M( $+"(08B%UE#,W3PXK&\EY3HED+H);T+8$2  RVT*00F(%><CT1:)@M=0,1
MH#<5D< IT(HWR -6J( 'T#8R)98%)LD_@ $;L( 0:!!+*('=),DV;8$9H( ?
MQ(K\W8160(&ER+Q,&($2>#VVB(&>TA_8N 'BA2E68 &[Q247>(,1>#*VD ,;
M>!8[P/ZX$-@(5EB!\NN)-S#=F+4U",B$K"D($>"6Y>$$+TX!5BB!]9" C,J$
M 2:!)<2%%W  $JZ#Z)@!-SB!!*&!%J;AL!&!'?3"5"R!C7"!-[X154 !I*"]
M32 !',8/:42S%)$#!Z  /.!4IJB!&*" E]LOQ*,!%U#5JG  "\@$-T !%L;D
M60@;^Q.I^<@#)\U:KG7E5W:2(/!:MDB=N: !R6 #:FP)^4V)%"@WK@A!??F<
M'?,I6[!=!3BY1X.%N+")%9.]D" K&GB,0-!BX'&.!J&_-WH R@N9:0LID-@#
MLFJ!<BF/?RED!R#).AB)%(@.F"T(E8N-2!XQF,!,MJ"$"/XX"$)D!5=X@. 0
M@;R8MF?F PLH0<GP Q*3 $2 -7PFB97DJEMP )^J! 5@JD@&'@S."SSX,97@
M"PK,%PVE@#M(KZ(0@+4PFNL@Z)^PC19()D'R#)QXBS\X"E4@@!C(!%R  -MP
M P.8A(6A/"YCMM3  P.P"7K!D8(IGDIP#8( ! L 'D3SR NP&0<P$D"8:0+P
MC3JP"S^P,Y;&J*JR )B @$G A3@;OJ/P@P*P"1=(C1&@BC]8)?6B0M> %R7\
M%Y.0 )8* =? CT!P-I^8@0EC@=18#H3@U@N1#1LU 'A1FY&>@6JJ! )(D19@
M 6E)%J .@3@P26(;D57" PH"GOX\H*"=T#:_. @):)A)J("G>=:&$3D,JBH"
MB!UX83/#F)];2)5*H%JFT(J]$03RJH">@!%<2)#]&C/C8 6-V(D4&0J2<("Y
M0(];>  ^$X ;88M-B("U8 ,2NX7UX33ZJ(!,R!!\LU5KA.7SWMI9[DA+X(,2
ML V76Y)NBI=A*8$]J ,ZVH,].(")(9(Y\(- 0 &3T&+ZZ)$W\!=6&'"0* ']
M4HC:RYOKEH!I99H3L(/5>)58,UYI89K*S,1]HX1$JHA4J_!DV@/GR' $:9@2
M$+&%T25.B/!4$[$4J(/5\(,2AP"J6(H4: %!\ ,Y4("E> ,$,$ 73PD(@(,_
MX)E*.OZ05$60%&Z)"U P%ZLJG5&%0%BP@Z >MJ@#.L7I3#!+1/"#.4B R5G4
M6Y !EL@0!:^#PP@,AI">R8B.6;@$/T@!DZ@#*:\#%, )?*DO#@P$/0"$!$#-
ML[B1-[*#Y#"<.4!PBQT)W*@(NX ! <F^P,@$Z_$)%*B#/[@>EV(#"8 #52U9
MA'@!C[@R7G0*-@ +% !T" B$/0AT<:V*_GC665A )(>!$+@U/2AQ_A"?4W(K
M<U*6C>BF6\L#/I@$"Y",SK'5$X@!5M"#<C:1)2&^X*FW^6&,5@\$!3"2<=47
M&3@Y"Z \X@.)D:(%!LB#/MC<$QM8GZ" AI$ G0 )@($,.O[@+T#8@VS_ P^S
M@3_ %Q/("S\XD<&RTQNP!*T "1(@2?1,%SO55!I@"0;  S^8!!'PC*-P\:U$
M[XS/526E91%(@3NH ;Z ;S>4[VJA%A+8 XR3 S8H0-@@#1MP S;0OSA"%X>Z
M =NH2@K0)67_E0C(!%5X\']Z\4^2"DEV@#=@ S:@@]U "&5_&C_X8_[3*?K8
M)3RXA*-/>CJ(3 L@R9!IK0DHG(*8 )A8M%2K@\Q >J4O8*FHF1MX X K"@,8
M%B)GG!J(>3EH&":/(RQ?"^"Y 'P=>?BF@PJ@@3VX@*IYB[&@@Z!(G$FP7CAP
M^YY@ 1P_#I9@ \9G*+S!%T.-GO[K*200*R34H# ZK0,5>-:1_A<*6/G.<QPB
M,0V0> /J\)N%>2BI$#$7?ZE;F'1=R81$6@HCUO2PD! _< $(<#"?"'60'> Y
MH&.ZH""GJ8,)D(,I>(,[R-+)20_(^;480'HX$ 2&BWDVF(.?=ZB">*J6".&&
M>'<*TW,'"/\YL D2P.*6,-?2.P$%R(NF5LUHW[?YJ(!* (@]#^2P>5.'TZV$
MK"9DNB5CQJT*?FX%JI#0Q1M6#-RP83.'TBU<MU:PN37K5@@^MR(T3'B+$P55
M%5CI@4#039V&F6:$@-"PQ)Q;?"S<F@&QZ!1+%%R* .32Y2P)EHK&2#BC!BL'
M'6_(F?YT2T6=.3">DKU%Y"S:M&K7LFWK]BW<N'+GTJUK]VX1(DMLE17))D1"
M&RUNR3D1\C =P[=.U$EH8@\@HB;QG$Q80>4M02 E-(RJ:H_%6YD4;#HL8_ M
M2@]N;9)0660F":QNH:"3$,6=60]4)=R#4.0,U']4F#RAHN0>"0E5B?A:!Y>#
M3KU+NZP0J.B*A)4>5&8M^U8*.0E5S(&.\-:>TL!=+,=SJQ*%30^\<OH>PGWJ
MZQ,JW;)%@7\%3CUEP1^WT(%"0@?>PL!$44T58$(BX:'<2PS,P@9JJKC7PAN'
MS4##+8!$(!(N$$RBBFN6@;3'"+?ID5Q"<IAP2QTSTFB8 _Y3?16()13B0IE+
M),"1T!ML9,)=0A($P@H$)VT"P2TV$(>> [>\@!Q@$5ER9&413.('"0GA,2,-
MO,W" '\B77F1''^L9F )":4  WN32"#2+7C,)E(,BOFA7 GBW6))@0_HZ,<F
MK'Q7WYZWP&##+8J65H=A#_!WBQ]3B:!'0K0\!4>+(KT!V!^2'1990A<4>(L%
MDSQ9F9XN2>H0B!9,%(AD+I0$ 4@A3B72',W=HHH#G. R 74NK0##8)8T*>8L
M=$Q$&T0D-.8'434<]>$M#G JR %>=6<29[?0<-2Y*WEURQ\@ 5+""9>6E=!=
M]=I[+[[YZKOO$'O->\LD#[SA!OX*$+ 22 )3//5' I".$-0M(XB'PL,6H)90
M( _<4$.."UYBD@,-B9 "'"<DT%*D%KP !P1VB.; N*P\< (N)PQY"PD=O@$!
M'"I0T"@K%K@ QP/XS6' >2U4_ +..O/<PL]/G2#5+$+#$4%C>,I\@BTH=+B8
M&X1!\ ;4LRE4P0I$BP<!IWK K-L)K%CR@ TV,."5 [WRNI@$7N%9<"9UM$A8
MBRU8.T,$5:70]V%X*.""'!1 %+0*<D!0T@DEB>1"58Z&,,<(@V4"<T(/7(='
M:"3,0:P;;ZC@@(99U@%8'1'(T4(%)[E@@1PC*":2)1'8P(8#_,'PN0C9;<+
M;,O/HOXH#&Z(P, M+=20F@(QE.C4\: 35\<%"=U!E L4B!7"22)9/QX;616D
MP@,@U0& @#!4, <)O]\2@P,SO.& >R[Q@!D0;R)X<, ;8  !5:B"><-RX.8@
M0JS2S $P!TP@!!#B @>XZ@%F6XEM1**) FR"$PF 07=&PS0*]"%)*IG!_4HP
M CR%I (A8,4,QB*!/83H3E^YW@'=H,!DX:($X:% 2;*",I'H 0 \O$4-*""'
M$@!F#PQ@@QL8!X.[ 0)*,!B+0]AC"0N$ (:34!1O7'(!"["B!NPIRF#T\  V
MS. !+1%!F/Y%KWWQL8]^_",@U](OOOSK$F_X R[\@!! 3/[+)8&82"72: G>
MX&(/;%C54SCQ!CA0<A*5\:1)Z. &3E!B7+.H@Y$2,HM)T# AF<"#+2:9$$N<
MAQ)LL,.X3(+*7Q$FCR'QPPU61<N$V+(.N60%'A!R2C9\C"ROG$4FSC/,][#!
MF&19)G]4(2"*\.:5L^$$'-X@'8"9#1&S06:R(H4'!NI(%?R9A1[BP$ >HA,Q
M+,B$#1JYS%Y-4S0H^\,-IK5*/%%B-JK@)T(R 8<^X.(/B>J5.V=9S0_Z@0U/
M?(HJY/"&\[ KH*I<URH5\@9Y>B43U*$$#PN:$$#<H(7#NE1$V<4&.7S0GZ[4
MQ"TT(8<]X (0#6$%(+KS!S;HH?Z5T02$#4 BDHR^03VWN 0;Z#";@9J$E2[)
M!$YQ 4I5Z"@3'C$;,C/14SS-(JA/"01O4-I*2G!*I:DQ&R"(VLJ7X,$5FV@(
M)7C#BEZ9U)5?O68>V+ N@.5R%G_H3B#DZLHBM805><C$7FTJFDUHU25]LP4)
M>'F+3NCIKJYL22;<,(=&B: Q>C1+(%.KVM6R5I#^.BUL8RO;V9)EKK2]K4)H
MX(!MXK:VO?TM<(,;VV )M[C&/2YRDZO<Y3*WN<XU+@E4@(<3&*85IL6M2"9A
M@MS!MK7>_2YX[Y67U_X+3[9]RGE=DEY<G+>5Z0W)>V7[7K+*X3J^G==ZT5O>
MT\Z7MO[QU6-\Y]I*3OBM+[/][WYAV]X$ZU?!"S:P@OT;8?Q"N,'%%;!Q XS<
M_-[6MO^=ZRSV\(8]Y-+"%(;-&])XVO"RN,4N=BTAGROC&=.XQC:^,8YSK.,=
M\[C'/J[QBX,L9.\.\L<RQG!O$;QA(S.YR4Y^,I2CW&,E2SBV0[[RO8: 91A+
MN<M>_C*8PRSF,9-9S%L^,YKQHI<8,[@_]ZVP>FNKX7^I8HD>QL4,5(R'#IG7
M)25$[UPSH0)*WN*0ZGWP8>9EB=GHX6OL93 <"H1D"[N7RF6^-*8SK>DOI[G3
MGGY+D7]K:>6*1'"QA0XO_X ?_:Y 80L&! "R(Y(0#&G4\_Z2@%, <=T(GR!L
MMMXTL(,M[&%#^=/&/C810CVO4][ OHO^PW5PH8=FEV43;TAQA/9@@U7);1-3
M<)DJ0"J(D^3!!O;EQ%TI<[Q 9/<&>"!K'9I: 92Q B&TW,,-&L*)Z.H(WXT4
MB1]&4 '\E, VJ9F"-?.:$$TTQ!)LD"<QT5D)"-Q %?4.R;0;&:&,BT0%= B$
M#704(AO@\B69>&5(\+W-2533%<1^.<QC+G/@(KOF:59V;2T @SY8X Z+L< (
MW*."%>"!UHD.! 3<8(.0?84Q(1A+)4XH!PG40!4+F T@E+,"Z88@;&]X0 G8
ML&\)E 0. V_!E$C@M1,PH"%^"?X3"BCPAADH@, 2N$_3ZR ","9$#R<0A )F
M0P+QO,%\N[N%"\ H CP$P@&!#0%[)4""$53B@";(!.B*@@(_5(#OYMI\!9B&
M.S;00 $-X<D?6#"8.3C@!!!Q 0KP( +D5& /+JC KV>N^]WS'LPV__V5BX#S
MIS@V(6P@S@E04_2$<,*#+J$ IPKM!T LQ21V7-YL!!&!B#4&<A59C@-P40<D
MW<(.ANG$;A)" 4K\H?J72$!6;Q$'Y$,*9T%I 7*J7Z("\P$P+4 0"= !+C
M=9Q ',3&L+@&C]P"+4C QPR$&CE%'"!(!8@'*PC"@%C@=:C 41A@GO"&L^2)
M \R&'_Y4WRJ$WPTH1B"46.^UH N^H)0!GPP&V? MC J\@,[AC&FQ@03 @ I
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M8B:F8NI11C:F:@T!$WC*LAD.# 1<)MP #XE$((0 "9" O)@$3X1 25 $'I4
M?V1"=HA&:O[!#6$,'HF 5^#!#1R&*I! =JC""8S !>!''EC [+6 4^$!I,S
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M:2<P0!^<7 LHA_#VFMF80(><Q!TH1PR(D5@>1I\\CP2X# FXQQ]8A!P0P$%
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MR*C":J@ " >/LPHD!:Q+<1_&'CB &XQ;^>61'<3)0P:"'82,S'03@_@!)4P
M&^A&96+L::N 8?A!EKB$>%N&?94A'_1-'R",?=U"<@;")-A/1-@7,%]RDB#"
M8;1 _8WR))A*0K"F90B(R?J!B? !PO S!7!;0T!(!'S&RHJ&HVPW ^P!=KNC
MN/ZTC/X%M9@&P5 7"X;*07?\7],4X61CC M,0&M&BA"ZQ N(P!O, 5'  0NH
M$D.XA 500@S8;D)<YR4DH1PX(2"(P#V?Q )A"'S%1PJHP!O8P!NX1WC8)1[
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M0[ALNV?XNUOI4!\ 3CV%(#C "KC.(-XSFI/ (++!0-@ !7 4TBG= W!"5,S
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MBX@#$4Q0P049;-#!!R&,4,()*:S0P@N)"&()6_2;!9#3YF*%#AOH8 4Y/=[
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M#RH "@.A2_S@ LYC)B+B%"OB"%^Q(FC!1%8A$#K![Q+D%6ZAWGY ")Q@"8*
M$5[!$'81"WC,$QQ/\$[A%DZA",I@+KI@"(( #9CN%LK@!PSO%F+!"X" #&Z!
M$&YA#0PA%@S/%LR@%&[A%9B X @!"+;@%L1 "0KN![;@&)5@]S1'=OXF,:1"
M/1C  M"$%4S  4A %5S@!& C!$P$#BS@!2H 6RHB!DJ@!2!@$_;  23 .6:
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M!>3"#58@.(:S*H[T%MY@*FX!#Z+##IIP*US +BPA 99D#V0&!4!N!>+ ,PP
M.U1! 3:!#K2"#MQ#!>JR(BS -]Z@3?(@.E8@.??R >2" 81266\!1Z)$ CBA
M$PX (OP@,E. %9>#$R!@,3/!5641 HQO%BP@$ZQ5)5Q5 OID*3(!#V@C!>AP
M+.BP8D@ !>R #EJ /B)# A[@ N! +E: (VH",KG4[6;!!GYE!O#"/FXA#PP
M+R[!$GG08"M" A+% 52$ ##N%OYH(&8C<^A,1$.?@S#LPT0V(3I4@!5'HC8B
M8$EHE!4VLB)$P#D>P/BZE0Y6X3XX(3KX@  @$FO%(@] MCAO@0+.)@1\HR;(
M4SHHH$4O;A8.P#<F@>A>H#);H%G=Y@2F8"B];P:F !<,@-%N(08(0Q4*P%]L
MH#P/@NC^0 %J)%VM,%@3]PT H4W\@##6HR( ]Q9LP 5F5A5) ./ E14"H]O<
M554K$^AF 5Y_IB9@@",H &4?H&RCQ 5@9&5NH03L@A,*EU\HH-L<@&H?P!("
M84IM8!88 'DM 5QO(0X>H$\HH!):0"@[ >K80#R))D&6 !=>(=[:E!F'P/"T
M  C<S/X+!F$4;@$-:&\1>L *;L$0?$#SGL#>?B 1;L$*?N 59*$(@& -ZO13
M!P$(L/$6G@ (8N$4@  *;F$0*C41Z-$:Y9$1?J )OF 0/B&"1754D48?\4,.
MPN(BG0,7* !9P(-6?]<.*H($]D .*  .;H -I-59)> %T*0%+E85YH -;O,6
M3( PQ\(NOD,$6A1554$/3*(V6L N**%X#V(XW<)%LF(K+*%X:P(%YJ %3N -
MV  &B$X%3O@6'O(61* SJ (".J$%G*->W>X6SO7DI+A%9, !."%L:^(2ZE("
MUM!89]@&;-@\*&$%MV(/5-$%X$ 39,9MYL ]JO@-2D#F:OZC!"Z !F# !LB$
M!_&  <#R!+="9<.#!-A@DW%A#]A@!:+C#II8#B0 #L8C ; E/'3M%ER@#F@4
M,DXYE2,@6;7"#DS"=^?@E6W@#1+ #RQ@2^Z _.2' JC6$F$ "UL #E3A ;ZC
M!:;R 6#9F"O!#Y"U-D9 +(#Y]TX 5[L7#B0 96\A;KO&/F"222% +L)V%B[
MTZ;S%MA !4[ /("7*L!.6%! !*JV(C(Y(B@ 1IAU*RJ!Z/9 YO1@*B3 TFR9
M!*RE!A( %V9 /&%@)D;W%EKS%F+B=_W@#X*BF!6@3VK";2NB<U771#@A#MA
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MG7_WLTL@#^1=%6;@N2;A!&JB#R)3!822#=K$!=QN.+:"5X]<YNCU#FC#;59
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ML]Y@K358ZXN<X@<9OK42.WR*(OJZ7,,F5[''=6PO%.'8J):*J)\-35)C\R*
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M2P20EJI!]$IX("JB '  (D KS/$ &&@""M )ED  9UH! S #@.  "3"I=0
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MY.M%_OAI\6KO]X[OH:;OQ_1YIV;!D\$&T/@&%0D?=&"-Z'D"B!$!-E '+J
ME,#FAE0)!!#JQ:ZQ8S:.'@[B=&#R<\ I<! !=0 #:9*.(F!^B4+VY>TLDX
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MU*VF !70DQ2J6;A""7" UK-?E_A0G&"%:C6-8R/;BOCA0UWBA*#6GFC2OA*
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M P:PX[WSJVH<@1"H@72&9KR<YFK6I;[T#R-V*RIF*UG3LDLV"LEMXU4\B#<
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M46PM234G&PS(-FG\/:MF7(JFF([&?KNU8[M4=EC.]FP@ FG_F*?6/II_OJR
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M=@< !.!AE\H$ VR(%H>&H 0EL,##(*"'&%5 #TWM5!TH  &;G<4/#+CD&TA
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M@ J0@" 9R1X\D2M8P(W^C@H\0 W @ *4H7?N")]XU![XCL"0 $*:"9]D@@.
M:8^\7B=FY\.]FY/, @G8S":$ /X)C( (V% =2$ )2  <W8(-H  )& \KN$"H
M5F>,;$+B;<K$B0 %(.(+5 !'&B4>2( )U&HHD4 )@!(-E.3/L%<-^*J12("$
ME47PE F?O( ,*(^'OFFYFJM7Q"F-T  %/.<$U, MN$($2)@;/)&3HD4FI.>O
MG8P,6-G.<%&EX"M:S *4;LJEE,4<&%%9G,R1?223QH@-0)597((!,!0KV.MU
M9D+" !B?#.Q'VM"MT4$(\,DE/$ G;(HEN)?F7*RE'!E#;4+*!FQ:W (G!,S
MEL5*X<++HH7%:@RG\!HD74+/H@4=P(XE -]9M%BEW($%<&S,1,U'L9VG7,*N
M?53*WOY"'50  CS2"=B 6<" [_#;* 6" K ")PP1'?A.QRC/+* LJ!"LVJD"
M)TA 60C9$-VJ\+256=C 0UK"0MV"2#V2!5Q")PQ1(+P;L'""P]Z"'FBAP%;"
MK@WL(OV:XAILQ5C"TUY $_*)'BC1#*&%E3ZMP 2MI4SMC(#4SG+I+<3 N\9.
MV[Y,X"ULZ,[EN=)NFZ*H*EBMIS@ 3C(L(.@=#3! [M3!!<1 "$C *+6""9R
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MG\R E5F '9Q 'MB 'US"F)Z%[7Q4E*E"#3Z<(-L!N]Y"#>C=S(R 8QMS#I.
MK1G;N[G #-S #.B!#;#"&VSL+<@ M\V;Q?'!A5U*#,"1)D29'SCU+=P 8,$
MT]Y"",A!*X#JWT)5)J@ G[@ #*TSS/R! ;!:(.@==$LW#,GUXHI." Q-",QR
M)33WQ]P""HP2'I2;,\_;?7%"E &"  1BM\%0(_;:[(+S?OY_IJ0HZ,O4 0
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M\;) ( 7]%>U!PHJ 'L1 )KP &[PKI2>5'S#5 X0]'@!"W%[Z1VGZ1D4 [B;
M*GPD ]A>\Q(B#%4*"FS""CS,HIX%%..!(%A )4< +-Q"(Z9W2'9"Z.>RF9L%
MA4$25#5TB:M UU:*#>3!'3!X!T.>1G&"4P%"P2,U">!!V^-"XYM%6]_""W2M
M[;G!MX?,$ D"ZU3"#'3MN6_NY5'4)%C" ]A ^H>_BD( #/X,&Q[<@1W\0=3B
M@AX Q(P%=695:/$'#XE;,&K<4D$"SZ0*L_Z$N'7Q5@5*)P)A]/@19$B1(TF6
M-'D2)4DB*UFV=/D29DR9,VG6M'D39TZ=.U<NL942XQP%G"YN6B#G%BX*DVZY
M87'QS8I;(>I<Q//G%H1,&''=BN'BUBRQ7?=,A.!G*AVK?W YH'210B8Y)2Z*
M:#A'(2T)EV[M*7&"J T5%RW!\4A'P2:K!F91>C#KEBH'FS))Z.J"35@(K.J@
MN&@!T*U)$FZE,%QGQ$5.CV<]L 25DR4(D%FQ@7QQCN=;%K".OD4BSD4]>FY)
MJ'0KX<43>%@9>-N:4J;986W<JOYS@O"*KH$<W.)T&SD#5K<L,;CU!ONM3&YN
MZ;'8U88%M2LL,"WQYN*>/;<>O#V?297I*@/O%E8D4&46!?SC[A9 '!B/$P;X
M@LR.&6Y9+J.M;MDD 55N0:2[ "';!(+S%+*. <BZFH,"%;N" 0;A*FA0O%LZ
M8>"UKC*A2XZG6D *,A4L/$^$6RKRB!,$/)RDNSU.S,.B%ZJ[Y07;&/!PCA);
M:$&Y&S(*[2(_%/#0J%E>>.K"-U@Y ;+R9J$ JUOD>(NL(>$XP<&+X+ (AAMP
M.4"Q2LSSPZ*DY!1A,* 479311AV]A:=()9V4TDHMW6D(GTCJ*B0V&""!! <R
MNV@%!OXRF2/1-U*XY1()6E"! J*T^J@& RB0@ (&WH#.R,<V<1563=J38(80
M!B,1A1@FJ(X2!6"89:^P'. R+!-&B &"_3SRM(00&$#KEALJH($"]BRQ[)86
MJH/E <[2JR TWU# CQ(&N"RH E;^>" &$DJ S 8*9J" AHNZDN/=WDCCA (5
M5I!@JPB.PZ/(WYAS0 48+*!V"F(%OF4.NI(Z(00:*C#,@8ZZP@."%F"  "E<
M4!!A!@CP((\!%B +I("M9B#-NPI4:$&"U_QX (824MODL5LTF0XC5B)0C(X'
M7'#A@9MOJ2&"%R# [Z)93O#P#Q%@X))3%$RH@08)YF#EP?X-9YM%A!)@,$&"
M\2X*P8$+*&@YK+]@H, _&R# &NR+7D!+%1%H&$'OR(QU(:Y;_)C1(Q5*H&%@
M.@BURH);7)AR]-(J@.&$&0.)@/,6*&#E JS(>J %&23(;/4:9G!=E18LJ,&"
MZ@*!X 62(U>E@A-^]J,@%V:8P34;+'S(!G+E "3TJ!-0B]-'O?\>_)0N'9_\
M\LT_OXA,?V)4%3[V\!"CQEAA!7[ZP]Z#>=6ZOXB53/S/Q!+STY#3QC,+_(%'
M%1&)VAXX83_OO.8[JHG<+0*1!_A]1!5[^,-X.)4)/&@(%T2)C-X4X\ (SH(H
MJM!;;/A'"<@DL",8R80=!L@_^/Z=4(2SX ,?;A-!6'3B(BH,X2STP!09XN$U
M!;H@+B9AAR1R@A914T4":R@(/%Q0%$D,85<<&)8^\! CJLB#(+H20H.)$$F<
M4L5P+DB>#WID%A?,Q!X(A(M A$856U%,4G+HAS^@$$F9N$0F,+%'BN1A@I=X
M(Y+">,6/S,(/= R;*#YB1SQF I!A\9 *@\A!0$PBDYS80Z#B")XX)C")WAGE
M+2H!&4K<P3\%T@,@]A<6A.R1%7YXRR94Z"%<""(0N%"%)C)9E >T,7S)5*8R
MS]=,9SX3FC'1U#*I64UK7K.2V-0F5[BY36]^$YSA%*='WL" S-1RG.E\5#39
MV4YW3OXJ"--L%#I+0D^1V-,CM<0G4/!)SWTF4Y^,^F<^03+038'/GP(-"3H'
M:E![)C2;BW*H,OMIDH#>DZ"&RFA(+!%#=7[T>^\4Z4A)"A-Y@A2E*57I2EG:
M4I>^%*8Q969):5K3:*I/ICG5Z4YYVE.?_A2HZ;3I4(E*OGBN+ZA)5>I2F=I4
MISX5FRL9PA"D*M6IMF2J5,6J3(*PU:JR)*M:!:M8MTK6K&+UJBXAJU>_FM:V
MJC4G:UU)5W$B5JIJ]:@CX10N^&JHOOXU*64L8V )*]C"%G:P?S5L8!-KV,3Z
M=;"$A:Q&'PM8R3K68'X][&4W6]G(]G6R>]6L94&+V=%V5OZTI!WM9U/[V=.6
MMK6472UE8YO:T!JLMIEM+&UUZ]K=[C6WKV5M;V7K6=P2U[:5Y:QJ?WO<VPJ7
MM\\U+G"1JUOI!G>ZSC5M=I?K6T,A ;SA%>]XR3M>(QBAO.5%;WK)NU[VOA>\
M[A7O>>$;7OG:5[WW/>]]D4!?\_*7"/7%KQ&D@%2H'AC!"5;P@AF\T@ULP ,/
M]L"$*5SA"4,8PA66L(4?C.$+9WC#%,ZPB$>,81-'V,(HUG"(2WQB"8\XQ2B&
M<81G'&,1?\#&'#:QBSTLX0]P( JU$,D>\%!D(Q\9R4E6\I*9W&0G/QG*49;R
ME*E<92M?&<M9UO*6N=QE+W\9S/YA%O.8R9QE'.0 S6G. 0_4W&8WOSD'9X;S
MG.E<9S:[^<YUIG.>]=QG/_^YSD$6B24H46A*3,+0B5;THAG=:$<_&M*1EO2D
M*5UI2U\:TYG6]*8YW6E/?QK4H1;UJ$E=:E-G6KX![B\1]KO?_K;:U;!>KZK[
M:U]9O[K5\85U?&O]:E;+&MBXSG6MT0OL7-\ZV,F^M;#]NVQB^Q<)14!"%0S<
M8&M?&]O9UO:VP=KM2]EU?&ZEB5QG8E9R%_7<)XVH1KD94'=G\]T$C7>[(]J]
MR&K6NOC.M[Z]2^]]NY;=]Q:X; -><'L3_. )][=H_VWPS#J\X0Q7>,0?/G%^
M(]S?%_Z7>,8'OG&*YYOA&E_XPT4.<I)W?.00+WG(46YRE;><Y2_'^,?QO;^B
MWASG/,'IMGG><Y__'.@OA4D1BD"$HN/DZ#E7^C/3I^Z3&%2<(2>YO#,ZT8U.
M/>A9U_K6K^V2( 3A!V"GJTW ?NZEG[U2.^<Z2<3B/5Q,<.UQE_O<A=Z2,QB"
M$(88A!;$2O27''T-C-B"5I-N]*$;O? K2?K1"^]WER2^)8S_^^,GSY*D&T'Q
ME;=\.]6>$CGLIRN;2-Q'NGAU=G-B]!<E_0U*4((Y[*\.2/%((![2@N.$Q0TR
MD$$,;(!&@Z5 ,;CX@QQN[YU*5&(21,%%'K05&?BI()5TE_[^]*G_3:Q^XB-E
M"$+Z@B#6KD[U!V>XA2R^,(0B?-W[1+@J5;^N_A]@M?WJ__[8W6_6]WM])??O
M?DO0G_0A_,#\YFK_YHHEZ.JN"C (C@"LX@^:.F_=/J("#$"$\J3@KB,ENL(Q
M%"5 3L /\B "I()_(, !E*\ICN(/;.  &.< 9N -WD %KL0CXL S<.$$[,(!
MV.,6+L "3, "#&,&8& %V&,64$"$++#ZCA )DS"DP,H3;@$,DJ +;N$5BN '
MG. +L. (S.\*F( )J* ('.$6OB!]CD +O, )NHH)KJ (J& )ED -MP +@H )
MS)#]LN +M*#HTO (KL +CFX(KOX #*B@JQ1P"[Z "<:N"+! "9; "Y0@"+1@
M"XJ.JK8 # Y1_8J@"[[ ">X*"\3@"J8J#96 ")@ "XI "4KQ"3:1# W1_(+@
M"<1@"]0OFIS.)&8F/0*! NZG#GRI!D0@$[K'@.S@@CBA#O3 E3#'@.I@%3 B
M$.:@^+I"!5:%?Q[@]N9@!6  !S/A +:B*]Z +B1#6"ZB O"#4RJ ..3@ 0A#
M 5"H4,*F F"!$T)'#C*#-AX@')40'_-1'T'B^FX!"GQ "%[A%HJ@#&[A)R(A
M"*[@%L!0$<P (\J "$C!(&\!#8! _!@A#!OA%IKP%@PA%@SR"H) (S\2$GZ@
M("'A(OY*(7TT\B(,80B80"(O@@ON2B%3018V<A$N8A%^ "8Q@@M^X H^4LBZ
MX =RLA1N 11^0 S"T <*X1:HX MN 2/+8 @DTA9LP0M^@ QNX11L(1:6H %I
M\2* *21BIP*0 A!R<19(8'0H8!,VH0(@H :Z!P6JA &PP@\@  Z*AY5(8RU;
MX 8HX#78@ 3DX'8,9188@$ZXZ#9$  _2\B((D]WXQP$&" *(HRLB!(C^0%M4
M00'TI03LP 7VHR!881-$8!7^Q2,LH"J@;A]?$S:##JN:D!$( 12DT@EN01&
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M%(]"#?(J':$)EK(4/&$4;J$1<O[3$8" "'Z@.*T@"&1A"G^ .[W "R@2"'X
M(].S%DH!"-S3$"*5$"#A)J\@*L>@!\;@%K0@.Z%@"(+ 3[O2$T!!(+%@JJA
M*C?5"7L )9W@*$'!5&_A$P/O*#TA"%#R%D@A01%409\R40_!!XB@*V55(+-
M_+@R#:"IZ:H-(_1@  2@^3""-T0G!7S#7V( !E2 -.I 9##"#1Y !'8E*>C
M!5K  52A56ZA!$A 6[FU5RP@!BXH1KE1-3SD#12 #3S%0K;U(B;A#:; 1.'&
M!N: #DJ 6O[5 50$9!Z #;A(;RAA82WG^%P@$$* $BA 6$Z@(=S48S_6YURB
M"5$U??Z4LB.[ %&O0%458?N(DU:#X!5DX0B 8"NY("K78 B. ".I@ ABH10>
M\18&X0DV\@H6U JBD@R H""Q@!#"TP=>D0E* 2N_(!.9@ B"( ND$@@<T@N
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MM%*:59E8P?=P@4 *A)CB!W["VC3A2!/@+HR6J*"BAA, KIOXIP)\Z=YNH16
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M#=C (#CH!BS@!>*@R)/B!D2=#2Q@!?3F#41 !)A7/1Y"!80ET.F@ FH@$U3
M K0E$U* +=L(=3Q"#[1E!FI@#M)C#Q[ P?F[,@U%!,[I(C;]/*21%:YD1\(B
M;$* ?D+'!434C)L\SL]=SNE<W<M'N>V\0$[@!.".2$&"%;)F%MX@%RV! %Z
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MXP4:8A8VPPXJ@!,JP1(0@"^Z@@(*UR, (6\*@GE?@%K04?X"Q ,6'( "EMP
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MP3TH\(,<_!03/D23D^ ,ISCA]\ERTL]Z8#0,( Q@@(89QI2W8,!^6,6*3"C
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M@T#V8*,+<,<%1IT*-^7-\I;[J-[UQK5?!<*3&32*%3&(94LHT4P<ED D>X!
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M@3!  WW5=(GE!U!V B<1 ]Z&"R(@12B1=FC"=#$1 _'!$[-P KZD"H*P&Y2
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M"?;R"8, !%=P"XS0L];#JH,82CR!" )@  $0  "0 )4  .V7&3S!";J[0*Q
M /'5=1V+;)$Q RG0D.\H B1P ,SK EX;$ZKP>(VQ A2 (M%[&&S@)YBD7N51
M<*P0 KYR J#230"0%7<! PX  R_  (1Q(P>  B5  @IP@I1A1&J6O?@":)/@
MAA]808KQOP#<7QZY&'G  "D05B=P.,VK0;-  A(P RJ A@JQ:R=@ A)@ 78K
M.3(T!^^+$:IP2)S!$S"0@S+$&+.  CJ!@Q6DOUL4&DL@!F#P";=P"%_ !2?+
M!$K NB=K/4>@!$<PE#G,LT/@!/ZJB[FAJ@0[_*E#\,-%<+)#< JR8#U&S @_
M4 1H@ 5#("5!H 2MV\1,\*D$R%^44  EX =[H <J2 >(\!9^Y&2L@)&NH&9*
MB!%TX#08,<<\H0H)H!*3IP!0-@N;5EJV-#IO3%2 7"*'G!AYX68E$U>X  O]
M0D;AEPFX 5X1A N:L&D4T(YQ6\>OHR%7MAS-@1A8YC698#0K0!$#L<FCC!C1
M%1.?<A<I$ .LAQ*T=PN:0  O<@.KN#BELPEQRPEQA6G,UVF+%7Z:T&EQ/!";
M8+=QQ#JBC!=R)!6T8#2J4,VJU2]7%E?$C!AJU@G%'+:<P(^\T@D[DV6SL,R'
MD0D/!_X@,E8)HO*]XT%EM^ '!. 6$$!*QE08KI#*AG'-_0+0A_%DAJ$*HA 3
M->"&(!QXEG;0FG XL_#,!QTAKZ,3-  >RHS,F884+0&/4E-DWXPNH_$#/L (
MMV %0/ #7Q +MF +:@ $8B +9Q +8C $D' +I\ (IU %/R &M' +KX %17 *
M&!$)^C4$3  )M?$)3A $6&#4ME &/[ (MV +I^ $I8 1C. $IS (0? )D6#5
MIX %/V %6PT*:OVPML9?DS  UB(53"02T14#!S !*#(++Z  "A ")'("M7P
MUPM'+L#7+4 +JW !A+$)(\#7O\8*"7 2-9< #A !BR4""?ZP .@V%2IP Q&
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M%1( %.H+93- AR7P,0S0-9;  *+0"@5@ W'\3PJQ5-T$ 0A3!]&T!P2 (GK
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M[6ZA@%#*CZ.#N3<<<+4"RRD(@9,#7+K%%5LD=\F%!&HD(+S1KYJ3)-57<(,
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MS,"+SDGA);TH F[=(%&,4E0C83B'ZHB@A[?XP[]<$$!2<HL&+] #A6[!ANI
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M+%E%X<,#:( ""U!Y>B6P@;YND0<'!%@"#)G%"4B0=ZFL0,!^>  ;YDX!9"V
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M)JV$2C5,5L!)$3?%5%0%$R>(+:D$RP-4%E_MJQR1PJSQ#Y7O'"\<LDGM20"
M@L32PF2%Y^($ ' ZPI0#!E@!(C9LJ&#:_^R)("=JAPD!"! \!W"!]K:! Q \
M"0@=R;X$KLMN<OK3%BC>;+6I95$ %8 !*T^(0#  $BB!Y\"5XQ&\GB.)&V P
MJP@$R+E,;AUSPS2YZ9;L.O#,JWP!X[-M1:$$C!":@G:8L%8%/> 4%["98@%-
MWJ;N7 GM1;4$V2-TF<W39TH^J[ # :L -U50T-3Q5I^-U'8<1X]&K)AUEI)=
M\IP%5_X(DU8@@%UYR9AYXEK/BK[Z1@4(E$%&""WFDIF9Y)C1A)&!@]K*"*-6
M$@@ )H0(<(_XTJNH@:=R@>!%%J9<34XHBH(0QBQ$B$YX1&E4/E.42@:Y)@K@
M ZPX@4"AA /0+EQP@), A @(DVO9$A&0"O2@@&A!.57BH^ -EE9LX)RZ3F67
M(X9]=ZPX23!!172?+[1B0%K029:"^)M ]RW!@TZ/G/YL2:RX !/3"'3'!51L
M1590G[&-&7+OEBUIY(18!0A(DI:?B)-HX&1_Q!6O^2?.*5/T9AM5I38&DUW6
M"!(G$CPV209$EJ+(7G4T^BT)@7B]B?=)B"F0]MS%X:SW"/X&P7C,=/6S=XW'
M9LZ6&H"':"4V8( '" HVD D&B!05<P %N !+L(7]P@42R)\Y<( $R+E#5@ &
M2(&W8@A6B $&6'.7H?LW<8 >X@2(O(T3&!=A=!DIR@0YMP"IF(4E.X&VR];"
M1>1.+<@+L.D_""\\:%[*-($M8842. @:J( 3@ &)2 @:D';[P".?.0$1X"X2
MP$D4F*H1D+F@T#@C"H$2(('WP0-+[PT7T8/,@P :J ,1*/Q9: $2$ &3H9$6
MLG:EN+5$]D,,\V*@N8DD.;_G$0&&B,PI&HJ"4?E,& X5F 560($4& &3V005
M (@W$%1Q"A'"10H]MS:5.!&"SOXM-@PHX+D5@P0)%;-N<;Q%HP2*$ZQNW;A!
M8L:M-R%,G%#5\98(&B<HO,!UJY*(%1;LW%)U D4(&QSA7#C1\A8K%194L$#Q
MDM,)$A;8<&Q!(P4$E!W=3*Q(@T1(EVQNG( 1D4*)&!IOR0EQP@0K518<H)@U
MR0+00!SW4! Q@X+>6[1:,+"0:5*+6S"$HLA$"06-$!(JW9K5HD(*%R@IB5!1
MH:+-GE$KW.!(QT()$99N 4I!0\(+/"(>\&Q-(X(+/"0>U+EE8P['&'EHG;"Q
M&SB@Q+=FA.@\<D^(%1<HL0KQ0"2K$R5"P.'HI^]?/R_9C$A!PBZ$K!T#I8]Q
MJP0,%?X27'"LXY8$IY?Z]_/O3^0_@ $*.""!!1IX((()*K@@@PTZ^.!_2]BR
MGTV4#) 8# "(\,8""> R@X9O,)# +'@ $,,D$9#H0@"J9 + &ZH88 ,K%#"
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M5L"M6V1"41VI09HZ H$_X$$">Z #'@[@F/W9P :<8  >Z+"'!\A!%7XZ@>'
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MV9M>:>A@*9.^:9P*2D>P0E!R%87P1YSB IMVA(O@Z47=J475Z9R2Z#-!J25
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MMGXL'/ $JV9L(/C-TW;LZ'2"9^C+>+KIIPXLQ[+,EZA"8,P":IILW#(L*[0
M^6"L-#DMW)XMQZH""M@GU1ZL:V[,##1)M<KIQC[NCV:"EW+$OE:NF?;KJKH+
M56"J'$A-HK; ET@K"1B.O58J'MQ,Z1*KO=Q7O-;!*O#''%R1FK261>6@3<!!
M"RQ&!>S/'C# '$A$D\R!(KE8"QS3?N#B'B1 ' 2"ND3 W(T.'%" 3F:0C[91
M':1NZ/B!F:@ W/P)( 3"&R# 'O[\@<%FKE6$:= 4"?9FC QLPB:X )XX:294
M!""8"5(X0'[8:\8,*6W9KXNZ ATH:>N17N50 (K9*NF=W$M8+@,K).9V!"70
MJ+)80@BD0).PPAO( (H-UB30P=Y:0&V^A!_$P!N,Q"5<K9?.PAS @(T& HU6
ME  9DDV@  ;!P%>R0B!DP@R4\%JM\ 97PB3,P0<[$\N0\%^"YAM(;B;,P?A8
M@B%UQ"30J)VP B!8P@RXP1>M AO(0+WA30S(P7NRPA:KBR4X$B[TP2S@0AW
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M"?R('/S('TA 'LQ!(+:17<?-_FR.*F16"/6VQFB)#=C!; 3- N"0[\Y""DA
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M_8K Q&!"CU$>P[/"!-@)"71'2F18#4+-;-W"%)Q<(*S,V(/EW5A998 R1YC
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M2D*F6Q5"8\$$&#)Q@(446A!!IX)4Z&T5"6B)H0(75%!AA%DF.:K %20*@8Y
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MHRU4,XE9T  E$*!.MU(R-SHP@&248@4)%L4)!M@A6@>8F%PFD0"#2606F9
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M-QRKGTAW.&WB^8'XPUE8D0<BX<(/@FS[^.M=B;SC(OUR4<7N>XW> O#4)J\
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M2,R4(W2F#O#  #+!G]I8+N0X)6Z$$B##HEP#?>X #_3@!9IB6Q3C1F;-!FP
M!5] #O9@:7BB#_# #7!,5F)"#LAC4]IGJ=21%?R@GFKEEOI) 7*N!!) <^9
M OB@#O+@ "JA$AP@!E964U+ #R)+EIY##^#  2ZA?=0C60Q&B4I1-AYCD<#R
M*]?P%DH@!CI!66:! 0;#!%2 5.J@=, 2 E( !2#@8F.B%^7"AO<S)E9 #NXG
M*"?@!O)@#UP@2E0@/6_D#Y:F#IB#008( M0#.L3V!/B@R/X.8!;FX %L !!B
MC81#P@80A0*VY@'ZH [V  $FX0]( #W"90:D9I@L0&3FT@5,0)/E  %R9IC@
M"TX 0:^LZ0$"+8 S 0;FH#@,M5-=;C3VP [LX$A<H6ACH@0J @8Z%P_FX !8
MP0*^9A9$@8AZ-H\>XW=8X)KIP X2%U$VX@0JHF7@SY]%@#XG%$+E8H<J(H.6
M$@*<([E4>2Y<0)7QH 8<[=-:.*Z1#E\-CAL75R]N-$KV!E0H0*M5!B&P.HCA
M A=2H 3H( ],!@YF:'''X]5XI$ 4:#T0Q0,Y10(T@03L(@5(H [T($KB@(K!
M>& Y91;NH%<%*SS/&!+1N"@LS?X4*V!X$2*0@1IV[-A.?L@.WF .^N L,N$&
M1" "P%..T2,NDT53_@<F %(N%("(E>)N73)L;. E;BD$[!<J3H %ZH!^ P&'
M$J9>4H .Z@/5!$$"8@ 0A%B59S0@P8EQ*R"RY, />/N@TH-#LIL.1$8.*( -
M0(02\$@]* %8A.97)%(3\J@K6H .2\"##D>!&B(FFU<VZ&!_@D8"_D>8&L.&
M6T13YJ"=\P4H;( .W@ /,D8/8, !7B)Q229\>(.AGP,R]K>^_T V)H$&*D $
M%E %ZH! 6B /F(,.*. .<EL/9H&S-+H/X8("_O"CY6,A6N $<)L. ($5)L Y
MN(8P<O[Q%@ A;!*U(()6;2HA!FK%4>%$5U]M%GQ:FBNBR7%[#OX@%X0C*PK"
M#7H6 LYB*UI@#^@"#N0 #O)@_')X%>C<6.@\!&8 Q.U@.%[/ @CU]7J'T8E$
M7VV A ;& <XC)O) D@5)KC5]W^@ZAH_8G&8&RW&XJ_3J/^C8!IK"!$!0!22%
M$H#Y#Q!")#@B+;]X1_Y0#A@ *F!]/PI)!B(BJEX=(5)%"L/8R3EAW"A3<U$;
M* Y,+S9!OR>E(B@ + ZBQ=4C@)OD.UK 3C1J*>?&!JC# D PD$4 B&_!#9A#
M@E\-$ K%)0V $_"@*:0K)M"=AA*##4( 44IS/69H$S+%0_Y^J2E4 (@= ( K
MH07NI@2 6$8S$ ,+A!8HH=UG86[8X ]M(RD$+5,<0'-(^/-<!3TRQ@2BW%5^
MQ9FO49IUZX0M8!9LP:7E8U$.2S[@0C9<8-PX 7&Z8BK]YH@L*6QN5YJ)POV$
MHB J00$4)DHJ81QQ(0*VVY];/,5?[Y!@0'5PH>#10F@X!E'<( 3@HE46:6ZX
M\A8&I"@8 (A?VP)%QC8XXE)4H59*H%C4#"8XX0 2)G-OX0:PQ9] S@\ 107^
MG2MRK"TO[LQ-8"'"UEAJ16D13$=LH&=-40=10#U.$U_RXJ>SVA1;AKQ<C(CE
MHMQ<XV!O(0[$U %^,#R'B0 W/?[U0ZW3NT)?B4@IEIY2$4(%*& &9L#!_WL&
MC%AU_!(FJ.D.:AA%2AP0Y$!0& C+$Z "][!+-1<&*+<"7(P2 B!39N$"A-\!
M_L!2TI%*PJM6 "1,!QLM1O"1+<(!-B$/&( -8* "B"0%%D.$S-+&]X !=%\!
MCH2:.&7]W6!"?H?2)<2/ (*3 U:W,DF($4-"IELGWMQZB.M6( (A0EQP8..6
M'!*W+DF0D7#A#!<% ^BY-:?"K5DB3K!Y,$>B@QH)43!D<PL/!#8G1-S*$^%-
M#1,A6$F@="LB( :S'JHZ8.G6# IN++3(R<!&# J;;HTHP08"'*D7WLRH$$-@
MTUM[(/[<0.%SDX.F<M?>XO1@U:T0=9(R5("+5H))MTPH$!&"@L*]."/.\%G'
MY\.'$@"QI?#PA)Q9"W*&*"C!Q0P'A$60>!-B1D$%5]E0#?'B[D#9!$N0".N0
M!@0W*GS2X3AY5@*<?P9<>FB# IN6M_2HG+4";<-;$OX\I.#G%@P&V6VSB8"S
MTH,94X$_I#,^AH.3+$G,>(#'+\.%?T2PX4CGL]\5"2Y4L.! ? YT=8L(?>&"
MP@AL2(!3)Q6X0,,#2.F1P!NL,*#*+9T00,-#@(S7@@093C;# G[,@N$M%[+"
M"@4LU/! =A%1(L (%EQ074$1J.#" Y7<\H8 )OQGP2QR"/YPPG\A<))41),1
M 6644DY)99567HEEEEINR6677GX)9A%#+&'+9&:N%)4J!%K2%"O'G8#')'(P
MZ50=>!!4T(A)!;(0*WCLT5$FK"QTBYH/62*(F8).IDI4#PD"!U(050++0W[V
M@4LF@A+Z$"=_X+))AK/P 4>BD^'"YBVIJMI4)G+4,:(K?JA"BZ.=_-%4)72H
M21 N@C@**6$/93('K&;.DHF3K-1A!YZAGCD+)8$@$LB(JA"Z;!UX=D)G)DVU
M0B@N>\C!Z29Q '+M+<^J*\<>M!Q:1[* (&L7*XX^5 F>D\01R&2;%#NBN'%P
M"H@=JK 2R"SWLKM'4[-@\I#"9_ZVX$9!>*KXXRV5-*6)(($(0LE:F>C)RH\B
M9*<H08,^M$DKJ*J([1V[0N3'&Y8-&\B,<O2;E"41O9R4'W$<]Q E<>#A2D$G
MG)E)*VB:20D<-Z\,")XGC)7OL 3-\@>3N A]KRIR^+&RF9O0,0>=*XW+Z4J<
M4C('0>E.QLDD@DPR";JL:CT9V,'A,8>>DR#E\Z%Z<C(''G9%_$=7A:,:T2R
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MP0ILD@D*N""MG)" "EY0@=3Z@0(S&(%JV," "^!*!#%H 05(-@(8&#U#;+"
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M 5^WH''PEF@DTE@*8!T/H DHLA DX  7$ ()D%JW8 ,2($DS8 &F$A&YYX>
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M!1\Q^2)K\AOF%]]"8XY'!24(#R#2O\,)1(-#[^.JDEVN400\K$ "$N"8UR-
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MK,%ODA8\%T1Q!@H Q"4<8* XC8MGF^2D=X;V25"&4I17B8]+.A%"2R1@%FR
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M84X/3MJ#=6YC/X&<@ VX8  E4L@I2_RFJ=$2'1LT2DQ!_(8@<IK$;_YY"4!
M= 0+T823;) "908" >")XBUB$,4;Y+63PR6N4T9Y7.0FESVE!$G25F$U%;Q!
M/",H0?X,7/ "DPBU(5N[S4'>D)];X' &+8#!#(PU%P<TJ 35)6_"4%"U&B[$
MIAAQC UZ*X=;U<!Z<.CF'002@DG(00+C+6]N"/*&P@'" 3-PP74%P0H)1,=%
M<KA,Z$3'D/). J*@>4!"FY:?V417I(\IB!S$,QL*9 (/20KOB5-7!STDJZ?+
M3!+N;F4#C=)A) =-34E!0X,0., F!3FEL41\FQ28@ TCN-2111R($TC  KF9
MVT%MH^-;/( O723)D%6@5*823+L2&(VG+B@0/E@/2:"YQ6%;\E1*<,9X/9D!
MBU(@ C;"H :X<,X(0L0)%U3@ 4?I T3Q$((7X-!JJU/%;_[JE6<;&*82$1 A
M0?) %Q<DK (]$6DQ([ T#%WDT B;W1X(VC$(S((@,B > V#08!CP08JJ<$&H
M**""5\.@@!50T'!F P,W!,)TLPG!'P)A'6]."9 ON$">:3#69_LVBC9HD':*
M>^WB*E?;V^:V59B+$55,@"7LLX"=;SJ+@&D7(19(44O>P *!++0@E<"%'M[T
M $#$8'6SP-![!8*"A;#@4AVYP0I.,!IR1L<2&I4#1$30JPE48@^%8]F 1 3(
M^ADF$Z*+\"UL(0(+'&=$(#FV"P9^F\RTY*$'DC5"&4(X@;#B-79@<1XV[!A5
M+" ZE3B \UB\B00H2B4<8G&QV?YVN3S,1H$<(\@I6=*"3JF@06UN<J=:,(=,
M<#H&,O%I'@<WD@)1U=%6!_.JG.HW7 M$!7 12&5OP0?7_K17GO(;!%1U@=&0
MU;<L DW 5AK5/RQ 1(538%LX(5K7UF&6>/67W^7X (BQ@1)_P#1B.5V!NT$
M%R)(W![RM9=;'#Y*PR'(4A550YLXP%A3,A8,*A0=@]ZF+1:@1"76]E\]".+V
MLWB )@!11A,8:!-+PH^_,#2#P(PUCC:( ;:=_WR!=%OZTS_NMQO"B=<(A!(
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M5C$]5Y\85W8-5W5U5Q2%5W6E5GE%5WFE5VQ%5V5U5G4U G_]5X U B+P5R)
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MEA!0M=##2G\9'8,T]DM9,8\?^/Y,B Y6P'A_T?C9R(,3H(6)CSFR%(BD,8Q
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MXL>#S.EQRR04N%""7JI X!L*NJ$ TV^SS:>'*A3(L!AN%53("24/K.""!'
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MA0YILKSC4< \;9E%'6J0 CBV@'DJJ /I&#H+";R@!C<H ?L21!/"TN PK)#
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M"S@ (OXQ0*:9ET1P AL8  .P@ .<A0A,@.K, AW4 " PP%P( @04@ &(0$7
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M[3&%.._P) "1'"L$'3P1'H3I#:OV;\# ]KDQ!(Q=&O.!(^WPD>6!47AR.*K
M1)'V,_[?WEG(@4<[<R# D6#LP915\@T %"E3@@-T* ,X&*RP003400O !W,]
MP!Q4R*NP\1V,P(K0!P>I#W/&2F&K]WH7S#LG-ARPP<G-A%'%M4:Y )BRPF-0
M@B/. .+,@AWXM:;9@. Z4B8<ZMLDF VT=N?NP4E2[PV\0>[. 0U\WF#< !L,
MSANX@"7$0(5KE+Z-&E"PP:MDP@W4]6"PQ25P B98@AV\+?5. 1N<]&7M*'FY
MQ284XL[-PAS$=7?\1B78P(E3!>+NP0RT]BWT 0W,P?GN'"X 0I[HP0SD =IM
MPLY]K2J,  IL,2O  0V$J9-3+NA4@BKX@1^<<B9$A^*,N/[US42">X7UO8$-
MG!7NRL$-*.TD<,(-T&)/0&JHY $-2$C>S8 ?2(Y@<(**A"DK3/A4Y*UV9H(%
M)'J21<<2T8=O_'F@N]K?L$(EW#78N@$;[84J /9;YY[B=B@L.R@,M (,N $S
MOGD$S0 *F74-O('3ND%]ZPDG ,*%;$(@E(BBU\!9L8(<V("#X2X=X/HM\,$,
MX$$!5T(E,+NVS@"TMT8ES((J/'NT)P0>3#LEO"3D;F)U X(-Y)Z;) C.'04-
M9.'QG-4F@*X-P)SJ\ %ZT0!?'T^'#HXJI, (3 *ZTU,1@<Z.>[FFX?N&3,(F
ML$&MOR- V@%SXPP"O,V$"(T"(/[.'!Z%>JGA'\P%&TP4"<C&D;%WR(M\E2'V
M(X7 "ES;Y;P84TL [I* !-!!(+30"4@ L2_ X&1J.W[- 9/[120(<H? 'KR8
MNE. #XEH2@D&6=3!\76&@ 2"CA(.!, W W "+$Z!'#  #BF$)1S FDK "2S.
MFB#WTE/ %%+ !00"'3# ";R!)= 5J;W!@APU50!&((B #QT6'!#83,B%N3'
M3"B$!.T!'-BA8*R !) [ T#0NPI"Q 7" Y@3X:W "9P70K !49%E5X7 :;."
M@-3!5=W"W^/&"%4("?C!#&@2"=3!(-$!X7\\4#P1"=A 'SC >B@$X&E,R[=/
MD]*  _YT@BH<Q%"MB1V<S@D01XCZ00F<!?:\P0U P*TUT@7H0<[  !5A[PF\
ME I0/"Y<0 W8Z1[, @I  !O,P@N@0/)+8X68SQX< %Q'P K 06;<%OD?0 O4
M0;JZ1='+ 8S11!X\@ D A"4;$-ZX23#IE@L4?D[,N'4+URTZ$NK,># KTP,W
M<A[XN04C @D\-""8F(-+Q P]%?#<:OB'X"T*%MC<8&#IH\@4)6[Y.4"#S@,V
MM]Y(F#-CP= 'DP09L!%TJ(H1=5X4H 3QU@P'->0XD'.+#85 -$[@<A#H881
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MTP.D5R96,( 5-R !ETF@F1:<\ T+(Y"!V.+@!]1A%9.+2YA)T)@3P"N$L%!
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M)T (6T(0(#VT5@_'&=+&B9*G6;0 -7%E?D8K4(<_M'83:9J"",8O-**I^_F
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M+]'&1,4# $L 8BRA$&.@!0ZE#@#P!(1E!@*!$P@N!"C@4.SH!$+@$@8# EZ
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M:P-@1%I  "K   + +HC<R)'<,2C  "1  *X) A@@1PN@!#Z' $2  %CD A1
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MR-@4P/XW2N %]" SUN;'*7A)G74 1F0&!N!71L  6,$& F#S.W\& @ A9@
M-NKT P$ 7'4&"*4$#H#+8#EB#F!$)$ LU1P7;B  W& 62(  6*$& ,"852!
MY.!3\$#/D ,/..@!/-I$+JXT3"6H["\&6/$!LM)$9F! Z@#*@JI&YF N<FB8
MRRWJLX43 N$^6D'Z-:9&Q*=$]"*^*<;DKBD%OF(U<%<%O^565D ]^*82_ ,@
M6#G@=*M@!3H%$Q8,4:=@G1"W).RYM><!KELDYMR"@/#6BQ>W'&1:J(<5 U&W
M,CVX-8+-+5:3;FWZ4U"%RQDS;FF*<(L-BH*;&.#24Z$@'?X2MRZR6F!)X<5
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M$4R,9V!H8=5:6$&?MLRB%8="#_[[%'B+%9PE)<&J0'58B)<8',I@A"1A02Q
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M"SI@;!8G$-H+"J.0/?36N*3D\46:B.#>F$1A#JC5' "XT@P^#5>3.  >:,$
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M$90R;T ^&($'K3 9)80;G)"P;Z 7K.4'-3 >X%,0D;P1#=06=4 !@J '?G
MVW$P@# '#D E96@'IT$"WG$:W?('@2"R=/(")1%W)5 'H'-#%*$6HK(*#, '
M>Z _#G<O,@$!MG"W67(1+> 2T4(0%QUC?Z"% 5T0F+ 2;]+/<W"@";$R%FTF
M-RD!I_YQ$33PN9L02KZQ$B^  H+@!W2  +=)"9"VH^B4$K5J$GKPTQ1@ URA
M8(;B E:T%:H0%'4]"16 -Z^4M7A0"3RF$' @1R]P FE=!VQ= 7Y'C(QD$)0
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M"A"@D/"&*X)#<M)VW(6"%^L17#VQ'M:H$!1 >3 @-)M  BB003"*$TI/&9S
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M#ABY'7(/ X3LZ 0H&+<#6,")34A@"F\8R2U@(($1X.$/"*B! EF!RX.30'
M.Y"#"@"Q"@@!.'"!!^")& B!.BB!F,@$"GB#-R"(>.- +:JW#QRP>Q.+2E"
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MGV$;!5 =W%"!_B4--R 3.H"0O/X2@100BE58 1%8NO*H@!L@@:%3E0@ !$K
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MBA*!!UAB!R >LIH8.UB WYPEJY:G4HJ!"K@ !:@ "X@):-M0!VCC$G" O9"
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MN7P/1H'GBY.O"X$'F"W'4X&8_^71\WS(]Q8G4048T+J"L/Z!O2#<0UD.$:"
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M"1@0 &V !/""('*UL-:*K51B"0T"5!3" ZL)P$D@ /A!!_X JKP1P!N3S #
MC..1!P!NX_FQ @0"!-#B PFH'$ (B;U1T4@D0%!"1KB=\,(D@+RA *H7JN2"
M>FX$JI((?N ATD 4K'MWH3#-8LD?)[0%ID4HU"'* ^-M@HL*E?TA!P/CX0+!
MNFI.8(O> TU0^4CS82+4+).X00$$')4  0DE,!"H4!1DHB4;@CAM4>A[4("B
M""?@L1-Y%,PAT"T2O '()"TX.X+NO-=P._#"_S%)2[;QAP)>*FT"06(/]]''
M)!*PP0H$B[%"R1X5X+6'"$TF^L JUY(UO" O!*P2#3+<0L<(CU$/.OGF/Z9'
MP*Z3B?G<HE$6F=PF_!! "8Q%%?Z"L,,#!$&6/:D$#^GC2?XHP ;BP8 "*WG=
M"J+U@HKX@4DN0I>+*N&'"XPD$^(+A!T<,(E9;,DB+P)$(&8P,8NHX@&@:8$;
M @$!02@$ 92PP0DFX8<[&, 6-6B/TV;0GEOLZ!;OLH@>6*@2%<#A#WB3 Z%8
M8Y%.^+!:LZ@$'T3CFA'806,CZ6%\+.BB/<V" CB"R1Z8)$8+$,@"DV #"92(
MAP.P(@1D*E, ,10BGHA@%@S @Q\F(0)Q.0 7-1!7DRJ!!Q7@P@4O^$,@+C@2
MD9&RE*8\)2J30K)JJ802 EC!+%2! @!0P@\"$$$)4. ".;#B "P@$0-$$ ,"
M?"L$X?Z#B  NE8 7G.!',S" "4BP A<<\C$T$)I%-C&'SY6)  EZ0.EFX08
M?&MVUYG22$J@@C>PX0W60<%#WE:1&OAD2'C PZF"MZX[X(T$+4)>'6S0EA.@
M"#IXL(0$#EBH==K G?S)F$4P(8$Z"@07H-+*<8#'B1F-A )X.=$!,R44"23J
M+!6 U$@J48$6Z&&=MW"%'%#  +R4J04/@*4$(G(#.>!F%F"<J47V8%.<SL -
M#:7$)"[W-K<I:*+N>0 [V3"'3'#B1]=J01Y6D)T]!(P"$M3=&VA@KJ+>H(L*
MI4%[3+62 E:D2Q5@01ZT]9@\B-("QGD JO"R&#OR(5![5?YB3KF*KEFI) ]X
MX]L$(F(#.0!B%B?(D1M$6)'4V!"%=L1#M' Q'CV@!'V! %^#*" #-^PT*#R<
MJ$IF8 ,_0" .-W##'%CQ A)\[0TM4NUC4DL;*B:T)A:9@T@6$P,V_.&",<V+
M>JX$@9TX+1,66 $>7O"M6=2) 6VU5L]44L+KT#%S)9C1%?=(H I,H@8C@$-#
M\< *"J 0$(D, 6ZL2# 'L*&^<J"$*Q(WPK6&H ^J"($?5GN#AFHEE08^,((3
MK!2LF,P] L D'IC&B@"TAA5U&" "7L * 1!*$ %0CP4,!!$"",2F#,B.'0!@
M'4W0P5<6J4$ 3#L) $ @5'4  /YM\+.831P@4'+(SD@L !/-J@0&N^7$.^-Y
MBQ=LU8/IRH0=")4W@>#!!!8A@=V<S(;!%30%=+#%B%QC"3;XA(K5O,4%IA0'
MD>!IRAAU '-J0X!$J:0"<,!0F&Z1,'"Y[KZAR?,)6B,E58#M/K.P06)FH0!.
MF*!<[J$$)]1S"T,C>B4*V,0)ID0)1-!0$S;,\R:<"KXX^X$3/M(S)O>GAPN2
M]Q9Y4$$*$B4"CE8"A3]IC1#Y(X&@+$8%F%0!4X^#&S\8P%AX?0/K-,& 6?RA
M9U3<D@1")*NQ5$""A<6;'D1"@H)6HA)[P"MO1+)?!5K$ GMR$24RX8#%H$<5
MR%(?:/Y)4E# O1%6Y<;#]?C3HCBPCEFWB,%U+:*LG;AA 5:\H"6<398_;/<6
M,FC+#*(U:;S.#@91<@$;#JV23"B /^8Z-PQ\LNMG"X0$,$DC1%IS =.&8!)\
M&U>+3@!D-LR/73,/% ,M @@7AJ]9/(0S9$JP!U:@@ 3,\;B"DZ[TI7O,*@S6
M2BL!$"5  * ];)B,RHP3@ 2%P  #"T![EO:9I27*#P$H ',8-X )$" "H'F,
M7H*B$C840  '"( $@), Q(SK #]R  '>+H&"=HX"+9 #!/!RWK6JX%MN(0$=
M0B"N-UAY( Y(5!T"%H+=W<54/MS?+4J %SE(8 XK",&5#/XO!ZB"BQ(08(,-
M:KR>1-U"72,1TP'6I9*#P, -(NC:^Q[3@KE9!,YV8  <;B"!M-]/ G2X00A(
MH(J/U($$M%E!!>C@@O15P@$E0D[P5%#]ZV=??D!Z@ VF )OF#!X&":B>M=9M
M$3HD_@78XP2G\.!\-HB A99(0$I  !TY -XD' VPP?H]AAPDP$/ 0 C0 0G\
MTDC@0030 ?^IQDA,0@6$P RXCBHL&RV$P K,@?#P! *XP!Q40'O @ C800U(
M@+B<RV/@ 0OQ!$,8( (&0@^Y@40X ">\0&N\2GM(0'P1X;\)&0D0B@R(0!W0
MP 3 P >"1B9 0%$Y )FH1 ^=@/Y$8. ,5, <E$!PB0 \Y50!V8]6/ H)=&!N
M.!E$6  =Y!(5/0"310"'., ,Q($#P(0%H(M*?-L< !*DX%(=H,"*C,0>1, ;
MQ  %[,0-))X+)(! O  #4 (@_$B\W,($'%)"] >1B)9[T!<;2$ BB0 %W  ;
M3&*9/  ;S("!.)+IP%,%2)H<$ !'A$# 5, 5,ITN[B(O'D41$,'350LK^ 'P
MS (Q6H0EO$$=)!H@"(2%S8$J!() S (@[($M9((?N,)*$(_D ((;[(''M9 ?
MO)VUU,$;#-U !(+L6$0@[$DFT)Y%0)HP6F#E5 +O6$N<Y<8-Q!<G ,\M"$)B
MJ$(]<OY$)KR!'^!"J66"&UD"[U0"&]0!?[B"!<+C2'3"&[Q!?$P":&@DU 5"
M.&Z"'$R!'O"'/%H$)XQ%!B8&);23&XU$(+R!6N3!>034'DC-#<2625XD[\Q"
M'=R 'M@D3E*13HY$@$T"OBC&N5F$0])!HDV"2KRD6NA!8DR"=7"D>S"?T;Q!
M2QZ0'YS;'ZQ6M0A"TLR"5%H$+-#>Y#!'<JP$'MP [:E")ES"#1P2+NP!'&R"
M*I ));R=*KSE6\*!&[B1)IPC+OR!0L89)?SD7@H<:/R!2*I$76HE*X"C4[Z1
M'+A!/MY")RS'&P2EL-C 3](.'DS!N1VE4,"E14PA%5$D(/[,Y7APPAO\ 2>L
MRW!10@V@) P,63R^@>R@(Q[8 !Z$H[5(%6A$)B<LIBO@@0N-Q5%.0GQ0 D?,
M0ELFY2:PP1UT D56@BK@ 1NT9":P 2^MQ RM1!Y,@019!"N49ISIH$7THGN^
M9]*M4H/-IU"8$WW>)W[FIW[N)W_VIW_^)X &:'[:IX 6J('R)X&R4@BTP-U$
MR8$^*(329Q0>*"=$@ W4 05<"((N&12-Q#*:3()&J(A&*'R6J(F:DGR":'VN
MJ(I"78NRZ(O>'GV&Z'S2:'W:*(MJUGU"IHO&*'[:)X[6:(LZ#9#VJ(S*Z.SH
M*(SNZ)&"2Y J5(PF*('.0AZX ?X?%"F2)FF3_JB1LE*7@@N4AND!F1.S+0:6
MBFF#J0(=O$%2>FF. DE%"2G42:DYU>F&WFB#*>F8RNF65LN)_BF@<DR*CBBA
M%JJA'BJB)JJB+BJC-JJC/BJD1NJA!BJE5NI2_&(P\JFD;NI_/BFG@NFG'JBG
MANJ7DJJ;BFB0/BF/FJJ CBJC6BJLQBH1!$&FLJJMWBJNYJJN[BJO]JJO%JBL
M!BNEUFJUL,$4F(PF[,0F@(WDA.F9YBF: NEX_(U*L.E:G2JH]BF8VNECL('<
M92NX.FN77D)B<$*K@&J1JLWMP0#O>.JSZN@<F!8/K8#CK>J6CD:VSLX 45%*
M9*O#_/Z68]0I@3H-M2XIN.QKES;KBN)K"W&$Z("KE&+K8ZPDMK)""PB:26H,
M*\R F>(IM!KI[*016A+IJ7)KN.HIFM[>P#;IF*DL??Y!"82 ")S9R@Z$R?:I
MT] !1^7KQ@BKSY;HH%:+CSS 5EI$"F3').P&J4YA8M!6I,X!2HIJM5  ;EB"
M ]""IBI*_D F&[B8B,K<694 .=ZG6>#G)JJ;<*K$DA@MV/@G'.4G+@JH (++
MYO&&"45H!=VME](<.=* 3^#?V$+H983FKZZH[7#I'"1 '5@"'C!@N$*HVEXA
M?OXLY;IGT&K%&[S <('I)HP "V!G"%0G'J@$)VQ")K1(7?[>0-2RPA\6;3P:
MC74  AODXQ[LHY@P)!N,[OU$0(ND0!T$P@UD)EM. ;KT)>V,9^V>6^F>+EO>
M@*U]YQZ8;FU@#.[J[KATYFP*Q26H@AZ\0;T0UTBLI.YV#Z(Y%R>X07".T47Z
M2B;<0,P0BN+LV/H*!2?$F?3FAK>.!&S*@:\ @@UH0@O GRJ40 MX&D+> (&<
MD86]':+@@1OXRIA]J*W0@"IL@@5L@C)ZW"S40 4$A0LDC0WXHQ\X;[7P 1L<
M$AX\P(>R+AO4(ROH ;Y(  W<X[C\&/!H9QT\\ %Q9R>$P'G>0B6@!+.@P++*
MJ]' @==:T3[R$&D@\$AHP@:]7/X+L0%34M$)I$ ^JD(*E !5<28=/)0=L($_
M*N5V!N9(1#"[58*%J8(?9$KV$*=23J9Q-/&ER,%^9--0GI'1W#%;LD'4HK%6
M2"<;(()F<LYB?B=.DAL5R<$;=(+)J ("6-M%7! K7&:<497L3L<)D[$>=&?X
M4G%BL((E?*=U4%%\M&8UC5E05BXK[R*Q"D4'!P(;6L0?0( %^,'#P  <2$!:
MC<VWK( *T"!>J((%T  )1FU(:>&\L 8#<(0*9)H(M,?_P4 <D"$,.("&N<"+
MS  #>-I(A( +]($%2&4S3UI"M0 *6%!VK%Z@L4L+*!!,-!L;W( #^,0(0.,!
MO, ;4/Z N*C"$[Y!".S0%@G/"8#S*5J''%2 ';0 H<R! Y0 I#' "\"!X:E)
M!-07!)0=?=$ 90C% QB'[[C!B*@$@OR$3]3 ">213]@*.Z%4*,*!"S" DLFR
M&RZ9R9' <ZC;"9R KUP ";!!#!!M\\G!"WQ'#)6 <S* "\#!2CV&*C13173@
M%-" O<% "=R-I,U=":31<[!B"QA;[CH)69# "%#E0_/AN%RT_B4*!=#61/0:
M"4#) L!C"I, )?P! T0$ Z (0KF!FVQEQ-V-6.E! M# &SC G0F" PQ8?H"+
M_L5!#&"+)52 [Z342=5!#[4 '(1 @LP"">0F!2Q2:(@&*_Y2&074 0R(1!::
M0'4R@ IPPAY @!QT8"W^'B4$P@&$QP1H2PBT1=+2 5-/AP*LP&;[E3K-P46[
MVFG'  EH\'%'P%TR@#;BGS$B8E S&Y-L@@;M<V96D =)SHY1@&%+ )G4 'UA
M'Q"QWN_9 #<G"NEI1K0  @"^ ?KEA4_8@ C@P0FT1Q#C 0U<S%"TLH K&*V6
MC(LBE&:1E%8$\*\DAA IRC'E@0EQPF[,P&[E@;,0V4#<!F\DU'6 DH=?!E4Q
M *Y,PH]H=V*<@..1P$.@I^Z^ :&,0,7 P20XF2I4$@2)SXLGB)!91 P\1Z9]
M($?4!8E$R>&.!$C4AJ7< CVM!_[O6 "95 "Z/,R0X]5+_%;Z5$"+0(:4680$
M; (ER)\]CL0;%*(-M(?_I">&.-H,V \#: PN1$"8J(0,?,L?1,!X2,!G'0 R
MWT(%6H0+M$:8L8!8K9R",,!.9$+B/ 9&6$0+I-I4_<BX/ !SV=PMP *Z' M'
M: *!:%7P9 ?=?*N"'))<O9NY6$(E+#HG) "=6<3,\H2'TT'Z;)M%L,&*.(@$
MJ,1EH$:N\T;ZB$!!,;=B/ #M76(-T :/GCD5C<@F[ 8<L XE1  L:^@,K BQ
M7UD=X$("F):FUQY*QH!/5(!869$$9$4(J,<EX-5MVY!',D!]4'A#X$TFQ  M
M*#ATY/Z9'.2/M;3'", $&SP'MUB$#4Q"(# )"@#9LU?+&XB24*2 I+$6B70V
M ^!&YF$(V+!!M,!P'(:.LY4/>0A&&9D+)^"!DSEG@ \XY0Y!@F&J@5?+#2B
MA2O N#^&I]=X/";4&TA@*+Y XTB )J" "+@ "Z" L^SS!,!$!#!'';#."/S!
M&]23E' "!;120N5+BD\)D8!+(*P #%B 3QP7!1A-!%A<"T1 )]0!_$X:"[S
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M)_&?S"%K.+&)2BQ #Z*@7@A$*2>+B& &JLA$)B 03IY,8F6??("7/"(#^MB
M!+2PV0'L<@,+:&02$##ZW)&??(+?G?D)SSMK-J&8]^6J$E,@FRHT.Q$LQ^ !
M*%W!&]Q  @#-0FVM=X\=_%!#C=;!$BX@$2!:H *5X*(.@7#!"1+B'9<F!/LH
MT/[V4& &,L56\"!#ZB#]7&"7%$(%5 !7]( 2V$ R B$ \6 W#B1^ .0!([#?
MVB]V>&(&NH^W/&(%W. -2"!U6/XA7FPF*/R ;.1@!?2 !&Q *DPH!H:+#U:
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M1"$!"LMZ]N MBV*J-N)Q$%-2I&N'M&A<CD(A8@7SBF(/(D<%Q@4]5B"<,*1
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M01@TL50N$ZHD$SYG0"K(+*%'0FCAD;KCGG !3\J#N=1$4D94 CI!3 J#*>2
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M#RAAAG.L$C(!07)CH":!I-1F!=IJ#XA8^WQ1*>L#!JY/0 \8/2@AB_@ !5!
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M 2  #A3 8:[[%FH  %2!!.(2 GR#! Q@ 5S@#Q[  79"!!  %ZHKI*Z,! *
M!%0  -CB#=C\!0" #P(! .A;>B_AN"O! 1S #5C! $(N!0A Q@F $RP! !Q
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M'L^6^U-(Z2ILXQZ!W/+& 73]RO)MH[:,9K -!4(  S:T ( %MW 2  WLZ@'
M'PX![8=!G P@V+PA458> #;<0G2]4D^=*5\D&,KN) #@<8L@ - Q,-5NSJ(
M4P[<4(%@+SS=4$@N#%#'=PF<Q1$N"9Q@4@(UW )SWW['K*I"(QA@(!XPE%?
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M( %>W-D!(# #!@1@%7"X9@4R(0$'H%$"1P$ 8VB$"P480 4A  #OJG8+-P@
M1"\1@0U>@ =6A F6,(#!UB8! 0;$8#MSH"(>9L& W1F@!;?P$D<I 8 1P$ H
MAUQ@# A0B3LD@ (P8<-%WXC6M )'9@M110),<" &$"  ?&#% -Y@B:V=<&N!
ML.DA 5"225C"FG_H:]%V9H"VR"$ G'B# .I0B:=T9Q*50($!6H$45K"B /+;
MW!UN$4E<D  "?%&))2QAAP/(@!4(&,TM1.  0%Q)9P8) 05"(@$1V)(&EX@!
M "8124   DNL.."# A$ S0W $OYO"$# O.9,3 !@#G\ ["U4$('72D S%9A
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MN,",*S)TY)W9U@84&$V&#>)C(/-8 A)0]ALP_&W'5N+)'%=KE!4B!P"<H!*
MD,  _&!7-K B #29)\D!$,,6!" 3%&#IEP.1Y9TE&BB,W?Z<T/" !U4$@"DT
M(+<-R(WG%N"BU %3P0**+0!+M-H&-H@G*](\BYW? @9SP04<1'>+$!R $IDP
M0 I8(0"?38(-M@#Q==X0B*L+)D,02( ,*$" _@H@/:VFZAQ^6]TW3$(!%+C%
M" XPB4P<0,.X;KQ=0J+KO[OGO ?1V@WV"I,9&( 5\"F4&QXXF =P HA/FZI;
M5+YISX-+ 2E ""<^&H,''*#< 7B@UN0W@WB&' ^"3 $M'O" 30 B '/?5#B?
M=1\\C(8!>YC$OPT2&4ZHX@!X&[B4H!J"681;)0]P...K&P(?LQ0%"W#%+-R@
M$FRFYP4_[KC[VQA'#ROD!@<0P/X>'["'63YM#BTYP-/RL'CU)Q@I,P$G8 !Z
M8&;GL7/FMG4&(%<PH0('8 ';Q DW0  "\DO;LV?7Q0#D(0('@  2H J4H  9
MY@ Q9$D#\H$*H  4% +()A0/5 <((%=4Q0J'EQB5('<"HPHS\ (:AVK;@0<)
ML!:"P0H5$  2< $L%0(/@'<,0"V.)X4>T5R[-G.0=B(6\#69\#6W4 .S%U]5
M 0'YQ@H/4 $0(  4\")[H!8&@#>;X$V=X2 +@"$/D@DN0 ,U<('D92 LL196
ME D.$  6( $G@ M." $$( $OTBJMEDX&(0+/X@8/$ %/$Q*'D1@5P!A.ER<Q
M$  F(/X*#X!C*@9M<"5J*N &K!$B5-$9[D$9EO$7?/-^LP@S']=6D\ 8(M(B
M !(('H0@EG )/Y$)E= =K( +U&$C+=(=/[$)@F H-Y())%(HUW$@FV",G( Z
MVW$C$G(>DZ!9=+&+(V()W'@0%, M<0<MK2 ('B2.W!@B6&,2)? &K! #[48B
MY4(@^682E/"-Y50!\@&/4RB0&=$@!^(@M[ *"C(+&"6-ZG$@"?0@&>4"K" (
M4D*16@(>EH =\)@)(F 'K% "W]0@#R(*VG$0K2 AK< *9,,"% DHFL)^"7(0
M&Q(ME$ )/X$BA[()5#8)*OD?N\@'(]"+-&(C&U(=N)!'F_ZC$K3(E+]BBTR"
M/\Y1 I9Q,!0!!PZP  Y@!Q=A C4RD%^I)'LR"Q'0%O%2E0U! UX2 6!G)P="
M ?<4*ZPP V'B$?)W(N3W)72I$'3 ;$WIEZ;RE!@3EB#!+F%S+@F!)VVI)\;8
M-@Z1F& )F6ORF)2R*HQY$;-P'U%)*YKIF %IF&+REZ'9* (A1Y%IFJ>)FJE9
M%YQ9)#\AFJ\).':IFK-)F[5IFYH"F[E9)J5YF[WIF[\)G NBF\/Y(X%Y$ PC
M*06AG.J4G.K$G :QG-'IG+;0G,YIG=6)G="IG=>YG=G)G=UYG-,IGM*IG,G9
MG,OYG=ZIGMJYGND)GM8IGNXIG_[M29_OF9WH69_S:9_[J9_PN1SY69WQ*9W]
MV9[/R9\"&IX(BIS\": $RJ#;R9W1>9[C2:$2^IX1^J %09P;NB/&&9P?"J(A
M*J(1P:$E.AR\>0N0H 5=P 5<P*(LVJ)= *,PZJ(SVJ(U&J,W*J,Y^J(N&J,T
MVJ,_"J0^*J0Z2J0U.J1 NJ,\JJ,V^J,Y^J1'NJ0SJJ1)VJ166J1,FJ4^6J5&
MNJ,OBJ5(ZJ57:J0XJJ5B>J8R:J-@.J9;&J1H2J1+RJ5DFJ9:< C,\0IN*J5R
M^J9JRJ1\NJ=AZJ=0"JA=FJ9R:J9PVJ>%2J=SJJ>&ZJAFJJ10*JE-^J=Q*JB,
MR@5>8/ZBG>H;0V*7!;$(09 $16"JIXJJJ:JJJ\JJK>JJKPJKL2JKLTJKM6JK
MMXJKN:JKN\JKN)H$0] %S'$*O4JLQ6JLQXJLR=JK3."I'?<R01)_#4&=TTJM
MU6JMUXJMV:JMV\JMW>JMWPJNX2JNXTJNY6JNYXJNZ4J=S:&N[>JN[PJO\2JO
MX]JL]5H;I"F;(ZJO^\JOOVFO_TH$'MJO TNP!2N0 &NO FNP"\NP#5LO"%NO
M"NNP$TNQ%>LG$.NI^&JQ&\NQ'>LF&.NI$NNQ(TNR)=L1(-NI(FNR*\NR+<L0
M*-NI*.JRL\F:A7EK(K,F->MXV6*SGG*6GPF:,+NA*CNS1?YKM!TKM"4JL\\Q
M"S?@0980,#]A":>Q)V^@C=]51/KXF2/3LYI21&'R(-AXF#82$H#@ C,P S1P
M4^C"M>;BMG&2"6@+ S[4,'Q1$GET"W*0;SP[1WJI$($ !UJ;FAB5"84%"#>I
M98)W$'H@.JJ *PPQ"6^@)9J@N(L[!X;""7*P'=$HBTD[G$3[>*AA #!Q"W90
MEB&!!U3%$/,(7L!F %ZDL[ 2$OTD/PM! NS3$)= !W:P!PQ@1=]%3'= !Q)@
M0@RQ!R51 N B!^P($34  P_Q!K\C 0\4NV*C"A+06"*@ B@@4)4@ 6Y@ 6!#
M!S"P D(S Z#G$,[C!A%P,I1  ?YL$+X0AP(SD'VXD (W0%65,'>>.YP:JR2.
MAF2WD <SX =L0!=Y( -_8 .N$"&BQ@J7H!F3 $#M- -3H (AH0J58 =Q P=@
M8Q)O %F,T0EL<#JC8PER0 ?5FR0UP 8J4!U_4 -%X[Y6.XZGD0DDG"=X@#<
MP@9RH!E>(0=R$!*S, =LP(BJP :R!$$V0$%O@@?W! BC(4^L^T$V "[21W,W
ML) "8@DW@ >SVU^G82,SD "6R!"S@+U H;JH.0DZP8XT &NG 8>WX *;\ =L
ML FAUC8;4[H8 CY:!FB4$&G<Q@E4=0+2 WK\^[E+VQRL$ *<]T!^\ !R4 ,U
M\@>37/X#([=BJF !LQ "JC ))1 (*< U^0HKGLP*)Z 2?N  =. [=6 !7',"
M,S"$7",">F #SUL#%: '(O"(FH(+CVQ&J$$"@MP>$< &AW$"044!?W #/N,]
M#L 8((D';- 6;# !>D "E^<";*!\>"("<F #EG$#TD8"@DLEJ*NZJ_%:<. &
MHP$'+@ (%, *;&# $E #N% "E+ )%K 'UP9:X",!AQ42X^N8EG ?;P"7ITD+
MHF4@=V"#CVP0)) )-3 )>  ';(!0JT*,>4M5W#+1FS '>X,6*Z **%!P?F#&
MO?*LBEPFH&L7?M!Z+"S K7<+R0L(.VQ&*: *?B #MT "JOZ@ @'3QF)C)7A#
M=2)Q%GB (71@ YS@6B[ !W; %+- SVR03JD!M'$B"!KF!H*!!X]<*+=P MA(
M ?_!"N"R!W03=AX\!\]KU?(D/X&@7R%0$"N@!WKPO$ A5!AX,BJ<'+V+ B-
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MMSO3PY]N"=,<A9AR^1!R,H%  W5PB1^)" ?!!P8,")M0"7A0![9?$DC,NIG
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M*+^" #G($_?)D*D220'F,09^H $I^[H'%Q1O$RC Y9'?4 D'1^34J[1C'D[
M"DV#_(E[M2P,TOG!6W#BC9/6@PO.!@<[;(YX;"!;#>J@R3]80 YLD(,J;N#.
M\X'M!$SYP_@X08%!HP00&IVTDA'AMZG?0@\SF,3D;D$#]/Y+>B^8B"K>B +N
MWB+5$?E#"QQ]"Q0@^@1^X/4M*O'#/%A@!4@#Q$YGO@HREU+3HF%W60X>D1N0
M#0\H@( JK"MMO%MB!="\["5<D&W+GH_S-XR>'$:@@A'X,BTZ7W<YV7Z]\ZUW
M!<F< ;Q1P@8_J& 6,T@F)4:0 OX3L%HBG!!OZ=!(!_MQ480JV0,=;#")/\"
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M"3V  5RH !A( >VC@P?@A,*;@1!H%L_"!960 [+)(*2*@^ZZ*!L@ 1=XHQJ
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MG1?<]Y97M1!!+W\71\O^Y3?  AXP@3/;WP,G3KKZ>H-+*A$C.Q:7*V^ W!Y
M@UR$L/X"(W-H!0(K8HD8X==YEH #B=ZPK-T>KR*9\-)",J$"BRED$LC""(E"
MG,$_T, &-(A):&S "JE%<;>IW,1*9G!.,"+1#]K1WBT,:ER%9$(.EY (*_*"
MBTI,(A!_+7#N_! MW=4A7YNH"((ER]WU!4'!4\)% JPE!Y#T-A, H'$*YC5
MPBQ&='B LP8K4@< 6+@2 -@0!_6@G+J1@ \GN%I%/%.'/T@ 0*NL2+/J8(,'
M:(\"E& %&VS\PHK@ 0)T>(,$-O20/,3H!#%Y@ULC\@>-70 Z$&'#D0 ! 1>4
M($8 YK+S8' "&(@ 12J@P9$01I R([M/:I;2+$Y0@1#=A/X@?F!#3"HQD%D<
M!&]U.%TE1G :F6#$: Q>CB4J@2- Q,HLF5@/(&YP$#W@Q!(YRR >)$#B6[@!
M N&NP[@SL0D]#"0LR^)#L0^"0!+4ZC<UL4!),W$"%;/AP:AT 8UG$"L*3 (7
MH &$'?;@A_7<8=RJR$0@3OQ#/%@+$&[Y\1P@IP<V@*83JN!$!=PPBTWH)A-L
MF!,F8"7Q''%+,0ZAP0&V\@9"\_I^*B*("PP*$OK4X,3)GOI4U NE7*  #X6A
MPY'<D/4*9((..-F#"DHSAQA8Z2POT,^',**"&<BA+VHY 60J4(<2N"8$J@A$
M"0!1@4OX(0:L 'L&_0P#%;!H!?XJD%H+V#"' K&! BZ8!1U(@ <*6"(RKJ@
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M)>@&(!+$%&B&"TB 64C("?0'"E2".3:A);@ M 7.+=2 "- !I!#$&U0 "5A
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M( 7:#!(YAP'^@#!"<05 RU1,( :J0P]T)4).@ (@J 6RL5XZ0034(A-JQ +
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M_@ .W/[  @!XVV:2#=C ,UBA(/,W@$J@JBB#!C"#$N1F#OY $RC.:"3H/TB
M?'"!#0"!!!;B#1:3? ;C!4X !0SB#^;@#2Q@!8I/#N" /*JSA>6@7C9A!4A@
M!3!C??%@!$; ,]9W#T9 %=X@*2A!!7(%*42 88YB!DA@A4^#=%^J#O@I0Q#"
M$DI@!.J@ M!B$UB ATDE99?DBBW@!E3I!0KC#=[PI2"XX#AA/E1 $TZ##51A
M#AQ !, K@+;J4"IAB5M@*>3*IF9 )5B-!-0)$48D!HCSCBOA#>+ L 2"!"
M!EP!%R:)!/CX(#JA!49 !50E4&;G(.Z@#FB@ FK )B9A1/ZX%U-()1.>I XL
M0'GD^"V38A+D(*W*8HEM214J&09FX0U(A1-<@ 14 ")2]K1$8(^L8P8<X 0P
M0>]&I-<^.06HHI)?H"*F8#$OR0W^X 3(ASK">3!:X 3REPXN20X68A;8@#,/
MI;3F( 10X#]OP16<Q 3LB TNC8D.@DFF!Q"89Y[;$ZM(P'M,P@(M BST8 [
MQ9!7PF38P 7D!X0!9"%8@0W^( 0X@00"80]\KA.D8YA!& _82]OH( 16@ ZZ
ML,"JUZ5I[GKG4W#\0  J"(3>R!(B@';F8 $.I (2:7(V00"<HK 88F$V0@4L
MH&D60'E.X&$J8,/F@ !NH!)8(?[;2D7KY,  #L0"H@)*=$T R,>I+_-\! $"
M: %!;',* _  EB(")D$5#J"!QN.49E/DE,<!'&<6["L[:)DA3&!"]$!]Z(
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M!C2'<VT* A['!9)$9:Q#0O8ZBN1@ M#"!5!@%=)L(RA@ NA@>,ZK3@ST%E9
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M9$*!Y#E#"U[%1.DM*AI+TP5YQA2"@75 P)$=06ET"P125>#@9IFH<N0M@3A
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M@!L+M. /+Q  34Z@)AH^C$"CRX,>GJ@*2Z#Q46M*P0D T0+;#$HSG&! QQA
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MVX,+3KJ9;S7G3G]P&2"0V)0;M& 2E6H(7/.:U<FVYDY'%0T*NA:32K@KIK.
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M..FH&6[@ B[P &_0CA*P)RA $X&PE15 4B(%ES]C?!=P B&P%H!P C00 A)
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M#Q">.(&WJ]97'&$F-2$GD8P5O#('=. 'L[ >'%$82\)T&;&ZDEQS#5S1EO;
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M"3EDO74 5H*RXS 8?P H*$]& 9?@!_DU$I/PANQRWG7@'ZS@8&<_*E$?(9Q
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M/  D='BI3V&ZB0<HKWR/E /J"A*"%U;RIW)HWP.@Q8J12*!EVR$!*6^!5E5
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M_Y>_GN@, 21 (AC  RQ !#1 !61  E1  TS !?2)!H3 "J3 SC"" ;3 "-S
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M< ,WI$DD(JN#^>(01QSF$!#M:OY('51H@SKTBA(OR"*6 #$_C:A"#H-LB5U
MH;KW;*^3GOSD7Z05F5M\+R2L8 &6YD""%EP%#ZH0E$ LX095H. .'FK!"$8P
MOU%=H%T]>2)45#4)$92 #GKJ@ZKPI)E,.&</>0R!"OJH!Q&,  878</\1+8'
M$HA@!A=YY24%@C$;/>H6K4! "Z9@@P=<T8^W6&4?65+#UY6) I4(V2UF8(,?
MCC(_^^%/IEPGEY[X@00C6D%$//2"1,T"!0F5PV\ZH8(+>"4/MV!%#*CY&U4L
M]*(N2%0=0E"".<P@G&O1R/,\=C6;W$)Z(6, "M29@@5H9IX8G, ?&@JZE/0D
M4+C!A?X#3L"&"0UH$@Z  R!FP"08>%!V!XBC34=I/?N LJJ%&8)5A23*AIPM
M97$YP?PHP:25XLB%46W(66G"*):P8A-:R<2*4E+.5CQ ,]91P%,Z@8=[WH(6
M19E$\2B@AYX@Q8$#F04G-*,*5NPA393P XQP 0B7'380.6U()O!@UP;QX;)<
M5<$,8%0)/+"J07XP+ =;P(J>:$*S G$%*UAQD-3)DP2J2JM D$@]R]!P);@]
M2UKJZ)9-AB1BOKQ%":J#"U;D@5]9"X0>L!0"&5[$%9C(1";,UZ _&)9O>& %
M#6A ( DD=!8+V,0,"K<S.>13O:%Q0*(RH8?;8!)9U\LJ?O[SNZRM'FD(U?(8
M2"AQ@A.08)=Q^>VD1K@231P@!+,0P115,M<&9(*2"5!%("A0 Q)4!Q,4:$$%
M6/$&!E0@*15@ 0LLD"87H* "<E#% V"0@@K8H 46\" K0N""&E0@319( 0PL
M4(+V48<"5>G$!5RP@A*$4"!]@( $JO("VWJ)$R%8P0HHL)4'2$!5;Z".!:9P
M"SM88,"W(!EQ1>( 6*YD#6BS3V3SXL)((?@E6SB"$C&"AQ7   8MV.=*(#%<
MWT+@N"*XP1HI,(,2@ 87)5#!%"IP&PL$@A;PI80(5'"" VSBP2UP00C6\P<(
MM* %%!!SUA(H$.!9P@\(<.5*:?[0Z- LX!9\J  ;FE-?O.1Y)_K]-; 9P]^&
ME)*>NXV1%AK%$CD(8 4%8,A*3&A.!U#%?6*,P"4$\C=5& #:M[A 1$A0E5O<
M0#8I3I0FJ'0+%@SHC*K(1#)38)X'U"%RFR 4T42 BQ2P]Q8P '1/9J \5MC@
M(G,8<@D0?9ZJQ$"\E)ABYS+A!_$)I(C_3,DL6.R "IS@@BKQCU>/+7*1S-&W
MN0G!@$?@@K,*:] AD\ *V# %%*@@411(* GVT J%-[Q5@0C5*AJ" D3_N7V%
M@P!#9B$!1%\-YFQ@PP4Z-)L*0( "_,OGK,5ZM'VR8@YI/=:.J!KLL9-],-WC
M*BDI _XRK1%RY!\174M. (!92U@^TXZ!&VSP&[':( ;KG$.)A$AIP^5O4*):
M0=+(F"B_-TAB:Z3!#!ZPL#(&!4UR2$%?5QT!%\R !@;%" R4YR$VT. "\ZII
M0V)0'3;D*E$KF$-!:9*?DF'\!"%@@ 1PS<]1GBR);O_]2%+*UDTTA1-84HD=
M>2J!F[VA!![41'3\KNA;6,(&,X! 52H B( IQ092K\ *9C"#$XB $S 32 VJ
MDS4*L  Y=HBC*JHHWAEDG0&X6%\(9A!/E4Q5667_/P .V]D(U+'5&;' W4I0
MS %HF4IH1'R<4"O 2D-0 @18 B500B:,D01\S. ]0+91G_[1(-[R((J_[5/
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M J2) <H%*[J'2NR! 6#("QQ (*+$ UX4!1PD]7&<!<C H(3 QY! N[ ""I
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M?RO$5FRIPORO/T"P:K5J%2M6!5493,A*5<&!!0\R5#A1H?[#@@0-"KRX:J#
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%,@," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>comp_0031.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0031.gif
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ML QQM09PM1-SMAQZNAEVN!1LLR)]NRA\NS9\LD=PFE)\ID)=C8%_@"R"OB>
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M]O+V^O;Y_/____CW^/;P[>;CWP
M
M
M
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M73P0FT #MN#,2=P+$H  9[S%#F  A9P';K#%Q%P00ET+#@ !0DW1/-$+#N
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M RH0#)Y Q47,!P#PXQ)0V-GL +10 07 !C#@T<%@T'V0W@[P @Y0U;6=RR&
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M0 %%_-:*_>)VH.PX4<1QT.X$\>D&H-@M4 $W$ @E ..>[?X $[ )(6 'LLP
M%2\0)T  A1 ""B !G;  (T *!R !FR *)@  G[ ' & #?3#JQ"P!"D#O&L\&
M > "P5#GK[W=HW  #E +3(T G1 "!@#8=!  ?<X' 1#C%M\3*3  SKX):WX"
MA<S$A WV5.P"-$ #"# +%?#2 L'<*0 !,^  ;\T)<V#I!Y#S#@ *3]X'=8[*
MI2X"O1 !!Y#<*P  ]4SK9QP!/@WTQNX)!2 "A4  )" 0 1W7,0  ](WG8;\2
M;Z#QP3 +):#1FV 0GD  $B#DP= '(3#THE #!C#7.<X"#E ##N " ^ &EK_?
M@LX >P#T-G#F;2 0(I#2=5[/=/X  $RO G"=SGP^"@)0 6F=TY P 0@0Q^S>
M]= _^CSQ^?7L"0IP #, R;VP!XDL$#$0 !]=Q**@ +0@ B_-[4=L!ZZ. IZ0
MRTX-S@#10EBO38-ZM0 @: X %:)J#"#12P("3\%6!-@3# *"6<$D&"C%!X"+
M8)X,6)C% ($?3A$(] FF(@"A8#5MWL294^=.GCU]_@0:5.A0HD6-'D6:5.E1
M8<%$P@A6*P2!$J9ZU>HD 06M8'D(6&@:3)B#37$(!!,T8%3-4 @8." U8<&!
M3;0.3.#J2= L.P!L; (PP=.>! IJN0A@)]A"J!?]+ 9 8Y2!"L"$33@P*D4
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MB2>FUA2(U6(.-2@<H/0F1?_548[Z$^*7!E"!IA2"7SYI"B$"D*VYE=!5?3C
M ?:(IYQL8@$$&  #CE6+$PP@ 00XF3!$ 8$"&$ !?^J$<B 0J13$ 67!( 4!
M&J"8IM@GBG KR0#0B,<\J@95?PH&>.;8DPJ(B10#&$VL'OZ"  &(RG\O&( B
M8= 4/R22 !,0D#!L0( $#& %(VI!!29@,4],((X]0<P)N-(4$E3@-">@0"T+
MU@(#K(4& Y@A+?:P!X )PP]SR)8NV#" .<Q"B\&@Q29Z(0@_+(P4=@ %*2I2
MDX#VHA!<X8L=.D(06@Q&;[78 R'PM;!!T.%M-0$3KS8Q !7041@0,( H-F&
M$@2#!@#@ RTNDJT0', 3LX"  H0Q ^TXP ZC,&<5>^$'.PBH:0)@PRR:THLY
M(%5 L]A#41=8EU%DJQ=\V(M :T*(.<R0J4Y5IY>J)@"HE.( 00H&)^: ,%3.
M80^%\P0$*M")7O1!0)TH!5]F*/X60? !7]_L!"IFD8B:%&(."AR%)VJA*)ML
MHJB>2&$I[."'#'J(!K1X P T=$%M^:44+@" 8G.#+P&@P$,SF!$ [- + I""
M$ @(Q@GX4,5@B((.@VB**"(@@4Z$9104@ #"-C$'W :C%'058R>*"HJW\:4/
M(Q)%!8)+R["V1B3KF8 PGL0F!JRE! Z0"1N>Q  &%,)&P;## $*0@  $J1 &
M0,!$S D;JH1V$P&8 (!&40H!5( ! 9  X?H# 0<8 !7", $")E" C(S(2%>*
MK8R6R(8&*T!,$)A 33P!@#;0(@ ^6T@GWC"!7BR #RI0(!@EH(#^"((4MV'
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M"?"#E*H)B*.)7F  T\H\G+B4FA $% @!:^D%&QB ISH BPD&!X"!6U"PZ6L
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MX5P8!C#7FLB#T&"#T3@!3Q"%*JR94EB1[2")FJ#C$?F.5246"!!!/0@26HB
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M2819JUGHD3J8(4\8%G05A!1P SZX$CO(89^OB3C8I3> BAF'@1AP 04"A!.
MUO&=@1*@ 7EN0QP:A:]6& H0$"H>HQ=  :Y>(-1R40'=42XB!!50:T(C&UJ@
M@1-0@2MIFL*AO)0K"1<@ 1DXWUH0!C8 F*8IA5$X/? I]"X1"?/>,(NA'%K@
ME=2(KA&I 0L@ 0MXFS;H)1' $_Z!)@$*F%<Z0($3.!9:> $V$@'^Q D0"6P*
M* $*B-8;L'S._U43*'T7:)E2J(#"&03PFH$)**FE8H!QJPFGN6<'0,L:4  5
M>!1FGXUHYYY-D( 9@($)B!0W: $7& VW)EF=".\M6?F1.8@/-HT]"*8!(84!
M3IN@L 'HOQZNPN432.W"&0450(&]@M6@X0,'")*FL $' (@;P8+UVD1J8*]>
M"!76"B9,6*].PH)YFK7084.%M#P-[*1PX$08-(+9<:"0!HE@@"30"L9&Q$ +
M;X+-<E H6 5A@E0$H\''8; ]*0<2G47CP(I@I1P<)(2":# _%":R82.L0B^G
MP6SL ?X*M$8,F@H&@7S0-:B*$YL&$E)@4>Q:&C"(PC@1K ],J'KW\NWK]R_@
MP(('$RY,>.*). -=S @68E:O$%O[>/7;2Y3AS'Y%3=S;&>KGSA,_$QWM]R%H
MSYY'HT[-E[3>SA_[B@:IF>CLVI55FU8]^S;PX,*'$]=+R\Z"QDL#T6K1(I@)
M081*!!L$ W;Q[+&#T5E!@F.M$BWF%JH0@\2<8*,FS!)F@7.(B!9FB%!QXP0$
MLBC(SLI91X0,%<@P PD5E *5!&3MX<= FT 0S ET@.3 +*-$0%0;SU40S"8M
MH)(44:0X<(M>M0@RPU-OS%"+'V\!A8(?H_BA4"\64,3"+/X\[54!97&DA-HL
M!P5# B!MN# 0"FQ4=M)< ]'P5$TN:C<EE5469\<*GFQRPDTBC%+*":4\)U@O
MH5@9&&=GJKDFFVVZ^2:<P(UB@P4CV5!#,"U9)$(OPI @C HM :;++(4:*LLL
MK-C"BJ&--HJHHHPZ.JFCMN12"Z:W-!3,'#6T$98=,,1QI!MKB3+!1&^X4(,-
M>4H0D5O!.-!&,&VD,"2#LSP@S!L;SF+ 3>@114L#F!4E@1LX$0)4!9L0DE<P
M?$@& XHG>K*'&PPY4(HG?T*5!W4UD#">!'9 =8(*+;@@ 2?!P" #"H#0P D?
M;<S6BP-KP3 7;+-,D.<$"E7P4_XO<[ QQUHV5.!&&P0>U L$G<0Y,<7 ^5M"
M""0H!,@))1 RPR9NI+ 6=K@9.W&:%:N\,LLMN[PF&R\$TT(,+9 @PH$NN/&&
M#7S,,8L@@(%2RBR(-KJH+90:;2C22C\ZRZ*S>.))*563LLI$<\ PRX4F;*(J
M07;0H$('1)$@P4"UY+3)4".LA64P)0"BE 3"N(%G*18H]$)Z$]'B &83N1%!
M>L%T0-9 %'12B&0/\0&3,'DXRT8>,+CQ'+ZCT*)':9S:50,$"I42@443A3#F
MXP/MD4@A;.SQ0AP\383O6C,\UUDM!\[! ,,)!-U!'A"Q88,#<]E P1N7=] 2
MQ"2__/X\Q5?]Y)*.1+>^!PRB8/57F16; @STX8L_/OG1]S37"A+H'@)$-MA0
MB@M;[ON7*17/LJE><SQGPA[4W3"7"&#0B5%XBQ0G$,&R:(&538Q@("*X"=Q(
MD$"TN4$Y%6B("R0$D@BL968H$%0P4C 3@CB %J5X %%N<"2BG* 6)QB%8X01
M);[8P03!B$-23,<1).4A;3EA(2U0@)GX$"5!P2"$ Z"R@L:$  9O> ,*>$(#
MZA#%!".9@0R($@(YT,0!J"@?&*M4D\Z0XD$LK(4+@E8"&%KF9'$*!?C"*,<Y
MTK&.K]G*7%K0JH%4P$4V2(0-S!6" _4E%+]Y$]&V,X=;\?ZA #.9P9$4@)DY
MF,0]A!@%A2#6BT*435F<>DH);M +.QS )6$I!4N"H0(N=B8QP7A# T8QBDX<
MI!" ZP4,GA*W&?3"$PQ8BT*>& P8Y>V(-D+%68 RAY2@,A'"X -69O$305"@
M%+V )$$X12L5[&$6>B.*"I0DC!.00'-V0$ I1,$ HI0" ;/X&PUF40HW&*!5
M,%@!1(+!@K 4@@)V_*=F5(""36RB W@27++>T().?-,OP' CG$Q1,H!2M*(6
M=9,-9 :(;Y8'-9ZX%0P$24B^C.(7%'LG7_H@D%J0X" &"TI]L+0'ZPS$#4I2
M@3 \T:072,P/K0)%QMB SSS,9/X6*V@(&R@#%#^DQ 8B&($(+( GDE@@!$<=
MR"Q0$((._&1VO R&*%!0@J"Y8"9L(TT?&A.,1(B !"3 #"&&0@<1B* %'[FF
M0L(Z5ML\"R$SF$!5;S*'5J%F!0PJ!0HH4($;"&(F;Q GIQHS@RE<M+)\Z04;
M4I""PCG$#@H11AM4T$&HW*)1JS 3Q5)FV=6RMK6&F8@-PK*5TU7@)@Z!0;LZ
M00+&0*474#.4)^(8IU5(:3#YM(UF#AF8@9X&?\/Z2SY+P:?!%+<T(/0,B?2B
M MMB9#"U4*Y>9B&"Z[JVO(*Q1=56P0I1H!9E$S4O?.-[T5[@;Q2#<"X(9[&L
MWI9B%?Y5X]9[U<0*\@8FP&JB176A2]T$LREWP DP+;XHW\J^U\ .@>B;)#KA
M#7.XP_0#+YM680L/D[C$)D8(AMVDVA.SN,4JL_!?1&'2B96"P"Z^,8[M>)F*
MI3C'/OXQR^!(L578&,A&/K+*=DPQ#2.YR4Y6DRA O"9%/;G*5E;3+GK,IA5?
MN<M>%LPH8$PE*G^YS&8FC)+=>^8UKYG+;B(SF^,<Y^XM6<QROK.+HTRQ&N.Y
MSU].<YS<[.=!YWG&<>(SH1.-9$##2<N*?O2&]3PQ(D.ZTCAF])L$;>E-NU;3
M:RH4IT--8DR[B<FB/O5J12%<.%$:U:XV+ZG;Y.E7TQJ,L_X^TX!KK>O*QGK+
M=MXUL'DL936).-C&KF.OUW3K8S.[T:M&9)&;+6V699G'OYXVMK,CZ>%&.]O>
M=A.=U?SM<4-YV+@>,;G3#>[ZI?;:ZG[W7\),,3C#N][:23:4W6WO?8-5W\.A
M-[_K[6\46SO@Y"9-:P:S;3@AVN .-PR^SZ3JAU.<+Q.G<;<K?FRAC&"$I%B!
M"HSU!@;WUM%J,K7&=?W,M+DAI+-CPQ0^0HB,+_Q-K4XYM@4!@8I,P%PG\ ,A
M;$B(%U@XXE9:-LXA+4,:H*U&,.B#!60& S: 310I,'?-W03JI$];@L'0!4V"
MP2<_"2,%&2=XN[G^:C1* "9]V/X031C0"Q+<0AB26>AN]B+O29]=[:CV$QM0
M( (73.0%;XB#3^9 B_W^I=H4"\7 _1[G36RH%F\!A /&.8A"M& 3(Z'YL]_<
M=\F'NA<14$$M #626M2 !F*27Y/:Z+W(D[[,$R&$C8@2!P<LR^I"=($G7'""
M.L38W%8J=NV#38$.BJ*3 [%!(6Y@K@Y(N"]&K]*M:2\8U"#<(:&YS<"UGWRB
MX'X@I+  "JH_$3OD(0YLZ$4%HIWU-C5\_*^>" UDYI+;!0,4/ FI8XS49;57
MH)D7*7R&\>$&8 B#D-A?8=R>C:@-@Y0(=;0 @[247Z"<S8V> SY:+YQ %(E
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M.%H-]! &2@8-+ MI; +:S(("L%%4" 1-6, @L$^>, ! ALQ=2,9 ^!)!/ !
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M*4A&?<S #-! #YU \/R%"$R@ZE 15 A"'.Q!#+C'@5"%76Q"$@&%*+3**"A
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M%@=*W9$;V) ,[58*S,4FF$ +V/X%'U# G%J 1;0!">CD+'3"!$A :3:('T
M##V D&Q"5'((3 R"L=C 3)2 *=3 JRY%ZCD 1WR$1 1#+4# +(1 T.!+F&93
M37Q$+?SCS!!6V1;'U!:'F9[&#>+&'H#I:KZN:WPE5RK8:W9MZO;%Q0W7+-SF
M'7;.&]B0H!9.HWJ" 1"",-#" V!&)R! N^:>'=B%&QP)+8C D39EC47 II3"
MT@X$U*E+G01#)XB 4!5"/+&!)!+"@Z "A?#%'MP**0:#B%A$*5"=';R3 SBN
M&Y#F0$R!+NWN<*PN<2"= !-:?7[:)T3C*(0"#P:#&]@%6]@ #%!(%3:(C9A.
M+;2!!?X,3PQ<"-B,DG.9'BG0 O>:'_=.A" <  SUP@3<1"?,02^\0!?N00AP
MQ$0,PH/,$$A8$X2(P!O P +TPM^T!RG(0 T40"'@"PVT@0U$P%FT 8T><' 0
M\' 8<(%1\94EL)J4@FJFQAM(L%,1 DO- ML,Q"B8D3"8!!NHP"ALPB@<8>S%
MA@3 $ 082R(D;B> J+MPEL]LPJU0G7>:1%,&(?W*W2Q 0+V^@01T1;E Q2_A
MRT<4PJZX"PIJ<7)Q9)6T+B8KFJF^":/\A:0.1 BDQ_.2 B0T3C" 7!_$@ *T
M( 1\D1TT!AN4P'=9)FCLW%:(0"W0@@4HAA^4@MW1@3"(0OX$P) ,E4!$=( P
MK #7$H0$2(P@($ ?T,(HT*2+2C"G^),K5K,HM  !;$(M,$!VJI-"C( E=C+$
M*6*FZ:XZ UGOP@F/ H4=R%;YH@#/T$#P0<4LOR0,V3 )O)!Z='"-"* PH,!!
M",,,=( %[%$)! +]EL#-,,A$\,'TW  *P,!O7.Q "((%6$ %S,!$K$##]HEX
M6<0@=.; O,$FS)V@T ()O-,$5.D[HQF[B5M-/YIM!H-PQ5'H@4]/#\2S^;10
M$P7XC*5@; II]$+(5<>K@ 3)_44MT#14M(=?$)AXX<]W>:V!U4#@YG1@6+%P
M8#%8EQF[^8*:H+5Q<.!?^$$)=/X,3PY'A15&ON:=@M%N98"".Y.JX^%T60_:
M)ZR!(C "81>V81.V(@SV82\V8S<V(SA"(K*7(59Q< 381(7E7O^U6 <'6?^U
ME8&/)/A $(RV:(^V:9\V:9]V:9-V::\V:INV#SQ!ZME@;[T6;1B?^ D#(.".
M0>R%<IFQP>I"+RNUL;(,6U<<?T94N7HVFTG"$! !$D!W=!,!$0A!$5 W=B/!
M=6^W=E-W='?W=%=W>!-!$5SW$PP#;9"$TRJE"C^S:@!%M_"%)ZA !:0 *!@'
M#50 "4Q@MYA X(2C\*K5&T1 "$R +0,%'[ P4/3"NH2 !+B 0B!1KG[T?:-
M#[G,(?Z$[F' 268#U/=!G"9326<S=Y5)0A!@-XJC^',_=XJWN(N_.!$,@16@
MMU^<0 A@;#8-!!OPWV41!2?X4V6,P@'L[P0<0 .Z!P'4  H  (,X !LP'7>8
M0,)!\T&41 NK +2H0 B@KLTT!*/*#!],0"_30@S8R!YWN& < AQH>(_[]KYM
M-G",.(G#%^WY@HG#.)[GN9X/P7G?T2:$@-\2!2JD0$!S"P5(P!P(0PPTA.?1
M1 ND0 DD H?DGFVP00 <!"T00*LH1+1>> 6$ "T8@-0@ "U00'4) HA"0-!
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MP?DL(@D?=(^0/3+*3X DDC<B3QA]6&1*>K'$U_G!#@2T"!)+@#4(L$(B)YB
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M%BF%&GL!"D5R2[VRI:/VZ!I?H%R!&.ZU[WWQ6R+@M:NY%6D!3'1K'(\TQ!,
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MAK[V)EE2!U,MD1L6A".SFM:UMG71EDLB4^B6#3.P0YP:4@@2D  &O?!$!21
MTABL:A/MH84+4F""1 2#$UNC34V"(0@ 2+(7RW'( 5Q0" 3HK02CL'9P9Y 5
MR*RJ(:+ X!Q<P <L[N'<H]!5'S3-"0<P1 +_DQ>E[O":L^V$!C90@4X\,9]@
MS. $4.E%("!0 <TTA$$N"(%./*V"8KI/ HYA.%16=8,3K" $2+UUB!#F(UAW
MSP=7@.W)63V+Z'IN4Y9<)+R X?X'0,)\7KT(Q;Q$T0M@ "-NH^J$,"*P*B1N
MXMDNZ,4,5*"E",R&#W:K@4[^1N<W*'6E,'! "CAK!P2D( 0.*(5RYB"!.+!
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M!#I!TR"B(UD PJ;1 4: HWJA!1Q@!6A!REX@DX*A#^ $G^) P5I !!R#!DQ
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M1N72L/X422LB!N$WZ(($/D8$7$ "!*-CB 1D1(9D2& &4$9E["8$)D[#".
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M4=M3*)[2OLKG0R+I7GHUKYAU)7KO1EZ--QMF#0N6G69! 4Z $V8   BA%PC
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M"$4&*F 0?KAXOG?)&-?WB.RUF'B1N8H6. F [*>RF)=H!_Y*485RB1DY1"R
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M&++]*-1==_F5KN'=LN8  >2,$"0@^5ZQ%WKX!#+X!#.B%RR@!7R'$'YQ)5I
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M@022<4 ?0&$!0?"'P"?8!,MFX4HU^\P/#PX&* !PN1?$0! D(!\,4$"+&<R
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M"VYPG.81##OI B71"<15 WK",JD1%\.(:X%C&2MPC2=@<R?0!Z50."HA#"F
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MKW.79C,0&K$E<U]1" R -9W*$"X0'C2 1OYJ9"1 ,VP@K _F CQ4 ZJFMZ7
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MXI<CJ8$C"IR30"J0",O#@"1H$2:&0J),,_X*XWL0 [-  3HR"J2 DFZAHWW
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M-E"-A:,%!["+%!"%%T:[JP@&9(N#)3,S*"2(WXLQT) :?K,#H_6#A_ #XW*
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M,^@" VFB5-"+"+^Q<0,M#LS2"_Y4(LQR@V>;A!:")\'LD5E$@U 0$0J"=/+
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M 6\3R;)!#$ZPMN&PAS@.V$Z\%&FU"<:Q/K6P@ UNX(#L52 8,,A#+TQ@ QB
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M;$# R!'" ^A%_*%..3H I>R?=02'ZB& %?Z+'F250,P $9E(&R!%'U@ N*6
M8[K'ZJ3 ;UA *92"*?7%A(Q7'O@=(>P!5;D!F)Q74<8DR>E!4^D%Y* <7ED(
M33ID5I%"!;0!8_;"'$S $<' &UQCSP4#/8("7]1""RA ,=814JS47H3 "<*A
MF1C?Z@P"29Q7+]C!;GI6'O 5:UG(SHG"+1 1+>AD@-B \3V&"M2!"YC'++2)
M"P @$L8E/]%"1PD"!+#!"F!3(4Q "I" QCB 3!02?;@ #?Z08WS8@ 6T@0@X
MYKUH! 2H! J,P R@  3<PB8$1_2LP R@AQV(8QO03 R\104$2:+<B@C<X8A
MP!2T0 I F#O]A ,$A2A0 %:, .0Y0 4(#42H  O00 .(!QO8IEE(!9C(*%:0
M0$V8!('286PP $[$!RV<SBL.YANTQX>YHV A(8Y)T@S0TO8Y0 A4X)HX%>[
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M1'F&K:!7A+"OR\[ &[P!48!;@-8$"SAF>%A;)_+!!)R?R%+ *&"4F(!B+]2
M(,1 &["!><2'3N 6)>\!=@1C]WE"<%!*'(!)3?0F(4"*-1,'!'0 #$"6!%!5
M'S2+ US$ D9$"%R()"*%"M@(A*4$^97"((1&1+CA=*A 5)] AZQ7,'3 )OA!
M]QW(_C) L\@ !3A,XY+ "<*O1:V<&V3@'L<+ PC"%.2%Z<2+\8K (+CN9\Q
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M*!@V!%S8'/3SY$1L1/!!QY(OV=&""@B-,'S(Q.[%"IA *78)O$;% Y#"*##
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M !S9H,,7'=)#M*. ];#7DA40PBB]0,$)<F:!3;"!.20@&0D\013(H& A<W
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MI >'@^]HYR="H$GB@(AB!:%HX$VNYY;D4",J1R,F@!,X=BJ^13-F@'TX84F
MQ.A(0T)@XRXVP5B4(WD4@&00ES&.8@]^PA-&HQ?B!D\/(CJ$(0XX!4#GASFF
M)(TD;@\BP",8:PXXI1060!C:1/XN5CO)PC8T8_UR DA$@/X0^B!#4($!3K0-
MBL,TO\1X^. DF"4L( 22'*#D'$ 7YL $-.(-S.1[PS>S]K9@#BAE.NLP<F=#
M+ !+-A<F\D0"3$,&&F=N36-JG6-M&Q,!"DE^#^0W3F(%@ =3BV,"<,03N**4
MFH/DA&YN79'32F%%;B1 !&\HE (V1F$3*& HN"($ FD0^.#D_D8E3U;8B%(S
MM/<WLL,%5J0!<.3'?*,"5A<%S&3Y* )LAJ,.*L CYLJAE$+L-.(]+P(E6D H
M+  ZWC96A$$0(C3P*")W;T),>F.&:VA2P%<CY@73YJ!&W&! \-3TF*L4'B!=
M-(4%;H">DB,$,B;..(EOG.0I5OX/(FK@!& @ L3U(BZ$#"%B!0X')WJ! FK/
MD/M0A(4AA!]C!%9 !5) !2QL9<^D8,_8LPB!#0#A!&9A I@2A].C%VY@CT72
M1)KD#5A@G4@(BEH@!59@:68A6]R*!"0@;DR$;E1 !>A"(E?PE5F@ DC" @:!
MM61C2FI"&.R@)AQ5!5;@!/969 SF2^8 +5F@F7=H#^B")$0 IX9C#\H7*7.E
M!=S 7/JV)&1$&/8@5UKN*02A<"_T*=PQ.V@@A2()Z%+"B5$BA]>T!9I9!/R,
M!Y^"%B2@14X DJ_&1D"%)&[@3<@WJZ)%&"#@%G:-!H2A%D@SG<EF!O:X70MV
M(6;A ?Z@@@W>6"-D!I)10"61BPTD0 (>8@8FH)]7@ 1H022LQ4%*V3%.0 X\
M*@Y2("5(@)5&8!!6.J9)8#120G'I27I*X#!7  56('<"+?\>(WFD1ZEK00Z^
MI@V YVZ"A'4C@!90( ^>PMR2HP, (9XE8!1*(0+HJ@+2XPV 1QC>H 7P5)=9
MH 1F!R4H0*KM #<8H)]90 3TPFG-0P)J(3I0X2E(H2=4 $CFX&Q#8-8P8BB&
M" 8,UEE"3:W%FJ1[00(DV9GW324RPIV$03>D=#,X:K2\P@(@>9=YBJC:(%<*
M#IWW #E:H'\@H0(D@ 38*!@P)@_H( 8\@7L\09==8 )4@_X&6'JD'6J6/VZO
MI^,;8: "5J0"H$-CA0&D$2([:G4"[TH"="T8T.A8^N==_)4!K)D%1/1,V& %
MA$$%VN"-@7J[ %@C[ YEID(%G0426>,HQ"@87B#HMB884( %5&,%7D-C34@C
M$J$WVK$32%<]CMI#?%8E+F033D)H-6.E1,&6-.)]"^?O#,E!F,,%QB(Y<C@8
M6 !D.P4G3@!((BX86$$Q%-:H-&T"1.MB_0 !J$;:#H(/RC<Y2D$!TH,6_,.3
M(DF628(.LD:9@X1D]C,Y1@$"-.4$]F"*;[P30KHY%* 4:..<-2(/Q!F.6B .
M:J$G^(!3U'E^)*226FGMY$)&HOYE0VR 7O.9-![Q[S#G@&!@=F;A,"P@';5;
M.89D3VK$:&MHI\$:+Q[BHB>"S4D !D@"!0HAHCVB4OX&U1Q/=*=BI68N)5(E
M#^* @P^"P9,#I56#ADX Q;5&)>G[,0@!LC5#L7V##50R.GH!QO?L("H@D%Z3
MJKT:(@Y[#E1Y*-^D!*KZ8K/E!A0X#T0X1X D.F@!%;0QQ8_B?-\">,#.?3!*
M&"1@<]K !0"]E=0JQSM+&S%[=<@"2)I<(R3[PDFCS6PB%-0CMR: %%X CFIA
M4K@7(C!*.#0%$*;C!FI@!4 EO#="[E["!0YM*"K&#= YS$LB5UR@#?2J.:!(
MA0I!!?Y>H!2P"5UJ 2?U^89!9%^&@E88(NA(<VL\@G]((Q$\&N6EN#CJQ@16
MZJUC>$+DZ 3LP&T'"O_VA%T>QS<2?L>XLA0BO!!.C@]FH6?, VD/J!,6H+5\
M\Z'*[[URI01F@!8( 0'>@"K&TEBJ]C%88!8^8SI*%,N0<RQ1KA"&0SG]$-@Y
M' '<@!3R0")ZX7(ZA8,UHT PM9,KX.Z<90IJ805:@!8*00%*1 3DP#=@V>HZ
MPCGL8!:V1KL7H _D(SK:H.U[X63]T 54>4W%N[,4H)1HP,N#@0)J8*5F@0'V
MH!?FH#BB9"@K@+3B.'@&@ 9*P0_>MF O<31)X@4LH 9:P/Y.^!-3P[8W4,!X
MYJ46%, X_,,.(C04'B &-NYF05P%4"$1UC4&LC\EW@M+(L ]@B$"9FT"WF 6
MW#/H:X !:+5,,%4"0&&;5@0"LM+@(:*Z9R$IPVIZ-0(@7L (5LN!J&!V*@0+
M88.6( -V>BV8%6S6@EJE'/29%2-$L#T1.I4Z<2.8L& H4ZI<B?+&!%*T1,RA
MI7$6&Q'!/"T@=!(EB1FT!B%P$PR%"E,G3\Z1L"F8!3TH+?"AR<>FB*3!VA
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M!PG1I<2'"**P$F@PH_ 83!]?TM#+2J.H$ ()A01#2PJEV!9F2KVPL:DP-IQ
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MQX$U*!%AU_,R*>$ R]<+$? 6%9 :'-8'!% ED!$!LQ AWT$+$N <C)5B>8
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M#&]P B^# DU1" KQ!@8@"/9&,*)@ (1 "EIY%A[1"0/V7PU0*@K0!OQ8"Z)
M *%"DPA1 4US$\$  :'B!B\B IO"CAGV,@ZP'![AF[/0!XG!!M=R$G@T!WI1
M"W:88]9)$9M ('; 1+W0 L>18<'@ BM :"00'V;YDL?B H]AAW,Q :5@'"@1
M XQS$B!"@=<R!S=Y$!+@";0  5$6))6#%[V0-VH#'3G! %8R$.\A##406MJ'
M'"1 0;*C,IN$ &1Y'&M8('@A._Z(T@M^@  'L3V-HP"%4 N#4 %W&0PV<'0N
M4#PI@1EHN DC=Q)[\!5Y8!:XM@G"<  +=#JN42J*%PQF=RE8X@"\4A]MI1!M
M4%LP4$!H!&FGEH\F>8A. 2VBDEF]D'1[4 =T< !&IA(NH(TW$%IM,'4.\ 9V
ML ?%(AIL0*EZDP@/@AM[D*7", *;0!U[0 =\P ![@&-N9 =Z 2.%)0$',0M\
M\ 80D >J$28H$)C>$QV]$#E_$PPG<#-Y(B@*<0(KD =V, 4(H"@20V*#- <J
M4 H,H =UL ?P@2F]$P'!$ H0D!)S@!<1@#)T4%LA$"J@H%^CL =L@)JH\*WH
MP:TH0/XYA1,9=G"I$<!E%%A)+U!XLZ!?I+ ';4"C*F !;.":*9$>)V$#EE(!
MKDD+?;!$1#$!G."9)S$+WZJ?:HBGVHAC/?$")7&)'%DZ8&('<7  M>$K=N(
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MYV<NI^5F +B:)7:@CB[@  K7KD;' "EV B(P Q"P+E3G +A>"!'@W*:6,@Q
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M("@G6AHG3@BC8:'&# LP(6P*5F."49A@9[RH0,I@L!L5XOX,1FK &X.D)+2
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M@RG%#K4.6C F#@VTHZ,C,Z1%L&!&$4I$(/NHI9=-Q.S%NV &L<-+*.T()#X
M+Z.E2DCX*!,2@PBA(Q'JRKIL%B-1_'*/D,XD);0 K;QH4>GB$V4.472D",]$
M]Z0C)/A(@210.]Z#3YA"9A&S%B][Z2./&&-:5)@K@R'$#N\$R5 %Y801Q(]>
M:+EQ/E_A$U.8/OP;K$(P!Q.%#A =TA2^34I!T[M!,*P%+T*_?#(84$I$%<11
M2*FS.%"#H6#93>CX\2!",G1UPFM11+-9(HUT2,T:2^2D(/Y1\!HEPU'HQ=6.
M*B_R<I8P7]VDCA)#W$/7D,*]B(\]#@ZF2PB]C'+*B#.%KQ,Z_!"03#.Q-:B3
M.I(,!A4[]E@UF$[L0-G$P7K98^(MX]ND(>]<18W-9HL;M=20!*4N5C5[X4./
ME@>C0"W4C!YL$SYF$6:3.>/C,Z3+ !'2(%'LJ*S1$%-]D0;M\/LU;?@($2&$
M;-6&.VZYYT-[;KOE_-43"62H 0) <E+;@73MKOMNPP]'W/ W'& C<<<?#W4Y
M"FQ0(82E(<<\\\-=$.$&$E H7'/11R?]\-!+1_UP02SH2O->8F#@O=/IEC!S
M_&H4*G*Z'Y]]L-ZI^QWPWH.#>_[V6IH<&'#?J>MDPKJ#+\[TXG67&S6TGU]>
M=^@WT1AOX+U/^_?3H<_^2SX">9+\N*]?/W'UO_=UDSV6C5YT]N''W]?WZ\]^
M?^K+SY_R!%@X D[/@. S7 'E0PH,(5" ^AN,(&+&/P>FSH(7Q& &-;A!#G;0
M@Q\$80A%.$(2EM"$)P0@"E5X-_\=\'X/3&$,\T<;TRDP@#%IH?B>A[T65D^&
M_UMA"8DGO2 6T8A'9"$2E;C$TKUM9DR$8A2E.$4J5M&*5_P5+0IQF1: "#_6
MVQWV?'<9.S!&A@2T(0Z!2+Q:%")]=9N0#9P6##O80'@I%", 2V&UR%E/$!38
M#W[>4/X!0NXG1#*@0 5"T >#P$!V!T$!S6H@DA*0P))Q.!T@<B<(&-3 33%!
M08&&2)U"P& &Z9J%#6"@)8/L 08WH%<G3*FFY7V1@H%J0;8*(8,8].H@-GA!
M]_@  QO0:Q;TH] 64V.U%U+G#2.H) GVL,8Q7O RLE3>&]I@&=1X BGOXZ%\
M:%A+<M:"$)>I04>&YSM!A& 0I B!'8MC2_S,*'I]:-PX?=6"*MF2>FFDX#R!
MM\/(N4!K0]&#979'/39,LP6LX.0=;ZB]:E(3?S2\3!RTLT8X"F,.&\7C9>8P
M!X7R;P5X"<YEV!"'DHY.%!,)!A\^*3H;L "&'>0,W$1 TO[+;(*5F)M0'T*@
MM@K8 1C4>0%E&'@ [?2B B?H1"GZH)FA#-4@=I! ,)X#*P0,HA!\F #H@!6(
MA 3##17(0QL$!S@]T$L^=G  '=B@ +R0P@$U@*L986 !.[@  M/Q@P/FT 8&
MH-1PLPA*3L RAS<HH$40,!L$&C>4HD:F(+,X 7&^MXFL!D,"/]V=6P@QB#P@
MX)% W* @.CN81(1M;:L5X6<,$@(ZV(T"VI&!"T(#-P@,K@TG*-Y:D2B9"/HR
MB2JXP4(Z,8IQK5 V-U6;"V0 7>K ( 9I6Y%\"J&GU-7"!A*80R\Z08M-_*@4
M'2F%#4X9'SO,(+PN\P0@7#"N0?ZX )\O8.>$;O$>471"$"XP)(YF4$P<<7<0
M"CDP&VC@IC[ 0 X9ZL4<8("37K A G,HR"8&C*"KOF 3*C@;E%I2B%',@0:W
MD*4A"Q$E&-!O#S)XPRT8Q(88@&@6+:B DZC#R38 %K(<ZBD"<A>,/JS@.[#=
MQ %TI  CD8"E-0 N(2Q2' ;\#3]H<0 M>@$!(\U!LQ3I12\((8H9L&'(P6"
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M%,0$^#"'"BC$!2&P0PP0$,CE1*4$$J!#"R1 > 9,\P00:$/LI[F"$A0B!BJ
MD@1NH <'R*$4*)C >PUR POLP0:WWP,': &46;,'$@&6PH\)F"8*J"W.4(@"
ME#+G"0;>"!5:N H+1 U!F#*#:/Z 3I@% X !K@"NXB"$W'$!F'@ PYH 6CDG
M@Y  /^ ,Y^&,@K@,\2"$&XB*4C@ %["#2CH(![ !.Q !")"Q[<B=]_.LWP@&
M"]"5%@R&"J@M87@#(X./6? K-_@T$:@C!M"R#K@!/P@!GC((%5 !P>L#$;B1
M3NBT/9@ O, J.W #!RB%.1B!,7P#0I@ @W@FPT&!GQB$ &@)%6"#44" &J"#
M"4 *)(0!$4BZ":@:!: !.JB ZYH0.^ )6B@ QMB##M@R-B $[/N.$2"$%^B
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MZF,0!A"&&?@)._BR>9R%/QJ,WLH#^)N!$E@7"1 &)C2(&8")?X2/$+B!'IE
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M$9  "^@(%, )82"%VYN %,C9$LA+:(V)]GP#%J AF6O;6.V$RZ  PYJ%4[0
MM>#0UNT*%]BF"& N@Q56NMVVA9P0&F",;/EAVA"$%/"L862!$\"O"D@$'U:1
M UX!"P %&IB"G!"$$VB!$@ N<(T@-3Z!J !783!&@0@-8;B!V?"($@",S0 -
MVKB!O!QB(!DJ87"!Y*H P2ODU1F*Z^($"Y" $;B1U054R.$$(2&!_= #8F*I
M$%AA8: 73Z"K+QFJR=P_&2A,@ZB!RZ0%MIU<L^I8I$!0F2B(.7"!$MB/7GB
M!5$ON_[*"5+AS<'HN5'(0QLUT%GHA U,R)P(YA.HK5&87X[ER]I"NPI !0:P
M,==  3.B!>T0QNA9T,&P 9BH@-_HD0.@E\5YBB3=#@2@-#HT$JZ%%:<PB&T$
MD3#;K5I V8Z8$$$(7H.H3SM.C+^]C(",F9T*$00]QACI!0;PCEWT.0< &6'@
MB5F8WU<^9(- !2),4#L=#!(PHX-L"3<( 8 )ACA8V,$H!*MR)X.PSAO0SH/
MCQ28+"#1B@X()'U-S1>A/#HB)I*B6H\@#O]Q 1I 9<AHG$'0,T)P#1NP 5&@
M9\P(/#TK!#TCHQ/L!7[#8CIH3Y_6EIC8! ;0O&"0INT( ?Y20 "\* 7&W(2N
M\00A&=K$\+V+U4,L-H@*>(\?#E;E()I9F-2L0 V#><+K/&F[/DC!2,@22)^K
MR-K9$E@;< /$;(']2,$0*0@:MIY\]0,$Z(46,"-16$C6C E])9<;$88)*(6@
M=D&)A-5S[)4*Z!57"09=$ 1(R];+4 AA#4= 8+3)<@'E$"X+,%;J. 'ER O@
M^JS1+@@+")L* (5!N-J4$888(--"8("6V(2NF&,@N6X<T6YY,L:'R!!S5:D*
M* @W8(->:( ,>8&?&.2JO@RRB]=-L"I&=C46O@B;Q.?=>IQVW:(<NP@*0%D^
MB !/F(44D-U.8( #<8$LLP$JI/X!^%L!%)B%0DB)F8& .2 %&$@ PH _B<7B
M&2"!4B!F06C7LE  "^6G3EB RA !&JAP"$"%U-R#6;B!K!J%!0 $8; !$2@%
M4C#<"3@W/@B :5(I$\@/ED)1H: !+%:!WM+><T, 4?!K)BL$R9@%V\6,N\ /
M+#VF"PV&"$ FK6( &YF# _ B$D#A3IB#! @Q.R  _*I!@QV$ ]@#/I # 92/
MU$1L"M\$B0:<"T6L"3%;"%, MJN9EA@$;"8%?92* 6#&FBF(&W XB8C"@Z"K
M66"# R@%Q/(,0PWKJ%H!!*"SP6T!0=B#/+B11%B =T(!XA@%2&^2/> P-@ N
M-LE<!OZH# E8.%G]C&DKP,$8#8FQ@]2CHW#$K.1Z@1- A2A]#PND@ Q;@$[P
MA F 3A\2! +0#AHX@(9 TS71BADPL@HHIJFJA5W<DPT\" 8PLFS7CK.J!5%X
MJD]K 5I !>*Z#/SS!-V(@U)  %*P0B[\\\'(<?05@;2= 04P[>BL<3?XUSJM
M#!1(+EG<!,0S6.2H\ ?VK',;C#D8 !B< :N:*@0LC@80!5WXQUF(@_F5 P.H
MC!.0SF,D!>W5#@8PKBUS UK@A-N,C$V8A1"X+C:P@)D'1>):"$^H!0;H TT'
MQ)SPS85($J,'1S:@!4_(,JL?E1G 8HE',U'@ VTF4Q68)/X[> #U:@#MX/C+
M0-$!FP#XL[U1* 60KM-E0=5> *\:J5D7 -9!R++[Z]NSR(E!:( &28&^=8'K
MTLOK*H$6F(5!,(#DN@P;((%:\ 0(: '18'Q",  [BH#W((3.:C.(_WR#\ .G
M>($8Z 4%F)A ^%O7@;(*2Q(W(%,Z(@$1J(%LF0,2<(%2 @1 ,-8](*E:@($0
MF $W "D@$0$4:"\B,U8\W[\1R% ; )4YP"0+X$Q/AA#.(8%E\004@ X$Z07/
MF0[P' %C)07O9X,;\"*=^$ZU0(6/C2F24H&_"($:(*/D(X0:("E?18X)H85&
M XA@ H/5@B&"Q""!-#P-'&A'1/X%$H0&"F,3(N)$80)IG=@43.,>-L% H3A1
M0L6>A@U[Q9@5K->,$"'LJ)11JF"O8+-@:-3)(D6)$R)H!NL3HL.,G)M2H A*
MPF,PBQWFJ/1#8H4@-F]ZO<A)"T9./2%*S*&1,QBM%BE("*4C$)!,L,&6-CWQ
M5* ?-\$&2>CY<@8*838Z*21<J(2(%BX'SCEQPL0)HL'LC"!A0V,O&R1(I!3(
M1J3 .19DS'FC\C1J@;56D I&"(9 3S1BSPBVA^JL%B1*>/14.YBHV0UG]-&Y
MPB7,$S4VH1!52[<(J@-1U' APH9 .B1<%(K!9U8,BC9*]&HS,1B?"*<]H1"A
MHI3 &?ZB@KTI'LPJ"12M:;G8G+"H"!YI)(@;-X2@PF*T(  ?13/ )PH*)*C0
M6C"CJ%!+,'G<\%$P;AQD6C Q,#C0*!&*X$<P+<@ 0PA)">1&97J%.(I ,=!8
MR C1T4"C1F^@:&-\/ 9#REHBV#<("2.\0$LP<10'PRR;8%=?:/:1$L<H,.A5
M04H]]3('(7R4$)H((X"VD$(,D:+"""<0-D>7'98 PR8M%,)''@VY,6<BW.U!
ME!TTS<)""#2T$6=!*-BPR0DWM5#HH<'0X!$HO\$9C'S!"<3);':XM<EF=Z4V
M*JFEFGHJ1:BJ.E O#"RFDE^IJAJKJB301&M#N*ZZ*Z^]^O[Z*[#!HNH):+,*
M>RRRN2:;FD86\,%AK[UX,A6TRII*JZZC"C/*#">4FJVO?IE %;C+RFKMJBO8
M(8PG#FPBV'P"O1%#+[2$8%JYL)H+;+Z[]BMLK/\*]&^VY?:D:R\N+":PL<;>
M (C !I]:,*\'H\HPKA0/O/&UYY**K;;*ZCH+R!5SZ!>X 9_&\+$IA\PQRJC5
M<%[)I<XB0E?AKKQSKK&R..*Y+%>+FL5L](&QOD0WS+/2HJA@TK/"O$K0#":4
MP(;&%4L<\M8> [POV&&+/3;999M]-MIIJ[TVVVV[_3;<<<OMMM#\KEWWW&R#
M+ S>>?O]-^!OZ\HWTQ,'V_>J??XCWO'0Z :>[.*/2SXYY95;?CGF=V?N>.&;
M>_XYV() 538H3)J-&2>I@>)2W:C$^S<G9_5*RQZOBB(((8,,4@C0K'*R>.2@
M>UX+0\*KE%E.L]CQ1B(J=1+''*\+Q,<>N&[">C" =+;R)K*3V@N%#97BO4Z]
M@X]J)^2;V@L?;O@1/-NS%'\V+:&\K!(MTOO[;MD:L>% G#;&AQJ8:R:-6U/-
M?K4)"(@O!3D9@702UR%O->Y^O]+(+!R8&@>DKFZ]L( )6M.C#I3@*@/ 5ZI&
MX0#U<<Q?S#(>X&: (H--*!B""('FE)8TKZ6*!K4IA ->8(,)M$ CPFB! URP
M @7$@?Y#+T"!"EI0K5(00 4#F84$IG;%!,0+7'&8@ @D4 B!=,("(9" 6S[R
M @M80 2H" T8)7">TQ#B!0)QUPY1TRX1P, "%,">!7O5KQ>,L8+*VH,%# F_
M5/&!!*B* 8H:V4)5T<(!6OS5^1I""M,%PU97?%4;O)7 U,S">\)HS0DZ4XOP
M>0("LB,%"P>R296@PGNSJ,4H)K Q43B 22;@0R]Z!TO4C$\@<;"B0&:QL!<&
MHY@K.=6(2&')*XYH H1YR4"<J9):C*@4KDR-:%[9$U)(X"RTT"(W804T9>+O
M%@(!&O@6"</#D8!< NG%.#'TD@<01ACJZTDI.'F\\&6KE/XK"5\V#XJ_J043
M-;5P0&NB<\\'3&0*Y20C ?JY0F&L<&,V:($(PN>"#=%J%@YX'2T$*A!"((!&
M=EAA+QQ $U$H8(PVH( NCCBF0B3 I1T]S1XZH)$)C*(64SLE:F(*HF"4Y)/'
M6PPJ+":,WI4"G<OTF#"<Q:%,LFI$DKSG:1IZ/(#2BA3ZO.)9ST(X39YU*!^1
M'2UZ-U65S!(M$E"IR8R" @MX1!02NE<PYN  "9B&!@=I02\V(0$'Q* 6)*#0
M#/*DD144$@6C<)H-SOBL8!2B B&0@052XJ&UW(0$#B#!+$8QEA#8AZXF4($(
MVA ,]F06 H+X" PJ< (6#806)OXX;6Y:T(()J" GHA!!"4*P68&0@BT6T,L;
MK-@+D.)LJB3(B0UJ(XP3D*(4R.V 'H"S C9D\9XE@ \M2B ,/[A@!A68P.].
M<%I1"",&0=&@! C# M,TEP0&],L;0K"9\:'  2*8'X<$80 &$:(#)+# ;4<1
M@9S<@ (EB($*>C26$[B$#3!P040P-(/-7"A%-3#!!/:0VQ-@: _N"<$UY^DV
MP4K #IUHP1#!]]<FPL !%=B$*%;0"]2^I%&],%&Q.+2'L8B 1C,0"2=(((Q.
MJ, &%I# 9ODPEA',QPXMR*T%X..'$*"@ H6TP4%*#)<3F#E5?M!EBHC\DEIP
M-"/)U/YG#*9  ]@T1 *>:(%L<[*'"J"FDO.I\@D>,(63!8,.V!&( F@!"$(+
MY 96;$$@8N. R3PZ& P0TD!$00$'M* 6+4(!!!Y]0Q/ .%5[8""':'%;KI1)
MR%&!00L@, <VO'<^;* !B$7@DEF@($*_:4$-4!"!VJ"@D'%(\O\F0),Y"%@$
M\1(-":R-'AQV8@0T:@BULSV?6:C@#1!EA4Q<H *:>.*O;B&V#4:@:]=(T2 J
MZ$!X0O%7JKR! 5CNQ H^8E@2I(!)<7!!;D/@$K^F( 14H04$+MDK!S2/#[.9
M 55Z$?%>E, -O7@#!6-0@XJ@ $-51HL#1E2!&?I9% $X6OXB%%!*!P#"-008
M1"U$@%W8%.*NO9C &&?QQ]/<0"\<K84H"##&.>A2#A;H12]2((&&="*+PFA*
M+7KQ !158"*TH !\-/)AM 1F#BA($0O\J9Q@0*!Y#QY)7SHPZPF4HA0#8$,I
MO.0 &IFT%WL@@$?L\ !AB ("I! &HP02F6!(8!3 YAMK7S*!^6C$#^6=0P6V
M9?B2'N"VS<1C)UR%BDT+X@&T$,8-&)"]1 8V!2FJ )U3/ K5!P,&$XD 6.Q@
M $\(0P(I$0%\[& "&=.-XUM)Q #FX!(:9-P!M:B%!!(A#$),O9ZNH4 P5" C
M$7B>C!+ D!]$\/E-*'<N SC:)OX0D+_OVQ"';F@ R5!0&]O:L#9T&%,P:C#_
MVPKB-P-A@R/IA&F% )"0@JN\1!_PP2 PB!\ @'3U1"'H$B$DDD9PPD\U!"U\
MFJ?=P+;(7&K8P-1]%#;Q >L-Q BX@$J0%_GP31Z$ (9(0 T$D\S-0@3 QR8\
MW7 @DTH !M^H  JR0 7T@B@,P+H(5XHX0%3!@"/-P6_D%]LEQ2P@P"RX@>L)
M ]!!BR[,1"\(PC39P=01P@,$W]3M@7Y,P!QI!"&D7(;T!2T8P R,@C"0P*+-
M @/(U@ODR2RX4BT< $T0@NKY :$IDR<PP!C! $U44M;54R\ 8E3H7(AX"PU
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M.6(*)Q;2=OR)#:A>#4R #1221U$0<_&!"AC )M""S D#1Y1  F"''7!EQ-D
MBGBD"6R"("! O( " ^!5!LZ'!%#(!" 8<R57:\R %&E$']PB(4R K6D$*92
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MUC$)(M:(2+A ",1!4=8"Q#&)20G##3TJA;((TEJ 2Y0 3<RG!/#/0PE&?\Y
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M,RW * PB+%N 6!KM#!#S?F:PI65?!6A&P-5"!Z1 *C[+"J1U":3=2L"K-))
M#"PU@\0  ZC ;HC<?23128S #&0U+@\NBC@DIH1O,BG ?#@ 0PC# T2V0+Q
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MO(&Q;N&-QXHH-"7?+$8IT &*)-9L><\HH$(N84AJY8HG&-=9-+KX=$*>)Z]
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M=2\.0>8]8GB19C:6!8D/!AYJH_Z&+"D0I(*V),"1(12Z4R$_@ORPCKR!-JF
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M PF"$8@'S.$-#+#)!&I "!$8C@8.J $M2."&8-B@ W:@P01H(0P'E& .+Y!
M1N8#@3G,P0$50H$$FC<S"XA ,A0XP1Q@  %AS*(";>!#!?Y2!1$(B. --V#
M:F @@HVMH!<+6$TO&#"*33A@EP]XBC>=YX!2^,$!*M#4JRA  SM(X# ,,$HM
M&$"+/B  !3>@!0.ZTPD'Q,X"?;#!"#9#P19 P V]$ $)YE!*:+5 !7Y0@:!
M @,'Q"$."@C0'"S AQN$H!=]@  *9$:0&YQ@$"9ZU48' <U@5" ]+D"!'U:
MQ4$\"$Q#'(@*3+,7D&@E&!)@V"CRV1(5/(T@,/!=?P01@1(0HA#\O!(*4D"(
M%ER)$ 8HW 1B$ P4S$!J->B%1FU0BZ[9X0U#ZD4#2)""6;RA3#6 0 OB, '3
MQ$$")2,I?4C0I8%"@&&S8$ M+OX9.!1 Q0 <DX )WM""/Y5B G'8PX.",0="
M&M)7$@#$'&8$SJ"40@&990 *V-"+$\# #R7(3QU(%H,)))0@*-2C [ HB+K-
M80)!@0 I1K$ 84Q ,K5PP%Q#T <:D$ 8HD# "5YS@L,X@ 1T2.8R'7 #.H3
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M @XCRMAI$#L@0&1  B8 $1W"Q!JB%-*#%!+@!%1 !&ZO%!: )6JA$#"(C%1
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M VDBH""")[?!H%=G!DI@PT,AD-"!0W[ ((,((LUR@EZ%^?$ !#2,5$@);+P
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M$:6Q!(,3$PC&#6@@"@?TP0Y^6,#B'" ,0>C* 7'( Q](8#6ID29/P1!!(>8
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M6N8J]]+/O0&.;IA#'/C0"6%(8#2O*\4)=/H&.P@&!68;A 1F  @5Y*B2#W%
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M$7Z0LVW  ++*L0\,P:ZT!^1JDN7Q0&Q !Q)@$S9 L@HQ R%@!\E'->M2" %
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M\50;#T,+ 4H+CU,*!Z \>X  HM/-GG@ QV*[KE3L(N$ .;)Y@B (?-  $WL
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MP6 X20(2?/(%0@E!>GK1@L3LZ)9SB, F:'$"%4F2!@RH +_8D)46:(P0*[*
M;#*RB1&D0)%<:D$;2C ![GTHFA8@Q"R0(Y 5>,*;([! L%"0GE_6@@T-J, :
MNX<"!XA %+5  0I&L"/WB: "FR %!1Z@ @%2R (&:L$<)& 72OU%!"$P3!8A
M("2"P, P)0G!(&8!.($\A!1F+/Y$"GI1Q*B08$>": $-)#"#/8P  FL,!F*
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MP2C&5K_:$DH"F^C%&T)0"V'$H#%?V@0&Y7IF-*>Y%X2P@Q]'W+Z,$4<@FZ!
M,&Q@ T\X !!Y ,1!&!L,/Z# JG/80Q]$P()@O#$8= BK"/XV$8<. $(/>R!
M+=[0JC>L($HI@)<;-"T0Q+K! H#8 Z5I(8>;!B,.N'% ' H=HF XH,CPZ8,;
M9!V,?0:C!"[H@X85X*\)L,&!4(D(#+PX)@D4>0X\$88G[L1=.YQH!FPHQ0-P
MI&D(H'<"@VEFFT+"-S_0EA5V<#!\@@$(,WKBQ%2"4B_A!0IK4TG:%[%4+T)@
M5!;L-#=[H$$L>^*".7CB!9T@P0O:.! (\(MX B$!34;Q[5H,P@X4D*1_%)!J
M/ICQ!3O:ZV#V(!868.L$>SAR2=C0J@HX,R-]..E 'C#L'><0+D<&%"%:, @_
MU.4$E P&+3*++$CA^EC7[84( /Z69J0G_:VBJ( +]C"#&HSX%@5;W'0!Z2\;
M;,(!='B#</KC:!B0W %O>(.K/7'D]\2!T\&PP":.R=,Y/+(-)6(#;N8 )4N]
M(:S"",D-[N.&N'?YTVRXJ0/:4/8]=(+O169#!91C@5!T=Q/"$($+Y/ &.PR"
M(,V-@ KJO0(2O($/(7B5,":P1;V<2 6AYZ0P="$!5(1@%IO@+D'HP)-LZY6S
M;%^.I4IAJ&"\@0(WD#(I5JTX@1@Z&(FHO3 6/@'0/;-Q71I!,.PJK3K8X"I\
M\,2P87#P%8RB!6*J0'\H-0&&Y*&((EBC)R(0#$Y,  9\V+A 2.$ 0;OH?2]
M$ _?0_[$I7@#@A"1$?,*&V@5"I"=;V&!7,LHFBB)"^L%!FBB('N*TPH!DYD
M84 %!A@,2GF4_M@RC'D 72 !/R@?I4M!%22:+X*28'@!E(@ ?CDC[INN0A@*
M&Z"!ZZ(4.QB,.5 !%/"*"9"-09B\"'B/.5B[*;LZ*BF(5*N[X NKC!B%!2BS
M.4@ 81"$Z8H2&BD1-\ -"J")Q9F\;*L)!*@-JQH,"0 4&6B562"Y5!,&!/!
M]4" .>.NIW  ,0F&')N% YBSQF&-$\"-ZRJRT(NU_NB$"<2U82.(4I@ C:E"
M@0BR/,.8"N@%/Z@^Q@*?$]B1"5! NW$ 3D20&*@<@1"$3_ZKA06HA3R(M_
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M5F5=5F9MUI<IUDPI&IWQ&&>M5FN]5FS-5FW=5F[MUI>IA9(@!8: H>G@F,D
M,Z@@!4J%5F]M5W=]5VQ5@: 2!%<D"+*3E/*#BDWX-'CM5W_]UW>=!1&X 5H8
M!.3P \V!BT(@*JA0B[[R#X8=3S\(FX=[4'"]A=IXE85=&X#M6(_]V'>T/0=
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M;5Q([TXF<E87"#!H[B"0;6# A5U0 Q\8 U[ !6"(A2$X FX.@Q\(@W,>ZQ\
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M$,*SYH&TFBH=S$$I%(*B\H&VZOXIMV;E+"# ! 1#)X3 %#!$"%AJ+2! "-@
M"K"!+J " /@!+<AL"<S!2M"" A1 +6P" $A ,%@I#<R"! 3  01 "@3#)@0
M! 1#'/@H C" NY;H!.!H -A!(0A  QC "7C" $A +3A  E   "QM+= "T18
M Q# SWH" 9" QX8ER+)M"!QJ,(A  &Q"(01 "\" "MB!A : '\R"C)+ S3I$
MSAH S_HLT%[IT!8MG"9M /SL&[AI C2 N^[! %! U5XM 3B  :3 GP;# H1L
MCT* V1*M :@MV[HMW([E8G9"ZS9$+\" U_:"()RI!#@  %2 ,+2  LSI'E3
M++S "OYX0F:^@*>^ 0$H "HDKR? @,P* PT P""0 @&$0"DP@ ((K 18:N8^
M@""P 0%0@#!(:0ST0B<80 74 @48P L40@4$P"!(J0N@PA040 A(: )(0,>Z
M;@(N)B?(;JW6J03T0@T   )4  ),:3"L /"&0!X,+PRPP/$RA NX:QPP;RG
M0 !X0@Q(+_5:+_9J+_>&@O=NPAX$@ .(+_D&PQL   ST AT @))*P/O&[_S6
M+RN,K_Z20@), )3^;U=NP@"40&:.0@@ P 0<*2UL JO60@<,0(/R01W<0@78
M@05T  HDP+1N; V80 4P@!M4P ,,K0*(P A,  "LP"@, /X)% (!''$PV
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M5P- 'V2F6'>Q#=PH:9NI'0@#6[MU","U7--U 10"7AN 7M-! / U#?.R!""
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M0B8\B!1!C NFDSX>&H &6F;10Y>#1"%$HV!FF:671%Y<#4F'>I& @E$\62$
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MP*P0'*I@/8HHXJ,"AQS0B>B#:" -@F7M<!H"5)M&B*(48MM(!?=\=.!$6A0
MK@:'7 #Y+Q$F@,"$8";HKQ0*%%@ @EGL"*"A"D*@!0(%)%! E%(.8($ -TA
M ($Y:#G@C5XHH& "!$8*9A0$2' @ !*T?., !PZ(>PX%2#"@A6#(G46$!2HG
MQ( 56T@=@:M@8$"$ 0X0NT_$Y@+:+  $\6. Q5=P7.D^!A %% <82""$6OJ(
M$FD)2(&  098G64!%0A@0Y  %C\A&-PG#V"&8/PXX  +$/Y0V@X$5-^J^/[]
M_Y\P%!E% RX4#!.$@!!]0% MH#:*%L3/(8/032G>4(%-",(!J!*!C1PPBUI(
MX V<@ $)@B$!E-   ;\!31O89S="^,%S@EK!< 8 B)1490Z%6 $"/%@!.XSB
M!3/HA0(FM(<.],("=" %#%P0C-$$8PX32,0@(&"C$EB%$ Z(5PFZQ@8%V( 0
M$#A*"UXP"CM8X#X#F )$2%B'!Y I#B00G 1.%(P0'*4-!C#(!%YH 5!L8@(C
M<8 %V%"*/5C $X#DQ$9>4()-V$$!LR"% Y)3@B;:H0!V*,0$W ,!/Y B!$XA
M@7M2< )(H*XL(7 #*6R0 I44X/X%99F!"D9!-1!)P :)@,$!&D*1.E2M!1DD
M! ,.)0QAB& &G6##!(0QAP4%XP;L<X$":%"I-)7B-Z) 0"WR0,+?""(JI: %
M1>@0 :0YY3<TB-U&:!$FT"6 %GQ8$$4($17['&0%L1/%B59P-+;P2BU?41I%
M1,$ 5'BJ#:E1@0P\50H&1.TO'1#!65 &-!4<H$X(0,$L!O"&6@3 #K.802U*
M$0 VS.( #]C#+$0A $:)(@ Y!$ ?:!&K61G  MT" !]F$0 :M L FZB !#B$
MDA<4H$T#F,@> -")0\Q4&"@P0"]H$( ]>(( _@3@8);4 !6H( &1U,-1; "
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M,@(;V;$04YA "^C] M<X9Q2HT9(P-N%=$F3F%C*H@3!^4P*>AL 3,>A#&^;
MG!OH=@\4(0$@1!&5LEV%(C!P+$4H0 LV2, %+0@Y+;ZUI%Y\W 4L&/D<\-)!
M@K87!7TPYBA@3H<WB3@8-IB!)Q@  WK?BQ3,Q(IW22&!(+G! @Z 05Y*80%1
MO$ 0-MA#$Q^@ GJS(%X3 (4P:A&!?-([7A0I1-6,R=F(_V8"HU@)0NR0MU&<
M8 (1D)(*ZB *[QH3!G78 P12GO)2\*$$%'+ "WY.B#FHH.PBH(U*1@ <IPC#
M!8\/!OZZ"!X,&+C!#WE+B+$B7W8RD\ "79J#-X,!SH-T8@(I^ AL*J_.8,R
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M EQ"242 ?V"$&V>)5,[L(/J '?XW(@6T<2-6(&X(:KS68MGBYC FP $H(@8
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MF/=T/<\)0S=]P5=\/0]V]81\Q5=W\_<O[E=_^]=__Q>  UB !S@QZ)> _]>
M^?> %WAZ4;>!%9B!(UB"*XL/XJQ]RVX3P+:!\5=[$8-_(1A6#Z\Y.B%SH4\J
MM(='Z3=\K?<GF^,$RG:"8UB&9YB&:]@P>N$ )DPJ: !YP/ZB;0L#A&WX% >
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M31) ;1"@#38AW$*@ P1 $+*B4NI,Q2&W!L(S!$A<[@YS,DIA 8IDO JJ%UK
M*?I@00J"*J,"%(0.,SJL2B+ 1E&"? J(0S6B#U(CMP:6-$H@!,1EV>*E$ #E
MLFS0#A)@76*L+%KG-^3N%J3M#4CC/'XC!EP@QC:V DIA#IBP#G@36A:=VM<:
M MCG 4@(K]UUV8*2QLOTBQ*!(/Y+H1-&6_< @$#. A38@  * 2P+P7'H0Q0,
MH11TVY+1K #,VK)+Z)DL(+ZN:"Q(: "!1 #BAQ0(P$ #5P*>*6%I(!%J7%$F
M%@#J0/[B0!@.@,0/X@2?[ !&@10$H ]>'.,D  <[BA1X\%1DD7LD4(>K'58I
MH@:8(QH/(K@.MSG<B@;8+ 2HI&I68$3M()J<1A)_X[&%*B7&,!@"ISF\Y^CE
M7!@BH!1.( 5NX 9<(#5:(B568"MF@ 5_@P0$P;4/8DF"8@EI'M5!M *:J W6
MZ0U@(-21P@1XQ09@H!_5U>7OWG^$ 0&<!@&J1MRQDR$M?"S+= !6()J'K0(4
M^B#R8/[4=H<^22&'V8 !X@<&"N &UFH6^ #=U:(40N">'<"5&" JY"< $!4
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M=DJH*!3,4XVX/#T-(M7+ 0J5<W@22G&";+!2,%P4JC%JU@$;,TX0@LKY*2<
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M8@^ . $,;C2($]!@#QVH8Y=XLHD(3$E2U(*!"MK D$(((@\EL %%^+ )-I2
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MDCYA 8[Q+Q4R"(1422O5BTWQ!B, %*+P60A1DY(4 N9AD$4(%+5 FTLQ"B2
M,Q9@>?1&%!! 5C/9!REA%''T=>VQ+BCP>3RA:"O# "V9(PQA O?$!@3B9<&P
M!RI@21,Q!\) FYQP&),8GOKA989T,\S6$R8 ?T.A*Y<).YX $@Q1 OHQ!WU(
M"B$@#"S@$GNP7,A7%)WP +60!ZI7"OMY5AH! WL@B#1@!_ZW-0<](Y@^T@+E
MQA.WX  +F0([-26;,"3 XPG5)@P'(PHCJ@N/D1K->&)3PC";D)?!8 )PY!X2
MP#"]4 BX91[<)A,T4"N1.22S$#$40TD4X0DA-B2]8 &D4#/F]%7F(C$!TT\N
M4P@3:AZL,'GNU#+EPAO_TSLL.@H@=UE[LA,',PHU20I"VA</X EO>:.  3P5
MHZ9L&G^\D9$[P9%E\9&B\ "*^3\WJIH/1DD6T EFJAH,T3.T4*<+01%Q&DC,
M:(:BT!$W2A&T,"4.,PI HQ$SX"0+L0DG]Y$KPQ>KTC!HHA%H&C2J@9!(82?7
MIQ,A8"'AV0LT8 &6&0R=V0DHZ/X)*L";&J&KI* @*"",UDA\QL$&;1"0/<$&
M$T"LF%0(=:E \0%NHU BM/ &I& #?/ "MAD?-] &-H!;GC(!FS$'!YJ@@!$#
MB=$'?$!]-N!46$JA3@$*[QH\+-"AJJ6A/($"AA9_([ "*]";QV54H(([(B"P
M*H [:/$ G# +(8 ")6 "JS4U<_ "-;$"+$ "%I(0#5,"#$ "04H!*M !.U43
M,P !SLD'"D"+P.-5*A !H3$+)+ ")W"PPB "+X "$Q '+S !I2(*#O ")^
M9)$J1TD5F0(1,< 0M8 "#C "2PHJ[+$0-C&<,E$#!3N+[E0!)?"O+*$"G68"
MA# +FO[&!@Q0 :2A$:Z' J1X,#80 C PBZ'6L>/W$,FV J%("A5@5$H9#"K
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M(@ )JE$!@W +#[6H*V#.RY4=54,AH@ *G.";@E!JB6$'O?EVJ<$'Q'*-+2"
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M,+TB [C2"P]0?>:^^53E-0PQ P@@ 1 0 0Q +,MF5R7!B1+0 C/ WK-0 2A
M*2B .Q,0^R(P^XO"+Z70 0ZKBPR1 @/F!ZL_ R]@ :'6E18)<L L 2K *POA
MY\G*_"5P>TTY 7;;AS50 2R@)]"H%1@1(D[OMI22$5U:Y&K"%T,<,*5  >:1
MR92B>M3VBQ:@:C4  9L0;!N6:N[A /(46XE,$0 QHX&@8/X%+9Q006)$KUD6
M5L"P$:&0,!$3:L%P$RR1!!4B4/0J):%7,%(3>@DC(6&6'0@K0K@05C!8+P9V
M@A5","M8R),E5/HI49!/T(*T2)Q $4*GA4(%*X@:1")8S#P35E1HLU-"K6"S
M) 3S([56"1,H.N@L&(+0S1 %7; IR.9!S& S*JB0D*<NC6">*J0@D6*D"()M
M)*18(6%M5PFT@M&X*\&FIP@E8%2@,Y6N3,Z=/7\&'5KT:-*E39]&G5KU:M:M
M7;^&'5OV;-JT&<["/6MDP5&;''>>M6EDJ5HJ-VTJV,LX\J*;;W+BW(MKP> C
M206KM7OJ[YF$1LFDY9PZ(4C:>_X1$L59%*'?OVM-=RQ=8Z?DMX*%9PA>NS#N
MY],W[ZR734KIBJM>!KFN/>%Z&8D[4NPK: )1/&FJ(&$VN6X6KH A19A;=CO/
M$PM_X\_"#KL:1,3.:HFIQ.U,?'$F[@HZCJ[P"F)1/IEF(83 HD:<:KI@.)F(
MLQM[<6\W%>"B:Q3V<-Q-F$)4O&\W4@9A4#L'GRQ(ETVRTZXV,<<DLTPSST0S
M33779+/-F'J!X#J9X/3Q-?%$N[/--._,$[0)F$.M3SU;$Y0U44*H8,9!%V6T
M44<?A31222?UC$_34!&OE$(M9#-/\3;M#-311)U-MSTI-8U4 </D%#1/1ZV4
M-KI:;/[1PEDUF\I63H6I%==<><W55UJ#!?;77HL==M9;@55VUUY#:]988I<]
MEMIIG;U6VFB3U57;;KG%E514QR6W7'//13=====EMUUWWX4W7E?EI;=>>^/=
M9 X[]K6CCGW]Y;???P<.&&"# Q8X88#Y/3AAA@E>&&*"'U88X8;IV*///?0M
M6.*.*_ZX88I%]CABD$UN&&6/'YYCL7M?ACEFF6>F>;9:2L$Y9U1RQGEGGGO6
M^6>?<V;E9Z"/#IKGHHT>>FBD<5Y:Z*231NNS64B9^NE2HN:Y::F5-KH4K[O^
MNFRGQ2Z;[*<5K;GMUMI SCE+@YT)!IV>=3MOO??FNV^___Y^MX(]6.N%#2$!
M1SQQQ1=GO'''/R.!#^P(L<X-.T82!I19X@ D&$+8(%"8$V>9XXTZ'T<]==57
M9[WU14,01+DX@AE$@C=F"(%!!U"H80(49GCA@>P4F&44!]Z88X+376>^>>>?
MA[YU$NP@87!A)DBD(!4R8@"YY NB8"T(:*&P(!$&CSY]]?$D5=QY4WW^4\[<
M_TS^^=>7.:83('  .50<:$$+7- !&@@# K,01AQ6,)40#"(8#R"0'53P @?X
M@6[XPV &-;A!#B[J?)U8@'0<H#E:E% YUYF#"M+B0.'-@ 0B:H'D.CC#U=GA
M!3& P7^*)9,6L8%!HQ!&*=[0JO[[S<\.;ZA::$HA"$%@:76DN!L?W% G3[!!
M1<*P0X5P4YI:_(<35MS1&RQ8$$&@KQ??H:&[+" Y%J0@&"N R5@$(8P&7.<-
M)X@0010P%KB( @$VH5\:!3FS$,A@#S90"9[B( Q1N)$4-BD-,'[GA@HLSS,M
M(,$+7'"XQ@FC(6MA@0O>4 %0!*,/$[C!!/H0##;00 4B<D$20=,+%\P@&'OH
MP TD0!!24, &)N#+(%H0@SFPDB"!'.2B7N# 7KRP%RL000AN((Q>H$ G>^!+
M,%R G!/00A0B. $;J,>J9)9S;R7X#PL&1P@;=&XG-GC#2#K1BS9, $OT"48>
M;  =6OYL0A TN$Y,.*'"QPRQ3\)H0>M$40($>&(64@F&&_AB@?1THBTHN*4=
M-I&10O4"!@C(2 @<4XI5PF"(P9@ +=B0B%JTH!8N,.>[Z)*=U' RIC?-&PD@
M@9T)>$(0(>B#">9 $4&P(:$3V-P$IF2!Q\2P @YE0!S:8 $028<0KQ1-0V(P
M@C&BCE<J& 0U=0$)%?BF+0RD10M&P89#GF14PGB#X5#@!Q1 D@1 #$8+!F$'
M.FS"!G0H$D[WADS!%A9=^IN "2@@@V",(#VS$$$O[(DD82QD% OTA IHP52P
MO& 69RT!&FD4 A*X=2;2.4E,1I&"XT3@/ZE+@0/[0@(+Z/X"%".0B0A(X0D2
MV( /^B*!RWKQ(09Q)JZT8, -"%&"8EK 1\3LA0I40(@;#.($)S5L=K6[7=64
MH ]0G$D(6$21,Y(  D,402TZ@0)A>&(%GL!C+QI)"CP*XP1HG 6$;I#-L9 V
M!*^5"1L,FKH3%.(]!8D##&K1EIB$@$ CH8$@8ED"NDS! B3 3+#BJIR"E"(H
M(L"K"VPRDC<(0@6S2$%Z",M=-:V8Q2]FEPGP69 7[D0$J'"@,"1 "A/T8J!]
M44$M.,L'NQ$%!6B< PR$0M#32@=8@SAI"R"9.A1TXJH%*410*O"=0P'+#W9(
M1 V"4=KD@"E*P7B##8(ATF L5/Z;Q0S&EJDS@UK@<08N@W&>]2S8$#0%6( (
M 1U$H ?EL&$.)>A%HF;A #Z(H@/!N$$*DB>*49Q5!/^YA0AH$ <)^!DTLYC
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M#^H;4MQ4(;ND'6*]'Y,*DN<;!";< \* M!;PI,9[ 1(@5W'JA9\*N+:HA0E
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M$#2!"CZO%P#:SG"#F@@&$+T/"G"!.(B &W@CYJJ!!YC.-T" /2 %UYS"J7
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ME"V\?3GOO?L>C 7;>N+ L'[89H$?HPPE# T/ %A '\(0L@ M)MQ T .;E.(
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M3PQ<CWOR@0.\ 4)VQ2@X0*YTW[$%C(L8RT*L25=X9Y0@C(J4!D'4PB;\1)J
MA'R:W";@!!UHB5ZX00102RT@DOX<5&,P5( ]2@@)A(Z9#$0:<H6I#(3-$)*J
M; ]/^&>6JHI8M@Z[5 ";?DKV$ )!UALMQ)W'[)[TZ. C!D,+B( ;L,$-#,L<
MJ"DD.L4<<(X'$>EF2)JY35@%.>JFC56!/"I72%J@C8BEFAO,<2JE:6JF(AJF
MDD79B1BF;NJE4NJCGJJD?NJIMDBKJBJLLFJJ?BIS%()*>5>JKL ?VA<7M8!
M^.JK>8? '(US"N>"/>-=>%M;7H]75*>^B,R&#$1H=F>>M4%X2N!_3-PLC D7
MN0&;% 0@V$!419;T\(L=A(!?&-L-U  ;O$$I= *[ $*ZF(A\QM$$;-DL1,#-
M[:@P[?[='*0E>@K@P!I@,)C 'NP&5[3 3DA *-1<0]EE*1S(B%1 *<S!!$R!
M#=S '-""'4"-T;"GTK30#N5&(0 >H'0%*^02\8Q)04R6T[0 J0!/E]3)EAQI
MRKR,UWQ40^5!"&"C#"QI9$U *:C =-B !?R?!;"$>?0!#(A""UQ@,* "!.C/
M'MB$XGQI0;Q ' 2%!#"2;(R7\R1"L5H D9HM5TQ605@ 4'&)'T  &]B #<B!
MY"@$OA1$"9A0@%EG>** 1V6BWPT$!$ %"4B +PE;<N:FXG81P]; :IF)_] /
M!%2 8D0C'W2***2 "J# 4L *(-H '92 , S"":# "[#$'/ZT 0Q4@$>- F5]
M83@Z#1NL[NX5P@B4 'C>9GMI6 M4AJ2!XG6BV[0& ]D6QB8QTFKU[D!DY/U0
M@*2%0@)DQ$58A0,@UPG$09PU!!O(:U=T7< :"%^L ,@LU1_>!@6@3=?-QL?N
M4_6VQ1R<I[D)@O-RQ6!1A!Y4'V1(0!X$P]$%PP*\#;H- DXDA +,@HY^%)BD
M#,GTA<4(A'O. <$DFP!Z4PU(R@<%@Q[HAQZ4#_[V08+>PDJ$[D"X %\ 9# X
M@&].P+"\F\-(0-#10 SXU2P<0&[LJ\I05##< .[NDX2$0"Q]:4RP23#$ )4T
MY804'"#PB-1620&J$JX6H&]VP/XFC,+-#$0@0(8P,,"V",,"K!H!^&9A^"Y-
M!2M7U &DM!,#1)EM_0<GI/'BOG$IW0+$N&Y!#(($C (MD( ;U (*U$ M>,*Q
MV8"4J$!WV($)1))'F8P!U( GU(((6$H+>)0*6.PH,(!YD1,)V,I+1!(E,P!)
MH# ML,%0S!@*6!U7T "03$!W(  M;$(5/^-ME$ '[%33\7 -U%IWU-9=L0$#
MT( -.( ^V4 (D Q"3(\;S($$@ C#6@!?H$#YBH!)J( %3&8D164M1*?D;ML<
M;"(;4, <(%\O# ]\]<$%Y\2;9*#26$ <Q( !F 0##$LPI$ *T$$-.$ 3A< *
MR$$*&/[ [*# LOE2.RD.';I0FK"! NS!*"A .SG '+A!_R:" DQ!HN+G!*R
M._$('R  #"0J7_"! C!+!1#84=9 &S@ @3F JNP4'=C  VQ2'"B '90" P0=
M* # ]>A"!<S ',   W1'0="" 0B$'P# L) " VB&"J!)!&8%APPQ ]C '$QH
M)T# #:Q?+'4" OB*!/BF!.A:#68U7D 1_T['"W3 '*3 H'!%O*Q #/!0;O0!
M RR-"M"'O]7R0- ! =Q:!W"0TMQ<C"8N' =VM705!'R*]14&_SB11G2*)X1
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M"<P.+;@ "EC*)L0G6M0"'MR!*8!%'!QR!4F B*@.0UF*'33 U<;4#(A 2*0
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MP(UF,8""H%  @)/P%%I@E%)L@*H7&[ K304#P(-*-3J0(^0 .NB80XX^&@(
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MD, %-"B. X1! CI$A0TE$-L%\P2#KRFD%BLP 0I>P@82D$!D>1.&"=HPBQ<
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M2#^,JB)O.(B1$C*'%H05!BR @03X5PBQ5&"%):B?=V 9C%D\0!@HX(,G:N4
M47!"K&*!@!_<<+J$5( 4HY@ /-WX$V%$8!9V.(CE5A ,!ZQ +"(X"!T<8($9
M<-03!X#!#"Q L3D(JB(AF 4=XB86!Y""#[\1AAT$-5R5K0D"M-C#;SK1 +H(
M<*VUJ,@(" $(XD2 %K=E+@EFT((#G"<8>_BC4M$K(*.FE[WM[8A>,-('!QR
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M%%#! 7!$D<('>$F#ZH*!#PS Q'YG\D1@.R$ .5#@!CK'#FCAACMM3=B8%EI
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MQ\^;&$#P:I 6-F$.((@0:H6;F(EE-^X&,JZ7.D$!-F$*GC!A.,FAH3NZ?^U
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MSQ#,(DP<+)QDP2:0,& S# \(XOZ)23=T! $JP=P"02TW3&"S"Q"4,HL%$YP
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M*^ &I7)DG9  <0%@<_&.B($1$($7#Z$"-[ G1U:$LT!G$_XQ?\%U$BK0.[6
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M4M&&.R20 MX9#((0KH6J )LP!7S:A2/(% 2ICT>1@CZA"[K3!RH  4C#!C$
MCYU8 R32"S=H/"<1!Q%06?C).*6 H&WP,KU  75!I5A&:W8@@IU@7@]Q JR&
M$("@ A%  KI@BBT&NK20..REB8O#)R=A Q5@ P"G&2K !WQ""BJA!R2 $&L&
M S&:D=8((14@66]T$C> NZ$8!YX3#"E0&<(P"BHQ VY0",YU$B$P0)GS$*>'
MGPPKI; !7714 Q0D 2A6"D45'_[ &@(D<  2!1?-TPFE92"$-0%U81D5L EV
MJDU.*K19"A+-65G7!*?(TT+-:!/KFSN@P"=4F1  ]!!L0 ,J-!&J=Q)T  &Y
MFQF>1P&U )#0V0<='(IN4 JB(&<WT >Y8;H0L0F%8%_NBS .4 .A2"+CT0(3
M, &TL >$55DU8 .; ,2"Z0>;8#>=*P<KH +8UQ01R1E\>1(DT!(U<Q##5Y,_
M@:.):@.R2P)^<&N&D@(:40BRRC4BH *=:"%V4@H5< *BY'@349H/00@., .(
ML1"I=0(U:0=,#!JI4P*B= -T^!!Q((AC,V!T,@<-T&^;XHFUNT,X(W?"4)"0
MG#G\=?X"G6@#/?@3<N8"H, "A!!;H]JL)W!2<W "#N!BK$("_K1C#C"S=C '
M?- [EF<H?H  \>I1C$('J3R#:K7 %:!('O&_0_H"-_P;!W$#),  K#8!G&"G
MHOD -A$!Y;EC?\HM%#!_I2N[7SL+$^"-Q-,"(G #RYP0!O$098P0%@ ?A^91
M.7N-9MER(K 8A"4#63<#%&0!(TM!=F#"-= &I'!P?**Y>CM=HK)FW9:?<8 8
M#C"I+?&HB<&;$0"A7 .^FN@ ;P$^W%=G->B"YH4 +-(\HC!XK_I3;W!($!"4
MV!- =&,[O6!DM,E]=C (G<HWP8 ",<<'7&,''B0,=7L2%/X]"F(5)$&3CD)H
M!__E$^K3E%\3#'UP/)Y0 BH0,OU;%Z>'2NH$$5=6"JIR&P] 1S;0$32  JII
M7FU@ NPE##% H9&,1_&X7!2TOS_AO]T[>7#QOU\'%PRP!USZU";A F_0"P;P
M%I)U&VV:QWP3-#!@=PA1"N-G+F5U$E[F$X:1 L@:.:(PHB=A& F&'0VA<Q#!
M"86@9?0&(+H#(:7 !RQ2 FU0"M8JBQM]$K"\"?;U@E1Q> !B +EJJ<& =1-A
M [WC)\T:#!J:%[#LJD!A6S]C.PA\C  2INXQ5#NFG2=! Q2JV7GE!EHF-R[E
M'AW0R!#"=V163GNP3C_!!^<=%/Z*"" GX!5Z0X>+";ES@ HFP;"ZJB>H[#,N
M6Y.U=Q(HX"VH)7A.AV4O,]O8!P/]1F&'1 N$9<$)$=X^40)L$%S"T#3(XQ,*
M@!J.C0"&-B^+!QD*ND.=, O%)HR#>C<\)*1%VTK8G*@0T#MLX%S0!1@H8 -T
MZ =;!PB$!0-F:6F^0Z G,0<48QDS$&T$R=FQ9>0GL>21TPL(( IEN-2]8#ZF
MP0#?"25=UVW>20,28 =L@)HV0*$H&@=LP "=\--E\0"43&LM0$%2@\H*0!$>
M!(]UD1*"69$SL !T10 M, <J%WH0,($[>A E4)$TP !N( PEA78O0Y!QT 9M
M& S11_X'218,*^  ;C '(Q&W" ! C([H<4!AM!.$A/  <> &9X[)=!!]1Y8"
M#L &BWS7*H"\/L%3G@"$" $*07@O;O &%::)*F4")>!IO5 #="@* %!I(RD,
MG+Y/'[I##- 3<>#E,]"C#C ?EH'ME-<&V#IY[A,"$^O,5AL" MO%)F@',,
M?  ,$( "K. )#M &U0H?:;PIZDX8W+*3XVP'*M !#V$' '!E$  ?+1 "_=X!
MMX \!. 5%:"I 81C\Y+>2OD &<@ JJT <T '!+,2"Z$"L54(". "E7X^@GH2
M)G\08P4V>($0?L  ,3 '[(8:*)"YP1"&0-&8O4 "+(!V'?YAZD(1 P] "!,9
M&/CRNS6@D"<E6 '@ BC@],L#4VXP [ <#"H@\A#(,L.'HQ)0=:FU!TSO]/V7
M$(_(0 _Q42L @0!T]LUE70>! BF09?'="01PUW4<![\N"J. L+,0 3-0!Q&
M4#Y1"@/ :G8P ,;A!MKL!A7@$*6V%VE'?1*@ F]0 1Y$6L)0" PP Y'.D2BE
M!^-1 3L]G1-@3XYQ #V!$-B*TP=O Q:@2+4P 360[NO^$P[P4Q/)!G'  'X
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MH@8I @5U@Y&"+Q<=0@N<!0,HT@D("*,%F9=-+2!0BSU,X,@,R*((GBB"O72
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M!!(%"1"&6D@Z&YB!9?L,0L@W=SF^%"D$"E"!(+$ M%@V!J2C)Z(P.2 G"'F
M#4DO:OY20_Q0*>OH$@5@)GL2"$_8(_.2@S>( 0?(H3GHEED !>VK@)=XNF"(
M QB 0H9XB%K(@S8( >(H 8["N=5X SDJD0=@H%YPP;UX@Q9(*8&  1SKP%'0
M/M4@J5*H S:  -9 @3H0B!68)'I3 128@S>H 040!CI8+QA,$4_(NA5X@V
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MK;K(KY CUI@#K7*7$""I@4"!/? #@.PP&[@VF9B%&D2E%E  0FF4R&I0UZ,
M-J#,09 -BMR+. J&QA0("]B$.6"WM)  CWR77D@ZB#B 4G"DIU != (%!Z"(
M04@^!? /03" 4A &!^BD$/BRO#N)*>T(!QC$[GP# K!-=1,AMNH%0A  5Z$W
M#J&WROZ+@SWH@ I]HA4P% GH@P7KB'=T,8$@@=EC#5) @%+P@PF #$44+61!
MOU'$H;1,U-)92Y@[ .ZJ .E:@9<;TBTTK#[(NH*A 9K2 P.CJ0D@J:9+D1!
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ML-U"!A !$5@ J)B#&ZJ O)B%EDV\7N $!V@!%I@ FG B4I" -Q,!QANT@86
MEQ##$?YZN0JXI0[ #4Y KCFH@-DIGNH:!8\=%X"!)';*#(2 CJ0]"FTQB#@N
M"$$(.1L WNJ8G6SCHRZ!'EWXXQE4,LR-9- QT#C9$.,1$U2 'DHV)(0:!8NC
MN..9P>>HA0W)B041!.^H!6T1!E18#CNY$DKNB/LH!#\(DDX0"<80AF<1!O&+
M956NCCXP#P<QC%$@Y6.#A#[P2(^PGQGT Z_H!4BFA<^(4E"H %UPYN9YCHH
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MX+H)B"(1 AMCO51ED+Q8Q 5Q8!$;D_8O"_ !)WWXD)22!C<'#&00 AM("/C
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M8KIS6 '77"!B$@3BQD;EJCM'X8<6%((-;_###'9[D0E8!P8W&&,$9N&8$*_
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MN, )!%//L$0,Z$T'S4*Q6 0I",,*Q(])@)0=J$ O7$AQX(8>S%5/:0;5 =Q
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M)@P" N@- P .C+21'Z1(*71""&B7'0R '8B""XQ>:+B.B@W" 9#.&[2!"L%
MPM$" 8S")F0>YQE 7B# #) .&US2"X3 *(0,PBC 1 Y""!(" ^S&F(W"'@R
MZS@ )'00&XS"'+1,#%0 R$S ,[X/&]B4+C3, CQ7,.A!UWD"]MB4E) "=/#!
MX&WC#8P"E-1"Y$A)*4"'"P 4#/Z00/4I "=PC@N4@N7Q!P+LV@@L"1]$P"9X
M@@4,1PN8$JBPS"8D @., FM,D#P1A,#,  D4S@-\1*=X6!"E3QQT@@HPP VM
M "D4CXM@%E^@P F,PB# EB!(0/KLP2BTP0$(1'&ZB##D32_4P!GU2##40 B
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M6+0!"L =X6S"'.C(F+8$&SA+F[H "[!9"LC'#8@@O<["#+C@#(R",-0 F[4
M"N1=+T 5"?B3':! 2?RHN+H0+1"*1 J&#43&+/ D"QB$,+"!"<CJK"(,#; $
M+=3 O\B&"92 "IELR9Y+)_@&QT%F"QA$RS;>N>R!I[)!"9R AC8>#-C=:,P
M#-@ "9PL7_3!"9A A>3L0'R)6 C'OQE7)]  (9#"YGC"YA3C"5PC+<1FB.+$
M?/7!<-1"#-A=WF&CH0F"95#6<&Q""K  (>2!WBR("O8$'@Z"6_A!X;T!S]IM
M/ D;TZ@ "<! R?C!5+RMF^S!N?X$P@F0 B'XTR; @%;T @V00+!D1B?H31O&
M  D\7LEX[?FP@5+PQ;4>! RD %@X5QTP!EC0PI8)U[D,1+P4APW8G5N A!MD
M"0E\AG62  ID3+SP12*<0+B>B*E*TZRM!4OD@:?: #"UP)@5!H^I !^XK>L
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M$(]S.:-S.JOS.K-S.[OS.\-S/,OS/--S/=OS/?\P!UYAV<U"%(-&#2S-RMC
MK3*-&]S -:)(9W4",D$?.(.R2U$F$]K &^!69G"")V;C)J0&(:3R-R]*0VKC
MU-"!E/2"'_!!'PA"'^Q!6 R"E&Q"% =:9'2"B\R"0-!"O8I%_@D#1P^$(-B
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MW>,]HU? V%EI,"! #'1+UVGGDOZ\'4@ 22U8V*/=4 4,K!R]D%M@A_BD"%]
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MG4RHEQ%2V,/08-X +Q@WLHO((3L(/D@/]ZA"@!1!(& CD1;^,\%;4$HB 06
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MQ0%9"\8);B C&CS 1W: 0' *,<11%:TC-7'!!/ZS J;%(5W]65(1\9,3A1R
M$Q(:RR8(\)1@1(\T"#'!6I;X$Q<TAVP'F04*,,+%,)9" ?ZB.A=#$C(+$92@
M+Q9 50QAR(99X.0@-NC%I7($R"29#B$=((3+DF2KKP4# ?";0!]JP0"6".,!
MFP!=:F@G&8>0X$&#>-/JOE(#3Z#*#UKB)$OB8+M-)$*5O9C" V?%%ELE@B$T
M&!)7AJ2;YOT2F,$4YC")>9@\.& %+D!B;AJ"@@>0PF#!\,0$6L#&7I ,!C.
M <I.X"U(:"E<,:"!!9B6D!34+!A]& @)%O"38(QB B%H00A"(!)12* ")'#
M"QR2)?G<IR&]($$*9C"#!_AA#KM\PY 2\0 7N* "MD)(&QR0 A4XX"=\D$ ,
M9J""C;C  BYHP0-(P[&"2L .O?Z@0#U+48$5K, "+%DA@ 14PAA*3H0<A>DL
M0E "%Z#  HAL2 LDP (4.( 09^&0CW3! !#%)H(B<2):6.  $E2@ H[:Q $D
M( &!(.<-#"!!"!P OSDX  4K<$"9$$*"M0RB ")Q 9)@50$*0. $B*P#6M4Z
M!>F<Q9]_/8'.>H$ #<+0?C!@T1LB -'L] $C#ID#!$#J@@?"9)&AH=Q!)@ H
MO+Z !"?@"!TF (,.I,@/;SK("23PF<M"A@UTVB0AM%2#&/3" B: @02\]1 (
ML&2A=M(5#"KP@@BLK3\/&$4T:Z,E@9[ !1#P!"T4<+-B7A>[V=7N=B,C"D$$
MD".^#/X&,#K1"Y6DQ@_)4J,@$@3 6:"F%[K9A$RL!95%^:@6@P"$ (,!"3X8
M13J;&(0O4;"668@V(<(@A%%F@8H CNHEM."#>Z,R"T#XX7$1$\EGKN0)IE"%
M$(D828)J45ZT $(0P7GO>1ZHFUD@LA0.T; T X@50 0'*J/H@R!0DQKQDH(C
MK- %55[R8H2,8A  1LLH1"$*)ON(.)%+B.'\(%XU&D08119)+9@L"OX:K@]6
MWM7YH$(+&/O(S =)\Q<G#.&$D((/<CR(@\^CYI>4HA>T<$D@DHJ04K09+0*T
M4/$BXPE;"$,W\07*2PC!!W/Y679W]I&'K4M>\[Y$T77Q _YJ8LQ=3W\:U*$.
M)HZ;EP='D?HQO;C*.WL&+%1'YM6B]J2L@_5'H6HWUK36]:YYW>M=DSK74 EV
M5&+]ZF$36S'#-K944!WL8Q]FV=#.3*Z;C6S(.%M8RK[V5HH]ZL<\6]B^%O>X
MR5UN7^,8W.8V3+K5W6YWOQO>\9:W,-F=O'K/F];WQO>^^=UO?_\;X $OLYP%
M7G"#'QSA"<]V@H-CMJ,E6!!"W1 'J>*A%/#WM683&(M@ #\9R0C'@GC<:Q,L
M;'1_W-KAJ?99C,T1/O"M(<$AA0H:/I6: _N+-#^+"_BF\7 ?9!-9-#FSD[26
MXOG\LL(H@5$T>9"K26?E+2"XPOZI7G6K7]UXS,2Q ZR[7JD0I>N&Z8111+"6
M9R,E/-N- X50[8D.4884;V\*?XFNV+0?1@5L30R&OU+.0J@2,1%H-=8)7WC#
M'SXA?7C!#!S5"S]X0@8P8(D088 CG$$@!J3P!"<06HL^=R(&,$CJ+21PR6!P
M8A-[4,$H2.&"&W D*28\K!U:P(9;'(00+Y !:?(  1A\AA2#,4O\-M$'%=B!
MB+HW5R%T+T<_;*47>^#(*,S2"\JY9Q"DF(/_KA\501Q_8$#7_58\00&'@&(&
M+S"+@!LB?6$8K%+B<4&A*A!$"A&B$W-0@:X.TH<6T( EP(8$^B A-J%*&*PF
M%*0F6O[@#?1 !0@P4_*O!6;AE%9M$&I!%$) !##,!20@#CBB#^;O)6KA!EH
M;)!#WQ!/!5>0!<7-(=C@:^R@? I+!?C@!29 &/:@?BQ/!QG/#11 !0#F12"!
M 00A$21 %/+DU,8F 1@$F?8@! B#!BB$!#0(!E*@$&Q@239! A*!#QA@%/C
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MP@G"E.) "B^$X+. D,T@ T40*,F&NQ6\8!%1%HU<80H$SF+!"BU\2,L$+\P
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M+A'X818.D!8*YD * ('"*Q$@4@M( H'\5.0-6XJ)58/A!_Z-H"#)_PI&&V!
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M8X 5&JA@)Y'1CZ?1-<' !C*R&2(0@;,P TXR&>J3*H;S$?)#$9"@& I0"(6
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M95D!?- &VQ4;Z-<&!) '@QD2.D,@CSE >*@"*> '+J!A<K*@"S,'-@!(?F
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M*] GL^ ".3(0H.Z$;3X+*G$3@/XP+W9PH6->\IY1"(0FBN#5"PC<"<+0"25
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MPA.B0$ B2E(($1B$%KT0A9<J2(.56(@-:>*#!0Z"@CD(@P$;NHL8#9*"^9"
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M6<I65K(G"!_7@M$)CB%D LL9S@2XN$#=^>@$<I ?H&)ED#A\!05?F0-.@^$
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M UX&<F0'O"\$$\#0 ^:PAP8X!P6+(K5S.I [;[6!#Q+XH T",+E)58 /-G@
M+30X SZHP #T&T&D;8  .VBV8ZU;R0)F,8<A)F>((N"H<3G'8QN8ERD(8%[1
M_& #3%^U:Z)PTK"\<TRE&,19P_[1;0)LP <1W)%@ZZ[ 6TTPA9*X8-,G4$$?
M,I0D!B#1 <OA@]Y&$"P&\&$/)2AA'M18FN1,@ ]L<$!4\L('%T2I)'[@7HS9
MP <8($ 0M)! #8C[KC<P )LJ0$$?7" "891" 9C4X0E4'H) 5<!5!B%$ !@@
M@@!4,7 '2  ! ##$J=E:) RH00)JE!T)\,$-#CA-I=6T@E".PN1[0 $#1C&#
MD$B-S5\'>]C%CN91E!.TLY#E0?P0!P>12#3+\4.VDE3.^S+HI$N]#G*HQB2#
M=&(Y!2E%#5Q01H0(@@9YH-HL5$ '82(GIXQO@>,%<1K 8[7N+UOK"VY I5D(
MA!-^H/X24]I0 U%XP@ZTD"4M?,0<+-[7$Q8:Q%('$9J[O& *&^H#Z.HW>D^,
M0E*U<(.C^4 H&<B UH2@('HH^-$5"*(%A-?/ F5)"%HSR.W"$.8< E6+X7<X
M*J7(+?*U-X,YU,(.HD#%&_''5!C0X#S8=\$; L47\!N$%#:XP2P*H97KN$ K
MPYD#1K*#^ N47N #JSJ( 90_IJ(?^YL")@F44*@#[\@#.[BO6OB_WF@!MSL(
M0FB_,MDLT#J(63B5CJ$!.:"%/) 7*1J[%G3!%X3!&(03MCB)8*!!&32*V,+!
M'>3!'O3!'P1"F?"Z'ZL2-4&(5#)"<SG"&D1")E0(OB@(G?Y1$REL0B>LP2*\
M0B0L*BV<B2K\,2ZTPB040Y/ +3'T0C D0BQ,I3.\PC TB>B!0BQ,0C9L0SE4
MPC5<PB>T0R*$PR#TPS\$Q$ 4Q$$DQ$(TQ$-$Q$040D5\02]DQ$>$Q$B4Q$FD
MQ$JTQ$O$Q$P,1$<<#C32Q$\$Q5 4Q5'LP<00+%)$Q514Q55D13DQ0$*8EI4
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MS"T5W-*)"$J^04HP;\1@Y:5TG0"!!15(T :H3L**93 J[ 'LK,$$TH -<:%
M+ 43/!M,&RU86228T%[)QR#01ALLNK#*:A>SRGX;S!XJU+5D&R2(8 =<@Y0@
M@@U#>OZ" @DKE/)6+S2(4,(F=-4" PDD% (7'0WC^]:_)*C :S"AI& QQA17
M<&4P-$10 0045!"",#,X4"P$; 0CB@,56#!!!Z.X"[*R4.I(R+9-]N(&GW$E
M D,,,;102"<NS ##TN7>0$$;.I+B,KMOU7)"!0/#^D;0X49;Z5N;3-PDN,&0
M\*P=A 3#20C)LN&"N4EN4D<PO5A@\[EYKWMSU6^]T0 ?YL8QP@B!S\N&O7G
M)8B]5+\EQP@D!-YF#"64&TPG?MBE @EPB5)!G.;F+$P?* 2S K*Q%CF')\"V
M*WK<;\W1B;IX@<VWV6H+$^NE,=#P+NR%B7* '6J*PH#C@O[5XD MJM;E@"C!
MV #W7A/,L><F"CP\6 EC,]F"RT56\$8MLP!R0."S:,V7CBU,$7R!>W2N%PT5
M>%*( L_B#P@H(GA;"@/F((H83$!-)T"!*/:@@.@=R7^BL ,"HN<&"7!B$PZ@
MVRP<(, 92$ 8M B@*#@8ITXX($YURJ ?]A2,$\R %K381 (@00H%D*)\+K"
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M;A9O\$,)3)"P4L3!#R1 6#!*\09"E& 6PKA!"5#PL#ALSP^*>Z@)W#"D.(2
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MBXUD+PQ"6*$ OI3":3$2D.)-'!058K"  [ !%_7:$Q. VY'0'(B8RTR 2,*
M"0R"'#A ,S65!7TMJU'3]P+66]2 Z1P?(,@654I ",0 #*B  B3,"Y" (-B
M!)2/ Q31"BS0"%L="B3U (CD6^RL(-S IJU0BL$%!5@ D[(*&"'.;1:4%+I!
MK?X.'_Y  !\HD-K,  0( NV.6054BQO,3RDH !L00L7%!0G @""P@0+0P2PD
M0 OX 0VH52D@0 L 0F+WPBC4U5O8P!&Z <L% RTLP JGU$<#0@<4DATX@'(Q
M0(;!A0FX0&#K=1 ; &[!@ MHSO&P@7NZC T4@ W(Z0P "@Q0 !_00$"_RR8
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MY@$%B(#YW>3K:MAKS\  E(LO ?["#$1 +X@8\UK2#%5C"EXB0T:9H=&%(+B
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M[2;$ ";E#8RF#Y2B LP( 2 !*=J"#P:/(FZK K[HOP)$ B8%^-)K L"'!/R
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MH1/@-?[\AB@%M$\%2&LB8B!I0$$"3(.2*'$&+M;GB"T$=-83G%8$"H$$H(E
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M(FP'NX:H^/;4%LN/[ SB7V'"@@%R;WZ#%&J! F;@70&X_-C *B<$$'3+D_;
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M('^08AU"?&X\)IC9BAXPFE$@P X# 00!P%.XC)1B 0N1@!T@J"<+N( 4A'!
M(811B!"$ &MVL ,?*C"[N2E@#J2PPP.A*((I!@,&)/ $(!#P.,RI<8T\LH-%
MW@ (%)!@; 5A PI0D(B(P#$%<V1)'CK0FBLBI!0.:$HO%- +/TP (81@'T%(
M,0<_D  %N^E#"E P,S^0"V V$$8I7% "&&!$%)'K!!UZH2X7R(8@=CC!"?@0
M#%&$8 )3:,@F N U@K0 >W8 @!T(0@@ V" 8*A! U0BB@ERZ  "$44$!7P"
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M#EC(!/+8FEEX3)<.6X&!6"*(%5R)$#% " 0*00L66.!IMANDC=@(V]B2: *
M,P ,.O&&_U6)!BF@!43E<H#;YA93>Z@K;_9 @2J5@@&A<),W62<3TD6U2IL8
M@ TZX4TH0J 4LY@ )SRA6YKV0F:CL $+![&Z8!17&': @"#:$@PW6, 3FX#
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MMOSN]_Z"!B*"0 3#A<* 0-T*8R=!/'"\298 :/8 2)X@=Y ,J$ (= 6>/B!
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M8#,7X3IBT6A,!A%[  "3%0R#P/X&M-!+=T 0@   "5),@P [QM$+HI!D-0
M^_8B=0AB-A  GT 0+B  E_%A\,(2-#  R<0N(0 5=F  #G!]P0!GCL@3"_0=
MBR00>^ UWI4E,;$0=L _2J4"H^  ,O ",! #:!,,!<)B"O10Z442[K45+8$
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M;=V^W=O.C=S4S=NW/=O*C=VT[=S'K=M5T-W-7=NK?=W??=O9O0240!]CD-O
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M3'A%AE)*F[R(O$./5?&I[DA!*HBW6?(!.$-+M6P6.D'%"GF+-ER334@ !E"
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MK=Q.!54(@R; !!1?*$7@%R;WC6;M[M;)A/1\\9OH.0B!BCD  #_8B>=$1:=
M\Z$:@DF8;848@[K!A4K8#HC)A+)L[EUHA3!PWL^Q!%48Y37 !#5 )THXO0X9
M@V#AA4H(CY18A/".'C$H;Q>KA+L9@C78='.YA N?.U0/:SVC@1NP 5=_=5B/
M]1MP 00HZ[)F  +MA+4FQTW. DE A"420"R0!.;3@E\'C"@X!4? @!QX!%S
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M]M81<$%L-400ZU9'!+LNC=H1N^@.NJX/ZT9U;[OT8A7<E.G&-(02R3TH#"<
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M^A$\1H3N3D((0^#%@AN*RIN#GM U.;3.@[&)!*B% &Q82%CPYLG88L$6&/@
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M(KA2303B4 "/""X!MXI!:RX!N(H9(]B4&##"+_ K* )-J7K%9.H60W#" 2#
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HJ5I5JUX5JUG5ZE:YVE6O?A6L817K6,E:5K.>%:UI5>M:V5K+@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>sign-half.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sign-half.jpg
M_]C_X0.V17AI9@  34T *@    @ "0$.  (    8    >@$2  ,    !  $
M  $:  4    !    D@$;  4    !    F@$H  ,    !  (   $Q  (    ?
M    H@$R  (    4    P0$[  (    "(    (=I  0    !    V    012
M15-44DE#5$5$7TY/5D%25$E37TU$1   &W=    G$  ;=T   "<0061O8F4@
M4&AO=&]S:&]P(#(S+C @*%=I;F1O=W,I #(P,C(Z,#$Z,C<@,34Z,S@Z,3@
M      .@ 0 #     ?__  "@ @ $     0   !&@ P $     0   !,
M    !@$#  ,    !  8   $:  4    !   !4@$;  4    !   !6@$H  ,
M   !  (   (!  0    !   !8@("  0    !   "3         !(     0
M $@    !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(  @
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M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0&:            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      !  M     $  @"T     0 ".$))300F       .
M         #^    X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -'    !@
M        $P   !$    ) ', :0!G &X +0!F '4 ; !L     0
M               !               1    $P                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    $P    !29VAT;&]N9P   !$
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3004       $     CA"24T$#      ":     $    '    "    !@
M  #    "3  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ "  ' P$B  (1 0,1 ?_=  0  ?_$ 3\   $% 0$! 0$!          ,
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M "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0
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M!]<  P "  H !P I86-S<                                     $
M /;6  $     TRUB24-#G&TTI:VD1?84;9BP40P2;0
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M          IE8VE21T(@=C(           H 90!C &D 4@!' $( ( !V #(
M    "F5C:5)'0B!V,@
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M= =TEG4F=;9V1W;8=VEW_'B.>2%YM7I(>MU[<GP'?)U],WW*?F%^^7^1@"J
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M^'[Y;/I;^TK\.OTJ_AO_#?__6%E:(        *9X  !1_@    !865H@
M    +90  )H@   175A96B         BR0  $^(  ,'0_^X (4%D;V)E &1
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G>#SAE8U8C8>:E-GEKB<?T7+?4M%PXL119VW1%NM(EY&FJ<_/H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>sign-full.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sign-full.jpg
M_]C_X0.^17AI9@  34T *@    @ "0$.  (    8    >@$2  ,    !  $
M  $:  4    !    D@$;  4    !    F@$H  ,    !  (   $Q  (    ?
M    H@$R  (    4    P0$[  (    "(    (=I  0    !    V    012
M15-44DE#5$5$7TY/5D%25$E37TU$1   &W=    G$  ;=T   "<0061O8F4@
M4&AO=&]S:&]P(#(S+C @*%=I;F1O=W,I #(P,C(Z,#$Z,C<@,34Z,S<Z,S<
M      .@ 0 #     ?__  "@ @ $     0   !&@ P $     0   !(
M    !@$#  ,    !  8   $:  4    !   !4@$;  4    !   !6@$H  ,
M   !  (   (!  0    !   !8@("  0    !   "5         !(     0
M $@    !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(  <
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M .K6KZ>'_*?SG^%Q?]X__]G_[0O,4&AO=&]S:&]P(#,N,  X0DE-! 0
M #<< 5H  QLE1QP"   "   < G@ %U)%4U1224-4141?3D]605)425-?341$
M' )0  $@' (%  $@ #A"24T$)0      $,?F9;=5'9;+'O,66(CORZ<X0DE-
M!#H      /$    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    $@!0 '( ;P!O &8 +0!% &D ;@!S '0 90!L
M &P =0!N &<       IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ "T     0 " +0    !  (X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      WT
M   &               2    $0   "0 ,@ P "T 1@!? $, ;P!M '  90!N
M ', 80!T &D ;P!N %\ 4 !D &8 4 !R &\ ;P!F "  10!. "T ,0 R #
M+0 R #0    !                          $              !$    2
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<    2
M     %)G:'1L;VYG    $0    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    $@    !29VAT;&]N9P
M !$    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M# P,# P,# P,# P,# S_P  1"  '  <# 2(  A$! Q$!_]T !  !_\0!/P
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1$)% D   &UN=')21T(@6%E:( ?7  ,  @ *  < *6%C<W
M                       !  #VU@ !     -,M8DE#0YQM-*6MI$7V%&V8
ML%$,$FT                                         "6-P<G0   #P
M    BF1E<V,   %\    >'=T<'0   'T    %')44D,   ((   %A&=44D,
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M &4 8P!I %( 1P!" "  =@ R      IE8VE21T(@=C(
M
M6%E:(        /;6  $     TRUC=7)V         KP    * !4 'P J #0
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M4_ [\23R#?+W\^'TS/6X]J3WD?A^^6SZ6_M*_#K]*OX;_PW__UA96B
M  "F>   4?X     6%E:(        "V4  ":(   $5U865H@        (LD
M !/B  #!T/_N "%!9&]B90!D0     $# ! # @,&                _]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P@ 1
M"  2 !$# 1$  A$! Q$!_\0 A  ! 0$                 "@ ( 0 # 0
M                !P@&$  !! ,! 0             '!08("0 "!" #$0 "
M P$!  $%           $!@,%!P(!"  @$1,4$@ " 00" @,!           !
M @,1$@0%(08B$P @,2/_V@ , P$! A$#$0   $S/-69+VF:2-+#X,96D^X(8
M^,;5 E:P00?_V@ ( 0(  04 $0;W(FA)CQS-Q R/Q1;R$DE@O,[A:7C_V@ (
M 0,  04 (9(T9VS*,/V65;"ZQ5A54!^.W'U.#Q__V@ ( 0$  04 M$M;XX)=
M< KUE\\FK+OZY3F8R9695Q*MXR=\?__:  @! @(&/P#+VVTSI,;K\,GKK&![
M99  S*A8%45 REG*M4D*JGR*YG8.I[/(GCQ(S)-#D6%S$HJ\D<B)&O\ -069
M&3E0Q#W*$?YD]1['FQXA][2P32&V)@X6Z-W/","I96<A6#%:AE ;<ZC4;C'V
M&VS\:2!%QY%E1%E0H\DDB%D6Q6)5:EW:T6VW,OT__]H " $# @8_ ,?7X.*D
M^WD2^CDV1I4@%@I!8L0:*"O N)_ V-J-_@PQ/D.$CDBN"WDT5'1V<^9\0P;A
MJ K0EE^0]ATV*^0/4(Y8TY<%2;75?U@0:$*"P(K0@DKK=AL-=-B:_$G25FE0
MHS&-@ZHB-1C<0 6I:JU-;K5;Z?_:  @! 0$&/P!:S'.D^FT'<&NCX:NQV8DZ
M)-2%:8TROK[*_&J"0K:[L[PVM(X& @*"]XABZ(EGYY]@C(5<.^2^>(R@?IET
M"KY^]YC$R 4D#A:D<!+ZRS++)>-UC[&T6,\8@U@,?YR.9W%Q*-[#+(2-]4/R
MAP51N=/CD3:I,T1$68.[1RK"5\JQ[IF>@H8?R>Q5AX%AP(2*#Q,8-,/S-Y')
M%++V/E&GZ?ECSB&98SH*GI=W<:<LVB;=L%BD7H++1J:RJL4%6PV<E]:5<<1)
1OD' 00?[9/9O9_YQR/L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>comp_0023.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0023.gif
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M]_3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
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M=FU@ :'0F??7 *!G"FZ  :'P='W7E6;P "Q D2*Q >?IAZR9!F:@!@Q@!HH
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M@! =D 9<X':(-YY:T 5=0 9(:'-=,'ZF0 %6^ 92&94NX 87@ @[VHL\ZJ-
MNC*A4 +P)Q.=T)H200H14',+R*9N< (2P &D< D>&0I:X/ZCHO %)AIUH1"R
M<\<(CGD"@&J0+A";U+BC9G<"&, %:D !=^@%92@1]8D0$S (93@!BV ($W "
M9J"*@FIS3@=ZR;J/7("N>*H%HXH"<C<&$.JF7XIU(K %1QNC6F!_FJ"HE4F9
M*:!W91@!BX !*""P8S!X76"B9A !8 "N:!"-?.%W5A<*#: (H@ !H5 &'FF
ME#D!P1B;-PD!C#!W%!"Y*D " 4ET;N  I+ "/&B5VXF3H\H%'L!UB#<&FC"N
M"+&N*8NC"&&)BL"N;CL&\/H&4_B@-\D!$/A^9S ($\J)G<"MM6>%-@<&)FH*
M%F"%=5 !IJ  8OEW$VL*4#N&)O[TGFQH? C! ;9I"F#PI2: > J@".^9?H/
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MQ.'"H DV2" 4@F! (2Y! @0\1CL4'*)&+J&!RLUJ 5WLP@$V<AY]/6@C8]"
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M\!K.R/X7^5  #5$$3CJ#=AD$"Q"M"JBS#;";!)B+1> DW"D(,ZB9H8@1::H
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MVD\/2/[1MV"J;,L B^N"TM,"$&B!N3.<$PB!D !(,-B4"; ;R<B?$K  #YB
M+'.3#&B:+@C&$LBE$ B9EPL[4LN*#=@ #?B YJ" GPF\MD Y-ID*"?@<J-2$
M#  !$^B""2"$ZQ !4JC2'?& *B6!>,I4H1 ]#[B C0B2 D4O-!#/6RN(#GBR
MH0 !NZDY"9" 0!$*#="0-@C"$O@(4F73\5"$"[".^B0%$3"^%C A%="8E\O5
M#=&"RAF..DN9E^* BEB!LMB.3C&#IP". &&!CN0VR4&@4G53-\$ #AB^NZ@
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MV,6 CUBE#>" /[V$\=0H8VF!CG2 /RT!H/B (-@ 'RZ)$JB IK$R[?@ #;B
MGR$#H\H OW@#M9  .MV !T HMG4N\!L -7"U1@P7X9@;)(-430B%#D@/,+"
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M[05PM0&>' Q!D  ,40!P20"-R?Z&*:2CG70,!K1!$A%@^9F>/!+$)5)E!H3
M!41$"R17RX  !J#/('A "V" _NW%XVB !]@$(6! !_ *07C!!&R "DR  ^U=
M64* "W@!!D3 8)3 97% 1'P0^44+"Y&%!#S =#4$XGB !D!(D7D ! !756Y
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M($@MD2A"!JB$(F" 2C#C!ES ^(X :38$(F* .-*,68;1,98CJC2P.-H$W7"
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M%S@PI_F-"9! T##C!,2$"TA=!61 281""2C="5B$"*S !T2 ID ,YUA$;(2
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M0R%"EW&'[RQ"%[S5Y7C!(51 ])K!H8Z>&+6&+"M7G5@$(W_-346 37S!-(I
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MFM!""Q"ALL,@PCHWN81ONM.%$H !>X-  0H(01"OE" ,)AO0&Q1""IN5CX=
MP5Y5%($6[/V0*F\CHK=ZZ! >&E&)34SB$WL%K#:,X0$QA/[B%;&812UND8M=
M]"(2:P/&,%IEB#Y,C@I6H)(BFG&-3FQC$W_HM8,Q\8UB5.(1OS@^4AAJ?*&0
M&<8T\<?R^3$JFL#C]P1IE3,D,H^-=.0C(5F5AY@!!&-D8W/F:)2.X/&'H9!
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MX!*($!0F+) P@ERB :%X0Z0N40 7(((++TD# =" " \<Q 'N:X B"(4(472
M+@#SX0-*(X$-(,(-"5A$H-*P"!)\Y@*0N,0&P#,!#2#B#0G@B042F@8.*2MV
M$"#%Z_Y"<08,I/0@X%O$&PIQ@BW@M#M;J)U'"($&$@Q($UM @;D(P@84D!0.
M%/B 9/*RB!:< '\:/%%>W,6%$Z#0( 01Q'ACA%9$J, +.B3!<D+1A1,,J!"#
M6 ,)S'6)$'3N/%U @02_JD5I>:$0H3#9)A 1AI>8X2<BR6!*4G,91' ($10X
MY5M@^8!%J$ B$XBA)^/4@"Y4.)-?V01C8[@("&SEF1T*#1NX0P&%'*ADFKB$
M("AD%,HEI:5!P=\%!J&%NR;(%!C@ D^TP*'$_J4B'0 /,%N5MQ-XP; AS$S]
M5N 6[3'+ "<8@P? $@H-M( -&Y"("Q( AC$L #P>6,$;;/Y5D FX(0P6"$4;
M)L !-[QA6HAX@.$FD#@-3& ,75# T+JC@16P@0-(T<((WD(!@%* :0SX -TL
ML 5++X(4&U!!&X34J@-T80P,(,,B/C"!@-KU#1I@3X2W6 @14&!-6;+ "3SU
M%L.P:P1?6,PE(G#4*@^""ZPZ&!F&LY4+"$(%05 3(?8X@9L@8M@2L")!-O
M#6Q  =U21 0&9=G0G,$P>#G/!!2!"0]X0 MF-4JW3HE,4U0@814@A FX<"/%
MI H%*@@H!OQ"B@NLP10;N)<:$J.("6RB I?@C I>V((8GN @6Z5*'<1"$ ?T
M)#2+4  IML X%[!' E]XR$VX)OXR",1(!/=J5@B@95A2= !V&S#70UBWV)=S
MX2 02%,)J%-%4Y0A4AAP QOH=0D%A"(,/\E2)<T0NJ!H82N8!O85W9"7%81
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M&F!HW,J3;B(,Q$X#WD">@")&NJ"YNF XQJ"2K*8[TL!W!OX0BPBA109$$5I
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MO@ZE/!1 (2Y!-=S@-4C#%/JU2A8@U)(R=%@/6LI0!68)8TZ@6DP& JY'B;2
M.F+35_&M-MA  2R@ B:  G2"FN)#8GUE(GJS,#TSYKH#(C@'1*NL(MXL*<Q@
M+2)@!%QD [Q.9.+B(<8K4Q_"$/X:  5,( 4D8 MZK 60 AYUK#; ; *@0A$U
MH74^8#"7B0:#!<Q.@$K8X@)2H#[?XP*@SYW:12R;BZS.M4IH PU.X 0:X W2
MEBC&8@6!0JBJ9+TPJCKFP^3:1&;,P&&\AE&^" +FYPS@3218E3+QE3F-DY&
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MP (%&*<%$N<B#^!>\&1IAK7*CA@$SF8,)*"Y0*/*.N)![D4" @H-W Y6*RY
M#L95=:A=)H4M9LD-:*,-AL,%6G(@S,-_F@M3":M*&FLBPR0!()03&2L4!J$!
M8D2*]0*'@J<Z.*1%CO02.H#MEO,$\N:93J(B8<(P!)>X_/[%%#3 "T*!#1HB
M#2!$XRHVK0*)3S+  A"!$!3@'&]7$13P13=1"[1@!1#D$@8M%/HM+1; #12A
M JBD*%$L* )*6HXK<5P-$MK@$!%A $S ;5Z'%+1 FPK" T)!QS0!$0@@-TGA
M61R+U 3J+$+!;F^X?""% U356020(.SQ#=H E- @;T)!<C3@ TH%,R8 ABF@
M(_Q/9A1AW3! !29V0-)@.!9A*BU@2-A  C2 !38@3M9- T" C\;  =@ #L2N
M#4*G!=S8%)QM RH@:DT <DXT*KR@6YR%:[@T)#(@F\VJ!4Y4 W+#_F#" C0Z
MACX 3$8@<F*"#<*@/*?"!0(  /X:,RKZ^##:120(P0420W!9;T]"Z! + 1$8
M@ V IZ\$R8^>:P+ XVHK#J<9)Q3\V&D58 54( 4T0"*Z0)@*S.W @''2.B0P
M8@O U3"TH%KNB5" 8@56@+& (@0\(%'>)D)(P@%>J[&BI0$(87@E ':ZHQ,8
M 0XJ(*!@LT)Y]<2<Z!)8!C->8F2VZ>Z(1+/=)7E%9C$=XC"E(A.C@K+;*#+=
M2H:4LVDN:3<5[BH,@0(RP+.3(C], (Q98)]= "P$5RB20D3<H '&5P5:0"'@
M  1"EF4*@:&[X&JQ^CM9@A1$X5L*V&':KI^2I.$ M M C4 .H@7V>1^Y0A,$
ML^+08/X00,+"3D3CPD@+-* !RA,Q:-'N1HP,'6"X6P J;NZ=NV #'/MQI6(1
M+L!Q 3R2?I4J5F!"3N(-#M84!N&HKZ-1S5=G.B-V,EF-0J!8M@(#H(5=NZ_B
MW&!W"8(1.)'R%J1*$@ =O:HT)K$L46 1$& G%H0$6@ $I.IEI,<4)G<1U-,K
MB,.U (]?1F("^F]:QF92/6"60B!E"URUFYPS$2$ &,=+Q< ,0N#26F XE"0,
M5(  H**CS0 %=NP,%& ,X.*G004-ND!3@\)S*H ,T -]/L  1$I2"( $P-0!
MJB44AH?#?F(C/X?M'  ,S$ $]B5!  !V,. +%&=W5B!>=_[8(?@##5J 3]&M
M!,[@=OIJD#^' LR@!50,*+2@ M# "R3@ PC\R56]$\U@9*&G!8KJ# ;!$%*)
MRQ^EF;P0:>VK110K*7(:#C"A"TA!@PBB#4R(6-K44"((#,"@"Y(IP-PL*=.$
M?0RA!;I $]3 +T(!)3UF:-)@HG+C-9("#(XB>36!"T"H)TI4 R?*L\F@!=Q
M$XIJU>F]WNW]WO&]W@\S,HGS,2]S.:?)WS&3-#DIE"0;B02^CG!)D [&:MZ&
M$3#M(0@I6F@[WRW^XF=S!>;2#=8",3S@-+KC!#@ !#@ +4)@"XKP$MYYGS&^
MY5V^,]]  AX"!,!@,M"BQ$BA$/X8)P3H @(\X"38F"!*H.)?_I$(X=?D2)(0
MGF13<^D!_NDO4XZZ]XTT 02@^1O39 6L*CH_,H>@/K0'/HQ$0"BS"&UWC PD
M@ R^8 P. #DXB L.^V'LZP%"8!V+'I<> M$>EV)CR8!E9I)"P[^+Y%<:H%IZ
M*#9&,TM4@ U"IPLLP"G-(-[1&-XGRA2@MC;N[P,:P-7O/I+<@%[&X!!"(JZQ
M5-S3('G?X#\0<0MH:+'<  Y(@ TV(5YB9! (@0UZCIQ8P 0LA1 $89TE*/45
MLSN@ND5B1&Y.8(87@4Z,<!'VU P.9A%VY5YH/@Q" ']"@?6!T5W(@T224A#4
MH.?(4/YE1* T/"Y$+<4-5%]V9UB+;JN\PPHH@D!69NEU+%_M+(67O[GSO^?S
M30$% (*#)DT8M+C9T 53@DNF%C5@2,K4& EFP"PP1,J"BC0?0IAZ0Z!%& @;
MQI2@8&K+ 2UC)J@P50C"%S04NIC2@@",F09C3)&AP&8,A4NB%'PP<T)"*#,/
M4!0R%1$1A"XTNUSZ,&%,*%.F%(6@T%,$V# )GFY8X>;#"JA<3=$TI2$,5S &
MO)!Q8-,#A#%D$15JP#6-!(D2WIB9H,F4A*=M&SM^##DRY*01;TXX0>&$*340
M5*SX>HF"(*YJ'I@XN4BRZM6L6[M^#3NV[-41VVQ0X6'N!OZNBQ*8(K'EIHFV
MH2 P-B.(C(:V#Q ABL 51 M3G0!_66[JTH)0(K1P5>3 5)</7+>0, 7A#=<2
M*$PUYPHA-05$;$V)F&Z*$0-3'-M&1$.>*1YPP54'9[2!DBF:,) :6QZ 88H9
M&,S% 5=AY/:!=P*.H<@$7+$Q82&)7;*88D]5-IML'P17&2)F$-*6(FFD-D@H
MBVS%U25FG)%8BC[^"&200K8F2 (<;+ 5"A.0$((( @V"T@6C173) YJ04AD)
M+9"R%0=H%))@"!!62<H6*F!)B@2(:, &FE9V<1XI6IQ B@,BW-F!=Q$HPJ4$
MBI@RP6AM6= FEA#HZ &*$G40D?X'/9G2 1I@0,"D"!O0QY4F"V#P@08(T->%
M1Z1\09X'843T 1D=1@1B0R1\@ ($])4X)&N%:(!8K;KNRFNOM4;DAH<?:-:"
M"&TM@N4&87306"@.--B&(%YXQ)4$@QP2)H280$ *%\::$DH#FGP@EX(,D (G
M5UH,YP"FH5R2YI^A^&G*?/4]R%4G#"R5&U<1C0$"5XX6F(89N_'FKT07#/+&
M(!I,%^I<Y)$;G1F(>&A*JQ)T$1$&]$W F*^.:<)&CXTI*G+**J\\)!O0::*
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M0 HV5)$"@[@$M])T"1,$IW'GJ<!P?!HC.@(N!"BH0,!,40(-J$ "!!+$!%A
M @Z$8A,/B&,%PM: #11B3HMX@/<\))2;K25&$FB!"X92'/):H%^=0H$''F#6
M14A@!4&H +PF\)5"7&P%)=C )AI31!=4H"=>>, */H !$YC@ =X!@P1,<(+
MP60"*S"!!A(C"-.<8 (E,(47(' "$CR@)X=I@0>^2P(,H/X ! V@3T3 L!L2
M4& %(G" 66?C!@(, '$1><,#VM@%LK !$8/)V0>>PQ8S>(#,;%EE8Q2A@A-P
MZC?Q+(%5(, 6%;B +8OP4$1.,)TWG. $$+@LTR(R3#[CN00<+8&0&6(&%3?
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MJ+-SU,B8E^ "*G#!8] "A> & ]&[B- %J>$&*N &A/ 4:6 X@Z "+<"8&MU
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M&4-!YE,2F:(>X.X3F#*AICXD;4":@8%G*)*I_&L&4U$"I>(=@E  ])%TB-
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M%,Y.L 'P9610,OZ !8Y#B)=:8 -@Z !XK^-5#LSE!"1@J@9"488&2.!P*]A
M""@ 3<PXSP+940$#N,>5%32  FXP0P6T!X']: )\&S#!/Y&6!@  (%UA2MA<
M&J"&ZYJB W?9"O6XTAP2D %2*NB"%T"@%M440DXBX  8N-""8IT@"%Q)D?'2
M96A38#306R1%LAKM990P0@(72D'Z$L0%N3XF)CPVP::G-Q<S>$"^7> "&"@
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M$=@@<7N*+8  $^@R[ZF VIN _2BV]>%##" !"""*:>D(-Y" $U"!$IB 2[@
M'[*X+YB 2PPK"Z@]"6@F0^DY#"B-2Z@ $M Z"/B5-R" 84&!]$$YI/@*08
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M]FK2>1)2O@)2,*TB!=51=[H01/@535@IKLC0U$0$#_ JM-L +N"IU5B$$?"
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MT'G ]>ID#JB8"R"P2V@D.#! INL>#9A(\W  :$*!-]@E\]@(-G@9ZY$1Q[
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MJ+# P8L'""X(JMA PL)$$NXI7#0%AX('"GA)F=CP80,FBAM#5!58527HM\%
MZ84P@2*%2/" "9I@< DB%Z37 /X9&:WW00@?))0"5@D-8L$'&+!@T@8G?!!!
M;Z2L!T((8(EDDXPSRO1& 3K%=!)1*BB@R2(2A$**(D"2 @8))30 %4*A2!#"
MD?KQQ$4((9V@A282:%+"&"T0,ID9'!!DQF43@% "@6!1,)0IA5 PP0<3?6D2
M&AD$I@63I&S4PHJFH'&9*60\<,(()CRG@A8;:3*!*6?XZ85F%+P1R@,8)64"
M"290X$(H$&1"RA:]F4(!(6PT(.@)#[@AR&2DM &8(!0LE,8#%9@P$"(@O<%
M RY%Q$ 78XQ!P90;7&C*!GHEH )&I$R D!9LF=(%8%PD, @I@QP $@9@(;)
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M *1M0/"%")I""V RQ:!LMQ-CF2$4#5@2!!8A)8(((F,QZ9,'^N."*<TS#(4
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ML" &%.(2)TB ]5)3@N.VS RD@*,FS!" 7<XS29K0>:D%H(5A7L( *K@$'!2
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M04(%GE^D!@B4R$K6A1M,  :<P$$6!(1<S@3@!1DP80.88PD4Y"4$9BA8P B
MP0343JYT@19$ +28@ 6 @ AP"'=1(MTP4<+@7N"-6C&Z0!<\@%ZT@&;,G8%-
M ,68 @BPUF[<CE4X%P5,!!O024%HG;'<U+' H$-(GR_I!EEPP%,%9]A5Q96
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M8A6IZ Y8K3%NI*7;Z\+N[>(NFIDH*/K%UJ4N9 'O1BC"R9""!I!CE6U$@WE
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MY%49&?[Q96B -R)" E1%2L?$@-L5!(PI!E2 K30 ') "(%/D7+0."5_"%V#
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MCD+.8!)2V.A99G #9TAQ*T1P9@05T\2<PJ!*13! %*I:E^O.91# +@)";)@
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M #Q "YHB C2@#4B  ;J #13 .P8&$5I@)\Q  ,(@#1K  ]B@!/0(E[3 #4(
M3Q;!4@K!&1E( 4[ #="@ A3A#+XG+8 (#.K@ W[)#!Z "SZ"%/YQ[M;P#'1C
M4#I@!1#A433MLLS #*S(*1+@$O1DJ23 #0:A FY$"RK@#<P@ 0I!$V@M++Z%
M)2X!!?Y 0 M,8AI%P'5"@0P&81#_ B8'H01 8#!(80M @ N=8A W(]/<@ 1$
M@&[80 (V@&X*(MP40@+&90%&H@N 95L48@,J!C/6@X&PHS0*X2;+0Q$X +K
MXHHF@ L*8@RJ\"^$D!!(H"VT %MFT""Z  100"/&X %" +MB44M8 "W, ,0P
M  U" 83.R3O< ,M ( P2"!% C=X$L_^FZ U2QQ2^<!"XQ24BI0TBJ043PVQ@
M2B&^AS6Z:!#P9RU:ZQ65I$=0ZC.- KP68GE,@:Q^PP40X4E<H@%<RBD4X -
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MS& !RE6-S8 \S2,$!@$,G@A6QOY $$2  !9(;$ @&=/M4#0@A] @ +I X;1
M(UH (SE15S;@ W Q$_&F/!2E$"C@G0BA <Q@$&PQ?_0()<Z  >CFO@B!"PX@
M#13JIR" #"& (F!V$,;  8R" DK SR#8EF\9EPV"$>;C"0E#!2:B$%1@/<Q
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M!"81 E*$!#;@EPI"$!J@D13")R!+*2B@$-:@N4A! ]A@T:;'="9((\2@N4@
M+52@.>)+%Q$A3ID4V="@ 4Q !&"F$$EARTS  09A$T81B$Q!!(1"22;@T\P)
M8$E!!?Z"8'V&D@0N0(W@E0$@@4D(@3P7-DRBE%!#P 0F "TL($Y^JTM><R4T
M  040@1 3&C%1"&\P/%"+Q3\MG@6PM0CHBFT:DMNP^C#9DE<""*\),]"PDR@
M_@%;8B'N/:AG V\.]5J[!@U.IIQ6S27,.91C;@ TX=[UE1&>U-Y<AV!A\U#=
MC2,V=9'D,#DIMP$@ 1/X0A/. $6#^RZB"<C- PX*YR4887I, '(R8137)=CX
M:GI3X E7JN]C@H8= "6Z3 ON3P(*H97VPPL&PI#:E%J&S+YQ&CG,S3-$*KZ
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MI05*H($0M+.O$Y@+&C8P @W\BPT/B,"05H"!$ 2V,I<8SW@N< (/(&8L9J
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,O,([O,1;O.@8$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>cogo_0002.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0002.gif
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M]/'V^O7Y_/____CW]_#P[P
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     /\"L $ "/X 90D<2+"@P8,($RI<R+"APX<0(TJ<2+&B
MQ8L8,VK<R+&CQX\@0XH<2;*D28^S"J8\R?+BRI8P8\J<2;.FS9LX<^K<.?.5
MJ5<\@W;\*;2HT:-(DRI=RK0IQ%=M-D!X(($#G)=./;X*T<$#J8Q1-[21U48!
M!4NRL&9=R[:MV[=PX][$A&% @@,&#AP@T,%43;4: 1,4;(I! 0-H!3M,N4)
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MP0Z") \(8, !!"$0 ,&)-"*PA*L>X)Y96.!5>7@% _)6)'R5 @Z"<Q'2%I
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M9"1<I8!2@*!68TG)Y A AS/XKF8".:H!$I; /D;" %GDZ2Q(40D+7L(.,CM
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M(@0S.^D&]'7@O"7 BB_-P+B,I0*_F *B#NCH&5Q%3?I$($TR$B:T,@"')()
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M.B,'+!F8D4*85)D=?L22>=!">: &:B"4(QF/CO   #   /  V0$"X0(  0
M;0 ' -  :.%<:G ) F   +";"2 +(=": 8  \Y,6%   %Y42(: L!2%! >!F
M&2   V ))'":NPF;ES  R;*;#OX@FP%P& ( FR<  (YPG020(I$  #U#"AD0
M .QY % V"R<P .PY .%C&_*YFP3 )B(0  0 G>BC!@  &;+0 @# ([( !_PY
M))& G:XY !@@"\Z5+*\) I8  !=P8 !0,Z2  >&R:6-QG@\:'K^)F@$P 5L"
MH!(*  044:\I *KIF_SI2V@PFO"X"A)  ,$%H(AC CCZ"*1F"G"@%ZS1!@#
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M<0'V*A".0  9, L2L #,*@@", %N4 FE !1M$ "]&@E8.OX6Q!,"&;!+6TH
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M/I%P-P!0"2@@ &;@M,9!I+$I !PP &IPM(_B1P5"5QB0)YTK"W00 "OP"AM
M %MBKEYTAI,P "O@ 14@ 230OIC0OF60!WNSI7F[:G. 301UN>))"@,@ I+
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M P$'T"FO/)X ,#ND\ "R0Q8"<  DD $'8+^4/"X@\&';HOY8%2VOC[H:^Z,
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M*!(>IH\!0'F6)U &%N#Z(C4"'OY 9F31 O($ GYA!^OM 49. CX1 B  _2L
MZ?!S G @ 91 "ARP[I3 LI2\O.%C"1YP_H9Z(WH//R00YFM  B1@1K+ \7:@
M 81O^ !10I:L2B1FM>"PH84L1RO.;+!# 8*+2"IDY=' P8,E6;-DO6J0I^-
M1Z\B.;3P2@V&#"9>R3H1:2 )4G'(J*#@@=3 @98\9,B YR,*#1C.R()T@HP%
M"S(Q>NA0298E$!HRV)%E!\,L$J9DM: 08D4&AAQ ;*!D2L,#$*8P>=BPP5%'
M%V%9D"4I 4*+BE_/B)"P\& 'A;(B*;UP0:9/H%A7S&VSP4.(5Z8@[/289P,'
M#J0@Z?ZU"$<R94>@LVK8(**47Q 3\KB80/GTAA"F7IE LT'"'%,;'GPPY2B#
MAXT\>982\2$#'%EM6JB8T%86' L;S$S8*:O4A@8A*IUX!8<%=.EN1K]Z=>*A
MA#@#T6# <$+6&S5ES\K$,&>D<?[]_?\',$ !!R2P0 ,/1#!!!1=D$,!2'C"E
M$@B\(N, 1V8Q@2P,*"#%E G4B"2 (BZ)I(&YU*"@E :D8J$$4B2X1!8U:&+
MJQ&8\T@2$V640)8,.$2% C)DH8 .ABB810,)['A%A84LB> 52R# B@([(AD
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MC@L91TLH@C:XA+FXA#. @X64"4=X25)LQZEP 94$QIZ0"5,0"6-DB-68 S/
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MI- *M= +Q= ,U= -Y= .]= /!=$%.<_)_$X1W<_4!,_#\<X,/5$":5'CJ,\
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M!#.H,!0P/?X K%)( U;E"3KUUQYY49Z@ &FMT8C5N3^)M(&=55_E6,.A!#.
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M>"?E*OZ6(R8+(6Z!%E   GH >:J$U=/A,*4[,T !O*&#*PXH65B#U]&UA?$
M$%"#"3B#-GR).* K"D@!.! =1V@ #R !3@D90_E2$5"JK:.C=^)C;:'8OZ(C
M.,##$WB A7"!PN, EZE"G5H\%\B6$[  3%H 9*2OZP@6#"@"-6" 7'P%"E !
M.LZ#61CB%FB-/WD %!#B^K *>4*#+/L 8LF#!" !,J  S4-3/:!D61@!B.(
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M["EM.EH#8K$$59*KM(JG/%"#+N1@.R"!$Y" ,RBLE]BN5D)9"A@!Z)8%.C
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M8 ,M"($J0&F;#'P+BK(P@05 T (+F8)ZM6D>0<1XPA6$(!)GV%-!6/!(SVE
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M:0<9@D LLRA"!S:P/$>TH&2OD$,,SS !G9:"!!](D"S:4 053 "7]HEA&29
MLWG;)"&2N*,L6("196E@NWG(@ 9 4 I5[ Y *,"@U4QAACF<H"&O* &I/, !
M#B!,XV\1Z1QF@@?YI1%$:@ !!?1 A@FT)!+&D@ +]+"!"9Q&<WY.)P@<T/=9
MG& #F"=9!FSIV5>4'_.NO@0(  TEDHD0.6UH  7<@$H-S)D@(A"1+(  <EA"
M_&D 'HP%!WB "*3$"<#!!% "@GC1K<$!&:A OMQ'!IR6)7R _($(&D!?'DR?
M ^4!!OZ<0?((7!K 7FU$0N-=0*JDWPD4UM\1Q /0@<[)D =,R2RX0 =HP HV
M'JV0 070!K.LBDV(5!Q80N>P0.?ABB-X@ =L )10C!R@P0EPA4MMP/$ED/*9
M7_.UP ?&AA Z4"2LP!E8  84G!JDWPJJ0!F@H21DTP9T0 XRCP=P8&5LP .$
M0"6@0$.H0?TQH)Y, $88X5PDWPW&WI2 80A$GPB"BQM*P KXS038( M$@K*!
M7P.$ ,V<@ :<'^MME\]%XB1NGPV^ @K(T'Q 0B1F'P=P7]F100E0P I<4/P1
M'XC @09H!A1.Q[/5'3!B%!DU0'2@0;_,@014 E51  >L"_X '1$QDLSIU!%!
M?$4D!( +6 *R1 +[*4!#O,M;6 *_D8$"*",%J ''=.-D84Q3G4 +9,H'M$ >
M1$#F:4"AJ$$I,(!LN  &Y".N2()@(*-<5, <C$0V3< L2!OS$$M!0  W714E
M-,!,&./)*48;$ !HQ,K/V8%K9, KP($#G-Q09 "HR,$#ND5P5 (<9("<>(E=
M% 0)O(4I4$ EQ(A".D*_N,'D8<E;9,#RA$!QW%U"G( DJH#P90K>. (#7()7
MB 4)+$D"Z$<I1,"@7:1LO$0+*,"X&,!;'(0L4,!0>$1%U@H!Q,$LY LE$,"W
MW)]]V&, ML$UM@"0^4P(*$A",/ZC,Q9'1$:'&O1+#A$$!41"7%Y"Z)D"*5S
MC+B$0ZX6&1#,*U@ 0%V #:XD7>2!&AB &^ 8#1X@C>SES_1+_)!E'+P"6@(
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MC!H(,$!.6,!3M@ 9Y($(J.Q+E ($-,2.@@M#AD2ZYH4=/( 9M( +J,%IH09
MW1L9R($*U-O)R<="OH0)H,Q2"/YLNVYIESY<OUS" W $&&+%4[) &<P!3.FM
MV+8 RBP?]X1MXUE"!1P@5?DK0="!"$" ![C4_ZU%'%  968*"Z# U'Q &Y1
M8-!,&V1%IG  I1*K;<01'(# U];$V%X"E[[M+YU!9(Q,MGG TY(!'MA!5E2M
ML_@*@?T=RLHLS;;MS>:L([S'!!@1"=K:V;Y$VII!A@Z/+)3/&9R!!IR<'E#O
MJ&$ ]J"M'!CMRKJM1\ MRIANKK2![I(!"T2MJQ&%6LS"\S' \I" !F3O]N)D
M:T1 *5@ 9[I&C^:$U>K4!42O+*0M^;8MOI[O+UGIFPQ:W<ZN!^"MAO+M&?BM
M^YJ!MO[%+\->PE= 0.&BC'=$,(! P)8^Y.#) 03 +AI@ G.\A!U,[FB8K W7
MSAJ.%,M0PE(X:?]YP K(P8S0"RFD*%/$S7>< 9* "P,\E2DD@%Q8; )7+QGH
M(D% 0A/#)#U]E0N@P+ $H#I50B24KO\4'D/H'+^=*T%D6W.D !DJ!T',P2FL
M!1PDP%.50@'D01P,L=%X $:8Q<6@S'> P+>0@D2 Z_J"*5P(W)\\I?\<X&Q)
M@,#I@;%N0"7 \?8<#SW)@848)!F(:^"M14RN!2U5@@-XU 7,01DL\=K>1$X,
M::8$3O]YR.K*117I+4W-P7*$I04$LF?@"G]8@B.W2MBH!?[S.%L;M(4/KP40
M[[$.DT*A,H5J?(<' )16?,=+U/$=$X C>&_J%<&E)%"RZL$96,C897,"- 8>
MZX$SAVDG6!'S]+)CH$QQO@*D#K,E0$()$X4&F *HR,(EWXPX#ZQRC  ]V<&M
M#(=KR)M]V+%"%  [\_$EP#,@.X;M#O*WX.@L,(=!BN4B$T0CGX\E0'(V&3,A
M TB./BE(7T*,!."78@*A;( ZE4$(&%LN8TEU?/)F_N(-]W1_;4!=5D!Q6-UL
M0< $@( '6$!8E%T(N,$SKL %Q$$+1$ *F,Y(29 :<$ Z%\0(P4$*+  <M #F
M^$0$G, :;,!6SYL">$#Z4< <]/X,KFCA0JS A\X'4 ^+36@ !V1U P"( IA
M0LZ'' " @JP !;1!")A,0:R  IR "BS Q]TU+7[E?.B!8%QO4D1<!M2G); -
MU9A  ^0!*2A "<R"B:!!"S2 )6#" ]!U \#!3#*T'#B &K0 T^;!Z:A _H7
M>%B""'_H:9R 1$[U//7F6HB  B#U!C" #:K MH3 ]GZM&WR.!9BRN(J !K@!
M"1@ I::);02*?7R$"E0 8H]'!4CI ^C64U*" 9! &VP 0EPR7?N*(]!CJS2
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M!0FV/ '=,0 2(B%AM4)B@3-@!P%VX-"I0J\!=UI" =?$^@/L%(<*2O^?LMB
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MF./_ G">S(!+["#T0*#O)! .OB^A.*\2+7%&+B$#9B$2MO[,S;:,>3! !4(
M-EK  C"@]G9' 17H0BI@ S* 4SA@.TRA Z*"! *L!?HN$C)@ S#@#60!#?PB
M#<!B#B#@ZM*I$P="& <";C @J]J ^> @JWYQGL+"$3#  \@ #4:Q#[?,$C;@
M H)L^T(B#BR %RW!#20-#K:,&.VC%#.@]EXA%M?% V31 W & SZ #-( !/+
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M94MV9#^692769E,V9DEV9C6V9_YI5F=A%F>#=B,B@0 ,  "8E@K)   T1 X
M( ,N@0  P  .P&H#$@ *   "  !"P!*4]FL)H(*2M@!\)!( 8(,$@@( X ,B
MXP$,0$!-;@ (0 ^0" "JQ104P !6@00"P&H'P&!D80T X R>=@ .P "^-A(J
M00("('*'BY4"8&D#X !6Z54U=W,M8A(.@+'H8 [J(!9B 0,&  XLP #^ PZT
MR0!:  XB 0X"@ 3P@ Y@-SLN8 [H@ , P U((0$28&0HH0 JU!$0@ $6P$ZB
MB % IB! ( $.X*E 8 #V]@&<Y@0&H 7L '#% PX 8)'@8#VZ!PXP@0(&P P
M9@#$P_X-9G<+(8  HG4C&"$+MB +[+=^[3=_MZ!^]Y<*L( + !B MR" !9B
MN6" "1B!#SB %5B!"SB!&3B"'UB"*7B"(=B %QB#';B".=B".7B#09B"&]B
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M9&&R/65M-:8!!, #3"$!'L -O,< P"@"PIJNEWJR58"[/   XL . "![+
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M-$NU0XD""@1^!K@ X3'>2F.!"@1^WN<4%HS@E:,@XTE>2D-A"3K>X^<T%&[
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MEL^RM)"!!FW(8LH*;6Q0P<MNMJ!!!J/KC88%&E2R'24'<*#92RW@ 0#NS0V
M@2D0 %J  @70(9A&L@"IA\T;F$(*D#5><D #E#C8P &EJ!!SOQ8.(,<K=31
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MLD)J"( !%BD -"0$ "S8208 P#8 *  ## C &B@(S& *<YC$W,EWDE*)!50
M Q7P 'D<<#T[3( G)#@#'!!T OXRR$("D9"  I?G@D@X(!*"H 0#YD "#]CA
M7SO!PS1W(@(TH($$8^(BW<QP*1693 *2B(!;FK.!64! @<);G"D>\,TW>, 1
M%=B)'2RPG4Z<  4H.$$+OA0=-W@@ RFX7AM"L"U1J8 %E3 !LE0( A":0 4H
M4,$;5N&3/(@  R((T4>OYY,VK!0%9 BI(T!@AQ>>]*=YB$3@3J""$D!'A23
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M%"20& ?3'(YU?2L0":Q%**-S"1 P"QOP,GF0 7C 6C?6'"1P ACD"*EE!QI
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M"+(@"EBP!5W !510"+" !8FP$XU !5)0"%HQG*8I"X,0!M:!"%0 !0?ZF(,
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ME*1 @4$0FG"#&[0B%##@ RM>H!M9B&*OHL !#]B*@S[&( KU>0$,D_4%FL)
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M8@I+L$$?4H&#O[#"!U&H@56/[>8:V%P6.(=SS)E \UB$H@: "8)"P]:*'L0
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M#_D 8H4(/  5&L$ $9@ 2. 8C?Z1A60= 0PH!8Z9@&@U 0W@@%TU!63-  N
M Q"0@(8Y@70-@5<P!0Y8 0]X@#,PA0QH@ X@A1;8 ! 8UY!@@0T@ 0S A%=
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M3VYEV6F75.[>_L0,#R#C7!%BRSR%^W4#"3"#2/  /' $'HF(#I@#(]F43<&
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M&,OXC/7A=Z((8$$:L04O>,)\3VF%^JCGP BQ;PN%6% K!H$%/D3O98>0!2+
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M(SG)B?7D1&[E 1"\@G'YG< 95V"*.,P6=)Z3Q03R0 82'$0%*KB$ BQ!BA!
MH!(-H)PI&&"*/#P@$J6@P!D<48%(,,#,(6C *S 0Q5L500*8, 4&VH")!.#!
M%,]\11D,$(E*)&!:&+"R'!YP6OXPOZ(!D=AJ,B=]94NS ,RR4 &8/1 "4VB
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M1J2LQQ0P0:7PP"*HGXCTP0T8@8G\AJ>(B@S,WZDD"0[@B$'\@*JD% *JH/1
MU@JZX M21A_(0+D,3BH$@0P<P0W<@-FDA0ZH#=O(0LW #<[\@=S4C=0@C4%0
M00S@"-_4  [, .#$0,38!@Q:(=;,UU900AM,DBSH >7<2BE W%9 PE@]Q"SD
M 1<541RXP!J8(42\@E8AA)Q=81V"1R9XP1:HS@E9T![\CB)L$"(L1B%X4.R,
M BST@>V4D HEA")<S_ XSQ^XD"P<PA]88A] GAUJHI!DW^;) BD\P ETX0-0
M@*[(0>/,@@#"WBMX0%EE !T06?Y".$( J-*M5 ($9  +>  #C*%#E,($C)4'
M@ L%_-DF&N,Q(J,5NDI4F((;'80-[0H'-,#!R<(<5!99P5;I_%!;H8*VO,+'
M04#+$=$L5$(V8HL)G$ &F*$$N$"VP!.S,,0WRD)4#5D&V,$KE%4RZB-%,-1&
MK=1$J11 =A1+.=0^&B1FQ%U%W$H;6( '6$!:84 #<  F(,0%P,$##-D<"%4I
M>  '8( JA<#EK)(=Y($%D( %>%8/A1@+,( %1(()>-8'@  &U$I"V-4ED%>R
M,  1'40IZ,HKZ)0LM,$&'$0)M$$(D (*M*0CA  )B, $'-5!2N544J61:1Y%
MZ($#P/Z6'7B.(TP 3\["!%B"&C3.'"33!J3;&;6!&JP3*)+"/54C0F& !5S"
M+$#8D%% 'LB!4,V""8!+MC254"+4&5366+J!'73A!I!."<R6:TD"!/B7!&Q:
MJI7<757E96)F9AY6)T8$"@S7K5A 'E@"E27$! S9!*A!'F! 5)GA'&0 *4#
M5L'2*^2!&H# AOE9$<G8&=F!;(6 &KSA07C /<%! I@"0SYCR!% RRVDQY&
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M-9[ @:&5$Y$ SI'""JR 5U)DTW)NYQK*N%)$5*%!)&! +R5 CZT GSF" 9R
M''A ;XU6Z+2!!,B!C)*"(S" '>"!6$%" IS '(  46) '<B"!;A S%&5RDX
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M+$A<J%X"<JV!'90 RJE!!GC ).#8D$&"!VP 0"=$'!0<"<"6ALE!*<BU'9R
M([2C,K';0:V +HT:5_.0([# )%%"EIZ!"T3"*W!6!O@80N1!QJF!&<S!RTE.
M!D@8"YS"5;MV5<?L52B:TN(LA1SM:^-V;A>**8]GR94 LP+8<*%>O!+WR8I>
MZVD+0Y4>ZQD6PW(>[-VV;DNWRX+N=%OW=1\@ 2ODT!8@=GOW=U<2/H/W>)/W
MJU%Q1$29$C\NM#C"OYI"+U*2)8"+')9W?0>P=D]$EIK!"/[(E4.0P@2$LD/8
M 95%]U4TMTR-V@G,@H,1MWT[>,OR]D+8000@1!&LTSCN"A&90F'U5SYF"Q[
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M<%WG LC*BE)[@7%R2S.Q!MRB&9Y!3AO^]%?END?$"4" "9   TQ8" C5*R@
M595"J9^DL*, BH& "T1RM@RX+(B P:G !)@GIHY5P<F"[/Y7:0:LJ>)DCJAF
M"Z$!1 @5$"+)(I&AQ00ULBS D>5(PBQ9)<A08A""!843LE1L9%"*Q 8R*B2H
M(6-"EJP5* ^V@+#P#(06&4"DM'D39TZ=.WGV]/D3:%"A0XD6-7H4:5*E2YDV
M=?H4:E2I4ZE691JFCZQ81"O!@7/))BFPLBJ9DC6KDD1':O)(?$6G34&;KRJ=
MQ3/G%2E(LDS5E86)E*PY*&\Z:N/7DEE9B6^^FN,F<$I':RBE9$PWY:57>3:8
M6N,H):G E&;-RH.W5*12G5*6&CNY<DI*:_)8M7T;=V[=NWGW]OT;>'#AN;$6
ME1C<CM_<=B8,=_X<>G3ITZE7M_Y^_7KQK42/!^UN\WO*[N&!DN\9WCQ.4P73
MB__YO;W/5Z^PU[=_'W]^_?OY+PW#A[_X^@.J$@\PN( $Q<[JKA+0Q$OON ;=
M&\\F2AP\"Z?2,,QC!/!VHH\--5[AH!3W'KQ)H@A!RT.$$STT+T6;W)"@-HG.
M(,$F4T)03$,343P.R(?J(L,,%W6*T<,745Q0EE(Z*!%)TQ3L,:?NMH*/KP1_
M3!)#'WU$LDLEN4S)%!',HC+(,8W\$CTU9\'#+!%JK!*^]L!D$KPVO:1SRPRQ
MG% B,XI,\4^;'+&$RS8I7+1/4]J2980Y*0R3T@%MVJJXI<@3\+WH.,6- C),
M*24$#/ZJE(6,FCB5*-5*/23C U=SLD2.3CN2I0WZO$/5 [)J36J6!^QP[P0
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M@*IDN,@:;)('"9Q3MB!8&0/J8(<()*T O)S "F;!2'<.ZP%GB 0&'!*2E%G
M%"IX0!EF08$Y=.(!:(@#&&6! 0K @0P)> 4:])K-&\I"#%E!BD0BT8#4L:HF
MW@I*!S @"5+ P0!S^DVX*O.5X<PB#B"8  ,VZX%$RH(-X#3#3[EI%L:DA 0M
MFL4D9(&&%IGBG<?K8BEE<8:?GH$#/VR *68*8>6:Z@$.:L,27T&0E'" !;*
M@"E@+ M8I#4E(% #' HK"U*@] PML@.*'40&$D0B A*Q U53$HD'Z*I=Z_2+
M1$*P60? 014->$4(R" 9"9 " OZDF,4$++%"65SBR68P[P<6L@(6F"(!!7%-
MAKH(!ZHB,B5G $%[Z1,L.7;Y(1(P!01F08:?J@0%ZZR,""1,&D,%YA(.B(6A
M4Z(",K@AQ+* A +>BV-4D< 19'5$!IRLJP=((@W9G)%9Z@("0*]A Y9P@*X@
MH <,+.05L>&+!5!9(O+*9L04 ,T&WH A-/2X$@QX2 8^<*P.'%@-'$"SKLA
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M!#A @<@JO-: !2! 92:@RQ2 M*1+E3"@!=9O(1 @!.0@!,BJ#/0*XLC HL[
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M 241""B+'!ZLP->2KQ0AI0=K1,=!'@_(L88<_HFI0ATHRC+!L<*^FH>BLIS
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M "7*_)2J$":+")02 \Y!E:H^T"M2I(\"X2$!4+:9 %G$CU?1Z9Y%$**&4JC
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M]![1.^AA>8! "U8 @<6/_O6PC[WL*W8QG689-B=2@&YKK ('Z!8"'&#!!S!
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MKX!O=E"4G3!$EM$"MQ*3=GF7>.F2%:D>* !.YY45*2 "#&"5&S ")V !G-<
M$\ &+,  &U$)$J!4;(("%Q!^<" 'BCD'J$,Z4X(C&6"8B/[I" ]P B=01LL"
M ESQ)61@ 66AFJPY%#&E,CBB$B!E( _P"BR& H(95@U  ;7TF8=I"MDB*)=
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M:.K,B@T:)LZ!26>#YX<$C<XJDO6!S3,5956(9"8H!ZL60*Q8 6(#G RW96T
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MH0V^4=P7LR6'!RBV!"MPPP1,0107''%_'T2H6'6[VR4&D$G!>ED+:B*6,V3
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M   44 $$ $ &6:@A *CV0 ":1@D#&"!;LNF[)4Q @ &\! T#($!%'J" 28!
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M_),%S:,X2BB F(&#N3,% HB92! [#>3 N@. (H"/T8 $'/0..@" $[@$ _"
M X #-4@ #BB 2SB!!<@ ZVJ #5" BHB !7 L$L"_S9E![R"! J" #+".L"$
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M":@$HB %.5 3B"JGHK"#B$R5^6322)74V@E L["E$A@!" #"5^" $"@;'+6
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M@L*&4K+09/C@0:^C"QA4A/#:(D.&H:9$D,&@(8\("2J .E;,>,,#.*8R//#
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5KN-V90N'-0W)69QW7 NJ9%I    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>cogo_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0026.gif
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M\>_P\>;Q^.OT^>3P]_/T]/3W^?;Y^_____CW]^#?W\"_OP
M
M
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M&LWC/'ZQ"]7R!L_U5E*X>2NC!GC0:%6&"91#"J%@?9<6"E[ #'(@!%K :$%
M!-%7.=,6#%PC!T\F!VD4!3]V!&&P.&V@>4/ !;_ #-$0#6S0>[)7!%W@"]0
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M3[Q6!). D\SA'K:9&R?&B:[2%\H@"6MUB?-57+ZV,MGH@ !Y7;T0;J, #4E
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M1MSO'=0:S#U#D G&O!P@O!+)O"C$8%'87=:@JU%"P 6FH!#-(.6I?MBNSMB
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M,A #F@#2A[  ?& ),N  K* )!_X@ @2O"16@"=#@#!$ "+O@"@W@![F@" 2
M"+N ""!  10@!8,=\" -\%3?V%C^X*PPO@CA"]5&YX[5\F1>88^47@",,:.8
M?Q<,3@!AA,A @@4-'D184"#"A7>J/80(\=@K5:XL7L28\2(KBB40C""Q((*B
M6*A6\*%PHH,"1,9&O*@6:Y>#%ZX0&-JEZE4N17U@)-@CS-*"0\4$,5"E*0&+
M5(<:Q,CEBD6A1(IRO6+EBA5'K%DW:K3HU97.8Q$C3I,S).'!A6O;KB7REB'<
MN$/F*!,FK%A>OGW]_NUK5O!@PH4-#Y8F#-G?88 =\]VEQ(A<N@0IQTTH\*UF
MA9F'*/XQ1=A:+K$:2YN.%4+"J5TY)S1@!8L" D7&BI$ L4N"B!,C0(#0XVH!
MH5BO-(&@H )E'V&*$B0J!JB!,!4=C+DR=M3X@0HE&)S@R"I6K*WAP9[?F,L:
MX5%),&>N#+\S7,J;,7<B]E@_X+*'_?\'$+"]]@-,F36&F&R@RRYC*SX'WU-0
M"#" (>RZT] S+1=!#& -%?%804 &:%+H8!=48CD$@51 *,&00E)Y)156&O!#
M)AD>B&4892CXPYA"&$BEF!<J$$8"*7*"Y1 %4!$$@4-V2>2 /79Y!1%$QKL0
MPXQ48:4_P7[A0@@&Y:ML3 ?E,F*(+@ADDZ_U (0S3HB::?Y3/V1V2883!"=;
M:,$'WS/S3"*&R$,T\K0T#2-6=F%A M*R6K0%!XS18X)8*M)D 45@@("79HP1
MH05A&  $EUA@6$"35&8@H IC_*!MEQ5(8":"/8S19!= %A#F!!.,4647"F P
MA@4&*NB I"P1#2LV:0:;I@TA(*3/H$ S\Y.N(># 2[_&A/GV,6/D)#? .L-U
M;(L$J?W3,C(5A'<^A00"A;!CMGJ%6?0BI>!0K71%0!5$$,AU%TUHBZ6#!QJ=
M()581@!DEZU4H" $/6"( )54.M!TA!.<84&"7(1YI0$6A&E@CVM>P28!1% Q
MH!!C4$4%*WW/RZH9PC!1JUUKY?[U.=Z$D/ DOSKU>[-<I04[YFC]EJD#P9Y_
M;O#!:^5+,XE2"'OTYGUWV2.!FK42[X\E56F@ RLG&"$65U[IXX4^8(&E/*U>
M*6F6:V#A,E]L7/G#D$M'B$"%!T: !9'G7+EF#P=DD84"$5S9I81#_/5:(U6$
M(8P4]\8$W=TRKQ:]+C",=EK I5>'R)H!4_?KF%:*2'/=TH%F-VCZAN""0FK,
MLJ;NS#$TS@ ]@-W*F!,<S<4W$PK7::M=A-E%J[<AQ9=L62Z"Q95<ZGX%%D%@
M$.058:2( )99A$'AA&MF.64E/R0>'CV=DHZHERT0O#WW,H6>R[L((@1)*&-Z
M?!G0Z_[:A#_6D:MI@$$7FX@!!K7P27?U":!ET*00(9 !&H-I1O;"4C]%[2(&
M!" $+UK#!Q2^8A<M^-6B;%:>"V'%9HG*2&M(XXI3),(BLT  (_[0 6+(H@H&
M,,0.26@:58Q+,,P( _\"13K_4>U!2L %[/C30*59(W41S$LR,E'%_EDQ@T$S
M@A#00!AAX&M9)!3/"@@0 A1$( %]R 4J=M$'!-1L*TO<UQ_?UCVM] $5BC"
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MZ<K4T2UG@\)QY, D*$J)L+J!6A355$Q95#)5>"IF$,9Y4:@+BCR"R )/U$?
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M.( 2>/Z(:WB !!  0*@&&!B NY[R!,"&:N@# 4!N!A   '!O:RB! *#R :
MSE&$ B" NS8  1"!:D $ 1@ "&@  )B :D@$!)CR :CJJ)Z! 5B !X!S)T_O
MB'"! E" !$#T1" QE=[?-*X&>!9M+ZR62Z!Q+'QDIHED3SC:DG00VW.L^AV>
M5SA"UCGN!7" $B"!!D!T$Y"&5"" CXB%1&B $;>&"DCT8W@!%V !+ ^ !'"!
M:^@#N]YU$C" !3 $88@ !2B :\"& F" X9X %I"&",AK/E $QP8 6=@#/S^
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MV%/=Q6,CT(+1?8C)VEYX!*PC-X#T3@5P'P!$X .KE@%4. 5LZ"%8D 99( 1
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MTZQ&"AXP@3Y4  $(0 $RJK$'!CS@#RPX@ % ((L8"(8!A?!C#!CPS@CX022
M8( #^B"#!-"ODYH)T +V(#=3"2-5S0S**XP2Q?#UC7$NI0D4AO &"'HQ85N,
MH#"2L8F7X+*E V,I%XP2PI/^A/XZ&XNF 1(1PQ?PI7^),$\"* "A"5A##_=I
M00XY^@!KG$  !H   PPP@(HV**K5P(8!^ (9ON@)!.XI0 !H*( 45&,&5EF
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MK@AZ*N@%:4'!(D+0PC+-&(4S.$$".EW5 QR@,4@^935(P-%$$$,N#.B#'RI
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ML=1X[UDRZT@LZOC*[]YDY7S6)PJ;BC$,W]4"L28C8F\*P3+1\.ZJW1M+\L:
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MYCRZASW!&#@*DGI/F'K,!"Z+"/[#UD/.)%8)E%Q#$.T""R2 !"A #"A"!+!
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M@V(?BESJ6+"HSRSGQ0J?D'$+F/$1O-1TT1#*\ R..*,^_67F?32#"CKB(IF
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MF0;%0C:]3_X*<R!+%?>1FLBE=E1E'Y7.IKWBHTO4#"PT$0$)P( \%! !+!A
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M+HN^@D,)+N$KK&$_>DU6D*5VZB,5#*%B5&$$*  %5B "2OX V!) !0I!&%X
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M.U-S4(C!#(8,3:.23=D5!/,3 SR "1R!&;AI5:Q!&AI681*&7/\$57BA$7H
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..RWC&-*ZQC6^\HH   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>cogo_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0005.gif
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M\
M
M
M
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M!X42BD^ZIA3*)PB]\DEM!<'RR:X$A4*;D@44L,= ?JQ%4"Z@B&)21;E\@NM
M<;S'0D&Q5#L20;:&4B2R5X%B;IX%^4(?+UFVQT8NH6"B00'(R=%1*)Z\6Y"P
M_OJD[D\$O0(*K^NZYMT!NNEZ$D&B@$+L53L11%X!(L22"PN=,L#+)ARXN<
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M@)(=I T! ( '!I*!YK!A508H  D&8H?R** 7< AA!TC8G#;P8@'_\8V'"H
M!_0$#_X4^H!^G :UJAGQB$A,8D/:0 "R;8LGM=G#<@@0(?^L 6T+(, "'!"
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M I ^+-$F-'$432#T *% <0;JL(D6]R(CF^C4 70(!^8\$(">\E"E1OB!\C2
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M0#:Q@LK=$I#JFJ)5X2VM$EDJQA;L(28L)[J.-\<!G%W.7/Z*=3VM"20/Y3F
MW((F.K)5<Q,;L#>S_3U!CS\3%@LST_8(<.\:$\ J '3U1<A4 #]PH%,=]Z0
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MFNW'PFW:K#W<RXW*R5W(R%W<P_[=V]!=W9@=VM*MW,;=V=E-$$^0U[1M Z-
MW(U=CH$@ WH=V3-0!N7=WJIR"T(PVX<] X[@WB+;!?+MUS-P!?;=WS52@:W
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M05*"ET VMK%K3N.%"C*P"2E1I T'4,$*%'"U"#R$;+S(@-$*\J@/4(L7';@
M"0K4QP_8(0YO$($H,J 2.#2  BF(GQM+DX;&K211M>*%1E8"BS[!87I-B94(
MZ%.6"2A$?K@R 0,L@"H4F&"06HO%"@I4-EAH 'N*@04''/Z0 =V]H0$E" $)
M&J")/&#@9;[@&@0PH$L"#$19'EB#51[ "Q)0H 0B  $$-O.0G:G D9#AQ030
M"0%<<49<$-&$ CX""SG<X4IWL-M#2I &/UR ('?P)T(< """P$$$)+!++AC
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M2!P0=(%.U"H#KL0O>E5 )!%D$B)XB$ $'O &.5@1$Q?PE5;XD+<^Z.<#%L"
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MR9(<1]\Z)3=4 ,OP@U]#C8(L0S#L!1;8B.-21524A05XB8<0DTRLB"3Z0E%
M  #IA5<X ,B90P4H$3;8IH.DB#/$2).4RJFDRA11 =92%EA8@!*)!03 "EM2
M+.Y* PRX *2$A1&H'*TP)6_A@(-0 3CH@ @0I+YS$YV BH9JN]6ZB!+8LDV
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M&6T*3WB (22)+J3(93J;&P$!5-D HT&! 4D2:54!-8 %?/XB"$>EJQ%(HY7
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M("F8"$F(N'B)#T:0@>?@A4"0@4* #B&P 4; P"/0@5UHA)S&&"%PA'N1B!6
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M3B7*B;A9H=&$/H  %OB0I@ \W_ME##@7"+@#)9WCZW4RFU" 'X$ 6R(!!?
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M!D**+XSB%H0-!"$FD9%'C($0@"#$&$RA"C$0(A""H 1X'%&&UJ*6%+H8PR
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MV  (,.:.%LS]GB;/H@>$T$@)!C>0";3&GZ]8P!S\X(>)\:(/#\ ;0FC 3GC
M!X"""GR 6]74!9@ )O@!'&B*2\7&!6#"'OC!CF!)!J# )GS J&#*1,B)"F1
M)J1!&?YYP@%P@-[YG0JN($X!G@TD$GB00L"-69.97@T$G<OA#M.5@@S(&>#Q
M!W>0@1 ,09@1F0SXRB7Q@ WTPA4L&@SD@+C)@!!80;CP@,'A"@P\(2^H@@Q$
M@17,@")(A^<17Y@-@B,LVNGD!Q  P1C( "$X@0W V/#-CO$Y@2(!00WT0AC
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M5,(]K"L5:BCA"EU0E88R^ (^AQ>(>LE@%(9$A2+.B-95T$L(& 6$2GG!"AT
MX0:+>X@AH5:0&2!A$((XA"X, 0/\Z*(2J=@%$&P@AC)P8088XX$.;O"$6=1
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M&&X4B0("$H[0A8\8=5M0Y 473#8&>]M@%9"[12G$8$6FR* ,B_!=>EQAW(:
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M4,&*/@(FUJ-46J$'8H 5S*A4]@8&;# &&&%=# :Z>,$,3/Z&1)I %7B+%VY
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MC%0B5F$FOJ 5L$I-"D$*I" VYN6M'")8N)1%9X$2ND#*!/Y!9 JA3&5"H\9
M4'E!$KI@%"SU,PB!#%1J$J[@"<2 (%!!#":5#&2T#'A@R@:5(F9-.NOT*+4
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M&DE>Q%9F;BQD1G<7QDML![V*_,D'CD (JJ#QB&PGV\:&DO[ NJ_$J+XWA6
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M7"$5!QG#&*$(R4@:KQ0,8M ,^#2+(<#@!C>( ;"$(P.?W()2-. %%F!@(%X
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MS* 0@N)%:LM EBM(Z[SIA9!)]-D>XJJ""3N6P2&.L-$2JYG$\72"04CAV(2
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MOEP0:3 !O0RY+OT!$  "<)P!)I !#5#5N9"O&O !#>H!*^  FSJA:KW'" #
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M*.NL?I"X.@^^;9 "KIT)$9P&(4"HF)#FR4/$;&  P.L0(] &/,\!=Q ';-P
MTOL'+\\!!7X!D/WEL? !U\P+&G '5?X&:B 'W!X+J%T'\DNH%X#0U4[(+NSR
M!3'WO) )/J\ I^ )+\\&;ZP)U7T\&H#5/1[E#=H'([T'B+ "0,L&@>VNJ@O+
M@5H'0EZVQMH 8)H'06T0;EJR!0$'4]P'[/SR<L#&[LO#%,S$!E[J#K$&#4NG
M'W"P'_[@T0:^!WC@ '&@!G!0 )L@ FL=P U;$!' "7O L76@L.'\!C-?OA*
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M@!H&DA7\M($ $V"B TKGAP5\@ 1KI-8#4#"!M8'  EF\"&&\Y@D\B$T@KZ!
M!T  Q\&@+25[,$RB%J"!"3A@6/YUP%,=!**&" Q% S;[$=]*(@*6S?$N>%B
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M(1>L 85WU'"Z.XS !,F>N+,LX#L*V#PERYY( YP*"S6   X]H9D'PE4C$;
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M6($#H)@(F( 1\ 0VP(!-: .RL ]B"0#36 $1B!]/< .J@?Y -B@!/U" GH@
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M (IA, >P93QY@PG@@*^@#3,C@3N UH#NDI"U/E_1@!2X@'<V,HDH 07@  Z
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M?G6H-_ ]8I$#%E" 3]"4(6F(5W@ (_&$&5V 'Y>R2W8#/A!>*"^)NX%B/(@
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M$YD S@3$50<.B$ #Q11!/4=P._X4E& @FOBQ"%39M"G"P@)Y_D@'ZK")O4
M%F45RLY>H=<+7"D"I0O.J[&:"3PL8 0? /%U'U*":X'MOVP: 1L\@+ % "87
M$<@%)A;,(<U9+D:8RR;70,& 7*AY(LSEA0>:DCN/0"<-F>:%$4QLJSI8@ -Q
M48.H#ZBY7!&%#Q?PEHWWVMLUA( 7<2AF+\ JF]X4>;'M4P Y&0OINA1@CA_)
M %0.;<X)U-,"".-<1TIP L'% @-OL)<GKKT@?;?9.5C)!0N*/.<)R-4/=EA
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M'*C!3X4$)K !')#?0T;E1[Q! 'R=F_"!SZ0)*!3 !6Q !B" ;:'$ZU' "62
M NP,O'"%'U#-7Z9C'QQ 4,#" <A-'BC UT <G04 >$1 '<S!6(5$&OP>/1+D
M!2! "Y'$!\SC2&C  OR$;AX0FZ# 8(R  E019'6)8"W*'2B !YA  T"+2*@
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M3E0$2@ I>B%?ZL $!&4%G@)'T?ZE#O S).H/%B!B$]!%?;Z42/Y&15CQ4$0
M!(1B#02C%PH&$^9B$^+%/CY FE!@0G)4YA@G).#  R@4%N1 )>C&*2)R#E+
M$]9@(M( %& !!!C'=1(B#C2  TS )1P(!.AI+N+@R6"!0U'@ V1"[$:5UU:@
M#ZCK:@0'43KJ]^"SHC2$ PI"*&3!;U+4=JR43V73<*"42*:2G]S 0\7/M3Y@
M+NB1A>X&556 #QJ&3G$B3H52(!JS)X<4/WBA#4P@6WO!:@)/!%8 2L!P PJ&
M#LPI!$" .>6 4MP /P\I.S3$<$BQ+TA #M:)#42!3E1"!42 (AL2/U\!G*;B
M%48@!/XX("1(3@54 !,X491XX5]T P2ZC0TV(0[>+A%[P6"8!@]0[@0^(#2
MBBQ*\0&G)!8<("]JI&OD0 4DEA=2@,P\((2LZ2N0@@38Y(I4BD@PY3_6P&;_
M\U"P+0TP5"S>H!/81VFPUE7Q%4*0=EJIH_O0ECGJ[Q3BA5L\P2_Q(!0:)F"2
MP@/X(&Q X$!Y(0[@DP]R800LC3TW DJHJ3V(#5D0=W$7]])<A$86X@ZDC2$D
M=R':(Z 25X860G.' G$78A>P8G%!*G03 G5!EW$S-UD<-W4A0R%B]UZIB78;
MXG855R.F@G9)8'<N+7)#5W)SUW9GMW@3MW:-=W93EWAI-_YR225:XR1Y51=Y
M<Q<,=?1UD85X6Q=XE\MSE1=YPW=ZO9=UPY=YRU<AP"A[Q9<]MY=]N_=]VY=\
MXQ<C'/<BW%=9W#<33H1^=[=_Y9=^>?=_^_=S>]!UE>43WF!T\?=]-9>!S7>
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M%):J#YX&*E\B!("-/QKFP<F-FS/!!([P M: #=@@$VZP&,EM#O9@J=K"@]Y
M#E( SS0 %)ZKB0*3O]_@$0\\(8!<Y@YI!6!P!-Z@#>;B*&+6)<J1+A#BLSQ#
M/1<*/]Y@ E2  ]Z$?&KD%1I@C9:N:4(PS,T<WN-=WN>=?4N@#T)A 6J6KFJ=
M,2)(W*?D AZ#?A(-+K&L1[1*%BA@,XRJ!-CDP<KB=3)L#IS291\)%B  73S@
M$\@-P?Z<(@.2(P->P01:#"%._3\0 B:P"Q-> 0+^@Z[&Y@(K]G7LTB;64EK^
ME)O3&EX@0ZZ>\&Z^RUZV$3O0KD;@H"30\C@V %_C  ^,9)9*30.V@P00XKHL
MX*'I@EM(JVGK8!E?0IHRH/X^ 30L )@M !0RX0%>E3DTNBW@V0*V(WGJ +7@
M0 $TS(,P(,,\H#*RB-[[WN___N_9H#4^ !0B]6I"(L970PTUK ,ZH&'H("3X
MP-@D2# ,]VH\8.!";3/88$JZ)E(?403N1LWD93-6X!7NH Y>8:RBW"5, &1!
MP(E:_\[-Y@/LA:E[09+:!1/:0"78P")8= \= K#^QH,\(9">-I Z?CINEBL6
M/N #[N,.,'%:YP(35!DA]GQGYX)M;C-P4\!"V"D%Z&5MLDZ:/>$-6N/Y4L #
M. !"8"&5,V!G>,$.-$ #7$?)2<A..$X$-* V0 '^\!4@X/!:<R$#&S:P-*49
M*#"%ISMK>$F<2+&BQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<4 P(
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>cogo_0027.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0027.gif
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M\O7Z_/____3W^?#O[P
M
M
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MN-#0<L !^<:X  &;W!! OP.1,$ + I5)@ S)_ OG,XD0H$ M7&5BP &S\'*
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MZF )J,!6D%$! 3@@!AW@32V,02H0QN@  ""!(FAPO5^(K '0^)X"P/,,9$A
M 0@ WD!&@  9ID ^"C"&PCXX$!D$0 $Q:,$!4):W6^E%%+?J&*EN\ Q&#,
M*8@! @!P F))\ISH3.=)H&$!!D#@G1(X@2,&P@,$3,"3S_[@P1H):+04*"
M![  *$0% 02$:BNSL, !7@<!23P#!PJ0@">Y,+H2#(26!I@G6$9 @!*L0  &
M@$ GC':P)(Z&!PT(P  >D,3P,$ !#J7%2T$1C0<@0'#=7)< &$ #<ZKSIT -
M*D:B$0UD(",9ASL-,@X'C:62IA>SX)% G%H07LRB%C!JZN&2\0M/"HH$"%A
MT0A" @*HX!FVF(5VIHJ,M0[D&+2@15*-VA6Z/J.H8/DC+8XAU+[Z]:]-@0$
M#!  G!*D @!@'V 7R]C&8L6GI6&$"F#@EX+L( 6&=0AD'<O9SGKVLZ -K6A'
M2]K2FO:TJ$VM:E?+VM:Z]K6PC?ZM;&=+V]K:]K:XS:UN=\O;WOKVM\ -KG"'
M2]SB&O>XR$VN<I?+W.8Z][G0C:YTITO=ZEKWNMC-KG:WR]WN>O>[X VO>,=+
MWO+>9[/F02^9S,O>X28C!1T0'$)'D(*QBB87&N**"MA4GXKT@@0E2 8T6N
MZ!F#%FU,2"\>,%#]%/6VO"#!"/88VUZ4X 0G*,&%3S""U7&6E;<BWS,\\4S[
M&J1<!*#%,Y(Q3KRI5S1;R87SC-$,0E4B9 #0I$"@4I!*((  #;Z/)$H  0=8
M(!#XQ,@**%">OXJL  U(*D%>S%A:O$X M[M,+&M#91\:HP&C>]R(0VKBT$ C
M.F*K1?[N!D(LXIQ1(+EHSHAJ@;=G% ( ,5"(,6PUT"ZGA08#&  "=C6 $D@9
M(;,1#00 <&.&^!E9_&F !0B0+S-_);3($,4L0-&?&&Q:JL1RJV:GS+(LNI,
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M0H466HTS #@E#$Q3-,GP  ?@<NIA1H-@ %>C:A.@'9G@?<\0"M"2 K20#)Y
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M F+#-:48GFJ!,PJP;<) -A#P*I$R$+^P&8TR JKXAR9$+R.2"V!48PJ BL;
M"]%@/0I0'0ZZ)8PP-#@"#<W@ M.X%3,P 'A" 0PP+L<P&3&@")HG3)X5)@%0
M>A&46+,D:,A ;Q#@14Z4#"I4BB= .A,P8BN%3\@P 8FI""I <RWZ%L80AT&6
M @O0I-&0 H1E 3^  !;(/ ]0(,\P 0@ 03= *'_88'WD2C=@ '!B";OB)R6
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MP' ^SI"TF #SA)_\RD_XB&#XP?Z]U&3^_&A.!&  [?F1#,&@3)1/^9;?[M%
M"36@^?.]])Z?\)T._;1.]Z,__,42#%J/!%V>^O(/Z^7O^TLMZ_U] 2$0!@9>
M%LX0"P!A)\V:-@79'$284.'"A&OF-,G@0>)$BA,U5/0 XF+%#R N; "C[-E(
MDB5-GD294N5*EBU=OH09<]FL2H8,(5JTJ%%.GCU]YGQT)8,&HA\V8O1P\8/1
M#!@R$ D#+.94JE6M7AW9K)<N7<:2'0,;5FQ88\Q W=BA0^U:MFIS;$%J,>[<
MB4LQ@%SVS!E6OGW]\MW+; ^4)U"B0$&<6/%BQHT3*P%!5S+&C2",7B!R:N3>
MOYT]?_Y.*4L@P38,39].Z.9AALB3)6LPZF&I!PPA)D$#G5OW[I.^."VR^5/X
M<$2,A!HU>E3R[ P7-&31S%OZ=)+.AG'EI<O76.YBD?GBP:/M>!TY;,1VG5XB
M[ \8@D3G3%W^_%=3D#C&G]^Q$@VMU<]%KZCFL@AF/@/G(\8/-0@Z: W4'F3(
M(8C\^X^RY)32X((C=CFP0P]'@D873()K9*?A3NS)N*&2^X N]"AJ\0+,)LE+
MKP]O7(FS[W3AI<?LAOFJN[&,.8:,&\AC*P<=MDBN0KDJ4NZ#YK08!D<KK=I+
M&3SN.TP_+_53PLG_V*MMDLVN1#,F5]I0HR '(813(=6:P/Z 0C$Y.JJ]#,#
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MN&<@)6"[;L5."%C5$C==V$50Z0$=^($L,.SH)0)I4>;S16['J%A,U3^W3FS
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MN/:-+ I" $(+%]>X& YE?33$'Y$L=YR=_1!_-UE"'DS'PZ   FEB"I-'"#A
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M]Z1*@56B_IG%;-C>Z<06"BI"(XR!'(2?1VI+U*F=5-G$(*I6Y97C@*W&-&;
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MS,!;%KF%%(,/B,A"#%.8A5;=HRJ:5A4\NH@BV"T[#-6O)(6%(D]5*EW77XN
MZ4->)?2;5:HXD0CL02K_C1 :8F#AM8\\T.ABBHOKO!@--/+ 0UE8BFFV(H8;
M+EFQT(X!!I5)P@ C"R.,($)FF6'.X@LP)CEEEV%$;M?DGS."N!0\\JA"3%OQ
M0P)II&.M @T\2H&%F,)(!AI38DI! [4.#3Y(3.K0N,YJ(*N>DAEHG$D[(Z#*
M'MMMCMI.ZFVW&7:&&6* @:454TKIF^]26H%%:F:HC'ON*@NKKPK_WC0XU(?P
M#%#NP_ZMC-MPRL=&"JB>-5(;\\\O_QQS9X#)6EXWN2XKU/X>BB)9'T,77?;9
M::]]W=JHMMUM96#IE4UA&W=J5-:+70+9/5[A\V3=F6_>^>>AC_ZXVJ !YI4]
M\/#UUR=*-398*#3. WE@.)?>_//13U_]]9TE[.Z\87FEE?D#AP688@C'*';V
M^>_?__\!>*;]M2J !33@ 1&80 AI;DH*=. #(1A!"4Z0@A6TX 4QF$$-;I"#
M'?3@!T$80A&.D(0E-.$)49A"%:Z0A2UTX0MA&$,9SI"&-;3A#7&80QWND(<]
M].$/@1A$(0Z1B$4TXA&1F$0E+I&)373B$Z$812E.D8I5M/[B%;&812UND8M=
M].(7P1A&,8Z1C&4TXQG1F$8UKI&-;73C&^$81SENI'R7JN,<4WA'Z.GQ69SC
MX^%$]L>@E$^0Q_EC(4W&0(\@$E.!M @C?S0A/!)1$"0P 0DL4(MGQ( $)!A!
M"I"!D5ZL@ $0$(24C!&#!DA $"2J9#2>(8-+CN $T2@$!$K0BV> (@;1FT4)
M&%"!1/P+&H& 0 -4P(N)T&("LSA&"4PY$1EXHF276($)9&"+C02B!:&\"#0@
M:1QH>"(1GA 9*+3I"T',8B+) ,7<JI:,&L3 $1.Y1 QFX(MG]"P4*Z#%/O<9
MSNS8(A&6@.4SDF$)1MR"(I8HQ/Y!9Z'+MX5!"V  P\V641$*'$ %*AA!+9!A
M  BHX 2@O @R)'  1MP  (IXA@4$0(,4 & ' )6/+W:   4@(Z002,$)5- )
M LQB!"IXJ27F%HR*WFQ2&3$&+P:P@!^,  "7L.FS:   &."  !9(AB,D  !/
MR* #LP@ +VX!@8/VR1FO4,7\5"$1BB0"  \8P0 "\,Z,G$ !QEA5,D@0@ ,(
M@ 2A] 0 8B ,!;!  9EXA@I^0+=G#(,4IR#%91_DBP,$8 (3":P ]%J100
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M856WK2+/.0%#11PQ@0-,@!&+40$"3 !+:%3@ - XA%A9=8D'($ 2SVC&#@
MBD2,&@*%2$$R&"%1 4ZA3@V9 E9@ ( )T" 3/KEK,T9;B61H%04'X(4%'C#3
M'? B 2,@P99)U M:-(,6*6B +Q(A@P'PX!(%2,8$>- "5;_M%./Z0 @P$ F
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M$'F)>$& ZD[D%M6%1M]/D(@3>((")] GT*1TB@M@Y@,72/)$>F& %DP !C>
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M-3N H0J0M@NJ8 \F1P:T"@<&P )D=&0!( 4D(0*RZU)8R@7$SZO 2JQFH*P
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M%C8OT"9 1.?C&!/2+FO*%W1KXV# &!" U$P-U::T3Y\!%NQE"?K@(BSA 0Y
M9-OEF!K +K?UM@A@O4Z  !;T1RX! A*@GJ(!V90MN!Y@$)[-$2A4/@DE_XA
M54^K$U[6)V J8 G@ 2*YKUJ  &Y@ A8 L.#2 C(! 'X@]GQ*JXR! "@@$ :@
M!?)3 63- )2++5+M&98, IJ!13\/ 3(!% ; $QA $$J %H3A4&&Y%<*B3I8
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M2NME XP 9%"_#5 !",'T!AP":@'R8J]WMP,:)  ")L+EP#!S(\LB-O  .M
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M!?IK!VCAUOSJRPL!Z"XA&BR !%CJG2IQ$TSN&0B-FB952AC!T2QA%D"!%@#
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MO,D$XFLM!!RBP"'/5. (IQIO?)X=::RQAAILD'K1)0;\8)($$/0BBB=R%8(
M9<*4R @ C#R3" "*X" #0@Y@?, S/)2P20D<3_M,,6FH 7(:@/#73 <1O%8@
M,@B<@/Z0( #,\@P7%*!UPPC'6'C## A-T$ H"#!@@)(X/%/ )BGL2:(S;2RM
M1AIMD'=1# & ,I<$!-#"R ] X5#))0P\< -A,:20R#.B!,!#("=LPN!%J*Y]
M"P4!'/##(0T\DT(,H)!0Z-&JKRX:'VJTT08;<RB#42\K*("K+0\\H"L!"I\
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MYX9F00 $P& 0-^B$ PA@"4LP0 '\Y-DS!. )2QQ@19LJ1AMR>H<V2"LC(S!
M<P84O;,TP $XJ84"-)HA:#A  (ZXQ ,,(!?[7<(BT8# +Q*A@&9$X&VH!(\S
MWJ &IOZIX0WK>48,", #1L!@ !! Q@@.,(MI'FL"#.C%]RX1#0N,P!,!Z Y)
M3TFA% !6<@+HV46X4(,'-H,1!JNI;VVHGN!V"1G+8%$,#$  !MQ,%((C@ 00
MN;!G!$(!$%   @20F>8RP!)>LL#,N-" !EB,8\+M4DZL52^,^,("!8$ =)]1
M NPVRC^U8&]R;R9= ]"M$%H2A@4B0 '?<*@8!"XP0LA340( @  68(@@ A
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MP3-1NBF&.0QB,I!8(A)@,0MD;-TD+WFAC6&(E"]B$ E$R @&( .&_"  T5P
MZJ Q @:@!$@VBL8#C&8!LQ7@$B-X*X>@P8B4&V(0C1!+M\9K"0MP]Q<T&,$/
MML*#2SCB$(XHA"=2P 5AX" %"3S$"5B N40$(A,IN$&XRZ,Y "B  ;>PP.=^
M4(C1E4Y))N^[WVN,\D4T8A&( !Q&>+$#(-Z@$MKJQ5(GX!.2@N+#<IQ1"C[Y
MC$HL@ (G^,$,9@&#.W>($HL0/"+P:Y&"Q<08PNA%,I+Q  ?@( $I2,8!%""
M& S\1_X$@( $#)  9)3K!QF<!? > (&!=5LDPBB6 7)Q;LJ)8@#LG%X,9_CW
M[&N?=<<PQ. ;80A4\*D9A3  !* Q@_8RH (7,08!;@ N?L*HE5I"2"W / )%
M*( '!Q!]7B61"*6W")" --' *C&1 @% ;(P7"+.P @!@"16@ +, #2=@ )PQ
M ,<R P)0"[Q@";5  ^@# ZL4#0I 8>ZA2JSD2L\@"!+ !8+0 GEW2_.U?35H
M@S;2"X:P" '(<@7" PH( [,0#0A'"[P@$1BA @WP<S-R$=\3&F)1.8/0423P
M$$<'"8DP> ,H%B-@5(0A" -P X(P8;'" H_@  I7 @D #?ZW &+/4"ZTH CK
MQP))U0('D!(F^!ZRA18J9388,0(O!24W*(B#."/&T CQ1@F-$#X8\2UJX@L%
M, &.,'"PU0D'8 "H!R,3L"L\U #0( D'0 L+@"<= @F&@ B)8 @$B""*   4
M$ J\4%$W$ H 0":>$ BUT  F@! G@ #-4 LKY88#$!$=\ SJ4PG$= S-T  *
MUQZR)1?39UM=DUL T R.T%N$B(W9&"+0(".S0 +K-RFELE7R]R+0L (L0%:)
M8#'-( ,0  -95B'.@ S'\'JOIQ$T0  !  ";="R>U  !< +"8  4X'($T RV
MX"T5!CZJ9 $5X$27=PSM\S[N,?YP*(8P*_8,+183%# ",::-'PF2-<)MQ0@!
M 0 #J[-\[5$+CH )T" O""$*B6!XHA!->Y$3H" 7=,&-E6 )R;!FO  *%S$+
MMO >MW <71$77A)-R7 (_A>23PF51X<1>O0#V*<I*1F56:F56\F55TDHVL8?
MH 8@-#@?6-F59XF6:2DA7JF6;>F6;UD=B+89ON +O3 ;&R$,(800N4"."/$+
MOF"6T:%J<$F8A6F850$#!7  PU8!J($1%@  R7 )+<!O 3 !C9*&_[8?PN "
M#N  +C S-P !+/ :DO VAXF:J5F8NL":NF +O.!T!# #@D # H U&>$(;U,#
M " 7F?Z%$,W %6D(G!ER @0@"(,0 "V0"010"P[0'1"PB*HIG=/9E9]P"9J@
M"9> 2\\P P' $+Q0 "T #23  S 0 X'@ JO" !$ "E@$#37@  O 1BFP #7
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M"8,07Y; BIA3 @U0"0,P"!!# C)@"15H "EA<^\!#5XJ S2  &,*"F7* S<
M Z0U/.-+P16L$>7KH* ::Z&#$*!0 "6 ,&3"JRIP7#(@" * ":PX%2B@OP/
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MT)!!M((,MD0DUXL,C) "%&  ,H"0!I\((T_6.3.G&;V_W8$,![#:X5("%2
M@V M(L&&,, (#T\#N,$(QA #@F !+3 !*1WP24]H:MX#.9 #-\#7&"$#-)<,
MD+P)$3 !26P)E] ,I#4!F\ JS'@#&;@5/=8 $N )GE )G;"BBE +"$ #VSX(
M^89F<)\S>Y("RTT 6C+6/ \ 7  *F5 )HG"&(F$+#-  <]X !'!GM1#Q I!Y
MUZCTDZ]GAA (@4 (@6 (8L&UX3,( ^"=Z30('X<GNVD"T #MHW@+ G!!R)<
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M> D=*I(&O9#!-,^3 JA%TZ"A9%<+DC&N4SY#!G-:VF>AH5)8XRH1R))!*%;
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*'5W2+5V@" @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>cogo_0059.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0059.gif
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M^_____CW]P
M
M
M
M
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MAQ#@0 ()M'#* P-D, 0$C8XID 8!A)'(" &TR5D7AAA@P'NM3*#:G?N&*:!
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MC_E0P(4'!* I+0   AS0BC4 8($"40, 'F Y # @ 16@X@1,9 '&,*I1A I
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M@@HT(*&2$!K(($LW G#AL@1"^,* "B30 (,U2"!@E,M44/Y )C0@"4 %6,P
M0 XT +BM3UCB4.T2 -103X 38"DA@$AB8>""4DAHP(+R-I%  EA&(< $Z!K
M8(('WBA@T5/82X. -3/   T5 J@D%0,Z@(6V,C108$T-0##D@!!@>0. ,RH)
M8(4(CT66J%%*>" $#@R(I!78-*BD)ZTR2,. -TR8 *@DC+S!!K1@7 (56+
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MB 6$ 28HZ10-8 46  E $*"+1  H 98P $7P#30(:*"! "BX+WKU " !EA
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M0"Q0,  TM(;Z '! !PS0@%@<1P2T!@,B C ",1@@?+"P0 ;^9@9VN@$2 JC
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MGR@%= 5C\>4RGS %K;"G4A#3NB$S0VYCE\I4=(TXNAN*2C" "8"#%2  ^QB
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M"2;O=X2%#M 464QL.*D$%I4 $4"4$H#0!!AD6#@! 5BA@WB9N8P%5R'J1 (
M,/B;\D&#%=" V/ -POF",50?$\!C!#@$!: ,+T!SCEP#]S0!$%"-KC;)#$@
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ME:13*WNC&^-X1SO"<5,E64@B#H   0R@ 4.ACU_*X(%*K/ZJ.Z0P@'H6P@8
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MP (D<(@X), !#$"$'""@  > @3L8P "-%M  $0S@"YVHP%"^T%422" .7<A
M(BJP  5\810:4  #1A +,@  H<U3:*TP\ "_4( U)AC*(T/PA0; 8@,H^,()
M0J7+&A !$$\0@A-@T9\:?$(4,_C$B@)A T#,H9BP"$5&HLE&:@X5J=YT(VW)
MR1(0T7$FV4S7'8.Z$@M]R+?:!.<,26(3 VA@(:5H0 1>Q85$L&44'C! 7S'0
M 4APH)ZPB$0 U%") %# #!80P!<@ 8 60 *B99@  -P@@@!4X@L$"$$D7-"
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MQ!5D %-8./,B.97F3U7MH:'&S*?CQ!2+VX543/E192M^]4E8/,?98LBI!7"
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MG*P<0M5-*51 <,A)*QR?1HI*" ! ;M#'EPU%;"(.&23  !0 !Q0)&"#  1@
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MK@1+S%^/H=JH_9B\8A.:%I$B. 8 !   E$$L,$#6K5P8\"@<%%T:$)8AC$$
M/,"R/4 #5 *PLL!30< :@   Q$$)!$ 7B(&EKH$'!  DG $ID8($1$ I2( !
MD$&TJ< H($ &F (<>,!>$H 'P,(#2(";.$#$KL$)I$)%K4$E.( #B"H")$(9
M#(!M<!(:>  I "L8O$&PYF;BP%=$J48 \.8#G D$6  $B %>D8 +[*%]U(!T
MHEW=82<L0,$,P  2B.N(^0$LN/Y"4*:K!6TIX9'I;^485L9+PW4(J%E*<?44
M-\4KC#F5 5R (1A"')3"*2@ 6BE"/I4" :A "Q! *XR2(1 6&O!9 /!%+#R
M!<2! .P98;T!"6#N* A <' ! /!!"3!7!K"J'$B SEY"Z<)" D15*Y!!!U0
M GA +&@JC'!!I5( BQ(O4A! &2! :RZ$"0P ))1"%V@ !1! %[A!L%H.%<6"
MSQ) >AV Y'EL9XQ"&I"""'S!!)0 !71&]4F+#+HM+( "#/S!*^2 0808#O@
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M?,"I4BN-3, #H$"1E,(*Y.Q0@/Y!J!J"!4A %WC &,2QA5T.''AP!= E46P
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M.(R/N(O'..HP^$\>8_-4 AG 4]WH.'THP@3$01R401HD^1ETX"B0 1>0093
M0BFD0<>J2BMLP%'4HNX0S98CCZATN4)5)(]F.7>K3:_H.'C# @@<0"M@0 #X
MZVB>'&\B0  H@'0H @0   $$P $@% H,0/_M^"U& A+%"!7I@0CN)1P$ +7Z
M120@0BS4B5\R\7WRYU, >2L8Z([(R&Q$.1-%":<7^H\<0J +B2&0Z"A<Q6#T
MN0^9J#N9 2R8@0%D%@8(@ NTA@$8@.8!0!B@MZ#+62MX /X!"&P9M$*<2D##
MUD3T(@ &#$"6VU?/'0!BB($""&H+P&D&(X*SD\($$ !5G9F?)L )8( $5$
M,  \42H#'$ 8A.X$F'MTP,(8),!PN@ LR$$#&  !C,"0"-10:( !K($B( (C
MF3,(H$$D[ DB4!5W,-&!'D O_SH?1L(&K,$H)-TH-$89K!P8Q!P(( ((<&R>
M&( %)$)%<4&7+9(VNP$*!  I]%<CI&XD@"8+0 )ZH( >+,<8N.ZU<\ 9D$($
M, "W&X 81!L+5,( 9$ D),DA3$ $F.^_&G: U<4 ^"MRP(4   !Q1H+VE@ L
MD$()2"LDQ$(#6(#$T^(:A  &+/X !50" T0N$8^!S,5!C\X<)=&) 'C!EUE8
M>ZU M97!!DC *3R  W# !AP !<@! ;AO X!H)0A 8<O7!3  !/"PSH["YXK9
M6P;2!&A !D#50MPR* &\&1@"'*2HBGY!!GRS&PA +X^"S[ERV9]]\"6215$"
MN5\\6AE" (3!EZ6&F$E%(@B !YS"EWT!CW9NS,E&V2M H3F ?,1!&K"!XB/&
M;_BP ' !W8N G3; *'QH+$2"K6OO&#!>A2& KKQ!&N0U@'4NP/-E7Z@]CXS"
M D! )#2&K(3  ,!!+ @Q[7L;0,2"Q06 &#0%(%0R4 &6(0!<*@UX@.(!@!:P
M8*T8D/[@08$6I1(T&&-A@"%8)0 80 3+Q<,Q";I  E "5BD%$&#)9)$&@!<U
M"114:N  5B0 )DHQ4/"E(J00!,0,.9 &(Z( +F"19-#@@8$W7@ T"'$!  E8
M80 D #$A08 WHP*P@"408UV[=_'FU;N7;U^_?P$'%CR8<&'#AQ';'27B@0D5
M(49Y0%$T QE8:"10^*(!#:Q6C<RX>2- +B(.#3"\P6@H PJ!L;I :' B524,
M8#R#H+DI@YA6)1Z06/&AT@BSHS)\@97( VHXL$BA: "A2RN,L1YD@*6"@P<.
M'3 \%X/AP80AUB]G<, !#H=$:P#(23R??GW[]_'GU[__;F6I" Q<L$  DZ[C
M;R^Z^!(#@)7V0N\N!&&18 ((#:S0P@LQS#!#"@N<*Z]*3+@ !-4Z// O"#GL
M*\58W*#$PP?K0I#"5MRH1,,;<<Q1QQUY[-'''X$,4L@A\Z(K12*13%+))9D,
#"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>cogo_0030.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0030.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   00# 0$             ! ,%!@<! @@) /_$ $40  $# P,!!00'! <'
M!0    $" P0 !1$&$B$Q!Q,B05$R87&!"!050E*1H2,DP=$)%C-3<K'2-51B
M9)3A\4-5@I*3_\0 ' $  04! 0$              P ! @0%!@<(_\0 ,A$
M @(! P,# @4"!P$       $" Q$$$B$%,4$3(E$&,A1A<9&A@;$'(T)2P?#Q
MHO_:  P# 0 "$0,1 #\ DC[&.:Z%Q9@J0(M'7'-#<1\@JQ@]*BXDXL3)YYI)
M#MF,BGP+<C0KP:1$P7#BED1HI62*3$).4PA/>$<YIFQL&CKRLX3UQTI+D3$1
M(]<<U)<"VY-2\=Q\-)L?:DC0NG\-+ L(UW<^+FFR)FQ(SP:9HCY/E' -)#^1
M,*XYJ3&8BZO''K29) I.#UI9)GW>$<"D(U+M,(SWM(1:;JDE)&:NM(J9 E#
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M)/'%,V14F#.,('E46LB4F!OLI2>*@T%3R/W9^XIN]I92X07L)!]#G JKJEG
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MF:Z<[6^TY$2),[1>SMAML2U,R$6QTM28K60$R%-<I*2>-J3G@TIZ.BM[H2Y
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:+]PK5F.#J;[+N_\ N4K_ /!?\JM[C-V'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>skill-x.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-x.jpg
M_]C_X01G17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.#HU,@   Z !
M  ,    !__\  * "  0    !    $J #  0    !    &0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M259N/__9_^T,<%!H;W1O<VAO<" S+C  .$))300E       0
M         #A"24T$.@      \0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M $4
M:0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!2
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  ( 2
M  $  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-!         (  3A"24T$ @      !      X0DE-!#        (! 3A"
M24T$+0      !@ !     CA"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -+    !@              &0
M !(    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M         0              $@   !D                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   !D     4F=H=&QO;F<    2    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<    9     %)G:'1L;VYG    $@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M%       !     0X0DE-! P      TT    !    $@   !D    X   %>
M S$ &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( !D
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
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M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  9 !(# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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&O?NO=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>skill-g.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-g.jpg
M_]C_X03817AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HU-0   Z !
M  ,    !__\  * "  0    !    %: #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M,  X0DE-!"4      !                      .$))300Z      #Q
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P
M3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%(            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      !  2     $  @!(     0 ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$         @ !.$))300"
M   $     #A"24T$,        @$!.$))300M       &  $    ".$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     TL    &               8    %0    L 50!N &( 90!N &$ ;@!N
M '0 +0 Q     0                         !               5
M&                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M&     !29VAT;&]N9P   !4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   !@     4F=H=&QO;F<
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M# P,# P,# P,# P,# P,_\  $0@ &  5 P$B  (1 0,1 ?_=  0  O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
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M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  8 !4# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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L^K75U)G]1]M_</[G\0_5>/\ 4?4>'%J^JI3QO#T>%33^GX6CP_ _1IHZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>skill-l.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-l.jpg
M_]C_X04417AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR." R,SHQ-CHU.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M[0T<4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      #Q    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /
M<')I;G10<F]O9E-E='5P3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T
M &4 ; !L '4 ;@!G       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$
M     @ !.$))300"       $     #A"24T$,        @$!.$))300M
M   &  $    ".$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      TL    &               8    &P    L
M50!N &( 90!N &$ ;@!N '0 +0 Q     0                         !
M               ;    &                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    &     !29VAT;&]N9P   !L    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M !@     4F=H=&QO;F<    ;     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M(%A96B 'UP #  ( "@ ' "EA8W-P
M     0  ]M8  0    #3+6))0T.<;32EK:1%]A1MF+!1#!)M
M                              EC<')T    \    (ID97-C   !?
M 'AW='!T   !]    !1R5%)#   ""   !81G5%)#   ""   !81B5%)#   "
M"   !81R6%E:   'C    !1G6%E:   'H    !1B6%E:   'M    !1T97AT
M     $-O<'ER:6=H=" H0RD@,C P-R!B>2!#;VQO<B!3;VQU=&EO;G,L($%L
M;"!2:6=H=',@4F5S97)V960N($QI8V5N<V4@9&5T86EL<R!C86X@8F4@9F]U
M;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R9R]E8VDO96XO96-I4D="+G!H<
M &1E<V,         "F5C:5)'0B!V,@          "@!E &, :0!2 $< 0@ @
M '8 ,@     *96-I4D="('8R
M                                         %A96B        #VU@ !
M     -,M8W5R=@        *\    "@ 5 !\ *@ T #X 20!3 %T : !R 'T
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M;0B&")\(N C2".P)!@D@"3H)50EO"8H)I0G!"=P)^ H4"C *30II"H8*HPK
M"MX*^PL9"S<+50MT"Y(+L0O0"_ ,#PPO#$\,;PR/#+ ,T0SR#1,--0U6#7@-
MF@V]#=\. @XE#DD.; Z0#K0.V []#R$/1@]K#Y$/M@_<$ (0*!!/$'80G1#$
M$.P1$Q$[$601C!&U$=X2!Q(Q$EH2A!*N$MD3!!,O$UH3A1.Q$]T4"10V%&,4
MD!2]%.H5&!5&%705HQ72%@$6,!9@%I 6P!;P%R$74A>#%[47YA@9&$L8?1BP
M&.,9%QE*&7X9LQGG&AP:41J&&KP:\ALH&U\;E1O,' 0<.QQS'*L<Y!T='58=
MCQW)'@,>/1YW'K(>[1\I'V0?H!_=(!D@5B"3(-$A#R%-(8LARB()(D@BB"+(
M(P@C22.)(\LD#"1.)) DTB45)5@EFR7?)B,F9R:L)O$G-B=\)\(H""A.*)4H
MW"DD*6PIM"G\*D4JCBK8*R(K;"NV+ $L3"R8+.,M,"U\+<DN%BYC+K$N_R].
M+YTO[# [,(LPW#$L,7TQSC(@,G(RQ#,7,VHSO301-&4TN34.-6,UN#8.-F0V
MNS<2-VDWP#@8.'$XR3DB.7PYUCHP.HHZY3M .YP[^#Q4/+$]#CUK/<D^)SZ&
M/N4_1#^D0 1 9$#%029!B$'J0DQ"KT,20W5#V40]1*)%!T5M1=)&.$:?1P9'
M;4?52#U(IDD/27A)XDI,2K9+(4N,2_A,9$S133U-JTX83H9.]4]D3]-00U"S
M42-1E%(&4G=2ZE-<4\]40E2V52I5GU845HI6_U=V5^Q89%C;65-9RUI$6KY;
M-UNQ7"Q<IUTB79Y>&EZ77Q1?D6 /8(YA#&&,8@MBBV,,8XUD#F2091)EE688
M9IQG(&>D:"EHKVDT:;MJ06K(:U!KV&QA;.EM<VW];H=O$F^=<"EPM7%!<<YR
M7'+J<WAT!W26=29UMG9'=MAW:7?\>(YY(7FU>DAZW7MR? =\G7TS?<I^87[Y
M?Y& *H##@5R!]H*1@RR#QX1CA0"%G88ZAMB'=X@5B+6)58GUBI:+-XO9C'N-
M'HW!CF6/"8^ND%.0^9&?DD:2[9.5E#V4YI6/ECF6XY>-F#F8Y)F1FCV:ZIN8
MG$:<]9VDGE2?!)^UH&>A&*'+HGVC,:/EI)FE3J8#IKFG<*@GJ-ZIEJI/JPBK
MP:Q[K3:M\:ZMKVFP)K#CL:&R7[,>L]VTG;5>MAZVX+>BN&6Y*+GKNK"[=+PY
MO/^]QKZ,OU3 ',#DP:W"=\-!Q S$U\6CQF_'/,@)R-?)ILIURT7,%<SFS;?.
MB<];T"[1 M'6TJK3@-15U2S6 ];:U[+8B]EDVC[;&-OSW,[=JMZ'WV3@0N$@
MX?_BWN.^Y)_E@.9BYT3H)^D*Z>[JT^NX[)[MA.YK[U/P._$D\@WR]_/A],SU
MN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@        IG@  %'^     %A9
M6B         ME   FB   !%=6%E:(        "+)   3X@  P=#_[@ .061O
M8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P/_P  1"  8 !L# 1$  A$! Q$!_]T !  $_\0!H@    8" P$
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'7W:ZYZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>cogo_0061.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0061.gif
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MBLBEE]2LF]:HE=BQG<VSG<6KI=JTI-R[K-BVI<^UKN*XJ^&JE-W LN+"L^#
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MYH*:&2@.CJKEEJ&PZY:&_Y@%ZS2OTESOF@D]XV:NTSQTYD0&^>M=G10AC(Q
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M$ISL9.QT'+M%[[B\.([G3\>[Q$;P.*A K@184U@OA@C8OZJM5QRG7*\Y[M'
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M<FC(=QO(27EG?,H'"7DW. 01&(K#$$IF,S53#C1#+YU&0XIS$-H##N( #N2
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M  8GV!W*$#U]6"_R4DO=H#<%\6XG^8<<%0Z".(CM@&74:/X,PQ ,RI )B[@
MWN@!(D"/00!V)V9Q&#<#[(B.AM!F.V"41QD#]Z>$ (B$2GEQ57A[Z]2#6-B/
M#-![$X !67!8B8=HPAB+9)B!65"!MH@%5G"69PF17- %!>D%9M %OF@&9J %
M75 &8E &:; =):A+?C%"KZ*'->."-'0-1Q<-WW"(@PB3+RF3P7 TE] !W,@
M$= ",R"4E0F)A>!K^F<#Z6@(A[ (A[ *AV (17F.^S=B1Q@$];B3),9__O<!
M$8!['I=-/;AG>P:+DR!CN?D%7!"+:<EW9!F6&5B!&2D&8% &72"7ROF685 &
M:X &W:$S)ZA+:?*"!5$.S$AE/_Z'506A#/;UG85X6M2 C<.@#,-@!?T8 0[P
M >U( ZK)CIQI QL&B8:P"(N@"(J "/EY"%3  U0PFC:PA#, =IG8B91(8HXX
M20=77?AS3OW88ET(;9D@#)9@"356D%>P!;-(EAL:AF\I!B!:!F$@!LMI!FL0
M!FN0HFX0#1]Y@MH!- ]5$-W7#-WG#:3%#2AY.*=E7^3P#85X7^#C7L@0"230
MCW,U T%0 T% !*H9!$D:H.S(B88 "_BY"OG)"H<PFE1 FH:@CIK(A)>)FCL9
M=E?'=AH0 >E41 #)8@VHE;EI"6E0H7 *!B:'!5NP!690@7DZBWAJIQC9!6&
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MM&^2NJH[#9-3$-OWG9$G;PR5HXKS6:\2M>$)'LT0#<.0.O7S?D)  SD@!$6
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MR$O !/YZ[LTZT+=!4)^+H&A7@$-$U $E( 7-#=W(B9S4_>@;&>-YO==]\ >
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M_@8<5LD9QA$K"CG*8R2KZ]57Q1>?O)>75_ZN*Z[*PLHJJYAU1>=>H0JXD,*
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MU'JM.W!&B]BSI4I#HFN,J2D#/RD#F> J;>"JIU.Q4%F)&*F><9R]XELK#=3
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MQV5P1V+P.C[8!"&8@49 OB"8@1D0@A!P@! X@14(T@7P #(-@1@XA"4H@NH
M)J> @8F<#AV  1CH@94[ 2 -T@;86"5HA498S(2[K/]B0EMDUF;;!#=A-1[8
M 33] <^\@BMHD&,$@^-T1CVP@SS 4#F+ PE5%(?H.:,< R^HV@5AD!"K"=O4
M!F\4!W)X.MZT!FD86Q-M!D:=+DC-M']-*$M )7F<1]\3A(2M(X<5@BGRP1!X
M@! PA%&P 0\84AM8!$/8@4/@KX_U*&DR61HH D1@ AW0 2<0L$+P@%YE@ ^P
M@?4<')]1@KWX+\=DA%PSMF9UD_Y$4 0";0$?.,\>D%Q"<-TM.,;\FP,YR -
M2!2>C(,X>]H+^8S4F ,W*(.J'0,P0! %>1K:Q :G9#2P_=H3,X?DC1&KQ$I]
MY9Y-NP,_L#09$UA4ZKVMU-1-4((I$E]*I ' ! $9X %$.(0;D 'H6X55@ 7_
M0H0B*(57D 5I@D48> &8O3X"985:H(4@^( (B( 90 3U#('%]!@Y4J#Z,LG*
MY 0WP28>H (@Z %=6(4>8(5-N +7U8+*0*T(U8,\X(,ZP#W,>UJ>5-K12(/=
M0<;A19#'V" 1>Q&9D(EQD$IR$(>P]:II> :",E&[XIX^&(1(/0,Y %A@4$X+
M'$1";/X&43B$*54$L_.N[[P!-1U0*CB$0XC6^%T%NDR%5PB@)DB"(<B!'(#9
M-5D%5FB[RC($&Z@!'B %'+B!%X !'4"UD&O"^%569[N/*58"'V"!(;"%6N@!
M5=B$+2"$1[@,S>"_.N"T/.B_.<@\AZ!3<07>,4#&+_ @#I6"F)"):AB'VUS>
M';Y-F3 TCV@81K4N[AD$3M,Z2WB#@%7.#Q2&)C8&45B$'>@8(D/%%YB/ N5B
M53@%5CC=0T"$-38$)$B%J9"%)C""M!,")$"$CCD$'L#F14 "NCP"0^ !', !
MCH0!(YL/16A@ 5-641"\YFN"&\ !)Y"%7#AD46@0+VADK/Y[VF]UQLSCYV_U
M9W$E@S$X2F0TI,G0'6Y<-Q#%X9,8U.=]$4/;(1V*!EGJ!F_@GC_H TB= V"8
M926V96) I7D4A43( 23P+B);026PK_==A5CP7V1^W^AHN+78G"1  B-POKQ
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M(\BBM$ %:B&%NEB"0X"X*ETI65@% RH%4@ 9G>$^N*BF6N1C=58$1>B!!W@
M()CM)7B%'^ !69 $/OF",0#Q"$T4$L<\1$=Q.UAT-M#0H_XTW@2!A$B(A#6@
M L:@<:]JRML$^'4(5!O>AG$PM%6^*H&KWB'? SP8SG9\4;\F[&" ]2?B 2=
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MX,,?E@&T81PE&$II1C14*8I6UDD6K6 "^5[!+1CX8 BI*((+6  !$.3@$*1
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M&;+A'$A@ ^J!'I@A!F2 !^Y%E@BP /,# >/P#8>@ 77 ];P'!ES !_90!WR
M!WBAU )1$ -1W^A!'L1!#2B@!,6N MQ1 8IOM8SOIYS*C<SLJ4;K^: /S' 0
MJEH+3+9!&VIB&P@RH'+.=JZ!K7J1"]4*2S+A#"CA"ZZ %F61"R"!%B'!%JL0
M$B!!$C"!*[J0_I#P&NA/'")A 4I 'NCA'6K !W9)EW( EB8$/Z+1318$#N&P
M 9NN>V[ !WSR!H R!VZAZVZ/OO[,\=1 \!QY3@HH8!$/0 $H0 $J("HK(!*Q
M20KJ,08U$9S$J0K>#IRR8,%RT!/_<10)$DRN@2"O82W1DJW4ZBV'X1BPQ!*>
M<")ED2(WTB(MDB.9#1,\0?+H+R%KAQO. 1DN  "H@!WD(1\6H05*JM%,J:3R
M@R9OL@D: WJDC@_S"J):H/5BSQ<H:Y@T,!_P <KPX31-DQW 80HJX  6$2JC
M\@05P!%34+4\$2O-S ;#Z>W #+7(,@MT[AJR(2USSA37\CC7TBT;D@FGY5F>
M$!:O(#KUDB-KA3H)P>4P(1B2@=JXP?ZJ[1VV(0H&@ (B :OR011:@.H < =D
M:3WO(_YL;/(F,1/J^'"&BLX'[I 1[(WK3$TT<:\T_2T=C($U7?,U9W/X** U
M(;'*#&ZUY*ZIPNPKP7*T/-$3G^ X#S+GD'-#E;,AY1)+LJ02K@ 2*E(O+5(C
M.=(*'P$3CF$[ZT\8[6\; &X )@ 9Z.$8XV$&&(U"8G)"3*KIX#,_X,(RYW"C
M'FJO?#+V6L'>](%)-? TK^@T[T$>#A$=C&$$@D_@%J 1&W$V#V !$.  #N "
M1L ?L1+7LF WQ<GMR"D?GV]#X30M PT;UE+:Y/(8\/08-.$C)Z%/271$,9(6
M944*(0$[01+%-(_0P*$$#$  ." ;X$$EZ8$16D"68J][FOYHL=[B/>5P"%I/
MKXZ4&X$2%@#1/^T!'TC3-/V-2M-!'( A \2N! U 3!EQ$1=@5AM1[,BN!,+)
M*]_NCG2SP%[+0L.)&^+T6),3%-[R$_1T+BMA$D;T+JN0"PC!_,R/"B$/YIYK
M\LYA&IAR$4>@\Z@T'_RA$"@04P'P7B %"1H+"8Y ,W@ *!WJ2+>1!7S@$":+
MOD33'E[J-/UU57G.)"E 3&7U5A?Q8&UU 0A@81>  3: !)[@CL[439M*+&]P
MM0[NM;AA&I!U+<%30Z]!K4 A3_7T6>@2%PD56SD2%Q4O$_AL6[FA'H:A!";@
M5@N@!"((O_J!%V2 T7" /G% B/YXB%Z"]@@P! _WJJ)<0 9ZD@6((%_U=33[
MU5_/D4HQ2!RDH#6#[V!EE0 :%0 ,@   8$L5=F$1P )2T. *[. B-F+!\K,R
M=IRJ@&,[5BU!]BVA 4\?Z5G]]%JY8!(XLD=PL4^_8!+B;PLI;QZ2@68G($P-
M( JP"A[P*Q_L@0ABX%^&X)36]5&@;@>.  EZ8%[UL&<GD 5BH!?LK2BM"*;^
MU5\/D4G$@34K0. 0ME$/UFL!@  4-@#(-@$(0 $VX*>H0 JL:=:@J@IT\, ,
MK&.1<QO^X1J>]Q_REF3W=A+2('!3-!<A 7 +ER/[U#PT01FHBQ-*8 ,N0 )F
M]0"DX/X>L"KKFM0?:F 9(7 ]B<!=BR (=,F);F ;*ZJA@')I:V$_-3#?7 I5
M79=*]^%UC24#6E/@%I9V!>"!%Q$  @  <G=+=9=L*6 #C*]!(_:.I IYBW>I
MB+<*$K)N/98DKP$4E)59]=9D170C)X%'"G6& =<1)@&',<%ELR$<AD$+.,!\
M)X "$& VK6 ?ZD$>A(D0-T%M>."4=@ )W'6)V+-[Z'5I;P /:2" *8O?FHPT
M__4>Z&$?$EB!I4 "!$Y+(_B!V9&" ^"-U[AL%99L%R >AS>/N#)->W5-QPDX
MUU(;CO5Y098DU2I/P5<3*J$2KC=%><2&=\2&^[02AD$:E/YA$DK@ BY@ S9@
M A3  ,(4$O9A.;).7^-A$981BATE>Q9E,_40BX&2!O2329E,7U=5'NX!-:D4
M'NHA.Z# '1LUC8&Y@@$@C2G8C=]8=S,8@P6  C(@"L0)CYD*A,7)C8J7;BLI
M+=?2;M7R.-^29)N0;P$7<%VN3\F9G!]!DI$A$J9@ B8@ S0Y R0 3-TQ$N0!
MJY:8'^Z!']YA7X#6;=B5B;K'QC#C!F)O A5A/YN,E@]1)6W9EN_AH>$!D4;
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MODHS%Z@ !Y"@I'@@ '>@!WH@!WK@!A8A'GC/U%X;]U -J^;AH5_]R^MA'K1
M %HS*K=TP\,6PX%9HR'8S7]9PT4ZHRU8KIN; *:, .*1>#&4.+,YQ4'6L)\A
M_%BQ9"]!QI/+T/5,$F8*016  4X0R"^ ^$ZP'<?4&.I9'KSNTC']'12!!GC
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M;QD)T"@ TPQ%7(M&O4OI,T]Q<PTWT#BBP@6A9L=:20&@=-UWW?D8P$U=<7M
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M)S\148@%  J+BJ*-;0 0&SXYQSZN@0G666 "%W@=A%;BDIG,#B2[$Q%-!#
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;IY:UGFN]@0GL^0*,WD"M&0WL7@<;V+X."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>cogo_0028.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0028.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MY)I$-J<6T6J"M)3"=?*G6AE#HZ/#^M$J7R0?<A-?Z.M6N=/2+1/1\2"$*/\
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M3-UU&_"D3%<7-(AQJ&A]J+)66RX\206=\8P-\[T-V7_VO^@4NI2X4J?Z_P#
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M1^"YD]5?ER?S#'K6>U73^H*?>2B_RSDNM/U+IS@Z8[DOOC!HC[+_ /E[2/\
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G39?JTFWX3_/R$?\ !4O_ &=C?\.'_35?W+/YF77T>F_DC_GZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>cogo_0032.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0032.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M5(&1K)U:P20<](U9Z;'+#;DV82UF:.I^-8TO[EIH5KWW6'VZT]3V:,Y(*U3
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M)Z7$D*=743X:<CF!IR=^@B12C!6V8VIT7Q_5!+*L:LM*EY:\JA*O+"1,/LL
MI1S\J<G>*>75+*]L40PTSP*Y.S1[=HR)6K(:8'D\4G4$YR#$F)-2*V5[XM]6
M:+?<P*18=3=;.%(EO#;)_,LA/]Q,='H8*>1*2.;\AF^+33I\_P#Z<]R81L$@
M9Y _WQNREM5(Y.,4^7W^2>I[:SL"3"@_Z SZIDNF6<*.L31*TF,W::^M>4@_
MI!W0R5CRDM.L32=0AE(*B^F;*I1(].\27:(7PR/?7EI2M4 T'%E5J#FI2OG
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M9*LE9 Z':(B2AXIL-I6[T2D'/TAF.D0FE1_$!((5J!',&&9(:EPZ]H[B+P]
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M5>DZF5;=#4N"5NO@9\-/?T/2.1T>FEJ\RQ+_ '.FU>M6AP;I=^BWHLI%&?\
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MY35]EF,&#D+&O0JUN67<&XR<TJ8_DAK7Y'IOT/Y:S;O=G?\ -"X,(YG[*F,
M 9/[$"Y(-)_@F_9OX+U3BY[0=*I]]656ON^''I^:;FZ<^TVXTPG+;14I &ZM
M.V=]X+&HSERR.>['&TC[$6M0_=9%L)EU-AM(2A.C2$)Q@ #&V!M"U62_JF2:
M;$JMHEU4M.RDR^Z3E&6\Z3W&T0?,^B3XD/):4T9"D*)SDY'6(W+V2*/H*IM2
MUZBT=N7E.T!'Z]$CYX9!7S<LK8]HU6[ZA*S+[%$DG9M;3+*G'%Z4G 2E()4H
MG P!U@X5=-@SON*/A+Q$9XJ<2+WKE^5^SKG=J%>GG9UU2Z1,DIU*RE'P<DIT
MI'RBUN2X16<7*2;*P;!OW'^8ER?\'F?Y(5K\BIGAL._2-)L6Y0GKBC37\D+<
MOR*G^!FSPZX@3#QG5V!<VA *&@JC3("4_F/DYG$-%Q:NPYIQX2#/6'?X'A_<
M2YE;9R*+,C]VB'N/Y 6Y^ADOA]?ZB$_<*YL#_P!&FO\ IPMT?R'M?X';'#N_
M,$_<6YA@=*+,DG/_ +(2D@9)_@?*X><0$)2G[AW&EP[$_9<R E/;9N"M?D91
M8W?L._''@Q]P;A,NR<D)HTUYU?\ Q[P.Y?D>FO03_P /[X!)19US)'1O['F@
M/ELW#.2_(6U_@/+6'?1PI5C7*G3R I$SD'K@^'^XP2:_(#B['/W)OO\ U*N+
.._@LQ_P!.'W+\BVL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>skill-m.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-m.jpg
M_]C_X1#117AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHR,#HU-P   Z !
M  ,    !__\  * "  0    !    &J #  0    !    %P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $   ^;         $@    !    2     '_
MV/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #V
MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ %P : P$B  (1 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,
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MW/Z(=&1PG7.Y/2;^OO9FY#!ALI+78+7-_3>US;/6R=6O9N:W]%B[O9O]2_\
M2?HV=$EP#;B]7;^M^[Q)]R6IX/18]5_H_O<#_]#L^L U=<JR3CU9;?1K;74^
M]E3FVBRST7^G<1ZF[?\ H?\ A5'.SK'9>([/Z15]J8^</U<J@/W'V_HFN/Z3
MW;?[:^>4E9%U&^&^'3^>XN'_ *GZ6E*N*?#[G#Q>JONW!Q_]6];]*CJ/7)'^
M2"!.I^T5+57RJDF>B_\ )[?ZZF3];PG^>NQ_XFXO^\?_V?_M&-I0:&]T;W-H
M;W @,RXP #A"24T$)0      $                      X0DE-!#H
M /$    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ !(     0 " $@    !  (X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300        "  $X0DE-
M! (       0     .$))300P       " 0$X0DE-!"T       8  0    (X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #2P    8              !<    :    "P!5 &X 8@!E &X
M80!N &X =  M #$    !                          $
M !H    7                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<    7     %)G:'1L;VYG    &@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    %P    !29VAT
M;&]N9P   !H    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!0       0    ,.$))300,
M      ^W     0   !H    7    4   !S    ^; !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  7 !H# 2(
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MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T5N1<>OOQMY]$8C+
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M29Z+_P GM_KJ9/UO"?YZ['_B;B_[Q__9 #A"24T$(0      50    $!
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M0YQM-*6MI$7V%&V8L%$,$FT
M    "6-P<G0   #P    BF1E<V,   %\    >'=T<'0   'T    %')44D,
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M('8R           * &4 8P!I %( 1P!" "  =@ R      IE8VE21T(@=C(
M
M                6%E:(        /;6  $     TRUC=7)V         KP
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#]?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>skill-z.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-z.jpg
M_]C_X03Q17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HR.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    %0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $   .[         $@    !    2     '_
MV/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)
M#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ %0 ; P$B  (1
M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M']#;_J3_ /_9_^T,^E!H;W1O<VAO<" S+C  .$))300E       0
M             #A"24T$.@      \0   !     !       +<')I;G1/=71P
M=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L
M<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M     0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M
M $4 :0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  (
M2     $  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-!         (  3A"24T$ @      !      X0DE-!#        (!
M 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -+    !@
M%0   !L    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M             0              &P   !4                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   !4     4F=H=&QO;F<    ;
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<    5     %)G:'1L;VYG    &P    -U<FQ415A4     0
M     &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A
M9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X
M=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI
M9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!
M;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"
M1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE
M9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG          MR
M:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\        #A"
M24T$%       !     8X0DE-! P      ]<    !    &P   !4   !4   &
MY    [L &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M !4 &P,!(@ "$0$#$0'_W0 $  +_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&
M!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ ._ZMU8U
M;\;%>&6, ^TY)&YM(=]!K6?X;-N_[38W]NS_ (4'2OK#26VXN<YXR\5Y8X!A
ML<6'^9-SL5ME/VG9[;ZV?X9EB75^A- OZAA664WM#KG4,]S'OV_I+*Z_I4YE
M];?1^U5?I*_^,6)CW= &#%--]&0XBS&8]^YE1GUOM.+<Z:]C?1_G;OTGH_SW
MI8GJ6*U"&.4- 3M9'S1E_P!ZTLF7+#)J8QT-"1]$H_H\/];^7^SV+^JYEF6^
MWU/V?116;,2K(;M^U:[;'V%PWU-;]"G';^M_I/M%M?\ @5I?M&__ +A7?T;[
M1PWZ?_</Z7](5'I-[^KY!NS6-W=/(8RL#V^L1N.5L?[JK/3=Z;*7_I,?],MQ
M,('$(<(L#;Z?O?\ .9!(\$LG&>$D4?\ "_=_YC__T/55QG5!TG]H6FAV4&^N
MV6XS:B/M$_IOLC[WM=N^A]O]!G^C]?\ 1+PA)38+LUQ;?H\/X\;7YJN&-\._
MZ?%_S?;?I?ZO_LS[!_DW?Z>[])ZN[U-^UO\ .>I_P7I>GM_1>EZ?I?HUIKY5
M20_ROZ>__5%W^1_0V_ZD_P#_V0 X0DE-!"$      %4    ! 0    \ 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (
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M(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_X@?824-#7U!23T9)3$4
M 0$   ?(041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                                 0  ]M8  0    #3+6))0T.<;32E
MK:1%]A1MF+!1#!)M                                          EC
M<')T    \    (ID97-C   !?    'AW='!T   !]    !1R5%)#   ""
M!81G5%)#   ""   !81B5%)#   ""   !81R6%E:   'C    !1G6%E:   '
MH    !1B6%E:   'M    !1T97AT     $-O<'ER:6=H=" H0RD@,C P-R!B
M>2!#;VQO<B!3;VQU=&EO;G,L($%L;"!2:6=H=',@4F5S97)V960N($QI8V5N
M<V4@9&5T86EL<R!C86X@8F4@9F]U;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R
M9R]E8VDO96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M        "@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M         %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5
M !\ *@ T #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D!
M P$. 1@!(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H
M ?(!_0(' A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"
MXP+O OP#" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01
M!"$$, 1 !% $8 1P!( $D02A!+($PP34!.4$]P4(!1H%+ 4^!5 %8P5U!8@%
MFP6N!<$%U07H!?P&$ 8D!C@&309A!G8&BP:@!K4&RP;@!O8'# <C!SD'3P=F
M!WT'E >L!\,'VP?S" L((P@["%0(;0B&")\(N C2".P)!@D@"3H)50EO"8H)
MI0G!"=P)^ H4"C *30II"H8*HPK "MX*^PL9"S<+50MT"Y(+L0O0"_ ,#PPO
M#$\,;PR/#+ ,T0SR#1,--0U6#7@-F@V]#=\. @XE#DD.; Z0#K0.V []#R$/
M1@]K#Y$/M@_<$ (0*!!/$'80G1#$$.P1$Q$[$601C!&U$=X2!Q(Q$EH2A!*N
M$MD3!!,O$UH3A1.Q$]T4"10V%&,4D!2]%.H5&!5&%705HQ72%@$6,!9@%I 6
MP!;P%R$74A>#%[47YA@9&$L8?1BP&.,9%QE*&7X9LQGG&AP:41J&&KP:\ALH
M&U\;E1O,' 0<.QQS'*L<Y!T='58=CQW)'@,>/1YW'K(>[1\I'V0?H!_=(!D@
M5B"3(-$A#R%-(8LARB()(D@BB"+((P@C22.)(\LD#"1.)) DTB45)5@EFR7?
M)B,F9R:L)O$G-B=\)\(H""A.*)4HW"DD*6PIM"G\*D4JCBK8*R(K;"NV+ $L
M3"R8+.,M,"U\+<DN%BYC+K$N_R].+YTO[# [,(LPW#$L,7TQSC(@,G(RQ#,7
M,VHSO301-&4TN34.-6,UN#8.-F0VNS<2-VDWP#@8.'$XR3DB.7PYUCHP.HHZ
MY3M .YP[^#Q4/+$]#CUK/<D^)SZ&/N4_1#^D0 1 9$#%029!B$'J0DQ"KT,2
M0W5#V40]1*)%!T5M1=)&.$:?1P9';4?52#U(IDD/27A)XDI,2K9+(4N,2_A,
M9$S133U-JTX83H9.]4]D3]-00U"S42-1E%(&4G=2ZE-<4\]40E2V52I5GU84
M5HI6_U=V5^Q89%C;65-9RUI$6KY;-UNQ7"Q<IUTB79Y>&EZ77Q1?D6 /8(YA
M#&&,8@MBBV,,8XUD#F2091)EE6889IQG(&>D:"EHKVDT:;MJ06K(:U!KV&QA
M;.EM<VW];H=O$F^=<"EPM7%!<<YR7'+J<WAT!W26=29UMG9'=MAW:7?\>(YY
M(7FU>DAZW7MR? =\G7TS?<I^87[Y?Y& *H##@5R!]H*1@RR#QX1CA0"%G88Z
MAMB'=X@5B+6)58GUBI:+-XO9C'N-'HW!CF6/"8^ND%.0^9&?DD:2[9.5E#V4
MYI6/ECF6XY>-F#F8Y)F1FCV:ZIN8G$:<]9VDGE2?!)^UH&>A&*'+HGVC,:/E
MI)FE3J8#IKFG<*@GJ-ZIEJI/JPBKP:Q[K3:M\:ZMKVFP)K#CL:&R7[,>L]VT
MG;5>MAZVX+>BN&6Y*+GKNK"[=+PYO/^]QKZ,OU3 ',#DP:W"=\-!Q S$U\6C
MQF_'/,@)R-?)ILIURT7,%<SFS;?.B<];T"[1 M'6TJK3@-15U2S6 ];:U[+8
MB]EDVC[;&-OSW,[=JMZ'WV3@0N$@X?_BWN.^Y)_E@.9BYT3H)^D*Z>[JT^NX
M[)[MA.YK[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]8
M65H@        IG@  %'^     %A96B         ME   FB   !%=6%E:(
M     "+)   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(#
M P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1"  5 !L# 1$  A$!
M Q$!_]T !  $_\0!H@    8" P$             !P@&!00) PH" 0 + 0
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H<G^Z#ZGZ;QFU^/XGB^)1:ZO$_#HT>'X?Z/A:/!_3T]'$]@KH8]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>cogo_0025.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0025.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M"1T4"/U Y^F*]9H8XX8MT3P_E)9<F;;D?[$-+/G\W45LY_H<I*U<NQPVWD@
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LE)3S8WJ=DHM^PW&3,M:$(=4I;#A95\NJ3^U64FN!.2"NPCS2_5RKVQ-(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>skill-y.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-y.jpg
M_]C_X0/#17AI9@  34T *@    @ " $.  (    ^    ;@$2  ,    !  $
M  $:  4    !    K $;  4    !    M $H  ,    !  (   $Q  (    ?
M    O $R  (    4    VX=I  0    !    \    1Q215-44DE#5$5$7TY/
M5D%25$E37TU$1"P@3F]T(%1O($)E(%)E;&5A<V5D($)E9F]R93HR,#(Q+3 Q
M+3(V   MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @,C$N,B H5VEN
M9&]W<RD ,C R,3HP,3HR-" P.#HU,SHT,@    .@ 0 #     ?__  "@ @ $
M     0   !R@ P $     0   !4         !@$#  ,    !  8   $:  4
M   !   !:@$;  4    !   !<@$H  ,    !  (   (!  0    !   !>@("
M  0    !   "00        !(     0   $@    !_]C_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$(  4 !P,!(@ "$0$#$0'_W0 $  '_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ .ZJ&?ZL6.N]+8_:X-;Z7I[7;1L#_6W_ $/S_M'J
M_P# I+YP24VO%TV_JL.G#^EO_6?_V?_M"YI0:&]T;W-H;W @,RXP #A"24T$
M!       41P!6@ #&R5'' (   (  !P">  ]4D535%))0U1%1%].3U9!4E1)
M4U]-1$0L($YO="!4;R!"92!296QE87-E9"!"969O<F4Z,C R,2TP,2TR-@ X
M0DE-!"4      !#B 1<C!Y>:WYN=)$D4?"D2.$))300Z      #Q    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! !+     $  @$L     0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -#    !@
M%0   !P    ' ', :P!I &P ;  M 'D    !
M  $              !P    5                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<    5     %)G:'1L;VYG    '     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    %0    !29VAT;&]N9P   !P    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
M  0    ".$))300,      )=     0    <    %    &    '@   )! !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  %  <# 2(
M A$! Q$!_]T !  !_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#NJAG^K%CKO2V/VN#6
M^EZ>UVT; _UM_P!#\_[1ZO\ P*2^<$E-KQ=-OZK#IP_I;_UG_]D .$))300A
M      !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #
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M  H !P I86-S<                                     $  /;6  $
M    TRUB24-#G&TTI:VD1?84;9BP40P2;0
M               )8W!R=    /    "*9&5S8P   7P   !X=W1P=    ?0
M   4<E120P   @@   6$9U120P   @@   6$8E120P   @@   6$<EA96@
M!XP    49UA96@  !Z     48EA96@  ![0    4=&5X=     !#;W!Y<FEG
M:'0@*$,I(#(P,#<@8GD@0V]L;W(@4V]L=71I;VYS+"!!;&P@4FEG:'1S(%)E
M<V5R=F5D+B!,:6-E;G-E(&1E=&%I;',@8V%N(&)E(&9O=6YD(&]N.B!H='1P
M.B\O=W=W+F5C:2YO<F<O96-I+V5N+V5C:5)'0BYP:'    !D97-C
M  IE8VE21T(@=C(           H 90!C &D 4@!' $( ( !V #(     "F5C
M:5)'0B!V,@
M                          !865H@        ]M8  0    #3+6-U<G8
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M.,DY(CE\.=8Z,#J*.N4[0#N<._@\5#RQ/0X]:SW)/B<^AC[E/T0_I$ $0&1
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ML":PX[&ALE^S'K/=M)VU7K8>MN"WHKAEN2BYZ[JPNW2\.;S_O<:^C+]4P!S
MY,&MPG?#0<0,Q-?%H\9OQSS("<C7R:;*=<M%S!7,YLVWSHG/6] NT0+1UM*J
MTX#45=4LU@/6VM>RV(O99-H^VQC;\]S.W:K>A]]DX$+A(.'_XM[CON2?Y8#F
M8N=$Z"?I"NGNZM/KN.R>[83N:^]3\#OQ)/(-\O?SX?3,];CVI/>1^'[Y;/I;
M^TK\.OTJ_AO_#?__6%E:(        *9X  !1_@    !865H@        +90
M )H@   175A96B         BR0  $^(  ,'0_^X #D%D;V)E &1      ?_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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F;*N^"ZD.Y37C0>&:"5+-5U5' V\C/6E<$::5J:TZ-][!'0GZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>cogo_0035.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0035.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   @(# 0$!            !@<$!0(#" $ "?_$ $D0  $# P,!!@,$!@0,
M!P$   $" P0 !1$&$B$Q!Q,B05%A,G&!"!05D2-"4J&QTA9BP=$7)3,U-E-R
MA9+"X? D)D-4@I.R\?_$ !L!  $% 0$               0! @,%!@ '_\0
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M2FYZ/&EW=RE+GFD^]-+L>1'[4(Q^\ -:VI:)R7&&PM<=TA39'Q(/!_*E1R#
MGKYS!NYVYF':5+2VDA#R5=.1GK12MDP=D!&9BN%'EVYBW@@C(D 'A(*1_P!:
MD!]9 5QQ*:58!%N##[CA4ZDDI43RE'F /3VIX;(C"N/-#N3I"+IR+;9DIP+9
M>FH;&3CA1Z8^1J%7+DB*0 ,PO?9B::DSY2FBIB5;9")"0.%K1C"@/]DTSOC$
M:0,$&5,>9)MM^E/QI2G6PJ.2DIV\!L<CYC%2UNW!C+*U.5CCTSJF5<+;'=)
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M9 ]/:JXIMET')Y,JI+9#[<EQ ;2VE2F$YYV^]2*<#$5N^8Y^P%M,O1*&$OM
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M@!Z5F;BX&6,U=(16P%YBHN]K;@3G6I2TI:2GO%[>=R^@!H<-NYAQ7"\P2O\
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M)QM/I0SU<9$-2_G!C @=HEJC(6I4EL;CD'=4!R.(8NTC,I+IV@VE3BI"I:%
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M9R,#UKKT.S(,6BQ5/F411!86LY3P3]:JPO$/-H].TD/IWM!(2-OY5'9I58<
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8Y_A5V_\ 9O\ _P!2O[JRV4^,O\-\)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>cogo_0060.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0060.gif
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M87?I6R-I '_Y 1[@ 1V0G2GYHC'JHA]PHS<JHQN0 1G@@J>5 BL 2P:6 B9
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M!]HZ9/?6K!<+7&EU4A9J9F@+KO[@"NJ%$4J0 P$5O[LFM"6+6AV, 2:PR4;
M"]4 "T'+V!!@ 7H V3%L"9/MT]5@V98M89<-U(\<R7Z0!WJPU.R\ >]LN1.@
MR2WI@D,05KPE!!Z8.!G4!"=@I-&0VP*\VZ 0RT!@T/UJN@#+FU%["M;@S];
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M8[$K!>.03B'&4_@O?_?3%2J:4$2YB2 'H&(""KQ9EST>0()&91,Y*WB1#&!
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MV"@C(\I8I#)10-98^G;9'/0U1[#K6]]L8-G86,YO?86A%Y"PP-D&9$(1,)"
M  #@CG6IX 9>+#0)5,0_,2C"'VXP QM"0,:&KH@,<. U0/YH$+C#A71%)F!N
M<_>YS\K*\(<:)8@F]+L(9IH6#Y^%@"Q!L+4J20$3B+@"LXQB%+GT99.E#&4I
MVR*]MM"$,&L1;& +V^,?W_*QDYW?86!C%T,@F Y44#>/&('.U>Y96R',9PG
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M!3#:7AZ+VR(Z5C[%.<1_#G2<@^_J$+S@_7YX]@L['>:PAEEL,+ EI. ?1,P
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M/IBAR(B,R"BKA7=P!W5PAWUHAR7\2'T R8ZT12?\.UN$S'20!W?0AE7Z!R'
M@!7( =NP 2]Y%@P DP>[/4<D@/YJNPL%TX&>!("5<$;<TP : "YN>9"M@@'1
M*$"G H09, &N_ -!* +F,@%SFP G$ 15B GE%#XGJ(%\3,9-R@$7.8$#0 !&
M40$!0AB?R8%=$(9BN,OPS,N&),]B\ 7S/$^8@1GL>ZGL^X58/,Q7W =]H,_Z
M!$F1C$Q;9,+%7$(FC,7,Q)(#2($<^,70;* [R[&E.@T)*  !J+89( =52#
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M T @.K.R@=R%M-CB"*@JP!E(SJH;SAI"@>$L@(#M2>?UX+0 /B<HB2<@ 4Y
M!WNP!V?X:%[^Y?KEY69@!WA@AY16Z92N0O%3V0)N8Y"D!\Z=X%FDYFD^22;,
MYFP0A1O2AGQX!VW !>NR(Q:@LZ(R-!CJIX7P WWB X,P1TI8D*G!I\[@EG>M
M!$L $+,I)*K2.8"6 5..O=+ O: 3-Z@,SJKCK4[B$G+S8$ P (:M-@0P@11X
MFR9(D0-@ 5E0!WCXZ)#>97;8Y2N&A\(V[)1N!V2FPG-XYGM(8)8E8&O&Z6J>
M8P<.2?_,YM$URVRHAW=X!VR8A/XA^"F%FJZAW9 1#MZK-@Q"0 R!V!UIL(1
MZ*VK/@1+N(08)@Q,AJ%N7-0'T2T;=CU$-N$"W(,@[M3A5*N!2DT J $)L%L
M,$OVF 27\!D1B 7#]&C WN7X]>AF\&C#+NR4#F-D/H=TX%($;F-]F.G*KN,'
MMF9J;H=G58=3* $).()U>&/,I 8F$($O(0$,&UH8\@!$ONH^T)H.4HP#J9I"
MH&1]$MX^P)U)6)J&$(UV]482*HBMVJ>BL]T]B,!!""/>&JA\48$""  !",'G
M/M\H5@LD^,<2L 9]\&N/WFZ0IO'L?H?PAH>:%>_"]=^5=6PWYESVKFS/O6QU
MR.Q*L?X&,;V'>7@':)BS;F)1"YN #! -!X23.#'P0L#G<C$02V!P;A%>I\EJ
M2R ,H_. =;(=K*($!+$:W*+DHK-A1@.$3N6W3K:A%8   1"  ; C?KTC CB!
M(5@![_I')-"&;/!N[>;N[';TPHZ'E1;<,:;"\V;C-:8'];YL(K]FSZW%?<AF
M;+@6:X#C8-6&2;"!)*X+ UA0*^\ $ @!&9@3.N'RJKF$,F=P2IYU&.86%0*0
M$+AG@@"AJJ$$P^B#I5F:SBCN5,:ZX<0(%3@!"O7SL"6 TS$E2FR"8]P!NF0'
M7:[Q1G=T>X#T2&>',/;?<U=9+L6'!"9@+&W6^)Z'>-_<!?Z^:7=P5G3H 2(P
MAR]=X&P !"*0@"_) %;?/2MW 0\0FZ5AE]K&G:J!<W:A;0@O$-Q"2K J#%I?
MU X"\S"7$SVH 3W( [1>Z&C[-(P@=#YGNH7]DA) *X]PJ[E!A6*HV>V.AQD/
M=T=_!WM@AW0H7&7NWWS AW4'<C4.5GB0Q5J<APF>]XZ$8VJ&AWG8!W18AX]T
M['PPA[GUDM:U,'#-@$,^Y%CGEBWG<GP&\QB&^*NV!(8O]@T/ZSGT%L1XI[@'
M\SXXA*6!@4FB33?47N'SM!HB@AEH4+:D5 43 1:86R&@E#?: 7.8>9JWAWBX
M>8_.>7L0YC)>W&187*!76:&';/YZB'>CG^!GG0=Y6/JFI\71GP<N=<PPS0=K
M2(&??4T(FP -..0.2'@_. 1V&?LZR775YI8Y47O.*#H7 ! !,7!XPAT&/X2.
M7V0/;]LZ5X5^:P+F\LT)$( '0 "8ZZ8#&"@=C186"(9Y\'9OCU_(GW%\H/QP
M]VPN%N"?3W>@QP?(CD4F'/T))OUX]_3+//W'=.QV$(52!8@$"#!@R+!!@@87
M"D' D*&G3Y]"?2Q9*E0H$)\\,G#D\:,GCQX_?BA6LM0G#PX<,3IT\! B1!X^
M@2Q1HEG1TJ$^>G;FV<.GR)^@A%2I$M2DB9,9)R2<*" !08  ":82." AAXX<
M/[*U8_ZWS!G8L,[BV2N+KRS:LLW6+E.F+!E<N/GFTIU[KQX]>O/:[97G3EX[
MO_+JX:MG>%Y?>8KEQ:NG3U^^?9YLB"! P  &"1DD2&BAT(4,ASO]Y"Q4,1!&
M&2%PB/0#TD\@2-VZ64HM8V6'#[I#R.#3)U#-FH4.>=RY)RAR/H!4#2)5-.D+
M"1@@O  0%8#  YB5R.($ZM@[9\W QA-[MNR]M&C?K77KMIBR8\GJUGVLS]U>
M_'\7(YYG^#!@[0@HH&*&S17,$"D8\ 1G&10T00>?P=#0:'Y$A!I$&7%DX4D?
M%6+(;)5@A%(,H(7P000?P$"#;Q/5!%%Q,.Q!""& !'4#(/Z"Z*@*4C.\D(%3
M)P" '0 ('% "4TM88XXYZ<3#SGABA666/>>AQ0Z4:S4#GS+,O$4?78^YHX]>
M\/C7'YH%+B:@.@,.5@]=YS2A @I-Z%"0@P5Y\!D((>P4$D0CA@92"!9:@H,,
M%E8"CC?2%.(''XBNAD,(%GP 0F\1F2;13FWX.>,@@Q#RQPU_" )($3PZX<12
M F1@PI!3/7$ "R68$(0MRRS33#R]/LF.KV2IIQY8[37S7I?*@#F7?63V)P^:
MSQ;8CCIMLEF@@?BHLT0))UQC#083Y)F!!R6VX &%%:+D@@<>;,0:1!I!6D@W
MWHC8D1^A[83B!AQT$(,,$$6DT_Z?,M! R""JV B4CDWP6$0-&!SPP PI8'?
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M &AD$$,*1" "D/0G!2R@@1DU@09.$&*.5/$,)NRM!B\0Q#,,$( <)&$4G#C
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M"MN_$=*F"ZXY[0G-',0[Y*'T;%[Y&LA@VM.>(;/=JA0(,'4ZVIR !  ;"KP
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M9NID'BHE>(AC.+9F:C;E,1A#;#8E4]8FT=1F51+-/>[F/18##:[5T6R3\KA
MA(Q;B62A 5C5"1CA-I #-6P#/XB#*L@ )0P"(*#E#5##'QC "2C@ .1E  !
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M)IYVYC&$J%*&:&<. Y[^PCT*ZB]T9C!8@SA  QV=EHI^QG$:9PWP@0Q4WMM
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M0BV4;B>T\<=^[ 2#@N[J+B[PPA^O:<VZ BVT BS @B$?LB'3 B*+\"W0 BY
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M9H,P87_P 3-RM=H AM&K(.%&N0A2(D4 0C.%Z<WR.XVUAIFJ!JAJFY7<1U)
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MD6-"$C1NI(/['H<"D)=[D'MPM59V8E=VD<-"*+"[JCO^D@,] 2<!?ALY+,P
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M#,Y@@<H."E='(BBB##CMK,HP /5M  GP]/1-"L8PC<P0=':Q"HAFC9"P"<M
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M*3IYN9)W:U1"#PZ1?=E&F; WRZX*H1<.QL"LDE<OLU.^ ?[KI%W1%<5[L;<
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M&()!"U'@PE""\RD,?4I)\X)+D[;0%26Q80M:4%)7YK*&*U1A+FR(UWW@8@9
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3-EF.R Q&=JF#,A02KU6M@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cogo_0066.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0066.gif
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M[HWAF6=1,0H:D&.(%C57IK578Y"SV=856Q:?!>6U8UDZI;<.)J+((N&.?*5
M%9IK$$$G;WBR1BZE*YB:(JDTL_Y,>'N'1WOA!:X&$ J%HD80A.,1'A _  &$
M'8\_KGB=9?P0$VQ_6HT&;*A=)616[#G-:&U*D^[L@5PER+5:9Z&%%@V..EGI
M@N NDJDB589+\A]S\5[A<"O'W9QS&G%4YF!U<)2\F'3:$9X<:BRA!AZ.]]##
M#S\$T7@HB.L PPPZA*_#]8Q3_F_E[,V7U:)(VJ>?CO#3YA]79FB=.K<#@@$#
M&#*@M3^"".(6D\#E+6\E8A&"4,0@PA6(*UVI+A6RBZ?:!D'G:(A,'1&,!B]"
M$87@ 7(_L%X/' >$Z2TA%$ (@OA6R((6IH %,$B!#&&@ \0![(9URM>?ZJ.4
M1#'*??Y%DI]_3".?/VD-4A6;% Q:U[\QS& ,-M 6V-!60+*%ZT$C"T3<Z)(R
M/*1,9<)1V<I<5KS!8$1PD1N?^'J@/<<M@83<6Z$.4J ".KZ0!7>40?@:=P<\
M"$TJI"O-5XSVL(?%QBOM@Y_I[/>HM23(+&CARO[ ,(.+7>Q)4R)@%1,8%P4.
M0HL4XN) "B(0+XI1>.9B3@9!U$<U8*\'X0/?#H* N""P47NT5*$<Q?<"/+)
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MNJ@TO](9<$D&<*F1"C)E4S8V:/Y#18F0"%I4<X8W;V!V88A'GJ>&?72P!WL
MD^\ #X>9F*PP8Z$(>Z^I!$4P!470!$U0!590"J5@"JFP"L,P#*M@"E4PF:,9
MFDQ0!:'Y!$^PGZJ9"JEP"E;PFJ\YFZ$XE:P0"ZS0H3,V"[! /;;$E7 @G%[I
M!L/I!BBJHBC:!L5IG,N)G+F8EKGH)]$I)3U G1J)G-?2D35716:S"(&P"%\D
M;R>9DJQ6AQ[VC']0!^JIGH6 #?@@#X@9"Z: =J%HH4: !$TP!51@!5;@!5X
MIK9@"Z=P"EH IDX IE;@!*5@"[F0"UH0IV5JIJ=0IE<P!?HY!4C@I7DZGZ;0
MH1OJ?_ZQ  ON-3BX1PHI>J(IRJ*.^J+%>9Q>&('-.080^"MI29%IV1XY6IV=
MX1N*( D%U)T21J1$FI>H%F]<)FM>=GA=M@=.FIY[8 >MX [U\)[^)ZBN::%\
M2@59D 5<L 5=T 5; *=X>@5<D O&F@M;D NXT NZT N[@ O*ZJRZ@*=.@ 3:
MZJ=70 53< 7@FJ&Q0 N%&H/_AGZ*FJ)QX 9MX*CNRJ+MV@8QJIS)699FF8M2
M(J/MD8MJ21915D"2( F#57,?^$5N8)*#  ?:]9<\!PA^L*1<YG-U  BP  _R
M\)ZS\ ^L()M8X*U4X 1.\*M9\ 5?,*S#N@LH:PNX@ N[T/X++@NM+NL+O> +
M--NR*\NRN, %64 %/.NK.IL%W?JMNG *6!"HLI"8A=IZ;5<(A+ ';,"B;."B
M<2"U++JN*CJ<+FJ<6LN<;\ &7BB+L^B0;*"+:3"V]7.V9I &9E! 5,1N67:J
M"5N'#-MAK\JP?4@'CZ -%OL.LT +R[ ,Q-"M/(L$OBJR(TNR)?L%* L,+^L+
MP""S,^L+QC"YOE ,DQL,D+L+NJ"SA4NR(MNSX'H%!3JHA-H*!J6($<6*;^ &
M;R"OK=NN;C"UCUJ<<2"<;6"UK#N67MFU9:FZ7FD&]FJ+>L(&;,NV-6>J*3-O
MJCIT779AAD>'7N8'L_H*\+"W??Z+#<2P"CN+!#MKN"3K!8C[!;_P"[L #(_K
M"\$PN9.;#,F@#,K OL60#,80L])Z"UW !5H0K(?[!3M+!5S !:&["K) #+)
MJ#$(.4OGD#+JM2[JHN_:P.O:KB7:J"O*KL#9M;_+!L ;M@MH!FP@JE4DD@?T
M12HS;X-PL"=)='_IM'I@"+2:#>_P#O_P#\10P[J0!=S+O;_JN8?["U\@#+\
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M@@M>J,(06" #%JB !)?%P ,^4 $7L& '0=A!934P6@*45@ $Z  ,4C"#&>B
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M)* !$F X!4RH@A(ZF@05E* #&:B "2S 8 E4P,$01O0**&QA%6B  !P0P C
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M'5"Z#R" $."A;,N]!4L"5K ^#72 %S %(Y@ (S".%&BV&4@%63"%%.  &Z2
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M!N4A4V"%)< K'6B ,@6X024<+M "+6A3*] ?*^B%4G@ %A"]7C@& /,"&.
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MA2KP EQPBENX@N[Y3"K8 B9X@!=05(HJHG%&9W3.R6487@](!0#[!<5$YUT
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M:1$W(CJU:F#(!2^(%UG@!5MH=)GO<ZT><4:N5BX06F3P%&126SN&Z"C !2=
M!7=(AW)0WTY77R(O!_LE>"/?8O$F<O:^98[^XFYHW%=W45B%[)+%\I;F<G)
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M^(S%6 SB9%Y!U,WAQ2Q:>;GMCC#!9?:G'"##/I " !@ #?B #_P #OCM#=Q
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M(&L23S(EXVE2VJE1XNR9FJDG+_'.!K$3RZO42NW^4J[_JO+_#O0>;*8=9#$
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MRM:SL7KR)F-RYKZV*1L"'EAQ;-/R5>?VY)(N+&^F0<OR*U?U*P?TY.9K=+=
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MRD\!GQ.!$0R6*$B#.\!#-D"##WC[ 23 S2^ XR,  AA  YS #/3 ([,WIO/
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MH-&! RA  0) EK'**,:Q%*!RQ3H6,Z'DGF&]IP$GP,$?'*% A+P1$MV$!"/
M2<=#S'%H"'RC(SJHKG59S6KX0A%J8@(BE<P!7U\3GD( 40?E+2\&,$0!)H$@
MCWS$0QZT4$(I2TD]A)72"MDCXOYQ\F:34I5O A68  M0\0YZN ,6\'.'5W#I
MCC$$  +V&Z/D8"9&__GOF<F,SY3(X@ 4^$ 0K7A$(2#Q")U*PIMQ/(0<&ZA
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M[A.:RP4N4 &M5UGN*738!"((@2D3H( $<&S7":Q@&?WP[I*D$5[QAG<>KE!
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M*\IP'GK1'@@*'^ !!7+FX(:E]\Y.^8#ER9[,6*AD<THP?U9F^)@O6-0#+1R
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M1)73?$'4[#0T?1$ 9V+('CWY?IT8?X=45(OT T*@ D197TV7!#9U 0Z@ ^2
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MD0FL5UA+ZD+4P()9!NA81X\A$--%@:6:9;R(S;K2?(,5Z61@^!8PT$4?F:0
M:@N4<--!"TDEFP;" 6543V\FE8$#%N_Y[&PV266B'?!@^QRVW"Z:#X[A1@IS
M6VS)M4_+^:AQP)&=,93>7YLN6)Z564H$9KT0-#   "M)]%=B^"'@7TH>0:G8
MP#HM0&JKKR,A)J3#?NZDD),[-<5AG1CT))N=&72@P4$YZ<D;",5-2U7*7LT#
MUCXU@Z<WN&A!FF.E;>V3UCLH%*"SD E6V9)@"A56DJD$*=S T0X@4!'31/]K
7DL(>74;T2($=9U!+M7XZWT<?*1 0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>cogo_0033.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0033.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M1LBZ! VE0X]Z91=A(Z5>6T]2/UI4.L3]<L?ROWT*!920HBK5F5=A$J(YHU8
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MQ);<5M*DX .0D9\A5S#P5-331$ZXE=Y'C>+/>'?GVK4T/.=)?3,'R_&BM/\
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M_'V/CCN=N.4C/5..#GK79Z/0K2KTXKOLX?7Z]Z^7JR?"NCYW7+M?TQV-]O\
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C]VD(9NVR\+4L*M$[:.G^:N?V4A _JJZ_[(G?\JY_=I"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cogo_0038.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0038.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MWB+(4L92E+HWG_A//Z5+715*&2/#7 8^(]U?\BOZ4+17M9S,2UL.2*J.H*X
M1@)S4(>H3D>)-0A\H) Z'GTJ !\F$IQU+K3O=K;/A7C/!ZC'I0:"G0NTVAE7
M@&2>I-2@[AUMZ?K4H&XS9&Q>0>/YTRX8LU<;1U5_T>O:8[K#L78TS=%)5+TS
M(<MS#F>2Q^-M*O<!2L>PJC+!KW&O#D3X-IB\D(W8)ST%4*1>5C]HKMPMW87V
M=3-3.Q$SKM*5\%9H.<F3,6GPY]$I_$KV]S2VY2&M51R1UM=^T>+JZY/]I*9$
M2^7?^WS'WAN=DJ7RES=TVD'  Z  5OC<5M:HS+W<V/OB(4ZW.2FV1O2VD_>#
MDGGS]:*BI(*=%Q?9ZTK"N^IH%^9<7$N=M>48,QE1#D=P$*"Q[]1\B15D,$9T
MGT4Y,SQ<Q[.AEWE'M#[+;A%DI"):8VV4R  "XD9"AZ!77]*JAB_+YZ?*!+-Y
ML=I<G'G6MI7IKM&OELQM2Q<'"D#CPJ.X?SJ^7$V4UP)7-OO?O4G!/-&7(JX(
MS/8#B@G;M .XGSXJIQ+$[&*0$')Y\A2]!'\9> "C&1TIDP.@I;KL[&<PA6,=
M,'%&Q;?P2^->ES4(/>NM26SN9D-.%+B%>1!%,X1ES\A61KACS]^NU3_US<?_
M )32;)?4EP^A4G='=R:6B69;!M(/I4H%GJ4I"4XJ42Q%TJ0ZD*'A.4D_/SJ4
M3<(K/B((Q1H-GJ-H&#0(*A61@"@ ] /"<].GI4^0OE4;A_Z.+7"K7VCWK0\B
M04L7R")3'/"9#!_%_P JC1<=R:&BVFJ.EC=VCFV/R9KS3*8P)DK6<)2$IR23
MY BL>3'R;XSXHH)&CE=K^L&>V#5[:W;?#2IO2UL<1]W&C%1_M*TG@NN$;N>B
M<"MFFA%>^1GS2:6Q KMK^S[8.VCL\?@NQ&F;S [UVV3 D!3+@!(03U[M7 (]
M\UHR263CY,L'+&[.;K<MRS-/Z=NT)PNH4Y%"61N^]059&1QY&DC+:J9JCRB]
M/LF:IAN:U185/H9?<=26T.82I8(.0 >N//%68Y?!7FA<3HF8;FG[8=3QVB\B
M/'6)<0#)?8 \7'J!DBLF>6Z5?0?%#:K^IRN^UI M=N[=KG(LCJ7+?=8<2YQ%
MIX"V7490?GCCZ&K93WU+YX*'':W$@9)=C!8'D*L^! ',0=W/2D8R!+H ."/,
MG%5L8RC+*'1MYW$#%1 8Y)+;IP. :(H<M$A1P<XP:LBR-?)(=Q_Q3^56"D#-
MHNI_\*G_ /2N?TK/:#3,%6N[@'_LJ=T_W5S^E2T1(]%INA;!-KG<8Z17/_K4
MM!VGRK1<W4J2;5.ST']E<_\ K4M$H;&TW98WJM,_.<'^RN=?^6A9-IXNTW8<
M"TSO^E<_I4X#1DW;+NKK:9W_ $KG]*'!*8LFU74+!%JG8\_[*Y_2H2F6)V W
MN\Z![8M):E1;9R6F;BU'?RPXD%ET]VK)QTPJFBU:L*M.T=<KCI^+J^THMUT1
M)##BD_$MLN*0'PE7X%X_$@@#(\Z$TNC1%M4PL[#2PPIAIDH2 $I2$X2D = /
M*I"K!)%?Z\U@[H30&JM2QXCKKL6&I$5L)/CDK\" !Y\JS]*>3MJQ=NY)'(_6
M<6\L7V"EBT7(%MQR4ZI##AWK/7H/>DR.FBV*M66%HQ=YT_=X.HH%O?C7"$XF
M1$<4PYN0X,'!\/0]#\ZLX3!%N2=G4CL:[5K;VNZ"A:EA0E1GEI^&N4-Q*@Y%
MD 86@\=#R0>FT^HK'->[<6=+:<[_ +:O9I<=-:DT[=6V)CY=1+M*DI84H-(C
M.[FD@@=-CE:>*4OJ8\CDVX_<IFV0+FN'@VN;G'^[.?TJV,K0C3&,ZSW172V3
M!_[9S^E+)C17)'Y%LO"7#NL\[H5$_#.8_E53'H<6^QW=U])%JFD)5U$9S'\J
M,78DD.[E8KJTX%"US3GTC.?TII4A:8O9+;="Z$*M<[@Y_P"[.?TJ18>:)+^R
0[C_Y9-_Z=?\ 2K+$IG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>cogo_0067.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0067.gif
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M5\&%Y\#8%(R-9'^*Y-@YAJ)CCJ$77:3H0\Q*9E*0BXKT7GOPG%/..>2HY))
M.Q$T(3?F<"N-9WNA$HHGDJ@AR3__J &)&O](XDDHJ&ASCCKGC#,@4#G]%UI%
M9%J5%;U,?Z5/<L4E5Q:( +_IKZ[5W=D--7M2@]*?^?SI7J(+/S88H!H!N1&C
M&;,M9,6=523.83J9YS&6^MT3BOX::92AQ1(LF/ ""S/(((,--]BPQ U+>)&&
M&CP3=16Y.57U[IC0S=L55^KH\]R]\QP7NNCWTNHAP'/JVM-UW=A5L$GD/22D
M1K33?G9&(0V6.TC.YL-[D"-Q])@Y'W]LV$KBD(;D7J$<@G,HH:RQ! @6Y,!
M AZ0, ())+P@PPV&5X$X"^3?H,49AX0B#3Z>4=>3B53QEM99&>J3JCZ<=_Z<
M_;.*3J*;QY&'/.84,('A"1O;V<[!&!*[]P#J@;2K6#0 DX]G.2LD%02)[WP7
MF<=\+!X=LX@YN-$9;>!#&Z'X1QB64 06D( %2UA<]2Q PQSDX ,X' $+7N ]
M&\C@!?Z,LX$++0!#-G@"%5S)%:K2<2%]B>6)^N/*T_#AN<[QSTWZ8DZ)YB'
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M6,K2FK:T^<K*$E$T'8/V!$]:0_[@=A::K/[@[FUIE0Q:UPK,>] C'L>L(\/
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MLCK"F,64HV-F:]M)U$$FSR!W#5I@Z0P4QT[U5H\!)@@#&?Z>4(04E  "#A@
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M$.2 =HCS=C@W B @ 0U0 4T0!G5P"(9@"(NP"!W8@7R !W40!D]P!!C0=Q(
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ML)&'"'<5< $/@ '%1PC+R(S,R BV8 NJX JJH BJX(R,P/X(B4 (V_@&/O
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MS1+)>?[[S.WB:(T;,Q8K1JT43)8V3YH\MMIDZYG";HXJ=:IF2TE+9*! $
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MQ!_^$&$)RZ&+4<#P&P@1BUSTB#JP6 0B\L!;)$S IP0@P  HD&('2*"9%4A
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MY'%">6$DXQ1?T((  XH!8P B"#T^.*U?>@(A (($(  !Z!L!0#$*4 '9.S!
M>P2MP#W=LX,V& (HF(,X> ,H&(/]V1^M^CD)&X,36+X-0 !J 0SJX@$)<#L>
MZX%*DX +$#(RR;LB(X(G" ,U0(5U6 AP< =W$(=R"#P):1[UDS+V^RNP^0@L
M$YB!<?Z4["D&^WL)ES"4E/ %8U &3^""+3BS'!C S$J )J"]C/$L,>B!"W"
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M@"AP*7%"K210@G[\!T\@ @=X0 >( # XA#U(@C;XO3_8@T70A5S G%N BRA
M B>X@S^ @R3  39(!39(@"J@@BD*@!23@!38  CX"0'0@ U8 A0X 2*X !"
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M E6_S;0&SC10DV!)EZ13T"RB9'108XA)(\I"8? %85"&4BB#*K !&9A+OG$
M!WA+!P ]KU.%E^(VLAPZ,, !?P*#+2 "18R#/TB%QRF$!UL$'>6%6# T/( "
M,4# XIL#,/B"+5""!V@T!]C4+:"6Z=H  HB8 J#2XI* $EA4'N !^;R ![BI
M(%@/?G+'(7N"W3D$:5 '=PC)JDD'<^ :";G,=OC/S=R&S=3%:Q!-T+Q38*C3
M4NC34B")F=1"U.@>90 %+RB"0]T #_V;N6" "A "// Z6_Y ' ?;33W[.3(P
MP3OS@U8P6%7PND10!%MH-UE@A4)(M&PS!&'Q@U0(SB/P)W_Z@2.H@A^X-!PP
M 485 (%; ;ZD2(/4&RV5S\'<RR*H@ A(H?C,.R\J@B.;AR.4Q7#PI+]3/YW]
MSR>#,@,UT#K]3)1C25\@5\A#AIF<"6,SUS#[0F!0!DS@ BT(C _P2:!HINH+
M4D586&$1%E:H1G("A% MA$\UV%88#[ EG%CH#EEHA43  SEX@P93A50P!+2%
MJN <@RTP@B% @A6X &/:3@(H@ 5 @250@1YH H?LJ@OP 1X0@A]H@ H@@B!0
MCTE:5C=Y B 8@U20Q5@T!YTM!_Z'6(?_M$QMO4PH\]9OG2\[94FY40F84+ET
M9=J F5! )88PO +6&8$-"-&WC$O;"=*[507+<87'$1833816*(2TA5Y;&!9%
M4-A9  ]^G=O2Z@,V,MM$N-L;%;<Q (,CZ $@X($2@("'>=(*J*X3$ (,J  3
M8 !C]0$@<,\'  (A.($<]!96XUPA. *.)(<CM!-Q" >&\-EU:(?3;8<&YLP'
MO@;9\)?NT2A%28D&=5":;(E26%JF+0E?J#QE^ <.VH\,0( "$ "H+-\@($J$
M505=D07I5=XV.ECH5=LF4855\"9%L%Y><-A$V ,YH(,[Z(/GC52S-03&Z;:H
M>H(G /Z#)N"!"!@ B$D !2@"(L  ^R5,!Z" 8?6!$ZB !^@!(0B"!C".^$3,
M)V""(_"!-9"&<S"'!JY6RZ2:S-#9!FY@G6W=UFT;C.(>EWR)#D:&D4!78SB&
M9?@7G #AF%2#FAM(@ ,*?D0"(?"!* BF5I&%6$C>8#G>5L&163#86=@%@Y4<
M\_#>5SB+6U@%B*4#4REBL(W;4!4G/MB#G_NY,(@^"7Q2"+B!)G#?('  %*@
M L  =Q1,"\" (2B"!W" 'Q@"!C2")H[/O=,X=PB'.C%@A]!6!5X'>\#C:V@'
M<-YCER,VF/BR+2P);$"&#7:)$/E@F#R%%-D"R_K&1F7<O_ZUY%"%G )JBZLH
MH/&@A:]HA:[HBE9P$M!)A%68!5S8!5V(5 2\@RS:5UM07E#MU_;ALS$P A.8
MXDZ1 !-H@A\( B&H  S@:,CU 8FT@"YM @QH@!7P 2)X9FF.:8( AX]TB'"0
MUFSF9CQNX'78XW &U^[ITY=\R4!>VI#@X)9(!G?^X&0@!3:P@2VH 9[A&P'
MWR=@8S'  W)BA,AI"UK9BJN@!<P1$N\ 955@!(1>A5=(BU=8!=W*(C[H T2
M'/])6T^697$2 R-P:4X9  4 @2_R@?>M@!60@ 8H["!P2,@] AW /F<N['!Q
M@LFEC,<TW8^\$Z#.#'OP9I_>X_[-/$URKD*-(N=!/H:9I$E#;F=%F11?@&K-
M6P)ZWDX#J #7&H(XHP-R6H15B)RI> 61N8I<6)GNP*96D%[0601%,)FW9@5
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M-+?'T[4&D*E!7;HJ=&M5D^%ZC.'=9"A4HLC@(3#VH(4B4'D#) CL>@EP!$/
M-Q5[0.R@\H!2Q>HM#HA(#2(2\1A&4+;-JW"$9 HQ,3[0^0^$$.GW!H&(/N"A
M#W[(@Q\@K <!)N$V&1Z 8&E4 AZXA@=/L,T$2*P#(# ! R:0ZB)3Q]7DY.0)
M9)"&.[KQ$V_\D\?0O48XHF8-(0=9NV<R<IA.F5"$1O0[IO[PA!:". ,K0P
M@@T !/:0"E2@8@^\-- =[*#L?ME!#@UKHQX(E8A%^%0RD;%;A0"1BD[1V1"#
MH#/@[H!20"2[7V.N\*I8FV$&5(Y&$%!!#S9WA"AP-0'!\<$35A#5$_2@"1QT
MR8MQTJ2AA9K4_NQ&CQ.^PG  .6K4>/BLLS5*(GOENW05TREP#80BI,#*"0"
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MGR;:$%QQA5TA0S+8U5T%H5L93S& 7UF<PA+^P JP0 6@0*\9E;RL'_L!@ *
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M 08"&<;!&8:A($0C(<BA(^0!-,J!7N"D$Y2,:YQ- E1 !#Q #\R,#WP5!CB
MZ+S.#UC5"30!$?# 5CT/!X4!&1Q"*#0?\UFE50*9;EY#5SI<0%)-008A66(?
M*2D#6H(%\I#"&BP!?IC *Y+ '@I  <@%76HD 31!_2$"A/&E=@)F3TW, 3(F
M OH?>1(@ I(A>CXF^\CA?4TF-+Z!&]0D%-RA:^PA UQ9</R #A!+%#@A!BQ!
M3JQ :O) $SR0 SD!L?S (Y)!*N!F-ECE-D2H-62E/Z[:JFVB\8#B0>*00<[=
M7=V56_[A$#-L7S L@T.J@18(* F  !'1I6 A@ $< "V"' O,06(12E\"!F#*
M&87D06$.H/_U'P&F)QG"3WS"H??\16H(4 4B'39J8P,P   @P 9$ *Y(%0:X
MS _@B,LL 3O^P D0@1%TE1&\A!.P@!/4 1EX0O-E@YMF S9TPS9@0X1FY83>
MJ2927_:%(HA^:'#.'54(83(P0YC,W4-N >"10 7@P ;,BP$8  +LX0%D),@A
M0!A@X4CI:$CJZ'T-PB!\3X0!@M\ 8'@F&-(9:1OR2Y(:$R%0H*M& 89-P#8*
M0*5"0 -,@ _T +^!01!40 G@V^^I@! E298:2? QWB&L0_Z;PNF;5D.=XNGT
M 61 PM6?^NEP8A]='6<PS-TH2,(62&0)E( )C$ "1&$!(,#Z!<", @ 1X-)>
M+L*FPNM](<(@Y(&?$8(?W('?T($>*%N_GFI\[I_+B5OJ&9/K(9WKW9%4S>I&
M&L YS1,/], 3$,$#E  0A $8G("P]L *XM[HK,"+.0$9[ &;RBFS&D\V.(.S
M<B57 J2T:F(RR!U!?J(R- -P\BF'SAK5C,(_?$$1K*-;W@E=)@ "U"7(%<#Z
M,4 8W*@4;:KB%(JG&HC/T0$=C%'5-I/\R($;UF0TYH&R$8(Q+<($6J:@(%UF
MFLP%.(#1^AH!W)95]0 8$$$%F/X 4_&*L!K'B?D $3C!$CC!!8CLFJ8)G!I/
MFBA#-1B/RJJL5\(L]GUH,]2L*-[0*"H#$=9=]BE4?)2")$3D#5#D#Y!  LB+
M 82NK]7E E J"Q2(]_R2=K(NO4Y;(311'_2!W]1N,PFLJ]I!ORJ;VX2DUE*@
MY+T!?>[>VA[1!/1 <0P!&#2!I5TLK_#;"LQ$2R#'Z)B R J;X$(#*I %-BA#
M]U:#RC9#;T;K]$UN,CQN*#:#,^#0#6FH7=V=$!(#DX$?7OF")W@!$;@%;^&
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M.!\UFT"#]W(?-C@#-8"O-31#.G^ESH+R]X$BU1@#,X!?B2+#5D>"%MP <UX
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MXJ^__=^__*O_)WQ"*$B")+ !0*184>1'"0</2IB ,(!!!! 0$C!0D*   (L
M2@31Z/[$AY,H=>C@X>/'CRI ?PJ=).F'CQT[<N2\>>,FBA =.G8,>2+FB8\)
M '(XZ8&!AXH(!@H$L!A@@8,$&W@0,?(CQ8\3/((066+B0A 56$]@\"%DR! ?
M.H*0096MVK9LVYQMB[9M6S5KU9Q9:V;M&C5JTYCY]8LIDR9,AA%?NH2)$Z=,
MCQ\?UK1I$R;+EB-+@H1&C9HU6U+T,%%5A0,'&TI8B @!@@,$"!0H!1  P84E
M09SDQKWS#1TZ?(#_P6/'-Q\Z,66^B0+ER%D?8Y]$]]$@P  B1#"HN*!B X"*
MW@U =(#B!Q$@)ZJ>*-_DQP7;/[ &(8I[R$T?AZ1A^]8M&OZXN7#KLLN:O*H1
MS$!FFK',L,LN4XPP3A:TC+()&:P,$TG0.,,+-K[ P0032BA!!:HF@" "UB 2
MP( $$D! J0(X@.""W#K*+;<CGH@B##'>F*/'-^  \@TQH(CN"2?,ZJ&'L81P
MX@@D'"" @!*PFT %[@P(H( M"U!@@P$<Z.&Z@E8(*P@CFCCA 0R"X.&$)7BX
M@ <>.,) !R<\T28;:[89AQNZZ(JKFF^L*52PP (3[# &+;'$LD8OBQ 3RBBA
M9,)-)L%T$THF@<2,+[[8@@@K2WA@@@JNC.!$"%1C8  !&#  J!$4L "W((9P
MHHD;A0!"""..8.*))IX(P\@CCOX0HE<>='C.A[*<>,((!P 08 ,C@(C 2A,D
M$(#+ @X P8$!2OCAAR)4F*"("AX(HHDT'>@*@Q.<.$%..GW  (,O0OFSFFJX
MB>8;N@9V1L!"K3'PT 0Q:=22RC:IQ.%'(:8LTTHCV21C33>%9+,RV%AC#.W2
MG>"""1XPS:D('& @@  $L.B#%W+(804:EW""B9V%\"$(('P&@@@;B1@"B*/S
MO>I9('1Z0H@'"#!@ !6.(!F$#39 *JD L!X@@A'-G:"$%2*8T8D?4&C@A"!.
M,,&)(![@0:Q\=5@#%7*\P>M/0)WYYE]"GZ&FFK[\2I2:!!N5F+*&+9&X\4HF
MG43R2?XDF00-RB671!)+*ZW48TC2 &*[*R>88  "*% 5A <>,&$%$!)08(01
M/LC!;"=NRXT)W)$$(H@E-?HA".&%EYN'YZ3"L0<' F Q B)*NZ"$$Q<H (&D
MO!Q@@-%Z*.*$"$:K  ,F@ECA @GH->&'>B^86X<+FO $&V^XP68;<;K99N
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M:@0Y%8FKNK,2H,AJ*((;W.'2<QJ4H )91\""%30A9TT0@W1U%(7=W<H'%CC
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M"FJ@RCC@  X@!Y9HXY:HL,JO9B@OUW*-\CX@_P1OK"1/_RQ@%T]$ E*F 09
M:C: 90[B2MRC @*  ![@= 2  "#@!CP!%:"!&[PA&OHC&I0!VY8A&(HN&)ZN
M&/YP%/X0$%<0!3MA&$8!_(9A"(>A,(Q/!D%!,3)A^60P[!*G$B?#ZR@#!W$P
M!WL0^CBQ$T$1%+MJ&@0N_*C !FC !4)@ 3@ XSJ@U5H-(A_2"V=1!#+N%D7
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MQAO8UCM2B;*87+50\O0R!,1*!%[ EDIV4@7O3I>UBL.;G_D<A,N;"K( T-$
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<+KV0@QE*U@-,UN!M23:PBPNG:U\?EP$- 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cogo_0037.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0037.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MN;5^P(\OOKM^/>QX/,^9Q;%/Z'.W:9"$+M OC#0"4_.2H >6X UZ.$^,GEF
M&4C/U<DU<Y8*I2Y)B8BU *V]*:$N1-XKN-HR16E3YP6P>4/L<*VGIY58\#$A
M;9QTH+!6WR([D^U3"!N-SS='**.$@_=2>FCG*Y_4!C2*RZ00/PJ*O(_Q#78^
M=%*".@Y]J/H@^)($G1RP2 !CX4KKP%7I@JX:3=;03M%52K+HVI@1&DGI<M#
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M6)(KDR8NQO+;X'Y4R12V"WM/O!9!'Y4&F-"6"3 LSB%#CI[4N"U2#(MSVP#
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MU?:[W$$JVS$N)VY*!PI'Q3Y?'I4_01Q9.^EO^[\J&X3:>?((W=/7BGR:L#J
M 2:.28P.*Y(^%'(!"N.,YXH##;3CJ26BOI[=: 1:=H5G'/3/M48HAP)!!QC
M.?>E((0O;ZCT(-!<!?6#M#_)P=H<JWZNO_9O,N2D6R[P_I-B,GJN2WX%'=U
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M.X\@J4E2@0>.:F,DS@N^F=8S+2MJ6Q*6AUI2%Y!ZIS@@^H/I0<<<ASE&Y?\
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DNT=DGZ+GCHGB*YTS_P!M"3"HL+9OG_#KA_X[G^&EW(;:S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cogo_0036.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0036.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M+)/;YD:6Q)EP(B);/@!:4_>U-R X1Y4EM?Q=#OGI2W(7HM=@B/J*[1IJ7%P
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M^*>7E</0#Y [UG:K-7"+^GQ)]D1U7)<?1#MID/F,A'.\VRG*GM\D^3*@G?\
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M^NU&3[Y)M?HVZ'KS$12<%(S6BII&'--C(6YE:\I32:W<@+@7-H8*<D8]:AE
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MOZ5!)_=23SXHHXMS!R2VT=9:+X'(0X;UJ]:9]S=67723S)*SU))ZU-++&+I
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5JY_=2$:_@]S_ -DW#_I7/[J0Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cogo_0063.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0063.gif
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M]^SS^>CQ]_3T]/CW]_'V^OCW^/7Y_/___P
M
M
M
M
M
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M!754=/43%3AP/-U)0S=@!"^'&SY !(1R4CT@D"GA2DHP3#2D Y\WGN-9$3H
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M$8\*A6 "1J_RDI#TJ, "#8#O#<_E.*'S*K_UO_+D9@ &KF$*'4 !AM#M<N
M&! "%# !Q=[MI# "C?[LJ) "3O_T*;X(4K\4G*#T(<'I(2$'%B#J2Q$!;! 2
MG+  ;R 2G&#R(<'K62\2G+X!5J_X(4$*C#\*?(\*EF_X(J$!A>_WBL_XW1X2
MBA !*S_H#Z )AR#M?6_EB_\7'_ %7*_YH+_MF7_CG,  IWX(!T#JF=#DFM#D
MI)#YG&X&'C#[FD *.#$*HH\*$?X !Z@P!B" "K4OZLV_[4D>_".Q]UY!!AR
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MBP9 N1 />&$.[?0=<B"<.87,E&+Y0HE6[ ;<L(SBE+']928X<"L=,: B;9C
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M1=B\PS.%!^B)#[@,-O ^M%DO5/ ZA6"$<,.]'_2E\C$ .JL "G BT/ "%JB
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M3XUAF?Z 'O]QCMD $*!*M)C$8R6%11 LU:" $.  QT&%Q+ 8_[F $( :,8
M#Q@!!W@,J""%]D8!"M@B#O  $K  #/B[,"AS'$]"9=&$#&" 0CJ,>00QB-6$
MU%$!%V(!F%&!%#C$FLB V9 B4_!)_%$-F'@?A>@ CF$ 4\ ;A2@$^$ETA2"!
M,.@$!+AC4O&=!6B43%B$3H" GF@$:+3QA7@G$)!0GWRA0W##C:O?QI:^)TS
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MQ$^=4H(X&<*A%_ A)Y3JI C((1,3V  ([*D04Y3@JUW(P),TJ$ZA<,(!%(B
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M*:  U'A/7'FC@1YH>1@'BS4 )U345TA$)HP"B:G*^(R$?@R$(TBH(3R 5YB
M <W'ROZ@%PEPS2)D B=,@-;!R@)8A2&5Z(FFP5RHB:]X0!F0J(E.0%[BA F$
MP!IP J8H1!K@Q GP*">,3?"@'9U\BU@40DY,E)K029":C\)P@@J("^FMZ'(P
M@+2\@2.< $,!#B?,"2K 21/U5,4PH_0L0@:$ 2E@Z9@2"&#YZ!]J3R;$00)
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M1, <+D!NP($ 7*X)#/(8,,!&9&P&#80)3-087$W8" #X=-*35+,<?'--G $
M, H(+ ""#>\ZCZD[HT(8T,4;)$#4-@#',$"D#01W-4(T#<08$(<\KD%X3L8"
M'((DH,U/I( WAV4FY)$<8,![C %O=,!+M*T<D$$"2 (8=/"">< HT$;_C4O=
M>D ;F,  3*M>N2&)5, 'S,%)E=Z&L4 %;'0".,)M@($<: ")F(%K3-$AW"E^
M4H8"Y(<8\ 8(M$<7. #.="N!M ![F0$#-$4&A( <K !)-),<+-B:=41XX4$8
M\-.F:L4;("4</(#6=40*1-\#K/X &VQ YVDFXKR'5,N!2S:%#2D"&]"''#A
M7IKT U0+!, !*1P [W8)_J#"2)$ U3Q,9&W&AS31H71M@<!R!YC)7^=ES- S
M [0!&2G*(0P V'P!>:7! I2842)*!>3LO+4RKR6?A"+-WXU;;6/.;2];(Y
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MLD%-X'$(P*9N;, (L$$^=<0&1/Y%,IO4%](S#Y)?<406SO3U!:Q!)IB!''B
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M9& "P,%("3[2B 1T9PPDR 37NK" AJ0A B=0:C(?10$'D( 3%UCH!#[@%0I
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M1J$#9$P1#.P+&;$1'?$1">2\0 #O"J;]M(8^UB "." $TOXF\A3 JFC#%"J
M-DB@ B(E:T(@GD3 =ESB$QA +-Z@SA0!@5A@<-(@WT[,)20FL"Y@DM@+;"*@
M R*@S3+"0C8 M2I@DBR@.VI1I_;"B3!B>$X1)D"  2(@ AY O3*B S1@ S1
M24B >KK@ LJ@#59P$&GK C:# ? )$E$!NT:@"S @#.# 9=9@+S+! C8@=^ /
M.XKKL(ZC ZYE"#R#N)2$!4S1SWX)5H)Q L:$#7KN^<)C C; %/3&._SE S["
M'3F2*OQH*C#"$9B$#0KIMO*/UXR"%,Y(7)RE)4N-).^O<$Z-GDBG$5@ GYBM
M/32!2?I/)M@ 6;R@#$@'*6@2=OX$BEDXP41JA!1JA!,(P402R27>I39T I9T
MD1"J\E5<)2:L4I N GK *)9*Q M' 2FK4B><<IA@XA FB2JE4B?"\CBV$C">
MDBO?92K7LBW%!V>.2"REL@L%R0O=<1%H [3$TB\)P32\T!0(H22M<BPO EX(
M2BO1<@Z*Z#"7$CA@:62XCQ2BLB-!\R><(P7ZL=3L*P]Y<D X80/:B"O"JRE&
M80$FAWI*$B=(0#GD8(-X8@+V*P4R  *8!75J@A04H+,X:5;RSYB24UJ6,S3'
M;A8O8"B=<SIK0A'PZ/I8P).&J1'80$(J333<1Q,*PXU<)6)@0@ZZ UZLR">L
M4RW=DOX4XJ =2R2@'N,M1Z&S..$-+ DP$,D#MB2/C@B+X@!ZD*@VZ8@4)L#;
MPB,"Y.!5LD@JR41=LF2<".$"3 $.C-,4XE,F1.LNRB,_]7*(\LA52&&2#J%!
M)\ XJ9-=FC-VAJ)%5]0E%<04%.$S8S1&,0(A0R A7J8"DLH!NL,+*D %*D)Y
MG(9)UF "2G$UY" "DHH!-H,3,&"S,F O#K$#0@"UP  #3L !,JPV?D,3+J $
M.B ZL>B[.H"Z0&+/[..W1N ",L0,'N"I0J<0U"\->&@4/F ?1T^\E/0"@F]X
M0&!'U44%%L#>#I$#0,#/%@K 6L)_(J ,ZL($/& !E(,B1OZ@ T @*J7G+"1A
M K+F#91K3%U"LX@J:\1  SJ@9$Z  D  !!Z@-F]T5FFU5FW5'56%QI;#-;J@
M!9'#,TY 2>9 ,.1 ,  MS?+H-PX! <IEMU"!FURB!6*DXUS"O5"A ;*F$=I,
M(T8!#_M)00FA +I#$Q#@HQ  9^1B[]Q@%!* -AJA ,2/2-*@;WKJ/DQ (XHH
M0K['.=C  (+&)::.T-H$#\L47@IO-0H! 7;FQS( #5S"[G0" QS  BX  3Q#
MS@AG M1@%!0GFOH) 6AC>9SC#0K -&#T5E$V955V94\%K:+N^CSC90[EHEC@
M&(M$,"[@#0AA 0QN"!+@18C$2/Y.@ID,@43\B@580 3L@@P:H /*YR5L8SHN
M@ )*H!WGP#4P8@/88 S(Q@TVQ#D,+E0P@@/:8&%&S)0J[F<8P.#BB@V\($.V
MHR2_;4HJX%HB0A/\4R9"P"2.)F,T(@54Q*_&@@*Z0.0(80+2X'"CSF,;P0M4
M@&HYQ5.HU015E&4M]W(Q-W-=U 1&J/NP[S-0@!,>0 4( 0\H+48P(#X?0/.4
MYFB$M@,X\ TVI *\8 [H@E#" ^8N0(LFD#6Z0 %2LS5:0@/:@&M=0L5:8MS$
M%A4V0&>])/E0P0)\YCWD8'7E8 X.89O@-D''@N+<)R*@J %=0C4VADC\U@'8
M8(\.H?XUW? EQB #9J0EO, $%&$!P,!@Z,,+3NQS\[!R-?=_ 3B !=@FOD=)
M// SGE %0JX,02(RX@!GF<@!UFD$-$%Q;U9Y%@ .KI9$6F!@GV<"D#(!: DU
MP"!F1R T,*(0SBP\$$ 3K#4CU$PCXF!N6&41"B .$&$!L*UOO""^6  $TJQN
M1B 3-.@XU,  U&5N02*^QB!&R /4/F (&/,Z2,(\H*8+K@5@_0DN(H %(F)7
MTFP.,.]A[4-_62/3V(  %G& V;B-W7AEOX "/" "=H4%8M;@3D0#2* +3K!+
M4($#8#$81:A(XFL.XHL0.L $R(!$2 $$+@ 1@S0"/(!PH?X6A"EB \I474@B
M!(1Q-;XCZHIUDL<$5AY@ TB  MC %#Y N3Z /DR!!#  $7$F#@1YGE"!J$"(
M B9G&2\B'#M@%*V&5]*  15!8PQA0\YK S)  ]2R ZP1&TG@.(SDE]/* C:J
M"V@O;%KB<7-95M_XF\$YG)V3B)>RG/]%,96D!N<R8"2$*5_#@*\%#-I$?-JQ
M@B>'171"2([M.Q/3C:(R8%JS@M_F5:AOD*X2)DBAGU]B$:+%1%K%)ZH(:FWT
MBV3P-:#'$/:S5>[2BQ@SB0U!!I42)AAA2AQ:G$WZI%%Z14]6%RM >ZC(YEYT
M.39'.&'Z*%8Z0.@/)%-ZIWFZI_YO[J9;C29$3O]84C2E4T" VJ>5>JF9NJF=
M^JFA.JJE>JF3>JH;Y-2JHJJU0JO_U]=NE*LQY]AJU?ZLNJS-^JS1&JE_#=2^
MX*&^Z#<.HC5[TM18;=7$NB7BP#4^JBC&X#+]9J[3.E[<"MAL+B5!XNO$!0R^
M+@1,PQ"8)0U&>=F(.B8<F^O4AZR!Q0R"SR5.0%<VLJA!6R:(D (P8%= 8K2P
M&B.&@)EX)0Q\QB1+;7<(>__,;A$XP,1&X ,P@"[<>JW_2 WQS[??AA!82P76
MR;=1Q;A#.[0!VQ36@ (0@0R"R*N!Q;#-0&WL*. :3%9^K1$JU[LSXEZKVRC,
M8%4]P/X#LEBR@[JHG>,,_./F6("DBL(0,((/%\1WQ$<WJT1! YM:9$(*)4XI
MV@95!AP,F 4OBJ36D,+/^&9QV@ !7B4,.:$0%'PH6( !7L0,#(!)-B"R:2)Q
M:4),:GHFRB"^Y"\J."$-V  $(( -TJ 1U(!A[H]OW',GTB!&'L"HA@("$-LJ
MT-<4V$#'J:($X/9E-B431+@EQ\8I.H5,%."H9\(# &T-Q  !=N6F3^ ),:<0
M"+ +G ,.UF!+O?PBO*!M4B!#+L(,1(H!0  B5L #2*!RY2"QXHFG0(@V1F$,
M .<$-($%,(!)%L$,T@ #R* 1*J@[&B%61L !3B 3PJ !3/ZG2'(G-?4-! @'
M>08/K$]:+G!F7L"@"]PS$[R@!>I&O%3 $)P(%=H@!0[!B2"B25D@+@JI$;K
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M1F-L@ H("NTDTF"D,."?5FF8$NIWI$:%D0E]<H41E2"Q09 B#\@T9+ \$C(
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MCHH6F/T!&&=)&O0IAX6Y0>ZCQ@ +'#X_@K1A82W P 6P3<T,8$ #Y R)&"A
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M/DI%D#!C3U.T(PLR!@Q,/XO !FY"9%V08I4G=?KD+\_!4U#1%EUPO95W;FS
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M10,^<P(&&<P@:9C;'*RXABRVCB 9,,,44;&&#'!' VLP!0*:=($T-((!!:%
M'.0PGA.,@" F2 $JO( "'#*@#?Y<2@_X3'E*5&+%$"B[3 C&0(8'-&T$$_"(
M"B_#")N=#X>F,(//(,#%,<#1%!>0@RD(@3Y.K  $)'! (QHQ@8$< G882(-E
M5K0 $H!@!!4H0^#,4 )#K* +;V#!NSS IQ*L8" 3.,1$)K"(">XE HLP QQ1
MP<(Y8< AB%QG.TTQ3S(X0)84R,] ,,"GO;@*%1-(CRF^EC\/E"!TJ(C (3(!
M@=5821$324,'%K$ 67)S$WGJZ!4_,$523"0%",4*!1HZBA8LTP&&X 0$3-2(
M/)7 "Q/!&2JV.8(0@. "FR"(-"=BBC:@3 4F8 Q*5?"NCC8"I-J\ -4J\!XU
MA" 3$_[HA"8FD%)3J( %)1V%*5+0A3F@S 0M.,@)?L,"$@Q$#A&80 <"F$J\
MYE6O/HGF#5&A@32D00,W,T5(R*#"@33"9HJ@(D&ZH,F*$B28C%K2,5&AN1UA
MP)D1N PB8.>!CO&H#8IP "<X,0K3*J1H*GC#'$[@ <B  )WO<NAW)-"(QQ6$
M 8G2Y#UWHP;<D020!&'H_AJ1!GT*1!/]@5=C"=(!$Y:1N(QX6&CR1M%#:.(!
MJBI(<?,' DWL]K2F;005T\"!*XJL;01!'E@HX*T,E$ 2J-@ HAYP4RJ& ;TG
MFB0)4D *3FBM((YH0'_:=4]0DN0#:/#,G#K "09D8A2H-?Z1P5R3 A:8,!/N
M(P@)P" 'E,V/#'@8CPFBYM9[GH!' ZJ0S?;Z8AC'.":+*$ 8. &'!&B"$PYP
M RG64 %3@ &]B=TM*C"@@AY1!Q4,:!(8@AN!$,J!BB0B!1L(0(A%,"":DY2#
M P[!B1#X# /T4L0$#O/%@H"  9H8Q0/6V &JE<"N]FMHVPC1@"_+;4[-5$0#
M=K,&!R#"(&P(M/V*---1.& -52X>0=I4N$5T 0$AP0]!VI8"$)A"$0Q@ >LL
MN@#F$N0!&\B$(QI&WQ2,8A'LS(0"4&$&\[S:/&'8W@H68"#K".4!WIJ C>!0
M@#>0[*8,&$4G)N!A#<#NSH48A?X7/*!@$G "$0XH3 H8Q) W)$"!:;!B!TP0
MI?<:!@$J-D,!/)<)O/4H >U\0"'=8$ VH&\$G40%"53,@@LTPA$)*"8<YIB&
M$,I8X .7<30KT 4,5"#@A,@ X2:S!MI>3 08TD0(V!-!$B"&#6PUWF02H4DY
M1,X,83!!(^(:IA$,!+D8&(&)- $"#$!R@6LFB1IZ:X(S.)9WAK  GT80&E.0
M(#0K;SD.55"!%%CH8A_(=$$XX8%,"YT@(\B+(3(0,%FESP03F( &OE.:J4.I
M _-Z@P8R40(H@2#4B?'=P0G"B1&PQT"Y085O"&+W!;; $'L*7%-*T"1":* #
MKQQ!)OY&T(F+A0!#IAC#& [Q552PX0(8 ,$.N40"N5^1>P4A10;L)(=.<@+S
M%T S"#BTB W<E ((KP#O4 %/#&0@/W+8#1@2]$K#'!D5;V /!I:T4H('7_AY
ME2,.%;*HE7 7)E]1/I<*HHD3--\FS<_U1J1OD+57)/LJ6?OU%3*"PC2B 5D7
MR_8+0@@08*@+<Z/C1LS/DO<7)!.8R[[W58+\X>=?_]];1--?$ARK*(F+P;^<
M $":^(JKR+7:T I#Z  -P( >>@M26#\-J+R5J#[!$ D>.2D-W#\/_$ 0#$'F
MB+^V($$1/$$43$$5E N9P$#P> X77$$9G$$:K$$;O$$<S/Y!'6R+)]D(1; _
MH2 %+N*('IR)'VP)32"$0E#"&#2(1CB;'8Q"*9S"I6C"P!B-3)BX#.R[B@B#
MX)(K>GL \N,-OF )C3"$"% ^,OC"%RP(UR(("!A#D0 # V@X"GB ST! A0"!
MB*-"/_Q#0-P)@0B,TS*(U#((38B(00R3!B! BY 3IXN,5ULCE8LUTD$M[(/"
MAG#$M\L^A%BND>"N 3DOI\,_ %.(-;"BA2H4 M3$@>B9@I"S4DR(0^2- 3$!
M#PI$7=Q%7DR)12"!+[B "> =12B!,(B 1#P>#*"M%-B #'"B,$$7#"@,10B!
M+KB ""BF#F" #1C"#,D !PP--OXH 16@  LH%>(9 :#BB#(3*$ZX !8P&NX9
M@]@KNBZ JPE(OX(PN8>9@)S[Q6/4L0Z(.=3)'H*P/4[(M%$@'A'(IH-(@:OC
M.%C;@ VX*T6H  <( 4X8LPZ   \B!,+) $$K"%A<(9\QA15H.&B$.W2I'Y,;
M@PC(A$; @(S1 );J19S,R3\<"$4(@ N1 P20R0!@@41(C-TP,CD@A,;R@/R0
MN4R(R48(@#7H$F6+@$*AQ7SS)!,: P3X06WRJ?3#J=["H;M(Q A ,G*Y,0JX
MC!;8C0^@ !TC$8Y8A !(%4*8--U1@79:QL+"#\D[B @PA$Q8 %0X@0X@A?*"
M(Q7H+?X.X!T%" E4X0A2, ,+&! ).(%HF;0I$K1+>@V/P:81V "XO"<-F+ .
M4+$P4* :XH0!2(%VL@ O( 5", #4L4*=O$W<S#]I*@@.,(,-<[0'$(,U> ,/
MZ !-<  2*!$V$B6 <P R>,H.@9VGO#[9["@5FJQ7>S9!@I>3) @V>"&K)"[<
M"@$W6 ,PL)L0^*+<XDF_\H Q"*]H<J[D81U.. 24480T#,_\\9GM80,V& 'S
MT( ,& -OW#T,(*XF>:<U@+(T> ,#R(Z!\(((,(/&TX!W>8#O6(0YRITWB)?L
M0B'#R)/Y$:/<+%$3E<%5,K['>4IH>8 A8!4S6!).Z (-6/X 0C@$!A@#93$#
M1E@$SEH@V%$L1\P$#/  ,A@"%0J#9X,7%6J Q9B3)54Y]IN R?BG_I,M+QB#
MP@@![@&!CN%)*[H,$O "[;H,74HI-)B;#F #,& KSYHBH%.#9WN O/F"&"6(
MPUH VAJ(OURH(IDG,YB ,%"6--B15URC,)DT,YN(\N(E"5"!-K@ L8& 3S@1
MV+F,$\C%$]U43M4_GAP?$?(1:&*4PC@10V"#_D$%%0B!'%J40EVUO@J3_]FE
M@@ #5?0"%1(#>R*#9YL SP'+/=( !-T?2?""WN($ P$!,9B?+WV]!$ ,"(@#
M3?A13K"CYV*K-?@ #\@+_+RL5/XE 9^1.3:2@TSXC04BS() ).(J$C,KOBOB
MKI(\I 0@A9G!4_-8 &]I)NW"$ A## EHUK&PS4X=6(*U"458  ]H 7!D(\Q9
MD09(@118 $0XA 0XJP@HC!&)J<5!!"V;.1YY@-($ \1B(Z'I A!H@$4@@Q>R
MG-WCM!1P !7BB+M, =9I*"]#&A!H 0?@$SA[+JH9B"Q+6'0Q#!"-'8^T.!-1
MGS7:M.+@-!5PLP5R@!.P%T(@!0J ,PR@-X(HA'$3H$-;DGX9@@MHNE<L@(:[
M@ 7@'6E*@:?-C^/Q@A28 ,4@MH-\@+9,@)N,,8$=BKTM6+]E"T/(MZY)GR3*
MG<9;%/Y-& ,P:)(%ZIJ!Z(3O&(7O: 1&(@1$#1,RV!9RK4^">!%"\0(X\%R#
M((008I$X,A%2<)BB- S$4 1(,8P*:(3!185.R#I%<-R". 3$D%R@_8(W$-W$
M'8,M,84T\ ([F940HJDX0KSB -V$R 0YB ,X@ ,HY 0R>,^"> /?Y(0W.!2&
M( 0OH!#+@XH)&P5#*2OC*XHF-,$+M,*;<8E08]^_G5^E,(1)JHE<2THN9(J#
M+<-=Q,\*X#J,? ,Y^(",VE^42& N'(@V>#9ZFHL,S(0+,!&IB A<Y(B!8(&?
M18F(\(B!,#$VBH"2FP *YN"!@(,H184.V!8#% V_J(L6YOZ-OJ7?7N0$/( -
M 6P(C="*"N:*"N[  ZX()<'A+21#(]:+*[R-#L0,B7AA!9[A Y2(1L@$%K
MF4S= R6*-$"9N8*)#>/$D5B$\>6DEB"$615C5/@"%1J%=E*)-P@Q@J" XZ5A
M.J[C/P0#826(CN*C;_/.#_@ -S!$,K#<D  #Z%I=XOR G-.$+T@L/@$D3NA(
M%4"M%(@HRYO #P@!R"@O$U%2$/ 611B!>0DU.%@24AB" =T.'DF!#D@!$T$0
M/BH!T_J !Z#9I$P$"CB=%L&04&89A!"L%!B#%R*("QBE-P"#@1@#Z((,,."B
M AE=$1">@3 #0S !WGD#;<V4@_Y08Q HI3& .F^QX_F%X*T@"B+&"1Y.0<T
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MF(>84$'44#@*6*8"/D8%>#)A OX6Q,$,+CD#]9Q2N D@0FL/(P$@3R#F(Y.
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MI)Q<C/Z <U 38G@ "Y ")X#  Z0 )YB!(90 :=S)R[W0!5! =RQ"32Z'N&R
M":S!YG5!,Z4!9!5D7_KEUH7 %I&! 73'"81 ([#!!(Q"C65)C>1)([R!LF@<
M*:3C&1Q""'C 402 %\P!"6#+&@3 &=3.!E02MK !!1R"(B@=!(!+&BB>(:34
M]B"2 YC!(6RE4SA &>1&09"$(AA ;DQ :\3-(83! XP"&>1>!IA!'$#((D#
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M68C%DISE$8*)7*K.O*4SHD(+$ R97&'C"5X*S-BS;0"A1>O+PNPP\9\<@,$
M3(E[R0'@C @A!,!&L<!K <Z1($#B.  8R($&N$0;%$ 7R &#54Y%48!;((+E
MQ0$#I/X!;\6' ^C, \3*!HA4VD2$'&R 2[")OW9KMJ0  ,P&TLK!"BA+EO!(
M7ZP1(8Q! G@!)R0 4#F "0"=8BX S\'/$/XM(0Q!@A@" L1'!(B3!U1&W?X$
M<>'I S#M1V1)'?$?T"@" OR$>ZY3S'KNY[Z.9$01&[C(7Y  (C",%^CC&8!
M"0#6<31"<AB;1:Q$!_"17.395K22)J1&7=S%2D(D(_ &"IQ=(Z  :F@A&8 %
M>JR'5'D!CWG!!ZR H:2!.(U)"<#!(;1 5$J3')B )C3">&7"::1 %X[O!Z"
MX/Q&"[W1F)# &RC"3XS"$,2'(R3'7#9I)L0!Z* " XS(K?[M"N@*\ !3UAE4
MU!^*)"',002,EUW,&"=X 2L2\ 13<,Q,S$=Y##=ZQR$$I4-I\ =K'0;GDT)]
M<"Z^(D%,H@B;S*28<.B\*5TD9#F%8P73< W;\ WC< Y3F$"R#.KPL#%*(@KW
ML X3<1$;\1$C<1+'C"(T[\/0Z</T(5HH0@KP) G[HQ4'8R2*A3T5(\N,PAFL
M$ZD\\0CMQ^( S \K<1JKL5FP <%HS /(((VY$UH(11?*C&H(A;^.12;D;5I
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M(12.!)! *BF?[%E&KUF >UC$BLU!0<"!5N#:)4<JK*'$!VR+[(65IH9%&:4
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MJZBH$36%*$9A 18A$Q9@#C0A \S@$X;@41] +S @J<+  48!#KB#$)['GQX
M#DCA0!+DW&:$#![ #,B #,: $\C*)0K!UE0  51@53'@! ZA659) +J $!RL
M5"(@LT:@>HJF$4(@ ^1Q 4P@0<(E$Y2U$9C5GR[ 26'G/Q;! 2B !13I2LO5
M7 >#<1)E!,: % "04BY #(JC)C) #>3@:EQ']&KB3%)FV5!A", J&8=@ TF!
M(AI!3MQ@.F+.K$A@ PKA* =L!5"!$##.X")Q$48A$TAA$0))8CTM1@HA. V"
M ]* V_X,(@X&R,4TA5/$;9H48 1$H+V0)/^*#!56 (-0P6IJH@/,P! 6Q"#
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MLL,@^"=?'B .L@=6R(KRQN  4O[ !$[@ECA'!=I@ VR-!.HP@]B"!<Y4#@Q
MD$C TV(NAP="5 +E.!E@N&YN0[5G?AHY@>4  4[ #$P@ 71(#A* !=[ #!8
M1LIRA5-Y&N'(%"@.'4& D72K) RQ(3J \WA0@4_@ ]#(CU#!#8B"DKRB#/"E
MC$# "@\A=O/H!=EUG*#S]!S$[,R@549!!93'#&!E#$C #'())*3(+68)G4!@
M!5:GEP_3R?8H>*]D%,9 L0ZA!6B.!5+ *Q2!!%1 #KP"#@YG)," 3F&%#3:
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23+BPX<.($RM>S+BQXY<! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>cogo_0021.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0021.gif
M1TE&.#EA_P(@ ?<   0! 0D%!@X)"PL'"!$-#A,/$!82$QD5%AL7&!X:&R$=
M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%
M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9FIG:&UJ:W!N
M;G)O<'5R<WAV=WIW>'UZ>X!^?P!'GP!,H@!'H !4I@%7J %;J@%CK@EDK@)G
ML -JL@MLLPMGL!-MLPUQM1-SMAMTMQIWN!QZNA9WN!-CKB-\NRI]O"=UMS5Y
MN0 _FX%_@"R"OB: O3.$OSN"OC2&P#6(P3R+PSJ'P2^%P$6-PTV+PT61QDN3
MQTV6R$^8RE*7R52:REN=S%:2QE6-PV2=S&>6R5Z@SF2BSFFCSV:ET&JFT6ZI
MTG2KU'JNU7&FT7RQUGVSUTZ$OX6#@XB&AXF'B(R*BY".CY&/D)22DYB6EYF7
MF)R;FZ">GZ&?H*2CHZBGIZFGJ*RKJ["OK[&OL+2SL[BWM[R[N[FWN,"_OX.U
MV(RZVX:TV).]W9J[W(:OU<"_P);!WIK!WYW$X*+&X:7)XZO,Y;'/YK+1Y[;3
MZ+O5Z;[9Z[O1YZ_0YJ+!W\3#P\C'Q\S+R\C'R-#/S]#/T-33T]C7U]C7V-S;
MV];7V.#?W\/;[,G>[L'7ZN#?X,W@[\[B\-/D\=SJ]-CG\M#A[^3CY.CGY^SK
M[.CGZ/#O[^/N]NCO]_#O\.;P]^SS^>?Q]_3T]/#U^O;Z_/____CW]P
M
M
M
M
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M<K2@0B9_>)"?!"8T[8(+*WSVBOX;'F"PP0HO\\3""2N\\@8&%I@ 2I 5)+!
MX+O\40+0'+3PV2Z?J("V!B@LNJ'5?FCRP=9U$/2*"QM@P($;XH%R@@EOX,("
M!XL?JF8"G@RT!X $K!R3'R%@@ &^5$;^<]!MXH:ZZJQ?9[0;KZ"P-&*?E+#T
M&S$MFT %GIP@/!OTZ4)'WQH /E +)J#P"F!#.RU  0_T= <!"FBPBP( .+Z
MJ CA(@$";!(('B0% <R5ZP#N\9\""/ K""2  &W2@P$6  %>>.( Y9*-"@8%
M H&HP#BEF]?,1DC"$G;D!(/B&5!:$8A+0*L%!2C  ))$ !%HY@\!(  %*I _
MX[@  OX P&  WK"+-9C' O@;U #6P!-<>. \,T0/&P22B046AP"2(ML&
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M:(#$0 "!,$I@%V\PP / @X(,)* !!NC/"010,CW$P0%Q3%8("L  /;B"#@8
M@/U @*8[?&(-V:G '32!BPCLKQ,C.\"]]-""_"C %+PH*;\\H($$.*IKGBR5
M_7;ABN<DX Z7"($"!,!$$4A,#ZWH(P!X-A YP.\ $#B;?@B B5U0P  ,6($>
M2O# $+#(3(!] %@\"=@$4$@@;J!?!':AAVDJE0X.- #9\B!'!S3& <'D3@4D
M)5@3+-"PFU  :!7P405)Z@,22/Y0_);%  0X8 TL8(!(XV P^GE #VR 4<;\
MJA^I*N!720%%W^PE@MN0M9S\>PHN]!235V#@4P]#X0'\M91X*H "1Z%NI:YK
M@ Z&=RF9P"D!B+B+/3CR80V-KWSGRQ ,$"H%!='%48Z"T0,,+1/EF@\F *L
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M7/]3QGG1 .( "JE*P"^?P,\"%O>*".2'Z0B0 !9 %N<V 7#P(O"''%NU"Q/
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MP:NS1 !*61"NH'JMM*DL !3U9P %(" J('=BMQ.:*BB:@OXF"E",?T4 !<L
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M-4 $NU &,K $0U #J9 *-! $._YPTY,0!C6  P_=($!@V,D] _?, T&0W##
MW#6P"I!0 U/@!#0@V_\\!G4G"310!3IP!;N  T"P"X\P SZ@WHN@"C- !#2
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M,R*H@510OK<(@G4-@J-+@QFP-E58"RG( ;88!4>PSJ-;!!@P0S28@5, @QI
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M4+0OVQ%;&(*I PHFA%_^VP%KAF^;^ Y[ZS"&<SA[0[?U^.\-@8X!#X\!=XL
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M$C+P;2H). "$ANN$"Y@ #7" $G *2 FGL;B$"V@F;<(%!QJ+/5  "Z@ "?"
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M/QKH8-B0:6 <#QS<[,(%(>+ .T8-.HC9P@^&3&XN2=RTZ\\&#7%:\-R%A^Y
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MI( X="(3$&@%+S90!U> 0 2=@,6 >%$'#22) I_@A 1"X H%T&</%,A(0=X
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MYZ4?7_Z]0@* AW-5S$?A#RCDP0=@DN5H@H1A0$P8A!T@@$<L@"8P%T>,0!M
M8 FXWQM41$WT 6HD'PK %2]X@!)Z@)VDA"@P@+7L @,$BJ4P0%SLPAL0P,8Y
M7PO U87TS/^ P!^  @AP0,Y) $>4@*(LE$%T@ (V!@/DBRM,0$3@W"Z4P!MT
MDD&$0"9$P)QD@LW@VK^("/)QX=,-! K4!./$ 1@&QF?07MC4U) 8Q!H\8DQ@
M &,P6ASP0N?TFFW)1D',P0-"8/8P7(+0@FCM0@JL 2@\G@JYUD!\D6/,"0F&
MF- @1!^<TPE@0!V8P%R= '*X 02\ @N0C(C0P0D0@!X@&OX)C)#]J$#W60Q<
ME4 $>,P%V.(NV %E\0<(Z$?QB-H=G$ %X,(E$$ )T$$(D) *:, =L $$D  M
M,,!VI%D!C( (;  #Q 1B)<@NM( $Q($*% !6Q,$$;$ ):!73$( (E,D^-H8&
MA$!L@4"1!<!A-(Q$<MH_!HH*B <*>!AID8 Z5DP+P,TF844?>),>.$ <N $#
M:$(F@-4E4 3IF87?0<#J>(0&#.&I0$ +T $$N,$K+( *]-S$!-BZN8$<6$".
M[ %+O@$#H!;C843:#&4)1-2=N$0$Y(L.8@0+Q8'SM4'VN$ %V($*4 !.P$("
M=,"%0  ;W $)*,"W:  &> (SB?X+ UB(*4  "]"!! 37+;I4'R1 "*P!!SA
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M)CA </XX0!W@PKD$9HA]PCW510U&!@JX@>7DP8Y-!8HT1AR8P"4X3V.\ 0J
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MKPW[74.L@0:P@ 54&BYLP 2L  DDP%;L(IYP )/@22L\@$TVQ D   !R!0#
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M>$ /#\1Q=, )%%T<L$0K] <&7.7A;, (T,HFU>-,+BY_O: ^NE8%.( )O )
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MHA 5>8-R%S*(D(4\YVX39)<GJEC*D1E:U(64&9S *+0R8%AD%REF*&,72(R
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MBA=3.F(4\DWN#""1QEKH@JAD*,0,U%O,4:QB"SX089<$=0,EW,(6JJ@3MFI
M!D'TX M F 0-:M.( \=1$<[=E"-\0 -"V:(*-QA6J'61"N.($ O\/>926!E9
MTEEA%C30SY@HJF&![$\^O<G.#9[THFLR3@LS$&TB3IHI->D"$I.0!6(/4<S!
M.F(*I(":0++C&?A&N:Y98,4,7.C?5.B@Q% T]A)LH8M1C");P-Y%%+)*$")$
M<1=P?=4N?B:+,,Z[:$\8X2[ 8/ZJ74C:-5@^7A,2-JC( L%.8,@!#T:!A2#H
MP!:DD$&++"$#20Q"CJ.0A"R$Z#U_DT$&:A*<W&S2M4TEL!2GH,&J$+L(7<A"
M$JI0E&AW004=E(L'0PCY*4B.@S+)0@?9;5CI4/O>0<" 48<&-0[<V@25G342
MDSBZ6^^2!!P$^=5SI,&"4E4(B3*.D).XT*QKD-UPWN!YO(@>K0?KG22OXI1$
M)80M9B %791"D1QD',%)'DA"?.'F<K?%YW5Q@RSP*CSU\Q(, '4K&3#!%H@F
M1!-@0 A&O&!4G9)/:+S% ^*2(09/JH4/I%X(#2[B!?E&9B$*NPA;Z" 'DAMN
M#G+0F_X;C)@SS9]\\VJPKJZ!P0F*Y%4-FJ )GNY@[ K)#H=,G.-HFL@YW.A5
MG@"2GH@&; &QJJ#?L&#G)*5K@( 7=N@"!V9-I(Y$:D" !DH+V(11'F$&$$40
M8L!61L%1"&$(8, 16) 4L$ &""&0!B$28J!C<H!<Q@ &4J\F&JB"XB@)PNU;
M@L8'<H ,EF"$1@$&(JN+AH4"!><+;($&[*<6',4Y%(6A@BI^9* +T. '5P'H
MW"I9=B$5#,B_$ \OCFA8]"T&*B%:>F ,X ^08H!FT$02GG 0L& &3"><)(5:
M&FH70L6)5 &Y@@ &%DN"VHT(G@\&"B$17H!F6*H&"D$,9/[ $:QO%X#.%J)
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M0 $7+@ #7,%.A_-)XX(-]/0"', /=L$-1$ V<0$"(E0VH?Z1$QY !!8T--9
M 3#  AX !!;4/.?S/7<A#D* 3@M"%"P !"H@0LOB$A*@ BQ  BC@4N>#-Z Q
M#CQ@8+Z2!-P@40\"&NO@3@_B4"6  RJ  C(A/O%S.I5S%^J #G9A$R"@5$]U
M6HO3*5J  C3@3)%5-WE!-P_D*S?@#X!5($( 0;^27*^S#V25/%E@5:&Q%3@
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M=B!4X 2L-DH556:3 AH]@ 0Z(1/NX  0%"* M" HH ]68Q?DM&Q+  "L=1=
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MYE1H.X"!/6$7X, .WG875J #-F!8^T ")& -7D$%%M0-W/[7!02"!>0 !"C
M3^^VAIW" Y97(#Y@#42A#RX!!79!%%1 !) 5%]C@;1UT#W3T%>KU#S2 =$%A
ME8-V%PZT!4! 7?5  CX 4O&3!$X@ M08%!Y@?5<@!,84%N3@*^E@0UV !-:
M%GAYBO_@#R3  _[@%4BW%52 !.) -T,@A?'@$GQ9=O' F#<A4A_@!$!A$S3A
M;B-@#6+A#BYT%^R@%>(@GM\9$TJ !&17G,E940_"#?*V(#:  T"A$Q*@$Q"A
M=T\ !7BA%2K@$EI! UH >'?! FHW!5)@0Q, %]I  30!HY<7 _#W#C[6!5#:
M%2I@>2F #6#!#Q8 4.O =._T#OXT8!=@5R \P74'XA,8 $0E(!-P(9@S@1<L
MX Y<@0%$= TH8!=4H 2PM@(RH1,"8 7^P'+-0A088)\)0@X4X!)<00-26 %
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MRKA>P04)'L !##R 3;C80 72\H"Z2" YX16SH0]-P QVH$O[]0H)&( !#$2
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M23X3L<4-+G!2S/_N;E# /00</D'7(:-U!N)*(C^7HGE64)H^;$ #(=A*'#Z
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M"2&'"P9  B-V$B)0 0:#1($1 7^@,9?P"FR0(FYP BA@'J"  7H$/1O0:AY
M![S0?JX@!P( 8PE02Q3P":Z  2#R'-#S%Z^G0!(@!S6&(OXP!GW,<49!)WD@
MH0&M!CZ[8 )!UPGIT0(&<"N9H#^OP )SJ !KP!%@8Q*6DAQQ4!<'D!P?9R3
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M1P C-CMYJ!&2@T-N  <AP#)MJ$ *$!Z[81XG4 %Q  +)=@*5TP),]*0$T7Z
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M%;X<!KN0"T30 YA-TZ4PX#I0U)50 TJ0RSU@"V,@ [!,!31@"ZJPVSVP!#0
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M#PB^K<$%"\T$Z#S.B/NHQ:G4AV*#3(@#!H6<.G@S-KB$6MH%=M)5"1"%3""
M8%-/,ZN ;DR 1WPJ.F@:S<& 3/[P.DZ('@Q  E?X@"3<@P1 I*9I!7M;SL2)
MP.YQ@#NXA# <-P-(4J_:!0\X@5:  ]FY4YU< P+0L9M0@0?[&!*@@#[H@P3
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M.($QS1<-\ ,W@+A7H  .TP,-X(4)&#6M.0%-L)\6N*7)*@$3H*S;+0@6: %
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M$&C/'0PB7#" PXW4UTR!>GM%$&#<%Z.U@L %R2'=#4[DI'0^>_* V=N8'OZ
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MOW[LSW[MWW[N[W[O_W[P#W_Q'W_R+W_S/W_T3W_U7W_V;W_W?W_XCW_Y7YB
#   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>cogo_0039.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0039.gif
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M^?3T]/3V^?7Z_/____CW]_#O\
M
M
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M1-,"  \<$@ ## 1  BW.^4%8!0"@0)@T$@ @ 0( $!# "_[1*'+GH@A4V.D
M @0P 3*9 ,!I !5D$@  G!RC  $X1).) H0*$$.;T$8K[;3%36" !<?!<  "
MNN!  * V?.N,,Q 8J@L!"1"R2X0('%.) 0XX: ,O WKVB 032'.# 1&H*"$B
M@Z5   G1V*(  F@*),+!+3Q"PK&T9&)  P[>@(P$!)00L00#I""-(@D@\(<O
MG4@HB[$$]%$: 3+L@HD# WBV';4TUVQS70V*<%8,!B!@2[@.2",+ @;,T@FZ
MQ^ P@ 2=T-))N85D0@ "L$9SS&\E] $)A]+00, #T=!BP &="*0( 0H<0\@
M$" SD C7"J3+L8!@,G75D?0<H_X?D1ZCGP%H;D*T*<<P0$ @FZ#]""VTF%"
MJ3='+OGD8&DWP0%POHV  LC<(*XT%03@1Q^>1H/" 0L,"RD ,&!2  +LB>4'
M I,.D !V,GPM- ('8"(6,A ,<(@+KZ(EP@ P$*9,N32X?@![@1:P@"Z$05+?
M+&(;X-DF]1&^  &#($)  [FV.D #,U.N_OKL(Y7S0(I(^&#N;4=CPP B6!
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M@ F1A1,'<$"/OBI40@2B1\ +@%L-A)N#I,46"6B ,T#%@!YMH@\.!>LQ#C$
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MFW$]5#?WFI_6I04$<;UPM"3::KA67R"NTP< 5$VH+&"5!/Y<@  :""03'!,
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M!.3=Y?X#0>(OU=FWX>>3HPS7N>(NWN*X -V*K@LP_@%13N>0'NDT[@%7K@%
M@ 6GH-?< =C-P IRP 1&0 3V[>1(7NJF7NH]H $?,.>1CN%27N-6;N$A  6>
M  SHO4/#D IW@ 9B$ 9I7@9F$.S!ON9KWN9OG@&13N=3;N/Z_=T;( 19< OG
M/;>-5-<4\7N"SB;.( RR8 F4< LN'MV+SN*)?N@P'N6/GNSJ/NG[#01:D M]
M/CG0X IRT 3RO>2GGN_YGNH8GNYTSNH _^H:D.,;  6?0.#L,PQ[  >]+@;
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MH@JY>=-ZQ0LG$[DESSP!+0M9N20NE)9'_>22/[=$C-3Z2!G(_)%;Q4P4,3$
M!%ZI$R*_:$(1B251_QV!GM3<#(<:$8UE9K,9J?RFH<BS.X% TS5*,((<3.C0
MB 2.@\PQPSOI%LYQCG-Q+<)  2])BQ6R4',^S:-B9.5+J0$,F,+4T"#'I!X,
M_. Z8T2D*QP939-0]"1/L"E& WF!>[*T(<V(P^!"BJ(L)L]./8C3%^< 58<6
M8X,^PM;U8GJHK-ZFKAMJJKRBJ/Y/_1R&GRQLVM,HL<?. 6@7H+BH5G?C5*]&
M0ZI(F"I5K2JGQ&K5 QO@:F.+$595RG2LZKHKMS1@3F*A= Y>:^Q#AD$6;XY5
M>Y7E'D$TX!NV%DV?^C*,7WV*.:;QUC\$U44NBKH+1XA&AY9]"4T8RM)?1/:(
M5)V=V4*KF<I65B 7V&AM$5@,-5#K#$EI[2KI:CH0A&2RKJF@=A$)"RI^ECEE
M16Y&0[-1#/*"$KGUYQUW^].^WK$2M&#?0 'DBT88EZ1)56X<+_FQ)D#WN1%;
M@D7CNZ$+7+.C0/SHW!H87N4@;KIV I)M,L #LJ%4I>H%8BLV>928NO<HK?PP
M]V2RK/X+_%!\NU :OEYHI< "E+]6*D7GLM0+XF[KIG!17F9X1A,A7/B$S7!"
M[!S\R&EJ)L99$P@&+#E+:,!!PRX63SP--F-B5C6M1,B#5QDRQ:5XMI/6"B=2
MD=NBM6&!H[]+1N7^RD\>N]!R^ODM@ 2JBUOLHL!;3/)Q,7K=*6 3D=   X6F
M;,0Y3;B:&Q#C)87G3@XW\($)-8\HC?C%=+*4S4MIL7A2/=--(9J:9&8)AQK-
M.F0H8C^*\;.4 'L^ITUIT+\@:JT,K&BU*?5 -,DN&1GR$>=..DZPJ;*E7;0;
M'304B S9 P-AZN:0PA<ZKF;)!G;0[-(:@16.GF4KC@/F,/X?#]P"1')+-J">
M"]@9Q6J"QB,$@8A]^G//E8/:OUW51X'2RA$WC+?\=D>3MI%1%%*6C4G-/&4)
M2[N'.47W"54<7FZ'U"U7]I1Y/C!E<#'S%>MFMWC<(F=I7]?.;N.$( PQ<T?D
MY]].N_5?+<&)5PGX,88>MFAE' +( ?$7YW5V[2J41!=97#>8M?$)AT&&N*;\
M1!],VP;0"B>D3\P(3D#M)8=A=;**TR5*!/E!Z4W?E^D"$#.?>2(>@8FEY8ON
MN]7Q?E>%B4P #!>_F S@(>.+12#/V,1.JA8Q((2,B^\93.BZQ(H8^0<_P>FW
MH8DE[QVN#-MLU6.M.HN/XI2TD?YVHA5*Z2F;@8;0D_V*G[Y\K&FR,(8A(Q%P
MAWLB;)W;O/,SU_O%!&&!"QED:,'P[\8ANZ*#_+A@H*L8'"+9D$#YBL:^AQG0
M@8+%I\GD='J5,BV<<YB/F_(ZFPCGWCS#NOQEUR]EO-;736?T*BY)W![W<>=W
MW>^N<Q[CFK>64)^" QC""R#2$1.$ K&FJQ_XR8#Y8QV&8 4B(+>D*Y9*@[\%
MI DI:+S(V;AM:[\R\+9DF2!G:P)KPR!IR#;O8S?86QS82KAZRKYPT0I9V+?[
MN[](T(1+J"-_TS/]LI)<*ZK(^!=?,+[Q$Z0P.;RH4"YI2+](:08FH,!B.:]H
MPRC8POZAV=.?9N@^YL"6CONLXT&9#YA (TJ]*.K #UPC*Y0Q Z0DQG,R)4D&
M&Y1#0Y"$'[,C7<JE*?$K2J@%/L(26^"%1?">8;(XFGB^R%DVB(M"(ZJX"TPN
M#0@![?N;37,O+U0U5]*0#)"XV)@\.#&W#?P;AB@&JE/!!FH]I6!!BWO!M;FG
M)L0.29"Y.<2]1&"$I;F[P,*C'L0O52D%7@B8R @06R"\073$0-J Z_@=5Y"T
M1:2TM).D'5J;*P#%CGD%;?NLSZL;3#P0TZ- (V""L-,?+RO%#?/"][L\6,LH
M#) E2<&%6)3%652$S.$Q\YG'/]L[&8*,+R%"$!@_LUHXC/YSQ26Q@F5DQK*Q
MP&*LG]" HJ\!JW,QG%-,"H@4*36,BTV<L@@K-?U)A6YR/:ICCE:BR#DCB!^0
MQ"61!D1X1SF\O9["PWK<,1:B(:+"!2*\@'[\MB3D%G4,Q6@(A;&Q$.I+.@!"
M2!R:B<5CG8W$QG2Q1(DLNY!DB:U;1,A* F+0GV$XBP\,KU1\QB9:,@QHM( T
M#1J$.T)(R=PSA$C(!,3XO3S20Q=*FCVZA:(BO* 3N5<S0IL RQ!YAH@JR&@Z
MR*%L"2QT&RT<F>))2BO*%J?,F[X4B3*$'G%$0_$X T]"&2NTR3R)-9U,$X9
MAK)\QT2HPWSQOYOCET#31RUH'/Y"?,8[(9T+H*VOX9\Q9$RE(XDEH,(#<4JH
MJ"R" (*\?!#N,\5QG$ANL<B?++&28QU5X,C(?*^WF+/#NY.%NB UV01W]$P;
M)(1:1!6]"RK- ; !(4*Z3)8<0L=$"Q,@>,-(@89F:+"(L2JK(LB1L!WJNTW
MS"C7O+..*8;"/!SA!#VMI"YN[$LDF(-IG)?58\K@-!P +496S$\:L;WK_,Q#
M6*&;>YK]PX1*$+Y8\04L$,^0TR+6=#6$&<^U><V.B4V@G$V38#K[),H,Z,VB
M$13_Y*0$%;,5D<U).P(D0$ZW <Y*/,P3,1D?P,E"%(BBHY'JE-#/-(1^^RF@
M8B&Z6_X?7.B%7@C/RX2W).1-W]2.O5S11Q)*%VV^+6.8_8PI&B5'+TS,6T&K
M\Z(=%8V-V.&",-"#R"$&2V1.=7'*W&07FI@U&G&&^R/+)97#T*R27>,M3,B2
M(:.%#DW-K82*%\P,AGN94(C/B?O2Y_I+,5T6HYP7;&,@/&TS-.W/YJ1( 5U$
M.9W,F"J&262_/%6.0\'2V,, !WP06K!.0IU#6GQ)>KQ0Q1BXR>@%77!41"O/
MN"C2Q:$)*.@8:+ ".#5."JS/8D1'FO@0+@T.! W2JR-5!QHI!,G1:((L+@#!
M,L"6,-@# R45J^Q6%-E6R0Q!2Y/4YF/6&8$&1AA47?W,FO[[MRC5A$HP3<>P
M4M1T-034H63='0Q8R%Y1QJF"4VBES3AI481<ON;[TW!13AKMPI1C4)B RK*)
MO'$=&8\T5S283O6+AIEI5Q?KV%<C2A"K574-CEW(57V=0T(X!%SDP3P"3RP@
M1DYEB1ICF.CS'XBM*#[MH6?\@)*,%.^ 56]E.9C( >DCEMCI@LE$M3!H!9GU
MDV'P@C98V;&:*[.+5)N<UW^, A!AB)BSV92\O974' M5E6 =P"L  6>,O0SX
M 6<0EV4(UTR5$Y4@*:5"V#RY@$?!5M,8!FM\6O&P&]PH3JI: G)M ^80@SMH
MUFA8#7)5I<8%IWCEH2!!+@Q 1OX'.4E"S5<)!4U5Z3%<4LLI"3+*L%*[11O%
MP5M+TS*N5=MH>+B_?; HG#X65<.S79%! B0F$Y<4]-QV([W;(+'HDABK!2?Q
M$(-AZ!ABV!LEX *38;&P]2#05<5)Y1K=_0M>L+^V35U9)(1'L+E<ZC]5.0Q?
MTH5&M=N5P-O;S8S$6IN+)95(RU2C%0FL0D((BE0L*UU)0=#E/1$PW)"D,X(E
MZ (SJ%QW#8-40%&(:PTN\ +"\5Z2V5B:LBS")5[=^ ".H8],J%GT?4="L+6=
MW:U@!1U?N +ON5N@U2$=X-M>(0;&!."K2JS"%:3"'2 ,8#M).;D.=J_)U$8<
MBMS9</Y/"%8+DE4U,8 #]7."R<O@""844:U$!AX3G&1-Q$L4FG@4^H"&0TA?
M74UC64P$1.#.P#(%@N*%*\B N[VR&,-?S,. ,TE<OQ %"91/3 5<UPC3-<P3
M(4Z^3F6\7OE1!4Y#S4#5HD4"*&Z#HB!%'YD6ZQ475E!$I8/BF.)B]_+B!!2M
M$)O5Y,)+^@"&-5Y25IY#1+B]-]8U3OA%&:[C&K:K/$:9Z*"DEU//: B6I.MA
M"YE8&\ZH94%2/X&&. CEQFW9#VCB.#F"!]9B<\6>0ID>"^YCP"#:DY@^".;/
MR&Q9&0L38Q4Q6Q4.60 $E/1,5U9=6*9#"YV2[QR\*V@<7/X64\X@DAA%X/8<
M9/^))+P!M47K5-K[$ZN,S.\BF8X%@><UHNG38 DVS,OMV[\%9R3.1J1*0D0V
MMO+,,M_99HJ(A!JT67=V6^U\XSC6!5ZP4BGXT*C0Y9LZ8#]1QF<K6F>SJ-M%
MEM#5*IKPY3]!2D>^1'K*@25XZ"18@@VN(N+9V*4XV5^.A4LEHD;:WN1H9L/I
M$9I"-(/5F?C:4NTXW;95X_O3O3<.*-!I5)<^979!6E1&7&6.AMATSW\>B8 >
M,V)2EH1$6!@-Z:X@$8P6Y27V@&@F(I%(:K -,U1SLVG96FAAMKFNZG>UHL)I
M)3DKTH0[UIOR@)CM:X@XAO,5:_ZQ;F/N;)7':.F7MD_0H EI[.R? (-ACMB"
M+.9"3!;0V(!D!AS6 ^PO7&*'CIAIYH((#JGI2==>\5*038*(-M>K1@KO>]Q=
MOD)21E8]/D3AP-705M^9,VFXPT&]FX5_F6/4?HF8QK(L"P))>3RZ]F9I)F_H
M-J;<;6V>8%>AYD( '3GWA(W(_BPJAI::)D,CB.C*?:<$39>Q%>\LG;8%;+Y%
MQ@ZVQ>X'CV<J\;$!BP+1V*+V!B6B5&T35A-C>%CU'HG9[FK5S&N>QKS,BN^=
MR%CZABEM)&R2, (DB.C='AF3[16Y[N&0".[P^$_!#LS,!M$0_@#</HWZ@W#L
M3@1>[?ZG);^2Q_ %*#CP6\%P%XD?S=S,:(AJWY5"KA-D.0$YLUWK6#LV#$C;
M/^&#,:#QL9+5ELB 2":B<55H=LOD7AE(!]O1BY9BQ(RS?@1R\^QI##!HU CK
M(W]P6PLJ6= %6]B%"@]S^"-C\LT..Y#JU^!AB1%QO$%D?[03?MY,[TCS;OO6
M/'GQ_,9:JYL>52"595@"V&[,VN0" O?@>&IT'1H_$5Z1\4U/KNC,N#,$T$[)
M]-UN7]]5N&4A_Q!&*)]RKQ[?/PD6+0=QD9A6$,AT@A8(#E>29E #YF;.'DG%
MCXU3[8USLB/N7_9O!Y[<556CRE:L?N3J(6;PX  &02"$0OZ@]T(8!$)(77S'
MO>V&\#JTQ56ATD6/6@'ZL!'.S#+WDV>5#5:75B,CIV-%6*7* *S(=>RXTW"6
M;%@%2;3Y !"8VNBJZC((=S C18K^$X;H26>G]'-*;G3_KC.]F36M)@.$H)T>
M,YG( :;UBRE:@S6@@RW0@D6XO7HO!'T?RT(05$+'O9KS,U?AA2BXJ$%*=MW0
M&?/^$_8<Y!Z&MFE7\+HTG<SSDR,><!9/D5@KSNG37H?\+(D\4S*H8DF1 ZED
M1AW?X.7.^"L"24T_YL3#LI]!Y[X 53=@ \%G ^1  Y_? J 7^GFO=Z,W!'ZW
M64;8/RK9!"*# BOD^K0),0W0 ?YP5!+L??:RN?0VROQ8JS!(%PY50/-/7R4E
M;I$VY\3)K1EM5Z.8LO&3=P)Q)18=U^)+3I=Q+G$QQIB-SH'#'8X9Q93D&(,Q
M8 ,V2 LT2(,U2'PM"'I#0 1$H'?'?WPYA/S<0X3)QX1&'0)^-&8>BI^$2/&,
M^(5)+^S8_M(G$-SR#\S>\1/E/1'6KQL?V);[KBKM#>?(! @R9LJ4*1;M(,*$
M"A<R;.CP83,E2292K&CQ(L:,%Y$@X=+%S$ R!$>2+#F23!L>&3RP;.GR)<R8
M,F>^_*"!9DL-'RYHB0;M(="@!^^(,3ERX, R9,:48<.TC)DT:^ALV:(E42)"
MA;9RS?Y*R!#8L&&_BBT+EI(F2YHJH?(U! 0(G'+GTJ6KTX.&7T+W\@7J"HE$
MC8('$RY,^(B&FW5SLK2Y^+%BF!\P8.EK^?)//F&2&B4ILC/HT*)'$TR)X0.(
M'A>-+.E2IHU2TK+-?)9-,JF889=W]_WY"TE%X(:':SS"NLL9SK)1JGS,V#GT
MF).C^.3-EZART4BA$APSA@SX-F^D5M5RU1#7K836FVT?-I&DM)4VN84;_?[+
ME3(CN[PY^51UU@G(4"Q$:"3<8 @2MZ!&3VS 'TP01@B=8SE)B-=,&%#WTX =
M(J2'&+39-N)(9Y H6THK[6 1:US4=J)H L$8FQEBO!*@A_XYLF($@ST*AL02
M+H9$VADI0G<7?O?IE$$0.0(%1U$SQD904N"1X<88;K@QWAIKE+=((EQI50A9
MAI0Y5B*/:(*))KP(D4%<22ZFWUP5LH3D9*@XV>%/HO!HF((^"IJ1@Q?6=6%B
M-$GX082,2I>!$'MZ>(>,4EIZ:4HZ6=2:&;!=&MJ+)];8BJ1\1A,*$8$1%NB@
M&"G!17(H-O<2DC,A:JB<_=FD@S.E*@2-&I5^6A)G5GXG$DCD675>>NR5I0@F
MEO0BQ 5QYGIM?_TI-MDH./IJ&:JJMCKNCQ@]H1.NT=D9DX3IQH1!I-_R!F5V
MI)EAXK!2FJ'2$TD@<1QW^=H6JOYV8:@BKX!V&$@NN<#!"A)XH!D9H;O25?S<
MA'+I) S"T32#!L$"$[N=4E=^YT8;9J Q57F)+#)F(8<0<H@EL@B! ;8YR[43
M*!WW%DT=1HA+'*L,#U?HQ3I[L.YC3/IL61Q1EA2RR)\6R<,'$W'J:=7VWD8U
ME08__;,<0C=<6-$L'L&%%V=$;-3$M":M=%T9Z/7M3Q^#W75H^(+G'<IEH$&>
M>>=E$D2M&M-E+=U+7_!)--*,+5301EON[V&)-JYH9'.WE $0D^\%A[!'\5UU
M&SL<P6F]IY.V-U1AI"(Z7W/\>7G#; =<4HH7.DKK7$DSO1@& "+<3.NNSP:2
M<MYE"?[2RC^<=N?F=M6UDR>T!Q7*[1BEC;MA$B%Q1 \\Y)!X]4E""#J'VC,$
M31RP*V^IB1ZE/+^H>YLAN[?N+P1&]R[W/4 !R35<*XU*?I>M]'FN)A<@1?_V
M! V0)0]_)'J;2+Y@! 6F;V<8D\E.(-<^_QWD)^$*#OA02)$!*D$)1^"!#W:0
M@Q!X( -TLA6ZHM- '')0 Z$CX4* %2(+5HT,;JL@$:7$/R"^SPH#3"&#"L@\
MD<2M@W*[SV1Z=CR0)5%D9YA(#VZ((2M2C"Y99.)"ZI"J)T*1(A(A7P]B^ $:
M@L"&=&)<379X)SU&)P-#0&-"H$$Z$1U%?ET\I 7W=S! !O[2"6Q<H458]4@?
M 88+W$D1"'*X&)OP,4DA[)C>$/DI,RQ!.#O0 ![KDDHK<BN"[C/APMKH*CC*
M$34UO.5,5HD7=^%J>)N#%R,10B_EE$Z4QDRB(EU)0F@P89*R'([08/4&']"I
M@9V4TV0:$3EY :N8QR22&;J H",LYIIRTESQ@GF06)@-BF\LGPQSP"@-V) _
M'-298W:(/G;=4S(8@((ZHS'(4!GRFP8=#2$[D\R ,O.9X'/8K'"R3S/.37@8
MR%['X# &)![4)%^T"#7)B!\\I5.=.UH0"Y- /A[L8 <?L&4F(=3/ZO%1<YS;
M&0:FH$SW8:>C/B5BC6 14)\PH?Y<#O71$7Q91N?85*(3E1OV?-;3GQ(D9 +A
MPA$LHH29BO10N[P;('_BBJPR: E)<.%*X_F!!STH,7-3:E=QPDG\3*8RDD/C
M3T#$4:KR55\V&NHSBGI4W)'SG'"]$U<I=-&=>@@/0^RK4<+IKT 5-JY*^D R
M FJ,PIA5I>2+80[DV59Z:LX_Y<25.;&5KHMED[&TX\-C(2M;2PG$#&,@QE ;
M"L5'.M,B.] E4YVJ/I=,!G(=T\Q>E9=<@GPT(SM0[>;0Q:N ,J.S;O3L9^.I
M@0V,UJTLV0"[4GLM0T'HFIQLU[8P8-Q@IF(SLWUO9[Q)+($T8ZC1  -@*#E8
MC"0VKOY-I8E-6LG-:+1WN08U Q<"6)&M*LFK'ZS8DH(PPK RX0@NC&,\/;"!
M#)"V<]M=FG@;QQ]-ZBK$>/&E8_X34%7$%KXN%@CLP*.&^@X5@/LUVA. ^\'J
M'59;&TCG7;_5BA;+M@WB/)!*=4RKWYD8IP =JA"VN^$.(Q:UP;-LSN::,PT
M(Z"O(+*+PQR:&L'!OM&PW=D,0U:B780'UUH7B77(0PSDPK76^<F7#7S,,Y22
M,#E0LH40*]*ZVIEV5SC-31*7*/+N!\L['J[.-#!==18#/'H6LVP%$@8]F+EL
M0[MQ1I[87[L@2J(2Y>H\N]RQ8E0UH7Q%L((S NBN+NH"VOZ<,!!_XHG3C#HG
MO0Y>DQW]F,G$2YW-")8Q\34B94-6?B#A'ZYS#;18;P34@LGQ3??SZYDPK;R*
MRL$R?":-8%WZD%X@#@]F+6P5#Q45&/ NL+'58\4Y>MYC7!H&KE!HT4T5T[)-
M[JC,S,Y/6RYMO85DNN6*6G-Z>-L>P  0HETJ$+V7E O*P=)R]50E;4#5 17&
M@TX=/(<+>Y>"/I+U&G,!C ;S)WMPK[]C/C4RZ,:^KJ#VJE*HH*)Q];_!;;!<
M@=DQEX<!LK1!\,&3.EXK0X9]9@:"&,.KL6!OKD(^C[?&%)A.B9-0%3"7.=C+
MH :N,W&S:&/8P3%268LQ$, XU?[WTV A-1@Q6V0":>Z"(IKM*YZS)AK:-^VF
M,+V2]SW2)]>X#F@<T&$4-.Q]%<,=S$S44%N[,"'M8.=:<MBK^QH#V@RRO)HQ
M6U*F_:R_[C;)@0="S]M7UX.W+-4UCB3.VVHF%WAR;J/F^)C7:':2!R#!V>Q0
M)6"\\(I*\:,A,QD(CHU>KSXR4M?=Z)+:]Q<X:W+L"9^KG61!\GKX^NX1V7@J
M_57R><!Y@G:;D2-$?:003NVBN3RYE]>KW%X\>T:4<$K#3SV\.F"&Y$D#U*&<
M]OT<EK&;?7F=_87?I1S=!:&!XC%4- Q<Y3&(FT$&@#'<]7Q !OP V4E*GE$5
M@JV9H/ZD7KK8V^I1A^1%PZ$I$.VE6/858*/LG<7\P#-('C'4%@.*GX'5"!ZL
M8#08@X*57K5=#LFAH-*4ET[D%. -2"C]E#A]SR3U@#7!52=]T@<"T2B\'HCA
M$/5L61*6$PWJ2M#IU HZWPX>4N/5R"(%H&!5(.8<AKHE'QF16&+LA#:)CEZ!
M2A*1@>7L0/O1U'YD@,>9&3.$@*$@8=8QG;"M5NIIW@-MDYG1WY[MGB$AA4%(
MWD^4S5$1X43HW2;1GJDQU8CA6YV-S4^T OA%EF><3AM@E=&0D[>!X1[U$ <V
M"1!&0Q0@&M\98,;,(-!=%@UZC@:$0 3:US#,71I>2MV-F?ZS05XN1H,HI,I#
M64[Q$:"Z4,B(<: -TLX3&A3T&4T8[0=ZC6+MZ0KK9>$R1<,6/N(YRF ,FM$%
MP!T0#M,ROIK8Y*+9P6%A*)U_P9LG,:$Z[HEF')3%J="@$!\(^4Z3<5(A2AXS
MZ$ O$:,[_N*]?:$,V@H"FME/%-@]]I499&(N.M%P (<G^H@/T,T=)J*)\8S[
MA*!G9,<"V@L7G&1QS&$23@;NK>!/8 $7+M!%9B0^+5I%:A[$#203L=KN?.2!
MB0&GY>)/U(%--DS:*.3(E1QJ89;_0,EH&-+XC<2YI= 2@.+BJ,\2]@Q2 M$I
M!.*][9,B"B6[:$M ?EXT.M9,XOY/,V+:_@A5-$;#;_ C89R6.<:E&!Z>W^TD
M[2C@I\B7=O09_BT('6'@.4U:7P8!KPTF1@Y;/#):%XK8+GU N/6E*MXE4\Y(
MO9!!'/0E0N 78&K$.$(7M]44MUT 6KK/-W;1*SX3^Q6ENF! ]ZEF-(#"!;QE
M4!:GU,'>/,7>33P(H0$G&I8F$85*,J4E"4D#-)Q0-0J*_K$E4_571=D%: +1
M'H!9C,PD>'A!\!D-<  B[&T QP#G,^@ AUD1(Q*F\3&0_ &G8D*G,9$!!*KF
M3Q #2CWFH*P=O:F+*(KBZND;=>Z)4NJ9J\$(%Q HH%P$BL7>9-!C7_Y$(_PD
M7'YH&?X"YT$@#V/RIW*%P1Z(Z$&@V6!-$EEZYO%A9F-D@/'X3V:LX@4MET!T
M ?I=SA& ET4"Y7VXIXI&0T1^&(A*YGTV4,<U(2!YI(D>DAD<8U_>',&QT22E
MW?Z-EV5-AH2A$?(,S&*F)X$^TOD$Z3DM864T*"!E 2_*:)*Z7Z\M"A,6Z6U&
MZ?SL3XJR*1-!@Q.TTZ!,I1L19W@Y2CSJ"FTR4GL!58+IW/KQ)N<$V':]9Y$>
M:9T$6AE='5'"'SD>ITH28I'^A *2)IXB%'V%Z@0":FN^YI'TW*$N30;HP T"
MTK%]QE>.2#@)*H-0X7U6V1WR1)&64#1\PIMZ86>2X;'ZFOZ0#B4PYJ1O!FL)
MD5NIGJCO!6M@W=@3L:<.967*+>MLTF6?1L-H+F75D-ZXE-Z9*DIP;1<]_8 S
M\"DC"6 &,)E_Q:EQPD2L B"TBBN.^E1>@J08S-B^GDHL"1"#^*.]9N#_!52_
M%5$9-&H4D<N/BI@&Y, %=,O 1L,I>"A<4ATO;1QB7:R3#E7#3NNP($48W,C
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M_M,V%ZG7S<;B$O%@O.QL#@$ IC0R_\0IK+-]FAPQ+[1%>_1":'06PY@8D(I
M2R#W.-2<AN$[^M,N:VXK((MHG$&6VN](.Q 4$#)&VW0(()K#*>A$[S!=05R7
M%;4FTO-&BYF,#+5/*T302++WJ/[9$>/QD?@'/',,63_-*Y3!"Q/$0;?Q\/57
M$M/T6O^"]"AB]1;@3@2!VJYU0L!6,T/GT:DL8R/$^>US"E'3(T)82\3UDJ'2
M16ON,,!!OR*82QL&CTRL9&C LTYV0PB#'7NUNL*L3EQ %'@M:RO$RP4O?]:(
M&M3<;6\B-2*T-:/P=NTO"S?#'11=;<@(A1+QF28:OGV #]]V,CN#%%S V=[K
M3N]'#F0 L$HB=2/$D*GQ,IZ!&,!!*H<W)Q(6,:-M <]P*HB!L!PD/Q*A/^J$
ME\IS>">$FZY$N[POYJW>!DSW?B?$,-1(04-G&/#!70-G'@2WT:1D@ =D3S>X
M_[P"&OX,D9%1<VE?A \H1@90AN18N(J>PB;/DUQFK;!=0!#HA6#_ML<D=X(O
M8XV(01L6>$)4CM%LE2=G)D[]P&>KLL<<,'A(<F^)<V'(TP6$ //A>$/\1#)$
MP06@RQW"62,ZQV2(>-#Z]'B2M\SM#QSXMI,+JY^<5846QWB-,3H&06:1.!.I
M0AL,<8>'3Q',+B^/^9,?Q"=L]7GU^/:]U 4 @9[@^4,,0QQL1H2"W3TS.*$O
M!"LH 2OWR.69I8A=P!38MD\70]E$>@=#$JA)!!$P09,W^D,(@Q1@P+RZ%6QG
M9)9K@2B3^ON,YU[C[4"$ 1Q(-JQ7AS'\::LH](>"ETVPWOYD<P@K_"F2O_5@
M@+%@\(@=8'6N*\0H ,&[W?%AN_-+G*UW"\$I/KM## -1>'E?)4=1[,%/N/F^
M/L-Z1]]27[-VE]-DA "!L_9U-H&!N'5K&@$1R($Q""NWY_DS-$((3/E+^;G6
M;EB@QWN_,X0JJ$$8J/&MG@[SB(%3BGG"(X0H0+J]5\02?#B(VL3M+79X+X,=
M-,&?9'S$^HA$&($1S($K5#Q?"$,6!+Q. *F/PYY_<. %_( G8+K+-T0SI,+^
M0,59"TS$0QZN]SQ"& ,8U/O%@76]3<8&Y.&+^S2'$,/($\&Q:V<2$,'*MSS2
M!P6')(,6Z, %\)K5$?Q=8 #$>?["K)K[*#?#'NR/S3Y\UR +2$@\')#*U__*
M080"Q@\'(J>I]V;@[04YGA=#'?PICY@\[H@/C\B!UV_YLW/(,GB"M$\[HT0T
M2P0NCW$@J@O!*+3]WC\$A_P\PX?(C(L2;80!Y,&"V\_P71&#\>8784RZO.E1
M7"RY<;T^<$(#*\S!UB\^J/T+$3A!'> 6OX\^V!^$-)S"%&0Y?F,(S7>KJ>%W
MB&. #F#!MO-^5JL"430\\TCIW6\&'U"\\O-]-+B"$V#]8"Q!V>9Q:M'\6EU
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MK+#SH'32L"28 "./6%RI3$(BN=S/PFB$0<43+*  (@21,&A-S35'TD '(*#
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MH4$, .$ %W2B!!"@Y3%8P( *&/3 A%#!+%*PW#Y(0 *!0%H?(  !&"##%B4
M1 H<X&'-'$,!\$2!-!Y@  /TX0\0$"\-#@')LC6D$1RH208XT C%V2(!$D"
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MGL4!MAN-3@#@])! 021N0(,70( !AUB:3"]0FJPK3A<#H($(4$ "$TA2%\>
MQ"%0,(!#I* !D2A TRE_^K13L],(P.]#>''E+2/C!2^010<.,?@.L'QHS_A
M0R\0@O[_(N,0$@" !<YO@0E4%@*$T&:\)4#8[,7Y,@$9=@$!I,XA(&$%:&$
MHH'H?B\:>HRF'$K(EFD67L  <NFX#  07NJEHB$2",T!A*Y+&N(12L"@9&$
MJJT$ DH6W.PA*H 62.#T$,#WMF\S^HYE/(!4@*4A*J$ &H "((  ( GQI&$6
M:"\:8L  <" !2  &8L &'L$$$D"(,F$ 9L !2$"*D($0#( $1(OTKBT:. ZM
M]J(A@ H!"H !#(#P,L'T'@(9+" +D0'$RL83^(LEI(OX!  '_.  #&#R!D 7
M9,  6. &!N#B&N 1PE *;4 1)H6GMBD:_.#THN$1RM#  /[AGJ*A )8K!X<$
M&CPA"TPQ"VY*(CB!!B($!@!@Z>S/ C +FAX&&8HN!HK0%) &&1[ YPS #RQ
M!<KF%[3 64SQ%B3B&&P@$W   "Q* 0A@]:1A @;@!82%%@I@ "P@ 02 $W:!
MD40@ 0: O2QQKFB@_\:,[\PD!'0@!(#@,EB  %Q "A?K&% @\900G6+@[- +
M&38A!63A'I/(F?Q !01@$S ! &*@!!# &63!])00FH++H$0Q(H ($PX! :*J
MF0!@!A1'!0AA%P  &7 @Z9;F$S9 !W3@!S:@TAIB\6P !C]+]#(! ;KP#[!K
M!1* %Q1 !/QQ!?HJ3TQ@ !RK!?ZN31;J"@=YX0%&3@6D@0!"D70B00:X#!D
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M WVUTU)TB/KT.V*%%8S5%2ZC(8[! <KP  4@  #  7C( FX)6MT2$$I3 "Q
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MG2$#WW 7SHL%*F %6& "4$  ), /H-$:P5 !% ":3D "3F  && NEV/D)J
M_)< K/$A#X$0&B :+. &;N!<S484B  ^E+<A<"$&'V(3SFW&"H\!7,  $N /
M*D ;D4$6S"GAE,$$$("/1*   M@\E\,$*, A)L"X<-, C/[3 #)![C:!\\Q&
MAWGX,J@  92A$P)@$*+!!0J@!%(@ "! &7AU%W:A=1VQ E@@,W6AN_KJ.>>4
M0OZ,!#+A$ NM!)R3$$Q@$RR !5C88HI7()2 ")0W(AR1 5+5E5W908V-SMJI
MTPR@!4*-S_#$'LL059O7(0ZA 1H@$%" UBC@UOB."12#2N;0 1H@B0ZA!OH@
M$W@J4EO,%L,P$DP@ $26 !K@$"J@ ,J7!HYA*#\N &0 $ 9@KIBC(409G4RX
MZ()I%Q; !!R@$$9 %VB@$L\S&BI8F8E @Z.!>16  19  3BA 2S %X*+%C@N
M!0@A 0S@#UP@EZJ@!*SRRR13&?YL5A<X07_C%S.<H2' BS9YL0' "1<G( 9<
M(! PH2TG>(?5HX>ER  LP 5&0",AP1G62 :$*RX-@   P+362!,#P<OZJ@,B
MBTO&V>@<P&5I01I0@.@&@03@;5AK0Q32 C&0H)GQR)8L((I(  !D#.>4$ 5@
M8.=*P+%0H/\"P("YQ(X)8)\<PO!6=!<PX>X@@!'V+J:H6BVL>H@@0 $2R@44
MX)$D+@6H3V]YR2$0C^Z6\)6*Z 9,  *.[!X;0@&Z\#N<R09XL@0@H0H,X/1V
M 1!VP06 D3<Q<6F*5SV2=\@0  )8@ 5<H!":-P7"S@9XBHH8DY\ @!"0P0]2
M8 ((8/[Z%$ 7', !5@#C7):>4 #GUBC<//K5!JJX7L"TGP8:FH!MFT1I51<%
M+, "(H !&* /YA&<5"  9H$3!L%3"0$3<, $N&P0N"TA68G@CHE(CN$1,D$9
M? $!\CH3+TP ,#8"U[9)D.!M\T,:7$  M/FE)@'<RC@3=$$$+* "'@!H]5($
M(8 $NU2@UBE7P4D:+& !^@@_9K &Y0L'5X6_#0,R -PA6"  _L A'L'X5,
MNNT1%$$7&,"A(<L92H\59:  #D$!)B 3W)47!DQT51,\_LP/>*H2'&*]-94$
M3($ 2.N,U;8(D  ]6'PL=*$ X.U6!T"Y(D&G.*X3I$'"0OXP /R (5\M !Y!
M!12 %W@I$B+AU?0:027@ &CI(1B2RR+DS7(N&A" $?8[%.K U4,!;B6BI*[\
MIB&@ @# !!A9$0 @ 3I BW=AY ! !!:  /1R2&RQ %[@W/H*&1R@%T*M#X)Q
M&.N@VEU=+QK"VE*3 02 %BG"%9NH5*G1&H/<_A+@HA0 &7P! "; 3OS ',LN
M'6-*#L  #.8 #.3 <CT4 0@@!699 &*@$F@/$R; F V@ QSBV,A<I*+A!?Y0
MH64A?76A! A@[8RI.1K"F6Y LSKLIB'II9SW&!")!>;LTS>#%>P]Y5EAR (
MOSXP ">A#QI@%G RD0P@ C*1]OZ&<!:2,OJ<P98.X1$:X,K!([8<0 5(+H\(
M;8<B@?!60 0:$ T)AQ9D +<R<05, !#N2'&65!9>H 1J($6=X2I? %2)!!EL
M@ 1<(-P]M!(WH03*DG XX09PX 9L@ 8D.VT=(A)82II00/6&&N/[P 9$UN[I
MJ :T\B$ \W1K@ 3LW.3W(B -_!!BX/0"P0%XNQ><000*C F/";2$U@\J8!9P
MH %J4 1TH09\4AJB$#QD80*N_!$H0 $:0 ;6:!9:P"'^P $LH-_69A<H )W
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M-M@ 8(XZ @B-&6&((4889LP5S2'=&80# IG((HLNR##0 "VR( !!;7L)I,(
MND2#P@"T**" +(P 0$,@#$1C@0R\2/!6<JG\"&08JAC$"R 41A,# @I 6" G
METG3B6.)"60# 0A84"0 AT0#"/X BC"0"2\!(*/"HFV:!0T<9;1A1AEQ$-DE
M)M+<$("=B$DS68R8$#+0+K-8&8TNO=QU3 SB228 ";00 @ @CR#@# 0W(./
M,9?NB&RR7D$3!QEFF$%&'#.M , $AR"& @,TI #(=0#@&,T+ 1R9&" &/#)+
M!27LHD(@L0[P@B+ 0E"%"BHJZY J8CR+AIP'T0+  2_,(A @!#RB@ F8)0!!
M-)M\^]HAME80C2P&W&"+"PS0PD AF2CPB C)0:.&&&64(<:G!IDPP R;[(*,
M,R00>(@!G$BSP LO2( ,#0J =Y@(#"3P@*!P]3+!! 14@@P!+T1C2@"'$-(
MFC;<X/X'OEIOK5:F9)P<+9'.9.*" 2(X4T$"*I! YB$ N"M-'P \8EM>NS0P
M0 (!R#>0+! $P(DS(CA0 B$F<&*!"B)NK8J0S_K[6" 5+"W+ +)(8T *!]T
MP"Y]!/!G:-(H@*@T)02@0  0'M*  X8_<D,%=+]&LK-EA'W0)@T    #+" C
M-RXP ("#+'.CH$ D -10*R&! ! )+RK,7I<?<T=C ^H$0(#,+@R4X+H(NM!
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M OD# $PQ$ :@H ]5L\ -:J#02 M[V,2^\:0K;6E&**1L"D"  !3 "U.PU 7
M-$ :!Y")3$A5!3W-A ITT:4R#4!A<1&(\F00&P-,8!:$<T A2* +&92OV/2N
MM[T1?&Q$(.+22''!  HABT@H0/X$F!" &:-1@@1@+P#'*"LA5IH "@!"&B9
M@$ 4\!^[2",& S  *PET#$(($! 54 $$FGSOE*M\Y?9$!" 2(0A!($(A,!!
M)X[, $)X>B )=T8-!) 9 /3Q$85(:B%8P$UG+"#C=7$&+2:Q"5Y\SR"RB.<
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M(G0LD  Q,W6 MX/.X N9<Q",H/X"F21EZ8B1&8D^N\ +,]21"B$W!@ !!R
MF  ( R"'!.  O  !#& #%C WMM8_%(  ;M,',? MPQ,))# ITD  *4063S(
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M#;2@#%1W*BX@I)2!>[9; <BP"9?7O8-*$-J[%9D'OI=7FAYA$LSK&H(Q$S$
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M(L=X_,(.[ =H!+W3FYK(X,=C"WF6Y%(SH&PW. NCA0QJ1)K2H )]  /]$P.
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MEP.A,&LNXH3@!S)(&)H3JQV? M( ".1S MCCXJ=L_:W'"RLP#3U>=KI/AH#
M+<8_&33 @Q8S&!8 "-,O"\;_PM;!)=&  ^'% NLA X\ $(H>H0 $B!"R:-%0
M9$H8K<\Q%-*B\7I!"T8T0H"BR9!UJ%"T&+*BI5 6HQ>R% E3(+-E(>.@620
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)<8]]G*:    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>cogo_0043.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0043.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MI"N4E64[9(KA9\4,<VHGJM%EGEQ*4SFWB_<-=1-67*UR;M+8AL/J:86UE*5
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M<R)O,(\ U7N7+HC;PRLT2%L'<&#5H4U8F% )YNU.B)F"25 DTQ(2V(<R?6B
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MN57KO7O=(E'3P3X='RCR#>36991Y6Y\_\DTAK'A)/RIK,J/3W1X%1!2(VZZ
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K=LU'!12HO<T$R;@8>7.7QI#OE2$_I3Z#TH8P^06W($\:Z^C?[TS:@+/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>cogo_0069.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0069.gif
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M'D;9A_X\H.0'$4A  1(0P0,"(  "+"  >![Q5W\K #H#X,\!&(  _EQ< 11
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M&M0( ?80MZ +HG8+M\I>FN (FA"LF/"RN7DZ4)&BUG>#N#64'^:$)B:)A&8
M%[ !_PJP'? "5]L!,? ",K"U7"L# $NU&#"O&I"O8SNO&) ! SND%'  Y"8
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M  A0M> MP7MMP85=TCV XMA=V->=TBB]U]G\ C&@M0 ;V2$@V3L*4/XT1![
M H]PSB21;^I\%[+'LPYH<.QUG&Z:H#Q,U?KKLD,,I_]M"1F%%X9 .X; 43^3
ML[QDE9[ VXEP"&UP"&\PX<-]!6B]RV29"^KPUG/5>2U&;N%L  B0 ;7;P22N
MQS< V/X[P -^_N<\X-<H;MT9'.@CG=@@;+LQL.@=0 (DL 'E/0$VVE4OYP&
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M*." KJ3^B@9R:SA+A\&&&$)K*/KL.OH!G^>/7;L09'ZP!A-;+(8:_HT,D$
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MYP(W_^>>7U "&8QU/NF2+G^H,(FA2Z$2E)C$).#"P^I!P6M^<FO6;F#IC*X
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MR -"$/Z2(>P2JG(.:]"%%K",NBF3 WB  \"M#."M,^0  7P!&G "-JR/#M@
M#1B!.83##!B!$C"7K8D"4XHQN+C $SLQ&SB!#:@ "9@ /*.V!$@?"3 !%OB]
MWV,!#Y  %G1!PBJ1$FD'L^LOBG$^,EH(8M-!N2.YW_#!G&J#RA&.-DB'[S,$
M0LBZ,A $1M $T*F&:P"YTHF%"ZJ-Q<N(]V,S\( @=&"!]"&3RC" !X" X&F/
M#?"PW0) J9&!&R@+&2B!#<B "X  ;$R ;<Q&#=B $:B!)=B:MGJ+*5 W%I.N
M'2B!$;" "YB 0SS$$*P %PB!%0 ^1V2!KFN!<O W(</$&?XT!X(C.&A0"%#
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M4>P4U9N9!2#-!"$%H/H2"<'\!%5X!6H)!..! 6U\@ GPP/2QI(T=P+'RTA*
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MCQZHQK^&P\XL@;(2;.': 4)I;,,P9G:?@M?38IA67$F(;DJ(%R9(\O;=XL+
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MB1F28Q3H1$X+SQP2=DBF.7"&L_X3F5@9!!N!"/28P2>'N,0H3!&-:X1D'?X
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MRN%1#ABD$W9\D^-]DP+!GP-A"2N$QWB,12-80B)8@B>80BQ4 _]]"CRI@R$
MWR'Q5M$<(._D@!/\P*6Q&](-! I X$.UX4,YU$"8@ D,Q$3X  Z\TM&0X ^L
MF@T@ 7GM@O*]@PK>@_AH!/29S\'(%_5=T\(TC(Z(' ^*&1GPH/>161@,GG+T
M#^3\@;'QH/I= A)6!>1EP@)A"7DT8>>,A25@@B9XPBO(0H9M6#F<0_2I R1X
M83ZUV^Q\55C]@!+< %C=0'(I@8>8D@021 0"69"9&E\M ?Z/55U&65=U_0 )
M<@\2B$,\B(,^N$,_4%D+O@/=4=%M2-8,_IHH"!NQA9E33.(.>H'W959-Y11_
M\0UPE,$7?$SZ104KFDP<@1,I+M!1T=&V94DK- (K=H(KXH8YV :'J<,YS*(M
MFL  FMZ[&8T3V-O/&,T/--T2K!#S.$@%6ITD%,1F4* Q@@CL(0'5I<#:C: ?
MLL CP$,YK /SK2 ^G!3=(.(X2A7[],W"_,:.-)-,& X9>)\[NJ/W-55_/4=T
MV&, E8&%204F5,4G1-X_BM/DX1PIII8J/$N&+>06GL,ZJ$,_0(()X**CE< )
MH-XNSLX.""/MX( D6=)!7$W8W?Y)01R10$B@)$1!OFG:[+"D2]K \9&#3+X#
M6:[@18!/>^EDJ/0DE['$;S@,,SE%FJW!47J!9H[!)>94FO4/<'!BXIV!6NRC
MY(%3*(!"51P5*]!1':F" GF")ZP"-'SE0L[B0Y+E(YA !CA:6L::O;7E[/R,
M$.! "M3 $BA!$HC-V#3/2%:@+1G![I4DU6G:PI'(\46<"AB"/<"#.K"#.F"$
M/N #^+C@;, @EY%"W_BDWU#F3%0'&DRB9GI!%VBF#BIEF=$"*;B$/7(?S('B
MYGR":BI0*(S%@F%;:R$D*(S"*R@D6-*&=Y+E+J@ FCB:(9U C FGAMK #5#+
MG8@&U_ZM5?- @=4M% 6B377*3A\R7,/Y0 K4FCN<@SNH0XK,PWBZ!MT4S-U-
M%GOVAM_H2&7BBGS.9WWJ8$W5U!@8R2*(G+%]P1#J8R@653@9Z#\BJ.>L K"\
M0BU,516=@Z%M7.BQP :0 "ZJ98SQ#@+:  +BP%XMP0X0HR2,#1,D@1*(G5PQ
MU ](X Y0W5\BP2L=GXNZZ I @CS01F/AVF("4\% 5O6MYT^"V9O)F?B)F69F
M@:5Z 6:"GWR")B'X09.2@84Q'A)"R1P!))7FF8-!V"RL@BN\PBNP4X9UJ=T]
M)(>= PN$0)F2 %Z=0 VH*7#Q(IL>IT89W-A  9V:Z! $0?Y&_4 $7ETH+4$0
MB.#"I<#9K4 *: $YN ,\V$T4V8-&W*1&!%.6)0S?\ VPU:##R%EU3.(:B(&E
M7BJF\F"9><%S0$Y_?H&9104HQE$G@$*_@D*!&NC+*!BV08,P9*FKPB(6?H2A
M?1X[K$,Z&(()D&DB5=1=Q=AQS@X)UAM8O9L"6MU!/$&QRFEIB%+!A5VG#=P0
M+ $07.<*6.L*/(*VPD-*=>MBD6<]L)<XDFM/]DTR@1DSB=RD?H%F=@&\DAEF
M>@$0BB:^AJHE: (G+!"4@$)K&E7H#&PC/%@3>L4KQ$(LP (L7H.LT@9MI ,Z
M6,.MDJE:5A0*D$ *\&K#\6*]K?X>[U0=R"IG6WU2)$!!63T!$YS-022!C0W<
MJA$9$&C!RZZ "KB=.\0#.[B#/$1NW*D78W:$,/4:.;(/,B63(H"94V@?T7K!
MN\+K?&KF+9@"Y S"IPK">B3"-Y$J=S306. 1LV2M,*RJ5X M+-1"+52#-9BM
MEW88/*%#-W0#*8A "&S@Q6(H7JW>QK+;<<;M#^PIM2@G0.VM0>0+%(B&WQ(!
M/0V<=2X<"YA="K  (*H#/-#L.T2N.^B#>IU4;+2#;1S,;O"->F[N9,;/#6J?
MF'U!%HCNNR9MTHI!_[B9ZB:>^GT3)\B1KSA8)F""6<A,62C8_'F%5WAM-2AD
MH04=V?Z"!#8L SH,0@B0 (:6\%V1< JH'E@!)PG>FYLV ;78V/;N;23<R3PM
M%-\2@<I:9TAQ 2"P@+7^@;?&0_JZ2.32@XTNYJ7LVKA6'_M0UM_HR""('!DT
MJ>A>\:6.[A7TCTML'P^>P<@T@B9LP@+YRK65!1N,3NF8CJI" RSL;BU8@S6(
M+3QY!-EZ@S(< S) @Q:(P*XR+PF7L+>@X>HMF495#XTI@8W%5;X G(E:G1*
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M'MS!+T##%\CA"ICP7?VQ#4R76JZ>'4)2<BJ@F0SN(UN=1B4K2''!4 ,Q"Z@
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MEV504AD%388+83B\30Z&&%D#A_Y_<D@-4'Y2%W[0@"JM-Z^,:N^5)#CB"4K
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MFJ&O[D37_ -<H.:PP*$;M"&'F$<<LD$:B"$;1H$%QL;R5*G_3  %\&4$CBT
M*P """8/\.#G[L# 4($/>&$!A8$5[N#G>J$.,B$;P@$>XH$EQB$0?PK#8DL#
M5>Q'J$H1WL#WB"(Y>DO%.('X4) 3ZHA(LJH1A&441F%-EO[G!J_O&T#Q&(R!
M!_? &/;@#N[@](YA 95A%6?M&'H!%8#A& *C0+ AO&)(ROIC%\'%H:HPE/QC
M&PQ+0$[1%*Z L3: \T8 !<907BS@EGS( ;# Y^C@#@J0S:SQ#H A%.B@]%"!
M#NK@#H2!#_$B'9[BF42A%#11'46!$P[1$!(Q!"_'9(;B$8=/$H]/$09!TK!$
MJS[!$ZB%^A@N&U8-&[*OU/3 %.^@%$<1%7B!Z&:M+U;Q&(2A%X0!&0+#6Y:!
M:72-3UQ(\9@!"M'E&N:/K[8A&%IA#N(@#N9@&:(!$)!-( J%!,@0!9+1\S8#
M AQ "WR.BCP+Z(1!#JP #DJ/#?Y140_LH,"002.\(1UTY0+5T15*@1/<T1$6
M(=VHJA'>;1Y_#\4*P1$B$1?$,A\EK0R(*Q$P42Z61UN> 1NP3_M20>),40\6
MD@?AD.AHL5NT3_N$@>@RTEM<R.2:L EKJ IO<!L0)!GN0"7[( [DX Z4(<@8
M@05"0 ,V  4(!0508"$P( /(!@(>P .V@(I8K_2* 1MZ00ZJ@"7W  _>(!Q1
M$0\*D B#@1JVH26>0JB$:A0X81.J4E4:@=W@;2A^+YN^\A[%$A=J 19$P1#$
M3M+D"!/.CJVHX>&"(1BTK[O^SB%1\0[L !4-+!50H9)FC6DP$AF$(14N\@F#
MP<D"\_XC1PY<TJ76N $QMZ$5\J *&I,E[>#T0D$8IJ$;'F$%\F49-Q,%G.VR
M(  "/( 0"I#UWK 7@"$85',E\4 /6,H[K3$/Z*#B@ $8MA =HN'18$$31T&:
MJK(1%B$>>\LMZI$-CE,2Q3(:8($3%D$0]M$L$X$5F"$;'NX9LF\5BX$71O$4
M*:X[D10.*^D8[F09AF$9L%-"D:%IGK1; ,.OON4O>C$DJ8$9O@$;?*D/5K,Q
MYV />$&\MN$96@$8M"$8PJ %,D S-5/9TG!!08# P!$50P$8PB(_]W,/P)'
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M$VE;:!F0 1@^*[LNUA5G+;W\ KT8[U?YH JLH KDH'#9,.^B!C&51AA:01C
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M"JAM/ M$:PZ3+Q C,;9!'&R-$U0@ SKO;3*@!;Z$BKJ1#E+A#N! <*V@#^;
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D8[V+5[S/MA:@(7(E0)WXG51%20X<OQW&ZUSA*KBX2A4! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>cogo_0068.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0068.gif
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M>]:6?<^)<>"2<R9IGUUR@TYNB6-T@V5ZBFI]C&=YAFU\BD]\JS-_P<!\@VR
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MG3Y1R<]+M6XANA,CN'9WC6N<<8RZ%$;NA-&+7G!0%\*HA$-3J%$_;A2D(#T
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M #D&DLB."=F.6Q! W\:05\AWDA99%NF%Y::+[<:0Z54-WN)3]75OC\=K![
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MLJ5PW"(NT51<T;7 W!1="[9@"[=P"R=>R[.\"JL0RWB-UTU<W/F;"(D0!$&
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M*/OGBQO+@T[%N+SSY>[B/@_70,\*L*P*UQW+URV_<YT*KG *GG\*B_ #$'
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M<3'^[5"',H-@;R,1=(23#A3L/0 !0, ,A@!X(N#@!R[X0 0^L($'Y&P  A#
M -H4<YI'@ 4Q2!+^&H(@R($<2 0=V(";@SF8 Q#&\P 7F($9< $9D($;8($>
MR+_$VP#$BST)J( %:  ,J(%4$ 8_V ,^*)IT82K=";38> TN0(1YV3-T S2K
MH@*L2@FP\SIC>+??HK=(*RM("QYZVS=+&X90X@7NZX6T*25F()&@V(9G8(<M
M8#@ ./X_!8 !K2@"(@BV8G,!UY,Y_P   6B5(+,Y!X@ &"@"*L !&T@!Q-L
M#^  _G. Q8L #J"!(0B%4A@"10B"GRN%(G@ _/L\H], "Y  #:" F$N!&]B!
M7^"%.M@#@K (<SJ:V6%!J6ND%\RP1\(Z>PDT*>BP0O.ZKY,DZ"D;LANN>V.#
MZ*.#.O"%7=@%7MB%MK.T7N@%N8,>4L*4G%B&:SB'?T $!6   KC"&0@%(4B$
M1, !#G@ !X@_:R&<T<. !F@ FNL_8TM#$,  14R (*.Y!]B #_@ #G !%^@
M#U!'"K0!'U@$5#B%RN(  :" \]N #,@ &ZB!%,@ "M@ &?YH@1;(A&&H ]HA
M%PDI#=" "$IL ]80 ZMY02S@@B_0,'MY(:L:@V;02!T\!G=C!N@AAF*(M'R+
MM.!YQ5CD!2-LNUR4NY8D&&E8AF< OVN@@FLJ1NM8  QX@1O(/)E[  X R@\P
M 1HX1\UK@ U 2OG[ !> @6A$@ 2(/0&(.0I@ 19@RA?P  > N0$P@//# '7$
M 5>8!7^P 0$XOP6P 5#XA%D8!0_0  ^H 2H R$_PA3W8@S<XR#8()]E1FC9
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MY+.4KP/)'C*N/S@Q!!VK?<N%7K"T/65)[NL79@@*;&@&9S@'6*""'*C*!A"
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MTQ?*UD"K@S8=U#]^MY"<AA[R@^*JONC#!3H@.\PT84PJFW>=Y'VAYSYV"6R
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MHQG72$<ZG.&NZVT/7VY3XCG^H0@?^$!\-P""^8  @_X180A#*$*D!)<#',A
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MIRZGM(LNC@%$EB9QEX)ZFVCCQ2 &GY8(/G6!"9;;6@R;,[8XL',BJ* ("7D
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M97%-,?"=98%9+O1")RH#/U[#,QC1R!UA^1'>5X8E-Z@?-@1&61[""?P "J"
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MEBZHO>AF$IV#K!+#)R#"$(A/P*) "92 F=8 A=V F[%*#-   %83-JG/"^#
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M=>O%BQ,Z-Z!S$3*Z9Q4A.;2#(:B !(C & V!T .]*9A"T+OS#VAZ"*B "FB
M!FPZD9= /(= "NBJ#:# V\JRE:/Z'T$#'EQ07/ 3/_V*M,J:'10M9TIJ"^<Z
M9=X$<)]:(WR!'R\B7@7_AC.B=\]UE6V+F.7Y??18UPE%)&@X)NC%-F-"+EQ"
M+\CO,A &HA<^5W*_.JA#.^3#,YR !*1 ^1B!SR=!T*NWXP^]<A5Y"&A^_&]^
M!L0ND3L5%9N #2!;2D;]+  20/@1J&>7GCY]_/ )!(B7GSYV_JRA,VG-I$>X
M'F7$M?ZQ3L<Z<$#":20F3"-'AKX8*CE2#!LS;-;$E"G&(CAPX[)EPT:-)[-C
MS'KUXN5KXQ\VDR)-4DIQ::0_E70% X8L6;-FU[!V\[;5FSJN7M6I*]=NWC-'
M*&3<  )DB*E2I=R^+36D%)$?=V> "!%" P05%RY T* A@X80'3)DZ!#"1 U%
MB1;!HC49';ISO_;XV6.',\2$ AW^N<,&YAHQ8AZ5R?@(3D:/(5N3_/*%"^W9
MM\>(,?.2-)O3IQ_9!)>3)S5FS(0="^HKU\:82B,='8-TZ:1*4($)N^8,*U9O
M6KF.\]I5W3AR]<J5RW?N[A CI9+(?;OH[9 A=N_^R+L70OY_%8(%&^R##Q8S
MP0=%3H%%LEG,,0<=<W39I8[-Z+CCCC_^X(,//_[8XXXU2'LDC9)46RTUUD(J
M XXRJ "#"R^PX *+&&.L[44OPAACC"YTU/$+1[89;AML=EKF.&*"ZJ6Y.F3J
M+9*DH%L**EVR$T899[C+:JMNQMFRJWC$4:^=<N99;Q&VY"LE%;F&6&0(3.[+
M[P<08. /P/X&,VRQ&0Z,#)99&'3P'T@ @</"->Z8P\(Y.K2P#3+8Z"(,+L((
MXXF,GJB44C7*X)0++LJ0@D8LGL B"AEGG%$++5[LPHLNLOAB54/ P4:GG8P[
M3AIA>M$E%U\H,HV-I&BBB3HHL?ZS4IEEN^O&V6[&2T>=>.(1:TQXU,N''3CI
M2E.^^X@(%[_\]-H+@W,'_" $$$#XH<]7)@/405 ,&08.2-,@@XPVXIB#C#D>
MU=?53PGFXHF"N5!#886M6/@*+*YXPHHG2HW"8BL@SGC5AU?E8ILA=]KI..5X
M]86H8->8;CJDHHMR$EVH5-;*:ZRYQMEQQ/ONRW?2R8><=GPFYYGUYNJ6EC73
MM,]-^\+-;P88V%UWKW7;/3"1!<UAL+(:HN"%C"[ !EO?L;_N0HTKSK["X"C4
MH)@+*:* VV*XY:;8[B<LCL+4**SHN^\KK  <BRVLB()((JMA)E>?B/'U9-).
M,RV2F/[$>++R23!Y61=CDN%<&6JJP2H;9[VYYLMXX($']=15G\?U?,SY)!$U
M4S'BE-KG2T3W(1()%Q%W\4(A+Q#RFF&&']I<9+(&LZZLB2B4*>,)*29](M1.
M'59#BHGKOKM[BIT(7_PHG&CB^>?S=B)O@]VF>,;#16:&&/F15+*YR4W[S;1)
MAHU\\NM@9@QC'$,8U%!&Z+IC.F^L(W7N8!T\ZE$/>+0#'O/ !S[RT8E2'"$5
MJ3C%[>0"&2+<!Q'B\H$/G&8\O+BK39.AS(,LDP)$>.,1IY)"&:2'!2E<00IW
M U_ZPA<%BN5-B. 37_C,E\3R/4]\/APB%PR'C6HL(U?'(/[&%8'1*UQ0I"6Y
M.8UO)E$Y,3YI$I<(X#$&*(P"=B<=W% ' U6WN@C68QX33-T\^('!3]"G@VKZ
M%K@PX;L3GA O,) 3$19Q"A?2HC+F\,<B*!"&:SQB>NR+V/2,Z(0G+-%\2SBB
M)O'6!"A X8A-0&(2S<?)(-[M"D(4XN$6=T6@],(7NM@B&WKT&UV*L7))J<0E
MS+BY7B1'&=UQ1CK6(4%XD -U<Z1C':&)1WV@@Q:)H O29L>[1 0R7+T+%R$/
M>1=$TJ(3M#C'.6#H#Q10 !%J'&(1>_A)3W*R"9Y<0BHUN412.L&328P"*DUI
MRB""<H@Q.E4U$'H<QLTR*+G(2/Z/NJ %'FFA1V.@:!;$:)U@<@)FO<B.,[B!
M3'G4XQWN0-T\)%@/?-#Q@2B]8#YH01^YT&<1;EK$"$U(A!/:!3_B&L(B'60+
M1])"!9'$RB:OD$\HF/*>3 6H^4[@SX ^-8E+!>@__:F^NQ4Q"LLPTLB4,TQ=
MT+(2%HGHJM":UE5E00NQ>M(O81;,8 0#&>EXQSSD <%WM",>=%3I!27H4GQ4
M,!_PP&!,2P'"$(+K/H%4A$[%^0-Q$:$4RC/G.9J'CA\40 20$,8Z&M&$)\S3
MJDWEYU-'0%753I6JY?NG5MUVJAAY51G'X55V>F7+2CRB$6B]@A9^^UNUKO5R
M903F)?XJ$8QEV+6"[X@@//9:0<!>,)H2)$OJ#DL+;RG-FN B0A FB\)PM9 6
MT&C0+&@Q"TU<( %.\,4UUA&,$X2OGYU,8E/-1X+5VO>IG%Q":@&J/DV>RF*D
MBD(R?'*,+(XUM[G8[2-D!5S@7D&X$M9"JK*0!3+^\I?&>(9=]]J.=XSTF:Z[
MX(GQ44?6H6ZE=#33(I F4][1A0B/#5<0P-NT$5K6G(":#"(*4 $X].(:ZC@'
M5IE@U7HN ;^H52V 4:EDU2ZQB':SV!..@4:8;5D7UU%*(R)<A2HX0<QEQH*8
M^Z:J+!@B*91(KC! 7(YTK*Z"9;+@B?\ZQP<:=A[,K,=ZM/X+0ON40G>)>*R-
M@^"#1.. !D)(Q"<4] KTTN(4BN@  43@"VE88QWR$,8CDMJ$$8R R?<%Z CT
M"]"FCN $36VRJ)^Z5 '#%HJ?&J QMGP=75ND$3 2,YG'7.8R;T',6\""6R,A
M"5TT8QUP;,>8Z$P6%-^YQ1>$X!WK2$$,GH,60T :78:@"*9]][LXO@L.@J (
M/\$+%HM ! HN4  F#*-FWKC'.JY!C5Y$ HI+( &3 7[/_[Z:JJW>;W^7>N6M
M B,8QCAN69OBB"Q@P0I5&"4_Q2=F* B["EM8LR,BL6QWD!2Z[D@/.<J1.FFC
M6*5_!:PR#;M2UO$CIN\I!2:*!OZN0]\8O.E6MX)@<8I%*,('*9!  MPPC&%<
M0QG-OL8XQ.$-9>B"?*-.0:G]_=]1 U2_I&YU5)\<8%&&;X@%G2LP+<&R1D0"
M$F">N,6A\'4GS-=\&Q^VJB(!#&_$PQWJZ+LZVO$SE*>NQ-1M.8H!"\%\N$Z9
M%S3'3>LC;D6(&\?EQC&.)Z_N3XQBZ(@P@082(($Z6,,:XTB'//#=#7&L(RS7
MD(8O'!&%_Y* U*2NYY.7T&J"KY9\!"4P%(]["4FPK)<2']PF3_#UY-]SE':/
M0A6>D(5*),/OZ1"'.M+A#G*8-![D8!U*_=KBPZ.8=<^V(.LP: Z<5Y9I0[C\
M^WON\_ZA*P(1-9!!"C!P@ K06SPB]8ZTRB,GK(%7'H$+^ G5:,_5_"VUP&[W
MH R@]HE\%.Y4T.XZGB02&"$2LL#XMH!\DN_KFF^4+"[YK* 1@ $<PN(;N$$<
MM(\<7+#[)B@]VD&9G"F"$&^P^.R.GDO:M,L^K$G<A@ 1$FT(?0#=T@T1J(#H
M:@ %4B #*.  F* 7LF$KD.G>3*?9U*$;2D\+NZ1T?*$1N(#)1"#K\.N_3H#5
M7NV>'K#N9(U\GB@*+,'-)$$2,# 2)"[#WB[NOB[W/G"4D@\*#.&SY '[_$[[
MQ(%:5*?\QH*O($C\7"Z/J,MUZBS%S@]U\B$?3N$^VD1<X/[O\G  $>BO!FS@
M_C(  RC  ** ]+ B'=+A'N1A%<=#];1B'%A/':YO' ;P$0[AGTB@%[=NX +N
M##NIR9I/ K<*"RK!S2XP"QB!&0\APXCM Y=O#T^ ! #Q%])A'MIA'=XA'KJ1
M6KK/^\ QVE;GQ 0+S_#,@O+AI2[1L"BH': !%$8HW"8/QWQ "%&H!D[(!J(
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M&5(.'OHN2LG!/*+4/:]O+GUR+E.G6K[!/B'(!B4(-%5*Q2"H3!:OK^(A&J;
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M002$LYOC8!>D@4O"@?1X@1=*+QR\X1(6XUB%NIV\@?2&P0V4&G#?8 ^&(1P
MX9[E  ]X(1O686E'-R+#0CF[&*SMH:N]FJ /FA_ZP1_ZX1R&,96<B&(D 1-
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M7O ^_\Z.5_FO6=R.K1LGH&[&-_J.%H^EGBL168<8U, "1O[ #?Z &*:A#^
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MG3P%*PF#$&U:,SH(K8\K,XG14EC'E'&@17[#",<P;@BB;Y#C&]D T='^]A,
M)G*1IMI>R^ &M][4L8ZV"LI@^"$I*9Z#$E;4Q26T&(PM@J=N<\/'W,(S+1O-
MK1[S -[0?(?"4ODN)4^JQU^\\R[@^2Y>TB(C4+KHGS0Q3(]=:]%,7M(.SK@C
L2BQ#8E^V]4R>-5,PAOE1 =T621;A)20NRHM9.J !#6. 4QC0<(8SGA$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>cogo_0070.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0070.gif
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M^8@?$8D%N=6,Q01)M5($*[K209ITL4,<D/B ;VG:4KU"N,$1GC!QASOA!"0
MPPA(;OYR 0  DY))!6-Y&HABF2'&_>R6^60LF4#PX>].%K)K@I4*&.L!K_AE
MF'NZ!2-Z#)&,6>8C'8%O/382DXI8<&058:9^-]V2<^6G/^VP$3WF 0:X0D"F
M E#I!RI@@ FP>@(;V( &)BSK6$^@S 0X0(.-&X -LUD  RC BQ&F,!$ =3G2
M.2&+67PA/TM63= V2U1^%LR![.D@EZA880XS$2'7Z&N0R1'9EKR8'VT3THW!
MW;E7)@ZWU18,%(CI;GG;  IH0 ,;2$&MI7"#6L=: QB8P 0>,.$&Z)H :<XM
MFP$0@ "TN889>DN#1+BPGYGIIT'[\(O%!&(_0W9H_PI3T/[$P@'J6.T@% ,4
M1$;%'I;L#]SA7L<UQDW-3 >IHA:MT3;[$SPE[:\:)RAI 08 @ C\@P*R_L<4
M1C&%?VR W_V.==3O/6&"*^#@&3[XFHG.9@G\K$&W<6X'\?A*C.O9:/GLN)^O
M9YQ\$NWB?DD6RAG=62"?SMP8*0_K-A) )=\WT^(9CTPD$X^9O(UM<_-(.UC2
M#CS(--BI_@"^IS %*42!\E*@_ TR'W4<W  'L2;X PC> #,S(->[1H##V8P
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M';>Y8\@W/^FU"(H@+4L$:<(9??-0#XL2,NPQ#:]#(^O $8H2-AZQ/]$Y-WC
M6U(1 1HP!9Q "_#0G=[9DSWYD^.YCEAPB:00!5@0C^@9C^RY U3@GNZI SN0
M P[ E*K'<!R0G[9A<=X#BUGRI'9F*VZ1,\9V2[#R+RP&7;?)(LS "[<0A[G
MFQ"*2-JW/Z,U#_H@?1_*3)?A**>#4%"D.HF"0-7H2?,0#2*U3@WP#YLP"[,
M#]NYG?XWR0HSZI.0>:-!&8^6N:.:R9Z<&:2<N0-$( 5$( ,6< #_B !T%*7
MA(N=&HO>PS-V5EBR6!=\MD_4EG&UU $+&@U?"H)A>@CIU1")<7?7P'U'-@_T
M\#\ZHGT$]",(14GF 1F0@3O$.3?40)U8D0*F]*?P(*B RIVS(*..V8Z0N8Z>
M$)3RR*@[RI[@*J0Z( 4Z0 ,:H*GVR8I4B8O>0Y6N^#-\%J_ =&S[*2NS$G)D
M<A;!Y*7!> OR8S^CTPA< XC!N:9&ABV6MF3-X PN]Z$8X4QX&1,V,@^7$&_L
M]P$ID)WA  _:":BSL JL$+*&>@JH4*.)RHZ> (^9*8_@BOZ93= $F+D#3; #
MXTJN-]  22H )0 X66("3:JN32J@,.2N$M>*>08F@Y9/BC-HPK(,7?H7S!"F
M\E-(B<"64=5,]9"FT@= (:&P=N@,']$.Q9H1;A-IU3@/@A !%TL!*? ,X."B
MVDD+J_"Q(&NHCRD*V:JMI)"R[3B40]FR0CJI.H #]9< JT<!6S "/MND*/"S
M3?JXN&ALU/:XDCNYEJLXTK$,T."TT/ 74CL_#8$($2HM=FD[%;JU238-V-=D
M#)N<'/D8-K(1\I"#)T !'U "%% !>+"Q'"NH<@NH=?N8IX"W>;N.[:BC[9B9
M6*"9C]J>0SJDX[H!H]EF GD"//[+N*QHN=J[O9.K.-V[JM2VN?P:C(G@H! 1
MH7>GA_&0M='G/XHR&=M";LX0).<0G$;D$>M0#X^ %:5$ ?_0HM'*G=OYL;6P
M"L'+DR:;K>V8LI/)CLA;C\T+I,]+LSHPK@VP9A10&UD .#_3N-G+O2 <PB"L
MN=6Q#&'JKZ!+JZ(+'N*2#:?+@L39*,>8?<3CL$;T/Z'&#GC0 <YENWB@F"\J
MK1Z["@7<D^"9P,:[MYZPK9>XO"S+LLXKI#3+;X0[!9JZA5[P,X##!5Q0&UTL
MPAL<QEH,QMI+'9W[I5';"%,+(X-BM;U0#=GPH=-GH4;F.G-IA^^Q/]YWPZ,5
M#VQU OXH0!49NPD;.ZT#/+<@NPHR>@HU2KR6* I+S*WS.)3+2P55 +C0BY1-
M6%P 0  HL 5A# 9?S,$BS,5;#,IDG 6@_ 59<,8?J)M3&[J+($1U*"X?RK[#
M^1&P8X=VB()Z#'-QJ0^]  9NY;]X  G/0 MQ.ZC 6[<A6[*,3 JB@+>.O,2>
M\(['Z[<L>\E!*L4T"X520+@RD #*Q0%_PP5;8,I<O 6@W,X_X\[IS,ZJ;,JI
MK,IA0,)F"<LI_&/H*PW6< URW+X72GU]MV0.-60V<L/F<0WU< A-X<-X$ C,
M+,"K\+N*7,"&6@J-[ G4O+>0?(FC<*/:C(F8/*2$6\52\/X  A  *\#.Z*P%
M6R#*8"#/\NP%JZS*[)S36] %Z<S*D\O*K,P7[&S36Z"YFTM>8*K&VI%>B< (
ME[ ,*I&K\7"A="P/E&1]\8O'0?(_"ET/T< )1Z>V_PL)BAFH, J\="NRWVD*
MT4P*G_ )>+O$D%R$?2L*VGS)5?"HG%G!3]B$GB>] 5  +[T%,#W3.CW4.4W4
M6V#31 T&-IT%7]#.K'S8ARV^?\$+LKK&H8L==?C/^3M]HP;#O[H8Q]@UDQ*<
M[#!:B$(/T6 &;V6[_Q %BCG ATRW!%RW1]S(<"W-U@R4Y3G2$?R>[UG!GU=_
M-R #$=!K(X &6N %S;T47A#=TOX=W8N]V$3-V-@]V33=SHAMTU] PCD&IHM6
MOFP,H4_=#+8\U19:9!P!DG[7#-J2$_5K'NT0?<$Y'M'PVJ;$"9LPV[2-U@9<
MP""[UFTMUTJ\Q*/@VR/-S>Q9P9/ZS5 G Q70<!V !F=P!F6 !M&MX=']!1[N
MV-$-XM--W5[@X3@=V3B=Q8R]V)M[QI@=C)K=QD\=U>L@MM&GVO-@42OA4$ZF
M2(@R#^T0G$%.#>?$MO_+WXBI"HALP$S>Y,_,UI98H]9LS?+7CM,LR9C(X)\H
MKGPMA5.@ :,9 4JQ!64 !F50!M;M!6,PXEZ@X3<CW5V !F@ RHY-TR;NX9&-
MY]"PY_XK@MF?RQ"$A @( =6V7*%'QA&?M./T!2Z*%)S1UP[U .ESPPFK1@%M
MP DLN@D&3+=-WN2U\,PE.\VB(.53W@E]"Y2H((]YO9XPZXE2W.6>.0&C"0%*
M(=UFO@4:#@9O/N)?D :U7NMEH-A\ =D>O@5XWN%;T M[S@M?"N/_RL:B6Q#4
M ,=$YI'VO8<[WF0IP:$W^!A 'ND72@_M  ?GE *.T'3];=&=+N '#.6BSM%+
MW F>$ I\.PK;>M?-&ZGPR=<UNWD8<  +R 5L  ;,@P9I(.=>P 9*\05K+MT,
M']UIT.;2K=-Y_C-AP,H=7N)[#@T$\>(HS)N(X-10;0WM4/[C\^ .1K:U,:'H
MQR@-X?)>*_CHX(X/[6!&_ML\2&[ 2L[DG$[$N,W6T0S)G7 %\S[OH9#@DXSE
M57#),-OTKP[K4*@!!L!F)B (BPT&;/ %9X &-[/P;#[=<HX&CAW9.0W4QI[Q
M)?X%RN[BXAWCBC#H_NR7$\N"![ORU3!?V^[C&5$/-U[?[; +Y\1._W#I_7V3
MJ(#(!<SN:@V>&CV>UCST5W %G1 *1/B.06G7F'@%5/"R,RNS[OG@3QB%X2SK
M , !2M$&7M &2I'U>' SD<WK7A#Q'"[Q[(SBD1T&9^_A:<_G'>_GBF"^A,0(
MOD#H)&JA[3!JHP62(;/MOASDWOY.6O. #X6P4FS+HBVZF)W>\XH,GD _GJ%
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M6Y%%<:KA#49Y?O.IFN$$GB)'3E9)M:KFG*.JEJM.865BZZ(,92P]PG+2+%!
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M7D#4&A!3 ((,LJSK][YW"33H@1&,,(0@\)<,2?!!$;Q<!"4$X05N7H "JLP
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MA3B @"DHA4T8!2EHJ@;8@"E0 1@R  U( &I[ !QH@0O( !\(!# 9 YE; @M
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MS%@:<('HY@2WQNNXINCLYH:ZMNMND.LC5@9NJ/&.SNX?WX:.SFN]MH;!CH9
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M^A@;:>)A0WYULC7FJ)>E>BC0>;P#'K@AXO9$(0HK0.&54'*  B*:@ :H !"
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MAN<)+X,(K!:D,Y]I1PR/ASQ%;1)M[LZA.1P]FH&E-1\%G?1UMX==B.4 !Q?
M@ V0H(?H."<Z9" ##"R0@8T=W(M+D.^3(XKK!3B !7EKD@N$ (4JY 2F9H%E
M#&1P QK@(1%O:40N<N'3N"Q5S6B.[9E*E]/3HBZG>HR@+>9PAPA28VK+D! \
MJXH(3MP"T)YI1SUB8^A#RZ,=J%E-1CB$8A7W$+H$=4<X.-6247QBKJ+P1!-T
M\ (<N&!QT*FB+&!AC%;(H@]B@?[*KY8 @UXMX$ES[Q54YMXD#,A "DUPHQ&X
M)--GR0 ()#>Y+1H!%V4T0AFW.$8N5-N?GQ(2%V=Z"^ZRO4>;XPZ"-Z_#'+C=
M;7;MF1%5;00G@+N+9QP=W<=3-].=GMQ%PWOJD!:E1$J9=1EA=ZX/@T)F4XH$
M*+2*.K(X_O%!<3CVC#0(2 [/KV  +/>R[$DWD,(3H- $(GP<Y"$OO"!N80A<
M5.OR*J_+?O:3[#-='O-U< 3\WU^'TM)?#G.@/^AY3@UI0&,9R]B%,NR"Z5D5
MN?F"N768A\@0BY@&B4@#I*Q-VX@21!Q:B,B#/=C#O;&$*"240EU!%!!!#>1
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M)'@1*JQ"IY3NO6Y"C- "*J1"^P1"<PS)(O(2['81>R5E?(2@ERFLK381#<B
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M=8KS@ ;3 '9O  98]P9(@<ZT  8T *WQ028,@O%60B1,0@B7^B1L@@A#PB-
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MC*$\1RBZF)^7T@,5E4+%6>8@!S;6$<9X0'.-Z^A'..)(!B5<TW2GPP";+N0
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M.GF7B%/LE+T4%7P\91^^E@>7B(&.C$.3&./(>##0H8][(%"!#=:#'I1-NB(
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M!AW*8W()".,+21)'L9#0%X*!'-;!LLJ!_,2!',@A_,B/_)SA&W91V.SA%_Q
M$HR!$/S %4 A#SJA#\JPP4CG!W[@Y"R :S"@JV0NPT(/Q':N@@*C]&Z ")J@
MMI(J%*P "I0@"(H@%(Q!%HH!'>X!'8KA$?1)&"JA%<0F(BXM%99G8(ZH$AZ!
M#_R1#U"$(3;)O#81&,Z.&(#!\(@A!Q?O&X;!!K_!(>>N!STJ")&$"!7A%BY!
M%WIA&@1('C[+&8)L&OQG"G7Q"LGO&VK1'"ZQZ?Z #R1AM/I@#\IP9RSO!\C@
M#T!!!MH0 #',VN90,"Y(#K?M:?Z>8 \Z80\F#]GV !1281A+J[0(P1C0P1@L
M(=(HH:PPH2$Z,&XX0ZY,) \V)2+ #A.TLNQ"+1@^$10CLB$1LJ&>(1,B\AO
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M(FI4V"[A$AR32-/A',8SR.R&'-(!_9C.B?,)77_5;5J!:5LA95.V%4 A@ES
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M+L)6RY,*+^$7GF$\SH$<+"%A?D&'J;3IU@BZ?+LJB0$JE5%R92%R8S(/6B
M0U,TB1(OJ "8<](8U+</8M.ZJQN9M1N[2U"[ =(?O]M$V3<,X0^$\]4@A:'L
MUK*%?YJ$%V^=/YO(T<$>QB&S[>$=W$$IH$$:?L4>]M8=[,$=7 H<+NH1"F$W
MK1 ]K=!5S8$=Q*'!=Q,8!N]5:3 P%]+L%F\<U*%LT8&T.N%]96&68WFTVN(%
M;" (J"UFGZ;.P.D*2DL6WL$?BD%>P=2Z2<L/H+BE 3)DW_[WQ2?T<!T]9.=3
MCVGP!FG0[$+->.DRG<]7XS0.4^?9'3Y;Y-KQUWSM'I3"&KQH'OZ22[YSGX]4
ME()L%[&0!I=L2\2!M;MZ22]*&&B*LT"1OM5!'8H!:$&A#U 6?FVY+7* !Z(]
M9J^MSA!$@,/!^Z:;NJO;?2<43.W4?2W!CA_AE2=TW-T710"2::^R@HWA$W.0
MT]ER\(AZG4V8&(@\'^YAW]LQU?F=H[ZB'JJW':AW5A?\M=L&B";!%</O&1(2
MD\/\&U@[$QJV?(5!2KG$^R+;V-6A%<@0%/1 &4$!95/!\61!"?2\!JBEA/;H
M";HE*9T@$-1A']"A$*>[Q?F $/Z,V6VH]E=QS)7[Q4[UZ5>=N(]?>O%6V#G?
MTFN'6K,UKLW'P;/UG=]#BQWY/;1CD9+3P7-PV']4&!.LCLM]N$F;M&'9P1DR
M8A* P9X=DSF9^K)DM.-&N;XEX8!#?GW)0)+X11AD@0Q@0,^CO82<P F>X GP
M(BE5(:?9<1]FL[2HF]MU_C2*WDX]I6J;.''[);KZ!5W'^@(K&-Z-=\U_052%
M6ATT6^/7TK/Y?=]5_1X4;-^MH1K:@1_:P:>I'(=K\>L5HE,FH<N_81KXU7]X
MM7LQN1R&P3%!+AUB'7MIZAS> 1VV73-5/!4@MQ5@(6AAX+=\H >*P*@,/PKV
M(!!<(?X<?HT=H=+%]92TW&;];VRL!R&?TM50F7CHT_6E+S"R/;]3>3KCU@BS
M/3N5 6)<,6+$T-G+=V]?OGWV#.I+N.^>M6OT\)TKU\X=.W;DII%K)P[3I$&3
M'DW"%"R8LV\KR9$[1RX8)4S Q,$$9BD8,7/GY*4[=VZ<.'3HSJ%3YZ]5GZ5]
M9/7Y\X=0*V'%0"V!,2-'CQY&FCC1HP<**'_^U*%+6(R,6D)K^Q!R2RCNH+F$
M(A&R-.C1(&&6+ G[RY=OI+Z A1$D9@P=.'"'QQT&!@Q=NLGV[KF[=XX@,(+W
M$B:T5QFBPL[6VLW+=]&=/7?F6(HS1^Y7R9$G5:X4)^[E1?Y@F# U>_DM4R9@
MP=#)LP<4G3BAYWZ.0V>,3%Q9<9]*;=6*D)(7-G+D&$)$BA,G@ C!>J<NG;M]
MQ=Y*?]]'.MM!A.A'&HP_,"&^4P'[]4L550,94] XZA1T&#CH$#-,0>FET]D]
MZ2QXV&01=M909?OTTT]GUYC63CGGV"//.>(\HQ),LI$TR224^.),C.  =0Y'
MO/WR#4S#9/*+3CR!EHXYXPR9W%GH9(<==7\\E4HEQ<A"!@PY=&>$$4@4D8<J
M9+W367MJD;$46W&-.:8E=_4UF%Y[!5A88<4(F!A11Q4T$#%!.4;,+\2H!UIE
ME3FF)S%]VL//A1OV,YH]'[H38OZ-[)3S33 XFE-.)BU&TJ)?P7SSC4WGM,..
M.)(^0XXYSOR2R3# Y*B:/3^5,TXY194C:SK$%%-,*\:T(I\LV!FCQPLU!!'$
M$$60 8HK2!EC3'M]\ %F?&Q)!U>9=P76BB61!"8,.H 1P^:; BXH)U%X[MG8
MGNIUE@]"%#:X9V7I1!3A/O9RV(^B],S3SHR,DH/BI.7P=E^+E_@2S#3.>'J.
M.^)\0TQNXN29ZC?@L+,:.^VD ^LX/UTDV3VW%M.L4W_XBATH-LS0 P\\("$+
M6<80 JU:?%07%QG"D'GF5-AERQ=A?]V*#JX#&1U@,>66B]O$% X9;[T('5:G
MA! JA/Y01/SDTP_7][2#SSSDY+C1-,"@^@TY V."Z4FU.?/,C V'RBELTP23
M:C%I-SR/.\W!6HY9'*-C3F4'WII=4V/&$H0++NN1"B&2C)D'4TNZ%5^VTIEI
M9G;"8/<7T&U25;31MQ(TT-)$99;9N>:F8P_6G;U#H4[$7.A9:/<B:L]'[Y#C
M##D;G4A3VM_P=FF+*+7TDVKG=%H..,\\@^HP-KF#_:LBSEHC[ 8UM&!V<8DO
M"Q(9R)!'*JG$E\?E;Y%IU\Z<_Q<ZFP$"V"W118]\>D%+QZ,ZH3@F* 99"+WN
M0:%F56A>GHD0APZ%#HR!)#?L6(>H,)$)<(PM&+UI4:8VD_X;];@#-6J#U#"&
M$0Q@/$-$V,/>16AEE.2P@S*N"DI[QK0^I[C@!Y%;$E0N1Y\QV>4N1!P,@  $
MKM0!!AN&09"W#D.0<2B(*/+XGD'(-0YS5(@H#_',/B:#&*-)QAWOB(@_ZK6A
M0]WC.,\+'CO,T8Q?8,)Z8P.&,#RHO![9I!WMR,=J: 6P9YQM52P$C=_>T0YU
M;"^"Z5@'D":3CESQ+!6@^,$?UD>('_H!*CSKG%_VTY<W&4U<X"KE8<B%*Z)
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6T#_O9:^(T(XQ(QMC0KA4+X;>(R  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>cogo_0064.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0064.gif
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M14B2)"2J\8(2:<X3H"O@0 F,"$07 N$'V<WN"4T0 LE@@S9-:(%XQ4."!I&
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M+*SNNWDKJZ (?+,8D+YCBJP$X  7\,4^QP 00 %RE@$*FOXLI!5T%:  "\
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M<XD;OC]GT<(JS,2L 1AP8".@ P#-WA1  I9=P-9LQQA S)J'Q0K:K!^0;15
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M@@DL1,'B"".6B,.,(4RP0$L.-C"#DCM@^) !BR!J84,C<)( @Q94()&&%B"
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MC$](Y(+)A2P)-\J "5X5*PV0H =FP$T/=+ Y"*:*!R5@  %$]8$1C8 Y$F@
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M35,M>!@G6<Q)L1YM"V3U.PJ]A (+G=C$%;K0"R;\X(T_8\$,A' #8Y)!#6Z
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M%  :JQ "(!"30-"$4. "O#C'WDP%%@7.:",&;'A18L@&&NU14<V&;?#1KN1
M61@%81 %SD "XP"30^$!.T!2XI, *&V. WC&"<@^!X" [1L@*'65'IB58@T#
MWDH#.J@#.["#N1,#^^0#_513.(@[,R".()&T5#&#-L J.S@F,C"!!R !%7B
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MZ(:*/?X')NZ&)L[;;%!?NJ5B7V $LRS)''@K#% "-HBTIZVP#1@ #XC!V#&
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M L-X B@X!5H(Z5O@;,Z>A5N Y?Z )6F2)H9SB&)=[N69EFE>3FTFSH;RK5M
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M_*R#.J#6L>:,L/9'AP"!$,",@FB".(@#0 "$>AY=M1:#'C@!!=!5>J++"]"
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MB8],@BLSN.+8JZ^1U%HL(LF>U$<9P/;Q&Q^.2%MK:-5&   $&4P@ 0%6'E
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M0U[U*B-)RT@?>H0(YBFO>7S882-2V A"V.$,.R@  +"D@,B P /5L4 %!!"
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M<*.XQBW'<9/+'N9N(Q?.Y9,YTH$.<P!9+H6RTW7UE UAB,(7VCC%$;R(/B*
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MEK((NXYTPJ-8>]&+."A!YW$8P@\R/HA)Q($&&5  =3*  QQ@0 - )<K3#\"
M#.@@#[W[:+H/NPP]PV98:E##&QJQC-^-H0=$J$.^(V&'(1!!#'$/0[REMH<Z
MO$$-R^K#'EYJ=TD7HA!$-"*WGDYB"6R. !QH@7,@@/L.6H !%5A*"K  #LB
MY/W *9Q#'=D)R$F5&)E<KMU"-RB9_9P#!9H%!<(%7!3*-H05,@2"$V!!6OW
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M9=H.H5U$(BA"(42-T=1*U+P$"IJ!' #"C.#!:1H$0KP!&L" Z'0+N13 !F"
M VA !?Y$P/5D"0-,Y ,L0 .,@ DHU0G 80DP03($ Q? PCJ1PS:QHQ[*#9S
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M'22)(BA"9^0.U*+!C,"!:<[(0>C!0<B!&9P !I!9UV1)>%"E;<I  PS B6&
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M ,,MO,DUP\>IHBJ]Q/%U/;4WVR@W?\,Y!X,H!)"M^L(>4TPR% (;[$ 0C$
M7  2N, "=([E;.ZWK#4 ', (?/Z'#X0!:YAN[ZQ;0B^('<B! [5 $HS",M2N
M-,AN8/.#.UC#[+)#[!+6,40#,HQ"$=!T!BP!&Z !2:2I'JQRB>@!&A#!$H@
M,PU ZQF !< @?;TGN&B  _P$ 81)(ZG-":P 7Y0 $F#!*@R#+;0'?% %G%2%
MYND".9,S-]PA5'=S.9!S &4#-KR"*PR#+_P#(T3,#YR +UB#' P!7[( !K!
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M)4 "$2C]9CR#/RQ#GD]])E_](EAT\8_")F]R@<(P#%=M'-!(21-$+<O!$G2
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MPQ_M4(< !G 0A'!$(00G.$,L\CV D$,<S/"Y%42@4(0RE($* ((*." %&\"
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M"[C@$C9!$ZX/[=0NMFJK^U*LQ("P%&)'$_ZAX%[L"8C+F60@!99 \-# #&
M23(  E: !H9 !TA@:EA !6@  R#  R+@]AA'!$3@#!& #?  #ZS"D>3@$9I!
M&I[A&=#&??2I ?? #MZ KP:0 -_P#?% VGY@!WK@ G_.#(!."'2@; 3LL3AB
M A @ !C@ :ZN E))E!; LU3*V_I, K3N=' D!\9O"RX!$T)!I_@MMA[-MF#1
MMDA!%7"&"%O,"98@N)P ")Y "&2 ")1 I8C@#(+Q!BY@<FY \5! XVB@!4:
M0";@_QXK!$* . Z@">0##@OA3_[B0 X*@0[%L:X(R(_^B0[X2@ )"BP$$ Z2
M@+)T0 @*T1[MD?;RD:(D",#0$ $6X 1\P <($@4W0 -,H":Q3K3,H@!,AP-^
MH : P E.01-T)A1VBJ?43J>R#](V4K<H36><0"2-P,66L"Z9II-VX I;P 5<
M0 5^  9&0 P?K!D7P ,@X.3^BW$0I7&0( ^T<9'P "S8H WFH!"681GRR>8(
M 1WIX T6Y@VHDBI3T]KX2P>V$J+L$>ATP 9.XK'"TJ(<  9TP <6P,Y>X 1(
MH*1JP 1(P-L:@"Y<R>]R!.%L\!1U".V\4X?:[K903-*0Z0KH[@>.P#R!X B4
M:@Z<H/X&4H 'EJ -@@ &6N '5N-(L"<O5* $%D N!H"[B+-0?H  N:*A4-,>
MN[$1"F@/\. -X$ -U" -U@ .WH VT0!0I&8W:P"+T( -(*XKK0T''(9Q.O!A
M'*"D1D9D1H8$4(BC8("E."!]WJT$4F &,ZT+.$$3-D&'+-)'+X$64@RHQG,5
M;NF8R,\)"NT)KB#OG/#OE$##;@"+VH '<N '/@ ""%'C7L!)6( "YH(G!_0^
M;*  &>D-!^$=M2*OT!%")30-SB -TJ -T* -VJ K/Z+J>F (AN ,?C$)PN#G
M\/$&5"#)Q/)$TT\',L4Y1^8$=. $3H#:\F(#"H  "N"58O[J[YZ "SAA$WK4
M1]$NWS"A%X**2$M,:(KI%%;!%"C-"9J 2;V "[2@"J[@"5-@"65@ VX "7@@
M"'" !Y @ W* 4%4 G"C@ EJ@!>1"3"WJL4 @#\*L*AY!L,J#@,YC$*SP#+15
M#,* 6\-@",+@ LT HC*0!XC@6\. 3M'@$"'*\7; Z/:1K!H'H^XC17W@ 19@
MSVK@03*1!(2@!BZ$ UQ05%)G(LP/"Q"M.V,+[4(L/$OUME),>/XA"@X3"VKQ
M"K@ 8YM "&Z4$2*N"8#N!CHT"'[ QIJD+7"@"&;@!C[ _S!*U@" 4 )@ D+@
M#,VJ Y!2S.*G/.Y$&0:F@.#@#/[,P%O!E4_YU$\A;@@@B@C$0 R$%FEG;UWQ
M40=>@% 0( WG-6OOHP!:(!/SU0=T ,.(0*6$P)5^  1<D -0*[7J\@>>8 M
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M91%@ CP "$+@ULR *QI!G\)Y8,@Y=/?IG]YT0N'T#-0 #@:Y=?MTD.MT#=8
M#>  #<Y@"8( *W5 !1RK ]*S_"2HDF/6 FH W5"(;&G@ 4!1!M!* OQN!H
M!Q*S"[1@"\H.WQ2M4SFAAWZ'F%!UJ/Z!%/Y@4[O@"HS ;<,O=8:9$0"A#9+@
MF+GI!5CH!EX@!HP "61 4CX@ _X*  *.+ =P0 9RP ;ZUP@FP  V  T*R)U$
MUSP*89P;\ 'Y:D+C- W4>9#KN757EX\11T[18*MI#PLIBP4D0-9"@!%\X1_
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M"-8O#II N<S<!H!@!G@ #79@93X  \R5!;(9!&8 "D2!"6S6 /0#"YB@")@
M[T(@ ##@!6 @MFN[$1XA$AX=MT-WC_[)#=; #=Z #NA X%MW:+DU3K^ZTQ-9
M: T74@&#PA0@ #C %W@<&53=%XS@,Q$ ! 2V>(M\LS:@4A(  7J]-D3%FDU'
MRI_ "X(A/$NL%5K!%4IL&'P*B/Z$"NY:# NXH N:Z@A^8 B<( [B8 E060AP
MX%?1@ ?*R 9NP =2( 3BX@)B@ EL( &B&P%X& F@P M^ 1B @0GP6@6"40D&
M0;<CP3Q*G!#">?0480_Z * "R> %WJH7'JL;F$)_^Y[A%*)H8,(@=03P=0!
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M@0Y)L&%((Y-6&DDCA402B5V%\,''7FJ4,8;*:ZQ!AUYON(%JS!Z&84880^C
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M 0^G+I.9_5A'.]0!#FI\PQK)H*(U_S '2(R!"(SP!1/ 8)H$&*  6TN!9&<
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MH 0V_ (8HC""$?[ AB0,H0F"Z(5E/0 "#Q2A%]^(!S\>C^E\8!K3]H#"  @
MR1.DX 5!$$K(0Y[*5.9!,6^@PQA*G_([T-H0+,^#'0Y#W.GQ6O;)?4 #5K0/
M)-_CY_XA1G:2F0KE%JTC1M: !!$@@?2BQ0AIS(?>:&J6I!K40 F,Z((1OB *
M+7A%KFE_MUWO>]]Z(FT8OHC#$L+;A'H)P0)&*4(1UG,$)*PI#.CD2@Y P+ N
MJ$-H]MB'_X?M?Q*W#\@P 9A7 QM0 O\A!X/ @"&7*:G$!W8@!BJC,@YB!W>
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M@ *_\(W]$ _]YX+YH&D]5VQ)QOY,S31\R4 -5N=TH0$,,7*#1\>#,L((-D
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MU-8%?R *4 !V8. +\$H/<1BP:;L/]Q!=]E!\V.0W<J '&J@7LF13$2L&;["
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M#-G@I]H J(IJBI!@!(%P#.XP-#);M9K[NJ/@!Z+@"'/@"\"@#5\0 N;&(NS
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0ZC<-W_%J++&B,BZ>@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>cogo_0047.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0047.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MDW+LZBX0R,0/#S^DC/! ZT46XBY*V?IEO#B, #IFKDV6D@#<(" "%CCTH;=
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M5C,45@?*'=B0['4W<(Y \).'$#@.(],=L5S98G%G7CJDU:8_:7N GM[T $
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M=;24 A.4A7(R.OO3HY+Z,.3$[Y C<=QE[<3@#U& 31;F+V#/8I+SY2G8"%<
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@3[4F<K&1X)7FBH[=J@![4,71;C;LY^2__?XJ]Q5'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>cogo_0065.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0065.gif
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M$&X(1-M)XV?L>-L&&X2WX.C&6&4(R!O>4&JE6VLSL[&-5G3X=<OUH>M&88C
MF (-6]1F&H" P22XE 9BL(4M*-&#%C36L2U8@0I6T .8!I4&/1AO.Q,K1<H"
M8<670$4M&%B)-Y3AR5PX0Y2/2N7^5GEO[6)7/==6X$A*LL#CD24_PV-'W.(6
MK6GE1OZ$P2&."3/HAL5I)G%6(>>M;6,4V]#&UB95+>:N;A2C4,5(:X6B3,[@
M"RZ.(HY; (1.=,*Q*"@!"U9 Z1Q8>@<_Z$$2@MJ#3N=@O>UL@0W$HT$:<*(6
M]/P"&LS :E9_X0M3QN^4I]Q?_J8JJ4E-%1;KJ39\NLM$_=R)FAM\YH*H&:P1
M;C.%*>(@8D;M:\7-AK37,8ILD**C&:E6-IHK:)* B&[#>X$** $$%#BV!"L8
M+ V"4.,5H  %*]#!#G3@ TPWX=Y,^$43?O"#)H ZIL4+;&!K %]O>O:^7$CX
M%XX:Y80G7,IIF/)1^6OK-/25;\+KJ^_(>"*F0E6WQ$:KL?Z[ 0XV*SN0<'[4
MURXFR&RL8VO4[K.E5($(5JB"%=F"PQFT>$$;<&(&%7CW"EK0@D\'P=(K2($.
MA. $*$0!"E.0 A2@[H0I*&$(2F@"$YJP!%#3( DT/8$*&,UB#(J67 QWN)0=
M3CPNP)K*$*?X?HUJZU2)-M?1<UE3T]6HAN46K1'N!CM.#L@&,<Q!SMJ-*[+1
MBG6XO!6L>!U@JD4QFZNB%*'X@MT$*\X3U. 3*JA "5)0]!P$@0E)L#0.F(X+
M81C#&,7@!16H((4H6'T(1IC"%*;N"28PH>OKI2D*9.I8P<ZM5&&R@<.7S_R$
MWRW*%,\;W"=^U"^\X0PJUEM1T?[@!M/.0BN^I"VRD]V-X'JCK [2BH- NC5I
MNUP;K,#Y*"B5D5?0'!&O2$P:9+!%<=K@!"> !D!0 A60 3F@ _PF!$VP PRH
M!%'@>J_W>K,W@;7W!!;X!$XW=5MW;SM =.9V B4 @ILD1=1E03'0?,T7<6N7
M-PM7?0<'=UM097-'<1R'!N'W8+M%<B1W<F6%*&#Q(,5Q/Q[6"N\'>8&&$?>W
M49N2!B]P3F*W19[W:!J@ 3GP T*@!+[7!%@(!<*@#!'8#*]7#,XP@61(@;4G
M!1NH!*F7 BA@ 14PA5Q4/"B2<%B @BE(91(7967P:F40@VM@?5Z0=E)V5*RV
M:J55B/YH\#D%@0HX. N[%6'LL%MH!C^'YR@5\PIKY7[:8'\:0W_XQPK68D$N
M $HGD$&:%%0EH $IH(6[)P6^\(K.X Q>&(&S&(&]P N\8 RR1X:X( 6U!P59
MF'HM@ )3J %BIP(TD%AHP F&& -F8 -F<(+0R'P,MW:O]G )AU]G8 9J8 9>
ML 4/=P9;\&1EL ;FN(VKMFJ,^'U^9VS'MF9_-U%6,8^.8C&+EPW:D WQ=WFE
M(&BJ0#&O0 NB\$GG1#PSD 2=L *JJ 2Z%P520 7$X S'< S-X(41J0P868NO
MEXMA2(:UAPM/AX9*P(!L6(QB=S?& QD[UVI<T&HG6(?4R/YJ7% &9J!V9D"3
MW*@&:M %+*D%6L"-;. &0FD&;M!J[.A+NP56X_>(W  +:;46SA:$=-8*]RAM
MH,A1_4AS]I=_$11!Y[0\4I0$*: !&= $M>>0PB ,$%D,R7 ,RL"6SL ,S3"7
MQG ,$1B!Q6 ,$$D,PB %O>B+4Z<$2B $.= "8PF'!QD3(X(&9="2.,EJT%B3
M=MB8DIF-K*8&9, &7> %K<9J9* &0AF:15F49F!'ZXAF20F/8-4P-Z1^C@([
MF>A^-J<Q',4*-6<(7/ "&;1%Z<)B*O!N*2 $OHB6:5D,PU ,QR"1R" -R["<
M<ZD,=GF7$@A[5" ,O=B+#BEU5OXG!*FG E,8:3/P1:*P$@#VF)UI VLG92PY
MDS8 DRUYDV0@!V20F?/9:O.Y!W( "'P "'M FF; B*@0CZC9#3I(<FE59HZB
M?FMU,8SG?MOF43=G>6MP4^IT"8IU AH ;T+@=%% !;Y0G<) #,10#,10E\?
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M/ ;YHXG+!.NKM.VKM+%8#?'KJ)5+O_9[O_F+#)X;KS5:HZ^8"[YP"TNP RO
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M %S@YI8-37DQ/K^Q,5?  KD?H^XHG;,'0#SWN7%;*ZKPT%!2_((:T-!%$(
M!$K,#*/0G"DP<($+\D*!O$QH@A": (4=X,#**<B "C*0@ASX@ FYL-#-,!.[
M7N1"7KL8 A%TP (-6, "%]  "^#<@QY\XA?>JK."&XP*=/Y8(@9>* H@RMG0
M(<F!T(2^ R%HVX<4T@%Z&H[#4RE&SS"(,[>6?B>F6]P4Z715%GH;UOB(TK:
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M>*):G&-EK&H5K%KV(HG0K%9^8!T@2H8ID*QA-W  6B!"<0I-?,(6O^C%)\:
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M@D(4HE"%*@Q!._*^I*_"& 8NB&<U*3C!:;I,IB?HQEBKQ!(9BMT%^FYX/B9
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M961=[_Z=0Z.I6(M!6HOUT\7$2(R4G1N8@?,=G"8@7"FH0BD\' Y>'Q$TP1+
M#9?]E3-(S;T0PS(XP\U)035 @;'E0!(D 1,0 3"@Q2\,X!(L@6;]0 Z@ +)A
M@+D,P2[L$ ]1P1!* 3!$80'N@RV4 5LQH(4)':-X4R($$+@I@E^L4X?9QAN$
M@0;J00=F1AC@R ,5FB$8PN8($HHA5W*YPO"IX$-PD,W0F(UE3*9T3-KU!L.E
MT VJPBJH B)P0A)T%O@P@1/8!!FNEQ0$ Q(FH?]IG/C@EP^( 4Z55BW4PC-
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M.!-R("DEK"#".0<9.OJ!IUY3'G2!%QCF%IC!%FB!&<@VAL !;V@"T,3F&[B
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MKVO:;F!IL O2R9]\(/DJ"ILY(JQPH<F&'*SYQ,,YG)<!%\1VA>A&A,)"&8P
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M20\\XG$>^)B'*$R   I4H (@*,$):&8SF^4*5RQ C3M+> (0Z'.2%#@ "+*
MR7*H(WA@J (CPF"9""2@ 0=8P/X$(@ !#HC !16MZ M<\()4;I2C&R4E*3FJ
MQ/Q$L3]QV:4ON=$O;=3M$(E:@UBTH 8W;$$&(\",IE)8 &AV9IJ(&\ T#=(9
M ?B/ /QC  !$H ZEID,=*9('/()GCWZ@8P8II #Q)@ SK=(*9B\#@06V6@(3
MOJP"%D!  TP0AD9DTA_H,.A!&^&!B$*@4YXB'-,D$ (1G""C&+7H7V4 6%16
M-+"$#6D,W%*O<,2%;>%PFS=26HYL:(,5A6II&\JBAC*4Q0TR\$#$'G8Q4/54
MJ *@IC4[\U/_%1 !#P!  E9QCU.-AAWW: =4[R%5?]P@A5@E7@6R"C,+L!.X
MQ=6J6/YII4_@4H ",!A$(\KACWN(H0I5L (C&C&"!& J G5EP%TET &]FN"O
M?OWK>5/YT<"N-Y7/VP\XPF$.MK'#L;ST)?NTL5)#^*68?".F#41@&0=HBB "
M"( U?6I:4'5&J#RU)@%_"JH!D("@[J#'4]LAC^#-(Q[\Z(<_2%$"2C+W +XU
M\6\GT$X3N+.K,)O  2+@W$S>8QTDJ,(5KEL.&! @HMT] ,<NIAD)A%>\)N"K
M><^;9,""E*-VRL\YX!*.<%01LMS0!C#_Y9>RT&<-,1"!!RRSJ<X$8*@)GJ9I
M$>=3 TIXFG",G $4(( [JH,<\<#C/>+!8:B6DQ_WL,0)B/YWU1=3,M 0)6X[
MC\OBY4Y K2]<AP@^4-T<PT  G\1,QJSY78CBM0,F\#1?E6Q8]'Y4HZ:L95OL
M-!<IIP^RP'1?( X!AT.L@0LQ,$$',!2!30T@  4@LT\+K+$TIYD!;$8< 0V0
M /X)( &CB <XXQ&\X$&U'O7(<S_ZH8].W, $2R,>*"?@ :RV$]'()>MOPZ .
M>MP#!AOXP >L<-UT9 $ F(E 1!/0(>5PYE*<[L!>*1KJ4'=4!FV!\CEHT0XI
M._8;_'+%W 9$BE&$P@U<<$$(P P!#'5HS <N" ,.S&O/##O-$E9MXAJW;!&(
M0YSQB#8>]0@/E^L6V^@@U"%(<?Z(,.C<#UYXP00Z@&B8(1=F[)Q "7IRCS!X
M0 &1MBXCRB$" !P ,PZXS.$.#$V=?G("%PKO"/9Z@B-_=. :U:$.40T.6L@%
MON%XV\-?T8J\K*,5A\"""W!=&0@X8,#/E#"9?ZHQ,KNYS#XU^6@3QSAE)V
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M4"$HMP$37B $/A,T[VT!>/#8R&]C"(*:2JYC]G% 7=-B"B@FD]! #T !$D
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M*XGH@ <1/*226RX)9A==#0QVV/Y!X[W%(WP<21:D1^ZEQ)F1.EI7D&CWB96
M "[,T\\\1'&(CY;WS,/4ETO)PTX\D( 1B3Q;[J95E:P%Y\X\^*3FE0"2&>#
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+)N!F-WL)@H   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>cogo_0045.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0045.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MC =2Z]UAJ^47=5ZPN%W>=7N![]1:^02,)3Y<"L[FV:UB2*MJ"AIOO>_3W/\
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M"O RS:[,UP(J9,7>I"U*0GW?3I_C2_607II/H;M]LGQ(Q;DQ1O9;6.4GWLC
M_*F612*W@DNT7U@N:+;9)MO=0K=#+?<E1P5*X*CCQY/'RK5"2HPY,;NS2NQ[
M4K%@N[+TB6X$7'*9*R<A2OLD_P#2M.*=2HQZC%O5KT>B6YBB0=^0>1@^'G6P
MYSC18MRO='K0[)^DDMN#')ZTM#C@*%=>M'K@3<AQ#*%'&/QJ!'!$;/VA1H*)
M/LK=2@VS.E'(K:<@:/6E8T12.AH#M6+#85R312!="@@ ?%1H%D*Y2!!@RY1!
M4&&%N8'4D)) JK)\8MEN);IJ)XYOUM?==07&EN3):E.J:!QL!.<'R^=<&;MM
MGJ<*I;1&D-(:CU+.5 M\4.-)X4KN_<0?VNIK'FS+&N3KZ32RRNDC;M)?1R89
M;]KN<Y7>J&=J0  ?+UKF9==?1W\/BE_<'</LJ@1D):8@K0!U.[(/KC%5+4N3
M-;\?&*X1:,=EK3C>T,I".BPI(PORR*+SLJ_**N1YOLGMS:VWG8S:%H)&YL[<
MCR(H?F&,M'#BR3.T/:6F%LB$WW9(. .,^E9IYYFU:3&ET"%UT':'@II,-*4*
M/.!S3X]3-&7-I(?8R;7?9\W;5+DH;= ZY2?= ]:[&EU.\\[K=']-64NFPMTI
M[NXQMQ(05/K4GNQ^J,8XKL8Y(\[EC7!Z1T9=&9-AC@/AYV,>Y<6%9R1XUNQN
MT<K,J84LS H 9Z>M6I44MDYF0%8PH?G02LHRS:7!-CN-J<&Y0Q3[?N<]Y)M\
M%HM3"6LI<%*XFG'DE[(2KBVD_%^^IT;8NQSZR_6%2Q[ ?))QZ5J]G*&R>5>E
M :(XW\.: XK.*-@<;.[QXU+!M*N_H5+M-PAH7W:G(ZQO'@-M)E5P:+<+VY8M
M'G&=;DRG76H32G'WL,K?4>"GIGY5P)K:FSUF)_)4;=HNPVO3=K@VNWL *2V.
M^6/MK/)/RKSNLR.39[GQN",8HTZSQ$% +K8P"#FN:N7R=ITN@P9A(2VAP(3R
M,CCI5T8I"K+*7#'_ &1O:2I.,\Y%7;4RB4K3LB/QXKBRE9Y2D5)1444P;DRA
MN/<AQ3>X8^59Y<NC?%M1!V4P@DA(!!.:"X*)MM64M[T_'N,!4=>.0<$"M^E>
MWE''UJWJF>>+U9)&GKW+MLE@/-I.\*Z8'I7?T\G)6>0U4-LJ-([*H[[,.3,4
M\G8XL)"$@@ "NCBDT<C/!-FE1W,)!).:OWMF24$ATRRD?%BK(,IE!/@0+NM"
M]NXT[Y95]&)*%Z=*<;^*!/IQ&7+J1SDT&7)<'/KASS-"D/0YM2.<5K.4,J W
M&@AD=2K Q4H-G4J)- 9"G$)"<@<T 655[<4W:9C@3DI8<P#X\5,J^(^'F:,A
MM<",U+:6M:5K0@J2V#D 8ZGY'BN'GC\&>HTT_P"JC2].G?W"UKP1@#'3%>6U
M$>SW^DS4D:I 0VAH9]Y/' K!T=.,KL(X_?N-C*0$D83FK$R1)*6W5(.TC \J
MU0?!ER=\$-;*G2<$)"LX/F*29;B6T'[C'6%KWIW!/ _C6=KDTN?#!]3*E*.W
M)QYU*Y*'/XEHFUM+@M\*S@GITKJ:?'P</59K,=US9!-G//I!P$IW@CD@GD?A
M7:T\:C9YG62N1+TC;&;39FV6B<N+4X?Q-;8.D<?-RPH;.4"K4S)+@;>)XK1
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MWHY&HGC<^&#L^SM7%]UM37Z8K6'ACHD'BNSIXIX^#S>LDEEKT#9B-QEJCMG
M0HC'A6A1V]G*R-3=HG--A2 .F*M@DS+.5\''HXP"#6A1*)28RB/N5L!IMJ*W
M.BPC69;B=Q\:=8P_51TV5T$\F@\8ZR#WU2]4V$WB\<=*<YPRKK4"A!ZU!A]D
M'9TJ$.+ZT&0:P=P.,\TZZ%DZ,'[4IEQT-)GNL-*6V)*$(1CW@7#[J1\\D?C7
M&U<4[7H]-X^;52]@7I?6>L)FL+BG4VLKI$BF,R];[1 )BA"EK*2A:L;E8QUS
MXUQLCQXL?]-<GJL/U<F3^M+XTJ2#;56MM/:/B2F93&H+O<83;;TR-#G.E,9M
M9PDNN+5X\\ 5FP+/E;J22_A&S59,&!)RBV_Y9G=JN%YU>S_.2V6R;!MSLWV-
MI7MRW7 OJGKCC%7Y%+&OD[_T9]-):I_&-?Y9I.FFNWV+V@:?T/;M718:;S'D
M25*O4$2DM--8.]&TA1!SCK561X5A>2<+Y^[+<;U/YE8H9/3]#':]+[9=.Z_M
MND+WKZ'>6[RVLL1[/;_8@EP* PHY*E I.< BDTRP9,<LL(;6OWLLU,M3CS1Q
M3R;D_P!D@4N6@=9MP+E>K3I/OQ;%I!;G9[V5[V%%L CIUY/-:,>53XD_^C/J
M-/+$E/''C^27H74UQ39A>]>]G[%LA-RS%4J$I2WT)QPZIM604#@$@_+-+FQP
MKXRY!I\V6<_E&D'6I>QC1>K=2:(NUOE.0DK?E/(GVP=TXXA+.Y*58QG"R#YT
M=+JG4OV%UFC^I.-\6$SFL[GH>ZQ-*ZFGO7#NF"J'=D-$N2"#@LNCQ7CQKI8]
M5CV*4NSDY?'YGE>+'["LVJ[&R1]2O1"S&EN*0A*E J Z@G'G5VEU$-2Z1E\O
MXO/XV*E+V+8944@I\JZ,8T<"33'O975#DU?%%,FA"HCR'$G.*DN&2,5)!% 0
MX&>?*K8LIE$DQEE2MI'[J;@ED_"?(?E3<$W,%L@]#5:1D8RX#GI0;&@<2#B@
M6#S?PXJ$$. YZ4&08G+EMVV:_;$)7);8<4PA?PE8&>:SZS).&"4H]HZ'A\,-
M5K<>*:N+;X_A&0OR;1J>&A^XV.1 N+*P][/)7WB5*!^)"OM8]>E>/QY\ZM2E
M:/J^O\=I54L6+9)?P2;EI2W+NMNU#(4RRT6##<D+2,,/;@MI:O3.Y(]<>=4O
M(YIHSQPJ$E)F@V#L=LT:*MYAE,XS\+G.+ =]H).<*/B/3PQ6;'FRQX1OGBPR
MCRD_Y"RV=G]FLR4F-"ALLQE]]_5I;CL\\KYP,CY5;NG-_(ICLPQN"2!FR6NS
M:D[797:%;5%328:+/%D#(0\A.2Z\A)^%).U(P.0DT=5G^*Q(L\=HT\KU$G91
M=KVB3J#4$.\!/>3[)*1-C%)P5%!R49_6&0/7%5:3,\<90^Y=Y+3QG*.1?V\F
ME6O5NA[LP$N7VWN90 ['?=2TZT<?"M)'4=/PK2HY*X3.:\F.'&Y(J[M.[*HK
M*V)-ZM&Q6&UM!>\K!\, '-4SAFO]++\>;%TYHJ+59K4_J*#=K7"D1K5"COHC
MAQ!;[YYT)!6AL\I2E*<;CUSQ5FGN,6ON#(GDR1;7297:ZG:4TM>XDJ_RML^>
MR6[8PIGO$AT DND#P&1^.*O3I),&/#_4<U]N"99X$IQVZWNXSU2EW%$%+*=W
MN-@-^]M3T3DUT/&K=F^/I,P_B:45XU;WS.47_JT7[41#+8X\*](FVN3YK-)2
MX.]XPVKG%.BF0LJCNJ1P#S4F-CZ#.R6AF3$R$^%2!&F?DV-M,H \598NPG?4
MJ/*A8VPROOP.2:=Q9SDT<5(2?&DVLL@T=0^GSJ4/:'VG$XR34HEG'705'%!I
MD1P.JV+2E(]X8_,8I)XXY<;A+V6:?4Y-/GCEQKIH&)VEC<;:K/>-!#ZN]+6
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MD.%2RKUJ-$&.]/K^="@\ !@5N.3V-*."1CK08T3K:\>[@8H#59)3THH"(TA
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MJ+'=0-QL\_)/C%<_RU+1!+MFNJEA!M$_&=Q_HKG/E]FC:)3$_5EW_P!BSO\
)X[O^6A:)3/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>cogo_0071.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0071.gif
M1TE&.#EAL0"P /<   8#!1@)!P8+&!02%R<4"R@8%# 8#CDD&"@@' H6*14:
M* P<,A(>- ,-(14C.AHE/!<C-Q@A,# K+R$>(T<I&%(P&D8L)$LS)E<Y*%D\
M,THW-&0]*60\-E(J%%Q!+5Q#-4U"/V9#+&-$,VM,.VA(-W--.W5+-VY1/712
M/7M4/'5&+1TJ0QPG01\Q0R$M12LU2CQ&6#].9%%)2VE,0W9,0VI31W140WM5
M0WQ:17Q<2W9727!:5'QC5GMA4$A29G1K;U]?:D,_2(56/8-<3(9;1X9<4I-:
M3(1B38QD3(IC2)5G3(1D4XMD4XQJ5(IJ6I1L5)-M6YEJ5IQT7)AR69%Q6*1L
M5Z-T7*1Z7*IX6K=Y6Z=J3YUZ9)IV9(YS;:1\8ZM]8Z=Y9[9[9JQV;:):3\5\
M;<)]7H4_09F#>9B!<ZR!9*R$;*>$:[*$9+.%:[2*;+N,;+J%::F(=;2,<[N,
M<[>'=;R2=+N3>K>4>K:1=+"!7L:(:L62;L>+==2,><>7>=>7>=6.;..<=^6.
M=-&B?>>B?,6!7EUUC61YCF5VBV9\DFE]E&-WDG)ZB(=\A<M_@FR"EW6,G'F.
MG7.$F7J1GG>0GWN"BGR4HWZ6J7Z9JW:4IW61J'ZCMI&/DZF6B+B9A:R6D;BE
MF;&BE(&6I8&9JX69J).;JZ>=J)BFK(.DM(JELXRIMH.FN86INXVKNHFFN)JG
MLY2IM)RJMI.NNIRMNI2FLY6PO9NQO9ZQM(BBKJ>GJ;:JIJ&NO*>JM:*QO:JS
MN[>TNK6MM)N@FL>:A=>:A<Z5C>.=B,FDB-BEB<JGEMFGE]BSF-*QEN2DB^FH
MB>2LF^BKE>JSFO.TEO*MD=2QJ>6SH^FXJ.B]LNZTI>F?H>S"MO+$M-;!N(NM
MP9.QP9VTP9VXR)"PQ:.UPJ.YQ:6\RJJ^RZNVQK6YQ[6\U:NTSJS!SJ;!SK3#
MS:W#T:C#U;;#U[O(Y+S5YY_ TLS)U>K3T,3,Y<K5ZM7<[-7>\=G?\<[;\-KA
M[=GB\M/H]NCI\>W?X<N]QR'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     +$ L   "/X 7[V*);"@P%FO> V,Q;!A+%X/8^UB.)'@
MK%VO=FG4..LB+V\;T6W<.,N;P&X")U:,=0O6K5FP8-6*V;(A1($$8[ZJ>8LE
M2UBV8L5D"/0GS)BP7B%%&K26K:>V>HF3ZDN<N*KALDZUZNVIMZY?O3KU=NOI
M+:=/:ZE5VTJ5*H(%:1E\A1!A1(*W5E)LJ#'C2(TB=X7C%6YC89$@.R:LN[!B
M39@S80EU"/<4+,M(&9XZU5-RP\Y$)2==NO1H4*B]GFZ=&LY7UG"]I$H5YQ6L
M[:^XO3E5>[96J]]N<<(M6'&6S81\&?:4V#"CW[_H9G4KK-$;KXV\.DJ'VTWO
M+<PQ-_XOE#S^LOE3JEZI&CU4-.CV,5/%5XI4EF1;9WMU#;>UUVO^KE7EC3C>
M?"/54]]\8TMNN-4"%EIJR:)*6^D-9!!<QBT&T4H0W>507W_M$M@NO(@4CG4@
M;622=0D5U!QE0K5D62R6U4C+9:]L=EF-FSF467L$"04>9CW9@A947<DF3E98
MG=C?5K8H2!N!#'[E(%EIU6*?6^FQB))=R7FXET6O>&-<+(I=-])%@'T4(DD=
MW;100SMN9N>=.IY"RYYRV2E0+@F=(E1F@@K$'GWAQ323++>4I9HM5E4EU7^O
M]>++4^ID"A5M45H%:97=>-.-6A.ZM0E& BE$UYAH,O<01/X;MLA<=GZQ.=)@
M*+ZI'9AP$56HH$M9MEXJJFQ&B[%[)E60H*<4=*BR.9$V5$=0(3G;.%.YII6V
MMJ@36U2]?#.E@E%^,\Y75.)VRV^PN(6+*GVQV-&'%*F4W$VT[GK1+&H6!A**
M:I8Y4D;STL+0A3G5J HNP<*"RYW'/MSL931B-JAH]"&*%'U&5AO5@)!:-1N3
MK67E[2W?>*L.I.**LS)7XGQ3I3? J9)**KB,])6;(_72\RZ]W!+;+CL7_5=A
MAR6=E3?HF"A8=;O"2!E2P%[&2RY8GY*+G3M232.A%GLFF:-HO526HZFEY@V
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MX8<][.$-6D5""#9^ Q)D  ,4L  &1'"!OI<\ QG@  ELD(,E<&$+4.B!#G2
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M =<W C8P A>0 1^@;#I0!#K0 S*'7#U@?C70 SV !$WP>#SP?D^P54NP SS
M"6<A'V=G%>9"2$2G79%V=.M 8]?%'S$$/XD%/ZNC:0F8@.G%)>_B'+.')OL2
M$8@C-1,A1@=W<#T11?SE,X7!+UWA@;HP#<N@#,I @L;@!W[P!42  [55 AO
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MXHKZ]#!-B4+(A(8AQI2AK!HT%2KH36J4H<899YY1\!A"O,6S#SWU(!="+*I
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MQ48G;8X'U]855FS,I7^$J36C9PF:3@(392'%\UP5#&/TU)'B/&<=X,"]\:G
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M9Y"&82 #+IJJ3VB$1N@"69V!JE(WT9L&0JO2XB*$/\DW(ZC)6OV'?P""(-"
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M:F"Q%E,NNXV&8GAM?>8 (LB"/G &XCHB TD0%NLY.*"NW2NJ#<"Y "" M@:
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MI ,D?.$)5*M9!_G@'>U8B73$H($%.#"M+B06>.JJH<QUEX$<6F#;[K' $,3
M!2Z(86TW2 $3]1H]"G![ %WY@+K3L 8^,[TC@CY!U 7-]#6XA;8@QMO63>QU
M>X>]J<+=-SK-/@I<T-C3.-;$)B;6B+F_034ODJY&W" %*8A!#FJ0@S&$<:LM
M@ $,4L"!#B0HA3?4[..*)\0@CG&,<<GD&5#@0!7<VPA/? (9CN@"%,A0#]#
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MY4T-,?@!';R*%20!FK&4"<"4!V2@(7K 5*9 'GC@5=ZC"H0 ;J[!GH!@&O0
M^5BB6>Z')N+-+1RD*K E+;B"*Z0"=*:"*J "*UBG_4PDCAF<P56&5TU"'*P!
M=5G.%;Q!:?S1&LA!') D'IR/'<0!&%"A%.3 !]C 8WV!UNS!'\#D'_C!,8@A
M-!Q%,3SC-#H"E6"#(#A"@B*;&*C<LY09Z:EF&\R!&#P!$;!4ZH6 "%R .P;
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MF*07X!P>@$$/-&*[ZS0%7$ )W(#M#($.% $6V,S\SF^G0^L?&(]XY6_^*OD
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M[O-!M)AQ$0P!#:C99GT !SBQP:=2VT/1PU,1 G % L1[3Q]J;\JC5=SNU&*
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M:* 1Z#!%*:S[ QV<X A2R(,7E+#=)[CQ2RD(052LQM=<HV#7>BTY>]P[B&.
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MJO@0PV2@$4JA%$SA!R;  HH@@*( #,(@$?D@$8'/!(>/Q,:I@!PMTJ)O'W.
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M#HQA&92A&8S!& 8B&KGH(*# ((Z$BCQH!GB@$4R!%\Z!'NCA'49A![I !HI
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M'R&G#4$\-;H+G"HD!T$9H$&Q\+@'G(!DEKF0$9 3Y$$>L#JKZV&PZ<$4@B
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MT@^'[=!$8 ^F.:?";B:@ /,++ #O?&>WH+8#+*"S20P.N.555_3U*7>"64'
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MQL>.>5S5^(74O/?(9\?.\0]'B$&USZ!&,LJ=,OF>.G3/B(8S1%U:TF C&M'
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9X(9NZ(5F& .RJ(9M*(:-@HLP](9J&!  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>cogo_0044.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0044.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M@+4JUA%JF[T5K8X''NWB!.\&E!N6XA&:4,$FQX0GII&A7',"C;%R?!)R4\@
MMYK"&CP\&7?I=W(VG'5N+*DZ#O:(2AB1.A8C@!^(O$1G!2J52)*1%5Q'7YQJ
M0H]+0Y8O.N*"0I9_*V"=3N>D UNOCIZG!++?HT]!TRS4W1L?$4#N-,/5[AMB
M^:<4E,S+H<*)MMI)"$.@_>9;ZY,U[7UM:/%M2U;.2]Y/=]+'L50:Y31-TVMT
MM"F*E+S:5R[R0%$G5!Z@QF2B_!IUV1?(8*D&)N65,@^!2004ZF(17);>&AH,
M$8)#1F'\/MS<VN]W'%JU]0#:+D;)>,@G7!\[12F8?IR$E-*E3+.,GQ-I4;*'
MI$X\M\@;(I8#R7EF9?#J)>9;\4V>6S;3*8M5XA#DS;GOM^/@WQ!+/T25H-'0
MZI:7@Y,/$FV8A0";_P XZ;H="A7*3\G'?4FIG.RNKPL/^0VHFLF@G8#2-B.6
M^3G,+G!)@"UX*1/E.*;&FMX=RX$ER0=?63+DZ;&(1?(UG@KJ8=5S%&PWBTI8
M*FS/(@F8NK*JT:.DD9^KKX)V@Y>>DI]8/>O+ 41]!?F,4\%W:44)-:S=)T$4
MHUMKDO2MVO!JIG)H3$=NU\A(SW(T:6E+F\6*Y)2 61R2;2@O<1M02G!,S9PD
MI?@W+R4BQ-CTB+NE7P34%+P?2RB"IRUTCQ*439*4][P"-\G+R//3I0?&2HN+
MOM/8;P5++HV"WI:M5Q5TEU*LTK*]R5#\10[#3N8#J^J1J6VOF1+IW1IWRWV\
M1^QS1@3'$S6^/V :SB*J//NOXFDUS$TM5[%3@L0/R@:6 T CGW.5EBE-\G6J
MF-5>VM<'I5[06#T,8M<GUC-+UMOGH5;PAQ/A<1_14<-U:C]-<Y)<,[CHUZU>
MEC"7F/\ !RQC'"U8PM,E^GE2I*:/ATN/I%"J<;5SY+]E4J7QX9/X+XSF@R**
M/7J<XH)&5+R4W&7S[1)Z=3YB2AJ7#XS"!SB7270MV4659C<)28=4-!/U>/ 1
MX5Q([4ZDS-RLBY8 !8(T4?.%VMK(RO<EDM:2E>8XU6:QRFRR;2TJI?A!.ZS_
M (;0;*:Q(HMO.8 .[Q(IV,>/-2X6T^;9FUT;#3%0"D$$)?YBBXW?R01'3])M
MEE?9G+_45$9P_P"Z)<5&;R2C;5] D$>L=+*I^O)Q]<N,/U_))!&EC$>W,(I1
M]GRV@1M Y1DER$^)"5UH>[G3H8'#.>2-JXX*UFT .+T\XLE6/!'^'FF\7]++
M#*]\4UR$6'39P$1?U#6S**U,$F&<9FYEK".=$8N8:%E&W2!PN6 LZ6V,IC%\
MLI2LJH%.:DPU=;BALQBIA;AR@6&I/:!J>)!' 9UCC?@/"Z5?:M>9*TC1EC[U
M9/:R;V^<:E>OKIKQ)\E:6BNNE\?!5.+?;+D);.C"F& XH7 F*B]MYAM'_4Q0
MOZFY?L1=IZ4H+,V4OB_VB,=XV:,O6,0K1)K5E]VE4AENV]K)U(]8H3U%EGEF
MC5IJZEPBLZC7W)Q\-M6"-@1IO PZXX0[H%9%)Q7AZK+6$B1JDH^I2MDI2ZFY
M]+0MW*8WK![KXHPXWQ/X;RR*>\ER?EDHFJ:\/A<<M\-^RTZ>I!Z1G=7TBU%;
M2_R7^BZMZ*:D_'@YYG:.F>IBF)N74G+=*FE)\39!L4D="#>."V.J31Z'&2OC
MN]%95C!TB0XR6U%!)N+;'S@L+9>BO*I>&#0P*W(/!QAY>51OKTBPK9, Z4O!
M:F#Z[+8;DN2HA0 "E$[1%3R^1Y5YCA -QIX_S,E*.2M,4.<M/+0+WMZ1=JIW
M\LJSEVEP"W[.NC3>*?:,Q56ZQS7[T4\U8)!S.N9+ ]-";>D=-HHJ-;:_M.:Z
MA/=/#]EA82]LAKAQC:M<*>-%/=OA^J35+37)5O,K(VX0CGLC4FUO&GOJ(V:]
M0W',_L<[=H<-N!TO@[B1@+'\LW-8-QA2JNE5ONY:;05CU0?$">Q$6JYI^RE.
MF4/*"*8<+)4DI%@;:$W![&\3EB2P#64R%K+H7*K)UTBIC#"OE%:SI^^4!!%X
M -88P=2 H*MO%NAX97N\!#AHI6NP&T7+)9C@K5^0QRGO%3!8R<.UO%E I(6F
M>J[*5C=#:\RA\A&<Y)>S;C2Y%=USC?1Y(K1399Q]0V4\H)'S @;L7H,M*53B
MGC35:DI8-0<2T=F6U%"1\AK W8V'C6H^2MI_%TY-9PE13F)-RJ(^?))_@BC-
MS,QHZNX[@P^!C<N@*#3:KY4W.L1$9;<R:6A"%'E*F&BA)L<M@89B\,]S?8PQ
MTUCO@-@ZM-J(6JD,LN)S;.-?=+'U2#$KG&44V-'*DTB5XR8+=I\RK%\C+Y96
M;-I]"4_AN[!S3HH;^D<IU?0K=WJUP=;T3J$G'LW/DH7$TL&WBM+@63J2!:__
M &CFU)*7!U::FL(''F7YA&;D V$$>6P48KE,@ZLB80@E()*4FZ!TBQ7AO# 2
M2P\%)8MH#]9J3DP$FR4G7H#&M4U%&5<L\L[,]@KA0,'8;JN+9E)]ZKJFW-$Z
MI:2/"/GJ8Z330=6F3?F7_P"'*ZR4;=1_XG&7[1##;^#?:OQ%,I2$,8DDI.M,
MA.FJV^6O_F;/U@]7R6'Z*TDL91SC)8GFJ/.HFY29>EGDJN'V7%-K'HI)!B:^
M+!O\G2_"+VX>(6#6&Z7B:<.+J;H F?F%"9:3V;=].B@8L0NE'SR LT\9^.#J
MC!?M1<*N)TJF7IU?%*J3@M]GU'[IPJ[)7\"_D1>'RI<IE.>FFA]-U1 ?45@Z
MZWMH8+6\\E6RMQ8W<JC-H.G'T5I)A/@Z>:6X-H+&:\#. ?<YKN(GOB1P>)\]
MC.8?)4A3BDN7.]]8P>3JEA S-U.;F5+45+&8Z"\(?>QD6W7+$@D^MX7@6<F
MU;10UAT(R&P=!"&-76$(L4H*%;YA_P#K1$<4;+@2"O4'0'J83$AT560+:GJ!
M#(=X._/8>]H'$>&.!T_@+"-&GZC7I*KN-MNMLE;5.E9BR@^LC;Q9@!WB6-RQ
M@%/A[LG8V",*<0GE-UO$/$NK3<PXG-,R,Q9;;K=K%"DG2Q'3I!955..R2X Q
MNMSN3Y!3$%$I%9D9VLX1Q!3ZU39-];;WN;H=<DU ^)M8'[ITO'#]0Z4ZY.RE
M9C]T=YTOK2E%57?&7Y]@FU0W'LJ9=[PN;:;QD\I<HW$DY93(_$6&':=(NS*U
M9W%(*4Z;1*OEIX)9S!HA,+\%:[7:"]/EAN58>25N3DU=#;:+ZJTU5\A&YI]%
M;?\ +PCGM5KZ-/F+^3^R&/%#BS7)6I43"O#K$D_+X?PXXP)ER44IG[1>!"22
M!J4 7RCKN8Z.=O=<8KQ$Y+9MS9+S(Y<]M?B53<9\2*)0).?<J,_A20=DJE.E
MW. ZXYG$N%?FY8T/F2.D6,K.$"QE)G/,^\]RLIMD)N2-_E$LCFDG-S#+A-@-
MK([#_&%G[B3)Z5KY:2%*3H#K:]XDF/Y#["O&W&6''F33L2SJ6V2/N5NE;2QV
M*5$Z02,\< YU1GY+\PI[35!K:$,XFE#37E6'/8NMB_=0^)/RN((I+[X*5FE?
M]IT'PZKDK4V45"D5!B<EE_"\RL*2?IM\XEN:Y*DJFN&BR?M97[W\H7=_)#M'
MBI+_ (00OIM%%F^?*;'6&$:%(Z*M"$8Y9.HUAQ&0E*?7K#B/FTMJ)NDJ(WO#
M"-%:N G07T$(0JDC,.L,([!_9@XAEJ9[1$QAJ<F%MHK]#>0T =%.LJ"Q<;?#
M?I$H2QX(S2:Y/5NIX.$VD3=.G%L.7"BE'PWMJ==SWZ$0/N-MIA>TE'**OP5P
M-P_PUQ/B*MT1D21Q"IMR:0I)5+!2"3X$CX023<&'K4*LJ2RF0LWV--/#0G.8
M7E*;B)V4"^=*+LZQ,!-FP5;IOL+'O'']0TDZ;W."S%G:=-UL;M.E-XDB2<P-
M*U>IR<H]*>\2H=;4ZE&N9.;77L!O =+4K+4X^"SJ;Y5523\^B4XBT^HU:0F\
M 8)0@)4 )Y]LY TW?1L'8FVACM(04ZU"/!PCGML<Y\LI&J^S,_3,'5IQY]MN
M=?;LRL#Q(5F&H\P!!J].N2M;>W@\I\=X:?PEQ(Q5A>8<#JZ;5IADJUU\5\US
MU-X2BHMH*GN29#OHT%AZPA#13*@O,@"W8](8="K+B5E3842H6TA(D*G);,%$
M+':)C,=R-4F)9P)4HJ%[[Q)"186!.*&)L$5%-9PU6)F1F&]3D4<CMORK3LI,
M)MQ7!"4%+R79_GZ\1_\ T_0/_HO_ !B&Y@/TT3CEL6&L#9:-[:&XA8R(0<(!
M![Z0L",MJ!2?*%@0@M2BHD;1(0I++ 40?S#2&P(V<L;E(,(1EHBWG#"+:]ES
M%Z\!^T+P^Q0'^4EBML,/*O8%IX\M0/R5#Q>&-)*2PSWG2%HNG*FR?"G+MH8#
MCDFF]JP9<;2ZD!>A&_4'Y0\7*.6AW%37(QFJ+)STXVZ$A*DC*0E(U'_N':%E
MJ+4EY$GB:<7P@=Q75FL'4R9EJ?K4)Y2VY4-I!#2%;$GZQ5T6@A1/=$L:WJ-E
MT-LQS@2DN4VB)#R5%]Y06\M6ZR==>\:%KQP4:N5N?D<8N88>I;C#@2HJ'\[P
M]4ON*Z,6L(\5?;-H0PU[4F.94-A")I^7G4@=0XRDW^MX>>-[:(PRHHIMT7O$
M28@I%TF\,QT,)2Z9MP _N_TAT/DD"+:D=8F,:FZ%I/0PA#\.EN76H*_(3\X7
M@CAY&7O3_P#M4?2(<?<?D10$JL"(B2,K1N+[0Z$-'DV%K](0A$+*;@0XC 58
M;7^<(1M?*I*@-H0AYD38'0WB(C4-^*X-H0A[)S3M.?:J#"K/2CB'VR-\R%!0
MM](2&?!^A#ACB9C&6 ,.XIEUEUNITJ5F@Y?XBMI)5_.\*SACU<K 1O'2X$,A
M^1K//KDY"<FF90S3S<NIQI@+"2ZL E* 3H+D6UT@5G@G5C/)5?"REXUQ+297
M%?$Y"?M";6I;<L6@VIMLJ)0DH&B2!8'O:_6"4RQ6FP.HCNM:7@MY+0;82D
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,_P"#<_3"X^XL'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>cogo_0049.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0049.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MK.#&JYYYE922KUB"W3-6<2:K4+8(K+33KBKJ48FHIWG!E?4W;!D0QN%.RY4
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M3)[SERK$1-MS,2A,#L\XDQ0#F$9!I2'4J6-+Q<TI*-F#=<HM0@PTI2%H"M+
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MTB#TI8]8RLP$IL0><"JS@PY:,B%I)E*VU7/*#%>&6!V!1\P?,)0ETHS<X:N
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M.:QG-84=53*\TLM)(")@#ATOX0,%/K>Y>(5:PT</+"P3M)HM32EIJ=0IT6!
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MR,202TB6)-MCCH+F*K@'+&6JB5PHF:,0/&>QM4YX$6<J#C:/ZK=A^L%4!KI
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MA!L&1++P17ZCB;#DIAEFI*8ETM!U](Z:DV/D(\QZWHS^.:U%^XC$]"Z5J?\
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%1N#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>cogo_0062.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0062.gif
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M^.;P]_3S\_+W^_3X^_____KT^O#O[P
M
M
M
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MA3WB0A/#$-("P</@LF4KJ/@P8)KM0>'#9;&P:E8L.+RP$Q*DOO#**R_,<))
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M!9   ! 'H7  !V !"   ;>!JP5B1,8F(>$B7HVF+A*B/"_B1\$B:ZFB:KKF
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M"I(@!5,@":MP" F+KV00!#^@!MC+!HPP!6+ "$'0ODZ0".<I!FHL!9)0"E.
MLA^9!?Y1X+)(!@12L BP\ <A4[N($ 4Y@ 1GH)I<*P5>@ A(  1?8 I8  1(
MD CAF[$Y$ 1EH J2H 2/U02'4#);< 8_$ 1PVWML@ 0Z  6#(*RFX 5   1J
M0"7=>PE;$ 1 4 6,L J6 #1HP J\' 0]( 50C'9;L,I_< 52, A]+ FI@ DR
M;,<B^(?M.&\MO+I08 H)DB QH#*2,"PR4 -H,+LM\ ,O @6V8"DW$ ,L@ 9
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M$&O!#:)@"56YS[,).V4I_:7=]W5V=2YL5V259S=EQ45::M )*K EK=4N%"[
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M;@J<7V0012X%B56!"4 TB;*F,/[[8S#QGI1):D2EZ,I&<+YR0%B]-?VKD"6
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M$Q )&5G:&9R"8&1!M4UTU4[.]7A*JG4!&07B$XJ$+P"!"Q3"V:.]K5/%E,1
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M?$^D??@G\&"  [!;#@%P0R/D@/Z" G"@#GJ0@P X@ <\W*$3H4  !?*0!P\
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M>,UX1 \ Y* .!, #_FX8Q,T#AZ$.L.\.Y$ .@,'H'L "(OY@YW 0 .(@#P;
M$3VP PP %#Y! +(O!WV+! A@ BA  1"@X8;P#>Y@#AI.^P3 #1#@ ZY0 21
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MX.".\ $>@!8(;@(L  ,@@ ^., ((@ %JX0H/  *$D PO$P+Z8#0+0 !N$@(
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M%K9 "G9A#,I@/TZH.D D!_KI2"+C#*3 %EBAA<9I/NAR%_Z@"FP!"0AI))3
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MXWJJ@!4P(4E:@RPQ(0FD8%6F)0NX2T&F("."=56UPE7)4CWAPU;9!$JLU@F
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MCP$YF_]$D(TVHC"!#0+ID5)!$KS 2<ZC% ;A-3#A$((')<2 ;^&CEUGC#]C
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MTB>=TDG,<26/L5O\JPM[U$&]TX.=M@-=SEW\SY][O;<7M(4C%F9@T9L]!UY
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M@^?A%[,T-=E12(2A@@AQ')H2@\#Q6%NP>V60!"(Q9"X(>R=(1AL1@J?U@T"
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M 08%C_ZB"H* *$. !E_ !F=0 S$BAL5TJE$+4TOP!8JPG!P%A67P!0^'!F7
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MG50*)TA!#%<@$V02<\+%06F ,_/SH:7G:$2;@KJ8\*!A2I'C1M=9FT810Q:
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M+#C6*)'Q0UBAZLFM+0 .=8%"MV"$S:AR_,JK.CT$CL $--@"-/B8(@,#S:)
M4R#SPB:41;!R"ZD>O<GS(+D$-E!R86&$JW+.)/^#7JV35+ $M\$C]K8+#P@
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M7CKF*4JI!B09"@N[N,(7;B'&)BP"");82B7^ R,V^>^"ZJH"&J: !KFPHI1
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MXSW6(93"#QR"):!!#^09B%6"]U0,W@Q"$ZS"]K#!&1C8#$B!R;CD>PE)!<W
M%KA+*?2 *92!%$B"):17QGA!)2B"#BB"+CG1&%A!QF1!8/X4*TS!%E@"(_3
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MS<(L4U%]<4,([L*Y"Q!<T X,[&'^@")80@R<(==8,9E8 D-L@9E*01HX$19
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M'9TEA$KQR9S $.Y+%:#@$!(!2)P#$90 8Q2A1 H"(E;A#*[ %L9#":1 $7/
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MW0Q"HW1KT7?_BI9DN79]O=9_VY=] 19_2RYHY]?4@-?5?G-N:5;6]&XR+E9
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0H ,:G3E9H N:GF$A(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>x_coverback.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverback.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
M'@    <! 0$!              $" P0%!@<("0K_Q !E$  ! P,# 08#!@,$
M!@4% A\! @,$  41!A(A,0<3(D%1810R<0@C0E*!D14SH19BL<$))$-3<M$7
M5(*2X1@E-%5CDZ+P\416<Y0U-K/2&29%5W6#E;*TM<(W.%AD971VA):C_\0
M' $  P$! 0$! 0            $" P0%!@<(_\0 0!$  @(!!  % @,&!@$#
M! $%  $"$0,$$B$Q!1,B05$R8084<2-"@9&Q\!4SH<'1X5(D-&(')4/Q%C53
M<I*"_]H # ,!  (1 Q$ /P#T[7W9\.'UH , BFD2V*33&A5 P8)H &#0 H=*
M !0 * !0 * !0 *  >E F(/-!(6#0 ,&@ NE  P: #P: !@T )R*+'0K!H$
M T *H %  H %  H %  H ,))Y%.@'4#"0#4OLI"J0P4 "@ 4  =:$ JJ %
MH %)C0*10* !0 H))'%9R[*01&.*D P@GF@!-  K8D5L50 :4D')H 4H9&!0
M C8J@ ;%4 *2",YH ,J ZTT2P @\BF(.@!)4 <4 &#GFLWV 6\4@%5J * !0
M * !0 *F0 J !0 ,$T "@ 8-  P: %"@ 4 "@ 4 "@ 4 "@J/82J3+ FA '3
M %  H %  H 5L- K#"%9% 6.U @4 "@ 4 'C-  P: !@T &.* #H %  H %
M H %  H %   ).!0-"MBJ!@V*H 4D$=: #H % !X-  P: '!4FH= P4  #/%
M "DI(.30 N@#&]:Z#D# Q32);#IB%)&<T%(5M- PP,46 *5@"BP!18"MA]J+
M &P^U%@#8?:BP!L/M18 *2!FBP$GD46#""">F*+)H5W2O446%!%!'7%%A0@I
M)HL*#"3BBPH/::84#:: H3W8H"A6TT!05 @4 "E8 HL 46 823THL ]A]J+
M ;4?,4QT+2@@8XIIA0H<"I?92#I '@TZ &TT4 -IHH 8-"0!TP!0 *5CH.DV
M-( 23T-3N15 *<=31N04#]:-R"A25 #%0W;&A).3FD H+ &.: $T *""#GBM
M-R%0NC<@H%4(% @B<#)IT%A;Q2? 6&"#TI6%A*23TJHB;L('9P:8@]X]Z $$
MY.: %!0 Q4.+ 31M8#M/<@!1N0 HW( 4;D *-R %)NP!4@"@ P<4  C/- !C
M@4 "@ 4 "@ 4 "@K:P4!M8* VL% TJ"(S290 ,4( Z8 H % "PVHC(Q2L+!W
M2O:BPL7M-%DAX-%@'4@"@ 4 "@!2: #H %  H %  H %  H %  H %  H'0I
M'S4 D+H&"@ 4 &!F@ ;30 H).*+*2;#VFE8;6*I%@H&"@ T_,* '* !0!C@G
MGK72D<38K;[TQ V^] "D#&:"D*H&"DP!2 % "@C(SF@!= !T "@ 4 $H9&*
M$[#ZT &E.WSH 50 E2=WG0 6P^M  V'UH &P^M4@!L/K0 -A]: !L/K0 C8?
M6G1 -A]:&N "*,#.:@ J !0 I'4T +H 4GI312#IC!4L 4 *'2J %  H %
MH %)C0*10?E42&@TJVU P_GY'&* !L/K0 -A]: !L/K0 -A]: !L/K0 N@ 4
MUV *U)!30F$H9&*9(G8?6ID :4[:@!57$!M?6J 30 * !0 * 'JR %  H %
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M*SEV4@5( H %  H %,'T"J,@4X]@"M !4R %0 * !0 *TCT *8 K-]@"D *
M!0 * !0 * !0  ,T 'M% !@8H %  H ,T&BZ"H&"@ 4 "@ 4 "@!;8W&DQ,7
ML'K4B!L'K0 :4[: #H % "@* !M%  VB@ 8H .@ 4 "@ 4 "@ 4#0*!@H %
M"@C(SF@ ]@]: %4 "@ ZD ]HH &T4 &E(S05'L5M%.S0&P&BQ58 @#TI6%!X
MQ0/H%  H %  H 7L'K0  @ YS0 H=:3 74E H R-=EG$"E8 H %  H 4%$<"
M@!:3D9H .@=@H"P4% H % J .32!(/:*5E4&$@FBPH/8FBQT'M HL5 VBBPH
M&T46% VBBPH(\&DY,*"I;F% *1FK)H%584"BPH!Z46*A-%B"ZTK &T4"H&T4
MTK"@;1104#:**"@;1104#I10PZ* /)HL Z8 H %#5AT"IV(K<P4FMO*!/=PQ
M21DX-3O96U"PD#I33W=B<4'3H5 H %,8*3286"EM0[!4/AC!2 %  H %.R=J
M!33Y$XT"KW,D%)NP!2 %  H %--H 4]S %2 * !0 * !0 * !0 * #30 =
MH %  H %)LK<T"E8;F*"0:+*L<[I/O18K!W2?>BPL'=)]Z+"P=TGWHL+#2@)
M.1186'2 %  H % "@G./>@#GSWV@^Q"-J!>E'^U+3Z+PW,_ARH*GU=\)6_N^
MZQM^;?X<>M8?FL"ELWJ^CH_)YW'?L==G0B""01@@X-;G."@= H"@4"!0"!0.
M@4!0* H% ZH% "DI!&: #V#WH 4!@8H %  I6 =%@'@4@#H , 8H+2L5@ 9%
M2F5M2Y!5#!0%T"@=@H$"@!00",\T 'L'O0 -@]Z %4@%;12L= P*+"@Z0P4
M9&NLX@4 "@ 4 *2D$<T *V)H ,  8% !T "@ 4%@H % !I^84F"%X%24'@"@
M 4 "@ 4 "@ 4 )/6I8!4@#/6M20J8 - "<F@0*"04 "@ 4T *8 H %  H %
M J0!DT[ 53 %  H %3/HJ/88)'(K$L6E1)YJXB8JK$"@ 4 "@ 4 "LGV4"D
M* !0 * !30I= JC,%  H %  H %  H %  H %  H %  H %  H &<4 &#F@
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M4<48??\ HC;733&[_23VZ1W?@7;6[T>/-%M6WG_O)%;RA_\ <D_M?^AC&?\
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M,[-+[9KIHW7$ D/6"\A'>.@#<5,/()0\-OB&,$I\0!&34X=7#)-XI+;+X?\
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MT^E6I>U22?\ $H__ "DK^QI*'V@3?L\:[.F9D)NXBX0),"<6XJT[PZMEMWO
M-IR>.//%1^;DHJ;QNN_9E_DX[O+617_%'0^S/M1T/VO:8;U=H&])N%O6LLN
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M8I, #K20!X'I1+@ ;<]*BP!L-  V&@ 8QP:=@# ]*+ &!Z5:0 I@"L@!0 *
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M@ Z !0 *E]FD>@4A@I@"@ 4@!0 * !0 ,GUI@#)]: !D^M  I "@ 4P!D^M
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M7 MYU/JA)0A 5T*MV/E->?X1A:W97UTCT?&,Z>W$N^V>WZ]H\,% '+=,$?\
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M% 4QT4"H.@ 4 "@ 4 "@ 4 "@ 4 "@ 5+-(] I#!@^E  P?2@ 8/I0 ,'TH
M&#Z4 #!]* #2#GI30!J'M38"<'TJ0!@^E  P?2@ 8/I0 ,'TH 4.E4@!3 %
M"1UJ0%50 H /!]#0 -I/D:78 V$>5' !I!]*3$P\'TI"'$=* #H %!0>#Z4
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MHJOT_P"S3=L'89IKMOA-VC66I-4LVA!0X;7;;@B/%<=0HE+JTEI2E+&[ RK
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M=#B> * H/!I6BJ%TK0Z!M5Z5F4*0DA0XH =H$"@ 4 &FDRXBQ4V6*I@"@ 4
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M)!8=,D%  H 4FID7$/&:@L4.*I '3 %  H %  H % ![%>E.@ 4D<D4J *@
M4 $1F@35A;?>D+: C%-,B40J=BVB2#FF%4#!H &#0 ,&@ ;30  @9H 7A- !
M83Y4 "@ 4 "@ P">@I-6 -BO2B@!L5Z44 -BO2B@'!P!30 H %  H %  H %
M  H %  H %  H %  H %  H /!H &#0 ,&@ 8-  P: !@T #!H ,<4 '0 *
M!0 * !0 * !0  ,\"@!:4D')% "J !0 >,TF ,&D 8XH .@!0Z4&JZ#H&"@
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M9]J:(E38.[/H*9-!%M7EBFF2X@[I7M3L6UA;%4"!L50(&PT ) R<46 K8J@
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M '$C"0*AE+H50 * !0 * !2?0 K, 4 "@  9H /:: !M-  VF@ QP* !0 *
M!0 * # R<4 &4X&<T4 0&3B@!6P^M.@#2G;0D JF :>E!2#H&"@ 4 "@ 4 *
MP:D Z!H%!0* ,57H'F I-T"Y!Q4[AT&!GSHW%)!@8\Z-PZ!4MV-< I "@ 4
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ML*!W*?6BPH'<I]:+"A0&!CTJ'V G8/6D -@]: %4 "@ 4 "@ 4 "@ P,TTK
M/:** &T44 -HHH ;110 VBB@!M%% '3 74E!CDXH /8/6@ PG!SF@!5  J)
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M0#DU-CH/NAZFBPH'=#U-%A0.Z'J:+"A6P>]9[F, 0 <T;F JC<P!1N8 HW,
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M0 ,"F@!@50"5@ 4T)B*HD4GI4L Z0 H % "#UJ@!3 %02"FNP!6@ H %  H
M,#-)@ C%2P  #22 6D#%)C0>!0,&!0 * !0 #TH 1@55$@P** .F * #2 >M
M "MB: !L30 -B: !L30 XD8 %04@Z !0 *  .M9 *P* !@4 # H &!0 ,"@
M=* !0 * %A((S3H ]B:= *"$XHHL50 * !0 * !0 * !0 * !0 * !0 H 8H
M &!4EV%04'@4"L,<'(H%8942,&@ J !0 * !0 * %I2",F@ ]B: !L30 =
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M[1P.E @]B?RB@0G:GTK4 ;4^E  VI]* !M3Z4 #:GTH 2L #@4F BI &">E
M P1UH &!5(E]@P/2F(&!Z4 "@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "@!Q*00.* #V
MI]* !M3Z4 #:GTH &T>E !!&#F@!5*70!CK68!X'I0 2J  E(/6@:5A[$^U%
MCV@V)]J+#:#8GVHL-H.G H$.!*<=*H0526"@ 4 "@ 4 "@ 4 "@!2 ".130"
MP .E, 4 "I8"@!CI0 >!Z4 # ]* !@>E  Q0 * !0- H* "1T-  ))ZT +2
M1R* "42#@<4 * !&2* !M3Z4 #:GTH &U/I0 -J?2@ ]H'E0 * !0 * !0 "
M >HH   '2@ 4 "@ 4 &>M0:H*@ 4 "@ 4 "@#)8'I76>8# ]* !0 * !0 *
M!0 H=*#1=!T#'1TH&"@ 4 "@ 4 "@:#23GK2&*\JF0 J !3 =; *>E- *I@'
M0 H 8Z5)0*!ACJ/K4%#JP-IX%!*&V_G%!3'L#T%!(,#T%  P!T%  H %  H
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M  P/2@ 8'I0 ,#TI, 8'I2 &!Z4 8VNT\\%  H %  P?2@ \'T- P8/H: %
M''2@T70L-Y - Q73B@ 4  =: %T $>E !)ZT#0JD,'E4R %0 XUC;SZU2 73
M .@ 4 *'2I+#'6D _@>E2 * !B@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "D-=@
MJ30% !IZT *H )5 ": !0 *I$2[!3)!0 ,#TH %  /2FNP$UH0$1N&*E] !"
M"DYS4#%T""50 $T '0 * !0 * !0 * #'6@8J@H%  H %  H % "T=*: 53
M%  H %  H %  H %#''L%2: H %  H % "D]*")=AXH)!@^E #HZ"@ 4%@H
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MI0*Q>#4F89Z4@#H*!0 * !0 * !0 * !0 823R!0 73B@ 4 "@ PE7I0 Y0
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M  H ,=:3Z 568 H  &: #V^]  V^]  V^]  V^]  V^]  V^]  V^]  V^]
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M%DG&*+#:*HL-J!18;4"E=C2H% P4 "@ 4 "@!U/RBI9+#I"!0 * !0 * !0
M*&- I6.@46% HL*%H^6F@H50% H"@4!0* H% 4"@*!0% H"@4!0*!@H ,#-
M"@@'UJ7*@!L'O2W, ;![T;F -@]Z-S +:*-P![!ZFC<P%=T/4T;F7M!W0'F:
M-S8;0]@]:D-H-@]: V@",>= ;0$8H$U05!(1.* !N-  W&@ ;C0 -QH &XT
M#<: !DT %TH /<: ,V4<<9KK.6P@@D\T!8K8/>@+%(2$YQ0-"J!@H %  H %
M  P/2I-4N 8'I2'0= @]HH &WTH &T^=-$RZ!M%40&!B@ 4 "@ 4 'G% #@Y
M JD *DH% PZ #VB@ ;10 -HI,<>P;14F@8&* !0 * %)2",F@!6Q-  V)H /
MI0 * !0 ",\4 %L30 -B:  $@=* #(!ZT $ !TH !2#UH &Q-  V)H &Q-
MV)H ;H %  H %  H %  \J:)D"J(%)2#UH )0 /%  "B!@4 . Y&: &U?,:
M#WF@ ;U5!J *)X/G0 H) YH .@ 4 "@ 4 "@ 4 "@ 4 .I^45+)8=(0* !0
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MH"@;$^E 4'TXHL*% "@8>!2 + I6:;4'18;4"BPVH%*PI(% P4 "@!2 #U%
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MI0&U [M'I0&U [M'I0&U [M'I0&U![$^E PBE(!.* $4 "@ 4 $J@F0F@@%
M H %  H % !Y-.P"I "@ 4 "@"BP/2NLYPE 8Z4 )P/2@ 4 "@!2>E2RD.H^
M6A(8>!Z4Z &!Z44 *8 H +:GTI #:GTH / '04 "F " >M !;4^E( P .E
MI@"@ 4 * &* #H  ZT@!4FH* !0 * %( )YH 449Z"@ !&.HH , #I0 * !0
M * !0 * !0 * #3RKF@3%E(Z@=*F3I#BMSH(;7E9"]B1Z5BW9O&%"^[CXY>!
M-)9% J6+<,K<B-JVJ=&5=.:?YA$>0P9"!]VX2#363>)X]HMOE.33LG:*VCTI
MID27(-J?2G8J!M3Z5HA6-GK04%0 * !UZT # '04 "@!2 ">:!,7M3Z4"L&
M/*I8 P/2D(0OK5(I":8P4 "@!=00*P/2@ 8'I0 =  H %  H %  H %)E(6D
M IY%"&'M3Z4R6'0(6"<=:R+ * %8'I0 ,#TH &* !0 * "55Q 3@>E4 ,#TH
M &TGD46 -AHL 8H 760 /2@!-:@ =:3Z <2 3S4( U@ <"A@(I *307$6@ C
MD4%"MJ?2@ P,=* !0 * !0 * !0 .O6@!*@ .!0 B@ 4 & #U%-$R#VI]*9
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M0 * !0 * !0 * !0 * !0 XC&*I '@>E  P/2@ =T3SBB@!@>E, 8'I0 =
M'6DQKL54F@* %)H$PZ! H %2P!2 %, 4 "J %  /2@!(ZT%,502"@ E=*!H3
M0,%  H %  P/2@ 8'I0 T>M  H % !'I0)]":#,% %1BN@ )ZT *H )5 !8/
MI0 8Z4 '0 H=*SEV >#Z&D * !0 ,'T- !I!R.#0A,6OD53$AO!]#4E P?0T
M $H'T-5$ L'T-6 M P.: #H %  H 6 <=*DD&#Z4@!@^E24#!]* !@^E !CK
M0 K&>E  P?0T #!]#0 ,'T-  P?0T /-JPD U+7N4I^PV\I(SO4E/&>3CBEY
MJB4H.1G+GK[3%D.),K>0HIX4,9'D*Y\NNBN#HQ:"3=G/;SVPRY +EL2J/ R0
M%J&%'GRS7E9=7;/8PZ+:N3D^K>TU;,>2[\8R5NJP"XL#]<5Q?YO9W)48]?::
MV(6R7<D.J(P RR3D^F14REM6U&D533(K5[FW=AR0B<ZS'0,J+@*0/U-<<TK.
MI2;,W<]>IM:U1X;LFX.YQL;SL/ZCBG"/N/S/8IWM?:UF$ML0VH@/1(3@_J:U
M5$2<F5AG:K=DI,\]YR3E*^E5*22)BFWR+2EPJ+KBIC6,Y4E6#^GK6,IF\8#$
MK4<RVL!N*[-2/F()!*CZ\U6-[A9$5;?;A<[4L%OXEU39Y2LXKIC Y9'5>R_M
MPC:Q?1$EH<A2!D;?+ZBIR*B8XU)V=TT_K"3;);4AETDH( </ 4?K6FGU4L+L
MY]1IU-4=OTGVBV_4K"XKZ0U+2,*WG&Y0ZD9KW,.J4XIG@Y=(X29K CP!7E@=
M*ZXY$<LL5"<D=15&=!^+TH%0>*!!'I51[ 0OD53 )H$$Y%2P':D!MT$D8%4@
M"0,#FJ0#@Z5,NP#J0$'K6BZ %,!=9 "@  <T *H %  H %  H %  H %  H
M% #H(QU%6 ,CU%  R/44 #(/G0 =  H % !IJ67$52*"*-W)I.@L4D;1BD2P
MZ0 H 2>M:D!4 "I %  H -/6DQH54E H &">@H <1P*!H.@8*I$L%,!L@YZ&
MI +!]#0 G!]#5% '6@!6:DD'6D ,$=10 * !0 1ZU2&A-,8>* "H %  H %
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MD')%:(Q;%TR04 "@ 4 "@ 4 "@ 4 "@ 4 '@T %0 * #P:&- P:DH,#% !T
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M(95)'B3PN#Y1JSCIC!]*T4DV927 -N>M79F#8!18<B5(!QBBT GN_:BT I*
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M6%BJD0* !0 *"@ 9.* %;#[4 #8?:@ ;#[4 *2".M !T "@ \9H &TT #::
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MI,Z.TE1;#3KK()4M.,^(?BXY!/49\Q7'DE9U1A1J;1-N3!9@RY"782E)5%?
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M8*$7VP^Z3ZFJWBV+V!W0]31O%L"+8'F:-XG&@;![T;A;1I3?B/6K7(@N[^M
M@=W]: !W?UH &P>M  V#UH &P>M !%'I3  1GK0 >P>M"5B;H,# Q3H5L4!F
MI?!2Y#VBE8PP@'SHL0-@]:+%86WZTQ@V_6@ ;?K0 81D^=#&N101@YYI6/:*
M3D'I2;'0K<:FP%)YZTP% $#=CC.*F3HI0W%FEUN)#=>R?"G=CWKFE*YTSHC'
M;CM%!;KJJZ1W)9:"=JRD#GUQ7124;1RN4IRVM$S("5GS32;;5FBC%.K$W2Y7
M%JRJ>A02XM(P 0<']JS:3YL;R3QNDB-;9$Q^*R[)3W:W.J1T%=%)(R?+)E2^
M 4;#VBE9?E(&T46'EH&T46+8@8'K18G"@8'K3)V@P/6@-H,#UH#:$6PKG-!2
M07=#U- Z$EH9ZF@6YK@+NAZFF&]B^Z'J:0Z&J5CVH3L'O5[C.@P@ YH<N!J-
ML4.*BR]J#W>U&X-H-WM1N#:$3FFI":H(C-.R1)&*: (C-.P!G'%,I2H+=[44
M&X&P'GFIW$4#8/>C<%"=HJPH(IR,4FPH1W1]#4[A[4#NCZ&C<&U#&Q-;$ V)
MH &Q-  V)I,88 '2I % A0&10 -HH &T4 #:* !M%  VB@ ;10 -HH &!0 >
M!Z4 # ]* %(2#0 K8F@ ;$T #8F@ ;$T #8F@ ;$T +V 4%AB@!#A)\(H!!%
ME+K9:6DG>,#!QS6.HELA9OIU<SB&O];J?M\FUNX9$9PH<4G@J ]*^*\0U3<J
M/L/#]*DMQQ&.^[J2Y/S<%L(\#13QCR)'OBO)ER>_B:@K9N++:(ULA(:992&]
MIYQRHGJ3ZFB*M\D9)7T3@Y"A17)("4L1$%:AYJ5Y54FDZ,81;7)S_4>M?A(R
M"HN)EW/+<9&PJ0OVQY546F-P.+=H$Y_2<)28X2[>9>YV04*SW#7YE)Z@?2M8
MR665>Q+B\//N<1LR9FI52KS<67X\0/$=](/B=0GYBD>>?+TKMC'8<N27F\G2
M])0TJM%H>B1NZ:O+JF8R<>+!4<GZ[:SG/EKX+A"HI_)MM52&K4Y%84>^9D+
M;/Y$,H(VGVW5QUN9U7M1YNTK;G=9ZHD:CD-EU#DD1VDJ'RR.]VE8],)Z5]!:
MQ0/#_P QV>XHT)=I%N90O#4;N5N-_A(P <^=>)ESJ;;/:Q8:C1)[38C"]-R/
M&EM,2XL36G/- W *_3"C66#+<B<N%J)G^T31AU-H>]:1:C,A]<-V1$6>"LJ
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ME $ =:VL@/ HL ;?2BV -OK0 ,"D ,"@ Z !0 * !0 * !0 8Y(% "]B?2@
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MLI(5W6/,4K'P*"<#'6DV%(/ ]* I P/2@*06PG\5(7 ?=*]?Z5-CI#K,"42
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M6L&S;:5L.0N<R92D%)6<X(Q5QD1DC0^,U:,T)7U%,8B@ 4 -J!R>*"D%@^E
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MB:J"U/#.<6>W6>>E3+4MI2T_A"N17S?BFH\R1]3X5IGBB7"M/I1'1W:"03U
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M%"E;B\.[SZ8Z@?H<UVX72,,R;I%GV8Z09?OO>J2"U;2I+Z?S+XVY%1JLC4>
MT^-;K^!7:!<FC/N4W:E;DU[X5&!AS8D>(#Z4M)';!-AJI[FZ+2'HQYYJQ6A4
M9[;&B;_$,[5*&>36&7,E)NS?#B;2B;B46K6S;]*VAG>MPH?=+0R>["P"3CT-
M<VZ[FSJE';4(G5H4N-:+(W'CI&Y>Y@.>>_.<?3WKBE+>SK2VJCD?:?>''U-0
M5.*6HKVJ2GGA1_\ @%=VCA7+./52]B+II46TR$[L+>;1N*P,[4^GUKLGZE2.
M:/#-@W*=?9[Y1RMSYL^2:Y\O"IG5#Y97.+4X5);.">"?0>=3BBV7.2VD9$'^
M(SF;='&[*@ 1^+ZUT-[%;,5ZG2%:]F1XC+-@MI'=M*!=Q^?']:YX1WO<:9'M
MX%H2++I)V<YX5]RL-GSWJQ7%G6_)2-\;486<X@+2;TP^7.'BE2SZ8ZUW8^8T
M8.E(Z/V6I3?M(W^R2"7#$+SS((XQUZUSZFX33-M/ZH23.?PY/P;4AYY02>0!
M_A5N+<J)@^"HA0I%[GI[IO*W5[G7">$)K3)-8T2H.;+^4^&;A'@L.A984EE(
M'17'-+"FUN?N.;IT67Q=]MW^LQ$?%1%GA;C>\?0$5U**:HPDY+E%DF_Q!#0^
MR\NV35<E;.W!'H14.T^338J^&:K2>N1);;C71OOF-V0ZA6%G'GZ@^PXI<>QR
MS37+Z.R1XK-QM5S>;8;4^Y"<6IW;R^DISN1CZ $UA-U2'CYY.-]L5R>:^RM.
MA(>0B9.>:BMI6,A:M^XH_P"ZDUTZ)7JJ?PSFU<OV7!Y\T8_)#R+6Z.[AK8%P
M2K&X(VMX7M5T^7(/TKKRXUOM$8\GHI@L>IW)S*CN2VR\OP8Z)VCP']A@U;Q4
M8K+N.V=C4X_'Y02F(JYAA+F>-KC>2D>P(S^M>3JN&>GI^5]CVQV16T0[/,>9
M5O2VT@*(_"D'J/6O1\'W2MOY/'\6E&*4?DZ]8)27D*;4LK^&:6$J\R58Q7U:
MRQ5(^5V;;LN88&TE?50K235F2BQU#2D@#%06N"JU-;)4ZU/1VXZEJ<!V@#K2
M<XI475]$[3UG?A6F+'D-A*T!)(SG Q3WJB4FF70@M#G%9[RMK'=B$^(L@ <Y
M%+=?"%MKEAI+"^F?^Z:S;I[6:J2:M!DM-C=SQ[523;H3DD@)=0KIG]J;30E)
M2Z XI( W* R>,U*8Y(2I)2G<2,'WIVB=K8V'4D9Y ]Q2E*,>V@VR^!J5<(D*
M,Y+E.]VTU\RE#_X,USY]9ATV-YLC]*^.?Z&F'#///RX+DQUW[7]*VU"C'D.R
M%'IA("?ZU\9K?QKHLR\O1N3E]XM?U1]#@_#NL2W9$DOU1<:;U*WJW3R[E =(
M=.X-DCE!SCRX/2O:T7B635Z5[?K.'4Z/\MF2GT8J9:^UJXSWH@F;6D+(#FX(
M"AZ\<U\]GT_BF;(T^_U1ZV'+X?C@F^_T-3H?3.I]/1WFKI+COJ>45DJ6I1!-
M>]X7X?JL7.=T>9K]1@R_Y1/O&@K'>Y34V?#"W&NH!P%_6NC+X#I<SN2.>'B.
M?"JQLF0-+6>WI)B6J*PM)&U24[CCZGI71I_"M+I5Z8F>37Y\OUR+5"$)3XQ^
MU=^/TKTNT<S6_EH0[EP[0V"GUW5K23W)\BJ4O0UP!K8A90EM6X>QJ$VWRQ*,
M(\1[$F2&G"'@AM.,@E?^592U6/&VI,>W))U1 FZGL40AMV<%*/X4 JS^U>1J
MOQ)HM+]4O]ST-/X;J,JN,2DF:U@LG=%MSA/YMV!^U?/ZS\>8L2K!#=?ZJO\
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M7FDE#Y,[9YLXL&.W<EAI0Y0M9.*\?6ZR%N"/IO#_  ^:@LDF:* N3'0 T]O
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M['IKM(US>>SO3<*ZP;<U+1W@:6E?7IG.:^OS>(9-+BC1^?8=-CU6:29RV/\
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M";C*MKK2H3KR-N])W1U\\*]4J_>O3U&"X[D>1I=0][BSNF@=*L/K9N=Q6EQ
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ML/K5D'><"L)+.F:1G&N!*=/7&*>]@W)$A/EDYIJ4OWAMH:D7.[V]2OCK6A]
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MYL8K3-@PZM1=DO+/$_0B[A-=PPRP1GNTXSGVK[G28(X<45$\[,][<GV2JZC
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M#9/T%<[TZEPD=$<^WELP_:-H41K2)"$J0E*=P(XQ^M7BTS@PR:F,T<8Q</\
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MGSN&2F:JQ:@:N#:%%0\0W"IRZ?9T;8\UFD8F-E(\0&/*N5XSI4[)'?1]A4H
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MDO8[<A7(0/0$_M7[WIH[<,4^S\TFVYL76P@4 "@ 4 "@ 4 "@ 4 "@ 4 *H
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MDYQFK3MV76U4>@NQ)F,G3FLKG@[+)9WG&DI''CX ^N:\_7K=E@ON=FG=1DS
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MIT?B#)[=D-ZM\>.[!+[AWK)0[]V$YXY/.X>GG558D:!I+T>'\%;%I;?A-A*
MXX&PC:<X4KS.?*J&6%MCS;W"_M%<66XJ6UCOTNJ(WJ/F/5)Q32;Y!ES<;/(<
MC?'P(Z&D)2%*?2/YB"<8%:;&U:(W4):@662Q,M$AMSOV4!]0VD(3QXD[_P Q
MH\N^!;N29I]:'K?%AMSVF&K>V5I2I(*$ISD)"QR5>OO655P:(H^U%4JZ/L.N
M.RF0VTE"7EG>@[O3' 'K4WR*2LXW?)S;=IE--*84EE:6\%[Q9SRK;^*K;X(4
M&C 2W7E2E/,RE!UL!2%J1XDK!]?(8K"S8NTN_P 80S.4RA2U(^^\DA7ZU2Y
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MUSMDA'JH'.*J>M4^)(\R?X-U./F$DRP9U]HJY0^Y8G!M7JL8Q4QRP?N>?E\
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M<'&3Y&LK920I^S6G!"V$*< PAQ!'B]<C'%(JA+46*A#49ED?=@EQ9'./:@*
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M*/\ =GS-RQ:S-BR/E5_0Z!'R^EJ05<J3G],UU9?VD%%?*9EA3?[27P3*98*
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M1Q;J(:6HMVB&1 =2Z5-O(!VG!/0@CE/E7HZ/*W#;\&>J@HSW)<,IKK"M\.%
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M2AH**.Z?*CSO'Y?0GFJ3IB'[C*@+U \\J>OX5U&WX1Y)VNJ\D((_"/(^=#[
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M4)>!*S]?*L9ZN/NC58MPU_:-/_J!?_N+G_TM8?F_L;>6C&(TC&GD7 J>>80
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M^6AMZI'Q\Y7DD_NQN,IM9DLE6%JX_2E=097PSPW]KG2;4W7L=I\+=V,9&XY
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MKX;8!3\@_>O(G*>62C7!VY)0P)2OEG1>SQ</1^DV]27:0SL;W-I2KD;EIRI
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MYS_V?TK?62E".U^Z,='CQY7Z>K3_ )'A70]K=U#IQ^YPTI<UCKRZ"Y14D_\
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MVM#JE%Q82=Z5I/"./3RQ7!K'<+9Z&CC)3J!KK'V?72R=IB6V8ZE12ZEU&""
M1\I'N.GTKY7595L^Y]7IL33]1V'54A.M==L6Z*R1;M/Q@^XTCG=*4-H!]QG/
MZ5QX6L>.Y/EG1)/)/T]+^I>3H4U,(W/NTNP(2?A5R=X <;QXUI/XB#U YJ=C
MNT-YH_2V97L/<_M)J&[O2W (JK@B4T<'PI;&S:/^(8_:GGA+A1['AEZ92ET>
MN>R!N*O73B2V@./1'5[",[?(5Z'AF"$IM9?9'A^,Y)>5</D[<^XMF"!M2LH
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M>5XCI<V'%ZC5-*=V))">GG7T<JMG@0<]J'1O]$U!HG(/</2H\N)5A8-)XU7
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M;KM;HJ7;:U#=-P5E"E'Y8Z4],G\/OYDFE:7 %U8+PS.MTF.]);FW-QDI#A:
M0PTDYSGRQY>9HNQDAN\6E^VH2]+F?#A9 EJ42H \9;3GC/.2?:G%H1A+I B6
M);@>6J8RX\%H==;&4-D\%M.,J)/)-%4!FIZY\UY]EMU4G:@K2@KW.!>?(?3'
M Z4AG1-,6YU-G,>0\TH-)+G<NIVJ:)'&XGJCSK2*X$5#J+@B$6K5,?D+1D!(
M .]1/. ?P^A/-3^@R"W;+[8)&76>X;* IY)PK(ZC<?PYI4T,1=WV[DXJZN!
MGL[7$/M)[IL\8#:AZ(ZYJ6[ 7#DNP8K$2Y?^<'EN[TG"E(2DC)4H#CCT_>A
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ML[5%'A601C;Z BLW("+$;89M;C+<6:(SA6B%'^(*49'S*[S.5$'DI''K2N@
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M3#\DM6S/ZA=0X\&%CPGS\Z^1\?D\K4/O_P GL:&.WU(YOK:S-W1Q"$A6U/'
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M#EP/E$U17G QD=:UC-O(X>QDEQ814L=?2K@W*;7L)\#C9)2":H$ ]:!@H /
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M6F62:VF,%-/=([#JF]Z5[5M23=42]:/:?N5V;CIN]N<MZWT..( 2%1G4_AP
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M5)4^L+)&3Z5<694-1X+,>;X% <5M9#2)B)O>J6 @MMI.Q:QQG-3)%1X9K[1
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MP\1B_<F>CG[#*;K.9(DR8KD<M+R KQ>+INKLCJU+HY98)(GP[Y'"]P:2ZJ&
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MZS#5%&%%)R  L^(G_E30F,LA4DD?#IPD;%)QQQYU1(^PE45H/.)4X=Q./2@
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MOOI#J6HR4C.5D\<4KY*1LOX#K3_U#_\ \*?(RT7<H2W22_->2EE1<?5'W)"
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MPB;&NDL7%0RYR.[S^M=VFUD<4:DJ)>LFWPC+O?9.O+36&I[P6//</\JZ%XI
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M*FD9;7O*]H*#MR"#[UHC BK3*;2=J 5 9&#S5 *+#[C3"BXI96=SC?3Q>N:
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MIS0"'RSF(PM,AQMSG(SG'/'-9R*CP%<G]D=*%K#BL<*'G4Q*;L@-PUS%-I:
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M@**)ZELN#JVI!R/UZ478F@T^)PNLD$*21G.,51(E4E]Y 0I21MXSYT@%B0E
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M$LT:#?&6(=S(;6-K;C39"$[^BBGGE0ZYI2!&GU983;(;-JD(;<<C8+SJ7.
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M:Z8Y;.=X6B',[MDCP*.WIS\W_%ZUO&5F;BT$B001@8.>,T-")4;O0A+22%)
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MTKHM0)5MMB&5*=D->!QO+:L923Y@UG)L=4=.T;IN#;(KNJ[\66($%M/=MN*
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MO- #@<7GYJ "43US0 630 1<*//K0 $NJ5^*@ ^\(ZDT &'B. : "*RHYS0
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M*V\J'% F4\Y<]LAL--A6XYJD)CQ<EEG8N.#L'*D\DTP&0I$F.4%Q0!'*3U%
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M:VI86VM((X+9\(]#2M1)43I'9=V47;M2U%;],:0MZOB)[V'I+HX@-)/B?7[
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MHAK(95M5X2?(T;@(3ZU%S8W\X\AU%:F9'7(=WAR1G<UXA0 ZASOCWJTG'N*
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M[U="C\H%>'DSRR.ST885%6:P\#('[5C=F@C?^8''TH -*T9\*3GZ4 +R3Y4
M.,D G)Q0 M9!/!S0 TM3H/@Z4 &WO/*^M $A)&!S0 KKTH "VP10)#?P?G0,
M/NU>6<T & _F@0HE]'BH#@-#SRE86#BBADIM9QTH&AU"LYS0,-1'K0)@21CK
M0(/?C@4%(/[T\I( ]Z !O?'&1^]!($YSXNM #O3K0 RLC(Y%  RD\;A^]  P
MD<[A^] !*<"1D$4 $W* )^E "').3QS0 CX@^E "T/%0Z4 $M63DT 1Y"SC
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M\'S!I(ECN<=0?N;+\?;P4X!*_P"[^M.F3=,U]N5$3#$6"ZCN607,K&"A9XV
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MNM[T\*X]?\*JD^Q=&RT5HW4\_35XU_.@O&R693:&WE#:B3/4/ PA7GP-ZL<
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MD]#CZTA"Q,*CC- "TN.+X2"?UIV \R'=QWI(X]:0#N,4 #&: &W4*)X'E33
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M>$)\JQE(NG9-[-.W6P:7>FMW^W2$Y95\(ZRA*\J\@M)_QK6$TNV1*+NST/\
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M!63XE#T_2I<32.2C062:Y)F)CQY3C 2024>?HD^]9M&T96;AFS6;6K<F%,C
MK:!6EYL?>,NA.$'W3GJFD5)6C#:HT8-*V]^=."<@! <1R@J(X -$9.Z,YP25
MG/8LR9!F_%VW<W( &5]48^E;-)]F%M,]'?9JT->^U365N:@0'&$QWDNNO#Y-
MH()R>@SBO/U.50B=NFQ>H^K$>.IA*&$#[MAI#3?/D$X-?-9)N<TSV8\1H=4A
M6T\5I8AHMJ/ XH ,,8YW9-%@&&=W446 XW&2<Y%*P#5$0>G^-%@ 00>@_K18
M!_"!/&/ZT6 8:4!@4@%B,@@$CDT #X=KTH 1M3C^7_2@T&\)/1N@&N!UIK)
MQUH,Q]$8;AA/- $EII23R*8#P!%( SS@4 *#:P,D=: ##9/44 *" !@T 'M3
MZT !* #F@!7='TH (H ZT )<2<]/.@!6#0 -I]* ##:CQB@ BG;0 5  H %
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M%I"<8:3\J@.4J63CG%0WQP4J,%:K9J&0Q-TLW#>>C7^XK=<@QTJ7(E2.=K;
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MY'-.C2,%%E%JCM0MMN:6VVIF.A7^[.U2L>OD:SCCE(J4XHP7_3A;_P#KBO\
MOBM/R\C/SD>5W9$=F8AM=N6T&?E45<$GI]*^I/ NB<8Q[E4E,< N'*L*SN-3
M9=6BIGW*"PT69S>P.>''7%;PB8R=#C%TT?'BM([E(4G(*Q[_ .5;OHS+5-YM
MOPR^Z5W[:=I^^.1UZ"I<0L86CXA)C-H2V@[G,C]\8J=H$-BX1&@$-1.[<QE1
M5U(^GE2Z"PG3!D*,E44-J;'3.=U*Q595KGI6E8;C)2%'CSQ5)@1^^"?YK>WW
MI&B8#X@7'D J_P!WG&/?-,+(JY 6E2&T;BD'>0?"D>N?.GT0F-,Q7)!#<9IU
M^0?E;:05Y'U%&Y(?9<6SLSU]>7&TP-,S7G'5%*$!(!) R>ISP.:7J;Z#HAZE
MLMPT^["MEUBJC2FXWWC2L$I.X]<4UQ28NRG-,!3+FP+W(STQS33&63:/B(VP
M*[O/)/6DQA-(<2K*> D8SZT":L,.R<96C@DC=0+:&I8 6VROO,#KC%4GP*B*
MI<<A(4ET+'S '@FG=AR2$D]SM3R3T)ZBG8Z TP5?,[G]*+#:(5W>X, *&TYS
MMZTK"B4TU'61EP#GTI-L%$)V- ;7]V=N?F.,YJ595 _A32DEX.>$>>*>X*(3
MD78I6U6?3CK5"I"$L2$#O'4E(_#[T1Y[%)%G9[P(=R8D.#"FB-NX\5$HV-2H
MZQH7M)7;I:H+CX7#ENDE)RXM*E'D) (PD"L7&F;0R6J+?M(CPTS+3K: P^RI
M;P;>?8.$O->X/XT'W\ZEE)5R5&KT.-7:!JUHI NC24NI&"I;J1@%6/Q* Y]Z
M:?L*7/J*W0*V(.I[C:G4*2F05%A 5M("N2D^HSYTZH(2LZE;')3\95@<0QWR
M@K8VI>'%D="/S'@U+1JN'9R#M;N/\'6SIJ"0IQSEQ1/B&:<,?)GFRVJ(VB-/
MV2Y0OA5MLJE+.T.;LY7Z8JYIF</60KU:G;)=51'VDX;SWA0?E(\L=3]14JQ3
M]/!&9+24IE-C+:E>,%6U0'J/7Z4PC:-#!G2&(CC7?B?$>&]#S !*0.J5)/G2
M9HG9HHT&6I#DI+BW4J1AQMPI [M73;["E1:X)EO9@S&?A681;1(\'?\ 5*DI
MZ 8YSGH*078DPG#/<B0F7'WD E;3A\*E_B4G/3 QQS4M6,A/18\IL)CAQ+C*
MPM\NC/'0$?E^M35#[,AJR&E#ZUI(^?;GJ<8\SYFM(,QR1HS,E!*T[5<?2M;Y
M,-MHO--2'(\I#D52C(9.X*'S#/D#Z>WO6<S3%P>IH:;C,M^GHMEC,)$B(E3;
M"$9W.N+PI!'4DGSKBR9-MG8H[CZ%]C^CSHOLZAV>;]RZT@EQ)1C"E#)3CRP<
MC]*\+4R\V1Z.&.U&I+>XC'%8&A):1MPD\^5 #A:3C@4[ )+6318"RSZ*_I2$
M@T-;2<JH&+V#\U !%(!!SF@ ]P^E !'!\Z "H /8#S0*A"G=GX>GO3H87/7-
M(5B\GUH& A1& 30 C8X.2K/Z4VP $J-(!0210 H))H /8: %):R* #V;>,4
M&$9'2@!82 .E "2@9H /:B@ P$#RH 45I SB@!!=!&,#]Z $[Q0 -XH ,+ _
M^'0 XWES.T=*!I6.=PK'49]/.D[]D.E\G _M>VIV[=GZXJ&0XM] M[(4G![R
M0^TA(!]2<#]ZWTLMN5-HSR<1E]D<=[2^S%NV_;4A]IEC=0++J[2+\28XA)"$
M3XK:8[J%'SSW85GV/I7K9=1"4'1Q0TLED5OLNK AB&RL,(4M0RGP#=M"W$IZ
M^?*C7/*7I.F*M&,;N35SOE]F.H*V8SZVQDXPG<0*(<!5F:U3;HM[MZA'= ?&
M0$;<C'UJTZ)FK1462Y7)F!'L]P7M:CM*;2,^%:C\O-*4;Y%">W@Z!]DKL];U
M%&NMVFQVE0V]02W5J6,AXHV@-X\SYGT%<^2>W@UQXM[W&H[8X>F]2:E5?M7S
MG2U!1W,:$@92C'I]3[5,-S5(K(EVRHTFF.].99MD QHR6]P2H9R?2MHQV]F5
MG6(UOW--HQE:R#G'E5*/)+?N;FV-0K#;U7"Y2&X\=E(*UJ\JZ$MBLYWZW1"C
M]K.DY3ZFH;V\). LG&:C\U?%#>E:5V3UZNB@?$-NAQ!RK&<8XI>=?L'E-'D#
MMOU.;C=)Q4X2A2RD>+IUI=NRO:CR]+>#UV=DI&5H(9;Y\SYUH3T>YNQ>Q_P7
MLM2Q&3L?EM]\XK')R,8K&3Y-5T2NS/2BW=0.R76<-Q25$D5:,Y(YI_I X[5R
M[,R^)S,;^'2$N-J=5A+X#@^YZ>(\[L#TJL/#H,O,#R9V2?:LU-V;V=O0^J].
M0=:Z1C+/P\"X+*7;?N^<0Y*?$TA6>6SE)]*[HR7N<,XM/@Z7;OM8=A,,%ZT=
MC.L8RDO&0A@7YI; 7D=,M[@/( = >F:RR0OIF\6[*&\?:CT/J>X(^'T6BW-,
MNAQN/=9+]P:;(.1A!(3PKGIUHAB]VR99OW4BU3KQ_M!N1FR>TX%Z65%3:)0A
MY)Q@83M/ECD^E;1BODPG-FTTOV&Q[JZ704O*6=X[EQ*E+)^92E@D'/7UK91C
M\G.YROH[-IG[.&FX:&9-U0W$8*E<OK.5J S@ ]>.:C)*&)79$?,RRVI$W4?:
M!V9=F[ILNF(WQDY+6%2&&LH /5(\@:\S-K)3505'L:;P^./G([L\\:YU3KK4
MESGMW#6,Q+"TA2&D'_9_A03U''IBO/E)MVST8Q4>(\&$;L+PE[&UJ<('C4I
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M/.ZBABN[%2  V!0 %)3B@ MJ/6@ P$CIS0 8P?*@ ]Z$<*_PH ,.IQX4@B@
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M!@I?)Z3[/[^IVW-I4LE8;"B?[OI6:;4C?AQ-A,[4VM/6V0ZS;FUNMM*"5K)
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M;12 ;2\1GQ4T4A865\YIC"W*!QFDS.78?7DTT(3L/O0:+H/8G\HH&(VJ]30
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M4IL\%MM.5D>F?*F^! ;?O#Y*8+"(32NI4-RR/<GD5/JL"UCITPW'4+LH./\
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MRYCS4%!22>I2HCH:UPR<9KX,\T%*%4>>_M)(1?\ 1VE[W'0$R9$42P4<;$N
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M?0#LN[&]*=G-H1:['93#A929#KY29D]0_&ZOC'LD83CR-?!ZOQ&6MF\N7O\
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M#C(*^7 ,D^1^GM7C2DE*T>W"-JA:9;\9">J4J.!]:TCD<F6\,8JS168M26'
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M0@8QQ0-!!0/0UK%T#!E?Y32LB@!:@>AHL=,,NY'!J2Z$*7D8H&-K^6@!L<G
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M#+=N/?\ "L\=OEOL]77*:P2.^>!2LY"O+)/_ ,*O)C&CZ&N+)5F;#<Y"WD$
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M;/G\FJ<[,NF2B0]XVN^=/JHJ)KHV8\?9@]T^C5Z>T)K>_+!LFF9:T+QD]T0
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M[;?8,JX)421YFG2)M@=CNN#(5UJT@L2VA:?F--<$BCW8PE1R*=@.-G:,(X%
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MK./+%>?JM#&4>$=>#.\+]1V'4': W]H6=:W]&P4.V1]87W\915W384,]Z/\
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M]$I_SK*')K-4<(N0NBI;UQFOA^2^H$_3TKJ2^#!]\E/>-30[ TIZ2\"\H'#
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M9^<>*PE*<HXOJY('8K,M6G;=<KL],90A$C>ZL*'A0GDDU\]^.LF+(HXH=_\
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MS3*B6EM7O:<4HJ5C&T'%"9H:&%'0"@KP5'D"DP.S=@Z2-:1YP;(7 8=>0<9
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MD@CRQTH[8HLS4IZ0^6'Y#[R'I#*I*UM+ #JE*\.#Y%!V^^#6+=RH=FWA:=U
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MRVYS20#K4.2\<)841ZXJE%L5FMTU8VDQ&I3J/&XDJ.3[U25(E\C%XCXGMO\
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MN!82<80*A%(5>VRS<%GH5@9]ZH3(]P?^$L^P'!*3TI4A'.WU%;F5$DD^=9S
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M:9=6Y%O@7*:T69CC9!D-H24DMI_$.<;CP":X=5.T=."/)Z"_Z$.SG_UG>/\
MY:'_ "KS]QVT?+YE:4*RKRY'UKW<;2[/*DC?=DO9E<^TK5$>UPXV(C2PN8XH
M\!&1_P"%=>/!YLMJ7!E/)Y:LZ=]I3M'CVF*SV1Z2<;;@0&TMS%-\94!C'%5J
M\]+RHF>''<O,9L_L;=K;:Y"=(ZADA3,/)C@^8Q_X"O&U>)/&Y+M'TGAVH<I;
M9'H#7&HKA=--7B^.-%N);D*^& X"B>AKUO!]"M5"G\&/BOB'Y;(D9?L@NC>M
MK1;;LZH]XRI0<&?Q"O-\2TOY7+L1V:74^?BW'?=9N/&QVF%%\8E-K2K/-:::
M-XSRL[;S'"]0=F-J>TSJF->W<)::064C\RU<BL/,>AS+)C[9Z6"$<Z\N7L<-
M[;>RC3.B+9IIO2$QB',D-EQ]UQ!<7@#R%>QHX:GQBTW1R^)9,?A4=S.5N:(C
M3G$OWK4-QF*'B2G(2!] >E>QA\"P8H>J3L^?GK,V5>9)<%A!T9HMH;$VD/$?
M[1Y:E9KMCX1IL*WR5LYGJI:A5A=47,.+:HJTQX-HBH<R D,L!2L^6/.NOR<&
M+EQ2)@LV7LUMFT'J:\8D32S9XF<EZ2K:2/\ A\ZXL_B>GP)QCP_;^Z.J&ADV
MK.A:6T5V;6'#\F.=33ASWDA90TV?9/G7GS\261?)T_E=INQJJ6IA,2.U'AQ4
M\(9BHV >F2.M<<IN;N<N!J"1'7,*_&HY)]>:F\<>A[1LR2<\T]RET%4.;\MY
MS64T6@@HE.:QD;1#!R<UFT:HD-O]T,YXK&2Y-8]"I.H;7;VPJ1/2A7FGTK-F
MB9GKMVFV]H;;>R5J'&3Y^]9J7(VT4+^J-5W@_= H!X\/'^%$I&;L6-,SW$&5
M>']H/FM? J4RK^2; @VK;LM,5R:^GYNZ3X#^M,=V;*SVB/$B(7(9#+ZSD-DY
M-5$&C414-(2DI2,D8Z5OMX(?!$>0MAU;;. HG.1P<4MJ%9 N=O,B%)9DDI3)
M8<8W^FX8I;26SS/V/_9U[1--:VN=ROEH<CV9H.M-.$Y$GQ93C'L:AQ:,8*F>
MA+999-D=#;@Z-@KXQS_\*KQ&\RTCN@J.#QBNJ!BSI/8SVGR-"=KO9E8#-4BW
M:W_BEEEHSX0ZD!<<X]=Q5S7!J,2GCU$O_P#$ZH->6CW>TH''CW\=0.#7SF+%
M>.+_ /BR]P#X23ZUBN#=<HC%PN'B@&#D].OE0((E](PH#%!0G"5G:O!'O4C(
M3UCLK[F]S 7[#%,+'HMOB1U8CH1@#KM&:5@*<?"<I_2IDBHE'<M^\+:5A:05
MH2!RM70)_K4HL\P_:>^V%8.P1+^D[+'C7/5G=GO$[\1;:ZKIWGYWN<I3T]:[
MM+I?,ENDC')J-D:BSYS:M[0]1:^NTJ1J*>U?KW,Q,<G/2%*:9Y)(!!Z('H.I
MXP*^CPP4(\'D99N;*2!>)+*G8UDD(>:?(^(2\GOFSQDN.+5X5.9^1'.P'H37
M2G?1CT9Q7P[EQ9+,)2K@Y([TQ"T5*9Z_>I1^%/' //GYTU1+'HEQT6M4I-Y5
M(1/4I2WYDD]XZ\0?$KCY$CC _:M%*"0B1-U%?M:Q5VNT-/MPH"$-[7 6G)JR
M>"XKJ&P.2!U\Z5RR==?U#HSRX4=A^4VIT3YD9H!V6#AB"?\ =H'3CU\L5G2]
MRC-27N_W(;D;UQR7$K+6"X?)0ST3C)_YU-B'[-?VK5</C9*FY!D)VNJ#>P-J
M_P 3_2FI5RQ%^=:V-65.(;QCR&35.<:[&C-W.\V^>X%-E82%[CY<5.Y,913Y
M*9#Y+15W8X2#6,Y;GP,D69]*'BRY^,83GH#6N)\[267+,AR,0PYGQ9*?I70T
MA%MIQWN+DDD\J-9E(NKXA#UP9*GPC'.*H3,QJF<DL(C)7NVD\CSHO@3,BY\Q
MK&8T+;3L;*Z%PB@4R0>>:"B2R]BJ3$B?&EN,D+9.%#I@TWT#)IU-,BHW+23C
MCK4VD I.M%NC9@C]:3D@8L7AUT;@3S[TF(<1*4#WB^GE4C0ELF0]D9)Z@^8%
M)NBT>B?LL?99U']H:\+GSGW[1HFU.)1=;IM\3RR>(L?/5U8SE71 Y//%>;J]
M6L+V^YT8X.71]:M):*MO9[I2VZ;T]8&+/I^VMAF#%9Y 1Y*4>JUGJ5'DFO#R
M-REN9Z.'&DJ-E:G2D)"N3CUJTK0Y<.C0M?#$#/6BB6PW ASPA(HH5D65& /
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M<K2NI(=ZBN%)9< 7CS03S3AP[+C+;),]?=H?V@BWHR!!T^TT^S=HW=R$*YP
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M6FB7#O!2D%(.#FDY6*A_4@<M-D:5.U(_(>6TD[5$$HR,[?ZTK!&-M=D5>Y8
M*BE:@2:&!UBTZ8B6R.@NCQ8P/I5*(UR5/:'"M4+2\R0-H>6D(2">3FHRI*+*
M79SF'K61;(ZH\.!'7O;2E2U)R>$@<UEOI*A5;*1RXON/+>6 %+45$)Z?I361
M^X;17\2D+;*2YBFI6%415K2M:U'SZ5+:;8Z"8:=DO-QX[:G'75!"$)&2I1.
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MCKD>E5-PGV:1@WT?,WML^SB.S!Z=J?L&[5F]96)E)?7![Q3%VA-A6"%)( ?
M/Y<'U%<L\<5T;*UR<IL';AVAV]H-(GRRWG"PM92L8Z\'D8KF<$WRC2,VO<TJ
M.V74UQ0E+\R<HJXQWI()]*AXTNBWD8Y_;K4/^[E_^Z&EY9/F'E:O3//!30"T
M$CPI.,^=:P;7")8XXE"4#&2KS-:32BN!+DLK<\%)0C!R*UB[5D,E3MDAHMD8
M/D:=$KLZ#V*ZO7I^]MVYU\AB0-N":T@RK._2G$@93T//6M)<#3*Y;WCY'2LZ
M*4APAMY&.!10BGN$9)Z8HVE*1GY43"LC_"DD5NLARDJ&U.>*;Z$2K.R"K=Z5
M<4)NC5Q"DI V^5.B;W.B>T<=#3'M)2%G'6AH30M#GO4M"'D+\LU$BXL<[P@U
M#-$Q7?9XK.2-$PTK\\UC)&RY%)?.>,\5FT4D2XTY1Z\5FXFT62#('E46:/D4
MW+P0.::ER3)<#WQ&?.KW&5!%_P!,U1-C:G%'SH&)[P\\TK 94]@Y)Z4TP&ER
M=Q&%8 JXJW0FK8';BB.TXZM7@2V2>?3FNS O51SZA;59Y0U=)<O>H[E=5*)4
M_(44$\X XKV<47&*1X^2>]E>WWC?.U/[5NC%)Q+>W/O)P2K''E6B271I%M<I
MFGM6H9$%QMYA]Q#[1!0ZA6U23_=(Y3^E1+3PR?6CJCJ&CHJ^T^_:KN?\8U#J
M&=(O*6$QFYTA\K4EL=$@'H![<UX^J\(CD5PX._#J5$:O_:QJ>SQDP$6Y$9I2
M2D3E8=4X3Z$_*#7C/1RT[IG5^8\QI'/WYLZ[)[U3J%..**@I:O'GW/I3!\,N
M]+QXL5#CLV]0XIV*"UN_*E)')-)RHWQX]Q>VV#*EQ9;E@3\2W"(2M];>$KSR
M"E1X.16D9689([6!$>;*:07U[G>26AU  ]/*K5HG=N0EF0F.WM2^A/>* W]1
M]*I(ERO@FIG16N\<==0E82$ISSSG-6YJ(X8V^65%RO+3\MQ\'Q+. 3C*![5C
M.5FJC1!DO$I*P\DG'4^=0NC1<(Q^HK@M(*1@?FQYTC.;LP>I"EZ%MVG<E7>9
M]O2I.;+&T97:.<*'%2SE.P=DOV5.UOM@MDC4-CMT2UV-E*@W=+P^(D:0Z$DA
MII2AXU''&./>BXMTY46H3:M1.:ZDTI>])W5^S7J,&Y$=10KNUAQ!(ZX4G@TT
MT_<3C)=HJ=JORG]J7(A26'E\):4?TJDFP)3%FN4@9:B+/MBC:P)K>C[\Z,IA
MG]Z* ?:T+?ED!4<)SY44 \=#W1"598Y2.A\Z8G]AZ'HB\.;7"RA"1R"KD9]"
M*30UP6C>A9+>UU]*4!7 ""<$U-#M^Q:1M%.-I45!*2C@I(R:>VPMCZK/&C*0
MPM.YU0X2$GFFDQVBSB65 ;[Q:4C'X2.:=,EDA=C\*DJ0-RL;2/+_ ,:5,!8L
MKB5(7A8<;("D*'!_7H:$F!)[EJ$A2E1TH+OA00,E2O0 5IM8K0ZAL)"5$) )
MR=QQ_3K3H+18-DM'PMX0K\>_<?VH4:$Z'E6J%(0HA#:N,JR.HIM)B7'0XH7H
MQ@NV/I46N$LK&$8]-W49_P JEP*MC5OU-K2(M2KM:'2QNP'&B%("?+'K4UM'
MN-=$N@DH;[Q"PG;O5D8./852"QQU_N@A'>++?>=X!Y_7-4*QXOK6X%QUJ"5<
MD9Y_:@"S1<4M16WVW<O('"?(D?FJE5#L4W.DN'O5RPYCQ8=;VHS^4>OU-&VR
M6+B763'06'7&4*>4L$D$H5GH4CSQ54T'(N+/E$N*,E:ULGPI'&\CT/E106RS
MA7^6[]Y<,*6?"I0("$(]"/7WH<4QIEW;=3Q;< [=83:(K3V651PHG:>!N X4
M<GKY5/EKME^9P6=WUJM"$)C!Y:5.)(+*^4)]U*X_2CRQ>:9B_P"IWR\I^$XE
M'A&Y05XC@YS_ ,7&,CR)K2./:[(EEW<&6U,Y#UKIV18=5E2F9(W)21XHSF?"
M^WZ*3_4<5,L=AOL\QZ@L%W[/]3"+-(>"T[V9"#X)*/(@] KU'D:2>UTQ4:)L
MB[14(B*)5(4A (ZI6HXS_C5N2:**_7VK&=0ZE8L%J7LM5AB&WPQY%?\ M'>/
M,JS^U1%-L3=%+ D+@L&.2HH<4<X/F#UK4S;+R-=9:7(HD'O&4++AST_N_M33
MH"R7/95/2\):D?#QU'<A/A;<<.U.?TIV!"L#:&DN7)QUE"&U*=W/-84TLY26
MRKJK"0%8''B\Z6-WV#-%/N,&)&@W3X-M]QL 2BTH;0#^+'_.M6T(OI$:!+A-
MO-H'W@2KP^>:TI2)3HJHT#X/52C%;)2ZSD8Z#BHV[65N35&4N[J85QF.,<N+
M///2LVQHMK(DR8/PZQGODD+*JI.T-NSGEVMJM-:I;=0G#07E)'^%1M=V!NKV
M!.MK3Z^2$@TYNT"=&"U'.2F,6-I!.4@UA)TF-.RYLC[4/2\-HE*5+W.[2<%9
MK3'Q!(39*1<'WFXT6:I82492G/ S2[$9;4$-#8(V8VGK3:M4%T4MO?$2:AQ0
M)2#R!64/3*BWRC13G52&EN-.+RH#&#C'[5L9C-TF?P^WLM*EN+D+Y*<\I^M1
M.:@4E902+I,DC#KI(KG>9M%[41,UG90*38 J; %%@"FF :4E7R\DG&**L#T/
MV-_99E7J$QK;M8>E62P.)[Z';VTD3KG@_*E)_E((_&H<CI6&7.L/#1I#"\O1
MT'M8[28L32C?9SV?Q&K;'DO-P8EL@>%+:7#M(]5.*.T9.3R:C1[LD_,LWRM0
MAL/JI]EOL5_Z"NQ#2F@GI3/\09C&3=E(1M*YKN5+)(Z[<@#/Y17HZAN?I7!Y
MV..[U>YUM^^VYA2HGQ8<6PWE>T9QCJ3Z>YZ"LE451TQC+W/,7:=V^WC55[N6
MA]"7%-JAQU*;<G,\N2U <A)\AGC-<T\M\(ZXP2[.86BUPI"@Z^W*7<\C?(EN
M]XZ<>AK+=(TX(>L=,P6I";I'?CP)*VT!QQS:0Z4G.%<94D]<#G/K56V0D<4[
M0^Q30NN7WKW;FV+)J=/#K;8)CS\#A6 ,@_I0UQP.DV<,OS.D.S]MUC53N;BT
MV5_PEL*$A7D"3T0GSR?*B&&4F93FH\&'_P"E[2?_ ,9,3_\ "*ZZ?)^Z,?/7
MP<5JC(% "D\<U<>!,=0GP%1Y]JZ%U;)9)MSG=NX4.IJL;]B9$J6_A9QZ5HW2
M$D18\]<:8S):60IM84"#TK-3IE4>GM":L:U%86W%. OM)"5)W9S[UU1>X2+E
MYS!/-.@$-R2.IJ-H!/*2L&B@*UY 4>E#B4F5$]OQX'E4^Y9)M Q6T$2S0L?*
M/*FT9KLF-+QYYH'8^ESTH#L<"_>DT%#B%^]0RD.!X?\ P&LVC1!]Z.M0RT&'
MLC_QK&1O$"7.>M9,T0X'?RG%0RT/-ODGDUGM*W$A#F2.:>T>XD!8 ZU21# '
M!GDU=$!*>3TZ44,C.R=ORJI4(AKEXSE54D!$<FCDA7('3-6D)NC(Z\U.8=I<
MB,N8>?&#A7RBO5T6&W;.'43LY.B(TH=,D\D^IKVJ7L>:XH;=@#)V]/+BG0;4
M!I!;XQTXJE$ENB:RA"?%6BB+<3XLA:5!2P%?THJ_8<,S1J;5<DO,_#3$I>96
M-I0KD >U8Y-+'(G:-UJ&E:*N^:%=LREZDTTAR9!QO<C?,XTH\$D>:>>E?.ZW
M02@[CT>GI=0I+U&(?O2GG@ZS'6M"LI44)!"#[I/I7ERBXKD]!9%?!H+3=TLJ
M[F3?GG%.D*3'25(0,#A2\<<=/UHC*B9K<6KVH[R'5NQ[LIED(VN.QW4D!/JH
MD5LIT82B_8@HUO9VN]CO2>_=*0&G&DY2KU)'KTJ92^!XX\\DQJ6;BWXR&$9"
MD%U7MZUE;.EI(??>C..)#*-P2D!2L\*5YFCD1&<>*PMM8VI2..:I 8K44L]X
M!OW;3^]!DS-W.4'8[F6O+'6I3IF<UZ61--W]K3TM-P:M$69+;5EHRT]XTV?S
M!OH5?7(]J3?!R07J-=?NV'M4U>CN+SJ:XRFC@!I3Q#0QPG:A.$IP.,  5BL.
M,Z7FR>Y3L6VY3@D/.+7LW$MY\()\^:T6*$>B'DE+LL(>DW5J27&Q[^&KLS;1
M>0]-Q6]@R-Q\MM--D,MD6IEH A(].!3)).Q#*6R6CUYYHH*))9*'0ZE"BC'K
MFB@&EI"I!0VV5K6. ?"!^M%!0!;8Y=#<@N(4!P2<(_>B@#D1U0TET$K/F.N1
MY8IT,D6IP2(KKAC.LMYZKY/ZU20K);24%O[M+2W".N,C]#5*(FPW$M;-H3XO
M,#UHVBL:4RB2SWK2BVI*]N%\?]KZT]H[&6H<A3I=<FNN+!VEM7R?4#RI;0LE
M,L,H"Y'=.%P<*YR0/8>1I@.*82!LP@E6%)4M.2![^A]J:$^!:UN103'9"G@G
MA"D[0H4Q6)C1)[\AN<'MC;GA<: SM/IFBK"RT1M8D*67"EO&3MYQCV\Z-H62
MU,Q)!VM%;A*-[:5$X(],>5*2&AQEN6M'<QFFV7PG>E))P/7G_*I&28$APH+D
MO((X'W> ?<>U (E(<2PXE\NM!*N#S@T#'RV%%*^[V@JRHE60/U\ZH1+=G=TT
MN(IQ!&,I4ZG*4CU'K56 A2F-K+,Y&%E.&E*.-A]?:M*(L4MTLEL(C.;$?[9)
M\*CZT4%AN;5/E\+W;TX6W^%0_P"?O106/MW*5&6%*W%#7(0DX%%!8'K@\^AN
M0A\I9:"B49PG)]1Y^U4D2V5CT\**7Q@KWA. G''N/.JHFR'=$K:6%F0@-;L*
M!^561T/H/:IDBHLP>IK7;KY#7:KK)*V4N_=2?PL*/0Y]/:L7$NSFK\RZZ&?E
MVR8@N2%-J$1Q'"3G@.#VP3^IH^P[,C$?V2DR4<Y/(JH)>Q++28^9+00P[M6C
MG'K5DDZTWQ++(AW!L;P, E5%#+:+=PPU.9(4AMYM2-O=[BI&T C/D23D&H;H
M"S@W=\1%3)F%(>Y=+J I:TI 2D'' PE(' JH\ 6B7+;<+=<FH:6T1WX^T*2.
MI Z8K1<@3=*W OVQ@N'">[&!G.,<5<&3M+I)6A3DG;T;VI7GK57;!(PDN A$
MYV2I!*GB>IK-QHHN8"D):;1LV[3R0:M1 SO:1;0[;OXA'SN:5N/GQ43X7 T3
M+/)1/TRTZ3PEOGSYJ.U8CG-S2NY74,#(02I7'. *PG'=)(I.DV6URMJYVE85
MUB@@PPI*T@_AS6KBZM>PDR;I]Q-PAH:>5ET)!;)/6CL0SJ1@J01YXR?TI@8A
M2B%UR2E3-$B_M<O+6U:<X'F:ZE;5F?123GW),MUYT^)2JXLO,G9K'H8K.Q@H
ML 4@  3TJDF 83D'KQ3 E6RU7&\S6+;:H3TJ5)<2RRRT@J6XM71*0.231[6!
M[![(?L_:6[(FF]6]IJ(=TU0T ZQ;EJ2N+;3C(+F>''0?+Y1]>:X\NIKTQ[.C
M'A]Y#VKM<WWM#O\ _"]/M2GW9CP94^2=SJSPE+8SG_+%<JBTGN.A+U>DU+VC
MM-]F/:AV%Z7VQYMW5K!B;>Y3J0XM3RMJ4M@?D;]/S9-=WAW//W.?5+V/K39[
MY&C+7;+K;BW)&>Z(5X'!GYL_A^G.*ZW)RY.:$:7!PSMK[5T7R[3.SW0<AN,V
MT2FZW!E6%N@?,TA7D/4^=<V2?P=>*'NSBZ+<JVSX\EQE#4%LJ2ES;@@_F..M
M<O9N=#T5V1ZM[5XJ=06)^/;(/>!HRGU$*7SSM3Y\>?K6L8MF<IJ!Z)TA]G?L
MVTL&Y+MJ3=;D$[7)D[+A7[A!.U/Z"MU!(Y7F;-%<]+VJ*^;BW9K=\2U@M/"(
MD*;2/+PC-74:MD[G5)G(NVW[*O9-VWLVZ_:NT9;)=WMLD26)9;".\(.0RZE.
M"ZV2,;5>M5%0?3'%_P#D5O\ T':9_P#W?NS[_P#UY'_.K]/]HJH?)^?>LS,%
M !IJX@QYO*E;CP!6\>79FPR[AP+0G&.*;E<K05P.RCPE25$Y'/UJIB1%K&BS
M<=F&JS8KJAAUS#;Q"<$\5U8LGLR7]COAFM/MH<:4%)5S775K@FQ/? $X52*%
M]\A7G2H*&EXW=:&RJ*N<,N>U9/LI<CUM*4JQZUM#HSDZ+UE0*1S3HS8^E8!I
M#7(\EP"BRD*[X$<TF :7LJQFLV5$6AXGJ?.H9HA1=&.M0RTP@_Q63-8L,.@'
M).*Q:Y-4.)<-0T6AU#I2<\4MHR2W)2>AIT#8IN4M1*5  ?6A(FP+E@>=6%$=
M<X9(R**L3(SDS=GQ#CWJMK]A)V5LNXI;&2H'CUK2.-^X-T8[4^O85D84XMU)
M=(PAM)RI5:PQ6Z.?)E:X,&]<I-U<$N659<Y"3Y#RKW,$-D3ARS'D')&U&!71
M%'.I$D%)&T@<5JD&X:7%!!4G-:I&<HKL@.*=0K!S6L8(YI3<?8?:=<K3RT+S
M?L64*6ZTM)SP#3VJJ*69I]&PLVHG8I00YSGGW'H?6LIXDU3-XS<G?0QJOLUL
M.M3_ !>Q+9M]SVY4"<,O*]QY'TKY_6^%QDM\&[/3T^>I5(YI+_C5@E"S72'\
M"Z@G>EP>!S^\%'K^GK7@9=/+$Z9Z<,J:*I];#2BN1)1XU%7<-J(PD?G'0UA=
M\,JZY'85Q9BCXQ30;[W"D(0WD!/D<^1JUT0YOV-/&G.RF4%;R0%<I;P% CU]
MJI(>YLM6$E83E81CR-6-,9O,AN*PL[P5*&*AODM]'-[E*4IW"CG!I-T9.1"*
M%S7/A6 "5]2?*LURR9ND7%NTI%6?O5+!'H!5M6CEC+8[1H8ME;VGND=!U(IJ
M*1G*4I%M;VHS2>Z6E2'3QN*/"HTZ7P)2:X+1+#>[8W(02!D\=*=#'FXG=,I!
M05+/((IT*@E+*D!O:-X5D;>GTIT ZTR'5?ZTG8K'"1T--"LELMMATI<?4WG&
M$@<4Z"PY#" =Y0K:/"#Q\U% !20XR7-@4ZWX5*Z@>V*=!8C:MS:XMU);X"DX
MZ>_THHEL=:8V2E@ I*.$8.4D?3SIT%CKZ6W4^(!LIX(0,"M%&Q6%'2G?WA;!
M \CU-&T+%LHY6IN.5QU)V]ZL]#]*=!8L]TA:%]T0I(P.."?>B@L"F%]VI,5I
M:W7/E'X<_6IV!N E1+:F6QW:BH!UH)SN6//)Z4*(78X_&69++:WBV2G?W9&3
MQYY]*>TD=<4&VD-L26$.+RHA!)'Z^E%4-(-EMEV,M8>[LCYG,<H-%#HDL=P$
M)4U+0Z0/$ZI/A'NJFHV%T36YR5O#<E>[&WP*(4D>OT-9R5%63HWQ#I6'W@MM
M7"01T Z5"0QSX<-)PA;:P/F2M(XIT%BC++0!6 2I.$XY"O<CRJDN!!(:2I2X
MZ6U%C:%[EC/C/7'M3H+)!0TZVEE3B1)=3]R%\APCR/I^E;&00CRUN=T^WW8'
M3*B,_ITI@("5-J#SF2-VPA RH>^* $ORVH\O:Y( 4L>%&0%'_LFCW 9D.8VD
M(4C/0I/A6/\ (U2);("U@J5LRV"/E1_EZ&FR;$O2,H7%=0A;;G\P?F'E^OO4
M/DJ)F9[93(6Q'0E4<I#9:4.!_P ZAHME1>M.PK_"5;;HA6YI7^KNHX<:..H]
MO45FXCB<FU#I>Y::EE,M*5QE'#<IL9;/U Z&A3<5R/LIUJ*%80OQ)YW YS6B
M=H5!!Y3@W.<K_-YBJ3L"XMS[LV$_ !6X$%+JFPK"W".GB\JRFN Z+BSWN+;H
M49#Z E+J%92#TYYJER@)T.8TW*)BNI3&EM.A#.?E4D\']15IT!H=&-J:@M+D
M],%*4^1Y\ZJ &IE)?+?<(.$@;JUJF!F;ZGN'F6T\J-1*3L!I3;[,93[BMJ4C
M)]:NZ5C7(4)MS4<)ZU1F5//NC8$$@ */1))X!J+W<"?!LM#=A<ZVV@Q]1ZDB
M(45<QX@+I:SY*5T)^E:8]-)KED2G1C-4=CMVT7<)ER[[XZ$^VH,+0C!3GR(]
M:G)I98WN!9$T9O14AM;$BQRE $!0+9\S6?*X9:YY*F5&DV"6(^U3>Y9[A7H,
M\CZ4N@=D^Y+;EV\R0KQ@8(\JGL# OC:ZH#U-<67B1K'HF6ULN[AWA3]*ZL,F
MX\D2X8U<(RF72O'"CQ6.HA7J147[$2N9%!H0IP[4#)JHP<GP)NA];;#*1DK+
MGF/*M914!6V-;#L*]I'IZ5+3V[JH?V+[1>B;]K>^Q-/V&'W\V:O8TA1PG&,E
M:C^%*1R5'C%"C7+#OA'MSL<[$$=F+*7M$6<7O4JF^ZE7]] [AK/"D, _*GRW
M?,< YQ7GYLDYNH]+LZ\6+;R:F[=F\!UM1UM+EW!9R5Q(V4H/MNZFN?S,?2[.
MM*UR0V[Q,T6TD]G/9E#M+Z&RP+G* =?;2K\F?E^O[5G)\7)\_ DO+Z1C;'(U
M%??M ]F6B+]9[5<YURU#"GO[V"9$<(<R'.]2=X)0E2MO3 R:]?1QVP5G#G:=
MNSZ[366 R6W65-,.E> .2@\^$'T.<U*DXQVF4&WR?/2#?)6G];WAFX!;L!=W
MDH2O)RPKO,)23Z8]:Y9,[8_<[YV=]EE[[6V$S8TUJ+IMN0IE<T\+>VGQ=VG\
M1SQ3QP<WR++D6-<'KRQ66!8X#-EMT5EF)%;"6&D-A(2 /;KZUU.*@N#CC-S^
MHJ];=HFF- 6=^^:MO<"T0&!XY,M[:G/HD=5'V )J\"GE5T9RC4ML3PUVZ_Z6
M'1NC'7+'V::75J.65%L3)2RVP3Y%#:3O5^N,UUO#B47YCX-5!Q:9YENOV^?M
MM]I=W;LND6V[*N0KO&$1H"&.[;]5*.2/J?*N=ZC3X544C39*3^DM/[?_ .DR
M_P#MG,?_ (7BU'Y_#_XH/RTO_$^>=!B"@ QUJH@+3XB$^5:Q>YT2^!UU: D(
M0.G6M)-)4B4+;VNM;>=V:J/J0GPP_@EGG::-EAN'&X;S+K3S8.0<YHC#:[#<
M=ATEJ=#EM;9DOI2L )Y/G7;BR+IB-&B\)5T4%?0U19+;GH4>%T4!)^(2OD*%
M)HHBS#RD@]:S:&NQ$1Y*'1S6D#.9=QI"2.M40^B5WR<=:5 A7?\ 3!H2+0X%
MA0ZTJ  6$GK4- @^]VXQZUFS5"UNIQR>:S9:0A+X! S6;-XH);N\X)X]JAHM
M$M#Z<=:S<31"PZ,\DU5$6.)?2G@&E0[ N80, BA(1'=F( )*N:I(5E;(NS+9
M.59_6JJB6S/7C6$2 VI;LA"$#.3GI3BS/?M.8:B[4Y$LKBV9*CU'>GY3]*TQ
M[IND8SS5V9ZW,2[C,1,G/%]Q)SDGI[?2O5T^F:5LXYY]S-:RRO'(ZUZ484C!
MSLEMME')\ZWC#@S;'4).W=CFM% G</(4 /+FM8P$Y6,OQ4/<XJZ,W"R)W2T>
M571B2&% #Q=:=#)S3^W"L\BE29HI;2ZMUV=:V[5#'I4/&O<IY&^(FFDFS:OM
MW\,U)#;E(V^!U7"V?=)]O2O,UFACF7"/0TV:4?J..:Y[)-16!]$JV*7=[2MS
M(DM(RM'LL?YU\QJ/#\F%W7!Z/G;Z5C\#2S<R*)#]RBLE&$]RK).1^O\ 2N/:
MTZ.A*U9:,0&HR<+?00D8 R$@UI1-AJ5'3E60/3:K-*BE(S^H)!<;V!6,5#[!
MS,7<7-KZ4D\D9-3,E2MDS3<8RI:GE%02@9\-$8^YCDF= @04*9W9.\^]51BG
M9/2IQM2MK!X( Q_G54273#H2$IE@$D<<#"33H %D-2%%I <0X/$2.E%#L:+C
MC8(2HX3Y>U"0,=C,@([T@-I5RD^6:="'G,*3DN(64GDI'04Q"N]1@+4L)0#X
M5XZB@8\&^]4I+:%)0H=<^$^]-(EL*%&D(2X']A:!V@H&,^Y]35I!8^8K = 3
ML4@ =!P?4&GM#L)U15EL@)+1PD@<D>F/.B@&\,.+0XZ\$*3G<G_"K1#'VP@N
M!+HV*/1?M10A.Z&L[TI4@_G!Y_[M QIR2HLA#G4KV XY4/+% %DRJ"_"0I+C
MQ"3M46U=#Z$>5, ,*0I?=@(P!U(ZCS)]Z2 6RXTH$[BC9GPGD'T]Z="$+A-R
M^Z7'9;CK2K!4D<*'I]<T;;'9)VD-B/*:RZH^+ PA8]<>M&T+)3:XV P&DJ;3
MQ@C@&J21+83R&X:TOO(*6G/ "T,J%1*)2D2EI<:6A*6SL4 4X/7ZGRJ'&N"K
M'EMK;< 6T5;T\8ZJ5^7]:5#L?#3>Y+3>%E:<E)ZH/H** >@M/!?</. [5':/
M0>AH ?%M2\ 5+1\0RHK0?)/TK:C,:;EI?;_UDK/>)(*E?,D]./?/-%@-1H;G
M?.NE\;4(PD?F]S[T 5=RBME]J1&+9>4G)4\-V#[>E2^.1KDKN]F]\5*D.*PH
M!3:SDX_RH3$T%<)Z&5)CO)[M60IM8_PJ[)H@/2@'7.]5W9!\"O(GSHH5T1UN
MMKW$K!4?&MP=./6BA*5C,COD)[PI3N2O(5^G4#Z5G)&B953&4/AQE26^[>2K
M>TM/"OT/2LQV<^OO9_'0@RK$\0O&Y3"^$_\ 9/E2Z^DJ[[,;(CKB+*)+#K2B
M<86, ?KYU2DEV'?0N$4B0XPII3R'D[=K:L;C]:'SQ[!T/1)3KC:(_=M[V,I0
M%CRSYTX=4$NS1QFUSK05HCI:DM2=V]/&U)/^%6(M$ZWMFG&F8CR')3C:LD(.
M!4O(L?8Z;Z)ZNU&UR7$R!N:2H !)_P ZU65/D5#[]S9NJVGFE CJ#0Y6P$SU
MR):V[;;T+=D2"&FT>14?\AUS[4Y2XI#1G[S>V;7?&;'"67HUJ6'9;R#@R'T]
M2?4 ]*PW^O:@?5G;=*]JED6RK+I2L<J"^JCCRKMQY]AC*&XU$#4TO4"6PFQ&
M9'><[D)*NI/GCV'G71#4/)Q1A*+1RWM&T7:X.IUR+.ON2SA:G$)RE*_,*QY>
M]99<7JX-,62E3,S=+<Y>HZF9Z TZD>!P=%>A!KGGC9T*29E/AWH/?6V6G&[Y
M2#U_6LJH'V9">SW+Q0KY\G/TKESJN2XNQIEY;)RDXS48IN)35C\V6I]MM!Q@
M<].:UU$[2HF*(E<J+'&GULCP <^9%;1FX="<;)"'F7, I\1^97H/.MO,C1.U
MG2.SOL+[0.U<LOVBV)A6<$-"Y3E=VSUY*/-P^R:RGE4N/8M1/5V@^PRU=E-N
ME1M-?$76\34!J;<7T!)(Z]VA/X$9YQU-<F7(_8Z(8?<VFE]2=HNED?PQV Y-
MCI^6/CG:.N/4"L%#=T;1EL[-5*[5-.PX/QFLHS5BCD'#TH@HSY@#YC4+2J;X
M17G)'/W.V:^=HUP5I7[.'9;=-8W=64JGJAGX:,KR6 < XZ@J4 /0UVX-!&$K
MGR99<Z<:/3_V,OL0W'LIU%([9NV.YLWG7MR2I02VX7&K8EP?>J4K&%.E/ARG
MP@< 5UY=L%Z3S;E*5>Q[/,2(^T.^;2EEM9?*SC P?/TR #7#VN3IZ?!\S]?N
MP6^T_6*X[>^UR;TZXA"#X70,[E(/G@]:YI'=&/![/^RLAVW]B6FF9<%IKO ^
M]&;' 5N=.%Y/F175#B*./*]TF2OM&_:3T?\ 9[T2[J6^O-R;A(*XMNAA>PR'
MPGDJ\TMI\U?M75CQ;N68J+O@^-_:EVT=MGVH+Y<=23IL^5:+8TN0^Y'<*66(
MZ5 892?EQGD\J-+5ZV&-;<?".C'#?+@R&DM"V:1>HUX+"5L1EI<VE>"XH<Y4
MHUY7YB62W9U2Q;7N/8'9YJ7LYES_ .,RV$,W);:&7R5 A:4CA/ICC]:YI)/L
MWAD7='5/[9]G?_JRU?\ RLW_ ,JFH&OG?8^.=>X>&"@ 4 +22G@5I%UPA-#J
M0$<GE1K9+;^I'8N)Q(&\<$YJH6GR*71H4M*(3@#!]JT()3D<): V^5(:(QA.
M26"EM:FUI/A(416N))NF*3VA-72_VM82U+,@#J".E=&UH/,LN87:.ZP0FX05
MM^614[J7):;9JK9K6!-2.YDI/.#DXHL>YHN/XNV[M4E0('F#2=-<#C*V&J:V
MVXE:58'G3CN14TBVAST% (7S6NUU:,663<E*D]:FFNP0:GQZTNC1*QT2!M&5
M4BJ0M$@8ZU+!) ,D9ZUFT4@ER@4]>:S:-4($CH<\UFT:)L<3)SU-%%626WDG
MSJ=H]PZJ0@?B%&U"Y([ER8:/*QQ2VWP4B'*U!':&4J"CZ$TMK0I22,K?.T&V
MVY*OB): K\HYJNE9D\ASN\=J,^<I;=JC%(_.KTHBG-\(QGEHR;G\2NCO?39#
MCA4<E). /TKLQ:-R[.3)J2QBVH ;0K:#@X ZU[&GTBC['#DU"?9J+3 2EO*$
MX(.#7HK&D98VFK+MJ.H8*C5K&78ZMI*@!Y"K44A-V!*.,"G0@N[P:M%4+2@I
MZ?X4!;$/,$YYJSEY(ICK2<^E U8H**135 [)D24$*&:)I-#A<7:+>+/3N&TX
M(K%HZ(Y)&JLE^7'.P/$I4,*"N01]*QRXHS521OCRRBR+J7L]@Z@CN7/399CW
M%(W%G\#OT'D?\:\#6>'P7.-'IXM3)\-G*)D^9!EN0+H51GV1@MN#9SZ>]>,X
M2AQ(W3OD+^(F2A/?.)&1T2<U&^)2*VZ.(6ZEMM61CFI[=B;,;<7B]+(3U!VU
MG+ET1?/!M=(0X3,;[U9W.H Q_>IIT92[-?&CNH2%-(Y''6K7)'18,,*0A3)6
M=ZU I^E:("49".Z=;= W)! /K3I#0E3ZD- MY"E#CTI4AC+JDNM*2L* (\1!
MQBG2$(8EE+882[N0$D("AU'K10B5$62E3:-H5CP\=3Z&BA,EI2T^W@HP$^%0
M/0*'D!3I!8ZA]AM04XM12GPE(/E5)(EA!(9D%UV0I,=SY%#H!Y)(\_K5)(DE
M.M2L=XVPTD8P!NQSY4PL97\3EN0Y@.MC!V^5.AV.HC+DY>'=H0X0%G:/ ?(T
M42!@20ZZA]M:@DD!2D80?H:8")K+Z'-J@EO/XL9S^M*@$M,I?FA92KOTI"$G
M=A'MCW]Z )FYN+)4D,AD+3A;8/"CZFBP$R(Q83C>A3;I!.%'(_6@"0H]ZM)0
MELA*.0.<@50-B(2S)9$EB5AI64A)')]3[8JDO<FRP4ZF4I);<\0 !)'S)]1Z
M4Z$):=2DN,A![L\(/][ZTA]]DH25L(+RU(4&RE&W'B]\>M2['=$EY>Y+JD-N
M +\*$DA/B]\]:E\OD:8^EA2E1PAU25L\G<<\TMH[%NM!,UUU0+9"4E&PY*L^
MM)QY*3'4,_";UO!2-Q*@6U;U?J#2<:"RR[UI.Z0I#JBD# ",&M2""X$2E*6G
M""HYXXP?^$]!2 CQI+H0&'/O'^\VI4E. 12 B2H"I@"W4=PE'A*MV?Z4-6-.
MA+%H8:=+@=<<QC*OF)/G1M065<_3[;[[DI1>""HY#G1)]OI32)EPBLD1PVPC
M<XE_G<H$8P/:M$D9.V.*92IL!I#>S;N 3U2??UHDA1('<NN-!2UH5M!VC!"@
M<^7EBLFC1#)*)K82YN;3RVH.8.3YYQT'I6;18%6N,PT+:EE*6RG.3E52T!GY
M]D;<*6G(Z)#.,]VM.?".IR:70T8^ZZ&07^]MRRPXGQMI2?NQ]3Y?2H;9HD92
M\P9=MFAV5%4P5CQ(220@^N?//6JW---B7*H3!O4J&'0R^</ !8/.<5M&28J*
MR6^J0^IU?51KDRNY%Q5()E:2.Y4E)W$8).,&E"?&U@U[G0-(6R[7=U$:')8C
M,1V.]FRWSB/";S\ZU=3GH$CDUVJVN#,VB[S88=I^*TA'E2IKO>1X\E[Q/2O(
MJ;83\B2<A.>2/.JXE&XBY1EK'V)]H#[JKC?+>FSQGDE2G+@^EI:@?[I.[/U%
M9X\$[<I*ARDJI&JM6CM V&6%7_M"C2'<Y5'AHROZ9/%="C!?4S.Y>QT>!VBZ
M9MD=%JTXRX$E. ZLY<QTZ^7Z5T0RPC])+C*78B4_ GM!+2021SGFMUD31A.#
M4C(W:Q/,+[V D*1U6R>1^GI6<HV5%M%&;58[ZZE,^&]&=:XPAS&#^O6L?+@W
MR6YR) [(M"7-X.N3[@'5#E*2,'_E0])AF[9#SY%T2WNP/0JFPH7*<P?4N)-#
M\/P(/S&0J+MV)Z+:0/A]4O,$>J-U99-'C:I,J.HR)G.9F@U'4#-@LM[A3G)#
MJ66U.J^&&Y1P-Q<PD#WS7!/3N#X.N.2^SIMV^R#K_25O9GZ\U%IBPF2I C1%
M33*F20H9'=,,A2EY\O7UIK!)+U-(:G?1Z4^S_P#Z.36EVBQ=2W335OA=Z0J*
M[JM"U+=!_&W;VCG'F.]5GSQ36.,/J)<W?!Z"U5]EOM [/MKDCMYTQ&64;&HK
MNE_"DXX"6VEDI3[XS6,HZ:3^_P#$V@YOFCF-[D:[[.;4B^7!6EM6/A\-/0;0
MN3!66B<!Q"I"-JEYZHS@#FL''&G2.A3R)#END?:>[47OX-V6?9V5;4K< _C]
M^G-+CL)\U':K9QGRR?:MXX<,N6N?U,<F22[9WKLF_P!'-IMFX,ZU^T-?GM?Z
ME^=41>Y%L86>0$M Y6GW4<'T%:O+'$C'?*?1ZF78M%Z%TTED6^UZ<MC"1M9C
MA#"  ./",9/IUK!YUEB[? UA=V8"Z_:D[,=/H#;+]WNVXE 0W&"&UJ'F2>I]
MZRBX0Z-_*FSG':'V[ZLUE#-MLD95CL[QRHEP%]X>BB.GT'EBLYO<;8\:@N>S
MB]YTLB3;E.!00[ W/,E1P%;CD@>JSYUS2LVL],?94_B0[)X2I[\B3%$^6PSO
M1XHJ"4E  /D%%5=,'32.1Q2RT?-/[8W:0KMV^V*]H*Z79YO3]JN;5B P0"PU
M_-(QT*EYY]Z]#--X<?I)CZLFWV/43?9+H'1W9-?M,:"LK<"!.AK*T[RI;A"2
M0-QYQGR\Z\+))R[/1P14/I/$C4!S1^HW[1,92672%8(R.1TKG_>31M+JF:=S
M3T:0!<+(Z6%) )2'#M_:MUD;[,7&N4.]W?/^O-_]ZJ])-R/%=>H>8"@ 4 *!
MQR*T3H35CK83RXL]#TK6"]V2_@5N5WB5XVC.!56[3%7%&WAPE.LH5Z)!K4S%
MOL+40A/%)"OD3W):\"O/I6V'ZB,CX&)$<GD"O1:31$9$9V.AWAQ 5]:S>,T3
M*Y^RI!WLKV8YRDUC+ GR/S!R-<-16S'P[RW&QT"NAK*4)Q7')2G$L5Z_GAON
MI$$;AU(-0YRBZ:+N^F3[5VF!DAN6RM _,.:N&:GR2XLVUKUG!FI'=RF\D<#<
M,UMOW#2+QJ[M*&%*2?I0^#16/IN2,=<BI*#7<!P4*P*E@+3-21DJYJ&4@S-1
MY&H:-$)^.14,T0L3&4>)3V,TZ%8A5ZBM=71^]2T%E=<-8P8B27)2$@#D[NE3
M8/)1BKUVIPFBI$(KD*QQZ9I.21D\K9CKGKB_70E#;A80KR1UIK'/)TC*60JF
MX3TI>]]2U*/)4HUV8M"Y/U'-DS[46;%M"<'9SZUZV'0UR<&34-EE'@DG&T#-
M>EATRAV<<LMEO MQR"0,^5=2@D@VN1?,,A"< =*ET;XH[%3']BS1:-;#2R2!
MD4=B'4,I )Z$44 ?=$\\T6%AI0<[5#C\U,!6Q)5RBBR-H2F0KH!56.B*[$(.
M<=*+#:,+1@8'%-$3X0;<A;)!R339,9%I#NF#C&/6HE'<:;J-39[\6%I4EPHP
M0:SEB5<F^/-1-U/I[2^OHG=75/=2D_RY:!XT'U/J*\S5Z".96CLQZGBCAVM=
M#ZHT&HKN$?XB&\26)S'*5?\ $/(U\OJ='/3R]2X.R&6S%MWJ5WBE+5G(P,>5
M<BD/?9*LEO5+E%R0SOW\I)H^XU\G1K7"BLL-,K24.Y&%8Z4(ANRR;"D$I.4\
M]<]:U1#)4IUQ!0X 4E/ 5Z"K0(6 F6,A:QM'"<?.?6J <<4XV$%9QMZ$B@5C
MB%AIU"E(V;P24KYQ@=?I0!&4RM;RE*2A!6<C8?+_ ,:0QA;DEIYMH$A*T$D^
MI!H!E@J8ZXT#WA4ML;5'&"L>7%.R1<5T\N[L9&%"J0F2C*2&L%*?"0 YUP#Y
M>@^M622(\L-/[,]ZV2% +_"!UQZT 6#<=M;X*%..)=Y42.E4@)*K>V5H2E[<
M$#&/[OI54(2A;C2UH4$AI7A"B<A H #[K;22EYD+;'^U/RI^M $1N$ZD;TK+
MQ)WA2> $^5% (4E2Y F#.X'81ZU- 2T-O+4XT^E#;2AE&W'B]?U]**!"&'%,
M.]P7$;D<J21E8]!D<<^=- R0CN'$JDI82DI.%I'7;["K(#4ZPC#R,N,\D*_$
M"?(X\J &&I$P'8I3 92=R%!)W)5Y9I W1,:PY%6I1;6O/*T]2?7ZTTN!63&'
ME.EMIX[E(^\&X C'F?KZ4.(TR2H/+2W(3M#A)*L^8SQ_2C:.R8Q(;W*+V2IP
M!/ XR/2BBDQ]/>-*W*5E'F3\U2XA9,C&0"2W(+V[KNP.*:0$9YN*DJ)92HI/
M(_'CW-)H!#2-GWV,L]=H'05($=;*5J3W:U'<2>>@QS0 P]&PI+R'BVE1ZCS)
MI@0;BM$>08 ;>6I3>Y22KG'K]*5T#*Y:BPR>Y9:(0,;,<XJDS-HA@K6"_'9
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MI19.VB\_BB?]PW2W$T>(J]T\4%  H 5Q6D1,6C;G*N?:M(\=DL>4V[WC6\$
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M;3@?B/G]:YE[HZ&WPSSM8VGKFI15&4E/X3^:B@NR]_@$C_<N56T7)XDKVSQ
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M' G>WA2AW@V^A\J8QAU;"$)?2HE!5A7UH1+&7"U.6[&V%;S?C(1\P3Y8I]B
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M'8ZTTVV"4+))Z<4<C2H2["<DJ2"GUH']70I4$0$E.Q).-P.1^W]*EAM/6/\
MH_\ 73LS3>K.S21)R-/3V[S!!/(C/C8XD>P7Y4X]G'GB]UGLIAQ4Q"7'$)2
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MLV+BT\A(!4A"U8)!Z&K4D%$\RVUN+:6M.Y(V[<?,GV/0TW3$0)]M;;:<FM+
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M.1>P<0G9XLTDPVI 4_Y$9HL8E+F3R*.PZ%!P>E%"L'!-- $%#)SQ2 <;9?D
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MT8VXI,VB *2?.I* I?((%%B% Y%.P%(&> !3 ,^#YNE2P'2M!2-HJ1B#S3[
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M>0D;S\HXX]ZN*37([:'IUN;<)" @*S\X "A^M0U%]H6YBV;GJ>V+"K9?9S0
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M R:I,*0E3K*1E(JD1+CH1\0H#H,_2@G<Q9>6L#=_0578K#"%+.><44.V/H9
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M%<Y]\U#5HI2HZ6JUQ-31D)EM!2)48.$$>>>/ZUC*'!M#);,__P!#2/\ V?\
'2N;DZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955646608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Novartis AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001114448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,119,609,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG AG<span></span>
</td>
<td class="text">PricewaterhouseCoopers AG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Basel, Switzerland<span></span>
</td>
<td class="text">Basel, Switzerland<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3240<span></span>
</td>
<td class="text">1358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-15024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lichtstrasse 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember', window );">American Depositary Shares each representing 1 share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares each representing 1 share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember', window );">Ordinary shares, nominal value CHF 0.50 per share*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value CHF 0.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NOVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lichtstrasse 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Karen L. Hale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">324-1111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">324-7826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313948661680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(15,486)<span></span>
</td>
<td class="num">(15,867)<span></span>
</td>
<td class="num">(15,121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">36,342<span></span>
</td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(14,253)<span></span>
</td>
<td class="num">(14,886)<span></span>
</td>
<td class="num">(14,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(9,540)<span></span>
</td>
<td class="num">(8,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(3,701)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">9,197<span></span>
</td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">26,137<span></span>
</td>
<td class="nump">9,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsPerShareAbstract', window );"><strong>Diluted earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955601024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,018<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income to be eventually recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Associated companies' movements in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items to eventually recycle</a></td>
<td class="num">(359)<span></span>
</td>
<td class="num">(4,500)<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income never to be recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items never to be recycled</a></td>
<td class="num">(485)<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">6,111<span></span>
</td>
<td class="nump">21,521<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,116<span></span>
</td>
<td class="nump">21,528<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Comprehensive income, attributable to non-controlling interests</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2022-03-24<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949031808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 10,764<span></span>
</td>
<td class="nump">$ 11,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,411<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">80,543<span></span>
</td>
<td class="nump">86,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">7,175<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Current trade receivables</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivable</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">15,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">36,910<span></span>
</td>
<td class="nump">45,718<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">117,453<span></span>
</td>
<td class="nump">131,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">58,544<span></span>
</td>
<td class="nump">66,802<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to Novartis AG shareholders</a></td>
<td class="nump">59,342<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">67,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Financial debts</a></td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">22,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">4,906<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">29,374<span></span>
</td>
<td class="nump">33,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Financial debts and derivative financial instruments</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">14,795<span></span>
</td>
<td class="nump">15,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">28,656<span></span>
</td>
<td class="nump">30,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">58,030<span></span>
</td>
<td class="nump">63,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">$ 117,453<span></span>
</td>
<td class="nump">$ 131,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945548480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Total value adjustments</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">$ 55,551<span></span>
</td>
<td class="nump">$ 55,474<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="nump">$ 59,275<span></span>
</td>
<td class="num">$ (4,657)<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Restated Value Adjustments [member]) at Dec. 31, 2019</a></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">3,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">11,401<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,016<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(3,056)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(3,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RepurchaseOfOptions', window );">Repurchase of options</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(10,286)<span></span>
</td>
<td class="num">(10,279)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(10,134)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">57,157<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">57,157<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(2,497)<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">21,521<span></span>
</td>
<td class="nump">21,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(7,368)<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(2,920)<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(2,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="nump">102<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(10,365)<span></span>
</td>
<td class="num">(10,471)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(10,235)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">70,989<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">70,989<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">6,111<span></span>
</td>
<td class="nump">6,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(7,506)<span></span>
</td>
<td class="num">(7,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(10,910)<span></span>
</td>
<td class="num">(10,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(10,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(14,510)<span></span>
</td>
<td class="num">(14,429)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(14,404)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2022</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">59,342<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">63,540<span></span>
</td>
<td class="num">(4,996)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">$ 59,423<span></span>
</td>
<td class="nump">$ 59,342<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="nump">$ 63,540<span></span>
</td>
<td class="num">$ (4,996)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseInNoncontrolingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseInNoncontrolingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RepurchaseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RepurchaseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxesOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxesOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCostsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCostsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945493136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated cash flow statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,018<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Reversal of non-cash items and other adjustments</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="num">(5,299)<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities', window );">Dividends received from associated companies and others</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(696)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Other financial receipts</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Other financial payments</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(2,342)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges', window );">Net cash flows from operating activities before working capital and provision changes</a></td>
<td class="nump">16,124<span></span>
</td>
<td class="nump">15,949<span></span>
</td>
<td class="nump">16,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities', window );">Payments out of provisions and other net cash movements in non-current liabilities</a></td>
<td class="num">(885)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(2,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Change in net current assets and other operating cash flow items</a></td>
<td class="num">(1,003)<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">14,236<span></span>
</td>
<td class="nump">15,071<span></span>
</td>
<td class="nump">13,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
<td class="num">(1,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchases of intangible assets</a></td>
<td class="num">(1,473)<span></span>
</td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Purchases of financial assets</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Proceeds from sale of financial assets</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Purchases of other non-current assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies', window );">Acquisitions and divestments of interests in associated companies, net</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">20,669<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Acquisitions and divestments of businesses, net</a></td>
<td class="num">(879)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
<td class="num">(9,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of marketable securities, commodities and time deposits</a></td>
<td class="num">(34,695)<span></span>
</td>
<td class="num">(16,403)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from sale of marketable securities, commodities and time deposits</a></td>
<td class="nump">39,357<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations', window );">Net cash flows from/(used in) investing activities from continuing operations</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="num">(13,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows from/(used in) investing activities</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="num">(13,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to shareholders of Novartis AG</a></td>
<td class="num">(7,506)<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="num">(10,652)<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
<td class="num">(2,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions', window );">Proceeds from exercised options and other treasury share transactions, net</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other financing cash flows, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash flows used in financing activities from continuing operations</a></td>
<td class="num">(20,562)<span></span>
</td>
<td class="num">(16,264)<span></span>
</td>
<td class="num">(2,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in financing activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(20,562)<span></span>
</td>
<td class="num">(16,264)<span></span>
</td>
<td class="num">(2,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net change in cash and cash equivalents before effect of exchange rate changes</a></td>
<td class="num">(4,858)<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(4,890)<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">12,407<span></span>
</td>
<td class="nump">9,658<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 12,407<span></span>
</td>
<td class="nump">$ 9,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949753888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text">
          <div>
            <div id="anchorId001516794"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s financial year-end is December 31, which is also the annual closing date of the individual entities&#8217; financial statements incorporated into the Group&#8217;s consolidated financial statements.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.</div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#8217;s voting interest). Consolidated entities are also referred to as &#8220;subsidiaries.&#8221; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#8217;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#8220;&#8212;Impairment of goodwill and intangible assets&#8221; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#8220;Other income.&#8221; </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#8220;Other expense&#8221; in the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#8220;Other&#8221; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#8220;Research and development.&#8221; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#8220;Currently marketed products&#8221; category.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#8217;s activities with regard to:</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#8217;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other income&#8221; and &#8220;Other expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#8220;solely payment of principal and interest&#8221; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#8220;Other financial income and expense.&#8221; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#8220;Other income&#8221; for gains and &#8220;Other expense&#8221; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#8220;Other expense&#8221; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#8220;Other income&#8221; or &#8220;Other financial income&#8221; in the consolidated income statement, depending on the nature of the item.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#8217;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#8217;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#8220;Other financial income and expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#8220;Cost of goods sold&#8221; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#8220;Cost of goods sold.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#8217;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#8220;Selling, general and administration&#8221; expenses.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#8220;Cost of goods sold&#8221; for currently marketed products and in &#8220;Research and development&#8221; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#8220;Other income&#8221; or &#8220;Other expense,&#8221; depending on their nature. </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#8220;Interest expense&#8221; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#8220;Other financial income and expense.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#160;other&#160;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#8220;Other expense&#8221; or &#8220;Other income.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#8220;Retained earnings&#8221; in the consolidated statement of changes in equity.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#8220;Net sales to third parties&#8221; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#8217;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#8220;Other revenue&#8221; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#8220;Other revenue&#8221; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#8220;Research and development&#8221; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#8220;Other expense&#8221; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#8220;Other income&#8221; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#8217;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#8220;Other expense&#8221; in the consolidated income statements. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#8217;s healthcare costs, other than programs described in &#8220;Revenue recognition&#8221; in this Note 1, are recognized in &#8220;Other expense&#8221; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#8217;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#8217;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#8217;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#8211; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#8211; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#8217;s financial instruments and risk management strategies did not have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949864464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsAbstract', window );"><strong>Disclosure of significant transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text">
          <div>
            <div id="anchorId001517458"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2022</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#8211; acquisition of Gyroscope Therapeutics Holdings plc</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD 0.8 billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD 0.7 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 1.0 billion. The amount consisted of an upfront cash payment of USD 0.8 billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD 0.2 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.9 billion, consisting primarily of intangible assets of USD 1.1 billion and net deferred tax liabilities of USD 0.2 billion. Goodwill amounted to USD 0.1 billion.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The results of operations since the date of acquisition are not material.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2021</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; acquisition of GSK&#8217;s cephalosporin antibiotics business</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#8217;s cephalosporin antibiotics business. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the agreement, Sandoz acquired the global rights to three established brands (Zinnat&#174;, Zinacef&#174; and Fortum&#174;) in more than 100 markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of a USD 350 million upfront payment paid at closing and potential milestone payments up to USD 150 million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 415 million. The amount consisted of a payment of USD 351 million, including purchase price adjustments, and the fair value of contingent consideration of USD 64 million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 308 million, consisting of USD 292 million intangible assets and USD 16 million deferred tax assets. Goodwill amounted to USD 107 million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2021 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &#8211; divestment of the investment in Roche Holding AG </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell 53.3 million (approximately <span>33.3%</span>) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD 20.7 billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The transaction closed on December 6, 2021. Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#8211; acquisition of The&#160;Medicines Company</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (&#8220;the Merger Agreement&#8221;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#8217;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#8217; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4</div>
          </div>

          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; acquisition of the Japanese business of Aspen Global Incorporated </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#8217;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets and USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.</div>
          </div>

          <div/>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950014800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segmentation of key figures</a></td>
<td class="text">
          <div>
            <div id="anchorId001517705"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2022, 2021 and 2020</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#8217;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.</div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            825
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            42 121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 454
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 569</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 978</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 061
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 486</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 801
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 504
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            36 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 679</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-512</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 172</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-824</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 695</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-733</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 701</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 786
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 448
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 037</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-204</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-122</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 728</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-222</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-260</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 069</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-259</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 368</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-706</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-280</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 048</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 835
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 927</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 058
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 121</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 636
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 657</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 076</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 197</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 118</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-862</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 980</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 871</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-831</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-488</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 190</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 152
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            670
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 071
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-912</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-282</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-330</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 080</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-370</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 462</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-116</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-440</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            335
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-217</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-354</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-714</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            75 510
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79 220
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16 078
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 865
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 383
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            117 453
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            131 795
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-16 966</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-15 929</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 710</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 632</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-37 354</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-44 412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-58 030</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63 973</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            59 423
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67 822
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            58 544
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63 291
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 161</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66 668
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            68 690
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            991
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to right-of-use assets<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            222
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51 357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53 919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 603
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 791
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            102
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            970
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            800
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 708
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 353
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 615
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 870
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 518
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 229
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 378
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 052
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 573
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            599
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            703
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 683
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 804
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            165
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            217
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 525
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 806
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 781
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 041
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s largest, second-largest and third-largest customers account for approximately <span>16%</span>, <span>11%</span> and <span>7%</span> of net sales to third parties, respectively (2021: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively; 2020: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively). All segments had sales to these customers in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately <span>16%</span>, <span>14%</span> and <span>7%</span>, respectively, of the trade receivables at December 31, 2022 (2021: <span>16%</span>, <span>12%</span> and <span>7%</span>, respectively).</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021<br/> to 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020<br/> to 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 554
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 919
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 484
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 929
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 304
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 914
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31 459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 643
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 748
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 913
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 613
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 662
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            969
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 460
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 855
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 776
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 557
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 883
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37 008
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 537
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 927
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 756
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 287
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            372
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 051
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 007
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 272
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            577
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            475
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            445
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            320
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            271
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            157
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 723
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 101
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 666
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            479
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            623
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            203
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            334
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            323
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            393
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 944
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 694
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 018
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 354
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 290
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 046
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            678
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            434
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            936
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            800
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            472
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            759
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            540
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            729
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            597
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            340
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 753
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            19 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            32 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 159
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 883
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 836
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 427
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 178
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 069
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            606
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 087
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            843
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            558
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            263
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            761
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            521
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            417
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            598
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            887
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            722
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 976
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 664
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 311
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 331
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 996
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 516
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 479
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 562
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 277
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            833
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            569
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            973
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            837
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            315
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            879
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            964
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            461
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            369
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            515
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 881
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 097
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 671
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 776
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 092
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 244
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 928
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            423
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.</div>
              </div>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            74
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949674976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Disclosure of associates [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Associated companies</a></td>
<td class="text">
          <div>
            <div id="anchorId001530159"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 387
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its <span>33.3%</span> of Roche Holding AG (Roche) voting shares, representing approximately <span>6.2%</span> of Roche&#8217;s total outstanding voting and non-voting equity instruments, to Roche for USD 20.7 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies. See Note 2.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s holding in Roche voting shares was <span>33.3%</span> at December 31, 2020. This investment represented approximately <span>6.2%</span> of Roche&#8217;s total outstanding voting and non-voting equity instruments at December 31, 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#8217;s share of Roche&#8217;s net income. Any differences between these estimates and actual results were adjusted in the Group&#8217;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#8217;s consolidated financial statements.</div>
              </div>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#160;522 million.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            815
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-172</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949754016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestExpenseExplanatory', window );">Interest expense and other financial income and expense</a></td>
<td class="text">
          <div>
            <div id="anchorId001530632"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&#160;other&#160;financial&#160;income&#160;and&#160;expense</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-669</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-651</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-708</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-60</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-108</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-184</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-69</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-135</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest expense. [Refer: Interest expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950315200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of Income Tax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text">
          <div>
            <div id="anchorId001530884"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Income taxes</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 986
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22 028
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 786
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#8217;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-617</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-932</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 454</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 470</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 168</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 071</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 428</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-142</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The applicable tax rate changes from year to year due to changes in the mix of the Group&#8217;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#8217;s overall applicable tax rate and the effective tax rate are shown in the following table:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-7.3</span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">that impact the comparability of the effective tax rate between years.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The utilization of tax-loss carry-forwards lowered the tax charge by USD&#160;1 million in 2022, by USD&#160;5 million in 2021, and by USD&#160;29 million in 2020.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950315328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text">
          <div>
            <div id="anchorId001531581"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 181
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 277
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.55
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
                  No options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950306400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock', window );">Changes in consolidated statements of comprehensive income</a></td>
<td class="text">
          <div>
            <div id="anchorId001531800"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&#160;comprehensive income</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#8217;s net income for the year as well as all other valuation adjustments recorded in the Group&#8217;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Fair value<br/> adjustments <br/> on financial<br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Actuarial<br/> gains/(losses)<br/> from defined<br/> benefit plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Cumulative<br/> currency <br/> translation<br/> effects</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br/> adjustments<br/> attributable to <br/> Novartis AG <br/> shareholders</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Non-<br/> controlling<br/> interest</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total value<br/> adjustments</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            120
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 919</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 657</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 686</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-36</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-3</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 10 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 992
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 387
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 386
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 773</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 134
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 419</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 448</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-44</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD 33 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-323</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 17 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 762</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 541</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 543</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 968</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 187</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 220</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD 81 million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-30</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-104</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-103</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 18 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-450</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-353</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-839</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-844</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-4</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-198</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 038</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-760</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 034</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">8.1) In 2022, net cumulative currency translation gains of USD 13 million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD 3.2 billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were no currency translation losses or gains recycled through the income statement.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313948785904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">
          <div>
            <div id="anchorId001533452"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-964</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            667
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            780
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-155</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-351</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-166</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-57</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-288</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 184
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 170</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 109</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            549
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            555
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 377
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 063</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 955</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-610</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 027
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-453</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-755</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-203</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-199</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-509</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-411</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-315</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-326</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-447</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952436880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract', window );"><strong>Lease liabilities and Right of use assets Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Disclosure of leases [text block]</a></td>
<td class="text">
          <div/>

          <div>
            <div id="anchorId001534980"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 676
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br/> 2022<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br/> charge<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br/> 2021<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br/> charge<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            505
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            522
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            866
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            117
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            136
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Lease liabilities<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br/> undiscounted<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Lease liabilities<br/> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br/> undiscounted<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            324
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            232
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            258
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            167
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            201
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            198
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            982
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 349
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-251</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-297</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-275</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 908
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 025
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            134
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#8217;s most material lease with a lease term extension, representing a lease liability value of USD 0.7 billion (2021: USD 0.6 billion), has a determined lease term end date of 2071 (2021: 2071). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD 49 million and the recognition of USD 23 million of lease liabilities, and USD 13 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 17 million. There were no significant sale and leaseback transactions in 2021 or 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            355
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            381
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Thereof:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of interest<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of lease liabilities<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952815088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and intangible assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001535930"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 429</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 603</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-342</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-72</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-427</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-176</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-243</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-432</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 305
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69 684
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 671</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32 736</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 716</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38 040</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 115
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            57 333
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67 725
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-885</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26 566</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 272</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30 916</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            270
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-36</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 607</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-255</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-350</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-642</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-584</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-672</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 531
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 186
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 139
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 826
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 460
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21 562
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 313
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 938
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 091
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32 357
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 577
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As at December 31, 2022, the most significant intangible assets within currently marketed products category are <i>Leqvio</i> (Innovative Medicines: acquisition of The Medicines Company) and <i>Zolgensma</i> (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for <i>Leqvio</i> is USD 7.4 billion and 13 years, respectively (2021: USD 7.9 billion and 14 years, respectively), and for <i>Zolgensma</i> USD 5.9 billion and 8 years, respectively (2021: USD 6.6 billion and 9 years, respectively). </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines and Sandoz Divisions&#8217; cash-generating units, to which goodwill is allocated, </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br/> Medicines</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Sandoz</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#8217;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#8220;Note 1. Significant accounting policies&#8212;Impairment of goodwill and intangible assets&#8221; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges and reversals by reporting segment: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952436880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Deferred tax assets and liablities</a></td>
<td class="text">
          <div>
            <div id="anchorId001538419"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Property, <br/> plant and<br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br/> other benefit <br/> obligations <br/> of employees</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Inventories</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Tax loss<br/> carry-<br/> forwards</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other assets,<br/> provisions<br/> and accruals</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            125
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 307
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 273
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 727
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 832
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            628
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 726
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            739
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 051
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-343</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 785</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-420</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-138</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 312</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 998</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 739
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 686</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 502
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            507
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 344
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-430</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-340</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 552</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-323</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-317</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-46</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 307
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 273
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 727
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 832
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 070</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#8217;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 880
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            885
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 610
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 140
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            166
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            418
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            684
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 799
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952436880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock', window );">Financial and other non-current assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001540678"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 145
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 663
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 063
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            184
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 411
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 036
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            419
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 210
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955829072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">
          <div>
            <div id="anchorId001540931"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            934
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            870
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 568
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 636
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 666
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#8220;Cost of goods sold&#8221; in the consolidated income statements: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.8</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-573</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-702</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955327696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock', window );">Trade receivables</a></td>
<td class="text">
          <div>
            <div id="anchorId001541112"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-59</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 664
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 639
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 709
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 344
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 426
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            383
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            106
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952430512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock', window );">Disclosure of marketable securities commodities deposits derivative instruments and cash</a></td>
<td class="text">
          <div>
            <div id="anchorId001541662"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&#160;deposits, derivative financial instruments, and&#160;cash and cash equivalents</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&#160;deposits and derivative financial instruments</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 922
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 396
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 640
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 011
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949998016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other current assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001541818"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            509
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            911
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 440
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955327696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityTextBlock', window );">Equity</a></td>
<td class="text">
          <div>
            <div id="anchorId001541932"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Jan 1, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Dec 31, 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            936
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            890
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-92</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            856
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            853
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Number of outstanding shares <br/>(in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 527.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-262.3</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 265.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-84.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            52.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 403.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-284.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 119.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;5&#160;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.10
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3.00
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.95
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 787</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 775</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 897</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-123</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-145</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-127.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 910</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 920</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 056</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            88
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            806
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            854
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            730
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9 963</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD 2.8 billion as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is <span>no</span> liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2022, the market maker held 3 million (2021: 3 million; 2020: 1 million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD 66.07 (2021: USD 61.45; 2020: USD 60.09), and they have contractual lives of 10 years, with remaining lives less than one year (2021: two years; 2020: three years). </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313953380416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of financial liabilities [text block]</a></td>
<td class="text">
          <div>
            <div id="anchorId001543827"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 621</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Average interest rate 2.3% (2021: 0.9%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was <span>86%</span> at December 31, 2022, and <span>87%</span> at December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2022 was <span>2.4%</span> (2021: <span>1.9%</span>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#8217;s future contractual interest payments commitments.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Coupon</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Issuance <br/> year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Maturity <br/> year</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issuer</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issue price</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.225%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 498
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2042
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.325%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 150
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2024
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.287%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2044
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.196%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 827
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 826
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2026
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.697%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            676
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.250%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.640%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            541
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            547
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            550
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2029
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.502%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.050%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2035
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.479%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            352
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            356
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.010%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 740
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2045
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.029%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.127%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 409
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.480%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            559
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.449%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.100%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.109%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            994
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            993
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.874%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.500%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.655%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.375%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.957%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2038
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.217%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            840
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.852%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.909%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.200%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.869%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 494
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 493
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2050
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              97.712%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 214
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.000%</span>
                            <sup style="white-space: nowrap">&#160;1</sup>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.354%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The EUR 1 850 million bond issued in 2020 features a coupon step-up of <span>0.25%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Breakdown by maturity:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 342
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 284
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 909
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 269
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 376
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 862
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 505
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 277
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 079
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 306
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Provisions and other non-current liabilities</a></td>
<td class="text">
          <div>
            <div id="anchorId001545529"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Defined benefit pension plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 723
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 640
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            554
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            662
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other post-employment benefits<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            704
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            956
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            519
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 906
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#8217;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            616
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            714
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-169</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-  105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            616
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            642
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br/> cash outflows</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#8217;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#8217; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#8217;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingent liabilities.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#8217;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#8217;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#8217; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD 195 million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#8217;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD 185 million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  50 US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin&#174; matters</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin<sup>&#174;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#160;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD 452 million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#8217;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD 1.2 million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD 225 million for moral damages allegedly arising from the conduct that was the subject of the Company&#8217;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">340B Drug Pricing Program investigations</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#8217;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#8217;s determination and to enjoin HRSA from taking action with respect to NPC&#8217;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#8217;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#8217;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#8217;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#8217;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Swiss and EU investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect <i>Cosentyx</i> from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD 245 million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 20 US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere&#174; (docetaxel)</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than 3 100 US product liability actions involving Taxotere&#174; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#174; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in two multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 400 US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder derivative lawsuit</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation &#8211; Concluded matter </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Entresto matter&#8211; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation &#8211; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 369
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-292</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 863</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            466
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            702
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-548</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-306</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            181
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92__IAS37_g84-92_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313962291936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock', window );">Current financial debt and derivative financial instruments</a></td>
<td class="text">
          <div>
            <div id="anchorId001546397"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&#160;derivative&#160;financial&#160;instruments</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> Weighted average interest rate 9.7% (2021: 6.1%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD 0.9 billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short-term borrowings are provided under &#8220;Liquidity risk&#8221; in Note&#160;29. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955327696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text">
          <div>
            <div id="anchorId001546573"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            836
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            619
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            752
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            119
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 670
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#8217;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 481
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 595
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-218</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            234
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-22 261</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 838</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 294</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-245</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-151</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 072
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            345
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            354
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-468</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-268</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, additions to provisions of USD&#160;1.4 billion were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp; Technology Solutions) 2021 restructuring initiatives.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, additions to provisions of USD 328 million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&#160;354 million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140314035499264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Details to the consolidated statements of cash flows</a></td>
<td class="text">
          <div>
            <div id="anchorId001547223"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">
              <b>23. Details to the consolidated statements of cash flows</b>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Non-cash items and other adjustments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">cash flows.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 570
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 489
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 758
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            303
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 306
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 376
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial assets<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-335</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 411
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-333</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-677</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-478</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            823
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            736
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 339</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-673</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 807
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            891
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 546
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 881
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.</div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of income taxes paid </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the total amount of income taxes paid was USD&#160;2.0 billion (2021: USD&#160;2.3 billion), which was included within &#8220;Net cash flows from operating activities.&#8221;</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, the total amount of income taxes paid was USD&#160;1.9 billion, of which USD&#160;1.8 billion was included within &#8220;Net cash flows from operating activities,&#8221; and USD&#160;88 million was included within &#8220;Net cash flows used in investing activities from discontinued operations.&#8221;</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-830</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            81
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-589</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-389</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-202</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            229
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-291</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, acquisitions and divestments of interests in associated companies, net included USD 20.7 billion proceeds from the divestment of the Group&#8217;s investment in Roche (see Notes 2 and 4).</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 077</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-735</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 173</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-864</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 006</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            66
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-879</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-567</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-9 957</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2020, USD 49 million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 902
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 295
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 575</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            173
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-366</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-401</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 325</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-224</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            224
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 524</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-774</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-309</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 624</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 624
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-247</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 353
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 031
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 703
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            246
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-312</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            832
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 067</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-250</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, net cash flows used in investing activities from discontinued operations of USD 127 million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, net cash flows used in financing activities from discontinued operations of USD 50 million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17__IAS07_g10-17_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952470560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Acquisition of businesses</a></td>
<td class="text">
          <div>
            <div id="anchorId001549327"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions of businesses:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 600
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 977</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-144</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            612
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 669
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-89</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 580
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 077
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            735
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 173
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, no goodwill (2021: USD 107 million; 2020: USD 74 million) is tax deductible. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949899376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Post-employment benefits for employees</a></td>
<td class="text">
          <div>
            <div id="anchorId001549711"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for employees</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</span>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent <span>95%</span> of the Group&#8217;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent <span>83%</span> of the Group&#8217;s total DBO for post-employment benefit plans, are provided below.</div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#8217;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#8217;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#8217;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#8211; for the principal plans &#8211; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million) recognized in 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#8217;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.</div>
                <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 602
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            632
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            348
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 046</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-713</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-377</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-650</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-865</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 500</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 644</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 336</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-348</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-415</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 071
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 723</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 640</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 824
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 746
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 963
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 268
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 670
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            363
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            1 127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 799
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            620
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 510
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            830
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 691
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 208
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 730
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 025
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 681
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 135
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 701
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 978
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 436
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 551
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-697</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 237</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            346
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            464
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-286</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-400</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.6%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              3.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.4%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.3%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.2%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.1%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#8217;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#8217;s other comprehensive income, long-term liabilities and prepaid pension assets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#8217;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#8217;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#8217;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-466</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-790</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            839
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            869
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-136</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.5%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#160;2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(as a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> minimum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> maximum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            40
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit pension obligation is 11.8 years (2021: 14.9 years).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Pension plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br/> employment<br/> benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 268
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#8211;2032</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            523
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s total personnel costs amounted to USD 14.9 billion in 2022.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7__IAS19_g2-7_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313962295456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Equity-based participation plans for employees</a></td>
<td class="text">
          <div>
            <div id="anchorId001552874"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for employees</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 048
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            979
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            269
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Employee share savings plan</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#8220;Select&#8221; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Employee share purchase plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#8220;Select&#8221;</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#8220;Select&#8221; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#8220;Select.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#8220;Select&#8221; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10<sup>th</sup> anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10<sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#8220;Select&#8221; outside North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            63.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#8217;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#160;86.1. </div>
              </div>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#8220;Select&#8221; for North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period:</div>
              </div>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            64.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#160;89.1. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#8220;buyouts&#8221; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of share grants</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            87.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            89.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949085312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Transactions with related parties</a></td>
<td class="text">
          <div/>

          <div>
            <div id="anchorId001553971"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its <span>33.3%</span> of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Lucentis</i>
              </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of <i>Lucentis</i> products outside the United States. From January 1, 2021 until December 6, 2021, <i>Lucentis</i> sales of USD&#160;2.0 billion (2020: USD&#160;1.9 billion) were recognized by Novartis.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Xolair</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of <i>Xolair</i> of USD&#160;1.3 billion (2020: USD&#160;1.3 billion), including sales to Genentech/Roche for the United States market.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Luxturna</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&#160;188 million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#160;217 million).</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, there were 11 Executive Committee members (&#8220;Executive Officers&#8221;). During 2022, 5 Executive Officers stepped down. At December 31, 2021, there were 12 Executive Officers. During 2021, 3 Executive Officers stepped down. At December 31, 2020, there were 13 Executive Officers. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total compensation for Executive Committee members and the 15 Non-Executive Directors (14 in 2021 and 14 in 2020) using the Group&#8217;s accounting policies for equity-based compensation and pension benefits was as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30.2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            47.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            70.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            60.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            69.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            79.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            70.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#8220;persons closely&#8221; linked to them:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952446512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">
          <div>
            <div id="anchorId001554416"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingent liabilities</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, the amount and estimated timing of the Group&#8217;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            420
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            808
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            282
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 169
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 814
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#8217;s investments in funds amounts to USD 83 million. Note 29 contains further information on the Group&#8217;s investments in funds.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent liabilities</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">claims that could have a material adverse effect on its results of operations or cash flow.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#8217;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#8217;s financial position but could be material to the results of operations or cash flow in a given period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#8217;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCommitmentsAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949854960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of detailed information about financial instruments [text block]</a></td>
<td class="text">
          <div>
            <div id="anchorId001554566"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments&#160;&#8211;&#160;additional disclosures</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 971
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 581
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 553
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 094
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#160;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#160;2022 and 2021. </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            189
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#160;31,&#160;2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 158
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 070
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-186</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 697
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 704
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other<br/> financial<br/> liabiltiies</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            338
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            617
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            641
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-114</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-231</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> payables</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            460
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            625
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 046</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-189</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-88</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div/>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).</div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#8220;Other income&#8221; or &#8220;Other expense,&#8221; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 316 million and USD 55 million, respectively.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&#160;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#160;154 million and USD&#160;140 million, respectively.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds 65 non-listed equity securities (December 31, 2021: 60) and 46 listed equity securities (December 31, 2021: 40) in this category with the following fair values:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            888
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            390
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            307
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#160;22 million were sold (2021: USD 9 million), and the USD&#160;7 million gain on disposal (2021: USD 1 million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#160;3 million (2021: USD&#160;254 million), were sold, and the USD&#160;3 million loss on disposal (2021: USD&#160;211 million gain) was transferred from other comprehensive income to retained earnings (see Note 8).</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</span>
                </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#8217;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#8217;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#8220;Financial reporting in Hyperinflationary Economies.&#8221; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#160;1.8 billion (USD&#160;2.0 billion; December 31, 2021: USD 2.1 billion), has been designated as a hedge instrument. During 2022, USD&#160;91 million of net of taxes unrealized income (2021: USD 216 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#8217;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than <span>10%</span> of the margin and thus below the Group&#8217;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than <span>5%</span> of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">receivables over the entire holding period of the trade receivables.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s largest customer accounted for approximately <span>16%</span> of net sales to third parties, and the second largest and third largest customers accounted for <span>11%</span> and <span>7%</span> of net sales to third parties, respectively (2021: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively; 2020: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to <span>16%</span>, <span>14%</span> and <span>7%</span>, respectively, of the Group&#8217;s trade receivables at December 31, 2022 (2021: <span>16%</span>, <span>12%</span> and <span>7%</span>, respectively). There is no other significant concentration of customer credit risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately <span>13.2%</span>, <span>9.2%</span> and <span>6.8%</span>, respectively (2021: <span>9.7%</span>, <span>9.7%</span> and <span>7.6%</span>, respectively). As of December 31, 2021, the Group&#8217;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately <span>16%</span> (2022: nil).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#8217;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD&#160;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has one Japanese commercial paper program under which it can issue up to JPY&#160;150 billion (approximately USD&#160;1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#160;2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD&#160;0.9 billion). Novartis further has a committed credit facility of USD&#160;6.0 billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 911
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            36
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 098
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 011
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 506
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 564
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            135
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-9 002</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-11 394</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-20 396</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 515</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 876</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-2 517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-5 878</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 519</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 931</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 405
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 245</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 585
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 706
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 406
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 001
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 095
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-8 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-14 587</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-23 077</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 926</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 227</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-6 229</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-50</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 830</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-537</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-6 295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 608
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 833</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 460</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 296</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-868</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 029</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 598</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 943</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 029
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 062
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-843</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 482</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-461</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 786</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            847
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 516
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            457
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 820
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#8217;s monitoring of the net debt or liquidity consist of the following items:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 432</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 624</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 532</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-616</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-922</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 789</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 020</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 146</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-115</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-267</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-82</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-445</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 628</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 908</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 063</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-197</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-639</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 896</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 373</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 553</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-439</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#8217;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sensitivity analysis</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The sensitivity analysis disclosures are in line with the Group&#8217;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures below illustrate the potential impact on the Group&#8217;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#8217;s view of changes that are reasonably possible over a one-year period. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate sensitivity</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span>5%</span> increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#8217;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the Group designated EUR 1.8 billion (December 31, 2021: EUR 1.8 billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span>5%</span> increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#8217;s consolidated equity as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity price sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of these fund investments and equity securities was USD 1.6 billion as of December 31, 2022 (December 31, 2021: USD 2.2 billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of <span>15%</span> in the risk factors would have impacted the Group&#8217;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            109
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-109</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-154</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A hypothetical increase or decrease of <span>15%</span> in the risk factors would have impacted the Group&#8217;s consolidated equity as presented below:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-179</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949907536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to the December 31 consolidated balance sheet date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events subsequent to the December 31 consolidated balance sheet date</a></td>
<td class="text">
          <div>
            <div id="anchorId001561740"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">South Korea investigation &#8211; Concluded matter</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2022 and approval of&#160;the Group&#8217;s 2022 consolidated financial statements  </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF 3.20 per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD 7.3 billion (2021: USD&#160;7.5  billion), using the CHF/USD December 31, 2022, exchange rate.</div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950094272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text">
          <div>
            <div id="anchorId001561775"/>
            <div id="anchorNote31"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Principal Group subsidiaries and&#160;associated&#160;companies </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#173;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#160;25&#160;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Soci&#233;t&#233; par actions SANDOZ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Algiers
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Argentina S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Buenos Aires
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            906.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Austria GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kundl
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Unterach am Attersee
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Bangladesh) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gazipur
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              60%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Alcon - Couvreur NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Puurs
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Securities Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Services Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Triangle International Reinsurance Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Trinity River Insurance Co Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            370 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioci&#234;ncias S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            S&#227;o Paulo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            507.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Camb&#233;, PR
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dorval, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Boucherville, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Chile S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santiago de Chile
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing Novartis Pharma Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals (HK) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hong Kong
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            320.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Suzhou Novartis Technical
Development Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Changshu
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai Novartis Trading Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zhongshan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Colombia S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santaf&#233; de Bogot&#225;
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz d.o.o. farmaceutska industrija
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zagreb
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ecuador S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Quito
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cairo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.96%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Egypt Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            New Cairo City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finland Oy
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Espoo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            459 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Groupe France S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            903.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies France SAS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Molecular Imaging France
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Saint-Genis-Pouilly
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CELLforCURE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Ulis
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Levallois-Perret
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Deutschland GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Business Services GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Produktions GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz International GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 A Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            HEXAL AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Salutas Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barleben
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Aeropharm GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rudolstadt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Hellas) S.A.C.I.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Metamorphosis / Athens
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            233.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Hungary Healthcare Limited Liability
Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            545.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Hungary Limited Liability Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            883.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis India Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              70.68%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            PT. Novartis Indonesia
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Jakarta
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ireland Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Integrated Services Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cork City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies EU Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Israel Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tel Aviv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Milan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (Italy) S.r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Pozzilli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Origgio
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ciba-Geigy Japan Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Baltics SIA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riga
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investments S.&#224; r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Petaling Jaya
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            468.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Maroc SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Casablanca
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Netherlands B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            IDB Holland BV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Baarle-Nassau
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Almere
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            907 560
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis New Zealand Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Auckland
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            820 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Norge AS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oslo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Pakistan) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Karachi
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Logistics), Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Panama City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Philippines, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            298.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Philippines Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Poland Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Polska Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Strykow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Portugal, S.G.P.S., Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma - Produtos Farmac&#234;uticos, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#234;utica, Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            499 900
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services Romania S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bucharest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Targu-Mures
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Neva LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            St. Petersburg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            JSC Sandoz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saudi Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riyadh
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Singapore) Pte Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            45.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Slovakia s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bratislava
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Korea Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Seoul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Esplugues de Llobregat
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#233;utica S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Madrid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            270 450
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Industrial Products
S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Franqueses del Vall&#233;s / Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Abadia Retuerta S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sard&#243;n de Duero / Valladolid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Sverige AB
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stockholm
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Holding AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International Pharmaceutical Investment AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioventures AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Forschungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Kaderausbildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Mensch und Umwelt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Overseas Investments AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Japat AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            350.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweizerhalle AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Muttenz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Stein AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stein
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweiz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cellerys AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Schlieren
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129 630
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              20%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Arctos Medical AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bern
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            360 020
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Innovative Therapies AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications International SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Geneva
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Taiwan) Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Taipei
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            170.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Thailand) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bangkok
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            302.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ila&#231; Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            880.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gebze - Kocaeli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ukraine LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kyiv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Middle East FZE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dubai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Grimsby Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (UK &amp; Ireland)
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Neutec Pharma Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gyroscope Therapeutics Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 492
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Frimley / Camberley
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis US Foundation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications USA, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Millburn, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bannockburn, IL
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Technology LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Institutes for BioMedical
Research, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cadent Therapeutics
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Endocyte, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Navigate BioPharma Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Carlsbad, CA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            The Medicines Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oriel Therapeutics, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Durham, NC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Fougera Pharmaceuticals Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Melville, NY
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Eon Labs, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Venezuela, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Caracas
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Vietnam Company Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ho Chi Minh City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            70
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313954954176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory', window );">Scope of consolidation</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#8217;s voting interest). Consolidated entities are also referred to as &#8220;subsidiaries.&#8221; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currencies</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#8217;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Non-current assets held for sale or held for distribution to owners</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Acquisition of assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#8220;&#8212;Impairment of goodwill and intangible assets&#8221; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property plant and equipment</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases and right-of-use assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#8220;Other income.&#8221; </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#8220;Other expense&#8221; in the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock', window );">Intangible assets available-for-use</a></td>
<td class="text">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#8220;Other&#8221; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock', window );">Intangible assets not yet available-for-use</a></td>
<td class="text">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#8220;Research and development.&#8221; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#8220;Currently marketed products&#8221; category.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock', window );">Impairment of goodwill and intangible assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#8217;s activities with regard to:</div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#8217;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock', window );">Marketable securities, commodities and non-current financial assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other income&#8221; and &#8220;Other expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#8220;solely payment of principal and interest&#8221; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#8220;Other financial income and expense.&#8221; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#8220;Other income&#8221; for gains and &#8220;Other expense&#8221; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#8220;Other expense&#8221; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#8220;Other income&#8221; or &#8220;Other financial income&#8221; in the consolidated income statement, depending on the nature of the item.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Description of accounting policy for financial assets [text block]</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#8217;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#8217;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#8220;Other financial income and expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#8220;Cost of goods sold&#8221; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#8220;Cost of goods sold.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade receivables</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#8217;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#8220;Selling, general and administration&#8221; expenses.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Legal and environmental liabilities</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory', window );">Contingent consideration</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#8220;Cost of goods sold&#8221; for currently marketed products and in &#8220;Research and development&#8221; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#8220;Other income&#8221; or &#8220;Other expense,&#8221; depending on their nature. </div>
                </div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#8220;Interest expense&#8221; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#8220;Other financial income and expense.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Defined benefit pension plans and other post retirement benefits</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#160;other&#160;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#8220;Other expense&#8221; or &#8220;Other income.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#8220;Retained earnings&#8221; in the consolidated statement of changes in equity.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#8220;Net sales to third parties&#8221; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#8217;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#8220;Other revenue&#8221; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#8220;Other revenue&#8221; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#8220;Research and development&#8221; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#8220;Other expense&#8221; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#8220;Other income&#8221; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based compensation</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#8217;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory', window );">Restructuring charges</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#8220;Other expense&#8221; in the consolidated income statements. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock', window );">Healthcare contributions</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#8217;s healthcare costs, other than programs described in &#8220;Revenue recognition&#8221; in this Note 1, are recognized in &#8220;Other expense&#8221; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#8217;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Impact of adopting significant new IFRS standards</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#8217;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#8217;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#8211; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#8211; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#8217;s financial instruments and risk management strategies did not have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]
Effective 2023-01-01: The description of the entity's material accounting policy information for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.
Effective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.
Effective 2023-01-01: The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]
Effective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]
Effective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]
Effective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]
Effective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313953102272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Respective Useful Lives of property, plant and equipment</a></td>
<td class="text">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>
                    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock', window );">Respective Useful Lives of Available-for-Use Intangible Assets</a></td>
<td class="text">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313954920400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segmentation - Consolidated income statements</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            825
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            42 121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 454
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 569</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 978</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 061
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 486</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 801
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 504
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            36 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 679</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-512</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 172</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-824</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 695</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-733</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 701</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 786
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 448
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 037</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-204</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-122</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 728</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-222</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-260</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 069</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-259</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 368</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-706</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-280</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 048</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 835
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 927</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 058
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 121</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 636
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 657</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 076</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 197</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 118</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-862</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 980</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 871</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-831</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-488</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 190</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 152
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            670
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 071
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-912</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-282</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-330</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 080</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-370</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 462</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-116</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-440</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            335
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-217</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-354</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-714</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock', window );">Segmentation - Consolidated balance sheets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            75 510
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79 220
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16 078
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 865
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 383
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            117 453
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            131 795
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-16 966</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-15 929</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 710</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 632</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-37 354</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-44 412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-58 030</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63 973</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            59 423
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67 822
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            58 544
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63 291
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 161</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66 668
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            68 690
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            991
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to right-of-use assets<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            222
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51 357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53 919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 603
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 791
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            102
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock', window );">Net sales and total of selected non-current assets, by countries and regions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            970
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            800
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 708
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 353
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 615
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 870
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 518
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 229
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 378
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 052
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 573
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            599
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            703
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 683
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 804
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            165
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            217
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 525
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 806
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 781
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 041
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock', window );">Net sales by region</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021<br/> to 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020<br/> to 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 554
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 919
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 484
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 929
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 304
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 914
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31 459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 643
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 748
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 913
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 613
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 662
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            969
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 460
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 855
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 776
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 557
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 883
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37 008
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 537
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 927
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock', window );">Other revenue</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            74
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock', window );">Net sales</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 756
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 287
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            372
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 051
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 007
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 272
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            577
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            475
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            445
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            320
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            271
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            157
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 723
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 101
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 666
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            479
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            623
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            203
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            334
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            323
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            393
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 944
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 694
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock', window );">Net sales of Top 20 products</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 018
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 354
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 290
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 046
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            678
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            434
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            936
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            800
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            472
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            759
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            540
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            729
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            597
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            340
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 753
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            19 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            32 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 159
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 883
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 836
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 427
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 178
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 069
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            606
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 087
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            843
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            558
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            263
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            761
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            521
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            417
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            598
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            887
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            722
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 976
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 664
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 311
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 331
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 996
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 516
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 479
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 562
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 277
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            833
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            569
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            973
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            837
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            315
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            879
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            964
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            461
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            369
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            515
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 881
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 097
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 671
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock', window );">Net sales</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 776
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 092
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 244
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 928
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            423
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952463184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Schedule disclosing information related to associates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 387
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock', window );">Schedule disclosing information related to associates, net income effect</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            815
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-172</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955631600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseTableTextBlock', window );">Interest expense</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-669</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-651</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-708</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-60</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-108</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock', window );">Other financial income and expense</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-184</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-69</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-135</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949693776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of Income Tax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeBeforeTaxesTableTextBlock', window );">Income before taxes</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 986
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22 028
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 786
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#8217;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock', window );">Current and deferred income tax expense</a></td>
<td class="text">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-617</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-932</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 454</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 470</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 168</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 071</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 428</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-142</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfTaxRateTableTextBlock', window );">Analysis of tax rate</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-7.3</span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AnalysisOfTaxRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AnalysisOfTaxRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeBeforeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeBeforeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949953696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings per share</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 181
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 277
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.55
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949974336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock', window );">Comprehensive income</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Fair value<br/> adjustments <br/> on financial<br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Actuarial<br/> gains/(losses)<br/> from defined<br/> benefit plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Cumulative<br/> currency <br/> translation<br/> effects</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br/> adjustments<br/> attributable to <br/> Novartis AG <br/> shareholders</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Non-<br/> controlling<br/> interest</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total value<br/> adjustments</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            120
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 919</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 657</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 686</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-36</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-3</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 10 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 992
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 387
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 386
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 773</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 134
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 419</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 448</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-44</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD 33 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-323</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 17 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 762</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 541</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 543</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 968</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 187</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 220</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD 81 million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-30</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-104</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-103</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 18 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-450</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-353</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-839</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-844</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-4</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-198</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 038</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-760</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 034</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955368448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PropertyPlantAndEquipmentTableTextBlock', window );">Property, plant and equipment [table text block]</a></td>
<td class="text">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-964</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            667
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            780
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-155</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-351</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-166</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-57</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-288</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 184
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 170</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 109</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            549
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            555
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 377
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 063</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 955</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-610</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 027
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-453</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-755</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-203</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-199</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-509</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock', window );">Property, plant and equipment impairment charges and reversals [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-411</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-315</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-326</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-447</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313948625680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract', window );"><strong>Right of use assets Disclosure and Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock', window );">Disclosure of Right-of-use assets roll forward</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 676
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock', window );">Disclosure of right-of-use assets carrying value and depreciation charge</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br/> 2022<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br/> charge<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br/> 2021<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br/> charge<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            505
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            522
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            866
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            117
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            136
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock', window );">Disclosure of maturity analysis of lease liability</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Lease liabilities<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br/> undiscounted<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Lease liabilities<br/> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br/> undiscounted<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            324
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            232
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            258
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            167
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            201
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            198
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            982
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 349
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-251</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-297</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-275</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 908
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 025
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            134
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Additional disclosures related to right-of-use assets and lease liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            355
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            381
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Thereof:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of interest<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of lease liabilities<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952874176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock', window );">Movements of goodwill and intangible assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 429</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 603</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-342</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-72</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-427</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-176</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-243</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-432</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 305
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69 684
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 671</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32 736</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 716</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38 040</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 115
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            57 333
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67 725
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-885</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26 566</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 272</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30 916</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            270
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-36</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 607</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-255</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-350</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-642</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-584</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-672</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock', window );">Allocation of net book values of goodwill and intangible assets by reporting segment</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 531
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 186
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 139
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 826
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 460
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21 562
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 313
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 938
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 091
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32 357
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 577
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock', window );">Assumptions used in the calculation of valuation</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br/> Medicines</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Sandoz</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IntangibleAssetImpairmentChargesTextBlock', window );">Intangible asset impairment charges and reversals</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IntangibleAssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IntangibleAssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955538544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Property, <br/> plant and<br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br/> other benefit <br/> obligations <br/> of employees</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Inventories</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Tax loss<br/> carry-<br/> forwards</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other assets,<br/> provisions<br/> and accruals</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            125
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 307
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 273
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 727
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 832
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            628
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 726
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            739
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 051
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-343</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 785</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-420</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-138</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 312</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 998</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 739
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 686</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 502
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            507
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 344
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-430</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-340</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 552</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-323</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-317</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-46</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 307
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 273
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 727
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 832
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 070</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#8217;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Gross value of tax-loss carry-forwards</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 880
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            885
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 610
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 140
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            166
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            418
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            684
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 799
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949921904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsTableTextBlock', window );">Financial assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 145
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 663
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 063
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            184
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 411
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 036
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock', window );">Other non-current assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            419
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 210
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949661984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories by class</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            934
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            870
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 568
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 636
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 666
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock', window );">Amount of inventory recognized as an expense in cost of goods sold</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.8</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock', window );">Recognized amount of inventory provisions and reversals of inventory provision</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-573</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-702</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952547152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForTradeReceivablesTableTextBlock', window );">Provisions for trade receivables</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock', window );">Trade receivables provision movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-59</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock', window );">Overdue amounts and related provision</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 664
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 639
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock', window );">Trade receivables denominated in other currencies</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 709
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 344
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 426
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            383
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            106
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesProvisionMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955403456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock', window );">Marketable securities, commodities, timedeposits, and derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 922
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsTableTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 396
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 640
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 011
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949924752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsTableTextBlock', window );">Other current assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            509
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            911
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 440
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952577952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInTheShareCapitalTableTextBlock', window );">Schedule disclosing information related to movement in the share capital</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Jan 1, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Dec 31, 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            936
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            890
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-92</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            856
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            853
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInTheShareslTableTextBlock', window );">Schedule disclosing information related to movement in the shares</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Number of outstanding shares <br/>(in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 527.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-262.3</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 265.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-84.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            52.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 403.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-284.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 119.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;5&#160;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DividendTableTextBlock', window );">Schedule disclosing information related to Dividend</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.10
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3.00
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.95
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock', window );">Schedule disclosing information related treasury shares movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 787</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 775</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 897</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-123</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-145</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-127.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 910</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 920</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 056</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            88
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            806
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            854
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            730
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9 963</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareslTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareslTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SummaryOfTreasurySharesMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313954915744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock', window );">Disclosure of non-current portion of non-current borrowings by type</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 621</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Average interest rate 2.3% (2021: 0.9%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock', window );">Disclosure of detailed information about borrowings</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Coupon</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Issuance <br/> year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Maturity <br/> year</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issuer</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issue price</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.225%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 498
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2042
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.325%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 150
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2024
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.287%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2044
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.196%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 827
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 826
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2026
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.697%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            676
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.250%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.640%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            541
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            547
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            550
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2029
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.502%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.050%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2035
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.479%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            352
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            356
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.010%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 740
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2045
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.029%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.127%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 409
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.480%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            559
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.449%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.100%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.109%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            994
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            993
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.874%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.500%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.655%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.375%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.957%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2038
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.217%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            840
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.852%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.909%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.200%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.869%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 494
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 493
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2050
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              97.712%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 214
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.000%</span>
                            <sup style="white-space: nowrap">&#160;1</sup>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.354%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The EUR 1 850 million bond issued in 2020 features a coupon step-up of <span>0.25%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock', window );">Non-current financial debt including current portion by maturity</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 342
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 284
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 909
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 269
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock', window );">Non-current financial debt including current portion by currency</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 376
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 862
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 505
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock', window );">Comparison of balance sheet and fair value of total non-current financial debt including current portion</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 277
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 079
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 306
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949933744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Disclosure of other provisions [text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Defined benefit pension plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 723
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 640
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            554
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            662
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other post-employment benefits<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            704
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            956
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            519
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 906
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock', window );">Accrual for environmental loss contingencies [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            616
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            714
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-169</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-  105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            616
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            642
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock', window );">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br/> cash outflows</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock', window );">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 369
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-292</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 863</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            466
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            702
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-548</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-306</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            181
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950091152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock', window );">Current financial debt and derivative instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> Weighted average interest rate 9.7% (2021: 6.1%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955833824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            836
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            619
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            752
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            119
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 670
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock', window );">Provisions for reduction of revenue</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 481
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 595
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-218</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            234
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-22 261</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 838</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 294</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-245</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-151</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 072
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsTableTextBlock', window );">Restructuring provisions movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            345
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            354
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-468</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-268</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForReductionOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RestructuringProvisionsMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RestructuringProvisionsMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952493552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock', window );">Adjustments for non-cash items from continuing operations</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 570
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 489
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 758
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            303
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 306
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 376
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial assets<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-335</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 411
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-333</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-677</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-478</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            823
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            736
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 339</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-673</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 807
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            891
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 546
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 881
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock', window );">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-830</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            81
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-589</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-389</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-202</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            229
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-291</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock', window );">Cash flows arising from acquisitions and divestments of businesses</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 077</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-735</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 173</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-864</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 006</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            66
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-879</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-567</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-9 957</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2020, USD 49 million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock', window );">Reconciliation of liabilities arising from financing activities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 902
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 295
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 575</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            173
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-366</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-401</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 325</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-224</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            224
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 524</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-774</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-309</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 624</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 624
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-247</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 353
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 031
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 703
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            246
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-312</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            832
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 067</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-250</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949883392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock', window );">Fair value of assets and liabilities arising from acquisitions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 600
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 977</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-144</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            612
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 669
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-89</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 580
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 077
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            735
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 173
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945169936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock', window );">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 602
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            632
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            348
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 046</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-713</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-377</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-650</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-865</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 500</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 644</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Reconciliation of the net liability table</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 336</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-348</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-415</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 071
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 723</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 640</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock', window );">Principal weighted average actuarial assumptions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.6%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              3.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.4%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.3%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.2%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.1%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock', window );">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-466</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-790</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            839
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            869
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-136</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">The healthcare cost trend rate assumptions used for other post-employment benefits</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.5%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">The weighted average plan asset allocation of funded defined benefit pension plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(as a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> minimum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> maximum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            40
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock', window );">Asset allocation, investments in shares of Novartis AG</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">The expected future cash flows in respect of pension and other post- employment benefit plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Pension plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br/> employment<br/> benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 268
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#8211;2032</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock', window );">Defined contribution plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            523
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s total personnel costs amounted to USD 14.9 billion in 2022.</div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 824
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 746
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 963
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 268
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 670
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            363
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            1 127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 799
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            620
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 510
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            830
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 691
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 208
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 730
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 025
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 681
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 135
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 701
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 978
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 436
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 551
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-697</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 237</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            346
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            464
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-286</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-400</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDefinedBenefitPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDefinedContributionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952084560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock', window );">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 048
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            979
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            269
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of unvested restricted stock units roll forward</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            87.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            89.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember', window );">Select outside North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            63.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember', window );">Select North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            64.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313953153680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OfficerAndDirectorCompensationTableTextBlock', window );">Executive Officers and Non-Executive Directors Compensation</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30.2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            47.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            70.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            60.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            69.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            79.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            70.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock', window );">Transactions with former members of the Board of Directors</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OfficerAndDirectorCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OfficerAndDirectorCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949924752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock', window );">Leasing commitments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            420
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            808
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            282
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 169
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 814
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfLeasingCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945354592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">Disclosure of financial assets and financial liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 971
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 581
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 553
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 094
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            189
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock', window );">Contract or underlying principal amount the derivative financial instruments, by currency</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 158
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value by hierarchy</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 070
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-186</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 697
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 704
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock', window );">Reconciliation of changes in fair value measurement</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other<br/> financial<br/> liabiltiies</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            338
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            617
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            641
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-114</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-231</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> payables</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            460
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            625
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 046</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-189</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-88</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">Equity securities measured at fair value through other comprehensive income</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            888
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            390
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            307
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock', window );">Monitoring of net debt or liquidity based on contractual maturities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 911
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            36
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 098
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 011
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 506
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 564
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            135
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-9 002</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-11 394</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-20 396</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 515</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 876</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-2 517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-5 878</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 519</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 931</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 405
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 245</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 585
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 706
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 406
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 001
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 095
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-8 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-14 587</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-23 077</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 926</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 227</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-6 229</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-50</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 830</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-537</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-6 295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 608
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 833</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 460</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 296</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-868</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock', window );">Derivative financial instruments and accrued interest on derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 029</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 598</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 943</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 029
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 062
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-843</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 482</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-461</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 786</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            847
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 516
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            457
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 820
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock', window );">Other contractual liabilities of the net debt or liquidity</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 432</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 624</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 532</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-616</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-922</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 789</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 020</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 146</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-115</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-267</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-82</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-445</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 628</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 908</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 063</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-197</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-639</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 896</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 373</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 553</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-439</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock', window );">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock', window );">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock', window );">Potential impact on the consolidated income statement due to increase (decrease) in equity prices</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            109
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-109</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-154</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock', window );">Potential impact on the consolidated equity due to increase (decrease) in equity prices</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-179</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949872864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Soci&#233;t&#233; par actions SANDOZ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Algiers
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Argentina S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Buenos Aires
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            906.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Austria GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kundl
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Unterach am Attersee
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Bangladesh) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gazipur
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              60%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Alcon - Couvreur NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Puurs
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Securities Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Services Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Triangle International Reinsurance Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Trinity River Insurance Co Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            370 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioci&#234;ncias S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            S&#227;o Paulo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            507.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Camb&#233;, PR
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dorval, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Boucherville, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Chile S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santiago de Chile
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing Novartis Pharma Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals (HK) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hong Kong
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            320.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Suzhou Novartis Technical
Development Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Changshu
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai Novartis Trading Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zhongshan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Colombia S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santaf&#233; de Bogot&#225;
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz d.o.o. farmaceutska industrija
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zagreb
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ecuador S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Quito
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cairo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.96%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Egypt Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            New Cairo City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finland Oy
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Espoo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            459 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Groupe France S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            903.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies France SAS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Molecular Imaging France
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Saint-Genis-Pouilly
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CELLforCURE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Ulis
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Levallois-Perret
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Deutschland GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Business Services GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Produktions GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz International GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 A Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            HEXAL AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Salutas Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barleben
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Aeropharm GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rudolstadt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Hellas) S.A.C.I.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Metamorphosis / Athens
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            233.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Hungary Healthcare Limited Liability
Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            545.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Hungary Limited Liability Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            883.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis India Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              70.68%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            PT. Novartis Indonesia
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Jakarta
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ireland Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Integrated Services Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cork City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies EU Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Israel Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tel Aviv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Milan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (Italy) S.r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Pozzilli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Origgio
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ciba-Geigy Japan Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Baltics SIA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riga
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investments S.&#224; r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Petaling Jaya
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            468.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Maroc SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Casablanca
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Netherlands B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            IDB Holland BV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Baarle-Nassau
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Almere
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            907 560
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis New Zealand Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Auckland
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            820 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Norge AS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oslo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Pakistan) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Karachi
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Logistics), Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Panama City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Philippines, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            298.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Philippines Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Poland Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Polska Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Strykow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Portugal, S.G.P.S., Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma - Produtos Farmac&#234;uticos, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#234;utica, Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            499 900
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services Romania S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bucharest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Targu-Mures
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Neva LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            St. Petersburg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            JSC Sandoz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saudi Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riyadh
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Singapore) Pte Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            45.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Slovakia s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bratislava
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Korea Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Seoul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Esplugues de Llobregat
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#233;utica S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Madrid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            270 450
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Industrial Products
S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Franqueses del Vall&#233;s / Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Abadia Retuerta S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sard&#243;n de Duero / Valladolid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Sverige AB
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stockholm
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Holding AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International Pharmaceutical Investment AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioventures AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Forschungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Kaderausbildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Mensch und Umwelt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Overseas Investments AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Japat AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            350.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweizerhalle AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Muttenz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Stein AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stein
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweiz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cellerys AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Schlieren
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129 630
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              20%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Arctos Medical AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bern
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            360 020
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Innovative Therapies AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications International SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Geneva
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Taiwan) Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Taipei
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            170.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Thailand) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bangkok
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            302.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ila&#231; Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            880.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gebze - Kocaeli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ukraine LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kyiv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Middle East FZE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dubai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Grimsby Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (UK &amp; Ireland)
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Neutec Pharma Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gyroscope Therapeutics Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 492
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Frimley / Camberley
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis US Foundation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications USA, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Millburn, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bannockburn, IL
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Technology LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Institutes for BioMedical
Research, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cadent Therapeutics
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Endocyte, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Navigate BioPharma Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Carlsbad, CA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            The Medicines Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oriel Therapeutics, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Durham, NC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Fougera Pharmaceuticals Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Melville, NY
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Eon Labs, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Venezuela, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Caracas
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Vietnam Company Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ho Chi Minh City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            70
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313950056096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share</a></td>
<td class="nump">SFr 0.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942656272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,077,000,000<span></span>
</td>
<td class="nump">$ 735,000,000<span></span>
</td>
<td class="nump">$ 10,173,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,053,000,000)<span></span>
</td>
<td class="num">(673,000,000)<span></span>
</td>
<td class="num">(792,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,644,000,000<span></span>
</td>
<td class="nump">34,182,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,545,000,000<span></span>
</td>
<td class="nump">51,626,000,000<span></span>
</td>
<td class="nump">48,659,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,485,000,000<span></span>
</td>
<td class="nump">25,523,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,000,000<span></span>
</td>
<td class="nump">1,208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,121,000,000<span></span>
</td>
<td class="nump">42,790,000,000<span></span>
</td>
<td class="nump">39,805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,454,000,000<span></span>
</td>
<td class="nump">9,811,000,000<span></span>
</td>
<td class="nump">9,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,030,000,000)<span></span>
</td>
<td class="num">(975,000,000)<span></span>
</td>
<td class="num">$ (981,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBearerShares', window );">Number of bearer shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment of interests in associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,556,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember', window );">Sandoz | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, divestment-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember', window );">Aspen Global Incorporated | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,000,000)<span></span>
</td>
<td class="num">&#8364; (274.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000,000<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">&#8364; 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember', window );">The Medicines Company | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember', window );">GlaxoSmithKline plc (GSK) | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBrandsInPortfolioToAcquire', window );">Number of brands in portfolio to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfMarketsForTheAcquiredBrands', window );">Number of markets for the acquired brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember', window );">Gyroscope Therapeutics Holdings plc. | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="num">(800,000,000)<span></span>
</td>
<td class="num">$ (800,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | The Medicines Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOfferPerOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOfferPerOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomaryPurchasePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomaryPurchasePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentDateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBearerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBearerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBrandsInPortfolioToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBrandsInPortfolioToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfMarketsForTheAcquiredBrands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfMarketsForTheAcquiredBrands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialMilestoneMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialMilestoneMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955320032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBusinessUnits', window );">Number of Business Units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfCommercialOrganizationalUnits', window );">Number of commercial organizational units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfFranchises', window );">Number of Franchises</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBusinessUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBusinessUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfCommercialOrganizationalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfCommercialOrganizationalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfFranchises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfFranchises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945279360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">50,545<span></span>
</td>
<td class="nump">51,626<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(15,486)<span></span>
</td>
<td class="num">(15,867)<span></span>
</td>
<td class="num">(15,121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">36,342<span></span>
</td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(14,253)<span></span>
</td>
<td class="num">(14,886)<span></span>
</td>
<td class="num">(14,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(9,540)<span></span>
</td>
<td class="num">(8,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(3,701)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">9,197<span></span>
</td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">26,137<span></span>
</td>
<td class="nump">9,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">41,296<span></span>
</td>
<td class="nump">41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">42,121<span></span>
</td>
<td class="nump">42,790<span></span>
</td>
<td class="nump">39,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(11,569)<span></span>
</td>
<td class="num">(11,751)<span></span>
</td>
<td class="num">(10,927)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,801<span></span>
</td>
<td class="nump">32,218<span></span>
</td>
<td class="nump">29,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(11,679)<span></span>
</td>
<td class="num">(12,306)<span></span>
</td>
<td class="num">(11,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,172)<span></span>
</td>
<td class="num">(8,641)<span></span>
</td>
<td class="num">(8,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(2,695)<span></span>
</td>
<td class="num">(1,732)<span></span>
</td>
<td class="num">(1,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">8,786<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
<td class="nump">9,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="nump">9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,454<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
<td class="nump">9,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(4,978)<span></span>
</td>
<td class="num">(5,147)<span></span>
</td>
<td class="num">(5,252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,504<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(2,062)<span></span>
</td>
<td class="num">(2,062)<span></span>
</td>
<td class="num">(2,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(824)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="num">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(733)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,332<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955092864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(260)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="num">(979)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="num">(3,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(3,638)<span></span>
</td>
<td class="num">(3,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">$ (122)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942548400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">$ 117,453<span></span>
</td>
<td class="nump">$ 131,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(58,030)<span></span>
</td>
<td class="num">(63,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">$ 56,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">66,668<span></span>
</td>
<td class="nump">68,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">60,945<span></span>
</td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">18,930<span></span>
</td>
<td class="nump">28,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax liabilities and deferred tax liabilities</a></td>
<td class="nump">5,219<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">75,510<span></span>
</td>
<td class="nump">79,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(16,966)<span></span>
</td>
<td class="num">(15,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">58,544<span></span>
</td>
<td class="nump">63,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">8,488<span></span>
</td>
<td class="nump">9,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">51,357<span></span>
</td>
<td class="nump">53,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">1,791<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">16,078<span></span>
</td>
<td class="nump">16,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(3,710)<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">12,368<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">25,865<span></span>
</td>
<td class="nump">36,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(37,354)<span></span>
</td>
<td class="num">(44,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="num">(4,244)<span></span>
</td>
<td class="num">(7,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">18,930<span></span>
</td>
<td class="nump">28,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax liabilities and deferred tax liabilities</a></td>
<td class="nump">$ 5,219<span></span>
</td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionsToInvestmentInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionsToInvestmentInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentIncomeTaxAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialDebtsAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialDebtsAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313946099456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 73,483<span></span>
</td>
<td class="nump">$ 77,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 23,708<span></span>
</td>
<td class="nump">$ 25,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 17,653<span></span>
</td>
<td class="nump">$ 16,818<span></span>
</td>
<td class="nump">$ 16,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,353<span></span>
</td>
<td class="nump">$ 37,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,257<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 2,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">$ 3,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,278<span></span>
</td>
<td class="nump">$ 4,870<span></span>
</td>
<td class="nump">$ 4,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 2,229<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,205<span></span>
</td>
<td class="nump">$ 2,683<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="nump">$ 3,052<span></span>
</td>
<td class="nump">$ 2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 20,054<span></span>
</td>
<td class="nump">$ 20,808<span></span>
</td>
<td class="nump">$ 19,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 8,241<span></span>
</td>
<td class="nump">$ 7,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313946161120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 73,483<span></span>
</td>
<td class="nump">$ 77,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 18,467<span></span>
</td>
<td class="nump">$ 20,197<span></span>
</td>
<td class="nump">$ 18,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,896<span></span>
</td>
<td class="nump">$ 37,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember', window );">Americas [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 21,536<span></span>
</td>
<td class="nump">$ 20,463<span></span>
</td>
<td class="nump">$ 19,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,806<span></span>
</td>
<td class="nump">$ 37,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,542<span></span>
</td>
<td class="nump">$ 10,966<span></span>
</td>
<td class="nump">$ 10,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313946152496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 6)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomersWithNetSalesOverFivePercent', window );">Customers with net sales over five percent</a></td>
<td class="text">

                  The Group&#8217;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember', window );">Largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember', window );">Second largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember', window );">Third largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomersWithNetSalesOverFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomersWithNetSalesOverFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEntitysTradeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEntitysTradeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313939727488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Net sales by region (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 18,467<span></span>
</td>
<td class="nump">$ 20,197<span></span>
</td>
<td class="nump">18,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 17,653<span></span>
</td>
<td class="nump">$ 16,818<span></span>
</td>
<td class="nump">16,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,542<span></span>
</td>
<td class="nump">$ 10,966<span></span>
</td>
<td class="nump">10,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,883<span></span>
</td>
<td class="nump">$ 3,645<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 37,008<span></span>
</td>
<td class="nump">$ 38,314<span></span>
</td>
<td class="nump">36,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 13,537<span></span>
</td>
<td class="nump">$ 13,312<span></span>
</td>
<td class="nump">11,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 41,296<span></span>
</td>
<td class="nump">$ 41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">13,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 15,899<span></span>
</td>
<td class="nump">$ 14,999<span></span>
</td>
<td class="nump">14,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 8,929<span></span>
</td>
<td class="nump">$ 9,304<span></span>
</td>
<td class="nump">8,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,914<span></span>
</td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 30,548<span></span>
</td>
<td class="nump">$ 31,459<span></span>
</td>
<td class="nump">29,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,748<span></span>
</td>
<td class="nump">$ 10,536<span></span>
</td>
<td class="nump">9,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">$ 9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,913<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">2,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,613<span></span>
</td>
<td class="nump">$ 1,662<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 969<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,460<span></span>
</td>
<td class="nump">$ 6,855<span></span>
</td>
<td class="nump">7,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">$ 2,776<span></span>
</td>
<td class="nump">$ 2,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313943513632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 41,296<span></span>
</td>
<td class="nump">$ 41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 31,396<span></span>
</td>
<td class="nump">$ 29,754<span></span>
</td>
<td class="nump">25,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,756<span></span>
</td>
<td class="nump">$ 3,560<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,644<span></span>
</td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Leqvio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 7,287<span></span>
</td>
<td class="nump">$ 7,205<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="nump">$ 4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,133<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 5,051<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,013<span></span>
</td>
<td class="nump">$ 2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(28.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">194.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Mayzent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Aimovig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,723<span></span>
</td>
<td class="nump">$ 4,101<span></span>
</td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Lutathera [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Piqray [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Pluvicto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tabrecta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">157.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,452<span></span>
</td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="nump">$ 2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,923<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Scemblix [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(67.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,127<span></span>
</td>
<td class="nump">$ 3,451<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Xiidra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Beovu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Other Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">$ 12,241<span></span>
</td>
<td class="nump">13,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(45.00%)<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(43.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Contract manufacturing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
<td class="nump">$ 4,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_PromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_PromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PluvictoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PluvictoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ScemblixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ScemblixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935268336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Top 20 (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">17,653<span></span>
</td>
<td class="nump">16,818<span></span>
</td>
<td class="nump">16,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">41,296<span></span>
</td>
<td class="nump">41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">32,137<span></span>
</td>
<td class="nump">32,664<span></span>
</td>
<td class="nump">29,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,159<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="nump">9,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,644<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">15,899<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
<td class="nump">14,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">12,753<span></span>
</td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">11,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">3,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">25,397<span></span>
</td>
<td class="nump">26,996<span></span>
</td>
<td class="nump">24,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">19,384<span></span>
</td>
<td class="nump">20,976<span></span>
</td>
<td class="nump">18,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">31,396<span></span>
</td>
<td class="nump">29,754<span></span>
</td>
<td class="nump">25,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,756<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,644<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,723<span></span>
</td>
<td class="nump">4,101<span></span>
</td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">6,452<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">3,127<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">12,241<span></span>
</td>
<td class="nump">13,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_Top20ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_Top20ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_PromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_PromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945117856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 10) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">$ 9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Retail Generics [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,776<span></span>
</td>
<td class="nump">$ 7,092<span></span>
</td>
<td class="nump">7,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Biopharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="nump">$ 2,116<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member] | Total anti-infectives net sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RetailGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RetailGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_AntiInfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_AntiInfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_TotalAntiinfectivesNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_TotalAntiinfectivesNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955775664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 11) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MilestoneIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MilestoneIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherRevenueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherRevenueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitSharingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitSharingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313944995152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,339<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies', window );">Recycling of the Novartis share of other comprehensive income from associated companies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the total comprehensive income of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952527264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 1) - Roche Holding AG, Switzerland - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceived', window );">Dividends received</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment of interests in associated companies</a></td>
<td class="nump">14,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</a></td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955304304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,339<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareOfCurrentYearNetIncome', window );">Novartis share of current year consolidated net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PriorYearAdjustment', window );">Prior year adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets', window );">Amortization of fair value adjustments relating to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax', window );">Amortization of fair value adjustments relating to intangible assets tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PriorYearAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PriorYearAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareOfCurrentYearNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareOfCurrentYearNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955738528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseAbstract', window );"><strong>Interest expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions', window );">Interest expense</a></td>
<td class="num">$ (669)<span></span>
</td>
<td class="num">$ (651)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Expense arising from discounting long-term liabilities and capitalized borrowing costs</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Total interest expense</a></td>
<td class="num">$ (837)<span></span>
</td>
<td class="num">$ (811)<span></span>
</td>
<td class="num">$ (869)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952756592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseAbstract', window );"><strong>Other financial income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromDividends', window );">Other financial income</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Financial expense</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Currency result, net</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Total other financial income and expense</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as income. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313953108896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 8,371<span></span>
</td>
<td class="nump">$ 26,137<span></span>
</td>
<td class="nump">$ 9,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">5,986<span></span>
</td>
<td class="nump">22,028<span></span>
</td>
<td class="nump">9,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 2,385<span></span>
</td>
<td class="nump">$ 4,109<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945358320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">$ (2,071)<span></span>
</td>
<td class="num">$ (2,428)<span></span>
</td>
<td class="num">$ (2,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(617)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
<td class="num">(932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952942208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">16.80%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Effect of disallowed expenditures</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Effect of utilization of tax losses brought forward from prior periods</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates', window );">Effect of income taxed at reduced rates</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation', window );">Tax rate effect of revenues exempt from taxation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfCreditsAndAllowances', window );">Effect of tax credits and allowances</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability', window );">Effect of release of contingent consideration liability</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Effect of tax rate change on current and deferred tax assets and liabilities</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectOfWriteoffOfDeferredTaxAssets', window );">Effect of derecognition and reversals of derecognition of deferred tax assets</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries', window );">Effect of write down and reversal of write down of investments in subsidiaries</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods', window );">Effect of prior year items</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Effective income tax rate reconciliation change in uncertain tax positions</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Effect of other items</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">16.90%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">18.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain', window );">Effect of income not subject to tax on divestment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfWriteoffOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfWriteoffOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfCreditsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfCreditsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfIncomeTaxedAtReducedRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951768608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/loss attributable to shareholders of Novartis AG | $</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,021<span></span>
</td>
<td class="nump">$ 8,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used in the basic earnings per share</a></td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares in diluted earnings per share</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total basic earnings per share | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted earnings per share | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OptionsExcludedFromTheCalculation', window );">Options excluded from the calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OptionsExcludedFromTheCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OptionsExcludedFromTheCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313939755936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember', window );">Fair value adjustments on financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember', window );">Fair value adjustments on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">81<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember', window );">Fair value adjustments on equity securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember', window );">Value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember', window );">Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember', window );">Actuarial gains/losses from defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(5,773)<span></span>
</td>
<td class="num">(5,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(4,038)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(5,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(407)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,757)<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(4,541)<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(760)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember', window );">Total value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,187)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,757)<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(839)<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(4,996)<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember', window );">Total fair value adjustments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,220)<span></span>
</td>
<td class="num">(1,448)<span></span>
</td>
<td class="num">(4,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(2,543)<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">$ (5,034)<span></span>
</td>
<td class="num">$ (4,220)<span></span>
</td>
<td class="num">$ (1,448)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2022-03-24<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956181904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">$ 11,545<span></span>
</td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(414)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
<td class="num">$ (447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments for purchases of property, plant and equipment</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Capitalized borrowing costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">27,147<span></span>
</td>
<td class="nump">28,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">24,873<span></span>
</td>
<td class="nump">27,147<span></span>
</td>
<td class="nump">28,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(15,602)<span></span>
</td>
<td class="num">(15,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(14,109)<span></span>
</td>
<td class="num">(15,602)<span></span>
</td>
<td class="num">(15,955)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">5,493<span></span>
</td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">12,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">11,396<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">12,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(5,744)<span></span>
</td>
<td class="num">(5,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(5,903)<span></span>
</td>
<td class="num">(5,744)<span></span>
</td>
<td class="num">(5,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(964)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,672<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">13,328<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">11,842<span></span>
</td>
<td class="nump">13,328<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(9,786)<span></span>
</td>
<td class="num">(10,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">$ (8,170)<span></span>
</td>
<td class="num">$ (9,786)<span></span>
</td>
<td class="num">$ (10,063)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2022-03-24<br> -Paragraph 26<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 74<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_74_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfPropertyPlantAndEquipmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945681600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">$ (414)<span></span>
</td>
<td class="num">$ (384)<span></span>
</td>
<td class="num">$ (447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(411)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951648176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfTheRightofuseAssetsRollForward', window );"><strong>Movements of the right-of-use assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets', window );">Impact of business combinations</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseContractTerminationsRightofuseAssets', window );">Lease contract terminations, right-of-use assets</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets', window );">Impairment loss recognised in profit or loss, right of use assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets', window );">Increase decrease through net exchange differences, right-of-use assets</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseContractTerminationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseContractTerminationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfTheRightofuseAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfTheRightofuseAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951884720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember', window );">Land [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Machinery &amp; equipment and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942082464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">3,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Less current lease liabilities</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentLeaseLiabilitiesUndiscounted', window );">Less current lease liabilities undiscounted</a></td>
<td class="num">(297)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted', window );">Non-current lease liabilities undiscounted</a></td>
<td class="nump">2,908<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsForLeasesNotYetCommenced', window );">Commitments for leases not yet commenced</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MostMaterialLeaseWithLeaseTermExtension', window );">Most material lease with lease term extension</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseTermEndDate', window );">Lease term end date</a></td>
<td class="text">2071<span></span>
</td>
<td class="text">2071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsForLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsForLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseTermEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseTermEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MostMaterialLeaseWithLeaseTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MostMaterialLeaseWithLeaseTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313953081552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember', window );">Sale and lease back [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashInflowForSaleAndLeaseback', window );">Cash inflow for sale and leaseback</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions', window );">Gains or losses from sales leaseback</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) arising from sale and leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashInflowForSaleAndLeaseback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashInflowForSaleAndLeaseback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951601680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases for which recognition exemption has been used</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets for which recognition exemption has been used</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsForShortTermAndLowValueLeases', window );">Cash outflows for short term and low value leases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsForPaymentsOfLeasesInterest', window );">Cash outflows for payments of leases interest</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateLeaseLiabilities', window );">Weighted average interest rate lease liabilities</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForPaymentsOfLeasesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForPaymentsOfLeasesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForShortTermAndLowValueLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForShortTermAndLowValueLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956041808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">$ 63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">60,945<span></span>
</td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">29,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">4,421<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(3,603)<span></span>
</td>
<td class="num">(3,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">25,513<span></span>
</td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">29,596<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">68,211<span></span>
</td>
<td class="nump">67,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">69,684<span></span>
</td>
<td class="nump">68,211<span></span>
</td>
<td class="nump">67,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">8,013<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">7,092<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">56,213<span></span>
</td>
<td class="nump">57,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">58,249<span></span>
</td>
<td class="nump">56,213<span></span>
</td>
<td class="nump">57,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(30,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(38,040)<span></span>
</td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(30,916)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(2,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(2,671)<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(2,193)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(29,107)<span></span>
</td>
<td class="num">(26,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(32,736)<span></span>
</td>
<td class="num">(29,107)<span></span>
</td>
<td class="num">(26,566)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(1,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">$ (1,716)<span></span>
</td>
<td class="num">$ (1,505)<span></span>
</td>
<td class="num">$ (1,272)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313946141136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">$ 60,945<span></span>
</td>
<td class="nump">$ 63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">51,357<span></span>
</td>
<td class="nump">53,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">21,531<span></span>
</td>
<td class="nump">21,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">7,770<span></span>
</td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">29,826<span></span>
</td>
<td class="nump">32,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">4,421<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member] | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member] | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">25,513<span></span>
</td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">24,487<span></span>
</td>
<td class="nump">25,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955487392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 2) - Operating segments [member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal Growth Rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal', window );">Discount Rate (post-tax)</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal Growth Rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal', window );">Discount Rate (post-tax)</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used in the current measurement of fair value less costs of disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph f<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_f_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952977952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 3) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember', window );">Leqvio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntity', window );">Carrying value</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember', window );">Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntity', window );">Carrying value</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that are material to the entity&#8217;s financial statements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955028720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (1,326.0)<span></span>
</td>
<td class="num">$ (403.0)<span></span>
</td>
<td class="num">$ (914.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(917.0)<span></span>
</td>
<td class="num">(350.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(15.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(322.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(72.0)<span></span>
</td>
<td class="num">(35.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Votrient [member] | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(900.0)<span></span>
</td>
<td class="num">(1,300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(1,299.0)<span></span>
</td>
<td class="num">(367.0)<span></span>
</td>
<td class="num">(768.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(25.0)<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
<td class="num">(141.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Innovative Medicines | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Innovative Medicines | Votrient [member] | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945046576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">$ 8,051<span></span>
</td>
<td class="nump">$ 7,832<span></span>
</td>
<td class="nump">$ 8,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(6,998)<span></span>
</td>
<td class="num">(7,159)<span></span>
</td>
<td class="num">(7,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Charged to equity</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction', window );">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</a></td>
<td class="nump">4,312<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(4,785)<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(5,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember', window );">Pensions and other benefit obligations of associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember', window );">Inventories [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember', window );">Tax loss carryforwards [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember', window );">Other assets, provisions and accruals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(1,335)<span></span>
</td>
<td class="num">(1,344)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Charged to equity</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="nump">$ 1,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInDeferredTaxBalanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInDeferredTaxBalanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942160032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">$ 8,140<span></span>
</td>
<td class="nump">$ 6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueOfTaxLossCarryforwardsExpired', window );">Tax loss carryforwards expired</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_OneYearMember', window );">One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_TwoYearsMember', window );">Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_ThreeYearsMember', window );">Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_FourYearsMember', window );">Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_FiveYearsMember', window );">Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember', window );">More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">6,260<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember', window );">Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">4,610<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueOfTaxLossCarryforwardsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueOfTaxLossCarryforwardsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_TwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_TwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_ThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_ThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_FourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_FourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_FiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_FiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949111392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details 2) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment', window );">Unremitted earnings retained by consolidated entities for reinvestment</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951627520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial and other non-current assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsEquityInvestments', window );">Non-current financial assets, equity securities</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAsstetsDebtSecurities', window );">Non-current financial asstets debt securities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsFundInvestments', window );">Non-current financial assets, fund investments</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsTotalFinancialInvestments', window );">Non-current financial assets, total financial investments</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LongTermReceivablesFromFinanceSubleases', window );">Long term receivables from finance subleases</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other long-term receivables</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationReceivable', window );">Contingent consideration receivables</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLoansAndReceivables', window );">Long-term loans, advances and security deposits</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">$ 2,411<span></span>
</td>
<td class="nump">$ 3,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current loans and receivables. [Refer: Loans and receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LongTermReceivablesFromFinanceSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LongTermReceivablesFromFinanceSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsFundInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsFundInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsTotalFinancialInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsTotalFinancialInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAsstetsDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAsstetsDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313954697408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial and other non-current assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DeferredCompensationPlansAssets', window );">Deferred compensation plans assets</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid post-employment benefit plans assets</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total other non-current assets</a></td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="nump">$ 2,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DeferredCompensationPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DeferredCompensationPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrepaidPostemploymentBenefitPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrepaidPostemploymentBenefitPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935257424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">$ 7,175<span></span>
</td>
<td class="nump">$ 6,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Amount of inventory recognized as expense</a></td>
<td class="num">(8,600)<span></span>
</td>
<td class="num">(8,800)<span></span>
</td>
<td class="num">$ (8,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory provisions</a></td>
<td class="num">(633)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfInventoryWritedown', window );">Reversals of inventory provisions</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember', window );">Raw material, consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember', window );">Work in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">3,673<span></span>
</td>
<td class="nump">3,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember', window );">Finished products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945036512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,128<span></span>
</td>
<td class="nump">8,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
<td class="num">$ (95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935255760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions for doubtful trade receivables</a></td>
<td class="nump">$ 22,261<span></span>
</td>
<td class="nump">$ 19,838<span></span>
</td>
<td class="nump">$ 19,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable at beginning of period</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions for doubtful trade receivables charged to the consolidated income statement</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions for doubtful trade receivables</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversal of provisions for doubtful trade receivables</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation effects</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable at end of period</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955353424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Current [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="nump">7,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than three months and not later than six months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than six months and not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
<td class="num">$ (95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AnalysisOfOverdueAmountsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AnalysisOfOverdueAmountsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956190512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="nump">3,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | RUB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | JPY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CNY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | BRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | AUD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_RUB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_RUB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_BRL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_BRL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952547024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_Commodities', window );">Commodities</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtInstrumentsHeld', window );">Debt securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Time deposits and short-term investments with original maturity more than 90 days</a></td>
<td class="nump">11,089<span></span>
</td>
<td class="nump">12,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Total marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">$ 11,413<span></span>
</td>
<td class="nump">$ 15,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of instruments representing indebtedness held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_Commodities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_Commodities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952701904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Current accounts</a></td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="nump">$ 3,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Time deposits and short term investments with original maturity less than 90 days</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 12,407<span></span>
</td>
<td class="nump">$ 9,658<span></span>
</td>
<td class="nump">$ 11,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945380496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT Receivable</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WithholdingTaxRecoverable', window );">Withholding tax recoverable</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentPrepaidExpensesThirdParty', window );">Prepaid expenses - third party</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationReceivableCurrent', window );">Contingent consideration receivable</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherReceivablesAndCurrentAssets', window );">Other receivables and current assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Total other current assets</a></td>
<td class="nump">$ 2,471<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentPrepaidExpensesThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentPrepaidExpensesThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherReceivablesAndCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherReceivablesAndCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WithholdingTaxRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WithholdingTaxRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951418816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital at beginning of period</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares at beginning of period</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapital', window );">Total outstanding share capital at beginning of period</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IssuedCapitalMovement', window );">Share capital movement of period</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesMovementOfPeriod', window );">Treasury shares movement of period</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapitalMovement', window );">Total shares outstanding movement of period</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital at end of period</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares at end of period</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapital', window );">Total outstanding share capital at end of period</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IssuedCapitalMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IssuedCapitalMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OutstandingShareCapitalMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OutstandingShareCapitalMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesMovementOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesMovementOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949064368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 1) - CHF (SFr)<br> shares in Millions, SFr in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period</a></td>
<td class="nump">2,234.9<span></span>
</td>
<td class="nump">2,256.8<span></span>
</td>
<td class="nump">2,265.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(115.3)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period</a></td>
<td class="nump">2,119.6<span></span>
</td>
<td class="nump">2,234.9<span></span>
</td>
<td class="nump">2,256.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StockRepurchaseProgramAuthorizedAmount1', window );">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</a></td>
<td class="nump">SFr 10<span></span>
</td>
<td class="nump">SFr 10<span></span>
</td>
<td class="nump">SFr 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Total Novartis shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at beginning of period</a></td>
<td class="nump">2,434.4<span></span>
</td>
<td class="nump">2,467.0<span></span>
</td>
<td class="nump">2,527.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesCancelledForCapitalReduction', window );">Shares cancelled for capital reduction</a></td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(60.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(60.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at end of period</a></td>
<td class="nump">2,403.7<span></span>
</td>
<td class="nump">2,434.4<span></span>
</td>
<td class="nump">2,467.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember', window );">Total treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfTreasuryShares', window );">Number of treasury shares at beginning of period</a></td>
<td class="num">(199.5)<span></span>
</td>
<td class="num">(210.2)<span></span>
</td>
<td class="num">(262.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesCancelledForCapitalReduction', window );">Shares cancelled for capital reduction</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="nump">60.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(84.6)<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfTreasuryShares', window );">Number of treasury shares at end of period</a></td>
<td class="num">(284.1)<span></span>
</td>
<td class="num">(199.5)<span></span>
</td>
<td class="num">(210.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesWithRestrictedUse', window );">Treasury shares with restricted use</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
<td class="nump">103.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ExerciseOfOptionsAndEmployeeTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesCancelledForCapitalReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesCancelledForCapitalReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredToBeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredToBeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesWithRestrictedUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesWithRestrictedUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955911376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3.10<span></span>
</td>
<td class="nump">SFr 3.00<span></span>
</td>
<td class="nump">SFr 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends recognised as distributions to owners | $</a></td>
<td class="nump">$ 7,506<span></span>
</td>
<td class="nump">$ 7,368<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951909648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 3) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredForCancellationValue', window );">Shares acquired for cancellation, equity impact</a></td>
<td class="num">$ (10,787)<span></span>
</td>
<td class="num">$ (2,775)<span></span>
</td>
<td class="num">$ (2,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchasesValue', window );">Other share purchases, equity impact</a></td>
<td class="num">$ (123)<span></span>
</td>
<td class="num">$ (145)<span></span>
</td>
<td class="num">$ (159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharepurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(127.6)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
<td class="num">(34.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares, equity impact</a></td>
<td class="num">$ (10,910)<span></span>
</td>
<td class="num">$ (2,920)<span></span>
</td>
<td class="num">$ (3,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation, equity impact</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesMovement', window );">Total number of outstanding treasury shares</a></td>
<td class="num">(115.3)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityImpactOfTreasuryShareMovements', window );">Total equity impact of treasury share movements</a></td>
<td class="num">$ (9,963)<span></span>
</td>
<td class="num">$ (2,119)<span></span>
</td>
<td class="num">$ (1,490)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityImpactOfTreasuryShareMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityImpactOfTreasuryShareMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ExerciseOfOptionsAndEmployeeTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchasesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchasesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharepurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharepurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredForCancellationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredForCancellationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredToBeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredToBeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945046720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 4)<br> $ / shares in Units, Pure in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares | $</a></td>
<td class="nump">$ 2,809<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximalAmountOfShareBuybackProgramm', window );">Maximal amount of share buyback programm | $</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsHeldByMarketMaker', window );">Written call options held by market maker</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsContractualLive', window );">Written call options, contractual live | year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsContractualLiveRemaining', window );">Written call options, contractual live, remaining | year</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsWeightedAverageExercisePrice', window );">Written call options, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 61.45<span></span>
</td>
<td class="nump">$ 60.09<span></span>
</td>
<td class="nump">$ 66.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfOptionsRepurchased', window );">Number of options repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximalAmountOfShareBuybackProgramm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximalAmountOfShareBuybackProgramm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfOptionsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfOptionsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsContractualLive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsContractualLive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsContractualLiveRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsContractualLiveRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsHeldByMarketMaker">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsHeldByMarketMaker</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955790816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract', window );"><strong>Disclosure of components of non-current financial debts [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LiabilitiesToBanksAndOtherInstitutions', window );">Liabilities to banks and other institutions</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total including current portion of non-current financial debt</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Less current portion of non-current financial debt</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(2,621)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Total non-current financial debts</a></td>
<td class="nump">$ 20,244<span></span>
</td>
<td class="nump">$ 22,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AverageInterestRateOnLoansReceived', window );">Average interest rate on loans received</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt', window );">Ratio fixed rate financial debt to total financial debt</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AverageInterestRateOnBorrowings', window );">Average interest rate on borrowings</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AverageInterestRateOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AverageInterestRateOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AverageInterestRateOnLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AverageInterestRateOnLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LiabilitiesToBanksAndOtherInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LiabilitiesToBanksAndOtherInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935778304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Details 1)<br> &#8364; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member', window );">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.225%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member', window );">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.325%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member', window );">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.287%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member', window );">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.196%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member', window );">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.697%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member', window );">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member', window );">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.502%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member', window );">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.479%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member', window );">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member', window );">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.029%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member', window );">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.127%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member', window );">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member', window );">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.449%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member', window );">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.109%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member', window );">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.874%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member', window );">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.655%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member', window );">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.957%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member', window );">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.217%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member', window );">1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.852%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member', window );">2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.909%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member', window );">2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.869%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member', window );">2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">97.712%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member', window );">0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.354%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsInterestRateStepUp', window );">Borrowings interest rate step up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsOriginalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The currency in which the borrowings are denominated. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsOriginalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsInterestRateStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsInterestRateStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942163744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 22,485<span></span>
</td>
<td class="nump">$ 25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember', window );">Later than five years and not later than six years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 11,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember', window );">Later than six years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956181408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 22,485<span></span>
</td>
<td class="nump">$ 25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">13,376<span></span>
</td>
<td class="nump">15,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">7,478<span></span>
</td>
<td class="nump">7,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">JPY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=nvs_CurrencyOthersMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951886416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember', window );">Balance sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">22,341<span></span>
</td>
<td class="nump">25,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNoncurrentFinancialDebt', window );">Others</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember', window );">Fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">20,277<span></span>
</td>
<td class="nump">27,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNoncurrentFinancialDebt', window );">Others</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">$ 20,421<span></span>
</td>
<td class="nump">$ 27,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNoncurrentFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNoncurrentFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952027088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Defined benefit pension plans</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation', window );">Other long-term employee benefits and deferred compensation</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherPostemploymentBenefits', window );">Other post-employment benefits</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalRemediationProvisionNoncurrent', window );">Environmental remediation provisions</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationNonCurrent', window );">Contingent consideration</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Total provisions and other non-current liabilities</a></td>
<td class="nump">$ 4,906<span></span>
</td>
<td class="nump">$ 6,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalRemediationProvisionNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalRemediationProvisionNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945516208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionRollForward', window );"><strong>Environmental provision [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Environmental liabilities provision at beginning of period</a></td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionPayments', window );">Cash payments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionReleases', window );">Releases</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionAdditions', window );">Additions</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss', window );">Currency translation effects</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Environmental liabilities provision at end of period</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionCurrent', window );">Less current provision</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalRemediationProvisionNoncurrent', window );">Non-current environmental remediation provisions at end of period</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalRemediationProvisionNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalRemediationProvisionNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313954912160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionFiscalYearMaturityAbstract', window );"><strong>Environmental provision, fiscal year maturity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears', window );">Due within two years</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears', window );">Due later than two years, but within five years</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears', window );">Due later than five years, but within ten years</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears', window );">Due after ten years</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Total environmental remediation liability provisions</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942635840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 3)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="nump">$ 154.0<span></span>
</td>
<td class="nump">$ 341.0<span></span>
</td>
<td class="nump">$ 181.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IT', window );">Italy | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed', window );">Estimated financial effect of contingent liabilities, damages claimed</a></td>
<td class="nump">330.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IT', window );">Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="nump">$ 245.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations', window );">Description of nature of obligation contingent liabilities, number of states with alleged violations</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member] | Taxotere [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member] | Amiodarone [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | NPC and others [member] | Reclast/Aclasta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | NPC and others [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | F Hoffman La Roche AG and Roche SpA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GR', window );">Greece | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages', window );">Estimated financial effect of contingent liabilities, compensation for moral damages</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 86<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfSettlementInPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfSettlementInPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses a maximal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NAGAndNovartisPharmaSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NAGAndNovartisPharmaSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TaxotereMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TaxotereMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AmiodaroneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AmiodaroneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ReclastAclastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ReclastAclastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_FHoffmanLaRocheAGAndRocheSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_FHoffmanLaRocheAGAndRocheSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935203312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward', window );"><strong>Product liability, government investigations, other legal matters provisions [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liabilities government investigations other legal matters provisions at beginning of period</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations', window );">Impact of business combinations</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments', window );">Cash payments</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases', window );">Releases</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions', window );">Additions</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss', window );">Currency translation effects</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liabilities government investigations other legal matters provisions at end of period</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent', window );">Less current provision</a></td>
<td class="num">(548)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313977537088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestBearningAccountsOfAssociatesPayableOnDemand', window );">Interest bearning accounts of associates payable on demand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Bank and other financial debt</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial Papers</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Current portion of non-current financial debt</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Fair value of derivative financial instruments</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Total current financial debt and derivative financial instruments</a></td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateAssociates', window );">Weighted average interest rate, associates</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt', window );">Weighted average interest rate on Bank and other financial debt</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PaymentOfInterestBearingAccountsToBeneficiaries', window );">Payment of interest bearing accounts to beneficiaries</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestBearningAccountsOfAssociatesPayableOnDemand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestBearningAccountsOfAssociatesPayableOnDemand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentOfInterestBearingAccountsToBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentOfInterestBearingAccountsToBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on interest bearning accounts of associates payable on demand.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on Bank and other financial debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942151936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Taxes other than income taxes</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermRestructuringProvision', window );">Restructuring provisions</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued expenses for goods and services received but not invoiced</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccruedRoyaltiesPayableClassifiedAsCurrent', window );">Accruals for royalties</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestPayable', window );">Accrued interests on financial debt</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue</a></td>
<td class="nump">6,732<span></span>
</td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Accruals for compensation and benefits including social security</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionCurrent', window );">Environmental remediation liabilities</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Current deferred income other than current contract liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent', window );">Provisions for product liabilities, governmental investigations and other legal matters</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Accrued share-based payments</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Total provisions and other current liabilities</a></td>
<td class="nump">$ 14,795<span></span>
</td>
<td class="nump">$ 15,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest payable. [Refer: Interest payable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermRestructuringProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermRestructuringProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccruedRoyaltiesPayableClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccruedRoyaltiesPayableClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942159792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForDeductionsFromRevenueRollForward', window );"><strong>Provisions for deductions from revenue [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue, at beginning of period</a></td>
<td class="nump">$ 6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Effects of currency translation and business combinations</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Payments/utilizations</a></td>
<td class="num">(22,261)<span></span>
</td>
<td class="num">(19,838)<span></span>
</td>
<td class="num">(19,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeStatementAdjustmentsOfPriorYear', window );">Additions prior year</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeStatementAdjustmentsOfCurrentYear', window );">Additions current year</a></td>
<td class="nump">23,072<span></span>
</td>
<td class="nump">20,413<span></span>
</td>
<td class="nump">19,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInOffsetAgainstGrossTradeReceivables', window );">Changes in offset against gross trade receivables</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue, at end of period</a></td>
<td class="nump">$ 6,732<span></span>
</td>
<td class="nump">$ 6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInOffsetAgainstGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInOffsetAgainstGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeStatementAdjustmentsOfCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeStatementAdjustmentsOfCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeStatementAdjustmentsOfPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeStatementAdjustmentsOfPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForDeductionsFromRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForDeductionsFromRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951858224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsRollForward', window );"><strong>Restructuring provisions movements [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Cash payments</a></td>
<td class="num">$ (22,261)<span></span>
</td>
<td class="num">$ (19,838)<span></span>
</td>
<td class="num">$ (19,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Restructuring provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsRollForward', window );"><strong>Restructuring provisions movements [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Provision at beginning of period</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Cash payments</a></td>
<td class="num">(468)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Releases</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation effects</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Provision at end of period</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RestructuringProvisionsMovementsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RestructuringProvisionsMovementsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951228752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities', window );">Change in provisions and other non-current liabilities</a></td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">$ 1,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Equity-settled compensation expense</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Loss/(income) from associated companies</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(15,339)<span></span>
</td>
<td class="num">(673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net financial expense</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="num">(5,299)<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing', window );">Acquisition of assets (right of use assets) through leasing</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">5,308<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember', window );">Financial assets impaired [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">260<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (335)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets other than goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities', window );">Acquisition of assets (other than through business combinations) by assuming directly related liabilities</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss; Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949091296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income taxes paid (refund)</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid (refund), classified as operating activities</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 2,342<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities', window );">Income taxes paid (refund), classified as investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313946143184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="num">$ (830)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="num">$ (543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in trade receivables</a></td>
<td class="num">(589)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Decrease in trade payables</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Change in other current and non-current assets</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities', window );">Change in other current liabilities</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other adjustments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Total</a></td>
<td class="num">$ (1,003)<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="num">$ (291)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942053792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">$ (879)<span></span>
</td>
<td class="num">$ (567)<span></span>
</td>
<td class="num">$ (9,957)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowFromNetIdentifiableAssets', window );">Net assets recognized as a result of acquistions of businesses</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="num">(10,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Fair value of previously held equity interests</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReceivablesAndPayablesContingentConsiderationNet', window );">Contingent consideration payables, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherPaymentsAndDeferredConsiderationNet', window );">Payments, deferred consideration and other adjustments, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="num">(10,006)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember', window );">Divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentAssetsDivested', window );">Non-current assets divested</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Net cash inflows from divestment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAssetsDivested', window );">Current assets divested</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents in subsidiary or businesses acquired or disposed</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DeferredSalePriceAndOtherAdjustments', window );">Deferred sale price and other adjustments</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents', window );">Cash outflows due to derecognized cash and cash equivalents</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentAndCurrentLiabilitiesDivested', window );">Non-current and current liabilities divested</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetIdentifiableAssetsOfDivestedBusiness', window );">Net identifiable assets of divested business</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember', window );">Divestments | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Net cash inflows from divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph p<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_p_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowFromNetIdentifiableAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow (outflow) from Net identifiable assets (acquired) or divested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowFromNetIdentifiableAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAssetsDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAssetsDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DeferredSalePriceAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DeferredSalePriceAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIdentifiableAssetsOfDivestedBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIdentifiableAssetsOfDivestedBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentAndCurrentLiabilitiesDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentAndCurrentLiabilitiesDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentAssetsDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentAssetsDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherPaymentsAndDeferredConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherPaymentsAndDeferredConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReceivablesAndPayablesContingentConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReceivablesAndPayablesContingentConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956273648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">$ 29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 7,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand', window );">Cash outflows from interest bearing accounts of employees payable on demand</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember', window );">Non-current financial debts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">22,902<span></span>
</td>
<td class="nump">26,259<span></span>
</td>
<td class="nump">20,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfBondsDiscount', window );">Amortization of bonds discount</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(2,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">22,902<span></span>
</td>
<td class="nump">26,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember', window );">Current financial debts and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">6,295<span></span>
</td>
<td class="nump">9,785<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfBondsDiscount', window );">Amortization of bonds discount</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">2,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
<td class="nump">9,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember', window );">Non-current lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities', window );">New, modified and terminated leases, net</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember', window );">Current lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities', window );">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities', window );">New, modified and terminated leases, net</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from obtaining or losing control of subsidiaries or other businesses. [Refer: Liabilities arising from financing activities; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfBondsDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfBondsDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialDebtsAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialDebtsAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReclassificationFromNoncurrentToCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReclassificationFromNoncurrentToCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949900512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 7)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in financing activities from discontinued operations</a></td>
<td class="num">$ (50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955258880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions of businesses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RightOfUseAssetsAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Acquired research and development</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate', window );">Deferred tax assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialAndOtherAssets', window );">Non-current financial and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate', window );">Trade receivables and financial and other current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current and non-current financial debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate', window );">Current and non-current lease liabilities</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradePayablesAndOtherLiabilities', window );">Trade payables and other liabilities</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IdentifiableAssetsAcquired', window );">Net identifiable assets acquired</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">7,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquiredCashAndCashEquivalents', window );">Acquired cash and cash equivalents</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate', window );">Non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets recognized as a result of acquisitions of business</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill in a business combination that is expected to be deductible for tax purposes. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_k&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillExpectedDeductibleForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph o<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_o_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IdentifiableAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IdentifiableAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradePayablesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradePayablesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313944586000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ConcentrationOfMajorPlansGeographic', window );">Concentration of major plans, geographic</a></td>
<td class="text">

                  In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#8217;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 83% of the Group&#8217;s total DBO for post-employment benefit plans, are provided below.

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MajorPlansPercentageInGroupDBOPensions', window );">Major plans percentage in group DBO pensions</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans', window );">Most signigicant countries percentage on group DBO post employment benefit plans</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Net Pre-tax curtailment gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">SFr 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConcentrationOfMajorPlansGeographic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the major plans and the concentration of the Group's DBO by geography.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConcentrationOfMajorPlansGeographic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MajorPlansPercentageInGroupDBOPensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MajorPlansPercentageInGroupDBOPensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956006320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 25,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset', window );">Administrative expenses</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement losses/(gains) arising from changes in financial assumptions</a></td>
<td class="num">(5,046)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement (gains) arising from changes in demographic assumptions</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience-related remeasurement losses/(gains)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability', window );">Currency translation effects</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation', window );">Contributions of associates</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1', window );">Effect of acquisitions, divestments or transfers</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">17,533<span></span>
</td>
<td class="nump">23,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">22,420<span></span>
</td>
<td class="nump">22,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset', window );">Currency translation effects</a></td>
<td class="num">(539)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions of associates</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">18,945<span></span>
</td>
<td class="nump">22,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at beginning of period</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling', window );">Change in limitation on recognition of fund surplus</a></td>
<td class="num">(2,504)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus', window );">Currency translation effects</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestIncomeOnLimitationOfFundSurplus', window );">Interest income on limitation of fund surplus</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at end of period</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability in the balance sheet at end of period</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">$ (3,336)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">14,701<span></span>
</td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at end of period</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement losses/(gains) arising from changes in financial assumptions</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement (gains) arising from changes in demographic assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience-related remeasurement losses/(gains)</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability', window );">Currency translation effects</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability in the balance sheet at end of period</a></td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (487)<span></span>
</td>
<td class="num">$ (543)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestIncomeOnLimitationOfFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestIncomeOnLimitationOfFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LimitationOnRecognitionOfFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LimitationOnRecognitionOfFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313944575632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid benefit cost</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward', window );"><strong>Defined benefit plan, change in net liability [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at beginning of period</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(3,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets', window );">Administrative expenses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurements</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation effects</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1', window );">Effect of acquisitions, divestments or transfers</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling', window );">Change in limitation on recognition of fund surplus</a></td>
<td class="num">(2,504)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at end of period</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid benefit cost</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities', window );">Accrued benefit liability</a></td>
<td class="num">(1,723)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward', window );"><strong>Defined benefit plan, change in net liability [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at beginning of period</a></td>
<td class="num">(487)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurements</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation effects</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at end of period</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities', window );">Accrued benefit liability</a></td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (487)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrepaidPostemploymentBenefitPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrepaidPostemploymentBenefitPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313934844720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">$ 17,533<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 25,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">18,945<span></span>
</td>
<td class="nump">22,420<span></span>
</td>
<td class="nump">22,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">6,161<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">9,681<span></span>
</td>
<td class="nump">12,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">14,701<span></span>
</td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">4,799<span></span>
</td>
<td class="nump">6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">7,025<span></span>
</td>
<td class="nump">8,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">2,746<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">2,963<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(697)<span></span>
</td>
<td class="num">(1,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_UnfundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_UnfundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_ActiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_ActiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_DeferredPensionersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_DeferredPensionersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_PensionersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_PensionersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955466704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 4)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Expected rate of pension increase</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Expected rate of salary increase</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount', window );">Interest on savings account</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale', window );">Current life expectancy for a 65-year-old male</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale', window );">Current life expectancy for a 65-year-old female</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">24 years<span></span>
</td>
<td class="text">24 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale', window );">Current life expectancy for a 65-year-old male</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale', window );">Current life expectancy for a 65-year-old female</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">23 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitAssumptionLifeExpectancyFemale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitAssumptionLifeExpectancyMale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945721136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Discount rate | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="num">$ (466)<span></span>
</td>
<td class="num">$ (790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember', window );">Life expectancy | 1 year increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember', window );">Rate of pension increase | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember', window );">Interest on savings account | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember', window );">Salary increase | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInActuarialAssumptionAxis=nvs_Change25BasisPointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInActuarialAssumptionAxis=nvs_Change25BasisPointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInActuarialAssumptionAxis=nvs_Increase1YearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInActuarialAssumptionAxis=nvs_Increase1YearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949669024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 6) - Other post-employment benefit plans<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Year that the rate reaches the ultimate trend rate</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">2028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935239552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 7) - Pension plans - USD ($)<br> shares in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EmployerSharesHeldByDefinedBenefitPlan', window );">Shares held by defined benefit plan</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan', window );">Value of shares held by defined benefit plan</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageDurationOfDefinedBenefitObligationYears', window );">Weighted average duration of defined benefit obligation years</a></td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Alternative investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Cash and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanPlanAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanPlanAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EmployerSharesHeldByDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EmployerSharesHeldByDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageDurationOfDefinedBenefitObligationYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageDurationOfDefinedBenefitObligationYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_EquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_EquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_RealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_RealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_AlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_AlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_CashAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_CashAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956197184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 8)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract', window );"><strong>Novartis Group contributions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contributions, next fiscal year (estimated)</a></td>
<td class="nump">$ 397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than five years and not later than ten years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">5,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract', window );"><strong>Novartis Group contributions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contributions, next fiscal year (estimated)</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than five years and not later than ten years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureBenefitPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935238976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems', window );"><strong>Defined contribution pension and other post-retirement plans disclosure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems', window );"><strong>Defined contribution pension and other post-retirement plans disclosure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Post-employment benefit expense, defined contribution plans</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313948785904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment transactions</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945269328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember', window );">Annual incentive</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember', window );">Employee Share Ownership Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">


                    Employee share savings plan

                  Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.
                  The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#8220;Select&#8221; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember', window );">Share purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">


                    Novartis Employee share purchase plan

                  In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember', window );">Select</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The equity plan &#8220;Select&#8221; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#8220;Select.&#8221;
                  The equity plan &#8220;Select&#8221; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
                  Tradable share options expire on their 10th anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember', window );">Long-Term Performance Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.
                  Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.
                  The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods.
                  TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.

                    Long-Term Relative Performance Plan

                  The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember', window );">Special share awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#8220;buyouts&#8221; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.
                  Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.
                  In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.



              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 2) - Select outside North America<br> Pure in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward', window );"><strong>Disclosure of number and weighted average exercise prices of share options [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at beginning of period</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</a></td>
<td class="nump">$ 63.6<span></span>
</td>
<td class="nump">$ 62.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised or sold</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercised in share-based payment arrangement</a></td>
<td class="nump">$ 62.6<span></span>
</td>
<td class="nump">$ 58.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at end of period</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercisable in share-based payment arrangement</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</a></td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313948693104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 3) - Select North America<br> Pure in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward', window );"><strong>Disclosure of number and weighted average exercise prices of share options [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at beginning of period</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</a></td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="nump">$ 62.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised or sold</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercised in share-based payment arrangement</a></td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="nump">$ 60.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at end of period</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercisable in share-based payment arrangement</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</a></td>
<td class="nump">$ 89.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955765776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 4)<br> Pure in Millions, $ / shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember', window );">Equity-Based Participation Annual Incentive RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 74.7<span></span>
</td>
<td class="nump">$ 87.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember', window );">Equity Based Participation Annual Incentive Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember', window );">Equity Based Participation Share savings plans RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember', window );">Equity Based Participation Share savings plans Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember', window );">Equity-Based Participation Employee share purchase plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 82.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember', window );">Equity Based Participation Novartis Equity Plan Select North America RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 74.5<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember', window );">Based Participation Novartis Equity Plan Select outside North America RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 75.1<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember', window );">Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember', window );">Equity Based Participation Long Term Performance PSU Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 82.0<span></span>
</td>
<td class="nump">$ 89.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember', window );">Equity Based Participation Other share awards RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 76.3<span></span>
</td>
<td class="nump">$ 78.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember', window );">Equity Based Participation Other share awards Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember', window );">Equity Based Participation Other share awards Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="nump">$ 91.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952899952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transaction with related parties (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers', window );">Executive Committee members</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown', window );">Related parties, number of executive committee members who stepped down</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfNonexecutiveDirectors', window );">Non-executive directors</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing', window );">Net expense, royalties cost sharing and profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188)<span></span>
</td>
<td class="num">$ (217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfContractsWithRelatedParties', window );">Number of contracts with related parties</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member', window );">Spark Therapeutics, Inc. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfContractsWithRelatedParties', window );">Number of contracts with related parties</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfContractsWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfContractsWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfNonexecutiveDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfNonexecutiveDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313942563888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="nump">46.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">79.8<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember', window );">Non-Executive Director [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313939745824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember', window );">Novartis Pension Fund [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCreditFacilityUncommitted', window );">Borrowings credit facility uncommitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 70.4<span></span>
</td>
<td class="nump">$ 60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember', window );">Dr. Alex Krauer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCreditFacilityUncommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCreditFacilityUncommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951880768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">$ 5,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UncalledCapitalCommitmentsForInvestmentsInFunds', window );">Uncalled capital commitments for investments in funds</a></td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">$ 3,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsUnderLongtermResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsUnderLongtermResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UncalledCapitalCommitmentsForInvestmentsInFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UncalledCapitalCommitmentsForInvestmentsInFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955068944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member] | Financial assets at amortised cost, category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 10,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member] | Financial assets at fair value through other comprehensive income, category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">5,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale marketable securities [member] | Debt securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Debt securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Available-for-sale long-term financial investments [member] | Equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Available-for-sale long-term financial investments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">27,971<span></span>
</td>
<td class="nump">32,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Other current assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Time deposits with original maturity more than 90 days [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">11,089<span></span>
</td>
<td class="nump">12,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableForSaleMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableForSaleMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableforsaleLongtermFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableforsaleLongtermFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313938556464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 31,266<span></span>
</td>
<td class="nump">$ 37,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Interest bearning accounts of associates payable on demand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Bank and other financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Commercial paper [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Straight bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">22,341<span></span>
</td>
<td class="nump">25,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Liabilities to banks and other financial institutions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Trade payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Commitment for repurchase of own shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Other financial liabilities, category [member] | Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Other financial liabilities, category [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Contingent consideration and other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_BankAndOtherFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_BankAndOtherFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_StraightBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_StraightBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommitmentForRepurchaseOfOwnSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommitmentForRepurchaseOfOwnSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=nvs_OtherFinancialLiabilitiesCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=nvs_OtherFinancialLiabilitiesCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313945254736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">Contract or underlying principal amout [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">$ 8,043<span></span>
</td>
<td class="nump">$ 13,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember', window );">Positive fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember', window );">Negative fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Contract or underlying principal amout [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">7,907<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Positive fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Negative fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R165.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955258752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 3) - Contract or underlying principal amout [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">$ 8,043<span></span>
</td>
<td class="nump">$ 13,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">5,715<span></span>
</td>
<td class="nump">5,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">6,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">7,907<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">5,659<span></span>
</td>
<td class="nump">5,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 6,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R166.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313943471824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 4) - Recurring fair value measurement [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Cash and cash equivalents [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialInvestmentsAndLongtermLoansGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialInvestmentsAndLongtermLoansGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R167.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313935729760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 5) - Recurring fair value measurement [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (131)<span></span>
</td>
<td class="num">$ (1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Non-current contingent consideration liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(936)<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Non-current contingent consideration liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (936)<span></span>
</td>
<td class="num">$ (1,094)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_NoncurrentContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_NoncurrentContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R168.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951782672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember', window );">Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember', window );">Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember', window );">Long term financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember', window );">Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember', window );">Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="num">(1,075)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="nump">416<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember', window );">Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisposalsFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisposalsFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsCarryingValueLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsCarryingValueLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PurchaseFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PurchaseFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReclassificationFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is a reclassification that can be debit or credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReclassificationFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R169.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313934865776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">$ 18,930<span></span>
</td>
<td class="nump">$ 28,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,244)<span></span>
</td>
<td class="num">(22,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,931)<span></span>
</td>
<td class="num">(6,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(7,245)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember', window );">Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">11,098<span></span>
</td>
<td class="nump">15,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember', window );">Commodities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember', window );">Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember', window );">Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,244)<span></span>
</td>
<td class="num">(22,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,876)<span></span>
</td>
<td class="num">(6,227)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember', window );">Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,396)<span></span>
</td>
<td class="num">(23,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,878)<span></span>
</td>
<td class="num">(6,229)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember', window );">Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">8,176<span></span>
</td>
<td class="nump">7,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,253)<span></span>
</td>
<td class="num">(2,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">4,923<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">4,142<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(2,780)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(2,780)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">10,564<span></span>
</td>
<td class="nump">19,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">19,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">5,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,519)<span></span>
</td>
<td class="num">(2,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(2,464)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,515)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,517)<span></span>
</td>
<td class="num">(2,928)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,460)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,464)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(9,002)<span></span>
</td>
<td class="num">(8,490)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(11,134)<span></span>
</td>
<td class="num">(14,296)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Commodities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">$ (11,394)<span></span>
</td>
<td class="num">$ (14,587)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaturityOfNetDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaturityOfNetDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R170.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313951627264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">$ (6,943)<span></span>
</td>
<td class="num">$ (6,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(2,029)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(4,598)<span></span>
</td>
<td class="num">(5,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">4,712<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R171.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313956024288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">$ (5,532)<span></span>
</td>
<td class="num">$ (6,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(1,789)<span></span>
</td>
<td class="num">(1,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(5,146)<span></span>
</td>
<td class="num">(5,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,809)<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(5,020)<span></span>
</td>
<td class="num">(5,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(1,432)<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(616)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(3,624)<span></span>
</td>
<td class="num">(3,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(922)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">$ (267)<span></span>
</td>
<td class="num">$ (439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContractualInterestOnNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContractualInterestOnNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R172.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955755376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 10)<br> $ in Millions, &#8364; in Billions, &#165; in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Transfers out of Level 3 of fair value hierarchy, assets</a></td>
<td class="num">$ (44)<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets', window );">Transfers into Level 3 of fair value hierarchy, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Description of reasons for transfers out of Level 3 of fair value hierarchy, assets</a></td>
<td class="text">

                  During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10', window );">Amount of change in OCI when most significant parameters for level 3 change more than 10%</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10', window );">Amount of change in OCI when POS for level 3 change more than 10%</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LongtermFinancialDebtWithACarryingAmount', window );">Long-term financial debt with a carrying amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">&#8364; 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximumMarginPercentageImpactOfCommodityPriceChange', window );">Maximum margin percentage impact of commodity price change</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximumHoldingInUnrelatedCompany', window );">Maximum holding in unrelated company</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge', window );">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCreditFacilityCommitted', window );">Borrowings credit facility committed</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement', window );">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfFundInvestmentsAndEquitySecurities', window );">Fair value of fund investments and equity securities</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember', window );">US commercial paper programs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember', window );">JP commercial paper programs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_LargestFinancialInstitutionMember', window );">Largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember', window );">Second largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember', window );">Third largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the reasons for transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCommercialPaperMaximumBorrowingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCommercialPaperNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCommercialPaperNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCreditFacilityCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCreditFacilityCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsHeldWithFinancialInstitution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CounterpartyRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CounterpartyRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfFundInvestmentsAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfFundInvestmentsAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfOtherFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfOtherFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LongtermFinancialDebtWithACarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LongtermFinancialDebtWithACarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximumHoldingInUnrelatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximumHoldingInUnrelatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximumMarginPercentageImpactOfCommodityPriceChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximumMarginPercentageImpactOfCommodityPriceChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_LargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_LargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R173.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313939652320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 11)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomersWithNetSalesOverFivePercent', window );">Customers with net sales over five percent</a></td>
<td class="text">

                  The Group&#8217;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfGovernmentBackedDebtSecurities', window );">Percentage of government backed debt securities</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember', window );">Largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember', window );">Second largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember', window );">Third largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomersWithNetSalesOverFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomersWithNetSalesOverFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEntitysTradeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEntitysTradeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfGovernmentBackedDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfGovernmentBackedDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R174.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313955773408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 12)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember', window );">Listed equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome', window );">Number of investments in equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember', window );">Non-listed equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome', window );">Number of investments in equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember', window );">Alcon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember', window );">Alcon | Total fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainLossOnSaleOfOtherFinancialAssets', window );">Gain (loss) on sale of other financial assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others | Total fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainLossOnSaleOfOtherFinancialAssets', window );">Gain (loss) on sale of other financial assets</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfOtherFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfOtherFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainLossOnSaleOfOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainLossOnSaleOfOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R175.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952966592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 13) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity', window );">Hypothetical increase decrease percentage in currency rate sensitivity</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember', window );">Hypothetical 5% increase [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement', window );">Currency exchange rate sensitivity impact against USD in the income statement</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity', window );">Currency exchange rate sensitivity impact against USD in the equity</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember', window );">Hypothetical 5% decrease [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement', window );">Currency exchange rate sensitivity impact against USD in the income statement</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity', window );">Currency exchange rate sensitivity impact against USD in the equity</a></td>
<td class="num">$ (98)<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R176.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313949102528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 15) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity', window );">Hypothetical increase decrease percentage in equity price sensitivity</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember', window );">Hypothetical 15% increase [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement', window );">Equity price sensitivity impact of the risk factors in the income statement</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity', window );">Equity price sensitivity impact of the risk factors in the equity</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember', window );">Hypothetical 15% decrease [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement', window );">Equity price sensitivity impact of the risk factors in the income statement</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity', window );">Equity price sensitivity impact of the risk factors in the equity</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">$ (179)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R177.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313952452896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to the December 31 consolidated balance sheet date (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners', window );">Dividends proposed | $</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember', window );">Subsequent Event [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare', window );">Dividends proposed, cash per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends proposed or declared after the reporting period but before financial statements are authorised for issue. Such dividends are not recognised as a liability at the end of the reporting period because no obligation exists at that time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 13<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 137<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_137_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 137<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_137_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R178.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140313679200768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies (Details) - 12 months ended Dec. 31, 2022<br> &#8381; in Millions, &#8378; in Millions, &#8372; in Millions, &#8369; in Millions, &#8360; in Millions, &#3647; in Millions, &#2547; in Millions, &#1585;.&#1587; in Millions, &#1583;&#1580; in Millions, &#1583;.&#1605;. in Millions, &#1583;.&#1573; in Millions, &#165; in Millions, z&#322; in Millions, kr in Millions, kr in Millions, kr in Millions, kn in Millions, RON in Millions, RM in Millions, R$ in Millions, R in Millions, K&#269; in Millions, Ft in Millions, $ in Millions, $ in Millions, $ in Millions, $ in Millions, &#8363; in Billions, &#8361; in Billions, &#8360; in Billions, Rp in Billions, $ in Billions, $ in Billions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
<th class="th"><div>JPY (&#165;)</div></th>
<th class="th"><div>DZD (&#1583;&#1580;)</div></th>
<th class="th"><div>ARS ($)</div></th>
<th class="th"><div>AUD ($)</div></th>
<th class="th"><div>BDT (&#2547;)</div></th>
<th class="th"><div>BRL (R$)</div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>CLP ($)</div></th>
<th class="th"><div>HKD ($)</div></th>
<th class="th"><div>COP ($)</div></th>
<th class="th"><div>HRK (kn)</div></th>
<th class="th"><div>CZK (K&#269;)</div></th>
<th class="th"><div>DKK (kr)</div></th>
<th class="th"><div>EGP (&#1580;.&#1605;.)</div></th>
<th class="th"><div>HUF (Ft)</div></th>
<th class="th"><div>INR (&#8360;)</div></th>
<th class="th"><div>IDR (Rp)</div></th>
<th class="th"><div>ILS (&#8362;)</div></th>
<th class="th"><div>MYR (RM)</div></th>
<th class="th"><div>MXN ($)</div></th>
<th class="th"><div>MAD (&#1583;.&#1605;.)</div></th>
<th class="th"><div>NZD ($)</div></th>
<th class="th"><div>NOK (kr)</div></th>
<th class="th"><div>PKR (&#8360;)</div></th>
<th class="th"><div>PHP (&#8369;)</div></th>
<th class="th"><div>PLN (z&#322;)</div></th>
<th class="th"><div>RON</div></th>
<th class="th"><div>RUB (&#8381;)</div></th>
<th class="th"><div>SAR (&#1585;.&#1587;)</div></th>
<th class="th"><div>SGD ($)</div></th>
<th class="th"><div>ZAR (R)</div></th>
<th class="th"><div>KRW (&#8361;)</div></th>
<th class="th"><div>SEK (kr)</div></th>
<th class="th"><div>TWD ($)</div></th>
<th class="th"><div>THB (&#3647;)</div></th>
<th class="th"><div>TRY (&#8378;)</div></th>
<th class="th"><div>UAH (&#8372;)</div></th>
<th class="th"><div>AED (&#1583;.&#1573;)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
<th class="th"><div>VEF</div></th>
<th class="th"><div>VND (&#8363;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties', window );">Principal group companies materiality of assets or sales to third parties | $</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Societe par actions SANDOZ, Algiers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Soci&#233;t&#233; par actions SANDOZ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Algiers<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Algeria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;&#1580;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;&#1580; 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Argentina S.A., Buenos Aires [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Argentina S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Buenos Aires<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Argentina<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Australia Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals
Australia Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Austria GmbH, Vienna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Austria GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma GmbH, Vienna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz GmbH, Kundl [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Kundl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">EBEWE Pharma Ges.m.b.H Nfg. KG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Unterach am Attersee<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Bangladesh) Limited, Gazipur [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Bangladesh) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Gazipur<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bangladesh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#2547;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#2547; 162.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma NV, Vilvoorde [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vilvoorde<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz NV, Vilvoorde [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vilvoorde<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Alcon - Couvreur NV, Puurs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Alcon - Couvreur NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Puurs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Investment Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Investment Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Securities Investment Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Securities Investment Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance Services Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance Services Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Triangle International Reinsurance Limited, Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Triangle International Reinsurance Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Trinity River Insurance Co Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Trinity River Insurance Co Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Biociencias S.A., Sao Paulo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Bioci&#234;ncias S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">S&#227;o Paulo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Brazil<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 507.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Camb&#233;, PR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Brazil<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals Canada Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dorval, Quebec<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Canada Inc., Boucherville, Quebec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Canada Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Boucherville, Quebec<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Chile S.A., Santiago de Chile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Chile S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Santiago de Chile<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Chile<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Beijing Novartis Pharma Co., Ltd., Beijing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Beijing Novartis Pharma Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Beijing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals (HK) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hong Kong<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">China Novartis Institutes for
BioMedical Research Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Shanghai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Suzhou Novartis Technical
Development Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Changshu<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Shanghai Novartis Trading Ltd., Shanghai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Shanghai Novartis Trading Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Shanghai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz (China) Pharmaceutical
Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Zhongshan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 57,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis de Colombia S.A., Santafe de Bogota [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis de Colombia S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Santaf&#233; de Bogot&#225;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Colombia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz d.o.o. farmaceutska industrija<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Zagreb<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Croatia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kn 25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis s.r.o., Prague [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Prague<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Czech Republic<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | K&#269;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">K&#269; 51.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz s.r.o., Prague [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Prague<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Czech Republic<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | K&#269;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">K&#269; 44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare A/S, Copenhagen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare A/S<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Copenhagen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz A/S, Copenhagen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz A/S<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Copenhagen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Ecuador S.A., Quito [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Ecuador S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Quito<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ecuador<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma S.A.E., Cairo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma S.A.E.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cairo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Egypt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1580;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1580;.&#1605;. 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Egypt Pharma S.A.E., New Cairo City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Egypt Pharma S.A.E.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">New Cairo City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Egypt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1580;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1580;.&#1605;. 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finland Oy, Espoo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finland Oy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Espoo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Finland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Groupe France S.A., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Groupe France S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma S.A.S., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma S.A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies France SAS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications S.A., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications
Molecular Imaging France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Saint-Genis-Pouilly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | CELLforCURE, Les Ulis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">CELLforCURE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Les Ulis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.A.S., Levallois-Perret [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Levallois-Perret<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Deutschland GmbH, Nuremberg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Deutschland GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Nuremberg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Business Services GmbH, Wehr [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Business Services GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Wehr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma GmbH, Nuremberg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Nuremberg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Produktions GmbH, Wehr [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Produktions GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Wehr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz International GmbH, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz International GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | 1 A Pharma GmbH, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">1 A Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | HEXAL AG, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">HEXAL AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Salutas Pharma GmbH, Barleben [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Salutas Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Barleben<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Aeropharm GmbH, Rudolstadt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Aeropharm GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rudolstadt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Hellas) S.A.C.I.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Metamorphosis / Athens<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Greece<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Hungary Healthcare Limited Liability
Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Budapest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Hungary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Ft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Ft 545.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Hungary Limited Liability Company, Budapest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Hungary Limited Liability Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Budapest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Hungary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Ft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Ft 883.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis India Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis India Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 123.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">70.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">70.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare Private Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Private Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | PT. Novartis Indonesia, Jakarta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">PT. Novartis Indonesia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Jakarta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Indonesia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Rp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Rp 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Ireland Limited, Dublin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Ireland Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Integrated Services Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cork City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies EU Limited, Dublin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies EU Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Israel Ltd., Tel Aviv [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Israel Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tel Aviv<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farma S.p.A., Milan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farma S.p.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Milan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications (Italy) S.r.l.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Pozzilli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.p.A., Origgio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.p.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Origgio<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma K.K., Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma K.K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Ciba-Geigy Japan Limited, Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Ciba-Geigy Japan Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz K.K., Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz K.K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Baltics SIA, Riga [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Baltics SIA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Riga<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Latvia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Investments S.a r.l., Luxembourg City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Investments S.&#224; r.l.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Luxembourg City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance S.A., Luxembourg City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Luxembourg City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Corporation (Malaysia) Sdn. Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Petaling Jaya<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Malaysia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farmac&#233;utica, S.A. de C.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mexico City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Mexico<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz, S.A. de C.V., Mexico City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz, S.A. de C.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mexico City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Mexico<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Maroc SA, Casablanca [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Maroc SA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Casablanca<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Morocco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;.&#1605;. 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Netherlands B.V., Amsterdam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Netherlands B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Amsterdam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma B.V., Amsterdam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Amsterdam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | IDB Holland BV, Baarle-Nassau [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">IDB Holland BV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Baarle-Nassau<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz B.V., Almere [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Almere<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis New Zealand Ltd, Auckland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis New Zealand Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Auckland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">New Zealand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Norge AS, Oslo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Norge AS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Oslo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Norway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma (Pakistan) Limited, Karachi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma (Pakistan) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Karachi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Pakistan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma (Logistics), Inc., Panama City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma (Logistics), Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Panama City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Panama<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare Philippines, Inc., Makati City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare Philippines, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Makati City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Philippines<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8369;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8369; 298.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Philippines Corporation, Makati City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Philippines Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Makati City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Philippines<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8369;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8369; 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Poland Sp. z o.o., Warsaw [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Poland Sp. z o.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Warsaw<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">z&#322; 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Polska Sp. z o.o., Warsaw [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Polska Sp. z o.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Warsaw<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Lek S.A., Strykow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Lek S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Strykow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">z&#322; 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Portugal SGPS Lda., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Portugal, S.G.P.S., Lda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farma - Produtos Farmac&#234;uticos, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Farmaceutica Lda., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Farmac&#234;utica, Lda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Services Romania S.R.L., Bucharest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Services Romania S.R.L.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bucharest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Romania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RON 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.R.L., Targu-Mures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.R.L.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Targu-Mures<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Romania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RON 119.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma LLC, Moscow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Moscow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8381; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Neva LLC, St. Petersburg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Neva LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">St. Petersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | JSC Sandoz, Moscow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">JSC Sandoz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Moscow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8381; 57.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Saudi Ltd., Riyadh [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Saudi Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Riyadh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Saudi Arabia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1585;.&#1587;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1585;.&#1587; 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Singapore) Pte Ltd., Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Singapore) Pte Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Asia Pacific Pharmaceuticals
Pte Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Slovakia s.r.o., Bratislava [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Slovakia s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bratislava<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovakia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Lek Pharmaceuticals d.d., Ljubjana [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Lek Pharmaceuticals d.d.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ljubljana<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovenia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pharmaceuticals d.d., Ljubjana [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pharmaceuticals d.d.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ljubljana<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovenia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis South Africa (Pty) Ltd, Midrand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis South Africa (Pty) Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Midrand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Africa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R 86.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz South Africa (Pty) Ltd, Midrand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz South Africa (Pty) Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Midrand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Africa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Korea Ltd., Seoul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Korea Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Seoul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Korea<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farmaceutica, S.A., Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farmac&#233;utica, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Barcelona<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications
Iberica, S.L.U.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Esplugues de Llobregat<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Farmaceutica S.A., Madrid [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Farmac&#233;utica S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Madrid<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Industrial Products
S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Les Franqueses del Vall&#233;s / Barcelona<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Abadia Retuerta S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Sard&#243;n de Duero / Valladolid<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Sverige AB, Stockholm [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Sverige AB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Stockholm<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Sweden<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Holding AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Holding AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis International Pharmaceutical Investment AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis International Pharmaceutical Investment AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Bioventures AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Bioventures AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Forschungsstiftung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Forschungsstiftung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Stiftung fuer Kaderausbildung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Stiftung f&#252;r Kaderausbildung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis-Mitarbeiterbeteiligungsstiftung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Stiftung f&#252;r Mensch und Umwelt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Overseas Investments AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Overseas Investments AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Japat AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Japat AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Services AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Services AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Schweizerhalle AG, Muttenz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Schweizerhalle AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Muttenz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Stein AG, Stein [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Stein AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Stein<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Schweiz AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Schweiz AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Cellerys AG, Schlieren [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Cellerys AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Schlieren<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Arctos Medical AG, Bern [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Arctos Medical AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Innovative Therapies AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Innovative Therapies AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications International SA, Geneve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications International SA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Geneva<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pharmaceuticals AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pharmaceuticals AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Taiwan) Co., Ltd., Taipei [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Taiwan) Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Taipei<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Taiwan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Thailand) Limited, Bangkok [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Thailand) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bangkok<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Thailand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8378; 448.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Farmanova Saglik Hizmetleri Ltd. Sti.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Ila&#231; Sanayi ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Gebze - Kocaeli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8378; 96.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Ukraine LLC, Kyiv [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Ukraine LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Kyiv<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ukraine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8372;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8372; 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Middle East FZE, Dubai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Middle East FZE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dubai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Arab Emirates<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;.&#1573;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;.&#1573; 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis UK Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis UK Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals UK Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals UK Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Grimsby Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Grimsby Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications (UK &amp; Ireland), London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications (UK & Ireland)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Neutec Pharma Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Neutec Pharma Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Gyroscope Therapeutics Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Gyroscope Therapeutics Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Limited, Frimley/Camberley [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Frimley / Camberley<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Capital Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Capital Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Services, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Services, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis US Foundation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis US Foundation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications USA, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Millburn, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies, Inc., Bannockburn, IL [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bannockburn, IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Technology LLC, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Technology LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Institutes for BioMedical
Research, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cambridge, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Cadent Therapeutics, Cambridge, MA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Cadent Therapeutics<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cambridge, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Endocyte, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Endocyte, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Navigate BioPharma Services, Inc., Carlsbad, CA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Navigate BioPharma Services, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Carlsbad, CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | The Medicines Company, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">The Medicines Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Inc., Princeton, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Princeton, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Oriel Therapeutics, Inc., Durham, NC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Oriel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Durham, NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Fougera Pharmaceuticals Inc., Melville, NY [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Fougera Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Melville, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Eon Labs, Inc., Princeton, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Eon Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Princeton, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis de Venezuela, S.A., Caracas [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis de Venezuela, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Caracas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Venezuela<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | VEF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">VEF 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Vietnam Company Limited, Ho Chi Minh City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Vietnam Company Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ho Chi Minh City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Vietnam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8363;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8363; 70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis International AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis International AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of a subsidiary. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses a limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharePaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharePaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SocieteParActionsSANDOZAlgiersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SocieteParActionsSANDOZAlgiersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisArgentinaS.A.BuenosAiresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisArgentinaS.A.BuenosAiresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAustriaGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAustriaGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBangladeshLimitedGazipurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBangladeshLimitedGazipurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaNVVilvoordeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaNVVilvoordeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozNVVilvoordeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozNVVilvoordeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AlconCouvreurNVPuursMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AlconCouvreurNVPuursMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInvestmentLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInvestmentLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceServicesLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceServicesLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TriangleInternationalReinsuranceLimitedHamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TriangleInternationalReinsuranceLimitedHamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TrinityRiverInsuranceCoLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TrinityRiverInsuranceCoLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBiocienciasS.A.SaoPauloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBiocienciasS.A.SaoPauloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozCanadaInc.BouchervilleQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozCanadaInc.BouchervilleQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisChileS.A.SantiagoDeChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisChileS.A.SantiagoDeChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsHKLimitedHongKongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsHKLimitedHongKongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ShanghaiNovartisTradingLtd.ShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ShanghaiNovartisTradingLtd.ShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisS.r.o.PragueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisS.r.o.PragueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.r.o.PragueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.r.o.PragueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcareASCopenhagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcareASCopenhagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozASCopenhagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozASCopenhagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisEcuadorS.A.QuitoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisEcuadorS.A.QuitoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaS.A.E.CairoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaS.A.E.CairoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinlandOyEspooMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinlandOyEspooMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaS.A.S.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaS.A.S.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CELLforCURELesUlisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CELLforCURELesUlisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.A.S.LevalloisPerretMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.A.S.LevalloisPerretMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeutschlandGmbHNurembergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeutschlandGmbHNurembergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBusinessServicesGmbHWehrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBusinessServicesGmbHWehrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaGmbHNurembergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaGmbHNurembergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaProduktionsGmbHWehrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaProduktionsGmbHWehrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozInternationalGmbHHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozInternationalGmbHHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_A1APharmaGmbHHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_A1APharmaGmbHHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_HEXALAGHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_HEXALAGHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SalutasPharmaGmbHBarlebenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SalutasPharmaGmbHBarlebenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AeropharmGmbHRudolstadtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AeropharmGmbHRudolstadtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIndiaLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIndiaLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcarePrivateLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcarePrivateLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPrivateLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPrivateLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_PT.NovartisIndonesiaJakartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_PT.NovartisIndonesiaJakartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIrelandLimitedDublinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIrelandLimitedDublinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesEULimitedDublinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesEULimitedDublinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIsraelLtd.TelAvivMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIsraelLtd.TelAvivMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaS.p.A.MilanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaS.p.A.MilanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.p.A.OriggioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.p.A.OriggioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaK.K.TokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaK.K.TokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CibaGeigyJapanLimitedTokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CibaGeigyJapanLimitedTokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozK.K.TokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozK.K.TokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBalticsSIARigaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBalticsSIARigaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceS.A.LuxembourgCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceS.A.LuxembourgCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.A.DeC.V.MexicoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.A.DeC.V.MexicoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaMarocSACasablancaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaMarocSACasablancaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNetherlandsB.V.AmsterdamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNetherlandsB.V.AmsterdamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaB.V.AmsterdamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaB.V.AmsterdamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_IDBHollandBVBaarleNassauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_IDBHollandBVBaarleNassauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozB.V.AlmereMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozB.V.AlmereMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNewZealandLtdAucklandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNewZealandLtdAucklandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNorgeASOsloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNorgeASOsloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaPakistanLimitedKarachiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaPakistanLimitedKarachiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaLogisticsInc.PanamaCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaLogisticsInc.PanamaCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPhilippinesCorporationMakatiCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPhilippinesCorporationMakatiCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPolandSp.ZO.o.WarsawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPolandSp.ZO.o.WarsawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPolskaSp.ZO.o.WarsawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPolskaSp.ZO.o.WarsawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_LekS.A.StrykowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_LekS.A.StrykowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPortugalSGPSLda.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPortugalSGPSLda.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozFarmaceuticaLda.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozFarmaceuticaLda.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.R.L.TarguMuresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.R.L.TarguMuresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaLLCMoscowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaLLCMoscowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNevaLLCSt.PetersburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNevaLLCSt.PetersburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_JSCSandozMoscowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_JSCSandozMoscowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSaudiLtd.RiyadhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSaudiLtd.RiyadhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSingaporePteLtd.SingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSingaporePteLtd.SingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSlovakiaS.r.o.BratislavaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSlovakiaS.r.o.BratislavaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_LekPharmaceuticalsD.d.LjubjanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_LekPharmaceuticalsD.d.LjubjanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPharmaceuticalsD.d.LjubjanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPharmaceuticalsD.d.LjubjanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSouthAfricaPtyLtdMidrandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSouthAfricaPtyLtdMidrandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozSouthAfricaPtyLtdMidrandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozSouthAfricaPtyLtdMidrandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisKoreaLtd.SeoulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisKoreaLtd.SeoulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.BarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.BarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozFarmaceuticaS.A.MadridMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozFarmaceuticaS.A.MadridMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSverigeABStockholmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSverigeABStockholmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHoldingAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHoldingAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBioventuresAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBioventuresAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisForschungsstiftungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisForschungsstiftungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisStiftungFuerKaderausbildungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisStiftungFuerKaderausbildungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisStiftungFuerMenschUndUmweltBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisStiftungFuerMenschUndUmweltBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisOverseasInvestmentsAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisOverseasInvestmentsAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_JapatAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_JapatAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaServicesAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaServicesAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSchweizerhalleAGMuttenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSchweizerhalleAGMuttenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSteinAGSteinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSteinAGSteinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSchweizAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSchweizAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CellerysAGSchlierenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CellerysAGSchlierenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ArctosMedicalAGBernMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ArctosMedicalAGBernMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInnovativeTherapiesAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInnovativeTherapiesAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPharmaceuticalsAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPharmaceuticalsAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisTaiwanCo.Ltd.TaipeiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisTaiwanCo.Ltd.TaipeiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisThailandLimitedBangkokMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisThailandLimitedBangkokMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozUkraineLLCKievMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozUkraineLLCKievMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisMiddleEastFZEDubaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisMiddleEastFZEDubaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisUKLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisUKLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsUKLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsUKLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGrimsbyLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGrimsbyLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NeutecPharmaLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NeutecPharmaLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozLimitedFrimleyCamberleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozLimitedFrimleyCamberleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCorporationEastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCorporationEastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCapitalCorporationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCapitalCorporationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisServicesInc.EastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisServicesInc.EastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisUSFoundationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisUSFoundationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesInc.BannockburnILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesInc.BannockburnILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisTechnologyLLCInc.EastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisTechnologyLLCInc.EastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CadentTherapeuticsCambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CadentTherapeuticsCambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EndocyteInc.EastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EndocyteInc.EastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozInc.PrincetonNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozInc.PrincetonNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_OrielTherapeuticsInc.DurhamNCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_OrielTherapeuticsInc.DurhamNCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_FougeraPharmaceuticalsInc.MelvilleNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_FougeraPharmaceuticalsInc.MelvilleNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EonLabsInc.PrincetonNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EonLabsInc.PrincetonNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeVenezuelaS.A.CaracasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeVenezuelaS.A.CaracasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInternationalAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInternationalAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceCorporationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceCorporationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>nvs-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ns0="http://www.novartis.com/custom-units"
  xmlns:nvs="http://novartis.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvs-20221231.xsd" xlink:type="simple"/>
    <context id="AR_I-CurrentYearEnd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-23</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-23</startDate>
            <endDate>2019-11-23</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-06</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-06</endDate>
        </period>
    </context>
    <context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-06</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ValueAdjustmentsRelatedToDivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:AmericanDepositarySharesEachRepresenting1ShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:OrdinarySharesNominalValueCHF0.50PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="CHFPerShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Year">
        <measure>ns0:year</measure>
    </unit>
    <unit id="CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="JPY">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="DZD">
        <measure>iso4217:DZD</measure>
    </unit>
    <unit id="ARS">
        <measure>iso4217:ARS</measure>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="BDT">
        <measure>iso4217:BDT</measure>
    </unit>
    <unit id="BRL">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="CLP">
        <measure>iso4217:CLP</measure>
    </unit>
    <unit id="HKD">
        <measure>iso4217:HKD</measure>
    </unit>
    <unit id="COP">
        <measure>iso4217:COP</measure>
    </unit>
    <unit id="HRK">
        <measure>iso4217:HRK</measure>
    </unit>
    <unit id="CZK">
        <measure>iso4217:CZK</measure>
    </unit>
    <unit id="DKK">
        <measure>iso4217:DKK</measure>
    </unit>
    <unit id="EGP">
        <measure>iso4217:EGP</measure>
    </unit>
    <unit id="HUF">
        <measure>iso4217:HUF</measure>
    </unit>
    <unit id="INR">
        <measure>iso4217:INR</measure>
    </unit>
    <unit id="IDR">
        <measure>iso4217:IDR</measure>
    </unit>
    <unit id="ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="MYR">
        <measure>iso4217:MYR</measure>
    </unit>
    <unit id="MXN">
        <measure>iso4217:MXN</measure>
    </unit>
    <unit id="MAD">
        <measure>iso4217:MAD</measure>
    </unit>
    <unit id="NZD">
        <measure>iso4217:NZD</measure>
    </unit>
    <unit id="NOK">
        <measure>iso4217:NOK</measure>
    </unit>
    <unit id="PKR">
        <measure>iso4217:PKR</measure>
    </unit>
    <unit id="PHP">
        <measure>iso4217:PHP</measure>
    </unit>
    <unit id="PLN">
        <measure>iso4217:PLN</measure>
    </unit>
    <unit id="RON">
        <measure>iso4217:RON</measure>
    </unit>
    <unit id="RUB">
        <measure>iso4217:RUB</measure>
    </unit>
    <unit id="SAR">
        <measure>iso4217:SAR</measure>
    </unit>
    <unit id="SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="ZAR">
        <measure>iso4217:ZAR</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="SEK">
        <measure>iso4217:SEK</measure>
    </unit>
    <unit id="TWD">
        <measure>iso4217:TWD</measure>
    </unit>
    <unit id="THB">
        <measure>iso4217:THB</measure>
    </unit>
    <unit id="TRY">
        <measure>iso4217:TRY</measure>
    </unit>
    <unit id="UAH">
        <measure>iso4217:UAH</measure>
    </unit>
    <unit id="AED">
        <measure>iso4217:AED</measure>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="VEF">
        <measure>iso4217:VEF</measure>
    </unit>
    <unit id="VND">
        <measure>iso4217:VND</measure>
    </unit>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.60</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9996</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.7068</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.20</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <dei:EntityCentralIndexKey contextRef="AR_D-CurrentYear">0001114448</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AR_D-CurrentYear">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AR_D-CurrentYear">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="AR_D-CurrentYear">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="AR_D-CurrentYear">FY</dei:DocumentFiscalPeriodFocus>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <dei:EntityIncorporationStateCountryCode contextRef="AR_D-CurrentYear">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Lichtstrasse 35</dei:EntityAddressAddressLine1>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Algeria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Argentina</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bangladesh</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Chile</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Colombia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Croatia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ecuador</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Finland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Greece</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Indonesia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Israel</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Latvia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Morocco</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">New Zealand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Norway</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Pakistan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Panama</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Saudi Arabia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovakia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Korea</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sweden</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ukraine</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Arab Emirates</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Venezuela</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vietnam</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <dei:DocumentType contextRef="AR_D-CurrentYear">20-F/A</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="AR_D-CurrentYear">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="AR_D-CurrentYear">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="AR_D-CurrentYear">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="AR_D-CurrentYear">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="AR_D-CurrentYear">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="AR_D-CurrentYear">1-15024</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="AR_D-CurrentYear">Novartis AG</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="AR_D-CurrentYear">Lichtstrasse 35</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="AR_D-CurrentYear">4056</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AR_D-CurrentYear">Basel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AR_D-CurrentYear">CH</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Karen L. Hale</dei:ContactPersonnelName>
    <dei:EntityAddressPostalZipCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">4056</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Basel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">CH</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">41</dei:CountryRegion>
    <dei:CityAreaCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">324-1111</dei:LocalPhoneNumber>
    <dei:CountryRegion contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">41</dei:CountryRegion>
    <dei:CityAreaCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">61</dei:CityAreaCode>
    <dei:ContactPersonnelFaxNumber contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">324-7826</dei:ContactPersonnelFaxNumber>
    <dei:Security12bTitle contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">American Depositary Shares each representing 1 share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">NVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">Ordinary shares, nominal value CHF 0.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">NOVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Shares">2119609057</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="AR_D-CurrentYear">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="AR_D-CurrentYear">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="AR_D-CurrentYear">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="AR_D-CurrentYear">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="AR_D-CurrentYear">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="AR_D-CurrentYear">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="AR_D-CurrentYear">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="AR_D-CurrentYear">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="AR_D-CurrentYear">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="AR_D-CurrentYear">3240</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="AR_D-CurrentYear-1">1358</dei:AuditorFirmId>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">15486000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">15121000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">36342000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">34777000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14253000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9996000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">805000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1742000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3701000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3190000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9197000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.71</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.17</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.52</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-450000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-4762000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-359000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-4500000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2937000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-103000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1809000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-382000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">250000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-485000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2003000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">393000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6111000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21521000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11401000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6116000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21528000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-5000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-7000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">205000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3739000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188392"
      unitRef="USD">3743000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2411000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3036000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1110000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2210000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">80543000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">86077000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7175000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6666000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">268000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">278000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11413000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15922000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2471000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2440000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:CurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">36910000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">45718000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:IssuedCapital>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:TreasuryShares>
    <ifrs-full:OtherReserves
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58544000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">66802000000</ifrs-full:OtherReserves>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59342000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67655000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1538000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1621000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2686000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188393"
      unitRef="USD">3070000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4906000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6172000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">29374000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">33765000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2533000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2415000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">14795000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15670000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">28656000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">30208000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58030000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63973000000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-80000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">59275000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4657000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">55474000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">77000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">55551000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8072000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">8072000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-56000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">3331000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3330000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8016000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">11403000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11401000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">3038000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-31000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">798000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:RepurchaseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <nvs:RepurchaseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">724000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-10134000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-149000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-10279000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-10286000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">913000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">57157000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1419000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">56598000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">56666000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">24021000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">24021000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">46000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-2493000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-2497000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">24067000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">21528000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21521000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">2902000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-18000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">740000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:TransactionCostsRecordedInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:TransactionCostsRecordedInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:IncreaseDecreaseInNoncontrolingInterests
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">102000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-10235000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-229000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-10471000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">106000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-10365000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-48000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">70989000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4187000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">67655000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-844000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6116000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6111000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">66000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">10844000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-15000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">848000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseInNoncontrolingInterests
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-81000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-81000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-11000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-44000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-14404000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-14429000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-81000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-14510000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-92000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">63540000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4996000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">59342000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">11546000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5299000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">525000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">490000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">254000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">13000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">47000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">696000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">664000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">703000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">71000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">464000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">32000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">302000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">39000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1975000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2342000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1833000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">16124000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15949000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">16378000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">885000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1119000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2437000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-1003000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">241000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14236000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15071000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1198000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1378000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1275000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">167000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">240000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">88000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1473000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1593000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1310000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">202000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">748000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">380000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">121000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">191000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">230000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">133000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">442000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">723000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-24000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">20669000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-7000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-879000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-567000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">34695000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">16403000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1900000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">39357000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2298000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">492000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1468000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4208000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-13055000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1468000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4208000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-13182000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7506000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7368000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">6987000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10652000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3057000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2842000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">100000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">53000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">748000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2575000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2162000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3524000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">55000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">97000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-147000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-20562000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-16264000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2158000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-20562000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-16264000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2208000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-4858000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3015000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1740000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-32000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-266000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">286000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-4890000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2749000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1454000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">9658000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">11112000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">9658000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_da73ab4f-51f7-4057-ae74-786bf4269c5e_0">
          &lt;div&gt;
            &lt;div id="anchorId001516794"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;1. Significant accounting policies&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Balance sheet using year-end exchange rates&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&#x2014;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for property, plant and equipment:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201c;Other income.&#x201d; &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D).&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201c;Currently marketed products&#x201d; category.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected future cash flows&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales forecasts &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Profit margins&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Probability of obtaining regulatory approval&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Future tax rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate terminal growth rate&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate discount rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Probability-weighted scenarios are typically used.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201c;Interest expense&#x201d; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit pension plans and&#160;other&#160;post-employment benefits&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales to third parties&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201c;Other revenue&#x201d; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue performing R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201c;Revenue recognition&#x201d; in this Note 1, are recognized in &#x201c;Other expense&#x201d; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Income taxes&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of new IFRS standards, amendments and interpretations in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2021:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combinations amendments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_39a10fbd-4182-48f5-ba9b-99c9a34135c7_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_07231127-9425-430c-b394-4d59666b16c9_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Balance sheet using year-end exchange rates&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5d38989b-8be2-47c1-8eb6-af32cc0f7563_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_b1b2b7e3-323a-4b9b-9a8f-6d81b4fbfb2b_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&#x2014;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0a3dd331-c789-4faa-87e7-d4da39c2eb98_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for property, plant and equipment:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_34de13cc-3418-4128-83a8-7eaa7bb3ace3_0">
                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    </nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5e3e419f-26c7-4cf8-b2b1-88964217cf82_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201c;Other income.&#x201d; &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_82603315-d767-4329-9e0d-f8bf4201d420_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
    <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2088dfc1-3b0e-4fd0-a301-a7591e64d360_0">
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
    <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_16334c25-2e8d-4b69-a548-55d5fdaeea26_0">
                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    </nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
    <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c3e1cc23-36ef-472c-942e-43427d19a088_0">
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D).&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201c;Currently marketed products&#x201d; category.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock>
    <nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_66e712bd-20b8-47d4-b827-4eb36d688f88_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:&lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected future cash flows&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales forecasts &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Profit margins&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Probability of obtaining regulatory approval&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Future tax rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate terminal growth rate&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate discount rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Probability-weighted scenarios are typically used.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock>
    <nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_983fe451-b074-40a2-9972-59ca87ab180e_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock>
    <nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0ce1f161-c385-4f83-afb2-5723971b4e95_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9ae30d2d-61c0-48ba-9bde-7f5e2b679ebe_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9ef856b4-8a9c-4a9e-a0fc-ea2b3191b0e6_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6534693b-a560-44aa-8ab2-cd1be0ebbf45_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4147075a-0a09-430d-93de-b132724415d5_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ffba300c-0e5b-45bc-bed2-56dad24b7728_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201c;Interest expense&#x201d; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_505a237d-f10f-4367-99e0-757f698ed14d_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit pension plans and&#160;other&#160;post-employment benefits&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_df6d0571-69ff-4f80-ba7c-d9881e9662a4_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <ifrs-full:ParValuePerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">0.50</ifrs-full:ParValuePerShare>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_da7928e2-e1f3-4eb8-9144-365c8d8b90f8_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales to third parties&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201c;Other revenue&#x201d; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_caa17904-3a5a-4130-8b66-b502a69dc92b_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue performing R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f548d520-32d8-4845-aa13-e25e9f690f2d_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_17a28d6a-d7e1-44b1-aed9-4fa56a15ab10_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c887e09e-556d-4316-a60c-ebba4ca9dd31_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory>
    <nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ba217540-8056-4f88-b3e4-fb13e4416e8e_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201c;Revenue recognition&#x201d; in this Note 1, are recognized in &#x201c;Other expense&#x201d; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0d8c1266-6a61-46bf-bba0-f99bdf8c46c1_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Income taxes&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5299fc15-c452-4359-bc5d-a91387e538b4_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of new IFRS standards, amendments and interpretations in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2021:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combinations amendments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.&lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <nvs:DisclosureOfSignificantTransactionsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_21fa6a0b-0b46-4d15-b00e-465efa639f62_0">
          &lt;div&gt;
            &lt;div id="anchorId001517458"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;2. Significant transactions&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2022&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &#x2013; acquisition of Gyroscope Therapeutics Holdings plc&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD 0.8 billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD 0.7 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 1.0 billion. The amount consisted of an upfront cash payment of USD 0.8 billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD 0.2 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.9 billion, consisting primarily of intangible assets of USD 1.1 billion and net deferred tax liabilities of USD 0.2 billion. Goodwill amounted to USD 0.1 billion.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The results of operations since the date of acquisition are not material.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2021&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; acquisition of GSK&#x2019;s cephalosporin antibiotics business&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#x2019;s cephalosporin antibiotics business. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Under the agreement, Sandoz acquired the global rights to three established brands (Zinnat&#xae;, Zinacef&#xae; and Fortum&#xae;) in more than 100 markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consisted of a USD 350 million upfront payment paid at closing and potential milestone payments up to USD 150 million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 415 million. The amount consisted of a payment of USD 351 million, including purchase price adjustments, and the fair value of contingent consideration of USD 64 million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 308 million, consisting of USD 292 million intangible assets and USD 16 million deferred tax assets. Goodwill amounted to USD 107 million. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2021 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Corporate &#x2013; divestment of the investment in Roche Holding AG &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell 53.3 million (approximately &lt;span&gt;33.3%&lt;/span&gt;) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD 20.7 billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The transaction closed on December 6, 2021. Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2020&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &#x2013; acquisition of The&#160;Medicines Company&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 23, 2019, Novartis entered into an agreement and plan of merger (&#x201c;the Merger Agreement&#x201d;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4&lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2020 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; acquisition of the Japanese business of Aspen Global Incorporated &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Aspen&#x2019;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consisted of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets and USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2020 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.&lt;/div&gt;
          &lt;/div&gt;

          &lt;div/&gt;
        </nvs:DisclosureOfSignificantTransactionsTextBlock>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">700000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1000000000.0</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">200000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">900000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1100000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">200000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">100000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:NumberOfBrandsInPortfolioToAcquire
      contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3</nvs:NumberOfBrandsInPortfolioToAcquire>
    <nvs:NumberOfMarketsForTheAcquiredBrands
      contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">100</nvs:NumberOfMarketsForTheAcquiredBrands>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">350000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">150000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">351000000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">308000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:NumberOfBearerShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-5"
      unitRef="Shares">53300000</nvs:NumberOfBearerShares>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:CashOfferPerOrdinaryShare
      contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="1"
      unitRef="USD">85</nvs:CashOfferPerOrdinaryShare>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">9600000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">9600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">7100000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1400000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">2500000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">274000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">303000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:CustomaryPurchasePriceAdjustment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">27000000</nvs:CustomaryPurchasePriceAdjustment>
    <nvs:CustomaryPurchasePriceAdjustment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">30000000</nvs:CustomaryPurchasePriceAdjustment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">70000000</nvs:PotentialMilestoneMaximumPayments>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">77000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">294000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">324000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">247000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">273000000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">47000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">51000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">238000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">196000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <nvs:OtherNetAssets
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">26000000</nvs:OtherNetAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">16000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">86000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:DivestmentDateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:DivestmentDateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">38000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">102000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_34b5fc84-94f4-4988-833e-1b6b0aeff59d_0">
          &lt;div&gt;
            &lt;div id="anchorId001517705"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;3. Segmentation of key figures 2022, 2021 and 2020&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The reporting segments are as follows:&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp;amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.&lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated income statements&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            825
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            42 121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 454
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 569&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 978&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 061
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 486&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 801
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 504
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            36 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 679&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-512&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-824&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 695&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-733&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 701&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 037&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Loss)/income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-204&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-122&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 728&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-222&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-260&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 069&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-259&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 368&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-706&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-280&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 048&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 927&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 058
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 076&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 118&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-862&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 980&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 871&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-831&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-488&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 190&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 152
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-912&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-282&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-330&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 080&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-370&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 462&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-116&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-440&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            335
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-217&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-714&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated balance sheets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            75 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16 078
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 865
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            117 453
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            131 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-16 966&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-15 929&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 710&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 632&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-37 354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-44 412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-58 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63 973&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            59 423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67 822
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            58 544
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63 291
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 161&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66 668
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            68 690
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to property, plant and equipment&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            991
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to right-of-use assets&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            222
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total goodwill and intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 603
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to goodwill and intangible assets&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 791
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial debts and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Excluding the impact of business acquisitions&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales to third parties&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            970
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 708
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 615
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 518
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 378
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 052
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 573
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            599
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 683
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 804
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            165
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            217
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 525
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 781
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 041
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s largest, second-largest and third-largest customers account for approximately &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt; of net sales to third parties, respectively (2021: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively; 2020: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively). All segments had sales to these customers in 2022, 2021 and 2020.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;14%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively, of the trade receivables at December 31, 2022 (2021: &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;12%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively).&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; net sales to third parties&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties by region&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021&lt;br/&gt; to 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020&lt;br/&gt; to 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 929
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 304
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 914
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31 459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 643
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 748
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 613
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            969
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 855
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 557
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37 008
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 537
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 927
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Leqvio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 756
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 287
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            372
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 007
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 272
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            475
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            445
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            320
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Pluvicto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            271
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 101
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Scemblix&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other Promoted Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            623
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            203
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other respiratory&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;i&gt;Voltaren/Cataflam&lt;/i&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            334
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            323
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            393
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contract manufacturing&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 944
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 694
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure,  hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 290
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis  (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia  (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 046
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            678
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            434
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            472
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            759
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing-remitting   multiple sclerosis (RRMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            540
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            729
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            597
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            340
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex   (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 brands total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 753
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            19 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            32 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 159
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 427
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 178
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 069
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            606
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 087
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors, acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            843
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            558
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            761
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            521
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            417
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            598
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            887
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            722
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cronic obstructive  pulmonary disease  (COPD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 976
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 311
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 331
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 996
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            833
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            569
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            973
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            837
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            315
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            879
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            964
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            461
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            515
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma (RCC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 097
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 671
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales to third parties by business franchise&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 928
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; other revenue&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate   (including eliminations)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            74
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <nvs:NumberOfReportableSegments contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">2</nvs:NumberOfReportableSegments>
    <nvs:NumberOfCommercialOrganizationalUnits
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfCommercialOrganizationalUnits>
    <nvs:NumberOfBusinessUnits
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfBusinessUnits>
    <nvs:NumberOfFranchises
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3</nvs:NumberOfFranchises>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_94a60ae5-89e2-4fcb-a93a-0b67f7bf2eff_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated income statements&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            825
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            42 121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 454
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 569&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 978&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 061
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 486&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 801
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 504
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            36 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 679&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-512&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-824&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 695&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-733&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 701&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 037&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Loss)/income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-204&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-122&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 728&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-222&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-260&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 069&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-259&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 368&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-706&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-280&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 048&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 927&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 058
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 076&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 118&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-862&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 980&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 871&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-831&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-488&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 190&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 152
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-912&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-282&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-330&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 080&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-370&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 462&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-116&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-440&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            335
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-217&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-714&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">825000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">795000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">180000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1030000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42121000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42790000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9454000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9811000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1030000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1249000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11569000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11751000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4978000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5147000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1061000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1031000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">15486000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">31801000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32218000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4504000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4725000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">36342000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11679000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">12306000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">512000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">518000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14253000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9172000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8641000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">824000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9996000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">531000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1149000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">103000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">233000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">171000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">470000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">805000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2695000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1732000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">273000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">397000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">733000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">618000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3701000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8786000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10688000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1448000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1600000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1037000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-599000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9197000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15332000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">379000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">837000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">859000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">210000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1163000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">252000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">265000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3728000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3638000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">222000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3982000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">407000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">271000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">407000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1299000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-134000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-126000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-260000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1069000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">240000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">40000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">259000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1368000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">706000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">721000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">65000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">280000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">193000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1048000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">795000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">792000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">180000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-981000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42790000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39805000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9811000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9835000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-981000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1018000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11751000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10927000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5147000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5252000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1031000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1058000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">15121000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32218000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29896000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4725000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4636000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">245000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">34777000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">12306000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11657000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2076000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">518000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">464000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8641000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8118000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">862000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1149000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">233000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">176000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">470000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">644000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1742000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1732000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1871000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">397000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">831000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">618000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">488000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3190000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10688000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9172000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1600000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1043000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-599000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-63000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15332000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">670000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">91000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">859000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">912000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">210000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">282000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">124000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">265000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">273000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">41000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3638000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3080000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">370000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3462000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">271000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">324000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">116000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">440000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">768000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">141000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">914000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">153000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">182000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">335000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">240000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">98000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">721000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">714000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">65000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">193000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3eee49b6-a748-4b7a-a5ee-101cd0fd8a09_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated balance sheets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            75 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16 078
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 865
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            117 453
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            131 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-16 966&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-15 929&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 710&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 632&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-37 354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-44 412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-58 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63 973&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            59 423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67 822
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            58 544
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63 291
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 161&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66 668
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            68 690
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to property, plant and equipment&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            991
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to right-of-use assets&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            222
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total goodwill and intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 603
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to goodwill and intangible assets&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 791
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial debts and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Excluding the impact of business acquisitions&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">75510000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">79220000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16078000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16192000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">25865000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">36383000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:Assets>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">16966000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15929000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3710000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3632000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">37354000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">44412000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58030000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63973000000</ifrs-full:Liabilities>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">58544000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">63291000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">12368000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">12560000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-4244000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-7161000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">66668000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">68690000000</nvs:NetOperatingAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8488000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9168000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1861000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1901000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">476000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">842000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">991000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">349000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">85000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">90000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1219000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1430000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1233000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1349000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">90000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">104000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">196000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">222000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">31000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">247000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">321000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">51357000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">53919000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9603000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">255000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">60945000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63777000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1791000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1491000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">163000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">102000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2093000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1736000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">170000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">205000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-25000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-24000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-13000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-38000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-43000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26175000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">29197000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">26175000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">29197000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5219000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5485000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5219000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5485000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fefb2f0c-8f54-4ad5-8d91-d6f5294ce23a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales to third parties&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            970
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 708
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 615
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 518
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 378
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 052
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 573
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            599
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 683
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 804
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            165
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            217
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 525
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 781
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 041
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">970000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">23708000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.32</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">25770000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.33</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">17653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">35353000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.48</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">37054000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.48</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2257000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2522000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">3188000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.04</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">3615000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4870000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4518000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">2229000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">2378000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">3128000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">3052000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">2573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">599000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">703000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2683000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">165000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">217000000</nvs:SelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">20054000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">20808000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">19038000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">8241000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">7351000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">73483000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">77088000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18467000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.37</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">20197000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">35896000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">37525000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">21536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.42</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">20463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">19725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">35806000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">37522000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10966000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">1781000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">2041000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">73483000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">77088000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:CustomersWithNetSalesOverFivePercent
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_60d6f47f-8b49-42f7-b024-3f309603bd5c_0">

                  The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              </nvs:CustomersWithNetSalesOverFivePercent>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_96ee93e0-29ef-4668-aa89-2397f674961b_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; net sales to third parties&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties by region&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021&lt;br/&gt; to 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020&lt;br/&gt; to 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 929
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 304
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 914
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31 459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 643
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 748
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 613
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            969
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 855
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 557
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37 008
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 537
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 927
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">13554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14919000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">13484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15899000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14999000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9304000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2914000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">30548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">31459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29643000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10748000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4913000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1819000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2142000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1613000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1662000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">969000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">872000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">772000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">6460000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">6855000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7089000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2789000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2557000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18467000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">20197000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">17653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10966000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3883000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3645000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">37008000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">38314000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">36732000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">13537000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">13312000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">11927000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      id="SectionBlock_2a2f22b0-c817-4b31-b2ef-031b77d30428_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Leqvio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 756
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 287
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            372
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 007
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 272
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            475
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            445
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            320
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Pluvicto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            271
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 101
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Scemblix&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other Promoted Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            623
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            203
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other respiratory&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;i&gt;Voltaren/Cataflam&lt;/i&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            334
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            323
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            393
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contract manufacturing&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 944
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 694
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">4644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">3548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.42</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">112000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">4756000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">3560000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">4788000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">4718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1059000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">7287000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">7205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">6119000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">2013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">2787000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">-0.28</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.47</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">372000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">1.94</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">357000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">281000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">170000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.65</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">218000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">215000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">5051000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">5007000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">4272000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1693000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">937000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">577000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">471000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">475000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">373000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">329000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">271000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">90000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.48</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">1.57</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">4723000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">4101000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">3666000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2088000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2016000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1923000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2060000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.56</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.67</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">6452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">6430000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">5617000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">487000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">468000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">623000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">203000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">186000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">190000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">84000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.58</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">1.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3127000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3451000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3148000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">31396000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">29754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">25319000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1238000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">745000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1024000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">743000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">901000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">652000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">512000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">938000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.45</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">334000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">373000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">329000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">431000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">563000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">310000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">368000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">393000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">214000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">108000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">0.98</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">3641000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">4257000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">4944000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">9900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">12241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">13694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      id="SectionBlock_830aaffb-edf5-4abe-ad8d-c4d2a65c5159_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure,  hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 290
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis  (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia  (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 046
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            678
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            434
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            472
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            759
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing-remitting   multiple sclerosis (RRMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            540
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            729
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            597
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            340
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex   (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 brands total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 753
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            19 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            32 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 159
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 427
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 178
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 069
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            606
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 087
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors, acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            843
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            558
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            761
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            521
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            417
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            598
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            887
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            722
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cronic obstructive  pulmonary disease  (COPD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 976
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 311
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 331
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 996
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            833
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            569
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            973
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            837
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            315
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            879
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            964
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            461
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            515
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma (RCC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 097
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 671
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2018000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4788000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2354000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2290000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1005000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2088000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1153000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">860000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">877000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1923000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">678000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">434000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">936000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">438000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1238000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">472000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">759000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">570000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">563000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">921000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">540000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">745000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">729000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">743000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">55000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">597000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">652000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">196000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">340000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">512000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">12753000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">19384000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">32137000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3146000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">6013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9159000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15899000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">25397000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2883000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1835000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1712000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1836000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1427000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2787000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">882000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1178000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2060000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">947000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1069000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2016000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">606000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1087000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1693000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">843000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">570000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">882000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">558000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1059000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">761000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1024000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">521000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">417000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">938000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">598000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">937000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">887000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">901000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">51000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">722000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">357000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">11688000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">20976000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">32664000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3311000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">6020000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9331000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14999000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">26996000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2516000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1562000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1277000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">833000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">905000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">569000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">973000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">602000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">315000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">879000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">964000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">461000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">400000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">473000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">318000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">369000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">515000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">11126000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">18790000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">29916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3216000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">5881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">24671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      id="SectionBlock_eba89ff5-1c70-419a-bd8b-99a4ddcb0a3b_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales to third parties by business franchise&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 928
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">6776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">7092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">7244000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">2093000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">2116000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="2"
      unitRef="Pure">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">1928000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">380000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="2"
      unitRef="Pure">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="2"
      unitRef="Pure">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1100000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">777000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">707000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">380000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4926d87c-b09b-41cd-afc1-d0c23b6bdb27_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; other revenue&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate   (including eliminations)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            74
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">921000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">835000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">921000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">873000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">835000000</nvs:ProfitSharingIncome>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">24000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">52000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">109000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">300000000</ifrs-full:RevenueFromRoyalties>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">145000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">127000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">148000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">155000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">50000000</nvs:MilestoneIncome>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">155000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">162000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">114000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">54000000</nvs:OtherRevenueOther>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1249000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1018000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3e5bbd9c-1f4f-4f29-95c6-acb6d4566009_0">
          &lt;div&gt;
            &lt;div id="anchorId001530159"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;4. Associated companies&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its &lt;span&gt;33.3%&lt;/span&gt; of Roche Holding AG (Roche) voting shares, representing approximately &lt;span&gt;6.2%&lt;/span&gt; of Roche&#x2019;s total outstanding voting and non-voting equity instruments, to Roche for USD 20.7 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies. See Note 2.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s holding in Roche voting shares was &lt;span&gt;33.3%&lt;/span&gt; at December 31, 2020. This investment represented approximately &lt;span&gt;6.2%&lt;/span&gt; of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results were adjusted in the Group&#x2019;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#x2019;s consolidated financial statements.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#160;522 million.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's  estimated current-year  consolidated net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            815
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on divestment of the  investment in Roche&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_bc7a172d-8194-47e3-bb62-2186a26ff0a5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15341000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15387000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">621000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15385000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">617000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3000000</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
    <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DividendsReceived
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">522000000</ifrs-full:DividendsReceived>
    <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      id="SectionBlock_274be8b0-50d8-43ee-9d81-db18741255e0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's  estimated current-year  consolidated net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            815
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on divestment of the  investment in Roche&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
    <nvs:ShareOfCurrentYearNetIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">815000000</nvs:ShareOfCurrentYearNetIncome>
    <nvs:ShareOfCurrentYearNetIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">913000000</nvs:ShareOfCurrentYearNetIncome>
    <nvs:PriorYearAdjustment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">40000000</nvs:PriorYearAdjustment>
    <nvs:PriorYearAdjustment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-64000000</nvs:PriorYearAdjustment>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-70000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-172000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">14556000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15341000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-8"
      unitRef="USD">3200000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <ifrs-full:DisclosureOfInterestExpenseExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_db6fcc50-f24c-4205-a55a-8199c9aa22ca_0">
          &lt;div&gt;
            &lt;div id="anchorId001530632"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;5. Interest expense and&#160;other&#160;financial&#160;income&#160;and&#160;expense&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest expense&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-669&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-651&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-708&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-60&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from  discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-108&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other financial income and expense&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-184&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-69&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-135&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income  and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInterestExpenseExplanatory>
    <nvs:InterestExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_aa003d3c-ae7c-49e6-9007-46bb1904b4d5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-669&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-651&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-708&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-60&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from  discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-108&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:InterestExpenseTableTextBlock>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">669000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">651000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">708000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">60000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">62000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">108000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">98000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">94000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <nvs:OtherFinancialIncomeAndExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0c95a118-0c2c-4f79-a62a-d62c6a956d4f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-184&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-69&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-135&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income  and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OtherFinancialIncomeAndExpenseTableTextBlock>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">379000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">91000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">19000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">12000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">18000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">194000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">94000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">52000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-184000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-69000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-135000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_811479e0-5aba-4152-bd76-324857fd74c9_0">
          &lt;div&gt;
            &lt;div id="anchorId001530884"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;6. Income taxes&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Income before taxes&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 986
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22 028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Current and deferred income tax expense&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The significant components of the provision for income taxes are as follows:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-617&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-932&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 454&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 470&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 168&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 071&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 428&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-142&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Analysis of tax rate&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The applicable tax rate changes from year to year due to changes in the mix of the Group&#x2019;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate and the effective tax rate are shown in the following table:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of previously unrecognized tax losses brought forward from prior periods&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of  contingent consideration liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change  on current and deferred  tax assets and liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of derecognition and reversals of derecognition  of deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of  write-down of investments in subsidiaries&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of changes in uncertain tax positions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes the effect of income not subject to tax (&lt;span&gt;-7.3&lt;/span&gt;%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.&lt;/span&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;that impact the comparability of the effective tax rate between years.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The utilization of tax-loss carry-forwards lowered the tax charge by USD&#160;1 million in 2022, by USD&#160;5 million in 2021, and by USD&#160;29 million in 2020.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <nvs:IncomeBeforeTaxesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2245204e-26cf-41ad-98e1-f9088d9951ec_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 986
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22 028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:IncomeBeforeTaxesTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">5986000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">22028000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">9786000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">2385000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">4109000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1ae83aa4-abd9-456d-8af3-386ea0d57a5e_0">
                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The significant components of the provision for income taxes are as follows:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-617&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-932&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 454&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 470&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 168&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 071&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 428&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-142&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">617000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">932000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1454000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1470000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2071000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2428000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2100000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">142000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-286000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-430000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-655000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-309000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-293000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <nvs:AnalysisOfTaxRateTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_bc4e921e-c03e-4b78-8995-930f42d29b77_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of previously unrecognized tax losses brought forward from prior periods&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of  contingent consideration liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change  on current and deferred  tax assets and liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of derecognition and reversals of derecognition  of deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of  write-down of investments in subsidiaries&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of changes in uncertain tax positions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes the effect of income not subject to tax (&lt;span&gt;-7.3&lt;/span&gt;%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.&lt;/span&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AnalysisOfTaxRateTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.168</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.148</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.136</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.026</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.010</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.046</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.003</ifrs-full:TaxRateEffectOfTaxLosses>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.001</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.001</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.075</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.007</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.038</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.014</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.005</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.001</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.001</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.003</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.012</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.0</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.008</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.004</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.001</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.023</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.014</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.013</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.020</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.169</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.081</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.183</ifrs-full:AverageEffectiveTaxRate>
    <nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="3"
      unitRef="Pure">-0.073</nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">5000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">29000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8e702e78-1736-41aa-a15c-346092ef57ba_0">
          &lt;div&gt;
            &lt;div id="anchorId001531581"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;7. Earnings per share&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;
                  No options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:EarningsPerShareExplanatory>
    <nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_49227af3-d816-49a0-8a9d-fc6a80a1ff85_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">2181000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">2243000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">2277000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">16000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">17000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">19000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">2197000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">2260000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">2296000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.71</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.17</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.52</ifrs-full:DilutedEarningsLossPerShare>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_56d1257d-165f-411d-ab22-ab30ea6a8f2e_0">
          &lt;div&gt;
            &lt;div id="anchorId001531800"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;8. Changes in consolidated statements of&#160;comprehensive income&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Fair value&lt;br/&gt; adjustments &lt;br/&gt; on financial&lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; from defined&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Cumulative&lt;br/&gt; currency &lt;br/&gt; translation&lt;br/&gt; effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value&lt;br/&gt; adjustments&lt;br/&gt; attributable to &lt;br/&gt; Novartis AG &lt;br/&gt; shareholders&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-&lt;br/&gt; controlling&lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total value&lt;br/&gt; adjustments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            120
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 919&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-36&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-3&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 10 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 992
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 386
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities  sold, reclassified to retained earnings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 773&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 419&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 448&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-44&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD 33 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-323&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 17 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 762&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 541&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 968&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 187&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 220&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD 81 million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD &lt;span&gt;-30&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-104&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-103&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 18 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-353&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-839&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-844&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments, net of taxes of USD &lt;span&gt;-4&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-198&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 038&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-760&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 034&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;8.1) In 2022, net cumulative currency translation gains of USD 13 million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD 3.2 billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were no currency translation losses or gains recycled through the income statement.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock>
    <nvs:ScheduleOfComprehensiveIncomeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5ec7eff2-43d4-416d-8d39-9cd38dc55ac5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Fair value&lt;br/&gt; adjustments &lt;br/&gt; on financial&lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; from defined&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Cumulative&lt;br/&gt; currency &lt;br/&gt; translation&lt;br/&gt; effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value&lt;br/&gt; adjustments&lt;br/&gt; attributable to &lt;br/&gt; Novartis AG &lt;br/&gt; shareholders&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-&lt;br/&gt; controlling&lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total value&lt;br/&gt; adjustments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            120
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 919&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-36&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-3&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 10 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 992
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 386
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities  sold, reclassified to retained earnings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 773&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 419&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 448&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-44&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD 33 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-323&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 17 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 762&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 541&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 968&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 187&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 220&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD 81 million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD &lt;span&gt;-30&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-104&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-103&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 18 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-353&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-839&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-844&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments, net of taxes of USD &lt;span&gt;-4&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-198&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 038&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-760&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 034&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfComprehensiveIncomeTableTextBlock>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">120000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-5919000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">1142000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4657000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4686000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">145000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">2992000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">3386000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-5773000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">4134000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1419000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-1448000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-44000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-323000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1808000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">1808000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">1809000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-4757000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4757000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4762000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1808000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-4541000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-2543000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">188000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3968000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-407000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4187000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-33000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember"
      decimals="-6"
      unitRef="USD">-30000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-103000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-444000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-444000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-450000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-353000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-844000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-198000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-4038000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-760000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4996000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-38000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-5034000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-8"
      unitRef="USD">3200000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">0</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c6f2d8a9-afa9-42bd-802f-7fab885dd191_0">
          &lt;div&gt;
            &lt;div id="anchorId001533452"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;9. Property, plant and equipment&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-964&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            667
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            780
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-155&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-351&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-166&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-57&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-288&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 170&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            549
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            555
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 377
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 955&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-610&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-453&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-755&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-203&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-199&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-509&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-411&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-315&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-447&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <nvs:PropertyPlantAndEquipmentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_45d52e46-4eaa-4876-9e9d-22161598a5a2_0">
                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-964&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            667
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            780
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-155&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-351&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-166&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-57&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-288&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 170&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            549
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            555
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 377
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 955&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-610&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-453&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-755&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-203&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-199&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-509&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">492000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11819000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1508000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13328000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">27147000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-65000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-9786000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15602000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">13000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">297000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-964000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">667000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">124000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">780000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">312000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1219000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">49000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">45000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">155000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">437000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">726000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1163000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">351000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">414000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-166000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-57000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-288000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">442000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">5493000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1157000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3672000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">451000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11396000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1184000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">11842000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">24873000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5903000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-8170000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-14109000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">442000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">5493000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1157000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3672000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">549000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">555000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">12377000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1248000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">14038000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">28218000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-19000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5807000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-66000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-10063000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15955000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">536000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6570000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3975000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">12263000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">536000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6570000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3975000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">12263000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-610000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">413000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">109000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1027000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">293000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1430000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">150000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">453000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">755000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1208000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">384000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">103000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-203000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-84000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-199000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-509000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">492000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11819000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1508000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13328000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">27147000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-65000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-9786000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15602000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4000000</ifrs-full:BorrowingCostsCapitalised>
    <nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_32ec21d1-5255-4485-b396-a8f0b52bd724_0">
                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-411&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-315&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-447&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">411000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">315000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">59000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">414000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">384000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">447000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">103000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_53d461e4-2ac6-411f-abc2-72e0aef89bbb_0">
          &lt;div/&gt;

          &lt;div&gt;
            &lt;div id="anchorId001534980"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;10. Right-of-use assets and lease liabilities&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of the right-of-use assets:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Impairment charges in 2022 were recorded in the Innovative Medicines segment.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31,&lt;br/&gt; 2022&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31,&lt;br/&gt; 2021&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            866
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            117
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            136
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            324
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            232
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            258
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            167
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            201
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            198
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            982
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-251&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-297&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-275&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 908
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for leases not yet commenced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.7 billion (2021: USD 0.6 billion), has a determined lease term end date of 2071 (2021: 2071). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD 49 million and the recognition of USD 23 million of lease liabilities, and USD 13 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 17 million. There were no significant sale and leaseback transactions in 2021 or 2020.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            355
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            381
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Thereof:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of interest&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Included within total net cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Reported as cash outflows in financing activities net of lease incentives received, if any.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfLeasesExplanatory>
    <nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_df810e39-bcfd-4ce2-b27e-6b749289218e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Impairment charges in 2022 were recorded in the Innovative Medicines segment.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">1676000000</ifrs-full:RightofuseAssets>
    <nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">12000000</nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">247000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">321000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">300000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">318000000</ifrs-full:DepreciationRightofuseAssets>
    <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-3000000</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
    <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">34000000</nvs:LeaseContractTerminationsRightofuseAssets>
    <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">66000000</nvs:LeaseContractTerminationsRightofuseAssets>
    <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-52000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-52000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d11e550a-90e7-4d7a-a75e-9b065c045380_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31,&lt;br/&gt; 2022&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31,&lt;br/&gt; 2021&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            866
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            117
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            136
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">505000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">522000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">745000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">866000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">117000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">96000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">136000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">300000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">318000000</ifrs-full:DepreciationRightofuseAssets>
    <nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e70d24c1-a6ae-4d5f-9ed0-f6d505dfb2ec_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            324
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            232
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            258
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            167
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            201
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            198
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            982
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-251&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-297&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-275&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 908
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for leases not yet commenced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">297000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">324000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">190000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">232000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">258000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">201000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">198000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">172000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">172000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2149000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">982000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2243000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3205000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3349000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:CurrentLeaseLiabilities>
    <nvs:CurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">297000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:CurrentLeaseLiabilities>
    <nvs:CurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">324000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1538000000</ifrs-full:NoncurrentLeaseLiabilities>
    <nvs:NoncurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2908000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1621000000</ifrs-full:NoncurrentLeaseLiabilities>
    <nvs:NoncurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3025000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
    <nvs:CommitmentsForLeasesNotYetCommenced
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">83000000</nvs:CommitmentsForLeasesNotYetCommenced>
    <nvs:CommitmentsForLeasesNotYetCommenced
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">134000000</nvs:CommitmentsForLeasesNotYetCommenced>
    <nvs:MostMaterialLeaseWithLeaseTermExtension
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">700000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
    <nvs:MostMaterialLeaseWithLeaseTermExtension
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
    <nvs:LeaseTermEndDate contextRef="AR_D-CurrentYear">2071</nvs:LeaseTermEndDate>
    <nvs:LeaseTermEndDate contextRef="AR_D-CurrentYear-1">2071</nvs:LeaseTermEndDate>
    <nvs:CashInflowForSaleAndLeaseback
      contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">-49000000</nvs:CashInflowForSaleAndLeaseback>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:RightofuseAssets>
    <ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions
      contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions>
    <nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e10165ed-12a3-4346-9e01-9fcd5f380640_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            355
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            381
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Thereof:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of interest&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Included within total net cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Reported as cash outflows in financing activities net of lease incentives received, if any.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">60000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">62000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">4000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">355000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">381000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">379000000</ifrs-full:CashOutflowForLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">13000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">51000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">52000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">56000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.033</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.032</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.034</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_af0e64b4-8e57-415a-bfb1-a540fd9cc322_0">
          &lt;div&gt;
            &lt;div id="anchorId001535930"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;11. Goodwill and intangible assets&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 429&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 603&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-342&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-72&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-427&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-176&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-243&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 305
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69 684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 671&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32 736&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 716&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38 040&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 115
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            57 333
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-885&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26 566&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 272&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30 916&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            270
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-36&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 607&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-255&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-350&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-642&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-584&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-672&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 313
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 091
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As at December 31, 2022, the most significant intangible assets within currently marketed products category are &lt;i&gt;Leqvio&lt;/i&gt; (Innovative Medicines: acquisition of The Medicines Company) and &lt;i&gt;Zolgensma&lt;/i&gt; (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for &lt;i&gt;Leqvio&lt;/i&gt; is USD 7.4 billion and 13 years, respectively (2021: USD 7.9 billion and 14 years, respectively), and for &lt;i&gt;Zolgensma&lt;/i&gt; USD 5.9 billion and 8 years, respectively (2021: USD 6.6 billion and 9 years, respectively). &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following assumptions are used in the calculations:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br/&gt; Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;&#x201c;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201d; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the intangible asset impairment charges and reversals by reporting segment: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program UNR844.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program GTX312.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product (&lt;i&gt;Votrient&lt;/i&gt; carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2d69d497-2de4-4dd1-93ac-5bfe724d3389_0">
                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 429&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 603&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-342&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-72&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-427&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-176&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-243&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 305
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69 684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 671&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32 736&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 716&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38 040&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 115
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            57 333
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-885&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26 566&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 272&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30 916&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            270
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-36&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 607&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-255&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-350&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-642&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-584&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-672&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29900000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">8013000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">56213000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2905000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">68211000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2514000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-903000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-29107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1505000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-34029000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">161000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">1209000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1209000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-1429000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1403000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">24000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1175000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">588000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">2093000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">95000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">100000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3603000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">342000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">3982000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">917000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">322000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">72000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-427000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-176000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-243000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-432000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29596000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">7092000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1038000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">58249000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">3305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">69684000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-295000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2671000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-917000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-32736000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1716000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-38040000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">30321000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">6893000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1115000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">57333000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2384000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">67725000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-322000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2193000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-885000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-26566000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1272000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-30916000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">262000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">98000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">652000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">270000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">508000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1736000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">36000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">41000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3607000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">255000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">350000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">35000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-642000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-51000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-10000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-584000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-672000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29900000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">8013000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">56213000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2905000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">68211000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2514000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-903000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-29107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1505000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-34029000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_46b5d5d4-cc61-426a-8711-581e92f84af1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 313
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 091
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">21531000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">4186000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">24487000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1139000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29826000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7770000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1026000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1460000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">21562000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5313000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">25938000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1091000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32357000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">8026000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">186000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1577000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">248000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">248000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember"
      decimals="-8"
      unitRef="USD">7400000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">P13Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember"
      decimals="-8"
      unitRef="USD">7900000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">P14Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember"
      decimals="-8"
      unitRef="USD">5900000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">P8Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember"
      decimals="-8"
      unitRef="USD">6600000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">P9Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7283400a-d2cb-4f1c-a33b-f41a5dcac4f0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br/&gt; Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="3"
      unitRef="Pure">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="3"
      unitRef="Pure">0.010</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="3"
      unitRef="Pure">0.080</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="3"
      unitRef="Pure">0.080</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <nvs:IntangibleAssetImpairmentChargesTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3c77806b-7b9b-412b-b856-1b0e9633954b_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program UNR844.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program GTX312.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product (&lt;i&gt;Votrient&lt;/i&gt; carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:IntangibleAssetImpairmentChargesTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1299000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">768000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">141000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">600000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">200000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">500000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">200000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">900000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1300000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2703deaf-07cf-4cac-9481-e5995b6d3cd1_0">
          &lt;div&gt;
            &lt;div id="anchorId001538419"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;12. Deferred tax assets and liabilities &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Property, &lt;br/&gt; plant and&lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and&lt;br/&gt; other benefit &lt;br/&gt; obligations &lt;br/&gt; of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Tax loss&lt;br/&gt; carry-&lt;br/&gt; forwards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other assets,&lt;br/&gt; provisions&lt;br/&gt; and accruals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            628
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 726
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-343&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 785&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-420&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-138&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 998&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 502
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            507
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-430&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-340&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 552&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-323&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-317&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-46&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 070&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Recognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 880
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            885
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 610
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 140
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rcognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            166
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            418
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward  that expired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e81a5d25-3e37-4ffc-9bd4-bdb078067dc0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Property, &lt;br/&gt; plant and&lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and&lt;br/&gt; other benefit &lt;br/&gt; obligations &lt;br/&gt; of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Tax loss&lt;br/&gt; carry-&lt;br/&gt; forwards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other assets,&lt;br/&gt; provisions&lt;br/&gt; and accruals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            628
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 726
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-343&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 785&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-420&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-138&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 998&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 502
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            507
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-430&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-340&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 552&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-323&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-317&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-46&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 070&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:&lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">125000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1307000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1026000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2273000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">374000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2727000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7832000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">381000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4704000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">591000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">148000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1335000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7159000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">69000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">628000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-43000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">655000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">63000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-43000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-55000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">244000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">-10000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">6000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-11000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">185000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3059000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-319000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2076000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-425000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1477000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">158000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1726000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">739000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2214000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">425000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2789000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">8051000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">343000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4785000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">420000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1312000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6998000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">185000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3059000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-319000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2076000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-425000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1477000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4312000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3739000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2686000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1137000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2502000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">507000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2658000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">8344000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">430000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">5269000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">340000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">159000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1344000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">7552000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">241000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">241000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">567000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-22000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-215000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-121000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">309000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-35000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-35000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-323000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-317000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">30000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">125000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1307000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1026000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2273000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">374000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2727000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7832000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">381000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4704000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">591000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">148000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1335000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7159000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">4089000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188392_1"
      unitRef="USD">3743000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188393_1"
      unitRef="USD">3070000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear" decimals="-9" unitRef="USD">32000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
    <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear-1" decimals="-9" unitRef="USD">29000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_09329877-cda6-42a0-b711-973ac96c5ccb_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Recognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 880
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            885
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 610
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 140
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rcognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            166
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            418
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward  that expired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">42000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">25000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">79000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">688000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">767000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3880000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2380000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">6260000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">433000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">885000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember"
      decimals="-6"
      unitRef="USD">4610000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember"
      decimals="-6"
      unitRef="USD">3530000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8140000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">19000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">47000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">146000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">166000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3536000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">1872000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">5408000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">418000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">684000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">1102000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember"
      decimals="-6"
      unitRef="USD">4192000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember"
      decimals="-6"
      unitRef="USD">2607000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6799000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">18000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_665104ec-f67b-4b46-8de6-6a241467938d_0">
          &lt;div&gt;
            &lt;div id="anchorId001540678"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;13. Financial and other non-current assets&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Financial assets&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 663
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 063
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 036
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other non-current assets&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            419
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 210
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-emplyment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock>
    <nvs:DisclosureOfFinancialAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_b95f0e57-b8bc-4d04-a31d-39eebc99913d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 663
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 063
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 036
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfFinancialAssetsTableTextBlock>
    <nvs:NoncurrentFinancialAssetsEquityInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1145000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
    <nvs:NoncurrentFinancialAssetsEquityInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1663000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
    <nvs:NoncurrentFinancialAsstetsDebtSecurities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">37000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
    <nvs:NoncurrentFinancialAsstetsDebtSecurities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">34000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
    <nvs:NoncurrentFinancialAssetsFundInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">281000000</nvs:NoncurrentFinancialAssetsFundInvestments>
    <nvs:NoncurrentFinancialAssetsFundInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">366000000</nvs:NoncurrentFinancialAssetsFundInvestments>
    <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1463000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
    <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2063000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
    <nvs:LongTermReceivablesFromFinanceSubleases
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59000000</nvs:LongTermReceivablesFromFinanceSubleases>
    <nvs:LongTermReceivablesFromFinanceSubleases
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">70000000</nvs:LongTermReceivablesFromFinanceSubleases>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">184000000</ifrs-full:OtherNoncurrentReceivables>
    <nvs:ContingentConsiderationReceivable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">607000000</nvs:ContingentConsiderationReceivable>
    <nvs:ContingentConsiderationReceivable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">641000000</nvs:ContingentConsiderationReceivable>
    <ifrs-full:NoncurrentLoansAndReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">85000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentLoansAndReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2411000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3036000000</ifrs-full:NoncurrentFinancialAssets>
    <nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c83d7f4e-cf56-4191-9193-ee181dbd4c79_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            419
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 210
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-emplyment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock>
    <nvs:DeferredCompensationPlansAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">419000000</nvs:DeferredCompensationPlansAssets>
    <nvs:DeferredCompensationPlansAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">520000000</nvs:DeferredCompensationPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">491000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1415000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">200000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1110000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2210000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a3683b67-1363-497e-8f7d-71d582c64df8_0">
          &lt;div&gt;
            &lt;div id="anchorId001540931"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;14. Inventories&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            934
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 568
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the amount of inventory recognized as an expense in &#x201c;Cost of goods sold&#x201d; in the consolidated income statements: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-573&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-702&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInventoriesExplanatory>
    <nvs:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_601102b7-b545-437e-9f5e-0e7ae56bd172_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            934
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 568
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfInventoryCurrentTableTextBlock>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember"
      decimals="-6"
      unitRef="USD">934000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember"
      decimals="-6"
      unitRef="USD">870000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember"
      decimals="-6"
      unitRef="USD">3673000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember"
      decimals="-6"
      unitRef="USD">3160000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember"
      decimals="-6"
      unitRef="USD">2568000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember"
      decimals="-6"
      unitRef="USD">2636000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7175000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6666000000</ifrs-full:Inventories>
    <nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0d8eb127-9524-498c-830a-b4d0b07d9802_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">8600000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">8800000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e612d4bc-e1db-4660-ba72-20aaa26c3ff4_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-573&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-702&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">633000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">573000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">702000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">161000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">158000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">255000000</ifrs-full:ReversalOfInventoryWritedown>
    <nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8f0a4893-1d2b-4c5b-abcc-02519e4e75bd_0">
          &lt;div&gt;
            &lt;div id="anchorId001541112"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;15. Trade receivables&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movement in the provision for doubtful trade receivables:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-59&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 639
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month  but less than three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months  but less than six months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months  but less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Total trade receivables include amounts denominated in the following major currencies:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 709
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 426
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock>
    <nvs:ProvisionsForTradeReceivablesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_70cfb4f9-fe1b-4628-81f3-dadcf50985b9_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ProvisionsForTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8128000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8088000000</ifrs-full:CurrentTradeReceivables>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:TradeReceivablesProvisionMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1d53d226-b03e-4b31-893a-86656fc1f579_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-59&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TradeReceivablesProvisionMovementsTableTextBlock>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-93000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-95000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">59000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">56000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">34000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-93000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0253630b-3afc-4492-ac28-0d3fc1719906_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 639
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month  but less than three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months  but less than six months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months  but less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember"
      decimals="-6"
      unitRef="USD">7664000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember"
      decimals="-6"
      unitRef="USD">7639000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">190000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">110000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">99000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"
      decimals="-6"
      unitRef="USD">63000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">79000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">97000000</ifrs-full:CurrentTradeReceivables>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f44e0344-acab-4fa1-a0a3-6e3662a3b947_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 709
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 426
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">3709000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">3344000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1426000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1408000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB"
      decimals="-6"
      unitRef="USD">430000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">383000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP"
      decimals="-6"
      unitRef="USD">176000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP"
      decimals="-6"
      unitRef="USD">200000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY"
      decimals="-6"
      unitRef="USD">155000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD"
      decimals="-6"
      unitRef="USD">151000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">106000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1452000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1487000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7d5c18e3-dbbb-4ac9-aafb-ea0352908c2b_0">
          &lt;div&gt;
            &lt;div id="anchorId001541662"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;16. Marketable securities, commodities, time&#160;deposits, derivative financial instruments, and&#160;cash and cash equivalents&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities, time&#160;deposits and derivative financial instruments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock>
    <nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_043cffcb-c500-4bd0-9b14-17b2a337a058_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock>
    <nvs:Commodities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">111000000</nvs:Commodities>
    <nvs:Commodities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">111000000</nvs:Commodities>
    <ifrs-full:DebtInstrumentsHeld
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:DebtInstrumentsHeld>
    <ifrs-full:DebtInstrumentsHeld
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:DebtInstrumentsHeld>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11089000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12965000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11413000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15922000000</ifrs-full:OtherCurrentFinancialAssets>
    <nvs:CashAndCashEquivalentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6b22e8c8-9393-46e3-8ef3-47b152e8f071_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashAndCashEquivalentsTableTextBlock>
    <ifrs-full:Cash
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2877000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3396000000</ifrs-full:Cash>
    <ifrs-full:CashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4640000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">9011000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ef9a4b09-078e-410c-9ee5-3513a3bc5acf_0">
          &lt;div&gt;
            &lt;div id="anchorId001541818"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;17. Other current assets&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            509
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivable&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 440
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <nvs:OtherCurrentAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f7bc064c-68bc-450d-bffe-4ea81869acf0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            509
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivable&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 440
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OtherCurrentAssetsTableTextBlock>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">509000000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:CurrentValueAddedTaxReceivables>
    <nvs:WithholdingTaxRecoverable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">50000000</nvs:WithholdingTaxRecoverable>
    <nvs:WithholdingTaxRecoverable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">58000000</nvs:WithholdingTaxRecoverable>
    <nvs:CurrentPrepaidExpensesThirdParty
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">911000000</nvs:CurrentPrepaidExpensesThirdParty>
    <nvs:CurrentPrepaidExpensesThirdParty
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1102000000</nvs:CurrentPrepaidExpensesThirdParty>
    <nvs:ContingentConsiderationReceivableCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">43000000</nvs:ContingentConsiderationReceivableCurrent>
    <nvs:OtherReceivablesAndCurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">958000000</nvs:OtherReceivablesAndCurrentAssets>
    <nvs:OtherReceivablesAndCurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">793000000</nvs:OtherReceivablesAndCurrentAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2471000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2440000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <nvs:DisclosureOfEquityTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cb5c768b-fd3e-49fc-975f-ef2a0a1e59b4_0">
          &lt;div&gt;
            &lt;div id="anchorId001541932"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;18. Equity&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the share capital:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Jan 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Dec 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            890
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-92&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            856
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            853
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the shares:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Number of outstanding shares &lt;br/&gt;(in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 527.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-262.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 265.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital  reduction&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be  canceled&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options  and employee transactions&lt;sup style="white-space: nowrap"&gt; &#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-84.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            52.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 403.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-284.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 119.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;5&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3.00
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.95
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment  (in USD billion)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.2) The following table summarizes the treasury shares movements:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 787&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 775&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 897&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-123&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-145&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-127.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 910&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 920&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 056&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            88
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            854
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9 963&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD 2.8 billion as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is &lt;span&gt;no&lt;/span&gt; liability related to this plan recognized as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.9) At December 31, 2022, the market maker held 3 million (2021: 3 million; 2020: 1 million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD 66.07 (2021: USD 61.45; 2020: USD 60.09), and they have contractual lives of 10 years, with remaining lives less than one year (2021: two years; 2020: three years). &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfEquityTextBlock>
    <nvs:MovementInTheShareCapitalTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c1cc41fb-b80c-4512-bae5-76f11cb0b2a1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Jan 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Dec 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            890
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-92&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            856
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            853
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MovementInTheShareCapitalTableTextBlock>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-23000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">913000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-12000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-11000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:IssuedCapital>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">80000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">27000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">5000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-44000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:TreasuryShares>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">856000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">4000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">860000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-7000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">853000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-55000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">798000000</nvs:OutstandingShareCapital>
    <ifrs-full:ParValuePerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">0.50</ifrs-full:ParValuePerShare>
    <nvs:MovementInTheShareslTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3dd23758-dfdb-4a9c-aec4-c13a7dd29c48_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Number of outstanding shares &lt;br/&gt;(in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 527.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-262.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 265.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital  reduction&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be  canceled&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options  and employee transactions&lt;sup style="white-space: nowrap"&gt; &#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-84.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            52.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 403.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-284.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 119.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;5&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MovementInTheShareslTableTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2434400000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-199500000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-5"
      unitRef="Shares">2234900000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2467000000.0</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-210200000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-5"
      unitRef="Shares">2256800000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2527300000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-262300000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-5"
      unitRef="Shares">2265000000.0</ifrs-full:NumberOfSharesOutstanding>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">30700000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">32600000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-60300000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">60300000</nvs:SharesCancelledForCapitalReduction>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-84600000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-115300000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">10700000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-21900000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-60300000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">52100000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-8200000</nvs:ShareMovements>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2403700000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-284100000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd"
      decimals="-5"
      unitRef="Shares">2119600000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2434400000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-199500000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-5"
      unitRef="Shares">2234900000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2467000000.0</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-210200000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-5"
      unitRef="Shares">2256800000</ifrs-full:NumberOfSharesOutstanding>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">99000000.0</nvs:TreasurySharesWithRestrictedUse>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">102500000</nvs:TreasurySharesWithRestrictedUse>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">103000000.0</nvs:TreasurySharesWithRestrictedUse>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:DividendTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_33a1d528-3f63-4144-b763-23e72c53273d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3.00
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.95
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment  (in USD billion)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DividendTableTextBlock>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">3.10</nvs:DividendsPayableAmountPerShare>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="CHFPerShares">3.00</nvs:DividendsPayableAmountPerShare>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="2"
      unitRef="CHFPerShares">2.95</nvs:DividendsPayableAmountPerShare>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">7500000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">7400000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">7000000000.0</ifrs-full:DividendsPaid>
    <nvs:SummaryOfTreasurySharesMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a129fd4e-3fd5-48e7-abfe-b106e2a737e7_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 787&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 775&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 897&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-123&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-145&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-127.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 910&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 920&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 056&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            88
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            854
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9 963&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:SummaryOfTreasurySharesMovementsTableTextBlock>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10787000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2775000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2897000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">123000000</nvs:OtherSharePurchasesValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">145000000</nvs:OtherSharePurchasesValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">159000000</nvs:OtherSharePurchasesValue>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-127600000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-32200000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-34300000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-115300000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9963000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-21900000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-8200000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1490000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">15000000000.0</nvs:MaximalAmountOfShareBuybackProgramm>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2800000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">2500000000</nvs:MaximalAmountOfShareBuybackProgramm>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-8"
      unitRef="USD">1800000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:NumberOfOptionsRepurchased
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Pure">-3700000</nvs:NumberOfOptionsRepurchased>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="Pure">3000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="Pure">3000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="Pure">1000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="USDPerShares">66.07</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="USDPerShares">61.45</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="2"
      unitRef="USDPerShares">60.09</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsContractualLive
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Year">10</nvs:WrittenCallOptionsContractualLive>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Year">1</nvs:WrittenCallOptionsContractualLiveRemaining>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="0"
      unitRef="Year">2</nvs:WrittenCallOptionsContractualLiveRemaining>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="0"
      unitRef="Year">3</nvs:WrittenCallOptionsContractualLiveRemaining>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7d4803ee-8033-486a-a7d2-e2a51af6e473_0">
          &lt;div&gt;
            &lt;div id="anchorId001543827"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;19. Non-current financial debt&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 621&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Average interest rate 2.3% (2021: 0.9%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The percentage of fixed-rate financial debt to total financial debt was &lt;span&gt;86%&lt;/span&gt; at December 31, 2022, and &lt;span&gt;87%&lt;/span&gt; at December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The average interest rate on total financial debt in 2022 was &lt;span&gt;2.4%&lt;/span&gt; (2021: &lt;span&gt;1.9%&lt;/span&gt;).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table provides a breakdown of straight bonds:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Coupon&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Notional &lt;br/&gt; amount&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Issuance &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Maturity &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issuer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issue price&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.225%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 498
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2042
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.325%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 150
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.287%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2044
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.196%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 827
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.697%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.250%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.640%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            541
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            547
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            550
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.502%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.050%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2035
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.479%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            352
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            356
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.010%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 740
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2045
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.029%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.127%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 409
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.480%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            559
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.449%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.109%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            994
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            993
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.874%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.500%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.655%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.375%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.957%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.217%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            840
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.852%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.909%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.200%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.869%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 494
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2050
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              97.712%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.000%&lt;/span&gt;
                            &lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.354%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of &lt;span&gt;0.25%&lt;/span&gt; commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Breakdown by maturity:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 284
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 909
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by currency:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 862
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 079
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_98b4e328-6abd-47cd-b636-d62bc882699c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 621&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Average interest rate 2.3% (2021: 0.9%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <nvs:LiabilitiesToBanksAndOtherInstitutions
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">144000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
    <nvs:LiabilitiesToBanksAndOtherInstitutions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">227000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.023</nvs:AverageInterestRateOnLoansReceived>
    <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.009</nvs:AverageInterestRateOnLoansReceived>
    <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.86</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
    <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">0.87</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
    <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.024</nvs:AverageInterestRateOnBorrowings>
    <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.019</nvs:AverageInterestRateOnBorrowings>
    <nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4dbd830d-946d-452a-a54e-2e4af1ba97d4_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Coupon&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Notional &lt;br/&gt; amount&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Issuance &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Maturity &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issuer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issue price&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.225%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 498
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2042
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.325%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 150
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.287%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2044
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.196%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 827
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.697%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.250%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.640%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            541
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            547
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            550
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.502%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.050%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2035
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.479%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            352
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            356
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.010%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 740
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2045
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.029%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.127%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 409
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.480%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            559
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.449%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.109%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            994
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            993
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.874%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.500%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.655%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.375%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.957%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.217%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            840
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.852%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.909%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.200%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.869%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 494
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2050
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              97.712%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.000%&lt;/span&gt;
                            &lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.354%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of &lt;span&gt;0.25%&lt;/span&gt; commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="5"
      unitRef="Pure">0.02400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="-6"
      unitRef="USD">1500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2012</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2022</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="5"
      unitRef="Pure">0.99225</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="-6"
      unitRef="USD">1498000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="5"
      unitRef="Pure">0.03700</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2012</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2042</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="5"
      unitRef="Pure">0.98325</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="5"
      unitRef="Pure">0.03400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2150000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2024</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="5"
      unitRef="Pure">0.99287</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2147000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2144000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="5"
      unitRef="Pure">0.04400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2044</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="5"
      unitRef="Pure">0.99196</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1827000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1826000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="5"
      unitRef="Pure">0.01625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="EUR">600000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2026</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="5"
      unitRef="Pure">0.99697</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="USD">676000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="5"
      unitRef="Pure">0.00250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="CHF">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="5"
      unitRef="Pure">1.00640</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="USD">541000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="USD">547000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="5"
      unitRef="Pure">0.00625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="CHF">550000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2029</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="5"
      unitRef="Pure">1.00502</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="USD">595000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="USD">602000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="5"
      unitRef="Pure">0.01050</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="CHF">325000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2035</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="5"
      unitRef="Pure">1.00479</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="USD">352000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="USD">356000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="5"
      unitRef="Pure">0.03000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="5"
      unitRef="Pure">0.99010</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1742000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1740000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="5"
      unitRef="Pure">0.04000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2045</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="5"
      unitRef="Pure">0.98029</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1221000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1220000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="5"
      unitRef="Pure">0.00125</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="EUR">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2016</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2023</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="5"
      unitRef="Pure">0.99127</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="USD">1330000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="USD">1409000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="5"
      unitRef="Pure">0.00625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="EUR">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2016</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2028</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="5"
      unitRef="Pure">0.98480</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="USD">528000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="USD">559000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="5"
      unitRef="Pure">0.02400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2022</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="5"
      unitRef="Pure">0.99449</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="5"
      unitRef="Pure">0.03100</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="5"
      unitRef="Pure">0.99109</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">994000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">993000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="5"
      unitRef="Pure">0.01125</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="EUR">600000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="5"
      unitRef="Pure">0.99874</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="5"
      unitRef="Pure">0.00500</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2023</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="5"
      unitRef="Pure">0.99655</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="USD">798000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="USD">846000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="5"
      unitRef="Pure">0.01375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2030</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="5"
      unitRef="Pure">0.99957</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="USD">797000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="USD">846000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="5"
      unitRef="Pure">0.01700</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2038</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="5"
      unitRef="Pure">0.99217</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="USD">792000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="USD">840000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="5"
      unitRef="Pure">0.01750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="5"
      unitRef="Pure">0.99852</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">998000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">998000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="5"
      unitRef="Pure">0.02000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="5"
      unitRef="Pure">0.99909</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1246000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1246000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="5"
      unitRef="Pure">0.02200</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2030</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="5"
      unitRef="Pure">0.99869</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1494000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1493000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="5"
      unitRef="Pure">0.02750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2050</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="5"
      unitRef="Pure">0.97712</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1215000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1214000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="5"
      unitRef="Pure">0.000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="EUR">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2028</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="5"
      unitRef="Pure">0.99354</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="USD">1958000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="USD">2076000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="EUR">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsInterestRateStepUp
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="4"
      unitRef="Pure">0.25</nvs:BorrowingsInterestRateStepUp>
    <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d36f6143-68b2-43b6-8580-ad7407394d5a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 284
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 909
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">2342000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">2147000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">2144000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">3281000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">3284000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">693000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2909000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember"
      decimals="-6"
      unitRef="USD">2916000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember"
      decimals="-6"
      unitRef="USD">11523000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_31badf28-4ca2-4b24-a4ab-a18965eb3493_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 862
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">13376000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">15862000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">7478000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">7930000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">174000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">1488000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">1505000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">52000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c2ff21ff-7e97-40c8-a558-656deaaf8ee7_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 079
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">20277000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">27079000000</ifrs-full:BondsIssued>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">144000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">144000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">227000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">227000000</nvs:OtherNoncurrentFinancialDebt>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">20421000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">27306000000</ifrs-full:Borrowings>
    <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_10fb6813-d408-4b0f-84f7-ff193efb0677_0">
          &lt;div&gt;
            &lt;div id="anchorId001545529"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;20. Provisions and other non-current liabilities&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Defined benefit pension plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other long-term employee benefits and deferred compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other post-employment benefits&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            956
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            519
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 906
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Environmental remediation provisions&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movements in the environmental liability provisions:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            714
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-169&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-  105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            642
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br/&gt; cash outflows&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#x2019; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 28 contains additional information on contingent liabilities.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of significant legal proceedings&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Investigations and related litigations&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for &lt;i&gt;Gilenya&lt;/i&gt;, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#x2019;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Government generic pricing antitrust investigations, antitrust class actions&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#x2019; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD 195 million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD 185 million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  50 US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Lucentis/Avastin&#xae; matters&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin&lt;sup&gt;&#xae;&lt;/sup&gt; and &lt;i&gt;Lucentis&lt;/i&gt;, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#160;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD 452 million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Greece investigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD 1.2 million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD 225 million for moral damages allegedly arising from the conduct that was the subject of the Company&#x2019;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;340B Drug Pricing Program investigations&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#x2019;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#x2019;s determination and to enjoin HRSA from taking action with respect to NPC&#x2019;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#x2019;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#x2019;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#x2019;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#x2019;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Swiss and EU investigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect &lt;i&gt;Cosentyx&lt;/i&gt; from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Antitrust class actions&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Exforge&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of &lt;i&gt;Exforge&lt;/i&gt; in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD 245 million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Product liability litigation&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Reclast &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 20 US product liability actions involving &lt;i&gt;Reclast&lt;/i&gt; and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Taxotere&#xae; (docetaxel)&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz is a defendant in more than 3 100 US product liability actions involving Taxotere&#xae; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#xae; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Amiodarone&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz entities are named in two multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Sartans and ranitidine&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Tasigna&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 400 US product liability actions involving &lt;i&gt;Tasigna&lt;/i&gt;, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other matters&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Shareholder derivative lawsuit&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Concluded legal matters&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Average Wholesale Price (AWP) litigation &#x2013; Concluded matter &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Entresto matter&#x2013; Concluded matter&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;South Korea investigation &#x2013; Concluded matter&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Summary of product liability, governmental investigations and other legal matters provision movements&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-292&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 863&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            466
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            702
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-548&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_edc1f0e8-df59-41d2-b0ac-f92719dd2750_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Defined benefit pension plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other long-term employee benefits and deferred compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other post-employment benefits&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            956
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            519
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 906
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1723000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2640000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">554000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
    <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">662000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
    <nvs:OtherPostemploymentBenefits
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">362000000</nvs:OtherPostemploymentBenefits>
    <nvs:OtherPostemploymentBenefits
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">487000000</nvs:OtherPostemploymentBenefits>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">535000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">567000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">154000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">341000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ContingentConsiderationNonCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">704000000</nvs:ContingentConsiderationNonCurrent>
    <nvs:ContingentConsiderationNonCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">956000000</nvs:ContingentConsiderationNonCurrent>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">874000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">519000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4906000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6172000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_eb2ff43f-83a0-47a6-8e2e-d2a4d5047209_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            714
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-169&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-  105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            642
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">616000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">809000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">714000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-6000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-169000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-10000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">18000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">105000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">27000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">105000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">82000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-10000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-24000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">50000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">588000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">616000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">809000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">53000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">49000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">167000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">535000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">567000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">642000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d942b459-9e57-4477-87fa-7008d0abbe53_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br/&gt; cash outflows&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock>
    <nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">128000000</nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">163000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">46000000</nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">588000000</nvs:EnvironmentalProvision>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">195000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">185000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">50</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember"
      decimals="-6"
      unitRef="USD">125000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember"
      decimals="-6"
      unitRef="USD">330000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember"
      decimals="-5"
      unitRef="USD">1200000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember"
      decimals="-6"
      unitRef="USD">225000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember"
      decimals="-6"
      unitRef="USD">245000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember"
      decimals="0"
      unitRef="Pure">20</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3100</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">2</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember"
      decimals="0"
      unitRef="Pure">400</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1d1f3f5a-6847-4829-8086-faabb6032fc4_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-292&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 863&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            466
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            702
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-548&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">397000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">1369000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">4000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-105000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-292000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1863000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">52000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">44000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">31000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">466000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">251000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1018000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-8000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-17000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">702000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">397000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">548000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">56000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">306000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">154000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">341000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">181000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8d7eada3-af1d-43b7-9382-beabf1c29fae_0">
          &lt;div&gt;
            &lt;div id="anchorId001546397"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;21. Current financial debt and&#160;derivative&#160;financial&#160;instruments&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees  payable on demand&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 9.7% (2021: 6.1%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD 0.9 billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Details on commercial papers and short-term borrowings are provided under &#x201c;Liquidity risk&#x201d; in Note&#160;29. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock>
    <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8f57c294-b1a6-49ed-a39b-e93fd16423ca_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees  payable on demand&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 9.7% (2021: 6.1%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock>
    <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1814000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
    <ifrs-full:ShorttermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">863000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CommercialPapersIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2772000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">893000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear" decimals="4" unitRef="Pure">0.0025</nvs:WeightedAverageInterestRateAssociates>
    <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear-1" decimals="4" unitRef="Pure">0.0025</nvs:WeightedAverageInterestRateAssociates>
    <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.097</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
    <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.061</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
    <nvs:PaymentOfInterestBearingAccountsToBeneficiaries contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">900000000</nvs:PaymentOfInterestBearingAccountsToBeneficiaries>
    <nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_18e53185-a2be-4e8d-af99-cf347f756c4e_0">
          &lt;div&gt;
            &lt;div id="anchorId001546573"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;22. Provisions and other current liabilities&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            619
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            752
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for deductions from revenue&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement of the provisions for deductions from revenue:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of currency translation, business combinations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-218&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            234
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments/utilizations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-22 261&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 838&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 294&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustments of prior years charged to income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-151&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current year income statement charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions offset against gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring provisions movements&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-468&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-268&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, additions to provisions of USD&#160;1.4 billion were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp;amp; Technology Solutions) 2021 restructuring initiatives.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, additions to provisions of USD 328 million were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp;amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, additions to provisions of USD&#160;354 million were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp;amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock>
    <nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_85f45d9a-f982-42e7-a2b9-465e25ce5436_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            619
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            752
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock>
    <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">836000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">619000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <ifrs-full:ShorttermRestructuringProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1131000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1059000000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1089000000</ifrs-full:AccrualsClassifiedAsCurrent>
    <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">767000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
    <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">752000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
    <ifrs-full:CurrentInterestPayable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">116000000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentInterestPayable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6732000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2321000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2260000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">53000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">49000000</nvs:EnvironmentalProvisionCurrent>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">123000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">123000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">548000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">56000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">253000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <nvs:ContingentConsiderationCurrentPortion
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">131000000</nvs:ContingentConsiderationCurrentPortion>
    <nvs:ContingentConsiderationCurrentPortion
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">119000000</nvs:ContingentConsiderationCurrentPortion>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <ifrs-full:OtherCurrentPayables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">743000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">588000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">14795000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15670000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <nvs:ProvisionsForReductionOfRevenueTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_33e204c4-9044-41ef-ba80-2972435303ae_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of currency translation, business combinations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-218&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            234
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments/utilizations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-22 261&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 838&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 294&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustments of prior years charged to income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-151&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current year income statement charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions offset against gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:ProvisionsForReductionOfRevenueTableTextBlock>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">6256000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">5595000000</ifrs-full:CurrentRefundsProvision>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-210000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-218000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">234000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">22261000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">19838000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">19294000000</ifrs-full:ProvisionUsedOtherProvisions>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-322000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-245000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-151000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">23072000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">20413000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">19773000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">28000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-113000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-99000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6732000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">6256000000</ifrs-full:CurrentRefundsProvision>
    <nvs:RestructuringProvisionsMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5725d866-58ab-4cfd-808f-079ee014425c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-468&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-268&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:RestructuringProvisionsMovementsTableTextBlock>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">459000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">438000000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1368000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">468000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">344000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">268000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">42000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">54000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-19000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1131000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">459000000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-8"
      unitRef="USD">1400000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8cb58fb1-c1f5-4020-a017-f0f0050ec5a2_0">
          &lt;div&gt;
            &lt;div id="anchorId001547223"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;
              &lt;b&gt;23. Details to the consolidated statements of cash flows&lt;/b&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.1) Non-cash items and other adjustments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;cash flows.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 489
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 758
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            303
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial assets&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-333&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-677&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-478&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            823
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Loss/(income) from associated companies&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 339&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-673&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 807
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            891
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 546
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value changes&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.2) Total amount of income taxes paid &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, the total amount of income taxes paid was USD&#160;2.0 billion (2021: USD&#160;2.3 billion), which was included within &#x201c;Net cash flows from operating activities.&#x201d;&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, the total amount of income taxes paid was USD&#160;1.9 billion, of which USD&#160;1.8 billion was included within &#x201c;Net cash flows from operating activities,&#x201d; and USD&#160;88 million was included within &#x201c;Net cash flows used in investing activities from discontinued operations.&#x201d;&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            81
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-589&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-389&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease in trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current and non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-202&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-291&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, acquisitions and divestments of interests in associated companies, net included USD 20.7 billion proceeds from the divestment of the Group&#x2019;s investment in Roche (see Notes 2 and 4).&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.5) Cash flows arising from acquisitions and divestments of businesses, net&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-735&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 173&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-864&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 006&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows (used for)/from divestments of businesses, net&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            66
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-879&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-567&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-9 957&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.6) Reconciliation of liabilities arising from financing activities&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 575&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-366&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-401&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 325&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-224&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            224
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 524&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-774&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-309&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 624
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-247&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 067&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-250&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, net cash flows used in investing activities from discontinued operations of USD 127 million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, net cash flows used in financing activities from discontinued operations of USD 50 million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7e5013d4-0013-4da1-b19e-3f6fdc37e67d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 489
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 758
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            303
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial assets&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-333&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-677&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-478&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            823
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Loss/(income) from associated companies&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 339&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-673&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 807
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            891
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 546
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value changes&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1570000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1489000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1758000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">303000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">5308000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4306000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4376000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">260000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">-38000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">-335000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1403000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">896000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1411000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-333000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-677000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-478000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">823000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">736000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">738000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-817000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-891000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-947000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-30000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">11546000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5299000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">247000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">321000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">346000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">2000000000.0</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">2300000000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">1900000000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">1800000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember"
      decimals="-6"
      unitRef="USD">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
    <nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4702071f-730d-44e2-93b3-a9ee612f741e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            81
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-589&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-389&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease in trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current and non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-202&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-291&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-830000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">81000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-543000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-589000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-389000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">137000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-48000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-21000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-324000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-194000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-202000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">229000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">658000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">772000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">211000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">0</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-1003000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">241000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_213b3d94-fc64-4a39-87d0-f4ab309d7da3_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-735&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 173&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-864&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 006&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows (used for)/from divestments of businesses, net&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            66
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-879&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-567&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-9 957&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">1077000000</nvs:CashFlowFromNetIdentifiableAssets>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">735000000</nvs:CashFlowFromNetIdentifiableAssets>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">10173000000</nvs:CashFlowFromNetIdentifiableAssets>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">21000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">42000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">59000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">98000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-13000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">62000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-864000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-633000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-10006000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-15000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">66000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-879000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-567000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-15000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:ConsiderationPaidReceived>
    <nvs:NetIdentifiableAssetsOfDivestedBusiness
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">173000000</nvs:NetIdentifiableAssetsOfDivestedBusiness>
    <nvs:NoncurrentAssetsDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">132000000</nvs:NoncurrentAssetsDivested>
    <nvs:CurrentAssetsDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">113000000</nvs:CurrentAssetsDivested>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">71000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <nvs:NoncurrentAndCurrentLiabilitiesDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">72000000</nvs:NoncurrentAndCurrentLiabilitiesDivested>
    <nvs:DeferredSalePriceAndOtherAdjustments
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:DeferredSalePriceAndOtherAdjustments>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">66000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-52000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-14000000</ifrs-full:ConsiderationPaidReceived>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f3ae1956-2298-4cc3-bd00-674cab660988_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 575&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-366&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-401&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 325&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-224&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            224
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 524&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-774&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-309&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 624
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-247&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 067&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-250&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">22902000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">6295000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1621000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">275000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2575000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">295000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-51000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">173000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-60000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-17000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-366000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-401000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-41000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-14000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2325000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2325000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-224000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">224000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">20244000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">5931000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1538000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">251000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">1700000000</nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2162000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-3524000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-52000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">61000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-25000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-774000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-309000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-43000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-13000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2624000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2624000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-247000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">247000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">22902000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">6295000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1621000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">275000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">20353000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">7031000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1703000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">246000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-56000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">221000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">73000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">36000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-16000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">832000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">392000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0b997621-1ac7-41d6-bc5b-5e52935c7c47_0">
          &lt;div&gt;
            &lt;div id="anchorId001549327"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;24. Acquisitions of businesses&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Fair value of assets and liabilities arising from acquisitions of businesses:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 977&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-144&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            612
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 669
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-89&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 580
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 077
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            735
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, no goodwill (2021: USD 107 million; 2020: USD 74 million) is tax deductible. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cb7fa6de-176a-49f2-b17b-f8479c6f7440_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 977&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-144&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            612
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 669
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-89&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 580
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 077
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            735
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <nvs:RightOfUseAssetsAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">12000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
    <nvs:RightOfUseAssetsAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">32000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
    <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">292000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">196000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1209000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">262000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">8600000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">98000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">218000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">56000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">476000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <nvs:FinancialAndOtherAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">49000000</nvs:FinancialAndOtherAssets>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">84000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">109000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">89000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">1977000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
    <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">12000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
    <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">44000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">67000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">4000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">144000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1005000000</nvs:IdentifiableAssetsAcquired>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">612000000</nvs:IdentifiableAssetsAcquired>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">7669000000</nvs:IdentifiableAssetsAcquired>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">89000000</nvs:AcquiredCashAndCashEquivalents>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">10000000</nvs:AcquiredCashAndCashEquivalents>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">76000000</nvs:AcquiredCashAndCashEquivalents>
    <ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">161000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">2580000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1077000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">735000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">10173000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">0</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_11f4dfff-454a-4f62-83fa-de9771932dbd_0">
          &lt;div&gt;
            &lt;div id="anchorId001549711"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;25. Post-employment benefits for employees&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit plans&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent &lt;span&gt;95%&lt;/span&gt; of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent &lt;span&gt;83%&lt;/span&gt; of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#x2013; for the principal plans &#x2013; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million) recognized in 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.&lt;/div&gt;
                &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            632
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            348
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement gains arising from changes in financial assumptions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-713&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-377&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-650&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-865&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 500&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 644&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reconciliation of the net liability from January 1 to December 31 is as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 336&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-348&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-415&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 723&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 640&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 824
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 746
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 963
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            363
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            1 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            620
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            830
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 691
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 208
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 681
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 701
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 978
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 436
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 551
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-697&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 237&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            346
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            464
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-286&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-400&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine  benefit obligations at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.6%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              3.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.4%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.2%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.1%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old male in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old female in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#x2019;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#x2019;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2022 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change in 2021 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-466&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-790&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            839
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            869
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-136&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate assumed for next year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches the ultimate trend rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#160;2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(as a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; minimum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; maximum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The weighted average duration of the defined benefit pension obligation is 11.8 years (2021: 14.9 years).&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-&lt;br/&gt; employment&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023 (estimated)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2028&#x2013;2032&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s total personnel costs amounted to USD 14.9 billion in 2022.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <nvs:ConcentrationOfMajorPlansGeographic
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0f607534-21f9-45b8-bd8e-dc6e61a5db38_0">

                  In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 83% of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.

              </nvs:ConcentrationOfMajorPlansGeographic>
    <nvs:MajorPlansPercentageInGroupDBOPensions
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.95</nvs:MajorPlansPercentageInGroupDBOPensions>
    <nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.83</nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans>
    <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">101000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="CHF">90000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <nvs:DisclosureOfDefinedBenefitPlansTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_62a89c36-0428-4294-84e6-05e678bd11c1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            632
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            348
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement gains arising from changes in financial assumptions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-713&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-377&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-650&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-865&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 500&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 644&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDefinedBenefitPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">25602000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">632000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">348000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">249000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">151000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-40000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">63000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
    <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">5046000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">713000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">94000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">377000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-199000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-531000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-650000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-865000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1253000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1450000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">174000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
    <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">179000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">17533000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">422000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22317000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">89000000</ifrs-full:PlanAssetsAtFairValue>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-220000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-105000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2500000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1512000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">539000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">726000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">424000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">174000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">179000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <nvs:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
    <nvs:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1253000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1450000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">18945000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1163000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-362000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-487000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-51000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2504000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-16000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">76000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-6000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus>
    <nvs:InterestIncomeOnLimitationOfFundSurplus
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
    <nvs:InterestIncomeOnLimitationOfFundSurplus
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2644000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1232000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2587000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_258459ca-cea0-4f0b-8bc3-b62cbce0845c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 336&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-348&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-415&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 723&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 640&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3336000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">543000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">348000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">31000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-24000000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-39000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2400000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2071000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">110000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-35000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-145000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">424000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2504000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-16000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1232000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">491000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1415000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1723000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2640000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      id="SectionBlock_eb302481-bb4e-437d-a53d-9f2e33149f5e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 824
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 746
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 963
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            363
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            1 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            620
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            830
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 691
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 208
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 681
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 701
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 978
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 436
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 551
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-697&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 237&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">11824000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2746000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2963000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">17533000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">15268000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3645000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">4670000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">556000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">363000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">919000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">688000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">439000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1127000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">4799000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">431000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">931000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">6161000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">6478000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">620000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">8510000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">830000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">861000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1691000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1730000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2938000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">7025000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1485000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1171000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">9681000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">8790000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1817000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1528000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">12135000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">14701000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1978000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2266000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">18945000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">16436000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2551000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3433000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2877000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-768000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-697000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1094000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1237000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1163000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      id="SectionBlock_b240e56d-e896-4921-85d9-9dd40ab35870_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            346
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            464
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-286&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-400&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">346000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">422000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">286000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">83000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">308000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">464000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-286000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-76000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-362000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-400000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-87000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-487000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_152fce46-9c49-4905-bd9d-7b2341a406c8_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine  benefit obligations at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.6%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              3.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.4%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.2%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.1%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old male in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old female in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAssumptionsUsedTableTextBlock>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.030</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.009</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.006</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.063</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.033</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.029</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.004</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.005</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.029</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.022</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.005</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.001</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_da31e53a-02a9-4e2f-9a94-9d2a0c740463_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2022 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change in 2021 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-466&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-790&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            839
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            869
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-136&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-466000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-790000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">491000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">839000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember"
      decimals="-6"
      unitRef="USD">535000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember"
      decimals="-6"
      unitRef="USD">869000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">316000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">512000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-63000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-136000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">38000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-58000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">54000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-54000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_82907174-5821-4004-a4cf-e7aa402f7099_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate assumed for next year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches the ultimate trend rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.065</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.060</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.063</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2031</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9daf4502-4011-439c-8fc0-d79eb1e47c08_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(as a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; minimum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; maximum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.27</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.60</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.33</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.30</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.19</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">1</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">1</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1b9aa832-6fbc-4638-a2f3-32fc72949372_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock>
    <nvs:EmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-5"
      unitRef="Shares">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
    <nvs:EmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-5"
      unitRef="Shares">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
    <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-8"
      unitRef="USD">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
    <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-8"
      unitRef="USD">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
    <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P11Y9M18D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
    <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P14Y10M24D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
    <nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_b8cdde5f-7b1d-4b6d-b1ca-3ed4a25a400c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-&lt;br/&gt; employment&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023 (estimated)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2028&#x2013;2032&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">397000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1268000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1441000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1128000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1114000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1099000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">5310000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:ScheduleOfDefinedContributionPlansTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1a0aace6-22b9-4d63-a82a-64101e94a30b_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s total personnel costs amounted to USD 14.9 billion in 2022.&lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">520000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">523000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">501000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:EmployeeBenefitsExpense contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">14900000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4b130f8c-84e4-4ac8-a316-4c502be2539d_0">
          &lt;div&gt;
            &lt;div id="anchorId001552874"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;26. Equity-based participation plans for employees&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based  participation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 048
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            979
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based  payment transactions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity-based participation plans can be separated into the following plans:&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Annual Incentive&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Employee share savings plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Employee share purchase plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis equity plan &#x201c;Select&#x201d;&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201c;Select.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The equity plan &#x201c;Select&#x201d; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tradable share options expire on their 10&lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10&lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &#x201c;Select&#x201d; outside North America&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#160;86.1. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &#x201c;Select&#x201d; for North America&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the ADR options during the period:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#160;89.1. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Performance Plan&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. &lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Relative Performance Plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other share awards&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201c;buyouts&#x201d; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of share grants&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Annual Incentive&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            87.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Share savings plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Employee Share Purchase Plan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select North America (RSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select outside North America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-Term Performance Plan (PSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            89.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other share awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_58d0bbc7-1ca2-45a7-bfb7-0454d782f610_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based  participation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 048
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            979
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based  payment transactions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1048000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">253000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">269000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember"
      id="SectionBlock_fac23996-f2b4-4994-a0b7-766de49f79a6_0">

                  The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember"
      id="SectionBlock_fbf10437-518a-4d8d-8d8f-26f94cd51aae_0">


                    Employee share savings plan

                  Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.
                  The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      id="SectionBlock_2def460a-2dba-4607-82b6-0f397de211ce_0">


                    Novartis Employee share purchase plan

                  In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember"
      id="SectionBlock_1110b63f-1350-4cf3-879b-9a9dcd6c52df_0">

                  The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201c;Select.&#x201d;
                  The equity plan &#x201c;Select&#x201d; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
                  Tradable share options expire on their 10th anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      id="SectionBlock_943531d9-b95f-4ab4-812a-0d30a0151300_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2600000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1200000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">58.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">86.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      id="SectionBlock_ef8ef9d5-e3df-4ccc-a2a1-5058bed22c9a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">6700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2700000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">60.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">89.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember"
      id="SectionBlock_92a38d22-1d8a-4995-8ced-6fc414f27854_0">

                  The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.
                  Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.
                  The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods.
                  TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.

                    Long-Term Relative Performance Plan

                  The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember"
      id="SectionBlock_e5b59076-384e-41f9-a61b-6c8616c22c7b_0">

                  Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201c;buyouts&#x201d; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.
                  Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.
                  In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.



              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_33584103-7f55-41fa-a432-12fb2653f1d1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Annual Incentive&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            87.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Share savings plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Employee Share Purchase Plan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select North America (RSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select outside North America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-Term Performance Plan (PSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            89.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other share awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="Pure">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="USDPerShares">74700000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="Pure">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="USDPerShares">87500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="Pure">400000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="USDPerShares">75000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="Pure">400000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="Pure">1200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      decimals="-5"
      unitRef="Pure">800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      decimals="-5"
      unitRef="USDPerShares">82800000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">4900000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">74500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">4300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">2000000.0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">75100000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">1800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">700000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="USDPerShares">82000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="Pure">1800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="USDPerShares">89500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="USDPerShares">76300000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="Pure">600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="USDPerShares">78400000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="USDPerShares">86100000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="USDPerShares">91900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_03359118-a0ec-4c9d-9b54-a9d5e127488e_0">
          &lt;div/&gt;

          &lt;div&gt;
            &lt;div id="anchorId001553971"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;27. Transactions with related parties&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its &lt;span&gt;33.3%&lt;/span&gt; of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Lucentis&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has licensed from Genentech/Roche the exclusive rights to develop and market &lt;i&gt;Lucentis&lt;/i&gt; outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of &lt;i&gt;Lucentis&lt;/i&gt; products outside the United States. From January 1, 2021 until December 6, 2021, &lt;i&gt;Lucentis&lt;/i&gt; sales of USD&#160;2.0 billion (2020: USD&#160;1.9 billion) were recognized by Novartis.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Xolair&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and Genentech/Roche are co-promoting &lt;i&gt;Xolair&lt;/i&gt; in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis markets &lt;i&gt;Xolair&lt;/i&gt; and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of &lt;i&gt;Xolair&lt;/i&gt; of USD&#160;1.3 billion (2020: USD&#160;1.3 billion), including sales to Genentech/Roche for the United States market.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Luxturna&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for &lt;i&gt;Luxturna&lt;/i&gt; outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The net income for royalties, cost sharing and profit sharing arising out of the &lt;i&gt;Lucentis&lt;/i&gt;, &lt;i&gt;Xolair&lt;/i&gt; and &lt;i&gt;Luxturna&lt;/i&gt; agreements with Roche totaled USD&#160;188 million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#160;217 million).&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Pension Fund&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Executive Officers and Non-Executive Directors compensation&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2022, there were 11 Executive Committee members (&#x201c;Executive Officers&#x201d;). During 2022, 5 Executive Officers stepped down. At December 31, 2021, there were 12 Executive Officers. During 2021, 3 Executive Officers stepped down. At December 31, 2020, there were 13 Executive Officers. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The total compensation for Executive Committee members and the 15 Non-Executive Directors (14 in 2021 and 14 in 2020) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            47.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            70.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            60.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            69.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            79.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            70.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Transactions with former members of the Board of Directors&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#x201c;persons closely&#x201d; linked to them:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <nvs:NumberOfContractsWithRelatedParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfContractsWithRelatedParties>
    <nvs:NumberOfContractsWithRelatedParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member"
      decimals="0"
      unitRef="Pure">1</nvs:NumberOfContractsWithRelatedParties>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">2000000000.0</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-6"
      unitRef="USD">188000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
    <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-6"
      unitRef="USD">217000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
    <nvs:BorrowingsCreditFacilityUncommitted
      contextRef="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember"
      decimals="-6"
      unitRef="USD">500000000</nvs:BorrowingsCreditFacilityUncommitted>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">11</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">5</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">12</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">3</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">13</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">15</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:OfficerAndDirectorCompensationTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f8ce85dd-5c43-4b83-871d-5af5fbcaae66_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            47.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            70.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            60.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            69.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            79.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            70.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OfficerAndDirectorCompensationTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">25000000.0</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">20300000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">25600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">29600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">25000000.0</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">30200000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2800000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">2800000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">42600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">37300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">41100000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4800000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">47400000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">42500000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">46300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">70400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">60100000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">69400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9900000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9800000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">79800000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">70000000.0</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">79200000</ifrs-full:KeyManagementPersonnelCompensation>
    <nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e5dd701d-4d9d-4379-ad23-80acfcde8ac2_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember"
      decimals="0"
      unitRef="CHF">60000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember"
      decimals="0"
      unitRef="CHF">60000</ifrs-full:KeyManagementPersonnelCompensation>
    <nvs:DisclosureOfCommitmentsAndContingenciesTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4a435624-4502-46ac-8c7c-008392cb28af_0">
          &lt;div&gt;
            &lt;div id="anchorId001554416"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;28. Commitments and contingent liabilities&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development commitments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2022, the amount and estimated timing of the Group&#x2019;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            282
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 169
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Commitments for capital calls&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD 83 million. Note 29 contains further information on the Group&#x2019;s investments in funds.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other commitments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Guarantees issued&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. &lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent liabilities&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Group companies have to observe the laws, government orders and regulations of the country in which they operate.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;claims that could have a material adverse effect on its results of operations or cash flow.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on these matters.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on environmental liabilities.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfCommitmentsAndContingenciesTextBlock>
    <nvs:DisclosureOfLeasingCommitmentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6b5c1239-9656-406c-88fe-ce7b4fc5a4ca_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            282
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 169
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfLeasingCommitmentsTableTextBlock>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">420000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">808000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">448000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">282000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3169000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5814000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:UncalledCapitalCommitmentsForInvestmentsInFunds
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">83000000</nvs:UncalledCapitalCommitmentsForInvestmentsInFunds>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8bc0277f-426a-4dac-a8e1-5c7ef72c875f_0">
          &lt;div&gt;
            &lt;div id="anchorId001554566"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;29. Financial instruments&#160;&#x2013;&#160;additional disclosures&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13/17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 971
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 581
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees payable on demand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 553
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 094
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#160;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#160;2022 and 2021. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying  principal amount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in  marketable securities and in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#160;31,&#160;2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments effective for hedge accounting purposes&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Fair value by hierarchy&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 070
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial liabilities at fair values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-186&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 697
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabiltiies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-114&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-231&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            625
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-189&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-88&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 316 million and USD 55 million, respectively.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the most significant parameters for the Level&#160;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#160;154 million and USD&#160;140 million, respectively.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Equity securities measured at fair value through other comprehensive income&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds 65 non-listed equity securities (December 31, 2021: 60) and 46 listed equity securities (December 31, 2021: 40) in this category with the following fair values:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            888
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            390
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#160;22 million were sold (2021: USD 9 million), and the USD&#160;7 million gain on disposal (2021: USD 1 million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#160;3 million (2021: USD&#160;254 million), were sold, and the USD&#160;3 million loss on disposal (2021: USD&#160;211 million gain) was transferred from other comprehensive income to retained earnings (see Note 8).&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Nature and extent of risks arising from financial instruments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Market risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#x201c;Financial reporting in Hyperinflationary Economies.&#x201d; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#160;1.8 billion (USD&#160;2.0 billion; December 31, 2021: USD 2.1 billion), has been designated as a hedge instrument. During 2022, USD&#160;91 million of net of taxes unrealized income (2021: USD 216 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Commodity price risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than &lt;span&gt;10%&lt;/span&gt; of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than &lt;span&gt;5%&lt;/span&gt; of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Credit risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;receivables over the entire holding period of the trade receivables.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s largest customer accounted for approximately &lt;span&gt;16%&lt;/span&gt; of net sales to third parties, and the second largest and third largest customers accounted for &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt; of net sales to third parties, respectively (2021: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively; 2020: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;14%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively, of the Group&#x2019;s trade receivables at December 31, 2022 (2021: &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;12%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively). There is no other significant concentration of customer credit risk.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Counterparty risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately &lt;span&gt;13.2%&lt;/span&gt;, &lt;span&gt;9.2%&lt;/span&gt; and &lt;span&gt;6.8%&lt;/span&gt;, respectively (2021: &lt;span&gt;9.7%&lt;/span&gt;, &lt;span&gt;9.7%&lt;/span&gt; and &lt;span&gt;7.6%&lt;/span&gt;, respectively). As of December 31, 2021, the Group&#x2019;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately &lt;span&gt;16%&lt;/span&gt; (2022: nil).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Liquidity risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has two US commercial paper programs under which it can issue up to USD&#160;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has one Japanese commercial paper program under which it can issue up to JPY&#160;150 billion (approximately USD&#160;1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#160;2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD&#160;0.9 billion). Novartis further has a committed credit facility of USD&#160;6.0 billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 098
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 506
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 564
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-9 002&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-11 394&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-20 396&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 515&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 876&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-2 517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-5 878&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 519&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 931&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 405
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 585
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 706
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 406
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 001
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 095
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-8 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-14 587&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-23 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 926&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 227&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-6 229&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-50&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-537&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-6 295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 608
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 833&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 460&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 296&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-868&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 598&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 943&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 062
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-843&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 482&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-461&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            847
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            457
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 820
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 532&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-616&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-922&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 789&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 020&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-115&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-267&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-82&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-445&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 628&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 908&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-639&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 896&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 373&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 553&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-439&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Capital risk management&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. &lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Sensitivity analysis&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The sensitivity analysis disclosures are in line with the Group&#x2019;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures below illustrate the potential impact on the Group&#x2019;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#x2019;s view of changes that are reasonably possible over a one-year period. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical &lt;span&gt;5%&lt;/span&gt; increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#x2019;s consolidated income statement as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As of December 31, 2022, the Group designated EUR 1.8 billion (December 31, 2021: EUR 1.8 billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical &lt;span&gt;5%&lt;/span&gt; increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#x2019;s consolidated equity as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity price sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of these fund investments and equity securities was USD 1.6 billion as of December 31, 2022 (December 31, 2021: USD 2.2 billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of &lt;span&gt;15%&lt;/span&gt; in the risk factors would have impacted the Group&#x2019;s consolidated income statement as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-154&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;A hypothetical increase or decrease of &lt;span&gt;15%&lt;/span&gt; in the risk factors would have impacted the Group&#x2019;s consolidated equity as presented below:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-179&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_83455b65-ee84-4322-bc8c-0ee8ab565917_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13/17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 971
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 581
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees payable on demand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 553
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 094
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember"
      decimals="-6"
      unitRef="USD">11089000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">828000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">317000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember"
      decimals="-6"
      unitRef="USD">341000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">650000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">27971000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">874000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">1581000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">863000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">2772000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">144000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1067000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">31266000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1122000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">10397000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember"
      decimals="-6"
      unitRef="USD">12965000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember"
      decimals="-6"
      unitRef="USD">793000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">1195000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">468000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">34000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember"
      decimals="-6"
      unitRef="USD">332000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">32492000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">5980000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">1772000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">1814000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">893000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">227000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember"
      decimals="-6"
      unitRef="USD">2809000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1094000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">37491000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1162000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_bbe7a3f1-bd36-4956-9339-9215d10601c4_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying  principal amount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in  marketable securities and in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">7907000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13248000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">92000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-41000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-35000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">97000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-33000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">8043000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13347000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">204000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-55000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-68000000</nvs:DerivativeFinancialInstruments>
    <nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d1ab7852-8b86-4823-b778-bfeb636da15c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">687000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5659000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">7907000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">80000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">97000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">767000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5715000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">8043000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1485000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5158000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">6605000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13248000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1485000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5257000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">6605000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13347000000</nvs:DerivativeFinancialInstruments>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_62f6dc80-01e8-4ae5-89bf-0e67786794f1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 070
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial liabilities at fair values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-186&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 697
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">213000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">213000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">699000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">261000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">607000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">607000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">493000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1567000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">2070000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">186000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">704000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">704000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">232000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">232000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2719000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">22000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2719000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2846000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">617000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1697000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">338000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1108000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1596000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">2704000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">1075000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">1075000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">19000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">19000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1094000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1162000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9da19097-084d-48ba-affd-00fc749eb4f2_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabiltiies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-114&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-231&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            625
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-189&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-88&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">338000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">617000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1075000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">35000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">530000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">63000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">78000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">84000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">114000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">24000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">160000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-231000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-238000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">28000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-40000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">261000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">699000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">650000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-835000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-232000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-63000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-74000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-49000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">416000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">211000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">366000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">460000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">625000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1046000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">70000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">69000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">182000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">8000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">51000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-22000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">22000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">137000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-88000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-42000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">27000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">71000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-30000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-44000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">338000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">617000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1075000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-24000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">62000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">56000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">80000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-7000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ac7a5ed5-584b-4bc8-9e40-4ec9fdf6e40c_0">

                  During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).

              </ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">44000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">73000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">29000000</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">316000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
    <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">55000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
    <nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">154000000</nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10>
    <nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-140000000</nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">65</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">60</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">46</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">40</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a230cb1a-e9ec-4f38-854e-af27c697c178_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            888
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            390
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">438000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">888000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">390000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">307000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">828000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1195000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <nvs:FairValueOfOtherFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">22000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:FairValueOfOtherFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">254000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">211000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">2000000000.0</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2100000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">91000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
    <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">216000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
    <nvs:MaximumMarginPercentageImpactOfCommodityPriceChange contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.10</nvs:MaximumMarginPercentageImpactOfCommodityPriceChange>
    <nvs:MaximumHoldingInUnrelatedCompany contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:MaximumHoldingInUnrelatedCompany>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.132</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.092</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.068</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.076</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:PercentageOfGovernmentBackedDebtSecurities contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">0.16</nvs:PercentageOfGovernmentBackedDebtSecurities>
    <nvs:PercentageOfGovernmentBackedDebtSecurities contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0</nvs:PercentageOfGovernmentBackedDebtSecurities>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember"
      decimals="0"
      unitRef="Pure">2</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember"
      decimals="-9"
      unitRef="USD">9000000000.0</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="0"
      unitRef="Pure">1</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="-9"
      unitRef="JPY">150000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="-8"
      unitRef="USD">1100000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">2800000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Pure">3</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">900000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCreditFacilityCommitted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="USD">6000000000.0</nvs:BorrowingsCreditFacilityCommitted>
    <nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6ede1c8c-2045-424c-9224-55af834fb9ee_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 098
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 506
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 564
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-9 002&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-11 394&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-20 396&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 515&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 876&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-2 517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-5 878&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 519&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 931&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 405
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 585
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 706
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 406
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 001
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 095
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-8 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-14 587&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-23 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 926&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 227&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-6 229&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-50&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-537&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-6 295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 608
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 833&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 460&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 296&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-868&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">4142000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">6911000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">36000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">11098000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">147000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">19000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">204000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">4011000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">3506000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7517000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">8176000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">10564000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">55000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">135000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">9002000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">11394000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">20396000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">3215000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">146000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2515000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">5876000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">3215000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">146000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2517000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">5878000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">38000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">3253000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">159000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2519000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">-4923000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-10405000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2464000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11134000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">14585000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">1088000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">15706000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">21000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">64000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7406000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">5001000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">12407000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">7438000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">19650000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">1095000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">142000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">8464000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">14438000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">8490000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">14587000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">23077000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8464000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">14438000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2780000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">521000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2926000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">6227000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2780000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">521000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2928000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">6229000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">50000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2830000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">537000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2928000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">-4608000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-19113000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">1833000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8460000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">14296000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3defb8d3-21f0-4891-9ee7-418d75bf2263_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 598&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 943&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 062
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-843&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 482&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-461&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            847
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            457
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 820
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2029000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">4598000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">316000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6943000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2029000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">4712000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">321000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7062000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">843000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5482000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">461000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6786000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">847000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5516000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">457000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6820000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_49e23e5c-d9f3-448d-8a54-4b28af29f6eb_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 532&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-616&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-922&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 789&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 020&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-115&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-267&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-82&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-445&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 628&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 908&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-639&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 896&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 373&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 553&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-439&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-64000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">-412000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-1432000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-3624000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-5532000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">71000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">616000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5020000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">126000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">115000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">437000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">267000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">835000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-82000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">-445000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-1628000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-3908000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-6063000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">639000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">982000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5373000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">54000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">65000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">517000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">439000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1075000000</nvs:ContingentConsiderationLiabilities>
    <nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f8825478-f50f-4846-9d23-624d8b1cc861_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">-6000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2c20f494-743e-49d9-987b-c70507db517c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">93000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">99000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-98000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-104000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:FairValueOfFundInvestmentsAndEquitySecurities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">1600000000</nvs:FairValueOfFundInvestmentsAndEquitySecurities>
    <nvs:FairValueOfFundInvestmentsAndEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2200000000</nvs:FairValueOfFundInvestmentsAndEquitySecurities>
    <nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.15</nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5e0927b6-e24d-41ad-a5d6-8856dcca5c15_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-154&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">109000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-109000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-154000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.15</nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d48c7316-5ef1-4f11-a893-c5a3990a0d76_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-179&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">179000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-124000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-179000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4b6a3970-287a-432a-a01a-a90cf72e8b6a_0">
          &lt;div&gt;
            &lt;div id="anchorId001561740"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;30. Events subsequent to the December 31, 2022, consolidated balance sheet date&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;South Korea investigation &#x2013; Concluded matter&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Dividend proposal for 2022 and approval of&#160;the Group&#x2019;s 2022 consolidated financial statements  &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF 3.20 per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD 7.3 billion (2021: USD&#160;7.5  billion), using the CHF/USD December 31, 2022, exchange rate.&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare
      contextRef="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember"
      decimals="2"
      unitRef="CHFPerShares">3.20</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">7300000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">7500000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_678875a9-2bdc-4ad4-9517-5d067920b3ee_0">
          &lt;div&gt;
            &lt;div id="anchorId001561775"/&gt;
            &lt;div id="anchorNote31"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;31. Principal Group subsidiaries and&#160;associated&#160;companies &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#173;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#160;25&#160;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Soci&#xe9;t&#xe9; par actions SANDOZ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Algiers
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Argentina S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Buenos Aires
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            906.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Austria GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kundl
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Unterach am Attersee
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Bangladesh) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gazipur
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              60%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Alcon - Couvreur NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Puurs
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Securities Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Services Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Triangle International Reinsurance Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Trinity River Insurance Co Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            370 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioci&#xea;ncias S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            S&#xe3;o Paulo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            507.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Camb&#xe9;, PR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dorval, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Boucherville, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Chile S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santiago de Chile
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing Novartis Pharma Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals (HK) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hong Kong
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            320.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Suzhou Novartis Technical
Development Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Changshu
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai Novartis Trading Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zhongshan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Colombia S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santaf&#xe9; de Bogot&#xe1;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz d.o.o. farmaceutska industrija
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zagreb
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ecuador S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Quito
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cairo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.96%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Egypt Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            New Cairo City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finland Oy
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Espoo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            459 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Groupe France S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            903.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies France SAS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Molecular Imaging France
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Saint-Genis-Pouilly
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CELLforCURE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Ulis
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Levallois-Perret
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Deutschland GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Business Services GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Produktions GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz International GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 A Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            HEXAL AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Salutas Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barleben
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Aeropharm GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rudolstadt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Hellas) S.A.C.I.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Metamorphosis / Athens
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            233.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Hungary Healthcare Limited Liability
Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            545.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Hungary Limited Liability Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            883.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis India Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              70.68%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            PT. Novartis Indonesia
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Jakarta
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ireland Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Integrated Services Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cork City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies EU Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Israel Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tel Aviv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Milan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (Italy) S.r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Pozzilli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Origgio
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ciba-Geigy Japan Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Baltics SIA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riga
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investments S.&#xe0; r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Petaling Jaya
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            468.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Maroc SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Casablanca
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Netherlands B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            IDB Holland BV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Baarle-Nassau
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Almere
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            907 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis New Zealand Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Auckland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            820 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Norge AS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oslo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Pakistan) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Karachi
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Logistics), Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Panama City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Philippines, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            298.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Philippines Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Poland Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Polska Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Strykow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Portugal, S.G.P.S., Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma - Produtos Farmac&#xea;uticos, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xea;utica, Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            499 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services Romania S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bucharest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Targu-Mures
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Neva LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            St. Petersburg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            JSC Sandoz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saudi Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riyadh
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Singapore) Pte Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            45.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Slovakia s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bratislava
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Korea Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Seoul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Esplugues de Llobregat
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xe9;utica S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Madrid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            270 450
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Industrial Products
S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Franqueses del Vall&#xe9;s / Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Abadia Retuerta S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sard&#xf3;n de Duero / Valladolid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Sverige AB
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stockholm
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Holding AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International Pharmaceutical Investment AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioventures AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Forschungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Kaderausbildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Mensch und Umwelt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Overseas Investments AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Japat AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            350.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweizerhalle AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Muttenz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Stein AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stein
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweiz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cellerys AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Schlieren
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129 630
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              20%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Arctos Medical AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bern
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            360 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Innovative Therapies AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications International SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Geneva
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Taiwan) Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Taipei
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            170.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Thailand) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bangkok
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            302.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            880.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gebze - Kocaeli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ukraine LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kyiv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Middle East FZE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dubai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Grimsby Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (UK &amp;amp; Ireland)
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Neutec Pharma Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gyroscope Therapeutics Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Frimley / Camberley
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis US Foundation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications USA, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Millburn, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bannockburn, IL
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Technology LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Institutes for BioMedical
Research, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cadent Therapeutics
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Endocyte, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Navigate BioPharma Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Carlsbad, CA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            The Medicines Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oriel Therapeutics, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Durham, NC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Fougera Pharmaceuticals Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Melville, NY
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Eon Labs, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Venezuela, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Caracas
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Vietnam Company Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ho Chi Minh City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Fully consolidated Foundation&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">25000000</nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties>
    <nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7d464c9d-f56e-4e6c-8046-3f076ac73db8_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Soci&#xe9;t&#xe9; par actions SANDOZ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Algiers
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Argentina S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Buenos Aires
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            906.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Austria GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kundl
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Unterach am Attersee
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Bangladesh) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gazipur
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              60%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Alcon - Couvreur NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Puurs
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Securities Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Services Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Triangle International Reinsurance Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Trinity River Insurance Co Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            370 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioci&#xea;ncias S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            S&#xe3;o Paulo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            507.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Camb&#xe9;, PR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dorval, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Boucherville, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Chile S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santiago de Chile
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing Novartis Pharma Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals (HK) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hong Kong
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            320.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Suzhou Novartis Technical
Development Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Changshu
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai Novartis Trading Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zhongshan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Colombia S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santaf&#xe9; de Bogot&#xe1;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz d.o.o. farmaceutska industrija
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zagreb
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ecuador S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Quito
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cairo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.96%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Egypt Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            New Cairo City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finland Oy
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Espoo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            459 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Groupe France S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            903.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies France SAS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Molecular Imaging France
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Saint-Genis-Pouilly
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CELLforCURE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Ulis
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Levallois-Perret
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Deutschland GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Business Services GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Produktions GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz International GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 A Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            HEXAL AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Salutas Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barleben
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Aeropharm GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rudolstadt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Hellas) S.A.C.I.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Metamorphosis / Athens
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            233.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Hungary Healthcare Limited Liability
Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            545.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Hungary Limited Liability Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            883.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis India Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              70.68%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            PT. Novartis Indonesia
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Jakarta
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ireland Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Integrated Services Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cork City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies EU Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Israel Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tel Aviv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Milan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (Italy) S.r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Pozzilli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Origgio
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ciba-Geigy Japan Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Baltics SIA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riga
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investments S.&#xe0; r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Petaling Jaya
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            468.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Maroc SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Casablanca
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Netherlands B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            IDB Holland BV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Baarle-Nassau
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Almere
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            907 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis New Zealand Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Auckland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            820 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Norge AS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oslo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Pakistan) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Karachi
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Logistics), Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Panama City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Philippines, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            298.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Philippines Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Poland Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Polska Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Strykow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Portugal, S.G.P.S., Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma - Produtos Farmac&#xea;uticos, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xea;utica, Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            499 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services Romania S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bucharest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Targu-Mures
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Neva LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            St. Petersburg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            JSC Sandoz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saudi Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riyadh
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Singapore) Pte Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            45.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Slovakia s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bratislava
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Korea Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Seoul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Esplugues de Llobregat
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xe9;utica S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Madrid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            270 450
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Industrial Products
S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Franqueses del Vall&#xe9;s / Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Abadia Retuerta S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sard&#xf3;n de Duero / Valladolid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Sverige AB
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stockholm
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Holding AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International Pharmaceutical Investment AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioventures AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Forschungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Kaderausbildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Mensch und Umwelt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Overseas Investments AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Japat AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            350.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweizerhalle AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Muttenz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Stein AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stein
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweiz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cellerys AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Schlieren
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129 630
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              20%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Arctos Medical AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bern
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            360 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Innovative Therapies AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications International SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Geneva
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Taiwan) Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Taipei
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            170.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Thailand) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bangkok
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            302.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            880.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gebze - Kocaeli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ukraine LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kyiv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Middle East FZE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dubai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Grimsby Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (UK &amp;amp; Ireland)
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Neutec Pharma Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gyroscope Therapeutics Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Frimley / Camberley
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis US Foundation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications USA, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Millburn, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bannockburn, IL
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Technology LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Institutes for BioMedical
Research, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cadent Therapeutics
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Endocyte, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Navigate BioPharma Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Carlsbad, CA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            The Medicines Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oriel Therapeutics, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Durham, NC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Fougera Pharmaceuticals Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Melville, NY
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Eon Labs, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Venezuela, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Caracas
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Vietnam Company Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ho Chi Minh City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Fully consolidated Foundation&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Soci&#xe9;t&#xe9; par actions SANDOZ</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Algiers</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DZD">650000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Argentina S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Buenos Aires</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ARS">906100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="AUD">2</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals
Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AUD">3800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AUD">11600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Austria GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Kundl</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">32700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">EBEWE Pharma Ges.m.b.H Nfg. KG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Unterach am Attersee</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Bangladesh) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gazipur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BDT">162500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.60</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">72100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">19200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Alcon - Couvreur NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Puurs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">110600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Investment Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">12000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Securities Investment Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">30000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance Services Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">20000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Triangle International Reinsurance Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Trinity River Insurance Co Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">370000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Bioci&#xea;ncias S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">S&#xe3;o Paulo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BRL">507100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Camb&#xe9;, PR</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BRL">190000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals Canada Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dorval, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CAD">1200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Canada Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CAD">80800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Chile S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Santiago de Chile</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="CLP">2000000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Beijing Novartis Pharma Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Beijing</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals (HK) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hong Kong</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="HKD">200</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China Novartis Institutes for
BioMedical Research Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">320000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Suzhou Novartis Technical
Development Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Changshu</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">12000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai Novartis Trading Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">3200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz (China) Pharmaceutical
Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Zhongshan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">57600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis de Colombia S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Santaf&#xe9; de Bogot&#xe1;</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="COP">7900000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz d.o.o. farmaceutska industrija</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Zagreb</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HRK">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CZK">51500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CZK">44700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DKK">14000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DKK">12000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Ecuador S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Quito</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">4000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cairo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="EGP">1300000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Egypt Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">New Cairo City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EGP">250000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finland Oy</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Espoo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">459000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Groupe France S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">903000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma S.A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">43400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies France SAS</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-6"
      unitRef="EUR">10000000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">9600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications
Molecular Imaging France</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Saint-Genis-Pouilly</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">7500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">CELLforCURE</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Les Ulis</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">4200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Levallois-Perret</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">5400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Deutschland GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">155500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Business Services GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Produktions GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz International GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">1 A Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">26000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">HEXAL AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">93700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Salutas Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Barleben</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">42100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Aeropharm GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rudolstadt</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">26000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Hellas) S.A.C.I.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Metamorphosis / Athens</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">233900000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Hungary Healthcare Limited Liability
Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HUF">545600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Hungary Limited Liability Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HUF">883000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis India Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">123500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.7068</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare Private Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">60000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Private Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">32000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">PT. Novartis Indonesia</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Jakarta</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="IDR">7700000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Ireland Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Integrated Services Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cork City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies EU Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Israel Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tel Aviv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="ILS">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farma S.p.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Milan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">18200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications (Italy) S.r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Pozzilli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">119000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.p.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma K.K.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ciba-Geigy Japan Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz K.K.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Baltics SIA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Riga</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Investments S.&#xe0; r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Corporation (Malaysia) Sdn. Bhd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Petaling Jaya</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MYR">3300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farmac&#xe9;utica, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MXN">205000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MXN">468200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Maroc SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Casablanca</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MAD">80000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Netherlands B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">4500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">IDB Holland BV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Baarle-Nassau</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">18000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Almere</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">907560</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis New Zealand Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Auckland</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="NZD">820000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Norge AS</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Oslo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="NOK">1500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma (Pakistan) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Karachi</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="PKR">6700000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma (Logistics), Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Panama City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">10000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare Philippines, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PHP">298800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Philippines Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PHP">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Poland Sp. z o.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">44200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Polska Sp. z o.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Lek S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Strykow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">11400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Portugal, S.G.P.S., Lda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farma - Produtos Farmac&#xea;uticos, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Farmac&#xea;utica, Lda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">499900</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Services Romania S.R.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bucharest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RON">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.R.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Targu-Mures</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RON">119500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">20000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Neva LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">St. Petersburg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">500000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">JSC Sandoz</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">57400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Saudi Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Riyadh</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SAR">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Singapore) Pte Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="SGD">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SGD">45000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Asia Pacific Pharmaceuticals
Pte Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SGD">39000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Slovakia s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bratislava</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Lek Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">48400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ZAR">86300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ZAR">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Korea Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Seoul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="KRW">24500000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farmac&#xe9;utica, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">63000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications
Iberica, S.L.U.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Esplugues de Llobregat</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">22600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Farmac&#xe9;utica S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Madrid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">270450</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Industrial Products
S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Les Franqueses del Vall&#xe9;s / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">9300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Abadia Retuerta S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sard&#xf3;n de Duero / Valladolid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">6000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Sverige AB</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stockholm</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SEK">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis International AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">10000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Holding AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">100200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis International Pharmaceutical Investment AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Bioventures AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Forschungsstiftung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Stiftung f&#xfc;r Kaderausbildung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis-Mitarbeiterbeteiligungsstiftung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Stiftung f&#xfc;r Mensch und Umwelt</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Overseas Investments AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japat AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">50000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">350000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Services AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">20000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Schweizerhalle AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Muttenz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">18900000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Stein AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stein</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">251000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Schweiz AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cellerys AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Schlieren</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">129630</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.20</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Arctos Medical AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bern</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">360020</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Innovative Therapies AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications International SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Geneva</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">9300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pharmaceuticals AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Taiwan) Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Taipei</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TWD">170000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Thailand) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bangkok</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="THB">302000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">448000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Farmanova Saglik Hizmetleri Ltd. Sti.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">6700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">880000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gebze - Kocaeli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">96000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Ukraine LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Kyiv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="UAH">8000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Middle East FZE</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dubai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AED">7000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">25500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">5400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Grimsby Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">250000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications (UK &amp; Ireland)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="GBP">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Neutec Pharma Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="1"
      unitRef="GBP">7.7</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gyroscope Therapeutics Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="GBP">1492</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Frimley / Camberley</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">72200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Capital Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Services, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis US Foundation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">650</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications USA, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Millburn, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bannockburn, IL</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Technology LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Institutes for BioMedical
Research, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cadent Therapeutics</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="1"
      unitRef="USD">0.1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Endocyte, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Navigate BioPharma Services, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Carlsbad, CA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">The Medicines Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Oriel Therapeutics, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Durham, NC</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">50000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Fougera Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Melville, NY</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Eon Labs, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis de Venezuela, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Caracas</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="VEF">0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Vietnam Company Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ho Chi Minh City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-9"
      unitRef="VND">70000000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <dei:AuditorName contextRef="AR_D-CurrentYear">KPMG AG</dei:AuditorName>
    <dei:AuditorLocation contextRef="AR_D-CurrentYear">Basel, Switzerland</dei:AuditorLocation>
    <dei:AuditorName contextRef="AR_D-CurrentYear-1">PricewaterhouseCoopers AG</dei:AuditorName>
    <dei:AuditorLocation contextRef="AR_D-CurrentYear-1">Basel, Switzerland</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>249
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  ,A:]6FCG-ZR@(  !J-   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;:V_;.!:&_PKA!0:SBR36U4D[20!'J5NC:6K$G0RZ@_W 2(PM5"(]%!TG
M^^N7I&33Z5!'BM;JA\:2=5[SY?7AD72^8?Q'L21$H.<\H\7%8"G$ZOUP6,1+
MDN/BA*T(E=\\,IYC(0_Y8EBL.,&)#LJSH><XHV&.4SJX/-?G9OSRG*U%EE(R
MXZA8YSGF+U<D8YN+@3O8GKA+%TNA3@POSU=X0>9$_+Z:<7DTW*DD:4YHD3**
M.'F\&(S=]U$8J@!]Q7U*-L7>9Z2L/##V0QU,DXN!HTI$,A(+)8'EGR<2D2Q3
M2K(<?U6B@]UOJL#]SUOUB38OS3S@@D0L^R--Q/)B<#9 "7G$ZTS<L<TG4AG2
M!8Q95NC_T::\-O0'*%X7@N55L"Q!GM+R+WZN*J)-@%<%>#\%>*.: +\*\+71
MLF3:UC46^/*<LPWBZFJIIC[HNM'1TDU*53/.!9??IC).7%ZS>"U;12!,$_2!
MBE2\H"DMNX>JYF-4+#$GQ?E0R%]3,<.X4KXJE;T:9==#7Q@5RT+*)B1Y+3"4
MQ=R5U=N6]<H#%:])?()\]PAYCN=9"A2U#W>!XOB[JO.UGM]4=?OU]>>-O I-
M!<F+_]CJK)0,[))JS+XO5C@F%P,Y* O"G\C@\I=_N"/G-YO? XF]<A_LW >0
MNG'_[65%;$[A<,\YG@S'-E-@7$=3X<Y4")9J+!TEVM4DPPN;*SC^$6>%K3(B
M,*RCJ='.U*A=2XTI7>,,W9$5X\)F#M81?&WU!D9U]':Z\W;:LA=R+)<6/03K
M_<%:M8T'AG4T>+8S>-;.X'PIESH4L7R%Z0O@$9:K]0B&=?3X;N?Q73N/,\)3
MII:A!,G%S#JK-"AMI_C:)0*,[^C3=<QBZ[1S.DF+6 [%[P1S-)$G[>LK+%9G
M$0[KZG$/*-PW>:P:M=XE+#?Y;O4(!G7UZ!F/'EBH"I3NR"(MA)QY!+K%N;6_
M-@C=LB?,15J@\4>K33"ZJTT#."Y($%N;D6Q-+EMR*CGN&7TF+U:CL)3C.*[K
M!D%P9O79!\FX!F5<&$:B-><_CTIH$FJ0.SYVO6/?M1KM@VY<@S<NS"=5@_XA
MEY+C'Y1M*)H37#!*$C0MBC7A5K>PYG?KYB""H[HZ-<SCPK"R[;I5RY;K94H7
M:"ZPJ)F(8,4ZGWW@CVOXQX6AI?)YS[(U%7(?+OMP1KC='ZQTRZSV^H ?U]"/
M"_-*94^;0I$<C@O&[=,/K'.#^8*@<1P3*21EDE+2ZK@/%'(-"[DPPFP[+LMS
MR;)SP>(?1Q+^U!X<?5V+0LB-NNS'UCHHE4.MK/(W3Y>>Z[X;.>^<\/1\^/3*
M91\@Y!D0\F!VJ5R^@EJ;I0:96IR%X[K:,PSDP=!2V?N0$[Y0D\Y'J2"6H%%8
ML-YH'R#D&1#R6H'0E HYK'1&3BV:>#OO6IW"BC73+!S5U:<A(0_&EVDTN4/C
M=9(*QM%8""+'H=YLUN4)&O3J]M)P6%>;!H0\F%RV#NMHMB'\\^S+QQJ2;8B<
M\30F&SDQ\R5;JZ0L6\E5[&]:KVT9[/$:TCJ5K1L6ZU:S6H,EKG!!,CD1;U+Q
M7\(S.0E;7?Y_(J_M&=;Q8#+9VIND/$?3:ZL[6,'W L?J!PYS_? ,<F HQFM%
M,6I-1K?K_,$.H@TB[K$;.EY@]=$'Q7B&8KQ6%#.E,>.20W4?/-(D2I!LMXA)
M=N-JS4_LHPY6O[=NJ>"@KI8-QGBM,&:<)%*].-I^0#H]_I7:?<*2-VF\%&J[
M710$^:'5=!]4XQNJ\5M1S<YTI(YD W^3.RWKS0!83D\7UKQ_'W3C&[KQ6]'-
MSN:,R=4P0_].5[5=N$$Q<,*1U6@?=.,;NO%;T8UISW*@6@W"2M$GJ[T^H,;?
MNW\%0\@N4[?-8VFBT=-27@-O#8JUF K'=75JN,9O>;-*[@!5&U:) )I@;EO'
MKQKD-.Y275VRWT]2BFF<[NZL[(M;6196[UH9AH;\QIM<DK8P1=>RN$6JLP;5
M!I/@>(DXT3];UI);WO^U5M*!,CQ5I?21+_(-0_FC'F[F'BCW4]5 'YDDWS"8
M#^/3MU1(^F*/R/5^??@GFI-XS>7L9_4-*QVH@T7PSW2M$$-M/LQ5WSA.]%A^
MR1^8;1V^:A"XO9];;?5!9KXA,Q_&J&W#H@_/\1+3!:G=[34(W7Z??[#ZZP/"
M @-A 4Q-7[EL-=7ER@=7CA!E>:KFZ2><K0F*/DV0<Q(Z2&XPRTO^97UZX4"(
M53W3T >P!0;8 O?PDUMP(/:J:J /D@L,R04P?[UA<FM0>G/WLM9&'^ 7&/ +
M8$QKGMD:!&Z_WM]:??7R1-+>(TDPE[6?VAJ$ZJ8V.*RK/T-N04/^:%W(,W(7
M'3$J<"S0GU^(2I;8Q^]!\>Q0:J^=&SP+>L"SX*!X=BBUUS5@\"QHE2)[4T*E
M0;)%0@56Z&K:(%C0*G'6.J'2(%>;4('CNMHT2!:\+5G6(J'2H%B74('#NCY=
M:=@L?&."K#ZATJ!D3ZC 05WM&<X*X336=EJ>$5XP2DE6N_XT"'V6W$#1S0GZ
MA#/[\Z1]X%1H<"IL2&=5&6N5.++?3FD0"*Q/Q\!!75T9+ IAJM&SRY@37#OJ
M&@1&=E=]0%%HH"B$64;=],K0;,DH=&^E0<3W@F-7_K/ZZP.*PKU'MF$H^ON@
MF^!GR"DLIYR>GGG6V1,.?:O3X=Y;&^I! ?TR2X%T@K)\*6)W=O?"S%B_)O+3
M^2OW?52^]F)DRK=POF#U_$&!,O(H)9V34VF ER^VE >"K?2[(0],");KCTN"
M$\+5!?+[1\;$]D#]P.[UHLO_ 5!+ P04    "  ,A:]6:_Z2:Y4%  "I&
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MHIL/4"3)6!X "0&@=$(0NW ",)T0$[V-#%J#N+7&9]Y<Y+Q1@K?Z5J=WUP_
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M)F( ^OV:<_5\8P;H_SNQ_!]02P,$%     @ #(6O5EQD1%C/!   F1,  !@
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M*1=;OPE%N9&NWHW<WP=LO:BN  YG%]HZ<+%K=^G8[@QZC@.X*3SWI'#(1B9
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M?D>4_'!__+F[AB-@+(5-/?L^7Q#.H$F B\H!CAD%4AL^;0MBUZ$',^L>:0&
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M5^1O^-\'=UA./X@_X-$S'M@WME%[3>\8?F)G?9&LSMZ<Y)W3OV(LV)KKI%-
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M<TY"N7TAP.0M)I*C2MY9AB#VV'A*?=KTVJ<2=&]\T^D"< *1/P$2RDJE()Q
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MEPBFQTJPWQQZ#N.+ZT\'!%MP5U)ETHJ9*A09'D\O8?.\E,6RWR$\Q3ER(/D
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MXHX1^V/XXE%3$(-A)IETKNP,S^\3Y]'@I6=.?*GQ%]\:HI:QWS;*PC/0.,Y
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MJ>.JQA%?F9B 2W7S5)W>ZDR&(.HI6TB34^Q%5I:Z5M,*8:EI\0/\M9VK%GK
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M=*-IB6?\!61MX_>( L5J1@\RA.J&7>/WRQKW&)>S8FT9JADQ(I/1P;Q&'+B
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M"JTE-S,F3-T4>3;)"Z%_:!RFEAO)-ZP0H%X915J7(3T!0,WS);3W2[-B(#O
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MN\\Z07SXP+@?_8[$=[7L7(Q*!1\@:P-'O]W5C(6S3TESUE0@7V!^DG@<M?T
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M+JL;=O6.G1DAV._*0DA&(KC/],4X>%UK34BTB<076.6M#I"#B3N42B,"TL_
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MR'AV6\$8P'OT88?^-'Q4XSE/1Q0%1Q3Z8?B(OJB/1N3T10]%8X^?] =;:J-
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M0WMO]MW;NRL<0.N:FO1[-JR;0Y7P%7Q^>]VVYE[1>9O?Z+(J:">CK0#[0B1
M?X0M1&+Y8R&[ TCS$4,HS-#T AM8G#-BV@(M*HM1]L: M7$W&7IX+E'\=.C0
M]-"A:?'D2-QHI$4'?P>B^]:/I^/]Z/[=XGP\4G\R'U],;L!*A4VYUBNX!D=I
M/.-V/.R/-]YTPP%[:3R.Z\/E!N]'VI(!GJ^,\8\W-,'^C>OL+U!+ P04
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MK'DFC'DAXF=1MM([-C^V_I7<D)2>F-QRP5<OO$7>F]*SRDHP][B3C$NV?_(
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MOSJ,L$@74'$9+:@(H92D/$JF[%Y7E7*A\&&XZBMVK1UL1!G!-HJ"S-DB!6;
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M$M$& ]JOC?$ODQ#@\,DN_P%02P,$%     @ #(6O5DV.K4N/ P  "0@  !D
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MYG"'-Z;3CIGUWO\)GWYA*BU_XGD<&-=,/&)) D'TWKZ9I6E\<67 .U7&E,#
MJ-)O)!=D0[@DT2A9HN82UPK3X*D.9UA?')P/D5H=B10.<? [?' V&^4TS&B8
MO*+J4,$1@1C%C?15CNL2C3?" E?PDA&AV=+K^'-MQ[+ :[OY_00(SO(L"\XF
M>.%GTS@-[EZA!$&2)T$RP0R8#+%X%D&-0=$E M9)MK:FV89$"2RF!+A+(D26
M#A/26S]TTE(H>5E**M^840\=5](]D5YG#648M$-M!Q^X VP.@#E+^G]EO.&J
M$\1)=VM\_5@**(>EL<P9=*LZQ;T=;TD;GKGJD#-N][4LZN?E'A,1NA4@343V
MA N!W:4<'2L!T4%Y;H2M?!,"U(&9,%3J_>J^SWT8RONS^= DOW!;H6ZFQ!I=
MX]%T$C([-)YAXDSKB_W*.&P=_K?&7BTL&>#^VABWF] !^^Z__!]02P,$%
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M IZO#8*JN:$-NG\TN/H/4$L#!!0    (  R%KU8C(.)NX@<  /@5   9
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M\P3<7__R;K1_0K#)%O;LYT-VCM8,;XD+I-R_4C>H/%X8!'X:8VN"\IW %L%
MT"$E6Z3BFY"2@ .I2* ;RKH?C)S@S!$I^C9.<58<>%'"\4OA_F#KF2S9J]]3
M/1.$ 7DFB[D[(LYVA?"MD/B[A>0^[$9".!*0C@&L&X[NWPA)29/HZ0$0\HS
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M+@F#@MMT#V&6E[ B&CD7#X;X^0R["*:M\B\(Z.3YI@;T,J3PA[</1?,O7=.
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MAFQZ#+&RD:6*U@Z G&4L/V/OY%JB>&5?!<2?A;]'.6 >)7%8X1-@?2_MS@M
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M9"4"O%\JP*'N VTP_%KE^O]02P,$%     @ #(6O5LD%V\"D!   60H  !D
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MSB&1"6X= L._C;@56>: X,:/!C/8FW2*Q]\M^B?/'5R6S(A;E?TE$[N>!Y.
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M^T&/BSQ$U<6HRIHUNS10 0[AX?=ZW$\GM/[IWQ&^X,J!"L4IA$=22A-\*5C
MC<)!F;6[1MV4;/G9WJ\,LZ^OR)F,J3S]"&158SR@!]I%]K%X=]HC&:.P[HB
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ME.!'4N<>&Y"]UR9##O?$TI4UY*F"1^DT)Z=JY,'WNK2B7^VVF=_Y6JUAJ:M
M/S*1.O=D>)#Q35$K3R-B)&IC/5,/_1P@N6_FX54(_^U+9/")%M(-FAF9!PVI
M51<<;:J-=$&%$QBFW)#JE(<?!###VS/N#D#0U\&.2BSLQTX9WBLB^*D,;&[5
MVE)2;8<(P>\8.C#J.QI #W84#1I'K!-Z68^C>0//\1GR5G%%QN.,KDH3;9,J
M)^TG!-VMG! R.L,L\HN27X?Z,I6&9?=@IJ2*FC@HU!HU:2B(?'%O[ (0_IVC
M+HV9O.X]QBRB$\A2(&IF33B\&2\9$H>'8^&T$)V:6BMT=/.*0J5KAGDA,TD7
M.@[-;P@8+HA 23-[ NE;I;L=G+:,$M6\UK1Q=UBE&T@'2&7ZF]K#CCVZ(*R1
M"[MZ2A.(^\V#.O4YF2M$L:Q2G<D'W^N9U^.<5T #])_2@>R'R/IE=BR^&INE
M:W VZ'@V3DPUO<]H,5=KIVN7\.HT6)F<FX[FV9;V@^Q!BS)Z>>IG8ZD_>_#$
MHH&X,.3CM6E#4$G[E7%=$+LP]JH'=%8M$.QL;T(71S/_(Y/FU;U/,?[5<W?R
M$ZQ$<U3WQ)8W]<L9R#L(@SQP[ALE AW-_L)KU><:]T>O7'GX 1B"9#2,Q]'Q
M(;IPNI@>QT?MTTT58,DHFAZAN::+DV.:&#UZH>8VJ!]&QW['832=H/>OG\X\
M29HO,<E13?+QZXLMKQM ;QI-Q_CPV6)SFH^S=Z-#' ?1CG!QX \/B[>.!7M\
MTS0,?--,8=KG>YM6CFNM3+P(SW7C5\093;RF8Y8:Y$_ XI8\V-?C470\@1AT
MQO$4RGS!2EM4'>Z/O/5&\<FVWWCL=W[1 [TL^'=+SK_>]#_N:>XV/XTZ][\(
M:I?[WU7]@M9?%PY>?8NMT-+1CN]6ZR^E6?'O@]#[E";GRR6_.:<%>'YK3%E_
MH0.:'XR=_0=02P,$%     @ #(6O5N[;ZH$?"   *Q0  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&ULG5A;;]LX&GW7KR \F$$#N+(M.]<F 7)MN[MM
M@Z2=76"Q#[1$VT0D4D-2L3V_?L]'2K*5VAE@'F13O)SO?J'.E]H\VX40CJV*
M7-F+WL*Y\FPPL.E"%-S&NA0**S-M"N[P:N8#6QK!,W^HR ?)<'@T*+A4O<MS
M/_=@+L]UY7*IQ(-AMBH*;M;7(M?+B]ZHUTP\ROG"T<3@\KSD<_$DW(_RP>!M
MT*)DLA#*2JV8$;.+WM7H['I"^_V&WZ58VJTQ(TFF6C_3R^?LHC<DAD0N4D<(
M''\OXD;D.0&!C3]JS%Y+D@YNCQOT>R\[9)ER*VYT_F^9N<5%[Z3',C'C5>X>
M]?*3J.4Y)+Q4Y];_LF78>Y3T6%I9IXOZ,#@HI K_?%7K8>O R7#/@:0^D'B^
M R'/Y2UW_/+<Z"4SM!MH-/"B^M-@3BHRRI,S6)4XYRZ_&ZXL]QJR(.T6T'3.
MG<A8R8V3PIX/',C0YD%:0UX'R&0/Y"AA7[1R"\ON5":R+L  _+5,)@V3U\F;
MB+<BC=EXU&?),$G>P!NW0H\]WG@?GK1IKFUE!-,SYK95,!5N*81ZK07V7SZU
MV)BZ_^U22" WV4V.XNK,ECP5%ST$CA7F1?0N?_ME=#3\\(8PDU:8R5OH?\^"
M;T+N9C@YCME?THH>-=(&^Z3S3*HYN_K(ONH76K)LP2US2\WXW B!L'8UPD>A
M\"+219]]5FG<9S^4),0G!V#+WK7K!WW&5<:T$AN, /$$ZL_L^T(87HK*R=3N
MP?(;#V)VK7$JU47)%1F7PQ%L-;4RD]S0!+SB)T'>^1DPL5S(=,&6 H>DRJ1!
M?LG7&*9Y!7?'@#F<3*$BG<O,:V<F%5>IY#FSQ$F0OK*$+/ZHI%LC.Z6Z4HYF
MZ"\GO8EB*@P;>[<?$5WX9:M.THGQY!QTJEZK)+"/I0Q)SSHF07 \CL>_1O^J
M4NP"0L<RN<2L)5:-+C8V&=0X>,0* EJ@,4.9SGIP\8*T7GJ[(*<_HXBT\#\-
MHO_HG$NSH4NG7E,B4Z3Z?0DNM-?&ZT.!C&WFPQ^$6KG** ZS0UNCD_Y^16WD
M"#(3$>($[E (0T:2?_)0,5J5TCJ'BY0E++W3^5 >6<L$/)$IZ (^H0OAUXQ>
M\YPBI ]"L(==P--JRA!V)K>FC/1,H83Z] 2P5I>UU"VE^\I@W13:B'[7H!:F
M,7"X$OX&5FO[]ELA0#>32&ER6G6%M5L.%$<MYD-=B.\KG&RUS-E'HZMR$SUK
MDN9%4B! UQ4IH)".8@#^;!1Y#DMA#L@[XZG,R?=A%Q)R)ZD^>P([?PJ3<WHA
M58(<3OQXNF6'PR%J8I[39L^T]+:&>KGSD#^>V+W(O!X(S+)': -I; $JK[E8
M0FE*.P9UP / <%9Y<_A@KHQI_*#DP%\+;FP<W:U$6E%;P;[-9M"P"4[]5:OW
MFZ5;GR(TUBCC0+;@75>.H:[5,5[7MCY10P3XY#(:L0W(3:U'P0I_!,GLMU].
MDF3XX6<>_,+H _+<;1 A0!^R'>Q:)\J2A-5+%>_B:=3E*=D!LDT'V\=_B\ZP
M2V<72.P#RVD'<W9425[QEJK()F3&T>%>T[P;32ASDP1^>_LZ/*@3-0%X9R?U
MCHX_V.V<72+5IU0YB)60TM]3LYAU&?7^4WOW%)EO1FF9'(_3R1P=LCW;X531
M'JZC[Z2+Z!W%0AT']B B:]//B'Z&?_%ZP^TBE%72?H?;*#F,:7\\IM%1-/'/
ML?]/3NF'UL?#.(D>D-+>BZ+,]=HGQD:V*(E/\!SB.>Z,[_:I*)HD0!X?@^AD
M%(] ["0Z! 5Z)L?QA-8/H\D1UH/PQT-,'@VQ]>@4H_"<XCF)COW/$$QBE$2=
M8*A]C52O*$_C0F-%4[L_WS\^=0TG5C0.J5RTAM"-=_M6@HH,$E,(@LQ@ XSL
M*SON(,;W 34,W"W=KW<_O=>'#M!R88V((:/AJ&>6^ I%NN&M\?WE0G>"KW9K
MJ$ J[\$F0VLB0OX$!*K+EB'1Q?BN=Q-#:/C$"U>^N%%- JD2N9DA\1:^N&TT
M0=MW2I]5OC79H<@]W([BJ)-BWC92)H(YLX80M8Q&YZCXPMJF-MS=? T-):*.
M+- 8I&[(NA9QH5#R:>X!Z3*,,X!H]-P/'3#/45LAC47UA^W=IA$(#E;7\_V\
M8T-3;+;00^:[4JI"ZOO<*IXON<F:AA0E;5;EKSK1_:E(D'OZEK+D,O/-!O:3
M%OH$-4>G[P+&/SC(FG43'%3ZZF35I$4C2FU"'A1&ZBRPF[6W+#34"CTWF T:
M;NW>X:CUZUIQ*/RPUHW.O%:^37,YY^'F02"[O;<^],UDON.FFP*7"@7[;I7"
M]G5YV- $RI/3Z3.M+[B:H]5"4P0>;KJ7@T7MBT2B _#H16_LZNM#'/U\3:H=
MI@G*>GM0"5XV=:B3I-IJU-;'+<67?!W:M7>(_26': $X18=8V(-01PN>;3ML
M(-AR86BI;B-@.4OLDLE$OJY["/2-ZKF-YN(LNO'.F:Y?UY%;$[-_&EX)$]U\
MND="9L/AL/FCQ:M<K.H=_2;O?M)*&W*MFP6ZV@(SX+]S/:"-Y.PN#TS01:>@
MHDL[08@%"C[_\1 >P05MN,A0Y%]]_-)D(R56KF[_:A@B,).KX.FCT],3M)<P
M*^W(!(4T?23P4!N#A9VGP<MS:@=K6]09V7E\8\B?PCT!1)I$QG9=^0=;'W!@
MI[G_3$5E!2R&;SGM;/LE["I\ -IL#Y_1OG SA\<CU<UP=!@?'_;"A:UY<;KT
MGX.FVCE=^.%"P$T,;<#Z3&O7O!"!]OO@Y?\!4$L#!!0    (  R%KU;GS76'
M9PL  #,=   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)U976\;-Q9]
MUZ\@7*!H :ULRT[B)+:!)-W-]J';(&FV#XM]H&8HB3%G."4YDK6_?L^])&<X
MMN)-%VAC:8:\O)_GGDM=[ZV[\UNE@KAO3.MO3K8A=*].3WVU58WT"]NI%F_6
MUC4RX*O;G/K.*5GSIL:<+L_.GI\V4K<GM]?\[(.[O;9],+I5'YSP?=-(=WBK
MC-W?G)R?Y <?]68;Z,'I[74G-^J3"I^[#P[?3@<IM6Y4Z[5MA5/KFY,WYZ_>
M7M)Z7O!/K?:^^"S(DI6U=_3EY_KFY(P44D95@21(_-FI=\H8$@0U_D@R3X8C
M:6/Y.4O_&]L.6U;2JW?6_*[KL+TYN3H1M5K+WH2/=O]WE>QY1O(J:SS_*_9Q
M[25.K'H?;),VXWNCV_A7WB<_%!NNSKZR89DV+%GO>!!K^9,,\O;:V;UPM!K2
MZ .;RKNAG&XI*)^"PUN-?>'VG6T:'>#EX(5L:U'9-NAVH]I**W]]&G $+3RM
MDKBW4=SR*^+.E^(72-AZ\=>V5O54P"ET&Q1<9@7?+I^4^).J%N+B?"Z69\OE
M$_(N!H,O6-[%_V.P^)=<^>"0*O\^9GN4?'E<,I7/*]_)2MV<H#Z\<CMU<OO]
M=^?/SUX_H??EH/?E4]+_?*">%K>\6HBOB@S":+G21@?(GGV$+=)56UY3JQT*
MN:--6#_N_VVKQ'MG^TYLI1=XI)RJA6Z#%<:VF[_@>R/<UR3)C5,J"MKKL!4[
MZ;3M/?;[H$-/]>NQV\@ H1 )N;+=Z)510GJO $ND@%>EH,[9G:Z5 '")S@8\
MT]*@A(Q"4;5*=/(0%ZX.XA\6)P;MYV*_U:2?4] /P%>3=@ /WU>5\G[=&U'!
ME;J"J,* N< A#6H0[A.^4Y5>:VCJ)0X30;H-5.0U-FR5(T?7.AHUGC=NTZW
MLL*6A7CCA5T+U()J5A"0ZV$>%S:V)R?"J;!--]%+NB%EL"ODT'S_W=7R_,5K
M/PD<O-G(N\(=/8QVV&0G[BP]X[=VWW*@@/+":7\G9/T%6!5C"34(;EN2I'U%
MND$?0"?[%WF!F"$J!OW OYK]\/G33Q050^[X<496T3\7L\OE&7VXG%V=7=&'
M9[/+2_[P?+:\XC4O9L^O7LP0>'2C-1)L=B'.G[^<_6:#-+-GXNK\<E:F."5"
M)3N-M_AKS"1IK:DIW7;*I]4(PAH&\(=HN@Z<V]%Y0R+2#JQT'-B^L[0M]#!R
M<M3_B& @E>$O6@O!P]8'VC^.Y%&-8SYP:,FY5Q?9OPLD>E!B^9)+'1W;#YKK
M-C9XZI2V_<:3%K-?4SY_$Q#DJNYZ8  ZZ2/["#,UZHQSB-+8H60]I<L>;3NF
MC1/JCUY'V$B%8EVM6S *R.L=Q,+/J]X#\/R "^5)E,( .>7@[,-40PE0ZYTC
MV: H=^!$G1L4 ET@+B%:<I09CA @2(X=A]/ % 0EO;&><@": (;P/ASFHC,R
M5^E@P3%7S.$'%2/U<C%[WTN'?0I*:.][:#KU<'JX&9?!CK#5KD9).P+P;W#3
M7#36!WB#LTS>SQ/U\"-F;>Q.N984A.TR]9T%"NQ8STCZP:A.MO1]*W>4Y<*N
MN"^R/D;N<? HEQ14+OMZTYOHU QA#"30?JA'/#PDYRO4EVA[KBPLSW!>*("@
MSUGR'J4 5>^4.:2&U[-F*[SW_>H+1;C(5:,VL!=!K)2"^S91O5@,>I,T#%LD
M#C; J6MG&\)>EDE_YUA<F9[V3L3 0NGRT[JO1O\=7J?&$:N TC N(P:+9'S-
MR:)<1?T,R=;U@1ZJIC/V,$#PWJ'M4K^B=-Q2"WK-SY$D.CA$E](,R<[QFHNM
MDB;$QNSE6E&^JG:G(22&?![30E.UM&PV#@=3JF$@:F0GJT/R3$"IPHE]=!OG
M/M4R]D44E$0#P)GG(\C@_0$!@%FJC $^^B!CWRZ3B]U-6UH;L WNV'$)KR@Y
M4'>RK10KPPN1-P9FK]<D%9E?)/T:]="R&SOK=9P2./G@4K9Q(7[?@C","55;
MG!^/-5IQ(E/HVT/*4F3 XXSAE.,*D .JH6-":2Q72;$6_<4?T6@NR.J8:2AV
M6$C]KJ5B[5OPS%I703(1@N:&XBR^]/4F0IV'1RD)44058IW\C[3W@""4,((W
MF$8.34B1.A@2%^X:I1'V4OPC5H)V!9.XEEW/*B-UXTN7?YO%,1FXRD<@%=RJ
M_5:L01(6XOV $1-TL$ #V8.%Q"1&!0(B:K8 HV#68*44^%M074=5A&3#>\T]
MJT-2Y50!&,$XP%^E8@G1M*@S?#JT;3P\@+WR]SL@#Q!%^K*ZCY0JUT:%1P!4
MZUS?Q8ARW9#E 6_98%1;LT+P+*6/]A'Z2+C7S,:P@:44U5L=".U2#<?BJS$!
MYFI$+XJMG9B;HJ:NIEA[S(N'R/X"""%Y>HIS<V) .J8_J HPB,C.D0;A)]*Y
M(0UB'T+G"(,4-B\;ZE/"@[PBET?<P S2$6FF=00,1,>F@ACMN8?%#$&+==F(
MBD)%>Q-31JXULD43(VT'AL.HS1 9>%J@\O\9B%#7J1"/'4M54V#+"!T($$X-
M5 ',D(D*#%.(ND?2\+T&]XLB+D[I9D7M.=(#9S=.-D,+_]QJ(IZ?<$3J#WF@
MH-[(0,[)K"2STQ_@RK$M_5@@2>9%:R0JA8@KA=JATZL^<=L:\XAG(XL):7)H
M;JY)N]A#*LG042-)W2$E7TU31!YLM(MM1%$6XYRCF/)H))SRCZ>J'@5 +,8R
M+*\C6<NVD"D\,A4"R$G,B4+V2A&/$N7828B_-3M5I^[\&#/Y=4)BQK \6<T+
M.,X>@^: <$:_/ /1YQK3$4$-397633@$;1L3"?D6I=.NS/MIB-BH&J5@5\3R
MR?--[,6I/&( ,=\B8)PUA7RGJ)O4LD%]^(<5,,'\TD]%[-=.]C3#^)2B V:E
M9Q:S6ILKM,BB:2H +SM+U(Z391,Q[N@X2N_ILHD$)-3)8HE5(&J4#VL.,UR@
M;4VZ,Y8OQ*\H6M0OJ 67U)#F[]+QF1-\PC_V/_!&M>!#,[?.:/18->[ZZK[3
MK"(->\]8$DVP<P+_3O&-I %4OS'>SC/:1; T!XK&).L?0 ]SM2(@D41%'$TD
M"G9Z9 B[D?L"_I8@$-D-WY3$2A\[9B/SW8FS*R88&/:I'7/DP=5:V^B*[$#E
M<*N+9H_ RE7O([<6A,#@C"P''N\H'1WYG&D@W0G@?W05ZA((*+D61[0P0M41
M "*[RA<</L^R9^,LF_.47?5PG,7>D846L\+#246ZHL81M\=T#N=!S9;"<YSM
M.KH)CJ/G0-=*LL8DGV-#F5.*;I3,XT3T2H7^!>^UENZY(K/E>9AG/$)2<"?V
M!T6'^#,;IRB^.Y6X%5E!I?#@M,32!BPA:(@,S0PMC:%RU#=%Y]A\Q>"-A(]:
MI9$FWGGE2F?D&M&J9/<);7BU/410BOY+UU@R(7RRDO8?G\S2^0- CH0ZT4Z*
M+S&8@CHSR+%T4$3.F)(?8#:R>U!]-W^H0<PJ6:6;/*IWDIP)[]2-T]N4(Y,'
M^FX*R4J-I#D&^AM8,D=9;!#V-J'<8KPI&,XM*$@YW4$^^K..]3+,H<2IZ'H5
M__']G8H7>^G&CU\,X^8$F_+(GH=H6$@]CRY3XPUGZL*Q]I#.,ETC\O7.5Q4#
MF/*URC'#4OM]L%RU/I5TC$0\6A;E/X&<W/^G.!1[(X"*(I33QR O(T^*:8'&
MOK61%*C[D%*\T":N0F!HD$!FQ1S+DU&(O(OA,44\^2:D\(]F16?R9;C>I>4T
M@SZ0D5I\;%/SH8#&Q*MD-X[4*6!I4P$)CHFWYZOV).Q/(>\TFL44OSCVF\AI
M\4-6H\"@Z.<Z'^EM_$UK>#K\(O@F_A V+H\_)_X" D:J&;7&UK/%BV<G$9CS
MEV [_EEL94.P#7\$B4'GI05XO[:P,GVA X;?26__"U!+ P04    "  ,A:]6
M%W44]'HD  #4?0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6SM7>N/
MVT:2_\Z_@O B"QLGR2+UCI, CA/O>I&'$7OW<%C<!TIL2=RA2(6/&6O_^JM?
M57>S25$C39+=O3T<X!EK)'9W=76]J[KTQ4->W)5[I2K_TR'-RB^?[:OJ^/G+
ME^5FKPY1.<J/*J-/MGEQB"KZL]B]+(^%BF(>=$A?AN/Q_.4A2K)G7WW![[TO
MOOHBKZLTR=3[PB_KPR$J3E^K-'_X\EGPS+SQ4[+;5WCCY5=?'*.=^J"J/Q_?
M%_372SM+G!Q45B9YYA=J^^6SU\'G7T_Q/#_PET0]E,YK'SM9Y_D=_G@7?_EL
M#(!4JC859HCHOWOU1J4I)B(P?M9S/K-+8J#[VLS^EO=.>UE'I7J3I_^9Q-7^
MRV?+9WZLME&=5C_E#W]4>C\SS+?)TY)_^P_R[&+^S-_4994?]&""X)!D\G_T
M2>/!&; <7Q@0Z@$APRT+,93?1%7TU1=%_N 7>)IFPPO>*H\FX)(,A_*A*NC3
MA,957[U-LBC;)%'J)UE9%37ANRK]H1_%<0*TT0=Q4F[2O*P+57[QLJ(U,?+E
M1L__M<P?7I@_"/WO\ZS:E_ZW6:SB]@0O"5@+<6@@_CI\=,9OU&;D3X*!'X[#
M\)'Y)A8#$YYO<A4#[ZYCP/]KM*:'B);^NP\7LM*T?R7PU^?E,=JH+Y\1 Y6J
MN%?/OOK][X+Y^-4C^YC:?4P?F_VK;QH@\RT19A4EJ8KI6(5SF076Q);^MO?(
M_UJI3Y6_3O/-7>_6'E\\7(W\?E+Z_>^681"\ND!0_L>]\K=Y2K(AR79^%:U3
M>K/<T]8K^F03%<4)']Q':4T?T,;ZH5^?_(.*,"7^IG&5VN7%R8]X#)&,.JQ5
M8<G&C[(8+X*1_^VGC3H24G*25'2P8&)_G6=QZ3\OE?)_R"OE!ZL7@UYX(D*V
M^KDF8*I\X-,4$0FJJ*1=TC[\Z'@L\D^)1GZ^E3FV45+H\2,/P'@6<=Z;J-PS
M;!N\H)D3>A ;](*YM_!GP<+[2"*13O>8EPGM&\\2MHIJ6*GB0"BY5V4E*'E(
MJCV!E.P2X)R J(ND(C3E!'.UCS)_-?;CZ,13!X$_7JZ\CT44*]K!1M&Z. DO
MF'E+?SR?>S\2Z(7[D8!9%P7P'96E I +;S5;>M]'Q9WBH_1+M<&RB0)'Q6I=
M.>]@X97W79[M!'CW9)MM#!D-!+@[<.(MPZ4WH?6N#S];=>)-;AFWK;/8?0L#
MPV7@C$SS*"L'1-GW-(&B5WJ54_M\<D9=:H>U\$O 3 /O=5GF!$)%_+K)#\<H
M \*BRJ$5.K(BKW=[GTAJFU0\,?$0S1"NO&]401-"O?6S!S =CJ?>&Y+$1+W,
M(3GIU5@50IMMD%X27N>SL?<QKVB>9D9]RN'"7RT";[F8>H$_(XQ\'65WSDX=
M>FS&XA2\D$;-)P3&X: *?OL8'56!]T-_L0B]#RT.](*51[P*!#E(3Z)UD@I)
M53EIY.S.17-[_TE58W\\4S"=:@(_1B?9ZLP/IO/+6'&7:H1!.'X9AB]ZEW0&
M$&K&\\7UDZ&MSV;>=R0T5'OXF&98@"<[A^ ^- G\D'@S\ .2(O(XA-HM L4/
MF._'_F2U(.2/:;U_C&0)_=5\=E&RC&<W2Y;%:O(4R4($U:*;)TD7PNAJYDWG
MRU\H7Z:_4+Y,Z#1_<_DR"7^5?%F%-\F7@([R1OGBS>ED+@B72>A/:<69OUHR
M!Y!0>)?1M@A+P[6*"BC?:+/):R"15+LZ'-/\I&@[FJM]6BXFQR6+P5N!OPRF
M3Q-0JU6O@%H2^?6(IYD?KN:_A7@*P\6Y>)K-1%HF3")LI!3J6!>;/>0%;3]_
MR&@[9(;0'$N22T3VR_'J'R?25M.;1!H8IU^D+0E;CXJT!9T_SBV8A_KQX.J2
MUZQ(P@9,=AAHQ'2J2-F&.Q(Q;9(C:.\@] 0$..:9V-%7EHY(!I[^3HQ%)FAU
M.O*IV 6)Q1ZS/=_<"EB2Q0EL6M[.KB"^]._SE"# :NNZ)&N<WB+COJQH=N:1
MRFR]S-,D9M9?1RD$B2_>/MYC6.+<S_(*A 6G!#+7H(/>3,J[D:#7P0O,7G(P
MB-YI8=XYN=+$HYB<B/[ 4AK;V "),*QIG:B(^2U =\ACE990%I5?@Y+7\(:8
M??7@)#O6 L(C"/1N1*#W'M*2S[#9A?>#VD5G;S[_\X=OR,].4_#E"['/6:?V
MO7J;%P_8%O$E>?^9KSX18Q+;^05P:ZB@),M]-5Z0X//#Z9+X=.61A!N2#!Q.
M9LS>>0RA;OG:#/1(-9/B(TU),O/'(XL*B+=SE359D4'L#4G4#2<3S5]7*9=P
ME-8QNX@:ZUW%&K&&LKJX+2Q+Z._I!-N:3!=L7T('#,F<&1+_][ D<R3-ZJ_)
M2;J+(;N(=&3VS0FD_ 1NO8TY'R.?S^4D.R?^[9]_\N@=,4L$E3>?\WRY(*$]
MGZU@&,\#?>Z/G3"4W +G?.UX)ZL;C]5;S '$ E3#0,@I,;W^AEL-_.ER!@.:
M_+VY/Q_/#'D_MMN Z?G1K1(9T[\;MVJ "&>+!@@0XU6%H;9;M9'/B<SV*J8=
M:K."B:TNR, B#G@M8E1!,V[;Y,/>/ G"!_S*<A]Q4IX)$[AK886(Y@7U0@P3
M+K(RXJ!D.?+>-B88,<,^(4U-:#OYKTL2JH2>0@3LN[<_?1B<F4MBICDZG0RM
MO !/MXT[8N(S;=#,1>*Y4IIA"F6")PDK-3J_V*^/N4R0JGN5 A-_J^/=0=OG
MQK)DMP!/:=E=8RC4@01F\!$!U$#%>H7>C_BS@HP1LWO2=:FL14:O@$  $/\C
MN +TEO7Z;WQ^H)Y'0*#5F8@<&2]V$,Z$GB/B[$?DP'\@*/8,6U1J059^SII0
MCT L*!%,?\=H"5R,Z\@0PP<=VW82,.>#2E.>N^,'$!AE)5)90M9:.)<C=W6R
M[0A7:7IJB7$!)'0!:2A*M+9A##@6\+-4445)U@50UG(IJW_!:I^4_:NQW5EV
MQ+3,6PIZ> 01%Y\HD6V1K_."CU'; $2GT4CO:6(M AI99X[!H(]2$ .E8: ^
MW8RPR66$W9/+D==EZX!H' Y-B*;.?JYS -V692=WA%AZO0;Y%9O;I;(.=9T=
M@PEZCGKUFJ91_7^H_Y\8L=_UPWH];9*K;5^7+)D;_ &R#/ C0OVRI7&+-F]P
M0&[&A'_>:.MD<XOS29J0_EUQSF6; .E</TT7$S@R\Q5T?$"JZFW7C0_'7DAJ
M%Z'"'_)LN'D*>',R%_ CJ$JOQ!#:^)BN)N)BS>8<T5F,?VU8$3]O>[VTJSAW
M'QX&DT!^7245-A[I1_9_;G>ZG-':AQXJ*RWGMV&^!>2"*)1__?B(!SP,)Z'\
M$@@S9YD;H/2&J\E<?O798T]DT<O)@@Z;^H&.\.DXGR#W8F2PPV;.R/[PVRV\
M>R8Y0K)0$?30<;KK$288=^/9;RY$&(P@!,<LI_-?(QF00B'! !O7GY-%?RX8
MEMYDLN08WTV!,D3)FDC9TX0!R:;Q$K)@Q9%0(NM?&0+$SP59<&DO-HXU)-0L
M9N:_ZT* O$?\/,J(=&KX>224U&4]S"H1K*&.+K&/JMT;N+G=Y%['KK2V0A_4
M VW'E.0T)5LR8 D=+3-%FR]QS2%,&"PG%17P+&C^EI-*JAR6#-DUM.@:91/:
M4VV.T/M3E-51<4(4GPX&9 7" [589*]<UV)'-IX;AXSBO]6:<@;:D@!8VR(_
M^''24!7\"=K0WXV9T?$A:&1^4(T#X4V]"3ED$_HW1MS"@0"4A*!CLUA"5)@4
M)HH6PZ\OJN3O3#SEBWY@GPS0<#XAL4Y'O\2Y(T 2+%VPGC"WG51"?(=CH?:H
M3KE7>ED7DS:JP=Y>*APA7B=)@JD7!-Y[[1^348$_@_D8JB7 KZ4(=Y8&1XT>
M8B?-'].I1_](G'R3E.2F1BGX >&?B?>3VJ1$MTR!6)(>IOGH]]AS:(PU.XP4
MF#'(] V7=&R.7D.>O8]X]"$^\1#$ ^YW6/<JC7O#-/KD"/SI"A0U#4ASZCA&
M+R.$A$/(UBGA<1Z*N"&)_B]@@M!;P$(D+-/!PD3\UW-!2,A;,H6 >H:(0?ZK
MF0!D&7@ST'L(0Z!AAPFAC<3S9$$P7^&$$)S@L $I\N&"IISVL0+)).R^Q0C]
MTO-_"Q< .5.B9F\V1ZAPN/"^$?T!#K$!*!2Y9$J0O*7!2(MUS1.A:J/"JKR)
M61!4,$.G4V.)^L\Y.LKO+B;FW1<#TET<WG^7T8R$GO?U.DTV_H]TG@R3CM^*
M46+-#/+"^V#603,#<WD5Z* !>F(@B=40P1),[L <KBS,(Z*"*.4C.CN^2^K]
MFJ&EPUE=E]P83]?I ,Z[C=/=1#D<!N=*JG#\2LPB>8;?"EXAZM'Z5'TZ$E.J
M@?F\4.51XITIG<<_'2<BP/JD!2-#LD^;TP;U:K?C<5U7.A!"Y!;%F$(SO,0=
M"Y3 (3]%=E9&-%):2C36EQ1D961L8?^,"/P!M#0GA"!-C^T\. _<"2*?8*9?
MLKB%/4#+DV!NV1*?XKW9S+PUZ!SLQ[Q)RW5JS<!?T457>&#C7'TV*X?<2A6/
M_->.N2SA4_W(@=/B!$V=5ARY= WA%''M'4@ T;G\0;E18+=N3P)V;OB8EAY
M)4*\@(A*.3+"UUH'^;"QLMYL5(D"B0B)7^0NR*L5?-+9U0>=<2C4+BIB0P$H
M0^1,4F$RH55RX-PI_,ADRQE-<EHW*@-R6$151;+;B;@CULA,4-9!5()JA4*E
MH!;YL,'$1I:IRVBGM+@LW5BUBC;[R^&*0W3",9VL]-,@(LFJQ8BS@3-(6=(;
MU8F3T&,RU.\8<'045<./54Q*K@^DD?].1AURPK;K^ARC(CJ %$L;GVW%<87"
M:7I-3VNRX,:?^4>=IR6*H5&93M"F)ZZM?&#-<?GX_>?O?_SP NY3+TBRK@5L
MP LR&%',?%X0\\3UAG,CT#N,CN,QA3BY1'#8W,4#,PZPA%EN</D'$LA]R&LR
M!S1F& J=D.]J#<Y'71&2)Y89P6QZ)D>"Z?B"(/&^/=/$OUS"G\\EUD[)];:5
MVI$-X4C( :HHD ""U,"#J&H@;/&&?\B) 2I"T5_H45 M@BP#YKLFOA\K'#NC
M(])E#A!^&X*C3"3H7IYGTG0VXLG;8SU)EDQ9D]S\N0;.19>)F.F5[VX6Y("2
MG_H($%'E<9_$->\"H<4V^3KIA-<]#I-(QC_0@D=_GZ=QZ<]G/(O.)YU;5\_/
MS,W/_?E8?([IW'_2N"F-ZR8BFG1<4PC@A&P_OUQL\=V%I;TIV>I+<@I^>&1?
MWF0U]B8VBMZ78U[J"C_',G7RNGP*"@D>X4U'()2J!Q\L1,@*:4Z+!&.F#X73
M>&!;%O\6(^U4++%W+!Z?_SJECVCX9J0+NQQ7U#^F7!%X_@S/&W7T/1O#H>5[
M!I,6C5UC>>78]ZPV]F)X+.PPMH905*>]+'=TT'KJ!;LBQJ0O#-H>89X^*\V$
MR( ^QJ.Y.<"X%*2>GP&7$AFO D88+REREMU6+6H&EU$UZ7. PD9P$H8L"MO(
M:D:R]78!66'P#T%74\:W)'_G!]'F'*+^5&D_'55<L$Z2TL8W^D.O$N#GYWWW
M-2%>RU<!+(&S8+U[/#(0PX<(5<PI'L;..JK ]".D-O<0OAM;(^*$TJ5<;-3(
M>/I'?DQNJ@@:< 9XEOY.TI-KJ9B2%0M7JW:E[$!8VA/4,UM::)S80V/AB5R-
MM(8DZX*<X+S09=)*W95R.&0_J(&V5$C@QTH=2KS@JR $-=?PY2BY*W.R'E(R
M-VK-^-:DYDWC<@Q1?V7,&5Z?[](L7I5D)Y'G?=+X!5!2>*>P06PS)P*'1:_$
M7+F:%&'\9I$V-^YSA&J,K=,'5)P3_N"VN2MF)V=VM\B%;1^B6C9-A3*874E2
M8HZU\G^N42"SU8EN;<D*,,Y$P 5-)6GOKFAP@"I16<%%OD:YNY_NHWO%]J1]
MYR[+'_#( S&G_E@;6-L:W.120)ZE)UX Q*EC#WJ1O!!TE(*/%@:XLI0G:[__
MW/C_NI[7U@E!?7)94OE"D)6PW;B%8H)#!0]_(SNS8+>A=BIGCG"&,((H@K30
M"%5>C["*'%&SY[I4I99UA+0TC1#'\A,V2(^(5CJAOA$*ER+M";HF29N;+_/J
M(;]7VA!LN)PV]FU-#*0B.NH_1>2!L_D$X7%0!5=<:2[6$W()R]MS]NK(!**]
MZD&IK+L[&W1MI@.U"I9;OJT.9P++ZUSK]C:O"BK8>Z0-B-'?BC<+$J&D(N,L
M&.$^< N%= V6?=P*K+PV@<5!.P%FLKM;%"^!BI-22+LN"(_P)]M>>B1[$?OD
M %>I<7E /'D\K/*AO.K?U\C_FEQO+NFM=1B*.)1O^M&Z'QZ2$D$]DA'B+/<&
M"?@*"887<%SK\Z$#5T+I<VU);^?A2\>&L+L<VV6<NJ?07R1F5(CC=S=:E[6=
M RD@62MVVY,-XB3$!Z3CXV13F5(X8I(H+?.VE-056ARK*)@2V3]L^)D>CU53
MVR9(2 J')]E-I\GS#;U7#D288!*-!N8,6Q*I"[<?E/9$"6@.!XF[7NRDY@H8
M(J4&CUEG+@"YH!J2^9XDH7+PS.R!05>BHUFG4'WD?R#7*HF3B#?_L"<9@MC;
M1M\F=5B4%V_P$B/B51_J5%1?DFUU"J+0/F%S8RD8CS_S2?)(J(+EI90D(DQ8
M<AC@I$,/7(:<RNV =Z\_(-RL8Z]-?KR1BW1P?SP!(+,X CC?$@KR V24"=!"
MV.[/GE/F.4PC!8G6.A*>T\7XKPL$%FCY 3QC]?>:K"+&Y,>:I"(10/M=^[@8
MM.<+<ZJ"I(ZP>NGKFP%*V[TR*]'%)CKTPFU)Z7N2,=8_E7I6$7E5D>OJ1J*0
ME(_>4F][0K<N5Z[SVIS?0#L)'()C0N//^;3PN#X>[19TPT&\0SE?NS]7U8M%
M)(INE^;KAM9.UAQ"?$5ENT@7_=KZWY:2%W-0IF,:%[/0L0D=JQ=2V;&J3%S6
M5EZ+4"C4-K6BFA5:>28)K]C#6OSP-?3V0*-+-O;FD6;P2T7,#?0L ]A>V.I"
M\@9P3-'9W1F(.4=JW=WF8@;1&JH5!,%V2U<P)%DSG1658(XF)-^UZEOER!:/
M)FAC+9$;D.G2S9ZHU(U!60G.,D%('#35P*7(MAF284>\GNDLJWO1;*#O6 J)
M$<DOV2X0\]#H/#?%*LZ7=O> 3@V M>:S<UR:#3:Z7#QEP-8C;L70Z[M;/^C-
M@7!]L7:];:%-<Y/CVS__Y >CI;\V'C@[S*.Q>>/5>6I4.]6CP#Q#_CE0OX8]
MY^(?]JA4^#<N3R<IR9&0QCLG@( AH"OZI) 4*4S*3.NKEEMO4S3BT;?SPH_E
MOL!3&ZVAE'/5IC]C[G-62K^G TG$<NVS--S""H4W7:B#CAA8J4QTL6$HU%&\
M)\Y\Y>8\SC=Q/1EG0S- C(FEC4?N=1 ;".CP"KM4Y*\J$NDI&5(<U#/RE864
M'>AX^ZXP,C=-F" ;>TE6AAB07!+M*GH +Y%V(4'%-_;.S'5SFPX\W4YWP>[0
MIA'$6)16VER0"WGD@.R$Q\C2).<,BL;.-N!L91.C7I]8(;D&R&?VHFNO$T:N
M;L%@L>S H;LXZ@F^X-39:&GRJ<S81OQLDT\J'O+S'3;5:@<V7^_GVIT7TDA8
M2+>K\/@I2+LM$4S.>4D;7H"*2SX-+BJ\]D[*AXBVOB-+S);I:$,HJ:P(+K6=
M0OBV^2WK^T9 M(@N3=[,=I@R'O+%%D8$OVMVW8D4V7Q(YT@ N;WDQ%$L?;7#
M%:U&V"?T>2SW!K2/+$$<-L:9[.5D$;KGN!X,E(Q%3^IDGD\XG139+B:;V6?>
M&[@0.D[GO)9XGVI2640L9:+].7$LN+L0XA78B([$&$.?+( J-7=V\G6:[+12
M@#AEY)T=JX3F&H_?' H3/&P*IE[1S2=]R5\@\#<-W.QLD>PNG72(^5S0I-VN
MZ [(UB86 EB$_AU?4G,0(J:7&WU[#MM6?8I@=1IR\7=D3Y) 4?#I]'#2%75A
M4[9;6BB'PG@AHI7FNT]*7EKF0S0&AZ0!E7(*S@Y:+,,6<<A2&TC#-,_O.$O;
M,X>YAJ3O>I3Z$%-E&D^9W*[V8RM<(/?<7@K6IX'!#UM?R$L?CF,\M-LS<'1-
M<GXF7=Z_Q\'Y6$G'@03L!;)<WU*/6X<#9Y+P2I"4),L1R=;QX2.'*Q540DFV
M[U$*C9PE)$>%'A/BJ\6X3?8NL]4/C\%LHL$-H9H\0=ETG<CBL_,Y1)LBUQ[9
M1A.$ML99'32Q$R=JPHK34D"+K]J)7ZQ(3 0BX\MO%E"A+RX,,&DU*#DSIV-X
M6A66PD<O&P8W'A1GF@JG+1$BV<'\,S\(/O,7]-]"7LY;+]F20&2F;&Z&<R5$
M]]C=Z^?L<C67[,KH8.[X.?P@U8X"&*&&(9D*)'@9XB49$'B@.)*RT +X_!V5
ML7 4[5B6-?J)X/W\L8O-ASPC']9>-[?!\%<M&H7U')7[@02D6WTWG&MMK]PX
MG1PQRQ6> FAHRDF<E8AD'6 A03E_P/<]V2A:UVPF=]-<?"F1B%F!]%\/F4[B
M41LO[AXD1]$&2HK0[')&&W$9'F819Z,;QF:K<].LP]E@Z7&17VINH>/76Z4S
M4W!N4,]C((S@V:,/5V/-"-&(%D/,G[C!2;IH97V'MET ")X5O=GT(VB*3\PU
M1M:NLN4=&=M%HY!B?91-,X/FQJN&D#L\E$F[1OC\\JP.MQX3V$+$&S_7$7)C
M;'(5ZA[M!#LY"\0W$2.S+3W8)[+&CES&U9ZP";U8LPF6,Y\4FV$(S0FT97T\
M<N:CF8=/S002Y+28)INL4-N;_PB'KZBD+0](A,55AX):Y0:P>4P8AUU><FFJ
M9&B]&:-GRU-)R!KHZY UX/DNR>YHR(=F]N=OOOOP8B JEI'-D\$(0OZ1+%\I
M^-1S#D5)#.T2=J(7+"AM_%OG/;OWVCM;/Q.FC]R3@CI%A0KC]Q#]C;NS[+0S
MU\\,KT3=LB0T8IKDD)A]7<D\&9$(7.'7?+3$JX7^M1C-148VMFB3D6.5Q]DX
M8X5@WR@$(9W/O0!AU(COPY?S6]PL#4&<5!G/Y ;.6+/K>E^;%>2<3L,3"LK1
MY]HHL?:XCXCW'1O!UI+N_)D@;+)E)HPDW]0$P5UEC9!TO[5*"Q[0V@3<WK99
MVV6M_?>%K&R5V5@NQBHE_F!IR.?/5_F[]W4Y7C;2\'TLV&HZB3POC[ MS#7E
MU&Q8BD=-RL#AK"9(V)$5=JA.)<IH%I$B&(R;0!2T$4N;L\.0ZI*J0(T?RQO%
M;3?<E1Q?K EYINW389NUTTZF1,2/BUO8X,J;5C09.0@ZPQZ1LV?$8L,AL&-:
M=7 0KQ*Z)3(CA VLYYJ1MBP@*LJ<Q&2K"Z1$Q% 35T@..V'/E!A>?4K,)? W
M9PD4INM4[00B:]/!XR/SRW:GZ-ARK6ACU=2NZ\O@NE929SMU)I;8S4HA6U8T
MD,Y>3$RVMQ?B UKON6#HYCPFK=).6W4,35F:.RYH)A":;3AAY'_?1*%M#<-Y
M$ 3A!7;B7:+5U9F\MIQ,D:=<YF8*;BW6A#1$0&@#W,E#MG18]9 C\[KIM-P"
M'>](C9>Z^-TZ_<BBL8WGRUXY=-<$"@WFH]T.U;Z2YZDS-J'$B6XO0\A59P'L
MO;Y183/-EZ"[!MR?WO^7'\P:X)ZW)3R74#D!S-M@[78GD_<E"(/3D+!H$TL5
M&(6V1/-8W+*9WFH;Q;&4GJ8Y3L!S/%I9B!W,&9-ASP%7R1TXKA<Y3)98,<N\
M.3/CY2+NR.E37>+Z@2P\ <.D>6 ,=J9+2FTI&$.V/)EF6>B-9?NO)5R6(7-#
M4BD;%(SHJ<T=>25'6ZO\&$&:=EAZ?0[-ZQRU"^^,5\66"/]%])!=Q*W([[/X
M]JB_A9*22F[28FAO=NAAYW[FM8ZX= :V>0,)#TL+#C$UZZ:I8Z)#JF=7W"\E
MQ,FLTA9R3UA KF[I/QI_R=7!C]93]UT3O( \?6/V&URYBRI=5'#ESS?MEI.]
ME]W[_,!?V273I &*6BQY#CQZ4W*%0V_NK_A6H[?B%KVKIKT2WSC'K='@ALOS
MX<0+I@MN@CJ31K 76P=,_3%6]&=CVW#X0B\&C::E'RRXD>AL/D4KTV!"/TM_
M-1FWFC"XE[??M@+%WI">YAO+Z&:Z\H;AV ^GT\Y3_A!\I&]LJ-@;KOSQ..1!
M$USI#M')=/YH6X;'%GMS Y@3/PPP<CJG880:M*KPE[3Y*Y!VQRUDW/*&F_ 3
M<V?ST:X8%KP9/1K,5K+,"LNL)H'W@Y8'=+8K4,+8GZ)/6^A/Z<0<? 03=, @
M=,RD"/O?EWG %U-_MIQQ4X8E[E<OB?3]Q7C^"QD(G1B\!;>&19_3B^RS(-S.
MO1G1)BY9TQ]7^8=&T"D'*Q_WL,'C,X!+O!\N_4FX>@(3\7'2OC'?D%3V:AQ>
M(TT:M!KSH-ER@0O@_GBQN(F)^A:[A8E"?X&+K#.^VDKT2#PQ]]'[] JDW7%+
M&7=#^Z$A[K?C\G@H?0D?9:+07^*6\ QWCYMEZ$P<)IJ/^;P",&9 ST\$'X)'
M=(,=+G7_PTZBN]._WM5[[69.L.QS-O@E\F1O29K<)6ZYV(BB<TG+J&^S'FZ*
M<1!4^$?G+DPS3+GO>-X$4ZR$*R7#3;O02M^A[ - +"T3;.'J7@N,UQ-L<:9P
MSY]@1E5=8OK6. &=6VJ;UXU/SVZL)&RU_]KN\':3W7"])^RY4+H%J=Y[NTTR
MRF631!"V!JBI=!MVJ_B=J=L-B_PQ,<F0&)R,A^$D8'Y;32?.4JBT^F4KF8;P
MO,;47P2A-PG1]G(\#V_2(?]&B%P2SDBA3M%G=3H/@,;%<OY;HG$Y1>/.&1W1
ME/M9+L.Q[H'CLD5OQ JR 1$\+FJT+H%E*^T:.)?T^WT$IV=?^]960G[-;;SQ
MQ@'5/;'L@AH;0H],N7L)Z9(09LP\A+GCSR;A>1-I/Y#^#@&4P1S4O IY[,)^
M?473=HC4< BI#"5S>ZM_418!3+8IJX'Y0OJC!+>0])/WS_0TY78E<ZB;":E2
MUCKC^>3"_F$4KA9HD$*<O>+&O])7^VS_D\5$X^IIO<2'TD9\>'LW<5J!3FT.
MFQ@&[A2@22^-@,PEB?[ILA3KL=K0 >)=]ZILA? NY8F0E\840I:E"2TZ!27;
M?,,5B*SX$N?FB9ZP4UU\L8SM^SR/3Y:'WK%U"O_Z@RKNN2))2I&(4=[HTHS7
MTDZCJ7]SW&B(LO=#>< Q>ILGQ)/]\/OH<'SUWO^#%)S^Q+LN^]9Z/7Q\L=?#
MX#\NKS;R/J 8S;10-89&Y])'V?>,^_4]7)[%T1=]AZ>RM=:=;QUR[F_Q,!LS
M:RZ&Z.ORU]:46_8^OH*HN4_9MB,:,=NE.5-TPYJE79"19VIH4X=Z(/J4ZVH9
M6R0@3TH! $,1%;8NK]PG1WNI1+*_NE  7TC@7**BG38!\"9:&>N$MLVKM"[M
M]=YK;ZWR_+9+>>Z5.WY7"BJT%<J%T;VQG@N-UMR&9:83@?DN!GRUF_^6Q+R<
MKGN0W-O,3]*TENN9NDS)*M16K/O,4+S6R;BYAJ1KRI&VJ;BZ0M-B4^#KU@X_
MX?9@Y^;B1RZQRZ2W@ZDE(UA1.9B9DNVR3T$C.\R!-EN"')D^,?K;I$Y-Z0^7
M] @1<@LY*>6Y>JG+Y:M_][M=K7M1FN*<2S^HW"224MF./F#A__Q!17?\\H6Q
M;IP-<Q\<DWYQC+9KWQZF[\=(<H;K?[20=K^+[.)WEKD%W_;R9P=YNA5S4CJ^
M(!J:6!HA%$@ZTM(;UTAR.G>#4H<.W0YTP)<YJ.*KZJ_;S#'[[/*]_-EGON["
MK6[@&8M8-)D?SKT)QL?JEXU?H/O;15W=T*)3^7U65-Y30]YYYL63B_-_627^
M;U* _W^"+E83;[7Z-80QA&,;C*>=\FE7W/V(JVJF'%D8$K7/NHB]Y7!>(C D
M<G1%-6K-6-;AO'NJPCJ-U*U=RJ(VKDTW'_T5*+E;]>$4ZJ:JW6O)N==S ?B1
M_[4Q9D26R!(#U_PAE9NH>TLEN/<VE#C(,4]@W]LE+7EP60:-CMM?;MB%\H)6
M:F!J;!I]5\#IN!&U2:T+E:6MYX9(7K1 %*)XL)4A+)!%38EL[=S][)^NVG>B
M8-H+OHCN5H'&/WX+)OC7.U>[U"FJR*-:UY6MCT%A[>6-?&3R*BLI8M))6ES5
M=%/#G6]_D4J9MBC4Q36?W&A-8RW)]SS0N^!NWJ35F:A'<8VQ"_7W8J^ZG-UM
MLMS?FUG*M/1UC]X>0NX7$MS4HFWT_WV-+O0UZG16T6;-;><$*2M%$7.KM2\9
M87W:7$H?0J<\X6,O4Y>J#4QA[H\J2R9G33#H6//-G;9%!\YWB3B]SDR[,+YD
MT.V]E)BZ=>?"INFJTJTK_V<K=RM2N"[4O-[ZP6-:/^BH_98[Y 5CI)NG_)2K
MV]M/#?'8$,_]$R!"/][%ZBI$B#_2<WW?R?S2^:9M>"?\?>+Z4HM\Z;9]UWYE
M^6OYIN[F<?F^\^_YOAA9FFI+0\>CQ>P9F8O\'>+R1Y4?^7N[UWE5Y0=^N5=1
MK H\0)]O<W*5]1]8P'Z1^U?_ U!+ P04    "  ,A:]6.!GT42X$  !R"0
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MJE:(Q5>Y0"]#LV07;M3@YO7%Z;5[,Z+?*V#VN<)*HZWR;0Y'A-N/1%%('ZT
MV#T%(3+'#-+ S<:C%V<R$-)% &F,@RH48U%)0!IIKB'%/(5DG5O3-K%D!V]=
MI_:@]"4BT[F$@?,0U+&#?OM>R;YC^FH.J3L^IQ,C;!%@SJ3%Y6^LZREMJYOG
MW/C85SV7'T3OM0>L&$*,<@BN;YEC#9**SE$%B_\K=&^X(I"R*V'SB@XZ[D@N
MF@\]4:/@H2&<"3J/A]B%-40BT+-]PL'K].(]34?9.-Q"F)90:U1^R3VSH.__
M&[/+<K %OO%0'@ ;<==E9(/)*$)SM]U,1XM;B?9@=4>?;L[H8#2EI50JM,MK
M>)X<]>*]K?C-#K4N< CT$$<:SA^Y&/@VKX1>,5EX'SUV'Z;WWL&:[2J^]@Z%
M!;ON21RDPP?%<?>.?E?OOD:0C)7$7"HN83H>'>PE9+L7OMMXT\17=6D\WNBX
MQ)P5;(,"SDN#N>@W 6#XS%K\ U!+ P04    "  ,A:]64=(F5>01  !),
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M!4UN!(#WSTK%^0,QV/[? Y__#U!+ P04    "  ,A:]6\W!2EA<X  !2T@
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6S=?6MOW$:6Z'?]"L*+7=A
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M.'#^,+3=*3[%B\.1?FZ;_C#$A/QP $CASSP#[M*<1[>#EZ[X_82,@38;P(%
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ME@@DR2-%OWC2UNL6MBD_XSLIP,8F?%G;6"<YO$J-9!,4C1P.[F)9TM3D9NJ
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MYC#S-@(>IQQI>9<-S&I5((>#N PG>E>DY8*-H+JNJTQ>BV;3)"7AJ =6K'O
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MTB=6&8I(K<6^5N>QL=7Y;9VMKF0V5U^7;5-+>QACE$S2\Q>/:BH-I"(AN;!
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M:@)C0H HAB27<&B(-[>=.7Y1UJ<J^Z@RBB_76>JRNLJTY^G0:V>]?GR]6G^
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MPB]@)IJ)F89UN=M65$186=24<5NV&<MD$BG:-5@U3#Q1I+'$3!_^=OG^D3@
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MEFR:GEPP^;8?R_V&3!M&X<H0#]:PK/DE0^L56%X:0_N-=S"\C;/O4$L#!!0
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M!_%@VF_,E8L<J)ZK+ON"MR;*A\J\2&FT9V\P5]"A0,NX:IV**U@51"H-(6D
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M2IQOHY\FJ!IQ]P?-1 4&]H2U))+AI\A) ^0302S99PQ'8&4@N.:>>QM6OI,
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M9U"6 =_G$EW=7:R"9AN?_ U02P,$%     @ #(6O5O[UITG_ @  3 <  !D
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ME29>&#(_3+T56V* U$=B5U[(HG3AQ2SP5]XJ](Y0\U(6+0&;L"!:0CI=IE[
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MQ2O1=?=XE@M-&["^5;C,N@$I&![ZZ_\ 4$L#!!0    (  R%KU8@BAP'YP(
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MA]2=TPXYT>>-+FKE7+6NBB$'Q\(<L/-$LB1!JF4Y&C/,#B5+LX!% H%XB.*
MYYUQJG9#YJ5&)<RFW1G,4;"YS-D\BO ;4^(QNWA8KF*K[$;C882(:4BUX2*)
M!OAC"?=3,"&*!2:0+_H7$M!OM$5TRJMZ9"+P%[.4G??6ZK:XXU!2Z^HQLEZO
ML70#(U*9BP218^I51* S*C=6!-VLM-VO"DRBO#&7.>K !69'/$E1AX"G*-5!
MBY%*0(VN1'E"=ID<> 57H>19&CV?2CE1*0\((9!F7*0!D$LN@OP1E::0GINF
MJ?PH&ZQ&O.LM"@8^/"DB%J.9YZJKO*JAP1(AK1WE62!3AVK_5Z(5DZ(58Z5C
MT M;0Y2FQ$X)T4H>1!!M!JYFSZ^T&$J=!2@S$0-U"\!)DFV."%_5.HX2R#!&
M,ZB[(6J=IP.,$#8'D$[.?ZQ%05I,1, DB/]%BZ!40$M3 "Z$0Y]E%#RA1DR8
MI]G(>+H6<? --9(,TI@$"\S9(35*$B)IENJ3D#:SI^0(*2)GB("8&#VARI!H
M3ES/*%).#4&^!T0FGEPW'UO\+U?X[Y!E&,A)6<J)_3[>[_?Q=^SWC[H],M#N
M".&>^4(P#>'@VK(UM^.R,KV2/ EP=8>;SEA/OIW>T-2CQ\QW#X?VUNS%N^L+
MO$#7-2GM)S8L_@/5\!5\??NZ;<V-HO,"O]1E5=!V3/L9-K=(@$,1]D&)-9R%
M[!H@S6<,@5V#<@5VX3AG1!<+M* G1ME;@]:/6^(@Q+D$@]-!9NFAWB\>O-(W
M&FG1P<6!+7WKQ[?[_>C^;'0Z'@F^3!\/5I>H2H4WBUJO81J\2M%#.QY6QAMO
MNN& L#(>QXWA<HOSG;8T <_7QOC[&PJP/S$N_P%02P,$%     @ #(6O5A'A
MJ#PK!0  [@P  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULE5=;;]LV
M%'[GKR \=&B!*M9==I88R*7#.K1#T-L>ACW0TG$D5!)=DHKK?[^/E*TXL^*M
M"*(;#\_M^\[A\<5&JJ^Z)#+\>U.W^G)2&K,^GTYU7E(C])E<4XN5E52-,'A5
M]U.]5B0*MZFIIZ'OI]-&5.UD<>&^W:G%A>Q,7;5TI[CNFD:H[375<G,Y"2;[
M#Q^J^]+8#]/%Q5K<TT<RG]=W"F_304M1-=3J2K9<T>IR<A6<7V=6W@E\J6BC
M#YZYC60IY5?[\K:XG/C6(:HI-U:#P.V!;JBNK2*X\6VG<S*8M!L/G_?:?W6Q
M(Y:ET'0CZS^KPI27D]F$%[0276T^R,UOM(LGL?IR66MWY9M>-DLG/.^TD<UN
M,SQHJK:_B^^[/!QLF/G/; AW&T+G=V_(>7DKC%A<*+GARDI#FWUPH;K=<*YJ
M+2@?C<)JA7UFX5#PY,KK-'&A-1G-15OPFA JKRNQK.K*5*3YRT]B69-^=3$U
ML&MW3_.=C>O>1OB,C2#D[V5K2LW?M 453Q5,X?#@=;CW^CH\J?&6\C,>!:]Y
MZ(?A"7W1D(7(Z8M.98'+%3_(PFVE\UKJ3I%+R+NCA/PEEMHHT.KOL93T!N-Q
M@[;4SO5:Y'0Y02UI4@\T6?S\4Y#ZOYP()Q["B4]I7QRXCIC&(%:RKCE*>B-4
M,>;]2?WCWK_\_/$6#*UK%)M^Q2PR]A*P48H9_KMH.[0!'K" )ZF]IEG*WC;0
MZZ 0^;>NTI6M76W?EYV&&]BN61"RJZ+HEU@89RR"F5N"+WDE7+'GI5#WQ+S(
M]W$)9DYOI=!-S&X-=KV(]:CF8*<%DAM2J#'1VPPA$#,O3=E-IQ2U^99#JM5U
M;X)6*W06S;PD=/^?I!$U5^/!@K#4+$F!M @TCH:@6<A/ )X,@"<_ /B8#[E0
M:ENU]_Q!U%W/Z.(X86-4^ _+CX&]?@(!>W[E':RSQ$]8D+($+ D"=MU5=0'W
M-,MB?,\R-D/>@WG(OE!9Y;4%/<C8'-\B_&/O>Y&7\ 4$LK$0N+*VZ+YVK]*4
M,-R'SM+86H@R;'L>I!TJEB\],B#-"6#2 9CT!X#!(=*IREB71;W5E>/UTTZ[
M'8/@M(VCSL3&OFC-32E:+EOB6Q**A0G(-\]8F"6HGYA=D]D0]0(VAV8CG2!2
M,_=9&*&:@5>8S 9)*^$D2T6TETVAT0>Q4^ Z/Y!U,E9Z)3NU%[:@9!",YNZ^
M%W8B3A8G]E[6$B6)A_O5"L5Z*#"W_88'\9S-9_8IC*,=W$=G&2#.9G,6X?@
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MG'T;?.T>M X^/[R2O?N@"G[I)+M'..$\$(3TN%EKWV%!=CA_)U%P,S=2;OK
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MA]\MCE0P7@#O:ZW=T\8[&(?T\E]02P,$%     @ #(6O5NFT-Z?Y @  4P<
M !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULC57;CM,P$'WW5UA!0B"Q
MF]LF+4M;:2\@]@%IU>7R@'APDVEKX=C%X[:[?#UCIQN*R 9>)K$]<^:<L3V>
M[(W]CFL Q^\;I7$:K9W;G,<Q5FMH!)Z:#6A:61K;"$=#NXIQ8T'4(:A1<98D
M9=P(J:/9),S=VMG$;)V2&FXMQVW3"/MP"<KLIU$:/4[,Y6KM_$0\FVS$"N[
M?=K<6AK%'4HM&] HC>86EM/H(CV_++U_</@L88]'_]PK61CSW0]NZFF4>$*@
MH'(>0=!G!U>@E <B&C\.F%&7T@<>_S^BOPO:2<M"(%P9]476;CV-QA&O82FV
MRLW-_CT<]!0>KS(*@^7[UG?T.N+5%IUI#L'$H)&Z_8K[0QV. L;)$P'9(2 +
MO-M$@>6U<&(VL6;/K?<F-/\3I(9H(B>UWY0[9VE54IR;W>@=:&>L!.0O/HJ%
M GPYB1TA^_6X.J!<MBC9$RAIQC\8[=;(W^H:ZC\!8J+4\<H>>5UF@XC74)WR
M/'W%LR3+!O#R3F<>\/+_T'DML5(&MQ;X5[% 9^EH?.L3W4*>]4/ZZW*.&U'!
M-*+[@&!W$,V>/TO+Y,T X;..\-D0^A^$%P^\4@*QC^,PRHM/=]=T;)2B&X O
MF2^F-RF;BST=(P=6"O6*5[2Z;<+NL]?Y&1N/$O:%;A.7FF^L69$\9#DO1SE9
M$LC>22WIT-5^M=Y6#EG&BW),MLQ+]M$XH2BV4\!&/!T5K.1E60[4INAJ4PRJ
MNFC,5CMNEEV.!VH0E5EI^9,X">1"<[BGQH7@)50&@_?*F!HY&E7W57(X9ZCD
MHJ>29!)V]5<&=C(^+;T9>U,,J"X[U>4@@_F1PIX"T$[LI.^57GU-]=B!1:'P
M":^^"@SG?_(LA0K<]!!A)V6>LY."CLW)*,G8_!^<D*5ERM*"SE'16['XJ-$U
M8%>AG2/M+U6C[7G=;/=B7+2-\K=[^]Q\$'8EJ58*EA2:G(YH^VW;PMN!,YO0
M-A?&41,.OVMZ]<!Z!UI?&N,>!SY!]X[.?@%02P,$%     @ #(6O5IA%VV]H
M!   P L  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULQ59M;]LV$/[.
M7T%HP.  =:P72[(SVT#LI.N*M36<>,,P[ ,MG2.BE.B2E)WTU^\HV:J;V$**
M?1@,4WRY>_C<\7B\T4ZJSSH#,/0Q%X4>.YDQFZM>3R<9Y$Q?R@T4N+*6*F<&
MA^JAIS<*6%HIY:+GNV[4RQDOG,FHFINKR4B61O "YHKJ,L^9>IJ"D+NQXSF'
MB05_R(R=Z$U&&_8 =V"6F[G"4:]!27D.A>:RH K68^?:NYK&5KX2^(/#3A_U
MJ;5D)>5G._@M'3NN)00"$F,1&'ZV, ,A+!#2^++'=)HMK>)Q_X#^MK(=;5DQ
M#3,I_N2IR<;.P*$IK%DIS$+NWL'>GM#B)5+HJJ6[6C9T'9J4VLA\KXP,<E[4
M7_:X]\.1PN"<@K]7\"O>]485RQMFV&2DY(XJ*XUHME.96FDC.5[80[DS"E<Y
MZIG)O6(IH'<3X%NV$J!IY[[Z7HQZ!O&M5"_98TUK+/\,EN?3#[(PF::W10KI
M]P ])-:P\P_LIGXKX@TDES3PWE#?]?T6O*"Q-JCP@G-X7"="ZE(!E6MJ7MC^
M-UMIG$W,/Z>LK['[I['M[;G2&Y; V,'KH4%MP9G\_),7N;^T,.\WS/MMZ).Y
MDEMN;X*F>!-?4C_%MQVQL[R[P8@2PH)>$.MAVWCD7AHFZ(.26K_<APRHYP^P
M=0<#\HQ4*LN569?BA%8W\DEW$.RQ7ZR_H048"QI%MG7#%H^%C<?"5OM>1O;F
M0)?F<@N86<Q)M[7#GG4;-BYYSXH2<QOU*FN[0_L/7^\GFF1,/4!*C:0F YJ@
MBA0\90;G>)'('*@V.++D2;<?DVXP)-UP2):&"_Z559D.0WOSZI,9XL\+R *V
MH#2>S8\HTT1!RLUK^881"?HD#,BL5 J*Y,DB%EK4K&&]QDRM24 BM(C@U8=\
M!0JO?Q,]Z,^6P(B:P(A:3_ 36IJ60%DN2PP!RHH4C1(5Y\;T4X'1#GLV,#Y*
M0V6])XEI%/5MB\<V9]I02\0ZN4"A7&)>,AG#$RP 1YA*B3=TB8?F?R=\0I"N
M2D/Q2'0];S(%^Q5-/,\EP^$YB&/19RB:/QXPD$(4G(/X)O<,P-)[ J:('Q#,
M&BU&5%(Q!F/\_V25N F>^ >S2@J%Q(=Y'_)4XCU0^')7$<Y/)^;V+<X&TO(.
MG2$$4]2*7)" QNX0VZ#?)[>EDK1SNUQ<$(_V_<BV[H L2JTYNEB5R)5V%LOI
M!>D'+NG' >:J#2OPH4+?%[3S?OX7JL8Q"="A4\4-UQG=X U):>?7Z=RN14C#
M);.,UUHEXG9F'ZU:&&*@QF3&"I;:[0XT9]<W=M7###-$4/85DY1E WA<G>GB
M=USLHZH_)->E?7C%L?+UTBH'<:5\M^,85&O,%PG"OGN+*VB>YT;DTS.'6\M#
MW[:#^#]%1N^HJLH!T[*M'3'GV:Q1%UC-;%.>7M=5V3?QNK;]@%F=8SP+6*.J
M>QGC&Z/J>K$>&+FI:K25-%CQ5=T,2VQ05@#7UU*:P\!NT!3MDW\!4$L#!!0
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MACD]U:#M =I?*(6[B;V@>?S'?P!02P,$%     @ #(6O5J\<Y8J$ @  H 4
M !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULE53;;MLP#'W75P@>,'3
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MNU'K_J60!"V)=P^ B*4('L<4DY#FK>L0?!$$'CK;%3H+>881 2N%R!^6#MH
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MHY;V="$%=G@T ,_G"L6CN: %N@^ U_\#4$L#!!0    (  R%KU;;$B6PN ,
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MB<:89--VKW;C=.T[QEH[[#]^66+#!T,,2"^T=H<-*>A^(1;_ %!+ P04
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MYN<A[3UR<1C9S]&%ZW@-LY@&Q8%]AKAZ^R:;I!^.\"X&WL4Q].HK<$<\B>_
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M;#^=K5WVL_EHO88,LELQ 9-F9!7$.+V,U@]CQE'HV2E[D*P<_;IL<2:94\+
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M6PYL01^AJG5U11@"AZKT9LV1KY>[^S"CM?LSWCSVUI&!L22I-CH*S 8 <[E
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MU0@%WU,I@4OA].XFB-ZZVN:K*_>JM9-&XQZ@C#$Z:#3254V-PD7J*7(<\G$
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M/G:<VK'\/$83KP%GB4N02YF,YZH,*(2FG=&_SKHD$\^FB>'>VL'4YZ0MZ=Z
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M9=H\\)P#N?*!!H<A6M! -;W5>M_8CX5GGC30@4U4LU#-1C4'U5Q4\U#-1[4
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M\;A9HA#TQYX$1)!8+A[;:T;+KQ7M>&PM[H@P[EP S@*A%+-_NP_F,%F6N+B
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MLWUK$#_T,_[ER0V <3:?43>\0;. N>D-,N."]N0W _>AG^Y'SF\QA%A4N#X
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MMZ.J22PU^VE/AMOCD7Y>&H.]*TY80D;4;=6#C/JZ@&(#Y_'/_&%I#$&[NWC
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M@(US.AMWTC<(AC<%SIL#TRH!(:-=2QABE.'^^.HU7"E&G/8<F%<)Z(BGK1W
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MZ+Q';N(8"9EJ(DE$P]T(4*\=+BPU*9QGHH'3(_3V:!=AY3;J)%H J?DI04/
M\0-@*_IH)GBII$(DEB[(&C"GM$[YN)(F@$T!NR'H07- "'6(39(.-I)6J5Z8
M"#"PEU%01;!,0/*(JVU3J$J-#:;7C'G^DGRMHREO3UBP^_.V([!*WEZ6>7O9
MFK=_U)8[^9H8$1M+7RO4L:6O2S"_(["*A,-2PN$;ODZ&76K:)9C?$5A%TU&I
MZ:AU6=[G[PK<_FI-L<74\X\2$W<%Z1*:=,SQW'RSI;?<JYG3<X<3>[4K4+/5
MJ&KEOV95H30N*8V/IB1?5+(F:N.#J!UDY;?&>.*D?BP5^-BJP(-YYY+Z&[:U
MY+0B'IL>78+Y'8%5E'2=[=G!><.B4X!W)&NG:'Y7:%5A=PYE;L>5IP"L9YY;
MR\_#S/Q7S:J\O"TO[XW*3P%<CVA0Y]=LYM7YM89YZO1NCWYNZREH]L5LR8\J
M0>V(1R=+IT>^KM"J:FX/?>[@+:M0E[OHNT[1_*[0JL)N=^5N^[;\A"ITV91^
MSLBI?%X4I6:O^J[A5;,JS>W.V6W=1/Z?HC0\B>XI7GX[B6/7@KUS8XAILC W
MKY*8.X;\1J[L+6]W;\R=9JW_5M_ZFIO(+4Q^9?P)RQM+)8EACI!.;X33)_);
MV/Q!\<S<2SYRA;EJFA&@Z$(;X/]SSM7F00]0WH7/_@-02P,$%     @ #(6O
M5FDITF)##@  1J(  !D   !X;"]W;W)K<VAE971S+W-H965T-S<N>&ULM5UK
M;]RX%?TKPG2W<(#=C*@'):6V@<1,VP6:-E@C[8=%/\@SLD?(S,B5Y'A3],=7
M&LO#ARCJ@<-\B.TQ>2@>\?K>(U[J7CX7Y==JEV6U\_MA?ZRN5KNZ?GRW7E>;
M779(J[?%8W9L?G-?E(>T;GXL'];58YFEVU.GPW[MN2Y=']+\N+J^/'WVN;R^
M+)[J?7[,/I=.]70XI.7W#]F^>+Y:D=7K![_F#[NZ_6!]??F8/F2W6?WE\7/9
M_+0^HVSS0W:L\N+HE-G]U>H]><>(?^IQ:O+//'NNA.^==BYW1?&U_>&7[=7*
M;2\IVV>;NL5(FR_?LIMLOV^AF@OY3X>Z.@_:=A2_?T7_\VGVS6SNTBJ[*?;_
MRK?U[FH5KYQM=I\^[>M?B^>_9MV,PA9O4^RKT__.<]?673F;IZHN#EWGY@H.
M^?'E:_I[QX30@="!#E[7P5,[! ,=_*Z#/[5#T'4(3LR\3.7$ TOK]/JR+)Z=
MLFW=H+7?G,@\]6ZFGQ_;&W];E\UO\Z9??7V;/32WL4Y/-Z&X=[YFWYW[_.&I
MS"KG9^?OS<JKTGWS_=WWYC8_M(TN6%:G^;YRHC=-BR^WS+GXX8WS@Y,?G4_Y
M?M\TJ2[7=7-I[0#K37<9'UXNPQNX#.(YGXICO:N<C\=MMI4!ULV<SA/S7B?V
MP3,BLFSSUO')3X[G>I[F@FZF=R>:[FQZ=]<P&_]\F_P3GC^$EU>;?5$UMZ6]
M28W9E\T=.SXXU<OMJYS?VAY.7F>'ZM\Z^E_@ SU\^]?E7?68;K*K5?/GH\K*
M;]GJ^H]_(-3]DXXZ)!@#@4FT!F=: Q/Z-5_?=>'4N[S<.H]I6>>9=@F_8-$3
M5OL']=MUZ(9!>+G^)I*C:46H1^56K-\JB&F8G%M)TPG/TPF-T[G9I<>'K)W+
M8YD7I?,]2\N?L^/6^>V0'>ZR4KLRC)!S5P82C(' )"KIF4IJU^ HDE8D& .!
M2;1&9UJC:0;WD[-Y6:R-V_A1QY\9Y\)[Z[H_OM%Q]=*1$,&TW+>N:G]&^(4D
MQ&<28N/%?WPJFP5E-$HCP-S5@P1C(#")N.1,7&+7*!,DK4@P!@*3:"4N#P)=
MH!_LP$3G1>* 1HHCU#3S7)(HS5C7+)30(A+J72$1 ELRQ\J<_SF+W*-YE+EK
M!HK&4&@RPQYGV+-KCAT^BELD&D.AR=SR>)\8X]X9CG($Z"(9])1=3]55QJJ!
MVHC0"0_1B3E&_W*KG;6QT^RE@T1C*#29,"X"2&C9+*&2 (K&4&@RMUP5$&-T
M/-=1TKZCC&CHJXY2TXS&I&>'M.\H:1 ' XZ2A^3$'$M_N5WL&T%1=$<#$HVA
MT&12>8A/8LM&")4 4#2&0I.YY2J &*/A.;XQT7HX]9'-0#-/-4 ;0;K'@W3/
M'*2_K_)T_?Z^S#?-EZ>J+M-]VGQDM% SY-Q5!$5C*#293JX//&+70CVH,H"B
M,12:S"U7!IXQ.I[I)CLPR?^Y8:"8WXVV64+5)SM=,\E-NAX9>+3J\8C<,P?2
M8^:WU(F:AYV]C*#/YE%H,N4\]/<"RR8*50E0-(9"D[GE*L$S[Q5,=Z(C0!?!
MH,#L>JI^-7*E?T0U8!LAOL=#?,\<XM^DQW2;.FECMG]KEYOS_I"U1F\V8NCC
M?B@:0Z')?')YX466C1BJ,J!H#(4F<\M5AF?>29CI9^.> _7C6%6CNE94W>5D
M72O1R_I>0 :<+ _M/7-H/VI\B[TL]-$_%(VAT.3, JXK?-=R;@%49$#1& I-
MYI:+#-^\"3'=RW9 \WSEC;X7496K^2J7LL#E@&^6 Q^K.KW;Y]4NVSJ?TO)K
MUBXJ@[&:X68O*.B^  I-IE+( [*="(3-!,*F MF0&SZ7&SXR&\COI_#XC;7&
MJH5JFL4^"50+#?K^E$:^IW>H/@_S?7-T;C*]I;[4/.3L)03='T"AR71S\>!;
M3AORH4("BL90:#*W7$CXJ-RA$: +?U"Q^OKLH9ZUV@C[?1[V^R,)1$U0_- N
MJ[\T7>O=-)\*W4^ HC$4FDPG%QV^Y;0B'RHNH&@,A2;GUW)Q$2 SBP)-9I$?
M^FIFD;:9WXMZ TUF$4F\2.]3 Q[4!R.912/FM]2OFH>=NXR@: R%)E/.%41@
M.=4H@$H**!I#H<G<<DD1H%*- GW"D+I1HV_6-T\KF?]"ZK\YVO_E>"R^I>VI
M(^=3MLTWS:_U?Y.@>PA0-(9"DRGDXB*PG&D40)4$%(VAT&1NN9((D)E&03^%
M*"!>0E7+U#5+$O7A;M#/-/(3E_@#CI-'\($Y\-:9W&)G"=T5@*(Q%)I,,Y<'
M@>7<HP"J%:!H#(4F<\NU0H#*/1H!,IQ@"?3I2&H^H'F A4R$/+(/S9']@#%/
M.-QB!IY]Y RZ7X!"DTGETB*TG)040C4$%(VAT&1NN88(D4E)H2;;R ]#Y4G0
MC:Y9D C91MW4-4E)_F#N;LAC]] <NT\SPJ4^UCSX[,4$W2M H<G$<_406DY-
M"J&R HK&4&@RM\(I9E1JT@B0X>Q+J$U-(FHNDGF I4QP$1":1<" >>N/Q)BQ
M9J\HZ-8!"DWFD0N/T'(.4@A5&U TAD*3N>5J(T3F((7]["(2QDFBNE5-LR!1
MF[&PGX5$ C\8V#4->90?FH/S0;M;[$FA.P10-(9"D]^SP'4$M9Q^1*%R HK&
M4&@RMUQ.4%3Z$=6G'ZD/D ::J0^0S)>U=-H\TJ?F2'_ ?)<<H#&/-'MQ0?<-
M4&@RRUQ[4,NI2!0J+Z!H#(4F<\OE!46F(M%^CE&<>*I/U;1*_%YJ ^TG(L61
M<!95GA"/Z:DY%%]HDDO]K?EJ9B\MZ,8""DV^$\*+C6R_V0C[:B/LNXULZ S*
M=09%I2B- !D.U5!]BM+(H1KS>$N)X2*!FD7"T,[/DK,VYJ%FKS_H[@0*3::9
MZQ9J.9.)0G4*%(VAT.07EW&=$B$SF2+-RX\2->OW1M<JBI03.2SJYS%Y 1TX
MT!IQ<1"9Q<%2FUSJD\V7,W=M0=$8"DV^%5RP1);3FR*H3(&B,12:S"V7*1$J
MO2G2IS>I;XO0-^NE-YDO:^FTN8*(YJ<WM3M#,X_BF$>9O;"@VQ0H-)EA+FDB
MR]E/$52D0-$8"DWFEHN4")G]%/73FGPW#-2C.+IF) C5A\I1/_O)2V@PD/T4
M":\^793]9..$COE*9J\LZ'8%"DV^"UR)1):3HR*H_("B,12:S"V7'Q$J.6H$
MR'!")](G1_7>[VM#+,1<+,3+DJ,6'-PQCS1WO4'1& I-9IDKF-ARME0,E210
M-(9"D[GEDB1&9DO%NG<S13T/K&T6^JKQQOULJ<2/7+T#CKD2B)<E2UDZSF.^
MFMF+"[J]@4*3[P07)['E[*D8*DN@: R%)G/+94F,RIZ*]:]G4H_SZ)OU]*[Y
MLI9.FRN&V*P8;M/CMOBO=IK0_0HH&D.AR:1Q21);SHN*H4(#BL90:#*W0I$'
M9%Y4W$]X2KQ W<+5M:*^NM<3][.B&OU*!]PGC^YC5'0_ F38W(IUT;TZ/1NA
M?<)#^\0<VK_\H5D:%)C!YQH,%(VAT&1B>32?6([F$V@T#T5C*#296Q[-)Q.C
M^5';'0$RV&[7TVB[9O2E-' %D)@5P-EV)YQ2,D/-7DW0\!V%)M/(P_?$<OB>
M0,-W*!I#H<G<\O ]F1B^3PH;.C#I0&]"U%<Z:EJ%7J2>)^Q:A5(K?^"5C@D/
MS),I@3GN4))YN-EK!QK.H]!DJGDXGU@.YQ-H. ]%8R@TF5L>SB<3P_EQ#VH&
MNHB&/6BL%>1J?&\>8"D30A$V<_A^-FC],21S[]EK"%MES4Z9-;'.FN7##J\#
M@.C%PC$8G$*P4/3-G7CB86(E.])_(!WU#OEJF\6]0[ZOS:2=8S)T&HFXGC K
M<]0MF-SB6CWF(>8O'&RU-12<0K%0;\VU?)KA=0 8P5#% (-3"!;*N+GFA*09
M57M&D P:=+0K"8?ZLI&^BRD2"K>YYMC_;.9+3BJ-@,]??]BZ;2@XA5RA<IMK
M^=S#ZP P@J'2 P:G$"R4D7,G'GZ8Z'JCOD^E/>FJ;T9[I;FZ9M))X- =$*_$
M%>JXN>9P?;)-+G?,V$IO4#@&@U-N@%#LS;5\IN%U !C!4$D"@U/*) N:9&KQ
MYW''/()D2-MZ[3KVPHV1(1;3(9:--BL(OK^SY'#2"/KLQ88N&&VE8K18,MIZ
MS6APT6APU6@[9:/%NM%3"T=/\\(=FKRCK&X[ZUK%4<\'=ZU$'QQ%0^I7+  ]
M4@%ZND4N+_(.W9# PC$8G'('!&%BO:0TN*8TN*BTG:K28EGIJ76E)_A@.L61
MW@RU4P\7CES9XKD+NF&D_C3?()IY-FD$>/ZBPA:@ME.!6BQ!;;T&-;@(-;@*
MM9TRU&(=ZJF%J"?ZVJ3G16E W9[A:IK%H?J*G==FDK=UXX%3P40H,TU&ZDQ/
MLL?%GA9;D1H+QV!P"OF"^K!=E9I@RU)CX1@,3B%8$"!32U./>]H1I LZK';'
MN@X*93;2=3%#@H(8*73-[7_!::41\/G+#[L+8J6@-1$J6A/;):T)MJ8U%H[!
MX!2"!:DRM:[U-)_L]5.CO"CN"6!MLT@]MZ1M%H8#!8>(4).:C!2EGFR3R_TR
M=G,#6\(:!J?< $&DV*YB3;!EK+%P# :G$"R(E:FEK"?X95V:5,]B];E4O9P-
M\V4MGK@@(D9*7O]#LY:X,4^M4C0RROSEA=WDL%+BF@@UKHGM(M<$6^4:"\=@
M< K!@G"!5;H>0S)41B$#5;+55.:1(>;2L6XD<%:SM$ZO+UO_F]UD^WWE;(JG
M8P/?:H_SITZ9W;=LO7OOK=:]SS^0=XRTGZ\YS/7E8_J0-7Z\<>N5L\_N&TCW
M;?O^E3)_V)U_J(O'9MXKYZZHZ^)P^G:7I=NL;!LTO[\OBOKUAW: YZ+\>KKL
MZ_\#4$L#!!0    (  R%KU:5C4*7KQ<  ,4, 0 9    >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;,U=:W/CQI7]*RAMLB77)D-TX^V=496'[74<9QR7Q_:F
MDMH/& J2L$,2,@AI/%OY\0$UI/J);C3K-'?RP=%(MP^ V^S+>W%N]WGYH>O?
M[^Z:9HA^VZRWNU<7=\-P_^5BL5O=-9MZ]Z*[;[;C7VZZ?E,/XS_[V\7NOF_J
MZZ=!F_6"QG&^V-3M]N+JY=/O?NBO7G8/P[K=-C_TT>YALZG[CZ^;=??AU06Y
M./[BQ_;V;MC_8G'U\KZ^;=XVP\_W/_3COQ;/*-?MIMGNVFX;]<W-JXNOR)>,
MDGP_XLGDE[;YL!-^CO;/\J[KWN__\>WUJXMX?TO-NED->XQZ_+_'9MFLUWNH
M\49^/:!>/%]T/U#\^8C^7T]//S[-NWK7++OU?[?7P]VKB_(BNFYNZH?U\&/W
MX4_-X8FR/=ZJ6^^>_AM].-C&%]'J83=TF\/@\0XV[?;3_]>_'3PA#!@?U#R
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M2><>)H@'$@N:;/%YSVN=IA;?]<W*L4/)<;/^'U-HP0&#4R9+D(V+ Q_;>KP
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MN37^']G]_X%2-MJ>QT514\I:@KRH*66C+2D+1SNDS#?6V[=_^^[2JW]P16)
M=, %,P%IQ8.M2>V7/_@7=Z?.W!5:G7KCS'UXXL4,CCZOE]RZ1,.NT.K<FDF"
MWW&2T*E)2[#-_H/(:QJ.MBC8C,+[L(J"^ANKDA(J%OGJ+@FF?)VJ8G%/=;1:
M0?8Y7S?5.'X#KW"Q#LS %,O2[HA8L%2"F,XUI'<9:>40Q4JO8D?Q5;[VZ8DK
MQ9-\<TF)?@-G ?K\G'/UOI-=H%IO-_D?4$L#!!0    (  R%KU9OU_A1KP0
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M C4% PA%:@XZ:*C+P<Z70+LQ&1PM39QUU*U,($^=AP:0/U3ZSHM NQEY?;Y
M@]5 DYF:@0$%(]61F% >G XDT9D2:'<E#TFY)O\9Q5L#W]S]QF2+QV+K%ZWS
M0C!ZY\EB-5MOKNV8;/%8;/W:=J8-VEW;!0W98+:TAJQCD-:0#9BA>=)Y-F@W
M;1?UXYG>C53].D0=.K$! Z%9/^I,$[(:A^%FW,3U1IPBV@!1NY@! @<:,>K,
M"+*;D=<;,=*]@S;##9A0M?D&3. /R.\L"+);D!6A>R(ZB/%9L<>^M5.,RA:/
MQ=:O6V=]T#OO$Z%1-XI&98O'8NO7MO-DR.[)7N_"2+=4H?I&&:R9]D89,.&
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M^51)S*M.374CV:KL73PQ*5E>7J9 8N#:0#U/&).[&SU!TR];_ 102P,$%
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M7.D[T39+_<P!80!Z?L:Y6G?, MW#*?T#4$L#!!0    (  R%KU8]&DZ5_P(
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M"GO?O2JW4C(#N36GRF=\Q"6,.YHX3(8=11PF8[<>PT:/X?_,"4J!DBS97)8
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M6'1 L>EV !2:Q.:T!D)1YA"N9RO$/UL9L()"@!4!0(R-@L0 **>8HUTN_O6
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M2]@?"FT!01/3_T P1)'Y^ '(QH_&XKYR;?QHL-TBIPM0%'!\]JXH &7OB@)
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M31XKB6;_"'>2S[)-(V Y<>K<' A%1<RYI_L2#!YI!H]P!L?O7'>).4Y\NTP
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M$<"WX"U^_06/@]]L#G8)EC@"ZS@_;IT?#Z$O/A85H=PX4,5 J-*6LE5)A0F
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M8M,7QDR#5O))IO=]*KEZ2Q1.3GZ ,@U1@F>$$OF,<!8CL_D=EG16ZA46 J1
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MSO^[[51GCUGYH*" N<NC%R)UFC1LYEO/A,3K-#1F#:X<!]>V2>?E4JUJ+&*
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MUJ#Y]_NBJ%]^: MX+LHOFVK?_!]02P,$%     @ #(6O5JC@_)T("0  )&
M !H   !X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;,5=78_;-A;]*X*W6+3
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MW>P]MC";K=#7FKZ\DJA@=QHR.AGKEHG-[N+-@>++>K_M+5>*E_7/!4LR)DR
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M/%ZW(Q4RW0!SZ>>TWBJ84 W JY*=/$C_]UBFU28])$+0,$#@XXQ0,PR(RH]
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M)?M>2)6D6<F\']B?V,^?!/O^U0_L%4NW[$.:9=7'5UY/574R->1TV1[XW?[
M_I$#>S[[D&_5NF0_;E=R90),JRP.J?C?4GGGDXA"+E^SP/LC\V>^[SBAV^'#
M/<=P,7SXC,@F.'PP08,7','[I!(E*X$I]KE^BZ75L_+?+I[W.-R-4U\WWI2[
M9"EO)M6%H93%DYPL_O"=%\W^[.(("29 8 9__, ?I] 7?RGRLF2_)-FC9/E]
M,[VS^I5E4A1?J^OE<U*L2J;6B6+KY*F**?9_M[EB=U)NJ\!=JI(L_6\ECJ2L
MKR6V4%P?QOZDHN:DZFONTV+N\6H^/'5)[@=%\=65&23(]$XD+SR0%Y+D_=/-
MEORR2PM;J_N\]WAA-R4KZ7Z$-[=2#GN\>/P08B02'1*)R$3^42GGJTP*]GDC
M-W>R< J(A!@K("28 ($9U,4'ZF+0!2A&\H<$$R P@[_Y@;_Y)5Z YK\KLUM'
MB'WQ(5,[D;BK W%7],7G.6\T6Y*B)3'&3CHDF "!&=QY,[V>FX%DVP*!*(2B
M"12:26)G4>Q=HG;;L^HJD_N6>!TQOK6^$'1VI[+G:_9\6L#K0LH!$J9A1D]
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MGN$=T6!$&#)PGGJS05IO8(O((0O#9++P#WT?'4)I&G="C]B3CCWY?^QH#["
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M3R@(=!R Q(2*3^@4W=T$Z/CH$SI")$%7A%)56S&TI>I8R^VHZ.0B[\1[I9,
MHC/4<D^0YWA>C?QR?[E;(P_VESLU\G!ON3NHRFV5[#+C7IEQ+^.U7N,1$5$F
M4@Z(S="2LQ7)OCJUZ#EY1/<Z'A$)L?A=E^D<WJZ':ULY%TL<P<A2OB& K\#R
M/WYPN\[GNKR;A 4F8:$A6*5"K;)"K2:Z?\LDIDAN?QDG* %95Y*<ULUHVIA7
M?M_I=H?V:C/5=4%.IQH4-([KT!0:@E52V"Y3V&Y.X8ZMW,<03X#7KNE&UJ%K
MVB0L, D+#<$J!>F4!>F\I^MT3%;()"PP"0L-P2H5ZI85ZAIUG9S6:7:=NJ =
MUVD<UZ$I- 2KI+!7IK#W1M=!?]$WSH1 $>;\B21SA&.6)K+1EAH[.W31FX0%
M)F&A(5BE8OVR8OWWM*6^R0J9A 4F8:$A6*5"@[)" Z.V--AU'-?K;]E239#3
MWPH*&L=U: H-P2HI=)V739;S=F,:EZM>[?O1E*43.4OI1G2C237W?.@W8)06
M&*6%IFC5&FYLE-WWM*J";JI.)FF!45IHBE:MT\OVVFW<&_K__9QJJ^/M;,].
MN]Z6:]4%]5M;KE47--@*"FN#7OZ6Y3.W-TYU]*'=%>9SD@A$8:94SEE/^2?/
MS\'RAF3+[*!GPJ1D<7:[ &4\7 >H]S/&Y'-#GQV5IY'^/U!+ P04    "  ,
MA:]6!NQJ'+H#  #E#@  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL
MO5=-;^,V$/TKA+HH=H$F^K1BI[: C=6B/00(DJ8]+/9 2V.;6(IT2=K.%OWQ
M)2E%D65:2;%N+[%(O7G#]T1..-,]%U_D&D"AIXHR.?/62FVN?5\6:ZBPO.0;
M8/K-DHL**ST4*U]N!.#2!E74CX(@]2M,F)=-[=R=R*9\JRAA<">0W%85%E]O
M@/+]S N]YXE[LEHK,^%GTPU>P0.HQ\V=T"._92E)!4P2SI" Y<S[&%[G860"
M+.)W GO9>49&RH+S+V;P:SGS K,BH% H0X'USP[F0*EATNOXLR'UVIPFL/O\
MS/ZS%:_%++"$.:=_D%*M9][80R4L\9:J>[[_!1I!(\-7<"KM7[1OL(&'BJU4
MO&J"]0HJPNI?_-08T0D(TQ,!41,0]0.2$P%Q$Q"_-2!I A+K3"W%^I!CA;.I
MX'LD#%JSF0=KIHW6\@DSW_U!"?V6Z#B5_29P"?H#%D!V>$%!HO<Y*$RH1.$'
M=($>'W+T_MT'] X1AFX)I?ICR:FO=&I#X!=-FILZ370B31BA6\[46J*?6 GE
M(8&OU]PN/'I>^$TTR)A#<8GB\ <4!5'D6-#\[>&A(SQ_>W@PH"9N/T-L^>)3
M?$06E,NM ,27:"/XCMB3I3>V($_HD\$CHJ"2GUWFU^2)F]R4CFNYP07,/%T;
M)(@=>-GWWX5I\*/+N'.2Y6<B.S U:4U-AMBS1T4H^0O;^M)U52)=+U')MPNU
MW%*D^D? Y7"=*;693"W=95$4I7KG[+K6':/"R3@>'Z)R%RJ:)"WJ0.RH%3L:
M%'M\D#]54"U ?$9_H[MV0QTH?T&W8)?VP<3_=G>=DRP_$]F!X6EK>/I?'MGT
MG*:>DRP_$]F!J5>MJ5>#N_CUC8H56L"*,$;8RAH/@O#2Y7"=:=0Y9A?CN'=@
M'9A)#Y.[,"/W81VW,L=OD_E:*4+%&HL5E$AQI-: "AW"*2FQTG.$%;P"))4>
MZ:N8<IDP/EY\<M4SP8&))ST3')C1Q&W"I#5A\K^5Y\G1\GH"YJ\B\F-$&+L5
MAL'+[2H8U'@/.Q 2TV\6V.3IKFZ4]B0Z,''2$^GB.:6R<X<,!U7.MT( *[X:
M*4S2^I/"<JGO]FXQX?%"^UJ.(6E?RC'DXL2Y#*,7*=&W%R!@Y7#I:9)T_\5?
MI%%?H@/4+U"Y"S3I?S"_<_^O0-<+TT?IVL&W3-4WZG:V[=4^V@ZE-W]C>CC;
M5[S0U W@K2Y#1.]<"DM-&5Q>:=M%W5/5 \4WMLM8<*5[%ONXUGTH" /0[Y><
MJ^>!2=!VMMD_4$L#!!0    (  R%KU8;1?'6$@4   HL   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,BYX;6RUFM&.FS@4AE_%8JM5*[4#. E)9I-(;<QJ
M5VI7HTZ[>U'MA9,X$U3 6=M)9J1]^ )A  /CA.IP,X%PSF=S#OS*/_;LQ,5W
MN6-,H<<HC.7<VBFUO[5MN=ZQB,H;OF=Q<F7+1415<BH>;+D7C&ZRI"BTL>-X
M=D2#V%K,LN_NQ&+&#RH,8G8GD#Q$$15/'UC(3W/+M9Z_^!P\[%3ZA;V8[>D#
MNV?JZ_Y.)&=V0=D$$8MEP&,DV'9NO7=O?3Q.$[*(OP-VDI5CE-[*BO/OZ<F?
MF[GEI#-B(5NK%$&3CR-;LC!,2<D\_LNA5C%FFE@]?J;_GMU\<C,K*MF2A_\$
M&[6;6Q,+;=B6'D+UF9_^8/D-C5+>FH<R^XM.>:QCH?5!*A[ER<D,HB ^?]+'
MO!"5!'?X0@+.$_"U"8,\87!MPC!/&%Z;,,H3LENWS_>>%8Y011<SP4](I-$)
M+3W(JI]E)_4*XO1!N5<BN1HD>6KQ1= -2SJ^9L&1KD(FT6O"% U"B? ;] Y]
MO2?H]:LWZ!4*8O0I",.DNW)FJV3H%&"O\V$^G(?!+PQ#V/H&#=RW"#L8MZ0O
MKT]W6]+)]>E.2[I_=;H[U=/MI-Q%S7%1<YSQ!B_PWL<T?)*!1'R+^)&)S8$A
M&O%#K"3ZE@:C0+%(_MM6YC-YV$Y.5>56[NF:S:U$-B031V8M?OW%]9S?VHH.
M"2.0,!\(IK5G4+1G8*(OOG!%0Z3J+\9;%#/5UI(SS<MHJ2X?%Q/'\V;VL5KJ
MMB!GI <1X[RZEA (II5P6)1P:"YA0U6^12Q:,='Z3!M979]I2!B!A/E ,*TA
MHZ(AH]XD9P39'D@8@83Y0#"M/5[1'@]4<LZTD5ERVH(:DF.<5]<2 L&T$HZ+
M$HY_4G+0_VAY$(+%RJA"1GS7QQP21B!A/A!,Z]&DZ-&D-Q6:0+8'$D8@83X0
M3&O/M&C/%%2%I@V!&7O>L*9";4&#:4V%C//J6D(@F%9"URG]E//S.O075RBD
MB@FD=C1&/'GB(QZKG5&8S -V??1!:024YD/1]-95K+#;FSSE:*@F0=((*,V'
MHNE-*KVS:_1^G44JQU4%R)TZ-9%J"_)P3:3,$^M<QCXLKEMZ7/>"R37)U,<V
MB:+Q!L6Z?JF=8/EEL\,S3Z;SVP%)(Z T'XJFM[7TW>ZP/PD#]>&@- )*\Z%H
M>I-*+^X:O61W"1LUU<EM2%@S:%K_F66>5^<J]N&8W=(RNQ<\\Y4*IHE4BXC)
MX/$J"8-TRDM0&@&E^5 TO:^ECW?'_4D8J(D'I1%0F@]%TYM4&GG7:$2[2]BD
MH4[UWU?+MIA!7<% S38432]B:;?="W[[2@6K*%2+?J6_T)X8%6;U@G382U :
M :7Y4#1]9:^T_]CI;VT/U.B#T@@HS8>BZ4TJC3XV>M3.ZI7CJLJ$:\JT;(N9
MU-3+/*W.1>S#B./*(O8%(][!05[4)_-8G1]]V(5MV)7M/GP_+GT_'O2G3Z N
M'I1&0&D^%$UO4NGB\87E\Z[Z-&S^DWU:UZ=FS'1<UR=0EPU%TXM8NFQ\P66;
M].E.\&.0;7;;<H$V_+!2VT-8B3:K%>B2."B-@-)\*)K>P]+C8Z\_M0(U[* T
M DKSH6AZDTK#CLTK[Q??I=;NC!L;HMXU'&%;T*1N"=N"IK4@OS6HW MQOG.[
MLHTRW27[B8J'()8H9-LDR[D9)R^#.&\\/9\HOL]V5JZX4CS*#G<L41V1!B37
MMYRKYY-TLV:Q_7?Q U!+ P04    "  ,A:]6WDKBT/ $  "A)0  &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q,3,N>&ULM5IK;]LV%/TKA%8,+=!%$NEG9AO(
M8UTWK%N0-!N&8A\4FXZ%2J)'T78*],>/E!71E"FZRJZ^)))][]%]'-/'EYSL
M&/^<KR@5Z"E-LGSJK818G_M^/E_1-,K/V)IF\ITEXVDDY"U_]/,UI]&B<$H3
M'P?!P$^C./-FD^*U&SZ;L(U(XHS><)1OTC3B7RYIPG93+_2>7[B-'U="O>#/
M)NOHD=Y1<;^^X?+.KU 6<4JS/&89XG0Y]2["\RLR5@Z%Q9\QW>4'UTBE\L#8
M9W7SRV+J!2HBFM"Y4!"1_+>E5S1)%)*,X]\2U*N>J1P/KY_1WQ7)RV0>HIQ>
ML>2O>"%64V_DH05=1IM$W++=>UHFU%=X<Y;DQ5^TV]OV>QZ:;W+!TM)91I#&
MV?Y_]%06XL A;'+ I0/^5@=2.I BT7UD15K7D8AF$\YVB"MKB:8NBMH4WC*;
M.%-MO!-<OAM+/S'[R*,%E?V8TW@;/20T1Z^OJ8CB)$?D#?H!W=]=H]>OWJ!7
M*,[0ASA)9.WSB2_DHQ6 /R\?<[E_#&YXS#6=GR$2OD4XP-CB?O7M[J'I[LN$
MJZQQE34N\$@37IS/$Y9O.$5LB=:<;>."EY(6/'Y"GY0]B@5-\W]LN>[!>W9P
M]<$[S]?1G$X]^<G**=]2;_;]=^$@^-&6.1"840=2U8&XT&<?F8@2).H<>(LR
M*FR)[]$&!9I:(+:S43 83/SM84(VHZ!?&1F!]JI >^Y CVCZ*:7I ^76_CBQ
MVO8'",Q(NU^EW>^2IWW(.@"!&7485'48@/)TC]9W\]1FU,33817H\(4\15_5
M6FH+UHG8MDM 8$;RHRKY49=L'4'6 0C,J,.XJL,8E*WC(R*283"NL=5B1'H]
M.UO#0'_[!R_GZT_WM]9O>B=DVT9!H9D%.) _89><+=&A:@&$9M9"BZ+0J35:
M\[:$.^1DV,/U9=9J%8P:F*N52WA"NKB8>WM_:0W8"=FZ6T!H9@&T(@I[G3(7
M5"1!H9FUT#(I=*J/]LSM'W&R1X(Z<2U&0]+ 6ZUDPA-2QL7;7V_^MH;KA&S=
M*R TLP!:(87#3GD+*I>@T,Q::,$4.G5(>]Z.CM?2X;#.VV,C,FKBK=8TX0E1
MX^+MSY<WUG"=D*U[!81F3@RT5,)!IS,#4-4$A6;60JLF[%0BK7E;PIF\K0L%
MBQ$. CMO\<&DYX2H<?'VZG?K>NN&;-VK+B8\6 LE3#KE+:AF@D(S:Z$U$SXQ
M1FK+V]XQ;_O].F\M1N-A V^UI,$G)(V3MQ?628(;LG6ONICX8"V4\*!3WH)J
M)B@TLQ9:,^$38Z6VO!U:>!O6>6LQ(N,&WFI)@T](&A=O+V]_LX8+.OJ!0C,+
MH(42'G?*6U#-!(5F[BYHS41.C)?:[B\$EEE!?;VU&>$&WA(M:<@)2>/B[<6]
M=;UU0[;M%12:60 ME$BG>V($5#-!H9FU.-@6 ]X7(Y:EM/Z[S&K4Q%LM:<A+
M=\:43GC_SAHNZ.P'"LTL@!9*I-,],@*JF:#0S%IHS41@]\G(\1Y8>#":+7.R
M&0T:>*LE#?D?.V5_B!7EUF,&;M36[>IB_$.T5B*=;I@14-D$A6;60LLF KMI
M5L(-3*F Z]RU68WJ/\[\@_,SZO#2AX@_QEF.$KJ4;L'94'*?[\\#[6\$6Q='
M:AZ8$"PM+E=41LZ5@7Q_R9AXOE&G=*I36;/_ %!+ P04    "  ,A:]6Z>3O
MX?@"  "E"   &@   'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&ULK5;;3MM
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M,1M[YQY+8<Y7$F_4YAM4>GHV7Z*D<;]L4\4&'DM6!E5>@8E!+HKRGS]6/C0
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M0)H _7TA!+YTS+W3_F;$OP%02P,$%     @ #(6O5KZ*TZ[M P  61(  !H
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MHDUAZSH&"E=<T+042P]2DA5/_%I^AQV!<TC@E +G5$&[%+1/%71*0>>]H'M
MX)8"]U2!5PJ\4P7=4M#5R2J^KDY-@ 7V!XQN$%/6DJ8&.K]:+3-",E6),\'D
M6R)UPI^\K(AX0Y<!"$P2CIPK=(%(ANY)DLA2X0-3R%V4K1F6Q%%!= X0;0?=
MTTS$'$VR"*(ZP)3N53XZ6Q]'SE%B &$+M>UKY%B.@YYF ;J\N-KCV/ATC'T$
M$YR.L8Y@)N<$-;MCR$0\Q@SV??*[<R+[A#4])[S#K%HFVU6UM36\?0 ^$UB
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MU>K* %C1+A8307/=K<RID+V/'L:RPP:F#.3[!:5B.U$;5#V[_P]02P,$%
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M$JQ90G$-BU,L3F,XIT<89DD@9DDL7I]Z^:;-\DU5X##BS_M9S)(PS)*@S5(
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MO[_?;/;'/_0%/F^V?SOL]IO_!U!+ P04    "  ,A:]6NNA/Q%<$  "K'
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M#-#OYYRKUQMS7E6=3X[^ U!+ P04    "  ,A:]6\H#4(GL#  "F$@  &@
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M X9XA&94W?#%)2X;B@Q?QJDL/L&BK/4<D,VDXGD)U@IRPI;?Z*$T8@T PRT
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M8YB0!5.W?/49JH0BPY=R)HM?M"IC.Y&#TH54/*O 6D%&\_*?/%:%V #H1.T
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M3DN4E_FRH_B\N ^/N-*WZZ(YTQ] ($R GI]PKIXZYHI=?U(E_P!02P,$%
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M$_R A+'6T4S#BFF]-3YA9MX?E=!OB?93BP?!]\1,HD28Y8BK+0C$.+O-=D(
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MU[2VN=7?*2",@7Z_X5P=.Z:P;;]\%O\!4$L#!!0    (  R%KU;VB&EPD ,
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MN'2VN/Y1.U2#6C5MI2UH6V':3J)_V[>N#TW#-GC_:%O:ILWZX:;MAY^HPOM
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M80#Z_9IS]38P"S1M[.(O4$L#!!0    (  R%KU;XRV57)08  $DC   :
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M5!=4M*4 %Y7&)1B"3Q\C</'J$KP"- ?O:9JJ2(J;D51V:?117-EP7]J 3M@
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M)B7+BL,-P0GA6D#=7S$F#R?Z ?7NF?G_4$L#!!0    (  R%KU;H0J;>"0,
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MG9ADRJ8E;"9:;%R3M!3:M%QN6)DV&J0U,/LK(?1A8A_0->;9?U!+ P04
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M3C,HML1%'41C(?%C87"P)D#E$5-S&4 B>Q5XA_ZU>4\C)O$CYO7$3&PPM#:
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M)U"?[^JZ/;WI.C@_I[7^/U!+ P04    "  ,A:]612]KB6@"  "A!0  &@
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MA8V_M,SK]E_RV-D.>B1=U[)<=@>K")99L?D_>>J$V#D@B X<0+L#J'D /W
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M(FP%>$>F:N6L97ONB:J@VRM@)BI8#)OVK@)3"]O&7&EC/%17*302!C@3PD6
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M5+B-W'1DMIE, *L@L&8I/!;77'<:8%_7 >MS/X7[[8SUVQI[B4* ZT* XX6
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MG<I;.P<-,Q/R4\4_\0J!HY-S(F_MY#2Z@/AUP8\> $B?^\^B^:S;U@ZK231
M7:21",0O$9Y[!"!]UC>[>!>CRVA ;Y%&&A"_-'CN(8 XN!UWA9;3:$!@DT8
M$+\ ^"&!35P\WH7;MQDJ></TQ,_T3\MKTJ=LC+OJVF$T)/U)0^KD.2?2YVMK
MTC]U]IJR;S+4D@VWDB?.I4<*:^+@V%ZI^S8#Q].PX=?0SZ_'B[K0P9[AM)M3
ME]7AEM6&VU!LB'_Z+Z GI=]3>6OGIZ'?T'\P/DHN[7U-GZBDPZI?R?'!E4$*
M<E/>I"A3%5.NZO?V^FU]6W-=WE%TWM_@BV5UY]*XJ:Z WE-IV%(A#FOC,GAC
M[TQD=:M2/6B1EQ<3*Z&U2,N/6Z )2&M@OE\+H1\?[ 3UW=;B?U!+ P04
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MGL0,*F&@:!R%)M,M) PC:_8W)_$!7M:Z"0N4+#:%A2Q2_Q+3C9U*QF#]?\0
ML%I^9+I0\(+852<P4U@4^)':]3D$!1."@M&"8G2I\G"]5$HE<:QV5H_R//UC
MGJ/49Z+49_0R.C%9DRLA-*SU- (MYU%H,J6BG&?A\K,VJ"P_T(U$XR@TF6XA
M&1@M&=X\:^N>0A"GZC*F(2H*8BV9YRCZF2CZF9WW("<SK:5H:.L1!BWN46@R
MK:*X9\L;$@SJ2$#1. I-IEOH!S:O*\%TRR%VF6J%&J*2.%67-NFF3GV80 @
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M$5A77_GPU25;0U"D/3%*-W0J$:+*#^B%>V,&G_@8" UM.[Z@:!R%)M,JJOF
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M,S_^!K4@V\&$,VG_HV,5.],9D[U4/*_!NIW3HOHES[41%P _&@#@&H"[@'
M$-2 X*V L :$UIE*BO4A)HJLEX(?D3#1FLU<6#,M6LNGA1GW+TKHIU3CU/J1
M2W4#><GXBQY-A9Z@@(PJB?240M5] (E^C$$1RB0*?UJZ2N<U:#>I<SQ4.?!
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MCT*?V07*@D802\IC)& YM=[@NWO7,0EIQ#\4=O+H&!DJ<\Z_FI/WBZGEF(J
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MO)S;+SH"3S8%<&:;A9;T6/';1![]4_J#Z&7AM]GT]FV2%IL@;&RJ2/V=Z[T
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M1*[RF;*(IXOSCX<"&TNI4_%\]#U\3R32+7E_O&ZH0V!O=>)A##8,]E]-W:&
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M%/UN;):N(.N@$^N0(=7TU4+KA;6]NB<54GU][A3N) P/9W41AXZ-W^''J$\
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M1<5"E9-8N3$R=\/,3!H:C=QR2=,K*BM [^=2FLW&'E#/P]._ 5!+ P04
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M NL(/6J$'IG0E[^K+"M(JO23#,F$\D;0(0TKK$F)I9/K_7+LC4?CN7N_*\Z
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MN ::@# #]/DEY^JY81S4>['S?P%02P,$%     @ #(6O5K@T7[:J P  C1,
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M/!<.T^PLX6I)4JV<4&M0J0!+WMV XT):0M^3-T0H\DE(B<FTT]AA<.\B3JM
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M[9S.R\L,."+V"W!^I;5['/@CG/H$;OX?4$L#!!0    (  R%KU89;&2M&@<
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M /WYG'-U?V$F?^M)[^G_4$L#!!0    (  R%KU83([(!5 0  ,H8   :
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M/BPUT3< ?"YZ;=H=UI.]?O5-?=9SK0)4<]6H]BN]IQFQ>V_W-N5I4*VV_PC
M<U;#DOK\VC%@8@7/!5!T9RU.NZ@$B*4FMBT! 7KHY6FUHG;GDJ2./=J]X0&]
M>6IZ0\V0:25L]8RT_6)B8= #GO1F+6%[J!R)I2;Z!CC20R]AJQ6U[1\6Q!4Y
MT^EA5#.@1L[,TQZEGJ^VUTRL-WK K-ZL96L/E6"QU$3? ,%ZZ&5KM:*V_;*R
MM1V/9!30IZ>FS^^:4;@M)&I+M?UM@I\]X&=OUGJWATK+6&JB;X"6/?1ZMUI1
MVWY)]7PT%WT@75]-NAJYB%-$5\]'N_'=Q&JH#SSMSUI$]U%9&4M-] VPLH]>
M1/>'Y7$O[B\R2 ;9MA6-) +@JZ_&5Z.)H%MN5\]5.Q!,+*+Z -#^K.5V'Q5_
ML=1$WW0V$Z&7VWU)N;W?9R(;,Y8A@*.^&D=-9PA*75YM@W9TF%BF]0&4_5GK
M\CXJK&*IB;X!6/71Z_+^L.+NA8/+BZ0L;T5CFP:!'WTU/QZ3Q_G_K"*HYZL=
M#";6:P.@V&#6BGV RJA8:J)O@%$#](I],"S&#[=:20;9SDC[2@#4&*BI\;OF
MR;05;;4%VM%A8M4V .P-9JW^!ZC@BJ4F^@; -4"O_@?#PGZ_]J\^Z;E& 7$&
M:N+\W@F&N/BFME0[V(QLHN_LHI]W&SWN/GH3'!P !P?H[0IJ16W[)9OI1]IU
M B#88$J[PO>\U#T"']6V:?O7Q.)N ' >S-H*$:"B-9::^"46@-8A>BM$*&M>
MZ&_TD@P:W>@5 NR&4QH<)N44SG*V>C[:W]EA8LDV!/@.9VUO"%%!&4M-] V
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MQ$.Z_XD6"^HKO3"-LOPOV!=C?0^$VTRD<3%91A"SY/"??"N,J$R P9D)J)B
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MT!2RE(/CE/,@H:^)N7WI'#U<HR30$\&6=7"\TW,N"J6OHLG"Y,@U[=1S5&O
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M,\SU&R76U6/ %T(ID5<O5XQJ7#$&^OA""'7]QIQ@^R3Y]']02P,$%     @
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MR;/O.7ZQ1Q%N(-=_]0E?Q17TQV5;Q(5>L12F#O8 #6H#SNSGGVCD_=HGVHG
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M^6[)"&&O4M=@;>[;=*(J1\]7&#Z?)<*RR>[X1N/QW1K/KU>OC*)NW,'^$_4
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M3%;?<:ANM-B4WQVX%5J+O+Q,&4V8-!G@]Y40^O'&5+#[FL;%_P%02P,$%
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MR\TMUUIN8;FEY3K+K2RWMMS&<EO+[2RWM]S!<@GV< <$AT!P"02G0' +!,=
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M<G/+M99;6&YIN<YR*\NM+;>QW-9R.\OM+7>P7(;>^PL6'_5P" 270' *!+=
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M@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S(+@+XL+@9/&].EI\O0?FQ3'
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M,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87 R&Y\<S<;;D_9_Q*'
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M6VYFN<9R<\NUEEM8;FFYSG(KRZTMM['<UG([R^TM=[!<AE[]\W>?]7 (!)=
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M' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P9GH_#UR2@<O$#_V:<
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M=9;K+;>VW,9R6\OM++>WW,%R1\ME[.V_8OU1#X= < D$IT!P"P3'0' -!.=
M< \$!T%P$00G07 3!$=!<!4$9T%P%\2%P=GZ>W.R_@9OS%]W Q"=K;\?@Y*[
MM=S$<E/+%98K+5=9;F:YN>5JRRTLUUAN:;G6<BO+=9;K+;>^YYZ^^M/[\*\U
M/WOZ_SL"*#]T:[F=Y?:6.UCN:+F,O?!7;#SJX?<]^($/?N&#G_C@-S[XD0]^
MY8.?^>!W/OBA#W[I@Y_ZX+<^^+$/?NV#G_NX]_[CC??F\5\;[\W@)7EQ!/#N
M$X9/0@Q_&Q</.<I-+#>U7&&YTG*5Y6:6FUNNMMS"<HWEEI9K+;>R7&>YWG)K
MRVTLM[7<SG)[RQTL=[1<QM[[RQ>?]7 (!)= < H$MT!P# 370' .!/= <! $
M%T%P$@0W07 4!%=!<!8$=T%<&)PMOB<GBV_PL+PX GCW"2.+#]VWOU]\DIM8
M;FJYPG*EY2K+S2PWMUQMN87E&LLM+==:;F6YSG*]Y=:6VUAN:[F=Y?:6.UCN
M:+F,O?=7+#[JX1 (+H'@% AN@> 8"*Z!X!P([H'@( @N@N D"&Z"X"@(KH+@
M+ CN@K@P.%M\3T\6W^!A^4\> 6S7WSQJ?O[GV]_'X"^/JI^^_?FG=[]\__9O
MCV9O_^OW_]W;X2N PY]YX4_IQG*WEIM8;FJYPG*EY2K+S2PWMUQMN87E&LLM
M+==:;F6YSG*]Y=:6VUAN:[F=Y?:6.UCN:+F,M<(5:Y%Z. 2"2R X!8);(#@&
M@FL@. >">R X"(*+(#@)@IL@. J"JR X"X*[("X,SM;BLY.U^.$H_=>X O@&
MW;N_'X62N[7<Q')3RQ66*RU766YFN;GE:LLM+-=8;FFYUG(KRW66ZRVWMMS&
M<EO+[2RWM]S!<D?+)=C#'1 < L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!
M31 <!<%5$)P%P5T0%P9GH_#YR2A\/O@KQ,^\ CBB//P+QX>GWZ!T^?23W,1R
M4\L5EBLM5UEN9KFYY6K++2S76&YIN=9R*\MUENLMM[;<QG);R^TLM[?<P7)'
MRV7LX;]B^E$/AT!P"02G0' +!,= < T$YT!P#P0'07 1!"=!<!,$1T%P%01G
M07 7Q(7!V?1[<3+]!D_,?^$5P!'\[J^:/CP!![_T\@DHN8GEII8K+%=:KK+<
MS')SR]666UBNL=S2<JWE5I;K+-=;;FVYC>6VEMM9;F^Y@^6.ELM8 %PQ :F'
M0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S(+@+XL+@; *^
M/)F @Z?FO^0,X(@\\DO P2^^? %*;F*YJ>4*RY66JRPWL]S<<K7E%I9K++>T
M7&NYE>4ZR_666UMN8[FMY7:6VUON8+FCY3+V_E^Q *F'0R"X!()3(+@%@F,@
MN :"<R"X!X*#(+@(@I,@N F"HR"X"H*S(+@+XL+@; &^.EF @Z?F/WD*L/O'
MPZL/':Z_WX&2N[7<Q')3RQ66*RU766YFN;GE:LLM+-=8;FFYUG(KRW66ZRVW
MMMSFGGOZ^D_OP[_^_.J;5Q__^\];^ZD[R^TM=[#<T7(9>]VOV'?4PP]\\ L?
M_,0'O_'!CWSP*Q_\S >_\\$/??!+'_S4![_UP8]]\&L?_-P'O_=Q#_[9OGM]
MLN\&C\F3,X ?/F'D* 2Z:7^_Y"0WL=S4<H7E2LM5EIM9;FZYVG(+RS666UJN
MM=S*<IWE>LNM+;>QW-9R.\OM+7>PW-%R&7OOKUA\U,,A$%P"P2D0W +!,1!<
M \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87"V^-Z<++[!T_+D#.";SUE\
MZ,+]_>*3W,1R4\L5EBLM5UEN9KFYY6K++2S76&YIN=9R*\MUENLMM[;<QG);
MR^TLM[?<P7)'RV7LO;]B\5$/AT!P"02G0' +!,= < T$YT!P#P0'07 1!"=!
M<!,$1T%P%01G07 7Q(7!1XOOQ>/'_UI\?_S/0XOO4V< __H7.=^_^^'M3]\^
MJK__\?M?WWW[MT>WO_W'[\C@'<"1#[WPQW1CN5O+32PWM5QAN=)RE>5FEIM;
MKK;<PG*-Y9:6:RVWLEQGN=YR:\MM++>UW,YR>\L=+'>T7,9BX>*YB#T< L$E
M$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P9G<_')R5S\
M<)?^*]P!O*?9*)3<K>4FEIM:KK!<:;G*<C/+S2WW_]%V;SUNW&>ZM[]* [,P
M6 OP$K1I[3!'=[JY*;*J6&21Q<U9CRTDPCAV8#MY5X+Y\*\C=8\IIE4E4I=S
MDAD@?;'=)__?C9;UE):K+%=;;F&YQG)+RZTLUUIN;;F-Y3K+;2VWL]S><@?+
M)=C#'1 < L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0
M%P8GH_#YT2CL/3__A7< !Y7/_,;Q\?'7:YT__B0WLMS8<A/+32U76&YFN;GE
M2LM5EJLMM[!<8[FEY5:6:RVWMMS&<IWEMI;;66YON8/E,O3T7S#^J(=#(+@$
M@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@N OBPN!D_+TX&G^]
M9^:_[A+@$/[QSYH^O@![O_+\!2BYD>7&EIM8;FJYPG(SR\TM5UJNLEQMN87E
M&LLM+;>R7&NYM>4VENLLM[7<SG)[RQTLEZ'W_X(%2#T< L$E$)P"P2T0' /!
M-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P8G"_#Z: %>]XZTRP\!#LGW
MOPE\?/_U?NGY^T]R(\N-+3>QW-1RA>5FEIM;KK1<9;G:<@O+-99;6FYEN=9R
M:\MM+-=9;FNYG>7VECM8+D.O_P7[CWHX!()+(#@%@EL@. :":R X!X)[(#@(
M@HL@. F"FR X"H*K(#@+@KL@+@Q.]M_+H_W7>VK^\3. C\\]=+/^80)^Y%Y^
MX#[^3://7SY]^O33OVWTUG[LR')CRTTL-[5<8;F9Y>:6*RU76:ZVW,)RC>66
MEEM9KK7<VG(;RW66VUIN9[F]Y0Z6R]#+?L&VH]X-]G )!*= < L$QT!P#03G
M0' /! =!<!$$)T%P$P1'07 5!&=!<!?$A<')MGMUM.UZC\B#$X /G]![$&+@
MVSC_MWF2&UEN;+F)Y::6*RPWL]S<<J7E*LO5EEM8KK'<TG(KR[666UMN8[G.
M<EO+[2RWM]S!<AEZ[R]8?-3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0
MW 3!41!<!<%9$-P%<6%PLOA>'RV^WK/RX 3@PR<,+#YTW?YA\4EN9+FQY2:6
MFUJNL-S,<G/+E9:K+%=;;F&YQG)+RZTLUUIN;;F-Y3K+;2VWL]S><@?+9>B]
MOV#Q40^'0' )!*= < L$QT!P#03G0' /! =!<!$$)T%P$P1'07 5!&=!<!?$
MA<')XGMSM/AZS\I_P0G 'WYY]\>?[GYY]]U5^^OGO__VU__=_YP#7/VZ#^]^
M_J_WWWWW]V^N/ORK@'__];]^^J^! X'HTOW#F)3<K>5&EAM;;F*YJ>4*R\TL
M-[=<:;G*<K7E%I9K++>TW,IRK>76EMM8KK/<UG([R^TM=[!<AE+B@C%)/1P"
MP240G +!+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%P540G 7!71 7!B=C\NW1
MF/QXL?YW.1#XUHY"R=U:;F2YL>4FEIM:KK#<S')SRY66JRQ76VYAN<9R2\NM
M+-=:;FVYC>4ZRVTMM[/<WG('RR78PQT0' +!)1"< L$M$!P#P340G /!/1 <
M!,%%$)P$P4T0' 7!51"<!<%=$!<&GX["9T]_&X7/>N_2?^F!P"'E"WX?^>@0
M['?/'H*4&UEN;+F)Y::6*RPWL]S<<J7E*LO5EEM8KK'<TG(KR[666UMN8[G.
M<EO+[2RWM]S!<AG*@/.'H/5P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($
M-T%P% 1707 6!'=!7!B<#,%G1T.P]Q;]5QX+', __*G3F_>_//;%-P-??/X(
ME-S(<F/+32PWM5QAN9GEYI8K+5=9KK;<PG*-Y9:66UFNM=S:<AO+=9;;6FYG
MN;WE#I;+4 )<, *IAT,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)@J,@
MN J"LR"X"^+"X&0$/C\:@;TWZ;_F7N" W'<OL/]+S]]_DAM9;FRYB>6FEBLL
M-[/<W'*EY2K+U99;6*ZQW-)R*\NUEEM;;F.YSG);R^TLM[?<P7(9>OTOV'_4
MPR$07 +!*1#< L$Q$%P#P3D0W /!01!<!,%)$-P$P5$07 7!61#<!7%A<++_
M7ASMO]Z+]&?<"^R'SOQ'OWG@CN\%/OO7:X'T0T>6&UMN8KFIY0K+S2PWMUQI
MN<IRM>46EFLLM[3<RG*MY=:6VUBNL]S6<CO+[2UWL%R&WO4+EAWU;K"'2R X
M!8);(#@&@FL@. >">R X"(*+(#@)@IL@. J"JR X"X*[("X,3I;=]=&RN^Y=
M=N!:X/TG]-^.Z/\VSO]=GN1&EAM;;F*YJ>4*R\TL-[=<:;G*<K7E%I9K++>T
MW,IRK>76EMM8KK/<UG([R^TM=[!<AM[["Q8?]7 (!)= < H$MT!P# 370' .
M!/= <! $%T%P$@0W07 4!%=!<!8$=T%<&)PLOI='BZ_W KVX%GC_"0.+K_?;
M.'_Q26YDN;'E)I:;6JZPW,QR<\N5EJLL5UMN8;G&<DO+K2S76FYMN8WE.LMM
M+;>SW-YR!\MEZ+V_8/%1#X= < D$IT!P"P3'0' -!.= < \$!T%P$00G07 3
M!$=!<!4$9T%P%\2%P<GB>W6T^'HOT ]?"YR\^^'=U?I/[WZZ^\L__R>CS6^W
M F__^I^_<OV7 ?L__LP?V(WE;BTWLMS8<A/+32U76&YFN;GE2LM5EJLMM[!<
M8[FEY5:6:RVWMMS&<IWEMI;;66YON8/E,I0-%PQ'ZN$0""Z!X!0(;H'@& BN
M@> <".Z!X" (+H+@) AN@N H"*Z"X"P([H*X,#@9CJ^/AN/'0_:_QV7 >YJ-
M0LG=6FYDN;'E)I:;6JZPW,QR<\N5EJLL5UMN8;G&<DO+K2S76FYMN8WE.LMM
M+;>SW-YR!\LEV,,=$!P"P240G +!+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%
MP540G 7!71 7!B>C\,W1*.P]2/_%EP$'E,'?/3X^ WO5\V>@Y$:6&UMN8KFI
MY0K+S2PWMUQIN<IRM>46EFLLM[3<RG*MY=:6VUBNL]S6<CO+[2UWL%R&(N""
M&4@]' +!)1"< L$M$!P#P340G /!/1 <!,%%$)P$P4T0' 7!51"<!<%=$!<&
M)S/P[=$,[#U!_[5W ?OQCW_J]/$%V/N5YR] R8TL-[;<Q')3RQ66FUEN;KG2
M<I7E:LLM+-=8;FFYE>5:RZTMM[%<9[FMY7:6VUON8+D,O?\7+$#JX1 (+H'@
M% AN@> 8"*Z!X!P([H'@( @N@N D"&Z"X"@(KH+@+ CN@K@P^'0!/G_ZVP)\
MWGM[_FN. @[(?4<!^[_T[/U'N9'EQI:;6&YJN<)R,\O-+5=:KK)<;;F%Y1K+
M+2VWLEQKN;7E-I;K++>UW,YR>\L=+)>AU__\_6<]' +!)1"< L$M$!P#P340
MG /!/1 <!,%%$)P$P4T0' 7!51"<!<%=$!<&)_OOV='^ZST[?\91P'[HS'_T
MFP=NX"@@_="1Y<:6FUAN:KG"<C/+S2U76JZR7&VYA>4:RRTMM[)<:[FUY3:6
MZRRWM=S.<GO+'2R7H7?]@F5'O1OLX1((3H'@%@B.@> :",Z!X!X(#H+@(@A.
M@N F"(Z"X"H(SH+@+H@+@Y-E]_QHV?4>E!=' >\_H?]$1/^W<?[O\B0WLMS8
M<A/+32U76&YFN;GE2LM5EJLMM[!<8[FEY5:6:RVWMMS&<IWEMI;;66YON8/E
M,O3>7[#XJ(=#(+@$@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@
MN OBPN!D\;TX6GR]A^;%4<#[3QA8?.C>_</BD]S(<F/+32PWM5QAN9GEYI8K
M+5=9KK;<PG*-Y9:66UFNM=S:<AO+=9;;6FYGN;WE#I;+T'M_P>*C'@Z!X!((
M3H'@%@B.@> :",Z!X!X(#H+@(@A.@N F"(Z"X"H(SH+@+H@+@Y/%=WVT^*Y[
M%]_@4<#BYY_NWGU_5?[RW9-OKM:__E_YV_N_]1\"[/_(,W](-Y:[M=S(<F/+
M32PWM5QAN9GEYI8K+5=9KK;<PG*-Y9:66UFNM=S:<AO+=9;;6FYGN;WE#I;+
M4"I<,!:IAT,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)@J,@N J"LR"X
M"^+"X&0LOCP:BQ]OU/\>AP#O:38*)7=KN9'EQI:;6&YJN<)R,\O-+5=:KK)<
M;;F%Y1K++2VWLEQKN;7E-I;K++>UW,YR>\L=+)=@#W= < @$ET!P"@2W0' ,
M!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8G(S"5T>CL/?^_)<> AQ2
M'OE]X^/#K]<Y?_A);F2YL>4FEIM:KK#<S')SRY66JRQ76VYAN<9R2\NM+-=:
M;FVYC>4ZRVTMM[/<WG('RV7HV;]@^%$/AT!P"02G0' +!,= < T$YT!P#P0'
M07 1!"=!<!,$1T%P%01G07 7Q(7!R?![?33\>F_,?^7IOP'\X4^:/KX!>[_V
M_ THN9'EQI:;6&YJN<)R,\O-+5=:KK)<;;F%Y1K++2VWLEQKN;7E-I;K++>U
MW,YR>\L=+)>A KA@ U(/AT!P"02G0' +!,= < T$YT!P#P0'07 1!"=!<!,$
M1T%P%01G07 7Q(7!R09\<[0!>P_,?]7QOW[YX^\!'Y]_Z.C]P_R3W,AR8\M-
M+#>U7&&YF>7FEBLM5UFNMMS"<HWEEI9;6:ZUW-IR&\MUEMM:;F>YO>4.ELO0
MXW_!_*,>#H'@$@A.@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@*@C.@N N
MB N#D_GW]FC^]5Z7?_SVW]5_7_W[O[UY\>KY8]_U'P;(,W\(-Y:[M=S(<F/+
M32PWM5QAN9GEYI8K+5=9KK;<PG*-Y9:66UFNM=S:<AO+=0_</__KEZ,;KR='
M7K?V8W>6VUON8+D,O?$7K#SJX1<^^(D/?N.#'_G@5S[XF0]^YX,?^N"7/OBI
M#W[K@Q_[X-<^^+D/?N^#'_RX%__3E??BZ6\K[T7O#7EQ!_#^$_JO0O1_&V=/
M.<J-+#>VW,1R4\L5EIM9;FZYTG*5Y6K++2S76&YIN97E6LNM+;>Q7&>YK>5V
MEMM;[F"Y#+WWYR\^Z^$0""Z!X!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H
M"*Z"X"P([H*X,#A9?,^.%E_O;7EQ!_#^$P86'SIQ_[#X)#>RW-AR$\M-+5=8
M;F:YN>5*RU66JRVWL%QCN:7E5I9K+;>VW,9RG>6VEMM9;F^Y@^4R]-Y?L/BH
MAT,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)@J,@N J"LR"X"^+"X&3Q
M/3]:?+VWY8?O ([O?OKSW57[Y"]/\N2;J^K]]W<_]%\![/_ ,W]$-Y:[M=S(
M<F/+32PWM5QAN9GEYI8K+5=9KK;<PG*-Y9:66UFNM=S:<AO+=9;;6FYGN;WE
M#I;+4"A<,!6IAT,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)@J,@N J"
MLR"X"^+"X&0JOCB:BA^/TO\>5P!?H'OW#Z-0<K>6&UEN;+F)Y::6*RPWL]S<
M<J7E*LO5EEM8KK'<TG(KR[666UMN8[G.<EO+[2RWM]S!<@GV< <$AT!P"02G
M0' +!,= < T$YT!P#P0'07 1!"=!<!,$1T%P%01G07 7Q(7!R2B\/AJ%U[V_
M/_S"*X!#RF._;7Q\^?5"YR\_R8TL-[;<Q')3RQ66FUEN;KG2<I7E:LLM+-=8
M;FFYE>5:RZTMM[%<9[FMY7:6VUON8+D,O?L7+#_JX1 (+H'@% AN@> 8"*Z!
MX!P([H'@( @N@N D"&Z"X"@(KH+@+ CN@K@P.%E^+X^67^^%^:\\ SB ?_AS
MIH\/0'3W_F$ 2FYDN;'E)I:;6JZPW,QR<\N5EJLL5UMN8;G&<DO+K2S76FYM
MN8WE.LMM+;>SW-YR!\MEZ/F_8 !2#X= < D$IT!P"P3'0' -!.= < \$!T%P
M$00G07 3!$=!<!4$9T%P%\2%P<D ?'4T 'LOS7_-#< !N?CE[OO'OO!FX O/
M7W^2&UEN;+F)Y::6*RPWL]S<<J7E*LO5EEM8KK'<TG(KR[666UMN8[G.<EO+
M[2RWM]S!<AEZ^R]8?]3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!
M41!<!<%9$-P%<6%PLOY>'ZV_WAOSCY\ ?'SLH6/U#Q/P(_?R W?_]XN^>?[T
MZ;^<A[JUGSRRW-AR$\M-+5=8;F:YN>5*RU66JRVWL%QCN:7E5I9K+;>VW,9R
MG>6VEMM9;F^Y@^4R]+A?,.^H=X,]7 +!*1#< L$Q$%P#P3D0W /!01!<!,%)
M$-P$P5$07 7!61#<!7%A<#+OWAS-N]X;\N3VW\=/&+@$@4[9/RP^R8TL-[;<
MQ')3RQ66FUEN;KG2<I7E:LLM+-=8;FFYE>5:RZTMM[%<9[FMY7:6VUON8+D,
MO?<7+#[JX1 (+H'@% AN@> 8"*Z!X!P([H'@( @N@N D"&Z"X"@(KH+@+ CN
M@K@P.%E\;X\67^\]>7+[[^V7+#YTUOYA\4EN9+FQY2:6FUJNL-S,<G/+E9:K
M+%=;;F&YQG)+RZTLUUIN;;F-Y3K+;2VWL]S><@?+9>B]OV#Q40^'0' )!*=
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MK>76EMM8KK/<UG([R^TM=[!<AM[["Q8?]7 (!)= < H$MT!P# 370' .!/=
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MK2S76FYMN8WE.LMM+;>SW-YR!\MEZ+V_8/%1#X= < D$IT!P"P3'0' -!.=
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M-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P8GB^_%T>+K/3(O#@+>?\+
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MN<9R2\NM+-=:;FVYC>4ZRVTMM[/<WG('RV7HV;]@^%$/AT!P"02G0' +!,=
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MK2S76FYMN8WE.LMM+;>SW-YR!\MEZ-&_8/91#X= < D$IT!P"P3'0' -!.=
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M@G,@N >"@R"X"(*3(+@)@J,@N J"LR"X"^+"X&@&OCJ8@9UWZ1]S,K!'OMV
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M6LLM+;>RW-IR&\MM+;>SW-YRZ2N ,S8@]7 (!)= < H$MT!P# 370' .!/=
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MY>:6JRVWL%QCN=9R2\NM++>VW,9R6\OM++>W7/H>_]/GG_5P" 270' *!+=
M< P$UT!P#@3W0' 0!!=!<!($-T%P% 1707 6!'=!7!@<S;]G!_.O\^;\%Z\!
M_N,/__;B^?.'ONL_]I G_A"N+'=MN8'EAI8;66YLN8GEII:;6:ZP7&FYRG)S
MR]666UBNL5QKN:7E5I9;6VYCN:WE=I;;6RY]*7#&&*0>#H'\7@(O;L';/VA^
M>?GD^=%]0?S&!S_RP:]\\#,?_,X'/_3!+WWP4Q_\U@<_]L&O??!S'_S>!S_X
M<2_^T<I[?K#R.J_*BWN =Y_0?1VB^]LX?<I);F"YH>5&EAM;;F*YJ>5FEBLL
M5UJNLMS<<K7E%I9K+-=:;FFYE>76EMM8;FNYG>7VEDO?>W_&E*,>#H'@$@A.
M@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@*@C.@N NB N#H\7WXF#Q==Z8
M%_< [SZA9_&A4_?WBT]R \L-+3>RW-AR$\M-+3>S7&&YTG*5Y>:6JRVWL%QC
MN=9R2\NM++>VW,9R6\OM++>W7/K>^S,6'_5P" 270' *!+= < P$UT!P#@3W
M0' 0!!=!<!($-T%P% 1707 6!'=!7!@<+;[+@\5WV;GXOG0/L+WYZ8?W__CG
M7^;\\)>;DZ\!=G_HB3^F*\M=6VY@N:'E1I8;6VYBN:GE9I8K+%=:KK+<W'*U
MY1:6:RS76FYIN97EUI;;6&YKN9WE]I9+7RR<,1>IAT,@N 2"4R"X!8)C(+@&
M@G,@N >"@R"X"(*3(+@)@J,@N J"LR"X"^+"X&@NOCR8B[<'ZK_%-< [FHU"
MR5U;;F"YH>5&EAM;;F*YJ>5FEBLL5UJNLMS<<K7E%I9K+-=:;FFYE>76EMM8
M;FNYG>7VEDNPASL@. 2"2R X!8);(#@&@FL@. >">R X"(*+(#@)@IL@. J"
MJR X"X*[("X,CD;AJX-1V'F$_FNO ?8H7_J-X\/CK],Z??Q);F"YH>5&EAM;
M;F*YJ>5FEBLL5UJNLMS<<K7E%I9K+-=:;FFYE>76EMM8;FNYG>7VEDO?TW_&
M^*,>#H'@$@A.@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@*@C.@N NB N#
MH_'W^F#\=1Z;?^0MP!Z\XQ9@]U>>O@ E-[#<T'(CRXTM-['<U'(SRQ66*RU7
M66YNN=IR"\LUEFLMM[3<RG)KRVTLM[7<SG)[RZ7O_3]C 5(/AT!P"02G0' +
M!,= < T$YT!P#P0'07 1!"=!<!,$1T%P%01G07 7Q(7!T0)\<[  .^_-/^H6
M8+?<=0NP\RM/GW^2&UAN:+F1Y<:6FUAN:KF9Y0K+E9:K+#>W7&VYA>4:R[66
M6UIN9;FUY3:6VUIN9[F]Y=+W^)\Q_ZB'0R"X!()3(+@%@F,@N :"<R"X!X*#
M(+@(@I,@N F"HR"X"H*S(+@+XL+@:/Z]/9A_G<?FS[L%B.[7WX]!R5U;;F"Y
MH>5&EAM;;F*YJ>5FEBLL5UJNLMS<<K7E%I9K+-=:;FFYE>76EMM8;FNYG>7V
MEDM?"IPQ!JF'0R"_E\#;W[S;OV7^_.635_]Z"I!^+G[C@Q_YX%<^^)D/?N>#
M'_K@ES[XJ0]^ZX,?^^#7/OBY#W[OXQ[\ST?>BZ>?1MZ+SI/RXA3@W2=T'X;H
M_C9.7G*4&UAN:+F1Y<:6FUAN:KF9Y0K+E9:K+#>W7&VYA>4:R[666UIN9;FU
MY3:6VUIN9[F]Y=+WWI^^Y*R'0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@
MN F"HR"X"H*S(+@+XL+@:/$].UA\G>?EQ2G NT_H67SHROW]XI/<P')#RXTL
M-[;<Q')3R\TL5UBNM%QEN;GE:LLM+-=8KK7<TG(KRZTMM['<UG([R^TME[[W
M_HS%1ST< L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0
M%P9'B^_YP>+K/"__Q5. Q8]_N6B?Y,EW%Q__T__UE_<]M_^Z/^7$G\N5Y:XM
M-[#<T'(CRXTM-['<U'(SRQ66*RU766YNN=IR"\LUEFLMM[3<RG)KRVTLM[7<
MSG)[RZ6O#L[8A]3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!41!<
M!<%9$-P%<6%PM ]?'.S#VV/TW^+VWPMTY_Y^%$KNVG(#RPTM-[+<V'(3RTTM
M-[-<8;G2<I7EYI:K+;>P7&.YUG)+RZTLM[;<QG);R^TLM[=<@CW< <$A$%P"
MP2D0W +!,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87 T"B\/1N%E
MYR\-O_+V7X]R_RO&A\=>Y]>>/O8D-[#<T'(CRXTM-['<U'(SRQ66*RU766YN
MN=IR"\LUEFLMM[3<RG)KRVTLM[7<SG)[RZ7OJ3]C[%$/AT!P"02G0' +!,=
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MY>:6JRVWL%QCN=9R2\NM++>VW,9R6\OM++>W7/K>^S,6'_5P" 270' *!+=
M< P$UT!P#@3W0' 0!!=!<!($-T%P% 1707 6!'=!7!@<+;Z7!XNO\R*]N!YX
M]PD]BZ_SVSA]\4EN8+FAY4:6&UMN8KFIY6:6*RQ76JZRW-QRM>46EFLLUUIN
M:;F5Y=:6VUAN:[F=Y?:62]][?\;BHQX.@> 2"$Z!X!8(CH'@&@C.@> >" Z"
MX"((3H+@)@B.@N J",Z"X"Z("X.CQ??J8/%U7J3_XO7 ]N:G'][_X_!4X,U%
M\</-*9<"NS_YQ)_5E>6N+3>PW-!R(\N-+3>QW-1R,\L5EBLM5UEN;KG:<@O+
M-99K+;>TW,IR:\MM++>UW,YR>\NEKQC.V(S4PR$07 +!*1#< L$Q$%P#P3D0
MW /!01!<!,%)$-P$P5$07 7!61#<!7%A<+097Q]LQMN;]M_B4N =S4:AY*XM
M-[#<T'(CRXTM-['<U'(SRQ66*RU766YNN=IR"\LUEFLMM[3<RG)KRVTLM[7<
MSG)[RR78PQT0' +!)1"< L$M$!P#P340G /!/1 <!,%%$)P$P4T0' 7!51"<
M!<%=$!<&1Z/PS<$H[#Q0_]67 KN5SW[M^.DLX,UWO_WR\>$)V"F>/@$E-[#<
MT'(CRXTM-['<U'(SRQ66*RU766YNN=IR"\LUEFLMM[3<RG)KRVTLM[7<SG)[
MRZ4O ,Z8@-3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!41!<!<%9
M$-P%<6%P- '?'DS SG/TC[T*V(/W707L_/+39Z#D!I8;6FYDN;'E)I:;6FYF
MN<)RI>4JR\TM5UMN8;G&<JWEEI9;66YMN8WEMI;;66YON?1%P!DSD'HX!()+
M(#@%@EL@. :":R X!X)[(#@(@HL@. F"FR X"H*K(#@+@KL@+@P^GX&OGGZ:
M@:\ZS\\_YBI@C]QY%;#[:T\>@)0;6&YHN9'EQI:;6&YJN9GE"LN5EJLL-[=<
M;;F%Y1K+M99;6FYEN;7E-I;;6FYGN;WETO?\GSX K8=#(+@$@E,@N 6"8R"X
M!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@N OBPN!H #X[&("=A^=/N K8#9WX
M7_WJGCN\"GCY]NW;?ST*2#]W8+FAY4:6&UMN8KFIY6:6*RQ76JZRW-QRM>46
MEFLLUUIN:;F5Y=:6VUAN:[F=Y?:62]_3?L:XH]X5]G )!*= < L$QT!P#03G
M0' /! =!<!$$)T%P$P1'07 5!&=!<!?$A<'1N'M^,.XZC\J+HX!WG]!](J+[
MVSC]UWF2&UAN:+F1Y<:6FUAN:KF9Y0K+E9:K+#>W7&VYA>4:R[666UIN9;FU
MY3:6VUIN9[F]Y=+WWI^Q^*B'0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@
MN F"HR"X"H*S(+@+XL+@:/&].%A\G8?FQ5' NT_H67SHWOW]XI/<P')#RXTL
M-[;<Q')3R\TL5UBNM%QEN;GE:LLM+-=8KK7<TG(KRZTMM['<UG([R^TME[[W
M_HS%1ST< L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0
M%P9'B^_R8/%==BZ^+QT%K-[__>;C$/QP4?_YGW^@\Z+]^-GOOO_XGVG>_^WF
MIW<?_XTGS9/BR7<7?_SU^W_^,Z ??NF^$-C];9SX@[NRW+7E!I8;6FYDN;'E
M)I:;6FYFN<)RI>4JR\TM5UMN8;G&<JWEEI9;66YMN8WEMI;;66YON?3EPQD#
MDGHX!()+(#@%@EL@. :":R X!X)[(#@(@HL@. F"FR X"H*K(#@+@KL@+@R.
M!N3+@P%Y>[?^6UP(O*/9*)3<M>4&EAM:;F2YL>4FEIM:;F:YPG*EY2K+S2U7
M6VYAN<9RK>66EEM9;FVYC>6VEMM9;F^Y!'NX X)#(+@$@E,@N 6"8R"X!H)S
M(+@'@H,@N B"DR"X"8*C(+@*@K,@N OBPN!H%+XZ&(6=A^F_]D)@G_)UOX-\
M> MVTJ=O0<D-+#>TW,AR8\M-+#>UW,QRA>5*RU66FUNNMMS"<HWE6LLM+;>R
MW-IR&\MM+;>SW-YRZ2N!,[8@]7 (!)= < H$MT!P# 370' .!/= <! $%T%P
M$@0W07 4!%=!<!8$=T%<&!QMP=<'6[#S'OTC3P7VX+__TZ</C\#.+SY]!$IN
M8+FAY4:6&UMN8KFIY6:6*RQ76JZRW-QRM>46EFLLUUIN:;F5Y=:6VUAN:[F=
MY?:62U\"G#$"J8=#(+@$@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*
M@K,@N OBPN!H!+XY&(&=%^D?=2BP6[[[7>##^Z_S2T_??Y(;6&YHN9'EQI:;
M6&YJN9GE"LN5EJLL-[=<;;F%Y1K+M99;6FYEN;7E-I;;6FYGN;WETO?ZG['_
MJ(=#(+@$@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@N OBPN!H
M_[T]V'^=I^@?OA-X\?\NFGGU\.A#E^WOAZ#DKBTWL-S0<B/+C2TWL=S4<C/+
M%98K+5=9;FZYVG(+RS66:RVWM-S*<FO+;2RWM=S.<GO+I2\#SAB"U,,A$%P"
M^3T%7AS>-7[Q^5]/#W[A@Y_XX#<^^)$/?N6#G_G@=S[XH0]^Z8.?^N"W/OBQ
M#W[MXY[[S^?=ZZ>?YMWKSD/SXE+@W2=TWXWH_C9.WG&4&UAN:+F1Y<:6FUAN
M:KF9Y0K+E9:K+#>W7&VYA>4:R[666UIN9;FUY3:6VUIN9[F]Y=+WWI^^XZR'
M0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S(+@+XL+@:/$]
M.UA\G=?GQ:7 NT_H67R=W\;IBT]R \L-+3>RW-AR$\M-+3>S7&&YTG*5Y>:6
MJRVWL%QCN=9R2\NM++>VW,9R6\OM++>W7/K>^S,6'_5P" 270' *!+= < P$
MUT!P#@3W0' 0!!=!<!($-T%P% 1707 6!'=!7!@<+;[G!XNO\_K\%R\%MC<_
M_?#^'[_? US>_/RG7_]'^>O/!_^IA^<?.G9_/Q0E=VVY@>6&EAM9;FRYB>6F
MEIM9KK!<:;G*<G/+U99;6*ZQ7&NYI>56EEM;;F.YK>5VEMM;+GV9<,90I!X.
M@> 2"$Z!X!8(CH'@&@C.@> >" Z"X"((3H+@)@B.@N J",Z"X"Z("X.CH?CB
M8"C>'JW_%A<![V@V"B5W;;F!Y8:6&UEN;+F)Y::6FUFNL%QIN<IR<\O5EEM8
MKK%<:[FEY5:66UMN8[FMY7:6VULNP1[N@. 0""Z!X!0(;H'@& BN@> <".Z!
MX" (+H+@) AN@N H"*Z"X"P([H*X,#@:A9<'H_"R\[>'7WD1L$?Y['>-#R^^
M3N#TQ2>Y@>6&EAM9;FRYB>6FEIM9KK!<:;G*<G/+U99;6*ZQ7&NYI>56EEM;
M;F.YK>5VEMM;+GWO_1F+CWHX!()+(#@%@EL@. :":R X!X)[(#@(@HL@. F"
MFR X"H*K(#@+@KL@+@R.%M_+@\77>67^D7?_>O"#?\KTX1G8^>6GST#)#2PW
MM-S(<F/+32PWM=S,<H7E2LM5EIM;KK;<PG*-Y5K++2VWLMS:<AO+;2VWL]S>
M<NF+@#-F(/5P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($-T%P% 1707 6
M!'=!7!@<S<!7!S.P\\#\8R[_]<A=E_^ZO_3T_2>Y@>6&EAM9;FRYB>6FEIM9
MKK!<:;G*<G/+U99;6*ZQ7&NYI>56EEM;;F.YK>5VEMM;+GVO_QG[CWHX!()+
M(#@%@EL@. :":R X!X)[(#@(@HL@. F"FR X"H*K(#@+@KL@+@R.]M_K@_W7
M>5O^Y,M_W=R)/X KRUU;;F"YH>5&EAM;;F*YJ>5FEBLL5UJNLMS<<K7E%I9K
M+-=:;FFYE>76EMM8;FNYG>7VEDM?!IPQ!*F'0R"X!/)["KQX]1MX]]?0G[U]
M\O)?KO_93\;/?/ ['_S0![_TP4]]\%L?_-@'O_;!SWWP>Q_\X >_^'%/_M'$
M>W,P\3K/QY/K?[>?T',+ EVQO]]RDAM8;FBYD>7&EIM8;FJYF>4*RY66JRPW
MMUQMN87E&LNUEEM:;F6YM>4VEMM:;F>YO>72]]Z?L>6HAT,@N 2"4R"X!8)C
M(+@&@G,@N >"@R"X"(*3(+@)@J,@N J"LR"X"^+"X&CQO3U8?)T7Y<GUO[=?
ML_C08?O[Q2>Y@>6&EAM9;FRYB>6FEIM9KK!<:;G*<G/+U99;6*ZQ7&NYI>56
MEEM;;F.YK>5VEMM;+GWO_1F+CWHX!()+(#@%@EL@. :":R X!X)[(#@(@HL@
M. F"FR X"H*K(#@+@KL@+@P^7WQOGGY:?&\Z+\I_\?I?]?[O-Q^'X(>+^L\W
M/__MYJ(HKKZ[*-]_^/[C1W2>_^O^O!-_0E>6N[;<P')#RXTL-[;<Q')3R\TL
M5UBNM%QEN;GE:LLM+-=8KK7<TG(KRZTMM['<UG([R^TME[Y..'TI6@^'0' )
M!*= < L$QT!P#03G0' /! =!<!$$)T%P$P1'07 5!&=!<!?$A<'14GQVL!1O
M+]%_B_-_;]"1^_M1*+EKRPTL-[3<R')CRTTL-[7<S'*%Y4K+59:;6ZZVW,)R
MC>5:RRTMM[+<VG(;RVTMM[/<WG()]G '!(= < D$IT!P"P3'0' -!.= < \$
M!T%P$00G07 3!$=!<!4$9T%P%\2%P=$H?'XP"CNOSG_M^;\^Y5]_V?CP[NMD
M3M]]DAM8;FBYD>7&EIM8;FJYF>4*RY66JRPWMUQMN87E&LNUEEM:;F6YM>4V
MEMM:;F>YO>72]^J?L?NHAT,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)
M@J,@N J"LR"X"^+"X&CWO3C8?9V'Y1]Y!+ 'O_W'3!]>@.C>_?T"E-S <D/+
MC2PWMMS$<E/+S2Q76*ZT7&6YN>5JRRTLUUBNM=S2<BO+K2VWL=S6<CO+[2V7
MOO?_C 5(/1P"P240G +!+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%P540G 7!
M71 7!D<+\/)@ 5YVCK1'W/_KD9M?/WQX=_/3Q?#''WZ\-1^>@IW*Z5-0<@/+
M#2TWLMS8<A/+32TWLUQAN=)RE>7FEJLMM[!<8[G6<DO+K2RWMMS&<EO+[2RW
MMUSZ0N",*4@]' +!)1"< L$M$!P#P340G /!/1 <!,%%$)P$P4T0' 7!51"<
M!<%=$!<&1U/PY<$4[#PV_\53@'_XMS<OWCQ[Z+O^8P]YX@_ARG+7EAM8;FBY
MD>7&EIM8;FJYF>4*RY66JRPWMUQMN87E&LNUEEM:;F6YM>4VEMM:;F>YO>72
MEP)GC$'JX1 (+H'@%,CO+?#B]6_@[9];?_[TZ+8@?N.#'_G@5S[XF0]^YX,?
M^N"7/OBI#W[K@Q_[X-<^^+F/>^^/-MZK@XW7>5!>W *\^X3NRQ#=W\;I0TYR
M \L-+3>RW-AR$\M-+3>S7&&YTG*5Y>:6JRVWL%QCN=9R2\NM++>VW,9R6\OM
M++>W7/K>^S.&'/5P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($-T%P% 17
M07 6!'=!7!@<+;[7!XNO\[Z\N 5X]PD]BP^=N;]??)(;6&YHN9'EQI:;6&YJ
MN9GE"LN5EJLL-[=<;;F%Y1K+M99;6FYEN;7E-I;;6FYGN;WETO?>G['XJ(=#
M(+@$@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@N OBPN!H\;TY
M6'R=]^7[;P%6/_[][A)@^\N3B_K'7W[\^</__O7G/_5<!$17[>_WHN2N+3>P
MW-!R(\N-+3>QW-1R,\L5EBLM5UEN;KG:<@O+-99K+;>TW,IR:\MM++>UW,YR
M>\NEKQ;.V(O4PR$07 +!*1#< L$Q$%P#P3D0W /!01!<!,%)$-P$P5$07 7!
M61#<!7%A<+07WQ[LQ=OK]-_D(B Z?'\_"B5W;;F!Y8:6&UEN;+F)Y::6FUFN
ML%QIN<IR<\O5EEM8KK%<:[FEY5:66UMN8[FMY7:6VULNP1[N@. 0""Z!X!0(
M;H'@& BN@> <".Z!X" (+H+@) AN@N H"*Z"X"P([H*X,/A\%+Y]^FD4ONT\
M1/^U%P'[E.-?.3ZX^KJ1DU<?Y0:6&UIN9+FQY2:6FUIN9KG"<J7E*LO-+5=;
M;F&YQG*MY9:66UEN;;F-Y;:6VUEN;[GTO?FGKS[KX1 (+H'@% AN@> 8"*Z!
MX!P([H'@( @N@N D"&Z"X"@(KH+@+ CN@K@P.%I]SPY67^>E^4?> ^S!/_^'
M31]>@IW"Z4M0<@/+#2TWLMS8<A/+32TWLUQAN=)RE>7FEJLMM[!<8[G6<DO+
MK2RWMMS&<EO+[2RWMUSZ.N",)4@]' +!)1"< L$M$!P#P340G /!/1 <!,%%
M$)P$P4T0' 7!51"<!<%=$!<&1TOP^<$2[+P]_YB[@#WR5]X%[%9.GX*2&UAN
M:+F1Y<:6FUAN:KF9Y0K+E9:K+#>W7&VYA>4:R[666UIN9;FUY3:6VUIN9[F]
MY=(7 F=,0>KA$ @N@> 4"&Z!X!@(KH'@' CN@> @""Z"X"0(;H+@* BN@N L
M".Z"N# XFH(O#J9@YQ'ZL^X"=I,G_A"N+'=MN8'EAI8;66YLN8GEII:;6:ZP
M7&FYRG)SR]666UBNL5QKN:7E5I9;6VYCN:WE=I;;6RY]*7#&&*0>#H'@$@A.
M@?S> B]_\V[_\OK+I_]Z%]!^+'[D@U_YX&<^^)T/?NB#7_K@IS[XK0]^[(-?
M^^#G/NZ]/]IXEP<;[[)SXX&[@'>?T'TEHOO;.'W(26Y@N:'E1I8;6VYBN:GE
M9I8K+%=:KK+<W'*UY1:6:RS76FYIN97EUI;;6&YKN9WE]I9+WWM_QI"C'@Z!
MX!((3H'@%@B.@> :",Z!X!X(#H+@(@A.@N F"(Z"X"H(SH+@+H@+@Z/%]_)@
M\77>FA=W >\^H6?QH9/W]XM/<@/+#2TWLMS8<A/+32TWLUQAN=)RE>7FEJLM
MM[!<8[G6<DO+K2RWMMS&<EO+[2RWMUSZWOLS%A_U< @$ET!P"@2W0' ,!-=
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MS2Q76*ZT7&6YN>5JRRTLUUBNM=S2<BO+K2VWL=S6<CO+[2V7OA X>0IB#X=
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M< @$ET!P"@2W0' ,!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8'(W
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MR\TM5UMN8;G&<JWEEI9;66YMN8WEMI;;66YON?2][6>L.^I=80^70' *!+=
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M$%P$P4D0W 3!41!<!<%9$-P%<6%PM/B>'BR^SB/SY"#@TV]9?.C6_?7BD]S
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MR]66FUFNL=S<<@O+M99;6FYEN;7E-I;;6FYGN;WETO>\/V/Q40^'0' )!*=
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MI3?"WAA[!?8FV)MB;X:].?9*["VPM\3>"GMK[&VPM\5>A;T:>PWV=MC;8^^
MO2/V3MA+;Q@,F8L4U(D0W0C1D1!="=&9$-T)T:$070K1J1#="M&Q$%T+T;D0
MW0O1P1!=#(')<#X7K]MS\;IST'W)_<4>NO?^8O?K!RQ&Z8VP-\9>@;T)]J;8
MFV%OCKT2>POL+;&WPMX:>QOL;;%78:_&7H.]'?;VV#M@[XB]$_;2VP9#%B,%
M=2)$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="="Y$]T)T,$070V RG"_&
ME^W%^+)[UCWW_F*W]\P/X1Y[#[]X[?N+-R\^_?6K XSTT6/L%=B;8&^*O1GV
MYM@KL;? WA)[*^RML;?!WA9[%?9J[#78VV%OC[T#]H[8.V$OO;_[ARQ""NK?
M_GG0H(Z$Z$J(SH3H3H@.A>A2B$Z%Z%:(CH7H6HC.A>A>B Z&Z&((3(;S17C3
M7H0WG8M0'&!\?$3/@8WN-S)@^DEOA+TQ]@KL3; WQ=X,>W/LE=A;8&^)O17V
MUMC;8&^+O0I[-?8:[.VPM\?> 7M'[)VPE]X2&+(/*:@3(;H1HB,ANA*B,R&Z
M$Z)#(;H4HE,ANA6B8R&Z%J)S(;H7HH,ANA@"D^%\'[YJ[\-7S]B'PPXP/CZB
M;Q]VOI$!^U!Z(^R-L5=@;X*]*?9FV)MCK\3> GM+[*VPM\;>!GM;[%78J['7
M8&^'O3WV#M@[8N^$O?26P)!]2$&="-&-$!T)T940G0G1G1 ="M&E$)T*T:T0
M'0O1M1"="]&]$!T,T<40F SG^_!U>Q^^[MR'3QU@O'_[_OW;#__X_M/%Q>KK
M/[]_]_;#VV][KBYV/^N9'] ]]AZP-\+>&'L%]B;8FV)OAKTY]DKL+;"WQ-X*
M>VOL;;"WQ5Z%O1I[#?9VV-MC[X"](_9.V$MO/ R9E!34B1#="-&1$%T)T9D0
MW0G1H1!="M&I$-T*T;$070O1N1#="]'!$%T,@<EP/BEOVY/R]M,S?I^KB[=X
M0DKO 7LC[(VQ5V!O@KTI]F;8FV.OQ-X">TOLK;"WQMX&>UOL5=BKL==@;X>]
M/?8.V#MB[X2]1(.Z$*(3(;H1HB,ANA*B,R&Z$Z)#(;H4HE,ANA6B8R&Z%J)S
M(;H7HH,ANA@"D^%\0MZU)^1=Y[>2GWUUL9MI?8GYQ#KL?/V =2B]$?;&V"NP
M-\'>%'LS[,VQ5V)O@;TE]E;86V-O@[TM]BKLU=AKL+?#WAY[!^P=L7?"7GH[
M8,@ZI*!.A.A&B(Z$Z$J(SH3H3H@.A>A2B$Z%Z%:(CH7H6HC.A>A>B Z&Z&((
M3(:S=?CR16L=?ORA:]9]X9G%'OV7/^SZVY.Q^]7/GXS4&V%OC+T">Q/L3;$W
MP]X<>R7V%MA;8F^%O37V-MC;8J_"7HV]!GL[[.VQ=\#>$7LG[*4W#@9,1@OJ
M1(ANA.A(B*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&P&0XGXR7
M[<EXV?U-X!><6NRA>T\M=K]^P&*4W@A[8^P5V)M@;XJ]&?;FV"NQM\#>$GLK
M[*VQM\'>%GL5]FKL-=C;86^/O0/VCM@[82^];3!D,5)0)T)T(T1'0G0E1&="
M="=$AT)T*42G0G0K1,="="U$YT)T+T0'0W0Q!";#^6*\:B_&J^Y9]]Q3B]W>
M,S^$>^P]_.*U3RU>7MV]NO[UI47ZY#'V"NQ-L#?%W@Q[<^R5V%M@;XF]%?;6
MV-M@;XN]"GLU]AKL[;"WQ]X!>T?LG;"7WE_]0P8A!?4O_SQH4$="="5$9T)T
M)T2'0G0I1*="="M$QT)T+43G0G0O1 =#=#$$)L/Y(+QN#\+KSD$H+BT^/N)_
M7=)X\=75KVYI=+^5 =M/>B/LC;%78&^"O2GV9MB;8Z_$W@)[2^RML+?&W@9[
M6^Q5V*NQUV!OA[T]]@[8.V+OA+WTML"0A4A!G0C1C1 ="=&5$)T)T9T0'0K1
MI1"="M&M$!T+T;40G0O1O1 =#-'%$)@,YPOQ97LAOGS&0AQV:_'Q$?T+L?.M
M#%B(TAMA;XR] GL3[$VQ-\/>''LE]A;86V)OA;TU]C;8VV*OPEZ-O09[.^SM
ML7? WA%[)^REMP6&+$0*ZD2(;H3H2(BNA.A,B.Z$Z%"(+H7H5(ANA>A8B*Z%
MZ%R([H7H8(@NAL!D.%^(-^V%>-.Y$)^ZMI@/7__PW?<7B[??O/OZS?M/-Q?_
M]/9#W[G%[H<]\Q.ZQ]X#]D;8&V.OP-X$>U/LS; WQUZ)O07VEMA;86^-O0WV
MMMBKL%=CK\'>#GM[[!VP=\3>"7OIK8<AFY*".A&B&R$Z$J(K(3H3HCLA.A2B
M2R$Z%:);(3H6HFLA.A>B>R$Z&**+(3 9SC?EJ_:F?/7I&;_+N<5'VTU(Z3U@
M;X2],?8*[$VP-\7>#'MS[)786V!OB;T5]M;8VV!OB[T*>S7V&NSML+?'W@%[
M1^R=L)=H4!="=")$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="="Y$]T)T
M,$070V RG$_(U^T)^;KS:\G//;?8P_SJ6\PG-F*G,F C2F^$O3'V"NQ-L#?%
MW@Q[<^R5V%M@;XF]%?;6V-M@;XN]"GLU]AKL[;"WQ]X!>T?LG;"7WAH8LA$I
MJ!,ANA&B(R&Z$J(S(;H3HD,ANA2B4R&Z%:)C(;H6HG,ANA>B@R&Z& *3X7PC
MWK8WXFWGN/O2HXO=^D]_VO6)M=CYP@%K47HC[(VQ5V!O@KTI]F;8FV.OQ-X"
M>TOLK;"WQMX&>UOL5=BKL==@;X>]/?8.V#MB[X2]]';!D+5(09T(T8T0'0G1
ME1"="=&=$!T*T:40G0K1K1 ="]&U$)T+T;T0'0S1Q1"8#.=K\:Z]%N\Z]]P7
MW5OLIOOO+7:^?L!BE-X(>V/L%=B;8&^*O1GVYM@KL;? WA)[*^RML;?!WA9[
M%?9J[#78VV%OC[T#]H[8.V$OO6TP9#%24"="="-$1T)T)41G0G0G1(="="E$
MIT)T*T3'0G0M1.="="]$!T-T,00FP]EBO'G16HP??^B<=<^]M]CM/?-#N,?>
MPR]>^][B]:L7+ZY^?6^1/GF,O0)[$^Q-L3?#WAQ[)?86V%MB;X6]-?8VV-MB
MK\)>C;T&>SOL[;%WP-X1>R?LI?=7_X!!:$']RS\/&M21$%T)T9D0W0G1H1!=
M"M&I$-T*T;$070O1N1#="]'!$%T,@<EP/@@OVX/PLG,0BGN+CX_X7]<T+G]U
M2Z/[C0Q8?M(;86^,O0)[$^Q-L3?#WAQ[)?86V%MB;X6]-?8VV-MBK\)>C;T&
M>SOL[;%WP-X1>R?LI;<$ANQ#"NI$B&Z$Z$B(KH3H3(CNA.A0B"Z%Z%2(;H7H
M6(BNA>A<B.Z%Z&"(+H; 9#C?AU?M?7CUC'TX[-KBXR/Z]F'G&QFP#Z4WPMX8
M>P7V)MB;8F^&O3GV2NPML+?$W@I[:^QML+?%7H6]&GL-]G;8VV/O@+TC]D[8
M2V\)#-F'%-2)$-T(T9$070G1F1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$0
M70R!R7"^#Z_;^_"Z<Q\^=6MQ^=V/;S[.QN\OIM]^^_%O?WCWX]N+^L]O/[SY
MVT__QI].+V[???_UGWMN+W8__)F?V#WV'K WPMX8>P7V)MB;8F^&O3GV2NPM
ML+?$W@I[:^QML+?%7H6]&GL-]G;8VV/O@+TC]D[82V]-#-F8%-2)$-T(T9$0
M70G1F1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$070R!R7"^,5^V-^;+3\_X
M76XO/MIN0DKO 7LC[(VQ5V!O@KTI]F;8FV.OQ-X">TOLK;"WQMX&>UOL5=BK
ML==@;X>]/?8.V#MB[X2]1(.Z$*(3(;H1HB,ANA*B,R&Z$Z)#(;H4HE,ANA6B
M8R&Z%J)S(;H7HH,ANA@"D^%\0MZT)^1-Y]>4GWM[L8_I^5;SB<G8B0Z8C-(;
M86^,O0)[$^Q-L3?#WAQ[)?86V%MB;X6]-?8VV-MBK\)>C;T&>SOL[;%WP-X1
M>R?LI3<.ADQ&"NI$B&Z$Z$B(KH3H3(CNA.A0B"Z%Z%2(;H7H6(BNA>A<B.Z%
MZ&"(+H; 9#B?C*_:D_%5Y];[PE.,/?JG/_WZQ%SL?.6 N2B]$?;&V"NP-\'>
M%'LS[,VQ5V)O@;TE]E;86V-O@[TM]BKLU=AKL+?#WAY[!^P=L7?"7GK#8,A<
MI*!.A.A&B(Z$Z$J(SH3H3H@.A>A2B$Z%Z%:(CH7H6HC.A>A>B Z&Z&((3(;S
MN?BZ/1=?=PZZ+[G%V$/WWF+L?OV Q2B]$?;&V"NP-\'>%'LS[,VQ5V)O@;TE
M]E;86V-O@[TM]BKLU=AKL+?#WAY[!^P=L7?"7GK;8,ABI*!.A.A&B(Z$Z$J(
MSH3H3H@.A>A2B$Z%Z%:(CH7H6HC.A>A>B Z&Z&((3(;SQ7C;7HRWW;/NV;<8
M.[UG?@CWV'OXQ6O?8KQ\\=-?O[[%*)\\QEZ!O0GVIMB;86^.O1)["^PML;?"
MWAI[&^QML5=AK\9>@[T=]O;8.V#OB+T3]M+[JW_((*2@_N6?!PWJ2(BNA.A,
MB.Z$Z%"(+H7H5(ANA>A8B*Z%Z%R([H7H8(@NAL!D.!^$=^U!>-<Y",DMQI\?
MT7=KH_.-#%A^TAMA;XR] GL3[$VQ-\/>''LE]A;86V)OA;TU]C;8VV*OPEZ-
MO09[.^SML7? WA%[)^REMP2&[$,*ZD2(;H3H2(BNA.A,B.Z$Z%"(+H7H5(AN
MA>A8B*Z%Z%R([H7H8(@NAL!D.-N'KUZT]N'''SY_'PZ[Q?CXB)Y]V/U&GK\/
MJ3?"WAA[!?8FV)MB;X:].?9*["VPM\3>"GMK[&VPM\5>A;T:>PWV=MC;8^^
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MT:D0W0K1L1!="]&Y$-T+T<$070R!R7"^#U^V]^'+9^S#8=<7'Q_1MP\[W\B
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M2HC.A.A.B Z%Z%*(3H7H5HB.A;1JX>=_D,K/)QGN7OWZU*-]L,Z Z Z(#H'
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MV!MA;XR] GL3[$VQ-\/>''LE]A;86V)OA;TU]C;8VV*OPEZ-O09[.^SML7?
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M:@["5YV#4!QAO'W$Y67C!WCY[Z<U.E_(@-DGO0)[(^R-L3?!WA1[,^S-L;?
MWA)[)?96V%MC;X.]+?8J[-78VV%OC[T#]H[8.V'OC+WTEL"0V4=!G0C1C1 =
M"=&5$)T)T9T0'0K1I1"="M&M$!T+T;40G0O1O1 =#-'%$)@,[7WXNKD/7S]@
M'PZ\O_CZ7ONP\X4,V(?2*[ WPMX8>Q/L3;$WP]X<>POL+;%78F^%O37V-MC;
M8J_"7HV]'?;VV#M@[XB]$_;.V$MO"0S9AQ34B1#="-&1$%T)T9D0W0G1H1!=
M"M&I$-T*T;$070O1N1#="]'!$%T,@<G0WH=OFOOP3><^O.OTXOCOGSY^?O?Q
MYYN+^H>;3]<_W_SRY?V[SP^]P=CY[ ?^P-YB[PI[!?9&V!MC;X*]*?9FV)MC
M;X&])?9*[*VPM\;>!GM;[%78J[&WP]X>>P?L';%WPMX9>^F-B2$3DX(Z$:(;
M(3H2HBLA.A.B.R$Z%*)+(3H5HELA.A:B:R$Z%Z)[(3H8HHLA,!E:$_/-D\;$
M_/K%/Y[QI]Q@O+79A*3>%?8*[(VP-\;>!'M3[,VP-\?> GM+[)786V%OC;T-
M]K;8J[!78V^'O3WV#M@[8N^$O3/V$@WJ0HA.A.A&B(Z$Z$J(SH3H3H@.A>A2
MB$Z%Z%:(CH7H6HC.A>A>B Z&Z&((3(;VA+QL3LC+SG<I[WN#L8?I?E/SCL'8
M20X8C-(KL#?"WAA[$^Q-L3?#WAQ["^PML5=B;X6]-?8VV-MBK\)>C;T=]O;8
M.V#OB+T3]L[82V\:#!F,%-2)$-T(T9$070G1F1#="=&A$%T*T:D0W0K1L1!=
M"]&Y$-T+T<$070R!R= >C$^;@_%IY])[Y#'&'KWK&&/WMP[8B](KL#?"WAA[
M$^Q-L3?#WAQ["^PML5=B;X6]-?8VV-MBK\)>C;T=]O;8.V#OB+T3]L[82V\9
M#-F+%-2)$-T(T9$070G1F1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$070R!
MR=#>B\^:>_%9YZ)[S#'&'OH^QQB[B0&C47H%]D;8&V-O@KTI]F;8FV-O@;TE
M]DKLK;"WQMX&>UOL5=BKL;?#WAY[!^P=L7?"WAE[Z<V#(:.1@CH1HALA.A*B
M*R$Z$Z([(3H4HDLA.A6B6R$Z%J)K(3H7HGLA.ABBBR$P&=JC\7ES-#[O7'9#
MCC%VDP_\.;S%WA7V"NR-L#?&W@1[4^S-L#?'W@)[2^R5V%MA;XV]#?:VV*NP
M5V-OA[T]]@[8.V+OA+TS]M+;"$.6(P5U(D0W0G0D1%="="9$=T)T*$270G0J
M1+="="Q$UT)T+D3W0OX9#"^^@;>W(IZ_>?KOUQCMDV$*M!?AB^8B?-&Y",4U
MQMM']%S;Z'XA W:?] KLC; WQMX$>U/LS; WQ]X">TOLE=A;86^-O0WVMMBK
ML%=C;X>]/?8.V#MB[X2],_;26P)#=A\%=2)$-T)T)$170G0F1'="="A$ET)T
M*D2W0G0L1-="="Y$]T)T,$070V RM/?AR^8^?/F ?3CL&N/M(_KV8><+&; /
MI5=@;X2],?8FV)MB;X:].?86V%MBK\3>"GMK[&VPM\5>A;T:>SOL[;%WP-X1
M>R?LG;&7WA(8L@\IJ!,ANA&B(R&Z$J(S(;H3HD,ANA2B4R&Z%:)C(;H6HG,A
MNA>B@R&Z& *3H;T/7S7WX:O.?7C7-<;J^L/W'__[G]<71Y_>__3CS=__^O;Z
M'__&UW_J.<38_=@'_JS>8N\*>P7V1M@;8V^"O2GV9MB;8V^!O27V2NRML+?&
MW@9[6^Q5V*NQM\/>'GL'[!VQ=\+>&7OI[8@AZY*".A&B&R$Z$J(K(3H3HCLA
M.A2B2R$Z%:);(3H6HFLA.A>B>R$Z&**+(3 9VNOR=7-=OO[VC#_G$.-K/"&E
M=X6] GLC[(VQ-\'>%'LS[,VQM\#>$GLE]E;86V-O@[TM]BKLU=C;86^/O0/V
MCM@[8>^,O42#NA"B$R&Z$:(C(;H2HC,ANA.B0R&Z%*)3(;H5HF,ANA:B<R&Z
M%Z*#(;H8 I.A/2'?-"?DF\XW*.]]B+&;^=?W,^\8B)W$@($HO0)[(^R-L3?!
MWA1[,^S-L;? WA)[)?96V%MC;X.]+?8J[-78VV%OC[T#]H[8.V'OC+WTIL"0
M@4A!G0C1C1 ="=&5$)T)T9T0'0K1I1"="M&M$!T+T;40G0O1O1 =#-'%$)@,
M_SH0GSYY\L^!^(\ONI;=XPXO]NFW?_=Z\=>+__N7KW\X'GN<!X]'ZQ78&V%O
MC+T)]J;8FV%OCKT%]I;8*[&WPMX:>QOL;;%78:_&W@Y[>^P=L'?$W@E[9^RE
M-Q,>/AXQJ!,ANA&B(R&Z$J(S(;H3HD,ANA2B4R&Z%:)C(;H6HG,ANA>B@R&Z
M& *3H3T>+YOC\;)SWCWB"F,??8\KC#W$@-$HO0)[(^R-L3?!WA1[,^S-L;?
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M'__WAYM/GW]X__/%^P]?;KX^\\O7?^A]]_#V$9>7C85X^6_[L/N%/'P?4J_
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MALQ%"NI$B&Z$Z$B(KH3H3(CNA.A0B"Z%Z%2(;H7H6(BNA>A<B.Z%Z&"(+H;
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M9T/:A 7R(SQ]6*SQ;N,,J<X#M*=5&8)6BC,1K13'6B#RN D+_BE)NMO(C[!
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M;^J_^BH??NO6XP9M6+]R_H7Z*N_!>9!O_>.J<+G_]ERY,JMV=F#I_E\3,$:
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M"[)C8/U/8B+'+,B.@?4_@1DCQ\3LF<V3];_C+A0CW<1DW< BH&Q-Y)R8O1(
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MHP0  "UH   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-W$UNVT@
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M(T#OT?4> 7J/KO<(T'N,+RL!>H^N]PC0>W2]1X#>H^L] O0>7>\1H'=WO3M
M[^YZ=X#>W?7N +V[Z]T!>G?7NP/T[JYW!^C=XV83@-[=]>X O;OKW0%Z=]>[
M _2>7.\)H/?D>D\ O2?7>P+H/;G>$T#OR?6> 'I/KO<$T'MRO2> WE/<+ C0
M>W*])X#>D^L] ?2>7>\9H/?L>L\ O6?7>P;H/;O>,T#OV?6> 7K/KO<,T'MV
MO6> WK/K/0/TGN-F;X#>L^L] _1>7.\%H/?B>B\ O1?7>P'HO;C>"T#OQ?5>
M 'HOKO<"T'MQO1> WHOKO0#T7ESO!:#W$K$.0&^5S'4 ?JM$L%, @JM$LE,
MAJM$M%, BJM$ME, CJM$N%, DJM$NE, EJM$O%, FJM$OE, GJM$P%,(HF>
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M3U!+ 0(4 Q0    (  R%KU8'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #(6O5F$N2QOO    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ #(6O5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  ,A:]6FCG-ZR@(  !J-   &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ #(6O5FO^DFN5!0  J1@  !@              ("!;!   'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  R%KU9<9$18SP0  )D3   8
M              " @3<6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  ,A:]63:9\)[T&   O(   &               @($\&P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ #(6O5JDC3(%9#0
M474  !@              ("!+R(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    (  R%KU97/&HW2@D  %TN   8              " @;XO
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  ,A:]6W@%C
M7Q<G  !DAP  &               @($^.0  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ #(6O5O+8VUC7#   N28  !@
M ("!BV   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  R%
MKU9^(?H:!A\  *19   8              " @9AM  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  ,A:]6F<9\@>@%   4#P  &0
M        @('4C   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   (  R%KU;]73G8\0(  $,'   9              " @?.2  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ #(6O5O/JRTSA!@  ,A$
M !D              ("!&Y8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  ,A:]6LM89S<H#  !F"0  &0              @($SG0
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  R%KU;-"/TI
M3@4  #L0   9              " @32A  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ #(6O5D]N3?\?!0  ?0T  !D
M ("!N:8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  ,
MA:]6O*^4E,8'  !6$P  &0              @($/K   >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  R%KU;2M)!F?@@  )88   9
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M970R,2YX;6Q02P$"% ,4    "  ,A:]6/:,\7T<#   4"0  &0
M    @(%7T@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M  R%KU;.J*G.@0(  + %   9              " @=75  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ #(6O5C(Z-/SN"@  ="   !D
M             ("!C=@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  ,A:]6(R#B;N('  #X%0  &0              @(&RXP  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  R%KU:WO09B5QH
M /)*   9              " @<OK  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ #(6O5EK6.,L6!   _@D  !D              ("!
M608! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  ,A:]6
M#Z*4OQH(   T%0  &0              @(&F"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    (  R%KU8$=['P#PL  +DB   9
M      " @?<2 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ #(6O5LD%V\"D!   60H  !D              ("!/1X! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  ,A:]6Y2D-PHX4  "U.P
M&0              @($8(P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    (  R%KU9Q^O!24PT  #PF   9              " @=TW 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ #(6O5N[;ZH$?
M"   *Q0  !D              ("!9T4! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  ,A:]6Y\UUAV<+   S'0  &0
M@(&]30$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  R%
MKU87=13T>B0  -1]   9              " @5M9 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ #(6O5C@9]%$N!   <@D  !D
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M=#0P+GAM;%!+ 0(4 Q0    (  R%KU8L.XVW( 0  )D+   9
M  " @5+I 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M#(6O5O[UITG_ @  3 <  !D              ("!J>T! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  ,A:]6K 5@9 H%  #T"P  &0
M            @('?\ $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    (  R%KU8@BAP'YP(  * &   9              " @2#V 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ #(6O5NHG@@@[!
M<@P  !D              ("!/OD! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    "  ,A:]6Q_A*54 %   ]#@  &0              @(&P
M_0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  R%KU81
MX:@\*P4  .X,   9              " @2<# @!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ #(6O5DTF[)'"!@  @!0  !D
M     ("!B0@" 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  R%KU:>Z:88#0,   @(   9              "
M@4XB @!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ #(6O
M5J\<Y8J$ @  H 4  !D              ("!DB4" 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    "  ,A:]60\BKFR &   :$0  &0
M        @(%-* ( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   (  R%KU9P/B@M3P8  +83   9              " @:0N @!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ #(6O5G5-L##.!   $ T
M !D              ("!*C4" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    "  ,A:]6]ES27?4"  #<!@  &0              @($O.@(
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  R%KU;YIJ;'
MK@4  &8-   9              " @5L] @!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ #(6O5BZF7OE2"0  #!P  !D
M ("!0$," 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  ,
MA:]6VQ(EL+@#   /"   &0              @(')3 ( >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  R%KU:"@:7I$PL  *,C   9
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M970V-BYX;6Q02P$"% ,4    "  ,A:]6ENCY$RP1   P+@  &0
M    @('$= ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M  R%KU:-0@RJ_@$  !,$   9              " @2>& @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ #(6O5L_FJ.DK%P  +GT! !D
M             ("!7(@" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    "  ,A:]6$SCV#KP"  #M"   &0              @(&^GP( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  R%KU9\\^(+<@D
M /HW   9              " @;&B @!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ #(6O5@6T%;7/"0  $UD  !D              ("!
M6JP" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  ,A:]6
M[!M,P4()  !/00  &0              @(%@M@( >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    (  R%KU;T'B*;^P8  $@U   9
M      " @=F_ @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ #(6O5B_!H)7L!    AT  !D              ("!"\<" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  ,A:]6PS^&4YP$   7%P
M&0              @($NS ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    (  R%KU9I*=)B0PX  $:B   9              " @0'1 @!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ #(6O5I6-0I>O
M%P  Q0P! !D              ("!>]\" 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    "  ,A:]6QCM*=;0@   +O@$ &0
M@(%A]P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (  R%
MKU8O"\(EH04  'LG   9              " @4P8 P!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ #(6O5F_7^%&O!   @QD  !D
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M=#@U+GAM;%!+ 0(4 Q0    (  R%KU8]&DZ5_P(  ,X)   9
M  " @5LR P!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
M#(6O5HSD8%T) P  ZPP  !D              ("!D34# 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    "  ,A:]6**(+"H\#  !.$   &0
M            @('1. , >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    (  R%KU9;92[X=P4  "T6   9              " @9<\ P!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ #(6O5G*/G@+, P
ML0P  !D              ("!14(# 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    "  ,A:]6H\MM,TD*   )5   &0              @(%(
M1@, >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (  R%KU9X
M.4\O"0P  )]L   9              " @<A0 P!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ #(6O5BGXC)KG P  T10  !D
M     ("!"%T# 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  R%KU9$R%@YS@,   0-   9              "
M@=-R P!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ #(6O
M5L;4:ME?#0  68   !D              ("!V'8# 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    "  ,A:]6J.#\G0@)   D8   &@
M        @(%NA , >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M    "  ,A:]6!1+T&98"  #J!P  &@              @(&NC0, >&PO=V]R
M:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    "  ,A:]6G,%4S0L#   8
M"P  &@              @(%\D , >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX
M;6Q02P$"% ,4    "  ,A:]6_6H_.>,%  #O+0  &@              @(&_
MDP, >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    "  ,A:]6
M)Z?,[1L+  !)6@  &@              @(':F0, >&PO=V]R:W-H965T<R]S
M:&5E=#$P-"YX;6Q02P$"% ,4    "  ,A:]6<%#A+M<(   G8   &@
M        @($MI0, >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4
M    "  ,A:]6/V*DHGL"  #;!0  &@              @($\K@, >&PO=V]R
M:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    "  ,A:]6B=.MR%L#  #:
M"@  &@              @('OL , >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX
M;6Q02P$"% ,4    "  ,A:]6.,!M^J "   X!P  &@              @(&"
MM , >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    "  ,A:]6
M)*U,Z,L#   5$P  &@              @(%:MP, >&PO=V]R:W-H965T<R]S
M:&5E=#$P.2YX;6Q02P$"% ,4    "  ,A:]6FD33EG #  "9%   &@
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M:&5E=#$Q-"YX;6Q02P$"% ,4    "  ,A:]617FRB0,#  #D"0  &@
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M:&5E=#$Q.2YX;6Q02P$"% ,4    "  ,A:]6R-O@D8P$   7$@  &@
M        @('4Y , >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4
M    "  ,A:]6KG-PK[T#   M#0  &@              @(&8Z0, >&PO=V]R
M:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4    "  ,A:]6^_+S(H$#   '
M"P  &@              @(&-[0, >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX
M;6Q02P$"% ,4    "  ,A:]6LY\ E&4<  #1K0$ &@              @(%&
M\0, >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4    "  ,A:]6
MNNA/Q%<$  "K'   &@              @('C#00 >&PO=V]R:W-H965T<R]S
M:&5E=#$R-"YX;6Q02P$"% ,4    "  ,A:]6\H#4(GL#  "F$@  &@
M        @(%R$@0 >&PO=V]R:W-H965T<R]S:&5E=#$R-2YX;6Q02P$"% ,4
M    "  ,A:]6;,05JC,#  !>#0  &@              @($E%@0 >&PO=V]R
M:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4    "  ,A:]6O;LQ0I@#   %
M#0  &@              @(&0&00 >&PO=V]R:W-H965T<R]S:&5E=#$R-RYX
M;6Q02P$"% ,4    "  ,A:]6]HAI<) #  !B#   &@              @(%@
M'00 >&PO=V]R:W-H965T<R]S:&5E=#$R."YX;6Q02P$"% ,4    "  ,A:]6
M5&0/*"(#  #/#   &@              @($H(00 >&PO=V]R:W-H965T<R]S
M:&5E=#$R.2YX;6Q02P$"% ,4    "  ,A:]6H.8[OW\&  # ,0  &@
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M:&5E=#$S-"YX;6Q02P$"% ,4    "  ,A:]675$>?[<#  #2#@  &@
M        @(&0/ 0 >&PO=V]R:W-H965T<R]S:&5E=#$S-2YX;6Q02P$"% ,4
M    "  ,A:]6^,ME5R4&  !)(P  &@              @(%_0 0 >&PO=V]R
M:W-H965T<R]S:&5E=#$S-BYX;6Q02P$"% ,4    "  ,A:]6Z$*FW@D#  !1
M"P  &@              @('<1@0 >&PO=V]R:W-H965T<R]S:&5E=#$S-RYX
M;6Q02P$"% ,4    "  ,A:]6ND,9,&\#  "D"P  &@              @($=
M2@0 >&PO=V]R:W-H965T<R]S:&5E=#$S."YX;6Q02P$"% ,4    "  ,A:]6
MJ#EN9:0%  #('0  &@              @('$300 >&PO=V]R:W-H965T<R]S
M:&5E=#$S.2YX;6Q02P$"% ,4    "  ,A:]6JN@#2T$(  "S-0  &@
M        @(&@4P0 >&PO=V]R:W-H965T<R]S:&5E=#$T,"YX;6Q02P$"% ,4
M    "  ,A:]612]KB6@"  "A!0  &@              @($97 0 >&PO=V]R
M:W-H965T<R]S:&5E=#$T,2YX;6Q02P$"% ,4    "  ,A:]6:OF6,U\%  #"
M%P  &@              @(&Y7@0 >&PO=V]R:W-H965T<R]S:&5E=#$T,BYX
M;6Q02P$"% ,4    "  ,A:]61L$8+>\$   9#P  &@              @(%0
M9 0 >&PO=V]R:W-H965T<R]S:&5E=#$T,RYX;6Q02P$"% ,4    "  ,A:]6
M O92X@@*   _2P  &@              @(%W:00 >&PO=V]R:W-H965T<R]S
M:&5E=#$T-"YX;6Q02P$"% ,4    "  ,A:]6QP6^U9H%  #G&@  &@
M        @(&W<P0 >&PO=V]R:W-H965T<R]S:&5E=#$T-2YX;6Q02P$"% ,4
M    "  ,A:]6Q_='EH(,  "PC@  &@              @(&)>00 >&PO=V]R
M:W-H965T<R]S:&5E=#$T-BYX;6Q02P$"% ,4    "  ,A:]6]P%7;-(#  !G
M$@  &@              @(%#A@0 >&PO=V]R:W-H965T<R]S:&5E=#$T-RYX
M;6Q02P$"% ,4    "  ,A:]6X]TI'B $   Z%P  &@              @(%-
MB@0 >&PO=V]R:W-H965T<R]S:&5E=#$T."YX;6Q02P$"% ,4    "  ,A:]6
M -:R8O("  #A"   &@              @(&EC@0 >&PO=V]R:W-H965T<R]S
M:&5E=#$T.2YX;6Q02P$"% ,4    "  ,A:]6,L<87@,%   -(   &@
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M:&5E=#$U-"YX;6Q02P$"% ,4    "  ,A:]6.KHE\NX#  #?#@  &@
M        @($?KP0 >&PO=V]R:W-H965T<R]S:&5E=#$U-2YX;6Q02P$"% ,4
M    "  ,A:]6W&-CQ>P#   ;#P  &@              @(%%LP0 >&PO=V]R
M:W-H965T<R]S:&5E=#$U-BYX;6Q02P$"% ,4    "  ,A:]69E3_L+$&  #<
M-   &@              @(%IMP0 >&PO=V]R:W-H965T<R]S:&5E=#$U-RYX
M;6Q02P$"% ,4    "  ,A:]6&!.]Q00%  "4'0  &@              @(%2
MO@0 >&PO=V]R:W-H965T<R]S:&5E=#$U."YX;6Q02P$"% ,4    "  ,A:]6
MZ_;>CDX$  !G%   &@              @(&.PP0 >&PO=V]R:W-H965T<R]S
M:&5E=#$U.2YX;6Q02P$"% ,4    "  ,A:]65"]5@U$$  "7'0  &@
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M:&5E=#$V-"YX;6Q02P$"% ,4    "  ,A:]6EDK$EL@$   H'@  &@
M        @(&+X@0 >&PO=V]R:W-H965T<R]S:&5E=#$V-2YX;6Q02P$"% ,4
M    "  ,A:]6WT';RG\)  "M90  &@              @(&+YP0 >&PO=V]R
M:W-H965T<R]S:&5E=#$V-BYX;6Q02P$"% ,4    "  ,A:]6;P=7>((%  !V
M+@  &@              @(%"\00 >&PO=V]R:W-H965T<R]S:&5E=#$V-RYX
M;6Q02P$"% ,4    "  ,A:]6O1UY5D4(  !5/@  &@              @('\
M]@0 >&PO=V]R:W-H965T<R]S:&5E=#$V."YX;6Q02P$"% ,4    "  ,A:]6
MA ->:2$,  #@=P  &@              @(%Y_P0 >&PO=V]R:W-H965T<R]S
M:&5E=#$V.2YX;6Q02P$"% ,4    "  ,A:]6"@C10?,#  !8$P  &@
M        @('2"P4 >&PO=V]R:W-H965T<R]S:&5E=#$W,"YX;6Q02P$"% ,4
M    "  ,A:]6_Q^B48(%   2)0  &@              @(']#P4 >&PO=V]R
M:W-H965T<R]S:&5E=#$W,2YX;6Q02P$"% ,4    "  ,A:]65IVS_3$)  !9
M0P  &@              @(&W%04 >&PO=V]R:W-H965T<R]S:&5E=#$W,BYX
M;6Q02P$"% ,4    "  ,A:]6P;?%H]4$   X&   &@              @($@
M'P4 >&PO=V]R:W-H965T<R]S:&5E=#$W,RYX;6Q02P$"% ,4    "  ,A:]6
M64%-*$T$   9&   &@              @($M) 4 >&PO=V]R:W-H965T<R]S
M:&5E=#$W-"YX;6Q02P$"% ,4    "  ,A:]66/6SZEP#  !(#0  &@
M        @(&R* 4 >&PO=V]R:W-H965T<R]S:&5E=#$W-2YX;6Q02P$"% ,4
M    "  ,A:]6IP@NCE@#  !,#0  &@              @(%&+ 4 >&PO=V]R
M:W-H965T<R]S:&5E=#$W-BYX;6Q02P$"% ,4    "  ,A:]6T-T,I_0"  "@
M"@  &@              @('6+P4 >&PO=V]R:W-H965T<R]S:&5E=#$W-RYX
M;6Q02P$"% ,4    "  ,A:]6()L2R>V\ @!Q $L &@              @($"
M,P4 >&PO=V]R:W-H965T<R]S:&5E=#$W."YX;6Q02P$"% ,4    "  ,A:]6
MY*K\N44%  "2-@  #0              @ $G\ < >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    (  R%KU:7BKL<P    !,"   +              "  9?U!P!?
M<F5L<R\N<F5L<U!+ 0(4 Q0    (  R%KU8.07:&*0H   QU   /
M      "  8#V!P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,A:]6[A#(
M[*,$   M:   &@              @ '6  @ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  ,A:]6R'ZZ!TH#  #/8@  $P
M    @ &Q!0@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     N@"Z )PS   L
%"0@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1959</ContextCount>
  <ElementCount>778</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>518</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>49</UnitCount>
  <MyReports>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated income statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfIncome</Role>
      <ShortName>Consolidated income statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfComprehensiveIncome</Role>
      <ShortName>Consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/BalanceSheet</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfChangesInEquity</Role>
      <ShortName>Consolidated statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated cash flow statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementsOfCashFlow</Role>
      <ShortName>Consolidated cash flow statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2100100 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2100200 - Disclosure - Significant transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2100300 - Disclosure - Segmentation of key figures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures</Role>
      <ShortName>Segmentation of key figures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2100400 - Disclosure - Associated companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompanies</Role>
      <ShortName>Associated companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2100500 - Disclosure - Interest expense and other financial income and expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense</Role>
      <ShortName>Interest expense and other financial income and expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2100600 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2100700 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Changes in consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2100900 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2101000 - Disclosure - Right-of-use assets and lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability</Role>
      <ShortName>Right-of-use assets and lease liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Goodwill and intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2101200 - Disclosure - Deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Deferred tax assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2101300 - Disclosure - Financial and other non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets</Role>
      <ShortName>Financial and other non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2101400 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2101500 - Disclosure - Trade receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivables</Role>
      <ShortName>Trade receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2101700 - Disclosure - Other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssets</Role>
      <ShortName>Other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2101800 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2101900 - Disclosure - Non-current financial debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt</Role>
      <ShortName>Non-current financial debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2102000 - Disclosure - Provisions and other non-current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities</Role>
      <ShortName>Provisions and other non-current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Current financial debt and derivative financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments</Role>
      <ShortName>Current financial debt and derivative financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2102200 - Disclosure - Provisions and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities</Role>
      <ShortName>Provisions and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2102300 - Disclosure - Details to the consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements</Role>
      <ShortName>Details to the consolidated statements of cash flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2102400 - Disclosure - Acquisitions of businesses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses</Role>
      <ShortName>Acquisitions of businesses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2102500 - Disclosure - Post-employment benefits for employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates</Role>
      <ShortName>Post-employment benefits for employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2102600 - Disclosure - Equity-based participation plans for employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates</Role>
      <ShortName>Equity-based participation plans for employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2102700 - Disclosure - Transactions with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties</Role>
      <ShortName>Transactions with related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2102800 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2102900 - Disclosure - Financial instruments - additional disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures</Role>
      <ShortName>Financial instruments - additional disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSubsequentEvents</Role>
      <ShortName>Events subsequent to the December 31 consolidated balance sheet date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Principal Group subsidiaries and associated companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies</Role>
      <ShortName>Principal Group subsidiaries and associated companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2200100 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2300100 - Disclosure - Significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2300300 - Disclosure - Segmentation of key figures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</Role>
      <ShortName>Segmentation of key figures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2300400 - Disclosure - Associated companies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</Role>
      <ShortName>Associated companies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompanies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</Role>
      <ShortName>Interest expense and other financial income and expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2300600 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2300700 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables</Role>
      <ShortName>Changes in consolidated statements of comprehensive income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2300900 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables</Role>
      <ShortName>Right-of-use assets and lease liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2301100 - Disclosure - Goodwill and intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</Role>
      <ShortName>Deferred tax assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2301300 - Disclosure - Financial and other non-current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</Role>
      <ShortName>Financial and other non-current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2301400 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInventories</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2301500 - Disclosure - Trade receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</Role>
      <ShortName>Trade receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecurities</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2301700 - Disclosure - Other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables</Role>
      <ShortName>Other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureOtherCurrentAssets</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2301800 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquity</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2301900 - Disclosure - Non-current financial debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</Role>
      <ShortName>Non-current financial debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</Role>
      <ShortName>Provisions and other non-current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables</Role>
      <ShortName>Current financial debt and derivative financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2302200 - Disclosure - Provisions and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Provisions and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables</Role>
      <ShortName>Details to the consolidated statements of cash flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2302400 - Disclosure - Acquisitions of businesses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables</Role>
      <ShortName>Acquisitions of businesses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2302500 - Disclosure - Post-employment benefits for employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</Role>
      <ShortName>Post-employment benefits for employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2302600 - Disclosure - Equity-based participation plans for employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</Role>
      <ShortName>Equity-based participation plans for employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2302700 - Disclosure - Transactions with related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</Role>
      <ShortName>Transactions with related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2302800 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</Role>
      <ShortName>Financial instruments - additional disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables</Role>
      <ShortName>Principal Group subsidiaries and associated companies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2400100 - Disclosure - Significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2400200 - Disclosure - Significant transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails</Role>
      <ShortName>Significant transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSignificantTransactions</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2400300 - Disclosure - Segmentation of key figures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails</Role>
      <ShortName>Segmentation of key figures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2400301 - Disclosure - Segmentation of key figures (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1</Role>
      <ShortName>Segmentation of key figures (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2400302 - Disclosure - Segmentation of key figures (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2</Role>
      <ShortName>Segmentation of key figures (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2400303 - Disclosure - Segmentation of key figures (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3</Role>
      <ShortName>Segmentation of key figures (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2400304 - Disclosure - Segmentation of key figures (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4</Role>
      <ShortName>Segmentation of key figures (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2400305 - Disclosure - Segmentation of key figures (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5</Role>
      <ShortName>Segmentation of key figures (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2400306 - Disclosure - Segmentation of key figures (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6</Role>
      <ShortName>Segmentation of key figures (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12</Role>
      <ShortName>Segmentation of key figures - Net sales by region (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2400308 - Disclosure - Segmentation of key figures (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7</Role>
      <ShortName>Segmentation of key figures (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11</Role>
      <ShortName>Segmentation of key figures - Top 20 (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2400310 - Disclosure - Segmentation of key figures (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8</Role>
      <ShortName>Segmentation of key figures (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2400311 - Disclosure - Segmentation of key figures (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10</Role>
      <ShortName>Segmentation of key figures (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2400400 - Disclosure - Associated companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails</Role>
      <ShortName>Associated companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2400401 - Disclosure - Associated companies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3</Role>
      <ShortName>Associated companies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2400402 - Disclosure - Associated companies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6</Role>
      <ShortName>Associated companies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails</Role>
      <ShortName>Interest expense and other financial income and expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2</Role>
      <ShortName>Interest expense and other financial income and expense (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2400600 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2400601 - Disclosure - Income taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails2</Role>
      <ShortName>Income taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2400602 - Disclosure - Income taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails3</Role>
      <ShortName>Income taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2400700 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEarningsPerShareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails</Role>
      <ShortName>Changes in consolidated statements of comprehensive income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2400900 - Disclosure - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2400901 - Disclosure - Property, plant and equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2</Role>
      <ShortName>Property, plant and equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3</Role>
      <ShortName>Lease liability and Right-of-use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2401100 - Disclosure - Goodwill and intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2401101 - Disclosure - Goodwill and intangible assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2</Role>
      <ShortName>Goodwill and intangible assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2401102 - Disclosure - Goodwill and intangible assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3</Role>
      <ShortName>Goodwill and intangible assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2401103 - Disclosure - Goodwill and intangible assets (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5</Role>
      <ShortName>Goodwill and intangible assets (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2401104 - Disclosure - Goodwill and intangible assets (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4</Role>
      <ShortName>Goodwill and intangible assets (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3</Role>
      <ShortName>Deferred tax assets and liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4</Role>
      <ShortName>Deferred tax assets and liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2401300 - Disclosure - Financial and other non-current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails</Role>
      <ShortName>Financial and other non-current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2401301 - Disclosure - Financial and other non-current assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2</Role>
      <ShortName>Financial and other non-current assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2401400 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInventoriesTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2401500 - Disclosure - Trade receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails</Role>
      <ShortName>Trade receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2401501 - Disclosure - Trade receivables (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2</Role>
      <ShortName>Trade receivables (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2401502 - Disclosure - Trade receivables (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3</Role>
      <ShortName>Trade receivables (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2401503 - Disclosure - Trade receivables (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4</Role>
      <ShortName>Trade receivables (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2401700 - Disclosure - Other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails</Role>
      <ShortName>Other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2401800 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2401801 - Disclosure - Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails2</Role>
      <ShortName>Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2401802 - Disclosure - Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails3</Role>
      <ShortName>Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2401803 - Disclosure - Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails4</Role>
      <ShortName>Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2401804 - Disclosure - Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails5</Role>
      <ShortName>Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2401900 - Disclosure - Non-current financial debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails</Role>
      <ShortName>Non-current financial debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2401901 - Disclosure - Non-current financial debt (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2</Role>
      <ShortName>Non-current financial debt (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2401902 - Disclosure - Non-current financial debt (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3</Role>
      <ShortName>Non-current financial debt (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2401903 - Disclosure - Non-current financial debt (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4</Role>
      <ShortName>Non-current financial debt (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>2401904 - Disclosure - Non-current financial debt (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5</Role>
      <ShortName>Non-current financial debt (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions and other non-current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2</Role>
      <ShortName>Provisions and other non-current liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3</Role>
      <ShortName>Provisions and other non-current liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4</Role>
      <ShortName>Provisions and other non-current liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>130</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5</Role>
      <ShortName>Provisions and other non-current liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>131</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Current financial debt and derivative financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables</ParentRole>
      <Position>132</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>2402200 - Disclosure - Provisions and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>133</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>2402201 - Disclosure - Provisions and other current liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2</Role>
      <ShortName>Provisions and other current liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>134</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>2402202 - Disclosure - Provisions and other current liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3</Role>
      <ShortName>Provisions and other current liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>135</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails</Role>
      <ShortName>Details to the consolidated cash flow statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>2402400 - Disclosure - Acquisitions of businesses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails</Role>
      <ShortName>Acquisitions of businesses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables</ParentRole>
      <Position>142</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>2402500 - Disclosure - Post-employment benefits for employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails</Role>
      <ShortName>Post-employment benefits for employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>143</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>2402501 - Disclosure - Post-employment benefits for employees (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2</Role>
      <ShortName>Post-employment benefits for employees (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>144</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>2402502 - Disclosure - Post-employment benefits for employees (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3</Role>
      <ShortName>Post-employment benefits for employees (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>145</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>2402503 - Disclosure - Post-employment benefits for employees (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4</Role>
      <ShortName>Post-employment benefits for employees (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>146</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>2402504 - Disclosure - Post-employment benefits for employees (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5</Role>
      <ShortName>Post-employment benefits for employees (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>147</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>2402505 - Disclosure - Post-employment benefits for employees (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6</Role>
      <ShortName>Post-employment benefits for employees (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>148</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>2402506 - Disclosure - Post-employment benefits for employees (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7</Role>
      <ShortName>Post-employment benefits for employees (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>149</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>2402507 - Disclosure - Post-employment benefits for employees (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8</Role>
      <ShortName>Post-employment benefits for employees (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>150</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>2402508 - Disclosure - Post-employment benefits for employees (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9</Role>
      <ShortName>Post-employment benefits for employees (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>151</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>2402509 - Disclosure - Post-employment benefits for employees (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10</Role>
      <ShortName>Post-employment benefits for employees (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>152</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>2402600 - Disclosure - Equity-based participation plans for employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails</Role>
      <ShortName>Equity-based participation plans for employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>153</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>2402601 - Disclosure - Equity-based participation plans for employees (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2</Role>
      <ShortName>Equity-based participation plans for employees (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>154</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>2402602 - Disclosure - Equity-based participation plans for employees (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3</Role>
      <ShortName>Equity-based participation plans for employees (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>155</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>2402603 - Disclosure - Equity-based participation plans for employees (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4</Role>
      <ShortName>Equity-based participation plans for employees (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>156</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>2402604 - Disclosure - Equity-based participation plans for employees (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5</Role>
      <ShortName>Equity-based participation plans for employees (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>157</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>2402700 - Disclosure - Transaction with related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1</Role>
      <ShortName>Transaction with related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>2402701 - Disclosure - Transactions with related parties (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2</Role>
      <ShortName>Transactions with related parties (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</ParentRole>
      <Position>159</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>2402702 - Disclosure - Transactions with related parties (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3</Role>
      <ShortName>Transactions with related parties (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</ParentRole>
      <Position>160</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>2402801 - Disclosure - Commitments and contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>161</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails</Role>
      <ShortName>Financial instruments - additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>162</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2</Role>
      <ShortName>Financial instruments - additional disclosures (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>163</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3</Role>
      <ShortName>Financial instruments - additional disclosures (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>164</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R165.htm</HtmlFileName>
      <LongName>2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4</Role>
      <ShortName>Financial instruments - additional disclosures (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>165</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R166.htm</HtmlFileName>
      <LongName>2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5</Role>
      <ShortName>Financial instruments - additional disclosures (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>166</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R167.htm</HtmlFileName>
      <LongName>2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6</Role>
      <ShortName>Financial instruments - additional disclosures (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>167</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R168.htm</HtmlFileName>
      <LongName>2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7</Role>
      <ShortName>Financial instruments - additional disclosures (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>168</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R169.htm</HtmlFileName>
      <LongName>2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8</Role>
      <ShortName>Financial instruments - additional disclosures (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>169</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R170.htm</HtmlFileName>
      <LongName>2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9</Role>
      <ShortName>Financial instruments - additional disclosures (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>170</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R171.htm</HtmlFileName>
      <LongName>2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10</Role>
      <ShortName>Financial instruments - additional disclosures (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>171</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R172.htm</HtmlFileName>
      <LongName>2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12</Role>
      <ShortName>Financial instruments - additional disclosures (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>172</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R173.htm</HtmlFileName>
      <LongName>2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13</Role>
      <ShortName>Financial instruments - additional disclosures (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>173</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R174.htm</HtmlFileName>
      <LongName>2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14</Role>
      <ShortName>Financial instruments - additional disclosures (Details 12)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>174</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R175.htm</HtmlFileName>
      <LongName>2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15</Role>
      <ShortName>Financial instruments - additional disclosures (Details 13)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>175</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R176.htm</HtmlFileName>
      <LongName>2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16</Role>
      <ShortName>Financial instruments - additional disclosures (Details 15)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>176</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R177.htm</HtmlFileName>
      <LongName>2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Events subsequent to the December 31 consolidated balance sheet date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSubsequentEvents</ParentRole>
      <Position>177</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R178.htm</HtmlFileName>
      <LongName>2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails</Role>
      <ShortName>Principal Group subsidiaries and associated companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables</ParentRole>
      <Position>178</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 344 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityAddressAddressLine1, dei:EntityIncorporationStateCountryCode, ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary, ifrs-full:ProportionOfVotingPowerHeldInSubsidiary, nvs:OptionsExcludedFromTheCalculation -  nvs-20221231.htm 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 181, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F/A" original="nvs-20221231.htm">nvs-20221231.htm</File>
    <File>a23020120f-ex12_1.htm</File>
    <File>a23020120f-ex12_2.htm</File>
    <File>a23020120f-ex13_1.htm</File>
    <File>a23020120f-ex13_2.htm</File>
    <File>nvs-20221231.xsd</File>
    <File>nvs-20221231_cal.xml</File>
    <File>nvs-20221231_def.xml</File>
    <File>nvs-20221231_lab.xml</File>
    <File>nvs-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cogo_0002.gif</File>
    <File>cogo_0005.gif</File>
    <File>cogo_0021.gif</File>
    <File>cogo_0025.jpg</File>
    <File>cogo_0026.gif</File>
    <File>cogo_0027.gif</File>
    <File>cogo_0028.jpg</File>
    <File>cogo_0030.jpg</File>
    <File>cogo_0032.jpg</File>
    <File>cogo_0033.jpg</File>
    <File>cogo_0035.jpg</File>
    <File>cogo_0036.jpg</File>
    <File>cogo_0037.jpg</File>
    <File>cogo_0038.jpg</File>
    <File>cogo_0039.gif</File>
    <File>cogo_0043.jpg</File>
    <File>cogo_0044.jpg</File>
    <File>cogo_0045.jpg</File>
    <File>cogo_0047.jpg</File>
    <File>cogo_0049.jpg</File>
    <File>cogo_0059.gif</File>
    <File>cogo_0060.gif</File>
    <File>cogo_0061.gif</File>
    <File>cogo_0062.gif</File>
    <File>cogo_0063.gif</File>
    <File>cogo_0064.gif</File>
    <File>cogo_0065.gif</File>
    <File>cogo_0066.gif</File>
    <File>cogo_0067.gif</File>
    <File>cogo_0068.gif</File>
    <File>cogo_0069.gif</File>
    <File>cogo_0070.gif</File>
    <File>cogo_0071.gif</File>
    <File>comp_0003.gif</File>
    <File>comp_0005.gif</File>
    <File>comp_0006.gif</File>
    <File>comp_0007.gif</File>
    <File>comp_0008.gif</File>
    <File>comp_0009.gif</File>
    <File>comp_0010.gif</File>
    <File>comp_0012.gif</File>
    <File>comp_0014.gif</File>
    <File>comp_0016.gif</File>
    <File>comp_0023.gif</File>
    <File>comp_0026.gif</File>
    <File>comp_0028.gif</File>
    <File>comp_0029.gif</File>
    <File>comp_0030.gif</File>
    <File>comp_0031.gif</File>
    <File>sign-full.jpg</File>
    <File>sign-half.jpg</File>
    <File>skill-g.jpg</File>
    <File>skill-l.jpg</File>
    <File>skill-m.jpg</File>
    <File>skill-x.jpg</File>
    <File>skill-y.jpg</File>
    <File>skill-z.jpg</File>
    <File>x_coverback.jpg</File>
    <File>x_coverfront.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="51">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="3575">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>255
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nvs-20221231.htm": {
   "axisCustom": 19,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 51,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 3575
   },
   "contextCount": 1959,
   "dts": {
    "calculationLink": {
     "local": [
      "nvs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nvs-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 2141,
   "entityCount": 1,
   "hidden": {
    "http://novartis.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 7,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 339,
    "total": 348
   },
   "keyCustom": 385,
   "keyStandard": 393,
   "memberCustom": 410,
   "memberStandard": 84,
   "nsprefix": "nvs",
   "nsuri": "http://novartis.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://novartis.com/20221231/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100400 - Disclosure - Associated companies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompanies",
     "shortName": "Associated companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401101 - Disclosure - Goodwill and intangible assets (Details 1)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
     "shortName": "Goodwill and intangible assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401102 - Disclosure - Goodwill and intangible assets (Details 2)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
     "shortName": "Goodwill and intangible assets (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsMaterialToEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401103 - Disclosure - Goodwill and intangible assets (Details 3)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
     "shortName": "Goodwill and intangible assets (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsMaterialToEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401104 - Disclosure - Goodwill and intangible assets (Details 4)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
     "shortName": "Goodwill and intangible assets (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:IntangibleAssetImpairmentChargesTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-8",
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401200 - Disclosure - Deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3",
     "shortName": "Deferred tax assets and liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
     "shortName": "Deferred tax assets and liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NoncurrentFinancialAssetsEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401300 - Disclosure - Financial and other non-current assets (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails",
     "shortName": "Financial and other non-current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NoncurrentFinancialAssetsEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DeferredCompensationPlansAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401301 - Disclosure - Financial and other non-current assets (Details 1)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2",
     "shortName": "Financial and other non-current assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DeferredCompensationPlansAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Inventories",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401400 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://novartis.com/20221231/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "lang": null,
      "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100500 - Disclosure - Interest expense and other financial income and expense",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense",
     "shortName": "Interest expense and other financial income and expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401500 - Disclosure - Trade receivables (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
     "shortName": "Trade receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForTradeReceivablesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401501 - Disclosure - Trade receivables (Details 1)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
     "shortName": "Trade receivables (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:TradeReceivablesProvisionMovementsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401502 - Disclosure - Trade receivables (Details 2)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
     "shortName": "Trade receivables (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401503 - Disclosure - Trade receivables (Details 3)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4",
     "shortName": "Trade receivables (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:Commodities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:Commodities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401700 - Disclosure - Other current assets (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails",
     "shortName": "Other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IssuedCapital",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401800 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareCapitalTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IssuedCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401801 - Disclosure - Equity (Details 1)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails2",
     "shortName": "Equity (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DividendTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401802 - Disclosure - Equity (Details 2)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails3",
     "shortName": "Equity (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DividendTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100600 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://novartis.com/20221231/role/DisclosureTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nvs:TreasurySharesAcquiredToBeCancelled",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401803 - Disclosure - Equity (Details 3)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails4",
     "shortName": "Equity (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:SummaryOfTreasurySharesMovementsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:TreasurySharesAcquiredForCancellationValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentForRepurchaseOwnShares",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401804 - Disclosure - Equity (Details 4)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails5",
     "shortName": "Equity (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:MaximalAmountOfShareBuybackProgramm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401900 - Disclosure - Non-current financial debt (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
     "shortName": "Non-current financial debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:LiabilitiesToBanksAndOtherInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401901 - Disclosure - Non-current financial debt (Details 1)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
     "shortName": "Non-current financial debt (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:BorrowingsOriginalCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401902 - Disclosure - Non-current financial debt (Details 2)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
     "shortName": "Non-current financial debt (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401903 - Disclosure - Non-current financial debt (Details 3)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
     "shortName": "Non-current financial debt (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401904 - Disclosure - Non-current financial debt (Details 4)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5",
     "shortName": "Non-current financial debt (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402000 - Disclosure - Provisions and other non-current liabilities (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
     "shortName": "Provisions and other non-current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvision",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
     "shortName": "Provisions and other non-current liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:EnvironmentalProvisionPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3",
     "shortName": "Provisions and other non-current liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100700 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)",
     "menuCat": "Details",
     "order": "130",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
     "shortName": "Provisions and other non-current liabilities (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)",
     "menuCat": "Details",
     "order": "131",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
     "shortName": "Provisions and other non-current liabilities (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestBearningAccountsOfAssociatesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)",
     "menuCat": "Details",
     "order": "132",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
     "shortName": "Current financial debt and derivative financial instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestBearningAccountsOfAssociatesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402200 - Disclosure - Provisions and other current liabilities (Details)",
     "menuCat": "Details",
     "order": "133",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
     "shortName": "Provisions and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentRefundsProvision",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402201 - Disclosure - Provisions and other current liabilities (Details 1)",
     "menuCat": "Details",
     "order": "134",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
     "shortName": "Provisions and other current liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402202 - Disclosure - Provisions and other current liabilities (Details 2)",
     "menuCat": "Details",
     "order": "135",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
     "shortName": "Provisions and other current liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:RestructuringProvisionsMovementsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402300 - Disclosure - Details to the consolidated cash flow statements (Details)",
     "menuCat": "Details",
     "order": "136",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
     "shortName": "Details to the consolidated cash flow statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)",
     "menuCat": "Details",
     "order": "137",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
     "shortName": "Details to the consolidated cash flow statements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R138": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)",
     "menuCat": "Details",
     "order": "138",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
     "shortName": "Details to the consolidated cash flow statements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R139": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)",
     "menuCat": "Details",
     "order": "139",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
     "shortName": "Details to the consolidated cash flow statements (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashFlowFromNetIdentifiableAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100800 - Disclosure - Changes in consolidated statements of comprehensive income",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Changes in consolidated statements of comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R140": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:FinancialDebtsAndDerivativeInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)",
     "menuCat": "Details",
     "order": "140",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
     "shortName": "Details to the consolidated cash flow statements (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R141": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)",
     "menuCat": "Details",
     "order": "141",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
     "shortName": "Details to the consolidated cash flow statements (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R142": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402400 - Disclosure - Acquisitions of businesses (Details)",
     "menuCat": "Details",
     "order": "142",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails",
     "shortName": "Acquisitions of businesses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R143": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ConcentrationOfMajorPlansGeographic",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402500 - Disclosure - Post-employment benefits for employees (Details)",
     "menuCat": "Details",
     "order": "143",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
     "shortName": "Post-employment benefits for employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ConcentrationOfMajorPlansGeographic",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R144": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402501 - Disclosure - Post-employment benefits for employees (Details 1)",
     "menuCat": "Details",
     "order": "144",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
     "shortName": "Post-employment benefits for employees (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DefinedBenefitPlanInterestCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R145": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrepaidPostemploymentBenefitPlansAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402502 - Disclosure - Post-employment benefits for employees (Details 2)",
     "menuCat": "Details",
     "order": "145",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
     "shortName": "Post-employment benefits for employees (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R146": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402503 - Disclosure - Post-employment benefits for employees (Details 3)",
     "menuCat": "Details",
     "order": "146",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
     "shortName": "Post-employment benefits for employees (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R147": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402504 - Disclosure - Post-employment benefits for employees (Details 4)",
     "menuCat": "Details",
     "order": "147",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
     "shortName": "Post-employment benefits for employees (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R148": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402505 - Disclosure - Post-employment benefits for employees (Details 5)",
     "menuCat": "Details",
     "order": "148",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6",
     "shortName": "Post-employment benefits for employees (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R149": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402506 - Disclosure - Post-employment benefits for employees (Details 6)",
     "menuCat": "Details",
     "order": "149",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
     "shortName": "Post-employment benefits for employees (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100900 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R150": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanPlanAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402507 - Disclosure - Post-employment benefits for employees (Details 7)",
     "menuCat": "Details",
     "order": "150",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
     "shortName": "Post-employment benefits for employees (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanPlanAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R151": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402508 - Disclosure - Post-employment benefits for employees (Details 8)",
     "menuCat": "Details",
     "order": "151",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
     "shortName": "Post-employment benefits for employees (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R152": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ScheduleOfDefinedContributionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402509 - Disclosure - Post-employment benefits for employees (Details 9)",
     "menuCat": "Details",
     "order": "152",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
     "shortName": "Post-employment benefits for employees (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ScheduleOfDefinedContributionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R153": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402600 - Disclosure - Equity-based participation plans for employees (Details)",
     "menuCat": "Details",
     "order": "153",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
     "shortName": "Equity-based participation plans for employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R154": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402601 - Disclosure - Equity-based participation plans for employees (Details 1)",
     "menuCat": "Details",
     "order": "154",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
     "shortName": "Equity-based participation plans for employees (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R155": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402602 - Disclosure - Equity-based participation plans for employees (Details 2)",
     "menuCat": "Details",
     "order": "155",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
     "shortName": "Equity-based participation plans for employees (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R156": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402603 - Disclosure - Equity-based participation plans for employees (Details 3)",
     "menuCat": "Details",
     "order": "156",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
     "shortName": "Equity-based participation plans for employees (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R157": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402604 - Disclosure - Equity-based participation plans for employees (Details 4)",
     "menuCat": "Details",
     "order": "157",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
     "shortName": "Equity-based participation plans for employees (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R158": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402700 - Disclosure - Transaction with related parties (Details)",
     "menuCat": "Details",
     "order": "158",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
     "shortName": "Transaction with related parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "lang": null,
      "name": "nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R159": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402701 - Disclosure - Transactions with related parties (Details 1)",
     "menuCat": "Details",
     "order": "159",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
     "shortName": "Transactions with related parties (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101000 - Disclosure - Right-of-use assets and lease liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability",
     "shortName": "Right-of-use assets and lease liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R160": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402702 - Disclosure - Transactions with related parties (Details 2)",
     "menuCat": "Details",
     "order": "160",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3",
     "shortName": "Transactions with related parties (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:BorrowingsCreditFacilityUncommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R161": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentsUnderLongtermResearchAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402801 - Disclosure - Commitments and contingencies (Details 1)",
     "menuCat": "Details",
     "order": "161",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentsUnderLongtermResearchAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R162": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402900 - Disclosure - Financial instruments - additional disclosures (Details)",
     "menuCat": "Details",
     "order": "162",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
     "shortName": "Financial instruments - additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R163": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)",
     "menuCat": "Details",
     "order": "163",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
     "shortName": "Financial instruments - additional disclosures (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R164": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)",
     "menuCat": "Details",
     "order": "164",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
     "shortName": "Financial instruments - additional disclosures (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R165": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)",
     "menuCat": "Details",
     "order": "165",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
     "shortName": "Financial instruments - additional disclosures (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R166": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)",
     "menuCat": "Details",
     "order": "166",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
     "shortName": "Financial instruments - additional disclosures (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R167": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)",
     "menuCat": "Details",
     "order": "167",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
     "shortName": "Financial instruments - additional disclosures (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R168": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:FinancialInstrumentsCarryingValueLevel3",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)",
     "menuCat": "Details",
     "order": "168",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
     "shortName": "Financial instruments - additional disclosures (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:FinancialInstrumentsCarryingValueLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R169": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)",
     "menuCat": "Details",
     "order": "169",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
     "shortName": "Financial instruments - additional disclosures (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Goodwill and intangible assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R170": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)",
     "menuCat": "Details",
     "order": "170",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
     "shortName": "Financial instruments - additional disclosures (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R171": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ContractualInterestOnNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)",
     "menuCat": "Details",
     "order": "171",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
     "shortName": "Financial instruments - additional disclosures (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ContractualInterestOnNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R172": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)",
     "menuCat": "Details",
     "order": "172",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
     "shortName": "Financial instruments - additional disclosures (Details 10)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R173": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:CustomersWithNetSalesOverFivePercent",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)",
     "menuCat": "Details",
     "order": "173",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
     "shortName": "Financial instruments - additional disclosures (Details 11)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "lang": null,
      "name": "nvs:PercentageOfGovernmentBackedDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R174": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)",
     "menuCat": "Details",
     "order": "174",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
     "shortName": "Financial instruments - additional disclosures (Details 12)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R175": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)",
     "menuCat": "Details",
     "order": "175",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
     "shortName": "Financial instruments - additional disclosures (Details 13)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R176": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)",
     "menuCat": "Details",
     "order": "176",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
     "shortName": "Financial instruments - additional disclosures (Details 15)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R177": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)",
     "menuCat": "Details",
     "order": "177",
     "role": "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
     "shortName": "Events subsequent to the December 31 consolidated balance sheet date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R178": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)",
     "menuCat": "Details",
     "order": "178",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
     "shortName": "Principal Group subsidiaries and associated companies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101200 - Disclosure - Deferred tax assets and liabilities",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities",
     "shortName": "Deferred tax assets and liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101300 - Disclosure - Financial and other non-current assets",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets",
     "shortName": "Financial and other non-current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated income statements",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://novartis.com/20221231/role/StatementOfIncome",
     "shortName": "Consolidated income statements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101400 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://novartis.com/20221231/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101500 - Disclosure - Trade receivables",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivables",
     "shortName": "Trade receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecurities",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101700 - Disclosure - Other current assets",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssets",
     "shortName": "Other current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101800 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://novartis.com/20221231/role/DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101900 - Disclosure - Non-current financial debt",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt",
     "shortName": "Non-current financial debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102000 - Disclosure - Provisions and other non-current liabilities",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities",
     "shortName": "Provisions and other non-current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Current financial debt and derivative financial instruments",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments",
     "shortName": "Current financial debt and derivative financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102200 - Disclosure - Provisions and other current liabilities",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities",
     "shortName": "Provisions and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102300 - Disclosure - Details to the consolidated statements of cash flows",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements",
     "shortName": "Details to the consolidated statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated statements of comprehensive income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
     "shortName": "Consolidated statements of comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102400 - Disclosure - Acquisitions of businesses",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses",
     "shortName": "Acquisitions of businesses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102500 - Disclosure - Post-employment benefits for employees",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates",
     "shortName": "Post-employment benefits for employees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102600 - Disclosure - Equity-based participation plans for employees",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates",
     "shortName": "Equity-based participation plans for employees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102700 - Disclosure - Transactions with related parties",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties",
     "shortName": "Transactions with related parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102800 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "34",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102900 - Disclosure - Financial instruments - additional disclosures",
     "menuCat": "Notes",
     "order": "35",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures",
     "shortName": "Financial instruments - additional disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date",
     "menuCat": "Notes",
     "order": "36",
     "role": "http://novartis.com/20221231/role/DisclosureSubsequentEvents",
     "shortName": "Events subsequent to the December 31 consolidated balance sheet date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Principal Group subsidiaries and associated companies",
     "menuCat": "Notes",
     "order": "37",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies",
     "shortName": "Principal Group subsidiaries and associated companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2200100 - Disclosure - Significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "38",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300100 - Disclosure - Significant accounting policies (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated balance sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://novartis.com/20221231/role/BalanceSheet",
     "shortName": "Consolidated balance sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300300 - Disclosure - Segmentation of key figures (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
     "shortName": "Segmentation of key figures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300400 - Disclosure - Associated companies (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
     "shortName": "Associated companies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:InterestExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300500 - Disclosure - Interest expense and other financial income and expense (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables",
     "shortName": "Interest expense and other financial income and expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:InterestExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:IncomeBeforeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300600 - Disclosure - Income taxes (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:IncomeBeforeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300700 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables",
     "shortName": "Changes in consolidated statements of comprehensive income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300900 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables",
     "shortName": "Right-of-use assets and lease liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301100 - Disclosure - Goodwill and intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301200 - Disclosure - Deferred tax assets and liabilities (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables",
     "shortName": "Deferred tax assets and liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated statements of changes in equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://novartis.com/20221231/role/StatementOfChangesInEquity",
     "shortName": "Consolidated statements of changes in equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301300 - Disclosure - Financial and other non-current assets (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables",
     "shortName": "Financial and other non-current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301400 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://novartis.com/20221231/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ProvisionsForTradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301500 - Disclosure - Trade receivables (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables",
     "shortName": "Trade receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ProvisionsForTradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301700 - Disclosure - Other current assets (Tables)",
     "menuCat": "Tables",
     "order": "54",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables",
     "shortName": "Other current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MovementInTheShareCapitalTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301800 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "55",
     "role": "http://novartis.com/20221231/role/DisclosureEquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MovementInTheShareCapitalTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301900 - Disclosure - Non-current financial debt (Tables)",
     "menuCat": "Tables",
     "order": "56",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables",
     "shortName": "Non-current financial debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302000 - Disclosure - Provisions and other non-current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "57",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables",
     "shortName": "Provisions and other non-current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)",
     "menuCat": "Tables",
     "order": "58",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables",
     "shortName": "Current financial debt and derivative financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302200 - Disclosure - Provisions and other current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "59",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables",
     "shortName": "Provisions and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated cash flow statements",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://novartis.com/20221231/role/StatementsOfCashFlow",
     "shortName": "Consolidated cash flow statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DividendsReceivedClassifiedAsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)",
     "menuCat": "Tables",
     "order": "60",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables",
     "shortName": "Details to the consolidated statements of cash flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302400 - Disclosure - Acquisitions of businesses (Tables)",
     "menuCat": "Tables",
     "order": "61",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables",
     "shortName": "Acquisitions of businesses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302500 - Disclosure - Post-employment benefits for employees (Tables)",
     "menuCat": "Tables",
     "order": "62",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
     "shortName": "Post-employment benefits for employees (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302600 - Disclosure - Equity-based participation plans for employees (Tables)",
     "menuCat": "Tables",
     "order": "63",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
     "shortName": "Equity-based participation plans for employees (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OfficerAndDirectorCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302700 - Disclosure - Transactions with related parties (Tables)",
     "menuCat": "Tables",
     "order": "64",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables",
     "shortName": "Transactions with related parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OfficerAndDirectorCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302800 - Disclosure - Commitments and contingencies (Tables)",
     "menuCat": "Tables",
     "order": "65",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302900 - Disclosure - Financial instruments - additional disclosures (Tables)",
     "menuCat": "Tables",
     "order": "66",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables",
     "shortName": "Financial instruments - additional disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)",
     "menuCat": "Tables",
     "order": "67",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables",
     "shortName": "Principal Group subsidiaries and associated companies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400100 - Disclosure - Significant accounting policies (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "Significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400200 - Disclosure - Significant transactions (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
     "shortName": "Significant transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfSignificantTransactionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "-5",
      "lang": null,
      "name": "nvs:NumberOfBearerShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100100 - Disclosure - Significant accounting policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nvs:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400300 - Disclosure - Segmentation of key figures (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
     "shortName": "Segmentation of key figures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nvs:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400301 - Disclosure - Segmentation of key figures (Details 1)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
     "shortName": "Segmentation of key figures (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsSalesToOtherSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400302 - Disclosure - Segmentation of key figures (Details 2)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
     "shortName": "Segmentation of key figures (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400303 - Disclosure - Segmentation of key figures (Details 3)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
     "shortName": "Segmentation of key figures (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:NetOperatingAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400304 - Disclosure - Segmentation of key figures (Details 4)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
     "shortName": "Segmentation of key figures (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400305 - Disclosure - Segmentation of key figures (Details 5)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
     "shortName": "Segmentation of key figures (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:CustomersWithNetSalesOverFivePercent",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400306 - Disclosure - Segmentation of key figures (Details 6)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6",
     "shortName": "Segmentation of key figures (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
     "shortName": "Segmentation of key figures - Net sales by region (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400308 - Disclosure - Segmentation of key figures (Details 8)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
     "shortName": "Segmentation of key figures (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
     "shortName": "Segmentation of key figures - Top 20 (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100200 - Disclosure - Significant transactions",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantTransactions",
     "shortName": "Significant transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400310 - Disclosure - Segmentation of key figures (Details 10)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
     "shortName": "Segmentation of key figures (Details 10)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProfitSharingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400311 - Disclosure - Segmentation of key figures (Details 11)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
     "shortName": "Segmentation of key figures (Details 11)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProfitSharingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400400 - Disclosure - Associated companies (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
     "shortName": "Associated companies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "nvs:DisclosureOfSignificantTransactionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfVotingPowerHeldInAssociate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400401 - Disclosure - Associated companies (Details 1)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
     "shortName": "Associated companies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "3",
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400402 - Disclosure - Associated companies (Details 2)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
     "shortName": "Associated companies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ShareOfCurrentYearNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400500 - Disclosure - Interest expense and other financial income and expense (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
     "shortName": "Interest expense and other financial income and expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
     "shortName": "Interest expense and other financial income and expense (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherFinancialIncomeAndExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RevenueFromDividends",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400600 - Disclosure - Income taxes (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:IncomeBeforeTaxesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400601 - Disclosure - Income taxes (Details 1)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
     "shortName": "Income taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AnalysisOfTaxRateTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400602 - Disclosure - Income taxes (Details 2)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
     "shortName": "Income taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AnalysisOfTaxRateTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100300 - Disclosure - Segmentation of key figures",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures",
     "shortName": "Segmentation of key figures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400700 - Disclosure - Earnings per share (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
     "shortName": "Changes in consolidated statements of comprehensive income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ValueAdjustmentOnComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400900 - Disclosure - Property, plant and equipment (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
     "shortName": "Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400901 - Disclosure - Property, plant and equipment (Details 1)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
     "shortName": "Property, plant and equipment (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401000 - Disclosure - Lease liability and Right-of-use assets (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
     "shortName": "Lease liability and Right-of-use assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
     "shortName": "Lease liability and Right-of-use assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
     "shortName": "Lease liability and Right-of-use assets (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:LeaseLiabilitiesUndiscounted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
     "shortName": "Lease liability and Right-of-use assets (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashInflowForSaleAndLeaseback",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
     "shortName": "Lease liability and Right-of-use assets (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401100 - Disclosure - Goodwill and intangible assets (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 518,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "UK"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GREECE",
        "terseLabel": "Greece"
       }
      }
     },
     "localname": "GR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars",
        "terseLabel": "AUD"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_BRL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil, Brazil Real",
        "terseLabel": "BRL"
       }
      }
     },
     "localname": "BRL",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CAD"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CNY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China, Yuan Renminbi",
        "terseLabel": "CNY"
       }
      }
     },
     "localname": "CNY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "JPY"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_RUB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Russia, Rubles",
        "terseLabel": "RUB"
       }
      }
     },
     "localname": "RUB",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "totalLabel": "Total Income before taxes"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued expenses for goods and services received but not invoiced"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "auth_ref": [
      "r65",
      "r77",
      "r149",
      "r160",
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Accumulated depreciation, amortisation and impairment"
       }
      }
     },
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date",
        "negatedTerseLabel": "Fair value of previously held equity interests",
        "terseLabel": "Fair value of previously held equity interests"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, intangible assets and goodwill",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, other provisions",
        "negatedTerseLabel": "Impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, property, plant and equipment",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates [member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of pension increases",
        "terseLabel": "Expected rate of pension increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of pension increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of pension increases [member]",
        "terseLabel": "Rate of pension increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases",
        "terseLabel": "Expected rate of salary increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases [member]",
        "terseLabel": "Salary increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)",
        "negatedTerseLabel": "Remeasurement (gains) arising from changes in demographic assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)",
        "negatedTerseLabel": "Remeasurement losses/(gains) arising from changes in financial assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments",
        "negatedTerseLabel": "Experience-related remeasurement losses/(gains)"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "negatedLabel": "Provisions for doubtful trade receivables charged to the consolidated income statement",
        "negatedTerseLabel": "Additions to restructuring provisions",
        "terseLabel": "Additions",
        "verboseLabel": "Provisions for doubtful trade receivables charged to the consolidated income statement"
       }
      }
     },
     "localname": "AdditionalProvisionsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalRecognitionGoodwill": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional recognition, goodwill",
        "terseLabel": "Implicit Novartis goodwill"
       }
      }
     },
     "localname": "AdditionalRecognitionGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions",
        "verboseLabel": "Additions to intangible assets and goodwill"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions",
        "verboseLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares in diluted earnings per share"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "(Increase)/decrease in inventories"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Change in other current and non-current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "(Increase)/decrease in trade receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss; Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income (cost)",
        "negatedTerseLabel": "Net financial expense",
        "terseLabel": "Net financial expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other current liabilities",
        "terseLabel": "Change in other current liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts payable",
        "terseLabel": "Decrease in trade payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for losses (gains) on disposal of non-current assets",
        "terseLabel": "Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net"
       }
      }
     },
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss)",
        "terseLabel": "Reversal of non-cash items and other adjustments",
        "totalLabel": "Total reversal of non-cash items",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustment for share based payments",
        "terseLabel": "Equity-settled compensation expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdministrativeExpense": {
     "auth_ref": [
      "r53",
      "r116",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      },
      "en-us": {
       "role": {
        "label": "Administrative expenses",
        "negatedTerseLabel": "General and Administration",
        "verboseLabel": "Need new ITEM here"
       }
      }
     },
     "localname": "AdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the aggregate of continuing and discontinued operations. [Refer: Discontinued operations [member]; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregate continuing and discontinued operations [member]"
       }
      }
     },
     "localname": "AggregateContinuingAndDiscontinuedOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r158",
      "r162",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r29",
      "r235",
      "r249",
      "r250",
      "r288",
      "r330",
      "r331",
      "r333",
      "r334",
      "r361",
      "r396",
      "r403"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "negatedTerseLabel": "Amortization charge",
        "terseLabel": "Amortization charge"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Applicable tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r25",
      "r227",
      "r228",
      "r230",
      "r315",
      "r318"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are classified as held for sale. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are not classified as held for sale. It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities not classified as held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets, other than cash or cash equivalents, in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed",
        "terseLabel": "Non-current assets divested"
       }
      }
     },
     "localname": "AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Average effective tax rate",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "AverageEffectiveTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic earnings per share",
        "totalLabel": "Total basic earnings per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from continuing operation",
        "terseLabel": "Basic earnings per share, Continuing operations",
        "verboseLabel": "Continuing operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from discontinued operations",
        "terseLabel": "Basic earnings per share, Discontinued operations",
        "verboseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "localname": "BasicEarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BondsIssued": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Bonds issued",
        "terseLabel": "Straight bonds"
       }
      }
     },
     "localname": "BondsIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingCostsCapitalised": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowing costs capitalised",
        "terseLabel": "Capitalized borrowing costs"
       }
      }
     },
     "localname": "BorrowingCostsCapitalised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings",
        "terseLabel": "Total including current portion of non-current financial debt",
        "totalLabel": "Total",
        "verboseLabel": "The amount of outstanding funds that the entity is obligated to repay"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Interest rate on borrowings for new additions",
        "verboseLabel": "Borrowings, coupon"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BorrowingsMaturity": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, maturity",
        "terseLabel": "Borrowings, maturity year"
       }
      }
     },
     "localname": "BorrowingsMaturity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsOriginalCurrency": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The currency in which the borrowings are denominated. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, original currency"
       }
      }
     },
     "localname": "BorrowingsOriginalCurrency",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Low"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r65",
      "r72",
      "r149",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r278",
      "r292",
      "r293",
      "r475",
      "r477"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r72",
      "r153",
      "r159",
      "r161",
      "r162",
      "r278",
      "r292",
      "r293",
      "r416",
      "r420"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Current accounts"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r18",
      "r182",
      "r216"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents in subsidiary or businesses acquired or disposed"
       }
      }
     },
     "localname": "CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 9.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "negatedTerseLabel": "Acquired cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalents": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "terseLabel": "Time deposits and short term investments with original maturity less than 90 days"
       }
      }
     },
     "localname": "CashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities",
        "terseLabel": "Divested business"
       }
      }
     },
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, continuing operations",
        "terseLabel": "Net cash flows used in financing activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, discontinued operations",
        "terseLabel": "Net cash flows used in financing activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) increase (decrease) in current borrowings",
        "negatedTerseLabel": "Change in current financial debts",
        "terseLabel": "Change in current financial debts",
        "totalLabel": "Financial debts cash flows from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "terseLabel": "Net cash flows from/(used in) investing activities",
        "totalLabel": "Total cash flows used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, continuing operations",
        "terseLabel": "Net cash flows from/(used in) investing activities from continuing operations",
        "totalLabel": "Cash flows used in investing activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, discontinued operations",
        "terseLabel": "Cash flows used in/from investing activities from discontinued operations",
        "totalLabel": "Cash flows used in/from investing activities from discontinued operations",
        "verboseLabel": "Net cash flows used in investing activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, continuing operations",
        "totalLabel": "Net cash flows from operating activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, discontinued operations",
        "terseLabel": "Net cash flows from operating activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashTransferred": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash transferred"
       }
      }
     },
     "localname": "CashTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in equity",
        "terseLabel": "Movement in the year",
        "totalLabel": "Total of other equity movements"
       }
      }
     },
     "localname": "ChangesInEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r134",
      "r136",
      "r231",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r134",
      "r231",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r336"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Total outstanding shares"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommercialPapersIssued": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Commercial papers issued",
        "terseLabel": "Commercial Papers"
       }
      }
     },
     "localname": "CommercialPapersIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Other comprehensive income to be eventually recycled into the consolidated income statement"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Other comprehensive income never to be recycled into the consolidated income statement"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r2",
      "r40",
      "r195",
      "r197",
      "r212",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income [abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "terseLabel": "Attributable to"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r2",
      "r43"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r2",
      "r44"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "terseLabel": "Shareholders of Novartis AG"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration paid (received)",
        "terseLabel": "Net cash inflows from divestment"
       }
      }
     },
     "localname": "ConsiderationPaidReceived",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Construction in progress [member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date"
       }
      }
     },
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities recognised as of acquisition date"
       }
      }
     },
     "localname": "ContingentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing and discontinued operations [axis]"
       }
      }
     },
     "localname": "ContinuingAndDiscontinuedOperationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ContinuingOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing operations [member]",
        "terseLabel": "Continuing operations"
       }
      }
     },
     "localname": "ContinuingOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contractual commitments for acquisition of property, plant and equipment",
        "terseLabel": "Commitments for purchases of property, plant and equipment"
       }
      }
     },
     "localname": "ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by employer, net defined benefit liability (asset)",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by plan participants, net defined benefit liability (asset)",
        "negatedTerseLabel": "Contributions of associates",
        "terseLabel": "Contributions of associates"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of inventories recognised as expense during period",
        "negatedTerseLabel": "Amount of inventory recognized as expense"
       }
      }
     },
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r0",
      "r53"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "negatedTerseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CountryOfDomicileMember": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office."
       }
      },
      "en-us": {
       "role": {
        "label": "Country of domicile [member]",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CountryOfDomicileMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "auth_ref": [
      "r121",
      "r125",
      "r200",
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r30",
      "r208",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 17.2,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "totalLabel": "Total current assets without disposal group"
       }
      }
     },
     "localname": "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current deferred income other than current contract liabilities"
       }
      }
     },
     "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentInterestPayable": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current interest payable. [Refer: Interest payable]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current interest payable",
        "terseLabel": "Accrued interests on financial debt"
       }
      }
     },
     "localname": "CurrentInterestPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "negatedTerseLabel": "Less current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r31",
      "r210",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities other than liabilities included in disposal groups classified as held for sale",
        "totalLabel": "Total current liabilities without disposal group"
       }
      }
     },
     "localname": "CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentMember": {
     "auth_ref": [
      "r391",
      "r404",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a current time band."
       }
      },
      "en-us": {
       "role": {
        "label": "Current [member]"
       }
      }
     },
     "localname": "CurrentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentPortionOfLongtermBorrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current portion of non-current borrowings",
        "negatedTerseLabel": "Less current portion of non-current financial debt",
        "terseLabel": "Current portion of non-current financial debt",
        "verboseLabel": "Less current portion of non-current financial debt"
       }
      }
     },
     "localname": "CurrentPortionOfLongtermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentRefundsProvision": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 15.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current refunds provision",
        "periodEndLabel": "Provisions for deductions from revenue, at end of period",
        "periodStartLabel": "Provisions for deductions from revenue, at beginning of period",
        "terseLabel": "Provisions for deductions from revenue"
       }
      }
     },
     "localname": "CurrentRefundsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current service cost, net defined benefit liability (asset)",
        "negatedTerseLabel": "Current service cost",
        "terseLabel": "Current service cost"
       }
      }
     },
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "CurrentTaxAssetsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "negatedTerseLabel": "Current tax expense (income)",
        "terseLabel": "Current income tax expense"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Current income tax liabilities"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "periodEndLabel": "Provisions at end of period",
        "periodStartLabel": "Provisions at beginning of period",
        "terseLabel": "Total trade receivables, net",
        "verboseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "terseLabel": "VAT Receivable"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DebtInstrumentsHeld": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of instruments representing indebtedness held by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Debt instruments held",
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt securities held"
       }
      }
     },
     "localname": "DebtInstrumentsHeld",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DebtSecuritiesMember": {
     "auth_ref": [
      "r381",
      "r383"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      },
      "en-us": {
       "role": {
        "label": "Debt securities [member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in other provisions resulting from the loss of control of a subsidiary. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through loss of control of subsidiary, other provisions",
        "negatedTerseLabel": "Provisions related to discontinued operations",
        "terseLabel": "Provisions for doubtful trade receivables related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssets": {
     "auth_ref": [
      "r21",
      "r26",
      "r61"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 8.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "negatedTerseLabel": "Deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets and liabilities [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 5.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets recognised as of acquisition date",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "negatedTerseLabel": "Deferred tax expense (income)",
        "terseLabel": "Deferred tax income"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "terseLabel": "Credited/(charged) to income"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r26",
      "r61"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 10.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities recognised as of acquisition date",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "negatedPeriodEndLabel": "Net deferred tax balance at end of period",
        "negatedPeriodStartLabel": "Net deferred tax balance at beginning of period",
        "negatedTerseLabel": "Net deferred tax balance at beginning of period continuing operations",
        "negatedTotalLabel": "Net deferred tax balance",
        "totalLabel": "Net deferred tax balance"
       }
      }
     },
     "localname": "DeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax relating to items credited (charged) directly to equity",
        "terseLabel": "Charged to equity"
       }
      }
     },
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, at present value",
        "periodEndLabel": "Benefit obligation at end of period",
        "periodStartLabel": "Benefit obligation at beginning of period"
       }
      }
     },
     "localname": "DefinedBenefitObligationAtPresentValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [member]"
       }
      }
     },
     "localname": "DefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]",
        "terseLabel": "Depreciation, amortization and impairments on:"
       }
      }
     },
     "localname": "DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r53",
      "r219",
      "r312",
      "r320",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedTerseLabel": "Depreciation and amortisation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70",
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedTerseLabel": "Depreciation charge",
        "terseLabel": "Depreciation charge"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedTerseLabel": "Depreciation charge",
        "terseLabel": "Depreciation charge"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial assets",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial liabilities",
        "terseLabel": "Fair value of derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for available-for-sale financial assets [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for business combinations [text block]",
        "terseLabel": "Acquisition of assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for contingent liabilities and contingent assets [text block]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]\nEffective 2023-01-01: The description of the entity's material accounting policy information for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Defined benefit pension plans and other post retirement benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currencies"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for goodwill [text block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Government grants"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases",
        "terseLabel": "Leases and right-of-use assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]\nEffective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]",
        "terseLabel": "Non-current assets held for sale or held for distribution to owners"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]\nEffective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Legal and environmental liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for subsidiaries [text block]",
        "terseLabel": "Scope of consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other receivables [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]\nEffective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for treasury shares [text block]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the contingent consideration arrangements and the arrangements for indemnification assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of arrangement for contingent consideration arrangements and indemnification assets"
       }
      }
     },
     "localname": "DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "Impact of adopting significant new IFRS standards"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Growth rate used to extrapolate cash flow projections",
        "terseLabel": "Terminal Growth Rate"
       }
      }
     },
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the justification for using any growth rate to extrapolate cash flow projections that exceeds the long-term average growth rate for the products, industries or country (countries) in which the entity operates, or for the market to which a cash-generating unit (group of units) is dedicated. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of justification for using growth rate that exceeds long-term average growth rate",
        "terseLabel": "Description of growth rate"
       }
      }
     },
     "localname": "DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the nature of a change in accounting policy related to an initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of nature of change in accounting policy"
       }
      }
     },
     "localname": "DescriptionOfNatureOfChangeInAccountingPolicy",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of defined benefit plan amendments, curtailments and settlements. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of plan amendments, curtailments and settlements"
       }
      }
     },
     "localname": "DescriptionOfPlanAmendmentsCurtailmentsAndSettlements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the reasons for transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of reasons for transfers out of Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed",
        "terseLabel": "Gain on distribution",
        "verboseLabel": "Difference between net assets and distribution liability"
       }
      }
     },
     "localname": "DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings per share",
        "totalLabel": "Total diluted earnings per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from continuing operations",
        "terseLabel": "Diluted earnings per share, Continuing operations",
        "verboseLabel": "Continuing operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from discontinued operations",
        "terseLabel": "Diluted earnings per share, Discontinued operations",
        "verboseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings per share [abstract]"
       }
      }
     },
     "localname": "DilutedEarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Dilutive effect of share options on number of ordinary shares",
        "terseLabel": "Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options"
       }
      }
     },
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of business combinations [text block]",
        "terseLabel": "Acquisition of businesses"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Details to the consolidated statements of cash flows"
       }
      }
     },
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "terseLabel": "Deferred tax assets and liablities"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [line items]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments [text block]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r290",
      "r294",
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of employee benefits [text block]",
        "terseLabel": "Post-employment benefits for employees"
       }
      }
     },
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Segmentation of key figures"
       }
      }
     },
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events subsequent to the December 31 consolidated balance sheet date"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement [text block]",
        "terseLabel": "Fair value by hierarchy"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]",
        "terseLabel": "Equity securities measured at fair value through other comprehensive income"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value of investments in equity instruments designated at fair value through other comprehensive income."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Non-current financial debt"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets and goodwill [text block]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInterestExpenseExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interest expense. [Refer: Interest expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interest expense [text block]",
        "terseLabel": "Interest expense and other financial income and expense"
       }
      }
     },
     "localname": "DisclosureOfInterestExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of investments accounted for using equity method [text block]",
        "terseLabel": "Associated companies"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersTable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the entity's major customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [table]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Segmentation - Consolidated income statements"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [line items]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [table]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other current assets [text block]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]",
        "terseLabel": "Provisions and other non-current liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [text block]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [line items]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixTable": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the provision matrix."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [table]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about leases for lessee [abstract]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Disclosure of range of exercise prices of outstanding share options"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Transactions with related parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Equity-based participation plans for employees"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "auth_ref": [
      "r123",
      "r127",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [text block]",
        "terseLabel": "Schedule disclosing information related to associates"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "auth_ref": [
      "r123",
      "r127",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [text block]",
        "terseLabel": "Principal Group subsidiaries and associated companies"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Significant accounting policies",
        "verboseLabel": "Selected critical accounting policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Gross value of tax-loss carry-forwards"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DiscontinuedOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Discontinued operations [member]",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used in the current measurement of fair value less costs of disposal."
       }
      },
      "en-us": {
       "role": {
        "label": "Discount rate used in current measurement of fair value less costs of disposal",
        "terseLabel": "Discount Rate (post-tax)"
       }
      }
     },
     "localname": "DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r285",
      "r469"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for groups of assets, which are to be disposed of together as a group in a single transaction, and the liabilities directly associated with those assets that will be transferred in the transaction."
       }
      },
      "en-us": {
       "role": {
        "label": "Disposal groups classified as held for sale [member]"
       }
      }
     },
     "localname": "DisposalGroupsClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, intangible assets and goodwill",
        "negatedLabel": "Disposals and derecognitions"
       }
      }
     },
     "localname": "DisposalsAndRetirementsIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, property, plant and equipment",
        "negatedTerseLabel": "Disposals and derecognitions",
        "terseLabel": "Disposals and derecognitions"
       }
      }
     },
     "localname": "DisposalsAndRetirementsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaid": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised as distributions to owners",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsPaid",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails3",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid to equity holders of parent, classified as financing activities",
        "negatedTerseLabel": "Dividends paid to shareholders of Novartis AG"
       }
      }
     },
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPayable": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends payable by means of the distribution of non-cash assets to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends payable, non-cash assets distributions",
        "terseLabel": "Dividend in kind distribution liability",
        "verboseLabel": "Derecognition of distribution liability"
       }
      }
     },
     "localname": "DividendsPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners": {
     "auth_ref": [
      "r11",
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends proposed or declared after the reporting period but before financial statements are authorised for issue. Such dividends are not recognised as a liability at the end of the reporting period because no obligation exists at that time."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners",
        "terseLabel": "Dividends proposed"
       }
      }
     },
     "localname": "DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share",
        "terseLabel": "Dividends proposed, cash per share"
       }
      }
     },
     "localname": "DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DividendsReceived": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends received."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends received"
       }
      }
     },
     "localname": "DividendsReceived",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends received, classified as operating activities",
        "terseLabel": "Dividends received from associated companies and others"
       }
      }
     },
     "localname": "DividendsReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends related to investments in equity instruments that the entity has designated at fair value through other comprehensive income, held at the end of the reporting period. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period"
       }
      }
     },
     "localname": "DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r53",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "auth_ref": [
      "r123",
      "r127",
      "r226",
      "r339",
      "r343"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for associates [member]"
       }
      }
     },
     "localname": "EntitysTotalForAssociatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r276",
      "r279"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for segment consolidation items [member]"
       }
      }
     },
     "localname": "EntitysTotalForSegmentConsolidationItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r25",
      "r34",
      "r194",
      "r196",
      "r227",
      "r228",
      "r230"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity at end of period",
        "periodStartLabel": "Equity at beginning of period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Equity attributable to Novartis AG shareholders"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityInstrumentsHeld": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of instruments held by the entity that provide evidence of a residual interest in the assets of another entity after deducting all of its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity instruments held",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquityInstrumentsHeld",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityInvestmentsMember": {
     "auth_ref": [
      "r392",
      "r406"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity investments [member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquityInvestmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense due to unwinding of discount on provisions",
        "negatedTerseLabel": "Expense arising from discounting long-term liabilities and capitalized borrowing costs"
       }
      }
     },
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedTerseLabel": "Equity-based compensation of Novartis equity plans",
        "terseLabel": "Equity-based compensation of Novartis equity plans"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "negatedTerseLabel": "Recognition exception for low value leases",
        "terseLabel": "Recognition exception for low value leases"
       }
      }
     },
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "negatedTerseLabel": "Recognition exemption for short term leases",
        "terseLabel": "Recognition exemption for short term leases"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities"
       }
      }
     },
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of share-based payment arrangement"
       }
      }
     },
     "localname": "ExplanationOfShareOptionsInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "auth_ref": [
      "r286",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs paid, classified as operating activities",
        "negatedTerseLabel": "Other financial payments"
       }
      }
     },
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income received, classified as operating activities",
        "terseLabel": "Other financial receipts"
       }
      }
     },
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r289",
      "r292",
      "r293",
      "r296",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsImpairedMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for financial assets that have been impaired. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets impaired [member]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssetsImpairedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember": {
     "auth_ref": [
      "r186",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy [member]"
       }
      }
     },
     "localname": "FinancialEffectOfChangesInAccountingPolicyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r306",
      "r346"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value",
        "negatedTerseLabel": "Financial liabilities, at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r336"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 11.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities recognised as of acquisition date",
        "negatedTerseLabel": "Current and non-current financial debts"
       }
      }
     },
     "localname": "FinancialLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ForeignCountriesMember": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign countries [member]",
        "terseLabel": "Foreign",
        "verboseLabel": "Rest of the world"
       }
      }
     },
     "localname": "ForeignCountriesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on changes in effect of limiting net defined benefit asset to asset ceiling excluding interest income or expense",
        "terseLabel": "Change in limitation on recognition of fund surplus"
       }
      }
     },
     "localname": "GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on remeasurement, net defined benefit liability (asset)",
        "terseLabel": "Remeasurements"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) recognised as result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before the business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination"
       }
      }
     },
     "localname": "GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) arising from sale and leaseback transactions."
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) arising from sale and leaseback transactions",
        "terseLabel": "Gains or losses from sales leaseback"
       }
      }
     },
     "localname": "GainsLossesArisingFromSaleAndLeasebackTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on available-for-sale financial assets",
        "terseLabel": "Net capital losses on available-for-sale securities"
       }
      }
     },
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r12",
      "r105"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Currency result, net"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnNetMonetaryPosition": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) representing the difference resulting from the restatement of non-monetary assets, owners' equity and items in the statement of comprehensive income and the adjustment of index linked assets and liabilities in hyperinflationary reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on net monetary position",
        "terseLabel": "Monetary loss from hyperinflation"
       }
      }
     },
     "localname": "GainsLossesOnNetMonetaryPosition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r325",
      "r359",
      "r386",
      "r412"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r325",
      "r359",
      "r386",
      "r412"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Goodwill": {
     "auth_ref": [
      "r14",
      "r138",
      "r141",
      "r278"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GoodwillExpectedDeductibleForTaxPurposes": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of goodwill in a business combination that is expected to be deductible for tax purposes. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "GoodwillExpectedDeductibleForTaxPurposes",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GoodwillMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill [member]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill recognised as of acquisition date",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r65",
      "r149",
      "r160",
      "r163",
      "r278",
      "r293",
      "r296",
      "r391",
      "r475",
      "r477"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r248",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Operating lease commitments"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossProfit": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired (liabilities assumed)",
        "terseLabel": "Net assets recognized as a result of acquisitions of business"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLoss": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "negatedLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "negatedTerseLabel": "Impairment charge",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "negatedTerseLabel": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss",
        "negatedLabel": "Impairment (loss) reversal of impairment loss recognised in profit or loss",
        "negatedTerseLabel": "Impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      }
     },
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Consolidated income statements [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r46",
      "r56",
      "r59",
      "r60",
      "r118",
      "r222",
      "r314"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income), continuing operations",
        "negatedLabel": "Income tax expense",
        "negatedTerseLabel": "Income taxes",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r49",
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to components of other comprehensive income",
        "terseLabel": "Credited/(charged) to other comprehensive income",
        "verboseLabel": "Deferred tax on above items"
       }
      }
     },
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "negatedTerseLabel": "Income taxes (paid)/refund"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r172",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as investing activities",
        "negatedTerseLabel": "Income taxes (paid)/refund, classified as investing activities"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r172",
      "r368"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes refund/(paid), classified as operating activities",
        "negatedTerseLabel": "Income taxes paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy and corrections of prior period errors."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember": {
     "auth_ref": [
      "r186",
      "r187"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy required by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy required by IFRSs [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "terseLabel": "Net change in cash and cash equivalents before effect of exchange rate changes"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents from discontinued operations. [Refer: Cash and cash equivalents; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents, discontinued operations",
        "terseLabel": "Net cash flows used in discontinued operations",
        "verboseLabel": "Cash and cash equivalents of discontinued operations"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption"
       }
      }
     },
     "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption"
       }
      }
     },
     "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in dividends payable through a change in the fair value of non-cash assets held for distribution to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners",
        "terseLabel": "Decrease of distribution liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets",
        "terseLabel": "Administrative expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations, deferred tax liability (asset)",
        "negatedTerseLabel": "Impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity",
        "negatedTerseLabel": "Impact of change in ownership of consolidated entities",
        "terseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Exercise of options and employee transactions, equity impact"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, other provisions",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from obtaining or losing control of subsidiaries or other businesses. [Refer: Liabilities arising from financing activities; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities",
        "terseLabel": "Impact of acquisitions and divestments of businesses, net"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Equity-based compensation, equity impact",
        "verboseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, equity",
        "terseLabel": "Other movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers and other changes, other provisions",
        "terseLabel": "Transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets and goodwill",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r375",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "New leases"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "periodEndLabel": "Intangible assets and goodwill at end of period",
        "periodStartLabel": "Intangible assets and goodwill at beginning of period",
        "terseLabel": "Net book value"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Intangible assets [member]"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsMaterialToEntity": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that are material to the entity\u2019s financial statements. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets material to entity",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "IntangibleAssetsMaterialToEntity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r14",
      "r153"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r154",
      "r363",
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r221",
      "r311",
      "r320"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "negatedTotalLabel": "Total interest expense",
        "totalLabel": "Total Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense (income), net defined benefit liability (asset)",
        "negatedTerseLabel": "Net interest expense",
        "terseLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedTerseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivable": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a receivable."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "terseLabel": "Accrued interest on debt securities and time deposits"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r17",
      "r99",
      "r350"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 7.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory recognised as of acquisition date",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r51",
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "negatedTerseLabel": "Inventory provisions",
        "terseLabel": "Inventory provisions"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r16",
      "r224",
      "r316"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "terseLabel": "Investment in associated companies",
        "verboseLabel": "Balance sheet value"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]"
       }
      }
     },
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r286",
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments that the entity has designated at fair value through other comprehensive income. It also represents the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in subsidiaries, joint ventures and associates"
       }
      }
     },
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 1.0,
       "parentTag": "nvs_OutstandingShareCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "periodEndLabel": "Share capital at end of period",
        "periodStartLabel": "Share capital at beginning of period",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 1.5,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Benefits other than equity-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel of entity or parent [member]"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LandMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Land [member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": {
     "auth_ref": [
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years and not later than ten years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years and not later than ten years [member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r402",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "Later than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than four years and not later than five years [member]"
       }
      }
     },
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r394",
      "r399",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one month and not later than three months [member]"
       }
      }
     },
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r395",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "Between one and five years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r28",
      "r415",
      "r419"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "auth_ref": [
      "r396",
      "r401",
      "r405",
      "r415",
      "r418"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than six months and not later than one year [member]"
       }
      }
     },
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "auth_ref": [
      "r396",
      "r400",
      "r405",
      "r415",
      "r417"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three months and not later than six months [member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than four years [member]"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than three years [member]"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "negatedLabel": "Lease liability",
        "negatedTerseLabel": "Current and non-current lease liabilities",
        "terseLabel": "Lease liability",
        "totalLabel": "Impact of adoption of IFRS 16 Leases"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LegalProceedingsProvisionMember": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a provision for legal proceedings. [Refer: Other provisions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Legal proceedings provision [member]"
       }
      }
     },
     "localname": "LegalProceedingsProvisionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r25",
      "r227",
      "r228",
      "r230",
      "r315",
      "r319"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "negatedLabel": "Total liabilities",
        "negatedTotalLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities from share-based payment transactions",
        "terseLabel": "Accrued share-based payments"
       }
      }
     },
     "localname": "LiabilitiesFromSharebasedPaymentTransactions2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities in subsidiary or businesses acquired or disposed"
       }
      }
     },
     "localname": "LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r22",
      "r284"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities included in disposal groups classified as held for sale",
        "terseLabel": "Liabilities of disposal group held for sale"
       }
      }
     },
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "negatedPeriodEndLabel": "Net liability at end of period",
        "negatedPeriodStartLabel": "Net liability at beginning of period",
        "negatedTerseLabel": "Net liability in the balance sheet at end of period"
       }
      }
     },
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MachineryMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Machinery [member]",
        "terseLabel": "Machinery and other equipment"
       }
      }
     },
     "localname": "MachineryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Material reconciling items [member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r29",
      "r235",
      "r249",
      "r250",
      "r288",
      "r299",
      "r330",
      "r331",
      "r333",
      "r334",
      "r361",
      "r396"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r158",
      "r162",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NameOfSubsidiary": {
     "auth_ref": [
      "r120",
      "r124",
      "r199",
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Name of subsidiary"
       }
      }
     },
     "localname": "NameOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r379",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Net assets liabilities",
        "verboseLabel": "Net assets"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDebt": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Net debt",
        "negatedTerseLabel": "Net debt",
        "terseLabel": "Net debt"
       }
      }
     },
     "localname": "NetDebt",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interest in acquiree recognised at acquisition date",
        "negatedTerseLabel": "Non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterests": {
     "auth_ref": [
      "r23",
      "r198",
      "r202"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests"
       }
      }
     },
     "localname": "NoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r30",
      "r209",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 10.2,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale",
        "terseLabel": "Assets of disposal group held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinanceLeaseReceivables": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current finance lease receivables",
        "terseLabel": "Minimum lease payments from finance lease agreements"
       }
      }
     },
     "localname": "NoncurrentFinanceLeaseReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial assets",
        "terseLabel": "Financial assets",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "NoncurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r31",
      "r211",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLoansAndReceivables": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current loans and receivables",
        "terseLabel": "Long-term loans, advances and security deposits"
       }
      }
     },
     "localname": "NoncurrentLoansAndReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current net defined benefit liability",
        "terseLabel": "Defined benefit pension plans"
       }
      }
     },
     "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentTradeReceivables": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current trade receivables",
        "terseLabel": "Long-term receivables from customers"
       }
      }
     },
     "localname": "NoncurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "auth_ref": [
      "r393",
      "r398",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one month [member]"
       }
      }
     },
     "localname": "NotLaterThanOneMonthMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r27",
      "r249",
      "r250",
      "r334",
      "r396",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Not later than one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotionalAmount": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      },
      "en-us": {
       "role": {
        "label": "Notional amount"
       }
      }
     },
     "localname": "NotionalAmount",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r264",
      "r466"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares",
        "terseLabel": "Granted, number of shares"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r256",
      "r259",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of share options outstanding at end of period",
        "periodStartLabel": "Number of share options outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Number of share options exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedLabel": "Number of share options exercised or sold",
        "negatedTerseLabel": "Number of share options exercised",
        "terseLabel": "Number of share options exercised or sold",
        "verboseLabel": "Number of share options exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "terseLabel": "Number of share options forfeited or expired"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "periodEndLabel": "Number of shares issued at end of period",
        "periodStartLabel": "Number of shares issued at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares outstanding at end of period",
        "periodStartLabel": "Number of shares outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingSegmentsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Operating segments [member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r130",
      "r438"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Total Novartis shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments for non-cash items",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAdjustmentsForNoncashItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments to reconcile profit (loss)",
        "terseLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAssetsMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets [member]",
        "terseLabel": "Financial and other assets including deferred tax assets",
        "verboseLabel": "Machinery &amp; equipment and other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherBorrowings": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other borrowings"
       }
      }
     },
     "localname": "OtherBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities."
       }
      }
     },
     "localname": "OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities."
       }
      }
     },
     "localname": "OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r5",
      "r39",
      "r50",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to available-for-sale financial assets. [Refer: Financial assets available-for-sale; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, available-for-sale financial assets",
        "terseLabel": "Fair value adjustments on marketable securities, net of taxes",
        "verboseLabel": "Available-for-sale marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 7.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges",
        "terseLabel": "Fair value adjustments on deferred cash flow hedges, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxCashFlowHedges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 11.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments",
        "terseLabel": "Fair value adjustments on equity securities, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r32",
      "r50",
      "r444"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 10.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Actuarial gains/losses from defined benefit plans, net of taxes",
        "totalLabel": "Remeasurements from defined benefit plans, total after tax",
        "verboseLabel": "Net actuarial gains/losses from defined benefit plans, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations": {
     "auth_ref": [
      "r50",
      "r157",
      "r328"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 9.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, hedges of net investments in foreign operations",
        "terseLabel": "Net investment hedge"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Total of items to eventually recycle"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.8,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "terseLabel": "Total of items never to be recycled"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Marketable securities, commodities, time deposits and derivative financial instruments",
        "totalLabel": "Total marketable securities, commodities, time deposits and derivative financial instruments"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r19",
      "r217"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "negatedTerseLabel": "Current financial debt",
        "terseLabel": "Financial debts and derivative financial instruments",
        "totalLabel": "Total current financial debt and derivative financial instruments"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentNonfinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current non-financial assets",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets"
       }
      }
     },
     "localname": "OtherCurrentNonfinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentNonfinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current non-financial liabilities",
        "terseLabel": "Provisions and other current liabilities",
        "totalLabel": "Total provisions and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentNonfinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 14.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherExpenseByFunction": {
     "auth_ref": [
      "r53",
      "r117",
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.5,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Other expense, by function",
        "negatedTerseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherExpenseByFunction",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceCost": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance cost",
        "negatedTerseLabel": "Financial expense"
       }
      }
     },
     "localname": "OtherFinanceCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial income and expense",
        "negatedTerseLabel": "Other financial income and expense",
        "terseLabel": "Other financial income and expense",
        "totalLabel": "Total other financial income and expense"
       }
      }
     },
     "localname": "OtherFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r115",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as financing activities",
        "negatedTerseLabel": "Dividends paid to non-controlling interests and other financing cash flows",
        "terseLabel": "Other financing cash flows, net",
        "verboseLabel": "Transaction cost payments"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as investing activities",
        "terseLabel": "Other cash flows used in investing activities, net"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash",
        "terseLabel": "Change in other net current assets and other operating cash flow items"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other intangible assets [member]",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "totalLabel": "Total other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r19",
      "r218"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current financial liabilities",
        "negatedTerseLabel": "Non-current financial debts",
        "terseLabel": "Financial debts",
        "totalLabel": "Total non-current financial debts"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current non-financial assets",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentNonfinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentNonfinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current non-financial liabilities",
        "terseLabel": "Provisions and other non-current liabilities",
        "totalLabel": "Total provisions and other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentNonfinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current receivables",
        "terseLabel": "Other long-term receivables"
       }
      }
     },
     "localname": "OtherNoncurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisions": {
     "auth_ref": [
      "r33",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions",
        "periodEndLabel": "Provision at end of period",
        "periodStartLabel": "Provision at beginning of period"
       }
      }
     },
     "localname": "OtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherRevenue": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other revenue",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Effect of other items"
       }
      }
     },
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PastDueStatusAxis": {
     "auth_ref": [
      "r391",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [axis]"
       }
      }
     },
     "localname": "PastDueStatusAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PastDueStatusMember": {
     "auth_ref": [
      "r391",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [member]"
       }
      }
     },
     "localname": "PastDueStatusMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Past service cost and gains losses arising from settlements, net defined benefit liability (asset)",
        "negatedTerseLabel": "Past service cost and settlements",
        "terseLabel": "Past service cost and settlements"
       }
      }
     },
     "localname": "PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments from changes in ownership interests in subsidiaries that do not result in loss of control",
        "negatedTerseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "PaymentsFromChangesInOwnershipInterestsInSubsidiaries",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments from plan, net defined benefit liability (asset)",
        "negatedTerseLabel": "Benefit payments",
        "terseLabel": "Benefit payments"
       }
      }
     },
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments of lease liabilities",
        "terseLabel": "Repayment of lease liability",
        "verboseLabel": "Payments of lease liabilities, net"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedTerseLabel": "Acquisitions of treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue"
       }
      }
     },
     "localname": "PercentageOfEntitysRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets, at fair value",
        "periodEndLabel": "Fair value of plan assets at end of period",
        "periodStartLabel": "Fair value of plan assets at beginning of period"
       }
      }
     },
     "localname": "PlanAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents",
        "negatedTerseLabel": "Portion of consideration paid (received) consisting of cash and cash equivalents"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined contribution plans"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated [member]"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary": {
     "auth_ref": [
      "r121",
      "r125",
      "r200",
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Principal place of business of subsidiary"
       }
      }
     },
     "localname": "PrincipalPlaceOfBusinessOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations"
       }
      }
     },
     "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from non-current borrowings",
        "negatedTerseLabel": "Proceeds from non-current financial debts",
        "terseLabel": "Proceeds from non-current financial debts",
        "verboseLabel": "Increase in non-current financial debts"
       }
      }
     },
     "localname": "ProceedsFromNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of other long-term assets, classified as investing activities",
        "terseLabel": "Proceeds from sale of other non-current assets"
       }
      }
     },
     "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of intangible assets, classified as investing activities",
        "terseLabel": "Proceeds from sale of intangible assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInterestsInAssociates": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of interests in associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of interests in associates",
        "terseLabel": "Acquisitions and divestments of interests in associated companies, net"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInterestsInAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments other than investments accounted for using equity method",
        "terseLabel": "Proceeds from sale of financial assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of property, plant and equipment",
        "terseLabel": "Proceeds from sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.7,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities",
        "terseLabel": "Proceeds from sale of marketable securities, commodities and time deposits"
       }
      }
     },
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r322",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r322",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r38",
      "r166",
      "r195",
      "r197",
      "r315",
      "r317",
      "r380",
      "r411",
      "r414"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 4.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "Attributable to"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r41",
      "r201"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Profit/loss attributable to shareholders of Novartis AG",
        "verboseLabel": "Shareholders of Novartis AG"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r282",
      "r347",
      "r348",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Income before taxes",
        "totalLabel": "Income before taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "auth_ref": [
      "r38",
      "r213",
      "r315",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations",
        "terseLabel": "Net income",
        "verboseLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "auth_ref": [
      "r47",
      "r52",
      "r214",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from discontinued operations",
        "terseLabel": "Net income from discontinued operations",
        "totalLabel": "Net income from discontinued operations"
       }
      }
     },
     "localname": "ProfitLossFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r362",
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "terseLabel": "Operating income of discontinued operations",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r13",
      "r72"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "periodStartLabel": "Property, plant and equipment at beginning of period"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r73",
      "r363",
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, pledged as security",
        "terseLabel": "Total net book value of property, plant and equipment pledged as collateral for non-current financial debts"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPledgedAsSecurity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 1.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment recognised as of acquisition date",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r122",
      "r126",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r122",
      "r126",
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInAssociate": {
     "auth_ref": [
      "r122",
      "r126",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in associate"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": {
     "auth_ref": [
      "r122",
      "r126",
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in subsidiary"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "Payments/utilizations",
        "negatedTerseLabel": "Cash payments",
        "terseLabel": "Utilization of provisions for doubtful trade receivables"
       }
      }
     },
     "localname": "ProvisionUsedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedTerseLabel": "Purchases of marketable securities, commodities and time deposits"
       }
      }
     },
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investments other than investments accounted for using equity method",
        "negatedTerseLabel": "Purchases of financial assets"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of other long-term assets, classified as investing activities",
        "negatedTerseLabel": "Purchases of other non-current assets"
       }
      }
     },
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Purchase of treasury shares, equity impact",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares, equity impact"
       }
      }
     },
     "localname": "PurchaseOfTreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Exercise prices for outstanding share options [member]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of average effective tax rate and applicable tax rate [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RecurringFairValueMeasurementMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Recurring fair value measurement [member]"
       }
      }
     },
     "localname": "RecurringFairValueMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reduction of issued capital",
        "negatedTerseLabel": "Reduction of share capital"
       }
      }
     },
     "localname": "ReductionOfIssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RefundsProvision": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]"
       }
      }
     },
     "localname": "RefundsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Remaining amortisation period of intangible assets material to entity",
        "terseLabel": "Remaining amortisation period"
       }
      }
     },
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of non-current borrowings",
        "negatedTerseLabel": "Repayments of the current portion of non-current financial debts",
        "terseLabel": "Repayments of non-current financial debts"
       }
      }
     },
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedTerseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190",
      "r332",
      "r434"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestructuringProvisionMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Restructuring provision [member]",
        "terseLabel": "Restructuring provision"
       }
      }
     },
     "localname": "RestructuringProvisionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r8",
      "r349"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense",
        "negatedTerseLabel": "Return on plan assets excluding interest income"
       }
      }
     },
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromDividends": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as income. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial income"
       }
      }
     },
     "localname": "RevenueFromDividends",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromInterest": {
     "auth_ref": [
      "r220",
      "r310",
      "r320",
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 9.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income"
       }
      }
     },
     "localname": "RevenueFromInterest",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromRoyalties": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      },
      "en-us": {
       "role": {
        "label": "Royalty income"
       }
      }
     },
     "localname": "RevenueFromRoyalties",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Net sales",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueOfAcquiree": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "RevenueOfAcquiree",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLoss": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as an increase of the carrying amount of an asset or cash-generating unit to its recoverable amount when an impairment loss had been previously recognised. [Refer: Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss"
       }
      }
     },
     "localname": "ReversalOfImpairmentLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill",
        "terseLabel": "Reversal of impairment charge"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Reversal of impairment charge"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfInventoryWritedown": {
     "auth_ref": [
      "r51",
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of inventory write-down",
        "terseLabel": "Reversals of inventory provisions"
       }
      }
     },
     "localname": "ReversalOfInventoryWritedown",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 9.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use assets at end of period",
        "periodStartLabel": "Right-of-use assets at beginning of period"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssetsMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets [member]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Treasury shares movement of period",
        "verboseLabel": "Sale of treasury shares"
       }
      }
     },
     "localname": "SaleOrIssueOfTreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segment consolidation items [axis]"
       }
      }
     },
     "localname": "SegmentConsolidationItemsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r136",
      "r234",
      "r315",
      "r360",
      "r413"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r136",
      "r234",
      "r321",
      "r360",
      "r413"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedTerseLabel": "Selling, general and administration"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax",
        "terseLabel": "Associated companies' movements in comprehensive income",
        "verboseLabel": "Other comprehensive income effect"
       }
      }
     },
     "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r45",
      "r313",
      "r320",
      "r338"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method",
        "negatedTerseLabel": "Loss/(income) from associated companies",
        "terseLabel": "(Loss)/income from associated companies",
        "verboseLabel": "Net income statement effect"
       }
      }
     },
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the total comprehensive income of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Joint ventures [member]; Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of total comprehensive income of associates and joint ventures accounted for using equity method",
        "terseLabel": "Total comprehensive income effect"
       }
      }
     },
     "localname": "ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermBorrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current borrowings",
        "terseLabel": "Bank and other financial debt"
       }
      }
     },
     "localname": "ShorttermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, not classified as cash equivalents",
        "terseLabel": "Time deposits and short-term investments with original maturity more than 90 days"
       }
      }
     },
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits accruals",
        "terseLabel": "Accruals for compensation and benefits including social security"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermRestructuringProvision": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provision for restructuring. [Refer: Restructuring provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current restructuring provision",
        "terseLabel": "Restructuring provisions"
       }
      }
     },
     "localname": "ShorttermRestructuringProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "auth_ref": [
      "r123",
      "r127",
      "r226",
      "r339",
      "r343"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubsidiariesMember": {
     "auth_ref": [
      "r111",
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SurplusDeficitInPlan": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Surplus (deficit) in plan",
        "negatedTerseLabel": "Funded status",
        "terseLabel": "Funded status"
       }
      }
     },
     "localname": "SurplusDeficitInPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense"
       }
      }
     },
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxRateEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect from change in tax rate",
        "terseLabel": "Effect of tax rate change on current and deferred tax assets and liabilities"
       }
      }
     },
     "localname": "TaxRateEffectFromChangeInTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect of adjustments for current tax of prior periods",
        "terseLabel": "Effect of prior year items"
       }
      }
     },
     "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect of expense not deductible in determining taxable profit tax loss",
        "terseLabel": "Effect of disallowed expenditures"
       }
      }
     },
     "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect of revenues exempt from taxation"
       }
      }
     },
     "localname": "TaxRateEffectOfRevenuesExemptFromTaxation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfTaxLosses": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect of tax losses",
        "terseLabel": "Effect of utilization of tax losses brought forward from prior periods"
       }
      }
     },
     "localname": "TaxRateEffectOfTaxLosses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TechnologybasedIntangibleAssetsMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing assets based on technology. Such assets may include patented and unpatented technology, databases as well as trade secrets. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Technology-based intangible assets [member]",
        "terseLabel": "Technologies"
       }
      }
     },
     "localname": "TechnologybasedIntangibleAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "High"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payables",
        "negatedTerseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r291",
      "r295",
      "r391",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "negatedTerseLabel": "Transfers out of Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r129",
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": -1.0
      },
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 2.0,
       "parentTag": "nvs_OutstandingShareCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedPeriodEndLabel": "Treasury shares at end of period",
        "negatedPeriodStartLabel": "Treasury shares at beginning of period",
        "negatedTerseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury shares",
        "verboseLabel": "Total treasury shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnallocatedAmountsMember": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for items that have not been allocated to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Unallocated amounts [member]"
       }
      }
     },
     "localname": "UnallocatedAmountsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused provision reversed, other provisions",
        "negatedTerseLabel": "Releases",
        "terseLabel": "Reversal of provisions for doubtful trade receivables"
       }
      }
     },
     "localname": "UnusedProvisionReversedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period",
        "periodStartLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_WeightedAverageMember": {
     "auth_ref": [
      "r233",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average [member]",
        "terseLabel": "Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares outstanding used in the basic earnings per share"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]"
       }
      }
     },
     "localname": "A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]"
       }
      }
     },
     "localname": "A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]"
       }
      }
     },
     "localname": "A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]"
       }
      }
     },
     "localname": "A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]"
       }
      }
     },
     "localname": "A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]"
       }
      }
     },
     "localname": "A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]"
       }
      }
     },
     "localname": "A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]"
       }
      }
     },
     "localname": "A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]"
       }
      }
     },
     "localname": "A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]"
       }
      }
     },
     "localname": "A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]"
       }
      }
     },
     "localname": "A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]"
       }
      }
     },
     "localname": "A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]"
       }
      }
     },
     "localname": "A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]"
       }
      }
     },
     "localname": "A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]"
       }
      }
     },
     "localname": "A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1APharmaGmbHHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 A Pharma GmbH, Holzkirchen [member]"
       }
      }
     },
     "localname": "A1APharmaGmbHHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]"
       }
      }
     },
     "localname": "A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]"
       }
      }
     },
     "localname": "A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]"
       }
      }
     },
     "localname": "A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]"
       }
      }
     },
     "localname": "A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]"
       }
      }
     },
     "localname": "A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]"
       }
      }
     },
     "localname": "A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]"
       }
      }
     },
     "localname": "A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]"
       }
      }
     },
     "localname": "A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]"
       }
      }
     },
     "localname": "A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]"
       }
      }
     },
     "localname": "A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]"
       }
      }
     },
     "localname": "A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]"
       }
      }
     },
     "localname": "A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]"
       }
      }
     },
     "localname": "A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]"
       }
      }
     },
     "localname": "A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]"
       }
      }
     },
     "localname": "AbadiaRetuertaS.A.SardonDeDueroValladolidMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, fiscal year maturity [table text block]"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies [table text block]"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]"
       }
      }
     },
     "localname": "AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for taxes other than income taxes, current",
        "terseLabel": "Taxes other than income taxes"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest on debt securities and time deposits [member]"
       }
      }
     },
     "localname": "AccruedInterestOnDebtSecuritiesAndTimeDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AccruedRoyaltiesPayableClassifiedAsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued royalties payable classified as current",
        "terseLabel": "Accruals for royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesPayableClassifiedAsCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets held for sale intangible assets and goodwill",
        "terseLabel": "Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets held for sale property plant and equipment",
        "terseLabel": "Accumulated depreciation on assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets related to discontinued operations"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation on disposals, property plant and equipment",
        "terseLabel": "Accumulated depreciation on disposals and derecognitions"
       }
      }
     },
     "localname": "AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated impairments on disposals and derecognition"
       }
      }
     },
     "localname": "AccumulatedImpairmentsOnDisposalsAndDerecognitions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired cash and cash equivalents",
        "negatedTerseLabel": "Acquired cash and cash equivalents"
       }
      }
     },
     "localname": "AcquiredCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 3.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired research and development intangible assets recognised as of acquisition date",
        "terseLabel": "Acquired research and development"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired research and development [member]",
        "terseLabel": "Acquired research and development"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of potentially refundable contingent consideration"
       }
      }
     },
     "localname": "AcquisitionFairValuePotentiallyRefundableContingentConsideration",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of assets (other than through business combinations) by assuming directly related liabilities"
       }
      }
     },
     "localname": "AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of assets (right of use assets) through leasing"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRightOfUseAssetsThroughLeasing",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsAndDivestmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions and divestments [axis]"
       }
      }
     },
     "localname": "AcquisitionsAndDivestmentsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AcquisitionsAndDivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions and divestments [member]"
       }
      }
     },
     "localname": "AcquisitionsAndDivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions [member]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AcquisitionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions",
        "terseLabel": "Effects of currency translation and business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations right-of-use assets",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through finance lease contracts property plant and equipment"
       }
      }
     },
     "localname": "AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ActiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Active [member]",
        "terseLabel": "Active"
       }
      }
     },
     "localname": "ActiveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of interest on savings account",
        "terseLabel": "Interest on savings account"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of interest on savings account [member]",
        "terseLabel": "Interest on savings account"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ActuarialLossesFromDefinedBenefitPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial gains/losses from defined benefit plans [member]",
        "terseLabel": "Actuarial gains/losses from defined benefit plans"
       }
      }
     },
     "localname": "ActuarialLossesFromDefinedBenefitPlansMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdakveoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adakveo [member]"
       }
      }
     },
     "localname": "AdakveoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdditionalAmountOfSettlementInPrinciple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional amount of settlement in principle"
       }
      }
     },
     "localname": "AdditionalAmountOfSettlementInPrinciple",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional borrowings"
       }
      }
     },
     "localname": "AdditionalBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional disclosures related to right-of-use assets and lease liabilities [table text block]",
        "terseLabel": "Additional disclosures related to right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions included in disposal group prior to classification to assets held for sale"
       }
      }
     },
     "localname": "AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions included in disposal group to the date of reclassification"
       }
      }
     },
     "localname": "AdditionsIncludedInDisposalGroupToTheDateOfReclassification",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionsToInvestmentInAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to investment in associated companies",
        "negatedTerseLabel": "Additions to investment in associated companies"
       }
      }
     },
     "localname": "AdditionsToInvestmentInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for change in provisions and other non-current liabilities",
        "terseLabel": "Change in provisions and other non-current liabilities"
       }
      }
     },
     "localname": "AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items from continuing operations [table text block]",
        "terseLabel": "Adjustments for non-cash items from continuing operations"
       }
      }
     },
     "localname": "AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for prepayments and accrued lease payments"
       }
      }
     },
     "localname": "AdjustmentsForPrepaymentsAndAccruedLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Administration costs not reflected in return on plan assets, defined benefit plans",
        "negatedTerseLabel": "Administrative expenses",
        "terseLabel": "Administrative expenses"
       }
      }
     },
     "localname": "AdministrativeExpenseNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdmuneTheraputicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Admune Theraputics [member]",
        "terseLabel": "Admune Theraputics"
       }
      }
     },
     "localname": "AdmuneTheraputicsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advaced Accelerator Applications Iberica, S.L.U. [member]"
       }
      }
     },
     "localname": "AdvacedAcceleratorApplicationsIbericaS.L.U.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advaced Accelerator Applications (Italy) S.r.l. [member]"
       }
      }
     },
     "localname": "AdvacedAcceleratorApplicationsItalyS.r.l.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsAAAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (AAA) [member]",
        "terseLabel": "Advanced Accelerator Applications (AAA)"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsAAAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications International SA, Geneve [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsInternationalSAGeneveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications S.A., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Switzerland SA, Geneve [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (UK &amp; Ireland), London [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUKIrelandLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications USA, Inc., New York, NY [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AeropharmGmbHRudolstadtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aeropharm GmbH, Rudolstadt [member]"
       }
      }
     },
     "localname": "AeropharmGmbHRudolstadtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AfinitorVotubiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Afinitor/Votubia [member]"
       }
      }
     },
     "localname": "AfinitorVotubiaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AimovigMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aimovig [member]"
       }
      }
     },
     "localname": "AimovigMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconAGFribourgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon AG, Fribourg [member]"
       }
      }
     },
     "localname": "AlconAGFribourgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconBrandNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon brand name [member]",
        "verboseLabel": "Alcon brand name"
       }
      }
     },
     "localname": "AlconBrandNameMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCanadaInc.MississaugaOntarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Canada Inc., Mississauga, Ontario [member]"
       }
      }
     },
     "localname": "AlconCanadaInc.MississaugaOntarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCentroamericaS.A.PanamaCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Centroamerica S.A., Panama City [member]"
       }
      }
     },
     "localname": "AlconCentroamericaS.A.PanamaCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]"
       }
      }
     },
     "localname": "AlconChinaOphthalmicProductCo.Ltd.BeijingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCouvreurNVPuursMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon - Couvreur NV, Puurs [member]"
       }
      }
     },
     "localname": "AlconCouvreurNVPuursMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCusiS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Cusi S.A., Barcelona [member]"
       }
      }
     },
     "localname": "AlconCusiS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Eye Care UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "AlconEyeCareUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconFarmacevtikaLLCMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Farmacevtika LLC, Moscow [member]"
       }
      }
     },
     "localname": "AlconFarmacevtikaLLCMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconHealthcareS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Healthcare, S.A., Barcelona [member]"
       }
      }
     },
     "localname": "AlconHealthcareS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconHongKongLimitedHongKongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Hong Kong Limited, Hong Kong [member]"
       }
      }
     },
     "localname": "AlconHongKongLimitedHongKongMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plan, converted, Novartis share options [member]"
       }
      }
     },
     "localname": "AlconInc.EquityPlanConvertedNovartisShareOptionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]"
       }
      }
     },
     "localname": "AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plans, granted to associates prior merger [member]",
        "terseLabel": "Alcon equity plans granted to associates prior merger"
       }
      }
     },
     "localname": "AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconItaliaS.p.A.MilanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Italia S.p.A., Milan [member]"
       }
      }
     },
     "localname": "AlconItaliaS.p.A.MilanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconJapanLtd.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Japan Ltd., Tokyo [member]"
       }
      }
     },
     "localname": "AlconJapanLtd.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "AlconKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesBelgiumBVBAPuursMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Belgium BVBA, Puurs [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesBelgiumBVBAPuursMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Holding Corporation, Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesHoldingCorporationFortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (India) Private Limited, Bangalore [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesIndiaPrivateLimitedBangaloreMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesIrelandLimitedCorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Ireland Limited, Cork City [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesIrelandLimitedCorkCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesThailandLimitedBangkokMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Thailand) Limited, Bangkok [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesThailandLimitedBangkokMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios Chile Ltd., Santiago de Chile [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosChileLtd.SantiagoDeChileMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosS.A.BuenosAiresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios S.A., Buenos Aires [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosS.A.BuenosAiresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "AlconLaboratuvarlariTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLensxInc.AlisoViejoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Lensx, Inc., Aliso Viejo, CA [member]"
       }
      }
     },
     "localname": "AlconLensxInc.AlisoViejoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconManagementSAGenevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Management SA, Geneva [member]"
       }
      }
     },
     "localname": "AlconManagementSAGenevaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon [member]",
        "terseLabel": "Alcon"
       }
      }
     },
     "localname": "AlconMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "AlconNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNederlandB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Nederland B.V., Arnhem [member]"
       }
      }
     },
     "localname": "AlconNederlandB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNordicASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Nordic A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "AlconNordicASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconOphthalmikaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Ophthalmika GmbH, Vienna [member]"
       }
      }
     },
     "localname": "AlconOphthalmikaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaGmbHFreiburgImBreisgauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharma GmbH, Freiburg im Breisgau [member]"
       }
      }
     },
     "localname": "AlconPharmaGmbHFreiburgImBreisgauMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalC.A.CaracasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceutical, C.A., Caracas [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalC.A.CaracasMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalsLtd.FribourgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceuticals Ltd., Fribourg [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalsLtd.FribourgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPolskaSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Polska Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "AlconPolskaSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "AlconPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconRefractivehorizonsLLCFortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Refractivehorizons, LLC, Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconRefractivehorizonsLLCFortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconResearchLtd.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Research, Ltd., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconResearchLtd.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconRomaniaS.R.L.BucharestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Romania S.R.L., Bucharest [member]"
       }
      }
     },
     "localname": "AlconRomaniaS.R.L.BucharestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconSingaporeManufacturingPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]"
       }
      }
     },
     "localname": "AlconSingaporeManufacturingPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconSwitzerlandSARischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Switzerland SA, Risch [member]"
       }
      }
     },
     "localname": "AlconSwitzerlandSARischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation of net book values of goodwill and intangible assets by reporting segment [text block]",
        "terseLabel": "Allocation of net book values of goodwill and intangible assets by reporting segment"
       }
      }
     },
     "localname": "AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AlternativeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative investments [member]",
        "terseLabel": "Alternative investments"
       }
      }
     },
     "localname": "AlternativeInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmblyotechInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amblyotech Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "AmblyotechInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmericanDepositarySharesEachRepresenting1ShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Shares each representing 1 share [member]",
        "terseLabel": "American Depositary Shares each representing 1 share"
       }
      }
     },
     "localname": "AmericanDepositarySharesEachRepresenting1ShareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmiodaroneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amiodarone [member]"
       }
      }
     },
     "localname": "AmiodaroneMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmortizationOfBondsDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of bonds discount",
        "negatedTerseLabel": "Amortization of bonds discount",
        "terseLabel": "Amortization of bonds discount"
       }
      }
     },
     "localname": "AmortizationOfBondsDiscount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of fair value adjustments relating to intangible assets"
       }
      }
     },
     "localname": "AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of fair value adjustments relating to intangible assets tax"
       }
      }
     },
     "localname": "AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationPriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization prior to classification to assets held for sale"
       }
      }
     },
     "localname": "AmortizationPriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountBorrowedUnderTheCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount borrowed under the credit facility"
       }
      }
     },
     "localname": "AmountBorrowedUnderTheCreditFacility",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when most significant parameters for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when POS for level 3 change more than 10%",
        "negatedTerseLabel": "Amount of change in OCI when POS for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when pricing parameters for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfResolvedAction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of resolved action"
       }
      }
     },
     "localname": "AmountOfResolvedAction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfSettlementInPrinciple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of settlement in principle"
       }
      }
     },
     "localname": "AmountOfSettlementInPrinciple",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountRecordedInEquityRelatedToHyperinflation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount recorded in equity related to hyperinflation"
       }
      }
     },
     "localname": "AmountRecordedInEquityRelatedToHyperinflation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognized in the consolidated balance sheet [abstract]"
       }
      }
     },
     "localname": "AmountsRecognizedInTheConsolidatedBalanceSheetAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfOverdueAmountsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of overdue amounts [line items]"
       }
      }
     },
     "localname": "AnalysisOfOverdueAmountsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfOverdueAmountsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of overdue amounts [table]"
       }
      }
     },
     "localname": "AnalysisOfOverdueAmountsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfTaxRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of Tax Rate [table text block]",
        "terseLabel": "Analysis of tax rate"
       }
      }
     },
     "localname": "AnalysisOfTaxRateTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AntiInfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti Infectives [member]"
       }
      }
     },
     "localname": "AntiInfectivesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AntiInfectivesSoldUnderSandozNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti Infectives sold under Sandoz name [member]"
       }
      }
     },
     "localname": "AntiInfectivesSoldUnderSandozNameMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ArctosMedicalAGBernMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arctos Medical AG, Bern [member]"
       }
      }
     },
     "localname": "ArctosMedicalAGBernMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AsiaAfricaAustralasiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia/Africa/Australasia [member]"
       }
      }
     },
     "localname": "AsiaAfricaAustralasiaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AspenGlobalIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aspen Global Incorporated [member]",
        "terseLabel": "Aspen Global Incorporated"
       }
      }
     },
     "localname": "AspenGlobalIncorporatedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AspenJapanK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aspen Japan K.K., Tokyo [member]"
       }
      }
     },
     "localname": "AspenJapanK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associated companies at fair value through profit and loss [member]"
       }
      }
     },
     "localname": "AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AssociatesSummarizedFinancialInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates summarized financial information [table text block]",
        "terseLabel": "Associates summarized financial information"
       }
      }
     },
     "localname": "AssociatesSummarizedFinancialInformationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions used in the calculation of valuation [text block]",
        "terseLabel": "Assumptions used in the calculation of valuation"
       }
      }
     },
     "localname": "AssumptionsUsedInTheCalculationOfValuationTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AvailableForSaleMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale marketable securities [member]"
       }
      }
     },
     "localname": "AvailableForSaleMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AvailableforsaleFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale financial investments [member]"
       }
      }
     },
     "localname": "AvailableforsaleFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AvailableforsaleLongtermFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale long-term financial investments [member]"
       }
      }
     },
     "localname": "AvailableforsaleLongtermFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AveXisIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AveXis, Inc. [member]",
        "terseLabel": "AveXis, Inc."
       }
      }
     },
     "localname": "AveXisIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AverageEffectiveTaxRateContinuingOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average effective tax rate continuing operations",
        "terseLabel": "Effective tax rate for continuing operations"
       }
      }
     },
     "localname": "AverageEffectiveTaxRateContinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageEffectiveTaxRateDiscontinuedOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average effective tax rate discontinued operations",
        "terseLabel": "Effective tax rate for discontinued operations"
       }
      }
     },
     "localname": "AverageEffectiveTaxRateDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageInterestRateOnBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average interest rate on borrowings"
       }
      }
     },
     "localname": "AverageInterestRateOnBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageInterestRateOnLoansReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average interest rate on loans received"
       }
      }
     },
     "localname": "AverageInterestRateOnLoansReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BalanceSheetItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet item [axis]"
       }
      }
     },
     "localname": "BalanceSheetItemAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BalanceSheetItemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet item [member]"
       }
      }
     },
     "localname": "BalanceSheetItemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BalanceSheetTreatmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet treatment [axis]"
       }
      }
     },
     "localname": "BalanceSheetTreatmentAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BalanceSheetTreatmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet treatment [member]"
       }
      }
     },
     "localname": "BalanceSheetTreatmentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BankAndOtherFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank and other financial debt [member]"
       }
      }
     },
     "localname": "BankAndOtherFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Based Participation Novartis Equity Plan Select outside North America RSU [member]",
        "terseLabel": "dup_7_Annual incentive"
       }
      }
     },
     "localname": "BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beijing Novartis Pharma Co., Ltd., Beijing [member]"
       }
      }
     },
     "localname": "BeijingNovartisPharmaCo.Ltd.BeijingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BeovuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beovu [member]"
       }
      }
     },
     "localname": "BeovuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biopharmaceuticals [member]"
       }
      }
     },
     "localname": "BiopharmaceuticalsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BorrowingsCommercialPaperMaximumAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper maximum amount outstanding"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperMaximumAmountOutstanding",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCommercialPaperMaximumBorrowingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper maximum borrowing amount"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperMaximumBorrowingAmount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCommercialPaperNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper, number of programs"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperNumberOfPrograms",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_BorrowingsCreditFacilityCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility committed"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityCommitted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCreditFacilityShortTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility short term"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityShortTerm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCreditFacilityUncommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility uncommitted"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityUncommitted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsEURMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, EUR [member]"
       }
      }
     },
     "localname": "BorrowingsEURMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BorrowingsInterestRateStepUp": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings interest rate step up",
        "terseLabel": "dup_1_Straight bonds"
       }
      }
     },
     "localname": "BorrowingsInterestRateStepUp",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BorrowingsIssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, issuance date",
        "terseLabel": "Borrowings, issuance year"
       }
      }
     },
     "localname": "BorrowingsIssuanceDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BorrowingsLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, lender",
        "terseLabel": "Borrowings, issuer"
       }
      }
     },
     "localname": "BorrowingsLender",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BorrowingsPremiumDiscount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, premium discount",
        "terseLabel": "Borrowings, issue price"
       }
      }
     },
     "localname": "BorrowingsPremiumDiscount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BorrowingsUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, USD [member]"
       }
      }
     },
     "localname": "BorrowingsUSDMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BrandsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brands [axis]"
       }
      }
     },
     "localname": "BrandsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brands [member]"
       }
      }
     },
     "localname": "BrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Breakdown of defined benefit obligation for pension plans [table]"
       }
      }
     },
     "localname": "BreakdownOfDefinedBenefitObligationForPensionPlansTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]",
        "terseLabel": "Breakdown of defined benefit obligation for pension plans and other post-employment benefit"
       }
      }
     },
     "localname": "BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Divested interest in associate"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_CELLforCURELesUlisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CELLforCURE, Les Ulis [member]"
       }
      }
     },
     "localname": "CELLforCURELesUlisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CELLforCUREMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CELLforCURE [member]"
       }
      }
     },
     "localname": "CELLforCUREMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]",
        "terseLabel": "CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]"
       }
      }
     },
     "localname": "CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionCanadaInc.MississaugaOntarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Canada Inc., Mississauga, Ontario [member]"
       }
      }
     },
     "localname": "CIBAVisionCanadaInc.MississaugaOntarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionCorporationLLCDuluthGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Corporation LLC, Duluth, GA [member]"
       }
      }
     },
     "localname": "CIBAVisionCorporationLLCDuluthGAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionGmbHGrosswallstadtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision GmbH, Grosswallstadt [member]"
       }
      }
     },
     "localname": "CIBAVisionGmbHGrosswallstadtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]"
       }
      }
     },
     "localname": "CIBAVisionJohorSdn.Bhd.KualaLumpurMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_COPDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COPD [member]"
       }
      }
     },
     "localname": "COPDMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSL [member]",
        "terseLabel": "CSL"
       }
      }
     },
     "localname": "CSLMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CadentTherapeuticsCambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cadent Therapeutics, Cambridge, MA [member]"
       }
      }
     },
     "localname": "CadentTherapeuticsCambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CanadaAndLatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada and Latin America [member]"
       }
      }
     },
     "localname": "CanadaAndLatinAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CapitalizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized [member]"
       }
      }
     },
     "localname": "CapitalizedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CardiovascularMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cardiovascular [member]"
       }
      }
     },
     "localname": "CardiovascularMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying reported amount fair value disclosure [member]",
        "terseLabel": "Balance sheet"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CarryingValueOfTheDivestedBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of the divested business"
       }
      }
     },
     "localname": "CarryingValueOfTheDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashAndCashEquivalentsHeldWithFinancialInstitution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's cash and cash equivalents held with financial institution"
       }
      }
     },
     "localname": "CashAndCashEquivalentsHeldWithFinancialInstitution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments",
        "terseLabel": "Current financial assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [table text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and other investments [member]",
        "terseLabel": "Cash and other investments"
       }
      }
     },
     "localname": "CashAndOtherInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CashFlowFromNetIdentifiableAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow (outflow) from Net identifiable assets (acquired) or divested",
        "label": "Net identifiable assets (acquired) or divested",
        "negatedTerseLabel": "Net assets recognized as a result of acquistions of businesses"
       }
      }
     },
     "localname": "CashFlowFromNetIdentifiableAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows arising from acquisitions and divestments of businesses [table text block]",
        "terseLabel": "Cash flows arising from acquisitions and divestments of businesses"
       }
      }
     },
     "localname": "CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashFlowsAttributableToDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows attributable to divested business",
        "terseLabel": "Cash flows attributable to the spin-off of the Alcon business"
       }
      }
     },
     "localname": "CashFlowsAttributableToDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows Attributable to divested business before divested cash and cash equivalents",
        "terseLabel": "Payments out of provisions for transaction costs attributable to the divested business",
        "verboseLabel": "Payments attributable to the spin-off of the Alcon business"
       }
      }
     },
     "localname": "CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows before working capital and provision changes",
        "totalLabel": "Net cash flows from operating activities before working capital and provision changes"
       }
      }
     },
     "localname": "CashFlowsBeforeWorkingCapitalAndProvisionChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]",
        "terseLabel": "Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from discontinued operations [table text block]",
        "terseLabel": "Cash flows from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromDiscontinuedOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashInflowForSaleAndLeaseback": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash inflow for sale and leaseback",
        "negatedTerseLabel": "Cash inflow for sale and leaseback"
       }
      }
     },
     "localname": "CashInflowForSaleAndLeaseback",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash inflow outflow from net identifiable assets divested acquired"
       }
      }
     },
     "localname": "CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOfferPerADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses the amount of cash Novartis paid to the owners of AAA per ADS.",
        "label": "Cash offer per ADS"
       }
      }
     },
     "localname": "CashOfferPerADS",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOfferPerOrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.",
        "label": "Cash offer per ordinary share"
       }
      }
     },
     "localname": "CashOfferPerOrdinaryShare",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows due to derecognized cash and cash equivalents",
        "terseLabel": "dup_3_Divested business"
       }
      }
     },
     "localname": "CashOutflowsDueToDerecognizedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsForPaymentsOfLeasesInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows for payments of leases interest"
       }
      }
     },
     "localname": "CashOutflowsForPaymentsOfLeasesInterest",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsForShortTermAndLowValueLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows for short term and low value leases"
       }
      }
     },
     "localname": "CashOutflowsForShortTermAndLowValueLeases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows from interest bearing accounts of employees payable on demand"
       }
      }
     },
     "localname": "CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash receipts and payments fair value measurement assets"
       }
      }
     },
     "localname": "CashReceiptsAndPaymentsFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]"
       }
      }
     },
     "localname": "CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CellerysAGSchlierenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cellerys AG, Schlieren [member]"
       }
      }
     },
     "localname": "CellerysAGSchlierenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Change25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change, 25 basis point [member]",
        "terseLabel": "25 basis point change"
       }
      }
     },
     "localname": "Change25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChangeInActuarialAssumptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in actuarial assumption [axis]"
       }
      }
     },
     "localname": "ChangeInActuarialAssumptionAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangeInActuarialAssumptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in actuarial assumption [member]"
       }
      }
     },
     "localname": "ChangeInActuarialAssumptionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChangeInCashSettledShareBasedPaymentsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in cash settled share based payments liabilities"
       }
      }
     },
     "localname": "ChangeInCashSettledShareBasedPaymentsLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in net current assets and other operating cash flow items",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChangeOverPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change over period [axis]"
       }
      }
     },
     "localname": "ChangeOverPeriodAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [line items]"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [table]"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [text block]",
        "terseLabel": "Changes in consolidated statements of comprehensive income"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ChangesInOffsetAgainstGrossTradeReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in offset against gross trade receivables",
        "negatedTerseLabel": "Changes in offset against gross trade receivables"
       }
      }
     },
     "localname": "ChangesInOffsetAgainstGrossTradeReceivables",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China Novartis Institute for BioMedical Research Co.,Ltd. [member]"
       }
      }
     },
     "localname": "ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]"
       }
      }
     },
     "localname": "ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CibaGeigyJapanLimitedTokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ciba-Geigy Japan Limited, Tokyo [member]"
       }
      }
     },
     "localname": "CibaGeigyJapanLimitedTokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ClarVistaMedicalInc.AlisoViejoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ClarVista Medical, Inc., Aliso Viejo, CA [member]"
       }
      }
     },
     "localname": "ClarVistaMedicalInc.AlisoViejoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CoStimPharmaceuticalsInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CoStim Pharmaceuticals Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "CoStimPharmaceuticalsInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coalesce Product Development Limited, Cambridge, Cambs [member]"
       }
      }
     },
     "localname": "CoalesceProductDevelopmentLimitedCambridgeCambsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial paper [member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommitmentForRepurchaseOfOwnSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment for repurchase of own shares [member]"
       }
      }
     },
     "localname": "CommitmentForRepurchaseOfOwnSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommitmentForRepurchaseOwnShares": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 13.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment for repurchase own shares",
        "negatedTerseLabel": "Commitment for repurchase own shares"
       }
      }
     },
     "localname": "CommitmentForRepurchaseOwnShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies [abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_CommitmentsForLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments for leases not yet commenced"
       }
      }
     },
     "localname": "CommitmentsForLeasesNotYetCommenced",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommitmentsUnderLongtermResearchAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": 1.0,
       "parentTag": "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments under long-term research and development agreements"
       }
      }
     },
     "localname": "CommitmentsUnderLongtermResearchAgreements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_Commodities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commodities"
       }
      }
     },
     "localname": "Commodities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommoditiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commodities [member]"
       }
      }
     },
     "localname": "CommoditiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ConcentrationOfMajorPlansGeographic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the major plans and the concentration of the Group's DBO by geography.",
        "label": "Concentration of major plans, geographic"
       }
      }
     },
     "localname": "ConcentrationOfMajorPlansGeographic",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid for share capital tendered at the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ConsolidatedIncomeStatementEffectsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated income statement effects [table]"
       }
      }
     },
     "localname": "ConsolidatedIncomeStatementEffectsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ConsumerHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consumer Health [member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerHealthMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Lenses [member]"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration and other financial liabilities [member]"
       }
      }
     },
     "localname": "ContingentConsiderationAndOtherFinancialLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration, current portion",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationCurrentPortion",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liabilities",
        "negatedTerseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationNonCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration paid"
       }
      }
     },
     "localname": "ContingentConsiderationPaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration payables [member]"
       }
      }
     },
     "localname": "ContingentConsiderationPayablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Receivable",
        "terseLabel": "Contingent consideration receivables"
       }
      }
     },
     "localname": "ContingentConsiderationReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivable, current",
        "terseLabel": "Contingent consideration receivable"
       }
      }
     },
     "localname": "ContingentConsiderationReceivableCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivables [member]"
       }
      }
     },
     "localname": "ContingentConsiderationReceivablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationReceivablesShorttermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivables short-term [member]"
       }
      }
     },
     "localname": "ContingentConsiderationReceivablesShorttermMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract manufacturing [member]"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractOrUnderlyingPrincipalAmoutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract or underlying principal amout [member]"
       }
      }
     },
     "localname": "ContractOrUnderlyingPrincipalAmoutMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractRightOfFirstNegotiationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract right of first negotiation term"
       }
      }
     },
     "localname": "ContractRightOfFirstNegotiationTerm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_ContractualInterestOnNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual interest on non-current liabilities",
        "terseLabel": "Contractual interest on non-current liabilities"
       }
      }
     },
     "localname": "ContractualInterestOnNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContributionOfBusinessToJointVenture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of business to joint venture"
       }
      }
     },
     "localname": "ContributionOfBusinessToJointVenture",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation",
        "terseLabel": "Contributions of associates"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Core therapeutic area; other promoted brands; and established brands [axis]"
       }
      }
     },
     "localname": "CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Core therapeutic area; other promoted brands; and established brands [member]"
       }
      }
     },
     "localname": "CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CorporateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate [member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CortheraInc.SanMateoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corthera, Inc., San Mateo, CA [member]"
       }
      }
     },
     "localname": "CortheraInc.SanMateoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CosentyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cosentyx [member]"
       }
      }
     },
     "localname": "CosentyxMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CounterpartyRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty risk [abstract]"
       }
      }
     },
     "localname": "CounterpartyRiskAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CumulativeCurrencyTranslationEffectsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative currency translation effects [member]",
        "terseLabel": "Cumulative currency translation effects"
       }
      }
     },
     "localname": "CumulativeCurrencyTranslationEffectsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative currency translation gains/losses recycled through income statement"
       }
      }
     },
     "localname": "CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Currency exchange rate sensitivity impact against USD in the equity"
       }
      }
     },
     "localname": "CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Currency exchange rate sensitivity impact against USD in the income statement"
       }
      }
     },
     "localname": "CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency, others [member]",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "CurrencyOthersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency translation reserve for net investment hedge, net of taxes"
       }
      }
     },
     "localname": "CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current and deferred Income Tax Expense [table text block]",
        "terseLabel": "Current and deferred income tax expense"
       }
      }
     },
     "localname": "CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 14.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current and non current lease liabilities as of acquisition date",
        "negatedTerseLabel": "Current and non-current lease liabilities"
       }
      }
     },
     "localname": "CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentAssetsDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets divested"
       }
      }
     },
     "localname": "CurrentAssetsDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial debt [member]"
       }
      }
     },
     "localname": "CurrentFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial debts and derivative financial instruments [member]"
       }
      }
     },
     "localname": "CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentFinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial liabilities at fair value [member]"
       }
      }
     },
     "localname": "CurrentFinancialLiabilitiesAtFairValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentIncomeTaxAndDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax liabilities and deferred tax liabilities"
       }
      }
     },
     "localname": "CurrentIncomeTaxAndDeferredTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities [member]"
       }
      }
     },
     "localname": "CurrentLeaseLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentLeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities undiscounted",
        "negatedTerseLabel": "Less current lease liabilities undiscounted",
        "verboseLabel": "Less current lease liabilities undiscounted"
       }
      }
     },
     "localname": "CurrentLeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLiabilitiesDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities divested"
       }
      }
     },
     "localname": "CurrentLiabilitiesDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [member]"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentPortionOfNoncurrentDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of non-current debt [member]"
       }
      }
     },
     "localname": "CurrentPortionOfNoncurrentDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentPortionOfNoncurrentFinancialDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of non-current financial debt"
       }
      }
     },
     "localname": "CurrentPortionOfNoncurrentFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentPrepaidExpensesAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses associated companies",
        "terseLabel": "Prepaid expenses - associated companies"
       }
      }
     },
     "localname": "CurrentPrepaidExpensesAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentPrepaidExpensesThirdParty": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses, third party",
        "terseLabel": "Prepaid expenses - third party"
       }
      }
     },
     "localname": "CurrentPrepaidExpensesThirdParty",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentRefundsProvisionDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current refunds provision, Discontinued operations",
        "periodEndLabel": "Provisions for deductions from revenue, discontinued operations, at end of period",
        "periodStartLabel": "Provisions for deductions from revenue, discontinued operations, at beginning of period",
        "terseLabel": "Provisions for deductions from revenue, discontinued operations"
       }
      }
     },
     "localname": "CurrentRefundsProvisionDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 2.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently marketed products intangible assets recognised as of acquisition date",
        "terseLabel": "Currently marketed products"
       }
      }
     },
     "localname": "CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentlyMarketedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently marketed products [member]",
        "terseLabel": "Currently marketed products"
       }
      }
     },
     "localname": "CurrentlyMarketedProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CustomaryPurchasePriceAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Customary purchase price adjustment"
       }
      }
     },
     "localname": "CustomaryPurchasePriceAdjustment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CustomersWithNetSalesOverFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers with net sales over five percent"
       }
      }
     },
     "localname": "CustomersWithNetSalesOverFivePercent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CyPassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CyPass [member]"
       }
      }
     },
     "localname": "CyPassMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DebtEquityRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt/equity ratio"
       }
      }
     },
     "localname": "DebtEquityRatio",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt securities, breakdown by currency [table text block]",
        "terseLabel": "Debt securities, breakdown by currency"
       }
      }
     },
     "localname": "DebtSecuritiesBreakdownByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_Decrease25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease, 25 basis point [member]",
        "terseLabel": "25 basis point decrease"
       }
      }
     },
     "localname": "Decrease25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through assets related to discontinued operations, intangible assets and goodwill",
        "negatedTerseLabel": "Cost of assets related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through assets related to discontinued operations",
        "negatedTerseLabel": "Costs of assets related to discontinued operations",
        "terseLabel": "Costs of assets related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through liabilities related to discontinued operations",
        "terseLabel": "Financial debts and lease liabilities related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through reclassification to right-of-use assets",
        "negatedTerseLabel": "Decrease through reclassification to right-of-use assets"
       }
      }
     },
     "localname": "DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredCompensationPlansAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation plans assets"
       }
      }
     },
     "localname": "DeferredCompensationPlansAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredPensionersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred pensioners [member]",
        "terseLabel": "Deferred pensioners"
       }
      }
     },
     "localname": "DeferredPensionersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DeferredSalePriceAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred sale price and other adjustments",
        "terseLabel": "dup_1_Divested business"
       }
      }
     },
     "localname": "DeferredSalePriceAndOtherAdjustments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredTaxAssetAndLiabilityValuationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset and liability valuation [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetAndLiabilityValuationAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitAssumptionLifeExpectancyFemale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit assumption life expectancy, female",
        "terseLabel": "Current life expectancy for a 65-year-old female"
       }
      }
     },
     "localname": "DefinedBenefitAssumptionLifeExpectancyFemale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_DefinedBenefitAssumptionLifeExpectancyMale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit assumption life expectancy, male",
        "terseLabel": "Current life expectancy for a 65-year-old male"
       }
      }
     },
     "localname": "DefinedBenefitAssumptionLifeExpectancyMale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, Discontinued operations, at present value",
        "periodEndLabel": "Benefit obligation, Discontinued operations at end of period",
        "periodStartLabel": "Benefit obligation, Discontinued operations at beginning of period"
       }
      }
     },
     "localname": "DefinedBenefitObligationDiscontinuedOperationsAtPresentValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit pension plan, accrued benefit liability",
        "negatedTerseLabel": "Accrued benefit liability",
        "terseLabel": "Accrued benefit liability"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanAccruedBenefitLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in benefit obligation [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in fair value of plan assets [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in net liability [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInNetLiabilityRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureBenefitPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future benefit payment",
        "terseLabel": "Expected future benefit payment"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future benefit payment [abstract]",
        "terseLabel": "Expected future benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future employer contributions [abstract]",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future employer contributions, next fiscal year",
        "terseLabel": "Contributions, next fiscal year (estimated)"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Healthcare cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanInterestCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.",
        "label": "Defined benefit plan, interest cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanPlanAssetAllocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, plan asset allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetAllocations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, recognized net gain (loss) due to curtailments",
        "terseLabel": "Net Pre-tax curtailment gain (loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Settlements, Plan Assets",
        "negatedTerseLabel": "Settlements",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, target plan asset allocations range maximum"
       }
      }
     },
     "localname": "DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, target plan asset allocations range minimum"
       }
      }
     },
     "localname": "DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Year that the rate reaches the ultimate trend rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "gYearItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [abstract]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [line items]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [table]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation charge prior to classification to assets held for sale",
        "negatedTerseLabel": "Depreciation charge prior to classification to assets held for sale"
       }
      }
     },
     "localname": "DepreciationChargePriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instrument, nature of instrument [axis]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentNatureOfInstrumentAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instrument, nature of instrument [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentNatureOfInstrumentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments and accrued interest on derivative financial instruments [line items]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments and accrued interest on derivative financial instruments [table]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, at fair value currency related [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, commodity purchase contract"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsCommodityPurchaseContract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, forward foreign exchange rate contracts"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, options on equity securities"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsOptionsOnEquitySecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, over-the-counter currency options"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsOverthecounterCurrencyOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deriviative financial instruments and accrued interest [member]"
       }
      }
     },
     "localname": "DeriviativeFinancialInstrumentsAndAccruedInterestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets, cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]",
        "terseLabel": "Marketable securities, commodities and non-current financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for healthcare contributions [text block]",
        "terseLabel": "Healthcare contributions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Impairment of associated companies accounted for at equity [text block]",
        "terseLabel": "Impairment of associated companies accounted for at equity"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Impairment of goodwill and intangible assets [text block]",
        "terseLabel": "Impairment of goodwill and intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Intangible assets available-for-use [text block]",
        "terseLabel": "Intangible assets available-for-use"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Intangible assets not yet available-for-use [text block]",
        "terseLabel": "Intangible assets not yet available-for-use"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for other revenue [text block]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForOtherRevenueTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Revenue from Contracts with Customers [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAnnualIncentive": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Annual Incentive"
       }
      }
     },
     "localname": "DescriptionOfAnnualIncentive",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of cases still pending"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of legal questions referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of other cases referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of putative cases referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of states with alleged violations"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DetailedInformationAboutSignificantTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Detailed information about significant transaction"
       }
      }
     },
     "localname": "DetailedInformationAboutSignificantTransaction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net",
        "terseLabel": "Gain on distribution of Alcon Inc. to Novartis AG shareholders"
       }
      }
     },
     "localname": "DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Difference between fair value of distribution liability and net assets at the date of distribution"
       }
      }
     },
     "localname": "DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DiovanGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diovan Group [member]"
       }
      }
     },
     "localname": "DiovanGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DisclosureOfAcquisitionOfBusinessesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of acquisition of businesses [abstract]"
       }
      }
     },
     "localname": "DisclosureOfAcquisitionOfBusinessesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]",
        "terseLabel": "Amount of inventory recognized as an expense in cost of goods sold"
       }
      }
     },
     "localname": "DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]",
        "terseLabel": "Assets and liabilities of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of assets of disposal group classified as held for sale [table text block]",
        "terseLabel": "Assets of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates balance sheet [table text block]",
        "terseLabel": "Schedule disclosing information related to associates, balance sheet value"
       }
      }
     },
     "localname": "DisclosureOfAssociatesBalanceSheetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates, net income effect [table text block]",
        "terseLabel": "Schedule disclosing information related to associates, net income effect"
       }
      }
     },
     "localname": "DisclosureOfAssociatesNetIncomeEffectTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of collaerallized non-current financial debt and pledged assets [table text block]",
        "terseLabel": "Collaerallized non-current financial debt and pledged assets"
       }
      }
     },
     "localname": "DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCommitmentsAndContingenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingencies [text block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingenciesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]",
        "terseLabel": "Comparison of balance sheet and fair value of total non-current financial debt including current portion"
       }
      }
     },
     "localname": "DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of components of non-current financial debts [abstract]"
       }
      }
     },
     "localname": "DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [table text block]",
        "terseLabel": "Current financial debt and derivative instruments"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [text block]",
        "terseLabel": "Current financial debt and derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Deferred Tax Assets and Liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]",
        "terseLabel": "Deferred tax assets/liabilities, expected to have impact on current taxes payable"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDefinedBenefitPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table text block]",
        "terseLabel": "Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]",
        "terseLabel": "Derivative financial instruments and accrued interest on derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, by currency contract [table]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, by type of contract [table]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]",
        "terseLabel": "Contract or underlying principal amount the derivative financial instruments, by currency"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table text block]",
        "terseLabel": "Disclosure of detailed information about borrowings"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about provisions and non-current liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of details to the consolidated statements of cash flows [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of discontinued operations [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDiscontinuedOperationsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of equity [abstract]"
       }
      }
     },
     "localname": "DisclosureOfEquityAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of equity [text block]",
        "terseLabel": "Equity",
        "verboseLabel": "Summary of equity attributable to Novartis AG shareholders"
       }
      }
     },
     "localname": "DisclosureOfEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial and other non-current assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial and other non-current assets [text block]",
        "terseLabel": "Financial and other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets and financial liabilities [table text block]",
        "terseLabel": "Disclosure of financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialInstrumentsNarrativeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments - narrative [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsNarrativeTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of impact on adoption of IFRS 16 [table text block]",
        "terseLabel": "Disclosure of impact on adoption of IFRS 16"
       }
      }
     },
     "localname": "DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfIncomeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Income Tax [abstract]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Interest Expense and Other Financial Income and Expense [abstract]"
       }
      }
     },
     "localname": "DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfLeasingCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Leasing commitments [table text block]",
        "terseLabel": "Leasing commitments"
       }
      }
     },
     "localname": "DisclosureOfLeasingCommitmentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of liabilities of disposal group classified as held for sale [table text block]",
        "terseLabel": "Liabilities of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]",
        "terseLabel": "Disclosure of marketable securities commodities deposits derivative instruments and cash"
       }
      }
     },
     "localname": "DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of lease liability [table text block]",
        "terseLabel": "Disclosure of maturity analysis of lease liability"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of minimum finance lease payments [table text block]",
        "terseLabel": "Minimum finance lease payments"
       }
      }
     },
     "localname": "DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]",
        "terseLabel": "Monitoring of net debt or liquidity based on contractual maturities"
       }
      }
     },
     "localname": "DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Movements of goodwill and intangible assets [text block]",
        "terseLabel": "Movements of goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table text block]",
        "terseLabel": "Reconciliation of the net liability table"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net gain at completion of spin-off [table text block]",
        "terseLabel": "Net gain at completion of spin-off"
       }
      }
     },
     "localname": "DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net sales and selected non-current assets, by countries and regions [table text block]",
        "terseLabel": "Net sales and selected non-current assets, by countries and regions"
       }
      }
     },
     "localname": "DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net sales, by segements and regions [table text block]",
        "terseLabel": "Net sales by region"
       }
      }
     },
     "localname": "DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current financial debt including current portion by currency [table text block]",
        "terseLabel": "Non-current financial debt including current portion by currency"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current financial debt including current portion by maturity [table text block]",
        "terseLabel": "Non-current financial debt including current portion by maturity"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current portion of non-current borrowings by type [table text block]",
        "terseLabel": "Disclosure of non-current portion of non-current borrowings by type"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [roll forward]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, balance sheet and income statement [table text block]",
        "terseLabel": "Segmentation - Consolidated balance sheets and income statement"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, balance sheet [table text block]",
        "terseLabel": "Segmentation - Consolidated balance sheets"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, by countries and regions [table text block]",
        "terseLabel": "Net sales and total of selected non-current assets, by countries and regions",
        "verboseLabel": "Net sales by region"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, net sales of Top 20 products [table text block]",
        "terseLabel": "Net sales of Top 20 products"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, net sales [table text block]",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, other revenue [table text block]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other contractual liabilities of the net debt or liquidity [table text block]",
        "terseLabel": "Other contractual liabilities of the net debt or liquidity"
       }
      }
     },
     "localname": "DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOtherNoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [table text block]",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions and other current liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions and other current liabilities explanatory [text block]",
        "terseLabel": "Provisions and other current liabilities"
       }
      }
     },
     "localname": "DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of receivables denominated in various currencies [table]"
       }
      }
     },
     "localname": "DisclosureOfReceivablesDenominatedInVariousCurrenciesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]",
        "terseLabel": "Recognized amount of inventory provisions and reversals of inventory provision"
       }
      }
     },
     "localname": "DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in fair value measurement [table text block]",
        "terseLabel": "Reconciliation of changes in fair value measurement"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of research and development commitments [table text block]",
        "terseLabel": "Research and Development and other intangible purchase commitments"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of right-of-use assets carrying value and depreciation charge [table text block]",
        "terseLabel": "Disclosure of right-of-use assets carrying value and depreciation charge"
       }
      }
     },
     "localname": "DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Right-of-use assets roll forward [table text block]",
        "terseLabel": "Disclosure of Right-of-use assets roll forward"
       }
      }
     },
     "localname": "DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfSignificantTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant transactions [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantTransactionsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfSignificantTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Significant transactions [text block]",
        "terseLabel": "Significant transactions"
       }
      }
     },
     "localname": "DisclosureOfSignificantTransactionsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]",
        "terseLabel": "Ten day loss fair value VAR model, average, high, and low VAR amounts"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model [table text block]",
        "terseLabel": "Ten day loss fair value VAR model"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]",
        "terseLabel": "Ten day loss fair value VAR model, worst case loss scenario"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of the collateralized non-current financial debt and pledged assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfTradeReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade receivables [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade receivables explanatory [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesExplanatoryTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]",
        "terseLabel": "Unremitted earnings retained by consolidated entities for reinvestment"
       }
      }
     },
     "localname": "DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisposalsAndRetirementsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals and retirements, right-of-use assets",
        "negatedTerseLabel": "Impact of divestments"
       }
      }
     },
     "localname": "DisposalsAndRetirementsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DisposalsFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals fair value measurement assets",
        "negatedTerseLabel": "Disposals fair value measurement assets",
        "terseLabel": "Disposals fair value measurement assets"
       }
      }
     },
     "localname": "DisposalsFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DistributionByWayOfDivindendInKindToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for distribution by way of divindend in kind to shareholders",
        "terseLabel": "Distribution by way of dividend in kind to shareholders"
       }
      }
     },
     "localname": "DistributionByWayOfDivindendInKindToShareholders",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution of dividend to dividend bearing shares to consolidated foundations",
        "terseLabel": "Shares obtained through consolidated foundation"
       }
      }
     },
     "localname": "DistributionOfDividendBearingSharesToConsolidatedFoundations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DistributionOfDividendToDividendBearingShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution of dividend to dividend bearing shares"
       }
      }
     },
     "localname": "DistributionOfDividendToDividendBearingShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divested cash and cash equivalents",
        "negatedTerseLabel": "Divested cash and cash equivalents"
       }
      }
     },
     "localname": "DivestedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentCostToSell": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestment cost to sell"
       }
      }
     },
     "localname": "DivestmentCostToSell",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentDateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration transferred, divestment-date fair value"
       }
      }
     },
     "localname": "DivestmentDateFairValueOfTotalConsiderationTransferred",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentFairValueOfContingentConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contingent consideration received"
       }
      }
     },
     "localname": "DivestmentFairValueOfContingentConsiderationReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestments aquisitions of interests in associated companies",
        "terseLabel": "Acquisitions and divestments of interests in associated companies, net"
       }
      }
     },
     "localname": "DivestmentsAquisitionsOfInterestsInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestments [member]",
        "terseLabel": "Divestments"
       }
      }
     },
     "localname": "DivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DividendPaidNoncashAssetsDistribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend paid, non-cash assets distribution",
        "negatedTerseLabel": "Dividend in kind"
       }
      }
     },
     "localname": "DividendPaidNoncashAssetsDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DividendTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend [table text block]",
        "terseLabel": "Schedule disclosing information related to Dividend"
       }
      }
     },
     "localname": "DividendTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DividendsPayableAmountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends payable, amount per share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "nvs_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DrAlexKrauerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Alex Krauer [member]"
       }
      }
     },
     "localname": "DrAlexKrauerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DrDanielVasellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Daniel Vasella [member]"
       }
      }
     },
     "localname": "DrDanielVasellaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DrJamesBradnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. James Bradner [member]"
       }
      }
     },
     "localname": "DrJamesBradnerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value and remaining amortization period of the most significant assets within currently marketed products [text block]",
        "terseLabel": "Carrying value and remaining amortization period of the most significant assets within currently marketed products"
       }
      }
     },
     "localname": "Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]"
       }
      }
     },
     "localname": "EBEWEPharmaGes.m.b.HNfg.KGViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EffectOfDiscounting": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of discounting",
        "negatedTerseLabel": "Effect of discounting"
       }
      }
     },
     "localname": "EffectOfDiscounting",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of income not subject to tax on divestment gain"
       }
      }
     },
     "localname": "EffectOfIncomeNotSubjectToTaxOnDivestmentGain",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectOfUSTaxReformLegislation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of US tax reform legislation"
       }
      }
     },
     "localname": "EffectOfUSTaxReformLegislation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectOfWriteoffOfDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of write-off of deferred tax assets",
        "terseLabel": "Effect of derecognition and reversals of derecognition of deferred tax assets"
       }
      }
     },
     "localname": "EffectOfWriteoffOfDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation change in enacted tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eli Lilly and Company [member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EmergingGrowthMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Markets [member]"
       }
      }
     },
     "localname": "EmergingGrowthMarketsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EmployerSharesHeldByDefinedBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares held by defined benefit plan"
       }
      }
     },
     "localname": "EmployerSharesHeldByDefinedBenefitPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_EncoreVisionInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "EncoreVisionInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EncoreVisionInc.NewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc., New York, NY [member]"
       }
      }
     },
     "localname": "EncoreVisionInc.NewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EncoreVisionIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc [member]",
        "terseLabel": "Encore Vision, Inc."
       }
      }
     },
     "localname": "EncoreVisionIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "EndocyteInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteInc.LafayetteINMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte, Inc., Lafayette, IN [member]"
       }
      }
     },
     "localname": "EndocyteInc.LafayetteINMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte [member]",
        "terseLabel": "Endocyte"
       }
      }
     },
     "localname": "EndocyteMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EnoxaparinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enoxaparin [member]"
       }
      }
     },
     "localname": "EnoxaparinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EntrestoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entresto [member]"
       }
      }
     },
     "localname": "EntrestoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EnvironmentalProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies",
        "periodEndLabel": "Environmental liabilities provision at end of period",
        "periodStartLabel": "Environmental liabilities provision at beginning of period",
        "totalLabel": "Total environmental remediation liability provisions"
       }
      }
     },
     "localname": "EnvironmentalProvision",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "EnvironmentalProvisionAdditions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, Current",
        "negatedTerseLabel": "Less current provision",
        "verboseLabel": "Environmental remediation liabilities"
       }
      }
     },
     "localname": "EnvironmentalProvisionCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, after ten years",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowAfterTenYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, later than five years, but within ten years",
        "terseLabel": "Due later than five years, but within ten years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, later than two years, but within five years",
        "terseLabel": "Due later than two years, but within five years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, next two years",
        "terseLabel": "Due within two years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, fiscal year maturity [abstract]"
       }
      }
     },
     "localname": "EnvironmentalProvisionFiscalYearMaturityAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, foreign currency translation gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "EnvironmentalProvisionForeignCurrencyTranslationGainLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, payments",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "EnvironmentalProvisionPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionReleases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, releases",
        "negatedTerseLabel": "Releases"
       }
      }
     },
     "localname": "EnvironmentalProvisionReleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision [roll forward]"
       }
      }
     },
     "localname": "EnvironmentalProvisionRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_EnvironmentalRemediationProvisionNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental remediation provisions, non-current",
        "periodEndLabel": "Non-current environmental remediation provisions at end of period",
        "terseLabel": "Environmental remediation provisions"
       }
      }
     },
     "localname": "EnvironmentalRemediationProvisionNoncurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EonLabsInc.PrincetonNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eon Labs, Inc., Princeton, NJ [member]"
       }
      }
     },
     "localname": "EonLabsInc.PrincetonNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedCompensationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation shares"
       }
      }
     },
     "localname": "EquityBasedCompensationShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Annual Incentive Plan [member]",
        "terseLabel": "Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentivePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Annual Incentive RSU [member]",
        "terseLabel": "dup_1_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Annual Incentive Restricted Shares [member]",
        "terseLabel": "dup_2_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Annual Incentive Shares [member]",
        "terseLabel": "dup_3_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Employee Share Ownership Plan [member]",
        "terseLabel": "Employee Share Ownership Plan (ESOP)"
       }
      }
     },
     "localname": "EquityBasedParticipationEmployeeShareOwnershipPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Employee share purchase plan [member]",
        "terseLabel": "Share purchase plans"
       }
      }
     },
     "localname": "EquityBasedParticipationEmployeeSharePurchasePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Leveraged Share Savings Plan [member]",
        "terseLabel": "Leveraged Share Savings Plan (LSSP)"
       }
      }
     },
     "localname": "EquityBasedParticipationLeveragedShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Long Term Performance PSU Plan [member]",
        "terseLabel": "dup_9_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermPerformancePSUPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermPerformancePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Long-Term Performance Plan [member]",
        "terseLabel": "Long-Term Performance Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermPerformancePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Long Term Relative Performance Plan [member]",
        "terseLabel": "Long-Term Relative Performance Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermRelativePerformancePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Long Term Relative Performance Plan PSU [member]"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermRelativePerformancePlanPSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\" [member]",
        "terseLabel": "Select"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\", North America [member]",
        "terseLabel": "Select North America"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Novartis Equity Plan Select North America RSU [member]",
        "terseLabel": "dup_6_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\", outside North America [member]",
        "terseLabel": "Select outside North America"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]",
        "terseLabel": "dup_8_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Other Share Awards [member]",
        "terseLabel": "Other share awards"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards RSU [member]",
        "terseLabel": "dup_11_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards Restricted Shares [member]",
        "terseLabel": "dup_12_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards Shares [member]",
        "terseLabel": "dup_13_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Restricted Shares [member]",
        "terseLabel": "Restricted Shares"
       }
      }
     },
     "localname": "EquityBasedParticipationRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Share Savings Plan [member]",
        "terseLabel": "Share savings plans"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlansRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Share savings plans RSU [member]",
        "terseLabel": "dup_4_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlansRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlansSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Share savings plans Shares [member]",
        "terseLabel": "dup_5_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlansSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationSpecialShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Special Share Awards [member]",
        "terseLabel": "Special share awards"
       }
      }
     },
     "localname": "EquityBasedParticipationSpecialShareAwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationUKShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation UK Share Savings Plan [member]",
        "terseLabel": "UK Share Savings Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationUKShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityImpactOfTreasuryShareMovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity impact of treasury share movements",
        "negatedTotalLabel": "Total equity impact of treasury share movements",
        "totalLabel": "Total equity impact of treasury share movements"
       }
      }
     },
     "localname": "EquityImpactOfTreasuryShareMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Equity price sensitivity impact of the risk factors in the equity"
       }
      }
     },
     "localname": "EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Equity price sensitivity impact of the risk factors in the income statement"
       }
      }
     },
     "localname": "EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity securities [member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstablishedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Established Brands [member]"
       }
      }
     },
     "localname": "EstablishedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstablishedMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Established Markets [member]"
       }
      }
     },
     "localname": "EstablishedMarketsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstimatedAcquisitionFairValueOfTotalConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated acquisition fair value of total consideration",
        "terseLabel": "Estimated fair value purchase price"
       }
      }
     },
     "localname": "EstimatedAcquisitionFairValueOfTotalConsideration",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities, compensation for moral damages"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities, damages claimed"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses a maximal amount.",
        "label": "Estimated financial effect of contingent liabilities, maximum fine"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ExelonExelonPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exelon/Exelon Patch [member]"
       }
      }
     },
     "localname": "ExelonExelonPatchMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExerciseOfOptionsAndEmployeeTransactionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and employee transactions shares"
       }
      }
     },
     "localname": "ExerciseOfOptionsAndEmployeeTransactionsShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ExercisePrice46.4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 46.4 [member]",
        "terseLabel": "46.4"
       }
      }
     },
     "localname": "ExercisePrice46.4Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice46.7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 46.7 [member]",
        "terseLabel": "46.7"
       }
      }
     },
     "localname": "ExercisePrice46.7Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice53.7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 53.7 [member]",
        "terseLabel": "53.7"
       }
      }
     },
     "localname": "ExercisePrice53.7Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice54.5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 54.5 [member]",
        "terseLabel": "54.5"
       }
      }
     },
     "localname": "ExercisePrice54.5Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.0Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.0 [member]",
        "terseLabel": "57.0"
       }
      }
     },
     "localname": "ExercisePrice57.0Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.1 [member]",
        "terseLabel": "57.1"
       }
      }
     },
     "localname": "ExercisePrice57.1Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.6 [member]",
        "terseLabel": "57.6"
       }
      }
     },
     "localname": "ExercisePrice57.6Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice58.3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 58.3 [member]",
        "terseLabel": "58.3"
       }
      }
     },
     "localname": "ExercisePrice58.3Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice65.9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 65.9 [member]",
        "terseLabel": "65.9"
       }
      }
     },
     "localname": "ExercisePrice65.9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice66.0Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 66.0 [member]",
        "terseLabel": "66.0"
       }
      }
     },
     "localname": "ExercisePrice66.0Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice66.1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 66.1 [member]",
        "terseLabel": "66.1"
       }
      }
     },
     "localname": "ExercisePrice66.1Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExforgeGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exforge Group [member]"
       }
      }
     },
     "localname": "ExforgeGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExjadeJadenuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exjade/Jadenu [member]"
       }
      }
     },
     "localname": "ExjadeJadenuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FHoffmanLaRocheAGAndRocheSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "F Hoffman La Roche AG and Roche SpA [member]"
       }
      }
     },
     "localname": "FHoffmanLaRocheAGAndRocheSpAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments financial instruments reconciliation [table text block]",
        "terseLabel": "Fair value adjustments financial instruments reconciliation"
       }
      }
     },
     "localname": "FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_FairValueAdjustmentsOnDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on debt securities [member]",
        "terseLabel": "Fair value adjustments on debt securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnDebtSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on deferred cash flow hedges [member]",
        "terseLabel": "Fair value adjustments on deferred cash flow hedges"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnDeferredCashFlowHedgesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on equity securities [member]",
        "terseLabel": "Fair value adjustments on equity securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on equity securities sold [member]",
        "terseLabel": "Fair value adjustments on equity securities sold"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnEquitySecuritiesSoldMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnFinancialAssetsSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on financial assets sold",
        "negatedTerseLabel": "Fair value adjustments on financial assets sold",
        "terseLabel": "Fair value adjustments on equity securities sold, reclassified to retained earnings"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnFinancialAssetsSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueAdjustmentsOnFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on financial instruments [member]",
        "terseLabel": "dup_1_Fair value adjustments on marketable securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on marketable securities [member]",
        "terseLabel": "Fair value adjustments on marketable securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.",
        "label": "Fair value adjustments recognized in the consolidated statement of comprehensive income"
       }
      }
     },
     "localname": "FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueAdjustmentsRelatedToDivestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments related to divestments"
       }
      }
     },
     "localname": "FairValueAdjustmentsRelatedToDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueByMeasurementBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value by measurement basis [axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FairValueByMeasurementBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value by measurement basis [member]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueDisclosureItemAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value disclosure item amounts [member]",
        "terseLabel": "Fair values"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.",
        "label": "Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held",
        "terseLabel": "Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end"
       }
      }
     },
     "localname": "FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of assets and liabilities arising from acquisitions [table text block]",
        "terseLabel": "Fair value of assets and liabilities arising from acquisitions"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_FairValueOfFundInvestmentsAndEquitySecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of fund investments and equity securities"
       }
      }
     },
     "localname": "FairValueOfFundInvestmentsAndEquitySecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueOfOtherFinancialAssetsSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of other financial assets sold"
       }
      }
     },
     "localname": "FairValueOfOtherFinancialAssetsSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]"
       }
      }
     },
     "localname": "FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities",
        "terseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinanceLeaseObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations [member]"
       }
      }
     },
     "localname": "FinanceLeaseObligationsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 6.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial and other assets"
       }
      }
     },
     "localname": "FinancialAndOtherAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debt [member]"
       }
      }
     },
     "localname": "FinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialDebtUndiscountedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debt - undiscounted [member]"
       }
      }
     },
     "localname": "FinancialDebtUndiscountedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialDebtsAndDerivativeInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debts and derivative instruments",
        "periodEndLabel": "Financial debts and derivative instruments at end of period",
        "periodStartLabel": "Financial debts and derivative instruments at beginning of period"
       }
      }
     },
     "localname": "FinancialDebtsAndDerivativeInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsAdditionalDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - additional disclosure [abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAdditionalDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_FinancialInstrumentsCarryingValueLevel3": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement, carrying value, level 3",
        "periodEndLabel": "Fair value measurement, carrying value, level 3, at end of period",
        "periodStartLabel": "Fair value measurement, carrying value, level 3, at beginning of period"
       }
      }
     },
     "localname": "FinancialInstrumentsCarryingValueLevel3",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsPrincipalAmountsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, principal amounts [axis]"
       }
      }
     },
     "localname": "FinancialInstrumentsPrincipalAmountsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FinancialInstrumentsPrincipalAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, principal amounts [member]"
       }
      }
     },
     "localname": "FinancialInstrumentsPrincipalAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation",
        "terseLabel": "All financial instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to equity market movements",
        "terseLabel": "Instruments sensitive to equity market movements"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to foreign currency exchange rates",
        "terseLabel": "Instruments sensitive to foreign currency exchange rates"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to interest rates",
        "terseLabel": "Instruments sensitive to interest rates"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInvestmentsAndLongtermLoansGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial investments and long-term loans [member]"
       }
      }
     },
     "localname": "FinancialInvestmentsAndLongtermLoansGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five years [member]"
       }
      }
     },
     "localname": "FiveYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FougeraPharmaceuticalsInc.MelvilleNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fougera Pharmaceuticals Inc., Melville, NY [member]"
       }
      }
     },
     "localname": "FougeraPharmaceuticalsInc.MelvilleNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FourYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four years [member]"
       }
      }
     },
     "localname": "FourYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FranchiseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise [axis]"
       }
      }
     },
     "localname": "FranchiseAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FranchiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise [member]"
       }
      }
     },
     "localname": "FranchiseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FundInstrumentsHeld": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund instruments held",
        "terseLabel": "Fund investments"
       }
      }
     },
     "localname": "FundInstrumentsHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FundInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund investments [member]"
       }
      }
     },
     "localname": "FundInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FuturePutOptionToSellBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future put option to sell business"
       }
      }
     },
     "localname": "FuturePutOptionToSellBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_GSKConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Consumer Healthcare [member]",
        "terseLabel": "GSK Consumer Healthcare"
       }
      }
     },
     "localname": "GSKConsumerHealthcareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Oncology Products [member]",
        "terseLabel": "GSK Oncology Products"
       }
      }
     },
     "localname": "GSKOncologyProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKTotalTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Total Transaction [member]",
        "terseLabel": "GSK Total Transaction"
       }
      }
     },
     "localname": "GSKTotalTransactionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Vaccines [member]",
        "terseLabel": "GSK Vaccines"
       }
      }
     },
     "localname": "GSKVaccinesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GainLossOnSaleOfOtherFinancialAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on sale of other financial assets",
        "terseLabel": "Other financial assets sold"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherFinancialAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainOnDivestmentOfInterestsInAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on divestment of interests in associated companies",
        "terseLabel": "Gain on divestment"
       }
      }
     },
     "localname": "GainOnDivestmentOfInterestsInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on value adjustment on comprehensive income",
        "totalLabel": "Total value adjustments"
       }
      }
     },
     "localname": "GainsLossesOnValueAdjustmentOnComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value gains and other adjustments including from divestments recognized in the consolidated income statement"
       }
      }
     },
     "localname": "GainsRecognisedInProfitOrLossFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GalvusGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Galvus Group [member]"
       }
      }
     },
     "localname": "GalvusGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GenentechInc.USAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genentech, Inc., USA [member]"
       }
      }
     },
     "localname": "GenentechInc.USAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GenentechRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genentech / Roche [member]"
       }
      }
     },
     "localname": "GenentechRocheMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GilenyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilenya [member]"
       }
      }
     },
     "localname": "GilenyaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]",
        "terseLabel": "GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK"
       }
      }
     },
     "localname": "GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxoSmithKlinePlcGSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GlaxoSmithKline plc (GSK) [member]",
        "terseLabel": "GlaxoSmithKline plc (GSK)"
       }
      }
     },
     "localname": "GlaxoSmithKlinePlcGSKMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]",
        "terseLabel": "Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex"
       }
      }
     },
     "localname": "GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GleevecGlivecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gleevec/Glivec [member]"
       }
      }
     },
     "localname": "GleevecGlivecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GleevecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gleevec [member]"
       }
      }
     },
     "localname": "GleevecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GrossDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax assets"
       }
      }
     },
     "localname": "GrossDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax liabilities",
        "negatedTerseLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "GrossDeferredTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossLeaseLiabilitiesDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross lease liabilities, Discontinued operations",
        "terseLabel": "Operating lease commitments, discontinued operations"
       }
      }
     },
     "localname": "GrossLeaseLiabilitiesDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross trade receivable from closely monitored countries [table text block]",
        "terseLabel": "Gross trade receivable from closely monitored countries"
       }
      }
     },
     "localname": "GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross value of tax loss carry forwards expiring in future years",
        "terseLabel": "Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets"
       }
      }
     },
     "localname": "GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GroupsOfFinancialAssetsLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Groups of financial assets/liabilities [axis]"
       }
      }
     },
     "localname": "GroupsOfFinancialAssetsLiabilitiesAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_GroupsOfFinancialAssetsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Groups of financial assets/liabilities [member]"
       }
      }
     },
     "localname": "GroupsOfFinancialAssetsLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GyroscopeTherapeuticsHoldingsPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gyroscope Therapeutics Holdings plc. [member]",
        "terseLabel": "Gyroscope Therapeutics Holdings plc."
       }
      }
     },
     "localname": "GyroscopeTherapeuticsHoldingsPlcMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GyroscopeTherapeuticsLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gyroscope Therapeutics Limited, London [member]"
       }
      }
     },
     "localname": "GyroscopeTherapeuticsLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HEXALAGHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HEXAL AG, Holzkirchen [member]"
       }
      }
     },
     "localname": "HEXALAGHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HematologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hematology [member]"
       }
      }
     },
     "localname": "HematologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical100basisPointDecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 100-basis point decrease [member]"
       }
      }
     },
     "localname": "Hypothetical100basisPointDecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical100basisPointIncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 100-basis point increase [member]"
       }
      }
     },
     "localname": "Hypothetical100basisPointIncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical15DecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 15% decrease [member]"
       }
      }
     },
     "localname": "Hypothetical15DecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical15IncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 15% increase [member]"
       }
      }
     },
     "localname": "Hypothetical15IncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical5DecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 5% decrease [member]"
       }
      }
     },
     "localname": "Hypothetical5DecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical5IncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 5% increase [member]"
       }
      }
     },
     "localname": "Hypothetical5IncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease basis point in interest rate sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease percentage in currency rate sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease percentage in equity price sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_IDBHollandBVBaarleNassauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IDB Holland BV, Baarle-Nassau [member]"
       }
      }
     },
     "localname": "IDBHollandBVBaarleNassauMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IDBHollandBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IDB Holland BV [member]"
       }
      }
     },
     "localname": "IDBHollandBVMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IFMTreInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IFM Tre, Inc. [member]",
        "terseLabel": "IFM Tre, Inc."
       }
      }
     },
     "localname": "IFMTreInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IdentifiableAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired",
        "totalLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IlarisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ilaris [member]"
       }
      }
     },
     "localname": "IlarisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImagingEquipmentLtdLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imaging Equipment Ltd, London [member]"
       }
      }
     },
     "localname": "ImagingEquipmentLtdLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImagingEquipmentLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imaging Equipment Ltd [member]"
       }
      }
     },
     "localname": "ImagingEquipmentLtdMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immunology [member]"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImpactLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact location [axis]"
       }
      }
     },
     "localname": "ImpactLocationAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ImpactLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact location [member]"
       }
      }
     },
     "localname": "ImpactLocationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImpactOfDivestmentsOtherProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of divestments, other provisions",
        "terseLabel": "Impact of divestments"
       }
      }
     },
     "localname": "ImpactOfDivestmentsOtherProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities",
        "negatedTerseLabel": "Total revaluation of deferred tax assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law deferred tax expense income recognised in profit or loss",
        "negatedTerseLabel": "Items previously recognized in consolidated income statement"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law deferred tax relating to components of other comprehensive income",
        "negatedTerseLabel": "Items previously recognized in other comprehensive income"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law effective tax rate after implemetation of new law changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI",
        "negatedTerseLabel": "Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to deferred tax assets on unremitted earnings"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings",
        "negatedTerseLabel": "Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law increase decrease in current income tax liability",
        "negatedTerseLabel": "Total revaluation of current income tax liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law increase decrease in deferred tax liability asset",
        "negatedTerseLabel": "Total revaluation of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law tax on unremitted earnings period allowed for payment"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax reform applicable blended tax rate after implemetation of new reform changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax reform applicable tax rate after implemetation of new reform changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charge prior to classification to assets held for sale",
        "negatedTerseLabel": "Impairment charge prior to classification to assets held for sale"
       }
      }
     },
     "localname": "ImpairmentChargePriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges and fair value gains on financial assets, net",
        "negatedTerseLabel": "Impairment charges and fair value gains on financial assets, net",
        "terseLabel": "Impairment charges and fair value gains on financial assets, net"
       }
      }
     },
     "localname": "ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges related to disposal group held for sale"
       }
      }
     },
     "localname": "ImpairmentChargesRelatedToDisposalGroupHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges related to disposal group held for sale to the date of reclassification"
       }
      }
     },
     "localname": "ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 5.5,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss on commodities and available-for-sale securities, net",
        "negatedTerseLabel": "Impairment of commodities and available-for-sale securities, net"
       }
      }
     },
     "localname": "ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, right of use assets",
        "negatedTerseLabel": "Impairment loss recognised in profit or loss, right of use assets"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeBeforeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Before Taxes [table text block]",
        "terseLabel": "Income before taxes"
       }
      }
     },
     "localname": "IncomeBeforeTaxesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_IncomeOnForwardContractsAndOptions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income on forward contracts and options"
       }
      }
     },
     "localname": "IncomeOnForwardContractsAndOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementAdjustmentsOfCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement adjustments of current year",
        "terseLabel": "Additions current year"
       }
      }
     },
     "localname": "IncomeStatementAdjustmentsOfCurrentYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementAdjustmentsOfPriorYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement adjustments of prior year",
        "terseLabel": "Additions prior year"
       }
      }
     },
     "localname": "IncomeStatementAdjustmentsOfPriorYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement location [axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_IncomeStatementLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement location [member]"
       }
      }
     },
     "localname": "IncomeStatementLocationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncomeStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement [member]"
       }
      }
     },
     "localname": "IncomeStatementMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncomeTaxExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "negatedTerseLabel": "Total Income Tax Expense",
        "totalLabel": "Total Income Tax Expense"
       }
      }
     },
     "localname": "IncomeTaxExpense",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_Increase1YearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase, 1 year [member]",
        "terseLabel": "1 year increase"
       }
      }
     },
     "localname": "Increase1YearMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Increase25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase, 25 basis point [member]",
        "terseLabel": "25 basis point increase"
       }
      }
     },
     "localname": "Increase25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy, IFRS 16 [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy, IFRS 9 [member]",
        "terseLabel": "Adjustment, IFRS 9"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease due to revision of prior year amounts [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease in fair value measurement liabilities",
        "negatedTerseLabel": "Changes in fair values, lease interest and other changes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseInNoncontrolingInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in non-controling interests",
        "terseLabel": "Changes in non-controlling interests"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncontrolingInterests",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease of treasury share repurchase obligation under a share buyback trading plan",
        "negatedTerseLabel": "Increase/decrease of treasury share repurchase obligation under a share buyback trading plan",
        "terseLabel": "(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan"
       }
      }
     },
     "localname": "IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, benefit obligation",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)",
        "negatedTerseLabel": "Effect of acquisitions, divestments or transfers",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)",
        "negatedTerseLabel": "Effect of acquisitions, divestments or transfers",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/Decrease through changes in foreign exchange rates fund surplus",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, foreign currency exchange rate gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/Decrease through classified as held for sale, intangible assets and goodwill",
        "negatedTerseLabel": "Cost of assets related to disposal group held for sale"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease through classified as held for sale property plant and equipment",
        "negatedTerseLabel": "Cost of assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease through net exchange differences, right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(Decrease) through new, modified, terminated leases, arising from financing activities",
        "terseLabel": "New, modified and terminated leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other movements deferred tax liability (asset)",
        "negatedTerseLabel": "Other movements",
        "terseLabel": "Other movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase to retained earnings arising from first application of IFRS 9"
       }
      }
     },
     "localname": "IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InnovativeMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innovative Medicines [member]",
        "terseLabel": "Innovative Medicines"
       }
      }
     },
     "localname": "InnovativeMedicinesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IntangibleAssetImpairmentChargesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset impairment charges [text block]",
        "terseLabel": "Intangible asset impairment charges and reversals"
       }
      }
     },
     "localname": "IntangibleAssetImpairmentChargesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_InterestBearningAccountsOfAssociatesPayableOnDemand": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest bearning accounts of associates payable on demand"
       }
      }
     },
     "localname": "InterestBearningAccountsOfAssociatesPayableOnDemand",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest bearning accounts of associates payable on demand [member]"
       }
      }
     },
     "localname": "InterestBearningAccountsOfAssociatesPayableOnDemandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InterestExchanged": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest exchanged"
       }
      }
     },
     "localname": "InterestExchanged",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense [abstract]"
       }
      }
     },
     "localname": "InterestExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, gross",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, defined benefit plans",
        "negatedTerseLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestExpenseIncomeDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [table text block]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_InterestIncomeOnLimitationOfFundSurplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on limitation of fund surplus",
        "negatedTerseLabel": "Interest income on limitation of fund surplus",
        "terseLabel": "Interest income on limitation of fund surplus"
       }
      }
     },
     "localname": "InterestIncomeOnLimitationOfFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payments for amounts included in lease liabilities",
        "negatedTerseLabel": "Interest payments for amounts included in lease liabilities classified as cash flows from operating activities",
        "terseLabel": "Interest payments for amounts included in lease liabilities classified as cash flows from operating activities"
       }
      }
     },
     "localname": "InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestRateSensitivityImpactInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Interest rate sensitivity impact in the income statement"
       }
      }
     },
     "localname": "InterestRateSensitivityImpactInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InventoriesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Disclosure [abstract]"
       }
      }
     },
     "localname": "InventoriesDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "InventoryAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryFinishedGoodsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished goods, Gross [member]",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [line items]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [member]"
       }
      }
     },
     "localname": "InventoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryRawMaterialsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross [member]",
        "terseLabel": "Raw material, consumables"
       }
      }
     },
     "localname": "InventoryRawMaterialsGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryWorkInProgressGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in progress, Gross [member]",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProgressGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IssuedCapitalMovement": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 2.0,
       "parentTag": "nvs_OutstandingShareCapitalMovement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital, movement",
        "terseLabel": "Share capital movement of period"
       }
      }
     },
     "localname": "IssuedCapitalMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_JPCommercialPaperProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JP commercial paper programs [member]"
       }
      }
     },
     "localname": "JPCommercialPaperProgramsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JSCSandozMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JSC Sandoz, Moscow [member]"
       }
      }
     },
     "localname": "JSCSandozMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JakaviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jakavi [member]"
       }
      }
     },
     "localname": "JakaviMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JapatAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japat AG, Basel [member]"
       }
      }
     },
     "localname": "JapatAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KedalionTherapeuticsInc.MenloParkCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kedalion Therapeutics, Inc., Menlo Park, CA [member]"
       }
      }
     },
     "localname": "KedalionTherapeuticsInc.MenloParkCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KesimptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kesimpta [member]"
       }
      }
     },
     "localname": "KesimptaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, annual guaranteed minimum"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationAnnualGuaranteedMinimum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KeyManagementPersonnelCompensationDailyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, daily rate"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationDailyRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, ownership interest acquired"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOwnershipInterestAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_KeyManagementPersonnelCompensationSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, shares acquired"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharesAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, shares acquired, price"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharesAcquiredPrice",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KisqaliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kisqali [member]"
       }
      }
     },
     "localname": "KisqaliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KymriahMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kymriah [member]"
       }
      }
     },
     "localname": "KymriahMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratoires Alcon S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "LaboratoiresAlconS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]"
       }
      }
     },
     "localname": "LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Largest customer [member]"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Largest financial institution [member]"
       }
      }
     },
     "localname": "LargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than five years and not later than six years [member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsAndNotLaterThanSixYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanSixYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than six years [member]",
        "terseLabel": "Later than six years"
       }
      }
     },
     "localname": "LaterThanSixYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than three month and not later than twelve months [member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LeaseContractTerminationsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease contract terminations, right-of-use assets",
        "negatedTerseLabel": "Lease contract terminations, right-of-use assets"
       }
      }
     },
     "localname": "LeaseContractTerminationsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseIncentives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease incentives"
       }
      }
     },
     "localname": "LeaseIncentives",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities and Right of use assets Disclosure Abstract"
       }
      }
     },
     "localname": "LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_LeaseLiabilitiesToBeRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities to be recognized"
       }
      }
     },
     "localname": "LeaseLiabilitiesToBeRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities undiscounted"
       }
      }
     },
     "localname": "LeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseTermEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term end date"
       }
      }
     },
     "localname": "LeaseTermEndDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "gYearItemType"
    },
    "nvs_LeasingCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing commitments [abstract]"
       }
      }
     },
     "localname": "LeasingCommitmentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_LekPharmaceuticalsD.d.LjubjanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lek Pharmaceuticals d.d., Ljubjana [member]"
       }
      }
     },
     "localname": "LekPharmaceuticalsD.d.LjubjanaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LekS.A.StrykowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lek S.A., Strykow [member]"
       }
      }
     },
     "localname": "LekS.A.StrykowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LeqvioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leqvio [member]"
       }
      }
     },
     "localname": "LeqvioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities to banks and other financial institutions [member]"
       }
      }
     },
     "localname": "LiabilitiesToBanksAndOtherFinancialInstitutionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LiabilitiesToBanksAndOtherInstitutions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities to banks and other institutions",
        "negatedTerseLabel": "Liabilities to banks and other financial institutions"
       }
      }
     },
     "localname": "LiabilitiesToBanksAndOtherInstitutions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LifeExpectancyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Life expectancy [member]",
        "terseLabel": "Life expectancy"
       }
      }
     },
     "localname": "LifeExpectancyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LimitationOnRecognitionOfFundSurplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Limitation on recognition of fund surplus",
        "periodEndLabel": "Limitation on recognition of fund surplus at end of period",
        "periodStartLabel": "Limitation on recognition of fund surplus at beginning of period"
       }
      }
     },
     "localname": "LimitationOnRecognitionOfFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ListedEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Listed equity securities [member]"
       }
      }
     },
     "localname": "ListedEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LitigationCaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [member]"
       }
      }
     },
     "localname": "LitigationCaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongTermFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term financial investments [member]"
       }
      }
     },
     "localname": "LongTermFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongTermReceivablesFromFinanceSubleases": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 9.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term receivables from finance subleases"
       }
      }
     },
     "localname": "LongTermReceivablesFromFinanceSubleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LongtermFinancialDebtWithACarryingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term financial debt with a carrying amount"
       }
      }
     },
     "localname": "LongtermFinancialDebtWithACarryingAmount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term financial investments, fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term loans and receivables from customers and finance lease, advances, security deposits [member]"
       }
      }
     },
     "localname": "LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement",
        "negatedTerseLabel": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement",
        "terseLabel": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement"
       }
      }
     },
     "localname": "LossesRecognisedInProfitOrLossFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LucentisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lucentis [member]"
       }
      }
     },
     "localname": "LucentisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LutatheraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lutathera [member]"
       }
      }
     },
     "localname": "LutatheraMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MajorPlansPercentageInGroupDBOPensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major plans percentage in group DBO pensions"
       }
      }
     },
     "localname": "MajorPlansPercentageInGroupDBOPensions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MarketableSecuritiesAndTimeDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities and time deposits [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndTimeDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]",
        "terseLabel": "Marketable securities, commodities, timedeposits, and derivative financial instruments"
       }
      }
     },
     "localname": "MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing related intangible assets [member]",
        "terseLabel": "Marketing know-how"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MassachusettsCaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Massachusetts case [member]"
       }
      }
     },
     "localname": "MassachusettsCaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MatureOphthaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mature Ophtha [member]"
       }
      }
     },
     "localname": "MatureOphthaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MaturityOfNetDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of net debt [line items]"
       }
      }
     },
     "localname": "MaturityOfNetDebtLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MaximalAmountOfShareBuybackProgramm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximal amount of share buyback programm"
       }
      }
     },
     "localname": "MaximalAmountOfShareBuybackProgramm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MaximumHoldingInUnrelatedCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum holding in unrelated company"
       }
      }
     },
     "localname": "MaximumHoldingInUnrelatedCompany",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MaximumMarginPercentageImpactOfCommodityPriceChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum margin percentage impact of commodity price change"
       }
      }
     },
     "localname": "MaximumMarginPercentageImpactOfCommodityPriceChange",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MayzentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mayzent [member]"
       }
      }
     },
     "localname": "MayzentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MilestoneIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone income"
       }
      }
     },
     "localname": "MilestoneIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MilestonePaymentAlreadyReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment already received"
       }
      }
     },
     "localname": "MilestonePaymentAlreadyReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monitoring of net debt or liquidity based on contractual maturities [table]"
       }
      }
     },
     "localname": "MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MoreThanFiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "More than five years [member]"
       }
      }
     },
     "localname": "MoreThanFiveYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MostMaterialLeaseWithLeaseTermExtension": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Most material lease with lease term extension"
       }
      }
     },
     "localname": "MostMaterialLeaseWithLeaseTermExtension",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MostSignificantForeignExchangeLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Most significant foreign exchange losses"
       }
      }
     },
     "localname": "MostSignificantForeignExchangeLosses",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Most signigicant countries percentage on group DBO post employment benefit plans"
       }
      }
     },
     "localname": "MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MovementInDeferredTaxBalanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in deferred tax balance [roll forward]"
       }
      }
     },
     "localname": "MovementInDeferredTaxBalanceRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MovementInTheShareCapitalTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in the share capital [table text block]",
        "terseLabel": "Schedule disclosing information related to movement in the share capital"
       }
      }
     },
     "localname": "MovementInTheShareCapitalTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MovementInTheShareslTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in the shares [table text block]",
        "terseLabel": "Schedule disclosing information related to movement in the shares"
       }
      }
     },
     "localname": "MovementInTheShareslTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MovementsOfPropertyPlantAndEquipmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movements of property, plant and equipment [roll forward]"
       }
      }
     },
     "localname": "MovementsOfPropertyPlantAndEquipmentRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MovementsOfTheRightofuseAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movements of the right-of-use assets [roll forward]"
       }
      }
     },
     "localname": "MovementsOfTheRightofuseAssetsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MyforticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Myfortic [member]"
       }
      }
     },
     "localname": "MyforticMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NAGAndNovartisPharmaSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAG and Novartis Pharma SpA [member]"
       }
      }
     },
     "localname": "NAGAndNovartisPharmaSpAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAG [member]"
       }
      }
     },
     "localname": "NAGMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NPCAndOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NPC and others [member]"
       }
      }
     },
     "localname": "NPCAndOthersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Navigate BioPharma Services, Inc., Carlsbad, CA [member]"
       }
      }
     },
     "localname": "NavigateBioPharmaServicesInc.CarlsbadCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NegativeFairValuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Negative fair values [member]"
       }
      }
     },
     "localname": "NegativeFairValuesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NeoralSandimmunEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neoral/Sandimmun(e) [member]"
       }
      }
     },
     "localname": "NeoralSandimmunEMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NetAssetsDerecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net assets derecognized",
        "negatedTerseLabel": "Net assets derecognized"
       }
      }
     },
     "localname": "NetAssetsDerecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value of Property, plant and equipment under finance lease contracts"
       }
      }
     },
     "localname": "NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in acquisitions and divestments of businesses, classified as investing activities",
        "terseLabel": "Acquisitions and divestments of businesses, net",
        "totalLabel": "Net cash flows"
       }
      }
     },
     "localname": "NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in from divestments of businesses classified as investing activities"
       }
      }
     },
     "localname": "NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashOutflowsFromDivestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash outflows from divestments"
       }
      }
     },
     "localname": "NetCashOutflowsFromDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax balance related to discontinued operations"
       }
      }
     },
     "localname": "NetDeferredTaxBalanceRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets or deferred tax liabilities related to disposal group held for sale",
        "label": "Net deferred tax balance related to disposal group held for sale"
       }
      }
     },
     "localname": "NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net expense, royalties cost sharing and profit sharing",
        "negatedTerseLabel": "Net expense, royalties cost sharing and profit sharing"
       }
      }
     },
     "localname": "NetExpenseRoyaltiesCostSharingAndProfitSharing",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetIdentifiableAssetsOfDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net identifiable assets of divested business"
       }
      }
     },
     "localname": "NetIdentifiableAssetsOfDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss from discontinued operations before gain on distribution"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetInvestmentHedgeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net investment hedge [member]",
        "terseLabel": "Net investment hedge"
       }
      }
     },
     "localname": "NetInvestmentHedgeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net investment hedge recognized in the income statement"
       }
      }
     },
     "localname": "NetInvestmentHedgeRecognizedInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement"
       }
      }
     },
     "localname": "NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetOperatingAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating assets",
        "totalLabel": "Net operating assets"
       }
      }
     },
     "localname": "NetOperatingAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neuroscience [member]"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NeutecPharmaLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neutec Pharma Limited, London [member]"
       }
      }
     },
     "localname": "NeutecPharmaLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NewLeaseArrangements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "New lease arrangements"
       }
      }
     },
     "localname": "NewLeaseArrangements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NonCurrentFinancialDebtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debts [member]"
       }
      }
     },
     "localname": "NonCurrentFinancialDebtsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonExecutiveDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Executive Director [member]"
       }
      }
     },
     "localname": "NonExecutiveDirectorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US-specific healthcare plans and program rebates [member]"
       }
      }
     },
     "localname": "NonUSspecificHealthcarePlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentAndCurrentLiabilitiesDivested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current and current liabilities divested"
       }
      }
     },
     "localname": "NoncurrentAndCurrentLiabilitiesDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentAssetsDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets divested"
       }
      }
     },
     "localname": "NoncurrentAssetsDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [member]"
       }
      }
     },
     "localname": "NoncurrentAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentContingentConsiderationLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current contingent consideration liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentContingentConsiderationLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentFinancialAssetsEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, equity securities"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsEquityInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAssetsFundInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, fund investments"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsFundInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, total financial investments",
        "totalLabel": "Non-current financial assets, total financial investments"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsTotalFinancialInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAsstetsDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial asstets debt securities"
       }
      }
     },
     "localname": "NoncurrentFinancialAsstetsDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debt [member]"
       }
      }
     },
     "localname": "NoncurrentFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentFinancialDebtsCoveredByCollateral": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debts covered by collateral",
        "terseLabel": "Total amount of collateralized non-current financial debts"
       }
      }
     },
     "localname": "NoncurrentFinancialDebtsCoveredByCollateral",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial liabilities at fair value [member]"
       }
      }
     },
     "localname": "NoncurrentFinancialLiabilitiesAtFairValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentLeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities undiscounted"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-healthcare plans and program-related rebates, returns and other deductions [member]"
       }
      }
     },
     "localname": "NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonlistedEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-listed equity securities [member]"
       }
      }
     },
     "localname": "NonlistedEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NotCapitalizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not capitalized [member]"
       }
      }
     },
     "localname": "NotCapitalizedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NotSubjectToExpiryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not subject to expiry [member]"
       }
      }
     },
     "localname": "NotSubjectToExpiryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisArgentinaS.A.BuenosAiresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Argentina S.A., Buenos Aires [member]"
       }
      }
     },
     "localname": "NovartisArgentinaS.A.BuenosAiresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Australia Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "NovartisAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAustriaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Austria GmbH, Vienna [member]"
       }
      }
     },
     "localname": "NovartisAustriaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisB2Ltd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis B2 Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisB2Ltd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisB3Ltd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis B3 Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisB3Ltd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBalticsSIARigaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Baltics SIA, Riga [member]"
       }
      }
     },
     "localname": "NovartisBalticsSIARigaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBangladeshLimitedGazipurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Bangladesh) Limited, Gazipur [member]"
       }
      }
     },
     "localname": "NovartisBangladeshLimitedGazipurMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBiocienciasS.A.SaoPauloMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Biociencias S.A., Sao Paulo [member]"
       }
      }
     },
     "localname": "NovartisBiocienciasS.A.SaoPauloMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBiosciencesPeruS.A.LimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Biosciences Peru S.A., Lima [member]"
       }
      }
     },
     "localname": "NovartisBiosciencesPeruS.A.LimaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBioventuresAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Bioventures AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisBioventuresAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBusinessServicesGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Business Services GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisBusinessServicesGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates1.752025Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.002027Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.202030Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.752050Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisChileS.A.SantiagoDeChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Chile S.A., Santiago de Chile [member]"
       }
      }
     },
     "localname": "NovartisChileS.A.SantiagoDeChileMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCorporationEastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisCorporationEastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]"
       }
      }
     },
     "localname": "NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis de Colombia S.A., Santafe de Bogota [member]"
       }
      }
     },
     "localname": "NovartisDeColombiaS.A.SantafeDeBobotaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeVenezuelaS.A.CaracasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis de Venezuela, S.A., Caracas [member]"
       }
      }
     },
     "localname": "NovartisDeVenezuelaS.A.CaracasMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeutschlandGmbHNurembergMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Deutschland GmbH, Nuremberg [member]"
       }
      }
     },
     "localname": "NovartisDeutschlandGmbHNurembergMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeutschlandGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Deutschland GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisDeutschlandGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisEcuadorS.A.QuitoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ecuador S.A., Quito [member]"
       }
      }
     },
     "localname": "NovartisEcuadorS.A.QuitoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]"
       }
      }
     },
     "localname": "NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaS.p.A.MilanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farma S.p.A., Milan [member]"
       }
      }
     },
     "localname": "NovartisFarmaS.p.A.MilanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaceuticaS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farmaceutica, S.A., Barcelona [member]"
       }
      }
     },
     "localname": "NovartisFarmaceuticaS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farmaceutica, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisFinanceCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceCorporationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Corporation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisFinanceCorporationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceS.A.LuxembourgCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance S.A., Luxembourg City [member]"
       }
      }
     },
     "localname": "NovartisFinanceS.A.LuxembourgCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceServicesLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Services Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisFinanceServicesLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinlandOyEspooMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finland Oy, Espoo [member]"
       }
      }
     },
     "localname": "NovartisFinlandOyEspooMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisForschungsstiftungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Forschungsstiftung, Basel [member]"
       }
      }
     },
     "localname": "NovartisForschungsstiftungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesEULimitedDublinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies EU Limited, Dublin [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesEULimitedDublinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesInc.BannockburnILMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies, Inc., Bannockburn, IL [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesInc.BannockburnILMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Grimsby Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisGrimsbyLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGrimsbyLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Grimsby Limited, London [member]"
       }
      }
     },
     "localname": "NovartisGrimsbyLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Groupe France S.A., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisGroupeFranceS.A.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcareASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "NovartisHealthcareASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare Philippines, Inc., Makati City [member]"
       }
      }
     },
     "localname": "NovartisHealthcarePhilippinesInc.MakatiCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcarePrivateLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare Private Limited, Mumbai [member]"
       }
      }
     },
     "localname": "NovartisHealthcarePrivateLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]"
       }
      }
     },
     "localname": "NovartisHellasS.A.C.I.MetamorphosisAthensMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHoldingAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Holding AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisHoldingAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHoldingJapanK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Holding Japan K.K., Tokyo [member]"
       }
      }
     },
     "localname": "NovartisHoldingJapanK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Hungary Healthcare Limited Liability Company, Budapest [member]"
       }
      }
     },
     "localname": "NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Hungary Healthcare Limited Liability Company [member]"
       }
      }
     },
     "localname": "NovartisHungaryHealthcareLimitedLiabilityCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIndiaLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis India Limited, Mumbai [member]"
       }
      }
     },
     "localname": "NovartisIndiaLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Inflammasome Research, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisInflammasomeResearchInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInflammasomeResearchInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Inflammasome Research, Inc. [member]"
       }
      }
     },
     "localname": "NovartisInflammasomeResearchInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInnovativeTherapiesAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Innovative Therapies AG, Risch [member]"
       }
      }
     },
     "localname": "NovartisInnovativeTherapiesAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]"
       }
      }
     },
     "localname": "NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]"
       }
      }
     },
     "localname": "NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalPharmaceuticalAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International Pharmaceutical AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International Pharmaceutical Investment AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalInvestmentAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInvestmentLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Investment Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisInvestmentLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Investments S.a r.l., Luxembourg City [member]"
       }
      }
     },
     "localname": "NovartisInvestmentsS.aR.l.LuxembourgCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIrelandLimitedDublinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ireland Limited, Dublin [member]"
       }
      }
     },
     "localname": "NovartisIrelandLimitedDublinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIsraelLtd.TelAvivMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Israel Ltd., Tel Aviv [member]"
       }
      }
     },
     "localname": "NovartisIsraelLtd.TelAvivMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "NovartisKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisManufacturingGmbHMarburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Manufacturing GmbH, Marburg [member]"
       }
      }
     },
     "localname": "NovartisManufacturingGmbHMarburgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisManufacturingGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Manufacturing GmbH [member]"
       }
      }
     },
     "localname": "NovartisManufacturingGmbHMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisMiddleEastFZEDubaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Middle East FZE, Dubai [member]"
       }
      }
     },
     "localname": "NovartisMiddleEastFZEDubaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]"
       }
      }
     },
     "localname": "NovartisMitarbeiterbeteiligungsstiftungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis NC [member]"
       }
      }
     },
     "localname": "NovartisNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNetherlandsB.V.AmsterdamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Netherlands B.V., Amsterdam [member]"
       }
      }
     },
     "localname": "NovartisNetherlandsB.V.AmsterdamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNetherlandsB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Netherlands B.V., Arnhem [member]"
       }
      }
     },
     "localname": "NovartisNetherlandsB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNevaLLCSt.PetersburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Neva LLC, St. Petersburg [member]"
       }
      }
     },
     "localname": "NovartisNevaLLCSt.PetersburgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNewZealandLtdAucklandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis New Zealand Ltd, Auckland [member]"
       }
      }
     },
     "localname": "NovartisNewZealandLtdAucklandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNorgeASOsloMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Norge AS, Oslo [member]"
       }
      }
     },
     "localname": "NovartisNorgeASOsloMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Optogenetics Research, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisOptogeneticsResearchInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisOverseasInvestmentsAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Overseas Investments AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisOverseasInvestmentsAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPensionFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pension Fund [member]"
       }
      }
     },
     "localname": "NovartisPensionFundMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisPharmaAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaB.V.AmsterdamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma B.V., Amsterdam [member]"
       }
      }
     },
     "localname": "NovartisPharmaB.V.AmsterdamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma B.V., Arnhem [member]"
       }
      }
     },
     "localname": "NovartisPharmaB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaGmbHNurembergMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma GmbH, Nuremberg [member]"
       }
      }
     },
     "localname": "NovartisPharmaGmbHNurembergMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma GmbH, Vienna [member]"
       }
      }
     },
     "localname": "NovartisPharmaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma K.K., Tokyo [member]"
       }
      }
     },
     "localname": "NovartisPharmaK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaKKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma K.K. [member]"
       }
      }
     },
     "localname": "NovartisPharmaKKMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaLLCMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma LLC, Moscow [member]"
       }
      }
     },
     "localname": "NovartisPharmaLLCMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaLogisticsInc.PanamaCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma (Logistics), Inc., Panama City [member]"
       }
      }
     },
     "localname": "NovartisPharmaLogisticsInc.PanamaCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaMarocSACasablancaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Maroc SA, Casablanca [member]"
       }
      }
     },
     "localname": "NovartisPharmaMarocSACasablancaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "NovartisPharmaNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaPakistanLimitedKarachiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma (Pakistan) Limited, Karachi [member]"
       }
      }
     },
     "localname": "NovartisPharmaPakistanLimitedKarachiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaProduktionsGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Produktions GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisPharmaProduktionsGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaS.A.E.CairoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma S.A.E., Cairo [member]"
       }
      }
     },
     "localname": "NovartisPharmaS.A.E.CairoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisPharmaS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSchweizAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Schweiz AG, Risch [member]"
       }
      }
     },
     "localname": "NovartisPharmaSchweizAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSchweizerhalleAGMuttenzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Schweizerhalle AG, Muttenz [member]"
       }
      }
     },
     "localname": "NovartisPharmaSchweizerhalleAGMuttenzMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaServicesAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Services AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisPharmaServicesAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Services Romania S.R.L., Bucharest [member]"
       }
      }
     },
     "localname": "NovartisPharmaServicesRomaniaS.R.L.BucharestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSteinAGSteinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Stein AG, Stein [member]"
       }
      }
     },
     "localname": "NovartisPharmaSteinAGSteinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsCorporationEastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsHKLimitedHongKongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsHKLimitedHongKongMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsUKLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals UK Limited, London [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsUKLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPolandSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Poland Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "NovartisPolandSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPortugalSGPSLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Portugal SGPS Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "NovartisPortugalSGPSLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]"
       }
      }
     },
     "localname": "NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis s.r.o., Prague [member]"
       }
      }
     },
     "localname": "NovartisS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSaudiLtd.RiyadhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Saudi Ltd., Riyadh [member]"
       }
      }
     },
     "localname": "NovartisSaudiLtd.RiyadhMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Securities Investment Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisSecuritiesInvestmentLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisServicesInc.EastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Services, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisServicesInc.EastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSingaporePteLtd.SingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Singapore) Pte Ltd., Singapore [member]"
       }
      }
     },
     "localname": "NovartisSingaporePteLtd.SingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSlovakiaS.r.o.BratislavaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Slovakia s.r.o., Bratislava [member]"
       }
      }
     },
     "localname": "NovartisSlovakiaS.r.o.BratislavaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSouthAfricaPtyLtdMidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis South Africa (Pty) Ltd, Midrand [member]"
       }
      }
     },
     "localname": "NovartisSouthAfricaPtyLtdMidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisStiftungFuerKaderausbildungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Stiftung fuer Kaderausbildung, Basel [member]"
       }
      }
     },
     "localname": "NovartisStiftungFuerKaderausbildungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisStiftungFuerMenschUndUmweltBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Stiftung fuer Mensch und Umwelt, Basel [member]"
       }
      }
     },
     "localname": "NovartisStiftungFuerMenschUndUmweltBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSverigeABStockholmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Sverige AB, Stockholm [member]"
       }
      }
     },
     "localname": "NovartisSverigeABStockholmMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTaiwanCo.Ltd.TaipeiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Taiwan) Co., Ltd., Taipei [member]"
       }
      }
     },
     "localname": "NovartisTaiwanCo.Ltd.TaipeiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTechnologyLLCInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Technology LLC, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisTechnologyLLCInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTechnologyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Technology LLC [member]"
       }
      }
     },
     "localname": "NovartisTechnologyLLCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisThailandLimitedBangkokMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Thailand) Limited, Bangkok [member]"
       }
      }
     },
     "localname": "NovartisThailandLimitedBangkokMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUKLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis UK Limited, London [member]"
       }
      }
     },
     "localname": "NovartisUKLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUSFoundationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis US Foundation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisUSFoundationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUSFoundationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis US Foundation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisUSFoundationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vietnam Company Limited, Ho Chi Minh City [member]"
       }
      }
     },
     "localname": "NovartisVietnamCompanyLimitedHoChiMinhCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovistaInsuranceLimitedGibraltarCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novista Insurance Limited, Gibraltar City [member]"
       }
      }
     },
     "localname": "NovistaInsuranceLimitedGibraltarCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NumberOfBearerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of bearer shares"
       }
      }
     },
     "localname": "NumberOfBearerShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_NumberOfBrandsInPortfolioToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of brands in portfolio to acquire"
       }
      }
     },
     "localname": "NumberOfBrandsInPortfolioToAcquire",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfBusinessUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Business Units"
       }
      }
     },
     "localname": "NumberOfBusinessUnits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfCommercialOrganizationalUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of commercial organizational units"
       }
      }
     },
     "localname": "NumberOfCommercialOrganizationalUnits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfContractsWithRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of contracts with related parties"
       }
      }
     },
     "localname": "NumberOfContractsWithRelatedParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfEmployeesAssociatedWithTheProductTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employees associated with the product transfer"
       }
      }
     },
     "localname": "NumberOfEmployeesAssociatedWithTheProductTransfer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfFranchises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Franchises"
       }
      }
     },
     "localname": "NumberOfFranchises",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of investments in equity instruments designated at fair value through other comprehensive income"
       }
      }
     },
     "localname": "NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfMarketsForTheAcquiredBrands": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of markets for the acquired brands"
       }
      }
     },
     "localname": "NumberOfMarketsForTheAcquiredBrands",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfOptionsRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options repurchased"
       }
      }
     },
     "localname": "NumberOfOptionsRepurchased",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "pureItemType"
    },
    "nvs_NumberOfOrdinarySharePerADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary share per ADS"
       }
      }
     },
     "localname": "NumberOfOrdinarySharePerADS",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfOtherShareSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other share sales",
        "terseLabel": "Other share sales"
       }
      }
     },
     "localname": "NumberOfOtherShareSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_NumberOfProductsInPortfolioToBeSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of products in portfolio to be sold"
       }
      }
     },
     "localname": "NumberOfProductsInPortfolioToBeSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfTreasuryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of treasury shares",
        "periodEndLabel": "Number of treasury shares at end of period",
        "periodStartLabel": "Number of treasury shares at beginning of period"
       }
      }
     },
     "localname": "NumberOfTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ObligationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation by type [axis]"
       }
      }
     },
     "localname": "ObligationByTypeAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ObligationByTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation by type [member]",
        "terseLabel": "Obligation by type"
       }
      }
     },
     "localname": "ObligationByTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OfficerAndDirectorCompensationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and director compensation [table text block]",
        "terseLabel": "Executive Officers and Non-Executive Directors Compensation"
       }
      }
     },
     "localname": "OfficerAndDirectorCompensationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting of deferred tax assets and liabilities within the same tax jurisdiction"
       }
      }
     },
     "localname": "OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OnbrezBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Onbrez Breezhaler [member]"
       }
      }
     },
     "localname": "OnbrezBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One year [member]"
       }
      }
     },
     "localname": "OneYearMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OpenHedgesForAnticipatedTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Open hedges for anticipated transactions"
       }
      }
     },
     "localname": "OpenHedgesForAnticipatedTransactions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OperatingIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income [member]"
       }
      }
     },
     "localname": "OperatingIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OptionsExcludedFromTheCalculation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options excluded from the calculation"
       }
      }
     },
     "localname": "OptionsExcludedFromTheCalculation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_OptonolLtd.NeveIlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Optonol Ltd., Neve-Ilan [member]"
       }
      }
     },
     "localname": "OptonolLtd.NeveIlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OrdinarySharesNominalValueCHF0.50PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, nominal value CHF 0.50 per share [member]",
        "terseLabel": "Ordinary shares, nominal value CHF 0.50 per share*"
       }
      }
     },
     "localname": "OrdinarySharesNominalValueCHF0.50PerShareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OrielTherapeuticsInc.DurhamNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oriel Therapeutics, Inc., Durham, NC [member]"
       }
      }
     },
     "localname": "OrielTherapeuticsInc.DurhamNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherAssetsProvisionsAccrualsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets, provisions and accruals [member]"
       }
      }
     },
     "localname": "OtherAssetsProvisionsAccrualsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Defined benefit pension plans before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans",
        "terseLabel": "Other post-employment benefit plans before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeDebtSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 8.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, equity securities",
        "terseLabel": "Fair value adjustments on equity securities, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation",
        "terseLabel": "Taxation on above items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeMaketableSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, maketable securities",
        "terseLabel": "Available-for-sale marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMaketableSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 6.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, debt securities",
        "terseLabel": "Fair value adjustments on debt securities, net of taxes",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income net of tax exchange differences on translation related to discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 5.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, financial instruments",
        "terseLabel": "Fair value adjustments on financial instruments",
        "totalLabel": "Total fair value adjustments on financial instruments, net of taxes",
        "verboseLabel": "Fair value adjustments during the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income recycled into the consolidated income statement"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other countries [member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [abstract]"
       }
      }
     },
     "localname": "OtherCurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_OtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [table text block]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OtherFinancialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial income and expense [abstract]"
       }
      }
     },
     "localname": "OtherFinancialIncomeAndExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_OtherFinancialIncomeAndExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Financial Income and Expense [table text block]",
        "terseLabel": "Other financial income and expense"
       }
      }
     },
     "localname": "OtherFinancialIncomeAndExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OtherFinancialLiabilitiesCategoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities, category [member]"
       }
      }
     },
     "localname": "OtherFinancialLiabilitiesCategoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities [member]"
       }
      }
     },
     "localname": "OtherFinancialLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherHematologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Hematology [member]"
       }
      }
     },
     "localname": "OtherHematologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 4.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets recognised as of acquisition date",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherIntangiblePurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": 2.0,
       "parentTag": "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible asset purchase commitments"
       }
      }
     },
     "localname": "OtherIntangiblePurchaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term employee benefits and deferred compensation"
       }
      }
     },
     "localname": "OtherLongtermEmployeeBenefitsAndDeferredCompensation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNetAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other net assets"
       }
      }
     },
     "localname": "OtherNetAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNetCashInflowsFromDivestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other net cash inflows from divestments",
        "terseLabel": "dup_2_Divested business"
       }
      }
     },
     "localname": "OtherNetCashInflowsFromDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNoncurrentFinancialDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current financial debt",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherPaymentsAndDeferredConsiderationNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payments and deferred consideration, net",
        "terseLabel": "Payments, deferred consideration and other adjustments, net"
       }
      }
     },
     "localname": "OtherPaymentsAndDeferredConsiderationNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherPostemploymentBenefitPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other post-employment benefit plans [member]",
        "terseLabel": "Other post-employment benefit plans"
       }
      }
     },
     "localname": "OtherPostemploymentBenefitPlansMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherPostemploymentBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other post-employment benefits"
       }
      }
     },
     "localname": "OtherPostemploymentBenefits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherPromotedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Promoted Brands [member]"
       }
      }
     },
     "localname": "OtherPromotedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherReceivablesAndCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables and current assets"
       }
      }
     },
     "localname": "OtherReceivablesAndCurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherRespiratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Respiratory [member]"
       }
      }
     },
     "localname": "OtherRespiratoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherRevenueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue, other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRevenueOther",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherSharePurchases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share purchases"
       }
      }
     },
     "localname": "OtherSharePurchases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_OtherSharePurchasesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share purchases, equity impact",
        "negatedTerseLabel": "Other share purchases, equity impact"
       }
      }
     },
     "localname": "OtherSharePurchasesValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherShareSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share sales",
        "negativeLabel": "Other share sales"
       }
      }
     },
     "localname": "OtherShareSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherShareSalesEquityImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share sales, equity impact"
       }
      }
     },
     "localname": "OtherShareSalesEquityImpact",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherSolidTumorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Solid Tumor [member]"
       }
      }
     },
     "localname": "OtherSolidTumorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OthersAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others associates [member]",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OthersAssociatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OutstandingShareCapital": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding share capital",
        "periodEndLabel": "Total outstanding share capital at end of period",
        "periodStartLabel": "Total outstanding share capital at beginning of period"
       }
      }
     },
     "localname": "OutstandingShareCapital",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OutstandingShareCapitalMovement": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding share capital, movement",
        "terseLabel": "Total shares outstanding movement of period"
       }
      }
     },
     "localname": "OutstandingShareCapitalMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overdue amounts and related provisions [table text block]",
        "terseLabel": "Overdue amounts and related provision"
       }
      }
     },
     "localname": "OverdueAmountsAndRelatedProvisionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PT.CIBAVisionBatamBatamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PT. CIBA Vision Batam, Batam [member]"
       }
      }
     },
     "localname": "PT.CIBAVisionBatamBatamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PT.NovartisIndonesiaJakartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PT. Novartis Indonesia, Jakarta [member]"
       }
      }
     },
     "localname": "PT.NovartisIndonesiaJakartaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PartialReleaseOfDeferredTaxLiabilityRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Partial release of deferred tax liability recognized"
       }
      }
     },
     "localname": "PartialReleaseOfDeferredTaxLiabilityRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Past service cost and gains losses arising from settlements, defined benefit liability (asset)",
        "terseLabel": "Past service cost and settlements"
       }
      }
     },
     "localname": "PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentOfInterestBearingAccountsToBeneficiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of interest bearing accounts to beneficiaries"
       }
      }
     },
     "localname": "PaymentOfInterestBearingAccountsToBeneficiaries",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentPutOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment put option"
       }
      }
     },
     "localname": "PaymentPutOption",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments out of provisions and other net cash movements in non-current liabilities",
        "negatedTerseLabel": "Payments out of provisions and other net cash movements in non-current liabilities"
       }
      }
     },
     "localname": "PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PensionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension plan [member]",
        "terseLabel": "Pension plans"
       }
      }
     },
     "localname": "PensionPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PensionersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pensioners [member]",
        "terseLabel": "Pensioners"
       }
      }
     },
     "localname": "PensionersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pensions and other benefit obligations of associates [member]"
       }
      }
     },
     "localname": "PensionsAndOtherBenefitObligationsOfAssociatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of income not subject to tax on the divestment gain on GSK investment"
       }
      }
     },
     "localname": "PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfEntitysTradeReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entitys trade receivable"
       }
      }
     },
     "localname": "PercentageOfEntitysTradeReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfEquityInterestSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of equity interest shares received"
       }
      }
     },
     "localname": "PercentageOfEquityInterestSharesReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfGovernmentBackedDebtSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of government backed debt securities"
       }
      }
     },
     "localname": "PercentageOfGovernmentBackedDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalInTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Share capital in tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalInTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of share capital tendered at the expiration of the tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of share capital tendered at the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfVotingEquityInterestsContributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests contributed"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsContributed",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PiqrayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Piqray [member]"
       }
      }
     },
     "localname": "PiqrayMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PlansAndProgramRebatesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plans and program rebates [axis]"
       }
      }
     },
     "localname": "PlansAndProgramRebatesAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_PlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plans and program rebates [member]"
       }
      }
     },
     "localname": "PlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PluvictoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pluvicto [member]"
       }
      }
     },
     "localname": "PluvictoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PoPChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change over period [member]"
       }
      }
     },
     "localname": "PoPChangeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PoPYEChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change to prior year-end [member]"
       }
      }
     },
     "localname": "PoPYEChangeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment",
        "negatedTerseLabel": "Portion of consideration paid consisting of cash and cash equivalents upfront payment"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PositiveFairValuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Positive fair values [member]"
       }
      }
     },
     "localname": "PositiveFairValuesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in interest rates [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in interest rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates [table text block]",
        "terseLabel": "Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated equity due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated equity due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential inflows in various currencies - from financial derivative assets"
       }
      }
     },
     "localname": "PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialMilestoneMaximumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential milestone maximum payments"
       }
      }
     },
     "localname": "PotentialMilestoneMaximumPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential outflows in various currencies - from financial derivative liabilities",
        "negatedTerseLabel": "Potential outflows in various currencies - from financial derivative liabilities"
       }
      }
     },
     "localname": "PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialReceivableFromDivestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential receivable from divestment"
       }
      }
     },
     "localname": "PotentialReceivableFromDivestment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentiallyRefundableConsiderationFromAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially refundable consideration from acquisition"
       }
      }
     },
     "localname": "PotentiallyRefundableConsiderationFromAcquisition",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PowerVisionInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PowerVision, Inc. [member]",
        "terseLabel": "PowerVision, Inc."
       }
      }
     },
     "localname": "PowerVisionInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PreTaxProfitLossFromDivestmentOfBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre tax profit (loss) from divestment of business"
       }
      }
     },
     "localname": "PreTaxProfitLossFromDivestmentOfBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrepaidPostemploymentBenefitPlansAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid post-employment benefit plans assets",
        "terseLabel": "Prepaid benefit cost"
       }
      }
     },
     "localname": "PrepaidPostemploymentBenefitPlansAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrepaymentsAndAccruedLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments and accrued lease payments"
       }
      }
     },
     "localname": "PrepaymentsAndAccruedLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously reported finance lease obligation of divested business"
       }
      }
     },
     "localname": "PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses a limit.",
        "label": "Principal group companies materiality of assets or sales to third parties"
       }
      }
     },
     "localname": "PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Group subsidiaries and associated companies [table text block]",
        "terseLabel": "Principal Group subsidiaries and associated companies"
       }
      }
     },
     "localname": "PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PriorYearAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year adjustment"
       }
      }
     },
     "localname": "PriorYearAdjustment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProceedsFromCurrentAndNoncurrentBorrowings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from current and non-current borrowings",
        "terseLabel": "Transaction costs payment",
        "verboseLabel": "Cash inflow from borrowings"
       }
      }
     },
     "localname": "ProceedsFromCurrentAndNoncurrentBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options and other treasury share transactions",
        "terseLabel": "Proceeds from exercised options and other treasury share transactions, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability contingency, loss exposure not accrued, best estimate"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability contingency, loss exposure not accrued, number of cases"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions",
        "periodEndLabel": "Product liabilities government investigations other legal matters provisions at end of period",
        "periodStartLabel": "Product liabilities government investigations other legal matters provisions at beginning of period"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": 1.0,
       "parentTag": "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, current",
        "negatedTerseLabel": "Less current provision",
        "terseLabel": "Provisions for product liabilities, governmental investigations and other legal matters"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, discontinued operations",
        "terseLabel": "Provisions related to discontinued operations"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": 2.0,
       "parentTag": "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, non-current",
        "periodEndLabel": "Non-current product liabilities, governmental investigations and other legal matters provisions at end of period",
        "terseLabel": "Product liability, government investigations, other legal matters provisions"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, payments",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, releases",
        "negatedTerseLabel": "Releases"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions [roll forward]"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProductPortfolioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product portfolio [axis]"
       }
      }
     },
     "localname": "ProductPortfolioAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProductPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product portfolio [member]"
       }
      }
     },
     "localname": "ProductPortfolioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfDrBrodyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prof. Dr. Brody [member]"
       }
      }
     },
     "localname": "ProfDrBrodyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfDrZinkernagelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prof. Dr. Zinkernagel [member]"
       }
      }
     },
     "localname": "ProfDrZinkernagelMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities, as a percentage from net sales",
        "terseLabel": "Operating income as % of net sales"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ProfitSharingIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit sharing income"
       }
      }
     },
     "localname": "ProfitSharingIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProformaNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proforma net sales"
       }
      }
     },
     "localname": "ProformaNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PromactaRevoladeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promacta/Revolade [member]"
       }
      }
     },
     "localname": "PromactaRevoladeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PromotedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promoted Brands [member]"
       }
      }
     },
     "localname": "PromotedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment impairment charges and reversals [table text block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [table text block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ProvisionForDeductionFromRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for deduction from revenue [table]"
       }
      }
     },
     "localname": "ProvisionForDeductionFromRevenueTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionForDoubtfulReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for doubtful receivable",
        "periodEndLabel": "Provision for doubtful receivable at end of period",
        "periodStartLabel": "Provision for doubtful receivable at beginning of period"
       }
      }
     },
     "localname": "ProvisionForDoubtfulReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProvisionForDoubtfulReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for doubtful receivable [member]"
       }
      }
     },
     "localname": "ProvisionForDoubtfulReceivableMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions and other current liabilities [line items]"
       }
      }
     },
     "localname": "ProvisionsAndOtherCurrentLiabilitiesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionsForDeductionsFromRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for deductions from revenue [roll forward]"
       }
      }
     },
     "localname": "ProvisionsForDeductionsFromRevenueRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionsForReductionOfRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for reduction of revenue [table text block]",
        "terseLabel": "Provisions for reduction of revenue"
       }
      }
     },
     "localname": "ProvisionsForReductionOfRevenueTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ProvisionsForTradeReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for trade receivables [table text block]",
        "terseLabel": "Provisions for trade receivables"
       }
      }
     },
     "localname": "ProvisionsForTradeReceivablesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PurchaseFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases fair value measurement assets"
       }
      }
     },
     "localname": "PurchaseFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PurchasePriceAllocationAssociatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price allocation associates [table text block]",
        "terseLabel": "Purchase price allocation associates"
       }
      }
     },
     "localname": "PurchasePriceAllocationAssociatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ratio fixed rate financial debt to total financial debt"
       }
      }
     },
     "localname": "RatioFixedRateFinancialDebtToTotalFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RealEstateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real estate [member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "RealEstateMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReceivablesAndPayablesContingentConsiderationNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables and payables contingent consideration, net",
        "terseLabel": "Contingent consideration payables, net"
       }
      }
     },
     "localname": "ReceivablesAndPayablesContingentConsiderationNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReceivablesAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables associated companies"
       }
      }
     },
     "localname": "ReceivablesAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationFairValueMeasurementAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is a reclassification that can be debit or credit.",
        "label": "Reclassification fair value measurement assets"
       }
      }
     },
     "localname": "ReclassificationFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationFromNoncurrentToCurrentNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from non-current to current, net"
       }
      }
     },
     "localname": "ReclassificationFromNoncurrentToCurrentNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationToPresentationRequiredUnderIFRS9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification to presentation required under IFRS 9 [member]"
       }
      }
     },
     "localname": "ReclassificationToPresentationRequiredUnderIFRS9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReclastAclastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclast/Aclasta [member]"
       }
      }
     },
     "localname": "ReclastAclastaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement [table]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInFairValueMeasurementAssetsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of lease commitment and lease liability [table text block]",
        "terseLabel": "Reconciliation of lease commitment and lease liability"
       }
      }
     },
     "localname": "ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of liabilities arising from financing activities [table text block]",
        "terseLabel": "Reconciliation of liabilities arising from financing activities"
       }
      }
     },
     "localname": "ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recycling of the Novartis share of other comprehensive income from associated companies"
       }
      }
     },
     "localname": "RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursements from plan to employer net defined benefit liability (asset)",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of executive committee members",
        "terseLabel": "Executive Committee members"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfExecutiveCommitteeMembers",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of executive committee members who stepped down",
        "terseLabel": "Executive Committee members who stepped down"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RelatedPartiesNumberOfNonexecutiveDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of non-executive directors",
        "terseLabel": "Non-executive directors"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfNonexecutiveDirectors",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RemainingLeaseCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease commitments"
       }
      }
     },
     "localname": "RemainingLeaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RepaymentOfIntercompanyBalances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of intercompany balances",
        "negatedTerseLabel": "Repayment of intercompany balances"
       }
      }
     },
     "localname": "RepaymentOfIntercompanyBalances",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RepaymentOfLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of lease liability"
       }
      }
     },
     "localname": "RepaymentOfLeaseLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReportedValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported value [member]"
       }
      }
     },
     "localname": "ReportedValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "ReprixysPharmaceuticalsCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReprixysPharmaceuticalsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reprixys Pharmaceuticals Corporation [member]",
        "terseLabel": "Reprixys Pharmaceuticals Corporation"
       }
      }
     },
     "localname": "ReprixysPharmaceuticalsCorporationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RepurchaseOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of options",
        "negatedTerseLabel": "Repurchase of options"
       }
      }
     },
     "localname": "RepurchaseOfOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development and other intangible asset purchase commitments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ResearchAndDevelopmentCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development and other intangible asset purchase commitments [abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitmentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development commitments for transactions entered into current year, closed after current year end"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Respective Useful Lives of Available-for-Use Intangible Assets [table text block]",
        "terseLabel": "Respective Useful Lives of Available-for-Use Intangible Assets"
       }
      }
     },
     "localname": "RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Respective Useful Lives of property, plant and equipment [table text block]",
        "terseLabel": "Respective Useful Lives of property, plant and equipment"
       }
      }
     },
     "localname": "RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RestOfPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest of portfolio [member]"
       }
      }
     },
     "localname": "RestOfPortfolioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest of the world [member]"
       }
      }
     },
     "localname": "RestOfTheWorldMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestatedValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restated Value Adjustments [member]"
       }
      }
     },
     "localname": "RestatedValueAdjustmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestructuringProvisionsMovementsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [roll forward]"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RestructuringProvisionsMovementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [table]"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RestructuringProvisionsMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [table text block]",
        "terseLabel": "Restructuring provisions movements"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RetailGenericsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retail Generics [member]"
       }
      }
     },
     "localname": "RetailGenericsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RetirementPlanTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement plan type [axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RetirementPlanTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement plan type [member]"
       }
      }
     },
     "localname": "RetirementPlanTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RevenueFromSaleOfGoodsSalesToOtherSegments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_RevenueFromSaleOfGoods",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, sales to other segments",
        "terseLabel": "Sales to discontinued segment",
        "verboseLabel": "Sales to other segments"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsSalesToOtherSegments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_RevenueFromSaleOfGoods",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties and other segments",
        "terseLabel": "Net sales to third parties",
        "verboseLabel": "Net sales to third parties of discontinued operations"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties and other segments, as percent of total net sales",
        "terseLabel": "Net sales (in % of total net sales)"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties, change in percent",
        "terseLabel": "Net sales, change in %"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties, change in percent, cc",
        "terseLabel": "Net sales, change in %, cc"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueOfAcquireeFullYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue of acquiree full year"
       }
      }
     },
     "localname": "RevenueOfAcquireeFullYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversal impairment loss recognised in profit or loss, right of use assets"
       }
      }
     },
     "localname": "ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RightOfUseAssetsAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 13.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets as of acquisition date",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetsAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets Disclosure and Lease liabilities [abstract]"
       }
      }
     },
     "localname": "RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_RightOfUseAssetsToBeRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets to be recognized"
       }
      }
     },
     "localname": "RightOfUseAssetsToBeRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RitalinFocalinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ritalin/Focalin [member]"
       }
      }
     },
     "localname": "RitalinFocalinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RocheHoldingAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roche Holding AG, Basel [member]"
       }
      }
     },
     "localname": "RocheHoldingAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RocheHoldingAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roche Holding AG [member]",
        "terseLabel": "Roche Holding AG, Switzerland"
       }
      }
     },
     "localname": "RocheHoldingAGMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaleAndLeaseBackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale and lease back [member]",
        "terseLabel": "Sale and leaseback"
       }
      }
     },
     "localname": "SaleAndLeaseBackMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business assets arising from contingencies amount recognized"
       }
      }
     },
     "localname": "SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business assets arising from contingencies amount recognized other than at fair value"
       }
      }
     },
     "localname": "SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent consideration arrangements, range of outcomes, value, high"
       }
      }
     },
     "localname": "SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentOptionArrangementsFeePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent option arrangements, fee paid"
       }
      }
     },
     "localname": "SaleOfBusinessContingentOptionArrangementsFeePaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent option arrangements, range of outcomes, value, high"
       }
      }
     },
     "localname": "SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SalutasPharmaGmbHBarlebenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salutas Pharma GmbH, Barleben [member]"
       }
      }
     },
     "localname": "SalutasPharmaGmbHBarlebenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandostatinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandostatin [member]"
       }
      }
     },
     "localname": "SandostatinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz AG, Basel [member]"
       }
      }
     },
     "localname": "SandozAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "SandozASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozB.V.AlmereMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz B.V., Almere [member]"
       }
      }
     },
     "localname": "SandozB.V.AlmereMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozCanadaInc.BouchervilleQuebecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Canada Inc., Boucherville, Quebec [member]"
       }
      }
     },
     "localname": "SandozCanadaInc.BouchervilleQuebecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]"
       }
      }
     },
     "localname": "SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz d.o.o. farmaceutska industrija, Zagreb [member]"
       }
      }
     },
     "localname": "SandozD.o.o.FarmaceutskaIndustrijaZagrebMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]"
       }
      }
     },
     "localname": "SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Egypt Pharma S.A.E., New Cairo City [member]"
       }
      }
     },
     "localname": "SandozEgyptPharmaS.A.E.NewCairoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozFarmaceuticaLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Farmaceutica Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "SandozFarmaceuticaLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozFarmaceuticaS.A.MadridMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Farmaceutica S.A., Madrid [member]"
       }
      }
     },
     "localname": "SandozFarmaceuticaS.A.MadridMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz GmbH, Kundl [member]"
       }
      }
     },
     "localname": "SandozGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]"
       }
      }
     },
     "localname": "SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Hungary Limited Liability Company, Budapest [member]"
       }
      }
     },
     "localname": "SandozHungaryLimitedLiabilityCompanyBudapestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "SandozIlacSanayiVeTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozInc.PrincetonNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Inc., Princeton, NJ [member]"
       }
      }
     },
     "localname": "SandozInc.PrincetonNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]"
       }
      }
     },
     "localname": "SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIndustrialProductsS.p.A.RoveretoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Industrial Products S.p.A., Rovereto [member]"
       }
      }
     },
     "localname": "SandozIndustrialProductsS.p.A.RoveretoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozInternationalGmbHHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz International GmbH, Holzkirchen [member]"
       }
      }
     },
     "localname": "SandozInternationalGmbHHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz K.K., Tokyo [member]"
       }
      }
     },
     "localname": "SandozK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "SandozKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "SandozLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozManufacturingInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Manufacturing Inc. [member]"
       }
      }
     },
     "localname": "SandozManufacturingInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz [member]",
        "terseLabel": "Sandoz"
       }
      }
     },
     "localname": "SandozMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "SandozNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPharmaceuticalsAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pharmaceuticals AG, Risch [member]"
       }
      }
     },
     "localname": "SandozPharmaceuticalsAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPharmaceuticalsD.d.LjubjanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pharmaceuticals d.d., Ljubjana [member]"
       }
      }
     },
     "localname": "SandozPharmaceuticalsD.d.LjubjanaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPhilippinesCorporationMakatiCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Philippines Corporation, Makati City [member]"
       }
      }
     },
     "localname": "SandozPhilippinesCorporationMakatiCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPolskaSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Polska Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "SandozPolskaSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPrivateLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Private Limited, Mumbai [member]"
       }
      }
     },
     "localname": "SandozPrivateLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "SandozPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "SandozS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.A.S.LevalloisPerretMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.A.S., Levallois-Perret [member]"
       }
      }
     },
     "localname": "SandozS.A.S.LevalloisPerretMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.R.L.TarguMuresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.R.L., Targu-Mures [member]"
       }
      }
     },
     "localname": "SandozS.R.L.TarguMuresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.p.A.OriggioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.p.A., Origgio [member]"
       }
      }
     },
     "localname": "SandozS.p.A.OriggioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz s.r.o., Prague [member]"
       }
      }
     },
     "localname": "SandozS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozSouthAfricaPtyLtdMidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz South Africa (Pty) Ltd, Midrand [member]"
       }
      }
     },
     "localname": "SandozSouthAfricaPtyLtdMidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozUkraineLLCKievMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Ukraine LLC, Kyiv [member]"
       }
      }
     },
     "localname": "SandozUkraineLLCKievMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]"
       }
      }
     },
     "localname": "SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ScemblixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scemblix [member]"
       }
      }
     },
     "localname": "ScemblixMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under fixed term operating leases [line items]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under fixed term operating leases [table]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under research and development and other intangible asset purchase [line items]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under research and development and other intangible asset purchase [table]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderResearchAndDevelopmentTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfAllocationOfPlanAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allocation of plan assets [table]"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allocation of plan assets [table text block]",
        "terseLabel": "The weighted average plan asset allocation of funded defined benefit pension plans"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of asset allocation, investments in shares of Novartis AG [table text block]",
        "terseLabel": "Asset allocation, investments in shares of Novartis AG"
       }
      }
     },
     "localname": "ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used [table text block]",
        "terseLabel": "Principal weighted average actuarial assumptions"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of comprehensive income [table text block]",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [table text block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]",
        "terseLabel": "Schedule of defined benefit plan amounts recognized in other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined benefit plans disclosures [table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfDefinedContributionPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined contribution plans [table text block]",
        "terseLabel": "Defined contribution plans"
       }
      }
     },
     "localname": "ScheduleOfDefinedContributionPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [table text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfExpectedBenefitPaymentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected benefit payments [table]"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected benefit payments [table text block]",
        "terseLabel": "The expected future cash flows in respect of pension and other post- employment benefit plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]",
        "terseLabel": "Expense related to all equity-based participation and liabilities arising from equity-based payment transactions"
       }
      }
     },
     "localname": "ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfHealthCareCostTrendRatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of health care cost trend rates [table]"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of health care cost trend rates [table text block]",
        "terseLabel": "The healthcare cost trend rate assumptions used for other post-employment benefits"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [table text block]",
        "terseLabel": "Inventories by class"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provisions and other current liabilities [table text block]",
        "terseLabel": "Provisions and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of sensitivity analysis for actuarial assumptions [table text block]",
        "terseLabel": "The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions"
       }
      }
     },
     "localname": "ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share value adjustments currency translation effects [table text block]",
        "terseLabel": "Schedule of share value adjustments currency translation effects"
       }
      }
     },
     "localname": "ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based compensation, activity [table text block]",
        "terseLabel": "Schedule of share-based compensation, activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationActivityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unvested restricted stock units roll forward [table]"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unvested restricted stock units roll forward [table text block]",
        "terseLabel": "Schedule of unvested restricted stock units roll forward"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_SecondLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second largest customer [member]"
       }
      }
     },
     "localname": "SecondLargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SecondLargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second largest financial institution [member]"
       }
      }
     },
     "localname": "SecondLargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SeebriBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seebri Breezhaler [member]"
       }
      }
     },
     "localname": "SeebriBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SelectedNoncurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies",
        "label": "Total of selected non-current assets"
       }
      }
     },
     "localname": "SelectedNoncurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.",
        "label": "Selected non-current assets, as percent",
        "terseLabel": "Selected non-current assets (in % of total selected non-current assets)"
       }
      }
     },
     "localname": "SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_SelexysPharmaceuticalsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selexys Pharmaceuticals Corporation [member]",
        "terseLabel": "Selexys Pharmaceuticals Corporation"
       }
      }
     },
     "localname": "SelexysPharmaceuticalsCorporationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SerelaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serelaxin [member]"
       }
      }
     },
     "localname": "SerelaxinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ShanghaiNovartisTradingLtd.ShanghaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shanghai Novartis Trading Ltd., Shanghai [member]"
       }
      }
     },
     "localname": "ShanghaiNovartisTradingLtd.ShanghaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ShareMovements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share movements in period",
        "terseLabel": "Total movements"
       }
      }
     },
     "localname": "ShareMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ShareOfCurrentYearNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis share of current year consolidated net income"
       }
      }
     },
     "localname": "ShareOfCurrentYearNetIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SharePaidinCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share/paid-in capital"
       }
      }
     },
     "localname": "SharePaidinCapital",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SharepurchaseOfTreasuryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "SharepurchaseOfTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesCancelledForCapitalReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares cancelled for capital reduction"
       }
      }
     },
     "localname": "SharesCancelledForCapitalReduction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesDeliveredToDivestedBusinessEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares delivered to divested business employees"
       }
      }
     },
     "localname": "SharesDeliveredToDivestedBusinessEmployees",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares delivered to divested business employees, equity impact"
       }
      }
     },
     "localname": "SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ShortTermLeasesAndLowValueLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term leases and low value leases"
       }
      }
     },
     "localname": "ShortTermLeasesAndLowValueLeases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [abstract]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_SocieteParActionsSANDOZAlgiersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Societe par actions SANDOZ, Algiers [member]"
       }
      }
     },
     "localname": "SocieteParActionsSANDOZAlgiersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SolidTumorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Solid Tumors [member]"
       }
      }
     },
     "localname": "SolidTumorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SolodynMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Solodyn [member]"
       }
      }
     },
     "localname": "SolodynMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SparkTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spark Therapeutics, Inc. [member]"
       }
      }
     },
     "localname": "SparkTherapeuticsInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex [member]",
        "terseLabel": "Spinifex"
       }
      }
     },
     "localname": "SpinifexMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "SpinifexPharmaceuticalsInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]"
       }
      }
     },
     "localname": "SpinifexPharmaceuticalsInc.WilmingtonNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [line items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]"
       }
      }
     },
     "localname": "StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock repurchase program, authorized amount",
        "negatedTerseLabel": "Increase of treasury share repurchase obligation under a share buyback trading plan",
        "terseLabel": "Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_StraightBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Straight bonds [member]"
       }
      }
     },
     "localname": "StraightBondsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SubsequentEventTypAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Typ [axis]"
       }
      }
     },
     "localname": "SubsequentEventTypAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_SubsequentEventTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [member]"
       }
      }
     },
     "localname": "SubsequentEventTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SummaryOfTreasurySharesMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of treasury shares movements [table text block]",
        "terseLabel": "Schedule disclosing information related treasury shares movements"
       }
      }
     },
     "localname": "SummaryOfTreasurySharesMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]"
       }
      }
     },
     "localname": "SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Technical Development Co., Ltd., Changshu [member]"
       }
      }
     },
     "localname": "SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Technical Development Co., Ltd. [member]"
       }
      }
     },
     "localname": "SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SystaneGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Systane Group [member]"
       }
      }
     },
     "localname": "SystaneGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TabrectaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabrecta [member]"
       }
      }
     },
     "localname": "TabrectaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TafinlarMekinistMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tafinlar + Mekinist [member]"
       }
      }
     },
     "localname": "TafinlarMekinistMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Takeda Pharmaceutical Company Limited [member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TasignaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tasigna [member]"
       }
      }
     },
     "localname": "TasignaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TaxExpenseIncomeDiscontinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income), discontinuing operations",
        "negatedTerseLabel": "Income tax expense from discontinued operations",
        "terseLabel": "Income tax expense from discontinued operations"
       }
      }
     },
     "localname": "TaxExpenseIncomeDiscontinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss carry forwards",
        "terseLabel": "dup_1_Tax loss carryforwards expired"
       }
      }
     },
     "localname": "TaxLossCarryForwards",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxLossCarryforwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss carryforwards [member]"
       }
      }
     },
     "localname": "TaxLossCarryforwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TaxOnTransactionCostsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax on transaction costs recorded in equity"
       }
      }
     },
     "localname": "TaxOnTransactionCostsRecordedInEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxRateEffectFromBenefitsExpiring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from benefits expiring",
        "terseLabel": "Effect of tax benefits expiring in 2017"
       }
      }
     },
     "localname": "TaxRateEffectFromBenefitsExpiring",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectFromNondeductibleLossesInRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from non-deductible losses",
        "terseLabel": "Effect of non-deductible losses in Venezuela"
       }
      }
     },
     "localname": "TaxRateEffectFromNondeductibleLossesInRegion",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from write down and reversal of write down of invest subsidiaries",
        "terseLabel": "Effect of write down and reversal of write down of investments in subsidiaries"
       }
      }
     },
     "localname": "TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfCreditsAndAllowances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of credits and allowances",
        "terseLabel": "Effect of tax credits and allowances"
       }
      }
     },
     "localname": "TaxRateEffectOfCreditsAndAllowances",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfIncomeTaxedAtReducedRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of income taxed at reduced rates",
        "terseLabel": "Effect of income taxed at reduced rates"
       }
      }
     },
     "localname": "TaxRateEffectOfIncomeTaxedAtReducedRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of release of contingent consideration liability",
        "terseLabel": "Effect of release of contingent consideration liability"
       }
      }
     },
     "localname": "TaxRateEffectOfReleaseOfContingentConsiderationLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax reform impact on deferred tax on treasury shares"
       }
      }
     },
     "localname": "TaxReformImpactOnDeferredTaxOnTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Amortization of fair value adjustments relating to intangible assets"
       }
      }
     },
     "localname": "TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxesOnTreasuryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on treasury shares",
        "negatedTerseLabel": "Taxes on treasury shares"
       }
      }
     },
     "localname": "TaxesOnTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxotereMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxotere [member]"
       }
      }
     },
     "localname": "TaxotereMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TearFilmInnovationsInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tear Film Innovations, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "TearFilmInnovationsInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TekturnaRasilezValturnaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tekturna/Rasilez/Valturna [member]"
       }
      }
     },
     "localname": "TekturnaRasilezValturnaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]",
        "terseLabel": "Temporary differences on which no deferred tax assets have been provided"
       }
      }
     },
     "localname": "TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TenDayLossFairValueVARModelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ten day loss fair value VAR model [line items]"
       }
      }
     },
     "localname": "TenDayLossFairValueVARModelLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_TenDayLossFairValueVARModelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ten day loss fair value VAR model [table]"
       }
      }
     },
     "localname": "TenDayLossFairValueVARModelTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_TennesseeClassActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tennessee class action [member]"
       }
      }
     },
     "localname": "TennesseeClassActionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TheMedicinesCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Medicines Company, East Hanover, NJ [member]",
        "terseLabel": "The Medicines Company"
       }
      }
     },
     "localname": "TheMedicinesCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThirdLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third largest customer [member]"
       }
      }
     },
     "localname": "ThirdLargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThirdLargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third largest financial institution [member]"
       }
      }
     },
     "localname": "ThirdLargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three years [member]"
       }
      }
     },
     "localname": "ThreeYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time deposits with original maturity more than 90 days [member]"
       }
      }
     },
     "localname": "TimeDepositsWithOriginalMaturityMoreThan90DaysMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Top20ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top 20 products [member]"
       }
      }
     },
     "localname": "Top20ProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TopicalOlopatadineGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Topical Olopatadine Group [member]"
       }
      }
     },
     "localname": "TopicalOlopatadineGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalAntiinfectivesNetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-infectives net sales [member]"
       }
      }
     },
     "localname": "TotalAntiinfectivesNetSalesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalAvailableforsaleMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total available-for-sale marketable securities [member]"
       }
      }
     },
     "localname": "TotalAvailableforsaleMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalFairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total fair value adjustments [member]",
        "terseLabel": "Total fair value adjustments"
       }
      }
     },
     "localname": "TotalFairValueAdjustmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, time deposits and derivative financial instruments [member]"
       }
      }
     },
     "localname": "TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total percentage of share capital tendered after the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total value adjustments attributable to Novartis shareholders [Member]",
        "terseLabel": "Total value adjustments"
       }
      }
     },
     "localname": "TotalValueAdjustmentsAttributableToNovartisShareholdersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradePayablesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 12.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables and other liabilities",
        "negatedTerseLabel": "Trade payables and other liabilities"
       }
      }
     },
     "localname": "TradePayablesAndOtherLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TradePayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables [member]"
       }
      }
     },
     "localname": "TradePayablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables and other current assets excluding pre-payments [member]"
       }
      }
     },
     "localname": "TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 8.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables and other current assets recognised as of acquisition date",
        "terseLabel": "Trade receivables and financial and other current assets"
       }
      }
     },
     "localname": "TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables denominated in other currencies [table text block]",
        "terseLabel": "Trade receivables denominated in other currencies"
       }
      }
     },
     "localname": "TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TradeReceivablesProvisionMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables provision movements [table text block]",
        "terseLabel": "Trade receivables provision movements"
       }
      }
     },
     "localname": "TradeReceivablesProvisionMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs",
        "negatedTerseLabel": "Transaction costs recognized in the consolidated income statement",
        "terseLabel": "Transaction costs recognized in the consolidated income statement"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in equity",
        "negatedTerseLabel": "Transaction costs recorded in equity"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquityPaid": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in equity paid",
        "negatedTerseLabel": "Transaction costs payments",
        "terseLabel": "Transaction costs payments"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquityPaid",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in Equity [text block]",
        "terseLabel": "Transaction costs recorded in Equity"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TransactionRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction related costs",
        "negatedTerseLabel": "Transaction related costs"
       }
      }
     },
     "localname": "TransactionRelatedCosts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionRelatedCostsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction related costs paid",
        "negatedTerseLabel": "Transaction related costs paid"
       }
      }
     },
     "localname": "TransactionRelatedCostsPaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with former members of the Board of Directors [table text block]",
        "terseLabel": "Transactions with former members of the Board of Directors"
       }
      }
     },
     "localname": "TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TranscendMedicalInc.LakeForestILMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transcend Medical, Inc., Lake Forest, IL [member]"
       }
      }
     },
     "localname": "TranscendMedicalInc.LakeForestILMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TranscendMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transcend Medical Inc [member]",
        "terseLabel": "Transcend Medical Inc."
       }
      }
     },
     "localname": "TranscendMedicalIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TravoprostGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Travoprost Group [member]"
       }
      }
     },
     "localname": "TravoprostGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TreasurySharesAcquiredForCancellationValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired for cancellation, equity impact",
        "negatedTerseLabel": "Shares acquired for cancellation, equity impact",
        "terseLabel": "Shares acquired for cancellation, equity impact"
       }
      }
     },
     "localname": "TreasurySharesAcquiredForCancellationValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesAcquiredToBeCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be cancelled",
        "terseLabel": "Shares acquired to be cancelled"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeCancelled",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesAcquiredToBeHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be held"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesAcquiredToBeHeldValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be held, equity impact"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeHeldValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesMovement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares, movement",
        "totalLabel": "Total number of outstanding treasury shares"
       }
      }
     },
     "localname": "TreasurySharesMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesMovementOfPeriod": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 3.0,
       "parentTag": "nvs_OutstandingShareCapitalMovement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares movement of period",
        "terseLabel": "Treasury shares movement of period"
       }
      }
     },
     "localname": "TreasurySharesMovementOfPeriod",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesWithRestrictedUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares with restricted use"
       }
      }
     },
     "localname": "TreasurySharesWithRestrictedUse",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TriangleInternationalReinsuranceLimitedHamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Triangle International Reinsurance Limited, Hamilton [member]"
       }
      }
     },
     "localname": "TriangleInternationalReinsuranceLimitedHamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TrinityRiverInsuranceCoLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trinity River Insurance Co Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "TrinityRiverInsuranceCoLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TrueVisionSystemsInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TrueVision Systems, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "TrueVisionSystemsInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two years [member]"
       }
      }
     },
     "localname": "TwoYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_USCommercialPaperProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US commercial paper programs [member]"
       }
      }
     },
     "localname": "USCommercialPaperProgramsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]",
        "terseLabel": "US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_USspecificHealthcarePlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US-specific healthcare plans and program rebates [member]"
       }
      }
     },
     "localname": "USspecificHealthcarePlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UltibroBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ultibro Breezhaler [member]"
       }
      }
     },
     "localname": "UltibroBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UltibroGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ultibro Group [member]"
       }
      }
     },
     "localname": "UltibroGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UncalledCapitalCommitmentsForInvestmentsInFunds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncalled capital commitments for investments in funds"
       }
      }
     },
     "localname": "UncalledCapitalCommitmentsForInvestmentsInFunds",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UndiscountedFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Undiscounted future lease payments"
       }
      }
     },
     "localname": "UndiscountedFutureLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UndiscountedOperatingLeaseCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Undiscounted operating lease commitments"
       }
      }
     },
     "localname": "UndiscountedOperatingLeaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnfundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfunded [member]",
        "terseLabel": "Unfunded"
       }
      }
     },
     "localname": "UnfundedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge"
       }
      }
     },
     "localname": "UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge"
       }
      }
     },
     "localname": "UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unremitted earnings retained by consolidated entities for reinvestment"
       }
      }
     },
     "localname": "UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UpperLimitOnHoldingsOnUnrelatedCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upper limit on holdings on unrelated company"
       }
      }
     },
     "localname": "UpperLimitOnHoldingsOnUnrelatedCompany",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_VAREstimateConfidenceInterval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VAR estimate confidence interval"
       }
      }
     },
     "localname": "VAREstimateConfidenceInterval",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control",
        "terseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueAdjustmentOnComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value adjustment on comprehensive income",
        "periodEndLabel": "Value adjustments on comprehensive income at end of period",
        "periodStartLabel": "Value adjustments on comprehensive income at beginning of period"
       }
      }
     },
     "localname": "ValueAdjustmentOnComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueAdjustmentsRelatedToDivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value adjustments related to divestments [member]",
        "terseLabel": "Value adjustments related to divestments"
       }
      }
     },
     "localname": "ValueAdjustmentsRelatedToDivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares held by defined benefit plan"
       }
      }
     },
     "localname": "ValueOfEmployerSharesHeldByDefinedBenefitPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueOfEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of equity"
       }
      }
     },
     "localname": "ValueOfEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueOfTaxLossCarryforwardsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of tax loss carryforwards expired",
        "terseLabel": "Tax loss carryforwards expired"
       }
      }
     },
     "localname": "ValueOfTaxLossCarryforwardsExpired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValuedAtAmortizedCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valued at amortized cost [member]"
       }
      }
     },
     "localname": "ValuedAtAmortizedCostMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VendorAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [axis]"
       }
      }
     },
     "localname": "VendorAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [member]"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VivactaLimitedFrimleyCamberleySurreyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vivacta Limited, Frimley/Camberley, Surrey [member]"
       }
      }
     },
     "localname": "VivactaLimitedFrimleyCamberleySurreyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VoltarenCataflamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voltaren/Cataflam [member]"
       }
      }
     },
     "localname": "VoltarenCataflamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VotrientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Votrient [member]"
       }
      }
     },
     "localname": "VotrientMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WaveLightGmbHErlangenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WaveLight GmbH, Erlangen [member]"
       }
      }
     },
     "localname": "WaveLightGmbHErlangenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WaveLightInc.SterlingVAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WaveLight, Inc., Sterling, VA [member]"
       }
      }
     },
     "localname": "WaveLightInc.SterlingVAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WeightedAverageDurationOfDefinedBenefitObligationYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average duration of defined benefit obligation years"
       }
      }
     },
     "localname": "WeightedAverageDurationOfDefinedBenefitObligationYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_WeightedAverageInterestRateAssociates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on interest bearning accounts of associates payable on demand.",
        "label": "Weighted average interest rate, associates"
       }
      }
     },
     "localname": "WeightedAverageInterestRateAssociates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WeightedAverageInterestRateLeaseLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average interest rate lease liabilities"
       }
      }
     },
     "localname": "WeightedAverageInterestRateLeaseLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on Bank and other financial debt",
        "label": "Weighted average interest rate on Bank and other financial debt"
       }
      }
     },
     "localname": "WeightedAverageInterestRateOnBankAndOtherFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WithholdingTaxRecoverable": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding tax recoverable"
       }
      }
     },
     "localname": "WithholdingTaxRecoverable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_WorstCaseLossScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Worst case loss scenario [member]",
        "terseLabel": "Worst case loss scenario"
       }
      }
     },
     "localname": "WorstCaseLossScenarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WrittenCallOptionsContractualLive": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, contractual live"
       }
      }
     },
     "localname": "WrittenCallOptionsContractualLive",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsContractualLiveRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, contractual live, remaining"
       }
      }
     },
     "localname": "WrittenCallOptionsContractualLiveRemaining",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsHeldByMarketMaker": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options held by market maker"
       }
      }
     },
     "localname": "WrittenCallOptionsHeldByMarketMaker",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, weighted average exercise price"
       }
      }
     },
     "localname": "WrittenCallOptionsWeightedAverageExercisePrice",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "nvs_XiidraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Xiidra [member]"
       }
      }
     },
     "localname": "XiidraMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_XolairMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Xolair [member]"
       }
      }
     },
     "localname": "XolairMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_YearOfExpiryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiry [axis]"
       }
      }
     },
     "localname": "YearOfExpiryAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_YearOfExpiryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiry [member]"
       }
      }
     },
     "localname": "YearOfExpiryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedFrimleyCamberleySurreyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited, London [member]"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited [member]",
        "terseLabel": "Ziarco Group Limited"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZolgensmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zolgensma [member]"
       }
      }
     },
     "localname": "ZolgensmaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZortressCerticanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zortress/Certican [member]"
       }
      }
     },
     "localname": "ZortressCerticanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AmericasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Americas [member]"
       }
      }
     },
     "localname": "AmericasMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation case [axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 49
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "23",
   "Paragraph": "26",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2022-en-r&anchor=para_26_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "137",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_137_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "29",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_f_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS37_g84-92__IAS37_g84-92_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "102",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2022-en-r&anchor=para_102_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "15",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_15&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "10",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_p&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r270": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_k&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_o_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_p_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r280": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11A",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r290": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r300": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r310": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r320": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "6.5.13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.13_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r330": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r340": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_7&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_91_a&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r350": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r360": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Example 10 A court case",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r370": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r380": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r390": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r400": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r410": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "IG4",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_IG4&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r420": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r430": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r431": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r440": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r450": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r460": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r470": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "13",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_13&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "74",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_74_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "74",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_74_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "139",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_139_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>256
<FILENAME>0001370368-23-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370368-23-000048-xbrl.zip
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M+OKB7:P>=.%<>.:<$<GSLVFN"SX[QR<EJ7EJICF=!5\7R[ME!,-Q;S3MMV.
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MM;TR%0%#%<^5@F@#,B#+M39L%I[3E]>$AL@WI:=A4(N;&1FED(H@5>V^EA@
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MY+$8:]$$<\OR9/G1*&V.@Q&.J5U1Y%P1=$SO4'=Q^HASN@2;2"\QTBXL6
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MRQAW26OB&+VN9!M98[&] O[Q)9O<$'$,;F5WT0)U]3-8KTTS<XXXI9>I?S)
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M_*8KR/EA_0+,(CO+T&JAT62+VTJV=18F_%N>M\3_R(_0,-O+';X[][56T<1
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M<]:)'"BES[_SD2H66XOPG:C1APH1VJJ116&M4P#G SQ0FU\3'+X^T4_WKY$
M"1=&18\Z_LIMXQ_?M.UUR.U:M!7BFFIPZQ$B_'LQSPD!<@Q%5J8>P6>%.6&N
MAJUHJWAW[Q!/RPJ2=SM $><5*H=.Q?L\J";^,=QK#BL]H>*3#NA8DMW4:^M)
M!-7J1RI>(V<#Z'S?RJPSF9F6O9XU(X?'GSE.Q3O\%J&Y"?RU* ._H!XKN2A
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MZMS3P:')1HOCQ^-V7'NJ>V-:LQ1?[+%A:_TP]M2:U?:9#NO>W2^WZ^*O"[C
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M="FQ5W9XA&16;QK8/;B_&BQ&2"BG4C,&$A:2! 6OUIXU9,/.&K<9Z_XN_7-
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MR[H*TI, D;B?2THY\'Y5"H8X<53 !6),0B.DG6;^3.SFGGD:)28)_,#@Z0P
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M]=L(]O&5,@3Q0X-PK6'/#RLUSA<QK;'+'H@<( B ']YV<7+-9B8&F"J_1)L
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M#YVK H'W(]JXR)8.).$0.FI>%=0%M.:.&%?Y4V2NR9NY<)G[F!(\TD+?<L6
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M2!RK.?Z@"MAO!70Q4G-" :6HN:0_@\89!-(P<^@/K5*[S(@;NOS7DO[TN[:
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M+0^A9Z(T/JB# PL=43KP1R %C^',,9R84.RMP'7D@"N[0N<[D"HE>0-,HUY
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MZ,YUQ8Z/#C$BDTFX^_1U1QW=BQG[3V$KY5MKS\S?E2-=F<.S5G<>B",*8:1
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MV(*8EAQ.3XVL.\9VF<-[MK%E6QXI/E<U^:]=LNS[HL>:%Q5APZ&G:/Y7WWU
M[]KG&>IP)./LX?V:@.GUJ=A<27O','8Q,][8VJ/0QO&U@VH%1/0SO2!UUE?N
M.;/"_/#RU,YKZ\<JK?],2,]'6O[0VJ([\_*K/?0"&].]4;4]6Q5)JKS&*H>
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MTEVO_UA\J@Q>WG_ZU ?#,\UXH-'GZX\]89WU\QAE,'?^9X7<3FW<2AK<C9O
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M[H0<Y0"F$X**IV9OX+L'8*:77%0_FKX^2I!WP%(>CFEO%TJ$6%R!JJZ]/ H
MG-DX2+Q-$J.JV%KC=0 H6P\ <C@! /#() ?,^9,+IBAY4PH*(4B(O-U5 AN
MR"PH@M5)HB%4/>P&()OI($!7( L J!,6D8!0"P1Q *%8 9I@"AL0V0"0!(KH
MR/<%P"7&E$HS\=P(LX$%VE%98%4 "\0H*@0J_A5+U]>I3P?H"P4:B1@ZLY1W
MYQ]1NW[,<\_3O;5CE+O5,8;.7AFM,*#?;'.'  0  -@ .W@ "U)4>H%Z7V]R
MOPSC;NP'V,#'76I7.@)@$ @SML$46[X%WNNO$8D18+CA2E\RP $<YYR\>0!H
M9:NI?<D.S3L>Q"@R?LM)BW8!$)$\>LW5V&0 X2\&('G(HVAO9?.UYUHUE08
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ME7''+E80Q(KJEZ[;C8@KH' 0;R,9 3( CAX>OZ,3H"#(3B.$E2N<Q&#:(.(
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MBH_]F<_-R-XB_W5_U3ML0(<;L00#I<2$\%.35285UA2%E^Y=-WWW1FI;B?S
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M05QV>NX*1?1 JH+^-UDB_;WD2S.*C)>E[B(Q^#%4E1:KT%\&=$O=]P 5N+5
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MKCR]O^A NCMYII6/2;C+='9*.<97*'M*4]NMLA\V?NM^O$=ZR? #1GQI?9-
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M^69\Z1;:PD><Y?[<IOW<8R_6Y.,W1Q O2^K6YN /R[)Y !#]?U!+ P04
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MQF'+$L4FNV#[8_PESJ%>'!N$]HLL!^FB\>AG[Y/QP'7T$FH>?6,I8*G4S@'
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MJ"?.TA'(#6H^;ELVF]A)#.0A?^0@DU@O=S@J7:6H1A;E  _I Q,0];C -&2
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M(O*QSLFDWD@Q1.U'U-\K1OY\PO.Y>PA!>1 ,=C7IBW@6V90XR#2FQB<^T:'
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MP.Q!CX>]X3IAF!;ZSJ$#6]'FVH\)H0_1FKO$Y48D<XOV.AAM([,.1:X;1?V
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MPHEV ZD>^AB81GEK.2MDM("&4G(9O4FKWG)#)8Y3!SM9BSBSFZV*2Q*(_<>
M\C@WYF<BVLHX>(WI.B+=KX)1^R7RRBUE<2:M3%)@$%W0>[^A=T5%R/=OQRQ<
ME.7=GSJ7X#@PT@\J9_87+:'TD;SU.EX5W=V)]H;YQ8K>71:X #Y0TUSA"R.3
M!U!:LZ&>KN!O'/J?2PV^8KA,AGP'@A18O$+:->Q3\GMWD4!<<OLW"KD/&? .
M72J9FK3+ %<\5K4L(CZH2LSK!"D<M&BJQ%8L"*&+7%6"B'"-AF9<[9JW#3/@
M'YM%%[T(^&CW2&!3!R9*JLVD@C3*YH9JA#X#G=1R5<0'HB*#.^=0 2;_ G,
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MV,!MGXX3,88'E=#S+<9TXNL?[U:E8G#! (C2XCNC)BM=#<)E* LE'/2U%VG
MDB._08WF-^IC=O!AO"O@&:N_CGZU#D 'LNT1TQE_60G0:(*"&!>LHO$E1T-1
M6[&]V72DCK<.EA5O:**!0BT949A@2DOQ!4"@&0Z-P1T0-(M48'U!"=J;C_ N
MYO]U%891$6C0+U%L:1H.KF5*V[FIL%ZV6-N92_&(\E9M;E#*T/U'I,2%&;*V
M"D:MR^KU_[B%=DXY &VO)R1E-NH>$*.<,'G$Q*Y%(>U\U@#31TB,"'^1UL-M
M=-1Y4YXR^F)_Q\82^UWR\M>3O3I'IP>8J?45*90\2^E$D(G^82)U7:->1OV1
M+0%L@^C[4X=O2*RGWJIUCRE=]:Y,H\W>JH].>%?MOU-H$Y8^59:]*U![)UC2
MV+@D^@6I7W/$&,><I\7\?7]*$_EC[22OINQ8SFJ6LC#..5@>O3_\G.75A2A_
MC_&# E'#QL),3H"CY5G.J-L?;W_ \[/*$M?[:QI4 %)]7UD6ORW4@2,S0JP<
MVY^][8SI;T;X$NPIL;!1;[>W3<1RGS/IV[99 M81RUQJ/ Z-=S5[WK"+B7@R
M?F)>)\[Q679LD?W]^B?;%AL-#=XX5?I<K[3*/QNVUCZA_ER"FN,A?N[R-N&B
M86+SND.6:>3&^+:W"8\SOIY=^>Q<TO&?U$93;$OP'H?4E_:/KHY[+,FXZ)#^
M^=RC&_.)K45T%!WK6N&*0E $N.!9B>6^D,QBG37>[^F<]AHVL%JO$2BRQ 26
M.U>^T"TFH\QM:FK"*@44F-ZO'U5/<*%84(025(%QW+Z'#8=UKNGWT8&R"A>6
M4*^:L8FN0XU(E[QH+W$,6D>,VY>D$4BY3 \V #(F7-U7T[M9S*P07W&82$ [
MQ[AH@ #QD,\WJ4 _:-W.L7+7U'K2W8R!]6S??9&I'905N*+M6ZC_0G7UE,6^
M5SB:,Q\D3F19MJM@V%$I.)Z/0EO[V:;%02"X2J9ANA,Y*1L&#R+:L^PE3R9_
MVK^@'IBPNJZ0DQ9]"0;2A6U+&!3G<T 1G:6'<?-^1E)^/6FJX.E=/2-G9#U"
ML*4- \R]@8)&2I'N=0GEX367"K QTX#Y&!U<S2X4&2&MU:M'+J]Y3\\A(0VZ
MH17^,)M64%]AJH1H [T/WFT;J$CHKAYQY04*I"IAA!0[<L:MN"YVZ%58W<=!
M#_H 8[#2P17Y0C= !![L8ZU?>@O&*L];.T?RP1A>KP:Z@!^:G@MDK$.@2;@L
MS%[O1\>B)*AC4+\Q26U3)5$A#1;+!L $7(975PDRB^DB+7)\?V91A:E!:;8=
M9A&3*K7\.KM!S744GQ"%A'B!C]IO256834!ZE2WLUH)ZG#Y)F!(6'F)=)_%-
MY[(Q%;RU# /S(KLN"RU(+&=>HR-#)U_47..4D#';B%,N KT5@(D#S@5I/-M+
M=54B'([>()I/AFGU,+;;IKB@E9<::!Y@-X7C0LA?]I/@TM)ON9I?$F/*QC06
M]/<EXX=3OO P%6H7TCX^,5XL?%H3/N#8J#1-ZVIX5=."WD-_7+)1T'STRF.%
M@SZT++4(H;L+-4!:(I6DRS)0V8P6SD =E?#K&-NN+CJ:1XU+GQ:2-<XNXHWA
M0&I/F>K=E_$B6P[P+>/SC4]^STHT<]2KTLTSM&H*^OEG_?<9185-1JUZ1KM\
MVVPG,@-3N$] [WZP,(N3JUSUD=:FYD]R-V;0IRQ"] /VYT52'F%.O_LX^^3B
MIJ(^0&L_Y#9B"89O?J["79-X.V)6S[_+#*:YA?>V;E CT_D@AK%?,%\@+];O
M$OHO;^F?VEDS;X>:IU;KGZ5L@,*3)@ <:Z9:=_3W*9N[#=AB93@>XR7&=PV>
M;N/*C'^I2LOF&C0U94:!6;*8 AD6%A(*X90']]%U@,T":)Q5OFQ@$,WK-5V0
M5_,B,!*93:&LA3<2K"@C9$(VC6R#Q9V](!_^]\=)0BL]!CQ%MM(J$ ?*JI(/
M'$TGHT[>FM*X=TA(4ABHYK [Q (*B5U'/4I:&+&>@\E?>FE,0](TW#T,4[CL
M;C4LGR*0_,R=6X2D8 %M%+8(+WU-755'%EHRG[R9QE( N;X",/<6D&43ZMO5
M<TL$%B";_"507P;-#L,:"[#&*+RC>.K=B3OV5KV76A+IYFRR']:N\@Z4$*A9
M>YJ\ '6%@,[A0F+PJ?<M "(+P$ 09O3>[V0(DPDAB\O,^D=,X*J'8]'+W[/_
M)SN$\9;9!<BP5@=#&^6(0AA; &"-90ZS8*\,$?.K/UC&=HI2_)H:6 19)&+H
M&7?A0:)-[;K;,FJ+T%X2*.@*)-,%]K-/]6?IU[Q3C^W!7OF*O1HB)'49FV?]
M"XE/TTQ3S:6!]A<0'T=EY$E8PQW<<RG%_Q@BX%HO*1B\PC&>3V:3*,_U9)#%
MY+\C38'V,/;*[4"M28 R :D-)@,W%,^9"'A739V9:=;>DY1B4'L4IJF%?UTP
MOON;0.(W[*KI#?\-66Z>4J-T1Y-!AU%88YL\SYAM<[LW_$$Q/@MB9"+<'XX[
M,&2.CB]-<X20NM?D8 VF'W3-!7 P7"&CC=SOQTX8+LON?[RV?[JGU\@;QA4
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M>IFG][[#\7N'\^<\%G(KZ[^\11<S-U?;3M<=\NYX-C,69(9U.G2Z>L2R=;)
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MO;YBY%D3P9B$(SJ@] 'B'2+NS7-O$V3$X!Z$4X(F,$B%SYHC=>'I.)46:/U
MH.3B 'U<FAFH(9$(,#%7 +0.HM)"4=U+47NNCZE4U;"J<2\RH5^"(ZB>.2I5
M&;H;%';?LB$<H,#=,2425<^:+?N?Q/<389P_$85KQU7NP_7%H"QB@3/'"-YC
MN&M3?W&.H<XX$!L^X0#A]4<OZ_:Q <&'UZ>W3&*KP6]#,%TPI,=IGL=IW 7,
M7K;YT_"4J&LCROE(M]T-RO^.$O9H<#W!UY^:72".$!P$0VH.6*F!_#]-6YR
MTF"<TVV2'M!T# "Q)01G YQ8_PLMYHWMQ^9]BC9/@QM;%:CS)PB4XQ"+TU"I
M>#O@VY,F #0?8<L1R.LNN O&I8T!]W_AG.^"V'V@XK\W%W7@DV&2J1"W9A9*
M9>+&S$D-<;@O(0T,9.31RGZGJ2]8EW_5"H+W!>",EN!\%]K63'BTU\L4>;3,
M_(W>,YQE!TZN0G&&(-&G\TVD(5$TSB?^:M\S0' 4Q]T*IT>W8$'<ZC'<U.\O
MVS5]GX>ZC89[H/@/^A<AO9 S\X2J>;/:>] -7+86R%!"0CYPC(G:,E>C%P-3
M-'^J<'&G4C7^&UJX_@85:5::G=DG_'KL+JEO/9REN7A"!SD*WS&];^E^$XF<
M:_MW#.V^^PRO^Y2VI?Z/K<U003N>DZX])^EIZS??)>7H.O;H.N0CD WR+!=Y
MOQ. &=EZEY4'UIK":-IC$?N/'.,[C+HF-B88<+W4V]]L[N8RB32UL;2@WP&+
MD]FM.9_T]'Z='\R*T_\MJ*FU0:N#I<-K+AH<HZ#7*">O".Z<\-SK\V:[+E59
MCZ<Z_/RAV*1\2-YLX:3**4?9-*#_"]7Z3W29K3!*W%B@&>+Q\[--[]3&/#D?
M0INM-/J<H.37]% "LOUUOB+&' ,UW>.-K)&%6X+Y%+L5'O(U.[#+W:U_]:T[
M\\+4;!TE[):SLX'KG,K(E&J#AJOJT2\^8=SB^22EUS+M(YOJ'F_]VI?6\>JZ
M3U6Y9K41"L)*GWC?W4MT1A\[":';O!MRA0?6-J!/VO@@;CCK"XOS%V:WK:X\
M8J:G]E;9-=KX!KWZ\>WO]54)MW5E]ST.,?C$?G_,S^P!P2%/&^VKAN7\TZLL
M"FQT&Y1XKZ=HB>A#VUV1FZYAPZ&5V55,'\!2[DC'N(;9,O ^3WV9\1^T[(/X
MESHK=*A@,\+P^GRX_S#6=N)O7D4PO*H,RT,I#*&D6<I'I,4K6VC0L1)I<(V/
M_U%B0(*Z+(<-7!LV'"9L!W<PETB-%IQ>Y.=Q[A!D%6P9*M-R!L1%V8W(H4X_
M[:OB7YP)V9 HP!8,FN7P1(QUV]^_;P_"H3KKXWU$S(:E;[]@1/'WH\J.T.@G
MD"L>3FG,14_?YOR-,L@[S)-]TE^-N"R&M5A*2_;T:7&\_HB4L<H(L3Z<%X5\
M5/88[_QN+PN8+&>X]5O8U9W(3F"AC!H.WA6[0_:L:K*%Y3>OI=FO@(7QBY2^
M+M/ZU+OZ)(^&3.6BB5?88C3'!%^,RKF7='[%,Q^F3UCZBT^J3U:)OG]MLOS^
MC]Y!2&Q=459VN,D -2O8_<H[W@G?*%H[,;E&%G7@(\<A/D"N.2+BI?#N[N=F
M]P(%,Y,D[X>/^9/H*BOZT;#_03G8#8WWA9?TL*\E^ KL=WP=6+!=Q"LF0M<M
MAPUQ8LUAKY3+%+<*_T7370_\)BO<<441XX%+/9I+NB&;H8VB%;FOW^B;_GLR
M*^4_8\VP 6:[J+?_3-%<6_J&]W/Q1O+0J&J&4\?41@,OR7 =L'_QO9TK$K=9
MZQ!O7OG"NK5'7\MZ,1N"-'KQMFS;[\MG4W+6MW!JS#:(A[''SU/)<BV(AY6C
MH@$C^W& :).BP32&*@$LWF*U"%,M?H9!4;PJF?3!"U?T)4V42G;=["=:-!?4
MLQ5HN[QSOOF*XX-53)F1;11K+WWE!?F5O^8V,LRU)R%3)2&*R8S/)^;;8&!6
M'64+BJ5#L.S(\_*O8K0ILQ/M5 ONV PLW"E$_CM:9TQO[C'4KXPPI2I DBW
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MJ<.@M.-#\%Y\8S+9&KV"TF=@.;X>LQ&3MJT&H&)DQ>(RQ#AR/C!UUT4DE(U
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MC)U/X7%$RHPO8T]3QUSY;N8MW"'7<B?9G83X%K_C54WG#B>0^TPC&E:?;OO
M$97W3YW1O_E6HKD.$MSI+M(UU>4&.3\O8TJ_WVO6KL3Y@4]AH[^OI? HO,RK
M\*M4^F8QQ^GN^L]%[IR&MH!(H-/5O*GAP@_X:85S+2N2'!A_]X5K1:_8FI<T
M]J+WT26%TN/7N7'/=9>%_#7ZQ6LR[5BJTBT7H86^S:M%=[]GD*Z'53Y945O#
M6U-0Z'?%T(XP,JMS<7IPZ0&X=,?KIMKV#G%=YM:BZ]_67 FTD/I/.#++W66U
M 7_B=I=76=+ OV9>F^K3'V>-\J\+6;^DT*<",GOIIP-2WK->Q-YV+N^&!M+8
M8H]"Y44AJYID)OQT?_+WJNIWY\U7ZM<4-"SGI!?FE(M_*3'O+ UGE[_/RNS\
M317P8AR?ZS&QL,38I"@)7,F;A2MM<#5O&TCSK63\$8O59*>+WL5N-Z8#<#MO
M]WAP73K:)-_'NQ2>VIRJE=[SAI[$DK$DBG':.SQ_RO'=;/F9NZ<<*KI794^"
M7=+X]H=6N_@/U!>VTGOH,<]0@=+ ,7I'[DTIF=HRJGOUX7)</T-P%=2M4.1>
M4=;<3Q+FLI0/P8#6<5?/$^*+B\S?6]#U*Z.S:M$'2^4_'JV4[7U%>I'HOB''
MB3%4$!PFYC=+2LB\Z854QH"H=A%UH <V\[-H="CW'I+F]/AY&X]23 8"8BGB
MY<GG%,ND*B37Y*LKSNOPEE&$:C1]&U$L6UY-4KQ'8F0EPQL.YH(BC^2WIH:2
MB^T+&2\+<OU6S/25TJ@F_T/Q"]V!^/N*@)[V<I$0:50PPE$2?9?3C7;0AZ,)
M,C.:&+IT5&],"^70/-Z,Y_C.9&_)-17Z7GMS8=*#6\*07G3(,88>*"%3;RW!
M;'^PQ$MB^A5O<M1(&C.*9_B*5'A=BX<Q[J@QJV(MA9$X$9S#X,]K-BZ[&XXG
M^,Y_M=*^J7>-)U D]X)GA*3_8>$BX%^ MA*VP#F;PEH'FO[+5KC>=" :]Z=B
MH#2HQ%>J.NJR,\Q"]5DTH'6@D!)-!8JVUP, @3'2X9BSZV>S'K V+:N)BCVZ
MH7G%$$I=2Z@#&-*QE-M#H)H,D5)SJ8-*A&VDV?\GR6QMLD.ML>'/QQ93GVD0
MNH@M:,\Q%C7#C!4N\S[2P7=X*\MF8C0?AIHE04\LI\BW"C%>&YMKN<HH/V[X
M(S[D/G_6&P&?G@ (+M.Y1$ZT58 W0JE%;4C%>_--FE60SYM<:[EC4)6N'J>(
M'T6W+U>2MYV :6T CCBB(>HWX_!YI^&WTE'9Y7C >^0^QN+C0-\"R=+4?X"=
M?YN4>0_+: L;5[LM]\!%I8,2VYY<V]8DG)D"B\J0K"-/5\B6)$IHI4<Z-X9K
M,,>DM]L3+SXFCGC(EVOE(,=(=J:Y(8]<'[4AE61B$&4/!K?0(,?^=9;>VCPQ
M% 8YB%1' HYWB;!:W $,6L]W!H5%G\!,\GJ>H\.OIJVK-CBP9;_[8LL-FB.A
M%'8M:VUIH5XCD$$?ZAA^N="6T30*#<8\\SZ>Y"XK-B'8M8;;J,=DD9C\ISO-
M "NKYT@@G+_H,")SDB?6G C3E6Y<L*%]#?6[WK(89,E5#C>5[]'P3*&DUE:C
MD8+F_)^<H?V&L]";</!T(7GBJ" S!^]]PFA9O0HZ-91CS%>293="80+.#AHK
M+8Q/PNAP\@,;WQBB_S,<H;8 8;^M,K@AY8&?'BN<L#>%QO6JU;;1^%\D,;C:
M.(!^0/LH,KSUAA]FQY'V(VYN'L9^<!?]IL!&G\=;+F+\@C]OT!M)=<X_OQ9F
M",9R;58IR5])W@Q+P3NH+Z6^8:L+=>]PSF['=(<E\(2I6:E9R=17?]J'VF/F
M/;ELEI'U&VE"989FK?6 DGQC3A[DHLW!7\WH\6^>!#^^.$)J2%QY(7:-SBYV
MQWW],2P?/@.+,Y98N^NTLG5MA?@[F03V]"EP;](OU$1RI_6PRTER-@^NZ"TU
M6C1&-$*?U.SRY%G_,'+<,2O'*P5X6]YN6W$Q0E<V QR)RL[$@AI#?A/DKNV7
MB4AK+_$,$YAY2>METL]44AB)>#9!-MMA<C$R^R\K]:K[;]"QR,CA#LL9H,AD
M4!55K735F\G-A^/K\&VBCS8C9;)GTM4$NWL*_Q?/\^+M8B$ZVJ,?I98O:U)M
M<KF(YP=<74"=P]'9\R<BQ/S.=4+8_,+!L)TGY\Q8H[*-%E/!)!WBXA-3:FY[
MZ[FKI[:Z:F']+S9#>*M/J*@G]@M>%WD4<0L8E<5I]H?;8_2M_NE$4:*4YCJ4
M0SR(F_(FSFZWZ2N-V&4243%;=^5G+>K&[C>())E14Z<59XJ#3%OBX ?IT_B-
M$G#5=K&_@TOS\]BY_@=8-$Q-0X-8S-_+#+>H<RK.G9M^N*_GQK4\RKJ3\&BS
MP3F1-D)>#>22QCSD_NDW%N5Z,8O$!T[D5G\)C"4<ERQZ[D&QFP2/G@^W_#O]
MUK[W<UOTG4\B ]H\_X[?Q,)P$M.RDNC_=SS$]*"<7U%)W'P0\-JN =9GU.91
MZN/I9J1]5F*[_$L]'@'&,>WZ JW>4DT\/2VLQX:O7;\R^4;AQ)^/"(/IE^^?
MQ^)>Z'SVL.77\KW31=0=:+OKH+0(GN7F1U[,L2R.UOH8+7W5!LN66(?*;4S-
M]K-?IS?^Y6$7Z0L0%J8#ZXP2B&X_PS>OB&0[6\X8F%K44O9_0K<CDH'N'[*C
M/9=*W@<<URQK1FG#&V2:M%[P2%M=8EI\&=.F329N0M;^5R<->&4G#/^#([A8
M]EMA[-9:SANZ-:W7LC'"[)9!S.WA+Q](OJ/Y!CVC<<E+GULU??]J.O39]!^_
MWS@WSA0>^Y/[*+T[Y_ NGDE94!?^;#-F]9!0&Q!7&>4TW]X]_8',:,/1TN )
MJS@B5ZR1<4Z3!O1C@7Q8!MQTF ]2?[V]_+XK9-;2H@LK&])TWISK%GCM/$*:
M, *9#I];F*T6Y+<:7_7S'OSMD7-M=2N=!RS#X"O247V1QZE_6,,+R9-6G,9L
M^?)KJA=9C<=""A;S87-/PR..C32FX*@6,!N2TP8 H#R"[AG.V=]-:^/!;U':
M2VP(D=##E?13C>;+58!7&GVLD1(@.QJ ^GU -[(QRI"$\(\#]25,'2$\V6_D
MVF&_S#_>:ZIXUP8\/O8<!7[M*,2H6?'*GD)S#0S*29"\( Y24P8?4K7HHKXB
M<\8E@RVUHU(<*&J.GV[H,Y%#GG"D!MTH#(*U ,C#+78DV0VB1W5.YCX."CW[
MA)9?_-6Z!/"K ]YWU# P&(X.AV/A96Z24'$]9$@D?$*IL)HJA.G]DT5U0C-O
MU0H6X,51TJ@.]P/L**<20-\8]DM@HV"EX?M)_+R&>G8KG3<&QMI_&0"/^XQ"
M#5"<8XB<-T8=4KB,C%%'QHSVV#%&0%JTY'^249(79E[VN": !/) : [K]1FE
MAI.CWB([_M8L6JZ9&@&I/?+1K\D!L3&P?M3'$2!%0TZP",))< 0S#WP#2(-2
M:?H+\=5;W(5(X?9I\B*$D54+R1WQIV9,;Q::1VL.\.()TP*J0'.GV8#58P!F
MC$(SN02-AO8UAQ:",$;LS8\:K8*5]W1O,=PSEOANM_DL%C6@I/Z-'HW&]K5$
M$+ZBT6D@]!:P/E@;[_:HAE-G_C=Z&8NQ=!=P+$,(GFD>'-BLP]GL;J0=&V T
M&GIV]>(W;$DV48-#3F9L#915"R;(?AD9QW^X2IN!&/U)[I?SCGK8Q4_KT]G
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M- + Y-Q1X'7%+@H!QF&-2O=C!Q[W^0=VZFT>@_)'3?@),XH6(Z=A^"]S*WC
MC-0WNB 3@!VDBUXI -PTH!0 +^2E;K6W<%-F@\ CI7YBKMK+A:=K!E44PT:%
M0(7U,\+?5.%-[P>I@0#@V6@.3M[2[S)! 0(?A=2O#;7H2E%?_BG*^%IFD_L
MU!5%_,XK!_120^WHPD-C6B5IQ9GY6W[  )XI -C\ZJ.K:QNH9_ST7<Z@]TC
ML=KL#R$'RXJ)G"$G8Z1\%Z'V*3MD+6IBB@+]F:80"0FR;2%4XJ0 050$Q$<R
MB\@D0-]EA$T",H&G[]#5=8%W6 [H H50"7S:! !39R-K%.)Z8:8(#R%P&ZV#
MX*I$.7I]V<92%$X^7T]>*##.9J$X)[FUD;L>I)B6HYY/3#QR+O346@])5C\2
MAF-]7&^U:[V/\6W^[C24;S]4\7B,!'JJZW&-RSO8.)#Y&U6#U%2T"P$P3K#
M> -'B5?FB[1L9"!A_#X9XL_U[NH ,T-B210EX*T0Z1  ]#>"'E^0MUS[R4FE
MN2M62IHXIS]S@?+JI$KTBZ4T:&?-NNXEPR#W4^L/.>W]O7FDY*V-6J>&A.$@
M)6]&8(ANT_A,('<>S4/Y&:"Y']A!0HN3^$I *QZS"-8H:?*>$'0[$.]%'H+X
M@<P,V3)H<WWA6H>].CJNP).OS "B:S?8,18&V]C&ZSNIY ?X0*JA)@(.>H_7
M"YSF_ZJ^"4#N FTG 1KX2L#YN07134,CNG^=LCSIH(X+ OU>3MB*GDE;ZGYM
MH[ G#2KC!.HH7=\1\%=+5:X#B@NHSSAV=CVJ4Y S:Y]R%EBD*/5V_YJBO>M<
MWML[-"V: PSWWXS8+>K':SGKO]ZO:P><!BX$:4+<_\MO>Z-/+/869"K&'< A
M38GQ'-EF)!3];=&*>J XXWWC4!6"UBU+%U7A.F#( $5CIS" *K/O NB])!.T
MN%U1"[H^K5Q8=3NFC2,Q4]I*W1FWEAG_]ZAPOM6H82]WN4Z/^6P+SY%%- "<
MU@N,TU>5A#620?-QR!G]&G3K;)&.S@[)-&'8S6&L2F#\PTUY;G,$D1+"U(D-
M0ZISOJB@HE']RZ_N[66H7R8)CB22<V%9BOABDJ*CG"&\N2_,0?J'+LO6DQM#
MTYSGG+6K]0&Z<KJVELY7!X!75@3:L02SIW<IW6>8]YCG4L"WP2=BR9[VJ[Y$
M 3'DL6!RJM'VPM"T?[, CVWS2"POU_VUKI^"#M('*^KLGL6/=QJ2$@"V:1Y:
MM,Y.Y]T<KJ7%S0-'G)9R%:EX8.$Q@$P*9=I4;QSC!#Z./U-[QYD?GNTZDPL)
MF:?_G6-@-GBTOVORF=R[5\P(Y(-NWT\7?:BN:OO"I[5EQ,DT3O=(B<S[%*$
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MM(>NRL%GNV8N:!HWU(-X H*K_-Y1Y#TSE'2* \W7AD<27R6S:?ADPB4!/@R
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M":&+S9EH@!-JQS$.*$/,$ %9\=(LFA<Z":ZSL:0H#6?GHGI;T8,-8A8';9G
MX:&28QPD<:+3C*;L]EA&53Z43/;]0966*(XD1.X% 0%5Z!&G*FXVBIM'P(^5
M.H8@//4PNTIIEEW!%2-V/&7=2M%=]=/K1:2OF2,#VA!E$'K5!=()W6M4R4.#
M@U)ZEZG7\A !L(*3P-#XO)W<G][KS^WKP/L(?G 212I1ZD<?RAF0Y76(<N41
MDE>^HH],+JA5,7F6=0-D 6)>JTP\"&0I0*@=1Y66%:DZR#34@FDZ32Z3_FY$
M_EFBE;@7@7+[X*%1]A"XZ@N1-![PI>BI>1T"JSMM:0A9Q25)I914I;D<A*2
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MN[P0*$))'L1@R$I3U(6Q"BCM/G =NAVJ9R6B^U./!#0IW>U0RT9EE[+LQ!E
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MNWC&I?LVOC+55!YS4J:LY/7\ H\IJ]HQ9=+8+:*-Q#$5Q:<AWH>47>0NQU2
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M\@ZX#S.#?KBL&)XST'%&?=.RG4NJTS%CK;IT!DQW)2SQLYP=_^-08H^YHN/
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M+B#D%B07%AB>P^C-MGK5"DI)-CNE6WP!BS56D^M5>OH=U-Q%G#D58/X?I-?
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M&#B-(2X SD6%LT/@"!#G4N1;<<<G@ Y]5'BU%4!O%5X/5*"'"#+5T@@OV#P
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MML_FJTHO7RFST)LBA9<-LC*Z'+\JJY9<?<5^84W]Q2W"RF9.W?*Q/;B5U_8
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M-M9!3N9":4##>HX#H':9$$H"9KG@OL[EMC]TV'_WRF%;+=XY:^%X.J)E2^2
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M2CC6NN/*/>4Q86.@(P>I=U]36BII;R\EH=79"LC-:LGSWH"B?_.=MY]<^3,
MI^AL 5$V;OZ4_C@B,A866;R\R7Z3RPJK3YFCL[TS*(OG2^3BOI4-?.Q8@'MW
MVH]X3:DWLS8Z\U/NYAR9*(XY!:K=SCKK2D 92N$E"?ZMB $:AR,2*2B=FE%
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M_>(:91EM/IDL< -2CY(&K=GJO;6O7ZFUGDG1V^Z8F&MBFO%(/7SNYY;S=RW
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M3ZKDU]?E_4EN[6"%(0OL09U??%XBEJ-FM.BBVB1FEG]/B,BN<M<^I4&!I()
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M@UG=]W*XAI!)(E1)?X@,]>@F+TD;;X#,!#8RU*E0GW)M(,B)"D9305J CAA
M13WTSW\UW=GX?XNU0;DT$):*7E<.9 +:ZZD0-$  TV10_^CY+TFOUX'_:N_'
MU<8OAPIXF3FJ-'MSCCW=8N)3?</,ZW#N_[2 7&0J+!PH J"! ZC ];@7G.YD
ML9!^%&^NC+H>;J]R<O^+.96+0 LBTT#A "_4:9_%5@%)^?&_"L#L]XJC\J!
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M-+ S"FA$ +M> #AJ <_?I?(S:?^; XH<32" B='?N<D)R=&BY[&[H%Q(" 8
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M5D= 2N ]U%WMW@R#@% 1,<D]EU;A]%XJ2_K4P,&!R:WZ)GNJ?0QVBS/YS.W
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M'#4?6MRR"'S_(PP\-\B("MR(S?;3R*F()"%I"JO'?>XZW7(\#)#52MWJ'V:
M1/Y=>U;->RKI,)[S</SM)^G$E4!\;6\[?[A\\"0JTD!I-@KK<%7Y]MEBE[C2
MBV<B*XGJ6TW"(3[[7T*8_/13WOU1'/[4N+.G8_L#3SNIN)Y-@P$%+QP&N_+T
M9@3!_ZE@V6V^)R'>U2U@Q$]_(OHC!TY^=O\M=$2-<.#U**SG9ZR--<FAY7W
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M+E\I)KK;QC"N#5@-FZ0:WCDN0,83'- _BVNFFY(\0@^7SS;?V6AP6!#1U)<
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M*LNXP 4LQ!@@FVRCY\89=I\XB<UV(8O0 + ]'DJ_SCUD5 I/?AY7!U$GHT6
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M#U*F]+D]%\\.US,! -/_ 5!+ P04    "  -A:]6^Q"&8+IY  #W>P  #0
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M^P_OAS]Z_/#1_R#P3JB6TT/"TZ>TAC&<QI&T=B\8S1)$;1/D'>.4/3/D\:F
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M/ J@Q49!0 &G10+(EVH?0""Q_F$L*#Y3-S(=U0^ (KHYW*5[VAHQW@(1&!1
M/SR?""!>C$<20(7H!@GZJ0L4 1(O=$H (H6J3D<E6\:MJ%XF_S!"PCB"QA@V
MU!OB0?#C7KK*%B$! #JH]F&L/1U=0@ CQL$3%;04C&'LW,02H8*:I<B6'XI!
M30@[V8C@J*FQF-<BI;0S-6!DW$S2(/6O@:B'PZ7>!.$IG_&ZRQGH!3 !H;I
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M71R+4%"/-48=TIA"H&[>!4"7;1@0=29^8NAZ;/534J-'7"2 ])F! C@P%P8
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M!F@^VHW52X%!2E0?P+)!H2^P=/ZO>9O0UZ?7:" HT&(P#01SM7!-.Y#E)AL
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M-Z"R"DA^%\I77\)!OR[[X0#:J&N-KG&!P^[L@>D7-5H*8MD7]!('+W5#3U,
M#05X>O#S>#!0IZ1*2^*LC+"01?%,'1-4R?XMH?GI48)'OYZVI8'=^A3+. K]
M(N1I28&]6"74L7B:'.H]B3-9#OSVU_.KVC*"Z71X2W=:0L(@F6X:?X,6QTO?
M+IR$45 &(R?6P!]:6>4Q0+@F"(&1'L)PRA;!<T6,"EFO@G /&3-M&X1\AK%W
M4&LZ)ID(<<L$$>QU9HR;1(SI, 847PD7QX9*_6$;1#W7R ;344JGB>!H3]!-
M L VK,: 0T]A_E<5-*YA19_-XY]L&5S# T%N-!T;(L($H+D(<\F 4PBQY^O%
M@IE]Z< G=)5]ID1.9-[&%5&T%CW*DX(!KU3"I8F/**3BZ5918ZO'@C@(/5:<
M/@:"+X??Q(IUH\J"9[4D@X $2QVC$O\&'/P%622&BX]G0%P"+52450D/TG-(
M0VRP2+)@U?.50>R:="WZ.A''[I*L][5\3 L;63MQ8"H4L*8@,.)F4ZYA"5F7
MIT_W&,:ZWQ>N%I)3A$XC8LW43MK=JOI93_PL W10H_VL;45P.B#'.1V!P0A+
M"--*4X!"#T0#%T"%!P=OP6$XL$,:#1P/6ERGV4\G2.&!!6JS=_(@DQ=TJES9
MJIF([]=1=YMH>,D0A^!+^"HUFY)FYBOA6D@POB[WG<5 +?4;7D-AU)8]JHN
M[[Z'H"*(\-I(#@99.9PT@$%6KC1(0*Y6GPTYY_X.GX9HQ-'A3_ :60@FLC@=
M&J BA!PV:<GL>%/0\)O'<!?[YAL1A=-G$.&MYKNJ+($PQIW9YGL=+<8G7H_]
M61_^;8E4;8UV:(U]U!J7UYKPB.V8%CT!H .;++45VW1T+%/IWB4;MFD+MV7F
MM>6.M67LMV4L6>?^;2UQ:$_[VUKIWU;5T4Y,;-.AZGAGV%Z;V-8HT=%<U=ZZ
MU-Y!UU&9YZ'*V#J0WM%8]3]">[5_Y^N\SKI';6F&;4UC':6J'>VJ76V7W!T?
M);K>/.J:WN_H>M2QL/\_=^Q>6K+.H7OW-*R]PK\SR[\SW;\[KZIS.+'KS7[W
MN6'7V5C[AD/WWZKW6_OOY\;>_Y?X?D65_&.I+0H-N48B(Y;)]!=D5"=9$=/#
M>$!F<>QA=80P5O=<(_=P)O7P(GKY.GL$''LYU'H9U"#7_J*\,Z6D#GHQ%[W2
MRPA9QSX%QSZY<=82L[[KDGV8Y3YE1+]J9Q]6LE^'IU_YH%>WNE^]L]]HO$]%
MC3&^B(Q4ZQ%-ZD7G#]B/DVT#>JY>](A<# CQ#'HX#B+4(,8PQA'2@-7R0,#%
M()YGR%UR"'4PZ"@Y> \QQ%CMT(:#*!\/71(NAFX2(&ID2!3/<"1B^'D2)'%Y
M."%I..(Q)*YS.,YQ6 TU'),_3.P<R5\>R<H?(2!&,P]&2HU&LY-&7EP,J05!
M:%M::XU8;O+TZ5WT-ZKU-P>,-3B.W5 ;,TGJ-UT>JQL?Z[[H)8_W]_*,J5V,
MCG:.CR^/3UZ,4W@F9M0F9ATG/CZ>F,^?6.R<6%Z>6+V86..9W%";W'*<W'D\
MN9L_^;5S\F!Y\NAB\IAGZA2AKZ:$.A^W/T>PJL&0:F%3[[:GOB^S !-VD'\H
MJA4[:B?4/QZ*0AU_'YFNF6C]FD";@:$M#Z*M A!?_]A!#A'C. 0)H'N#HRTC
M49>A8&F82]I2PC09@WC=[$[SST+V'V(278*4_8"88!PATU43:))1< ?2Z TL
M1&L%<B,(="MYENL8Q!\$M0-@I22Z40R/\K];DU@$"4<;3H!9H*A,25!\,O36
M,523 -)/GN4X!FFLS;IB:<G',U:\^C9.B+HU6@( ?TRF#@NBOD^ATL!"M?%0
MNR(J/.5C%0HA\R1,Y0DCKJXT$P._CI^]$011*8*HD2#7253729!<7C#?,:CH
M$,15!.+$?^0@@/CQ4'P0;1_Z ]0,\89";86B,B1 \4BJ5EZJ-B25.1E:]&^I
MZ,9B^8UE#2*5*X%VE#@E9_SIV1IU$ 7F1X3-7-; 9KM@?CAJXR 05] B)W&V
M' DVKJ$RZT) &3\E%J F2(AA')T<!9+5M9!3 SF5^GS2!5$Y!G&M@?Y(+5XY
M7BCN6O&J >FA8%7H3B<PDH1>PG=!38E+[<E+*+YU@R(0-^GSQ>'G]\@U#MQR
M!@KQ51M1!\#ODV S!3 _,BR0N"&^"@L@PT(I4$[*YV+D\I\;RQS_>^>[Z.)K
M["^J*?$-_"-XQ!!F*QKS6??IUO<)B!+E,]OM]9*:S\6'H#>\4#R!;K]9B\:9
MJJD+BCM>8[S<=E%?-U;?^5/PN2?P(R<>RGM[2LT248NG#D"O^!,V)%<WPIR_
M2'7#9/@V+]WIP7^1RUQ\4)<@6M5N6QQ_R1AQ=P*_*@YI&H4^U;J-F 9H;A"V
MLKL75-:^>*QN_49N7P&@9<D@;0Q-38TR7@-11J%J6=EVIM^I35DR(($*NC\W
M=.]YIX"XB%3E %O2I'#_\<[TDPWQE/^I'@S6?L%T[^6K+W(^78SLIGTZAQBB
MT#43: N#:+( FB02/#V(BAL%U<! =3#S> Q-.8#82E8^OKYU,'DT2$84X2 G
M3_9TN[=&GWYCH5]<X07;D^@2(8AP[)+CY5<HPXXA;O^G\P[;Y=(D'XU%C7+]
M&G5P-TSL]@';LY. -9A,"@A=M$?SWQ?.IR".(&@&^;(V#8H<Q-&](M 0"?#8
MXU.99_ X$CR6#+<A@I13OWLE?^1$K68<?QR906A(;QT>'0V3Z<YN[SF0MZ[<
MW!GOGN4* G$2J:HH^T,][B0B=<O*5ZK/YVZK9S]KOU4@867=<I/ @1_F2WC*
M2< 4;+@0A/^V1?OYLQ<O&+^V[FQ-EPO0/ >^R[^')U+@D0R_"'>^R]*?DU<^
ME][8ML/07#[=_E7'KUF(&,&=99O"OQ6<G791\1..@V46GTEO<V#/Q3/.JU;/
M*V36N=9.7IGN7R1_9C\&>;QW'PSY<1^_P?KY1_NK+X]6_S2G?/9%PLA!ZI/$
MQAS@>_2KBU'37W'X7SV77;,>EQ<^)E \</@[#=%39)1I^CO[\]$TED:QZ/?W
MKK/"5\<%]/\:37Z6W+P88$+8IT*="O^<,NQO?_MK*+7_[PF('P6#.;--HN@
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M0,5U<B& 2/U^AET)F"B4Q;L5,L#=^L%V"+/$S>IK<$0'_D^+V4.T[U&_OGR
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MB+*9RV1]JC4NM"5M5[6645]LV13I7/-S@DQ>QMGZV4"[82JK0O+H ?4P%IT
M*'=KQ$;:BY^E!A%6KR]?#@3,K^[UL]&*:PHF1?!$O]+S,YRM++!<Z$>_M=[.
MVB34#"IXD0/(9:VV[GU;L^6_7FDS>3IK6F7'(717/72G;0UI<<^M]&!/MSQ5
ML@Y H"$?,]C%VB;1_D:[Y0!K"<\\>S-Z58)5N.2>'@L 6LC:_')H_\P3YJ?N
M8?I0U_&/@+4TH]BJL,[@SCUA3Q5I[BE7SL>_$EPO!?>0KFZ#:+8>G-/3I*,
MUV]PAGQ%8_SU H[77Z;R"P/?Z#H^]$X9+N-A_1)Q78MUV&L NK%XR&@B-!W!
MU.<]L3%C^WQJVE7@,D+ONT:$69.!AB\A_$^J5+Z0^( 53_CZ<T4GX8)X,1/O
M=34-UOPR14^-<]$*OS=+5([;$4<]B6KVEQS"3WIA3!R[$:<:UC7TS_F<I_A]
M%496KXBQG/XVE2>F!PJ#N7DW;<"[SYE$[^_Y\!</BN&!,3&?SLIL.=[=:TP^
M,>I6[#E[+]7[IJ$^+*YO/D@)JB9LNR(%4$%8(4E&<5(%QHV'E\!NA14^F":Z
M&FO\Y-TU08&BZGTC+Q>I=F<B5G,?C%;&-*^$2S/+1_-;%([(F>\%GS-Z_#%5
M0#AS*?8*$C74]'4RK:F/(_Q8T#U>9E]-B+U4U;[ECF_O\PEL IQE;)#+@$@_
M[\6*6?VW[YS1,T*4NX3Y[!7;Y'2Q6&FS1&$1=;?\4+FWS)=B,8.KI7_\Y*$@
M]#_1-Q_I?VA+F$A+-)B([F$TWOUY*ZE6F7GJU90^PE4MR#CI;W0K8H]U1N["
MB7;4:C#^2D&EW_JQ>.<IE$3KWY'^ 5K W\G4%T=;':/AWW]]3S)DMVEGYSU7
M6=^I$>O!3,)7Y]N<?%.'[G<F?-T&XX9T)150H(XCO?F1[8[>_:ML8D/.V>&B
M+HVO=0NMTQ\*"7(ONSGKSC$G/2](H%7PP3V;?.%9N\CB-,;<!/K 5ERA>RA7
M[$O*I:JS#O 6M42)XOO5H^2,-"B77A-_)'F2+C_6/+6PA!M^&AV605J/1E#7
M2V7(<#BQ1_HRNYG/!*TQW,"S;HF4O8:=XPZX=ZKY<Z>*:P[G&AVZ"R2=Q7TE
M;(],2B=?Q]K6=A_Z/SZ4\^W5[^9L_<JF-\.YJ?,!SUK]Y?6@])GHT\Q MBPJ
MQ\6M TW1G1C1KM$]YB+0M+VT_/CA0QZ*FJ_TO8% (:FHZVT5W7+K!&FZ+.?=
MBM?K[$DU>>2R+9/:6R9$#6?B%W4MW#K'<63^>N=MMTNWW_7E-N?68O8YJ",_
M7?L,_9DQKKJ(,;EM;4"R-'=4//N.J:@6:HUS<^W(4;KB79?$_,-5^?"OSME5
M=8=?&U"8%_,@0_7X]Y=_KBJS.>QL[$+>S<N/"PHTID_N^3XJNF,I$&&"QYCF
M]U*Q9")R:XZ^<J8F!76U2>T]Q2RR?OS<>SSM]5*WD^F[--W?=M,O7S&-Z"B.
MV;?6]S@+1OS3E?9K\#*(G]IL4'^P11ER<S"M,OMO+T9R+9?5 L,[>ILMJGHF
M/_ZQ"::!_AU5KPQXP(WPD)/5XA,S#E3O52?/$<2N=<0>.BK?>SSU]*TV;QVW
M1@#;-ZBL1_^8>7\.C!23+.OMBL]VI?MT/??M!C1#Z=2D"/SSMBY(G.1^R6[[
M&* N8A$-U6<?EVF#O9.QVV6>%6,V7+RO?^+UX_B[;/W5MX57109J_E3:'GV]
M9&R6^YT0D=M<)?9HM/ !0HX=(O JV"B7EK7"6U UBG<KA/DCITA).?RSA^QL
MH%X]O>2V,).G3*=FWZ92:.>#D\  (&NEGJJ[=_#T='.NGU= WI1%BXNRH6!H
M(7G3I6<F='K+'W^ZIZ3R5KE=U]BJI^WTN[QD'XCNE+L]U!;]6ML%F0934/\,
M[>>Z^W[ZY&YG8=KDJ2%'\;OTQN7@0.6/+*PL?;I_H1A*$%@/E<K)<K1H,B(K
M+;H)HKQN=$X9O\L/FAZ_JQL<JO*N9\AXY3Y%YB3A;#.@]"6&ZA&%5WAJ1TU0
MT;0H,K>W0<3U+-"(*-YQU5RU[X^"XH&<.>M[F GJ4L;F9I3$;5*RBFN,V&F-
M8^CTPT_J]A)Z*@,JG];5#9L"P?OH#II-1S+[@*(IID]B_U!/IF=#[H<\"^3V
MHM]JR)N?^/G%ZU&ZY_Y-THK<F1I\AC[W#^0]OT%AQI&Y]F>NJCOE1"'WDEBY
MBF(]NCM&:G>U0YLDC&1N 1B>J3>"<V^^%&XF#;Y.OJ?MQ7 V(*GQY8V2:9$N
M1]*I_P<8/(@0H'5-%KZ@9SK'HLWENG35BIW"10R[/\3'Y!CT^VFS7D2VT*:B
MRP;_W;_]0K@6.ZO[<P2-<+W]L,_?=^1:)%U*/7[*>I; KCZ+?E 2+ YF9MKJ
M>?J=J%M)TF/#W=4LZMO09KE\?/KX)]3?D!*Y?M^A>2?V)S2P:OW!I_[:USVW
MRYN]O3,N"I43ON69ZAT(:0SPJJZ$V'QD,NJQ3@V_>U,KMS :M'J_>#OYUV5R
MZE^H;!)(\M5/9H5?"5HM\APM&UE*_PH3//3:OKQ)^: ]/=.X%9A*SV0)4A)1
M,:W6A#^^=[2#VO0@P]"Y+_6NX?J4C4KOY^NU\%;T\'3*$JBK[ZJ?RU<JWQSK
M;2[:G#R4PTK_GP[.,ZJII7W[LW=VPDX!=D(("0(F-.F$IBBH.S1I0B@J(FJ"
M"!$4(S;$\NS0I"D!I:H8$!7$ H(*BIJ@(F A*"J6XPE8#M:#]=@.Y_7_KC4?
MY\/,W/=UK=^U9JV[.&KP6\&A7J&9*.WR]'O;U$<Q$3$[\WLE?#)OYI*8,?S)
MWP<B9_K?G<GN/G-<\B.R;4U=V+=8Z\X\&V3S'UUBSQQ. G@6^ZQ%TO!.IAZQ
MYQ^K<G42*R8KKK]D>2OR;YSW^+4X0#-C[\$O4YL4:XO[S<"Y@%U=-C=FB94]
M$?6Y<=>C%N524-3^['\(A4DRK6Y+_N]FLV=FC=5/C^=)_H9GNGA>J;_.>_7#
M9N%O%J4B1Y=_$'V&* ^W<O1RF D$\M"@;*=YJ%(GVNTCWM!OP0^X//6!B#A_
MY5. 4IDU_[O["@\2'[] L[IF_7.+CY]F=\K(M5-Y'@$]$>;=_%TUM1%^%X]V
MB]5^QJH+:DO(]+/WK4^YLV=\?VQ[U:B[5>U1X;1Z?5;'4YFA3[MZ%ONMHG)Y
M=SQTA7,0B3-\,V9&IR3A',]M@P=[+;3[)X)$]C=_/?@'$59WSKLR.2,M;FNY
M3XYCM\@T3F^F5>!N$QO1<\V9@Q?%^^'?YU;>O6U3:]C_(8NIGODG/5 8O/M_
M?ZWW=(.,GHLN3)OC<?/[O"E?FO?-]/@EFG+S7Y/:#L.[6A9?8:+:-K1^HT>X
M'SIR/FU/I/X>=Z_DS_RH6:?T-';"K+%/Y29\T;.<YWNV*A1C.P:KLEO_F2B.
MZZYQ)/TUN/WCCKB\>7?'JW:\U[L=X>3/133D@"S.T*4XK5PFP;'P[.O[=R3X
MY#@T"3)SNS!.@/$X\GVMI]MSS1&CIKZ R><_,ZM63YHW0KN\ K=V>^,XTULI
M$>7H,?T*/UK3]MJ$:;NSII<E!A:;N"4/=TZ6K9A7.E6T(W9Z81^983$G4ZM3
MK RK<I7VEC0K7H963Y4GJO'<V/;"VWX4XUE[95%*_.!,CP4OZGMR(^N#?A.I
MU&1!\*[D>^<K6JY%Q]8%&_M4'A^VB8C=N.#"II;VN&WW&Z/NYKOL\TIKW%MA
M>E;BOS.L00<%,1V77-G)_&\_^BZ6HV_BJ0NWWY/QHFJJ961Z3?1?.YV.HM,X
ML[/>M?A&*M'/](I3RYIVE/GVDUJ$JQZ?\W%XDY-U)NW/RWKNBCOS>.G/=A;^
MVV:T2'_?K'2B^/#YYX55T5=WISR8=(OC6G)=DOJZ19^2]U7:W]T;?C>I+%AS
M]GK5<N9(G7U8HL\NEZ6Z2:-?,5^YJR]!(23;TB-?T]9</FHQX(_#@B>H8TI1
M5+K^S-MQ?F?(,W+'J#:>'2>KT9#N$ZU+>^S&W!A721!R2Y;ZRO>S^*,D1]^]
M$YRVZLELO3I5_PJM=M%$IR%U-.N97-5JX9=(\UVF>'GT$7'\HU7C[U+,LJ%'
M*_FN!U/[YGI*VN[<+"Y:=[C4_M>ADV?R?R7VA;D=*FB_->V8VM_X[>VW,2=Z
ML@6!=$M/4'JMPCKLL_M>]A<^::+'RH\>K:/?&@S;E?BR8LYY>3#UTNL-^A%'
MQ6'.@XNJV]AW%SCWT"KO>H:7AUTT]4LL?!CW98]?S%=\1=%E"UKE*>GCU=%7
M[+63(X<J)(VQ7@]29CLP:B413"NZY9S,8?&!N)OJ)9RN/':.84&?'R.F.F_A
M'X<<:A<:^YXOL!QQ]F'<.V6=EV<9N<!AZ8/EQ<0K_V4VG_<M..9=AKX5.?RW
M"S--E(R>*?75CB<6%;_IYNI[?E3[+XXK6G76,G^*R^(V[6Z(4A'2 ZSH5B5\
MO^0:Z>TQNM!VYLHJ:4#Z@^<'/;([V;X?F_S"EWSPAU<UKC@!Z_N&*O*J>X(I
MIC&)H2+2&0/].<'AK[6=MU/Y+77E/-G^$!\KU8#%XS6['T6\7G..MRF?ET@H
M#AO'A+[:]W=TO"(P-;FI9.M[!WK+*=I_3SV]AW=.,,3OKTR>*'DL'[@>1&NJ
M\XJ>\FG0]3^S]2E$?_RR&5TNCL.3%D66BZ?ZFRS]^G#5J>U_/&HZ^\>:E9)7
M%?.E4S:GQMXO7@H_G+UL]%/2'S5KGW[_J[YTLO.1"GI9,7MBXLN#::%>T^/L
M/&^3MDB\JY[^^C04N?S?+P=LWK[OEFXY7/&=M)-<G8A>M]OT]?O??_[W'Y1Y
MY-\S#@394P<QJW%T57HH;8..)."*J!'*;.,.'=FM6J2?KLPQ_ZS3$W']F+N5
MN3:>H]2H:C_CD\H\YPVC="G7GW=;F>_5,:J_KMK?_+URY^S/HX8*;H# H*P@
MT'.,658=8.-25CA_PYA1/3?0/J*L:$''Y)AQ6W6@<WI9\=+/8R8:;I#;[K*2
ME9[/>$/505XGRW:MV?!LRBAWWLSTQFU5QYZ9Q63.&W_U8?'^9\]& [Y>5^V-
M5%[_OD(POQ<OY;-B%!VHU?\\!;ZL*,Q:"%&=Q,4I5PG$FBNB*15ERXX3$(;E
M[BUAYE""<<SZ6))GG2 G;+<.&;)#D%!M<0IA21G:%TCEBA4!O^BF"@(GQ:J+
M"[6)<+MW$#5\)I.7V9!4%:>@)DF*=R$-Y/INU)._RDR6:<FLPWAV':_HHIN)
MEOW@VI-CE26F5]5,HZX 1K*N..6S$]M1=6W./[S;;T<LF97$"X]R*37H2;9E
MI=W525%*_8US>2*Z!%RY51G%I)GA9 >NR%DI!6B3#E%UH^[6<A#T!("BS'PR
M@N>P@40/5)2Z;B( F6_5B 5KJ+%:*GPS$7'(;+9YR2DI>KHZFN=&<:6T$E-+
M *AJ?=4N X"K(P G.-_*&H#(/A6I'06NZ9 BYVL_[Y3XVJ]8 ;/(&@:&7 V
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M,G,"U&CIUA+J=2&309",^\ ,^<'OA1:&?.BW?&TP-&L&J4A>OJGE?(NCJ7Q
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M=!**#%8D"2E1J)&I-V;=DLL*SZUV9''Q_&I:NU^<]XQZ:)GZ\.*^O?=K.I<
M;E!P;H!:85*3ER&BA/"A8W:X-#A?N)=6WW9X>1STA.?30O+@?"/+).XA!2>,
M.G-7:"]-Q2N3Y 4]+"0)FUL%V0JR*(%QT"?9Q>>:MF1<,>=SKFM.OGDGLD)I
MW-S:T;:58B(VDLFF!VZE//M)9O615ZC(I2L0CK#4#UQ<[T$QB4,WMBB*LB@7
M' +/^)G-Z$?N-Y"YXWE,'7F9NBU\6SZOR;C;AQ&FK#4(@>+[R.S.7%YK[F*N
MNUFU,XNO'!RK#OUVIE0N#%%"NUO;!B?'NI+4D'7:3-?31*B*;-9BLD+I'D2
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MQ%>^ZFTT6VH'!55#+MZ'F"%==WUSJ1C%F*C&=9HI<8=66)>L(*I+=>2/$^1
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MO*4/T%T*)KGE0I(*CVB^G%'V5&S?B&P$ \T4<3:A;FC4:,SAXE/2*DJ6ML\
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M6DLG<*+'88Z02D"RQ="^HKP[N>WHB,(5UN)&;T%NYJM.:ZXX^][D]U[>FH-
M.6?CBP-N*>&O4H2L&-Q)$B3U &J.TE',_380;U49?(I+.+<#Z EQVRK?Z"%N
M<BTPS-L+0CO^^%''B3FWGZ%A=6KE,:F.+. ZP.4;YHXK)Q?@DH[S)0];IIIM
MFT?\Q1)QG-^3:"4-? #VZ49B3$LY+GW>I3K@_$7YE.Y*YNZ1T:';\9#[2$:[
M@?B8\,)<<'3'W/L^3[FRZA5FVHX+Z5"GW[K.?;"5O*^BE?A(&\-#I5:6R=\E
MBG$4VA)+[0#<+=^J !^Q"=/FJ?X13<OZF7%";<\LW[#&."9#"PLXB%?.#[QB
M96N3@P81J>\Q0J+E?.Q2H3TJI_,3>/]X/_S;!S;5!6><*C$47NT7L!#*7TDL
MR(-A?I]15QV2 ;T]&U/,'GB]C\\%%7/L^3U"EL9G-=\[_+A[57:"=V^K^M#?
M-B+%;OLT8JZ+[YE9#*N=Z.\"4DYB_"G7HK6#!1D)J#9:+?NCBZ[M+@_'TRX9
MG"WU5[7JJX=I%:U*C1Z3_9[ZQ%^@7H8R"UP)N]*30JOFXSP@_'S4_Q3HH%P,
M'V\;\H;HV*\Q2/O+,=NQO%63**O]<E5T7#U")JRI^#6WD[78;XM1^*?X5*X'
M8HN//2(:K^@9\/N2./EG^YCTQDW+#>'JM%[!I/\*^3E*V*M]#&MIUHD+$KR*
MY,V5A(*\^F-UVR11ASFR.RR[P@#5'9K5^_B&)$W)K(/;B?"I[X=:JOBM" 9I
M; PF:21; ;D^?>X#QEQ>ER8/%O@."L$0"4;T5B&R(K1F*-U7X#Q@B8 <77L,
M  FU[F3 1\VJVCFV@$*W-KG $2\=:,HG4O?+(G?GA>2JD3= TYRNYIWPQ-0W
M^9WQ*&,X4DKKWZ67.O%V:8X9ZC;%2A?5;BCP24.7>?FZ(T( :#9S=?>V3^!J
M:+XISZ!(XT@DV2N+4M7PH_UC;1A!P0]5 $,Y(038+?M/U3OXY*HYL5T+W*_J
M.R3K;6?-ALB&'>..F6/0F'EU"0J '\K/T^!$*?T+3]I)#OM3_84OO9YL&R=6
MR,,CC!+3+X3>_OZB;R@O=LR%10].<D<]:E\2A+EJJ4>(G ^;3)&9]QD.YO;3
M2R*+E6S<L16Y(V3\C#)DT!1VFIN7BE63(K,,S_*[#R&$7K)>X2?\H$=B9N#.
MA,)E1<74NCGWN8_>J.!4VN^W*O9H5Z6&0RE874J+6D+9N[G4OW6_5PC.8LLM
MNA82SM7^F7H&<-A7S@I',_*9[IF])C ]/A'@.8!$>;5YQ&R^F,.0W;+'?E(R
MU%:S?4O)RU!=/<1QKC<5X#98T)DQT,5R,H(D:27GXF3S IV^"(-*7C:V<(00
M3=;%]Q*&_=L I!)\LJA9>.H=]"P)P$&AG,5*2N<.=BZY6@P5L"T]/S!%[QM$
MS.FKN%6VF7B7Z@E^[LM\%>MO8\HC0S3$#&62;F?]^H+PYI1RE:6"$+)W%NHW
MKPB/,<H6$C.4.HHM75=6(%+H/K-QEC&KFKCVS/KUWJ&;:#/#_:6*&.UK JI7
MQ2[!1O17$R$M=.C%90N:G8*A)2B>CA3+'OP&\$P3>S0(T69OJO?;T]]GE>2.
M7&FLC-_U:Q\N_7,G,O4!$_44Y5UMULB,^V,VKRS3=W\?Z/+F^!RX! 4LICNG
M?HDL>R#%VQM9$'[UK0@8#]O9;AYPN%%NRLE*7_ \L*!%Q17R##A\4@?/>D0'
M?IH=7=CW$]S*02LJ^QOK:?@3+L+]K122[[W,K&U&,3IRIU_=VL'D3(3-V 1\
MV5\8 <0><>600\/9A'43!D>>&__VH?:M>%,E\'9TX@.MP; )VF-UM8="FATB
MT,'KC=/1^$'#I[H(!:!W91+PECI6#A:@;W,1PYTI(* DBCI-_MW2O?G0O(-4
M+00WM;^3K7H_4A/RZ:C;,G;.:$'\[;>N[LN+<BU&+M?TSLP-+-3]^7T%IQ6;
MRLP_TGV4I%R^!+JGW:D"/">,NE]#UV*:NL[3I5@)QL9NR%=<.B1';*&%(*_L
M??THGGMEXF26;X-JNA+A'..#_/IY/!:X7P>A!Q;F/O2X]SK7YC1:^8&\SKC-
M!+18+GBZX6\XX8MV\/YVEGX\RW81+2TM8*\!)EA.D8U*!\6L]C1>P^Z<N[F-
M%?L9P,[WPH>T4M?XMO"%NM_AZI(*]QZ/$%%.'U76, WI3^(MT[#8JE;'2>'L
M1F^J1R4E@\:J^DWMY>VZ6[.Z-$JPZ_FBIV<Y]XON&YT@U//ZL(+0MMCU_E_H
M]GPC1?1+^2 X 5#KC8H\YZ@,/R#=.89(H;5;5]L\<H25CW'\/+U0FS,=GSKM
MM!!-+U.T2U[UJ48DA]E6=;E>6S R92F-#1(ZAC;1T74GXQ3P/=E6</5>WQA#
M$_7U>RPU@'T]V\>_(02N*KH>J>ES&0T8*K/KO@N%G*KU*PSP .MC 0^".GSN
M5 ZXDR1<=:>;(?&.8*L<Y+L)%L_\:90R%9GY61,#J68+=$"ZVO6581_TA)9?
MRL;[<N>X H'8YGYZ5+PD*421G=X;N7O.5<WV"\'[G84%&L^ 8YIO,7S\UOV.
MTU3-9OC\F 3FKDJ.1@[[5.B6+H4XLW;SVD:26U,)H:RYO84XZCEC% ^4XK]0
MB+>$3K$8!J>:0E5?-I^8&>(^>:RU'/E*#[8N[9AAA.6!.9(S,.:X;#A2DWUL
M7L)V^TB<MI$N8TY,:MN#[.JL=!:.Z(9M#V (WF!TN@E6HK&)J^082"<R<DMW
MA[B,0)A1N$&P#0L;A8>Y>H#X]*,Z.<B=61"2Z,>KT5C#-KBIA<BI/B'['."X
M<!#MK!^%8>8D@!]L,ZF^DCYO963JL*HH,G#'+V5XW]CEM$O[A:RH>=]"#>=K
MF_&Z7'LT*J6M<C!+%)-D7Q_,\N/%4IW/?4(QK^VBME.-.AX6"J7,$BUIC'KF
M_$GS;@O%E;*J#[OW>2V@*/_FM!Y=?-GJXC[#WX%!1M_S_K5A]E8EKANL*E]L
M:?7W( WUCY2J_2M2Q\IYY7$*([]XSU/3UGF7K.&1-/O.;^TBQ04.?UA^],IN
M&\!,(1O;=;F^8T3K9P\VMD?ALF+2T#FXM$#?M.'U% RZCEM=[1UAQ-;FWW2Q
M2OG87WX\MA[Y&3_M8^QW3/;BQU<11!OV9O$R?O7)+R753J\:U$8V\'2WI(>)
M.E<15YF6;6,= M4UAE*+Y>7J*@\/&S(6!Y^K?#F%Z)(N_H:0=>)E51V\NS2B
M:[OZ(EI]M1),QU3/2V<-(=DXQ@*WKDHN#&K+8OS3[31N/VS])O<?LF8N00B]
M@3_>SP 90?YW5^ KG&UG7,7M =X=GEDD;LXK]V8'K@P>YLBYDBX#,74DQGK+
MU.7"LE'@4&+8MP<=7\+LZN:3"]=)*D>66A>,%9[U5&QH.>UYLC_P4-;?AL.K
M@X?KYP2R(P!=+";A6[#!M([:^PUJ)5^<E% /CAE8> :I+6S70_"R]-*QRX;.
M!>70(8D$I!M2F?)$DM$WXJ_&#_-HWTJWK>S^#8J;,"\4<#H_DJ<.$)QQ:QT/
M*2RCE&(VH1<Z_5,>,_3]/+YO\39/I<QQZ9CEA ;IYF9NSM,,\ZVB;NJ_WB%,
M7-#_!BG#B0BI7K[%,-A(_ZY@YH"B?E6\?4Y(GIX9A]X$?:'-(\<RK"'Y<@YH
M7B/+%M8U[0&$EUY7;W%+B9993/L-5.NQX1EDMD"92J">/ZWK?'S^%/RQU;^2
M<G&L[@OC(&W#NDUQM48O&5ZA"[+C)15O&]HP'-[!J/IU9U!6MW3W9DR38Q2L
M@7&=W?44YY4M= ^+N)A\0*$H@V:01A:$_-7M766/SQRI2YDVNN*:2OS@TS;A
MH *!DG"*@T^\7@9JZSTYS8D.I(\IC*I'_(2OY7?VN^G9PLN9V?G2Z0M-]TS@
M;R%4B'/UF0@)Y99\VQ I"F7JJ&= G9(/ AXR@G$WJ3-K0H8J16/(J^N_]\Y1
MXI _C4XGIA$7'2WVG1%SJA0)!@<=_U4MKDCO!)$))S)4I!VQ/C8-<J9BK4]F
M-4VH_LW *W1H)_GYI,I?^U"YH50!DA!@YW/O5J[20;J/]?#^GV@H>:C=QG#_
MRSB=U#J-^Y"TI!_@R<2$"+W#QG(M"\@@5M"LJDO -X>"S_7@ 3_*KZ9L31!2
M3YG,-U,P,3V6F<1'ZG4T=!188BIGEEE]R_LEO>WN29\K*OWZH9?VG0\=ICOD
M>#D[;G4\2'8.,0D^MLT5^S!D6MY-(5!$&*1Y+]:'6XFLR>TQJ]3$A,S89Y8/
M\:+<'-#SV !IQ -M9P02H7[,5$+PAG1./(;#X,8S\WVR.$QK$L>&[+KS%S&Q
MHKJ_2[QSIQTO?<<SN( ?6$3O6TNJVV?.2!_>Q#T#'&P_ET17+>=K3IGF:=P!
M6-1P&613%V3P^57WIX-H?!Z-ET+H)ZX<KN_,/]./MVWN#%D4/_@XC":@#$GM
M#$*+2I#,5LR%:XE3^Q(\(&W(9XM&_R$7(]H/.A/JIVN+WNLT8W%>-M)=/SKW
M)F/637!%:9 LO#@!U4HF$[$\6 VS9E>@Z%O/B0.UZ>IZ)>/'5I<"R@EGG;T'
MB[ZH'25H=-4M.PZAR5AI:X"(:>!)A%VA4Z*%*S>S?[+X95'E=G.D)E'#_@WT
MA "HS"GUM=7M5"JZTM2!O1<4(Z@[:K.%0YN=5@) W'COFJ=G,:TQ=JS'SE+"
M?UDB53,OK[=:*."'?]@W>,H"TA]"#DPY,Z:^D9G@7BM_^M.\$9(];70X\$M8
M_29YH75YT;&B "@9]ZMH!'B..EAOHY<H)B!>*:79D:X6'#I"?H_<TRT9AR\6
M6+E65:Y12N6 FR%@/'G/7=WK(Z^=ORI<EQE?D;'/@/1G@/2.U#=-S8#-Z .;
M>VNEP8UKYX# -D/SD/#@/W>$&^>TR& #9TWT*]IW1UA@0]&W68EAZTG[1LX^
M[7X4A[Y(5CKQL>\;($[FV^3L_0VP$>6QED%=C'']U A7>72$C+KY:C1]/QY[
MD?\4N"2]8W_^NI92Z&PY9P@2:]:8FZL_EA*"X:;JI'4T()^O@_U+<O%,[*R:
M*#G_O7.XB=M<#S)P*,5OQ,S#^L62UYD7;GA1N8JMMU1RNS36/>Q>CQM^:,AA
M_/! ]%6[<OH>R9>QP\=U\7:P:+V0'*$8P._S0"TWTRG'$E*MF*RRWI$^^RZ+
M[0(G:.[?IW@?41C(_GD,R(MX4J\4$[?IX.M]XY "?P;<!:L^ [X2/@,L\*\Z
M_^Q8/XE$KD\4K-[OY_$F(QT"4FK7> 7")B$$C5=^YU#T#]TM33)9PMUS0B7-
M)X'/ *U&GY6>M+N_XZ6=,AQ:)>L/>KG>"*MO7-"BY+QG0.Q43'_NTICR#K4:
MF>;%)XV#,1RVTA)'6,RRVUYJ2U2CASY_\L'X.EY>_'<G(5#>[0YE0V&5=PQK
M?#12;'5GS,\0F@,(Q\/V/ZTE)5T&.SAG\F1H?V45=DTB=GN[@U6)FL@L?@=D
M49,X$L_X8'HL/&?T=EE& 1GD)"QR4KE\%O8N53@$H1'5?F8K[QF[S=Q.M(D-
M,J-BL]G#8DV)T!)+&+.CN?!J'E7'\D@6FNTQXBKA.6KLO5-GI_<%0P%W[N!=
M:]=@0M%141]7P!$MQB_$<4>RLVON5#!X"12QQDQ:M364QQR29"LL>C+3$/@^
M5DZ+L9R/.FIMO"'3Q0G!YZ$3JWNXKHE5<[[M*!37*!>\K)])JZ7-<5%S=VZB
M$OY1<)77LH[DEEH?A_45!K';1P2,3\*')!Y(>XOQ6\OW[S_)7LX5&BNW59BA
MCLE^_NGW#4NA#=.#VAF_>,R[4];,U*W,=BUB:1TQQ0[9H_ 0G<A+MATSO)22
M)(+[A.X6K/FK\[F)?9_>UX5G'T6/52HJ%3X2K7HFNGFF%@9Y\#$X?4''TJ&5
M_2.OK6F7_IUI_^G386X#;QXS_#&T<%"[/6[ 6,"'6YK*094XPR\TM+Q?H0KS
MB/(Q;F0BN%*W]=(N*&RFS:*?<\N\/L_ Z]'FS],W,=> :7/@>D.EM8WY4L1F
MFX0)#E,^#^(%>)EEY1)[7/;BK&:ME,LW-YL]C,15'#SM\X,G[?/?LN[0S^#Z
M^1;WSD@=I1D]VC0>?)96HM\"F1UZ?YU=PRF6IQ#B%),6P:]Q*7AKW]:,P?*\
M$LZ> 71%HNB2603[#)AR_?'=CS'BLU%UVD/<E0;N;QN(;IX!DM':OW*B,@MC
M<E!<*@L17( ,_%C4KT$1.OEQ?9^G40Q^59: A@>Z@_]I "S>S3-37BY#/6&E
M;R00L)K4]CV!)@MMQM*-_!7F^P\&QS)TTZDQZ),<_G"]/JPO:BR6V(5>*?38
M':9GI,-V2\K/ !>>9\"9H$*HQ;OAM\^ <HMGP/#GB9FLZ_:@LRHQ9/73;YR;
M[ 2.-TNJR1LH%3]?R'ZY8CM4.7P'%.P1D>#0%4RLEV+"9D=8Z"A_?2"N9'H&
MU.-2[.(6#5'OX#*;-G[)4&E=(SH8%5<.0+>\9**:?K^1@GIHJ%0GP_Q@R+4W
MBYMYE$56:)J:(=Z.Q\>YW)/HGMO@$;B5,5*<%->W&W?V0':2OW'U]U>MTH$2
M!$RO"9H07P)G?0^CPPT_K3F\,K"H-.@^&>5VVI_;]R7JK>AR%?W**#R8GA 6
M67]E/JP'91(;:!@T(MVL0\@7;']Y5#S?OI^D5!N/DZ]ZV(%W5?77/F2I3V"%
M17/8-A^0^Q-M^3FG.ZN$(C\U)/*P,9W>Q?<D4WD^4'2)NFYDY<_'4:MVO)7^
M%LG[@+?V3_AQ9!]U+KN+(>QF@5$W<9R#?U]$3N[5>$(K2=:,E6OUK#T2WY&_
M^_FY!U8V[B=$VO7"U*@+;R<ZJ6_ALNZ/WO11<UF[B 65WDH-KW:Z!M %FN'-
MR=7EPX#\ "KWM#N'>F^G6G.-.5A+%'W<7/I<+GL8B&E89R6DHI9"#QRU$9>/
M6VFM XBRE:M1+FOL&V<*S&&_B\OM/0O[]#=EXRBNV7;81#&AU--H14M4W3+Y
MIJ9UN=S4 0'7TVL%JB^,^KYM>SM$([-Y)_B^XMIGJ_)O];&P9[>LMU1>LXY^
M.<K68H@:K127D587J*FP;%#[P)="L]6(,GDD:$IW1:-'V">%"YU[4!\#!?QE
M4='KDB3D.,%$@TRH0UKN4-P71\(E.D]IT@B8(@9O]/&)*A/RTEH#?J$E-:JI
M;']ZBXNO/5,O8?RVT>KR\'VEI%#+H-NDE_P),;5"W(T10.=8,#E?7"?UFWLA
M7?0'RQ&0WZ1>F.TSH%WV.G'.\$G_F\D<\(]2H.HQ$WRIWURRE.:EX%24T;RO
MZ]!(X/OX)^'L%O+;$?1JGXKRN'K;I09*MQU<EQ>4]JLP#M6#?\.TO?8OK.A
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ME98HHRSSRN*<W56N;JL5T/LD:9K^>6C&0^SYDUH=0KO;%V.#0F'SE+7C (9
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MU=2'?%D%]<96;8H$\Q+FKG:6O1Y!ITN0T8;B )%P\CWP25?:I_/&%O^KD+T
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M%$;>*#GC; -J;UEJ(,UQ3/>*HYP,VY?J*G54]3N53T+;UI*),T YM?Z+988
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MDW@GW2/RZS-@OBKV"4_@&:#%Z/D0^T[N>>7_ %!+ P04    "  -A:]6KO(
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M(!.*$BRLT[(,ZQJ? %(]9663U;5V3UT7$M;6\4BI/S[YIT6/\<\* ^-_66$
M_HG],\/_QPK^&PH3 _M?86+AX?P_&I,,"_N?#\Y_/@*X(+"%VS^;PKJN=4I6
M0:WZQP7 DW^#_[M$!I "C(GO%T!.%EG?G'+AX(SX:]$3O?-/FGEV4?+"AVP;
M*XQ(..7'^)N832RA;L_KM<#T&'6AA5O<G5/7EA!0G@<,=Q+ZK5>=44?Q![B)
M=3,/XTQ(N[:OZ5PX&#(B(#A)@^:V8LDU9&"7!/GN3V1*M5@:8[M*;R*?^%L0
M(AFTX3V>94IX2)*" IM' /-,)D7S,FL>US@%08;N;\0,AO2TRPC)KA*G=Q=W
M5U=!'W\W%_\1!(^FN)^ZFCL$"3RE=/B)I!=Z#:KH#"E)LNU_-@$KG$G@);<?
MH\ZEU2$@'BC]6O CY<6RP>MO WB#.6S'ZD]/(WY.SQAKX ;^ZFZ/6A1+_^A$
M4"..ZOMN\]G +B,5F?IW;ELNO?/7,"698%A+KH%V\#6#P^<+<_E^>ZM%[$>
M?<LN([X\,) 3,"8#"H&&HY+EY2ZT.!*0V.(?C'T_<VVZM=F\O"?0)@I+_5B[
MXJ:IKLD^1#K1*_[D_&+A!&KG10XW=>01962(("[1C$(8U".*%2)+O%B.B#(S
M/DVZ9^,\VXG$SB7G_LM;J9SW\^><B6@MH7I7/3JU)&Z'P2%HW#2-:^"8;=&?
MY)EM]JXW/.I(YIB1B'\6LZZH**(*+>A(A$0D 4^+0>S=5[(S^6,X;%@@S&@W
M#4B!!/$08M3('6/54T*>F:;V&)_2HE8E;<R:TXHQC84Y* +^;2.</M(GA@'!
M/'SJ\T7(GHHLF82QB<(D2H+LMO3@C:P*>PDW=,6IW41ZZQD]J&QI6M76M"I<
M7SK\'>]PN/9;"O69XO5/D52DY-H=6&#J/55K4=$.VX,W!16X\>0G'.N%M5!]
M<BOCS:>H5DK6ZT^*:ER*-XENFV'^)X5._<H\\?QVW36<6GJ3/[Z4/ &EG%V4
M:5%7VZYD4&BDD['U9MF3?O@A"AQ]39&;LH=(CCR' 2EF<H1\@2;7FDP6U[MT
M"VYTR<>[>5!71%68;0U9^V&KDUR.9Q.<5\S%('.P)7B*F5'H9):E6@'&4GWR
M:H'EO&R"ZO<FV;1K8PS9HA)QC:AR(7@T3T!BKT>86R)5P/XJF'T>,24RM/TE
MIZ;2R#SN>A"4OX)_*HR J:?:C0A$/PG,XG3UVAPIJ:3-7-YB-O<,5XAVP33F
MVK),(^CAK!#B%$-]6P>5ZS%D@$1QL\?.O]^KTN&K_4U[/W+I+KJK;_1RJEQ?
MM/^L9)FL(2=5@DN(DC42K4@_D?@ZI9F3UU\3\$N@81N)-*&077HO85(.MVEQ
M$>RF562DQ\HWS[C4$VD1<"\N/9G;I\V8SQ(,S@GVK%RF>?FF<=WEQ;,C-]F3
M(_I$$SU^9[79KK$W$Z*G"-JW';$N.H2-O]9?K?B4&R7!C;W, ^-.26M+B*/+
MC*B]W#*(DFW'U.C1UJE*7W4@1;W%#>(3I[6;G[7[M=[E_))4J):0(__2P]0X
MQ'&=:/S%C*W3TJC1R;0,(-'P!G 3)CHLG6),.6[W-#[C,O0KU?I;FS[65/1%
ME<]\B)+2*<=*Y9"QTU<&$ASN7?SA<&XA'4S6#T<N)TZ;= I!B2S931^]",PD
MA.9&51!W!-4-E)Q<1,V@G@P=<LS$=1SS:!\(]V:<;5/C#1CE;K$O](>B/!F*
M\\NSL4VDPSW??9$WDB)9UN'BV:E$?W_5;6".C4K_M,4R0_^$%=P0LD1" Q&E
MKE&\M&2?K&0L7#IK#[/*QY )W;/OQ+!,BJ#8$.*ERY".L,Z3!@5C0AQHW3IJ
M"-B0#6B9P1@09U#,M;9,:.OHMV&SE_F88WENTJ&?(NOB)O-?DVHG0AU((WE
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M@FG"G1V7&[87]KNKP1H9L;1B'I:Y/5G"JD(B<B*E35E*2>06(E2K=]MOBG]
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M[L/ION$;#M3M@>[Q[2(:RX!&\_# 9XR*#'XU _+2Z*#,NE^'GGK3-KE9'QU
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M+5*IRMJO!S&KI[7OO),2'^?_!U!+ P04    "  -A:]62PJ^.!HP  !",
M#0   &-O9V]?,# S-2YJ<&>5=F5,',X7[>)NBQ27+KK(#R_NNKB[ZT)Q*]:B
MQ=W==G%W;7$O[E:LN&N!%E[_'U[ROKXSR622._>><\\D-_.V\K8-P(?(*<H!
M$! 0 0S_%N!M'2 -0$+\'_ZW(_T#,BKR_X".BHJ"BH&.B8F!CH&!B8V'C8F%
MBX6!@4. @XN'CT^ CXD-) 3B$_X[X_^O",+_,I&0T?\EXF-A8.'_?^.M%T"
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M0NI?VDGO[^@)=8&YDZ&6G8RVLH"G9=7)I886 ]BPG1T:=ZB6B0SID2K&)88
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MG0IZ'@F,=^A:@6G,?@GB-<Z>Y,*(J&B(YE[/:VWX<LI.1G?C^B'I<T!$K2#
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M')^!&N,>/P_\GB2Y=*F0DEJ\N5#[H]SBW9.T5K<:@O,&4.?MMVVJ,8LC9O9
M29=QVUEOMDL(>%HLDSB^O[LH]:P:Q<2[L,$S7%Y=:*;F][Z@_X+*0&[12M"
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MXI:AXI3HDXOIM\<GASU\C&S@^SSGQS0?$_3&-M<:KSEA1_0ZS2CF3H@8(G!
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M!6.!;J[.]<#XI<8ZR*GJA86SLJV?1W9VA4=3<UNE!1Q;K:\KZK<AY!P)L5P
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MIBQ=Q4P*7I#K-9&3X=8]!V\CO3WA*EUL!=B0BLVHL:*/=[(IZ=;5_B,"IVJ
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MS3!+&PT\V8[V0+P4P5K%+Y%?2VFH:'])22WVQV>#T=\0BM1'*(R]*5]RG1X
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MJ7IPSF06[@'4\L8GK6&R)CP_M0X**?K49U\FTX \K\<99>)S9ENXH/@Q;LN
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M)Y"0JX5>GS?6:O'G]7Z#/ ,CM-%'M4.%M[ALRHR"JH*6#VI(E0^5(,_"#/"
MMR=)T Q5*[@/6:===B9 ]\&32</!_"A&[/V9@@X;M[YGU]E$ '+@=9Z%MPD!
MY/'PUOH7O3ZT(.=OUZ.$R1U&G?<3P$60*<%L1]R]59T--@[P+_L5(+B=ZAH5
MI7]/2_BC&6C6DG8?[39ME4_0DI@:P#(U3P>?*PW#<W=]*1 LVF85QI>[3BIT
MJOLFCXGJG@/W5V&^ 9=$C5JW!-1?!'AL[7#'</7#J'YVG[G@-+5JR2P0N5#@
M<AC4_5'_S4CYS,3J1C9SBY]/9F5/4$%LEJ@ZSTU,$>MS@!!P+ +TN\QB1;>*
M6_D TVZEKEXIF7(EV<WWS"BOJH"HC6HCB[=-P%FP7?5+*M#I(:MEF273GW(?
MN@:/\\]@'.IAP<*H_^4]X3S .43/DBN:YE*@49*W$.[P6Y3TESPI^?"Q^=2'
M_3">A^4""/>JN"TTI,VWIG'_AZBRBZPX _PO\S(_X>!AYXJ2RX=)H15OD8.]
M[UTVT.*3/8QO+:[;FO2@[O/XBL#T;3]^;5&@:PBM=AG_YY^ON@CL2#/0\M")
MP7ZALJY6!$J.//R%[IJ1T/D<A\-1$VY495U\MU5IB&9=63DI>GP;Z_W759TZ
M'U_S<@J<>DOR(#7UO1V9OT%)3X">(H^I>KBFKU:D<4E3J(;H'V,:WPLY95E(
M5^^XO"_EZ-=C,O"IAQZ?]2H8G.$;XH];>S9@:SM_])?ZE9I4JLDJT6AUP.[>
M^OQK.?"G0,R"73SMVC6Z?="A^UWG]8V/7]*VVFCWY\4^T3JZ6 +SW#R9:0J/
M-_OD972&5.2M:T0[>88IZ".ONS[Z(!0P9UKYT.WJ*O2S6-LZ<'R[H_:@1.</
M/,A'EH'M:?DVCOK[%[D#^XU/@)\KCVK;-QZ'$22EY6A#(*/MR+2T\TEO*S*\
M6FU&T+SU;XI$>0A;N[.SN:&_!Q&HXMU<Y6!N8Y?>3]A)!EH<M8\=_#N7I/=O
M(HH<G:C:HAR\_G0X])$NSEWWG1><FH/QY%3#WAT]),KMVNUAR"*?6[K&F;7U
M&R VM6&#8SR%R7@S)ON<C4*=MMRV1THF+A=-%5!GK^+]=PZ:PCK$0157(M9.
MN;0 7U>21; M!#=F,$EB,#*K3Y@GD\+,U""N)I1]^FN&L/++967V?_VN@]X6
M#[OXOD:<2Z^!0=R(I-1$<]QV;<#-((Z*-I-47BK-D!?Q"![S;[I9<"0_S,TQ
MH.4C+4K_X@:D=RVN&++(RW<YO=/#G0ZM>@+42F>6MLE"H+&\9"M)]$(>=4W4
M/* 4>B%"5U00J[QL[;4OUA. \TP^H?(5\"*C[=(>$HZ7+:Q)DL"DJ8#I@7/^
MN^?W*V]((=W(*Q<GFT.<XX;^"#"*>SN[8FJ8KBVGAEGKG7-Q]^+4DB(H5<J(
M-%Y*PAR]&E.2YYYESTA_=T_):MIZ43#\&X58T1_V&7-CX2$SKK2!2(WE=5;?
M"AZ73R4%(%H1M1IL?B7RWVCTSN\@I=VLS>G)L'F"(N!J//QC B=/1Z!]&YZ:
MN@85>Y.KP*.M#E3>T"=46/?"K-O4Y/N7K[2ZY;QJFKSM[_NMU.VY&?B*)29#
M/:U%7#KO"JV163Z9Q[LI8J.S?_Q*8>@A!V)@[4X-5 5]ZRBD&R$ +1#.0;(T
M)HG%9HWEC=B9'4W"*!*E=K2>HP9K U&&2I?61PG,-%)ALQW5G'QU3+\*21Y/
M.481FSF6V5Y[U]Y+6!_AHG[YOD.^>*\_9)$:+WSK;:,%_C49] ^)Y;XHE4LT
MI=2R()/%78GKZZS1/@=952Y6#IK1FYDA@QJG(/O86J1A&>],DE]!X3\"^<:*
M'O.[-5-<'7A_CX41["E*\NVDII]1U?L!CYMK*@KF6JZT?8*6N]<V!ON]UG<\
MAN^K5XGU<Q1GVU)HH:\J:ZL1*X_K@"],&6P(DA&)D\?V^GDM*TZ43-QO2BTX
MLB0%%<2]LG39JEV]B$SZ6YW!=RG[HUXEII*_MF'&\R7'&,5>..[Z<I-]%O+&
M,?8) )<:@KX68+L-?*11O,[S>%@))1L2/;!E TX*;5Y#4M3UQ;9YGF5T/5O&
M?<L%9,DS9%;1U)/XM8;(J0!-"$!3GI.XA,[)P7AD767JU-=P*\DU0JR_J?6#
MUMR[;^<\_9Q3N0UH*15K>.&)K&(E44B0F(C"I-@&_<B>^EB6TEB.[KRX;3+L
M'>S9I^-?AI3BG"?.I<=0G>(O*F&']F&A"TS8UI[@8CPTOKRW,K[7#60'G6SE
MT+P@OU",*=\_YM2VA9Y%0?E*K_&2)D,/1D?.@K7P,A*A<$[0%V*]+9(#(_4#
M6\A01.YR/%OV]S;)?E:I0N*A#.X$]\B)Z7JMZ= 8/M:F#4N/Q)"X>I<=0D"3
M01EFNUF&G#=4K#;TY^HOC#S?J\HD5GX0+%(,9\S 1B0Z+0:K#&:+C2R4:N(>
M_[M-%;81E&S'$S)?=&\>>I@*EH(PM!A;>(67:0469?1^H\]&YN1NN@9PX;IZ
MK9B<ELNJ5_0=C=C-[HO_:EA=^A@4LY1I?-ST[1/D<^PHT0>WS9?!O@V*.&.&
MK<#F(8<"6;H""^2R"4_\N" #IBE>:"P:GJ_SLH6G2@9=R$2P.W!:EB'7]L&R
MD.]>9__T,C0\A_$*I1%.1]1+H8T #4^J^MRX3/?KPLSUR11!%'F/B*0XIU.B
M8F7,1P1=C&>1+PI?'^T7W=]IBX\^^"EH57\POO;5_GW!7BNT_K)";Y^[ET Z
M3FO_F6$>_5R.) %TB\)[5JM<)6G5X"_6HDA*F/U6_A)UA2FVKJUYS%)T5(J.
ME/28+;JTT.VR(AWJN'$6;;272>%X-Y!A3GQ&N=L\ Q_4V2+%T5=$7!(@U\O0
M,G"O3)$.*K\(7RM(/SE8JO&X;3C\\-#[.WA -3C+S%3'[,0K;N0BB?>:KU9J
M[.%@1$/G/=&++RV.PPVE-169<\.$3X"EHT(]':/)WUNS<,[CS4]_8.^N-QOF
MR[PDN)5&\?1;U;[,D4>/TD_6]I SH,>C/&1/>+1$Z;Q2IP>S^*)GENZF:;7\
M6B!';"RG_A_O3\$M^+MQSO*I<W$*:P[%7!&U;I!GR"00YZDM,FT^WQ$LJCZ2
MS\;3S'85_"X2OO"BEWF3QUUHN]W"FL%V1/XE#^L96">"0<9SJ^ *XF #Z7&[
M5NY)1C>7.&A_$Q\JPJ_=5&>^0C7(>H# GX4(VK>997Q#YB]R4$,D&>$-[KM4
MT-$S^>B0H=,P?UD1CU>9A<<=JL%WZXRL,<0IZTC [4)CLF$&H]A(I(F&_BW^
MXWWSVKHF!P:],UL:?T+CVUS#O\\D:U&5R7,\C%*39SDRO#Z3=6"IJ@>G0*Q,
M2M[?S?9\FZP/+L/;&M3;D0K99CWX>OH:C&8U["I+I<]R-%ZG_(EX% WS!6^Y
MG*@[^"H/Z]SI\Z!G?_F*U>Z2!2N]+MOYD9*60B<BXFC4FXP^]W?:U-2E/Z5L
M/RZSP.+E78Y];D2WX7._JX.H+"*YBS%./P+&'O)*M)"( Z/NO)+= 5'KMQ!J
MK_;]4 B&NIFYX<<9%@T8*:&8R)B]"\>N  \'7)X__^O>K?[ICNGS8WQ?<?;?
M0&S7$=H(>D+Y M<!;?W2'YNYB6W,BL_"KG*AL(A)G"'0 *O?6^F*CW2X3(-]
M'J?GM6<A695.PNX)]-9)3,KT1)*ER#YQW)$VD4IR)5+2 &KR0&R67 .<E&MM
M6Z@,RWR!=/P.^1U;DO,WC[:Q6%K<G]0@>1E/L\:-7M-)9+::H=CA=$ILV^%K
MDP#RC%<,"G3AMS47[7><\SO+Z;?DCI"'<LW.JS1?"!'I0(=S]!1V"@XURT'.
M56_A QW7??,.0_T7T2J(+\.+HR5LFE$]%A[=VP55%^J!@J37>W4Z7..A^XV*
M._9I*%;IE.!0T.1EF$_OVR^\D4D_"I5-5TLOX=N-;!4*?SO3+FYT-YK/)W1X
M\%#LK!,;FHM8+A/&9V)CFY6)1H1A8L#3FO/R'X.G*D'W&>\&U:MK^5C1VT>Y
M3'A$:%GUWVR!K3;C"-"NXOG-/FREZX\@W+8&(OI$_,F<5M7__%!FF^BZT8<%
MX:5U].(S)7?P/@$:)WY/(I=MCL=6\"NU^+K\ X3J5OJLY&SKQ)PL2ZT*0#@Y
M?MO%YJC;8G?51/,6R_BR/I:3UL>PT]*]D>&K!IY]*9/(8-15\WR00\WYZP+)
M+UY/ *_NC[*O5,VYK6;RZ'RQAQ=H66E"Z \#0^%4*Y>"]C.XUY\1C$0RKW*(
ML&I*[H,R?);$6O<_U+Q[N\44@&9Q(F@T1&N92[YN\A:7)I/L/9<+-@9@IS]T
M;U;NJ_>':[!%\1<V)AT 97WI:/T0!GL(K)VW,;!-D  W\1>_%,Y7.06;EL>,
M(PF4^;87:>0%/4_9L114[R[7SI&5L_ /)RM<_E$%KTTC::2JE+^-)Y&N_-\X
MJ:Q4,98EY7I>WE[>PS8@LRX+RO1GW+%J]( S<.2VOHFN2JZ(?Y?,%<NWJ_]^
MA+U622XJS8RE&*X*F4)44JX$>VDSQ%A$6 :"7E/+.@DMQO$>N:.!J$7@B0MH
MA?]:+&=%HP1YSH_9.?MWB6OA--78C&\&@?%QQY;*T/S--\@&"D:5(MES@\5W
MM7P&E<T]$EAEG!0[8RRCF5PA:6JCAP>5_.)EG3-WU-C20!FCT[L7]5R8%^Y.
M.\WU:R*9'3<EJPZL%3(#6+8DJ](FA9G>%Q6KL'2[:H0OA]Y>%X>SE-&*UA9K
MLZ!T=B@VM_,;^S9B8.$Y-D6N4:QPNV;)(?5.O-X(X838'(W47:DO:P+60R6S
MACL;#P9G((.FQCFF+X-:=T$E^ 24?7AA.A^P_&<K>97W5>$1 2]G96I1+8DA
MD!F<71]@OZK&Q[\1T<@?%]IVQ+)C1OYF+CO3(LUGZ&-&,'A^AN1:?I2!"KUB
MF+!9&[HF?&<YPL>E:4:+28%>#]PVTF:;\A_5@?Y (+*QHH$>M55'F)=#^8;E
M=L59R^8F8<=7UMA:H9M@%\F/L>2PMUA\E=V<'#\OZW<J%$$F%Q)6C1QTP2:W
M7_K@^& +^7R_G]B?P /F:I[QG(F2$-=*!B,;4DM22FHTZJ_W5;!A=P]WSDU4
M$3,F7^B?^>A._H^<C2(":.2-U!<,QT,G*:,%T:30J>-)%T3\:NT'J_GO;RI9
MU2%EYZ/#Z EW!/CVX2%'0GTVSI:C1J*S#("3HM @%.HO_^+HD/Y51VA7%O%L
M',O0<A&-O;DBQ^REB*0%\XU:&D;8U7DQ 7R N, (:62H',,GKA2)GED/K!.R
M:72]@.G@8BDJ<- [-=$#[TBNJG\ZK26;D=Y'2_K.;)G5HSER_UBD7T96&=C*
MR\QE,V;BWI?4NMK]>V$'1SS-KAQ.5VQ?VT4RMUCX53[!H =X<K:S02E2?;F8
MWD-VR;'T:MHR\UH.Q:X%DY>.CLUS&'K?]$NK'L8K^GB[!?NP[RKI]5W'#T0"
M!<8.@W6T+NG,/BWH["J5]>,97[P7GOG1U*]-S[O(PN9TQJ)/[4-!_,P3F?_Z
MG.H+?^D)V*>7$=)/KA2!@5X#:[N@2''9:D4DJK3$M#?T%^!6#F&'8'!7K7:R
MR+LGR;-/7]FT_,0CAV<^:!"ZP%(5E=UBVI"5M*ZHW<9#8-HE70/OFH^341<B
M.Y7^^:KY36O*.K>$E:Q2]V-+9XZ?ESW.!/.WF2!H7RC7C2G<?H[0+.#(.+0[
MZ34<UBZ1/N:#'2N<9QNE[<-_\$MNHF>[#,]7J\0]K;M&>'0'E: .EU/#;>SZ
MX;8<SEU7JL5*$^'NFPH55F1:C92=^?D$P',AG=;83_YA&=A&U3+HP$R$!I)>
M9?F+!UJ6\61; N_+3;%;4-:=69AES*FJJLPV;5/5?W@'/RN'&N]_#M5&]Q#V
MCZ:@VZ' UJ)96NV5=7H-K*MZ>0/FC)>%3**OLB2K*M!J/*;TSL0F''UR-ITD
M7[E,8*9$!:B4!62;C)\5UIF^&$XR:ZXY%3 #!J4G?\+.&8(:[]$_UROWPM['
MI^A]P+J#+/\8'V[@L%GQL.=AV)SU+9EUI&]2,%^7/?&9L#O"/QP(:I,X/,+<
M=QQ:-7P)>JT<M6 3AW>U9Y'WF-'C]OT)$#7E+!NX?N5H/0*RK%V0%FE9^>-1
MKI"J@>.F;"\AU[$;9M/>(;+D\^<GV;3MW/KLD!\[)<J+5='L>RJLK3^R[R3M
M("=->VPY0ISFL;34OHMQRI^V^E/O3UH+<W/0GU+$!L@BL_C&*_W&C#YP&TBQ
M/./,(!^"E-VW*J=K/+&Q*72K<7V1TE31K?5>>OBT=,PI[<9P9E>7,1,XWRG!
M/+MPYM&D#:GP(O#LE2,VMX C=C!0G6!Q!D(SM[Y#"_NOKYF _2%)AINJ"_89
M)=+.78N&T=BH<UE\'7L-EI6IV49[G+FL'PE'-2H_QB _\#.'-+:!@_-AMFG&
ME8SI[%I>-WR4FRN.W[2&O:B@_8/ZFSSX8#F;_!,[_Q?#4RM4V-(>1"PI\VD#
MO0G%(A(VJR._GL\N+]A*)LO;5]X+&D3XY\UXK?,#\63N]TL#/H%@0M4P196V
M03!G*EC+ZT"%3873A[G\65]2V75Q3S0?-@\@,.@>#M3RB=Y68;6;Q: OSX"<
M,E:6*V$C,LZL<GM61)]CI;'/",(G;%-H7? >/+4REBEWCS.39G5;PG(0^UTN
MJ/:L#UJ3]AJ[RA] O?G:=L[NXOTF> 2I.'TEBEVU8@&>;[GZ9!+CI5MY*#6]
M01-:=W9^1^4^8VG2_%'H/P.[KNM 77'F_"$L=,3(:LK/7H&_O'>,;:*]:H9K
M7\CHW+HE606W4BS_X46B=.LZ/6]&\2">4#CXLZ&$P=L-W?1C?<]MY6^Q9-Z)
M3DVFYR!:NMH5]R;@\OKCS/83H(80E4%)V6R/%X19H?[<RH8UKYWL82$]A4;F
M-KZ&5_)+!(NTN8E]QE5[Y.7Y9VU-.]>3,0BBJFR+BTWA)&1050[+NXP?_(*#
MT>?J=695?;)2@@NR2D*T5W;ZO7M02UGG+Z7 D8U,/1K>)+$X%JXWA3*L_P;4
MXI5?@FZ=H \(J$?0ID2%(9>M4_U<0Z>5;I931Q?]>,#[>_R_92<N ]\0)IQJ
M%NH](H7+Z"M^BQ.W-*:^ULDJ8?HZG3)QH\D'G)F%3P#2<<2^)L70V[8?S,/Z
M@_JP3O'"&QWY<DU+"A URS>+9W(L:]9G/+>Z").6O'%-<T+UZN2B>H :NK=N
M7!48^%$4)Z0H58HAE!O R$Z:Y\N/^./7BHP)0&)7#94_B\S'1RQ3F[RW*RB;
M+3JFA^S=SA:Y"=N]LU+<_#O#3]5L0@LT"I\^6+;M_-;H)S(QK6'8(\PTYDWH
M"!W:A'!?HX&&/E<+]35X-A"JW(A]ZDY-6N20Q=(MLS*6=ZI?Y5N+N?(5-I F
M$:Y'99P8.TF.I LZG^Q,<]V#KJY%6K>9ZHSHTN87PJ8W]@_2'\HJ5#2W?]Z%
M#/V@S8>6GV6)^RPK?L4H AC?K!K/5XWWK"[>;3"!VR2Y6M4N6M.OHZ"!YY<E
M)661^2]>+!V ^KOVG5[\MK#0S&_9IA*FUB,$>A 7-?Z9#?E(82>@YE.H*BDL
M8S'47)P5"$3(C;F1V)4QF]E"8,, ] TUI;@B$VM4=>RKL9W*4<SFP,9EB[S
M^=:,O?KIALQQB.8+;#R%S?[2]G"I7@MMV *ZB=C=SQZ-/IGI+.9ZG/$KC'C<
M%01&>Z$<=R7I]T.;5&*OP#/R'LQPZ@! *34]5SI&47GGX:&C0(PMO8"GVD#;
MB>:F598HCNQ!G<:[8P=E,'E[3""QJG"T/7+86*W=%OFS?D[^<F+H"0!#O<N:
MS2(JUO<'^K-G?G0P?X8B*@=A%91SX8*Y]7A54652J<7KDAKR\E(P[7X>.6:<
M 1J"@E(G*A$<;HJT]YR "XQ^[YG*<IW47B/:N,=D/H\::Z?K.B)F1<T7P\P&
M="?9SQD'G@#<22_H1XI+EEV2,\7]DB$I(SGG6A4"[*!Y#UAT)6OZ%DYMH."9
M>^)-2:1:LHGK;5_!HFBPJ]]/ FYW37,ZX-I@HF$XHHXC\B#:;:?$@\<AA\3J
M+_6Y1GDC>I?KG=RBM-/AZ0W_=^?<<<++%;NOJ>1C[TF)=:R.+-!ES\V$-.PV
MM\:P>=TFW=KXQH1U]E80'/A5!FE*IK2]EUBFU'2!-.IC+A4N*9P]<B,Y%;0Y
M<Y04<K'6GK.94[])RR,)%;#K94Z-;;/ZK)PLP!\_N3G?O9T]77[%+./[T1,P
M$OI>QB(H LK#'NB6$8H]0%#]6,G3.Y_*YW>\5N_%FUP^%CI/IYFG6OF^U5)-
M-RQ@<]=E22=4<R<RCK[N>P34,I$2.[5&#A-M7'$-"5(3PNP$2+",YQF]L^4<
MX_2!['AB4!!3;4%7*C'>.\73(=3U^B8%7(:;1,_4_1E/=;:-\10F2O;#3^!/
M@(OZ<!#2262<PK7K??@A?$U^S>(Q@X^$9=JYD[)/K&/5MLQ$_G8605\YBK!8
M T$A!LU3X?;>3X Z397B1L1:IGCUC+QDW^/HCO5?)U.Q OX9/SI\K3^W)O+E
M8 PU[17^_0/G_"< :.>BN(\K@7W.%Q_3K-(6><=3B"KFRN1X(]XU&7&4H.%B
M:.[(5N'&!PSGE4@U];EV&1G2XL[A,_M< YY>X$DN3*@YXFRS)&$5V$@_Y6O:
M2&7$-?EE)4^*@\$R&8W:G::<$VC^C/J&][8"1 H Z9-%EZ%-$7&GUF"F61],
MO#F.GJ*IT1_Z<% _$%NF^H[U9JOAZWOL0FXDJ@"\W.AWK$&7,N_ISFO]ICQ!
M=9ARU<N@6IF0_D VB"A(*SF'+[[%/J;T1>#,=8!4/%;/S0(.F%T%2/XM-_57
M7]_)A2S19.VZ@&H'AZ.^-,V1V<KR<60,_*V2H6-F86R'LB<WH6KJ,\JH(>41
M[(J9?1ZZA2Y/1TWGR2= :X-#%KTH7.1HKI5=SE*E"P3-)"]"L4AWE$5B:R<;
M%W!I[ML.;ZVDK%9 4OE=XZ)<<_/"NR0?N!='IY($$P]DIRWYTK$?EY![FNPB
M)JQAJDTG680',L<Q*O?"GQZ-#!CB*._HUQ90JM7.N"9ZU./AW()^K*G'VS:=
MB%^Z+1.2%XD[%Q493,X)2WQM2KM*==[MDD^ __A5XW)8OS0=R_^U^WGK^Z]N
M3=\KPI^6_@=02P,$%     @ #86O5E,0"%HA<@  #70   T   !C;V=O7S P
M,SDN9VEFS)?E5]0-L,=_&RR[[()+-R[=L*2D+DM(EW2Y-"@H(8@(NG0CW;&D
M("$E(=T-2[<"HB""@H*)>)][[C]QY\V\F7/FS)R9SW?FIHZ6@J(C".(.^@$
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MF!A6&;PMJ/#<6X// _J(8FE. 8TCOOJL2<QC1P-$4"B*\DT87*"*9+C+BAG
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MR]?-R]P+@C]0-*Z'O6#&1L;.'UC.O S]>QG:?I>>7R\'93L?:=4HYO#ZP<[
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M*3;;?[)2ED=I;]S8B9 BG3:F+66-$;4%2GW-/0(G]QQ8M2DWYA*RG(82FY]
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MR1R02V_2Z\?M0&*YF)/$/II6)IG.-TV'9!E(5^<X9C_\\?<74D=S.SKFKLK
MZTG6F2:3%R%3JXIG.>EE/_>FLZO\YK1+Z#ADHE$_Y>^76RSY+:%7ZB*7\[VO
MRJ>6MV3*=T2Q_[V<S)3F[>Q2_&46L(P8,Q;3\.#;),#IVDA:1EY]5_716O!"
M9T6=V!5]%N,?"T1.GO(8EI8U^5UM]Q0A6UW18P+M7;O%P%(/<#]+/JM3%QTI
MYE*QR0D:H4H5/40G$:VQSBJ,?\C\Y,?'##6T(ICBIHG,B):QZ7;JS@C+O7:I
M-VQW,]JT>>P\S>'6T1F*%CS//,+C!+K@J6IV.A*5;^T8FR+W7*H4UG:,2D\\
M<L*O4^6E1C O!S@ZR>K\5(M,U,T.0S\.#HI)-+4)]M15LE[,8VVP9UM/$%Q>
MC2\/T:*GH@VC93H@L0CW:_H)R?^@2Y/AOE-5\'>M/$*F0@2:Q);YQ(;.W>*)
M()WVGG6 0_!19@5<(.N,9XC"]T.P]]._PO)K0@J_[["^>-&J]/D9BVH)??W<
M&FMZY,>12+7RMU]AKH'EN8Z[#:9Y)?/T.AA?CH>_UIE>7 8Z5O&\) :R:$MT
M]/53T0616%E+.N?-+S8C_3[RH0;F9"-@_6#ZSD)3RR?[6NQN)"GS1W%BTF[<
M,6B_6/XF>!BH57'R%;T0YP\F TZM6#V.&M05RX-AI<<-GYWU?WM9<YAD,32-
M%3.-#U+2^QYZ+GU_HR67";OQMYD#?\W.:DZ,JS^*V5W#:W&H1:#N@3WKP?FQ
MT=6(K0"/G^'[G!.N)+6B1_NN=!IU; NNXEMZMT]T9.<3Q<W(6K:?OSC&R==[
MN/BW98#0Z5\H8AINGMH'L"MS]'MV/T]OO6;F6,ZC=-O_XM&C02]*.]-X9B7=
M3W8Z,MTL,(!G4_]3_2PLS>^-*^)R?N)&0>#^A\"E5^F"+92,$\<L%4F=CG3<
MOAI75/92@LYU\'"EF'49J %'@^C]ZCBN"I7>JL?YW)UMGR6A6C\D?JCB0.-R
M=J))ND^RZ\X>U0LP8S3_?8=2I_!?><H7G*_=0X!25-YW9TD?-\2L7/_'N2>X
M0T7STU@[%22BAKBY'78E,"4"'82!/&AB?%VZ@./P,X:4\.[@B8P\2(LDU+T:
M#&W%T U,SRP51)\[@FI,)76H+L*O<]8E.% EA=_$Q3U'^\J]6&Y1TT0):Y==
M_&'*"T%\*@\=]^TK3C]!;.%]T0^<[ P"@P15M00AZCAG/$E-B993\XF]2CG%
MCX=8'.QR'N%E5Z)I=:Y]%12-W-2AA?NUL^2?2.EP'^6\0?\2EA%34U F UR?
MTG1%_43#/\OL#*P?B"A,T,K)=;W7MXAC?KAS)R@_@IF7%B_Y/L,P8T2_E,=>
M!^^!=4QKXD@F$\YA5\G58849"RYLM(J/0#4YHWQIK*^))%ZQ#WE^\W:GX8]2
MK'*HX^^+%:/\^X2H5U-N<"SF.@?&7@_<NB7-0@Q7*I,:,V;]F@_CI.963I\B
M2G_+W?9?K?5I,I*9,0AB&7,8W<;"^+@6^6ZWP.7&8Z^J5-PJ5+9!(]-QU[F.
M")17&UP%N!=G#T]-_ LV6&&5)/T?CL_+KO,[)1%HC8NQ)9=V-.=SM"'66ONK
M9J7TF>S?0Y87BNGX7, [ [1BI9&Y\6?&G5WLF*>[\;72'@@=GQW==[_"*%6%
MI/QOW;'T'="YT*^43E-_9X0;,GGQU?RV/-NA3'RPV6;JMP*?;GI+X0=SA<'P
M*^I'-28#'U_B&.7K=7_CI,%W$@=RS"OV$AQI]M8L@N_,W'@_E*G8F%F?X)K>
MV/)NT)E;U%8/,81RQHP8LU,-WU1:X%$F\]\J?'$]6Q_FQ[DPY9"9;1<>(LNK
M;'S\@3Q<0Y0N:[YW=N3^KCJ,.G&Y3FP-Z#1]+*ZN=I!7X+72BB5L$BJ=9)I#
M[[MWZ8B%R3I7S0$0@I"B52*??/VE046<@<WXM$?+PPZ8'(09;)5:)S)><[5V
M-2T<.] @O0.72'1646T(0Z6T^F_8YP6QCUXU.!09"CJM<+ZD-S8?8NJ18((?
M]95%_Z9A)/Z16Z<G_ND_Y+2P9=?>M^]=BF>:;*7>54G1#="O>9O+\AS@?(%N
M[=RAX65ZU=_L-?,A3X8:X"6]Q#0E#'+DL?7W]\PU;*VAU"U*[2,I5VR8XP+&
MU%%[ Z^6?XUG4X=,R62D816-FZ+0HO.OUW,#+16F#>BRA;Y^IIQ4YJJ?D<7:
M!S!!5(*9FKTHZ&"J.1U>ZIV^6D6KMSLQNJ5T[P]5.C<;G<SD2D(T&\)EP ?U
M$H?@]<L"+/KI;MQ"HI)@-XU#.N??G/$AO<)I>);4J1R/J[K%$\S.U7I_ZA:K
M^]#%\/%3@Q_?/N5BZ[KB)_JE0P22"/:_4QPP-%?<Q+T8KS RLIQ(-#0N.0\K
M!K]QMF.#U1M[S!DP+C09?*Z:FIHQLI7P[HYR>?T^WL8_.&B#JP] E]J+H+NS
M,Y 3_?-^YV;\WK@E$.-(A"&G2@SR<7;X];1S-G]0(NR;X&.?E[W.U^6D#T9Z
MZDG?7YA6D4I]SWO[O1OLPM:DLF- 32UJ)_WI2@ZBZM&A;K!PEL&:1L+]>OSU
M9VTC##F&<>G&C-ALQ=5)$JQ>QK?9PWFU7\K4.D$*W:>P=/EC@< MQR)EZP+V
M_!S.DW<L6M0LP+9^[;@2VYWV0W5><*6=QH.#[,@@>Q3*.,@YI;]H;-N)Y3XF
M[-OXK=;\88.LHYJZ\J1L32O_UO9^EA\/H\3/;EBN1+2)+<DE\\ULW!%@#O*[
M5_;A9\Z*1V :):9_[<B8G]!U$J][6L8MPPI/3G)X>5W:=&7K(&W]![/"7;\C
M1'%-H8O:U^"?OS_3K@6)_#7_^JCO47A@?BJO1F@YVO"XM$.E(WNE9M-!Y;%6
MAH_NH)%JEQ(A>D\'LEA2\/TO1U9C?NBCPK]1;RLXMBA*PG:ES&11=N^E8O/5
M8$2IS?,0'.P"6-/1+3)A#*_+)5V6.[Q>W3@TB=G3'"P11A]76'UG))0=%0Y?
M],EH<TDM,D'BB\.6X%RU!%F6B/!,AU?V-.,EI/F,;,,]AFUJ;:&_&0JALWSG
M1+E^<\'0>4KPG% 75^P.^MS+FBZ+GOI0E_QQD4KI+0V7Z;NE,1X*$L$<\X$C
M^C7_5=94*Z>C2/FX9(<P7;K4L/='N#]SBT]<B*.YK#*1Q!*,X[)484.=Q:'G
M&XAW>N[<VZ+C(F[N*#7M-T89TR:T.QH'6P)S1=522[$[MH5)TT8MX)^:6>X%
MANR$S+F4]+:P':YS-*4\ JVESH!A>\M*&)G"D.V9J(.389$XZ/H*=LJ>S4%W
M*RGWLEG-04(K0JA\0MW:\)26]-IX+-:71#T_0\_&<,9JP'),&9SD=/R1ZI/K
MCK3F(-/U7<4) BIOCJ*/$TVS(-V3M[I7NM;OZ"A4^+0_7U"J1.ESG!M'QG U
MF82^"O]EF.YKRJW+)7. DZ0M4[[<[0XM0:U3@?/6C!A65;]GLKHX22C-^0 Q
M@K]CKY"G.05*XTX3_T22W%U&P>M(Y@(7WRE'.D/8Y[IM(P*(68*LZ<9W7=Q&
M\P[7$#4??>/ZYY"]L#C0\_>[1HMA!O+ZZT)[8YD<=QRS_N'&/5CF?R8-=520
MZ8B[NU6S=-]1IN Y8>AN]W$Z#Q5_IX<>[HF#K-*R_NZED8S3^B7<7%9K\/X)
MKV-!EN)(!0M7T=MCOF.A[>=CV8%GK)?B<$[';44#F]LPT$MJ 2T:6Q5I&^;X
M58E07/MYA<@;_ELSVMTI:AQG_/AM9L*=(04\<]L20YL]8/-Z]EK@G.AU^C^,
M%:\)N!_5;K+$ 8HN5V.FYXO];U2&WQBHP$M @FQ9 K11NM(5_ @=B&R!L1Q5
M_&4C_ZUS2\TU"@_P'!?1.G&*+RA([825V@?@.?(&1H%]F0,@QIJ6EZ[R5"KE
M O3<"?]<*A4$??'!" W15?U JN7LKDX0BM\]_,@>\#G.]#"WIA_.C!8BV4'C
MA]^XD)UO7VKP7O#9/?%@O03OJV&N.']][A?5SQ5[H$9:(QC060=_.'5T<W8A
MGOXT<JO=I1#/QCT _;:?H25F:X+?A[8_C]=2UWC"$JO[(53>>%2.&_.H/(XK
MC97#^?8;CO[&.;Z*K<ND;%>#Z,@2VJ^H*:=*P;#K\[^@'Q7%'5UEA3"N(,D)
MC[37MU^*4]$S??36^GAQ9!3?)$RO%D'?LD#2KV"G=0]2U%4YI/*6-GT,,@__
MN/G[5& ?NAK8[9[*Y5D(M6&UYS09N*K(]5R7SBGU,A*<)E#$PQ :=0@%W[G;
M\R'U;+-$P@!VT$<-GF\,';%,UE9 B$08[X1:K'%^U4C-,I8-&<@/=G1/VVG\
MG7>90L./_5!^'W87D6I;753UA>(N86N5OO$YC:OKA/@GKWG78JU!#PG7I90W
M[1EO<D5T?;R95?\294Z$>1$$&#;WZ7"U[X!&+1C3$B^:_-O,(;R<96JUITA7
M#(&.^%G6[;;]C\*LE]&$5?8.0^KDL_@<V%X?Q8/)/JU!X2 A.U-.26\.)_O:
M=!KS0<-/#1A-ELVQ/EA6?3*R1D#LAJIHUV\J*2^&ZCRH;F1%L'3LE4@.K\.]
ML?45!I1@@=.;6HI\S>KMGDL-*8;AZ;S*_^!RRTU,V9J9X]("ZY [XNE0^WW"
M6,US14$@;=ST=?(*;%4#;GQG1 +"0W>G+.#(F.[C5-.E92_=7.]K%FT&C9&L
M%%Z0P("\H4"44Z(\#+8HH*ZZ+U2B83 QS\L(,DRV*_WL'0#?5XU:K>':?J=]
M#\%=/VXS\4!70G3(=%)"^TJ(D*3O<79>KBG5U%;2/?R=FI'W $P[[(- Y+;:
MBU;7M^\EUHZ6/ZMAN3H"ZZMP95]FU"8_V\WT2Z@X7#G/76O_D-"17%?FD+UQ
M9])%K/8+6[7&KL14<,TMW^V!F3JEN#M;5%\^%;SX*6U*?)U"TN?_<>GL#^;V
M*_12:'6C.Q&1G[M56/%226=F)(_PLO3C:W'')#=)KHR7OY*M?[E*!E;>YDC3
MNU*U\;FG[N5[T7\\*-D,L:W4:LCE3;H.+V&FPCF**^:\Z&/M $F76A<S5TD\
M!_LC 9^0C\+([)0D5?H:H2_0A9)#*1B,X"7+!&%^5+^T_D6#H_^=[@B%V0@*
M^8ELP3<V4)1&9UEZ'&F8=&(,DD3-1K-<D!AKTHEI!-K=F3\\=4UTEG0)0N\R
MJP(7[Y/^.TF[JE0,U9@W5F2L/N@YO@O#-SHA^CF>2?:Z2>'CU#B,/;^;;C]A
M]6!(6.3$;U)_/VT+R:WPP=Z@*^:B93\0/U7CBZ!AJ/G^'JN/%3PX$!7@'2H%
M-^&C8K4E3@5>',H(2U+U9FQ!/WW;%1EJG=.Y]( 8P-  B??*DJ0/R9366;@4
MZ^2(NUQ/]L-H#EYD?=A2XIWFEL'C(AC/JMYC<P#D;DG(//]-WE\?CKV"^G5>
MUVOUG1Z"U#SPS0T?P/X]:P^_WJYQP\%5^)2>OEV0QGA?F$O>S:+3?\_+>KI,
ML\ZZ_XW8F',M^_DJT^9[XR96M4W%,G\\*7S6;>L&DI\R&K!2E,5S^*C>].YS
M/%.SJCZ1BA6E=R@(W5F[7)!GKEZ9'MFE.R5T'7G1@(!*6>E_0\*US:%Y'%*2
M+9J/S_ >#Y@&<UA2XG%ZF!\*BP71.\J_%R3NWA/%)'@4J&6M?]%61C.@I;4V
M'L Q>8/"!QI?L/9J=MF,KP3FOVDEY":B7AF):I"UFWY47:[1OCM-_4FIXH^R
MOC$MFM&/I!]2:SL].;>D6SBS^1=^)N1TSK1M" U;KP_ ]UG(J._/58LY\P[]
M.O:G,EG@Q5OI#9VGE<QKWOV,[5/KY<G18X<]TZ]U\>AK-@Q4AT=P/G[U>J#6
MT ['$"1^5W1HDD+RZ7(LV^*F]WT>.9X6N;*3P&-)Y+5!3@9[[S%X%-UIK@!;
M3RCQRMM :>4(!KN^M3>?#+_<I'$!&G1Y GB'4JI/I8O"6/K41&*N"=(Q295Y
M@V9]1&+#&CCX;M"5W#B,S)[P#Q*,S*_7Z.R2_%#W!J;_XXG@$'916TW=G>6D
MWQ[BS@5MFRMW(5*Z&%UK_]<%9KM$I:::^'O>CKPBI 4SCMZS:H\O&A"83;=S
MJVNPQZ$/H@C_6D?Y'H9+.B?%JK$S!>'-DN>\,@7=!0S_]KG7-(UR8(.T_>['
M^3N.+5!$ M]V@M0O-*0U^BE(DYP#UKQ*HRZQ0>3?9T%I;5/'5SA^MJ8C:XH+
MS*.81H.2I)1@:FZI"O35>':4;TR,$>V4A.2S7^E7AP2]SA^=__S>O4@!A!5M
M_U)'J7-X:46&;ZG^3P7F&=!4UG7A<V\*J7"30!J(202D$XJ BGH#2!,U(BI8
M,!01%#4H*O8;BH0>BC110Q'!2AL'!34!!%140,4R.!/L!1U0'!OF_?S^GE_[
MK'7VVL\^KIY53G@[:\CN:]_+\I/*=1KC1Q>7<GP>^^XU\&'6!^(98DF1QX_?
MHAO+-!V731(VQI1L5E@7_?B9\SKB^0<T#3(+<#^[*L-Y*OZ,]61&2NGBQK_U
M,3M(=E,VA=>^R+ FV;ARFFSG>;MN:Z!M?SH1V?YY4>6YW52MS?QV'QIN6?*>
M]9;^R\:T2]N^7YW?M=?_GY#U+;M*[\6D 47+?SO=%8JVG9OY$*-/X4RR^_/U
M=U<W;U+P]T7?+PUO#5/W[KOFFF9;+^'63YP[;OA9J5B>M:=S1IHU>OG*JF[F
M?D_ED^X/#KN2G5*GN6E/Q.SO_J'TY2H8_0J[4*_U)!\VOF,):,CO.GY(KB-,
M83-EEV]Y^+K6=NK1Z^'4X&X?\_-?O;RY..[]G]<5.Z\L[B&^&,W^Z9:!=/6Q
MM$V;-S(1[<T_O88,"!D6J>PW&L)XQ0/&U#H9Z-ZC[SQ;\=/:H\M\+/_V_/T/
M!=2  "\SU<V'_[LI28-[C Q$IQJ^QNH^$&8?Y_A,F[+)+_/ZJ#3*[U,\W/:]
M94>?2W)*Z]*Y-;YNB_".^8F"TU2M=>NOOQ?@,Z:\NC+Z<K*96]*@%]J4O^Z.
MKV.D3KSB1 9?[GB[;*W]I<0K\^7>.+M^[;#3_/I?5(:G9)J.?2U__J/I:6Z5
MG<8QLP]&DV[O/M,PNEL9C1G*M!<_'UQY!E[FYO4YX.W3;<3ITHY/GP^XM:6P
M9+]D]I+'KQ(W#4ZM7H<299)8R_T_I[RGA4F87(5</!^U8'BJ9)(4_QRW@JZ@
MU6X91D*_8L^"J(79'.?8^VWZ@NCK,2>J]VLP29=!D<"K-K1!LF%1J=.:BOXJ
M85? M! _Y_=M11N7GEB@\#:[Z)_+=8ZY639[^>'XY:>65OGE;NH)YCE'WAQ9
M]L ^;M6%]5KO-#:]PGJFK\K:V7J\SZ!LVVC/D?=5M6MHO-HI2GOIOP^;C X]
M3DQ)4S(L HOKU[4GGUM]W2_'++)9=:;KV@'GC<->$\UBZ?*#.1VWAFH#2W:L
M*'$/_-I)H*%U+XS;RW=MZ1^(F,B,GK1>T2 ]HU_RKIW&JPE?3F^Y4GGI[L:J
M.^;N?3C<IO</H[>VF5J6OGSUSQ96MF5O(+//CV1EWA:CCNK%W9T1#UL5G]E(
MOY'R\-JA4_K6M;FUP+MV.&!(Y_8 61OH]M +.U>P?OQSWC6R34?.V54AVB[:
MWWUHUNG3:,R['$0R);4Y<Y[I0Y\?:G.XD_,]U8IM-^"=H)X6U+G$OVUD"*32
MZ]X8]@BU*3W<E>_*NBA_Y%B?;?RL3AIJM"@#,_+#UC8$>XLNC=SMC$N37&?9
MJX$(7R".6WQ[EO\0:B!0:ZH+EJ=ERF\Y3DR=Y]&^8%VGQ9VZ#]:U<\:0A2Z
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MQH2V&#M -XEHOE[<YOHC;X,7%HJ=%-I6 3X&"S @($_41K+CG/A1&B 70 &
M&*4AFFOQ3%3I$@EB-5  FJ52(#0,[YL]>=Z![VEX[K]J(4:!*!A$P\9=M)/F
M,,]>0"V NF_VL+YE6]9F?\,#@RD=H,D^$5%.C :$Z8A$W3.^CM$II6Q!&5;I
MIR[:\*=TD]6CC)L#&J ?/5Y=!4KL##+P?"\A-=B9NC5(Y*D@BO!$('L[=A<6
M4RO,B;PL1V+6@+&*R#/7O*9IC.Q1PLU7G%9->/ $V^(9-T' D@-@'P219%]J
M(V&BCI"6SJ;(@+T PF.L78H"7P%$Q*[8)YZ/4_^O)^???@M\D@"/Z5S",+ 6
MI7#><Z6"B6+D6)1N;(#*<Q<28D;-B_K*IU "7L820R!*C4<TO!CM9#%2D7)+
M[>LLPD@L0PBJ/ET.9$1C?P(ID@, 3RYX6_**Y8X:).D,W-5#_*B)!$!<L&C2
M!8(NCQLU;B8P,8XQBI]*)/RP71HL V9G"/KSB]GO* 9[1B&_)81:!? N2!))
MB&TT'M#B0S1?[8F\K2@^3& =7\6<K<#_KN-!SQ)*%5'ZD1B#<E1^_!  X-,B
MUU1.G!J_5E!0'<GYZ.)42D:J^WAY^6;IUZ/+(OEEDHUY"LA*)XQ#@;&$,)X(
M!MX>28ID,3% Q/ J+:4HC@4#)*\*)F'@YMAOMR&!'=%\J$BO-HW'\1"46Q/)
MRKDKC*N"^2)"LE%N4!R/Z>KLY,,AZ8BU51#RGD#1.)(U4) ,L;S'$T-\C\^#
MAV/XZ8OYJE&\V^=[JB""ESV++X,#L%_%/8>M4AQO9^S<5;?"-DK/,1: .>B\
M8QEY:?7"L:)\U2MNFC*?'\6/D3R?VK'@WR)V?9]P5^3;J:(%&6^X;Y9G1V0M
MF"B2//^0ZRYY3NR=/_?<@FEN_(XX'X/[PJ<A*]Y9BY(E[+;^3/,HSI/36:W*
MC1'6\TX9)J+(@H\#[]]9^KG"^&WU^\U;TVOCRQU3,D*OIRUY[6\3DS&^O$(U
MN3 Y-, NI7RH)? 07)YR7SY>%% 3ZI?9';!"&61GL1N0YLU]%KC/S5[C=G H
M-.R1([,Z8")A5"EV$^VJ4B8)[YFE<,PC6<-),V-'&4D,"3G2]Q0I,0YB?IL4
MQ0B5YT-#5!!+H+BE?+,D7I);'<D4Z*$%L5K[(V\0PU&T*FG14XH7OY.G"N+O
MJNI(&BVF^?_6DN4B9(FK+@QM\IOFS19+_&>^X(9,X@[\<2\D2?EC<FY4NDG.
M Q/'&F&>%KHY#@@" #10<A^\E;SZ*1,)6@[LT>/G78E$ -F^+>2#X_+-!*\;
M"4IMV(,C7$$*T:WE47^ST*4*(#=67DICF^G"Z6JF/@'  @C6(:>QTMH\=DI#
M1$DD3ZG@9D%))8'\D2\E*QN"VM.N;])!M\G02L KKL*+U'!;/[&Q(>&X@LO<
M%1F>QPYB ;5)4W*UT!X#9UE>>4*"H1K8ZGP9ZF8+]0]1%62F,=+/.=??_XI7
MK/-2JLD]IV%C'4ASIY(5#7$K @J$D P]/4<KS,[E4"+OMG4_B4!?GL]%0F["
ML>J3)9/QWE6DBFY2EL#8V+\E2,:VWG;&^PC'G@+]".(T[W+R4"S_.F-,(&$;
MHW R-,*-?/WIYNG&H#-C)DO56@HRP[E29L\7C<R1L6(4\)RM3OZA<TUA7O"1
MCS]V^-9(>!5WA76C><F1L;-\^%,"&-81\R*!GXR=3$&X0J@.@A-0GIEFY^Q8
M>U^AL%A&SD&-S3O9B 861S)%T+F0W1R%2?S*G>7O[@C=&O*;2T-KM";Q&B,2
MAH^%"&$Z@L5O-M7JH3>+0*W"8?KNY%O1@DI9QA(-;"P$7N0U#]X3^[>S2>!$
MA""[P_[JL,/<HOO,]%O"T):V2@@NW'SI9JR]MY9T/XJL EM[.XV7:-0(!$+M
M12H))-,0.VX)4]X/]RQ*UC[7F*5\'>_ZRV*".%L"F8_^;";PRS!!F<XE[]R%
M2NWB8T+</W+.G6R"K8P0)H.E*+#0&*D'^5HI9 PJEJ#P$AG@RAQ+HU]8J<%4
M*3@[(312('P!WUY'W*I;>]O/6 GF%_\IE N)TZ-8=[;T4/*AM1K U!G9HJ8%
M$G:_S6BQ%H]@^;YJ #_R*NW"6VN$5IHV^3V0H[\'7"0?W16?^_TR]GQSJ0=0
M<14+EB'56@)%C0\1  '*2][)V56U<UH3'"9PW5G5_N/=[-?%WOH<O,LH0CV'
MKRQ"@F4L>XP0]B@J:Y6@&",5>XC,"J"0!T?6/9;DYMYYTG"/IB9XY]X=[S:_
MA:PX^E!H6 7Q!8@4&[;6#7_+(QNG!KT:^'V2:5A%_"%@)=N&K.EG=XF9P0+@
M6P+X.L16#6Z6_C;?>H$CB $(47:^K$;HRSL6W/8F)9[#UN#-U(@?^CM]F7==
M^;9AY9EH:HUBCPD&L5'(LPJRUW!2LMF>C@22$*+IC-8*2D^K\6<_W;)8SM,G
MK.1X2@X]Y[A65@DUV>Y[FB -F3-30%PK0,15#C.3,Q[49)SL _8:@A\Z0ZCE
M#0<0T^P<Z=CO#F\=#F#AM+=^G,:)LA?U/'YCIMD0+^%+L3=$!5ZW)6RSC_$0
M[*Q2ET_TE=@+L@( B*&]+D8(,MGK($V35/T_6(-=ZLXCRTZ8=8ZO3.*(1S\*
M,,9_CG7UJQW.[E4*4(AYDV"L*[!P)-0OW;;GAA#)_U@R?B3K#3$8P'ECYJ;>
MO^?9W,H;Q.1FO*"*0M--[H*075H"5N#AG!B?M6I>X>X^!,!A&&&M&JGP('3>
M(29G97&+3@ ,46F-0F0P2:;_88QRS#2_\^/YVI+C4O!ZV'K$Z\<#XNFV"$WK
M"2*_ MMRU#=^!8=@KX%%&,15&[UB5(8*0*R"1=0N)T,LN0;?EH"T.0C#,W5Y
MF0%YHPP7"6\_!'V:PW(*!F)W^.'%0)5NRV<?_EH4M'X_:06-W/1D)4GP]FK8
M',1]"<$+,7Q[J'K89I4VD&\O@WZ0%L0V$E]2#5:E7Z/C7,"(,$P ]!JAN?9;
MJ 9<_L PEG"XFBKA+5Y0OLD&-3"40%8"UL@1#C$X:07+2]]OE'R::19U9=81
M?+ "!+S/>7"1I +SPO;;)U4!W8>5!N@ED>24YWE6K:336R\&4YAPO0,PEQ",
M,4ZR#5,T^F"2+['4@;BW0F[A+=&+V]L=^<AO6^8:O],\\(&V6E;7GI^J$ZIA
MH,%SPQE  ,U!LW='O@ HGHV!R>T!"4T@0C?R@\(S4W.\SQFE)'+?JY^L6^?$
M[WP24O0;A-@VG29'ZT,;!OFI(WJFKMH8_-8+6&F63&G,;CE.BPXRU #:*T![
MH=D^SQ@B"0BQX;_)AQEGQ++2E-'5.+-GC_K6UE:/$O32J@W" SNK\"39AYR&
MV?S.\JUHRYRQ.N';DY5?N4@FX=78/8]4D[%Y+\,C^V!P;;X8S*PRXLO8<I<"
MF@!V*?A/?UC.+G3Y4:DM,1QE\'4WM3,NFJ&$ ,=\TI8,D6)\)8KG(W1R!CL&
M_.F22 @&R,> Q))0=H0:OTFP\-BH[7H0FHGG)6"_F6=D7BO3HPI_LU#N.4J4
MZX@)&-%B[I9I(F984(44_7*8__RGAN@[_/%M/;'UDQ!\3MJ,X<=&7GP5">A3
M2)1N$M9"R>V<2@F>DD/.)[>F#1O9_BY4#6V2XI.JB/M#^-6(5TPD?'Z*88U"
M?)0X',=>K1'J-9"]^I_A6(XU.*8Q>L%7&]6.(E985A#*G1T)SSE6NE4S7+V>
M5QM)K/]& %]W%N7C;=7PL-&W]/\)HP1Z=?+H0,>!E+]<%2EU=LG-+X6'=F?Q
M3_WP6?'LA(@[._'CB46G[D<TG]B24RP"WJM;XV #IEG8@+HSG68Z9S]I4*U)
MH]GX=2B=:WIRC4XN;GTD%KHL2,]+],H,&?7/- FOVT]VM?(N%FQXXD5J>G7[
MF)?KNS%2ZZF!*M_LB,JV\5/+R@4.(:&7W6R#ZT.RYY_+>E#5JPQMZ1E[-^OL
MHZ:86WF$S>[GGN0,)%>OH_ZY<<VYQ/=/KF1[7(BX3#QV>R@]>_B\HE>TT/MB
MJ; Y,"N.-T*(9SZ+:R=-\)4)*Y\U]HEN;+]TJ>K\7;R'S9-0^5!-2HM51D_R
M&$,8?$?N,H9O4"_7=\ %)DD]MVHEJT7K31?DF;TZL[)1YGS*U$:#_1YCOEVU
MV&\T/1IQ*TJ&:C'306,>%U%#3NMIP=9OCE<O_91[??65[7^?#EN4:06*RZX-
M.-.\$+K+-)I& RP]9^#P+#5"=S!J^V^U\W6W>_WIE,1"#.#Q4H6<'@A0<5]D
M%&HQ:-P)8%(M1G.Q\)5I9>Z/@"QO#DS*Y44JA7[<V'Z3V\*GO#0<7-XGRG;L
M$P\ AV8!D&S91Z[M!)=]4SM!J[4:L\\!J(^ YANMH'4$C*_<WC!%BN&>YG93
M!<9^+!Q,0<,$,TL#[V5&9Y)C<! I3&H!,GQQ)#W($JO(3I"@IK-Z2P6!;K:A
M-=*/EX@\MK0:&D&P8\I U_"<,L1EP+$EC)?K>&5D9S#M6: 5(+<B,!#D"W0T
MO(?@N<:Y]*,RH3E"PC+@Q99)_,Q<S_T.A@S!81CG5@OZ=@(=]S85,BOG"HA>
M+HL(EF/5WH(FP_$4D<9;FDZQM7VOLHWRRCY<:3 (:R"G?A$BP'M58^0R2R!Q
M.[K_YQ/AQ95(KCUQ1)9-I0UTHL)RZW$EZ8:DYC!W0[&PYQ2Q7*RA'1U+R7&U
M0)*54&5 BX;J%(#1Z!1L=QF)9C&.J>5?7+1X?&@*#7+RC0X"&<@0J' ?T>D-
MKJ[>=FYE74REF4/!G9AG*9#(<[D$ME6AKX2@S6[Q=. 5M2:BW4V,PE"?A\H>
MP6LR746>4EAH)8]24$1;SV6I[O[X&28PL7>X!9H#HE&*P5.@<3R ']\8-V2-
MU;M9XM4H0,R',-SA!=M]"$G7_)I;-J0=&+"B P!P]H(9'HYB@*7:[ZA1HQ;@
MOM1.J  (V<FV/Z)T^@[_:-P[/(KU.]**=9=)EP?0OJ:U)_+U@?TE$V=/^?H%
M=$$L]::7>&2*@0X/RO-NQ XID;KH-MG:08$O))A5&5<&&#0NGORM]H^+;ZCT
MN\RNRE?5.?Y) *@\(3A&I8<)GMBV5@2=[HLZ/S?S@8QO_2W,F^@X^R&*4Q:@
MI8O&27"<E=O[?6S>_?'Y\;XI1(LLA2,LQS&"U7@W@<99=2K[QCR,<+EL(8P(
M%*;V2QS@ E.KY"K ]*TV(JB@#:0F*N>;,-&P7O)TR*#7L[/6/[*^1O5DJ(0#
M=- !S\.. 3K'*(DF2E34@T=TV;<%/A"+V_?9?$()E$OY?S#Z9JR4=HI6?-B_
M#0Y1A3!R+[Y) 3A4>WNK3$$)54,TN4)B/P#P4Z.Y>QE(=1"*W>H7 7MQ'SY.
MVQUG@3):.ZAN/TQFNO5?YUF_V> 6&XD9>OK M#+4@C\ ] 5'4*A7=5VX5841
MO\&L=*7BW4?1GXO'3S-QB2@NS"?EYKFXHNUG3\U;6IT5^L;59(=+W_3ZC!PR
MD!WI[C('%FCUUG0_X@-;+2#N.7Z"@>'+$C''XDALOH7A@:Y'7?._BFFI;YX1
M4\/[' $ZF&J6 BB/"BED5!W@HL,_?KO>[8=:S/>4(7CYVUBU-F/N&\AHM\YG
M#3XE1=&#XA'3"'(M!('^0EC@"NAQ0HBDT\E^]WY:OX>Q-P18+9YQ@K4 ; SJ
M@LL\>]K"L/I]-W>>#\X\[ HK4M[R\$R;,.T5W]V!K$<Z;F^;9/K6)-S*A5WL
MK*>^Y!CYS,MZ6SS/(\S8V],9*^;W\MRYW:CG1 JS&W,;)'5OJ$O$,1\9AQ<?
MP6"+ 0-%0A2<KHD@..)P3,\:Q# ,);B/YG#%LKK2IEN_*3HSSJL3%J6-H;&C
M07ZS-?!%U=F=YWY>?;_IX<S9F8=I7OC,#W<,5O*$3I;KG^><F5S8,;;EPJ+[
M^\R>]N-M]B<Z+10/&FR__O5*('1[.(\PW&A1:P7MNJ PRM'A[3S/KB%G+B?9
M7R8L2OZ]7JQ7V.6,TC8G=YE];,SXR28'RT2LS+4!,^LYN?'J"?>B.'E$)>2:
M/@"O+/C5F+LMY[G9A>N\V]+#^3?.I  $VTW^]AX-2*-YR_7_1KK)E(3*ME(?
ML4:ZN(2!MQ67F>K>=,[YV%QZC1:;CJ8R,L5X$4U+JNW @.)-=Y"_@%XDB.:_
M*":NW@!U.&RHJ[6082Y)30O;^KP+RW0C0FX!)J.?"5MKV%(SG1Y/6Y3:?UCL
M*QI*0!(71_'+!>CTV(G?*XB(R+;NOLO7&3P<[#Q&0A0N%]]*"6=W.<#?<2#8
M&2&JU48K6C3T3>J! .J^1]U7)VKMML3[6=<F4% ,&&NHRQOO$S1N*-] E1D<
ML((P[W8:)6GPI L=C4QD*#_%(*:X8!D[;0<J#%!3><47'DV>__,*8W^"K^#9
M4$"B%E"$V0'6J!Y?AF"\FF4I>)D3Z+6V$ZZL !3@S;=",=1X?'I[P PB3@SL
MR$DT;Q*"F$@A?,7^?XO/['_YGR]>P!22) )OH1A!9^;U ^_DO0+R;C\Z7L4#
MDQ.,](!-PC#-XHWV@N<[$XD.5DWDB/UW!<W*U^#5C4]G-Q]X/Z?0S\8Z,K-Q
MQ[/Z09(+WAY9P9+!X$6FGP%)0#<-S5AU0 [!'63@78F!JYFQSK>VT_#!@&G;
M=MS?6D7^,S:%('I^^?ETH^_/=2C>0KV?EB?)IH2Y$RU41*=@*>0=IDNWP@II
ME<XXIG57DK,FV[Z,"JTDQ["7%FTU.&WZ?>3]P:_Z\!L?%Z_-^?OCIX/?NIVN
MAH*$J1=VA[Y3B'9IL_3%D.NA'_<O7/UR(?_7V#8/IJ,8HL>F%T%G5@G:I7.]
M*4P2/W2[0XLX1+*+02K=M?SGY(4%5\C9AZ)YM<C;!@T@H:M-M63OUS$X:724
MD.XD!B0Q,!Z8M^^3^5J71?_Y*TR^;1A2DXO5BF+Q9@LI.*$@FTA)[2IR'PA<
M64U-4Y.LM%1++CD##<0:+9M_/Q0FW6( 7):36JQD@_*MZ4T>H:E6KHU6DQL4
M_LHTLQZRJ(Y<TDCV35EYM83\1R(._O\_QI AC1U+$]0K)1BDISN/BS&$3&$N
M:L=@V@R@AX 'J<\:H'PZ"F-JT >@ VJX2)6VKR^#VT,N&4A;XLGJ5<,D " -
M:$%($+8U[@@Y7V<P)-M<(",E_&EEB 0J5#"PIBK&?7& S*X)CQXD \U*9QE@
MRFE6.F"%DNI"MRN&,UH"LH=74# EN41*N=RTMQ<CXVKAX>7K;OJ06C'8T 44
M:.Q.0/,+\*26<0]2(WRF#'!ZDV(F2(8RX,J"<%54X]TD"DJR5(MS5V:_5N8M
M.$(N4"N$PQQ$E6KB"B9&K0=U!A!*,M2!/A494N= *C)E$LQ.PQT=)^T4)=FK
M@+/K3NS/U#LZ:OD.)$>MA\LM-KQ5%O RY[=KJ*[W"RA"#R* # 2@#)!P@@R\
M#G0 B";#L<4>%X<7&&-@ZST#YW&'+A;90FPSA (;7_92%V"O R  Z94MNR<#
MGE)H\&3!4O*1-ZED%PP6RW<<0$&J#G:4KAOX I?+<,';<:6)I(,HU7U@VG,E
M;+N=Y*EC')"%;U#05LA@L<QMSB./OW=CRVZ4'K@THW+'CH,V9:GA^X=F4@^(
MN9\6KA^:N7[4@R5O,LT/+"L*+.^8V,>P.J!?47[T1OG+X?(3Y(K._TA.C99^
M<:::UPQ82W5J).>M6)OL3&\64T-<N.V E.)RJ*KA:'LF\YX>H]W4T';4(?<[
M4\VJMAS2V-W8D#<W<BLD /<A7'LCZ+LWS5JLZ,@\]KC!!%-0G[X-@2=@>&!:
M1GQJ02?U1).=DQMR=5RNU))/-E,/-9;&"A%/-:@74YMULPTQ*S<U-;>U\HF-
MFG>#>EFFOJRADJO\6P 9+X/IB!59 .$;X72QU$BS^)@<&*H!?6#QGJ]>UWF<
M/A:NG4U7-JI6_P'O]50[G#[6@5&)6=0+/$<@IAY]1#Z&DEH0B 1([>,D3$?;
MOH-TX/ >XFOYC>^[)\,AB@;^-0K7/0?6XUGE4LA.)G(\??($F2ZVK;E.. X)
MCAZ*!O8:9WWN0W)O&$3"<$P=(!$@Z\9=J>I:IUC+^%3N/V'P:#+I15OM&DK]
ML@9J*T:]B-2X0CB<ADR,/PH:78W3:6'=^9"49*+.:FJJW^-/PJ=Q6@7P(62C
MPVQ>EJP.5@<JLDX7\6;<P&AGYU2" ;+G'MPS)BEEE<!(5VBBMLX'P$H5FB/S
MP@1%AX+8]T 12P. >D%W-?5.8[&)+KC!]EPECVRQ K52P0[$TKM?X-^,OF)@
M6ID:ME&+VN6XX"B<VR9.^TG887Q5JRR\&8/=Q/1[FRY\S;KP_?2%F*JRPMGK
M\^,95T\EZF\RH<L7#+(;R6<:J;<:Z>\;C:CZ)H9=$VM1D\GF)DYV$^],D^FM
MIFGOFZ93FX5VS3,6-5MN;IZ9W6SSOGQM@3WQ3*3CK86VIO$:CU4-CTU><3<"
M;Q-Q^PSW?>6IVSE>^XQG#EIYKSG@LSHJ=0"RDWH.RE?X"I%CR)S *E$+<*0+
M_V R(E8>9:8-0#88;"W(YC61UVS'S7^PGCAXREH&+]_'W&A*'S6A'[4R)CM3
M/0>.GN.P)!3C68T^# ;YK0GNQ4Z&_K'!@X4>N\\P$>%>F=U%1$)--F6X:#P,
M=_#D=L9W&O]8M>ALBQQGNLHYEGI097=)HF# 0NK6,TB'^D_?-1;6=<B=<;C>
M^SPNL<10DC)33VEG))+:CS*O[#/VZ]FW+7RML\[@Z8XUC@/3A@;X1&>JY0IG
MT:<.6R&]54T+W6WK**@M5NR[N ;J:R27/KR2&H0\:3<I-[A:NJK"/)+9_YZ?
MXLQR!JEWI*97)8A208/JJ98;+"=_PNIW%@\7(;"$:NF.% A@JPG2L8VK\*Z:
M=AFS56X[-'#VK@5R14>[K,/Z!' =>C!OT-1P_\&K8NY%'?_V>T9?HZ7K"_&S
MS<CWN<IZ.U&?X.*AN8=>'XFZ2[ARKI.:AIJ?BK+L$%C;R"W,)PKF5$:)Y+/;
M3M$,^Z_.7WAU4 4WO*==E$'.(6O'__+(GH&XR$F3[29#V$;]G<W,T>P]U (>
M'$DU'KBZBYUI+S[Z)0B)KHQJ!G;W[!@/['KOB'M:Y=</Q;9;OF0,9R/1'>1A
MB?A_B[2GO'OW!T>OJ:8U"WJ)@]2!=FH*LZ?AK?]+ZNGB2+=[ LL7KW+]?*AQ
MIG1Z*6*1V&WBRC6SI^>#&5<*U(,ZZC_A%M;BVO3&FZL3D*?W%V9H.L_!G2M%
MO<E3G89C!G'X*_>.5O3I>J.I>TI>A+BJ$SP\J37IM$V^%4-J^ # _6+A,)G3
MDGU%MB+$60>[H;!S,^R.=O?*("L=-0O%>4HO?4\F'9PRL!IP6!6-.VX-6^M"
M%#J0NPSZV6]KHX9%7_7P3@^[60,&+K([/Y]G:AGT2N2DK?RXH[SH#P;.10,K
M-+?-!^%#,?"KT]1:'OW^L(&G8- @$7Y1J#ZF@C^.^4\;,/ALBWL_1?H[ _8<
MAZ_46F5(!XX"R%5JX2*[:WAO(/7G6A&VW$V L\1HO0,#CNI3[FK82;QG<124
M'&!^=&! +*!GR6 G.<UMW.!YPBH+&<YI )[?!Q]"?T<O3*B&:YX-L8Z14RSA
M-#7UG#]5C,USD^'":^!:!<E*O*=>"Q_05!RL67C>]Y[[.>J)FW?3<W'* R4=
MZ/TLW:5!*6X%@BMH3'QFWS%+3.H%VJ9.!T?@:BO%60V0E^GQI/)I?[@7P\+7
M6\\-03/I0[,:[_2-7W-$S!P R5I^Z>5^Y,W9.T]384P#MVO6Y"!/7%"<HR[<
M>1R^>YLZT@G3.2>=-521'+9>/+*38V8O_\O1DIIZ_6\X%W$!0RV^I+<C>Q4:
M6Z/75/:X03KN[LQS)!<9[M.R@VYJ>/=BZ]7NBP[)<(</("KQ0Q<IDH;",U\\
M\N"I0G_!)HC*Y)Y!A^Z?P5SD-W%MW34J&ICFA@R.;MBZ8QIN2%I[0 HG[?C'
M#<7UJF??;(03_WQX*15N.4!S/?]L:/S1W[;T/3M)ONO6])22+;\4NLCA<U^W
M')3AK)3PD#A=@3QGR"CZ:>5D\:<314W5=E?(-\SLC--Q9;*SXIIG99"P>7SZ
MU?'IE2J><LC@4#JM8@:5TD)=^F71S^6$.W+2S6S8U@LJFBATUL _/O^3M!PN
M%].=@/S*"UH:VF4^,?T $F&C.9ZFIMF+R5''WWA]S:5$P@]VDMS'_0DO@IQT
MBQ=?A)-<X9LZ^(J 7L&BWR/=O8K1V *J+4:^.3!PX//T]'$W1QGE$(:[J28A
MWI#8SSD?*TM< ?\S;\Q)'C>LH#'5)ZY;>BHEOSTP8PM0AS"OC/FO\,O@-=7#
M'<C#YH%%EIY441>L>&OPHHHT2T!OK3H2DF!OI7J1-UAR3O]Z4*4G%XQ &_RI
MSJ@9TDQV4]79]O>PQC\82*S9"$[+I;\.M"G *K--R*VZUSS_Q#6?%H?0"FT+
MX;'[<*5.UR<GR1.@C@'^$?7'DU??[_T&%PTL[M/ 23AAI1QW5!?\W/'=Z+//
MR;%.EU4/C][Y=#P:E_81?KO]1F<3>99JC[>]V8@_,N-;J-UM<H;.$5/?,GY)
MW;3$E*U[SU93W:5KBC1)1U4\433L%./6L(_VS!7!U/^Z#?R[^\%>40OYA7"-
M/G"9@1-2/A!S4.>WY?%KVZDK!Y9_[).2TM8=/.2(.&)DL9I:CN%8_SL!)\!K
MF&2;1S&39U^6+GG$;+3LE3^\I9^)N$D)[:J3)CR<&R!=+1SVE!)BBX>L5.2%
M'!*&O<5-P'G.N')9*:Y*O-GQ69K.P"6 6\$Z,^T$/ 1(+W; CYX_.Y7PZUPO
MU4Y,GQ>QZ_+2PYC&H6<!STV3RG;EL@'IGA.UYW^=PUK+00PW>AU^+\3E R3+
MO K@E4ASW* T)HA[[JZS\5#UQ%X)U<_-&ZN^H=I9+VWE-E>?E+)K.,W&Y.6"
ME@W"Y^IP"_!+V"VN:.!R9]U\8YQ*5*/YJ@:EW_N%K?Y8THV @.C"S')%#&-.
ML?0AE:5BBM8(%_.SHLLBC%T2[4/4MI<-JTC&;V1N&RPM_#[5O*\>C--CFQ!O
M1FYZ7\>*Z4^E?CA_DSK9L0;/V,Y-M-6S]RS$^]9(U[-;8]YX#^\NROT#)0?6
M*+TW=\6YB:O<*7T++?KH'B]''G@\<;O$6I>TQ'KP\#"[-22Z4/)\J6#AH+@)
MU;[?+D@EU:P(GI=92D6=S&=_SDE%JM+$L8-E*W[M53^\'+8_]_#S@G_6.>4L
MSRT)7$@9'=QKN_'X-:-O:>Z)0F&^,71!Y9-4]2$M;FM?&J=4#V(XG+2YA^OC
M:AMRG.+KFD;3YEMD614V21LMA2B^1<+CR=^D'HX+D!KZ9<ZY)&S.3#!E^"W
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M@(X(H7O8O<SN#KX6735;*)71B&AZ=:X'?)+\6(0%E]*! #U N1\P\=II%?9
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MGQA,?#*'H-[?F,*&="W*96>D^TYQ I1O_>K5[[W(35<*-5.?$)D$DO+\S7\
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MT2_NL%I9(?1'^VMG.DNAG_\L_A]02P,$%     @ #86O5CJPS^DT*0  6RD
M  T   !C;V=O7S P-#0N:G!GE79U4!M.U&TH&IS@[J[%W0,$"!+<G>(.15H*
M%'?20+#B 8(4UU)!"@1K<2FE.$4+E!8MO/[>FS?S_?N=G=G9F7//E9W=O?NP
M]+ .(-?5@F@!L+ > ;C_#<##5X & /O1?_AOQOX''#R<_T" AX>+!R0@) 02
M (&$Q&3$A$2D1$ @"04)*1DY.04Y(3&($D1.^6]-_I\3K/^4V#@$_X3D1$ B
M\O\U'CX"* @ S8 6;"P*P",*+&P*K(<A  L @(6#C86%!?C_P,/&P<7'>D0
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MK84X$DAQ^BE9]>^VXH[[98[A24OV5J,2';TE XW"3T-4B%H>U^G0TR^"W%$
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M(RW?BLIS.\-T1G?R:[J=UF636"UIO^U&NE.]<?WR3F%??5*TKT^36U3&]NY
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MC6N"4E.=$WL_>)2DP1J>$:,*8+8X),]=Q-/1KK,]-<0XDMOHX;F$DISY'S5
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M;C7>EUJ:P;-Z1W3\_5*5A]_8038R<3$$F%5?+[K&:?"VWF]-8P!.G NBOG/
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M0N\N;Q;'$*.IVM[ 3GA<J&@'OP2S.B]O@GPX-5$O?T^M$ GFQ8K/()+KK7N
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M'GI*V!->+S*1'CE'W:6S\O*/%'>+$^Q78)D;K19T9C.*T=YQF+X>GX<-3PN
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M=UJ\0)';_[UWO=_?WZPU:]8Z>_:<;V?/\]+S!H 4H@I6!:"AH0,X_RW \RI
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M*U=I +XA;9T37)N+/S&[YSFL<-*'O6>8U<NNLO%M1]VIA"\R.J_<4,\"YT]
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MY,D$*ZCM_9@'C=>,SI+!TW^UY.A(_O^6F2:8<)\!W&-T(!IZBG^#H_*G;:5
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M04;Y;TSV7Q*,_R*QL/'_!9(1 @G)_L\\C@+(\0'M@ XL#'( )CD&%CG&(P+
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M%>/3]HY?>&TNJB5D-W,%-!Q?6?;2'VIF\=Z)PG_7<EP-=E)IW/5>J!'CU2@
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M[C<.U6R9?[LXS=>&>&5S09&$"(%U(8;P^1/&)&;4D6<P=A.?/&70TP1BW4?
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M$P<.'!9!D%^%DM9(8N*3X+489%:(O" C6I0BT!)B 3%=_)?7D(V:7>.8E",
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M8\;$HC1&XT<ZH3[$G G:]V&SUU/H2INO)S!(#"!?8$RQ3,FWV;RB/I.+A8_
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MW2@T1AFL'!C$' @@ @AP;)X8@ 4D0D5Q09<MDC:[ 0H$ "GT5R.D;B2 )@M
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M@0Q2R"'SHBM%(I%,4LDEF0P( #M02P,$%     @ #86O5@*7(I9]70  \5T
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M[3'MW$MY:XY'?O98G>M,DTQ#[0;,/=#C;D',\0SAUA5 P0/"ZX9;.?!IX<U
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MLA<E%!AT\)OL/26'&IPLF;8#]$!96$D\E1L[,HX]9%8V 88?EK@DI)!I5)G
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M5U"JNEXURL2B_J%<F7RPC*/+@S'_H, >59ZWA?:RX\Y[&N=_/!%6J:"8W[B
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M,'L0O)87('1C-[BH"1.L_$)N:& VDQC)'T5%OW@K\_I+3U'U:W]JH*@9ONR
M"T6_0(S^Z.DG3V_9AZ&\W-EUV4&Z*Z)N@^PM5KU9;%+_;RP4^X"[WE2>#(%3
M@.9#:B/KYSY'1L["7)&F.+NP$9SY0=&LWI46^&#Q$F"<*??!T;)N0V'\F>WG
M;TM+HA]._-/-"'CNC!^-&[9D&7SI/I#0.OK/%O&^(?!/W.\W/]ZN6XU?[>J!
M'4+Y\_[E#)]2I(,Q8#_LAJ>UX[\9H& R6];DBHIN?<]72;%]7ZBD2!!BX43
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MYP6T98MPZ&U?H&2\X;5>^G)6W^(;9*L*5]SJ4;OD(PE3^JH:C?;1^OVWE3[
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MY%TB&2K%<;EEQ+U<&GM/_QQR>/%A2)MM]7[LI8-L@.?!PF6L$=>W+AR"(*V
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ML,[HU%(:UOI'$__CLPPTNF\A9E.QEW2>>.C)B.K*B.K\MFJ5]D:IMKI:]/0
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MO=<[ :MTE9?3T(E+!O"&O@Z/P2"*<;:HU;L V8XMUK?9:/%V5_5V6)U-! A
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M;0V\@,GG&XA-C4=U^B/=C\JA3&GQ\ Y'V[1'<B11,@XDCI[?H \JX<&]P1O
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M["T[NS,SZTBR$D*22ELEG]_W]WZ\_WS_\7X_W^_WX_%Z/][FEF8ZNIYM@%;
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M<I?W(3K/LZ]C=>D:NL=0SZ-SFW\IC[\F>>*2_%JI1A;#_,<M O@+$K% . T
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M)"J6)$@;ELP"<N*):*@]2P%)F#DFQ2")HJ'_?8$^&9@1:+W$3P3PZYQQB +
M\"0!/.2I=<^[ZQ"95F6Y0WN@=Y(' 687=M\4S73J@?KMD\0$$Y5T^I1BJ=ZS
MNMK[%/-Y,-MK89X(WD4+]K?6%+5]4%0I$ENH'0IQ7--,OB&X6*^<]PICQR9]
MX<XI99%]0%NH T((>.H;9NYUI'=A&2)10#+##J$+2$(H,BJ,B-(A\<$7H$<
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M^H"RCYK@#ND4S/[8W\&'GJ:N_YQ2U#1'SR48ZU09ZRV.7HR<HM(L>2)3%-!
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MDS\\;T5]J_1:;_VM='NC#B3F<&XTN/!Z?>T_5ME(OQ0 S/TW)F)9(8\B+Z#
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M4ODI\R(VY!9-C0F_6;3B578#)GS6P5\:_->*]K2HP*%;0?:GYUFAJ#6P5!<
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M,T93G8&VVM2\S1+D[]\?+4001;_="%U_S9"NB$)9LS<:R7+['"0)Z0Y:\R/
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MO"_^YQ\O38;G0Y7^=J(6)H^& #L9Y(B.R%ZD2QW0X[2HV*6]$<?\QW9Z4HT
MG,6N2R  \6QX$@&>Q.63).(3WDSZX79<A&]_XW%._7VYS,!W40%O/;7[,8.#
MDH-,KUKB]*O+7H.61K4:GJW5U<"M/&"V*$&GE-)I^)0VU7:3N._9'J!%>U;R
M<FS+ 1V$H$FD@)R0(UHINTYMLL.3F"4O_,,?$SI_9<69? E]8$<UP%*6)-4O
MM\3\5DK$+?5WA#GOK#%WN+R7C$\.WD%X.[:L!#L;%XFZ\)>G,3,(HK_0_,CS
M/<=8N-:[\+OU>G7=39 39)WRGS2>3)8^H"5Q>')W+JK_GFSO!8NY$1YQT"W/
MKU_'7<P6.\8]F-*!#!$__>_>\TT>?I:&%>+P]629-19\%N/)QB2FVXQ@2GD8
M&I*Z %(9'7JYP)#C,ZV1< U]>FS@57(/LQ*5@0.D^]Y-]-3 V$#Y!4!R.[_P
M;[[J)9#VL:>Y8D[,2&F1?ZH%L46RU>@N%M* "AZ35KN_"47]#ZI$-1@L'15E
M0TN);G(S%U=OX[LY,[.TM_$I%SHH0' *HH)G5<; E(*,&YGKI329;[PK2XE<
MX4N/=WB/Y27$^+;O/.KZ]91L_\ZT]OUO#SAWQ;?%X]P)[O2E7A![M1KW@W<)
MX!XC^">]R3\^XWHIR7\?O2:.MJ+_JG4#=8NWH,B_L$=WGB<?( J*[#J=\*1"
M,5-=#(N#WV6(&9P"QW/YP-I2OXE?;&VV/A#O"VIM/>5Q0+/XAXEKKU]5W__I
M9Y+P9_N((9N=F@H1%"%0(JB 51Z?$/\NJ0\ (% ^,B9EO7:X0$)8''"A TPP
M%  (2,(9 &1X=^]AMW#C&[;%9;^29_G_=M;;<V2-#83>M@64NOFXL.F@*9@
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M*!>%QVZ/MT+?LS2=?E'H*T>B?G%7GD"^E!/5GW0N1"<:+#@M6+-_'T/Z?Y*
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M#H\($%]7]?HNA[%<Q<6AA?<4W*#C"4NM(07N##U+Z#]G(6QGO,)C<3_$$G)
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ME!4>!*AR90U0@$L_ ?*\NLN2!H Y=YP$ I!D;U  <'-.34O5#SAR4@(_P@7
MN%4RIY+K+M2OP]*+<VNTWF6=F[TF#=U#RYZMH2773R=FS_PG(\,#R%"NJ0*0
MJA1 )@[Y909H:@XXAD:D UKJ.;7.YDAU+D!U.PB"EOV! <JB$9U>M%8>(O!)
M5L- C1FF[?PUQ& ^4Z8:T4;+;.$@?*K9W7Q$*S=OL2HSZ4W;B&;;!")]<+9T
MA]:9%F*Y(@5PSP>AA>*>0@%D1  0!1 S P10 "!29\'C:A4L"H4&4 =E7R.
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MYQ]"<DEV452972@(=3GS, VR'0#-1K=?%4-Q $@RSOAI)CP*!<&1H(4\1"7
M(4F &-X"V8&&D@I/1O%FSU&AP5C8&4MX"PUN=_B6P6;N!^>C5L.#) H"7HJV
MY=J58BWM2. D[)"5!&P#@O91,-M08$N:#,[#<LG>_9S8D+8("N8@GI1-CA;
M/ER$?5X9\50#%PH0"0*0/0<13^)_=@-;T61H/- V,;_Q&+BG\*2.JBO+ DX4
M@$($"*D..$]DV14BU2\5X^VI\%R2_BY.6!2WKPT%JS2Z8\L)>9D%OH86V8C
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MPKI;[_V@P!UQV;[$QE$R:U<UR'BZH8L&PO#S/FV"G9:DZ.[J>QZ4; )7WD\
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MI^$.9(:E@*T_#;JW!#+B+:(W01:;#$L P_HQR!27;0-@^%*8^@#&+AX3#=/
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MT:'JI4GD]VHQ:^9FZD>GFCB1YN9#EOF6HZP2]E6S$JAADD-7MGF,LU*+RCX
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M[-TR;[Y @H93#&![3U'^!+.@:+<<M0C-[,E2#9CI6I-EXA)(.RT';EIZ%)&
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MH#01%145-105.W8^2[S>OSL[>W;/GO/,^\[L[#KHZ(:9W>IUOL&'4E9XZO
M5\%&UJL?5]CLS(.7_'R!9/<F2'_?4KM$G9Z-^SQF$IQM',F6F1REW.UWR#CR
MS+*<@DIQ:GI%)O&<EC+OU3U9W/?E^7:C4>V7HVU$N]-Z\O]6]15X]EG>.*)-
M4-*4Z\77LPWJCI=+DM>>Z\@VI*-RXOZDUL7!C[WS#:@?R,KT>%*KIQO"QGU=
MWK/5O?V>( P^8DFG5-3])R\$]6Z[S+K]Q)_7YP\8C[UN/$?X3H;_G-3A3T"!
M@>V@?5-]F0S7,7>^\/25IY"E>NX$?2O57YO/?#6ZZZ)M_!&#C&[;&O1C&@G"
M^SGI6H([U+!RNTC-CUILDL3>^WV1:>'U6;3?U.D.8;_G#U;IK-NSD]J^II_1
M4=6<[]FCJO$_4337T8*?#W4YA0"9-J9YFR'Q)98\?%\#I!))"5H<51?UJM"J
M3/ 2;#D',_KE8:0K9D5<;F>-B00>>N1JPP1BM#E8>("A+ULO&.@63UGZ$F0S
MN8"I=XK8SC84]*I*HU@O+BQQ=^'WL"5^P&6OWC974@(_V/4L&S--BEZ?5?-\
MTQ+%CD5":J_Z:\R159M[/LM\U1S:9(=6U!@E>UNW(: -!J1A#%'[J!5'%8W0
M"'NL4<5AQ%/Z_#+O^\]\R_)NW0_4@"ZIYO,L &P41O*H[FI'T%CI*/F\]JTG
M,*"TW570<B.IP16M#2)[(FN3RQIT2_Q;G"!CI?)6+?0_ 1*3.X*@MF[?@ 99
MOC(Z*"Y6WBD$"9>$I(@\76.GIDJ#H6Q&2>U.;"/>WUPVT<U7, V-:VPWZ?/.
M/QO2AB$P]^^$Z7,\955WBY-"6LVL3!HT_P,'A%A8>.<-2UHQ;<;)WJ^;ZR=)
MFJ%.I9:;&KPG"*$ZICI%&8W!\J0SP5'_C<#S6KM#)T6;$I#CPKHDE@CI:JU7
M&A$V8QG:UV!,,::G !%+P8AS(>T Q["$-\%OQRZJ7X@U>Q+\B#FPMRZ0>^[@
MWN?7V7+J6ZJRTI=OIM_;J?"K+V.^548F3"$5SKB?B>C)+XA'4X/..FUR2GA[
MMR&H!>UE]2WNDB&^!=XD64G_UF&6/.]Y*43-1U;1ZH]C0O*#6+A6S*]Y7'Q^
M!&RB%NE!+]93MFBU?&'SB1[$PY]D.;S.C[ ,&RNPDI5S2(\RT7NQ-HVBAM('
M!\3QA5V*OT8P'BE=Z *K9^'4KN!2W,J9GE2K,36/TD$#N:!HB:3CCKS;4LFE
MVJ#""3=O9GQ9D6* 1,UL$RJVS+0[S:K,YS#-,)<R'A@_%:P2$%O_V#NOR/'!
M&VV$VLKZNWNWMP(W^^->?2!E6JW6-[\V(,VA)<.F_>L$LD%I^1(Z)## #;&Q
M4S!J&0(+L&C\8G!HK[*5QL1PODFG.!9N.SG/(86@=\5BRY+XKEZFG2(]E.&H
M* ]K(>\(+@H6R,3UI<:<7(["P_"V#TAC)Q(8Y3Y U"^T"HU3$==U2_OM\!8:
M^@6O6VG+:A[B)&S>J+=W V;H73+G7FA3KH^_SNW!A!L1($1KNUD_VMO.UX]9
MMX-8)8):W^I>=RL;\R[N1KA'FB[G[RJC)Q085@I JJZ?2M]C_+^_\RLGAZ4^
M>G'6*]K\Y5AH7FI?R,S\DI*Q=Y>!^)W#SV6Y>Z%Q]87::E[NA  K9G?P.BS6
M .YCT,(K[A8+OHT%E8H-'D3<=>M1\1I/#2\SPE5(5*CM/E\;^NK$>;;^&EVC
MF(V!70>&4JZONQ+W:AS:A;*2&3V,=._ \8IU,;?G4*%+U6WFH;+*=;"+A_DB
M/(_;Y<#%^HQ6Q:)'Z,K+"RX^7:]1TQ;%BKY!H_%?]P;5!W-:\\?$"R5 GTN0
MT\7G=G?VJ?MY_?=BN7B[;+#B+-?O4J6JV=O"4KTG)66;%(MMRZ)4V+$"ZQ0O
MOKI%?%1E5V-02[S0W<F_H5Y[;P"WV$KWXIYYZT8:3X\8"@3=#$K])$?(8Z+H
M#F.&K6D7K**6; 13/MOHZ96!4:<\=$W=.NCIQ3YS0A6$!N\LB9>GP5A")6SB
M'YBWRXXJ7U(+D0:@#8J1$X:2+6&#T CS !A[/!L;1AXYLU/24SQK F^G51K7
MXXNU'B]Q!U87C$<S^6K5M.0VD4S'5%&9%U$O48NJI.].&KD2Q.!@)ZV7->XX
M$-TZ[AQ/3I)D3C(JC#UK5,Z*):PL<;8/O1:1** J*@)U\7C77=PTCG%LIJ['
MFAAS@CIJ#%J\[O.;(M=(Q(>]E.1J>1((N70O ROU7&[:*$&KQ57!-1A*I.OE
M9&CJHT'L/'??19B!34#8N$'%IG@OI%4N83>+G]=["^#B(M;63$K+I4"8ITJO
M<$P.HP</&0^CKO\":O(T(#:1'#F7>LZNI/W@OU>,L(&#'$.2,M^,$2N7.PC1
MJYKE!D?6R#>M#IN(6. 4;S\%09VW858:W#?SE%Q0>-T$YP?2QKRTQBRH3O:E
M7-7Z9-5B4"YM9'02#35.89K#"UTQUQ@U[IX49  NREC*A05E+=J>A>\RF1?:
MA?*\D4&"4=]MVV;,(M]@"LE<.1\GJ)G93M22UQCA!MXM1+18%V*I=-KC9X6W
M:!&5)YB_ EO$^492ZG(=1H)NYD*+;B!<3Z2YJH#9\)!"(#*(S#6L%\,W3\*V
M! (@IN969L39^LC,/V!"V.G:O$<3J T=KP*\*OD^\12%''%@X-^TW$V^!.2)
M6:06FC-_.U*"2L"1M+@[/)ZCXWHE=(U=VX]HS;4>P-6_*-H=8:H]?^T SG2Y
MR-+3.>+Q#37[2R_,=K.U(E=XGX1\IZ58V<F(LK/E*=A7KQ\HVP=N-/+SQ<+?
MJU&2>Y11$RBFJ,4[!=;V]*-NOMW-Z@+Y<SXSYXS]3,-W%872[RT4!0\X?HZ"
MEMK5VO!"# GJ7O"4,[_T_LO^8?LU:DQNZZ_*E]=6:/<[D(V!-65YKW^X</T^
M1FI7H34X9QP;+*/=*(4N3WZ^KM&VLQKSEP^8]5:WBXCKJHD^VH1K&K0;UIHH
MR,U9*A]SQ_J]M2Q*G*[RH9GN,DZMS(Q8C@M*X=S@YX>58 ]KT5;9:GVS8&*J
M-6HS#X0YDL0[^T.*"'PWK%2].JI+!A9NSGJD5#?^N>RY-O)^YZ.^'BGXS"$P
M<DMF[73/X*V-5V0+N=8YL4K5XJ*-ZY8H:R7P+">5M^'&0NZ3K%@E,2[[S OY
M?)<%X.T1/O'+^*/X@%-.629VI;L]=>X\LE'J/3L?3AW+VDBS@.W[7-FWYOO]
M3?#4XXF-H[?D &MY+@ I\/@9,."9  A 2P%0  N\@ <DR@$ NG H4![- J#Q
M8#'.#KQR5 Y0);4[\F_D>]HY9H'0GCC?WZ^,SV'26  P -#WA0P$CE>H(1FL
MC2I2 ),A?/8#)M99?9^(!)"51G! P!I9#I1T#K!'&M1>MN]ME+U&S8''6?EY
M4[L5<WXO&V5?W$?>;%VT]^CV^F/K&]<8++ H0A&8YJ:_PI)Q0&E"Q<,"+L"!
M)>>R4*-:0P9 /PODE #"5YN4ABVS]Z3G;) "] <5=$%DSN,;_1 0D:(K%;*@
M<WI@1"YW]BVYP [ 4!R1NCTH2,^,39$"$F]R=9+3.8!W;#7YYG5+HUG6=CP>
M5(]VA\+Q2$K'E96ZG4<OAG6\*3Y2=>-4T^^5[;?2IT]4T72V9VCL^)[A@I8"
MH7"HKN#8?H#GL7G#YDUFV4 D.%YJMX]Q6==S+RM@#0@PQGF88:1 !2+@>_/#
MGWM"0T& ^B,XM(.8M(D!V#X;JW;F Q7@9"FO"F IB3U9D%SE/_ZTYW>;#[IM
M5!0!%*<E !TX'Z@MR)'1IFO5SMCYYVGM?3.Y<7"NY)7#!*VH")XP8K[]/N[B
MEY^G/@=VK@!FY]!I*]Z$26WS>=IVB*X0G/U>(;Q-$2"&I-8IR@. O0H ,E--
M40QT8($UQ: DX%L/,= .\.WHWODU\?</#%SAQP%O%L"&!;8! )<8.$LI .D/
MS@;BC%C I&$01HAC;0=E$\"Y-    ,YF8^19X,=B(!D/^H 'V*"AS0( 4:AH
M/O-79<TQ=AGH_IZU4BM6&TDE79S+WK@<GN^E".N]L=J"3/OR4C#W;E9QJYD"
M06DEZU8650FP(E2$B,&R5-SH+7!.C:+HH^(*69$UO*HK_O\C_E=I:, 27@DF
M5MXL LL#,%LH@&X+N6,%$#@#1"0#T<+%[#6%#PQ%3?]?$+$"6@KNI $-R+C:
MVVKIG^PL\2"2&+P&^'=L@+S9]V=B,-52O6"Y1C.M*)"2OM-;/WIY3%&@?!R/
M6DU6'@*K5C*\=\I/$+<_7#/X7&Z@7.J:&4I16*<Y'DW!WL6CY&$WY$6??W[\
M!+BK\^4B .'>JVT.<!G^#5 "RI/!A*X?J6X+VH&3BF(XGPT&"%6_,KYE#X/0
M0L!CL7J\,M"S9#WKXWI:W*\UUIWH=)R-&, X9?]=#- 3 SY+U8WQ2)3XMF O
M[K$4((^'[@0",0"0C%6C:B>%]9W2WV_J8',RGIB('@>[O8SU*8]S^\ S:VW#
MT"6H_!7>) N9NJA2LD*4KQ.WESA&UU[Z3'64[HZ&@W0=EU3PB<WOJ*93M?*]
M+!)1_E+Y"M'7%_T'K? W;84V\S?6[T9X*H[, CD&*G7[O7&@J>R> 9)8JNYX
M#$0,\IQ2 ."5[+HAV4RC8=J"AU3%*D/QN_21)0!L()[UE$I/K@%U66KP5! )
M ,:SE$Y:@N L8/(B4@D X@GD+51!/QDV*#(@507TCR[9PZHS>R"^8B!$/.N1
MXA"LV&M"04R*[WMXV,& "FK,V,.PS7?Q:>?UE>\*G3TXLATF-?[>!%1H'LF'
MH#PK-E8T5)XA=UR9:B(EQBZ=MC.H\9<:;"VNO]D-@9-R[!YP-I^&)7Y-Q^(6
ME>;PIOXU7 .*PD(0WKU3P?;C*+)':6"?@?Q=B"X#\UT*7-F#HXF!CU-Q/Z7
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MF.S7E3O.ASIMAUJ>B-2U3YE]3*]X<LU9Z]IP>,_E'=</'NDV=+'3HSD(\3#
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M(@ 280D]A\%QT9 P&K2\!9DHJHA:VW_.$!HAA$1(B[=V(9.%L5[B;25KX#:
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MVC(T:PKN+ BS[T*&,8+(6;"D@LUH-?BQ\(,*E*YP2WB.<$LK Y5(@UK%(Y(
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M"R$"Z(<C""\GJ/OG"PD"9,#L,0<,]'98=+4JU*\D9*)TDW,Z,X4/X0RX.&9
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MEX@#0"RY\Y7W>  L#@B< I@33RBS 1E )9P2!,!5/J!" 0#+R(!8GC((G <
M-TW..<9,'3[22M>]'OJ+_E#E<\$C;PI+09<_,TQ-'TEW\0?I#@ $SG4&Z PA
MC[ W(5=,R7'.FY&B^N(S]7L^("DB_E"1*!.2.4_=%W_^8BC]!0,53P^E9 RG
MY/J<V"9"Q*KP=>Z*%$V\V.@\B@Q5%Z]$8-:B/&::4+7M\MSKK]H:_J9SMO,
M65MMV&HW60ICP2?5;+WL/-W;!Q(?<95PK$9CVO8I9$-\%LE!BH)H7]5L%^<:
MN]54^XED)*.365NALY?/]#S*F#,..!\EC;*V<H'5B6T)'"FF+%)Q;R=7R21X
MMBA:Q\M\@34A39&I5T\I;'IOJ>SXJL7A=+R326YXM@,J'%O#S5!Q$P_.+?'
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MSSR:^F-$_N<VC'#[YM&_?XYM7CUBDO8[\^#1I4;^AYJJW.4WBZEO7LMWZO_
M5X/?79+B9[Y2JS?*:=]G#RI.'P3SI[N#91@ Z#>5M;SL>BN216L*FL.#EM$S
M/\9"0/QJH$$H68]_T+%"IR@0DA6Z5J"VLC]O?#\+=DZ;.#OS^HH,E?_PV-0F
M;^;T'_/JN9RQC#YP$<J#+P2BK/5O8G6-;7AU)/;/FM>0VDW>*IN1'J%SMC7'
MBX!H:WWD-V&>:!!F!N)R\)\49Q5 >^;69C:!#J[B]4.#^4[UGJ.G1G='YL!Z
MU=361WV@P[M5P_[":VM2>.:.>K=PI7!")4GL>4M/8]]Q$=/Y 7[2.7D-[KUQ
MX5%-CLET4 9B[C)OSL=-9 !2(7O Y7\=7_3W!..Z!S !T*'ZN=MN\*?YP%2'
ME_VLG*\3 N7IT)\3;_HB9=IT'I((1 FEAO.@S7Z&8=ZA?^K+=1:X+FVRBZ,E
M!+.7A&">L(Z/)_+Q 53?(T!$X=MI;RH:/'8L19K=Q&.F2['IRER)#\Y(AJL$
MZ5B",!0@9E1P<31\M_R>]OQ^;3A>I^_%]D1#0X<(;R,0;F- *T!+U7UH^XOL
M6VP9)EU%P=V(6\<W$*I4\B+0''<"\R':,;<_A(8QPVX[D*,3(<4#J *@DF[Z
MH',+K=]+BN=(M7K4'A+YV'3AC@ZJ>LG9/9B9?L7[B5Y\9!]7K4O"Z.8RWLLE
M.HLLVS3" D?M:\>ET_/>.)4<0B6/%RQ3=Z"N5H(NS0,P4#Z)2'V[<Q)?)(/I
M\0EB*FQ>6\C@KP9 IZ$TS3;92KM4&SL%=>,][)D_J>JN^%B"Z?$D+7%)13R4
M&Y]0M^]^"I5 Y&L0^1;;QK!,ZOT(*DN.,O628I@@PR5)#U$7S:&R/D5N''^4
ML@! 8F6$2B!L81CJ135@@C "D=(IZ6$0;\"+I]$U0D@?+ G@H=UH! <>=HJF
M#08:NO&UQ@$Z* (R((?0)"1Y4>T0<!UGR,:$KK8?*R%%^M^JZM%2PVB0"86O
MO<1-MP-:I+\[HZ&@U* =*J>K^-0_--_P(@]S#=(O:))Y5"9\2[X+ : *IX-U
MZ@96;<I(>J/8%%X+4*6V6)K]GD)H%W#*^;PJT!V!%!+SC$3AZ7SA^SM$P!8&
MS%-<#<QXFI=X6",0ZHMB2$,384IF;DG#Z9TK^0(VA((,]3Z0Q4#W=Q+]*3X)
MMZ!5)(.6+01===<.D)KWO2,L<LD!0-0K_JVN00N<+),C(.-X')*J!5"JG7L
MU@XLF^9KU47!TT6$)N3)[@^?2)L2A5*UOO\<:DE8H^D,2M1PU'V@:-BG&C"D
MVMM(\'C4F8R3(:/A[ZB#V@T@A!RH(Z9JMPVBH%*MM4QS-YY\]^.'=LN/S0.
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M5TCF+[HX!@5X>$<L8H]7!YBY[6^/LZJP3(D?FYW\6T'=C!(T_CEH$6($\5B
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M,G\Y]MV5L*/+!Y9M]VU+H+ 9D%/=X2.8(X^2(Q[Y'OAN%_XL^;DP677KLOQ
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M5%>H+Y_UYI_N>?5JTW$NNJ';D-SMT-6M[WS&,+N;2N[]>N7ZYRO72=D]F(!
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M >ZE4H*FTD\.#&:JOJZ$X<8FI\]ZV1GW0*5&TA6"U6:897607?9%OWA+K^"
MJ'70@6!DF )J.&7X%H 1=+[M^4"^N^B?9N@1#R1<VY>=KYA0 @8,R2$&<K67
MP( 'X3X0]"$V@[G1* \H T5FCA-H:#Y:8?[,56"D U(3(,*R\M2Z.<CF3T[%
M(X"@B&B3]ZV=+PDA.-]70 0=<#-0TJ<B_>F$")"E.P08DF#H/+R2(OD[]#^L
M-(,9P%@%X&>O,.C;R,O8&<-B/ ]B^Y?M0KA+[XM'8V#F:3!YC(#([#NH@1[)
M:,MGPG_'Z,OSYDFF@8I48+G:2D)'S(;G2B@"QC0"T;$V]O-A9&9U9+PX&H*.
M9"(RVSY+\AP(,N[1@H8@?F_YZ6<W:J\Y1*I]+46\!KD1 YF3S3'&!G)[KKWF
M0$FW;7?X890:W!T&TBL6T;NP+Y(CZF+*R;O 3,1@<2:PI<B)=:AA8@1Q/L][
MYFOSHF#I5(2^8:;*9(YO@%828N,AZE4S0MZ%UE$$G+1/7J?/;-?;MLS*"3?/
M<QJS:Y74A-]#_7+_5WBY$;1$-N!DY5<M? 3=&@/D"96APXC4?6,GQ"TV$7<D
M%-C.4FDU&D< W"^NV[=]G:# \<@ +F9%I0C.P[,G\4=C,2B%I;D([/UZ[.%R
MS))#-XY0-@8 1HSWN#L=?^O.6^-T9<I2C &K/)(+L%9"'MDJLVF/]#H HP3T
M&$!@X)<G"7KC2G-EL0BNP]?T&H9 _XQFBG_?.3"21V4S^SK/_9/>:1^4>6)9
M(^YUW9CW+'"RZ:?JX3ZFRGTYAQ&G"&Z @"B";2P/5G6,O9S2-F?J=A8G%:T=
M=HT&=DM( C(51'=LN00,8NF"PLS+5Z#0T@(#YL&2*9I5?(G"6WLV9HQ3K/LN
M[<]DC&VQ[XPPL1.4+RW?=4%O:Z7TXM*^4$!0OD90VE(\VBQUY1DW1(#>>3N<
M']%_+_SEI_&,SJU #3%CF6)DIH"8*4 QP)+''#,6]$9[]E%O?48CX.P=OOM$
MW7N4%*U$G<W1-MQ2"I2<$/IY87\A7NDEB,FA(IS0I=PZRXY,H>/R<IK=>Q([
MTA[I$MN6ITZCR4W-/9TLE>M$[(KU\1"E[JN#5L$N,E[!'.P3>>M9DZ>D;X5U
M@JWVD.Y%[EOT:3 JA#'G)2M'Q9F$!KQGP4Q+C95#S.FJ- R<G>.*'R(*]I^D
MTE&QC-$!F),*X9>>J&:'E&)2'H@_Y,&B[^ W<#/R95P3Q.FM\4WQ%'1-^@G0
M.[)]HZFG@UYZ0A[SBBG<(J3D14#>L0'82<$6)\64U[H05/$F9[R7K;MOH:^?
MU?88H\D,I&;9RZYNG1=H=>)*C%&CMG('RNQ@297;EL4GZM!1 _6LC6D4/;,B
M&MWK\Y? 8T^-OA11[C4TD\_N8:$R#&55 DLPIP=R=.P2#V)X_+0:&E4W.BQ6
MTN$]Z*8 7HT=?%>@<'DY91KFM)7%PCDT9:;=QZS-A32[O!_GV5;,^;WM>+Y,
M[ 444M=!$(X49)P@I'VK\PJ-GI_;'8.(RKF/P3@-48NHY;E]UGNVEW_IEW5N
ME]VPM,83K0\H9W?:IXNU:#A)V40U<K*MVRH%Q1K!36J]5" X(G:NTK(-L\6#
M]#IIB(9EY!PKLRAM(C@@2IC&@9M)S<,F*9)F:A&YR*M1"J80&F_(#$;%F?;E
M\86#M',&Q!Z2Y(T?FG90EO76<I[BB_K41KZ.Z&@FH]RDF6;VV[:"&]@";*>^
M5^".<@_<#?"H(S&TG;7=FVME',)"*1LO7S)#"IP\!BUS5_JD))*CM Z\['B'
M]>B#>2M='=9Y_5V=>RSJE6:NJ'KR!ARY(7U$L!7C?]]H [)BE86#:5G,YKVX
M1>IIUH*X^VJZ]?G*[DW.TX[#5KD#CC%A%G2'"^!:^E0(3AFGO5$G;BJPOF/=
MW;UZ)VY[3R@6GS[NW&J]72#@Q'DS>UB.,J9 O-59)774>W&S^,&X.XOFQ&<Q
MM*B<=56 XT;2(!83)'0/M!>36"@:CJ=_XZIR*.>B(R^=AP/7IU?!X9D6?EJ,
MGBX2AUPC8VL0/TU'@-%ZCM3K5=W&:YU<:T'#%PQ=**!54H#%88?1P:;&8B<Q
M0E ]>[C!@VSH2@S<<8PIRWA82E<46ZQK9 <>@I_Q*SCT;0]AO:7YBP=S'+".
M86==5<[@F3K8QF>,[%;F:GO.I?P;D7%;&:QN J6<*1:[*8ER;2*Z6-'#XJG.
MAQZP%YO"Q^;EYJQFI]4XQHG5>J].UV+-*@M=#U.<;91UCEZ\Y@JO'J!S0R^\
MO:_3\F(+HEDGMO<7X-QGT_%&C'XR ?*.*@LSP'#%I?[>!$+N.=#849 X2D3%
M-?$0M!S6WE"8,$85F%''AU9,92P.*DN#"6(>64Y7J91&C8R?[@C8#,42+^\F
MAM63_K&34:+M=)[<GUB41A>"AH:)3FI-XHXQH^4!%'U*0#"X(UY@W4@K%_-I
M3I?Y9CX=S4;)"Q&PQ?>,3$AS6/#;,>!.-@KML?D% 2D5[;CC463:P 8'!Z3M
M/M)C[W,H2+Z&93M".'&Q[Z21C1I ,1YAC<K6$]O(&/#4=NG'\Y2%]1C!BAO
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M8E7JP]JPRAULM!@'RM48&8!EA8:1X9PF3=_*]QCB.[! B*;WXV+G]U>I;^Z
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MO5BD%/7XX6*P08E UNZZ7;T!8?M+>[P"%X$D69;[DO1Q>1,JJ8XQBHCB(HK
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MRWBMF,&M*5TQXAO?<&FVRE1+[R1SE*\UY>];*<5JP$WL2[S+;\[@Y_0YQEE
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M]^+Y'Q84S&S#*A=AWZKW/AN@X6?#8'Q-B^!_[_X&0I2X/[]#DX3AG5Q./5A
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M7@#<O3H+;W!LXL<PZ7[Q;$(UPTO6BTNNUX1S>.V &=ORX?&10SN@AC\$28%
MG*%$T-#65.X[W'9XA:FQ-;/5*+W!YM,E/80EQP!V17G_[.*#QQPD4A>W=A^9
M"[.NB:CG7I6.MDIN9:HX#BR)5A,:X-N#FU.*:C<@9ZJ8'JV8#^A.5SSLQ;56
MG-4=*8?MZKFL@8>Q&[?-B#;!#O%IU@$.R=8,D&K_32_&O2@3:P7.>6GA;HIZ
M;<8R)ET6?M!5,G#\H'U#*8"X&>2O#I?59+:;\#.>M&^DS./N,:<N#(J35I>>
M%W=1EE%RS;8%WW*[:%F4M::X[?13W8XK@S_TN$[CGNOWNY?HUW181#\N+8-1
MLL.^FC9W9/K8!FDAT_ID+=FK5A-.FD[?JH>1]:+7I>C4VIZRUHEP%5QCT$YW
M;TZ%Q#9UG&82U)!7&<YG)E7)5K.]?&>FE_1G#!"2Q=G+W=*\-,NEV1K>XL;]
M%4U]HC2-YL90?=W9GZ6&IK4]95[>@UI20-I +Z?(L1GOX647=NC6D<,'+[TZ
M?L[Z]-+KTS,SB\%[?28@)ZF9B">T2=I[1%ET3:\@O3AW]H]X"JP SSD,HE)&
MWOM2-H<-]XPC)]]C@M9 <3:N)&<4=6P^D0RF(T?%('=->Y0V;D9B59B;/:60
MX9'-0I4NE(\KR,C2' $-I[]3\'E0C]#[!'9B)5YM9"RM-(.9[&Y'D:9LEE'$
MY*%8*&3!1PJ/*]-XW8Y$H(38JF6NC,<\V"5D&8_';/@,]6L(;9P/I)( KP5]
MF6W7G" ?O8R;LGTX1TM2:<+3,K6=VP4$2IZ1DAPH=1%WX]TX%2RG-B(_:&"O
MHHJ7Q107<K>/LMR*BYA.;*V'58$ZJ:NPH.)>%"\1"VK;8=SF5# ^P7!=>Q\I
M2V6'D+@F18$D!6>OTI*5,54AZ3R<O>$G;G2[&T-C@7)GR_^O]O76 %'^@QT[
M'",'MF&(72\F<*[9[5,E7:0?PMSG?RRV8W?9:-+E>$#1M0SRJS-SW7S*+TY[
M\/F#U[Q$5OJ;@C-[#K34IU:G28YD^%1&^:7@^UI][IV-..<EF/DTK* RWJVD
M++V"]41XLR[EP9FZ S'[W/:Y=]E70Z:Z4/_#GYM</![>V@%)#-JO([-^W11Q
M_F/.BG1MO33T@GVE@]KPCQ1W0?A<R]CF!>])K)_J-=OG3*%Q)\$E=IG2J@G_
M'L%#'H7=W-H/NY6:):V^!SP69F7:1QM'=BZ1(0[=LC*W2LAK>0Q..=P^N-Q!
MR%3XZTG&*E( FVQW6 02)5%5$9='*I/ORI$! T?6:])HKL3OBKC;'&F4KEB^
MZ2?5OM+.YK0'//=)<\SA3+JB/;D%+3T>SWH/F"[[+S#T+73Q-9$H^<FL54,
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M:%^M!?.NDPI1EW837"&K7!%6.1;F<EE[-IWKT?S,@2LCYANC8&QJ/TC2W.3
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M=0E*X F$-F1,\.9M)Y(/;W[-?/Z?-\+;V?,'GKQ:Q $KOPT>,I):N3'>A[I
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M'4 U2-R1O5/N]7T2Y9].9?6@9VB-2/I.)-HXG:6%U2CM,D2CK10:L<CD(FH
M1@U&$5M79C]1>1THL#V.[%],N?\XSAU!4"PL"V)$\V"UY4+5C61NU.XY7V=(
M@7KK@)%@XW+VZXTG>!?JPUN'%S>TX' 'E$#]1'1KK/EE'-EW&E,\^U7KZ\&V
M#T7[UWX]LB-(7/CU4%>8>\'-;0<S15F9^^G'#FV]U'(XX=B1AF/'OWKN'A2K
M'BLZ&A2=P\=^Y9RXEG#B^M?+@8UXN\^43VV"ARUVU]Z+.=J@+SK64)"X?W/T
MDV&?U0_VWVXX\<_P:?#9(OO)A,L:,-B(LS6XK W9IOW3?N,@Z_/KMO4QXD%+
M2O-,CWV#_'>D1/FY(]^'S_T0M/R+^>2SEC4)GJ$]0L#>/1&+_OG4"E;$H."+
M3/AGL3-IL_1?P2_<-8(6V4OG3S-3!Q-8QYG]9><C:L[/<[QX+LXJM =3O3'!
M*/KUVSF>0NK_DX>VK_]0]G2FT& C-CQ6F6PN-\'A BBA6WJ!CHOK<%-J&&Z1
MU'\BS6(,UMR.L315'B$:T81H7S-+9OB%;_#X-AT7IX%9613Y&L@7$)JQ0['&
MG90FQ-L"*2VB>4864;O,*^9XM"'YTJR+\RXGS@<4]OS$(0/0UEKX8CDKHEPB
MET4C=P[5IMZN)7T^]@)46.*8J$.4F6+;Z88I:43-NLL4NTN_1/MB/WI/4J#G
M-LH"Q!=8/MW"5_!2]BTWL=$4=__RSI6*;._W$4"@V@(\!.9TX"A>AN@  Z+4
M%HX9@(#YB'.3ZI4U"O<-[OKS<KA/.7(VE2HL*G<63 [7Y7!55]Q7I#0+$M$[
MJS+<9RA-]/L +$1*AUTF;F\IF41_5@L7#!KOF#205KGF^S6X&(WI$BV( T[0
MWH=WVO\1H 7CEN-^ P*'UPCK_!(MP"/O8M+"@+SW3QZ-#+(B+=!E8SW<6IDQ
M"A;WLYYB;M;FODP.,FA,N^JZX*N_'35E.7H8U\/;\"T%HHRL?0 ,/.[C!<^D
M!EH"%TV"Y![6A[UIDM#"L\*#?[I!<=N,V/TT93*BZK\O,- _/(S8\R^4\'S>
M!B<["Y:S?>G(Q;,,,E;Q>>N8[S_0C>RY'\8IML;<Z!2 .+C.VIT6>[;H5\ES
M>B_!:?'BE\.X1P1:( L2J0TQG-'(< OLAU(HD!S_YH!R30I1>O,7#5CFB2@B
M:6>%R&>GP&#@CUX>4FN_?=N7>>WGG*5IPLN;1XY?'5".S+ELA-D\ZA#P3/1C
MB@/V7&"\DR5#; U7Z)9 #AB5$P)6%2RV!&[_L0M\-PMVUM_[>Q0DCU _70^S
MYT,;!D *6"B^ #;_=%<8EQ.+0EC!L@@^&'>=H3KY'T%PHOZG?W.12]BBZI!_
M=2%S.",#O4UTM)=ESK,TMR(<_#65=G/[\*OERS@;R>&W=4Q.&)-SE&'$J&M_
MG1F80ME<RJ)O%.;I_PEXX1E%G#:KGS=WTL+TLR101LX[EC([SU#,P++B94+?
MQNV^C;R<@K^W??]<^MV\L)'1OW&2#;VN.&\#__FY1??U%O!/^3+/SKMYE,9V
MWW_HK0L^_3/MQ)0I/!6)JVPWF J(S !=%50!BZ&%C8)<06-WX2KG?(=1S>WN
MGW@A9=RPL\U]NT0QQQ+[SK;<W"M>?F-_V+G66_MXKL[W2\O<98>$ZZ&%$^O2
M%Q7(9JX-]RM6F>1E.[=+,ML9#KZ5.9F_WSA__-%IS;4RIP473CP^EW[OV-*;
M%T[^]G/.LQL'%OR\.NR8^/WP[S=_/OW'KQC.QCFBLWWDFIXY/:F_\\RSO2 (
MS/E_4$L#!!0    (  V%KU;2:DZ(%FP  *%N   -    8V]G;U\P,#8T+F=I
M9A17>3R4Z_M^M]EG& P&@[&/K0:#L<2+D25JE$J6&A)#U BE4N>=Q5;2D*2B
M,UHIU2252IUW4*G4H532<D9?2IU.1^MQ6IQ?O^??YWD^G_N^[ON^KNN.BIDK
M#$@_ W0 _P  !,(T"*$2J28P8H4@'"K=G$2UI!M;F9B9&3 =:71W!LV)1'0S
M8OB8, +-&4X&QH[&+ \3$S>VI8^IB<#2-,B*)>!8!5E;^IN9>AO0YMASA'96
M;G;6LZSM@AWMA2[./FZ>UFS["&OS" L#D0-GGA,GVMDRT963Z&D5X60O<G.,
M<W>,\W2;Z^JRR,-QB:=SG+='C+=KHH]'BL ]2<"+]?--#?)9$N@KFN65)71;
M&>R3,T>P;L[L=+Y-2D30_/"0U:*@;%' AJB HFB?N#GARV+F+A&+L^>)-L1%
MY"R:5Y(8+5VV9'W*XI*5R7GI:=EIZ<NR"E-SUB_/V[0TLR"M8,O2E?DY6=(-
M.5GI:S9+\XI7KMNZNFCSAO4EQ6ME2Y9G!X>@JOC BH5S]BR;4Q/OITD+42V*
MV+XXO"HY9E=RY/XT44-J=$7JPNV+8X^DQC=EQ.W)F%>Y*JE1NE2=DW@H<UYK
M=NSAU8DG\A*/KDYJ7Y=Z;%WRV:+4KO7+.O(6E:U>55F8L[<HJV+CACTELK8-
MV9V;,B]LSCY9M/IH:D9/:4K?RN4W-^:-;=U8I]K4K<SKDN=<*B]J*RNZ7I9S
M;5OQ[?K-#_>4#._(&]ZY.JU8M;RP)K-(D;=9E;>U.FM#Y;JMVXHVJU86[\K>
MW" M*B_?JNC8K,A3U*Q25!<J=FQ45>4KZW(J&M>IZM=M;R@LVU^\;?_&;<V;
M*G9MJ&O*W=544MVRNN'8IL:C!0WM&X]=*#K2D5JU;\.YF^O/W]G2.[KIYLN*
M\LJZVMJ3NW><.KI7M;=M6].)\H/MY<?.[SG;7=]^YL*E"R>T[7L/-]UL++_7
MN&WD\+9';7M^;]O]LKUV]%S;8$?[1-?)5W7;.WLOUUT_?:?OXMMK7547;NZ\
M<.=D][7JW\8JKCUMN#:Z4W?WTHT;'0/W*FY/- V,[[DY437T9M_0:_6#J8-W
M7QV\]Z;CP9MKMV[=?OCX_N,G W=__W/H[NW1\0?/_C?R?*+_^?N1_[T>G?ST
M^\2?$Z__'/_KX^MWGR?>?W[S8?J??[Y^?/?7V(NGSR_W%*M^L?L7 ?[_V/U'
MB\E/SUX5GYZ=LW(U(SL]/S]]#G^6P%?@ZPMX_/^+_Q\8@#P#K*"P6F/UKHN/
MS3_I7;QMV'41TV']&Z3 /G(!RS?M:>7[>N>%^V+WCG96L6+BCPK*/(X,W7>.
M9Z\X/M 7N6KWO#TS!>_[RN:YSMISO+[G\:YYL?%"_X(7G4>H+K,6^*XZ;E]\
MN^'795V9U'-.BQ[-2^F23=0YU2_9MU>Z9"S\7.SN4TM.9NV=YW^[/F[1T9$[
MFZM./>].V,1PG'ZC2:\\;/S?]LF;NURWJVV7/OW4>#"RGO?+5L=_[_'://?Y
ME7VHIV2YM!U9])43*&AO.^#F*[_[VJ1S^(C(]T3PC\!32\XLB=AXLN[AGX]?
M]!^[M>868<U3<?'[=W=67[A4_UO.$>VZB5Q)6#G9=L:OM+$N.+::Y1Z1EUIK
MO^K&48Y2U59P/^?9Y_N_ONRL.I+P.&U*1'4Y\EUD8@X^1!XX-4D7[DKL6_7!
MQ'QI8FOD@KX =BQOSV#FXHKT(TZI"U*.3*2F7FU)6EHT/+%[#VOS*OLREORB
M_8CDN=TXT]7>R\PV<S)>M,QE2C=.<3T@>5D5Y6KD>M\Y)I>US?E8B3VU+#EQ
M)#(\4K?D5DIH_.0BE2QL>I=KFM2H9Y]-^\8^4W"3]Z/R:Y_[3.,'BR<6%[@<
M9"\U2VD7[MFN,@N\5KU7]'Z;^\DB_T8WM8V(*AJ/1!:5?K@6=4NT>YG N"XZ
MT.SPW&:5=T*>V^X7!),H7CIB/'/*4J<RVT,_LC ^[//P@SAI0"-EOF#5317#
M3B_Q,)C5)8DP6C$\G)1LG75F\;)!<.D+,XGOQ"NS5-!M4E/^<O=D]<+^Z&L'
MKQ8=>W?HN&C\U)%F.F59YH&K]0M7)62PDNN^.M^L,XY-E1/,()-2A#DW=:Q,
MD6P:O2N16OY@D?ER<2G!9"X&*(SC^6-O#$,YZ3 91<_PE]GO6V66G.)KOF?I
M$^*;O[:-F5E&LO[7L'G6ANU?XD;<R7OK&@<;8LTLYC8GC]^[$GW=:O2^I]'>
M3)?#LG21R8&D]C*SM.]C?08!CJG4PCRC1T>4J9FN4Z:G[0MZJ>%% Z(;<[$\
M$<,4DXEF"C,HV4L2;,K)A8N4)WC2Y?)+)=8M>\4)[ZH3FK[%\G53 Y/HT?:.
MV,M_KU^S+#+FB?\?T5'A/S[-F]4V/.*Z?&10Q6-M'HLL^Z]$?LW0?02[YDK?
MGA-T(OJ[I,]H+EO>R_#7\GL97@. ^XWU_V%*@CEOZ.F29/(>BF;K?NF# TNN
ME+VH+,Y/YUV<C J;=3<Q;VG AAJ#\P&'FPYYNPX=6+^O,S*ZSM'Q^'N%<<Y=
M$XV['J54DT7FT!CI\9UWE'@F=%.B](N7RDNN12B(M1ALI=>3!"5A#"D.60S@
M1)<^T#CXH4KH. 9QIL/-UAQQT>GBDKVV6Z09WQ"Z"4X5S(34#W4-1Q$2\)U!
M.S(2-RP!!=%[>ZJ:=U6*7IJ>CLLO=SP\LJTMUK1N'_,F%EO9;-[$#+881HFA
M20HZBB,+]./&Y(7A!H,\Q*X[ENPCD7_*Y"K->0O(P$K(A'D4V>DU1@EMQ&C5
M0-G^Q/0(_-_X7]N]"2Q&S:SDJ7G+2Z?+;!?J"@0+5R2SBD7%:36F'_?;L@Y)
M.W_$(R&S8JK_BU,>N%?0$KM<J*"K^5IWWAC)5PB2_,1R!E='#M"&F5_"S;;M
M>$OTP</HF5J%6;>&D)6GH\P?A-2@L>1&DQ5^0*,R; 5(4>H>)T&"Y]7B,O<_
MMM].Z7MEM2_>Q:1YYGLXLPT[N_7#+NJI$MOOR3JJHN.%Z?&B@V[O'@7</4>*
M;GY1/5=L3_4LL6-QP]2VC4S8M DE14M[#.>KH1#B1\0L26>8 4 .DO2]5[H@
M4I969=U42Q >>>DW#[]OW*0A>DSKC;?^"SLRUZ[Q\(7PFBD".V?M HRZPF!B
MG?#*P"2M<6K,)73CV5/.VZC-/*??#;Y2$X^'[Z:E\T1"_]JE7:OMVP=W;DDT
MPJL^A=/: WN\O?R\35LQ@@OOJ,6**=@.OT7VF\2)2RZ!5IPQ<F8]0%*AL.6
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MW39"H:]&R4=!5I*I+0:R>*#I-&!>,L.Q L[;3LNMT-8/XE.H/9;B<]BXD6K
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M+8Z\7@S+&' P3JO&_!4D6C=.S -H): 'KO ?'FU6-UE4)=AFE/DC![G&&6-
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M@XQ7<CO-K2F#)IOJH]8:,&R@\N/=$S9T7<42?#+O%)BTBI&H%O-JN]K0.\D
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M+^P=>R(,U\IC.^T\>@3TM>_V?:#OS+8]*[>H[.-.<;@<58Y!CR4SC$G/@T4
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M79HATXVNN2++9FE(K'*$@:(,#0!E(! JI60A4"[ ,<H%-P,41'I[0 H%P(R
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MZB'V('H]]Y(D P6N5E9('IM<K]=B1O/4!(= .+TPIP_X.\:YCP!)5=2\6*!
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M;G,C9R=P[]7 7E[[6O9+"8_HC"R9?G%*Y#2&/C>-C_'\\GQBA#< ,W>5K_\
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MUO-66V'Z4O?9;D"FT>"(X.O1F21AOG&K0YG=:R^Q.F_G6/)VHOHD"LB62IK
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M4.AHZ[=KC8NT0L=N*Z99H$-;I4+?3O]5=^-?2M1^?>P,W3 43/LRT>OY^'C
M8QFR[<&-/(B:Q2E_1?]8&@AG["^\P\DXX @EE8DYYA,_7M4S#BT7!Q>9C)0)
M4D.O:HK<$1=&%5=_$W(D1(N+/]#N>]]X;.P(@R;)C49/ >M5PH.?3UD3[%]Z
M>(8.-\*=UQ1LWU[KL3ADCFHEKY2> Y8M1)NKOKQYJ?78B+UAZ!A54JGKD&/^
M7W]3W'NF2KLL0<&.0CN-K>%R<;@*#M\WPA1S0W@\W]L4KL%4$/U]ZIS@&)Z;
MSZ[4'!"E"N\#A/OLI'#9CR!C/R4>W.:V'/Y+TT9O#S='CR) +;Z0^S]<%->
M"4.A!UC^+#(C+A;6_GOS_#!5RH/8V=;9V6OQZ5^$$NQ@Y_'%9Y,%($WQ>C)!
MU&:+.G7[+;.">J512VT%DPH=Q3%H GB*((#:,5TU]6';VEK0R=%IQ4/P,Y+^
M:(<EAJ>*2CSJ+U)R)'Q8,IT?'(@I>4O3]@9)LJA2WA#>LO7J*O^-26IC4J?K
M/VN6FGWX.N)$28X"?Y-1;]S3YQH;:O43-%Q%O"5;:0=.='O'ILH /DI##A^+
M+I^AT=0X%JDC("EC )Q!U^KPL)^N^I*T\[QPB^B;?]7XP87]_S[YDXEXJ@Z.
M6H6%_\9,DW^#\!>NAU_]^!\1V%B@]%Y=SW=-^8YWX=[5P<2&('W[0M "!C^*
M<0S(WPF-(TTNI+WJ/,@8Z3PW C]O\<4&-7Q&OB)Q;/+V*+8VY+U*<]T64)HM
M$>)O^WTU@0'+/VUURK]T5+:& *X F&U8"B/<?\QI;?!0Q5I;KR4M2U!C>!2]
M?/Q6T#2D/_B)4/*B]MX1?55+W2U0J*+=IY:/T@E4&1;5>LXF8!RX>C,:\N!)
MS-N'\ G838\]%U_[T9OOVG)0E]87.S_:(#[!(OF+;M+H>V\?5=RF44U) O^S
MJ/N[\>U'#I.;4'U-ZUL438T">IE!0R91P$D$E64Z=H-C7^DDQ!&4_(X2_O[V
M;,=+9ZTQ73FZK^Z8+H;>QS]&VJ<]XF+Q*G1-X<S#NP67?4+5TZB2218'P%L:
M\BI?Y<8M_D$\6*O J85%N?^%*H<FQ(6.@S_,R7:,P.]V/C6UP2BKFJ6-&9OY
M&@Z.8O5'L?NA=8R1H!0JZ,N49 +P!H.1LH)AV<;\!PCBR $F4<U9EC)L#O_<
M=3QT3=)ZA**C8MFLZK)K96"5I&=K6;H[?M+;1]?8TN:]')Y@*;'03GU+4[\(
M5 !Y*JCHR<]1HP.>]O#AV@82*+&3\)>?G[AEV.Q4GM":C&=8\%T<E]UMPY1V
M/X[KH-YD&Q_#*<]2=5*I,FQ/:0^$%.+PE6\VW(X [" 50:! K ! %L%TRE*K
MA<(_^.+/:\J7;R_$]8'B^M]6=JU\W0[NZ%O=L3(:T\6"3V+&2@>_E";I)[T#
MA6I;2.8"D5DC+@O"R@W?Y+RK]9Y.8##VHP=RA$Z-.';;DQ];3C<"=I>C8^+/
M\EVU,!9+Q.!4.S"C)G!IT]_4&X'NAY*H4NAMR8H1R4BJ])1A!@=X.A+$'=^6
M[:- 8K^#,!0PFF;&&E/< ."AQ1V+ 1N$$>*?%SK^=GH>EB[C/58.EOK?&![>
MN9IZEOH[&WI6[A+$,G7>LB %@&KQDJHY8W_D;,LQ'!6"4Y:U'YE3/R2;$ZJ,
MB#,/6/_\K?/WM_ (6\S=L6W$*8Q@9&[_J&;+'O_#)+D]1=D[/R1C+6)B+#S*
M=[_#\D</ON./6Q(@5@0@ H!LI)N6T*5:.&=N$ 18E;A' L^ZUL\J*[I,)5O]
M86CAQG2PDO_7<)GX,_WX<?SSV69SS,PPUS:;*Y%;CAQM$4+N2HZ:LU6.H9P=
MF_L^BN2HM@B)7)&0W^;.5SD3A:82E1RE4%J__H/WX_5\O%[OQU//*I&^7&;S
M>W_ 0H$F Q"L!J0#CLD@!_.^:50IVJ517-F=.D:M%!DJ_0^P&%#DM1)KM;%J
MG?,U15Y-CG9]O?.PG&5#PEGIU]=_:<K+!$ESHI+.@V5>]<>T9H7H ,(6@.TC
M0V48@!F'4&WY[QB%,HY0YYWV74:$B,<\B;3O2(_3X+:5?J*><J++9K?.<EOT
M6\D+[7D& ER8+4-HEBR3U4UB</'$H2IU6QR/P@=0YRQ_)OZNFVAD$J8':R"+
MP=LDA4C]8ZO]%A ]RO)GOHE@V[KX-XNGA\XVZX08;)^KCY7F[)26@M*#/^LW
MK??^@V8/(!S(T'T<"(X, @S!BL2T(BAND"SD,&;G^\4A76QN)V_D9T(1L<<J
M5T$Z7N@RS$D+L(Q^JYCWN\6 DBA,Y, 8'"$Z]Q&?HI?(/?=R]9K>_>P/3+G.
M9D3B^DA(RO/AE,+5#;]@INT'#Z$?,R2U$H9$A*GDM@81DU :2PKZJ#"<NRGW
M,=AK\)'-MOMYZ7W3G%N_HV"[AM#U)R NP33+4IE\2&F:(43C> S(%0MX3!A1
MKB] M'D)G= SMVGI+LB:\.K<I^\*7B$Z-=W)@ ,94<813>,>D('XU/)KGD\C
MI[6^9PUR>YMCN6GSI3,'"/_;@S"%UY]_'4H]VR R_NS.)>*.NG"IB6(MG?TL
M!5>[T]MC4E8$2O=&)2];)W4?DLT";MMP0 ,R=+<30', @"%48'D@"VJ:E6A8
M#;+K)3^\",94<&YAP">.S!(=H>M)RK_*<C&BS,-Q3S6M-!UC+Z"= 6XI1X1*
MD<FS-%&^^(>N7M45$.S16W(=G//J]'T=3=C]$!^A)!A/2;+9KDPRL\@Q6Q/M
M8$A8:#8D:EAY"C^@_Z?1T&?9%6S?A9W>E;-2$SO3 B4SEJ)-R40/9S*'D1 T
MF^UV\P7^KHR*^P?;:_X#J Q-^H=U$C_)QD91(1LMJ_>A')UC=0DMWGS^U1X?
MK:M]M?OA5@R8A,/L8'?@G+FK+V,H7V)/SMT#-N\%"RU3LN3T?5AQ^9]5'&Z;
M1?!WP1J;$7=]S^&;,TV!1V>,0E!XR"O4[.O6E=>-T(&<6QHG9CVS/8UJQJHM
MK^YZ'"NOS,3V>+;=7+@;*%*D?X:7)*QL"4D2%)7;YT%$,[D)@'=>9)'S([/C
M>^P>#9+"?WR6VGM\.T^SU&9(L3E^>3F_/'6%Z&\1.[[_DK&!#T4=1N9Q85G[
M?.,>]HRK9;F:O?K".R)7*;*@%7#7\<?=5-%2G9-_Z;>&VI#26EXO"C::/CX_
M:;[THL7_@<)#OG=4\TJ$2FFG]=[1/,O-P<1L[J1.<&-/O]P74>,A8R942&O"
M@?5<ADH& *0K1RQF.CRU+'P^?$E*UH#F>Q=/&V0G2WE4AR=+Q7RAV.!CO=C)
MV"BD8II3@OR+>TYQXN]3A" L#E2F+''U=DC) Y28R<.>]ZBO-1HKIOO:OG1G
M5D\3+7/,QB>@:O=14/M:P?_.E8L:34.6REJG[V;BPZ=CD^5/M)X-K'=!"O7F
MFL]2R[.YPYQN'1LEL_?9^MX\#BA(I+%Z4&)DU@1(_A,,"[&[8'-K;%Y\ "FM
M6./;@H^R!P70077Y E*APQ<%O,,W*;:*9CL5]YQZT>4(M!J?=BU1[=59JUNQ
MH6DLJ.RPK7K.ER0(5'U_@XY29EBCH+1Z-4/1_[EN!Z?;7"O8>?BIX'_./9FM
MP[IG_L?_B$F5#VOZ5%0(D2?UB5D,^3N+V/PO3JQ+WT_0%X3+#:X#4&$= '02
M1?_3=6&(%#S"[G+JK0OS^0,%LHH)+OT*T9J^Q]&TPQ0!J8#;LJ^P2;MUT[<N
M=K(APH+&+*A,-T\$<W&%G9PHI"S#?+UO WCO%=838C#[0(R/K0ZO[^].H?OK
ME,\U*/3>%?GS^59F'?VGY(!\6"NX61B,- M 6VPZ^X\U=/T::NCWSN,P! R>
M9S$AZ,<Q?E XD1/>*Z##$8OFS\LBKD7K#)3A#8)H_Z*,8[%3Y8-FCPE@G6V?
M!F&C?"@VI$R5NX_'PM06E@!%05(F96IO%2YD]<E DI JC756VH^:@=S7]5PQ
M18839)%96UIDD?F _9@$_WH'49I);P$&3FT\S\\,B>@--RT-F:XJ'84^\Q^]
M;]3BX9^9LE_%VPVZ;8,#(>C1@X/B+  F P#&SJCHO"RMDNLV%L[Y*=BTAP@-
M-/[3E<D$^4=:)_2%K^7%,1+ETYP%5 "* !K-$$)G1W=I#)A_%$\1M&7%(&/^
M/7MBHLPE#;@>_122NMZYY!.6RFN__;V!:*42FIM^Y-*IU].NVN;YT,OT-_Q^
MQM1&_:$-KNAYYT3IYV2XONT]4<\8$&'PO2%5ENHG88^#J-\PSCX[3 0&(6:V
MRF*Q#?ZY<<,#'PV A.+&56N3:5YV4*_&RP\T(WU34/C<F4-H!P;DOYFY U/L
M'.F[B='::1ZPC-3B]T\XJ>8K;*3S?4N5 P@["NPNVN6)E8H?&[_44"0YXXO:
M3"^7G]UV^]]R4)IF.U=4]-<[CZE1N-9-HMM-$QQ4*ZH-PAF["EU&&N"7C/N%
M>& *(]6TZXB8V;MPPO;-5#4'!B#LSH(0U;A"M"#]TD7A$_O(V:;V,1#T<N0U
M26- L(GQ+*):*89:#5'JIA8+*K- A >'#U,$0%0:1T"J;EG$>SW!/;2@7%Y%
M9:])3>^N5>/!\)E[VD_&M$,FOZ+3/1,]'K'@1L$4N!(GJ]+5 Z!%!96DR7,,
M1,=EP>U<8-<? *Q8J'N5EOB]UQ!F"6=RK[#\X7LK@ U50+]N7#A(&\H4:/6$
M2'350K!D,M0!G6(=,*ZPK+-,D5]@IAUBN=U6Q$THHR'B9<1RF9;ETX& A_MQ
M@X8DT;/(6==Z>F]RR *]U,C5,R>8EBB5?.ZL_-#=%+V"/E&]=7(O(4K7^8=[
M-815N=_TN]M?*30H!I AQ\-SW;)3\%LTA/L:Z=C566*RA\HI@29A?9$&B;:^
MES4>_+/WG'BN#(B.C)72T$)N?!I;^%@#1$E.-P%&58=<#.3XJ(R"3TMX]5?^
M?(EUVQGC/#0J''DC9MSMBVIM[&GLW%3Y_:C1U7+[WLU+2I6B5E19!"V#"!%D
M[+]\SM/YHG6U68LJ>%6X!LQCL%99 VYO2+F\YTJ$W>74@[8N$#N]+:!K_T;8
MGE%'B;;F!SJE'%"1-^LP[X]7KNZ6>NB%DD$3[\Z9 P-:E;)"22<Z57D/8D=*
M S@)!>510R,F/$P.W5V\:784KO-WL:AI](RH+IJ)V-=\_P6,6BUTN_*L^)(;
MU"ZFA)Y5!DH2&:8UB;@-SGOS=US?ZAO7%;8:>H72^-$OI=WT1M$JH::Y_[U;
M="37:7NG"EHXS^%ZR,"=7H?^VAV?M'<M4-5U@].%P1Z;5]S+*VL#O58,I/=6
MB35Q+IPFHL!4RUJFB*X.!:$CR3PJ2@0$B,U.(K6-!E7%8+ U#A3- _A"1+ \
M#6'\7KR31VDA_!B,//B+G>LXRX'9*Q'4]O# VE:)L4&5+V$]+%3<+!0NO\U!
MU-+G+@2 P,UTLI7$*&F1_M&U;)5S:J_<9^=H=W@(\YL);0RUU_2G_&Y$WRS<
M*L,EJ5O4FTX1Y"!!Y$7:,$)+$(H:/C^"-'V..1[R3NYQL'B:9=E&FB'AAZ!8
MT1?LFV7B),DVG)^FLSPK=BJ&"SO H-TD20>ME)&%XB)R=6+(8'ZKEM(0"0+@
M 'U4V_ ""GGTUI4(B+3PFN#/N 2EJQ=X<B_9*!=1E.>@0-="S)N>TV,9G;7E
M4JF<!!&ZCZR@,94S4J!3?+5&5Z_CR;#%_AV:Q(!QX!XJX)'WT]S@TE+\X"7"
M):U4SP$3N7OM[PGO/*Z-4NC@$8P1Q$]PGGAS==76:T$\GP@"2'IQVMD:RQ+F
MQ^C[5]9(8B<[J6\U?"F>\S_[O^'>3O<;T3:RP\HL<8WT*QH!XADNTRIHS^76
M?A.6\[#:FZH 5&SU1UI><,[5YP?OR?P=O1,,B>&@-YVW:+>%=_A#(XF$'XQ>
M*0Z07KZW!?>)./#1C0M#']VT(V]FA$*"6/AM7WE#SIPDZ]/M4%Q%*( C/\1F
MK"&7=L?3Z!_/I42%P0X18;V.DZ<X*Z<X!;?W[+CG85N96)XJ-H"D?9STZ\9]
MJ!D'JOZ^$D,-MT.Y0P  PN,( [O\U%T,:W=<6TB4!<( >/^17$YZV6=?PLJ:
M\+H81M&7-4["*_J*/,[#MW)N]68L9Z!@K4R%*1 N2?XQ-=I.8./, "L,$<2J
M@_"LGS*<:D-G_=6C6U'U9_N_P QK8('D<D<=.(TD[HO>\?/%EH5)56C_D@L:
M-.,=TGH/8%C/4YXC#O)A@HD-1+A:J6'_/W_Q(Q\6*GP.PCG0*2Z!QR1H!7^+
MT!A9)8G8<H2_:>,OV> 5V=(#;.DYDGPP0J"?_D"9+# *$B8;0#P=6OM 7(X+
M F24K#I$AWYU> 3XMMXQGO9%)WF+G'?7;KW .1TM[H*E.F-'Q^3'7?!'?(NU
MDJ!:O9]Q5,3>C]-(Q>F/U1*)SM7]3B!NCX2&ZA^XWA\9,?@JD[ O>&X=.;("
M8H)7A%'"F-=<A0I[?#]79/\GN%^*@/*G)#(9N4+!VS)DY^K !5&YV!#_Y5$Y
MW?4.VWP& 0%V:5P-5?=;5^_<_#P80(4+NZ1/ZJK-N6!I()9OYRNR[O@^95A.
MGCQ3G>X/&='_./CJ@+A@5;A_QE"X 7RF "VUU/#'L!9?64?@<;$JW]KE%@B;
M%(5="GZ<I/36%;]OX4)HLDR+L, HES#$%K8@_YBOTZYCB2/9X!5G0"MY[6$C
M6YCFGY2M:A3H-CXH=O';UO!JK*.SVAEGO/\_>!508^+:/J@^BNJ7,<HPM.Y.
M>OZA<PU1I5MZ(T15I$ECJ0$4),,&?867P)2$/00,NUU9M&/05_,'!;_I=%VR
M&AO*RZ/U)FGQ1':YA":F]M_Q3X8\858X#"#[KZ#='FYT\)>N0L@:_V6IXK_K
M_FD8'!2!HS9B)S<D[4A\J8 %^8 %I"-C*\7AMW7S5;D!AE6XPE+:,#(XIW)#
M78@\\\M&",$A[IQ!"0 B$1(IA$?[E$0''GX1EP/QKYG7Y4B8?C8N!VX23DP*
MZK_EP9",.(]7_J;]X(NP+0\JP^XG*T=H'>98-;,S\H89*WY#D433@(FH>NB!
M[$['=7@ 2]*9I/88E#A%A%E(&*R%@#'KTX-A_H())78/_7^&DWTF_(355*^/
MDL7(((8,F)&Q%?\IAOPG[WGAT,DU<1FP8_Z1^#Y)#,O^0!P<04L2H+.PJUP%
M:]+AR_KSM3PLB23B$&K:4L]N<]=H&=<W\!?,/N<6Y Y1;X22.1/]_$9)*U]L
M "@9G#VXVBP6DEM5<6&WX=INY>3!)36-(XW'.B(,S /]9$8$?KD;?24AW3>%
M97PQBMRCGWA'&^W_MNO@/7UM@I*,+K&PG[D*W<3YZ<UV&8JB/!-)((.2:ZY8
M=:_H=3^_<7<ALB5<#T1348\?#*C_>%O2(W"([?:8-_7MW!916/]0)G<(>>SK
M2Z]&O=,M]ZO'1\(A:=DZ*=G6$ZB%%?2O%:MZZJ&]!>)Q^8[,%NG'#2+/N!BU
MY8N7>+AM-KX)0"*%!XQO^,J#TO),6&_!U>T7>D.%WATOO8P.5T%LO9^U>/=]
MA6L7=DZ.P>G/?:+KBP^=%\Q<=U][N9_?C#EFTT@>TV9L_Z )1)W5U07?C<)6
M?/\U7V&3-[>>*\[AG9!?P+?13S0V2'./XQ]Q/1)8"(MNQ"A388A[P!0K+0MB
M?HF=ER>)&!(7?Z'=2EP#'[N;_>]'L0QUX^/Z_#(:$CH*W;2#6;$P-]P[HX[_
MU'OO&Y6A6U7@G_#SU,LUP9V7GB[Y5^%1!H'[00('/ 0J;#-QGIO8MU,1+'%,
M6X.T M-QSX*X,N5O/Q<3!T3U4I%\KH(<B)PB(6MUSO_/$$\$.Y89L(RAR'CD
M6VS&58]"%R'&>UH$Y<QUE#R#+O(*RM>$]6JLZ2@;A(F5]KI%:!C13AB6]A_S
MWEGB^V6<\WXS&"E_#G7]*&A%?+QL./YM[8_9!4LN5F0/*4H%#+:A(!.H@A'1
MTIL@P?@X'KYP3I[D]P0K=Z\?2A;H_ZAN$#)Y[+=^W'>=@S,TPU(]/YU[KA0
MQKRP]? %>"  B*IA& <=<Y*B/:LW&*@_#2[[34:C)EZY^;V,+/T9AN"!*"[:
MN4F80\0X"A *,AP[Z!Y/UL5//9;>\]/(C.WQFHE[:(_G2W:T.^.G%_#+)'R<
M--*6%:X3_K#6Z$J^H:I3BZ6ZJEAA]F?R=ESC"8*3\:N D>P_"## ^-COF-/G
MMVG7L4$#+7E]+R]?OOGY0YLE>0N.Y\Q=N,B:!'-O\&5$'H]J/J%CB,P32A3Y
M VR)FU1I6ZY3<PR>0[64A42J+>&'0"2?*((;8/]:GV\=(8R%G18? -&(DFNB
M$M^GXFP\XI^B+#](1:326SKW'U-(I1W6/?NRGBPRF2<RXQ:EDU]J&$39 HG%
M*(^B^XZ'2>F1ED]NW._,BVETEDS@87O)V%5?-(>*H66A#$P*[:UST]SPR 4P
MH3_A]WJEV;0?3##<(#E9VF"F)I^]K!.O71%#+%(]\I SM)4+[B2#1%I3!*K<
MY+)F2MZ#G<NE4ZEXXHPM\/>7V'4AN[(/H)+FCKO>P$45"LYX 6L!X@>9_B1?
MN_E67#_E_H=_R]_W+/K=.2#H>D=H4\E?J3\YV9QKV7$B _.*-7037OC<-%O4
MJ:5_)#FWSCUU*K=JH_KO -FD/4]WK.3@Z\@E9[!, S-/N3]=PN*QJQ87-/-C
M"O?NP2A3,/U,R;0DG$.Q[QH;)^=;59P1H97U?9"+OK#2<F-=QYS!EJO)SFDU
MF-M.C&YHLHSIL):Q[7,HL744]#$N3:F35%AJWA/G[RD1>;&-)2I[W/1U[9).
MOCQ5ZA5(<*UH/;I8X9O?>K'Q/E4\,J[0TI0B^9H=+;V 7V7B"![WW4T>^]+D
MIT@BPHHSJ]EKM)E(L8)=)+'BX#1+EO$Y%!.OH?O(^#=[ LFP_LUG'\E_E'PC
MXJ RK2LR[]Z.7[\GU;RMI;2)W$-.U]YW[[HQR3>\\*I+W2=29#_[AS%%<M87
M50N(K#%C)BCI3O>JWOO.?0;O-/- C&1_V=3G@)%VS4K)#@.Q_TE*_)V:3W@"
MK=V\.3',_K(_)T]VQLI+P^NE^\$D%;$9\NFH$M\;M1+%D6( 8)'2BNB\7V <
M,_6UVU,N"^%-F%]X>((M.<]$?1MI6SO9ZMCWOR\CBT,4,;5M,*(>\BF/;69L
MEUM74CQ5)"^LGU ,=1#)L;TX75M@;_G[QKW-2V?+@,J-XD7IVF@9B4]OVM]4
METN0'6R8_#C/LLF0:Y?CA!=]"_7/<$SXDIAV"J'!$&,\@I=<)A@XC7UB?_O,
MQB.9"0C66?P3,7,<BW)):&9YI'2JEQO?4BN9LVF\865J:#_VXKR'9'.DM\@D
M^<13M]["@9%+!K*Q )7!/Q4^-^_YCXQ1-BY+X0]>^6F '%.\GUT5*))K#2W#
M1O#?+8SU2DIH.-,/3PS?VB)HJ.9<Q5\Y$]81V@"M<?^"&F"7?Z+;ZC+\)F(G
M@OM36[UFVN[V'2LUCBZ)ESG^W).ZM![V/=NAA;GOBQCVSF<IB2;"W:DJ3<([
M>V6%C&@<CTUH\GG-.9)[X.FW=2:.2J0LY;4K\9JUQ)OR?T[?H(=/_2GR::)+
M5 '8I=-\L26 WD7\*_5V[=9IJ-XK?>O^C=V6@KIJ*I9ULF-@!.>7E1'NQUMX
M4/=ZT_;# TV%E851;<*[#4K63EK/((ET+Z1L%33ZRB7L,C:F"5[RY(>$^/L^
M9N&L"^&U.Y6_UN$G=D]?S.@Z\>=5AY[&WQ^QND81K7K^ )_V<F[52W[T<INE
MGWP/B2>USGZ]0E)0.S43WTY87_CV@(#54-C\3L+CV '?D(37(+;J.=[PH()Z
M_043<O77]5!\?%=^7%_IC<B_NZIK1]?6Q/^HPNU.^AP7:CJ]/R9P3(S6W'QY
M(LR;^;;\;?0&[T1'IB9\2$CA&[?LT-_/B]R)[R2%=VS"9R?^;IVFPJSO^8Z#
MKU]TS?1]DM*\2EAA$QROC#Y["?'J.MU<DBW'VYG!KXD4^0%^9! &1^%T.!Q6
M=S)<U-C F0%04@60Z(;E=47K3-@!#!I@D!-@,/$\!SH 6B8+B,@Y#!)5$Q&0
M YP')T9.6\1OK[SLV*-->WII9[FOW"B,X!BW&=IUOC?TE-E]F\O\),0:P3'>
M^VN@;!Z'G"#H_\R:1B>N4& P$:L+:5/L0X\0HX8T-"D!(097Q:C1J5Q(HLAR
M96 QQJ\O54K<>W/;F-N7=O5@BL.^QZRAQ#)3!=M!$]7N8CAA_=,SIZ47<9L)
M>BT9;N=<HBD;]\\7Y!!>\.,]OX3?BM9^L%KQ9SO;3H?,G.Z,6\NY='-,:;;W
MMG3.T09I7R\.4TJUH?2&UH6T]SU1!ND;C5Z/%00$T3MYS9Y/).3UR,MY%,C8
M'40:K:CDX!_) <_S:SQW,0L!]9<E9D;W>FP/?-ON?V/N<T1JUN7(1D^N,8$1
MZ Q!ZT2?L$P_UCIMJ_[D@VN,TF)?$>V+N.KT(1I[<C1F]&S!;7^_NJ4;\3
M(%^R=IQTS43,I8Y?^=UGP '8Z_XC9C\W)ZXG;,[Z2YX7U'I98OJ#W#UHO+K\
MTRWL6'^/UW&?'Y&Y(E2I#YRTV,*;2K%7?P1ZV&ND+S,0XF85U[RTA(*D?421
M4=-\RONG?4J7<$>P%3:K]WJ+\P]XGLBC;:47,@"MX8D1,ZOPM-P;6\,]DT7V
MSWH<S?(8XNEF7JN5QPIK!99>F&U7?"P$KLGR.!ZHLD6<O]3^XVB[C=@I3B::
MS/KD1WH7$Y(M\LGXFO7\@4G-^ *F\OV<").:BC-;YLXG0&1UMYC%#@M;[W3D
M:)O4B?8YRQ?F^:/G--SJ2,O77;ZV23A9\+=[G(B17;9W(U4;[WEDJ)S[[ -%
M3>[L:S>\>T\S!BF>H9R;$>B^$0\(4D.OC7S<@W7XE9XR"NC,7E=WPO5[.;G"
M?D^\O'$R7_;(^?9_U"V,302=S,QF)A92L2KTE<:8P__Q,8<_- K.M;Y=D (I
M;^3:,>6*N<$/8S,/5]TDK_JD! 2]G]DZZ:"='?460'5>^UQOZG8RT-4G_,?$
MC:V\XA>FD('WZ@D>)V^J']Q* Z9LJ6\7<>U#MTV-,N%GD<R6B_B $-B=S.";
MT2=3]_^P%6K8<]9&_&E(4V5Q7<7H<+FY#D/:?,;2_:WYWD7Y!0%Y"\<D!]UY
MXX3OL,#%SN]4%V7O@?GT\N;0EHM:08O)J=+7:+DYKH^4+F[MM#P\B'A(%N@,
MI=E Z9/Y\9J1CG-W;E'V0LS<,1=K%L3%*#;GG95Q+H^FU.IBNTSL-EP7D]68
M&I")[K+H1S]KVV;7SHLNW_9Y$<UO;_=>TMIOY^XY)8V5#%)._J[/('L; ^"C
M=5(M=,'^5!,C2;*2).X!6*%&X9QG#\),QZ2^KX0;Q'"$,6L-A>/807+_#NQ<
M!=%>>"^M"M.7?/&RB<.CME9,]F&6^5H^W@:^+I-Q6&A?SOUAFP\VP*(:&8@L
M\P=G$P=DND25K13'XS$Z UL\%]O 6H5_I@T<^B@._#-@"X?]]>Y[LRFV_G9T
MGB[*-LLR/-M2 C0_*78EJ0<*"%9$=D%MTW'7<H2W!W$*Y0.%0DWFH4?("#(U
M ?UA'-9I0$&$SMB?R@"*5&4J=3+W.J!G(VXJMBUJF_+L3_/U8),K9$$K=(+3
M&3NWXBY)KA9;]OFI#!Z,.[FXO_Y3-BBZ',;Y-E#_R[HMKO,]_DS)B4YCV/ZH
M")4(W#<;+%UHF J7@#V',?4*/QT]E4 N4N4%&<4+)3  P/3_4$L#!!0    (
M  V%KU8PJV*O_UH  %);   -    8V]G;U\P,#8V+F=I9A27>3P3_A_'9W;9
M''/?S#WWB**4S14Y<N<V]QQICB14V]CF;@DA":$E-&=R-;=<K5(AU0C)%;IT
M^?[Z??YZ/SZ/]^/Q?G[>[_?K\7F_3]K9F)@&-0-8@!\ @+"HE)2\"ES.0%X9
M+:%AJJRNHZ:IAT;KJ&L;:.D::>F:ZF".Z!J::AB8&A@?,S8Y?EA7ST!&TOF0
M7J3I(3L%F3.6QR*LCR:>/';X&.[H"2N3(R=UC]A+&CC8';<^:VYEAK,Y86EG
M;&%_Q,;KL$.PA;7#25N',[:VM@YNCJ[>GIX^G@YN%\[8A?GX)ONYQ3I:)P=[
M>_F&V'D2P@."?8.C?".3W&-2_&-2SD2<]XJ[;!^13 B+2(J,Q)^[%!&=$!QW
M.2;^8O+YY OGXK+/.-'#O6Y$>I?&^V=&N-5&^]U-\*?%A)<F1="2+UQ+C&$F
M1W2D1#XX'U/G%SB4%E>2?I%)B>G,B+Y'N]"9>:&[(+61<7F8?G8D^\+D]=31
MZQ=?EJ0^STV>*3_OEYCNFY3IE9H?=CX],BD]ZB(U)"DW-"TG.BTG+)E^/HT:
MFG(]*N5Z6$I95-K-D N%<:D%D9>J:)?) >G%8>2\Z/3\*!(]@9*?FIX=EGX]
M)N-Z='913,;-F)R;8?2R1.KUA*SBQ)R;*;GEY^DEB06W+EZ_'5MP*R:O*I)6
MG9A[YV)^34).;50A,_'ZG93K-:GE]Y-O,*/+6Y/+6U.K&F/N=%VL?128=R>F
M?NC"_:&+;9,7NV;.MG-2[TVG#+Z)'7R;]F3E,F<SDTHOSJ+?*"K)S2_NR$V_
M5Y#969QYM^3&HYM%S)R,KIJRICMEU+)[>;<:J76=!7=;F$QF)[/N?EMG2TM;
MX\WJL1+:BYOI+TMIXT6YXU6Y<W>R1^M*YNX5+S27?;B;O7R_<+6M;+>E9.1^
M[9.V>\_;&M>Z:C<Z[_;?K-[JO[\[V#@UT$.]/T1O'\_L?GV]=[:T9?3NP]$'
MW>.9/>_H@PO7!]_>&'F3RW[Z:/A)Y^CKQM'9])&EC/&5G(F5C*GU[.GUW,&E
MHB<KQ1.?RJ8V;HPM9S[?*G^^F?-RCS;SI>+E;M;3G>KG6]4O]^[,?6V>7AV?
M?O'D]:<7"UNOWWQ\\6YW]/7F_-+VF^4OKY>_3B]]75[_MK[U?77CQ^;NS\WM
M+Y]>S0P^9BO]! '^?Y3^0]B=#8H(<PR*B R)%H@(.GLVZ#A&S\C8R-@8H/-_
MC_\+!@ [ (#YY#)..N/,2#LHL:_0Q=NT9)D3[E\P2[?,+^B%IR4+A]A@90YE
M][B=%"H_2EA?P"5 IT^9$#BS=M*B O*E!A&K#4]$(Z:,S)\5*JDDHDL-;2=J
M3%.,\FY5A3!^L0:-'%UK/%\0Y ?;-Z04C;IH A/G-Z4P(9/Q6_U%A>R'% @?
MT C&L.H65O14+3FC:DM7.0+I"SE98W]<Q7M<M3PNPL$X6]9RV[O5P6'"H#U*
M-V1DTOF.Y3-&\]$N!W=%S^8ZI^RC>4**8<Z#VZ=&-N;;@N-N].8=VY0]25S1
M4AU#*N.RA,4/R.G-U2=S+XK^^F92TKPXD'>H_AG?S^GO3Z(Z#E0\TML(KE].
MZ>HW.M;U_JXCC!0ZE:5,KC/W0K3;/_L<E&#\>E_Y>H>NK(H+F!6^3%=N9!1D
MHF)[P6,95V;"7BOR&9RY9BUO-[-H.^,A.1LL/=4FXI0T.?368;F47A&V=;QV
MQO-4+[TPU3[.V,?-98HN[NGG_;)(GGGK99%0X%M/E$"4 1_D>G?>+B1=> !L
MZP?[>SXH(!ESXP9=8;'9)4'YXO+S4^1[JJY!!HTU+T(*O8L+Y<W]C,NBDPJ>
ME1*V2Y\%7#UX>?A#WJ?:(V5I++L5'YF .8P-I<LZ4J+0S'U\L*8&O8?RBY,>
M<K8(C->L"U!<#ZO/9':IOBA-FKE6[7A@\/:KUNEXY6^%S@1"<<5MFV^?[J;6
MK71^B' 4EO:(29O_4>31$@>&^)BX9_L*.2O82E"**'&1/D;HI;/:V<3Y3QF\
M=J'U\4^I8LKUK^[]@@;+/*H7#<I_Y@,)-7=H?RL4NL_X+'3ZTK#8[<^]=,7+
MEHMV\RY4A3\^K,:Y$5YIAN#8<H&?Z;RLP&F*=N9H(U'KM5^B@9&M97I-S/JX
M;IS5VRZ5ZEVHC,;+1:TR,V,:Y&)4,GU$2)EG4CE(\U31W8KMO,72"!<#N PC
M)%/"^$Q=^YD01NO<*W%?B=O@E?80[Z.U#P75J\>4%_/3:K'B9=%(G,:YY!8;
MO5KMDC+E>T:M!P[)J?23J8O@)@@23JVV069\$%9 F@-X,N2OFC<EWPK[@Q2-
MN>*3!XEA^JN%>FZ:3A'.GKJ^O4GV4QMK]XFHHDH(Y!_U_D3AZA7<4_:@V>\I
M)NP&+!*U1]^6)\C$N:_BSQ,+>TH2YX4KY*)TJB *^3\X@T+FH&?)Z,P-P"#_
MT8P'@]]RW0[.K6Q.W7A9;3M_]W;^SHM5Q3/AA%M''_)2>'BE#"O;S2FP)8GK
M[!7=<VK!PA3G(=2 >*:V_ST]\9:<N_,0W$="IH.\<"Y$WT*8RN6)-V<%",E!
M,S[I*HEA891]SS&*1!T)C+$E\P=5\@[Q;-+.C[^^O7ZGT,I@_-*!=<'M*PXJ
MM\TC!5S%;XKQ^[Q^;#")YS_,D9CE>&);J!LX%835PEJ!H5F-0]B R]RXGV=/
M/]Z*>$WV]GY*Y?%177+&@F^5H&LE\&@? WRA$+<O<P%J!G/4JM&>.I/[G44?
M'M'>2K_]:?,'LUUU3(>P.'[ QJ3G^&_:N2GCQ46E),&"%CEB2TM8N#)2/]LE
M>378"8*;.6F,?P!=Y'TO2"%UHE@NJ6WN57+#/X!F+5BPN#,/8N1&I]!EC'7Q
M[_Z4>5Y9F\6LA.9^497> 065\VJX-RF%;01 NEI%&.3!&ZE1 B?;A-N4O1C,
MQ2Y3JJZ3FRF:=^S?C)B,(.)JXEX=( +A7TU.^(_CH8O7R?QIWI8HP,R-Y 82
MOPN#(L\VA%55NOV$G3%5#)V.E)"ON6Q"?_3K6GZF[3U%%=VB8GL/+9WPY%<"
MY3 G^Q.?@M\;?MSJ4<N$@I7U H<8_NI6-RHHPDAR)LJ?UFI=U-^O=F), P$J
M \K78(J!EWC,SW,&)-;Q4-T%LN>],B"U#W.;>Q,'#T>]DOY#,N.[_E3HO+OI
MA!(UOO>4SZ^#(6/[72[T:H_$P0C+*K]]IJ#XJZ><C\MTZ_!*W>W)>\=%+5KX
M7EJ'[>7J?&;O-^EU%>3]*EQT/U\Y*L]?"&ZM65GTDNJ3[\%"]9.K^&@7/:1+
M*H%JZ ,R7_!-R@B?6J!S_]67P=>9LU^?X%_ZJ1ZN'9:(XB'J&+"G GF..27"
ME[/A,\%FWUI>./\JO$OB\E(54@WI>()0,FQ8R&MB+HB6=-^C<=W\!BK;1:JI
M6,=/%Y'"Y]/0 NA0<R9<MN?,B"F)VH$1++\7&N8JJR/\H2\%$B0GN;%5;FZ1
MHE:H7T1#^.ZB?TIR9HBV$>SX'_>[TA)1DN+!=%/!0S2PFA)V4#)#C>,J6(4:
M1MLH07V."E;Z.)Z+?@"?E/0D@=IT^Z%.[*51[^DH8 ?Z,<@/W_0$&_V-MT%:
M9H$+/:<5EF5;FO0?&WH\^:=2X'?#TX?*@[J)/Y3.E^8<H%!04/WT&9KQ9*W>
M!4"&VEC52)+$\*T5/,?G._=V;-.ZSFVM/K&QXBH=+$_UZ$<S&M_^LWYQY;_E
M7H_5IK&0</97"A@V*^75DO3P_CUE(&Z]O."G/_.RI/]7XF*77_)+$H?W]/E3
MP2,N1?=UB M"<NLC:OME?/8 YBV/?=X3KW_F:?@!/1Q1@1(@W/VGX62^;9/)
MF6D#L#[!: 5UZQ'E$SKRBZ4\Y3V;*Y5<=O,CC0=_3VI]<+R6G-;)DG50CG:_
M7391G]].#[GU=KQ@Z;WK/AX)*0L>5=(3<YU-$)&HL'\Z3BI.6OTB6""?C;=_
M4U]^*_E6+1:.4BUKUTZ*XAZ4["F8B^\^([<(>/?8O6*5=[\H3C/%][;#M-0Y
MUS415IG>?Z&'U_H_!A27WAA,BS*\\DB<1;1&[Z# FI68.-4A!=U4%J^AZN*T
M;M+NT.=RBV/=LZ]]P,>PIWTM U72Q!I8O-'>>'IF\3X4KB3E0BH2LW5S6^F^
MJ'E74B=!IB=-N"QMV['5#'8B,7G-YH<A1]@\\=*A &03:?CQR46<\1B/T$CQ
M(>3WR8NF^T>7\.?B\HZ_H4B$%K7KPRQ>O$6#41E 1.-[LCP<FK'A>%J B.9U
M^)-86K/\CM\ 5U:1/59TQ.PB?]F[*1--NQ6PN<FM#"&KGEZS<R,;5:IJ+G^6
MI _^0WI9A8S<(1R%MT(QFK,F8@;JPQ67>HG??_^:W3C2Z.DX09&H"8!7$[K$
M"K@C7D/*8BVO$S-(EV.64Q9Y1&-($#Y;[9/BHH^@T%  &4G ^'PQ/D3"ITHF
M3-^%I5NKQ6&3XPPN77&^]$HR,7,4,G<D,8D%;:P4F 4@FK$7UQX&?VSG=3IB
MDM1!_/(0Q"X&)=$N;]5&C-=Y('X ]5F\=DCX8H3S[[L>7LCT2Q"0*P:>@8>"
MF2:"3!+"]A!A!R+"3#U7F7I2G,PC$>O'XV1?8^X0[#=UTHE?V<NH*,S'Z%+
MJS#5L>2+Q$LIA$.6T(!6AL L$D%E7+8D./>*^1QDAD#YZ!'LCHCJG<QJ$KR
M *]&QK2*Q9PHN?+KX157%N@4"NP%2-6PLL@@@3,8Q-R$5+XQ"!\,VF![2)@
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ME[4?D5_/RG(C@1L J=6P[ Q.?C,G[L.AX["Q;+Z+[G"^8B*7>@Z5$X FA^Y
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MOCG'[Y^T'ZW+/EU/Y5\[]@Y]K.]G3$MV:N.&_]:0,W_[8_[/*"%2B0" 9T-
MBH(/%@.)0G)+,>%21XV^J%</'1'1:+K86C=EDR__H2U+%.IB6Y#C8^>J:E>K
M;)WCTQ7Z")TO9Z<D^=9/;,WYMO4EP;]^0[9KVC&MP?)AP^L3A;7NY9?)\&]G
M;N@];H C:,:EF+#Q C#O;V.OEM"1D<O&LI,W'OB???/N^<OA1CW_P+4]&9L&
M+X/@H>(@W^].F,,QUS>7V==,#.3E@F3HTJ+JCF68('1?T/6XO%+CZ*'D@U>S
MUSZ<+*@]VY689;@2]9+YP;9 ]&2=PPERXO?^OVX?E2P;PZ5KK74B_>^ZETC\
M9]%>_S+0NU5] W[\Z"PK[&F]/X)_=D&_FVNQ4KTAYN_?\W7[FSW_3>Z%# %M
MS]S9N+ GP3(6B5*KN=(&,4/E07<./9U?<VC+<SBTI6HMYI>G9N<\J*EJM8]5
MU;!*:V%=Q4K\S!)^GY]-+?)([ ^&B^99ZIDRDYJSNYHSKC7=_Y0FK:V[GL(S
M<D/NRI,XR8[$.:I9M\TF53+PU_J&OL]!U /,,:Z]0Z[<FFWFB4/?4V'5N;,F
M'UJGI[U"!($XY2]W#.T+!(0+?0PBIR#>*7QW<?N5!UN,^;2CH&NWDM:W'GH1
M[. Y(G>QU1RQ"S^7)"7(]_*U6\8*7*37%=J?Z6XME"%L]SREKTE^83@4V W
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M=XH[06HZ.+Y3@+Z#(6K4 ?5Y""-297F;T3/&BWV">#0Y8::!,(T#0(FP1Q$
M:$0E+2(9*$D":K 4Y9DD"(D4'DU"8HVN^))CTTE0)FD% 7ASGZ0TUHM(QDC
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MY[38*=?=_WP,)* 8^5FR]G4]\3=D^;0XI!3.X):K],D;RYM O:\#'IL6'G^
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M2<Y<U2VGZ!921+B9PD-%4@^,%]9AHF-DG9Y!,[:E- @+P& A>#;?/L#D8Z+
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M5+VJXY_R1HEZQSR@(N+)D08WC>W.F/7K><$C'\XD?DG/2 8N2*A[Y;#)#$@
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MI0TVN#H&'Z\'-^("+)IA0:/:IQ[6LX$M6ZD]LEHH0>?0$F0XE2Q0*99)Z%6
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MV#'D@UP<6^--/MGB]Z-0@.G_ %!+ P04    "  -A:]6#W8\=&=>   U7P
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M:!/R@)Y7_T$EF)GBE+S"(($3*+?[IIQ2G]HVA5-O*+YG1<@("IP*Y->ZP8@
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M1F=BQ6KT<TVVNU*PHIE>&7YM@<%"T"@G$?()PD:,NO4<:<%,VCZK0,FW-[:
M5)?4CX7+GM_I7/@N"GT5;:S:69<B65VS+/=J/%7E[]4X.OE,WLICJCHM,EG1
M=6][28S/=C-DG=<=2VTT#*208#!$$@VS*A;"@X-;VA)G+D?=?%43%I9\K)J7
MB,5[1DSZ?!GY'%.37NTN?Y%3A"!MD.!(:U(?13Y*(F1U(P16'9CDG<PTO[W:
MJ7$E%$SEE;/9&O+#]44&/OO//]);?*)SPJZ_567WFD;!<W],RVCM5=BG31<\
MM$P/*3*8%D@EJW1&'QN! Q@K %GS6E +*F#0X0+.;)#G*A&YSH4$910H!7M]
M;PM^SUS6-ZW=7NA>?5$Q R=KH"FTA:=<-E% J[>10?#LE3N-Q2J!8<M%6OY,
M$W/#N@W#^OS7%9YGQM5+O=0SS77WI+;?7E;5?5*'C:3WC#[\8>"><?#BQYW3
M(4&[ZK+KU99WWA'^WGF/]>L9=?6#D'/"1=F,*V7>C]%=5"AE.);9?J<T*X6$
MQ"*-6^/PH6L^69?%6H D=*K8P[*(59Z$T'X.P5"],GO&2T]@ ND%1O14A$5Q
MS4>ZD*V?-(8PIK(2]%P+@QI<-7%RS]W::E0F$_;J1&>=.G=O5NH$13?]VXI;
M(Z)0 *UOW[NUS_L>)E?!K3K.T'KD&8B#[MUS)#&Y(KB68A_:S*$1ZR94P_G0
MV1@J@# 0]2FOB=#!&UN5=TZYAQW4:_^OTT4N-VJPBSA5W&\:)^/"A$!% ':/
M(89O; 8QM=6;FR;*D<Z41JP_B<?<VZ>P(2AR*"RZANYT/:"4_)QK[B*-/\Q5
M77<):I2WHAQ5DF-HUHT6I[!QWDFQV(!F'0!DL SO.,OD,'=IOY:(W35KA0@3
M$@N4YP%8.AY4(/2K_^$7AZZM'%]\6VH*)GEZZNG('1'&K6PPBG]\7,;*"OC@
M1J"I>IF(XD[5P&2(.8H-;Q'.5)9>N(B[)->(/41S-QA=)K7'3IQ4G+HO??JI
MU?&PXBJGCM#%PEZWAJN/Z7^_A&Y.BZ^7F5E53 UC2WLQ8 A V&R@!&'/BPOM
M"/V$_#R.7/XD1T%,PCAOL+!;""PT'0*EA339<DK1_8D5I:Y>]_T+YTO=@'[9
MH[4<8C^ :F-K2\63!C1')KFX_XT#AJJ'"9Q\*#>X!:1:*.#6PD'K,\#^$["G
MGT8(I=GC'/7@^!CG)SD2NJIYMFY^Z5-/\4S)3M%8P.];9_\IGW+43:]R/:&!
M-/(/0*DMDD[GV[]EAA&09M.PVO@U%GW=ILAN$A:?G>=*+(=86-(RQC.I7VU#
MB&LZ6&!Z@LG5VB"AR4 L*.-%0US2&R41^C#;UMI"9T8[^B%2A-K_M)\?C:WS
M!T"0!X780.:XSM51K#O 4>TQDYV ,B];=11;/YZQ*LN?T'W<I-D(H"AIEM]W
M_4T)*LHWPZ7EK>"M"6]WF.,!1 ?_2D[Q.=EL0H$M[PJAA#RH)2'$8L<:CP4(
MQ6H8N6-1WXKMNL(0.E^$D7J^P@L(DA @\^+07OS32EZT0=XUEF0N^B+& '!&
M6#/8\G/EB!]W#'&APAU'<%PIF%7HY\$^!]6>,9VGO5Y6?Q!S 0^WGT\:>[JY
MZ_.#WYH^3;LTA^8]8-([YAZC]#0H *8+4;/"DMDA[E,@2"V[..3(RK<.J,^.
MH.VF89LS20B3>R[X"C,=.:YP0.TL?07MRP"-1,ZR932$CJ(S<CH3 ._=NB(-
MM)ZU"5DM/^3["&O"\O6R9\G6O>;N*^@C9!MYVCW0'M _Y*J&EWZUZ_+G2WDY
M@P^830+Y&S_D8Z=_%!_+]):73L59A?5M5Z?0ZI#"W4\>+F/I>7 -^E#1MDF6
MS/[G YHB<:'-G/.-EFMP'<WET@A)PD.E,D:I!E_$U9.*Q=QM=E4V['AF6\;"
MJ/W_*Y(/2>D!R&0=$$<BP)#$KVB;ZS3L:+9+:_="<L)DH9WR-,'?[O3=PYG[
MJC\K#;[#CA\TN"%MO9'J5G.%JV_Y<\C<MQNEEL1"RIR\+NMPK,BN.%8FBU*M
M(11]9?[W1WHEUU4^(15CW_Q;3OVANHEJG^)S@V5L !_^\@-OWS9%E[ 2KR'U
M(SP()N4 1_'3<5[T?@Q$@CDXP1SU:08ANT@S[C+]G_HA7/X=GO.@;I'[[&W#
ME*B7EX^82WNF<RX?!R,9\YQ\XY/24KO^G%<<I11L(EF #;)A@+, KOE]<L^V
M9Y+&-YZ "ZZ4![I+ ,Q=KHO\("/"0:H__LX(,MW]3Z%>&4[F* ^NSI4MLM\1
M%G8(<$5(,8 4LQ=)J?\Y(QB^;'F!!"T_F?[1GQ\R(K; A-QM=B!FAF;4OLSC
M[$JB>KA*7^[^Y^DTN3X6GT/6C[N\:_TN>37#Y4"LWDO%79-L %X*BP=T,(Y.
MU,Y=!T%M@(T@ ; U-1C-#$>'S=M3:(<0G4+'I2L<:R)(KN50\^!D(N?OO%;G
M+UNL&D<A[)XT#4B!2;U;@6&9]IKO63XG(3S!W'STMHXNVQ #MZ(5Y(1AF$ST
M?D)1)L8!FZRY?M+\^V_CKI\8$X5:5H:DZL-FU.]#V%.4JBHQ,IZ.VB%BFU*O
MJ!.%XSZ0 ?]NV6<3LS46G@F=#8> +I81!H*M=6MZ@52&EMT()WBTX(J@X.))
MN.$<S ;BF!$Y;FYLG366HA?KW=<+-N(;,*(JC'$O:3/KW4% D0GAF.T^AR!<
M&%NAYXP6"=3Y#3/ <'1OM^<PT5ES4OF,?OH[U/K[PE3&MFU3[AJ!#C_CSK.2
M;>,Y#F6_7.(HJ#2!_F\2"T&%D",=  ,R\%)WG8.?W6DIQ8?0)([E' #C*X-,
MR(AVSS5!W:$73G,XYDERTQ+#;/CPY>V@DA"F1 %@M3IP(H"FPWR::J0E$/'L
M9E">? E'AN$A0%D$T]E@X06 IA!2&KFDE:2@30 -&6PRAN,ZB4HG%.E.EWV-
M%%2,#QV;<__AZLU2D8O=Z-D:[QU++HQS0U622J#-A5N#JA(@[J]:93@9D";(
M5*5 9.;F#)=./3K[R!_T#A*(SJ.ABP$*E>OHQ;;>N+MMCN,^61 E;(B$CI%I
MH&$O9QO$T1/"K+V0UEZ0$9^]&0<IGH04YP#,!A;V/\D7!BI283J]  $R4^Z]
MH"4$L#RO&[<@+9+YOREL0T)_IUQ1=EA16+UV;G@/L\MW+-]\_\W"Z"?NTF95
ME2+!<=!B9*>M).+XD=%^2;6X()%::"4 36MKD&)O)"0TTH%GFB-,5C@"';;F
M!HPRQS&CL[!"F+X72U[OGF)5ESO!,DI8$+KA8TBVH7BQ'=.001M@HC? IP#J
MQ4!&P_82F.>=-*][5?=N'+//3X&\(]@*24!I-J@EO' GE7W7&*WCIIGIA6X_
M@+ETTW=L<3SJ3B%S;CQESO?DV*F%I-$_%JB$I,GJ$<R'\.,!O=[Q8F0BI=""
MS#818Y&U.A@O(%H54DCJ<O="NHALJ! 8] &F3V8;S+&WIH!M*5TA7@4,(T0D
MKR!F!$G019#SP%HV2"WVI%*Y9B/0#3<S#)%C1( :3X_Q,9+>3[< '2_6.J5)
M03SQ_C:0G[E#(4FAR:N1>0#<0;^,TG;Y8JP9==L=#/YGXBKJH27]),/[5//.
M29/S"=GT^&)OW0<NL6)D++TPD,PQZH*IU&Z_EP&@\[:C <?+.PM.K5CWJ-M1
MA+"C(,>4!+J7<;9Y%0QOYJ(C$1JO"L(HE@X0:$83KM3#*1ML4SH;G62)GILV
MY=>\70# XEJ0_WBE$I(/"](4P7[>@="]%TEALD<RA[4/L9=L$<ET]'[,:)LW
M.DNDBKTYGKOQ:&*Q<&)Z*)7@-WEG)T/P)'#M22"IY/2TR_2:9B* W$IFNRX!
MLG_K;S(@' %T$-M%2FCJZ&=^CK]MS2E]]E\Y(92P8/$M-SHB,LDFG%'@XG4U
MS0(1^YD3A'FH*S8\^HNE*V!K]5JJ4V >2@ K$G:OV8LSK69:_:AO<4Q' &&\
M&C?&[;<:L77KBW2KAICBYG]V;COS]Y$AQQQN-6GWU[<JWGL7*73$M?!T S;>
MXBGEMPN#CO(5@::8,EFQ-S^I]1T^T#TL+%9..43@D0ERZ:;<'59S(439+OV&
ML#69\*0"-R'<-H^#VED01$%<+6@3J7-,*6QM&ENI%XA?\ ?)$)+&TJ>S-)/
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M2F:@R8>>!).3?<3Q#^5!":7U\!Y#"6HG8^RN6\E?H"8YP2,(N -CR:7U#89
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M!EGA1;<'A0/&.[,9GDK-V4VRY'HY@NNP]0.,9;=(#">XZ;(1M=H@#3I.PXM
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MW/30BXO]EC<?2K?1JPR?NVF^T@KQL$H/O6,V$1 B]W6T5,*356,\O8E2X=#
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M"J"_D*KF6QFMQUCG(CR'X:V!$J#'7%S\9<S0=I$C7UZ3L6GV;D[,]"UCA&U
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M]5*LI7^(\5_30C':EP9!YH&Y)R;"*'[DLX$\?$&>@#9"]GOF5[NS@*%ENP5
M-T3^5-Y7J;-9#TA5:N; =6D]!(' @*?_V#EVX"G^^E0:!B4):](30>TA4 QH
M@C T - N+*B\(0U&#F!Q9/+ VOQ$))X$03LQN36B'U#83/#)W E[.6\!-&KA
MH9Y >KEU;>[,<W@D5_@J^\%-?W"[Q:S5OC>Z'M[!K3XM#9MN4OBN 6.EWR;U
M=7G Y 'XE/)SE#-YW688JBP $=M1#QI[6!DV>5P=RR7V4-QQ*#*@0D,R"D+M
M&0'\ZQ HF@;(0_X "Y$"R'\>("P+ E>L^0\.C0 5M\<!Y:=TH?!,D9R_-T^X
MEX90I(%8A_BL$)8F9:POPVR"AXVV*VS><LJ9.STA!Y?-H^2YS?H4S#+<F/VM
MWCF1\$V*_+J..WA!7Z0NCSHI'3U"R1=  [>)>(I,^D$/7&KB46+ZV[?],DK6
M(A]YP<.-&1(8+H"%@$2!6 D'[KY\\<2&[2-$')NYRW0?PMZ7*VLM3D$JB";<
MO;F$PEM0N1TP?4]N3B0KH*=?>"=M+EH8SIPBG^S-R/BXGJGKLKE_!_9DOO:L
M]9M>BY^M^.DI+=_ZOG?K_G4/6Q)WT>D(Y6$)0H,&'(D5IFE'!V'F=_>XL;W-
M=X_7"\DHMHP]+FH<KA2E3N*BK$6 0HJ(KP6RYNH3H+3"%TVK#2!\Z"C V!8:
MK1Q 0-9< IF"#Z0J1J_9Y0O982J:Y"?>2#,A\"UL(OG91R6:^7!I3'AH3U#&
M;?CU-UTO%)Z]N5E:=[QRPM7/?G_+HX(^_4KVR%@C4H7HNP"1V\_R5QZ,@6O5
ML! NK$&5AS8R*@LL&1MP.S8"$D75-4ER%0*(3 'BWM#1(/I"'JJ"A3@@EP.#
M+X")-_OAAVI!A/[P.B5SBP"J' &!A=)D#[&F2(\92+.L_3]B-$/(?:S>D4O<
M[!J=5-)@S0FS%SDQ3EOZAXO 7_?$0[YQK^_YM#RUJA[<U.XB#!@U>J<?SS;%
M>D+NXHVL0=3>O./*S2+8J7E;V35CJ/B((!S=QT;ZIX&(A\8P_$:QC MK22D1
MA*DO6*/4RJ"%C1 G[(+)N!NME280 5^"69_?/H!@K-_(EB\X6V:7'0X9?#?3
M1^O]<O"\7-"7,E+7_"E34'TM6"Z$5.0]N!&7*CL],#['OV%E6_Y^TQVK%OR]
M].:LAG[/AH[2T7U?G71. WRE.!:L??GD^VT2KDK-_6,DG3-&_UJ_WJ-?)J1F
MMD@<:2N/CT ZM2%<<!?XT8<#U>+L]4W_CY4F<YH&R F@&@Y0-<^3^BQ,/XW8
M1Z<* <J7P9FLH;)L-NG;H>5CL;^RN+_ 6%)&+"D-0)Q[-I?W#*'X8 [W=0YW
M^*'@%IX)R Q\0R8O(._TOX?DMITN)UA+E9D OH:&M/2$R7.$J%OA F%XM-Z3
M"%=@^M:84/MO,P.^- \[AH6[T)XZP6&>6Z'OMD-]/](<8KO56! B9R\%W(<4
M6=I%&:U/BXMRE[.^P;8)B<Y!<%<<(EVJ[+^@G'E^Q8:.O.!E:BA%%,_/J9TM
M???5QS+(+";O]XFXNDYY(G,=(#H!1-&S/XP<=*2@WUH"D:?)7(Z8NEPC[+\5
MKFOR,B%GR9[V%QY;K^7UUY"C[.4$]:D"D*Q(2S!,_H/;Y TH%(2H21+A((0F
M0=H!B@(NM9-.^:U)R0?>7*:3LHQ)98VD]3CB.@ZW"X>P#2(Y VL90:BSY8QL
M+R2;;6H6M!K*^(*OQNL\F-.%R<0S9$[B?EO?)K 5B/<B*7#CM1H1,D*$<.
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M+CGL:BD\AZF..J!^!< " ,3V_U!+ P04    "  -A:]6B!7\T:I<  #\7
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MOFQ-!MAXBEDZE>M:3CR[U!$BUG-*HBLR*B.P+#2]A_OBA_BY-#<BGF^P+M[
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M)M1RTS-NKRI.ZRC!=1GJMIS0^:C=;0_:'2=J-9A7YI 8B$VZ@V."$@!PUZ
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M\!]( ('#PC7NF,/".3JTL TRV.@B#"[""..)C)ZHE%(URN"4"R[*D()&+)[
M(@H99YQ1"RU>[,*++K+X8E5#P,%&IYV,.TX:87K1)1=?*#*-C:1HHHDZ*+'^
MLU*99;OKQMENQDM'G7CB$6M,>-3+AQTXZ4I3OON("!>__/3:"X-S!_P@!!!
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M>549Q^%5=GIERTH\HA%HO8(6?OM;M:[U<F4$YB7^*A&,9=BU@N^((#SV6D'
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M(O6.M,HC)ZR!5QZ!"_@)U6C/U?PMM<!N]Z ,H/:)?!3N5-#N.IXD$A@A$K+
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M5$JK!3^I)3^_D>_<X55_L@;G:-HL2,\,E(+((1?<8 KF8!JT01O$(1T^P0=
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M*"@?RN$.I !P 2$<Q@%\H\YP0>%DD;58CY4K.Z#^*V7 %VK&*Z0@3Y5 ":8
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MH_5Z*\Z68$-ZMKV1<T>3+.H!:.PLQ?**$N-!%TA@6D5[?M\@#^![& 3B#_Q
MZ:1A&*+AFW.A!# @!(Y'OS,A';[#&O;@J8M<Z<BRV2AS,M5ABD_9P058B\':
MPO>!H!4ZS?=AK-^<'YQ!]NKIDW84I;!E=5[P/O_.CE?YKUG<CJT;)Z!NQC?Z
MCA:/I9XK$5F'&-3  D;^P W^@!BFH0_@ !"FP<FE81J>W _P(!! /1 $ 1
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MX24D+LJ+63J@ 0UC@%,8T'"&,YX1$  [4$L#!!0    (  V%KU;9:8A_K%\
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ML]MAM6C.03G9 0!G/:8R%].907D627ONO?H\EPH7V^21J.&YC?.]S#9@?*6
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M:FW$FX(>OKQ+8G?C]&.CW/X @/@_3ROZ8I[F+:$;:_!V5L^VL/?O[W_I!-@
M]4@5)L,E1V@?BF*LLTM@&Z79QU/(:F1!<QP5R"U+IK+%'<^>OW]SKV/\7L*2
MK>(HUJ%O5,C+)B:U<%$L^:I,IB7?#+?^ 0 F)[F&V:3H(PVG#8KS?1'%ON$O
MM@W=T%^V^.TU>/>-=!>1*DIZ2]@1WHO1O.>KSLDP&)W?9W0P #"BETK\%40V
M2Q.9ZF>]HO]9_>K,9[I_PD.3R\<$G98G8^S;Z7S-U[1.D<C9;"B*EQD1(J:$
MP;-;]J:><OS=E'Z/_Y79;+&OI\[VJ*N--%OQ&^OUD,(,3=LM??UE1L<XY;:
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MJV2")"NF5:QFV,[?BEJ\J,W;/]LDS;VT[ZLSY9H;V[XI4>0UQ'E (%INQ-W
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MP_)>ZW3F)(^]6LB+P9UK@=RO:H,EWQT'?P6"*E;G:^L%H_$+AVIX_N.9^K>
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M.V[1D0?!2D(>!J)[YV0:=UM [8/FZ@X>@E7$ZJM^>QTT=@I X^'E["\(T#(
MM$$+4*<CD+5RV=S\<G@^<I6?UFL>&R;"9>V2#%U5\GY6_QX<33!A6 >O+P>!
MW.AHSQ^MN\Z$MQ4ORHXSRD)#\?7)P%#"_12"@O2Q64$^/E5+BL_\A010KFBG
MC&BVI-9"4!T<4FUW2[O>M&8JEUX%YB2AR_(! 55H[D;EZ"\R%5(/K$57E]#
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M%5+2&><: JIFB!N^4\H&%9O#%+S,I5)G?Y7A]TV6U-PM=+=  6Y%:3%>_Y+
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M=_ Q)T! &P'H8PGKF9,,7-],19')#"X7CJ2 @#[%(UO14MQ"KEH3;'T.YN<
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ME)GA(6BQ/U,IK^3,]Z)CB5&/YFU*3W58VQ?>&'G@;+=++A[7!QQ);^GH+_&
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M^RI:4D^__R3_1MW,#S.D[_[EIZ[%?+F[P"T@R1,ME[69?<+94F/&W.IRF^)
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M, ?<PTH,3 M%*I. <6T50-OQ$"K(FCF#*;'PB6@&G8O%RX#0]HN<2[#X3:?
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M$P/0OL+2W])JI+KU"KEU9%K251-ZLP='*T^S7Q[U2M^=U),:4Z8GV6'[%'.
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MXND:,"0LD 3OPTD@DG2[9W4"I3&X96$$F"<0I!T)OHH#L1\"L'D(CDO"IY,
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M;ZA7M,U-6/G:@EK84RGM+>WH@5."_8]<CVRG7"*GV-9Y81Y"XD\_BU*=+'
MA(T"0G>!.2PHC"Q);)7H"T#JU]TO3V3E02^2?X(C1?59S^EGH<E%Q$LL%?)Y
M[A='0S ]]T(??8@.UUO8RYXF2RM1A 1YX-U9=/.U[R["'5*O0OT,A!E_!7^?
MR74/\JJ-#6DIKG9>-N#H'Z&TM"]$/<[!73'=ALLX4Z'NV"O_ZE#!'!,&@ARG
M*:XY( X*.G$'_3_P=0\JF!-X<IV9 ,"3WL!4O"39M:>EG:<(\""0(?^Q%[V!
M\Y',FCY\P?6E*U2+/$0?'FS?>>V9UGP)SWP@/$ETE*'9E9TY<_Y4L78A.Y3+
M)OF"3!/(55AJ'6YJ%%PGH+?/(>)0[L-6N;HIT(:'#?90S)3[R +GZ XTIDK+
M%POF'A;*T,TA^OIQ05I94;922E0MJTL[*EB>L"]]Q[I>!I'/9(='N*>6V/2@
M_10+AC)7N+EF)\7]/+*?+_O*Y:V_=*R5.;2\L;'&K1B7_(%6+A'1RE&K]"C(
MA.%ABK91&$O8Y[DJ#3Z=4F*=BB"LXEM4;XI'ZCY PTDE(',H*8?J$II^: B#
M= XQBW\CPR+G2[Y(^A%,G0"+#<FC3P)(4GO0^@"B/X,?'L*S)<1\,\A0-F)[
MJ4_ZVFQ@]DF)>?'24K5L0UPF1>8 GX*P\PV>SD%IMZ0CK#? \Y5!)CH^OH<&
MTS7\C2Y6QNI)/NP_4<^@42;JZBMYMO$^;=6GAJR1IV"^/J];\TW5TE[>F8X3
MU4P^Q,NI)T5 HJ?,EMGM+^P.!YNB#!-8.BM\#7.?Z-*-20 AJM8OPP/B]%?6
MY^Y5-Y9U>/OH$0L+YXTX^L\=STW*=AD3U)Z,\/6]"XL^*6&^%@:5( QDW.#C
M?_?27FVIHG+#:.3NIQR..D/SDBAN[SMM3(GZ ?;I4$Q7NF:'^N69WBWU'YG*
M"%/&5T^\ .F?'<=F:CG#K)1YJ' \WYZ0W" ZW!OA[G!T+O5D^OZ/_&,E#X&O
M47CHG_?74Q87KS/>IN@>QEHC@["^W-.K),7CA(\N[/V_$OJCR"D3J PR/,T4
M4MMJ]3:5Q9#/-74B46=UY/G3)(QH@;Z''AM*#[F'19%M(B_YKDMMV$E3AR4/
M0=S*))8_U-8<XG\/D",4Y("C98Q<O[CP8#4E,IYF_83-QTOKBY0S"JN#K8?&
M7DEO=]=NE*CK6PM5L6V^_W>2*#(#X@BHXCAXQ(=+Y-0??S7$*K*1\,H=B?\E
MZ-2=J,96#)X;"<J9B-#SPEB]2K^VI;7**\-7H%\Q#'_-[KD/,*N#V(Z')&O1
MTE1].\,4@:1E!E5AOVVFPE4 .4@=[0(L/KYAFG)@Z*+"YZEPRR$Q47!)V@YY
M/T'((4,HD]M]3[_;N>K*XGL^]VWVX&T^*HCCQ1#?($@VH(KSA[O?\9IL^?Q*
MP;9L%TZ%@:=>FK^ZFW?9V^#RMDOZU=3D=#-#K:W$Y]S+TF0P3?;PB /(!4MD
MDS:1'#64D1PSCAKV>6SBG$IB@(,*,]F8MBC7!@FHK6*FO%=;8UAR*"!Q 1;.
M% Z:!&'SUB1YP"P\HM(!52)4HHR/D,$G84-C4=E//JK.B9R:QEQTN]=<9L6D
M(<IXKD45:*HM13O5685L51.?ETZ8N#6;J+.7:+CJIC=4&"59P!YCPXX"W=<9
M8I5_*3F1(#6J+Q7(QJW\:.1?.J93:MP9$$\U&>LB6#(/,5ON,VUBX[4MVMDV
MQ;43A=43T-1'3N,^TIK@(#/OH!5A@_HZ5T4_7BI1MIG(TP5R;Q[BG?_/+_=Y
M_2 JR@CCSR7R+!XBH?HFI;P9TN^JB,9:HM T^3>Z)#M^<Z_/LWX-.6"IY16,
M\U ],XB-@3:7H"])WLJ5)'**^2N(^=L-UV@=F(]161P90,P,>GPGLTC+I9_;
M0^*F(TIH,!]"GP^1@):OO7EY$-[F[]JSS]NU;_!B_]9P'?=,W>U%?R-7O^OP
M7<!GA4O60,D!4B54X;V3N*0P]=5Y5*41B7G*GNI<@=E/C'LQ8AY)%ZW#(!4S
MS*H\%' P(:%L$NF>DA,)_K/QD$E9D.#I*+J)EM['NKAS('/XR1-4^ 06'9@@
M'C\B]J<>KUC+T^C/R_6!%'#X7R/<!1ID+P,"W14;>,A$[G(B3_D03RN(GRJ6
M8I0H9SRB"/6Z5C'/+9L8G>QW1]PUPF5$V2OQG]$RWP-('$> WS,N*>H-_W1]
M"<,A@7A]R:T;.88OM]LI(R7U?BJ"G<X<A9G\CI&3Q>2QT/MI[7U4^!^JN)?^
M?\C(L>DG=X!X&T'E'43WUTT5I7H5PV(I4_NZ&W5IEY*4TB&><E"5\0>CWX^X
M7+->E5?U?SQ<U#/4SC2-T$B7H&TR)'\ /]O3:D^-^P')R];WGUJ1R-2/E+8<
M,DHQD?%A3EHPZ^?TRW)@'/5%*4\'[V#_&6)QK2V8[L/")P!TZ+"HW[ <=$1L
M2R^Y!_1?L9<\?H?_D:&R6H^RTY1J'9)FW-+-$1QI/JMHN?+(?US8K_#O-8-O
MJ;55)(06IM3HXC!9O<+7W#=TPSO%>5>+ (D*XV]<#T&'\DNA^(;N%3C%V'*(
MU3&QZ3%A'>-/J1-( >E[C.^W=I&'-0Q^ $K[4#00+*YM(,\&Y@HE<I #N4.)
MW:6!M'^".J<^=K0-Z38.Z2:%=D6L]GOM]=!MK?C!\6/3>$F/_N0)<1=H3IQ=
M.HZ_=NWM-_1#3;81\RZHE!=G='^25*B^A1\3YAB4VXY^,,XD/^1K]YJ@-0=<
M9?1$LC46Y]HPG%8P_,&B^\!BV$9Q=0/Y+CV.01G.T<<;$9=ZM,N/N3./)TKU
MN+<^IO8,\9(#NS<?;[5)4XP_3$]A>J./7C/4WUB>/MM@%;<R-+(,#BX?T2!
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MB6J(C'+(25F-\2P.]% JG;_B,@NX>7K;[4[]N6JD#4O!="?E!'C79(?/Y B
M4"9>?=L=NTDH+.Q_UIDZ1X_#KJI>&XKQ%HYZ8$A$6+,1[V.R?E&!<SS7KO(
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M;AQ(AIP9VBJP?8$ ]50I&(3G$D)^F--/AS8QS\A+I<+24,$.3-N+@_Q%]IO
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M?.T--UXQF9YWYK@#TZSGP^*/ %8G-=@WL3$(Z1F>(*?P>^#]T3/2/K19EWV
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MT/?"+SX!':D?=FUVJ,W)2,"-X=/F?YUZ3RR&_YRH+6[T70ZI;_??(+S4:^!
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M82N)?#?:&*#S*4/?-OETB@6Z2AZ?OVWNX_6*<!K=9%<3M63CYMCO>*LAIR5
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MZ^9V[1IB]2AR'RU=!LA\;#)?(W/G"P0Q349R?Y;.1-Q"%D%]<".P.IZ+A/:
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MQIO[>"XW\NR6EN:N[M?0F;>V!:Y%Z9I&3=:X^,784.P.NNR3VBO9J"0Q] I
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M*W! )EQU2FMN*(>*M:/P,P!(YJ@4%82E _GI +X%<N6FK2Q&5GH *,VBB.*
MY=@'1RM"%(J5J9O('7T[=NH(6#QY=D@DSY\^,1F-*(TN:!]QN+H#BP\2N)P-
M>72SS1ID9WV\U EGXZ[I^*=9-]QAT(O&H43FO2]4C<KI TGP"1]Z ?:/N #
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M#N'=?(U<O?RW$2]8KC +/K,)QI&! ,".+5EDK;![#JR6]N<_\5$=<@9!8+$
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MX7B[*W\@:ERD[Y8\/XV8_8]/?]Y1OZ:?0 6QMSS1"SJZ28X83!P%>=R!IS%
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M%>0KBBOIEJ')P9!<L3LR#+[(2,OZ)7JV0264GR+^1;R<&9]*?2^0MC8N:YF
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M.1XTBNC?[-5L2OHFJR;**S8$\&[PU%<4 ,3Z"!K7&&YFP>D Z'>R>=;>7YW
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M;'A3=.A0.ZIF;NL5E=HE"ZWG)4[PO_#:PBU."*<"PVU;"T-<Z+XOZ_::J G
M55.1GXE$Y<<N*>RASEPVI63;GD]#7L@6)>07#3UG69?[3*Y?$&/<SZGM=9:%
M7,;5[1<^LZYCU;T@N2I%0-*MBZ'H?EHAL3[B'ZOB8[@C"<2K62,?;=9( 7F%
M04%5=U6SFE_?K&^6[ ( 7[B+D=<FGQL726S 14L$!O5G9L;E'2Z]1+F,2'FJ
M$,9A[;TWM*,UZE5+?.US_,/GZ-21 1H[=]]GE_TM*;8W S^LN)%6_'*'JU0U
M1AKKYQH',SG%W]2YQ/0\A N5PJG8_\$4;96ZG^CPO>)<U[G<H8LJ-1,G^755
MB\:A UST$H@[8E_I99Y=-/%I9T'RR>12HW,.._C/GK;&WEDH[3=0:UHM3*%^
M+F/OD^8H;+),=4QL;'*+?C31/$AZ*C1_'FHP?%@BKZ5:/,VP'MM*Y-,#2JKS
MO@S LME'0CNT]4:ZPK>NZ)SPMKVR9_D31HW4BTA??/ %4\.NR QK6"->)H6"
MIV:_T5J.#=R"\902[^04+GX.KG"<F2+,DP(ZG@[09AJBRU4:K".-/VC;Z3P[
M]*]&:Z&1^GU-QVKK8LW]?O?RU;>G(FT:H3BH;X=VR+)E^8_!R@W)-;3S_1\B
M'O$=W,& %S=2?$W<PYCW.>2]B1E[XQ]=WJ&[]\'35PI-^_Y3_!S5(53;^ZPK
M_V38Z,K9D;8?W0>[^K\2MF2Q[@\(/2Q[2RQ72^T3!K(RK-SV[!IBZU$'1<CH
MX%\+KWBD,SIY6/-$&&+[Q0ZYQ?J/%Q^8'!F(SW7Q^3O59/=HB+/=P5>/</3I
M4U3 _XR3;RSTJD:(\P;W5O*N1A+$I:#G\.B. D'E=QFJ ;>@$_=?.2D?,'L>
MT'R7X?K.W;S6LSKGF.<A-SBUMJ'0*NL6^_1*6JE>TY;-ML=H2X8BU/FBLT6X
MA<]D2Z2FN1\A3&M#^.[>\61"*'=5^O.-XYZV[,EAE:YK9@_H_(F6OH8<&(W-
M5]CT]_O<?M3FY@9"?'=:G5HYRKGU)R&A97!VE"[=>#PU ?_L8IJF:?<%TD[2
MKD'^<,]*EZ::]Y.593U5+RCXT4>;2V>&JZUT5F/>#N*U6SXTW");$%_9'T37
MV#G)<6-SI^SQE_.^W'P7MUF#2PPZ@41+%98E%N4]2C]7OE9H5[([GWHK8!,H
M<IF6U1:U3DA]],1:]W>;C>\']I$2PR?7--OL"D)C8LR_M6A7^_%W^A:48B!0
M+<;-N+.!: 3,[Q2AVB^F<,\NKLV+=P9N(V$89N+Q_1'',_T'F_W_L%GT2TB6
M[(3C,\*BVNXU$5[ A"HRE3(?:/9T4JIDF&  6ZB?6O @_L.#?60QJ]*"Z+M_
ME\L)W./ID[<38W*?$3:#9ZK5_OHX!<N2*7Z)4WXXC#=*0)>[G3JZWVO U?FH
M^Y$8WIFJI=U/GJKNJ3%GBE2=I7!+*9Q)SW"6G&6R,TZ9^V5$UV0P9^ ?F*<[
M[JK+ACU_^1'>R^!,-GVS;-.;!YNU%PEO9)AN-FY<B!MGXZY?L,O+LMJ"S#Z7
MA)NNMGL)VM4G9EXKRUYKQ -T**N1?D*'#PFG.TO0'P""PH_099FBI30C=N[L
M 0K\;DU&C&%&'B^'N90132%"'/X'4$L#!!0    (  V%KU9X857@A64! -EJ
M 0 -    8V]M<%\P,# S+F=I9L17^3N47]P^SS.+61G[V,<28VUL)5MC2,@R
M6B1)8ZDFJ:9=4CW#D+(THI*D(5FR-"0)9<A.#$K2-I9*^[2K?/7V7N\?\9Y?
MSB_G.M>YSGU_[F6EK[?3LLB_< 'T$P 4!!'0:#(>KT(FJ>#1&BHJVNKJ^EK:
MNII4=8J2H9Z^L0'-U,C$?)&IN9FYM865K;6-C;6=[6);!SN'98Y+'!Q=EBU=
MYNKLNL1IN8>;^U(G#Q=7+]?EOA[+6>X>_EXL+U]O;Z\5J_S]5OFM] T.#/+P
M7NT?L,9[U8;506Q_]L9UJ]>$AH2L6;MQ4]C&#>LW<"(V^Z^-"5K/#0N/"0Z+
MV[ Q>FW$GJC-G(C(V)#( V%;$C9N3=P2%<W=NBTR9N?.V!VQV[B\7;NW;M_'
MW7%PSV[>KKU'=_(.'=BW+_[@H:,)1^(/'4:.'8^(Y8=M0R)WI43M3HO9FQZ[
M+V7/P:1#B2</'4F+/9R[\U@^]U V_SB2R,_:C5PZE)P7AQ3M2[ER\%3%X<SJ
M VEE1\_4'S_;>.2T.%60DI9Z(C,]X^2)-&%65FIF@>!47O9I86Y.3D'^Q;SS
MYT\)+XL*+V?FEF2<JSB37Y5SH30IK^7\9;'HLBB_N+ZP[/;%HFM7KY147JLL
M+RL37[]>5'FWID9\L[[^]JV&YL:&YN;FQEN-->)Z26MKZJ7VM,N=::*NC*L#
MIZ[TG:X8/EW])+-,FEWU,/?ZXW-US_)N/+]TXV%)37OES=[FNQUU=T:JFD8O
M-$Q=O/VJL.7MN?JIDI9)4>L'2:NDJ>M9X[W'K9*V(LFGRHXW=_NF[@Z]O7+O
M:T7_?%GWK]K1A8Y['?U]_3W=/0]&'SQY\N31H_&A(:GLQ8NVP5?WAF:['WSH
M>?AQ8/Q3Y\C+YR]D?8_D]R>^#3[[*7W^2_K\QPO9Y%/9[(.I^:?O_HZ]_#/S
M\M6KU[.O9]^\??=^]O7KCY_DLD\+G^2?I[_\?2?_]>[/WZ_?OOWX.?=S[O??
MOW_G?OZ4?_HD>R$#_Z_+\!?Z__:_1-^=D=NV!$1NVQZ]@[PM<N?.2#>&C8.C
M@Z,CL/K?$_\[, "W *[B=7W$HK9DG*I%>(^XZ-X)BK%?@4]M<6<ZU3[V:4_M
ME>[3-,]3NKYU);TY]#77K)PRS_:?9T1WQ2VZ41IPWF'WV\0+^\J&+C/Y/TC7
M]M&#"U?F: >\W?<FN(P9O2C./-?<OWQI;=BSOIN5CZYS;L5N<6XP'SC+'35U
M+2VK?G*+-]UW:=6MFF?-\5_?/NN_=?U%*X(BZI-^!EP6#.$L(P8::Z>[A<:K
MNBH;ZE[VY]GO>#YP^\;K(9%GNO[]96$.V\N"E?R/YM^,Y9=>#5!UTFG8^:@B
M^'+-IC\'WCVI/*1499W8\/EQ379_B+7K(8?G=<?_1-QM:=SUMNO$DU?5X4OV
MO!U=MW!H<^%_1_:_KS@R:GHYHNG;U]ZR:<6LHXZ\5]^*GG2]D/[Z[V?M&[,7
M1Q_A9_/CWV6O?W:P?L\)V:&NJ^?UDFJSR\*/H"SF1,>G\ HOCCWP/7_IP/35
M6X5[1\/+]5('/#0Y25IWEV:>T&WZ&<9G#'8;;'?]@3N30(0JA(=5\(=7[UI>
M^'KZC';F:V%VB0<^.U?1L)=RUG]KQ<MSX0??O#S/235_E1=S;H.*8Z6XN-#J
M<@M+:FM3T=UGUD&M]].JTDU&6ZTQ1/=H#SD(7N:.T/9UT5#/-KP6K8>CL+9'
MJPRE]AGY>&W'G>(V;YTCNM/LJ-CXMU=HB)&7^3_-NH&EJ5XR]=%:8 7>PQI@
M;J_&7E9=%_NFIB7"!(>"<1R^99UA, (PNH840PF64>5P/9$A 0H^SA0:2DW4
M30,%ALIX\*!"Q1+,B_*50572<%PT6B2QH.$8 58$\;!E3@U)R!1#_K2/+.MO
M&P-.EU53F)<6[K0C6M@-YD1@LA9=8X5UVX>@)VHAB?[2Y^\^=]/U]DG@$JPX
MR4'[CZ1/";0HDV&3ZY%U#C0 <%9:)-FK?=YH\4J'..5])-NN7I5RAUH?1XIC
M[!>VI+6#G?^:5RO>JVT[%:CJZ'&]_LR!2]T=9RY:7I?8(<K7S W!XPY%+Y+E
M9LW8[\PA<9*E(XTN>K5@H?M3&:@4-XT0[&C'?_1!>HV"FCII'>M^R0'O '^4
M!LDJX-DNPMH 41W7FEP MR55,M<]6E+O4*R*3A^_]_BHU/Z D6KCR(B<AS2*
M)=9"0PCL&=C.6^U*L:JA[),0Q<J><Z\;KQO9O!_QTDO7KUBG1W=40FADR_YW
MRJ#R\KN%K9=J,K*<?PX\2CTP^?[6<JFE9CE?&Z7I\Y4/"PRN2'!UX;*=#M]R
MNO0E93 :%Z2$X3&A<3$!/>NAH4!ILV?*04R/$0K+D"B\K3^E@*.A: RD,:8(
MJ(0R 9DA<""U ;2N!.[Q:0>AAF03*G/[J*P-J/$06Q\490$K]D"A:7 0F1]F
MPY!0SN4(X$8FA)*W;1_C #15LI'Y%!*?HF<&.4D 9ISO@ B9*.H41HO3"5,Y
MP, G6H&(2$"?S/V^I!A,/(D PFT"-(T)G;"]!V71 +->!$A<8/N#AZ"HB,*H
MR!L5(N<KB=O!8@0!B/0&')^NKL2;1)<4P[@JL.&,$99 8 .<5*A. =.$K(8"
M>UT:'IZ]9^_%!BA_)'0)9=+>1^R)>3^I1>9.]GY# %I-<F*$BK)<+T)R[J>B
MR?&Z.%,>2=V$"1'BDQT>< #KQR2.Q,1:154@"E(II ':%#=\3\WT35;*7/ '
M*K@O20I5S,U_$E.7:B*(FS@*_!EXI.X<TIWZ)59[-HKZ7U@TA$V+U5X)@,-5
MO@26^M&Z03L8YV4L!\S5T11$<=F2) QE6AU+B<82&#@FLB;>Q!71!\'(;T,^
M>C04 R8 ,=-O&M*B1F"_T<@1WBA*^]MD,J"EA0".0JW8 TB7Z)B\SU9W]3EO
MZ?";=/UN%"7X&01^,S+_<T-1K#V[_B-]SOCC%JT$,V"[*N?4[?5%I)"]7+_
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MF#:_VAZ*O&;X(9<J88SK1Q21&09:5I"6A0'<3J)M& <:)%D W# 7@@]*DI6
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M*#1)SRMRY51MSHJ#=6?OG.-249<OS0/>!.>$$DZDG@@0[86;2PX4&M8G]*1
MIB(%9:XR!=#OV3-?=<4M="MKNPMU#-D \:!-[FG-DT <CZ1+U4; FX'^!U?&
MTD;:GIXT#/IC^1)W>1VUF"Y1*#34BPY'(*5/<0Z)-,3#RC,+QV8:N#Z?^M'Q
M9<>GPUU'?>09,6K3FE*JJ<XQ?HJ>57(N0F6#\,A4A7%_6)6'@>=+8>A]I+K
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M<D,]JL=OT;K2/ZQ]C7[\06N#Q1K78,RZG)$5F9UKUWPOQ%;CE .J+AQX>#%
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M2]\Z:&UA8K<HBE,B*3\4RG6PY9C;T0@Q%$ B]/)_+9R#M0+(LO(4D UGS<U
MLV^#/T*0!!4V1R8B"$B#(SET51$ 0M1FB=Q(=B-,D@Q" 3$M87E>,C84J#8*
ME&G(!@X?- K"?!#%\10R&S2=UYO4BWMUV+7KW7CC=^4W:],[O+\AP_P%F,[W
MYP"%M%VW$] PPO\UC PJ:"KZ()A0L%*X2U$*,&D@D LKQIZUF+/8'?A1!8=H
MTPWU?%+4<,!+"L$^6[\_$"@@CC9TH/BOJ<5[>RX36' $:WJ@VU,5JT8%[RY"
M/J(D3Z>4=ZL@_5=)5)IF&>WLT9JDE4X8/790X:F*CP:(%AMMT7AL;O'YS Z
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MQ>-XVLV8KK]\M2_ZV:LUX/L&@=Z?_CG_GAZZ-OU^=?;(HWYZFZ)HVF ^?;]
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MXB+4$XV^#P",#&(*E& >9!H!$)L24#",6::B07+*H #U83LJ4$EQ S "B,A
MC#UV8-\AF%*8-:D!R@44!D)%A!A;@!P_O5<.$KP$^EE*;*G1BIMR< QFS<K!
M80T!4F('^9TF'].+6Z0YC>B[BH=1 IQ8I6\#DTX@*%A("(89#@F !F:&E9B8
M0R2-$O4!9B0#07<0$QLYOEF.MI&;O%6B1*&H5&&&2$4UTB'XQSQ<3J/1,@BO
M5J(T$,-)B0Y4ZCDK41,"$P\8-Z%$26'&8SD8K,1E^: ] ;(7@LZ!_F\;*6)C
MHN1ZO@)"K0^.A9":$)"TD-K0B;>!C#8UHEW&46KH@<F'KN:*Z1977RL7"@-^
M[<4V,($H@6Q<\2UT(DQG*,FK09P%]-I"H'<(1G4A. ^$3E.!GG(,8YIHH20F
M(N FR-@3,K>6X[Q 0[<$ PO@]2(-ID6.2M48G=, J4JB.8!?#5(61>"MH W6
M"7O<V&0+ ;KKOQ0#<"U*5 -@G*I)/BHGT^0XO@9<">,[-[_9 :1XP^C5;+S.
M L;O0,!SD#&<14Y5HA=-DQE*=)B SD?0YX!-OT;L1UOH0"-@*\=RE0 ),!$H
M@6UI& N8]10&7* ?\G.4SR0 EZ /"*AJ$\#DSKSWVXP;&L%EP*0>@OW@QG\Y
M4W-"A6<@V%@Y.GX!TU:N#_7C<F%6C)S2#-)L(=8VA #UZ[G +,C4EZ!RWBI?
M%2T$E_FP8E6TW& CAN*S/;#4>Q=!Y@-2P)W+IQGF2CTH&5NN,64!)A &._8%
M1)T=11((X7 _H&)0IC/7"3Z7?D4U-7I<OF-M(V#%"U'9P=B[&E-SI*E)B/H)
MT"R"64U^R_:M /ZAZ[ )*C 0P4;(01DR& [XYB%XJ-F8!3&A\,^5,"L<NN,2
MR8H"01<9*G=@U\?MHGAH]W$??9H'*_>^L=0'M4TZV.2#NF+$\M10H7Y"/,RR
M@O6OW04/OT(_16A6",NF%HP74ET$O$D @_H+TPRFEOOH;YNA6T#-3@+>767!
M?,$V[TB,[9G[_L,48J%I&(R*@K$."":-/34!,ZN$A&3(R$)N^AC"%,,,3TAO
MI8]>K0\C"B:4+\2(?)@B ;;6A_D, 7/8)$^YJ4BEW[^U>%H#9ODP4GU WP12
ML+STCP;D5A.J&DW$0D(.Q!)#:R1L(P9B\D*'@*EL1JXJYABHSX)-:U689DU8
MOI Y(4?7-N*384:M$">&&"RYH=B'(188-FLP53Z,_^;Q'=/2"2-ISI*,A\1G
MO5QZ+PQVCJ+--<35/A0+F-Y0#AHFX/@P?;4 K2?4LU723P.&8:"!A<# (@$\
M#1A#"> ,9.SE@]Z$T/N7&$,^E$P7NKD*M%(1/31&Y>6@42/Y$-/XG!P5ID+S
M >.P1N+G"P8,H0&++6^%C7=\,PJ;IC$0>J8<Y<XV[H+B0X5H/FQLJ )E+H:+
M&C&(_/D5A+[I/R"#QHGRYO-* UY" Q.DZ"$&/#9EYO)S"Y@R^,E )P_:3 90
MGA Z J%YF8(W+H)O:\0AI5N.-QH?GB#@D*;D1B!+PPR$ 1R$IH F% '*28,R
M E X'O]F3IR-E'%B&A\(T&8%5%M$/U,%QBJQ,0#&ZC[VE2F-1<? <NRU"$PY
M^[_BSXQ/8#8W,F-@XB$V\R& <E+BXH5[:X0T%T@RV-:^ <#D02R+>E2\QE@F
M1-G/,F\HL0 ;33%CE7YAVB#&W"VH""&#!Z/<!-2F!)K+?=^#PMUS 5:$G"('
M40Z)J'8>*C8AYY&2QE#B8N5+[D.L4@!E#Q _O!4^VPC<.WV+):?H8'UDS^_'
MWQBP@)I8JOL3H]+C:IA.L!'011U4XII\VET$QB]NXR(T6!?!J-5^[.,L9A6,
MRH)ZYLM;V=!EUVR46M\$@A:N1S!9"-->0&L64OT%7']8?U(#'OZ%LY<;3R'=
MY!",@SFFW(D9,=T8"^]YA'37)U!Y&D9\/:-&I<?32/?<K'.P*;S%QZ1I]%X
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M%60R*?\0L/3#T@+?$;G_F/Q# LA SKNE4/+G(;0F'.JGAI$Y;8JPF2Z0]AV
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M8Q;IN]6)SNYU>_ WLJU>5O?#8 % 74YSW7\IY>()U#4W4,!I.CE4Y=65DEA
MJ0P$?0^51WJ44!Z8TM+WT:(]LQ+ ;#@Z:UQVXA3Y.(0]+HB]NI;?;HSUFSZD
M2WRX]*(,5WQA6R8-/QAP_$;*H5G3OW*G"[IF#GTZ6**81[UY@;B.![KW[YK
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MJZ\%%BH)X"OB.OX&<QKN)(2;)T 3J3B;>43;"!1#,QZGO,?@@(G*)%<^[*H
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M12S1 ":OS,IY8)F 9"=#G^*!L0H"14THG@:*#<#],M(:-7+\'Y C(Y9K@'@
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M1RS$X@E^. =:P8(<#C8A2JEO5R\9LZ<5>W0M,"*W^'N6!9+CU"B]ONQAT-<
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M[RTBMP_(3I*K,>7^SXW,J7P/,K4DS:05Q!4'.FI+41MSUQL79U ]$WME&7T
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MT!U^2_JD8%*GZKI:8DL=1%^BN]U#FCQ)<JH!QRC!3K.*@Y$!=BJP2PW81OK
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M,?57Q^._E%H0(PEW/;!?J7=A$G9<*-SQ2$,@TWC"36'H&_R%93)FO6/,(]<
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M'G2Y&&D;<)X9/+;:U9WE*[*\7N4N0KET8\68*@8+@G;)4>WM[V(+BI?--0M
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MZ-3C(.@M(<PM"52:X/?&2,@56B@7#UI7#KJA1'=VBW$'#* G\88M0RY2*HP
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M>-+ P2DP&PA ?,7JQT]HC>]S(4@65[+>[.1A!#;$O7Q1SUBHA>1P.NB=?N!
MIS=&.P;<#JPZCANA08]43.I@%KM5Z+1Q)<2<)7'-K[B>C#U?.'H=H#<IX-,A
M5/T!,M.I6"4R@%)YIV9V=.F,ZW@YZIJ+,T/SH8H;FYH:($["(&PC5\_X3B.I
M1PA!*$L141=.)X".V_UF=9(!>7;S6O>Y^_X#OHHCW+E5&R8  Z82Q. '$C9J
M $2$0![GU( ZII!:16OE43,LB(4\P""3 ZJ]J^WS2!1HK+=SS:_(@_'-#>SM
M1![T6%6(T3"C]XM^A>VM*Z]UP^PU=7Q%-5U&EM\.\:B>Q _J;YAD- R'*'D/
MADF289.Z)=?]8PD2*XCM[9EN<_/6X50FQ/;^S)+'"V19ZC]@4L02H#.-JC^8
MXG>2_,N0>):>67#YK]%4(]]Q(]/X:>*7P"=]?,\LV<F#I\Z'&=^1O'.17C@H
MF=_E/T"_NPM?\'62>9WXFT!M8_#]0_*=1F-I]-6G!]=]':DU_^,BO&!P>D?R
M]\+U*;W-F7ND5CGBTLLGUK6H[2TJ4,8Z.\(A3; M351(V"KNJ> /(JC4XBB_
ME,_23-/I-_MRH3M6OERYY[(XZ'?:OL.]7P]U?+@1]Q_OX%*^-OXJ^R9/O/N8
M8X7\XHU]A_8<KRBW'"#ON; B(E:,>74A!;;G@OWG ]L>3-B]0?RV6K8Z)YO]
M<D#ZW2L*[A[:NKM4\Y-2T&NX.'UAX^(#_R<$QTT_=4\?H)E^W+&\\]_:'QQ*
M3KYA>6WQT+6?;U)+KALV31R="=2SKE<LL._/L4$1]=9?2Z^&UQ<W54T'3$"&
MC[W?]PK3@;1F]:^NJX?G:K_O5*8F%\O[7JVNE7X*1[F3Q\.JE"59)\+RCR,*
MI/:/3'2>YBN?;M9__*!O*;#]Z8/SO)KV=T<+BN[WFVG^O;O9>>$$D[AQC*P_
M T)!\C9!KVX,?_3<P'DB(KU^)F"RC"U>O55I7/D*>UU)-L4A=6O[-D U-F-N
M54JV:I)\B8?9;?GBU@G]>W'_O#0];\(SG)W$[C=^-1FW&TK]]^DDSEV!$=43
MO:@&=1NA7C128@/[Y\WK^Z@ZF^&UY%ZJ[7!$1-O@FE:+SU=XMJ&W3"T@C/S7
MP?E/_GGZ$O.9YS#;0'G\VJ)SRM^H =N)P#LT6,5JP\(GI_T;K1Q2%(-8U\#&
MDGR>C<7)R*)&]XCPB(N; K!)LWV#IBY61YC%JVM3 O:>^*FOL;B*<.Y'G-OW
MAC)MJ=]+L\3S?KX\[%>7FN:D&6(&DKPF&<,;K[DE,%(LC'J18XP4U_YC_M$T
M=[CU0P[4DY06_I5H=[4^P.4M>W#2OI/F%&AM\8FBKZ.&!#;MW7MR^2OM/T:W
MG;TTTA@*0T\__%T*Y*AU1*"R+$W)NO26U4P-&DZ3U_$B'UN'<:VBDM]:X+&^
MX[I&[Y0F)WBZTV>JK^R0;T8J7IR&6;1Z$$F)^X[$M*99G=LXSD@?]RY;G7&J
M4LK#-4R&*!M2U$U1XD&FF':$TB1OD,[OL[%O?8<N27_LG>:EFUR3F):<\C9Y
MUII3;V6Y/VU5=GU$ZW,K&LUMEN8/SA _5<2[V%8&G_@VMLGC6=+7#NZR<LJG
M#;:AG.G0TLJ,W.:PKP^1U=Q?/;-W7X7P;;/SI,MTX,^H%QZAF[-DT_Q7KU(W
M36?70QF*C/DCT&6=%EGW;.G3TT/^8^F/I_E@NV_7I9I;VDU>IRW*3^P(M5L*
M?[];^CJFQ-BOV7J<J"P69((S>,5$+3O;;M?1$2N=RCJU^7W0<:WBVZ8]!G5N
MZLR]IOB]WRTB>NSV367N?WQZSVC)_F>9[LK@VF^;W'HBA)_?[].=WO?YM/AJ
MIF3X_5[X"4EBL/!5L3!BYG=:4"!ID(DYL7^TY/?'=M)[=OMMZ:)X^EX27XZO
MD/2>_GVTQ&UMR_R53.DK.ZE%BUPVHQ#QA94M(1<S%W[2I0XMY>XM8MN!P(G^
M<6?[PUZMAT.3'WX /W+.>FC?ZC+17V]O7YWXX7!_98V/O=.*UMJ5'\;G-]1\
M>OIPUX>JV#_JCGXXG/>A=K@US!;JP@3;"0)MY6S;N5;KMQ_JI^Q/?,JR;3DF
M_]I:_SU+^:I5[N30^+WUZCM[7<-4:P,^^Z3!K'*V]92+0U/B&65HH#)^5DES
M.%V2/;7/X72&0^M*A],69Y018/OC?295 29JA_;'V6W/',Z-.IQ[/-OVR:%]
M]LSY5PYMX+/GO\^JIL]TD#Z>IVU166QILW7LJ!:9U/:12_LN)F[I2OQX,??L
MI:,@DTA'D[T?R5+'*[L_7CZZI3OV[-5&QRN5(%*3X]7>CY<O?>QI_GA%?/;:
M4<?>2V=[>K=TC7_LK@Q0]W^\1&KKFW7LC78DJ1R[*@,Z=0Z7&C]>NO3Q*JFM
MI_ICW^S'*[DYP^-GK\L^JE-RAG,_]I>T7<YVN@)O&SS:UK?;:2BTK:OD[*6,
MLUW?'3J&9XEL7<"]"-#][W/WOCMIX.T:@ZT:G=.8A?/X7VUCMLX/2//C>&<C
MYOS8O3/GSHC:SH&(3J+'N<Y/"MJ?[)]_,@M,E#L_K9Y_7-+^M+G]V;GV9[,
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MGWC3\OJ\F(?RG8W$*!_$!J]8"KZR>5@!%GJS[CP^@H<I16:Y(O6M\[,U+9L
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MW6?,[DW2N=%[*^&S8NS"^+9WWCI&D[5+O2+-IY\V%C]O--*MF3NCX:*N5:>
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MOD!EH,\9NBHMV)1+4SNP L1L(C<$ATI4MOB=(*^N A&KV^4T /8FYV0%+ZK
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M&)1A\9FY'&=J-DG(&?_&N=W#LUQEN?D"2&67AY>"^L<;+:>X,FM/".T ;A6
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M?Q'X8OKR"PEE@';!]8-2I[C\IVB6D(5AK@\334 BBT:J (E8+DES&-<IP0^
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M[J:,X,-@4&$&V@T#K_>M%$G<%5/XF+,E)J8!'QIPJ:0[NZP) VZB__X4N70
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M>H"A?5AFDJUDCBQJ'7YXTG@O(.JP@W/'!M,=WFRT2P--KC!K]$7Z>[,F2D>
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MMK!FMNCN;/'$;*EFMJP>I^.@ES7O*CGRKK+F7=7==]43[VH^V?4JC]KK:D^
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M8HYR+^BT!:-%A149G'8IT$S$D&C0S260/WI00PKHBD$Y45$1!51F0<]/P4H
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MU; $H2Z<G@BTH6;%RTYV4$6%)V%+=N;@:]B"F+M#!&HS,= \1A> 2X5U<N_
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MG?#%I++5*V@8T:'+';<NM9V^W/OP\A77?YY//>;'Y>'(_NN'^D_481I%_8T
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MH3"6?QA ->]HV/#&91B[^SID;"[V81O?*D8@!;RX'KM) I.&2]N'_ICQ:%W
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M@/R*YC?.EZXIM"2 K2&-_I2FHR8G&F["H>OS\+N91PO&AB<C!Z^'TJ7NC2S
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M&LBQ0\G/(?+".LP. O]H1:#P8Z@YJN<+\G:,R\K?_O2R;A4@1Q0C,/_8QA_
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M.Q\LN?0":]JC)OT(Q9O(47 +J__?0E_(.Q. Z&/[Z7ZHA-QK:[J?")HSIX
M]4V,>3MJCO7"ZV:J,5VJ 2QU2A);2D/GRGL0TN)U!,.9+=!32B&19JAC(@0P
M=NQ5YL:PQ%_5C!GF<;!QJI.10@1R& ,@D^T%__XR,.A2KK)9HI*2!NPHIFH4
M9V.K\(^GE=TY!F#8_&+\"=LUW<J!)]CL KR/%BNI3L$EUJD,'0!4K$ L;9%K
ML;EJ=(Y7V"2D^3"):W6Z9T+TXYM(MG0[T_G<$&:&44E0CS8ZJ1!'[U+(EJK[
MR/+"4#.ALGC2'(K5ZKQI>^%[&79 MF&+Y-"9/(G/0#*N,!>'*35!C;EVIN9U
M$_C$F<*[%R1 AD__NWLBE=&0[D'G<3,G8U'!\B$)V,75X 4QQ7JT.QC*')QG
M#ZGR?6IIICI:@!$R@?H.]$&9*FMLBPG@KY+JZ8K?:+@2,('?#$$3B$62)I\4
MU0F6T0>A]U/%@0Y"XZU4P$'@"5UD=('ERA (2Y$>^+.S? -]T!&&2[QT3V'F
M#JC)@B^%T A?3E9A7!_# %?Y CC9$PR,\DFQ?"]3A4+M:M,$\'JENB:B==@V
M1S"<GPP.SY<0YP;)QCF(<6N&VC()).$2XVC[Q8#%%R'@<TRYW0:AN3HI"-$6
MY%TE%9#N7K6<@7B0(@KS3,[ )8Z":'Q,)%:G#=;Q."/$=\Y@]189ELSK0>J.
MS%_^^PDG#RG?#@!$<^LY-OR"L<%HXVUL&>2>551(;L'<.M-NM82UY"))#AX1
M8IY2A?B 40WF[).'YJ4E00D^RE75A9.$6X!_Q9?/FPR(0N8#-1CC@.AGM<LP
M0_#R;E^:Z0X!0-[@JHC5-NG!0RNL618E1+Z=/I7*)8P)"X!K0?KXQD?VO"\H
M?&9BFYEHPM%*32;!'/WL_W0>H@'RS+^LV=)^"*'!A6.#?>N@BF#,^ZG\^<9:
M0SJB0<3?"P>CE>G&8_.P%T,UL%4=A+'57/_QO9@P4G9%K$(8QNK_ZKUUS<&(
M.YKS2^Y<5TNHYP_:QG=@DUR"#(^IJG3O#12:B6Q-EZ,F<_3$M;*X!NBLZ$WU
M#'F:;!*%%N%C-,17"E#2P($8[1B<"X=$G(T\TDV4_/U,>]4'"3 UZ FQK/U=
MZE4MT;,ZTE1^,.UI9.\+DTO[<,3LVH?KZR<VP>T#1U^K0!Y=JYO*PEC2LXKP
M=-?4\V$<G 6MF(L@V"W\"4G_ 2_>R+XL.[;,VIU_#7LM"+)RQ9G[B9*D0JU\
MIV,>=HEPO:_6EF(PD\.,54)7S4NS3)$C$,4YV2\0>) NEM&#%*=/3VCV==>A
M.G=5(88&<MWCJX+1T^SN/=U]0\Y7=UBS6'Z1:PZ4$>N]X(9O+L,KUQ)_*\09
M):H+C+],U$3'5=G-)?+E@M)<DE,!QV4).,+>SSO;7,S9>,ADB)Q).T2 /3#Y
M.# O2ZW73$,1V@0J4$U<HD<!X>_:/C=MS5PCGOI3N.)VU.*4;QCO7BRV;5O^
M>5^EGH^;QM48]@_@WGCP(%N]W':)Q%\A3.[6 CM>TY))(7WWR2EJ>].D:XM<
M1SZ)M9N9M^#5]_9L[LO:D4[;^.1^_>M.DVZQ?$MD%AH^\,GDC!'70;$H*:%+
M<J6Z?;5#S/+3,=K/<OU5FI6KGW81Y7K;>Y=8_?;3L@2O_:4O?G:H*=!0Q[&Z
M<WTXBF.R.8_I/5K"SHB^S]>L2J+4"'Y/81)S"2@W5_>9N#F;C*R>TS\6$-P"
M?6]FX(=$$*$+^ RM?^.JYN(I5E_U\%0-V8;_R0LKF'9F2R"FZ2NR8BUDA-G\
MZRT0Y1!&#]G>S=KT1P+H@D!Z"!,>G&_ 8I)$&WD_\20$RX#7?X[G4%E@*TPB
M(%#H54]G!$P1@HNNXF<'I5@P=K\2<&#A806?O)6S R$3%,%Z".2B!'Q3\'HJ
MR$$$I#C \X2@RQ2(A6/QVB6+3WLP8-"W&CQ\#DQ^!7B'D(@P].$:UP4%UFWU
MQJ.(*Y)GK@5UOY)-6&"=B)"_/?EH'$%W%#V5(MB>C8U2NV^',*%J'%^!B1K%
M2*DZC<#6.1\U-GS4B:7 )HEP 8 K3XD=7U[T[">\GY;TEQTA$R&WB @AOBD#
ML>1,UO)JF'0UB)2F6'\9\E^OP)_$K$F="D@^@M^@]3I3ZU<^&MH;F[!%A-\;
M3$H?Q2NND<5A\7\'D=8I\->FB1M@9)O23<'W5@@]Q'S\F;&-R4>*!";,%A4^
M#<C">A,&3I6<.X)?S_>#)HBI4\3>97 V'[\?(6EB(\;%^TJKDR?8<*5J<870
M8\,V6*S^K8R/_SN.F2WT%X>1Q=M)IYP"<!IZY"F&L1G&RAF.4?OL:5^YXDZ!
MQ8HB45C4<@TP^Y#*N"=F<EP4TQ@>@'URE%$&S55VG/7=+S",J?4TD,'^17YZ
M_;"8Y97SA@D;I84P#/U75',ZJO0DU9P5Y V*D(AW+/8OKP41\/GI7*_ZFB-!
M&+LBE[(L5W7UGI7U-:O?U42N,-HX0TFTQQC[UVY^Y.2]KE8GIB8)K-J9[2Q>
M[[Y$1"P<=590:LO[Z)+KC+6DRC22H4-P*A2#]ZLIM5.R7K3!W.O5I'Z6 B[Y
MJX]E/;C/+#C^HGT-Q"$]C*WG7/#81DL)7 %G"4$C%5?'NS[@UX&8>EC7O*;H
M>G4[D973L=MR)V/>.\A=Y&X44-'WDQ 9YVCYRV5X)Z/>J^(0U'#%O\%B)T/S
MJ&#3N^R"(L._YZ2@U!FN4\6X@IOB.SS(:!A)0R9/U>M5_>:1 I?_ITQ// DF
M5 "_^8U1%*+Y%EF;_KP.ETYC(X78U0"N7KIB%8"/ %PC 1R;AIL/\ XHL8D7
ML$(E;KZ"P5=A VFX !C'?(1;#&!6*G'L*9? 4=QN[6YO19.S"^[F+\QJ-<[V
M+Y<H "]0UXR9[]?U)+BH\>N^XAEJKHT*WV^"=-&26D5X5QBI0%OJ\2W'O,O+
M4&@_2DY5XF]FDU+X^+NGEC4K\"DL-Y$8XE\GKU=">=_)&VG+R[_B7=!=&P_@
M6Q!2LXC@[D!.5T(Y(21S%5CO1."L]$]#\'/[A9[C=GXI+/R1HB LZT VBR4*
MQJ>@J_?3""XBMLO4KG*$G*F$CA017!3XQW<V5BB@L83*Q0RX707!,&$8.M9,
M]C_3AO_[5-@VA/04(KG"G;Y^4-0WHJL0?_XTG!^$Z7L8V3U%< >P1T4+NU&<
M&\VG]SQV%*.C!/;<]=\32L.HE.1GQ=E'1R,/JXF0ANBNQ=[NW[T2P)S0=G6K
M".XT',,.7JJ%;H>O;%07B!*J=#B0*8U@JTKHUH*6"KS)Z'Q;&IBFA BL<F]'
MLI$2VC@%E/$)66Q\SDO01HVG\C=OX.</? =3:>#&UT0#!3Z-!@[< :C".;PM
M:W&F$K 2$3 <,E"'A]6K&6K  6'&]D2;CLYG* %[&MEQ"K!0X?5^X@VFB.4P
M:*SU<!O$6])2$D*A=!'XX0=^,8:DQ\*G*@"?WSTRT!C=(\R#_O@@@;>#"DB#
M(4,82E$#MQQ (Q:>H0"B?/"&K,0]3@0L"J6I@0P1:8$8=??>LDU 3@? ;!0"
M$P@$->@ZE.@J!$)@G2TPN%$!F?#)6>I3VZ:(\!3>E15M$-/5\AWKI]X=@#HL
M #"' !U//M'I//9>2K8[FEV 9#/"5^Z%L17?2?ZC67DB3&\!9JF*X*W J+2Y
M+:^Q"*!3T$[NG!-B%BI(>Y1.\E%HDHRG%:Q\])^VOQ$_.Q*RALA&+\&#I\%,
MM5>W"!(M#U,\**G4$M^MDI0ZP08*_E-C'2<'F*%*T$-*L$1UCL/F2+K?C?A4
M>"ORH<[OJY&.W>@Z>O7Z>2HH.L=KA_)P2CAYG6A1Y=$+8#I8[T"8FSYM+0,S
M:/ VT7P';4JW8NM+$R&%%1P=XI^M9#:E$_YB$#;G@*2ST-LS'A5*T6,IR3J?
M0("9)X$X\QH/75J2E<+#_]IB&#W77UP@:B8W\AV%L,Y28>1A^$0W@#VW(&OD
M*-%C%-?-PFVXFCXQ7.NXCNB&XKH!G)N(MU"($2I)<\K17)?]Y/W-Y$-*ITL+
M,.YJ2/F-5&:E4SI5H>VOF7\,KH:A>6IP<15DM-7/2H7_NP\T^)%DR0=MM: 5
M?\%U)_+1.+R>:-A6Q:_*G__G*R)%)++2@C0@E-$?8G&ZQ!B-ZD;!3-IF0Y6P
MVQ_>SP(-A*!IO]< !0I/R[%B00:L8$=$NEX-V&G![BB2(X(_[$1>_!6_9_OJ
MB@!XG?#<7WWD#..DO_K6=O,A"R99)RUGCQ.H4'E\VTVRGP+GC0)USLG9:,P6
M6&A$*^N&(]Z'0/, Z%PZ879P6/:5+%Q%)@$W=*DZ$9T>^N)^.*;+U1GCQB+6
MW"<=4\UA$15V*8()>^FRT>KDH>\KCDVE;[Y:X[B#Z 'P8K70T6K,*PN<'Z!S
M ,#X+\0<'27%5)&6O,"M '#!I^]$JPJSKIXD99'>;F,OWKIYVS>RC5)L-77Y
M\[+!;SGLJ>_W"W/P"0+R2;7?1M$B$^2T;X)T0\H#0W3=-2L=8T7;WR] U%A'
M5T32S6=OTO/?(@)$WX$V10;16"<$#8FN]G"BI3!GR-OCV&FB166JS0!^??UV
MTE \"2MB'B@!/OQ\]"$!>AU&KDC/(=@W$K:#)U5 P-F]SF&C9_O))C#!=-9#
MC,9T&W4NMK]-P@Q:N=TBJ9E=VJ)NT>! '[EL%"B>>P@/[B([F>TY"F#6.1$3
MM*0WNWA/AG.CHC$/+N&X?3@6+;<Z,]M->S4./M[^BJ128W?#.DU:J.^ADTI%
M=A?Z[-42CF,QA[7DA%'",:5@V>KK]Z1C;8KSF$& U('W;@79#>!&]'ZWD'#*
M:.G!=/ ASA^^149FR>N%0ICO7:8"_D@%&\=NZP!9N_9[I?+GZ_+W.:LSFU6
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M($'X&#>T5E^W,)BAB^##ZY#SH1?ZH2F$H.N#H(!'+"X$+3!R<(DUT0(VC]5
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MBF/SID5Y<;343(XTV(E;02?[B1"_C6\B^ZJ*,3TF0B#0$]/UOB7N,6 9=TG
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MQH"C,D"Z%D.<08U11_@TVAHV+T*!ZK4#!F)K[\DK&QP%3W8"NU9?<-SK3@9
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M1=6\*401)._"&FPK+-][+*Y8-Y&&,>$^X3A<!0B!-!#/X9B<I):PM7,Q^N)
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MH'!)?I%7#YWR1R=B8S?Q2X8RH^^L#\5\VEK?MK3H7=C-'#U'E'2L=VV"OG+
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M$A+52\3JC\U<J$%]U>2F1"F'$OLL?8#_: \G0#QY*QFEHV3YH>78(3Q_@"A
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MJ>!#'=W[IW1'4/!03G#_]^_VT,I 1'@RO2>(>Q%/@N[ .N]ANH.$U?%2>ZB
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M()1R7%2[368W[![2?:H1B/XYU=5,,6OO,WH=M9N6"U,]=''D244UK=Z'F:3
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M_WW,J9I9.GN(D4,#PX@[WU6XDY1DNAS?(29@U,RQ"H8VC9@R26P30S?TH22
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M,K_WDL%\16.]/F*ZI*4Q,J/S]8F;$9K/3X$SD0KF?U<M6M+:IHL;7R6J'&J
M(\N[%8=OAI[3?C/J<J-CU[S.RTL&79@OMI#6"'=(^"^OE@E;%KUYV/O6>X)H
M ZP42P@>I@YU(E)U5]/W%NBE(#I= >EO)DWE074B<K+FG1PF9Z-0U*(_3:WO
M?@DL^\,X4H(.+:C(#_^_E+FMS6*"931ICM5X/SS\^LU7=T^_\XS$OQ! F.:;
M.M_):VFIBVJ;:'(\%TW=$P6-W=?+#,=;:P S!$\7%YF. K9\_(DT1$>.WU!(
MNN4*;J#=*AN^63X*)"/X7%,HZP*^60/L*P(<M3\^V_2"'N'*^AN>75DT%OWD
MV\N>_9;D.+,/)Q=NJ.C#;YP%4BP^=P.0%G--S0)0V#]?:Q/TPX>T:ONQ]C5W
MYB3G#S_AU&@T$5>61!V,..A@D'S?:H6+M7P'G/C2IEN1)2YR]VX3I^X@A8+Z
MTYL_%48-%IFKSOZ3Q.Y"+!#32@VPS'';V6&'C+=FEN>SJ#0P?N+;&^PL,.=J
M7N7(_-\AAAT,=8\"N=W&)A^::JT71&22-E8PM(3D]>@^[63D"R7WOHJL37N?
M+M6_XB9-]'U'A1>=-1LE1/W4 ]8,SOU@LW[.;'KC&=G=6P-LO0>DPV0[/G!F
M;1A;I%<N NK41%KUB9<?%VZ]P_^V^#1,I1GZ]T=E^C"/4-(3]XR*BRJAN&YN
M*2>@4,J+9,7T/^);Q76X4?TO<74GGP57V\1V)C^\\SRTWC'E9NNRZ.>4!H^<
M]U,/[[Z,4/@4:%N>KRHL-7<+V-DE\KD9Y,UP:B!]S+A)KFGVC6_7N-S??X@C
M&*@\Y:A'$G3S]E(B3_H2XTX0W6(Y"^[D.\\U(_X[S%7A':PE2X<L/UG=/[8T
M:=\V6LK=CTE#%981NY:-S:2,['7]Y/_#O?G9+9[?A<>*KICK2UO^XF[8NV]F
M[7AW2O337]&!ZQ^?R^L5>*XXNY)5:#[\9=7CV<PINYSY:Y[N6/-RZG9;Q.'5
MJ\YFOWVXX.KT^B<_MV@F#M]".7T7*6SGD:HKE^9^;?ORX<E_#F:+Y[XW/+]U
M^*^__KNXZ]?L]O*%WX<NG+@"O@F-N(1+X/EZ$\VKQ;[[7+HUOA3G:U@_;=?;
M77V4!=C;O3I!+H[]VJ'^%7ZL95/^ V'>3>) P[6G/P8:9X]E!IFF2)^WFBTF
M.PDX$OL[0^9%I0'!YKN]LZ[5U,_MH%O:1&?=N1[_GF=.=1Y!GE'XM_B8$<<^
MEU-ASG?M&4M<;Z^\N\1I@AE]T_E:F'.8VP?FW?"%GRYF+UEX;^K3+>2C<<RH
M[[>8SQ$>%UPVW0PR65@=L9C@FK?'ICNL,Z3NZ&>7D"7+HBIKHD)<O\3$1,?F
MQ,:MR/D2&Y]4DQ.W?.V9+W$KLY><"5J]_<N7!\2%K_H9B26N7^.3BTS<'B;6
MI<2-KVFIV?PHZ4#-5X;HU+W:P.:RUZ_<&C)ZWKH9;IIQLQ9G5OJLS+D26_=D
M\SV_!VXWQ_P25^SXA(NXT'SG>9W'T\^L7/74KN6:O_*[\\I$A4:';CS.2E<T
M76Y*'N(DE/Z]K\=K[UQ4TO-GY<^C;EC>"UP4[OI :+[A?*7/YB+7W0EW@O$!
M49DXO5CZ=Q!?E&W[8"5[EZR UKAFUB"QL>SKN<3'OTPRGNTS3A=)B; "E7@Y
M+?_>INWM;E\KL(<WO+DOC-:*CK.03:VM&='\:"7/93PW/S<%2-[5Q%FML+ST
M*HZ4%W2YL14DM7?"\ZY<"6^B7/RKK$WJ15_P[Z'CWVYN/[G7JVA OEBOR)+Q
MV9#YI.#S-D&^%CMJMPJG/V.^<U-Q[,:%SS(]RHIJ0OUU?3"1#@F6E?C41S P
M89J@G-DW5:\V%X3-\>@80XR7I.*A4G&>H)G]H8OEG9NB,TV[5F([THJG3L_M
MR)%RJN+31""^(4$IU3$633?K?.D9RJ^8)YIN*N<-*716UDNYO\2.WQVYNL(>
M*HVH*O)EJKSC1VGZC7X7%/8=5KQ993!\FT7-5=/-,O,)[EV%U>L '%7I;V_*
MN1R/3&*,1(\MV?I:<:432;8:A,C3U0H:FJ!:]>3C31507%>38Z8:(4S*Z20%
M7\]&L]Q2H)0P&@JI!C*<D?''"M?6 *:E<")]=4*A-JHNX:GR2+<TNJZ/)5C]
M]KX@OJZ4,M0$/:HJ^1B>1<+X^],YXZC!E*^44:V""OLGV)X:,*0ZD9*U-< @
MY&.A;BT79\3VL;JK(6K/OL?.&4^WIAF_DISVGZ3FS*(K[W2!M ZJ93D1) S!
M=:[C35B]W,FDU$-%\<;-V4=1J=;X50Q;I(5?*0LP^T4KL2$>U]64#%B'ZY;X
M]BATQF/\[9L!3.P.7\K!67_*V=&P14HH)Z1/H5JWN](E6;T[U4OR8,J7A"E5
MZ:[(Y& U0A*%E^_.%/>3.ZW/Q L2P2RT'R]0%F,[EFCKR' $ 9_L%@/KK67_
MT7B$S!2HM6E[L)9L,4E]O(+_H&K(9/4$X":78BW&>?KSQ7VDTQ.9:WKZV6ZT
M$I=XA)E%NQ9L.D.,C%?R*4K4_)$8B.R:!.W$_20\S?T%!Z9FS GZ<$)!$6%L
M@FZJO$XR%.[VME#R.;-*H:6&C$^[I4N1#2PSVR(5U/_1"A@'.HGP<7(1MAGV
MP_$,2NB;$&8VBMB_IJ&ZHA!<TT4_;""O+I0'Z#0+_G2 4.(]I (^G;X6CFXE
M1W1 >JO%(#=1$A;> ^'S9 7ZM2C6T+N=QG<OL-N&8.(W]>*[1_.UBP&MB"E8
MK[&]E[Y+#?GT^^J$QO<./+*I;KGXR;R:" #NH^[GQCZM5?X<LI1^D]#EB>WD
M^&6XUS+4,T;:R>&9^2^+E.[)1:C=F@.\I[2+EQM:M>T+ $N>!/#PSW&I<P?L
M>+>!D<N3=)O1.43_W!!8T ]A-BO[, ()*9*MIF_,59H(/W97:5A;V'#>&LQ'
MW3-/$K::)2CUGT-%F!T UDR.!KU>1HY4JP!9@"HH7 [-7?9E;E*\80>*]<H%
M:MTRQ7206]=?V%*-/6K."N&KR)'C$[FYBK7V?X"SM=(78SUK6/]79)%VUUXH
M>U86O6/OP:3*LIV+>?[VV]30$F4BWD.\WEYF<_K)T4FF>V2 E6GK=#3JRW"N
M[W5-4A&-IM0TL\@!IO;F5?^FZ>\VXJ'B&.[3ES[J0>83 .]/D^K"'RTV=V+N
M\[9)%G0=4I:U(X\,[Q:297"KT>_WCZ=@MUOX]]KL7&0.Y["=3AJ3V+I32DD9
MYVZ_R02H9@^[C SY4II,A%T<DX<S5$M&Y5PL6Z!:LO#8PEM1OE03\0T<]YON
MXEWY+'RN/\E*DZ';H&;-+IP*G!1):.T =*4*L+/2]!&17NKB/<,DH;(8KRB'
M6?'HLM>%XH)3O=IZXYT0X !%UR5BV8@/7NX->NYHA38%-H:F#EXV'X6)2JR4
MD_@18]C@RW+.E3+34.P4!.[GQP\TKU&0PT?5V<\CI?1MH@+S653G:7(O,TV,
M7=HP>3<<X[K5?X_?J^/Y><]VVHT;&D'EWCJ6^HI/RZR0&=VNAR-D-@D_,NJS
MHTS.W)/2%S'WG$YP",FGR^L/$Y]NKKRR!<[ZWV^9\>7A0O(:I)C1@S&U$%<*
M+C9KZVXMP#+I%;J;E$.I\B%#2YATZV#KX+]:3X-=0@LE?)UN_UDB:4,P>N92
MXD1W_?5_K31$P=CJOG7*V?C5$S51%L"Q/^8^R<L@[-FW%VR9E?'<FMQKRQ+,
M6;*M]O;";W>:M9@VP?E:2EI)U]_^Z/Y_#YGE;R:R[4G6W?$%6I\U'H&R@H4]
M$C,0*WH$SB<>6O]HWF;;"WL]+IQ,D)V08+\6-V&%6CA!GE<[X&:N39RVC!,"
M?T[P0HQW.\HMP7$!] H-A\O%>-@"(?&8/95:7NZ 6^X<#J? <K9C@GJ \GB#
M2!Y:.$R_8<BOB,][SLDCU&.<B:@UV<W;'8R-EN![\KQXW2<,\DCB_/]- G%*
M0\.^O*6Y*+,GCPX 1IAFH*N'J0#(0B<\#^,]!)SX"%SZ";BM !C>(*:]Q04
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M]>+="ZS',^AQ!SM?[/]#@SL.[+^@Y%!D:%X70%$">;-$I]QWVDHFJ=[Z]6_
ME [F+;27'&B",+9$#<":16DR3950@FTWGW27D-2 C7G)M3(.:1PE\]>[B>8
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M]XVHK[(U46<4"06++%AW1FGYJ$"F)?N/?;.-O1FRQ/EALL]VBLW!.-82=J2
M#HGR@&WN#!'6L[#P(;HH1P0$'G%T')CS/-/%\"=,MRLU)DWN /'@'LB(&&EJ
M% NO/N+N*C1M*@[.RDI(R7R*&A-^DF$75M&+-SE2V3Z"F%CU*$G_+/1XK;X3
M39(M"OO;&^,IK +LCPRL>6Q/O_6Q#Q<?T8](:2'!/MY-;M&%))*;%S%T?9"5
M9BLY-KZ\_(G)MZ'D?=Y+T*</@*8UIQ7!&X>M,  -C W?/3'L>6J%.#?-+%$M
M(EGR@8T"@QRW 4M:SYH->)MGG5G5JLS&#BMB0Q)H0*[F^*%#]S9V>$9=!E$9
M^N30NVC#%;P\-/M XWK"QIQD8)/8+2FZ^H*K5$4B)\W*).18QXYU^CDJ)<DL
M]LO<YJN>CQ7OC*O;N")I51I#S\QTG*$DO7QRW/0@O+;/*I;5Y1:R627:340C
M_4O8O&*96(2M+I<#]KYA*7>-;=SAIYC=S5IXVY[DB!+U_'3SRUV*#FEYRLXR
MV&'/"(5Y%WVA;2Q98*I6=5H4YMCD8@^[A82>U!^-"L*_"%V7BU8IU'7@89T"
M;U4M(25>N.Z*^&%HRQR#!D(_8H()PO9/P@;_5X5X*S;E;V_TN2K(TFJ+M%'C
M6=WV48,>O/!P%^\X.>6N*3/)D3',)D?\'OE<F/=,DT_%?AYI&ORJ*FN*8%=G
MSL<L#L$< =+>(OIW@TZ38DL5:PCSW9([+<?*YV;C_]PD%>%"YUTO6M=YO=/Y
M\ON;W_[9^*&-F;?\S'!)UY:>*W4[-)Y[FJNC,.OO]">#Y]J"E5[FM/(.>Y**
M[X>ZY@J4>A?K3LJQAA=@H8 JYG:_+@ZYOQ@=N!=PG63W?J01C\QLT7H:U"@8
M](03)0+D+YDY8%N5ZV4ZR"81$Q:@&@:?>=+@7,/F# 8UJ=MT8 EHX"ZF+%0"
MN3@QER33V_7Q2BNBUIJ1;O&-C*!\GAV,^MB%"G%"1[W]\IJOIY9#*:F9'1F=
M3B,<IUP_\\#9M!C.VVHHZ,C)W]*S+C9HHX!U1%_4R&4S W<=F@6O(4B8RGEW
M1U%F  H[%SA&("3"(">UW8I=\Y<>&P..%2+/>/1\O\&'=F8M+XC7%H$F0BZH
M(VG$[EB4?BF$-:!YD=A]*$)9-45?AV#$.TOT8M5@X D*WG'I,?PN.>@NS@?*
M^[,^ET:CC?M@?EQ.=G8$+(Z3 %]8ET%B$AOD:3T?U'TJ\@HGH*=-2 ;P/P"G
M4B<FW.LV/GE9\0*"XKS;'M%OOKFOTB"Q+UP(C2S1BLKBH_0CQMU2*=MK1!IM
MB..<#X5#23Z-8TQD7_MT77"@?DT40]&H6O'OW5-KX PF$HWMR>A?-=((T@T-
MO%Z:-S7M)TT%N>66>M4K'^[S:,LG/>Y!4>:B.2$R"6,BC6 ]^P_MP(_)2O;$
ME.B>R</K4I?335"[V[LO]T^#S&6C,YM6>2D4%'IHJB=1L[MH>N"\ ZDNN-PN
M=+_AP(KUH;DK&^I2^*->%W^<8QS"V >=ECRY4G6U[J^?I1\N_[A?>6[QQ>1R
M^_5O-S\=^C-ES];[]>0\:,V5D<6-RD/3<JQ>V6VZW:6]X'28WMO!3I'KY<#0
MQ"4&+U:V?!UHF''G]]G)E_8JC1HSF"2YO_US_Z[)LX%#A_BN^\"/Q4^650U"
M+.BFV<.OD[G5?.'2A1QE<L>3:P4G3^5$.X%S*YS^/'Q6L/.HF\6.<Z'@)L?,
M>.SRXNU;&V+V-';MNS8XUU19K0 ^E-E9TV>-5IGHZ@-3QCWE-FOK79?<N;%E
M9L^"DUE.B61].WFKU"]([=((ZE/8Z59LYRPG-RLC;%VZQ<607(8JAR*N.<KO
M;E2./9_W5Y ?JI@<D#43+'+$%WN2OF3F^11S*7:G<C'C2!YI2$BQ&RPUE_:-
M#DLAJM[> 2OI;L0G1]012)P=VO:F"+U\@JZOL_7"/7DN44,;-G%:2<YV>";D
MRRC*$>=2JD#"+06S."=!Z55I&M8U>%-1LO"49]CEK6,X= Q?\RLZ*(O4&(69
MSL6 KCI%<&,4RAQ)MS25XIP=X?^Q<B#<2!*?'K(3'?,=]G)H@N<6W1I%_8H!
M<#V <D,[B#&5M&)[#4^[% O!0!._/K[Z-"T6HIBYZ5O1&U%4]3NZ10)@$#GT
MAN:B6\#5068)'6:DV]%H9V<'=+<C#ETSB6(ZIA-P86]SW93N>Z2 V0!-$4QX
M6Z^20()I"&84*U#"7#$Z##%&5'+TUD$X83QIF_B4@L%*6&+/TN6X,&P'[%,S
ML7Y(%K%Z]N+62+=*=?YR'$3$V,@SP1!KFP]QNT"W0LB<I<TJ2-.Y.P0AZ]*T
MO* (;9?Y=^EW5C_LS_AQ]M*?\)T0Q\CM[5JJS_XN]*R4A&9<MTN5LG+4#+:D
MRX>OQW>,):]Y+Y@[)%=PW/K1R^YXL--_;#Q,4QGY/P2L[=U6ITANF#N/<?HN
M*.CC>[O X,"O/Z"Q .;L/\B/K7GM7M,[M\2W+%EP+RQ[CV -XP#6S)V6B\E
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M(&O6PE<&A'.HC/NY:4"D(T0\P;4W!N)FU@4"@Q9DR$(%WM5D"Z:-]\G$IA+
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M;$B'3-'SC7)"0 QH[5C%G)."%DIHOAI(\8&-_FN4!MAI3K)1@#9<, ]#C#6
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ME'7?H^:1\1E"US#@K_M<IQ[&T?N.4DBJ#X -[R; )4:S@#P4G"='M-3G;?B
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M0N E\P-/$$$CV;(0:XP"X,(0D18-%RXYJA4O\GE;#-0LLR3BM;S%H<RJIU+
MBX<CR$1A*9@+16S@#01H=/RR '<ZGDR1NL@!/P2/#"($0(#209B&\^)@;7&
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M#/'\(]28CBK$9%#,/'$HD*.]<CERC$[+;JI^DH#3E6+:G8=:_QXXV3YT:GK
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MOW07 *0L[-/78D<68)"%X11B% "000P$#N5-]W4LV^L6)084&$@'&^9K.P/
M@>?>53*CO]\*X4[AU2&)APQ@J:"'7XH]O,D1]<3K:>!"&;#H,817\1$*Z,S3
MGM.Y CE% 4_1[.O'@>3-@.Z,4)^)'*>+^MCXB!; ^P:V$"$8\;'[4]CE2]#W
M$) T*/9G =1Q2%M)KYII?G =^AX!GM]+UQV'R$I@)@I;L@?054$S>;H$B3\\
M*#;N_*M^#T;AX79W"5ERX'@YP!J'2-(__;TQPT'A*@?3)EFQ"PMWY(32( ]@
MN1\>[*Q^B4=,HFEB4UM(B,+Q06T"19*VV+/1>[WI-Q[.Q)#"*MY#$=YNX39V
M\6@$/W^3XLJ@S;-*6S$44$C-/L=5_2D*M8HJ2O,3%)((L4&N- ^2(2[PL!G?
MU1^TR?$[8E/T\QS*':RS#+(UF^,E/ZB@5-+*Q\OB'(^1%B@C6V2>*W!N/":O
MZ@T#?XQE/*!0:5++6R*2==O'OP"W6E"#*SM*-4SMO(@"6&K:G(131PB=HF:%
M-R$2RQ@K&B+O'GX2VAR\-%[)Z&]F%<:B+3M27S -YP]BWFU[J0PDJ@OU=B\0
MYK@LL%@?'4MD'W8W*FKDR0,+H?QFQZ62#9/II'?1!HK/.S"\B:YI4+Y++>%O
M(U)J= IMY['$9!.]:/X>!<&)D-*)3=A2LQD#D$&]&C1EE&L>[TL6<^>;DXOT
M84)!T;:>M6>;02&I4:%!M3;8G /L&IWN8;;7+LU:%;&J0-2LDD+O9<[E6'#]
M;!,!:: M',F[20-2XFX"SD7G@@ >1C#0!ICG8""A_#N1@%"L"F XTFK I+$)
M!&B;:?E$<Y$Z\IXM,6-U%5[7PJW9/B,R\288LYH.^DLF37O#R-*X$*9>>;D
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MQAK-<IKB4*"9P%30A #]I8=P(40[ED[U-+,69E,']."69^%2G'#7"(=G4)D
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MZ(C*=B3P=9[ZXQ7_OEOY/\5:<%I">,M>PT.RN\8PJ4=47R._HW^^6&3"_LI
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MC]B9OD[YH%1UR%[6]"U^9.=+,LW@\_NK=F\<6LX4TEW!;#_(3G6VV4B<VNS
M$B&8$;150781]]:J%M4O!FTLQ6DX")8QZ0NVNV/(G7'AGJ^WG@?\T(83Q;W3
M?J& M?*@W3FL:7KVFW;[;RMO-Q6EJ/\2YX!_4!20%T:9]!&"S O>\RZ /KN(
M'AT^__R,_NA)Z=R2[@#*0X/OJM&EJ9=!^=!+P@+((0*RE4&!K<SPS9 '>M9;
M ;H#\($SH$+H7I)S:[276]7!].<AIT+ OY0@NW6^5R6T9IS,T",NELNV(//'
MV<%8KIME <09 H0S-TW=1:R^70/&AVV?$B[]U#AG <,3Z_Q!->4$.QS3SV\R
M07Y)CQR%!PZR2%7C21O5I-(-W&R>R_<,O]1YME_:T;F3V[*[.6Y&XN0AWV;=
ML%L.T=; 2B2 4\QD!0"FWX 61+C,>P[T\Q![X^8E-_BC_:"/\&0NSX_83>*B
ME_\WS)J32/:Z,?GA2\]3<S!I*DKQZ@:!2!+5&2RP%(7R*%[FUT$;20MSP>V9
MH%HX7O.1:XM"/NND7,,O__NX-84.-NO=.^N1MVF,,RDD$@.R!4"F@D3J87G*
M'?<NY[U>-A(U)\E5%%6" B7F%6&Y"]NKEL^M9)&\^6>>D8?:T9L1WI3$X%IC
MX7-%OU<E<B?"<T4*M'#]$^:"\$6=?QT>1ZQR],'/ JQBG=I;V,4B<,$QGF1G
M8$2K8^ RT#X5.JB2A_$8;D".A1ISY,A+)Q5)F<-ZQGOKB"8:OONOPE,N-9(J
MYY <&,]HQJD']C$3.Y#*4QG;3WA36^YGC*?%W;=7&39Z3@[9V5H<?VKF-EM[
M7^IEW50]N;^3X0XPBX&V-<;FR$6^0Y=9MEB69 ,H@D@>]_Y&9_Z8H<0R\,"?
MMXY 7>!!A;AI(>0"N)S0\!]>$DS#,W-[2>_VDJH2H5X>!5^<P=]I7VZ[IE8'
M^.?ZOKOM:V<A^@ZR)"2T+;J8XCQ4K8[D7$#Z,&5RH=@[#$G.776WF-,F)C\W
MJC5&55M81IA?+IM:RKF+G$25.EB'+MS =9;UVJE43F6+NZ%V8P W6B%UMO0T
M1<XB-G8\;WDI2"@HXNR;N:9@;V*M2RJS.*JO(][:DQR?_'K(0;78JZRG)Z*M
MH]JSJ)G1 );W[Y_,__+GB\<//JPPJH@V;DN'+8J^W7XI!CU1"]G)_)I"/BG2
M]21H3L:%=JR:"R]2[PI[CI7:4\+]<A1CQ 7JZ5GB!N-=<ZD]DP*G)>G%R77T
MMB1YR#,(6D341.],UX<];X#=S^V0ZY0U>ZU6&L,$C;QK'9$TX3Z:WQI5LG#M
MW&7&_%T=5B^F8TWC-2J-/4/,FMV5?E"]5,=%,FJ$GL+8L@@'Z<HRFHMA'95@
M?35.!-$=/6EB;JJ,@'@^S&8'H1TNY20CT@;ZB\\]5_D,"GA@<,^G=!J-PR72
MSH3IBV&"4/$,][UM-)^G!8:X,&Y&\T8T+S@A?<S)P<DN(US)G_(BTLY!V,LD
MI4I[-3;PHS&*U0!22& ,"7@%";M&L8+(?MD'*B$&7EE&6J.F7IURC]!K9 F%
M!"IDX!X 3_IGF:&N24=B0L E)5:0>"X/HXFO(S?+_,)R1 SF\T?: OKM,;&Z
M,W@F#_09U(FHB=A0#XV-R@M*20,YIP36X2'/8(H_^3"!'E\(L!ABJ7.IS]Q\
M3.?G(B70*/X6#<P645;1H$?&.+U0\#Y=G77DL@0Z%UUI]J']&<G#15XJ8W63
MTX2:AAAE55?+S1M2EAT%G(BPS:X#(G8$=PQZZ@,OG'$97=PC4<U%8!%-U:7%
MRWPF.8+G.L)I:0'A;$@JTLX*K\*B-E^3OEO5L+(N/[-Q[>E\O6]=.\732SK6
M.B^N.;:W)<&(KBIE#J MU*[H&$GA/[@G+'C1[,:C;K,ZW,$,,,2V%<IH+6MH
MS,7<.+:?#[CUPG[KQ C-]/Z!JQI6NX,K_860W#8O8HA2<"02NK^)[0>LYGV8
MU ^HX51B4E_;(9$#(:>;?G9*H8]P1!QZ]W.CXP7\ILR'/NCW>A0-?N?4VQ(Z
M/T1AK3-OF**-O=%1K&,F<]O=_'_OZ2MDP[R581%)]Q^\YE \''R"+]B^^!2%
MV2G'7D_M@4O9T\?'**>)Y\(O)YSN:OQC/S-K!)V,@JR7ZD?GR9^Y)WQ>-FV3
MZARJ* LB.;:-OAUJ_=^?1\A\N4(0X6 )+@G2RZD'G268W-W-1QXGQA21V"6A
M^A"F)GI+-0Z4=!*++</F.G?;FJRJ?*0Y[(8N-07*U7XHBV# 2=U<G^[95B59
M;!4NNB,:+29+!30/;N\7+T61_1XU+>#[$^2^G/3>[W"61A1!_F-&R<L7K@R?
M):VB ?G4Q#P5+$+O"SH$/8D[$K$,PPW^8F"6<"ANXY,%+(J;$NG(C6"7Z$5_
M;]%R@BE]M/MGTWCT?*G$+:FR"%3'<+Y*I<R7K.6F^5+^63NQR.A>_SS#?7:^
M-$$3 4TN,5&7]NN)?7ER]?XR>[O/IQ@+^Y/J?FTZ()#;SXK;]=8]APPO7!<J
MGO:'?\.YP1=(>7[\Q0F+^Y2OJ_RV/K1;]>;V[H$RMX"6O?%^"C'1?;JKS_FL
MJYDS[_S40XOACRKCUTR>R!KY[N9WT;XJIZ@U*Z?XI=];C_E;7S)]1MK=?*[F
M7]OUQ55_3?+RS,O#O:NW5#?5+74/^S1:S-%7^1JRE>)_S]:KOJUJ?#1 C0HJ
MF5?J$-"V3>'N/6];4LW!Y /35V7%+?N6U-"??##@0-:\]5MN-M2>%(9<?Q67
M_\9NWU_)PCFS:8EK.7>3MGUN_T=S./&'DJ1#X2D_+SBP)N67;2E',U..+)E\
ML6;18_+=+441G@9:H=W=A3+=FC[F%,;;6:&4!AD>03SS&7Y\SEB;>?]7FO5A
M]Z2-646=5>Q?_CZIL=OU)C*J2;ZZK0N^B%2V7IJ_Z="/XR-VS]WN;H]>P#[(
M.NCZ2(+,WISL6V<24^//7Z\HJ?-M[>J+)B7J[GTDTEV&RZ8%E YI@NFLQ8"#
MUY2W"\VDK;YS@@B+WQ07LT8_-?X1]^?LAVGSFN]7=\SYY2WE3$Y/Q[:4\Y6?
MWT8G&X9E0N.&AU,O.PO,3\[K_MZ[5BDZ%YQ..J-M#<55I23:%_^N;"/?;SI,
M>%2S4)>-PT<<HTA_G"&V#)T ;U2G\3DY/?&?<]G+99,VJ8_EP)US./'WLKWN
M+OK3 8!2Z*G$.3,W.S;.YL/-$S#QQ@!XKF-!Y91;T/QS#U5X]R#!9X'O]!'^
MI:,:8\5CUPTNT_V*0%4&?95\RH:*>"FZ5_6#%T<ZY8:NF!*/GHR1^+A5.2)^
MN!\=122"CB9;_[PXK!8M=.!,UR4TC-!RQF$TT+"P8.D(M-NB(=ZH\E%EA_I.
M0PG\DHG(@'?O&*VIO4T125J_>"&L$/:U_,HL":1)&75_C'#1SLQ#4R$&6[G
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M)G,K_,9Z$X<A:ZWM*VR/#M7 '<!+]@Q5%]1_#?$9BS5>J)IW#BK%(PTZ0%4
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M,O?J-/&,9XL;0*0W)M_I>):5Q\ 52E&;%-%EE0<U-,,O4BF\#E3E,'V$:3I
M-HSXEC([3"D>V0W.88H232M)&2>?9Q>@ S'"D6F-@V@ ;CDQHM=B LH0M&CH
M6%D=TXPD;>MN(<QB?!;CDM2)5EM05&C<9[A+4NT7TMV;))223*Z)WY@N,K#8
M2''4/79)&E":54L$2M$BIO<<.B<;@]?'ACK+%> KV)GK&2<H\E0BD[)QRB^[
M J=0$N30@E#K"P"MX0;"BFA1UJ.!8;?HLSEQVH*47(":>T@CR2,#H=0=3'>M
MZJ_RVH;>[U?A8T2)6Y. PCDM#7/9<<:KDH12B%":MZ[ #>[+SSG40S]54>XI
MQDR+FG"%J[A0@I,6)5KRJ:>T&&PC4<UEF8"&0S^2B)7U&M)6K">\^!!B$@<[
MB[*H$8K:M8E^1(:'$8K0&2%5<:G716*?)XJQ"C']YG8Q(>:KX+<OI6#20 (M
M5\).T,QUQC1CA7*M$:XGI:6T:\"DN!$@P4_-T+U'/9:3G)(O]T16&!18*0!K
M>J0F ;74>'H=R/#O7"<E 0_NR$PU*:-5[E*ZYXTP3C[<JKQ%^EF6&2AU/A1B
M!N80+==6J]M3:+%$R60Y9C&NQR"ROP9$Y K.E>H(X;KL8A-%'8<+W!>)^\ZS
MBL$$1MP]#"JFIQUZ"8X7J1D<!54J(DQK=<N=&8[ND(X4FU5U"D19!9$O9)1\
MFMAVWK)"N4XQ+;Z'='F"'PX,5:!5(F59"PX&MH+024J2U".4!K6B2' $X=+^
MX[$/GV05&7'ZH@^$I"$5*-WX0G0.)<<"<2USOPB@=1M+Q HC>P>)1[B("^7
M\-[D'L*E/Y\N"\70*C^P</H/NMM,&!;BL TZH.54R5$+[0HP J=-$@'L.I*T
M]@8+K?>E KJ/Q&$G13&.8W.MXV1.WG(W^J-5IG0_^&%QU[[ ZOELU^(:AJ_Z
MN=4"F&W6!#O3[L2:<0T<VBC!"ZB%S##HW\):@LK0%Z[ZS&E6T(!Z;N*NS<3
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M,X-I@N.;Z!"2I+8]DFR=I'8JV,7 X]9FX!0?SAA<J@]QER[*T<](5B(^!4C
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M7H;JZ]K6=1/+7.0XS6\'<F3'V95 X>Z05">(+B9,8E5Y=BFTLH5(,3$F+97
M/_92?>:9ED;#;4"D_W9*%4[W Z0+5>[[B/_1-S<>),)CI8@68,:1H04 M8DT
MP0EYMF12*4D9F!V4"R*:;>>=*Q&YG?\LXNT_5V@^@R9YRJW* :K?;"2/I"L
MDU:U$_ G4TZ4)!(EZX'&;88:*&Q4299-=CIP*,3ET\6@//*G9AI#05);NRQ]
M@$"OA8PR$HKHM9&3YS^^KOC;R;E!<JKON@N9$ . 5-JTBI:OG'(2#C#8M#GS
MOE1,.$3X[ 1,D@#IA"ZG.(+>!HR_$DI7 TP?/"+^23A..*%2I,MB;^K*^%05
MHIV(.,KRG\/\A0 U;PRFY>&]:VCL[;@B?BC0Z)9KMI<W/:^A3 UK *1_3YG\
M>OM10GJ$:"W"*4TGZB=&7 L;%@'_6[>4.^BF AL>"'-3G45A+UE6% 7'>NC
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MR]!9(YF4HUY+<*VI[#&NI9[S[0+"_"$'Y?UN(HNY:F:M<7/TH[FK)IJEM:_
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MG?3PE)AR:Q%QZKLX(T,JV W,845J;78["8\A[+$>.;??>!CU9D,"TU#<BBY
MY@!^J 22#:/D0BZU=M=M B9Q?T:]U<S-Z.$)IB@XD2:*"7X"JS:[4!=R:;6-
M5PC'=)7)2]@U1(^Z-R3*AIE-CYP5&G26XG=7S CM%&_!A!@".1S$%0TR_83L
MNX#(8TZV.IK[T(&I=#!U)& ::+'^$AH+(.LGH+3:G><.N'B"M,A56*26&"0<
MHS9[T/5P2S-S%G:X0RL,=& _ 42G<2XU%'+G6*B;&]>K6'(2::WS5*YF4MW0
M4&!6T^]P+N .:M&AE@0SO3C:T>>&$5ZP9MD@@<822&1X[GU.)%?)\A*,>8F'
M&9&*B0O=3"'%-RX&8@ (8 )2 6!:$%"8RO001T&ADI[M .!,@+ 1Y*12. HP
MTH@"&!<T>D<  $>)P-H9=QHYPFLPA"%) QZ1F'RHCLE3,$D"Y F/]0,LD?9(
M>Q/<HZ#LS*_I,C+ML?"I&$1J80Q '+.=>!CEG)'!TTZ)(RB#6L07XS*40"S&
M\@96/BLPC<-<%A>S;A*)W&$*VF.A^,#&C(P>+<11,<TPZ3A@;O PZ$TR=03X
M*0@.P- XS)<K@8XI6+?3'5T%J+UQ)@E -S'6[85L6X!I "BC@6P1D>F.>1G&
M)GK,D( 93R<&@<&[&N-S#: PR%U=2 DE63+<P0P$ XRP9VT-"=006B87\)NE
MH)R[4>8CA#NTSBOK3#&@964/BX4QR=]S$9IBVFM<PO3UPZBF3&0DC>6>_KM/
MSQM831<!F2VV\@(H_0HVUP@;",K. QQ7G#E@A'JC%]+ MF"0Z?B6(<:XOD:A
MG_&=,PHE; ')MQ0IL'$HD\TRQH@ 2IL6L24M[(<!J9'IZ>@L(^"T01^(QKSM
M(Q #S-N*B,_/M?V8VQ4 DN)H-^D^ZQ]F%P!Q.F'G&TPNF2Y]R'$'F(, !:Z#
M9_S_1[Q,X!)GS$S[NQ-(K& F:<'7DU,F9]:PC R25(KU,*9@9KYAW#2&Y6Q&
MW+6FTD\J!D"[SY7;D<QV -K9&;;RL06+@&/SA5\., T$.*^.:0C<?^PEH/*&
M%QUBVJ:SLP+9R].2?(P6[D;&($YQS#@UB ,'MD%<C&T%@KZD!9?P$.LI'48F
M0*8?,\Z\C %RTB(. &XK+&BX(TL0$B0!I3C7%H/?O7>X"0#G"%/R/3O3@&RZ
MY.DG91*P)U?8%DDH_:2L18<\DD@+QR78,^XDSS=.:08D(GT%M0Z>!U@HZAP&
M%6P,=AFL"XYBLJ6"/^ZF482=K"K?,;=83!(RS.8![H>* W(AJ ?-B0\4#H[
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M,16+VX D-T>'&SEM.!*7"U5><#]'-J4[+A*WLZZ<B=MGFY*1P>TE2@,P5H
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M'M6:37XT P1+XD? %7(U@ <7PP$0FZ(X"=F7%U,!5]2TZ3EP:E1P=V,3LC9
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MDH'EG?>0S]N:%*E:DM=N1"AQ9\)L,(;C *3(HJV=LXEH!MV]0-\&=I\RO4J
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MML:A<8387@Z*!!#W&<+7".W&!@PL0*3*XA0I )J NJN9NK85_*G?!Y>S)XQ
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M*.NPB5E/+AB!,27P%/6?7H=5X*"E>)_*"A:&:6SZ#\^\6ICVGZ[XT!]K;P'
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M1G6T(^IWT(8("W()Z^,WTMDWT<G;GA^=G6))EZ$/V/+X=.WV#:-6Z^BZOZX
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MZFY!;[>J@YD<7D3O=,96N73V[8Z.*-&%F_]RTX5.S17$FME^O,/:>$0!;TW
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M6"\"S#91Y[FPV,9+,BY!8&3*C]-G(P!+ P,X\S$ S# 2R>AV' ">==!B(GP
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M MC=2&;@M,FK<7[8H]]:H<!54RSX,T)N,AV ZQXR5]K'OB5'R992U%IE-\4
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MGAM$?GQ'>%1Q</9F&R6)1VI9<\V-E9SMK,I+#MRPAQUV((]!Q_QHS EOX>P
MTFEUSGJ%"O.@!T']G?2]18^S%W'FNU0'O*0U;7@1G?>IU4*1K?YA7V:3,W@_
MS+E@?:OP*2;^B1[L  ,98AO$DU8_U7AG5[[9B/W*Y15>7A!TUK(=8^D@YC\W
M?^\E='GD?YIZ#; Y4[1F_V3AV% ,]?&5,_^ZTHC=WQ?._?3UT.&U+[C'V![@
MN::>M]=<(\@9(-EU!RWI)Z8*.E[6\,JGR#5T^ZL[^AZ_3MPRVZ"+/"^9ZD-L
M8_BR2N%5S^5)#_YPS2P&X'[CDG?I[*@H3ZN[\4GDB;THLY(F,PF1SA/$8YQ,
M/48J=*=8EPP0F'T,6S8*UO%<S=+Z!$MY_%^#CG?F&\28?UWY9CF8G)IST2U%
M+\'36Y/+D!$3+RELKBCGE&MQF^(&=TOV<V>)YEBY@T$6N1N N<!CCU\G+'L-
M7FNUM L.9;L&OEM#;?6/4,5(+?TZ.)9>X[IKJW[4)R&C:QT-F,GDX_(*RXYW
MX=0-"B2<69Y[F$V7B$K=>$:,X< PY:B!QN"[@&E'ZXU%&F!G\/R#>J(*+CB*
MIS@.R -2#'14-*@Y)PW\UM&:Z:JAF&Z\)N<]]@G5G3"W"]6 3,4-2ZX>^!Q5
M1T)$P%2;HPI*O[Z7KY1 &KM(5B@.6@3_2=MK7$?2#S:0I.PHWW&<%/L0BJ2U
MP>5GUI2]OPU-56*06S"!%*J%K4;G,OTZU\?,>5[&/HXR%Z/!MJ,K212V,],K
M]%;CW#NP[(-ERK=L\&!X@9RT>V*&/F\@>G1SG_=\YX<.F2,N EIF>WAZ'".Z
MP@9HA*^1=7"ZX4[YU4E]#D,)48\N$%;XZ<H1$>ZYQH"2!&(F/WWL_INLU?=M
M*A";3 .MJABSY8W!2,I6S@HMOM5/Y4GMQ1GY8O0?:ZP\NA,%6J3\Q[&JQZ;8
M&!U"^3M_3%;$I; /R3[BB'X#P/,9=<[5H&Z3Q!GEDN>4I:OGYF3:[[K<T_II
MA],E*%ZK#+ISCN$4.A#%>@Y#.6,9#K2*B'U7@4"?-A@T"JT9@966\:Z$Q7T*
M(%Y+2OPRNIJEK(!?SB411M^Z5(0"-*\,$EPL)\[EY'&BCY+(W9PD9JC"V8'F
M\/#*_D],NU)PA/T]4<*/_\,6)CS.A@X[A%E"!H&;5C\Y&B*Q8DHKJ32$IZGS
MUM!IRQP2,> (MQZ78$IIQ9Q$,H7;%"(&OL4H*'IY'*^4F%)ZM][2E[4C@E)3
M*U: $EG-332.#3!H%WIUBM%-"E\ME9^#H5HB0T,W(2OB68!5#G]G,29F*1"1
M0HSZ;?F!,;0* 9OIR 1_4JHAO;Q0!@C("B*N$*H W(CII5C($!$:DL>.0V0:
MS,< _G'O\>+=+VC$$#86U$FDBZAT*069 ")I"B+7'B8KHD4RHM*J'(M(4 &G
MOI,C<K!> Q983#3MD\=J%00:^)P-TCL5URCF"&\G7X0)10I^-]%J$L6>V!+)
MO-)XH+3Z4/-+AHRF)3X@$^/%P%MUM5TS+=" M6[O=.TF6HC\*'V! C%P:M%9
MP"B/'H=,)MC(*)D^+H^NMF(#8$0L:(XJHM-+XW!(M[04S)&%&&8<B;L2,,S>
M>P8JI9M5_JB,YQ'S TN%VNHJ-C%^7/YLC5F"'OJ357;5%C9G$[JP!A-RZ70:
MD6[PI/B#NMSF*MXN&[Z,3U9,30'*)Y3M[5YQ9(6W&M#;NS)I"G1<#D]X^MN7
M(7VS=?YU?N+FQ.+!Z1*" ,/\N82M#DB\04[/<3@P ? ZD7(RC$S(49K"T75F
MO0&#;ON4C%1-^G<2'7JQ\>V8!2C;?C J3H*%Y!"VWJI,^0XU.U3$ H327!E3
M;<H8K:_MO!R'7XG64AEL4* F^*/ JS[,G^=D_Q82\/PT!>!?+K(('L&. QX6
M$4ZSX.G=GBV\"JJR8L^P=6,=YB>*96J'F0K \F;LPV(FA:7H^^)SYG&(;9<G
M'U?D]"MI>NA_C"%:GR@ Q:(7*>[Y^#;F@N_/*D__0[-1>5.*6?&ABB#>MF>
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M7VD>LW)4SNIE5K9+G.F5AF:/7A0,4;8IEVFN<HZQVQ)=!;M4%0_=+_'L@U&
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M$E[:7X8M$KA-\G"//JQ1BEJ70"JQ5VPG?Y7@LNWH7.LOMJ22VN5?;*];)16
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MJHM8A#F-B$F51X(2@ATC#5 W0)0Y.U$U1SK58*L;P6]BB8L0% ?OEXV#'\-
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MF5/S;\Z! -U3ZCE@6+=>Q*C_1&>K3[4F.HGQ;Y9 BCKJKY\.]?,!&,5<_[U
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MJQ <SEU*07"*&59^NG'&EJK"/2BX6\8P%T(QAZ/M$<A.(%FF]FL+@V9BY&8
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M]E,(<667&5*4ORXZ0P<DV(.6 B4582+([]F"WT?&8RE7R>-6KO;2BPH4]+\
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M=:O]*^/SSSTN*!K="51G;UR?[OER34=-TS@XG/>T?OFC*/>GG_)A,\NG:X[
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MJ"$55&_=;,EJPE=0_[&G[<0D,;>9&KB@\/2M,E7W2(QVN/9=:4C6C3,OX]J
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MQ8,KE/=7GLCRXA3@F(YXS8!?] =-$' R>Y>1 (PV &8R0"0 RX!SIOIY5U(
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M^:85TNF*2MJ'O\%A[61'BP[X(4Y_,"@MB<[TC^Q?ACV/2<-H+7+ [K[B9+6
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M"_168WK)E,7#Q$Z*T$0-=U^.W(H9TDNBL,)Z"T1!GA>'$S>.6CLUO>PV0<L
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M;0NPX((_00OL=6"D/W65B1C@3PWM 1UU3#<WJI=ICZ?!LI8!V2O!:RVN>P;
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M=UXW3=GHXVRN.N(X"2S[/IY_H;CI@71NL 5W7KR"><(#J1L%HG\ESIOOF*(
M\7IH-O68 G44Q3 YR4PW'9".'RFM!E3X_D1P?YV.\G NU57'*D*!!+WZ]!MP
M6PKENBTWW>25H 0/Z"A<[H)$!;B\[GN%^Y!YLV_>(%T-SW!20BNWV1Q!O\_
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M=^UWS,?<'%)1+#&OJO\!6NF'(Z//_E5Y.<1\%7P$>S-(_&C1,F/>A)K2\&#
M]<OZA>M^G)V:TW<"^+L1I+AP'!2^&1>""*KU<%/_G_=(5PMM;4U?;OTK/!4#
M9HB18[8DEFGVAS-@#[2)FY(SDZWG>!IRO= ,6_!B]9W#X4W "TL2Q !4!M+=
M7P% 'OCXO/5:@ 'T5KR!N#I[D.GGZV]ZK8. A"& ,??X-0"AL$7A,-K7+@42
MXP),*($(J._).?,\XHI(+>8@.L>#ALVK=>+HQ.BU]MF 2,32H55\0"#>P;F&
M&=OG$*"&[(,\]$!,<^+&%P_NOEUE2+ZVUXQFO"GRMN_9G6AHUQ$Z52F'LI7%
MP47[6(:]B:^R:Q[%E'(,/2E@;[N$'M>M )[OU]@DAHOC[Z1?%5FPNK6FJ>P3
MB$5B7&!/OBCCIA?#H-4K!E^(I!;2II7#;.O?+.(#<S_)>++D&5KA65_A>*QW
MN:W91$6*Y.F-4CC^[(.DJ71F*3U1W)"UX&)07<?]N8I!4_*XK5D+O"CK-J3F
MJJW\5G]A+J39,BSHE/"I.S<)GJ$Z?76G^#RF\13@'IU3B0$"E<7)+RBA,[P'
MNV01F'-,8]:M "%;:DQD.:4?28<8W:-Z5_(#UM%*JEBN4H?WX_JCLS=RGH//
MV:&I3*X AXAPR9WC.G+7 %]#-J7RP/\(D&1FM+<XF6;-^2*MD=&!9V?K/)/1
MJAAI5I,PVH?!,S[%D8TUU'ZL4_5K(E\&?I IFH2+EBXP0IY^$VC-'!'KZ*V
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MH2GLMU(N+%LOE& BVJ!/J]TG?UQD(V,X2!Z73Q-%X<(&H$TW8<L1*"X*.Y2
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M95CT0Y66.BL=9H'<4=W$CF\DWKV4KY#$GD%AVV#;UZUWZ;6;S"5ROQ$LG%9
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M&LZX+"Q/"&7^>7FY\)(=--R/W.DZQLZJ-B^?28Y"25(%U/G7O=,W5Y?KJY6
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M2B#"@#8C@MV*@=,%.C%<GZ]PSQ>E.O5CI)ZI=E>AKOA>Z4@B7X $:$IQL^?
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M[K12[2>RL\3Y[Y54MB3/R8.VS%#P%+6OD@W1G.>SLW$ =-12P8Y$ )#P'6P
MWJK8%>(=L7J0PV=R ;C9D*K5 0H!Z!Q UQ>]"&0N((&:SW0'0$FR+P0R%^G
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M*?#0 1<<, Q4-K_B;1=MZDJ +V P#9 5!XS:2J,:AE.O,"NM;.K!X5"I= U
MC=0Z@D:3M"[64?.G@QF33IL2J%8/7/E,-A\:J3F!S&?82@%3!^0R&DT/:+IA
M98&@WU04V]^P@&$R9(!L^!6IDYA>,L#1 40&UTBAQ""F(X"H>V Z"4PTJ),!
MC."4+"$T;"F@2:&/[!9W/;9@):-&!Q\L!T$':30<-N6 ,3)X_L'C]AQH)!_0
M-64ED@O,9I#,9WIK@(L44)KA$@T89:QF8;#53RK0TV9T P8)U?%I3,VPIYS7
M\CML)%#P),BQXJ 9 6@<N(E'.[@3C#1HV7JPK9Q6QT$MR8OV_)U.'&@4!] ,
M;8M)@$G 2%#YMQNB:8 9AOI='SXAK.0/;P1@&72<1[N[$IQX2*/K8 ;1ACX$
M4[?"RSY R;D7ZII/-9V!AJHQE,Z!MU9<&,D_ALC "7MFYD[ )#J),S"LHW&;
MS[,DC.SF3CH!A;V%+"4P3=-MKX& #EH@ P@._PUO,9'NKI-U<?B IJ?^?0BM
M<(0LPU&,O#A*7Q6+=99-1'VN@W/3=RQ9><&1OS-)UT%EY9D3D#T'L$A:U"1@
MY@74.(VBI['3P?R'L'HGL'L'#GV )CD"DW KK1%:<>9D#7&HZ SH2Z,Q= #5
M0.4R]-F98S:RXLE;@;T.-)1W?W\/G1.KYO//Y4QFCI*!C155*18H,%*SR;)/
M;_5)>A@8J/Z/@?VYVRD/RU(!^*J%3JA+2W1#-* O9+4/*_P4(* 4 Q0?3@<$
MK (PJD/91J"5%(WA,ZUPL!"G(<U0%=$:$0=#$L88 +2<V[[=)54<R-0SA7YU
M6+2PM1$\R8584H;:>+Q*"E-E-$\FR-'1*"08HT'C-*7E^/DZ8X\[06/A((&D
M H):+0,CL")@V)<?25M[#JZ2P8AAG_\7QE(^\,;N 3Q7_ M-_7A?I;OMIJ.9
MXF"Q@0H,<!4."M507IO.VEAI(T.K"$#DPI3F:L^GN8 #[])0)Y]F7)E.6P"
M![_ &P-<&>JJ*4W0E&KU[5;S&?;8R9IF:'\E6#OT'F)(&*,B.P8>/#Z\4^5V
M_79X&=H9!Z7H(-#\D*%YI#\'RR401<)(E4"W&H&MK ("< KYK$0R'"C#T[MJ
MTT20R6<NPX%K,ZK$P"B-QN5_C*DFL/C)'0H!)1BU[&;&*@S,_ W]7MDA;RY*
M,3!BFZO-#< P!;QVNN"MHS$X4%4SL#4P5NGAG]-AJ)F6@T$FY'.$@$OT-!H'
M2FHN6:[;K1KQ("1N6)CPM*N:9.S\E$4 KX)=\HKQK4]625$*@)*(TJ#I.S@8
MX&$HFP-R9+2,CXQ7/QF+#*=C=6@..)5M9%B20(6A"-DQB@]L,-I0#KDO40_#
M'"B%.-$4!PVJ=>*)!U-(P-*59,Q 63JH&D#6V#VXN4OP&-XE'2Z\Z*\*X*XK
MK>9#3!Q-XH X"8.B@W(XM&U3F.8R<#WYA7H[36X$"($>OGE#O.=.Q69TI Z4
MX'2JQ+#-JT7%>Y5) GO)O6-C:2V+8*Z^#A"T' DP-]Y>;$0!"643]0UC($MB
M/ZPO&W O'9E;FBIA8$:0131[U, 4LLK<"&R"P.^=**1Y!VL^_U[$@#AW(-UQ
M>#,</ ,=/:.MSG"'&=1[920Z)Z56)0,V$MC5H)_C#;$@Z-L-F*(I<=$_4_)[
M#>E#C)!XV(4# <Q0)WONJ(,<".AM;X&=DF'>/.S2T)U#J%8#;!;#39.8<=@P
MQ@S?5.N13V<ZXV$K7;$  Z?%D,,1%#+ JS'@)(&= 3B7"ESB&530XCKIVSB/
MVX?/P @&NY*0E??M2G4[/I%I8R@OX0!/@K'H\QE3$K/1?:DST&*-T-0U)6Z.
M+8EZ:OS/:H^=#+KT9N[BZ^S4O9\8=55\,+:YZ/'OJZSFF=+_6=ARCK.,W:[-
MPQ9;X%91]MZ:669\8J+?*2?Z1E>7C25N"/\'7I_Y>:5*>Y<-W]EVT_+M,#N@
MEH=HZ](K60G5I],,E6KJYO CS"'^"9;THD?[,"04K\>'_PD\6O?FKSW-70;U
MK4#56Z%QFH/A?R&48/3<R+&7-?N;05S\QH(VD,K8O?DT>F3LGA,>MY=AM.7Q
M,/@"X9I@,#-7R$ZQ=H9B0T\SL,08'5@4FL#,Z.@@?+/A0!9"U@K-F?R\((HA
MET%QB9 "O1L+^*)A BT_1T+8HB%LTE\!:J.KV%+V,AZY.SH61AQ<T>DH#0O-
M#)3=H61$F&O<7!)!L-J2YMS;&;>BAPN-M61P"F0QW*IU2?OL;9@*:I2Y)R?1
MP.VAF*!'@5CD]IIG"WL>C2G?5.P,C\$\S9;ZU2PNKYFZ=FCD/?QBB*\GGS7X
M%25R3MC< Y)_;N,[(Y9TCY3I9#$/1766%H'BOJ;E+ZI<G,0:7"['2Q G%W_I
M]+V0GAIYY''6OEJ*=4<+D(BWVG<[,>,CYO^S7&=+V;*4:8VV9XU;U%7A,Y4;
MTX#:A39R\$.6:/\A.>8Y*"UFC#1V3/5UGEVG,/77DXI@U45^L.F$5\W!YM.>
MZ*WH+CC/U88O !FT[@8/%:2:)0 A]P&'%1W:KI/;7&JMGR*T=KD]VH[CW+YS
M7)>TKI BU'X@,IK3?"X&P%VI5#C>Z,SR8274A2KG8H1&XHG. C:3?8APDY%&
M%VN3FXJO2("+;DA:[(6T&L?[M@)<L]-R$!11</3? DJDYGI8)2R]04&X>E.N
M&1OG72GB:W6%5*_8HZPHS$$)6.LG">3!4\6&>LUY#@+V/3HC@0_Z)QN*HJUG
MO]P)(F*7PH'5S+U42)6"*QDBC<GU410+@CK)[J(2,@L()RDO J3 *OH1FZ.T
MN=W_3OXKV6&9QGLJIJ/D.#G\2T'X/W'H1$"#39&O1 . /_8U47X[] M,X)8,
M?&?TOO7)9_EP+/>:#U+#,^G&G.MKLIVW-(1:. XNV>?'?+?B:D'H%XY\A@36
ML7:W&)?D\JU_PB!@,%-W,V=K&[,!LY28%-$T0[7).Z50H,C'HJ?KBR=BRRT[
M> X3NF "YJ#N_&^]+^[-97P*/R6D-:?6!B_/F7&$^>OKK2):TS;=S6AR>J0A
M>B[;<!2V/MV0-V/[Q8<OU=\*#>.>P^V(XL*O%P8KAK51R )DK/*VQ/.[L\L^
M7DJ?!1S8_(M5'M'Z^-0[ZUQRKNFMWI*0_3,E+J ?[JJU?%#T"RV"/ .74DH&
M_B!([9DF1HTIVBKR^0\QZT:$@1R'QR)K;M_.<K%3II]-RK0$PF0.#N1[R-D4
M*[L8E;7HVZVP:?_[EK?DG^)' >QE&0BV^<,]$-^02 7+$?Q7TJU6Q!;;<$X(
M5G /_A3!0[Y2AH @3$LYH(@W6Q'=.MQCD2)'!SVM._D-)1-EF'R@*B+T7<Y_
M&>0N3ZF-:!@"$-#.\R2)J$,R:UL)X<Y<2UQ([%.4I,U@6T*$.><%/Q$O.I$2
M+,@DDBBIJ#Q"4@B05B+0B8^S)\OEJ4^-4!UHA] $M17[PS_ B(<"8VE9,F0Q
M$H\4NUQ6@,YW.YW8N D<+0=K#0M58J VN]AN6V]<Q0C$'XXM.J:.E[A3C+AS
MBZ1.X@2V%]S!X;'1UA=B7F <2?#!9HQI0X:RS/B=[CP]B!034*8T UBZ7"A*
M)*&2!IPI<9N26?Q_$$W"DX?Z+,PP9Q?NP6A7(%%,;X 0=7*)S>@Y1TW9=PL>
M6;R@!K?#)4130;R&A0[CI#!YN)Z*P]G\/JIENK/T:%_BS*D^$!6K-2T?_1#:
M<AG\579*GTQ&&' ]2@O4+:2G(=T8?\(>Y 7 C)T(1Z<2*75N3!\+9S$ 0@X,
M=I^.7N2I(?#Z5\BX3N"\Q,V'YI0/U3&@DILD45/?B20FX_?;1#=90&?9TTXX
MOK8E(BIJ(+M9JJ$.7(4TOX6^)N)TZP3-/A<KP(OMX8T9IDF<!$TU!,4:.G>=
M]VJ\.]XYW(%G18L-T+^C9Z*8K.9LI!1>)0$K6?(A,(ZG'J\*)()G2@F*A@,M
M(1&:&5]>:=%A2C-6""69:C^VSBV11UYOT0"*"[Y%W8!#+".8-D?'9UXE@SE\
M(J#% $0,$2?J!4/N[.YGKSCX:_V9!<]2EEO)C\_I\\)R(J1XBYE!RIE[D.;-
MQBU6\4DV]I6A'V$ MO/;X]<.V(G2-UBGIA&0Z+_9U,X0B\V5*H2FR\(QW4H[
M^Y&U9PDQI9ACG=+E+(SG7/[XZS7P,HHVAQ7(T71/RH:@X'5._]D)&TK/T33/
M[&R'4;R%:&5)"_>9U6)V?(,[>3L/84GP&YJ$COU;R'!_O#:"=0N8:LMF3*U1
M#"$L'7 B'[O/E2ZD)=+:(MMA6+5$'K3*,$SE)-1&6%(Y!$7K$/)/C2*3$L^S
MH&G(_:E+&.XA5.B#[]$-LS%FM:O8;Z38Y]+9.(+IXFP]*I"DL*;3(F.'T4E*
MK*?X0.]7X]XCI:[=3999%!X.C0A4"_E]T'LAD5$U"* (S%:##\ZMV+O''4X
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MX>E(-4.!>3.!8!7JV)RG'&"C!Y1 )&J(-/723B]D@'U6P(QM14N6TX@[#P@
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M"XO)7&@0A8EFS/&Z,NVIR%F3&<G*FIZJJ-K;N6CRT-ZD5HCVXO)JGL(QV4+
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MX]GV=K<T(;O'VY$E7J7Z]&I+*+N5%9$LAS0D-U7(EE&=T^0O1BJ75ZU6MPC
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MS?9;WT7VF=O\9[A=Q%$5]<FR>^O0M !!*S\)Y#_N%YBH3R/C?F0J3M[B']9
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M?<-@^E*(?S:E?R9XZ/3_?G3<7AWJ-CO,F@3["0\Q@#A2PYQP;/H;L2:!@<V
M6R"\K('69*J;<TVQ7ZWON1,+N/#J<[X+7T&[<2@IOZ[O6VCK#M>L;6#](]$O
M ;51UI'0'><Q"?0/;8 Q'&(G!>_T#,PX2[G28S-!AZJVSEFE$,U:31MF&,R
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MS%%F:.G+JJ'O4PO_T?OCCED[F<<%K'D]:%JX7AEWS>K6A,<NCI%YP.M#3.7
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M/6>&8X!F'&LC"Y#L%!DOC.0"3IP*-*2V[<M*"\)H7"Z <3)V<:6W%$!B (V
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M_DR/WJ%35#K"J\Q#" XMT"#@'>21G?I\)[WWT)7'Q-(X$[H50UT9D;Y&8?S
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M?MSP41J;%T]#Z8J884VMI8O&35X>T+V/8=LV<2/]3!OR2M/A%2Y[L>%8OCN
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M=7P;#3#31M0^.]X:/35Y/W/A0*[J=,!%F^]:Y)KE_*D3YB3Z@;YFA^=B+H7
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M2^9^[Y3<Q=]I@Z#[>'S.2X44(Y[6S_.]$HI'KHLO?_00'Q%&0###_.FR+G?
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MAS(L';5U(,%K.YE.-= F G 3(#R"= !X@E '>Z-@W\L-YH,\F[TKA*TS%U#
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M&)@QV83Y).WLK24G**RAUW_%8_]HL"W/99N]Y!,55_\!5#-SV3V1J(AE,%W
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M[BE.N:Z]&(52O!KC>@ULJU+P^Z9O3!)%U'C4!]<,R1&?ESE*6^U&XL<")C7
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M4%L?$0C']J<TCNYPBY*3[/WA3*@;2SY1__?;@0\'92NWK?$X[ASP9J/_H6_
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MQWA9^I[)Y;]LA+C?UA31IW4)]TU7[4'H,7BW[,]&HPR!*0"'9=R_[U[^9;0
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MYD?39K8#3^BY1]>>9>^<8#[; J><(YG=>(TS#DOXW"^;CAEIN'.,WG3-TMS
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MA9!<4C6#ITC!"53^.>7S 6%0A[K<N4XHR!#ZD\T2X2I3ZE590%BXFK)C$F]
MZ"#"XX7,N#EB\MKRZ4-TD"_6G2!M4!'Y[EP3(%')J!9+EZL (&G5\7#*[*$
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M6%61)&/L;2___NV+@W_J>S;A*<M(EV_@25'J(&2/;>XW:6AE]7[?G9@H/U\
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M4F5V*IZ!6S207<U:C,!_>$E^3BMW-(J]WU/INWA7C>6.*O670NPW.XFCJT3
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MR$5'DE&,"HB#Z1)8)W49GPS^V$E#<(HK *,TOA<.88"$X/?J(#@,APUB!V]
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M/G]?I;)[Z$PB](71<?KQDV7'2&$F^TXQRB4HB3BRMM\W7TS]QDGOXUV(P@Y
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M-*_.HZG;-$7]U V [H/G6+XELUHV=P9+S7W&;@RLT$VC3D?W7(KJ D51EW/
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M 1+JSV(&F&J!W#Q\40C E$\L I(;6!+#!Y=1-*@?.%J GQQ+ L#3@G"UL#L
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MX)SE=G5IGG$T$"9ZS 862P8[:SA*[<QI %*8;/8OZQ%Q2<[:%[0)U>5W-D@
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MY!4/+YD.*4EI?3CP4N/YM39L$9-2^DO624YJLX?=% FF()'[A]5[]\G$)F^
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M3^8'*"%:<&4+\O(-\,MV6O.\&%->\KZX[E%T8*PMB,Y0YRAJPF@!!ROTLW)
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M&^+PPCMET8)OG7D,BH 8+S+K!NTH(EL*J)6Q*H@,$FB"S./!ZP\Q1J-%]SI
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M:@8?R_9][(^OR"J\&6I;5KY<-)I[KW2BK(HX5A%-SDZIN#CV\016IZZ?'),
MDA@"Z8N*$JQ[?9E+[?)';&Y"72,Y^4%Y?6/YFERP\ Z9EO#IS+/R[0\^(5^7
MMYT$SP7VUN[>=54MT>SGITLO/UY\65Z/.IWTH+QVW^=FU.>;HY_KO"K*"A,O
M9WTZ[3![SVNV-VRV[V1^MQJ^H.+FM:RFGUN3;CG@'S82[L?-/IZ9?;(X^Q3U
M95FNE7PC1VQ+!K7B88N'M>L:$?=O^1*6Y.V^(DW\KBWS3V*=*N.VE/]\H<^
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M'8M;110?.OKM)M^SO"4DR*A_5W:R,+XU!:",Z ^>I>R$8.44IDVT^-,D?V2
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M>-9[)Y:-1'L@"!75-2 PY7^GMJ=39_O./#R2:%D0;&8F[@Q8#'BM$2R^]NY
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M[CG"6HDM*Z:DAVRVRKSQ2A>9K0 =)F1WFN%4#,M$TCK:PGZO69R,JIZBWEZ
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MIS,HE3O:FH9D=-+^_+ KK^8UTN:W]= 1E<6SG=Z#Y6:-AOG[$SPF!X83KA]
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MJE=;B<%'MZWX*H1'PQ_5\KMHS;.UT6:B-V!(+(=.AR;"HG;K (P;0XH"0=M
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M!> 7-] 7 +T*2JD)LJ1S*M/9DW*W&*4G0>;?;9:@]5H<1 C.QZA4F*@3#:$
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MO8%1 9Y\31TV(V,0K&3.&2H\S8&4*JQY01(8%.<,(@6Q4^HZ*2MVNH*(CW5
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M6=LAC5^)KDZFXZRL"*$3+P$)6W$D:A#987K$CT9I<-RV^)(CP.BBT_([/)?
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MCN+MA&X---QO[907OA!C#!QN:CD(++F3!'S!+REBTP.'@#H_<.U,V7"$;F1
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M]:6)-]>O_N^N _[<X)IC,,KR#6&& 09&)9''(RGL;;&E1R,/8FLXLU3MP:'
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MOQM=C[S_U)AU89K\]:^YQ2;],^H 4L9G+:71C3I!#H21N6%$;\.(7Z=JK:S
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MP_E1 D</ 67^=>J$8E.,VGV'8&4I#[/%HUW,M#Z,41SWT1H>=:WF@" /-.0
M.DI*MOH$G5Y'.XUMP0^)U"<R2"P#6-+W"!,2)CE*3=<6.=8_MS=949=1@;W:
M?+CR<6_9:5HB@(3*0$,IXD=@7F3F4=4F!D$UPX\<4@$WU,=SZV&WZS2^0MZN
M B,?TPCU](,JM'0/55<]I09'S%?3_%6II8)3G<3I0AED)Z,:JPS\!6"]&O60
M'RL4((/3$+;7\30!G#^":BL75Y+(5Q)RXAUOD9W[9SG=1P!BB,X"GE,KL3^=
MQ*QQP(O$<M7P,10+E5(R.-A")9+.P^8IX'#9R3@1DJQ&5@HH"Y1=RZ7(6@ZR
M1'X^#D#\16B.E!*J[%HHH&2)T% 5)4/>6_6CCW.V82<),6IH7B(H00EI:Y)0
M+P"):<&"5%"@L6&H%,X,<DL%$!^!\4I[ZAK<8I4,]A,9QI >62Y(E JR#73S
MKYSB^!,6%2#.ZBFE4HJ' +&:0+^+77+QX"N+$ \B,]V LE2*SFNCW!JY^$MX
M.5!EG*B^N,_N<F CQ2K6,'XJ-5ITV8 _(+7V7D.Z),KA@)\!]O,@'Q%U+N=B
M(8Y]UT,+.2?X"B,^8.&D.+/5F[I(8127A-0H!CU57LMC*6?/V. <9 ,3(^3:
M8@'8L9V?KT WQAH&R&%1+.(A-U[7[=CS#N7+X<!*T[T]6* 4WC9V4:QM'*:$
MDE^B/@K8&J+,XKCG\_HT*1G1"20:IH(Z/J'F*I#SWZ A+R)$#2:J(/;U&S[
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M&X[D+;5XO<C2SM/*\-Z@K86WR$X3\EEED:-4.+@J.^<KQ6#GU8MKYI_"9O*
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MG0W3O0G5G,I]V-'R\.12-Z1AW]6Z":6+)1&S;>KV+1%8M E9KXRJ#]6Q  L
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M$V#"$2AV-U*W9^5G_(P' !4KW(T-BL4$<'2&Q:2<MN(Y%L"I?2DZVRRRT^5
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MVCF6T68JUS#>S##1<J*?/>8R:)E8&M(\.+# I9*=$ : GDK(60VS)B@8L6(
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MPX )??8QC4M^#JG 5A %.#X -G+ZT'PA:#0)0@>:+\*W_XCW=T3++P%)B^"
M>MU"^,LTOJ^CLK"+1U"<!(3^/V0!]05'UUS0I\N2%:5L_KR'P^B:<B$J=-ZU
MFC9N4/%/5H )IVA UU#2OUT[O!2566(VD_6$(\=9[P6'H:T*I^9]1%''#:[K
M1*0%J6YCY\FX"],+(5<F.EKV^4#DS0-+@R2W0T^(!2L7O)YK"^SA>!]GAROY
M::HC^JY%]DA,$DD-$4!:,J&V/@^AO9_8YO5.:&[%*X"? ,BN=Q2DZ35IF:\"
MM(X1E<NW=2?8SXL*+IY5$6L[YC'2B-'V7M=TER@) _HQ&D-;&YZK)-B?U:3C
MC3Y&*GD)F>1#Z>Y6NCXJTER)E[I.]F' (RURYTBIY[M8W9A)19W#]2>O//\[
MT#CK-3Z _7U#@^NTKGYF;BYUYMR]!34(@?!:8*'?9P58J0Z@:?\HL&GB=WG,
MN,$6MY2@(3;T(55?E(6X^6R#'2]H<)H>^?4)9#:IV%9YZ#^KR)5O-8+\S6K2
M3DI"!C.Z:4;#).I<A])"^O"<1"KJX%UR-/V:;J::$+8("AA"8I9_XM6.J@)4
M&QCGL.5 N+MJ%O)C<H (LW:>[Q 224[LW4V-,[K@61KA^G"PKO)YILD3U#E]
MR%"S DER[)<0L]\="4\C-WS+.W/>>^_(=7[8T98'3P)7W!BY.O>*L'U.^ NZ
M0XY 1KQDB[EKIRUK%BPY =?.ZUOM9O9=*?&5.QUR'.3N\L_SS[.N^?#NA<\M
MDZK8%2);0]O .5II4D%#9I;^@C>+6DWWGIC\9-MGLCY,U_-66N!+V4[V2]L+
MFVL/&>V=XKWE[=SR;W<5.B?D)J?&'0Z+*X[[OFX[7/%TGEW4M<YC1]BL'6O]
M?;[=_AM-<%]0EN#_S41Y+L6-6[+@?7IK[M[C@EG3WJD25Y\T?9!S/^NH4]G3
MVOL>RB"=/0=B?ZV+<#U5,:J3?>YB\X;@K>*AK4;'; V=7Z>-U92.::IZ+^UZ
M?+G\8ONHX'Z<F=OYB0C1D^>%[R:O3']?5K,J3VJ+'1^<%9->>[&/L6K)J8%9
MFGO-M[Q?S<!._1U4];3J C36]6[TIL?[C)HS(^,A?IMO;'6:6#G_YVN!'\?\
M'>_+@0\M;^[L_'KO/^)+U^)?;Y?J_G@PD/_ER =3W8SQT_<V[?AZY.2Y=S$#
M 4_.Y&>=>LY_*SIYYN$MG:PC'U;J9.WZ^O2@3O:1ZUL>Y"H"S"=U_CMZ88M.
M>FG>7?N%WZZ]_;#*0VWR:M:%G!NYOI]\W]Z^X/X[9VCM^4]M'VI?A5XHO'4F
MYK-ODL_XP@O?E7<TGX\>]GD?<"OWR8_\SUZ<<V-+?O_X^\SY2=]/FH([N1.P
M\J#FFW)LR^>.A5O>5)__/GSK_->3MWZ]S_W]0Z5[87)@H>9CZ^^?_WO5@UN:
MKV=^_QIZQC>[2V16W;F@F7PV^>O3K=_?/VS5)(O07R?1)'D:97#K[[5;DPD2
M&=^J/4BBU *M23*)V&HXF,88WFKJOA7+)B?'"KZ,%5358O\SVS9AY<'BC3*Q
M?3:6P\/L>O_GM[5M$N?(Q8[98EM)H6=G=B91:#]8.+NST"NRT#&QT".D**"S
MT#^RR':R<'IGD6]34<APD:=[86AGD;U[\3R)>'Y3\4IJB;>D*+JS4, J"LPN
M(4**ED:6)(:($\9+4L=+UH\7V4=J2H61)?'<TKR0XBV#)5LGBT4L20:W-'FX
M-#=$DA52=%"^5KQ?M'#-:GJ'2*N$7N]>=DI%?W!?DBY*KA_W.=- O_TJE5:Z
M>K>D++(D]<Z<=:EKRJ(WE=,[Z#L[R^[O+QMHV!@56#9_;<[9X8IS(17+3G"S
M[,J7+$WZ2[7.[H'HGEU2@4'%CD[ZW]PDWP<^;EB@O"'#?';Y/?>5PR@]('!=
MUJN*4?>JL]35^[CE^]U3[Q6+1M"D*R';3C2(?I](VMJPK@ )WFBW<N&:=0;U
M(LUP5??=:G%<XO7@*C1'^N9B<K<\C?I?&M!8:8^E,++F7BVI-K4/47:F-I](
M2SU19M1<W:-9FO'?>+7VJ0U^-K4&$4&))5+'A[62%]O2Y=@67MUA7MT615 &
M@&6+5F2K:=E*;.#EVFW<]4:?RTZ-T[.%&V*+*IO7U'.N5EYIJ!"[\?.S5E>S
MMML:2F^_]''N"IYY=[O0).B?1"Q4"%ESD-"K07X\R$%)R5&BV8*&N9!6EH#B
M@$.>^':MJ9G.RS(][5>Z8XWQ0M!96K]%A. B)#1J=>[7--?9W+E&Z9W'TK)5
MMC%RS&I9];+]^)?Q="=,%&@2LN05UT=M:TJ"+"&8(8>^3VROBD.Y:M!3Y)FG
M@$V6>(03D"6/M]\?XBA:VX1ZAT[Y4KYMMY"%R(XP-+]FMB7NA\YZM)7(,5,<
MO9;C-^TA%^_P=09 O9$6"R&:J@([X!UMQ,[8G)VOCG)S5#"D!'1P8)JZ@8T#
MAE( 4R,7; %M]<ZI2FR)%*#B("@%5ZW&7*YN%#5G>W?1M\CKRHSG;%$WH*?7
M9HAD9UY18 [4= KS X#OA%C;HRY70<_AU6UJI+N]3CC%J9L=VNSV$,TE(5!*
M$:^I.[QZA6$Y9JT&/=;)F(_HCBWU'[X*MXVBT3S:O  #,P!Y^QS=SZ2XE1BS
MI10N!^P?0K1Y2*@"\%5AD7.14"4P)MJ!O@#NFAC\7!(P1:#_\@YR)C(H10%L
M4&JX3^ZA#&+_>'/']T^)6@K S!ZD<[ I!XRCA "+@]%5'<E 9S(  6ID"P^"
MY$C3U2 O'C1-2<D54&;)*9XB*%R.K1; "PG$CD"R!:@'T16C@I:0S=YD5PH-
MQ0C(S &!U+"W$%I";(Q30-;2QM0&)',[0K=';%30:FG]EQ,-4Z64Q2>G6DOA
M9"4VE0"BE-@%S[_62[%@!2P4P'$\A  :8V20C0CYW-O 51^0?;/?\TK+$&BS
M4,,^:M#V$VREA"R>8TX"OW4R8*/ ]/A1L*0 G%6 1(I!>;N\C5S^XYIUM H)
M$ASF#R%1<OC?EUB*1M&ZAN,<+8)LE"T[C]-\!%"8"MQ@>L0ZB9K .:(P0<[V
M6;=QM!U4#BE*R$H)\\,/PR-.TW!6-$X)XYG-%=$RI+"5&NZ(/SHVBOH+'?!%
M2 M L1%"^^*0-0+GAO3CB(&CYQE8%(YYX-W9N)NS"G#&IRT20#9"1WTU)04'
M106H P<*_X%^5V%+ <OH"H:5%$X]T!&;0T]6P\%*K.(-D*P&*2K*F2L@IJ3X
M2WLKWG2$"J;E<[K>.V#Z/,!>!3"$F"\ Z*H!1 :L55)@)8"30!T=!03L8 #P
M4F*[ID4RE&B<$+#YD[;1 %,(TD6 )DJ$4I2 G1 HMT5@ 62- X02LR$ 2]'I
MU8J@;!*B*"$6 :P4H*@"L!<""]/_&O$Z__(ZN 6'8!R$I132 8LB 7T5"*N@
M+22$*""6$%"NYZ;BA\\)P!A] TL!&/I'DW&8MC@4+X47C1PY9$4I5D&^H+$?
M!S^<0/604J><U1&.8A8<*$4%+;P-HP B4 %O5" N10)%0(+ M$0EKQY!8GE@
M(!.\>U77']";?*GO4;DLT!(,XJ$!5O86/-2+UQ_1AWJJ%VE>H#G\_C< 9*E&
M9QV)H/*@[P335 DE"*#+?,.2 .UM,N#N53!GB28B38GH*T_:_@"RMJ/I;93T
MG\?U9'"JPBR? ]FK4$MUQ/&+D9X\=UR&S 7 NU9@^L&(=0#H(Z6PE'IT#M.<
MM$U3 &D$.X4#/>"A"7-Z-[>L7?N68H0#OG*,)0/B><G6 F )KTY(@J#B:)8*
M2Q9   ]*;:83@NMV.+!<@(""V&D ,(^#4DDPS01P$J 4D7:H]&"&&CZ>!X$"
MREHA8"MOYTMOY*L12 0EJ>!X'G8I"9L* /X<=*$2#0=VY<H10 F55V#Z,F"A
MDK)$<<8/OVXD!;+D$*RBK);]G:Z^EDY"L!"B1(),(69! E+-8Q!5HBPI\)M-
M65RB-;S1U^0(C2W09PN1'6RKN-M:RZ_MM1=9E7 08P7-0P%$"^\8]- :7V-S
M25L_&<.;C'28Q@@BT#TUT6PMZ\TR<#X=7.MI..MF#T.-IBKNFN)7;&9@F22Z
M))EJ*-/]*8!9(EJ* I,*J4[J"'.1CL?HOD@K)&<U59]$TS=XT7',6PAZ]Z,S
M#:#YRP=MK'%]CL,T,A)7M!IPG*>)EL+A#@]5F!D)58QXI'# 1L%PB0Q1JZ+J
M'.U=?J$, 68OTN7(XL)P!EL$B4:6FXN,]W=WD"68/PG0":3B 8AQ4%'74(P2
M\_^3_'31+%$4!><!3KR-?RDB]'@@14H)!( 8& &5-YC_8LNE%^)YP( <.?4$
M\R-!?1Z(BEPHPH/)BMF@",D1H5IR,%T)/?\%Y$>CICP PL$E' 3E@#@'9!!0
M:!FVD ."!&"F>/PN$/S\%'4@@.7X,P.%*O_:A96R7GT.F"P M3F@+@<<74*!
MY@*F /K.K28ZQQ?M;F/CQVNW(=43BMU/PEO5*%L [CL">5",_]GHIH=#V^\L
MY$A]%LA!&P(*'H)++L- K>Z<ORYMQQD94H@M@VP9(/+*R;8'T^,PN7+P4[ON
M_Y'QWD%-+7_8^.XY)SD)@>006@PM5!$! R+2E$,O @8+@B W%!$$,8BH7!"3
MT!$U@"(J>H.BJ* &!$1$#4U046/OWF OJ-'KM<M]_?Y^,^\_[Y^[L[,S.[N?
MI^P\\YDGAFPA#.X'K'#$3#7A5*I$)G3NSU+ R4KH\2_4N8FM3D!^(TCY$(O0
MS"%X3XY961/@_BP_)%* >LHP;NY<_X4CI5>?]5M#'@^QU,!320FU#V& P>]]
M&@KYY[,5>,R[]BTD3%!366K<1-GTDP<359@%07%2H"-^S T_7]E1W=M,Z]KN
MX($DF,2CAI[$/0!XP:<R2+B>Q# Q%/+52Y1 1X5MC#W2F3'76S@ZTLKRX8$(
M/I4B0-;+*)@ 7:KIK=<% 1H,B+3OFU&6B<"8]K[N/XT6@IX9  23_5H*ZD(5
MMER.T<4P0L-=)_H]I/SW&7L4W]/)! &$L63B H+QJ4[*]_K_J4#!6OT5^"0E
M:.NE//J)1<FIX^E(O4=33("REW]LEPK.N@5#%(;-3Z@A@Y=?*.AA!-Q%(([5
M%%W2^T3BPGW(1=V:IW,>/0VO9 6)%\VJH=4=7105U_Y3@UZT,<K1*!=LB2]5
MH*D3AGW2@%@1?:\I)8+W>:U?OQ^)<V;9Y[^[HROCZU51"Y24?EV<J7R>IH8V
M!"56+MC)@^<^+OX195_\-VU;,O;RPY39?3..N2S<./VW18?:R5/R F&RFCH6
MA;@<F)O.QTW$[8OE O['Q%\R\/[ZFQ>OMM!5/2P98"FR+^L@+#Z8HZ(>^QNP
MY&""R<-- - &4%L$;CG-@@0R6P. XN^1,T:C#E0 > L!F**B#NV"3/%X%/_7
M11:(E/^>1XP7]VAKH"X $:)Q1S5"$X$5*@0J$5\!L)#A_UU$S$D0JJI=(X)B
M/KB!\#M0U6.I4%6*\ Z@RKTC(8A@VVUJFWB[JS+JN"RQS.*EI?+X;5O\]NOO
M6C_L7P3'9<QAZ#X]\:(,!K1\N._[./6&,+JE1OAI8-_].4E=3]3/@R75-XX/
M/)TID0P>O[Y@S@%926H-?_BZ;\O 6/,8JKWUQ'ANU%@PXG*[2=$_%YUVZN?O
M9S:XJ5RG,*Q ,RPOV8&&/'^JFE"_\*?-##7A/7D27$QU2^&)TOTN,:CK30OO
M;)0^QZ0>)/\:]V6P=/-,3]MQXW1;J9X/S]^E_GBS!%_L8[UNDI5ON=*A0QR^
MSG-LQU^;TWK3#LJ622L](DUZ#VTK]>WD19X.^#JDW&A,*3SG&O+X>1%ML;5^
M[]4G\B61!MER]^[C^T:.#%49>Q5J>[0_/;]U:MR9*H_CSR\U>.4?S6R.,/9*
M$C3Q)=RAERY3'-;%U#2[5NK9A!\\FBC]3&?'^5T<2TP<K-9=<KAXW;7FT'+'
M94'@KE7IH&S6'/=U[DE)Y\W45E7E(]<.8#+5FCTR=P3Q)[Q7S!.DZ0X.3O+V
M=A((&DLG?FDQC,N+2Z</<^T%0LC*Z6CTHSA@47[&@54"JE2+ZNMG["_CEYJL
MZ%;X&><M"(9:R6H+GL0[C3.G<DJ/,R/%0S"D7^43,!9L.E4$I(9=($I*LRP6
M(].RY7)?6O+X8RG=0J;Q915V"!!:^$<A@VW>H"YAAJ1\V&@>^=/%:KZK;5L?
M/>2G>EAF#L8"Z=E/E4&.4:"OB#IYL/J EH4BU,\LMD )Z>E?JX,9[OTA%\V<
M1$K)@D*-VI>1(HP=%(06"*5&%;D26T</^1C.M<X4^#64N+Q.<XSL5E]V[]!.
M?$CLD7ZWW[?8^5]?1G*#;,C$)F9RB6-.APR?< Q<IY0D%7:KSRDZ4F _=8;F
M<;!^Z_>V(G9'=Z(TU_6Y?'S9X\USLDX^W[,QJ^?UFJ[*TE6?X,K>QK&KPV:?
M-]\J,__PSJ+L](?/8W%G/[^[6F:RYE.?F5G^Z(>C]CF?JL\K\\9UG4_WCGS(
MLN7$]9:9_G0;GW;NWTAOW.37XVK<K'V\D7_63$_[F,FG)(?LOJ$D!X5)EET5
M;F[S5ZNBTF_XVN.>(/--JZ^%3;NT^GJDCT[NC<AD[\5I>Y?,XMYZN_STO_9[
MQ\;?W5RP[&'I^;T[WN;>2\BP^VQ_9KVCV_V8XT<:C8_<63'38>E ==>#[):W
M00_>O1X/&LO;OON+JG+FU*RHC9*FB>'D/P,2-CZY,?OYUR==@MFQ43MN]Y]<
MNF-#Y)R7.[?DGTPY%)?:X]AD%+#US;PKD?EON_Z>?;04QJTH,W7'M==HWE+G
MSOC .=%_X<-1SM].']U9_WD/#)Y]?.ICY2F7>VK.G&.G'8:.)[DXW/K#YY-)
M]U];"K^_/G:E\,>[$RM%MYZ^<KKW,\/XO_5W;I;-*OSO:]%_/F.4]P8#5G]_
ME.-NV)^L3&HFSR&F8\=-W\W.QVK#W]1U]=Q;*',Q:FT8?X3W$Y6BXNY]W#SQ
M9!]LXGWA?Z?,/I6>Z 2%Q\3,\*O_=#3[&8RUELX8U*-OH WRM+++ QR24M9\
MZ<0N3RO\=MWL0P+M3.-YV41>I*L9J^+ *7#4+]"A9R^ZOGR'!WTL)'V>GUZ#
M^)QM_176'X0?02QES)3+8S;N&&#1'N-6O#&72#FZ]+,<<[DFU0F-25XZ"H;C
MGDHV;SP_8"1+W'CT01)SE:ZAT6&)HYVWK99CFF1S^6,L:+/$?F6(GVZ5L-CY
MT5[FH1;4]*.PK.)JDG:"L,G\N2CTG,.JZBX.:IW15A;/S:X?='B>TAYT-N7,
MD8K1<-[$T9E#J=%MZQ(^)2@7= \L7WX]I;ZB"$?X8L!1&T5QQ! 08+5E,F5,
M>YE/5K;4T/4<RE55,TUDF,]JE>%4\KJ) V]D9% ".(HA.I"%C(A3\ E-6A7S
MZ4F.RP(2U?\*3.?PH[3)>72V&F!'AZ)8)+DG2B%.]E.+#>4D]- ,&+-%UK*#
MP"K2CJ21A%1G_*JAQ<ADQ][?PB5>B>H(JG"^6D+'IF[1^TI2UH@89N[BO;P[
MMZAGV(AGJ@0QD9%S-M%O*;BUWB-5YN\_EEU*?\3?-6]P;/'N"I^7*ZZG+$Y1
MQY].&[E0#(!]B+\A%X#I51)@-B+5;R+W\8 831;Y:P$1$C?89]4Q4F1T>9X5
M74G#/ \.&2^?='Z:_C/4(42_D0P>GB8;,\SJ%L]/^T#53JLSS%$AMO\J&:/G
M^A@9/R']I_)^0HT8M$Y\?X =72BIZU$VS75)-V&25JYV)"/?76R[?\XVK:<Y
MN3/$P$.;7]K46F?H%%.I5]!?;RLB@7_% [-'ZM)9G$;Y+$6%KC5ACYND,YGR
M*$=7/M-3V(56_XOB M$<G&,1L5:WI<C<) !'WE>L.=WR5?T]G/%'C#CZA@C-
MC78]IUSKG,874UYR2@QH;N!L9R"%29[S#.'!^D\H6_,&=XSA88:J$BT.7V)G
M+8%$VB'"@8<PE&D^9@JQL4P)=G_RV[S;LV]::_+DN"9?U%+@NW!SF)5MC!J;
M];F(""&0=?J->_7N6!%.9!--?965(O [RIV$+'YUGD5P)BK-7ZJ :WWC4.%!
M4E=_'H/Q<R]6W$69O:*ZQ/UI(WRROB8ON[?>P=KW5%L+A6NKN&?N,,0*XZ?K
MWHMJU0MP6Y5[1VPH$P^[NH+CL2)E=/T;W+2*V]_[;L8/D_K3)R*O#-R)2T0J
MEHSW;&;=79$;SN&JQ-/6J>C0SO< 2R%&K7G ZTX18BMP2"@GP8**>":';7A8
MU8@$[Q5O"!6@/B)?Y/E%Z6RQ\H')@H68XT-TADR@\B25.C9?[6D]3_&9"^1T
MMET=M4H(N=6\F,7*E80V:37-9( U3WF,X(J;]:K4A@Z:]N01F;@QL\&PX6B@
MKC[_X&*.+QSY*ID(+1&N\E%(X-E6RH;J'LAR%TZ+"E%2W<22AMM^S1O'R&:7
M:S>Z@1&2$;#*L5<D)K8"A+99NO;$D-A[7(U2[G8<N[+Y\WV8O^%<JMN2W>41
M)Y+K=V25V7*,T.+5KZ4Y481RY?SM%"1>B+,N^9GJ$S"H5 @6C)4T'KX)>"])
M&I.\C@D#I'7/Y4CI5PD<5<,C]<>PW0^+L%$9?KCE-HLIDK"D2KNY\TV5Z>!+
MYA=UL7FY<O+>-<&T@G=EY@MF?$V9>42KMZ$OWHNT7QF3U[B>B[-'ZPRS"8@)
M];'U[GVABB4DN7'HCYAE$NWPCT6)#:#$=O3;6:\C@883UJ3CG66)VDY?Q4]L
M5$CU3T/K+(%4IL^G+M;DTM?J)S?/;2I-2&\6,T9<F5O#^:Z9(T&)'-NUUU9G
MYC:[6ZQAY(L*6J8;$>+80#6()*DWUS"X)."[Q&J#(+=%CH0P+)"@K!#JU-^>
MYPB$?F*L;R^L[&/LN[U2E[?"3(S9:QA,@(4(IDB?4A_]BT[6H G/P8(V:"[#
M; P*SGZQWK!VL8^@(.%.>J&HH$H7YQ"($(-]\Z8Q2:*S#MV\+_N/9U-T<AEL
ME4WU<<@(2F^;GY @3:]JA/F#'C:R'*L8!EN]+$&)9LE06P$C3YWP08#E**4=
M&HJ.&@^<$,ZK_@?5[A/_1:M\_5A\96#-M_D2/7=RM"YQI$A";9+4^M),"(J_
M'*!J:@(I\);_MCUHGA(#/!C&HYB):;+4C)^!09Z*Q0;"HL*0]1^WHONH^86_
MO<"VWS9K18C0M.@QHT.(S=XF(@@\6PX-22(SC4H7.$2HBX<690PE41]1L#]"
MUFR>7II+Y'0H8-@+W(Z_W$_\1YX:O-TN5(<P+'ASK9ZOPOD)04*0Q4]O&6),
M%2;H:CB2F+*= 0Q#L# =$>?PX4TEOCZ:X2M.2)<#+!'NODF<_4+5!E9L.:.#
M73DCO;;!N7+FUH!#=A+BCM^HH?\[2\;$D9#9Q^PF%2@0*@&@"MRKH5#% "4!
M)A90VU8\[D .Z*7D#>9RU9#GO-Y26>/(,_P:;#>R"DGG%-#%M@1O16WJBM5N
MT() ]#1S(F)T+ 6"UN 2,U$!GX.=BD:7TA?.XB^?)2AHVX<LP>'J8BI- /5)
M6+W=EBLLG5\?3.'%Z:EU(_B@?2%DD<2J+@>W*(:G BP: M_T<6U!^I87&#K"
M^5N5GJ7,>6<$%R75%<I0MA#1$P@[>8@^B1R9.8>M@<9"6+]4VUH \ZMQ?E[M
M]=#=6]O6J.;/FK:ZTJ4C\/#7Z("[_CNKJ5$\2D8'GB*FOIJ2ML=@@L+OXY#R
MDDP!5BZEWOA(%>I3 PG!/"%63XD?$?QU'PG*$P9U/<5EKGA]"74L:(]GV9\S
MHHT"^0GTL+@)>MPR9]Q,N$<Z@YJBI@BM4S)<\10^U8:;D$ONM0DC_ 0%V:!1
ML32H-(6Z^<G>8K_:JC%JKI"1K\HIOH8%"=)71V-_K68D@*;^&BQ2YIG%_VM/
M7<%-^GZ!?2)M:W3SRUJMI[MU:7LFC40(CN-.?;.-MTY*5?_QC(WYVOO]T-^?
M<>' %N=%%[OV7[0BL\.:J:O7;K<X\&;?@17<&7,O-&_@5JXU",RM]/8(.%AF
M/WN)UL$G-<T;7Q_<LG--^>M$3WISS<3BYE6BYAU7#V[JX>1_]]]S[T"#UJ%=
MTP\'I1PR[*IL_O-@4.BDO95.\AY.X>+#<^?[]LUHZ=(TG@CS.^QY*'.H)7?G
MHFVZ%!,58(H0^6.,+8;!S5"7P-I>S8\2EB65PYN54$\5:RZ'W^30DQ=V<?D1
M PTU6=-0N!5C@X7WEA_14]OOY"Q]M#RU/(01HEJ6V0@7V<3%*E"VFMIVUR9'
M :WE[)!%1PQ%^UZJ 5,)R_TP#IGB)-]W\3&WO@2)/I'.T81^[8)I2JJ!&LD1
M;/YR&.H)D'EJG5%[.+TFBJ/F-ITS-U*P3Y52G]VQB56V/R&0N@K(Y<$(-75B
MDCSMRKS-]]B(0P;DJ)&A&M10<:3=9JY'!@S?A68T5>@ :"_$3\@H>[HYXP<9
MR?Q4LZ><6&!EJBB4M?TVRU$=HH1E4R=%$@VZ^QVKQC!K$EG*U;-0"#N4.*E:
M>O83:B%'6BC8)ENO".'V;^VL! 5N^"\G2ZGS0Y"UFSO)V+JE4X&FK3I9WX:G
M1"?_"F;8_,@X:W]P@7]/KI;O]C&ZEII U2"'=X0C [@0$B3F!\ 2*5:P5(CR
M851<2J$2T.2Z!(A]-Q-H"Z&!HE=NB0 Y@RD$:7)<1PA&XTX]4"( 0%L2 N&*
M&0!<^(@"$O,E)J"A$&B)X>U%"%#%0#GK9O^B%!ZX$ >_S:E-4_\&/&@A #A)
M. ' )*TW#C%XO&WW+)=@O"TH'\"KC/E3TH &KA9U, 5 EP_7OM'1$IV>$H<]
M,.[4 ZQ*"K09AUN?4*@",'H307D@>-UI Q%DJK T_C:^=I_K YA+!] "@9I3
MG5/G$D+ M8! DW_C@-Y@VL[O=E.K$N%F*9+O/.EP$"-,=FBS+\[B9W02".3K
M[\I@! ?YKA18O_>0D7+@GTC5D:':>)2-&$;*$1V!CK481LF&ESFOK])%5A64
M/[L+^OYDM(4RQB^X]HH06JK3^XDT1L+P*FK%[.:XGJ+*\P'G#V^I_A,9U1^>
MPVC?&/KLC5V8H,I< /Y^ 30OYNEHP.JG%)38WL7#M35F)W\L8ZDO=!)43 #7
MS?O?KVZ>$@6*^20XW<%;DG^2A9*$B1!@;;^O@I+*!U;#'%OYQ3Q7,$--Q?@P
M8_!2CW@>4UT>* /ZPFRZ["Q^&!C*@#0(G!UF/,XX;RP"'=)3<[_8 _653@V%
M3HX&M_?2Y0RV!A0^O3C> EIR5?2(W$8_P,E&JA:5E17,(92@-Y;V_1/JJ%3A
MW',[0A!'D6$H@#:J1B,E?,);8ZU!;SRF.A!(92.;\PJ;2)$$)_#U8P5(C*6#
MB1CNWLOFR!W_Y&&_1<!-#44@HWSL,+54H,_G8^8$Q4*UHE-.,9:#GR&,+>=V
M:7^ MLNH#E^IN#CTC !?KJ,M"$2$$0QV27=@8\IJ_E5D$V)#6JT4(6P5FB<K
M\R(1_L?]UC*MU=2;4TG'/!FVF$1F*4RM^,O.&-PI)+LT4V*LP3%[-1(!D/G:
M\9.%"+\&2Y.C_E=1BE'KJ7F(OS-N)RRSM+__L L&*G\KW -G.E'J=]==O1%G
MM!YP[IP_:;AR\9NSG6HJ0[;.> >H?X:B /&0H4]LYQYN16;)42\E/N$FRB<H
MF*P^7C:QT4N +MV);>0OSR.@MN)AK5$!4,7RJO&;!#V_973)8RI-!#OY"&?)
MF;,\V.5&G6;"?+&$D:L!VNJ_;LI'?T4[7GN+\P TT8 ?/,@5C1E-1J@R:I ,
MF.ZA>C;48PU7KL]A^/$ 3X-Z"M!@-H9JX&SEQA8#CT0AL!0#?S45YR-4WE2V
M G@H4 ]-I\=FX"N[924"]$O BX]-5@)V,+"3/]38PQ,[*+A8-Y0 6BKK67_^
M\;03[EP%"XA=G"2JEQ?37(S\(3Q1**,F&%#TQ-<RG8AD.2IMA'YJ2OFZHSF?
MYWH*]1SE2/A:Q%A(+=X3'#NQ_:B%D'(Y=#E=CJXN^,VW&Q:_\<]FPJ47TN=L
MTZNTH-RH,2A4H[;_4M-VHBF3CY6D4M:I >\U")1A+#G'#L KC9 KPSSEX*8\
M]P\1<G8[%CM<XY0+;!3IAJK'V[JM$_CC2?4@4/6[&I$PX8NYU\!C]<)"(84M
M:PI[AAN2#<D"U%Q(M56/UI\NB"#@/,D;'Z4J3XZ</(H'Z#"U@+T53V'/+Y@W
M_0&<IA')>JJ<L9?Z3ATJ#!(-A_!5ES?%SA( 7B:@"P#\ -]XG2KKQ0D9T/HM
M?I:&Q!T%=!E 1>/9X8#8]J?M7\#@[=6]ZW<"\=\/QZD3='&&I?AJBA!8D%24
MB%TL EK\3U!I7WU]YVGO?WJ4#.\KA-U^]+K#[_J!7;88ID2I0FPR"1V$&]-X
M8]7^2NP5_CU\JB_Y&W4_8G+'M&.?I[VWSW4&*;%(B!AXBPF/L8]4@:!H"-&7
MC^/B+_.<DU5KP.Y'Q)N-@$8F/]1\Z(R!]=:8'KF-7,GP$0@N!4\-?,@XZE)Z
M)R'V["/$L?1>H0*Q702W/P/O*1LFJ>T\R#)>Z-$%V09WQ'<+MU(>[<=:WN/:
MBSQ7IJW9D;:S5X:6GMHW!<#LCR" JWUA_;'-3ZC!PPS3,=Q7G.$PK/-M>-7I
MFMNG-=I;JR9*2KI.C+ZD_'$"U^;_?S';3]2M"]%]MPR-(AE'=Z"WSOVQ0!?C
M-"+OTC),E.OK6;1"0\_"0FO+/PM32TJ,?4IB686Q!E6R;85&_B6&4:G,_!)F
M5-W_W]BV4/3_-+85K<HY%$O7BMV?@)I696GI54CI624^8%9>GC]P+#3'SJW-
M*\QCZO@&&N-!A8V+4<O"U7F-)>9T SSA,9-8F?^AT!=T:VI'YK!G>0'K*1@&
M9'YI[!AA0!(YVX?+>TE3#6XQ0BP&G^5%ITD1UY*7=I-J5\0UVD&_4J$LT)=)
M"?5V!QQ>)85ML'B<)CXW,0J(JG@@"%Y5!+<6MK\EC!SLQ8?R#AMR]>0X0\N&
M'P#)P;G%U*S/\?\,; MF*':#S!H5;_-?[DS]KQY7]1+<?6PEG ]"7OE?,\=&
M]7?PE#$'>=O:77FZ21AN(=VJ/Z^ZG\6BV?B5WR%M!_>=+5P@MPOH"[.=$N07
M]I7G5XP;5'TDZZ_O':JOT#.,_D;L'<1\@MSU'W^0\/[R"]SZPV-1&$[WN3+'
M%YJ&L[#D*X[Z4SKV0=:<69QPQY2GZ\Q.5?6:W-'T^2WQ,6AZ><N^K]Y\ICQ$
M$DII4C<'LIG%;O>,(M,$E<;$G6?]]-9J"8_.JW(+8G0/.?=9!KJOZY\@__-5
M4ZDF-S[#$HY[U(B)90#H\Z\*%ZB-63>JA[+K:!PMJBD]*5"OMJ++5])B?2BE
MYHSKJZ>U@J I2Z=EC3163MI8[P*AT_<H%'0;2'V1E7P,I!;:Z2K=+/1E5V;\
M^=+-UWVD>,%(\.WSM<,Y(>(=@<"X')5@:XYLHR+,JNQZ# Q&%;N5U,L%%EF_
MF3H0B_\T  V\B='@]R/3YUHXD*^#_2>/9HO1C2]U^^<5%LN4)L:DAC3I7/RL
MA*FM&AP 6?5PWCR0EDKW%.A>W1:R[FOC>-YMN=LY,.O&H)B9 /A[,.;6D\&F
MA3)GP)HQ0^;?==^3"#<SY! 395J(;.\M3[V#QD>AI)!/2FPP=9)E1(BT]'39
MW?V^,GNUVR"ERB')KS[KDWI8:ZK^/(FS]T$!PA93=I2YKE=:28R31>+^/#WW
MMF"DJ3O;A"WY+AD,*/FDP$=5H<,CS-L[]A9CE2[]OLR2P:OBO4Z9XIW;P^)J
MBO!F.>''B5IGT;?.Z'J;L96!:/QJY+SXG:$2@S1="J5*?J.XZ.ZOR;X[/.J%
M'SCS-"_Q,'N%>MA$7^:\N\A>P'D7R3EHQ0PCV:NKC;3BG^+4)VTWE=:NTY,H
MERI\L@(-V0['/]7(RRY?V-JT/>O[J^:+C3TOKX1F*P%7 ,04S3>+/K#T^T2U
MRFI$\FJ8^IM8E @E?KL2Z6OR%3_<8,;K1?""#Z40=_C8M[#0CA0CPWH:&H&8
MR"&*_'I! D,! 2BK25=E]I4E[_^:A .!G\7BXO]^PHF')1"PN\6 *V9K3,4H
M$RB]?JHE8-S"0E K3N#6E&2^"J2 D*))0-X@: 71=0=!U $(DD0K5T'G1*2G
MTR!D"@ )(PC0OBY^JYL,?$1%C$0[?RY;#=F8,C?!QONQ[Q%(M;MNS.9[3-96
M C,E^!X46!8P9(^ME$G1CQ:2DO$2O[QZ,?,Y*+Z\J1%&E!?A\BZ$\?4M;.)P
MJ/VZF'Q''S)[0EALRE'/9-HIG9@QM(N/55*TNX^VK85D/A?L>:5JI1FF[3*/
M5S7HQ/I!2P%"%*BY4]28CO$Z?-$:(<;[I-9)I8$I&S1%@2(R*4)4X:Y/5K[H
MD+-URQ$S?=FI5R%*1JJ@R7RO7+PYA!?"%D4)GO,QVE<+^II]^NB%)BG%3ZSO
M6^$__6SWB7W??&G;!'UPIX;*C&^F$1K$F$]V.*W:B^5HI 9ZDN+5>R%ZOUPZ
MW;&Q).GQ<(9^3#DEFH^O_CQO-6TI^[7A!56IYP+#Z+"71I%"J/U2OJ:V>)E%
M@UJ"Y/6A3\8@/5P@57D_QNQI0V;L.M/I6]68#6_"EQZ@*;5=)W?(U)5HT:9<
M9]?SL"654IJ#4C(R)8G"O4,RFJ(ZV,0*KH6XTGP5@?PG']MOLSN]KO( JA,#
M*'&;_&CV2DE$^)/"5. ;'"_>95>@7&G#"\A\K*%>Y_?3S-5^N2' O*W?]4!+
MM90V$2;5_VFC8Z&^PWP73&5Q_)-M9O3AUVA([K@2R^<,X"%MTIH+^K0QT!^R
MU%YZ"'LWS9'TY;<#?>U6\:$JD;WW8KF$N?I5O*K"A!ND)W58VH=R!;Y))-_@
M;WU+W!49H;KQG(/&QSK3+8O-%\M8MNO$6-0=2/1J%O@T23!CFN3O)MY#A]8R
MW=!UY1/&9NH3IQK$V.!=L+-! 0M*_1EEY>^-SO&DQ.!M1@Z_VKR>L.V2"Q<X
M/?1GCBBN[=]=A/;>1QF/)/<//1_04?\B9[>K'AH= O&A_-'5OTH3=<0\<W]!
ML-D"P0$'8B_--PU2BQF[GQUM[E]IUT=U5W>>6B5$7R1N=)AT54IH8%R)2&(X
MD8-\+[!H%$2_]&\.?V;O-65OU.7VNA.CSYSROUUL9$RJ/UM%919DC:8]=[&X
MWH"^.O#MDFCS\0;=Y<\\[W^[W+8.K;ON$.JXK/E*%>B8$C)/RW=JA:J._\D^
MJ$2+G.JY>O.YRWLC/KR<S^=>^J4HKG_AT"-;Z+GZ?>AJBPG[7^DS>9X&5[ZY
M-F^[X;9P[;<;+:4N>Y9%O"F[,&;4=KGSZ.F?Z8O>?[_]O[!M6<2XS;>>.V&'
M.]NW+^FYN?3;M<'9;NW-$6^7Q_VX=^=R5]>DOO&L_/M&EQ]U=0__+VS[XT%H
MC5O/H5]OUYRZ;YA/?2BI(5=:IPU=S'EI_O(Q*#;DC(TNWHPH;Q^IM'OP0S\M
MQL6J7:1)1.=?:Q85.??R%CK.?\#.D_G5]*H>Y9QJW';H3M&YO^4KI[EGL:+$
MN5N'51^<MUBD]5U&@D+W-#DHW2Z^OWSR\IA@?W&T$+&(L<*[>IX9> =H;8MC
MZW/4$L,8.<*YN<K,7GZ09==+Z;7Z*C>=D+^?9_T89]H/FCFHNY-JY2</TOKW
MAX@2'(=S#Q?S_5%NH1$SQ HS\)\9E9BEY?:20D]+#IA9OYQ*42U9G?<2A 45
M/W_10(KZ9M>;NWT>O;R[GW&I;TM4]IE_+F_P>C3GL-AH]YR:L^-CC"\'!CC4
MRSK;B_UJ[$W];SR1@WVKE)'_Y;7;/"*_[C_9^"5IVJ S0[(V:#3QWSI>;./<
MOK+QD3VZ%:H+_T1(2C_[Y9N6K"LRJNLJ.SR8J*O776Z\V.SHRM397[&H0=^_
ME5]._QK2-KA29+1\^]VB"QO24]SM/K>]+ZWT8BS_1T;[=2+_+9YQ;#N-OY^6
M(Z5^WTZ-7H#,OUJ8/"'?L)7M6NS&&E^D]7 1+9TG>9M,UUNGE4U2KRBIA)+*
MY4AM/H8[SZ?9J,$:*37.BIDL,##J9B;*-RQ%>)4N]N/XBCR"JD;6O_TWGQ,L
MW=4XLP1L>%E6F,>GFL>X%GPI7KUV?06?Q05SMOM1<2,*FV#BQ_& +\7^W=9[
MUI9>?$XM.Z&U9+Y6FA!N))'2,0I'8)ZZ$#-00WVUI84Z</,V3!M 'Y*:>@ F
MJF@.99 GA*G_FLPFIU\9HW)G+@G8#ROW(C[_ F\%PM%8%,J0QC$P2XX8\:%=
M&TQ5(PR92P ;!J"A%F(X89&<D6)T)0I;LQ?6.U,GF"[4W#3(<J9&#+/6?H)&
MO"3]J]!<;A(JG&PLY/2^_%^>Y[<8^29'7+IT?/C06(R<=5W"4<,U:SG&(CC1
M29;P5V?)X50QF;H-37D6]$"&$BI="P7D\MRCR$T<(4>NCZ +::&_C\<)YA*(
M$6%;(4=8V<;F ,J^1$CV(ELTT!X@A(([WV"SL5A:H<1VO(!;A%1F.^+/FT3(
MT#0>M!>3OKS4?+X>1TQU5$,; >0*C5($91PBI4J,C.V'>2HLQ#G\4B-JI(8'
MW4/MY; %;OT28YL@A%P2,1-RK"<%KFCV,E1#(QG+4@D,53Z+11/PIIUSNCH\
ME%A3HH:D$*JZ9PB$T%P Z_N@@"S8H]&;]0J/X,<8RG ;7EV*$@U ,0X_^OMS
MS) ?;3J&F<@1-@_Q54"FAO @YL_=SK(3&R\]!SD*KB=A&RLWF=U6?NX:NOH0
M+*RE<'B(OBS>J\AX_@O+*###7$;Q_VUFA5@T'T;D1:3O@SI*N'PUC2W8.MLY
M>M_DI6E?&]9VE1Z60SWYUJ.Y\>O+Z7KR[!P^?#(,-JJPW?M@]7SXV9V(58=;
M\(EY))P?K/60GF.3JT6*Z;,$='/"+IX/3#_ EL:M9LY@)T2ZKX*YT7")'W)?
M.&.-+QU,6)AZU[KI*'#;=3Y>!'O*$SR7A*ER;R\^FV;/U%>[2V_6^9.XCL99
M/C;IDO-F;[&^I3 P&>R)\@59BCK!D,XJO:#N%SA30\D2 "<I;\0"JMM1 0K-
M>3J396LM>,[6*MT$=7A@UTP;$E_!$R:(3)S$^CD"Y+0^$O $W-=0M55%4;IV
M2:_W&?Q#U9)1(WANOJ+"E0(CLX_,;:]P2SXQ6<'5;9P4J="["&!A#I)4!/-2
M8&F.\X?$R7-?XSH*VMS7>B4\[((8T5:DU"^B69&N!AI:CA*\B')O$%M'$!8N
M3\*S".A8AI@D4P_WZ(7RW%;$8@DR,)&K%L=>!=PRJK:2ZJ%A_J7$[?EFJ3QZ
M%!\$J6:OTFQBH8?.";&'_U()N5VJRB-2"#;RH,485GL=T>;I. GHN[^YSZ54
MI?/7UI[0N7F8QA:OJA=/-^,3*4*DW)9R^2E%1Z&S7HO#&*,-; 7?Y&B'9WB.
M5/=++:XCU-:5L=+4NU-IN]D92V>5"8P42!2YLO9@LQ9/)TK ]!%@V@+,1YR_
MI@U6U[I;D[2&)W@D>=2+O\]/C0;**VH,Y[\J,VW45"6] %D\Q"K4KE!HJJW?
MT2='OZ 0OS -;40-!-@L J.25"L"\5>MU.+;MY=CCCPD3PTCA!-4;0*;)<28
M,G^FZ(]G@BZF*C$+=$ZWI,V384M^=+[FXSM7R]H^+O 2%;*%5$UNI]H3_]MN
MTXME7LE*JB[!3%&'FZMK^X16;WC0$6#^ $FJI?@*D=VU%":O;.F\(,%4[*N&
M4OO;-7>VB\?,]50^?H2=)4D[,K4@680$4K"9C08F:BQ2CE@!*Y8S,D/&W9U]
M9$Q1$_65RA9+K4E+(B1_5P>GN]ITI0";S8/S^R#+ N:($%.RW5,$"@5'[R[#
M?'CPEAIHLA$?/JZE# M4UMR9C S$L6.5^.08K5B V0%H;M62>;V.%66<Q?<(
M)%NF_J!Z37Q 9^VC^,J1&A56KYBYP>N,0;*)H]AZ!/[O+RU0Z?*C?O,N7M&A
MZK44;V='N6)A(K;=;T^AT#)"#4Q_]D7)4-EUU%L$<L28C@CY;XW6@:^HD\@T
M^9L[HP^6]F':3]KUO.GU8IA@;6C.Z P4Y.MZM<5D9LR^G5Q'[&M28X08\^5C
M$3+<4>2SZ*M7:0XT]44"CEL]!JY<(76Q&H3P,#\U-L\&JUM$RRC2K7YBF@DZ
M,OM.S\\UM8P=Z9/MF-9JA[&GW!>@''EH($')%]:&\#BQ?/L9*F2JG&*[ ^:K
M3P81F!\9F<R#%4(*4W#!7XW%7L.;PY9,6(O,/-3G8X4U7#[NE(Q$:M!+$+ED
MT%H3#??[(CLRL<4$7KSXD&" 1B9+Q_C4R\6#ESM[I'YAI R;VU45P-_^MHCJ
MHX;:!.XKA*]F8%$\G705:JX"A;6_BY#V*_%L%1]33#W5ZD4MDR4$*<Y['4<F
MC2.^<FCGBPSLXE<J9J0JNJO((WB$Y;)%R@ >Y@LN5JE+'&44.X6.'P^9I^99
MJ,I(,=:D7#=@#1V45XO%AB4DXB,\X"^\$*F>><4W_M67$4)&K0,)K^/A:KDR
MG;VF0EVW%L(OW^2/%48&T^LLY),LY1NC!3"?:#XW&186(6$<B@.8@+-0HL_W
MNO\4MZ4&3C5RQ%IJ=.49LNZ#4=AOY#2E,%VP)2DG(V7X9#6T2,7F :=D4F$@
M6EDA1&:)_I>0MK"T#<[D1)#3(Q2#V^5WDMB4^[I)KPMR#LN&=CX4R)NM5W3C
M^1IM.S'RAQ+D\O%6/[,:&FR473C[#RU+"9H4!T0-7)[(=-W5A%F*A?F*8TF3
M84M4;6&OGKFPHRR^8RQII.K!T>,9-'0,JYN)!_@OC*O.-8LJ<_EG8?X_P'<
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MT%P-S(@Q$Y%Q.C,Q4W+8B6";R((WSUYRNRVP[1IHTJ T#<V>#QWYT* 6]SF
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MBC5HPOTRIVN9 <N/JG53>Z?T([-4"!:^ ]5)Z:-PO]*HT08(A9#JD30NW83
M>-:@LD2!HN>$I8PTN:FY^S8:+1!#Q^4X\ZM8UTW8MF6\$8E*Z\/W?M$U7:!,
M-!9*[5>)IIJ22IV&?O+3&3'4)OMTM-TE['L5]) @B/JZ5WB&_):))*ALJ"?U
M'@NU7.^T$\=JZBTFFC1]A/ ::[*0)*0\%Y\0@ :E0?0G42S_UD=QFN.'[B5'
M4[SE9EXJL864#WU&^Q!/&4(M5"ZDO%16?;P@1<5$B,\".6*I\N.6#@TZA-UB
M+6EM7>KSS]!S5^$D/<5U^FPU%)3+BYN4=UVLU5AFIQ_2:IEN6VL/=]$LTLRZ
MMYM["FY\D)%%UM=1KC7??GJX7-='P<'#0Z4\LA&I%BK=9W^4['"XJ3L]T.\_
M=I%X)F:QX=,_*'V5&F=Q^NBWM]D;GY$M\G&U2-O]C[_)GP<6N(HLXBH:C>YI
M795\3P2U^2-Z7!-5)7VT>$>"?!KWLZKXTW-8:PE:<Q@3V<@T9_7J;$TP>C!1
M8AU@<3J+.&A1K#'2S9R!?7F,F7YZAAN$3Z%KF26QG03E6OJ=.X_4D-120*'?
MN$)8Z$53%#<.9_^^/)N0#UMGN^PQ6'=>6T> G5>Y(P9:.4;V:23WJPH4I,D/
M-HJ5T;\$"Q=N%8;12S7*B1>X%BT222"E%Q,R6''CB4CLR$ \NE_ %,D1IB*0
MX9"ZY?AA9:JCQSZJOF')W,5DPNJ/-U)L\N^&S+GGXB[=I,<5((2,1->'H: F
M.+H@4 *M:1(:'QSM785@'W<J'=:0TMGN8F["UR:\NR##OWCQ!C8/-;:46;M\
M4K%FC?Q%Q-M.2#PT -EAV$<%"\M?5FZSFW[)=]Z_2ERK>^Q.(:__#ULAX\-'
M,O5)HWB2ZD>3O+$1,Q?8R.^,EYG_?DTV[LR_W<0(S$A"V0?!$3<3.W8]^]'L
M^K75.;SI/\4\6O+7I\%2,&BW@(=P%2:'_$GIRL_*I"=MY")WF.U3SLNSFCEH
M*C!)]''8]=!2189,/,87W/='.LX/N/I_.$\^ \\+"3\TH8]2]B.1MF9AGU([
M<75$B)RYLUR\UI&4LHK%J#W$L1!!Q2R3ZX3AR_EF86KQ2XG'H8Z[1:@]/Q?%
MM'L+^;Z#=L(C5RW@<Z_RC\8"-5RX/)')<K_,LM>43#BD0/3+A>0;_F#PN'?Q
M#D;!"/I:+(DET8PM>\:;IOUQ-^UD$&-^4,W:)4+H-[C1Z-PZL87^6 G+T ^M
MR/!N_:4XZN=]C66N7O46_5?R="CQ>&9,CWWQ?9IYS+A.W)H=+'%W^0=RK;)8
M781U,/[Q=%?J^(^8?SAAO,)*'S[/61=YA"$IED<HNSCKUG+N[+VM0VAQ)XOS
MZ*E)E;9V8IVEV:2')XBA%UCHY=PA&5OET07B>%*1_UJ-1+GI%B3#__8SY02V
M)G#)5P)SFK_J46=RH1!G*?SM^#8L=\[#SZDN+RCZ<BU#M=_9(;JYKTDI23W[
ME,-4:'NJ73Q2%DZ4R%/R+. :.=U\ZZK-C5J1\@V'%;#+ -<FLH*7+4S\K.M0
M1\EZ B?IN1'1:*7!VC^$&'_9"N=FW^\!N#*5YBTN* 38Z)#)[#M%*6J0+X;2
M)Y0#9?"YI<<V/+T^N"QT?KI"LG*U!F-IJ,EW<B*-*#HB':X@A2M&<@D*2*52
MY&@.@>UZANN*0[TT1C-$,(VDZO+UN""F4 Z-..5_::#+=*KQ$WUM =U+DSI9
M!M9\I!($-IBSI&59F+90BV7@%TK@C@3(!MA(,T+CN;M$S?FDW)BJH=)56*H<
MCE+@=%V,JF+>E_)E&IC@8F8C=(Y5@@1D GHH\-+];(X<62W$$+Y>4#D6U(U/
M:EK0O0]=EC*M(QC)X2]/4%-Q%7-#\)8<84S3 %CX!(%B%L4@H>M?J!ZBY\C
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MPMD\<+U]K-I$!,_XFV:K?^,T-+*S6*E"K14PT!!CR('6].O&LR F K@8T&2
M)@3"2VO>MZ&(&B"R6_S'$!4!URG&S=%P_DMFLBD(*3?)D@%\@@ -6A8I*H")
M;AV_];\DI,>3)1P!;+IQ4V\%I"N!MO 6+@0;+_W>Q3OC#7?S-6<@!U!YLQW>
M&\OVSME=U-:(ZPD!2KJFJX".$%@>YI[J862I@+;@_HQU9LV."*8&6@I@0N!L
M$F  /HF"%!)\\Y^TDWV7N@+2E$"+1!R$J]G"APPE\%UAYBF&'J)[MFP$EP-"
MQ6E+_%^/D4FUK&T/[W?K&&?R_B[X]7]X>,^H)MKNC7?NR223! )#:*$G2%<P
M(+U.Z*AHP 86#(J(#8)80#0.H1<A%!7$,F!#; %[3Q %K+&#[0E%144-5GS4
M>)[W?\XZ7^]U?]E[76OM:Z]U[1_72 8Q^>"F@NJ\G,E1OXSQ>L$^BCZZ#979
M8<8$Q!)"TEK3$CNDW --PFG[*'I!$)+_EA8#(2$B))MGLEC#N;(4"8%,M/ H
M-45-W8E10R!DDS_'NC+A'QQ-XM,XV@%WB6&<IG^! =Q@!:(^4$.A@>RX?B/U
M2ZZ(EBZC;5T )0U0;20V%V1HL%O3PA3:8CRXGD1N;]>_\.)9(OZJMHDJT%#"
MA089HGY#=S2&&/@KV!\D9,)-5#8)T14@#6)DX+3I!NAB?A^J!JD:5A(1C:N1
MJ7/4:%#?MA<;U\1#>CCT^?Y>AO@Q30Q9B!F1.)3S$>$)(1K_738KE8E#%#Y$
M%4-V$'/W'8@BEEY.@4Y)(.LY]!C-6U2-V/+?G4I_5R1#G4AHZ:I>!@GO)-_G
MO$24"Z"[VB76/[7O:3+*FZ-04@LS403J-XU<>DM!%-#+V\]FOGF!J&!<^+[G
M _BF0MC"]WOO0*8M !5"%QY  $H;O?UL:=S[I59S)W2#^MOO&$+XYG]KK SJ
M2@%[*S4_'C <A2-[)9 Y3H_)><%40"A_B"-\;\5'*-C'EYO>YQAH$"Y4],=]
M2[K*F/^$F4ZW$T&%"V::0!^'-T$Z(D@/8D2*(%T5U+VK3T_>=Z3]<5D0J'T!
M443N@=.??2"*+GQ\F7.LZD'?%Y;F4<.E9Q3NNME^$$L&A4[O@Q7PU9G?YASO
MHZC7FN)0Z7_&0 XQ^$.M)$(CH+B0)QT?2F!9+T<[';+0T$SU :IY>\(5HN0C
M5!):\N%E8]#WW6?_,8% JM42_<S1NJ3WY;$0?TX930YY7X$0D67:3$A7#6'<
M)\&?7H8K 47U,\?ZV_\BC=C',M?GZTE QX=M-K_H3X<X,G3AEE$S_O.6CZXN
M-BKZ;@AFTU+D%(8<TIM&<R-_,-245 ()S8!^7OWR^2@8SP4,%83*0@S5+Y<]
MI0#Q_X[(8N7?J2H]<^P+4T-)$_]Y\@*Z<>*[[W$P@0_J8H=;(7H20(%+9CJ7
MKJ,KF4S5U:&:NQK26:B%))BB1S>.F6Q"UV5B:R0M&2RF#C8Y+9#!HMKD)&D-
MF2@O-3W]L"Z*C;= ]^GF9.KHT#FS%SNA+"1.8GZ-26?JC6^1++M^*S+"L!V)
M>$339<6DXNT4-XDK]3#*=6&]<I6X[:3[I^[ $T1$F*6S@7R99J!0OPBA>]X:
M7<13 OV4ETX\%:'DA&1-P#!54V-/K=.,UOD][?MO;N<OOK$SYL2!VXV^6>^>
M]YPX>'</GM]N= K/B]O[=E].R8,VO#(]YKZ5^&K!(-!K41U9Y(W"WNS4[R-F
MDR++]K3<W[>1IR;QP)D1O7I.[&LN:)!$Y2N4D;!-2/:5DZI[@W5[+*N,SF9V
M&(#B(,GSD5B\Z6D+-:7]V&0,3/>QMM2R[-YNZU#83Y2X)$S(>]<8AZ8*<YR*
M"!8&O[N_9E"F($J67V,G</:B'BX]D;RS@JWV@$*QNUAO\L*U&%#U]8I?OW8L
MRZ(<N62N_NXS^22EQ3!IY#L?T&;JZ__^;MCIF6^;85N5['3RRM^_$,U)32 F
M:>H\>NN^8B==V6HC"@/#E((#/#Q4S_4L*?5O?F1_&Y/@UP7>QF-*, _E0DJ:
M'[ENVS(D)?.9?6(!Q\R.ME/1.R$42AT S)FBG3$INM7YZ!%1;9$AU1>'2F1K
MQ82X!@SF54D(L0+>U72_"\5#^<55<8KN?!NCH=#0%:S0I8-ZEO;X=?J3"*TP
M3,=UB,R#=:-EJ+LN5T2=?-E)1# 2@HVJ]=[R2:G.^+-\J3=:#Y92Z&=[MS8Y
M5 CFT3G+>W$*;4Q=O&%.QW8BM_5&<9GIV: N!6*'N:=*S[YN?7_LXO=W[X\K
M6F<:..L9S5M)=1V:TSE.5Q=2G(",1!#DGYU&&$I^7P,R^PWW1NHP QQJCE;4
M%^J<=9:9N>38#<TS_,I1A?O$TTKG^."!(N($!6</+UIIIBBH>G8^*K+1D80;
MF&_#Q2N\#L>+C]LD^;Z9O?Q2V[K%=BYCV8?@Y&@&[^1_0PL"--*]$69S4FLL
M6&R%E0M/G-OA!7 + CSP!^;.;=J?@N(+3G5FDWJ<*#+YG#EKLT#XIY^C)]U>
MG.1#X/!<3P)^B+S_]D14[/J]-^5'%YI/CQ846V1V)K,O_BQ129GCCRA"=?QG
M1[R[V&*T$KAD&?%"J8H)*AR:-L+9JW?67FT;/5 -G;EX(3,@$P,:>R4S[K=,
M#YYR?P;!?I%-X+!I?=OVC!;UK-!=:]>$Z=YTRS"(!?[D(8=&72.5>U)@H%3!
M\3H1>(;I\ORVE)D^MNG^0GY(L33&8F>ZDKEEMZ*#N>8X\8-342NEN:S3K=N[
M!BM2A;[H.4-T^+&':EIM/D18+:0[;*F^2F,G#.'\,)=&"(W^/[ M6"2$M9?)
M&O<Z"MTI3Y<]<.V,3=,=5ERWU/2S&O5&FIQ=A?--=BBVP3LI'HER!*Q3-]WK
M2ULB>5M$FUT(]/X5T#LH]11=W/_BK0,3UT3/<$[W*M9FOC;*CA/L%%(:;#Q+
M5[=FUOJ8SX32\0/H%D$8BZDJ*T[N\6B9PK#PG@$L#C196XNDR_147H5]+=2W
M0L48=VD+^U;>=*1[@0]<XO(=/SIK;&^]83O6Z%>1C-S)M(3_/[ MU7+V@94%
M-:L.[5WAZJO0Z\)#E\V4B\R[._X;&(35R6,PDXOK!89#CL/)QDQ2,38L=XUO
M2(X*/#(?=A"Q=8::[5J@&>0V;:<)+)OF?7#0GGG$5NI9WY3Z<YB=]9@#Z]7P
M8)UH@K+HH/DVYV3=>Y/P+B$XB#<I=:;;*9V[^4 DNF9^Q/;A1#T<]B3!U/LE
M74E2HT;_ H5?ETJP2+H-/?#' <GLW&:SCKP-WSI<U5KV)FRRLI(],M6]!2^W
MY?7<J_P?V)9:-G'.J&]=-L\"NX]3(PV@WSQ!+2IL*663A$Y]2XRNDU)KPB,F
MU+W=_,4E](J1"M+_6@6 .I(M\C]^)9L+=.2*SFB% 95HA2UYUQ;I0@_3-RK\
M[#\;Q9WIA)ZOZ9SN$"> /O. _F\I%(D7TL[>@,!*W'@[YZ!-MD([BTK2J)3N
MKC+O2:R0E0JGN(#2B0^3G>(3I!,;#);'<117%B%JYX81NL >:_&J3C9SGA6[
MH&V@>)V#FC+B7D9+6;P'3!@R[XY74HBX!MG3[Z?/WEX5S9.?@.J,[./$]P&=
MZSJ\4TJ'N*\N<O/S(+&MAZT[ >V\>2+;B'<.XK V;3@Q<;<9296=<W,^-27D
MC3]W<\?:;? TD0>TL8G1&P'G3GX,==/[(2K1#7F+8 @3@:2OE*NZ0JC.  ?<
MT$+#HBETUMD\Q>03<7HU[Y]AK+$4Q\7$NO'J^8Q]=BQ'"D&?P"4>&*NA-W@A
M9B1>5&>FAGYA?&B:R4EM !N"#MV0(G3^?&M#"$E_%I8(Y'-G1G,AH%ZR'E,,
M DT\_9+S?WY5W([^GGTFX7]AV]^'N5@D^C,YQI+ I'IKR#3)<+[-UZY\2^2V
M?F2O4F_#4'$@IPFQ4!'H3.%>KS<*U"]AN\TML9VN&*=641;J0_=9XX9%J(!.
M6E2>7.K1F<=W#0W3VR#+KU)$W!$,%YE.)?-B;@ET_'H!!I<P75L("D>#ZZVI
M#;%J42,1W13];)+2D)K\P#]AVN%9*J!70* =W\,,UI 4_SUV^B%I)TQ>DM+X
M/>HS:2HEZJO.,PET8_JKE7K6)JNL9-OU0C%!6RQWQK_:$1S-C+B&#>U<%")3
M/G8DU.1:2!I?#-'3!]L5Z#2-U.*WFC[];(?I'7'1] K[S0TQG0L\,NOEY^V-
MHV*N,SJ+2S*>;PDZ-S8U7!M1WE@PQ)I^[L:<.Y^W7?C]BE]U[M;2:5E5K>=>
M^]X]=V?]G2^[?_U^@^N?5Q5/^]IL\6<X>OKY^]OO?#T0\.>ML.K\PX/3OK7.
M^_,NX>[YQV<N?VL\WOG>"?R*Z;3^OD.V:61)1D]?;.CW4R<6?%@6%?#DS;0?
MYY_]^9A]-^#F*L6/R[_^?"+T+ZK1Z6,=%EI-R?2+ Z9WQZ[\HQ[U40<,_=+[
MV?.,_%QS)O#UQ+_9-^8$?][Y:>.PX$K.S2IM\)?FB4%OO8[G/%P:_+5EX:9W
MB2&YJJO:[[N6;AI9?S?GY?:7WRX=O#12_"GWWJ#D>]?$X,_3[V[LNY(T=L-1
M^Z'JRK]#/@M_/)D>I,E:F/OV\.7ON]=+--O__GFW=,_79U6!7^\>_ZTY^,^_
MKS9O^OZK,M_L%D$;N_OW?V!;[> _6BU*:'T()&WSKX.;T9;-R%D"U!-_NPAL
M;+->-,60D_?'D=#QI7C(\RR=*.Z:/*NS>>Z8U-I7:I<FM4^0.G7GC7>2NCI)
M)_A*;<:D$SE2!]]\QV&I;TF^7[0TF)[ODBWU\"T0].:'].8']N;Y^.9[#.<%
M)^1'G2WP;,GG]A9$9FL+)D<7X@F%4Q,*IY<41M.EWM&%L0GYPK'\>$Z14UKA
M8GI18D)!1F_AM.C\I6.%XFYIBF_QNN&B>4Y%F=T%&[(+T^N+5O463N*CF7RT
M+!I=0Y:4]Y94TDNS%"69(K32M[2ROJ0JN[2<4[K;%UW'1;<YE99P2O=UE^PY
M6WJHI62';^E!I]+CV:7[$LI:$\K;SI;)2TIW1Z.;R-1+P^4^/\H5]:F7HBN2
M/I=WTBLN9U=<ZZVXTUUQH[YB&6W+_>&*NPD5/;X5O6>W/$K;<CUMRU-.Y3^<
M"F7OEGO96[K'*OI\*[M\*]^45+YOJ>SHKARIKQSF5&H2JF[Z;OD^5CG@6_59
MFU9UO:5*&RT;X%2-#5>^3I-]I<NN1LM>U*=N)*K0MS)*3I5.3I6QL^Q9O>Q/
MMPPT5%UR0C-4.JO5-'L&FLY%5Y,U;@Q4K*'Q2VLF]-3P&;5VRVJ<^G1\&FH"
M_&J=G&O%7'25N'9\8LWXG[5AI35NSK7I4%V&JL;1#/5IJ(UIJ)GRML[]9\TE
M;.N4F*V^I76.I5L7]]7-CZE=V%<[_=RV#.%_/VM7D^M7^VUG1=5X':H)_5GC
M<VZ[H*=FE:IFEME6[YZZ(.>Z58=J[/JVK3^W?9U??<ZA[0E^M=4]]=*^F@*_
MVN4]VVO-ZM?G-,A^UD6>:^"?:R#[:CQBMK<T[- B7=MGG=M^[.>.\,3:\M*&
MXXF-8<MJ<W]N/QO3>+JO\7)/XQ6SG<<8.SH2=UYRWMK:L/-&P[P*1OV%GXWM
MAQJ)TMH'C%V=B5M/Y#1>7[;S[KE=E_MVO7R[*_/<SJ'$W;*4Q@SGG>V)M1&)
MC8\2=[XWV_W9;\_7Q#U=RW:/->RA(8V7%+7*M]M'?^[0GMLU\G/W]QR2OH.L
M\*OSZ5_W[T\2>V=XNX^6)4>S1>@'1N/'0XTZ3#2;CT+O=K<QR/9#I,.&9O1&
MC<'YY@DWQM_V,YDB0Q;)4;AUU['$YEYG=#J?QG79*C^WF[J<=/+?%_ZT,1T3
M\3-I23)J(C_*JPW-<##*P+3[)U2C4@?#-/YN?W<TEH]&339,P\3)5[V1T ,3
MW=&31;0O4IIW.)ZZPW"*=+5[->UDI'>JZD#HJ($-ZGVN%/4C()@+\6G-93VU
MWHF[[A^J&=]'RY91(0S.Y>Z:GE-3SB3O-^R*V'%HQ]RM7GE 3[A<ES]ID@'U
MU".;  AV389;JJD&W$R)&BQM-LPE $=#XZDH$C6RX17;1C0YMRRS!:->>&H8
MSY]F(W8(Q)8[&Z!VQ#YO _CR.W8(8=SZX(B1<-SJ\VPGD0GB@=K)+<=IC/J>
MLM,@P-7PDV1\ER9X06VF/;?5<U3\I_I8BQ#<M-^OAZ7"*76Y6@B!1&"*"C$7
M3NY6[=W6W<(I0[,UV]>1\LVEJ"NC;)4:GH*5Y2IJ<OAUF [*&H]F06WX^4.V
MAP]-3S0TEBU*E4&;O-'L=V@V<;"LEZ6?K^O$.^ X2COBC1J_\0[&HAT,4$-'
M\%!-M8Y$@1'J.B_3!A)XZ[#=\IEKB8,;R>.O_!UR%()P68)G(_MGYN$7&&HW
MI\E!V;YE6T*(!9[S7ZDWT4SQQ$BA[=KK @?^D1=JG7_-3QC4K71T/)"KSHR>
M?)K7(8C!O*8?/MXB*[G[^( Q=Z%3TXGQ]TYRXS)SH7/%SZ#!6C1LT5EBW.IE
MSUC3H#,O5(CU8U91.=!^.XVFBRP=Y?KZZ&D'Y6G'-M1[W^F[)J(<+,"C_&#+
M,U8<_WQVZSDN;W7)"O8:XF"VN TCSV4_8QF^.7_.HW9"#*"KJ)=\:?-AFCD!
MZ]P$=G)T"@YT23!+C88+0:@(A,EA<SDMF[P\2P$"9.A*,:RK@=3?*$_*4&LA
MO$F.&,J0'.XN,_]V9&/SW!WL1=5LQV<L([%>=A%8VH[:DQ1+"(003!?94JLP
MVHJ!_YT8F&/PSV3DO\7'6"URZ*>::P"'<(TD8(<C8"7$Y@F!/0Y;/3>WD0,.
M9.NJ@(PQZF(<^!' $&?E$O#^U,D2(1S*U8)>V,R6@.V%P);OD"M<Q2&C#$<
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M16QK[L(XQ900 FKH!XQQ\)4F_Y+FIP?V^<?)438V9[>'>9 ZV8D\9L$WUU6
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M5JW-D%EHS4XTB6%OVWV\&!<\VC**\=1I20&%_9LHVB#8")?:^ _A4N2=<1-
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MQ(*M/N](-&=PNS/D:,0:H_,656FB**OFRF-*E'>VZ0IAOQ%'%4/;/PEJ)0I
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MCG=(^#,@0_%GQ #PR672]>U@F.127H<UH0!X*814>RB3YYSQ@YU&@O@1U-H
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MZ[HYY$&/B%-6WC#?\VHTD$R[+*L0$^G<J"#?%IO0.0K2.44G\%$8V(F W"G
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MI9 <G6X$/@=X)(L]&JYZV0-(LC&V@D#.%4(A>I1JM'J^&Z&(:-X$Y&QB%)"
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MN=B#VBOM8@D@5,_& 4Z.&"PP4V$]5&1"H <(J(6_B[451H\"C,HB67:XKQ5
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M37&A]U%3@'Y<NV6+ 1' [-=OT03\\FVQO7I>8I)XU07=V:F8M3/FY-3L]'P
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M*N.CJMT6!Z'+QDB6WNEZI(7M_@Q7O>/6G0"EFF"LA:*?QJU/0E@:G"F41/-
M)YF'7&=FC_^OYY\JA>[WYDCR9862HA@ =-7U;)= :_NJ*V]F.>N!*1-;.[Y.
MS%: ]MCOL>Z@]P("2W)EUK=53 P/[D%I,]&H43ANR<P2 &)KH)<O'>]WD*/N
ME]AJ=IODF=& ;)80S1&"?$E):I&=J^Y*P%>,J<@\,*?_T!(W.SVV*1\2:(&
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MZ(A!$:[X-VHV(=--3US7+F N6O59A10N* 2&(9(.G2OS_*.M;JZ4E2USYUT
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M%FK%>W4@4_W(2^-=X6EV?0KVE04-4)-*JO)4Q\R_%Y$"145M[I\QYZ_TJ&
M'HMDDBTJBF%.B,\*OY.[W3/%LSZ#<Q@.:^@FH]7;/47(1QJTFW(YD6,GC'1.
M2R*R>%UH(-[L+0,@8P=2S,S(%U/*+WU>?^2X>2XW2$X>-'(VH[J@ \W<O!S4
MWWN4-Z:UG)NE<>-RBOD=.#"MN7G;?7$2K,ZY/$MZUG@W"2SAR(P]8X^A*X\1
MX'O2LC:EKH$75S[S[4Y^D.8AR="+DC'-&3K.M?[]WCL:1MV%GORJMI>+Q ;?
MU(KL.C$OM2(!.TC\Z]R%)#!*VRQZ*E1Z0<.&AJHT@^#IRDVU&Q=/S29>Y]]X
M*:'+J*H]Z]2'[^AK\A;F8%DZ@%*K*F4^O6MD,]HZ]:%@F=WO^_V+S8H$/'V]
MW]/'1K2X<GZ?2.&]5ZHJ71_$^')(6:1H34FQ/63EJ?$TE/T&);\YLM9/.$K[
M*BY/YA<3<'9LL5C)M=>*N>Q^0L22'"Q@5&%E@K,O?@W:5*P125[-JJ!/XN;@
M6Y 49Z8)_@3N MX?B$S07<]1Z% .[S;/2;&/]&<7N!"^$/C>D<?Y'4RD[Q1:
M/U67GWC'IY!E"5LW-,58_IQ\#7;<=/FB5F"=PP84+8+$RLQ/CO.V7H>FES^5
M@@OE./& ]B!<T_'<?^W#$)NI::09_^) E4\QM=2NFSL_C)8;+/5R]E*<MF@L
M-X$5AL\_$5#.37#;>[6/@Q3H-(F!:._$),90$-M359W?.7PSVZ(7D<C,Q^\H
MP<C^8@.JJ%R@>F1 "8^!6BY Q"4KE@1H[A'"1:II:C&8-!3TY@6&$O>^)+"I
M6=QVJ7?Z GB]R[M(&J6"OFJE?B7;+SS43RU&):F7'#M[,0?>'7&%.NZAAQE)
MT^05'15LO;]#P2L!=O!24U&6K,?"4QW_D2=%DRH""7!S*1+<3+/7U'P/HYVL
M/*(&$U3_Z] RU>$14B!"CY0N1WI?VE"$BXJE$%N$QC5'%JNF4!,,\M& ,4%0
MD6K^Z'XO6@F8I4!H.)NLHOPZPSD*...E2#P QWSVC&! ?"'ZW_S9!#4TIQ5(
MEQ2LKXX3Z,)<%6 )G4C5>)8H0+8"R=(#NS7+<O5$FFIE8=+L)CZ8AJ$L/:TP
M9LYC+71H/EB$*])UQ++>W%7GC44/R[+,6&MXZ&H\Y8X&"M2"9KH%V:)?ZYL6
M*O((UTF\%;]&",4XH7@#% ;2XS5H807X_E HGUEQ.=C,3F-BJ0:3[\_;LXO(
MUCDZ:?F?]X,!:BA+ASQK)>SY<YY;4=E*_:Q-?7+1S/QX#$K4S-Z]4U B1&T5
MH(7"*F8*+QG]S=15Y^L+\!4VD$0#B3#TV2"</[R8*UP@%\(6/&BN%N)X"'/U
MA!5)J]GZ+<4\JU<ST"<FZRMT\*+3!*_N;>@GVH<\:$<)M,X=N3\*!KQB#>I#
MS(LJY/@6AQ(H>P>TP]-BSPYB"HL8-\NRZM"6<A710@*:2,,'6D![W(CB37)6
M4=*TT0XRR$$*VO,LEVC!RE,N65(H>1QQ>L/O"B+EJZ"J<ZIR*1RB7QV LQ\^
M*/>Z!^U8#WHNL-76$/QT1&P4W1%C-.?%]GPU]'N>2;8:(BE!XG#5#C4C ."G
MZ<"4G6C$.;*%BL!7@-=WH\[:<O/IYE,%$NA>DMQ,O<5)18G1EEMK+=,QR$)5
M_J]F>\;0[O#Q,H5Y72\/S>*A@;\9>"".+W!R@1IDS4^QTJVN&:%L-C<TDJCD
M$22..LF9MV9.4OR>&\8?L&D=>N2NIT$,#FZ7.JV*VW-@LWPO$-GLW="1;U"4
MWW">C*[1I%R,;S@K]5M5$7"_PN;?!5"(9T.!R*Q G^G[NOY*/NDHP] %B^G0
M$C@X:(T)[YH;7'.P>!5"WW*A\?GAL@OQ38H+#9>$36./]KY]U/3A>Y/>?-^G
M&U@_5EZ\N:E;NN\&5KZFS6 RGSKQ9A]X<Q\A00WZ4-%*@Q\W#$HOI-P2[L/8
MS0R?J6;CA&:3BXU75>K.-_O,+QJPCZBY8P8&D6KPL?JR>I_!D0;RJA9*99/-
M$0.7L6:W!#7U1[/CXP;3^OT^%_?[/=X_VZG9Z7&+TX]]P9'JH%7[0NI;PR^V
M1EYLB-K8*G J#[W9.G=5J^1BJRO[P,+( PLWMDKJ#RRHW!?KU+IV8G_:QH/I
M]0=773QX!D!7*PRRQPX>\CJ4.W9P35[EFLA#ZWS*5RL._7[DD'SCH2S5(<7-
M0_-O'LK-:RLAMV7I#Y;5MQ4FU&VZV9;]N&W;Q8;MD6T;-QXNV]A6<[--O;&R
M:&-E9L*1@QN/M-4?&;^ YN%'\O5'-/5H 7:T #]RFGWTY,:C%U8=/3]5?[3C
MYM'+1XY>\3EZ[C':_?CH^<AC[?5'CU<>ZS]R[!SEV!^11V^QC]_Q.3YXY%C[
MQN/JPT?^^G%<QS[QW.=_V.#9.L++FX31FP1__,3[,8(?=O+#D1/O$TY^=#KY
M^>*);T=.3-2?^%%_<H*MT8^=>#EV\@U;,^&C&4_0($].D!HTGVYJ/F[4&-TZ
M2;^E^3*F866<NCY*><TXZ<L[R=]RTL9"8[.XW4_1;FW0SC[:SKO5[KQ%8VO1
M[K3XM'M#NU?&:4'!:8^,]MD_VWTM.KQ^MGO^/.WGW.XKZ0@TZ)AUJ2/Z9T?4
MVXZ8GQW^1SMB"SH6'#T==.E,PJV.A9?.Q-\Z_91P-O7)Z:DDY]-"WS.KYIS-
M>-L>U-"Q/*,CS>)<H.^YI;?.A+X]$U=P9F/!V:>?"7G8^3P5FJLX6KSX_$GV
M^9.5YS4;SV_U/5^2<;ZZX;SJUOG-OA<TJ]!33N=K+YW?O>5H_<_S^>KS.W]>
M.,6^V&AP8;_OA2,-%QI\S[>^O7#4X&+#I8NE;RE#]9<N7KK4^>32E9^7<(O.
M;M_.WL6=?06=W8O1_DN=MQLNW7S2J;6X?,_W\J#OB3\++@\U7'Y\Z?+3)Y?_
M^GE99W'EN>^5D<577A5<&6VX,G;IRKLG5S[\O**WN/K)]^J7Q5>_%5R=:+CZ
MX]+5R2=7IWY>!3@XY(?#2W"D$"?MQ2F=./4I3IO<AV.<+H9?E_&2+I/"+K.]
M7>S.+L[3+NYD%X_3;>W7+5C2;5?8[;"WVZFSV^5IM]MDMY#3,]VOQW-)S\S"
M'J^]/3Z=/7Y/>V9/_G(QO8%^O<%+>D,+>\/W]D9V]D8][9T[V2OA7)OO=RUV
MR;5%A=?B]EY+Z+RVY.FUQ,EK4DY?LE]?ZI*^M,+_LV,9<XYE[3F6<^=8WI]C
M!3+'BVR.E\0<+^LYVLC 8 T 4$L#!!0    (  V%KU:!0V\C+1L" /,E @ -
M    8V]M<%\P,#$R+F=I9M1W^3N4C1?W?=^S+Z:Q#UF&T-B'5))T6T/46+,W
MI$C25))*=<\PMM"0D(JQ)E1C22KJ)J22I50(C365>J;UT>9YO^_U_A7O^>&<
M\\.YSG6NSW4^Y_J<+6XNUAO"_X.FH7\!  L %"Q$(Q$5Y*@J"@IJRLI:ZNHK
M51E*]!4ZFEJKM)D&NJL,]0V,5[-,C8PM3,TLS=EK+==L6+O.9KWU)IN-Z]=N
M,#=EVV^RL]ODX+ 9=G9P='-V<=_BZNF^U=G9W6O;-@\/'^_M'#]OGT!__Z =
M :%!P3Z^P=LY.\+#PH)"(@.#=T7LY(:%Q^R.V+5W3U1,5/3^F'WAD?MY<0>B
M8HX<.L"+.WCRR*'#B0E'CQ]-/'G\!"_^-'+J-!!<"_A= 3S*@5W729$WP.@&
M8FR36D(KG==L<*K-Z.1=JY-WCY[(.';RS.&C*0?B$?YIQ#SY_FJD?4WR_5,I
MYT[P<VPR.\V%J'U.U\Z2/I^B1Q[G'NZI&HR],I10-QQ7\VQGZ5-A<G)Z:EI&
M6GKVF:S<G+-(:GYJUB5A5G'N65%^WKFB@L(+A467BB]FYI:*2TJSSE6<+:PY
M=[%>5'BEH$125BJ^4-944GV[2'R]LJ*BIOK*U2LU]75UDALWRFK;&VY(;C8U
MM]ZZ=?M6:]O=N^C]^QEW7J?<'+UP=S+OWD35C0<W;O?7-O<VW1MN:.M'[Z,%
MZ.0%=/).S\2M!Z,-G<.7NZ0UCV<E _/W'D^W/%]H'7YW8W"^ZT%7[\.'O0][
M^YX\&1P8Z'XT]/#)\\&!P>'GST=>O1IY-3+^^K7TS1OTZ=R#@86'PQ][7_S3
M-_I/U^O%QZ]D3\>^#4PL/1O[//3FI_2-]*GTG\$9V?.I/^,?_AM;6!J8ELW.
MS"Z\?;NXN+CP=D'VSS\SG_Z5_2/[\&5I[NN?;U^__????S^6?@'_WYK.3^S_
MB_]1W/:'1^WV#(_:NVN?7%3X_OWAF]AF5FNMUJX%3/YOQ?\E#$!<!DY4"7#&
MRJ9<]+B?3;I$A[WS?,1:7Y9\@(1/D__4J)11YI"*1ON16_8Q.WP5COK9W*:$
M=W")R:;85"\IZEO#Q=6=)U=W%J!A>S3<FVN&*ES/&84^;K[Z_ JGPOVR^\W:
M%W4!33$3CV_6O;K!?:"5_6T5\6QC,.(UW:&_JL_4]A+J^SO9U?2,0V:?<XTS
M<846_*QS>DAOGLY$F_,W/7G@&H%N/D5T"Z[:HI>2=9P(J402)>YG3E_ZZ"?<
MHL]-.1[@YAK9&]8@V?6DQ/-NR\?7K8<_3#Z]>]1QJVVUB8)OY98JWTUC=S0M
M9]/T4O)U=[JQNIJ<N6>.6^7FOW=;88H6+_\1!60\C#'=5&M"5B(^FS$YSY";
MRJW-.VM$O"H3*]=_?:OMP^X,8Z*1^!)E6R60:C3_<UZ:3'=A3:4H^4=/"1O!
M6^HQF^AYY&!'MT['G2O=OSC*VX88I"C2U#YC3(A#WIIL_C>8>;RP[*&K2U!E
M^J!* ?@\B-U>[WHY:L[P%=UTL\=Z)T7[P;S1'(;_WKGS 7NNSA6$1! UE!LJ
M'82[>PU'1<J;!Y]AZ>TUW0]47*@-6_?)?51("9/;9#%I9LL!LQ0=FBL#]CD2
M#P:=#7'2[3UGJI/^.$CZT7)5] ME=R;;F<IWIP=AY4DJMK[#<S65!3'OK]94
MQX3KV6,_.ZY8/EE[_I+S83<CYXA-K:LS]N1&%^QU;/B#1CCZ_D'<$YTJOSQ(
MW>0>+E3>,5Y51-_S%Z[2+_Y.K*AT-5@R42X$'SC3!7]$C^DAKN&7:Q=;/GRZ
M*^NAF/.\?17<ML=%#-$]LOZP4Y2V_9&NUM]4^0(K[R3=ZR6_-R9%(M[,^^S8
M:OUEY(&NE?*8=ZZW;7AHKHG!!J7 [72P3WD;O>Q&F\FMQ2]/V ]-"C)6KE.Z
MK)0+=_8V^ +@?F5';-G@1:N;-B8.@F],G$E#@!?;H0'[F;TSUKFS5[>0U(DY
M'UTMX"A?$QR=/6V]!B+I[7_FD$(_5?#AW1'+AZ;_CL>_TCR@9^=Q:\>R7E3'
M^V25]F\R)\>@)9AH9%>)\U#99-UB7G/ZPJT=BG;U>,7CI[\/)C\2KA!P5.QL
M"=0W\[K#%'J)_!^C%<4GY*C*IT_W8.3AT?V_/[:^O7[B0#M'M_9=OL8.-_V[
MWW0?V;,_ZI),VD]T37 :)&]M)/F(TU;9U4KOQPW-KE#^%]C0JMTCS#'^DN'W
MI\H4_?UY]W__ECTT_^_/MU<'_ON[]';%?R$WW%[\Y]6Q5.KXZU]UL-/S--%#
M#*GVHG@;&9^>)<:N=NT@!\D$(99BX.=ZM"A1@L2]XWI9LSI/"B4IS99E7JXU
MG2K')2GJ>F3*SH5.S#-9JG62#K@]P)%.VYV\;#VN0]Y/[-+&YZ9MT2B7\V-U
M:>DVI*^.C5 ()3K+NQ_,\*[75<Q-[U[]6'8F5"-"I8/A;!8VE!8R7*;V*N"!
M1N?'K-C87?)3+!?]"%E.8E^%UG;G#+M?G\\BE2EZD%NO@_J7L\FVD;HK'O6Z
MV'S)%?E&ZJUV>^0>]"6OJ*_28/VC1]N.?SDGIE:QMK@]]B[^DE^>=<EHQZ/'
M_G>^G,]-5C:)<GL2U.E=4-]49>:7\23T?6-A8Y<^>Y=;7]]GR\)NIVKVV6-]
MN]6_7GCJ46UY88-'E.[7XML:!E8W2![[#_D4]PQ7K^TF/3WHLN9"1_X>\Z:,
M;;S&PQ??F>Q9^YJT/;;G7,G <MN5#3M(QONVG2OYU?5VXQ,W#N^'8ND'C06[
M^Q>VIY0TE?4U7UFOZMXG_-1$@!DI+NL?#^4<_U;!E+OJNL7]65[QMTJ6YU7W
M]489!7>^516D7]4/<_=QZVJN7G_DJD=4D,_%Q\U7V-V&V\-M?(M[\A5R 2.O
MW%K?4O+YF@U^,5[)ZGZ7?\376GO&^!RI]1/[WZSRF[BZX_28;_VI%U=WW,3Z
MW#H^?#WL^S7?[EJO]DS_<KNUU_9-U'I.'-]Q]WU^O<.F#R'9,?ZWE_UN^)\W
M"KEF-"*^][W^T-KZ7=^+?=R;IQN+GM;O\2L;[3_^HTDL=RUZRX=1OWI!<[$S
M+F;MB;$7F3^4;K0O+VI%;7T]%M&MU-J]7]_#*W/\UX];U2/[XX0?7D\JJ+8^
M_+[_4%I=L/3+NM;[H6;Q)SZ$+)3?N-/W-.[@X:T3"S8[[DQVFQEQ!3WM2[(V
ME]BR8R].P KE_Z9_$)HK'[!V5"__;!.45*$\M^\-O6='=O"WB-._5[Y1:^2E
M_><L4<RP[OZ=MSX3-VE^^O6'-S\M$S-4J]E\S)])MIUUFL:?4O[*K,X55PYV
M+7G>R'!.<ER\L]3-SFG(BJ*.^PPR;JV[UY!S-"34;^3'0YAFZ9WH,:N[\F>O
MZS;+K.WAZ+IJBW;UE@K-BR8/Y1U&'[O^O!$;X.&R>JM:JA^>6]A@LMML:_IC
MID'3<N&KODFK,S\?Q_3(_N1[O+5Y_;,_WJY ]&_?6^V9GP,([5O.X4O!#JIW
M>IS+</81'0L!PYU#V&/-%2O_1E=;W%'Q.-%<O0L\$^0:].Q<BU7EZO9WKCM_
M#5^JCK]B?S+&:\WQ%]EQ1^HW3.SU30MZ<2ZA^0H)6B4A.@U?[#]2$:[YP7U@
M;+ASW8^J-9XQVTZ,O7RL];W:./1#""'X>5=U?.VNR_L##]]]WD<Y<W5-=BQG
MR\KG V8_6M(NQ^V_6_RR-&']]2L?%Q-/!(\]-;O55C@1%UA1>2K!7WCXKG'T
MHOJO?LB\M<-S*+-\88M5;4KBK-ZRZA#GSW1=I?4NMMWGK!,A,U%3UKW+JQ0_
M9][RGE$Q/_9PP&&C1"2<4=:^W;M]^>#YB^/S!FD;=O'N'?;/2YJSW'&[AX]B
M''I_&K5']S\]5O(E:V#\G<.58X^.Y'PIOI'T+N!-ZX!YW.?.P7^Z"6\;C"*G
M,M\7Z$X=,; ^\.+4K%^O@[1VP71,.6P7Z,XG8M1%3&SNO_>:TOXY]>J$]#=M
MJ4/UE(QOG32I;)[8N5+K\YDTVS>J.D+F\'7CR*E.WO*IQ)[5=K(20ONLSG__
M#IVS^U;S[XGW!*QJQ6E]AB.O\[CKF\07FR<_MUSY^U9>^U?OUY(?=0,;==)Y
M5C_G$I33N#!&EPT262CV.K/[\,'7P;<+RW]-7+MGZ+L\1&3UAG^J+4K!JP,$
M?\[]6\_^,S5L')CX,>.OS.P%<E9[@2LXIW\]:%].F-B<,:ZN2Q9*R>DP8$@_
M^:8[@;A#Z;VN?0 =>T]ZR!8FR5LQ&%^/.[ UY8>QY"]'6F^24P'(@ OB)""3
MC;DN)3<R*75<<MPM\G6)@)4HN X<-611KDC(V73 D$T9UZ<<@ $<%YJ/(E]'
MR:P:034G.7(U+VXUCY4>7,]);O4#59A'<T2 /)QBN230+!*$] J\H\DN#.&!
MU91X -@EI60#$$<DL&H5K+5.01+(Y%;^-]P>M=2(7R_VS.T.]RK@+KY(.T94
ME!LQV EJ+!>((A*7T@STTG/2T\Z.[#G&RD 8BNS/.K[3RAT\OF%DA/I+I_.]
MZ=K8C,K>M"IKKIBX?ALWK:<PN!8E-XD@2$QHDI*S.1BF"!(R*<?9&"$'<XA)
MB:%#:U'\FD$BQ, PQ=C7BA@2&_2"HQL!2)X+X:5$XQILI!2_FH,Y)R&[ [CQ
MA>QZ;M8;(FXK,Y7'A9AT7*L05)&=.B<&E'GD6 E6*((,N<1:].0:.K253;H1
M0#0"H$A><@P'<UA\-EV2BI>"<1SR&B;A$!V3SJ0(4>CN"'XU#SK$3+-124C;
ML^OX.B4*PUXN\5@(J%'^%2XBJEQ,7^;3FS.!'2'U8JB)<7(%#+@#($E,YM !
M%3; D^)!SFD<&TB%R7)28 T/T."25W.!;>\RLSF (8H'8'PCARP' _*# $#'
MU*, ]QT HE 3%X)XN8H<H$Z,!P#(@@ZX2\G* /BE!I"7DHV8^70FH(2>E.,"
M!@@@)R8?A@$M$81A8_89YBLS 8:(R. "=#8^'0 ,F01 C+TGA@ ID<,$<!N
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MSN;>H5"+$0J-3PB5N?R[UAFED\N6 6JY%+)P4M866/21E2\&K&D!\=HP9(Y
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M%>64 D0K Q&;)=POA8TX('5C8D-WHL7*=( =#6+H0B_8P242\'+5)WH \<<
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M95+#=/,=,B=RZR$2VYE:O(ZB[_3.$10D Q%(.E #JZ2F]QKITOG>10XJL41
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MB@N1P7ON=U'J%"2JF3SO\V[=<05(?82L%Q&L,SLZV/OP[)QJ683X"H]UY,-
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M"7QU3B[Z:K(4[#A+2B*1S.O.MGUM>SGNIL@>R_?"@:BVA7HYB-5Y_UC$NV@
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MB]0M# %\U&4YQR=J,W7[K4G2@/-DB9@KC#?#!1ZV\>AY*=HZ@1$%:[,J>D.
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M@E)3@!#K+W)!GY>'QZ(X=&\*L@;N2E^P</68+$B*?"H1\YZ*<P1N^1D<CDN
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M=,^J"@7N?WN>&+E>%LW32APY=3$F3P ]XNB:SIS62_[\05[-O%PZ1P!TS1K
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MXWZ(7&'I"+4[@1$'P6D[5O+[X7)2HJTE5'C;D(FRSY_F"22_=B^*JDI^)T^
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M]9;S_KG@.>,TR6<,S1&BQ70%GD1 )&AXLX):9Z8S:D8C>W)P:*N&#G[SA2%
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MS2C)%XX#\+%!4AR)4+B]B*03N7<8M0IX^,G?UU)>A*6N\)Y[NHW4)5T@H:Q
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M""7@CW_ =H.' IRE9'-<#HJS(#4YJ!"F/^":T8[/0/65*#^CG9"#X;FY5&<
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MHOOY\E049;T@_-TA^7W*8IE3'0IT2YV\^/ AS+XX=4:1%#CTTJ87 'I1ECT
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M$*'4 J"ES*D2 [@8D(),KY01< "^N6]F,PAUO025:F=[$.( (!<8OX4".DO
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M?-08<73-!N_+'Y^U15[P^/PJ>OK9I:0G5_887?WRM#7C7X\?<5>^O+JQH^5
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MT!G65NN=AUXR6.![T-F#!4Z1T88"WSH6N. .KFI<W?59;Z+A&>(26'8??44
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M1Y2<7+I!=\V%6JRZ'K->O*[A&_W@F-7Y5W0,V]E,@.Z2 Z*-P+&_#<P5]"F
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M->O2+_2%Z!$QU8T50='E)V5P&Z@1!;Z726%$IH*G[P*CI^BOIE>SY ;YY98
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M-')NGP-MIC",,:;;-="[J9NR1$LM@A3M?6<N9H>$CZ7J&=(4YO$9)2L[102
M#E_L*SNWMF@40)+$]J1D"$?G$,!6MB6*]'=C80%1,S% EKHHVK,7U)<-T
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MCO7?R,F+,RTPVBGRV3%GB_%9,-E@14WSAF0&:FP;>UR388[XTVV!@)G;PQP
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M2B*W26\!BDEGQQZP9ON!1-8[(@^<C5*NT@#$:2LF7YE@*"$#H+>.D,QZ3R2
M:[Y86<T#["^BE%!8C ;X^ZE^6:\^"61&*\DT,#!4:%\2X$0"R3RK9 /V^L1*
ML@#TGU,LFVMR<1FW&SO._?*&Y&B9I#'90$IE,U7=1 ';;@:RDE?K+RC\4!RB
MG&/W'<C6MR*F"]GQ(/$[Q_H[P.[F$#$<YM/W>H"_/HE-8DTX44 ]$MOW,6Q=
M*,@4"$F .*MA(Y/&)@,]%!+_5X@R!B:FA%LS:<(]*ZWL9@#SZ@T.O1SB=YLM
M/Q6.O=;97V [/!#6,PJ+_"H2G\V,;M;CLZVBV;6*;GT,S!O738Q5^AE*G# B
M_5Z./Q-FCX&9?U]MC1'J<IN"MRD/]'.L>KOCNCGZ 2)KKI7?>C!HI8@4SK9#
MB$F230+<!^T&@ZAU%@;-(Y8Z*66#[^'F&]9WP]:OZ28&@U0N:-GU04/L3-4+
MM[9FV5H*FO07FMF>UA4_6705A[[ LDX]M><G1Y<K)'$W686W%,-Z'#%*O066
M5>K?R&V(TWS_Z48*@JT7*]23C\]83T+.D_O6V)%3)_4(;'*G;5W_^+Z?@&5U
MBW7 1Z+\_;XYP*H(83\#L'5 2U\A/1YTF!;!1Z?T:$K2-(RZ )%S/S@2E.(Y
MEO5W3JP'FYA^BHW@D$AL*_H&O7B0-&]##F8[ &QRL/ *#*XW\Y[(A5DBE*2N
MD[K3ME4?X[B54[=^CQG_K%Q\Q>QV]WH,N;()Q2;- &25J&B%D.(II-];1*ZV
MZ0T2;6S88)>NS#9$Y 1I.,=PRMAU[":84%^UA9QJ'Y ("E<J22-M]&@A.56X
M;[VPWUO6$JJ\_VKR?90PV<*^=XUR\SJAJ%]$6F#YSDTMZ^^6>%OS+=[WST&U
M!PI6K4^U]@67;@;U.S_R?85K_#;1XS_1RR39#8VG?W83IYMNPGHL^.!Y;?;V
MGQRK)MA?Q5>9-NDC0&^<D&YU5K^IFV0,,@GLTBN+A\:VW#+XD.$X/FJQ5HE2
MZE5SK*=3"DL"^A]SF%SPFK=U]JX^^G?H+$Q,_P[8!]NRYQ95KFF[&"IL7)^Z
MU4/9U\!8_MQFB-.=9RC1GVX1UB2)5L*L1\9)""5%;IU@*-2E2=9J=%)?_639
M5=NR_3:=._!%%-)R=E>@4SQHF;^!["9B/[5=5L/G<QSV>;12W-@O;[V[C^./
MP[:5KN&HUVVRK_YP8-TF=75KUL<F?>-4LF1:9,H??7ML3//&;>Z?HT&A_/=M
M,=4G*9*/>I#USFW\]P<"G"C*@;FIO:'=FV!PN_R-S(6/%O,*_6@1L4FT=C/;
M;PZ@\@6YHG,B?>'+C6RB)%T78+>N5,8=^KCY@ 23,D[LM&52P(T>$MWJL]EC
M)Q/UE1:4][-[VVO;)HBL,S'12KI"U*TMS)E;9(V!$9NZ'>>!X2N61-\F*KI'
M']ZC.R\(IBA)JNY'HB_=!=N6)&[0Z%8[, %07\71&Y@R6#5!FG#ZWZO7]'5C
M.-2K-PFO(Q^L&PI<A["P/8%A'O\NHAA/\)M$\QY_E6,O\U/ZK12153![FG+K
MW4:]IQOULU)MEV_6G=FLR]IF>X=#[A71N4H^U.84#!:CQ'H,P9)7B\CIPAB>
M\CGL:\HV4_WI]AB^<K&1A.ES0;W3DOK4AEIF]TQ'J*L2!!N""04(/;7ULIJ9
MW=K";1X(_72;\X\YNKDM;'M1;,$'1S?AV4QV08'D!Z[;*9C]MTXI1>?(T^.>
M.IQ_&FRLW837OK3^P&TFQKJ:+7E]VF"._C;) CTM^+BE5,O%_!+/66>D\4TJ
MTE3S.M (88]@5^C03YVEV>5OUJ-L;HI5WC3,NGFSX?8OYZ=+Y5S'.5Z:6SJ2
M%ERE#G\88C\Q?60P9&0]&/$ :U^V.=0LRQR6>?MM\O_ #=O)V:M\W*O^C/D3
M+0U#W0/_6WSB.&S%LLOOL>HU!T?PII?_I]]2!6MLZ.V(:<Q>=\G08M.KU7"J
M(BAE[.[EZK9Z!B[4W4^FYZFDA+-UYW\D+?DKTT_>?S\2B3N3=*\D6?Y,MMV9
MXNK!<_)(7KY3-]PC==G.]9$[-_PO>Z./QZ8E5S:E_-S@P^:O^KG!\DKR]I\;
MJG[ROF9OV+)S?>.5]:<]TGUV;H5?T:5=6K?,<"61&E]Z^>@%]VH-+GT=>8W*
M6ZA+86?:+LDTRR%:YI!]KV;Z+\DDGL]:G+/#9TD6L34[[-\=NW.R5RVQ]K^Z
M8Y7+CH/_SE0NR1/_FV>6D]WX[Z["G%VWK^;=N;K[ZI(]IW/VC/^;_^'?W$\Y
M^\RNYK<LV;TI1WCI*D3TS-V^9/?BW*S_KN;&_;OOV]6<G!QA8XZP*B?[8$YF
MF'#-IY]/CER..YAM_C\/TN]_"AMS2Y*>CWJG9*Q(*74RWYB7FWS?,S(H)@)-
M=VC+-:N:_Y\W_=OQ'P?PUV0^;F-S9L!_G8L0<I/Y%W9'5.\6507]TRWA=P?7
M9SLNB+I?=E>^[N:K86;S$MU3E>]^/?O-*F7GY[6"_AK&C+ =*3;+>F&JE=?8
M]T-@]"O.<I/@V GCYT=.O+B6</59X/]$*"Z+)E$B^$#%P0 3^TBI\Z[D!!@\
ME;:V*1L](V30KZ.*6# ZV<R7A0T''@%B QF$H11MCT9BWR@0<@!>>[U%[)U!
M#T/((;B:3.@ T#Q)#>-W[4.#[8U'ZO[U/!23(+LSB!_ Y$(21X0VU"6A9D&U
M5U=>VJU$#7@Y?0<-_[PZEA/#!#@,/FPN-_#"GO+@?)'9@JCVFU4OEA4EN_;:
MI!<FT+UWTPA9Q.'3(M-R:\YU(6RL6!>.A/H'0+P%X7>F%$R7_N/[6XL>M?^_
MWP=_S.OJ^(2U:-2$FF>G>1( !JL2'&>K%%1!']RJEE =>&\/!^$+!/.[$<.L
M#[X#" 7K-'7 *1^Z5@8E5@M#4EGX#A8"TF). Z<;%8B12)=MG#*"Z:IP8$<O
M^W^Y@;09#'*XVR$><"H"=A#DKZ;1S!D.K*O;=%(:HT+PN 4Q,H V+$I4@[AA
MT<Q2WX; A8Y?7D=7^.KKK&$8[X]^=X *(9@*8*V<W=XE4HXK)<&'V=7"%$11
MO1X4.<%^^$Y1/:R(S[\+ZSKFD-IO$]!O38/:9U/1G@4QZ8"I,[@S-]!4(M7J
M! BY;$-(R$@=XEV#$K/ "T"/J200'1T^5XU :[*$)U\KS!:$(3>7CN"7^%>E
M!3R\'*9KNS+,T*SF&<.>]>A\'JSBR7[%RH+]6((O@(N],VH48#8-$>3]-@O+
MBY\NS^*+6IH0B"8MQ$BW0?5>)E=1O^=6X!^A.$LX!?<WY:+I8,#Q*&MF6JL_
MF\*4[KPEP8XC*>T\G'!1#1=&;7>TLH*-NX*Q:%>3K1W 3OR]DWX>,_G,'N'Z
M\*.N:<\[\G0WK3CND_?S^R]=/K?>/Z?&9?/'IU$G0P\[)KSZ?FK5J57U*R[O
MTMNRII%[;$W@]=5V+UK7G3\!PX'[NXLW&0-#H+]YF9%"5339.16.H"H>#_\?
M"V<>#>7_OO'GF=TL#(89:V,;8Q^[K&--EAJE4K8A286$2J5ZQAXJ6U&IAC8A
MQE:RCC5;&DM2J*%(4DW:%$V_S_><W__WN>\_WM=]G]=USOM<R+12YQL^"BZG
M,[F,,?$LX2CI($P"A>2AKT%_3[('AU&I[51-S3\*\1$CMSC'V/C*GNES1PWC
M$=_4[N(=PH5-E(U'GEXP#(I-S%18Z+AYX1@]'G_K96KV -\E_D/?]$X)&[Y9
MA/IIE5/'/DT]/GYO54Y_1^W;_IT_%,6+OWGOKI=K?]E1N5KY@/:G?KLPK],3
M23']0#V2I (9.YLRK8LP%]'01N<ZMDS?%UEXI'&DNK?D8$>UTBO8+40_';<
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M2?>\DH3=2A;'JPUH1Y @3S+#]B<S 9<8(V$HP9EWQ?#?">8,I$2U_4'LU??
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MH4&%G=?"2O(+29R+-OP4 E.3SX-9"5QJ8)L2!= C$=@1D^V>!Q1TX*0%JK*
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M?8B+ ?TG.^6YFPFK72V4YMX^G:=Y7763*0--D!S_,6,U4_#1;%2#0X# _Y;
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M/M(9H6]+<>'1!S$Q#^:Z-FZ9KO7FN?A@D#X)J6P@-:AXT$K6C53$M*5SS"+
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M5X1=Y70>>7,,5_U@7G[+GP>?^VT-S7H3K#_]ZP3^RKZ.L$?3&_\\?NB?I\V
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MMJ7=.#5S:])I*&AFX$KWGY-.NS0G1JG.=ZL3'7@66QZVC7T\MG5=4GA^XMV
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M5MZ+X(TB\SZ=#[4OXSZ]%XK)%B]/D/,4-)UP'3X[S.1"F,7JYXZVL)OM_*\
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M>CT7;!:T?J=^[WWZV;C#\*V0Y*<;,?GG(LFX_8//M'35WEEE$^[W"-;O3$F
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MLEE28RTXPV0:@"N4?%O5 RN5;=E^ED0';+Z]<7F#2;8DO$>"[;C\P$RRK =
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M@LI[Q 45(%\7M(,Q8.U>LE [WJ?,2X$%YZ##DT ^ O3I8C7(>4%,?=$D<CT
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MS#9"YFPE0P&M;.!1F=]MZ7PBO<.6T67)%ALW\:?W0ULM?*<WXV="^5;<-L8
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MO=4SAW.KXG<LKC626&2(<4DV<%((S!ZC!*+8*56YWNG2?3^W+9,3VN5^(N:
MB'EPC@O6,NE\$4Q-V9XU"O-1[%4\)9/[,A$5^-K?]T#=Q"RBN0AC&;">S8SA
M\"7)S'")/T8HAPV2*(Y<C#-0T/VW><PUJ3N""91/?E(5J OTTMINE7S:W:06
MP&SL+;$8'H%OZ; ?E/5>79JD7Y&L<>$K+GV2,G(#WG(FI/=C0\ .[( ,P[E4
M<" %S.#2=):4ES=V'9PFBIAF3B>@J$(H0O>LN4K#(D\G\$5OU:GCU!25*AIC
M:4,?DS_&+62)05*& QV8A!V9^P:'04<F-$ [RSP+=RIRVV;@=/!\$ 9[X6S]
M.KT/ C&U(<A E:;7T&\MX#D^ANZMX.E7C=D.YMII*W6CQ.[YSZRGYFVU09NI
M^8%[[2Y=?6"77#>8"V@K-P]X#1SML%-+'(GK]#,E+?->#S?Q'0AUNAT'J?F&
M T_F^]?QM.V9FM;B04)=9B!X[U>,OCH4A8D\;;(*P]A82X'O'3^A*V U;88=
M4OT=E=6KJ%TK.\(HN2;;NR)7>&[0T.U8ORA^6?(&UML-5:(WH52(]EPJ'+#T
MUH[TF;>B>RMCRC"4+NG)92Q*&V;IV#CEN<]2O!5K4=U?5GUQ[3;<W?&YCR[Z
M.O,L&M>]7)BW[*KTF9MO@#?KN2'_S5"WP:'$1\E%K^SX):R.YV>M1BZOBR%.
M>%47O'@O9U)B5[":".N0LXC5Z%K,*@[K];5U%J=OCAJK:8YU@>[/#;0P4?CN
M<>-C^U;?\G45FW>?>F',IS1MBW1DG7&SI/@V!-U_^?S<2V[?.DH'L<<4BAY.
M#"G7,/>*5?^]QYOJ&&\$6XT^P!"3WD#.W\U#R_ZB26@>5WQE1SV@6U!!O7?&
MF=%Q']9F%F5W; QG&RL\]M.^1,I7W;]OOAN]&>.X M3G?[9NKU[8<G'Z*&2C
MZK?&6[B-!LULZ;#&_Y[^?8L:A6ZD<XGED"/YMOLQ_M<NB;X6Z#1&<"-)Y9YQ
M7\9G9S8E8*FJRU'##\(H-JOBM:L_ %Y,]I$$=^J>+T4_OF[;]31GW5S!\;F2
MUW/[S'Y4QOVH.3ZWI0[V*OUA,0$#O_Y-/,$/5,'57C_-)"</[_IU>]F/+6),
M2RI4I3]?\UJ[[TS'Z]V0WZ_YU[]_B>/4?Q]7?WBM?O.;.C2[T%;]M_IQAW4$
MR(PY:"10,)7A.(IMQ)M&O1/AD+Y!UI6^BI.1C98& ^R*\;,BE%_,"&BN[ZUD
MKVR,Z6T^U5_#6=]W).!+(CO&;77Q\Z\E&Q0KCF=JF02V3/8<7;K7]M]3 1$!
M1P)/!KJ=O=1X9^6JRZDFV:GZP^=%G:GVIXK7KY+1NU<M=;MR_J]K&>-]1X.N
M77AY(_O+^Z4I[\\]7XD\^9-8(E3$*Y)T[$Q'4B^.WRT_("D-ON[\IK?:Q3,V
MN+AJ)+(9WQ?MIJCZN]MH]?7 TK8K:=+THC%)-.5R7_W*+3>&'+[4;+KGO*>3
M:NI,W]*[8"_LJ5Z;$_S*INZPUZ?*MK /64?A!VJ[F18;69[.H?!M4(?E954W
MS=M*H\@B<F]Y*^LCV#GW&==9<__! ?GVR(S6OY]&*FP6,=.,6'@#VQ&K!7J"
M7$YY9Y:EKL9^<YI[*X-S.%TX*K@Z.E,06"D>B@^X^N]P_%8=2!I$'Q0/04;=
M*7-U@E:$99+G,%R[/^/VT4N:G*1R!:O86]+Z G.0<3W>A.U^77-OX'.\)>=$
M,FHL$$(N2BM_R==>3#LCQ5]S<?13L-;*?$D@[I$8\\B(99DS+DA.AHBF?A[/
M5$>])0E^ L<IU<8#7FH\D4CI*TK47I=^9C6_.:*O+[NY]<19NZBC)][9T^D9
MK[@7(FP)_J?Z,M7O[!<"JA[[,HQ0XG3:5Z3D-J84VRT_T-A1;%>3$)WJ=R8Q
MU=ZFJ<WH>;S6K23AY7\#9%IA5AP6U<GG0E4O[ WZ\$\ZI'1\#/I?!5<>E63B
MM=^%'00$5%P#5ZQ47#)+,S U-2W,,LOMU=31ML%*TTI[ 7%+$RO3M 7-S';,
M,L8V,&UL1]LLEW#-IJ9HF[&9AN_K]_<]Y_YWG^6>YSQC%U@D^'*U3Q![^3W'
M>]#;,:S63C/ B(@Z'E82BG<;$4JB&_TXPU8V8L*PQ\LM8>)K<T/X3<NITTW]
M;LKN8*&-YNGHZ*J"8/I^7L=ULWMSYOQDF-O[[]4H&':H!C>GJEF'8]@%-Y)B
MYV4*BO&DBLYR:TX>_W;^V?<4J?4E-:B%."S&$LB4UQB!-17XE! M!2D1?=Z]
MV1#Y@..HD'%&T5&$GVUCO]=A[H/W(.-";[0$BKIH;#K>_K>K#V<$D_/*FCGK
MH/*-'3T3;0O;H^! -9J\1BUUQX"P^9@&Y9+<?_G1']);@\?BB(X&,-+9#CZ@
M)OQ2=!!G-S^3SYMEFJDJ#LM B16V>:N6=Q&:-HYES\HI*EKZ07.."Q$+*IKO
M8O-W"[H4C;M-]SMG8& 9[#YDS7#WV:2X0Y!ML/-S=KBQ$F<WJX+.XM<J#$*+
M.XFOI7]QGYEVX??#7\+)#@-HC&VA2F*99UJ\N%1OEJQ+LI.6G P#QRTB9WK<
M$(/$0O& 0IO1. 7^KR^ B[<"EH059LM,=H,F'6?76%(R]_HHYK)XTQJK[:OP
MC&8AS)^1NQD#Z1)KS'JI?9XD)G0K3C?YR#Q#\/I+T%@)3:FDLG0/+7T!5U/Z
M77. 0ISUGE[!1]/*5U/*;(,YT-AA"<U] /B$E-XB5_12E>_T849]]\)(#KLV
MS);_@WZ=G]"$*:1C*]\C)>Z9&C+',H2\4%',]TM?3M-KG/XR2/PV*;$B+6Q9
M=FIA'WB"9OL40PHR8!7Z()Q#IG8RV !8862T/3-8]F>ZE"[ZP'!@"VT1Q_VC
M^9+R<.UM0K#BUJM&E%9K2&,'H=?'WFMRW#7">X:5]+5U'"!"W6)'\02P(B4(
MLF_/744'Z)D<T(2SCHM30EZ. FQ[JQ9(-2(0V)M"I8:A^*]T&1R'$,^V IBQ
M4(#^  &\ZWJ($"HA<0#H-06P3AN5P$^5$"ZSFXM3H*4=0AI5A.))0JN;A[?/
M*?P4'[DRB^SO(V!=54_<$&PM(V1"%K;LIU1G S& !>"24CD8HX&( \8A'Y(<
MFGT5; G@L!M0@,\WE40.C<'O&4*,.TB >5(+ZSAACR!5%KC9S,2*4*PN_$3<
M,@E$:?*T9-041QU(9;*0 T8J(A,5:5MKV19VSD"%GY^>RB#?Q:^RQ$$/J%A'
M-M;.2A7XGXF2W)0GQ*&-1)PAA77Z01UL0)F*NA2HOK<;DOYM1/5:H-5)!# #
MN21(@>3:U]'Y/(T@:2X0F3?S M-I*'<?\CRS@'#'T@>H8/CH&;5A KOZ95#T
M0 I@BPGGD<3Q27Y ),T@Y=71@7C#*)!#D..6Y\*DBE),_Y 6OV$[CF1H.G]5
MU0-LY9"LZ;%7=NN"\9B.1GXPPMPM!NK9AC+7X@EHAT8.HMG%L,M 6+8.Y05E
M2R86*>'CJB70)M,*0AZ7Y<L!-MMR2-'!G'Q.7S?T65E&8S_3:GHEU<Y\D*\?
MHQ85:"$C9]P?<(#\Z3T6&,$":I1FSYM$&<]/)QU,5/98T&W#[JG6(GDT"[H!
M]H@5PT9$*<!5?E%8)%$JS \>!GSI/=1FJ_)GTE0L<9JXEH:4K,C48'<U ;R1
M@_ZD8#U9C6H3-NLDHADM6 C<(05QRGU8&O*3ZWN%7_GX&(X0$(F#03_^W@4$
M):Z9@^(S4LI/1G6QSF7"P$I^29"BR11G0$.9(LG:!RAP<0,&C-/\08I#S2Q%
M J[SJ 0\:(^#=? <*PT0RX(:Y("&$LE]9^73!)Q]+OO? S'9/W7MGG!=N G3
M>NL"Q(LO\"8%\_:;#J$6ZE89O&^3OS50 W^_IG$*&FTKF'?A7H=F/L>*7[XB
M[ K&=P;K_AY9Q5"1V?J-VYJ=OQ"KC%ECR1T*M7W<T/,[H!7;E_<%-HCW)FL0
MC/6K8)C1(%F$2E6:7GA;8F3#"CJ;;1EWVXTM<D:& %VJ5+"B:7;6DM]:P0YU
M"*9_4O76%6)?)!2[B5X.'0!A%H5CR6<)XZ*&HAWY/&_B'RK\5'$:S+[OQ=<A
M(2P_%28I3>,6M!):E%H&GB#<Q=@<;9P4:,QW#,19S<A+*L\CF( ^$W?'"T3\
MIC%SFB9<@XY*O=H_ODF*2!J?Z7'\.);*LEM2P)^@5G@H[$P.X%.FL57Z+KP,
MK%?U; @_]T:]<Q$S=%Y2V$W1))%OH&)W2=XD KCVO450%(.H\7X^V?W1^)S2
M_C:H-O$KVKKM'<Y)E[+&XAD8]:,I<@\O@*+'?]OY9P-Q#H&HS5XO._!O -N:
M +MO'Y7OX<YS]$5X%'YP"(-"^7U'^E\NAV-9_S62T@3S'IIC]_&WM*NB(U#"
MEV97CL[;LI$4H0)  1 A)N !$)*#'!7)4P!L.$# **"S7%$- %($H+D"9*($
M3Q0H5I%^>M1+2CR(8C8+ "8 ,@6@-RIQ%4DP=/A<E]3IF<7:MOGO.MAP/]L=
MY/X?Q$A&''-W.-H:0+X.<M=C.^C@$A8.[0 IS2#\QC-KACR+LW"/"N2I,IIT
MV1H#F#8 >?"YCDKC4GL^+\6/(9[!NFPKR9V?I]2X)8G2>?.Y5*38#8 KQG=S
M/*%,@7A==P)FS;I=P7$<";11L[TE/<29 2YS65UQV<8I-W_8A=&I!X022Z<B
M> [J["3"<?NRZX1@O1Y+[ W.ZBE/1IW3&<46"O],?K*3X%<G!%?WQGJS+R^5
M 1XP!1O%^"]8AH5NY1<L)8N?G*?/O:6 +70 E<6H4X&.>FQK.IDF<F[4N,EG
M/,_Y!=$$"W)%+DR H-&!NQ6X3TO%=6^J8ED@SP#5^O%8'$52/W*&0+'BV^-8
M($NTEBO.OJCW['JQL\>E.E?/E0?Q,O3X!UB&M5$1I-& VA@\]H!G\QJ(KX<\
M!+]R3*$\G1-/"7J)R^:CS.)NH/]@(:>M4&L =OU-^C<#[E_ED7:)^\Z"\;4U
MR5%4O("XO1I'\5(MH/ZD-PG^)SZ9< Z%KJD@MWK!C:12#N"L)P>Q-Q TT"5$
M<OH0>$% HBJ6I\<0TOC$9CTX-VS^B6C"-@YY#@J4\,G%_$V-0M!,10KP)EY"
M"%OU)%<!L(@ "N(($(IY48QI%Y"VHH12@]0L#B!B-Y?03=?$T6-;V79MYB0>
M(Q!OQA-E\#B+[*,A:C=K:6Y.$C'3BA[@Y"OVPQ^Q!QAD93K30-I="CV'*,;K
M2A='@9.,EW7S-R["@1T%@=X=-BS.4;LGV/T#4/^JG&\KUQ[7 2(AN%LO_@:7
M,W7;O"T8PE/DG18,#P%LWT;\Y?>2_[-D7$3=L^K<F?KP;-1_?#\N5+KC5EXN
M!\2Y"Z"H#AM;/39S*UZ^8U7H3QW\2T@?F^&F<:?R$V\9@/83B?]..S482"2!
M5X,(N&JH.K,^)$_$OX7@%Z60B>*]&MTZ6@<Q*[/*;KT7MY% 0ZU9_$2-#AO+
MJM[V!IJC",!<W2GZ _LE!.Q>3Q96K^&V51>BVV[I@7H#D;8-SH$87FC&^R>
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MM09(U.!9P%:2 K[<Z%>G;Y/9PVY$')6>Y]P%>.(N-^F!*P? ])9=ZZYQ\PQ
MO@)/5!)J-0"JP5MKW!SU@@;!&;_/@'BU@]W9=&L#5*^#K#7[9XG)F5B*O5[@
M@/#VT$%''62J2)S;P***<](!D(="PVOP6_Y6%R@ VV:078Z+<6'8 O#M3"##
M0"+KF(O/+B:K<(4JD*CG90%9.2K@RR3@("63%;%QEU9EZX#=W0"6R<U5($;;
MX.M<X0VF *X%8-! K%-<@C)XJ9> +#W>EI]2CP ;$3R9OD<1N[A(#B6]@%QB
M4G@JB$8OX'(A*X2L7;WX_Z ;!7K@M+?E+SO!Q?\ D2C1ENZTOI68+:IZ\V[O
M%G,*$65>OK;#2P JYH$W:F&B&%?+!].G\": @,;GF0H\CN!7)>J3LM!=28?!
M6ET<\S/8779V2S3]K(C@JH#D*&8KG[@0]=FGPAQ>2PK3>_V*8FKX]'-B@BO'
MIU+DNP6!G/FS3@E(J7SXXFF\-^*=JIQW%NAQX=S9HL3$4+"I(M-YBL,M')R+
M_O8%'2&"/VO[7/PY98^GTGAAHZ?J,>0F]73SDN <$5A2N\W]+I=O"+9/"<A0
MP()OY&04*D#PM4N<KG.28O-A+Y18*\+M^W>OAZ9WUUC5SE2RGR:<*\'1UI./
MO+_[SP[<^K50E@:?>!=?]0\_=BU^CPCRX>2678-K-8+="+QK?E B'\I&\5$,
MRD8!Y,,/YHZJ.<*'&CK)2P11,)3= O@(D[%'<;_K"82(R4D&8N_E19<"&'?6
M,!KUV' )N?T5MNP;D:\B<CM<.F1XQ"L_*@@:F+9_%[G/L?C7>CJ%3B=]?[!V
M_XF$ZJ8%OH?YWZ"[Y0IB,O*P;DG,' !&%;@.<&FB'O^(EWO%>.X1)QM?\"_^
M^S9BU1_A6?Q@CT0/7Q&T6Y'T?AQZDFG=]!7:H^\;"J@LY"ST/+]8"R];YZAH
MS]8E>S$&*HA-&L%QC6!N0:13-/[(T^0G?D$'WD-]M3AF/QY5)BS2DB\](-\R
MD-R>-]L+X?D*7*L#(R8J($NYJ%!7DT?OZTG!M;;C'3YC*\MOKTRAGT-<SZ22
MY)6DPU[TFDNN6,^!FB"K8ZFSC_;/B8]Q;1'-5E\:.%QI5G>>=$+B6E7I6COV
M,G?\Y?$_?V^S5+5P>G/ZL)]V-*"V@_?6PZ]X9G(;4J8>2-W!Z.2#F1S2L,-@
M_2<R2X1K$L.SUEG6 ^"7[Z#1!<]P1S-4;D,-7%/YJ"WADYD^>_Z_V?0=V^;'
M:8=)0O.9MEFCV2-8[L@J@BJN]95SSZO;?8Q7C39[D#3:5B>.U-(UU=9\Z^O<
M?N=%^WFY7GHX</A' 0\3R,@70'ML]52J/D)*[OX%9A0X\)Y#D>('OE*OI]7V
M-B-N1MLQ'CCZ"N19][]VYI+\=)"_X2'5^'JXRSY\JTTM_6"&TCI?'Q[6Q'OH
M.?S4EMGZ</Z'*-4ZSPGAR.\)G\8C;DY$CDPL-TZT%4RL3))OZ)M;!O9>]&PX
MI21Y-]H$4B=W?IJ,GS;?]WG,)6G*:\L4,C(99C^U;70J5S(6 ;W);=L2NL6X
M<D?@9!!5=4;P9J/Q#6HW+0V<CK[PIGCYY*7\Z;@+IH8_&?EZ;"+][;,81@??
M_[!RW(1!49V:XNV/\RGV^GQCG/;UQ-;+H\Z!8PT?.&K5&6C$O5.@"8_&O][=
M," A;PU<Z"5:6__3[P%O$^\&>BE*1"E/9\7\T56-G_">*EWIT* )[Y*0,_5O
MFO;9=RQGJ/5/G#Z1.X4VMU2XND9BGSLC1]R[(/K/Z*/Z\)7XJNU_W ]D;2IQ
MR #>/BQIN$Y]NY#ZAT*[!=LU E^;WGESOO'8_.!C$YZFH(T"_K43MBN\6AE3
M/?<3V9[ST,T47] /6OS^]I,)7-="=!)-17\B4XS[/AY)[_!J VGK8>N_$^UO
M?7;I V\5,D:NP$UJ&*> ?3DP$>&9,G#Y*'2^H4;< +CV/9]+8V:I"IQ-2?:Z
M7=D2,DL_]N+ZUUE=&)?UMA_MRS, H)=(,0'6S]/^'+'R.65NIJ#HWM0"L)FA
M8!WC UEO(*(R/D,$^ E@7Q70[^;Z".H%_^]CV0>K_ ]SUQ&8#^,82A2_I(A8
MA,7M9U,*#/@6C-F!7VHT'$\M/W^W@J\UX,L-2QP^+>-NB_\1OSVY!.]N1[E6
M0&9L(^<I^->!YUN#("^]=;I]=H<*/V$DM5PDJ[._W]+A+5_%'''('O@LL*\F
M[A)8&QMN$:$(F[O!UAT*_,M4,E/_Q-$ +9*L^UR"3_V;W(DD+0()45,SBL4/
M\U89K^H';S42[\YB2%9[VE<_L-[:.0+='&$$7/N-NYOO?O5X(\W'$J@N>^R&
M8,DCI)8P)C]^M]ARJ&CI06UR_J9GWT7\@>.+M13S">Q["_>$?.?"RY/5C6'[
MG<EC_Z2_BQ%&44V*[S'+IV2+-6+L 6)D;:B@8%6GP)-5QRN;!:8PS+C-2[U9
MSM.8T$87571>AM>J\)6.QP-OH5B'UK<O3N%#)7),2U;5^2H?-_.G!OS!0>GQ
MZS>#_UT=<ZP$FUWX'_O]RI>UM[9PW0<F>TK]"VQ9YCE&E*;RMJ9L\!(H7"<Z
M3T8=#SWZZK+K\_.)[;'?UOVUZ55+Z@O?G(B.+4,W"@:-MD/S?WW>G?7:?.2?
M57^L("^+:77X7/N[NT5:I!_\?B4&02( . ?$$DTTS],H?W'\E>1;]A70-WT(
M&8<$%T[KQN"2QRP[-= BIR+3""2M4VN*B9]G,J7+@NOU3(&S2BBSV3T&%#-X
M!!P-9^\WSOS07R<H9K"GW^[#K\L$I?<"7J5)S46E@F*I)DPLG7XTS<$PT#*$
MRUJ8ER(]5OCR5SG=7?36@1VLTDJ.S2C%,FOTK10D_3-]0D*X"3"8R,TP^D(D
M[*!01MO*TTKX1C0_1&860= ZF$3P5F+F6JB!JJIU T Q8:>]!*3Z+B#7V7Z=
M6TK#HL3U8 -C\VA$U8P8J(MR5TMDICXD'1E)(VB+<3]F,F6,=:4</.B@O%]L
M4J?4K! Y<T#L:LM7@)P1B)+K1'8 KHH4F8!45?'BPFH)XE$'B"V*TZRP[KT-
MLBUPS7KM0O=>KM0=;<R%H\V?H<0$NYF06I-@GE:SV"[3C.W#4TFD/H_L?\4R
MCLWK)5MVZFEU1-&--3A2+A *+Y:\U- 2(IY6<4E)*,*T8@UP6($!]QMEUC:&
MF),V@>R7CTW"?AIFDX![0ID[+PZNLPX>T(0:+?W4'X0!FJ/Z")GX._*_#*D/
M_LCF33J:=]#T1K SH-Z4[>T5QF+"TE$X8?=JV']3V[N("YO:'_M^4+>_R!A\
M?[ER28]/E?L"/8IO*!J04-Q+]6:15H1PUNGYHX_\2[4VW[")-H2I \0DX [.
MVIKMQ((SNEALCX4\'N4#8]%%#@-X,)MFNHC1=TZ:IJJFF?0O>:I?8425'!_S
MK1(BXG7:MA(?T EB$380W(QK^D)@8<I_3P>CEN.KKBTDS?PAB7Y@H+ #2_^4
M;D/J,I67IW(^WW[,(7<J3Y%%MM^Z$'O *2>E[+PL&[%!\FBIX7E,-OM. 6JY
MNPL(-B8J:4JO)?GH*#YU&((PX0<M[.@XCPD]U$ LMK WH.1S6H<YJH-_>=7(
M9OWW4Y9\Y]2Q^$Q!\.\<>MX!6Y*!;O)^&8X6#K\)U/"14HZ#$WWU1!"O/#)_
MFIO46RI\=&HO?DA*([-)[  8)@04+:V<_1@WXE,^?]0>8E9K8;N@;L#3#6_1
M!5)0[:&2@;$=66J!\($":,^;(+NQD[9SQ,3XN8C]+;'&^9'2)4J,IV7RPJY*
MA0!(FMRK4<M^81N4R]2&N0>>+G_(XU_XRGJ,VZY=DA\:JEB8]IB6_4.CWF2*
MJ\KKQC9[+['9I@,(SF<48BF0Z*M%2_*,W>3)\"4%US48D^"EF,YXIY$['9$9
MYLV;>[,&Q0D'.L9X+O7G)2V;+AU^N-'997.KJ$7XOSQ97#_' I"Y^4IX-H)'
M#K-:E_#4VY8BH@N<00F;HS/(FS<I\VAY\O',+EO3-!=WTMRPZ9VEO78CH,E8
MDY#*4-&K>%)_#_YM%Y8*MMK>"*8#.'S:93.+A-(=L?]2FQ,X) +FM@-O8(TP
M]6 KXPC7A#8M-=F*H*)SDNB/S!["7Y/5>%2*\<Q)\-NF1T]L^ 5<H!):V'#.
MN)EA<!80#A,LP1&V<YMJV^$3/F)!I$BSR$.MI2[4_/;%,C+2(I+%#U385F'*
MC&57; [ G0H9/V/,H2EL"3A2)*5GN+.8O2B%TR[-?KBR-6\;G?]9<8-Q_:XY
M4OIRAYW>I@*XB\WZ3_#7H:"Y_HYMU",QX9CNHKWX,>VNDT_-:6!-C*6NC4:=
MUE"GQWK*#E[FS#U:5[>.6&$CH)KLK#P#NH]*.:\@Q,XS818#V4O,[*(>\;Y/
M[D3W1N8+*\G=$A/GN]U=*G-6S^PJ"RN1Z+HDY4:&H10D[Y<\'+*G+!@ WJ0A
M,NEU08:O4@B)LXEX,0>_W;/WYTG0<0",]RG=*!0#DGE'N."__1@/9@_&J)2
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M%J:EW)E<$9>VWC=C1CZ5>6@JJV5J0\=4N0D!\/]_4$L#!!0    (  V%KU;
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M3?B LHS;GRM'@S_[/9F&\ZF<G,W3W4E)6*!QO'W"7[]RF:/_2O&[)_-G3N7
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MR0 %LS4PA0O!UP%/ $GG 8F-H#T36:$$3(.0\4F8@0&>93MX 'CJ+>!Y#48
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M3JI!)![<T@BD(?T/=4&7TCMKFX"+%SK/9ZP61'E2S/G[Z#+IZFZ@#$,0H$2
MMEVCMI)D1!%0*5=?;I$@L%HB49"64AY5_R1LF2V ;@-I%8#';T+AC9,_Q@8+
MJ/OV:IZ%%3TC:0@?FH#@%+AD=6F.MM9(_40.@%DRTJIHTPS/4M-.D4<GR9 B
M-Z"4[]CZ..8D2,9 <PPT493JE<OETKTQO> ,W<[2MR<=?Q V/KBZ@ZSWEPIP
MF@2,<ZN,RBE>6DQPC)3!:Y@:>YSM3O%D@O[G2!:26T@\U*2&)FZ<W+8(1IAU
M-W=2C"B(0-L W88S24C:9.WLU+\A 62+4:A*U8Y<6*?]34@H SU^/UJC(<*R
M<0DV)J>T(#5_*@KH@E%,U01H?#=T&V1)VX,+H8DM<*75;IZ"1)0)]Z)0Y^:S
M&XX_/'R<-.Y!V4DY^>U5)W22<'+:R^/'#I,OEB['7E$,H6G<KF@Z>)?\<MN_
M,,Q'H/B)IXOAX$Y1)G<<NJTYH@"\APB'UNS(P,[43A&6A=0MNU!&5M;O+GIN
MQ>VZ)#FC;]=J(.UK]*"@-TLG*^44Q<G IT0O&7CA ;!+]F;SYL;2!]14[+T<
M>R=1 WOYD],B+E.P]N\-$)$&IO2 )M)6.RW@H""1I'VZ[P=63P("]/WZ[@&1
ME*A/.=U\3/<*,H:6%5W<9@.YJ4M.T3]-PP AEV2C )QL178 Z/80#/[O40YO
M1RZOZ@A_8L$EP%C9:>"-L!_4KLS9\;VS=AKE'^_YHF]GD>QIK89,0=D6V:3M
MO<1&(D,+VBN4T3<:HM.+S?B2_.L==EH0IB'9LF?%%#"ZB4 "P&D:,8TOW_'S
M*HE6^DY50N(_:WX/N V!)C+P2G2W+A!Q!J#IS"F+_4VS?]2F53TR\(8ILANG
M;Y0&WE1=&_L.'2"*/HX9:0_;20G,"Z M)A,&ES9C .?2#HPB*HXR9? :+#\U
M?Z;O1EC/;&Q@&@4RX[_JJMKG $"VLKHCFDO?=*[P]G1P5UR%QN.3A?;52*20
MH?Q^\..$J13:!_0+:3\_R4F'%*3W_W84/B$:T8X<F]&QF'\6EP+WKP6WN<,K
M;]5:T:J<)B%'-06PAT7R9#GLK7("0TL-[$P*7]>AIJQDC%J0-JC<*4\XTIW%
M=1XGA]7(DU(IB=)0BZIT5(SQV<E61#//RFMMF&E8K8-=80Z=);HF=&5W!-]1
M@K"OR]Y62L8I B)<^D?<-0*1'L$]*3OMDST>YRVG).=P[2/<DBG*QE^9+/,]
M>F9N2>JAY(KF9KSQ;-ZJ4Z8X3CMB^>)4;R?#Q*E0;G+GK$SL(Z>2?7[$WW70
M)[LH=+P*F,T2.:,8%_N1WSL#Y^M-[TJIA3C5"[''P[*:;-1V9D2A9L,G_L3@
MSEDW$AI:]2Q<C+WI_VP]S(C-XSBI_"X$E^'W_C'09CEJA[B2+98<OWC<]60#
MJ+AFD;16&%9A$9.4W8J/3[:_<.H&^R2%RUPIQ0/&3A2.#S'/V)?9\1IG3 &S
M+I1%)1!V-B\HXCG6!JWLQ^-S'=^?*\O)EPM]_%B:G7C]#'5G&"4MV[P?SL )
MF)34;&$8.;3-&)^"M)D97^(.TGNMI1R_UM9H)T& ">?%/#-]:[QB/+@HE !9
ML#+P51V+F(*P*R]DA.0<WTZ\(;U+8>SK9JUK,PLPG().D^!KB&_;&_;\Z/(A
M#.O!Y_J&F5.2N-G@W.Q%LH @:V18Y+$@$MBIA:^UU0ZZT*0.L5!.:#UIU/;X
M3LC%X9@I+MSA)G0B8DMDO0$C)[0V "8=A)*[N3)R6% -[S <8M:_D)R2N:HF
MIJL#,/YDD>2,\[P2PG(9:7'OA\C#!Y&:N"!^1DR -3:\L,H:628E[7@Q 95'
M]7J(B6,J)PII9$,NSO]!6J_WR!5MO2=J/8D7A@PN:JL--U,=IZ$6VBXPX$J>
M0"1E^*Z$JCP+H\T-C]<K18'!X'.Z66Q/F6G99'HVGM+V%_^D::L/4>I)1D+K
MDT@Z]C@].5T+'!<XJ#,3/UN\ED>87.#G4KSM9"3AJ23[0J^7["'VZ[B;=#^U
M,LFJ\NIUG\1A-V?]$;QQ3^%F6=(\7YNAF3Y.7/).A)2/$W@Q3\L"X<V)[?YO
MD$5':T?IC#8S"[-%8:9/'CK:&G."9GNMO_'CNH-P, 3=8"S>G^A,OAH3I=GI
M?3EHL3D>=ENVRM)KSOM0/!1/P'DA0LW.&'+'^_L])AG 9=,8S2T\R[X[0&PF
M.?6P+>S;K/&')T@I[60]J0TQ-.!G)OJ/3X=/&>AG8<,!SPPU*MW(FQ>,.<5&
M46>9XC?NUQ<D1]%['/#!WC$N8S*@MLX!=)S9^UH7?!M89R\S=+G&_M<%FQNG
M7FL,:TU)=ERIL., +JY(:87_-+<V#W4Y[!/I:,AU'>AL-=!'ABTWN[B_HBK7
MX;RC09_;KK59$X!X%5A@<?H4.:0Z&)F,Q>%9+3'#KPUL_(C(J!@<?V<TEY 1
M"C2S*91W[YT\%?$[<Y,\29I24\L.]/29^EE)38/ 6E9K9 1@,I54$1]A+V/8
MR8*3I;T+EXXUW[408.]H+].\)J/=K-6VAZ5 Y/*92@8'G1-'Y1EGYP K S2-
MW5PG_#%WUK;P+!-SC .^2APD?:OW*.>S9K878L;Z^3"$/X''U30]M+ _)TG&
M9\CIK(</=7=\A[@#RUR*]D<&*8L3*+Q@*FKW[^-2)Z*"8RY 4;=1)3#"%RQ#
M?5FN#.8T$V1G79 ^^S]RJ;#+F6B\-@(%S=5U!NEY7F1FO7\84QJ >M=WQQ-(
M\!\'W)Q%8'NHH*)18*YS"8T@<-U^:1FZ1<X"@9 ]C!ZF&85/WB?GBO)3: TW
MS#0Q9.7B<;BU;.:GJ^(11\SEDMK2CY)@;A!TZ^\"^3EA%ZW:Y;9RFO&GN9PQ
M?OB?W@N^]-*,X\?#12YF($X*H4&$)F:7\A')CF::W*$$&"F#;CL&,=F!41JL
MG#_3<AF$%*($<P5V.$0Q_8R2!>(RT7-C4AU@K  @56(Q0I,)#5!-F^TLW)S5
M]=B,K G0*J?WV*$[H7 (CY+#S8OHX1K#&$ @<TU7-NX&C64 &)$O@K@89!J!
MX5M0U-[DF\ <;PJU:_;S3!0<;SI-0.(^H5EK'L#(U<-NE%X"/FP:,9VVS*01
M(=$4D!&'-BLU+0DW-.@P;.9$,.3VZE%S+>2=&.@!BJ$8&60: ^ 5[X\SNF2
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MB6.$5T:=QU=!A0"17Z>?::YZ46V( OH*C(@"XU/1BP8X_Z9&88\A?/=!R I
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M@K*Q.V2^P+! P%)!/;F@@09[92,VR,$,J>( K6T5'S3H<%5^P<@TP3L5A'0
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MR^RH5\X%XN6.2J:I2P([_<B(\FKT1O&FN<O'L/%JZI6[^,Y:CG;X=S35LU3
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M'[]5.)K#Q5=FJP[OG(\"*6\%MGL" )N_ I86E3%=RZ_3SC A"[W7\;L[<\T
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MYW2K@CV4Q/;X6:BNX<@"WRK@&I^.'G>@4CQ(IBN"HPU2RCSI*,$Q:A+P!U1
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M3C]<2 +-P33 "8\#E-JS):;^2AMY#?$J&#'ZLA\5!=?7P6/9&%;8..^I,>:
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MG]L=EW/?D"CR4ZS^FT_*7^-9\G.'/++.Q^G):;O)$3<"556@UX>^U&&0(EE
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M4 ! Q#S10QTA&4.W29$0#OC5L94KAJ8=\4(<Z+ )T&)O5^CUT?@,20C@FC1
MCAN/"_C_X6&$'!>'W8!%G'''. Q, ]6Y  Z'44D#2M@8@@@02R$4PTQ#&WVY
M+Q82@ZHX0 O ($4UR'2,70B0!<"0O: :#J#0/:^>)Y3@\O7^SXQ$F @ZH"0!
MX&QH5@=  J@GF:">(/<6#_SWQ#]!C#&1\KMW82+I(G0:D):&(9N#J'E *$)#
MN/UE:5UU$AQE',!3T&7S ""5@2Y6"29/D>_.Q*< @'F[IP(C99 '@^% 72J:
MBXL^&!,E-?=I'@=!-KN9 L'_ "<@# 8 =7_6#\4"\@SOI/D*'W<(.0^LP0%1
MXTF^GP <T+LE(S_(EY:TU+",3_MR(H63S7@2HUU-MYTC:I<L4H)\@C>];$C1
M#\KYV'BPT\;YBS#./^2.;]K89$%\?U_F1%]NM@V;7."SW/??\7ZW+?W("X4K
MP=%=7)![R'NMY5F=Y6B&"Q#/Q30 E&(<Q)Q'[J[ <47065^K8!R"SR'L[(56
MST'&XY"  QWEHA*XJ*,B*(M.%3,&=M)1"?-, 1DA2,,+<(CULGF7B].0L119
MS,"L^8A<3X$: $R;%#*2PK* Q 0V.TL$F;5!2;V$O%XD$T Y,SFP,U"G&D:
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ML_4:/K2B(DZ_C,5G1@_GKNR*IUQIY3OM&CZ\#EY/[68%N)T<SMO 6V_VL#7
MZ^IP_E;%>HN7K$"?1\-'=G>MM_S2&NCW=?CHGW "#?V'5L"EC!0<Y"70C:\+
M KQ&CNV.Y>LL.MTA"!,>.EEA94M8U1=897#\#-&*,<'H=RT<R:YZF\ 470^.
MOCIRXJ*1%<VM+)=?(D$[AH,$CXAL85&3T:IP*;Y5O=PXP)"4/*=D1-3DBC*E
MQ0OS*FQ5M [!=CK1<E1A&[4-P\]+,S[<E. EDF)X+L>SCA%YY@.G#SD7_[;
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M*$:X+GS0DHV.EH)4&FBM-+*5 &$:T/HNRD@%ADN,!0C TX 6;'(TB((!% T
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MZ<YXB:/2V0R) 91"%X1C+GNAK32BM"]</@GA-3L9VM^'QM9&(YHJ0\@% +&
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M(_]00-+3NT3)%A_SF%.HDV0S-ABN1/_:8%W;:?<@])F:9A\"T:]WZ4(:* P
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MV*"\&DQSVL.)1Z6SS+#/16-Y,)6PGH;RESW5_;H -]MTF" LZG:Y3?2+:_L
M-7C+7%H?RSC 8*U@/I@)86R!O1W ^N6^# @Y^PGT_TCP/2U'K(SN![)-L!.%
M1B^'(6C]E ]23:\A8Y^]8.&J_W^\[FJ=I6RP 6!O;A=EP*'C7*?6:.49I(']
MVVA4FM!+I",D(9LD[L,:,JXX5"?]$I_"BW)%C6A,O?'=+?]+%Y?IQOC[-=S\
M0A\*G8[!!O,GVY,XTCQ/^5TF .4,PQ$/3&1RUP $A(_[<7%48E0^_OMX*_+7
M5I59N/K__TS\?"E392=7?6J_340';T*[PTUJ*HNB&8YH]MK3ZI NP]G!2E"8
M$)!62\XV /RY@)\L8I8!W&? '-HWGTZB6)O"U(,H0T?N$D,+PUE*W-?=A%3J
M@.T]G)GWL)<>8/@@]/N?Z\/Y$%&/3+%D#G9:,$],2=:"30"A@B '\29; IWW
M(3^="_SWB4C7D3>8@:*!S.U?\:\E.^!\*E>XSPAT&!&C"G,R+KEZ>?IUU(J)
M.[Z)9!83H)O!P]O=(X;!_/!CA)#^O6LDTSUK>=Q=QVMW :49+38#00)6E83I
M)P:3:3#?M&(-USVC._'E8#2JQ-8#T*PQOE )7K('SWF 333(.8M"?P8&HE".
M&&5PL8WXEGV-?-L_%C9SL6PSH/D+L2W.V>!=2- P3Z*49J"<^C.R;.]&.Q-R
MN8W"DD5DL+DB$$O!15.G/>@6A  P+P/88@:VAT..,!CN.06NK?7L,& ;<&C#
M7RIA!N3\#%@VEA;<@]'9WBU<;*T9>+ZY4*ZHLN<&?C,3[(J'SJNA9*YRO04M
M5J3BE\ EX=!F/86FQ?Q,(K;)]:^0;U7<C?Q/0(M'7KX6=-V#S)C[;3$-OB79
MWN5>VFE!/9(#EGY8G[8)W>(Y-Y-7LR78T3JDRNHRZLAVVS\$31,X.G"Q',#?
MQX@XTC&0O"&X%MPVN;[+!+4_8\W\!;@Y'DWQW=S?"CH7Y-\: 5Q8Z(%[Z]+8
MWSERA<FZP'3#;+4[YEX&KC5@^3\N/T>R4B="#[Q 50A[N@)2ZE*I (\)6&VQ
M3\S[8['*7!$Y]:)Z/0TB9].8.)1G#)4#_IW:3?8UU<(@S.Y4N3 (RC2A5PJ+
M\(3R^>,R<CG6+N6'?]C83 -;=*C1IVKUY'2-HF3F,L?UW-K@6B1X4T* I]OY
M.,K#K;O19S_DQ#DOW-PPT(\2)H!OA *,2/CGP,><^2I+G)<E*8..K9S@N7:[
M#75C+69PN@[Q,7"<+?P#OMO03>7QASTRGH'G;SNN=8R:I9/MTX$Y1IX=QLL2
M@]Z$YE934,\H\BZ>,<OX=1@,5R,ZD\ X9M2%RS3[@"R#']/BUNWC$4" LV3)
M73KRWWT4.@'YBW7YLA@A?2\\!A$&-Y0.3;EJD0#S-HY)Y&%!WN@I#P>U\\YN
MFY$ SF2C@U*%1NLS50\^57,>ROW.?U8EC4*<:\CR<%:=/.=-+J@T:M6MX0QN
M,(/=DFKDM7#!%BTY\C+B:8GDRP1WG3!O+?)F617!K=WLR21PL,UI=9<%+1]%
MEW9#/>"A</>$2Z)%KR)$SOA<3W;2PAYPK=BM60$V&=%SG@=2+;[".'"#8B7C
M%>2'LV::5GBMC=51UBW]@Y^R8R5-1Y;C4"8;3>4Z+*Z-7'TX,-/7@Q![5$H.
MEJLYI$%>"9<=Y>BN$HHX=Z!96B33$--<WY:BC*=V'U"%9M.O@'-*&]'^*<C5
M'$%M!=7]=8X</W7<<L\(1[88W;4](3*B=2 (K3W8<<5JP1;[5-FU%$\NR#3G
M'C\S'1K,=^+^\,6%^>VOO$"%6U*AUYI@IB?[NX'Y[G6C_)^3_(0?O+Q* 0K'
M[=U84E;W@8QN#%.L;[U#7LU-2+7$,14R.UD$G>M8?18:L\)F?2P7/@/7:@^O
MUU.<UD7:,9@4;8(HBF4=Z<B, CU.8L\_(M/8KK.,X,P&3W?YD?-\4#BKLIP
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MF? 2TS5$PY=SZNXXM/2$&($)FS1)\H.VU9,=I#)&5](Q?$UKM9_3FDL^J?#
M)12GG)+?NM.=6,P?>)@7-W&YN*P7N:Z1M[Z^F4?10-EQP]GAJ%.G2?'[&8&$
M9>N6Z"D<=_]6]]Z9JT@O4+$YCN)Y>K]__G>ZG7%-3QPNX5VUTS)[M(3UU+Q0
MO=E&<L$,(>01VB7(MG!LC-KWR">B9':(WAPJ>6"*#@X)%OL,4J5LO8.]/]Y:
M$FK9.0%#3I2Q2KK7J,#=82Y7V3X;>P[92%+P-<6/I:G]CE.X65;<G@@>/#:Z
M^//KZNZS*K]*AA]-V7[_ 13>.N_0Y^"V4Y?_4;%QT]@K&XKC_P2,%7[A2K4#
M^OH(A"69Q^$3(=OSSC$]:20;JCI>3[4)[O,_-6>Q;M9)&VFEOO*>)3@;X<(>
M1ZLCSS3*?%07+&QK"BZJ<K /-0.VU4D3 \&X@)4_]/G&UW2'14L[%MF$^;1[
MDW5ASQ?:BSJOJ\Z<#L[0GWW?C$_9+''F](-V3-_XAEBAF6S[:<\-7?(/=R3?
MI&U[N-7)4SA=<= A\'71&B D9'[&$E7T$:(R]I%<5A/+LE#H:.+M 6)V;8)/
MG4W2<'NU56*W;!Y_NC2BQ#[I=KO*C*6T@Z&\JYF0)-&"UT5X]6TA65T;AJLI
M(<G9\$O'UX.(#<WW!<APR0@'5P37 (OO<3R)2GY($WL^XY]QLY+OV8\CDD,I
M)7763Z0EX'[/7"*;/& >7"B1#K/K(CCF*C;/1^1#LG4=!JKC>[",AEBN+)QA
M]V3SI2<5RZ^RLZI9(G]KZN@><S19M84/2X0RO$H8G M41_>PV [!@:*I=ZJ(
MX'ZB,IK%/J)F,FL(3]MMUQW];"D]NL]7$E9,5%>X2V;"[^%G/@XDD<74&N$H
MCJ@&G[#./ ST%+]0H[1-EP"GX+\)/YI*+"KF1B<OJ..Z3!P!>=''\7.5%QIE
M])BPX=FP?0@9!@.CXF0^\W@5>A75A@-J%(_%/?A\NLQ&<:.;@&_HRH-% 'T?
MT)\@($Z%ZGU4#H/X5GLC^=ZTY=9L42VT+PE\7V^48%N*;]>NT>[&1+X_+D]S
MY7U =@%0MC]/@Z4B&")[%]'4Q"8M/JA1;P+!8A8,Q9HP1SD>9H?#1T7#2G2X
MRN;.FT&D]BY=TM<*D:?. *<=%:IHZDV':AGN&MP/D?0OPBB VBN4F&OS*)?F
M8(8Y*+LT6JJ#-/)B*(FN(=\X1MU^R0C/$)?&UC\#.W 8/OJ<X"L$R#1L#8E2
M0[;W]%>2FHSKP\33RHZ.V= *PWTO*.@XC9CCJ0 '@GWW?/,B?N]/XQUG8TW>
M)=$X324]X ?$W>"V1;M[ZVUA^Y,U(UHNQWVTFO4F_B>&VKM205-;V0IH3E4R
M=^7$(,D%;%^PR1S;*5[!!FZ7H 5JJJ<_ F/C-U;:CMELY.+>1O'"4L\V&[:N
M8@&#<^Y .4A38DJKQ(P54R)V$#LAPLEG:42)7)5"^C %<W[E@K=P8'$700A
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M$Q,KHL9WQ:<@L)G6'UT+/XQ\%C/5TJICY32L> O55O8!.]4GNF?F&M;6T0&
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M(-%[^2N<)XN,WV3@V*.;J9Z[LZI0]-&A%.F$ZXO-9%9H9K/VQ>"O@GU*NI6
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M* 0E:&A"$[R8MS$>PT4!H"\/E@*PU_>S$B=] ES(QZ4#Q2(D41)+_L/LZ@=
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MBDTUEQGKL$S90D:6^#,UMK/KP*@S"TI]RV(:VSK55QJ4?OTVDG)U6KK9>\>
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MMK"$0%QC+NQ "5[L'.XPB3G$\#%*?6V(V$'=*D/6'F-D:N'JM-TK4H?+]YC
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M?;)(W&T@%(Y?1*6K1L@H?0?K6@Q[^5139&@35E^#NF8.]AV!7-3EK[T8K0H
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MUBG )Q4OK@=D,S!1OXZCG_,.5D?8P@2E=KX'+H&(:RN?W56 (Z?"2='.\L]
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M#1G'[9[;:)TPX+1)B%MH*.=OV'T)K[94@()BJX!NH'T%-F^IVLOVNQ94])N
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M4"<O6++KE5_=ZEWVQ-H=J223Y\KW.?E@.\1#:]UFKI4/ 66?L:MOX1O<;64
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M0(B%?<1X+/YWC^#Q 7@W8A^V.D"(\';KM\YNYKH8A&06XPK[*!GT &;'GIW
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M1E"UDQ(S$1FRZ-Y$=&1XS+V8'0'-_LSNS,9*HBS/9DD,T(B8LA)?CK5$Q>[
MX4IVAY.A\ ^OD;+QI*PIE;#WY73O#-0Z87-4YA;H:1S\J8G"Y.AGE&K^=!2\
M2-$-)+H:9186>/ M9E:\936:TF"O:3'\UOE)?XOWAWM>5)()5E5 NS2_6JD$
M+#UD//>8$NV)J!$]5& BH^<T15VI 1ZYTH PT\+%[H=4!Y*ZM?MGF#&!Y06<
M3"7%W=#JCHK:[<#W)2T+TM),YLC9FD]\DU1<C!U2"TF&Y[ 6\F144;D1W^]9
MYL6+#J J)M>YA4EBU:EM2MSSM/=7A3R;5BY<H=1'Q'C6N/]@*)3'FD:,#:<4
MJ#GI]_[X&31.FNLCN7Z9,!IQX#),,';7_E5/XW.+6(7WC"87'U[RN"6"PS[-
M= N.1P7[9?G;RSV *7>BP<RV/LE^?G ASG2$$[!?Y&F^/35&\BFOR/"6S]*M
MU+$Q8L6H;:+N_O/W.0DVY'WN;>77YBN/ D8&08^!(O>A7NNV&+O,9C>W^M]W
MTXE2^56*2>QX?G5,:)=/_D3#Z_&R_;];63I2BPM\+A0L&"MRKU(:!FT*,8_0
M M[J1BC3Q]K*[YV223)<2_1]!">J/"7H% >\B"4]VG3.'7W)304*\:'<$E&>
M2[;)^$+M$P5XIZI)N"W@T#8[7;>[)Q#MXL$AS*SSX1I5J ,]I^D5;,OGVC>P
MH0S_U^$?G4RK4L#A?Q[Q"'SZZ']9*WXY%$S*;J)[CW8PI>XX@N<4NKA53#')
M'[>TT'70VU)HT1?1)^*Y$\9?U(;$1T84MOLUYT]N.]Z]@C/X32>/UJ] 2!JU
MQ?3\U2)Z:S_^T'7Q#9K2[,;P?IS8PFP;=J+54'M#G(045I\9$,:@\M#4 (L1
MDPON7XN465:?Z WZ%KH;<MV&&P\+MI\C"ZEE$>:9EC'ZCS;44/YZ=2:"TI1H
M:)&4ESJ'V%,Y%<A Y(H.>;)*(F]243L,![:4$%^T-C@/2TVS,3J/A78##?JL
MG(Y1GJQ6LN?WRN/_??CMN[5GU9"TA4+9E?+BR5P+2QY&-?'IP[]F^"[BN7K6
M^;000S6>>]NTD*T:,-M;4N_M@Z::<$#2 FEQ(Y/0<C7O'A%!AU1\>:C5(B5<
MV%Q"+D1A2QW0[.,&4JO$AB9",/C*D7FKNCLT6! /PF,TPBFE*[5C$B.$S@$D
MKY.0E8/20(C9$OEB5WLI2%Y 4P?*^;!IO)IB)U>1=$ 4!RM[;/'1.Z8&!97L
M1@D&-)TK1F"3,?-3=@#$F!VP2:O%WHCE3"+UE&'04X (]8SN[VDNX1.5N$03
MK5M2#M4B/MU JE-] _.DDWH89JF8X7+TU(HE+\-]N@!R& IM>'PK5#R'5I\#
M0+8&V.@5239*T\)+]AQ7@!:K7T4<N7COK\>-H?3S4>J-2TY,P:GND80=60]R
M=Y"DCF,*PM"3--HZMF%W4G^3<ROGTO,]5\U[JYA>/6"46GZ?,R)?//_A2O)/
MS:\&.% SR8/8XCG_](!EXB'2[N*;C-&+?^RT/.NYN!5T_&05"IK.5$7IE(;_
M+2H ;9M(+CM\7/>L&N3X53S=5+'!E'\K(_61M)C%FQY8#!::#WLQ)RX4#CH3
M!LQ#*Y)NK(_;W9=H8Z^YVAGPM'DH2Q[O./)3:2!'=4--?%]D"SUWL8$<]YX[
MO./TT75>/]3>S/F804G<5G?%EA[5@6+)3SM?^/Y6>WO/QS^/?[Z4\8CH-]BU
MVK"1P;241"=X.X?>//;;I9>/:'YW6I2>#8L,,\,WUMUM^/CAE,@Z*_)@W42+
M]U]MD0U9,3_4W3N][:^.9.L-";?K[N\M>W=Z!9V\<E[O-W3QQ=8S >_>2.&?
MF+T?MW95[,E.93QF_$0XKRO9_R8EX/.#FR>]NW=9OTW;L.1Q_[:/W3\8YF9_
MM^O)5:._S]]^^G;3YJ-/IK<MOOB@X?=M5S\_?7WF[TMOPS?N^>WHKY\^_GCA
MF?7<+MQN_:S=IRM?<Q1%-S[K_\OUT?V\]&U4_*XG]^]O'4C-SBM]EOB,??S3
M&=<U.9J-5@^MS7;8B]>\J]CU9$:P?$>Y<BNCM-+_F=-W.T9\<S<?>79IQN^V
M[\CZ^3SMV2>_+5WH]\-2S986UX978>LOWCV^X*]3VSFOK;7_WOG!96OGAH97
M";_NO'OYS ?=YM6SZ0:?)\;W;CNW?>G;[+6?'SQ=L+WW]OS3V4T_+'E:N6Q;
MZ^.E?^1<^_S+US/;^S[_]WO1'Y\?&QI_&C!>\&[?;S]-6W_=WKWRV/OJ'[\\
M=SO^S\F-&%J/7GHA6KAS_. O@2>%@Y^E&_^]>V*O:4?&GC=KORZ[]_/>CYW;
M+[]--?X\>7M!?/?M/6^CO^Z:^F/^[Y.G+K_+6[G[^=V]GT;7[GW?L'#/RY7?
M?;K]PY4//ZS<\^NJ[S]/_G'EX]8__ILK^/KQX>*O?]_^;O[#D87_O8W[^?/#
MKWO_N79\_H+!U__N'OS^[S=KY[\<_/EKZD'/66/ 0/?U_1_ W\:@H1"T/7W?
M:@[D"B%;!>2H@Q;-06Y"G)<"YZO#+97B+*7>%D*XK0S^;@Z.G!?B.VX,9E^%
MXV[B8X2$= 7!ZS2C*?3RMA/,^\#AW!0G*)DVIA_:5-#Z0> ]@> \I_:X3^V2
MWK8UX?YL\>R2#]*2J2.?GB-33C$?(8;E$LJ%,2]@"H10 -*"]UN][Z2FDT'@
M8]&X5 [X*7$ ,*@(L&&!P(L [R=IRWHQ(.@9U8I#HP.A$7J0(T_W$>'X4[9$
M;9%NCLYU,PFP99AP /ZS$@( : OQ%[20*BR)RJ&R&JE$!)1.C]BED"HA1QDI
M_A;P35OH1$QBU<5D ZG^&/!2$:R:_6#'$T8Y'_=1)K'Z@.Q^>@R743A.WTH"
M_ I@)N8WS^X'NE&*##4TX@*L1OQT 3YH(!_2+Y=+3:YW6=UP8U@ T(=";E-D
M<%3VY6 $H 93(<3C4!XM=JJJ,T4RA(%,#"0VZ7K*P;V%>#YB:(&")BC%O1%
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ME- W&6 S< *M8>N[DLEH4R,E$)1&-]H<;(0>\9>[6]H(GZ %<V<9ZR)-7W.
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M8YO&T^**^O@$.AQIG(6%W#.#:XO)34"?E\@P05;;I&NEE)0(XEM-IOI2Y_'
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M.PY(F7C_S#C?%S[/3[B ]1XT)LX/_M:=6JI,YSD_;9F,%.M AD0K-*X+-E_
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MW H$\HTR"MAFQ1U4A;7M0$@\?. !3BE#YHT%>6QME%#PA@J"\LC3873JE#5
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M@0<4K '*0_LV?P;\J4%.%'I$4<%UUL*9>Q(Y>/>DFZZ>)+\5CY4_+R!Q,&.
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M5J!KK=%.#0:4 F#W4X4Z[B4)\$C+)8\;CE[BD =_*M?B_N,&LFV"SJ',Y?D
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M*BG-Z\989$$U<%$%4U@G[7!GW/I18R!1N4\LT1954B5&7:(=--??D2>M#=(
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MRO@*_+?X:"A;YJ+!Y@41J!:2'378:; &'76"4M'0Y5'#>YV_M5A9?W1)1"Q
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M*5XG(-L]\K&CT-WX0U_/1].#"'U/"=RIA:L4;IU3X6P6/&I$6#?[)JW4L91
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M/QPTZ7D'L$.K+VJ:2T4*):O!P^>O)X=AV[YQ2$L!CJW%YF_J[NC$5@_%R7_
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MXC>/&$6&E@D)'O! $T]W;&0%B/<2EZKC/,,]4+UUGB$\%[%H#Z\B%<05\;=
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MVC$&=<T"%KMY!-8 A]HKG??__?$(I!\SEB5V0TX*A5=M%7XG^2;$S4Z')P]
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MR*+KH-F 4*F!A/,"/ U[QS,8%I%,B>G]G>H'<'"T(&'GR;J<+#@('1?((3&
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M?!]&@F8%SX/M?H21(V_(M]]_(OV.2 -7CB!XWE)3J_I*)FEB*[P+88F &Q+
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MG^]_6((#]YWSPN/J<]NTN'AYS KZP1\##F;2Y4F\'Z]> .WU@"8&;S8-NE#
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M$FT<^=VW!!4+76#YPMD)X\3O9[R!P>*%PJE!19 Q#<FCBK.DW6:+"L8QUE%
M/S0WY/OH7!XQ:9D<C+Q">!XO<DO#>E9)9/H2[A[U847@9@[.U5/R'%M&6S9=
M5,&-FM9V> Y7[HCP0A8<??KU%;;R%.6*0=EK]2TQK\0J+ TI"])L'500!=.[
M1RD9:J/WP0CU&6L"M6S'7U'LGA(KHF_RCH?5XI#GCQIZF<]-_9^93D#^%XLN
M60GW5-QQID:^%T)1!LKHQZ EXCP<S;<="46V'](N(_ENRI6;>/]"Q-#^7-?3
M46\WK,4-(K_&5$8XA(1>V;!YE$7&<)Y)KO!XPREE$7;QS5;I+]])A3=>)R:/
M2L+BO7+'JG<[4\8S3%KS?@B??8&E.DZL7O_MZR\1<VH!Q"#AL&'UBK_GI4"_
MC*ERL!\[K6JU(&U77<[%:<?('B/6H6#LX7>?8S$!J/C=*<2I1Z0@5$+8?\<&
M'P92&A$>%F(D#,&:W\'J["#RW"ZTVGQJ*3 B)/O'UZ(PLDP"#T0[45:XG1<<
ML]+"FWZY&$& ]?)3K1#YQ<"1?('!;?P6*Z2ZM?)[U"(7:D$]V4(63Z++"KRV
ML*U6"^,<O_2L7.88D=R<E?OQ5\!+E=8 D4>KE*1' +*[7KAV5H&%7M-F,Y)Q
MKH9!TEPC2<YMH!2D85.1 ;D7G&=:0%?.W+QP,IC+-'44"3FV_78/829F!V74
M?L/'4._>.33IPJQ-2/N/)P4*SGH2H,X)\%*M8#&#U]$/[[-SPC]\LLER@[&&
MTS/M.)ME9-/UJ6&! (2H!1C?<OT_[?=P.)3 8L*U9[A6=$+.N\SF_[BK]<K%
MO^*NK?[CU(@:@?'^A% :#;B9[VL)KN(V_' +-#@%C!-]TV!^6YH0F]&X7'KL
M.9A6D'R(HVWKC?"$.AG]1*I3N"0P(ZQ.NH+ DRXF3X18D6<B\5=4WH,S%MSU
ME+!!.J7]Q_J1XQMDXQ'=,E BU88:';"X+2LC;+)>0:YTH9NG:*E*"IQR]Y!&
MJ..*:)0[UAMK1I@\/2U MI6S;1I+5$/@XQ;!G.F\K7IW4TO!QDV@N%1U=PT7
M($2R7BY]]2W*AB(G?!H7[?2V'-P>".3[@AW6#$I#Q)5IQ^Z[RJUYGPYUMU^M
M]5%)R9,#5/N ,D5CB):2%#]H_^;5PIUC)BR1^%9$'&0G45%9=FE7GVUB0EX:
M$%.L:C;=ZG?I]9>QWCMYV^=;U@.(8YO9Z%&J":(O#((AD4?<.XY U(W 6O.:
MN/;=9*"@W<O32C9=Q(1%W3X\[;+3]FO= O4229I6[5OM'OFKK>+?:"FY6'47
M'JS,:VC=@+6BEX*68I)Y9A7(H&+ %.9\RS3$ZNFM08ZK 3(+!KS&P%!;NK;(
MBZ6/F$LUQA:OOWE:)L?V5X%*-;.W$0$W4?!:RPM"7L/#DDVN<(L%-J*)NG[D
M-=8I+B]K;^9\&V?TDD76L1R1P0OKD4XQ-6#MR3*&;V!!YL_[;NUW$X412EZ1
M\>PAQMMQVL&/J;C!R4)24NX=AU"T*95WQYXSB2=.YYEU[,2L_?J ('%XL5@S
M*U[#5Q&+F$9OVM0$AQ)HYZ^$?-8/OX9)96&<;/3N%KI/@["5M%H$8TO9046<
M6/F$P[B9[J/UX;_:2;2=5!#DYA7O7XN\):8M7(P?MR4#[W'J9)I'RXWFIC7N
M8?$C.=L0(824XU:FUM?PV0GV=ZL+_;.:H9=SKG)(''0J*"WQZ*'R^Y'#J23S
M[AT8]1_/(+5XG8^?=C_>H?27W]SD8X'&1!?DJ,GVZX5D\OD+9._?HO7.^=JW
MBQ6^.]?L[WAYJ?$_>OK^6PAACYB ;>]?%L;'0H/Z0KSUAM"+S*O6:T1U4P^>
MO%JTY@;3W(JPLQ6B++UCBQ]4-SM4*K#6.H P ^6;D/?_N*,;Q;KR>A=I>CT<
M6NX\NW)?8R9&?O=QXI]>FBHWJ[7:"AL0?(3J(BES'G]]3QTG,.$A7W492GL!
MX7Q1A1E%LF)M%8!S-%8'9< 8QO#:UA@4M 1VDU-U"-$; ?4Y((:E"90>"'"Y
MF+G_0%OUW'H&M3QOP<(7SB4O$;P0H;M9K,1\>X0>^.BGN'KF@*?E!$H*;">:
M^5YHMABVM/_5W%ZB<OK(T""]EP:FR;0#&!O8VYZIDM-24*MM:;PWOGK;!9-I
M-'NM)3Y0IE@HEEHZA5BXV=]$MID?%^?=TG-&[\BG=K_,_#B"-6'!)Q)V05C:
M,$"<OD+B><\BN29:@,@S%XU@+29^F=I)&$VX8H&B1!382I3/.IWD4XK^Q! M
M)A5*(T2%7<VZ@&\P> >8_U=</ZQ%S4+D9BKL31&&H .&TUN54CEW HTH"*1<
MK),$R,E3M61>KA?LV/-3B4.]Z9EI0"_*C9IS D?M!JX]!KPT\T#^I1N_UWIN
M.33VZ;BDH*^@QVIU01_C8H5$SS5SSZ,$!%)ALHT!F*4K30&09H3(!J4Y@K4=
M!:Y^NO0)J+32';'2<A/?+O%PQXCX2A+/T9P^#]&B9';!&))KVPXT4P2F1D#W
M86DM9D@TV&OVYM@9=A[;HW(Z5,5>,438,.22[-2-*"57R7?E6A<B_!>B_$(L
MCD^ZDOC>5)P1]";>4C>,?9QUW+.EV2R]U)4S5,W+6]O74CVE7"JG/(6"8SZ?
M/).&#6ZL29H<ND*@FY5=>T6I6H8UO1&J#!JI8K"*-S>='72OC'$BW_M &IC&
M"J>[Y\YH!%M2KE<;E4*DQ$:T[.=RBQNMUSID\MDW-?%AUQ.PIE$35KT%]*VU
MUZMG=#IVGO2C>34;MPI6!0\/;;QIZ]^_G#1S/5T<&HE<BV'G/M5U)I&+E9\/
M20J(DG'5T>^E7^*Q.R)6'NX+>/-\>!NY.*CE5,R'D2LS-C'"Z]64D6+KH1;U
M:.N3QB @.)>XLB#)=%M.!V^FV7VQ?1LV:):7^_Y&6">Y^&S)\.?5(U^22TZ/
M4QY=6GR.-7J.C:L<6=RKO!&D!9SM-1(]6D^.4-:'GV7?O/B]Z*KPQE#*S;/T
MX):(E4,1IC&!PYT!P]?%IB.^-P?'PW:_+5I-#LM21BB>SP7=<HCL%+F-B",'
M,R*6W8VXX159.1G1_GEI<D9DY_3E57VWGD[>>O;YULWQR&4-0[]]/M1-CWHA
MO#TIOEU3?.MEYNW7RMM#W#RN2/Y66+LP(*QS6+G &):\9%26Z129A8D4XR(-
M4,<PE@: ENR0^0D@OBTJRH#UG*!YQF']THXW8.W;O4<>Y82H>*7)@;F(YK:Q
MO2YT3/$UYXZ#)?87KH$[<Z8[,SPL!N=CH"=OD9^Y%Z8R*B]^@^8VW%H+8K<^
M$LT&8/2Z.Y2AD"L$+'5!Y#CW)K'R5L*D\E-[^$C28)![A*]TV'-:4% K\@IA
MGT$Q6.)UV\LMBPK,;C"P5G/3 -48<D$=_8BK_5_);8^AN]P_BA8A@.>4@A:"
M\@VF10[%0;"<>)\UK+;8\4D]D=X &;&8&/DB"@8'1[M] !8,*[AI\B@"]HV&
MB$,HAF]%J:,*9$K!6QIY-F39&1W@R\:I+8O_^1V+%<F7[I;/32LNICE QI._
MBTU3^DNX(8%=<7('RR.F0:;^<%<G('=P!PLY-\WH\_P1R;-Q)54[1!\J"9("
M(4'%).U1R@2J%A9S->IB$MC(I-L,+_NY<^&B82AH6]3J0/*"H0<90[&>A+;9
M@/%[B6H^&Q?GT00Q2X+HF)DM#:;#T)5AI3?<JI\QE1 4Y]*9<_@XW)\:XJ(6
MUUVK[^/C2ZI5 #94[OO93:XIY+941E!RLTI]?&!RY)1R"6]Q9 "OO1_ELS'_
MZD]",8?,RFYP.*NXGT@\V3V;T$+R=/@9[;T=[EH^!;-'J.0-8ZU:+&8-6$J
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MNV,D51[1*CO6?$H%AB0Z<[Y3#6T^,K9A,&O[\9^Z98'+<4R"OZ42)P*M$)"
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M&.G1FQ1D0I0)&I8+/._*#U<3EKQ,09L(63R".X]XV@2%X]M2$4*D%5+[PCT
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M",,.1?A=)KC'J#\Z/X7?-&&.%I9C1B\?[&9JR,'].G9EKL<:"]+LB?X4$2A
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M^,$$_'1&(J]G\UFR@-U=GM[PET_Q,+YV&B/NR)EI7G2+R2G'@L=VC8/.J%F
M!Y6&1)L"$=6_A.!_5'V;^G]?J014LEL0;7)P(43HPDFC^%XQU]K)',.<W'K+
M$^/_MWN\<"#Y#DV?Z"OO=/Z"9W"%I1&R. X=/3.O)/RU*,M$#RK!_8;D0+#R
M,<@#!DC1ZR%&GYFPL$5XXW?\"A+]G,X0(C]LOCTB'![DV2/G'1?)<Q#V%SBC
MJ9D@&P=_PP#SS1>0.T=02C.M AOCI7M$O&I2G9":[ZRBIM\D[EJGCH_8:MJR
MLK7\S)LV4Q"W G[4I_XZ)OIM)"*#1RB]IH4M\#33D609GHJ O_%4(3;MAH.5
MTWT)]Q6&73W4(<-N;18U-!L7/(!V-0"L/!5#1D30O=8T(JV.59.E;?T7#Y[T
M)9*X[. 2&DU(#6TG,VQ!;.7/9*1V2F_Y!(!N6M].ZMN=6N)$SH;'!TQ[3/B]
M!&0W\&.5#6?[(G^[H!J+VD%([#U8)H[4['RB/@50-MUNCK%20M+II1[^U#Z]
MG2TX8P((SM*1?)F_*_=5R54[76&23.>(_#SUU;D,)9!D).N4P!_<Z#,HN)CA
MXC A:"T!RM_.BFJI%@+:T/CR9_O$XVFZJ': ^N/14*4&:V8BN/N/0N2\IG)Y
MQT6U#"1QF\C#@'L'IAN&21-:)L)KZ<"C>\LK%$ [VD"O\]E=@H?S5<!"B4;!
MTP"S>^+WA=;%A"NK+ABK)KVUA]K"$&8[1==9=<Q7S_(%LU[#0#@RG3>+(N2'
M8YI$!:[NI@TONI"0+OYVB'18JQU6TPR'%OL12H\!D)]6RQ,M?O'383%(1%0H
MAN^1$THUT\O-TI/EW P+'C$!/1$,?CQ?^:,5RDW\P?8C-4BYY^L1[O@U]=<2
M(\> ,Q"08<&W@8-#??:(05ME4;/_^VEW#0TMT5^Q0&0#\%2FF_H(";7AS&'\
MHPKO743L2"7:&8895ESP$ $">91A.!@'F-US:0HX? (X.K&'Y'L-S=>$*NDT
M95U5E@-3%EP^%V%8JF+K@ >/H<\X@';/_0FO;#TXB<\ JYX_5MLK*D68=L*7
MIS'A]61- Z:Q'?NV$XE3H_/P4RV9F_A-["NNH1@ NL*??!YOOG#V4N](&E7%
M,.$%;):# :#(_#F"1(ZO%@$<:E"-O1 )5K8S;<?/M5]%K=^6##11@F7LJ6D%
M7@S#+W23_U^G6Q'#E(-7U56^NB6K5(+4BNA A&8,^#M03^O;C=BJD@&07 <L
M<Y/8VH.2OT4>VA"+ _,-HXSX^1F^3=]+VFC <+)A-$PQ#ZU+FHYH:XIZ0Y3E
MVQ[J(R;.F&TXICA.3W=M3L SQLY.4?L?&P;(?<#IL3U0F%Y:AS^<:Y\$[!%.
M*JN0^)E)EEDV#*:TWQ28]VFY!'NCY=O4[?L.1V"5/W:/GE7.'CP"V(3@'R]A
M9%B+HA4H *+#6N?:Q/^>2JJR="M8B)!7T;KM1%RW9<B !Y>G[!X&KG*U$Q;X
M(T#?]:@^58^+2@C3)Z#Q]9H96EF&08N[5:QP@^4B?;: RH+ EQX1.J'*43:S
M8NS&U+0KW5>A&X!G&PV<'NJ=47<S9,,>X"_SWRU3C@&>-(2'I =V)D[]W([O
M^?:-&ZM339555B@H=6822GCV[^V,":WKJ^A]6%FB+S$F3;?C8G\R#PQ+H_ST
M6B#==R@(&84.9@P\1?#.W>0=59-TPQ2.?OJ)2/T58<KE=?1:$Z9I!P1=3DU9
M'IJZ# Z#%3SF<22T@YFE8\O C8$:ZD3LUQ>,Z>TBFM)C:L<<_Q2-1'A_ZGK?
MD[>.?S3?(9NX&NF>Z?'49+2E\@6</':=7XV[0*WT'.(!D7Y3./)]D8/.@,NV
M!+?V(5@\WKI>_+;'ZP17IK/2WZTEB+&!?87,Z'6:G%5SE1T:,3=VT<I:L@P9
MJ8E=?U'\W[7CW8\C/_# >@"&VYLX&.T/FU;47;'5\X?9T5?_R,JXJ]SSZ2+R
M_88Y::_IFZ,?BMK) F>FXT1:ABQ>IP _1R9_P&#'*;3/A/G?)O*TI2Y#,2EN
ME1.DMVLG9*K5.^B_*2NO?IE3I>@4*^W#V\E..816(Y[H1XRPG9[1ZAP<N5 7
M#T0B<$!1]*)48'[[G+!AK2-6R8D79V2I3LDUI"P51]XU903G&)Q)MGUV7R"I
M$(1YTEW,AD3?W;[SJ&BD*EFI@8=CZL+T@2*]2!;:4;9 :H4=ONA1&QX+$';'
M:JD6/+5$8V<)>,.3TN1L*H\PE@L,K 9!_2$[KB;Q"S1E6Q4<Z7UKP][L?Z'Z
M$L*?AM0;/)7=V-XTNLPL]WIP5=TP#%&[#U!Y@21?H5T=BS*Q^*!0A5IA3(%_
M!$&FDGG@?S2.58N*TN')+^U9;++7VU,AD6=CNZ<G8T#$!!PJOQ42GW*L+C0#
M(4"&RN0Z/-AXANQ[@#)V3-(G)O4XT='*ESEPYR\L(@J+NZ>UT5HE"B#" CMR
MKUMJQ63]0)DO[3^"*DZ9AAE%H\/1"ZLH1%ELP.79C;E>6^$3V$@^3<_M_A%G
MR9AV)0_"<%R<I:5G3<4BR1]D.<[I^/3V,9%R\:!"D](E6[WCJ:4//]D9G<O'
M@Q6P$)F#/PE861/?(=82(T',U$K,JF8I@3"N-B@2:!J9GLR37[\K/8IZ1,&J
M6%1+%%:\T,5(\<3?E"JJ[\]]_H9>+@R7:)*M4&G I4G6L#9"#HAE%2<*&*_2
M=(SV<ADJ%F-#B;[@9]^^_&#[N267O8=^=FC3<RP#T"I<DJ45!ZKH%CBII%RO
MJZPGPR<,.*_O1NA_.74IO=Q48I"M5O90O?FA;ZL-I_D^_D"^_8$?N.BK6BSL
M>&C5MG_ (8+V.JKIC"3\9C"(C1.HWA"+@NB$.N*+G,.;6K.S'3;R/EC4]+XJ
M-1=.22,Z?L$Y ,RHVQ?+UH8H]V18(7I?,GFMYNBD^O;>'ZYG56, Z)]RGF[%
M+7+"O' 1/4NEQH=8)J!G\I1\+CA=K"E\ICY\5LK)8KS,T]"R0@R30% ) ?7=
M_V9L$@\_]8H6>UT"@/:W3E@OO$J-5*E1.;U;.IW+=YB8T5:<?CH>SFBN0ZW1
M,\-9C(D7^4RKQ[_)D@#^>'3&CC2BT*"OP@GV%F#=N#[0!# !C>DGA,/39\A5
MM*RX4+&J2S9C-GOE'R^BIC,(/VL<RW>O?G8=9YHJ4V7@W&ZOCATQ=UZN<!I#
M8I'6F63U8<>VVA,3 F?M'W[:/ZY"= N^Y^NO)R(JRIZI:5; Q4]#&WL^JMQS
MY[#!LP>_;'D1,@Q0K3@4 Z,\?O,=>DTD(>8_%M4*.9B G^>!,]>^I%LFIAY<
M^5:</(W'M\4ZU%:LJ<P-^) %<\801HB./>G+#.?QSWHG,T5AS!!]8CP8RE<Y
M6*%+I'R?Z([D2)4^Y1$MGCX=N^Y8QV+>?TT?QI,D$_TIJD!?W?_2_>O,+);U
M.T:NRA%_EW>[WN%]LYG1(,Q:AW9X-#C;ASBY-6V90_?3T?N:&8_Y4BO^\.WJ
M_^4"AR(8HC\.1B]?%^UP^"M9D!NDLK<"_<WN4Z*\/%*1'<&>'CU&_@S0 7\9
MLV8#DN!^%+1?W;#A[[>"F!LN\SY_B/F^8>;4AO^5N;J_>T\-=7]L1H6 IG.+
M,>//']Z=FIIQX*/$5)_T?8U;PH=Y3N[)8QOC_D18R*8E!S8R7C2D_;FQX 9O
MUGU7[\[N9?-=)DT/WF?](+C>M.F0^5-(^:8K-V7)7SXM7D#!? \LN?N#RX5]
MTVW/R.3/FVJ[9(8V<G67/3\C,W33ZJ6?7_@Q4I/*UOS]6??)L.3CYO:K[W<>
MF%WRV;!U/EGQ<B,E5$<^^-FA^K/^P)>2D^@F.T8JQR6UM63O"RWYR9><SZAA
MNG/E_SY5.]57_/FIY@5,'M9>?[:&_ 6PSPNFF' [><7H^MDZI0KN<S_(>]&^
M@D#(.MG]0/VUKKOJ6VGO[D;(A*M*0A+\8?N!GKC\O] 9QI,S8&K\X?&:KSES
MR.2N*K0$H+;C.3DZ5'AZ^1]5@=V(#IWH.8#3OG <S@6\HVV,NJHNR)V,<NH!
MPJ_!9.Z;F#F$9;!FHFMWR%!3ZXH J6]<[.:?=\W_^&%N^0('5^F38^XK"5']
MA]N-H>4/H*HYOF&;CE%,_ZU>VE#RD%^ZY ?3^ZU=Y[R"K"4U +A+!?A<-.9]
MO\,>N5UPLLHK;)/U^QIR'4ZQ;3OT>=VCI1N)"[64$D'M<N<@I:\P/B^YCK\Q
M$(:-_E(E+LCSHL3O3VW'\_8;7$\;?B%ED+/GDA_@P PF.B&8#U9/.,BH:YRG
MUQI>AE1_/DFG3:B3+3!N'9R;T9;<:2](;.],TZ3:+>C8>AM+\TGB1_A&<\M5
M [&$,'7@Y5 ^SZX!7B<J7,F(UP4FMT^JVSM3H/V=Z#1;BS]C.#D0G"NKFYMV
M;?_A(L=?^B@IMS3VI[6*\U#;J!@5[9<T=-_6)";][%X$AC51F9V.SO"B#2F$
M;K?!1S4=FT[TQZW8)_&L]O+^[3#M]PTOPQ%5PZ52!^\+6TM"GPSMGAI3O+*I
MLE/HB#:3O^:^%DN1R*"'!E5/I\A52$O5E6IV!=J?*;$>4U9K)>C%3O^[XQ(J
MVPLI-]D*"85.K9;HNL:YU\01[A$%JB^MHV1JCOTRT6,^G!8D2%\=^>3Y-7-R
M@)L@\0XT7B?,=:I-/<67OM2J)"61U9N^E(9VDK*%I20W=C/%3=GQCF@WI;&)
MXK3&;3*=5$C9:C'Z-];@H!-O0S5*4OBFD[0++YK-KL>ZK"H[M,$&;-YN?@M(
M(H_?(E.FEA@65O *U'&NG77]D!T/D,@<VU88'I(=<!E/BOD-7EU2V'Y*0NVL
MO*FRNW\^5$P<Y=> =<&X,M>Q32'IW[3K/[M2[RF8LA]#F\RE?MEU9C$I5M";
MX-BERHK?56C8)4@]I%#%V3G_ET5QJNBV6OR#2EHODSB=4#R1E7,>(4_5FVY1
M_&RM9,3!("MW60;?E'C<SR"I[9YNA,0>#OP-I79NA@.\C9P/+U_8A5R00T[<
MB:/EU)^WJ(;7Y<FMJJ3" E3-[=Z_2VW'FZ2E)B#MFWI*O\^*J+N*]*_%LAVE
M_'75%)*NN?^L4NL;X(3FZL6..6PRLO-J:4J!XW)<";K:[6AJW;82 XHD%?IN
MD'S.FSDHUKPFQKGZX.=EA/C5\K5^ 46FO\2Y@<B0&%W#6YZX"#=9Q9Y;;?E<
MUR*C2,#1J];OJ :G]%IBIMXK(W24A:J\&P+5YC4._]59"&L*!&YQG:-1H* Q
M'(_W<39=[DZUWW\5[/(MPA%7<I<Q@1C(>T<$[>[WQI.\/=^1")V];[$I%26V
M@R0VC:F'T)7=E_WSY<9RQY35\B&!ASC@X)7$0J7SHM_/6N:Z<A[=+8.+Z]:I
M*9.=!;F@0",TEGJ3-JCT%$YDG4KCJM@;3]0H&0?]F<"M]=X5Z?@7LEZ?"^2(
M%H_$.F9W#YJ77%69YSJYUKP;@@_/[BX5HY?']-[U6ODVQ+^FG_174;0\SH_7
M;2Q'?#>D[KI5CQJ(@N!$TV?"\NU2CBH+<SR+PGV! K 3$T.]0D1:)V5QY#'>
MF%QT2:O:5$Q(@9YM/APR=H+&4=Z! ;Z?PPDUH'P"P3R($9IC9&>^@%W5/0B1
M)Z"Z&Z@^-$PM-H+_KV)S_V>Z<?_X>^^]-SMJ-H<Y5&]SFB5)#OM(W>_-:(X-
M<TPU0DBUHM+Q?F_.H21%<G>/5"/52"659@DA*2I)&M'I[B"I=-K]O;__P75=
MK^N'Y_-Z/*[<OT2 G:V(B7A*C*9](?KJ%: ^)<[(&+C%:59CPI2HF&:/8UI+
MJV$+F"R3_)UB+2TAZ@2?,"6B/#-.,2$P%7 T:5;#P"%T,$9+/L4\D$F7X@61
MHJC$8^KY6!I>4 Q8I4@1&'](IOODC6.Q;YLZB/8[(PKJI\4%>L\NRYL-  %I
MJ@L:ZL]W*$W&67+[" ;3.4_3-> ?W6HB?4L.1E%E.$=ZBQ-PAC2FY&.L$8&I
MH8B$(%HV@R9(RKEC$B34D@NT<LC/@&!Z)-C(4@*8[.NXY.[PGFH@#"2$]^>[
MBY"<.5.^1/]@F7.Z9G_=%!_O<8A(4-7$KNV'F/W</#WU15E>D@R?G]B?R1(G
M%;V.3J:A,G(  N&/54Q:([PE?A*#"@5J.P\EK$[45:W2QPB\D#C,XJQQ<IE]
M-C95+E_)Z=B8.#LW5(C,"ZR58SF?AW[2)C#-2=6&>5K^O\TT(_WF]2YU_4#>
MCQH277P08O4+F$'%1/Q_X32]"0O@6C+IY9.8+[[M6*.+!-.]EAP:.S,\$ !7
MDXYLI\.9X2L!,) +6)JS!WE<%&-4J8 "B+Q<6)MSV%M+.2;->]V?1EO:UP!:
M2'Q%!@8YA D?$&_*,Q'0">>B.QF^XFS;Z,C]*<,K,&RAK*%OJY%A(<YN+<W^
M;9"=2: 3FDR3=BUKZ&('<2<HE['M"72Y_+4GVO ?-J8 I/EARK;M!H?4JQB:
M?#W:I*[6491=6-BBOC'AQK_\0DZ,"WGR3!F'8ZL?]FGH1JVN?8P379!(/V=U
M6,/8"C-I&XLVAC--5O/?L,Z)+B)+E:5G,&?[Y5'.:KP V4K[??SA.O-<VD(Q
M0.4M(UNO0CAAE=K@Q7]1=BS%G-/I:X#*60WD4K@_JU1SHH+CM<)@'-.=L8T6
M<KMB-ZPV#!,H;E*X\?86FL5/T+&4FWN<K)_T-]-B[K3,*4=QCB)@6CLA*RA'
M74R!G(-'3X-%76_G3EXCN.<9=05C1[OQ]PFIHP,-Q+^6_/7/B&&01:!1'#/V
MD$&<C,^+S^MK(1$U,+[<!7:E750[AK7E&-M"+%V>$,$[H;**F"N,LY'9)N':
M'/+$_S^ %!Z\=,?B?:T&3!V:X6S"@M -W#83A$=V?/&L\LW_(._2M"RA-&>1
MM(IBG70+-@.&ROA=]C;]"%DHE8>E)PR8' <$>(/2IJU7(%68[$\74:YCS!N,
M#;>-&"+%IW?4E W]L$FFT>7_".']>G<&L)ZB_0%"P)VV\Y;'ST(569J:55&L
M/B?HGUQW%DTQ<"*PK%6DI$:!+:I^=^O\5OEKH1ED^)]L//B9>A5=3UD[>V##
M7 V.ZB*YH9D\CHL'#S&:U88TIM#6^ 3ME0# NC1)[8UI1B8EV\%3J- X0$72
M8U\T--9%"BK=BU(^IE;@_EPMPS^XMB:?O.S&Y6VW$BR(H&.DPLGV4-9^/Q6)
M@J(CG->T+?HELF,??' .JM7D<-6;$ 0^04W,S)HC_W#YWTX-X>H3K$!E>+=N
MW&;1*_[<\+K ?ST1/P:ZL#>*A==O[FK(TZKUFE#9DOZ<199L+WOZ'5#ULJD3
MY[$Q!:SZ1'(Z!3D6%XS/I8/)(4_O*_"8M0R'/-85&>8$38 ]/?U@/A6$&,6H
M=0N,,2H'< Z1D(43##J*8%I=9.(FN)B0_!RZ1'UUZ:^>S;K_78F\I]A>Q\PZ
M2#/L/S\&B@]]G=__/#/LY?"#L"Z2M9_!G)A\["^FCEB/6$T\Y F!/.B8\FJG
M>?\!@L!T5;WF[!<C,P<0Y IV;VDC2*@QZ1I\#5)JGV6;@1(H&C@+T(OW7A5#
M"1;JX2H+HX3(8)Z,F1IU:?4JL<HT^52'226P-W7^C>)PRWB^[^^0C\GJZ2D<
M,;T+2EJ;7',;*L2,VF=Q[^)!&L[ED''*(=0D#]K%];=2&&_TM$BQA$3-(U&2
M1[>7':6UH.^5*&$ZF[D'( BHK<F@O)P?V,1[,5/%MRCKO6\Q/A=Z?74N$Y)G
M[T69UX]O6XP&[E%O0X!@%.!,YJR8FZ5?I1_0W#8:[_>B7OVF,G9+ \K>NKJN
MK1N/=&UDZZ#LR9ROWGV\),0\(/K2ZHZ_)9VC\6V;N9&62;2@9%GZ.63+W"QF
M5[NC*VA=^YBW9[4!JQWJ%8\>X3U<%IZLZ(S.-M-K/ZB\*\9:%-JR ;@48RW#
MZ.D, V^W0Y51>TL1L=3X?"6/QP/@KK7),3Z$#%XI >;G&7EU"2REH(6GY=4V
M'@\#-KD:O=OXG!&-A!KX)?]/P"H?^QX<[ZU/)=4_-I$<YI<BV&; )!6P96F$
M 0!E.P@FA8&ILC1U^^-3CX^D!H/6J[S"#D&5/!-8O5G995JO!EP(^K)RB# Q
M"H.0M,U4J-[VZPFO4FQ',37+0\$I?1^'4R]T3,#?\V!H/H!-K0!_=8!1:M-F
MQ/^3MSE7;2;R][%<89K7!GK2(G2YX. !3J4,.PACT3Q;:T"O/W_U?AX6[2+$
MHY%TY..68Y/"@QPGX.\F *K$V&[SQU:BY#JYN35:N44>7-U&M$;-2_G8<O1*
M^YQ_*V7&GG&VS($HYL#Z:*.UUWD@&J.7C[);7YK4\_ Q1!,7Y-J17##^KY36
ME7A%F\D[XQ"2")2V$0TD]M9J9$0$O$DTK6SS7&[VUB7HOV)N:/VQ8J&Q"XI8
MHQ&E&*"XPT2(FJ;S*F0R4/5PTU$,0?*05)X=$#!\1 G8U<H*RQ$]E6Q3:X^.
M_<G[DJLZF*\V5H*X8KSEZH?,2AY!2S-A B?$ZC=*Y%C3T'^@4#&W_6H60& ?
MXY0C!?F8Y;&O=J;',?=@P!CB@:D)0.0#PG+#(X!91M*B2T-,!$E!VD>H=E ]
M723LI908FA?R\.7W\>EYXHYV]B4>F"4S<Y@D(8!N,J==B=DWV(55J4^T:?%.
M>G,LT0-U?&QS)TFL-HWG;8IZ>7B->ENOGEFEOWT&0%3RC-GJ-2[ WS-%S,*V
MM8I$_($L;]);A5O'K$&H?RJ%4;W"KA0S:WAGG)+U;JC47FOY7)0\K_OV/%.!
M:2&BMCAZLA@P]V0:EH0; _AD!YV&5(H,*ML.%KV%Z]4ME<>'N<,'%_?Q%&VY
MNA6AOPWXI3QB$[+=$C)7 LQTC8DA 2Y>U9D,)DO!! I_D/T/,3W&<MKWM,,_
M7H469LUM]_HG#UI"#4=R5"=DQ$J4UBHC$S;8PD(^K"$U(U9-F(3K/%KE *.:
M1ZP'_)WJ[!V@-PE^*I;@(@<ZZ=/.T*T@E0)R+FFS<=S@1 <3@9BE"$GERYIZ
M:\Q]9 YI., [FSM/.LK5;0Y@7A9FTW7,D43^IW)]_U*-H6.[R8BW>>E_7BG8
MM <3 \A)4MX\MP>Q-I#9.V_8>I6M*.>D]8C+ZA!V?-:[2F10T790YWT.J$6-
M71; AJ!%.88("^%?A-?+_N'1WL6Y@G80G^>==_71"O-X&4_Y7S^K#J$I^Q;C
M/"?QF7ME :6RJZS4@#TR4I/,5BI;]DP0%(PW4R+,=+Y)992LM&V%YZ;3"I3(
M_<?8Y4BH5!9XWXZ4SLB;^HM?*F="-+.I?--2@*SU@6L 8C%>.5IPK%Z-I9(2
M2.!5HSL7Q_U/TM]^F/X0$X\YHD]EOA-_''UB B2F65"Z##Y..V_^G AQ1[,_
M5ZQ-S$MQB=*OV@20KO.,A0C@^_&;?/,LGOK=>_A+=TX,&F,V[O>]\<)W^?,?
M)S;_E$/]_PM3G$*NV7^,F+B@^]FZZ,>!HE\5FP%W;]WI"]']%T+']O^KN3!-
MG_H5W:<;S\::=V 60%U;[A.I4U\X3I!>DK_R@EZ:TZ_3Q_&[5<\3@F/%3L2"
M*2^V% B=^O%C@WTZAM2L-ENF K[Y8OR=0)-L_0(GW'Q5#T]**-AL8/[)X*-3
M/&TQ?<D6QM)/#*\MAOZ?#+TZ^C=F(X+-]VD?Z7_XA*/G>T*V, L6,]*V>+=^
M9)[<8L8())<MTD,) @?^K4@UI,"#C$_&84C[;RGI\^(Y5DX6HF!^(:;]O&J.
ME<JVV8>85G[#LOWH3L1@YP+LV4_6H5MM5DW;K-OZ_<;<M2/%C^/E?Z7<CM&N
M9L_7B>]QPPA[WJSCKILS,*GCM7?_A?N>..TPL'7AT^F%*SZ9=W7OG/7;]LZP
M70(PD]0!O"Q65L3:_&JCAY2W@[E,0[S9.]+.PNE 00!1Y:]*0 Z,0"9Y,EP2
M[YH$:;Q$UE," XUM)DDR7"4J6HU" C]+OMK0((LX:!FJXIG&?\B.SS.>(KNN
MWWPH'QE+SI:WF[$D*#0U'6@QLU/:MM_F>-;4W?/UYHZAZ=ZK9KS7I<>W?_HH
M ]+$0(JZ;>Y<)9D2AOE%L%B"1BCX1J[ZY)$P2^6+O6M8K*0YK"1^_3;<FB<*
M<K\^# &^:3)L5S& RBY%(7"6K#!) V6L).L$.!,86!B"/*T#\.GONE-18@T^
M_7KJ"T1)M@COL9:;:D/LFX;LO7&VE]J^<?/>"LN9Y9TX0'YS#8$<B1(7JEV^
MZT\)A^#(]C6E6WS(7R6,[;$K&^W303N*1J_^<6[SW ;<;9Y(/6EV,4*HAU?(
ML9Y,K0))]A:\D")D!SZ+9C=Z9VKWQOG+.L2X_KCXPT":VHA058[) "_;"(\5
M\HYI_8@S?@G;>/_NP;BR-#Y;U=<=Y[(,-1B%=_P?@@,_5HM>[P_EI7GLNKO)
M$J3L5Q-G(DP=U 6F7W=D[L@H<#=,TQ!247+EO451!'PS+SW;C$#['.499WVN
M)/X$H",IU0%MHR1VPO"Q/I/X1#LE^NQ_D%ZYC/>J ]J/R9HKL-HNMI]*)XWL
M>"7%W$EHVX&VZ=NT$P2YVQZHSAV*><X3$"H_3P1FV/XGQ _];%.C@X_FG*_P
M"6@_SGE'-&FZBY>J+]N\ROB<<?#G[$%R'2DF>./]C- $U-Q:XV,+V]D][K96
M'RR>C'+R-A:S0YO'.;_6.!O9_\'26*JT'_NM*-TK<Y$))MLT:^)BIE2Q\9KY
M3HHFX0/T7MP<FN26//> &6&4YYS!#T &2]L22GFI7=ZFZ4@ +4C^2])Y""6L
M65"\],=)KUTU\WV8D6+W58#=]</QH1U[*F4D+=W.1(<2RM5NWL>80.DG?A=K
MMO\V5QWLH]XVF/6@"G IRX=AE)CZ/N%Z&\;6EHL_@BL'BN($Y#U(I.&NQ5](
M@AK4VRB6J:X5=P\<%J+M-?/QQ8!93#LG7@/6 VGG)M?JNDSJGUNLZ> X(2GH
MB^*_'ZK%R-/(@II;NZ_W[*[9X>&YA6=;6)?BY&T?WZ::_,G/PI@DM9F@&Q(J
M4-*O0N:OPG>EZK9R^;/IW57OC^.O8XC-*(_YGI>WH,M1<//5^S^!C4T= B;E
MPC&+7EB)UK=@SE5$C.E'MN_(ZUCKZ3NR8R^LF=R>XY488>KY-DI9EUW*N]3W
MLY^Q][[Y,GUW_$W=%T>]2O77[1_O>^T=]/\]:+[U=]]'G5_CK\2]5NRJ^2;3
M^NOWTFXQ32H1FK:#9-? ^K;XP<J]3Z_]?GIK[TC/[Y&!O<]^SI*?[AW]Y_?H
MY[W/?_Y^CMVG)>NTC'UC<]QF<9?'+C:.S_<97Z)[X;5OPG]Y3<_TQ/PMINU5
MGU4(.88>&K\L<L\^Z$+A[CTWA@>\L=?: JKVOM[]^_35.\,76A]?G(9%^'M7
M=/^"JLF\=3_Q/B1W:?!,Z[OG3PY@'P?.KM!MW:!W<>^'XR;F!=)/=NTY]NUE
M]G\F\%,EF18SM_9]6/\6X7:O5BU_YY5E'DD8/GY3-[Y\S@8P(O;&$J)J#IF?
M2?FD^_J\=7;5/GXIAMR,@"A*;@(X@"#;N8Y@[))!B^5GDXFM.]6T.$$^=#L^
M^%)*G$\8!9\\4U[LCP]SZ-U3F1<<2,YB1JF<DFDG"XQ,UKJQ[OL^S%E2URX6
M*;U[>[)/62>5Y-V_A63"I6:>F-=P!\,ZJ:*=R5**LF+YRG%KC?)19FQSGNL&
MJ2@SFWDK(\-T.C7F:MJ;1Y<6I&N.R\V&(4YHG;;:>2[Y:+2X.-16GMH'V"IK
M \P+3W'/U64:;(DO1!UHAI1+"O,EE?3+R?5U [%A.6'V\\1XN[:0Q&%:S"DN
M+;E3CKOS2/PV ,ZL]F6DBGTRVCR2_,*X\2K=@*E;>9@1)[-K1ZUS+J:VRM'#
M;>:?!$2QW<&CGN.=\);V;D;7\C.HLE>R:/9TP% 8U_7<KHTS"^C&]I-7EM"#
M;6@N2B_KY6'[UM$0.E_TGKK$T(M]6$3HADZ&Z=^R9Y ;%1^Q0=WL"44(T -Q
MW^$78U4AW/B3E^5TTP"WH !,^Q^$076MH4OY4ZD1$M0#84VX,PYWGO\8.&O8
M.\)^H3$6PX3B]_KC_<).L8'#U0!GR9CF(7?Q?;9[BG67RR*OJL#+1ERUOC#(
M8_%)=WF 11:2&9/YGC4BQ#8(W40#);"@0WC@<(C'V,5#<F?B1]'R6Z2M+;W6
MH0G%)*<?%%T5J1]^[?HS<J1_<==,R"29#E^\!^-YJ]Y37 -X71Z12^VM!AZ%
M;_%JDP^S3S9?*UQF''7-J40B5GL. =E46SBPD!BN5K.>6 -%F3>=:6,06=_+
M2F[,I_&,$%L"!EOI%(<%TZ[M6@>&#2D5.$K+=!:6%C#T2!'B!ER1"UR2$:Y,
MC(G-I/,S%%8"#I<'S1$WH1"!]EVS<(FMB)=Y#+]3#=$M5$K#.9YLC'S8$__=
M+RR@&85H\]3Z5H%.(EG"[>AF()OD8/8$HK%%,HC<O0H'T>2VA8,$@=!L-:V[
M1)J-I_R.DSNXE==&,_A21;VSK71(MBB<K)-E,LK#;"C4^,L(CF96#*TA-D=.
M8'+_L,5@]9W&Y1](@_HFN&LFR5B0&".:A&B129(S<J=H65T W4E,H7GL5)0N
M8BH1JOL\A ?A\=$X*T8,>Q)#_/<1G!GF<@B%#)RF *OSP6HM%-:O1,="Q!))
M)D([A. ,G=7)F?I!0PIYO[D27A!NKE!0N+8 SYIB. )G&;/1E&QME!;-UM.H
M H_H*TZ=&"8&=2F@Y@M_SK?*%<VBFZRYYBEXX_/>L[F@'4%V>Q G,Y*"8"4S
M"\M^A#8"(&@E/>[G=$M%'Z(8G%4"1&M5PWD4P;(5 -&B U#&\Y),=2J"B9,*
MPY@*=*<C!C[X0[PKJWWC;(3#L2.T1?0]:"A==-M\ZI1LSD@WE\(-$$;#F((D
M>($IT\C,6B*G-GM3>OW_JDK2N%ZH%3!,M<>@[AH2\X0$Y&"RH$@1J _X)-NI
MT1$/F8RN4H!<_T<P,4I8)$"H+G=0/[&ES&V/HYM-C2]9V4@@_/^-#>XRZ?Z,
MTWAJ@_'E#VW_^*[<E8\<KC?SC7AG(]./=<[P?(-RNE4R!Y&WT3SV04Z,"A,F
M0>RMV61LXR4<7?V!SV"VL^A29N[4@X5U3K>(R\L"!- XABG+Q.@+:*XQ)4<+
M:%E88" ?#_/3<@UTLD7^#6B(5'8D:>H4ZQI2O&]A+[DNR?:,SQ'<[:FBHR28
MRC*D6<OJY(HJ!E%NIMH?7<?G0Y]08Z<W)=YLA=4NZZYG-$S0T)'Q/^F7".3$
M$!).HF=PQ*N _J3_4G8^9GN_O[59%_%*-GT"XO6?D0)7@P6E(.9DB#?4K\['
M,1.,:(  IB#E8:K[:VR"LW$4&Y:<ZUQF4]6GAQ_/.4V'L!NU@LL/SI",:B16
M4E&V=<5T3V=M'+CI=98A47.C+!Q'H\"!>,X=X.+I:?+J6L#42W1/?=Y6GBE"
M@X<4[>3K*XTL\DQ]N.INX^;L<N@.V*+([@<E9Z"(%)DN!V^ "5^LY9L#F5.;
MZO93E!MC;6<3EJT(F;<8?8DI>LV>D!)SIJ!JC%F)&O'XM%P_'H<=X)4+#&+Q
M!(DU6>@@-"X$^]VX*)STFN"#DIF!21(WUQ)D!0P\26/)+[/8!99/GJ[YYN9\
MB'D',%VBS7%W@O<ND*J926#_PJ[PY/54WHUP2[QA>3U#/N4K;D>;]*0LVA=.
M%N0@ M]1'KG1N#2?5K:$")R&\&R"7I9''C$)!&VY,I(CZDA0)I+MF.W@]$_
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M1//C/PJ9*][T(:KI8?.6_G=?UM__AT#9"7.4P[05HR3VB*OTIZZZUT#>N0*
M'W.^X:B T;X"=UI@R*]O?RXM_NR"OG:1+\/<8!EX=/7:82J$4SGBJ:K)-@50
M<@.S:Q'8M?E6I?PZS&T://C1)'2Q2X%2!S\CJA0M9- Q[/7OL6Y[/.K _2M
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M/+K&6$P2Z<I<T*5YIQGF;C)ER#6Y$+WDA:8G(+=Q(36>URN[MN\]'$?Q&]7
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MK$18:AZYU^7O**PW9NLX[XSF2?5#Y0[GX<,7B=FA>KUIO\W[3WSZK._XLB.
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M9I)28M- G*).ZXO#&'M> WB.JT$7@I]L*>#RB;GV@I.+UN2G#U?<6OQ,3%F
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M[#I0[(G?-_8A7<VW'0$Q-@"C]= OV^F%FZ"M2IK<*71<'+*;^A!1$B+\$GJ
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M5"8=@A ?> A7H<0$@,QV1;AN$+>L$.D\PWH(,J]$5%3OG?I"?/1MKJ;++DP
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M*;]#E5=+[UE(KG"SFC/59$0*PS9?6HM*HN;(%J_NN^Q8*3Z_Z3UE9_>PI?T
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MI7AJX5A0- ,:-$"),V"> N"H-!01BQ41!*A.EM)Q)GB$1^AQUR(P(6,AL<H
MT@&R(EI1!#9*BP6&]&FP:""SE=XX%!DUF&BPX? H%J;EH6'"0,D*3A(8D H-
M4[8$& 'R/I4*431R,T.=0%)J5XMO#SMAN@N^NLO7DY+A[; ;C*"WS&R2'5/N
M L".;=AE=Q011S!,PJKA[%264%TTE/\RLB@6^B9-D.)E:N%4X[D$%DG!D OY
M6FLG)5$$7?1X5,K5#W%]@\BB4DQM/%:++8\3JJKR-F]G$L@TE'LP;%X:MGTI
M)5[V6 O:*TPNU+7^% V>]_OEL:3S+E.$H_1B0C07.%\%-!A@\7RC=D $-M)0
M=T#4*P<H4AXZ;(K178*(.#U-/L?7&CRKABHRP.@!,/)]!34 5*-IHU>@\##P
MRJ!U+CJM;SNB* E[7 !1 ;!'!3P3C"7P:)PD+)X+Z8Y!;^.PAES%?M21UAOV
MSO7VR%=NKL-GXHRXHR^/^<@GC'72B0S8$28J"@#]5 I]54!T:7XG7Z63"KF'
M@=X#P+7*8C4S@BS7,FH)*N&>I]AH/*\4.\X#2L:@*)))(RS#@)!\U3BYMY@0
MQ2(/M9H9LN6[Y ED7J9W+/96EV6C3$GI2FG;$:SCAD-3]JE=8R6QWTHN'-A&
M-<:F+"%C&'8^Z5AZ-3U'=-2A$X<67U+I$@#)+*RDP*1+"#12445=I_G2>FP:
M<(ZDZ^L.N:>>S!P$= $3J274\QRL!DY=DUHBP*-QC,TQ2YN=X4@ZKB!*%CN+
M=C'"J7?RH>DJ,4FFBA2@=4H(Q O)\]8PYZ=0-@BCL,\>DCV6T,$ZM2OY%*DD
M&N[X*H&N/8[*3BBG?8M5N!G?VG!LIPE6$P=@F #(WMJY5#S@7\FF K75NR^?
MY]+7D'5E!&/V5DV TL6"FODHSQQ40RN&S )->-"?2DAM"4HF09+R=HWN!0_P
MAMBB&C(5T\R 5)F@(9<0QP"?%MK;SR'T%Y(*3!U,\#"1T!K2I,&22% C'[IP
MEE"&@R514:],L89,,&%Z4PD-="0'#,X?BL'3F^_3M0#01("4%-C]B-#38E98
MUXB)CVT_(YL$'M3;\K/R>S$A!0"H)"*9"UC9@D5:A"JNH8$A-O_C]K_6P((?
MG>+KTL4V6_'4Z[.U/OU,[&QDDU/-6:7![8^LL6]"]?*37&8-Z2R2DCJ3'6+0
M(.@XA.DL_WZ//M)U[G4U,%36R.<:'FK?WC7&CI"!KE"(-XO4Z\\2&DG:!C*$
M#O[V8D&JTUK"-8QO:4#2SGD42(,X).-'RQ!*"(CSQ)JI$)(%6"QFJK A2  <
MPQ$Y2P!A3-1X.C(J5*%Z8:UTT\VD!-]D<9*"UA)P)5)OV;%N9!"CR8#(  RS
MZ'QSZ!#M&<J$=2&*>J;K"-;OH!V>)?<]&/N(DT7F*J)F()4Q0TTAI$,#/RXC
MQ6E@7(16M!?T=D"1PB0T+@$[%<['X?3*^'8JK"IG./=<H_6:4Q))JPI@ 62:
M]N@R(!\!B8UASM&  P$@C IC"P$,M2$1 ,[DEJ,/EL0_O_3UF&,4#MA& Q*Z
MK%LT4MZH-=\K3K]TCF D!&2IH Y$]W.,;Q8 DR;8> $R;DQY&^UDV6P#)5(%
MSU7KW9 G"_C?K6L>@R"E:G-!GYCW(=2W'\A7H@CP3.X-_ /K$K$;\^0;D4>3
MB@5(F#;P1QKR;A+#\'6,N4#_0; Y9#.PI)ATI7,(D]$A'UK88$TNWT*KZ3JE
M[;N,HE=WBS5"]/1(>J.2H2$ ,WM*V"@E7"2AHG!@-#\SVP^\UG?SN@SXHO52
MR1+26  4<['IV]3=EY%ZO.ZHI6X9:HE3V+&5GSX#SCU;,E"Z5,<8 ,AN[<%F
M RI"I#$5E4C%$H0JG2040-V2T=KI--?I?Q2>ZJS7S@21.(A/NGUF_>" W)%-
M:Q","V!HP*!UN_$#.E&HZ@_"YJ>AYRLH*2&RC 8SL $;7MY)^%CE(0UQ^,F=
M J1(L@WC9H'U/I0B_ED@R4<==L'L$[O6HM#S/K7/T^2"3;H<P !3<&AU9J^@
M$NC 0^)\L78F;%4>@I/,"4Q@7WEOOWWK<UG^Y%SO>PB&6$)FO!E0;>*2;ME?
M]*1+U]C+&9PX><7Z' ]U4H!*9F<K%2-W,EKMUE!(=C:' 5Q:A%(6B]VM(4\6
M-DN>$'@"W'VS-G%FDQ1+KH4EN)Z,/<97"(C=@A_+#*FXL!0 CW>YES@:#_=$
M=##THK@ # >@A*IQ3 #)$XOP )!<8-8=E-(&D.PN_^5A^[D+P\4$BO#TR[6$
M/ >]4SA@H_3?@HXKTIO-?3':D_3;@2*]8JY:%Z/XJZ_#=BJTG6I7,W^]DS'2
MN''4-QT%X"%U -45I'N6!';)P63'Q%2XQXE+BL8\H&5$(>N)4KT!C,*%GOH:
MJI @?1(T[:&N3=/4^G7K:O;#_J:':E?TC76LBJD8T@-,3#RA9,GTD#Q8.YC:
M+KA AU?W%3?*%:GS.5W[=N\NJ7#L:7C^T$F/?.CD37.%L*O:,_@7Q]F#'>8*
M'51Z]K;30Q^A;0_I'[3M&A(R7(;I]V30?LLT<3BZJA!SY[6%<A'FX6NGR%FK
M+AXFKGT;A[9]WRSJ>11]7_*SQ))G3KWPM\WV!%JO^)]&_F_GYC%(@PHM+* ^
M<Z J4>7CQX7_R@^2[T(9WH12EU4,>+3>L!?[MM]^<K2.38-%,4'U,4S(-*1*
M@A:2,"]SH'(6]A0#%NH"-0LP#SY!1QO%-.4)"0*E*-*_FI +7D8V&, 2>!@?
M3JM[ZYGX[1,7BQE!"J^KK%Z/$<_USELJ$>^W%Q,,:1KG<-#@['DO@Z(>=RA]
M&77!&@61_OE,GG;5BP2OR;W;;YN?QXBSR4B!,06GI\:K/<<#\G5!9B7J42H*
M04)WC17'Y=AW+@%E? UW3EX\BZPV=K.3BI$=4] ^B+G 2G>N*4\;O#WQ[/BF
M[>\\GB#B>MX]>O&.JN:J%;8KV'&WX:1S(K58=(ZIW,['<+A0V-/3!C)F=^*P
M\3CU$8J"L;#!+5I/>_Y2XE&[,IS@""E'KNPRUPK[- 3#9J-17$PRXW(B3MVI
M<;:$AI42B)4QP"X:R*)BS@&P1R'*B0PHF?V/ZBKJ8S7.';R471/Q[]/C=OAZ
M?WG7ENT2(_<@80UU504:](0>FL)TJ%GN"I )"26@H%;V:#23H($I9_K\X\AG
MTR[%F-9 E.8VE+90*Z;J]"MW6(\D=BN>4)Z"31;JW)E4UN2A6.RM.!S,A ;;
M07FI.:90P<,XC-(;(OHVO7BR@8KSW$)H%$4%M+BL6SJ;R!/P0E0B>S"&2=!D
MHQK9(N"YN[J.)2WY*92WZ*STUFXPTJZ<J_WPTG];:15GGT&9JZ,WF!5)+/+K
M2ZB*MLP_TME:2_(JI*S'3T:"^Y#I*MJ-N(\*?YKG/MF)-@XN1WY=+_A:6??U
MWMJQ*^%]9_N08QM( D8Y@9F_< S*E@:-&2@]'E L^)#IA8'C%N^VM(8:%VR1
MG$E@KL0+MK)P8"( .UA40&:FY-A\?_^?SEDV8,S+8QI@Q1F7S_(N.VI71GI"
MCZ:AL6U]56_;FC[R_D8<>3FYVKFT6C6TB'(\=UL6_<;*<:@)11C&G.,;52PA
MDZ71J3BSZ[,+=Q*D3W>>]=F.G;6V$X):9QDP%L[DN(CZC_-VO+:?KT[*L7F:
M'*XE.(CT9,T]-G!L!U!QM&=*VQ>CGO'Z?-;^P'M^36UL)ZX-/7O^R0N%'[M^
M1VW9M_CS3O'ZFI03#W=Z/-D9.K[/I47/Y56H\FX]/4SV(FWNI,O#Z1VC*;(_
MCW\_\_?'WU>=W-_Q-:L)"-R-Z$0S\M(+ZW0,02]L8FS:-EM:W;6FE#ML=UK!
M*'INXLGL+JZ*78&:_].Y^V3;<_+-$T_W#VS;N;>WQG_\P\.T?9G/^C]2B87Z
MG7[?U0)D-1N5TTYKR)9J##?4NM?>^.P1MNC=;.<6_?[U\T^^_."<YE&G#A><
MO\V#ENMF7I5RY-86D?C(BR]//42.SYUVK\(6]PBL;N%BE298/JTY!/WPR=+L
MD?ZLS6*6%I[UUIPR@Z;GH\6KX8$\_63)?-S+OM'+ZW5Z^?SV0\];#+#IVD<7
MW?0K?,^\F%),_/RR.4OL[]3-CHC9ZD)55 I57Z7YP*45R4LW32(^#2:;N(EN
MFB8NO;TF9^+GO7)LL.#YM0/O1&3_-?SCNOQ][RK/DPMSGDX=>O>WSS.5$J;%
MJ?GU:2=\>5S*&JD<]]4:K;I]J_J&HLO":>5AT^K3AN9K2[8XJSDJ'>\\R1V4
MMG!Y,HCSE2VT(SZ@5>>2H\YJG2/7.\"&B,?2G]@II\G&#1N.;H W$3%Q3N+D
M"PE/Z:0<T>EM0X85$61';+NE@XW>K35\M=CU02IZVRET_ZCA Y?XW89OO QW
M;Y\],;Y[^W28YVZSKQWMKN;S0:MNYEG,_J'ZD. 0M.6?GO&'=H22LT]V;=[=
MX>ZD>GWUJ=$9TR)!X!AIW,U>_WK",T>5YX:/=VB7//-R614/P5SJ*"ZIU#]T
M/;'7M[5#_YSGWN5OOLPT@@^1F4/X/A%RQNC%R_V%WM]?[;N08>S7'!7[_;5O
M>0DQ,/SL^^^!K"N)WV5ML!+KDZS.]SZ!">W?7OB'[/^8Z'.<<//;WA-WQ=K?
MWJAY^JWVU(^,J_LXV+W:POLDFPGFKY7$C>DBTJQ)Q^=BU:_;7MQXX->5+SHS
MOA'ZT&9(?NXQ7_O!;+Z1?=E<@><1A>NY5CX/P\J]OWQM++B?=VQ^*NS+Y_?G
M_)'']O-BPDV=OV6RDPX.?;?Z>;"^^MSQR,:FNNR#S>TIHQ^1N]S#I.V)TLE1
M;0^,?T5UC/LD'[[QYDCRYXS MHQ"^[<W?D7WK+Y(CK)SZLLMOK9./,'J7XX>
M7,R\[C,9G'- =R!+F<VUC+O/X56LW#?L[%EY:'2G8O61P5?+A(?:?R<3GEG-
M;UH=M_L[G:4Q8J1%W.WI-O7MC;/FR<0I?]^+ZY-I?_\<?;=O/5C0M=4&MO)D
MU_J>C:FL=[\3%BY?V7'\X]5=F[_/29^)C%V*T0UI_O)5BYHMLB,="SOY7<7]
M\I]O4^>51=^G3LV=_/G55_G4QOS\G;]_WKN= BOVB7YK"GY9]<L$U#\)RN4C
MW-2H*>!VWA_1RQU@ #5-<92)L'+8^8NSE"J3L$\U%;C89%HK_=="B (7^G\>
M9J22:WC@?M-^XM/',GY=1>MC,CM(+W(/B9>?D<J'SOLYUA)MZ_.DD^-R=__X
M1$3&D=V%'K>UWJIE!Q8S6L+LRDBC8<;4\=V/1[H4\EK5]M]R5(W:-C1TIK4P
MHG/#)N@#5/R\/M8B[L3LR&W/5LNBYORT-=5XC[-RM4QILBLG][%(?OCS6NN9
MM-.JBM@?0TZB3!.4@1L1-F#'V!&1+4+GYNRW])?Y/=Q"^>T>1JRL+Y;]^;X8
MD''P#C![D)ON<=Y1Z?VIFE"GH!OPG*-1(51-,HY21=6:M^ :;+7A!IK+D&_5
M? A1U&S:Y]1.-G<,J2RMWYUK>2_"KC)D>Z_O W(%LL*C(=SBVW[7BJFJ;9^\
MY#?GC#VLY1==DN+,L#U,+Y[<,7@.-,JUD'A-T#>7U)U56] 5,.\U/(/.2.Q'
M>_SN'MT*)5QN9URQ0<+<4K=XU:@K[-/_9%NF/)95%=,]'W0;\[01 ]_J4.ZT
MCYV#4V20X!;7:9CP6&[!$=GZ3ESDK@.5*!\JO;[./=L\-K9\9Q>S'H-9]+J0
MRS6A =)B(NMYI^1M'OS,FAKJ12?CWG*<_B;P<ON%!?_]BG?+([>K7.#3U>49
M62YA(0WBB6AM>4'.I0H-*2)I1&<3-R=3?*W9"',HU"IN-Y:S7+?W[N, WYQ=
M;3Y7+U=4A=B&+[,=@41)G=(^C>C"G)WP$.25,IC8!R'*:3*$&,7@**6,9***
MB2IL]. F5T96VJ0UH>WJ@(YQ:Y95A5"JD<W!9E[(DD%#"..-C[JF!FD$X32)
MS:-O?LO%>8_2$'&F#Y7B#@4\IL6WGDZ,2C:$7B$K$]IDK]L=SN[>"QS.;1Y-
M&#X B\7)%],(<>@^W346>_EM%5)E01<4LO)DBGUZ.GFB =@D=7)<P :3)F"P
MWRPL*OT(49QA1]IT&H4J%DCI4OC*> :,7L.&=S+L$ M<#+YKFFC(%&"_TYX%
M-MM T3PZIB8 A>*#?*R[?LJ>F;V4&-UV]S+-E*QC2J,MOA5_H^IL=BB]'M=(
MQ$MU92B36(J^ED!KIX/U9IW8\*#3$_BN;)IFIB),8=,<PJCK+CS$ HNIGY$B
MF&:CYU@!VR[\(&5Z9RAYL+A.%.8]34:VA!<_PFC6!G(.;_.N^#U'L3AGXQC7
MZ/[])W<U9UFCMJ#!2M=9-@=96W*E+F!;ZTR#GN9<>V"O'<F5!\DS! +#&]%P
MO\)@\\]]H![#6H1U9>;XTX!>X#;(/CQV0'H7C9""Z[-VX&6-VS,GVGKM$!H&
M:6+49,3Y2WW7W>++7Q>]@4X),CKD/)S[3]Q4KXS6/W'-YE..U['>DL/W=;S
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MBHTFF2%H'%$@&H08?3@*^],MA \-!'AIYP3<'U5H5R8P'H(@T#@R&ZVR_(%
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M=!R[ZV)OE5U\.IN&!G8PGF71!.?1-]+:37?8<M!TT)S1$0@X&.<)*B6N.I'
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MV/W#L]Z6V29 Y_AP.IR?L6.X.R3LWT(1.W@@TK0CL 6M=.E#X/ \X_7\7\'
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MRSK@%!NVZ)4T2J&1412/?,J"%?/.";:89J?OG9H=L5+ OF8Z(,\WTLA:,//
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MI+02<9I>SBQA3\)-M1%QAEM.*-5M0FKVB)^Q*2D,=\J^WRP]+G6/]B[R<61
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M?FG'=65?7_(P/$!I^2S046TY ]L8.?O;5(.+*5LM8/MY&0KKC.(V<*5U($]
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M$4:][8OV#Z7S8#27>>H/X!L)V/V&5&9$H!^0_%L8IQJA&@BL#RY"V^U298K
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MFV,-@#([VO>,VB]J+X*X<Q6MSNQ.>_V=:6(I74V$E?K)=!MUX#5V9N,!@>+
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MPC>M^9!+0M?P";OSWM<CCZXH7NT,!TB\I\VM>"!/#Y2!JYE Q#8EI5&E,@A
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M,NGF^G'R> R9J>62UME,W20W\J<T8IWL-5K2[J3X\^B2#2L,H25YJ_V\O(1
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MY)(8PSCQXR&Y7V=Z&:46M"I:=CL1W4K%"MW,AFWT]QC:TTP!X!*R"TH<J&%
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M:<AH 8PE+3C6C?Q2LI"='9@K)<[G2#V[&N"UP0+F6QIQ=5ZTL?)"L;/=>M-
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MD3I8KY-KU_:@< ],:D*M!X#-8T9&?0!^+(+49P]O-] . JS+M(D0U.C-<)@
MN<YK5&*8?@HPM.Z8U/>@?X[)1968F0@+J\>(':SN3 @',*RG$X@)!PU%P/.:
MLJ,J?A?^0&-VV+P0TDC@B9'R&UJL? S+>EB=_Q\/]CM6V@J0FAPDTU+<#@KN
MZ9#=\*'%)YA9BX!V+\26DCKE#RQ[6^Z6 -SQK_=48T;#NKV+D*/ G7_CT*@^
M8$/(J@U7F-;"@[!*LX %R-Z&0L30L_.'FYH0HHH'UZQ\O;KFC:T3G^UD8@::
MC)[8IX6<QT@N"3))(N39 H7NC J;XK-&U?-^$<Y^3TO/KW 7:L)4&B>_U<X)
M-=9;+,.WRR)RFHAYVJ@.H<6..Q[9T#^Y&IMY/2];5&JGDS)GI?F9LDL]B>&Y
MD'.TQFDTN?LZS)H!W3DK=O\'7JJ\'Q\K6[FESVF -_94YCQJN>*;5*75S',?
MVR2,VEQ$W3#>[K/0JN0['IAF7@79C8'_9&K,7ZU?#\BBQB/QV>EVP[Q]8Z00
MS^?.@0_87NM74J-^V!G"9LFJ88U]0U/R3OF"O97$N3X^<;#Z/VG4V'.;O=.E
MCZ5=,'1WOKGZJSI[=O^E.9YMQ3WN&[6=#G+I(+B,JF,ZLS;R1VP 3<+L?@YQ
M<,6[YOS/S5&9LG"'R)P;=8YQF@S_P04#ZO LOE@HLX'#:K2\[H>6GHI,R589
MQXMV?+2Y2]_D%%YG$RZ2V4RKMWSI*]S1]]^1EZ4'^G8Y],\/-"?_$&N;"[F4
MR053LOOPC^MGU'E/FM>(9%VY?!82QRTV9]4,LT>38Q^I<X@:@9"_>T>(,UJ2
MYDW[Q\LXAMD4ZMI4?()S8E%3<!6G]')+Z0U.6<G=AT,8^4EDV9,CUP.'#ARD
MVG;<7'QEAML#%CYY+-=B^&O2W==^+-7/'/1]5>J]H5N 4%0@/%<R@[163QG!
MXRAK4W;MO@V\#->Z@ZZ_*%N.G&B=16M*2UKK=H8<TS\^MF;#C-BU^L:&>G)D
MN(HOW,HHG NOGX*.[927ZEZ%/FT-??BJOFIF,:_5&1G;\J15?_)@[#&'MF/T
MMN;8V<-WH=RJT\TWX.9W,^0K36?"VLY8S38<S&ELS/EEU/7T4;=6F>O1FVT=
MOHJC5:UG)]PZ7[1UOG,[]Z7MG-Y-16A745_OT[:=MW.7CN8T[&MMI[\^Z-M^
MX8=756V#Y?MF#SV!+\>VJP@YS5,S71-M[7SWBV'N5VYPNDZ\/L^4=M6Z_WJY
M_=<;&ZM+6-?NOJX_Z'Y]HKVSL?W&[=FK\0.+$Z'X %+-$]CED[;EAY5L&%^O
MM^QM&S12&!Q+>1W5PS>LQ\S!G-Z4@S?)N2=KVVY]>]6XL_WF1[59RVQK'M>S
M!4O.:E^04*W<Y]Q\ PN?.)DWQ<N:Z*,,Z['P)SR*)%']9;]11PA9,476011.
M:=]6N;7/+6+VRY,]Q6I%Q^A.M]H)%-\!%-Z%O/5R$B?W\CZNS1S<GI7+^CKT
M8.>;F>VR'V?NY%]]=8;*O=6E/=S"%VNAG*.YX]Y<]XO /^(.'W^/\1,>M]H@
M\IC+0[N.C7E:BD_$I=NO;O[PKCQ+=GAKWXVDSB-?7K==-4P4M]D(8AHO8X<%
M[B2+@]>3W.S&HU_1VZ^/K[KV2.TV=\LFK?+HQ=K0Y\H8C&?(#<._N6?GA=D(
M0JJU4H<K(D.;!_MT4W9.B TLNQJ"C1^@V@C1V*R*\LMQMDUY,U^E1UJ \7D2
M"]98LS [_;Q4G=69*-\P;$;ZDE5&R=6P>X 3?AO8"3"KCA3OA^P;VWB3XKKI
M\;G2JY M9\/KRC7/A4#)8[=7Q\>C1)XX=Z<7.V'GX98N$9_8A%2K--\EM\3H
MD=.P>B(%V71#OJ /LR[K<TX[>_BNQ@9##Q"@ TDU@&55C!(@J+%577Q6IH92
M,Y=R=HZP2N.D51LL,[U3,;=6]L):D,?6JK^*9/8[^IR&6XZK()9(0^E1FY^%
MK >0ZY,QE 'U3UT:9GNILQ_=\Y.:J^/;8HCOA,8FI,)Y%#5XN]_-9N7^L(A]
MBG(C"<.YA]\]AIFE08<1<^<>S);5;[B7T-F/ZB^=?6BM19U%R#_?M'$(MJ@U
M9%P02<R&,K:W70_"BO+&'$\^MUH%AT</W&N-6'%#9#2,Y2!.9E?4%)CPO73.
M_P:MNA?A1E"CO4TQTXWDW,Y]$EOY.\F?4R %5KD.UAN.IGK\Z1U_#:34G[ +
M'&*/ 4:Y+<Y>7<X)&O;H'U66GK;7Y4_]2=[WU&%:B)7&IR3 M@-HET1SX H:
M$:LV<YIPUFHHT:@MQA]3\?9E0KZ.'HT#:,7L?K<QP%H(+0O;1I$,<D>_4Y/=
MF'8^:F ;.SJ:^AMH/<QGU22O1TO<B) SAMG(;RYYW>$3U'6@I(BH,"!A\91<
M"N&6'OVPM2_L@II+U!@B;SQ"YHQ4TX[N\.2-3^6^7O$+IDLB&V 5&R=VPE>@
MB^-0(PE!HA@@8=(50B!@5\CP._5:)#/AI-U9-<"J087#/!B6V: .HQW @II;
M.[=<LN8 O%40=!&U!?!GKR,LY6>//A"G1,KJ4=B":HW.,0Z&P"&6+A>10Y>!
M(PWBT%$U#M;82"+9%@!E6NWV)<3R%0A+[A@I )86T3?'&<VH<</2W\?DOS4#
MY*\@:5YA,S^P0(#8:7FLRY6K;PWI<P^Z9281/U^^F5UL-*;.A8<@7<7[NWRR
M -G5 K/V%L:4(;N:,2AAX>4OSQ[J?S:I/1*_*P%CM[R9&<C(3F:2QGF40(";
M^SL9AL@#Z/-Y-1C]5WZ\.6E(>BV3<CRZ<,'>,.-BA.6/"5HPTB=>@I@9FD\_
M<Q>F7'/9,5E\73L,Y?61QU9?]#" G59!,_VP'+75HM)E6LH;-?YKC"Z:O_]W
M$!:053:/<"T8&[CGW+?P7O^ZR_<3%EQ$1UOXWYOE4HDYGCD CJ.($M!+#PZ/
M09F'O6S,JDJC/[V2W;:I-PGI%^T? @XU4)K&L 6?CE:5^7H2#RP0L>XX 1?,
MHO!C:E("1M'RH#JG8EA3EE#Q9X(&'N7AI;=)PTC6E5QV&7+LMW#BJ%1O%+C$
M4X$L+\1LBKZ'=M?O6O-M4FH]L&*<^\ZE%6KX0QWGLJ3EO>6+%TD^FT8:)8:,
M;7U&NCO67JD_(]'=?MCKJZ5"3H52)\7]9^6>;1?/>OQ#1/6?2L3_$" )O+MR
M6U_**EM7#XP[RMM.,)J10%5;X+^?L'X\C0IS-=!8L1'PT"GZ@Z'M[P+)\0RQ
MSKI# Z8DA>;"%'FGL[ 0[S-*UO*RP'\]AM7E"4#)"'ITA[R]J4,P#QJ3>L*=
M;JX[9-=8%V$[O](PXW;YL_='YWC/*ZN@LIDC%Z/^*[IYSJ2/6(=9C_$V1]0#
MJXIP%AUP_8GYFL$4?V!#$O3=S> 4^I#S<[?M)(^;MR];]:T8=/QU75KD^E&,
M6X:9G)>NE!,V+43S;4[LRQ^*"+ )IWU]F-[^OT%DIDUGW""ZU/+ROZWQE<3Z
M7741)"X-F- 0/]T\TEKL[H4YK7L4$*J='&J,D,CG8=E_)5B?F%\>9]=[00./
MD4C;PR,S14;\H=RG&K/Z-%:'=JS@^5/1]X?J'5Z'V8@T4,6]!L?;YSW(B3T)
MS[<T?N-6V/@,X6R\I6X>]X/Z?HGAV]*$[+YS,4VKECA4"0-1Q_.\HPFN\1RC
M8XR-+7_?" _R"A>VPL- T6%3P^L(<6\Q_SCC1FHL>O+0GI*RYTV-ABT868Y>
MVCMAJ%=2K(?#K1X\,1D\$*-]F-R,V6A!.&&YH0AU&P9OY,IM?0YTA4<=#<'F
M.?XXH[N\IS(.AI"'68CD20CXNT<4/>^ :MO&)%X(-:4EVZ3Q[EF9XYR(F_]Z
MJ"351+3C6JCA*IZ_6QX/:<@(+;9D;E9W/( JC7SWY5R+.,+/(%EV.TGV-/R5
MQ"9WSR@5_B_[/ +M\V)DG \:.W]7BXDNQ#5K%4F:$2M353[ )7:+-F44:EK<
M+'*[=AX8O,UK[C3KF6JL:+V+,W<5R>M&$Q^&)9J)Q_>(22_.QM#R+JEH<7A2
MDCG</QYU9D-$D5ELAVC+5.CO,13OY*U*@[;QU!J]C=;;;T<H,7#'4=^R?Z!W
M9\V7YL4-V(S'&Q[O<D_XZ.C@_'MJ/4M+!K\\.G%ZAP#NMC;]';?\ *ZU;:6#
M.\7Z@IWJZGK'\Q/1:-V?#I6+3#-_$(*)G(%(_NE4!G^=&K;PWH(6FJ70>&=D
M"3.;&*3LX@;(/$&8+D]F^[=A#">R]""B=./(WT-7E"QS7<G;\D?O_KT'C\0B
MQ55D!Y9T4=U8MOUIDUV4/@)9GY(.QUXEIY>GTLXKE=VBB'/*Y6[Y0Q I3'?;
MJ#S-D7_'X\J;^W<6JBDKM8L&N0^TBT>B5PXY%(DTS-^O3H4$)7)5D[6,[5W/
M0(>7PR-&S,R<MG9]I,-8-L$\+SU=73?A9=^NX4@<3Y,3CA0$EL[TA!;Z9_#M
M']11GPCD07,#G2R'%3*2\4>W8D^V%>V0[J;9=$^H*6ETF^.C">Y8IBF)?!5N
M,'.Z'LH(\MZ-+$T:+74MG$A(%C!,7F"1!]]DM"FH'2P+RN'DNUL/5)MFS 73
M+&+GC&7:&T&E4.R$L"U@0%):?"'UTX#GXZQ[C;C4%*>Q3F6$4X61A\'\K_W&
M<G$;SSBJKA?G[F>Y1_SK_PB&>=5!?)]'XC36UW5-J=,]NEH24-Q*1Q*D6KR5
M3T"[K.SOJ9[V9:)6W:\[U^<,&4.*J7>7#,2[[THE#Q_TRCIG,6<]0;>WH!V:
M=1N0%YWD[A&;+@\COEM68-?S7#Z1QRIGF,P>:L>'_YH!E".-;Q*H%?>..IS7
M392>DY?M2[1PH[W<\_=OCK^M#SUTZF7\YL'#-H;_#G<H*)D;K@8<,3S,*)U^
MQN35?(JY;R !^WYLX0[,_)&8]5AN[X^\C_R]+NQI997- H^91D>75_-G4VU8
M'YEO;%*?@@>WCW/82RI7K/GG^9'-$[L=QN47E$N=_%[+K7R"P,/^Q,;%RWRW
M_ALDDZ>?3*]%+,1O'M],V V4OPV>\3P50*%E,@TF=N&\Z3F'SCV2>:>C2[5\
M8XJ8J9?P]G.N-RS^K=28E.%ER&LJW[743:J/)3?962NGP5T2,L@^3S(8SO ]
MUGZ'F^1PDIC4N-R+U(?C2/DUXXT$LL#2G35\<:D\AKIZ70$^X3RY9%QF-%12
M3+;!R)^()4;F0KP['VN]"I_!YUFHXUX,7TK52OU_$I6-B;T,H\K*&92Q7NXX
M#;5FR(U2N ,4+E:<N;Z-5<LJ=W/P*K4$;A%NO":[TW7U-9F4(M<&G.><$'P<
M?0_D%ASX?C? N.](W,8YY9&PN#AY&'"F*6.[X[V7!GBAF349>!*SGT08LT\Q
MJ*M+8U<"!1&9S",5P"H6RR!E5%JSL#3"4$R0UAC%'Y(.K^MK[ OR+\1B:_,!
M(_T8 G*OVX-[)$.32>+BR'ID^1Y+EEU5"QDWD4$(F%K-GI?4I%(6F3:-]\8-
M+ZW[=WT;E9?>/_:N29;22&%7BQ%GT22$&^VJ[!$'[YPO5J0*.1Y=4!\LYH,;
M(5FZ.QH%97\PV''CKUV\+?UCD@8TD-.QXT$[.NLFCCEG^\ZX1X*[S#Y4B90Y
M>R_<HB:)*CN"Y#Z.OQ"M;6"7PR^-#K6$+IF-*QX^O32N3.%$XUELCB/E5%;#
MB^O@5#W-)ZE%Z?/+=C51X*5=VG+1?:<3CSQOJJ W <;;!67.L0ADUO*.O:BU
M_;;G',&D @V0'&K_Y0NK509 .1VH>DVHOLC0XFMG9UN^-'=.61U1 ^ W'9>F
MQN(+9&_4K8N$QNYK$(AN$^&YEZ4F*DL6&N0ZF6Z).:S9<VH5?D/8-J_'O4^S
M*DS"BL5PB#TM> XUB+1Y;GS] RY-- (A0Q!![+R)%<*"_+3H7J?7"W;MRP9C
M%\4TQ-JKUVWYD')%VXB?KN9I,G0G'U7IX*6S9+L0FHR&-;AO570VV;A;=U8J
M\;,1FZ,S,(L8I1AVP4*B==@?$]M#:8XJE.S]079NA[.IA]<8-X.V^FD>'^_@
M)UT]K?R#]J<#MN@(N [8\L2\/I2V\TG&=G,MV1_.2%Q$DD-E @MSD9@_.16R
M_H<R?:UYBX'Q?P52-RYXX3,:RE TPEJO,NCQ@#VL/W^.F"NL6%>"=+\W DDO
MO'"?X:F+7+^H&FMOW$32].#J!G 55]U#^T.#[VF!GW'4?@%SOG?B7*79BYG5
M6]2YA+NM:O% H(PA=V<OT46RLX05_@F93-]AB4BO_3UU^Q1<]IH<S[/-B2O?
M$S6RKFTX]GA.B>7"AQUY96EI,>>3%BUY=#'I\]G$M[,II_8PZUG@Z-6NUZON
M8>7=OA/B%2QKBVL?1R]7VW7&_9Q3P/OU\>@CQ=EM_^5N7&?]Z(^#ES?Z9E19
MB$)@R2LY^5W8IO2??GTR^\BW^_'UG-^C_WCRNNCO;M>P'/W/[X_]N2&CNO7Y
M@4T_W5JF4W?N9,^6;98]>_+X;59/6NP5:,^V'UL)[\D]-A,6JWYM@)TETJGI
MKE&1\5Z=X:H>5?G;O'7N\T]U$U_BW4]L.7QJ/>&7RP^XL>C*ZO?ST\P_/P\8
MWOU+>>[:'\O6[OJM<J+9WNGZGX#YMP<-=CM:5QR?3>S^]O#\B1UG-Q]_O?KO
MJVU'[':>KPX@QO[OV^,1S\]5W39/)A_MZ7UP=V=WZK69'>4_7?M]WZY3?Z:^
M3UGP[Y_@VH0+?Q^?*UPZ/VER,K]_X8D/;MW++N$6[!YT7-$:?;S?F;J9M/SN
M5 ;_'GRJV;QW4VGE;-M \,&50R41 $2;+"YV\U$G).JSXSUK6SK?_'>*-'SF
M"?U!TL\L"%3\D7K\KS,3\B9OWHUDO_!/1X@_L#CJ%!T.,MF6,G<VXES)Y.)]
MC#^6$F<;ALA_;]UO^NM2F_:3@EU^FZ;^D7[M3195&CA,:HQEN?]^?;VZ^-HS
MA_^VQO6_^^G !#0WRCX'&'E%CS61V9WN3C].YKPEN&DFR!KC0 \V%TO,FRRT
MF?L<C_C&H@<Y80PZ]J^N"?_&(;@L]';=;:,?"I]D-4#18GV*!\X(N2@0@]Y3
M1ED##R< H*57E*-Z*3B],1Z]$7\P QFTSZF (U&PAOL^H9,5D@VNFX+]GA..
MX4TMQ,PL'NA]BA2CA)WT+'BT%[9@43QTI9%B^RX/4P?,-64=P06,6V-$_OLN
M-1H?RQ%K,B!"2-8+7\BXEL!.D))"D9,6A1 ?@?>^3(E$%TEXA)WGW)-0<*H-
M]@2X A9LT4NP0R6B3M8LX.G7L"=+Z)F%;*.ZI D[.=-1D++H2KY6DS%U/ R!
MPMH". CLI+S3-0U(%UG\T<2LN\T\?8"I"67 %2/DQO_)8GP?N;"STTUKMSCV
MS#P4HF!:F=CSH*GPH-7+LYS[!?:^4_,L:KI8EBP[8'HZ!HI_D9KK7'SB+%X5
M?N?:HK'Z16R[7@7%8/RT$2W[MFN1B^?P%/?T?O#)NE+*=+E^YWON;.C2-?<8
MK+OE<YI"R-N4"OQET6@J4"S[6,EPN_4_H,++Z?XBMI@Y>OY+C;,WS9L]>\K)
M1NPE)+'=D/BL+E8*&OB-E9<6;/O/^ZEKI33>/9O-Z2X?MDS]X.VT+@-X:F0^
M9L)9N_D)ET7;MS6<F;&\YN/G/*GQ5/!BU4NF4.>,O>(VDCQHD+$P@RH^_>C1
MK7R1/93PDME#86?9NQMVN?MFNU[R6+ N _9K7E_G?.O;R!(6\)M641^B9,4B
MX;Z3@'>O,1V3V/S%U",@^P-3MFBQD>HCYR9=!1FG( 06:C3#@F_(ZGV)R.@Z
M9AKK1J;NP 0+GE8:6R!ZR E_-4GI5M^(SU)";JPS3@"4)GX2AE+M "XD39_7
M0='?D[W2QZ",!&3I!YVPZBUL(X83U(2MP[T"C'4 ;YNH(T2+?4XZON0B+CD8
MZ*;[+U[L88/ ">D$P1WX?QCH 'C.L^!8!'[#9T3JX/M_3:E6PO//\(VOSS]Z
M9B3 8@FOC39^,/JL<\X">:%BO\WIY 06S.^"PPKB^&A7$N@AU*G]Y$5N&:;1
M*.R&<G)82*+*P7"JT+?1T&!=Z+=J]X1)6*B#]A3<YKR^D #@0X"?_, 5+'&5
M/A<QT!#" &A[Z0'/Y_"T&.IX1;\YM8]PJEN<<8.NSX@;%V^@NGBNT^!S,9BC
MNXSTBFR<C:.=>\-8]_?M7QZLG'?3@0$5='["TD00GZ>+>"RA\C_!=V7T$!8^
MONV/,< SS1[N@6B!&?09G\5ZI8]O.LQG.3#Y< :"9XG')U"0HW2 ER#W.O!N
M+'R:+C[I3/)'[Y*>WHP$^TB(]U,D,"^&\)W&YFDHR%72PUJK]MV" CR=-N@@
MJHEY'P3EZ$Z(T_%ZH4;2"5\S8T]CH).2FB6%UGP"+Y<2;KS!EQD@QYSQ;_K
MO*;C? -A!E3$3B^*YV<*^"T^%];@RA=/9M+WW?9.!D$Q.[J_"!I=M^A]7[U5
M0JZ>!2A]^ON%2"8TR9E&0#<7?"2.*D ?7H:,6076AGV>@!24I >>@KP3=,O8
M8.,,"GQ"@JC\'=@;I@4J&$-7?L$M$3^*]>:!60V$[2&,!*3832>H'V0Y(3M"
M="OI._!K-+4./V[(PAP3)H/NM!76GB7?,BKFJ!60/1C/PJNV>74^9[8QN:;K
M"+GH4F^:5NE@G!+LE((Y?L6YQR+Q*:,B.]:2L:)(*;]B_I5QRD*"TA?*,,9O
M0EP;=S+GE=NVSS%/WW'X5L"@H(2[#O#<G8QO2QP_L7(Y'_($F+$>K:G"LPUP
M>"?$IZF5G(K2 >F2&V$08L*A.^K7O^5#2;4UGY0;<U!JHC+I=#95YV!L]DH2
M'[9DN@_PEAD7N2S/+'"]\6F)MO7B08?:[1J\R@"RZ*4?Y&^8IOOU1;BX*7WZ
M!CW%B;LK&UUS#MK?H,3.*4,>.I*>>Z^,;\._T!G-(HPYE)S*@E( ?"QKT=R
M_U<7G"OB^P8-'&,M6O+<.0=PIAJ8YZ'2!\'X,DG M R>*668H2N']SM.XS>M
M]C"%7DF.KF=VK,J>$]<GK <E#]<DB][H/5Y,9_3X:1PEZ3G>7I$_>'$E>(C.
M]N]G4\4:OYY3]#F <'#*:.RSD<IAT]4IZ,8IM@?H/08XD_GP)S&]44[@Z$?I
M)189^/Y%$CSWG/!J6WO9?##D96Q>POQYYH&8*\ZW;S.[HW*8_BC0UCAN/TV=
MPP!O]<DG(L]I/^<\.9W5VYB&^_D=8/Q)AS^:D6KV+"QKB) +X-<BU"_B#?F-
MQG.8D20Z*8-/'5BW\LF/K:.5C'GEB9SGM=\BP*V=,!W9]@*!OBJI'W6 6P/=
MAD5(2EH9CQD[1-6>"#;68:!GP\^CCLF4L.+(.%^[=9781_??YYB1+$( +SE+
M"A)ZX00T85:Y':-#\0">I<M8UVC^7%/T]V)V$D)]Y\)QT1$^BHW36)$)K*#-
MT\:UIZEU!3P"$1K%!?1]@;\J!_14,?.%#LP%:!D'Y,$: JT0NOP"_*:D?@%
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MBLUJH[I@V5HC&KG?V0@UG5.Z-KFSAX\7T0N,^$!<Y+:@K&Q3[_Y@_;Y6UP1
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MWZE$I6^;HU1HE%))HY+NZ=3E]_O^_[Q>S^MYWL_[> Z[I?Y]QF86EXV;#1P
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MF)@TM8G4MCS34Q"R@:YEV"G'9%:C,3W4<\UB+B:1Q7OPBP<YZ_ R)F5<K#(
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M*?OL#K7K.PS1%&H#Q[I?BM+]9D9L(XL(EX3MM6R,WO+LX##99XH$F?.<+@@
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MM#!C 1BQ#*UDFGFD"X[7^536;6K30$M!O3^OJ5T AL5U/54F6B:DAOD$;XE
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M<\O:H-,<C.,PQL6,?BX#[5VC,JAM4@T+:& E/)(3B'9.@4\^AU^*]6T.#0V
MDJ?@L$009KEC!'0O$V-2"?4)H<F]A6+TBEFW!$F&#^@T>=,BDBT^XPEXY L!
MF\29IDB++?0UJ[A(FX\M5,$IW?15=US727^!@Y8>7H3+2LS2NR-,IMJ[*>U>
M"\"OS\V\S%B1NW4T,*H7;9%)['ZP'EM0X"JH9TI'?2->"\&O71R<B)6JLV;W
M$<-24;6VL')[:A)F\OJ4Y6#0/W.SH@HXSPJ'HI6E:.^M<(^6V5FR*A%R7Q14
MV;E6)-'R216<3,/HA"OP.W)_[-+R$&10+?$OM+ GI%Y+3Q6=LQ_]6TI5KYO\
MDG#=3XP Q4/M-3KKZ]P X[1AH*"ITY6:!J[@J8&$O,'8!9L(K]NA<XZMEWQ,
MK2.".[&M6HEO=!A-HT:VZE3"TAR.+%">%_E =^-M$=KRLJ/;0\64;A^X?3/"
MT%@EHBT%X*BT,B/RO6;;,]/PB@LT3/1P.1%MR>B9I-G'"S4-$9NV$)F_+-)^
MRZ!!$0=^*-'[=-"?)"V>-K)U1"(F'"!PE@-#'&]*M#YY+-3(/)Y8AY6+?85&
M7].V.)U+%6_.!%;$= O@S+32K4<''Q_N!SV\[MPX%%UU9E[.1))E ";Z+I*@
MO$RWHP71W3(*RY1?X!D'[V#]E-*$G&1$??\@+.;/G3$R)7R5RG>?4X385>Z#
MJ(]H1_/'#=<NO]7]31,EQ1[M"JD7P-_$(I0[&2AE93RE0+U.VVP08WFMG:$;
M"&Z9Y(G#[G<@?OX]9LYE%Q#NVS&D%L.&&]F?U_\ANT"53S_(QWE76LXB+G;
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M:=6,36 =!ZPFN,L(6Q4<:.N$5"'';"*BX7B2@\ B4PC69UDN,OS-U9?V:*W
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MKR?YB")OV*#D#C?TM0]NMWZ7_S1/<?XUA*_8:[S^9?JCP)YI3O"P+[K\:6S
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M'6SB,5&B-<S;9CX=D6P[5;7JH11REO89%[&\U&B]T%D1CIR??A(G-X.C.!L
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MN@"< &(N^'2-=L.,(/XW8FYZP9$!?4,?Q"P#P(\"A@&1Q6Z X0-4XIPWC6W
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M=2B@(\-;1 #QS&L;=H#J )X% '!B1X0,:/EQ<(?RZJ'PXU]=>D]L&?C&!%0
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M?$[0,5B;IC&^C?DU!*(+OAMR%W;?"Q[O8VS:E:]K1@3*9'0T!P,61)N<Y&;
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M40.SD&UT]ARAD8;[Z&7VCL_\%4W/GSOU3@C.@V<V6.4L&F02QYGM<@K%4<V
M?6HF@4G^QEST#FIDDH+XN6&0<0%J-%=$-A,1&P70VR&FIAEE)(%VF6EZ&:-$
MW89TR%8EW<?(B31#NET^0EXC,3O90A8ZD3F_3&[T$LT'LI9%FAL&&77D>)>J
M+M#;>O/_C,P*D*YYM!XJ2.#J@$2J'*"*B/H1T'+'G#_J64<<U;0&]+X$G=/@
MX;;20=$.2R(?_*%CT\C%18QKS1\TF_S!WE=/VX?%K9TNK)G/-] N8"KL(_;:
MDR66N^LM[PX[47.+1.3B7?-%^2V<[$-:K6*3];XV)=-%X,ZBR/G"RI=6D*EW
M[LZ2VHR2^E#]LE#6&M.2*V3G _4EK;ZE5W>6ED"EUT,M+AXJO3E=^B>Y3*VJ
M]/8O<\DAFKJY-;ZR;":_;*:GC-!<-CA==FV@[-'.\F<9Y0/UY2^NE[_L*W]]
MJ.RI=<63^K*^EV7W?Y6_J:\8N5XQ3:YX;EWQR?J\ZJ/O^<_%Y5.AY[_N//]/
M_?FYZXQ?H>5?K,O_?5GQN.\\M+B"E%FV0);!_;)7?>6#ARHF?"OIORNT?LOP
MO#+#3O.[B\I,*%6FG"HM127;A=%U2"U'AM^"X<.Q*MN1JBW !>Y,U=*1JN6+
M+ZS@7%CYN\I^\85E(Q?64*I7<ZI=_*J7NU0CG1?<&BXX_?YO6NW=6;VTH=IW
MI#HXK#J@Y.+JL(M>G1>69%[TF;FX*;;:N>%BY.$:Q]@+(I>:S8NK8_RJ_?LO
M1I74A(E)#[Y0XCD7$W_7Q/97)W?61LS4"BAU6TIJ$F-KQ".U)_QJ]S;4ILW4
M13=4"SCU:W_7)G#JLOOQ6T6JJO(90_?(0GPSB9<#>XH::C,;ZAL:+O4W7)YI
MN$*YU,RYU.IWZ6KLI?;,2]<;+MWHO]11 KL/X!\D4&[Z-=Z);;R7V=@W<BE
M66_TPY%'/Z[!*W_J=_E9[.47F9=?-EQ^U7_Y]<SEMY2F,4[3A%_3N]BFOS*;
MIOW*'U8V?9QI^DRY\H5S96*D\>\PPVKK4O.&*__T7_ESYY7_^<'&(U=P_G*\
M30ZPZPJT2ZYV7ZZQ>0EI\Q7*![FV?[/N!TO:A_J?L<V&]YN-/E@8?*BG?V@V
M]V]AO])BOJHWV]5B<[_%[C[-ZE6]U4Q+:U_)B4.[S%HMEG](>AG96I%8<)Y<
MPKU1R7%M]53M:C.R:6-S6A\[J*U0\@IHW#41Y-IFRSVR4V\W>OS^66S^M+4D
MR"-BGCF<5.1$IZ-*:"D7MTR\8:K[ZOOQ:PEYY!@UW.HA;O)Z^J%]:HDY>]Q<
MO0_7TR0 ,:RTQ. <^02>M*)^N_0@[3#3I0&U47<@[Y&Q2V0=6:[$M&YRHMQH
MT"K+U[7,XY^DN@B FZ!V0%!@*B$*[]"^DK9BT<#6ZE8YG?XO:XT:#YI]2BM$
MB ?D1'61YUO/@(,(D2[BJS<3V>LAI1EQEJ2U',!I?B'\:0YJZMR(O$"A#X28
MR2 KIN <$XP7@2)W(E<.\9?B9'_1'DT0M,2.^0BHBJ/=HIV$EN8<[<B!5B ;
MSW$/5KB6+;[$.IT6U9Y#7*HDQB'ZAYBXXR)<$\VTZBZE4+;H+(!\7(;;((-,
M*RGG1,0$'%&TC;X'",T>),>)72YL(R<BQ&>EK.48@2,P.B[ >4[<"G8]79M+
M9I59)J$K@&Y"HFS15E-B(HW>RB7&8>D-&*$%YCDAO#U2X@^8=,%T7>,_/"?
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M7H@_2U[5O<6R2@0VI4B*[062.$LO*4S;A0]S=:>H-K4"S/'*#X)H)#3**]W
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MSD91P$(B"^Y$\H))0C'Q=SC0%V$@^" _N2,:J$CT8F&F9D'/CW7K@'3%<EW
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M#"GAR=Q^BJW+3EON--+$ M62:[<P;3%$H#J1]>@HL/%W=\)MYI96YM.4-+@
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MH7SLY6(R1W!).0-0_<?WX&KA'[9;7T*IQ8HD%LG5BO6L4/PL$VZOQSQJ,[E
M_L3;QHK2,8I#>>3O;RZ?N4VR:M\OJ;8#7;K]X6C<Q(6Q (PMI'*<CC^H3"X(
M_0C8VR=@E?<A-)\4H_3W/Y&P$WG@FADG')O/.6VU:D@IFXS89<_*$FBD6LP>
MD0K'3]9\$X(CC*HJ"XGR7_8^/?0ZOJA:)HI/2#[+GJ24]9;6ZM:1RWL"O8O4
M$GI(U8CT4QVW >?%J#3-6_+'2+?A\#OT_"F'U&,E;>71+8!25/4\D^ [9QSS
M:TC%&"AW-)XS/_SK*75C%4FEE(G5:@V&DP/O,#$ 7-Q15[A+\QUWW/^S8Y A
M3!#O/OU0JDWN[:_G-)E.-CQ@WDWMMW!W1!DD,8W+F7TA.\E UG;X+_C&',J*
M"<SQ_EPA?SKSX AF+O>R_KN%XP/:$DDGD4-A%Y0I)0_&;R;>;8DY^JA^DJ%W
MEHLLW/FNQK%MQU#W^[QS2=)? W-VC(M/\Q74U2_MN?-@L@F[<<UG]6M2^\";
M'DV;SKL!7ZKLW[YY=_5NZV?_-,KW\U,?&H4WVP/2<\\='IG/S^N<=OD:X/WG
M36LI_>)3C5*586K/[L>=/'C@LM1>U5%$$+='Z=GR<:>_,^A*KL @<*7<KT6D
M_-S^BFQZ%E,<^>>=AJSU@/OVQ<SJO[.&0?>'M+9G1X]%?R14WO?4[5H]__;O
M)_OG]Y\=>+;6\/3O9U550.@B6*F^PV@KWB@JWV-Y0K1Q1'CF;_;X6$-9X!$'
M^>%[5E3K4GE?Y2[AKG/<5UD696<-'F+BMG4:OV3D-0PS,(F%OP=+ G\^.- R
MSXO@2C_ E[HKQHP@J]S#=APMNA7\ 7QQ>X/6?,KJ0V\RS+;\\'6YUW.*]A?,
M#812F;Z/?Q7$_:<[8CLE&='_]<6Y<; 518:;G7M3Q4_\/]V/FHK3^NT=P%!L
M8MK<Y6M\=2TA;A0^/J"YZXXH9F!&(J>5E@2ZL/^^VIMOPLK'7BGI]A$)8@;6
M(JL8;VU_(J#YPD3;LJP!42?D"TW^%U>(R]8=/_HMHW#D?4F9Y"[+6RYGF5X-
MA%O&MQO1CIWYV+KEO,>CQRY@:9VK 2NOTI"&AL,1\'L62:!2C7UZ*?4BKPL]
MZ#HVB<M&QGG#33N0L5V2373Y7TKR2733W(Y0LN>Q&U<EG>88^&N2$4I8C+Q\
M;[^<(A$9^"E?Q5Z;,(EY?CQV22$6-)"'.4U;P3/3X1@=>V8;#GP+K>VJ+(^:
M1'^_EHHK<!S>4/D QTR=*\;T()VN,%MMC^G56OM]1-NP=!?LPNN)Z=1)A2Q#
M[3N9Q256J-G/Q2X(^7=V2?&3AT]Z9X_:B4OSO8]B5B5T.( .Q>#N)4"1@Z\C
M L94L-J*Q, U-*1*P00$SB%"%*G@5BK*F #3(X()RP09'#B;A7R4@[)# _I$
M(",!;HR&*!$5)^2 4RWQ504 EH".2O ET#WE..7R%(@>3?\BY(0AY\C^59 #
M [&^!QQ2A31OMMBN S 2[.IPP.,!!1L>J/^RI"ZA+)./U6,!VB"E-#10 :4I
M@$YRT/(O!H#Q M3@93-U"U20 M!*@VM3E3 4@T?)X%,VJGH$B Y!_FDR8$#4
M:*,!2FP@>-S<NPFPI@%HGN8A%I!_20GK@U:Y7Z6^&Z) 2#0FF-\1 3IBRBER
M.%B&!3RN0F*7028\21T0Q(AX^NX>,#_WH(D*\&"^/%,.8;HB@:4 )VJ5&,)J
M_GC-[BA 'PVXAD(D9B2VS4A@,_]7 @W398F'+\P7HH#S%O)M;(O6#4"/ &RC
M';V /H$E*(D^G/JY"3? L:J\[1=:5-)%@/DR*$-X"L/YGV3*TSEG%(DA.K!S
MKGN.*&4"VAPL+1.P1@,8HOP=%H"E)=4$%YQ9!J$I6@FOC6)4 %O+.DDD.&"!
M5EV::V&!U*8"BCA%&XZC7Y5<.@Y\B (_5:7+^%]X"L[>4D%<>E O$VQ-1']5
M]* G9S$W&UR5H,<+'/4YDN)-<M"#:"=+M-+Z.%)J-Z176^&ZNTHI#B01 KA>
M!ED(T>A,/:-EJQ([58]LW2HP9;P#Z)4[.]F<BLG42TJQ,Q;66G0 KCE(.$TM
MGZ69!](^BM1 -P'[+'7U/4'3Q:BM^RH(CF_EI((BQ:#?TC27M(T ;FKE %O%
MUAD4?;&2MAD5![?"]/<88'"J!T F\:OHHT*T8J;![BS0/CGE+A:<K"OGQD?_
MXV,,.'(R--M6%JB- T<N>SD>1!DN8V18#4TT"NL3&LN4#STOUPMFY>"O'N0W
M2XJ.7@K&*+(/68"\\#CXV4Q+C2J'\QVN!V?RT#C5LYRK&!VT-$GL1T<'8*A(
M.A&7PS.4)P"'#@'(#N"_#WF#8'GKS'(5"W1- 2I;%W&'!Y+L=6L%(> 4@X%)
M\TZK*P269CT1M%,>8@HVZN0DZ\O9$M<P*E;($F^- IQ9(164%P_9 U:0E@.>
MSP"+)(@#QO<.#=%T&J[<<2,O&Q(Y [*FPS_;A\MP\-D;P,F# "08K"V\@20@
M[RPS#]Q&+NR&] D<MVD#KM58!LO)?C[)"'YA73)G;"'_&!&NG5EN@P._6H\M
MG(VS(UZWH-F^"0Y)VI!_U6.>CE8P6<;4$'7UELWNH+5RJ,T9RQ?D:*X?W0@6
M'6AS4JHYJ$-^&;^0!;B((^"V/-"-XW!&$:J&2H7KJ2%0&&,VO($#RF<%TGZA
MN2MPV66@ %U, '>ZW5 Q9-U.8X->C.]0WXVR0$'64L!<$J8)!W[I .^T@IN@
M??,(\$,@\+J=:F>O7;T(,*3!\SB==RA@?CA<*AA=N6ICY>BCWL&&9UVKO8VT
MR"R#6)JCEVWJ:'([BN07=.3Y-JR#[/H<&AS.2\8LVWS<(5_(LTNVO/?21W'W
MGZ "%@@4&5+EJ%H#!C=D(MM' 0,V/'=9 DE 87$& 1WP'!Q8;??99"-Y&RJ\
M0 CHT-1QEU3R"5B1'IQ.LSY$P+)ZY!0+4,6C"G79J'RBBOC0J$8 "5.?^=_Y
MCB@+BQ8:S3K*"FPEP2JJ;A#Y**7SO;L(X#.4AR.[U7IS(.?L*FS(&AE\.2,<
M!LLQ\QE5EV7!LX7WZ2*)1"N(+:4#8G_+Q2W )+)=RC^SP+M881DH),2J:R.V
M)+WJ1!)ZF99IO +8812\'HDA5!:M&,K@X36C +I>4X=(/7)94NF&KI<QPI8
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M:X=Z"9<DBZ"%S#GD+AP0]'@WK/8(^(YR>>>U=TT2C15(27M/L/^C2T<O'5J
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M3VX,W"T=GDP?CZDPJ_QU7510K+2CP5N<?^-??%)WL6YWF<]FD9,]S7$34K^
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MJ#A$(CKHC']X]-Y_KB"9MZ\1XQT3*AV\=[Z487!RG6^RQY$&B@G/UYT"0*,
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MU7#>\9&=I^[_WOYPN_I!OD0J+R@L*I27E90JRO=6[%545>ZKW5]35U/;<."
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MOK6^G^$"=;K]'A;!Z8?N6GB@Q+1!/R/%TJPMEXQ="[#)ZK>=0"I"I_I,,.:
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MF@*!&NI2@9R'TGH1U*HG(@CXI1"VTH ,03XM!C85@)>.P!0%4:@G)FG R7/
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M$UN;J6,IZ#;\A\?X#[\98[H?9@T&W?4I.V*:CH>U($1/=U-$T-VJ(,X]88$
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M/7]IR6U908:U:04T]OM6LY0^,D^;7P0^]I&K,0L?)9CNY9K@E8,3/E??JM\
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MH@D[39MU(FK7) )?C1+R.00".L5!E?0X'9HU"M9+!-RG0& ,0C R%R>3=AG
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M)<P,<VDV0'.;P4G6!,MM@E&JB^("NR\T[JX\D9_XP8[655>J**>>  12(-%
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M^1OLJ1\P23YI&[>UOBM:.H\</W>Y1<_^\C-JL-%#ORW:XV:NLLZ!;;,\SF[
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M,)2NC%&(C4N$(>V\M^E5(BED&2;YP>C#=\YV<@KTZVX^Z&_IFX]>6&J"N"Y
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MAI6Y&;_)^7-I5)N67"N/RJUTBVM<\W( ZLYORTO_I>)$EZ_A[^=1O468F\Y
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ME/D).O-&W8Q]J);&\/;N7Q6F@AQ8G"'3&S,$U<>ZJG:0Y<^K2YT]/?*"YAG
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M_G33!2^<3S<>]QTSW_WP*4TQ2G<;ZUMG<IHW!419Z=W\N3?C>A@/YXQCXLL
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M9%89_\+8X:P*'KM6.T3*ZY7'6RHH,QE7J8JZ309.\\!Q8LL/24.@6V-K9^+
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MK-!"GG@(]]9F[PZROQE*,X,_M2+IZ+Z==D&FC>1I@PYJN-\>V[OP? WK<S!
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MY.V'KPUP77;P#GOV4<07@2WKQ+<+UT&C9I$\?H;9UVSF4D5"L@\P*QUAK07
M/)NSSDRAV(A&&R33DQS-I T ^,LHL%,(#3TSV5Z# :]UU-> P4RAVMC<#JBY
M"A3QR0'VPO(.X.X0^"DW/=6^:<X=HL$./GXS]TH35*^%/F8=913B3)-R<&#3
M9M/\B$C'X+WJ>\<EW-G)YQ/@<9(0@;S*R ^:H=I14M/\;]([_ /0R..)GNLP
MGK;#7PM0](6S=^,A[:_!2K]X?L?FD16"UZ#+;GM<VO3\GY\F>&UIH0:1+I_P
MJ;<39_]Z8N+I\7M])P]*28V=)^WNI_[JJ60=J(QM\Q+K-'?8&N><..B77<]C
MTM_XS9QZEW+ZSVVGW^=6_MUW^M]['ROB:8#7 2WJ@%=WD+9WD ]U4"]TT.]W
M./[3@? Z68LZ'1<5''B"< YU<B]TNM[OK.^@N+_H].!U>2_J<K_0*=G>Z;NH
M8,[Z+N$_72+:F4#>&=E]BL]W76'7NA9L/^._Z,QBVAG^/V=D<[H7+NH.?M$I
MW]X=M:@[X'[WHOM=,?^<2=-$)]PGKEA_-OG0V96+SJZX?W:_\6S:H;/:V+-9
ML3UK+IS];'=/]IR>W'_.YASJ2;G0D[JZ1\?KV1Q[KF![3\&<<]NO]7RY_MS6
MW><V\LZ5\'HR8WMWOB!BJWMW7.C==;_7<*AWPZ+S7]\_E[_H7.7ZLPF+_-CR
M^^>/_'/>S.MK6M37O+JO=7M?VZ&^$Q?ZVN_WG?JGKX-WH6O1A>[5%WJV7^@]
M=*'OPH7^^Q<N_7,!Y_5;%_4/K.Y_RD6 1?\'4$L#!!0    (  V%KU9]/%K9
M'70" )F! @ -    8V]M<%\P,#(V+F=I9M1WZ5^,[1OW=5VS+TTSK3.MTZI2
M&FTFPLPT[8N),%DR)2ER&XF["-=L-2TR44P+30DA3(0DS+09"9,U"E-"W&&0
M^\[RR^/Y/'_%<QPOSA?G\3E??#_'^5TBHL*9P2F_(7OD?P"  $$\"DW 8$DX
M/ F+IIB0S$W)5F;F-$LK6VNJ@XVM)=G4R=[!Q9'N[NSBZ>8^<X:'C]?,V3ZS
M_'T9@7[^P8%!\^8PY\^=-R>0R9Z_8,%\#F<A*XP3&A46'AT1&1<=$\:-3HB+
M7[R(MW3Q$O[292N6\U>O6+EXR<K8V"4IR<FI:P1IJ:D9Z](WK,_8M&%CRMI-
MPK\V9V\6;LO>FKO][QU_Y^[:L7/]AFTK5ZV#=^\!XAJ I<>!5:> Y4W VG.X
M]'.(#>?QFUL1Z]4F6RZ:;[UDEW>%MKW-_*]6MUU7Y^1?W;Y#)MH#>XNO!TBN
MYXO*%A1U!11J?0LTW+W=,0=N1AVXF5C5M_)P_^)*W>*2KHRZ;L&1.VL;[F6=
M&-C6_'!7RY-DU5V91"HO*"PJE.\M+BDLE"O*]I7O4U0<.* \>*CJD+*VIN;0
M(65!R2'5D;K*FA/U=:K&HT>;CI\X>:*I^?3I$R>:U.?.M9Q3MUZXT';Y<MOE
MMHZK5R^W76D^>Z'VV"7-C1O[K@U++S[=?_UY2YM.<T.CU+YL[QRH[38T][\^
MJAN]=.=UQZ-WE^Z/G]._Z>[JTMV\J;NIZ[]]NU=W2W_OWMU[>OV]/SWPX.&C
MP2=/'CT9''PR^/CIL^&A8</+EV\,0YWWQK5WW]Q\^$'WZ&/7T,2=H4^]#]X\
M?VGH?_KUR?"7@9??#2\-MPV?7AA&]".?'HY]'GX_^>3U]WNCQK%78^-O_]3X
M^-OQ]^_?OWGWWOCITZN/_W[Z9#1^,DY\_?[N\[^3DY-3__TW^=^/J?^F_OW^
MZ_?OWU-3__VY!OX_+*?OR/]W_B9$;4I9ORXN97WFVHTFZU,V;4J9SY@5$!@0
M& AX_]^)__MA .PT($&9!^H4LT10&!@M9:1H)= V&E1QRHFSNIA8Q)GRJFA*
M/,FYR!G$#S@OLQ+)5F4F+'>N@)8>A])G4QG[L$L+.#HOBSA1,]&S7<9(;%(T
M<#[8C">DQ=70=@5UR'3D6.EEJZ2P\=M- Z?G[SMN%F@VWE!OM9-#M/IW?+%H
MYN$%AVOTO(:+VRR_.^<M-YSE7FYWG_\^8."TH'WL!3>/(.SFNJRDH6CX8V.*
MPG<;7O1?N?#VGBJTQ"&NO?7=@Z8EIY/OM%_\YTG=Y8GQEE>Z%,'2'?IT3L"@
MU;.+,X_//;_VWX.U6B+%\X4$'S>C??T_3<Y&4_*;FYO00X'<RQ]=/#*GMS]E
MI_FFTL-V!R4^?'4SOCML.]$L<MW-^#7)L.ULY$+Y7XXA_<N[3=O_1^]9&2#C
MV&V*GWQS<]N%+2*%8SCC4)CX0YYU3^2RW"<2TA( 46KUP[)S:?[JC(@PT^D/
M JDC9$]9;;ID\C@M[C(7'*9\>NX79AHRP4/NT29JNRP@6D.78_VXWD$TE[?E
M-BD6N42NX#Z_WV6FG6II9!6."U?]-?"9=RSKA7T+-BOKTKLW-<)>S[>U.8\S
MWV9&+Z#@K2/07R,J3OXJ<G6>._X4)==XUW?1\<].V,^</Z766P2G48@YJZ;J
M3SIKB0U=%$YPO40:\$Y\Q*DD:_;J6&Y.1./)Z7>!7'/+A;]48=RP20"9L'A"
M76XUE]NBH[,G-'@&!_NY\/@>58#A?,/<^B/F\^SN]UD%\TZX4@J]SW-)# ?.
M"Z>BV/JN,PV3FF[G0N7.C>=6 J,W'3=FUTO,N_#U7>&WOC&0E(6/(CY)YJMR
MN.0]OR@]I$5-;]7-#3O*=8XAP!9%TPJI'U9D61Z\1KEZXOR$V7SAYYN\^2$I
M;IL>9MXZ=F@/[)E>/B^C_J1CX=2E4$M8,1X:]C?:9U+/M=XT.1!Y&X<UJ]V0
M]-ILP63XEUF%]);C#[1<)QEKA5'C&)?D;9-@:<99O[9T882KM(<"LI&K0M*L
M^TBK -%87DO0V.UITT3F[.[D=NR _;9EU-,QIGFVV;)%XA.)2'( ^+6;1.P9
M['(*:,F>&/O4DHHJK26,W8;;U><1EJS/Y##&-_#Y)0K9)QMU0A,[6YKUZ1'&
MW'+N1$ZWZ9N$J\=W++KS <G9P]]2XC'/SE=QXO)9II2B)7O5LQ[^BS[9)YMD
M<4WKC?NS#\W54/N=0B*;4*^MGL:X]EPVJYO\-?ED\^__3;UUK/;M^!OL-PV5
MKSKGM=[\Q>I%]"( (O>9$??+3CCI*</D,D/)RE^&3=BDP9W0?Q*77V4X\F=Q
M2ZU1<@PY:_,SW &GZ5;W)?-!?G.3N.5-P5S*ZC16F/+%>_ASVVKYB?SI9Y^[
M2+E&R0Q@-&3/@_@A**/K1V)ZC,08:E&J=O><VH@-]>"D;H==O]N7X4_J1<?X
M$9?9.5JL$[[W4Q_D+_6 R#(/+EL\Y39ZL=S]S.#B\AW&0OL<)\K<R/(X%:+U
M0U)F5"B_TR??>-[WL.^NG?W.5G$4XLX[,ZCGJ'730;=NQ>_X<D 5NU?<@"2N
M_D6??V%4NS,\"O45D!#F&<%R)'1Q+<5T[A*5V'+%=JT2^2K"=E6-52L9Y=CH
M(5SZY7Y^?)OU-PMSZAFF?:I4+5TV)<#_LS',N;%JOQ.@Q2<J.,6Y4XC5^K%%
MC!]%'JVL\^^F(&Q4EFZ6@1;\^!MI\<7I!I/WXH%Z#]Y(W9R1ACB[-Y[3=B!V
M9Q)%M!U %@!K]P9<>75LN\'QT__&%LV^D++M5T9HY):H@F:EV%2JD]6Q9O@7
M$,WI(=\*N?M]T]_6).VN)<=[EJ810C2K&%_XQW@_)D^P3$[Q2K9C'8FB2 T=
M(K_@G"^W^-:T*HEOV2\A>QDU7%0C*<=H5OJI$D4-]4@98E!+G9%.P?/(D'E:
M3@@_:<R*-06:*XV($K!KDW:<8YI64;R:'Q#5R5E&6=R0:#NK=(G6B+H&GP]:
MS:K'_&J7,1\I@VY_Z,Q)F.KQR5W?D#R;0;7R%N=94&2U[+?86'+G:UT;=HU'
M)Z;EQ[0]%W_HPN+G'.NK@SWLC/-Q;[=YXN?CK#C=LKDN+<[[_/KB&4J!MZK4
M-Y8Q5SS'%O> 4^I%7;W3E#/%;60;X;E?;$_EWHQY\:7ZLGM#DZ5U04]=:&:]
M)9R1S%C\&>$HU))EAGW8.J$\%!![4&TZG1;7GSK#?FNZQ0YY8KI;>M3XD7F,
ML\_9; 33W7(V^+>WV'2%R-NI>_:-U1M>+)QQR)]NIW7WR]XW_R0='V:1LL;>
M@>OTJ\3L6%_;@HBI,.YNNN.F(U\4,9%<CP:%Q (48]B[9=8- 60;MW?M]J.=
M]./]GH(XMD41G4.J./]DSS0V*MX":[&;5?'R>SW9S]MT>KUKQ)P$.\Z<!:L@
MTW9-<1A1F^ WC+/."3W5;-E_92E^2;]5O6WEIJVX<*<M#*X.%7R7<G EXZCI
M#I;FZXH?]Y5W Z;3=&OMQPV;KBL[LS9(S 26&S'!3/&:;4<1B6^)3C* <[KF
M;_(;4CDF>+ ^JWAK^\6)U/L] ]K=QW-213GUNM^O+I(*5+WVD\>C[O^8N=/N
M&"'!'Q-^W(MDFL,;$R3*G\0+9;[6"?6FH"ARYYN+6Y'[/XYR1^CU!M%7X,I%
MC];V1\$&L]^Y=VY&OS'(H2O^LYI5DKZG5YUO/V6?KC)J[K2FXK3HSNI!,3(Y
M)IJ.O'&/DAY^8,8X<.QBRV+2M*!OWBQP[9.>DYW-N6>,VNU[GX1I3AU?'_^U
M>NA7W/%(Z=V]G;Z"V'[RFQ290C91?G8\?WS5M1ZG:05VFU?GS,J1HHY6VP-'
M;5_3]^(6><Y+*.=-#+O<R&W?GO\BYZC%,5\()W-$@P=JR,\]N)]_+#_24'+,
M<32K63ZZ<_?^OQ=F/+$^"CSS-6NAU.]\[1:6-"]6/1Q[B=Z0D[&^YY5DY-LB
MKGW @IM/G\(M<O^AR'%V!!+1TKRV!DMK55#L1RC[BT.)XC59M)XAPHVM";QO
M;]KN7?OXMV^K\<5XQ_6WU_XG]OTU:OM[:NQ_1;\"BNU>FK_\'EWQZ%-YZ*$=
M"\*^;SRXX-_*Z<A?HL>N4_W_N7V[4K=_O&;-CR<+%[XY=^/7NY+?/XT1"[^>
MV??KQ]#OZ:E[-Z;_N_=[^N?OWP 5AI@PD@^C<V&L$L:WP3=G.']KS'^\/G3(
M.MAT"E[[MXBB% V?$ U&B*A3(KOQ&,LVT=A;D56NV!4K\J2:4YC;/:;$WFWB
M%R?$]DP)?4H4I)28426!;1(&53P7*W69DEA3I7YM$FJDU"I#&J"3.&=(HL>E
ML1ZRT%Q)C%S*]Y#.RI QE;*(0;&[3L9A%KAA9:F1LK1!28*R((-?L""W8 FU
M<&FDE,@OW)Y;F*LL7+3%/W^P</=4(4R5BYE_GI 7Y,JGY4IY<9N\=%!>-B57
M4(OV,XLJ^$4'<XN4RJ+JMJ+:P:(C_")OZ^(&9G$CO_AX;G&3LOA46W'S8/'9
MJ6(UM>0\LZ257W(IMZ1-6=+>5M(Q6')]JD1#+>W4E= 32GMS2W7*TKZVTO[!
MTKM3I7KJWOO,O0_Y>Q_G[AU4[GW6MG=X<.^+J;T&:MDHLVR,7_8FMVQ\<.\.
MY:Y_!LL^3I5U/)&.S=C-C]PGH(HG9^R;SY=^X^^+F-K]8U#TG\=,CXQ]7[&2
MN4K%;^JN'QD*Z(KX>Z1L4:X,$2PRNZ6P?JI(;I,2BA3_&Q3;1^V:;BJ?DI?C
MWY5;1NVC>>ZG1^TG9^YWR9N6X&@'9MS:C_$LMTV2.B4I'/,.!+Y3> 4?</O.
M"+QUP!.W+[*J(OI*1>S3BOCO%3Q:Y>+@RL2DRF5YE?RJRA57*E?=HG7J*P6T
M@ZFWX$H&\7@*KI5Q<,.5@S@^QE4-NI Q9Q)PE73R+#UT_#/:%2"<34#,(A.W
M,*!JP-;/"&32B.MYA]0"3*X"LYUWZ)H G2)45I)QT !$$2JSKE35%F6V:B W
M& V!A)D\2,BPKC9BK^G):P" 9 #) ."OL;&B@Y 6M%57-U(0@!%[-@7$DXD!
M^IIS*3C(B(*<T( "K16@ 0:  @!O,M%= #IJ0"V=:#:MQT B'$1&'Z8=&0U.
M5L, Q )/5Z$A,A! )K9[DD][(A"JJC(A8*4YU*H'(0WV&@M3K<&F&VJ@>ERZ
M$)U/(^8:L2T"#+0%DVI$9]["FM'!; UANT:E91&V\-!E='*- -,*8]#XNBUT
M]'9U=2 /V%9$KA:B,^"Z;7JL%B!D"W!: 6$+"PW9$&MX*LPSD$(FKF$ T 9,
M*HPYBFO($Z(E3U7NQ>0.(SI-7]^, ZH-6*(0P!C16@U$5N$$>,(E'K"+0818
MA'069*(%S8Q'7GT_+NR+4AL!:Q5@'PV9:8!HABI=@<[/Q#FI !<;XC03 -8;
MCL X@*G"O?T.H'A -IF8+00L#(")X"B)#E+TP#4&!&A H@"\IH=P!L!2A3,W
M EH5S@(&+!A ()F8 0#;O  S%J'5"* U($H-:1D(!%"%+0;,C #1@.U0@" /
MY\X J@&"N1!HP:&[;,#>]S5VY,8U=&!;%(02@"C&X<W 'Y0!" #S,R&(#$(,
MR#\:Q!M/-121[56GJEF(F71@51](,Z+<-,<Z8& S#X<AXRS)!!,* B$XNN69
MFK1RH5H#N&B 5#*1Q&AIF7NR\AF@AM$8(V"BP'Q\"B%X&'D?%C1 U893:L$T
M#J\ .XS 8# !)X"T A##0V04(8@K$("^WHH%0FR0,P1!AII9@F/9=, =(/@#
M0)ZA->@9B >(@6JUD09:*^I)9.CT>^!U'UJK.%?*N.3((%KP0%H?D'P;)-,;
M(19^.P"<.%E[4(6!>)#:<"$7Q@"\EO4"L!IHED1!.*'R&AFT@LE; *"\&L S
M(!H [(E"4P PA84(5&!H=$0F#@W2SYO.:V^<%_#Z*63'@,IX0*H0T-T"[!E'
ML8(+LP1 G%?M;1JQ@TS<NA*AI@-,.MG)".1I  L!^#H:[.*!ESS)4C5DRP)1
M]/-6//#T=-6E:ZS6H-F7A9IK6@ #:%1"!F1M!$AT8C2Y&1HY?W,C6/7C2IT7
MV9+>ZFUSSMIPG:(G.*A.!=*!_W8 =G '!*/S%%>W 4"N^@QQ)IFF!V@\T)P'
MB.GDV34@5HO.L24>%*KL5$#^=^P^@& -8U9&@WMPZ)&5[5X=G=D0 <- I))!
M)@#NX@%I:EQ%<0=14./' R[78% :\*HMT16XJ&8 #VA$:SIX$ 9<68?V:NHL
MZ:>T>@R@AFH%:)!WZ=&\U@VW09*Z^E4Q9NO,2Z_ZL)D <" 3PK*:^#.O.K$.
ME?(NM;) 4P5 [ --U%=SC*B#&F#:48"K9-S4 HW"V[@^&N:@$9NK5A94-\7@
M+VH$N, _>WX;6U*+J4ZJ"0TYNUUX+O$'B!&J'GY';]8 4J_6_UT]ZCW<=[;#
MIA4&_'BXWJM0J1>ZE0>XTW4)=D2&$*BF$?T P%P/60% T$\L7@4$,OISJR"4
M IUE!'3? 8JQ,AL  F',S=)&&N\//1$H!D +:V<JT"0C<!VXWE#5FT=&Y\S$
M)/41%EUMT++.KS>B_6*[(3W&DM'W- M*9P#L]Q!"<8]"/FT)]W5EXJJ%@ ,=
MHWRG2S=> UB86;%@.@L$C/4 @,C6@X[&(PQ#%U3>N\4X?17%0+C!_=ARS*4J
M#+</#/H)DAC=YVH?S)UO$U$+:>E@V6G<,SNB&P_(4J!-66>Z0J!_[8CK#-<M
MZ>C3-!Q& 3EI &_%P2Z>DF2 ,JN@ZZ>NRKZ#J0;0N01CKP$;WSW0*M"5?0^U
M0@Q-H]JN ,M8!!<#,%.%=-(0,C7@Y9A[ID9@)HM0J0 ?;L!8\P8R>"?=&<H.
M%N+-52C_'>2F?VPG.%H*]%IJCM7:GLS3@)%]6'L#0-,<?KWJI"/O$E:+!0QH
M* 5CJ\)HC5@7(V!FN/*41@PDGY3:@ X H54(,-0/>G<-'V83'.':%#W8"A#L
MZ-6MTYI'R6>TKBRP^3F9:4^L9%UI7VF^)MAZY#GMK[G6KU?;O(U[\7X3Y=WA
M)T,FQVKJ:^;G7]6M?OGO<_=J/6AI.^/5&=K_GI-_V[\\\=D</$NSC^D[2L$\
MW?62>-?P?'G NUT[@;LOZCX;:E)&MHE'3*Z/V+T8<9@>>74%YZ.J>GNM6JB
M/L59K^>U,-6&C&@$U68H@'X)*\)%\Q#S3N'6P*^.?GZ9I7YI+")7LEY"#NA(
MO,WK:]4IY%<12PSL,G*9YE .^71.^0MH9,PMN4?WW<)?<*]#CQW:^WKT.3E
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M1G,2Y#Z]B!,D]/%TJ9D"%Q,K6OC7VGEJT^KC,G^5Q)0L&>9<JN>-/DB4453
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M>=#/0M*?FI<#!"G:NQ%<=(FX>S?+;1@L6.=$OH6V,8@(,#Y&X[[1K,I^N@+
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MHS0B]T;6*8_PF"O)USU@>S6(\.##C3K,5,+Z,3;8J!G*9Q&0E8!*!^HA%R)
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M(0DA)!#@8<HF+$5$39@!$5DJ(F*";-$&M(BS3P88AA"& LZ B*!H@ZLX_T\
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M4.+L\SCE6\GNXT+"%1DZY M0[;=H)0XYC=!C95/-T#B8MSX@E8LQDP/1-=;
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MWJ(55N ]9YMQ$4)RGN2C0H[KST6^KB,@0L<1K$@E>LD>8J^N_-=Q_(]K59!
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MY"LAN14F#8*;KO=@SCD:=D\4LSWC 8_7.5"KIC2=9/ L7.[U+,W(R>Y?NIP
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MCX"'@KR"!NTX6!-NF/J#;D&4J/)&#12R'\HQ$&WMYKQ/,,O/A!ZYGG7V374
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MV3EA D=,'<P&*DZIZB(_""U;22WAN5@VOM67$>E19Q$HH9"]7/S"E@O7Y0H
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MN3R%'%5$"$6(#YUQM"=\I3 8RVS9 =+R!^);%FCFD-1CU+6!L'/*<TMJO:G
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M7- HO_2<KIF$?4[\+/D,[;[Y\SO*_MERA[R+5FF?6_##*C\L^-L-W:9$RD7
M5FY4E5N1YJ/XH,!Y2^/0A5TZ>:.;F:"1D;,GFB'OHY9&MG=FPAR'?) U6;)*
M!_!F#3BE%.=CJ5[56"-'P-XXO]<2X%T9'B?#I3#0:FHI]7,E<7)_M!C=&%_'
MGK3DY5@ND!VJEJ&K9/8*'>;]T6OR+-N?6SJJ5C9(P>J!!C_)O.4R($VCW-\B
M;I3C<1@C66VR/-6"+W B XCE/V>#48?JX I3Z4+E?CJ9<8 R:261.RSY_'T+
M.BN7:ZE4D6YAP/:Z%6Q2PDUE+,N/I=VW5*>,[SUI*K:^", W='"B;\/[KPNN
MJ-$'$AQ.@HNV4P>B+,J 34P2?02!31W(%:+N)B&JS:7<R %3I0U_''55%..J
M@L^/ M[SMJ&7&3U'Q+"#QQY'#X]9N3ID6Z]RESMCB?%<Q8(JN1'HV+ZGM1$T
MYZI';M)U6W$QP(&:;J_\;S7S!"!+HO4=*]E(_E])8\A%,9@7]?^?HMT]"R=W
M*T^>/)COJ)YGK(_@QXX?I)BUHY:-<F(Q9><FN7?RX('<_2]3JW"H.:\86"!1
MC1IP;P^<+;R(GKP,!,:U???O@VC3.[?#)V"NZ4EP9  5-8%$M7+BD9E !_BV
MRVG%/)]V5(" :XY>DC/BZ%PVZS/P[RMG$8#^9 >3DR\_?(VR/D,L(7JD72U0
MHX)V>5@H3$%@_NB=&I+\?S,W%W>X^K2[<@90MEA^L!9X- 7D6!VH7STK!V;Z
M5($P02 W1X%4J?+29T5+%WZU!,@: X@2J@*!28$'-E?PJ CHI$6'J7(ZMG!J
MILVV!H[=1$\AN<S3'&<):*0!6&I$V21ER&7N[^O@WWNI=)=E%@-G'G:@BRY=
MHXNUK3XN$3HX]NRU=Z[^W $@A5%*F483:Z@\(^ C.V\>5Y?V&5@4UK2U%O5&
M04117EBC\0D]2L'D]9VX-)GK@M%Y0>V=7:C<NQ@(FZ\D 3 O!_6Z6!$8AWH;
M5>1VT"=9[OYA[F\Z%6T X$[:/)^^PQH K"Z2LWP;F'7@7P[[51A,(,DY6I2!
M,4R6@!3S5DD.B)]E<"E&=*X]F&I71?D,6:I19;>2* -YW O6!>ANTC[YP'>.
M <D(//RA4B)#[S4&^F >&(J6Y^ 23\A_495[M< $(9TZ8$ON#C+R2"07LTV=
M<LMBU)972A /+5@-"C1 Q7 ?W.3)F+]XM0NHY(&_^"B):T#"#ARA43X;QK;"
M*TVY\A=NL8?_?*@J[A5@[A,"6#!IN41L&L2 EVHC)]1P_+^!Q?\H9G)49Y";
MS<LA^HV3_H%P,FJ^5*#Y&4\[+>O\APSNOPS[%N-^K:5&?%;X:RIT3RY=U3W:
M^E71>54YD?.[UWB)GT[0MN>J-PFVU,-^6DO:8-TL_6M-M\GJR,F2<BSZBACF
M XA*AOME>5UTMU[>KO(3*+<_#O)K![M>X8EU\)-4M?@SY)O,E+IP\63"_+@G
M4R!MW9? 2&.Y[:M'_WPN<_RJ]O^LJ';P,A\,9<Q7?A>%:$RY]'-3H[POT.7[
M2?!;>NU3!D*?!#1XNUR4-^YU;H836O!==FK%JR/_ /#X >IIP95;"\W/[("S
M'==,H(^J5_>T.*D7M8/!!M4,0EH@\U\J4&X<5$8;5*X/';%_JH,_*TY6-/T=
M0HH!X#_WKM8L^7X%3X(+?^_7X19HX/D&EBI']?"ZTIL!>W[YPYMQ1:)I/W4S
M],1"S:G+1WXWF25,^/9[R_PGNEU6:\JC&2F\-&9RM\NU?Z'FJVF1W(8_S6&?
M9&;P5E-_X.E%+CF%L5*E4QF'4K5:YLV%RLLHWB=.L;T5=M*F'K%>Y^OU[(2V
MY)+_LR???8CTA%2L?M(8'D W;\7 N54WYSO'2AGR)79@T<UUPL,F\S^5KR)G
MA"Z:.,W-""NM#XM0KZHT+553_Y#A?!&GR ?/3L1-'%#B_1E*UMV)./!Y)>.Y
M"GG>$9<QGZ$,S#E]"&^>>$&]XM/#E<XD\6WWBL;,$]CS\*>9:6\SU\YF2NA9
M4IL7\<Y9ZYQ?//SKN8F\/G%KZP6C:I9'"':I/3V)OW5^*/Q@R=2L'C<V4[XT
MYVA@169DUM/31M5<!3X*--^<ILZL4K_J*,]HHW>.JC83:IR9+T\;</M[[=)D
M#7]HLRL^>RB*LZ]HE?-&UR87XTH^99=(JCL&Z"$O*H[(7ORX**LBK4^HH*Y)
M"PLODM_K5KKSU8I#/PO$HY68.A)%WX^5T(QHL3,I@*D\#I>'C^UYU/[RM%"Y
MN+3\S@;JACUJQN/L$DS%FJ)P!#3Q"KG^8G/4C$;R'6Y/QJJC%-9$^>R-?102
MZ$?YXZ_BB@--YY](5A-=5KX\T70A+E/-D"L9V;6GU/58!&7:A?S9G"\$KG/E
M<^V5-%W"E0\+W3?<X@P 5)WI;(6Q).<1CL2U&MYVHV)C_A^"ZF2UVGZ,S>XH
M_XS6JL79[V0Y)1K@"J7FLDQUX]+/NQ\PYTKFG;::_&*H8<<AVO;.C6EJUPI2
MW!DFHVQ#1#Q3(8:?(>H=45:A#VMB"F(K&NFQKTK$-<#O_:]J4/ W&[44>WDC
MZ^4B::UUKM?OIY578T@\ 6WH@MJ>R1JV(9E_,%, /FI"S:&E/ZC1R7+9S1(@
M.V]1M?CVAI+&*7K*AM\PD[^Y<O\LM;+0A*.M9 JX*3+@2@UH>K0$$Y%2]"I*
M<\^(0&D]5V/.!5,0O:]VH]E'LUTA0[$^U5^*\EESU-+1SG&>VF]@5;]D5N7;
MA>-H2]Z7J;Z25B0WX\UT $<CS_\ R(=K(R>=@[Z1S%%\+ DT[?8$:D!?'9 6
M^(&][<D\3"Y[9;F>+.<R2M,&M!2&REN&$N[B7JA+J._0.X&'%^?N9TG2R(5[
MTAKE,SZ5Q\O14PC(^)IB^S>0_ K/:VQH06'-H,D\<C)UDF.F:;MWP'KSE_:L
MW'!X)\J0:+>6+>%*X%F1\FR4I54'3C>&ZL3P<((9'0-9C6CW9MSFLLU)7[ZO
ME$\:<'<II_QD!>,Y)FUC)8_KWJ,!+8/N5CM>E<18RM^M)BTE@07\[Y%$NVR)
M,E""2_WNY5\!4]T1^$N79+9D79_/,E8W;-:('L3@06V1'Y?- V S[<CQMX"I
M&W7X1Q-+;>.99GQDLJ=4#+[8^SZM6&7YGU_*)$K"9 5';5F&CQMW G29*G"4
M?C[J2(NNY,,40$DV_H78/&L&@B))$:CU0ZG2$@5WR_^/@O.,:BK[VOB]-YV$
MD(000D](""U(:(J*>A/IH 8$1$2]]%#4@ B(Z-R$CH@!!0'1"0@*5E3LZ-P
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M;ZM'9IW=I3MXNY-"'>B#6JDK\04J$N^QU&7]I;'X<#TH:=0YG67>N%T @K3
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MF"[^[/XM>J4>]9YNP]L!.-*S>^":!6U <DI=F&7W/:-<+*T:A<^& ZJYM_0
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M#4"GC0Z?]CQ\\.'A,Q.'VQ(S6V:].Y=QI.DVY#8@$],&SP_VB0?4\T>A"_3
MB[=EO7U0[T%7\4#FA89WEP:/]$X<N?#$U>VIZR5(?*'9]?)M]>7#KIB16/SZ
MW96+SR_;'NV5B?M>'IG__=T%Z.A%(_'%YLQ+ME.77*8N?W]WI>;=;S'BJ_3
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MGHN6+C ;*VD6UW3ZI$QB8[$:7]?V#Z7=)W(RU_!NL?)TB]/6LBD$PT7GU$:
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M]@EL<^%"X\JX(7FLK9K6/HO_YX,BPIJT_Y4\E4()WK?E-,F*B&5ECM:\^8D
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M3(<!/75'(N!Y["55P+GKQ:K\A4P4C44?I.Z8J;/5>@>H"\%C/-R*6)U[=TU
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M=@J=E'&((_R&(T@>!?6*="'.6=1V3HX+[./W1:8?]-0MSKM9/(7,)E,H@]J
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M@=A'I2R-GF6&UCX/N5%=I5)0Q9^+Q,FTO,#WS\97.#QC_MOK$FW\YOH7-,)
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M@B1#Z0.DU#G[/Z;A]=@/[3 %]4VHI]XDQ$-\_.(/HI!R$6Y@;Z-5W4"S3LG
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M..#PX9SC1D;S[1#"9&HSR_C\CPFRMVSU!VAU$FRENJTD.?D<$G3$2\0TOTG
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M/MJL2>67ZVC*A(XTDI8O7CQXL8Z<H)-$-41Q<@7/ZNP"T!CWOREY+TUM)Z8
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ME C3"M6 FP\MJ:Q7@JE3#Z*=:Q(2FMT9<Q@OJJR'\66+[6;06T0#8PEOK8B
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M5=?/S^!C/]J2:6P^#T7BD2L!3Y&R[$7Z2A,VWK# -449T?&0G#I-")NSWA+
M54,"DT2B"%AIXXDJ7*6^0D==Z<JK@LI[(8H!'^^@ O;!1%0XG@6YBP#+2Y09
M]=7EH)<(#T& _]98:(K0"%L5ZL"O%JAETX"-<I$AF\+2NT3_N]Q61RBX1]YY
MC[!E*A?-1$6]75^T![S"P1'4J$R5_ZP<>M78',=4XFDI[FFG34>3X]&NI;=R
MP7R$C 70BTL=5T-SU6H XN''T6<V4\%<>.X&$=% 69C*0YT3@F*$P!':NR.
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M(K51KN$.WD;J YDH);I53@XI.4J@#(H]QU^HB&=G]5EC^N<VG<1W6[L-O7P
M'C9=?1%73GV Z@CMEAK\G+*_@R\QL\1O"U^32?#$8Z,((7T&KH26+?N9&AWH
MZNFUJL_[<(U\C\S^67R>+KH.56XY#R)EH*[SDXUJG]<G:H8UI*'()J+FG5M@
M?+>KYJ)8>J+<8W&JT]36*8E5/-X;?Y V)-/((*[=V2#-DLD?AK6IIZ@CY)+=
M.)&D&#5S.VO*I8G$:0E&W39K_H=-GN!.TIJ\B7P*4RH9UXB<:9TE][IJ^VV[
M=6V5C0/1G V'O1/B^?T4/>&D.6Y&!C'\OY)+S%Y+6_K!5@9'UB'ZJ$(&9/"G
M?]BA'%X6AE&?9D,YTC?)7CS":EI*T8DZV965.7 7'2\=MKO6*M_".RERU:_N
ME#%6.,K/[>U@.T6&B%MJ_!.HDL:PZ;QW 7OO)-B<P*LZ4MT3%G)E+MYV:GL&
M%V?1LK3CBI^6$AX/08S3O/F3Y%/RU,G*Q](6_?P5<U?D7J]TG'RI\M>/88YZ
M9_6_89MF'^(9,U&M]I=)T>02V2?';S><LTZ<_3J3D'VF^*:<9BVQ1WEQ<C6'
MY[%%=M6DF2>3%82/;5X=_AQU?PWE+1DMF6?-Y-LR>TB2XM A$6QN&MUF9X@3
M$QS0WH';8(/0! 9L%JIW'I<)&*6JVE"6ZB7-*(T0(O7DT%[""T=R>-3P^=1
M!K&O*;V$O/<=NS:$4SA1 S##^-(M3H)JV:@ &J=QV3I,B+=U+A\X/9^J*3;2
MTOL/&V4'E(<S7<4:.>'QJDFIF?>6]#NA =SR%BI">#WGOX*SAV$@CC!>PV7I
M!@RQTV-. Z?*T]N*"6.*51A2"?%H,6E"9$?!!;Q 7D$A"F\G(T>!;87',WVQ
MU)3A.R,#7S-2V08A7+$-(V+ Y),KWG,5SRLR<8W D#BMBUE+-R'<J"6,*-*+
M'R_71K=3'DME9T5:AFJ<.3]GH(HP)2@S(\\7EU85O-GT4[(]EZNG^34=&Y1
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M46F7]S=CWV]!$?,3WZ=7-7*=.I43(B&P<CMP>\'J#1^?ABG4TVOKS!C@?'T
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M'"V,-?ZW/@XZO@HG:WXEW#V]<]'_9F;^AV:H8/17?'B@)@<(Q<\.UHV29E5
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M^\AN2+C".4:6HI&"6_+EZ))4XUEO:#%&4Q48)+B<)!KD]4ZB4:Q#Q_[SUR]
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MWKB?+,U GCE>[;EJKX_-%,?M-X.JDW(%-<.KI4R_(-S2B]O7GMU6Y*:/+ B
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M.X#^AD'PJ)XBFF6CO3=D9P'--AO0>QK-LP0>4\!IK6"- 4'#6EJ6EC(-./?
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MAR8%.@&A:0$*4R@=DWZ.1"B3;.PCE/&Y_?W3!OHZ@5NI)R,@9G/ $D\Q$!^
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MT;JF2+/-9MLP:OE +&<@T.;6MMH^"BRCV,!,1I%YH%8(LP?:EBT+JUJVZ'&
M[8B#@4W.T*)B#9ZP'2;  &G>&.EA;)P@296-YKF0109''YI1E("6";A&]-)%
M/'* -G2?3,=A2Y&+D-@P[W%0@LC \JO'J#@4_&NC!,1<7QA;RT4G:!E($LH;
M9%1^(L\R@\B)]6B7XRC1&,U3@+K3=JB+7>R=G<+O*NI"[$R_^/DCV/<.F%0
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MAF%N4M4FDAN RW\!3*;]3"-!N0RB!S&W"['E0M0580B4A*IN=#VCPV,$5IX
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M"K+= V))Y] %I.U:7U.8L+_-+C_$:JM<<<2"19O:U%)(SQXB[6RSV,EN0M/
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M0\#)2Z Q%56_ T2W=E5/81IUJ.@=O2[L$)00[*GS;YLZ]]3JH8Z*NA!W1E!
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M:@#TX(#.&E/EM.L9D*1DD4V0)7^\XQY^[S52CKH0SBC.QK*24<E2'$/OM4:
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MF+@LQ&#%I%J4',N'(]#DG9Q^8H]F6:$JD/E\=OZZX,1M]>%>MR@?;7I%;M&
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MYJX$3_TTY%%:,%$M0'M5B76CKY?R"8UJ+5?-JPNU"O.0F1%N)O8A0)[UTW^
M0AZ$'X<6]+DLW?T\:0 P[D.NK RZ?[>"-1SEUP!T-B#DCJ((Z6-BWZI$]?VC
M=K*;UHN?UJTR5LX]&"<SCIL%O0WFHA;$N VYF052ACM+F6!81P*SQF6!NC75
M94V-?YCW ++F:\-1L$I#SK_>,R\]OG_*/]CO([#+-<B]ZVQLM)#%!BD\L)P'
M$LOQ#3ZNMGF'+/"0Q._FGR39YQ-+<O9XY,'/3?6'35L@XW1'JF]WKO15;@Y$
M,KR<.9J;>16)BT@J$"M(;- # 9DMN16[<LM.RD@SR+N/G:;*OKAXD,24;<K$
MKQ++;FX#"Y6*%PY*?_YSDL2_TQ/\:SV(%.$9;4C#127K.;+BY(%5>W)%'D^,
MK>G"OI@FG[E,,3X^#J1WA-J\1NQM>-5)A[\:Y7MI$(I*1C7PCLTZC'VC+F]S
M(M@&C96/FSZ=L/W,->%-D*)R*,>G[)R*\,M0!^M51/B$\1/]R/?6,0]A4=0B
MXT=XPDLIZ\14E+9C;$DO\36!A-?A%[?D%8^KKZGPL,9LV<;4DI8[W?K<NZ\)
M<5-1<YQ5:F51\533]^<:I9-+D_^#KKC4,G7IY8RB0F5>%5#4C.1%WR#-WTF@
MEJ=1@PYD/2$=SP"7B(H6AZ>53!4%'5R++J2(F-H'\-W?MI(3G806[5V=4W_L
MM"F9SE"N8(P_TT"Q?N-^)V[E;1\O<"_<O(^<"*_M8H]WJDMK'W/V)U)*10]*
MM49*WXQ7.25E^>,5HHG*V(FJ](G9@]LG#E&*H[1T_?FC,_LM4#L)<PN-_M2$
M_\&D_(I9*^J[ D!1MP_OD2%CMLAR:0G:/L6NRM).7B:=)?.8'N]4';;@ELQS
M$MK^0"T9^W5GBWH,J=W*0LXSHZVQ^%[GPN)9956&T0R^. "N/JI1P0+HAX#U
MM"RC5J^NG7F3WW?XX!:\'XU\.7_B\R]\F+)NSBIA*[(J0?:+J7Y-WOEM>")^
MLDU),.E;E2>8? ;<3)+*[GTBX,;?E><HYFE!M/*LE_I]/E7A_;C^_GF%Y@5R
M\BVA^H><-H[<<"_\'$0<\2W9GTQ6P"7>^K7/F>>*Q2O:>C-\RL0%.;D3;K,$
MGG2>AE7SJU-DB(^NLB#[=90M7$#E,9-*X,<]C(Q$ _ GW[S:R3Z1K1;SS*SB
M-K96(]XSUAM9^*1A^N:40F\G7K$RSSNC=HU<]GXD[^I(;J$3,4[B'P"P\M@6
M1JW%M1[5[JS5<B5T+?LH52IS8^$7347%M=2N%$"G7SV,8!XQDF\LB M^ZJ>X
MDHU?P%;\-X3VRD#[.H'_VBG#54IW9U94&^;PX$%#YM&0S=<+AG.],JQ_EBF<
M-X=LK"-$X0L/C^>YG8 :^I;D29FMK=83FXV=.-6!A9:^S#(QC#1)'EO,AXJ=
MB"(--U$ W:G#E#/SYTMM\_ 6IPELF]D%4%.P,@F&KMPZ/'-O3<O/MK__:?AO
M]FC+RO0X@8(<?H\U7IFH_^IRF^#E9#L9;MPTCH_\I;"&9Y0E+O'J7%L/VT18
MX26S:6!;3("$.*W )@E*LB,LXD.G9T\5U%$/RO*P_WVK5=7S&4Y3GVJ/L92'
MF;:=*E:3"=3U5[F1BVUBY('T>L 3R6.<M2K 6Q0S"R.HET+NV/\OFGVPI?:>
M!O.GZ>:"/B1,.=VA9_X81M?H+0ZS4O]Z6QHQ _@J2Q!_9KER"28%77]T8UZ+
M#(>7!3!/6&AE$?^<TA>AXU6-?9YFGY>7&1ORYBL1CX\8ZFTP;:^2QW]>N$5&
M;9D[V_RL46S4O"4SB(0_6W9B[IREAN57%'N'!F$M[X_=#KY:=/BSTZQG+<P.
M"T_^C#P_;XN/1SA+1F72[M,=N+1<?-]OPFI,R5XTD9I/9\I:_@LDJ65FDA]\
MP/W/MYAW43*+%F2[W<_PP9P:HNSG*')4GV".@,3ALI\#EY\U5.[G.?K%%5ZU
M:"W\PS1KW3E8TIF\&;FG<F:R7<*W$^'U2OKX!>*X.4M5F>FI_KW+6]U^*/>_
M<LO_R?&J$N)PR;PVQ&(&.17QPU0I>[&YR@BO.!=1S)(BM RTW2V9A7K-C<M(
M8R-BIG3-BFG15E=YY_P*@L_?^@!SS0DW#]<[EV9;S]@>#00@:Z*,UH&\[ =&
MC@'$'RCO&*YH/ _/ \TU "-#=NN3T@O_)Q58A1-WJM_DS;8>SVVFU_5$YJEE
MU.&.&4#)<I-C4J*Y<7CS"*NQ$Y5">0GLXZDD"+G,!KPN,E6=Q)$WPWQ7%<&#
MJV81W1)">";D$B7,O8_>+2DL45#VIG:PQ>EH'7PA4*VFV2UN,[5Q;0PWX0P7
MX1R]^^L014\17&4O'4L;+1Z@I;IV$BQ<N_$L6_XWHB@YETG:^BF.G?/6>3\E
MPK?2X\/W>0:M'&?BOGZ&-]I39'PS">DNR3.U-)XFBMX&\YAS@PQE97-*B6'[
MYN;.#G +X(*'Y(ST^T6>P3Q2#KX9J*AL=L1>D/]VY^NAR-R5NC$M!;LHI5BF
MNQ,;!#O'S<-5_7ADY/M!R+-PQ-^9>":/Y"7288]64K&\S5BLN/A_%)UY6U/7
M]_;/.9E)"$F D$" DX%Y"J,@J"<Q0$30@$@!$<,@@Z("(N+8),RC85)$M %!
M45&#HE)%>Q) 45$#HL76VH X5*T%I6IM?WP?GQ>PKFNO8=_K<_^SMXP1J7*,
M8OR2W^+A+NPA-);\(OBB"Q#U*<H9,G:GR$ 48!_JE+YM KPH*V2C*M]^_@7*
M[UN;>K-0]S0Z27A9 K=&RE?(XH1\_/8-1*!5IUSGB?NHY QP<EL3KN]-46(M
MM?0:OEGLS;O$@;8Q4'0PT'"7(L6;$W!;3;^4YHO&&E20D#9QD.V->RAM\@$L
M:Z ;AY6'<34S831^1Q!:D5?0]HC@?I4N4=HNZ(1JKCNU?X<A_S-N+>BNFZQ_
ME;#S]3]IHL0;)>FX??!K!LGYZR-(DPD,@_&Z6'C$5KB)X="L*S*TD^\\\18)
M-P2Z%!^DCF:487>^%%6K=\;%5&*N3=&['"UI0V$.6-WG9]NQ40H+KUSIQ!JA
MY]ZQ:JAT5<=K&Y/$QX_YT85OXR1D.^>P=?43N\.P3[_N*E/Y7K>ZG=!Q>!V;
ML.ORVN++A5IU$P%[&)QPC_[  )VPZW/?@E5;9V)8V"[O$[WW3WR1>M'PC64J
MAL6OH-TZ^OQ*;*EG@,]MAR-[?>Z4SO&2BBCHM'[%EK42FNT!(0]C9V\49<FN
MQR*I'+<EZLR%D>ZS/X\0+H>HV\CL]%#5<* $%0T:Z 4;3C'6 ABR9XCFMB,S
M7@ZU[4*+[$DY+=X@1;Q9?/P1]BS ]#*W<!.Y;Y,R=29N>1K]GG\W*LH='Y$"
MJC&ST]'?K6MM74NB1)EAQ[5([QYFF_H*JDQW&,F"K ]J-S%)MIVM$.Y:BL6+
MJAQYG*BL5T<ZBKV]J:.>A"F#"1Z7ILO#P#KY0*J,WS_!?.<3S[E;Q)9-BHDM
MAQTH[@?297'KW'+4;TRL;RN*\SIQ@S?76,VX+,?:CHS<G/!]EZ'DY\GC#E/H
M*[2_NC-F8TBX>DN;)@_GV66!@E?@+E;+FP!Y>3*QF+[ UY1B8EZHR%DNV)XY
M,B%,W49';V("/\BKBE+*>H@"%@>-QF68'R/.0A2#7K1:H"4U%53\_X_+,7Z8
M8N((E_'(Y4!<#,'6IT^.HQ%7_*E*+2>FH[C2T\K\I%RU5^261!TRV"*/QECE
MTJ31UCIE:GJ;1YW&,Y4E77>SN*QP3 +--IAN>@>04W!=F$ER!"D^#8]+$7]?
MFZO(2!(J?5']3ANE3, [!-[&#D.]*QOC+'X\:J$6A>@0JY^3 /#WSI[&8_\)
MG*,?$^NOGV1DJNUB]:6:>-2("-!HX=YH9:H.<1J0@C%UE^I7#2L]S.0E#NY@
MM?BPPO'R JW*=K&!>W%OR@8>5^GHVOX-TCI\#@B+(5<Z:3%/0%W/"W6(U54F
M%P&A XJ')O 0&63.4#S4YMA96F3\D)AEH?B9G03C9TWQWPVG8M^JN&5_/G4R
MHRHP[M/:*^DI8X$!D@;1[P YR'D$RW1S=(=I31&H'NMG*!%F2FD'_B$[6[38
M"FI#>2N-5%/LD_5_Q2Z*&?RS@;I*+_6*,9SZG"7&'W45>(PP[J7@'4R9%RD9
MOUQ@J/4\@;"?Z.%,8YS$/H=V9I'=W\A!#U*QU:YXT7H? S$8K8 ]4*7P9EK;
M7.Q->HH<N:#GK_VT5V-V72@Z-O&&67U]"C-0M*#@NWO?$]?#-?MOH^R7"<YF
M/;?J=,Z@38S&V=E3FLI&Z>=VT_$O<N@)SF,'3>VYRW5;4UD()<R^9"UI<;X&
M=X"&)ZA;>I+[NLR$!F=3O66Q=6P9L_ +(+/+:"-4<%NT>9(F*=I*UTZ='WZ$
MS1DQMEH,I]9NS4[K]11>\^M74 CT)MP5K)/Y_(N+.E9S7)US_%J#GF&1=3=L
M7$;"2YNH)BJO_]ZG5X8'&DV/:#&R=W+5HO1ABJU1XB#UOB_SZ==1]\]:U6W$
MOYO_PV^78K/L?F[#TYME$D,E<LP'./84?K$9FU>"N0^44^!3V"E]5V2&L&;#
MGR]-=]2G+<AN&-JE(<:@?4 $\;2C,B2G \C/+[GK-Y96$_+"U'*RENR(Q23.
M\Z!__\#@Q+F1ELXG<1MW 0-98R"Y9(B:]_==]T\2&KF_Q!R^;)U.*V&;E)['
M9G0I5HXBX>;R#"S 4VZ1IG+PDFFJ.')Y<XFH_A+/ ;K8"+3]PBNF&0YB,=&Z
M0KL\(!C1^F2<0DT*/Q+QDZ+LBW0LIDA93AR=I?0T*!,W&LZS:[+QX1NQD-&B
MVF3RA$>A[ SG\D-5Q3S5W&KY^(J_9,K+)5/*E2^WY;Q#R<0)+JM>73=NTASM
M74Z'<J\^$$[_X7)HDQC<M5LQ\M6H\$/;H=5L4+,0"3N9[55:#<:;B?3&3B^.
M /-V"DEXC8",OE)\PH_'?O+1VER2#ODWK;_ ZG,XU'<,S[2'S=YJ<_X\_[?X
M7E'NJJB&T&H22F*::$=QNW65!'4[@SYIVG0N"TR$#\,;T%5\/P;$WJ<PU2*
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M0T.$D-_8Z6LLKV[&JD';>.31?UVD$8!?HDB?//]T"!$&HH1.$4LNC<H%;"I
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M\M0KP2R*V>_B4F@&K5AXWB#!<R>Q'L\4BN81(Z8-F06!0-HWHX?*98#'.Q0
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MRR@KL;BR%2_58,5GLP*FR7$=^,@Q7)S&V5WE%#E7^^$F-@;>*QC$1J*X +
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MB[674B@+.:+]QX5P?15NKW'L?)GY[N_4(F7:XJWIS@^8=T]+W"/8+MR7M;@
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M%_T=KA%#K&,N>/EH'WU[%[OE_.R"&_\7>V62X_3WY*E#=\;AA'-L"7LL/U.
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M#V]$&MO, 74ZG=D5.%,.U;0EP\O36\/WA]6='7$P8KRO]RB!B(-9$A.\X],
M$L1>"T %Q[O/I%B2+[F57[9L2+GY(<-R 'KC"2SO ]1Q+X.= ;-OA1+VXGXV
M0\DST'QG1;?VX LKO7DECPEL_,6#QGEE"FG(J._%$-RPLAMOY'>#TD+GI^=
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MK"0'VHF 3X04V;C/(_DZ!WHDY?996_YR\S!C0'+-9T==BL"&+S@IX&)<)@>
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MYUV_3M\'G8$XGE[(R<B?ML:6]H'Z]@]73H;NM ].GXR>TJ7]T&G4//EP_63
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MQXJ*_.\Z<&%)69C]K$Q?F-I+RX/H,VEF/L57;5AE;'].FN,IG')(E!3QZ#<
MN!/Y+8EC*5'PS!H8@(/L C&7^I Z9/ Y'+(ZG;<$!UVD/0W!C/L"ZJXT&+L"
M3(;\V)+,S3BBWY>ER%),>!#Z,,(AJSE.W0$'QE+A5>GP^0]QCB!N9R)8B>[
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M=\].AE[I#+54C<S-CRP)OY]K?^>2-+1)&%FM>K<M_&%U_OW/^0__YC_<;/\
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M*9FJHV4YQ$,+H8?;3]"8E#PJV%5_RZ*Q9!(?*BLE(G%[;1"R:5&#-&=;!:K
M)3VS$38+C:#2 !B*'F<(R.#T;<L,IZU1LLW-?3E"O:^QW8^/RS. '\;!/*]M
M:XJ.=GV  OS 7]&0I]<V6PTA7Z#;'M^P$P'?*R&.7AL2.\B<3RIQ(NQ'"41"
MJX,&'\L!"@6#CBJ0:2"MXK>>-1+I*"CB U-4Y$+@D3_SX=&X1QB7HQU326U7
MA:=^VCKQ<1]RH)@U4);J>I6!L$-%+$R%K4W4O/^H#0DJEDD Y0R27?B0C$YQ
MTO3A,L")OP"WE50!^@ 'D@GZW>M4 U8FPO-%Q K.^;-I%[Z4X"MVXP:=*3X
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M@E=)EZ5[877.J73PYU+,2\>$537,-+F448>VU/LHQ]QEG;9$)'SDE-0Q<FH
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MPU4T5J@Z?S,,V;T%%,T(?=]>4 =#*9,II-X)T'<2N->Y3$- 7A:>_?WR,=M
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ML>**'O55N% "3K)GG<R!TS*L;48FRKHT O>2NL#\"KPV'W%IQ!!'] C^RXH
ME(@"F(>I:4Z4);DA(R@D:G^9-@!@S0 Q0^U@VB4P%  YPA(F@.8A('SP<'G
MQ@Z K(?XM_EAS! 0Z(<%5-;;NS6+XX4@<@>:5O5M=/(;[W0*%!,8;F]0 7[
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M73H>[44/*@ /\:-Y$<9MNLA/,JBU<[&J[,Z3 S)4E*QH][I''F^K F?^SMU
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M?>SHD;;F8\>.__7DV/%3 ]K'3YP9BSY^\OQD\_'N2V0F!7#['U!+ P04
M"  -A:]6PK#)6S4+  #A"P  #0   &-O;7!?,# R."YG:6;%E.E7$_<"AG^S
M9#() 28;@@28L$A A+ (004G"QA0$0$E6K4#@J1J-75%I782 L1")8(+B)6
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ML\J863Z[B=!Y()%R94:3I+>09P9@YG\!4$L#!!0    (  V%KU8K%D5NZE$
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M1[.B,4"V !HH-1*K77VBZW.3%ECP 4X36W 1B"ZN=1!G"_3 :6@R6TMQO)Q
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MECH%#9'!Y@LV'"FV]VB%BFI3'.9[[=!0WQZ%73&)WZ:%;EG6+L"+7A62ME<
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MZP9<K?)(!;*#:F+UL<XP=(I72"U*U8/N8RL/4R(R!0F*<>.=!Q)L*JED5F@
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MRC/GO27<-21,DUFY\]Q"2Z',C5[6=(@FD#N-V>LT*@T0)\HM94I:-&+#5'#
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M$D-W8WJW_BR$QI-;B2%KM2*P&EPJ7D=C*@/YIQ6X_'M')H5?0^?5[>Z#:VI
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MJ@RO\1'Q$G!'I@)-_</K[:)J^Y"/04:HG"K%YUR74U-PFCK(K,]N[@?M_8
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M1SRB4!Y=>;M]T/5D;P[9TQ KFV/25;58G[PUY>T.D/W@'(%*6FL:"QD^';U
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M++WF#" BC"K!( <,MB 1Q4";V%Y\@I=6TH^>&IBW=.'>F<1O$8G+:J/[OM.
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M];XH>5^4.W'.<)*XY6XK>XO T6*N"<29$(;25"'L=ZW4H>;!F+F?%"R+Z$C
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M3B<&J]LE&='<7=YRR#$&4<,$2R&/"!8(7_%URG .;AK-H*DJ(9FPDP+:2WA
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MKARD0F()RTL,PMAV0/P;0.'>;98;[$K+0D'X#X3(,\<(Q1@,GM:[S-BB*%T
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MDBK0NS,70-@EI(J<PKR2)[J6/[+]ZA/:%]^+Q33R!K'EQ\/7'!\1,\ DEAR
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M/G+"=#'!FS; LQGP$1."_ <"XP9"=@[,V$J8IB!,QP=XSU_/]'P3]'E@CLU
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MI&>+%CD^M#P^>=^"WX&,?D,M.;!.AH1+^0QC#=DG6J&77(O9.%7AADU<A*%
MR'O$^;J-O7!*-6[X02DQ%MI3*+6PJ;D\5\OBP?.9"*FZ!A@V21"K_D%"O3"'
M[+T]T8G&M8Z62T*\7T(I]EQBDT9&*O<B"('LWQ0!H8T:^4B9TN2TW+!* :J^
MIK9"M8H<4I/.(?14EU&";SZ)5OTO+'P&JY[L@3'W+)CGY- \?4D@-GE_>KEH
MB2=?=694LFR-U;-I@8.W[6_T;/5FKY0:,8*>4)8N77UB%M58+M%)V#/;M^D1
M9?6Y.(T0-[3Z<<R^KT\R5:@BT'S:":RS""00K#Z?T6Z#7X"T%:%,@[+^P%),
M*5MV'['/S,<M7220!VWI3!LEQ=&UGNPFPNE%:MX>C#.[)DNQHPR34@Q?XC,8
MKR*VF;OR(Q2R$"_,(&X^9E/$**&"*,0O)7"344G^I=:+FT>/3%CPD+?WSVK7
MO"U3%QV[LV=6\NG=:GA^R9/"_&QS=KE7VH:QHK[F&>25U-8Y/ F+]/*PG@PC
MLH70QJUSR3H#+*)I/GYIJCJ7Q7E/WT7+-RKG4XQBD1ML#68X5<3 /U?U6= *
MDD,Y3 _AJJDL7%JRLL$V7Z0TF%6+Z42(#0^@KF([\:YD/BV/7*=!7*.Y=@=%
M<+Y"2<D48SI"N=1$.P[1!*6=ET/%RSW3 &M&0X/.2,7*D,?"0-$G.UO/A..7
M*@SR;8><_O3G)H)-X67HSK3V[WO#GOR)U]\\@YIZ->J (E_3G5D;F$:J)NNR
MJJD-O:T$^R<D=W.9K[Y"9CB?N:*B-I4253W%F)W*"."TOZ8)!G$M@*:X/-+9
M5@[X_N*<%;^Y.IZS$>M I6U-N,4@.QWIM3-T=*X ]JZB5@<;X9AG>*N!343[
M6IYRV03S,$)R5.Q5DT[F5M][N:;(R;=7IW+'3ADD)[LU5E'T3NBWH'<-0[).
MFL?Z!H['T_ ?@0Z_OD).Q @#6JC4B*DA"OQ$S V<:!)63Z2C6I00?G&!B:LZ
M>%4@@MPXH6<6\1'1R6+2:>4/;9AJ&ME+1=$QG]J[XM5)@X$3T))7@.^B*-63
M*ZCFY3])+5.":7Y*RDPQSF#W2F^6*ID>.?F4J^U_7.6BV9N%S?8VG#.F&%,_
M6:@TJL4DM=V+7RPZY8M,3K,3K%Z]7_NB;.8OQH"/Q>Q71PGN]-QEWM]_FN?/
MO$QN/W#=2C%5?;4&R%AB26 IXEFN%YQ?&I(O%>_;X:79[9P(38=WGJA&IO43
M:H9ALWXIOUQ:^Q'SK-WA%RUAUQ*\0ZD>(HD+<__4P?RIY7NE<W:%X%(3L=G?
M4+.:Q&R_T%:K;-2C4_5(K278U"#>ZFR7.EZ82.:AT-/WRV>+"9I^B:G2_O<R
M.U+JL?'#5>?[LZU:[>Z\K'I1XB0YG+UVDCUALK7*K7[0SOFCS^4YENTWV?R[
M<FQ*5'M0 K].%'A:W&9QHH+1?>8<Y<!,54WSC^U$OEL 'VMUJ+\AQE#&CD#6
M=4%#@Y+"J#EK,J:QKW[O.#F,.K'PDD#(". 53I)28Q@,S_W[FQ9=G[ZF_1%T
MZ)3R6JBLPGO@4GBU>9AADUY7Q55%=L,'UODP9:Z5'XEEK4_EW^($/?@9/ ?1
MBV+<6.?5L?[6]5.)SJ'\X&=<9/F07='/AELNWO46C<Q1?I)[T:3!MBQ$MTUK
MU(&GF11NGY VX)#-#WWL?6/C@'7!<>/T.KZVQ>Z2N7+V6(C]J_9?)8=2C#MW
M>CGOZ[(A35?$&=Z0>0E,'T_+30L)L["RMC_P@MYXY<>91MAN1]2!-_3Z5&F)
M>*R3N&A':8TU#[7,IW77>,N<8BE?[1VFL5L"5N^0+RK@LEO=UW6?D%%K_03K
M^Z@;HP2=JYSW/+U4H(O]W=5&>Z0H&N*_/=[5.!Y8W"PY*)MI<=;--!.A=0(=
M;XDB76:H!#IBT_Q^B8X:URO?RZ=!5#?HNB ;<$P)*A.TZ:Q"")UQDROJ8:=(
MF4XB5]75'14;>NY'^*G"]C,)V[TK.N\R#FHSQ_?K4>AJB_HUR/7M=;;\R=E6
M[*JF]EF]S) G!4C(X*P0<P<ZVU^@ #:!DE>'$1UF(5N,?_66_,ML.AXAJ,5O
M,.2&WI#^,'V1 /$1'O;(1'S8+3$O#<=J"2Y/FSUTJ1M\44$H4E<CX^43*DH0
MGT1>C 3QZ?1VQ.LJRI$*@>L$6?;1H?"385VGG^X_<_DHUL"<GM5UMCWP$>+(
M^L!O3-*]V7E;5V_'LSKK*4!W$LC&H@M,A2ICYC2R-^OX*,>%[>H1:FBF;#6I
MI<2Z(*BY;*,$96MPH_^]&<B\.X'Q,(X**71: :\)Y^.( 1.B*<(I_:V/$[4S
MK(,DNDK\<#JL0Y/HU+KR-(#>#ZKEV;JAD('X6D MN)6-Z/\@&-XT>2XEZ'(D
M.N@%>)Z3 %,/CUCJ"@[AKWVM?YV@";P)C3<.1'FSSLT*>2W0^U3$+[.>\D.J
M_ '3GUEY"\$T;QG*;IFACFJK O8J$V\1F-YJPF;[.YI#^4*86JNG6RL-",5-
MH_([UQGQTD%P:+8UCE+5_M2FLX]%T)E%]Q]UXBX_LLG>5%=U,:L!>/\@($T3
M6=X3G<N+0^0@*%JR;WUM=:UKC8/0=X/=U%MS4<KMT\.6,Q\;OZ0?_+MLYS6W
MJ NW;FPZ(J &-9W/F!E\?<$=9NACK21J$C-;$%08$@I1Q'L#!J/"FBY79TO+
MI/HFS/X:#;Z$)WDU6K=P,N323Z@X+'WU%4RS0"CL&FNAY%_LV=;R!S.EU_P@
M%S$LEZ)!<MQ$+'%DWPE@3PEK@@>SI*M/_8LW(?<'[M%/( NEID(I">.*MU01
MK!_F5<E7NC>E_:D,>^D+I=T>+!%NOQ4S*?UFT.T%!:^%6W?T3031Y4I@BAY'
MA5R/84Z5!O_>31G\>J#J"60FA-$?%%9]M$LG84>E@8%H.B\?#TF$==12_B!^
M8M)"%Y,'URZ;L4/O9ZNSZPZX3)-GA_R37H/4Z,FC['H\0X5[J'$!3M"B<L(T
M9O':>3&D[LJCR:'^.MY%)<^FC]LEZW+J-A3]CG=K-:?O'(\I'WELGMIW0Q*E
M OV/AP$M71902YBR$.J7_LLK!R?V!%XG ?\%#/+/^@EET"/)^_9)KJM,\\OW
M:'#4Q7NB0;FSJS<N& 2+GQ&(0DHG@V9T?=*ZPS+#1)@GQCW"85>Z9-\!A*XF
M^*3GN^*G)OJ@U$2NHQS/L(^8]I- %SZ[/X]Y=,.S_%[:B1FWM],/;#NY_>\Y
MM?IE2)W)98=_A=C\^HOE?0]_"C[]G!62B,1F(/KU<W3E0)LN,ZH'.HF2Q]&0
MSF D523I_-#[;W]- V43A1I0KP4T5N&G-BDE%W47[_&N!_J)$@.AS*\3-PB5
M*K[BQV/AQ5M@^ZJ].Q//Z??CIE[A>DI\0@G!]H#K9]P_[ ?^=!=PK\O><!:<
M:-"89LIT<QD!:M^,H7N/3-R:RKN4#8* OC;N%&RR4MBD&W??A9^V_^;)Z3+J
MQO"C. )OD16ML:Q-1W886LZ^X'"TOQ&+B^%%" /?:M*3U%_W.5WS/KG).KZ_
M[.%6=^RN14F8-M3T<]?+Q8]A8MB""]:ZN6_0*EI>V;/$6[ZK1\^L9F&\ZV^3
M-C;U7UZQ):K1P'#%TCOJ6?/?KINZDA__=L56VNB^Q0SXY:JC.G\-JRFW'V<>
M/!"L-5H9/.7M^K?OMAZEMLQ=*2AA!E2&IN^LL86S,RZ\BSOXD+_H9=:-VUON
M7YQQXK"\VUYDK%B4=#W66'%$>7W''>IU:-6VN/8T_<3&<G[!@$[]N9JS)SKG
M/%J>OGBP69*X15\@GK6B],'[:RX/=SEM/W:E[4ZJP/^P4\_"P7+_U2].K9(@
M"M_#.ZZL@ATC"/H HM/N&(@05\4' QID,VY  Q)]T?0:IFS^$Y<P;UG9K,?G
MYDL:(I#S&PN]$R6FV&Q/#'),#&MVZOV'DB:ATL.*Z]E15"]+V<+MERKC&+O^
M>W\H=\7>@>U?)R;^G?YRWXW0(W$?YI8-?CJNUVU%&T\D4,4NVA(FI)^8[2F6
MN%?!Y$'8LQPF,N_'KO)T3005H0@5G8(.YA?_49&5!8$*W%@!H^KFA46GG(6P
M6Y7,J?.ET>"C_A;_@0AIYG3)FN4[;OHFM<<Q\+?4TT6*D%6!Y%6T1O3+K](W
MI/M5F8WM@DR=V <Q@PMGOAM1_+=UX&GRS!WM7>G7U[9K'ELH).K!M>H?7^[^
M6#N'.IS*U[N'-[:YB<T7#M\,W7'@="4'2)DTF!F=K65*=@12#7#?F'O#%+5T
MZ4<#8_.I4]9)C':Y9L=#MMG9I&'WP;(3S]9 IGD@:U&!KF;B'O,+I-!> V;I
MQ>Q\DS.EDVID.DQV?G]V5XWVL%MHK\*U=M43W@P%KNB7&B5">/>JH0<E95XW
MSHJ.+N/+ZEJO<8<+.8<J^@=7]>?+NP4#_GH'PJ3/KGKW9$\^2#_[=;IM]O2.
MKW[OOOI?7*\"V?_1TP+>?>7V+,>^?YUQYD9 R!AO[1BO8_V,M6G!"\9431)S
MN<2L:\RB/RWBX=BLGK'9!AN$APX&$[[=I'V+>)<VV_:;,.3(@KP-63?>691_
M"]XNB>G07=CS+3IDP^R'NG,?CL4]W!"W[=O<)=_FFWVSP*T_CT#F3=_,4(+N
MPV'M,*CVG@H]R$9^9+NQIPC29:^&BKD*U+$)A'6":91"BKG:*4&ZK@=H0S?M
M'K8*T+);5A<3#'0*V;A'YH*6?3<)Z5)0@E*9VV$/,3XU&C9_X6AV'V8GXH&<
MZ %YMDOH'(]W5L,"A-_YHVA)R(XOZ3N_I._8MN.A^L>O7^F!H;) [XS2[S\B
M]'\6DS/DVS)*EH3LFRT+X-A^[27,?/2SXMW/RB\9A]YE'WR8[>N=?3@@TTN8
M>22 X!7ZZ\BV7T<V91X_EGET[:\3';_J'F:><"9X#6;67LNL*_Y5NS+SK,'F
M^H#-QT(R:[Y #+7D8M[OIH<2AOSWQ6._6_;^OM0#M;S8W'3M]^6.S4J#\>:.
MW]=LLUH-LMJ*-U]YL?GJN\W7 K(N7=S<D3>NN@@Y: [::FRCZ03MJG>#J\^\
MH+3%+[XB)=3/4:=8"C#XWJP[-:=PQPK9_3.N+V,H.C3*P0PD2&G1YG[>K7_7
MXR:XXNN>TD4%?O5@7(]:*LV_NP*AA&90\_6-&Z4!/P@&)W&W<CU=S&G[.^WQ
M?)F'JV!)W>2136$31QW\> ZC7XK'0FHF\K:-;?N@T@9]?U@]VD.-3=CVZC^K
M6.BOEOSW&"E? !/G6"8.,UNE1&</OWZ:77L^S=:RAMV[E!^F,VU26?I9A]!B
M9$JI^ZI15G>9ZX*#X_3#P3O,E[(%U5Y2XNT2FU)U3<(K675 D=><X^+!V56[
M4IW*O&LF9N\^:/186.@@D<T-$VX.R]?N8K>1],V%B8VOF%T.88M=QXK.50T1
M6%.FM."T\P.YM:NF2&MY;Y CZ#8V]V[M,9X]Q5G(>= Z.G&@L]1Y[NFDGY/>
MWMH_;?WGH9^3!]75(;L\DW]Y?>CP%[7GC]@7\0P]([8*[S;P=7)TCR>$-J]<
MW65BY]6Z"GO?(_.RM+@ N./<F.!B&\$QV1'8KK3 IK/W1_Q_)D,W7:9,ZQIN
M+SPWD[T*HO,RB!UEL8UV?$DIT=/RM6[$I[\!.$3U9DJ(ENE,*<4U/<8BT#A2
M1DMJOP$HS'21E:/EP'PC-.%^.\WX^\0$0PIU2-2*SA*6=B+L<+K*J*RLJ8WB
M<CH4HFJC0FD.8;1HC93"$G$%1K3P5"FQ /GO,,5>K.H$]G6T&AOJ'Z[$,,JK
M/B?8,E%18FHHE"!(P8_X"M-@3TAEH]/RTZDBM=O'N7+#XXR5N!@[N])H= .=
M+%BEC"^U':T<"#*.P'J/!>>Q)%(SRR/TZT;;]04%A]EI)7=9T2Q+HE'VB1RI
M8=C&_6SC\/81U*1V.A0JP)E5TMHRL9(_.Z6NODU4T'GLHWZVQL?];.D.;QM!
MA^GV8^?<IUP:JN_Q_#X4V[6'Y=$HEI8EK])];P<3"\6^GLVOER[R;'F_>N/I
MEMX48XL+=HLW#^51'6]^#K[_^$#2%9W[-1/.E>F>XVNW/3C(HBD_N58\9FTM
MJPEA;&BO"IE3=ID;9&VI9QABPS#S$S&BQMZ%,!P_EE@';F-.2K):D##OKD-T
MXMF]RGGBWB&'>9ZQ(NLHL-K0(494Q1*D1MNY.\KXC-2-XY_&O?HB9WHP V.B
MA884TP0-%VX^+N+J& _7($2+-!I$(EX0<:DTX<M=1/,L!4ZU_!2O-/E]A])*
M<O*K=Q'@T<Q6LCG;8@751EQO%NCFQ_FV+32:F9')^A.O^J="Q5=J>:!\FN'R
M]<,X67H)\OEP_=6!Z1\K)I9*X2N593?(914^QDQ=VI6EY SA+(&5H3$IY!E+
M]5+25) ^K%R\?M*85H98!JGV\)BBINRM)E%5=%+D6%0.8E'W?/J*#"_%@(-^
M8Q<-;8X\%_@I.E2^QTQ=PD?)^FY<DY]_?O\-Z&-R\UUC;[/R^AF.QBK(@[64
M>L=.0*Y13,LMZ2"FBK@UC8&20UN85'NYHO(N:.*4#-!-Y 3CL"-TTT8F?8-&
MV?-*#'E&,>/!K7![TF3*M%C-\DR1#(NH)U@DHP$[X_-)H\$4Y^$ON1%9]L8C
MC7O6T,\Z1R1BJ#G-)#?\Y<S75K.H_:;V!SE\XO6YL&CJ\(4)]K7><P>[F&SA
M 5.^,CXS'2.?KBX)$3$-,O/CC'WFYALPP8)?A3!BKRG33]<6VS'$TN *C>2@
M.]<G29?E-/EX5T_X658VCLUO_(<5UT=6FC:5X:O722<XSH(?V2$(J8U(':JB
M60AY\4-CJ)$0"W@<B6=MQ/:@G2%(PT\EE1E/I RJ<@]D%;',J_(H?:N+B]D]
MY*BH77I>I3"^B'[[H,N=U-*ODW3?\Z#-H[+']_E$_'@!.8J51Y'-Q<)IJG6)
M HJK&&=;FTM0>PRBW:48,LIO"]C,$^QRC8&!.7TMVTY:L%$)V79&^,P;O=QR
MOX;05-WN,/J=$<9Z*9'C0/%4?*CH7.,1SS=E,8"B>M17HZ>G;@56FDN.-;<Q
M]_T\^_E"WS"<J9W1W0*X;]II9FR%SGP%K#%_A>C^J-(WTA@28S#41W2<)4Y_
M.G/+/>!*:Z52AZT#A0K)C/$JP@^6C' 00PW#1[?\T76+^QH6,8-9QO)-M'>\
M, P99&$^94VPL>Z !UW,)/+GMDX3E"(G8M=A0J:*'Z#<5<J7$!C"5\P(-:1?
MF^BW37PH;J8AF9ZF(914(D9^3Z17!B'$0J@2LB?F3)L_]?S5/Q[B;+>GO6,;
MFV[,^'QN>(K]<I,%7M;Q!9-?\VFK]QUKGC!C?L.>F4$#ZRY>>O[',[W-[?E(
MX5N#;[=.VFT,>?[MW,4K^VZUV>._R=]:+E[][\J$@3%QW.4[9M>TVC\3\-[E
M>5ROI712A$QB5)$?PDJGHRG#4KM839"?/=U@HSCG>%N^GC./3DNISW;.TKQG
MEZNHI%393-UX(]OTUAWUPSF!ES46"\I;,SA\?'W=:^L>%WK6CS;;<5H"4\>G
M<RMM4FE!^ #+S*<K,'BT9$=2@I-;<^=L;:#-\^$!MF]S5]3;T;(S?@G,)8^Z
M0T@-MNNZ7D]I:+[]*H%_X*G[.Y][S1M&UIF&'3SRKK-/1M>_Z1D^NY3SQO]&
MRP9_KVHCCV,AWN&].[=ZU7S]E5\<U')WS]4T8[T=JU8DM]R;_B!-6='TCI+9
MTG?4YAC+-;@TL/8[W?Q^:-K,NSG>*X_N>ZH-:S\Y9>G+4H;]Q9I@BMV%^A==
M+'C^WYGM-[UX^>+/^_L7#9_WL=KR857 )ZJI&I#X]Z6ZB0HDT =9\S"PP#$I
M;$G_$<20-7P[)!\L9^W;3IV:TQ"]XB9QT5=LHTVJ5#<6$'/.\LA^FDO\6F:+
M;CR?&,HQSA793>OY1?"?5;J'W:??=_/Q\NA0!0O+PMSE-8B9GQHZX==Z]NW$
M:)+G"?E4^7)I 8V;LGM#_J3(2V\_W0V$2==E@SXO3SMR5+_799<'^ VS-O<_
MFQ^<ED\>O+5QPL?G?UZ-HQ2AY>QP!18?PQ$8C]V0-?&*3(:;L\VA</KF_NU6
M"2=*'-,P._%!K0[#GK:^4'!F\+CO[,6!\H-Z_;DT0W&X[3WU;&=FO%3\?+LM
MD^E9&OX2IF:T/YKR2E@3N=3 ?);NEN33&?<E#&=XF=+!3]$^G8\;NH36D;2T
M+[MTJPD7W@B,+450X'$%9%U^AAPWNX#M)_JO+!HB\X$T))0'UY_SQAN5U_)/
M,[,]E._N/^; /-W[K+E*')VD>&'@A2$+CV<3F1PK5U$ (4..H)8<.%B71W#J
M!ZS#&L: T4WJCA05Q6EBP XF-)B[YN1HQ5Y3D2U)F$/Q4I+-K9@)2D+?;5.:
M8AU#$^1"HXC!;(8427C^-EESK@@+:-XUQL19:1!9Z\=%D[A4!FS4V!6;!$YS
M6A'O7%)2\48T]U3_#0<AOJPV\DT)"$Q7/N&#-QXSS=(!DD86_( ( SM0E@0-
MY^JD0=51,QD87A^EVB+>O=\C\E/42Y'(SG&\5\B1?!_BOA=POSUZ%)\,B-XY
M^JO;$R-AJF:)$5METJXR4M]R7AYNAN%@N4@0RUV;-6?36'Q.<VG*H^"E;-@!
MV)/]EYYME!"+\%)V*RD=4(H ,2'/E,FU*\,LTW&C!'"7QD-HLPSE6"[_>FRX
M]4E):3!;XCJJ2:79($G%M'4W;9,DE!KE.I;D2:+,GBTQ3>/J""6HQC9>827B
MM&O? FFX)/33V"&>$+/1E8:G2@S+L;%P[O6?Q3:-><GI_T.<CY(RHR@N0X&;
M9@'#6[:.F(IU'R&EJ01TO;9OP<:-BV<E*$U#6UU6\ZW8$+6,XH"P6$XUE=AL
M([JM69/*)@J+P=%_LY1_)4#WV;O>6?J\J-,A'+-CP;QN>\=AD5DH;D2#J:'R
M$>Y,0R]+.R]@%PJ3V4\%..@X+V'%8IZ1AX/#<9O8@O.89+WP\.0'7,8J&24-
MF UPUWJKSP3==F@"O8T0$LK+F<>U]^92^K>C?1+*@!Y)5.;GRI\1L?C6PCS_
M",/ !& &:DJ3K$S')20:K+M:J^"]72Y5<N$^"6M<4N^N6ER)NWZ("4CF!DB4
MIL]$\)_*^4G%(=.Q3=%,1Z_J:%[I@UX9DMY#B'I6B=I&^D50+E^W ZVMG^)2
MT@%AH3*_$[H2J=HRP'V_H\,HJ\!L#L\D'#/WQTN]E$<35?!0W.*2GF)UT.,$
MP)KU3&Y,,@6YE'9T*=LJ3%)A>Z<B<W'(73^@2(/26#R";FZY4&K%QL[X@+@/
MCIG:G4883HK&B/5&E 2L>Q_5T4]E)6BE9&$4/S-M.B")\E'SPN!:0-3EV8LQ
M\OC*Q'42QZTXE:DB&</D@<?U?JUHTBPBOY 4"_*"\>^T7(K6.\@J#2/7E02'
M2XA9& D4VCPU$0Q!Q#X]DYK!0FD?.5')NL6FN*O(?A)3L/@O34J6!=E&2N>N
M4PZ4(=3& IMTG+U'=M\XHL:XE80MLHO%76/TT+[#P648D=-JJAOA>@ZP$I2O
MCCCOMT'GA\$'GAL<Z;W%&N*V,BI5X/;V"Y:!X\MCP@>::%(;QDT'#)X_NGVC
M;A6G>U7EU2=QY957AXBG>_DQ[8_[QJ%3)GP/0<7&*.L!U7O5$/%PSKUJ>[U#
M1UV.A^U=7F3PIU=P(MAQ>9UK<\6BJE22(B?F^(,3IR)R3Q;./?W<]<Q_)\YH
M7>M))^OUW<Z:GCQKXW;.Z:3VG*=;P]23#?YNC<$G&R/<SL\_>3[.[<**DQ=2
MW"YN/'EQJUM3[LFFG6[->TXV'W1K.;JF)?SA\=,Z*X8^5-PBUK7N/U_4?KF.
M?S[IYA7D\?J)9I=/N"E)=4K](6DH3Z<<4&L 58X5Z?)[O2HWGH?0'_JG_!<(
M0EOS&Y6TVW8A3S]>HMQ"?QA6/=>IZU[3 (JNK'YX:?G#_%"8X5W$2% JHH>Z
MCB!V0UBT.S>&UHI>WE&2BR_3+'E;@5/5MQP2N?_&#Y(ASWB\B!$K,>5_.I@B
M,8KESG"!%_Z$^H(]3'6)#K%0 KVNGQJJ[XK!-"7,P.+MMR-C?=<_VP!&Y/)P
M+4S@&Y!T5R:T0T >66P!1&(5)"YHYMYP)@*2$(#P4@8 (B'/%& I' !QE# ;
MW!ZY#J(Q..UH>SP QCUD!(=H&(@J0%$,1I0DF9$AP"Q9$-!5 @;V?A),I&%$
M@#_;X?%E?W \BPO$@ON,93'BE1/N(V:-F!%ZTQB9($CB,I3<D-4J:K0JM@\R
M',(VA<-$;QO3P3RS:)6)2!*ODNAX0[T<V-@/,J,!UHY.)@<R]+(V:U(:Y]]T
MB%;9)$H,&:U,EFJQ&&(TJ?2SYC*:,"-%C\F0ZE^QO"&$F6R(]*G7I XWUB6:
ML "YDVNOQ:#@#*Y.J 3^J#)EJ7H2'U(0O.>HF &DP-C #,&3,?!M:/OSQ\%6
M $_V6X!B..S-0 9L[<3VH";D8UP8@X-##.6MRTE6G'_(HP11E&\'5WZ).[N2
M*?DZIY5"4Y(82F)X*Y6%_]IG _(!X@U22'A6*(^ *:'P.93V$4ASSP3@>VE
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MX$R@9(Z[U+6E#0:21O/KIDH?^>,+7J[NA^IZ)+!('\>F^D_6E7AY!R?JPJH
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M[][5K6> 5\X=2K J4#Q7!CC:2U</F-,230[N:HWVK!59K_O914:6N>7\D+3
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ME?"+P]@Z'3=C3GZBD=E(Q<\03#.!D#<R?(DK&U:\N7;%ON)Z$&ON"&A4(6:
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MKW5]X<T)IF,QW]=1NWC+>!ZCN9_=:!:[HKH8,=>7!1$$JXO?/7:=GU24WAN
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M BJY[-9A#Q**"R:4W96P0 )T;>;I%[7G3_>//[[,$$G)P!+@>I\,GV4'.4'
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M47K<?54R,&A>,-H1^_M$1 T]>%'U_2OM'S%Q2\GD^5NU'9'?^9"@_;H=QH2
MW-M".YI9$)3.)L %$IV#:D-[[^"+I4D"W D3/>OP5[!=RUIQ->\LN'TKWL6N
M&7+)'#NU%]4:F5*MQ^*%_V;Z]1O_5&?KJK*8/R4MY2EQ.<O>3.)W5_I,C0]H
M"6595K7W=3+OQ6DN91I)/UOZ_'<O^/A/VO,S."Z_5D>PR2.!9(*2M'07JL..
MN,K!KYEU9Y/B0 P=0!\/RZ%1&"#&M9CE#?)1=!C\ZZUH+P-JT!D MRH86-!
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M9\ED(=4H-2JX:/X:RJVNW5>^.'L+?C.FY-ORYI*]*$(76&ZP!\;;S0+[VA2
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M4M\+@_B:V97YZ%:VR2[>>4V_+D??"W=:$ASI8XP)DXKNF_+.<X<K)X\RJF4
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MXY>J[6/2RU](R&:EH$Q<*UM5"LVIZ6)U;6H\;[<U<%TBIXANH))0AK/D Z$
MJ0,(C"#<6PE$R@%L_/5-7P4$]VV.."&#(@Z*B4L?*%P8^ !6"S 1(J:KG"@#
MB8& _23YP"@Q@FUC*"6'?U8(FY\)FX\=STZ(_6[59%%DW8A@7!&21)[GP6.]
MY,/_#A)YOHXRA" "1ME8[DD 6S1B%W_?#R,T@JVX,XIUGSGS<8,PR149"!RP
M!( 6E29)74UBR=ND E0!3#J+H',QZTZ^+8K#)9Z__FU.+*F]::1BVT,ZUO2<
M,7>,5VR8H0PTS*-:%V5NG&%K!&JI73$F1G<L4WS?=0U[J^2'CH<P1C,9AW%J
MU9HZ;H;WQ$N9*HC24=^56'I8$[?G]V N1VQ%)TOL&@<^7X>E@FB24*,:?OL&
MNU$'H-R4MWRWWK+Z-DSJ-\H=8&PMW+L?5JODFX; 1R(,)3XW'PY8/0QADDC6
M3#G?;M-0"+%XVS%C'-XF$-!0*3 I@T.:./N(P:&O HW<Q+%*XD,]O/^3DX;C
M$LK[<))JT+(()H_/8Q=QY6>C$)\.D#C]TBY%B?&#$UPR%\$ 924B2>*$[B4$
M4@2MX_+  L1Z3-[DX/-V.;#JL,@;XV4/R^U$L'HRH&C;NJ##WO9S+U10^$.]
M:V-ZQXK+AS2>#QDC;Q*OG-]QV&*]S?B.U)UOOPX.:CRPFWBU,/76GTM(]=94
MI0M 2,!2*]$\7RL&W/.J?.&XV-"(:)\I/^FR-<]'7EN@O*.)&6L(*,-X664B
M7%V.>RO?G*H42E'BV4'C"9(U3I@9X6W-+5O8FX]V/6\H>04'\AW>_Y/<[+"'
M40;0HHX<?63E_8(I0FGAA(;CV.AQ@,+UTW7)S"M:8]_!Q\Y3UE)B"..YI_85
M&UNK4=]*%GU;(V(8 90O2LR$MY6*[=@+Z__#)B0/>%.40A7D%T$39<H-Y7+4
M9^6S#KSU,*RA YM,DC4Z^!K>\L@.,,\X.1F:3:8G\X,_%EK(2@H$B;5#AGZR
M==JH@)NHQY0!9M%)5A'&L%[.3%(RC6)G!C,P<@A##S UWV6%U/<DG[Z=I&SA
MEATH\5Z',_E]XXD=#/==X6-2?+KA0<>ID54ZRO-=9%+BGKU[MA1V.%C:EC1<
M(5;-B:LUO0G5USZ=0ID[KV$A,8L&$%0' W/XY$)GG&&!_$"D9?S,1'@F;*\6
M8)D9BPH$3T;YK$S./$8NH13"WBD(JQEX0!5A_'(9#'B16LE45^?XL^J^Y]N&
MMS,[ #")8\^"4QOS.;F(1>KB >NXVC?GW="1'Y3$$RCQPN'P'Y7 ;34\RQZT
MNVI.><@B]DK24Y+S"%*65,XF]%-2$.Q,,!&#^GU:?I,U[#VK^#P!D.3RW3$S
M,$& C8"Q*KEW,]S_-2LM<H"1\DK>J[!4E4G5*&+O74SHFQ55"WJRHH,\2W;B
MA,F#P=/\M6NU!MI_='!IV.^Y-;PD4L)GSG#8M28$<_VWC[W:.;3CV":H*&WJ
M]H&#+?Q[\.2K%%Y$:S+/*>+,@IX?@A)IYY[DR4W?V<24/^AKKA+K^EYY5288
MW;45$:S(;WPQE1*I]<BJF6_*0L7J7XRE732E?(UU=-F\S,7,E6/:=L8D?$\R
M9MQ;_/?&_SHC\/C(_SH+^2?,O\-0[L7X$Q<3SKDDG$M-R$]-N."26'I1RYW]
M]B%O=Y_>3OJY[T0T8_(X>T:\M[A5\9;C:-O9VD:)7F_TEV]H=[I+Z6HE!(%4
M^$ *#=0FL+6YRU+-%/MW7TI==R#EP+>4]0?2:&SMF&\T"GJG1'37IH;DV9X(
M^%R:%5O5P]AJ@$G':X0"Q$#>I2)X4E0UVWC/T!LF!"+V:.PB&8O[67E9A&"Z
M$ XC^/S1ST>J8*UNE<F\Z)]8^>IMZ+%O[+.6ZU9O7W*@<#4'XBW+KOJ^S_-
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MP&"MP!50LJ@VM0+=)*U@M2$DVB]"",1QA:3J;Z&=F6"4V6 ).#<%LB)E!!5
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M5BN)-98HW.H8AK8%);2,(S]ZXO&R!)W[R%-],K4 4N.+WD%&%C;OS^ <_!V
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M6KMF[0BI2 Z1!>%WRB\@;R--TY!A]HEJ!KA9)4E \*@J!$%K_B!+J?Q@_#P
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M]P2HE+JN(U/:]4TFVEOQW2J=WJN*I(ZO1$9%O/A@^$_@>I7I3ME(^U!,+^]
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M@A+LY'=4C>)B13+I!,QET4/-")6+C.0BF,&4K^,&$-100R;M(:E1:'6Q@4H
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MT<<:/5E1_7=2A\^S>Y^FR_;6M04MVH1.=6SY/PK.-"#)]&OC#P_[HB(@4FZ
MJ&@NN"_9S /BADMH9&IFN&1F9I9F:LL\H.9:D4M9MN!6VEAI:CF-S0"NE169
ME35.H9E965E9.?T;Y^W]=NZ/Y]SWN7[7N3^<#[<C9FU6JF;\\7GQ]PZMSYT8
M^6?9ZL7J&HLB?<,?Y--B'6J8LMONK>A_7 F>=6C*(Y>GLIJA?0JC'1^9Q^^<
M\#GN#-K(8\+>8FZ_L^>&#Q\NW*^_08?R3V2]<2L[M_EP1XS_Q<T6"Y:&Z)!S
M&VW/+2.;,@SSKW.O31!:+WI.W_0+/_6L>O<Y=--B3>,OX8WBBTL=B*(_.^YZ
M;\SML_!Z.%ZPX(*88)\B[SOUY^S%59G(\A89+5K[#_ZLHAWY9?9BK%AFRY7]
MSS7!.%5&!C"1S$O77A3^2CY 41:%E2,FGA".<66^:ZNHJ3)Z.S##D_T<B+CE
M(F/*KG;\%$N=7^'MC<!#7Q]ML8]M1Q/'+[[[9F!4*\,'5>3JF_Z9*7MM@)$P
M+U%[R+14!$,)5\4@;C40:/"_OZ7U,/1EC%D^Z?C,^=>O7N]\%]-^GC);LBJG
M@U$B@6MW@0'XE=<ET+#?ZWX]0_G__T(FHBL(I?+;?,3S?OL(NH!6%C3KSS-:
MD2CATBKNE!IS4HTB[ZT07I+:+GD$ASH7:/J6\>(F<![EPO*R3CGZUUWL6J(1
M%\_2HP_)#L:P$KMP.ZHQ%<;\(Q0Y+)?84CPB%PT#Y(GM/IS4PG;#MH!UOV69
MCK0LV^7T[(_]_X'Z]KF\2<T! \OPMESGYX.'+/P.V>>YO+BIGE- RT':J65J
MWR*<=6(X3] ]%UIO59^"B\R2HMY8R1[B1XO2=LG%Q)0Q*BP*X?YF,VY-5 O&
MGDPG5I>4V*#P.UEM8*M4'HKZ56L37:^E2Z(8V2?'S(T[;$8:6%<5)=)]OH'9
MJU>,XP77L[$F]VP/YSWV*JBA+"?!B_5@I.LLB-S2(-&6X_[LV(%TT!\9)2Y)
MV",["S;7%=+E-NJY(S'" C'9D"#/_JC:ZZAX&((&ZR.9PK%[\P?$IPU'-9O<
MCFB")9QYPQ$35ZT+/VR[(AMI1H[9S,3W#1CZ.=#&W )9=2W*D )UM:Z4R66Z
MJZV+[(TJT U:70"O25PB<:BOEPZ)? *:Z$)J162E15VU<IG$L!6NLA$_KG^.
MG+H=R7=0CXO[K(^;81_@/L1$M38?2SS1>K9NYY/6<V=\Z/=,=T!"I$5.[DQP
M2F<364/2C*D/0$&[O/T(O!&MP+9;20;URI^P0+P=GP8Z:!8$<D>V"EX1[(K3
M'&#NE^BJB(6]GC3AK2^5F@[]+SN7!+8>I>Q0?*I^X5I;=]0_W!(>CKJ1;3_&
MLW=0-+3C]?8)LQTBH]"6!<PY=CFMLT=#?L?5]+.0):R*>3)^V0P_#J\?("34
M!OW#1PJSNNI-(RVK*8;$PA8QP833/[_&QL;>M(:Y@ODB &>SMX1V9\5C!>[4
MB+/H=8G;^W2L7MULB_'-J]'B^_B&=N= H3/9I1CGHM)JK&USI^)V!7>?DQ_>
M,SM[%G>=\U<YC[? 'UK[<RLM@B!N_EJU>?,O46>9'N.3:0]9I3R+E@)J?,]D
ML>7IGJG33Q*8Q^J4HK@]^[77 BT\4TU(^(:>#S5;_KSGB;6UD$_!\1P=YR9J
M@;_TH#PW^K*V_/?^VQIL;YEH?]QK5HN[(\&BDE=F:HYU#7)R'8X)2CGR^RM5
M3^PC\!6^;B0"&4G_;BSE.>,JB_LJ'EX&7VB@71<5:R<E94C1O89DWJED3!-O
MV\*R(TS%'^U#UF[':$W'FY52^G=$B%,L[V1\KCW9A]T?T3+01%U,U7>K+=HA
M/X)%L@X'%RB/XS,%V&4<@NU>IM F62![4YIHP#$,8W]7@4T3@^B^5G3^2!2E
M9EH6'HP_6$!_ ?Y,TNPH]2)$BK7XNO;ZW'9^>+J=MA0,EY%-_NJW+[QW<B#!
MN3QV@FW\^ZS_@)!CH)_I1VKO4R[O4JYRA-2F2QZ;B\]W!6;5M13AQH$"6MO!
M@YQYE"U'BUG>R_P);@=,8C,%^MT(=# )@Y92*XQ[8#UZB]GM&2GH40)9L<7)
MN /WESLBME-O7.:3PMNO3+87>^F/A_?2MG3C!SM^ZFZ']3)T\-Q:)H,W[.<4
M*D4R8+Q;>I!L2$@ND_;48SH5@$EZ.[CBC@;3-*D0AU(*:+Q2LK[43R\5Q"V5
M-ARR"YJZK_%'+H^K\$Z'9$,^D_ J<B*XO813)2+SS1Y(T;6T@4W]R3^G'P5L
M<G+K]09C9)'SP>P5J4B4T!9<WJY&%) QA!3QI?C<!C"]%H$J63PK50+%;N7#
MH25+'-#"L;7!HS9:HA,05[8;8N@,-)Y><[4M;]!VQ2D#?-.G@3.@>XO S"["
MS*]\N@EMVTQ&.93TX'^2%-,_+3.&TT:)$(2V7?UOK,/W><7UB@:#SI8&\3>%
M*_"X>N7^EN U1]B$#G81ZM2\WQV1=?6):LUYF'Q83'] /%\VM;7#L+_8]\.C
M7QQ>T_>1_8L4[(H=MQ-_TI!1&POXY:ML:RX$OBI:9^ERL7$P)6X?][%Y/./(
M3SVZ"S_(:%@U6FSYL '\?G)NW8;_G9%6L%<WSR([7.IHY[ZQ+IQB)CH=JGST
M+*W;H/P\VH[)QD5H!<8=SBM2BYQQ_/[-],9M;9'ORY8F6K2:0,E!^TBEGVU)
M2:57(7F0.QAK\].8@.&)(_P#&IZ9IKG_^>UOIU_^]^99GW\R^L*_[S=^4QZA
M3>-M"^8K-MY9S[U.'L_,"E(38YD]N"2OON5/><7_[8P?RF?P7O[+*_DJ2*02
M9_J/1G:4Z/5-78^K=7)Z=ZMXK6^2]6]>//>SSF6;]M8:?NKIW_?*OV+'Q*2E
MI?<-4;Q+5=W<M(V?]\W(TRXUOZ:_6)'D?2OVJ<NQW^=>.!5XCR2:NQZ_E3[C
MVNA].RW>M>ZON1G//N\[.T^[GGJ3_G+E<^^[^4]=S_QO[N7/2!^MW-RMGKAM
MUL_2YUY9O%NCR=O90#^?T<K3;LTKMKU:"DGRN7_BJ=NYE6]?K2[P&6LP=V\-
MV?9Z3://@_/Q[K^N?_MZ79_/P\NGW2]LW?9F_7.?1]>>NE_:\_;-1N3*<8VY
M1T?YMKDDRY6/;\9[=-:]G>,^8]S[\+CC\$'25*[1@7ZGLSG-C=M>^*#_&;RO
M?[ET]]PVUKJZB0COW>?&][5N^_FOFUL.[JY_X,' K;MFL)/]RB2CXQWMO^:>
M+W\=ZGZP;=IW+_>G1N:#/W?9)R6,R-U>960>/@+&%JQYW6H4N%N2WQ'N\;'(
M@'*X;&>X3G[R\Y2>NU)-&H<>E%9IT,JJXV:'QHT%XY/L_R[[9?U>GBB8+M*#
MSB[VE^H;7MX9-SSAD-^R=^^3)TMIO[MTJTRK0.=/<JHU6_G6WR3]YM3R-3?U
M\8$W-29+2<#!O<_WL/R7K56L;5*"I^P8X7G_7CT6.:Q#9;P,,7EZB+:J28=R
M)YO:9F3>63:">):R6J0WUG4L?C[!P/]0V+13+S[>Y\N+/<?1!";IRZC7Z&SP
MT =SNY DD8.9[<"+\3,W]1C[S__TL6QUV0NF+TX^E*(Z;\'KM3G];; ' /X[
MC@:C/]1&M&58;0D,%?JT-[5DLQ<J'A<BF=0CQN/<O]2I!24D/S_F8P3XO?P@
MBL%SC&#!>OM:U AS 1'5"^MM"Y+]@[Z_)K+?)L:F'>$:U@8:CD!H1>':<0A7
M4<Y<XC$V2E366@%Q)'[3@@8U4O=OA/YDO[JRYZ_$Y%!@S&#-K#BI!3[IIGQW
MZA1Z&+\0?.;+6_3G98/67(BT(#-AJO 9(-BN9Q8$F#L/1":?!-L/DAXBJM+E
M"(6JJQ5&C2,LE##2[1B3!IA ">A047EPY6T6VE8,$7MAU,3#$Q(H0@B+)E;K
MM4#"<4@A%OW)N8?\.+ ;PIAH_Y8J5'YB$;OP@)##3"#+4<)^;I"*8#KY2%AH
M T%$5(.B"2;R:A\N^-M(R,DG59G)S++;$"[]AKTOO.8Q__2"7/JV3#R.R'EQ
MFD<#I]UIE^W+>(L(B]#3-N-\8X)\:?K>S=/C?+NS1LPY=4.U7)?=$/58)L4C
M+6@"F^G1F;?\R%T3]F,:\X6CCO,R+@%%PD7EO>5O+96;D6^9>NE/LQIW29[_
M^1MTIN6I VO W&N 7:-!G%QKVA7HX+5:4@A1(@C<,=/'89"#2^GM'CS2U%_8
MSHSDPL#Q8GGJH0UO!\QCXR+=:L8_#]A7/XV/>_Y+4 UPZL'^1=QN"&#:&UO,
MR^*K2:SL)N.;-_.,!.;B!SLNX"]+2D05(382[.;/LL#*Q*!K:\V_8Y]$3_B=
M?VH7KDLJ$>!"X?[;JJ]CH 4@W_Q8XG1TT"GGF$V7,; _*NRUZ<:>1./X>'D-
MX'!V::H( >Y%X)SVZTWWQO'TDYS-IZUOUB)]-V[QA7I]5</X J0B@%2Q,1U2
M#1MJD+/^W^O#O7V YKDSNU#%KUFPT5*Y>7(-- (8'@\R8?I;1 ,]S7#2M:'7
M3:KMT9!MM=SV\T!AQ3KS13/6'&+M;XC:D^LB!CDW7O'7O$)/*TWC8W!A/LE1
M1P3H+D32%XUIJ,I0K3*)2[J+1JZ2@QO'!$0NY/S0,+)M++Y0A=?4'V<\>TT"
M@T^N<QI79^1'F<\;;8T9OE.J<2 ;.LPFP^/PAU4'"&,R8NV0?5<I$6!2!JU^
MOB<(Q(.H=C5!NH85"A$4\* 7'$JC[.L!])8427O'8727#.<U<ST5A6I!$2I4
M)"6 FM!8HP(7VG[$Q68E22;:4%*O/QH5W#!1AIN8+(%4M"Z( -6N_+<0B2KB
MBH&H"F#:&T+C](0M %$+(4NP)N-G8X+0M</<* 445HN2C2:D\X#P?JS#R3LK
M]&=,NH:*?VN4LEB'@D=)VM$OWA!.HCOA9?1.M0&7*7"B">[3"&LRFY[_:Z(G
MO<^5G+'PA2[RX/\J2E#IJ*? %JO\ Q9>0!0/&ACA^T;"FWL!I*Z""T%Z_3!N
ML0Y7#9,4T/T)?W1_/:\-N,41\C+K-]S1F#= WY4JU"+"(5I%5$$X-^,EO$)%
M4@!H>Y%I*$2*AO.Z2+M#X0O2-4YJ0+;<NBHT,3/Q,%@1<C%#@U*I"&[#)E)J
MH^H6KH**;NG'*^&2+^J#3_AQHQJF1*57"#_GE>IE0W*?>%)<$6H<5RCBHA9
MF[C9V!$8-0*:28>^[)OUBU"51 %%1U1F/G1"$V 2"FST1W&^6_68H3\_*&UI
MNT-B!.T5;PQ+-@Z.P*WKK_']., 40I(1.8A+Y"W*4-6C^,R'R%!@$[LHG2]T
MZKIQ\RBQBJ[-Z1TFHK;F[6J3:F \K9[7!./[ 51Z(*OK!2% Y62VA:>%@8L
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M$D,PC[N=QWL_$S%C,G]8K^Y%_+@LYLE=)&=[_]&DCY_]+;J*+1X6HI3U)EU
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M,=,^)W-#BQ38QR39D1'=3(O0FF5V6H?9!T0TQ).K@#(YU87E-%I+,5*9-,"
M]#'MN#NQ%$+PJI99LW!&0!9'F7E5BKC$7LF!L->9-'86TBL!^<R(Y,3,:=@)
M;#^"(T*RX2^&&Q$>1I. E2%R>P21/!\?L.2V]XHA6"= YDX".PWS-B<@AH;Q
M1BS$)G?@9GVJC0Z36@.$&6)1D<AG]XADB*@!CGEW %&6I.V9H%,!&!:!(WS
M8)BX+P&\!BE0"!%B\^CF]_#(+QOUQ'8$+>9[-+$! NH%5;@(1%@650T@ZJ<P
M3FRP3G-HV1<7_793\\FZ3BVV5(UYM).2ZX;-CR#FU"8]##:L@Y@Y*N%U+3AT
M)$&M U= J1RR1<H_E4-3X.&$XBQG1+/4E&N(K,BB, 6R1RY8SSPR18?O A 1
M=$Y-@?%UA6<:TLQ;#42YD-^S2.[DV"?%IAR(?[G1I:X02,XSW1K-S&6M7"H9
M)>Z' 6S'JH.-0)&86"!&[%Y&\LC,=A3[VLJ6I?;@+7=3]LP;Y4GI/5?PFDR
MF.US,<*NS)B4LMLV>@KHC;38UDS>)E[/$T.IJ"WGCAZVSBL)1S@T5,9<5V3O
M$6.S,X& LQ1'Y4%/<NPVWB[]>4Q..W: O3P=:LVOPAG(3?8HFC4\L XRVP-A
M]ZJ /7!21C(V'V%99(7 .A/WSF/("NQY0VLNN?8IU>PZV?L7*LDFTS6/S27L
M %<HL#D\-$[)I?@E%KAA[<0$DA*[JQT[+[.]3D6HR02R@I(%&QO"+MGB]2RR
MG5*YL;$=FPZ?:)F_,*N^P(66O(NHRW(R6PU5FVC1P4[BW$[EQJ9V[#:HT4Z*
M2->=L#UB;I. /!J)N!A,W-<N%#HC3NJ.VS@3GYT_DU9R[DE)TJH/H-6.4M,8
M'VDB=D<FT#VY(F<*.'<?:WZ/FMG8H<<@&?&07PG(/BN[L2"R]Y55RZA8G(H3
ME85<-HW/$R-'HWW<V@^+.?O=_EJ%[O@YATEP"22ZD;&G=,"YFUABY<6,:O#9
M9!=MUKM!BO40G]'HJMKMEF<KFC0*7(X6S+U6:WF,PA7CLIA&V5(LAIS\Z\.5
MK!+3TUS$ZB)+M:Z;G6DWFHM,V7$Q"]&F=PR[\=XA^N#E(IAJW0[F2Z\0ES)]
M.BC=>Y4@D\NCJ;#9"NR^7\%2%\(S$?:;X19K6>)$&O:;C+R"Q\Z#L-%CF*%<
M<#LOL2,(^;>E$_@&>-E1O9>\-ZL=B]7B8]Z >?,%8*-Q4Q VN\L"&;'LZS60
MX(RHZ!.Y*Z1-\U<9_U-:*9RW*X#1%>"[ ZU<!,X<@;S^%;2&_^!N1;AE7G+4
MKL_A(5VD_O9$ @%1]O,>@!9!V#./T5?@CG^..L#:$G3,VD:'W55)47GC4)<S
M//]WH;6&TJ*ZW-!AZ\3#9I&YP^.65^>!ZY!S#@^;IXOZJ^9@@S.:,M@C$VJR
MM5AAC#>R(XC (+EI,:X P5EY9DD#I.7QL-EBJU/*C7:3Y[-8B)VR,P4 P@W"
MK8H%97D@BV)4+R 8Z<"]BG.:?->-I12P;;FC5K,'<"R_[&XTGXRK!Y4Z(#@.
MNT],Z%JQ/)M#VA62*K9';/#''D] ]%[&7W^!H:DPI63P--Q1I[EV >O&5>/G
MU:'[M7'7R:#2G> TCTF9Q%!5PTJ*%T]Y:"^ISGDS)7*"[4K&[<D_>_JQ6_,\
M<&SG00W9WDH1'RI(A=)9$9<3D!ADH"LVGVE9W$QNJZ,]/TNQ@G_=#V7LAZDT
M,=)A!'M0WD&3=9P9'AB1X#IU57^.U++(V%T"8I<*DPYAV;LHX2N7$-8I+;#V
MQY5Z[Q*#S>*!X%"L'#IVK89B]T-C\^@$UO;M"IS9?/+7 +*A.!I$-F:F8F]&
M>P<.<6P1=ADP=\0-Q[W2R:;TD '&1(O)UX],_N,57X_N:!('#UD/9LQOR.']
M9FO7!DN1?PO<TRO.RF<-N5JL(X!K?(.Y,QBJQ7M6CJU_\<UTJ)+6,']AEV)9
M5COXON,N## B;@-W[OW_ZFBJ,D$L\&1K:2''R0[IV(),5888;"FE;"?'W%UT
M>KOCJIJ,>%-Q_F(,@G6"XBZE>P7<&KH'VHFQCG&X,$Z>Q1'&84UM+)7D (/I
MOLU&4N2C"=K;/@R[$9Q;2F/9ZVYOL[>A9"*+(-#E8UU;%W@HCR*-(^2\^F/I
MWDB_Y^.#;HC<J^"S#KS1)^?88LHN;:;]&^SII)-9]?XV'UI.V"70@Q%:@7H@
MK+/4!7FD&\\"[O<>.Q[5:.KX.G1R^<":[W4<L6]D_?)2S8#.T*JFBN&NS>S[
M]D>+-]%!N_[E!8]G'QQ7("RXDWME"R6@*S%'T33+/WB\R.6UW'3#YS&N(=BK
MP7MI@'L?EG>V=U9^QVCJ#RSV/,3=DT0O!_=U@-L8)"+92=[_E,LWZV0AJOA(
MV>BA3FCBPB.'B*GC51&WCE$FMUROO9S4F[KH-!=LBQ,3WX60%\HH#8\/+?UM
MZ:EC@2C+SGNFYL3[>%16!VN=H;?'O:Q[#G8JF],JX%D"X 9J$CDGG#(=RCXR
MNP"1/06>5;_8+B:>ZJ-<O'P"N(_8LGR36P1QRWJ[^5GMXPN6\O'U]"T_$(W9
MM@FH$^/"0VD-J@OP>KM(7V/K5I.:B?55Z.D8">WS.N_I+T^!:_58YSP;L5W,
M>8]+\HWF$<V+B^;OJSK_C$!V^V.'^,-J)OC&!;F-1[Q"&B#7@K)"OVRQ9* /
MTS.;;7KGVK/?'UY^?6&#'<D3<+STAV/,[[;7YX%Z#<:6?$ CNJ30F=)4?%LJ
M]V'PK6?YA[D1Q$D:>.?>\^5_7=I*F>R&EEX0._'OKE#JI+N&II3AR*,Y*$24
M\$E#/?;T?;SS#&BELGS?84_3+D>-@OXFRS.M0TM,D>BM[ALCO7QMD/HJ_&]W
MQEG*G&V3X);+[BL4UH6[L\N"9>1YT+Y]]C_#F)-,1, ZQ"T0@6010+)3#H!P
MG;=*15^R.X+#27VVKCJVAXEPAT*CP?"?#,-MI3F-\X!;YM.6F+9$47:QL[$U
M%9D3*B/,@TO.VUW:0?1_AJ]S=XG<?IO] '3?PV[=#5JWVQIHU^K,2<-ALB$^
MTDR,7,= KKEL>Z0CP<$3N;RCRI5<?%*"0S)=]O\?16<?U^+^__'KVJZM:VM;
MJZVU[J_5JI5N)NE.Y=JZF^ZLA$JR4ED)1<>)$^?:3;42DK (ZXX0<GM".=N$
M4"E"$F=U0H@3IT/'H>_/[^_/'Y_'^^;Q?KY>C\?[\?F8>+/$^,+_.8R%?OGZ
M-DV'X+=- XVS*&RBF7$U?+KB^WJ-Y_&7V4#[0:?-FEV>!H#\Y$S$;<!U,\Z!
MCZ>W>2:^!MK38%/#R+']WA047OHVBOSQK)ODG[M':I^E'AT=^%JXTXPO!KTU
M.)8<YRSY\D.._.<4IT!>#;S_.GP&1Q98W)QGY+OA)[T8#IACY=>&J"C\SIME
MFQ>#++.<VDN#:P;^_BJ?.AX#K_.P"LX$>>/K/=O6,[2.P%QC7'FR3MXK%+NI
M\?&ZK0'JEV]DNEBZ_)'9G@RB4D!\#;'-8QQV6GFP-PN!T"'\8IK%1=BY]8"*
M,<]FO-RR9S%!09.J,L5SABCD>6Y:?W]9.,745-[K:AHS.ZBT\.3V6+U$V+9F
M=M<^%?#_5):D):_HJ4)X+BE6+G%P8WK]+8HQGY-'7K9:'J^6K.EH0>]*VJS-
MQV8I$;E::T43]R(V"IQ5"@-*",\4AEYW(V%TP(33)%1N:<)>16,U"C@HB_)I
M].G8<7XZ3Q0J2<W5D]DF;JN(=JUXLD*?H!J:<&8?(L^7JL2ZVL<2Q1Q1/R:Y
M+:D'J8K./:BC<H<$X]FT:AQ*%;N8W\1E]JM"?DK9^E5#8\EW9RW<?,S8FG!)
M. G<U"2(R\\R2R@'LW1$ZLG=N]-:?IEJ"/ZJ[M?^+TRW@;D GMOB_F_8:-A)
M2GAM/R.$>;*UYLVLV2]SNX3'#I7LCI,_5>Y/EE[IV;M?[JIT44#G&A%%A.Y4
M.SGHX^K=%(7K3=HE6@K?F4:]V-CH.*\IO$T281H5AOS7TGP@MFORYC4)\=R-
M:-Y[F!L">#4V1XEF> PS!5SO:/KV[M4\EF/\MXV[J_JX3A>!TQW2^#=CC"Q:
M?&$3?#_L2Y,C=T8DXXH7O% L5@NS32^PO'YYX[B;O3HE43U'P>FB_07=$1->
M*DV[=J=)KQ2$K!IE+%&'?+-N%?*-&"4TNNT#YO78*,'#:P)^*\%+^'NQ-UL<
M%6;>%2\Z<<%?K*B7/(V=F/F("+T+?]*OC0^[D.RPLU#4:Q4]WH3,QD]9.=V(
MG[CY:)>;UZ>-^_FKGC?M,@L="7U2I>]4[0ZFT8Y%PYV5&^^JYI6<901^HU?%
MS#LWOV5O8#6%:+[@<])\==PD^K1+M_7IZC&//Y\U<?Y*#=_9F[W#^M)@%=3L
MN6S^+Z.AN_<;-:(>@Y5V>8R0;-/LO0%__CFOZ1Y@^@")GVQI': OV;:'^'[J
MO_GK9F!3CC+O4>F"]5=>A_ZR_MK+;X\8I,P6$(=N3'@F*WQ_YK_U-TPB1Z;\
M;"2.!;?M37X*(.>).<IFSNV@OV^LI(\2S<2\U$T#D2[?I_JC([_G"]PGHOY.
MRY 8.A^^V<_?]"V7Z;;QJOW1;6TO3OQG._5"H?AE]G/*01MV_A\GWF7JKRJ\
M^J;'?CI@/?_BT55I/T_X#; W&#H7__?E8?W]V>@0W);J;^UG5RTL^.?W+S_M
M#=Z_,ZWP\^CM/YY\>7=_^Z]O[]T_^@E*\L?%W<<,\U+!EZ%D"D>,?;6N1#)N
M+30ZUB>WZ)(0Y[<+:)O[%?90.ASN+S3;WZ]T@1#RTB*__]E.;3>)2:?\'6G]
MT)6/S<VIGSE2ULE:MKCT?RO22>4NG0AK0!69R3';U][UH'-==HPR@]GL'^ZV
M;*!B^3=S#W)!+0N#%SY^9ONY^&?+!?R(4N@BAR83=:0P';;]=*B*6L>B+!A"
MBUR9CD!T^J7NY,5TYI#)]A?B65#XP27,6X,2A/U&"BVZV4@ ]N8BU695VNH"
M?UMDHPO,'M3&SA4(9*6BPT*MA/CF8 E5HG%23()$/\UREY@3QUYNVR.7Y0HN
MDSD*]O1;Q+=(\&4&P%OWKV5--_:SEJR^9)'PFNK8PB5];KLU-VW*^WSB"^MA
MB>5@$<[UKS_KBZ5)T1L?R^D'3@@B2U\O$"@E]"989KMC=?2W'M[6;=(1_VV/
MY&Y/J[?F-!F"9+_=Z+Z"K@T=4&1MC@SVC;E :#6,VVYHZ<Q-8/SJTQ%C<_%"
MA#]Y-<WZYI]9K_A&)9\V$(I(?5E#]++J77%,!HEH'^(::-T&E-J.4T;"T >S
M]_+D^]2'Q/9"S67R$,@>W )FL8N ]],-.)>),->OFMIZRB-D<Q7*/X*? U$:
MZ,5J8 (S5RFA&U3S[E!KR,@_N#\Z9',^8#ND 3JJ].!\[)1EN@1<T [@'GY4
MX%_U$XF:P?P+<%2<UKO,CZ<)I_.M(2N_FH:(8\@%?[#@^F_EK<10W,+GAU?
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M^+Z I^^=5.)LRP\J^"=_K\R9H]6QJ>7G%(.-C?E=K>-;90RTA+?-Q+@)HZS
MXJ:4)"S.W@S"]=.L_+%2].'\@0I+_GDR[]B)DR4K1_92@V B_WS>DUT73A+B
MBTXN7@NFH(2QJY1O?T//58H?+9;0)O3\]K>NNV#:7';Q,$C@OY]H+?";>1)X
MFL(4>2:/0%WSDL9;IHP^MVZRK@Q@ ^PZ\-1!-\A]%Y%.6#ES.UFE^'<?'M]2
MR:CJ6\TEO']$(_+/>&S"IQB4SRHK8]4E]'9/WS:LUBA\+ 5>W$(@3N!CC;KJ
MIGI+1&:-1I&^&L+B;N]3]OLLM1GED?/B#?AUSDO,U=S9!47 /[G >\/,/70
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M(C>=C'-U>.2K;&L0KF?#]H4M0=+>K/E-;;+?WX8=(76D,V+#1)0PC1$["=U
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M4]7N)]\1H^C$J@S&3KOCH6']93=[7RYV,<RSY2?OB-RW[:[PK[1UD6)Z>IN
M>(1?1<W63+-99ZN=V,IY*\1DX\%P" -N'E5R3"E*: 9%M#>YKPP040X)=T/
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MM15'TF' 7W.',=Q(+Z:ZIV-4=^V_:,:1RHP@.0?ZI&W_BOXJJN#:2++?:X%
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MJ5X9#N[81V]YQ\);0;T'.J)*@WKL&YE2[/+ED9Y[J^EB#:OO[0D[?,0R#2
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M7#!=#IIK:T?GAK#-1K\]*&;P_^&8Y;)>A>4&''Z\+%4@E0WN"\M=TL"\'.9
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M"ZNF$)O9V )>"B,27S"SQ-'=O$ &Y<Z8.3U<N9.SP'&-)!3(L:8/<04L0JN
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M\^",MS.$'"; ]-P/4Q9?"[OT0I#9++R,KI<%(#Y5@I\AY,3M,_FL0RTLM+N
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MO;7"_7T4A&";YAL0%R"Y(7KHC![=,:0?D\=%E";JG6,AG^XR2'^W8N*+L!A
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MWZ*Q;@8"K767X8<J=AOYEQ$I'L"*/KG2EK'_R\ )&X$9N'K9Z7YL:1/V16N
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M FC0AS)0OZ+8^&7D43H>"<[5L^E%D8:3@X'@1KV #A8,UF4E,E?QA0OMZ6.
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MAMN9Y'GOC=&--Y%C23X),;R9I%4_T76X\99ZB76Z]!9]W%L;Z4P:;]R&MM/
M;*K8NA8E C!."C@.PK@7@FX+ ^5NA6#H0'*@'#9/!]V$:-'\>!"$\4J06'-1
MHE&TDP ,URX+%\ .4Q,)I7"P1AJ2FKPN6&SE"?X)"-(N<RZ$ X4I/$AL/36^
MG'H@5)-B6SONII3&%("."GC#C>38 N):C'@]J=P9>.N@@1..CX<!$^FE</1
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M^[+.<CV;:1F_G;YBI"6>EL4(=.U,Z&MZ+:;XKPL\'_XUYSCC1KC]#B8.TS%
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MZ.\7<I>K[]<3DT7F+O9#=?@2&WO2UGVH05'V$H>WG>W"^@>2-GI$WZ+]L^7
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MI46!D[1I9^!1YD4A8)ECLE*>>>Y.^0LU_X<0N)=R>F#U+H?3JY7O_6TKF$Z
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M.QM,-[6E7%_,JID 3JE)K8NI/S<D6("X34B)%TJ:/N--"K;1A-R#7EUEGC$
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M.2X60>&X#5+'M0BX#J&Z",VN;FG.GRSPZ/_/Q^G^9Z+A)86:FT).6+45AI0
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M9[WNR-7*G(I7T2D+;.:NEAN9U:LL![7,X2%;$\BQ9-; 1$VRH)@YV'+%:@V
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MX,6WQ0_H2YYM7GS-8\GC1P$"[>+K*Y;\XU') @.T!_S>'?"_^\CO_>8E5U9
M)M$!?QP0$CV7O/4(<,T7O.D*L/(,_),N6,QA^,\W&G=MYF H+AQH?41W4-+M
MH"3/X+3\X!77+4)N1):7[39/,VL=H Q:+[P/^FE/&)^_(WHZ*+:P8<;EN1Y)
M9L;6L F-!G+:<K$60HM8*6'>UA]<Z^3,B4"6LL;8K#)T$1B^]/K2!G#90FO
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M4\6H;&(4Y/@R%1A4VI]C$6'1&O=?#L5R )'^%)Q2&=->'X[7XY_!"R[_XGP
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M'V-)MH83&0X=+&P?0MJS1PCE&AE"3Q7FO(:_<5+I2)TQ+.$C#+8:1HH%PT0
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MYH8X&X]O<CEWMB9%.WTUKL4UJX0HR@=\!Q26W%"6DHA+<%'--;-\\$YS3QL
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M[YTO,#;R+HOCOEXE5\R?D.QK.F$U2;PP"DM.%3Y0QL?6 RMRW[S9MG<W4/)
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M-"/W'\7\P40?=D'JV;NRRW%6)> CN3QS1C3-X*&.IJ'W00MC=UX(]>.Q$'P
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MOT($@;0!-[I@-@7UW5?T#S,;B8J%12$4@>L,6C"Y/,A3Y$<1J(DE(9[(!9#
M7X4>B10XYZ,%^<7. 0*.!/6KYOYOH_O/(@>9D4)3B&\.\4W34 *ED#;)LZ+P
M33V1 IG0J'C0E(*<IP>:!O IS\+W4@2F%+[Y)(\V)POC0 (3.M]RAF?.1@L"
MA@R^\\QD0HZZV+HYPGP&8:5&"]E\$ZGP)[$D2(TP5450QQ&N:O0_F*GT@4.:
MTBKKP<(_/,LLM,L?A$?K \NV"($:7%2LY+!1)K%\3!2:VA'AUKS"7!1N RM7
M>?)-)X8X;4(3"I\3('#7 *G?$29U@WI^(TM'B\T@?M!,L1O$MX9*5K%!TU@A
MAUUL!?$7/..;L 6KI$)S"E]K9,1P(WKQ $I("@V9X5ED%2<%1#A!)?XS"#L9
M^M^?IFH^A_/0(@V=]@>Q/FG808V.E?!-VZ)&SOXCOT*@0H>PBUTG$0QV<:0(
M/1=+YYM+A)'-**L97@!48@>!_NSB8,]AFM7  HJ*OSA6((NQH8/KW40.,PA_
MJ,0R":GSG6?>+$P2%3.4#W]F@#;C@S0V?Y4,G8]&F@8@HV1"C="1NC_R&"F?
MP8"BVL+#OB/BW$0NRD$.A)P_>8]#CX@)0)NR^8*>AQ9^4&@^Z,80^<T@'*$2
MG\51B=S!FERP6:/$;Q)Q.DE@(V$[S2#.NXER.U!NBR%_8$@@*C:C@4/>R'T:
M&+M)7F@3RE0%"E7_N$7KG(L6<!+\)7QS[N/V3_P8"M]2I:QU2RC2X"\=&0D=
M$-)BP;H.E8DT]L!XXC^Y?6KGHJ^@!=#A)T+Q(RL(<Z4I?K#FR<9=Q2$!Z! 2
M6Y"%WGDX/"DTH7IMC# +S7@V*I"@**&#W&?//D8.7]$;B*6!Y@'%-8MC*EJ?
M^G/1,;2$^L6B!9.(=[G%EJW/'2!^+$5@XADV^)IO-O$T 5T2'YHPU*AZ-3PR
M=7:T+^J!912J]=/H?]WRD+1__GKXRCCIH4:<8$9E%_I0/^D91X3J0$>90.!
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M^]3;F:NKMIVZ4W#Q;V%;YJ]#!K^N'/WO\KJ"/3'_W7STW_&_V_:]132?^W)
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M^'&99AK Y.L7/47P*6A\-*G2B\3%")K]$M:'@]'(#QKFDFXZ#29$$#F8@E3
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MRJC6EP_/:9PNV:C,>5@F77LAU?CICZCDJP7'43L>?9A\>3V)<">TR#WD<4O
MUY)-1;^^/KM93= Z_V?K%]6UUI-Y.P[_S%)?SMSZ8L&.#Q+F^VLK,L9P-S9-
MSCWNN[#;](CWCK_/8S:$D>>MK#ON/EOYZH+7GYX$,7-.Y,.H6SG*/8;9]?5!
M[\*G1OU:BS5V]YWO1+D0-S6P%B(=Y5J/MH7*_TBO=\/ZINV[%_XY[1-ZQ[C@
MX^ =4QXQHL>LS'ZHQZ(Z).+N@X6)0W=_PQ][_2SK[<_TOCS_VBFX_XK1F6"-
M997L_I;3H^QS_Q7..C-<;OW^U/?F4@[#8]XU[^ !FZG^%?<7__KXX/Y2A$:D
MTBKA::?=?VGOECLM.5CXS2X^Y*DO2?N^79<6]->E(LS/\%#SWN#O3QNUZ!JG
MNUWCPYZ05P"+#6L7"](.-._>O7"73M.2U!G" \WL/V?ZG3:,1]Z8.UQ#&+1%
MFAW\>GIEU?OBJI57/DIKO./;>R,CKMZXLM^K2.^>9E)NO544<'&UN_NBC+9,
M77A?@V.3E[16*5F^%1VM.EL8Z$I9Y'MY)"C,1D?X\&3 <)!8G\U!CO[U?NRS
M*'SAJXW[GJ2_6S-T=D;"V^6I:N/MXD!W UOCQ0,Y(^=_Y$_H9RVU[![KLSXM
M&WOL>TK-K+&3_ @[].X,HOCZQYG\=6;/:/);BS-HFTIV+X[CI$U-0+RS\=:>
MO24'7J4?W,VX5KAA-S(WXY*;P4I&P9FX",]RD+C- O\_A=89EF3C?A\>'A 0
M$141]X,3S8'F;@$NG.&HM+3 U"QWPVR^+,T=FID-"V=69FA6-BQ<I0U#LS*S
M0EM::K1M_'C_[__;_>E\./=UG_N<ZSH6*(?Z8B+FYMI)*VY9JH!0$%VP)Q9M
M-NZHHS$T_OH]%\T#HN?&:%1U-5&).I-78[NE]_/IQ[I]G[DFTDN!I(J LQUM
M*5GRTJ7!$L:&"\!1IN>2M-MGR=ACXWZ@>,GT3DO#%"]&GE%%TX>SL=&=;UVQ
ME+.*Q!56TGNND4:6$/$Q.VL':?FT7K[V>-C'_H,G.$:-!]>'%XR-W H]WQ\O
M6IN>1L+>3-Z8'^O%&MRCBL+=/A0[-71E-";UT<US,;@T.A.5/K5:\]XWD)@P
M^$IM0\)H]$"1^[DH?YRP(DPE2+^D1-K-2JHKO]7JW7-]X""F%BV?/DNVS^IV
M8$0(UF.$>FN"Q.8XC$LIYC5?YG.7E9)T0*_AC;/>\35W\>V%&J0Z@S"'P^:Z
M.FIC-K;$74ST^_F.*(SIAO)$!0D+RU.(\:,LRO&Q*M3EF.)/M7VN==5Y9_Q<
M['C %&?Q#0N#/&J!\] Y[?U1]>]EKIK+[T^A6S5O._Y5>O-BAMUZ9'BJ27,Q
MMP $]R\4?TM\5&QX0DKJJ)8[P+OTP_&ZBVJFD?DEU;H\4@+4H^K]/8JY&2N1
MHK.?*U'F!;V5BA'7:[IB:ULWP9'0!M)^&M6?I>S:^ &J_F793]N=C=213)$]
MO+K)%W;>][1Z!]G:'8[:365?=HE:$^3]SL1O3!-+D!VEV?F;A[UE%YVP+T<'
M)?UK\P.M6<*BZ!/]J9#+\; %W@Z&VX#CMU6:ZGU,ARRZCA]:*Q)WK$^YD5T^
M"<O7X!Z+'\$BMOP#FW@M9ORBAXFC713$ZS@G0X#8W" 4PU]$3K,&/XH$QN0*
M1LQY'>NVNKSK[.$#^2/"TR;+&I+\LOPI4JG+B>G>#W$SA2QVNA/M/VIG%<4Z
MG71(@X3PS> BC+<KUUEE ;AD:A'6P1VEMTL$K9:!&ORS9&N&0--&55Y7SFU"
MUS(QJFN>1G08.M[<"R5(0/3>AF1G=C=6/%R,ZV2 A1AF^#L5O["22Z3B XS]
M&$C, (]ERT#@[1758QS ,B=+[A<N.Q ;*D?9>S'U')5"3!JH?^A2.F )B/34
MT7STHF8^9AT'-.9P(VLD?-Q:KN H#FRSD@H2WM']# I@M"V?H?U'"6#[!"1"
MEB NDTY]7N>QY]0E!GXK&?^DIP&4CHF@-,:]?=X$5+FEH'<],;(:5X\BP$P[
MKF0]2_&DM0>^OXN:%;^G"+B6:NF/,9$)_0X++]O+^#@;UP.X 2FH^N"KP<D2
M1E2O0G6-0>DKLYYS5:M ,5>$2E9--MIG5.A6,_E?]07D#AC<C47C_90@QBM-
MCT3,V'"!5:#1F04&[6G+6L,9)\OEB'KI6LW51'!@! 0O5B.0 ;+"M05<E!.&
M.:%+16#&^.0KJ0(HCBLQE*@!M)Y\P&^,&Z]QH@\T/,&G^2 $XU,&=M1J <Y>
M1=((91"ZV&U:]A(]DNHHI#>=EVH+7-!070#I$@$Y#X' Z_2 _SSX8F,"(*_>
MI%*NT1V35M2!^MP=)+TLAI8'3Q"C84G0ES$QR]_E]U5R,^'-+WD\:4PYMOZR
M2Q804)2.U-D[J[7"TC]C%0=\-)J#?KJ>!(W/ LS[4SFKULDTV:J+!G%'2-B%
M I.UJO2O3RP@NRPF*A@VUI<PKAPZAD1]62?BICV"/6GKR)OE*=%BX+X5FV0.
M R\^&XE)5]8)MIN?)E'$X:C6C^'.;I$87*<40IP24'E$#1:[5$W28S,U6:J+
M3PIZ<AJF\Z!KK['7VIH,0DYPZ%NX"$.I]%Y'%L,Y8/B#7H'4PX,FP"02\3Z5
MU\#L:JNR""+(^\9LW,9FTATXF.?^RFLNRL6HK2//KQ<Q&K<:"DHV<@>\K&R@
M^CIF@PT]"$=I0!KX,LTRVH!2J05B%H?6\NOLREO,/5 @DF--I3HXL04EHR >
MGSR^4]0,K,>S,^GO3$LH' :I*]>QERIOC9U]@-Y%"##+'S,R[,Q ZZO\G)W^
M ;>@ZE$=.8QKR2T:HDYI71U#'M(S1T(KZLBZ)WL?LI3?N07<K=HIH4U:%2^X
MS?"]YP>>^B5+UD?0E%2US.;',Y$.YO#6NEWA5Y<:KT]?[)&22!;?$PV'RV_]
M9E"LTK1+DG/*$E#C, 7^3P^46KL1B&DDZ63&-ZM9K0"8TE142F"4P7SB;V</
M,RD9,PE,).GY #96\L_A\&::%!7:.V?3!]B\U2IITJZL ^]C$##";ERHC3YH
MD7$.O#E]"_0#;5 +(ZF@_ #TE^_6T%.BJTQ2'MBFZU]=-@MNVF*A"OM-3R"?
M"" ZR&$_ ;BE%S%5IGB3 K*8)+R2FL)#0':8.24UFIO)F?PV!C_TDTMH?"K[
MH3J9I_>WF I+75;+!]@]>B2E$"W(2%-F5=M2.%QHRT9M=3Z-0F^;+&.1CAV8
M#)82WEF#0AX!=*;L[3E)@B,\J$3.L&N (*,U\_:-0=1+!H4H=WV"LHG[9"GF
MM:8( *=& RT+Z(=4#YVY1YD'-?=K1]O_YU41+18$5SKE+^R2H>0G3R*"==0F
M3A1[;N;E/-U+*]$53=L(A0B+362"\J&),LI5]=ZH'FFQ*5:B@(/Y+OSY]\D(
MHA],69OU[<.\O962Z@!O3> C<!B;$L+_HNU1XPR*$7],'?%QJLGYY/LO^![G
M=MK?T6:+3<.@4[]6\A;MYK-Z8.:]*F?4ZP0+/WZ\F H%SP^#F1!%2)[@HH,9
M6SBNUB9<=*)4C2Y(?4>RO(RO W$6[2>'M.ZBK;_,3P?SUUHI+3, -+Y.:[W2
MX.O08R%OU&<+E-&-FI 3,-TIX[#+#SDBF,%+GH52N.BU#$O]>F+S$/D]5R]4
M:<#CHM4?9@G#ZM"Y"Z[#>@GO41-PNY72.KA68B]-<WT(STI1 0)$&DRC\I]T
M9!3\O@>OYC^QZ6%].[TKLGD7N@R=*$>9*&E3,)@&HU,8")(P(P7NNOQV^-C[
M?VG#MTR2R6\";:)8H%L=:HJOC]ED06\;*@@"2VP?3UA#6(%U.<MMU4$M8'(A
M08HF<?70D^:V0F): *DSV^(O8XN]5./@[,84 >B@WJCM$4A,EH][3)(ME.+I
M)A29XWY7DY8*M*VV))\;0N\6(+X= K]9.$7(>1]:/,Z.X/($.8H,FPBNRH;U
M#&:!NV>^B"O07\(11KV7GHRXL1AE?[$H?1&T(#7PXX*K@;V1\-: ;G0R%XP+
MA.(:H7#P/P;M=*.0[MM;O31\ES)!%H >=\[QXJE80'1D*9G#^&7#*H ?02FO
MM3P&DQD1I)KTR=^X&E(]VD0)'0L+\+!3=;H]68B$\@="D$3KI535[;#+;!>*
M+E5E(R3D#[ V\PEQ_"U.3L@\@=;!]OR4",\M>JAC=V;Q/>B[33[^4G395,Z"
MZTL_ 4F]XF+=EG"7ZH<XC=IY/R79$Y??<%%;_5GAP=R"ER!>]!N6ET%LP')_
MJ]WN!U X<(F<3_5_-Q"^$IVA-.@=!.VEJ+T1WUFVCNL>H2D,XI;N-;%*R_!+
MI']N@V.H?SD7'B?"U%7@7H\LIY11V $F>/'T_":MU[>3S?A:/CP]]; >^N$,
MAJ?GP2.E4(FWLRZN1Z_=O-'N:\L2MVB7F_84&ZEX3'IA3.Z">A=OFQQH*X;>
M\;78"'0"L'Z,C\K9\C1Y%CVTBG3;CO=>CF9/HI*!]28 <6('B3/ S*0F!GID
M"+=/+ ]8OJE;SX1+\.-I6_UPN13N:BK7\ZC54[JK_^;34!TK4>Q4BP1X,X,)
MAHHJ:-EHIR?O"QRA[4_T3JR&< )(6LCP%)#2 K1-3A]7#6L'"Q O =)?Y::Q
M!ZZKN006T36"?[^L[O467W"BD80Y0+,\JRYKT8*Z?WITZTG/:/\E)=[.(JT_
M1QV(<F!<'%K?0RBQ0;, 8LHDA$$LZ%I#\?!FFP32W7OQWH+$"W4D,ZD'WY:A
M1TVR99%F@5O\"Q]:OB!T&^'NSTZO#J>_Y#8-M!QA74%',S8Q:TE&F\4<.9@0
MZ<#>L?Y*9BIM2HLBYWE$$4VDA  >84&55"+SU\:"*9-:-"5VG9RG=O7 ():$
MU(8=HJE8:H;=_K:\VZC@GTD%8UIC2WEXPR%(-GJ5'"ZFA+M8!5]+/H"6/TY^
M [N\N[M=VT)[[R/;U%Z_9^D6:1K7\YL7?HR2[QV<Q4]MX/4($5LS]XM(6P1@
MLC(>T?EW3&YO"Q&WWSOT0Q[_8D!ORHWBZNX348<:2;5*8/P*?7V[M:[S]TKW
MT"^?)_A:9%7TVR=P]&,]>+/ Y!L-5TNZR_&%E:LO/(*Y?*W(.6>/6BV2,F%A
MJZ4]3/I=)3*D%%.IC?@ZPOXFI),U-SYWN?SQ>_E*Y)E@)S]GRABL)T+/H04Z
M%]IWZ<[1@KD($1/=RD9L&=##RS^_9$! V)8,X"YMRD7->^!J)H6-GL$-EZ F
M^86Q?D0^5M]4"H=STZ=SMQ+2641YK+WN9C>5?9KR$"*R,@K>GL:GFO"_WEXY
MR8FP.Z'I/'*.'*F7$_!I4TLJRQZ^MUH!KP5(/1=271:CENI]YP(4!M/27Y#U
M \Z!J!^%@JQ+$:@R5E_RV9<V0FT2=X,Z M72_M*A40W>MSV>@%IN8V(K!G_(
MCY0>R"BUE?C3QH6\S&<I.&I"VPD"(4J^IZ%IR<;3R!NM!H21#?T6WTD[-Y3<
M1@0DD8GR$A/IU@WGB'$_?]C -I8:Z.J"U;]GK'X[;X8#BSR[V_$66X0(Q(_;
M1UY9UO]3;J]]FC#_57TQX]Z,0^_,=IX>+,]=RML:*00[VMQ\#EN\Y)#0_#:2
ME#PN__'%@A+*+TKE;@N&'Y8,PP%*JW!^4?P%LIG"CG9LFU%OJH@*XB;W5;#)
M2^1NWS9S?$L^6/E0O!"(GH-9$XSJCT<ROEQYCA?JV7,MT-VG5&L_8FP)^6R4
M50OZ+Y]$4_I-)UNLEOYW902?K .B05Y&+:YFS>2X/% DT$ZD4:RD8J-HSJ=[
M;A-2*)F**+GH^(6KLEKTD<9?K7QWQ^$H(?)\G0[C3W(MD',1L;Q.#YAG[#V*
M'B@@X@'+X)+J2>O]VJ%ZC4T/="\;S;7977X ?SNG%ZUI<W]NL;4Z[8U8@,!P
M>FZN+=(Z\V_E53+.*$#+ N#->;)A%RY./S.$*%F]/'JE.!+.>3,%.3499+5"
M/E([*(Z";EUP4*:RI$@2#6(S; XF[,',9V]$HEERJ.G,UU""]0<I&,H%.V*,
M/O+%K^3VFPHA/P U, !&%Q-=?2C)@/J-W#XLN],>AW:00M>\&*(=60XB-.$
M.<8D3*\1"1X@!_/[5\(9?LS9E*6!AKO))7];7\(7DFO!#W\Z9HV4]ESTM5Y"
M>V@F?@KEUGFJGZSO V]K/(&63VR[_!Z2W3U)X4:+)T=CI"GO&,3]36&!RM'6
M BA<3K93+HMD@&D"M'JKV]V54F3<:9*#W,VJJWPW$S4]!.GF$3W>PQFVE;YW
MM&WDD#W_R5VR-8ZWS6D6RJ^\WAVX$;: W'JR O: T5+W4R:ED:RGRS([ER>0
M6%S;-?)NLM2%4P'9_]GH%#IVG'9_>J+$1HK*OV=_Z+$K5XGP87:+ED%BT,H$
M1I^=L'.0N[:?&#(X/6''?_(N']J=25K*8P<QP!]-I.GY#^0CB \,ZTAE$ZX=
M56F!HO001B-NIM02TVK06QA0"O/)CCJPB=#G4VL1LJJHO^3Y'>U4&M;Q8HO!
MY7.H">7>G_##:&72RRY2^LK=&RW1#O*)^.H_$PSH"U\[[2G$YJHAMV42T_T@
M^<#8M1G&*I;[TEID.*,EI;Z"8>/N'0YR&!0_9;64;)TF!T/EX#%6;ZQ4BRW7
MVBV MBZ"/Z5VMIXC-Y6M<NQ5_@KF>8=#8LU)#GAG^^L>*RF(?@#S]]EJ;;[]
M^\/H)L'\]O,7UHIJS2WN!BI[0U\_0?II7.^HVZ*D)TT_/W8"FKJ-'EG$M9'?
MV=8Q'^N^6GW]<DL[9(-ZTC*B97_J*BSLCV(\G0;7M@I)']CN2Y_&P:"U7VTM
M;+&'*R(]L6UOKR.W_R\BU\6# )&,SO*WO':G->G]?0=/Y+U^^GZZ?>./N3N.
M*:]^K?J'%?<OK15EI?N6 ;.]KJDWU7-]U]6].EDUN-\'$2=O(N4TQZ989FVI
MWU1#^['CU+Z_30N:*21"DEH[8;E+3JP/<P/ JI9QH;SO%FQ%E)U8 _O#B-)2
MRQ!>\M-IT"^G]L36P#9QE#:4O;C'QS2-<E_/3MP=?!3O$<(Z'['(U*(!51Y-
MJR*D)G7L^FP=LK8FF7K",$WIMY*B4_2EKWVU;\3R5$-Q0>26/L$5!W1OH>N9
MTQ&HB#H'U./:.P7+M2RLDCJ>]AXBO@@/-2+KVYZ"0AQ)[_0::1<@[R]AN^LW
MBUDK=,A)FZNLE;=YO)R$&<_-CR)L3;>"05FDR0)GRV+0KJ0*R5GZ1WAV=K/5
MX#6:>EE_^@LOZV?"\[TO:V+V?(L_4'-,%W_88SOW[M["_$LUQE>^S8R>.]21
ML<_QQ]S$KA_CH\OVYLR.]Z]QSCQI^_O)QRL/ZSA7]_W^]4A#MW%EL3#B]\C;
MK_]J<_E@4V @BA;#Z.7COG@JS BC,JY8-[Q9^@]I/;MV+[GH"F^G:4)G_)XS
M G9=[NK# _&[S.L&IH1=_/8-Q3/GISEAKB\+-I8]G1G8>'!YV4_+,C=TT)LR
M?[/"Q(I@)^R49/%R;^Z!'4%5T06KON18'UJ;,?A6'-5^P+HZOBPH^:@^;OI)
MQ+7ID1#'M9=F;(*R5M_>Z.SBZE:<S=_UK2ENOT_A:X?MR9ZT'1>SU+KUS(R7
M=8>C3I*.O=TE<=U.E!)6C9_:?2C\RIG#X@2O>[RRW59'3BQ[W)-R.KGU[I9S
M.D7*P(:C=XLXYM:P.!BESX&9&MKW(S2A_^]WHCC8'CZ*S)8(F]OW!S661P]]
M"=C[M#RR&YL\+ <0F Y^N:G&&Z8"UI#IA&H2O.1\)+JC.]+<*H:.3(&>!3NS
MNV3# JP0BM+46HQ9VFO<=54*;MA;211J[?W.8V$*F>] B%-[9;5CQD+' 5PY
MZZ,"1Q0K 3RT8XJ/NA:@ )E"-MT!VJ;T* KM")_1P'6LML-KJ5;+JXMXD;'(
M:_K$K6\9>PNR:F!;[J^W:W^H=V2]'_+40&(>L=8<Q6!]-V'+S92QZ6^T"'\U
MAVWT.!P!L@V]&"E&]O<%TVTQZ[HAZVI]$=;V6UNY<;=L&,0[W^<[L>J;LT#<
M$7T;KP0KB;SZ7-6&FV]H0\<\):;ZDLKW)KH*BQ0[',E34XL(]6I %^]'!F.<
M)%JP/8%S^ANFXA( 8#,;%'OHVP#Z-OI^@.Y+I^&S6)J.4N)'1B8 LS2A4/YF
M$T#,7?:CJX#(P.D!LD!'35C*AQ!^C+<X .9&FP%L!@A<N;M"@ &JE<..A.9@
M';2)F'!E/!P;3-?DW0=!FQ Q<OU/GY*T*6 _<<"&R#CPLB1?[1-RD8"'K7#
M5 !ZL#XX-:7-6(SO 4UVP_]($DQ9>S.6VE0_*S*C'XN Y00D D+(HSI+*A,0
MFN5\4[C95K.33Q)G,:CBB *B&$C-D2'-[>G7K]IQ"0VR7F0M36B'1J*M5!!,
M5'G=/Y-=NK1=Y/\2P) DW#04#XGC2 H*_O/SVQ*#S'P4QQ99-) (*<'.)(7F
MBE" *N::,]DN&BLD .KZC"^.0U^\0J+)]2 &V,5Q0 K7CU3^$3+=7>MD,) /
MYWAU8Q>(^ @Q%XQ*&; !E>["#F!/#L WQ; PP!A,L2<R'F/JA''7 $ <P41L
M /BQ)MKQZBNY\G_?6)1XFO#+D#P1,EP*U+,!Q')O!"*8)X J#P'N,RB\B0)L
ME]5"-,IS$X]R(=/+"DW@=#LL9 F]"Y0HBL[MI:LD)[@D%B*X\"W=DRIX4J!$
M.QCV@?91FJ)? FU/#,*X<@J]VS5?^]I%Y(A8X^1Z!0/*3$'XOZ871]SO)CQ^
MOM*,K1(N^UM!=<<(C./H][U+IK2N'T7:<LJ[N6,\R#77U^D5!]3GV]9[6R)L
M,>V%N@U\;;U./3CNJL:!,7G]GH4UQCF/T&//:@T\4C#&ZW\*WSF*B0[X?)B3
M):QYTJWM@NEV7F<@E W59F?N"=$,)B)/Y5X\N4J]EGF/J#NXG5E@08@9@+Z,
M'8O-#3U"6"<0Q%@4Z,<5$ET8& C'U"3'*#=?-FXH'<,\'ZM( ?F+ ;S/Y_Q_
M5Q6B[:0HO[=;^<_?D:/V-"_*_,$0V!\6(FJS#GG&VNJ-^%\*/D[Y+]Q-AM%8
M4M+%:L!V:>VZ8S]8R?4RA*9&VS4N:0TEA\^'QW7QGC%RO>-\N5G*\%-;W<3=
MBU,'F._H?*)R%81D<W!X!M*[$U'UU"YSD#_,O?A@'H5D:^+168^Y5B @3&V&
M 1F6;,40VIT'P(**2$VYLUW/M BYP-$TD#)(^[/D268<@9?T=C_]!Q)<4!82
M*Y^@Z-7J?MB>6RD([88ZGT'(*17:NT- ZI&YI%,DMV_"W!(\K<]FO4E)YVX6
M$0/GP4VYPKY"F-#G)[#]D@5T>W/U\B@,LZ5,8=7,).(X/\5)8T2HEYN@K<%_
M>B)><F/M4@[Q7*ISS8P!WFAAL8X>S=\91Q>%=TPBNF$4\K<"2Z)+I3'GY)O!
M)0$ZVX7::,J[9Q53_ A2P@Z= OV[0AWAEJ[)S:X=Y]J"7<"M=JEZ8D:]PP;&
M:RP1!28>-8:FZ3@C,8-R?$$_Q8K8Y?!]!R$SMU>+(B-J=O"?9WHE6YS Z3)S
MPV#QTF1GB"DBNR42HR _["Q#2)R.NOQW_J=:B+80,J#>O!X^XP5NHRUS:=:-
MH"H@Y0? /@GOE.";&9CMJ)/+84:1GA>S0M2&#437@_NG48XIDX4XR2*H3;?;
M9FTA$9?6H[?C\)H0\B 1D^M/+(9HF6.,FY.8@X!V 0#!#/X;4R\$&L.?S^WY
ML&WS)FTT';BVFLM_,0H#[(\HU/9UUA$TN,66P4BW!_@-3=!<?SWF3_(D4" 3
MH+HE\ENPI4"D/ X#YU'(:%=-36DJ7)'Q!8Q3"@W@#@--KI;ON_N'(F7:Z%X3
M2^/=5(:05$?B5T_A+'8*EW%O4FF49)0/$^,R8OP4GS\69B(WT&<T@\>)_19J
M5.V2%?0'(+CF+(:NC9VO %BR@P-S:2I0*$T87:4K,.;^1"]TTN-[.X 1,5,0
MD3:U+4,5HP5;T2('/"E=-MWK0EP./"X$LKIA9DR$*B3O)Y-CQNM-%KD@;H<J
M+Q'&/%<F,Q >#*0[@%22\:8P2%>"CESGH&XTE0$&W=;X6.5$.AQ+9R#H@(ZI
M7[([ [<A)U)M([3T,K< ,-TJ(("IJ4.TW"]?ED9'--/7:^HX6+H0=\E9P</P
MX'<VGJ%_H%O#=9B&B<"$;B/:TS4NTH.TV4[;9& ',6(Q';E&9[>=)W&?W*V.
MN]A@TB=A."44K;,'  [IXT5R-;I#$;*30>3_]WTB0T7 DMO#FG621'< ^//#
M8@<FP8,(G&(0G6#@R&>>JD?7C0X,]CE1 ?T<+D#(VM<-;"H;T-/\9EIL1=RC
M=']YV-JEC9@C7Q'<"-8K 5<52"<B4_3PJ)X$W#?.C+_N_"5]1P'P3X1ULWPS
MG2MPY&0082)OP&T1H^!"-.X&C>A!#]538L_<V1F*= MB8KC5NKI2DJ<$#HS:
M>1% 'G7SUY5AP0B,-7<)#H.D<[;&=S)Z%& Z3.Q2K,+P$'8JL-%+HY&[&.V^
MYZDG8ORG=X-D9Y&7%\L#&>J[1B,7=&8DJEC@/CIQ?I-G?WT&40V#YC]!=R7Y
MY^J=1Q Z5,4&Y*3&K3=@8L&N*GVAPV<?#!.YLM=GY6FC55&X ^6I/UW]Q7)
M8KVVBB7T' S0M,N*C]'4E9D?<//8]513EZY[25&F]66[ Y6]SV7?JO;*Z"])
MF.Y2>PE\%^D5S$9B+3A-C[''Y:(0_1"O-<0)-K&_,9H62\'S ;%"\Z040"HT
M<XC $FL, J NX@#&$%V#GMY-7\:[=&2?][+],NP 4@\OV;G1"IA(7&,O Q?!
M"#P';(0Q"!O<%1EQ/_?H)0G#N'SGV6Z#Q5Q7/49@7GDU_72T'7UWK8[E13ZP
MTV#S+#+BO M*)X^X2!*BKNY>[B+Q<I:6X67F:8RT4!&([MU=_92TV6/KX(#;
M[5XW.KRV&PA>U5X!1>S66'!>S$72.)XU!U+Y01H6G*0_$;@6Q:& [#+Q5W:>
MF&@E"TI_IDG@Z-G30Q-CDQIEV 0QF"%=7"CGV.D<<D@L#\HVQ 81K8"0VDUK
MX&QP<#%QF^0X$3 C2<@UAW9!W0!:E)+!Q!'HNE8:'C$;CW]P]_6XXY/09[R8
ML?-:]-K;K]VS[ABD2?9Z!=6[%QEWZ.,O+NCCI,YZ<K2(@UQA@U^*HVO*=#U3
MUA7<X0?O6'(P$>@8" X;-SHA >@PABYCNS! ,5W#>AO1,PM8-*S6_.:**=E6
MK6F#B$KT20,V[ $0^Y3P[X[#^GD 0N$(,9PR "#MM@_ =?V.-!M';/<B \MC
MK=,!P&XQ$#^]_/^K[GP/]LY0C N898C'$P%,%@ Q@+759X[[ ![_Z127Y*Y
M""7K%G4#C;_T"41DMF'V=CG+G8,0PAK+*<ZK@C4<I0 G H/BYVJRD6 $J*M"
M$\?S7($09 1NW6UPT#=T<!ORDH]&P[B&SN/&O2HT2A5")X+-:P&2^R81?]L>
M&?L*W;MSUS]9]9G/<51MXJ*3=,!&#_]T[86,UTT3!])S^$E=LH2+4J#A-9"M
MU+#- AI^).4H-6ZKC? >C/,8P-E)@=A+1X(,W,7553=)^%K59KX$Q--Q8=!6
M EUCZ0$G/:!:7Q6R"-Z6(P7V9B6^<25V<1!N= Q- LJJDKKE($&)WB;U1-:"
ML:.Z*!F1 'B-4_&'2)@<&< _H[&X =Q^A7Q1!;C!F#3^N0_](FT:9B80=PD&
M+R35)RT1[F60=V1IZK2M%EG1I1S,XHT:J<9'4HV-TOA7HK*0 53<$A1]&\=P
MWR+3XS"8M!9)&=;,Y#8V<D*"\^HN92'M_Z-L&.ND0!^7[]_/0-;]%Q \/4[*
MN0Y,7+H"=*=[C!TF3]VA[.=DC+A@7&3@^741LD77U3TR#4<Z4G^+QC:^RW<C
MC:TN&A-DC6Q8XR)7HS?D1C;7Y)+B\H?O+>[9?N>9&+<LS7HYMTZ^?X\,=)&P
M>)[(=@W=BTIT[CVT!_?$A\>@O>HZ]#DJ\'.(F!\KXL?NDX-TKDZ=G)NC /D
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MCF2JCVG/#X>KR[5_J4[^^-H]W;1BAD%0K3BY0/GT43/S\_X5$%/YKQ] ]"_
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M^ # ]X[Y^/KJ;=+5_?_L/]2I\X]P>C^>?.13_#8^;)$%ZU@Q;5 AU9P8F0$
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M!*)@*APK%IC-*1DA4F*JQ!IQWW1)3!VF!JZ%:%J2JDPREFN+RL 6&K5U8=0
MWY.8?DWVQI['I&41&PK,EB ?%]Y'0YZ- VBTR'6=Q+6-5:-SX9PXX,XGJ5TA
MG"@2V>U6L5_)S?AP5NXFA@"(TIYLW6X(\@7K#JAF!A#('>C*5NA4ZT83!62
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M\0OOS)%8.D?B,4R9-;9EUMA>D$[NEP5.W<6I6=N'X=Q..[?U8*.3:E<GU4;
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M:"+73BKC>\=X%4R"23C29GA$:]@$*MG0$<:7X!-\PIW6Y$XP8REF(/F;E'Q
M:CY(O='1XS@7<4M=1X,Q:<3A49*$WU04T>1= >LOQI5^K^?F //&+X!Y8U^/
MXQGK>+2*3:*:\5UC? U^P:\IK^)>=;"+AK)A!+.AMXR'P3)8AI-MRLG@RZI\
MP1YJL@>@:Q5TG=/<BS3IJG+HIDU*RBQ/BR O4A6W'B^DY3P7ZD<#.S*Y.2.L
M=)P],0QX!^^,YQUNMPCK/&M$FTTTX_O0>!KL@ET3K^)<-7#+O_:SV?2RH?N,
M?\$Q.(:+;<3%8,N*;,$:ZK$&@&L3<.W5VS>[-(;=[,%N+X_);2LPZ4=CQ\(>
MBO/(\Z8DL[/Z<0=_G'@U,= 6;<9+O@'K/,]>[" :&95;W/(F/[.#7N2,-C$,
MMEAT!(-'L&6#^#5BG0WBX1@;6P]=X *M*&.<8!+5BPEDHFBQ@$]PP_Q]3CT"
M*?LMCE]@V"/?%"XPCQK&$K)1SKC&+RH;PRA&D6,7RV",59O^. A=MA^I"/=F
M/_1&X3/M=EWAG6=UC]E4H^QQC%W^53UF$XRBQRJ.P1>;GH2U"KC'P\ ]C,.I
M<KZOAR6)5*BSWR0^SF5G"G[/]>WHU^/6@]I0],RAR=,C.PS_9^)*U?,PVK$F
MF/[<R0T0'E[9('O&]T" /Y,?#W],Y<].[?RIA3U^E/ZV$,;$VA^/@26P!">A
MS64930SM<^$G< 6N6. J,_;EI+2?_'B_"&-\:>_HQJ(P;\I0PSQCF6?OSJ@T
M&J:-K5=4,['1@*_!+_B%>YGH7K0U#".8H6T-/ R6P3*<; DG.Y))*Q5W;16(
MJ)%*,85;^TD1Y^G]^<U!TM'ACYSGR=28#//CF8@8"51W[ "H.@Y5>S5U?)$^
M4'4<J@XMRP>K[F'5Z#4A ,YIP!FUL&(ZUH)^,'M7?&EZAZK!S__PI6D*?+RJ
M6$"?R>ASO0@!?2:CS_FZ O@9!C\+2P4P9"Z&+,O^/UYZ"Y^/EZ; Q]OL'_29
MACZ?LG_09QKZO,K^@9\!\+,\^P=#9F'(LNS_X-!;^!P<F@(?;[-_T&<:^GS*
M_D&?:>CS*OL'?@; S_+L'PR9A2'+LO_],V_ALW]F"GR\S?Y!GVGH\RG[!WVF
MH<^K[!_X&0 _R[-_,&06ABS+_O^X\!8^?UR8 A]OLW_09QKZ?,K^09]IZ/,J
M^P=^!L#/\NP?#)F%(0NR_Z<=O\[SMDS[3U0K]S=B?@9.Y4Y;TP)A"KB\J@W
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M-?8J[K6NK1R\I(AMFX[XXP,@U6ZDHJCD*^P[,_$J/K"^O=P@B04^X,\"&)S
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M0V.[V/O3Q#D5]S_T6U%ZE!Y-M5=31VAL]Y-NM' J:N$@]4@]23T&M.S0K-^
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MS.Z4)F^2WJ/^J#_JC_I7J?[3-<=((_"IY8,58 58P7PW@!5X9P4^-8*P JP
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MV?Q&-=TY1[MS]L)Z]C[FM$G\:),8M?TIS0Z:'<ZBE!K.HQK.!<!2B;E9B;F
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M7..,_M$?AG_PZ]\??O$'_6M9.X+/0 MH,1E<O.(%4AQ^N?2(%/K70@J\ EI
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M^YP#097'"Z"*T_G/[M:[[5[#;OMQ=/3(_+J[TG$D[][YW &M-J0&8MZJ/ C
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M*!)9^;#I_M;QUJG,12=)[]I)V7/-VQH-GK/JR !6+3A6!E+,OAX&!%L7P0Q
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MPH<O\4T1AS*$2<Z;R[Q?/@TQ_:\>!8N!7*V_^EF_I4%@K!!:UTUK^+@Z'Z'
M1#@MHL"*S0IHLPIMUHU<'_-?KVK&*IHK4)A,U',;-H+8,))<U&\25###_ *5
M&D&Y]P]$6A#+PV';:&[*;+AU!6:5Y27T]:3(JT>RX&F5A27DI:R$TF9,;\!%
MX.\<_"M9L@R1(-*<W[JY:M:K+E&U,Y80F)+2#0.VA:D4E4;0EZ(24L]):MA(
M-CSZG3X1H,KL\T#>2/U=X6#\9<JS4&2B+W/V.=@8R-_ZVT(;STDA-?GI@E\.
MU5^MA>IP=/SC'<U:H<7PM]7:085*Y+!N,[C^&K2&SBJT)HM=\,LA^ZLUD1V6
MCG\\>2S$V/SR'FAEQ'H7RTEN ;GK+U*K+%&A,:4I?+5\6@424XA"[;%OK'D:
M!4Y"@\E7':%!'<^30"@*3B_H77\WJ=I948A,R0EC:S=DBDXS_)BB$W*O;]83
M5D*$R5<=(4*UATEY>>2RH?DF)SV;,_D <:S/\*"3J2<8PAU,Q_[$K):3#J$.
MMC/QJB.$,O,D&ACGJ%FMWK\P?D__^E-)B\ZK@>A>62OT'_U&:T]8])*W4,4U
MJIAZ$J.7]"+_=8+5]=>T5IW8"-7)@!& ^M:QP-R%L0E97"*+B3O[>TDM\E\'
M]DJNOZ:U9O]_2$[F"_4G7S+Y\#DO.0M-W**)F:=9>4DM<EX'&%U_#6O1J5?0
MG*P7\D^^9/;I6%ZR%J*X11333R#PDF1DP([MT5Q_?6OE.060G[P82:B_,PR7
M_<B6H<_PMUE_>I>7E"-W=HSI]=?(EI[R!?W)GA$%$SK,L)G\&0)9<K"0ET0C
M:W9DG\SZZV*K]H*&[.3(2("=!Q5YR5WH\LHYNIA[XHF7%",7=H39]=>XEIV,
M MW)AA$!6T]0\9*]$.:5]80Y&";,FUU.#=K$J4%5(TJC)LT/1"Y+3&V_V=[1
M__OXG8^O/?-F&8=/;QV!X\,K9L(1";9](W9[83N[#]\(\D*D2B>V659T[DIO
MFE)\3+GJ_.9 9;V*]U+_@,FT9+\MXI8\CJ>\=8P<_2MW?]X3F<HN$A7G;O+A
MJ5YX+NC#-<6\(5]WCO+"N/6I^]R0F<)6H]MX4 [*.4VY^DOK.0GW1(@3=2,/
MO]_)0-]I<+\"LX[CH.P0R9WR3OPE58G8:3&MA3I3QL1 UEAD5/ &WAC#&VO<
MYN7TKC_J,NSE&N<W@Q[.PS"0\&TDX9MK$$@!I^'"2C.#EM#2%UI:XY5/%)D'
M#,?Z*U.9Y>=Q4W15W,H:0:]FAYEK2TI7'P:X.0T95EHF[(2=GK'3&N=<.)UM
MBDBD]V2S\^-[_=GLU#& DM-@8:5A0DI(Z0<I:UXE.,JT_4AD63F4.J@RGT+%
MP[\+_9./XZ[.B\K(++&ZUOF5AD^DF1+.84X]$\Q-+H.W8]7C[O++QW8-6SX&
MPV"8&0PS.C&$)M#$.)K8E:H=R.N\*8,B5?FTIQ^AQ]STF!9)N.%SD@:WX!;I
M&02!($80Q/C$;!CY(CK4MY<O<4Z6\Z2H#(MK8&3_WD8'SQ0J^)2'0:574(FT
M"SXL!DGXX%.6U8ARF<:B/+*2%K'-M)@UD*90Q,_L"XH]70#%R,K@"3PQB2<6
M96O[(FLWXK"WO14<61&F,X-)X]C;? V2#5U@M1&MA>%D;# %IAC&%-.>F3L5
M>3GO?#\YOW^6Y"?:[-*KMHC/8_FTWPW\F K1X4@.S^X_&T<R-=-,9*/4\'+_
M8TOH8M4VS%92:'R,M8</C_S5MZ3\*QG9,A1:*+:X$!3"F:RF%6ZU,:H]#/+X
MV+=3*3&LE9DU9WCQ+(B$;3E +IQK<X1['.:Q\?^8%"G6M3J[YHPOW@65,"\G
MZ(5[;8QRCZ,\/OJJ2]VU.KOF#"_>!9&P+@?(A7-MCG /HSQ>=LL8XUJ=6W-%
M%]^"1MB6]=3"M=;QG(:^4L6%BEMZ7'L'N?;^6X;G^IO%,]MS/[WIZ2K7"3)G
MH(:Y\WR83$&EO0]&C$!Z8K4WH ;4?63N+ _JG9I!O0NH1R\ U -D;B\/ZNW:
M'V$;%^LRJ2N/DFB+5%Z+3(87HI?+-=*T/-*A]_S&6*[>W[UXKW]QFNMAN>N-
MV5G2+?\SZ[]>9H%-&<D@/R_R3*/O+$GS=J.C?U0@7"?!O%'MI])K"Z@I=#'J
M$9MQ)0?Q(+Y*Q&^;5& "=L!.W3I?W0I7QH89KOA<#L^>)8 L8^,,62QOTQM0
M*0/U=4'="HQ[61N#<:\P[ELU#+S=AS?U+^R '52\T./5E N@A[DU[F9RHT8<
M%R(ZCH,R2EUYV?P"F.<!\W-Q,P6ZY#T@'^3;E=/4H_@RR[7SYC+L?;CS:]ZJ
M(<'4(!K)"+P 3L )7.(%1O0^HRFZ*FYEO8>$R(_FI,'SD3,2^_@!Z/<7_2C_
MRR-(#K0"_(W/?=!_.. [!W"!B4$\[.T4(&7OLRZ*-&CK2WS8.64]''@A?$:R
MP%XGJ'7RE])@C?._9E<+]C*DYO5#<,0;CGB<2ZWT= <4&:/(>J)I)$>\]A%8
M DMPDO7F6M/&ECGL:A_'M&A^VVN_@4M/%\ E7&G]3#I)XM:53#L7,KU)THZ(
M WG1_$*S>%ZBO!0_(WF I\ $F( C3!W'WH;CO0]J?!-IR/*I>0GP;.",1/[_
M9^]+F!O'E33_"J-F9Z)[UZ5GNZZNJIF*D.6CW.5K+%?W>[VQ,0&1L,0V1:A!
MTB[UKU\D %X2)5&V; %DSK[MLBT())#YY87,!.H Y/VV\CY*_=4$1+=Y$S"P
MQS>V5Q^\&"80"8]' O)_$^PA1$"#$= 4JZCO#T/!)2X)X]/P7FA@2;#3L!M%
MS/7%>\UR_PD-Q0CJCJZ9X,FF<W>][5&\7;4S1O*NO=+[B;S;GQ!^=R,D#9G0
M1 @?,=;M( OG++QD@Y"3G]4.N>+,2]P8KE+L4W[ONW/,>Y;(>O/T'DN4XO4A
ML&!S%<^7][4NFZ,:L=@$FNTPC."KIC:"SUCP677?VQ,UWS]90'R.T,L'&,;Y
M&Q0(15H;";PV:3T$WNP !%X5KZ+&6TOC(7B,  ^JC4>I#>3>]G&O5;)W[CZA
MMT]DX#2__TI1^S@)/>3BG(L7;H\IK)QWM]_[Q:3N]CVQCT/&?3@_O::!^$T=
MBFH&+(W]1J?G)"3J0/6*\HB%(0TN;X_DKEQR\47Q0=/9<OF.O?J2CUQGOTSA
MTX8>;2";9P.0S9MK%R.;9P.0S:TVH!]OLA1MYO#H!W43:)!^Z'/JQHRWG9^5
ML;QH7XSDV]98(<BY#>/<UA@6R+D-XUQ[;85'R]Q#W@WHCV^<)!0Y5G#L_'X8
MR:DME+'(J59RJE4R=?F5OT6J'/LA"5V?!-THHG%%H&%V0-P=,XC54Z_'HEA/
M-:W*\.@%1'QEP3-R//1(-.J&'OP#M3WW)("# CUAX0R0LV0R/]F93P9^X%?@
M;-F\[4!<Q;X70R+K4':3Z23RW+(6-96 6$;(YTES6<:YFWNGESNTVL*5S.9+
MH#6>,2>,#D@ #7?Z(TKCTYB.9T3/C6"J0SIAD1]'O_OQZ)+[0_& X)S$"1?4
M/&><WHQ(^''WD$R;+Y*6HJFN/'I6O-LA-*NX3HFCQS <BJEVBJER\3HG'KVF
M+A4J;! TO]8<9=&SRJ)"47\E8Z',::?,R3^6;1KT^M6$*')0Y#S1_%G$5"AN
MGEG<'!.?_T:"1!B7PJ$?CA0AV'C"Z0A(=T]/0Y>-Z3-)HNSQC[!\#ND@[E,7
MS&.?;B#<U+TG?@"J[ICQ/@GH.>%W-(8_S#X%1=TJ0IHGYA['Z-N,FM7GQY<V
M#:N0AY(:)76EO:C:?3V+H+YE/!+ @$;:,>7C;()"N0(*;!38+RZP:_/ERQG8
MU2A$H?W"0ON*LUL_ON1G+(I04*.@;J*@7LSC*)Q1.!LLG,VVJ%\F]H&2ND62
M&DUJC(54/=$ZR6VR60V]$.:X%&4URFJTJI_7JJX$'HKFMN<OI"QZQD@(;? *
M*2['G(U[210+$XC#1^K!](R2B':]>_@YTKI^FB;KH83%Y(<G"JIGX4@4=&B#
MYB9CVK++ V^/A*##%RQ ,!FL ,4:&H[KO/MR"?=8_D,AAD(L+[L5FWE/H("_
MX%U$,4_0TT6!M?:[+Q=8=7@-A1,*I[Q666R+'P[%1HB?(B$4N+S3$ MS4$ ]
MBX"JRV\HI)H9[T(YTMJ $T*U$?D>B&#[+8'-)E @L*UU%!#,]H/YZ68] KA,
MB-D<EFI(%4<]Q9Q^ZM/6=?D/2'C7#3VI [+I(1WLZ2D^>J<K9FV3H)G+.*D
M\RIROJ#8>=KKFI/3LYCY7BZ\L0);*)!1(%?%8,=CRF'.*S))6Y&B&$8QC&+X
MT5'F"D2A\$7A.R]\^S$G_G 4'[#0VT"2^P4+792^*'VW)7V7\M_+"> *5*'X
M1?%;D=6>SW3#P'N*YMPG2&#QXP2.B5% KP=2%- HH!?D[C\&=RC"6RG"UY:Q
ML@7O%9FV-'\,)>M6)&L%UZ' >C&!M;FS[*<\?$/IKW.ZL/ TE&<K!<3VCM ?
M_ZKFY\BN9DH4=RCNL!0))9NQD@W+DUY.B,W<?%$US@Z_LO0<V4$ K3&+O<OL
MVHS5'+DM;S)?4C6[H8AJ3QP,18L]HN4% E<(Z4:Y3HAN='80Z*UV+VHL!&7%
MMBV!=<^"-A0HM<3_:96L>KUG7AN$PH$2B4;=T(-_X':$>Q+0C31/7C9O@P63
M'2TRUTJ/7T+(9Q)+2RMA-_5.+RB#]AHF@YZ]OP.*I]GI7Z+&?$MH-[9-A*G2
M%"67;4VDZA]XWPC62OM+_^['HTON#\4#@G,2R][3YXP+9B?AQ]U#,FVYO,(6
M5;5>=OD)]V,8#@556P55:4*9OXJ--U$:K?.R=:[ZJF8LE#IME3HS$6^] VI"
M%#HH=)YH BUB*A0X]D>2:C[^$=;/L]T,>\QXGP3TG/ [&L,?9I^"PFX5(<T3
M=/9%JNKSXTN;AY;<!(NR>INR.O^X^M)WO!@6179C1;:!E\16HQ#%]HN+;9,O
M]T%1C:+:C [C*)Y1/*-5O:4(",KJ%LEJ-*LQ(E+U1 MEM\FF]7$2>G-\BM+Z
M*=)ZN455N>';2)ANDK)HFV&/PKFYN0PIEYPQ$D(STT+"RS%GXUX2Q<(,XO"1
M>C"5S1VZWCW\'&E]/TV3]YHI8S$1XB5[[#X'1Z*H0SNT:#9&$1,3Q<#IXPD)
MEU3#"S:#%:!@0^MMG7=?+N,>RW\HQE",86-*%%G8A!+%D_GB:4%'9BS601'U
MDAW L8:G-7$OE"2M#3PA6!N2_8$8MM\:V&PZ!4+;8G<!X6P_G*WJ"VL)A&WL
MZE[?]3\5&\1I%!^('0F%3]9U79:$L7BE+/0=Z4OG+L-#.B:A]_1DH%YK;JA=
MN^&7 7>G/IHE7BI=R;3NO2MD></[^*,8-T",PQ7'<Q?HY<(#A37*'"LOO35!
M'Z[ %HID%,G5AVKC,>4PYQ41>XR"N#X>41"C(*X\-JQ %(I?%+]5XK<?<^(/
M1_$!"[T-U"]=L-!%^8OR=UOR=RG_O9P(KD 5"F 4P)4%2_E,-PQ\J&C.B8*\
M1#].(/<'1?1Z,$41C2)Z05G68W"'0KRE0GQM*2N[K>OCGQ:F!:-LW8ILK> Z
M%%DHLFH&3MEX[,M^"L>,7]-)PMT1B>CE[>5#V!\1CG(,Y=A+A5%KLB(*MQ<4
M;IO+O7S*P]<_7ZHLHIDS]O&B[W7DQO92/A__JN97=JUF2A1X*/"PB!YEF\&R
M#0OK7U*,S=SB5C7.#C^T]!S9 0LM,HL=S^P*N-4<N2U',U]2-;NAD&I3Y R%
MBSW"!2M#[ "U20X4XAM='H1ZRYV,&@M!:;%M:V#=PZ(-A4PM\8):):WJAC4O
M2)QP>GF;_V6MH&A!JZCGN]-K&D [VSE!4_7U*^Z+/TT$DXYE!7C%"10GKM!1
MWT./\F#JA\/25QKJ@:P,!E93K4X4<17!-BV.ZE(]/]VI0W #(;^_=<@+ P5!
MCZ!'T*.>MPSR5W _!SPY?49#?8G60GP1@0V$-.IQ!/7::$!0FPUJU-,;@?0%
M'1*$=(,AO8C !D(:]32">FTT(*C-!K51>AIC5\_(E!8'?0S3/,BFR*9-E*5M
MBA\TUO&V7U8B&S: #6V7A6WRT1KKW-@O"Y$-&\"&1LE">\-F=3V#_XEXK')Y
M]3O(>5S]B_SDZ/MUTQ D%OVIN.!77](5?Q*KW70\K)5A/8M=T^UK0A1!91'T
MO7_8(A$D5HLB"$40BJ MBZ#"//K/LN2CH5[%O$ *LWLORBM'X83"R1CAA+Y1
MQ?3V^$8(FJHG-ALT:,TC:! T:'^:8G\BG*J>B$FI:$':8$&B]VB7$-K^ 1\*
M(;3(40BA$$(AM&TAA!X.1MC76 :*IZHG&IF+AQZ2.1X2PJ;JB4V'#=KT"!N$
M#5JAYEBA"*BJ)S[/L55UGV;5;'>^,S/<T]VG0I@6VNO.7MQR3P-HB9L:_%\%
M>Q+NCJ95E[R(L?M58ZMF/J<D$OY'YM>6/KR&EQ)$'Q8:F6?#Y_S7]2]S9C$)
MS@F_HS'<K)MOP8W@W$,Z@1(RN#Y\N1LD']M,85'17CKGH6)#Z2H.VJ3\R)\T
MPR_%EZC!+<_S3LO14;Z19CDV-BUSU[ID>M-H,% T;_\(=..B&04H"E [!2@*
M*#L%5-VC!S0D40X:+'[0?MN0>-R (EQ]V(02>TL2&^4JRM6UW@GE%LJM1\@M
MM Q1@ADBP= R1,?YJ>(,A0X*G;7>"4%M/JC7ME'>V&"CP%&[F%S,)7Z*!/*X
M8!<6BJ=2P3F"MQJ:"F&B%'BTZ;&$T[8II>KR%@H?HRV*MHJ(;;.[B6*LQ1!<
M'EOMWA,_ "+?,AZ1H&AOW=,HWMR9V)X-5D75ZH4Y>L;"84SY^(R1L!TNQIJ*
M? EQMZG(UR3G"\=@ZT,/)2]*WH;'G%'R-L>M,S2BW#9M@))WVY+7BD@:2M[F
M2%Y# VHH>:L^1<E;6_*B?#1 /K;<D;5(,*+\62!_CI/0P\!FFX68.;("@ZTO
M:>15(A_EJ8'R%)UFE*?H-*,\17F*KC!*/90J*%6>*E7J)GBAX88B# VWAHM8
M3&XV6NJB;$39B+('9<_&J[KPF (E$!Y3X)&K :(($Y)1%&%",HHB T01QJS,
M%T6&P*IU4G,#X;46BR(4&&B[F"?$6@S(9MH&XG,FQL74Z['QA(0P(K_B\&8D
MYAN.KCB[]6/)/E%#FUZ8B/FF'6P]EM=0.!EM+: (,5>$($2-@6AVJK5VQZDK
M,K4PRP;AC19"Q9GN.BW$RHR/,F9+,@8E@4V2 )%F"-*:=%$40MA@9?Y"QY-U
M10S>#6*NA$$Y8),<0)R9&->W(OU(KS@;7QP9%QZ)H$;E_JBFWVOP%PJAEAXN
MHA!JB! R]$ 1A5!C#A%15)@E*A"*ICO_%RQTU0P+8KJ%K^+)(>+;+E.@;A!D
M?12@]#%!^J",L$E&( ;+3S0#@Y?QB/(JBPO5/4*YF>I^!<NC7'EQN8+HMPG]
MB"Z,XZ\?G,L-/(S/&0=I,Q7ZNO'#-5D,19'1T7P4&,8)# 3DRP/R]=[JAH^E
M 8=T$/>!+S;GQEO1MZU'HE$W]."?H[\2_YX$>0I;<X5#99_#_.,J9G@>$\(<
M*?5HL\;0;G'+&-M D;G71)&)@@T%V]8%&PJ.%Q8<:"C9+D^V 1E;Q<LV[:96
MBQD4!AA209V^16<@A\,-B\7VS]PE?4[X'8WA#VV,J\@MJ=J"&\'%AW3"(E^V
M!5Q>2HBM'ENCRY]#[&V<"9_Y:'SVUI$UY0I*<LLDN17UO"C)VR3)#2WZ14F.
MDOP%)3G*6Y2W:[T3RC.49W-/VZ@\:U)/-Q2/+1./:(Z:);XM;>#5?)F-DA4E
MZUKOA)(+)=>C)!<>.Z$,,T2&X;'3AF0L"C1T=U&@62S0T-V=64J;!1J*'10[
M:[T3PMH&6"\/&<V>J53=IMN>+$*\#MHX(=,T9^V9KJO>4+BKOCA V6N/[+6B
M]0[*WN;(7D-;[Z#LK?H49>\:LA<E)$I(E$ H@9XN@8Z3T$,G&\68"6(,G>R7
M%+.5R$>):J1$1=<9)2JZSBA14:*B0XQR#^4*RI5-R)4%MR<)7J7^/00@T'A#
M(8;&6SN$;%UA@')W2W(7I2-*1Y0^*'W:6N2%,L@X&80'%BB,-BZ,T%TT7Q@9
M JS6R<T->+:M%D8H,M!^,4^,M1J2S;0/Q.=,C(NIUV/C"0G+5QC>C,1\P]$5
M9[=^+!DHPFL46J%]GT,J/9;74#P9;C&@$#%7B"!(#0)I%E9><G=1=8#YBDPM
M/.A&@*.54'&H4GT)5!W&1RFS-2F#LL F68!8,P9K36J-CB V6*&_4'NVND(&
M>^&:+&-0$M@D"1!IIB#M,AY1GFUS81QZY@C?9GKF*U@>)<L6) OBWR;\([Z,
M.YVWHKWZ!0M=M>PJ]BB<RR"HC5?JAC9/7Y/%4!BU-E4(A5%SA)&A&4(HC)J5
M&(0BPSB1@9#<"B0QN^[):,),-FM9N+(Q3MOY$[L%O0SS0=7+#>7CQ>V)V\Z)
MJW<(V7+C;%FWDT3;F1,[;IC&HN4T0>1/S*7<!G.N.#5K.UOBH>)JACPL,B3Z
M-VWR;P1O\?B0Q!0X;__U[I[X7_;,[+,%7Z:AEW^UQ+3I)S8P+?I%S?&+D)W1
MGVJH/X6LC7Y8X_PP9&KTWQKAOR$CX_EL2\]G[67]V4 <<C]R__QNU [<[6\]
MDHRQNS;%[AK#>AB!:TX$KC%,B7&T9L;1FLZ@& VS-AK6&-;$F%838EI&L>/K
M??3.T3M_ @OO6L["Z)];[)_;SGSHH3?20[>=+=%';[R/WE 612^]"5[ZRS-G
MZ;0>ZZG1)UJ??TOG]7N//Z_?VVZJ"E9BM\N;0K9%/ZQ1?A@R-'IPC?7@D+G1
M]VN@[]<0MBXWORMHR-/PZ*]$[$WIV@39A<V;]W'D,2;X0)R.@/KW]#1TV9C.
M-[\+_$BX2VKJ/O1Y:_!A<-[1[CGV-6M&MVQ+C42+59GALTH \8)X0>U2>)HQ
MVN4,H;)1J"S;3R-Q@GH%D8)(:9Q&F4M'1:@@5)X3*F9ENZ)J0'Y_,7[??@M$
M=+#M9GA+'.PVRWCD>N3ZK?<6+3%\WQ^&@OZN>(,2C;($J[F,M4!,WG1VK;<K
M.A4MWQ!3F*VAL1GDU:;SJE71D252%306"X$.E[=*+\UPY@V+29 INZ[W9U)*
MCT*^WSK?K_<RU017#U]!:R.!V!RE@5!$*%H-1=2)&P&B]"2C_&/$Y$POC+F]
M07BBID2 5M$? 6H10"W6GSDX?A//9GSVQ)#PH>";0I5-)'8L@<SM9H('6##?
M"7W,MVH3C&1*>[7&*J;L4_%M#UE3_%YS*Y!!7Y1!;T8^1_Z4VKS63B![/E\U
M&ZKU9JEU>VW-U6R)BKT1BKW)+(JJO0&JW2H&79Y#>< X9P]^.(P.IA=D+AOL
M>[_'QF/*@3971+S/%6=#3L:-#WU5[8OBVQ5;8@K#&I7#N!;/_7J%/#?#<RNV
M!'EN)<^=DQB2+M5Y0>F3"Q:?"1',;T8DO SIN9AUI$\+GM#3XYSP.QI#:XH\
MW;,;>C>"[H=TPB*_J8V8<G8N;OFK+_G?%V_X)D\+UNTO4IM@"+8G@&V.\&*+
MB_QP,^)4?1 A!I\1@VO3 :%9HDXSH%D,Z,T1?I8C'FAPC]!\+FBJ@.+Z1$!<
MEDC3#%Q6J\QC_Y["=Q%^+Z(99[8;@58B@DU 0Z @BQK.HEO4!1!98EXK2GQM
MDOES9$'@;/QBU(8S/K)<\^+*AV))]SZ)A: J'9KJ-@5"Y79=ER?4.Q6+X#2*
MF\G:MD:9'TD^!*(M,6?$9Q,CT C;V8\:%H]&V#8N.HV8G?W(SO@$0M/B* :"
M</:C[<0Z$$3(OMMFWZW&37HD G,%_H&*\7L2T,;>A6AK<&09C1!2MD1 $&G6
MACD0@+-/>\[CIQ;A!!G1$$VP6/$WC>5>P@A"%MN$L=$^SGLVHP 9<A,'"6UA
MR.>.ZB,WKA"/\-69W=Y@X#P;>$@'#8WGK2=J5V_W-IVO"G(AT P[BT)(&7K.
MA.!Y_H!%"Y@?V<X0F?VRQM'WT/,CER5B#5XS&;NQAM(\Z1" )AM-"#4+#"@$
MU<L:4\T'!;+C"[#CLQA93>/$;5E"R(HOENO5 D?5UA0O=)@MSNQ"7-F6T(5P
MV_)1,L+-R)-IQ)J16'MIV[#Y?G<C[$3T_QMB,R+>;+8?$88-L27;"T/K[4K$
MH 4VIJP:7E@TW"[$F6YHUJ$50LP6:Q.19[W)B8!LDMV)@+3;^$0T;JM93\M
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M*KV&V"I/C]@R&ENMTGNI"WU PF% /!J-SORQ'U/OA/SM3Q*.V"P-:!XVZS&
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M2K\I#QHMS+: L)+>IB#/*DV&R$'D&(.<5NFLU$L^($'LNU'_M'OM#['947E
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M-!>UCV<.4S!MI:Y$3"(F&XS)5NG98XAE0[ZNHMM7_^\QC8%<X/7W8Q\!W!8
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MBCW!)I%7AEN(POTW;TIAR5\$"G-7SO(S#;F\=Z^^_"*0UA,<".?\DCD+N2Y
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MK45U44[O;>H): P&XBV6$;F;0"@O()$_]R#]D2\FOA#:\@\JAH7>CG-. ^B
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MDB E^ (B0#0JU78:L>$]W?%(WCXX6W6YG6KTF0/R@KCUG"%G#Z4VC>K<"RH
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M=F4>K\ZN)3_D:EWI'/O9[60=X<?/< -5EP'(=NTRD@IO)_/LTUP15W=^DX=
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M7\6?$@D4<N>T@4<Z5+3@T#X;"7E=RTU.V5\5&_6JS;%J1<D\XI.B:>".5:[
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MDQ*W0<,S6\=.1*>+DLE3L)TYL0?#%!((?2!U'08UQ"><.5>YI-]CU&3FY;Z
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MT3N^*SA,BK+:R8<[8/?O@*\X\ PQHVG9@N O&$]JH)&.67:(G0[N(:;KN2
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M!K<,LAL[!I%TGR7Y:Z%JN\&M-V?/WFV;_D(I90E8BR.G(8-Q3BK',, (4_%
M:N:ENQ$^T96'LG=NI(6ST^$K:)6[]G'\B 1^)4H\+UM)=5!C+FD7:OM#S8,>
M&/(4B'/J!DX36"[^B%TPI*IM'SG(9<QXX=M,YD1L=>L34"%D8EMX"VWRC;!F
MB1M6*N50C9Y,TWRF*6QB5@9..\AQ)?U*-IBML;0G*6VE 36$ :M23I-5ZR 9
M#EE@FV_1UGHF58IQ95$LQI4,NH/I#*6DS/.'FJ8,17E,F6-0?TM>->H@:C,3
MK]G>RKP6LHT8K([,L^,T9\B1!,T!N4XK:C@K8&N3,$&@U:@VH2<*91D7WF@$
M9TA@[+*@W(UY_.K$#"/L,/?,[P?1 W G,!!FFY>3B=Y!0KLD"F+%7W%;BNM7
MX72@JZ'VZSZ)Z(%^B,U /7/J]QE<4-J++N"D_P8+ K[_-#I6$_!/!R/0&:\Q
M!QZ/ZU)7%7B*IPC \5)E7-B F"V_8L,C;.L"&.8DT:,<<5_2! @J2Q1W!R/$
MS.P2%*GV_T:Z<\:I9*P7D>(;$2#4(A_0LH,2"3*3/?A.)K0!7 _V8,IUF41Y
M3X'[:TQKDI7T%'%%*$;S- )5J2KY>5)CWA._1)X=?"N?CH'7THE\0-55GDPF
M=::])TLT>IH4' RE]#I&X4?> G:=Q)2VU^=%HL&:@%^\!I*/49E;<>MC!Z#E
M&9-UA7Z-A%:QE,\>DJ/Z><%-'/V^R*?$.">&$4%JOS_9[AF4L?E;Z?E+,,*
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MYDE*#-%#BS 2*CC1]AA<\LC5OF6^7%YT^5[BBP3-1SUKE.*P4>YB@[1N-^F
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M4!(B>'E#YL 5R*>I)XM2#!GW3"FJO+N%#C'JK(J899]GS38P1\.HO P,/)>
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MPHD-=CSZWZIF4YG\T' 75/1@[\%6?WOK8-O7^$#N)P(]13GTT,BGSK:<4;)
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MOT1JJ3-;A&I?2]!R6N82>J"X)4Y'VK 1 )S)& !WGJATC'!I_^B)BOL8G$[
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MZ*IR0%U)YNJ"PMTM)Q C&;!^G-=8F9S)TKFWT*%"'H_Q(D_XX$KF\7*I*[G
M'!0F7*"<WL#LU.L3BQILW")-6<9(:#1_2;EQP(;(A-4@HBH Y$5X-!'RTS&Z
M2B03PL*XJ 0C/Y5 4C9 4JK5QUD:!I>F($6X2C9/F2?#D@NY5)&ZWL E;*(M
MM(!AAQSZ%?6[!:7C89<53SF0^%I-GQ&02Z@\8"J?3R4Q: ")NP?B.LE\) IR
MB%/4&F"="$PH7A'94<R**S$!0L[ZU8^Z^0#]&;IDJ$8)MB(B!Y<SZ+:IUP9:
M\B9#H$S=1 X8G@\XP57J.1R4Y"]!+[V2!K%!^P*,8'8'G(7*:9 N.)=1G[TZ
M4MS.ZVED1O9PH3,\=:S2O?R8WZ["&W2.I>UV X$2=((.6ZLK2+[1&+[3^T^G
M1N[ F[;*XHU<?Z#SJNUEHZ'>.^IR;QH/N0'E?FETLSA7BXU*_)8.K&(3T/!4
M-U"6#2<"\088EHJ"&2O'5K'<5.T-$MX< _%TH-15Q=2JY: Q5]=I<:N.S4H4
M5B?M66R0G\'447RA3>@6G!14YO2;(G2FN%(#D%=54N24*N' &M9<K7*C#8]9
MP+)!_@A?Y1<PC0G&+["FVH1?9EW;G6UYKG7(EM%.# .<Q)B7RI)+K&1V@I(N
M 7&D3PJ-XI2<<PDX?QK-9G#<>&FNB:C&%5?4W0 ND*'*!-)W?SSA6F9V,,F0
M>B/]P\6=KO0R]))&]#),? XG 3JYR<%&I036S28$$V'\HO)1'>>R*LGYAA3F
MW*[2WQAX_PSM?BL(OLKKPK0)75L\BGT/,\A$KGK9::','D4YQ\G2\W@KLSF:
M 6EBUH[57APOROW;9BF4!+7\*'V<U,W RS/V<O/"&F5&!H#.B"MY_'+%<$4R
M'<D8SBX7B0ZHE@4114Q&G,ZLM@LAK-JR'*%(N\:7\AUIKOWY?(HZ!A4N;I+.
M.LI$>".E[K1 VY3;/5] )Y3,FL_/SY?S+MB=!B8,BR6L;\D3%[B3E2O]*R[1
M74%5EFU';##@27'=?=ZTRMU0*9?Y%JAT-0W1VS\M[GJ7'4-=2^52*.#LUW)0
MXLZZ4,E.B*.4*][QAEYWR3I@Z4TLJ2@+E_:-6K19O$#E;*G=H6/T=" F5U#A
M_/"5H&L#)\SB7)UFHX2<"%J:TX4K<+RU8@_9^XUF-G?NL6P[S$;4FTF27U.S
M7=%AL&P$>S;VTYS#*!:.),4%7?.IJB_'K(A4IVL9P%4_"3!4"O#,J3@!N8W"
M=.!BU7SQAXH_SJOT@1R8G]4O9<6AM\8UM9S6LBRCK%BDU5#%E!^P;J1\JDK
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MDJC(%3B&5^@A03Q(I^S%Z[(QBU?@&#BZDCO8^PD.JU)3 &Y_4(\?5/%\'E)
M<P=2Y6K1DTU\G,0>S^#"]CO=^75,/;/@YXW0BL+M_"UZ#,M:$!DG'2P[BH&/
M"-5>-^\;CTUK_?!)YVJO*5ET[\ZMZ!-/K1.S&"=PTM1@G)L)]N8$9TN8(1.6
MYXAZ/=(T*&<NHWD@<^F"V8/LE<.6;WY>(IR@+\=5LRK,I!%J_NMY,0U-41T
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MR K5RQ,]VH!4'VK;3FR,I<9<AHDLJB$BY9Z@9F@G: W8O-(0<Q[[TVH531O
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M/^T,,Y'.RFU?*S(C;N ]/!FD:EUJ]KQM4\C2G1;@N%96Z5E'HJ H+ +6@*>
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MQJ$B \G"L;B*8DK?9BV.M 60^=^(E8@Y9C\4R=4'B+QD=9LI9P_?C0<"QX4
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MG D0^MNSU:>XK=$JM:EW8%LT7=06CY32- )#;NS3382R2D=1VL(2,N9:5>5
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MD?YAN7-,/7=GU8G?]7OG#XF=CSRUOS^^&UO3;>/..T']:IH#O_-<_^':;4<
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M99U#-7WY^-[#R>H!<7[&]Q^H6S=('Q;0A^*E/>"EFO,U@:V^\:-YL3]T[<8
M+@]TUERC?K,HESB@@J77J]_8R67>=@=%=UMAV. 4X1V+6F_/3\+4;Y^':LY&
MXCA[JM< SQ1X>?+E_,4FU,'M03+'&1QUZPI&SKL<9]BO+0NV3Z/=J^UI%,#8
MWW[F54M;]79_V=<(N_'KT$G-4.EV\)QC-8YUN$'Y^-30Y8Q,07<PJ)\"L\;9
MW=_DW&:HGG#N][J\[CYSOU?S.OOU#^X;W<#HYN7_LOJVM/0?'C[<G#TK#A17
M(;V49 LV&X%G&2WYACBAF&&K:*Y++.7P.GL8CWCEE)IZOZ:9K*_*5[]H8422
MJV1H!M'A81Z7S1]TV#5?VP\Z.![JKU]@SQ<@#H\*\K,)E\657+Y5P4T,Z5(1
MTU&WZLV@?U:]>7A8]>9(]WO&S6KC9G'_3!%25WIK866+9'EA]YK0?N\)THW*
M^5]R]3M;D6MR'I;QL:4)4#652@KSW#C=0'>;QCQ1*@?PH@3S0K":@0N?:9K?
M+ JDFV'4O^B+X_X20,451*QRQE1G\)@"5::E7][W)+%3Z*N6P8WJB\Q#$T3A
ME5L^\%&=3BD1Z* Z3\7*:\'$'I[5:)+P8CFAX0RW51<TFPRK7,/;08C+*[L+
M+:H)F&UKSN?(CW!$%L_94PVY].1KFW[@NL0'J 16<.O^_92E4WA"J6U@@MD[
M+DMB?I\1*]3ML *>7*3 ATC/CTJXL$*DT5R-U1$F@Q8G-:F^N:?P\_<HQ%DF
M)V]?ZS)6JE%/5.L&8@::!\VR(/7G..;"#63>;\1/U);9F<I;S@3>\ZA-4VE5
ML;-[A4,<E2_@;$#,Y2L>HBJQM';_!=<?*B6J;Y=1:T;3R_O%W,1H?EH64U*D
MMH6_E)9EF,L22P$U?!ZP-.:RM2(JP<'%TE/M=2BO,97QC+J-2^)05%:-PA?9
M!ZD4*/#I,FP2B^VL1HLE/1@?M:08:(45 (EFP NVG%#9(596I$O"NV"8_$+-
MEW1MX4J[@RM(-F1*6 _;J'5 7-\PJ?5N6IH>9@HJ2$YA]Q?5)T7D0S4)06&A
M4^ V$C3$75'!71%U_VA75/#P106?2^-&UY8$A63EA^5C=\O37AZ@N@!%<()=
MM7:YU[O<ZUWN]?VS<K%%MX+$>#G59ZT-J8_*<U$;&'_V_/(\Y-;<,[Z5CG^N
M'/HG3J$?_M1I">=A&%UQ >-',$M=-#F>./_X\('RC]<(&1^I_/JCI\ZO?\(]
MZ/<Z]T[9JBOTN=3I=56FQ]'1S[L)_?W.O1/%Z@J]E0W3^^F.W@+^WNE;#U.4
ML:9TKGO&\^TGT]S,0972,AS>F^RV&KK]SF%SX+($I9*3W?HE1J\#W4&G?N4V
M:\FV!AV7!=:]JT-W(NJ^Y02G48P#$U-9.X2JH I5+SBH'ZLN U-7 '+>V]X_
MKE\-01F*N@)@$<5A RJWVD=/607P<[L6ER.Z-<.F]:N>>L?U$QSKV"Y'G0TJ
M5D\-EZ7=:^/EJ'Z"9AWW7;^AQLM=XI@U JNW04'[4#)JO4JU>]>O/&SBCJJ[
M,AE"R[*)1K>L;!M*/?I-1N] 9?,6D_!P<IC$67A)&F<Z9;@\(.&%,X]]6(V/
MTZS5E',*9E/[T$!B;A"/*%9)@=:$,1&&44:#R!-,Y)YQ)F 43T3H_T,W"2PC
M\630THO!EJ1^K(9.\U*Z^5(P.Y#G$'J8<,CC_B8 5*+[%IM&G2\ZSM*.\:;2
MQJ&<>%YH38FSU:CI)N7,+YQA9UC15'6O/>@<57Q_<]OOK4E9.\4);TM97M_D
MPAG[$\P07LH;_,&%5837*QC,%;<B#Q01)!FL$%;;NU]&W2X%;=,I:$X6!IC7
MJV:W2E6"<NTG<I>=5M_LM)\]<VN7U;1-64T_=[,5DLP3*K*:Q]'83QO:4G$-
MZV*H$EH&C>V@N89%/-0._OO[:>JZ"9L(DM4?]EVKT<)*GBAD> E& !@ +2Y9
MII8EL-W>#'L2T!3N**R=@Z?"G3/43N'ZQ=J7@W$:FJ/>!GO'/=79U*_/U8.V
M4-WQK74[SR=@HKE3XE>JOP1ZRQJ 32J U;U_NO-3 V/Q*@W,L'YQ@D:V2JY#
MN]&F\:K/U*.@IA'W)0P:;#)_XZGXTK"&<<L-%@9L$0Q/F2;Z4_,C^7TNPZ0!
M#*E]-*AM6IQMU2E-Z;"V[#4_DKO$B+85AMX&\\=VL8*[QPK*4?S:8=0ZV7QJ
M>MC!0?T\.6N5[#!X^S4T9=<XO?KY$M< :H,GM=/'UIREDSC/;YXB7#M$6[8:
M!YWZD<L20QOT._6W&W< V'?5;(C$$H\JY_UM8-<KDVMV$Q]637QX%\789Q#L
MZ4"$)E4XC,+V^;N+2V<F16)ZT\;2C4+7#WR^CG(TDY:32.D\XVSFX>M/RW<F
MCB?'E%P\6CB?HBN4"DGGV</.,WBPW&_5M%%X^ 6G0L^$1RG;2ZF[\)V(8^R%
M)%)X<E5V;VERANH7U-G/D\:I)6P,5US[Z32_9M@Y-M>H7MKSV(?37$@1O^C0
MP7K4HQ:.:![ :4@Z*3ZHT]=W/3!]/>90$C9@,F$9)<9Q-'/H:?"@+$A)&2#
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M3B*O16954(,02<H3,9^C3T_>\7CO1+2#02B]A!C\,;#7KY(DA(%(>O:.U*W
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M7D>];$-9$P[O63LU$;IMA+EZ;ZG;OOZQIEZHOM\F&I2O*ML>8!SWJ0G09P?
MXBE;":N7-3KE*$&M<^)UK]CM;;GRK<GR"^)1]8KF:EQ#$04UJ\;]$XZYU8<N
M=9W1>=[M$A4/F;6TJLDIGJ>F2]XO7;>K02-H(HXM\2DON3?WZJV(M%4EP.S
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M7_3_MO-G?S')TN4[N=57E5O%?+"@/9\\$+_,9X?%+W/YB9U\&JC*I[VEA^=
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M+6;LD8Q8.-P NQ^<.>TL*:TXZ.2$"VT.?_<"&W%P9#H\XUWA+; 2?S-=@?\
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M+_0!O@+_S_,A?G<?[2<> ,V!?6S'^&M!'$-\+[-4S#J R8TBEW)9 "[,X2"
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M?JC'G.&Y,&<CTSY($<5SV*!&&49K>I$^-S!2(J6&14^7UNLJ1NW^WN3UJ9A
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M9%F%)*D[$E$CV]09*HL@)A&AA8%M<M;[R5S=V)PH#+CA<X^GHFQ@H+Y:*T\
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M[W]T=,ZACC4)[2=-XD&WASPE [+==&E(4MK4-FER"):)WO8_9&I6OSI6L%Y
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MC_U]U+62O^.YC0&9DYM[)P0W.P^H'7*\\Y7M>.X36<04GQQ[2_O!#UB^,KE
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M,?4R&6/+#0^$8#@Q'4Q/0NTIIH>*/ T3AQ';=YQ*MX1U^H]L8"XK]1(S$#'
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M/UP=GGX_M21)Z6;U25!V%,]1]%F#8Z<Q2?4D_WW@1$YX3]9^["W(F\_O?]/
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M46,9%E]Y4+K22:=8.^BZOYR;;,$+N,N=\OJL"LLR'?8[DM_F_M _M^OYWNQ
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M<XZC9>J%2HDF=CYSD2;SN8HCZ:YW..(^EDYG' 2%SG/,NQ1H9()_1F 7[)2
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MW<4_ @?CBY7@]MN".BO=P6$SI;ZQ<Y@C]7(F>?ZT<:Z;L4R&E0U'D^7O(N1
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MRTL^ )WF.Q[#R6&$;;3JTH+2IWH<*JOH9@ZVLIE80 HZR/24H9AU'"P@E6O
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M?FY\@J36EDZTILMWBBH408&YPAQ3X-]%+PJSH74*@]9RP?T&=5;VR:V(=1I
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M9G/YG,^&0MGX>DU:7\M>:PH>J;R'<FO=@I>L'/H^1<2NW?9;/4I$E= Y#!(
MGUXQ6"71Z5=J)Q/A4H5Y@5I(";6%["J;F5Q'?=5H-:9L1E2+IF5-'(0GAO/
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M[J<5!+:OS!;>M-$M*>*X<E@FY.35T":E!7;G==K=N_G1+J=Z75* 8/S(O5Q
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MCRKM?Y-C?92T+_PX&82'*)K_1\6J[Y]$H?<AQ'B8OL;[9S*,,X2YI"_DT]D
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M(:V?L[\2/^<&:27#!<.^0"9KVE8C$A2;CHI!49=M-[M!UH[^?_;>M+EM7%D
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M)6&4>HW4'YDO2 J5>:'OP!/#1HXDX\J\4!F?5=V_(JF6'LQKJQ_#!\&RO"D
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M<F66/A7H#^3%_\!CTO(,0XCWSPY*<Y^UTOV!"AA1K)1[M].32IF4&%>6>J+
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MCF._KSP5NP:G&;VN-E[L&NQ-"DV_!J:8K?,9E?/8J0/[M'L:F!IPCZ*VCJV
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M_Q<CH0!-D*J'#^.YWA@/5*H((Q9.X6>#76M]C]^-7#_$;K3T'6RM,Q+ZJYN
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ML2!V30!5$W(^=KK4BQ^?N0WQZB;]3TT"#;/?]^UW/O:XVCYY)^&5:W.T)+F
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MK43* U2[I_2"W>E5'YJ^'J(U:-5@;U)HVL/J0Z-@&?:5AFI9-2"XH8+*'M0
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M6>2S&_]6!-X,X +I$?HC!W_ (P(G6K!P$49B%C;9U12NYC.07!&#WU#$H*3
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M5>]X%'I/ W/RJ@E$FC2(>5(<S5J.%AF;.9XSBV=L%KN1,T<#C"PS!^2W]./
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M Z4:-)CX)8.X,MR1QP]WPP2V4#E%Z6&0AM:?X\5D^1?!"M!(6U9C<PS&+IK
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M1+GNB3MW@=_X#O5X2'KJR(TI(! 2UKJ!6804 IOFQS=3W;_(Q2Z2,U\" *\
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M[$]2]G._9]J!)KU1>VU##. ,Y6X]:E<U[VX-(O1U[F%/RXJ#;?$S=9]KT1@
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M69U^73!N]X]J-R&OCCC7QY=UV%=YDETS!-# ,K ,K+>!97Q9!I:!51E?UJ<
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M@;5;K7=92F6_?'/^?V[VCK]<7EQ]8#+JM/)K2%K8_4?N,;N_SISVE!COPW]
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MQOG"L141(!49E]Z]16Z1X)*H(6RM%6.8*I,/0W]!$GH4>1:_,#!$R,'JSN/
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M60I'Y01IL@O0$KT%S;5PBR\3:G!CA:B%VHX,@+HH-0$4\4U [BCXR/7O4*;
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MNBDW[6K'M :5BB-5'U2\D^(*/,(<9[*XSL@1=JK,X1]4B7.J"S:8#E-S4(7
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MD]I#.QC#/N=:A.^!R7A\%=Y-!&'GFJ?@VTXDW-6\DP>$2\Q4$VSIBEU&':&
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M;5^ASEB1"#NOWK@E>HO]%6=#>!\QMM5+L2;SKA^[FB4^IHK$$0U1T?8^#DT
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M"T6]NYUCCUM:CX+PBZ(JWEMBX;YTP6X+2I9*MF==*%" HB\>08?,,#NE#;_
M,L18 B>R+M=QO>#277&\U+&G KZ2JTS8\X5*6/P0%7X+UVPBD@3_2X-XKN(D
MT7B.%+@P1#4SV$%YHM6!E4X, B-6=6&%1MA# 0(&W#>#(GE3-\ID*$CDB*^Q
MIN1&N1&#,3V4>0*[D!$F-;@32FSZN4?U(&/1BQ!.E=$Y"7ZJODG@37WIJ76:
M#0(2?O GB*K-X.]3P7MPG(L"IX,8R$]#INBW!DK3DK@U6SUM ';Q?G;HD&^%
MJ06YP\->E($9S'<:$53B8Y(";AC-LH=W5>,QGC8]RS%Z&(\-/W P58HRK?(I
M-26=:3^)(_,U!4=!DUH,5[!+[+R)N5<U+3+KVB)3S%]8; N'2-?E 00E,[7/
MB5]! LJ!42D&4-K6[1/0N@!U'*UX(:O':W88S4 (,M-A@<?&#[#SC2*T:EW+
MT(Q7@K\9@R&G#-/BSU]OTN0?)7EOQ%>^-'H>V/Q-GE%!KT$0&? %KB6'S163
MIT"O3?HJD>D  RI"C4J](N"@=?'!H]B,W6FQ"=?P,DJX E?J^T).IA:<?#3&
M3^M(_(6.Y\V,>B[D.!$6*OQ+4 0<.-8(]SXVU]E#7MXO$,EDL.<)50S_+7.5
MBNEJ$[D\N\;-$+2.2@&643@F+BEAU'G*DREPL._C(:AW% K/0SQ\E 5@@4]L
M6:A7;:M,N ,_F*3DF(A>V3/A^*$Q>.SG2P]LQVE;,DVMD^('&RB!W1=X<6<"
MXB (0"1\4A>:!GZ?<UA*G9OD5YC)M=ZW2(M8*QQ9"G>YWZ*#66G^K NEJL$&
MV2^\K<#YZTOKUFTX%GNV. XQ&VIH*OU_J-*?-:7^MZ]@>5G_"I85V>!FYD&M
MMO;A9QYL-Z7^]2WU;V8>K H?N&KP>RCS;Y1U[:K"FRU]9(CT:U#'YPE/LSOM
MWVBV]3&W=7^+=?AD>L?V=+.G]6O@6(,];1HXF@:.4L% T\'1='"LXFJ;#HZF
M@^,>.SA>-AT<]]_!41X4WS1G-,T9WVW.4,@R0>F)GNI,C%RQ"*9<15V*LVTI
M9[4@KEB\R2J[&K!O1=W_$/XGH1J[/A%,MPK:(49I'\2-; %)J) D,JT!\6B<
MT&U!?7:G(8WK0<YS@YVIP4H08P8O3Y6>H#"Q]HA(PY7@INZH+S7YEMQ7' $E
M-3PMHRLW,WZ%Y*UO';$K(PYJ%*,I)B<)D!2+[>:65=_<2-+4 ->R!GAN02L:
M=R"9M&"DY,\*:0+*/AX86>4QT$T=%Q7 K38MRC5]L&#\Z< (840]EE%,W_J2
M,CA-"JDR$!+'N!B<^ BNCXD'+W*M8T[T^>-*\3BUHRL"(EKYO=IT*PI.#8YQ
MFMFZO)0E/$^C(1-?(TRW8"(5Z/([AV/98L*0FU3=&#5;GA;5T(;H6(=V8D'S
MKP4[<V"VJTXOBQ3K(-F#BC3+48L(PC-79GZ@\@$[0+!M.<:CN=HD*=?E!4C9
MK1FCD8KT%+PW73)3 'J)4\KI('YQHQ=*AQ>\[W$RI4+(NM1Y.]%-C6.)U +6
M-Y+ .U)9@@82_8!G/*PQQA^=5:CKS$V#].X_#^26+70^%:#=#^(!U93OP^/8
MQNG!_C,'6%T3^LZ*M3Y/-'9>EO&U@SIZ8,98YN#U3,>F8MG^(BKL?'@LM7FA
M[;[RHP<JJK-@MYOEN)O)\$>'+J&Z^6"D!7YUZ8XZS5B!BXZ5G(#^M2S68N-X
M+!+LR_?.$0X7P$N,>$4'%&U>+ N'ZT@T9$C&NF@1HM(P5KW-<Q"!TQF;;>/R
M_.*L)F>RK"><\S=KG9T !R98Y8X.#L[%$$B9C9-S)$-F6@-:#/X4*?!4Y#UR
MI.*8J(BR3_G#"@JG)]!_4B+3SU:;AFUL/OEF2;C0T% RQW7SA,S^@IO@&"'9
M"W<;C%_@J_&P!D-CO+S'*,,FBHZ@@:KL0H<8(3@>#+4JJ%Y=XB_JZJ&V*J!.
MGW6<^_VE#YJ@&0/0C %XL-Z IH#\J6QPTQM0JZU]^#$ KYO>@*8W8+6WMPY\
M<(F] 1AK L%^#_T!C51_5(6]!5Y23V$2K=G3FNSIX18[D$.* S1[6I,]O;>F
MCV9;'WE;>P+#=NQ8IM]X(INM;?H$FCZ!'XYL-FT"39O *JZV:1-HV@3NL4W@
M5=,F</]M ITHIKHO@R!(U3GPF\&T:1UH6@=NMEK.3 F3+BHQ-?(20IY'+<JX
M;MI:D1:<<,M75-YA*U(%5]&098IPSZGD1NM<:%<[WU64:O,0A+96K(9#!]A)
M:JKGBX7-FR7 NS+/L'[5%++VBN+" A'00N.Y K"BYL8!Q(=[5-H5@WM>VIJ@
M9#M RNR"O!C"\DR5/A@ZSU:<_&T-U,U"ZE.-BA99MA!WU2/?>IIB+20R?4#6
M:9G3:TPK255<<$-:L:L<+@H1@XI1]]$L21=Q)HD#PYX7I*8.0LZLAPAP/2$A
MH6S?U5A2/14WL,FV(@_K>ZAOQK'>0J;[3M_(JOK,CF!^)@_U% %U2.<@ZX&B
M6/)@9D.>.<!1-^R!3U$/66AD.4FI$%P)4SC4$V($_Z-CQ;N)F(=HB[^J:O_O
M"H"FAZ>F/3Q!/P$Z@S'"*0_RV*2GI3G1 7.6E M^YZOG3U)PF;(\,T7+>[&D
M4ET0D1?^O'\^V;M8\0K(4NGLC)Z =6*#@*L5=O7%J[WDA0T6N,\+6DH\Q'$_
MIS9*QS:K38GS10>DF\=);S,?.P.BXTZ)<5UMW7D_3VUUYVSWS@PKQ;;F/8#+
M+[K'YM\_$1S$&$Y^:<I#F_+0!RH/?57_G-B*;'!3'EJKK7WH\M W#71TG<M#
M=U\WU:$KP0:_;X&3$:=#KGK9?92'-@J[?N6AS9X^YIX>;;%K<%,^RAP$=X-+
M6Y=M[6RQ,ZG ][W3JM_FJ-8/$WP-]O2F"Q]LNYOZCJ8TM2E-;4I35WNU36EJ
M4YIZCZ6IKYO2U/LO3;6Z!X,S]UTXN902N?0ZCMZ)4H%A)12<+A"D!HJ,/J8A
M*D*;P=,\2> E^948PNH(_Q8KI5*'T6D.XU@A2!+K\L3E?L=R(A3KBFPB1!H.
M8+9 <(=?1903:I=7TEOL!*^,-5,R$:W@1_3>[U>[4LKFAW60B2T9(*N]NDY.
M@$^&.]#$Q );RET??EGME1U:5O?%5@O'-$^DNF*BW\=ZJFN1W&,]PX/LJ+#E
MDGR &8>6>7=S?F5*9]Q0PM8JH.'<PC*AD:1,101_9RHG6L U/)&#W/S<DP@L
MFRC&'VZ."#M[M0GF&$6F-- <:6"Q\4R9<RHFEF(V'6M*/8!.0*\<+Q>]W (Y
MXO7XI1X#A4"@?_-5J2B.2W>I!]'\P2J*7"R,>%A35!3HKO:JS^F4P+*+H^#*
M/U$O6,A5D"QYZJ ]G28MI,\<#?I]GEA5?][Q24&P,GE\]=-L>38X_LYV:=FR
MVQE[AHK7\FX21RM@7_X91V+3F'+X[J=@3Y@J\Q,@'@8W@(+F@P-"@I7+FZ&5
M)=Y=S&[>.NXK_+4$X9Z,71[LY9 ;,=B722(GA!!?*<1><0OXM.)W8/DYU\8F
M@+4G$NL;=-7L9P1Z'_$QC^(,HR#U$VX%8::F2!CAL8,NE)*^1Z?!ZD&QJ$<E
M(%\+ZX*0F2;#.!K.(VXJ,P=$_70"GY6SP1,M70FZIAB@[3/1QN\HAW+I-UOK
M*N60FUB@"MBMM<"];JST>P9N\#_$Q6@"@\L/'!X->1KKD6[-#\PSF6>$R4U0
M\C(1 6#\_#5OL<N;OEY&Z*YXNZLY#6:55J[X-LLX(,F23L7JR]B%BW8]:N*:
M1F7T<=*3&;HB7:<6<,<_>>S@^&/$;:8,!/&P!N%D2S#A!\ZW?3S; @^(W^J*
MT7CCH0&UC Z'*0?O3EDVD15*P35='/=4UDUL XSR+IS/'CW[V=;#)!9_-!Q>
MQ$4Y"*28AIQUXA%LGROM .%0H=LYSQ3JGCT02?CU0AJV&*QL:/>@\%HX;<@9
MM3R]:E$KVDU4>C(^QT>92H70 $2*D4B?A#)I)^(K^Z1X+LSN'(#V$ G[$ZS*
M!/9G(I0(]G9F#:;M,I(#A*GWYA:>:G@.3=7 9J5H&(-$,.WJY(@/>=(/9\-L
M82,\.Q"1.02PISLM=@:JQ[[9F%,G#Y_P*;,Q1*S7ACOL;C_Q(X*K<-3TIJ+M
M<R*7VX8 75V!:5Z2PEQJBI6]B#!-)C?894^&V\]X:J>6Y1E*]7(SX[&2^?AI
M\'\421-I!/L77RX"D^@ER!542C0]@>TX!= V7Y/\.4E=L0#U"RQ19<!N+#-X
MUJH844D\BC-GLZ4XY\&.$L(A23=95&&]C:E]FI\4#%@BHUYFDW?\UR_;OS"<
M":;174P'_F][%_J[G*D$.B=\K,5[]X]?3/'5OWZ9D[S-%+NF7<"?X_N4O\<K
M>N[^'VR-U,Z+#]6K?HA#RBGZ"G_,)E8-5V:]V1?\;?['S"Z,[*N'>&-0@U_C
M43YBJ6E4^J^N8L]_HWXERR\_LR;X0%4W;\ZBX:7P(/_KEU=5QG!"J)S%?F%S
MTDL\[0=8Y<U=L\H\65+(M^7I6V8._]ZFNF_GUWDD^?[O7FS_^C#K!45RKTN]
M)U[; 5YSG%$'MOM"P?<DUFB-&<V"X%(Z'_MJT6$,B@6%MW@/)L0$5!@Y<>WM
M#SNF/NA']_$1A-X"7GQU=TM8-;Z;\R+^056]?@<;\.-Z\N?7=^\K":,CAM-*
M\8\=8\!7W\*6V]DC9?YC"^\^@NU++88TQ!+<%JE#MXAU#<!7G_6LBTL!$SGW
M3,._<G('- 4/G#[?^A'BPY]HX3U]4_OEHYC:A6T-SBYZ74'1)+F:7?CM)GIG
M\ *P1X%IWACBC2'>&.)/P1 W4%Q.>%*I&1YGFQA)!(5A?0"B?;PVAOMG:016
M8[X_(6:EO("-9&)"!!18:59V^YAAAB"T!D(^_O'=?#I&/&.OU]>,?VS^ V'I
M!O.:JE,P6%5LS ^I!L!SW]PW8"CE#H(7+">5:QND%J-Q(J="(#QL'V5M<&$=
MV//'(QY/ES^7]P0>NES%E!ON?W L:OX^^,!&@B/V\U!JX=++X&PI,1+,V/1H
MPG=E;VKRS=CHE>"<<QSG2V8 =D-0SMF,+N^BQ!V@MX4?V#L2T+3"0F'_)<I?
M;B2PP?KL2P6D3OT%6RP\3KVXWX<[IEGX!B53! X'W/5O3*7Y>@W\'"%%_:MA
M0MB:C,N7WS3-6;8YZTT=F[/BWK]^ ;]U*-5);WM[9WOGS?:KW9G?C7^<Z"^6
MS.G-*9?^K^?C[_N^!%H8D"0>#9A6T;]^B>1 _GM[^\7.UB#N_P(\F?WKE[\Z
MQX?_/CC_]S$&!/Y]YL>;XX+AAS\@N=Y4O>R?TA9 *JR?VO1BUU?A].G_(0H"
MR P7^=G@A.Q<Y+9?[IB:A6=_<HW)\0WX[S/V&62,CD=#GIJ!Y 6I[43RSE )
MH?B(M17O#:?B7 E,JZ99:Q%&J,&N-+=S6+'V9G_&5*.RER>9#&YT8C$QKP5=
M#ZO4[(].&RP#7,B%3-/I,W;,$SLS?2Y(IGW")Q!L*3O=8A]Y(LSUIR06[?<?
MN5)3]BE6.AJ:KX]B#,[$Q247$LB5X7.[S]@G.>&)OHK-M>="CA,WN.)+8*YX
M:F58+P(OP--!L, O8UM=I(_@?SC[B")<Z2%/DN"J.9"[V$RR&'+W4\)SS<ZD
MU",^%<KN8#:,(S"8+F)]9=\4^2*)J<K4OB<\/1:;1XH^NP1:X-CZN3O"BBTY
M01&<TCK@7<)MWB^TV/Q!]D^_;F ?CL! ^%D/<T7.PP,O+&7!='*X ZCO#MC2
M: O _OFM+#EW7]+(HCW'N._898&]86(\%ECZ,4E97\D1PZ@P56@6D<JY[1FN
M3 YIAF4Z ^7JFL_AZ(YX)'(:&V&L=O_P;JZ1G338);&UZ",E\*>^(N^/#GU<
M9KC 5"IY"M:^P>?.9=N-D[-G[""^IG=M!05=[;&*DZ*4:^Z96$3*Z@I#BDZX
M#DJ7[O)4W?#VH6AML7E2I?K*^T5PNP44;_W$&O#7"]_LHZ!2W2ZV0'%7;FC#
M[?,:H<QKG/$IVW&WL"+Y+Y%DXAJL9P%O_!'+]^ V^W 0)-!I=IQ01R:YX9"-
M_<O.,WOC(]%5.9:2F;OOS#T!MI'Y-B? UD\6]*8W,=K/BW\0W)=?GA%SPROA
MJ9% $VPO#*[!<W$#/4,=XY6PH\;-3_<[_/:&'2ZNO^$E?I?#% X)CXN-N DR
M?*XU<"/EBR<3)[SVJZ_8(XO7L>A];K!/6M7'OG&/G35&*@]>PC8)[_Y[GL#M
MW[G;'^':2R1N 1MD\*>Y\*W[\#3/O@'%P30%D1\*IX(/$GBB>3PHAHR#>4/U
M\%,@MU#7@AIV>,\@!<2C95X<1'9&RZ7*P.\?83BP,<9U>JS#IRD6U"XP+EMP
M0=J3W^9QPB+Q4-#P"T@\JMI\[:A3'%?D([LYA@DUMK/3 (U!BBK&(;K3\[&K
M$%S?!)U@F\MCXNL8GN/]8Z.BO-^N!7C2/>;J2>'Q+^%0\!'JF]\Y<,@>L&>*
M*RSICT63%6ZV\Y8\*(X>+[W<G+$V%YV6GWFWX@7@UX8UW N8)#46:W=C29G6
MN"AKQ\XGG*/BZM(7:P1;TTYA/K<!*+I9V_097PAJ2MD8<[3@=EZ]99OPO[OP
M;OR:QPD%43AP<#6!"W)7/Q_!NOAF$G>QOOBY^W[3M#!O*KKU)CYM)8J]+X+.
MFI^Q81\&U&18XL9%V^\XA J4"T EN!K#<,C5I<:?J6_!+T9$68I(I]J :4;>
MPR_I36/_CUK8N)B@!3A8\=;-"Q&I/,;Z[9:C-96*F,$P%O%!BS2F3AE'D]5>
M,[6<.ZM-H*Z):9_'OLG'\ .5@_NFFJ!= "^0XRP>45Q6@U&]XF -YWZK$??'
MB.O8>!YF."+\V/Q1:L[7;"R3.*HBI:[:ZJWY1[@>N!X:+X@MJ,;JB2,V3C#8
M3ZJNA%-F@#[BT3@AOC \A1D!<\%-+<VK0!@P$;LH9=U9"?R=L"N7!*JER'MF
MZIZH::3%8,'%'T#.5//(I?8PUP!_&5IC2^; ,A7UGW!,5^9P/K]&0E!YUA^=
M _9Z>YL!R1(_3R?BXS@C>:VNA/$F3.$:; JH9@QE]DT(#]^Z] +!!$G4$N6Y
M;7#"^Y@VQ%>'VQ=]0^ AV<57VT96>:?/"7#127Y=;/L_.:%K)F9 G45N,69/
M9?+I+&[2:I/$C$!UK+_G:B2156[!)"Z<=1,U5K7S]@"\20(@H/,*3E'Y"!7&
M&'::?A\-[1&0")2PQ96!-')X//YX&P,@ANT?XP>(!X:_#.NV)C)/"NN3:.'C
MF($EB="7=&IT3H@-P3V;K.JMLZIOZYA5?6H>(Z'\/0&O\"\' ^4P)A9[L2T'
M3VA*+*SO9RHEEO3S$%S"H-. DQ>V>8,>K%A[/N[KS,4I3F--X%I2IWV?/[2.
M@C%;])"/;4F^*P5G$7R-4Q/A/<2(4#9]@+3BP8($ <J.64\90]W-#&S-3.L%
M39V;FO MYGH"'G[[YA[@$_ T@,?=9%RC.TA%;'*-JA0#6CG*QF)#"X#3N?MN
M1K;/[#G-:72VS8B#8P/_WSH[17A*^#MF@H^VV!UQW(K'![RO['6= U9!X"8_
M2!@3%<8_)AL0$9\V07>, A]*4O,"^@.K39'07502U'P6"A$[[AZ9V@2DBLQ"
MX41:4"8_%;HF4+%%%.%&,+\0MR]PV$+HOM6FP^R9P6Q CL8E'@YO&6*UJRW+
MHQ@+EF88E93.E$BL& F",U(2L@K+3ER585^!YT38NA1! ,?*DR:8ZUT_OZD<
M@.PG<H*Z)29_<U8FH$[A480S(%'1Q"-AG?$(M.$-;/)D3,B#F +MV?3)ELA<
MFE);7QUGL'QF:N-:E%T"K49?NZ(,RITBDC*F\Q#^A<)9(AV J$.30:1@U+5P
M%_40\W,V0U7$TC 7FBW?LO>]LL67NPO+%OU._/MP__,*52[Z]\:<1#].Q.>"
M]COC]@AN&?'TU<ZOXV.!QN_.NU_'G4FL-?YC3\&FZN$N?(1-*_2O$ZTXV.BO
M?SVF?1N?\42\??GK^$B,X%\OWO[:'HCQ?R39AU>OX>I7KU]OPW_^8Y!]>+W]
M[L6OE[2E]/V+Z>O7OXY?O)K";^B"5U-XYLXY'$U-39O"P8LK<7/Z:L@1-ANC
M:P5C85R '8)A96U/O&7X)8MM/ZY-VYN$LV4P:@\US%4-+CQ]F5$CG)X7=],\
M?)<P/4US<-,<W#0'/WZ_V]HT^[YINGP?G^L:D!YDQ1?UZYY<EN\:D)YU >FQ
MB)X<S4'1:\!Y[MR^;K!Y&O.[,;]O?-K3-80:;)X&FV?UF+7!YF$--D^#S?.D
MV;/!YFFP>1ILGI6J(GU7QRK266R>%Z]?/ 8VS]GWVS?O!*OGU<NMO\>#2M+[
M/([^72#8K%"^>^72M0M @UKL;.M@ZQX3M;LSI3OSC^N"!O.2_>S1#]ZQ_V-!
M@<%[Y@H,X//_)SC]JALK<&S8SN[;-TOS4<VF$9XKV3>5CJBZOH[A/@(H^ @3
M:1^V>*L"J7$;0(O 5VNQSB3.O@F5X/4;P'9OC/GR\@.RX+/ZTZT@V6(4FEDJ
MO0JH]*9^5*H0:2^6XYO DDY2##JCJ:D=6$89,:C%3$74U!"O?@1;CJW^Y!%!
M$2&2$5'B1<!&=:3*9PGZR2DN'+2*:1"DT5RB($\!8?:QE$Q-Y\)#N8O--+Z8
M#U()=G7D*;K]+J#HB^4INC)%N[]+&G_I"0+^&ZSZ]=J.7"]J6.JM[XT'T_(6
M(6M'O"=&%#IP$&=T"&JW<CM(?,,8QN$4S!<&HZQ;FA +GV\7,@"N:;%VW]C-
MYUQ=:?999%CL#XI*YBB<Z,O:4:U:V=N:5>+8*:;9!88^3?AT8V\?H9+*6']'
MHA?@D90-(PPCY7T>8;\@>-<&E:L=1&?9QLG1^5G[6<F JAVMSTI08[Y"HB\P
M30^JZ2-7U_B9,\0[T5#*!$]K_?13:5PSM:PKP37R1ZO*/!ZC"R\K<Q)0SQD-
M&^?#"^*@6U"K9CKNL)>;QK6Z*[D#2?"@6'O@5=H=')Y56?X9Q^!\"-PYP'8-
M,/'&>3=!_!^".6H97,NC+?9)I& ,3BU-"-Z2\@K&[7"4^R-U?2LU%3D\@I>2
M<PG7C=%#)<;1$06&T%7P!"%H5FQW',CE:+-4%/C-O-8GC );-- F!'Q_(> J
M\NJ3B?W^'.9KB#=LX5YO" _;(JZ9*/&;%^NJ0M<U2ESD&OX$-@J@5&_$%S[
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M5<.+%K5J;O'INW6UR=8UK/@#D_O*$3##H#4-',X-%U)E()#A!(%(3=FD^>(
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M.^?W7,$R>X1XU&)_Q;!P/G*MHQR\CE,X(;5&"KL!MB<H]3C(K\3]>&"OWBX
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MI%3N< N0E)51A:&DL:B-Z>"[C+(=-"EM/TP [BD*EG6)EI2K$BC;[+ A6B:
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MY0KR6SZJHZ41GJPVG+S-?:E4/B:% >09Q5DFA+N@$(I$+=M#Y\/SQ?5.6)9
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M-3XHY;2PQFV5H8/C/,;,L-:W"&FO"@5,P$A7G::"#*W"NXTSU_I*$@O^)S%
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M4_SE.@K55PQ6H_7C@O0AYPV?,+B#\)L(.JB@V*"%9*5Q.X)SM0-#./8#UYW
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M/,YEH?FK3JF@JY/RVNX]L0>!PVLNH=Q>4-^YMH@H8F<@< 9,NLBBH27@-)<
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M)R^#625#3G+C GSX8W8)/H:#V-AOJL]XQ/+7RQ!J&T#+333QXK]@:$?C^<L
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M!+?RR]?7)C-%T0G>/;HO]8H3USW6+CC0KCY]^>/9XUM;;\!R]+ZQ>;6*L_?
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M1);J6S3W^1[L XT#Q0/0+7CD"B"9I>6,D<-LT CO<=]7'\<M4;ET'MTI"CY
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M.%Q-S!#M=Y0O6V3)"L#*:IR6"GQ,!9N!$0PM)M(MAPH1#R+IS\<_V-MID2S
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MZ/!39::E']D*R:;S>G.H2@9;F]7$X4_Q!UG-GQ($6'6GIF[4):-F(_F>+XY
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MK#E(L7!"*8#]3O^!+E0(*"T9TQ(*H-GI59\M>X.SK@S214X%(( 9O*=+O;3
M"!1IO12!40I@O]._'?O* T@[!]#1)?  >KVSM@P*0,X04-!UHDD0;(R 41Y
M[@K@A_.L/("TC,R@"JBG2U ^TV^?I9F4*QPY4BD 4=JJ']X57SI8NFE&LY3X
MW^_P+^E8V?^IV?^!A-$D<,L'VIDF01Q+3ON_'R1-)5#0_: $5"6 <Q?__.B5
M[#_T_"K/?0H !4!I %!2._G$V>\[9QFRN9U*C*=WH$3316=ZMR.B^NUN]0S'
M/0#%60_5B_/OA4$Q*$%O'S];KA@8U-NJMY7V;;/2]JU457S2XT-]O[YH(84C
M[A]L8J4 8.:@Q!<Z<V):V=BL\74EZV\![X%CC466,/!9\2-RX<R6<QOG[Q-O
MZKQXP8AFET9CF,4F]8>;?^+6=L^+%H)Z=.S@.E#7P,T79&;9E"QFR_ N+S0V
MS9FMS@D7_I&7J4.F!MQ]Y!MB"2J-!D2[SO)I2@SR0^R;"]=3D=L7F[K>U%J0
MNQF.$\:UX2=L5]6VE=ZD ;?Q*=&[8IE(8\1>"(>N6[CQBRW0XD.E<8E/^(YG
M)XIP(L+1$PEGG!KA1&.^<6BZUB0C/L%;K!D8+5]'QOA/8BS]J>/B2A@V</P9
MGL/7]1*]J6MD^.UWMA(FNEML/^3A-];9C9$ZX)UMS^#+'7'I ?XQ3H7OVK4&
MI,F_='$FUJQ%:S0;!)<ECXV%A3L%/-]=COTEO&^#7(CUZ_!T\6=%J7%*;252
M*@THE=$DH\<)X'),C#EN^^/R:2PN-C_"C_8S=7&GD&7[#OGC@9BXOL=E"Y_%
MNN,Y0#)M4-L\)4LOV&4?N_>G\%N$T(#XV<X\05JQS:CAO0Y!)?R*-PD_41N^
M&#&]8\-7JQ8;OGK-7M$;OJYQPS'G!!!@]_3)\E"FBOWE@\\>N<!M[)-7Y*=H
M%6<1:Y#5VKPCF:HM(U-M>?=L=S@F'O!>'%_\#LUO;*=YL"WV6VPA=!$L+1R*
MX3=<2NLM1_\&6XVM);?1T@'+S,+%OR^6/V4:>F:\\ W +GU:SH+EXA/4\OY_
MJ3O#/WT 0<:]";C"/146@%B*S;[L1>L+\8:G24:QNYR)9<.1%1%L7?]*/3^T
M#9D=FG2@'\-OKSTOL%?^L"TT:)AO!"]AV>/9DEG@/^@+^7^.^R?\R0%;.'RG
M#S_^W\/51_YJIVCXK*YRAQ<!K-NX'^P97\5B.QG9XZ(WP!7H^,ZSF?/"=J0O
MYV#D =K@^)TYO"O<P9K 3?'800BB6N"[XW$W^CAAS7"TC)B8UF0"AK[8RXK[
MX/F#^(YA$^X/J!^#A^$AX&".<:S@P40NPDPL<_7"9:[BO!#Z?#:Q)QK!XK[-
M^7S%+![ 8\3O+$H5OP %(?ZZ8C0/F&!C"E;7/Q,29P+F!$V!:1%OID-LT'G@
MOE#KF9(7%]?8VNC4.:Z/AXV.S>R5'S=W6,;ALMMWZ,>J'-353Q]);@;.(5]H
M3=!C!!YPP"?@)+9R?L*J']KV$K[TC=K4A7]_IY21%TJ-^-4?P*?\R+C*@3NB
MQPPL-:)XZ<HCV"W99F%D[PLAHX -PD7#$A[]/Z;6C*Z>[ACWX/GD&8,YX+X;
MLQFA?#LL,C4%MSR*Y)SBJ;TR=,'M+7_&3Q=O!:()A#5(E%/R2@T7R'D$+X&G
MCG?V\-:<M)FK_A/DF(_,$![VRM,D/'F4UOP ID":N%A^N2!&>&KDWO+^C)T&
MV^:&HMFCE#O7+EXPCT(>WJN'00X\SH7K@-3VA#*)D;U)9_3)\+D/;6$<R5N
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M$!9G(.N%B'\Q@F<P\$PZQA0$V$KGQ'9L^OF$3%TZ^?7D?R*RT#J:IG6 +BY
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M0W]SDJ2R&/*M7,D0T5]TTDR(22G4YE2LDB5J6P.9XQ-2V@FJ6D4!)%&Z5#J
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MP_==:[3DC:"^0WXXSX;K6QX9?N/&^A2^35TEXTL'4$EJ23@=#6-D].C<OMA
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M<51=E$#E 2I)M50L@G"L0S @K5Y-0OJE*9Y*#WVM%NEU)6Y[J(D6N%"RO_P
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M/5P)EX[+5OAXGXU*N+XL(&6\U58!)*7NW]='XB/(XQ+AA@F$XTR A.'!&=H
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M!VF&MIJ8$W]03D9;9BF_-&DCUK9$.JUZU1.7BUQ2\O&R(H[V0#D )2&.=SJ
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M"R:U39P+/*;6,R;0T:$P/,\96RSEQW/QX%!$*EX^O2X=0-FK])!T[@7E7,R
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M,UZ#U3VGHF$+E&TCD>Q,I;_,A,8_* 6&(G!?P8M-5D\T% Q;\SD-N6;8\!)
MWLL,;IZ)K)P-:JHS)U2$@]8@)_$J.,SZ?A*IWSPL)].RV.Y+YY%,?$J>K\_N
MN?*?2NM\HP8H]B1N,D<J$W-QV%J7,Y*P^"F6I!W\0U7RXG]@)ZBL\MBZ9#@
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MNR/!/L##PVSQ\W\FN2G$D5DU+Y-,S^^WY'?JLI%Z/,N%_?V)NIBJQC]'@NZ
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MG3Q<8#DS[@E#+,G>RA#IYTAUW<#**%45>$M>? NAA8DNHTW$[C+*Q-\=AO9
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MR=%Y=Y-Y]C-C1F.!SWB4G7*);D$EKOQ:>I9=1)77*A)MOU)3RAUE<>9]-!%
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M@8H%UH%TNV2CT_>B76]>AAG,]T1E$V() =O.>#A*9G3BII;J6"JW+YK84CP
M*ZT).A<AT_WV6(V9:)9T%'+5<P0M&K?"(@K<$)PM35R8NXT><FP^%PW\!HAL
MC7'L'T<[EX?/9T=;=-*(C@L,#LJ[H^.( >CS$S/ I\&28C-=IDQ6,3#6_)VG
MF@+MV/19@SY',.<&:.VG%-FF.AWN2VLDY_G4B0G0>1]2[BQ".//J)3R4K&(T
MP75:EKUFA+Q4%[UBZXM\_Z=@ 0X@?!YBZS(,7#C+)Z(:$"4WGK'K(IZYR].'
M(\R8?%IO&#=+WTL58DNVDMCC'9)<$3X51X[E*IRB_Y8ST.")E#,DPEEXZD2J
M;QM\\OWV@]SG/H7B= =$]+C+L2]?K&][<OZ;G4X3IO\/EWKPC\YO]-Z9?\2C
MYM5/+_J#;8;X^?_TU/#U:96S^G4^_1UO^ =$CB%PC+^ZI3PK)'.K!.$*X/S7
M^A;\%;RC$%!^+\[CO%K;\=QO@H+@/9\6]GQV$9N3*]^%_WQD"&%G5'CN=][R
M3+3D>(&'E(4SC_[VHCEZ0=CF"U!GEE3K]4@> >0,_DHF[)"$ 4,M4T4F###Y
M,W4'![Z,J#3&<:ZYEP%DL<")3LLX6>^YABQ#6(IWJ=(4TZ#:'/_N_/06JX7L
MBK=-.,,MPN'NH&1M:ER*HN4 4S^>2)06Y!5LIL$[DJ8V%_QJ5&L\+1T FLH%
MJY#'/3_12<B/_,.&"#.7IU3WZ'JA$F.0-E'!=JJO+O*#&03/!N!U4\Y%LSU$
M4!@&P"2;Y2H1)3A</K'9^1=,SLWL#J8EI6KN1&L[MA=M!F?[=6LC.*5+#^VO
MM [W53?& I2YX;-ODC(G+Y-DU7UT^"O%YI->2/RH=D^E8-4".D2"%5H_[]6X
M4X+\QI/EF&:\BJ!N5RVR#VR1;9-4IUS-GA7\G)VVN1QY[B%W74,I4XX[^M)E
M?:T-^0I'?"6.A;\E.8U70.R]34&V7H^WR'BJ5CV(@"U&MC6*J'.J9?#E3[8:
M,)]JI#NX>W#\ST'@@KM^VQ;4WJSO>)U$O+'NX=+G5=;@WCD_)6J?<(8/TTKL
M%"CD(?9U'HJYO$U;,YG4L>5;0N"Q&Y6M+:C<Z58R(+_QCE,]R:*>)#E=:Q<L
MB;?U P+/=(Q5^LJ%N=#RTP--<Z'=,K47_+79:7;[3RV#B"X?'':J6P8A5I'$
MWL0+T&4DO:0F.M"2TV=+.M#$H#>[SS!'0GHP4K7V,"=SYV=PNV"7_!,INKF;
M[/:?KU21=V82,?3[O(DT[H3\'<F2<'!REM0\*F<YICGP$I6DN?I&;?]U%=*M
M&V9K;Q=-6B),P;/I?H:.Y^-8/XM]09[_F]D[MKK=Z-J'L]DL8'KY+A &GJ[5
M6TJILW\A%W?,=@<VEQ&=OO%7BQ]!Z$;4?_%K_,!F<%WE,WN;&9!>!&RG$WPB
M>?G_>[[OQ PY5Q_?-@C[RYG2&?\3#99/[(U6"_X!MM$$2@).-74!\_X[=I"(
MV"#9'B--:BZ,?28>)MT-8G$A,_]:.1X(WJ4",F8@9T0PZR%3!4>P2+[X?ML@
M5RO(P60F(4[]9PILZT^ZKQ/7.M!Y</')@QD68RPA9RM81<!SZ D&[<D3Z(6D
M%5GRR&N?*9P&^>K\Z8'COD$^WC\MV8K[AP.[PLOL,^43^2'\_0/#B7JX(MT5
M3!C\H:+24,MR2OQU-],X@(C#2"3O&J:*=KO]#S RQ9B;H[*Q?V+_ST"ME<'6
MM=+MYZT5<522'CGIC,-.I- (AD$(*U!3WOP<%_[!_GN#Q/0<+_V^L][>,NO*
MS7/[3[6H-_IUN!62VY#4\7W@SXD<X-!/W#S*>%G*3<[$=7\>)[T1*"O6%;\O
M GOM_D8$;O'2'^67-V["09T>.Y'=?LZI7BWEQ+>^*RIZ<H^Z:7-_K-]\7P$-
M>GNI6DBS>(:6-<N#;IAL#_:3[[WH6CD!K46."_TRIO-9GO!]Y[ SSG'J2LMO
M/=H .JKZ4[F?\WMO,VZP>09S:(**<Y4;-JO[.\3WGME63H:+,D\JXBP'V1SD
M,1>L#GNXS,MR)[\/0N QU8ML7=4M2YKL"9<I['C?@BG[3 1GR-5G8J(3^4OP
MR+,PNSN2,,DMQ-[)-ZJV^ZNT5WEMN)R&GAL<ZJ;H9$4M$%&F%C:J 7Q:E*-?
MM6S]C[[;;&=6<Q*ZN$Z(9:_]*\DBFUWG^-;BI:\^;_&4LN?14+Z5ML#[V@+_
MM=]]W=VL(5]BTX^?2%(T?^+(_?5YWLQ4M<))!Y\HNZ]AL)2^FW\%G(N=+=B_
MT[FKW5N?E*Z:DV:'V2YYD_*+6 ROV&D?9E;+WET#TF,0:_F]'N\ "NQR(3!W
M:9X^AJJU'V/2NSA,'W^J*&G^IVS-1)_"8/'!BY9!Y,QO9E\"7U!-"1LIE-]A
MX4'T?@[UL6"P7T4@JD]!>,M$<N6[4-@BRTQNE(;>',;M;,N^S/!T)?V+M8?H
MO0T$?;@DM$YJ'Z+8X50(6,N=54M5"1?G^YU5JOM LD:H>0J!=0T[T9%[X?4V
M&)2@$3^SU[SQ/ZC-#RC .#^$?E?WO23KWI*UTGN=8T^JQ""@7PM%.R#!IH;8
MR&,$O[ 0>SY]@VDVT;.J5-CJ@&A>ZVUR*8?(D]%F40<54'N\5W$*A@>@CRL;
M[X*&]^SW+V7S&M"!O_//E.$D>]B\XA;4W8,^D6)VL#CE5A2G+-D6N'"FF/;C
MS&5="O2 <?^S8F\GWHM\=<+(6_*??Z$_R#^ QY[]^_OMU6O"#(MHY?B*H2S[
M5HV4RNIGQP_UXVR'N7](,=,WL(L9,/""*L..BR$GI]FO9"=W[+AY'W &UVHT
MF^S&ZK[BMGL<'W-^570^-/AB;V""OC+[,F33P681[4M=8;;WC "/<IS;2VE5
M-<@V&RAME!ZP^1@_VYHI54 ,<O-^-MZRG6$+9LCS1TX.>!D(E\]7G$@4:3@2
MUSF2F*@G<B$*-[E&JYR[9%*T2(^4#1=<6NQHS5F:T>(*78?WN>!\*5Z(+= E
M1Z^^=.G/)>:_:.P67<ENX?BISP?R<Y4GA'R[B8;@&E$Q40G]N4'G<7N2$V%M
MT T3Z._)@[)8/8=M&W\\!#"SP0]("-">S7 N]9=F?'&J#6&@I@X24L,IUG&0
M'1]S],! U.0\N@$S*+!]_"0(0V0N,B_!*7_VL%DZE# J]H],T2*@D6W?(>1H
M.$G0FTWNS LC>$QS"D<,)O ?X/9_8K8G+T?F98[8>D8PU[A,3EXDRY)%8Z,E
M^PO6DT0L85,>0]H94/#R#"L.3JW#&;3 H-C1%;C<L9LF.!?UMTNWL?,6P.D+
M.R=_&GN7!]'F!67)9HXGC\SA2$M^^_!;\SWT=J/SW2:E(4>.\T2.=RCYYC[)
MRV=3\X67>&W3[ 4%P8[<ABLFH6(*2X9;$LP+B(I5:T8/KQX9O<ZQ'B>; F.-
MBY_* PI&VJ_7@^Y[$MKD<$Y9QJAG,T;UZ\X8M2<_T+$,0YW]&(;.X*51&FIK
M;1M8>?<R"'V&TZY9FNS PJW.E@VA2L'HUH4&HW?4-L' ,)\>F*D5SQ/[XBI:
M4I]\YH4LT!Y6Q+1=LT/3[;;T0>ZL;]I2J/3,&7EY]?D:F8&VN!3XK[]RIRR<
M3Q7#T&_>PHNAS>+>Y45)=)/?E1=$_//U/U]GVZ"*,P.;:ZQY8.^YK>9!^6TD
MR:QA[@D<;>*U4DG:,!-\#E()N<%LUF1G>9#U0CDUN$N).S1X>RL:L3G%PC,\
MYD/NHC./GT0UR3JG"VX/HH>FD XVI5K*3KB\K_M4-8.-'[S0;<Z=\!Y(UGX$
MX9SI5)<BUU,(S^7E-\B^;MJ4[ZHS^?C]V^9=D7VY8U=$B?(EE:PH^&*?K3'W
MQ]0UO_ZDOV\6XG!S>BYY>:1!8J=^>Q+MYN2<5]G:GP:9PQZQ!T/,Y2Z9]W+P
M7\78O\+0K]3(#UP M</_2>:QN[FBBMDMR_DJVEZJIMCF+A.[SZMCVW?2AUN*
M!R\4O">:R,U:X)6L4F&6;2%5*@::7P<$;9Z]3*]-1U>Q 9N]]Y]QH0:8G>7\
MW:FS>99?;:NWS)(A7C+LMY5C[@WG7J'V5-UF;[CM2/#\,M6+1NNQ!:S["J6^
MB#[7#&\IX2[<^BJM1K@R8C\X&6)O+=<]:?5P=2;Z63D2^\YN>[RE*K;X] D#
M9QB.B3B77ZBH1CH,IEOF,<">8* @CBO/-GPFGYN$LC=&MTSM6OR\Z.+MRLSY
M_N'R?>=]M'G>;2#=O$!Z2-'7)8M#F<1!LNPV]T]:PR1(*>%A/K@F@"I43 C2
MHI<-G18/2H)\OGHF5)'DF1AROZ7+6*M4;(^TLB<V!J8%>+:\P^RT.%L@SNR]
MZ9])8\;$YDO"\R]OK[Y>B6JGJU483!C> A% A^(D",&_)B_55PGS*+!ZH8F)
M[:\@H9O'E'B#:@9,(4HF$$T(PB"=8F8XW":YZ@C1%E"5Q-^CF511/EM['5GE
MN6D;3][H0R&9TUL[,<B:F#2M'G5"'XK$^,E!4N^!"Y1-J>J? VMT LG[\&5(
M[U=S)DWHOP0)7H][D"Z?69->^^1WART(426CEE4<!'^*^HNI!Y4-_*"%C'9I
MQ$I@ZJCDW:;6D2PRW]C=KMB):TYXBZU6=LDN5C%0YF7X@9.5"348V!T7M'NF
M2(:+1[TUR"=V_H0VR)$2 B_8Y32CY!-UL6*?X<:E4(BR\+"40ZUQ/8$%;@=;
M!Y>Q*!N2_6(%AX2WH,#M8J2#?[I: "+AM"S\G,+/[U*V,\"2Q%W&AY(6MI_&
M3PW<)G@-*=1^\4*<8V-*'#W?(R52$_2,;N0FD_%53,17F(8KW_TH)^$P__/F
M$R_WZS&IL/7WEY+#.@'4A<_]%4Y A!-PHH-Q:S/AUBM<W7J)/RR.5"-L4?.O
MNF#G6)M307(A?$F.R(H#A8(& VB1D)OR?^W[%'$15KD1454-S\+D.6:@J"9N
M#:P\7"S9'JFH2#D/ S,V>/H7V"EAX*ZF!SJQ*@6H:S45OP51E#@MKV%IS[SX
M)H3/LU!C*_THD/6VD+KEBS]7LMM!8=H. YPKL; GNNU4Y6WB'<FT>#G*F,"C
M')M*12H#9?QXWMOX/%?0T9![;(2;6IC"*1QZ[&\H'"7L1(\UR=$#92<'N?F'
M5";(!ISI&P6RNR6M&0=G-F/B!*Q; P): 1974S_"G%_!SBX RGU=0.X0T@=V
MB?8S+/_&$O% ]AW5)CEG8FR;^A,6'0ULT=&!)4/EM7;7C$^MP3MW-[)-"X[Y
M$(>1F^G'GV"6X]$RI\E[MS?ISZ:C7G/<F_6:O?%HU!QUN[39G@PF+8?.9OVQ
M^YPF[WO=[^ F[\-6W_@F[]W71$R]BJG_28%SX'X%Y1%@AW .+=QR.%52>2XS
MV,6T75)CF< F4.PM/-#KRF.*?BAD $DJ!I#]@Q_(C^ "S.,L7$?S85U=?@3K
M)I8,T[+1A?@8)/L0CWE#<JFA0&+< LG8T3^HWGF>WX\DC)OPS$>T*TRSP[ZM
M#9UPF@HH%A%!;8<!W_=Q0^>)3M+-PAE#V08'[JQD$L7.#I%UY6MG'TM'2W/A
M_$E#&:0'!Q*[^.-/.EWA;*-;)8XI35.>\%9FN2_+WLX!7A9- A,Z=8"OC]WZ
MB5"'/0<&!-9F0]*$-.!WJQD3S0H(AER@]^"L&UAP ]R>+@:5IW%R!$+'L3#J
MV-= ,0.OP\]*G 00WN >)&TBC<J.:2;(Y\<,,B9G\",@]:3(=$ G912LPJE8
M"& X1Y%D^V%BQB4(-K"PU=?%91KZMX#* 7H99']Y8]A+YVHF"6\@21( CU((
MCW2(1PKC$>&U:&O4; R_'QF\I]P!R$L-T1';:X@]#$2<^RX?O$?N465H"L)[
M1YU=C]@=BF,MDWL++  :0E7=#7]'L;]]9R]5X#8S58^1<R&>@Z/?M-%<<ZTJ
MK@1AY5X&K:^POF^-"VG*FXVI%IN :8<];>J$KL=N%$W9<8X=3+S%8N7C8?DM
M\>D*>G-Z4"7X5ACK\6H1A!PN#U2>J]\"('Z A@1@X%F/:<A%$&OMT5258>85
M>/SU@2G2^8(?TN'>H'2\$(U4[MQ<[[CVFGS%T[;8760PCSNN_.>#$X[H.CJ/
MLUZ*Q^<[8945C$?1!% %# 4*U0YPXT\3L:A/OV9T@V$J47B%\A4?CD3TD@/"
M- XJ-XB8T8#SI]7A:KA&PP:^P=(Y:0 D%'<.5XT90DOV3<A^@YN==%:EU""?
M?V:BG 5QN]KXL0>S Y87T0,1EM\N<:;N^H9\@T#@G'P65<4-<L6L[N:U+[86
M+IUW7K"V^S#[>NVWQ\D9=4^T  I/IGJ8(33/BB]*'.^H9KP0>-="SL,Q9<H1
MF*(G8> PC>7X]]+226LXG0<Q%V[@=(1)\)))8,K677LDSD%FNM0<K(T\6BV7
M<_ZB.X IN0L%O)%8<>%X_OQ);WC*LP24>0_6].0I*Q*\U=J<-6$ 3Z+RE(9\
M(.LR?HX\V0*,*3MH@]N1[SCPFG3ZP#<OR2XKEJDN G9=Y#%%Y(2B;1,$=MGA
M+TK?07LTMP7#1P\L73:FQ)NY'U/SV>U!=*SBKBD=LKJ7-3F&"C>M,!"B6'G5
M/PL'MR+AC43E0!")@@%YBVD0(-,K:JL9VX!Y"@NT-W7^'< LK8"]4( W.2"O
MO80T'+R8\H7IK0U#4#"*%"PGYL:K(U*Y96:,,ML;; FP@QYD68A^>B'#E;^"
M!GH0Q <HSR'W!A(&9-!:-/9LJ-^DIY![[I=LKIITL9P'O*AGPM _\^!7U'_T
MPL!';P\<@?F"@KG18@GLY@SX'G_SQ!7 #/+ %VEHG.,! CAA]. MV>Q]CU:P
M333 ^:XEF[.)TJ82Y\X#J@:72L-(G;72O/::,R(_X,'L)W_J+24%)1STX6D\
MMW(2DY<JT07_D;"[XK*%58KC8UL$6T%X1RP_YPRE8/["7:)7#:W'"&^%D$.&
MSA>JB$6*J$Z2WBE4 ]MRFF*P306&S0+A*3JY@M3GP;AC^\TJ1#=<Q('"5@-H
M>G9DY0UCE8EV[;.[Q'BX X7,U"T:F6P6OBG7AZ")^1"N[LF'A"TU:6>7=%-
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MZ_H#78846JD#AH,968;!DH;Q4X,LYXX?\RY\_UEYRP5#;UU4P+Y:_=A4BC]
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M#RFF1/#7RJ=LU#[G@:9EG5W T:5-.F,;HZFB*Z\.Z.P.K)NYKGK3N%!VQQ+
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M<%L)HM9/8;"X?7!"BL+]ZCS!;>]"-G#^CM'_>O'#Q\5R'CQ1>F#%9L<6)9D
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M(U1M_."%H'Q#=-;"UW#_)V;-180RO+KD U/4<%0CW7:#P"$._[^-6IG]H]7
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M)(E%(8) (LC4(9LI\#50U)Q'*3$@A3@";_J3(.)7Y>@T?>3AD79.#Q!J!L0
MAJ<07""5E-[" *\LP2F$$'C]=*I!/HJ'H:G*0U-7#K]?T!0I"B[8%),?12@P
M*T0S(!\^D]<**2#8A @"B2"UU4,$29'VA "";\5CS0!)HDH()H#:J-M!:TZ6
MF!(""+XVTB&':#&F5*X=&S%Q4R0FN/C14H1$/T.I"<KL@"PE 1@=39DP%HEO
MTH2Q2'P=C)Q]B\1C41HL$-\<@Z9#]"Y&(J%4]L7BI8!PH>+A!"P,7U]8X,']
MK5]+K3FP)CP4S=$FFH9Y$E@/OL[ P /V&('!6O!8*1P#QKC"35IA+-E;6.S@
M"YO[7C"RF3MBM6<GK ..=<"1"Y +4+64<B#RTG:8NZ!-825P&6T)_3&7;7<\
M9MW\*;%UI:IA&KTDAR(11%!!U,$,"KF*<"&4"H=2KG6X,HK<82$NR$<F$6 P
M=95!5!4-OD- =+"N0L,/()ARU59I8Q"<LL(#E97'I/[C.;?,#:88E=IZ8&E1
MJ=4*H&0%9J9HQ.BH:*;($9="& &&$5;>E:1B%Z)(#C,?CSS($H-"1$'52ST=
MC3M9:G<ABB312R;D/4B,-U4>;_J-!?9T%F*X:>N!I86;E@N @A28.:(1M:<#
M%I[R&B0%1)L014!19'000W*$FA!"<ECT6@]RGZ<Z:Z5GQYH04D"UDH8UG)I=
MVA(C 2E#Y#-=_(\+D*;P.KA 0$)_U!7 =(71@AQ"!: LX$0!$$(P(:1W<7M<
MCB  (DB*&(".*DF2$  ""J9*TC"36)ID$\20%$JI#3FHA@&FR@-,?7OJW=FW
M39&DX ),"?U1C (S1730)8_E-44*"# AA*!""++M(:\.RC_ A B2PI;'>*TD
M\27$$TR-I+4Q2TN6^!)B2 J=9$!62AA?*M>@C=BX*4(37"AI*42BGZ'<A&9[
M ):3\EH>!823$$8(HYVH  HC>"$E1!$D(UY]%%.8= &HR0N "=?^H$DC.G@^
MW;%JX(74(=C,K0)O#K5?A39DBZA8:[&DKM_/=M 0&=4B0\4L]G(TQG-]+@0&
MG%T/U!Y0M(>.( &C/4RB8V&ADI#Q_"UWA 8@_0'9R&I>-$:-WN EHH#$LH!D
M"@.R)0U6AN-XW/".X=@TO4'A9>0"Y )X)&A"@/\FTK.#^=3S@^8R&(H9%#/(
M!<@%%7*!_,KFN4'OTP$=VZY#?>[HGI)_B2N?V7?;M8-07*D]!T)-$EXNRW(Q
M,#5K=Z0H,I\BZZG$_@8=K($C2Z8P8@DXEMH] [$D1;HP0JDL*.6Q?8%U'20Y
MB(ZP JZA6B9NF,MR(AW!))..TB"[47@PO83XWQ,]-NW@O_R;I@A4<(&HA/XH
M1(%9)#KHBA[R6B1%]-=$" &$4,^ G-PGKP8JH+DFX@>^'8_J2)9@$\()HCIJ
M=U$=R1)A0@3)H)#:@/&$@:7* TM_>*%O,^S9NOW TB)+RP5 ,0K*$#$[6'Q9
MDL 2(@@D@EH=-.4/T4#"M#E52@PP(8XD,.A)$'&L<G2:T?+IY[<1TR#*0$:<
M$%\@]53;P 3!0Q!TL)Y"BP\>DG+55#WXB@HC495'HC[-0RHXG39%P((+1:U6
M .4J* O%[."NLB2Q*(005 BAD2]5, J!))>-G]90X&S\.BNJ9P>C$%] %96)
MBDJ6!"C$D PZZA3R-B3&G2J/.WVS_^O315/D*+B@4TQ^E*"@K!"C@Z5H)(DX
M(7X@XD=/[WDA?B">JD/XP#?@-51&DD25$$T@E1'DXC+RXJ>(D!(""+XZ@JR-
M,)Y4?3S)F7-DAUY3Q"B\B%*R "A%09DA.F8Q/6Z&-&7"*X%!W&E3Y@S15T,Q
M"5),HI!\##^ERPRTJ"NWJ =TZ+-1B <#MAY88AN>> %058!2%9H!.10!0%G
MV:5%!(%$4 \CXW)LTR)^9(B,F^F2% @GD,X_X@FD/L)2%-+LU"*"9-!(6@NS
M_Q]B2WIC DJ/=M,>>"%U2,2<).+.H/:"]&FBE!-K0LE8F6UADHZ.\:+]4%%Z
M! EQ42$N-!4S$\K1%L\-#"$LX!C2"!$@JD-'C !1'0;A2XVX* 47SX_A(##
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M'G#&.251"\&FB&!P8:YX(:1MXRB;X'U9=><6VC.2!+D03O#AI!&UE[99$%"
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M"5!50%85)7&!CMH!LG8HBPNJ=2.A<@$,?; Z 5HX&V Y8\@:H3P^R.C+@HP
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M:##\ :@+7Z4Q4/32]W#E(:Q\AEE0^,HWZ%@Y[C\\)Q,_ZD4G#HP7NB\!#O,
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MNJ(4Z&]KR^2PO>4Y3>4[C+!@6/#&W1HN& [P8Y;S,?:IF\+<E@#]Z+C5.2@
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MD4W\!:G80GQN_.:+YZ9"#_=QS*$6".:,Q03\M1!_6_(QSU6I20(.LKU1FH!
MB"IEKBD_#/*Q,,L!,VBC %M+WPD=O)6#0/]!CVI/X;"M8H!2@@#13[^MWG:3
MU]9U!DD.P_='3*UE]_G)2S_Q@::HE,Z$6B$')D?=?PN6BX2TKU,GQ!)-(<!7
MR/5>?7-Q<8VBY"*%7+=<0/0*@GK5]_T4@W59DG8!5VY?^06'#Y,G*IY.ZR-F
M0"1/P#$EL"UMWA9AA%-I80V05J?> ]A2F&T1BRT/\Z:!\0H?P-63[OJHDFC
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M%-0;9Z[AT<4NU;EPHP0Y&GHB=T6J=.>LFFNGI2KJ50_K-[<19:VL\U+=M2B
M+KZI OR0!<>2S476:>WA.$DL-!R*/)H3D,6E2)H/V#2D#6#P<^TMM?A$2[C!
M:IU*T8!L]B9"3+C0"5^)E>T6)0Z<($J2N:;6KFR([I=-IPI;,S,(G(D3C23V
M<6BRJHID3G7KI4[G BEBZNWSNWWMB;J,B 0.@V\$]6?J[IS0"6AOR'GHWH)%
M$QRE.9D@279? (Q5[8*%9*S#O!U@G8V[0;9XX37E6^[9P68^S:Z.'!ORN*0]
M05?D27==FLXM6)C V*F'DWEZXS'BWB?O=LV[IYT="1P8$P \G5NP,-Q2J<<"
M[)/W:V"?EK'/Z7Y))Q@$G!"^MO;]?$$P0,M1HUQHFI#JO;I$:D^=!?O8<]F.
M,<>$0(Y%L[LB0\ EZ<R"10MBE32#]]ZU?&P&^!9'_WV:^M[R>7K#F#VX=Q\2
M7E]EF]R[WY;CP+$=\G0</$W-\)98=615P7)&;D=?YV%R$Z6I0%K)]J^!$UO'
MB54-@@76W >\AB-5S-Q!X5$(!9DB*03(A,M<PZ->,'LX9(:(\"AC9Z0I[Z!L
ML)4+YII4G)D!S;-RL+K2&Q6*!6NOA3@;6B7YOQ540QBHWR]L/@Y :XSP.JU\
ML#*QI2-%$[EQ1!/Q5(?@JBI<4$5=%]*5(4BR9B.OE"A !>!2 5D-1]9))]=<
MI)8^$!];$#C)7%-K"6%5HY84#O5B-8]:TK-VZ?:LI6"Y2$C[.G5"+)&O+7R%
M7._5-Q<7U^BO?_D^DM\KY+KEHOUAG,[%K;@=C?!@-XY3UL5N%B@ D&#!;5^P
M,**B-,\=9$?!!<!*U2Y8+%8ZS&$$9D'\G<6NIST3,"%G-0$:3>E<Z-(G]!S+
M-!M3J=FH:@&\P&LM>];5V7D\75EP=S5HYQ8LC,E0Y>@;)DS)@S<D;'#O?O1\
MHH/<AP7VV6-.K*=21&YE!QBK;0(.P YD.<\%B\5G98YJZ3(G@6_(U\B/TPS1
M.,HS1 N::"C*Z>$I:9$UGQYJ:F&V)#B2+5\PZ.*"!S9%8H@Q91T-Y&S&CS@:
M6@"X=6[!PO 79Y\2&*[@@F[AK\HIJWP@!O 2&%X5NO+<!%@V_UP<A(%/S]??
M2HX44+@^4T X.E2H_=SWG),/GB?!2G;&6&<=>'+7P:52^K*;'H8 KP<6W*AF
M4"*=4E<QCSY5Q('Z1E: "U<V!9BK.\( ,"RXH),PK#+04"W2LH.] 66BHJS"
M>$/EXJR7[:<M'-"@&#ES#8\N;@S,.?7)CDO;MY7O/@HJ;+IS[,VU U(5A;&'
M]6[C,R1:[)(=0%<5[=LX(0O.-T7H2\,[%,,-8&G[T-"AF78[ %=:?3AG#*K(
MT* 95Y,Q>%J/-]ZB#B#68(B=5+O/7Y#I#>B\"\&6S#6U=GZCVV6_0SZV9F80
M.!,G&K'LX]!DA1Z$25PB28.Z\T .:U5%IY&+D V2TX.QL]D@75FPL#KKU"YO
M>X)@(Z+90L9Q9[8L[8%Q!.DML&#Q!$>E(ZU!D@!C\5JPD(QU^K#KKK(.% ;P
MM=RS<];\:,PZ]1#M]:#UKL@3<&D*'BB(2W/8^7S>M8\1KI^\VS6JSQ.H@B0^
M-=VRZ#C.3\T4X(-Q,<+- '$P_IO$TY5ZU14H,D@5![9J"EN=[E-WDW'@-#9S
M#8_4]X,&F$,&?.L6O!\9>Z3J68,->3K9U64G#R WN5Q,E3$SDY=?6WT:E8:&
MO08,T 2@-7&.>2H?5(8Z[]: K$%3S76D# !Y#4>>J%/-<Z8A ;(:A2Q!IYKK
M2%5E\;'%.YJB=2&:4OY4\Y-CDFT=9GX]R%9APO!RB%GE+KCBN'^K)IBG3*.!
M&/D@HJ,+%MSV!8LE/QHVUAP$"O!7\_A+I%GG#>,@2'GGRSU'S#[GS$E"#D!/
M<5-A? 8*GV'!L.!V++C$])1S9&%SQZ$/8;13$P#6JEGH@#F0XL(R67,&H0O-
M1N G\F4AGG/0VS\%79$+NP^ ]P@+;NF"Q8K4-G\4^D'R1!R5+0 ".[=@L5BN
MA=/1@0<;Y8S!I/2M[[L%+C$/@\6"6%JB-2"_'0(!?#F,Y_#TMHY.AV;9*S@A
M&)W>QO>'!0NV8+$,HP8/3M?!RVL>WMHU-!T@V!@(-G=@>@\PUA",-7=<N@$U
MSM Q[I1AZ6KG!$WK%UQ'TXCR"W$%FIC>L,(?@%RSQZC#06C;X-:(D>J:T8 S
M*@!;:\>I#V"8>H/QUXA1Z@UHJPX :_ @]4$3XLD0ALE<4VNKN9/'J O6*8O?
M '5Y@QL)12S*D:\$A %V+ZY=9Y;#A2T7XIV+<HFMHP0?G-X -24 I&#!;5^P
M6$*C:4/308H 4S6#J80:F-X MH%2 +XL<^BX=#':!!PR %& ZH #.*ZSQ0*P
MX+8O>(\6%OVDO<I!J]=:5B"(HWL%P$[G%BP(LS1BOC=P#W"/N-Q3_QAOL?D#
M3O\RU_ X03]H;#?D8K=NP77D5FP/\&O![.Y42NP01BRW!&CB3O+6D:P!S%H"
M,U'G>/=[#:C9 XBU;HKW< @%R8W&G; SO$%E-AI7@D[P-H@Q!D?F DSPSGO%
M591%9J]3&2L-2H\>5+@Y7+=A;OK/CBO-\"2,!0X5!)+CVH0=KR3VT7X1LUQ<
MQ\.XH_]$([D1X=_9TL8!FAR1STY^3S:.92^8Y,HD<$#^H/DST5UL&O]*W32<
M^M[R>8H\>OY/5IB2(<AA0@2].N$4N1X*EN. /)0\G^;,OUE4[Y'?A!ZY"::"
MD/$)>WQ\91"2O^@+5P48\A6U\G*_+7IF_N>)G/NRG!/26UO?9Z_9_J3H^LW?
MI3&X,&V;[& B96)&+O[]U]&G.^G#X]WHG]+HX]/=XQ41DJ_F6_ >_7Y_^_3W
M*Z3(\@]IP*4O?KK[]Y,T^GS_Z<L5LC U5@HOBQ7?D:R"=D<<&6LPOKZB('8F
M;YOLHLJ7$;]\E-1ACHHY=N-R")2Z0RS?0V]1)-R+K]UZNI9+M@P1TS<C0*%6
M@^,NH\ZCCOW+Q3?,M.N'F6?]^8?1LQ75Z-N2TC,FDJXHMF2.597\GR9CLV<.
M)BK^0XEL#W(7;(_"4^Z@7F2V>!OVN9RR__VQU<>3B2KIFJV3I_=L:6!K0VEH
MV=K M@S#M SR_GF\21^X@T'3SSV-17/OP(->I^YV@1 [7ID=SZ&QAJ-LHA@,
MYH-+Y2>BF]B929029ZV"/.2?.6UUGVDA8 /:Z%*3>N=54:STD2D^;#]%:C.,
M[.QOB9X[K9=NMOP_28]#K\2KC+4MS4F,E375M]LJEJI\D_PT6,ZB1$7RFU0"
M(_V(*G#'=@A&<' 9DU'A2D9):2(A!RM"#HFS?9GM1(/&)9,K^20UUMAQT:-G
M3?$E^H8Q^N*%Q.!3D>G:2$]H*;^C%Y$W8*]Q!I74)E+I\#)%+TO 7-#/V#L@
MSX_A?Q!A+XO45X[ KU)EK6W1G;3.)@K?.H%%5K[T\</DJ^\ML!^^T0.A<.3:
ME/H+NLJ[[W1ZFAEZ_MM%5B%:O8EJ#\RA9$[(_^GJF!@ LCJ1^A-S/!@8MJT,
ME3\(E3 AV((\//27>)<Y<]#]E(,4+'M9XA=-/?_>EF7%T#3=4/-=VC.5;([/
MN!&30E%0*M:RL3VI4GLRI7AC^W)XB1):O&.#ZT+&^CBA1]'KYUIO1T*#\FHA
M$)Y8E)W<@E$J!PNZ81LJUGN2CDU3T@?]GC3$0UM25:6G&,.!:9CJ,5@XZ'[%
MQF6NI\C#F$(7UT]$7$R\V<Q[I9XS\UR)3IX3:I/[!$R:S+T7O-+7BUT41S9Q
M^\EMJ 2^*O:O\UP79M!17*%\9Z; UXY>./*=F)"U\(S&7BQRA]7?\1W9WYO>
M%MFAF;D(\%7RCPOTZMCA])>+K >Z^=QS$Y%4[@&R/5&?L8]^OOZ1FE*QG1?\
M='[,5*#X^\E[<LAOT&?"![!=!V_7AZ4SHRP9P)ZQ_;CQ6")59!3'GQ'CF@C;
M9V*.=V"7T*^F-75<[+\ERZ>*)0H QQ_LM"O:M1NE\1D[NZMZOTH[[%(AB_B(
M@^)1B/YA$A>,L$Q%&<.K=3.;Z$KY8=^V[[_'X ?^];2P+; ML"VP+:W<%M[*
MM^O-&6Z\H 0#5/ LM0IK^K:3T3*G+Z;OOQ'/<#3WEFXXLN)#(&S?XH6/+8=%
MG,F7-'TV^K=KW\\7IN-3UX#\\<GW@F#K+IE$R9P?16<!6R]#FS#B8$?,.7MK
M&@DHZG=1>)N3SNCT8?;49R<P +8;#P38IJY9163X8%=1T$#)MO@&^ )\3X)O
M.H!V[WZ-XV:<L(P,.9OM#E &*)\$Y54DE!-Z-:2I %^ +Q>TJ7VDZ'V!T0;^
M-%_62B&<X&D-<7;^XZR #2)G\X$EE('5(WF.O6_CW/)43;?X=6H ]-8!G:\C
MGZ[,[#=AX T@OG6(K]'W3\UUAW%B@'W^V.<;+%C#?8CZ ^@< H@_%O'< *H8
MJ"<W8#XW),]EKN&1//<%AVCL>7]&'0=:+Y3.;CM3JGP2V7V_U@=92TX<<0'8
M$=TCONXAN0\0:A>$ZCU>UO5L-3[@J<EXXGS&JR%#AUPQD2#$(;_*T$760KS]
M'OX=\H3T>Y*&;BWG[LZ-%H %PX)AP1SU4QN40?45I,*!JO&> P3"BB\ [$ @
M#" $@; 47@!/8N,) F%[+V@WA" 0!@4'15=4XD;2C!2+-;,U+8*LP*%X8*T-
MQ\N B"(JPEK/]!!,@ 6W?,$E:JU=7=^KL'E&*<$4=YG^$,NF&V\^=ER671>4
M70<JL))L,9Z _& C;;RM #;2([:H7',FY#J&M<YQ>^<6+*ZZW!NUO'<M'YL!
MOL71?V.9R08W3+#/9DGGQZU*KFT?BES8+C[&3BB%*!EJQT4W!<%=JBBG!P68
MS99U>UT#03!WW>N!K!/(@  #F2]U1[;M=-,P%E=V[LJ,6-'K@4X4>)J:+C?'
M6F2_&O!TCM]1(Z@4-6OI :P: :OC?(P:,=8?R("Q9F)L_PE#C?I0@00,40X:
M:E1@2!6Z_3,X5'Q!?^L$"R\@&&)]'\D^8<M[=L''RGM@_7'27:[6BI+D%H]D
MZ7XT.[3D4'NV83$$.AL(I+T^%A<TZ5E-!&AJ()J.<ZVX0$O+AG\ 6@V$UEZ/
MBH^@@B:3 J"I)N(K1@.H#WX39[\IW3+?FIK^<_N;V4&NENC:<K]9GX)MR2I2
M@[;[P#1-9)K])F9E3--7H9>S !CB27(%*;T&^*9@3_)%^+I?=U>M2>'UQ*[@
M^YI\G[T@>(P.40)LLVC8Q D??/IYR<I#?"D"L"JCS*(&;&F& NAJ [J.K*RH
M 6HY!9" M 8B;7\)10W@RNE;!. 2P+^J!0M* ZJTP._BB_Q'_(+]P)S1/C0.
M^& 5I4!6ZWPE-'R8U&*_")Q-*0"D.K=@<7GH.%\ N I 5H4;4"^N1.Y(V&)<
MB08#D8OHP07@B_D(IM8;"FDSAUF4TH,G$VR%4 *Q]<#ZPTP[3V'RFW1\P>'=
M=^+1N<_XUB%TI=3&5?6"R:FR$R[( #BKKOL57[#U('^D%6@KI0$65^@9</S<
M"N2=VOF*+]C@&$< L(F)#770@)I4WCZ=V@5'[J!!:P2:3+ A#4:M51#EV1XL
MTJA!:S"2IE7(X3QFS4#Z$)K,M0E ]0Y94W)<*D!3<]'$?<1:KP_Z3!P 52XP
M9-3/Z3LN#L'!Y\E<PP/2?_W+]Y'\OO6\W?D\(U@P+!@6?,:"NZ ,.AD  SZ"
M!<."8<&G+QA2\/A2]\8+PLY!FE_PRO3]-\=]'LV]I1N.+&LY7\[,$-OI+B?D
M2S]T@NC?KKU.RB5_?/*](-BZ2R;<E?.C*/#5J".AG+IW<2(J -H&@9;S:92B
M(&V8S08$\ )XFW<2-A YK@U ;A"0.1_"$2D\@*P2 "\/K*DZ&O1%3D !+YHO
M8Z403O"4ZD]-1_NLFUN P-E\X EIT2+(G6/OVSAG/#5?7?P$;X!YRV#.UWU/
ME;J@H0S5+H!WWGBOT>-/U?) 42$@GS?R^88(UF ?(*6?G?0,> >\[\([-W@J
M.E+D!EC>D&:<N89'9MD7'**QY_U)U[)L?Z?,AM>B0%%E\06 '''\8"BJ;!V
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M94X; N2XK'0#O1(3#OG8H@BUZ:>TU"IOKB0*HB:!ET"MTJFE;E!K1R24B+'
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MMWP9 EK:BY8.2ABP7.NQ7)F]R@Q7.EP5#-><!W(U1E8285M2$/)PT"LUS_8
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M]8G=C0H1RK8^Y4%0X>E,B.XE1-M' (>I4@41=4C^*U\>HNVWAX@;E0X1S[4
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M,)2SL0K@!."$BC5"W6&ZE#(8(D7.CE0%'@ >J%X;U!G:6[. @@SP"X #:N$
M4<*!*1]91[*:'44E'#M [GWF&AZY]U]PB,:>]R=B'05;+P'W;PC/XX\F1-NH
M16E __@VP$BP"-:U@?0A#$EL ; $# E=*_VL%PS0:ARTQ(FQ7*M]I,@P.J,%
MH!(F:'&M(!TR^UL'*5&B -3Y5P9=F.]RJ->O@=>_GB37>E%2=3$G+!@6# N&
M!;=HP5W0?M7WFQ$.5"TPJB'N?< % ".(>Q^"$P 6Q+T3Z "T!(06Q+T!5!#W
MWH ,0$IT2$'<6]2X=]>+86FNI\4F7)K4!0@<B@<V3FF\#!P74["W7L)4*$\V
MYHCQ\/9'*3(^37UO^3S]$%/RQIN/'9=E^0:EZZV>R"7V@*FR7?^Z8(94&2($
M H7%8<&PX,H7+)CL+,>T!PE:=#=P  JO*9^W'K%%<<\&-S/ _2U8+I)GO$Z=
M$$MT;BF^0J[WZIN+)$>&F'ODA]V319U;\![A>T(MI CVZ[UK^=@,\"V._AM+
MX">?;,P$^V6+W701KMZ$JD/Q@5>KUC_Y3(LKZJY%CO0!PDH]VN(++'I, <UO
MFP2N<XZX. NM;,\N ):P>8_@CY7<G=2VHY@ X+KM"Q9,0YQ])) @=Q4".R*L
ME0F;G7:\K4'N!/!8(WCL:!-? /92D-*'Q.\FX>UTJU\ N!F# 8"MJ6 [_5RL
M?N"I2!Z*'-T GXPOG]TZP<(+"(;8B BR3]CRGEWGF.,RM:/'96*>'AV54;>B
M/KG+(]D 'U,OJ/RP5U;9P:E04P!UKN_,"6,Y99N ,?"2A6>JHYUE3OP$,Q6:
MBZ[376->!@& JQW@.MD5Y@0T):?B4#BH@<_+^1PR/1G1FIK^<_N;H'?>#NS<
M@AN@/4Y,-4S/]*CHL!6F*3478N<<1%:/+-2#<74-!M<9IX[58TL'OZHER#K]
MB)&#!!OFM-D0#F?@5/%EJO5D-7"I.K)@,>7HV>5S*R!_]H+@,3H/9]X)L1XG
M3OC@T\]+/[Y2P.5H+N9**:"K!7<*')LV%W;G5-75@C9-;8#E"' KO\ZN%K3U
M 6PM =OI32;K4:I(4[/-<X7#'KC(?!DM8@KK#86TOG@6G3_BR003/0U29_.!
M(DB=_1UL<ZO'O^#P[KM%A-,SOG4(=2G-<75=5W05/,?F JZB9C^<,:CT&Z#N
M (/\V_]PQB&@L+DH++]%$&?PJ3H<[#<7?J4W$>*,/C "6X*],P9JB(!#76M
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M+<OV3U]I?/4FM%4YX ( D>A1*VBKT@Y8"1@&@K8J;0"6.'$5:*O2$D@)$ZB
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MS^WOW=UY:[!S"VZ$^C@Q>2@]C**:T)(.-DJ307;."4[EV-)03VZ 60+PJN+
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M-9A66.*69:,@0ZNWCP7 O"*8'Y> VC7DTUR->M/+ /@\Y/M!";)= W].!P-
M?@N0?W#^;M< K^I(']2;H@Z@YR'N=^07=PWS"E*T>@M^ /(\(']@_G/7X*\.
MT4!MF(4/71OY<O8WT[6]_[6^R*-A DT N14!@Y>HZJ-^'^J2&@;9!H37^*)8
MU:!O0<,PW)!(&5\<YW5T QP+C6.QXUZ<X8ODFMT> '"[8EA\\3L4N8(:P-OD
M:!1O0:SW1/;J(-C$EW%O/'_A$>RVO^]?J4T08,&P8%AP[0L6W.P0S69>"7MN
MS8>,@<"V!@"XR78S@'G[;E!AL7D-_^;9N;U56B_4]N^2X&*NAG[:FBSRH$X
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M-VBR+5=6H''<*(90@L Z]= *B'D$,97+["G9%C&5G^HT?NL;Z0&3WBN<]&[
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M%M3!=I9<>^.G;3\Y]PE+ 54DS7#".&&<,$X8)UR;S>98\&+X^P]M,.@,]3_
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MG*F^[/NF.?-24;VDU0X>(#$3D(,J1"XQ;]L%7>-P */CM'!:=4ZKX,KKZZN
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M<B,;&"'RQ7DNQ_-Y.36?/4934=6)T#FW4N"=XRCDG$6>)XXY67W]3 ,21.,
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M-S<>/ZYL$]'T>D,4#8=X12?V$>0G@5P=- SD6(1F5XM2]-/*-Q-1"<N+QB'
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M:$C\9!#PB3D^H4_4F=*Q,W7"!7\SB0)V6;89A.(R,Z:5N-2SXG)%/Y]9D<F
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MP,K,?;44V&Q_@#"0D)@/?)JI)N#KQ>W7!.""B?E1L\4JB"9*)/Z8.WXJ49=
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MA,0!2@BCM*V# 9[<SSY]#BY64[!64#P6WG+FWM6YQ6,K5&RG!<MZ'3RSWY1
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M,?Y>G\X=EM_!!:$!++GMN#$H>5\"IW/?"^;,#*/@DHP"/MO-)=$O^-,P9B>
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MZ>RPQD3=L2#D;>(B4:%'@H@7H'+B E;FE%%7E'GUF1WY8R>8"/D#LW)%';/
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M\J05"WTEB16Z )9X]3*>E[IV$[\/IU/LZHD[(^7^6,+N3CN*ETO@Q8[B+/O
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M="IP"3QB*'P&H.1DRW7'Q\?1(;B_ )7(S&RW3@B^//9JP0#C)_U&;9L5W:Y
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MA3!SDY!_P5)XCMXY0 TFY5B:N)#]BGQ'G')%5746*I%R=6-B^>@\A__'*T&
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M"2=$BU*.L%).IHPO 2[SO__S8]S\*+'OYZU!\<.8+8U SSE=/OPG$UXV@[R
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M1=Z[%E>-'\T>-GMB5(Z'DA$%."R7OPT&ST4I[E,\NV0#PM*&*"DML2;4>[8
MD#H\B'JR<.AFV<KF@>5@*C:]'IM.L63C33SYCC[B_9>A!YNKS$U2^8+=P[3=
M_R9+M, S@6/B%F6+M:"GQTOI"P4?<(WZZ70&L\0'P-+#3T]:D!*/%N[OUBC-
M+94PVD 8!?SDC^ULGP;A#!FCFX@9P<^S0BN6%(O"ZP3ILKXEL8"9$[EE']>A
MB!L&OAMZ6 (T#5TVI^VDXWKE7!>_84P\;<W%OV6O7+4-FL()6'3][?C+9>/S
MW>7XGXWQU</EW1G1[!=M[G\D?UQ?//R&Q76S]4S3-S]<_ONA,?YZ_>7[F5B
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M!E[VS9_= 7#Y0<ML##I-H]'MTG9CU)ET&MJ(TGZK;0ZZ+?IG\QVAL$5F,(/
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M0N&697W&'!TH\U*U(WTFON(5N#$_Q_-_M49/N]69=(Q1MV'J_6ZCJW5&C>'
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M]IZ0X3U2^8S N,OS9FPXK=<$U[+Z2F!3VO#'1P:X7<QJA>5>RJQR:I%$D_J
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MX+J=L;#3TJ]_?_'YQO_ G(R@=4P1^F^E%UMLCVJSF:>APQSN<T*V\I-Y9NE
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MR(D=N(BYBD$D38'!/T:,%E@$3CRR^M"FA><SCQUH-AIR6W]I:#S8A%M5&G&
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M/XN24^F5 5C*F*JXP6"5NK($ $L$XC('DTX>*EV[6JX]-J:68[%25E@VB_[
MM.LCZ  DH_1:J0)E"77)Z53&F4];Z3EU5Y>KP\IR 7N%E6/N!JV4A?5'5S]E
MX8Z*2F]QV38_[NS"2M7I3YKS2%G99^ TFL.JNVO8L(J5W?%_\<-9-*:7)RN@
M#:S_0<^(X[YXVNS=I__]GQ_CYD>PB.#"H]D]M?+R)2$H8UYX7;/S+9ISCH5K
MYRI"PC@!0AG"J$>:W>5C!.DL' FXM%0F=0V1-FC5P))6_&P'87:R(6^TK' K
MX$G.X X$>NT:G*8I@V"?!L%[9A%\^-EF6"VT# PZC1I@96R#(V%2,DK''>I@
M%PEUR];WE1)6.UE82Z!U!LMQC IIRMLIR5% R?IE9?LL%;@E\:F"4C&K92IX
M>N59U-%I(VI9Z66T3JYM_BR4SV/A0?4XN%Z;VR14'K-^.2P0IE0>TQJIW*8:
M"+<Z0JO742%]=;%\RU&>JL+<I_9R41%EF4AN ]<<<MT:&,-*2:^6H?.]H,])
MX,%-HNLN[V&H_+H++Y3"KXM1@M>.CAWGZ 7E_SX\>6[X^)0<++D>(,JY_,%]
M]W?8/J^8H6RG,O5[-3A=4H*LIN@:]I=K:2ET2<VYWIQH(Q/>E@MO*;1)SLMJ
MC;=E=X-T>%,:>;6L/&H?,=/FJF)"S@NET,(3X_Y6D DM>;RNE&)^I*U")NHG
MF:1!3U?9:'7C/!NZ&JO 4U=%,M>.%4D,IYR&#-+!2>G %7NEX7?/FH0L8"G3
M'_Y8V$@]HD30G,[0ZL'%BS[/\;^WF@>3M0#XKQYG+75ZV;!HI<SA9_*+I'VK
MQ;*A2849J:!A52)AL]'53^>X9(?>J&QH^M^AY5N,!9T0>!,501G$]?@YN4D]
MI8DLO% *O]P*__XX1=6+A*8/$3V7I$;KX%W[$O#4&J@D>\63*NJEM)!CTD)4
M#_D5/>2! S'N1#H[[R(O'>SWVEFY/JV[6P/2ZR@1(5&#Y%T?$9;9][U#>D,%
MGGKR'?EZ:W?;JF]E71F1?&CJ]9>#%N1!D]*+E^ZI@O=>:1:;1TC143<#:&(A
M(HI]A@+R#\T)-6].E'(L$6-9)P@*?F,'-_XX0 )OH="T23>GVID\;$,FK%0B
MA-HR8Z6CVAS6EJ]L&M&T,_P,E.%45SZS=^P,90XM4 ?/U9Y@Q-W9+4=WI_3@
M&47M(MPB HEV+->,3.45H6DK#?8 SHPKA4RKN9PFK2 C&8_9(%&U6KZC("0_
MUU$@6HD)I=A&HY5 L04PAYY#8#>D';7TAVZ'!I:7MY3BN^)_<@14)M8OI^:-
MDUC!I93%([VF2E:MCSR2!3@I79CT6C)+(<5X=N"*JX89Y>!(<2)9.9',2$JX
MD\P'3DH_KI8-J]J;<LJD\JLC;M,Z:?GH2,DDR:MOR RH05MUWE5Y1D>79W3L
MNL=W]QD+*OCD"W";&>-U<=F%8X&Z5*=#:SA2<FMC7/+*.%XIE;[:JJ!*#2Q?
M*:$S4D$,TO.<-Q\FWE%K.@D]GV:JPCVXI2))M62J 0^J!924\TTIP*K$H)2B
M:%,=YHVEX51=P<,507)#2.:(?PEXT+%,6+G7-AA=_;2+>QH$-E7].W)>*,U)
M7I;)XS4IJB7A )OQ>W6F<E"'=&5BI09=627@*L<R8:4@;#"Z^BD(JLM7#;0$
MU>5KS1N4WB !>E27K]IQ'HG;,JDN7_5C11+#277Y4CJPZKBA;%Z9;%Y%X4.G
ML*K2NG3/WJNTJB8&$A83K[3R9FM(1EU5L$BBZHFJHN\JTM<&*[)QE;W7V92Z
MA+Q,R)&/R^P=.U+7]U6*[=(]E2BVH6-0')L6A(?OCJB-G%E#([D/O9D=^NC7
MU*W@FEV[Z3F+*B^T8ZFR@9>\=!5V5X!)%Z9J]=7Y;BF,9@< JD WV3VD.OT:
M'*O(!"AI.9(TD.H.:Q"/J-3?I7NJX,)?K:D5\#)5\'\>U=U'Q^(?36*";DQ\
MCD?5C:MJ\;7#6.>$RC?.74+C&Q.M'\%PMN,Q2FK)*[5VT["K&ASU5)J%.F3>
M^X15V%"UU.65\8CE$'M=?>3H=L#N!469T?5?-,OYZOK^C1-7/>2Q83<F$R*6
M\YA?\?#!9?^<4\N&:[;L7$%Z317S6KN8U[K JZ7*;,HGNB783$I767]T-=15
M5(GO>BDEFU9DWM*F_310XN$ *@WM"3TISYHZF5;:A=(N-AI=_;2+A<[1Z 1)
MNT24#V3%_V12-S@5>6O.&R?E-]_659[3CE-I%75U:)2-%768HE2(HU,A5&3'
MVR,[TAE\?CB+!O?R9 6T <NOTS/BN"^>-GOWZ7__Y\>X^1'$$%QX^'M'ADB0
M&IW?MTE?E1F1-Q1$A135'D?'JKT<22B(TEYX,S,:$#NJ482!(<$3)1,-6)%.
MB?]$X6=5>*">BDARBI\M0G5C+I?DW=#L)>TZ%*>2"43U4T(J@5%[N::%@E']
M>-&&J3AE 4OE>!T*=Y(,6"K3*T>C[E2N4><-,5:OFVPXI>VDX<Y-IA(7I])E
MF&K>H^4T;&H&@M\@'VA8C@&[]JS!OGJ=PX0SX0!M\7^X&Y0\@'F"G$+S0\XP
MR*-F.3Z!P?J6\TA,SYT2'A[BHSD#^QU,&9@(EE$+IS/>L\[RB>%9S]0A4[C;
MGI/)/'T3VD"PJT.V L2P?-T-X4T>QIN0T*<&"5Q@&P'UIL!.N,DDBM*[$Z 1
M<]><*C#L'@SM-!C6$5)DS#H4I@S8$X(BY811;0H2A3G"+!,F!22><2V8%=[S
MR0L('4Y>5H./Z#R:F;QH/H#P[Q!D%H/"!"Z8S6P+/KW@'0"A^Q<K^"_UX#'
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MJL Y)8/M3B-(GQ*6C^S;45#>,&7)*6&PT5870M<$H3QK9$4$SCXT:S*'$5+
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M2+@'( 39LS"-]"B,5E\> NQB_KC?FR.<@2DW[%YUU&J_L'O=4:SC :]VT5/
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MS(R&RUK\ZK/O1>-__^MGO:;WW@=I< 211BE^#68O!P#%>U0PFV#"8"N"$+[
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MVUZHRQ<GX Y0T&!#[3!E]G/9M..QR-C/T,ME[RY>M":C.:)_H_DH- ,9U?^
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M!8$-[" IH+!9V:NS6CN].]M>=G66+XWA\;,/S?9\AI RQ!Z7:QZ\ZD+W=O-
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MKK9DRD'-CX2\W1$IF?..*YI^2DB3V:^E*/MAU?<G&@SQ[G><^D&Q]H45'H9
MX7CT79-'P)")02G:SI]6J"L+;Y?:RIT8[K;A[<>"WL[H5%OAK!R\72$M]WN9
M>7LEKK"NOA7^Z(74.7F=LEH.2@1*!'OF-"4P$'I-+;;6@\RAZ(D"S6H,2,4K
M&I4+=;G/L):I=W&$B4X\BT>S9"(0!WYMSMZ@(T/ZS @E_XL\C'8YHOX/%I(Q
M]!_/$Q",>6GPPP7BEPN2.>C+RZ/%!Q#.XY0KMFLXD8EI<<TGQF-EGF/IS_BZ
M:-4Y/&/Y- C]R @C7Y1J>*.19V*;9\J,@H@ZSF19HST??O#94^10'YZ,QB;%
M9UR,V\FC=P(%C=C%0F@LB4C:VFM$TL*TX1BD%"0#77BRC5S@4=Z=(!EBT[8L
MAIHP%WG4#F#(,;P3CT[Z8H<B#8XW^)N)@<62C*'-GC$,*HSW5. @1A@0EX=S
M/R>A]\2XPSHM W6Q;P\BD=%X3&%.#R;\E\^^%XWY0&(.8Q%2F#$80&A-$%F6
M;=A8?NC!V-EN"/^/4>(#S^7!.'FYGD.\9^;SXIY!TEX4</A@*WT[^)%VG'?S
M@GRDF%$Y&GLN_S;&!#:!07G>",3'W&?;]]P82X!K --<2-< 7H5.0)L]'ZH%
M" T8AD8;V6&8Y AZMA&^EN^-R!A4F3&)8V9!,W# YJ+$&L)&.9-D.@196.,\
M"X;49[Q+7SWH;0ARZG_&Q,_C6 0#YG@O(DKMY4+]==10L;.&,;/:OW4?>._N
MK*1O_<\K0\CJ@QZEW49=:UL#0VNV&UV-UJV&UJA;1J?>:_8:G;H*(5NZ:(2G
M%P5MC=S0,Y&?*Q42;E'72Q/>K:U<8PNW,Z8J?J$%.WI\CC7*:!XA=)&22_'.
MQ='E<F"]4=JC,$"OGVQ7<Y@57I+7I&I8-3-$0H3L?X&2H@$!Q1*KF+>@;: :
M!\GZ#B(52^Y/VY'#55#PP[E<K\6:SQ?U_L8<\^-DWJ.6]9YIK=1]UEY^/+@@
M]Z\\WK/R[O^N"9$=NE@K"Q)E9A:]L1>=^8=P!G'/'S<?WQ^NR$"9D.(*%^D'
M$-KA[,?_X5C=61MHB&ZJ(7K+#TE>U"76$.4U(^O 9(<VI.I .; I49MUN\Y!
M-Y=ISHS\=(^'[^PLR"SG#: X\:0=["MO[-*Y]V?<]+YH^57<\#MK=N;=I0W%
MVH.9R0;2,RZAQQ/<6/B@ZQ=SV2 )_@2K/IXD;W\)40_<T>9%K[BC[];:FCS"
M-B3?TX,E>;VF]]X'!)2$[5)_,K,+B-MCV0V[N:W( =^EB_?H_,@1'D/,#LJ?
MN2!]T[2Q).KDMA=!K9,1-6&^#$'88F?0YF7ZN(_L,[[YB/O24<AW@1WZ ESO
M@EU,MXWQU?@1#UJ>;"<Z4)P3$ N>B??9QE#<=-,T'())&7J."8/#-_@\%PH+
M0&RV!0+'+5?>/Y[V.FX-H=..)/5@%\*A%_"==13 =["94/[O\*/IC?AFY6>H
ME+J3,NU/LY]C9F _K(COWQMX L%R,),FW]<-\&<<Y@0-T[M/8R\(M6G&V:F*
M6Y@T\QST)4HWB'-W!E+FS;R.19)0#\J[MSIQYJ!KF"9K65IGH)M:<] VM8%N
M4*W!S":MMVBS5C/4KF?I=CU7,&F1@PW7I#MT:TJTO-A8)NL\<]ADG,>7&[F;
M:LY8 E,%&G\QHT;55FN^1?([L%8?*D@W6<51JQFN=/1=-$EV%P]_@%]):F^2
M4B[S16_LQ4<,7+M!WC+@_B,\/ZN<Y+D*I7"2SSLXDX7'#5^*)4[13UGK\!5:
M=F.CYU.L7S(>T?::FVN-WG'3]"CPK <>3A6_ 5.<,L0,5@*) "5S)"9%<//O
M'()P7.>\2NF:)O:EG+Q.4==/I1.!XJ"+WM@;!SUYC!^2.LQ$[OB#AG@'<#*?
MD.:K%WX!TN\_#JE[YS)\>^\1.V9YQJS??"-*H9-Z6V96H:"V,ZCMG.;N 'Z*
MT2H[EK%C3:5<9BL\A'+):Y:^:V;US>.+QX]IE-&V-9LJQ4AEX:?LG;)W"QLK
MA[UK*84S6^%!%4ZB6O(:9^@S5EJ3I]=E5C$*@?M&H+)ZRNHM;*P<5J^M=,YL
MA8?5.:ERR6F=&R_RRVOV]*;$.D9!<.\05'9/V;V%C97#[G64TIFM\*!*)]4M
M>9UC/Y=WM5?KR9SE5B%PWPA45D]9O86-E</J=<5EV,;[>JVQ@UB.2O]LKG\2
M/9-W-S&WI :P11JZS#'B%0#W#$ 9[9_>D7G3N:P&L(PQ4?(WQ44(R.(Y^2N*
M=8NX%<WYR3]_,/CL0XS_V7 4\058;,':4ISMZ6%C+&!078+Q'T@0#0+;M*%X
M#)N?1M#G,20,#(POXEV8"WM]068N:1!CB"'JS21"![S \<R3(]BNX8T8CXS!
M=1(J@9G0,_/%\S ,<D:BCY&0[3[7F:MCSM,:I09K:_7ZH*<US79#H]TZU=I-
MO::S7I,V:H.YZ N\@;8;,;,?;E*>KN(WO)+M'SY^PZG'9E@CAGU%XM4?(C:]
M'-VLE24N1%==FUN<2G[&Q*/57FRQCWZ#?XTR]"/$XM_A.G)9,G#!$L"6PA+Q
MR@Y2UG W9B*87#"_OIR^-'UJ=N6'CVOX_&7A6A&7@&[ %C&BS5P3]>,Z)DJ.
MNWV$5\V'/3Q9Y!TWIK="W@KDU4\6>;7C>KZ.%BUG3?)U^*C Q_72%,1##3$M
M.*;K"SS791B]- @#0D=>Y,9Y W$1N?GDFD=_'(PC\>P&,? 7QKB>"3J;PCB)
M@X^Q.G'^+8X\NA.?8_X;_GZL&.C,O)I]<MEHUV+T+7K^6__SM?;Q_KK_N]:_
M>;R^OX3)]4(GP7ORY^W5XV_HO9SU6&1??KS^[Z/6_W+[^>LE,6 LF+_PM>U]
MG=N$8KW16IT"5^=K!5<P1)D28BV +J<%*F#QN\7>J=RPS0UBMK <5 H\>+K5
M-"W+TIJM)M6:5KNN=1L6U4S6ZW3T7J-N#LR_VF=S EK7+[FB]NW\?4LF6.$$
M*1ZM[:983MJO],-.=1-:>\<+(I_=63PD/P_\'&\^]7V?ND_<TXQ*"ZPRQ7C,
M!1[9YD!OU*RNH76;K*DUJ='5:$-O:TVC5:L/6+W5Z)FO\<BN59Z^%CYX8ZEK
M##W_UJS5]%:KWNTTBR.2;!FYN\ G.>.R(\)G%^?DBJ=7':=7_!5.UWBZU=L7
MY)KG7=9$+.XQAI$T[#'-^/;1D9!N.:SJT#%L+Q.FCOC,H;%UQ>#=;%7',/(T
M[FLX-@6S)Q)@0_L"C,[-T_GF2A!1J4. :R#,9;!6^.G]!96&3M^+/C]Z?<<1
M(QG/K4QW@6]_F7:Q+WIX QV<>8'W[C'3N94[)*VN61L,C(ZF&[0.2I9VM($U
MZ&@UT+=FIUNWVGI-Q:=6^QN2^;_5_H;:W]AY-]7^1OZ=W?OFK^?M_(R%+C+R
M1_>]R.7UV_L^1X%C0HP:\HTY[I^E&W_:X3!Q8FSFE]-)K7G<0]DE1\<!=B..
MB8]>Y[BW2!0Z5NT8'!4=K9+IC@-3CJK?\?BREI>@T$V@3N//5KC-:?QY%9$9
MF)5JHE[3]8VT0[W1DOBT^_&&_##Y88\UZ"V9TX:?^* 7D('##'I;YKO&I?(S
ME/$RRZ$W,%9NOQC4)0-& @8_QO<SXEL;8M,!>0A_<D'NR]GN27A7I^^Z$77(
MK8L;ZO8S>^4-G4-=+YD]F(27]((5NYFY2WQBI#\6;,]@_]/NS]\RG5D-\?U1
MGFV8UWTWYMKNUEW6DH*]&XL:]4:OU]:L^J"I-7N]ID9K@X[6:;=-UNQ9G1YM
M9_=N+%"BVV_>'')7, ^K]!I3+EG>I^N[3 [:ZY_,B/CCG[S1R Y#QLB(CT9
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MKL.*_AR;_H@<&H2GPB5Q+ESR]O[A^[NJ0+_$G&>=Q,;'WA1L2KWQ4E[82<"
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M/J;#&K;K1=%.I'#1*"?3X@I/T,DTEVMWLQW<^I$WZ*IKVR1V,.T&6XW.D8^
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M_CC5"OG52J01M\ L3#,VZ$7UHO7-<)0I!8$1@FI#G)3\JAZNU-,KF^PGH"9
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M@QBBJ=**O_,L:'TR13,HFH4"*,RQAPM9#I8GH>0*[\7B[ZXI,!NKG:187)W
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M++P-V2C'JW#V7<63[T^88'?Q_$JB:OX!LPM#:/9J5S"U]LFW=)W4NC+'RI0
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M+NG5B$DGU3M\O@=>+FN?RT<R=L.X7U'':R]^X_R[BJ??GS#%[N(9]D<\P?Z
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ML*W JRT2)>7JD%"4*12-%FNV#UO$66VIH(5B0YF(MC'B=WC*R$#_L+T(JRT
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M;Z?[U#?K%[)1_<=:MY,C%J]E7,X4I9X08A)[%2\!Y/)[\]L:+TQ;9A+3#UN
M2K9Q<W^HUYN]WJC6;G:U6MO0])K6YXU:1^_Q4:^I]WN=T;>F5)CP%&Y<^=L\
MH7668?$B\+?L69\W0R7W<!<MW#VFL:'+M>^&\V)CFW$]C%++HP<V;N^^63?W
MG(;M.?W&+]5H-RY6NXT;C:^-/=@^S,'J9WR817L$CSA!CS!" =:<SN5&0QOV
M^IUFK3_L=VOM?K-5&_9Z_=IPQ(?=5M?0&AV=.I=3Y_+EQ"[K.=T[1,]I1?K!
M5;$I;':^J =S#G.HRW#E $5==]4)<N2?#'#[Y]<3H!)F]02H%.<6G@"=(O]
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M\K=Y7B//ZEANF5(G%NK$4EJ7@_4[(<* 5[RD^K1;:>R%3.K-<KJ HMXLZH2
M<^F-G*N3H73O"Y RE+9.@%+JTI(_I&-(G/FX$!\\>"WC^F<<XA1A8@NQA=A2
M=;:<@D+_0T1Y121I?_4L%07D>NX1HXA1Q*C39%3U5X=%EM[,;S\>G,-J0%$Y
MX*G)EE6O8SL>@X'[@[@]*)-9+70]O?O1E?! 14+BW 4(XZ1F*$R%G;M"Q&*\
MU [C[]%&;O9IXMIFWK5Y3TYM568?]14'Y9KV4][.9J84ZS?7":8XR,CEEO1^
M2G9\%W(Q1=PEL><2%CR:$W[#IXYG KML8W7^I7CM?-)FLCV[,)948=EVQS97
MJV^2FH)';*F\/B*M<<1:@QIUE&W%GGA5YZG6[*NA^C<MRB>[5-T5IEEO*UQ+
MI("$G1S!E54I)/C'(_B4\Y"YI[QF(9.\C;*PT&5-%>!<0O[1J\[R0_<59$%I
MZPF9E(JL+ V5ST!64D:(!>6I"1+FXQ'F:O6:.!HS,12OL)PPIW[3Y3HW12'J
M\<<@2;L3"Y1:X%YM![>J8 <GM>+7:57S-=$T):V(;947Q--&/N%3=7R2P9:Y
MIPP)_.1@[P7N3N;"=G$G#M)19* 0"X@%Y;.@^LHW-[,<]TKHZ!Q%=I*OGC73
M0@L,C"8/#*A42"U> 0M)46E4P8_*H_[*-M!"0 /ADP/S6V: L=U3V5XE*2I=
MBBJQ*Z>:%#7J)$0D1!4+Z:DF1-W!8?/M28KV*T6$]?0I/0TZ+8Q*26+1_KC0
MIYITV_P+R])M. _DERJ@()MD45-=Q(DH"/(6ME$0W09IB.,0&()U"M9]E6%-
M;D&Y,OS9L6LZ97N2&72Z!"NRC&V:7T:FX $"QW65#^0D&=I-A@CI54$Z58UG
M[BFO:MQ:G6-*I>&5J0>A>/$V>4P#RF,Z&@F@'"3*03II 2 W<*N<BDY79?/X
MM&6 D)H*\K-Z3V5M38Y<YIXR9!' Y0#(\-QNW9D !T7?K[DSMOTQP/1IS*:N
M,S)EH8OE>,<?]U>M<(I8H"8+R*3;::%,--!UI(!2:]VC5#Y?A.X1ZZ=75E5]
MHTFYX:J* @&V<H"E/A"9>XK?=?O[WWY<U=^1)B*[A%A +*#F#OL])=Q*;(2C
M1]K)B1813 3OD^#JJ\I7]X@E?4D$'R_!:X(?Z+V^K^TC\?'5'2J_:+,*I@^O
MB)^D.;!K$*65+8;YY6<Q>>K$4@CM!:&=,%G9^-ZIUVG12:!D<"Q_W8%4\#&=
M"EJ.;N]TU%?M"F#]Y @^"N$F$:RJ=47I<:DZIZ@<?I07^9_/EB.SZ^@(WCGM
MI7!=K:[-M--Q*I+B-1J>%H;U-Y! *!.T/"Z!J$0@BB2"<+N(VWY7?=R2B9^Y
MYT#=K6B?F@@^7H(5C"R!5(9"N60/+W4K;5IGU[=>O:W^^D;0WP?T":"5-<!.
M?0?[WA]S-S^H>G*:B0@^=H(57'N$ .:I>[*Q<AIHM+*'YRBWA!'.=\8YH;&R
M!M5)1+0VW;2V4Y&N#3:NCUY/J58J22Q0DP6T=UG$'E 2UE!H&VC0JL V$ D%
M0;>BT*U6BQ?X">N"<G]=QK?\[Z.9^1Q,0+[TA=^S]RQ^(^Z7NY&!-M>V9_[*
MM*A/-<, $8@X X+\([-^IZ__<O7;;>W#U]NK?]:N/C[>?KV$B7W19MX[]M?=
MS>/OEZQ1K[])"WKZYL?;?S_6KC[=_?;YDND@&-Q=>ENH#5ZID=AJKQ(51TT
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ME'$2Q@W7A>)AK<+/PE .X(=MM'WP<.$^&V\W!I1T=RQ8.^SY%:UL"A$!J9I
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MH>;)-CI3[(F!=P B;)VO[MYP2&7Y<:4,[ZY$]ZDP$XP$'O="OQ! 9ED:GI@
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MC)"C&'(*<,(*ADU7C>,@"#:%^4\% V305,+T)8 8^UHX6*^OQ'%9Y,K$HU7
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M^E:8 MLUNJY8*%HM=)W(EL<N^,K6."N-KZK&CJJ[T-%61Y7W](N-5&^O:)(
M]8!.%**=CP+QU*A7H,-459>M*FUYY ^RG(*0N[GJJ:+J/_:Y47,?N PK.48
M'$=6(_S@1BW,3T\7)"PI=SAG+YHGBM0MK$^;R$(/# 2;\ "#PV<S+ 8S^- '
MINBOJMXNN98KKL 7I2]&$+8V%,6THD99FTY=YP<HG[BN*RQ>"BV@,-8.)E[
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M<AX(8N0WO/89Y#<<F]]P8,$JSF5HDLNP+1'D,BRYJA270:&EC;R%_!>0MU"
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MR2!S"S7T+W!(&1E FPQ 55PU2 .V!L@#ZG8#>4#)54OA 1"2&I*!X@:0##2
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M"ER*)Q\O_^HB=*FI<_'1:+((OOQ JJ!O[68T>N_[FR5N]O)=D+&KPUP!+Z0
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M4"L*IR8/3-X9X,*DFMWH(I*$7YP E,JP-E'<@)ZU">V(2@7%:TIMA[J6<J=
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MXQ.+0F;&E39850=I6+),"4L.Z$_($2K> SE"5SB"TF!ZG@ZL5:0#.\9._^@
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MP?Y:_!\^[_./B 2 Q(RQ'[FE#\3U0NZ[UPXS0^E&(?U*QPXCP<*5XBE9'O=
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MQ/K39/Z7#&,K,L6XSY]TV:@%69Y)>AYWAUQ-O2#_;?*D^"64/QN>ZSENED/
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M=H/<7_.&?GL[]JP'_L_?WD[#6^?W_P]02P,$%     @ #86O5G^XOR?SE@
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M0O<1];@CFXK#5ILRI?Y["'M<P@W%\7ZGPGYO*.R*4CW.[.W;_VT7<3/:9C<
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M_J"ICJU%\$&Z5GMU>"8[*V>4]OR@Z2,^&#-X6.ZV@FDO@@_2PY*)=D2M)3
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MC /4YL\"=T 7,5.UAS3-J9H2B.4G@\;%,1NPD]4BF3&0@S)+T*0M* U%]L@
M*S=Q+J#_^5#.]OG:3WN$;;*"<,+?XY>[\[H'C+&+H;]XX%=^2/P%RQ;!;/(/
MH[%'W%(N.U-_&TS;#JF]622KN4QA]<M. Y-''H6EW#NU:7>Z,Z0.I(K _[&Z
M8XN(P-WFA?_,!/>A>/S,-HN2[;"F<XAU;23'$4MFY)F1;T@(5SL-,=RV2 \[
MP^0T<".G..P_\V<J%.+XL2I;J 8"=:JYI@OB2;"A/.#T'FL[;0LGHV,@W%](
M$*OT\4[B,EA.6I [S)6.D?WK[L]-4[,W9=E5MK$(8JC:C0#WN+O1'G'H/V*P
M#E2.,*'\^5KE7*WDMZSYA _"9X_29^KH5JCRC_BZ+0^\'H$8.?"_VJU>PS=\
M(![HD]P5?7)/ JF!?9<:K/JG=F_440@?K-O)9Z4RQAZ)=_(XNR*SM18%L:L0
M/EB77_A\OB+^-5%Q4%7_U5\5;$8E\0$L"^/77_4XM@U?$0+1 ]?>HHY6>WMW
MECZ=T#:1VB\( 21#X_:L?L@4?L?0^8J9JJ1U;W(U>@-:]<7K6IV4;WFH-'7J
MQL\%I_.S8M:4P53L=37FAW1!11MGK-3/WI!.Y0DEO0>QYHM&!+$*J[$KNP'*
MKFUCNS0$<TK3<A6.=C?D%:) RL(9KP91V!]&G=/ $6P=F^YNP3  OA"/7G*X
MK<6:SI:[*(Q#A\&LN4^="?D9CT1NW=H=?7R3= C8V)5O1YQL(_[G8J.ZAPI^
M8^%RXGFR=^XWQN.KNF ;C&PG_^=BI1HOLU""NJ.^6P@6OVVB?RZV*4O@?T9@
M((30!-N?S%T-(&"GYOQ[?/C+T='7V?GQT='1C>R>[,G)T?''DZ.3(XD^44S/
MR)J%Q#OC8LW3?*@O_\V%>AN5!&0,KH) JB63\-.GPY^//FD.Q#MO!H/"K+'V
MY/!] ^83>\SOW^NLW7DS"%G[[O"X ?-'>\S'E5&[\V80LO;H4(*]^'I_?/)!
MPWR<8XX5;SH[G!Q>1Z\2C5S?%OE?1;3OWFE,W6$#"-EY?"AQ2K0_MXP@<["_
M?'Q?65AW11\#,RN)+XD?R ^PN8*B=\E%]CH@F,X?EO24$^%.YVD"J8:KQ"W0
M07)-6!-.H,[)HR9@0&LQA+)/_+R2+.5)1J1 O1:!&$P;S<FRK=R^/"][(*\<
M<AQHTM-_Q2 L;=5;R?I$2&9IJU7U=WR=+SK]),ZF+6Y!E1+X7'RJW6U]7%(M
M@F2M:T@7W_1<IN$K3C!7O@,IFNDYC?][Y8,KF3QJ"N[!H$ARG62&DA[E]\C_
M,3U&WU.I2B=/Y\MA*EI+[/1T/0S1I=0XG"4K7(34?D&(H#XP2+:?%IZQ&Y7<
MH]'8C6<2W,69@Z3."#K5+0U5Q!1SCK10^..3&1D^Z-<QV#[\[T%GA[RQ,DJF
MZVVB;EZ\.EX$%M3DW^<1?>!?_1>FS*IPK C4\Y6IGWL/YRO[-D@A=MQN#- 3
MI_HHA$B9^.[DF3"%9"X/8:082J4V2H\-B?UAE=3\DU$0/W-1L@=K= 1#(7XD
M71A)YL7WAP7Q16\AU]DK9%*$9/*^P[PX:%F<-.C*_RH[('4$YLM2=Q!GI\B<
M;1!"MT+W 77A$UA<DS(V;*E00,>/IBBM$-AJ+OO=-PJQ>BL#]SGY5*)N=>+]
M_LWND5;5Q1RYX:GQ=<[D4(2T9\"DPK/.+<E@>#.8>:[YG=%(\,!A@%+S/*O[
M@L\D<Q' 48\%2^HV))!J+8$/4.+M=2?/L'-Y8.>5A-OU7_$!.9O>G6L._<5?
M\'4X<=G_[+$F;W[M$SX(#R1@BXK[N_8COFZK#&D!N(WI[U=J/N#K_D1NRRSD
MXAL/H\=*@+2&C_A@7+S^D[CT[_+__$A;0NN^X /P0"2O/2)NZ)/D>1#JTZ#A
M*SX@<I5?R9_)/7WFGN1Z90^H_XH/R'2]#)?$6W&/+S9:!)O:3_@@R'DKI!*D
M#:;*K_@Z_G?R1)Y9N=O:;_@Z_2L+_D4\K=?ZC_BZ';\AC76SNDA-E4_X(,@#
MSC-?2Y4_5!W0ULZ&C_A@S#9@HZ4U&&J_X /PP-?,(=[4XVL2$I?58NDJA _6
M&0_DY\VK_L17^Q5?QV\I%\0#192M5I%_H9^2&[[B _(/>684- C.**0ET]/]
M-7[%!^1**G%,SQ)=_@U?IV\V<PBWHYTK*[_BZ_AGYE%_HQUJ]!_Q=?NK%[)'
MP4\%I=^EFJF'$F[^C _*C-)'P9J0-'[%!V3J/PKZO0E(XU=\0"Y\6"M#S397
M^15?Q[]Q+R2"^F=2:YA[9*4?:AJ^X@-R\4H][L?_>T="9ZD;+)H^XX-R#T\$
MF'_)'?B/%H>C_AL&$,WA/<]IGB5JZI^S8,T#65B>@60S<7:I<.*K:)WK8D3#
M823VYZ*Z@#-W3P@*,.-4)]3A"[]\,VU5$S%C-#-JDK_QG@:4"&>IP#S+*:Q$
MK%E5S<IBF"@:2$BU=BKD@>%6 JE)PU;]A@&$GK-1\"!(@A5#'AH(G4:$V"1Y
MT(*')0F_D&<Z%?"_MSP\I;"MJ-=0$)9]$A2RV)1=P'9#&O$DJ#QF4#,<'M K
MSS9G4[AZCCT#[JFS<3P)<"F[OEB&6BS?_+G#%BAAOLHV=!_0O;P*.0$@(&#)
MB7@@C3\!MVY()359%W/JJV#F1>6Z)7:/E&O,.8\>PWGDQ>'  4#E\L6D+,(U
M.WG])-< E^8]#L #^<SC ?4V-US=5$*XQR2%2NXX"GY>PLW#KF^-&MX75SK_
M<M?1W'Q9_&EOD$RC$&J!E["*E)[LGMDT;_R\/P%RXH>K2<]O^'-I8VSZB'G%
M,A.ACK2[V!YACC,1GP%Q3^HL<@%.X-Q3N%QC>5A;HY(#7N,I\MM?H1^$<O?<
MQ-W79=GX%1^0^)T@'%$A\E:IXVF_<V]KL[+[H\!/GJD@X 0=/]8 !^BI5+>5
MLZZ6NL2D)#K/Z7NH<\E>Y>%;=KB4I/6!Q^_'B[]EIJS>U;"]Y*D5URD7@K]
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M'CCZ>M-5"!\L-<*2M[G/(7MJ0F90#A^X7-U\AO[.0C J41& JVZ38MI2$A_
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MY+NQGUQ[!I+VHO@@GH%['Q4DR?]P(P^BE=#<'64P@I)+R:KFH-F8&J)7#82
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MI?X.BT>OWJ7HG;]J(*@6(^FFF^QOC.-4-R5TJX&>0A[3_6UBX\ZF]]Q=K%Z
M\G1EX?S*<:1R=WKD@;K0UTO^(\S!]K!.D?<K\H9[A6%1@/+($S(%6)O5/"4W
M<3I//4K/@^/-"PNR?5&? O1FM"2O@Z_>H@-.RJ=C RE,YAT+C*B?]R(+JM/-
MN96,YT"L9^8K[L&./]!^:<7<+\;!;_K(P]C#O$<'X<O-)K-(GE?'B#K7FKWR
M<.$7K:ZYR:[ZY7@Z@YH2H.^CY>/(BS-%X?%X(.64 NKNVDP 5/UJ1+TQ.WU>
MP;"S<\+4O1S/IZL^2JK9I7RH;#Y_UA<:T><N&2C2Q%UI.KH48Y@PD,#QS!9!
M#S[H]ME93>N*HR&CU@YR\9\9D<ZAP3F7($P3QJ$&$QP6@I1ATUB?9NB\6L8S
M:#->LVFD/SJVN[PC,.?@;N+C44&)&,IF-4O!=Q$<C?>LHC[2IN,"^]&\"GE7
MX7&A3XF?"N2EG:BBVDJ,YS(B_8*^6^$LCESVEH-&HR!AV$5;0X,5U'?;W+>&
M%J9G@\!U#+Z?)TRGT3RO@PWGI-RNUOPUFGG2^6[$9YY7RQE6]RBMY@T\7PSG
MJP;C4K5.AA8>GRH*V6CA6Y?3%_37T( ZZ2NN[,#797"=50--I>07^#FXG,K9
M[@L5<VJUIBY?+1'UE6BSDM77;G^)#:M-CMYMY[P+LC8A"K#L+G\X>,)1_8N]
MXGW,]2N2<,,4!W_P@^ZV!=??7B5^_E7.L%.ECJE+GV(A99L(=^CF<F2>Z>!U
MV2K'<SKMIIV?"?C2-IQY'$8P#H/3,DDIIAA?<C?'?!YHE1L1:N/:6EW<.MIY
M.*$A,,A0VL1&A!FG-ARO>\SLX$0+OQ!D6GMKTZ?,B+21VFF73+C5!MF"]ULW
MX3%-=/E.]X%'&&D]C="%WN/Z7)G<0+;ODWN5)K+):U!&OF'M2V73KJH+UDU3
MD:;KHF6GKX[:KM;9^=705(_9%]1N,L\.D_$BU',BM/>O"]1)7W&55[>=IJD.
MQ6C"-WRMJZ:0:2!@.[ZULN14J^0R5=%4D[D8STY?V4G?QOJX<M_ZGP7>=*NM
MRDYZ+@\J;\4[EB.B "N*;L?O89/DX-$LB8:SPN8:!"B<XZU0,_&?@%D(K&?T
M&OTOZ6VY']K)M\N/Z37]GIU^P'L[QT/Q(85FEX)F"VZ(B=G?8)*K6/>6@82_
MHQ-RZN"="1[?#^9Q]]*5CNED5(1NYZ<K6W?[*O.\&L>KR4Z=Z-:/F+\5SUYN
M.O\HI?L"L,_IF\W5CDBG1D8#DV(SSU89+OQ.&LELOQ>L<#SG_U;ZS0:-#2Q+
MN9/95, '[G_TY#.R]3DR.,B@S*'1)D1PI;P7/@9IHR.)4^0[RKV-IE%";:5.
M"=DV8$C)T?@GI;$[*:8;&6A?3>,P;5^ F8::[+8$STU)GZ_*;/HW_ [E05;V
MAREL U0ZN^P>=2V3FT?#^;97B1%I8J[F2S@@1&CY$FXR:2;^;X95K%EJ- YA
M=@#15<SAXZG((1@)L" G3&5+Z0GG='OSN'IO)5@YJP8*,W-1(3FWPM/JJHBT
M^A5E"-=/CW40S%<4(%3Z)M=&?-:_)CSR;*I 16FA(I'1 L3]4.FI>.O7)D0O
M3KD49(Z'QB2NKCY8NW>I\0(O[.;Z%AK14MH]VK)_?";)#I 0#&5NB1\EP/"Q
MC"8:%UM] --^\WS+O'L6P3;4\*I/[O8W*6 8\\]IN'-F>'WSGQE1)S-)N.'8
MASPMQM*P>/82;:A[A,K(GK-J&)65(3NS/(5XO%$)SD.1SCK&)5/>,8J'GJ1_
MF><<W/?KW7",B8JJ#!1_\\^.YY-<00U'AJ'*1D8"D(VU-O1ZL/#U%J"<[&-X
M\=%8 ZZA77N6#4E F)(HYR<P8_MWQ?9LJ_J.V.<!QN=6,IX=9>X)GL:WKG@4
MZ5*WF/H(T!^,O$B=Q4>D@@3)(P^E=X39HT#/6ON6[H@H'NVN??G*#A@9;N4(
M+#^G<*@K-G[%?%?^N&=^O(&WL0KM*A&7M@G1@S7?P;R29N?#&1B;PV]D,!-2
MW?$S#_H;9X&SF\O)7>1:B,\H3T\9J_C'3L8IFC5W=CX"N.)'[DEU;UBI@_[%
MZ$&?7]_=;60P?WJ\MCYPQ0MZS4^57QAZ'_?/G^SPFC8QNM ^Q?X6INI/G'G1
MSH%#8,)0G1VE*EUU!I>FIXBI>V0.+GL.2$)Y&23A-OIB.F+>:34))IXU.OL7
MHP?]]FKV24*K?'?VQ3)@5[VA!Z#E(T"SX>_5Y&[RU._K51:D!_\6=N48!):Z
MG\!B8'W&!@%Z</+U?N.Q_9Z%<L_35;Z\*>HL31>H6M.E)[>GN[MY-;IJ$0J0
M2N3L@;8(6;=_PDTIJ=4+9;, H<K0M*?#)H#C9W+_G!FCWJ+F,9GSL"/@?M=3
MQK>-X=R2+;./)0JQWJ5&I!'[BLO,EI7B;Y$9S^D=4YG>LPBJ21+\('6_^@-Y
M/Z]?(YU^,7.%Z2P^'A7@8%[$T4;YELA@M8,9 =%@<(!\4== 97; K@5&U.\M
M6*F?3IK@+_7?J=%"@_B(=)!>TSSPERSZ4]LN825(PN.G&T!VB^%^>Y[F0 1Y
M+9RX8>1;I(O51RWA0B.T&:R+KEH.+JJQ0=524UR:!MT@.</+E>0.;!4_>X79
MIKLX79-JLVNXL8YV=,(]IX+Q+$RYZ]!<57S#'+6QRA:<LH]1O2!AV)8O%9?'
MV/*A*CPB>#Q)[ERSY; 806C=S-9+45XHJ]ESVHASB'+FU/(<=: X(@JIFFRQ
MRUFFFRCA^<,>C+5T5%7H.TN/1P%Y](YFL%M"?<%:SJVX,QW78_ LF%NP@>4I
MSV!E1A@D<2G3+0<J%$$[<63!PQV%1X0_=<GX&D!CY&93,.(4.7F[B9*C!EL&
MTN'<U:Y+%9RRY81_O4J,Q^WIR7>8YR%EUT%$*EEL0IB*!W?MZZ7^=>O?Q+YK
MI(GO6XSP'%E<\N]$ZK0).S)>7.MKWE%8Y"W* ^XKUSVN9F;M66-Q'C1)T -T
M#XUDSBZ&"0696>T/4_^: A1KS,'OAF'MC%K[=C1G>!M!1<A(LPCAN:+2PTW/
M_=R%;2$/UCM>/&H7_=U:9<<#OB;PKN)S=Y(D#+PX%_U3"#>PB$RL9P1GG:+U
M](Z]: XL94GU5,#L6I:FG86_>A%AN(0][2./1*!^PW32SQBCM+EM,;^MMM:^
MZ>^-:&N]--,HPZ"(3J&5UB+;<':1)+>Q+J3'PI-?2G']S P>NQ8ARM_3]J+-
M&S^#QMONLS5O"4X/S0$,N,&7H+B,Y39- =DM_J&I^&BV-2D?I4I@G$U.M=D@
MNXM3[NXUE@$]ES_(:!4__QN>K*4R@^0V:Z0^M6T$70O]]%NY@5[4ZEXQW%DW
M%,.+4Y@E:KVJ[WCXY G;ME__GAX8=,7T.WG2+N6/']!^47;E'%B>GC+2_OG
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M>#E9BKPYOQXB_NXE<YR.4L;(1Y-)R^2A-DC9PVMEH71A%R 3^_<W*#_W),Q
M*EF0\?3:SZ:MM_^9\3@E84B$#&'''P38=5Y8D/.!U[P;SPJ6K]*((^$95>$X
ML$+CQ7V@GEN>>-DN:FCI\2@HY[=/C?T8:K.*^.'ID 5R-<O\] A.>WE,N?NK
MKLIJWQ)<+:ZA!7NU[\Q-\8:_[%JJ$[I!O)P%W0XH2'C"LD/+6?!]O8.6'U2
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MA=O>LE&WX%,76#U1TU0(MZ6CA="7'.:)X!6_)8)MG&8X%58TW7'PAY;?EK8
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M:KGK;C75GZ[[1IMS>']& *GOT-N!4><XH"[;D(DJR:LIC)PEV&D J(K0U .
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M",E!C"9D1A;9'9JM2,J[G%O;$)AG30YBZB802C!RT'6TLMY=X8AN#LPS)I^
MQ(QB9X>VTQATHS#M/LQH/,S3(0<I6%#K+('OJO5BM&OK#L*-V7>P1_O:H%B^
MV7[P5&SS=>WSUV=G"JUQ!>%_"@!%-_PX$/I^4GV[5K@$=41C-<__6 "*E!S(
M]A!-?0W@AK([M*QN!XP>2>L#1J93@)X.. G$AN+(AK))7WW&I,ES[@_S/R.
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MED@OS_8Y,,VEG81UU,7.-GG9H^!V)UHO_6Z9AEB=@^TMA!>NWV4OO?$<Y5C
MAK>SJ+ LBDF^<93>U@]KDX>+:8[7K4>N5A/!>+KMB]*\N%0GXN0ISE!GEL5X
M#LPS9TM)42>B8Y^E""I2L99X>=:#TN:YJIE"NX* >2SM)G0_'@ )@]Q5P!$"
MS.-L-PWP8D%D!:AJ(<M=I;L6^("!663JI@K^? !B$,8)]C &%K.]*R;ZZ7'K
M9PFLZ8=A!:XHS[F;Y!TA0&W:[[7ZW9@0?>%O&LA*U,LK_2X6P!T,U!;^KK;
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M9[KVN%<R?>JS70\\=FC+\/[29<8/EV7:6B162SSPB>TR\$_#!FVXE1M@V,J
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M;$>6J)"Z@9ID6Z253Y8Z]423J+5YG<E" /,3?<Y$T&Q^7?';?]8/*#D:>[=
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M)RS)"!_:)'\2R^)Z%_\AX#9^[]AK^R5N5'G9'5[_FO YI*FZ%3KELXUE05L
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M6LS*.^"Y?^5=_'(E6Z:V_XKD_,*LO .>/3/<TI>V4("I:)V\&9+3  NM&85
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MS\0] '&)_JJ@SP\U_ZOU+(:P:( $Q8TZE2_-2AM@"E8J.!Q"DT-H<@A-8MG
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M'.?60"0@HD:>X%K)K+&T:(WC!!L(H+5\L4-3:[_R)D\>^5:]SDFE>"-/$:T
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M44)P;@)%!NR>+-?YXE-+P&R[0 "+$D1S$PBC YN*R8%<DNY_K\L+"QC]"$'
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MNM+C!"6!(UW=XKS;2SX,2^N.B4WH^J8NZ6Z7B5Q=U3)JVP]'6KOEDNDFE/?
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MZJ/7Y?CB^K<Y*47NI'@<.N&+/*DY2WSNZ3CJ&GZAC$SX?YV]E: 8C":.Q((
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MX]XOE0V?@,=^3?IK)H?B.#2 @:5.?>4!=QBE=>5'DF,-'+K%>7CR$DGB-5Z
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M1%B[?JFRNN6G!K'^+S5D>M6#,(K*KN,/-C&MHX58#!K98TA\!:@^A&9,)I@
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M/8OH?W!V[6NNU-]GWF8,.;@'R^&L]IGK[AVK]>>,_4KX+O_":+'*32\]N-7
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M64'X$B:#9U])3OCVR%>ZP$GOT2ID**"T$WIC1CXR=J^]!M\4Z-N!L(_2?.B
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MUZVXH[I>B2SV.?]B^4'$ NR=6,O:!@YE*F*.-$?$T=F2$-ZR#W[^:T!4F1O
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M0M*ZSG!5D@Q1PRNKEJ+]"'2R4.D& DSG4&[J;HO%/FK:<#'+4*P?T3P6&NT
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MG:-E7B^@N [=HE2)E_0JO+E KS20@1QF!P&F;H+_V!K6OJ9?]\/GX$R;'D*
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M?JS!=HXAJ,#<7^!,O0"-GU:<5<O5R4QZQ%3Y'9]8L]G29,N%MM6/U=<NH4A
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M;%452R%*LBCE7]RH=JH'X?NG1/:S!Z#PY?3PA2NY='] $C>JQ)S0W)E]OP9
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ML<6V<VK'<,*B[GSD\'/UQQP)+'_R_P%02P,$%     @ #86O5N8_LMLVG@(
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MHPIU1%@D\8-8YIEOW&MNZ-LFLKSYZ"+"-&A>L9^R']RQ!7E%V..Z3&)\ W1
M]V$'3B*QGB?79U,?0-HY\M!5DADG)@YE83/UB\W 1W[H'"[.S'&K!"=$+(SH
MA?_A$3_SZ&J-V-6$&#:X6H@E?T@/3K5@HYVC#MW^(0?[R)+=LCKRGRUYZG[B
M+]7NW%TN%+#T]"%6#[Y+'^KH\W?D(B?$TLGPS!6VWTXNR;M+5^K!ZZ =#0$"
M4Q.S/@0= E;N4070"#KI!MA*D!<,\U"OR][3@P#=&=PB-V6!:\OC/KS]AP.C
MV>RY*6$K!5FN *E3;WD>OQ0+W"$I!>%JQED(TBY?\'BKFWK8#Q*9U6W:.EV6
M-%\N=K1UMD!]M:.M'@3M$M% B>I#3!!*.I@C4,-INV'@V;(K7\<:L.X:X"7-
M_]T"4Q.S/F0= E9B2">>\YV8)-+-U[BH@*HE06AG7!XH). DJ"$($A*%,LT;
M>V"CT &1X0-R:'/<A<BS[(C(;FB,/3Y0Z,%7P.G!B9LH-FW?35HMW\1!4 H]
MNMP #<O9XQ*<AC[I3D8X[I[R\$X=VFOQMBK<%F![63:)2<.UYW'#*/1[W[+!
MM'Y WB7+BT/BR7SC,VQLQO=+#"J;?K(G7&5/Y&B[P_.K%R+I)GQ<4PO'EKO
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MZB3&!$LDE>5AT^ _27(^^X#7?W'D8\N6Y:9==@H>T_VC>7C+W;L5Y?>J2?'
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MP\YPXH(USNPEE]?>8O(O-C2_>\U$\W!9I@,_9A7>9/_DB;MI4=#O(CD!6[7
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M_=/' ]Z.V-"!OUQ?UX8"IIWT@2I;8&%LINV9)BQD^JYM>7,NBMJHJ$_J$NF
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M%:C_UO%Q&K7OR8/ ='S7=&?TWWZB!3&J>YP;Z?3CSE]^R][=/_X]3Z[/@SZ
MM&O8P-H?.\@*6VO4A8[E>?[L*=5_+7ABJ+_@S9;LRM1)4D4QSE1U("@MZO_-
M:54?DQ^[>' YIF@H<E(?HU 6]"/PW:2RQ$QB3[5 2$^?B$B-8ZP6]?=423SZ
MZ-8 K%1Q\*%GS=@E:1K*+E;/PC>5V!5EKIV8&C--D.VUQEVB('0]MB'U9HP]
MOTS )3)NQ%5])5[8%#8O9<VULORX=APIC4?\S$]4#9Q6XD;);AY#%OM'7MV/
M+HAP'J?TK@%W2WDL]55>WW>[R0\5Q$CYI09UQ3'MI@QD?1)X)+*>JXGU=7JV
MGM%.ED)WTI:5A"9J3SEL^X&/?'_.N..V;&W:*L'1'9EY56&&AK12B#GZ1SO9
M"ST@2OW \V71/.*C$_J^9[DS3@F_Y05YR"I.?K;&SK/\C@<]5SC+V3?1,Z]9
M5-)-EF#Q1%[5"E.7)SL4B1[+^0.*=PV(KPV&-\_71PC>-0!$1;=#\Q+Q3?3&
M]5D\54=H!ZV@-CSQ"');]\ZA'WJ!X\WH*/FR2XTJ")CM$]S4H<3;2RJ/3N.]
M:Y!)=9^PA-_YNAP5B504?KT^WU1 TPX6='!KN9C+7YG"E'6<X$U^]82S#;?O
MC$0EWI#W68[S.,.;^MJ>9""'_!P-&,K]WB")3)R&LGQ]0YI>9CO$4W(V_H9=
MV"U3/KR#]IIA>\W!&25A*R=0.MRY[TPI#1\=/0#0-8!O>E9HRYQ0,X_^,.LK
MP!@_U6/^QY9!3W>@!OJ=?(3] $NK*C<>7],+3-<V9PRA/(TY/^K)OH $KS2_
MVPXT-[.GNX9]'.]\&-NF=L)G1O&ZX>8&/>R>Q.#WK#\!C8-/.SD#WJR&EB^-
MVAH$[I;\J-XP4?X^_U5')>96#)\1<8#+<G<OE\D$_$+9>XF?3D@S>)AJ% 58
M9GD78[O",N0]B.3@/.$^\>T@D+FGY$*HNXS%U<O5M7RGS[B^ZSRS5DNZ/D9L
MNNMN%^1.=>VG"/2,Q':(907P^6@:<HY3RD'JY_J18P>H[U:;W.ZLJ80=D^N<
MR@@0Q'A1ZJF80X!+U',XA:!*&M@6B66QO_,S6#DKG/J$B=+ "R)+FASDJ+^?
MLCQ[V#[4=H%\Y#GRON!GD>IF5;U]J'$UDR@Q-B*+Y&,#;6;M!0ME*N'JJ<G#
MX4OT695@4-\,<:T@)K+K'$O17$&Y/W6R&[PFQHBX0=)^9.L'INW;LQ[9UF9J
M-I=+G64<Z%?I?WA]_0)@I)U#"/60^$YD>8&TKM+Y='<"Y]V/1S; 7#X+5%"1
M+-6F\8$LE!ZB4WQC1*\/88=#;EO4 6D&/I@GKAU9?5Z1J0FNO))36\59:4C2
M():9^,N>+;Q@DYO^R1=F??U4$(T^V@5&2I4&';HUBNW$MQQ9?OD96+:T"EEA
MZGN1+/='TR\1QWJ5)$U=I)AD3[R/\Q_8->T;3R)J&G,$33F@/08]YKP>00T7
MK3X:" 5*52@#CMLAV#<#6=*BZ2FJH'Y_N;HU#HV"MR<!07['@;%I.5;HAW/>
MT^.)R^_I)A&EM6K%HD^DZ.L%9%HZ>G4])+L72_K;^^SZ:M /D7:.'?@^C^V3
MU&Z]O!F:KN=Z:%@>)@5&?RG((\Z273W+TGAM5/=9D; ]> $O.N=9R&2J*PL+
M:O2V::>IY%FR&93&&8\&Y)6S<*Y6!UMMDGD\[S+>@Q$ELP2:T0F'H-T>(S)]
MM&8X9#J.'M#-D66B"*<R9_><Q)Q&$8?R\D0C6;=)9+=G=_'LD/U_X,Z8^N%H
M>IY%QX[>#U,LV _6UR8@3MHYGM![QCCV"4I:5R=AX''?&YK==5H<LR5/!FQR
MP)OG8[GFR<EFKFW'!_C)^GP!(Z5= PN-PC%]R_:E-T&.]\B?:9Z.#ONL:(4W
MP^SH+?^)U(6JQPZR6T:#A:H9"?MQ2OPWO50!,I/82100F:=_<F*.<1#RHVS5
MX.,$!:YIR?Q3XJ.%0B_T4;A8Z/$#+GXGM:?S$$3/9_@'FM2?$_)(RTQ4-2R8
M>:KJ4K1E56SK VQAZG%Y/U-X\J<]P&][?-<'>&\;=&_WX#X<L'$SRI ! YAG
M:&E]I9Z[@[2+O%"G;6A:*#'[0K(F@+]:#,B$6C97I,B$TEUP(/]E-0T6DC*?
M2D 7DV'@)-B5G4EHI+L*V_FY%!A\V.-@,[(CV7EICS!OLP>R0\-D=Y#I/F3V
M2+@+G[1^DLGQU;$@7QG5$?Y70FY'(CVLNXZ%._U9[7PR7G1 ]3&/"_21+JP>
M4!/IV,BW(YDG3RM-5HG^FT6=P<7DG91XIO0FC5BKUO/&NW]L66N;%8P=;_VP
M<",''#/8*TB'%>6DCPT9A)8J,P&HUR@*4M\ALFW+3/13T-!6#D*5+# #9'G2
MO1F)JB/[\V>R6:+09E2=S/SWK%4]_((2<<"$IH]^=8&CT$&';OJ):<98FMI\
M&F*IK/DYN^"Y) YGE-B+ BP+>N':7STOK25UJYKJB50D4-'IHRO=\"A\^*'Q
M)I83N"B5I>Z8BF0*&M,P;;C.."B,O=23G5J^W^;)TAK#VQRC+_+,V)<=@757
M'Y9W@:/0X8+&#MH^%Y^,X=-00N66<<V+78HS^)U%W_3#J+T*FQ^$;.,2VM9\
ME#[:1X)C3F+7#+ ONVGY[9X6%1/@P\Y5QRM:;7!99FE&DJOR;*D[N\(*/*\Y
M(..PN>1)JN,]*)Z>>LBJ=[DI<* PQP^'/@9%%3B=@H;0F#.'Q![Q9>?0\ZN!
M2M;H[($<_,]\LU<>M./(>!G?L^J>#6YVE^5X8SSP<N9\]CYDE@U-(\'/8'M!
M4A='\IMYEZZJ)1/'O1WA85IRQ]@BI"$"U4>U^R'28>0 'T&YCH^D2\DI:3C4
M42%AX-!,)<3"V)(M(C[D3"F86A]"QF;OT*[)HS _/;3H4A8@@>FC-QW8*'"X
MP8$6H8=CJ<&>A%$*EOHJCHLMX6OLAEXT9U/9B1M&S&C5\1PWH!!"ZOM$5@B!
M3]0+>6!W,8QQ3+?:S#V\_RUBT4<S3M#0UH&#[B]-"X>6M,*>(AN&'P>!W2,V
MVXNY87M!9V0CY-O6G"FP.XZO5"+]9B;SY7%+1]A?]P^&Y%5>Y<3K$BCMY 9T
MWV.:KIU*[VY*82P9#QZ//<=R_,BWXTBV2M1ITV9 -VT;4I;@3=NRJMCMNM#6
M-='C>IC$M8#\ 'NN-%QN:0_:M:(B62[V$]N4+2+%1\]&ONNZUHQU#<_.Z9@:
M,=XR]:@RFD^:)INU<PC,>7O<2E=,.?Q7ZY-^"%C:-<K@8U\>UYC*+AI/<^S[
M1(J(CCSX[3W].>Z1[;L!<;$T#(0^/&Z90>=J_<@[5=>57&C?T30N=/RQKW3.
MR509^&F4Q.V+3PMYMHVL.?,=?*)/A&-F4^%IC<D(;T2BN?]F+]T838F\"8J9
MULU]R(]*.;VIF_K*&GI?MR.1R,!?KJ_Q0P'3SI&'^NA0DOJNM/"$I';6LW#2
M#5&3L.983N[X3=LOI,AH\JW"135,9WC!$2G;,*]^RE9@O!@-CP=_%"V ITQB
M!9;9XJ&<J??O\F2ZOA.>]WQHKYT8^<@.V\M06K[G!KR:]HPKA9X\YIIM9#MR
M; ^NPJ%IVL@A8&DG6Z"!,[RJLBEW M*\8@K-C"$O;Y:Q/HN5SX)>]0,"XP0"
M,$D1*#*XKY,J@M&'3W"H5&W0H3N[./2<1%K->@Z:*2T(]UR+3[@&3-)VVMO8
M1'8LVP0>4HZO<O0[I"[ <H:]52A#!*B/TO5#I,/( %U&^K'IF5+WR92T&V;#
M/Q]EME<]Z[5,.R"1]([0I/JDZGY5KK6&'=.+D,PJ'OKUD>*<WV]:,F'E\:!M
M>/O"!:M=NLI.(0T5JH[VHPOFA0WI)PKX(#PE@25-1GQH[;; "5F+DQ5O7&<^
MGDMGD"AU9&(KQ@L:]A #>ASMQ6&* ]F^I-7DG]?E7'5ND]3DU(VD/>(;(WH=
M*0R%W+<XZZ$9=..=!A[V79G7:TZ"JP0A71:7W=#\K@Z@/0X@'7P/P$$>CE(B
MR_<TZ42CT.F/^QX>)^[CM#+B;5G1!_9*>+)*AYC$Z5Z^3K/,&]53L=)[9>#D
MB7LVFV/W^MCG>7!TF863&(6V+%Y"?/1Y45C?<68,T8%6B)LE,]>88L$OL$#P
M\*+ %P2 9O3T+60[D6QE( 6Q4/J[817<%D[(>"X3J.STX5HW/ H??RC+/!*X
MB2\[B9^*92.S?ZJ7#+23(#1Q(.N;^.B:MF.9OA7,:)IW1VD\6S+)R]K5R@OV
ME!-EQ-VU<'W4P!?^_HY+)*!?K*\+4*"T:TSA]<7LV)*68&]2>G^A944>'C=4
M%+5[0W*29M41G-GM[RZU.%N?5*\/2(RHAC(IJX!]5I>6/BP;"IB.804X2#V,
M@]"3Y;NOCT%MUW)LS_1F/#3_M(LQ_6_\(RLU.1K?@;IBD"3"D?UY?89)4='.
MX03/WA&)$VDXL_@8HL#Q'>3/F/7]ZNZNJ"-.ZMLY$=M-L;W&@XAQTX0U!XP\
MWOH-1UC'X$GDUOOL^GSJATB[.  ]R@XC',O#E3[3ZB-KOKB]Q_E-3OZ+X$(Y
MIG&H)[(R-KSI.NB=YL1X9JUKQK=6^0R1I3Y\ZX=(A_$"7*+ =I%ERM;OY\U<
MY<EQX^^S)_%UN1 M/THHR;U*^2E=4WX1F/]1-P,Y3)RCQT,?:BOBIA.P$'H=
MRTMBS[=D3E4=Z*X_I0>05W^:0@DY"?4\/P@=JR4<9;H5@((OOV49 #ZH<*.8
M$"+;7LT^L2CT]@VIOA-2=Y//*@>=@P<6.3:.I/D[U^V:U)+ PP^#,'"P-'N<
M.*XC'PDNR9>"/F5E1O/Y\\?5K1H;WJSQN&MW= 8Y66>@G=;'B'7#H_"!@RX?
ML>U[*)&%"8ZFQ^E=BUN5.H'#R;%@L$0M&FA@3\]OUJ<>'&I+4,3%#Q3]>CZR
MDB2%1*[VM;A$E,_.DBF$AMNQBTQ76H_P0Q[3!_*M8IK#?::[P],%_.>4N\EI
M86QHJ=^MGQ:QP 6HC[KU :1#B !UA::F';FI/*O15(13NV]1TDV6" ]I)I 8
MY0X*E(4GBU<<)Z%CR@).OI(GDF_)>S80W_"&W*2_4IK,;SB:9NNH(1$W15/C
MCC>MAV;)Q0*6GSYZU8./#F !5*MPX%C2NLN3<4UE^T<JP3/X3L$U8ROR94F?
MFJ*KHC,+A= 4=6MZ*,=Q_WO$HX\B2%'1W@&%GGQ8?A*Z,M*/)(L"U4\8 ]_O
M^YX9)=(T\=>TK&Y2KK(+))>A/)5?VJ^K"V8F.G2_6SCZD%T&BO8-)M2[' 4F
M-J79UA6),GIGO".-6$ 8;.T$3C7@^K&++5,6P_-KP9;\]09@=M:+MKCWAS6F
M!^F/>M\M&WU(+P-%^\82N@NWO,A)0]ET-XXG"I&.4+*<+,K"Q/>(+3L7%>IZ
ME2=U2;8LOWOW@X?.S;^R$0T+[_3#KFF#U&WKH0-MDAD@1'VTHQ<A'40'Z&01
M8#,-H[EX-WKFV#<N>/AMT ;!3$POE-99_4I*PD1S+THO/I$-%5FTEM*K7>M-
MR<1]^WHI5Z>,ALI4'S6#P:3#>0(]@$VL-(DMV160R5@Y6NO:&#I@U>8E4=(:
MI8\<W_)<<]8\<_4NJ_;.Z:%1 E'MN&S;AY[^=7UMD8&BG0,)7:^E@8^C0":(
M>JGVD:VAN"/JYE$DL\GOKN(J>Q))')<Z5?B)GRG\L7:!TAT, ^]QZ,&J7G&I
MB%@?!L*A4C7ZP//[FK8E+4D\!V$5MAW[A@%&[Z1G*3%C,Y;Y"[[=8WY!\M#!
MF_2J+&F<L7F%+PW_#\WRZB]L8M@R7%=U&022O*?%;R5?+XH2@I](=4_GK_,G
MH(I4AB?*R[[ >\1B.OL[QVP\-:!WQ1M(PC..&MM2;'+JVH</ KD>6C[=2,PZ
MS/K8C1GZ1&=6"F@,3.#'?F+*DOBNJJ\*GO"?.,8__M(<H8J)=J^M]?U*G ^H
M<FA[EHN(-"?#J8VN$^9M69\;HTGS5585\1[';H'!@.AA</H%IB1E?0S$ *S2
ME06 0^ M86+YKB]3Z%EHJW@Z.VQ5X9N>X]I8EA^NWD_<XA_-UG9LMT9O=VM
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M3$SB.'9<90TYJ9A\-#Y^.5K9YJ_&M3>==6Q%YGS-7V=I'^>7.E)I0]E LZ%
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M@\GZ\P1ZY':Y*V'&JB.WXDWQ?4%?&MN"\&.*MYLM/U+3O+C95BI#[RAGVK;
MCPL4?:J?IC=07AD"I]$ >F644(T:JZC&6:.],@YX1Y>*FD!F,RV%/IR?=#9L
M-K("-2B*G, Q5:O6?F1OP_(WNB&?WJH_93?/?+-)^2<W;V4!Q1./;/Z=H3T^
M),N3ESJ5-G2J\HVH\<1G8D1O]5]D1GJ83%U55,^CP=RKM@)1]%']Q6;*5E%!
MZ*:;!-3W@];*I*X5.K;IF.Y\JOTKYMKZ8</R_./)F9U_:+>1[0<R^BS[I(@P
M6,&:RM]+\RMM5Q61T4/CA2R^<TDTC[\_I!1NDQ\'&3RP/7U@Y"D9H]B95%D2
M:V%8WR:L-W76I7/08QUVP\@EJE;"\D?+="TO##TTHS(?7!BAMJ],!JY/=/00
MM]!#Z0Z8;Y,_).+C5=V?OU6AZ;Z?79_D_2&S3A)!\[)BZF([:JV&ATQ+5#'P
MT(SEY(\;KY$T?V$YWIR6J*R":RP[_,:C>,'']XL-_[<T2<OM26XOLN8.%B&Y
M+=&[@7.S&]F7:F*BG/.VFG<9:[K-ZG^3KQ;SS_LI7^?"J(G*-GRZUUL";O6\
M[, :*-BR\V6=2@1]-$+= '64LK(=>\[,@"\TC[/TI;X2Q5DFJO#+8O-"P>+#
M#<_Q;6GC%\NFB>F6T.>R%ECY"U+6>BA@8Y*WR?4!.5_IPQW(T05>XY=$Q\";
MX\F5/%*LV;P#K:]@,\^/M3,?NM?1"&/7;M4GQ#=1!X5V,&.Q\>.2FOL6*<W>
MHO6&U[P\&E2G6!F ;!:%W+?7V#>^K$I7-Z\T8!6'AWR5!I0=.P/621_H97U@
MVKZ-58YL7X!??[YPN@EYOCW0G\4G+MQ_SAX%',AI>L!J_*/@:(U(P%V<X2J9
MS;04[Y?YG;-ALY$5FJX?1#1T756\;"4-&I!$>@=4'&AJJ9?8)"$=M00#S[-M
MVW-G##P<FX9F/)__L0[XS;:_-6*QAPK(X"T-^&F]=!D*FG42 5SAA\8.M57!
M@TNUIQMJMO#^I HSYT,WH!6+E3<D.$[^>A(9"EJQ]_3C&_A*AL160E5AW'FY
M/N0Y0IN=!7?4M,039J3R2.6/@6NAT/>\&8."I[T'$CX%8D1TRW\J#"'0@;O&
M0BK[I43\J01\)_ "]QW )_5250A@UL4><(D).W&B0/54K GGZ_/+AKU16N%9
M<:NA%9*:MKIO,QV2&RYS/3D+ :S86N#<@D9X7=^B5JBRM/?Q$R6[#?#<(CO0
M+'?FK\'UBV+)SD7&A&?],3*:6.3Z\'R26;#)20@N')<@QPU4:= +:X0&9WC;
M-B/1W%Q]?U<-]8UE/ZBHVB4/?3_H*]WNZ,+VH#%Q<364U7C*-"&): ;U[R6#
ML3+41\&'P6;C>0,-:#N!'R>AJB3!W*P=I[-MU(6J:TRP2VU5U9 ?E#O$_'ME
MIM)AQ-_8:WG]M;"Z'L%I;N#/-: 9M+6?#$8+41]]'8B;34 =\-'*<VWLJEYY
MS,[< 2I[F;[@^I4(D\0)51-OY )7#[ZV1V^],C[F]E&DDS3B+4LK\K>CA/OZ
M 2)W/8Z>'I90R_RJ1A!^#B6?0FHS+88^!F'2V;#9Z HU'FX2(SM6Y56LI$,#
M3,HX18*74L?(3_Q+(2Q%1&UANP(*OTYN/'K)8*P,]3$'PV KPE-]>0,-4N'8
M=[!WZ7I]#M8.J4"V>W[&V9O@+3]^&\EN2T1F,%?EW;;ZPRF?6;1)'\O41'$$
M>*';7*8I[H_P+RPO^&&@2+,R_?%8$:0>@ N>N8$91:I;^:8L?Z?%L3AKJ_DF
M[>BJUF!+BS,)UE;RS?@@;>?'F:U#+_E,*6L]K<:P*2@LR!C>0=T%XOK\SRIW
M84D-&'3L$$O",> Z/B ,C%"' _U[V8(@L:A-57&23QG%_R3LS^VI6;W=FZIO
M++LK#=4:#L(>H,H_:+&GI;4\MJJ_E)=D1U9U>M,Q5IPSK) ^AF2RF;!9N MN
MRL?7W/95R4@K*-, ZS*C1H%]D\A-2!"H IB'NQ=9Y$:F^>=_SRE9\>(1'Y 8
M._$Z><X+QLYI#Q>8/F:@+^"S&\(^Q  J=6!'CA.HG.7Y^#CH"B'E?L$+WAA_
MTO3Q232BQ*\T$^]M<5SL<);R?VJP%1R=Q+[G.Y[*IAWF?R]L09&^"L]HBS=O
M>2KN5J[K<1OB65%5\P-(;JY*E-*2*>4SJR(/E=<LBZ"C^H^>RYEEF(BBT R"
MV,-.J*Z#OX;6#.F6S<\5396ICAIG<;C*#6AX!P63O_FRMTBC#)!C$@O%M-L
MEVUD/N.,?N;NQT-&M^0'+E9-27J2D S9)2D6L9M"H#(R 6M6XP*3Q03BU-%P
M]$1^9B8&$0G\R"Z);>4+H06(/- "/!U:?9V0^-SU%7MIYQD GG/D4R=.L*JE
M7\/IVDC*R=P-<6(J;W?6/ OL <F41/Y[]27.K(<"@!A&RU%'5>^%^_RDT)\]
M0#7'CI]XOK(9RMS<':CD9R>& W=/2-UR>7$4"P#W"G)HQ/^W6U!??[[0N#C<
MZ."W-7*5FEI.*T2'R5>89M5RD!S&2U)'/>\'_$S1AS ([.4GL1^3;B]_+@8/
MU/4]?9-=(2[39+^(9,/^S$6%//YA\<]R_U+>0/YB*(+EO=3>%375G435KT[^
MB%S7<T,4'#+!9B@:^LQV0F,O=@*0/@W%\9/QC/];U)L1M7B:V1EUG?6S-(VR
M#+=V[\.JF7=6T>>'T*]\RK^)&<OB0_O,F6JV)QDTY50[GI8M-^CZ=FO!N;).
MK0%W.4 XLI2]V\HO#CW'"^S FO&)_H+J*+?H\3W49EMDN2TLJD)'(_XKZ\_Q
M1%DGQZ%920FGAD_:]S+;\EW3=Y#Y+Z$\'! UTH(^YQIKT'<.\D9@7%2+SD;]
M5]:D\\FR3M)#M<E!@>DYJ@!9];1N\_8;SOY)N?MZES'Q1B:_V19<&=)]1Y3.
MV<[?!KF&R56LQ"E>!DB@HLAMA;16N"G[4*D[*4\BM=F60Q]5F7@^;$;2@EOR
MVJ&'7=6MR6JZ-*3U=+M"@=N;8L^S+%]5-:4V<C]H3KE$1>N[+_25;MB+.-[J
M95IJK.*(+L&6=84/<-<P,!,*<-[ET<?4S#$I-C>=H6FUEHF=D*@ZYJVK:D,+
M&'7I&SBA+70],W)4S_MDU0"]S(R$M(8IZ2^+202JCV$8@9U-1"?H/3;E_VLK
MWY@OPN@!VMQ":[ /87M^["'5C+_0LHGU _ZI@_[6<(P"_YQ#=V>M@MY'DJ.7
M0A_-'XB;34! Z,:./!2I3Q.S\W^ MBN4 %RQUL+4BSS5:>%F^\JW?9:]K:OA
M>QCO1:]A<ALL<'WTN"=>-H)6X%>S24*22-6#?38V#]#7&DN/JE1N[/@4Q2H]
M?<@PH65W>Q'Q/RW/I<,N+2$*_:TQ*DIU+>5XCQ?7+&N@CUI/.!<V$T.AVW@8
MA9X5J4JYK:(T0U)8E)J3I%N\C66">8L>@9/2[,AT$T=5'>,SSD780OQ']$5[
MQ1MZZ7IE_@L'D;TCYBS3>.@!UGMQ#@8(=9JET<>^C '/IJ(FM'^1'2''P:J'
M\\NHQY [A#8= 9_^/8L298;,#>'?DR8IWL<ZZK#A^:7I,I/]G9YZ#O];6@#<
M:)I[5'^K49T='-*,+1(098JS_-$R ]OV3(3L^2S?KXR1/]/-YI#06# C$N^3
M9.U$$>,1^0[B!/BRRU[8A=+S"W;RK8#7>:%?]H"_L8R?HN\JM KA]OWH^K:M
M-V+622-HHP2*@BAL3\MQ32>TO1 Y\]$36H5WJHPT<#5BA4QZ?W9]7O6'S+K6
M'WJI[O/3M+H4<D589"/;"9PY^RBS0NPY>+,1 2#Q'D,^.CCN?GE:'&XTNPZ#
M_MB/>=1'\:1^GHIE0[]# [8-ALXZV0&N96S26'7W4'ZM[=FF/V.R_'%9PI=6
M_BD;L8+C.5&$@C!4E5R7/R+7#FP/^>Z,C3%%BU"18&UDXCF4?.Z49GEA;.DC
M*ZJ"2]PE>QZ=EE6-\T,,<YM\$X/\?ACC@0^A\J_AGUI?8_J 99W+#&ZL2B/?
M[7A58KJNAP+7F9$_50'QO8>=46IPQSJFFIZ]*[S5L8RC50BO]7?6YU@[--:Y
M\.#.<A8A9J+*VRB_.'1"Y(:>/V/W:Q6CQ-(9;Q1GXVNAG\CO&__F_^1?#*'!
MZ>]J2(<SB*QS]:"&QH^PYRDK#<L?0]L)/2L(9\SX%]W?C]H(U@G\S=+ ^PTY
MEBG\,A>\$1(8_3(5;QJMYJK8QZ&4\N?FZ&4B^H_]V K13?%UZU-PDEFP+C)!
M _TV\5#BMOJ,R#$]UT'\__1F:75N+I[$<_3"2/:>Z)KTE<?-!P[INMC7%I^8
MTEU#O&^:=\Z,=5(4R'T/Q\3'5NLA'?GBF21W"V8,3IYR_ZKU?,35(>.?+#M&
M7!GR9_%)MBMB]DSY7TF^7QE/W).>EO7[=2J.CK+7#4 _Q$^WR6T%1J[6WSB0
MBW2?X+MUX_D44V*=/ 02/+;M)(X[@N^.;]N>O1:]V8LVO+Y]F8'0_;]47R8/
MF OKHAHTH&51/[&1:M<LX[.!ZUF>'<X8U.I/X82?O5YP.K'GW+46WRB]XP..
MXN;)=[PG*IY"9UT,@2;$^788)TY[F$B<"WTSG#-,)++=\J(L&91NC7P7\=TD
MQ2+[[<KX;Y9R HITN%U6);=POYG%J2@"IT?8J('_9GO?0/__"NQ_5-"OM^1Z
M#UQU=3[\6]8G\1CPK)-NT. 4193:D>JI=&F9$7)#UW:#<#X>WU'^]]L"EQO[
M*Q.*+-,KBC?QTH+RCW*&"[.:I=&N&!]S. QXF_PAA_LJ1[NI!_M\&$MU 37@
MX^M3;1!JUDD%<*3+2Y#CM:1W;G,L6U3^H!M.;R*J5>9+Y,W6XQI9.; L2]G'
M,K8EP:HF!)^Z/H2Y!)#U64*H0T=L)PFI*L^\91RQLZ]'ETD<N8Z9]9.#]MQ1
MN6'P=85N:=BB+DI:;X"]T P1,NT9KUMNGCDO,OF8?L.ZT^$6=+?VH+YS3"I/
M2OD+ZY.I!1?K6E-HC(\?'WT3M5["(-]Q3-/GWM6\=W-9CC?"^4EU)$X-\#:Y
M2*%+O[H^F2XB9)W+#R_HF80N[HBMA3ZR'-^;TZT&9PYNIBO'!<FG^]Y16&O0
MY]=GU3#8K),1X%Q"RS8145W17<=QML.;,D.6YOLKDYNMB,G)OZM@+E!U1D*I
M4ZDYZQHW<JG$4_[]54W1\25EH),?)3E].#@ ,QO)$[!7']N$(M5;J/LGEA4B
M%T[=FGVI0FOB38.J"[L>&_ %(?47JSZDA0)E0^@"37*(N.1IK.Q,-3D]![7J
M5'(37HJ 6$YH1^IJ2ESS*?G!WO!&[%%W^$VF)(L*CFF2BL=6B^X0HDQ2C474
MPR]3@O=HQ/NC*;<'T,Q'B4T?31N F8TD"?2531@X/HI4SO*L_!Q4S$ONE&6[
MMSU3P=UH*.:[8*2Z-)K551OR/+K+1P-WW"(6"1!5=M^I#>M7V06 TJJK05Y+
M>/Y6' +!+P)"U8F TGU[(0-7*#3;_]N$-43 ^E@F.-13+P!('G!;K9CZRN3U
M.=@ZUOIP=12=-:KDKRTYD)>KZF9'A*\@[PPW1D[YIID6;U"])0GQ JM3;;_3
M1[SA?E!,J1@I7]YCWP@$PANJ(6CKM;?*:I" -=3;RUA/%1=*'^@-(S]@^K:G
M;.TX!V,'M=7=1^-DT^NR^' S#G=E/+)7FFU%1)(S.Y6I 54KS&8(KR3^,Q:S
M@K^TMSV'8J^UU&*E595_-?_N>WL4C:P\?4VV6Y5 @'+31SD[T3'PRH/?"40D
MH$B51C(1O0;7ZH1PZ^@TXGF.%X>M.86V[WJ!B>;L*G5B*ZI*%/*/XJU#5CWF
M^@?_:AE1_1-G9,+(/3^$?-D/*1+QJQ=1/_APW\K1.B/W/3Z_OIX,@\VZ" %U
M-VV/6('77EPB=&S7LZT9[ZGE.9K*TBU59[8#\_Z!?Z:][H/F+.Y4XKQ-&O<L
M')U"<A=^<WV^70+(NA@ 34ZE$28(M;]<L2TS\#S3]^>CUNT9GY[I<T0S31@E
MX1V6X#>)K6WW:ON]]=G4#8]UKCF43&9"0EOY3K6L87'PI,OA9_<=JV$/Y-*,
M6VJQ@.6G#[LNX&,]6  -!=O<=B54M2=.1K9!=:"5'ABX)@EU(]L,5 'N$P5>
MZ-P%NT-:S1I?EI,^.M(&C$'6%^HI(H)-=4V2\?QYH5G*R-<M&1C/$.^IJ0A.
MB$Z_XJO MR&1%YHT;CTS3C"K^P)GQ8AY1?0QW6Y%)+7W['SB!WZL+/;XA<89
MQ3E]>,K8[O%)9)_=)C+[GFUND_TKD+>E;4.-RRA*8#(%4<P\+K&)'_>/C-ZN
MSHX,>MB2@=*=;IWTL4UC)\"FY"O0UB6):Q)3Y6TNH#9AJ39;^BCRT!]&17GK
M=P(%,TB:EX]"17X#>ZD>?,-+U$>)&V.L2FAOE(K+*[D<7D0^1^FV'&EI2]*$
MM;<F^_H=<0.9KE9DF& G6R%];,A(_&Q"GD*])1RZB:WLD[:8N@SI7?'\(DH&
M-@O=-!4%7&/:ISA1F<]K0N3$Y258-;/%[<(>0T/AM34!EP4V3,P:*7</L&PH
MC:!J&WL>L92UP.>A[I $C H(6!L3BB++5IFB/?2_YU4QHP7U\'#(V?'1=57
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M\TDF?L+98RD9#E446,K9)B55\%%VVL@+_J?G"YUNCMQ-VP^M.%0]H)_XL?D
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M'PH[7._6K<8K/ ;; S+^48B].N(+^$]-"-M+BF-701\:#X/-QC,/R'N+<B\
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M8O,$7DL+I>%%_1!.HD35\KX94R_O>O?1O7OZ*/XCAUI:I9O1ZRHAX!#HRQO
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MF;:,<G&2Q]+J81VB/!!%T LL!OUN.?]_V?>DXHIT.3+_=T8^@ +EEW/!@II
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M4M-=91M&C[,FR-2>#O,TB5,L"RZ88FU]R4=1''L^@3*5*5XVF^5+Z^$@V;J
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MQ\9#S38$P5[@P;]=N(&E((-)0PM"-T1)@&5^E'<54/"ZWL?;J )S_V<8HX0
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M]F6\'9X_ODT7< #H_9!FFJ:0 #?PL<QEIZ+C\O%I25\($61<?2])53\43_.
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MH$1/7T3L81N$.,R03$2OV70/N&;V]-I(J3^5;%V4*_]^8CL(Z.OY^36O6%/
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MY&GHJ0N3 0AC?AA$MA<WR(0-O2@@*5*?UT$8Q>Q& <RH/[D)"W.($A HE02
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MI5SVAG.9D:@6H-/,. ,!.M%"J0[HQ@+D>RD[O-0"Q),GH<V";_!7H!<@-)8
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MN:A?4Y2I1&1IUE'T'0B)A*=4QY5_"R$QZ?$[>-PAPH&(RXYJ9=@WTU7 "]W
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M['G^GT\&4+9.^>KG ]!=8JB*.Z8 =9$;D5QV&QK&\2&9?M]NC U@#_DAAC*
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M_"ALHD5,UL[%9Y(L6_'%])A0$49U[#)]<H81@$$FJW@H?@SB($2N;S,;:@V
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M<P!>T8:,X5K:4G/>$;-35K[MW'#3T7#7DM"TI>EOUQ1(MG*\0:=7O2.NA>J
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M/]RATS2?G=2/73$<"I:[*^%)ZN.N8')7^!MP,.A :%WX@B0Q3$G7Y:@V(E"
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M3)=&XLQ;J@Q(%4JWOQTIG;1Q_K]4="^S[6\T[Y%']#(#.![!O# AQ=J7 1'
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MN,8NW]7ACZ>?9PL>]\^VIQDOCYS0;5(<NSFU^G[Z:;5C<R\!^M,$G+8F*)R
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MRU+^'UO?L#/O<KEB16XG2:Q-6]OYW:'54#);N.Q;3@^NO@P+T\I;7QM"P*/
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MHL%:D8MX$B:A#F8844"I[S*[=,?-Y(=JB_WX'&RJ "Q;B*)_?4H0)TFL]R!
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M==%],-CZIU!Y%XI]0^59^3^1W$_.<RF? EG;=,/6<+)M,CV&K#D5QO6U!4Z
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M,=_Q3JW>W9.D6%?W6BES>;D:#1X[Y#O=-)?I>4WZ8T-9"Z(C>YH>:L<.0)B
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M4:^Q'_E1TS8?H [@61P)$EM\^AG ')T<GT,>5<<#Z9YUB200A:$VN;EZJH8
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MNY]Q?L].S/*-8;)EKT:1:<).+"B_,S] U$FE?:NK7,D:I:A'W2,'2@\'KLY
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M40/0U&_T[\GCG>V 0%'<N2&1N_V;-MM%0^78>%J-"N T7D^^>,O1-A/-@VJ
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M*)5533T+R=H5R97D3J6.5R9\*OMJW;S<?2JF8Y!J/D8.$[HX\-Z]ZCI4S<K
MS;2.[?IG:K-S'K31^?"B:D8Z7F2'KNS:8*DH'W/3SF\(XQ>CA&:-PG:H,*YL
MACH1PHDCK?_2P:EU!(V<V'1Y%@K[[Z4P@]=INPK_.N?GTSJL^F?1$+2>7)5/
M!C]59CZHC8/6&.P)<5,;-9.<4&O,OD7J7N?E(&XY5MK<#.C7[&>6?-58]33&
MJ>G*SC?+F(?V]!#<SLV"P*,D:]I#MM-'R+ K0N0C%$2.+&RZ,S,&3KCWVZR
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MG39&/ER+-4RHZSU<[3GPOF' BFUH&-Y.5F7S>IVIU.%5[N]H,C<U\TOE$IA
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M_G[\5N#H2_.S?@"M!Y+@(=-E@F!.?!%)-\6?6)'-JJ_,SV1E2@_/N2$SHNS
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M$SXR>EN-W-_VG&(&Z&6+4)'Y=%N3*3NJG7?D^47BW!.FO2*@*%NQZ>#8[RQ
M(LEVJ[/;8)X%3)@4'QD/6C.2]#4[3S;IQ[V X>1?NUKT9$)ZP2LTP^D4\O26
M455K4H[K7M'ER)V>:5']4J"Z_:61[7O2>_RY9738'MJ7K+J7Q@L#MMC"^,N&
MT_U7 U;Z> M5Y8+326P%Q)/97JU*5!]^/#$"*VZ>H4!@J]04$4,;?Q&L^>LR
M=%,7;P:P<3D:XRB%=! @5.-<?1)Z02SMW3X=\D9LFP?P&]B-,W&P'Y@R:;H4
M+2'FF5(U>&U.M^1J&>+4P1QU-BY'F(X12(? 05&4HHB)DB.[/9@.=0/='A7@
MAFKP@XT>QZ;%E(3T!AI#D?NN_7Z=-I6_X83Q=YIMR]\9.3M&<540GT#QQ&]%
MMKT7&_\74C[0Y.X!EW]DFPT_O#<U*N_H=4[3K%SG8#O4QL0('CZ3/*+C:L)(
M6YV3-"7J16&LV#%3-Y2U"OY)^3E"$ZXDA?W_C_%(GTEC3 UMQSPDE+ME<M[^
MBF]^W?SZ>?>#//*\IDO.MB-AW<,^,+\Z'$GW@3_&]6TW"/RIP^I%8SP><SEP
M$13?7 [W50D^C++W M>V':7<\0._1V*9<>++]$QU2VZYKAN&ED:W>]V1NLZ8
M^XQ3_$)*_HNO@T-+D8L2RY<V(N(_VJYCV1:;E[X)W1&<&Q^SS6,3-DNW13V[
MC^ H_H/]GX<+X^Z_)PLVA3%AR-:(,!Z,Q@>[^^].21GZZORB,IABV@< 59<Q
MMBUL=D?S.W;H6JZC,YC_+M^1*M/O]J4HR:-V5#4#5N,I8VK0BPM U#!Z:=^Z
MG[CEW>5X6\1DFWPA"62W 26?\9^$4<-VY:O//3P?\N(2>#Z(WL,P,SOP7"L<
MO-]9?ABA).U.'O<<Q_>1SAH"34[%.[PIL[@P;J]6D$=Q/UTJ3CU$-0(; #Y_
MU%3J>WQ^N"A12?O64O72FC!;RO%E%T.5PRIP_2 P+8V-_?8@R6@19X1QIC"N
M2;ZKTK<^9X]J<&E/S+,2+TC<[BA=SPTL*S ]C5M8,['U,QP(,:06[:_'(:/H
M'2X8R5.+0CU<VWOYB0]U5"Q47UV.B"A33'M77U6GNDP;6[CS#.%9+@H@&4@?
MJOZ.GW"I 3W\N\=PTOW0_(CHH8WV+9%J+%2<V.S?W7E\5A"$CNDBC7E\(L/U
M"]YBT5#6@-HKG\B6/$^<V[H?XG8EOM^?UGKL^?G1H48F[5W0$ZW=^O OC+_J
MX'_UM9.S2L_/SUDU,E]5_WMUTZ*>+>FFIM>]J_NNY[N.:6L,,5OG&2-(9 ;S
MHAS-P?3]+G_ CQ?&U\O)A)$/UAX+1A+C?+WL!,Z M^:'SQ!B:>]:JX+()!@C
MN\<TM-R02;ZMT>;] S^3SQ";66/GMB0Y>_7^POA]NO)%S2@P1CW"[]VY@$K/
MSX\8-3)I[Y).=%??.K+ B85?9+/CRO'CI\I[\W-Z&+F'D8ZO#XZJ)](H23U?
MVH6N^K"#;,_WD,:0\SOH";C+7T3'B\+XGI4/!ES4Y%D,'KK=H/B$CILO,03W
M<!9_L %NFN]_*V2S5WQC?M"H$DI[5U6Y4F9D!D$D<\;S'RWD6);O^IY&97Z'
M?Q@Y+FN_-P3(Y>29;'<,.N0'>7PJ17!<B7_P"_QEQ+8PJF\8T1\XS>OTIJ+X
M R<8PA#O*G)E6!SZ[@)0.9ADV@LC56,#F0%FN) PL8I%J?O"7^,7')VA:>8^
MYDJ,:SR)@9>!2CE3E+FW'+P=H8\.P("JTRZ-79*$6J$V)K(ECO,=3YD1@_-
M_Y0[_C.\X3V7E"]U(S]VB"<-*&MR)3_2_(8\,6(><$'6W[=B&](O5@T!O+UL
MWI!@T._;RI X.9O^R"1'\&5! J-**1VUXLH.$0L\(MU5;FW3MP(OT-@B]2O=
M_A)72GHO)[@H2DA]G+A'&1NL&NMC/=1*C'2T2]G05^>'V&"*:=_**ZOE(+#3
MI#.'-K \$_F.SJ:[JR3)1+'N;!MO=@G7QJ\[8S_E&=-;)37J@$A161I^4V7=
M*O?.5BOK7=%T59%TM3WH(WX-Y-S1RP-B[JA(8VTU&9?=2$_\Z?F!._F,:!\
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M+$86622C7[:\]$[ PVD0\C&*9"V:"$8ZTD5Y)D\9C%"1S9J7>V=#1I5O4HR
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M*'$M\?3RVD:&2-R%!4E)C2T(+5]4G>LWF*0YO>%$^65&3.3TN;SO)<8.D\<
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M.UYYC]_\T?C4Q)+"*TY@PS)N6L'E">'M,HVJ8\/EGFP+_%:R^:Q@QE4.LSS
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M1&,<-[@+KM(]S_PX<H0SSS[2>EE !R;PU<G!AW?;R<JA?J+1^@&Z_X^7A^T
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M0SSA:_[A"Q)%^?7_\?(2.H!FW D"68ER=4\W6R2*;[L?ON]0FJ.[=P;#,D8
MXN30B(Q>1ON1Y61&AN&8[16,/6"8G@X4WD=_>F>J#+@"5+BCGBYVZPUB]X/+
M2]89^G#7LLM>+0>1&7AV:R5@PP:Z;3E 5YBT=\VNSY^I+B83DB=1<8E.C>:>
MKO.V+N7%^Z^;K[_G;Q=P+O>#Y?$A22?N7$_9G!LC"LP B6YON!KW?=MU3$]A
M[M_7'!'YYI71MT0T#AD_&A51/CC6]LD6B<)H>4&E_0M,AT33JKR/82S1XM^?
M"X8N\WO&SEW\1)@YC:)D57V>"!\=4;B3O7-Y@$_'"NZ"JJS!87M!%#CM(F
MHH1UUU-HSE:GWY^B(BCW9RTZ(&;$OM#R3=2K\+YLR85V^_'A43.<R:)U2D+*
MV."; R*F'B?A-CTM84-'-YS6C7C\RY;'Z@0\X$XPR>[HKNM$J#5)VS=<@PB
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M; '@&2:PEM0WMX1M\B\71.%\^O7K; J'C\K''*IRVM^Q/+:&DXX[$2+K"["
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M>([K*@R5_+K9)T%6IJ!/%1-4O)6]M#7^I_VAY=5(!VVX<X4DQ=!S?*\CZ](
MAF&9KLH:FI<1_/,5X0GSW=C[.M+8!-\OO]!BLG#76G0LL<Q$/2!Z\XXB%D;2
M.ET=3RT_:5W$'5=W]&BUA49?'EE?7.!$( K:Y<-T;$#^NUP&_!?T3?MOG/UY
MH7U-:>4)C7D$\PO-^-6U_^-"(\MNSY 53\B@5' :. F4 #KZ@!QYZ;<M#\$I
MF,"=B)(UJ'0G=D.K/=O9 C[P+'N6K+Y^4#5_U74.57<9J%("Z.C30%7\MA\,
MJBU,X$Y$R89(Q,!WX_8L:->W+&#[JT2JR9%JZ4LAE?R>C#X54D5O^^&0*F0"
M=P%*%JAN%.D M19;8HEICC%+K:6^0"UV?WLQH-*MSIX,J**W_7! %3*!NP U
MTL:_Q_=%&'3;,K0\L?S4MA%VL@-9GN4"4^;8*SE?__WA_(R)GUG%G+60UIPU
MVS4\P[7<OAEE 82^*VQ853C:GN!W[HDK_GVVCM'4[\6]9!>E2VQ5/:-/)T9^
M"M>#K7,$XCY0D+UFBW4K")V.)N430&Y0FE3E;LU0B))7>J,GWWG=T9&OBR[/
M[FC#DSI5@WRJLB &=HN<I"\V]31C2MI1@L8 1S-P=">RA??_ZEC'9&/NQ_H3
M_4G=?G[""8@MSS2\]G(HMFU9C@<4^MG_Y_Z3Y?G3U71EKVNOX"KX>GE5)J0*
M=ZW#2+.BRM:[BQG.JX;07'<]XHTHM[''KY:?TS[$'I=-!H!Z&KS>K:UCY)#_
M$[NL>:H9[6%*-!_1U3N8OA613 NEO?'FM34U6E"0([UMN"&*#"1*5V(]DN_B
MKV6/Y,O\+F8)'CF+U;HAM"LWQ1@-E,FZ5S=- R9_@#4E&HT*':MR)+@=-D?K
M$:8^Q.*A&)"-U?<,QPR%%_5J<#? 5GGHURC^R,5C(=TRD"A_MC I+].(6"/%
MOYRF\"\A:N6IAUHEQ!ZI@@#>I^2K$<"!\S+=#*]'4,<R@*=$FNQ%$3*@98<B
M[_L,B!_?@?L8_;^THE\^8]PS74-8VJ2*Y;S<[[,D.+!0WR?,6Z"CZ.J0TV)2
M^17-4T;E7R=+&AY7[ 0V2-;VF$48Y;LD)6HR+E/P+S<$WUI0L"%=K,*S0=RH
M?=M_PF:/>54W&::GAY&XHB\Y08<(1:RB"VU:3P2'_&F'LOW;/2&4BEG58:19
M"D80,CS;D9\1S"NVL-;V9&YV!<T7VHY2S00/E71+G_PATD'LB(XYS6GZ\)T8
MR$F.[E@J(HWA8X>)IXP(]R%[>WR!&6)51VC(,GE@B7E!!8V1QA,FF^Z!?4&H
MEE-*R;_6I/8J-&1XIA_!2)0E0F,ADXQUI<%Y_H!"_)PF+-2<D!DG^[N,_IT<
M? @'"8%[%1OY&\;1MV2S&:ZM>SK)*D*U#:&(>LH*4FGT^8X1J]$J*.3+"WHV
M*@ANQCL^%S1+P\PV(]-R1 Z6!>=MP"[7F+R00.E9WKL(8X><J$7(:0C.-<Z7
MJ!7$!]=".GJ)A[\X'EA%F*[40>E@5NC8ON]W-."R+>!ZGJZP1^!]1H[]2<14
M:$Z@GH2(%]*JMA<M8EOB.<:D[JSX8&R'N:=#T=)CY4Y[4PTCU+R]?KF\N=V7
M8-RY[K)-<"PWCB)1"&!ABCZ@^)!&>>4P9P7(4K*!'U!45'(;ME4-.Q9FG)S:
M?WVA-2DJ*[$1DB8Z",KQ/W;^UH/"863C\9B1/>!!!*S(%*96*$;LN'LFJB(C
M%!VXP<2MK0R](D+6!2^IUP_#1W:Z:8 0!,)3GN))(;]-,(T!R?:S3LT%.?9H
M 7I.TI1F^5%3GE$BG:T+8AA8PFZ[\TS9A[2GR3G%A"%JS/>=*DNWD>X)?2H5
M362ONL&'8!\?-@_5I;'R7:$:GL](08#DM;6<^='%7^\)68^:EZ03#UAF6<O#
M#7W+%E6PGQQ4XW54&[Y&*B$WM*'M0C#?) S7.EU3,$BMV(X/8W'\RPV*B=4;
M7:$4T<-KL$F>F1(3J^#+/3&=<Z*QV16M<J53$$?6G5&GX8J\5EN4Z=X=)Y+7
MC1U=NVS$#$T\X>M1:I-P@2>'H'39A=B.#:%&G%D>!NO+*WF1&*DY@>][D>>N
M0'D,U*L]IVJ0AC6,"%I.1[MVW[<-RZZKQ$ZO+#^]+TE?YH7'?8M7RNC%TPN]
M(KD^/BT *)B2OC]=7M_UIAAW+;ZLFB(G)]=S1#[8:P)>=A-%4?N$Z3W0%;L-
MNJ=Y!&&R@^D^_X+VQQ):,L"+O+\3VSFJ'M94T_LS>A.D!6_\G[L&Z>R6@Y8N
M.-K_2W"_:3\QY_[/%P+38(*2B--/[5Q+N!Z)4<L>GD\,9+UEINZCV!+%U:U%
M6(=586Q(+-U(\AR'"4U#DO9I@#@TG=;4=YO\QW.=7AOC $:J5BA%@$>(M]N$
M>?GST3Y!QX"FI?NM+;D,Q_)TPS=-A8FHOV7T;E30ED:1SYZ-=[HK2GOL!_QZ
M>8TVA&C<"8-EJS>/Y>=4<F4#KG7/A<+Z K=I2.,>T WB_WQZR?#A^:49T_([
MVD0?<49O[B:Z8A\D;26E?RM)U?:<UI/N12^$7.;-H3>X8X(39$1RLNE3N33K
M$>?I6<)J82R;;.X9G@<=D7-C$0$;'ZF)\WUA>B 6[[%A@1WD^$#V[1TFHJ4]
MLVI?1](F?7(/(0R@)YJNHW"Q_#-^13P;Y)ZY!I0KF:>C(+!<VQ8$R'DG9#1&
M-X.]9V0]LBU))QZPSK)2:#B^[@FE<')8#3"'QV'KZ-Q##NEVT-%4VW9MGU:4
M4^CZJG;A)"WZ?2%N"N?-VY/HP&)V#RF"&?4JE$\6$6),K] # GGFZ"5U$\/I
M;CM+BF]3GN"&F!V6U]=.-P?TA+\6I!;/\'3AAX+.)]S\:1FOW7EE.N.HR^N
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ME7$?;_$F@<^$QL\(;(HU))2=EOA&OXKWA)$_)FB0<R"0>0$/)&H[1B,#Z?I
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M>*>J,^KB^U_ER'S8OJJS]37S8W(0];@5-K+:,K)LVW,;>QUZCF_KNN^JK#"
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M'9V1U*F4[?EO(Y0GCSRU$13UPE]5$G)Y9A:T(1\*24[F35R3_,HM=WVD\.I
MX*HXJ(PRD90=K@3MWP6\5S_8_)"?8(ZX#<G251%T,P[=QK;&KF,[NNO;"K-Z
MKI(G8N&D45XW4>F16:G 7&AKM&%?(T-3\<S0#F>L+/L.90GN791]7'/XP)RC
M[?<19]*@RK\B0#W#'>#UF;!E57Q(HYOXKF+)+>.( "-+)&]^V5\D5W";5,ON
MIZX1&Q T)FA8GF%8GJMR/[U$U(_^G&NK3Q?:/5QO$I2AM',&H(L\,A'4G 'H
M.V;@&$HS  D*"YQK7U'$+EWHA-X3TVBT3!/^_O+UJT_TW8T7*F>?G5^JSI.(
M6Q=0NIA:Z#NQW>S$,1W+"3Q=5W@>^0M%8$/],@]$W,$.[8L$YA>T_^*["X*7
M=(.U6Y#]N- N5Z.AI1JS/B0=D U'1[M<-:*G\W?G1U-WDG$K"*0+2I@Q0$YS
MBEM@!Z9/K[@5JE 0T;/M*;8NP3;,DNB1&$9?QP,5'ZH^TF&<K\UPZO"M^8'4
MA5C<NM*RKCE/CUH:3 <&>:NILBWP\4@;(I"13_F:_#/8*U*=F-ZSE]ZS=[8<
M'D6/S8^&5NIPRS+)+K[KQJ'E-C8#-HAA1ZPT7>^41=WC(O_#+P0)VLEYBG<-
M*!#2N-+(M9]KK.4%VNVHZ^Q,3\X3\](WPR!J<=?HCF,8KJ<P /(.;=AQ<@<R
MZHZZT-(#V-%AQG#0C.4N-1D9MYR*"E0'GA]8SO5+_N]K?,]'OQ)W)!WE??-+
MUSC3P&V0FOLV<^P)OE8(LF<]/30]O;%JE.$YNF_H"IL;]1/%B25ON*S]MM(E
MAML+6/Q6XM0@0*;M6,1,DPUX.+A6D>=Y (E:Q1W<.K4HH9OTY3W;/=Y$$]4@
MK%VU@EK@$DY?W[!J.2%KM -"5TZ,P,SE"%QORO$H,))N>4C[]0:B"]H)<-S#
M-.T*9NG:H5X8N)'?[#.T/<-S@T"E^_/Z9>!U5=,Y0T])3EU&9'O<90G.M&=R
M!#E$@W?UCQHN\( ;B6**N:?7UW7?"8Y=GE1$,K'66:S9,NYB47=N9\C&X<.(
MO!&BO\^O/,1DX;8UDMVX@.U&H+G3MJ<'IN_:GLK&EJP#.P&X1EO,*UQ[&@=(
MAJDWLJ\OO>#/"UAY$56X;8$&5KU[F;K#*N'?E0KG)KZEZN8_B+99<673N%,/
M>L_\?!]&/F[=*61CWPT_UAU7M!?3-*4DHUO=%YS7;AZOT]L,QTEQD['?)X_K
MXB;^GJ/N<? !E^04/5*C^J'[QGPD4=L06NKW_4E*=BU*ID9;>)(_7F@9)95N
M9WNRRW6+D ]BH$-A/QS.?M>S?-.TE?J1G@A_RJ8,RN8L=Z#EE/3#A_!\.\8+
MYQ?GD>:!VX E*]:AXT'4W,_/,!W',P.%QA8++-#(A+>8^ES>9X &Y(QURF-O
MKU[.W]VX29Q]=G[DG"<1MZV>[%5A!%W#=AI;S9N&H1N69=D*0[!O-_NG!)+C
MQ5A(J%[8N/SB!^9?\P:Z<.N"R!K<L>5%3M!X*>P%IN'[EDIGZSTD\]HDOT9;
MZ.J%C0LM?F#^A6Z@"[>MAZQ+W;2 YX!&N\32'=\T=%^A_^ K*/89TFYVZV(-
M1EML_E;^TL8%;WYH_D5OH0VW+9#DPL<N676K<=U-Q[<,W_(5QGSP_;V6D3[N
MWEY[<?O&WOC@_!@X0Q]N6S!95ZH3>K%A-7K5#-OR#<,W H6:_ELMRQXV)0M6
M6;K413H64,C Y;@-Z6U?CH,V@JC_2^8'V #:<2M(I&MGFW%D-[MT#=<AJ%89
MNUO"KFR.1T['=9R=1O"/%H'&Q_Q8#5GC<2V\NCD4K<?7YT=:+ZIQ"Q9D8V<A
M-%U@-SM>3-_S]<!56<*LKM^F!-I1NOMBK><;YH=;7\)Q*S2D<_RL.(A$Y4!*
MD\VE#6 4NDZN#O676);?"W\?S5+.*F>@X.]_[]<A66G*436?F_C4-[9*H\II
M]O)/'W[1ZA_,;A*LQ%BOG!_JH\T$MV!4%OFQX?BZW^@V=$S#T4W?5:AL^;'B
M,]J2R6WPX\BGBN-[VP\53<_-#Y=V\G#;8LFZCNW "*+&_$U#=VS'UBV%/D*.
M@7O::UI[V&]Q-BX(V(O9>]M!T/3<0D#02!YN6ZV!%[?<-]W0T_#U'^=GE8"F
MDVA=R[5-SW7&:N<F>26Q[-L(^8L(+Z"E8#Q3)A18JM9W7H!PD^3KLQP\\^3\
M3#Q'X D*/=]W+=L<+;QBN]VG[=M<TR/S,ZZ1LA,#QPE\T[!,F7QCN;2R+$KP
M$\CA?@.:]X6VQ^;G7"MUIQ>(ENT20\\8"W!GA'69$GI6+$W")]^T=;]SK:L8
M^<CR1+TVKE",R,$VN@<;WNB;6/F\BN0QL%1Y<'9%A$:.%F67>':L+&M''BD9
M:F_)S+8GDY:#HT[4XMXPD,6>%9I.*&R*J@A[/0*JH_WN'P:M:H%R&AP2[O,D
M1;E\O5*R7\) 6)^8"ZY.S5[+=!0Z:<C^GFQ9.M'1)XCB&/&6*+5[D)JC\((5
MCD%ISN]$:$D:8KZ3+T9@"QZ')[P>:#IXS3XPBF[BX_U S8]V62/F(SE&4%*N
M."5BBVODE\\ON@KFA%MQ*"O$(0*F;XDB=9C ?D/%)<C7UVF\P3]9C5(N2]-L
M'_Q\3FOQ0D*$EG J>,G>Z$C'*(?UUIGV8L]RT->!5MQS\27Q%B GMEQ1:J82
MN/7<,<S^.X9KVL S;%&6.YW9S;Y@4V,!V%>H#*G])XKH'\DN2?^A24A/9.><
M0L+H>!HNB:H2<J(:75SRJ,W&/J C;<,+;'1FQSA,78Y<#B$>CP4JZ9A.$(5N
M*+JMF@;8/679ZB_+ENN8IM?<U2H@QS;'\GR%%09KE9)9X6L6P*V]X>>G8DVK
MUI?U JO)4<LO)$8&_4K^AQ8^TR_MM[0Z8)2092DVSUI6YJ?7+,;!%;N.A-[$
M/,[\.BW(5))P4\:=,PW_0&C^A''T,]ELWM-"YHRTJY*R,NNY9@D)>*]ZJ/GU
M@O(9XC84RRH$Y'JAT9QG2?"A>Z8=J.RAU2 >@ER4/PZ"LD& 2,JC L"_3+0H
M*Q]^X0/*(5GN'8N$J"3IN!4CLN<6Z%M!V'R!;#@.>;<?Z),4DZ*E/%#&3N;D
MA8#L>TS]DA_W:3+<4JJJ/UP>AKDY&>4['43 B4[?FQ]2W<C%K:LM'=8>>@X4
M^G?NX1I%^PVZB5DIK)>U JK.:P\92/,-HY"?Z/,'0)3T _I5O*>1,<HM^(I.
MBD-6S4Q0/^#0[K(X4EOZD&@8#R58ZQ?,TY! ,0KKU"W*<C _]H2P2O#*"E7@
MF@YP1(?\^82JQ^EAJ&1)'S-,PXZCL+%AB6_KIN7:KL)CQD="/5PGQ%KZ._B5
MY,-KXU3O:PC@$/Y]?FD4DX7;UD(VUBDP]= UFH.=/-?R',.V.Q4_[+W(8Y5
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M4KZ03^2WU:_(?T*B7\AO_AM02P,$%     @ #86O5N2AQP-&2P$ &AT8 !0
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MA3!1!==X0B<GD.7ITGGTP"%N$"!BX!0KZ#A* (X/=!<9@,0$0D<#_,4!PD8
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MA]-__3.]2[5-ZWGR^2"^AM8H2>?YC _\%_]1P3&XRPN&QH5B9B;=U+/<9>>
MC?]!68+9O_YY>+!)\4)L_(2YCX^/!Q76E$TYQJ_>_+QJ\?,""0WYI_&,I,FZ
M]X31.6#.U(8#_/M:]-VEA L[/N>6<FXF*<^:VTD+<+ZW_".*^>W^.3:Y4&)'
M=72T( ,#_J5$?.TL1=,&4!O_#D+U=5A4%82TN+3.^&&.4JXK$9J<\=^IUI6T
M+0CN-W$(L8:H%J"O]]UC_FTF%.P$?_\5+QM@5[8#0?X^+.0&!+4'=^TXNL$+
MRH3?6OAG&X7=I#D(_$]1@&] 5VL\N"[O4C(^2REJTJ:D;6!'Y*L8X)92T^*.
M7F]EIUER@@J5%M+8#GAPOHMA)U<0U/H!^CM&S.SX?-82"/F'&"!7DM0"Z"*+
M4.Q:R_D=31N@;OQ[JRI_O<YO\)0(VRDKKM"\:=&IFH$$X%T,VYN*GA:XOTD:
M6 N=?)/3-05A_B$LYF8TM79Z_X;3]->,/F8CC'*:X>0\STO,I,*N:0_BP,<8
MI-Z(L-;8\(VF)0>&+<](BIE<@Y6T ZJN00]X X):@[OZV#%?95/*Y$9:8RL@
MU$$/=BTY[1EH=#ZGV:B@X_LJ;),/RR(O4";.<[F99M )R(:/X=E@3EV+^NT@
MRTJ4U@:CT@?^O!E0LWT=$GD]/:VM@-&,'RSU]2_Y3M/4"&8@!W8BZ\AI#>;3
M.693OH(^,_I8S'1X*UO#@ _L9S:FJS4.5$D'HO3& ^;Z*UKIM5(6J)O#>!#8
M^6Q.6(L[>U4!I2IPK]W=94V!._R;&'9X-4TMXKZ[YVF1ES<&8O\V!NQU5+6
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M7. [\Y:=3F:]^J]BF#&3 I&)<:6:KM"N739=>*^AJSLJKCY_/UWOS.[!$6G
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MLGY,>3BY1I*WPNPZ]C_RI3]1*1R8P$+P&Q9IJS@9/'!)G>**OB8=2=FN_V$
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M>&.+CE3/3.%?JQT<H-4BZ1K+10B?:T5):F"E;SOI6X82K$YTTS=NO0III[:
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MYU*!<T[4+Y1DQ3=.?\DA'XRKDL4XX2S[FG.J3_\L2;&\Q,6,)H[Y(3%-"_Y
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MPK991LV]8EE5-E.F$&:&W@S7-O[F%=?S3"@!U7FORYS2]8E%KS'FR+[CPXS
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M>_X+>1*W<1\8T!V;L);4N&_A# N?[HJE)^4=[ZC?Q+6=8%@'NDAJ2HZ'\[+
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M:OX9+E-O"])#Y5-['KI=A?X<-C*[W?W@WLOF],\8\P5RUUFFJC.#PX13K<^
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M?N[_O6<]O.6TV^32U?1O]!TC4!XR:VG:E=T1F@MZ.-@6:E!QPBD' ,_"A.:
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MJ=%@_0^!6:Y< %I!8E]6,J W:/_C8&YEP02U'FB5HWBNE4 IQ^I_C,VM'&F
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M(=KO+ZQ@1W5[21/V8Y(]PWYU+7(A7%O!CNJTH G[,<F>8?_7@P#VW1^]O_V
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M28O5@I9I.6+*6%'&$3@"3-EXR'D%WJ,!D=N5&^62+E=L"C5\C*:OM(BRC2?
MWJ>B,3C0P=*E3>'*P:*-!ISW/V>,;/*EH.N5_.@I;83F1*]_^FRA90_)+HN$
M7_]WS13%I@;XX8R0E0!_*5K[N& <N8Q6*=-M.H7 VSN:G;]#TJM9+URK+Y8S
MOOG$!24%=9EL;,IUS. 3#6["X5/UC\3A8,@I7?Y*Z W,X]NR7)-D,T4!&X6_
MPQ<CKO?4 3RCK;#\&HO6SGGU'MMS[Q#"T8O"E)]>U\5S38>(W>(&#AS\XW55
M5E&=][\/HF *+2WA!4#/1=-H 63@:/UX1DL/C$V7Y1>CC(R+6DF,9ZTK4J,U
M<$D@S:PQ6PS:\("/^@?:_"M]JG,%VNRBXW9 %KT]!Q9I  //[12O=P6;-'O
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MAU]7<<WJ^]^R*OU>4 W-V-(2>C/S\^=/P52C%DE@L?J=+!D6&9T_2S&5-7'
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MK!,KW6%R& HLJI=9Q.@HM^3(GBN1M\)BBU@QK)4^7%R2YZ2IVF%1&BJPQ?Q
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M+'%'[PPT0,/IT4GDRE74;((.@=E4UYJ_\8ZHX3_VM4P;H1GGQP]4FB_1MI&
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M1$7$S'-2\(G<D2>2O6L:?J4%86?\_,UKD87D:DPL&4L.6.H8$X-\3@_/M#G
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M$U"V.UHJ((\I7S0  *]:8=]BMX4N:]1?P];E=R? ,1U<P'Q\P-_X>),\9WI
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M"]*1?^1@$78&T#K?:;4?_Z+2(U,2]M+',%^WX3F*\1..</+* EJ'VI0.A^G
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M7/+RF8M] IC5N_UWD,GF9 #G5VPL!2:.[[(YR5?ULG@A5;G'U9T7&G+[YFJ
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M%G3]P)GK9^P!U,G3FN<39C5V683=EP+35?B9_JE0I&WD0*F.\6XZ'/_Z U4
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M*=S=/#U_^M$H*LZLD_$[X)S+ P1 )^P_%+8GDK+W']]0WG\'9-7/^!UISH4
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M[TZ,%5M#>5*PK?,"I>S-P_,28U9A9%N;DQK'I$2I&0U&(G?D69Q6T !4)KV
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MM1U_8@FEAM$C'\P*5K?J;5,\+E&^0A&N2C8(U67USJ(ZM!I^.?Z4"RHV@<
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M^5]^K-"G$NX@>S^AYQ*O.YJA+G+7UAB[RQJ1PH]T^V  +D1ZUV6WXT\7 I8
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M8 / Q.?$'+PVT!U+8.J2FFQ'?<91E?,23U3 5R3F?V1%%+9NZH-/'4J5RUG
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MCWG&:F.AZ3GP,.M=<ZKZP<&ARGU06ALIR^+&*4O2A$,QG5\N*0VL"MDA-93
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M7M32GQ]B_A->YJ!8:R/I(UWZY'0ZO5&"(D?#>F,#98-PY&?Z,(JLJE "@/(
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MY<_9%W$GI&3HCL\N&QL9 HPFB)V7:C =DOZ^H+KE'_MJJ\N[S#X_IBRH"T/
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M;V;>[.(ZY#J-;<BO-1D *"X&B0  'N CP0"%I2AXC43"  :?"/P!I"U@,V4
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MK>3^PURD)2$3'":NG5F#&+_@%_R"7_ +?L$O^/\'';D9+$&V%ME(YJ5^1JY
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MIP$6" <!P =*U)/A$XF?"/[G0=J^,FRPW6AB0;*,ACP+OUT7C )C@!.8 ()
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MO,X]]E1*\OQY[VRR-]QN33Q>6U]35O2(W:XWIBAWQK&.;V(/-L],OR+--"'
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MH>KU/O>^S^][?]\?'P/9S)ER=LZ<V9,S9U;1H&C1J _+Y:4#$!,#[   1$"
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M^3[1;P3_Y]!;D^V=M]Y:'7Q4>7<=8 +L@#L( %$@$8P&&4 "IH"YH "L!5O
M'G $G -702-X!-Z SQ &4H/T(7/($?*"0J!H*!5B0EE0-C0=RH=60J50!70
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M%X#45- 9 $ '-,@6D# ,PGX :@LH! Y #M3.C ^"O)MU8.S&P^_ %;NT$)_
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M64N^N3<DH*O[]GW[?M\_G\/OYLZ<-F?.G#ESY@[F*G,=\7!RD5(.0$8&" $
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MCA(\\/T)[J#'PMMG8'P]!5GXX$-(> *:X!YX%9M"2V3#* "A7Z.)*,"2'/C
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M$PSN@!8)!JW<6"C6HT(%'."_6Z86%NE Z!V8-[*MD$)XJOY2F(EN##/L_\Z
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MMNJ<O.W<>*F"_]+N8,7>R?#'TIJ>J+B"0[W4>.:#FP0M>N@'UIC5U,V=;^#
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M7"2FQ_/Y'%0BA">&89Z$J\3E;S^.4%[6177I;*E<PI<MENOTUPD+)S.X<&3
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MB+# D$D!:!I)O.SC[QN &0\ ER<6RH^'TZ;'D(CW !9@@ :2"]HRF"(!^&M
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M"O"[+-H)@K;$BHG#AK*2$I*R_[\_D^U 3ASGA>W (G( (X=@Y9#)*T 3 $!
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MW".9VCF"3.ECIAFC%9WNKKDG7$V,4K^N#7;$R%>=?4)7,FBE#U(DE?(Y9HY
M4Y0VIRS*@J/;X*4Q4MC2?"G_QQ&8I--\7YJ4:IPVLYN%I#AR\=)*;&5J(!)B
MH&$(+(\*.'CY:*LJ;(:U"^8PTY*])&E.+M+YJ9@8R>Z[&\^ :)>9P\9T6+57
MMGO>C?==PA2><,4M$8BK\WU(;/$4OU"6B:H)0TK5A*),#:";L1JX8S_X_?00
M[=A:#0P;3;' =DSGYOTK0Q%@XNG(R'(>, 19%:@UQ981ZV;"?K!P )/8CL95
M^0&^> A!FCE-E>#NAV?_W@A%,-*\*A\T8;/RC\&EKFB'M!8 :2\3? B/HD'B
M6Z#-W;B<MYZI[)I$( =(VAG5DPT(@OPB%A:DT'\E+T#,VU4+,L E+QX96[BH
MP.$WTD7V'G^>.F7LL+WL:00($JA,A@1U3)6(E\8JKB KOW4F; [W]E<F4'65
M-.:A=$4N.C1+]F-1<B?)B$-P_V>;?J?BD"<;IQOM: 1J8(=R16)WTTX_XK2P
M]_FZ[UUJ%&=:X6Q=I4CK@!R&9FSB>VA >QU[5BH?"5G$F YE@]+D/'_0?\*5
M@D!8Z-C0-@I771WQ^'^F!(@DQ Q9,*&1.=V[U);_I(%A%Q)!H(_]=;*(6;;?
MU@<=E:)42L2!AS_*'51&^1<U8'$ 2#RA8_BY,M-\A;@,^5Q-J11QXPHS\/8_
M6:5T)#7O&IF.XFY0!+2DAB$[%M1)XB!;08J]G)27%-Q5JME)!_UU0$V1-NAC
MK\$B*OJ\=!!V[.L^B^^CD&RZSY)2)E@#Z4M:F[5<D]B6Q[+RV3O#>6'<2$AR
MED4F%#4/);)T52:1G%_DE7NDG6ONHJ1A-HUW*$$RN%AQ[0S"DJ%^NJN*<GE#
MN9JT-G=,*\*>UI]0$[82U\@X:\S>MEY8-(?1;WMJT##/7NGNRXSPW&>DH56]
MPT$!08JTI$:&N)HTT)4J]F8:A]8 ?"]+U5\K]D2$R<X 6]Y.[Y#FE'/+FY74
M L)=O +%[@(.I9&(U9E3D)_'%+(:A!WN]G3M_ZQ1^VT@784N-#:<BS2ABX.C
MFXT5^=L=4^ZTQ1<1DQU :3ZD&YH8Q @0R[O&Q4ZAB/#PJ#"Y!<VEY%K^CZM
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MI=C7-'"LR=-5$FQIH(D#4D1B,'P3CP-_M'KQ@.85/L+3E@TW4Z_]Q1. !3Y
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M;'\"MPJ(YO-;AL/46WFJPVA&!CH-(H8#YX@XHZ-42B%\.CG)OKB53""+0SL
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M;P3UWZN@(WS19JI$*1X:IX&;9YPT'UZ._\>L]?'-:OT(K4!]@-T\%"3B-C*
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M=]D,?FS=?\R,]Q JY]LJZ@T,TWSP6I5]3D@\+HOQS-S%/<LZ3K?%P H;Z9G
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M$7P.\]?4K7GT'6_,EM1+-U.8#^Q<C/;Z=DYC>\7^@^*R*[])/UAZ,+[C1\B
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M/NS)I"G5-)1 .-OMOY$6,W 4FNAHYM,E85ZH M48S6"M6HS\^)>[T ='V@3
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MS;OL/**B*<'>V_U8S,Z7),YG.T_O.S[.\W>:GESIA$5HG@5[W]"-]CPKQY
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M.E3>PJ#.[?JQX'66I:)C0YQ7975T<YF'<[;D95Q8\9=3!YTT>,(!>#&JX?.
MGT3UGNUZ+*G^E1%O ?J)POOES95EBR*N&/5]_1$">NS6XK,S4G\L)A7)[0@
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MKA5[Z5J\YBZL[%2+K[TY+OB9GJ=A]Z(ZJZVLT3R8L'#BA:U(1I[M<GE1<*?
M: A.'KM4PR_$2W"^5C(S\MIK36#I\ZH1,K&27M'>N[7>2K ^J,@+_.T!\/F;
M;STU)3-F:H%G2V="*F_G]ZH-UG''I=6^%+_MT.0N8E% >_IWSD\\GA'L\WS<
M1<MZOMI&X=K$ UX<&3Z@D621N]@W/$U-YWBF^ H[>=3-P/R2(#&38O:M*AOM
MUZ3$+.N?%?(MFJ[-25.Y'2U4Z5.OYG/?:^H \,"FOE#!,TK68!CO3GIAGMU4
MV21R1""U;6Q*M54YGGG88.D;\R93NYB$"J+6O=_%KO'WJZ='>S.[IR^7W-PR
MN\,1CK.K9@T\A&,LJS\F_!</&OVU6#]Z1VSTQW?%?*Q33='<UW/I>/:^P<Q@
MP"ATPV?9MY^VK.AUNW%>S[@8EGW\*YV3*(9+L:Z/>^B,58=9I;R!CJ2R^F5(
MXH\TCBNMG.R1"8 _V1Y'#IGMJ=NQ,FVNCBU#!2A2,5YS=I.3QT T]4%L4@$]
M4\X+-]T>\CV3";B@J]GF"6+_E=+,S =OA_9/?2:"Q0H2>!-$F(<Y^*HCLH2>
MQV<DXPT.Y]D+]49&X.^F\45-7,O9[;"@T/-[G0.; 76_UKU7A*\6B!Q\A.2T
M'W8TH'.MRCP)J%RE7U;3/USC"S'8QOSL%Y^0_!>@/X;(CZ.B]_1Z'VP<N7&^
M+":,AL?W?B<%3OS0>7?B>[JGA?EG-8'TG4B*^8<>8E@48I70LO.2UFS4K=MY
M1F!C(+==3LX0 :3$*Q0F:!</3664AU-OG8!TX;1W"IBU:!9SRG*5WE)<0(S,
M8\Q R" L/J!9]5'@HM%T*0%Y(U*-XW]\&%^12!@(L#.U+Q'8B/R/!".EI#J:
MW4+3!VK"MZ'^_4T<,3UL)WX*PV/>$,@A)<_JQ*LKL'%,)V+.KW2V5G:4O\RA
M)]_:KS@F]LE)S5&7?,_6=<%ZW%Z47\4C9K"@2C'8SK3D6=RRB=?$\RK3'(-Z
MF#%K3?'@UN>8Y\$J 9BF$$R<D;;TV2CLBJEV.Y?9HQ1JQ%R%2[@#V^Z!?85J
MBNWIK?5D^%;,+/X*I1'82B-)>O @@13+;3LC?;3DP_E!)&$()OZANL<K2773
M/XHJ?!_F,-(94, $-J!T1@J0U%49$!2D8ANP)'7J;$.'VGM@<#N/(&MZV8A+
MAU0#OBG- / +("0F%215]8$=M!(X0B!< @"8#=CD?NO]56_'>VZ$!)8$1N4=
M5P" 5,-X#>/T47L.XQ3(Y_K@KZZRE :3DOC\J!RZF!8%G-0BI;;E)@_<EP<&
M[BN# @/WE4P&FQ3-4.;H2'),\*RNVM-CV$!<);&D>EO&-#8.JL#UCQRCDZD\
M7V!.T)O%#,DX,?:J1 EY<%+EG=(QQFT3"JF4WX8@#YMP,E(&)WG\; $/!V$+
MBSV7?/7ZAW(2;91Q/RS9W7Z6XV"4\Q0YE$FVR(_;9?N93*O=/PR^@D^]:>F@
MXA\LG9/%FUH.5H!<(E85JYR$ZS7+N 3U(V:,=L-ZJ:Q/*^:LYSL)M:LFFOV(
M8N4HN:(\\N9XBN2:^"TB:J*S0!\$MX5D3P)[11-WE+UF$CPF7CZP#R)#!TT5
M4/T>E?36<))A]S"(KNDD> UF>74F+PHT3%A-G'7O?1H&LJ#I7'FB#/.;8TGB
M<#7V[(U#S!>K5Q-N'.O!Y_.B[:<3JN4E8-0Z+A3Q(_.)0:KOK-F09?<LU>M9
M;6*;(-2/?M92#+4VP[2&1L+(J7TBLY2;^%GP0.^ZBB[V%Q>P23=6HC2GAT2+
MA%80U]K7K#?Z5M1;/SLX^!3"JWS(W]MR>PJ1F.T_J$B(DWO+BFZ_L!\=KW_B
M3P3E.'-N?1HS&'2L[X$P,.6Q0+5*' AXR?_2F(^:< &S:*NT&QI2!U:@4\(8
MN=92"TFN,F^:7J.W[M_H" @>;YZ\2FZ9:*(D:)J:%]'^LN*+O?V"<#V'U#=V
MH0CI]"PR.*PR*R7%^TG_Y#/H4:!+UX0'A]ABSWT68P&_&%N+'<7/1**2/QL:
MJL*,(Y8A^D&)8!'IG! VC$Z]IH<.ET\-HG&[#*??&,YWP4/[\'!0FR-MGS\F
MTR4J2"X-6_5EC9<WK$3 =.AF2>7@($0N^IW?B&Z6WM:1G9V,?^=,C7$3+S<-
MK0!(8WM@PV-W2#L#<F1(=?CTBYO-#33(V,%V/Q#*Q5>$JQ(?72$_WG-DKS1]
MH9=#N>*1L6JR<:SO]!? .2H(5#MJ^GZD,00+>"18C74P!AJ?;]Y(#-^8*7D?
M_HE2\?Y?@'*6./B.*-. YFLU5V/M^B+,'='LZ6?A5EAMH34/WS#NQ0>8@=SO
M5^T.BKR3 #=]W#D5*]U7UYVK+]OFT#3NGW,:,MTE:14H_+4$\_<8$-YR-5*+
M&*2V%M?>Y9!]#S<8U7\$FB\4>!U2>R#5SJ(,T<,YQZ$O,H]YW5@LM/E2/SYR
M2E7VV4.'2B??LB(H:^GX&HB]H=PCLI]E2L</,6C6QQD4EC]BH*C[^45\CNJ^
M_N9>'S]=6#W4<*T@_">U]+Y"CR9= 3,HJJSV^7,XL91@S1.=R%%/LLGIK4_[
M\8U&$=#M=&I$+57*^H\4LH[>5)QP ,=HL1R*61OLZ&$O*I+]Z&5(VU!&N@#-
MBCMC,O/CIZ[!@]JSSWFTXG*=V%V@G1^6"14T7JQ*FL8CI<OB_*DU< G+()+J
M<-$VVMTQUM*> K 6CH7E8.OV0\K+_53+_6B[9:NMZ=C>E?B \(]@C)53 KIG
M,:T[[WSAB=']7[T3!UHT4YD?GE,43\;5/%.&.G_9Y.*UM]PBU1MR(SL7EWE>
M.E3R3ODXKLAK :?(?_Q7(\T; \<#U=619K%FZ1=;S96?#:\P8W+F/IY"*5Z,
MY1"/F?G$HCSLHWR:VOG'G^ FH0V[3R<DC54C^5PE%>AI4N]]W4)8EL.Y!4\K
M3.E;";RW$/+5F&B<>VH,)D@U[C]R"#\;?_ 6L[;S_:#C]I0-0/7B"O%A<=_.
M3;":@L]1 K41L':$Q'X $SWWQ'RB)3.4\(067QL4\L8\*".E-\['K[09%!AK
M!PUA<*1/O;X3J;4YIV_2"F%P  =?YM^>0+:OZ.6 C5;Q)92.GPARMUU98K[6
M?&7I^"+4T:FMKTWBHC1KU4.PWY?T?2A?7':K3K6=9WWSDR!I1$'A:T:J:TV8
MRQ5UE$[M'DRB&X"?::[ ,&K+)CN)T1)C:SSL;O?K8P>UDL*[D79EWR.#,#/)
M'L'-C"9H9[KCJZ #BU8/ _U=8=#RTT'(7X!LU]U9ME,W\]ZMO3"+.6T_6+?+
M% 2F2P69@&6+NZ<&;O=S&L7QW[LT?=]DHZKR!F'46KQ@S3DK%J75T@CEQU2'
M/FOKC_,:<,9R/G#/9%U:"(.=OMAKOLF.5&M:6[)ZX?>>)WE;<W/C@?^6HM)"
MG4FFHH0%0/Z"?(I.*E>I?\,F^-%*(UN-$ZEHA3MT;:OIA4Q 8I2K/O."@'2>
M$#A9FTL<D_(V,N!+) ;/5D+P=+ CR>39/?KEJ<I5@ZBQ(8N.9@(W6F02@TU
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M3'\\4 ICE$MH]#:UZ7WOH.- ?W3%/4PS5/IIE?K-[TIJY$>?_P]V0(F_L6N
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M3C>FM=:YE:BFVG4<%;:&W#W#XQM<1G '!KNQ1BUR>1J,V:,JB=.;W) +G&X
MT2:O@ZH*>U.0:_'@IYJ2UP-+;5D<5:=(EJV/L0G5^,-G%9RF6HCIM3JSG.,^
M59^97!6RQF9&;A-I6ZL)R=N3YFGYL?<:T[D$VA!QA0)/-+S5DX1,<;QL4I*C
MT%6O2*?J!M5Z4 #:?2@ 8- !4 4:6R#S768L6!BAL$F* )Z4K*IA[%>E%A0-
MBO2BPH&Q7I184#8KTHL*"(QQ4LM=#J6P4@XH$'L-%"M V*HH6Y V*I64#8JB
MP!L518"DH(-%@+P:+'0,&BQ4$>.M,5C3K@!VIR58\O+T_?RI.2BN07+X,/?K
ME*U=,7H^(XXU;?\ [)NI."I(ZLXZA7J:YW+S'43MA'RUND.W.7:]*6YU]N*Q
MW<1CP@)VCPC"$I'F0 *SU&S%#U=E8%+/EJ'1Y0U3JN1K+6JKC,CJ?FE_NX;>
M2?ADD^(I\N1Y>5?/:C-/EQZ/I-/IXP24S4ZADM:=C0845"DOON;GD*^;NT^9
M]37FSFY*V=V*"3X.8JNRI=B>F(45]S+6ESU3]YGG]*X,LDIT>KA@]EE?"AMP
MW;A?9:3E0[IA YRM?  _0UF[<D:7MB[.8ZWO8<MS4=E*@X);Z<E7 .*]&"MV
M<,GQR=][%6&(W9XR^7"E*& O.//.3_3-<6>7[2C6$'M5'GGMNESF62NW(4I^
MYRU*"DI!P@'WKNT[3,\L:CS[D.?.3&@01.?)*6VU+V)3QY')'^%6HVVT<V:;
M5(VT&ZMZC[/)\:45.?#LK4=QSA ../?:164GLR(N-2QG-6KF]K#LT5-FJW3K
M&\;?,> ^9MM7W*CZG:<?I3G%QR?9A%^9B^Z*&]Q1=H$4*5N+P[O/ICJ!^AS7
M;A=(PS)ND6?9CI!E^^]ZI(+5M*DOI_,OC;D5&JR-1X#3XUNOX%=H%R:,^Y3=
MJ5N37OA48&'-B1X@/I2TD=L$V&JGN;HM(>C'GFK%:%1GML:)O\0SM4H9Y-89
M<R4F[-\.)M*)N)1:M;-OTK:&=ZW"A]TM#)[L+ )./0US;KN;.J4=M0B=6A2X
MUHLC<>.D;E[F YY[\YQ]/>N*4M[.M+:J.1]I]X<?4U!4XI:BO:I*>>%'_P"
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MX%=)D'L/M28XOD4E)'6D6V&5!/6@5 2=W04!0H))H /8?:@ =WZXH 6!@8H
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MOK=;L;2]RMX[P;AD^U<V'\/:'F>WW9TY/%]7-5N+V+;&8<<L0V&8[2C\C0V
M?2O8PX=/I%44>=DR9L[N3'V@I'@6Z2!Y=<?KYU=XIR;2)W.*ICH*G!M2%)QZ
MU4X6N&*V^6*[S R 3[BH>6"]R]K8V[,BM ]X\D?K7-/6XH_4^#2."<ND5KVI
M+:G<TP^EUX#A"><GTK@R^,8(\8.3I6@R=L6S.F2T@)82T%?B)Y'Z4\>NSY8\
MQI?/(O(6)W)E?J.\?V;M3UWG.+=0V1E('K]*G6ZB>GQ;R]'IUGR[492TZATY
MK-9=<DJ:<*<8+N./I7R\LV/Q)N&>6U+G^[/>GI<NBK)CC?\  @W2*Q;)BV&'
MONL92HGK^OG7SNM\-@I/RYW_ "._3ZCS(KS%1".Y*.\(24D_A%>-ETDH-;CK
MBH__ (V3V7(KB$M%U"<C)W'!K7%B2X,YJ:YH=E&U-LAD;773DI0 "3_X5WXE
M"'.ZF81624_4N#+R+C>!)[MFVEA"0<*P*YYREDR5*1[&+3X-MV>>.VZ;)DWY
M$*>K=WB.1ZU]#HX^5CW0.C+&.V,#S'V@=G267572 RHG)44X\Z^AT?B#:VR/
M&U/AR?JB/=D=G:B:KM$R<P%(7(0TXA0Y)4>./2M=5K%#THY_R-+>?6;3NBK'
M;K1$*+/ 2X&PIP=SNS[9KOT/AD<^-9)^Y\MJ_$<BR."9S;M^MGP#END0S&;:
M<!VL[ ,?M7E:S0+!FX/1T.K>3#3.9Q]1,1H7PTBWMK*.4E(Y!KER89MH]#%.
M--D^U7R+M.YA#>[S!YK.6*2*WIELW+96-[:D+S^$^E1RNPI/H2]&BRL=XUC!
M_"*UCE<2)1*V;IR ]E2&SN\MPKIAG?N9/'952-*JP%A"#MZ#RJO,W!MH*1'D
M1K6Y'3%2D*SDI%-8XS5L/,<>$8/^S*9"%L+R@J42<\'K2EIHR*6=HM8&D(R7
MXS#3ZNZ;1]YD]5>U<&71Y$VXG7CU4*2D5&H;U*M%U^#AJ60DE.?(XK#\MG2-
M_/PLGIUE(80DRDCH.E&/4YH.I#E@Q-6BPAZD:NH"DMD)/&=N*]"'BD8<21Q2
MTR?")GQ%J6I;7Q:-P'K6R\2A)\HPGH)KH;$="_%%DI)'09YKMAJ,.2-'(]/F
M@[?0Y%D2$.I'=%?B"20H^=$5&^!2;KD]*Z >CZ<TJJ;/?4T@MY\9\_+K7M::
M$I(\/4Y()\E5JV]QI]DDOHN#0;4V5A:5@Y]OK7H3GY4#SH-Y<E(A]ENL;+$M
MJ&;A<#OW8W*\Q7DKQ"3DTSUYZ'9%2C[G5HUPL]P'>1)[+@..BQQ7=BUD9=G)
M/330\[#:= VKW8\D\UN]3#JS)X91)C;:$M@9P!QFAN,Q)20ZD I!2>*BZ>TO
MGLQVOK-%OB(\":E)&[(^E?/^)X7+D]319-IY=^TA)?[)Q;+KIV2XE;CVS:#Q
M_P#"K+PS42PLZ-3@66-L[3V*ZV<U7IQ,AZ2VZX5!)P><XKZ;3:J6I[/"S:>.
M!\'45#:<$5O9GM!QY8HL-H/%^11_2C>&T&5_[I?[4;PVE*$[>>M=EG/ML4D[
MCC%)L%&A0234V4*"/4T[ ,)2*+ 6$9&12W!0?=$^8I;AT%W9]13L>T&P^U.P
MVBP@XZU.X>T&P^M*PV@V'UJ2@PC!SF@!5 K$KZ4T%V*#.$[MP^E)SIU0]I"N
M4Z/ BN/O+2DI'AR>I]!ZT2GL5DQY='-+WK?45P@S# 96S\-PHN8!YZ8'G7#/
M(\CI'?#&H*V9AD]IME[Q;CM[DP' 'W7+(A/Q#>1^1P94,#\)H6.4';&YQDNR
MSC:KC7VR*&FNT>6]*4\F.F-/4TQ)"SPK<VYM4,'VY\LU666^-(,:47;5G&^W
M*S7RTW^1:W'VI<AU# ?D*3X?4IX\\5X.J3B]K9]!H7&4$TJ)-H']E]'F/%93
M&>N".]6S^(#T%<$LNZ-'=Y:<C#7>8U"BP8R(27').^6X73O*5 \)('G6:6XV
M<E'BARS0K;>N\-QF..)8(<*4GA3AZ8]JSE"NC2.2S&=L2EW*=$MD8C,5)+Q!
M\*<?A]S7+@2?)US;JC%:4TLU+U7#MT(J?>G.A"2$G:<<GCK7H1XC;..:]7!W
MOM+;3_#X&G(@P 4K?QTP.2/Z5YDW3<CMQ+?P>7NT24Q=M52&W,[$O[4CV*<
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MCDZT1G9FE);<ZV.Y*&7$@22/S(&?&/H<^U0LJE]1ON>/HRD.VR>_S+)9V_S
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MXJD>]I_7RSMEQAR+LQ"MT5?<1514*2KH%$G&:\R$;=L[LDJI>QL)+46VVN'
M:> 6RD?=9'!_-7)EC)-FT)JC(ZDO[D1PV:" V[(CN+"CQN4E.0,_O6VFP;Y;
MI$9]1MCM1S:SR[@B*;HY*?6W/:"VFG#E;8).0K]1Q[5V[(REM^#F@W6X>;M$
MB9W;ZD*QNRK'F/>NQ1451%MLL46Y*5C+8 'R@"J22*)S=O&TG)_6J?(^Q7<*
M0-J5$>?%9M%+@2Y'4K8H$Y)Y]ZRDC1(U6D[E*M:GV""62CO6VQT\/S_^%>9J
M,2D:P;1T%^&C5UG0XVL_'1$*,=P'DMJZI/K7F[W"6TZ:35F,U0W_  5E4 )
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MB6");:]11(UR94Q<REY-J93*);V*XI=%A<O5VGJC)5]]VV%4@?/]W]$]KGZ
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MD4CEF[;IK"<JSGSUZU#-OP2\V<KWX5_-0F2&2FC?4DN+:]!VY"5UB21QGL;
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M: [PC%]_?N%0VG]1R>8MP3^J+[QG2,YH,.%IR2\8NKHE)9?]RH4]"FQE6%P
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M#?UB(W:YP8*4*U930!LB=?!W3O;M?;>[P1N,Q5=6=^1W.1T.R@RE]P</^\\
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M@[JN,,UE:GUG+7Q6J9(:$ZT;/<>I1JZZ]BO)MZ>M&UWOE9?F=HE/$I\!F,\
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M:KKJ2%BO*%ABS@*C4,ZOS%.CGP#PYVVA7&??[60$Y*GA"DMB-2[J9J4MY>9
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M[J5J>>@]*8N=U]PZ!VW17V9*ZW^0L.Q2D1;5O!V="A'W\&.9_UPK<$G"R_#
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M^PVIPF+^-]!0*U3.2>7B8E%QLY06RITL5C7(76'%-]G3()#1:M>D.^R#O^8
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MGOI<\.J\+((IG;N[;5C>)D^CRBH'D5_R;4@P6_WXR*A,V''9B0!_ZUUX\<)
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M4QQYRT8H5MF4+P,.X+TM?8S5?Y$G1A,B^ *%"N7M&1/G(E:/)#&VSJG%^WM
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MV S6X:-DP36?VZ$L-^L3YN!MPN"^XE2FRP0.8I7>F3:,1 A^64W\Z;68BK*
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M%95>6<_<5D\G/>!2]PFX8R=YB35D&F_&:64^X%&E@.?JYDKJ:.G.2=0#'W]
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MDW7 6V9L,_NT"5ZJ:,2"AV+\B'_[F_R\9/9OZSA&14 P:4*X381@^\:E:"V
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M1D_>?V@V_E,XA5[5A;3(8$S$ZG%:R))Z15]5SXP;!>G0&.F4WX*4Y_52=$3
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MUVYQ3[AX90I)2-PY*N?PCK7P)[A7F6_%<,ER0VM]ESO-BD;E;O+ZJ_\ "F!
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MQIDUY;\AJ*]<5LD[&RI&U/I@\%PTP*B^6U$*7&7#AO.2>[*GXJ?$%ND<ISZ
M <4GP [IB?&C+,B)%=$D)3O2'#SQD_3!H3H"_N5T8N,!V3.\+& $%P<]Z/QG
M-.[ H5W&3#6(,QA#_P!SO94XH%*@>JTCRI 2--S)+I4Q<2MR%#/>M+"AW;>>
MJCD94!Y GKFFD)ELB0N%/"'DQR.Z[YE 2%!*#SC<,[1[#FG5"*MZ.;ZX^VN6
M^AW<)'=(2=AQT.:&K**9;#T:80N,5-K_ )B/Q)-9M 5LMS:\I$+&4>)32^0?
MTK-L"-#;*GEOK9 )Y4E/&,=*:8&@TQ,BS+DEMQD152MWWVW:5.)&3G'(3@>5
M:Q8&E;M,3XUIY#S;CKSH;[ME6U/BYW=XO.>/*M*%9$O+;5L$VVVZ4IR-)<V2
M6@X?O$CDE1 ZCRK*7!:,^_-:B_ZN\'$QE =VTI9("#T4HXZ_TK&18VY$8DJ+
M<&*M2H^"HX\CSU\ZD!E7<- R$15+<Z%*N<4T M%T>*0AMHI&<D4#'G8S$]*)
M*EJ0M)&\D^$?H.:I "9'^(5B"\SL8.XIW$%P>WI0 A-H7*+BW,.!T!>$#R'E
MUI6316OL*;:++C8!\L#%2V%#<G9%M+>#W<CXG!VG'X>E*]X)[6:G2O:$WIQ;
M1909I2 7FW24<>83CE5<N;3N2='9BU*@SN$K[4$.W65I<?1\4N)0._0A02&O
M)*ECJ<UYW^'N_4SO_P 0M4D<QU+J&_\ :XM:8-]C,I0=PBJ>#7=J)\*L=%I'
MK79CPPT_J1QY,DL[VFJBR/[+=D"K;<9$>*_(FK#K0>2KOR/]HD#\/E^M83Q+
M)G4CH\UX\6T\[7F9\4XW(=0L/!2]Y4>%(W>&O:QJN#QLCN38SW;CK:Y*/2K(
M+*#+D*:9<QX4IP310718E,5] 3W)+;WA6$\=/R^AI4%C4=I"&%MK).S(3DY(
M'E28T16VUE!+B1W?X3[4AB C[E8ZI\J8AB-#(>[[\/IY4-@0@TA,MQ*!M!!R
M!T-%E;H,DH2$HW+&Y*1T/(Q2;LGCM#1<6\\DMJ*4I\@<"DTBU.0A20'.\(\0
MZ*\_WJ=J[*W/W(;SIY;W':5;L9XW>N/6MDN#%R5B$%)&T#CKCWI16UA)II4.
M!EUY20D>$=?:JL218MLHBM[@4%.4E14,GKR!]:S:W<EJ>S@N&(C=_N"+=:;2
MM0!!<3M4IYL>73YOI[UAD>TVQQ\QFTMG9GKK4$<14Z7GP;(XZ&6Y3[26T19/
M1*W/Q>+ISQR*Y?S>+']79V+19I+='HZ3K;L>G=@6AH&J+E=[=<;S*DI8;;0G
M+3#I3N;&_@A82" <8!XKGQZF.JG4#>>*6GA<NSC5PFMLW==RB2E.N!34T!#:
MDK!<'WFT[MJU^6:ZY+BCBZ=GH[1CWQTJTF$^Z^F7'1.M\HG"D=W\["OR[3SX
MNAZ5X>MBHVSW-#<Z1I.U?ML;MT%>D+:!_'W,JG/9\"<C!*AYK],?6O,QPOE]
M'K2FI>E=F8[)>SQR[AZX3$EEU:"\\\X,J6X.4-)]E5CJ<RCPCHT^!Q7),^T/
M&LZ7=/VZSMM,PX\4//E* DK=)YSCJ:C2)TVS355PET;+LL5&G6)N>QC9!1XQ
MY$ =#ZUAJ$XR_4TPNXW\$R[NQHVE7+@\XI"4E&5#KA:C@9\AQ3QJYT3DDE"P
M2;O)M\1"HS;YG0VT#:PKHR<$N'\WN/2KE!5R2K;5>QW[LCTW$-R+["8[@GN)
M=SLRT''$C*D@]!CR\CFO+E-W1UZB2C$Z!*@VB9VH6R%I@+AL2K>_&N!V?>?"
M;AN(/4;B"!71BDHS4O8\W)CF]-)OL7]KV^6%WL9>M5KM>]Q@MLLK4T!W+:02
M<>A"1BNO/K89<D8(X/#-)F@I29QK[(W:/-TE;[(AO#L<O? E9Y[QI22I']/\
M*PR:S4:/,Y8EQV>EET&+6:=1R/D]5CM<U>M)5;-()[L$[?"LK(]2 ,5KD_$>
MLS\*/]_S/*A^']-@5RF4MT[1NVV8L&RZ;2UNY&Z*?\S7,O%O$Y.E_?\ J=$?
M#?"X1N3Y_4A.+^T]>6ON>\AYY\ 0V/ZYK=9O$\GS_?\ $EP\)Q_! ?[(_M$:
M@1W=Z[2'8S:^"@/GD'J,)K3'X?K<F-XY?U8GXEX=@=P7^B.F=CO90KLLLLZW
MOSVY<F8_WZ]O&>,>?)YKVO _"<FBC)Y?<\;Q7Q'%JVO+1'O?8!HG4M^FZFOQ
MG27);B75M+5M2,#& 1SBKS>"+4Y+4R</BN728J)-N[".R*.1W6E&UE/^\=4K
M_.K?@F/$TI2LA>.:C+%N)<L=D79NPH%O1-N&.BEM!5;1\*TZ[1E+Q+5S_>9=
M0]&Z8A#9'TY:4( X"(J<C]Q6\/#M-'FCGEJM4^Y,LFK1:VQANV14#T2RD?Y5
M?Y'3?!/YC4>\F/)AQF_Y<=E'T; IK2:>/L)Y<TNV!0*#A#;?_=K2.#3_  0W
MF]AE;Q2HAY;#2<<DG::TK3Z=;D16;(]HMGX538#"D%L'.4G(5_SHW^<MT2DM
MCVS$@...$M[0#TX\JE4O5-E-3C]-4 QW@"/N,$Y.49S3<L<OI9-99=U_(DIC
M- 9VC]!4^7]W_,O@"H[>TX2.G'%'E+W;_F%I=(93]R#N3M'F<@?UH<<*_>$I
MY7[!*F1D(.)323ZJ>! K%Y<.+U.7!IMR3X2Y_0@R]166(C?,OD)L)(SN<&*R
MEXGI%_\ D1K#2:F742O>[0-((3WAU+;MHX^?_E63\8T2^N:9JO#=;/B,2KE]
MKN@VP6E7[=R,E"%$?H:YY^.^'Q]S:/@NO?[IA9GVI-+-:X_L_#ML^;&2R<NL
M-< ^X/\ 2N7)X]BXEA?!TX_ \SBUE[-WV?\ :=:]?NRQ;[?-9$!24*+X"22H
M^@KNT7B7YETSAU>A>F]S;]]@)\QN*?VKW-J[/+<VFCS3VS:CNT'M'D,Q+@\A
M*(K)2@9P,CDU^;>/:F2U+BF?KWX4\-T^HT*R9%S_ -LC=G/9Q9>U&YN7S5;"
MY;=N<SL4GA:Q@XYK?P##+49';X./\5ZF'AV../%']#MZ>S70"&@6='P6UJ&=
MG<)_RK[/_#L*GR?GK\2UDH;HLK+CV*=F5P2=VG;<TH]2VUM/]*YY^%S?TLUA
MXK7U&-N'V6]&RO\ YDSEQ_0!PK%<DO#,ZY1U1\5Q=-%',^RG+;S\!?D@^6[C
MFLGIM9\&Z\0PF0O?V?\ 7UG<(92W+;3^+I_6N;-'-ABYY8\(ZL6IQ99*,7V8
MR=V>ZU@20)%I2H ]$*R:Y8ZS!(Z7BDN4<I[=.S/5.I(4>V"&[$#SR,K(XZ&N
M[3:C$MTX^RL\OQ'3SU$8XOEI%Y]D+[/NMNS[4B]5S@A$=+RN\<_.V$G 'IS6
M/C7Y;QCP?+!+UKK_ $/SO-X;XEX?^(L.HA*L$>)+GGO^![$L/:!"FWEBW14?
MZP%[?KU/^5?@FA\9U$==CP13I-\G[1J_!?*TWF/JK.?_ &F6?XYJ?34)](W]
M^A9'7&5"OU/1*6IUV?/D_==?Z)GG:24<6F<$>H[2TAFWMLIQ]TVE!_0"OTK&
MH_EH;>J1\?.5Y)/[L;C*;69+)5A:N/TI74&5\,\-_:YTFU-U[':?"W=C&1N.
M0/I7RN;='+.2]V?5:2,<F&"//<S3'P3Z0T[(;"NH2L@5G"<I'1/#&)80X6HK
M6L+L>I9T8D9\6[%9J=/E%/3VN"ZA]M_;AHJ0E2;BW<&00<OG;73#40KNCER:
M*3[1O[=]LWM0+39FZ29DI"AN6AT\#UK9:YKJ1S_X?&/<3?Z;^W):D!$755BD
M10LX6I'B":T6NR+F[,EX=C<T^CI4/[379-J2U+"+RQ'40"&W3@UTR\3I)M'%
MI] Y3E&+X)FC^U7LYN+BDQ=015.$].\QD5V0\4QY.)QXHY)>$SQ<XW3LVSHT
MW= N6N=!$1#9<<5D'PIY//D*O2ZW3ZB?DXUR;:C3YE!-R?!YO[:OM"]FFD6'
M&=#MM7*Y/90VVV@H884>JU'\?TKZOP7\+YO->3.ZBZ./7^)XWIUCRNZ/)VO^
MU/4FJ2B=J.^+E!M82UM3W;:!Z!(X_7K7Z#IO#L&B_P N"7W:/F=;XA+\NH:?
MW,/.O:GI+<M;Z&6'3W:G'5<.J R /<=?>NA:F$7QPC&>ES.,7-\TBIGZ@,M$
M.,RP8\5L[%30C+SRCYD=!^O0>5<T]3!OOCY+6+:N2AFW=N8\^\7Y!(^[*V3@
M$)X\/J3C'%<674*3;1T0A21"F7.<X^TT1%8DJ! *MP2D'S('S*QG%<T\TF^>
MRU!(8DNRPQWC[RD.MI^Z+BQWASY)P, <=!6,I2KDV30VNX-!]Q+C@.[8I*FV
MN\PO'(]1[XK-S'P,N2@I+,=ET-I!*RO.$[CTSYX]CS2\Q]"4"PLT6[ZCD'^&
MP8[BT#*W<[6TD>>3P!6D)3GT#@D/]T_!D(;@MHRTX-[J"5!'.<I<'O\ OTH<
MFGP-11M?^E[ME_\ MEW#_P!QC_\ TM3;+\LYI=+FG2%QE")*$J(MO>REP>*.
M3P-X]>N!7SS6WHZ!-Z3'0U;8UGMTB:N='4IQ*V2I32?)0 X2"3U^E#7P-&<%
MOU!WQ#RI#,ALGNFW%)[Q2?[P'3VII%62+3!DR;7-D,!XW (64QCT61\Q*_P@
M=?>A\B;*NU0(TM2(LECN')9 ==<6I*B1^+ ^0?W3]:D1H;B[+E-HM+02F*I)
M9"_.04XSC/D/,^=4!4.6.3+N#TE<B*6HVUM;[J-J1M&  /()Z8J: GW"WS;R
MSWS;C C(QWDALA++^!^$>8JD@+"V66VMF)+^.# 2A7Q3SJ<=Z?PJ0 .$#ICJ
M:JD(E6^0E;SI;3+N++)^\D*1AIYW\*,#G \O/-("IN=JFQ;@A5L:FI8N/W4D
M26D[F5JY*4(\@/4U#0S.S&(;=QE%B6A.P%L=Z4I5A/F#_G6++11R)$PK7"2V
ME#6-Y65=YW@],TA,F6I3" QL#BWD*W\JRK:.3N/X0!Q6B)-XX[!-CBQ;.Q&+
MCZ$.**G>_4"58_[-:OK@0VZ\XIUPS8BW'F%*9E!MX  CH0![=:&6C/7!N"M;
MR'FW-B,)*3(\0W_+M'ID5@RT5D)U5L>6YLV@'8><J('3=[]:R]QCC[C27%SD
MI5XT[2"#3$P"(PVD*<>;2%#=A0.>: HG0IKD2.Z6.Z6UG:G8$[CZ]:I#&7FF
MD*0^_'4X'!M7QM.#TY%.R&A]$9IR0&4.O)\&$A/0) \2<^>.M#*16SR.\[CO
M^]S_ "<C%9L13N-*24M#)(.03ZT@%*2E/C?QWB>4D>M "T2;E%=3,2\E"AT5
MNZCI@^O'D:KLJR1&FF4XX['8BL[3XBPG8"?^'R/TXI4%C-Q<E34J)6LA(P L
MY4/_  JDD0V9XQ5J24.*R?K6MD!QEE&]C)X- B;$>#3G<._RU<_K0!+4H- A
M:2GH4KSY4#)CCH3L*6RZ%)^?UJ6 5LC*[_>^-K93PG/2@!\M1.\4IP':DG ]
MJ@L#"&6WW",8- %9,CCX_ '7VIQ?!*0U/.U 8 'A\7%%A1';A=RG?GY_>BQ4
M-7%O: <U47;!HJU]:MDC\>/WYV]*&"+1I(:3W7' QXNG_P /TJ&RU&S<Z<[.
M79;#4F_2GPRM.YIAOAU?F2H^0QYU#9<8TSOW8,G2-R-_L-EB-PYQMZT0I"FA
MWK@9PMSGKDISP/2O/U$'*5H[\<DE1T7LRNMKOTFZVV<72^QL>6''=Y<;0<*Y
M/7'SC]:\G5X6Y^8CTM/E2AM9F^WF5<(EBOFD;\TA:A<6+G9U2&@M,N ZV4*2
M@=20?$G'.21UQ73HZ:5')JI7:9YNM,2$U BIBVR+/7+*TQW(B2@;!X5-;5\A
MY(YV'R&:[I='/CYH[1I%]6A-"7%Y$54=-ME?", @DR,H"E+S^7GGWKPLZWY*
M/8P/9"SG3L;XK4D"X3'%2%W-:%O]Z#GYNGM7/+K@]''VFSUKV=-1U06[?;T*
M=2DX*2GE _+7DYO=L]2--JC*=L>B&+E9Q)MS@6[!4I@N9R"3SMI8YN*Y'DBI
M=$?L!CAC1VHOCE[<,H9SZ$*J\CND9XN(MLT5Q@L/W->GR._8>M#,E2?^%0Y_
M<BHW;5N^Y;CN>W[#<&%,;:C17(FVYRVTIR!G[D$_Y5E/(N[X+AB?"]STIV:6
MR1%TVB;&9+T9H);<0DX< )X4CW!Z^@R:SCZV1J_V='2-&:5MK7;#);>E-OHM
M-@:^(<*OF>=5D#Z =*[-)IT\J;Z/)UFMR/2M17;_ -#*_;EN5DLW9HIJWI=$
MY2BPTF$M/"EHPM3B3U 2/ZUU:^,)348UP8^"SS0C*;]SD7V<=(G2NF;/_%HB
MLO3[0Y&!'1U;N<?3NZ\C%<]52/=U?&EO['T-B(;##9;;0E.#M"1Y9XK]!P8X
MK&N$?G&63>3LK[G>[997=LM\!UPDI&*YM1K<>)[:Z.G3:/)FN2Z(QU/;BH*[
MJ42?,-\5C'Q.%44_#)N0B=JR';Q@,2)!/H!63\1C$TQ^'3R,I4]I2%.J919)
M 6!P58K)^+5P=\? F_4V6UCU8W=$N*F,&.$=<UII_$N>3FU?AGE_1R3EZCLK
M1(5+2179_B..K]SBCH<TGMK@2C55C=7W2']QQGKQ6;\4C[%OPS(NQQB_VUU:
M@V#E(SGRJ)>)*1/Y"<1,G445#:E(9+FP;B,U#\11I'028=HO+=]86ZEDMIR$
MGGFNC3YOS*;^#'48'IVD_<EBTV].?NTKSSE:CFNGRS#<P&T6U7*H<<_5LJ_K
M1Y=AN8\U#CQVBRTVA#2L[DI&T#Z"M(XZ);OEF&F08NE4WV;I^<XVN7NDNMN+
M+@:<Z;P#T!]*\C6J<')GJZ".+/DC"?\ $Q+^JM9(;25WYS..<-C!KAPY\K=6
M?53T&CQ1O:45OU'JZ5J$-/ZEN ;] X #3U.?)Y;;;(S:/3ITHHZ/9KE)9DK5
M(FRI!3SA3W'[5\Y@U4XS<FWQ]SEU6BQRA451E]2=I,6X&3:%,+0M"BD$*X!K
M#6^(O,CKT'A7DNS-"_-I3X5*)]U5X_JGRV_YGK.*@Z2*:^W1Z1&4E".21U%:
MPBK["Y?!0,,RBQWA2.5>E:32=<C]5="T,J6L)>=#?!P2*61=)#PT_J,)IZY6
M>5K*Y6QE_?(3@*(/(->GGQRAIDVCDQ.'GM19Z>^SQ"<MZ+Z71G+C03],5[_X
M8]46?-_B7B<:^YV5(3@@]5)W?X5];/Z6?-1IR1Y/[99/QG:/>'0?Y&UL?HD"
MORSQMWJY'[;^$X;?",3_ /\ +^IU3[/$J&O3<ZWC^:S*[Y7OD"OIOPQJ4HN!
M\3^.,$OS<)^S7^YU="D[E<@[.>M?92QW3/@UD:<D-SI#3,;,L)2D_BR*QU#@
MHU9>+S9OA&+N,UZVR@Y;;ZTM"B.#BO.57:9ZD8SJI1+1B;>5-MOB6A06>G%6
MLGW)E#[#PO5X2X&7;8'$'@KSTI3?F1<3/9S9$DB),<^^MH"\YX37G9-'?L=>
M/(H^YF]3:8TQJ!M+$V">% ],8XKARZ7-CYQ+D[,>>#XFRMMEMD1&W],6Y8BP
ME-*#:R,G)Z_TKQO$M%K]1CVQX-\>/!"7F=E1IC2NFM&:B8D(<6XM0*.]5D[U
M*//[?YU^?:+\-:S3^(1R9^5['KZOQ+\UIGC7%&PUAV96O6MWBWN0I6^*4+:*
M?R@_\Z_6EHY*46CYO#JEBQN#.CL_=1UH:^<# X] *^KDU#$HKX/#BM\G)_)2
MV^<A%V<8DG_6<C/IC'%>;')4CJ\KT\'EC[0;AD]H 4LC*62/ZFN/-@CDR2G\
MGM:?+*&.,5['+Y-A8GH#JDX..>,5@]/%'0LTF/1+2T $[<XXZ5C+ S>.5#=U
MTQ'EGQA) ]<5GY31IYB90*L,=,A4>/PD\5F\+:&LOL,RM%I<B;RD*P>A\ZS\
MJ479:R)\&3O&F#&<P(8ZC(/'%'E^5Z[(EM)$'19D!$^-,5:(K60Y)6X4I!QT
M&.5$],"O0\.T>L\3S+'"/#_H<VIS8L$-S(MQ[4+K;X:])V6ZW!V$X#\2J3(W
MOR4)Y ./E2#T _6OV3P#\*Z;PJ"S2^M_W\GPOBOBTYRV0Y1RR;J)VZR2\TK<
MHJ(3WI\(]/;C]J^ECE?M_ \3+BBJG??93W&]P'PL*?[SNUAMPDY!7Z) _P :
MPRYD_<<,947*X*[I,IUM"GF\M(2@90@J\^?;\7ES7#DR>_N=,8NBK8E.PFQ)
M,@AQ23A Y#8/!*L^9\O.L-U<V5MO@99*F"I3:=CJ.$("MV%>WY<C]:Q;I\&J
M7 Q\:A"MC2VU2&T[@5^%*$?F6?P@<@#SK-R*H2E2W.[DAM:PG>IEQ0V\$8W)
M3^%/UJ+]QT)0IME2"D?$.NC@MX&/=/M_6BZ"A+*@R6U@(>?=W!LGJ<=<^6T4
M)T%$U5^G_P (18V\H"W>]=<;&U*E#\)QY 4WD>W:&TE09#L9EQ,1AM2'D[1D
MG>$>?7C'I3C.EP-(/^%Q?;]Z5HKDS&G(L.\"2)K04]SWB4*.]#?D<*X'Z\UX
M2=FQ<W15]LT!$Q%P;=2TDQI.5$%+'4(R. "!DX]!5)L0N5>[5=X,&%9\*8>(
MV.I8VGO0,E&\^(X'(SQ5/JD(1K!*]+(1 LZF]KR4/R6DK27,*Z*6>I.<G;YT
MI*N$"Y,_&E1V)CEEBH0Y'F ?%.+0K"W3_M3YY!\@<5/V*'OXH]8+<J*J5 D-
M-N%MEPMGO.Y/S* \@2"/6BZ DQ6&[@6%0&W41)*5+VQW,J;63C[PKXR//%-<
MB(LV(Y:7WHZXZS&2D-I<:5CO0/))/ .<D@=:.AB[&$)N7>7**E24D(97(=*6
MV%GY24]"H^AXIH"VMJDVFZF''E_ZU<5*"6TNJ;2#GQ**^B4'U'/I32H147JY
MVYY^?)>O 6I!VNK [U6!PH<?+_B?.H8S,W)B!=7%2F9JRL-H2PXIG:IQ/Y>>
MF/4]:P997)9^'5N+S9;;Y>1SL _*@?,<^9I"8] 8>2VZW#;4&%J\:5>).[R1
MGJD5HB:-#;YTJUH9=F69A0=^[[I).W)YX(K0&3K2Q*N,^9<EL]S&2HJ4WO2V
M&U)'R ]5$CFG5E(8D%F'=67Y>]N#(9+S6S"G%.?A"P>G.?TK&2+10!;*):Y#
MR7U)>W=ZV4  $GJ,=<5B,D1U!2VX3TCO]HW=X3R1Y9ICH:DQ?]97)$E>#A ;
M'08\Z!D9\OPW!WG\Y?17MZ4S-]ELW%=D14K4X4H4,@>+B@:'!;Y+<%I<8!J.
MRKP([WO'''%'"OHDBF^@*B8E;]R*E'"<8;;'5'KQ4,"*ISN<I/WC9X 5\P_2
MI$0RA+;BEK6"%_*,]*8,CI20M7'4\52)1.A'+@0%I!((Y-512[)"X*G5%EA\
MM+'B)'XO:CA"9338BV'B'&TI/YAU-.+1#(CK9P%M'[T?+]/.K$3(0CR6U(4I
M/? <\\YH )YEUYQ#;BL!(&">E Z+%'>]R&$G*CY#KBI8#_=+962#2 4$O2'
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M_G<N/TI<+[&;G_9GT*Z"8"YT=77QOY%9RT#]I&D?%/\ R112OLM$\P-4+:]
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M*3M2%[MKA/*4_G<Z\^](H;7$>;8#(.Q9\:TN#<A)]73U)]!Y5#^ ['WE]\I
M4KXA;J0I;2?"A..BEGT_NU+9=4-)^\"%;"\9*MR3OVE2O3V;]QZ4NQT,C;WQ
M::*"E2N1C<E:A^'V0.IQUI6%$D(6XTZVZHN#>D$9X4?1(]!3[["BRV/)CMB,
MZ@A*BG*L9)Q\^/R@>OG5/A#2&.];_P#6SG_>%9?Q-."!IY^5!A/S;<X9CCSH
M"XA2$K#0/*U*/EBO*0C4VN/8U2$RF+H](4,+5!0D$!OJ4N*/ )/7U&*:I<@5
M5QTTPN4J:PZAMJ:YA@)20EM:>>GF/3RXYIV W>$QH;B!<)L@0D-[G7V4_>.%
M7&XY_$".":J_D&5)L3+17)3WC\4M]XHORDI3MZA61RI?KZ=** .W7Q"+6Y-2
MU;WV%.>$*3E9 'S('FCR^N:FQ%I8G(;VG_B;?97'UE24-#OMJ$Y/RCGQ*S37
M0$N38KNW-=;N80I3(YC+/A"P 1SG P.*>UWR!62[A(CV^<[>8[+O?MAY+B4>
M:3@ #UQ1?R O3]PLMP@R8K<"0@LQR64D=X&UGJ72>5 ^@IVF,R$1N?#*X9CL
MH2ZI25J6GQNDGC'J/0>59-#[)-WBYCI:#B'7D)W/2 HA;38Z)*>G-9LHS\A=
MI3*;!=*@LA*U-G.P^@]O4U PEREP674M#[OO,A &4;3Z^N:: V6G$27&F9+S
M"I(=2$EE+FQMM&1PCS'O71 F71:2;NQ;W9TSX=IB(V[W9<;;+A03T!W<')\Z
MNQ(IC=I[D*1<U1E-M=YW*@&T* 5Y#-8SZ+11W"UI9BMW)3Q)>RHMMIPK&>I
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MK$!Q]#>7,X4DCH/>IJQV5%[8;1 6Z'""X0<#H:TA&G8FRGMT<,1C(VDJR-H
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M;4A7F"*J%-#SQ:ER1G-,]X<J2?VJZ.:R%)TT\D$-!0!]%57 >9D1'3#OMO\
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MQT\U$5#-$2_C'O\ U3_^/_RJ+^P!0VDVU$-VWI>FXX+K?(<.<[%'\ROZ)KB
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M5M6IE)2I*?)2UCYE>K8./>E? R(S#8@NP82-UN0Y(P7%\J6%=>!E(!Z@<XH
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MJI>/D \O_"IL=#/\0E?[AW_NU.X>TZ&J',@-)LP6](+S@3(:20K><>8'573
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M;N@^E9T;H;U$S&5%3=)"DJ;4YM6&_$I*?,TF729F)J'HCB40W%.0R M&Y'S
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MAEWET?2N3,_VAHAVNDD2Y\A'D>M2P*@PV2^M091U/.VL7V:KHGI2-H&!P*I
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M4J&"L#S*@<9K+00GAE3Z.C69%./!>=LDY#MF<MB"H;DJ!*N#GSKJU;N3:-=
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M':(T9:;_ !^\'<, (80D^-2N!G.1C!\Z:),KKB\.PM2RV0T&$* &Q/"6\#'
M\L^U(<3GUW4T\E#FSO7RX3W7X0/6D4.(:^(A-,2"$;G-QSQ@#I^_2DP+30D9
M]^2V5-NAE2EGO$).6QDC*3Z$\5(C6W(RHS3"(T1IY#CIC[U?RT*/'=CUQU]C
M0^B>F4?;.VBVQ=/Z5;!3(0P;E(+GCR#PGZ^M7$F;*O2L->F--R];O3"AQI2F
M([*CA3BEC:3D_,4CD@4,M"]&0WM07!R1)>6^Y$P'$)22"#U'T\ZBBDZ.LW2X
M,66+%M%N4EK<E/>KW $I2<I(]U*)_:KJA-V9&;<T7"\LQ6F'4OQD+=4^H^$Y
M/*?^+GZ8J)=%Q1]#+!>WM/:%T[II%SV(C6:,V5!7 W)W$9_6O/EBAEDU(Z\>
M66%VD9R;%9+O>Q]3NI65;E '@BO/R>&XIR^D]*/BLXI&FM':3>]-0?AK==U<
M@;B3C..E=&F\,A@5QX.35ZQZETQ$GM^UFDA"+TXCGR-<6JT^3>G9V:2&)8VF
M9WMB[9];7#2;$U%T#BHZN2H<UU:3 I?6=^FU*T,[QHY1;?M*:P0VA*GDK(&"
M1QFO1?A\)\H]W_'5)<QLTMM^U)J9E&QQAM2O,D]:E^'(E^*8I]P+2%]J3417
MGN!GVIQ\-][*7B>DDMK@7T+[7-RM7WRVWBKT"JF6BG#Z69SR^'9%ZH%_#^VY
M=% ;WW0*P>FU'R9?X=X-+V?\O^RUB?;3W.H6Y*D$!0)2?,5/Y?47RQ2\*\'<
M7LN_;@Z%;/M=V%<1#[I5E?4 @8KLQX,AY.;P;![,LE?:KTM,CEL2-JE#'B4"
M*\_Q/39_R\O+7).'P;#O3W%4/M+6"0RY#?N+"E)5X=JD]*^%4/$8Y*=U_?V/
M0_PO2I[MR_F6VF.V]=\D-QX]P2AM*MO*AR*Z<NHUF-I-NC+_  K TY.CJ\O7
MEDMEH^)D3P'=N>#DFO4EXMY6'NV>$O"<D\W$>#'*[<;(TVMP/M%1. 2X,U\R
M_P 1ZB61P4&E^C/:_P#XZIU*R^T'K>)J&>M\O(]/F' ]:]/\/9I9=6YS_OHX
M_%O"WIL/I-?"ND1R8ZE,IHIR0#O'-?=-N<MT4?+1@X1J1+7*07"$N(5]% TY
MIUT5P&E:5?B&?K623-$N!=: $3@<TQ6B-WB/):<_6@+0%.?A(P33M?(4-JX'
M-.T#&"I)5U%)EQ8IL@@@'FA<&MH2^XV@#>,T[0R,E;:PK9X>1UXJX-4R9\P9
M+86D>)*@2K:.#]:E.HR2,Y\QB>9.U2497:!>%'_9O!O]DBOS7QB:EKI/[(_8
M_P ,0V>%P7ZC_91'[[7%I5^1TJJ?!%NUD2/Q5+;H9?H>@=<*<1IBZK;.T_"+
MR3^M?J.IXQ31^0Z#F:.7]BB5+L"U)21+!\)Q7C>&\;CV]5])8*[8XUMN2[-J
M..64)41N2/0]:Z?S#7%G%Y7O1L+'JW3>IF0+?<$/*'DI0S5^?%KL7ER7L1KY
M??X6X4C:K'X<]:YYY;-(HH'-?7-+@[B*V$CWKG\YP=FC@FA2.T&[J5@L-_O5
M+6?8GR42DZVN12"XVVD>H-5^<OV!X4B0WK-Y7\\#;]*/S:^ \HF-:DM,E*T*
M:PI22,D4+57T)XK-%HY+;<)3C:AM4HGK7HZ>:ER>7JHT/W&6_P#%X3P@H)!/
M0XK'59FLR7M1&GAZ#*:&URSJ&?<6G5(+L%2F@K(QG/ ^M:Q@DK9TR@Y(Y'VL
MWP;IS#I&]EL9&<D#=Z'I7)EZY/3T\=O1YEUW<3\5(7)4'$J)(2V-BQ['WKFB
MCMDSE\F2VJ3X4GZ=370CG87\3=94VVE)&!P?>K^X7[$E%Q4ZX''%>()RI7D:
MG?9<'79 N=RAD>([3Y*]*N*]R)Y?8YQJB!;KT7(<B."'1C Y"O<UOCS2@SFR
M88Y3B]_T+/MKDBX6YT[U?=[1SL1^8>]>K@U6[AL\K/HU%6C/H4N.6X3I"84/
MQK#J<%]?7'/J:]#'D3]SAGB<?8DMW E)N3H2J2_X8C 3@H)_$1[5LG?)@J7%
MDA) 'P*W M0&Z4YG&Y77'Z]*"ON,=X'<RB^M#DC*(XQ@-H3R5?T_84FT()/<
MMC>RD=W&_ECS4XKG=_6@!J2<K3%W#E/?3#ZI]*EC0A3RGT-H4D@2$[SD=&QT
MS4V,;6\"/B8R2D('=L@CD9ZJ^GO2$+#RRVE#9REL89 _VSOFH^U #6Y)( PI
MQ@[U'R6X?>D($B1X"R5'8@A2W/S*_)0,<:?+0<4\/O4;5+_?A(]J0T3?X[*_
M*:*+X)LMAR1&"9/>"(5G[I\84Z/0#\(]Z5F18ERVJ:9D/Q5*4^I#*$@<M@ X
MS[>],97W,LNR%"."D*264I<.U*E#KS2 :^$;B!I:'%/;&PE9<Z\^0'M2 C"&
M"75@N%A*@3CJ#CH/:@ %QB:PII:"@)R$%OYAZJ/^5,"/\7"3&,=!*R.!N^97
MN?>@!3SS?=(0MMUK9P#CB@ *4E#6<$E0SSYT %W:"QWKI"#[T ,NR&$M[6V2
M?H.E $-V0M2PD))2#D'UH2$54U:BIPK&#C@&J?0R?I66ZQ)^'>7]P[D%)]<<
M5*NN1,N)K<SOT,(([MO\9Z >E =D1*%H+C:TH"<Y"D^= $9Q@EMPY6,?EH0$
M8;BWWH<5EOCQ]:8$VW-RGR$MKP"K*C[4F!;7 1HD9!AM,K&?O%T#'8TA,?,-
M*5-;G .[1Y CJ/?-92[-(CTU$")$9DG<7G!M6!R14%2*1;C"DK5'1O6"< =:
MU1 2S;G0'9H<:7Y 4 2 &%K&<8SR:;)1.@RVE=XM@EM2? K&,E/MFLFBT:.R
M%=R>0AR8W&<2"&VCX"[@8&Y73=4-&\2QDL08[29S^U3S 4A\%.WQ>6<<&LI&
M\69.ZH+LI%T?BA">4I(\ P1UQYU43#*KY*]I$-YE)>=PO;X4XQCG^M:&-A[W
MT-J;26UI_*!DG_E3&(9=MX0LNP2U^$J3R,_\Z +".RVII;#+84"GPA8SDCJ
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M#=F%[1[9 CRY#UM7*"VOYS#V.6R05$'\W^5*AID'3[=J1-1%L;S:VIA*$,.
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M2@".@3[4 -.H<6\LLI20DX)SYT@&N]PYA06"GKA.13"R5\6E]"4M9('7/%(
MPH;%D_+Y4P(ZV7)+BVTG""D=>!0 A;DMD[$N)7GC*1D?O0!&EK+*-Q/..<4(
M11G[UTJ\E&GV,GPVE(03QGRYH$2T20TC<HG'2D ZA1=//0]* &PTV3O*L '
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M 3]:?E08+))$5R*TMM12SDCTJ7!1Z+61OLI93:]^U3&!BN7(D=$6R*J*A?\
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MAMK"6CO2TD8+RL<GV'G5RX?!";:Y#9/>HW!XJ(<[QU0Z9_+]*F@#4I:EEM.
M92MSG/\ *;'E^M!HAP)1) <([OO5^/\ N,I\_H<4 $&P5+<!.S'?K!XP/P)_
M6JLL26LDH"MH0H*)\\GR^E*QV!Q)Y?*CO5@*I6(<W*]: '+EH2[V9YU:6/B&
M6P2HLY5M&/2I5(R:91QG!NP5I2#R,^=--,'&B:U*0TL*="\>1'2@DD&6[DJ;
M7\WRYH >A3TN!Q+J4J4D9&?6@+'#(PVA9VI6H<I!Y/O0,<1/;3AM;) /J.:
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MJVO/B2$'"34/%"Q_F9D1RYZZ97L>LMP2?/+*LY_:EY, _,Y!HWO6?3^'3O\
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M4B&ZA05C./:BF%Q"DHD+;* V!GS%+:Q-KV(*XDH)RD'-&UDB4QY>?$/WHVM
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MBS*4B0V\AT+1@)SGBB@Z(PB=XL-H;VI0><^M71(YW.TJC!HKW=>:FAV(NI5
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MS18T+[Q?K18Z%)=<QPHTR6AQ+[H3@*H 2I;GS%1H 1W[F[ 5Q0 Z%K(!W&@
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MR?I5;@4&2?[':H_^-.]?_@YVEN*HP>^*E:/ XO'1./.O7L\2B0MY3J0AR(G
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MTNRB>78\A'>H;3N;^1XC(!]QYU,D)C,MYA;'^LM(&?F= P%_0>5- 1O@6E[
M\EKX7;N*B/$/<50RKF3?C@J-!+B&0=F[/*TCUI@)8W,I[MCE0X*QU-,ACG>1
MFDJ7<9.XCHVD^+]:8B+)OLA]OX:$A2&,8)'44NQB85LE2DE*4^%7)'D?K3X
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M4.N 0AO/F<?O2N^!H2ZIMT;%\!SBFBN!CX-$7:EI1&.>*;=@.%T* &!N\S2
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M#2 LY6_X,>>/6B+!C9A.E9<4TA<1"1O.?FQ3L70E3CDE#8;2G[CHAKA>/K0
MR[&7*0[)VK2 27$K^;WS5)@1H[H6<#IY4,$.R$F/WQ""02/*E8"%!@-MNH22
MI9Q]*H!II.Y;B<@9XS3;KD0!"<V-A1VY)(]34W8R9$O"V7?@KDT7(I&" ,D'
MR-2XUR.)8EMI2  OOFB<M+'4#T-0QL2ZTJ.@NJ6DC\(SS20"@XWW:%*(.X9/
MM3 !+:%X"@,ISR: #@LK6%J#KB DDX_#^U58QQ:G'V]Y6E6WS P/VIV2^R*R
M'GU+3YYH? BQCAT,]SR[ZA0QBIW%HAK(95M5X2?(T;@(3ZU%S8W\X\AU%:F9
M'7(=WAR1G<UXA0 ZASOCWJTG'N* %$1F.%<A7/% T/)DMH ,<85^+/I4,NQY
MR[1F4H*AE9/&*$B9,HKW='ITA06<I1PG%4^.!+GD8994N.7 1P:I= ,$$GQ"
MH=C EPI.VA.@H<VA7BXY]ZKLDG--CX8C(S]: ),:0XEC_6QD= <5+'R:K2UJ
M0ZZEYYM*D(25X6<-+ \AZ5DS7&K.JWN0U<=)I2A+,1,A(D(D)1E"0G@-Y/EB
MLG&V:2I(Q-V[2M-6R&A$ N7*Y-IV+RV R!TQOZG'2M5$Q;.?7C6=\OI[N;)4
MW%;.&XK7@:1GU ^8U<(T[);*P,)40G<#GQ=:UZ(JR4TVL#"#C%3)CJNB8PXX
MV=KAZ]*R9:)C> G<".OK6;*LG,R6]P[Q)((Q2H+)<9^'%#FQM02K'E0.R:Q=
M6&W2RPVTM3N >]&4C=Z^W%!:9.,S<.X4$C8@O''RYW8P*96X:1,:@,K4^DJ,
MI[ ; SD>M38]QW[[//V?9/:[<PVE8BMLL)4X\>@YZ'TKBU.HV(VQ8]S/H-V9
M=EFC.R>P"Q:.M(;<<&^;*=_]*>7Y[U="C\H%>'DSRR.ST885%6:P\#('[5C=
MF@C?^8''TH -*T9\*3GZ4 +R3Y4 .,D G)Q0 M9!/!S0 TM3H/@Z4 &WO/*^
MM $A)&!S0 KKTH "VP10)#?P?G0,/NU>6<T & _F@0HE]'BH#@-#SRE86#BB
MADIM9QTH&AU"LYS0,-1'K0)@21CK0(/?C@4%(/[T\I( ]Z !O?'&1^]!($YS
MXNM #O3K0 RLC(Y%  RD\;A^]  PD<[A^] !*<"1D$4 $W* )^E "').3QS0
M CX@^E "T/%0Z4 $M63DT 1Y"SC R: (:0HJ)VGK2?8!/AA^+(;$ON&6V7?B
M7\\M)V^+Z<=*M)]B/--M[=[O,UXWH+0UB@VK1T>*J&$)8!><#8)+KA\\DG]Z
M]3#G='+DTZODPVK)B)NLD-IMH&%#IY<UT/)9"QTCL^E+98K6P_K'4<I,6VVF
M(9DMQ7X$#RP?,XP!YT3:Q(RBG)GGGM#^UGVC=J^I'(^EHS5OTY&66H,= \2&
M!Q@GW(S7%/.Y.F=<(J,>#)ZUO2YT)DW!2V7BG[PD$$FG%E2Z*_LEM34_4"1$
M5O4%;M_L",BAODF-'KR7)@: T*J5,F,L*N&94EQ?*DIQA(3[UT4MABVW,\;]
MI':R+_-7;[(TY*2E:MJY+A"5<\>'SKF5^YM)_!T3L![/;B]-3KW4;LA^3'1B
M#'6UL;:4?-(\Q5P=ND1)4K9ZITC%:BW!A 2DJ1DK4@<$GDG^M=,X\F$9NJ,9
MVI7B%%2\VB RIUQ:D+>4X 0DD=!0G?!7EI\GD:QZ>FW#M&U!99USC-J;F++S
MS^.[[@\C.>O!K*5*7)</2J/5NG>RCL>:TGH[4<7LYT]?&),A-KN%U;@@M+6E
MQ:5G;C*U'<$DG@ ;AS6T^(69X)MY*9XI[8NR>TZ2U-=(EH=[BR(WQTLK!>D)
M=+V4)&>$H1UR1G;UJ(9+[1VY=.URGP<B<T2S)O5Q<@H;1&A-J2IMV067)@*<
M*>:"NH*AD-^2<5U1DF<$\<D4,335@=>B*DW94.*J&GNGFQO*'U.;=Q4>H!ZX
MZ5:E9@^#6Z*GV>--5&U9;8ZHMD0J2AO_ .*"C W-E0Z9QO'FGZFI:-X3V\LU
MKD&-HV$[;E6B1.>D*1-6'' &T=Z?"\P.>\=2%)2I"AA2<^=&TMY6B1IC23+[
M5YN&N&X<",X8ZH\Y,E+*8RU8#2TH/X%>(%)!Y!'E2:KH49V^2FUC;[I;F+YH
MF+)DS9K2"EV&EE+65*((<0,9VE.,9]^@H3^1N7LCFC\),6>];)TQEA32B&W(
MYRA9'^SST(Z@GUJFB')HC0KA(CRDO""V^UE389?02V4] /8CUH&I"V9[ZVDM
MI  3D  =.3Q^E#13E0M3BU[4K2!S\X/-*A67=H7'^/B":O+#&Y96Z? $^:CY
MA'J?:LYFV,[;H2RZ:[+-.N=O7:[;^_MD8E&D+$^0';O*_"YCJ&4\*]//SKEE
M<WMB;.H+?+^!R#6=SU5VAW:Y=H]QG-7>ZW9UR3*0\Z6ULH2G/=-I/A2A*< 8
MY.*Z(M8DHI',V\K<F[977+2]RU(8*(*EK[]A. YELIY'0')XJ[CB]1G*3R^D
M[!IJQVOLITL;D_EZ]7AW9$6^<K:2GYU)\DE?GZXK'))9'P:03Q*WV<N[;.T=
M4AD:+@! S][<5@>(*/*60?1/4XZUT884K9S9\M^DN.Q'LE<:6U>KRT/B9+>\
M(4G/PK1Z$GR<7UQU2G)ZFN'7ZSRU43KT&D\UW([K_9/3?_7(_P"Z?^=>)^9R
M?![GY3'\GBUB81AM+J5J/*2#TK[C:?&63%.)<4%/.)*@,;<\TJH3YX%1VG;D
MOX:,VG&X)4M71)/3]::%1*-D3!<0E<A9"'/$L^1'Y?\ .FQ@+()#16%942 #
MXB,_,?4>W6E04.7""5-A!<W.LI#H6GCCR2!Y#CD54261%.)7&[YG*2IE1*#\
MFXGR^M4!%ANN?&I!VM.*0$Y'0G'04_8!U2Y%O2XB42I145+)_+^6DP*^2['=
M 5 :*2>>*8$I,@.PPMU0VGC)Z5-!^HQW:6AX#E)ZGRQ5#$M1<*4IYM7=J]N#
M0Q "U.9+@(6W_+)\A3 "GF7TA+S;C2@?G JD VPXN*E2HCH )D#9O^J45^(*
M'X:30B6S<(SKJ$.@)7YD^=9R5%1=%@E#+2E/%HELIYXX)K-E6*42J.DM,,K3
MY;OF'M30K'&WG8X[_:0E0QMI@+9[F05J)" KH#0,K%?$PIZEMY*-W!%4!<Q'
M5I;4I>5J7XL#D\UE(8P[ 5&D[W58=4.$GQD4)CVC"K.\=SK*\/J2<N>1JU(D
MBOVUV(EI;N7ROJ$\T]P4&Y;YDIDE*5,A/DH8XI;Z CHBJ;46W?($A7EQ5;K$
MT((26%.%0W#@@^GK34A59$2T'N[QR,GD55V)HBS&DM.X%)L%P)8!5X0H 9JH
M@^"0\P$(^8'Z4^Q$(IYXJ:&+0!LR>"E5"Z L6F^ Z> ><TY-4)1Y-=9--71Y
MY+:VT,-* (3)&WKY\UA*9NG1KH<.Q6Y<6W.+;GR VI(6C(1NST]_I63E3+3.
M;ZOOFJY3G\/O$MY,*,\ON(Y\ 2G/!V]<?6MH-LRD^3*;G/$=U7;)X#"E!/)R
M*+8AYMXIY3_2K4B7$E(EN*X\A0^02)2'UN)R#G%0RMH\W(E!)#2,\\\4MJ8=
M%BV_,2WWZF5X2/$0.!4M(.6&U>&W#N+OZ*/AJ6AK@L$O_$M!&$(VCA2#UI4/
M>2X$I+3;J'<JV#"0>JL]:'P-.R2E26I*4K?0L,@% !_I4,T3/HM]AS4EIAZ+
M=L2U-JNSTGOY+VW^8R1X$_I7D:[%N1Z6CR;3U0W(;>2=KB5#D'!Z5XT5LX/0
MF]_(AQS8@[#D^U,S&#(>QP@_M0-=C:I;@^8$?6@NV!,U8/ S0%DA$Q 'C\Z!
M#B9[0'" :!,<1*0X-PPFBB18<R,@YH*0A1).:!T.MN;<9H ?0H$GF@"1D>M!
M 6U/D10 >#Z4 "@  C/6@!61ZB@ 9'K0 ,CUH (N!/&10 M,EM"<XR:+ <3,
M0H9V4[8!]^D\@@9I (<?41CDT -K6Z?]H* (ZWDDC"A02D*#B >% F@$A8!<
M/2@H/NO:@ BP5<8H <2R$B@ ^[H 4A.T4 $M&3F@!M3>5=* %M(0H]TE8*^F
MT'FI<-S149;4SD_:EJ"(QIG4DZ%? ^\XIJWM1FF5)99:(!=4'.CSBB!D?@_6
MO1G'9C5F&&6_(SS5V.AM6O!,=4$;V).PJXW?2L]/PS;/R74>URU=H#DMY"NZ
M2H*P1P<'->KV><WL3*_[8FNW=,=F5HTA$>$>;?G52I^%8W1T_P M)_K7+JG;
MVFVDC<-_R<P["=.QW-/1+A+94KOD=^KCIGE/]*YL*<&:3=\(I.V&_HF7D_#>
M!MI)0!ZTVK8VZ1TG[).DT3F9-_E#$2&KOWUGY=H]3TK=(P:O@ROV@^U5[5M\
MG084_NK>PXI##+:LYQQFDW0TJ(_81V9(N;R=27Z 'TDI[EMQ/7KS6;;DZ12:
MX;/6MEMCC$9MHQPA*!A(2/"!6V*-&.5V;G2K2&I6]1  !!)\B>E;_OD0^D\^
M]K\FR,WF8+@XIQWO?"VD@E/Z5+G4BG&S@>I]).W+5:KU:9KW<S4-*<2V"<D<
M$''TJLD=Z(NN#U/V)Q[A-^SW<M+IB.*N&G;\!$ =(<2V^$N)4E(Z$*21XN.M
M5&&Z&T7F;6>:>UUUBYZSNDR<]A4]];SYC*!ROH"DGA22022.#S7-AR.ZRGL3
MQQI/$<SUKV=M3!%N6D[^S+DF-W;K8PAQI12 H@*YP1QCJ,5TNOW#"6/_ ,C
M67L\[0[8P\W!T/.G+0E1A[F4J;;45<N>A/OU]JV4SE>!+Z49_46G-:6V3WE[
MMDIN2^5)EE7#DA*R-X)2/#P,?UK1-,YI8\BX$737]YEKD*9C-6PL,_!K0WO(
M=BMHP$JSU6KC*Q@\44B7Y@W;^T74(*HT\,R'&PAV.ZL(4(K@7N*D)5D*4> ,
M].2/.ATD2I2]STG8?[/]H-GB:YOTM<C5=Q0\M2UJ)E2EH3M3#0T@!"BHG)]$
MY]*PDW9O%^YQ2;I75K<F/:UV2% NEYF.17U):^[@H:Z1^? -Z<J_-P,UHG?
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M_<1G4Q@/Q*()H JI'W#Y*GC()Z+Z8/TI] ,K67,Y/-,!LI(YH"PJ0P46 *&
M1P>#4@&VR2K<D^(=*:B%EA;[G)ANE2O'[$T.-]BX+B->8\XEIXH0Z>B7!D#_
M (3Y5DU3&D/J85% ?R7%8S@J"C^XIC)5J<6RX\IV-%.U/>))'()YI2&F:.7(
M9G1H[;K0:W,X5A7RGTK!HW4N"D?8B+44B-M(Y3XN,U5D;41I!9^#*E-[ 3M4
M0.1]*:;L&D(:BM+=.]_(*1BJL21-_A3S*]L9(6X4;MO7PGSJ;*HD_P .C)[M
MQZ*XLH1O4 DD?K18MHINQI>2B;);/<J6>[.,!'UI-C4:*R]P)L"05Q^X>;1C
MO>?$V#T_3WJDQ-#$K3JKE:W[O"4XOX1 4\T1Y9ZU2GM(VV4[#0MSZ92$E("D
M%3>=W(ZFG>XI<'0;,R+U:Y=SC+0T\GQ*'YFA^'Z]>/>L9JG1I%&GLP3,MC4F
M"^R<+"5'(RE6.$_L*S9TQ7!F-;NJ?N[/@2LEM*SMYQD>?I5Q9AG1FU8BQU;T
MY*PK?[5=F4EP>Q.V76.FM,_8I[&+)+<C-R[E9Y$MB''&U;[RE%)<<3Y#:D@K
M/7/%<N.+;-\RBD>&+A<'KA)5+E$[OPMHX:2/( >U>E#'2MG"Y>R(AD*(QMQ5
MH!2 M1ZD>]-O@$.]R^1E)/[U-HJ@VUS&"=F3GKDTG3$^!]$QY'#IP#U\Z6U,
M6YEK$NF4["1M]2/\16;B&YEQ"OH3EI316@\%9/B4/3]*EQ-(Y*-!9)KDF8F/
M'E.,!)!)1Y^B3[UFT;1E9N&;-9M:MR84R,"MH%:7FQ]XRZ$X0?=.>J:14E:,
M-JC1@TK;WYTX)R $!Q'*"HC@ T1D[HSG!)6<]BS)D&;\7;=S<@ 97U1CZ5LT
MGV86TST=]FK0U[[5-96YJ! <83'>2ZZ\/DV@@G)Z#.*\_4Y5")VZ;%ZCZL1X
MZF$H80/NV&D--\^03@U\UDFYS3/9CQ&AU2%;3Q6EB&BVH\#B@ PQCG=DT6 8
M9W=118#C<9)SD4K -41!Z?XT6 !!!Z#^M%@'\($\8_K18!AI0&!2 6(R" 2.
M30 /AVO2@!&U./Y?]*#0;PD]&Z :X'6FLD#'6@S'T1AN&$\T 26FE)/(I@/
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M78'>>U37S.E>X?B_!N%N>V!A312<$']JYLV=8UR7BPN;/JGV4=D6ENR33_\
M ]-PFVE.8+\C:"M>/?RKY_49WEZ/5QXMANO.L8;4N>S9@4H?+4H !!ZTVP%M
MH*E8XI .I9QUQ0 91MZ44 :4*5T% #K;*RGRZT *[@^>* !\.?\ X#0 .Y7[
M4 #N#0 KNSYI%!5H&Q)XV#F@+%I80![T62&&B#D#]J % *'5)% "J #3CSH
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MHK//XE+/7W/6FH*3Y,Y:GR^O<ZUHK[/?Q7PVI>V[4285L"]S5O4HYD+ZI2A
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M;  2HT@%!)% "@DF@ ]AH 4EK(H /9MXQ0 81D=* %A( Z4 )*!F@ ]J* #
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MI[; F2IC,]/>)*0^3E>/(5FU0%?*F!8$=M>0CC=YJI;2DB.E0V*65IVI.#U
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M\T$CH2,B@!92D#.: "RGRH !5CRH +<30).P9/K0,(D^0S0 D[C0 80HC.:
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M+:UX 7NW)'H?^=51);0[5#YCH4Z\V5!*G$8PW[E/G_C54*SIFAOXCI\?$R)
M4&D[E..JP$HP<H)/(2>.*:X&B\U;IM:6W=36UPN0V(_?R(#+.0E*A@J3GE23
MZ#Y3S49%[FB,Q'98F[5LJ+(=:3DX/W1 ZG\W!QQTS6+941%XOD)J[AV)&3W;
M#1W$@Y4O:!^PXS4E#5SN2+K;3 ;DL.K;:46G%#!*>N/W/%)@8J/IJ2B6B0"
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ME84RTM8Z%*2G@=#D5GDG^TIG7LN)G?M'=DVF>U*5<M=]F;2H^L[3)=;O=E"
MT\ZVT0>\[LG(44^-*AX5IX'-<VHTZR)RCV7BRN+VL\W*A*N%U6MME*9 )4RZ
MIK:IMP'J >4\^5>(HO%+D[[W'2K7<(D#1#<B0PI%X=:#,=IMOPN$J.]7YE*)
M\^@J_<J$O2:?LHT9?V]7"X:FMW=N1V@IH%7*"K )_:N?4OBCIT<>;.FZF[4M
M#V>:K3S=R2[,2=JD)&0%_ES7-C@^SHR9%T2678MW4F2SR@("ADY(SZ&NJ*O@
MY9?)H[+ <2T6H_!QN!/)R*Z(JD<LG;,!VVZOBZ<M?P+3Z3(>&YU/7Q8/[5SS
M;;.B'"/+L"Y+N%];277VVGEX>+*]BE _A!'(S[5!5GH"W.*MENAVVU,-Q&'#
M@LI3U/\ >/51]R?.JB2^&;#5%Q<M79;/?D+PM0+8].E:B9X&U,\IU]:PK.7"
M:T1SLZ!V&VI4JZ%\-Y !.:61\%P1ZX[+'6D1Y#$@9)5@5S^Y3.D1TA)2TSQP
M :Z8=&,B#,;*[D!UQ5HS9E.V-Y L;<1Q *(J1)7CYBZ1@9/F .@\J3[HTQ]6
M>5M=S^TG7=K9[+K!<69=MBW5MZWV\QTH?$M:2$E,E&"A.Y62"<9YK*6W%.T:
MP<IQY.<7'[.>J)$"#:^TEV8I<2TOS[IO*>\M4E3B@EA)!VK4L)2K*LG;YUI^
M9DYI+HR\A;&Y=EOJ?[-[F@[3;KA;-6R;G;DJ0B/"G14I4RI:"HY6CA8'N*;F
MF2H-'.IG:-)LDIJ!'3W'<@-/Y2 VMT$[E((\L8X-0X*1>YQ-/<>U_6-JM[;<
M6R]ZVXV%)D.)RD_3'G63PJS59&92;VA:SNH*G;@VRE0R0T@@CZYI+&@<G9G9
M,],M2US[]/D; 2M*%' ]J(0<F4\BBN3,?VLT6@\09+SVX)!6G)//-=#TC?-F
M/YJ-FB?=A-ME]FR[4\;0M.#BH\NN+-G+<N"-)MD>_-J2_9VV6$MG:Z.#N]:I
MORJ,MMF1TU!>C7E4-2RLI44@^M=$GNA9C&.V1V&U6IWX/<\DG;T\JX9L[(,K
MGXY-Q$?'&:42VRWD7JTV7;"RJ7<'.&X+'B=)]3Y ?6K6-HP\PTFD^S?4G:=-
M0Q,>5'@MJ!D)C9#21_N]_59]2.!2G-0123FSUEH+06G]'VQBVVB,VAME  ;2
MGS\ZX,F1OLZX02-=W#7_ %%'_=K'<:T?+ZYQ)D20F;"0&8X0.Z<2@ H)_$>,
M5]RU1\JF.6/4D]GNEJ677"]E2EIRE('4J'H14INQINS7S8[&H$K=9D%U*T?(
M4;?$>4XQU%#7);;HX??XC\"Z2(K[)2I+A"AY;_/'MTJD8]E.ZV4D$IQ4R0T(
M2 I0"L8SR?05D^64CV+]F3L91JQO2L"Z-M-6.,VN_P!]==.QM25*^[CJ4>FY
M ''G6V-U%)?J)JSVO:>S_0TJ[JU1!T_:[9IV0A:(<>&Q\,VX]R I>T!0&<>?
ME71'(VDS-N,?3[E1,-LT+HU_6%TL\:3=77E-Q,#*0[NPAIM!\2U>9-7EELQ;
MO<S:W2I''K[;-4FX/7;54I*;I.'>K&_?M"AT4/P_0=*\_9[LZO,VHREPF0;.
MC;.FMA9]#G/[52R*)C+-B?9D;EJ9HA:8,):@?"%+.T?H.M9O,ES['+DU/'I9
ME;G<[[*\+"T1T#KM2G=^_6L7J84]IP9,V=NMW!EIL"1*63+<+I3T*N:X<F?(
MWPR%#>[GR5DNUE2 48:0E0RD>="FWPSLQQC$P]Q;%PF/(:P@-'"3[UZF%[8^
MH];#I<CCO70TJ-*5&$<NE3B<X-:*NR6^:13367FQM>.2.M:\4+FQ#.U0!].*
M2=BHL&.\#92E1"5=4XXH:L:'4W(1G4]ZQWA'G^6I<1V6+=RWJ*U*RE7(XHV"
ML#TI#*R^A&_>G"D#\0I;2N!YF6R@)$AE/H!CI4T!#EJC!X)92$C/D:N-B(I;
M0X\GO/,U?L [F,XDH6D.*20 #]:0"6;='<+Q!3A"AA \J "FK;0V5%/C3P#Z
M4T##4I9 VGC8#^M(.PD>%2"Z<I/5/K3L5(0^7I2]A2&8R>J_.FA-(AR)K8;,
M:WA6%#"W/S5+I] N!MD1XK2B[A>[D)]#3I10<MCL=#LU:Y4G)"N4I')54IE)
M(N+/9)\Y9*<1FL]%TN!V;*%9++9XI1\*V\Z.5ETGO!_PXX-4DAH0]J=]24)4
MV&FT^%+C"!A&?SY%%DC\.]7 M.E<8N)'A2MM6#_Q 4;@(4VZ%A<IZ,Y)1C#2
M XLJ3Z^=3;'1+ME[B,I<1/@QBX6DY:<6H/!:B,+!!QG--2"D;^RW&,\XNT3G
M'G6]RIA4Z!WK:2,#(_$G.<?2M>*Y V-EG7> N'(,Q16I*@LJ3N:2WC&=I\RG
M@^M0_N--D'4-D@6$BZI4E-KDM..H0'"KN>25ME/X>0#^M<L[3X+3./:DUDZ[
M(:7%C'[Q 0I;?\KN^JDXZY(P34)E676DX,B^RXK<. 7%H0H MY(*<>' //%)
MRHI*SV!]F3[)D_5,Z%J_7<7X>SV\YCL.H(,QS.=BD_D]_6N/49:5(Z(8^.3W
MS"MC3,*+$M\!,:-%0$,,H3A+:1T 'I]:\:]\O4=^)*'1+%K=4=TAYML'GDXJ
M9;4-[FQ#R;5%_P#2+E%/LC)-9.21HH29'=O=H9X1N<]*-R#RY#1OC2^$1ADT
M]R8;&A"K@^L$!I"1Z@]**9/ TJ4^H8[TT#&E%U7S+4?UH"R.L'/B.?K32$V!
M 0,Y IT3;%C;^&FDAH2Y\WZ4Z0P@ ?*BD2Y-,:4=JSBET3;#[Q?YJ=%I<!=^
M?S4Z"A_O6Z*"A(6<\FE0"RL <=:1(27%DX*J!V+W[>2: L >QT- !]^?S4"$
M+>4<850,"5%0R3F@!Q !%2V-!*.#@46,;*5$YIDL?:VCYQFF,=W,?E'[TAA!
MU YHL*"7.0CDG '6A.Q.- B"3/)[H )SG>>@%4L;FZ1#DH<LNXSL6,WWL1/>
M*3X5+5U!]A7H:?32.7-G1,BS%[E/.YP$\DUZT-(_9'GRS7PF55PO "E-CE1)
M(^E>IAQ0@O4<N24F0+?&E3))6XA11TSNQ@GV\ZVE*/L913]R=?K]9=#1DR+U
M*4EY:0&F&U)+SI]4I\AZJ5A(\S7,LKFZJBMC?1XD^T=]N!D3'M/Z(8%QN;"C
M\*VR>]BQGDY 62 1)>3Y#^4A6#DFL]0X8U:=LZ\,*]-<G!>QO0-UU-KB+J35
M-RE+2N2F8XS)>!0VZ?$I3ZNBU$Y('0=*\_#E>IGLAV=RP^6MV3H]!=OWVH[#
M;DO:;[((,)J]NQ40KGJM+:2\MM \++''(3DX4>$^6:^[\'_#N;.O/U3]-=?/
MW^3YS6^*:?3Y9*/LSS]V1ZA@ZID2;+=+F7+O;RI1+B_O) 4<AQ2CU/(!]Z^5
M_$GA?Y'+NQJH/W/;\.U#U"4I/AG1[-?+K'NC+,:3#;BV&$HI>[L+=<>!)X40
M<!.?E'6OGE*-'?'ATC7:;UU.BVK5-_E394J3!99@]Z_'[DEYY.X!*>AVCS\Z
MY\T7)HZ,<]B;1PT7#NKI_$I1)[UPNK*N2I6>N:TJEP8*7R>D^S^_J=MS:5+)
M6&PHG^[Z5FFU(WX<383.U-K3UMD.LVYM;K;2@E:R0 K'!IRR2]F1LCVT>4=>
M:TN^K;LY<+FHE2L@#CIGVJ7T-<C?9S %SU1$;[L$-Y412?0UV>A6T)?OT=M0
M!+3:/WK2'1GD=-#_ &^S$VWLX,9)VAWQX]3TIINRI?2>&+NLN;$IZK436Z.4
M]!_9]LA:BKE%O_99S_C49&;05([]HN*AE/?I3@*<-9)6-T;Z%.V+#A1D^M;1
MLSDD.V]I4V8J6Z-J 3UK7I'/[F![6 );+D9U85W@'>^Z16,I,Z8JEP<%[/H;
MUW[5Y*+5J.!96;?;Y-T_B$QCO([+C0!;2XD<J!(QCKSQ6>Q2Y+4WTB9>KJ]K
MK2MNU U<FKDO6EPCRG'V&E,M!(5W9:0V?$E* DI\1)Y-:1;4MK,YI5:-=VL6
MU+5@B+*$_P"KRTI3QSG81SZU+I,TBN+/#.KM/B<_<&4MC:77" /7/7ZUK%F,
MC9]F,]5RL8LDX[^Y3W0*^<42YY",FE0B[:/O3LOX"V6]MYW<3O6=J=GJ3T&*
MF325E0W2=,Q4NP)BSYL5*$NO)&%AOY%''X3YU2>RG$F4=S:9P=_O&I3H(*5I
M</Z$&O17,>3SY*I':T!V7I^WR02HO1T*63YG'->9-)3/1Q?2*6XMJW*2@$)(
MZ4Y)2E3*3X*S1UA>N%X5.#.0%$BKE*HTNC-H[8S8Y?\ #T=Q#*M[96LD?(!Y
MUR2]7".B#I'&-4:H<D7O^!Z=)^*<=V*E(Y./[GE71BQTKD99,DO9G8>R;LCC
MK=;D7,ALN-]Y-DJ\2U^V3YFIR9:0L<+[/5&E(E@LML9C0%);::3@!6$<>E>;
MDDY,]&$(I%ZK7.E+4 T]=&2OR0V"XO/H D<UGMDR[2$?](\'_P!53O\ Y3<_
MY4;![CPE<M.V:7;A;VK].1".#M2D*V>'.W'OUK[[:CY0RIT<4#;;G?B&%K D
MME("PD<9 Z@4M@FZ+B!+L5@4+=%"T* W(RI2G4GW!\JSEP:+E&0[3+7\1':O
M<:$H2,J[\J&,IXP=OEYU*9$D<RD*"U82LK2!P30W8(9"\(4D#D^?Z5E)\-#]
MSZR?9GNG8^=!VN(U<5M3KO#BNMN3F0(!>0V!M2L=5)(QXN :3DH<FL(MG6NU
M>Q.QK';[B]+=8A*DM?');4E3LE/4=V4>$#//%=6'-":Y,<N%J3DCS=VK]O,6
MTWKN=,PVY=S@*4(:%GO4-*/"WE'H%#RK//K(.5(X99/+[.%:@U]JF\*[VXW9
M[D[MC:ADY]:XIYV82U.[HRLB].!.XJ4@^YW5R3SLYIN4AAN[/J<"(_+BSA.3
MU/UKG\S?^O\ H$(M=DAI4@DER0E*EY#:5<Y5Y@GUH>*3]4O]#HI-45$FZ.-G
MNW<?-R4]*G=M=%*"11WR]):CE2I);!.$G&?%Y<5U8L6]V:0AO:1A42F675(5
M,[TJ5O(V;<&O27JCM/H\&IC'%L+"-N5O?;)5G'Z55TJ.)XZDY?(BXVXSXY[A
MM(D)&<$?,GS_ %I*1+1GF6S'7L=:VD'Y2/$/K6D2&B6_)!3AOPIQT'K5 0C(
M=;R1G!Z^]5=*R'\"T2_ ![=*I--"LEL2D+1@.$/>2O,5-%6'\4M7\Q95]32V
MA8^A(?5NVY/D4U/10XN,H#=YIYII@-)$=*L8"%D_,.M.A625-[5CN6PDKZK'
M4T#&W[<\X2V1O*N>:5@T!,9,4;2MU][&$HSD?K0 E]L14IEW)Q"1Y,M_,*+H
M"N??D7)00W_*_"GV]_>FE:);&WFS&&T':O'*15=="! MLJZ/I2AD[<^)1X"?
M?WJ.^RNC3VZ!;K?)[IMU+LA''>*'&?:I91>HMDB8\AM^:@M;%+4O=@ ^F//'
M[4"'FXX5([Q+KR@@!3!S\X'!'THLM$>Y,J6H.EC8XCE3F_P%)Z)V^9]Z@5 F
M,O,.;@^&U@) 2',]W_V>@_2@**N7*DH6 \VI/='"B#D;OS$^?TI@/P$]^XF<
M27,$)//)]/K]*$P.DZ.BQW[Q!2JX+:D%82'D\J;/JHG\/&!^]:H3-OKBY6UG
M4C^EYZI#:V4H<*DY;"_ ",J]%'S'ZU$WS0T2(,*5JWLQN5BD2@W+6[\:T4+!
M=&P\M@]#N&0/:LYK@I'*6H5G>N*F(UJ4XZ8P7WCJ<#KR%'H.F.*YT^&4CV?]
MDCL=B:@:&L]2Q$1(#",QXT9K8J2H8_%YI/\ E7#J,VP[,,+/;\*\1841ABVV
M%,=#300C=X@E/7;BO+GG<F=L<5(5(U%=G492\VQ[H&W^E9HNJ*UZ9*DY^(DK
M=)ZDJSFLI&L9(996A).T"L6;*2'@ZRGH@"K\LS\U#J7FB@@ <TUCIDRR)H2E
MS'3(K8Y[%=XKR4::0]P-[GYS5;0W RH]3FI:H+L2I6T4@&TO$9\5-%(6%E?.
M:8PMR@<9I,SEV'UY--"$[#[T&BZ#V)_**!B-JO4T *W'UH +O0.2:D@=0ZE0
MX'- PR2>IH$&@ GF@!?A3U H 0I2?("@ MWIQ0 XA1QUJ64A*UX4<FD,(.^]
M42QP$D4PL7L/K4%!=PL\ GFBK#H>:LK6U4B[NK;92,A*?Q^U=>GT^YG-EU%+
M@>,Q#B1#MT8LM=-I&"OZU[>'1J-2/.R:AO@LDHCPVT*F*"2>F:]+'BC'LXYR
ME+HCSK@H_<QB=IZX]*[(;3%)KED1-N*R9DQ2&6VT[E/.KVH;2/-7M]:SF^>2
MKLY;VM?:CT3V4VU3L.>EIU]):9=4C<_(<'E%8^8Y\W%X0GCK64]D.9O]#3'C
M^3Y_=IO;_P!I?;;=)MLM03&A/+V+B?$JQLZDRWQRO(YV)PCVKBS:B<E25([(
MP*!FQ:<T-;G[Y=9R(K:$!+DM]6XCT0RCSYZ)'ZUPJ$\[VXWR=,=F%;GV9Z'V
MEZDUK,7$L >L^G4C:YA>'IRO,NJ_"D_E%?H'X:_#D8R6;,CY?QOQG=!X<+]1
M+F2@M.QLX4G@D>9%?H3DK:AU]OZ'RN+ W"*S\SKFR$- :SV1.T+3T&0PVU)3
M';=2G*I[A/,=E!([TD=<<)\R*^*_$4])*#PS=M^WP?6^&X\T8I1Z.MZ:UG/M
MK\+5%N89DM,M*<1'<'@,A .6G?H01^E?E^7 H-T?2P;1I;3JB[ZE[*+1J"\0
M8]ON>I7)5WDQHR5)93]Z4H3A9/X0<5S.E*D=$9-PMF%N4=[N"M:,C.$Y\JNC
M,['V-7.1<(BW'%**6V]AR?("L<BHWQNQ?:)=2JU?!AT@+6"H ]<'SK+W-&CC
M,DM//X!P <'V%,GHZ1V+VEH7E4Q)"@A'S?K28D=<TJW_ !#53O.X#@9\L=*V
MAT92?**'[5T]4;3T:V-$]XZH)V^B?,T1[+G])XYDM=]/:9;/!<P/I6Z.8]>=
MD=C=@:2"6!E]\#D=4)K*;.B*X.L6MIED(;C$=V@#IYGS-$%:(DZ9?L!1 *20
M.HKHBC%LT]OC-,02V\K)5S2D**Y.5=II9"9<I;R(VS.%J4$I0 .I)X '4D^5
M8/G@ZE'@X[I?LTD]I2YNJ=*Z75+L\YAI+KMUE"!'GK;<Y4PVG+CC"L8"U; K
MJ/*HGE6GXD$,3ERBSE6?44#M+TMI+4FE';+">N"W[6I 2J$YL;24L!U/'>A.
M3M/*N5>M5!J:WHB<&G3)W;[J2VV6PL0E*"I,^0Y(81C(V).TD'V.:GMFL>(G
MD6X]TW(>?4E3@<45''4$U:9C(L-"Z8N<]WXJ*!;X <W/2%<<>@'XC[56Y$J-
MG99%BMLF$(\M[N \D)25\*4D#J1Y9\ZF;]-FD54D<S>TI"F2US[*RB,PRX6$
MEP8"L'*B/8TYND@C&Y.CR!JDMKU)="PA"6TRW<! PG&['%>O&G%4>7/B3.ZZ
M*LT:5V?V:3*N!2XMDG81G"=QQ7F9^)G?@_R^0XNG3<3)B!;I0A6$+1^+]#Q4
MR?-C7)H[?IVW:6LPN-WO'\'AM*'>R'D!)6?)* .5GV%3N<G2*I)6S(ZO[469
M<1^QZ%M\H*FH4RNX2PHJ>1YI::/RCW/-:8\>SF1$W71;]C/8W<5SF;K<XJQ(
M>.YAI0R&_4GWI9<Z2'#&YL]>:8T-'@PV670E65!PC'57K]:\N6:ST(XDC;Q=
M)P^Z*I#9EJ5\C;@R$FLG-LV44D7,'3]KM["I7P,=LM)*]@;'E2ML*1"_ME#_
M "II[2;/G5'M>J9,CO;/IZ8RMW&5N>!''GZ>=?H*BV?)[R]M^D=31'%7"8AA
MNX+PVI1?0E*D$]15[&A;T3SHZ_HELW"3_#%@I +JW@MQ/T(ZU$H,>\:OND+H
ME4@7 Q9,9Q RI2L.<].*GRQ;MQP?4W9[J*U2W7&;8^]%)*DNMI\.*QGC?L6F
M9MQI\J0RII2,';XDX.ZI?:3$JL]Q_9OT]$8[ [+(U(E]Z/<)<U;/=.G<SR,>
M'R&.:G:MJLTY]C4I[5-0Z$MEST_ NKMRM$]26&$2,E4 +.U3S>>AVYX'UK)O
M8VD9RDWPSE>LM.W6VSKO F1?A56Q_P"'>+1VEQQ7*>>IRFN+-%MG'FQ;S +@
M/@DN1U)Y..:Y'9PK$U8]9X"W+Q#9<&4*?"U)]4@Y(_:I46V7IX>KD[5J/LDA
M:DL,S5ND6V[?<8X3)3:W4A7Q#)\/>#;\B_[OIS7=L2]CUIX$^D<9?;>;=<BW
M".8SP5AU@_,EP="*-M\'.\.TCR+&[,1\2W'*=^ L>0]*QEA5B<2MNVBI4MH)
M0HMG(.0G-=&+T<A&+3,U.[,YKB%J7<%Y )&Y('-=2R*CK@:"#H)3*TMK>2H!
MM/ ']VGNLZ-P:-)HCK0\LD[<\5+92HBW[2,&>V'VH2&U#^<M1P=OK1&3(R-&
M2F:)EQY!2EV.8Y 4@E1S@UNI\'.D[(<S3I::\*DD#S2<BJ4K*91R+>XP3DG&
M:M13(W#;9 .1UJT!,#J3^$4F@'V949*2 LI^AJ**L?:D0E#!?7S[FB@LFK-K
M2E"EN)2/S$4N0 Y=K/&;[I"%O+\B**!NR(N\NJ.Y"U*;/!;;3E9'IGRIO@0&
MW[P^2F"PB$TKJ5#<LCW)Y%3ZK M8Z=,-QU"[*#C_ !XFR5N$^PJ[0N2,+:[+
M418[:J.C/5PY4L?F]OI4MH:$OVV##?2I]>Y_ W!7-+</@FAY;A8CLH1LP? D
M8-&YE5[DR/:&T*7/=1R/#A?5/T'G1R%EU9XB'I3,HA"W4-E&'6R 4>9/^%:*
M(6:)F!:[DI*&S(82V-L9&SQGU0!Y<<[C3V)A9-G=FXFMM)84 ^R.6T((<3[E
M*NN/3S%-X2/,*EW0=P$>/&O$-IUMY14S@%"LI/"MW5/T/%0\30_,LJ]0:;(+
ML,M/N*[P#NT-^$<>>.GUZ5#A15F;BI5;5JB2XRU(</=A24Y"2>@(\ZG;0'6^
MSJ-*5J!AEMPJ=0MHLGNP0XH<["/,8SQ3]P,]K'6$F\=H-SN/>%2EOO,E#B<]
MVALG(!Z!/D!Z5$G;'$VO91?$_P!H"Y-9^'0V0R^@CP*5M\&T=//R]:EFJ.AV
M'LA<UAJRW:8:@*$>0^L[N@+&=REY]0,UR9);$:0C;/H/IVP6VQVN+9K7'#,:
M$TAEM 0 ,)2!D8]>N:\#-)RGV>E!4B]2A2!M"L5DUR:6(=:W#Q<_6ER V&L#
M  HH NZ]*=(>YCH:&1T_:M:1F/[$] D?M3H @T <XI4@ L #I0QKL12+I!*H
M7),N!)YZTZ1(A2 3QQ29<1;:=J<4BA*UA*L8H ,'(S0 L=*DEB3UH %   &1
MQ0(#B$$8( 'M0 U\.GYD.'/UH'R'W:T>(J)_6@!2)(0<$4 B0EU+HX XH 6E
M 5Y"E5C3H/NAZ"BF/<* "1BE06$6TJ.:*'8H-)QR!^U/:TK%8H-_2H>51'8Z
MQ&?DO"/% )]ZJ*>5T@G4%;+!8M]I"D2C\1+P?"/Y:3Z@^=>MIO#Y.FSS\FL2
MM%;)F/2P.]*M@].2/H*]S%I*?1YT\Y7N:ACV^&F?L;<()2.\5@CRX]Z]*&%.
M-''*=LJ$W+4-^=+C<A3+!Z/N)&\'R\/3/IZUJ\.U$;Z'K]J[3VBF7';M=$.2
M&&^]$1*PA2 !RMQ:O"PD_P!_]*YI9;>U%XX2R.CQIVV_;1>ODM^T:%V7!,=P
ME!RK^&PW/]Z K"I+@\B<('4"N*>JQX.%RSKQZ?:SS#=+KJB1K>,]JAV5=9-T
M_P!8>DN9>D2TJ/'<[?"A()R4= D$GRKA=N\DF=CC37!=ZLU=I7LMB*M\>*R+
MBL[F(+ &]U9ZJ7^5!/F?+I5:33Y]=E48+@K49,>"%G(9;5_UY<A>]621M0<,
M149#3*?1"?\ /J:_0O#/!(:>E-+]3Y/7>)SRK]GT;&U05)0U#AL*P2$;$CYB
M>F .M?5JL$>?I/)QXWGEQV=EL?9I;M)-1+IVAP53)\J(NXQ=."0&G5M @(=D
M*/1M9\*66R75\XQBOE?%OQ'#%NP:?V]SW-+X:^'-'HW2OV?]07V3_;#MJ;9:
M_AV?@-*LMM]SW2DCNFR4G[IH$D!*?$K&5'DU\5NGK,KG-VSW<:6))(XEVO\
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M6S&A2[F HM65A(<6M?S;WE#.,$\J//' KITGA^;Q&2;340S9XX8=G&)\J_\
M:#=3<M63.^VE)8C()$>-QT2GWXY/)\Z_1/#/!L>D@K[/DM5KY:J3QPE5<W\_
MH7L""IC:RTWDK4$A&!R2<8'U\J^CCC4,?''W/'Q3E*>U1MGI[L;^RE*F%G5'
M:E;9+<5)#D6P)442I9_#WZNK37JD>)7L.:^0\6_$<8/\OI&G+W?LOC^/P?2:
M'PKS/VF9575GM/1NED65IB>_;8\;X9L)C18[:1'AH X2V@<!(]3D^M?&U+/)
MY,LN?O\ WT?11:A'8D65QNWQ7>S5NI*=V%'R)]:BW+EJBHI1565+LUF2U\+$
MP9,H'8@=5$>E5NV]$M?!PWM4[;H>D[>K35I;-WU(TZ6W("G<,15G\<A2>0!U
M#:?$?/ JE+BV1*27!YON"KI?KNYJ#4,U=SN;I#:WUHP$#\ :1T0V/)(_6K7/
M)RR;]CS#VUW95R[2KMW+Z768"FX*-O16U/(_16?WK:*IF,G9ST#/Q#PY435-
M?!*%L*4EI3^ 2@$@&FW2LGW.EV.,Q:M,0#)0'2E!<*">,GG%6GM@-<LP%YNS
MTB[KN"W%!:%A:%))0MK!X"2/2L9Q4^QIM=';>QG[3NL]).1[7JN,]?\ 2JI9
MDS4(4G^(/$C@J>/+N,?*H_K7%/2*:NCJQZAPXDSU]H"_:0[0K^_K32DM5PME
MW;#R5]VH&.[L\;*D_A6G R!]:\_+B\L[,>3=RCM;MP1!T,[+1(2H=RIM//0C
MJ/ZUA>_HWW)/D\,W]]$C4DN4XH$%Q1(_6KCT9R=GH+[.&GB^R]=TJQDJ"3[
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M.$U2*0ZDY2#02PE<=:"D-E*ARD4 *ROTH /<D\9H !V@=:!#1^;- P*&1Q0
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MEW5>H9K:3)&$-@^".C'RI'JJLW*^$:I>[*46R[]IU[1"D.OVO1\+F7CPN3$
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MXEL[FELJ6T=IP4*!PKZC'^-:/EDQ?L=+[1=/MW?3\;4$!E#;DR.AQ;".1PD
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M,]@_88[+.SC34"[-L6EF-K$.%UR0OEY^,>H:4>4(0<;@GDDCG&:Z<FNR:A+
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MI4Z_=IC<2(^EO 4LJ!VN9ZJ03SZBO3ROR^&>9C6]GT8C6]J,[;^SKL\_UC^
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M=Z0&64D^?%.V*AA"5,$+22E9Z^U"X#L>:DK2=RE;CG/-/L*'_C!+>"%M-@X
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M<'R-*K&N!#LAQX>+'%-(!"'7"D@\8XXH$1EN*;)\1/GS0 Y&<6[A7&,U2YY
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MHKX>@KFZ5&SWZ,^TDD;GF5(5_P"]S2=>Z$MWLQF1I'M2;=Q;-+V>2D?C<N@
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M(1V=07EE:F4-->1XYI.:GT)0:&W-/6RW$MB.ZXK\/=)X/UK-EK@>9M,F1%5
MF0N[:<.3L& H>6?>L90MVC:,J5,EP]-1VV4QT14 )]12VLI218M:89?0IZ<
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M"4)P4<@CR)KH71@3(]QCJ5N('-4,>;D1U2N]&?O/NN/2I8F6;,4IEH,B5X$
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MX72YQU)9.U !W'IQ6RBHG);R*Q6E=%STJM-Z=>3);<D%Q2#PEE",'*E>9.,
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M7=*V?!SM@TZYI[7FIM+.Y"K7=I44E0Q\KJAYU];I7<$>)G5R9@4VA9;></\
MLTGCWKN;2.%Q9N.T+LMO5B8LC%EMLB5#?M3$]V2!PZZXG>O'_",)_2L(2W<&
MV7%LJCF[\&9'=++\5U"T]4E)S52BUVC%.QL-J4-R1TJ]C:N(7[,6B4^WP%G
MZ FA9)0[%M3)+,Q!"BK.\I(K>.5,AQ:)S"2[&002?I6R=HFQ07X@D^5# ;2K
M;(4KKBBK DVUG8\MS/S*SUI4!9H=ROI0,?6V'\8/7WH <+3<9ASU'F*0%)&E
M):E!0Z*JJ$B\C+:DMG!Q^M(9C+P%BXJ)Y.1BN;,GN3+CT2[:XZM<ONT+R0C>
M$_-C>.GO6CE:=$M47%NF-Q53E/%Y#9E-A2"/%M]./Z56-I6(NX#-C[QRXO/.
M,QX[*S)*TY"FB>$@>9/05JW7+%1%E1CJK2AOD12F/X9+4T(P^0-*'@_48Y/O
M4Q]:W,?7!#AI#*6TK'B<&XT,#11($>44QF0"TL%QY)ZG;\N#ZY-(#I>EXT31
MUC27U!-RGX6Z1T0V3X4_7'6GTBD2$ER0DAM)[LK)!]>:199(4B%'4ZD95MJT
M2S+,1V+C<'[E-ZH/AS]*:Y('9,@-D!'('3SIL!E#BTI*G1P3D4R1Q,QM'( H
ML#G^N;U)G2A$;(&T@]>*Q<W'AE;=_)/[*NT[778[J4WC1<YT2)N$R[:]S%GM
M>:'$ "A U[_TP/)?45S9=/'419<,KQM)'T-T5]H/2':7HEJ_6%*VID="6[I!
M*O'"?/&TCJM)/18ZBO"UNG\A5$]?2Y;?)Q?^T"O1?[&O,Y/0WGDZ5<$7*W/V
M^?\ RGAM..H/D:^QC#UV?-Y)>FCT;]B&\)@M7OLZDOMX<<3<H:=PSTPM(]>H
MKQ_$L'JWH^A\(U"CC>/^)[1@1PVR!GJ 1]*XM/.N#KS<NR61M!H7,F9WP,2G
M>X8+P\CBM$)#+KN]MM:C@GGFJ?0XD2_**F4!OQ8'..:B'9HBA05=2#BM'V7?
M!8-1G7;>XHG&_P (!\Q32(;+"TM2ID/X*VQT)<2,&0>HQ279.^A+^F8D?QK3
MWD@]5.<UO%">7V($N EHY5Y>56S-,9"8RFE@(R<8Q6$WM5FT;?!C&M2N0;E+
MM:%A++61D],GRK%RODWBJX)5NU+;]3ONV-:D!UE&$DJ'/TK3'R^3GR0]T45T
MTA=8CZTLK)0H%0 'EZ_2G-((*1$MMDO*25*<[Q)X3MYQ6&Q,Z5-Q^HT#%DG/
M-%+CH24D<'BGY/P)9(-\B9EF@Z@MK^G=36R/=+7)26GX[@Y Q\R5>1^E$-V%
M\%988L\=K/)W:Q]C/4-E,F^]ECPNT,$K^ 43W\= \AGA8],UZV'4IKD^<U7A
ML\3W0Z/.5UMS]F>7;[Q!>A3 H!UB0WW:TGW2>E=JG%H\UN<>)#K4=#4HAOY>
MZXQYBJLEJQR&J1+4(S;J4R3PV2?Z5+*719S7>YBLMK0K&=JG,>+/TI")-FB/
M*BR5H[A:&74H=WJQM03R3Z#%,HGOV[X,]QL2E046H[FQ2P^#U (Z$>] (TVK
M7EZ/T*SI^ CNI]W:5WCQX4ML<DX]3\OZTWT#9B->_#VD0]/,(0U\'%1(?;00
M4AYU&21].E4N#.7*)>C!)A]GEVD.IW,7)UF-A710')QZXQ4W:+151YD*,$QD
M2-K*5*2RXLX._/RG^[2)79-:$]UPJ2\,=XD,AK!WA71!/X4YY%!9T#L\F2&[
MW%MES4T5/2DLH6) 4ME7 44'S.>"CTI.ZXY+Q14\BC+H]!]IGVC]#=E=E&BM
M"N-W&>PG$ES=M:2\?G&>JB".<<<\5GC_  ]GU+\W6/:O:CZ7_&,7AV/RL/9Y
MMN?VG=97Z:/C6F@VH[4=PC:0/.EJ/!<6-6I;ON88O'G.6QDXZPGJ_F.%2>N2
M<]>>M>/+31@Z1ZJU,<D;:&V;E>+EWO=;E)*TD8&>*-JB82R2EUT:G3VG4.GX
MRY/E1/(%)R^#!Q?;+"1I:Z7ZX*AVR&MF G_TB6\=K03Z(!Y4:ZL>FEF=LY<F
MHAC51-E'M,*UVYFVVY]3S3*<*4KS/K7K8L:PQH\;49I996NB&4%"RA0P#ZU9
MCV(CN(CE20HISYBA"(\NT0+BE0=:"L^8ZTF@,O*T/>82E2K)*.T'/=J\JF@"
MA7^Y6DJ;OMN"=V '2,#CKS34J OXTR!/0'+>^'"H95@YP:;=@24QW=N5&BAC
MB&N[!W'DTZ$(*5@D#\5%#"<#C120E1_2D \E/Q,8MJXSZTP$/PTI ;W#BE0>
MXKX)H)"N^.3Y4^@[%]T$C8E0!HNPH,E((2M.<#.?*J4$*A*2E2@YY'@'R-.D
M@J@WTE7"?.E=C8PLN,HVYI"%L.+6G/7G'%+W&G2)$J9:K#:'M6:EN*(%IC$H
M+JT;N^<'/=H'XE^WE52DHKDS2;96:7[2.T*_*1>M ]FU@L=A0I15?M7/'NBD
M=%)22"/HD*%<L]92\M'3#&WR=]TI8>T36EF1J#M-[=;\=+O1E-Q[=IF W9$W
M'S6AI9^^$?'"GAA2AP,US*:B[-G@<D<N[6_M"6W35H3H7LPMT>VVB$GX5AN,
MR4L15]%D%.=SA\W%'<KSK'+GE+]#;'#8N# =CVL]'V65.N6J=47(RYCZ5.1D
M@AI\>KIZK3Z(SM]17!/)D?THZX**^IGI&R]M-C>C 6:],I&?]D0V/\JS<FNS
M9*+Z-$UK^7</$+SO&,G#IZ5#R%;$<V[1-<ZNER4,VR4[$M9_ENMY"WU>:O8"
MA4UR9MM=&$8N^HWWBXS<%A8SN>=<QBG20;F&YKJYV?\ U6+(5-?4>7%<A/ZT
MZ3%N:Z$*[4M5QP [>%C/1 5P*-B8;VA"NUC43XV.75P@=.:?EH/,8PYV@W5T
M9>N+A\@,U2@A;V17]97);2NZ>7R<97QS1M0.;*]VZS(R!.E_>O$_= _A]Z$D
M)M]L6FX/3'$E2RI2N2?/-%4%V5NI0M;@:4<;.OM3C\B]S7]A&CG+WJ3XM:5+
M1#RYD#(P.:G-RC2$;9C.W;M(@/7V9#MSS8@VR24N2DJ!;<=\TI3YX\JUT^%R
M7)GGG'!])YSO6O;E<7E_!K4PDJ_F_P"T4/<=!^E>GCQ**/+RZB60J8MO?F$W
M&<M1;420I75T^@]:WBO=G/\ 8NK789ESF1[3#C*>F7!:6(C83DK6M6U('U)
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MD-NMH>>"PI6%X0KNP?NSM]>3FHAI%+U;:-)9J]Q;/8#.9*UQ+D8RUJ2=[;.
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M_P"M>0Y*35'IJDJ&VD/H*GDK*%GCCGBJL35A!U07\JRL]30V)1:9,9[ULAS
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M[$Z1=6C3C@*5NY6KS5ZUT)6K,<N2S3B Q'B*"@,@>E:Q7!R6[,9<X*530\A
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M'!\.!X%_E^M=4,F[A]F;C1JG0R6RXWA2%IW)QYBM&B3,7%"7&_$-J03P?.A
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MW$#D%/H12: LM)VR+(>=DQ65-..H4<MJVA(Z# _K510%E-1(M,HMVYP37GD
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M:6&XSJ >$K;&T_O7@9H>5D\I=,^EQOS8QR/V*7M#ODMB\N0X3A!F 8QY ?\
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M[.,L65@ISU-(1,#Q3N 1G &*0$B*VX1N=2G'48%% BR;"E)26T$J]J*-(EU
M><2C:ZD^76DS==&ALC7>N[QC:DC.:SGQ(2Z.&=H"(<?6=V:;2M/^L$CQ<<@9
M_K6T91NF<CLSQ!S\X-6(%-"%H0M8RE)('4@CBGS\ 6-HT_>;[*1!LEIEW%]:
ML!$9I3A_]Z,"C[!1W'0WV*.W/583(N%JAZ;AG!^(NCP1Q_P#FJVS^**4+.X:
M3^P]V664A_7>LI^J);>%*BPD]PP,?WAS4J,5]3LV6*7P=NTKIK0FA(J6-!=G
M]KMFP?SRP%/*_P")9Y-'F17THM8'[FB_M#(?5NN;BUM]"WN\/M@>5<^9RDN#
MMT\8Q?);,/-F*9$="G4IY+8(SCZUX\L61RY/666$(^E<ES:]+S;TQ'GO@QX$
MMPLLN ;E+\E;!^;R]LYI[7'EG+DS[^&=@<[-TR=.HMR(XB. !<5@*RA@)& W
MGS*NI]S663+N5&>-1PRW1?9Y^UV95LMTJV.!3:@Z&WATR0>GU%=6C+UO*LY^
M G=C)\/2O5OD\M\DA+BPD!*#@Y.0K'2M'R@,)]HR!\8_IB_L*!^*M2F5\Y\;
M;A _I6,9_M-IE./N<>2AA1P72/:MI<,P7 OND-'<IQ*QY;58P/IUJ99%%6"3
M;-]V?]C?:;VB/-LZ7TA+DLN'!E/)+;('_$:Y9Z^&/MG1' V>F^SW[ ##0;F=
MH6HW)1*DDPH"-@ SSE9YQ7ES\3<S2&F<>ST[HKL?[->SR*F-I[3$2,XE.WOP
M@%T_5?4UYV7+*?-G?#$HFS2MHN>$[ 1M.W'(]\UBIS]S1PC7 LH1NR%**?05
M6Y-$;&G8X7HR48PK)XI<#Y(DJ-QW@<5X@0$@]?K]*EPE*G'V*4DN&?.3_2=?
M9>9DVQ7VDM&0 BX0E-LZK0U\TA@D(;E; /F0>%JZX(/E7KZ/4[O1(X,^/;ZD
M>>_LJ_:.UI:=&WO[/+%^*+9>RY,MTG/WC*@DJ>:1_P :><?W3ZUZN+!CED4Y
M=G.\KC!HZ]]G3[/#';7J@Z^UQ#6KL^L,P,1("DG9>YJ.2%'S80<9/12N/6N?
MQ3Q*..'E1X96ATLLTM\NCWLTXAP(92R&DA(&Q'" D# 0 /"0  .G'E7R"4T]
MK9[TE%NT?/3[9O:SK*]=L%]TQ(N,RWV32Q_@L..P[W;C@4TEQYW<.=R]P3GR
M"<5])H(*,$>9G=29Y+@R(<"8P[%RIY2B3O/(0?Q?7%>PVN#C37)26M^%;7Y]
MRG2TMI;=6I*B,[Q^' IY'Z3#<MQK8<QYVQ1'76TH?DI*]N.4#W%5"5&DRDT_
M=$P[==KU);+\F?+3#AQF^2Z4_E^AZFKW7R9H=DSK.Y>1;7FI$^X,J&]"$X;:
M5C/]*>Y="9![1]5_ *C6B(E#3W=!3X0.$YZ#Z^=*>1+@FC/Z9L4O4<EN;*0O
MX2-RI:SC>KT^E"Y&C7WJX)8M$EFWA3;*4[,CA2O0>W-4_L-HS<2PF.PVIQ@;
ME("B4^2O.FB:'51G$I*0X4BE._8:5$BW)DL,R)J9"EK91]VT!QN]2:F+:&0D
MV+5%R>$^X76'O6 H)?65!(\N.E5ZF(NH]BU($A;EX@K;S@=P.@^E&UUR-%U'
MMDV"A4B1<VMB/$=XZBBF@94/:CL-U4N(Z^TM!)"DD<&EN3"C :CT\;6X7XA+
MD8]?,M^QK*<6N4),HZS*%M_-5HGW)Z;FF(R6(8PI?51\OI5.2713Z(#CBG5%
M3BRHGUJ'SV),3DXQ1T,&3ZTK (DTK #;;CRMJ$E1/I1MW";HLH40QY2$/)(*
ML8SZU5;70ER;VT:>+Z X^@ D9&.*31M%%Y$TXQ&4'770 ?+TJ%V[&H\G<OLJ
M]AK_ &\]J3-GF)']E[ ENYWM2DX2&D*^[8!_,\H$8\@":\G7ZG8J1U8X7P?6
M@)1&;9:A1&8[,9"$QV4(PF.$C"0@>6$^'Z5XNZ^ST(XZ$+E/E02,C)Q4FBX%
M[WT(.3S[TRJ%-/OD8 3S[4"X'HJW8X4$XY!)R*0,95**@2O&3QQ0%"7)I$=;
M*"G)2=I(\Z+'M9PS[66JX5I[*F83US=C,76>@OM,J =<CM#<I(5U22K R.:]
M/PV&^39S:GTH\$7SX*\+8U3?VD6S3=CW/0K6V".^=W'''J3R5'K7V6FA4;ET
MCYW,[EP<;U1*N&IM2"Z3W 7Y*\-,I4,)3Y)X]JUO<^3.7"X+_5LFWV*W,M75
MQN5/89"6(N<LQ%$?,H?B7[^57D]*Y,H=G+T27KH\^73R4;" <@USI[[.A/:=
MA[(K>=(=DU\U0VL(FW^:BT0]W.YIK*W5CV!('[5@EN;B=->6MQ7S74L6%1<(
MPXZVA1\R :Z)^F%'-^\5"M2/R9;KC$99:20VM21QM\BD^M8XO2:YNA3,Z_VI
M,Z[R(2)$)\'<F0V$*2@#P 8.595CBM&ZY,D53:FEH;MJ<=ZQX7ULR=C3DAU0
M5OQU);*2,8_".:CWHKV+2+<(XF"PPY5P;:0VG#I24-*2#X^3\V3S6B:7 C/3
M)J9$>3:$@J>86LMJ'3'E]*SDP)L07>ZZ/N,!2\EE39&[HEOJH_6M8<HE\,OT
MNJN%N8B0-H8;:2>\QP1Z&G)6$>"(VN(TX.Z<W+)YYX%3119R&DRH:D@9XH:!
MG/)L9=ON <Q@+5CFLV!H&$+<0E2#A..2:I 54EHW/5ENM: 5H;(><(\L#C^M
M '1Y,?8TF,G.T<GZ^=62.,LJ*4XQA X JP'8J%M-*(&2KG'O4HHFB2&4]ZXV
M4$#J/*G="79R77NIERKDC8\"(_"$^2??'K7-.7)9G;-&C2+NT_,2/O7-V1P5
M+\N:40?1O68;YB2"N6W)6MT+<43AT$?* ?\ *M/8DH=374STQK-.8;FO292$
M);V[7$@'+BBH=<C'[5G-^WR"^1F_+5?]01(%J><N+<1K(BK3M1'(.$A1Z$U5
MIN@Z"NM_>T[ 5;KM;VDRU**5-M)SA6.F?IBANNP7)EHD>+>83K!<SL4I>T\%
M*CY9J))20=&8EQ7X$E4=]&%H/3RKD:<)&J=HOK/J.+:F4J$9"7U'"E-C *??
MWKK62*2LS:;? QJM D2&[LP=S,E(Y\P16.>/NBX_!0U@B@T]:J &CMCD<P^Y
M4V"I7 R*[KX,:MB)MJ7;L7%IP(*"% 5,J2W+LFW>UD3^+O\ _54_L:Q_,+X+
M\MGN7M\DV#M#['HVHM.28Q1' 6V$D9&.3D>5>YJW"<$X'#C3C+D\X:9O$:Y0
M?X6^]XSE"$^O'3->--;>4>ICE?9Z@^R]K&% T#-TB\VV;@)ZW3GGNFL<D#S)
M/%>1K8M95)'T7A^13CL9U,V6[ZE+=TE99M;3A^';/!5CJ3Y^E1%*3=FV1O=2
MZ-%<+L@P$QHSH0I  /'7%2DD^"NT9RZ7EP!J(T=ZU?,0/*M[?0HI=F1,U[^*
MI:2R4@+\2L5S3C1V1:<32W;4O=.Q;!:W,/RAXB.<"NG2XIYI*,3ES:B&&-R,
M!JK5PTS/5%D2S(6T 7!Z>HKZ67X>U'E[D>+#QS#/+L3.J]FERMU_BQ)MN?"@
M^0%8/3CI7SNJPY,/&4^@QY%-7 \6?;64!VUN?W8B5#ZC@5OI::X/G/$_\S@X
M8T4K()ZUUGGEK%  !J0)P=VJ"ACGKQ3H*)J71N2I0Z\44(L&W VM+:%8S^+T
MHHI-EE%D)7DHR%'CGG]:ENC:+;-)9G %@ X5QQ^M92Y&<K[6]..0=:/R"D+:
MG@/)PH C P>O'E50=]F$UM?!E;+I/4&I928&F[++N4ATC:W&;4X1GID@8K11
M<N(\D'?="?83[6]2!J9JIR#I2 4[E*FOI6\1YX0GSK;RY1XEP.,7+H[7IG[(
MO8-HXH?U),N>L)C0V["H-L9_X0<X^M.+Q1=ODU>"5<'7;'<+1I6$+?H?2%ML
MC"0 .X82%$#IE6,FI>IFN(\(W6FQURAU^Y3[ACXZ4X\.NU:L@?I6;RSEVS18
MXQZ0XPM1 !Q@'TK,T0^\'EMJ2TZ4+(PDYX!JH13DDP;X(33+L=0$E\RG\YPG
MC^E=,H1B1?P7$.7<([Z7F$@-!)WH*N<5RY(IHVPSJ7)T[L^UA;[0VBRWM]?\
M,D.%]F0.50WB<[AZ#VKBRP=45D4)._<[%$U9:S!'Q5]CJ:0GO!)0X E8/0X\
MC7FY<4_8G&HW9YV^T+K;0*U,OVW43$B2ZLF0&L'ITS[UW:9;%R5ER.:J1Y\N
M/:E;VG"S;F%OK(R%8_2NV4_='*DK*5_5&LKV2(3:V1M*>$CPY\ZTW2VV0_JI
M$_6E@U?+O%IT#;VY-V?M<%M[[I@K)<? 6KH./FQSQ6./)C4=\OJ,\L9[W&/1
MT3LW^PQVL:L>;D:IBHTS 4 HJD$*><!_*!QFN7/XICQ#AAW'J;LW^QSV0]GY
M;DSK4N]W()&)%Q22@*QSX>E>;/7Y<G*?!UQT^-+H[I!MD"VQT1H41F,T@8"&
M$!"?V%<&3]H[D=,8*/0LL')6IY63U\7)%2Y-]FEJJH)UI"$#8.#USSQ0N&F2
MZ:=D=27?D;.$GVK1R;[)44A2%2&5!2E\=.E15%-VAYT*"]R0,$>E,0VLI 23
MU!JHS<+HB45*K,QKFPVO5&G+IIZ\1T.VVZPWX<X*Y!:6@@C'GDXJ,4G#+9KE
MA%X^#X,=G.E;DYV^6?0-J<7%?5J4VME]L>)""XI&[_N$_M7TD\NS&YKV/)6.
MY;6?:^P:;L6B]+V_1NEV1%M5GCB'&0T2G<@<[U>94H^(D^:C7RN;++4Y-V3F
MCWL,%BQU L;0ZN1<XL':$-J>#382D )*B#GZ=1BK2W._<A7&)\EOMIZ]N7:-
M]H#5R]+Z>7$?:NCD-U///=8;"_;.WDU]%I%459Y&H;O@X4YHV8TY_$+E,E)5
MC"74*!WGT^G_ ,'D:]':<EE)+C*^,;6J4%.Q$;T;D A6%<#9YTVK[(ZZ+A<S
M4%VE,Z;^)8C//.9ER KH3SW:3ZI3Y#K13?!3DWV7\SX?2;42V:>:_B%Z4R6(
M37S&,E2LJ?5C@*4?7RJKV\(2)T6"SV=Z9DWB].(D7%Y1<4K=RXZ>B ?;S^E/
MZ5R'9@K%IRX:IN;M]O *8W>ER0L\$GJ$ >]*$;=L#I28;<MEI#)^'@IQAM(Q
MQZ*K=H**2Y!$JYM6J(@"+$!>=.<EQSH 30AC[COP44"005NC=M(Z4Z)9FGW%
MNN+*B<9X\J3"RYTPA)9F-#DN(Q@\BD-<E2@GOW&E.*2VQ\PSU-*V#2+*P.=R
MR[)V[0M63GFK4F'11:\U&N0A%NBNJ0@'QX\_UJ9R;0K,6RHH5N3U'G6,4!I+
M;=>]:[B0-Z2-I"O//K6G8Z*FZ6H,E<J$"J*E6Q7.=BO2LI0KD965/( S@8I@
M%0 *3 ,'RVYS20#K4.2\<)841ZXJE%L5FMTU8VDQ&I3J/&XDJ.3[U25(E\C%
MXCXGMO\ 4-J3R*3[*CT=*M&QZ,TZ/E*1TI71LK+*VVR[:FU! TOIVWO7"YW.
M0U$AQF494\\X<)0/?/4^0&:Y<V7:G1HD?73[.O83;.P#LUBZ+:D1Y%V>7\5J
M*>$\.2U)X"3YI;&4@=*^:R2\[)N9VXDXK@ZRF(@) #@( X/K44CIWR N.TD\
MJ&:*B%L28Z5G"E#!HJ)7J$*:;:X9VE?D":5(%9'ER'&#XMB 1R<YI/[%(HY=
MP",_?#&?2HNNRE;Z*6;?G&DDI?'A(/04I22? U9Y3^USKAMO6;-G^#;E?P:V
M-*#;I*6UO+RI:R>@ \(QS["OI?"\4=KDD>?K9UP>*=5ZHE:AEI=N5Q>DAKY(
MD5HLQD@=!SRKZFOIHUM/ DVY%!&O?\.DJE1+>PQ(QPZ$A>SW&>A]ZA2:?!;2
M?90W%9N3A=6\M\DDE2CG<??UI-N79*A%#3#)80XMMC<1@! XW$_*!]3Q1%;>
MAKEG8;_$3;(-GT6R^A2;% ;:?#:LI5,7]X^H'ZJ"?^S2A!+(.<Y25,I=00UR
M+4W#;5R%!2OTK?+BM&,9\\F9C1YMO);BO,E<A)8#!W$$?F'!"3BN=1IF[FI+
MD9E(API,8/6F1 >C-_%R%2))?.,[64[<G W95^E5DI$H8TZS\1*2](7!0^@N
MNNNJ!4MEUQ6 AQ7EC&0D?FSFLHJV7Q1M(]KN^I8QM\R9!0N'DI#2<. *&.OT
MK;;NX)*![3ALLGNBG<K/*SR5?4^=9RA0UR3;2TX[%N,=G*"MG@CRP?3SJX,E
MHB3YRF(*+%;&RE#(!<4.I)ZU4GQ2!$**T&W0O?G/]*0S36]]*D%L'.:&!F-9
M0\;'4-\I.2:AH!RU2!(MF0H?+S370ZX)6B8"#=I=Q SO(9!/D!R1^]-*R6:Y
M2U.*)SS5")+;*FD!2NAI@-R)K<8[1Y>5*RDBHNMW7\(\LY"4H)-1*3+I)'$)
M4E$V<J0M:B%<G'F<\5@U8J-?IVR7"6AM2(I;Y&Q1Z_6KC$&:*[:;D0IJ+K$?
M7QA;C(.0YQ@@@U;C1!F&;PVTQ+GL0E/7N;),6*PXGAI'JGT]S42X5KL9/B6B
M+;IB(#5Y[R6AM<^9(3PRI[& @'S H2H.RLD7^2&)<B;:4NNRRVQ$*QE2B?G6
MGZ4G)H [E9+6S:Y MT[N'$LAYYDIRM*,@%>1SDG@"DZ S&K("_BPQ @NICQD
M %QQ65*R >3^M9Y$W271471ESD'!KFY3-"XM4^.Y'7:;D<,N?(Y^0UT0R;O3
M,AKW1628YCON,E05L.,CH:QE!QLI.QOE)S25Q&7UH[I]M)QXT'UKM4DXV9I5
M(VG9YHQ_M-UK:]-N**(2BJ7/=_W$5K)<_4@8'UK'4R48<!C6Z?)ZY_LSV/\
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M8>N<Q)[Q]1>&?R^0I(!NY17K@^9"GBG P!Z"J)9436$Q4;UN;CCSJ6(LM)/
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MY52DG]*(VU[EI!M5WGI2Y&M<Q\>6UI0'[\ 5K#3:G*_1$4LD8*VR[BZ+U2Z
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M41[7#C8B-+"YCBCP$9'_ (5UX\'FRVI<&4\GEJSIWVE.T>/:8K/9'I)QMN!
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MR-WL35+2T+\XI<(T<76_?+#DT+:44$$;CM ]O7-6L%">HLE#65T0A0$EYQ
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MR7=[;)$EB66PCO"#D,NI3@NMDC&U7K514'TQQ?\ Y%;_ -!VF?\ ]W[L^_\
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MH'MBG06(VK<VN+=26^ I..GO]**);'6F-DI8 *2CA&#E)'T\Z=!8Z^EMU/B
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M'A@H % "TDIX%:1=<(30ZD!')Y4:V2V_J1V+B<2!O'!.:J%I\BET:%+2B$X
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MZ_TE;V9^O-1:8L)DJ0(T14TRIDD*&1W3#(4I>?+U]::P22]32&IWT>E/L_\
M^CDUI=HL74MTTU;X7>D*BNZK0M2W0?QMV]HYQYCO59\\4UCC#ZB7-WP>@M5?
M9;[0.S[:Y([>=,1EE&QJ*[I?PI.. EMI9*4^^,UC*.FD_O\ Q-H.;YHYC>Y&
MN^SFU(OEP5I;5CX?#3T&T+DP5EHG <0J0C:I>>J,X YK!QQITCH4\B0Y;I'V
MGNU%[^#=EGV=E6U*W /X_?IS2X["?-1VJV<9\LGVK>.'#+EKG]3')DDNV=Z[
M)O\ 1S:;9N#.M?M#7Y[7^I?G5$7N1;&%GD!+0.5I]U'!]!6KRQQ(QWRGT>IE
MV+1>A=-)9%OM>G+8PD;68X0P@ #CPC&3Z=:P>=98NWP-87=F NOVI.S'3Z V
MR_=[MN)0$-Q@AM:AYDGJ?>LHN$.C?RILYQVA]N^K-90S;;)&58[.\<J)<!?>
M'HHCI]!Y8K.;W&V/&H+GLXO>=+(DVY3@4$.P-SS)4<!6XY('JL^=<TK-K/3'
MV5/XD.R>$J>_(DQ1/EL,[T>**@E)0 #Y!1573!TTCD<4LM'S3^V-VD*[=OMB
MO:"NEV>;T_:KFU8@,$ L-?S2,="I>>?>O0S3>''Z28^K)M]CU$WV2Z!T=V37
M[3&@K*W @3H:RM.\J6X0DD#<><9\O.O"R2<NST<$5#Z3Q(U <T?J-^T3&4EE
MTA6",CD=*Y_WDT;2ZIFG<T]&D 7"R.EA20"4AP[?VK=9&^S%QKE#O=WS_KS?
M_>JO23<CQ77J'F H % "@<<BM$Z$U8ZV$\N+/0]*U@O=DOX%;E=XE>-HS@55
MNTQ5Q1MX<)3K*%>B0:U,Q;["U$(3Q20KY$]R6O KSZ5MA^HC(^!B1')Y KT6
MDT1&1&=CH=X<0%?6LWC-$RN?LJ0=[*]F.<I-8RP)\C\P<C7#45LQ\.\MQL=
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M+"U"PX0RM]7) S_NU_F_6J3$:-B9$=0MI4I16TDC:!RH>PK1-,!I"W/B IN
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MW]^T"7FSM\7S$>U4B336R]8+*>\((5O2L^2_RCV]:T3!HT$>>TET90O:Y^)
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M2#510I,6A(2*NB!02%=*:0A248/2G0<BB@9&15)$2[#V@<BG1(I"<^+%,!>
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MD/Y>O&?04T)N@P4GIU^E%"W(/:K&35(ENQ26\86H]?*F(7QZ8H 4.4\#Z4T
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MMI3IRWVZ$Y>)/Q 9"PS'RE6SGG 3QNK>"20G9JM.:SL,_,&V(3#D#_>IRO\
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MIL> :0G*R?:M545R0VV3K7#4ZH/%& KBJ7')$W[&D:;*$;4J(HLE(  'S*H
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M7D<5#!?(W,NK"VTN I/D #Y>]1=%E=(NL6(TX\#N6>130GP8V9JM3KP<1)4
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M_P"OQO\ W6H_)R+_ #1XM2%O':WR*^@YEPCQW4>S06F"M*02GRJC+MV6Z$A
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ME@8&>*I(!X-YP"GI5H![NS@55"L6@!/*AFFN!,</'2F MM&\]?K0N2ET/!"
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MK)H9F2$1FB5I"T+_ !)'4^]2V6D,QGD*0>_2,>7'4TDR1S^<-HZ>E- ,O)2
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MQ83D46#083@T6% QSC%%A000G.#0F-H,MA/2G8@*2?*I8(6@J Q4V ZEP^E
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M]ZEL:0PVL(02@8R<.#U/K4-FB0S\2XVYW<A 4PX#M'H14MEU0M*QM25H (H
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M&;74?FI'\Y2;S_,3>+QJ108YGPGR>65ELRR[/S&4RJ!@3!J!OP8UYFJ2<JX
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MY&JYL.$92*/GMW1:%3VXH?4-&7F30GYE)WKINLJO9+\G/2O7RT!E^?%Q0&9
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MYD_!;IG6VDVO=0A<H:&)@#5&7FSYT6D-NXO8D4M(/[$K\W''1@ 5\!#/Z65
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M<E$KB.Y_(+/>P [1SD=3WGO3::IMS,4L0!7J9#Y\>/49Q2>;JBGX%;X*_0U
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M/$NG4>BGAFKO.^<2:ECYMR#/0.6)%3&,8\D!(143'V=>Z[62ZO?_F1CKR&^
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M9 LN'E:K66JG<?:$V.W;U7ZIQ]2WBJ<FJ\LF_T1&2+,N'M7KJ>T*M ?9RE\
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MQ WCU2Y&"JE_%PI1U@1HM\/3+ @-)5"YUPDBQ"N1OP:S K!T-  S+:)(RM#
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M9<+[&7< T<F<[3EE$P_?PGQ[0)3_I7:-$DU5*U^Y&OJ1Y]?<0JM!TP1YX?&
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MYO\ H>@NW!#@[&];9/'\#E_^)77UJ_[MD^3.+T__ '6/YH^?G9S_ /7%TO\
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ME_3?9G=O]'-5(E2X\=Q]*"DY2%!Q+I7GO$D* SC;Y<UMEK<&APP\/&]LK?\
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M/PY*:;\0VXZNM]4^J<I]*S=4T;RI:C#Q./\ -?JO[&OI&OCA;TV?G'+^3?\
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M1[,XO@-?M53RUQ19X9(LZ=7D'8?^S4/%H/";'*=/*S]!/_5H>8G' [.5I,.
MGNS]MM267X!+"R*D:72TX"6\?E366_(IGB:%&-,_,IPAKC.,XIO)Z(>/&V^1
M4:%<4<=V?TJOQ#3X-<#UGL\44@]V>G]-1\:O(:P7Y@/=GZT D(/']VFM3?D0
MEHZ\R#N&E)#.=K9X']-361,I>%Q&D?2\MY8'=J/MBF\B0XXG(L]NT.A;2D2V
M IMQ!0I*D!04#P00>"",\&H9,R<:HMQZ9IW9FLOX/],VB^N:J[+-5WW0-S?&
M'D6SNWX3HSG:N,Z"G;G\(( \@*Y7U6$)^)@;@_AV_!G6^MY)P\/414U\>_XH
M?.]D_;J&_ET=K]@6G&.__P!#4A[[X^8V9_ZN*T0EJ:KQ%_[?[F>4=)=^&_\
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M?I]/X\G?9% ^$#XR+_V]:JG]GFOM/6R'=VX+EQ@S+8EQMI]MM20XVMM:E;5
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M(H],=GGP.]K7;-H]OM1O.M+7:Y%_;$V$U<T///RFR,(==6GAI*@!MX40G:<
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MA;U_#M$CQ]I>C7NY(D@=0M2TJ&?NA2/RKJ=.IX/O9Q^J6M1SZ(V?6_:UV?\
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M=0TF7:I%NBMN<&1)?06VVT _4<JR<= DGH*[&JRJ&"6[THXFCPO)J(*/D[_
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M#(?A?"5?$=V;!0!'^DT,\C^\:IT_[V/S+]1QBE\CZW]H02K0.IB2/_@%</\
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M/!-37D=C/A6HQN#\_P#+/8OQ1]DT?XC]%V#MZ[&Q_%Y@MR4NQ&L%Z;#R5 )
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M;' WBR=GY^C/)'9#\07:1V#2KA:[ F*]$DN[IEHNC"RA+Z1MW@ I6TY@ 'U
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MM4Y./^Y-P_\ (.5[?4?NI_)_D?/=+^^A\U^:/EE8'F?XK:_Y[?\ WU&_&/\
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M 7'X;;BR!T&Y22>*'''/EH%/)#B+:^\=P[.F SW$"'&BM9*N[8:2TG)ZG:D
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M*DD9"@1P00<@BK4^"A\,,$ KYH"KY'S"&TI&4 TK+%$6WM?[,54R0DM;:O\
MH_WH ;K[E7X,58B,J$N[0HX'%.Z*^'V.++>,%.:DI60E$;N06%=4BI;J(J*?
M<;KM4=1R0#^5+>2V(,FU1L?0/TJ#R,/#0!M4?/T#]*7B,/#0"8K:#]-6QD1V
MC*<AM.<)QQTJS<*N"'D-[\X:J:D4N)'.6YQY?A;(YJ>_;R5/'NX'3=@*D#<@
M^W%)Y4$<+%V+"MM>4<>V*BYIEG@M$Q#@O-J!)S^54RE9?"+1/Q49;25<<5FE
M]IFN/8>!H$#)I#!#38Z)Q0 HWX2!28T+ YJ)(&@ R%[<\4 '#F?*DR<>QW>>
MU(D'!R,T =0!U  *.T9H0I=@H=!\L5(K 6L'I0 DLY-)@<.E" *0,GBDP"X]
MJ  *@!E7%"Y8/@@;W.;0A8"N<5LACHRY,A2)]X6ETA.<YZYK5&)BG(;+NREI
M 4?WJ;B5[@J;FI)X5C\Z6P3R-#AJ\/*.W<?UI>'9)962D-QU>'"KK54EM=&B
M$MRLEFRH $JJEEZ!2EQPXQUI=A[;%EVI+G*L?I4O%YH7@D=,LS7. ,_:K5D*
MGB1$2[ G&X$<GIMJ:R453Q)\(;IT_NZ8_P"S3\4K\ '^ !!Y_P#%H\2R4<-"
MPL[7=\]?M1XB'X0S?L[:E$ >?I34R+Q^0U=TH7 2&NOM1XU!X%E7O%G5$)RK
MI_=Q5B?)5*)7)(*<C%7I<&=]QOSY4# 4A9' -,!%QMQ(S@T#L9OJ7Z$4B$NX
MV4YQRHT$1JZZO)P#BI7P1?<34X%#'2BQ,;J2L#&X_I4[13MD)K2X4]32L>V0
MDI#F//\ 2E8;9!"VYY@T)CVOS"+0L#Z30V&T0VN'H*7<FE2.V+_IIC!V^] !
M", \T@"))STIB!43Z>=# %MLY)SUJ#1.(*D'THBK).5"*VU#FAQ%O04(4?*C
M:/<<&U$XHVBW(-W:Z1.PP970&X'N5>E%!N.#2L]!0&X/W:O2F&X]6&X+(QL%
M9]AI\5A?G%'JD4>&A/(V"F=MX('-"@@WL61/0!SBGL0U-T+"X-D<FC:A[Q!;
MZ5.I4D]5C_&FXW1#Q&F?("ZM,FZSCW+?_?;_ . ?[15>!DEN9]*@WM1-V_LL
M[0;M!8N5K[.K],B2D!QA]BTNN-NH/125!."/<5;'399K=&#:^13+58(-QE-)
MKXH<_P#,UVH__HKU-_\ ,1[_ -"G]4S_ /!_@R/UW3__ )B_%'L3X"K#J?0U
MAUI'U%INXV5<R?"<:3,AKCET):<!*0H#< 2!^==KI.GG&,]Z:Y7D<#K6IQSE
M#PY)\/L[/5'\<5^)8/W-=;P4<7QP/XT!UQSZT>"@\<*[>"I'A":DL*2(O.[X
M&ZKDI0YVC\ZDH)$7E;\CA+R,\5+:@W _-)\BFC:&Y@IDY/E2H'(/W^>,4G&P
M4J.2]GD&EX:'XC%VI6,C XH<$2C-BR)63C YJ%%B=BX62,U%HD8=\5'Q$GL,
MTU#A6!F/)U3?0OY%#Z=S45E& N0XG\6"0E*>A5G/"2#@UVJ^JQ2C]I_Y9T.G
MZ+ZW-N7V5W_0^?EXUWVM]JEZ(N>I=3ZCN#Y*DQF77G>//8PUX4I']U( KS\L
MN;/+EML]-'#@T\>$DO\ /,+9]<]K'9;>L6K4NIM.7&.05QW'GFB/0+9=\*@?
M122#1'+EP2X;3"6+#J(\I-'T&^%/XBU]NFFYMNU$Q'C:IL(;,T,)V-2V%DA$
MA"?P>(%*TC@*P1PH =_0ZOZS%J7VE_EGG.H:+ZI-./V7_+X%=^+'XJWNR)Q.
M@=!".]JR2PEZ5*>0'&[6TL>#P'A;RAX@%>%*<*(.0*KUVN\#]GC^U^19T_I_
MUG]ID^S^?]CQ#\[VS]LEX?=:D:PUA<4CO'@RJ1*+8/0E*/"V/08 ]*XEYM0_
M.3._6#31\HK[D/-+]JW;3V+W]4>U:DO]EF1%@2;7<"XIH^>UV,]Q@CV!]".M
M.&;-IY<-KX/]".33X-5&VDUZK]4?1?X<.WVT=O6CG+FB,W;[]:U)8N]O2LJ2
MVM0)0ZV3R6EX.,\I(4DYQD]_2:E:F%^:[GFM;I):2==T^S-<" 1G-:C&'3X>
M@H \T_\ *$I2KL!9"TI4/])('!&?P/USNJ?N/O1U>D<:C[G_ $/G+:K'/OUQ
MCV>R69ZX3Y:^[8BQ8Q===5@G"4)!*C@$X'I7 47)U%<GI)24%NDZ1:AV&=KY
MZ=C^K?RL$C_T*M^KY?\ @_P*?K6'_FOQ =["NV)3+@'8[JXY0H8_@$CT_P!R
ME]7R_P#!_@/ZSA_YK\3ZZ]GL:1"[/]+0I<=;#\>QV]IUIQ)2IM:8S84E0/((
M(((\B*]-C50BGZ(\CE=Y)->K_,LC2 1NS3;ICAV%<J3P ,5&V6)T#[T@./(Q
M0(04V "<FK%(I<0K8\?6ARM$8JG8KM%(F^1)U XY-!':<AL$9W'K0&TY:2CI
MS0-*@$'=P13L8BX<9 %3X1&AFY&4^0#D'I18]IR;4G'\S@5)3:(/$F+,VZ.A
M61D_<43R.2H>/"E*Q^F,RI &P#%5-V7J*081FA^&EN<0I!@T@'(32<FQU0IM
M!3CI40%D\) ]J #[14-Q*CD@9HW6%"@.*!G;C0)G;C0*PR5'%)DXR8.XT42W
M,63](I$D#0!V1ZTZ1#<P% *&,T< VV$+23^*F1"+0$8VG.: !0V%C*CBD^0#
M!I/J:+HDHV<64GS-(>T[ND^IXJ25D:(6]SE16BI*4G(.:MAC3:;*,DW&Z*'=
M)\A\GNT$@UM2BNQ@EDDUV()V)*?5G8K)JU32,[3D)"T3<_2KFGXB%L8X38II
M&4I7^E*61$HXFQ:/:);3@W-K_2HK(K)^%+T+%;8DI02CNL"JLDTY6C1BA*D3
MS5L<4!D*%9I2-<<3:)"+;2WU2H_E4=]CV-"[C*DI(VU%5NNR34J9'/15%60.
M*MW45>'8G_#N^\*@1CGBB62U01P\G"UI;R1D_>DI#EC8VD1@!@IYJ:D5N+0S
M^36LX"3BE8Z#(M2CR01^52W.J!07<?*9;C-C)SQY_:JW98HQHS_4T02UG8G
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M-",YI-(\5U#I^KRZK).&-M-\,NW_ -,AV);2#VKV$ #)_P!87_Z-:GU#2?\
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MN?.NMJ=?+3Y-BC9Q='TV.IQ^(Y5SZ&8+_P"4JU2A"E_\T5D.U)./XN_S@?\
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M'C71.>+6G_RS5>BZC_MI_(\MTQ?]\Q_/^AX"^'E.[MY[/T^NHX8_\.O-:/\
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M@?EBGRI62IG=P1Y4GR%!TL\=:!T'#)2-W7-19)+@[!]#18Z#!//2D2VH4+0
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M)Y\CGN_D=C2Z]:?$L>VZ^)1O_J8E^_\ TR6[_P"83O\ ]&JK_3'_ ,OY%_\
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MJZBER&CCAV\'!IT0L8R$J=&%JX%615%<V1S\0*0K"AQZU?!HRS7J5NX([M1
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M]%FLG2([M4ODS?UR6W1OXM?F?1%#YQC%>MVGA]R/GU\<$-F-V[.R&D@*F66
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M'%=,44&X!96<;B!]J*!2"$C/6FD1<@R>4]:*%N0H@$C&34&N2V/84PJCDD<
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M-K$YM>Y,'V8RM,9>XW:9_Z1 GS^MUK$+I)"/UUUD_HZX=72.OC&AM?+PVTS
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M]P0SR4CW^_"DZ,,6JPB9?)Z5]L]&&DY_F@E<6T;C.[XR.=U\V_0V1-;>?>D
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M,9'056CPUO.*9L?X3\1[ZDL?I8*_Z;XAM;_^3Z<5#?G_5.*V@F<(C@QVSF9
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M9:T/DD#N;9P:[QM8$Q\4UCEX5K' GS7BI'P';2D7+6FTDFTBD<9;I!(_._]
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M949S,>.E(N-WEPK%)QI@C25AJ3F83^ VR\*FY04.@EP/CO=!%=YV> C'/(
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MAERAETE6CGTM#O1_ Y'+(:/@4'1KPC?/_)*I%E 6VWQ:W^25T6)TTX <\ZW
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M+Z0[Q041:602?SK0\6^",?C;)LU=J6T^,MJS6?PZ+_$L5*5$?315$NX6F %
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MU8HVK+J+NB)%2$N(!2K"B:6[S)/T&9UK#"U)>FMMH3U4HX%24F^Q5*%!6>T
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M+8MS"4X_W17<I>$CSV]K.[-=C/@I23U(%8&CK1EQ8\2\4GP]*BT6IVAV@ET
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M$!8Q3;VJR"6YT$<C#R%)3"6(:R&0CRYJ['*T9\D=K&:D^+'E5R91)#R*0$@
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M=>>[Q13@XYSS6C3TY45Y4UCLE;S(,)E++SP*5CH372GQP<O$VW9FFJ6V&''
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M8I =O%  !SGI0 8+R>M%"L-D?U4Z"SL^AHH+#)<P,&DR28;O:!V'!)&:!!Z
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MZ6PM6.HHLBK8X1&2G"MM1<K);!93I"<9Z4NY)<#-^1(2=J0?THIB<^0\4NK
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M21A('Y5%MEJ0?NL#H*-P;+$76U;O">*%(BX,,TD) *^?O4UZC227)Q"2HX
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M<#'&Q27-[1]<FN5".Z1HFU1<=)]O,BR1U6*_3G6EM?V>T;@L8_:NE@U[PPE
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M*8(; ^FBR3@@"E0/6BQ;4"VT=V?.JVW9-15#A* GI0-!]H]ZKHT';1[T4!P
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M]*K)4@%I2!T% -"2^@H$@FW=0,*I(!Q0 &*DA,24!D\4""=W0 HCI3 &D!U
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M3*,KDRJ>".WA'I^T7J&J.VZN2G.,JZUN4HS=F.G$JO:>NZ2;.^_97%;^Z4<
MXR/7FL^NE*.)["W$TY<GB>[O:D$R2[*+J@EP[B1G%>2<IS9T_=I4,6%&1O+R
M?$*JE&N (Z87$.$H3P#4L8R-=46G<^=6J+D7)!?F=Y'BYS5FQ1Y'5%RL DLL
M EU6PC. :P9GR0;'TN_71A*6V;DZ$H5N"0>M3Q9)1IHBTF/O^<.[?[5W_M5T
M/KN7U*O!B7V^08B2F7;&_'C*@#7C<\=C]T[6)7W&H<1-BB/("$+Z@$\FLD<D
MVZEV-*2\BNRK 8\L+9>4@J.3Z5IC.+0Z)V-"2TVDNJ:='4G/-5R>YU$3BRM=
MH$:/\DAV.A.X'/AZBMF#(OLLJ?!9^RO4!1:4(6@*"$D*W>]3PR4,CW&74QE*
M/NCB_P ^))FJD,Q4).TC(3YU7J9\\%NDN*J1E<[3]YOUV?6U)3L1R!G%6K-'
M%"GW-<<;EV(/4,*X- 1/G RM&!G..:EBG:MD&DG3)_26Z-&"+E=@IW\(W<9K
M/J(N?V$5;4WP:%&N;$>#NF/80E.0H<@BN1;C.C3);8B$%$2[+$FU3DJ.>F?/
MW]ZT2RNJ93"]W)84RIS80R^TI2AQG%8)2J1L7) :QCZ@F(4W!64I'D/*IXYI
M=RK+!OL0^F';G%DMLS72AQ!ZJ.!4LN)-6A0D^QI<6Z29!!7("MJ3GBL#C"/!
M*>YK@CKNY'E*"E+PI'45?CP1DN#/XDH/D69^3+"51E'(P#D53DTDK-$<R8?4
M]P8-G2&2K<G 5Q6?ZNU+DL>6+5%+N;\]B"AUMW+*AE7/2NMH98W&4*Y,TW).
MT1TCM%AV1+1;4%D@ E7 SZ5;/HCU'O-<#CJ&B*U'J]>M1_!Y<(-M.(REU%='
M0:2'3XH)Y'D1':'U#?\ 0]U19#,>E6[\!4,[/:MW4M1DR8*P]S+L2=R/0%K[
M6+Y?V$VMT(2UC"CGD^E>?P=3SZB>S4=A/2K#SC,@[<+&^ZGYOO.0,G!KT^FC
MBQT\782W->\9/IIN]VYYU<2.5)6<!5=&6?'&/++%'@N?RS,H!,YQ*7",D5PM
M9J\D%NQJT04>2/O>EHK$)4MDK)'/ JG1=6EFGX<E1*6,K%JG 20V7U<'H>M=
MZ<=U,IE%$C>Y,Q]QAE*5!*R$A:AD59BA%=V1VI'H'LCT1<(&CG)S=R4OO]RE
M-Y('3]J[.B\2";\CE:B<'DIH::$[26=+Z@#*T<J?+:P5>>ZK<&KE@R7(E/3+
M+$]I::OT6\6-J:I22ISS%=G'<XV8I;(2H&XW^W0HKCG>@* .-W2GM:Y9-RA)
M4>7^UF_6G54MRWO3HRD@DD!?((]*\WU'5K*_#D=#38=O*//LA2M+W1+L1S>0
M[A*]V%%/IBN#X34CIIJN#09ED?O5D1?9"E,O!.4Y.0H=16B>">S=,Q_6(J6U
M%7NG:[>!:7+(J&V0AM3)>]1Y"L7#]U]S3"#?)0H]PBR5J*E! '4'UK0H^Z7I
M4-Y45N<E7RY*QDXQ4$U!\EBC10;_ &.8F7W?=J)/I6['EC5C:V]PB-*RD1E.
M.QU#CSJ/UF#[!%.1&Q9@MKY:SM6%8P:G6]!3NJ+7&OS4V"64+*E] E(.20 6
M0.F_^W6L.2"B[;-.+!/(ZBA]I_LXUMJ1\*C0!&CJY4],); '^Y]1_:LFHZGI
M]+%6[?P/:])]@>L=4]_PMD?65QOY<<FGZ<[$-/6N4FY7IPW1U*0$L*2$L@CG
M/JK[&N'JNLSRK;#@^F]$^C71Z"4<VIEOEZ>7ZFCQHZ&6D(1D):&&T# 2/; K
MBRE*<G)GTF6-[(XL<5&*\D."XLIRL^*G466Q@L,E'']CS]2"OT_N8ZE[\  Y
MJV&-N2HIS9X:=-2/+_:MK%3;KY1@*1E"0?-1'E_C7L.GZ=J*9\?]KNK1Q8Y3
M\WPOF6GX'X&=6WZ\O^)+4-MA)SU6I>?\J.L/]G&,3P70HO?/+/EU1Z;UAI]^
M/)>U;;TJ"FP#)V'.4_U8_2N6I*=+R.KBO'%N?<FK#J)-UM"7&G<@$-N*Q]0/
M45GE%PD:E+?&T16H95VCPGU,RU%Q#@2&VN5;,<*'VJU)9.PXY=O!FFI+['6R
M77YJG4L9WY&%;O/BKL6GE? YZS'C5R9CM[O,BZ3=C04&@24>F*ZF/&L<>3AY
M\[U$VX=ALBWK?6"M&<\U8\C\BB.+<^2&O\-$8!(2<^@&:(S<B63#"/8?: D_
MPF[HEI+>QQ/=NH ^OW/I2S0W0:):?)X4TS=X<C^(0@3="PUC/=H9Y_6N-DCL
M?8]1I,SR*DRIWZX0T*2EE#BH[2R5J6G:7%8Z8]/.IXU9K>&7?R*9>=1*&]Y3
MO=;.CB_"E*/S_P#?6['@;#-DQZ:.[(T9MJ7M ^:=5%LK!=6IO8J5T\.3R!_Q
MK?AP4N3RW4NOO)+P=-]GS*?!B3;O+[N.Z2ZI02IW)(5GK^@K8Z@CS'.>;MFZ
M]EW9BW(2U(>:6(K)W8(Y>4//_='_ *ZX>OURC<8GT;V1]FGJ\L<N=>YY?$W!
MB*W':"&P,(^D8Q7FISW.V?;X:6&&"@NR(^ZR>[;4<@8%68XN3,.KR;8E"O4P
MN.%*5=:ZF*%(\KJLV[A$;&@_,+YYS5SFHHS8\3F6>TVI"=IV=.M8LV4[.DTC
M+7#AH0G"4]:QRR6=[!@VDLPRI('%42=LZ$84/FFCM!JILM44*]UN/ ^]2WI=
MAK!%IN??R ?88C1G)KKA:2E!<=(/A( R<CTJS'EEN2,V5>)BGCU*]UIW^!D3
MVA[7.CIG,AV"I\E]*5**F022>!Y9S]J[D=?+&]O<^,=6^CC!KUXND=-\T^PP
M[^5IAQ$.9':9>7XE!!SE/X5#'4'VJ]8X:N.Y'R;J73-1TG*]-FC5$C$U*Y<4
MJV'P(.,^6[TJGZKX<N#EN_,*W<5+E!H;CZ\5>X.N2+X+*VI$=E*B,*/-8I6W
M1%-/@=Q'4R4E*E<J_2J-NV5C?H.+1#GVJY"=&EJ0,YPE5:/KTL2J!!XXR[FI
MZ3[3);#WR%TE%4<\94<UUNG]=SQ59CFY]%OYB-;O=K9:-1,W"V/H/?$API\@
M?2M\>H0ED4UP0^K24&F7ZR7ZV1)4>[O7!*21T4?6NW@ZCBD^9&*6#)54:M;=
M?6:X);:9FMN83^ UW(ZC#.*VR7XF&491?*),ZBMZ5=V7B2<8Q5B<7VDOQ*W.
MO)E0U[VDPM-,(4M6X']<_P#"J-1K,>D7OO\  <,4M0[B9?'[39,N_)E_-I;9
M/(258K!#JN#)+AFF6FG&)>+-VMP)=R^3+B%E/4J/!K=AUN/-+;%E+P.,=S-%
MA7B#*:2ZAT#O.@]*V45*:[%?UOK8:6MCDY&-K:%*.?/ J&?-###?? L,)994
M9QIGXBHL^2M#[?=#."I:< 5SL/5L.1TC7DT4XQW&FVW7EKN;"7A+0K=_00:Z
M<<L)1W6C#*,XNJ)^)+CRAEIY*CCIFI;D$6WPQ<J .,&G7F.QI<+DQ!94MU82
M ,E1Z"DY5'=Y"\Z(B!JVUW E+,M+NTX.P@TL<ED7#0Y)Q[HG8[S;XRVH$ 9-
M2N^!1Y%P0.M1:+E[O<5;"O3'WJI*RV3HI/:+KJ+8HJP74@A. %<#-1RR>-;A
MQBIJCQ?KS76H[_>Y"H]T=0RHD!"5$ <UQ<VHE)]SIXH0A'L!H?6UYT9?8<NZ
M2WG(NX!623UZ<4\&9XY7(6>$<L:B>X=#ZB:U!:FY+"LA8"ACIC KT$9+)"T<
MIQ\.5,LW7D&JTZ5$N_8':?44;_@PHR'M[AWAO3RI-H<6'T'<K!QQUJK-)J/!
M9I_M<GG!_5>NKW;F+A*B;(<?E!4>% 'SKE9<DY\FQ8XIT5?45]FW5E#2Y 0G
M=X@WY<USLVHV\&B$%$-;YSZ"PRV^<I4%;L\C%41SSD3:3[&]:*UG,<,=J=,0
MD(2$C*^H%=/3:M/AG/S87Y%AU1VW6ME)L:&4/+*"DN;?"GVS4M7KTJ@4X=.U
MRRFR)^BI5G?6ON5ON!17@ USWJ,2C\2ZIV8+<UM-37OEU>#><?:L$Y*3-:[$
M9)<W_3C\ZLQQ)40DU3G>9"2<\5?&J-*)FRZ?,P(D+Z@Y K-FR40E+R+.M!BL
M!M Y''%9%[S*&Z(9U,EUT@#]:W145'@G$)W$K^D?K4;)\%_O6I&+2V6US-IQ
MM'/2O-*+R]SJ1]TK;=^/>BY"6M2^@]#4UA2X+$R]6^Y-W2 CO6%J=<'! K!F
M6Q\%L>1XQ:WH[1*R0#R :JA-MDY1*!KM^3!6E#:]P4?$/6MF!W(SR0&F)=PB
MQSW8*$K3N2/8UN25V4S5JB7LTZ=,D+;?86>#YU1J*[EN& ]BI^24\4ME.].,
M^E9)2<GR7<Q1C^MH\Q^^9;DJY5G!/%=G3[=G)FDVV2MFM#4U"$.RL.)&Y//G
M6><JEP1IKDM#YN;4$6U]&6^F\^0KGY\<6]T2R&6^&*6:U/VM9?MSJTI4K>0,
M]:P^+;VR+-M\HNEBU'(?F(BS$DD>:L4Y84UN1;C=<,MDTO(0M;01M/()&:H\
M->9>Z92]0MEYK>&"E?\ 4FKH)K@S957,0FE]0LN Q7%DO8P1FLFIPM<HEA=K
MD3OHG-2LM9 4,@U?I7[O)7E@K!TO)G!U;<I>4@X_.K<U$X0X'.KS<4L!+ PA
M1&:SU%E;XE0[-G?D:<"E)R.[Y^]<]9'AS;UV1H>.XF!:MT7>[JR['@O%)#^Y
M!(/!S7L]'UO#.&UF.6.F76QZ?NK&G&PXP3*0C&['I7-SZAYM3[G8MBDHV.+)
M.D.E5NGVK^:#@+4,5V)36+$G,IDE)\%PLT9^%)0I1V;N17E-4_K4KP%^)5]H
M?:_8:O-H[IHA:P@[N*Z.CZK]2K%F\R$\6Z5Q*7I)V.B.['7"VJ22!NQSBLW4
MM1GU$T\3X&H)+DA7VXJM3+=GN!$="<XST.:ZZCEEI$HKDI5;BXIDZ;GQ_EV%
MAY!&W@5Y2<\NFS7/@UJ"DC+-4:;CV>[)E,H*4*5^E>XZ1K%JL5&7+#:Z)7^+
MV61!0TYCOFSX>G!%2GI<\=1N3X*MJ-"T3VT-V&QKLLE22I)4$G(P<UZ+%JWB
MBHG,S:52R.1G%QGOOWEVYM!.5.]XC'ES4EJ(RY+XQI4;AHOXBI-OTZBUSV'?
MF&TD)+:@ H^5;\?45CC3.?/2N4K14+WVN:PO3S[+D]Q#+A.U(5RD5R=5U*;;
M:9?CP)4469\R5+E_-++I.XJ).:XJU+R3Y.E"/!79<N?-DA;SP.U61[5JEDJB
M546EW6E\5:1:X\HA& /&<XJ<M5<=I0L"W65Q^6V&UM/C<I0R2#YFL33E+<:H
MQHAX]G6^ZLAS",]*OWEJBV6&QNVVV-JR\DE)PH*5T-9<_B2[(E#'%\V++F6V
M4^70P'7>J6VT[U*]Q@<_E5,WDQKEFW3X99WMA"V.7+'J2\-=VQ8U165)X<EJ
M#(5]@?%^U51UF+&ZNSU&@]A^K]16[%B=?'@I-UT*FSRA.U5;+JB&E>YU5KC9
M;5Z94K/^%="&J66/[-\FQ>RV7I>5/J6.2AYU_+GDVC0]BTRQ;XTZR6!4%#J
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MD<G-02LGJ<C\BF7Z8K=M!X\ZZ.&-'G=;FW%6#!DODYX)K9NI'$\/?(LEIM2
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MV)>%J;3M^&8.H+?*QU$9Y!/Z9S4)Z//C[Q.IIO:/I.9[.GYU/YN_T+! ?;=
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MI3)R53@=P&3Y5T\>/W248\#F8\IQE 3SG %0CC2D0V.P+._==.W!%W8)!'!
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M&F- E1'8+J2VL@; >E5X8-I[B4Y),7N\MCY9AU&%* \0'E246G13.GV(V-<
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MLU@7A8\*KUJ/_P"R.V],V[&50B/^L#_E2_[<]67\?Y_J#^BGV<?_ (:_!?\
M[(NBPP$ ]W'6@^O%1E[;]4ES*2=?/]2*^BWH&-W".WY5^@[C6EIAY#S2E*4!
M](J__P"T3JCQ/"XKY\_J<]_1%[/Y-0M4IY$UY-QK_P#5)-*ACD;3YBO'ZO5Y
MM?D>;-W/H>@Z?@Z;@6GTRJ*!W)]:R-,UM 5  I4G'6@!!Q0"3SS4D615#<-E
M:]V*D3O@>-  <'RH*F%<VG'/7I4T4VDZ8TFR(\&.J3(<2@#IN/4U.$7-TB<F
MH*V2W9;V'ZM[=-3LA,-35IB.)<D2G$?RHB!UX_&ZKR2>@YZUZ'I6BGDEPN/4
M^;^V'M%@Z=>.63]K_P ?3T;^+\O0U9[26EM+]I>HK3INRL0X-L9B1$(0K>M2
M@WO4HJ\R2<G[UOUN*&*6Q,^4X=5EU<WGR(F9#"&4!1.![URF;DQBY';<0<HP
M%< U"F6)A6[>R@<K -%$K':(@0D*97ST_*A(+L( 52%("2#CDT,B5?4T1(;<
M.W/-52[EN-TBJ" E6$NH2@=0?Q5'DT6FB1ML5P."-$4L$\*4KK^=-1OEE<IT
MJ+W;XB+6PER2OO9&T;7/Z1BGMLKC*B$N[[DAS80<'K]JDE?8E&37VB"%O83(
M.5#!/'O4G:0F]SHD')C-FB*FHV]\V#W /12QZ^U8,V1Q/1='Z;+J.50<>$4%
MZ6[<9\FX2'=ZGCR3Y$>7V]*QRM]SZ]I<4=!IHX<*^?X#1]77!H29>E%^\R+=
MRIS8!D8JU*D5R>YBS$,#!Q46V26.B488VI!QY56V.J8Y\JB.PF13HF 2,4)$
M6P.M2%89 (S0 >@ P(">M+S$^Y6=4+3*NUJMH6.'%2E)\R$#_B1^E:,'$92,
M>>LF7'!>M_@2"3X1D\XJE]SK1[(,GDC%1&Q<<\BHD3B0.M  CUI"#9!Z&D5R
M%$ XZ4K(!J  7TH0#9Q(]:LBV7#*2P%9.W./*K5)UP^2#AXG#=$++:(6594#
MZ"M.)Q7VU;,&:$H^[C2^_M_\_P!2)?CQ%N-OKC);E,',=YO@C!SM4?,$^1\N
M*W8=3EQ-M2M>G]3@ZKH.CZF_VRN?_.7+^5_\?.B\:(9[,KA=DIU<PY;V'4[U
MR 2$1UCKN0/P'C!\JU8-0\DMLV?,O:KV!>*+U&A6[U2\O['H6%\.>BY,./<+
M>RS(B26PZP\A_O X@_B"AP17>Q]/CDCNC*SXYJ%EP9/"S1<9>C)%GX=]*M %
M=L8//5>2:NCTZ_XBF<]GVN"0B]@^DFR!_"F<>H'%:\>CA#AF=YVW[I88'9)I
MN&!MMS.,#_HA5SQQ78COF_(LT+2ULMH(BQ%)JY14>Q%IL?-1T-$;6SD>=/=?
M"$HUR+8/I3Y]27W @>HH7S#[@R,IZ"HM/R8^ %Y4<[31%.N60EWX"[3_ $G]
M*EM?J1.V$^1HMH8!'WHWL=()M0>#C%-KT(TA%UEDCQ8(]JA33&J0E\O$_P!G
M3^XGN7H&1&BDY#><4G'=W#<O0<(2PT-J4@4ME=F&Y>@;O&AQQ0HL/$BO(*7V
M@<=WG'GZU-07FRMSOR&SG=N9R*GX1!S7H-'(T1:@E3?!X-/P_1E;=\4-7K/;
ME*X;&*CX4_\ D&Q""K#;5'E(%...2?O.Q.'H-EZ6M2B3M%3VHCM8REZ*M$E.
MU: :B\*GV%)>I"2.RS3[N2MEI0/KUH6E7J5N_(B)G8_I1[*3;&C^52^J1?F1
M\2:X(:3V':2<)'\-:_2HO2+U)++,:#L(T?G)M+7Z58]'A(+/E%T]ANC,8_@[
M1/H4U#ZIC?8FL^1 *[#=&@<V./C_ ':DM'#U!ZC(QFOL!T.M14Y8X^/+*:;T
ML5V9%:C(^X'_ # :#_\ N)&_[-+ZJO4EX\S%UZ4MMOB]T'&UJQC.X5\]W6SO
MVT0-\D0;<PA:" 4''3BK%C<NQ).R%3>&[L5890I!&-PI2PRB[)%3U'#4C)BI
M\>> *Z&*WRQ,J:]:7&SN!*V2KG S6M85D1!D1?\ 7$R7&D=\>ZW@[0#GFK<>
MDC'D$379"[JV&VJ])D*[E7/=*Y&*,^7&O=91EQ[C<&;PC4<!#D5P,24(Y X.
M:Q9<"9G3>)\D;9I_R4U[YE1,A9P<UCR8Z5&N&3<7F#%?,%4UU03QD>*N/G7O
M4;L<N!C$UXJ++,!]LK2HX&$YH>GM66*7)*S9R7(Y>@P=SBN?IHAB7\3+7RB"
MVW.8M(DL*:4#T%7^[%TBE\$T+(9\;NWG3N P-U)SVLA).1#RIR]+.!M" H'@
MXYJNO$)1X']\B27;?%O++A6CCCT_*H1:3<23C?(P?^>[IN2HJ5CD(]:5I\%>
MTG[-&G.(1)<B<IYR3Y5FFTG1JQQX+';[O#N+;T!YKQ],[>E:L6GCMW&+)EE&
M="'=MPT+*<$(R037-S1=LW8Y)-%$U3\S?"&V7RA(/)!HP/P^Y#,E)C1=K8,%
M$!Y:L$;2K/6MD<C:LS2C3)FRZ98MD-#4!XJ&<J!XQ5.3,Y/D<4I$O+0R4 ,2
M0E0\LXYJ<X7"R"DHS(#4*D-.L+DHR2 ":HT4_>V>1HR)/DH>NYP*8S$9/"N2
M16N<(*V04B#?6B/""GED*4/+FJL.?WZB6)D4%QI3*DH;!6.G'6M^3))<D*W,
M):KE_#I1:?9*$J'A.//R'W/E5<X^*MTOD6<8T771MHN-PE.W:XM 14J+,5"A
MRZHCQ$@] /+WJG%ECTZ6Y=SZI[!>Q<NMR^MZE5BC_,O<6&F.@=RTRS@8!0GG
M]:HU.LRZR3GER.GY'W+2:'IVABH:/#RNSY'0;3U423CFLL?$A^YIFZ664U63
M@* I0X-2'N%V8Y)\0J+8G+@-M&[;BD0W!T( -)\B;L;7!QV,W\Q';WK0.F<<
M5*,;X97DM+=%6Q*VWB#<DD-N;74G"FU<*!^WI[U*<)0*L6HADX7?T'^\9QSZ
M=*I=EN^CBL XJ!+N)T A!Q0J:+0S0/!IKN1DZ0Y:CJ<4"KA(Y-312Y(8W.Z0
M[;O4'=YZ!(&23]JFL<IT)Y();)=WV)[LC[)+[VU:YBVO>[#BL)+LJ1LW(AM?
MUJ\@X>0E)_.NMTW12S3V(\E[7>T>/H.D<)NY^2^/K]Q]"=)Z0L79YHZ-I/2D
M5<>%#;4=VX%<M9/B6XKJ5'J2:]QI]/'3-XX^1^;M9K\O5LGUG/\ :D_R/'T*
M>F?VE=H[AX,6ZM(2">B>Z&*\]KN<IZ/3K;@9-!2Y"RA0\(YYKGT;4^!-!2IP
M(40$D\&B@L5$9!=* K)3U]*-J%O8:6ZU&8 !.[(Z#-+:2C.V<6' TE\8*UC/
M!\J@T3L@KU&*6S(=&5=-OK[U7)<DX]B$%N;N #8&S')/3%1VD]Q.6>R1V,.(
M)4$_B(P34TN"#?)*S&G%(&,8QQS3VA97ID(!1 6>\')'E^M2FMG8E![^XC"@
MKE+)::4XM&20!G@#)_;-55+[3[%T$I24(]V4*^W1Q[YQQ*SW20KN@/(>7_O\
MZYF5[IGVGHW3(:+0K+_%1'-H+3+22.2V"O\ WC5?F=?%+=C3?<26A1\JDA]Q
M-$4YR13;&E0[:9P <5!LG? X P *K9$[(H 3J9(X#)P*"+#!)% D@P&*!@T
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MS:]![XQ^VJ#)!AQPVOZE#GWJMRODG!1D]R[$9WG>.D9.,U="2KDC.-O@DF?
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MZ@[2]4LIDVBTQ+!!7REZX$O/J'J&D\#\S6B>'!@[NW\#/BUNOZFD\&-8H_\
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M9\.!\A]KM$\6H\2*]U>9Z.+@2KK]72NDK9XZ45"7S![TGSIVA\@]X!]1H"F
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M).>E"#;8T3E]0\@#^M3? =F.-F.E1L-P/T\5%\DD[ /-  4P.H &D!Q&*+
MC*3SY4 RBW2 B?J-D+05!LD\5MAD>/&Z.)J-,M1J8WY%K5:4"V".CPX5OX'.
M:Q^(W.SJK#&./8D/K3+<=9#,GZT#&?4>52?P*Y1WQ4>U!+KIY&HX[L&2%)CN
M)VJ4/PCSJ_#-XG:*-9&&HP/!)$O#CQ[);F+9%7F/&;"&0H_1CS%$M1/(_?1@
MP]-P:**6D1'3Y^<A'C.,D \C_P!5123['5Q+))5F7]C*NT'MLTMHIEQEE]J[
M7,G"8C2LA'NM0Z?;K74TG3LF?WGPCR77/;31='3P8OVD_@>=]5=H6O\ M4F)
MM[C[B8KZQLA,)PVGTSYG\Z]!AT^'2JSY%U#JW5?:*>S<]K\O(UGLE[!XL((O
MNKH@>D A332APDUQ^H=6E'W,9]$]D_8?'CBM7JH^]\3>68[;#24-CA(P,CRK
MSC;G+=,^I8LTE#PUV0;))YZ42[>[P1<8)VER 49.1Q25U[SMDU+@#;[U*Q;@
M^WWI$:"GI0E81;3M! E)XY_,U.FNP2GD?FOP.[M"><?IQ1<G]ICW9'V?X\@+
M'I^_-!)<_:_03+>[E6">G2AT^1R<EQ!TCBR5 84$^X'-24Y1["C%)V[_ ! ^
M40<;U*5]^:/$EW'OR;N'2^7/X@.LI>;+3R6W$8^A;84/WJ:R-.TW^+,^;2X-
M3^^CN^?/YE<F: T7<' [/TG:7EC\7RR0?VK1]>U'E-G)S^SO2<[MZ>'_ +4/
MK?H[3$-(;@Z=ML5'_P 2C)!_7&:@]9J'_&_Q+L'1-!IE^RP8U_Z$_P"@^=TW
M8WVRU*L\%Y!&"E;"3_E3CK=1'G>_Q-&?I/3-5#;FT\+^$8K^A3;]V&Z NB2N
M- <MSJL^..X< GSVG(K=AZWJ,3I\GD-9]'G1=7%U%PEY-/A?->91W.ROM0T4
M\[*T3J1R:PD<-=YW:S_^+5E!XKM8]?H]9';GC3/%:GV0Z_[/2\7IV;=%>G'\
MFQS"[6^T/3C8;U=I)U]*>%NB.IE?ZCPFJY]*TV9?L9I(-/[;=5T&2NI87*2^
M[CR)%CXB;8]_(C:/OC[_ )-MH2K/YBL4^@4[\5?A_<]&_I/PY8*,='-/YK]!
M,:R[8]4[T:9T8JRL*)(D3CN5CV"\ ?I4UH>GZ;G+.V49.O>UOM MFATJA'R;
M4;KR[M#:6Y\0]J8,EY0EI3SMCH:=/YIXXK9CCTK+]GO_ )\#D:C_ +==-YRQ
MM?#:_P F59[M^N!=59M7VGY.0D$=ZV@ME*O[[9^D>XIRZ9"3WXY&33^W^JQR
M^K=3BU\?[$4FXM7.897S27 M64* R%#V--P>..TWQR1U,EFQJ[^)JF@VVR!A
M8!'M7'U<GZ'K^DX\L*:A?WHTR.LH0$XSZ>]<:49-VCVF-II17?\ (GXK?<,@
M@'*N>/\ "DFO4IS>[/81U[EL-QUK>=;92GJ7%!./UJ_%#+-W&/ 9I8]/!^)-
M*OB9G+U1I\7-*%7VW !1ZRT<_O74AI,KC]D\KGZ]T['E][*BS'M4T7:X6Y=U
M3((\HH[W]QP/SJK!T759I6U1'6>WO0NG0YR[WZ)/]"C:H[:]0SF7(^D=..*W
M' 6IE3ZU#U"1P*[.+I&/"UXTCPVM]O\ 6ZUM])P._)]_Y<&$:VO?:C?G'(^H
M3(997D=TII+22/MUKI8L6GQ_NSQ74];UWJ#K6MI/R[?U+KV"]E-BO3O\4O<=
MR4I"QL05D(&#YXZUSNH]1RZ?W<;/7>Q_L9H-=!Y]:G*O).C7NV.SV.VZ,E,1
M;1#:V(X_DI/E[\UR^GZK4:C/4Y'M_:3I&AT/3JP8HI?)7^)@NBM/6B1$;<DV
MR.I3AR<H!_QKN9LDX\)G@NC]-T[CNV+OYI,OD'2VG1+"?X+#(P#RTG/^%8IZ
MC*EW/3X^F:64^<4/_:BP/6"Q,1R6K7'20.G<H('[5F6IS2E]HZ,^G:22KPH\
M?^5?H9YK:P6Z3:Y"U0VE%E;:^&TI.T*Y''L:Z>'-/S9Y?K72]%DC4,:3^2_0
MEOA\N5F[.^VS16KD.?*(1<VV)*@HX[AT=TO/V"@?RK?#/*,U(\AU7V?T:T\U
M@55\;\CZYN$I>^7QA2,[TYSLZ<9\^M=E=T_4^42[.+XIM!',E/6K"M!,%6!Z
M470(<)8)3PX!^5&X=!"UW?5>1]J=B8FK!.0:+ (H$#.:FI$7$3[LD]:E95MY
M'#;2<\D56F7.%!'DI1X@0:DN2#"MJ!)SQQ4J(@8"R<#I2:$W0!.Q03ZT)4%B
MH0@\[A4E&R.XY01T!I; W"?<_P!_]J=BH26V%'&[K0F%!?ETIYR*E9$2=CH/
MB-,!-2$IQBA@%<:;6,=*!/D1,-!1MWC]* H;FU-D\\^XJ:5H5T-E0$A1 5YT
M4.PG=;0>:"MQ$^Y;\P:=5R)*W0/R3:QN"ORI;A[ CEO)'\LY/G34A-4)?PU[
MU'Z5+>(\11WWK>\JX6S8GOB.^;_ X/MZU\XAD</=9W>[*UK94:XI7,M3/<S,
M>-A/!7^7WKI8/>[ERX16[)IM^[MYN+#C+@Y[M76K9Y8P7!-,T"V:0APK6J3*
ML^X)!P2!BL3SSG(L4E10IVHS"NRFK;#0A:%8X'2MJQJ<?>)6A:X7"]7H@N3E
MI)3@H!XJM1QX_(K<KX*O=+/)9>")\DJ3Y9K5CR09!\#*\6FW2K.XX'TH4@$>
M"IQDW(11=*V1F[W)V$7]KW>8;)Q6B5I62;HOD^P:ATU)CIFQW'F>%!21X?V\
MZIWI@I)F_:-E.7'2$>0UD;#XDFN=D:4G8FK,?[9WKC:KS%O%O=<2I"@5X/'6
MMNG498Z851.:4[66KM&#$@-]\!M*^<\5BS:*N0CP[)LW^4I#[:W=S$A! .>?
MTK"]/L]Y%C>\H%LM+<2Y2Y"BK:23R/>NO*7B8T5B>HXKCS3<AH82M0 (K)CF
MKVL"TZ4U"J-IU<=.Y*FPH$U9'%%SL3>TQVX7];-T?FO/J*5/XY) 'M72\&,U
M0^_8UKL]E-WFT%V(M)6K.1G(Q7"UF!QGP#7!)+THW,;4VXT.\43RD9JI9IXF
MJ*MZ3*??^SF\07TR&DK7&\QCH:Z6/61DJ9.,T2/9_<$+E/Z9F%>Q])"-XYSZ
M5',DZFAR3?*%-16)>EX[T=J(2#DC:*@LD935L23*_I'34W4"OF'&5)(.?%Y5
M++GACB3VLU=JV1HUK3$EN*"DCR YK@RRO)DM=B:37)3;L;>9);+9.S)21ZCI
M6N,>[-.!.3C\7_4UBR14(CIC.#AJ.RT?;">E>9S9'>Y>;/UKT##ET6CP8X=X
MQBOY"5YTQ%O$JU):C,E<.<W*#RD K:""22D^6>GYUJPZW+&+W/R+NO=+P=5R
MX\FLBMR:=^=+_$3-S?#86D8&>3CR)K-+WI6=6>2/AQC'A)4B(MT54F4%X)&>
M:E.5(S8H[I6RSE(2!':^D#!/I6=>K.BEZ"P2  /04 <U_,7D_2.AH?!%CA:@
MD<5$@NXQE/+SL0 2KC\JG%>I;)TJ%F&PVT$Y)\ZC)VR,N%0I42 576F61[!2
M59X% P: .H $=:3 ,>:B 57"3]J=V!#0H0?NZGR,8ZXJV<JA1DJLNXL#B/P@
MY XK,F7*0W9M[[TH+:.$IY76B+6TA.2)AYY#;1;:7A'0^]./!2U?)5]6:JL^
MF+8[=[].3%BLCHH^-7V'G6C#ARZN6V*,^NZGI.A8GFRR/,?:1\0-[U)WEITD
MRJVPEC!?22'G4GK@^0_>O2Z3IF/ MT^6?).N^W&OZHI8-+[L'Z=VBB:<T->-
M12$]TVO:L^)6WDYY.36_)J,>)<LXO2O9S/U*:\CTGV<]D5FTS'9F/LI<E'Q;
ME#D5Y;7=2GDDXP['V+H?LUI^BI9,BW2-/;CI2,Y^P]*X[N3MGIHZB4GMK@%2
MSC!&/2I,MFHQK:$ R.:"'<'..* NCL \T!0- PAYIKN1  Q4K'9RNE XA2,T
M$P-OO0 (XI !DT (ET\C J5$;.;;*N33;H%$=-X!QC\ZBNXWV.6O'2I$&)J*
ME*&.GG2;HGCV<[@0AI(\>54MKEYCA'42=1? "MCB2A7*/153BYXO=BPS89KC
M)S_,0$)AK^Q9:1ZE* ,U+)FR>I3ABL;]U5]R'K;"0D;B,8\S5$IQEW[AL<'<
M+_ C[R\B&RI84@>1(."15F#;=+N59\C\-N5W\CS9VNFWZGDKCK907$J\#R1X
MTX_Q%>NZ<YPCR?'O:G1:3J4FLJ_:>31F-EO,W1MP$*YM%Z&I6Y*@>@SU3_PK
MI9(>+%J/<\#I-=J?9_-]7U/,/\['I?LXN%NN<3YF,XW(CG&'&CG ]#Z'VKS6
MNQ9(^1]P]FM5'5X5ET65-^EJ_P "WW;65AT9%<O%VE;&6TY;8"<NO'T0D=3^
MU8=/T_4ZR50[>9W>M>T'3NDZ;QNIRI^BY;^YM%(C=M.K^T%]<+0UM$//!>*=
M^T?WEGA->CATK1:&.[4.V?*7[8==]H9RP=!QM0^"=U\>&D$N_8SJF_LJ?U)J
ML%:O$4I6N1@_F0*/]9TV/W,4>$5X_8#JO45]8UVHVR?=-\_S11W/A\B*NZ!)
MOK[@SU$1/_&F^MJK411^C/!/)LRZG\C:=&]C>C+/$0^XR]-=(ZR5>$?9(XKE
MY^N:F?$>#V'3/H^Z1T]J6>#S?/\ L6"]IA6^&8[+33;01MVMH">/3BN<L^JS
M3W-GK8Z/2Z6*6CPK'^/]3S%VGR6Y=W<;:5C8<#'GFO3:/=L]X^3>T>IRYM4X
M2-M["+2W$L33B6\';D_>N%U7)>51/=>R.'P]&W0EV^R2O3S["3@J('%2Z.OV
M]D/:_+>CV?$R/2"%)CL^''%=W4?:9Y#I4=N,OL5KQ)?'48&*YV1^1Z3$N=Q)
MS%*4DI &",U5!>9KR<<E/NS)>8D1E8_FM*1]L@\UNQNCA:N&^TS.5+4F$" 5
M/(P4+\TD<@C\ZZ-'F<:\3#*,O,^NO8EK8=HW91I;6:&UEZX6UI4I><Y<;_E.
M9/KO237;TLMV)'Q?K.G\'6SC'MW_ !LN^Y*O#GFM!S /ISGI0.Z"][DXS0&X
M-E9&,4!=A<$=2: L%>-@Y\JD@8ENYJ5E;[AE$YR#4:)R8FI6[SJ<>Y5=B2'"
MI93C'%2 4[WNN3YT,3"=[WOBZ8XJ)$'!/.XU)=B+$5J4E1 53!"K;ZE#!'2G
M0Z$R^H^5%!09#I4<$4A"#\I0\( IH!#YDGJ!3 *N401A(-'<03YT[]I2**&)
MNRE!1PO%31%B7S!/. :!")6H]4T ZH16Y@8J3[%?F*,N<8)-0H>XY<K9G!Q4
MHKD3=B/S;G]9J7)&CYV:(UE;YZ/E7)*2\CZ037@M3IW>Y(] T/-662?*FL7B
MS[N\0?%S5>GU"3V3)1E?<E[?K2QPL0KPAMN64X[SSS6EX9M[X]@Y\BI:UU?K
MZV;G&6U.6PIRD-C.4^M;,,<.6-H$^>2DPNT2UN#O"SWCBL]485FK7@D^SX+&
MJ0\-YESUIE1FE,C&=I'6CP(M4Q+@ZZ3OG<*45!P=03Q48XU'L#MD3=U1X5A>
M>[HA2LYI8[W4QE$M*G&0+Q'2ZE8622DUMG35 _0U?0/:0]=G41+D!*90G!#B
M>4^^:QY,5<HBX5V-:L&JK,67H<)P(22,H'D:YV6T[F2@FBF]KP#<%J6&!(0K
MZMOES6G2RM\#HRN%<K#!?2Z7^[!.3QC!KI33R*F)KR1H$&\0GK8V]#>[U&-X
MR<USI89;J?8%)HE1$BW>W//1"4.%()YXS546\? I/S$)EHF.:=1'#&YQ"@ 0
M>E99;5.T2B2"HC473*HRF@AP-^(XYS6O KE:*<C=F(_.6B%/5'NK)4VITY*D
M<=:ZNZX\=RV$;1OC=MT[I313=QM+P;=D(2I(W>M<66667+LD:)PBHD;H?7[+
M\HQ;D$G^:4A0&*LS:91C:,$L:?)K$J)'D1$J;"7$+&X>?6N7X=.RB4I1[&6:
MSLDNP3F+Y:K;WFU6]6*U8,BR+9+R-6&;<59,.ZWLLNSMW6\,MI=V@+;4!G-9
M)Z?)++[KX-,:(O3][CSW"Y C)BQR>IZU//A>TNBD6"6FW.M!AJ5N6[X2HJSB
MN?&$X,DU$@5V!*KG%B)*5EUY)SUX!R:TSR;,4IG5Z!HWK>HX-/7>4?P339H,
M!60MUSZEJ5^@P!^U><:78_7F-I9)O&O=W-+Y(FHR$AM3YXXP,42F_LDTENWO
MGY\E>N;Q<=V)YR:MA&D9-1D<W1+V5CY6/WBAXE],U7D]YFG##;&R0800E6[Z
ME<JJ++TN 5K*< =.E 4*-I[MK8CRZ9J+]6#VXYUD 45ALK<(./2DI*Z(SGA<
MU''Q\QK%"WGBZI/ R!5DIQ2JA-4[<E^ ]/A'(-57O^R"CXCXD 5^@I[9$EBK
MNP,YYHJA[:[!AC'-1=@!4TB-G441W,' J(;F#2H:D OZ%8ZXH28VPELC]V77
M5#E1%2GSP5N*;'R&E+.!Z\U7%>I!\"KBT-Y;:5W:4C*E$U>H.*OR*9MQ2EW,
MM[3.VRPZ(85#;=3+G$'8AOD ^0(_SZ5U-'TYZKWNR/+]>]JM-TK'6-[I^AY?
MN]ZU=VE7@R9\EV0%J/=ME1V-\] .E>DA#%IHU%4?*,V;6]<S;\KM/R]#1]#]
MBKCFQZY1PI1.XGH:YNKZAM^PSV?1/9=IJ62/XF[Z;TK;;)%0EJ&VE:1C.,FO
M/:C43SOEGTG1].PZ1>XJ9.A&?#Z<UG7!THMQ=]_F'4H(  Z^]'<4I6%2G?XE
M?E22HBD<H8.!3)=@,"@5'4#"[C01L"A =4@ 5TIDH@4B9U !23FF!QIT1;H3
M2UD\TR*8X; P1462W!5D)5A-"$Y #*CC%2(AT)P>F*5CI,,3@]!^8J#C82;:
MJV%5A2N4CIY"G%;>PHVEMM_B*)3Y8&*'[W<:C7F*+2$@9IP?'82M>;*!VAWA
M$& OQ>O6NCH(>)-6CS77-3+'B:39Y_7'D7::]+.X)*LC'%>G3CC5(^>QB\MN
M7(:7IV'=DHA3FAM6=H('*2?,>])9WC>XRY>EXM8GAG&[\WW7WBL/LAU]I];E
MQT1>7EM[2KN6WNZ<Z>:3X%4+J&GR\9D<G_LEUCI<WDZ7-M?!U_4EY6@-7ZBG
M1)7:!<G5./LHWQ&<!12/)6W@>^.M)Z_#B@UI^#1_V6ZCK,T<O5Y.3?E?E\>6
M;/HBRP+'%:M]NA-1HK?1I",#/J?,GW->9U6>>65MGUWH.BT_3<'AZ:.SY<?C
MZEOG%*H^0 1CBLJ7O'9DDXW)6RD2?#=$GU4:VQ2VG&R**RKW5^!>[6[B"",>
M&L&9*SLX;E'DJ^LYZ&HCBU8& :U:.#W(P=1S^%C?)YDU O\ B6H@6SG>^/\
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MJ6FV EEO/GFM^<XNBAMQ1+S;%)2DI/.!7,R=SOZ:D)S',$'/"E5.(960%V;
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MJ:Y.=II>XBS6/.%@*&$^]8\J.QIF3A1WPW$]*SITSH-;U9!7I24*R$GCVK3
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M31EZ;"+LXY''3N94+*/S(R,5W</7NCZKB:;^;3_H>5U7T8>V.@_::/(II?\
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M*6><UFU618U[K+51H[UN<7H!ZV.MH4^PM03D_A^]<=9\<<ZDV+;Z%;T/:;A
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M@TFWQ'=Q0D@@=< \&O5+"FK9&A]"U!-0VJ+*.U@G "NM0G@CW0B/EZ9E*?\
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MAV1V.@](ATS1QRU[[[F@)QN5CIQ7-7"IGHFEM4O-AJ"(DY]=61[ <%@#&**
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M? T)2%91E((J/-@^$14%^.I]<AY"PZD[1N&/SJV5I4C/#8Y;WW)=#[3I![P
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MI)H 3#I3R#C% !''2ZDISR?>I )A_NQL53!H8O)7DK0@'/M2 0"%NY4\2-O
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M(CG]E,87G^EU)_SK.]-ECWBS5CZAI<G[O)%_>*]Z>.<YJMP:[G0Q0EF6Z"M
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MBG'3XD'%2LKH.RV H8ZTI=N!I/S%UJ24[<C/I21(C'RI"]P%,83OG7W!N&T
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M,50,#%(BP](0 &* ?(4]:"+##I02!'6@!6H@=0!U '4#3HZ@3Y.J2 Z@#JB
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MU67S-4UR5O46-KF#Y5KP]T9M5+;C/.W:/&*Y+BNO->MT?V#XW[2X_P!JV5R
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MU"/@?J!5BE@ERI'-U$>KZ?G/AE\VF07^DR6E!N=:W&%#@;3Q^]6>&G]EG/\
M]1YK+&B1MNIH/>;!,&2?I5X,>V3UJ,L;-6#J..^&65J?E 5M42>A]/>J'#D[
M&/5*2M,4$S8[WJ5'<>#CSH<4U1..?WMR98Y<UF:Q"F+0I)=9[LGR)2<$_P"%
M9U'8Z1Z..9Y\*E.B.0W;H%XCS]Z49/<NE./$E? S^>*L>YQHYO\ W7!E6?%+
MWKIKR'RG/E[FZVDXV_X]*H4;[G6<G@U$L;_S@NG9D$NZA>E#D-159/NHXKF]
M1DX0H]5[*P6HU<F_),LVI'?Y;ASCVK%IER=KJ.5N+;,GOKV7E$')W&N]B5(\
M%K<GO,<:82IV4WM -5ZFE$T]*CXF1*1O=D2&H+2E YQT'G7EL].9]6T>.:A&
M,>WQ+ V26.A&?7K52C;X(Y,N/'DV9'^!6KZ24N8R36R$7"G(S:QPG&D^#!>T
M<[%NJVJ./2O3Z.7N\'R?VF24W313(DE)*$K)1GU236YQL\IADH.FT6RTOMMJ
M2D^(?U=!63+!OL>MT+W)4K+/%GQ6DX*A^YK'*+\SMPDH=R2CW=A/5>/R-42Q
MV:\>J4?-"KTEI8)P!_\ C$TE%^A')K<2^TR'ESV6W!N?9X(\.X G]3BKXP;[
M(P3ZEI4_M)?-JBC:RN$)=U"T2&P%-8([Q)Y'V-='3XY)<GE^IZ[3>(Y+(G]Y
M0KI/86,*DM 9./%FMBQGF]1K<#Y4D;3\#*.^[>$.LJ;<4S99NWT!(2/\ZNP\
M9$F>>ZKD4\+E!KL?0C*T*VN8S[5V(T^3PS4H/WAS'=)6$^53[\$;HE6X^YKO
M#@5'<UP.D,G%]V> #4D18G'D/N.E*@-J::(MB,A+BW, <44.PZG@PT-^:="3
ML:FXA04%(X\J28VK"Q%L+<+JDYQQS37J)H7DH9<.4DI'H*D1&JAX0E SCSH&
M,FXSX<*W5#&3Q2H8=;(2DJ[P8 SP:8,;?RR<!7-2(@*1GC<<4 A'9G*2HTB5
M %!20 3@4PH*^V%_0KG%(*HYJ/AL!1.:!C*21N*>>#BDV%!P^A"=H&?O3$<%
M)<Y)QCTH !+B=^T8-, %.(!Y-(#N^3ZT6!\S#'+@.U.QU/4_B'YUQ;W':[DA
M;+R[#4(LM6]"O"DD<@_>HT(M^R/-MX2A[G<"!GFLN3AV2?8GH^A;;K2SJ@S4
M;)" H-.;L8R/WJ>GR7[I0Y;'94;KI9_2$%,"0[WJ8_A"_7TJR7,J)J5\CBRW
M!+L1M>04+.%\=:P9824FV-\<ED=T_:I=I1,MR%A:3_,3O)JO#JY;MN3L1NR!
MNNGG8BF+E#;4X,C>$GG-;<J3ANB.&1,MEQT>A^WQ9_SO<K 2L@'D'TKEX]2Y
M2<&2E(MMVU]=]0P8%MVK(B@!3A'F!BLJPJ,W)%))Z9M=YN[B4Q67I3A.#X3@
M4LF2*[BV6;5IOLF$5A-PU5<F8K8\7=%?B(K%+-?$!I[2;=UWHS2Z?EM+VU,M
M\<%QT[MOOS4H8IRYFPE)$)-[1+E=' IZ8=HZH0=B4^W%;8143)->A5M7]OVG
M>S]E8>6F;,VY2RV<_O6[28]SMDEIY3[F/J^.2Z72Z.0$:,;0@9!RO!%=26);
M2SZCM6ZRK:B[>]?ZN<>0Q.-MAX([IES!(_*LG@13LT8\*1ES$Z4);SJEJ><>
M6=ZE'<I1/F35WV5P6=N"(-R?N+\RT+82AP\)\&,UKCV)4TK&$RP36XR&WO\
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M4)(R14;)/E"R ,4B !)S032 R:!,Z@@SJ!!ATH)@T &"B3BE0!Z0'4 =0!U
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MS5E[T4Z_)WJ"2(K@ 4KR-<C68W!+D@U18F40XZ78["4NHW]>N#1'+-*FRI?
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MTVA)L.R\=Q'-*@W +?(7C-22X*Y3Y#)>1T5U-)\$DTQ5*&Z-S#<DZ'#;2?\
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M"HW=3G]*>V*![8]DOQ#+ &-V>>E%+^$AORR_=+\!)6W=M\\9Q4XMH?O_ ,8
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M^!6KG\+O;7:6E/HTF)*1SF,^APD?;.:S3Z5J5QL?\CLZ7Z0.BZI7DSI?-/\
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ML]LXJ:R%&3!2(:= 6"=J36K'-'-S89/LB EP72> ?>M<9I'-RX'YH9/0'5C
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M]YM_$?L=*JF;4/&4\9SUJEEB%P.*"30- !MWM2H8%, R3DTF@%$]:B :@#J
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MZ9A:R;V$DWPC(EW!I2%+9?4/"> <9KT34>Y%0DGR>O=+P@Q8;:RE("6XC#8
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M*WX]%""['G=5[5ZK,_<FZ*]+U=<9/B>GNNJ]=Q _2M$<$%Y'$S=6SY7<IO\
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MM6:08+#KA^G)YKI=/[-'EO:=)*#^9G!<8>CMG(XQ72/&[HUW+=\/UQ=MG:]
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MSSQ0((H;5;J!@$I7@9%  [$_U?O0!X,M$2;.4EI6W^8,$+Z8KE.T=6^"U?\
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MQ9.V_7VC[H0F#J2W/*/DAX?YUFEH,\.\3MZ;K^@U<5+%ECSZR2?X,FV9;4@
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MA^X%- 8&:!B8:5+27$DI YQ1W'V ;04* /(]Z0A%R.VIW=B@=G/KPV$A(%#
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M\I1PDGS%<W44IE<BYVG3UL;?3(DQDR7AT00"*SN3\BN4C5=(W"2RI*&8:$X
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M9*$3-;!(<M]U<W# 4 -W]7O6^78L:.U'<@]<$Q-V>1Y>U$.P$=> &9D-:CA
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M&XY\ZNC(RRBT.V6.^>"FL H!YSC<1Y5(BT-+D%*9<^93WBMJ6SL&W>H=2/7
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MLC8JCQY/I2)KD,623QCFA,FXV$5!5DY\ZEO5%3PL*J"=O44ED0O ="1MA7R
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M856F/7,&3[>-?R_0Y7_87JF.5:>3:^#K^I,P^U3L)UGX7;M87=W.)D5+2O\
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MEOS)1A1YOUUVMWK4Z3!BJ5&AJZA)*2KGK77Q:>.-67PQ+NRF7!A\M-/G*DD
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MQ4F;H^7E!VGND]X"1Z;<\5DGT[-C=.$OP9W\/M'T;4I/%J(\^K5_F5V98[U
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M;<@I]!_G4C&YKT?]!I)F1(PW2I3:/4J4#_A4E!OL9\F:,/M27XD8[J>VL_\
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MT'G 2$^O0 ?BP334;8/(E#XF<ZDO;;[Y'S!>;:?_ )+314M;\@?2?3&[.5=
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M-J;)_(((_:M+Q:34NH4ODJ,L-7U[IZO).=?%M_U*O?OA\['YV78]AE17%?\
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M28 0QN(2@$XZ[R*LCGRQ_B?XF6>DPR_\./X(3*D-DI(5E7_Q8U;'5ZE=IO\
M%F/)T[12?OXU?R7Z"*EI02OO%X'&.\%6K7ZE?^(_Q9EETG0/_P -?@OT&JG9
M'_1S7%#SRK_U5/\ U'4>IFET;1+LAJ\XH@I^8<'VP:?U[/ZE,NE:3T&;L?JL
MO.*^Z /WI?7<S*GTO2KR&2HB03XU *]#1];R/N+_ $_3P^RAL;8UD[WUX/O4
M7GG(DM'A] $VB$5>)M;GN#47EEYDUI,*\A9%I@(.2PG'HI(-1\21-8<*\ARF
M+&2!LCM@>6$"HN39-0BNRX%071P$@4N2:I>1VQU7EFE1+=?9!@RZ1MVC-'"'
MX620HB!)=/"0:-R)QTV0=-V64LC Q47.B^&CG+N/F=,2G"#N)-5O(;L72)S[
M#]C1DUW"MM52SJ)T,?0<E#UO14T8 ;&1[56]2C?C]GIL5.DY;:/[!6?6E]81
M<NASCY '3D]O_H%#\Z/&B6QZ7./D+QM/S^O.!4)9D:<6@R$W!M4QH J!XK+D
MR*7!T\>EGB6YDB9#\<@*SQ[U3MLT>+*(PN-]*4E"B<'@\U9#'9GS:QHG.S[2
M%UU:MUQMU4:U(5N=E'Z@KS"!^(].*EE:CQYG+S]2GCBZ?!Z'TSIV!9K>F-!8
M0AH@%1P,N'^I7J?\*Q23\S@9=5+43<_4FD =XTH#"$*P4^1_*H-%5UR$=$E4
ME1QE7]/EBA"8Y:8:<92J,%+4CEI(.,GSY\L4_,@PURE&3#"DI86B-XEEH_0?
M17J:DHD7(B+E\Q*#3K"4K2^UO#:N4\>WE15!;96@E]Z-W:G0VXE;BW>I PGR
M(JQ))D.6BIZDDVM*79+5R4MUYS8&22E"@GE6<^GEY5IQIF7,UZE5EW!4Q [X
MAA,DEY24Y[PM@@)2 .F3TS]^E:(Q,<W9"/W*0AM"G65J#'>*BLN.8)SQE8'!
MSXOR%7*)EE*C/-4RV)LN0TE8+:4 2WT#&%)Y*&T^9)X/H /O6O%'@Y^:7)-6
ME3-BBPVE/AIR-%^=0VVCPA2AM;&P<E:MV3GGCT%$N1QX(J7<8T1L2EPDN.1P
MXS%81XBXX!EQ9/\ 3G&5#C-2C$A.1#?Q9;#DRXN-HD7&4Z$M*SM0, ;B!_2C
M  _:K4BAR(-5[;4X[,+RBXC^6PR4\.'\2\^?I4J(LK[P"'EC.X).<GGKR1^5
M315?(M%E(P-J0/%CBF*3Y- T,]W$M5T"<]PC ]CZU1J'[AFRL1NEWF7N\A#@
M.,GDFN>HVB@M#%K>M\4/-$^].J&3]@47-N.I-)R*FS1+5%C,,)=D*Y(J['[W
M!7?)4]>ZB@%!A1P-V?(>U/+DVJB20VT=IM#K*)[YXZC-4M<6,N4.]V^-)+ Q
M@#%3PJV1(#6[[#R4EL\'FM<UM)Q[#'3+#CA&#D8J$.2,BXVN*IB4#GFMFG?)
M3)%J;FN>==-2,[0]867AD*(_.K"(IWSB3L:2%*\\^E ')3N4%.=?2@!=UQ#;
M?@Q0(3P'VMW4]* $$1BE9- Q"4[L7@<8XXH&$&-P5B@ [CX4H"@08D C:,''
ME0 JU'0LY=/E0 I\K&_JH ^=:A/C.K7(5D+\1&?.L-'5X+'8=8)8;^6D93D8
MYJ+C8FB.O\=JXO%]D\GTJ4501=$;(MJ(K*5J6 K'0GFI>87;#0+R_"2IMT%;
M*N,>E)@XWV-<[)K(3$<NKG]@L[F$8Y2H^=9-1/BBO)+BC9]&Z>>N=R:8</\
M+2=RCY >=<_+DVQ,C9.=HVJ(Z4)B(*46^WI* "<;E#T]:HP)M<CC"W9Y5U]<
M'+M?TW*4XMIH[DMX!RG'0UV\*J)L@J5$;'E3WFRJYSC(0.$\< 590P.XC[%/
M,8P>I% '7%0?MA;SGH*B!.W"W-O62*RR,O.)0./2A<.PL@];6T0DP((6%+D
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M:K<SX1Y\"O+]0;TFOAD79DFN2I]DRY]J[+-0O!X@1WW4 ^F.*LZ@UDU^.O\
M.Q)]K,N?O5[U0I,>X[E,IXQ7H7)44))2M%M@::1;89N+[>6U)P$YSCCK4(IR
M[D;29Z/^&N4XYII(4@J2W+=('K])'[5Q>HK;/@]KT&2\*7^>@7XD+(F'<;#J
M!EOPSH[C*C_=0K*/U!-4::2:<3W/3IO>C,H+FY !&#1D5,];!^1*-X">O6LS
M1JB.6_$.*@7Q 4",\4"8F,#))Z=*9%>H52P?.BF)L40NE18I(5!'6HOG@G0J
M@@U"F30L,8I%L -H/E3)4=C;QC%(=4#GVI@=M4>E <L.E.*1)(/M4?*BT.F
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MBX#@9H&+H'A J+)(,$#<%9H);?,.D"DQJ(H *B3092 />DR:C;#)1[8I46J
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MV)K<:?0I6=ZD>'@8YQFH]B=6B3MUO"H[L5\Y*RAUM8_ >IS1=]@2I4*22\\
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M]4K76KV>^/)BL)!S[9YZUDEU349^-/#CU98B81KCL4T=!7#T_IIJ;*2G#2U
M$@_:J%I]7G=YI5\AE%N_:=JK4KK+;L@Q(T<D-LI2$I2,\#G-;\'3\6-[O,>Y
MM4:[V:]J$2X_+Z>U3;XK;VW#+Z4CGWSZUR]?H)JY8VW\&55S99+Q;Y;-T5>+
M*XEM!'B"#R0//\ZXRG**VS+U31E';K8DZFM"=8VE):FVMP%]&WQ* YR/.NUT
MG44W@D_D1V4^"[=H6HS/^'^&[O/?2H+84?Q=*YFEP;.IO=Y VU&F>6(-KDS
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MO5@=2-P&YOP8_(]:HET^$OLLZ&G]M]5IG^WQI_Y\RV0.V?2\D#YA\PS_ /'
M*<_XUFGTN2Y3._I_;G0ZAKQE*'X46B!K*R7)L*C71AX'&.[4 1]\XXK)+1Y(
M>1Z/3]=Z?F2\//'Y-\DL9REI"FRVM/FI)'_&JO"?H=*.KPY%Q)OY"2K@E)P2
MD_XTUB?H$LN*K3D(JN*%'%3\%E+U$5V;8DN>D< @9IK'1!ZB,OM-H3^8).0:
M>TAXL5VL<QCWIP<'[U7/C@NQM3Y:9)1P$X^FJ9<FW'#TLD8[ZT8&T>U4N"9L
MQYE$?-2U('TU!XT:XZF/873<CCT%1\+XEJSP7F&3=$IY*L?>EX;\B3U<*XY#
MB\)'1[]Z7ALC]=2\F<+TA/5S/OFFL;']=@_)A';TGZDN) ]Z:QL/KV-=Q+^/
MM@8[Y&:/!;*WJX/WK8BO4"/]NW5BP,JEU+#'NV).:E8 _MTTUII%<NHI>:&Z
MM6QD]9(_6K%I&9WU9+NQD]KF(A6WOTDU9'1,S3Z]CAW:(]_M#C() =S_ +IJ
MSZDV99>U.)=FB-D]I338)0M1^ZNE6+0G/S^U\8]FB%E]JH&0AX$^_-7QT'P.
M1J/;%=[*]<NU1]05_KB$>Q5BM,- O0XV?VWFNQ7)?:4^[E)FJ5SY))'_ *ZT
MQT*7D<34>U\LK9"S-<OR!AEIQ1]S5\=&CBYO:/)-W9$/ZAN4C.2EHD8\)YK1
M'317<YN7K.?)V;&3LA]X?SGUK_WCFKU",>QS<F?-E^V^ @)Z5(I7'8*H 8(Z
MBEP3W,.E+DM?=I0XZ\<):2CDJ)/0)\ZADK'R2A>5[4>D>P_X>T)$;4VKHW>3
MO[6/%5]#0\E*!_%[=!7#UNO5[(L]-TSI3262:/3MMMT=AMM 90 L8QMQG\J\
M_).<K9ZZ$E&.V/!-QH+K2FT)40X#X5#J .?\*GN:137)*M3UQGRS+>46U^%2
MCSQ_NU#N6\+N.7$Q4Y@OS'C =(<0^A65.*_I]JM1FF_3L1JY\9@H8;4TKO1W
M>YP94D$_6KV%/;;!M;0)#B[2[(M=E97-0O#B5%(P7<<JS_3CI34;Y95==AM<
MH\2,P2;>\XZB/N[X+ &2>=I/4#SQS49)V33X9!.2HL1I+SUM6N,V@.; X5I"
M^?$<\X^]3BB$I.K,]O[RC)7*2XV25;G"T,)QY#'VJ])%+;JV4J\7B+O<QA\N
M9PA7(;;!.XCW)P!^=71@9IY$9_>[K%:C!QMY2GIIP@MG!0W^(@^W3\SZ5IC%
MHQY,@WLMG:NTUN&XE3(;1WCBRHI"$=0,^61BI2X17%*3+P[:;7;HK26%1HKI
M=W+P^I3C:0.-B>F/4D^=4J5E^U)%<N%ODW1XPK<[-5$4?]8+9+00/7'GD<DG
M/ZU8J\RJ2?D-5RXUO;;1:[<\['CN*>=D3%;0I70*2A/)'H3ZY\ZE1"QI"5-F
MN$SXPV)\8R<A:UD$C'3@9/'I4E78JDR!U;J%B6E4:*V U@C</,$8(_05HQ0;
M,TYUV*5E3SZ68[2W$NGNTI2<+6O'TI/I6K;M7)FE/BR_M:#3I2+"NEU<;-P?
M2"AHN^&,DC.W'FNL&LRRJH.C'.;ON)7U$,QFICR4K!( W#.*RXI.N2MT62S(
M91;4NH.!MX JY3W*F*BE:WN-PBW>(62ONU'!YJ:)VD3MJ?[YH=\PG"4A0&.I
MJ22(ODI^LI4^[.KA-M8#7TU%<,5$'HI#_P#'=K@VJ3PH>I]:KUDJ@2D:9J".
MER IE)VJV\D5@BU:*:(2R1HUG@*E7!>%#E!/I4U%Y)-(FE2&[NKN_BR%,YRD
MX&#4_"<'R .FK4F<I4^5]3O3-:75DZ7<D;JQ CM*;5M'AZXJR%D69S(8#S[B
M&OI*NM2;(&CZ,;;98;CK R1Q5>1TAB-^M+S4LO-*.,YK)OL"6L<TQ-A63D=:
M@I7(.YJVB;C"?;*W\*.//RKIX:7<JDBQPVV'Y^]L) !\JM4E9!DU,?94@-#
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ML*_]1Y[A1?&TCQ.8_.GX(Y=5^(C(O<=2L]Z3]SQ36)KDS3ZDI>8Q<OK:23D
M59X9EGU)Q[#![57<DX!Y\_2I+%9GEU><>S&;VMY24924N)!Y&1G]ZDL)GEU;
M(_,:.:^65<P6G$\<%*5&IK%\2O\ U254X)_&ANYK=ITG_N1&SZ&,#BI>'\2F
M6MW=\:_ 9NZF8>_^PT<G_P#!T_\ &IJ/Q,\M0O\ \M?@+0;O#6@N/VB-G.0I
M49/_ !J2A?F9IZE?\%^ LY?6$\(@PDCU$<9J2QOU,\M1#_@AFY?>3W<5C/\
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M72[%X3.4J$ *E!VRICZU1$.H#BCR>M=3##BRJ78G([:&AC((K=C5&=B[J$;
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MCU->5U&>6>5L]YHM)'38]J+W :9MB%#NEN1E H;21SN]3Z"H[>$6-TV'4ZB
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MY*K3-7X@X HI1Y?3TZ\ >8YIVF*I>1%R['<&D%UMMIY@YQ(97WB"/+D?2?\
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M/$G\ZBU1),C8K?>$IQM*?PD\BHL8L^-R%) \J #?)I,1:6P$$H4KPG9SCS-
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M5#=TQF@9&-Q&)$IV(^,AY*D!/F2>?\J &D%;JVUI4?Y;)+2![ ]: 8*P<]*
M"%HJ\6.*!H%O"58S0.Q8 J&0,B@B<'5A0RE77TH 4+W\P'RH =6:6N#,_EK2
MG>%$J)XH$2ZYR5GO%*&Y/.<]:=C('4LKYE+,EM.YUO<$@<XSBD"]!FPY/3'<
M??DH(6WMV \T (M,EL)VMJ2, \B@!9U2&P"%#<?+- $6\ZN4=H;)P>F.M UP
M2T&-=?"J/":81GGU% A_.M]PA)2JX.=X5\HP/I% A".$IDM=X5I\7&T<FDNX
MPD]EJ0E20XX=JR5;Q@"I >BOA5^(F5V*3)\:79U76Q7!G_7([91WFX#:E387
MX5''5/F/.I0EM[D904C6NT;XH]&O:#N'9[V*:&C:2BWY93<Y:V4,\+&70E+?
M W=,GIN.*DMM5%41VN[D[/)[EIC6JY1Y2%%E4I. TA14 4 82#YG!%0VT3NR
M9;;='A!) Z5,1&7&0"I+3"2IM"@5A/7'G41@Q$J2'5--.@.?0DN9Q^5 ,*^4
MH;+KZAA)_0TB)2K]>7'7B L%'08I,?8K3CR]RE!82#US2;KN%-\'H'X7="L%
M^3KRY-%YU*C%MZ%#PI(QWC@]^0D?G7$ZGJ*?AI^1Z/HFE3_:R79GJF%,95A2
M7TJ.-HYYXXQ7 C[C/52BIO<*J>VN*<D#Y<9X4GZC[U.[$UYAE!3R52!:W5I*
M2/F&W@AT<>A\J+(\$;_#D)0T&G5NNIP4*82AMP'U(1PL>W6IV*D2A>FR(^X.
M19"G<(=_U<MNMXZ!:1X>3YCFHMI$U\1+_N@ZXS#G(6&DN#E!2XMKCJDGR]A2
M^*':[,*B4JUR3$6LQXSB_P"<&@I*'$_A.P\!77)'6E=C[$?,B1YX4U;I/T$J
MV+.%)']0'G]JFI5W*)QOL5F\S9:1\NO&P('\P=5I]:;HA&TBIRYS,5U'RZ\;
MSP5'!-2BK(Y)+R"39JDI[SI'']JWY@^9%22&WP,G;BVPZ&V'$;5G;@D<Y\JE
M5E3E78(W-0"(CJ5%L*)*4#(-%4&Z^" O]U@(:<5*=4\[M* $GJ!TP:NQQ;?!
MFR23X9E%^U$_WG=MOO=WY-.KW[??/^5=+%CON<?-EITBLK?[Y2E+<22>@!K2
ME10T$;8)!R#G-2LK[,,MMMI.YU80/51Q2\R39'2[B7"8;>%-JXW#I5J14Y4-
MV$_*IPGG-6K@R3DY#QE[<G;M2HGC:H\&I=^Y%$]:9;3Y$>42I3?"'%=7![^_
ME[UAU.G4N4*[Y0[E6U3<MIVVJ#06<E)\ZP26S@'#<3T:_F*!%OT<O13@9QTJ
MMQL@VX%5U/I53EP3>M-K5M!WX'.T41>Q4Q*;DGN0YA:L"D?+2C_-2,'/G0Y*
MB*9.Z9UM(L[ZD*'?0GSM>CJ^DI]157B;GM9;&5=RS3[/;+K&-SM4_,;&4L%7
M*#]JC)5VY(36[L8=JC<J]"/O&U)'G6G%Q%MDL?$61<>!\Y<=I/A2>OK5RG4:
M)QGMA19C++SK4)'B2D<D<]*I5ME>Y=B=;A3I0^0B,J45)]#YU"46V2;1+Z5[
M%+S\PFX7$!I 5DE8VX_6KDN!<FOVRPV6WMAKYQI9VX.5C-53Q;^12;L"7H>R
M7IGN%3FF@<^(+%*.-Q(\C!?9A,M3839-0H)\@%@G%7JGW)6R+DQ)C3W\-O3#
M;V>.M/E=B7)6=6]E=KD1S,M3'=.K'T@<*/I4?$I6P[]B/TSH"Z6%I4F[0S';
MSX2M)3NSTQGK56]2\R<4[Y)&]36H=N<44X&,9J:2+"GZ>ML*5-^?0I)4[GD&
MK*HCP7(/)LD-QZ0M(20=N3BHKEB9DMVNS]RNG?E0PE?%6TFB!H^GGWG[.A>?
MP<_>N3D?OT!7KM(<D780MIX'-)I_:%?-$C:]-V^W+3,E@%Q9!P>IJR6=N-1&
ME0^U7KRX,LLV2UN; K"..H%68,=JV!"JT_=KFZER?(6L-#PI(ZD^=71C4B;C
MQ96-21)UO>+,A*DI_#D8J])>9#F^1M;HSZVB\VO&/WK1#$I*R+Y'%OFNMO*:
M>/.:YNJQ;965M[1P\9#[P2V3CRQ6=41WOLBQV>UO]UN4%<^U2\)ODT8I>H]A
MJ<:N+2"KT!%:,..V,TN*FVMPVTNJ3N5QUZ5LVKLQ,7CO6>TR$*WH*5]?$*%%
M+S*W9+2Y5EFME;1224\8(-7VFJ($3W$?^@U7M#DB;5J2Y(D,,R 5-[PV1Z)/
M4UES8W+A%CQIE$[1TVY6I5HMJD+!&YPIKIZ:,E"I%BX1&VZZ6JU-.]]*0"<$
MIYZXJ;7(K!L&HS>9LA3+6QIKC[CR-$HT*7!I&GM)./1#+>2I'>'=@^E9Y.BF
M<[X":MO2;+!5%C$ )&%*'^-3BO,A&/F81=[E+OUT"GEG:#X:O2-4>$*PX;[D
MQIKNSG< 1FA\1$V:.I:F6!@<;0*R=V(",V@-+=3G" 5YQYU;)VJ!F=S-0N,Z
MC5,4-[2%;5)]15\5[I)1N)Z)[*K>Q<&DW-GQLR0$X'ED5QM9/;[I1)&@2X*D
MERVO-E2$\?85R)RVS017!BG:5JMO1[\BQL'NT+)V(0,*VXKTNFDLT4R:A9D$
MN4[<F52I;W>]=H/7'E6NN2SL2G9G+N#5W<[IY2&4MX5Z5#+V%D2-7LDM9>D0
MU)WE]"N?RK+DC5,IHQJZ195HN$N1,:4ZLND(R.@)K6I675NX'-HA!2C<7@2I
MP8VD?30V32I4!=KDIII;+"#E:AP!32;[ N22#H:TZKOV_P":KH#YU1..V1)?
M9-'LL*;![(TW8,+;6^]LPK@]:ABG>I:,G>9 MWE;+BD[6RM)P,IZUT4Z:+FN
M JKA-N*2S&24>1<Z4,*H.D-PFTLESO7%<;O2@ []V>@@*C*&['GTHL5$<[>E
M.+2K* ZOQ*VCG/I2;&D1LR<^\L+5SN)%1)#5T22ZD-YVD<_>@!S'+J%[-YH
M?)EOQ3N"^33 <Q9DZ<K:WD\]3Q_C33 ?R[]:;$T D"3+\U+.4?I18NY55S)6
MKY1E -0VV%\]VG&^DQU0 95;K@'%G>>\3L5GU./\Z0"]YTM)LFHD1%I=0W.;
M:=9!2=BDN'PJ"NF"<C.:*H$[0TO5N>M,DQY#:T*3D%)'.: &J-P&U25)!YY&
M* "J0V%'F@!S'*0T4YY/2@ [J4$93_A0 U)QUH [=Z4 &5.4E.PG&* &CDDK
M. >3TH 3"EM*Q)&Q.-P.<T "F>9'@9W+4., &@*',/2USO3J5N-NL-CHKIFF
M.Z+3![/&F&P\\ZH)QNS_ )TZ(MV6F);K9$0&RD.*"MN,>>,TZ$1&I8Z)D%#3
M2"0T2LN =0.2*&AHK#]N*5-K0J0E7&W8,$G\^,<U 8^N5IC_ "3DA#TCEH*_
MFIP"?/%.A#NP&.@17G8 <6SA8!/7VP*$!=$NMK4A"XK9^8/>(2WSM/\ 2:L1
M$D)):E,N_P 4<CHEA7@0A/C; &/R"NGKUJ3^)'SX*W)N!9"(ZT=RH )Z>E09
M(B0PY(D+==5N"E I*.!2&2:&AW2E)7LQ^+TH$5'5E]" 8C"@!^)0\S46QHHX
M6X\YM4HJ4L\#UI":OL.K2S)ESTQ(6U2W"4'>$[!@C))/3&<YZ<4I>\J+5[KM
MGI'0VMV=.6N#IK3\N-/;M<=4EU4Y1CJ=458"5%6,J43D)/D1YUR=3H/'>X[>
MBZK'2Q4&OB7^W:XU'#E)B7"UK>DJ(2M*DICLM$C(2%GZSCR3S7+RZ)X^QWL'
M4(9URRUHU;$CGO+C?8$5U'&R.5O$G\LUE4)-U1K>11[R'S7:+II]U"&I4AI"
MLA+IC.M-K(ZG>4[<>^<5='23?)4]9@3IDR-41.Z:? CNH>0=A2I+W3KDI.4_
M?%0<9>A8E&/:5C:1<K=-(4I4;O/)<9XHV>R@>M4S3HNQRW.FN!TS=7HC60IM
M4=0V%(3R?L1QG\Z@I-*ASQKNB%DW2.])[EQ_+"L_RE9[P>^:E&-\E;DEP)20
M(>R9'<.6$^!0ZJ!/((ZU-*R,EYE=NUX<FIPI3*6MQP0.0?+/H*EMY(;N"GSQ
M&!+,AU)2GEL^>:OBC/)\D*_<&^\2V\5=X>$G/AJ>TK<B,7,6A&5I&$GA6>AJ
M6T@Y<$1+U<ZPE2&CAQLG)]<\5..%S?)3+4;5P4N^:B>=5M2[G;G'YUOQX=O)
MS\NHW%1=>4^OQKR2>1Z5IBJ,4W;%V(S0&?Q&FV/N&<EHCH.0"13JQ-I$),EO
MS75)*<-'I5L8\%,\G(1"$M@) SCBK$C+*=B@YH$"!MY]*="'+<DI0I0<V%"2
MLD=<#T]ZDUP.*HT+3L=6I&V'66R7FP&W4)_ 2,C]JY6?#3LE8>Y6J0'5VUQE
MPD9V^$U1M2(MD'!NMVT].7#GVYY499V[BG( JIPLSS;\Q6[Z"DWAIV\VIAU*
M4)WG:.,56H[. B5*V7=0F"+)3A39VG/J*AEQTMP33O<_,MSURF0(3DB([A&T
M91TSQ54)N)*+KL9U+EJN$[O%(\:SBMU4ATZLD[5IBX2GPD)6A*S]=/N)VR_V
MK3-FLS ?GNI4I(R1YU)<<#44.8O:YIZTR>X@6QM3B?#O4G-$HTK&X\634/7=
M]U+*[@'NVU= G@8JEY=I)<!+_+_AJ=WSJUN8YP?VI>*/NRN/ZCN*4%2)+R!Z
M[J?B6.2X*U<-8:OA7)E^W7-\I5T23D']*OC5613X-5[,;1K;M-F(CNH+(;&Y
MR6X0E"0.I)-0EEV(=FRM730.@6VX3'R^H+RR<J6\26$*]0/.LTE+*"3,]U[=
MW-4SA=)#N>['A;2-J&QZ "IQQ**)IF?ZF2E-H6IX82YX1G[5;)4B5E>TA;%)
M*0%D('B'IBIQ?!!DGJ]!7&92'MS:C@>],91KM8U(2S(CH/U^+'E1>U6.N"_6
M/_4[(RSCE0!-<B7.6R#7 S>3"B2';C(*<X.,U:FY1VD:*U*O,VX2T2&G2$[A
ML0/Z:V3TJQ8;0^1W:+>_.NZKC);4I#8\.?,U7CGMB/SLN5T6XS;TR H-K !P
M35T6WR2LRW4EV?O4A27#A+8QNSUJ]1ON0D^;.M;R(S/=E6X'H:UJ<81(7R)O
M(<;)DK;*<GC[5S,^3Q9T0R*Q_9[HP'$=ZD>Y-4^%MD1BJX+LWJ"%'BC8!T%7
MQX+D0$FY*?E"0VO:0<UNQX5 FV*&_7IY80RI:@D^5+)#S*]PNNXWI]([XK3C
MUK-*T#=DQ9+O<FW4-.*4<^52C*Q)46_YV9Z&KK"R/M<I,V.)<=.5%)21]_.H
M9+QNV33KAA9G9FT]I6=J!E[O)(*E.;E>()\L?G1'71<E 3;LQ%RRNNM%XNK)
M3N))''!]:Z2DJLFF7_L6TTJZRW'G6\-I.5'R(%59&4YIJ)M5_G"U6UQ;:=B4
MIPG'L*JBK?)E@G)GGS4.I)EYO+D-L^!8*<JX&:T)<&Q))$#<8OR,U*N. ,[>
M:D.[)VPM)=FI<*2#]?(\JAD=*A%K7ATA(Z <U1'CN,+>[W$TW:,+0I3\L=VA
M(&>HSSZ4X)MA6XR]J!\Z);\HA+@&_ K5Z(ENVT>C?AFN:78!@.JWX(*,^HKA
M=76WDKFK9MUU<0RZZN1'(2H_4!7'^W'<13K@\W_$AIQMTQ-0L(/<J&U2AU!/
MK[5VND9?<V/N6Q9BL2%,E1%(9VG!VY)Z^XKLO@DVDR^V*WL:7LADN[0XI)*R
M>M4S>Y\%;ML==FNKF;AJA;$M82A:]C6?\Z6?&_#X&XTB?[8;1'M$^#+:B;V'
MSE12G/2EA=Q'C=LJ-PGQ6XQ;CLD**-R?#Q5U$VT0L")>)*P68;;BU'&"KC[?
M>AY%#D7DS=>S7L32Q'3>=9#>E_#C,/.0D^I],_Y5Q=9KW)[<?<@\J2HL_:_
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M>:ZT+"N=JFK0E;[+3166#SCV%7Z7.\,Z99%F 1;7:0V7&VPR$>'NE<$8KO\
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M/X?M2?PZ^.6M]W^6]RE'O7,ZAB4X60R(]4/J$^T-36/K:&U2J\S?\#*C)OB
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M+ 3E/!'% #ER2_(V*>7N*$[$\ 83Z4[L0DLA*2<=:!D3-5O5GT%(!H20G(H
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MXOH);>;;2KS".12 .S<&TJR%@$?M3 <M2D+[L(<QN)S[T '=2RX2YW@41S0
M*FRML(<( 5T..E "D9A#3>=^[)Q0)CM@I2LI*<XZT"%CM02XA.W: K_JYIH
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M['P$SUAJ&1_&^S1;WUK:8*2!ZUY;"GCU%^14>5M&:<C:JU>Q;0<!;[CSK?F
M#YUZ?/D\/#N98W43TOK+55OT!I!Y47:VW%;2W''J<8R/SXK@Z6,M3FN12H[F
M>>[Y\YJK2;NIIKFZ4M9W ?@ZX%>B5+A&E)+A&;_-S7BA8=45-X2@#DD^E7UP
M6TD>C^PBS7V:69LJ(XA"DA&Y:<$Y]*YNIFEPF9<DEY&Z/0FK0ER-9W J6^,/
MNJ/#0K$I6C,DVS!^V*(C^*0TH=[Y2$D+5UY-=/16XTS3#L4%$?N^[P/$D *'
MH:V^1(=MD>= PJG-K@01P>#1V 06$ */=GK2 1"DN?V:>E !20GJ<4 (/D+
MV'/VH 43P@$]* !W)0 L*'- !.["CGUYH <PU+2Z0I6]*>4@?B]J %T-?.RF
M_ M" XG<!UZTP+"5Q_F772I9"5N;=W3ZJD(1_B [S*>">#2 ;.R#N4#YF@8V
M"E)\:%\4@"N/;B5I:(6>J_6@!J[$#KB5+CICD\]XTZ5*5[D>5 !6X\D)*N]R
M/\:0 MJ*LI4/N*"5A\LIYV4 $3M6HX\/'6@+"K2DG <"L>E F%[I9.U*L T"
M$U,(0LH*@30  BK4?"O[ 4  [%<(QWE !$Q4H2<CI0 *(^%#*"<]!B@!PEMH
MC;MVF@!0,!'..M !VFV=_P#K"0I&/I]Z !#2>?!D9X]A0 ;#+8R$<_:@!Q&6
ME0VJ.&_,^E,0NM:/[!M6<?\ 2#H:8SB%)&XY'N.M, ^QAM&Y#RU$]0:0"*T%
M>.* $EQE+/A<VE/44A -_.MKVMK*T]2D4T HN>ZA2678JEMKY5D[=A'3[T"$
M9+D2YI#;OB!_ L=WC]*5OL*4>$TRMW"UO1G/FK>K9@X..:3X[$FK7+(&6P^_
M(4J7XR>BJCM3))UV.:>=AD=P0E8\Z*0=RR677 MZPJ1%>6IO"D%M>P[P04X/
MER!46@2'?:+VMZW[5+R;]K?4$R9,^7:@E#0 ;2PW] &.HP>OG4VV^6-1C%5$
MJ2D[75[5 MY&SV&/.DR(%  [TC@J%%!09(*OI&:D X2VLJ VGK0 J6PCD\8H
M #?CE/)H !:U*&"DB@!)8Z4#2L)@T#2!VJ/0&@30LGA(SZ4"$!_WYO\ P^M
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M6K@4 .DX0DE2L >8H 6L,U29Z(Z@%(6O.X^W-- .YUP=9D+:[O'\PG\CTHL
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M;P-M(W<Y.*=H!0D'/=@)^](!4N1U-IX&0/%[FG8 *>:4 E()HM!093S2_$H
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MQVLR8+/'4[13BTPVL;-ZRT1>XZ5VMMI#JAP<8J5<@XM$WINWR;\3%B1%OE7
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MGW"#]2EG[JH#<''>#PI*$I/7P<U$0(;(.=V?RH ';[T6 (&*+ &BK .CZ:D
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M<4;:+\?N?ZD<1[*_GA8T;A\-4T\D7N)!OPK4/B/8J%W&Z#/1Z'(+MUZ]7<E
M5XKO3M H:TF,#B5,M0]G?I:YE468])V8[91::PM$EMB]<(%%/="(:.GWWJ?N
MB=(^G=;J_['53/$-&%VYA5P,O>O5,A>:.E/$DZ$[N(V]/AW;XVT6?&')[_#4
MMVGIH6/E?EU=K'Z!2#6-  W-3T"-Z:7*-K^[_D#!]_J";R</&\&"O0G8)_
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M)]G-?_5^]?,\BLG,&V2@E-!9SH$!C"HB[T%<OP*OPEG>SW#BZ,O^ GPQ/>*
M17-U"FNP.' 0X95O>ONZ3J^PS]' ;5JCH+8GLBI39B'&NU0I#U"T[FPSZ8#0
MTSMFP:;LU.%"4I_RIW"4=*B0Q:&*N$;0/X?#5V=6_U< @(Y+;WS"42GAEJUM
M@_*A#%JP7L/?XJ"&T<#+;L][ /F@ML:KMHA8<1HP@[02U5QI))G*HT *X_5<
M4YPO7;!?$A45-!UW*7DZRH*Z1I #9<8P5088#;958#PF(_:]060G9E%=;TYV
M$)O<H07X;%OB(!W("KOOT)>3^8T3)R[$NO63NN1_,[560_H857$TUH<,PN%%
M>)".:2;Q3A2C[+YK_S=<ZOL%X_1EC2Z\FY$ 9XTI]71<DJ:WP-(L;?)B4R<N
MM3%41O>DA3?@T0 -[DGT:$H?M059EB?EVM&C:;GH'7'49T[$VA>[]BBFO9WA
ME2H]<'[+0^.9CL+PUY8MCY5F'S^/RJPLU5O)D D[6L]\XVOK[LOPYM#\OJ3T
M-[J&%>TN=&S=(K+=0'AT^H(AYVUN.77$Z+0\>68W?7?%PV#,-^QWWP1>NROS
M+^ ]HJ&FT0PQ,#O(3VAE.0EX9?]<VAG#.#P*X]L"]U*?6 4]1 ?Y*/DIJ1=$
M#\2QP#Q576,DA$MJA?*/?=]N<P2+AY^//_N4XJ/S+/1[?MZF4&: C;_B%9['
M!P)SE:$UT6F6CC+5P5!J149/N(W'XJ> H7N]TU+('PZ!\].KDW,LQ0W":+DO
M$"R788FHM"96M=I#Z(NL-X0^Y+XSY8=-O?)BI543E\F<RY_=3W^F[QL]@O=!
M^8"SFF6780.Y(EFA]30A^+).";,74'>92MQ&1-GG5W]_.+&0/KHA],%QVST.
M@)_WIXW3?7IWP31*6;^'VMIOG2V1D5#B>/YPI=E<E5M\1HVVWPNU!09D1+SJ
MH&]U>G!ON.0Y!X<B1J,*LYUG8RK/EY^IB^!R"%(1PYOJD^>6(#4*F2N5K6/Z
M$#%1P^DJ3I$3=.N$LGFML8!9V%827D.Z.23/]D>A>&O&,A@WA<KH*9+TS\PM
M%RY!#'5W[O$8:*3).W<1:F$P>'L>-M$:G\UTT\<@XUIAYP3A%J] +5?]-K<H
M.#;5R?O1K_(Q!70UOV_PYK7EC&>9-0JA<OD=04/+#6:+'P)HD('/DG^N.T6G
M9X=SY\.T=F(J:JK?U WK(1JIWX+=;8(35]SGRQ]_!C-W'@\PK+I[$9UK>UG7
M&UKMM:5RK7$2;5K:=L7*_A@F/?=3H/LH_3U7GD?R-$Y%X]J.H^QKAK5P;E]Q
M-'Y#SLA\O='G=6_7U9$7+9P!$1XVW$8!(SS^RJZ.T=6YI;-;/R0Q14:R.MQP
M6VS0/$FHW43)V)O'0-\^_:Y0N=SS \(E'^O6#\B+L$Q5_)NGYHE2Y?6O#)SE
MS$/-LDAVBA<>S;>2Y*P7F?S!ET,U(FU[^&LLH]U5IF9''CA/8KM[O&(@S3E,
MT;VHQW,+/F8B!+DO-:?,C7A<ZQ<)+1$W%:VVL:FL@4]VXE\\,VIKAJ9;:=?9
M]$T@HBS*Y:ZU8*RJTR9FY*$U-"S-E^3"_9\FB!(>',,B4LKNM4R<\<1>7(??
M\KI<Y8@S2B]')^++@Q; +X17NT1V/)876,&8@G#(1X_7&LY>X)*0;70YR4;=
MHNN#X(J)/2QP^$EIU3"+GQE&^VPLJ#> 4G=NM8P_' HS;?\HWH[A]?#B=TOO
MUBKA$NZ-^3QPEN/@J$A$'W%5*P9Y!!1D9LV]'<&/I;W156@Y.89E9$:,]T &
M%+:]8:.PC;F(@H*T[7R3/D4>V5,[5;NG'NV._M@$WE]V#R]3OGONXT7])YY;
MW6IR+G%YX8_]TB?7%/+12:E:^;0P$5KFWZZ?%N)?L90R6/!EOOZUX:IH@[ZB
MUV,=;AWG2ZK&[M]S=JQ>T^XZ*0P^2V*U>.GB42/Y]COGVF@*WFMR)4G0U"$D
MCI803O6%B$?^D3JA_/=H8 0+U^*!E**=K[N$0,9N%L9ND]@59-,5%N>]6HH_
M#>YX/:.L.K\<LX_T@%NL:LJ[_ 6N],4;]02.G/!QJ]4(2-^8%*'EM7%,^Q5?
M_B"\[?LV9;L-K"645SY=A3<[;K@1(B* ?[TSFVL./]0OX1;ZH(V\;XR4 ;3%
MQ9*NZ%X0&$12NG=. ^3].RBCY@R_+*CN!D'I]#"BT("W./IA="*JFJC*3P+F
M@@NW?XBX+:,NUUJ^$:ZA!<2+R$W%.+J9Z%=19&JA_ 0H@V1".XK:!\<BS X\
MRW!D8([U&O\Z *3X]*YT5QQ=X$"198F%PS@:I]''3:]G02/JK"%0AF):UVNS
M9#75R6\XI@+5KPI,\?CM\NO>?'0LU:67R1+7_?\"MX5YL=Y4VLT5B9)X(-B)
M;ZO96A5'O\=H1*N+!Z06W\&H:__1\K3O[: W: :B$S<93&< P8&7L<>02)&O
M-51/QB5!/6^*JT'L=S]@"O86R0!^#UW5J@K[5\K8_WV"B#TW.AT1^"9< E5^
M'%P /1U2 '1.-SL 3Q2K8RZ6 WKY+LSR9W.Y%#>@;V^X):8 )#P7E.B=@E,E
MEN6^-U,..8#NP\31>^>0#\=J9%[67"(K']<B?9/W-:4!3.&S];V[$H"U*JOX
M!?^J!;5DUAKG?X@>0K/@C<X>+$LX@N;FAXA6^)!8"1 Z;KJN""H! K<9?9I;
MLKVI9 ]XTABG'.EUF*M?!N;]),M:M[:OPFS%P>F=@:73]Y)Q? /6:=2FS$!3
M06_I5:,)6G^JVT%0)@ZVS)#I.)*D%UIPK=)8!)C9M[L3)?*';%RBK'IA'X7E
MA<D21U)$)=^5+0[^YF>X:'+&#+_G5Z'[466C97O4\.3HF,0^I2(CQD??PV*]
M7[BR@U;3-5Q^SOW8/V4O=?K!&<_:EF;P$U_3Y'XKBLM:_%D)JPVD9FZ3)XT@
MVNN\K9]AXL)KLR[=!Y)2N5[V-G+6-WWKH B[Y'E8O"#Y9$*9KY6+-DFPH@C$
M![:%.$H;C]<X[=SQ*T5>['& .M"7?(V&IUZK6=\537OO5\8T0<?KU,V1_"%W
MA(DG<E(C2_K5U8 EJZ[S)&F[_8_]<$3RO/KX)V:WD9Q\?(JT00[4YT):+7Z%
M^X&CP8[ M2'5^@>K#BUX%4S HJ7&LL53I[PU257SY7:WT9 7][[*\81" I32
MPFG!$6DW'D:)J8LE@/5>N%:M-!6V5Z4X^IAFC:Q\8T-DGO<WW.2 !%HC)9E>
MMM'Y1M>&(R_9\?1(2)]>#HPHKIZ<OGW2J!Q6$AB?BZL@S_&4O:\/REX;-"0*
MF;P9'PHOE,_6E)@-D7NM>W!R>UM0MLH ,5N53<^^_$*30[GQ/%J8N2O*R2=T
M(SEN- LFN>$3;.C2MGU9[OY2O-O>NTU^(0@2]T5>T^=)IV%'9Y%H)_X5(V6V
M2+3).BE::LY<.LGQ%HU:?^+)E#.WR!"'FZ9QA9W?:QFH>S@KN*>#WB3ZUUS(
M2XD1?GAV(V(Q=];67"S!5EN"DGA7--]HB?/::R3E+R _WU ND!)2680'YHWH
M%3GK0;_"BED1B<TC6IW@!]E;"M"Q:;_R"/B.H'9[UYVH+H-4TGOEL YB=S!/
M6EF=<*VC,(_D/84T+1J@*E="0F&TMC?@A<$C45H?NQT['1%DD9$%1;K@Y8QO
MGR$]GY^)C<!UJTU?YN[$AO$;CBU&U#4T=N89)3X.RA(B;F_OQVV8+S=:-L%+
M&PNREPN@U*.-:71&[:BK5 ..MI#5JF641C$]PEGP%6_$\RB;+@GX3SLA^WSK
M1]Q&*PIF/085'MVQO1+&<5H<5X3O^%)\%:;[+VILQ$^/#8Y<IX@E23):%LD4
M'"MF^_EO2==R*V<C@NG >Z-3NPIWO:"=BY%0/"UDFTNQI6[/.N/P/5YK&0/J
M[FGS0!(%.D<[;Q3Z):F<#&]9]RR,V#T=F^I:)T[G1C)?J=7Z]H;5VB#@%VO@
MHG[7FZ< A]%1.@*3Y\SQ>MB_/4LW#$U8<B(86.4-^M&]$4X46BC6S))L?;/<
M7EB207!F.?)SSZK_2N0V*47*#'8(7W]S\/2Y$N7K[3C!IMKUEX'#,\OPY5#;
M4,73HTM6@U9?2I&7',S#& 6V2&9,\ P/]O==OFL^,FM($T]7Q_'$N(.%]-WM
M&>E36XNJ$><@#L[SILV'5,74X:[%#;-;'QA:S#H%*M6^%0:S8VBOOLK,QH2+
MK&9L._8M_LP3<@:_VH)2B]R[,=T06/E8J +I%I#&'=M^A,1N!,WN>"\;7%G'
MY'U^.(Q?:[J *"=?/5HY5Z$*&H -5ODK!T:QZ4(=)WJ*KH,0:)C&#[O2"5%5
M5?SBX"FB(B? BH/_[5=Y3/@DDB8H?6GF?J1RD<_WC2\[+?>[^,YR _.;,[\-
ME877CDK[H;=K2Y'/7DCR<22D#V UP&,%1GYC*P@9_R&$$1QZ=$XXF"/V#;&F
MU%<IY104]J&,JT4R0R^(Y%-'FUII\1 O9QN27L!,J@/75CK(!M^*!4\MYUK,
MS58P(N:V@- #J(CBH_LL)Y_=@&^X&U3$3DQ$7BZ]);1(<"P)/A@$[?V883A.
M!EW".S>4 -O3J&L(1ML-;X"]K$H51_7'&J"Y[,;[@QNXWC<6NWZJO5;N"SA7
M^&;R?]C+M "Y-W?B4H*Z/;_&?4_Y84%E6/!G %!RDF 4$;=0!PU ^LI/TZE1
MG0HL[P3X9AE;?@&T27DE-#"2SK#M^.-0(+CL$,*P;%@&2-185)#)(#*&G88V
M6!PT9E+6);%;!H1VUI!M\TZ,J.EMMWV8SFZ6H1#L24FGVWSB(/!'2XDU(Q:>
M-\N-L5G 3>O@R*DNG,X5T.8VANKQ[&5_)G1("?!0<";>&U1?#8Z 'D"9/SB.
M&)D"]&-:KWBIL6ID=9%[B\9-?P&%R^5JZDF%XNU//UL5OF4RM\JN*6/02$/*
M][%-F16@4HO#'<8@MDK?+G ,Q7*E%I*(-/X"H'?@HWK\L-9OLL+ 4[]^IH72
MKUMQK(T&4"Z)&WA !5'BP_6G!7HM9.<C# XSQP/)TJ(R3Z9#SG&Y/Y*?P6%K
MF=$6>D*SZ"V#)[Z Z;=JL0#OF'@>0G_M['0E5'26OXM]FH\<2#6H4T?W#@4,
M>@L(X<6"=N/(/ /4O$X615Z#WAM):GGQFH>J6N]X;6#R?EDB_7I4RZQ,[#:Y
MFLPA%1_E]8JN.[?%3MI6-.O,*KWEZ5R)8?%"D7[F?!K0'ZQY%]O_7,C1(>V_
M L=5B!7JIA,3+VO4]AC[])FPQPU+(9>744VVNU<?C!B<'F,M8(1S^BE0:-*T
MQY9.\;U"V^4S!DT&_$WK39.E-JF.IBCXY>(IE2XR2L>N.Y.I7G-DT#9=[]G6
MKH+^0)XH\JMCY]O?]7NGE187:^"D0^N*]0/<"]['5)'UZQ[[KJ23$/>)FB7N
MCUW#8XRV\FT/&OS"1;9/7RIDB3;N.&Q=<GRJ7G('8:UFZY]7$]"_8NT,)FSY
M<H[&"4K 9['U9M!Z8N$Q:32I?3@#?V*;U"A*:@!!@Z;:S!#+C84,D&A\ZU^@
MXNG[0*O05*ZB0TSMU)>ZQJ:8ZZ]D!SZ&RUTZGMJ^4"(?W^[K'?/3YHT],E Y
MN>TUPO4)P\;V4?E]0%JM##IZ'FTP0#W'KT.$P3ZYY:.WAHJ(:F5W?'QWOZ\6
M18GP^W2R*[KSNKY?BW]LM@9BF.+!Q.O#&1*RP)?6EOV7 DQ+#D* /&S0.2$L
M3&>TK&DC@&-.>NZ^=(YY5&)9GLOH>G=75V!W84D@OCJ0U3N]$N%6)O$]^5T3
M08] #1G*JY-Q$%>CS(?:5F<03YI\EO8UOT L/?KD2;/XY;1;RX%>W,F#E%@3
M^Y("[(F+]E29?D]=I>6*A+3T[52R+O+'9XN,=JK"_0-QK=KYQI48D":RZU((
M"^A&%&IC#^\$)O%4"A(&>@7-JL'2#C21UM7O&>6\S)69_#G0/S7LWPY/J,B!
M[_6B^EP8!"29CM+12:TR["X"_6EKU:)OKC9L,TGZ"(T%%#S]Q#X4*$<GC\6H
M;R3HFVV##]@N9=:)B5 0HM8PW?1M-TG5 =.;J<KN%*H4)IW\/3M#-#M<%"3V
M5M:VB:$E-.L=TQY8KGV?+V$^+N#.WZ7_ 5!+ 0(4 Q0    (  V%KU;>TBZF
M3 8  '47   5              "  0    !A,C,P,C Q,C!F+65X,3)?,2YH
M=&U02P$"% ,4    "  -A:]6TU>U?$ &  !F%P  %0              @ %_
M!@  83(S,#(P,3(P9BUE>#$R7S(N:'1M4$L! A0#%     @ #86O5H6-QP>#
M P  40D  !4              ( !\@P  &$R,S R,#$R,&8M97@Q,U\Q+FAT
M;5!+ 0(4 Q0    (  V%KU9NE<-,>@,  $()   5              "  :@0
M  !A,C,P,C Q,C!F+65X,3-?,BYH=&U02P$"% ,4    "  -A:]6>(1#Y-'<
M  #VX0  #0              @ %5%   8V]G;U\P,# R+F=I9E!+ 0(4 Q0
M   (  V%KU8F]C+44ZD  ":M   -              "  5'Q  !C;V=O7S P
M,#4N9VEF4$L! A0#%     @ #86O5@<=6&+O?@  <8(   T
M ( !SYH! &-O9V]?,# R,2YG:6902P$"% ,4    "  -A:]6$8[2VP\G   R
M)P  #0              @ 'I&0( 8V]G;U\P,#(U+FIP9U!+ 0(4 Q0    (
M  V%KU;J0WY+$5X  ,U>   -              "  2-! @!C;V=O7S P,C8N
M9VEF4$L! A0#%     @ #86O5OL0AF"Z>0  ]WL   T              ( !
M7Y\" &-O9V]?,# R-RYG:6902P$"% ,4    "  -A:]6*(TZC<\O  #W+P
M#0              @ %$&0, 8V]G;U\P,#(X+FIP9U!+ 0(4 Q0    (  V%
MKU;(%(?>M"@  .(H   -              "  3Y) P!C;V=O7S P,S N:G!G
M4$L! A0#%     @ #86O5E& SL3Z)P  (B@   T              ( !'7(#
M &-O9V]?,# S,BYJ<&=02P$"% ,4    "  -A:]6KO( "CHH  !D*   #0
M            @ %"F@, 8V]G;U\P,#,S+FIP9U!+ 0(4 Q0    (  V%KU9+
M"KXX&C   $(P   -              "  :?" P!C;V=O7S P,S4N:G!G4$L!
M A0#%     @ #86O5@:'S;;**0  ZRD   T              ( ![/(# &-O
M9V]?,# S-BYJ<&=02P$"% ,4    "  -A:]6E.5DA((F  "C)@  #0
M        @ 'A' 0 8V]G;U\P,#,W+FIP9U!+ 0(4 Q0    (  V%KU9K_SB"
M_2<  "0H   -              "  8Y#! !C;V=O7S P,S@N:G!G4$L! A0#
M%     @ #86O5E,0"%HA<@  #70   T              ( !MFL$ &-O9V]?
M,# S.2YG:6902P$"% ,4    "  -A:]66571,S<G  !>)P  #0
M    @ $"W@0 8V]G;U\P,#0S+FIP9U!+ 0(4 Q0    (  V%KU8ZL,_I-"D
M %LI   -              "  60%!0!C;V=O7S P-#0N:G!G4$L! A0#%
M  @ #86O5O0&@,K()P  \"<   T              ( !PRX% &-O9V]?,# T
M-2YJ<&=02P$"% ,4    "  -A:]64_L75S D  !6)   #0
M@ &V5@4 8V]G;U\P,#0W+FIP9U!+ 0(4 Q0    (  V%KU:9'^P[-2T  %\M
M   -              "  1%[!0!C;V=O7S P-#DN:G!G4$L! A0#%     @
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M2P$"% ,4    "  -A:]6A7'(*3ZI  "1K0  #0              @ $$3@<
M8V]G;U\P,#8S+F=I9E!+ 0(4 Q0    (  V%KU;2:DZ(%FP  *%N   -
M          "  6WW!P!C;V=O7S P-C0N9VEF4$L! A0#%     @ #86O5@^>
M!#7-7   -5T   T              ( !KF,( &-O9V]?,# V-2YG:6902P$"
M% ,4    "  -A:]6,*MBK_]:  !26P  #0              @ &FP @ 8V]G
M;U\P,#8V+F=I9E!+ 0(4 Q0    (  V%KU8/=CQT9UX  #5?   -
M      "  = ;"0!C;V=O7S P-C<N9VEF4$L! A0#%     @ #86O5H@5_-&J
M7   _%P   T              ( !8GH) &-O9V]?,# V."YG:6902P$"% ,4
M    "  -A:]6V6F(?ZQ?  #Q7P  #0              @ $WUPD 8V]G;U\P
M,#8Y+F=I9E!+ 0(4 Q0    (  V%KU8\9'<Y5UT  )I=   -
M  "  0XW"@!C;V=O7S P-S N9VEF4$L! A0#%     @ #86O5C&,XQ.S80
M7&(   T              ( !D)0* &-O9V]?,# W,2YG:6902P$"% ,4
M"  -A:]6>&%5X(5E 0#9:@$ #0              @ %N]@H 8V]M<%\P,# S
M+F=I9E!+ 0(4 Q0    (  V%KU;%0.79Z2X  ),P   -              "
M 1Y<# !C;VUP7S P,#4N9VEF4$L! A0#%     @ #86O5OM-O>TVJ   -:P
M  T              ( !,HL, &-O;7!?,# P-BYG:6902P$"% ,4    "  -
MA:]6X!*!9;;O 0"9_0$ #0              @ &3,PT 8V]M<%\P,# W+F=I
M9E!+ 0(4 Q0    (  V%KU8YU,97^E ! "9< 0 -              "  70C
M#P!C;VUP7S P,#@N9VEF4$L! A0#%     @ #86O5IK2&@R]]0  ;?L   T
M             ( !F700 &-O;7!?,# P.2YG:6902P$"% ,4    "  -A:]6
M2KZ3]?LX 0 >0@$ #0              @ &!:A$ 8V]M<%\P,#$P+F=I9E!+
M 0(4 Q0    (  V%KU:!0V\C+1L" /,E @ -              "  :>C$@!C
M;VUP7S P,3(N9VEF4$L! A0#%     @ #86O5L PDV?QH ( 3+$"  T
M         ( !_[X4 &-O;7!?,# Q-"YG:6902P$"% ,4    "  -A:]6T/:B
M;84Y @ J0@( #0              @ $;8!< 8V]M<%\P,#$V+F=I9E!+ 0(4
M Q0    (  V%KU8SHE2H%;8  ,B[   -              "  <N9&0!C;VUP
M7S P,C,N9VEF4$L! A0#%     @ #86O5GT\6MD== ( F8$"  T
M     ( !"U : &-O;7!?,# R-BYG:6902P$"% ,4    "  -A:]6PK#)6S4+
M  #A"P  #0              @ %3Q!P 8V]M<%\P,#(X+F=I9E!+ 0(4 Q0
M   (  V%KU8K%D5NZE$  !%5   -              "  ;//' !C;VUP7S P
M,CDN9VEF4$L! A0#%     @ #86O5A_""D^)5@  V%D   T
M ( !R"$= &-O;7!?,# S,"YG:6902P$"% ,4    "  -A:]6B%S(Y]6- @!>
MF@( #0              @ %\>!T 8V]M<%\P,#,Q+F=I9E!+ 0(4 Q0    (
M  V%KU:"U>O0\Z0( +[OG  0              "  7P&( !N=G,M,C R,C$R
M,S$N:'1M4$L! A0#%     @ #86O5G^XOR?SE@  9A8( !
M ( !G:LH &YV<RTR,#(R,3(S,2YX<V102P$"% ,4    "  -A:]6O.]D/<4<
M  !?Z $ %               @ &^0BD ;G9S+3(P,C(Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  -A:]6.-%_)24F 0#1>A0 %               @ &U7RD
M;G9S+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  -A:]6YC^RVS:> @!,
MHAP %               @ $,ABH ;G9S+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"
M% ,4    "  -A:]6Y*'' T9+ 0 :'1@ %               @ %T)"T ;G9S
M+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    "  -A:]6A2QX]XT4  "W+
M#0              @ 'L;RX <VEG;BUF=6QL+FIP9U!+ 0(4 Q0    (  V%
MKU9.U_IK?A0  *XM   -              "  :2$+@!S:6=N+6AA;&8N:G!G
M4$L! A0#%     @ #86O5LYIB1[:%P  P2X   L              ( !39DN
M '-K:6QL+6<N:G!G4$L! A0#%     @ #86O5KS96>=&&0  7C    L
M         ( !4+$N '-K:6QL+6PN:G!G4$L! A0#%     @ #86O5IW[*% \
M(   GT4   L              ( !O\HN '-K:6QL+6TN:G!G4$L! A0#%
M  @ #86O5NC+>JT:%@  K"P   L              ( !).LN '-K:6QL+7@N
M:G!G4$L! A0#%     @ #86O5M]L8-6<&   JC    L              ( !
M9P$O '-K:6QL+7DN:G!G4$L! A0#%     @ #86O5D?\PE- &   1"\   L
M             ( !+!HO '-K:6QL+7HN:G!G4$L! A0#%     @ #86O5G=(
M43+")@4 S30%  \              ( !E3(O 'A?8V]V97)B86-K+FIP9U!+
M 0(4 Q0    (  V%KU8D6*GM+W<% "=W!0 0              "  819- !X
E7V-O=F5R9G)O;G0N:G!G4$L%!@    !% $4 (A   .'0.0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
